,source,target
0,"{'outcomes': ['efficacy of pcit <sep>', 'overall levels of parental anger and physical discipline/force <sep> moderate stability and parent-child correspondence <sep> parental anger and physical discipline/force and family problems <sep>', 'structure <sep> autonomy <sep> autonomy-support <sep> adherence rate <sep> low attrition rate <sep>'], 'punchline_text': ['the relative superiority of pcit was mediated by greater reduction in negative parent-child interactions consistent with the pcit change model. <sep>', 'the overall levels of parental anger and physical discipline/force were lower in cbt than ft families though each group showed a reduction on these items from the early to late treatment sessions. <sep>', 'twenty-six maltreating families were randomly assigned to one of two conditions the 16-hour weekly intervention group or the 4-month wait list control group. <sep>'], 'population': ['physical abuse among abusive parents <sep> physically abusive parents n=110 <sep> participants had multiple past child welfare reports severe parent-to-child violence low household income and significant levels of depression substance abuse and antisocial behavior <sep>', 'child physical abuse <sep> physically abused school-aged children and their parents/guardians who were randomly assigned to <sep>', 'twenty-six maltreating families <sep> maltreating mothers and on the autonomy of their children 3-8 years <sep> maltreating families <sep>'], 'interventions': ['pcit b pcit plus individualized enhanced services or c a standard community-based parenting group <sep> parent-child interaction therapy pcit <sep> parent-child interaction therapy <sep> pcit <sep>', 'individual child and parent cognitive-behavioral treatment cbt or family therapy ft <sep>', 'webster-stratton parenting program <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",there is insufficient evidence to support the use of parenting programmes to treat physical abuse or neglect. there is however limited evidence to show that some parenting programmes may be effective in improving some outcomes that are associated with physically abusive parenting. further research is urgently needed.
1,"{'outcomes': ['migraine headache rate <sep> incidence of any specific treatment-emergent adverse event <sep> migraine headache rates <sep> reductions with extended-release divalproex sodium <sep> tolerance and safety <sep> migraine headaches <sep> efficacy and safety <sep>', 'various side effects <sep> frequency of headache attacks the frequency of use of drugs for the acute management of migraine the patients opinion of treatment and the hamilton anxiety and depression rating scales <sep> efficacy and safety <sep> mean score of the 21-item hamilton rating scale for depression <sep>', 'visual analog scale vas and headache duration <sep> mean sd of monthly headache frequency <sep> mean standard deviation sd of monthly migraine frequency <sep> headache intensity <sep> migraine headache <sep> duration monthly frequency and intensity of headache <sep> headache duration <sep> efficacy and safety <sep>', 'initial migraine frequency <sep> severity and duration of the migraine attacks <sep> number of responders <sep> number of days with migraine <sep>', 'frequency severity and duration of the attacks <sep>', 'responder rate <sep> frequency intensity and duration of migraine headaches as well as midas score and symptomatic medications <sep> symptoms with migraine <sep> reduction of headache severity <sep> frequency intensity duration associated symptoms with headaches analgesics use as well as drugs side effects <sep>', 'migraine attack frequencies <sep> adverse events <sep> nausea dizziness and tremor in which incidence rates <sep> nausea <sep> efficacy and safety <sep> 4-week migraine attack frequency <sep>', 'average peak severity or duration of individual migraine headaches <sep> mean migraine headache frequency <sep> symptomatic medication per episode <sep> functional restriction <sep> migraine headache frequency <sep>', 'migraine frequency <sep> migraine frequency <sep>', 'valproic acid serum levels <sep> headache days <sep> frequency of migraine attacks and the number of migraine headache days <sep> frequency of migraine attacks <sep> migraine attacks <sep> migraine headache days <sep> side effects <sep>'], 'punchline_text': ['no significant differences were detected between treatment groups in either the overall incidence or in the incidence of any specific treatment-emergent adverse event 8 of subjects treated with extended-release divalproex sodium and 9 of those treated with placebo discontinued for adverse events. <sep>', 'the patients who were treated with flunarizine showed an increase in the mean score of the 21-item hamilton rating scale for depression but the difference was not significant morning dysthymia however was significantly more often observed in the flunarizine patients compared to the valproate patients. <sep>', 'a total of 64 patients with migraine headache aged 14 to 57 years were randomly allocated to the 2 treatment groups. <sep>', 'the severity and duration of the migraine attacks that did occur were not affected by sodium valproate when compared with placebo. <sep>', 'our results show that in 86.2 of the patients sodium valproate was effective in preventing migraine or reducing the frequency severity and duration of the attacks. <sep>', 'the reduction of headache severity in the topiramate group was significantly more than that in the valproate group p  .027). <sep>', 'adverse events were similar in the dvpx and placebo treatment groups except for nausea dizziness and tremor in which incidence rates were significantly higher in the dvpx 1500 mg group nausea was also higher in 500 mg group than in the placebo group. <sep>', 'among those with migraine headaches divalproex-treated patients reported significantly less functional restriction than placebo-treated patients and used significantly less symptomatic medication per episode. <sep>', 'no significant difference was identified between divalproex and propranolol for the prophylaxis of migraine without aura. <sep>', 'the outcome of group 1 low serum level was significantly better than that of group 2 with respect to both parameters p<.05). <sep>'], 'population': ['subjects with more than two migraine headache attacks during a 4-week baseline <sep> migraine prophylaxis <sep>', 'twenty-two migraine sufferers <sep> migraine prophylaxis <sep>', 'october 2003 to september 2004 <sep> migraine prevention <sep> 64 patients with migraine headache aged 14 to 57 years <sep>', 'migraine without aura <sep> 43 patients with migraine without aura in a triple-blind <sep> 34 patients completed the trial <sep>', 'migraine <sep> twenty-nine patients <sep>', '56 patients who completed the course of study <sep> migraine prophylaxis <sep>', 'patients with two or more migraine attacks during the baseline <sep> patients with migraine <sep> patients were previously untreated or had failed no more than two adequate trials of prophylactic therapy <sep> one-hundred-and-seventy-six patients 44 placebo 132 dvpx were randomized 171 provided efficacy data and 137 completed the study <sep>', 'patients with migraine headaches <sep> one hundred seven patients randomized to <sep>', 'private practice of a general neurologist with a special interest in headache disorders <sep> migraine without aura <sep> 37 patients 30 women and 7 men selected 32 completed the study <sep>', '52 patients received <sep>'], 'interventions': ['divalproex sodium extended-release tablets <sep> divalproex sodium or matching placebo <sep> placebo <sep> divalproex sodium <sep>', 'valproate <sep> flunarizine <sep> valproate <sep>', 'topiramate <sep> topiramate and sodium valporate <sep> topiramate <sep> sodium valporate <sep>', 'slow-release sodium valproate <sep> placebo <sep> sodium valproate <sep> sodium valproate <sep>', 'placebo <sep> sodium valproate depalept versus placebo <sep> sodium valproate <sep> sodium valproate b.i.d or placebo <sep> sodium valproate <sep>', 'topiramate <sep> topiramate <sep> topiramate and valproate <sep> topiramate and valproate <sep> low-dose topiramate <sep> valproate <sep> sodium valproate <sep>', 'placebo <sep> divalproex sodium <sep> divalproex sodium dvpx <sep> dvpx <sep>', 'placebo <sep> divalproex or placebo 2:1 ratio <sep> divalproex <sep> divalproex and placebo <sep> divalproex sodium depakote and placebo <sep> divalproex <sep>', 'placebo <sep> divalproex sodium depakote <sep> divalproex or propranolol <sep> divalproex <sep> valproate sodium trough level was 68.5 mg/l. propranolol <sep> propranolol <sep> divalproex with propranolol and placebo <sep> divalproex and propranolol <sep> propranolol hydrochloride and placebo <sep>', 'valproic acid serum levels less than 50 microg/ml <sep> prophylactic valproic acid treatment <sep> valproic acid <sep> valproic acid <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",valproate is effective in reducing headache frequency and is reasonably well tolerated in adult patients with episodic migraine.
2,"{'outcomes': ['response rate <sep> response to treatment at least 20 improvement from basal conditions on clinical laboratory or specific neurological testing variables <sep>'], 'punchline_text': ['of the 32 patients studied 18/19 receiving cy and 7/13 receiving mp responded to treatment p<0.03). <sep>'], 'population': ['two tertiary care centres of patients with sle according to the acr criteria with incident no more than 15 days onset of severe np manifestations such as seizures optic neuritis peripheral or cranial neuropathy coma brainstem disease or transverse myelitis <sep> systemic lupus erythematosus <sep> 32 patients studied 18/19 receiving cy and 7/13 receiving mp responded to treatment p<0.03 <sep>'], 'interventions': ['methylprednisolone <sep> cyclophosphamide cy versus iv mp <sep> iv methylprednisolone mp <sep> cyclophosphamide <sep>'], 'punchline_effect': [' sig increase <sep>']}",this systematic review found one randomised controlled trial with a small number of patients in the different clinical subgroups of neurological manifestation. there is very low-quality evidence that cyclophosphamide is more effective in reducing symptoms of neuropsychiatric involvement in sle compared with methylprednisolone. however properly designed randomised controlled trials that involve large numbers of individuals with explicit clinical and laboratory diagnostic criteria sufficient duration of follow-up and description of all relevant outcome measures are necessary to guide practice. as we did not find any new trials to include in this review at update the conclusions of the review did not change.
3,"{'outcomes': ['discharge destination or dependence <sep> length of hospital stay discharge destination functional dependence barthel index and direct healthcare costs <sep> length of inpatient stay <sep> mean total cost <sep> daily cost of care <sep>', 'functional independence <sep> functional dependence barthel index discharge destination and length of hospital stay <sep>', 'initial length of stay <sep> inpatient length of stay <sep> mortality functional status or living arrangements at any time <sep> patients length of stay functional status subsequent move to more dependent living arrangement <sep>', 'cost savings <sep> average total cost of delivering care <sep> length of stay mortality or complications <sep> length of stay mortality readmission complications satisfaction and cost <sep>'], 'punchline_text': ['length of inpatient stay was significantly increased for the treatment group p=0.036 95 confidence interval 1.1-20.7 days). <sep>', 'patients undergoing usual care stayed in hospital for less time mean difference 18 days p<0.01 but the same number of patients were in hospital 90 days after recruitment 23 nliu 24 usual care p0.05 due to re-admissions. <sep>', 'inpatient length of stay was significantly longer in the nurse-led unit than in general medical wards 14.3 days longer 95 confidence interval 7.8 to 20.7 but this difference became non-significant when transfers to community hospitals were included in the measure of initial length of stay 4.5 days longer 3.6 to 12.5)). <sep>', 'few significant differences were found between the two groups in length of stay mortality or complications. <sep>'], 'population': ['175 patients assessed to be medically stable but requiring further inpatient care referred to the unit from acute wards <sep> 89 patients <sep>', 'of patients referred to a nliu from acute wards 80 were randomly assigned to <sep> patients were identified as medically stable but in need of additional nursing intervention by referring medical staff prior to full nursing assessment of suitability <sep>', 'urban teaching hospital and surrounding area including nine community hospitals <sep> 238 patients accepted for admission to nurse-led unit <sep> participants <sep>', '220 chronically critically ill patients <sep> chronically critically ill special care unit versus intensive care unit <sep>'], 'interventions': ['nursing-led intermediate care <sep> nursing-led inpatient unit with the system of consultant-managed care <sep> unit nursing-led care with no routine medical intervention and 86 to usual hospital care <sep>', 'usual care remain in normal hospital system and 97 to the nliu nursing-led care with no routine medical involvement <sep>', 'inpatient nurse-led unit with conventional post-acute care <sep>', 'icu <sep> scu <sep> low-technology environment of care and a nurse case management case delivery system special care unit scu with the traditional high-technology environment icu and primary nursing care delivery system <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>']}",there is some evidence that patients discharged from a nlu are better prepared for discharge but it is unclear if this is simply a product of an increased length of inpatient stay. no statistically significant adverse effects were noted but the possibility of increased early mortality cannot be discounted. more research is needed.
4,"{'outcomes': ['clinical complete response <sep> hematologic and gastrointestinal toxicity <sep> median survival <sep> complete response <sep> partial response rates <sep>', 'superior progression-free survival <sep>', 'response rate <sep> clinical toxicities and abnormalities in laboratory findings <sep> response rates <sep>', 'cell differentiation and volume of postoperative disease <sep>', 'clinical response rates <sep> hearing loss <sep> alopecia <sep> renal toxicity <sep> nausea and emesis <sep> tinnitus <sep> neuromuscular toxicities <sep> survival superiority <sep> therapeutic index <sep> median survivals <sep> pathologic complete response rates <sep> thrombocytopenia <sep> anemia <sep>', 'toxicity <sep> survival <sep> small survival <sep> early nausea and vomiting and later hematologic toxicity <sep>', 'survival curves <sep> bone marrow disorders and death due to toxicity <sep> larger proportion of 48-month survivors <sep>', 'likewise time to treatment failure <sep> lethal toxicities including gastrointestinal hemorrhage 1 patient and neutropenic sepsis <sep> clinical complete response rates and longer time to failure <sep> life-threatening toxicities including hematologic toxicity <sep> survival <sep> clinical complete response rates <sep> survival <sep> response to therapy time to treatment failure and overall survival <sep>', 'cap <sep> clinical complete response cr rate for ca <sep> response duration <sep> toxicity <sep> progression-free interval <sep> survival <sep>', 'overall median response rate <sep> median response duration <sep> median survival <sep> survival or response <sep>', 'overall response rates <sep> unacceptable toxicity <sep> better survival <sep>', 'myelosuppression especially thrombocytopenia <sep> overall pathological response rate <sep> severe hematological toxicity <sep> toxicity and treatment efficacy assessed by pathological response rate progression-free survival and survival <sep> survival or progression-free survival <sep> complete pathological response rate <sep>', 'survival <sep> response rates <sep> response rate to cmf <sep> survival and time to treatment failure <sep>', 'overall response rate <sep> toxicity <sep> survival rates <sep> median survival durations <sep> progressive disease pd nonresponse or toxicity <sep> 5-year survival rates <sep> 5-year relapse-free survival rates <sep> complete remissions crs <sep> median duration of response <sep>', 'clinical complete response <sep> response rate time to progression disease-free survival and overall survival <sep> median survival <sep> efficacy and toxicity <sep> partial response <sep> median time to progression <sep> nausea vomiting and alopecia <sep> myelosuppression <sep>', 'survival <sep> mortality <sep> overall survival and activity index <sep>', 'macroscopic disease left <sep> complete and partial response rates <sep> time to progression and survival <sep> median survival cap <sep>', 'side-effects and haematological toxicity <sep> efficacy and tolerance <sep> median survival <sep> optimal survival with minimal toxicity <sep>', 'overall survival <sep> time to progression and survival <sep> efficacy <sep> pathologic response rate <sep> clinical response rate <sep> myelosuppression particularly thrombocytopenia <sep> toxicity/refusal <sep> toxicity and efficacy <sep>', 'response rate <sep> toxicity deaths <sep> overall toxicity <sep> complete and partial response rate <sep> response rate of ac fu and cy <sep>', 'overall survival <sep> survival <sep> response rates <sep>', 'median duration of crs <sep> overall survival <sep> survival of crs <sep>', 'median survival times <sep> incidence of side effects <sep> response rates <sep>', 'progression free survival <sep> median progression free survival pfs <sep> median survival <sep> leucopenia <sep> nadir blood counts <sep>'], 'punchline_text': ['none of the other parameters showed a statistically significant advantage for combination chemotherapy but the combinations caused more hematologic and gastrointestinal toxicity. <sep>', 'following treatment crossover the relative risk of death associated with original allocation to cbdca receded from 1.79 to 0.97 indicating success of the salvage treatment using the cddp-based regimen. <sep>', 'no significant difference was observed between these two regimens in response rates and no significant differences were noted between the two regimens in each of the clinical toxicities and abnormalities in laboratory findings. <sep>', 'cell differentiation and volume of postoperative disease did not influence response. <sep>', 'there was less thrombocytopenia on the cisplatin arm p less than .001 however there was less nausea and emesis p less than or equal to .001 for courses 1 to 5 renal toxicity p less than .001 anemia p  .01 hearing loss p less than .001 tinnitus p  .01 neuromuscular toxicities p  .001 and alopecia p less than .001 on the carboplatin arm. <sep>', 'a univariate analysis of pretreatment prognostic factors indicated significantly better prognosis p less than 0.02 for patients with no palpable tumor platelet count less than 400,000/mm3 residual tumor less than 2 cm resting pulse less than 91/min. <sep>', 'combination-agent chemotherapy produced a larger proportion of 48-month survivors than single-agent therapy p  0.001 70 of these survivors were clinically free of disease. <sep>', 'survival did not differ between the two arms median survivals of 17.5 months with initial melphalan therapy and 19.5 months with chad probably because women treated initially with melphalan received salvage therapy with had). <sep>', 'the response duration for patients with measurable disease median 14.6 versus 8.8 months progression-free interval for all patients 13.1 versus 7.7 months and survival for patients with measurable disease 19.7 versus 15.7 months showed a statistically significant advantage for cap however there was no difference in survival of patients with nonmeasurable disease. <sep>', 'no statistical difference in median survival was observed between single-drug treatment 12 months and caf 14 months despite the fact that responders lived significantly longer than nonresponders 17 vs 10 months). <sep>', 'there was a strong trend for better survival in stage iii p less than .05 but not in stage iv patients treated with cisplatin alone. <sep>', 'cisplatin was more nephrotoxic while carboplatin induced a higher degree of myelosuppression especially thrombocytopenia however severe hematological toxicity was seldom observed. <sep>', 'patients with stage iv measurable disease had a greater response rate to cmf 22/52 42 versus l-pam 6/39 15%). <sep>', 'crossover due to toxicity was more frequent in the cisplatin than the carboplatin arm occurring in 50 and 3.3 of patients respectively. <sep>', 'no significant differences in response rate time to progression disease-free survival and overall survival were observed between the two treatment arms. <sep>', 'mortality attributed to cancer was slightly lower on arm t p  0.06 but this was offset by the greater toxicity of this regimen and overall survival and activity index were similar on the two arms. <sep>', 'the complete and partial response rates were 45.6 in the cap arm and 45.4 in the ca arm but the cap regimen is of special importance in patients with bulky disease. <sep>', 'no statistically significant difference was found between the two treatments in terms of median survival. <sep>', 'efficacy was similar with no significant differences for the cisplatin and carboplatin arms in clinical response rate 57 v 59 in those with measurable disease pathologic response rate 52 v 54 in those suitable for relaparotomy time to progression median 56 v 58 weeks or overall survival median 100 weeks v 110 weeks). <sep>', 'this response rate was not enhanced by the addition of fu or fu and ac and not substantially different than the response rate of ac fu and cy. <sep>', 'the extent of initial surgery significantly affected the survival of patients receiving prednimustine but not of those receiving combination chemotherapy. <sep>', 'in 1982 a randomized trial was started to compare a cisplatin-containing polychemotherapy cap <sep>', 'the incidence of side effects was significantly higher in the combination-treatment arm. <sep>', 'failure to achieve a significant degree of leucopenia was associated with worse progression free survival p less than 0.001). <sep>'], 'population': ['ovarian carcinoma <sep> 136 evaluable patients without measurable disease by progression-free interval and duration of survival <sep> 97 patients receiving <sep> women with suboptimal greater than or equal to 3 cm residual stage iii stage iv and recurrent ovarian adenocarcinoma <sep> 233 evaluable patients with measurable disease there were 64 treated with <sep>', 'stage iii-iv ovarian carcinoma <sep> 24 patients still receiving <sep> between march 1985 and january 1987 103 women with histologically proven stage iii-iv ovarian carcinoma <sep>', 'ovarian cancer was conducted by a cooperative study group consisting of 22 institutions nationwide <sep> ovarian cancer <sep>', 'patients with ovarian carcinoma figo stages iii and iv <sep> between 1974 and 1982 273 patients with epithelial cancer of the ovary international federation of gynaecology and obstetrics stages iii and iv <sep>', 'southwest oncology group of a phase iii randomized trial in stages iii and iv ovarian cancer <sep> patients with stage iii suboptimal and stage iv ovarian cancer <sep> stage iii suboptimal and stage iv ovarian cancer <sep> three hundred forty-two patients <sep>', 'ovarian carcinoma <sep> advanced ovarian carcinoma <sep> patients with large greater than 2 cm residual disease <sep>', 'four hundred twenty-nine patients were entered into four prospective randomized clinical studies between january 1 1973 and july 1 1979 <sep> ninety-six patients 24 were living at 48 months 89 of whom had second-look laparotomies <sep> advanced epithelial ovarian carcinoma <sep>', 'patients with advanced ovarian carcinoma <sep> 253 patients with advanced epithelial carcinoma of the ovary <sep> women with advanced ovarian cancer <sep> 118 eligible patients initially treated with melphalan and 126 with chad <sep> 18 long term survivors who had retrospective pathologic review 8 had borderline tumors of the ovary <sep> patients with international federation of gynecology and obstetrics figo stage iii or iv carcinoma of the ovary receive treatment with <sep>', 'advanced ovarian carcinoma <sep> 440 evaluable cases of which 227 had measurable disease <sep> women with bulky suboptimal stage iii and stage iv ovarian carcinoma using <sep> one hundred twenty of these latter patients were treated with <sep>', 'from 1977 until 1980 179 patients with newly diagnosed figo stages iib iii or iv ovarian adenocarcinoma <sep> stage iib patients <sep> twenty-three patients were excluded because of protocol violation leaving 156 patients evaluable for survival with an observation period of 3-6 yr <sep> figo stages iib iii and iv ovarian adenocarcinoma <sep> twenty patients were in stage iib while the remaining 136 patients were classified as stages iii and iv <sep>', 'advanced ovarian carcinoma <sep> sixty-one patients with figo stage iii ovarian carcinoma and 30 patients with stage iv ovarian carcinoma <sep>', 'advanced ovarian cancer <sep> patients who cannot be given <sep> one hundred seventy-three patients with advanced epithelial ovarian cancer f.i.g.o. international federation of gynecology and obstetrics stage iii and iv were accrued in the trial <sep> patients with untreated advanced epithelial ovarian cancer <sep>', '413 patients with advanced ovarian carcinoma <sep> patients with ovarian cancer <sep> three hundred seventy-five patients have been analyzed l-pam 190 cmf 185 <sep> one hundred fifty-three patients 41 had measurable disease 109 29 had evaluable disease and 113 30 had nonmeasurable nonevaluable disease <sep>', 'patients who had clinical or radiologic evidence of response after five courses of chemotherapy underwent second-look surgery <sep> patients with advanced ovarian cancer <sep> thirteen patients were excluded from response analyses because they were incorrectly randomized <sep> previously untreated patients with international federation of gynecology and obstetrics stage iii or iv carcinoma of the ovary following surgery <sep> sixty-four patients <sep> advanced epithelial ovarian cancer <sep>', 'advanced ovarian cancer patients <sep> untreated advanced epithelial ovarian cancer <sep> 73 patients were treated with <sep>', 'advanced ovarian cancer <sep> 264 eligible patients with advanced ovarian cancer <sep>', 'advanced ovarian cancer adovca <sep> patients with bulky disease <sep> 149 patients <sep> fifteen patients were not included in the final analysis and the remaining 134 patients <sep>', 'advanced ovarian carcinoma <sep> 135 women with advanced ovarian carcinoma <sep>', 'advanced ovarian cancer <sep> patients had stage iii 82 grade 3 54 tumors with bulky residual greater than 2 cm in 59 and good performance status eastern cooperative oncology group ecog 0 or 1 77 <sep> patients with advanced ovarian cancer <sep> women with postoperative macroscopic residual ovarian cancer <sep> between 1985 and 1989 447 417 eligible patients were randomized <sep>', 'patients with advanced or recurrent stage iii and iv ovarian epithelial carcinoma <sep> women with disseminated or recurrent advanced ovarian cancer with <sep> four hundred and twenty-seven patients were in the study 314 of whom are evaluable for progression-free interval pfi survival and toxicity 102 in regimen <sep>', 'advanced ovarian carcinoma <sep> advanced ovarian cancer <sep> 76 patients with advanced epithelial ovarian carcinoma <sep>', '44 patients undergoing <sep> stage iii-iv epithelial ovarian carcinoma <sep>', 'advanced ovarian cancer <sep> after intensive staging 74 ovarian cancer patients <sep>', 'advanced ovarian cancer <sep> 161 previously untreated patients with figo stage iii or iv epithelial ovarian cancer <sep>'], 'interventions': ['adriamycin and cyclophosphamide <sep> adriamycin plus cyclophosphamide <sep> melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide <sep> melphalan <sep> melphalan plus hexamethylmelamine <sep>', 'cbdca <sep> cyclophosphamide/m2 plus either 60 mg of cisplatin cddp)/m2 or 150 mg of carboplatin cbdca)/m2 <sep> cyclophosphamide <sep> cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin <sep>', 'carboplatin <sep> cisplatin <sep> carboplatin vs cisplatin <sep>', 'i adriamycin plus cisplatin versus cisplatin alone versus thiotepa plus methotrexate <sep> cisplatin <sep> cisplatin plus other drugs cyclophosphamide adriamycin hexamethylmelamine and thiotepa <sep> adriamycin plus cisplatin <sep>', 'carboplatin <sep> carboplatin-cyclophosphamide <sep> cisplatin-cyclophosphamide <sep> cisplatin and carboplatin <sep> cisplatin <sep> cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide <sep> cyclophosphamide <sep> carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide <sep>', 'cyclophosphamide ctx with ctx plus cis-diamminodichloroplatinum ddp <sep> cis-platin ddp and/or bcg to cyclophosphamide ctx chemotherapy <sep>', 'chemotherapy <sep> combination-agent chemotherapy <sep>', 'chad minus the cyclophosphamide had <sep> alkylating agent melphalan <sep> combination chemotherapy <sep> cyclophosphamide hexamethylmelamine doxorubicin and cisplatin chad <sep> cisplatin-based chemotherapy regimen the eastern cooperative oncology group ecog <sep> melphalan versus cisplatin-based combination chemotherapy <sep> melphalan <sep> cisplatin-based combination chemotherapy regimen <sep>', 'cyclophosphamide and doxorubicin with or without cisplatin <sep> cisplatin <sep> doxorubicin adriamycin and cyclophosphamide with or without cisplatin <sep> cyclophosphamide and doxorubicin ca <sep> cyclophosphamide doxorubicin and cisplatin cap <sep>', 'chemotherapy <sep> dihydroxybusulfan b <sep> cyclophosphamide c <sep> doxorubicin 30 mg/m2 and 5-fluorouracil 400 <sep> single agent vs combination chemotherapy <sep> caf <sep> cyclophosphamide <sep>', 'low-dose cisplatin <sep> chlorambucil <sep> cisplatin with low-dose cisplatin and chlorambucil <sep> high-dose cisplatin <sep> cisplatin <sep>', 'carboplatin <sep> cisplatin <sep> carboplatin <sep> cisplatin <sep> cisplatin and carboplatin <sep>', 'cyclophosphamide m methotrexate and f 5-fluorouracil cmf <sep> melphalan l-pam <sep> melphalan with cyclophosphamide methotrexate and 5-fluorouracil <sep> l-pam <sep>', 'carboplatin <sep> cisplatin <sep> single-agent cisplatin and single-agent carboplatin <sep> carboplatin <sep> cisplatin versus carboplatin <sep> cisplatin <sep> cisplatin and carboplatin <sep>', 'carboplatin <sep> carboplatin alone while 57 received the combination chemotherapy <sep> carboplatin alone <sep> carboplatin 300 mg/m2 epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 cb-ec <sep> initial laparotomy and cytoreductive surgery <sep> epirubicin and cyclophosphamide <sep>', 'cyclophosphamide hexamethylmelamine and methotrexate <sep> chemotherapy <sep> continuous oral cyclophosphamide <sep> triple agent cytotoxic therapy <sep>', 'cap <sep> cisplatin p to cyclophosphamide c  adriamycin a <sep> ca <sep> cyclophosphamide doxorubicin and cisplatin cap versus cyclophosphamide and doxorubicin ca <sep>', 'treosulfan plus cisplatinum <sep> treosulfan alone <sep> intravenous treosulfan versus intravenous treosulfan plus cisplatinum <sep>', 'cisplatin <sep> carboplatin-cyclophosphamide <sep> cisplatin-cyclophosphamide <sep> cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide <sep> cisplatin and carboplatin <sep>', '5-fluorouracil fu <sep> i--melphalan mel <sep> dactinomycin ac <sep> melphalan <sep> melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan 5-fluorouracil and dactinomycin <sep>', 'prednimustine with combination chemotherapy <sep> prednimustine <sep> hexamethylmelamine 5-fluorouracil cisplatin and prednimustine or prednimustine alone <sep>', 'cisplatin-containing polychemotherapy cap <sep> exploratory laparotomy or debulking surgery <sep> adriamycin  adm 50 mg/m2 cisplatin  p 50 mg/m2 on day 1 every 21 days with full-dose cisplatin <sep> cyclophosphamide  cpa <sep> cisplatin p versus cyclophosphamide adriamycin and cisplatin cap <sep>', 'ctx <sep> cyclophosphamide versus adriamycin plus cyclophosphamide <sep>', 'carboplatin 400 mg m-2 alone arm a or carboplatin 300 mg m-2 with chlorambucil <sep> carboplatin with chlorambucil and carboplatin <sep> chlorambucil <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",available evidence although not conclusive suggests platinum-based chemotherapy is better than non-platinum therapy. there is some evidence that combination therapy improves survival compared with platinum alone. no difference in effect has been shown between cisplatin and carboplatin.
5,"{'outcomes': ['time taken to attain full enteral feedings of at least 130 ml/kg/d <sep> mean time to attain full enteral feedings <sep> symptoms of gastroesophageal reflux <sep> tolerated <sep> mean birth weight <sep> gestational age at birth <sep> time taken to attain full enteral feedings <sep> gastroesophageal reflux <sep>', 'feed toleration time taken to establish full enteral feeding vomiting prescription of glycerine suppositories and occurrence of necrotising enterocolitis <sep>', 'gastric emptying and characteristics of antroduodenal motor contractions <sep> gastrointestinal function <sep> gastric emptying maturation of gastrointestinal motor patterns and time to achieve full enteral feedings <sep> gastric emptying <sep> feeding outcome <sep> feeding tolerance <sep>', 'time to full feeding <sep> number of withheld feeds <sep> times to full feeding <sep> episodes of sepsis necrotizing enterocolitis and cholestasis <sep> efficacy and safety <sep>', 'time to achieve full feeds <sep> median gestational age birth weight and postnatal age at start of feeds <sep> time to establish full enteral feeds <sep>', 'full enteral feeding earlier <sep> length of time taken to establish full enteral feeding since enrollment <sep> episodes of gastric residuals p<0.05 and shorter duration of parenteral nutrition pn <sep>', 'episodes of large residual gastric aspirates <sep> feed tolerance <sep> necrotizing enterocolitis <sep> total parenteral nutrition or to the time needed to regain birthweight <sep> gastric emptying and feed tolerance <sep>', 'full enteral feeding <sep> cardiac dysrhythmia pyloric stenosis or septicaemia <sep> cholestatic jaundice <sep> gastrointestinal dysmotility <sep>'], 'punchline_text': ['low-dose erythromycin did not reduce the time taken to attain full enteral feedings in preterm infants with very low birth weight and feeding intolerance. <sep>', 'there were no significant differences between the groups for any of the outcomes. <sep>', 'erythromycin a motilin receptor agonist triggers migrating motor complexes and accelerates gastric emptying in adults with feeding intolerance. <sep>', 'times to full feeding were significantly shorter and the number of withheld feeds were significantly less in the em group than the control group the respective medians interquartile ranges were 7 days 6 to 9 days versus 13 days 9 to 15 days <sep>', 'time to achieve full feeds was not significantly different in the two groups. <sep>', 'low-dose enteral erythromycin is associated with better tolerance of feeding and shorter duration of pn in infants 32 weeks gestation. <sep>', 'low-dose erythromycin promoted gastric emptying and feed tolerance in premature infants at a lower gestational age than previously reported. <sep>', 'oral erythromycin is effective in facilitating enteral feeding in preterm very low birthweight infants with moderately severe gastrointestinal dysmotility. <sep>'], 'population': ['1500 g with feeding intolerance <sep> two groups of preterm infants birth weight <sep> preterm infants with very low birth weight and feeding intolerance <sep> preterm infants with feeding intolerance <sep>', 'ventilated infants  31 weeks gestation <sep> preterm infants <sep>', 'adults with feeding intolerance <sep> feeding-intolerant preterm infants <sep> preterm infants with established feeding intolerance <sep> subjects were 27 preterm infants who were admitted to the neonatal intensive care unit and who did not achieve full enteral feeding volumes 150 ml/kg/day within 8 days of the initiation of feedings <sep>', 'preterm infants  35 weeks gestation <sep> 23 preterm infants almost all of whom were  32 weeks gestation <sep> preterm infants with feeding intolerance <sep> preterm infants <sep>', 'preterm neonates <sep> seventy-three consecutive neonates <sep> neonates  32 weeks ready for enteral feeds <sep>', 'younger preterm infants <sep> premature infants <sep> thirty infants <sep> preterm infants <sep> 60 premature infants suffering from feeding intolerance <sep>', 'preterm infants of  or  32 wk gestation <sep> premature infants at a lower gestational age than previously reported <sep> premature infants with established feed intolerance <sep> preterm infants <sep> eligible infants <sep>', 'moderately severe gastrointestinal dysmotility in preterm very low birthweight infants <sep> preterm very low birthweight infants with moderately severe gastrointestinal dysmotility <sep> a tertiary referral centre of a university teaching hospital was conducted on 56 preterm infants  1500 g consecutively admitted to the neonatal unit <sep> preterm infants <sep>'], 'interventions': ['placebo <sep> dextrose placebo <sep> low-dose erythromycin <sep> erythromycin <sep>', 'intravenous erythromycin <sep> erythromycin <sep> erythromycin <sep>', 'intragastric erythromycin or placebo <sep> intragastric erythromycin <sep> erythromycin or placebo <sep> placebo <sep> erythromycin <sep> intragastric erythromycin <sep> erythromycin <sep>', 'em ethyl succinate <sep> placebo <sep> oral em <sep> oral erythromycin <sep> oral erythromycin em <sep>', 'placebo <sep> erythromycin and placebo <sep> erythromycin <sep> oral erythromycin ethyl succinate <sep> oral prophylactic erythromycin <sep> erythromycin <sep>', 'placebo <sep> erythromycin <sep> low-dose enteral erythromycin <sep> placebo normal saline <sep> oral erythromycin <sep> erythromycin <sep>', 'placebo <sep> erythromycin <sep> birthweights erythromycin 1,216 <sep> gestation erythromycin 28.6 <sep> low-dose erythromycin <sep> placebo 1,355 <sep> placebo 29.3 <sep> placebo 3.6 <sep> erythromycin ethylsuccinate or placebo <sep> erythromycin <sep>', 'placebo solution normal saline <sep> placebo <sep> oral erythromycin <sep> oral erythromycin and placebo <sep> oral erythromycin <sep> erythromycin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",there is insufficient evidence to recommend the use of erythromycin in low or high doses for preterm infants with or at risk of feeding intolerance. future research is needed to determine if there is a more precise dose range where erythromycin might be effective as a prokinetic agent in preterm infants 32 weeks ga.
6,"{'outcomes': ['respiratory rate vital capacity peak expiratory volume in the first second pao2 paco2 arterial ph heart rate and systolic and diastolic blood pressure <sep> lung volume <sep> complications <sep> postoperative forced pulmonary volumes <sep> heart and respiratory rate <sep> time of hospitalization <sep>', 'intraoperative decrease in svo2 <sep> svo2 <sep> lowest value of svo2 after extubation <sep>', 'myocardial ischaemia or morbidity <sep> perioperative ischaemia <sep> perioperative myocardial ischaemia <sep> myocardial ischaemia <sep> haemodynamic stability <sep> postoperative ischaemia <sep> intraoperative ischaemia <sep>', 'visual analog pain scores <sep> respiratory inductive plethysmographic data <sep> duration of intensive care unit and hospital stay <sep> postoperative apneas slow respiratory rates desaturation and s-t segment depression <sep> visual analog pain scores <sep>', 'gastric electrical activity and serum gastrin secretion <sep> power ratio postprandial/fasting total power <sep> egg parameters or the serum gastrin integrated value area under the curve auc <sep> gastrin auc <sep> electrogastrographic activity and serum gastrin secretion <sep> frequency of electrical waves tachygastria <sep> gastrin levels <sep> egg activity and serum gastrin secretion <sep> serum gastrin secretion <sep>', 'postoperative hospital length of stay direct medical costs selected postoperative morbidities and postoperative recovery milestones <sep> times to intensive care unit discharge ward admission first bowel sounds first flatus tolerating clear liquids tolerating regular diet and independent ambulation <sep> postoperative outcomes <sep> length of stay and direct medical costs <sep> death myocardial infarction myocardial ischemia reoperation pneumonia and renal failure <sep> shorter time to extubation <sep> postoperative pain scores <sep>', 'total number or type of postoperative complications <sep> intraoperative cardiovascular changes and postoperative complications <sep> blood loss volume replacement or in the number of patients requiring postoperative ventilation <sep> intraoperative vasopressors <sep>', 'incidence of new myocardial infarction stroke and respiratory failure <sep> endotracheal intubation time <sep> intubation time and intensive care stay <sep> perioperative outcome <sep> surgical intensive care stay <sep> incidence of death and major complications <sep> pain relief <sep> postoperative pain relief <sep> analgesic medication <sep> overall incidence of death and major complications <sep> death and major complications <sep> postoperative pain time of ambulation and length of hospital stay <sep>', 'o2 delivery qo2 and consumption vo2 <sep> vo2 during recovery <sep> values of cardiac index ci and qo2 <sep> oxygen supply-demand ratio qo2/vo2 <sep> vo2 ci and mixed venous o2 saturation <sep> systemic hemodynamic function and systemic oxygen supply-demand relationship <sep> cardiac filling pressure and systemic vascular resistance <sep> heart rate <sep>', 'urinary cortisol excretion a marker of the stress response <sep> major infectious complications <sep> surgical risk <sep> overall postoperative complication rate <sep> cardiovascular failure <sep> operative outcome <sep> hospital costs <sep> postoperative morbidity <sep>', 'cardiac index <sep> plasma vasopressin and adrenaline <sep> plasma noradrenaline <sep> hypotensive <sep> cardiovascular and hormonal responses <sep> mean arterial pressure and in calculated systemic vascular resistance <sep> hypotension <sep> hypertension and tachycardia <sep> plasma vasopressin <sep> plasma catecholamines <sep>', 'postoperative myocardial ischemia <sep> myocardial ischemia <sep> early myocardial ischemia <sep> overall incidence of myocardial ischemia <sep> adverse cardiac outcome <sep> postoperative pain control <sep> total duration of ischemia <sep> postoperative myocardial ischemia <sep> myocardial ischemia <sep>', 'analgesic efficacy and side effects <sep> postoperative analgesia <sep> incidence of most side effects <sep> postoperative analgesia at rest and during coughing and movement <sep> pain relief <sep>', 'stress response <sep> length of hospitalization <sep> stress response indices <sep> cortisol epinephrine norepinephrine total catecholamines crp and il-6 in the postoperative period <sep> crp il-1beta il-6 and tnf-alpha levels <sep> serum cortisol epinephrine norepinephrine total catecholamines interleukin il)-1beta il-6 tumor necrosis factor tnf)-alpha and c-reactive protein crp <sep> 72-hour fluid requirement <sep> total operative time <sep> neuroendocrine response <sep> il-1beta and tnf-alpha <sep>'], 'punchline_text': ['postoperative forced pulmonary volumes were higher in the morphine group p less than 0.01). <sep>', 'in group i patients svo2 decreased during surgery to less than 60 n  2 and less than 70 n  4). <sep>', 'combined general and epidural anaesthesia and postoperative epidural analgesia do not reduce the incidence of myocardial ischaemia or morbidity compared with general anaesthesia and postoperative intravenous analgesia. <sep>', 'nurse-administered intravenous morphine and time to tracheal extubation were less in group epi as were visual analog pain scores at rest and after movement from 20 to 48 h. complications and the duration of intensive care unit and hospital stay were comparable. <sep>', 'before surgery no significant difference was found for any of the egg parameters or the serum gastrin integrated value area under the curve auc between the two groups of patients. <sep>', 'postoperative outcomes were similar among the four treatment groups with respect to death myocardial infarction myocardial ischemia reoperation pneumonia and renal failure. <sep>', 'there was no significant difference between groups in regard to blood loss volume replacement or in the number of patients requiring postoperative ventilation. <sep>', 'epidural anesthesia and epidural analgesia improve the overall outcome and shorten the intubation time and intensive care stay in patients undergoing abdominal aortic operations. <sep>', 'at comparable vo2 ci and mixed venous o2 saturation were always less in the tea group than in the nla group. <sep>', 'when compared to control patients patients who received eaa had a reduction in the overall postoperative complication rate p  0.002 and in the incidence of cardiovascular failure p  0.007 and major infectious complications p  0.007). <sep>', 'post-operative hypertension and tachycardia as well as the increase in plasma noradrenaline are prevented by epidural administration of bupivacaine-fentanyl. <sep>', 'in these patients undergoing elective aortic surgery the use of postoperative tea did not result in a lower incidence of early myocardial ischemia compared with intravenous pca with morphine despite better analgesia with tea. <sep>', 'postoperative analgesia with epidural sufentanil or morphine and bupivacaine after major abdominal surgery seemed to be better than the conventional method of im morphine treatment despite optimal administration i.e. fixed doses at fixed intervals with regular adjustments. <sep>', 'all patients showed a significant increase in cortisol epinephrine norepinephrine total catecholamines crp and il-6 in the postoperative period p  0.05). <sep>'], 'population': ['39 patients <sep> patients undergoing aortic surgery <sep>', 'patients undergoing aortic surgery under thoracic epidural anaesthesia <sep> fourteen patients <sep> patients undergoing aortic surgery <sep> aortic surgery <sep>', '9 patients <sep> patients undergoing elective aortic surgery <sep> aortic surgery <sep>', 'versus patient-controlled analgesia following abdominal aortic surgery <sep> forty patients classified as american society of anesthesiologists physical status 2 or 3 received <sep> patients undergoing major vascular surgery <sep> group pca n  21 or <sep>', 'thirty-four patients all males 28 with abdominal aorta aneurysm 6 with obstructive aorto-iliac disease mean age 68+/-7 years <sep> patients subjected to general anesthesia ga vs <sep> elective aortic surgery <sep>', 'patients undergoing surgery of the abdominal aorta thoracic epidural anesthesia combined with a <sep> one hundred sixty-eight patients undergoing surgery of the abdominal aorta <sep> abdominal aortic surgery <sep> patients surviving to discharge <sep> patients undergoing surgery of the abdominal aorta <sep>', 'fifty patients undergoing elective abdominal aortic surgery <sep> abdominal aortic surgery <sep>', '1,021 patients who required anesthesia for one of the intraabdominal aortic gastric biliary or colon operations <sep> patients undergoing abdominal aortic operations <sep>', 'patients undergoing abdominal aortic surgery <sep> one hundred and five patients undergoing abdominal aortic surgery <sep>', '53 patients were admitted to the study 28 received eaa and 25 received <sep> a group of high-risk surgical patients <sep> high-risk surgical patients <sep>', 'patients undergoing abdominal aortic surgery <sep> 20 patients anaesthetized either with <sep>', 'patients undergoing elective aortic surgery <sep> one hundred twenty-four patients <sep> after aortic surgery <sep>', '90 patients undergoing major abdominal surgery <sep> patients undergoing major abdominal surgery <sep>', '39 patients undergoing uncomplicated abdominal aortic replacement <sep> major surgical stress <sep>'], 'interventions': ['morphine <sep> postoperative pain <sep> extradural morphine <sep> intravenous analgesia <sep>', 'mixed venous oxygen saturation svo2 <sep> ephedrine <sep> thoracic epidural anaesthetic with a supplementary general anaesthetic <sep>', 'combined general and epidural anaesthesia and postoperative epidural analgesia <sep> combined general and epidural anaesthesia with postoperative epidural analgesia <sep> epidural/general anaesthesia and epidural analgesia vs general anaesthesia and i.v <sep> general anaesthesia followed by postoperative intravenous analgesia <sep> general anaesthesia and postoperative intravenous analgesia <sep> combined general and epidural anaesthesia and postoperative epidural analgesia <sep> mesenteric traction <sep>', 'epidural morphine and 5 ml 0.25 bupivacaine <sep> bupivacaine with 0.1 morphine <sep> morphine sulfate <sep> nurse-administered intravenous morphine <sep> patient-controlled analgesia pca <sep> pca morphine <sep> epidural bupivacaine-morphine <sep> epidural analgesia <sep> epidural morphine-bupivacaine <sep> general anesthesia plus postoperative pca using morphine sulfate <sep> epidural bupivacaine-morphine analgesia <sep> general anesthesia plus perioperative epidural morphine-bupivacaine <sep>', 'epidural plus general anesthesia vs general anesthesia alone <sep> blended anesthesia ba  ga plus epidural analgesia <sep> ga <sep>', 'general anesthesia alone followed by either intravenous or epidural patient-controlled analgesia <sep> intraoperative anesthesia and postoperative analgesia <sep> light general anesthesia and followed by either intravenous or epidural patient-controlled analgesia <sep> thoracic epidural anesthesia combined with a light general anesthesia or general anesthesia alone intraoperatively and either intravenous or epidural patient-controlled analgesia postoperatively <sep>', 'combined epidural and general anaesthesia versus general anaesthesia <sep> glyceryl trinitrate <sep> combined epidural and general anaesthesia and postoperative epidural analgesia cega or general anaesthesia and postoperative intravenous morphine infusion ga <sep> cega <sep>', 'epidural anesthesia and analgesia <sep> anesthetic and postoperative analgesic techniques <sep> epidural anesthesia and epidural analgesia <sep> general anesthesia and postoperative analgesia with parenteral opioids group 1 or epidural plus light general anesthesia and postoperative epidural morphine <sep>', 'tea <sep> thoracic epidural anesthesia <sep> nla <sep> thoracic epidural anesthesia plus light general anesthesia group tea 2 general anesthesia with halothane group h and 3 neuroleptanalgesia group nla <sep> thoracic epidural anesthesia tea <sep> tea and nla <sep>', 'epidural anesthesia and postoperative analgesia eaa <sep> eaa <sep> epidural anesthesia and analgesia <sep> standard anesthetic and analgesic techniques without eaa <sep>', 'bupivacaine-fentanyl <sep> bupivacaine <sep> isoflurane <sep> reconstructive abdominal aortic surgery <sep> moderate-dose fentanyl 20 micrograms kg-1 combined with isoflurane nitrous oxide and oxygen n  10 or with thoracolumbar epidural bupivacaine combined with isoflurane nitrous oxide and oxygen <sep> thoracolumbar epidural anaesthesia and isoflurane <sep>', 'bupivacaine <sep> tea <sep> fentanyl <sep> postoperative tea <sep> intravenous patient-controlled analgesia pca with thoracic epidural analgesia tea <sep> bupivacaine and fentanyl <sep> pca or tea <sep> epidural analgesia and intravenous patient-controlled analgesia <sep> morphine <sep>', 'bupivacaine <sep> epidural analgesia <sep> n2o/o2 and isoflurane <sep> sufentanil or morphine <sep> epidural sufentanil and morphine <sep> epidural sufentanil or morphine and bupivacaine <sep> epidural sufentanil and morphine <sep> epidural morphine em or sufentanil es both combined with bupivacaine or im morphine im <sep> epidural morphine <sep> iv sufentanil <sep> sufentanil and bupivacaine <sep> intramuscular morphine <sep> sufentanil 10 microg for inadequate analgesia <sep>', 'general anesthesia with postoperative patient-controlled intravenous morphine n  19 or combined regional/general anesthesia with intraoperative epidural catheter anesthesia using bupivacaine to the t4 dermatome level followed by postoperative epidural morphine <sep> epidural anesthesia <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",epidural analgesia provides better pain relief especially during movement in the period up to three postoperative days. it reduces the duration of postoperative tracheal intubation by roughly half. the occurrence of prolonged postoperative mechanical ventilation myocardial infarction gastric complications and renal complications was reduced by epidural analgesia. however current evidence does not confirm the beneficial effect of epidural analgesia on postoperative mortality and other types of complications.
7,"{'outcomes': ['visual acuity <sep> amblyopic eye acuity <sep> visual acuity <sep>', 'contrast sensitivity and slight linear acuity improvement <sep> single letter and linear acuity near and distance and contrast sensitivity <sep>', 'amblyopia <sep> residual visual acuity deficit <sep> visual acuity <sep> amblyopic eye acuity <sep> responder rates <sep>', 'average number of training sessions <sep> resolution of amblyopia <sep> amblyopia <sep> visual acuity <sep> visual acuity contrast sensitivity and resolution of amblyopia <sep> visual acuity <sep> mean time for patching <sep> visual acuity and contrast sensitivity <sep> corrected amblyopic logmar visual acuity and contrast sensitivity function <sep> mean visual acuities of the amblyopic eyes <sep>', 'visual outcome <sep> mean dose rates <sep> visual acuity <sep> visual outcome <sep> mean change in visual acuity of the amblyopic eye <sep>', 'moderate to severe amblyopia <sep>', 'severe amblyopia <sep> visual acuity outcome <sep> amblyopic eye visual acuity <sep> visual acuity <sep>', 'median anisometropia <sep> bcva binocular function and refractive errors <sep> median spherical equivalent refractive error <sep> bcva <sep> 1-year visual acuity outcome <sep> mean time to the resolution of amblyopia <sep> rapid visual acuity recovery <sep> binocular function <sep>'], 'punchline_text': ['visual acuity in the amblyopic eye improved a similar amount in both groups. <sep>', 'experimental and controls results were indistinguishable. <sep>', 'amblyopia improves with optical correction alone in about one fourth of patients aged 7 to 17 years although most patients who are initially treated with optical correction alone will require additional treatment for amblyopia. <sep>', 'amblyopia improved by two or more lines in 20 of 26 76 patients in the perceptual learning group and 26 of 27 96 patients in the patching group p=0.0001). <sep>', 'the mean change in visual acuity of the amblyopic eye was not significantly different p=0.64 between the two groups  <sep>', 'improvement in va of the amblyopic eye from baseline to 5 weeks averaged 1.1 lines in the patching group and 0.5 lines in the control group p  0.006 and improvement from baseline to best measured va at any visit averaged 2.2 lines in the patching group and 1.3 lines in the control group p<0.001). <sep>', 'performing common near activities does not improve visual acuity outcome when treating anisometropic strabismic or combined amblyopia with 2 hours of daily patching. <sep>', 'the median spherical equivalent refractive error increased significantly during the study in the amblyopic eyes p<0.05 and the fellow eyes p<0.001). <sep>'], 'population': ['one hundred seventy-five children younger than 7 years with amblyopia in the range of 20/100 to 20/400 <sep> children younger than 7 years <sep> severe amblyopia in children <sep>', 'amblyopia <sep>', 'children aged 7 to 17 years <sep> 507 patients with amblyopic eye visual acuity ranging from 20/40 to 20/400 were provided with <sep>', 'older children and adult patients with anisometropic amblyopia <sep> patients with anisometropic amblyopia <sep> adults and children by perceptual learning <sep> patients with anisometropic amblyopia <sep>', 'amblyopia <sep> ninety were eligible for occlusion but 10 dropped out in this phase leaving 80 children who were randomised to a prescribed dose rate of six n=40 or 12 n=40 hours a day <sep> younger children <sep> 97 children with a confirmed diagnosis of amblyopia associated with strabismus anisometropia or both <sep> research clinics in two london hospitals <sep>', 'strabismic and anisometropic amblyopia in children <sep> moderate to severe amblyopia in children 3 to 7 years old <sep> one hundred eighty children 3 to 7 years old with best-corrected amblyopic-eye visual acuity va of 20/40 to 20/400 associated with strabismus anisometropia or both who had worn optimal refractive correction if needed for at least 16 weeks or for 2 consecutive visits without improvement <sep>', '425 children aged 3 to 7 years with amblyopia 20/40-20/400 that was caused by anisometropia strabismus or both and that persisted after treatment with spectacles <sep> children aged 3 to less than 7 years <sep> children with severe amblyopia <sep>', 'eighty children mean age 4.4 years with untreated anisometropic amblyopia and a median best-corrected visual acuity bcva in the amblyopic eye of 0.4 logarithm of the minimum angle of resolution logmar <sep> eyes with anisometropic amblyopia <sep> anisometropic amblyopia in children <sep>'], 'interventions': ['patching regimens <sep>', 'cam treatment <sep>', 'atropine <sep> atropine sulfate <sep> amblyopia <sep> optical correction group optical correction alone <sep> patching combined with near visual activities <sep> optical correction alone <sep> optimal optical correction <sep>', 'perceptual learning or patching <sep> perceptual learning <sep> perceptual learning <sep> patching or perceptual learning treatment <sep> perceptual learning and patching <sep> anisometropic amblyopia <sep>', 'wearing glasses refractive adaptation followed by occlusion prescribed patching <sep>', 'daily patching combined with 1 hour of concurrent near visual activities <sep> daily patching <sep>', 'distance activities while patching for amblyopia <sep>', 'anisometropic amblyopia with spectacles or in combination with translucent bangerter filters <sep> spectacles or spectacles in combination with a bangerter filter worn on the spectacle lens of the better eye <sep> spectacle correction alone with spectacle correction with bangerter filters <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",in some cases of unilateral refractive amblyopia it appears that there is a treatment benefit from refractive correction alone. where amblyopia persists there is evidence that adding occlusion further improves vision. despite advances in the understanding of the treatment of amblyopia it is currently still not possible to tailor individual treatment plans for amblyopia. the nature of any dose/response effect from occlusion still needs to be clarified. partial occlusion appears to have the same treatment effect as glasses alone when started simultaneously for the treatment of unilateral refractive amblyopia. treatment regimes for bilateral and unilateral refractive amblyopia need to be investigated further.
8,"{'outcomes': ['wheezing <sep> wheezing score <sep> wheezing respiratory rate retractions and general condition and measured s(po(2 and heart rate <sep> respiratory rate <sep> retractions <sep> average hospital stay <sep> heart rate <sep>', ""intensive care unit admissions artificial ventilation antibiotic treatment description of side effects during procedures and parental perception of comfort <sep> time to recovery defined as 8 hours without oxygen supplementation associated with minimal or no chest recession and ingesting more than two-thirds of daily food requirements <sep> intensive care admission <sep> frequency of vomiting and transient respiratory destabilization <sep> exhalation technique iet and assisted cough ac <sep> child's comfort <sep> ventilatory support <sep> median time to recovery <sep> bradycardia with or without desaturation <sep>"", 'mean length of illness in hospital <sep> mean clinical score for respiratory disability <sep>'], 'punchline_text': ['between the groups at t30 the improvement was significantly better in the new-method-cpt group for overall wang score p  .02 retractions p  .05 respiratory rate p  .001 and heart rate p  .001). <sep>', 'no evidence of differences between groups in intensive care admission rr=0.7 95 ci 0.3-1.8 p=0.62 ventilatory support rr=2.5 95 ci 0.5-13.0 p=0.29 and antibiotic treatment rr=1.0 95 ci 0.7-1.3 p=1.00 was observed. <sep>', 'the treatment group showed a mean clinical score for respiratory disability at admission of 5.56  <sep>'], 'population': ['infants with acute respiratory syncytial virus bronchiolitis <sep> respiratory syncytial virus bronchiolitis in infants <sep> 20 infants mean age 4.2 months into 2 groups 8 patients received <sep> infants with respiratory syncytial virus bronchiolitis <sep>', 'hospitalized infants with bronchiolitis <sep> infants hospitalized with acute bronchiolitis <sep> seven french pediatric departments <sep> 496 infants hospitalized for first-episode acute bronchiolitis between october 2004 and january 2008 <sep> infants without a history of atopy <sep> previously healthy infants hospitalized for a first episode of acute bronchiolitis <sep>', 'acute bronchiolitis <sep> acute bronchiolitis 32 patients <sep>'], 'interventions': ['hypertonic saline <sep> alternative chest physiotherapy method <sep> 27 sessions of nebulization of hypertonic saline <sep> chest physiotherapy cpt secretion clearance method <sep>', 'iet  ac intervention group n=246 or nasal suction ns control <sep> chest physiotherapy iet  ac <sep> iet  ac <sep> chest physiotherapy <sep>', 'chest physiotherapy compared with 16 controls who were not given chest physiotherapy <sep> chest physiotherapy <sep> conventional chest physiotherapy <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",since the last publication of this review new good-quality evidence has appeared strengthening the conclusions of the review. chest physiotherapy does not improve the severity of the disease respiratory parameters or reduce length of hospital stay or oxygen requirements in hospitalised infants with acute bronchiolitis not on mechanical ventilation. chest physiotherapy modalities vibration and percussion or passive expiratory techniques have shown equally negative results.
9,"{'outcomes': ['specific airway conductance <sep> slopes of the salbutamol dose-response curves of specific airway conductance <sep> bronchomotor tone skeletal muscle and the circulatory system <sep> median cumulative salbutamol concentrations <sep> specific airway conductance finger tremor amplitude heart rate and blood pressure <sep>', 'expiratory volume fev1 and maximal midexpiratory flow rate <sep> effect of bronchodilator <sep> overall changes in fev1 <sep> pulmonary function <sep> pulmonary function <sep>', 'airway resistance <sep> hr sbp and dbp 2 h postmedication <sep> beta 1-selectivity <sep> pefr fev1 and vc <sep> awr <sep> awr and increased pefr fev1 and vc <sep> lung function parameters--vital capacity vc airway resistance awr peak expiratory flow rate pefr forced expiratory volume fev1)--at baseline and at predetermined intervals following each medication and salbutamol challenge <sep> heart rate hr systolic blood pressure sbp and diastolic blood pressure dbp <sep> cardiovascular parameters <sep>', 'ventilatory function <sep> forced vital capacity fvc and maximal midexpiratory flow mmef <sep> fev1 <sep>', 'heart rate and systolic blood pressure <sep> fev1 and fvc <sep> lung function heart rate and blood pressure <sep> fev1 and the forced vital capacity fvc <sep>', 'nonspecific bronchial reactivity <sep> histamine bronchial provocation <sep> changes in fev1 <sep> resting heart rate <sep> degree of reactivity with each active drug <sep> bronchial reactivity <sep> resting heart rate and forced expiratory volume in one sec fev1 <sep>', 'ventilatory effect <sep> bronchial obstruction largely <sep> ventilatory function <sep> highest plasma levels <sep> plasma levels <sep>', 'resting or exercise pao2 or paco2 <sep> ventilation <sep> resting minute ventilation <sep> resting heart rate <sep> o2 consumption <sep> exercise tolerance <sep> hyperventilation and exercise tolerance <sep> co2 production <sep> ventilation heart rate and arterial blood gas tensions <sep> time to exhaustion on a cycle ergometer <sep> 12-min walking distance <sep> forced expiratory volume in 1 s and forced vital capacity <sep> heart rate <sep> arterial o2 or co2 tension pao2 and paco2 respectively <sep>', 'lung function <sep> airways obstruction fev1 specific airways resistance <sep> blood pressure <sep> improvement of airflow <sep>', 'peak expiratory flow rate pefr <sep> heart rate hr <sep> vital capacity vc and forced expiratory volume in one second fev1 <sep> fev1 and pefr <sep> ventilatory indices hr or bp <sep> systolic and diastolic blood pressure bp <sep> plasma levels <sep> hr and bp <sep>', 'bronchodilator response <sep> fev1 <sep> respiratory function <sep>', 'bronchoconstrictor response <sep> bronchoconstriction <sep> bronchodilator response <sep> resting pulse rate <sep> 1 cardiovascular and airways response <sep> heart rate <sep>', 'mefv curves <sep> maximal expiratory flow-volume mefv curves <sep> expiratory airflow parameters <sep> lung function <sep> density dependence of expiratory airflow <sep>', 'blood pressure <sep> evening peak flow rate <sep>', 'heart rate and fev1 <sep> cardioselectivity <sep> resting heart rate and fev1 <sep>', 'peak expiratory flow rate pefr <sep> fev1 and in pefr <sep> maximal expiratory flow rates <sep> exercise heart rate <sep> forced expiratory volume <sep> pre and postexercise values of mef50 and mef25 <sep> ventilatory indices <sep> ventilatory effects <sep>', 'fev1 and vital capacity vc <sep> resting heart rate <sep> pulmonary function heart rate and blood pressure <sep> heart rate and fall in diastolic blood pressure <sep> basal forced expiratory volume <sep>', 'bronchial tone <sep> monthly asthma attacks <sep> blood pressure <sep> diastolic blood pressure <sep> fef <sep> average monthly asthma attacks <sep>', 'pulmonary function <sep> overall bronchodilatory effects <sep> changes in forced one-second expiratory volume fev1 and mid-maximal expiratory flow mmef <sep> pulmonary function <sep>', 'ventilatory function <sep> forced vital capacity fvc and maximal midexpiratory flow mmef <sep> dilevalol <sep> fev1 <sep>', 'forced expiratory volume in 1 second and specific airway conductance <sep> forced vital capacity and peak expiratory flow <sep> heart rate blood pressure and derived indexes at peak plasma drug levels <sep> beta-blocking activity <sep>', 'fev1 or forced vital capacity <sep> clinical exam spirometry or ejection fraction <sep> left or right ventricular ejection fraction <sep> baseline forced expiratory volume in 1 second fev1 <sep> cardiac and pulmonary function <sep> dyspnea <sep>', 'mean reduction in resting pulse rate <sep> pulse rate forced expiratory volume in one second fev1 and specific airways conductance <sep> mean plasma levels <sep> resting airways obstruction and reduction in bronchodilator response <sep>'], 'punchline_text': ['the median cumulative salbutamol concentrations causing a 35 increase in tremor were 732 and 706 micrograms for placebo 812 and 1213 micrograms for metoprolol and 797 and 1323 micrograms for atenolol.(abstract truncated at 250 words <sep>', 'changes in one-second forced expiratory volume fev1 and maximal midexpiratory flow rate fef25-75 prior to albuterol or isoproterenol were positive after placebo and both doses of celiprolol. <sep>', 'all active treatments produced only small nonsignificant reductions in pefr fev1 and vc compared with baseline without any significant differences between the four groups. <sep>', 'the effects of the three treatments on forced vital capacity fvc and maximal midexpiratory flow mmef were qualitatively similar to those observed in fev1. <sep>', 'there was no significant difference between the effects of atenolol and xamoterol of fev1 and fvc. <sep>', 'following each active drug resting heart rate changed to a similar extent and to a greater degree than after placebo p less than 0.01). <sep>', 'after administration of 200 mg in slow-release tablets the plasma levels were lower and the ventilatory effect was less marked. <sep>', 'metoprolol reduced heart rate by 14 p less than 0.001 and ventilation by 11 p less than 0.01 but there was no significant difference in arterial o2 or co2 tension pao2 and paco2 respectively). <sep>', 'following salbutamol labetalol was associated with a significantly greater improvement of airflow than either propranolol or metoprolol. <sep>', 'both beta-blockers in all the doses given caused a significant decrease in peak expiratory flow rate pefr). <sep>', 'unlike propranolol and oxprenolol which significantly reduced fev1 and inhibited the bronchodilator response to inhaled salbutamol atenolol and celiprolol did not significantly affect respiratory function and did not antagonize salbutamol effects. <sep>', 'in the remaining five patients bronchoconstriction was greatest following propranolol mean reduction in fev1 26.6 and least following atenolol mean reduction in fev1 6.5%). <sep>', 'inhalation of terbutaline to a cumulative dose of 2.0 mg induced a stepwise improvement in expiratory airflow parameters for large and small airways function when breathing air. <sep>', 'atenolol caused significantly p less than 0.05 less bronchospasm in terms of fewer asthmatic attacks more asthma-free days less frequent sensations of moderate to very severe wheeziness and less effect on the evening peak flow rate. <sep>', 'both atenolol and metoprolol lowered resting heart rate and fev1 <sep>', 'bevantolol significantly decreased the forced expiratory volume in 1 second fev1 and the peak expiratory flow rate pefr at rest while there was no such change with placebo or atenolol. <sep>', 'both beta-blockers reduced the basal forced expiratory volume in one second fev1 and the effect tended to be more pronounced after propranolol. <sep>', 'monthly asthma attacks increased by more than 100 in five patients on celiprolol and four on chlorthalidone. <sep>', 'celiprolol 400 mg and 600 mg neither caused bronchoconstriction nor antagonized albuterol in this acute study. <sep>', 'both dilevalol and metoprolol similarly and significantly p less than or equal to 0.01 inhibited the isoproterenol 160 and 480 micrograms response in fev1 as compared to placebo.(abstract truncated at 250 words <sep>', 'both metoprolol and atenolol significantly reduced forced vital capacity and peak expiratory flow with no difference between drugs. <sep>', 'compared to placebo metoprolol did not significantly affect fev1 or forced vital capacity. <sep>', 'mean reduction in resting pulse rate was statisitcally greater after acebutolol compared with placebo but not after practolol compared with placebo. <sep>'], 'population': ['hypertensive asthmatic patients <sep> 18 hypertensive asthmatic patients forced expiratory volume in 1 second  50 predicted diastolic blood pressure  90 mm hg <sep>', '34 asthmatic patients <sep> asthmatic patients <sep>', '12 hypertensive asthmatic patients <sep> hypertensive asthmatics <sep>', '18 patients with reversible bronchial asthma isoproterenol-induced increase in forced expiratory volume in 1 second fev1 of greater than or equal to 15 <sep> patients with bronchial asthma <sep> patients with concomitant bronchial asthma <sep>', 'asthmatic patients <sep> 11 patients with asthma <sep>', '12 mild asthmatics <sep>', 'eight asthmatic patients in relation to the plasma level of the agent following its administration in ordinary and slow-release tablets <sep> patients with obstructive lung disease <sep> asthmatic patients <sep>', 'emphysema <sep> 12 patients with emphysema <sep> 10 patients with emphysema after intravenous <sep>', 'chronic airway obstruction <sep> patients with obstructive airways disease <sep> patients with chronic airflow obstruction using a double-blind trial <sep>', '8 asthmatic patients <sep> asthmatic patients <sep>', 'ten asthmatic patients all males aged 50-66 years were studied <sep> hypertensive patients with chronic obstructive lung disease <sep>', 'twelve patients with asthma <sep> patients with asthma <sep>', 'asthmatic patients <sep>', '14 hypertensive patients with asthma involving <sep> patients with asthma who require beta blockade <sep>', 'asthmatic patients <sep> eight asthmatic patients <sep>', 'asthma <sep> patients with asthma <sep> healthy subjects <sep>', 'asthmatics <sep>', 'patients with asthma and hypertension <sep> hypertensive patients with reversible bronchial obstruction <sep> 66 patients <sep>', 'sixteen normotensive asthmatic patients <sep> asthmatic patients <sep>', 'asthmatics <sep> 16 patients with reversible bronchial asthma isoproterenol-induced increase in forced expiratory volume in 1 s fev1 of greater than or equal to 15 <sep>', '12 patients with reversible obstructive airway disease <sep>', 'chronic obstructive pulmonary disease <sep> 6 patients with chronic reversible airways obstruction and no cardiac dysfunction <sep> stable patients with chronic reactive airways disease <sep>', 'airways obstruction in asthmatics <sep>'], 'interventions': ['placebo <sep> inhaled salbutamol <sep> metoprolol <sep> atenolol <sep> atenolol and placebo <sep> salbutamol <sep>', 'placebo <sep> atenolol <sep> celiprolol 200 and 400 mg propranolol 40 mg and atenolol <sep> propranolol <sep> celiprolol atenolol and propranolol <sep> albuterol or isoproterenol aerosol <sep> propranolol <sep> atenolol and propranolol celiprolol <sep>', 'placebo <sep> cardioselective <sep> bisoprolol <sep> atenolol <sep> bisoprolol <sep> atenolol and placebo <sep> salbutamol <sep>', 'labetalol and isoproterenol <sep> labetalol <sep> labetalol <sep> isoproterenol <sep> labetalol metoprolol and placebo <sep> metoprolol <sep>', 'atenolol 50 mg and xamoterol <sep> atenolol <sep> 2-adrenoceptor agonist terbutaline <sep> xamoterol and atenolol <sep> atenolol <sep>', 'placebo <sep> propranolol <sep> inhaled histamine <sep> timolol <sep> metoprolol <sep>', '1-selective adrenoceptor blocker metoprolol <sep> metoprolol <sep> placebo <sep> metoprolol <sep>', 'beta-adrenergic blockade <sep> placebo <sep> atenolol <sep> atenolol and metoprolol <sep> metoprolol <sep> metoprolol <sep>', 'salbutamol labetalol <sep> labetalol <sep> labetalol atenolol or metoprolol <sep> propranolol <sep> adrenergic receptor blockers propranolol atenolol metoprolol <sep> propranolol <sep> labetalol beta blockers <sep> metoprolol <sep>', 'placebo <sep> bisoprolol and metoprolol <sep> 1-selective receptor blockers bisoprolol emd 33512 and metoprolol <sep> 2-adrenoceptor agonist terbutaline <sep> terbutaline <sep> bisoprolol 20 mg and metoprolol <sep> metoprolol <sep>', 'beta-blockers with different ancillary properties propranolol <sep> celiprolol propranolol oxprenolol and atenolol <sep> placebo <sep> oxprenolol <sep> atenolol <sep> celiprolol <sep> atenolol beta 1 selective and celipropol beta 1 selective with mild beta 2-agonist and alpha 2-antagonist activity <sep> propranolol <sep> propranolol and oxprenolol <sep>', 'acebutolol and atenolol <sep> propranolol and pindolol <sep> cardioselective beta-adrenoceptor blocking drugs acebutolol <sep> atenolol <sep> propranolol <sep> inhaled isoprenaline <sep> isoprenaline <sep> propranolol and pindolol with partial agonist activity <sep> beta-adrenoceptor antagonists <sep>', 'inhaled terbutaline <sep> terbutaline <sep> atenolol <sep> terbutaline and atenolol <sep>', 'atenolol 100 mg once daily and metoprolol 100 mg bid atenolol and metoprolol <sep> placebo <sep> atenolol <sep> atenolol <sep>', 'metoprolol and placebo <sep> terbutaline <sep> atenolol <sep> atenolol and metoprolol <sep>', 'bevantolol and 100 mg atenolol <sep> placebo <sep> atenolol <sep> atenolol and bevantolol <sep> 2-adrenoceptor agonist terbutaline <sep> terbutaline <sep>', 'placebo <sep> propranolol <sep> isoprenaline <sep> selective beta1-receptor antagonist metoprolol <sep> isoprenaline <sep> propranolol and metoprolol <sep> metoprolol <sep>', 'chlorthalidone <sep> placebo <sep> celiprolol <sep> celiprolol <sep> celiprolol and chlorthalidone <sep>', 'placebo <sep> celiprolol 400 mg placebo and atenolol <sep> celiprolol <sep> atenolol <sep> celiprolol 400 mg and 600 mg neither caused bronchoconstriction nor antagonized albuterol <sep> celiprolol and 100 mg of atenolol <sep>', 'placebo <sep> dilevalol <sep> dilevalol metoprolol and placebo <sep> isoproterenol <sep> metoprolol <sep>', 'placebo <sep> metoprolol and atenolol <sep> inhaled salbutamol <sep> atenolol <sep> metoprolol oral osmotic oros <sep> metoprolol oros and atenolol <sep> atenolol <sep> metoprolol <sep>', 'placebo metoprolol <sep> metoprolol <sep> oral metoprolol <sep> metoprolol <sep>', 'acebutolol sectral and practolol eraldin <sep> placebo <sep> practolol <sep> acebutolol <sep> acebutolol practolol or placebo <sep> oral practolol eraldin i.c.i. ltd <sep> acebutolol sectral may  baker ltd <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",cardioselective beta-blockers given in mild to moderate reversible airway disease or copd do not produce adverse respiratory effects. given their demonstrated benefit in conditions such as heart failure cardiac arrhythmias and hypertension these agents should not be withheld from such patients. long-term safety still needs to be established.
10,"{'outcomes': ['systolic blood pressure <sep> heart rate <sep> nyha functional class <sep>', 'pulmonary oedema <sep> pulmonary oedema of breathlessness <sep>', 'diuretic therapy <sep> blood pressure <sep> ankle oedema <sep> plasma potassium levels <sep> plasma urea <sep>', 'visual analogue scores for dyspnoea fatigue and general well-being <sep> symptom-limited exercise tolerance <sep> perceived exertion during submaximal exercise <sep> time taken to walk 100 m at a self-selected slow speed <sep>', 'exercise tolerance <sep>', 'occasional kaliuretic response <sep> serum creatinine levels <sep> mild hypokalemia <sep> 24-hour urinary potassium excretion <sep> bun <sep> blood physical ecg and audiometric examinations <sep> new york heart association functional class status <sep>', 'hemodynamics <sep> right-sided and pulmonary artery wedge pressures and systemic arterial pressures <sep> right-sided pulmonary arterial wedge pressure or cardiac outputs <sep>', 'diastolic pressure <sep> systolic blood pressure <sep> heart failure <sep> blood pressure to hypertensive values <sep>', 'ventricular arrhythmias on 24-hour ambulatory electrocardiography <sep> 24-hour urinary sodium excretion <sep> urinary sodium/potassium ratio <sep> cardiac norepinephrine uptake <sep> plasma magnesium <sep> cardiac sympathetic activity and increased ventricular arrhythmias <sep> reduced urinary magnesium excretion <sep> plasma renin activity plasma aldosterone <sep> myocardial norepinephrine uptake <sep> echocardiographic-determined measurements of left ventricular systolic and diastolic function <sep>', 'pulmonary wedge pressure <sep> pulmonary artery pressure on exercise <sep> cardiac output <sep> heart size and echocardiographically measured ventricular volume <sep> pulmonary wedge pressure <sep> pulmonary arterial pressure <sep>'], 'punchline_text': ['both drugs were well tolerated and both caused a similar reduction in systolic blood pressure. <sep>', 'although 10 patients remained stable on captopril alone 4 patients deteriorated with the development of pulmonary oedema of breathlessness. <sep>', 'blood pressure rose slightly in the placebo group and plasma urea rose slightly in the diuretic group. <sep>', 'the higher dose of frusemide also had a more favourable effect on visual analogue scores for dyspnoea fatigue and general well-being. <sep>', 'statistically significant clinical improvement occurred in both treatment groups. <sep>', 'however there was no significant increase in serum creatinine levels. <sep>', 'at rest there were no significant differences in the right-sided pulmonary arterial wedge pressure or cardiac outputs between the patients on amiloride a versus placebo p). <sep>', 'during follow up diuretic therapy was required in 50 patients in the withdrawal group and 13 in the control group risk difference 36 95 confidence interval 22 to 50%). <sep>', 'spironolactone also elevated plasma magnesium p  0.05 reduced urinary magnesium excretion p  0.05 and caused a reduction in ventricular arrhythmias on 24-hour ambulatory electrocardiography p  0.05). <sep>', 'cardiac output decreased at rest but not significantly and on exercise not at all. <sep>'], 'population': ['symptomatic mild heart failure <sep> patients with symptomatic nyha functional class 2 mild heart failure <sep>', 'mild heart failure <sep> 14 patients who had previously been treated with diuretics <sep> patients with mild heart failure and a history of overt pulmonary oedema <sep>', '141 elderly patients in the long-stay wards of six hospitals were found to be taking maintenance diuretics and for 33 of these the drugs were judged to be mandatory <sep> old people receiving long-term <sep> elderly <sep>', 'moderate heart failure <sep> patients with heart failure <sep> ten patients with moderate heart failure who still had symptoms despite 40 mg <sep>', 'moderate but deteriorating heart failure <sep> thirteen patients completed the 3 months study two dropped-out in the frusemide group <sep> 15 patients with moderate congestive heart failure not completely controlled on <sep>', 'patients with mild to moderately severe congestive heart failure <sep>', 'eleven men with a history of congestive heart failure <sep> patients taking digoxin for chronic heart failure <sep> patients with chronic congestive heart failure treated with chronic digoxin and diuretics <sep>', 'elderly patients <sep> 202 patients taking long-term diuretics without manifest heart failure or hypertension <sep>', '42 patients with new york heart association ii to iii congestive heart failure <sep> chronic congestive heart failure secondary to coronary artery disease <sep>', 'chronic heart failure <sep> sixteen patients in heart failure and sinus rhythm were after a four-week treatment-free period <sep>'], 'interventions': ['angiotensin-converting enzyme inhibitor benazepril <sep> benazepril and hydrochlorothiazide <sep> benazepril <sep> benazepril <sep> hydrochlorothiazide <sep>', 'captopril <sep> captopril alone against frusemide plus amiloride <sep> captopril <sep> frusemide and amiloride <sep> angiotensin converting enzyme inhibition alone <sep>', 'placebo <sep> diuretic therapy <sep> placebo tablets <sep> diuretics <sep> discontinuing long-term diuretic therapy <sep>', 'captopril <sep> diuretics and captopril <sep> frusemide <sep>', 'captopril <sep> frusemide <sep> digoxin <sep> diuretics <sep>', 'piretanide <sep> placebo <sep> piretanide <sep>', 'placebo <sep> amiloride <sep> potassium-sparing diuretics <sep> swan-ganz catheter was placed in the pulmonary artery and measurements made at rest and with increasing degrees of supine bicycle exercise <sep> digoxin alternating placebo with amiloride <sep> placebo p and amiloride <sep> amiloride <sep> digoxin <sep>', 'diuretic therapy <sep> placebo withdrawal group n  102 or continuation of diuretic treatment control group n  100 <sep> withdraw diuretic therapy <sep> withdrawal of long-term diuretic medication <sep>', 'aldosterone antagonist spironolactone <sep> spironolactone <sep> angiotensin-converting enzyme inhibitor <sep> blood pressure and plasma potassium or placebo <sep> angiotensin-converting enzyme ace inhibitor <sep> exogenous aldosterone <sep> spironolactone <sep>', 'diuretics <sep> diuretic combination hydrochlorothiazide  triamterene or a digitalis glycoside <sep> diuretic <sep> digitalis or diuretics <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",the available data from several small trials show that in patients with chronic heart failure conventional diuretics appear to reduce the risk of death and worsening heart failure compared to placebo. compared to active control diuretics appear to improve exercise capacity.
11,"{'outcomes': ['morbidity and mortality rates <sep> alive without bpd <sep> major dosing complications <sep> death at day 28 and 36 weeks postmenstrual age pma air leaks neuroimaging abnormalities and other complications related to either prematurity or rds <sep> incidences of common complications of prematurity including intraventricular hemorrhage grades 3 and 4 and cystic periventricular leukomalacia <sep> corresponding mortality rate <sep> excess mortality rates <sep> incidence of being alive without bronchopulmonary dysplasia bpd <sep> efficacy and safety <sep>', 'incidence of rds <sep> bpd <sep> incidence of bpd <sep> air leaks and causes of death <sep> mortality rates bronchopulmonary dysplasia bpd rates and rates of other complications of prematurity <sep> mortality rate <sep> rds-related mortality rates <sep> rates of rds at 24 hours and the rates of death related to rds <sep> efficacy and safety <sep>'], 'punchline_text': ['the corresponding mortality rate through day 28 for the lucinactant group was lower than that for the poractant alfa group 11.8 95 ci 6.0-17.6 vs 16.1 95 ci 9.7-22.6 as was the rate at 36 weeks pma 16 and 18.5 respectively). <sep>', 'lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of rds. <sep>'], 'population': ['premature infants treated with <sep> 252 infants born between 24 and 28 weeks of completed gestation with birth weights between 600 and 1250 g <sep> very premature infants at high risk for respiratory distress syndrome <sep> preterm infants <sep>', '1294 very preterm infants weighing 600 to 1250 g and of  or 32 weeks gestational age <sep> preterm infants at risk for rds <sep> n  509 lucinactant n  527 or beractant n  258 within 20 to 30 minutes after birth <sep> very preterm infants <sep>'], 'interventions': ['lucinactant <sep> placebo <sep> poractant alfa <sep> lucinactant versus poractant alfa <sep> lucinactant and poractant alfa <sep>', 'synthetic surfactant colfosceril palmitate glaxosmithkline <sep> colfosceril palmitate <sep> novel synthetic surfactant <sep> lucinactant colfosceril palmitate and beractant <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>']}",in two trials of protein containing synthetic surfactants compared to animal derived surfactant extract no statistically different clinical differences in death and chronic lung disease were noted. in general clinical outcomes between the two groups were similar. further well designed studies of adequate size and power will help confirm and refine these findings.
12,"{'outcomes': ['muscular power muscle state muscular functional ability vignos serum myoglobin and serum creative phosphokinase <sep>', 'muscle power functional ability locomotor score contractures and forced vital capacity <sep>', 'satisfactory blood levels <sep> flushing dizziness and leg edema <sep> muscle strength contractures functional ability cardiopulmonary changes and laboratory data <sep>', 'muscular x-ray density <sep> number of calcium-positive muscular fibres <sep>'], 'punchline_text': ['no significant difference was detected between the two groups regarding muscular power muscle state muscular functional ability vignos serum myoglobin and serum creative phosphokinase. <sep>', 'at monthly intervals muscle power functional ability locomotor score contractures and forced vital capacity were measured by a team not involved in clinical care. <sep>', 'the study had a power greater than 0.99 to detect a slowing of the illness to 25 of its original rate of progression. <sep>', 'compared with before therapy the number of calcium-positive muscular fibres was remarkably reduced in the treated dmd patients but not in the placebo group. <sep>'], 'population': ['17 patients in the <sep> duchenne muscular dystrophy <sep>', 'twenty-seven boys with duchenne muscular dystrophy dmd <sep> duchenne muscular dystrophy <sep>', 'one hundred and five patients <sep>', '13 dmd patients aged from 3-10 years mean 7 years <sep> 26 patients of the study and 20 additional dmd patients who were treated with <sep> 46 untreated dmd patients of the same age and stage in our department <sep> duchenne dystrophy <sep>'], 'interventions': ['calcium channel blocker diltiazem <sep> placebo <sep> diltiazem <sep>', 'flunarizine <sep> calcium antagonist flunarizine <sep>', 'calcium channel blocking agent nifedipine <sep> placebo <sep> nifedipine <sep>', 'placebo <sep> diltiazem <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",there is no evidence to show a significant beneficial effect of calcium antagonists on muscle function in dmd.
13,"{'outcomes': ['intensity of pain <sep> change of pain <sep> visual analogue pain scale <sep> intensity of low back pain and abdominal pain <sep>', 'operative delivery <sep> vas score reduction <sep> rate of vas score <sep> pain relief <sep> pain <sep> pain relief <sep> visual analogue scale vas <sep>', 'pain relief <sep> degree of pain relief <sep> duration of labor <sep>', 'quality or duration of labour analgesia <sep> duration of the spinal portion of the cse <sep> pain vas sensory level pinprick motor blockade bromage cervical dilatation and duration of analgesia and at delivery on fetal and neonatal outcome <sep> analgesia <sep>', 'operative delivery rate <sep> pain concept or relief <sep> pain relief <sep>', 'quality of analgesia <sep> visual analog scale vas sensory level pinprick motor blockade bromage score cervical dilation and duration of analgesia <sep> epidural labor analgesia <sep> kaplan-meier survival analysis and mantel-cox log rank analysis <sep> duration of analgesia <sep>', 'pain relief <sep> pain <sep> relief of pain <sep> labour pain <sep> analgesic effects <sep>', 'apgar score assays of blood samples from the umbilical vein including blood lactate plasma hypoxanthine and blood gas and neurobehavioral assessment <sep> course of labor uterine activity and fetal heart patterns <sep> minimal or moderate low-back pain <sep> pain relief <sep> low-back and suprapubic pain <sep> suprapubic pain <sep> pain component <sep> intensity of low-back pain <sep>', 'back pain <sep> mean pain intensity <sep> labour agentry scale and the labor and delivery satisfaction index <sep> level of control and satisfaction with labor and delivery <sep> unpleasantness <sep> intensity and unpleasantness of pain <sep>', 'pain <sep> pain relief amount of administered analgesics obstetrical and neonatal outcome and side effects <sep> relieving pain <sep> number of requests for pethidine/promethazine <sep>'], 'punchline_text': ['there was no difference in the intensity of pain recorded by each group. <sep>', 'tens group experienced vas score reduction 3 significantly more common than the tens placebo group 31/50 62 vs 7/50 14 p<0.001). <sep>', 'there was no difference between the two groups in the degree of pain relief. <sep>', 'in healthy labouring parturients the application of a tens unit did not alter the quality or duration of labour analgesia provided by the spinal portion of cse analgesia. <sep>', 'although the outcome of labour for mother and infant were similar in the two groups there was a higher operative delivery rate in women who also had epidural analgesia. <sep>', 'the duration of analgesia produced by the initial dose of epidural bupivacaine did not differ between groups tens turned off 82.3  <sep>', 'there was no significant difference between the placebo unspecific tns and control groups as regarded the increase in pain during the test period. <sep>', 'all newborn infants were in good condition and no significant differences between the two groups could be demonstrated. <sep>', 'mean pain intensity at 15 and 60 minutes after randomization was significantly reduced in the isw group compared with the 2 other groups. <sep>', 'no significant differences occurred between groups in the number of requests for pethidine/promethazine. <sep>'], 'population': ['pain relief in labour <sep> pain relief in labour was evaluated by randomizing 280 patients in early labour into 2 groups <sep>', 'first stage of labor <sep> randomly assigned healthy full-term parturients in active phase of first-stage labor to either <sep> one hundred women were eligible for analysis <sep>', 'seventy parturient women <sep> pain relief during labor <sep>', 'forty parturients in active spontaneous labour with a singleton vertex term fetus requesting analgesia <sep> healthy labouring parturients <sep>', '100 primigravidae and 50 women in their third labour <sep>', 'tertiary-care academic medical center <sep> 26 <sep> 40 asa physical status i and ii parturients in early active spontaneous labor with a singleton vertex term fetus and requesting analgesia <sep> healthy laboring parturients <sep>', 'in childbirth <sep> 10-th 12 one group of 5 had unspecific <sep> 30 parturient women during the first stage of labour <sep>', 'newborn infant <sep>', '34 women suffering from low back pain during labor <sep> low back pain during labor <sep>', 'forty-six patients during the first stage of labour were treated with tens and 48 with a placebo apparatus <sep>'], 'interventions': ['tens <sep> transcutaneous nerve stimulation tens <sep> transcutaneous electrical nerve stimulation <sep>', 'placebo <sep> transcutaneous electrical nerve stimulation tens <sep> tens on four acupuncture points hegu li 4 and sanyinjiao sp 6 n=52 or the tens placebo <sep> transcutaneous electrical nerve stimulation tens <sep> tens <sep> tens placebo <sep>', 'transcutaneous nerve stimulation the other mock stimulation with an identical looking apparatus <sep> transcutaneous nerve stimulation <sep>', 'combined spinal epidural technique cse <sep> standardized cse with either an active or inactive tens unit <sep> transcutaneous electrical nerve stimulation <sep> transcutaneous electrical nerve stimulation tens <sep>', 'tens/tens placebo <sep> tens <sep> transcutaneous electrical nerve stimulation tens <sep> tens or tens placebo <sep>', 'bupivacaine <sep> epidural bupivacaine <sep> transcutaneous electrical nerve stimulation tens <sep> transcutaneous electrical nerve stimulation <sep>', ""tns <sep> tns pethidine and placebos <sep> pethidine <sep> transcutaneous nerve stimulation tns pethidine and placebos author's transl <sep>"", 'transcutaneous electrical nerve stimulation tns <sep> tns nor nitrous oxide-oxygen mixture and pethidine <sep> transcutaneous electrical nerve stimulation <sep> control group not receiving tns <sep> tns <sep>', 'nonpharmacologic approaches <sep> tens <sep> intracutaneous sterile water injections isw 2 transcutaneous electrical nerve stimulation tens and 3 standard care including back massage whirlpool bath and liberal mobilization <sep> transcutaneous electrical nerve stimulation <sep>', 'placebo <sep> transcutaneous electrical nerve stimulation tens <sep> tens <sep> transcutaneous nerve stimulation tens <sep> tens and placebo <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>']}",there is only limited evidence that tens reduces pain in labour and it does not seem to have any impact either positive or negative on other outcomes for mothers or babies. the use of tens at home in early labour has not been evaluated. tens is widely available in hospital settings and women should have the choice of using it in labour.
14,"{'outcomes': ['cbz concentration <sep> cbz dosage reductions <sep> plasma cbz concentration <sep>'], 'punchline_text': ['cbz dosage reductions ranging from 14 to 50 were required by 63 of patients who received rem. <sep>'], 'population': ['patients with refractory epilepsy <sep> refractory epilepsy <sep> patients taking <sep>'], 'interventions': ['cbz <sep> remacemide hydrochloride <sep> carbamazepine <sep> carbamazepine cbz <sep> remacemide hydrochloride rem <sep>'], 'punchline_effect': [' sig increase <sep>']}",given the modest effect on seizure frequency and significant withdrawal rate it is unlikely that remacemide will be further developed as an antiepileptic drug.
15,"{'outcomes': ['recurrence rates <sep> clinical activity index cai and endoscopic index ei <sep>'], 'punchline_text': ['recurrence rates evaluated on the basis of intention to treat showed significant difference between curcumin and placebo p=.049). <sep>'], 'population': ['eighty-nine patients with quiescent uc <sep> ulcerative colitis <sep> patients with ulcerative colitis uc <sep> patients with quiescent ulcerative colitis uc <sep> patients with quiescent uc <sep>'], 'interventions': ['placebo <sep> placebo plus sz or mesalamine <sep> curcumin 1g after breakfast and 1g after the evening meal plus sulfasalazine sz or mesalamine <sep> curcumin <sep> curcumin maintenance therapy <sep> sz or mesalamine <sep>'], 'punchline_effect': [' no diff <sep>']}",curcumin may be a safe and effective therapy for maintenance of remission in quiescent uc when given as adjunctive therapy along with mesalamine or sulfasalazine. however further research in the form of a large scale methodologically rigorous randomized controlled trial is needed to confirm any possible benefit of curcumin in quiescent uc.
16,"{'outcomes': ['psychosocial functioning prophylaxis against recurrences of mood episodes or compliance with pharmacotherapy <sep> rate of recovery from mood episodes of bipolar i disorder <sep>', 'depressive and anxiety symptoms and family conflict <sep>'], 'punchline_text': ['neither adjunctive family therapy nor adjunctive multifamily psychoeducational group therapy significantly improves the rate of recovery from mood episodes of bipolar i disorder compared to treatment with pharmacotherapy alone. <sep>', 'at post-treatment 81 of the patients treated with abft no longer met criteria for mdd in contrast with 47 of patients in the waitlist group. <sep>'], 'population': ['ninety-two patients meeting criteria for a current bipolar i mood episode <sep>', 'depressed adolescents <sep> the sample was 78 female and 69 african american 69 were from low-income inner-city communities <sep> 32 adolescents meeting criteria for major depressive disorder mdd <sep>'], 'interventions': ['family therapy plus pharmacotherapy multifamily psychoeducational group therapy plus pharmacotherapy or pharmacotherapy alone <sep>', 'attachment-based family therapy abft <sep> attachment-based family therapy <sep> abft <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>']}",the current evidence base is too heterogeneous and sparse to draw conclusions on the overall effectiveness of family therapy in the treatment of depression. at this point use of psychological interventions for the treatment of depression for which there is already an evidence-base would seem to be preferable to family therapy. further high quality trials examining the effectiveness and comparative effectiveness of explicitly defined forms of family therapy are required.
17,"{'outcomes': ['renin activity and lower levels of angiotensin-ii and aldosterone <sep> hemodynamics levels of atrial and brain natriuretic peptides bnp angiotensin-ii and aldosterone renin activity and left ventricular lv function <sep> incidence of postoperative ventricular arrhythmia and the postoperative peak level of creatine kinase-mb <sep> postoperative lv remodeling <sep> lv function <sep>', 'urine output <sep> bleeding volume homologous blood transfusion volume furosemide dose and corrected kcl volume <sep> hemodynamics urine output intensive care unit icu and hospital stay bleeding volume homologous blood transfusion volume furosemide dose corrected kcl volume and postoperative respiratory hepatic and renal function <sep>', 'serum creatinine and urea <sep> renal function <sep> preoperative median serum creatinine <sep> incidence of postoperative hemodialysis <sep>', 'ccr <sep> dialysis <sep> creatinine clearances ccr <sep> age sex etiology of arf entry serum creatinines scr <sep> mortality rates <sep>', 'plasma renin-activity <sep> postoperative hypertension and renal dysfunction <sep> delayed hypertension ht and renal dysfunction rd <sep>', 'postoperative brain natriuretic peptide <sep> incidence of postoperative arrhythmias <sep> free-rate of cardiac events <sep> postoperative peak levels of creatine kinase-mb <sep>', 'fractional sodium excretion <sep> plasma anp levels <sep> systemic vascular resistance <sep> plasma cyclic guanosine monophosphate levels urine output and fractional sodium excretion and decreased preload afterload and plasma brain natriuretic peptide levels <sep> plasma cyclic guanosine monophosphate levels <sep> natriuresis and systemic vasodilation <sep> plasma anp brain natriuretic peptide and cyclic guanosine monophosphate cgmp levels hemodynamic variables and renal function <sep>', 'urine volume <sep> central venous pressure systemic vascular resistance index and pulmonary vascular resistance index <sep> levels of anp cyclic guanosine monophosphate glomerular filtration rate and respiratory index and significantly lower levels of renin angiotensin-ii aldosterone and pleural effusion <sep> hemodynamics urine volume dosage of furosemide respiratory index pleural effusion anp cyclic guanosine monophosphate renin activity renin angiotensin-ii aldosterone and glomerular filtration rate <sep>', 'serum creatinine levels <sep> bun levels <sep> renal function <sep> acute renal failure arf <sep> diuresis <sep> frequency of hemodialysis/hemofiltration <sep>', 'morbidity and mortality rates <sep> probability of dialysis and improves dialysis-free survival <sep> serum creatinine <sep> needed dialysis <sep> dialysis-free survival at day 21 and creatinine clearance <sep> dialysis or death <sep> acute renal failure <sep> creatinine clearance <sep> renal excretory function <sep> glomerular filtration rate and renal blood flow <sep>', 'frequency of hemodialysis <sep> cumulative duration of hemofiltration <sep> acute renal failure <sep> mean arterial blood pressure <sep> stable diuresis <sep> duration of hemofiltration and frequency of hemodialysis <sep> oliguria  anuria and required subsequent hemofiltration  hemodialysis <sep> acute renal failure <sep>', 'incidence of mechanical renal replacement therapy <sep> diuresis <sep>', 'incidence of rcin <sep> baseline serum creatinine change in serum creatinine or the incidence of rcin <sep> serum creatinine <sep> incidence of rcin placebo <sep>', 'postoperative creatinine clearance <sep> aldosterone level <sep> hemodynamic status <sep> hemodynamic status and renal function <sep>', 'systolic blood pressure <sep> dialysis-free survival <sep> safety and efficacy of anp <sep> dialysis-free survival rates <sep> mortality rates <sep> dialysis and mortality status <sep> systolic blood pressures <sep>', 'oliguria dialysis-free survival <sep> oliguria <sep> overall rate of dialysis-free survival <sep> glomerular filtration rate <sep> dialysis-free survival <sep> glomerular filtration urinary output and renal histopathology <sep> serum creatinine concentration and mortality <sep> rate of dialysis-free survival <sep>', 'rapid onset of diuresis <sep> acute renal failure <sep>', 'serum creatinine values <sep> and/or hyperkalemia <sep> renal function <sep> diuresis <sep> anuria <sep> peak serum creatinine <sep> acute renal failure <sep> total number of hemodialyses due to oligo-/anuria <sep>', 'plasma anp levels <sep> renal vasodilatory response <sep> baseline serum creatinine level <sep> medications and quantity of radiocontrast <sep> rbf <sep> glomerular filtration rate or rbf <sep> acute renal failure <sep> anp levels <sep> renal blood flow rbf and radiocontrast-induced nephropathy rcin <sep> renal blood flow <sep>'], 'punchline_text': ['the incidence of postoperative ventricular arrhythmia and the postoperative peak level of creatine kinase-mb were significantly lower in the hanp group. <sep>', 'the urine output during cpb and from cpb weaning to return to icu was significantly better in the hanp group. <sep>', 'the incidence of postoperative hemodialysis and the number of treatments did not differ between the groups either urodilatin group 4 vs. placebo group 6 and 22 for both groups respectively). <sep>', 'mortality rates of 17 for group i and 35 for group ii were not significantly different p  0.11). <sep>', 'group h showed significantly smaller furosemide dosage in the initial 3 days h vs. c 9.2  <sep>', 'the postoperative brain natriuretic peptide was significantly lower in the hanp group as compared with that in the non-hanp group until 1 year after the operation. <sep>', 'plasma cyclic guanosine monophosphate levels correlated with plasma anp levels r  0.95 p  0.0001 correlated with fractional sodium excretion r  0.53 p  0.02 and correlated inversely with systemic vascular resistance r  0.54 p  0.02). <sep>', 'the hanp group showed significantly higher levels of anp cyclic guanosine monophosphate glomerular filtration rate and respiratory index and significantly lower levels of renin angiotensin-ii aldosterone and pleural effusion as compared with the non-hanp group. <sep>', 'the frequency of hemodialysis/hemofiltration during uro or placebo infusion was significantly reduced p  0.03 in the uro-treated patients in comparison with placebo. <sep>', 'h-anp improved creatinine clearance in contrast to placebo p .040). <sep>', 'mean arterial blood pressure was stable during the urodilatin infusion period and was not different to that observed in placebo patients. <sep>', 'the results indicate that ularitide does not reduce the incidence of mechanical renal replacement therapy compared with placebo-treated patients during the first 12 h of treatment u0 36 20 u5 35 11 u20 36 9 u40 28 8 u80 41 12  n p  0.87)). <sep>', 'patients with diabetes mellitus had a significantly greater incidence of rcin placebo 26 versus 9 anaritide 0.01 33 versus 13 anaritide 0.05 26 versus 21 anaritide 0.1 39 versus 8 diabetic v nondiabetic p  0.002). <sep>', 'postoperative creatinine clearance was higher in group h p=0.03). <sep>', 'although a trend was present there was no statistically significant beneficial effect of anp in dialysis-free survival or reduction in dialysis in these subjects with oliguric acute renal failure. <sep>', 'the rate of dialysis-free survival was 47 percent in the placebo group and 43 percent in the anaritide group p  0.35). <sep>', 'urodilatin induced a rapid onset of diuresis in contrast to placebo-treated patients who remained oliguric. <sep>', 'no hemodynamic side effects or adverse events due to urodilatin were observed. <sep>', 'anp levels rose significantly from baseline at 5 15 65 and 120 minutes in both groups p less than 0.05). <sep>'], 'population': ['cardiac surgery under cardiopulmonary bypass cpb <sep> cardiac surgery <sep> 150 patients who underwent scheduled coronary artery bypass grafting to compare a group of patients receiving 0.02 microg x kg(-1 <sep>', '40 patients undergoing thoracic aortic surgery into two groups the <sep> patients undergoing thoracic aortic surgery <sep> thoracic aortic surgery <sep>', 'seventy consecutive recipients of primary liver transplants were included in the study following randomization and 33 patients continuously received <sep> liver transplantation <sep> renal impairment following liver transplantation <sep>', 'patients with established intrinsic arf <sep> clinical acute renal failure <sep> fifty-three consenting patients meeting clinical and urine composition criteria for established intrinsic arf <sep>', 'fifty patients undergoing elective aneurysmectomy for infrarenal-aaa between 1998 and 2001 m:f  43:7 mean age 70.5  7.7 years <sep>', 'one hundred and twenty-four patients patients undergoing emergent cabg for acs <sep> patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome <sep> acute coronary syndrome acs <sep>', 'patients undergoing cardiopulmonary bypass <sep> eighteen patients undergoing mitral valve surgery <sep>', 'forty patients undergoing coronary artery bypass grafting were investigated <sep>', 'patients with emerging arf following ltx <sep> acute kidney failure following liver transplantation <sep> five patients receiving i.v <sep> optional inclusion criteria were oliguria/anuria   0.5 ml/kg/h refractory to conventional treatment including administration of furosemide and dopamine increase of serum creatinine to a least 200 of preoperative values and bun levels  or  25 mmol/l <sep> patients suffering from arf following heart and liver transplantation htx ltx <sep>', 'twenty-nine patients <sep> clinical acute renal failure <sep> sixty-one patients with normal preoperative renal function suffering from postcardiac surgical heart failure requiring significant inotropic and vasoactive support <sep> cardiothoracic intensive care units of two tertiary care centers <sep> ischemic acute renal failure <sep>', '6 of the 12 patients in the urodilatin group and 6 of the 12 patients in the <sep> patients after heart transplantation <sep> 24 patients following heart transplantation to investigate whether prophylactic i.v <sep> acute renal failure requiring renal replacement therapy <sep> acute renal failure following heart and liver transplantation <sep>', '360 u80 158 ml/12h median p  0.16 <sep> critically ill patients suffering from oliguric acute renal failure <sep> acute renal failure <sep> patients suffering from oliguric acute renal failure to avoid mechanical renal replacement therapy during the first 12 hours <sep> 176 patients randomized into 4 different ularitide doses groups u5 u20 u40 and u80 ng/kg/min and a <sep> patients suffering from oliguric acute renal failure <sep>', 'patients with diabetes mellitus and a baseline serum creatinine  or  1.8 mg/dl with the lowest-risk group defined as patients without diabetes mellitus <sep> patients with preexisting chronic renal failure with or without diabetes mellitus <sep> patients with diabetes mellitus <sep> 247 patients who completed the study 50 had diabetes mellitus <sep> patients with stable chronic renal failure serum creatinine greater than 1.8 mg/dl or serum creatinine between 1.5 and 1.8 mg/dl with estimated creatinine clearance of  or  65 ml/min <sep>', 'acute renal failure requiring hemodialysis after liver transplantation <sep> renal impairment by continuous infusion of human atrial natriuretic peptide after liver transplantation <sep> thirty-seven patients who underwent live donor liver transplantation with model for end-stage liver disease scores greater than 15 were the subjects of the study <sep> acute renal failure occurring immediately after liver transplantation and requiring hemodialysis <sep> acute renal failure after liver transplantation <sep>', 'oliguric acute renal failure <sep> 222 patients with oliguric acute renal failure <sep> 504 patients with acute tubular necrosis oliguric and nonoliguric anp decreased the need for dialysis only in the oliguric patients <sep> subjects with oliguric acute renal failure <sep>', 'laboratory animals with acute renal dysfunction <sep> critically ill patients with acute tubular necrosis <sep> 504 critically ill patients with acute tubular necrosis <sep> 378 patients without <sep>', 'acute renal failure following cardiac surgery <sep> patients suffering from incipient acute renal failure following cardiac surgery <sep>', 'critically ill patients in intensive care units icu <sep> patients with acute renal insufficiency after major abdominal surgery and the necessity of apparatus-based renal replacement treatment <sep> patients with established acute renal failure and that urodilatin did not eliminate the need for apparatus-based renal replacement treatment <sep> patients with acute renal failure after major abdominal surgery <sep> 12 critically ill patients after major abdominal surgery with acute renal failure in an intensive care unit icu received 20 ng/kg b.w./min urodilatin ularitide inn or <sep>', 'patients with diabetes mellitus <sep> human subjects with chronic renal failure <sep> chronic renal failure <sep> twenty consecutive patients with chronic renal failure 60 with diabetes <sep> patients with diabetes mellitus <sep>'], 'interventions': ['hanp <sep> low-dose continuous infusion of alpha-human atrial natriuretic peptide hanp <sep> alpha-human atrial natriuretic peptide hanp <sep>', 'cardiac surgery performed under cardiopulmonary bypass cpb <sep> continuous low-dose human atrial natriuretic peptide <sep> hanp and the non-hanp <sep> hanp <sep> continuous low-dose human atrial natriuretic peptide hanp <sep>', 'placebo <sep> placebo infusion <sep> furosemide <sep> urodilatin <sep> prophylactic urodilatin <sep> low-dose urodilatin <sep>', 'atrial natriuretic peptide <sep> anp <sep> furosemide <sep> human atrial natriuretic peptide anp with or without diuretics <sep> diuretics and with no anp <sep>', 'synthetic human alpha-atrial natriuretic peptide <sep> synthetic human alpha-anp hanp <sep> maximum hanp <sep> nicardipine hydrochloride <sep> atrial natriuretic peptide anp <sep> hanp <sep> control group <sep> aldosterone <sep>', 'low-dose continuous human atrial natriuretic peptide hanp <sep> coronary artery bypass grafting cabg <sep> continuous low-dose hanp administration <sep> hanp <sep> hanp hanp group and a group not receiving hanp infusion <sep>', 'atrial natriuretic peptide <sep> exogenous anp <sep> anp <sep> endogenous atrial natriuretic peptide anp <sep> anp treatment anp group n  9 or no anp treatment <sep>', 'human atrial natriuretic peptide hanp <sep> furosemide <sep> hanp <sep>', 'placebo <sep> furosemide <sep> uro infusion <sep> urodilatin uro <sep> uro <sep>', 'placebo <sep> human atrial natriuretic peptide h-anp <sep> infusion of h-anp <sep> h-anp/placebo <sep> anp <sep> recombinant human atrial natriuretic peptide <sep> exogenous administration of h-anp <sep> recombinant h-anp 50 ng.kg(-1).min(-1 or placebo <sep>', 'urodilatin infusion <sep> placebo <sep> prophylactic urodilatin inn ularitide infusion <sep> furosemide cyclosporine and vancomycin doses <sep>', 'placebo <sep> ularitide <sep> natriuretic peptide ularitide <sep> mechanical renal replacement therapy <sep> ularitide/placebo <sep>', 'nonionic radiocontrast agents <sep> atrial natriuretic peptide <sep> placebo <sep> intravenous atrial natriuretic peptide anaritide anp 4-28 <sep> anaritide <sep> radiocontrast-induced nephropathy rcin <sep> intravenous 0.45 saline <sep> intravenous anaritide <sep>', 'synthetic human atrial natriuretic peptide <sep> conventional diuretics furosemide and potassium canrenoate <sep> synthetic human atrial natriuretic peptide infusion <sep>', 'anp <sep> placebo <sep> anp anaritide 0.2 microgram/kg/min synthetic form of human anp or placebo <sep>', 'placebo <sep> anaritide <sep>', 'placebo <sep> urodilatin inn:ularitide <sep>', 'mechanical ventilation <sep> placebo in addition to the standard diuretic therapy or low-dose dopamine <sep> placebo <sep> concomitant treatment with urodilatin ularitide <sep> furosemide <sep> urodilatin <sep> dopamine and furosemide <sep>', 'atrial natriuretic peptide versus mannitol <sep> anp or mannitol <sep> mannitol 2.5 <sep> anp <sep> atrial natriuretic peptide anp and mannitol <sep> mannitol <sep> mannitol <sep> radiocontrast infusion <sep> radiocontrast <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",anp may be associated with improved outcomes when used in low doses for preventing aki and in managing postsurgery aki and should be further explored in these two settings. there were no significant adverse events in the prevention studies however in the high dose anp treatment studies there were significant increases hypotension and arrhythmias.
18,"{'outcomes': ['total score for all rating scales <sep> extrapyramidal side effects <sep>', 'brief psychiatric rating scale the clinical global impression scale and safety measures <sep> tolerated <sep> extrapyramidal symptom rating scale total scores <sep> young mania rating scale total scores <sep> young mania rating scale <sep> young mania rating scale scores <sep> efficacy and safety <sep>', 'mania rating scale brief psychiatric rating scale physician global impression scale and side effects scales <sep> side effects <sep> magnitude of or time to response <sep>', 'manic symptoms without sedation <sep>', 'hypokinesia <sep> severity of illness scores <sep> rapid remission of symptoms on the brmas <sep> brief psychiatric rating scale bprs the bech-rafaelsen mania rating scale brmas only manic patients and globally on the clinical global impression cgi <sep>', 'standard ratings of psychopathology and side effects <sep> extrapyramidal side effects <sep>', 'rates of remission young-mania rating scale score of  or 12 and 21-item hamilton rating scale for depression score <sep> extrapyramidal symptoms <sep> quality of life on several dimensions <sep> weight gain <sep> survival analysis techniques <sep> psychotic features rates of remission <sep> quality of life <sep> rate of extrapyramidal symptoms <sep> relapse into an affective episode mania and/or depression <sep> efficacy and safety <sep> overall remission of bipolar mania <sep>', 'serious haematological changes nor abnormalities in clinical chemistry <sep> drowsiness <sep> extrapyramidal side-effects eps <sep> hp and gastrointestinal symptoms <sep>', 'ymrs scores <sep> adverse events <sep> mean young mania rating scale ymrs score reductions <sep>', 'manic and psychotic symptoms <sep> extrapyramidal side effects <sep> antimanic response <sep> young mania rating scale <sep> serum valproate concentrations <sep> side effects <sep>', 'side effects <sep>'], 'punchline_text': ['the patients in all three groups showed a similar improvement on the total score for all rating scales at day 28 brief psychiatric rating scale lithium 9.1 haloperidol 4.9 risperidone 6.5 f  1.01 df  2 p  0.37 mania rating scale lithium 15.7 haloperidol 10.2 risperidone 12.4 f  1.07 df  2 p  0.35 <sep>', 'significantly greater reductions in young mania rating scale scores at endpoint and over time were seen in the risperidone group and in the haloperidol group compared with the placebo group. <sep>', 'there was no evidence for a significant difference between the two treatment groups in the magnitude of or time to response 5.0  <sep>', 'the rating scales are not sensitive enough to monitor manic psychopathology this accounts for the lack of statistically significant differences among drug groups at treatment termination despite the widely disparate discharge rates. <sep>', 'the assessments on the cgi showed that all 3 treatments caused a clear reduction of the severity of illness scores in all 3 diagnostic categories with no differences between treatments. <sep>', 'by 8 weeks both groups were improved from baseline without statistically reliable differences between them. <sep>', 'weight gain was significantly greater in the olanzapine group compared with the haloperidol group 2.82 vs 0.02 kg p<.001). <sep>', 'no serious haematological changes nor abnormalities in clinical chemistry occurred in either group. <sep>', 'further reductions in ymrs scores were seen in patients receiving risperidone or haloperidol during the subsequent 9 weeks. <sep>', 'side effects were infrequent and minor for both treatments except for extrapyramidal side effects which were significantly more common with haloperidol. <sep>', 'groups b and c did not differ from each other either in degree of improvement or in side effects. <sep>'], 'population': ['mania <sep> acute mania <sep> forty-five inpatients with dsm-iv mania <sep>', 'acute mania <sep> 156 bipolar disorder patients with a current manic or mixed episode who received a <sep>', '20 hospitalized patients with a dsm-iii-r diagnosis of bipolar disorder who were being treated concomitantly with <sep>', 'severely ill hospitalized manics <sep>', 'acute psychosis <sep> acutely disturbed psychotic patients <sep> patients were stratified into 3 diagnostic categories acute psychoses 48 patients mania 22 patients and exacerbation of chronic psychoses 73 patients <sep> acutely disturbed psychotic patients <sep>', 'hospitalized manic patients <sep> mania <sep> sixty patients entered the study but only 33 remained for randomization after drug washout <sep>', 'acute mania <sep> patients taking these drugs in patients with bipolar mania <sep>', 'acute mania <sep> patients presenting with mania dsm iii <sep>', '438 patients 154 were randomized to <sep> patients with acute bipolar mania received <sep> bipolar mania <sep>', '36 consecutive hospitalized patients with bipolar disorder manic or mixed phase and with psychotic features <sep> acute psychotic mania <sep>', 'mania <sep> 21 severely ill manic patients who all met rigorous criteria for bipolar illness and who required in hospital treatment <sep>'], 'interventions': ['lithium and haloperidol <sep> risperidone and haloperidol <sep> risperidone <sep> risperidone <sep> haloperidol or 800 to 1200 mg daily of lithium <sep>', 'haloperidol <sep> placebo <sep> placebo risperidone and haloperidol <sep> mood stabilizer lithium or divalproex and placebo risperidone or haloperidol <sep> risperidone or haloperidol <sep> risperidone <sep> risperidone <sep>', 'haloperidol <sep> lithium <sep> benzodiazepine lorazepam <sep> lorazepam <sep> lorazepam <sep>', 'lithium carbonate and haloperidol <sep> haloperidol <sep> lithium carbonate and haloperidol <sep> neuroleptic drug <sep> lithium carbonate chlorpromazine and haloperidol <sep> lithium carbonate <sep> lithium carbonate haloperidol and chlorpromazine hydrochloride <sep> chlorpromazine <sep>', 'haloperidol <sep> zuclopenthixol <sep> haloperidol <sep> zuclopenthixol acetate in oil solution haloperidol and zuclopenthixol <sep> haloperidol and zuclopenthixol <sep> zuclopenthixol acetate <sep> zuclopenthixol acetate <sep>', 'haloperidol plus lithium hal-li with benztropine <sep> li <sep> carbamazepine plus lithium cbz-li <sep> cbz 200 mg and hal <sep> lithium combined with carbamazepine or haloperidol <sep>', 'haloperidol <sep> olanzapine <sep> olanzapine vs haloperidol <sep>', 'haloperidol <sep> cbz <sep> carbamazepine <sep> carbamazepine cbz <sep> haloperidol hp <sep>', 'haloperidol <sep> placebo <sep> risperidone and haloperidol <sep> risperidone or haloperidol <sep> risperidone monotherapy <sep> risperidone <sep> 1-6 mg/day of risperidone 2-12 mg/day of haloperidol or placebo <sep> haloperidol and 140 to placebo <sep>', 'haloperidol <sep> divalproex oral loading and haloperidol <sep> divalproex <sep> divalproex 20 mg/kg/day or haloperidol 0.2 mg/kg/day for 6 full days without other psychotropic agents except lorazepam <sep> divalproex oral loading versus haloperidol <sep> divalproex <sep>', 'haloperidol <sep> lithium <sep> haloperidol and placebo <sep> haloperidol lithium carbonate <sep> haloperidol--lithium <sep> lithium plus placebo b placebo plus haloperidol and c lithium plus haloperidol <sep> haloperidol--lithium combination <sep> lithium vs haloperidol <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>']}",there is some evidence that haloperidol is an effective treatment for acute mania. from the limited data available there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone. some evidence suggests that haloperidol could be less effective than aripiprazole. referring to tolerability when considering the poor evidence comparing drugs clinicians and patients should consider different side effect profiles as an important issue to inform their choice.
19,"{'outcomes': ['induration erythema or local pain <sep> respective rates <sep> stimulation index <sep> zoster <sep> mean stimulation index <sep> risk of zoster <sep>', 'antibody response <sep>', 'protective antibody titres of  or  4 to poliovirus type 1 pv1 poliovirus type 2 pv2 and poliovirus type 3 pv3 <sep> vaccination response <sep> protective antibody titre <sep> poliovirus antibody titres <sep>', 'antibody titers <sep> seroresponse rates <sep> seroconversion rates <sep> seroconversion and seroresponse rates <sep>', 'neutralizing antibody levels <sep> influenza a/h3 neutralizing antibody levels <sep>', 'severity scores <sep> clinical disease <sep> vzv reactivation <sep> mean se stimulation index si <sep>'], 'punchline_text': ['zoster developed in 7 of 53 vaccinated patients 13 percent and in 19 of 58 unvaccinated patients 33 percent p=0.01). <sep>', 'the responses were not improved by two doses compared with one influenza a virus serotypes h1/n1 18 vs. 22 and h3/n2 26 vs. 14 influenza b 25 vs. 22%). <sep>', ""chronic gvhd neither influenced the patient's ability to retain poliovirus antibodies prior to vaccination nor impaired responses to vaccinations. <sep>"", 'children with all developed significant antibody titers to a/panama 2007 99 antigen 4 weeks after the second immunization. <sep>', 'for each vaccine the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135 microg vaccine. <sep>', 'disease severity associated with vzv reactivation was decreased dramatically in vaccinees given three doses severity scores were 6.4  <sep>'], 'population': [""119 patients enrolled 111 received a transplant <sep> for non-hodgkin's or hodgkin's lymphoma to receive <sep> recipients of hematopoietic-cell transplants <sep>"", 'patients with haematological malignancies <sep> patients with haematological malignancies with one or two doses of <sep> 70 patients with haematological malignancies <sep>', 'forty-five adult hla-matched sibling bmt recipients <sep>', 'children with leukemia undergoing chemotherapy <sep> children with either all or asthma in taiwan <sep> children with all who received <sep> 65 children under 15 years old were studied including 25 children with all undergoing chemotherapy 30 with asthma in remission who were regularly followed at clinics and 10 healthy children <sep> children with acute lymphoblastic leukemia all <sep>', '27 patients randomized to receive <sep> adult patients with non-hodgkin b cell lymphoma <sep>', 'bmt patients <sep> varicella-zoster virus vzv causes herpes zoster after bone marrow transplantation bmt <sep> 75 bmt patients randomized to receive <sep> bone marrow transplant recipients immunized with <sep> 24 patients vaccinated at 1 2 and 3 months mean si was 8.43 <sep> 23 unvaccinated patients at 4 months and 8.56 <sep>'], 'interventions': ['autologous hematopoietic-cell transplantation <sep> inactivated varicella vaccine <sep> heat-inactivated live attenuated varicella vaccine <sep> varicella vaccine or no vaccine <sep>', 'influenza vaccine <sep>', 'early and late vaccination with inactivated poliovirus vaccine after allogeneic bmt <sep> inactivated poliovirus vaccine ipv <sep>', 'influenza vaccine contained antigens b/yamanashi/166/98 a/new caledonia/20/99 h1n1 and a/panama/2007/99 h3n2 <sep> panama/2007/99(h3n2 <sep> influenza vaccine <sep> reinduction chemotherapy <sep>', 'baculovirus-expressed trivalent influenza vaccine <sep> commercial trivalent influenza vaccine tiv containing 15 microg of the hemagglutinin ha of influenza a h3n2 and h1n1 and b virus or a recombinant vaccine rhao <sep> rhao <sep>', 'heat-inactivated varicella vaccine <sep> inactivated varicella vaccine <sep> vaccine or no intervention <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",inactivated vzv vaccine might reduce zoster severity in adult sct recipients. inactivated influenza vaccine might reduce respiratory infections and hospitalization in adults with multiple myeloma or children with leukemia or lymphoma. however the quality of evidence is low. local adverse effects occur frequently. further high-quality rcts are needed.
20,"{'outcomes': ['hypersensitivity reactions <sep> serious reaction <sep>', 'liver enzymes and hematological parameters <sep> plasma viral load pvl and cd(4)/cd(8 counts <sep> mean cd(4 counts <sep> incidence of new allergic reactions <sep> baseline cd(8 <sep> mean pvl <sep> liver enzymes <sep>', 'ability to take single-strength tmp-smz daily <sep> adverse reactions <sep>'], 'punchline_text': ['our study was undertaken to evaluate if desensitization treatment is more effective than rechallenge in preventing hypersensitivity reactions in hiv-positive patients with previous allergic reactions to tmp-smx the secondary aim was to evaluate the frequency of reactions to tmp alone. <sep>', 'dose regimen is not a predictor of the development of new allergic reactions amongst patients challenged with sulfonamides after an initial allergic reaction. <sep>', 'seventy-five percent of the dose-escalation group and 57 of the direct-rechallenge group continued to receive daily single-strength tmp-smz for 6 months p .014). <sep>'], 'population': ['hiv-positive patients with previous allergic reactions to tmp-smx <sep> seventy-three patients were enrolled 14 subjects 19 presented reactions on tmp alone during the pre-enrollment phase <sep> 59 subjects <sep> patients with previous documented hypersensitivity to tmp-smx who required primary or secondary pcp prophylaxis were enrolled subjects who had previously had serious adverse reactions to tmp-smx were excluded <sep> hiv-positive patients with previous hypersensitivity to tmp-smx <sep> patients with a previous not serious allergic reaction to tmp-smx <sep>', 'aids patients allergic to sulfonamides <sep> patients developing new reactions <sep> aids patients with previous allergic reactions to sulfonamides and requiring prophylaxis against pneumocistis carinii central nervous system toxoplasmosis and diarrhea caused by isospora belli <sep> eighteen patients were enrolled in the study 15 men and 3 women with ages ranging from 30 to 57 years mean 39.9 <sep> patients challenged with sulfonamides after an initial allergic reaction <sep>', 'hiv-infected patients who had experienced previous treatment-limiting reactions <sep> human immunodeficiency virus-infected patients with previous adverse reaction to tmp-smz <sep>'], 'interventions': ['tmp <sep> tmp-smx <sep>', 'cothrimoxazole <sep> sulfamethoxazole <sep>', 'trimethoprim-sulfamethoxazole tmp-smz <sep> tmp-smz reintroduction <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",in the small trials included in this review when compared to cotrimoxazole rechallenge for prophylaxis of opportunistic infections cotrimoxazole desensitization resulted in fewer treatment discontinuations and overall adverse reactions in hiv-infected patients with a previous history of mild or moderate hypersensitivity to cotrimoxazole. paediatric data and trials in resource-poor settings are urgently required. further randomised controlled trials are also needed for the treatment of opportunistic infections treating-through adjunctive medications and different desensitization-dosing schedules.
21,"{'outcomes': ['clearance of serum hepatitis b virus-dna and hbeag complete response <sep> complete response rate <sep>', 'reversion to hbeag and hbv dna negativity <sep> alanine aminotransferase values <sep> alanine aminotransferase normalization <sep> response rates <sep> active viral replication <sep> normalized alanine aminotransferase <sep> loss of hb surface antigen hbsag <sep> loss of hb virus dna and hbeag from serum <sep> chronic hepatitis b hb infection <sep> response rates <sep> posttreatment histologic scores <sep>', 'anti-hbe seroconversion <sep> response rate <sep> baseline transaminases levels and hbv-dna concentrations <sep>', 'hepatic decompensation <sep> hbeag clearance and seroconversion to anti-hbe <sep> active cirrhosis <sep> chronic persistent hepatitis <sep> hbeag disappearance and hbeag to anti-hbe seroconversion rates <sep> hbeag disappearance and hbeag to anti-hbe seroconversion <sep> chronic active hepatitis <sep>', 'normal serum aminotransferase levels <sep> hepatitis b e antigen and hepatitis b viral dna <sep> hepatitis b viral dna <sep> periportal necrosis <sep>', 'persistent loss of hepatitis b virus dna <sep>', 'partial or complete antiviral responses <sep> spontaneous seroconversion rate <sep> elevated transaminase levels <sep> normal transaminase levels <sep>', 'hbv-dna or degree of histological activity <sep> hbeag clearance <sep>', 'loss of hbeag with anti-hbe seroconversion <sep> baseline aspartate aminotransferase ast level <sep> rate of anti-hbe seroconversion <sep> baseline clinical biochemical and histological features <sep>', 'hepatorenal syndrome <sep> transaminase levels <sep> galactose elimination capacity and aminopyrine breath test <sep> flu-like syndrome granulocytopenia 1 depression 3 and thyroid dysfunction 2 <sep> inflammatory and fibrotic activity <sep> lost hepatitis b virus dna <sep> severe cytolytic episode <sep> biopsy score <sep>', 'loss of hepatitis b <sep> normal alanine aminotransferase alt activity <sep> surface antigen hbsag <sep> e antigen hbeag and hepatitis b virus hbv)-dna <sep> inflammation and disappearance of core antigen in liver tissue <sep> safety and effectiveness <sep> late seroconversion <sep>', 'loss of dna-polymerase activity <sep> efficacy of interferon therapy <sep>'], 'punchline_text': ['those with a baseline serum hepatitis b virus-dna  or  1000 pg/ml also showed a higher complete response rate when pretreated with prednisolone 59 than when treated with interferon alone 29 p  0.084 or untreated 22 p  0.03). <sep>', 'after a posttreatment 2-year follow-up there were still no differences in the response rates of the two treatments of the 21 pooled treated patients 61 lost hbeag and dna and 67 normalized alanine aminotransferase vs. 33 and 44 of controls respectively p  0.32 and 0.40). <sep>', 'only three patients 10.3 cleared hepatitis b surface antigen and seroconverted to anti-hbs. <sep>', 'prednisolone pre-treatment tended to be more effective in patients with higher transaminase levels and in patients with low levels of hbv dna. <sep>', 'hepatitis b e antigen and hepatitis b viral dna disappeared from serum significantly more often in the patients given prednisone plus interferon 16 of 44 patients or 36 percent or 5 million units of interferon alone 15 of 41 37 percent than in the untreated controls 3 of 43 7 percent p less than 0.001 the difference between those given 1 million units of interferon 7 of 41 17 percent and the controls was not significant. <sep>', 'at 24 months of follow-up persistent loss of hepatitis b virus dna occurred in none of the children in the control group in one child receiving recombinant alpha 2b-interferon alone who also seroconverted to anti-hbe and anti-hbs and in five children receiving interferon with steroid priming p  0.0571 compared with controls with four seroconverting to anti-hbe and one also seroconverting to anti-hbs. <sep>', 'partial or complete antiviral responses were achieved in 17 21.5 of 79 treated patients and 3 8.3 of 36 controls p  0.14). <sep>', 'hbeag clearance was similar in both groups 44 after prednisolone/interferon and 53 after interferon alone). <sep>', 'the majority 85 percent had a baseline aspartate aminotransferase ast level  or  100 iu/l. <sep>', 'transaminase levels were normal in 27/34 of the responders but in only 4/21 of the non-responders p  0.0001). <sep>', 'liver biopsies carried out in 20 patients showed that responders had a noticeable reduction in inflammation and disappearance of core antigen in liver tissue changes not seen in non-responders. <sep>', 'interferon induced a sustained cessation of hbv replication as judged by loss of dna-polymerase activity in 26 59 patients 20 45 patients seroconverted to anti-hbe. <sep>'], 'population': ['oriental patients with chronic active hepatitis b 120 male chinese patients <sep> chronic type b hepatitis in asians <sep>', 'children with chronic hepatitis b infection <sep> children with chronic hb infection <sep> 31 children with hb e antigen hbeag)-positive chronic hepatitis who randomly received either no treatment n  9 or 10 million units of <sep>', 'children with chb <sep> twenty-nine children with chronic hepatitis b chb <sep> children with chronic hepatitis <sep>', 'patients <sep> two hundred and thirteen patients with chronic hepatitis b <sep> 200 evaluable patients 33 16.5 were females and 50 25 were male homosexuals <sep> chronic hepatitis <sep> 22 patients with cirrhosis 14 <sep> patients with cirrhosis and avoided in patients showing signs or with a history of decompensated cirrhosis <sep> 102 patients 51 <sep>', 'patients with chronic hepatitis b to one of the following regimens <sep> chronic hepatitis b. the hepatitis interventional therapy group <sep>', 'ninety chinese hepatitis b surface antigen hbsag <sep> carrier children aged 2-17 years positive for hepatitis b e antigen hbeag and hepatitis b virus dna on at least three occasions in 6 months <sep> chinese hbsag carrier children <sep> thirty children <sep>', 'chronic hepatitis b <sep> chinese adults with chronic hepatitis b virus infection <sep>', 'children with chronic hepatitis b <sep> thirty-five children with chronic hbv infection hbv-dna and eag serum positivity and hbcag in liver tissue <sep>', 'children with chronic hepatitis b <sep> n  34 <sep> 95 hepatitis b virus hbv)-dna/hepatitis b e antigen hbeag)-positive children median age 9 years range 2-16 years 56 boys 84 89 percent white all having inflammatory changes on liver biopsy <sep>', 'fifty-six patients with biopsy-proven chronic active hepatitis b <sep> chronic active hepatitis b <sep>', 'chronic hepatitis b <sep> patients with chronic hepatitis b. patients <sep>', '30 patients had chronic active hepatitis on liver biopsy while 14 had chronic persistent hepatitis <sep> chronic hepatitis b. 44 patients with documented chronic hepatitis type b 12 women and 32 men mean age 37.5 years range 23-59 years and satisfying the entry criteria were subjects of the study <sep>'], 'interventions': ['placebo <sep> human lymphoblastoid interferon <sep> prednisolone withdrawal followed by human lymphoblastoid interferon <sep> interferon <sep> prednisolone <sep>', 'recombinant interferon alpha-2b alone or after prednisone <sep> interferon alone or after prednisone <sep> interferon alpha-2b/m2 alone n  13 or after prednisone priming <sep>', 'corticosteroid <sep> recombinant interferon-alpha-2a with or without steroid pretreatment <sep> interferon <sep> oral prednisone <sep> prednisone <sep> recombinant interferon alpha rifn-alpha alone <sep>', 'matching placebo <sep> placebo <sep> interferon <sep> lymphoblastoid interferon treatment <sep> prednisolone withdrawal therapy <sep> prednisolone <sep> placebo vs. prednisolone <sep> prednisolone <sep>', 'interferon alfa-2b alone and after prednisone withdrawal <sep> placebo <sep> interferon alfa-2b <sep> prednisone <sep> interferon <sep> recombinant interferon alfa-2b <sep> prednisone plus interferon <sep>', 'placebo/prednisone syrup <sep> recombinant alpha 2b-interferon <sep> recombinant alpha 2b-interferon with steroid <sep> syrup prednisone <sep> prednisone <sep> placebo syrup followed by 16 weeks of recombinant alpha 2b-interferon intron a rifn2b <sep> recombinant alpha 2 interferon with or without prednisone <sep> syrup vitamin b complex <sep>', 'recombinant interferon alfa-2b with or without prednisone <sep> prednisone <sep> interferon <sep> interferon with or without prednisone <sep>', 'interferon <sep> lymphoblastoid interferon alpha with or without steroid pretreatment <sep> prednisolone <sep> steroid or placebo <sep> prednisolone/interferon <sep> lymphoblastoid human interferon alpha <sep>', 'prednisolone/placebo <sep> placebo <sep> prednisolone followed by ifn-alpha <sep> lymphoblastoid ifn-alpha <sep> interferon alfa ifn-alpha versus ifn-alpha alone <sep> prednisolone <sep> lymphoblastoid interferon alfa with or without steroid pretreatment <sep>', 'steroid withdrawal and low-dose interferon treatment <sep> interferon <sep> steroid withdrawal followed by 1.5 mu recombinant interferon alpha 2b intron with placebo withdrawal followed by either 1.5 or 5 mu interferon <sep>', 'interferon alfa-2b <sep> prednisone <sep> interferon <sep> interferon with or without prednisone <sep> interferon alone and after prednisone withdrawal <sep>', 'interferon alpha wellferon-wellcome foundation ltd. either alone or in combination with short-term corticosteroid pretreatment <sep> interferon <sep> placebo or prednisone <sep> interferon <sep> prednisone <sep> interferon alpha wellferon <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",pretreatment with glucocorticosteroids before treatment with alfa interferon in patients with hepatitis b e antigen positive chronic hepatitis b may be more effective than treatment with alfa interferon alone with regard to loss of hepatitis b e antigen and hepatitis b virus dna but evidence for effect on clinical outcomes is lacking.
22,"{'outcomes': ['impedance at 5 hz r5 resistance as a function of oscillation frequency dr/df reactance at 5 hz x5 resonant frequency f(0  and integral of reactance between 5 hz and resonant frequency ax <sep> respiratory mechanics and sputum production <sep> r5 <sep> total and peripheral airway resistance <sep> flutter valve <sep>', 'radioaerosol clearance <sep> yield of sputum <sep>', 'sputum production <sep> removal of pulmonary secretions <sep> residual volume rv functional residual capacity frc and total lung capacity tlc p<0.05 <sep> lung hyperinflation <sep>', ""total lcq score <sep> leicester cough questionnaire lcq <sep> 24-h sputum volume forced expiratory volume in 1 s fev(1 forced vital capacity fvc forced expiratory flow at 25-75 of fvc fef(25-75 maximum inspiratory pressure mip maximum expiratory pressure mep exercise capacity sputum microbiology and st george's respiratory questionnaire sgrq <sep> 24-h sputum volume <sep> sputum bacteriology fev(1 fvc fef(25-75 mip or mep <sep> did exercise capacity <sep> sgrq total score <sep>""], 'punchline_text': ['flutter valve increases sputum removal during treatment and diminishes total and peripheral airway resistance in hypersecretive patients with bronchiectasis. <sep>', 'use of both nebulised saline and nebulised terbutaline immediately before chest physiotherapy gave a significantly greater yield of sputum than did physiotherapy alone and terbutaline also significantly increased radioaerosol clearance from the whole lung and from regions of interest. <sep>', 'there was a higher sputum production during eltgol compared with control and flutter vrp1 p<0.05). <sep>', 'no significant differences were seen in sputum bacteriology fev(1 fvc fef(25-75 mip or mep. <sep>'], 'population': ['hypersecretive patients with bronchiectasis <sep> patients with bronchiectasis <sep> bronchiectatic patients <sep>', 'eight patients with stable bronchiectasis <sep>', 'bronchiectasis patients <sep> 10 patients two males and eight females mean age 55.918.1 years <sep> hypersecretive patients <sep> methods patients with clinical and radiological diagnosis of bronchiectasis were included <sep> patients with bronchiectasis <sep>', 'non-cystic fibrosis bronchiectasis compared with no regular chest physiotherapy <sep> non-cystic fibrosis bronchiectasis <sep> 20 patients not practising regular chest physiotherapy <sep>'], 'interventions': ['copyright <sep>', 'patient resting in an upright position chest physiotherapy by the forced expiration technique with postural drainage and chest physiotherapy following five minutes inhalation of either nebulised normal saline or nebulised terbutaline <sep> nebulised saline or terbutaline <sep> nebulised saline and nebulised terbutaline <sep>', 'flutter vrp1 <sep> salbutamol <sep>', 'regular chest physiotherapy <sep> twice daily chest physiotherapy using an oscillatory positive expiratory pressure device compared with 3 months of no chest physiotherapy <sep> regular chest physiotherapy <sep> chest physiotherapy <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",acts appear to be safe for individuals adults and children with stable bronchiectasis where there may be improvements in sputum expectoration selected measures of lung function and health-related quality of life. the role of these techniques in people with an acute exacerbation of bronchiectasis is unknown. in view of the chronic nature of bronchiectasis more data are needed to establish the clinical value of acts over the short and long term on patient-important outcomes including symptoms on physiological outcomes which may clarify the rationale for each technique and on long-term parameters that impact on disease progression in individuals with stable bronchiectasis. this is necessary in order to provide further guidance of specific act prescription for people with bronchiectasis. it may also be important to establish the comparative effect of different types of acts in people with bronchiectasis.
23,"{'outcomes': ['number of wet episodes <sep> urinary incontinence <sep>', 'endurance strength and urinary incontinence <sep> timed measures of walking or wheeling a wheelchair mobility sit-to-stand exercises independence in locomotion and toileting as assessed using the functional independence measure fim one-repetition maximum weight for several measures of upper and lower body strength frequency of urine and stool incontinence and appropriate toileting ratios <sep>', 'urinary incontinence <sep> older american research and service physical and instrumental activities of daily living scales folstein mini mental state examination clock drawing test geriatric depression scale performance-based toileting assessment bladder diaries and physical examination <sep> structured continence and medical histories <sep> daytime incontinent episodes <sep>'], 'punchline_text': ['the number of wet episodes in the control group remained about the same throughout training and the 22-week follow-up period. <sep>', 'there was a significant effect of the fit intervention on virtually all measures of endurance strength and urinary incontinence but not on the fim for locomotion or toileting. <sep>', 'among all subjects completing the treatment protocol there was a 22 reduction in daytime incontinent episodes compared with true baseline immediately following the control phase for those crossing over from the control group). <sep>'], 'population': ['nursing homes <sep> one hundred thirty-three incontinent women in seven nursing homes <sep>', 'four va nursing homes <sep> older patients residing in va nursing homes <sep> older patients in department of veterans affairs va nursing homes <sep> veterans affairs nursing homes <sep> 64 subjects completed the intervention phase of the trial <sep> all 528 patients in the nursing homes were screened 178 were eligible and 107 were randomized to an <sep>', '15 subjects completed the pv protocol <sep> nineteen cognitively impaired older adults <sep> nineteen subjects <sep> cognitively impaired homebound older adults <sep> adults aged 60 years and older with urinary incontinence and who met center for medicare and medicaid services criteria for being homebound were referred to the study by home care nurses from 2 large medicare-approved home health agencies in a large metropolitan county in southwestern pennsylvania <sep>'], 'interventions': ['13-week behavior therapy program for urinary incontinence or to a control group that received usual incontinence-related care <sep> behavioral therapy <sep>', 'delayed intervention group <sep> rehabilitative intervention directed at continence mobility endurance and strength functional incidental training fit <sep> immediate intervention <sep> fit intervention <sep> functional incidental training <sep> intervention while group 2 served as a control group then group 2 received the intervention while group 1 crossed over to no intervention <sep>', 'voiding pv <sep> delayed attention-control group <sep> pv intervention or a usual care attention control group <sep> pv intervention <sep> pv <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",there was insufficient evidence to reach firm conclusions for practice. there was suggestive evidence of short-term benefit from prompted voiding but longer-term effects are not known and prompted voiding has significant resource implications.
24,"{'outcomes': ['mean hospital stay <sep> wound dehiscence six of them needed re-suturing under general anesthesia <sep> bacterial infections 2 reduce period of antibiotic use and hospital stay 3 accelerate wound healing 4 prevent wound dehiscence and need for re-suturing and 5 result in minimal scar formation <sep> complete wound healing without wound disruption or need for re-suturing <sep> complete wound healing <sep> eradication of bacterial infections <sep> mild dehiscence <sep> complete wound healing <sep> size of postoperative scar <sep>', 'median reduction in wound size <sep> probability of healing <sep> mean wound area covered in slough <sep> incidence of healing effective desloughing and a lower incidence of infection <sep> infection <sep> healing <sep> healing outcomes <sep>', 'residual scars <sep> amniotic membrane <sep>', 'itching <sep> itching and pain <sep> average cost <sep> wound healing <sep> healing times of shallow wounds and abrasions side-effects patient satisfaction with treatment and amount of honey and intrasite gel used <sep> mean healing times <sep>', 'time to healing change in ulcer area incidence of infection costs per healed ulcer adverse events and quality of life <sep> adverse events <sep> proportion of ulcers healed <sep> safety and effectiveness <sep> venous ulcer healing <sep>', 'hazard ratio <sep> unadjusted hazard ratio <sep> healing rates <sep> median time to healing <sep> healing rate <sep> healing rates of wounds healing <sep>', 'complete cure <sep>', 'mean healing times <sep> healing times <sep> time days taken for complete re-epithelialisation of the nail bed <sep> wound healing <sep>', 'admission point of time <sep> average duration of healing <sep> wound healing <sep>', 'mean healing time <sep> ulcer healing <sep>', 'bacterial contamination and promoting wound healing <sep> positive wound cultures <sep> bacterial colonisation wound size wound asepsis score and pain <sep> wound healing <sep> pain <sep> median rate of healing <sep>', 'cosmetic and functional results <sep> skin grafting <sep> graft take rate <sep> skin grafting take rate <sep> mean percentage of blood volume <sep>', 'relief of pain <sep> healthy granulation tissue <sep> control of infection <sep>'], 'punchline_text': ['after using honey 22/26 patients 84.4 showed complete wound healing without wound disruption or need for re-suturing and only 4 patients showed mild dehiscence. <sep>', 'mean wound area covered in slough reduced to 29 and 43 respectively p  0.065). <sep>', 'residual scars were noted in 8 per cent of patients treated with honey-impregnated gauze and in 16.6 per cent of cases treated with amniotic membrane p  0.001). <sep>', 'in the case of abrasions there was also no significant difference p  0.83 95 ci 4.98 6.19 days). <sep>', 'at 12 weeks 104 ulcers 55.6 per cent in the honey-treated group and 90 49.7 per cent in the usual care group had healed absolute increase 5.9 95 per cent confidence interval c.i. <sep>', 'the healing rate at 12 weeks was equal to 46.2 in the honey group compared with 34.0 in the conventional group and the difference in the healing rates 95 confidence interval ci at 12 weeks between the two groups was 12.2 13.6 37.9%). <sep>', 'in the glucantime alone treated group 32 patients 71.1 had complete cure whereas in the group treated with both glucantime  topical honey 23 patients 51.1 achieved complete cure. <sep>', 'partial avulsion wounds healed statistically significantly faster p=0.01 with paraffin tulle gras 19.62 days sd 9.31 than with the honey dressing 31.76 days sd 18.8 but no significant difference p=0.21 was found following total avulsion when comparing honey 45.28 days sd 18.03. with paraffin tulle gras dressings 52.03 days sd 21.3). <sep>', 'honey dressing improves wound healing makes the wound sterile in lesser time has a better outcome in terms of prevention of hypertrophic scarring and post-burn contractures and decreases the need of debridement irrespective of time of admission when compared to ssd dressing. <sep>', 'the mean healing time in the standard dressing group was 15.4 days range 9-36 days compared to 14.4 days range 7-26 days in the honey group p  0.005). <sep>', 'honey appears to be more effective than sugar in reducing bacterial contamination and promoting wound healing and slightly less painful than sugar during dressing changes and motion. <sep>', 'early tangential excision and skin grafting was clearly superior to expectant treatment using topical honey in patients with moderate burns in this randomised prospective study performed at a general hospital in the indian subcontinent. <sep>', 'of the wounds treated with honey 87 per cent healed within 15 days as against 10 per cent in the control group. <sep>'], 'population': ['fifty patients having postoperative wound infections following caesarean sections or total abdominal hysterectomies with gram positive or gram negative bacterial infections <sep> caesarean sections and hysterectomies <sep> twenty-six patients group a were treated with 12 hourly application of crude honey and 24 patients group b were treated with <sep>', 'one hundred and eight patients with venous leg ulcers having <sep> venous ulcers <sep>', 'partial thickness burns <sep> burns <sep> sixty-four patients were studied <sep>', 'goldmine workers <sep>', '368 participants 187 were randomized to honey and 181 to usual care <sep> 2008 british journal of surgery society ltd <sep> venous leg ulcers <sep>', 'a sample of 105 patients were involved in a single centre <sep>', 'cutaneous leishmaniasis <sep> 100 patients with confirmed cutaneous leishmaniasis <sep> 45 patients that had cutaneous leishmaniasis <sep> ten patients left out the study <sep>', 'participants n=100 <sep>', 'patients n=78 of both sexes with age group between 10 and 50 years and with first and second degree of burn of less than 50 of tbsa total body surface area were included in the study over a period of 2 years 2006-08 <sep> burn patients <sep>', ""30 patients age between 31 to 65-years-old mean of 52.1 years <sep> wagner type ii diabetic foot ulcers <sep> wagner's grade-ii diabetic foot ulcers with <sep> wagner grade-ii diabetic foot ulcers <sep>"", 'patients with open or infected wounds <sep> forty patients were enrolled 18 received <sep>', '25 patients in the tangential excision te group had burns of 23 <sep> 50 burn patients <sep> patients with moderate burns <sep>', '104 cases of superficial burn injury <sep> burns <sep> 52 patients treated with <sep>'], 'interventions': ['local antiseptics spirit 70 ethanol and povidone-iodine <sep> topical honey <sep> systemic antibiotics <sep>', 'woundcare <sep> manuka honey woundcare 18 vs. standard hydrogel therapy intrasite gel <sep> manuka honey vs. hydrogel <sep> manuka honey <sep> immunosuppressant therapy <sep>', 'honey-impregnated gauze versus amniotic membrane <sep> amniotic membrane <sep> honey-impregnated gauze <sep> honey-impregnated gauze with amniotic membrane dressing <sep>', 'intrasite gel <sep>', 'calcium alginate dressings impregnated with manuka honey or usual care <sep> honey-impregnated dressings <sep> compression bandaging <sep>', 'standardized antibacterial honey medihoney with standard therapy <sep> conventional wound dressing or honey <sep>', 'topical honey twice daily along with intralesional injection of glucantime <sep> topical honey and glucantime <sep> intralesional glucantime alone <sep> intralesional injection of glucantime <sep>', 'honey dressing <sep> honey dressing versus paraffin <sep> active manuka honey dressing n=52 or paraffin-impregnated tulle gras <sep>', 'honey dressing and silver sulfadiazene dressing <sep> ssd cream <sep> honey dressing and silver-sulfadiazene ssd dressing <sep> honey dressing <sep>', 'honey dressing <sep> controlled dressing group povidone iodine followed by normal saline <sep> surgical debridement and appropriate antibiotics <sep> honey and povidone iodine <sep> honey dressing <sep>', 'sugar dressings and 22 honey dressings <sep> honey or sugar dressings <sep> honey and sugar dressings <sep>', 'early tangential excision and skin grafting or by the application of honey dressings with delayed skin grafting as necessary <sep> tangential excision and skin grafting <sep> early tangential excision and skin grafting <sep>', 'silver sulfadiazine gauze dressing <sep> silver sulfadiazine <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",honey dressings do not increase rates of healing significantly in venous leg ulcers when used as an adjuvant to compression. honey may delay healing in partial and full-thickness burns in comparison to early excision and grafting and in cutaneous leishmaniasis when used as an adjuvant with meglumine antimoniate. honey might be superior to some conventional dressing materials but there is considerable uncertainty about the replicability and applicability of this evidence. there is insufficient evidence to guide clinical practice in other types of wounds and health services may wish to consider avoiding routine use of honey dressings until sufficient evidence of effect is available.
25,"{'outcomes': ['withdrawal time <sep> general adenoma detection rate <sep> adenoma detection rates <sep> adenoma detection rate ie number of adenomas/total number of patients <sep> total number of adenomas <sep>', 'adenoma detection rate <sep> detection rates <sep> increased adenoma detection rate means of nbi colonoscopy <sep> adenoma rates <sep> rates steadily <sep>', 'demographics indication for colonoscopy and quality of preparation <sep> number of diminutive <sep> prolongation of extubation time <sep> extubation time <sep> total number of adenomas <sep>', 'neoplasm detection rates <sep> neoplasm detection rate <sep> neoplasm miss rate <sep> miss or detection rates <sep> colorectal neoplasm miss rate <sep>', 'adenoma detection rate <sep> prevalence of non-polypoid and the total number of adenomas <sep> adenoma detection rates <sep> number of total and mean per-patient adenomas <sep> flat adenoma detection rates <sep>'], 'punchline_text': ['only hyperplastic polyps were found more frequently in the nbi group p  .03). <sep>', 'adenomas were detected more frequently in the nbi group 23 than in the control group 17 with a number of 17 colonoscopies needed to find one additional adenoma patient however the difference was not statistically significant p  0.129). <sep>', 'however the pan-colonic nbi system significantly increased the total number of adenomas detected p  0.05 and the number of diminutive 5 mm adenomas detected p  0.05). <sep>', 'in 276 tandem colonoscopy patients there was no significant difference of miss or detection rates between nbi or wl colonoscopy techniques. <sep>', 'the adenoma detection rates were 57.3 for patients examined by nbi and 58.3 for those examined by wl p  .88). <sep>'], 'population': ['multicenter private practice setting involving 6 examiners with substantial lifetime experience 10,000 colonoscopies 1256 patients men:women 47%:53 mean age 64.4 y <sep>', 'a total of 401 patients were included mean age 59.4 years 52.6 men <sep> eligible patients presenting for diagnostic colonoscopy <sep>', 'neoplastic colonic polyps <sep> two hundred forty-three patients were randomized 121 to <sep>', '130 patients 47 had at least one neoplasm <sep> elective colonoscopy adults <sep> 276 tandem colonoscopy patients <sep> colorectal cancer crc <sep>', 'consecutive 50 to 69-year-old patients with positive immunologic fecal occult blood tests <sep>'], 'interventions': ['hdtv screening colonoscopy with either nbi or white-light imaging on instrument withdrawal <sep> narrow-band imaging nbi <sep> narrow-band versus white-light high definition television endoscopic imaging <sep>', 'narrow-band imaging versus conventional colonoscopy <sep> undergo wide-angle colonoscopy using either conventional high-resolution imaging or nbi during instrument withdrawal <sep> narrow-band imaging nbi <sep>', 'conventional colonoscopy and 122 to pan-colonic nbi system <sep> pancolonic nbi system <sep> conventional colonoscopy and pan-colonic narrow-band imaging system <sep> pan-colonic nbi system <sep>', 'nbi versus white light wl <sep> narrow band imaging versus white light examination <sep> colonoscopic examination using nbi or wl <sep>', 'nbi <sep> narrow band imaging <sep> white light wl <sep> narrow band imaging nbi <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",we could not find convincing evidence that nbi is significantly better than high definition wlc for the detection of patients with colorectal polyps or colorectal adenomas. we found evidence that nbi might be better than standard definition wlc and equal to high definition wlc for detection the patients with colorectal polyps or colorectal adenomas.
26,"{'outcomes': ['clinical cure at end of therapy visit eot <sep> median time to the next exacerbation <sep>', 'resolution of symptoms <sep>', 'gasometric and spirometric measures <sep>', 'rate of failure with deterioration <sep> success rate <sep> peak flow <sep> dyspnea sputum production and sputum purulence <sep> side effects <sep>', 'symptom scores wheeze dyspnoea cough with and without mucus production and awakening with dyspnoea peak expiratory flow values pef expressed as  predicted and sublingual temperature <sep> number of relapses <sep> peak flow and symptom scores <sep> symptoms <sep> shortness of breath wheezing or exacerbations of cough with or without sputum production <sep> changes in symptoms peak expiratory flow and sputum flora <sep>', 'duration of mechanical ventilation and hospital stay <sep> need for additional courses of antibiotics <sep> death in hospital and need for additional antibiotics <sep> death in hospital and need for an additional course of antibiotics both separately and in combination <sep>', 'clinical and microbiologic response serum c-reactive protein crp level cutoffs 5 and 50 mg/l and serum procalcitonin level pct <sep> pct levels <sep> low pct levels <sep> clinical success rate <sep> crp levels <sep>'], 'punchline_text': ['the median time to the next exacerbation was significantly longer in patients receiving antibiotic compared with placebo 233 d interquartile range 110-365 compared with 160 d interquartile range 66-365 p  0.05). <sep>', 'the main effect parameter--the doctors overall evaluation of the treatment--did not demonstrate any statistically significant difference between amoxicillin or placebo 63 versus 64 of the patients. <sep>', 'the three groups were homogeneous at their admission and there were no statistical differences at their discharge. <sep>', 'side effects were uncommon and did not differ between antibiotic and placebo. <sep>', 'symptoms improved in all three groups improvements ranging from 0.54 to 0.75 points per day on a four point scale. <sep>', 'absolute risk reduction 17.5 95 ci 4.3-30.7 p=0.01). <sep>', 'although crp levels were higher in the presence of bacteria median 33.0 mg/l interquartile range 9.75-88.25 vs 17 mg/l interquartile range 5.0-61.0 p  .004 pct levels were similar. <sep>'], 'population': ['moderate exacerbations of mild-to-moderate copd <sep> 117 patients with amoxicillin/clavulanate 74.1 and 91 with <sep> chronic obstructive pulmonary disease copd <sep> patients aged 40 years or older smokers or ex-smokers of 10 pack-years or more with spirometrically confirmed mild-to-moderate copd fev(1  50 predicted and fev(1)/fvc ratio  0.7 and diagnosed with an exacerbation were enrolled in the study <sep> acute exacerbations of mild to moderate chronic obstructive pulmonary disease <sep> 310 subjects fulfilled all the criteria for efficacy analysis <sep>', 'acute exacerbations of chronic bronchitis in patients from general practice <sep> 131 general practitioners included 278 patients over a period of 30 months <sep> patients with pneumonia a temperature above 38.5 degrees c or heart rate over 100 were excluded for safety reasons <sep> patients with chronic bronchitis <sep> acute uncomplicated exacerbations of chronic bronchitis <sep>', '90 patients hospitalized due to an acute episode of copd <sep> acute episodes of chronic obstructive pulmonary disease <sep> acute episodes of chronic obstructive pulmonary disease copd <sep>', 'chronic obstructive pulmonary disease <sep> patients with chronic obstructive pulmonary disease in exacerbation <sep> 173 patients 362 exacerbations were treated 180 with placebo and 182 with antibiotic <sep>', 'patients with asthma or chronic obstructive pulmonary disease copd <sep> ambulatory patients with mild to moderate asthma or copd when treated by their general practitioners <sep> patients with asthma or copd seen in general practice <sep> patients with chronic obstructive pulmonary disease in general practice <sep> 195 patients enrolled 71 36 contacted their physician for symptoms of an exacerbation <sep>', 'chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation <sep> copd exacerbation requiring mechanical ventilation <sep> 93 patients with acute exacerbation of copd who required mechanical ventilation <sep> patients with moderate exacerbations of chronic obstructive pulmonary disease copd <sep> patients with exacerbations of copd who required mechanical ventilation <sep> group <sep>', 'acute exacerbations of copd <sep> acute exacerbations of copd aecopd <sep> 243 exacerbations out of 205 patients from a <sep>'], 'interventions': ['placebo <sep> amoxicillin/clavulanate <sep> amoxicillin/clavulanate 500/125 mg three times a day or placebo <sep> antibiotic therapy <sep> antimicrobial therapy <sep>', 'placebo <sep> amoxicillin 750 mg b.i.d. or corresponding placebo <sep> amoxicillin <sep> amoxicillin <sep> broad-spectrum penicillin amoxicillin <sep>', 'antibiotic treatment <sep> amoxicillin-clavulanic acid 32 patients and group iii placebo <sep> antibiotic therapy <sep> cotrimoxazole <sep> antibiotic therapy <sep>', 'placebo <sep> antibiotic therapy <sep> broad-spectrum antibiotic and placebo therapy <sep>', 'cotrimoxazole <sep> placebo <sep> antimicrobial drugs amoxicillin <sep> prednisolone <sep>', 'antibiotics <sep> placebo <sep> ofloxacin <sep> oral ofloxacin 400 mg once daily n=47 or placebo <sep>', 'systemic corticosteroids for aecopd <sep> doxycycline <sep> placebo <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",antibiotics for copd exacerbations showed large and consistent beneficial effects across outcomes of patients admitted to an icu. however for outpatients and inpatients the results were inconsistent. the risk for treatment failure was significantly reduced in both inpatients and outpatients when all trials 1957 to 2012 were included but not when the analysis for outpatients was restricted to currently used antibiotics. also antibiotics had no statistically significant effect on mortality and length of hospital stay in inpatients and almost no data on patient-reported outcomes exist. these inconsistent effects call for research into clinical signs and biomarkers that help identify patients who benefit from antibiotics and patients who experience no effect and in whom downsides of antibiotics side effects costs and multi-resistance could be avoided.
27,"{'outcomes': ['clonus <sep> flexor spasms pain and stiffness resistance to passive joint movements and tendon stretch reflexes <sep> side effects <sep>', 'safety tolerability and efficacy <sep> spasticity <sep>', 'hyperactive stretch reflexes and ankle clonus <sep> elevated liver function test <sep> clinical spasticity and hyperreflexia <sep> dry mouth and drowsiness <sep>', 'symptom well-being and intoxication scores on a daily basis using visual analogue scales <sep> pain relief <sep> tolerated <sep> observer rated severity and frequency of symptoms on numerical rating scales administered standard measures of disability barthel index mood and cognition and recorded adverse events <sep> intractable neurogenic symptoms <sep> impaired bladder control muscle spasms and spasticity <sep>', 'antispasmodic efficacy and safety <sep> subjective sensation of relief with reference to the symptoms of spasms <sep> muscular tonus <sep>', 'spasticity clonus and hyperreflexia and the complaints of muscle stiffness <sep>', 'efficacy and tolerance <sep> somnolence and xerostomia <sep> muscle weakness <sep>', 'motor weakness <sep> levels of threonine <sep>', 'muscle tone ashworth scale and type and frequency of muscle spasms patient diaries <sep> adverse events <sep> spasms and clonus patient diaries <sep> efficacy and tolerability <sep> antispastic efficacy <sep>', 'good overall tolerability <sep> functional status <sep> efficacy of baclofen <sep> antispastic efficacy of tizanidine <sep> efficacy and tolerability parameters <sep>', 'tiredness <sep> antispastic effect and tolerability <sep> overall spastic state spasms and clonus <sep> muscle strength bladder function and the activities of daily living <sep>', 'functionality and nursing care <sep> tolerated <sep> joint and muscle pain <sep> painful spasms <sep> muscle tone <sep>', 'moderate quadriceps spasticity <sep> cybex flexion scores <sep> cybex ii isokinetic unit timed gait ashworth scale <sep>', 'antispastic effect <sep> spasticity <sep> mild depressive effect on blood pressure <sep> physical or psychological dependence <sep> sleepiness muscular weakness and dry mouth <sep>', 'muscle strength <sep> adverse reactions <sep> resistance to passive stretch clonus and hyperreflexia <sep>', 'spasticity <sep> spasticity of the leg adductors <sep> adverse effects <sep> objective rating scale <sep> focal spastic muscle contractions <sep> ease of nursing care <sep>', 'spasticity <sep> increase weakness <sep> hepatic renal or hematological function <sep> sedation nausea and vomiting <sep> alleviating flexor and extensors spasms <sep> side effects <sep>', 'spasticity <sep> electromyographic recording of deep tendon reflexes <sep>'], 'punchline_text': ['patient self-evaluation results also showed a significant reduction in clonus. <sep>', ""both thc and plant-extract treatment worsened the participant's global impression. <sep>"", 'a statistically significant benefit was noted in spastic muscle groups in the legs with concomitant significant reduction in hyperactive stretch reflexes and ankle clonus. <sep>', 'pain relief associated with both thc and cbd was significantly superior to placebo. <sep>', 'as to the residual urinary volume no relevant differences and alterations were determinated in the course of the treatment as well. <sep>', 'both drugs reduced the findings of spasticity clonus and hyperreflexia and the complaints of muscle stiffness and cramping. <sep>', 'both baclofen and tizanidine appear to be useful adjuncts in the treatment of spasticity in patients with multiple sclerosis. <sep>', 'levels of threonine were elevated in serum and cerebrospinal fluid during treatment but glycine levels did not change. <sep>', 'tizanidine produced a significantly greater reduction than placebo in spasms and clonus patient diaries but no significant differences in ashworth scores. <sep>', 'tizanidine and baclofen improved the functional status of patients in 80 and 76 of cases respectively but there were no significant differences between the two drugs. <sep>', 'in contrast muscle strength bladder function and the activities of daily living were more improved on tizanidine than on baclofen. <sep>', 'in the spasticity group botulinum toxin a reduced the tone of all patients significantly improved functionality and nursing care in eight of 12 patients and alleviated painful spasms in five of five patients. <sep>', 'overall treatment with baclofen alone significantly improved moderate quadriceps spasticity as measured by cybex flexion scores. <sep>', 'tizanidine had a mild depressive effect on blood pressure. <sep>', 'in the fourteen subjects who completed the trial there was a statistically significant decrease in resistance to passive stretch clonus and hyperreflexia without significant reduction of muscle strength. <sep>', 'we found that botulinum toxin produced a significant reduction in spasticity p  0.009 and a significant improvement in the ease of nursing care p  0.009). <sep>', 'while on baclofen patients obtained a significant p less than 0.001 reduction in spasticity compared to controls. <sep>', 'there was not statistically significant superiority of either diazepam or ketazolam but both relieved symptoms significantly better than the placebo as measured clinically and by electromyographic recording of deep tendon reflexes. <sep>'], 'population': ['106 patients with spasticity secondary to multiple sclerosis <sep> patients with multiple sclerosis <sep>', '16 patients with ms who presented with severe spasticity <sep>', 'sixty-six patients entered an eight week therapeutic trial and fifty-nine completed the trial <sep> ms patients <sep>', 'three patients had transient hypotension and intoxication with rapid initial dosing of thc-containing cme <sep> twenty-four patients with multiple sclerosis 18 spinal cord injury 4 brachial plexus damage 1 and limb amputation due to neurofibromatosis 1 <sep> patients attended as outpatients but took the cme at home <sep>', 'spastic movement disorders of the lower extremities <sep> patients suffering from multiple sclerosis with spastic motor disturbances of the lower extremities <sep> 47 patients of either sex at the age of 23 until 63 <sep>', '42 patients with spasticity due to stable multiple sclerosis <sep> spastic patients <sep>', 'sixty-six patients entered the trial and forty-eight completed both treatment phases <sep> patients with multiple sclerosis <sep>', '26 ambulatory patients <sep> multiple sclerosis <sep>', 'spasticity caused by multiple sclerosis <sep>', '100 patients suffering from chronic spasticity due to multiple sclerosis <sep>', 'spasticity due to multiple sclerosis <sep> twenty-one hospitalized patients with stable spasticity participated in the 6-week trial <sep> chronic spasticity in multiple sclerosis <sep>', '12 patients with spasticity and in eight patients with rigidity <sep>', 'patients with minimal to moderate spasticity <sep> multiple sclerosis <sep> thirty men and women diagnosed with definite multiple sclerosis ms <sep>', '40 seriously handicapped patients with multiple sclerosis ms <sep> multiple sclerosis <sep>', 'chronic spasticity of varying etiology <sep> seventeen patients 13 males and 4 females with moderate to severe spasticity caused by varying neurological disorders <sep>', '9 patients who were either chair-bound or bed-bound with chronic stable multiple sclerosis <sep>', 'patients with multiple sclerosis ms <sep>', '50 patients for its effects in neurologic spasticity <sep> thirty-nine patients completed the study <sep> patients with multiple sclerosis <sep>'], 'interventions': ['placebo <sep> baclofen <sep>', 'placebo <sep> thc <sep> oral delta(9)-tetrahydrocannabinol thc and cannabis sativa plant extract <sep>', 'placebo <sep> diazepam <sep> tizanidine 5-chloro-4-(2imidazolin-2 yl amino)-2,1,3-benzothialdiazole <sep> tizanidine <sep> tizanidine <sep>', 'placebo <sep> whole-plant cannabis extracts <sep> plant-derived cannabis medicinal extracts cme <sep> delta-9-tetrahydrocannabinol <sep> cannabis medicinal extracts <sep>', 'baclofen tetrazepam and tizanidine <sep> three centrally effective antispasmodics tetrazepam baclofen and tizanidine <sep>', 'dantrolene sodium and diazepam <sep>', 'tizanidine sirdalud was compared to baclofen lioresal <sep> tizanidine versus baclofen <sep> tizanidine <sep>', 'threonine <sep> threonine <sep>', 'tizanidine <sep> placebo <sep> tizanidine <sep>', 'novel antispastic agent tizanidine <sep> tizanidine <sep> tizanidine hydrochloride with that of baclofen <sep> tizanidine <sep>', 'tizanidine <sep> new muscle relaxant tizanidine ds 103-282 with those of baclofen <sep> new muscle relaxant tizanidine ds 103-282 and baclofen <sep>', 'botulinum toxin a versus saline <sep> botulinum toxin <sep> botulinum toxin <sep> placebo <sep>', 'baclofen alone stretching regimen with placebo placebo alone and stretching regimen with baclofen <sep>', 'tizanidine <sep> tizanidin <sep> tizanidine <sep> baclofen <sep>', 'placebo <sep> dantrolene sodium <sep> dantrolene sodium <sep>', 'botulinum toxin <sep> botulinum toxin 400 mouse units or placebo <sep> botulinum-a toxin <sep>', 'baclofen <sep> placebo <sep> baclofen <sep>', 'ketazolam <sep> placebo <sep> diazepam <sep> ketazolam <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>']}",the absolute and comparative efficacy and tolerability of anti-spasticity agents in multiple sclerosis is poorly documented and no recommendations can be made to guide prescribing. the rationale for treating features of the upper motor neurone syndrome must be better understood and sensitive validated spasticity measures need to be developed.
28,"{'outcomes': ['rates of survival <sep> median survival <sep> severe weight loss <sep> serious infections requiring hospitalization <sep> excellent performance status minimal weight loss and visible disease on radiography <sep> survival <sep>', 'survival <sep> survival <sep>', '5-year survival rate <sep> recurrence <sep> 5-year survival <sep> gastrointestinal toxicity grade 3 to 4 who <sep> overall survival disease-free survival and relapse pattern <sep>', '5-year survivals <sep> overall response rate <sep> median survival <sep> long-term survival <sep> survival <sep>', 'mean survival <sep> survival analysis <sep> performance status karnofsky and weight loss <sep> peripheral neuropathy and hematologic and renal toxic effects <sep> median number of chemotherapy cycles <sep> toxic effects <sep> survival <sep> survival <sep> survival advantage <sep>', 'local control rate and survival <sep> survival and response rates <sep> survival <sep> response rates or in survival <sep>', 'distant metastasis rate <sep> 2-year survival rate <sep>', 'response rate <sep> response rate <sep> improved survival <sep> median survival <sep> toxicity <sep> survival and 58 for response and toxicity <sep> response rate and survival <sep> survival advantage <sep>', 'median survival <sep> overall response rates complete response cr plus partial response pr <sep> severe neurotoxicity <sep> severe vomiting <sep> toxicity <sep> leukopenia of severe <sep> survival benefit <sep> survival <sep>', 'survival rates <sep> median time to progression <sep> myelosuppression <sep> 5-year survival rates <sep> major clinical responses <sep> median survival time <sep> survival advantage <sep>', 'incidence of death with metastases metastasis-free survival mfs nor overall survival s <sep> acute toxicity dysphagia myelosuppression <sep> local response <sep> local tumor response <sep>', 'whole survival <sep>', 'death <sep> response rate <sep> toxicity <sep> median survival <sep> objective response <sep> median time to progression <sep>', 'serious toxicity <sep> karnofsky performance status score <sep> median survival <sep> quality of life <sep> survival benefit <sep>', 'acute or late radiation pulmonary or oesophageal toxicity <sep> overall response rate <sep> time to progressive disease <sep> reversible renal toxicity grade 2 <sep> partial response <sep> complete response <sep> acute toxicity <sep> toxic death <sep> overall survival time <sep> response and toxicity <sep> response rate and morbidity <sep> response rate time to progressive disease and overall survival <sep>', 'disease-free and overall survival <sep> 3-year disease-free survivals <sep> median survival times 5-year survival <sep> histology performance status extent of operation and tumor and nodal status <sep>', 'survival time <sep>', 'five-year survival <sep> toxic symptoms of varying severity <sep> drug mortality <sep>', 'time to recurrence or overall survival <sep>', 'toxicity <sep> response rates <sep> survival <sep> progressive disease in arm b. median survival <sep>', '5-year disease-free survival rate <sep> 5-year survival rate <sep> adjusted survival rate and disease-free survival rate <sep> 5-year survival <sep>', 'survival or delayed recurrence of disease <sep> toxic reactions <sep>', 'overall survival <sep> unacceptable toxicity <sep> overall response rate <sep> median survival <sep> toxicity <sep>'], 'punchline_text': ['the median survival was greater for those in group 1-13.8 versus 9.7 months p  0.0066 by log-rank test). <sep>', 'survival was significantly shorter in patients with histological involvement of the resected intrathoracic nodes log-rank test p much less than 0.001). <sep>', 'the 5-year survival rate was 67 in the chemotherapy group and was 56 in the control group p  .050). <sep>', 'the 5-year survivals were 3 3 and 1 respectively p  0.56). <sep>', 'survival was directly related to initial performance status in both groups p  .01 and was significantly p  .01 longer for patients with squamous cell carcinoma than for those with nonsquamous cell carcinoma. <sep>', 'when compared by chemotherapy immunotherapy and performance status no statistically significant difference was found in response rates or in survival. <sep>', 'the 2-year survival rate was 14 in group a and 21 in group b p  .08). <sep>', 'induction chemotherapy produced a better response rate and a trend of improved survival 4 months but a significant survival advantage was not achieved p  0.11 probably because of the small number of patients enrolled in the trial. <sep>', 'the treatment groups were comparable in terms of age sex performance status histology disease extent and weight loss. <sep>', 'major clinical responses were observed in 31 of 56 55 95 cl 42 to 68 patients treated with combination therapy and 37 of 58 64 <sep>', 'neither the incidence of death with metastases metastasis-free survival mfs nor overall survival s were significantly affected by treatment with the drug. <sep>', 'eighty-one patients were evaluated and for the group as a whole survival was better in the undifferentiated group assigned to receive adjuvant chemotherapy but survival in the patients with squamous tumours was not significantly prolonged. <sep>', 'median survival was 11.74 and 10.03 months respectively without statistically significant differences between the two groups of patients. <sep>', 'although the patients receiving combination chemotherapy had a slightly longer median survival 20.43 weeks versus 13.57 weeks it was not statistically significant p  0.09). <sep>', 'high-dose radiotherapy preceded by high-dose chemotherapy was more toxic than radiotherapy alone and did not result in this study in any benefit in terms of response rate time to progressive disease and overall survival. <sep>', 'the 3-year disease-free survivals of the chemotherapy and control groups were 37 and 42 respectively. <sep>', 'no statistically significant differences in survival time were found between the two treatment techniques. <sep>', 'no drug mortality was noted but toxic symptoms of varying severity were seen after 43.6 of the drug courses. <sep>', 'there were no differences in time to recurrence or overall survival not stratified by histology between the two groups even when analyses were adjusted for prognostic variables. <sep>', ""toxicity on the chemotherapy arm was hematologic world health organization who grade greater than 3 in 12 of ce'p and in 13 of mec courses and gastroenteric who grade greater than 3 in 24 of ce'p courses and in 8 of mec courses. <sep>"", 'thereafter the adjusted survival rate and disease-free survival rate for group a became significantly higher than for group b p  0.044 and p  0.036 respectively). <sep>', 'no evidence of improved survival or delayed recurrence of disease was seen in treated patients as a whole or when examined by cell type and by postsurgical tnm category. <sep>', 'the overall response rate to chemotherapy was 28 there were no significant differences according to major prognostic criteria. <sep>'], 'population': ['stage iii non-small-cell lung cancer <sep> eligible patients in group 1 n  78 and group 2 n  77 were comparable in terms of age median 60 years sex performance status histologic features stage of disease and completeness of radiation therapy <sep> patients had documented non-small-cell cancer of the lung with stage iii disease established by clinical or surgical staging <sep> patients with locally or regionally advanced non-small-cell lung cancer radiation <sep> patients with stage iii non-small-cell lung cancer <sep>', '726 patients with carcinoma of the bronchus <sep>', 'one hundred ten patients with t1-3n0 <sep> patients with nsclc at pathologic stage i who have undergone radical surgery benefit from adjuvant chemotherapy <sep> patients who underwent radical surgery for non-small-cell lung cancer nsclc <sep> non-small-cell lung cancer <sep>', 'patients who developed progressive disease while receiving <sep> 319 patients with locally advanced unresectable non-small cell lung cancer who had no evidence of extrathoracic metastases <sep> patients with non-small cell lung cancer who have inoperable <sep> patients with locally advanced non-small cell lung cancer treated with <sep> patients with locally advanced unresectable non-small cell lung cancer <sep>', 'patients with tnm stage iv non-small-cell lung cancer <sep> metastatic non-small-cell lung cancer <sep> patients n  102 with stage iv non-small-cell lung cancer <sep> patients with stage iv non-small-cell lung cancer <sep> metastatic non-small-cell lung cancer <sep> patients with advanced non-small-cell lung cancer <sep>', 'limited squamous cell carcinoma of the lung <sep> 107 eligible patients 15 14 had complete responses and 20 19 had partial responses <sep> patients with limited squamous cell carcinoma of the lung <sep>', '177 patients received <sep> 353 patients <sep> nonresectable non-small-cell lung cancer <sep> nonresectable squamous cell and large-cell lung carcinoma <sep>', 'locally advanced unresectable non-small-cell lung cancer <sep> 66 consecutive patients with stage iii unresectable nsclc <sep> 61 eligible patients were comparable in terms of age performance status histology and treatment <sep> regionally advanced unresectable non-small-cell lung cancer nsclc <sep>', 'patients with advanced non-small-cell carcinoma of the lung nsclc <sep> 233 patients were eligible <sep> eighteen centers participated in the three-arm schema 150 patients centers choosing not to participate in a study with a no-chemotherapy arm followed a two-arm schema comparing vp with cap 101 additional patients <sep> patients had measurable or evaluable disease with either distant metastases 82.5 or bulky limited disease considered inoperable or unsuitable for radical radiotherapy <sep> patients with advanced non-small-cell lung cancer <sep> between february 1983 and january 1986 23 centers across canada entered 251 patients on study <sep> national cancer institute of canada ncic <sep>', 'locally unresectable non-small cell lung cancer <sep> patients who had progression of disease after chest irradiation only were treated with <sep> a total of 121 patients were enrolled in the study of whom 7 5.8 were ineligible <sep> patients with medically inoperable or unresectable stage iii non-small cell lung cancer <sep> patients with medically inoperable or unresectable stage iii non-small cell lung cancer treated with <sep> all patients were ambulatory and had measurable or evaluable disease <sep>', 'patients with locoregional squamous cell lung cancer <sep> squamous cell lung cancer 50 patients with locoregional disease <sep>', 'bronchogenic carcinoma <sep> eighty-two patients with histologically confirmed lung cancer <sep>', 'between june 1980 and december 1983 111 patients with inoperable epidermoid bronchogenic carcinoma limited disease <sep> thirty-five of 62 56.4 <sep> locally advanced epidermoid bronchogenic carcinoma <sep>', 'metastatic non-small cell lung cancer <sep> patients with advanced metastatic non-small cell lung cancer <sep> patients with unresectable non-small cell lung cancer <sep>', 'locally advanced non-small-cell lung cancer <sep> seventy eligible patients <sep> patients with stage iii non-small-cell lung cancer <sep>', 'eligible patients in chemotherapy n  90 and control groups n  91 were equally distributed <sep> completely resected stage iii non-small-cell lung cancer <sep> two hundred nine patients with completely resected stage iii non-small-cell lung cancer <sep>', 'patients with extensive non-small cell lung cancer <sep> 87 patients with inoperable extensive non-small cell lung cancer nsclc <sep>', 'four hundred and seventeen patients were randomized into three groups 132 patients received <sep> after a successful curative resection of a carcinoma of the lung in men <sep> after resection of carcinoma of the lung <sep>', 'eligible patients with stage i disease were classified by known prognostic factors <sep> patients with completely resected stage i non-small-cell lung cancer <sep> 269 patients entered in the study 101 had recurrence and 127 have died <sep> non-small-cell lung cancer patients with complete surgical resection of disease <sep> patients with resected stage i lung cancer <sep>', 'from april 1985 to september 1988 128 patients with advanced non-small-cell lung cancer nsclc <sep> advanced non-small-cell lung cancer <sep> 123 patients 62 treated and 61 controls eligible for survival 115 were fully evaluable for response 58 treated and 57 controls <sep>', 'among them 24 cases 7.2 were excluded because of incomplete resection 15 pathologically benign tumour 3 small cell lung cancer 2 and other factors 4 <sep> three hundred and nine cases were eligible 155 cases in group a p-stage i 93 ii 19 iii 43 and 154 in group b <sep> patients with non-small cell lung cancer <sep> three hundred and thirty-three resected cases were registered <sep> lung cancer chubu japan <sep> patients for whom non-small cell lung cancer had been resected completely <sep> july 1985 to december 1987 <sep>', 'eight hundred sixty-five patients with a microscopically curative resection for carcinoma of the lung <sep> after resection of carcinoma of the lung <sep>', '188 evaluable patients 97 received chemotherapy and 91 were in the control arm <sep> advanced non-small cell lung cancer <sep> two hundred and one patients with stage iiib or iv nsclc <sep> 17 patients <sep> advanced non-small cell lung cancer nsclc <sep>'], 'interventions': ['same radiation therapy but began it immediately and received no chemotherapy <sep> induction chemotherapy plus high-dose radiation versus radiation alone <sep> vinblastine <sep> cisplatin and vinblastine <sep> cisplatin <sep>', 'placebo <sep> cyclophosphamide <sep> cytotoxic chemotherapy with either busulphan or cyclophosphamide <sep>', 'radical surgery <sep> cap <sep> adjuvant chemotherapy <sep> adjuvant chemotherapy n  54 cyclophosphamide 400 mg/m2 doxorubicin 40 mg/m2 and cisplatin 40 mg/m2 cap for six cycles or no active treatment <sep> nsclc underwent radical surgery <sep> adjuvant chemotherapy <sep>', 'vindesine <sep> radiotherapy <sep> radiotherapy <sep> vindesine <sep> radiotherapy plus vindesine <sep> radiotherapy or vindesine <sep> single-agent vindesine thoracic radiotherapy <sep> thoracic radiotherapy <sep> vindesine or radiotherapy <sep> immediate thoracic irradiation <sep> vindesine 3 mg/m2 body surface area weekly standard thoracic radiotherapy 60 gy over 6 weeks or both vindesine and thoracic radiotherapy <sep>', 'chemotherapy with cisplatin cyclophosphamide and mitomycin combined with appropriate supportive care <sep> mitomycin <sep> cisplatin-cyclophosphamide-mitomycin combination chemotherapy <sep> cisplatin 22.1 mg/m2 cyclophosphamide 118 mg/m2 and mitomycin <sep> supportive care and cisplatin-cyclophosphamide-mitomycin therapy <sep> supportive care alone <sep> supportive care along with cisplatin <sep> cyclophosphamide <sep>', 'chemotherapy and/or immunotherapy <sep> radiation with or without doxorubicin chemotherapy and with or without levamisole immunotherapy <sep> doxorubicin <sep> levamisole <sep> radiation therapy <sep>', 'radiotherapy <sep> radiotherapy alone <sep> radiotherapy and chemotherapy <sep> vindesine cyclophosphamide cisplatin and lomustine <sep> radiotherapy alone versus combined chemotherapy and radiotherapy <sep>', 'cisplatin cddp 100 mg/m2 on day 1 and etoposide <sep> high-dose radiation therapy <sep> radiotherapy <sep> induction chemotherapy <sep> radiotherapy alone <sep> radiotherapy 56 gy on pre-treatment tumor volume and 40 gy on mediastinum and bilateral supraclavicular nodes <sep> induction chemotherapy before high-dose radiotherapy <sep> induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone <sep> cisplatin <sep>', 'chemotherapy <sep> combination chemotherapy <sep> vindesine and cisplatin vp and cyclophosphamide doxorubicin and cisplatin cap <sep> supportive care bsc <sep>', 'thoracic radiotherapy alone or in combination with chemotherapy <sep> macc chemotherapy <sep> radiotherapy <sep> thoracic radiotherapy <sep> thoracic radiation therapy alone <sep> radiotherapy <sep> chemotherapy with macc <sep> methotrexate intravenous doxorubicin intravenous cyclophosphamide and oral lomustine ccnu <sep> chemotherapy <sep> combined chemoradiotherapy <sep>', 'vlb <sep> vlb 6 mg/m2 concurrently with and after locoregional radiotherapy rt <sep> vinblastine vlb <sep> vinblastine <sep> locoregional rt alone <sep>', 'adriamycin and 5-fluorouracil <sep> radiotherapy <sep> radiotherapy alone <sep> adjuvant chemotherapy <sep> radiotherapy alone and radiotherapy with chemotherapy using adriamycin and 5-fluorouracil <sep>', 'combined radiotherapy and chemotherapy versus radiotherapy alone <sep> radiotherapy alone versus radiotherapy and combination chemotherapy with cyclophosphamide adriamycin doxorubicin methotrexate and procarbazine <sep> combined radiotherapy and chemotherapy <sep>', 'combination chemotherapy <sep> supportive care treatment with palliative radiation psychosocial support analgesics nutritional support to supportive care plus combination chemotherapy with cisplatin and vinblastine <sep> chemotherapy <sep> supportive care versus supportive care and combination chemotherapy <sep>', 'vindesine <sep> high-dose split course radiotherapy <sep> radiotherapy <sep> ct  rt <sep> chemotherapy versus high-dose radiotherapy <sep> high-dose radiotherapy <sep> radiotherapy <sep> high-dose split course radiotherapy rt versus the same radiotherapy preceded by high-dose chemotherapy ct <sep> cisplatin <sep>', 'adjuvant chemotherapy <sep> postoperative cisplatin and vindesine chemotherapy or no further treatment <sep> postoperative cisplatin and vindesine chemotherapy <sep>', 'semicurative radiation therapy <sep> symptomatic treatment versus combination chemotherapy <sep> etoposide <sep> combination chemotherapy cisplatin at 70 mg/m2 intravenously i.v <sep>', 'cyclophosphamide cytoxan <sep> adjuvant cancer chemotherapy <sep> adjuvant cancer chemotherapy <sep> cyclophosphamide alternating with methotrexate regimen b and 143 patients received no additional therapy the controls <sep>', 'cap <sep> adjuvant chemotherapy with cyclophosphamide doxorubicin and cisplatin <sep> adjuvant chemotherapy radiotherapy or immunotherapy <sep> cyclophosphamide doxorubicin and cisplatin cap <sep> cyclophosphamide 40 mg/m2 doxorubicin and 60 mg/m2 cisplatin <sep>', 'chemotherapy <sep> methotrexate <sep> etoposide 200 mg/m2 iv day 1 and lomustine <sep> alternating chemotherapy <sep> epirubicin 50 mg/m2 iv day 1 and cisplatin <sep> cyclophosphamide <sep>', 'chemotherapy <sep> postoperative adjuvant chemotherapy <sep> cddp <sep> adm <sep> uft <sep> adjuvant chemotherapy <sep>', 'adjuvant therapy <sep> ccnu and hydroxyurea <sep>', 'discontinuing chemotherapy <sep> chemotherapy <sep> vindesine <sep> radiotherapy <sep> cisplatin 120 mg m-2 on days 1 and 29 and vindesine 3 mg m-2 weekly x 6 or to no chemotherapy <sep> cisplatin <sep> cisplatin and vindesine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",at the outset of this meta-analysis there was considerable pessimism about the role of chemotherapy in the treatment of non-small cell lung cancer. these results offer hope of progress and suggest that chemotherapy may have a role in treating this disease.
29,"{'outcomes': ['remaining dry and time to dry non-attendance and dropout rates <sep> maternal tolerance scale <sep>', 'maternal anger <sep>', 'functional enuresis fe <sep>'], 'punchline_text': ['no significant intervention effect was found for any of the outcome measures recorded during treatment at discharge or six-months post discharge. <sep>', ""both procedures were equally effective and in the total sample a better response to treatment was predicted by the child's report of being teased by siblings. <sep>"", 'functional enuresis fe was present in the majority of our patients 168/204). <sep>'], 'population': ['270 children collected longitudinally <sep> fifteen school nurse-led community enuresis clinics in leicestershire uk <sep> nocturnal enuresis education <sep>', '74 enuretic children <sep>', '168 subjects aged from 6 to 11 years <sep>'], 'interventions': ['multimedia educational programs <sep> multimedia versus written information <sep>', 'enuresis alarm alone with a brief version of dry bed training <sep>', 'therapy groups pharmacological therapy behavioral therapy and behavioral therapy with the aid of a personal computer <sep> bladder retention training and behavioral therapy <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",although dbt and fsht were better than no treatment when used in combination with an alarm there was insufficient evidence to support their use without an alarm. an alarm on its own was also better than dbt on its own but there was some evidence that combining an alarm with dbt was better than an alarm on its own suggesting that dbt may augment the effect of an alarm. there was also some evidence that direct contact with a therapist might enhance the effects of an intervention.
30,"{'outcomes': ['persistent coughing <sep> efficacy <sep> dyspnea <sep> intensity of wheezing <sep> oxatomide <sep> sleep disorders <sep> monitoring cough dyspnea at rest dyspnea following exercise wheezing sleep disorders <sep>', 'body weight gain <sep> slight drowsiness <sep> bronchodilatation and normalizing pulmonary function <sep> levels of eosinophil cationic protein and total asthma symptom scores <sep> total ige or igg4 <sep> efficacy and safety <sep>'], 'punchline_text': ['in all parameters examined oxatomide was significantly more active than placebo at the first examination p  0.05 and p  0.01). <sep>', 'the levels of eosinophil cationic protein and total asthma symptom scores were significantly reduced during treatment with oxatomide. <sep>'], 'population': ['young children <sep> infantile bronchial asthma <sep> eight patients 7 males 1 female aged 22 months <sep> paediatric clinic sixteen children divided into two balanced groups took <sep>', 'asthma in children <sep> childhood asthma <sep> sixty-four asthmatic children of both sexes aged between 5 and 16 years <sep> adults <sep>'], 'interventions': ['oxatomide <sep> placebo <sep> oxatomide <sep>', 'oxatomide <sep> placebo <sep> oxatomide <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>']}",there is no evidence to show that oxatomide has a significant effect on the control of stable asthma. some studies reported significant benefits in subjective parameters. there was improvement in some lung function outcomes reported but this were not consistent across measures or studies and may represent reporting bias. adverse events including drowsiness were significantly greater with oxatomide than placebo.
31,"{'outcomes': ['radiographic progression <sep>', 'ra activity <sep> esr tender and swollen joint counts the duration of morning stiffness disease activity score-28 das 28 visual analogue scale vas and health assessment questionnaire haq <sep> disease activity parameters <sep> disease activity assessed by das 28 <sep> rheumatoid arthritis activity <sep>', 'demri scans <sep> ire <sep> initial rate of enhancement ire and the maximal signal intensity si enhancement me <sep> clinical signs and symptoms <sep> synovial inflammation <sep>', 'elevated transaminases <sep> adverse events <sep> acr20 response rates <sep> diarrhea and nausea <sep> acr20 responder rates <sep>', 'efficacy and safety <sep> adverse events <sep> improvement in eular criteria and secondary endpoints were patient and physician global evaluation incidence of remission and biochemical and clinical adverse events <sep> remission <sep> improvement and remission <sep>', 'discontinuation rates <sep> adverse events <sep> overall incidences of adverse events <sep> health assessment questionnaire disability index <sep> rate of achievement of 20 improvement in acr criteria acr20 <sep> efficacy and safety <sep>', 'incidence of side reactions <sep> symptoms signs and joint functions <sep> general effective rate and notable effective rate <sep>', 'rates of remarkable improvement <sep> incidence of adverse events <sep> adverse events <sep> rate of withdrawal due to adverse events <sep> gastrointestinal symptoms skin rash alopecia nervous system symptoms decreased leukocyte count and elevation of alanine aminotransferase alt <sep> symptoms signs and joint function <sep> efficacy and safety <sep> overall rates of effectiveness <sep>', 'side effects <sep> severe gastrointestinal symptoms and hepatotoxicity <sep> rheumatoid arthritis <sep>', ""efficacy and safety <sep> alopecia <sep> tolerated <sep> nausea <sep> reversible agranulocytosis <sep> transiently abnormal liver function <sep> radiographic disease progression <sep> diarrhoea <sep> tender and swollen joint counts and investigator's and patient's overall assessments <sep> tender joint count <sep>"", 'radiographic progression <sep> adverse events <sep> radiographic disease progression <sep> erosive joint counts <sep> sustained retardation of radiographic progression <sep> larsen scores <sep> larsen scores and erosive joint counts <sep>', 'function and health-related quality of life <sep> function and health-related quality of life <sep> mhaq scores haq disability index weighted top 5 score of the pet physical component score of the sf-36 and bodily pain scale <sep> mhaq scores 5 of 8 scales and disability index of the haq <sep> pet score sf-36 physical component score and work productivity <sep> measures of function and heath-related quality of life mhaq scores all scales and disability index of the haq weighted top 5 score of the pet 5 of 8 scales and physical component score of the sf-36 and work productivity <sep> sf-36 scales and component scores <sep> acr response rates <sep> health assessment questionnaire haq modified health assessment questionnaire mhaq problem elicitation technique pet medical outcomes study short form 36 sf-36 and questions regarding work productivity <sep>', 'acr 50 response rate <sep> das28 response rate and secondary efficacy outcomes <sep> efficacy and safety <sep> das28 response <sep>', 'gastrointestinal symptoms weight loss allergic reactions skin rash and reversible alopecia <sep> incidence of infections <sep> safety and effectiveness <sep> adverse events aes <sep> incidence of aes <sep> safety and effectiveness <sep> opportunistic infections <sep>', 'efficacy and safety <sep> adverse events aes resulting in treatment withdrawal <sep> response rates <sep> tender joint count tjc swollen joint count sjc and health assessment questionnaire disability index haq di <sep> efficacy and safety profile <sep>', 'toxicity <sep> health assessment questionnaire haq disability index haq di and the physical component score of the medical outcomes survey 36-item short <sep> radiographic progression <sep> american college of rheumatology improvement response rates <sep> upper respiratory tract infections diarrhea nausea and vomiting rash reversible alopecia and transient liver enzyme elevations <sep> physical function <sep> mean change in total sharp radiologic damage scores <sep> mean <sep> serious treatment-related adverse events <sep> safety and efficacy <sep> haq di with lef4(-0.60 <sep>', 'mean das28 <sep> mean das28 <sep> disease activity <sep>', 'haq scores <sep> functional ability <sep> diarrhea nausea and alopecia <sep> functional disability <sep> safe and well tolerated <sep> adverse events <sep> haq disability index di <sep> patients functional ability <sep> health assessment questionnaire haq <sep> mean haq scores <sep>', 'improved haq scores <sep> adverse events or late toxicity <sep> slowing of disease progression <sep> deltahaq disability index <sep> functional ability <sep> global assessments acr20 response <sep> efficacy and safety <sep> diarrhoea nausea and alopecia <sep>', 'function and health-related quality of life <sep> asymptomatic transaminase elevations <sep> acr response and success rates <sep> gastrointestinal complaints skin rash and reversible alopecia <sep> signs and symptoms of active ra delayed disease progression <sep> disease progression <sep> mean time to initial response <sep> efficacy and safety <sep> physical function and health-related quality of life <sep>', 'discontinuation rates <sep> response rate <sep> adverse events <sep> comparable disease activity score 28 reduction rates <sep> serious adverse drug effects <sep>'], 'punchline_text': ['lef mtx and ssz treatment resulted in statistically significantly less radiographic progression compared with placebo at 6 and 12 months for protocol us301 lef versus placebo p  <sep>', 'disease activity assessed by das 28 decreased significantly in all groups the results were comparable in groups treated with mtx and lef and significantly more prominent in the group treated with a tnf-alpha blocker. <sep>', 'improvement in synovial inflammation as measured by ire was significantly better with leflunomide than with methotrexate over 4 months of therapy. <sep>', 'diarrhea and nausea were less frequent during the open-label extension in patients who did not receive a lef loading dose. <sep>', 'leflunomide though effective was associated with adverse events and has not been extensively studied in the indian population. <sep>', 'discontinuation rates were similar in both treatment groups 23.1 in the leflunomide group and 24.8 in the placebo group as were the overall incidences of adverse events 89.2 vs. 89.5 respectively). <sep>', 'the incidence of side reactions was lower in lef group 17.86 than in mtx group 40.00 p  0.05). <sep>', 'both leflunomide and mtx could improve the symptoms signs and joint function but there were no changes in x-ray observations of patients with rheumatoid arthritis. <sep>', 'by the fourth to sixth month the response was comparable on both groups 6/6 and 6/8 patients achieving acr 50 in the daily and weekly dose respectively and prevailed through the end of the study. <sep>', 'leflunomide and sulphasalazine were significantly superior to placebo <sep>', 'changes in larsen scores and erosive joint counts with leflunomide and sulfasalazine at 6 months showed significantly less radiographic progression than placebo. <sep>', 'significant improvements in function and health-related quality of life occurred in patients with ra during treatment with leflunomide or methotrexate. <sep>', 'the safety profiles of both groups were comparable. <sep>', 'the incidence of infections was similar between the treatment and placebo groups no opportunistic infections were seen. <sep>', 'adverse events aes resulting in treatment withdrawal were higher in the 10 mg 15.3 than in the 20 mg treatment group 12.0 as were serious adverse events saes 12.9 vs 10.0%. <sep>', 'lef was statistically significantly superior to mtx in improving physical function as measured by the haq di over 24 months of treatment. <sep>', '1.16 for the lef-group was significantly different neither in between the both treatment groups nor in comparison to the week 8 evaluation. <sep>', 'leflunomide significantly improved patients functional ability compared to placebo p  or  0.0001 and sulfasalazine p  or  0.01 at 6 months. <sep>', 'deltamean haq 0.65 v 0.36 p=0.0149 deltahaq disability index 0.89 v 0.60 p=0.059). <sep>', 'leflunomide and methotrexate treatment improved measures of physical function and health-related quality of life significantly more than placebo p<.001 and p<.05 respectively). <sep>', 'comparable disease activity score 28 reduction rates were noted at trial termination for all 3 treatment arms <sep>'], 'population': ['482 patients randomized in a 3:3:2 ratio <sep> 999 patients <sep> patients with active rheumatoid arthritis <sep> 358 patients <sep> rheumatoid arthritis <sep>', 'rheumatoid arthritis <sep> seventy-eight patients with active ra <sep>', 'thirty-four patients 17 treated with leflunomide and 17 with <sep> patients with active ra n  39 <sep>', 'patients with rheumatoid arthritis ra <sep> patients with active rheumatoid arthritis failing mtx monotherapy <sep>', '84 patients <sep> rheumatoid arthritis patients <sep> refractory rheumatoid arthritis <sep> patients refractory to conventional disease-modifying agents <sep>', 'patients with persistently active rheumatoid arthritis <sep> patients with persistent rheumatoid arthritis as defined by american college of rheumatology acr criteria despite receiving methotrexate for at least 6 months <sep> patients with active rheumatoid arthritis who are receiving methotrexate therapy <sep> patients with active rheumatoid arthritis <sep> 20 centers in the united states and canada <sep>', 'rheumatoid arthritis ra <sep> 81 patients with ra <sep> rheumatoid arthritis <sep>', 'patients with rheumatoid arthritis ra in china <sep> five hundred and sixty-six patients with active rheumatoid arthritis <sep> patients with rheumatoid arthritis <sep>', 'sixteen patients were included 18-72 years disease duration 2-32 years <sep> patients with refractory rheumatoid arthritis <sep> refractory rheumatoid arthritis patients <sep> refractory rheumatoid arthritis <sep>', 'active rheumatoid arthritis <sep> 358 patients <sep>', 'rheumatoid arthritis patients <sep> patients who complete 2 years of treatment <sep>', 'patients with active rheumatoid arthritis ra <sep> patients with active rheumatoid arthritis <sep>', 'patients with ra with an inadequate response to leflunomide monotherapy <sep> patients with active ra das28 3.2 who were enrolled in the first open label phase of the relief study received <sep> 106 inadequate responders entered the double blind phase 56 received <sep> patients inadequately responding to leflunomide <sep>', 'patients with active rheumatoid arthritis ra treated for 6 months <sep> patients with active rheumatoid arthritis <sep> patients with active ra <sep> four hundred two patients <sep>', '402 ra patients <sep> patients with active rheumatoid arthritis <sep> active rheumatoid arthritis ra <sep>', 'patients continuing into the second year of treatment with  or  1 dose of study medication and  or  1 followup visit after week 52 consisted of 235 patients lef n  98 placebo n  36 mtx n  101 <sep>', 'nave patients with ra mean time since diagnosis 2.3 years <sep> rheumatoid arthritis patients treated with <sep>', 'cohorts of patients with ra from the initial study who volunteered to continue treatment with leflunomide or sulfasalazine <sep> patients with rheumatoid arthritis--longterm treatment with <sep>', '6 12 and 24 month patient cohorts <sep> 358 patients with rheumatoid arthritis <sep>', '402 patients with active rheumatoid arthritis ra <sep> 482 patients studied were predominantly women mean age 54 years mean disease duration 6.7 years for whom a mean of 0.8 disease-modifying antirheumatic drugs had failed <sep> forty-seven university and private rheumatology practices in the united states and canada <sep> patients with active ra <sep>', 'one hundred six patients with active ra refractory to at least one disease modifying antirheumatic drug methotrexate obligatorily <sep> severe rheumatoid arthritis ra <sep> severe rheumatoid arthritis <sep>'], 'interventions': ['lef or ssz <sep> placebo <sep> leflunomide <sep> mtx <sep> lef or mtx <sep> lef mtx and ssz <sep> lef <sep> leflunomide lef methotrexate mtx or sulfasalazine ssz <sep>', 'methotrexate mtx <sep> mtx and lef <sep> mtx lef and a biologic agent tnf-alpha blocker combined with mtx <sep> tnf-alpha blocker etanercept 25 mg 2x weekly or infliximab <sep> tnf-alpha blocker combined with mtx <sep> mtx <sep> tnf-alpha blocker plus methotrexate versus methotrexate or leflunomide alone <sep> leflunomide lef <sep> tnf-alpha blocker <sep> lef <sep>', 'placebo <sep> methotrexate <sep> leflunomide <sep> leflunomide and methotrexate <sep> dynamic gadolinium-enhanced magnetic resonance imaging demri <sep>', 'lef <sep> placebo <sep> lef and mtx continued treatment lef/lef  mtx <sep> lef and mtx <sep> placebo pla or lef to stable mtx therapy <sep> mtx <sep> pla/lef  mtx <sep> leflunomide lef <sep> combination leflunomide and methotrexate mtx therapy <sep> methotrexate mtx therapy <sep> pla and mtx <sep>', 'leflunomide <sep> leflunomide alone and in combination with methotrexate <sep> methotrexate <sep>', 'leflunomide or matching placebo <sep> placebo <sep> methotrexate <sep> concomitant leflunomide therapy <sep> leflunomide versus placebo <sep> methotrexate therapy <sep> leflunomide and methotrexate <sep> leflunomide plus methotrexate <sep>', ""leflunomide <sep> methotrexate's mtx's <sep> mtx <sep> leflunomide lef <sep> lef <sep> lef and oxaprozin <sep>"", 'leflunomide at 20 mg once daily or mtx <sep> leflunomide <sep> methotrexate mtx <sep> mtx <sep> leflunomide and mtx <sep> leflunomide <sep>', 'leflunomide <sep> conventional leflunomide <sep>', 'placebo <sep> leflunomide <sep> leflunomide and sulphasalazine <sep> leflunomide and sulphasalazine <sep> placebo or sulphasalazine <sep> leflunomide <sep> leflunomide with placebo and sulphasalazine <sep> placebo and sulphasalazine <sep>', 'placebo <sep> leflunomide or sulfasalazine <sep> leflunomide and sulfasalazine <sep> leflunomide <sep> sulfasalazine <sep>', 'placebo <sep> methotrexate <sep> methotrexate leflunomide <sep> leflunomide versus methotrexate or placebo <sep> leflunomide or methotrexate <sep> methotrexate and placebo <sep>', 'leflunomide plus sulfasalazine <sep> leflunomide <sep> sulfasalazine <sep> placebo plus sulfasalazine <sep> leflunomide plus sulfasalazine and 50 placebo plus sulfasalazine <sep>', 'placebo <sep> leflunomide <sep> placebo or leflunomide <sep> leflunomide versus placebo <sep> leflunomide <sep>', 'leflunomide <sep>', 'methotrexate <sep> leflunomide <sep> methotrexate mtx <sep> lef and mtx <sep> mtx <sep> leflunomide lef <sep> leflunomide <sep> lef <sep>', 'oral prednisone <sep> prednisone <sep> mtx or lef <sep> mtx <sep> leflunomide or methotrexate accompanied by moderate dose prednisone <sep> lef <sep> ra with mtx or lef <sep>', 'placebo and sulfasalazine <sep> placebo <sep> leflunomide versus sulfasalazine <sep> leflunomide <sep> sulfasalazine <sep>', 'placebo <sep> leflunomide <sep> leflunomide with sulfasalazine <sep> leflunomide and sulfasalazine <sep> leflunomide 20 mg/day placebo or sulfasalazine <sep> sulfasalazine <sep> leflunomide <sep>', 'placebo <sep> methotrexate <sep> leflunomide <sep> placebo and methotrexate <sep> methotrexate therapy <sep> leflunomide treatment <sep> leflunomide <sep> leflunomide and methotrexate <sep> placebo or methotrexate treatment <sep>', 'lef <sep> csa <sep> combination comb of cyclosporine csa and leflunomide lef <sep> cyclosporine and leflunomide <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",leflunomide appears to improve all clinical outcomes and delay radiologic progression at both six and 12 months of treatment compared to placebo. its efficacy and adverse events are comparable to mtx ssz and cyclosporin a up to two years of treatment. combined leflunomide and mtx was more efficacious than mtx alone up to three years of treatment and the adverse events did not increase. different dosages of leflunomide were similar regarding their effectiveness and toxicity.
32,"{'outcomes': ['overall survival of ecmo <sep>', 'intracerebral hemorrhage <sep> survival <sep>'], 'punchline_text': ['all three treatment groups cmt and ecmo in phase i and ecmo phase ii were comparable in severity of illness and mechanical ventilator support. <sep>', 'extracorporeal membrane oxygenation allows lung rest and improves survival compared to conventional ventilator therapy in newborn infants with severe respiratory failure. <sep>'], 'population': ['neonates with persistent pulmonary hypertension of the newborn <sep> thirty-nine newborn infants with severe persistent pulmonary hypertension and respiratory failure who met criteria for 85 likelihood of dying <sep>', 'neonatal respiratory failure <sep> 12 infants with birth weight greater than 2 kg met objective criteria for high mortality risk <sep> newborns with respiratory failure <sep> newborn infants with severe respiratory failure <sep>'], 'interventions': ['conventional medical therapy cmt <sep> extracorporeal membrane oxygenation ecmo therapy <sep> extracorporeal membrane oxygenation and conventional medical therapy <sep> ecmo <sep>', 'extracorporeal membrane oxygenation <sep> extracorporeal membrane oxygenation <sep> extracorporeal circulation <sep> conventional ventilator therapy <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>']}",a policy of using ecmo in mature infants with severe but potentially reversible respiratory failure results in significantly improved survival without increased risk of severe disability. the benefit of ecmo for babies with diaphragmatic hernia is unclear. further studies are needed to consider the optimal timing for introducing ecmo to identify which infants are most likely to benefit and to address the implications of neonatal ecmo during later childhood and adult life.
33,"{'outcomes': ['time to the first skeletal complication <sep> skeletal complication <sep> bone pain use of analgesics quality of life performance status bone tumor response and biochemical parameters <sep> skeletal morbidity <sep> tolerated <sep> skeletal complications pathologic fractures spinal cord compression irradiation of or surgery on bone or hypercalcemia <sep> survival or in objective bone response rate <sep> skeletal morbidity rate <sep>', 'control of bone pain <sep> metastatic bone pain <sep> visual analog pain score <sep> bone pain visual analog score analgesic use and compliance with therapy <sep> analgesic use increased with disease progression <sep> bone pain <sep>', 'visual analog pain scores and adverse events <sep> adverse events <sep> compliance <sep> pain scores or analgesic requirements <sep> bone-derived isoenzyme alkaline phosphatase values <sep> fasting urinary calcium excretion <sep> bone alkaline phosphatase levels <sep> fasting calcium excretion <sep> safety and efficacy <sep>', 'excretion of hydroxyproline <sep> osteoclast number <sep> bone pain <sep> radiologic skeletal lesions <sep>', 'analgesic effect <sep> average change in dmed <sep> pain <sep> vas scores for general pain pain at rest and pain <sep> daily visual analogue scales vas and analgesic diaries <sep>', 'symptomatic response rate or analgesic requirement <sep>', 'activity scores <sep> pain scores <sep> visual analogue scale assessments <sep> daily oral morphine equivalent analgesic requirement <sep> clinical and laboratory parameters of toxicity <sep>', 'urinary calcium ohp and serum ictp levels <sep> pain <sep> pain score <sep> urinary calcium hydroxyproline ohp and serum cross-linked carboxyterminal telopeptide region of type i collagen ictp levels <sep> urinary calcium levels <sep> pain palliation <sep> pain score performance status and changes in analgesic use <sep> pain score <sep>', 'rate of bone resorption <sep> symptomatic response <sep> subjective benefit <sep> quality of life <sep> resorption markers <sep> bone resorption markers measured included urinary calcium uca hydroxyproline hyp and the collagen breakdown products ntx crosslaps and free dpd <sep>', 'number and/or size of bone lesions <sep> episodes of severe pain <sep> patient survival <sep> skeletal-related morbidity <sep> skeletal morbidity <sep> body height <sep>', 'skeletal pain relief <sep>', 'totally free of bone pain <sep> pain relief <sep> bone pain <sep> median survival or survival rates <sep> serum calcium concentration <sep>', 'toxicity <sep> myalgia <sep> pain and mobility <sep> bone pain and mobility scores <sep> daily consumption of analgesics <sep>', 'percentage of patients feeling no pain <sep> proportion of patients with progression of osteolytic bone lesions <sep> serum calcium and urinary calcium excretion <sep> progression of vertebral fractures <sep> degree of hypercalcaemia and hypercalciuria and decreases pain <sep> side-effects <sep>', 'incidence of bone-related complications pathological fractures tumor-induced hypercalcemia need for radiotherapy sclerotic response of lytic lesions who performance status and analgesic score <sep> delayed progression of bone metastases <sep> time to progressive bone disease evaluated by blind extramural review and improvement in pain according to a 6-point self-assessment scale <sep> bone pain <sep> median time to radiotherapy <sep> severe adverse reactions or worsening of chemotherapy-induced toxicities <sep> median time to bone progression <sep>', 'frequency of pathologic fractures hypercalcemia and bone pain <sep> vertebral index <sep> vertebral deformity <sep> height loss <sep> bone pain episodes of hypercalcemia or development of pathologic fractures <sep> osteolysis of multiple myeloma <sep>', 'trabecular bone volume <sep> iliac bone biopsy <sep> clinical pain karnofsky survival biological and radiological <sep> bone resorption <sep> histologic bone parameters <sep> bone resorption <sep>', 'pain with dichloromethylene diphosphonate <sep> urinary calcium levels <sep> urinary hydroxyproline levels <sep> hypercalcemia or hypercalciuria <sep>', 'bone remineralization <sep> median duration of pain response <sep> pain intensity <sep> bone pain <sep> palliative effects <sep> pain parameters analgesic consumption and performance status <sep> pain intensity pain frequency general well-being and who pain score <sep> performance status and reduced consumption of analgesics <sep> total-body bone mineral density <sep>', 'pain scores <sep> healing of lytic lesions <sep> bone pain <sep> urinary calcium/creatinine and hydroxyproline/creatinine ratios and bone alkaline phosphatase concentrations <sep> narcotic scores urinary calcium/creatinine and hydroxyproline/creatinine ratios serum osteocalcin and bone alkaline phosphatase concentrations and bone lesion radiologic response <sep> pain score <sep>', 'thickening of the preexisting osteolytic lesions <sep> pain <sep> intensity of pain <sep> urinary calcium <sep> daily consumption of analgesics <sep>', 'analgesics requirement <sep> opioid requirements <sep> pain <sep> mean pain scores <sep> toxicity <sep> karnofsky performance status <sep> occasional gastroenteric discomfort <sep> karnofsky performance status pain score measured by a visual-analogue scale and analgesic requirement <sep>', 'skeletal events <sep> bone pain and no deterioration in performance status and quality of life <sep> quality of life <sep> bone pain analgesic-drug use performance status and quality of life <sep> skeletal events pathologic fracture irradiation of or surgery on bone and spinal cord compression hypercalcemia symptoms or a serum calcium concentration <sep>', 'skeletal complication <sep> bone pain use of analgesic drugs performance status and quality of life <sep> bone pain <sep> skeletal complications <sep> deterioration of performance status <sep> tolerated <sep> skeletal complications including pathologic fractures the need for radiation to bone or bone surgery spinal cord compression and hypercalcemia a serum calcium concentration <sep> median time to the occurrence of the first skeletal complication <sep>', 'visual analogue scales vas <sep> mean pain <sep> mean baseline pain <sep> mean overall pain <sep> pain intensity <sep> analgesic efficacy <sep>', 'skeletal morbidity <sep> event-rates <sep> skeletal morbidity and the radiologic course of metastatic bone disease <sep> event-rates of systemic treatment and radiotherapy <sep> event-free period efp radiologic course of disease and survival <sep> efp <sep> gastrointestinal toxicity <sep> occurrence of hypercalcemia severe bone pain and symptomatic impending fractures <sep> gastrointestinal toxicity <sep>', 'efficacy <sep> rate of bone resorption <sep> symptomatic improvement <sep> sclerosis or stabilisation of lytic metastases <sep> gastrointestinal adverse events <sep> deoxypyridinoline <sep> nausea and vomiting <sep>'], 'punchline_text': ['the skeletal morbidity rate was significantly reduced at 12 18 and 24 cycles in patients treated with 90 mg of pamidronate p  .028 .023 and .008 respectively). <sep>', 'analgesic use increased with disease progression to a similar extent in both groups 59 increased use in the clodronate group v 64 of placebo group difference not significant). <sep>', 'bone-derived isoenzyme alkaline phosphatase values increased in all groups with a significant difference between baseline and final values in the 1,600-mg and 3,200-mg groups p  .01 and p  .03 respectively). <sep>', 'ci2mdp treatment resulted in a marked reduction in bone pain with no progression of radiologic skeletal lesions during the first year. <sep>', 'the average change in dmed was 6.4 se  2.9 following clodronate and was 24.6 se  14.9 following placebo p  0.03). <sep>', 'no difference was seen in the symptomatic response rate or analgesic requirement between patients treated with sodium etidronate and placebo. <sep>', 'no difference in clinical and laboratory parameters of toxicity was evident between the placebo and cl2mdp arms of the trial. <sep>', 'urinary calcium ohp and serum ictp levels increased in group c and decreased in groups a and b but only the decrease of urinary calcium levels of group b was significant p  0.003). <sep>', 'resorption markers did not decrease after placebo but ntx and crosslaps both decreased by 70 after pamidronate p  0.001). <sep>', 'however in patients treated with pamidronate there were fewer episodes of severe pain p=0.02 and a decreased reduction of body height of 1.5 cm p 0.02). <sep>', 'the results do not support the superiority of combined intravenous and oral treatment with clodronate compared with oral administration only. <sep>', 'no significant differences were seen in median survival or survival rates between the groups. <sep>', 'in weeks 0-6 the daily consumption of analgesics was reduced in 3 patients in the 45-mg arm in 4 patients in the 60-mg arm and in 7 patients in the 90-mg arm. <sep>', 'serum calcium and urinary calcium excretion decreased significantly in both groups but the changes were greater in the clodronate group. <sep>', 'marked improvement in bone pain was observed in 44 of patients receiving pamidronate compared to 30 in controls p  0.025). <sep>', 'although the repeated measures analysis showed a significant height loss there was no difference between treatment arms p  .98). <sep>', 'bone resorption decreased significantly in patients with etidronate compared with those with placebo p  0.05). <sep>', 'there were no adverse effects other than transient diarrhea in some patients. <sep>', 'patients in the 90-mg group had more pronounced bone remineralization as measured by total-body bone mineral density. <sep>', 'reduction in bone pain was accompanied by decreases in urinary calcium/creatinine and hydroxyproline/creatinine ratios and bone alkaline phosphatase concentrations. <sep>', 'unlike the controls the patients who received cl2mdp presented a significant reduction in urinary calcium p  0.003 and in hydroxyproline p  0.05 on the 7th day. <sep>', 'analgesics requirement increased in both groups but significantly more in patients receiving placebo p  0.042 in whom increase in opioid requirements was particularly evident. <sep>', 'the proportion of patients who had any skeletal events was significantly lower in the pamidronate group 24 percent than in the placebo group 41 percent p  0.001 and the reduction was evident in both stratum 1 p  0.04 and stratum 2 p  0.004). <sep>', 'there was significantly less increase in bone pain p=0.046 and deterioration of performance status p=0.027 in the pamidronate group than in the placebo group. <sep>', 'as regards mean worst pain a substantial numerical fall was registered for the treatment group 21 mm but the improvement was not significant compared to that of the placebo group. <sep>', 'the event-free period efp radiologic course of disease and survival did not improve. <sep>', 'oral pamidronate produced either sclerosis or stabilisation of lytic metastases for at least 24 weeks in 5 of 24 and 3 of 23 patients at the 300 and 150 mg dose levels respectively. <sep>'], 'population': ['three hundred seventy-two women with breast cancer who had at least one lytic bone lesion and who were receiving hormonal therapy <sep> protocol 18 aredia breast cancer study group <sep> women with advanced breast cancer and lytic bone lesions <sep> women with lytic bone metastases from breast cancer treated with hormone therapy <sep> one hundred eighty-two patients who received <sep>', 'patients with advanced metastatic bone disease <sep> patients with advanced metastatic cancer <sep> fifty-five patients with progressing bone metastases <sep>', 'eighty-four patients with tumor-induced osteolysis <sep> patients with bone metastases <sep> affected patients <sep>', 'multiple myeloma <sep>', 'patients with metastatic bone disease 60 patients with established osseous metastases and persistent bone pain <sep> patients with stable disease and persistent bone pain <sep> patients with refractory bone pain due to metastatic bone disease <sep> patients with metastatic bone disease and pain <sep>', 'fifty-seven patients <sep> all patients had hormone refractory metastatic prostatic cancer and bone pain requiring analgesics <sep>', 'metastatic bone pain <sep> 24 patients with metastatic bone disease and pain <sep>', 'fifty patients with bone pain caused by bm <sep> patients with bone metastases <sep> palliation of pain arising from bone metastases bm <sep>', 'fifty-two patients with painful bone metastases <sep> patients with bone metastases <sep> metastatic bone disease <sep>', 'multiple myeloma <sep> patients with newly diagnosed multiple myeloma who required chemotherapy 300 patients <sep>', 'fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy <sep> patients with prostate cancer <sep>', 'patients with metastic prostatic cancer <sep> patients with painful bone disease from prostatic cancer after failure of hormonal therapy <sep>', 'seventy patients were enrolled in this study for a total of 265 infusions <sep> patients with painful bone metastases <sep> forty-eight patients took nonsteroidal antinflammatory drugs while 22 patients received <sep> 64 patients who completed 12 weeks of therapy <sep> patients with painful osteolytic bone metastases <sep> cancer patients with painful osteolytic bone metastases who had failed initial treatment with hormones and/or chemotherapy <sep>', 'finnish leukaemia group <sep> multiple myeloma <sep> 350 patients from 23 hospitals <sep>', 'breast cancer patients <sep> 295 patients with lytic bone metastases from breast cancer <sep> patients with osteolytic metastases from breast cancer <sep>', '173 newly diagnosed multiple myeloma patients of <sep>', 'ninety-four previously untreated patients with stage ii or iii multiple myeloma <sep>', 'ten women with skeletal metastases from breast carcinoma received <sep> patients with bone metastases from breast cancer <sep> eight patients had moderate to severe bone pain <sep> women with breast carcinoma metastatic to the skeleton <sep>', 'patients with advanced osteolytic bone disease <sep> patients with malignant osteolytic bone disease and pain <sep> patients with advanced malignant osteolytic bone disease and bone pain <sep> seventy patients <sep>', 'ambulatory female patients age 18 years or older with breast cancer metastatic to bone and a life expectancy of at least 3 months were eligible for the study <sep> patients with breast cancer <sep> sixty-one patients were treated as outpatients <sep> patients with metastatic breast cancer <sep>', 'thirty-eight normocalcemic patients with bone metastases from breast carcinoma <sep> 12 evaluable patients treated with <sep> patients with breast carcinoma metastasizing to the skeleton <sep>', 'bone metastases from tumors poorly responsive to chemotherapy <sep> patients with bone metastases from tumors poorly responsive to chemotherapy <sep> sixty-six patients with poorly responsive tumors such as non-small cell lung cancer nsclc bladder cancer gastrointestinal cancers kidney cancer melanoma and metastatic carcinoma of unknown origin entered the study <sep> 66 patients enrolled 9 were observed for one month or less 7 were followed for two months only 50 patients were followed for more than 2 months and could be adequately evaluated <sep> patients with breast cancer prostate cancer and myeloma <sep>', 'patients with stage iii multiple myeloma <sep> patients with stage iii multiple myeloma and at least one lytic lesion <sep> patients with advanced multiple myeloma <sep> 392 treated patients <sep>', '380 of 382 randomized patients 185 receiving pamidronate and 195 receiving <sep> women with stage iv breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion <sep> women with stage iv breast cancer who have osteolytic bone metastases <sep> patients with breast cancer and lytic bone metastases <sep> protocol 19 aredia breast cancer study group <sep>', 'fifty-five patients with hormone refractory prostate cancer and painful bone metastases <sep> patients with painful bone metastases from prostatic cancer <sep>', 'patients with bone metastases from breast cancer <sep> breast cancer patients <sep>', '47 patients with progressive painful predominantly lytic bone metastases from breast cancer <sep> bone metastases from breast cancer <sep>'], 'interventions': ['pamidronate <sep> pamidronate <sep> placebo <sep> pamidronate or placebo <sep>', 'matching placebo <sep> placebo <sep> clodronate <sep> oral clodronate <sep> clodronate <sep>', 'clodronate <sep> oral clodronate <sep> placebo <sep> oral clodronate <sep>', 'ci2mdp <sep> placebo <sep> placebo six patients in addition to other chemotherapy <sep> dichloromethylene diphosphonate ci2mdp <sep>', 'intravenous clodronate <sep> placebo <sep> clodronate 600 mg or 1500 mg in 500 ml of normal saline or 500 ml of saline as placebo <sep> clodronate <sep> intravenous clodronate <sep>', 'sodium etidronate <sep> placebo <sep> sodium etidronate <sep> sodium etidronate and placebo <sep>', 'cl2mdp <sep> 2-dichloromethylene bisphosphonate cl2mdp 600 mg in 500 ml of normal saline or a 4-hr placebo infusion 500 ml of normal saline <sep> intravenous clodronate <sep> placebo <sep>', 'clodronate <sep> antitumor chemotherapy or hormonal therapy <sep> oral clodronate <sep>', 'pamidronate <sep> pamidronate 120 mg or an identical infusion of saline <sep> placebo <sep>', 'pamidronate <sep> placebo <sep> oral bisphosphonate therapy <sep> conventional intermittent melphalan/prednisolone <sep> oral pamidronate <sep> pamidronate <sep>', 'estramustine <sep> placebo <sep> clodronate or placebo <sep> clodronate <sep> oral clodronate <sep> clodronate <sep>', 'placebo <sep> estramustine phosphate <sep> clodronate <sep> oral clodronate <sep> clodronate <sep> estramustine phosphate orally <sep>', 'pamidronate <sep> morphine <sep>', 'clodronate <sep> clodronate 2.4 g daily or placebo <sep> placebo <sep> standard melphalan-prednisolone <sep>', 'chemotherapy or chemotherapy plus pamidronate aredia <sep> pamidronate therapy <sep> pamidronate <sep>', 'etidronate disodium ehdp <sep> diphosphonate compound <sep> daily etidronate <sep> ehdp therapy <sep> melphalan and prednisone <sep> oral ehdp 5 mg/kg/d or placebo until death or discontinuation due to intolerance or refusal <sep>', 'placebo etidronate <sep> placebo <sep> etidronate <sep>', 'dichloromethylene diphosphonate <sep> dichloromethylene diphosphonate cl2mdp <sep> oral dichloromethylene diphosphonate <sep> oral dichloromethylene diphosphonate treatment <sep>', 'pamidronate <sep> pamidronate 60 mg or 90 mg i.v <sep>', 'pamidronate <sep> bisphosphonate <sep> narcotic medication radiation therapy or hormonal therapy <sep> intravenous pamidronate disodium <sep> pamidronate disodium <sep> intravenous pamidronate <sep>', 'placebo <sep> specific antitumor treatment chemotherapy and/or hormone therapy <sep> dichloromethylene diphosphonate cl2mdp <sep> dichloromethylene diphosphonate <sep> cl2mdp <sep>', 'placebo <sep> clodronate <sep> bisphosphonates <sep> oral clodronate <sep> bisphosphonates <sep> clodronate 1,600 mg/day for one year or identical placebo-containing tablets <sep>', 'pamidronate <sep> placebo <sep> second-line stratum 2 antimyeloma chemotherapy <sep> placebo or pamidronate <sep> bisphosphonates <sep> pamidronate <sep>', 'pamidronate <sep> placebo <sep> pamidronate disodium <sep> placebo or pamidronate <sep> bisphosphonates <sep> pamidronate <sep>', 'clodronate <sep> placebo <sep> clodronate 300 mg i.v <sep> oral clodronate <sep>', 'pamidronate <sep> palliative pamidronate <sep> supportive pamidronate treatment <sep> pamidronate <sep> pamidronate ld <sep>', 'pamidronate <sep> oral pamidronate <sep> oral pamidronate <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there is evidence to support the effectiveness of bisphosphonates in providing some pain relief for bone metastases. there is insufficient evidence to recommend bisphosphonates for immediate effect as first line therapy to define the most effective bisphosphonates or their relative effectiveness for different primary neoplasms. bisphosphonates should be considered where analgesics and/or radiotherapy are inadequate for the management of painful bone metastases.
34,"{'outcomes': ['serious side effects <sep> numeric rating scales <sep> average pain scales <sep> pain scales <sep> pain relief <sep> morphine requirements <sep>'], 'punchline_text': ['no serious side effects were observed in this study. <sep>'], 'population': ['terminal cancer pain patients <sep> patients with terminal cancer pain <sep>'], 'interventions': ['intrathecal morphine <sep> ketamine and morphine <sep> intrathecal ketamine <sep> intrathecal ketamine <sep> intrathecal morphine alone twice daily phase m  k co-administration of ketamine <sep> ketamine <sep> ketamine <sep> morphine <sep>'], 'punchline_effect': [' no diff <sep>']}",since the last version of this review three new studies were identified but excluded from the review. current evidence is insufficient to assess the benefits and harms of ketamine as an adjuvant to opioids for the relief of cancer pain. more rcts are needed.
35,"{'outcomes': ['iop <sep> peripheral anterior synechiae <sep> iop medications need for surgery or visual function <sep> intraocular pressure iop peripheral anterior synechiae corneal endothelial cell count and complications <sep> efficacy and safety <sep>'], 'punchline_text': ['there was no significant difference in iop medications need for surgery or visual function between groups at the 1-year visit. <sep>'], 'population': ['2010 elsevier inc <sep> consecutive patients older than 40 years with synechial primary angle-closure or primary angle closure glaucoma were recruited <sep> eyes with synechial primary angle-closure or primary angle-closure glaucoma <sep> seventy-seven eyes 77 patients were randomized to the iridotomy group and 81 eyes 81 patients <sep> eligible patients <sep> in eyes with synechial primary angle-closure or primary angle-closure glaucoma <sep> primary angle-closure glaucoma <sep>'], 'interventions': ['iridotomy plus iridoplasty <sep> laser peripheral iridotomy with or without laser peripheral iridoplasty <sep> iridotomy or iridotomy plus iridoplasty <sep> iridotomy alone or combined with iridoplasty <sep> laser peripheral iridotomy with and without iridoplasty <sep>'], 'punchline_effect': [' no diff <sep>']}",there is currently no strong evidence for laser peripheral iridoplastys use in treating angle-closure.
36,"{'outcomes': ['severe asthmatics <sep> number of urgent care visits <sep> arterial oxygen tension <sep> hospital admissions <sep> forced expiratory volume in one second fev1 <sep> scheduled visits <sep>', 'psychosomatic discomfort scale <sep> quality of life <sep> resources productive output and in health status <sep> health status <sep> number of days lost through sickness <sep>', 'scores of knowledge of drugs <sep>', 'mean duration of illness <sep>', 'self-management ability or asthma morbidity <sep> knowledge of asthma shown <sep> asthma morbidity <sep>', 'asthma-related emergency visits <sep> cost and effectiveness <sep> asthma-related emergency department visits <sep>'], 'punchline_text': ['one year after the end of the school we could find no differences between the two groups school versus controls with regard to the number of urgent care visits 9 vs 9 scheduled visits 22 vs 21 and hospital admissions 2 vs 2). <sep>', 'changes in the use of resources productive output and in health status were measured for the patient education group and the control group. <sep>', 'knowledge about the use of drugs was significantly increased in the groups who received the material after three months and persisted after 12 months. <sep>', 'the knowledge test score of the experimental group was found to have decreased to the level of the control group. <sep>', 'neither group showed any change in self-management ability or asthma morbidity that differed significantly from changes in the control group. <sep>', 'the intervention group had significantly fewer asthma-related emergency visits 16 visits per 100 persons than did the control group 39 per 100 persons p  0.0005 for the 12 months of follow-up. <sep>'], 'population': ['up to november 1994 430 adult asthmatics were recruited classified and managed according to the recommendations of the international guidelines <sep> forty four patients were recruited stratified according to the severity of their asthma and randomized into two groups 22 patients attended the school and 22 patients did not <sep> 360 asthmatics attending the clinic between 1989 and 1994 53 45 and 2 of them were suffering from extrinsic intrinsic and occupational asthma respectively <sep>', 'asthmatic patients <sep> patients with asthma <sep>', 'patients with asthma <sep> 177 patients with asthma in general practice <sep> patients with asthma <sep>', 'people with asthma <sep> 62 patients <sep> adults with asthma <sep>', '274 patients were reassessed after one 1 year <sep> general practice <sep> 339 patients by means of a questionnaire <sep>', 'adults who have asthma <sep> patients with asthma <sep> 241 asthma patients between the ages of 18 and 70 years <sep> 119 patients in the intervention group and the 122 in the control group 185 76 were available for follow-up <sep> two sites--an urban emergency room and a suburban emergency room <sep> patients with asthma to decrease utilization of emergency services <sep>'], 'interventions': ['traditional educational approach <sep>', 'planned patient education programme <sep> intensive education programme <sep>', 'self management booklet and audiocassette <sep>', 'videotape educational program <sep> videotape educational program <sep>', 'patient education <sep> maximum education programme a second group received a limited education programme and a third acted as a control group <sep>', 'education program <sep> self-management training program <sep> educational program <sep> educational sessions on asthma conducted by a specially trained rn <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",use of limited asthma education as it has been practiced does not appear to improve health outcomes in adults with asthma although perceived symptoms may improve. provision of information in the emergency department may be effective but this needs to be confirmed.
37,"{'outcomes': ['atopic eczema <sep> mean concentration of essential amino acids in plasma <sep> serum total and milk-specific ige concentrations <sep>', 'mean reduction in surface area affected by eczema <sep> severity score <sep> disease activity <sep>', 'eczema activity number of areas affected pruritus sleeplessness and antihistamine usage <sep>', 'pruritus sleeplessness and antihistamine consumption <sep> activity of atopic dermatitis <sep> circulating eosinophilocytes serum ige orosomucoid hla-antigens and immunofluorescence of skin biopsies <sep>', 'length standard deviation score <sep> energy intake <sep> scorad index <sep> weight-for-length values <sep>', 'dermatitis severity <sep> percentage of surface area <sep> skin severity score <sep>', 'gastrointestinal reactions <sep> eczema <sep>'], 'punchline_text': ['the mean concentration of essential amino acids in plasma was lower in group <sep>', 'the mean reduction in surface area affected by eczema was significantly greater p  0.02 in the group receiving dietary advice from 19.6 to 10.9 area affected than in the control group from 21.9 to 18.9%). <sep>', 'there was no correlation between a positive prick test to egg and cows milk antigen and response to the trial diet. <sep>', 'four patients reported of less pruritus sleeplessness and antihistamine consumption three vivasorb one placebo while 21 did not 13 vivasorb eight placebo). <sep>', 'in the aa group there was a significant increase in the length standard deviation score p  0.04 whilst there was no difference in the ehf group. <sep>', 'after six weeks there was a significant reduction in all three groups in the percentage of surface area involved controls median reduction mr  4.9 95 confidence interval 1.5 11.9 whey hydrolysate group mr  17.8 8.3 23.0 casein hydrolysate group mr  5 1.6 21.2 and skin severity score controls mr  15.9 5.0 22.5 whey hydrolysate group mr  21.8 12.8 30.2 casein hydrolysate group mr  13.5 3.4 38.0). <sep>', 'thirty seven breast fed infants with eczema were studied to see whether changes in their mothers diets affected their skin condition. <sep>'], 'population': ['22 infants with a mean age of 6 months 95 confidence interval 4 to 7 who were fed an extensively hydrolyzed whey formula group we and 23 infants with a mean age of 17 95 confidence interval 4 to 7 months who were given an amino acid-derived formula group aa <sep> infants with cow milk allergy <sep> 74 atopic children with cow milk allergy <sep>', 'young children <sep> young children with atopic eczema and sensitivity to eggs <sep> fifty-five such children <sep>', 'atopic eczema <sep> 20 out of 36 children aged two to eight years with atopic eczema <sep>', 'adult patients with atopic dermatitis <sep> 33 adults with severe atopic dermatitis <sep> twenty-five patients were evaluable two of whom had their diet stopped after a few days due to exacerbation <sep>', ""infants with cow's milk allergy/intolerance and atopic dermatitis <sep> infants with severe cow's milk allergy intolerance <sep> infants with cow's milk allergy/intolerance <sep> 73 infants median age 5.7 months with cow's milk allergy/intolerance and atopic dermatitis <sep> infants with an early onset of symptoms of cow's milk allergy/intolerance <sep>"", 'severe atopic dermatitis <sep> eighty five children median age 2.3 years range 0.3 to 13.3 years with refractory atopic dermatitis affecting more than 12 of the body surface area <sep> thirty five patients who received the diet and four controls had to be withdrawn because of non-compliance with the diet or intercurrent illness <sep>', 'nineteen mothers and babies took part in a double blind crossover trial of exclusion of egg and cows milk and 18 took part in open exclusion of 11 foods followed by double blind challenge to those mothers whose infants seemed to respond <sep> breast fed infants with eczema <sep> thirty seven breast fed infants with eczema <sep>'], 'interventions': ['hydrolyzed cow milk and amino acid-derived formulas <sep> placebo <sep> protein hydrolysate or amino acid-derived formulas <sep> several protein hydrolysate or amino acid-derived formulas <sep>', 'egg exclusion diet <sep> exclusion diets <sep> general advice on care of eczema and additional specific advice from a dietician about an egg exclusion diet diet group or to a control group in which general advice only was given <sep>', 'soya-based milk substitute trial period or an egg and cows milk preparation control period <sep> antigen-avoidance diet <sep> egg and cows milk exclusion diet <sep>', 'antigen-free diet <sep> placebo <sep> antigen-free diet <sep>', 'placebo <sep> amino-acid-based formula <sep>', 'few foods diet eliminating all but five to eight foods supplemented with either a whey hydrolysate <sep> casein hydrolysate formula <sep> casein hydrolysate <sep>', 'maternal dietary exclusion <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>']}",there may be some benefit in using an egg-free diet in infants with suspected egg allergy who have positive specific ige to eggs. little evidence supports the use of various exclusion diets in unselected people with atopic eczema but that may be because they were not allergic to those substances in the first place. lack of any benefit may also be because the studies were too small and poorly reported. future studies should be appropriately powered focusing on participants with a proven food allergy. in addition a distinction should be made between young children whose food allergies improve with time and older children/adults.
38,"{'outcomes': ['visual analogue scale vas pain scores <sep> quality of life qol <sep>', 'morphine consumption visual analogue pain scale vas performance status ps determined by medical and nursing staffs and answers to qol questionnaires <sep> ps score slightly <sep> ps and qol scores <sep> morphine consumption and the vas score <sep> pain relief <sep> pain relief and quality of life qol <sep> quality of life <sep> morphine consumption <sep> morphine consumption vas ps and self-assessed qol scores <sep> self-assessed qol scores <sep> side effects <sep> qol <sep> vas scores <sep>', 'hospital mortality or complications return to oral intake or length of hospital stay <sep> existing pain <sep> standardized assessment of pain mood and disability due to pain <sep> pain <sep> pain mood and disability <sep> pain scores and delayed or prevented the subsequent onset of pain <sep> mean pain scores <sep> survival <sep>', 'transient diarrhoea and hypotension <sep> nausea and/or vomiting <sep> pain relief <sep> gastric ulcer and one gluteal abscess <sep> mean analgesic consumption <sep> immediate and long-term efficacy mean analgesic consumption mortality and morbidity <sep>', 'quality of life qol <sep> pain relief quality of life and survival <sep> pain intensity and qol scores <sep> opioid consumption <sep> pain relief qol and survival <sep> mean sd baseline pain <sep> pain intensity 0-10 numerical rating scale qol opioid consumption and related adverse effects and survival time <sep> pain <sep> frequency of opioid adverse effects <sep> qol <sep> moderate or severe pain pain intensity rating <sep> pain relief <sep> qol or survival <sep> survival <sep>'], 'punchline_text': ['however the differences in the improvement of quality of life qol between two groups were not statistically significant. <sep>', 'morphine consumption was significantly lower in weeks 4-7 inclusive following the procedure in the cpb group and continued to be lower thereafter though not significantly so. <sep>', 'mean pain scores were significantly lower in the alcohol group at 2 4 and 6-month follow-up and at the final assessment p  0.05). <sep>', 'drug-related adverse effects were constipation five of 12 patients in group 1 versus 12 of 12 in group 2 nausea and/or vomiting four of 12 patients in group 1 versus 12 of 12 in group 2 p  0.05 one gastric ulcer and one gluteal abscess in group 2. <sep>', 'the first week after randomization pain intensity and qol scores were improved pain intensity p or .01 for both groups qol p<.001 for both groups with a larger decrease in pain for the ncpb group p .005). <sep>'], 'population': ['pain due to pancreatic cancer <sep> pancreatic cancer pain <sep> 56 patients who were placed randomly in either a <sep> intractable pancreatic cancer pain <sep>', 'twenty-one patients with pancreatic cancer pain <sep> patients with pancreatic cancer pain <sep>', 'patients with unresectable pancreatic cancer <sep> patients with histologically proven unresectable pancreatic cancer <sep> 65 patients whereas 72 patients received the <sep>', 'twenty-four patients were divided into two groups 12 patients underwent <sep> pain from pancreatic cancer <sep> patients with pancreatic cancer <sep>', 'patients with unresectable pancreatic cancer <sep> enrolled october 1997 and january 2001 were 100 eligible patients with unresectable pancreatic cancer experiencing pain <sep> patients with pancreatic cancer <sep>'], 'interventions': ['neurolytic celiac plexus block guided by computerized tomography <sep> neurolytic coeliac plexus block ncpb guided by computerized tomography ct <sep> ct-guided ncpb with alcohol <sep> pharmacological therapy <sep> ncpb group and pharmacological therapy <sep>', 'standard nsaid-morphine <sep> morphine <sep> celiac plexus block cpb <sep> morphine-nsaid <sep>', 'chemical splanchnicectomy with alcohol <sep> placebo <sep> chemical splanchnicectomy <sep> chemical splanchnicectomy <sep> intraoperative chemical splanchnicectomy with 50 alcohol versus a placebo injection of saline <sep>', 'neurolytic coeliac plexus block ncpb <sep> ncpb <sep> neurolytic coeliac plexus block <sep> pharmacological therapy <sep>', 'neurolytic celiac plexus block ncpb vs opioids alone <sep> ncpb <sep> neurolytic celiac plexus block <sep> ncpb or systemic analgesic therapy alone with a sham injection <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",although statistical evidence is minimal for the superiority of pain relief over analgesic therapy the fact that cpb causes fewer adverse effects than opioids is important for patients. further studies and rcts are recommended to demonstrate the potential efficacy of a less invasive technique under eus guidance.
39,"{'outcomes': ['cardiotoxicity <sep>', 'toxicity <sep> ototoxicity and nephrotoxicity <sep> renal toxicity <sep> toxicity prevention <sep> renal hearing and cardiac toxicity <sep> grade 1 cardiac toxicity <sep> grade 1 and 2 audiologic toxicity <sep>', 'assessable endomyocardial biopsy <sep> noncardiac toxicity or antitumor efficacy <sep> lvef <sep> incidence of clinical congestive heart failure <sep> icrf-187 cardiac protection <sep> resting left ventricular ejection fraction lvef <sep>', 'rates of fever infection or hemorrhage <sep> time to progression and survival <sep> ejection fraction changes or congestive heart failure chf <sep> pain on injection <sep> response rate with dzr but time to progression and survival <sep> toxicities <sep> hazards ratio hr of pla to dzr <sep> objective response rates <sep> noninvasive testing and clinical chf <sep>', 'incidence and degree of cardiotoxicity response rates to four cycles of chemotherapy event-free and overall survival and incidence and severity of noncardiac toxicities <sep> risk of developing short-term subclinical cardiotoxicity <sep> cardiac toxicity <sep> hematologic toxicity <sep> event-free or overall survival <sep> resting left ventricular ejection fraction lvef <sep> objective response rates <sep> incidence of transient grade 1 serum transaminase elevations <sep> subclinical cardiotoxicity <sep> response rates to chemotherapy event-free and overall survival and noncardiac toxicities <sep>', 'cardiac toxicity <sep> cardiotoxicity <sep> clinical activity and the noncardiac toxicity of epirubicin <sep> doxorubicin cardiotoxicity <sep> resting left ventricular ejection fraction lvef <sep> cardiotoxicity <sep> cumulative probability of developing cardiotoxicity <sep> noncardiac toxicity objective response progression-free survival and overall survival <sep>', 'systolic and diastolic diameters <sep> mean ef at control echocardiography <sep> control ef <sep> died <sep> e velocities <sep> e velocities and e/a ratios <sep> systolic and diastolic functions <sep> left ventricular ejection fraction ef and systolic and diastolic diameters <sep> mean ef <sep>', 'interventricular septum wall thickening <sep> cardiac function <sep> percentage left ventricular fractional shortening lvfs <sep> septum wall motion abnormalities <sep> lvfs <sep>', 'overall survival <sep> excellent survival <sep> survival <sep> progressive disease <sep>', 'antitumor response rates time to progression and survival <sep> antitumor activity <sep> abnormal antimyosin uptake <sep> cardiotoxicity <sep> lvef <sep> value of radioimmunoscintigraphy ris <sep> congestive heart failure chf <sep> noncardiac toxicity <sep>', 'relative mrna levels <sep> plasma carnitine <sep> plasma lipid profile and relative mrna levels of key enzymes of oxidative metabolism carnitine acyltransferases <sep> oxidative metabolism <sep>', 'mode-m echocardiograms and 24-hour ambulatory ecgs <sep> severe supraventricular arrhythmia <sep>', 'cardiac events <sep> tumor response rate <sep> severe incidence of congestive heart failure <sep> frequency of adverse events <sep> occurrence and severity of anthracycline-induced cardiotoxicity <sep>', 'left ventricular ejection fraction <sep> systolic and diastolic echocardiographic parameters <sep>', 'qt interval dispersion <sep> arrhythmic risk <sep> qt and qtc dispersion <sep> qtc dispersion <sep> minimum qt interval <sep> qt dispersion <sep>', 'rate of event-free survival <sep> myocardial injury <sep> troponin t levels <sep> serum cardiac troponin t <sep> elevated troponin t levels <sep> elevations of troponin t <sep>'], 'punchline_text': ['so far no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens tad/tad  tad/ham). <sep>', 'grade 1 and 2 audiologic toxicity was present in 100 of the experimental group against 85 of the controls p  0.501). <sep>', 'icrf-187 cardiac protection was observed in patients with and without prior chest-wall radiation or other risk factors for developing doxorubicin cardiac toxicity. <sep>', 'toxicities on the dzr arms included lower granulocyte and platelet counts at nadir p  .009 and p  .004 respectively and more pain on injection p  .001 with no difference in the rates of fever infection or hemorrhage. <sep>', 'objective response rates were identical in the two groups with no significant differences seen in event-free or overall survival. <sep>', 'cardiotoxicity was recorded in 18 of 78 patients 23.1 in the control arm and in six of 82 7.3 in the dexrazoxone arm. <sep>', 'control ef was below 50 in 1 patient in the carvedilol group and in 5 in the control group. <sep>', 'percentage left ventricular fractional shortening lvfs decreased from baseline 40.36  <sep>', 'five-year event-free-survival was 84 86 for the rer and 83 for the slow early responders p  .85). <sep>', 'in either disease antitumor response rates time to progression and survival did not significantly differ between the two arms. <sep>', 'carnitine treated patients showed a rise in plasma carnitine which led to an increase of relative mrna levels from cpt1a liver isoform of carnitine palmitoyltransferase and octn2 carnitine transporter). <sep>', 'prenylamine pnl a calcium antagonistic drug provided partial protection against adm-induced cardiotoxicity in mice and in the rabbit. <sep>', 'the frequency of adverse events was similar between groups and there were no significant between-group differences in the number of dose modifications/interruptions. <sep>', 'left ventricular ejection fraction fell significantly in patients receiving placebo radiotherapy 67  <sep>', '4.3 ms p<0.001 while the 10 patients not supplemented with dexrazoxane did not qt dispersion 69.3  <sep>', 'serial measurements of serum cardiac troponin t were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin. <sep>'], 'population': ['since july 1986 64 patients have been included <sep> thirty patients have been evaluated for pre and posttreatment cardiological investigations <sep> induced cardiomyopathy <sep> patients with acute myeloid leukemia aml treated with double induction and consolidation chemotherapy aml coop study 1986 3 <sep>', 'pediatric osteosarcoma patients treated with <sep> 28 patients mean age was 11.6 years five had metastatic disease <sep> patients with osteosarcoma receiving <sep>', 'women with breast cancer <sep> twenty-six patients in the <sep> 150 women with advanced breast cancer <sep>', 'between november 1988 and january 1991 534 patients with advanced breast cancer <sep> advanced breast cancer <sep>', 'pediatric sarcoma patients <sep> thirty-eight patients <sep> pediatric sarcoma patients treated with <sep>', 'women receiving <sep> one hundred sixty patients were evaluated <sep> patients who had previously received adjuvant chemotherapy that contained anthracyclines were treated with <sep> for advanced breast cancer <sep> one hundred sixty-two advanced breast cancer patients <sep>', 'patients receiving ant <sep> 25 patients in carvedilol and control groups <sep>', 'children with acute lymphoblastic leukemia or non-hodgkin lymphoma treated with anthracyclines ant were studied group <sep> children with acute lymphoblastic leukemia and non-hodgkin lymphoma <sep>', '216 eligible patients were younger than 22 years with intermediate or high-risk hodgkin lymphoma <sep> children and adolescents with intermediate and high-risk hodgkin lymphoma <sep>', 'patients with advanced breast cancer and soft tissue sarcomas sts treated with <sep> patients with advanced breast cancer and soft tissue sarcomas <sep> patients with breast cancer <sep>', 'patients with non-hodgkin lymphoma <sep> 20 patients were scheduled to <sep>', 'group b n  13 <sep> group a n  13 <sep> twenty-six patients <sep>', '164 female breast cancer patients <sep> patients at high risk of cardiotoxicity due to prior anthracycline use <sep> patients who might benefit <sep> advanced/metastatic breast cancer patients treated with <sep>', 'patients with malignancies receiving high dose chemo or radiotherapy <sep> 14 patients with chemotherapy and 10 patients with <sep> 67 <sep>', 'patients who are at risk of arrhythmic events <sep> patients with aggressive non-hodgkin lymphoma nhl <sep> non-hodgkin lymphoma patients <sep> twenty untreated patients or=60 years of age with newly-diagnosed aggressive nhl eligible for a treatment with epirubicin-based chemotherapy were selected for the study <sep>', 'children with acute lymphoblastic leukemia all <sep> 101 children with all to receive <sep> massachusetts medical society <sep> treated children with acute lymphoblastic leukemia <sep>'], 'interventions': ['verapamil treatment <sep> anthracycline <sep> verapamil <sep>', 'cisplatin and doxorubicin <sep> amifostine <sep> cisplatin and doxorrubicin <sep> amifostine <sep>', 'icrf-187 <sep> doxorubicin <sep> icrf-187 against cumulative doxorubicin-dose-related cardiac toxicity <sep> fluorouracil 5fu 500 mg/m2 doxorubicin 50 mg/m2 and cyclophosphamide <sep> icrf-187 1,000 mg/m2 iv experimental regimen 76 patients <sep>', 'fluorouracil doxorubicin and cyclophosphamide fac with either dzr dzr-to-doxorubicin ratio 10:1 or placebo pla <sep> dexrazoxane <sep> doxorubicin <sep> dexrazoxane dzr <sep> doxorubicin-based combination therapy <sep> doxorubicin-containing therapy <sep>', 'icrf-187 <sep> doxorubicin-containing chemotherapy given as an intravenous bolus with or without icrf-187 <sep> multigated radionuclide angiography muga scan <sep> doxorubicin <sep> cardioprotective agent icrf-187 <sep> icrf-187-treated <sep>', 'epirubicin chemotherapy <sep> epirubicin 60 mg/m2 iv and fluorouracil <sep> dexrazoxane <sep> dexrazoxane versus no cardioprotection <sep> dexrazoxane:epirubicin <sep> epirubicin-based chemotherapy with or without dexrazoxane <sep> dexrazoxane <sep> ratio dexrazoxane doxorubicin <sep> epirubicin <sep> cyclophosphamide <sep>', 'carvedilol <sep> carvedilol against anthracycline <sep> placebo <sep> carvedilol or placebo <sep>', 'coenzyme q10 <sep> coq <sep> coenzyme q10 coq therapy <sep> coq therapy <sep>', 'abve-pc doxorubicin bleomycin vincristine etoposide prednisone cyclophosphamide <sep> abve-pc <sep> alkylators anthracyclines and epipodophyllotoxins <sep>', 'multigated radionuclide muga scans with determination of resting left ventricular ejection fraction lvef <sep> sts <sep> epi <sep> dexrazoxane dex <sep> dex <sep> dex 1,000 mg <sep> epirubicin and dexrazoxane <sep> high-dose epirubicin epi <sep>', 'placebo <sep> receive 3 g l-carnitine <sep> carnitine <sep> anthracycline doxorubicin <sep> doxorubicin-containing chemotherapy and a combination with l-carnitine <sep> l-carnitine <sep>', 'adriamycin adm <sep> placebo <sep> adm <sep> prenylamine pnl <sep> pnl <sep> adriamycin-induced cardiotoxicity by prenylamine <sep>', 'dexrazoxane cardioxane <sep> dexrazoxane <sep> anthracycline <sep> dexrazoxane <sep> anthracyclines received anthracycline-based chemotherapy either with n  85 or without n  79 dexrazoxane <sep> anthracycline-based chemotherapy <sep> anthracycline-induced cardiotoxicity <sep>', 'chemotherapy <sep> radiotherapy <sep> double-blind fashion placebo versus vitamin e and c and n-acetylcysteine <sep> placebo radiotherapy <sep> antioxidant regimen <sep> cardioprotection in chemo and radiotherapy <sep>', 'epirubicin-based chemotherapy and dexrazoxane supplementation <sep> epirubicin-based chemotherapy <sep> dexrazoxane hydrochloride <sep> dexrazoxane <sep> dexrazoxane supplementation <sep> epirubicin <sep> 12-lead electrocardiogram ecg before and after epirubicin infusion and after dexrazoxane supplementation <sep> epirubicin-based chemotherapy <sep> epirubicin infusion <sep>', 'dexrazoxane <sep> dexrazoxane and doxorubicin <sep> dexrazoxane <sep> doxorubicin <sep> doxorubicin alone <sep> doxorubicin chemotherapy <sep> dexrazoxane decreases doxorubicin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",no definitive conclusions can be made about the efficacy of cardioprotective agents for which pooling of results was impossible. dexrazoxane prevents heart damage and no evidence for a difference in response rate or survival between the dexrazoxane and control groups was identified. the evidence available did not allow us to reach any definite conclusions about adverse effects. we conclude that if the risk of cardiac damage is expected to be high it might be justified to use dexrazoxane in patients with cancer treated with anthracyclines. however clinicians should weigh the cardioprotective effect of dexrazoxane against the possible risk of adverse effects for each individual patient.
40,"{'outcomes': ['initiation of alcohol tobacco drug use and/or sexual activity found aa youth <sep> chances of initiating sex or substance use <sep> substance use and/or sexual activity <sep> rate of change in attitudes about drug use or frequency of delinquent or violent behavior <sep> violent behavior <sep> drug use harm or delinquency <sep>', ""alcohol initiation and frequency and marijuana initiation and frequency p's<.05 <sep>"", 'sexual risks <sep> self-efficacy <sep>', 'incidence of heavy weekly alcohol use and frequency of monthly drinking <sep> heavy weekly drinking weekly drinking and frequency of drinking <sep>', 'positive 2-year outcomes <sep> girls and mothers substance use and mediator variables related to girls substance use risk and protective factors <sep> rates of weekly alcohol consumption <sep>', '30-day use of alcohol and marijuana and lower intentions to smoke drink and take illicit drugs <sep>'], 'punchline_text': ['odds ratios indicated the chances of initiating sex or substance use were reduced by almost 70 or  0.31 for aa teens in the sa condition compared to controls and 75 or  0.25 for the aa teens in the pa compared to controls. <sep>', ""a significant repeated measures interaction group  time was found f(4,344)=2.48 p=.04 with univariate tests showing less alcohol use frequency and problems p's<.05 among adolescents exposed to parent materials. <sep>"", 'at follow-up girls in the intervention reported fewer sexual risks adjusted odds ratio aor  0.39 confidence interval ci  0.17-0.88 and less drinking aor  0.38 ci  0.15-0.97 p  .05). <sep>', 'at first follow-up only the combined student-parent intervention showed substantial and statistically significant effects on heavy weekly drinking weekly drinking and frequency of drinking. <sep>', 'a computer-delivered prevention program for adolescent girls and their mothers was effective in changing girls risk and protective factors and girls and mothers substance use behavior. <sep>', 'following program delivery and 1 year later girls randomly assigned to the intervention arm improved more than girls in a control arm on variables associated with reduced risks for substance use including communication with their mothers knowledge of family rules about substance use awareness of parental monitoring of their discretionary time non-acceptance of peer substance use problem-solving skills and ability to refuse peer pressure to use substances. <sep>'], 'population': ['parents <sep> european american ea and african american aa youth and their parents n  331 n aa  163 n ea  168 <sep>', 'adolescents and their parents <sep> 684 high school students <sep>', 'urban young adolescent girls <sep> urban black and latino parents <sep> 268 families with sixth-graders were recruited from new york city public schools <sep>', 'group from 152 classes of 19 high schools in the netherlands <sep> a total of 3490 first-year high school students mean 12.68 years sd=0.51 and their parents <sep> heavy drinking in first and second-year high school students <sep> 2937 students were eligible for analyses in this study <sep> adolescents pas <sep>', 'adolescent girls and their mothers <sep> september 2006 and february 2009 with participants from greater new york city including southern connecticut and eastern new jersey <sep> adolescent girls <sep> 916 girls aged 12.76+/-1.0 years and their mothers <sep>', 'girls mothers <sep> adolescent girls <sep>'], 'interventions': ['three conditions group-administered pa self-administered with telephone support sa and no-treatment control <sep>', 'brief image-based print mediated parent/caregiver and adolescent messages integrating physical activity with alcohol use avoidance <sep> brief image-based health behavior messages <sep> parent postcard or adolescent flyer arm with baseline and four-month post-intervention data collections <sep>', 'audio cds mailed home an attention-controlled condition print materials or controls <sep>', ""parent intervention modelled on the swedish rebro prevention program aimed at encouraging parental rule-setting concerning their children's alcohol consumption ii student intervention consisting of four digital lessons based on the principles of the theory of planned behaviour and social cognitive theory iii interventions 1 and 2 combined and iv the regular curriculum as control condition <sep> journal compilation <sep> control <sep>"", 'computer-delivered program <sep> intervention-arm dyads engaged in exercises to improve the mother-daughter relationship build girls substance use prevention skills <sep> computer-delivered parent-involvement intervention <sep> computer-delivered prevention program <sep>', 'control arm on variables associated with reduced risks for substance use including communication with their mothers knowledge of family rules about substance use awareness of parental monitoring of their discretionary time non-acceptance of peer substance use problem-solving skills and ability to refuse peer pressure to use substances <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",in conclusion in this cochrane systematic review we found that that the effects of family-based prevention interventions are small but generally consistent and also persistent into the medium to longer-term.
41,"{'outcomes': ['pain and function <sep> pain and function scores <sep> visual analog scales for pain and the functional index questionnaire <sep>', 'womac visual analogue and had scores <sep> womac and had <sep> visual analogue pain score the womac lower limb function score the hospital anxiety and depression scale had and quadriceps strength <sep> womac visual analogue and the anxiety score <sep>', 'isokinetic quadriceps strength quadriceps length pain measured during four activities and maximum eccentric posturally controlled pain-free knee flexion angle during a step-down <sep>', 'symptoms <sep> subjective visual analog scale and changes in isokinetic strength and electromyographic activity of the quadriceps muscle <sep> activity <sep> quadriceps muscle isokinetic strength <sep> patellofemoral pain <sep>'], 'punchline_text': ['there were no significant differences between the placebo taping-and-exercise group and exercise-alone group at any time point. <sep>', 'all groups showed significant improvements in womac visual analogue and had scores these improvements did not vary significantly between the four groups or between exercising/non-exercising and taped/non-taped patients at three and 12 months. <sep>', 'results showed significant changes over time p  0.01 in two out of seven measures for the taping group in five out of seven for the strengthening group and five out of seven for the stretching group and none in the control group. <sep>', 'likewise both groups demonstrated significant improvement in quadriceps muscle isokinetic strength p  0.05 and activity p  0.001 but no difference in improvement was noted between groups. <sep>'], 'population': ['1.2 years participated in the study <sep> twenty-four men and 6 women aged 17 to 25 years mean <sep> patellofemoral pain syndrome <sep> individuals with patellofemoral pain syndrome <sep>', 'subjects with anterior knee pain <sep> anterior knee pain <sep> 81 young adults with anterior knee pain <sep>', '41 subjects with 60 knees diagnosed with patellofemoral pain <sep> patellofemoral pain patients <sep>', 'patellofemoral pain <sep> twenty-five patients with patellofemoral pain <sep>'], 'interventions': ['taping <sep> daily patella taping and exercises <sep> patella taping and muscle-strengthening programs <sep> patella taping combined with a standardized exercise program placebo patella taping and exercise program or exercise program alone <sep> daily patella taping and exercise <sep> placebo taping-and-exercise <sep> patella taping and exercise <sep>', 'physiotherapy <sep> exercise taping and education 2 exercise and education 3 taping and education and 4 education alone <sep>', 'infrapatellar taping quadriceps strengthening quadriceps stretching and control <sep> quadriceps strengthening quadriceps stretching and patellar taping <sep> strengthening group followed a programme of non-weight-bearing terminal range quadriceps exercises the stretching group performed rectus femoris stretches <sep> copyright <sep> taping quadriceps strengthening and stretching prescribed separately or combined <sep>', 'same physical therapy program <sep> patellar taping <sep> patellar taping program <sep> patellar taping technique <sep> standard physical therapy program <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",the currently available evidence from trials reporting clinically relevant outcomes is low quality and insufficient to draw conclusions on the effects of taping whether used on its own or as part of a treatment programme. further research involving large preferably multi-centre good quality and well reported randomised controlled trials that measure clinically important outcomes and long-term results is warranted. before this consensus is required on the diagnosis of patellofemoral pain syndrome the standardisation of outcome measurement and an acceptable approach for patellar taping.
42,"{'outcomes': ['lateral gonial deviation <sep> postoperative changes of the proximal and distal segments <sep> horizontal and vertical stability of the b-point and the pogonion <sep>'], 'punchline_text': ['at 1 year after surgery there was no significant difference between the 2 groups in the horizontal and vertical stability of the b-point and the pogonion. <sep>'], 'population': ['thirty japanese adults with a diagnosis of prognathic mandible <sep>'], 'interventions': ['ssro <sep> intraoral vertical ramus osteotomy ivro <sep> sagittal split ramus osteotomy ssro <sep> vertical ramus versus sagittal split osteotomies <sep> ivro <sep>'], 'punchline_effect': [' no diff <sep>']}",there is insufficient evidence from the two included trials to conclude that one procedure is better or worse than another. the included trials compared different interventions and were at high risk of bias and therefore no implications for practice can be given. further high quality randomized controlled trials with long term follow-up are required.
43,"{'outcomes': ['pao2 <sep> lr manoeuvre end-expiratory lung volume <sep> partial arterial oxygen tension pao2 and end-expiratory lung volume <sep>', 'target tidal volumes of 6 ml/kg of predicted body weight plateau airway pressures not exceeding 30 cm h2o and conventional levels of positive end-expiratory pressure <sep> mean positive end-expiratory pressures <sep> hospital mortality rates <sep> tidal volumes <sep> barotrauma rates <sep> rates of refractory hypoxemia <sep> death with refractory hypoxemia <sep>', 'pao2/fio2 and qs <sep> oxygenation and venous admixture <sep>', 'barotrauma <sep> systolic blood pressure <sep> positive end-expiratory pressure peep and recruitment maneuvers rms <sep> oxyhemoglobin saturation by pulse oximetry spo2 fio2/peep blood pressure and heart rate <sep> fio2/peep requirements <sep>', 'survival <sep> rates of weaning from mechanical ventilation <sep> body weight and normal arterial carbon dioxide levels <sep> protective ventilation involved end-expiratory pressures <sep> rates of clinical barotrauma <sep> rate of barotrauma <sep> higher peep and mean airway pressures <sep> mortality <sep> survival to hospital discharge <sep>', 'arterial oxygen tension pa(o2 <sep> tracheal aspirate mass <sep> arterial carbon dioxide tension pa(co2 <sep> arterial blood gases <sep> negative pressure <sep>', 'pao2 <sep> lower q(va)/q(t <sep> gas exchange and respiratory mechanics <sep> cppv(vrm <sep> eelv <sep> gas exchange hemodynamics respiratory mechanics and the end expiratory lung volume eelv <sep> lower venous admixture q(va)/q(t <sep>'], 'punchline_text': ['without lr manoeuvre pao2 was reduced p  0.05 until 7 min after ets. <sep>', 'this open-lung strategy did appear to improve secondary end points related to hypoxemia and use of rescue therapies. <sep>', 'no significant differences in pao2/fio2 and qs <sep>', 'changes in fio2/peep requirements were not significantly different at any time after rms vs. sham rms. <sep>', 'as compared with conventional ventilation the protective strategy was associated with improved survival at 28 days a higher rate of weaning from mechanical ventilation and a lower rate of barotrauma in patients with the acute respiratory distress syndrome. <sep>', 'open endotracheal suctioning induced a significant 18 decrease in arterial oxygen tension pa(o2 range 13 to 71 and an 8 increase in arterial carbon dioxide tension pa(co2 range 2 to 16 that persisted 15 min after the end of the procedure. <sep>', 'compared to cppv(lo cppv(vrm resulted in higher pao2 117.9  <sep>'], 'population': ['15-bed general intensive care unit at a university hospital <sep> patients with acute lung injury and acute respiratory distress syndrome <sep> acute respiratory distress syndrome <sep> eight consecutive mechanically ventilated patients with acute lung injury or acute respiratory distress syndrome <sep>', 'august 2000 and march 2006 in 30 intensive care units in canada australia and saudi arabia <sep> patients with acute lung injury and acute respiratory distress syndrome <sep> acute lung injury and acute respiratory distress syndrome <sep> critically ill patients with acute lung injury and acute respiratory distress syndrome <sep> eighty-five percent of the 983 study patients met criteria for acute respiratory distress syndrome at enrollment <sep> nine hundred eighty-three consecutive patients with acute lung injury and a ratio of arterial oxygen tension to inspired oxygen fraction not exceeding 250 <sep>', 'early adult respiratory distress syndrome <sep> patients with early extrapulmonary adult respiratory distress syndrome <sep> 30 consecutive patients ventilated with low tidal volumes and high levels of peep <sep> patients ventilated with low tidal volumes and high levels of positive end-expiratory pressure peep <sep>', 'patients with acute lung injury and acute respiratory distress syndrome ali/ards receiving ventilation with low tidal volumes and high levels of peep <sep> patients seventy-two patients with early ali/ards <sep> patients with acute lung injury and acute respiratory distress syndrome ventilated with high positive end-expiratory pressure <sep> thirty-four intensive care units at 19 hospitals <sep>', 'patients with the acute respiratory distress syndrome massive alveolar collapse and cyclic lung reopening and overdistention during mechanical ventilation may perpetuate alveolar injury <sep> patients with the acute respiratory distress syndrome <sep> 53 patients with early acute respiratory distress syndrome including 28 described previously all of whom were receiving <sep> acute respiratory distress syndrome <sep>', '18 patients with acute lung injury <sep> acute lung injury <sep> patients with acute lung injury <sep>', 'mechanically ventilated acute respiratory distress syndrome ards patients <sep> acute respiratory distress syndrome ards patients ventilated at relatively low positive end-expiratory pressure <sep> 15 peep responder ards patients undergoing <sep>'], 'interventions': ['open endotracheal suctioning ets <sep> ets <sep>', 'low-tidal-volume ventilation <sep> original open-lung approach combining low tidal volume lung recruitment maneuvers and high positive-end-expiratory pressure <sep> ventilation strategy using low tidal volumes recruitment maneuvers and high positive end-expiratory pressure <sep>', 'sustained inflation of 50 cm h2o maintained for 30 s. compared with baseline the ratio of the arterial oxygen partial pressure to the fraction of inspired oxygen pao2/fio2 and <sep> peep trial on oxygenation and venous admixture qs/qt <sep>', 'mechanical ventilation <sep> oxygenation support fio2/peep <sep>', 'conventional ventilation <sep> protective-ventilation strategy <sep> identical hemodynamic and general support to conventional or protective mechanical ventilation <sep>', 'oes <sep> ces and oes <sep> closed-circuit endotracheal suctioning ces <sep> ces <sep> open endotracheal suctioning <sep> open and closed-circuit endotracheal suctioning <sep> closed-circuit endotracheal suctioning <sep>', 'cppv(lo cppv(vrm <sep> periodic lung recruitment maneuvers <sep> vrms <sep> volume recruitment maneuvers vrms <sep> cppv at the low peep level cppv(lo 2 cppv at the high peep level cppv(hi <sep> continuous positive pressure ventilation cppv <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is not evidence to make conclusions on whether recruitment manoeuvres reduce mortality or length of ventilation in patients with ali or ards.
44,"{'outcomes': [""prolonged time to first exacerbation <sep> mean prebronchodilator forced expiratory volume <sep> prebronchodilator peak expiratory flow <sep> fev1 <sep> exacerbations <sep> postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire sgrq <sep>"", 'exercise performance <sep> postdose frc and increased inspiratory capacity ic <sep> lung hyperinflation <sep> tidal volume and minute ventilation <sep> predose and postdose spirometry plethysmography and constant-load cycle cardiopulmonary exercise test evaluations <sep> exercise time <sep> lung hyperinflation and exercise endurance <sep> ic <sep> exercise endurance time <sep> postdose ic <sep>', '2-hour postdose fev(1 <sep> transition dyspnea index <sep> predose fev(1 <sep> adverse effects <sep> lung function <sep> severity of dyspnea <sep>', 'cd68 cells <sep> biopsy cd8 cells <sep> prebronchodilator fev1 <sep> biopsy cd45 and cd4 cells and cells expressing genes for tumor necrosis factor-alpha and ifn-gamma and sputum total eosinophils <sep> antiinflammatory effects <sep>', 'average daily morning pef <sep> 2-h postdose fev(1 <sep> adverse effects <sep> morning predose ie trough fev(1 for fsc compared with sm and 2-h postdose fev(1 <sep> morning predose fev(1 <sep> dyspnea quality of life and symptoms of chronic bronchitis <sep> morning lung function <sep> lung function <sep> efficacy and safety <sep> morning peak expiratory flow rate pef transition dyspnea index chronic respiratory disease questionnaire chronic bronchitis symptom questionnaire exacerbations <sep>', 'daily beta(2 short acting prn consumption <sep> fev(1 <sep> morning pef l/s the daily symptom score and the number of exacerbations <sep> daily symptoms score <sep> morning pef <sep> respiratory function such as fev(1 morning pef and and symptom score <sep> mean number of exacerbations/yr <sep> mean fev(1 <sep>', 'lung function measurements symptoms and rescue treatment use the number of exacerbations patient withdrawals and disease-specific health status <sep> pretreatment fev1 <sep> lung function and health status <sep> health status <sep> daily symptoms <sep> pretreatment forced expiratory volume in 1s fev1 <sep> adverse events serum cortisol concentrations skin bruising and electrocardiograms <sep> lung function symptoms and health status and reduced use of rescue medication and frequency of exacerbations <sep> frequency of adverse events bruising or clinically significant falls in serum cortisol concentration <sep>', 'symptom scores and use of reliever beta2-agonists <sep> efficacy and safety <sep> mean number of severe exacerbations <sep> fev1 <sep> severe exacerbations and fev1 primary variables peak expiratory flow pef copd symptoms health-related quality of life hrql mild exacerbations use of reliever beta2-agonist and safety variables <sep> tolerated <sep> morning pef <sep> efficacy and safety <sep>'], 'punchline_text': [""postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire sgrq by 4.5 units after run-in. <sep>"", '0.05 l over placebo with associated improvements in tidal volume and minute ventilation p  0.05 vs placebo at week 8). <sep>', 'the incidence of adverse effects except for an increase in oral candidiasis with fsc and f was similar among the treatment groups. <sep>', 'the combination also significantly reduced biopsy cd45 and cd4 cells and cells expressing genes for tumor necrosis factor-alpha and ifn-gamma and sputum total eosinophils all p  or  0.03). <sep>', 'the incidence of adverse effects except for an increase in oral candidiasis with fsc and fp were similar among the treatment groups. <sep>', 'morning pef l/min increased in subjects treated with sm&fp anova p<0.001 while it remained unchanged in sm and p group in both anova p=ns). <sep>', 'combination therapy improved pretreatment fev1 significantly more than did placebo treatment difference 133 ml 95 ci 105-161 p<0.0001 salmeterol 73 ml 46-101 p<0.0001 or fluticasone alone 95 ml 67-122 p<0.0001). <sep>', 'morning pef improved significantly on day 1 versus placebo and budesonide after 1 week morning pef was improved versus placebo budesonide and formoterol. <sep>'], 'population': ['chronic obstructive pulmonary disease <sep> chronic obstructive pulmonary disease copd <sep>', 'eligible patients were  or  40 years old with a diagnosis of copd prealbuterol fev(1 <sep> patients with copd <sep> 185 patients mean baseline fev1 of 41 predicted were enrolled <sep> copd <sep>', 'chronic obstructive pulmonary disease <sep> chronic obstructive pulmonary disease copd <sep> 691 patients with copd <sep>', '140 current and former smokers mean age 64 yr with moderate to severe disease <sep> chronic obstructive lung disease <sep> smokers with chronic obstructive pulmonary disease <sep>', 'seventy-six investigative sites in the united states <sep> patients with copd <sep> seven hundred twenty-three patients  or 40 years of age with copd and a mean baseline fev(1 of 42 predicted <sep>', 'copd patients already treated with <sep> eighteen moderate copd patients <sep> chronic obstructive pulmonary disease copd <sep>', 'chronic obstructive pulmonary disease <sep> patients with copd <sep> 1465 patients with copd were recruited from outpatient departments in 25 countries <sep> symptomatic chronic obstructive pulmonary disease copd <sep>', 'patients with moderate-to-severe chronic obstructive pulmonary disease copd <sep> chronic obstructive pulmonary disease <sep> 812 adults mean age 64 yrs mean forced expiratory volume in one second fev1 36 predicted normal <sep> moderate-to-severe chronic obstructive pulmonary disease <sep>'], 'interventions': ['oral prednisolone <sep> budesonide and formoterol <sep> formoterol <sep> placebo <sep> inhaled budesonide/formoterol 320/9 microg budesonide 400 microg formoterol 9 microg or placebo <sep> budesonide formoterol or placebo <sep> budesonide/formoterol <sep> budesonide/formoterol <sep> monocomponent <sep>', 'placebo <sep> fluticasone propionate/salmeterol <sep> fsc 250/50 salmeterol 50 microg or placebo <sep> fsc <sep> salmeterol and placebo <sep> fluticasone propionate 250 microg/salmeterol 50 microg combination fsc 250/50 <sep> salmeterol <sep>', 'placebo <sep> fluticasone propionate and salmeterol combination delivered via the diskus device <sep> combination of f and s fsc s 50 mcg f 500 mcg or placebo <sep> fsc <sep> inhaled corticosteroid fluticasone propionate f with an inhaled long-acting beta(2)-agonist salmeterol s <sep>', 'placebo <sep> salmeterol/fluticasone propionate <sep> bronchial biopsies and induced sputum <sep> salmeterol and fluticasone propionate <sep> inhaled combined long-acting beta2-agonist salmeterol and corticosteroid fluticasone propionate <sep>', 'sm <sep> placebo <sep> fp <sep> fsc fp <sep> inhaled corticosteroid fluticasone propionate fp and the inhaled long-acting beta(2)-agonist salmeterol sm <sep> placebo fsc <sep> fluticasone propionate <sep>', 'sm alone or p <sep> sm&fp <sep> salmeterol  fluticasone <sep> placebo <sep> theophylline <sep> salmeterol  fluticasone <sep> fev(1 <sep> theophylline 400 mg/day and beta(2 short acting prn <sep> salmeterol <sep> sm&fp 50/250 microcg or sm 50 microcg alone or p via diskus inhaler bid for 52 weeks <sep>', 'combined salmeterol and fluticasone <sep> placebo <sep> fluticasone <sep> inhaled long-acting beta2 agonists <sep> salmeterol <sep> salmeterol and 500 microg fluticasone <sep>', 'placebo <sep> placebo budesonide and formoterol <sep> budesonide/formoterol <sep> budesonide <sep> placebo and budesonide <sep> budesonide/formoterol symbicort 160/4.5 microg delivered dose budesonide 200 microg metered dose formoterol 4.5 microg or placebo <sep> budesonide/formoterol <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",compared with placebo combination therapy led to a significant reduction of a quarter in exacerbation rates. there was a significant reduction in all-cause mortality with the addition of data from the torch trial. the increased risk of pneumonia is a concern and better reporting of this outcome in future studies would be helpful. in order to draw firmer conclusions about the effects of combination therapy in a single inhaler more data are necessary particularly in relation to the profile of adverse events and benefits in relation to different doses of inhaled corticosteroids.
45,"{'outcomes': ['cure rate difference <sep> mean birth weight and mean gestational age at delivery <sep> bacteriologic cure on day 14 of treatment <sep> bacteriologic cure rates <sep> adverse effects <sep>', 'cure rates <sep>', 'development of symptomatic urinary infections <sep> number of reinfections <sep> eradication rate <sep> number of persistences <sep>', 'cure rates <sep> symptoms of urinary tract infection <sep>', 'significant bacteriuria <sep> cure rates <sep> asymptomatic bacteriuria <sep> bacteriological cure rates <sep> efficacy and tolerability <sep> side effects <sep>', 'maternal and foetal toxicity <sep> asymptomatic bacteriuria <sep>'], 'punchline_text': ['the cure rate difference was 10.5 95 confidence interval 16.1 to 4.9%). <sep>', 'treatment groups were comparable in terms of age gravidity and socioeconomic status and the outcome of pregnancy in the two groups did not differ significantly. <sep>', 'the efficacy of the two regimens was similar and the eradication rate was over 80 in both groups p  0.720 relative risk rr 1.195 95 confidence interval ci 0.451-3.165). <sep>', 'control urine cultures one week and 4-6 weeks after start of treatment revealed the same cure rates of approximately 50 in both groups. <sep>', 'bacteriological cure rates at 1 and 4 weeks were in group a 77 and 74 and in group b 62 each respectively. <sep>', 'according to recent studies long course antibiotherapy did not prove to be more effective than a single-dose one in the case of non-complicated bacteriuria. <sep>'], 'population': ['women with asymptomatic bacteriuria in pregnancy <sep> 1,248 women 778 women were successfully recruited and 386 and 392 women <sep> asymptomatic bacteriuria in pregnancy <sep> pregnant women seeking antenatal care between march 2004 and march 2007 who met the inclusion and exclusion criteria were invited to participate in the study <sep> antenatal clinics in thailand the philippines vietnam and argentina <sep> 1,248 of 24,430 eligible women had asymptomatic bacteriuria making the overall prevalence of 5.1 <sep>', 'ninety obstetric patients with significant bacteriuria <sep>', 'one hundred and nine patients <sep> pregnant women with asymptomatic bacteriuria <sep> asymptomatic bacteriuria during pregnancy <sep>', '4,274 pregnant women <sep> pregnant women <sep> 41 patients <sep>', '91 pregnant women with a mean gestational age of 25 weeks 14-38 <sep>', 'pregnant women <sep> pregnant women with bacteriuria <sep>'], 'interventions': ['placebo <sep> nitrofurantoin <sep> 7-day nitrofurantoin <sep> 1-day or a 7-day course of 100 mg capsules of nitrofurantoin <sep> 1-day nitrofurantoin regimen <sep>', 'ampicillin <sep> amoxycillin <sep>', 'fosfomycin <sep> amoxicillin-clavulanate <sep> amoxicillin-clavulanate and 53 with fosfomycin <sep> fosfomycin <sep>', 'sulfamethizole <sep> single-dose versus conventional six-day therapy with sulfamethizole <sep>', 'amoxicillin tablets <sep> amoxicillin <sep> amoxicillin <sep>', 'nitrofurantoin <sep> fosfomycin trometamol <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",single-dose regimen of antibiotics may be less effective than the seven-day regimen. women with asymptomatic bacteriuria in pregnancy should be treated by the standard regimen of antibiotics until more data become available testing seven-day compared with three or five-day regimens.
46,"{'outcomes': ['mean clinical-activity score fell <sep>', 'renal function <sep> severe attacks of ulcerative colitis <sep> clinical improvement discharge from the hospital and remission <sep> serious drug-related toxicity <sep> renal function <sep>'], 'punchline_text': ['the mean clinical-activity score fell from 13 to 6 in the cyclosporine group as compared with a decrease from 14 to 13 in the placebo group. <sep>', 'at 12 months 7 of 9 patients 78 initially controlled with cyclosporine maintained their remission vs. 3 of 8 37 initially treated with methylprednisolone. <sep>'], 'population': ['20 patients with severe ulcerative colitis <sep> 32 patients with active ulcerative colitis refractory to corticosteroid therapy had a response to cyclosporine therapy <sep> patients with severe ulcerative colitis since corticosteroids <sep> patients with severe corticosteroid-resistant ulcerative colitis <sep> severe ulcerative colitis refractory to steroid therapy <sep>', 'patients with severe attacks of uc <sep> patients with steroid-refractory attacks of ulcerative colitis uc <sep> patients with a severe attack of uc <sep> thirty patients were included <sep>'], 'interventions': ['placebo <sep> cyclosporine therapy <sep> intravenous cyclosporine therapy <sep> cyclosporine <sep> cyclosporine <sep> corticosteroid therapy <sep>', 'intravenous cyclosporine <sep> methylprednisolone <sep> intravenous iv cyclosporine <sep> iv cyclosporine 4 mg x kg(-1 <sep> azathioprine <sep> cyclosporine <sep> cyclosporine monotherapy <sep> cyclosporine <sep> corticosteroids <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>']}",there is limited evidence that cyclosporine is more effective than standard treatment alone for severe ulcerative colitis. the relatively quick response makes the short-term use of cyclosporine potentially attractive but the long-term benefit is unclear when adverse events such as cyclosporine-induced nephrotoxicity may become more obvious. there is a need for additional research on quality of life costs and long-term results from cyclosporine therapy in severe ulcerative colitis.
47,"{'outcomes': ['symmetry indexes of the knee range of motion cadence and walking speed <sep>', 'energy cost efficiency and relative exercise intensity <sep> energy expenditure gait efficiency and relative exercise intensity <sep>', 'oxygen consumption <sep> rate of energy expenditure <sep> energy cost <sep> rate of energy consumption <sep> energy expenditure <sep>', 'subjective responses and gait patterns <sep>', 'sach single axis and multiple axis foot in the velocity cadence stride length and single limb stance <sep> gait analysis and energy consumption <sep> walking under different speeds and different inclines <sep> energy consumption <sep>', 'bioenergetic efficiency <sep> free walking <sep> decline walking tests <sep> energy cost <sep> energy expenditure <sep> cardiocirculatory effects <sep> free velocity <sep> oxygen uptake vo2 <sep> distal pressure measurements pulse plethysmography transcutaneous oxygen tension <sep>', 'initial peak of the vertical ground reaction force on the sound limb <sep> terminal stance dorsiflexion <sep>', 'gait performance <sep> self-selected walking velocity sswv and steps per day daily activity <sep> physiologic responses energy expenditure gait efficiency exercise intensity rating of perceived exertion rpe <sep> physiologic measurements self-selected walking velocity and physical activity <sep> energy expenditure and gait efficiency <sep> physiologic responses <sep>', 'metabolic rate or efficiency <sep>', 'peak shank velocity peak ankle plantarflexion and peak knee flexion compromised shank and knee stability <sep> peak foot and shank velocities <sep> foot and shank mobility <sep> ankle mobility <sep> residual limb emg data <sep> foot and shank velocity as the thigh velocity <sep> prosthetic mobility <sep> stride length <sep> shank velocity <sep>'], 'punchline_text': ['however no significant differences were found for the symmetry indexes of the knee range of motion cadence and walking speed. <sep>', 'the following statistically significant differences improvements between the re-flex vsp versus the ff and the sach foot were found. <sep>', 'overall the traumatic amputees had a similar oxygen consumption per meter traveled compared to the dysvascular amputees however the rate of energy consumption was much higher in the traumatic group. <sep>', 'the main differences in the range of motion of the joints were in the frontal plane the eversion-inversion movement of the ankle and the adduction-abduction movement of the hip. <sep>', 'significant differences were found in energy consumption between the traumatic and vascular groups and significant changes in walking under different speeds and different inclines. <sep>', 'during the level treadmill test the traumatic amputee subjects showed a decrease of energy expenditure with the new prosthetic foot more significant at sufficient speed 4 km/h 17.00  <sep>', 'the sach foot consistently produced the greatest ground reaction forces on the sound limb however this was not statistically significant. <sep>', 'compared with the c-walk and sach the flex-foot showed no significant differences in energy expenditure and gait efficiency but significantly lower percentage of age-predicted maximum heart rate and rpe values. <sep>', 'because no energy savings resulted for the der feet the release of stored energy in the flexible feet may not occur at the proper time to assist in ambulation as a result of the natural frequency of oscillation. <sep>', 'in early stance peak foot and shank velocities were lower p  0.01 for both the sl and ff while only shank velocity was lower p  0.01 with the sa compared to na controls. <sep>'], 'population': ['traumatic unilateral transtibial amputees wearing two different prosthetic feet in the early rehabilitation stage <sep> nine right-limb traumatic amputees <sep>', 'persons with transtibial amputations with various prostheses <sep> five physically active men with unilateral transtibial amputations served as subjects aged 31.6 <sep> people with transtibial amputations with 3 different prostheses <sep>', 'seventeen male subjects with below-knee amputation nine traumatic and seven dysvascular <sep> dysvascular and traumatic below-knee amputees <sep>', 'knee disarticulation amputees <sep> nine amputees were included in the trial <sep>', '16 male below-knee amputees eight vascular and eight traumatic while <sep> below-knee amputees wearing three different prosthetic feet <sep>', '19.9 years and 12 patients with vascular below-knee amputations mean age 73 <sep> traumatic below-knee vascular amputations <sep> twelve patients with traumatic below-knee amputations mean age 50.0 <sep> subjects on a walkway at a self-selected velocity only the subjects with traumatic amputation <sep> elderly patients with amputation with a slow walk <sep> subjects with vascular amputation <sep>', 'adults with unilateral below-knee amputations <sep> 10 traumatic below-knee amputees <sep>', 'eight men with unilateral transtibial amputation <sep> people with transtibial amputation <sep>', 'nine individuals who had undergone unilateral below knee amputation <sep>', 'normal and transtibial amputees <sep>'], 'interventions': ['sagittal plane gait analysis <sep>', 'solid ankle cushion heel sach foot the flex-foot ff and the re-flex vertical shock pylon vsp prosthesis <sep>', 'energy expenditure douglas bag technique <sep>', 'multiflex foot versus a quantum foot <sep>', 'wearing solid ankle cushion heel sach single axis and multiple axis prosthetic feet via six-camera motion analysis metabolic measurement cart and heavy-duty treadmill <sep>', 'new energy-storing foot and sach foot <sep> new energy-storing foot proteor and of the solid-ankle cushion heel sach <sep> incline 5 and decline walking treadmill test at 4 km/h <sep>', 'prosthetic foot design <sep>', 'multispeed treadmill walking and physical activity profiles for the otto bock c-walk foot c-walk flex-foot and solid ankle cushion heel <sep>', 'energy storing prosthetic feet flex foot and seattle foot versus standard sach foot <sep>', 'wearing three different foot designs single axis sa seattle lite sl and flex foot ff <sep> dynamic elastic response foot and ankle prostheses seattle-lite flex foot etc <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is insufficient evidence from high quality comparative studies for the overall superiority of any individual type of prosthetic ankle-foot mechanism although there is a small trend towards the flex-foot in comparison with the sach foot for greater stride length and lower energy cost in individuals with a transtibial amputation and improved gait efficiency and lower energy cost in high activity individuals with a transfemoral amputation. in prescribing prosthetic-ankle foot mechanisms for individuals with a lower limb amputation practitioners should take into account availability patient functional needs the type of knee mechanism to be prescribed and the inter-relationship with ankle-foot mechanisms and cost.
48,"{'outcomes': ['hospital stay <sep> necrotizing enterocolitis <sep>', 'incidence of fungal enteric colonization <sep> numbers of fungal isolates <sep>', 'incidence of utis nec and sepsis <sep> urinary tract infection bacterial sepsis and necrotizing enterocolitis <sep> duration of lactobacillus gg and placebo supplementation <sep> urinary tract infections utis bacterial sepsis and necrotizing enterocolitis nec <sep> bacterial sepsis <sep>', 'incidence of a first episode of late-onset sepsis <sep> bacterial and fungal sepsis <sep> incidence of late-onset sepsis <sep>', 'weight gain <sep> colonisation rates <sep> colonisation rates of administered bacteria <sep>', 'birth weight treatment with antibiotics and the starting time of breast-feeding <sep> number of enterobacteriaceae present <sep>', 'gastrointestinal microbiota <sep> cell counts of bifidobacteria <sep> viable counts of enterobacteriaceae log(10 values <sep> intestinal microbiota <sep> bifidobacterial numbers <sep> cell counts of enterobacteria and clostridia <sep> bifidobacterial numbers <sep>', ""death or nec bell's stage 2 <sep> feeding intolerance <sep> incidence of death or nec <sep> necrotizing enterocolitis <sep>"", 'median log of colony forming units per gram of faeces for escherichia coli and enterococci <sep> weight gain <sep> d-xylose and lipid absorption <sep> number of bifidobacteria and staphylococci in the stools <sep> sb tolerance and weight gain faecal flora analysis intestinal d-xylose absorption and faecal lipid excretion <sep>', 'incidence of nec <sep> incidence and severity of nec <sep> necrotizing enterocolitis nec <sep> incidence and severity of necrotizing enterocolitis <sep> death or nec <sep> incidence of death or nec <sep>', 'lactobacilli <sep> gram-negative enteric organisms <sep> gastrointestinal bacterial colonization <sep>', 'gastrointestinal tolerance <sep> percentage of infants receiving 50 of their nutritional needs via enteral feeding on the 14th day of life <sep> fecal excretion of calprotectin <sep> time to reach full enteral feeding <sep>', ""death or necrotizing enterocolitis bell's stage <sep> adverse effect such as sepsis flatulence or diarrhea <sep> incidence of death or necrotizing enterocolitis <sep> necrotizing enterocolitis <sep>"", 'faecal reservoir of potential pathogens <sep>', 'intestinal permeability <sep> supplementation median bifidobacteria counts <sep> l/m ratio <sep> head growth <sep> intestinal permeability <sep> acceptance and tolerance of the formula <sep> somatic growth tolerance rates of sepsis and necrotizing enterocolitis <sep> median counts of stool bifidobacteria and lactulose/mannitol ratios <sep>', 'deaths <sep> incidence and severity of nec <sep> incidence of nec <sep> necrotizing enterocolitis <sep>'], 'punchline_text': ['our study showed that enteral administration of prophylactic probiotics in neonatal intensive care setup could significantly reduce morbidity due to necrotising enterocolitis in very low birth weight newborn. <sep>', 'orally administered l. casei subspecies rhamnosus significantly reduces the incidence and the intensity of enteric colonization by candida species among very low birth weight neonates. <sep>', 'bacterial sepsis was more frequent in the probiotics group 4.4 n  11 than in the placebo group 3.8 n  9 but the difference was not significant. <sep>', 'for blf vs control and risk ratio 0.27 95 confidence interval 0.12-0.60 p  .001 for blf plus lgg vs control). <sep>', 'b breve can colonise the immature bowel very effectively and is associated with fewer abnormal abdominal signs and better weight gain in vlbw infants probably as a result of stabilisation of their intestinal flora and accelerated feeding schedules. <sep>', 'in comparison between group a and b bifidobacterium was detected significantly earlier in group a and the number of enterobacteriaceae present in the infants at 2 weeks after birth was significantly lower in group a. <sep>', 'however the probiotic supplementation increased the cell counts of bifidobacteria and reduced the cell counts of enterobacteria and clostridia. <sep>', 'feeding intolerance was significantly lower in the probiotics group than in the control group 44.5 n 49 vs 63.1 n 70 respectively <sep>', 'median log of colony forming units per gram of faeces for escherichia coli and enterococci was significantly lower in the sb group e. coli 2.67 0.045 vs. 2.75 0.058 p<0.001 <sep>', 'the incidence of nec or stage 2 was also significantly lower in the study when compared with the control group 2 of 180 vs 10 of 187). <sep>', 'there was no significant difference between the study groups in the number of resistant organisms or in the proportion of resistant organisms per gram-negative enteric isolates 4 of 40 vs. 0 of 28). <sep>', 'the primary endpoint was not significantly different between the probiotic 57.8 and placebo 57.1 groups p  0.95). <sep>', 'the incidence of death or necrotizing enterocolitis stage or=2 was significantly lower in the study group 4 of 217 infants vs 20 of 217 infants). <sep>', 'however colonisation with lactobacillus gg did not reduce the faecal reservoir of potential pathogens and there was no evidence that colonisation had any positive clinical benefit for this particular group of infants. <sep>', 'after 7 days of supplementation median bifidobacteria counts were significantly higher in the study group than in the control group p=0.0356 and they remained higher to the end of the study p at day 30=0.075). <sep>', 'the incidence of nec was reduced in the study group 4 vs 16.4 p=.03). <sep>'], 'population': ['very low birth weight newborns <sep>', 'gastrointestinal colonization by candida species in preterm very low birth weight i.e.  1500-g neonates during their stay in a neonatal intensive care unit <sep> preterm neonates <sep> 80 preterm neonates with a very low birth weight was conducted in a large tertiary neonatal intensive care unit <sep>', '12 italian nicus <sep> five hundred eighty-five patients were studied <sep> newborn infants with a gestational age 33 weeks or birthweight 1,500 g <sep> preterm infants <sep>', 'very low-birth-weight neonates <sep> human infants <sep> 11 italian tertiary neonatal intensive care units <sep> patients were 472 vlbw infants enrolled from october 1 2007 through july 31 2008 and assessed until discharge for development of sepsis <sep>', 'to preterm infants <sep> 66 vlbw infants preliminary study <sep> 91 vlbw infants <sep>', 'intestinal flora of low birth weight infants <sep> low birth weight infants average birth weight 1489 g <sep>', '69 preterm infants <sep> preterm infants in a neonatal intensive care unit differs from that of term infants <sep> preterm infants <sep>', 'very low-birth weight infants <sep> very low-birth weight vlbw infants <sep> 221 infants were studied 110 in the study group and 111 in the control group <sep> 2011 macmillan publishers limited <sep> preterm infants with a gestational age of 33 weeks or birth weight of 1500 g. vlbw infants who survived to start enteral feeding <sep>', '87 healthy babies with gestational age 28-32 weeks were studied <sep> premature infants with saccharomyces boulardii <sep>', 'vlbw infants <sep> very low birth weight infants <sep> three hundred sixty-seven infants were enrolled 180 in the study group and 187 in the control group <sep> vlbw infants who started to fed enterally and survived beyond the seventh day after birth were eligible for the trial <sep> very low birth weight vlbw infants <sep>', 'thirty premature infants were matched by birth weight and gestational age <sep> premature infants <sep> premature infants in the neonatal intensive care unit <sep>', 'preterm infants born with a very low or extremely low birth weight <sep> premature infants <sep> very-low-birth-weight preterm infants <sep>', '7 nicus in taiwan <sep> necrotizing enterocolitis among very low birth weight infants birth weight <sep> four hundred thirty-four infants were enrolled 217 in the study group and 217 in the control group <sep> very low birth weight preterm infants <sep> very low birth weight infants who survived to start enteral feeding were eligible <sep>', 'premature infants with lactobacillus gg <sep> twenty preterm infants with a gestational age of 33 weeks or less who were resident on a neonatal unit were studied from the initiation of milk feeds until discharge <sep>', 'preterm infants <sep> preterm infants and leads to increased head growth <sep> 41 stable preterm infants of 27 to 36 weeks gestation and 34 matched comparison infants consecutively admitted to the neonatal unit were studied <sep> preterm infants <sep>', '278 g gestational age 30 <sep> for 72 study and 73 control infants respectively birth weight 1152 <sep> very low birth weight neonates <sep> preterm neonates <sep> neonates  or 1500 g birth weight <sep>'], 'interventions': ['prophylactic probiotics <sep> prophylactic probiotics <sep>', 'orally supplemented probiotic lactobacillus casei subspecies rhamnosus dicoflor dicofarm spa <sep> oral probiotic added to human maternal or pooled donors milk group a or human milk alone <sep> lactobacillus casei subspecies rhamnosus <sep>', 'lactobacillus gg supplementation <sep> placebo <sep> probiotics feeding <sep> standard milk feed supplemented with lactobacillus gg dicoflor dicofarm rome italy in a dose of 6 x 10(9 colony-forming units cfu once a day until discharge starting with the first feed or placebo <sep>', 'placebo <sep> bovine lactoferrin supplementation <sep> blf <sep> placebo blf supplementation alone or in combination with lgg <sep> probiotic lactobacillus rhamnosus gg lgg <sep> blf plus lgg <sep> bovine lactoferrin blf alone or in combination with lgg <sep> lactoferrin <sep>', 'bifidobacterium breve <sep>', 'bifidobacterium breve supplementation <sep> bifidobacterium breve b. breve supplements <sep> no supplement <sep>', 'probiotic supplementation <sep> placebo <sep> bifidobacterium lactis bb12 supplementation <sep>', 'oral probiotics <sep> fed without l. sporogenes supplementation <sep> lactobacillus sporogenes <sep>', 'probiotics <sep> preterm formula to which sb or maltodextrins <sep> saccharomyces boulardii sb <sep> sb <sep> staphylococci <sep>', 'oral probiotics <sep> infloran lactobacillus acidophilus and bifidobacterium infantis with breast milk twice daily until discharged <sep> breast milk alone <sep>', 'lactobacillus <sep> lactobacilli-containing formula or non-lactobacilli-containing formula <sep>', 'bb536-lgg <sep> placebo <sep> probiotics <sep> enteral probiotics bifidobacterium longum bb536 and lactobacillus rhamnosus gg bb536-lgg <sep> oral supplementation with probiotics <sep>', 'oral probiotics <sep> breast milk or mixed feeding <sep> bifidobacterium bifidum and lactobacillus acidophilus added to breast milk or mixed feeding breast milk and formula <sep> probiotics <sep>', 'probiotic lactobacillus gg <sep> milk feeds or milk feeds supplemented with lactobacillus gg 10(8 colony forming units twice a day for two weeks <sep> lactobacillus gg <sep>', 'preterm formula supplemented with bifidobacter lactis 2 x 10(7 cfu/g of dry milk while the control group received the same formula but without supplementation <sep> bifidobacter supplemented infant formula <sep> bifidobacter supplemented bovine milk <sep>', 'oral probiotics <sep> daily feeding supplementation with a probiotic mixture bifidobacteria infantis streptococcus thermophilus and bifidobacteria bifidus solgar israel of 10(9 colony forming units cfu)/day or to not receive feed supplements <sep> probiotic supplementation <sep> nec <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",enteral supplementation of probiotics prevents severe nec and all cause mortality in preterm infants. our updated review of available evidence supports a change in practice. more studies are needed to assess efficacy in elbw infants and assess the most effective formulation and dose to be utilized.
49,"{'outcomes': ['gestational age birth weight apgar scores the time of exposure to oxygen and in the incidence of pda or in the number of exchange transfusions and rbts <sep> rop stage ii or graver <sep> retinopathy of prematurity <sep>'], 'punchline_text': ['the two groups did not differ significantly in gestational age birth weight apgar scores the time of exposure to oxygen and in the incidence of pda or in the number of exchange transfusions and rbts. <sep>'], 'population': ['204 infants with birthweights between 751 and 2000 g and 26-35 weeks gestational age 100 treated and 104 control subjects <sep>'], 'interventions': ['d-penicillamine dpa <sep> d-penicillamine <sep>'], 'punchline_effect': [' no diff <sep>']}",d-penicillamine is unlikely to affect survival and may reduce the incidence of acute rop among survivors. studies to date justify further investigation of this drug in a broader population careful attention to possible side effects is needed.
50,"{'outcomes': ['2-year overall survival rates <sep> died <sep> progression-free survival rates <sep> progression-free survival or overall survival <sep> grade 2 or greater motor neurotoxicity and sensory neurotoxicity <sep>', 'peritoneal relapses <sep> disease-free survival and/or overall survival <sep> median overall survival time <sep> median disease-free survival <sep> overall survival or disease-free survival <sep> death <sep>', 'hazard ratio of progression <sep> median pfs <sep> thrombocytopenia <sep> partial response <sep> progression-free survival pfs <sep> pfs <sep> neutropenia <sep>', 'late radiation reactions <sep> late intestinal radiation reactions <sep> overall survival <sep> side effects <sep> pathologic remission progression-free survival <sep> survival <sep> number of recurrences <sep>', 'recurrence-free interval rfi and safety profile <sep> cumulative probability of recurring <sep> incidence of grade 2 or worse peripheral neuropathy <sep> infection/fever <sep> dermatologic events <sep> rfi <sep> probability of surviving 5 years <sep>'], 'punchline_text': ['a consolidation treatment with six cycles of paclitaxel does not prolong progression-free survival or overall survival in patients in complete response after first-line paclitaxel/platinum-based regimens. <sep>', 'peritoneal relapses were 25 for cisplatin treatment vs. 16.4  for nihil. <sep>', 'there was no statistically significant difference in pfs between the arms p .83 log-rank test median pfs was 18.2 months in the topotecan arm and 28.4 in the control arm. <sep>', 'in the subgroup with microscopic residual carcinoma there were no significant differences in survival between the radiotherapy and the chemotherapy-treated patients. <sep>', 'the incidence of grade 2 or worse peripheral neuropathy 15.5 vs. 6 infection/fever 19.9 vs. 8.7 and dermatologic events 70.8 vs. 52.1 was higher on the maintenance regimen p<0.001). <sep>'], 'population': ['patients with stages iib to iv disease in clinical or pathologic complete response after six courses of <sep> two hundred patients were randomly assigned from march 1999 to july 2006 <sep> patients with advanced epithelial ovarian cancer in complete response after six courses of <sep> patients with advanced epithelial ovarian cancer who are in complete response after first-line paclitaxel/platinum-based chemotherapy <sep>', 'sixty patients in the <sep> 122 randomized patients in complete remission as judged by laparoscopy or laparotomy following first-line chemotherapy consisting of <sep> patients affected by epithelial ovarian cancer <sep> epithelial ovarian cancer <sep>', 'patients with ovarian cancer <sep> patients with advanced ovarian cancer who respond to initial chemotherapy with <sep> two hundred seventy-three patients were randomly assigned topotecan n  137 observation n  136 with a median age of 56 years <sep> advanced ovarian cancer <sep>', '172 patients with epithelial ovarian carcinoma figo stage iii with complete surgical remission after primary cytoreductive surgery and induction chemotherapy <sep> advanced figo stage iii ovarian carcinoma in complete surgical remission after induction chemotherapy <sep>', 'patients with early-stage ovarian carcinoma <sep> patients with stage ia/b grade 3 or clear cell all ic or ii epithelial ovarian cancer <sep> patients with completely resected high-risk early-stage ovarian cancer treated with <sep> 571 patients enrolled onto this study of whom 29 were deemed ineligible due to inappropriate stage or pathology leaving 542 patients <sep>'], 'interventions': ['paclitaxel/platinum-based chemotherapy <sep> paclitaxel <sep>', 'cisplatin <sep> platinum+fu <sep> acy adriamycin  cyclophosphamide pcy cisplatin  cyclophosphamide or mitoxantrone  carboplatin <sep> consolidation chemotherapy with cisplatin <sep> 5-fluorouracil fu <sep>', 'standard carboplatin area under the curve 5 and paclitaxel <sep> carboplatin and paclitaxel <sep> carboplatin/paclitaxel <sep> topotecan <sep> topotecan <sep>', 'whole abdominal radiotherapy chemotherapy <sep> radiotherapy or chemotherapy <sep> radiotherapy <sep>', 'carboplatin auc 6 and paclitaxel 175 mg/m q3 weeks <sep> auc6 and paclitaxel <sep> intravenous iv carboplatin and paclitaxel with or without maintenance low-dose paclitaxel <sep> iv carboplatin and paclitaxel <sep> observation versus weekly maintenance low-dose paclitaxel <sep> observation or maintenance paclitaxel 40 mg <sep> maintenance paclitaxel <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there is no evidence to suggest that the use of platinum agents doxorubicin or paclitaxel used as maintenance chemotherapy is more effective than observation alone. further investigations regarding the effect of paclitaxel used as maintenance chemotherapy are required.
51,"{'outcomes': ['peak force of the pinch grip using a force transducer and manipulation functions of the upper extremity jebsen-test <sep> activities of daily living barthel index <sep> peak force of the pinch grip and generalized <sep>', 'demographic variable or movement scale <sep>', 'fugl-meyer and ara scores <sep> fugl-meyer assessment of motor recovery fugl-meyer and action research arm test ara <sep> feasibility and efficacy <sep>', 'motor activity log and action research arm ara test <sep> ara scores <sep> caregiver ratings of quality of movement <sep>', 'action research arm test and the upper extremity section of the fugl-meyer assessment <sep> demographic variable or movement scale <sep> daily arm function <sep>'], 'punchline_text': ['mental training resulted in an increase in the peak force of the pinch grip and generalized in a better functionality of the upper extremity jebsen-test). <sep>', 'however subjects in the mcit+mental practice group exhibited significantly larger changes on both movement measures after intervention <sep>', 'after intervention fugl-meyer and ara scores of patients in the therapy only group remained virtually the same therapy plus imagery group scores improved by 13.8 and 16.4 points respectively on the fugl-meyer and ara. <sep>', ""a wilcoxon test on the ara scores revealed significantly  p .004 greater changes in the mp group's scores. <sep>"", 'subjects receiving mp showed significant reductions in affected arm impairment and significant increases in daily arm function both at the p<0.0001 level). <sep>'], 'population': ['17 patients after their first hemiparetic stroke <sep>', 'ten patients with chronic stroke 7 males mean age 61.4+/-3.02 years age range 48 to 79 years mean time since stroke 28.5 months range 13 to 42 months exhibiting stable affected arm motor deficits <sep>', 'five patients participated in a control intervention consisting of exposure to stroke information <sep> acute stroke <sep> thirteen consecutively admitted patients between four weeks and one year post stroke exhibiting stable motor deficits in their affected upper limbs <sep>', 'range 53-71 y <sep> eleven patients who had a stroke more than 1 year before study entry 9 men mean age 62.3+/-5.1 <sep> stroke patients <sep> chronic stroke <sep>', 'thirty-two chronic stroke patients mean=3.6 years with moderate motor deficits <sep> patients with chronic stroke <sep> chronic stroke patients <sep> chronic stroke <sep>'], 'interventions': ['mental training of sequential finger movements <sep> mental practice <sep> mental training <sep> conventional physical therapy <sep>', 'modified constraint-induced therapy combined with mental practice <sep> mcit <sep> modified constraint-induced therapy mcit <sep> mcit+mental practice experimental condition also received 30-minute mental practice sessions <sep> mcit versus mcit <sep>', 'programme combining imagery and occupational therapy <sep>', 'mp condition concurrently received sessions requiring daily mp of the adls 5 subjects control group received an intervention consisting of relaxation techniques <sep> mental practice mp protocol <sep> mental practice <sep>', 'placebo <sep> 30-minute mp sessions provided directly after therapy requiring daily mp of the activities of daily living subjects assigned to the control group received the same amount of therapist interaction <sep> method <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is limited evidence to suggest that mp in combination with other rehabilitation treatment appears to be beneficial in improving upper extremity function after stroke as compared with other rehabilitation treatment without mp. evidence regarding improvement in motor recovery and quality of movement is less clear. there is no clear pattern regarding the ideal dosage of mp required to improve outcomes. further studies are required to evaluate the effect of mp on time post stroke volume of mp that is required to affect the outcomes and whether improvement is maintained long-term. numerous large ongoing studies will soon improve the evidence base.
52,"{'outcomes': ['number of antenatal day admissions and ultrasound scans <sep> ultrasound scans <sep> fetal and maternal morbidity health service use psychosocial outcomes and maternal and professional satisfaction <sep>', 'proportion of women with five or less visits <sep> rates of preterm delivery or low birthweight <sep> likelihood of haemoglobin testing <sep> median maternal age parity and gestational age at booking <sep> number of antenatal visits antepartum and intrapartum referrals utilization of health centre for delivery and perinatal outcomes <sep> perinatal mortality <sep> intrapartum transfers <sep> median number of visits <sep>', 'satisfaction with the prenatal care system subscale <sep> levels of satisfaction <sep> perinatal outcomes or anxiety <sep> satisfaction with provider subscale <sep> level of satisfaction <sep> anxiety scores <sep> perinatal outcomes anxiety and maternal satisfaction <sep> pregnancy outcomes of infant and maternal morbidity and mortality anxiety and satisfaction <sep>', ""low birth weight <sep> preterm delivery preeclampsia cesarean delivery low birth weight and patient's satisfaction with care <sep> adverse perinatal outcomes <sep> preeclampsia <sep> satisfaction with quality of prenatal care <sep> cesarean delivery <sep>"", 'level of satisfaction <sep> number of prenatal visits <sep> patient satisfaction regarding the number of prenatal visits <sep>'], 'punchline_text': ['pregnant women allocated to new style care had fewer day admissions 0.8 v 1.0 p=0.002 and ultrasound scans 1.6 v 1.7 p=0.003 and were less often suspected of carrying fetuses that were small for gestational age odds ratio 0.73 95 confidence interval 0.54 to 0.99). <sep>', 'there was no difference in median maternal age parity and gestational age at booking between women in the standard model and those in the new model. <sep>', 'women in the apcvs group reported significantly higher levels of satisfaction than women in the tpcvs group on both the satisfaction with provider subscale f  5.74 p  .02 and the satisfaction with the prenatal care system subscale f  2.01 p  .04). <sep>', 'there were no differences between the two groups in patients satisfaction with quality of prenatal care. <sep>', 'the study vs. control group differed significantly p  .0001 in patient satisfaction regarding the number of prenatal visits. <sep>'], 'population': [""2794 women at low risk fulfilling the trial's inclusion criteria between june 1993 and july 1994 <sep> low risk women together with maternal and professional satisfaction with care <sep> women receiving shared care and planning to deliver in one of three hospitals or at home <sep>"", 'two antenatal care models in rural zimbabwe <sep> women booking for anc in the clinics were eligible <sep> twenty-three rural health centres were stratified prior to random allocation to the new n  11 or standard n  12 model of care <sep> 13,517 women new n  6897 and standard n  6620 in the study and 78 10,572 of their pregnancy records were retrieved <sep> in a rural area in zimbabwe <sep>', '81 women receiving prenatal care at a free-standing birthing center according to either an alternative prenatal care visit schedule apcvs n  43 or the traditional prenatal care visit schedule tpcvs n  38 <sep> low-risk women at a free-standing birthing center <sep>', '2764 pregnant women judged to be at low risk of adverse perinatal outcomes <sep> low-risk women <sep>', 'five hundred forty-nine low-risk pregnant women <sep> low-risk patients <sep>'], 'interventions': ['traditional british antenatal visit schedule traditional care with a reduced schedule of visits new style care <sep>', 'five-visit antenatal care anc model with specified goals with the standard model <sep>', 'tpcvs <sep> apcvs <sep>', 'prenatal care visits <sep>', 'alternative prenatal care program <sep> usual prenatal care <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",in settings with limited resources where the number of visits is already low reduced visits programmes of antenatal care are associated with an increase in perinatal mortality compared to standard care although admission to neonatal intensive care may be reduced. women prefer the standard visits schedule. where the standard number of visits is low visits should not be reduced without close monitoring of fetal and neonatal outcome.
53,"{'outcomes': ['total dyskinesia score <sep> levodopa dyskinesias <sep>', ""dyskinesia severity <sep> self-scoring dyskinesia diaries <sep> daily off-time <sep> dyskinesia assessments on the unified parkinson's disease rating scale part iv <sep>"", ""motor fluctuations <sep> motor fluctuations and dyskinesias <sep> parkinsonian and dyskinesia scores <sep> dyskinesia severity <sep> patient-kept diaries and unified parkinson's disease rating scale updrs interviews <sep> motor response complications <sep>""], 'punchline_text': ['we found a 24 reduction in the total dyskinesia score after amantadine administration p  0.004). <sep>', 'the magnitude of the l-dopa motor response to oral challenges was not different after amantadine or placebo treatment and there was no significant reduction of daily off-time when patients received active treatment. <sep>', 'in the 14 patients completing this trial amantadine reduced dyskinesia severity by 60 p  0.001 compared to placebo without altering the antiparkinsonian effect of levodopa. <sep>'], 'population': [""parkinson's disease <sep>"", ""parkinson's disease <sep>"", ""parkinson's disease <sep> eighteen patients with advanced pd <sep> primates and pd patients <sep> parkinson's disease pd <sep>""], 'interventions': ['amantadine versus placebo <sep> amantadine <sep> placebo <sep>', 'nmda receptor antagonist amantadine <sep> amantadine or placebo <sep> amantadine <sep> placebo <sep>', 'n-methyl-d-aspartate nmda antagonist amantadine <sep> placebo <sep> amantadine <sep> levodopa <sep> amantadine <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>']}",due to lack of evidence it is impossible to determine whether amantadine is a safe and effective form of treatment for levodopa-induced dyskinesias in patients with parkinson's disease.
54,"{'outcomes': ['oxford hip score <sep> mean hospital stay <sep> function and quality of life <sep> hospital stay on function pain and quality of life qol <sep> fatal complications <sep>'], 'punchline_text': ['the difference in oxford hip score between the groups was not statistically significant before the operation but was better for the sg at 2 months p  0.03 and this difference remained more or less constant throughout the study. <sep>'], 'population': ['50 patients from two hospitals <sep> 27 patients receiving <sep> 50 patients with 6 months of follow-up <sep>'], 'interventions': ['preoperative and postoperative education programs as well as home visits from an outpatient team and a control group cg of 23 patients receiving conventional rehabilitation often augmented by a stay at a rehabilitation center <sep> short hospital stay augmented with education and home-based rehabilitation <sep>'], 'punchline_effect': [' no diff <sep>']}",based on the heterogeneity and the low quality of the included trials that precluded pooled meta-analysis there is silver level evidence that following hip or knee joint replacement early multidisciplinary rehabilitation can improve outcomes at the level of activity and participation. the optimal intensity frequency and effects of rehabilitation over a longer period and associated social costs need further study. future research should focus on improving methodological and scientific rigour of clinical trials and use of standardised outcome measures so that results can be pooled for statistical analysis.
55,"{'outcomes': ['symptomatic vasospasm <sep> mean global cbf <sep> net fluid balance or on blood volume <sep> cerebral blood flow <sep> minimum regional cbf values <sep> minimum regional cbf <sep> pulmonary artery diastolic and central venous pressures <sep> cardiac filling pressures and fluid intake <sep> cbf or blood volume <sep> cbf 133)xenon clearance <sep> cerebral blood flow cbf <sep>', 'regional cerebral blood flow <sep> clinical outcomes clinically evident and transcranial doppler sonography-evident vasospasm spect findings complications and costs <sep> spect findings and neuropsychological function results <sep> cerebral vasospasm <sep>'], 'punchline_text': ['hv therapy resulted in increased cardiac filling pressures and fluid intake but did not increase cbf or blood volume compared with nv therapy. <sep>', 'no differences were observed between the two groups with respect to cerebral vasospasm as observed clinically or on transcranial doppler recordings). <sep>'], 'population': ['subarachnoid hemorrhage <sep>', 'after aneurysmal subarachnoid hemorrhage <sep> sixteen patients received <sep> 32 patients with subarachnoid hemorrhage <sep>'], 'interventions': ['isotonic crystalloid 250 ml of 5 albumin solution was given every 2 hours to maintain normal nv group n=41 or elevated hv group n=41 cardiac filling pressures <sep> hv therapy <sep> hypervolemic therapy <sep>', 'hypervolemic hypertensive hemodilution fluid therapy <sep> prophylactic hyperdynamic postoperative fluid therapy <sep> prophylactic hyperdynamic postoperative fluid therapy <sep> normovolemic fluid therapy <sep> transcranial doppler recordings single-photon emission computed tomographic spect scanning and routine computed tomographic scanning <sep> nimodipine <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>']}",the effects of volume expansion therapy have been studied properly in only two trials of patients with aneurysmal sah with very small numbers. at present there is no sound evidence for the use of volume expansion therapy in patients with aneurysmal sah.
56,"{'outcomes': ['remission rate <sep> tolerated <sep> atypical symptoms <sep> hdrs scores <sep>', 'clinical response rates <sep> remission rates <sep> 24-item hamilton depression rating scale <sep> effectiveness and tolerability <sep> greater treatment-emergent adverse events agitation sleep disturbance palpitations <sep>', 'clinical response <sep> tolerated <sep> rate of clinical response <sep> lower depression scores <sep> 29-item modified hamilton depression rating scale administered by experienced clinicians and the self-rated beck depression inventory adverse events and safety data <sep> overall response <sep> depression score <sep> efficacy and safety <sep>', 'remission rate sigh-sad 8 <sep> hamilton depression rating scale sad version sigh-sad the clinical global impression of severity cgi-s and improvement cgi-i and the uku side effect rating scale <sep> time to response and to remission <sep> sigh-sad score cgi-s and cgi <sep> sigh-sad score <sep> number and severity of side effects <sep> response rate sigh-sad <sep>', 'response rate <sep> hamilton depression rating scale sad version sigh-sad and the clinical global impression cgi <sep> remission rate sigh-sad<8 <sep> social adaptation self evaluation scale sass the sheehan disability scale sds and assessments of days lost due to illness and days with reduction in productivity <sep> productivity <sep> negative social consequences of sad <sep> sigh-sad cgi severity sass and sds scores <sep>', 'response rate <sep> seasonal affective disorder sad fall-winter depression <sep> hamilton depression rating scale sad version sigh-sad the clinical global impression cgi and the social adaptation self evaluation scale sass <sep> sigh-sad score and cgi severity score <sep> uku side effect rating scale <sep> rate of remission <sep> efficacy and tolerability <sep> sass score <sep> side effects <sep>'], 'punchline_text': ['the remission rate in the bright light group tended to be superior bright light 50 fluoxetine 25 p  0.10). <sep>', 'fluoxetine was associated with greater treatment-emergent adverse events agitation sleep disturbance palpitations but both treatments were generally well-tolerated with no differences in overall number of adverse effects. <sep>', 'the fluoxetine group had lower depression scores at termination than the placebo group but these differences did not achieve statistical significance. <sep>', 'sigh-sad score was significantly lower in the reboxetine group at weeks 1 2 and 4 but not at the end of the study. <sep>', 'duloxetine led to a significant improvement p<0.001 of sigh-sad cgi severity sass and sds scores. <sep>', 'the response rate sigh-sad<50 of baseline value after treatment for 8 weeks was 95 the rate of remission sigh-sad  or 7 was 85%. <sep>'], 'population': ['forty patients entered phase ii and 35 completed it one drop-out in the <sep> 40 patients 20 in each treatment condition suffering from seasonal affective disorder sad according to dsm-iii-r who had a total score on the hamilton depression scale of at least 16 <sep> seasonal affective disorder winter type <sep> seasonal affective disorder <sep>', '96 patients <sep> four canadian centers over three winter seasons <sep> patients met dsm-iv criteria for major depressive disorder with a seasonal winter pattern and had scores  or  23 on the <sep> patients with winter seasonal affective disorder <sep>', 'sixty-eight outpatients who met the dsm-iii-r criteria for recurrent major depressive episodes seasonal winter pattern <sep> seasonal affective disorder <sep>', '20 sad patients <sep> seasonal affective disorder <sep>', 'seasonal affective disorder sad <sep> 26 sad patients <sep>', 'seasonal affective disorder <sep> twenty sad patients were included in an 8-week drug surveillance <sep>'], 'interventions': ['placebo light condition versus bright light <sep> placebo drug <sep> placebo <sep> fluoxetine <sep>', 'light therapy and fluoxetine <sep> fluoxetine <sep> light therapy <sep> fluoxetine <sep> placebo capsule or 2 100-lux light treatment placebo light and fluoxetine <sep>', 'placebo <sep> fluoxetine <sep> fluoxetine <sep>', 'escitalopram and reboxetine <sep> escitalopram <sep> nari reboxetine <sep> reboxetine <sep> reboxetine <sep>', 'open-label duloxetine <sep> duloxetine <sep> duloxetine <sep>', 'escitalopram <sep> open-label escitalopram <sep> escitalopram <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>']}",evidence for the effectiveness of sgas is limited to one small trial of fluoxetine compared with placebo which shows a non-significant effect in favour of fluoxetine and two small trials comparing fluoxetine against light therapy which suggest equivalence between the two interventions. the lack of available evidence precludes the ability to draw any overall conclusions on the use of sgas for sad. further larger rcts are required to expand and strengthen the evidence base on this topic and should also include comparisons with psychotherapy and other sgas. data on adverse events were sparse and a comparative analysis was not possible. therefore the data we obtained on adverse effects is not robust and our confidence in the data is limited. overall up to 27 of participants treated with sgas for sad withdrew from the studies early due to adverse effects. the overall quality of evidence in this review is very low.
57,"{'outcomes': ['blood samples <sep> mean carbamazepine levels <sep> serum carbamazepine concentrations <sep> side effects <sep> mean serum carbamazepine levels <sep>', 'bioavailability <sep> occurrence of dizziness <sep> stability in serum cbz and cbze concentrations <sep> fluctuations in serum cbz and cbze <sep> number of epileptic seizures <sep> serum concentrations of unchanged cbz and its main metabolite carbamazepine-10,11-epoxide cbze <sep> peak concentrations of cbz and cbze <sep> time-lapse before cbz reached its peak <sep> side effects <sep>', 'seizure frequency <sep> cbz levels and summation of cbz and cbz-e levels <sep> frequency of seizures <sep>', 'fluctuation in serum cbz concentrations <sep>', 'occurrence of seizures <sep> mean total number of seizures <sep> bioavailability of cbz <sep> mean fluctuation of serum cbz concentration cmax-cmin/css <sep> mean serum cbz concentration <sep>', 'fluctuations of total cbz and 10 11-epoxide plasma level daily profiles at steady-state <sep> tolerability and pharmacokinetics <sep> mean cbz daily dose <sep> intermittent side effects <sep>', 'serum cbz concentration <sep> peak serum cbz concentrations <sep> seizure frequency <sep> diurnal fluctuations <sep> mean cbz concentrations <sep>', 'occurrence of headache dizziness and disturbances of vision speech and coordination <sep> quality and severity of side effects <sep> side effects <sep> systemic toxicity strs and neurotoxicity ntrs <sep> mean total values of ntrs <sep> total score of strs <sep>', 'cognitive performance <sep> serum concentration of cbz <sep>'], 'punchline_text': ['at this stage the difference in mean carbamazepine levels of two groups became insignificant p  0.05). <sep>', 'there was no significant difference in bioavailability between the 2 preparations. <sep>', 'there was no difference in the frequency of seizures between treatment p  0.103). <sep>', 'the fluctuation in serum cbz concentrations did not differ significantly between the 2 treatment periods even though the interdose interval of neurotol slow was 4 h longer than that of tegretol. <sep>', 'the mean serum cbz concentration in the morning samples was significantly p less than 0.001 higher during sr treatment. <sep>', 'fluctuations of total cbz and 10 11-epoxide plasma level daily profiles at steady-state were significantly p less than 0.001 lower during cr cbz treatment leading to a significant p less than 0.001 decrease in intermittent side effects 6 patients on cr cbz vs 26 on conventional cbz). <sep>', '3 p less than 0.01 in serum cbz concentration were substantially less with cbz-cr and were similar to those calculated during a 6 or 8 hourly dosage interval with conventional cbz fluctuation 33  <sep>', 'all the items of ntrs scored lower during sr therapy and the difference was significant for the occurrence of headache dizziness and disturbances of vision speech and coordination. <sep>', 'a systematic tendency was found toward higher test performance in the cr condition. <sep>'], 'population': ['twenty consecutive untreated patients of partial seizures <sep> newly treated patients of epilepsy <sep> indian epileptic patients <sep>', 'eighteen adult epileptic patients under <sep>', '24 adult patients with epilepsy <sep> patients with epilepsy <sep>', '24 adult epileptic patients receiving cbz treatment of whom 20 patients were evaluable <sep>', 'mean age of the 20 evaluable patients was 24.9 and the duration of epilepsy 19.2 and carbamazepine treatment 7.0 years <sep> mentally retarded patients with a slow-release carbamazepine preparation <sep>', '38 patients on <sep> 48 epileptic patients 21 men 27 women mean age 34.2 years on <sep> but without complete seizure control n  22 or with intermittent side effects n  4 or with both n  22 <sep> eligible patients <sep>', 'epileptic patients <sep> twenty-one epileptic patients <sep>', 'twenty-one adult patients with epilepsy who had side effects related to the use of cbz took part in the trial <sep> twenty patients could be evaluated <sep>', 'patients with epilepsy <sep>'], 'interventions': ['conventional carbamazepine <sep> conventional and slow-release carbamazepine formulations <sep> carbamazepine <sep> slow-release carbamazepine formulation <sep> conventional and slow-release carbamazepine formulation <sep>', 'cbz therapy <sep> carbamazepine cbz <sep> slow-release carbamazepine preparation <sep>', 'twice-daily extended-release carbamazepine cbz and four-times-daily immediate-release cbz <sep> cbz carbatrol capsules <sep> carbamazepine cbz <sep>', 'carbamazepine <sep> carbamazepine cbz and carbamazepine-10,11-epoxide <sep>', 'conventional c carbamazepine cbz <sep> carbamazepine-10,11-epoxide <sep>', 'cr cbz <sep> conventional cbz <sep> conventional vs controlled-release carbamazepine <sep> conventional cbz or cr cbz <sep> carbamazepine cbz <sep> conventional cbz monotherapy <sep>', '5%).(abstract <sep> conventional carbamazepine cbz tegretol ciba-geigy with a new controlled-release formulation cbz-cr tegretol retard <sep> monotherapy with conventional and controlled-release carbamazepine <sep> cbz as monotherapy <sep>', 'cbz <sep> conventional carbamazepine <sep> carbamazepine <sep> carbamazepine cbz <sep> conventional c or slow-release sr cbz preparation <sep>', 'carbamazepine <sep> cbz-controlled release cr or a condition in which conventional cbz <sep> carbamazepine cbz <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",at present data from trials do not confirm or refute an advantage for cr cbz over ir cbz for seizure frequency or adverse events in patients with newly diagnosed epilepsy. for trials involving epilepsy patients already prescribed ir cbz no conclusions can be drawn concerning the superiority of cr cbz with respect to seizure frequency. there is a trend for cr cbz to be associated with fewer adverse events when compared to ir cbz. a change to cr cbz may therefore be a worthwhile strategy in patients with acceptable seizure control on ir cbz but experiencing unacceptable adverse events. the included trials were of small size poor methodological quality and possessed a high risk of bias limiting the validity of this conclusion. randomised controlled trials comparing cr cbz to ir cbz and using clinically relevant outcomes are required to inform the choice of cbz preparation for patients with newly diagnosed epilepsy.
58,"{'outcomes': ['electronic data and linear regression <sep> bmd measurement and osteoporosis medication <sep> osteoporosis management <sep> bmd measurement or osteoporosis medication provider reminder plus patient education <sep>'], 'punchline_text': ['the effect of provider advice combined with patient education was not significantly different from provider advice alone p=.88). <sep>'], 'population': ['female patients aged 50 to 89 who suffered a fracture in 1999 and had not received bone mineral density bmd measurement or medication for osteoporosis n=311 and their primary care providers n=159 <sep> patients aged 60 to 69 were 18 95 confidence interval=3-34 more likely to receive bmd measurement or an osteoporosis medication than those aged 80 to 89 <sep> after a fracture <sep>'], 'interventions': ['provider advice combined with patient education <sep> electronic medical record reminder <sep> electronic medical record emr message or electronic reminder to the provider plus an educational letter mailed to the patient <sep>'], 'punchline_effect': [' no diff <sep>']}",as only one study was identified for inclusion the results are inadequate to inform clinical practice in regard to the use of email for clinical communication between healthcare professionals. future research needs to use high-quality study designs that take advantage of the most recent developments in information technology with consideration of the complexity of email as an intervention and costs.
59,"{'outcomes': ['pain <sep> womac physical function scores <sep> disease-specific quality of life <sep> western ontario and mcmaster university osteoarthritis index womac and the mcmaster-toronto arthritis patient preference disability questionnaire mactar and function <sep>', ""compliance and tolerance <sep> patient's assessment of activity <sep> compliance <sep> nsaids consumption <sep> womac subscales <sep> disease activity 5 grade scale womac index subscales and concomitant treatments <sep> assessment of disease activity in womac pain joint stiffness and physical functioning subscales <sep> number of days with nsaids intake <sep>"", 'vas pain score <sep> talar tilt angle <sep> visual analog scale vas score for subjective knee pain <sep> femorotibial angle <sep>', 'aggregate score <sep> femorotibial angle <sep> femorotibial angle and symptomatic relief <sep> pain on getting up from a seated position <sep> symptomatic improvement <sep> pain <sep> aggregate severity score <sep> symptoms of knee oa <sep> maximum distance walked <sep>', 'alignment degree of oa origin of oa and age <sep> pain severity and knee function score <sep> walking distances <sep> walking distance and quality of life <sep>'], 'punchline_text': ['at the six-month follow-up evaluation there was a significant improvement in the disease-specific quality of life p  0.001 and in function p or 0.001 in both the neoprene-sleeve group and the unloader-brace group compared with the control group. <sep>', 'this study failed to demonstrate a relevant short-term symptomatic effect of laterally-wedged insoles in medial femoro-tibial oa. <sep>', 'participants wearing the elastically strapped insole n  46 had significantly decreased femorotibial angle p  0.0001 and talar tilt angle p  0.005 and significantly improved vas pain score p  0.045 in comparison with baseline assessments. <sep>', 'in contrast significant symptomatic improvement was detected only in the aggregate score p  0.016 in the sock-type ankle support group but not in any of the 10 specific categories. <sep>', 'the reported walking distances at 3 months 12 months and overall were significantly longer in the brace group p=0.03 p=0.04 and p=0.02 respectively). <sep>'], 'population': ['patients who had varus gonarthrosis were screened for eligibility <sep> nine patients withdrew from the study <sep> one hundred and nineteen patients were randomized <sep> forty patients thirty-one men and nine women mean age 60.9 years the neoprene-sleeve group of thirty-eight patients twenty-seven men and eleven women mean age 58.2 years and the unloader-brace group of forty-one patients twenty-eight men and thirteen women mean age 59.5 years <sep> patients were stratified according to age less than fifty years or at least fifty years deformity the mechanical axis in less than 5 degrees of varus or in at least 5 degrees of varus and the status of the anterior cruciate ligament torn or intact <sep> patients who had osteoarthritis in association with a varus deformity of the knee varus gonarthrosis <sep>', 'patients with medial femoro-tibial knee osteoarthritis oa <sep> outpatients with painful medial femoro-tibial knee oa <sep> medial femoro-tibial oa <sep> medial knee osteoarthritis <sep> 156 recruited patients 41 males 115 females mean age 64.8 years <sep>', 'patients with medial compartment osteoarthritis of the knee <sep> ninety female outpatients with oa of the knee <sep> patients with knee oa with varus deformity <sep> osteoarthritis oa of the knee <sep>', 'patients with medial compartment osteoarthritis of the knee <sep> patients with varus-deformity knee oa <sep> patients with medial compartment osteoarthritis oa of the knee <sep> eighty-eight female outpatients with knee oa <sep>', 'patients 117 patients with unicompartmental oa of the knee <sep> patients with medial or lateral compartmental osteoarthritis oa and concurrent varus or valgus alignment respectively <sep> orthopedic department of a university medical centre and of one general hospital <sep> patients with unicompartmental oa <sep> unicompartmental oa of the knee <sep> osteoarthritis of the knee <sep>'], 'interventions': ['medical treatment only control group medical treatment and use of a neoprene sleeve or medical treatment and use of an unloader brace <sep> custom-made valgus-producing functional knee unloader brace a neoprene sleeve and medical treatment only control group <sep>', 'laterally wedged insoles and neutrally wedged insoles used as control <sep>', 'lateral wedge insole with elastic strapping of the subtalar joint <sep>', 'subtalar strapping <sep> novel lateral wedged insoles with elastic subtalar strapping the subtalar strapping support group and ankle supporters with a lateral wedged heel insert the sock-type ankle support group <sep>', 'conservative treatment with additional brace treatment and a control group n=57 comprising conservative treatment alone <sep> brace treatment <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",based on two brace and three insole studies we conclude that there is silver level evidence www.cochranemsk.org that a brace and a lateral wedge insole have small beneficial effect. there is silver level evidence that strapped insoles correct leg alignment. however long-term adherence to brace and insole treatment is low. there is no evidence whether a brace is more effective than an insole.
60,"{'outcomes': ['mechanical ventilation <sep> while infections and arterial hypotension <sep> effectiveness rse control adverse events <sep> tolerability measures <sep> proportion of patients with rse <sep> mortality <sep>'], 'punchline_text': ['while infections and arterial hypotension did not differ between groups barbiturate use was associated with a significantly longer mechanical ventilation p  0.03). <sep>'], 'population': ['24 patients recruited of the 150 needed 14 subjects received <sep> adults with rse not due to cerebral anoxia medications were titrated toward eeg burst-suppression for 36-48 h and then progressively weaned <sep>'], 'interventions': ['propofol versus barbiturates <sep> propofol <sep> propofol 9 barbiturates <sep>'], 'punchline_effect': [' no diff <sep>']}",there is lack of robust and randomised controlled evidence that can clarify the efficacy of propofol and thiopental sodium over each other in the treatment of rse. there is a need for large randomised controlled trials for this serious condition.
61,"{'outcomes': ['totpar vps <sep> somnolence <sep> incident pain <sep> total pain score totpar <sep> postoperative pain intensity <sep> side effects <sep>', 'early postoperative maximal amplitude of knee flexion <sep> early postoperative knee mobilization levels <sep> surgical outcome and duration of rehabilitation <sep> visual analog scale scores <sep> pain <sep> durations of stay <sep> side effects <sep>', 'nonfatal pulmonary embolism <sep> total incidence of deep vein thrombosis <sep> incidence of calf vein thrombosis <sep> antithrombotic efficacy <sep> postoperative venous thrombosis <sep>', 'total blood loss <sep> perioperative blood loss frequency and quantity of transfusions <sep> perioperative blood loss <sep>', 'late postoperative pain fatigue and conservative attitudes and routines <sep> postoperative convalescence parameters such as ambulation patient activity including need for nursing care fatigue or hospital stay <sep> pain scores <sep> convalescence and hospital stay <sep> postoperative pain relief <sep>', 'plasma clearances of pethidine and the time to peak concentration <sep> plasma concentrations of pethidine <sep> low pain scores <sep> adverse effects <sep> visual analogue scale vas <sep> hypoalgesia to pin prick <sep> degree of analgesia the adverse effects <sep> area under the curve auc of pain score versus time <sep> pain score <sep>', 'respiratory depression <sep> visual analogue scale vas <sep> pain relief <sep> postoperative pain <sep> pulseoximetry arterial blood gas analysis and rate of breathing <sep> pain <sep> pain and consumption of postoperative analgesics <sep> nausea vomiting itching and urinary retention <sep>', 'pain relief visual analogue scale attainment of physical therapy goals and cardiopulmonary complications <sep> postoperative complications <sep> catabolic response <sep>', 'visual analogue pain scales total morphine consumption and stress hormones <sep> beta-endorphine release <sep> analgesic requirements <sep> pain relief <sep> stress hormones <sep> visual analogue pain scales <sep>', 'hypercapnia exceeding 6.0 kpa <sep> pain reduction <sep> pain scores pain reduction and additional analgesia requirement i.v. paracetamol <sep> side effects <sep> urinary retention <sep>', 'postoperative knee rehabilitation <sep> knee flexion <sep> postoperative analgesia <sep> pain scores <sep> supplemental analgesia <sep> pain relief <sep> pain scores supplemental analgesia side effects degree of maximal knee flexion day of first walk and duration of hospital stay <sep> side effects <sep> postoperative pain and knee rehabilitation <sep> pain relief and faster knee rehabilitation <sep> faster ambulation and shorter hospital stay <sep>', 'respiratory depression <sep> minimum respiratory rates <sep> pain <sep> pruritus <sep> pain <sep>', 'bradycardia <sep> pain control <sep> pain relief <sep> hypotension <sep> actual discharge time <sep> median time for first passage of flatus <sep> pain <sep> visual analog scales <sep> nausea and vomiting <sep>'], 'punchline_text': ['somnolence was observed more often in pca patients 8 vs 2 p 0.05 while no significant differences were noted among other side effects incidence. <sep>', 'the early postoperative knee mobilization levels in both continuous epidural infusion and continuous femoral block groups were significantly closer to the target levels prescribed by the surgeon than in the patient-controlled morphine group. <sep>', 'the incidence of calf vein thrombosis was 12 compared with 45 after general anaesthesia p  0.05). <sep>', 'perioperative blood loss frequency and quantity of transfusions were significantly higher in group d p<0.0001). <sep>', 'however the achieved pain relief had no impact on postoperative convalescence parameters such as ambulation patient activity including need for nursing care fatigue or hospital stay. <sep>', 'the terminal half-lives and plasma clearances of pethidine and the time to peak concentration were not different between the groups. <sep>', 'nausea vomiting itching and urinary retention were the most frequent side effects without significant differences between the groups. <sep>', 'epidural analgesia with a combination of bupivacaine and fentanyl did not result in any measurable improvement in rehabilitation milestones or reduction in postoperative complications following bilateral total knee arthroplasty than with fentanyl infusions alone. <sep>', 'application of intraarticular morphine did not reduce the amount of analgesics required for postoperative analgesia as compared to intravenous analgesia alone. <sep>', 'there were no significant differences between groups in pain scores pain reduction and additional analgesia requirement i.v. paracetamol). <sep>', 'patients in groups b and c reported significantly lower pain scores than those in group a. supplemental analgesia was comparable in the three groups. <sep>', 'minimum respiratory rates were lower in patients receiving epidural morphine 15.0  0.3 than in those receiving patient-controlled analgesia 16.5  <sep>', 'the median time for first passage of flatus was shorter in the eda group than in the ga/pca group 26 vs. 47 h). <sep>'], 'population': ['orthopedic surgery <sep>', 'after major knee surgery <sep> 56 adult scheduled for major knee surgery <sep>', 'forty-eight patients <sep> patients undergoing knee arthroplasty <sep>', 'sixty patients <sep> patients undergoing total hip arthroplasty <sep> total hip arthroplasty <sep>', 'forty-two patients scheduled for total knee arthroplasty n  20 or hip arthroplasty n  22 <sep> early convalescence after major orthopaedic surgery <sep> patients undergoing knee or hip arthroplasty treated with <sep>', 'twenty-one patients who had undergone total hip replacement <sep>', 'forty-one patients undergoing total knee arthroplasty <sep> patients with postoperative pain <sep> patients with epidural placebo premo <sep>', 'one-stage bilateral total knee arthroplasty <sep> 51 patients undergoing bilateral one-stage total knee arthroplasty <sep>', 'thirty-seven patients scheduled for total knee arthroplasty <sep> total knee arthroplasty <sep> after total knee arthroplasty patients regularly suffer from severe pain <sep>', 'pain after hip and knee arthroplasty <sep> 32 patients after hip and knee arthroplasty <sep>', 'unilateral total knee arthroplasty <sep> total knee arthroplasty tka <sep> forty-five patients scheduled for elective tka under general anesthesia <sep>', 'joint replacement surgery <sep> 30 patients recovering from total hip or total knee arthroplasty <sep>', '90 patients were enrolled <sep> hip replacement <sep>'], 'interventions': ['patient-controlled intravenous analgesia with morphine 30 mg and ketorolac 90 mg in 100 ml of saline <sep> figty asa class ii-iii patients undergoing total hip replacement under combined spinal-epidural anesthesia <sep> pcea <sep> postoperative pain treatment intravenous and epidural pca <sep> morphine 4 mg and bupivacaine <sep> postoperative pain treatment <sep> intravenous pca <sep>', 'perioperative analgesic technique <sep> lidocaine 0.03 mg/ml morphine and 2 microg/ml clonidine <sep> morphine <sep> postoperative analgesic technique for 72 h continuous epidural infusion continuous femoral block or intravenous patient-controlled morphine <sep>', 'compressive elastic stockings and no anticoagulant drugs <sep> bilateral venography <sep> general anaesthesia <sep> general anaesthesia or extradural analgesia with local anaesthetics <sep> extradural analgesia <sep> continuous extradural analgesia <sep>', 'aprotinin <sep> epidural  general anesthesia  aprotinin b epidural  general anesthesia  placebo equal volume c general anaesthesia  aprotinin d general anaesthesia  placebo <sep> antifibrinolytic agent aprotinin <sep> epidural anaesthesia <sep>', 'balanced analgesia <sep> continuous epidural bupivacaine/morphine for 48 h postoperatively plus oral piroxicam or general anaesthesia followed by a conventional intramuscular opioid and acetaminophen regimen <sep> epidural analgesia <sep>', 'extradural pethidine <sep> pethidine im i and 20 mg ii or 60 mg of extradural pethidine <sep> oxycodone <sep> pethidine <sep> morphine <sep>', 'epidural morphine <sep> pca-fentanyl <sep> epidural saline <sep> morphine <sep> opioid <sep> morphine 0.14 mg/kg <sep> epidural morphine <sep> morphine premedication <sep> morphine <sep> intravenous pca-fentanyl <sep> epidural morphine epimo <sep>', 'continuous epidural bupivacaine/fentanyl <sep> epidural analgesia with local anaesthetic <sep> bupivacaine and fentanyl <sep>', 'intraarticular morphine <sep> morphine via an epidural catheter <sep> epidural morphine <sep> intraarticular bolus of 1 mg of morphine was applied at the end of the operation with subsequent use of a patient-controlled analgesia pca pump group 3 control in which only pca <sep> morphine <sep> morphine plus <sep> epidural and intravenous analgesia <sep>', 'naloxone <sep> ketoprofen <sep> ketoprofen and extradural morphine <sep> ketoprofen <sep> extradural morphine <sep>', 'intravenous patient-controlled analgesia with morphine continuous epidural analgesia and continuous three-in-one block <sep> morphine <sep> total knee arthroplasty loco-regional analgesic techniques epidural analgesia or continuous 3-in-1 block <sep>', 'epidural and patient-controlled intravenous morphine <sep> morphine <sep> epidural morphine <sep> epidural morphine with patient-controlled intravenous iv morphine <sep>', 'ropivacaine <sep> ropivacaine <sep> general anesthesia isoflurane/n2o/fentanyl <sep> epidural anesthesia ropivacaine <sep> epidural anesthesia and analgesia eda <sep> ropivacaine epidural anesthesia and analgesia versus general anesthesia and intravenous patient-controlled analgesia with morphine <sep> morphine <sep> eda <sep> morphine ga/pca <sep> morphine epidural anesthesia and analgesia <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>']}",epidural analgesia may be useful for postoperative pain relief following major lower limb joint replacements. however the benefits may be limited to the early four to six hours postoperative period. an epidural infusion of local anaesthetic or local anaesthetic-narcotic mixture may be better than epidural narcotic alone. the magnitude of pain relief must be weighed against the frequency of adverse events. the current evidence is insufficient to draw conclusions on the frequency of rare complications from epidural analgesia postoperative morbidity or mortality functional outcomes or length of hospital stay.
62,"{'outcomes': ['typhoid fever <sep> vaccine efficacy <sep>', 'safety and immunogenicity <sep> immune responses <sep> seroconversion rate <sep>', 'typhoid fever <sep>', 'safety immunogenicity and efficacy <sep> attack rate of typhoid <sep> serious adverse reactions <sep> levels of serum igg vi antibodies <sep>', 'clinical and serum antibody responses <sep> fever oral temperature <sep> serum vi antibody levels ria <sep> erythema and/or induration <sep> frequencies of rises of fourfold or greater and of maximal vi antibody levels <sep> frequencies of adverse reactions and mean vi antibody levels <sep>', 'typhoid fever <sep> protective efficacy <sep>', 'attack rate of typhoid <sep> serum antibodies <sep>', 'degree of fever <sep> protective rate and index of vaccine <sep> mild local reaction <sep> efficacy and side effects <sep> mild and moderate fever <sep> fever seen <sep>', 'anti-vi antibodies <sep> protective efficacy <sep> antibody levels <sep>', 'rate of blood-culture-positive typhoid fever <sep> overall incidence of side-effects <sep> rates of typhoid fever <sep>'], 'punchline_text': ['vaccine efficacy in the first two years after vaccination was 59 for two doses and 29 for one dose no efficacy was found 3-5 years after vaccination. <sep>', 'the seroconversion rate was 69 for those who received vaccine versus 14 for those who received placebo p  0.005). <sep>', 'the results of the follow-up indicate that in the dosage schedule used the ty21a mutant strain found previously to be stable and safe is protective against typhoid fever for at least one year. <sep>', 'the vi-repa conjugate typhoid vaccine is safe and immunogenic and has more than 90 percent efficacy in children two to five years old. <sep>', 'fever oral temperature  or  100 degrees f 37.8 degrees c occurred in  2 of vaccinees. <sep>', 'most of the isolates were from school-aged children 22 cases in the placebo group versus 6 in the vi group pe  72 95 ci  32 82%). <sep>', 'the attack rate of typhoid was 16.2 per 1000 among the controls and 4.1 per 1000 among those immunized with vi p less than 0.00001). <sep>', 'a total number of 81,506 vaccinees were investigated on the efficacy of vi vaccine using positive blood culture of salmonolla typhi as a diagnostic criterion. <sep>', 'protective efficacy in relation to the unvaccinated group was 77.4 and 81.0 after 21 months calculated immediately and 6 weeks after vaccination respectively. <sep>', 'rates of typhoid fever were 379/100,000 per year for subjects who received the liquid formulation of vaccine and 468/100,000 per year for subjects who received enteric coated capsules. <sep>'], 'population': ['82,543 schoolchildren <sep>', '634 thai children 2 to 6 years of age <sep> young thai children <sep>', 'alexandria egypt in 1978-79 <sep> a total of 32 388 children were included in the study <sep>', 'children two to five years old <sep> persons who are more than five years old <sep> adults and in children 5 to 14 years old and has elicited a booster response in children 2 to 4 years old <sep> two-to-five-year-old children <sep> children two to five years old in 16 communes in dong thap province vietnam <sep> 11,091 children <sep> 5525 children who were fully vaccinated with vi-repa and from 47 of the 5566 children <sep> 771 children who received only one injection there was 1 case of typhoid in the vaccine group and 8 cases in the placebo group <sep>', 'healthy adults <sep> healthy adults <sep>', 'enrolled subjects were 3-50 years of age although the majority 92 were school-aged children who have the highest rate of typhoid fever in this setting <sep> guangxi zhuang autonomous region in south-western china using 30 micrograms doses of locally produced vi <sep> the study population was followed for 19 months with passive surveillance conducted in the ministry of health and the regional health and anti-epidemic centre haec <sep> south-western china <sep> a total of 131,271 people <sep>', '6907 participants of whom 6438 were members of the target population 5 to 44 years of age each was visited every two days <sep> typhoid fever in nepal with the vi capsular polysaccharide of salmonella typhi <sep>', '777 children and adults <sep>', '11,384 children <sep> 11,691 unvaccinated children 173 cases <sep>', '20,543 subjects age range 3-44 years <sep> indonesia with ty21a vaccine <sep>'], 'interventions': ['ty21a salmonella typhi vaccine <sep> ty21a vaccine in enteric-coated capsules or placebo <sep> placebo <sep>', 'salmonella typhi ty21a vaccine <sep> placebo <sep> vaccine <sep>', 'liver oral typhoid vaccine ty21a <sep> placebo <sep> live oral typhoid vaccine <sep>', 'vi-repa vaccine <sep> salmonella typhi vi conjugate vaccine <sep> placebo <sep> vi-repa or a saline placebo <sep>', '25 micrograms dose of liquid vi-liq n  182 or freeze-dried vi vaccine vi-lyoph n  55 or placebo <sep> salmonella typhi vi capsular polysaccharide vi <sep> salmonella typhi vi capsular polysaccharide vaccines <sep> vi vaccines <sep>', 'vi polysaccharide or saline placebo <sep> placebo <sep> vi vaccine <sep> vaccine <sep> vi polysaccharide vaccine <sep>', 'capsular polysaccharide of salmonella typhi vi <sep>', 'salmonella typhi vi capsular polysaccharide vaccine vi <sep> placebo <sep> salmonella typhi vi capsular polysaccharide vaccine <sep>', 'vi capsular polysaccharide vaccine <sep> vi capsular polysaccharide cps <sep> meningococcal a  c cps vaccine <sep> vi cps <sep>', 'enteric coated capsules containing placebo or live ty21a or three doses of lyophilised placebo or live ty21a reconstituted with phosphate buffer <sep> vaccine <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",the licensed ty21a and vi polysaccharide vaccines are efficacious. the new and unlicensed vi-repa vaccine is as efficacious and may confer longer immunity.
63,"{'outcomes': ['rate of mrsa infection <sep> coagulase-negative staphylococcus and enterococcus infection rates <sep> nosocomial mrsa infection rate <sep> nosocomial mrsa infections <sep> rate of nosocomial methicillin-resistant staphylococcus aureus infection <sep>', 'mortality and length of icu stay <sep> antimicrobial therapy costs antimicrobial resistance and superinfections without adversely affecting the length of stay or mortality <sep>', 'clostridium difficile-associated diarrhea and cost <sep> diarrhea <sep> clindamycin susceptibility <sep> mean number of cases of c. difficile-associated diarrhea <sep>', 'genital tract infection <sep> compliance with other recommendations patient satisfaction and costs of the implementation strategy secondary outcomes <sep> cervical cytology history <sep>', 'length of stay intensive care unit transfers readmission rates and in-hospital death rates <sep> rate of unnecessary use of the 2 target antibiotics <sep> number of days that unnecessary levofloxacin or ceftazidime <sep>', 'time-specific mortality risk <sep> median patient charges for radiology laboratory pharmacy and room were reduced by 4404/intervention and median hospital costs <sep> median length of stay <sep>', 'incidence of toxicity <sep> mean length of total hospital stay <sep> response rates <sep> reduced length of stay a potential cost savings <sep> serum aminoglycoside concentration data <sep> length of stay <sep>', 'cdad fell <sep> clostridium difficile-associated diarrhoea cdad <sep>', 'nosocomial infection and mortality <sep>', 'total antibiotic prescribing costs <sep> incidence of c. difficile diarrhoea <sep> c. difficile diarrhoea <sep> mortality rates and length of hospital stay <sep>', 'postoperative infection rate or death <sep> incidence of regimens involving 12-hour intervals <sep>', 'monthly incidence of c. difficile infection <sep> nosocomial clostridium difficile-associated diarrhea <sep>', 'vre prevalence <sep> vancomycin use <sep> icu vancomycin use and vre prevalence <sep>', 'mean risk of clostridium difficile-associated diarrhea <sep> mean overall mortality rate <sep> mean risk of infection-related mortality <sep> sd hospital stay <sep> mean durations of hospital stay <sep> mean numbers of defined daily doses of appropriate antibiotic therapy <sep> mean costs of antimicrobials per episode <sep> mortality rates <sep> bloodstream infections <sep>', 'acuity of patient care <sep> parenteral broad-spectrum antibiotics <sep> nosocomial infections <sep> vre rates <sep>', 'peak incidence <sep> infections <sep> incidence of colonization and infection <sep>', ""pharmacy's 1985 average cost per antibiotic day and its monthly expenditures <sep> antibiotic cost savings <sep> hospital length of stay or mortality <sep>"", 'level of compliance <sep>', 'number of infants treated with antibiotics and 2 the number of infants with infections missed at the initial evaluation <sep>', 'antibiotic use hospital admissions and mortality <sep> hospital admission severity of pneumonia and 30-day mortality <sep> hospital admissions <sep> 30-day mortality preintervention <sep> 30-day mortality <sep> mortality <sep>', 'febrile neutropenia and nosocomial infections <sep>', 'icu length of stay <sep> duration of antibiotic treatment for vap <sep> clinical pulmonary infection score <sep> hospital mortality <sep> severity of illness using apache acute physiology and chronic health evaluation ii score <sep> occurrence of a secondary episode of vap <sep>', 'acute exacerbation of chronic obstructive pulmonary disease <sep> serum calcitonin precursor concentrations <sep> antibiotic use <sep> adjusted relative risk of antibiotic exposure <sep> serological evidence of viral infection <sep> antibiotics and analysis was by intention to treat <sep> clinical and laboratory outcome <sep>', 'antibiotic prescriptions on admission <sep> pneumonia severity index the hazard ratio of antibiotic discontinuation <sep> total antibiotic exposure <sep> clinical laboratory and microbiology characteristics and pneumonia severity index <sep> clinical laboratory and radiographic outcome <sep> serum procalcitonin concentrations <sep> antibiotic treatment duration <sep>', 'time to first dose of antibiotics proportion receiving antibiotics within 8 h timely switch to oral antibiotics timely discharge length of stay or patient education outcomes <sep> quality efficiency and patient understanding of care <sep> quality and efficiency of pneumonia care <sep>', 'number of courses of therapy or cost <sep> total expenditures <sep> total number of courses of therapy <sep>', 'clinical outcomes <sep> appropriateness of cefotaxime prescribing <sep>', 'length of hospital stay costs related to future resistance and total antibiotic costs <sep> rate of appropriate empirical antibiotic treatment <sep> microbiologically documented infections mdi <sep> mortality <sep> antibiotic costs <sep> length of hospital stay adverse events mortality interventional trial and antibiotic costs both studies including costs related to future antibiotic resistance <sep>', 'mean durations of therapy <sep> medication costs <sep> crude mortality rates <sep> minimal fever diagnostic tests <sep>', 'mortality morbidity and cost <sep> turnaround time of the microbiological cycle <sep> turnaround time <sep> turnaround time of microbiological procedures <sep>', 'antibiotics in caesarean section and use of polyglycolic acid sutures <sep> rates of ventouse delivery <sep>', 'iv antibiotic expenditure <sep> iv antibiotic duration and appropriateness of the iv route and switching <sep> median duration of iv therapy <sep> duration of stay <sep>', 'cefx use <sep> concordance with national antibiotic guidelines <sep>', 'proportion of ceftazidime-resistant organisms acquired late <sep> incidence density of tobramycin-resistant organisms <sep>', 'cephalosporins <sep>', 'mortality from staphylococcal bacteraemia <sep>', 'diagnostic costs <sep> real-time pcr results <sep> partial or total cessation of antibiotic treatment <sep> overall antibiotic use <sep> diagnostic yields feasibility and costs of real-time polymerase chain reaction pcr <sep>', 'shorter length of stay <sep> per patient antibiotic charges <sep> clinical and microbiological response antibiotic-associated toxic effects in-hospital mortality and readmission rates <sep>', 'medical complications <sep> rates of discontinuation and hospital discharge <sep> duration of intravenous antibiotic therapy <sep> mortality rehospitalization and return to usual activities <sep> length of stay <sep>', 'time elapsed from randomization until a first modification of the initial intravenous antibiotic therapy <sep> time to modification of intravenous antibiotic therapy <sep>', 'amikacin resistance <sep> resistance to gentamicin and tobramycin <sep> gentamicin and tobramycin resistance <sep> reintroduction of gentamicin <sep> resistance among p. aeruginosa <sep> amikacin resistance <sep> gram-negative resistance to gentamicin <sep> aminoglycoside resistance <sep>', 'intraoperative redosing <sep> rate of surgical-site infection <sep>', 'incidence of nosocomial infections <sep>', 'mean antibiotic costs <sep> antibiotic costs length of stay need to restart intravenous antibiotics in-hospital mortality and 30-day readmissions <sep> labor costs <sep> readmissions <sep>', 'mrsa isolation <sep> annual rate of fluoroquinolone use <sep> rate of mrsa isolation <sep>', 'usage of cephalosporins imipenem clindamycin and vancomycin and increased usage of beta-lactam/beta-lactamase-inhibitor antibiotics <sep>', 'incidence and prevalence of patients with multiresistant enterobacteriaceae <sep>'], 'punchline_text': ['the rate of mrsa infection was positively correlated with levofloxacin use p=.01 and azithromycin use p=.08 whereas it was negatively correlated with summer season p=.05). <sep>', 'mortality and length of icu stay did not differ despite a shorter duration p  0.0001 and lower cost p  0.003 of antimicrobial therapy in the experimental as compared with the standard therapy arm. <sep>', 'hospital formulary restriction of clindamycin is an effective way to decrease the number of infections due to c. difficile. <sep>', 'no intervention benefit was observed for any secondary outcome. <sep>', 'length of stay intensive care unit transfers readmission rates and in-hospital death rates were similar in both groups p or .10 for all). <sep>', 'median length of stay after randomization for control and intervention groups was 9.0 days and 5.7 days respectively 3.3-day difference p=0.0001). <sep>', 'improved response rates were seen in the experimental 60 42/68 compared with the control group 48 36/68). <sep>', 'the predicted use of ceftriaxone exceeded by 65 an estimate based on prior use of cefotaxime. <sep>', 'the incidence of nosocomial infection and mortality also were similar across teams. <sep>', 'an outbreak of c. difficile infection in the elderly care unit at gloucestershire royal nhs trust continued despite increased ward cleaning and strict implementation of infection control measures. <sep>', 'a 2-year general hospital/drug utilization health record screen found no drug substitution effect nor any change in postoperative infection rate or death among metronidazole recipients. <sep>', 'for 13 months the monthly incidence of c. difficile infection averaged more than five times that for the previous 21 months. <sep>', 'in this study practice changes focused towards specific icus were associated with decreases in icu vancomycin use and vre prevalence. <sep>', 'for groups a b and c the proportions of days on which adequate treatment was received were 66.3 92.1 and 91.2 p<.001 the mean numbers of defined daily doses of appropriate antibiotic therapy were 16.4 22.2 and 20.7 p=.003 the mean durations of hospital stay were 19.8 23.6 and 24.1 days p=.761 and the mortality rates during the late period were 12.9 15.6 and 11 p=.670 respectively. <sep>', 'concomitantly there was a significant p  .002 decrease in nosocomial infections caused by c. difficile and a significant p  .02 decrease in nosocomial infections caused by resistant enterobacteriaceae. <sep>', 'reduction in ceftazidime use and barrier precautions markedly reduced the incidence of colonization and infection. <sep>', 'in the months following the formulary restrictions no significant detrimental changes occurred in hospital length of stay or mortality. <sep>', 'ad did not lead to statistically significant additional changes in already high levels 12.5 95 ci:-3 28 of compliance. <sep>', 'term and preterm infants who were 72 hours of age and had clinical signs or obstetric risk factors suggesting neonatal bacterial infection but stable enough to wait for results of diagnostic tests were enrolled into the study. <sep>', 'postintervention treatment with pa and oa according to the guidelines was not significantly different between the two groups of randomized snfs. <sep>', 'the costs of these 3 restricted drugs increased very sharply 69 in 1996 when there was loss of endorsement and capacity to perform auditing and feed back by infectious disease specialists. <sep>', 'the duration of antibiotic treatment for vap was statistically shorter among patients in the discontinuation group compared to patients in the conventional antibiotic management group 6.0  <sep>', 'in the procalcitonin group the adjusted relative risk of antibiotic exposure was 0.49 95 ci 0.44-0.55 p<0.0001 compared with the standard group. <sep>', 'procalcitonin guidance reduced total antibiotic exposure relative risk 0.52 95 confidence interval 0.48-0.55 p  0.001 antibiotic prescriptions on admission 85 vs. 99 p  0.001 and antibiotic treatment duration median 5 vs. 12 d p  0.001 compared with patients treated according to guidelines. <sep>', 'the intervention increased the use of guideline-recommended antimicrobial therapy from 78.1 to 83.4 p  0.003). <sep>', 'there were no significant changes in the number of courses of therapy or cost for the unrestricted antimicrobials. <sep>', 'there was a trend for improved clinical outcomes in patients who received cefotaxime within hospital guidelines or  1.73 p  .31). <sep>', 'the rate of appropriate empirical antibiotic treatment was higher in intervention versus control wards 73 versus 64 odds ratio or 1.48 95 confidence interval ci 0.95-2.29 intention to treat adjusted for location and clustering]. <sep>', 'only 39 of ward 2 patients underwent minimal fever diagnostic tests compared to 82 in ward 1 p  0.001). <sep>', 'for the rapid groups the turnaround time was significantly shorter for oral reporting of final susceptibility results in all three study periods and for reporting on paper in the third study period. <sep>', 'rates of ventouse delivery increased significantly in intervention units but not in control units there was no difference between the two types of units in uptake of other practices. <sep>', 'more patients in group 2 received appropriate exclusively iv therapy 65 vs. 96 p  0.01). <sep>', 'concordance with national antibiotic guidelines rose from 25 of courses pre-intervention to 51 within 5 months post-intervention p  0.002). <sep>', 'ceftazidime restriction resulted in a small but nonsignificant decrease in the proportion of ceftazidime-resistant organisms acquired late beyond 72 hrs in the patients icu course 56.5 vs. 45.9%). <sep>', 'there was an 80 decrease in the use of cloxacillin a 74 decrease of aminoglycosides and a 59 decrease of cephalosporins. <sep>', 'icf can be used safely to curb irrational overuse of vancomycin and teicoplanin in a hospital with high methicillin resistant s. aureus infection rates. <sep>', 'real-time pcr increased the diagnostic yield from 23 cases 21 of patients to 47 cases 43 of patients compared with conventional diagnostic tests. <sep>', 'per patient antibiotic charges were nearly 400 less in the intervention group vs controls p  .05). <sep>', 'patients had medical complications during the index hospitalization p  0.04 with no differences in other medical outcomes including mortality rehospitalization and return to usual activities between treatment arms. <sep>', 'the results suggest that a short questionnaire easily adaptable to automatization has the potential to foster reassessment of antibiotic therapy. <sep>', 'over a period of 54 months both gentamicin and tobramycin resistance decreased significantly when amikacin was used p less than 0.001 then increased with reintroduction of gentamicin p less than 0.05 and decreased significantly with reintroduction of amikacin p less than 0.001). <sep>', 'intraoperative redosing was significantly more frequent in the reminder group 93 of 137 68 than in the control group 55 of 136 40 adjusted odds ratio 3.31 95 confidence interval 1.97 to 5.56 p  .0001). <sep>', 'the proportion of gentamicin-resistant strains such as e. cloacae or staphylococci decreased and there was no increase in aminoglycoside-resistant strains except in escherichia coli in which resistance to amikacin rose from 0 to 3%. <sep>', 'the intervention significantly reduced mean antibiotic costs per patient 19.82 vs 35.84 p  0.03 but related labor costs exceeded this benefit. <sep>', 'at the end of the intervention the rate of mrsa isolation was significantly lower at caen hospital than at the control hospitals 353 32.3 of 1093 s. aureus isolates were mrsa compared with 2495 <sep>', 'however there was an increase in the number of patients with cultures positive for cefotaxime-resistant acinetobacter species from 2.4  <sep>', 'in the years since the incidence has remained at this low level and the antibiotic costs have decreased to a level lower than before intervention. <sep>'], 'population': ['87-bed veterans affairs teaching hospital with an extended-care facility <sep>', '1991;143 <sep> patients with cpis <sep> patients with pulmonary infiltrates in the intensive care unit <sep> patients with pulmonary infiltrates for whom monotherapy with a short course of antibiotics was appropriate <sep> patients with pulmonary infiltrates in the icu <sep>', 'hospitalized patients with symptomatic diarrhea <sep> university-affiliated veterans affairs medical center <sep>', 'all 26 hospital gynaecology units in scotland providing induced abortion care <sep>', '17 general medical oncology and cardiology services either received <sep>', 'hospitalized patients receiving intravenous antimicrobials <sep> 252 consecutive inpatients receiving suboptimal intravenous antibiotics identified by the clinical pharmacist 127 were prospectively randomized to intervention and 125 to a control group <sep>', 'patients with clinical infections <sep>', 'severe sepsis or pneumonia in medical patients <sep>', '1062 infants were studied during a 1-year period <sep>', 'hospital stay two hundred and fifty-two and 234 patients respectively with a discharge diagnosis of infection were admitted before and after the antibiotic policy change <sep> patients admitted with suspected infection were prescribed intravenous i.v <sep>', 'recipients <sep>', 'university-affiliated veterans affairs medical center located in southwestern united states <sep> hospitalized patients who developed diarrhea submitted stool specimens for cytotoxin assay <sep>', '50 intensive-care units icus at 20 u.s. hospitals reporting data on antimicrobial-resistant organisms and antimicrobial agent use <sep>', 'patients with bsis <sep>', 'all adult inpatients <sep> university-affiliated teaching hospital <sep>', 'one hundred fifty-five patients were colonized or infected representing more than 70 per 1000 average daily census <sep> four hundred thirty-two isolates of <sep> these included 14 bacteremias and 17 pulmonary infections among 52 infected patients <sep> a 487-bed general hospital in new york city <sep>', '322 patients with bacteremia treated before and after the onset of the controls revealed that antibiotics were more appropriately used afterwards <sep>', 'antimicrobial prescribing at university hospital groningen <sep> 2869 patients receiving 7471 prescriptions for an antimicrobial for an infection covered by the guidelines between july 2001 and september 2003 <sep>', 'term and preterm infants who were 72 hours of age and had clinical signs or obstetric risk factors suggesting neonatal bacterial infection but stable enough to wait for results of diagnostic tests were enrolled into the study <sep> newborn infants <sep> a total of 1291 infants <sep>', 'patients with an episode of pneumonia acquired more than 3 days after admission to snf n  350 <sep> 226 preintervention episodes of pneumonia and 116 postintervention episodes <sep> ten skilled nursing facilities snfs from a single metropolitan area <sep>', '1988-1996 at a 900-bed tertiary-care medical school hospital in bangkok <sep>', 'a medical icu from a university-affiliated urban teaching hospital <sep> between april 2002 and july 2003 290 patients completed the clinical trial <sep> clinically suspected ventilator-associated pneumonia vap <sep> clinically suspected ventilator-associated pneumonia <sep>', '243 patients admitted with suspected lower respiratory tract infections <sep> 141 of 175 tested patients 81 <sep> lower respiratory tract infections <sep> 60 25 acute bronchitis 59 24 asthma 13 5 and other respiratory affections 24 10 <sep>', '302 consecutive patients with suspected community-acquired pneumonia were included <sep> community-acquired pneumonia <sep>', 'all consecutive adults hospitalized for pneumonia during a 5-month period before n  1,013 and after n  1,081 implementation of an inpatient quality improvement qi initiative <sep> academic health centers <sep> four academic health centers in the new york city metropolitan area <sep>', 'patients who were less critically ill <sep> adults before and after removal of a restriction policy <sep>', 'acute care hospitals <sep> 323 patients who were prescribed <sep> hospitals <sep>', '2326 patients 570 with mdi <sep> patients suspected of harbouring bacterial infections in three hospitals israel germany and italy <sep> 1203 patients included in the cohort study 350 with mdi <sep>', 'hospitalised adults with community-acquired infection was assessed by studying 402 consecutive febrile adults who were admitted randomly to either of two internal medicine wards over a 4-month period and given <sep> hospitalised adults with community-acquired febrile syndromes <sep> 160 patients were treated in ward 1 and 242 in ward 2 median age 66 years 49 male <sep>', 'all hospitalised patients with a bacterial infection confirmed by culture <sep> hospitalised patients in the netherlands <sep>', '25 obstetric units <sep> 4508 pregnancies <sep> 25 of the 26 district general obstetric units in two former nhs regions <sep>', 'of 2365 admissions 757 32 had 806 treated episodes <sep> medical admissions to a general hospital <sep>', 'royal melbourne hospital a tertiary hospital in melbourne victoria <sep>', 'consecutive children admitted to the pediatric icu over a 19-mo period <sep> university hospital pediatric icu <sep> pediatric intensive care unit icu <sep>', 'norwegian paediatric department in 1994 <sep>', 'inpatients in a teaching hospital/tertiary referral centre where 33 of s. aureus isolates 72 from icu patients were methicillin resistant <sep> inpatient prescriptions surveyed revealed that only 31 17 conformed with centre for disease control cdc guidelines <sep> our hospital and others in hong kong were retrieved and analysed as were samples of records of our inpatients with staphylococcal septicaemia pre and during icf <sep>', 'nasopharyngeal and oropharyngeal swab specimens from patients admitted for antibiotic treatment of lrti <sep> patients with lower respiratory tract infection <sep> 107 patients mean age <sep>', 'adult inpatients receiving 1 or more of 10 designated parenteral antibiotics for 3 or more days during a 3-month period <sep>', 'patients with pneumonia <sep> patients hospitalized with pneumonia <sep> patients hospitalized with community-acquired pneumonia <sep> 283 intervention patients who were admitted by one of 116 physician groups <sep>', 'patients hospitalized on the surgical and medical wards of a university hospital and treated with an intravenous antibiotic for 3-4 days <sep> one hundred and twenty-six eligible patients <sep>', '14 united states hospitals with experience in the minneapolis veterans administration medical center <sep> 700-bed minneapolis veterans administration medical center <sep> 14 hospitals <sep>', 'university-affiliated hospital <sep>', '238 neonates g1 admitted between 1 january and 31 july 1989 and treated with gentamicin were compared with 398 g2 admitted between 1 august 1989 and 31 july 1990 who received <sep>', '102 inpatients meeting eligibility criteria <sep>', 'hospitalized patients <sep> consecutive hospitalized patients <sep> 4 large teaching hospitals in northwest france catering to a total of 5,882,600 persons <sep>', 'patients with methicillin-resistant staphylococcus aureus from 21.9 <sep>', 'neurology and neurosurgery wards of a university hospital <sep>'], 'interventions': ['fluoroquinolone <sep> fluoroquinolones <sep> azithromycin <sep> cephalosporin piperacillin-tazobactam and trimethoprim-sulfamethoxazole <sep> levofloxacin <sep> fluoroquinolone antibiotics <sep>', 'short-course empiric antibiotic therapy <sep> standard therapy <sep> ciprofloxacin monotherapy with reevaluation at 3 d ciprofloxacin <sep>', 'clindamycin restriction <sep> clindamycin <sep>', 'control units received printed guideline summaries alone <sep> misoprostol <sep>', 'levofloxacin or ceftazidime <sep> academic detailing or did not <sep>', 'antibiotic therapy intervention <sep>', 'computerized bayesian aminoglycoside administration <sep> aminoglycoside therapy <sep>', 'cefotaxime to ceftriaxone <sep> ceftriaxone <sep> levofloxacin <sep> cefotaxime <sep>', 'antibiotic rotation <sep> gentamicin piperacillin-tazobactam and ceftazidime <sep>', 'narrow-spectrum antibiotics <sep> cefuroxime <sep> cefuroxime <sep> trimethoprim <sep> gentamicin <sep>', 'metronidazole <sep> metronidazole <sep>', 'clindamycin <sep> clindamycin <sep>', 'vancomycin-resistant enterococci <sep> vancomycin <sep> vancomycin-resistant enterococci vre <sep>', 'conventional report group b for which physicians received a conventional report and a written alert on the chart with clinical advice and group c for which physicians received the above plus oral clinical advice <sep>', 'multidisciplinary antibiotic management program <sep> interventional multidisciplinary antibiotic management program <sep>', 'ceftazidime therapy <sep> ceftazidime <sep> imipenem <sep> ceftazidime <sep> ceftriaxone ceftizoxime cefotaxime <sep>', 'vancomycin <sep>', 'ciprofloxacin and co-amoxiclav <sep>', 'antibiotic therapy <sep> antibiotic therapy when il-8 was 70 pg/ml <sep> postnatal antibiotic therapy <sep> interleukin 8 in combination with c-reactive protein reduced unnecessary antibiotic therapy <sep>', 'oral antibiotics oa <sep> parenteral antibiotics pa <sep>', 'imipenem and injectable ciprofloxacin <sep> imipenem vancomycin and injectable ciprofloxacin <sep> ceftazidime <sep> netilmicin and ceftazidime <sep>', 'empiric antibiotic therapy <sep> conventional antibiotic management <sep> antibiotic treatment for vap determined by an antibiotic discontinuation policy discontinuation group or their treating physician teams conventional group <sep> antibiotic discontinuation policy <sep>', 'procalcitonin-guided treatment <sep> antimicrobial therapy <sep> procalcitonin-guided treatment procalcitonin <sep>', 'procalcitonin guidance of antibiotic therapy <sep> procalcitonin guidance <sep> antibiotics according to usual practice <sep>', 'multifactorial intervention <sep>', 'ceftazidime and imipenem-cilastatin <sep> imipenem-cilastatin <sep>', 'cefotaxime <sep>', 'antibiotic monitoring without treat control <sep>', 'cefuroxime <sep> regular attendance by infectious disease specialists <sep> amoxycillin <sep> ceftriaxone <sep> intravenous antibiotics <sep> erythromycin <sep>', 'microbiological procedures <sep> control conventional group or an intervention rapid group <sep>', 'educational visits <sep> perineal suturing with polyglycolic acid ventouse delivery prophylactic antibiotics <sep> educational visit or control group <sep>', 'pharmacy-led implementation of guidelines incorporating criteria for iv therapy and switching to the oral route <sep> intravenous iv antibiotic therapy <sep>', 'gentamicin <sep> cefotaxime and ceftriaxone cefx <sep>', 'antibiotic restriction <sep> ceftazidime <sep> aminoglycoside <sep> ceftazidime <sep> ceftazidime restriction policy <sep>', 'cephalosporins <sep> aminoglycosides <sep> antibiotics <sep> penicillin v and g <sep> cloxacillin <sep> antibiotic policy <sep>', 'vancomycin and teicoplanin <sep> icf <sep> vancomycin/teicoplanin <sep>', 'real-time polymerase chain reaction <sep>', 'antibiotic-related suggestions from a team consisting of an infectious disease fellow and a clinical pharmacist <sep>', 'practice guideline alone control arm or a practice guideline that was implemented using a multifaceted strategy intervention arm <sep> intravenous antibiotic therapy <sep>', 'intravenous antibiotic therapy <sep> intervention or control group <sep>', 'gentamicin and tobramycin <sep> amikacin <sep> tobramycin <sep> amikacin gentamicin and tobramycin <sep>', 'cefazolin <sep> intraoperative antibiotic prophylaxis <sep>', 'aminoglycoside <sep> amikacin <sep> antimicrobial therapy <sep> ampicillin plus an aminoglycoside <sep>', 'discontinue intravenous antibiotic therapy <sep>', 'fluoroquinolone <sep> fluoroquinolone <sep>', 'ceftazidime <sep>', 'gentamicin tobramycin quinolones cotrimoxazole broad-spectrum penicillins and cephalosporins <sep> amikacin <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",the results show that interventions to reduce excessive antibiotic prescribing to hospital inpatients can reduce antimicrobial resistance or hospital-acquired infections and interventions to increase effective prescribing can improve clinical outcome. this update provides more evidence about unintended clinical consequences of interventions and about the effect of interventions to reduce exposure of patients to antibiotics. the meta-analysis supports the use of restrictive interventions when the need is urgent but suggests that persuasive and restrictive interventions are equally effective after six months.
64,"{'outcomes': ['midluteal progesterone levels <sep> serum estradiol and progesterone and urinary pregnanediol and estradiol <sep> hormonal changes <sep> serum estradiol and progesterone levels and urinary estradiol and pregnanediol levels obtained during the luteal phase before 1 year and 2 years after sterilization <sep> hormone levels <sep> progesterone levels <sep>', 'demographic characteristics educational level and operator experience <sep>', 'mean duration of the procedure <sep> perioperative outcomes <sep> operating time <sep>', 'pain <sep> surgical complications <sep>', 'peri-operative complications <sep>', '24-month life-table pregnancy rate <sep> surgical difficulties and injuries and technical failures <sep>', 'average surgical time for minilaparotomy <sep>'], 'punchline_text': ['serum estradiol and progesterone and urinary pregnanediol and estradiol were not significantly changed over the 2-year period nor were there significant differences between the two groups. <sep>', 'the hulka-clemens clip and the falope ring have similar incidences of method failure when employed by inexperienced operators. <sep>', 'thirty-two obstetric patients consented for sterilization were randomized to pomeroy technique or filshie clip placement. <sep>', 'the spring-loaded clip and tubal ring techniques of laparoscopic female sterilization were compared for ease of performance safety and effectiveness at the asociacin demogrfica salvadorea in san salvador where they were randomly assigned to a total of 299 patients. <sep>', 'no significant difference between the two groups was found in respect to long-term sequelae. <sep>', 'surgical difficulties and injuries and technical failures occurred with comparable frequency in the two groups. <sep>', 'the results showed little differences among patients in the three groups for age number of living children contraceptive and abortion histories and pre-existing medical conditions. <sep>'], 'population': ['healthy volunteers in an academic research environment <sep> 118 fertile women seeking tubal sterilization and 57 fertile controls with at least three normal cyclic menstrual periods before entry into the study <sep>', '365 women undergoing <sep>', 'thirty-two obstetric patients consented for sterilization <sep> postpartum and intraoperative cesarean tubal sterilization <sep>', '299 patients <sep>', '200 postpartum women at tri-service general hospital taipei taiwan <sep>', 'patients 332 women were sterilized with the tubal ring and 331 were sterilized with the rocket clip <sep> female sterilization <sep>', 'equal numbers of women <sep> 300 voluntary acceptors at the university hospital in medan indonesia <sep>'], 'interventions': ['bipolar cautery or hulka clip <sep> bipolar cautery <sep>', 'falope rings or hulka-clemens clips <sep> tubal ring and spring-loaded clip <sep> interval laparoscopic tubal sterilization in a residency training program <sep> laparoscopic tubal sterilization <sep> chromopertubation utilizing methylene blue dye <sep>', 'filshie clip technique <sep> filshie clip <sep> filshie clip and pomeroy techniques <sep> filshie clip vs. pomeroy technique <sep> pomeroy technique or filshie clip placement <sep>', 'laparoscopic female sterilization <sep> laparoscopic sterilization via spring-loaded clip and tubal ring <sep>', 'filshie clip and pomeroy method <sep> filshie clip and pomeroy methods <sep>', 'rocket clip <sep>', 'tubal sterilisation <sep> laparoscopy culdoscopy and minilaparotomy <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",electrocoagulation was associated with less morbidity including post-operative pain when compared with the modified pomeroy and tubal ring methods despite the risk of burns to the small bowel. the small sample size and the relative short period of follow-up in these studies limited the power to show clinical or statistical differences for rare outcomes such as failure rates. aspects such as training costs and maintenance of the equipment may be important factors in deciding which method to choose.
65,"{'outcomes': ['bone maturation renal failure progression or metabolic control <sep> length gain <sep> body length body weight bone age biochemical and hormonal analyses renal function bone mass and adverse effects <sep> forearm bone mass and increased serum concentrations of total and free igf-i and igf-binding protein 3 igfbp-3 whereas igf-ii igfbp-1 igfbp-2 gh-binding protein ghrelin and leptin <sep>', 'igf <sep> bone maturation <sep> igf-i. fructosamine lipid and parathyroid concentrations <sep> height velocity <sep> gh-induced height-velocity increase <sep> prestudy height velocity and height-velocity increase <sep> renal function deterioration <sep> igf-ii plasma concentrations <sep> pretreatment elevation of igf-binding protein-1 <sep>', 'lipid and parathyroid concentrations <sep> accelerated bone maturation <sep> plasma igf-ii levels <sep> igf <sep> severe growth retardation <sep> bone maturation <sep> plasma insulin-like growth factor-i <sep> elevated pretreatment igfbp-3 levels <sep> renal function deterioration <sep> height velocity sd score <sep> fructosamine levels <sep> pretreatment elevation of igf-binding protein-1 igfbp-1 levels <sep>', 'growth rate standardized height bone age fasting and 2-hour postprandial glucose and insulin levels biochemical values and insulin-like growth factor <sep> mean delta height age minus the delta bone age <sep> growth rate <sep> calculated creatinine clearance <sep> mean fasting and 2-hour postprandial glucose values <sep> growth rates <sep> standardized height <sep> mean fasting and postprandial insulin values <sep> growth rate and standardized height <sep>', 'delta sds standardized height <sep> adverse events <sep> efficacy and safety of rhgh <sep> acute rejection episode <sep> rejection episodes <sep>', 'integrated insulin levels auc <sep> number of adverse events <sep> igf-i/igfbp-3 ratio <sep> height velocity sds hvsds <sep> hvsds <sep> height velocity <sep> overt insulin dependent diabetes mellitus <sep>', 'mean se hv and delta hsds <sep> phosphate alkaline phosphatase alp parathyroid hormone pth and fasting insulin concentrations <sep> incidence of rejection <sep> efficacy height velocity hv change in height standard deviation score delta hsds and safety glomerular filtration rate gfr incidence of rejection and calcium and glucose metabolism of recombinant human growth hormone rhgh <sep> phosphate alp pth and insulin <sep> gfr <sep> gfr or the incidence of rejection <sep>', 'serum insulin-like growth factor binding protein igfbp)-1 and 2 levels <sep> serum igfbp-1 levels <sep> serum levels of igf-i igf-ii free igf-i igfbp-3 and acid labile subunit als <sep> igfbp-3 levels <sep> serum igfbp-2 levels <sep> height <sep> serum als igfbp-3 total igf igf-i igf-ii and free igf-i levels <sep> height sds <sep> anthropometric measurements and circulating growth factors <sep>', 'growth bone maturation renal graft function plasma insulin-like growth factors serum binding proteins <sep> glomerular filtration rate <sep> growth and glomerular filtration rate <sep> bone maturation <sep> deterioration of graft function <sep> glomerular filtration rate and effective renal plasma flow <sep>', 'serum igf-i levels <sep> bone formation rates <sep> anthropometric measurements and blood for serum calcium phosphorus parathyroid hormone pth osteocalcin and insulin-like growth factor-i <sep> bone mass <sep> bone formation rates <sep> linear growth and maintains bone mass <sep> serum calcium phosphorus osteocalcin and pth levels <sep> annual growth velocity increased and standard deviation scores for height <sep>'], 'punchline_text': ['the gh-induced stimulation of growth was associated with no undesirable effects on bone maturation renal failure progression or metabolic control. <sep>', 'impressive height-velocity increase can be achieved with gh therapy in children with crf and growth retardation without changes in renal function. <sep>', 'there was a significant increase in plasma insulin-like growth factor-i <sep>', 'mean fasting and postprandial insulin values were elevated at 12 months but not at 24 months in the rhgh-treated patients. <sep>', 'there was no difference in adverse events between the two groups. <sep>', 'gh therapy in our patients resulted in a significant increase in height velocity with no inappropriate bone age progression and few serious adverse effects all without relation to the dose of rhgh. <sep>', 'phosphate alkaline phosphatase alp parathyroid hormone pth and fasting insulin concentrations rose during the first year of treatment but not thereafter. <sep>', 'at baseline serum insulin-like growth factor binding protein igfbp)-1 and 2 levels were while igfbp-3 levels were not higher than those of children with normal renal function. <sep>', 'the incidence of a  25 reduction in glomerular filtration rate over 2 years was not significantly higher in gh-treated patients than in non-gh-treated controls 39 vs 32 p  0.97). <sep>', 'serum calcium phosphorus osteocalcin and pth levels did not differ between the treated and control groups. <sep>'], 'population': ['well-nourished infants with growth retardation secondary to chronic renal failure <sep> infants with crf and growth retardation <sep> sixteen infants who had growth retardation were aged 12+/-3 months had crf gfr<or=60 ml/min per 1.73 m2 and had adequate nutritional intake and good metabolic control were recruited from eight pediatric nephrology departments from spain and portugal <sep> infants with chronic renal failure crf and persistent growth retardation despite adequate nutritional and metabolic management <sep>', 'sixteen children completed the study <sep> 20 prepubertal children eleven boys nine girls mean age 9.5 years range 4-16 with crf and severe growth retardation in a placebo-controlled double-blind cross-over trial <sep> children with crf and growth retardation without changes in renal function <sep> children with chronic renal failure crf <sep> prepubertal children with chronic renal failure <sep>', 'children with severe growth retardation secondary to cri <sep> prepubertal patients with chronic renal insufficiency <sep> 23 prepubertal children 18 boys and 5 girls mean <sep> children with chronic renal insufficiency cri <sep>', 'growth-retarded children with chronic renal failure <sep> 17 pediatric nephrology centers in the united states <sep> children with chronic renal failure <sep> one hundred twenty-five prepubertal growth-retarded children with chronic renal failure <sep>', 'children <sep> sixty-eight growth retarded pediatric renal allograft recipients <sep> renal allograft recipients despite successful transplantation <sep>', '29 growth-retarded children with chronic renal failure crf aged 3.4-15.1 years 23 completed the first year of therapy and 16 completed the second year <sep> children with crf during rhgh-treatment <sep> children with chronic renal failure <sep>', 'fifteen prepubertal and seven pubertal children mean sd age 13.0 2.6 and 15.2 2.4 years respectively <sep> six prepubertal and three pubertal children were controls during the first year all received rhgh in the second year <sep> prepubertal and pubertal renal transplant recipients <sep> prepubertal and pubertal children with renal transplants <sep>', '44 prepubertal children with growth failure and chronic renal failure gfr  10 to 40 ml/min/1.73 m2 <sep> children with growth failure associated with chronic renal failure <sep> children with chronic renal failure <sep> 30 children receiving <sep>', 'growth-retarded adolescents after renal transplant <sep> 18 adolescents mean age 15.6 range 11.3-19.5 with severe growth retardation after renal transplantation were treated with <sep> many patients who have undergone renal transplantation <sep> severely growth-retarded adolescents after renal transplantation <sep>', '2.5 years and histological findings of normal bone formation and adynamic bone on bone biopsies <sep> 23 stable prepubertal pediatric kidney recipients aged 10 <sep> pediatric renal allograft recipients <sep> stable pediatric renal allograft recipients <sep>'], 'interventions': ['growth hormone therapy <sep> gh <sep> growth hormone gh <sep>', 'placebo <sep> placebo <sep> biosynthetic growth hormone gh <sep> gh <sep> growth hormone treatment <sep> gh therapy <sep> placebo injection <sep>', 'gh therapy <sep> growth hormone <sep>', 'rhgh <sep> placebo <sep> recombinant human growth hormone treatment <sep> recombinant human growth hormone rhgh <sep>', 'recombinant human growth hormone rhgh <sep> recombinant human growth hormone post-renal transplantation <sep> rhgh <sep>', 'gh therapy <sep> growth hormone gh <sep> recombinant human growth hormone treatment <sep>', 'rhgh <sep> recombinant human growth hormone <sep>', 'rhgh <sep> rhgh <sep> recombinant human growth hormone rhgh n  30 or no treatment <sep> growth hormone <sep>', 'cyclosporin <sep> biosynthetic growth hormone gh <sep> prednisone <sep> azathioprine <sep> growth hormone treatment <sep>', 'growth hormone and a control group that did not receive any treatment <sep> growth hormone therapy <sep> recombinant human growth hormone <sep> tetracycline labeling <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",one year of 28 iu/m/wk rhgh in children with ckd resulted in a 3.88 cm increase in height velocity above that of untreated patients. studies were too short to determine if continuing treatment resulted in an increase in final adult height.
66,"{'outcomes': ['breastfeeding transmission <sep> death and prolonged hiv-free survival <sep> relation to transmission of hiv-1 through breastfeeding and early child mortality <sep> risk of hiv-1 transmission <sep> total risk of hiv-1 transmission <sep> risk of transmission <sep> child mortality and hiv-1 transmission through breastfeeding <sep> erythrocyte sedimentation rate <sep> transmission through breastfeeding and mortality <sep> mortality <sep>', 'estimated rate of hiv-1 infection <sep> postnatal hiv-1 infection <sep> number of adverse events primarily neutropenia <sep> frequency of breast-feeding <sep> rates of hiv-1 infection <sep>', 'grade 3 or 4 serious adverse events <sep> hiv infection <sep>', 'hiv infection rates <sep> hiv-free survival <sep> primary efficacy hiv infection by age 7 months and hiv-free survival <sep> cumulative infant mortality <sep> mortality rate <sep> cumulative mortality or hiv infection rates <sep> postnatal hiv transmission <sep> safety occurrence of infant adverse events <sep> time-to-mortality distributions <sep> efficacy and safety <sep>', 'transmission of hiv-1 <sep> 2-year mortality rates <sep> median duration of breastfeeding <sep> infant hiv-1 infection and death <sep> mortality rates and hiv-1-free survival <sep> hiv-1-free survival <sep> rate of hiv-1-free survival <sep> cumulative probability of hiv-1 infection <sep> hiv-1 infection <sep> estimated rate of breast milk transmission <sep>', 'rate of hiv-free survival <sep> higher mortality <sep> hiv infection or death of the child by 24 months <sep> hiv-free survival <sep> median duration of breast-feeding <sep>'], 'punchline_text': ['vitamin a increased the risk of transmission rr 1.38 95 ci 1.09-1.76 p  0.009). <sep>', 'infants receiving extended dual prophylaxis had a significant increase in the number of adverse events primarily neutropenia that were deemed to be possibly related to a study drug. <sep>', '393 infants in the single-dose group and 346 in the extended-dose group experienced grade 3 or 4 serious adverse events during the study p=0.54). <sep>', 'cumulative infant mortality at 7 months was significantly higher for the formula-fed group than for the breastfed plus zidovudine group 9.3 vs 4.9 p  .003 but this difference diminished beyond month 7 such that the time-to-mortality distributions through age 18 months were not significantly different p  .21). <sep>', 'the rate of hiv-1-free survival at 2 years was significantly lower in the breastfeeding arm than in the formula feeding arm 58.0 vs 70.0 respectively p  .02). <sep>', 'in the overall cohort there was no significant difference between the groups in the rate of hiv-free survival among the children 68.4 and 64.0 survived to 24 months without hiv infection in the intervention and control groups respectively p=0.13). <sep>'], 'population': ['children born to women with low maternal immunological or nutritional status <sep> 1078 hiv-infected pregnant women from tanzania <sep>', 'women with hiv-1 infection who were breast-feeding infants <sep> 2008 massachusetts medical society <sep> 9-month-old infants <sep> infants who were hiv-1-negative on dna polymerase-chain-reaction assay at birth <sep> 3016 infants <sep>', '393 infants <sep> hiv-infected women breastfeeding their infants were eligible for participation <sep> breastfed infants through 6 weeks of age can decrease hiv transmission via breastfeeding <sep> 2024 liveborn infants randomised in the study had at least one specimen tested before 6 months of age 1047 infants in the single-dose group and 977 infants in the extended-dose group <sep> 986 infants in the single-dose group and 901 in the extended-dose group <sep>', 'mothers and infants <sep> 1179 infants <sep> in botswana between march 27 2001 and october 29 2003 1200 hiv-positive pregnant women were randomized from 4 district hospitals <sep>', '425 hiv-1-seropositive antiretroviral-naive pregnant women enrolled 401 mother-infant pairs <sep> breastfed and formula-fed infants <sep> november 1992 to july 1998 in antenatal clinics in nairobi kenya with a median follow-up period of 24 months <sep> mother-infant pairs <sep>', '958 hiv-infected women and their infants in lusaka zambia <sep> 2008 massachusetts medical society <sep> children in zambia <sep> women who are infected with the human immunodeficiency virus hiv stop breast-feeding early <sep>'], 'interventions': ['vitamin supplements <sep> vitamin a or multivitamins excluding a from approximately 20 weeks gestation and throughout lactation <sep> multivitamin b c and e supplementation <sep>', 'nevirapine plus 1 week of zidovudine control regimen or the control regimen plus daily extended prophylaxis either with nevirapine extended nevirapine <sep> nevirapine and zidovudine <sep> nevirapine <sep> nevirapine plus zidovudine <sep>', 'nevirapine nevirapine 200 mg to women in labour and nevirapine 2 mg/kg to newborns after birth or 6 week extended-dose nevirapine nevirapine 200 mg to women in labour and nevirapine <sep> nevirapine <sep>', 'breastfeeding plus prophylactic infant zidovudine breastfed plus zidovudine or formula feeding plus 1 month of infant zidovudine formula fed <sep> breastfeeding plus infant zidovudine prophylaxis <sep> zidovudine <sep> zidovudine prophylaxis <sep> nevirapine or placebo <sep> peripartum single-dose nevirapine vs placebo <sep> postpartum infant feeding formula vs breastfeeding with infant zidovudine prophylaxis interventions <sep>', 'breastfeeding and formula feeding <sep>', 'counseling program that encouraged abrupt weaning at 4 months and 477 to a program that encouraged continued breast-feeding <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",complete avoidance of breastfeeding is efficacious in preventing mtct of hiv but this intervention has significant associated morbidity e.g. diarrheal morbidity if formula is prepared without clean water). if breastfeeding is initiated two interventions 1). exclusive breastfeeding during the first few months of life and 2 extended antiretroviral prophylaxis to the infant nevirapine alone or nevirapine with zidovudine are efficacious in preventing transmission.
67,"{'outcomes': ['survival analysis <sep> safe and well tolerated <sep> efficacy safety and tolerance <sep> interval to delivery <sep> preterm premature rupture of membranes <sep> duration of pregnancy <sep> birth weight <sep>', 'neonatal morbidity <sep> perinatal mortality and morbidity <sep> necrotising enterocolitis <sep>', ""frequency of contractions cervical bishop's score and white blood cell count on admission <sep> shorter interval to delivery lower gestational age at delivery lower mean birth weight <sep> tolerated <sep> upper genital tract infection <sep> postpartum infections <sep> neonatal hospitalization time <sep> interval to delivery birth weight and neonatal outcomes <sep>"", 'respiratory distress syndrome bronchopulmonary dysplasia intraventricular hemorrhage sepsis and admission and duration of newborn intensive special care unit hospitalization <sep> overall prevalence of microbial invasion of the amniotic cavity <sep> neonatal outcomes <sep> prolongation of pregnancy the rate of preterm birth and neonatal morbidity <sep> maternal outcomes including duration of randomization-to-delivery interval frequency of preterm delivery  37 weeks frequency of preterm premature rupture of membranes clinical chorioamnionitis endometritis and number of subsequent admissions for preterm labor <sep>', 'delivery interval or rate of delivery <sep> interval to delivery or duration of pregnancy <sep> rate of delivery <sep> interval to delivery <sep> prolongation of pregnancy <sep> prolongation of gestation <sep>', 'rate of admission to neonatal intensive care unit <sep> maternal and neonatal infectious morbidity <sep> higher gestational age at delivery <sep> infectious morbidity <sep> number of days from admission to delivery gestational age at delivery rates of preterm delivery low birthweight maternal infections and neonatal infections <sep> prolongation of pregnancy <sep> incidence of preterm birth <sep>', 'composite of neonatal death chronic lung disease or major cerebral abnormality on ultrasonography before discharge from hospital <sep>', 'episodes of recurrent labor requiring parenteral tocolysis <sep> frequency of preterm birth <sep> time to delivery <sep> birth weight <sep> genital microflora <sep>', 'overall prevalence of microbial invasion of the amniotic cavity <sep> rate of cesarean section <sep> maternal outcomes including duration of randomization-to-delivery interval frequency of preterm delivery and frequency of clinical chorioamnionitis and endometritis <sep> neonatal death respiratory distress syndrome proven sepsis and birthweight <sep> rate of neonatal suspected sepsis <sep> pregnancy outcome <sep> rate of cesarean section <sep> suspected sepsis <sep>', 'success of magnesium sulfate tocolysis <sep> mean cervical dilatation <sep> likelihood of a beta error <sep>'], 'punchline_text': ['women with bacterial vaginosis more often delivered preterm p  0.03 relative risk 1.4 95 confidence interval 1.04 to 2.0). <sep>', 'adjuvant ampicillin and metronidazole in the management of women in preterm labour with intact membranes significantly prolonged the pregnancy and decreased neonatal morbidity. <sep>', 'no significant differences in the interval to delivery birth weight and neonatal outcomes were observed between the 2 groups. <sep>', 'similarly no significant difference in neonatal outcomes could be detected between the two groups including respiratory distress syndrome bronchopulmonary dysplasia intraventricular hemorrhage sepsis and admission and duration of newborn intensive special care unit hospitalization. <sep>', 'ceftizoxime had no effect on interval to delivery or duration of pregnancy in women treated for preterm labor. <sep>', 'antibiotic treatment had no significant effects on infectious morbidity. <sep>', 'none of the trial antibiotics was associated with a lower rate of the composite primary outcome than placebo erythromycin 90 5.6 co-amoxiclav 76 5.0 both antibiotics 91 5.9 vs placebo 78 5.0%]). <sep>', 'compared with the placebo group the adjunctive antibiotic group had a similar frequency of preterm birth 38 versus 44 time to delivery 34 versus 34 days birth weight 2847 versus 2855 g and episodes of recurrent labor requiring parenteral tocolysis 0.43 versus 0.49). <sep>', 'no significant difference between both groups was found in maternal outcomes including duration of randomization-to-delivery interval frequency of preterm delivery and frequency of clinical chorioamnionitis and endometritis. <sep>', 'in our population adjunctive ampicillin-sulbactam with indomethacin did not improve the success of magnesium sulfate tocolysis. <sep>'], 'population': ['preterm labor <sep> hospitalized women with preterm labor at less than or equal to 34 weeks gestation who were treated with tocolytics <sep> one hundred three woman-perinate pairs were analyzed <sep> women with bacterial vaginosis <sep>', 'preterm labour <sep> women in preterm labour with intact membranes <sep> eighty-one women in active preterm labour with otherwise uncomplicated singleton pregnancies between 26 and 34 weeks gestation or an ultrasound fetal weight estimate of 800 g to 1500 g <sep>', 'treat preterm labor <sep> women in preterm labor  or 34 weeks gestation with intact membranes <sep>', 'preterm labor with intact membranes <sep> patients with preterm labor and intact membranes <sep> maternal-fetal medicine units network of the national institute of child health and human development <sep> women in preterm labor with intact membranes <sep> two hundred seventy-seven women with singleton pregnancies and preterm labor with intact membranes 24 to 34 weeks <sep> 2373 patients screened for participation in this study in six medical centers 277 women were enrolled n  133 for antibiotics group vs n  144 for placebo group <sep>', 'patients with preterm labor between 24 and 35 weeks gestation <sep> 117 consecutive eligible consenting patients <sep> preterm labor <sep> 545 patients with intact membranes and without chorioamnionitis who were receiving <sep> pregnancies receiving tocolysis for preterm labor <sep>', 'six obstetric departments in the copenhagen area <sep> one hundred and twelve women with singleton pregnancies with threatened idiopathic preterm labour and intact amniotic membranes at 26 to 34 weeks of gestation <sep> women with threatened idiopathic preterm labour <sep> idiopathic preterm labour <sep>', 'spontaneous preterm labour <sep> 6295 women in spontaneous preterm labour with intact membranes and without evidence of clinical infection <sep>', 'patients with idiopathic preterm labor <sep> one hundred three patients at 24-34 weeks gestation <sep> idiopathic preterm labor <sep>', 'those patients <sep> 196 patients with singleton pregnancies and preterm labor with intact membranes 22-36 weeks <sep> patients with preterm labor and intact membranes <sep> preterm labor and intact membranes <sep>', 'idiopathic preterm labor <sep> patients in preterm labor who were receiving intravenous <sep>'], 'interventions': ['placebo <sep> placebo clindamycin <sep> clindamycin <sep> clindamycin treatment <sep> adjunctive clindamycin therapy <sep> clindamycin <sep>', 'hexoprenaline and indomethacin <sep> adjuvant ampicillin and metronidazole <sep> betamethasone <sep> ampicillin and metronidazole <sep> no antibiotics <sep> ampicillin and metronidazole <sep>', 'antibiotic therapy plus tocolysis <sep> placebo <sep> antibiotic therapy <sep> antibiotics <sep> tocolytic therapy <sep> mezlocillin and oral erythromycin therapy vs. placebo <sep>', 'antibiotic treatment <sep> antibiotic administration <sep> placebo <sep> ampicillin-amoxicillin and erythromycin <sep> antibiotics or placebos <sep>', 'placebo <sep> magnesium sulfate <sep> adjunctive ceftizoxime <sep> ceftizoxime <sep> ceftizoxime <sep>', 'ampicillin and metronidazole or placebo <sep> placebo <sep> ampicillin and metronidazole <sep> ampicillin-metronidazole <sep>', 'placebo erythromycin <sep> placebo <sep> 325 mg co-amoxiclav 250 mg amoxicillin and 125 mg clavulanic acid <sep> erythromycin <sep>', 'placebo <sep> antibiotics <sep> adjunctive antibiotic therapy <sep> ampicillin plus oral erythromycin or corresponding placebos <sep> ampicillin plus erythromycin <sep>', 'antibiotic treatment <sep> placebo <sep> antibiotics or placebo plus adjunctive parenteral tocolysis and 173 patients antibiotics group n  83 vs. placebo <sep> antibiotic therapy <sep> amoxicillin and erythromycin <sep>', 'placebo <sep> ampicillin-sulbactam and indomethacin or corresponding placebos <sep> combination antibiotics and indomethacin <sep> magnesium sulfate tocolysis <sep> indomethacin <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",this review fails to demonstrate a clear overall benefit from prophylactic antibiotic treatment for preterm labour with intact membranes on neonatal outcomes and raises concerns about increased neonatal mortality for those who received antibiotics. this treatment cannot therefore be currently recommended for routine practice. further research may be justified when sensitive markers for subclinical infection become available in order to determine if there is a subgroup of women who could experience benefit from antibiotic treatment for preterm labour prior to membrane rupture and to identify which antibiotic or combination of antibiotics is most effective. note the 17 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
68,"{'outcomes': ['satisfactory pain relief <sep> complete pain relief <sep>'], 'punchline_text': [""de quervain's disease of pregnancy and lactation is usually self-limited and responds well to nonsurgical treatment. <sep>""], 'population': [""19 wrists of 18 patients with de quervain's disease who were either pregnant or breast-feeding <sep> de quervain's disease of pregnancy and lactation <sep>""], 'interventions': ['cortisone injection into the tendon sheath and the other group used thumb spica splints <sep>'], 'punchline_effect': [' no diff <sep>']}",the efficacy of corticosteroid injections for de quervain's tenosynovitis has been studied in only one small controlled clinical trial which found steroid injections to be superior to thumb spica splinting. however the applicability of our findings to daily clinical practice is limited as they are based on only one trial with a small number of included participants the methodological quality was poor and only pregnant and lactating women participated in the study. no adverse effects were observed.
69,"{'outcomes': ['self-report symptom check-list scl-90-r <sep> symptom scales <sep> disturbed eating behaviour <sep>', ""eating disorder examination questionnaire ede-q the children's version of the eating attitudes test eat the rosenberg self-esteem scale rses and a knowledge questionnaire kq <sep>"", 'body mass index <sep> knowledge <sep>', 'metabolic control <sep> disturbed eating attitudes and behavior <sep> eating disturbance <sep> frequency of purging by insulin omission or hemoglobin a1c levels <sep> restraint and eating concern subscales of the eating disorder examination ede and on the drive for thinness and body dissatisfaction subscales of the eating disorder inventory <sep>', 'risk of bulimic attitudes <sep> body dissatisfaction <sep> weight eating attitudes test and eating disorders inventory <sep>', 'media-related attitudes and behaviors including internalization of sociocultural ideals self-efficacy to impact weight-related social norms and print media habits <sep> dieting behaviors body image attitudes and media knowledge attitudes and habits <sep> dieting behaviors <sep> body size acceptance puberty knowledge and perceived weight status <sep> lasting changes in body image and dieting behaviors <sep> body-related knowledge and attitudes <sep>', 'weight concern <sep> eating disorder risk factors <sep> self-esteem measures <sep>', 'physical appearance <sep> body image and eating attitudes and behaviors <sep> physical appearance to their self-esteem <sep> body weight <sep> lower drive for thinness and greater body satisfaction <sep> students anxiety or depression <sep> body image eating attitudes and behaviors <sep> self-esteem social acceptance physical appearance and athletic ability <sep> body satisfaction <sep> weight-losing behaviors <sep>'], 'punchline_text': ['the data analyses revealed an improvement on all three symptom scales for both groups between t2 and t3 but there were no significant differences between the ighr and cghr groups. <sep>', 'unlike a previous school-based eating disorder prevention program in the experimental group both an increase in knowledge and a decrease in some attitudes were maintained at 12-month follow-up eating concerns ede-q scores). <sep>', 'we did observe a significant increase in knowledge among girls receiving the intervention and among high-risk students only there was a small albeit statistically significant effect on body mass index. <sep>', 'the pe group was associated with reductions in eating disturbance but not with improved metabolic control. <sep>', 'providing schoolgirls with the correct information about eating disorders did not encourage unhealthy attitudes to eating and weight regulation practices. <sep>', 'it is feasible to use community youth settings such as the girl scouts to implement interventions to prevent disordered eating behaviors. <sep>', 'at postintervention the media literacy group had lower mean scores on weight concern than the control group p 0.007 but the self-esteem group did not. <sep>', 'the program significantly improved the body satisfaction of the intervention students and significantly changed aspects of their self-esteem social acceptance physical appearance and athletic ability became less important for the intervention students and more important for control students. <sep>'], 'population': ['from the original sample t1 n  1944 a subgroup of 314 students of both sexes 14-19 years of age was selected <sep> disturbed eating behaviour <sep> children and adolescents <sep> 14 to 19-year-old swiss students <sep>', 'one hundred and six 61 females and 45 males 11 to 12-year-old students were evaluated 55 of whom participated in the program experimental group <sep> eating disorders <sep>', 'young adolescent girls <sep> nine hundred sixty-seven sixth and seventh-grade girls <sep>', 'eighty-five subjects <sep> young women with type 1 diabetes mellitus <sep> young women with type 1 diabetes mellitus dm and disordered eating attitudes and behavior <sep> of these women 130 passed the screening and were invited to participate in the intervention phase of the study <sep> two hundred twelve young women attending a pediatric diabetes clinic were screened for signs of eating disturbance <sep>', 'adolescent schoolgirls <sep> a total of 254 16-year-old schoolgirls were evaluated of whom 154 participated in the program and a further 154 subjects formed the control group <sep>', 'preadolescent girls <sep> 226 girls mean age  10.6 years standard deviation  0.7 from 24 girl scout troops <sep> disordered eating among preadolescent girls <sep> girl scout troop members <sep>', 'four classes of 86 grade 8 students 53 boys and 33 girls mean age of 13 years <sep>', 'all 470 eligible students 63 female aged 11-14 years volunteered to participate <sep> young male and female adolescents following the program and after 12 months <sep> 116 students 63 females with low self-esteem and higher anxiety who were considered at risk for the development of eating disorders <sep> young adolescents <sep> young male and female adolescents <sep>'], 'interventions': ['health promotion lessons intervention group high-risk ighr while the other 10 classes served as controls control group high-risk cghr <sep> health promotion lessons <sep>', 'middle school primary prevention program <sep> new school-based eating disorder prevention program <sep>', 'unhealthful weight regulation 2 promotion of healthful weight regulation through the practice of sound nutrition and dietary principles and regular aerobic physical activity 3 development of coping skills <sep> experimental healthy weight regulation curriculum or no-treatment control classes <sep>', 'six-session psychoeducation pe program <sep> psychoeducation <sep>', 'prevention program <sep>', 'community-based intervention <sep>', 'media literacy program and a self-esteem program <sep> school-based media literacy program and self-esteem program <sep>', 'interactive school-based self-esteem education program <sep> control group students received their scheduled personal development and health class <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",the one significant pooled effect in the current review does not allow for any firm conclusions to be made about the impact of prevention programs for eating disorders in children and adolescents although none of the pooled comparisons indicated evidence of harm. the meta-analysis is in the process of being revised to account for the impact of cluster randomised trials.
70,"{'outcomes': ['closed kinetic chain testing and perceived functional status <sep> quadriceps muscle performance <sep> peak torque <sep> perceived functional status <sep>', 'mean contraction values <sep> pain and functional status <sep> vas and fiq differences <sep> contraction values of the vastus medialis and the vastus lateralis muscles <sep> vastus lateralis muscles <sep> contraction values <sep> visual analog scale vas and the functional index questionnaire fiq respectively <sep>', 'cincinnati rating system and traditional measures of leg strength and flexibility <sep> walking stair activity running jumping/twisting and overall activity level <sep> quadriceps strength and hamstring range of motion <sep> knee functional capacity <sep>', 'womac visual analogue and had scores <sep> womac and had <sep> visual analogue pain score the womac lower limb function score the hospital anxiety and depression scale had and quadriceps strength <sep> womac visual analogue and the anxiety score <sep>', 'pain and improvements in torque vertical jumping ability and physical activity level <sep> physical activity pain and muscle function <sep> patellofemoral pain syndrome <sep> overall knee function <sep>', 'pfc kps and vas <sep> patellofemoral pain pfp and abnormal patellofemoral congruence pfc <sep> pfp and pfc <sep> kujala patellofemoral score kps and pain through a visual analog scale vas <sep> pfc and joint function improved and pfp <sep> patellar pain position and function <sep>', 'pain <sep> functional performance <sep> muscle characteristics subjective symptoms and functional performance <sep>', 'isokinetic strength on a cybex ii dynamometer <sep> muscular strength <sep>'], 'punchline_text': ['statistical analysis showed that both groups had significant improvement in peak torque at all speeds but only the closed kinetic chain group showed significant improvement in closed kinetic chain testing and perceived functional status. <sep>', 'electromyographic biofeedback treatment did not result in further clinical improvement when compared with a conventional exercise program in patients with patellofemoral pain syndrome. <sep>', 'no significant differences however were determined to exist between the static and isokinetic groups. <sep>', 'all groups showed significant improvements in womac visual analogue and had scores these improvements did not vary significantly between the four groups or between exercising/non-exercising and taped/non-taped patients at three and 12 months. <sep>', 'a reduction in pain and improvements in torque vertical jumping ability and physical activity level were seen in both groups after treatment. <sep>', 'one-way analysis of variance tests found no difference between pre and posttest results for the control group but found significant changes in pfc kps and vas all p  0.001). <sep>', 'both groups experienced a statistically significant decrease in pain and an increase in functional performance. <sep>', 'the clinical improvement was better on patients of groups i and iii. <sep>'], 'population': ['patients with patellofemoral pain <sep> patients with patellofemoral dysfunction <sep> twenty-three patients participated in an 8-week training period <sep>', 'patients with patellofemoral pain syndrome <sep> copyright 2001 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation <sep> sixty patients with patellofemoral pain syndrome <sep> patellofemoral pain syndrome <sep>', 'chondromalacia patella <sep> subjects with a clinical diagnosis of chondromalacia patella <sep> subjects with chondromalacia patella <sep> twenty-nine subjects were screened by an orthopaedic physician and assigned to a control n  9 static n  11 or isokinetic n  9 exercise group <sep>', 'subjects with anterior knee pain <sep> anterior knee pain <sep> 81 young adults with anterior knee pain <sep>', 'forty female patients with patellofemoral pain syndrome aged 15 to 28 years mean  20.2 sd  3.2 <sep> patients with patellofemoral pain syndrome and 2 <sep> young women <sep>', '100 subjects <sep> clinical patients with pfp and abnormal pfc <sep>', 'patients with anterior knee pain <sep> sixty patients <sep> patellofemoral pain <sep>', 'cases of patellar chondromalacia <sep>'], 'interventions': ['closed kinetic chain or a joint isolation exercise training group <sep> joint isolation and closed kinetic chain exercise <sep> closed kinetic chain training <sep> joint isolation exercise <sep> closed kinetic chain and isokinetic joint isolation exercise <sep>', 'conventional exercise program only <sep> electromyographic biofeedback treatment <sep> electromyographic biofeedback treatment <sep> electromyographic biofeedback training and a conventional exercise program <sep> biofeedback group <sep> conventional exercise program <sep> electromyographic biofeedback-controlled exercise versus conservative care <sep>', 'selected static and isokinetic physical therapy rehabilitation programs <sep> static therapy <sep> j orthop sports <sep>', 'physiotherapy <sep> exercise taping and education 2 exercise and education 3 taping and education and 4 education alone <sep>', 'training program using isometric muscle contractions with a training program <sep> isometric muscle contractions or a group using eccentric muscle contractions <sep>', 'submaximal knee exercise <sep> submaximal knee muscle exercise <sep> treatment group exercised during activities of daily living adl by wearing a protonics device the control group did not receive treatment <sep>', 'open versus closed kinetic chain exercises <sep> open and closed kinetic chain exercise programs <sep> closed kinetic chain exercises or only open kinetic chain exercises <sep> open versus closed kinetic chain exercises <sep>', 'muscle training techniques and retropatellar chondropathy <sep> muscle training programs electromyostimulation isokinetic training and isometric training <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",the evidence that exercise therapy is more effective in treating pfps than no exercise was limited with respect to pain reduction and conflicting with respect to functional improvement. there is strong evidence that open and closed kinetic chain exercise are equally effective. further research to substantiate the efficacy of exercise treatment compared to a non-exercising control group is needed and thorough consideration should be given to methodological aspects of study design and reporting.
71,"{'outcomes': ['anxiety <sep> treatment efficacy onset of symptom amelioration or maintenance of therapeutic gains <sep>', 'y-bocs scl-90-r oc and gsi scales and poms <sep> y-bocs scl-90-r oc scl-90-r gsi poms pss and pil <sep> pss and pil test <sep> yale-brown obsessive compulsive scale y-bocs symptoms checklist-90-revised obsessive compulsive scl-90-r oc and global severity index scl-90-r gsi scales profile of moods scale poms perceived stress scale pss and purpose in life pil test <sep>'], 'punchline_text': ['there were no differences between treatments with respect to treatment efficacy onset of symptom amelioration or maintenance of therapeutic gains. <sep>', ""within-group statistics student's paired t-tests showed that group 1 significantly improved on all six scales but group 2 had no improvements. <sep>""], 'population': ['chronic anxiety <sep>', ""11 adults and 1 adolescent and group 2 included 10 adults <sep> patients with obsessive-compulsive disorder ocd <sep> patients with obsessive-compulsive disorder <sep> children's hospital san diego calif <sep> patients were selected according to diagnostic and statistical manual of mental disorders third edition-revised dsm-iii-r criteria and recruited by advertisements and referral <sep>""], 'interventions': ['muscle biofeedback transcendental mediation and relaxation therapy <sep> muscle biofeedback and transcendental meditation <sep>', 'meditation protocols <sep> kundalini yoga techniques <sep> kundalini yoga meditation protocol and group 2 employed the relaxation response plus mindfulness meditation technique <sep> yogic meditation techniques <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>']}",the small number of studies included in this review do not permit any conclusions to be drawn on the effectiveness of meditation therapy for anxiety disorders. transcendental meditation is comparable with other kinds of relaxation therapies in reducing anxiety and kundalini yoga did not show significant effectiveness in treating obsessive-compulsive disorders compared with relaxation/meditation. drop out rates appear to be high and adverse effects of meditation have not been reported. more trials are needed.
72,"{'outcomes': ['strength and physical function <sep> strength <sep> walk speed and self efficacy satisfaction <sep> compliance rates <sep> functional gains <sep> outcome assessments muscle strength dynamometry six minute walk test womac oa index total drugs sf-12 quality of life adelaide activities profile and the arthritis self-efficacy scale <sep> left quadriceps strength <sep> strength and function <sep> right quadriceps strength <sep>', 'knee range of motion rom thigh girth subjective pain scale and time for a 1-mile walk <sep> knee rom thigh girth and time for a 1-mile walk <sep> functional levels <sep> subjective pain levels <sep>', 'arthritis-specific health assessment questionnaire haq center for epidemiologic studies-depression scale ces-d and perceived quality of life scale pqol <sep> quality of well-being scale qwb and current health desirability rating chdr <sep> aquatic exercisers reported equal qwb or better chdr haq pqol health-related quality of life <sep> aquatic exercise <sep> cost per quality-adjusted life year qaly <sep> costs/qaly gained discounted <sep>', 'lower limb oa <sep> womac physical function <sep> physical function <sep> mean pain score <sep> womac pain <sep> high levels of co-morbidity <sep> pain <sep> pain score on the western ontario and mcmaster universities oa index womac <sep> quality of life cost-effectiveness and physical function measurements <sep>', 'pain related to motion and pain on load <sep> disability in functional activities <sep> quality of life <sep> disability rating index dri global self-rating index gsi and visual analogue scale vas <sep> functional activity and quality of life <sep>'], 'punchline_text': ['the hydrotherapy group increased left quadriceps strength only at follow up and this was significantly different from the control group. <sep>', 'there were no significant differences between the aquatic exercise group and the land-based exercise group pertaining to knee rom thigh girth and time for a 1-mile walk. <sep>', 'aquatic exercise exceeded 50,000 per qaly gained using the community-weighted outcome but fell below this arbitrary budget constraint when using the participant-weighted measure. <sep>', 'water exercise remained effective in the main study but overall effect size was small on womac pain at 1 year a reduction of about 10 in group <sep>', 'pain related to motion and pain on load was reduced up to 3 months after last the treatment in the hydrotherapy group and up to 6 months in the ea group. <sep>'], 'population': ['patients with osteoarthritis <sep> osteoarthritis oa <sep> 105 community living participants aged 50 years and over with clinical oa of the hip or knee <sep>', 'patients with osteoarthritis <sep> persons with knee osteoarthritis <sep> forty-six subjects between the ages of 45 and 70 years participated in 1 of 2 exercise groups <sep>', 'persons with osteoarthritis <sep> recruited 249 adults from washington state aged 55 to 75 with a doctor-confirmed diagnosis of osteoarthritis to participate in aquatic classes <sep>', 'older patients with hip and/or knee oa <sep> fifty-four control and 53 exercise patients had hospital inpatient episodes during the study period <sep> 312 patients 196 women 116 men took part in the main study randomised into control 159 and water exercise 153 groups <sep> lower limb osteoarthritis <sep> older patients <sep> 106 patients 93 women 13 men over the age of 60 years with confirmed hip <sep> 153 patients randomised to treatment 82 53.5 were estimated to have complied satisfactorily with their treatment at the 1-year point <sep> older adults with lower limb oa <sep>', 'forty-five patients aged 42-86 years with radiographic changes consistent with osteoarthritis in the hip pain related to motion pain on load and ache were chosen <sep> osteoarthritis of the hip <sep>'], 'interventions': ['resistance exercise programme <sep> hydrotherapy <sep> hydrotherapy resistance exercise programme <sep> hydrotherapy based strengthening programme <sep>', 'aquatic and land-based exercise programs <sep> aquatic exercise <sep> aquatic exercise program and a land-based exercise program <sep> aquatic and traditional exercise programs <sep>', 'aquatic exercise <sep>', 'water-based therapy <sep> water-based exercise treatment <sep> usual care with quarterly semi-structured telephone interview follow-up only <sep> water exercise <sep> water exercise <sep> usual care control <sep> water-exercise programme <sep> water-based exercise treatment <sep> community water-based therapy <sep>', 'ea hydrotherapy both in combination with patient education or patient education alone <sep> electro-acupuncture and hydrotherapy <sep> ea and hydrotherapy <sep> electro-acupuncture ea and hydrotherapy both in combination with patient education or with patient education alone <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",aquatic exercise appears to have some beneficial short-term effects for patients with hip and/or knee oa while no long-term effects have been documented. based on this one may consider using aquatic exercise as the first part of a longer exercise programme for osteoarthritis patients. the controlled and randomised studies in this area are still too few to give further recommendations on how to apply the therapy and studies of clearly defined patient groups with long-term outcomes are needed to decide on the further use of this therapy in the treatment of osteoarthritis.
73,"{'outcomes': ['voice care knowledge areas <sep> voice-related quality of life vrqol and the voice symptom severity scale voiss <sep>', 'voice therapy perceptual auditory rating of voice quality measurement <sep> average median time taken to complete voice therapy <sep>', 'perceptual evaluation of voice quality and a questionnaire on the occurrence of vocal symptoms <sep> laryngeal status <sep>', 'voice quality <sep> ratings of laryngeal features buffalo voice profile amplitude and pitch perturbation voice profile questionnaire hospital anxiety and depression scale clinical interview schedule sf-36. voice therapy improved voice quality <sep> psychological distress and lower quality of life <sep>', 'voice quality <sep> voice severity electrolaryngograph and shimmer measurements and on ratings provided by a patient questionnaire <sep>'], 'punchline_text': ['the difference in voice care knowledge areas was also significant for the treatment group p  0.05). <sep>', 'subjects in both treatment groups demonstrated statistically significant improvements after voice therapy perceptual auditory rating of voice quality measurement p  0.01 instrumental electroglottographic measurement p  0.01 patient questionnaire measurement p  0.01). <sep>', 'no differences between groups were noted in the laryngeal status. <sep>', 'patients with dysphonia had appreciable psychological distress and lower quality of life than controls but voice therapy had no significant impact on either of these variables. <sep>', 'results revealed a significant difference between the 3 treatment groups in the amount of change for the voice severity electrolaryngograph and shimmer measurements and on ratings provided by a patient questionnaire p<0.05). <sep>'], 'population': ['teachers with self-reported voice problems <sep> 20 teachers with self-reported voice problems <sep> twenty subjects <sep>', 'fifty dysphonic subjects <sep>', '20 students with similar voice disorders served as a <sep> teacher students <sep> 20 teacher students with mild voice disorders <sep> students with mild voice disorders <sep>', 'participants 204 outpatients aged 17-87 with a primary symptom of persistent hoarseness for at least two months <sep> outpatient clinic in a teaching hospital <sep>', '45 patients with nonorganic dysphonia <sep> forty-five patients diagnosed as having nonorganic dysphonia <sep>'], 'interventions': ['vfes and vh education <sep> fibreoptic endoscopic evaluation <sep> vocal function exercises vfes and vocal hygiene vh education <sep>', 'transnasal flexible laryngoscopy <sep> transnasal flexible laryngoscopy tfl <sep> voice therapy <sep> tfl <sep> tfl-assisted treatment group <sep>', 'voice therapy <sep> control group and consequently did not receive voice therapy <sep>', 'voice therapy or no treatment <sep> voice therapy <sep>', 'voice therapy <sep> program of indirect therapy and direct with indirect therapy <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",evidence is available for the effectiveness of comprehensive voice therapy comprising both direct and indirect therapy elements. effects are similar in patients and in teachers and student teachers screened for voice problems. larger and methodologically better studies are needed with outcome measures that match treatment aims.
74,"{'outcomes': ['active ocular disease <sep> proportion of patients with pain scores <sep> pain <sep> intraocular complications <sep>', 'duration of viral shedding <sep> famciclovir accelerated lesion healing <sep> resolution of postherpetic neuralgia <sep> median duration of postherpetic neuralgia <sep> safety <sep> pain <sep>', 'risk ratios <sep> total crusting <sep> time to return to uninterrupted sleep <sep> resolution of pain <sep> laboratory adverse events <sep> accelerated time to cessation of acute neuritis <sep> quality of life <sep> chronic pain and quality-of-life outcomes <sep> lesion healing resolution of pain return to usual activity and return to uninterrupted sleep <sep> time to return to usual daily activity <sep> analgesic requirements each day and adverse events and laboratory abnormalities <sep> time to total crusting and healing <sep>', 'reduction pain <sep> loss of vesicles <sep> times to last new lesion formation <sep> full crusting <sep> rash healing <sep> frequency or severity of post-herpetic neuralgia <sep>', 'extent and duration of the rash <sep> weekly prevalence of pain <sep> incidence of ulceration <sep> total analgesic use <sep> medical events <sep> chronic pain <sep> local neurological symptoms <sep>'], 'punchline_text': ['the proportion of patients with pain scores greater than 0 was significantly lower in the acyclovir group between 2 and 3 months. <sep>', 'most importantly famciclovir recipients had faster resolution of postherpetic neuralgia approximately twofold faster than placebo recipients differences between the placebo group and both the 500-mg famciclovir group hazard ratio 1.7 95 ci 1.1 to 2.7 and the 750-mg famciclovir group hazard ratio 1.9 ci 1.2 to 2.9 were statistically significant p  0.02 and 0.01 respectively). <sep>', 'time to total crusting and healing was accelerated for patients receiving acyclovir plus prednisone compared with patients receiving two placebos the risk ratios were 2.27 <sep>', 'no significant hastening of rash healing was seen in those who started therapy later than 48 hours after the onset of rash. <sep>', 'total analgesic use in the first 4 weeks was reduced by acyclovir but during follow up there was no difference in the prevalence of analgesic use between groups. <sep>'], 'population': ['46 patients with acute herpes zoster ophthalmicus of less than 72 hours duration <sep> herpes zoster ophthalmicus <sep>', 'acute herpes zoster <sep> 419 immunocompetent adults with uncomplicated herpes zoster <sep> acute disease and postherpetic neuralgia <sep> 36 centers in the united states canada and australia <sep>', '15 university hospitals or affilliated clinics <sep> herpes zoster <sep> 208 immunocompetent patients older than 50 years of age who had localized herpes zoster that developed less than 72 hours before study enrollment <sep> relatively healthy persons older than 50 years of age who have localized herpes zoster combined <sep>', 'acute herpes zoster <sep> 364 elderly immunocompetent patients with herpes zoster who were entered within 72 hours of the onset of rash <sep>', 'herpes zoster in general practice <sep> forty patients aged 16 years or over presenting to their general practitioners within 3 days of rash onset received <sep> acute herpes zoster and postherpetic neuralgia <sep>'], 'interventions': ['acyclovir <sep> placebo <sep> oral acyclovir <sep> oral acyclovir <sep>', 'placebo <sep> famciclovir 500 mg famciclovir 750 mg or placebo <sep> oral famciclovir <sep> famciclovir <sep> famciclovir <sep>', 'placebo <sep> acyclovir <sep> placebos <sep> acyclovir and prednisone <sep> acyclovir plus prednisone acyclovir plus prednisone placebo prednisone plus acyclovir placebo <sep> acyclovir and prednisone therapy <sep> prednisone <sep> acyclovir plus prednisone <sep> acyclovir with and without prednisone <sep>', 'acyclovir <sep> placebo <sep> acyclovir <sep> oral acyclovir <sep> oral acyclovir <sep>', 'acyclovir <sep> placebo <sep> acyclovir <sep> oral acyclovir <sep> oral acyclovir <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",oral acyclovir did not reduce the incidence of phn significantly. there is insufficient evidence from randomised controlled trials to determine whether other antiviral treatments prevent phn. additional well-designed randomised controlled trials of famciclovir or other new antiviral agents with a greater number of participants are needed. future trials should pay more attention to the severity of pain and quality of life of participants and should be conducted among different subgroups of people such as people who are immunocompromised.
75,"{'outcomes': ['highest hiv-1 transmission rate <sep> cd4 counts <sep> cd4 cell count <sep> genetically-linked hiv-1 transmission <sep> transmission rates <sep> plasma hiv-1 <sep>', 'viral load <sep> hiv-1 incidence and sexual risk behaviors <sep> number of sexual partners or other risk behaviors <sep> hiv-1 transmission rates <sep> hiv-1 <sep> incidence rate difference <sep>', 'incidence rates of seroconversion <sep> incidence of seroconversion <sep> incidence of heterosexual transmission <sep> rate of transmission <sep> signs of disease progression symptoms of acquired immunodeficiency syndrome p24 antigen positivity or cd4 cell counts <sep> seroconversion <sep> hiv heterosexual transmission <sep>'], 'punchline_text': ['in participants not on art the highest hiv-1 transmission rate 8.79 per 100 person-years was from those with cd4 cell counts lower than 200 cells per microl. <sep>', 'couples reported more consistent condom use during art use but there was no significant difference in the number of sexual partners or other risk behaviors. <sep>', 'men with signs of disease progression transmitted infection to their partners more frequently and were more frequently treated with zidovudine. <sep>'], 'population': ['3381 couples were eligible for analysis <sep> 349 10 participants with hiv-1 initiated art during the study at a median cd4 cell count of 198 iqr 161-265 cells per microl <sep> patients infected with hiv-1 on risk of transmission to their uninfected partners <sep> enrolled heterosexual african adults who were seropositive for both hiv-1 and herpes simplex virus type 2 and their hiv-1 seronegative partners <sep>', 'hiv-1 discordant couples in rakai uganda <sep> two hundred and fifty hiv-1 discordant couples were followed between 2004 and 2009 and 32 hiv-1-positive partners initiated art <sep> study participants underwent annual screening for hiv-1 and were interviewed to evaluate risk behaviors <sep> hiv-1 discordant couples were retrospectively identified between 2004 and 2009 <sep>', 'human immunodeficiency virus type-1 infected men with <sep> men infected with human immunodeficiency virus type <sep> 436 monogamous seronegative female sexual partners of human immunodeficiency virus type 1-infected males was followed up for 740 person-years with regular structured interviews and laboratory tests <sep>'], 'interventions': ['antiretroviral therapy art <sep> antiretroviral therapy <sep> placebo <sep>', 'antiretroviral therapy art <sep> voluntary counseling and testing and provided with risk reduction counseling <sep>', 'zidovudine <sep> zidovudine therapy <sep> behavioral counseling <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",art is a potent intervention for prevention of hiv in discordant couples in which the index partner has 550 cd4 cells/l. a recent multicentre rct confirms the suspected benefit seen in earlier observational studies and reported in more recent ones. questions remain about durability of protection the balance of benefits and adverse events associated with earlier therapy long-term adherence and transmission of art-resistant strains to partners. resource limitations and implementation challenges must also be addressed. counselling support and follow up as well as mutual disclosure may have a role in supporting adherence so programmes should be designed with these components. in addition to art provision the operational aspects of delivering such programmes must be considered.
76,"{'outcomes': ['attacks <sep>'], 'punchline_text': ['stilboestrol 5 mg daily was better than the placebo in preventing attacks. <sep>'], 'population': ['homozygous sickle-cell disease <sep> 11 patients with stuttering attacks of priapism and homozygous sickle-cell ss disease <sep>'], 'interventions': ['stilboestrol <sep> placebo <sep>'], 'punchline_effect': [' sig increase <sep>']}",there is a lack of evidence for the benefits or risks of the different treatments for both stuttering and fulminant priapism in sickle cell disease. this systematic review has clearly identified the need for well-designed adequately-powered multicentre randomised controlled trials assessing the effectiveness of specific interventions for priapism in sickle cell disease.
77,"{'outcomes': ['total pregnancy rates and time for success <sep>'], 'punchline_text': ['women in the study group had a better possibility of becoming pregnant after polypectomy with a relative risk of 2.1 95 confidence interval 1.5-2.9). <sep>'], 'population': ['patients undergoing intrauterine insemination <sep> 215 infertile women from the infertility unit of a university tertiary hospital with ultrasonographically diagnosed endometrial polyps ep undergoing iui <sep>'], 'interventions': ['hysteroscopic polypectomy <sep> diagnostic hysteroscopy and polyp biopsy <sep> hysteroscopic polypectomy before intrauterine insemination iui <sep>'], 'punchline_effect': [' sig decrease <sep>']}",hysteroscopic myomectomy might increase the odds of clinical pregnancy in women with unexplained subfertility and submucous fibroids but the evidence is at present not conclusive. the hysteroscopic removal of endometrial polyps suspected on ultrasound in women prior to iui might increase the clinical pregnancy rate. more randomised studies are needed to substantiate the effectiveness of the hysteroscopic removal of suspected endometrial polyps submucous fibroids uterine septum or intrauterine adhesions in women with unexplained subfertility or prior to iui ivf or icsi.
78,"{'outcomes': ['liver function and immunoglobulin levels <sep> immunoglobulin g levels <sep> survival estimate <sep> total globulin levels <sep> serum albumin and bilirubin levels <sep>', 'mean serum levels of alkaline phosphatase total bilirubin gamma-glutamyltranspeptidase alanine aminotransferase aspartate aminotransferase and igm <sep>', 'serum cholesterol levels and udca also reduced high-density lipoprotein cholesterol levels <sep> hepatic reasons <sep> ductular proliferation <sep> liver function test <sep> serum level of carboxyterminal propeptide of type i procollagen <sep> serum total bilirubin levels <sep> clinical events laboratory test results and liver histology <sep> pruritus <sep> serum levels of immunoglobulin ig m and igg and colchicine reduced igg levels <sep> serum activities of aminotransferases alkaline phosphatase and gamma-glutamyltransferase <sep> elevated serum level of aminoterminal propeptide of type iii procollagen <sep>', 'histological scores <sep> improvement of liver enzymes related to cholestasis and cytolysis and of amelioration of pruritus <sep> mayo score values <sep> number of treatment failures i.e. dead orthotopic liver transplantation olt complications of cirrhosis doubling of bilirubin untreatable pruritus <sep> histological grading score <sep>', 'pruritus score <sep> mean pruritus score <sep> serum alkaline phosphatase alp levels <sep> serum bilirubin levels <sep> serum immunoglobulin g levels <sep> liver histology <sep> blood test results symptoms and/or liver histology <sep> alanine aminotransferase alt level <sep> alp level <sep> albumin levels <sep>', 'disease activity <sep> mean bilirubin and immunoglobulin m values <sep> mean alanine aminotransferase values <sep> alkaline phosphatase and alanine aminotransferase activities <sep> mean alkaline phosphatase and alanine aminotransferase values <sep> bilirubin values <sep> histologic progression <sep> mean alkaline phosphatase values <sep>', 'bsp elimination kinetics <sep> progression of esophageal varices <sep> symptoms laboratory findings serum bilirubin level alkaline phosphatase and alanine transaminase alt activities immunoglobulin ig m level serum markers of fibrosis or histological features except lobular inflammation <sep> variceal bleeding <sep> procollagen type iii aminoterminal peptide piiinp hyaluronic acid and sulfobromophthalein bsp elimination kinetics <sep>', 'number of markers of liver disease <sep> diarrhea <sep> levels of serum albumin serum bilirubin alkaline phosphatase cholesterol and aminotransferases <sep> histologic changes noted at liver biopsy <sep> severity of symptoms or physical findings <sep> cumulative mortality from liver disease <sep>'], 'punchline_text': ['in comparison with placebo colchicine produced a beneficial effect on serum albumin and bilirubin levels at 3 months in patients who had abnormal liver function bilirubin greater than 20 mumol/l at entry albumin p  0.047 bilirubin p  0.022). <sep>', 'in group 1 there were significant decreases in mean serum levels of alkaline phosphatase total bilirubin gamma-glutamyltranspeptidase alanine aminotransferase aspartate aminotransferase and igm and these changes were more remarkable in those who responded poorly to ursodeoxycholic acid. <sep>', 'both colchicine and udca reduced serum cholesterol levels and udca also reduced high-density lipoprotein cholesterol levels. <sep>', 'no significant differences were observed in terms of improvement of liver enzymes related to cholestasis and cytolysis and of amelioration of pruritus. <sep>', 'methotrexate but not colchicine significantly improved liver histology p  0.005 and serum immunoglobulin g levels p  0.0002). <sep>', 'differences in mean bilirubin and immunoglobulin m values although lower in the colchicine group did not reach statistical significance. <sep>', 'after 2 years of treatment relative to udca colchicine combined with udca did not significantly improve symptoms laboratory findings serum bilirubin level alkaline phosphatase and alanine transaminase alt activities immunoglobulin ig m level serum markers of fibrosis or histological features except lobular inflammation. <sep>', 'however there was no such improvement in the severity of symptoms or physical findings moreover there was no significant difference in the histologic changes noted at liver biopsy in the two treatment groups. <sep>'], 'population': ['primary biliary cirrhosis <sep> 64 patients with primary biliary cirrhosis <sep>', 'patients with primary biliary cirrhosis <sep> treated patients with primary biliary cirrhosis <sep> twenty-two patients with primary biliary cirrhosis treated with <sep> 600 mg/day for 30 months <sep>', 'primary biliary cirrhosis pbc <sep>', 'patients with symptomatic primary biliary cirrhosis <sep> a total of 90 patients <sep> 15 patients with pre-cirrhotic stage <sep> symptomatic primary biliary cirrhosis <sep> patients with symptomatic primary biliary cirrhosis pbc defined by the presence of liver cirrhosis pruritus or bilirubin exceeding 2 mg/ml <sep> patients with cirrhosis underwent endoscopy every 12 months <sep>', 'patients with histologically confirmed primary biliary cirrhosis <sep> patients with primary biliary cirrhosis <sep> primary biliary cirrhosis <sep>', 'patients with primary biliary cirrhosis <sep> primary biliary cirrhosis <sep> fifty-seven patients with biopsy-proven primary biliary cirrhosis <sep>', 'primary biliary cirrhosis <sep> patients with nonadvanced primary biliary cirrhosis pbc <sep> patients with nonadvanced pbc <sep> seventy-four patients with pbc who had been treated previously with udca at least 8 months but still had abnormal liver test results especially elevated alkaline phosphatase activity <sep>', 'patients with primary biliary cirrhosis <sep> 60 patients with primary biliary cirrhosis <sep> primary biliary cirrhosis <sep> thirty patients had early disease stages 1 and 2 and 30 had advanced disease stages 3 and 4 <sep> fifteen patients with early disease and 15 with advanced disease received <sep>'], 'interventions': ['placebo colchicine <sep> placebo <sep> colchicine <sep> colchicine <sep>', 'ursodeoxycholic acid <sep> ursodeoxycholic acid alone <sep> colchicine to ursodeoxycholic acid <sep> colchicine <sep>', 'colchicine and placebo <sep> placebo <sep> colchicine and ursodeoxycholic acid <sep> ursodeoxycholic acid udca <sep> colchicine <sep> colchicine and udca <sep> udca <sep> colchicine <sep>', 'ursodeoxycholic acid <sep> placebo <sep> ursodeoxycholic acid with or without colchicine <sep> ursodeoxycholic acid 500 mg/daily plus placebo udca <sep> colchicine <sep> ursodeoxycholic acid udca and colchicine <sep> udca <sep>', 'methotrexate <sep> colchicine <sep> colchicine or methotrexate <sep> colchicine and methotrexate <sep> methotrexate <sep>', 'colchicine twice daily or an identically appearing placebo <sep> colchicine <sep> placebo <sep> colchicine therapy <sep>', 'ursodeoxycholic acid <sep> placebo <sep> colchicine and ursodeoxycholic acid <sep> colchicine <sep> udca colchicine combined with udca <sep> colchicine combined with ursodeoxycholic acid udca and udca alone <sep> udca <sep> colchicine <sep>', 'placebo <sep> repeat liver biopsy and were then placed on open-label colchicine <sep> colchicine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",we did not find evidence either to support or refute the use of colchicine for patients with primary biliary cirrhosis. as we are not able to exclude a detrimental effect of colchicine we suggest that it is only used in randomised clinical trials.
79,"{'outcomes': ['point verbal pain rating scale vprs <sep> cbcl rating and experience of pain <sep> pre-surgical child behavior ratings and pain management <sep> pre-operative anxiety and pain <sep> child behavior checklist cbcl <sep> child behavior <sep>', 'severe agitation <sep> agitation score <sep> rate of postoperative nausea and vomiting <sep> symptoms of disorientation restlessness inconsolable crying and thrashing resemble an acute psychosis <sep> severe delirium <sep>', 'hannallah objective pain scale <sep> pain scores <sep> side effects <sep> analgesic efficacy <sep> analgesic efficacy <sep> pain <sep> rescue analgesic <sep>', 'pain <sep> relevant pain-relief medication <sep> self-report visual analogue scale to record pain <sep>', 'normal activity <sep> mean postoperative hospital stay <sep> postoperative analgesia <sep> oral fluid intake <sep> mean operative time <sep> blood loss <sep>', 'functional parameters <sep> efficiency of postoperative analgesia <sep> hemodynamic changes <sep>', 'pain <sep> maximum pain score and pain score <sep> post-operative pain <sep>', 'plasma proteins and igg levels <sep> enlarged hyperechoic kidneys <sep> low urine specific gravity <sep> hypertension oedema or evidence of acute infection <sep> normal blood pressure non-oliguric renal failure proteinuria hypostenuria and abnormal urinary sediment <sep> c3 and c4 levels <sep> fatigue fever gastrointestinal disturbances anorexia and weight loss <sep> renal function <sep> urinalysis complete blood count erytrocyte sedimentation rate esr plasma creatinine glomerular filtration rate gfr electrolytes proteins igg c3 c4 antinuclear-antibodies ana antistreptolysin-o and antibodies to hantaviruses <sep> concentration ability <sep> renal biopsy <sep> esr plasma urea and creatinine concentrations <sep> glycosuria aminoaciduria and decreased tubular reaposrption of phosphate trp <sep> headache arthralgias and maculopapular rash <sep>', 'postoperative analgesia made by analgin and promedol <sep> efficiency of postoperative analgesia <sep> visual-analogue 10-point scale and the 0-4 point verbal pain assessment scale <sep>', 'postoperative analgesic efficacy <sep> analgesic requirements and modified objective pain score <sep> postoperative nausea and vomiting or psychomotor reactions <sep> duration of postoperative analgesia <sep> median time to first analgesia <sep>', 'ops scores and requirement for supplementary analgesics <sep> objective pain scale ops <sep> postoperative pain <sep> postoperative pain <sep>', 'intra-operative bleeding <sep> blood loss <sep> pain relief <sep> postoperative pain and behaviour <sep> postoperative complications <sep>', 'analgesic effect <sep> worst pain <sep>', 'incidence of reactionary post-operative haemorrhage <sep>', 'mean vas score <sep> pain intensity and morphine requirements <sep> pain score verbal analogue scales vas 0-10 and sedation level at 5-min intervals and recorded the total morphine consumption of the first hour in the pacu <sep> pain scores and postoperative morphine requirements <sep> total morphine consumption <sep> mean total morphine consumption <sep>', 'postoperatively time to first eye opening sedation score pain score time for further analgesia requests and incidence of nausea and vomiting <sep>', 'movement pain scoring <sep> adverse effects and duration of pca <sep> analgesic efficacy <sep> cumulative morphine consumption <sep>', 'vomiting <sep> postoperative pain <sep> incidence and frequency of vomiting <sep> muscle relaxation <sep>', 'nausea and vomiting <sep> postoperative comfort <sep> nausea/vomiting analgesics and parents aspects <sep> immediate postoperative analgesia <sep> degree of pain <sep> total incidence of nausea/vomiting <sep> pain <sep>', 'demographics tracheal extubation times and pain scores <sep> analgesia behavioral pain scale bps score of 3 <sep> sedation scores and the heart rates <sep> nausea vomiting apnea desaturation reintubation within 24 h and constipation <sep>', 'postoperative analgesia <sep> need analgesia <sep>', 'postoperative pain <sep> pain scores <sep> pain <sep> number of children rating severe pain <sep> episodes of bleeding <sep> nausea/vomiting <sep> analgesic efficacy <sep> nausea and vomiting <sep> pain scores <sep>', 'postoperative bleeding <sep> morbidity and pain <sep> pain and postoperative morbidity <sep> pain <sep> bleeding <sep> postoperative morbidity <sep>', 'postoperative nausea <sep> recovery time <sep> vomiting <sep> frequency of vomiting and the degree of nausea <sep> pain rating scale <sep> severe vomiting <sep> serious adverse events <sep> postoperative pain <sep> postoperative nausea and vomiting ponv <sep> pain score <sep> postoperative analgesic requirement <sep> validated wong and baker scale faces <sep> nausea vomiting and pain <sep> incidence of ponv <sep>', 'postoperative pain <sep> plasma diclofenac and beta-endorphin concentrations <sep> total plasma clearance <sep> pain-free children <sep> plasma beta-endorphin level <sep> postoperative pain relief <sep>', 'sedation score <sep> degree of postoperative sedation <sep> satisfactory sedation scores <sep> sedation score or frequency of use of postoperative analgesics <sep>', 'operating theatre blood loss the frequency of bleeding on the ward or the need for operative haemostasis <sep> marked restlessness <sep> incidence of above average bleeding <sep> bleeding and restlessness <sep> blood loss <sep>', 'postoperative pain and anxiety <sep>', 'onset of eating at home <sep> scores for salivation <sep> efficacy and safety <sep> stridor scores <sep> perioperatively scores open scale 1-9 for stridor sedation bleeding nausea pain heart rate the need for analgesics and registered psychotomimesis and well-being at home <sep> salivation <sep> unpleasant psychotomimesis <sep> score for stridor <sep>', ""elimination clearance of hydroxyl metabolites <sep> volumes of distribution of parent diclofenac and its hydroxyl metabolite <sep> clearance <sep> formation clearance to 4'-hydroxydiclofenac <sep> formation clearance to 4'-hydroxydiclofenac diclofenac volume of distribution absorption half-time and lag time for the suppository <sep> formation clearances of diclofenac to hydroxyl metabolites <sep> relative bioavailability <sep> absorption half-life <sep> diclofenac 4'-hydroxydiclofenac and 5'-hydroxydiclofenac concentrations <sep>"", 'analgesic effects <sep> duration of anaesthesia <sep> post-operative pain scores <sep> objective pain score <sep>', 'pain <sep> pain and demeanour <sep>', 'secondary hemorrhage <sep> time to first solid intake <sep> nausea and vomiting and allowed safer and earlier hospital discharge <sep> postoperative pain oral intake vomiting temperature and complications <sep> emergency department visit for pain and dehydration <sep> analgesic efficacy <sep> nausea and vomiting <sep> pain less elevation of temperature more oral intake and started drinking <sep> otitis media <sep>', 'pain and appearance <sep> rapid return to calm wakefulness <sep> postoperative pain <sep> pain and restlessness <sep>', 'plasma morphine concentrations <sep> postoperative analgesia and side-effects <sep> rescue analgesia <sep> reduced enzyme activity <sep> plasma morphine concentration <sep> phenotype nor morphine concentration <sep> mean sd morphine concentrations <sep> pain score or the need for rescue analgesia <sep> phenotype and plasma morphine <sep>', 'postoperative analgesia <sep> incidence of motor block urinary retention postoperative vomiting or postoperative sedation <sep> median duration of analgesia <sep> postoperative pain <sep>', 'acta anaesthesiologica scandinavica <sep> leucocyte and differential counts lymphocyte and their subset counts lymphocyte proliferative responses and in serum cortisol c-reactive protein plasma interleukin-6 and group ii phospholipase a2 concentrations <sep>', 'postoperative pain scores <sep> pain scores <sep> mpca <sep> hourly visual analogue pain scores and morphine patient controlled analgesia mpca usage <sep> acceptable pain scores <sep> analgesic requirements <sep>', 'demographics induction technique duration of anaesthesia and time between premedication and induction of anaesthesia <sep> postoperative pain <sep> rescue analgesia <sep> overall cheops scores <sep> analgesic efficacy <sep>', 'pain scores <sep> postoperative morphine titration <sep> ketamine efficacy <sep> spontaneous and swallowing-evoked pain <sep> total paracetamol consumption <sep> incidence of vomiting or dreaming <sep> quality of oral intake <sep> swallowing-evoked pain <sep>', 'vt and total plasma clearance <sep>', 'respiratory depression <sep> age weight type of operation or induction of anaesthesia 4-h sedation and pain scores and further analgesic requirements <sep> pain relief <sep> postoperative pain scores analgesic requirements sedation scores signs of respiratory depression and nausea and vomiting as well as antiemetic requirements <sep> vomiting <sep> pain control <sep>', 'arousal <sep> incidence of airway irritation or emergence delirium <sep> times to leave recovery <sep> duration of anaesthesia <sep> rate of recovery <sep> end-tidal volatile agent concentration <sep>', 'pain score <sep> cheops pain scoring <sep>', 'analgesic efficacy <sep> time to awaken from anaesthesia or incidence of postoperative vomiting <sep> postoperative pain <sep>', 'longest analgesia duration <sep> postoperative analgesia <sep> pain <sep> effective pain relief <sep> side effects <sep>', 'pain scores <sep> median pain scores <sep> nurse pain assessments <sep>', 'visual pain scale vas 0-100 side-effects such as vomiting and postoperative haemorrhage <sep> postoperative haemorrhage and vomiting <sep> pain severity <sep> severity of the postoperative pain <sep> median of the vas <sep>', 'pain <sep> pain scale <sep> wong and baker pain scale <sep> pain score <sep>', 'pain scores <sep> pain score <sep>', 'blood loss <sep> nausea and vomiting scores <sep> pain scores <sep> nausea and vomiting scores sedation scores and pain scores <sep> pain scores <sep> blood loss <sep>', 'pain scores emetic episodes and supplemental morphine requirements <sep> incidence of postoperative vomiting <sep> pain scores in recovery and pain scores <sep> overall incidence of postoperative vomiting <sep> median range episodes of vomiting <sep>', 'side-effects <sep> heart rate and blood pressure <sep> postoperative vomiting <sep> modified aldrete score a pain/discomfort scale <sep> discomfort <sep> vomiting <sep> full aldrete scores <sep> quality of recovery <sep>'], 'punchline_text': ['these children with sdb scored significantly higher on cbcl than did normative groups but no connection was observed between cbcl rating and experience of pain. <sep>', 'an increased rate of postoperative nausea and vomiting 45 vs. 15 p  0.05 was the only adverse effect observed. <sep>', 'we find the analgesic efficacy of diclofenac suppository combined with local anesthetic infiltration at port sites comparable to caudal block. <sep>', 'voltarol appears to be the better pre-emptive analgesic for dental extractions under general anaesthesia when compared with paracetamol and no analgesia. <sep>', 'all operations were completed successfully and there were no intraoperative or postoperative complications except for subcutaneous emphysema in one patient case 4). <sep>', 'group 1 comprised 63 patients and group 2 included 26 patients with identical diseases inguinal hernias varicocele phimosis). <sep>', 'on re-auditing two years later in a group of 100 children post-operative pain was significantly improved. <sep>', 'esr plasma urea and creatinine concentrations were increased in all plasma proteins and igg levels in the majority of patients. <sep>', 'a comparative analysis of the efficiency of postoperative analgesia by the discussed drugs showed that diclofenac possesses a sufficient analgetic activity and is free of any side-effects inherent in narcotic analgetics. <sep>', 'ketamine median 2 or bupivacaine median 2.5 groups p<0.05). <sep>', 'rectal diclofenac 2 mg.kg(-1 i.v. <sep>', 'there were no obvious differences between the groups in intra-operative bleeding as estimated by the surgeon or in measured blood loss. <sep>', 'worst pain observed in the recovery room was lower in the diclofenac group both at rest and during swallowing. <sep>', 'the authors noticed a marked increase in the incidence of reactionary post-operative haemorrhage after tonsillectomy during the course of 1992. <sep>', 'preemptive diclofenac given rectally reduced pain intensity and morphine requirements of children anaesthetized with remifentanil for tonsillectomy. <sep>', 'there was no statistical significant difference in any of these parameters between the two groups. <sep>', 'analgesia as assessed by movement pain scoring was significantly improved by the addition of diclofenac despite lower morphine consumption. <sep>', 'clonidine 4 micrograms.kg-1 caused a lower incidence and frequency of vomiting than did placebo and diazepam incidence and frequency 11 and 1.37 and 3 and 34 and 2 in clonidine 4 micrograms.kg-1 placebo and diazepam respectively p  0.05 for clonidine 4 micrograms.kg-1 vs placebo and diazepam). <sep>', 'the total incidence of nausea/vomiting was 28 and fentanyl caused nausea and vomiting in a significantly higher proportion of cases. <sep>', 'after cessation of the opioid infusion the sedation scores and the heart rates were always higher in the remifentanil group compared with the fentanyl group. <sep>', 'children given a caudal block alone were more likely to need analgesia in the first 24 h postoperatively. <sep>', 'pain scores in the diclofenac group were only significantly lower at 12 h on day 1-3 compared to pain scores in the acetaminophen group p<0.05). <sep>', 'the pain recordings showed significantly less pain for the tt children from the second hour postoperatively onward and the tt children were pain free and in school 3 days earlier than the te group. <sep>', 'the incidence of ponv was much higher 72 p  0.0000 in the morphine group where 56 of the children also had severe vomiting. <sep>', 'caudal analgesia abolished the stress-induced increase in plasma beta-endorphin level which was found in the children given diclofenac and in those who served as controls. <sep>', 'there were no significant differences in sedation score or frequency of use of postoperative analgesics at any time of assessment among the three inhalation anesthetics. <sep>', 'there were no significant differences between the treatment groups in operating theatre blood loss the frequency of bleeding on the ward or the need for operative haemostasis. <sep>', 'an earlier awakening was observed in group 1 which we attributed to a more valuable antinociceptive protection and to lower doses of ketamine group 1--3.2 mg/kg group 2--4.3 mg/kg). <sep>', 'no other differences were found between the ketamine and diazepam/diclofenac groups before and after premedication until induction of anaesthesia. <sep>', 'the rectum is a suitable route for administration of diclofenac in children 2-8 year of age and was associated with a higher relative bioavailabilty than enteric-coated tablets and an earlier maximum concentration 50 vs. 108 min). <sep>', 'the duration of anaesthesia was longer in the diclofenac group 9.6 min sd 3.5 compared with control 7.2 min sd 2.6 and nalbuphine 6.9 min sd 3.0 groups respectively p  0.05). <sep>', 'caudal bupivacaine provided more pain-free patients at first but later the incidence of pain was similar in the two treatment groups. <sep>', 'the time to first solid intake was significantly earlier in the diclofenac sodium group p  0.0001). <sep>', 'no significant differences in postoperative pain were found between the groups at any time. <sep>', 'more children required rescue analgesia after codeine at both 2 p<0.05 and 4 h after administration p<0.01). <sep>', 'subjects in group l required significantly more doses of postoperative analgesia than those in group c p  0.05). <sep>', 'the only difference related to the analgesic method was shorter duration of post-operative leucocytosis and lower phytohaemagglutinin pha)-induced lymphocyte proliferative responses in peripheral blood in the opioid group than in the nsaid or epidural groups. <sep>', 'significantly more mpca was demanded t  2.02 p  0.02 and morphine received t  2.02 p  0.005 by adults than children following appendicectomy. <sep>', 'overall cheops scores were low for both groups at all times and did not differ between the groups at any time. <sep>', 'the ketamine group showed significantly lower pain scores both at rest and on swallowing with less total paracetamol consumption p  0.05 during the 24 h after surgery. <sep>', 'vt and total plasma clearance were higher than in adults but the elimination half-life was similar. <sep>', 'there were no statistically significant differences in age weight type of operation or induction of anaesthesia 4-h sedation and pain scores and further analgesic requirements. <sep>', 'there were no significant differences in incidence of airway irritation or emergence delirium between the two agents. <sep>', 'there was no difference between the groups except in the recovery area when group 3 cried more and had a higher pain score than group 2. <sep>', 'there were no significant differences between the two drugs in respect of time to awaken from anaesthesia or incidence of postoperative vomiting. <sep>', 'in the remaining 20 hours the longest analgesia duration was seen in group s which did not differ from groups f and m but was significantly longer than for groups b and d. rectal diclofenac has not promoted effective pain relief. <sep>', 'the median pain scores 2 at 15 min and 1 at 30 min postoperatively were the same in both groups. <sep>', 'the decrease of pain severity was statistically significant p 0.05). <sep>', 'children who received the rectal diclofenac-paracetamol combination experienced a lower pain scale and a decreased need for morphine compared with children receiving each drug alone. <sep>', 'the subpubic penile block provided significantly better analgesia than the subcutaneous ring block of the penis. <sep>', 'pain scores in the tenoxicam without fentanyl group were significantly higher in recovery p  0.05 than the diclofenac group without fentanyl and both fentanyl groups. <sep>', 'the incidence of postoperative vomiting was lower in the fentanyl group p  0.03 in the first 4 h but similar by 24 h. children who received morphine at any time in the first 24 h had more median range episodes of vomiting 2 0-7 than children receiving fentanyl only l 0-3 p  0.03]. <sep>', 'in children 1-3 yr sevoflurane provided more rapid early recovery but not discharge after anaesthesia of 30-min duration. <sep>'], 'population': ['ninety-two children 5-15 years with sleep-disordered breathing sdb and with or without recurrent tonsillitis <sep>', 'preschool children experiences severe emergence agitation after anaesthesia <sep> anaesthetized 211 children 1-5 yr with <sep> preschool children <sep> severely agitated children <sep>', 'pediatric laparoscopy <sep> 50 children undergoing laparoscopy for diagnostic and therapeutic purposes <sep> children undergoing laparoscopy <sep> their ages ranged from 3 to 13 years and all belonged to american society of anesthesiologists asa class <sep>', 'children undergoing extractions of primary teeth under general anaesthesia <sep> subjects were 70 children from each site who were aged between 3 and 12 years and were undergoing routine extractions of primary teeth <sep> children following extractions of primary teeth under general anaesthesia <sep>', 'four girls mean age 5.3 years <sep> three patients had an ectopic dysplastic kidney with ectopic ureter and one patient had hydronephrosis with megaureter due to distal ureteral atresia of the upper moiety in a duplicated dysplastic kidney <sep> children <sep> dysplastic kidney with ectopic ureter <sep>', 'children undergone minor surgical interventions <sep> children <sep> 26 patients with identical diseases inguinal hernias varicocele phimosis <sep>', '33 children <sep> children following tonsillectomy <sep>', 'all children had previously been healthy <sep> eight patients subsequently developed anterior uveitis as part of tinu syndrome <sep> 1003-1014 mild proteinuria 0.3-0.4 g/24 h <sep> children <sep> all patients had non-oliguric acute renal failure arf gfr was 21.7 <sep> 21 patients <sep> between 1986 and 1997 we observed 21 patients aged 7-16 years mean 12.8 with acute tubulointerstitial nephritis including eight with tubulointerstitial nephritis and uveitis tinu syndrome <sep>', 'forty-seven children and 10 children with identical diseases like groin hernia varicocele and dropsy of testicular membranes <sep> children after small-scope surgical interventions <sep> children <sep>', 'sixty children undergoing caudal block during general anaesthesia for hernia repair or orchidopexy <sep> children <sep>', '125 children <sep> children undergoing ophthalmological surgery <sep> patients asa i 2-12 years undergoing elective ophthalmological surgery <sep> children undergoing elective ophthalmological surgery <sep>', '44 children scheduled for adenoidectomy with or without myringotomy <sep> small children <sep>', '150 children aged 1-7 years <sep> small children <sep>', 'patients having tonsillectomy under the care of the senior author p.m.r. in 1992 revealed that four of the 73 patients 5.5 receiving diclofenac at induction of anaesthesia suffered reactionary haemorrhage requiring operative control as compared with two of 293 0.7 receiving other analgesics <sep>', 'forty children <sep> children undergoing tonsillectomy after <sep> 50 <sep> children anaesthetized with remifentanil for tonsillectomy <sep>', 'postoperative pain following adenotonsillectomy in children <sep> twenty-nine children scheduled for adenotonsillectomy <sep>', '80 children aged 5-13 yr who received <sep> after appendicectomy using a standardized tracheal general anaesthetic <sep> children receiving pca morphine <sep>', '140 children 3-12 yr undergoing strabismus surgery <sep> children after strabismus surgery <sep>', 'paediatric outpatient surgery <sep> 200 paediatric daycase patients by using questionnaires and telephone interviews <sep>', 'twenty-two postoperative orthopedic surgery patients <sep> pediatric icu patients <sep> pediatric postoperative icu patients <sep> mechanically ventilated postoperative pediatric patients <sep> mechanically ventilated postoperative children <sep>', 'pain following minor surgery in children <sep> thirty-nine asa grade 1 or 2 children undergoing inguinal or penoscrotal surgery <sep> children <sep> children undergoing minor lower abdominal surgery <sep>', '48 children 5 to 15 years of age following tonsillectomy <sep> 24 h(-1 <sep> paediatric tonsillectomy outpatients <sep>', 'one hundred fifty children between 5 and 15 years of age <sep> forty-nine children were operated on with tt and 43 with te <sep> one tertiary care ent clinic and two secondary care clinics <sep> children with both a history of obstructive problems and recurrent tonsillitis <sep>', 'children were consecutively operated upon from may 1999 to january 2001 <sep> children <sep> children undergoing strabismus surgery <sep> strabismus surgery in children <sep> parents 50 asa class i-ii children 4-16 years of age <sep>', 'children than in adults <sep> two hundred and fifty children undergoing herniotomy or orchidopexy under general anaesthesia <sep> children after inguinal herniotomy or orchidopexy <sep> children <sep>', '74 pediatric patients under 12 years of age <sep> pediatric patients <sep>', 'one hundred and ninety-eight children aged 3 to 12 years who were scheduled for tonsillectomy <sep> children <sep>', 'ambulatory orthopedic surgeries in children <sep>', 'one hundred children between 10 and 15 kg of body weight scheduled for day-case adenoidectomy <sep> children and adults <sep> four out of 59 children <sep>', 'mean sd age and weight of the patients were 4.5 1.5 years and 20.5 4.1 kg <sep> 11 children given enteric-coated <sep> children <sep> infants n  26 undergoing <sep>', '60 children undergoing the extraction of carious deciduous teeth under day-case general anaesthesia <sep> children following extraction of carious deciduous teeth under general anaesthesia <sep>', 'after inguinal herniotomy <sep> forty-three children for day case inguinal herniotomy under general anaesthesia <sep>', 'for either recurrent tonsillitis or adenotonsillar hypertrophy in prince zeid ben al-hussein hospital and prince rashid ben al-hussein hospital <sep> between january 1999 and july 2000 80 children aged 3-14 years underwent <sep> pain after adenotonsillectomy in children <sep>', 'after tonsillectomy in children <sep> pain relief following tonsillectomy <sep> sixty children between 3 and 13 years of age <sep> pain after tonsillectomy in children <sep>', 'ninety-six children <sep> urban population of children <sep> children undergoing adenotonsillectomy <sep>', 'forty boys weighing less than 25 kg undergoing unilateral orchidopexy <sep> children <sep>', '51 children aged from 2 to 12 years and undergoing major surgery under balanced anaesthesia <sep> children <sep> children undergoing surgery under general anaesthesia <sep>', 'patients between 6 and 30 years of age who underwent an unscheduled appendicectomy were prospectively recruited <sep> adults and children <sep> 19 children 6-16 years and 23 adults 17-30 years were recruited <sep> patients undergoing appendicectomy <sep>', 'paediatric myringotomy outpatients <sep> children receiving an anaesthetic which included intraoperative administration of fentanyl 1 microg x kg(-1 <sep> paediatric patients <sep> children with a cheops score  7 received further <sep> paediatric patients for outpatient bilateral myringotomy and tube insertion <sep> sixty-three asa 1 ora sa 2 children aged one year and above <sep>', 'fifty children <sep> children who received an analgesic regimen combining an opioid and a nsaid <sep> after paediatric tonsillectomy <sep>', 'children <sep>', 'children who were scheduled for elective tonsillectomy or adenotonsillectomy at the royal aberdeen children hospital <sep> children undergoing tonsillectomy <sep> paediatric patients undergoing tonsillectomy remains problematic <sep>', 'children after desflurane and isoflurane anaesthesia <sep> fifty-four infants and children assigned in groups according to age and expected length of operation <sep>', 'sixty-one children <sep> children having day case circumcision <sep>', 'post-tonsillectomy pain in children <sep>', '100 children aged 2 to 12 years allocated in 5 groups of 20 children each who received right after anesthesia the following analgesics group b 0.25 <sep> pediatric patients <sep>', 'pain relief following simple dental extractions in children <sep> 133 asa i or ii children aged 5-12 years undergoing general anaesthesia for simple dental extractions <sep>', '100 children aged between 6 and 14 years <sep> 7 patients suffered a postoperative haemorrhage 4 out of the 7 needed a surgical revision and 2 out of 100 patients vomited <sep> children <sep>', 'children undergoing inguinal hernia repair <sep> one hundred and eight patients <sep>', 'forty-five boys having circumcision as day-case patients <sep> 24 boys who had subpubic penile blocks and nine of the 16 boys who had subcutaneous ring blocks <sep>', '127 children scheduled for <sep> children undergoing adenotonsillectomy or tonsillectomy <sep>', 'children <sep> 60 children <sep>', 'children aged 1-3 years <sep> short day-case anaesthesia in a specifically limited age group of children 1-3 yr <sep> eighty unpremedicated children undergoing day-case adenoidectomy <sep>'], 'interventions': ['partial tonsil resection/tonsillotomy tt or full tonsillectomy te <sep> sdb <sep> cbcl <sep>', 'placebo <sep> midazolam premedication <sep> multimodal intraoperative and prophylactic pain therapy combined alfentanil piritramide diclofenac and regional/local bupivacaine <sep> physostigmine <sep> physostigmine and nine following placebo <sep> cholinesterase-inhibitor physostigmine <sep> physostigmine <sep> propofol <sep> sevoflurane <sep>', 'diclofenac suppository <sep> diclofenac <sep> caudal block versus diclofenac suppository <sep> caudal block with bupivacaine <sep>', 'paracetamol voltarol and no analgesia <sep> paracetamol <sep>', 'laparoscopic nephroureterectomy <sep> laparoscopic nephroureterectomy <sep> acetaminophen suppositories <sep> diclofenac sodium suppositories <sep> laparoscopy <sep>', 'diclofenac <sep> nonsteroidal anti-inflammatory drugs nsaids and paracetamol <sep> nonsteroidal anti-inflammatory drugs and paracetamol <sep> nsaids and paracetamol <sep> diclofenac and paracetamol <sep> postoperative analgesia using analgin and promedole <sep> paracetamol <sep>', 'diclofenac <sep>', 'topical steroids <sep> diclofenac <sep> prednisolone <sep>', 'diclofenac <sep> diclofenac <sep> steroid antiinflammatory drugs nad <sep> nonsteroid anti-inflammatory drugs <sep>', 'bupivacaine <sep> caudal plain bupivacaine 0.25 1 ml x kg(-1 plus s(+)-ketamine 0.5 mg x kg(-1 i.v <sep> caudal ketamine <sep> sub-umbilical surgery <sep> ketamine <sep> s(+)-ketamine combined with a plain bupivacaine <sep> bupivicaine group received plain bupivacaine 0.25 1 ml x kg(-1 the caudal ketamine group received caudal plain bupivacaine 0.25 1 ml x kg(-1 with s(+)-ketamine 0.5 mg x kg(-1 the i.v <sep> s(+)-ketamine <sep> caudal versus intravenous s(+)-ketamine <sep>', 'placebo premedication oral clonidine premedication rectal diclofenac 2 mg.kg(-1 following clonidine and i.v <sep> diclofenac or flurbiprofen <sep> clonidine <sep> sevoflurane and nitrous oxide <sep> diclofenac and flurbiprofen with or without clonidine <sep> diclofenac and clonidine and flurbiprofen and clonidine <sep> clonidine 4 microg.kg(-1 or placebo <sep> flurbiprofen <sep> rectal diclofenac 2 mg.kg(-1 following oral placebo premedication i. v. flurbiprofen <sep> rectal diclofenac <sep> diclofenac flurbiprofen and clonidine <sep>', 'paracetamol or diclofenac <sep> diclofenac <sep> diazepam <sep> pethidine <sep> paracetamol <sep>', 'diclofenac <sep> intra-operative intravenous diclofenac <sep> placebo <sep> halothane and nitrous oxide <sep> diazepam <sep> intraoperative diclofenac <sep> adenoidectomy <sep> thiopentone <sep> saline <sep>', 'diclofenac <sep> diclofenac <sep>', 'remifentanil and propofol <sep> diclofenac <sep> pacu <sep> remifentanil-based anaesthesia <sep> remifentanil-propofol anaesthesia <sep> pca morphine programme <sep> diclofenac suppositories <sep> preincisional rectal diclofenac <sep> preemptive diclofenac <sep> remifentanil patient-controlled analgesia pca with morphine <sep> background infusion 4 micro g x kg(-1 <sep>', 'morphine followed by 1 mg x kg(-1 diclofenac <sep> sublingual morphine <sep> receiving 0.1 mg x kg(-1 sublingual morphine <sep> sublingual morphine <sep> morphine <sep>', 'bupivacaine <sep> diclofenac <sep> postoperative analgesia with pca morphine alone morphine plus diclofenac 1 mg kg-1 morphine plus paracetamol 15-20 mg kg-1 or morphine plus a combination of both diclofenac and paracetamol <sep> paracetamol and diclofenac <sep> morphine 0.1 mg kg-1 before surgical incision <sep> paracetamol <sep> pca with morphine <sep>', 'placebo control diazepam 0.4 mg.kg-1 clonidine 2 micrograms.kg-1 and clonidine 4 micrograms.kg-1 <sep> vecuronium <sep> placebo <sep> clonidine premedication <sep> clonidine <sep> clonidine <sep> diazepam <sep> inhalational anaesthesia with halothane and nitrous oxide in oxygen <sep> diazepam and midazolam <sep> neostigmine and atropine <sep> diclofenac suppository <sep>', 'regional anaesthesia <sep>', 'remifentanil <sep> fentanyl <sep> propofol <sep> analgesia-based sedation techniques <sep> remifentanil <sep> remifentanil 0.1 microg.kg(-1).min(-1 or fentanyl 0.025 microg.kg(-1).min(-1 infusions diluted to the same volume <sep>', 'caudal anaesthesia and non-steroidal anti-inflammatory drugs <sep> caudal block using 0.125 bupivacaine with adrenaline or a similar caudal block in combination with rectally administered diclofenac 1 mg.kg-1 <sep> rectal diclofenac <sep> rectal diclofenac and caudal bupivacaine <sep> caudal analgesia and rectally administered diclofenac <sep>', 'diclofenac or acetaminophen <sep> diclofenac <sep> acetaminophen 90 mg kg(-1 <sep> acetaminophen <sep> diclofenac and high-dose acetaminophen <sep> diclofenac 2-3 mg kg(-1 <sep>', 'radiofrequency technique <sep> tt with rf using the surgitron ellman 1.7 mhz or regular te <sep> partial tonsil resection using radiofrequency rf technique tonsillotomy tt versus traditional tonsillectomy te <sep>', 'diclofenac <sep> nitrous oxide <sep> diclofenac <sep> propofol <sep> morphine <sep> fentanyl and propofol <sep> diclofenac voltaren <sep> opioid morphine <sep>', 'caudal bupivacaine <sep> diclofenac <sep> caudal bupivacaine <sep> pethidine <sep> diclofenac sodium <sep> diclofenac sodium 1 mg.kg-1 given intramuscularly or a caudal injection of bupivacaine 0.25 1 ml.kg-1 with or without adrenaline or no analgesia <sep>', 'inhalation anesthetics and postoperative analgesics <sep> oxygen and nitrous oxide <sep> postoperative sedation <sep> diclofenac and acetaminophen suppositories <sep> elective surgical procedures including repair of inguinal hernia orchidopexy tonsillectomy repair of cleft lip and certain orthopedic procedures <sep> pentazocine <sep> inhalation anesthetics sevoflurane isoflurane and halothane <sep>', 'diclofenac and papaveretum <sep> diclofenac 1.0 mg.kg-1 or papaveretum 0.2 mg.kg-1 by intramuscular injection <sep> diclofenac <sep>', 'diclofenac <sep> preventive analgesia <sep> ketamine <sep>', 'rectal diazepam/diclofenac and emla <sep> placebo <sep> oral ketamine <sep> racemic oral ketamine <sep> diazepam/diclofenac <sep> diclofenac 12.5 mg and diazepam 0.5 mg/kg rectally emla cream at the venepuncture site and placebo orally groups kg and ks received ketamine 6.0 mg/kg orally placebo cream <sep> ketamine <sep> oral ketamine <sep> glycopyrrolate <sep> glycopyrrolate <sep>', 'diclofenac <sep> diclofenac <sep> tonsillectomy <sep> diclofenac suppository <sep> diclofenac tablets <sep>', 'diclofenac <sep> nalbuphine and diclofenac <sep> diclofenac suppositories 12.5 mg to a dose of 1-2 mg kg-1 n  19 or no analgesia <sep> intravenous nalbuphine hydrochloride <sep> nalbuphine or diclofenac suppositories <sep>', 'caudal bupivacaine <sep> 1 ml/kg caudal bupivacaine 0.25 or rectal diclofenac 0.25 mg/kg intra-operatively to provide postoperative analgesia <sep> rectal diclofenac <sep> rectal diclofenac with caudal bupivacaine <sep>', 'diclofenac <sep> diclofenac sodium and paracetamol <sep> diclofenac sodium suppositories <sep> diclofenac sodium <sep> diclofenac sodium <sep> paracetamol syrup <sep> tonsillectomy and adenoidectomy <sep> paracetamol <sep>', 'diclofenac <sep> diclofenac and papaveretum <sep> rectal diclofenac 2 mg/kg intramuscular papaveretum 0.2 mg/kg or no medication immediately after induction of anaesthesia <sep> diclofenac <sep> rectal diclofenac with intramuscular papaveretum or placebo <sep> paracetamol <sep>', 'codeine analgesia <sep> codeine <sep> codeine or morphine combined with diclofenac <sep> codeine metabolism <sep> codeine 1.5 mg kg(-1 or morphine 0.15 mg kg(-1 <sep> morphine <sep>', 'bupivacaine and ketamine <sep> caudal epidural block with 0.25 bupivacaine 1 ml.kg-1 and preservative-free ketamine 0.5 mg.kg-1 group l received an ilioinguinal nerve block with 0.25 bupivacaine 0.5 ml.kg-1 and infiltration of the wound with 0.25 bupivacaine 0.5 ml.kg-1 <sep> diclofenac sodium 1-2 mg.kg-1 as a rectal suppository <sep>', 'post-operative pain treatment using non-steroidal anti-inflammatory analgesics opioids or epidural blockade <sep> oxycodone opioid group or continuous epidural infusion of bupivacaine  fentanyl <sep> diclofenac <sep> diclofenac nsaid oxycodone opioid and epidural blockade <sep>', 'morphine <sep>', 'diclofenac <sep> paracetamol 15 mg/kg(-1 <sep> paracetamol <sep> diclofenac or paracetamol <sep> intravenous fentanyl 1 microg/kg(-1 intraoperatively <sep> fentanyl <sep> inhalational sevoflurane <sep> thiopentone <sep> oral diclofenac <sep> paracetamol <sep>', 'placebo <sep> ketamine 0.1 mg kg(-1 <sep> rectal diclofenac <sep> ketamine <sep> ketamine <sep>', 'diclofenac sodium <sep> diclofenac sodium <sep>', 'tramadol <sep> tramadol <sep> tramadol 1 mg.kg(-1 and tramadol <sep> morphine <sep> morphine <sep> diclofenac 1 mg.kg(-1 rectally <sep>', 'isoflurane <sep> isoflurane i or desflurane d for anaesthesia <sep> desflurane <sep>', 'penile block group 2 received a penile block plus diclofenac suppository <sep> diclofenac suppository alone <sep>', 'diclofenac <sep> diclofenac sodium <sep> pethidine <sep>', 'bupivacaine <sep> rectal diclofenac <sep> bupivacaine with epinephrine 1:400,000 0.5 to 1 ml kg(-1 group f 1.5 microg kg(-1 fentanyl group m 30 microg kg(-1 morphine group s 0.3 microg kg(-1 sufentanil all by epidural caudal block and group d who received rectal diclofenac <sep>', 'bupivacaine <sep> swabs soaked in bupivacaine and epinephrine <sep> epinephrine <sep> sevoflurane <sep>', 'metamizol <sep> diclofenac <sep> acetaminophen <sep> pain therapy after tonsillectomy <sep> 35-40 mg/kg acetaminophen rectally and 0.1 mg/kg piritramide i.v <sep>', 'rectal diclofenac 1 mg.kg(-1 or paracetamol 40 mg.kg(-1 or their combination 1 h prior to surgery <sep> rectal diclofenac-paracetamol combination <sep> rectal diclofenac and paracetamol <sep> morphine <sep> rectal diclofenac and/or paracetamol <sep>', 'morphine <sep> analgesia morphine paracetamol or diclofenac <sep> subcutaneous ring block or a subpubic penile block <sep>', 'diclofenac <sep> elective tonsillectomy or adenotonsillectomy <sep> propofol and maintained with a volatile agent <sep> fentanyl <sep> rectal diclofenac 1 mg.kg-1 with or without fentanyl 0.75 microgram.kg-1 i.v. or intravenous tenoxicam 0.4 mg.kg-1 with or without fentanyl 0.75 microgram.kg-1 i.v <sep> diclofenac and tenoxicam <sep>', 'adenotonsillectomy <sep> standard anaesthetic induction with intravenous fentanyl 1 microg x kg(-1 and propofol 4-5 mg x kg(-1 and maintenance with oxygen nitrous oxide and isoflurane <sep> morphine <sep> morphine and fentanyl <sep> intravenous fentanyl 1 microg x kg(-1 intra-operatively or intramuscular morphine <sep> intra-operative fentanyl with fentanyl and morphine <sep>', 'sevoflurane or halothane <sep> inhalational induction with either sevoflurane 8 or halothane 5 and nitrous oxide in oxygen 70/30 via a face mask <sep> halothane <sep> sevoflurane and halothane <sep> sevoflurane <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",diclofenac is an effective analgesic for perioperative acute pain in children. it causes similar types of serious adverse reactions in children as in adults but these are rare. more research on optimum dosing and safety in asthmatic children is required.
80,"{'outcomes': ['complete remission <sep>'], 'punchline_text': ['at the 6-month follow-up timepoint tumour volume had decreased by 10 in a total of 7 patients with a 37.9 95 ci 31.3-44.5 mean volume reduction in this subgroup. <sep>'], 'population': ['patients with a tumour reduction <sep> central giant cell granuloma of the jaw <sep> patients with a central giant cell granuloma <sep> 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years <sep>'], 'interventions': ['salmon calcitonin <sep> calcitonin therapy <sep> placebo <sep> calcitonin <sep>'], 'punchline_effect': [' sig increase <sep>']}",we did not find rcts evaluating the effects of primary surgical versus primary non-surgical interventions for central giant cell granuloma of the jaws. although a number of non-surgical therapies have been proposed for treating central giant cell granuloma of the jaws our review did not identify evidence from rcts to support their use. more research is needed on this topic.
81,"{'outcomes': ['mean birth weight <sep> lower incidence of failed extubation <sep> extubation failure <sep> incidence of abdominal distension or feeding intolerance <sep>', 'demographics severity of initial illness and associated complications time to extubation ventilatory management before extubation weight age or nutritional status at the time of extubation <sep> respiratory failure <sep>', 'h(2)o intermittent mandatory ventilation rate <sep> pulmonary function tests pft <sep> blood gases <sep> extubation failure <sep> peak inspiratory pressure of 16 cm h(2)o positive end expiratory pressure of 5 <sep> apnea/bradycardia episodes <sep>'], 'punchline_text': ['the nsimv group had a lower incidence of failed extubation 4/27 compared with the continuous positive airway pressure group 12/27. <sep>', 'no statistically significant differences between groups with regard to demographics severity of initial illness and associated complications time to extubation ventilatory management before extubation weight age or nutritional status at the time of extubation were noted. <sep>', 'thirty-two 94 of 34 infants were extubated successfully with the use of snippv versus 18 60 of 30 with the use of ncpap p .01). <sep>'], 'population': ['after extubation of very low birth weight infants <sep> objective criteria for failure of extubation were as follows a paco(2 70 fio(2 0.7 or severe recurrent apnea 2 apneas requiring intermittent positive-pressure ventilation in 24 hours or 6 apneas 20 seconds per day <sep> infants of 1251-g birth weight who were due to be extubated before 6 weeks of age were eligible once they were receiving 35 oxygen and were on a ventilator rate of 18 breaths per minute bpm <sep>', 'very low birth weight infants after extubation <sep> premature infants <sep> 41 vlbw infants were studied 19 were in the npcpap group and 22 were in the np-simv group <sep> in a university-based level iii neonatal intensive care unit <sep>', 'infants who were 34 weeks gestational age and who were ventilated for rds <sep> infants with poor lung function dynamic lung compliance 0.5 ml/kg/cm h(2)o expiratory airway resistance 70 cm h(2)o/l/s successful extubation was seen in 93 27 of 29 in the snippv group and 60 15 of 25 in the ncpap group <sep> preterm infants being ventilated for respiratory distress syndrome rds <sep> 55 infants who had pft 80 8 of 10 with dynamic lung compliance of 0.5 ml/kg/cm h(2)o and expiratory airway resistance of 70 cm h(2)o/l/s were extubated successfully <sep>'], 'interventions': ['nsimv <sep> noninvasive ventilation <sep> endotracheal synchronized intermittent mandatory ventilation <sep> nasal synchronized intermittent mandatory ventilation <sep> nasal continuous positive airway pressure ncpap <sep> continuous positive airway pressure <sep> aminophylline <sep> noninvasive nasal synchronized intermittent mandatory ventilation nsimv <sep>', 'nasopharyngeal-synchronized intermittent mandatory ventilation versus nasopharyngeal continuous positive airway pressure <sep> npcpap <sep> nasopharyngeal continuous positive airway pressure npcpap or nasopharyngeal-synchronized intermittent mandatory ventilation np-simv <sep> npcpap or np-simv <sep>', 'snippv or ncpap <sep> synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure <sep> snippv <sep> ncpap <sep> pft <sep> nasal continuous positive airway pressure ncpap <sep> synchronized nasal intermittent positive pressure ventilation snippv <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",implications for practice nippv is a useful method of augmenting the beneficial effects of ncpap in preterm infants. its use reduces the incidence of symptoms of extubation failure more effectively than ncpap. within the limits of the small numbers of infants randomised to nippv there is a reassuring absence of the gastrointestinal side effects that were reported in previous case series. implications for research future trials should enroll a sufficient number of infants to detect differences in important outcomes such as chronic lung disease and gastrointestinal perforation. the impact of synchronisation of nippv on the technique's safety and efficacy should be established in future trials.
82,"{'outcomes': ['mean number of episodes of crisis <sep> mean duration of hospital stay <sep> sickle cell crisis <sep> mean number of infective episodes and associated morbidity <sep>', 'incidence of infections and hospital admissions <sep> number of hospitalizations and decreased number of vaso-occlusive pain crisis <sep> lymphocyte and granulocyte zinc <sep> zinc deficiency affects adversely t-helper1 th1 functions and cell mediated immunity and interleukin il)-2 production <sep> bacteriologically positive infections <sep> interleukin-2 production <sep>', 'linear growth in beta-thalassemia <sep> height <sep> growth velocity height <sep> mean height velocity of early-zinc supplemented children <sep> acceleration of growth in height <sep>', 'growth and body composition <sep> height-for-age and weight-for-age z scores <sep> sitting height <sep> anthropometric high-precision knee-height and plasma zinc measurements <sep> body composition <sep> circumference z scores <sep> knee height <sep>', 'serum testosterone levels <sep> body weight increased and serum lactic dehydrogenase activity <sep> serum testosterone neutrophil zinc and neutrophil alkaline phosphatase activity <sep> serum testosterone level <sep>', 'serum zinc and vitamin e superoxide dismutase sod glutathione peroxidase gpx total antioxidant capacity tac and body mass index bmi <sep> serum vitamin e levels <sep> serum zinc levels <sep> mean gpx activity <sep> mean sod activity and tac <sep> antioxidant status <sep> bmi <sep>'], 'punchline_text': ['there was a significant reduction of the mean number of infective episodes and associated morbidity in patients with sickle cell anaemia. <sep>', 'prolonged zinc supplementation resulted in an increase in lymphocyte and granulocyte zinc p  0.0001 and an increase in interleukin-2 production p  0.0001 decreased incidence of documented bacteriologically positive infections p  0.0026 decreased number of hospitalizations and decreased number of vaso-occlusive pain crisis p  0.0001). <sep>', 'the mean height velocity of early-zinc supplemented children was significantly greater than that of normal children p less than 0.01). <sep>', 'after 12 mo the zinc group had significantly greater mean  se increases in height 0.66  <sep>', 'an increase in serum testosterone neutrophil zinc and neutrophil alkaline phosphatase activity ws observed in the zinc-supplemented group in comparison with the group on placebo. <sep>', 'mean gpx activity in group1 2 and 3 decreased significantly p<0.015 p<0.032 and p<0.029 respectively). <sep>'], 'population': ['patients with sickle cell anaemia <sep> sickle cell anemia <sep> 145 patients were recruited in the trial while 130 completed it <sep>', 'patients with scd <sep> sickle cell disease scd <sep> 32 scd subjects <sep> adult sickle-cell disease scd patients <sep>', 'patients who received delayed zinc retardation <sep> 32 patients with beta-thalassemia major <sep>', 'children with sickle cell disease scd <sep> forty-two prepubertal children 20 girls and 22 boys aged 4-10 y with scd-ss <sep> children with sickle cell disease <sep> children with scd <sep> thirty-eight children completed the study <sep> prepubertal children with scd-ss <sep>', 'adult male sickle cell anemia subjects <sep> adult male patients with sickle cell anemia <sep> adult male subjects with sickle cell anemia <sep>', 'beta-thalassemic major patients <sep> beta thalassemia major patients <sep> 120 beta thalassemic patients older than 18 years <sep>'], 'interventions': ['zinc therapy <sep> placebo <sep> zinc sulphate capsules <sep>', 'placebo <sep> zinc supplementation <sep> prolonged zinc supplementation <sep> zinc acetate <sep>', 'conventional transfusion therapy <sep> zinc supplementation <sep> oral zinc sulphate <sep>', 'zinc supplementation <sep> 10 mg elemental zn/d in cherry syrup zinc group or cherry syrup alone control group <sep>', 'placebo <sep> zinc supplementation <sep> oral zinc supplementation <sep>', 'zinc 50mg/day and vitamin e <sep> zinc and vitamin e supplementation <sep> vitamin e and zinc supplementation <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}","according to the results there is no evidence from randomised controlled trials to indicate any benefit of zinc supplementation with regards to serum zinc level in patients with thalassaemia. however height velocity was noted to increase among those who received this intervention. there is mixed evidence on the benefit of using zinc supplementation in people with sickle cell disease. for instance there is evidence that zinc supplementation for one year increased the serum zinc levels in patients with sickle cell disease. however though serum zinc level was raised in patients receiving zinc supplementation haemoglobin level and anthropometry measurements were not significantly different between groups. evidence of benefit is seen with the reduction in the number of sickle cell crises among sickle cell patients who received one year of zinc sulphate supplementation and with the reduction in the total number of clinical infections among sickle cell patients who received zinc supplementation for both three months and for one year. the conclusion is based on the data from a small group of trials,which were generally of good quality with a low risk of bias. the authors recommend that more trials on zinc supplementation in thalassaemia and sickle cell disease be conducted given that the literature has shown the benefits of zinc in these types of diseases."
83,"{'outcomes': ['ginseng therapy elevated mood improved psychophysical performance and reduced fasting blood glucose fbg and body weight <sep> body weight <sep> psychophysical tests and measurements of glucose balance serum lipids aminoterminalpropeptide piiinp concentration and body weight <sep> glycated hemoglobin serum piiinp and physical activity <sep> serum lipid profile <sep>', 'glucose and hemoglobin a1c hba1c levels and symptom distress qol and health economic indicators by questionnaires and diaries <sep> absenteeism <sep> general perceived health <sep> overall visual analog scale vas <sep> subscales of acuity <sep> sleep <sep> health economic benefits and quality of life <sep> vas emotional health <sep> disorientation and detachment <sep> quality-of-life treatment differences sd units for symptom distress <sep> mean se hba1c and fasting blood glucose levels <sep> general health <sep> vitality <sep> cognitive functioning <sep> depression <sep> productive capacity <sep>'], 'punchline_text': ['ginseng therapy elevated mood improved psychophysical performance and reduced fasting blood glucose fbg and body weight. <sep>', 'quality-of-life treatment differences sd units for symptom distress 0.59 p<.001 general perceived health 0.36 p .004 cognitive functioning 0.34 p=.005 and the overall visual analog scale vas 0.24 p=.04 were significantly more favorable for active therapy. <sep>'], 'population': ['non-insulin-dependent diabetic patients <sep> newly diagnosed non-insulin-dependent diabetes mellitus niddm patients <sep> 36 niddm patients <sep>', 'patients with type 2 diabetes mellitus <sep> type 2 diabetes mellitus dm <sep> patients with diabetes <sep> 569 male and female volunteers with type 2 dm <sep>'], 'interventions': ['ginseng <sep> ginseng therapy <sep> placebo <sep> placebo <sep>', 'glycemic control <sep> placebo <sep> active therapy glipizide gits vs placebo <sep> diet and titration with either 5 to 20 mg of glipizide gastrointestinal therapeutic system gits <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>']}",there is no convincing evidence relating type or intensity of diabetic treatment to the prevention or management of cognitive impairment in type ii diabetes. future research on treatments for diabetes should include standardized assessments of cognitive function as outcome measures.
84,"{'outcomes': ['self-monitored glucose levels <sep> change in self-monitored glucose levels and insulin area under the curve <sep> fasting serum glucose and insulin <sep>', 'fasting glucose insulin serum lipids and lipoproteins or resting blood pressure <sep> glycemic control <sep> body weight <sep> glycemic control and body composition <sep> lean body mass lbm <sep>', 'brs hrv and hemodynamics <sep> cardiac index systemic vascular resistance index stroke index and pulse wave velocity <sep> muscle strength and glycemic control <sep> time or frequency domain measures of hrv or in systemic hemodynamics <sep> vo(2max <sep> brs sensitivity <sep> brs <sep> exercise capacity and muscle strength and improving glucose control <sep> baroreflex sensitivity <sep> baroreflex sensitivity brs and heart rate variability hrv <sep> vo(2max standard time and frequency domain measures of hrv during 24-h recording and brs <sep>', 'submaximal exercise heart rate and rate pressure product <sep> waist:hip ratio <sep> functional capacity lean body mass strength and glycemic control <sep> peak oxygen uptake p<0.05 and exercise test duration p<0.001 increased following training whilst glycated hemoglobin p<0.05 and fasting blood glucose <sep> muscular strength <sep> glycemic control cardiorespiratory fitness muscular strength and body composition <sep> glycemic control and fitness <sep> ventilatory threshold <sep>', 'muscle density <sep> reduced abdominal subcutaneous and visceral at and increased muscle density <sep> glucose disposal by hyperinsulinemic-euglycemic clamp and computed tomography scans of abdominal at and mid-thigh skeletal muscle <sep> subcutaneous at visceral at and muscle density <sep> insulin resistance <sep> glucose infusion rates <sep> improved glucose disposal <sep> insulin sensitivity <sep>', 'cardiovascular risk factors physical fitness systolic blood pressure plasma triglycerides and glycemic control <sep> resting heart rate <sep> triglycerides <sep> vo2max <sep> glycosylated hemoglobin <sep> risk for coronary artery disease <sep> resting systolic blood pressure <sep> coronary risk factors <sep> lipids glucose insulin glycosylated hemoglobin and cardiovascular fitness <sep> body weight total and hdl cholesterol glucose and insulin <sep>', 'vo2 peak <sep> abdominal fat distribution glycemic control and insulin sensitivity <sep> abdominal fat and glucose metabolism <sep> body weight <sep> visceral adipose tissue vat <sep> insulin sensitivity <sep> visceral abdominal fat <sep>', 'metabolic control <sep> mean fall in fasting plasma glucose <sep> responses of plasma insulin and c-peptide to oral glucose <sep> glycosylated hemoglobin a1 fell <sep> glucose metabolism <sep> 2 hour plasma glucose in oral glucose tolerance test <sep> physical fitness <sep> increased insulin response <sep>', 'metabolic control <sep> glucose metabolism <sep> plasma levels of triglycerides fructosamine and glycohemoglobin <sep>', 'muscular strength and endurance <sep> percent body fat <sep> fat free mass ffm <sep> glycosylated haemoglobin hba 1c  fasting glucose and insulin glucose and insulin 120 minutes 2h after a 75 g oral glucose load body composition and muscular strength and endurance <sep> fat mass fm <sep> glycaemic control and lowers fasting insulin levels <sep> glycaemic control <sep> fasting glucose and hba 1c <sep> 2-h glucose and insulin <sep> fasting glucose and insulin <sep>', 'beta-cell response <sep> insulin sensitivity and hb a(1c concentration <sep> beta-cell function <sep> insulin sensitivity and hb a(1c levels <sep> vo(2 max <sep> beta-cell responses <sep> insulin sensitivity <sep> heart rate <sep>'], 'punchline_text': ['significant reductions from baseline values were observed in both the glucose 213 mmol l-1 per 120 min p  0.05 and insulin 6130 pmol l-1 per 120 min p  0.05 area under the curve following cwt relative to controls. <sep>', 'high-intensity progressive resistance training in combination with moderate weight loss was effective in improving glycemic control in older patients with type 2 diabetes. <sep>', 'significant improvements in vo(2max exercise group 2.3 ml x kg(-1 <sep>', 'concurrently peak oxygen uptake p<0.05 and exercise test duration p<0.001 increased following training whilst glycated hemoglobin p<0.05 and fasting blood glucose p<0.05 decreased. <sep>', 'glucose infusion rates increased significantly p  0.05 in the ae+rt group. <sep>', 'body weight total and hdl cholesterol glucose and insulin did not change in either group. <sep>', 'physical training significantly decreased abdominal fat evaluated by magnetic resonance imaging umbilicus with a greater loss of visceral adipose tissue vat 48 in comparison with the loss of subcutaneous adipose tissue 18 but did not significantly affect body weight. <sep>', 'in the exercise group glycosylated hemoglobin a1 fell from 9.6-8.6 p less than 0.01 and the 2 hour plasma glucose in oral glucose tolerance test decreased from 19.7-16.5 mmol/l p less than 0.01). <sep>', 'at the end of the study the exercise group had a significant reduction in plasma levels of triglycerides fructosamine and glycohemoglobin. <sep>', 'in the rt group fasting glucose and insulin decreased with training p  0.05 and decreases in hba 1c approached significance p  0.057). <sep>', 'during the 3 mo of sedentary lifestyle insulin and c-peptide responses to the clamp procedures were unchanged in both moderate and low secretors. <sep>'], 'population': ['twenty-one subjects completed the study cwt n  11 control n  10 <sep> twenty-seven untrained sedentary subjects mean age 51 with niddm participated <sep>', 'sedentary overweight men and women with type 2 diabetes aged 60-80 years n  36 <sep> older patients with type 2 diabetes <sep>', 'type 2 diabetes subjects <sep> subjects 50 men mean age 53.3 <sep> type 2 diabetes patients <sep> 5.1 years with type 2 diabetes <sep> type 2 diabetes <sep> patients with type 2 diabetes <sep>', '16 subjects age 52 <sep> subjects with type 2 diabetes <sep> type 2 diabetes <sep> 2 years with type 2 diabetes <sep>', '28 obese postmenopausal women with type 2 diabetes <sep> postmenopausal women with type 2 diabetes <sep> women with type 2 diabetes <sep>', 'type ii diabetes <sep> patients with non-insulin-dependent diabetes <sep> nine women and seven men mean age 56 <sep>', 'patients with niddm <sep> twenty-four patients ages 45 <sep>', 'patients with mild and moderate non-insulin-dependent diabetes <sep> type 2 diabetic patients <sep> non-insulin-dependent diabetes were studied in 25 patients divided randomly into exercise n  13 and control n  12 groups <sep>', 'uncontrolled elderly patients with non-insulin-dependent diabetes mellitus <sep> forty patients aged 56.6 <sep> niddm patients <sep>', 'obese type 2 diabetic men <sep> eighteen subjects <sep> obese type 2 diabetics <sep> obese type 2 diabetic men <sep>', 'healthy young subjects <sep> patients stratified into moderate and low secretors according to individual c-peptide responses to an intravenous glucagon test <sep> type 2 diabetic patients <sep> type 2 diabetes <sep>'], 'interventions': ['short-term circuit weight training cwt <sep> no formal exercise control <sep> short-term circuit weight training program <sep>', 'high-intensity resistance training <sep> high-intensity progressive resistance training <sep> high-intensity progressive resistance training combined with moderate weight loss <sep> muscular strength and lbm identify high-intensity resistance training <sep> high-intensity progressive resistance training plus moderate weight loss rt  wl group or moderate weight loss plus a control program wl group <sep>', 'exercise training <sep> exercise training <sep> conventional treatment only or an exercise group in which they received conventional treatment together with heart rate-controlled endurance training twice a week and supervised muscle strength training <sep>', 'circuit training ct program combining aerobic and resistance exercise <sep> combined aerobic and resistance exercise <sep> ct <sep>', 'aerobic training alone <sep> aerobic plus resistance training ae+rt <sep> control aerobic only training <sep> resistance training to aerobic training <sep> combined resistance and aerobic training program <sep> ae+rt training <sep>', 'exercise training <sep> supervised exercise sessions consisted of 40-45 minutes of walking and/or slow jogging <sep> low-intensity aerobic exercise <sep>', 'intense physical training program <sep> physical training consisted of a supervised 45-min cycling exercise <sep> branched-chain amino acid bcaa supplements <sep> training plus bcaa supplement <sep> training plus placebo <sep> bcaa supplementation <sep> sedentary plus bcaa supplement n  6 and sedentary plus placebo <sep> physical training <sep> branched-chain amino acid supplements <sep>', 'physical exercise <sep> long-term physical exercise <sep>', 'moderate exercise <sep> moderate exercise training <sep>', '10-week rt program or a non-training control group c <sep> rt <sep> resistance training <sep> moderate intensity resistance training rt <sep>', 'physical training <sep> arginine <sep> training program ergometer cycling 30-40 min/day including at least 20 min at 75 maximum oxygen consumption vo(2 max <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>']}",the meta-analysis shows that exercise significantly improves glycaemic control and reduces visceral adipose tissue and plasma triglycerides but not plasma cholesterol in people with type 2 diabetes even without weight loss.
85,"{'outcomes': ['peripheral edema <sep> segmental valve preservation <sep>', 'minor bleeding and slight rise in temperature <sep> significant thrombolysis <sep> blood transfusions <sep> major bleeding <sep>', 'clinical symptoms of post-thrombotic syndrome <sep> complete lysis <sep> serious post-thrombotic changes <sep>', 'signs or symptoms of venous insufficiency <sep> average size of the thrombi <sep> venographic severity <sep> deep venous insufficiency <sep> initial thrombi <sep>', 'mean change in venographic score <sep>', 'major bleeding and pulmonary emboli <sep> pulmonary emboli <sep> number of closed vein segments <sep> postthrombotic syndrome <sep> rates of complete recanalization <sep> short and long-term efficacy <sep> number of closed vein segments and the occurrence of postthrombotic syndrome <sep> major bleeding complications <sep>', 'clot lysis and deep venous reflux <sep> venous reflux <sep> patency rate <sep>', 'plasma fibrinogen concentration <sep> symptoms of the postphlebitic syndrome <sep>', 'lysis rate <sep> risk of bleeding <sep> clot lysis <sep> nonfatal intracranial hemorrhage <sep> no lysis <sep> level of serum glutamic oxaloacetic transaminase <sep> efficacy and safety <sep>', 'overt bleeding <sep> degree of thrombosis evaluated phlebographically <sep>'], 'punchline_text': ['vein recanalization without preservation of valves occurred in 18 patients 8 54 of those on streptokinase and 10 83 of those on heparin. <sep>', 'using the chi2-test for overall association this difference was statistically highly significant p  0.002). <sep>', 'at follow-up examination after 12 months there were serious post-thrombotic changes in 14 of 22 patients in the rt-pa group in 9 of 22 patients in the urokinase group and in 15 of 22 patients in the group of patients who received no lysis treatment. <sep>', 'signs or symptoms of venous insufficiency were found in 37 and foot volumetry showed deep venous insufficiency in 26 of the cases. <sep>', 'bleeding complications classified as major were noted in 8/25 patients receiving the combined treatment. <sep>', 'systemic thrombolytic treatment for acute dvt achieved a significantly better short and long-term clinical outcome than conventional heparin/anticoagulation therapy but at the expense of a serious increase in major bleeding and pulmonary emboli. <sep>', 'in the short-term patients treated with catheter directed thrombolysis obtained better patency and competence than those treated with standard anticoagulation. <sep>', 'the 4-h infusion of rt-pa produced a 40 percent reduction and the 8-h infusion an 11 percent reduction in plasma fibrinogen concentration. <sep>', 'at 7 to 10 days after initiation of treatment the level of serum glutamic oxaloacetic transaminase nearly doubled among all patients including those assigned to receive heparin alone. <sep>', 'we found no superiority in the regimen consisting of urokinase preceding heparin infusion compared with that of heparin infusion alone. <sep>'], 'population': ['twenty-seven patients with deep vein thrombosis whose primary therapy <sep> all patients with complete or partial valve preservation became asymptomatic <sep>', 'deep vein thrombosis <sep> 42 medical patients with a history of deep vein thrombosis of less than five days <sep> only patients with extensive thromboses <sep> patients with acute deep vein thrombosis with proximal extension of the thrombus beyond the calf veins <sep>', 'patients benefited from locoregional lysis treatment of recent deep leg vein thrombosis after 1 year <sep> 69 patients aged between 22 and 58 years in whom recent lower leg vein and popliteal vein thromboses were diagnosed by phlebography <sep>', 'thirty-six patients with symptomatic cvt verified by venography <sep>', 'deep vein thrombosis of the lower extremities and/or pelvis <sep> patients with symptoms of deep vein thrombosis for less than 10 days <sep>', '250 patients averaging 40 years of age with acute dvt <sep> 12 patients receiving thrombolysis 9 systemic 3 local suffered <sep> deep venous thrombosis <sep> patients with leg or pelvic deep venous thrombosis dvt <sep>', 'patients with iliofemoral dvt <sep> 35 eligible patients <sep>', 'acute proximal deep vein thrombosis in 83 patients <sep>', 'proximal deep venous thrombosis <sep> venographically documented proximal deep venous thrombosis dvt of the leg <sep>', 'twenty patients with clinical signs of deep vein thrombosis of a duration not exceeding 72 hours and with the condition confirmed phlebographically <sep> patients with deep vein thrombosis <sep>'], 'interventions': ['streptokinase and heparin <sep> heparin <sep> streptokinase or heparin <sep>', 'streptokinase and heparin <sep> heparin <sep> streptokinase <sep> heparin <sep> streptokinase or heparin <sep> streptokinase <sep>', 'thrombolysis treatment with rt-pa and urokinase <sep> recombinant tissue plasminogen activator rt-pa <sep> full heparinization and daily dose of 20 mg rt-pa administered locoregionally over a period of 4 hours a second group received 100,000 iu/h urokinase locoregionally <sep> urokinase <sep> heparin infusions <sep> compression treatment <sep>', 'calf vein thrombosis cvt <sep> heparin or low-dose streptokinase sk combined with low-dose heparin <sep> heparin or low-dose streptokinase <sep>', 'systemic rt-pa administration <sep> placebo <sep> heparin <sep>', 'compression treatment with four groups also administered locoregional tissue plasminogen activator 20 mg/day or urokinase 100,000 iu/day or systemic streptokinase <sep> thrombolytic therapy regimens <sep> full heparinization <sep> conventional heparin/anticoagulation therapy <sep> anticoagulation and compression treatment <sep> urokinase <sep>', 'thrombolysis vs anticoagulation <sep> catheter directed thrombolysis followed by anticoagulation or to anticoagulation alone <sep> catheter directed thrombolysis <sep>', 'kg rt-pa plus heparin <sep> tissue plasminogen activator rt-pa <sep> heparin <sep> recombinant tissue plasminogen activator rt-pa plus heparin vs heparin alone <sep> placebo plus heparin <sep>', 'rt-pa plus heparin <sep> recombinant human tissue-type plasminogen activator rt-pa <sep> tissue plasminogen activator <sep> heparin <sep> heparin and warfarin <sep> heparin alone or rt-pa plus heparin <sep> heparin alone <sep>', 'heparin infusion alone <sep> urokinase preceding heparin <sep> urokinase or heparin <sep> heparin <sep> urokinase <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",thrombolysis appears to offer advantages in terms of reducing post-thrombotic syndrome and maintaining venous patency after dvt. use of strict eligibility criteria has improved the safety and acceptability of this treatment. the optimum drug dose and route of administration have yet to be determined.
86,"{'outcomes': ['incidence of dvt <sep> bleeding or other complications <sep> deep venous thrombosis dvt <sep> dvt <sep>', 'incidence of wound complications <sep> safe operative blood loss <sep> deep venous thrombosis <sep> deep venous thromboses <sep> deep vein thrombosis <sep>', 'bilateral thrombosis <sep> frequency of thrombosis <sep> overall frequency of thrombosis <sep> bleeding and transfusions <sep> frequency of pulmonary perfusion defects <sep> frequency of major thrombosis <sep> postoperative thromboembolic complications <sep> fatal pulmonary embolism <sep> pulmonary embolism <sep> deep vein thrombosis <sep>', 'overall frequency of venous thrombosis <sep> venous thromboembolism <sep>', 'thromboembolic disease <sep> pulmonary embolism and/or deep vein thrombosis <sep> incidence of a venous thromboembolic event <sep> thromboembolic incidence <sep> thromboembolic events <sep> thromboembolic event incidence <sep>', 'deep vein thrombosis <sep> postoperative haemorrhagic complications <sep>', 'incidence of pulmonary embolism <sep> deep vein thromboses <sep> wound hematoma or infection rate <sep>', 'haemorrhagic complications <sep> pulmonary embolism <sep> rate of venous thrombosis <sep> mortality <sep> deep vein thrombosis <sep> pulmonary embolism and venous thrombosis <sep>', 'haemorrhagic complications and blood loss indices <sep> efficacy and safety <sep> venographycally proven deep vein thrombosis dvt <sep>', 'incidence of thromboembolism <sep>', 'mortality <sep> antithrombotic efficacy <sep>', 'bleeding complications or transfusion requirements <sep> thromboembolic event <sep> incidence of observed bleeding complications <sep> mean blood transfusions <sep>', 'deep-vein thrombosis <sep>', 'distal and proximal thrombosis <sep> deep vein thrombosis <sep> efficacy and safety <sep> major hemorrhagic complication <sep>', 'incidence of dvt <sep> overall incidence of dvt <sep> thigh dvts <sep> absence of propagation or tail formation <sep> deep venous thrombosis dvt <sep> occurrence of dvts <sep> deep vein thrombosis <sep>', 'efficacy or safety <sep> frequency of deep vein thrombosis in blood loss or bleeding complications <sep>', 'frequency of postoperative deep-vein thrombosis <sep>', 'protection against postoperative deep vein thrombosis <sep>', 'frequency of deep-vein thrombosis <sep>', 'incidence of p. e <sep> venous thromboembolism <sep>'], 'punchline_text': ['there were no differences in bleeding or other complications in the two groups. <sep>', 'the heparin regime was safe operative blood loss was not increased nor was there an increased incidence of wound complications as compared to the placebo group. <sep>', 'deep vein thrombosis was diagnosed in both groups with the 125i-fibrinogen test and pulmonary perfusion defects in the arthroplasty group with a combination of pulmonary x-ray and perfusion scintigraphy. <sep>', 'low-dose heparin reduced the overall frequency of venous thrombosis and its extent as judged by the frequency of bilaterally abnormal scans but this reduction did not achieve statistical significance. <sep>', 'the incidence of a venous thromboembolic event in the control group was 11 and in the experimental group 4%. <sep>', 'postoperative haemorrhagic complications were seen in 6.1 in the group of standard-heparin and in 8 in the group of low-molecular-heparin. <sep>', 'there was no difference in the wound hematoma or infection rate. <sep>', 'mortality did not differ between the groups nor did haemorrhagic complications. <sep>', 'five patients in the alfa lmwh group 20 per cent developed venographycally proven deep vein thrombosis dvt versus seven 29 per cent in the ufh group. <sep>', 'sequential treatment was not shown to be better or worse than treatment with enoxaparin but the trends favoured sequential treatment rather than drug treatment alone. <sep>', 'a and b proved to be equally safe but failed to provide any protection against deep-vein thrombosis although b showed a tendency to reduce the incidence. <sep>', 'nineteen 59.4 per cent of thirty-two placebo-treated arthroplasty patients showed evidence of a thromboembolic event in contrast with eight 22.9 per cent of thirty-five heparin-treated patients p less than 0.003). <sep>', 'a deep-vein thrombosis developed in ten patients 19 per cent in the control group and in only one patient 2 per cent in the group that was treated with compression. <sep>', 'distal and proximal thrombosis occurred in 18.3 of patients in group a and in 10.4 in group b. no major hemorrhagic complication was observed except for two hematomas in each group. <sep>', 'there was no statistically significant difference in the incidence of dvt between the control and lmwh groups and the incidence of dvt in elderly chinese patients after hip replacement for a hip fracture is similar to that in other studies in caucasians. <sep>', 'there were no statistically significant differences in the frequency of deep vein thrombosis in blood loss or bleeding complications between the three prophylaxis groups. <sep>', 'dhe does not seem to reduce the incidence of d.v.t. any further in this group of patients. <sep>', 'significant improvement in protection against postoperative deep vein thrombosis assessed by venography was observed in the adjusted group undergoing hip replacement p  0.013 and overall in both groups p  0.017 compared with a conventional fixed dose subcutaneous regimen calcium heparin 5000 units 8-hourly). <sep>', 'this showed that the 0-hypothesis could not be rejected and that consequently no difference in the frequency of deep-vein thrombosis was detected. <sep>', 'there was significantly less d. v. t. in the heparinized group than in the control group p  0.01 and the incidence of p. e. was smaller in the heparinized group 0 and 4 per cent respectively. <sep>'], 'population': ['82 patients in whom hip fracture surgery <sep> hip fracture surgery <sep>', 'patients with a fractured neck of the femur <sep> 50 patients with a fractured neck of the femur <sep>', 'thromboembolism after elective and post-traumatic hip surgery <sep> after hip surgery <sep> patients with hip fracture 77 and patients undergoing elective hip arthroplasty 213 <sep>', 'elderly patients with hip fractures <sep>', 'orthopaedic trauma patients <sep> 304 orthopaedic trauma patients with hip and pelvic fractures <sep> patients with hip fractures <sep>', 'hip fracture <sep> patients with fractures of the proximal end of the femur <sep> patients with hip fracture <sep> 33 patients have been treated with <sep>', 'patients with transcervical and intertrochanteric femoral fractures <sep> one hundred and ten female patients over the age of 60 with intertrochanteric or transcervical fractures <sep>', '90 patients admitted because of hip fracture fulfilled the inclusion criteria and were analyzed for development of pulmonary embolism and deep vein thrombosis 46 patients were included in the low molecular weight heparin lmwh group and 44 in the conventional heparin group <sep> patients with hip fracture <sep>', 'deep-vein thrombosis after hip fractures <sep> forty-nine patients <sep> post-operative venous thromboembolism after hip fractures <sep>', 'hip fractures <sep> two hundred and thirty-eight patients with femoral neck fractures <sep> one hundred and ninety-three patients <sep>', 'hip-fracture patients <sep> one hundred and sixty-one patients were analyzed <sep> two hundred and thirteen patients surgically treated for fractures of the hip <sep>', 'sixty-seven hip-arthroplasty and <sep> fifty-two hip-fracture patients <sep> total hip arthroplasty and surgical repair of hip fractures <sep>', 'patients undergoing operations on the hip for either replacement or fracture <sep>', 'elderly patients with a fracture of the neck of the femur <sep> elderly surgically treated patients <sep> 103 elderly patients with a fracture of the neck of the femur <sep>', 'seventy-eight patients of average age 78 years suffering from an unilateral non-pathological hip fracture underwent <sep> elderly chinese patients <sep>', 'patients undergoing hip fracture surgery <sep> hip fracture surgery <sep> patients with hip fracture <sep> 197 patients were randomised <sep>', '210 patients undergoing nailing of a fractured neck of the femur <sep> patients undergoing post-traumatic hip surgery <sep>', 'deep vein thrombosis in hip surgery <sep> 100 patients undergoing surgery for hip replacement or fractured neck of femur <sep>', 'patients with proximal femoral fractures <sep> proximal femoral fractures <sep> 130 patients endured the trial and the results were registered on a sequential diagram <sep>', 'patients with proximal femur fractures <sep> proximal femoral fractures <sep> 150 patients with proximal femoral fractures <sep> 116 women and 34 men with a mean age of 73 years 38 to 92 <sep>'], 'interventions': ['thromboprophylaxis <sep> new low-molecular-weight heparin fragmin with placebo <sep> placebo <sep> low-molecular-weight heparin fragmin <sep> fragmin <sep>', 'placebo <sep> heparin <sep> calcium heparin <sep> heparin prophylaxis <sep> heparin <sep>', 'heparin <sep> dextran 70 and low-dose heparin <sep> control dextran 70 or low-dose heparin <sep>', 'heparin <sep> heparin dipyridamole aspirin and flurbiprofen <sep> heparin dipyridamole alone and in combination with aspirin <sep> flurbiprofen <sep>', 'pneumatic leg compression devices <sep> pneumatic sequential leg compression devices pslcds <sep> compression alone versus no prophylaxis <sep> pneumatic leg compression devices <sep>', 'standard-heparin and 35 with low-molecular-heparin <sep> lcct <sep> low-molecular-heparin sandoparin <sep> heparin <sep> liquid crystal contact thermography lcct colour coded ultrasound examination and with phlebography <sep> standard-heparin <sep> low-molecular-heparin respectively standard-heparin <sep>', 'heparin <sep>', 'lmwh <sep> low molecular weight heparin <sep> conventional low-dose heparin <sep> conventional heparin <sep>', 'unfractionated heparin <sep> alfa lmwh 7500 anti-xa coagulometric units twice daily or with ufh 5000 iu t.i.d <sep> alfa lmwh <sep> low molecular weight heparin alfa lhwh <sep> unfractionated heparin ufh <sep> low molecular weight heparin alfa lmwh <sep> ufh <sep>', 'flowtron dvt garments in the perioperative period followed by enoxaparin clexane-rhne-poulenc rorer and enoxaparin alone <sep> enoxaparin <sep> sequential mechanical and pharmacological thromboprophylaxis <sep>', 'heparin <sep> low-dose heparin with dihydroergotamine a low-molecular-weight heparin with dihydroergotamine b and placebo c <sep> dihydroergotamine <sep>', 'placebo <sep> low-dose heparin <sep> heparin <sep> heparin <sep> low-dose heparin prophylaxis <sep>', 'cyclic sequential compression <sep>', 'low-molecular weight heparin <sep> enoxaparin <sep> low-mw heparin enoxaparin lovenox <sep>', 'low molecular weight heparin <sep> prophylactic heparin <sep> compression ultrasound and pulsed and colour doppler examination of both legs <sep> low molecular weight heparin lmwh <sep> lmwh <sep> compression ultrasound and doppler imaging <sep>', 'danaparoid enoxaparin and dalteparin <sep> enoxaparin and dalteparin <sep> thromboprophylaxis <sep>', 'low-dose heparin and dihydroergotamine <sep> sodium heparin <sep> heparin <sep> heparin  dhe <sep> heparin  dihydroergotamine 71 patients or saline <sep> dihydroergotamine dhe <sep>', 'heparin prophylaxis <sep> heparin <sep>', 'low-dose heparin <sep> heparin <sep> heparin or placebo <sep>', 'heparin <sep> subcutaneous heparin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",u and lmw heparins protect against lower limb dvt. there is insufficient evidence to confirm either protection against pulmonary embolism or an overall benefit or to distinguish between various applications of heparin. foot and calf pumping devices appear to prevent dvt may protect against pulmonary embolism and reduce mortality but compliance remains a problem. good quality trials of mechanical methods as well as direct comparisons with heparin and low dose aspirin should be considered.
87,"{'outcomes': ['functional outcomes <sep> 5-year biochemical disease-free survival rates <sep> physical examination psa assay and compilation of ipss iief-5 and eortc-qlq-c30/pr25 questionnaires <sep> quality of life aspects <sep> longer lasting rate of urinary irritative disorders and better erective function <sep>'], 'punchline_text': ['with regards to oncological outcomes similar 5-year biochemical disease-free survival rates were reported for rrp 91.0 or bt 91.7%). <sep>'], 'population': ['200 patients studied 174 completed the 5-year follow-up assessment <sep> between may 1999 and october 2002 200 patients mean age 65.3 <sep> low-risk prostatic cancer cap <sep> low-risk prostatic cancer <sep>'], 'interventions': ['radical retropubic prostatectomy versus brachytherapy <sep> radical retropubic prostatectomy rrp versus brachytherapy bt <sep> rrp <sep> bt <sep>'], 'punchline_effect': [' no diff <sep>']}",low-dose rate brachytherapy did not reduce biochemical recurrence-free survival versus radical prostatectomy at 5 years. for short-term severe adverse events low-dose rate brachytherapy was significantly more favorable for urinary incontinence but radical prostatectomy was significantly more favorable for urinary irritation. evidence is based on one rct with high risk of bias.
88,"{'outcomes': ['annual incidence rates of erroneous extraction <sep> cognitive failure <sep> annual incidence of erroneous extraction <sep> incidence of erroneous extraction <sep> incidence of wrong-site tooth extraction <sep>'], 'punchline_text': ['there was a significant difference in the incidence of erroneous extraction between the preintervention and intervention periods p<.01). <sep>'], 'population': ['outpatient department of a university hospital in taiwan <sep>'], 'interventions': ['educational program <sep>'], 'punchline_effect': [' sig decrease <sep>']}",the findings of this review identified one its study for a non-medical procedure conducted in a dental outpatient setting. the study suggested that the use of a specific educational intervention in the above-mentioned context which targets junior dental staff using a training session that included cases of wrong-site surgery presentation of clinical guidelines and feedback by the instructor was associated with a reduction in the incidence of wrong-site tooth extractions. given the nature of the intervention in a very specific population application of these results to a broader population undergoing other forms of surgery or invasive procedures should be undertaken cautiously.
89,"{'outcomes': ['primary patency rate <sep> preoperative risk factors and operative and postoperative treatment <sep>', 'mortality primary assisted patency and secondary patency <sep> cumulative patency rates <sep> secondary patency rates <sep>', 'previous cerebro-vascular events <sep> graft occlusions <sep> overall secondary patency rates <sep> number of patent crural arteries <sep> primary patency rates for huv <sep> long-term graft performance <sep> cumulative primary patency rates <sep> overall cumulative limb salvage <sep>', 'median postoperative ankle-arm blood pressure index <sep> ptfe failure <sep> rest pain ulceration or gangrene <sep> ptfe patency rate <sep> preoperative risk factors and operative and postoperative treatment <sep>', 'hospital mortality <sep> primary patency <sep> history of myocardial infarction <sep> secondary patency <sep>', 'primary 3-year patency for dacron grafts <sep> secondary patency <sep> secondary patency or limb salvage <sep> 3-year secondary patency <sep> limb salvage rate <sep> major amputation <sep> distal gangrene <sep>', 'no perioperative 30 day limb loss or death <sep> primary assisted patency rate <sep> 5-year patency rate <sep> patency rate <sep>', '30-days mortality and complications wound infections <sep> ankle-brachial pressures or imaging in case of doubt <sep> number of patent crural vessels <sep> patency rates for dacron and ptfe <sep> major amputation <sep> mortality rates <sep> secondary patency rates <sep>', 'secondary patency rate for hbd <sep> major limb amputation <sep> died with patent grafts <sep> limb salvage rate <sep> incidence of major limb amputation <sep> patency rates <sep> prosthetic patency <sep> primary patency rate measured with kaplan-meier survival analysis <sep>', 'hospital mortality <sep> history of myocardial infarction <sep> secondary patency <sep>', 'limb salvage <sep> bypass graft patency and limb salvage <sep> patency rates <sep> cumulative 5-year patency rate <sep> cumulative 3-year patency rate <sep>'], 'punchline_text': ['at 6 years the primary patency rate was 38.7 in the ptfe group and 71.4 in the huv group p  0.001). <sep>', 'during prolonged follow-up 10 years dacron femoro-popliteal bypass grafts have superior patency compared to those of eptfe grafts. <sep>', 'there was no difference in long-term graft performance between huv and hbd for above knee infrainguinal bypass. <sep>', 'for umbilical vein the corresponding figures were 74 and 42 p  0.005 gehan test). <sep>', 'during a follow-up period of 2 years we found no statistically significant difference in primary and secondary patency between saphenous vein and polytetrafluoroethylene. <sep>', 'upon multivariate analysis below-knee anastomosis was the principal independent predictor of primary graft failure risk ratio 1.7 c.i. 1.05-2.8 impaired secondary patency was associated with infragenicular bypass risk ratio 3.3 c.i. 1.8-6.3 and distal gangrene risk ratio c.i. 1.01-3.8]p=0.048 major amputation was independently predicted by below-knee bypass tissue necrosis and poor run-off index. <sep>', 'there was no statistically significant difference in primary assisted patency rate for the two grafts 100 98 and 94 for sv grafts and 96 84 and 84 for ptfe grafts p .09 after 1 3 and 5 years respectively. <sep>', 'the two-year primary patency rates for dacron and ptfe were 70 and 57 p=0.02 whereas the secondary patency rates were 76 and 65 p=0.04 respectively. <sep>', 'significantly better patency rates were achieved with hbd than with ptfe at 3 years p  .044 but the difference was no longer statistically significant at 5 years p  .055). <sep>', 'during this follow-up period of 2 years we found no statistically significant difference in primary and secondary patency between saphenous vein and collagen impregnated woven polyester prosthesis. <sep>', 'miller cuffs had no effect on patency rates for femoral to above-knee popliteal bypasses at 5 years and did not improve limb salvage in either group. <sep>'], 'population': ['ninety-six extremities <sep>', 'patients were eligible for inclusion if presenting with disabling claudication rest pain or tissue loss <sep> between 1992 and 1996 228 ak femoro-popliteal bypass grafts <sep>', 'femoro-popliteal bypass <sep> 129 patients between 1996 and 2001 <sep>', 'fifty-five patients <sep> twenty-three limbs had three patent tibial arteries 46 limbs had two tibial arteries 31 limbs had one patent artery and five limbs had isolated popliteal segments <sep> one hundred five patients 105 limbs entered the trial <sep>', 'above-knee femoropopliteal bypass grafting <sep> 136 patients 77 male 59 female <sep>', '203 patients randomised 194 were included in the final analysis 103 dacron grafts and 91 ptfe grafts <sep> femoropopliteal bypass <sep>', 'patients with claudication <sep> between january 1994 and december 1997 51 patients 102 limbs with bilateral disabling claudication due to superficial femoral artery occlusion underwent above-knee femoropopliteal bypass grafting with sv in one limb and ptfe graft in the other limb <sep> patients with claudication who underwent bilateral above-knee femoropopliteal revascularization <sep>', 'age gender indication claudication 65 run-off 2 or 3 vessels 76 diabetes 17 and hypertension 31 as well as cerebrovascular 9 and cardiac 33 risks were evenly distributed <sep> fourteen 3 patients were excluded leaving 413 patients with 208 dacron and 205 ptfe grafts for analysis <sep> 13 centres in denmark n=261 norway n=113  finland n=53 between 1993 and 1998 <sep> 427 patients <sep>', '209 patients 179 above-knee disease 30 below-knee disease <sep>', 'above-knee femoropopliteal bypass grafting <sep> 85 patients 52 male 33 female <sep>', 'two hundred and sixty-one bypass operations <sep> 235 120 with a miller cuff 115 without <sep>'], 'interventions': ['polytetrafluoroethylene ptfe and 6 mm human umbilical vein huv <sep> ptfe <sep> polytetrafluoroethylene versus human umbilical vein <sep>', 'dacron <sep> eptfe <sep> warfarin <sep> dacron n=114 vascular graft <sep> dacron or eptfe <sep> dacron femoro-popliteal bypass grafts <sep> expanded polytetrafluoroethylene eptfe prosthesis and collagen-impregnated knitted polyester dacron <sep>', 'heparin-bonded dacron hbd and human umbilical vein huv vascular prostheses <sep> human umbilical vein versus heparin-bonded polyester <sep> huv and 59 an hbd prosthesis <sep>', 'polytetrafluoroethylene ptfe gore-tex and human umbilical vein biograft arterial grafts were compared for below-knee femoropopliteal bypass grafting <sep> ptfe grafts and 50 to receive human umbilical vein grafts <sep> polytetrafluoroethylene and modified human umbilical vein for below-knee femoropopliteal bypass <sep>', 'polytetrafluoroethylene prosthesis <sep> 151 above-knee femoropopliteal bypass graft operations <sep> polytetrafluoroethylene <sep> vein with polytetrafluoroethylene <sep>', 'dacron vs. polytetrafluoroethylene grafts <sep> ptfe polytetrafluoroethylene and unsealed knitted dacron femoro-popliteal bypasses <sep> ptfe and dacron <sep>', 'sv-ptfe or ptfe-sv <sep> ptfe <sep> polytetrafluoroethylene ptfe <sep> bilateral above-knee femoropopliteal revascularization polytetrafluoroethylene graft versus reversed saphenous vein <sep>', 'polytetrafluorethylene ptfe and polyester grafts dacron <sep> dacron or ptfe <sep> femoropopliteal bypass grafts <sep> dacron <sep>', 'bypass surgery <sep> dacron <sep> polytetrafluoroethylne ptfe <sep> aspirin <sep> heparin-bonded dacron hbd with ptfe <sep> heparin-bonded dacron or polytetrafluorethylene <sep> hbd <sep> ptfe <sep>', 'vein with collagen impregnated woven polyester prosthesis <sep> 103 above-knee femoropopliteal bypass graft operations <sep> collagen impregnated woven polyester prosthesis <sep> saphenous vein and collagen impregnated woven polyester prosthesis <sep>', 'miller vein cuff at the distal anastomosis <sep> femoral to above-knee and femoral to below-knee popliteal artery polytetrafluoroethylene ptfe <sep> distal anastomotic interposition vein cuff <sep> infrainguinal polytetrafluoroethylene bypass grafting <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",there was a clear primary patency benefit for autologous vein when compared to synthetic materials for above knee bypasses. in the long term five years dacron confers a small primary patency benefit over ptfe for above knee bypass. ptfe with a vein cuff improved primary patency when compared to ptfe alone for below knee bypasses. further randomised data is needed to ascertain whether this information translates into improvement in limb survival.
90,"{'outcomes': ['5-year survival rate <sep>', 'complete or partial response <sep> resectability and survival <sep> gastric cancer <sep> resectability rates <sep> median survival since randomisation <sep>', 'disease-free survival <sep> os <sep> curative resection rate <sep> grade 3 to 4 toxicity <sep> overall survival os <sep> stomach tumor localization <sep> curative resection rate disease-free survival and os <sep> postoperative morbidity <sep>', 'survival <sep> survival <sep> median survival <sep>', 'overall survival <sep> progression-free survival <sep> ecf-related adverse effects <sep> rates of postoperative complications <sep> numbers of deaths <sep> year survival rate <sep> progression-free and overall survival <sep> survival <sep>', 'expression rate of fasl <sep> fas/fasl,pd-ecgf and pcna <sep> palliative or radical resection <sep> lymphatic spread <sep> 3-year survival rates <sep> expression rates of fas and fasl <sep> uicc stages <sep> invasion depth <sep> pcna index pi <sep> expression rate of pd-ecgf <sep> frequency of fas expression <sep> apoptotic index ai <sep> patient mean age gender white blood cell count haematoglobin hb),thromboplastin perioperative complication incidence radical or palliation resection invasion depth t lymphonode involvement n),metastasis m and tnm staging <sep>', 'disease-free and overall survival <sep> 5-year survival <sep> survival <sep> survival benefit <sep> survival <sep>', 'progression-free survival nor overall survival <sep> progression-free survival <sep> complete resections with clear margins <sep> progression-free or overall survival <sep> overall survival tumour response toxic effects patterns of failure and quality of life <sep> positive lymph nodes <sep>', 'international union against cancer r0 resection rate <sep> median survival <sep> r0 resection rate <sep> lymph node metastases <sep> postoperative complications <sep> survival benefit <sep>', 'cell degeneration p<0.001 necrosis p<0.01 and the expression of nm23 p<0.001 <sep> survival rate <sep> postoperative 5-year survival rate <sep> intensity of cd44 expression <sep> expressions of nm23 and cd44 <sep> number of tumour emboli <sep>', 'five-year survival <sep> median survival <sep> survival response and patterns of failure of trimodality therapy <sep> tolerated <sep>', 'overall survival <sep> alive and free of disease <sep> type of resection r0 r1 r2 or no resection <sep> disease-free survival relapse pattern <sep> survival <sep> median survival rates <sep>', 'survival <sep> median survival <sep> survival <sep> median survival <sep>'], 'punchline_text': ['the pyrimidine nucleoside phosphorylase pynpase activity in gastric carcinoma tissue from group <sep>', 'with a median follow-up of 83 months the median survival since randomisation is 18 months in the famtx group vs. 30 months in the surgery alone group p=0.17). <sep>', 'perioperative chemotherapy significantly improved the curative resection rate 84 v 73 p  .04). <sep>', 'median survival based on intention-to-treat was 17 months for multimodal therapy vs. 12 months for surgery alone p=0.002). <sep>', 'rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group 46 percent and 45 percent respectively as were the numbers of deaths within 30 days after surgery. <sep>', ""the expression rate of fasl in 5'-dfur group was significantly lower than that in the other two groups chi2=6.708 p=0.035). <sep>"", 'three-year survival by type of resection was r0 42.4 r1 was 18.0 and r2 was 8.6%. <sep>', 'preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone. <sep>', 'the surgery-only group had more lymph node metastases than the neoadjuvant group 76.5 v 61.4 p  .018). <sep>', 'the postoperative 5-year survival rate was 40 in the fplc-treated group and 23 in the controls p=0.17). <sep>', 'patient and tumor characteristics were similar between groups. <sep>', 'the median survival rates for patients with r1 r2 or no resections were not significantly different. <sep>', 'survival at 3 years was 16 in arm i and 30 in arm ii p  .15). <sep>'], 'population': ['patients aged 75 years or less with advanced gastric cancer <sep> gastric cancer <sep> gastric carcinoma tissue from group <sep>', 'patients with proven adenocarcinoma of the stomach <sep> operable gastric cancer <sep> fifty-nine patients were randomised 29 patients <sep>', 'resectable gastroesophageal adenocarcinoma <sep> patients with resectable adenocarcinoma of the lower esophagus gej or stomach perioperative chemotherapy using <sep> 224 patients with resectable adenocarcinoma of the lower esophagus gastroesophageal junction gej or stomach <sep>', 'advanced-stage disease <sep> patients with minimal residual disease <sep> advanced stage esophageal adenocarcinoma <sep>', '149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died <sep> patients with advanced gastric cancer <sep> resectable gastroesophageal cancer <sep> patients with potentially curable gastric cancer <sep> patients with incurable locally advanced or metastatic gastric adenocarcinoma <sep> patients with operable gastric or lower esophageal adenocarcinomas <sep> patients with resectable adenocarcinoma of the stomach esophagogastric junction or lower esophagus to either perioperative chemotherapy and surgery 250 patients or surgery alone 253 patients <sep>', 'fifty-four patients received gastrectomy including 12 palliative resections and 42 radical resections <sep> patients with gastric cancer <sep> sixty gastric cancer patients <sep> six patients were excluded <sep>', 'patients undergoing radical surgery for esophageal cancer <sep> oeo2 recruited 802 patients 400 on cs and 402 on s <sep> operable esophageal cancer <sep> esophageal cancer <sep>', '128 patients <sep> patients with squamous-cell tumours <sep> resectable cancer of the oesophagus <sep> patients with resectable oesophageal cancer <sep>', 'patients with locally advanced gastric cancer benefit from <sep> locally advanced cancer of the stomach and cardia <sep> patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction aeg ii and iii <sep> 144 patients were randomly assigned 72:72 52.8 patients had tumors located in the proximal third of the stomach including aeg type ii and iii <sep>', 'sixty patients with gastric cardia cancer <sep> thirty patients were treated with <sep> patients with gastric cardia cancer <sep>', 'patients with carcinoma of the esophagus or gastroesophageal junction <sep> thirty patients <sep> esophageal cancer calgb 9781 <sep> patients with nonmetastatic esophageal cancer <sep> patients with this disease <sep> fifty-six patients were enrolled between october 1997 and march 2000 when the trial was closed due to poor accrual <sep> four hundred seventy-five eligible patients were planned for enrollment <sep>', 'patients with localized esophageal cancer <sep> two hundred sixteen patients received preoperative chemotherapy 227 underwent immediate surgery <sep> esophageal cancer <sep>', 'before surgery showed a median survival of 29 months in comparison with the 12-month median survival of 100 historical controls treated with surgery alone at the same institution <sep> 43 patients with potentially resectable esophageal carcinoma treated with an intensive regimen of preoperative chemoradiation with <sep> patients with potentially resectable esophageal carcinoma <sep> patients with locoregional esophageal carcinoma <sep> one hundred patients with esophageal carcinoma <sep>'], 'interventions': [""preoperative chemotherapy with 5'-deoxy-5-fluorouridine 5'-dfur <sep> oral 5'-dfur <sep> preoperative chemotherapy <sep> intravenous mmc <sep>"", 'famtx regimen prior to surgery and 30 patients had surgery alone <sep> pre-operative famtx vs. surgery alone <sep> neo-adjuvant chemotherapy <sep> pre-operative chemotherapy <sep> famtx <sep> chemotherapy using 5-fluorouracil doxorubicin and methotrexate famtx prior to surgery or to undergo surgery alone <sep>', 'surgery alone <sep> perioperative fluorouracil plus cisplatin <sep> intravenous cisplatin <sep> perioperative chemotherapy and surgery cs group n  113 or surgery alone <sep> fluorouracil plus cisplatin <sep> perioperative chemotherapy <sep> chemotherapy <sep> fluorouracil <sep>', 'multimodal therapy <sep> neoadjuvant therapy <sep>', 'ecf <sep> perioperative chemotherapy versus surgery alone <sep> epirubicin cisplatin and infused fluorouracil ecf <sep> chemotherapy <sep> intravenous epirubicin <sep> cisplatin <sep> fluorouracil <sep>', ""cf+5-fu <sep> 5-fu  200 mg/d cf by venous drip <sep> 5'-dfur <sep> 5-fu+cf <sep>"", 'surgery with or without preoperative chemotherapy <sep> preoperative chemotherapy <sep> combination cisplatin and fluorouracil before surgery cs <sep>', 'surgery alone and 128 patients to surgery after 80 mg/m(2 cisplatin on day 1 800 mg/m(2 fluorouracil <sep> short preoperative chemoradiotherapy regimen <sep> surgery alone versus chemoradiotherapy <sep> preoperative chemoradiotherapy with cisplatin and fluorouracil <sep> chemoradiotherapy <sep>', 'surgery alone <sep> preoperative chemotherapy followed by surgery or to surgery alone <sep> purely preoperative chemotherapy <sep> combined pre and postoperative chemotherapy <sep> neoadjuvant chemotherapy <sep> postoperative chemotherapy <sep>', 'preoperative fplc chemotherapy <sep> preoperative chemotherapy with fluorouracili polyphase liposome composita pro orale fplc <sep> preoperative fplc chemotherapy <sep> fplc <sep>', 'cisplatin fluorouracil radiotherapy and surgery compared with surgery alone <sep> esophagectomy alone <sep> trimodality therapy <sep> esophagectomy with node dissection alone or cisplatin 100 mg/m(2 and fluorouracil 1,000 mg/m(2)/d for 4 days on weeks 1 and 5 concurrent with radiation therapy 50.4 gy total 1.8 gy/fraction over 5.6 weeks followed by esophagectomy with node dissection <sep> chemoradiotherapy <sep>', 'chemotherapy <sep> r1 resection postoperative chemoradiotherapy therapy <sep> perioperative chemotherapy <sep> chemotherapy plus surgery versus surgery alone <sep> preoperative cisplatin plus fluorouracil <sep> r0 resection <sep>', 'preoperative chemoradiation versus surgery alone <sep> transhiatal esophagectomy with a cervical esophagogastric anastomosis <sep> radiotherapy <sep> fluorouracil 300 mg/m2/d on days 1 through 21 and vinblastine <sep> cisplatin fluorouracil and vinblastine <sep> preoperative chemoradiation regimen versus surgery alone <sep> surgery alone arm i or preoperative chemoradiation arm ii with cisplatin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",perioperative chemotherapy for resectable gastroesophageal adenocarcinoma increases survival compared to surgery alone. it should thus be offered to all eligible patients. there is a trend to a larger survival advantage for tumors of the ge junction as compared to other sites and for chemoradiotherapy as compared to chemotherapy in esophageal and ge junction tumors. likewise there is an interaction between age and treatment effect with younger patients having a larger survival advantage and no survival advantage for elderly patients.
91,"{'outcomes': ['delivery before 37 weeks of gestation <sep> preterm delivery resulting from spontaneous preterm labor <sep> delivery <sep>'], 'punchline_text': ['between randomization and follow-up trichomoniasis resolved in 249 of 269 women for whom follow-up cultures were available in the metronidazole group 92.6 percent and 92 of 260 women with follow-up cultures in the placebo group 35.4 percent). <sep>'], 'population': ['315 women in the metronidazole group and 289 women in the placebo group <sep> pregnant women with asymptomatic trichomonas vaginalis infection <sep> 617 women with asymptomatic trichomoniasis who were 16 to 23 weeks pregnant <sep> asymptomatic pregnant women <sep> screened pregnant women for trichomoniasis by culture of vaginal secretions <sep> pregnant women with asymptomatic trichomoniasis <sep> pregnant women <sep>'], 'interventions': ['placebo <sep> metronidazole <sep>'], 'punchline_effect': [' no diff <sep>']}",metronidazole given as a single dose is likely to provide parasitological cure for trichomoniasis but it is not known whether this treatment will have any effect on pregnancy outcomes. the cure rate could probably be higher if more partners used the treatment.
92,"{'outcomes': [""prolonged time to first exacerbation <sep> mean prebronchodilator forced expiratory volume <sep> prebronchodilator peak expiratory flow <sep> fev1 <sep> exacerbations <sep> postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire sgrq <sep>"", 'lung function measurements symptoms and rescue treatment use the number of exacerbations patient withdrawals and disease-specific health status <sep> pretreatment fev1 <sep> lung function and health status <sep> health status <sep> daily symptoms <sep> pretreatment forced expiratory volume in 1s fev1 <sep> adverse events serum cortisol concentrations skin bruising and electrocardiograms <sep> lung function symptoms and health status and reduced use of rescue medication and frequency of exacerbations <sep> frequency of adverse events bruising or clinically significant falls in serum cortisol concentration <sep>', '2-hour postdose fev(1 <sep> transition dyspnea index <sep> predose fev(1 <sep> adverse effects <sep> lung function <sep> severity of dyspnea <sep>', 'average daily morning pef <sep> 2-h postdose fev(1 <sep> adverse effects <sep> morning predose ie trough fev(1 for fsc compared with sm and 2-h postdose fev(1 <sep> morning predose fev(1 <sep> dyspnea quality of life and symptoms of chronic bronchitis <sep> morning lung function <sep> lung function <sep> efficacy and safety <sep> morning peak expiratory flow rate pef transition dyspnea index chronic respiratory disease questionnaire chronic bronchitis symptom questionnaire exacerbations <sep>', ""efficacy <sep> number of exacerbations resulting in hospitalization <sep> incidence of individual non-fatal serious adverse events <sep> dyspnoea measured using the breathlessness diary and health-related quality-of-life hr-qol scores based on the st george's respiratory questionnaire total score <sep> efficacy and safety <sep> efficacy for pulmonary function <sep> dyspnoea scores and hr-qol <sep> incidence of pneumonia <sep> tolerated <sep> tolerated relative <sep> efficacy and tolerability <sep> pre-dose forced expiratory volume in 1 second fev(1 and 1-hour post-dose fev(1 <sep>"", 'symptom scores and use of reliever beta2-agonists <sep> efficacy and safety <sep> mean number of severe exacerbations <sep> fev1 <sep> severe exacerbations and fev1 primary variables peak expiratory flow pef copd symptoms health-related quality of life hrql mild exacerbations use of reliever beta2-agonist and safety variables <sep> tolerated <sep> morning pef <sep> efficacy and safety <sep>'], 'punchline_text': [""postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire sgrq by 4.5 units after run-in. <sep>"", 'combination therapy improved pretreatment fev1 significantly more than did placebo treatment difference 133 ml 95 ci 105-161 p<0.0001 salmeterol 73 ml 46-101 p<0.0001 or fluticasone alone 95 ml 67-122 p<0.0001). <sep>', 'the incidence of adverse effects except for an increase in oral candidiasis with fsc and f was similar among the treatment groups. <sep>', 'the incidence of adverse effects except for an increase in oral candidiasis with fsc and fp were similar among the treatment groups. <sep>', 'dyspnoea scores and hr-qol were significantly improved with both budesonide/formoterol pmdi dosage strengths versus both monocomponents and placebo. <sep>', 'morning pef improved significantly on day 1 versus placebo and budesonide after 1 week morning pef was improved versus placebo budesonide and formoterol. <sep>'], 'population': ['chronic obstructive pulmonary disease <sep> chronic obstructive pulmonary disease copd <sep>', 'chronic obstructive pulmonary disease <sep> patients with copd <sep> 1465 patients with copd were recruited from outpatient departments in 25 countries <sep> symptomatic chronic obstructive pulmonary disease copd <sep>', 'chronic obstructive pulmonary disease <sep> chronic obstructive pulmonary disease copd <sep> 691 patients with copd <sep>', 'seventy-six investigative sites in the united states <sep> patients with copd <sep> seven hundred twenty-three patients  or 40 years of age with copd and a mean baseline fev(1 of 42 predicted <sep>', 'patients with chronic obstructive pulmonary disease copd who have frequent exacerbations <sep> patients with copd <sep> 1704 patients aged  or 40 years with moderate to very severe copd conducted in 194 centres in the us czech republic the netherlands poland and south africa <sep> patients with moderate to very severe chronic obstructive pulmonary disease <sep>', 'patients with moderate-to-severe chronic obstructive pulmonary disease copd <sep> chronic obstructive pulmonary disease <sep> 812 adults mean age 64 yrs mean forced expiratory volume in one second fev1 36 predicted normal <sep> moderate-to-severe chronic obstructive pulmonary disease <sep>'], 'interventions': ['oral prednisolone <sep> budesonide and formoterol <sep> formoterol <sep> placebo <sep> inhaled budesonide/formoterol 320/9 microg budesonide 400 microg formoterol 9 microg or placebo <sep> budesonide formoterol or placebo <sep> budesonide/formoterol <sep> budesonide/formoterol <sep> monocomponent <sep>', 'combined salmeterol and fluticasone <sep> placebo <sep> fluticasone <sep> inhaled long-acting beta2 agonists <sep> salmeterol <sep> salmeterol and 500 microg fluticasone <sep>', 'placebo <sep> fluticasone propionate and salmeterol combination delivered via the diskus device <sep> combination of f and s fsc s 50 mcg f 500 mcg or placebo <sep> fsc <sep> inhaled corticosteroid fluticasone propionate f with an inhaled long-acting beta(2)-agonist salmeterol s <sep>', 'sm <sep> placebo <sep> fp <sep> fsc fp <sep> inhaled corticosteroid fluticasone propionate fp and the inhaled long-acting beta(2)-agonist salmeterol sm <sep> placebo fsc <sep> fluticasone propionate <sep>', 'budesonide pmdi <sep> budesonide and formoterol <sep> placebo <sep> formoterol <sep> formoterol dpi 4.5 microg x two inhalations 9 microg or placebo <sep> previous therapy icss and short-acting bronchodilators <sep> budesonide/formoterol <sep> budesonide/formoterol <sep> inhaled corticosteroid ics <sep> budesonide formoterol and placebo <sep> oral corticosteroids <sep> budesonide <sep> budesonide/formoterol pmdi <sep> hydrofluoroalkane pressurized metered-dose inhaler pmdi <sep> budesonide/formoterol dry powder inhaler dpi <sep> budesonide/formoterol pmdi <sep> budesonide pmdi <sep>', 'placebo <sep> placebo budesonide and formoterol <sep> budesonide/formoterol <sep> budesonide <sep> placebo and budesonide <sep> budesonide/formoterol symbicort 160/4.5 microg delivered dose budesonide 200 microg metered dose formoterol 4.5 microg or placebo <sep> budesonide/formoterol <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",placebo-controlled trials have established the benefits of both long-acting beta-agonist and inhaled corticosteroid therapy for copd patients as individual therapies. this review which included trials allowing comparisons between laba and ics has shown that the two therapies confer similar benefits across the majority of outcomes including the frequency of exacerbations and mortality. use of long-acting beta-agonists appears to confer a small additional benefit in terms of improvements in lung function compared to inhaled corticosteroids. on the other hand inhaled corticosteroid therapy shows a small advantage over long-acting beta-agonist therapy in terms of health-related quality of life but inhaled corticosteroids also increase the risk of pneumonia. this review supports current guidelines advocating long-acting beta-agonists as frontline therapy for copd with regular inhaled corticosteroid therapy as an adjunct in patients experiencing frequent exacerbations.
93,"{'outcomes': ['geometric mean titer of antibodies <sep> detectable elisa anti-hav antibodies <sep>', 'symptomatic infection <sep>', 'incidence rates <sep>', 'quantitative anti-hav response <sep> safety tolerability and immunogenicity <sep> ria seropositivity in ihav vaccines <sep> safety tolerability and immunogenicity <sep> anti-hav seroconversion <sep> anti-hav seroconversion <sep>'], 'punchline_text': ['several weeks after each vaccine dose the geometric mean titer of antibodies was significantly lower in those who received vaccine with ig but higher than in those who received ig alone. <sep>', 'symptomatic infection with hepatitis a virus was confirmed in 25 contacts receiving vaccine 4.4 and in 17 contacts receiving immune globulin 3.3 relative risk 1.35 95 confidence interval 0.70 to 2.67). <sep>', 'the incidence rates were zero in group a 1.31/1000 in group b 0.61/1000 among the immunized and 1.72/1000 among the non-immunized and 2.49/1000 in group c over the 6-month follow-up. pre-exposure isg afforded excellent protection and even at the low rate of incidence was cost-effective. <sep>', 'administration of a booster dose given 1 or 2 months after primary immunization did not significantly improve the quantitative anti-hav response at 6 months as compared to the effect of the primary dose.(abstract truncated at 250 words <sep>'], 'population': ['healthy volunteers 28 received <sep>', 'of 4524 contacts who underwent randomization 1414 31 were susceptible to hepatitis a virus and 1090 were eligible for the per-protocol analysis <sep>', 'indigenous population in whom approximately 70 have antibody to hav at age 18 <sep>', '75 healthy volunteers aged 18-50 years <sep> 15 volunteers who received 25 units ihav i.m. at 0 and 24 weeks <sep> adults <sep>'], 'interventions': ['hepatitis b vaccine and a fourth group received ig alone <sep> vaccine alone <sep> inactivated hepatitis a virus hav vaccine <sep> hav vaccine <sep> vaccine with ig <sep> inactivated hepatitis a vaccine administered concomitantly with immune globulin <sep>', 'kazakhstan to receive one standard age-appropriate dose of hepatitis a vaccine or immune globulin <sep> hepatitis a vaccine <sep> vaccine <sep> immune globulin <sep>', 'immune serum globulin isg <sep> isg <sep> immune serum globulin <sep>', 'inactivated hepatitis a virus vaccine ihav <sep> ihav <sep> pre and post-exposure prophylaxis with immune globulin ig <sep> immune globulin <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",immunoglobulins seem to be effective for pre-exposure and post-exposure prophylaxis of hepatitis a. however caution is warranted for the positive findings due to the limited number of trials year of conductance and risk of bias. conductance of rigorous trials will be justifiable.
94,"{'outcomes': ['hba1c testing rates <sep> glycosylated hemoglobin hba1c measurements <sep>', 'end-stage renal disease esrd <sep> facility-specific mean urea reduction ratio urr <sep> proportions of patients dialyzed with prescribed blood flow <sep> time on dialysis <sep> mean center urr <sep>', 'health care quality <sep>', 'quality or safety of diabetes care and worsened a1c control <sep> time to next visit <sep> a1c test ordering <sep> safety or quality of diabetes care <sep> ldl cholesterol test ordering <sep> risky prescribing events <sep> ldl cholesterol values <sep> a1c values <sep>', 'mammography rates <sep> rates of delivery of selected preventive services <sep>', 'number of targeted tests requested by primary-care practices <sep>', 'hemoglobin a1c testing <sep> hemoglobin a1c and lipid monitoring and the achievement of intermediate clinical outcomes hemoglobin a1c 7.0 ldl cholesterol 100 mg/dl and blood pressure <sep> ldl testing <sep> diabetes care processes <sep>', 'length of in-hospital stay physician visits after discharge waiting times for invasive cardiac procedures and readmissions for cardiac complications <sep> adjusted mortality <sep> proportion of elderly survivors of ami <sep> adjusted prescription rates <sep>', 'quality <sep> quality assurance intervention quality of performance <sep> task performance <sep>', 'composite ami and chf indicators based on 12 ami and 6 chf process-of-care indicators <sep> mean 30-day ami mortality rates <sep> individual process-of-care indicators a hospital report card impact survey and all-cause ami and chf mortality <sep> quality of cardiac care <sep> hospital mortality rates for chf <sep>', 'overall chlamydia testing odds ratio or <sep> chlamydia screening <sep> post-intervention chlamydia testing rates <sep>', 'malaria diarrhoea and pneumonia <sep> malaria and diarrhoea <sep>', 'rate of adherence <sep>', 'efficacy of qcs <sep> asthma steps <sep> emergency visits <sep> reduced emergency visits <sep> quality circles qcs <sep> unscheduled emergency visits <sep> delivery of individual emergency plans <sep> asthma education and peak flow meter usage <sep> guideline adherence <sep>', 'quality of care <sep>', 'rates of three screening behaviors cholesterol blood pressure and cervical screening <sep> cholesterol screening <sep> accurate classification of hazardous or harmful alcohol drinkers <sep> blood pressure screening <sep>', 'qis measuring falls behavioral symptoms little or no activity and pressure ulcers <sep> minimum data set mds <sep>', 'genital tract infection <sep> compliance with other recommendations patient satisfaction and costs of the implementation strategy secondary outcomes <sep> cervical cytology history <sep>', 'moderate rates of improvement <sep>', 'wa-mrsa rates <sep> mean percentage reduction <sep> post-intervention out-of-control episodes <sep>', 'number of inappropriate prescriptions <sep>', 'blood pressure data <sep> systolic blood pressure <sep>', 'change in fraction of asthmatics treated with inhaled steroids and incidence rate of treatment with inhaled steroids <sep>', 'antibiotic prescription rate and 2 the fraction of prescriptions for narrow-spectrum antibiotics <sep>', 'cotinine levels <sep> total cholesterol <sep> mean blood pressure <sep> risk factors blood pressure cholesterol and smoking status prescribing of hypotensive agents lipid lowering drugs and antiplatelet drugs blood pressure serum cholesterol level and plasma cotinine levels <sep>', 'percentage of records containing at least one periodontal diagnostic notation <sep>', 'clinical breast examination <sep> provision of preventive care <sep> patient satisfaction scores <sep> rates of preventive services <sep> mammography <sep> pneumococcal immunization <sep> tetanus immunization <sep> influenza immunization <sep>', 'effectiveness and cost-effectiveness <sep>', 'acute in-hospital or discharge care <sep> acute ischemic stroke care quality <sep> care quality <sep>', 'proportion of oral corticosteroid use for exacerbation treatment <sep> overall attitudes of dutch and norwegian doctors <sep>', 'adequate surgical excision of skin lesions <sep> clinical and histologic diagnosis and excisions of skin lesions <sep> diagnostic performance <sep>', 'prescribing preference for thiazides <sep> prescribing preferences <sep>', 'number of consultations involving aids prevention and the number of talks about aids initiated by the gp and some elements of the content were registered on a chart <sep> frequency of consultations involving aids prevention <sep>', 'medication appropriateness <sep> mean change in mai and number of medications <sep> inappropriate prescribing according to the medication appropriateness index mai <sep>', 'number of radiograph requests <sep> lumbar spine <sep>', 'rates of practice specific ppv coverage <sep> cumulative ppv claims coverage <sep>', 'prescription rate <sep> prescription rate recordings <sep>', ""median prescription cost <sep> physician's median antibiotic cost and proportion of episodes of care in which a prespecified first-line antibiotic was used first <sep>"", 'communication skills <sep> information-giving and communication skills <sep>', 'risk of falls and fractures motor vehicle accidents and cognitive impairment <sep> proportion of long-acting benzodiazepine prescriptions <sep>', 'guideline-consistent behavior <sep> guideline adherence and resource utilization <sep> duration of pain prior history of low back pain and number of visits <sep>', 'venous thromboembolism <sep>', 'proportion of episodes with antibiotics <sep> antibiotic resistance <sep>', 'time in total compliance scores <sep>', 'mammography breast exam colorectal screening and pap testing compliance rates <sep> physician compliance <sep>', 'influenza and pneumococcal immunisation rates <sep> influenza and pneumococcal vaccination rates <sep> pneumococcal vaccination rates <sep> influenza vaccination <sep> vaccination rates <sep>', 'mean total number of requested tests per 6 months per physician <sep> mean total number of inappropriate tests <sep>', 'rationality <sep> number of requests <sep> test usage and cost savings <sep> request numbers <sep>', 'overall cost <sep> lower costs for carotid endarterectomies <sep> lumbar decompressions <sep>', 'ima intervention sites <sep> beta-blockade <sep>', 'mean charge for a prescription <sep> total prescribing charges <sep>', 'statin prescribing <sep> diabetic population <sep>', 'patient care processes lab work nursing dietary management ventilator management ventilator weaning <sep> hospital ventilator days <sep> total length of stay and icu length of stay fell <sep> quality of care <sep> clinical outcomes of mortality or nosocomial events <sep> patient care processes patient morbidity and mortality outcomes and resource use <sep> quality of rural icu care <sep>', 'internal qi <sep> g1 average treatment cost <sep>', 'cost-effectiveness <sep> cost-effectiveness ratio <sep> antibiotic prescribing <sep> overall antibiotic prescribing <sep>', 'rates of bmd testing and osteoporosis medication prescribing <sep> quality of osteoporosis care <sep> rates of bmd testing <sep> rates of giop management <sep> bmd testing or osteoporosis medication prescribing <sep> bone mineral density bmd testing and osteoporosis medication prescribing <sep> osteoporosis medication prescribing <sep>', 'clinical data and receipt of complete blood count cbc creatinine testing and cytoprotective agents process measures <sep> nsaid-related safety practices <sep>', 'antibiotic prescribing <sep> tonsillitis/streptococcal pharyngitis <sep> rate of antibiotic prescribing for all indications for urti and prescribing of select antibiotics for tonsillitis/streptococcal pharyngitis <sep>', 'risk factors <sep> angina pectoris <sep> compliance rates <sep> hypertension <sep>', 'rates of foot examination and eye examination <sep> compliance rates with evidence-based recommendations pertaining to discussion of body weight control discussion of problems with medication blood pressure measurement foot examination eye examination initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose and scheduling a follow-up appointment <sep> eye examination <sep>', 'practice facsimile fax referrals <sep> telephone referrals <sep>', 'quality indicators <sep> chf quality indicators <sep>', 'quality of care <sep>', 'hemoglobin a1c low density lipoprotein-cholesterol and systolic blood pressure <sep> glycemic lipid and blood pressure control <sep> sbp <sep> ldl <sep>', 'preventive cardiovascular care <sep> diagnoses of hypertension <sep> blood pressure control <sep>', 'physician questionnaires <sep> performance of clinical breast examination <sep>', 'blood cholesterol levels <sep> overall intern-documented cholesterol management <sep> intern documentation concerning a low-fat hospital diet cholesterol history screening blood cholesterol level assessment <sep> cholesterol management <sep>', 'inappropriate transfusions <sep> transfusion appropriateness <sep> rbc transfusions <sep> red blood cell rbc transfusions <sep>', 'mammography utilization <sep> compliance rates <sep> referral and completion rates <sep>', 'odds ratios ors <sep> glucose control cholesterol level and triglyceride level <sep> serum cholesterol and triglycerides <sep>', 'recording of peak flow <sep> objective assessment of attacks <sep> proportion with peak flow <sep>', 'prescribing rates <sep> median prescribing rates <sep>', 'diastolic pressure <sep> sustained control of hypertension <sep>', 'quantity of cholesterol testing <sep> quality of selective case finding and quality of diagnostic procedures <sep>', 'glycated hemoglobin hba1c levels <sep> health care provider behavior <sep> diabetes outcomes <sep> provider behavior and lowered hba1c levels <sep>', 'total number of encounters with antibiotics <sep> mean number of encounters with an inappropriate antibiotic with respect to diagnosis doses and or duration of therapy <sep>', 'delayed feedback of physician performance <sep> physician compliance <sep> fecal occult blood testing pneumococcal vaccination <sep> overall compliance <sep>', 'meeting patient preferences metabolic status and complication rates <sep> peritoneal dialysis <sep>', 'hemoglobin a(1c level <sep> number of patients with hemoglobin a(1c <sep> low-density lipoprotein ldl cholesterol level blood pressure annual hemoglobin a(1c testing annual ldl screening annual eye exam annual foot exam and annual renal assessment <sep>', 'physician performance <sep>', 'mortality rates <sep>'], 'punchline_text': ['physician interventions that included practice-level feedback about monitoring of glycemic control successfully led to improved care of diabetic medicare beneficiaries. <sep>', 'the intensive intervention had greater improvement in the increased proportions of patients dialyzed with prescribed blood flow p  0.02 and documented review of prescription p  0.01). <sep>', 'the groups did not differ in the change in proportion of patients who received a properly timed antimicrobial prophylaxis dose 3.8 percentage points 95 ci 13.9 to 6.2 percentage points after adjustment for region hospital size and surgery type. <sep>', 'interventions had no effect on ldl cholesterol values p  0.64 which improved in all groups over time. <sep>', 'intervention practices implemented more of the processes than control practices overall p  .003 for adults p  .05 and for children p  .04). <sep>', 'practices that received either or both the enhanced feedback and the reminder messages were significantly less likely than the control group to request the targeted tests in total enhanced feedback odds ratio 0.87 95 ci 0.81-0.94 reminder messages 0.89 0.83-0.93). <sep>', 'had higher adherence to guideline recommendations for hemoglobin a1c testing 61.5 vs 48.1 p  .01 and ldl testing 75.8 vs 64.1 p  .02). <sep>', 'in addition adjusted mortality was similar in both groups as were length of in-hospital stay physician visits after discharge waiting times for invasive cardiac procedures and readmissions for cardiac complications. <sep>', 'as a result of quality assurance intervention quality of performance was significantly improved in two of the tasks p less than 0.0001 with 6.7 and 9.8 percentage points improvement and marginally improved in one task p  0.06 5.7 percentage points improvement). <sep>', 'public release of hospital-specific quality indicators did not significantly improve composite process-of-care indicators for ami or chf. <sep>', 'however testing rates increased significantly among women making preventive care visits or pap test visit  1.23 95 ci 1.01-1.51 p  0.04 or physical exam visit  1.22 95 ci 1.06-1.42 p  0.009 intervention vs. control clinics). <sep>', 'the aggregated mean scores for all diseases and for malaria and diarrhoea improved significantly. <sep>', 'the tools and data-generating capabilities designed and constructed in stage i of the project were integral components of all subsequent stages of the program. <sep>', 'delivery of individual emergency plans increased p  0.008 and unscheduled emergency visits decreased p  0.064). <sep>', 'the intervention did not increase thrombolysis in the elderly from 0.73 at baseline but nearly two thirds of eligible nonrecipients were older than 85 years had severe comorbidities or presented after at least 6 hours. <sep>', 'at 3-month follow-up statistically significant differences were evident in the following outcome measures accurate classification of benzodiazepine users z  2.8540 p  0.05 accurate classification of non-benzodiazepine users z  2.7339 p  0.05 accurate classification of hazardous or harmful alcohol drinkers z  2.3079 p  0.02 blood pressure screening z  3.4136 p  0.001 and cholesterol screening z  6.6313 p  0.001). <sep>', 'with the exception of mds qi 27 little or no activity no significant differences in resident assessment measures were detected between the groups of facilities. <sep>', 'no intervention benefit was observed for any secondary outcome. <sep>', 'printed educational materials alone may be as effective as audit and feedback and educational outreach in improving nurses performance and outcomes of care for people with ui. <sep>', 'statistically significant and sustained decreases in wa-mrsa rates were identified in all three arms p<0.001 p=0.015 p<0.001). <sep>', 'audit and feedback together with seminars and practice guidelines reduced inappropriate prescriptions by 43 p  0.001). <sep>', 'the interaction of the 2 interventions was significant p=0.03 the largest impact was observed with the combination of physician and patient intervention 9.7  <sep>', 'none of the two types of feedback on prescribing of asthma drugs had a statistically significant impact on gps prescribing patterns. <sep>', 'the addition of feedback had no impact on gp prescribing patterns. <sep>', 'setting up a register and recall system improved patient assessment at 18 months follow up but was not consistently better than audit alone in improving treatment or risk factor levels. <sep>', 'practices participating in the intervention showed increases in the percentage of records containing at least one periodontal diagnostic notation and those practices employing hygienists showed an increase in the percentage of records with at least one preventive notation and one treatment item.(abstract truncated at 250 words <sep>', 'patient satisfaction scores improved significantly in the comprehensive intervention group by 0.06 points on a 1 to 5 scale p  0.02 but not in the education only group by 0.02 points p  0.42 however the improvement was not significantly greater in the comprehensive intervention group p  0.20). <sep>', 'the weighted t-test for a and f versus no a and f p=0.62 and cal versus no cal p=0.76 were not statistically significant. <sep>', 'secular trends were significant with improvement in both experimental and control hospitals for acute odds ratio  2.7 p  0.007 and in-hospital odds ratio  1.5 p  0.0001 care but not discharge care. <sep>', 'overall attitudes of dutch and norwegian doctors also improved significantly effect sizes 1.06 and 0.87 respectively as did both knowledge effect size 1.06 and attitudes effect size 1.49 concerning exacerbation treatment in slovakia. <sep>', 'the intervention group of doctors showed improved performance in providing clinical information on pathology requests and in adequate surgical excision of skin lesions. <sep>', 'preference in the group receiving both module and portrait increased by 0.115 <sep>', 'no statistically significant difference was observed in the frequency of consultations involving aids prevention between the intervention group 1.2 of consultations and the control group 1.4%). <sep>', 'medication appropriateness improved in the combined intervention group but not in the single intervention group. <sep>', 'concordance between groups did not differ significantly. <sep>', 'physicians randomized to telephone follow-up showed significantly higher rates of practice specific ppv coverage in 2000 than those receiving the routine mailing only and 27 vs. 17 p  0.01 of high volume physicians and 34 vs. 22 p  .052 of african american serving physicians achieved at least a 5 increase in their cumulative ppv claims coverage. <sep>', 'there was a general decline in the prescription rate recordings but there were no significant differences between the intervention groups and the control group. <sep>', 'a simple program of confidential feedback and educational materials blunted cost increases increased the use of first-line antibiotics and was highly acceptable to ontario primary care physicians. <sep>', 'information-giving and communication skills improved significantly in subjects receiving training and feedback on their performance with the greatest improvements occurring before feedback was given. <sep>', 'there was no significant difference over the study period in either combination prescribing of benzodiazepines or in prescriptions for long-term benzodiazepine therapy. <sep>', 'implementation of an education and feedback-supported acute low back pain care guideline for primary care clinicians was associated with an increase in guideline-consistent behavior. <sep>', 'this increase was seen in all study groups control hospitals 40 to 51 p  .001 cme hospitals 21 to 49 p  .0001 and cme+qa hospitals 27 to 55 p  .0001). <sep>', 'prescribing in the patient education group and the patient education and feedback group increased at a significantly lower rate than in the control group. <sep>', 'repeated measures anova demonstrated a significant increase in all three study groups throughout the time in total compliance scores from 56%-73 as well as scores for immunizations from 62%-79 and other preventive care from 54%-71%). <sep>', 'from 1993 to 1995 screening rates doubled overall from 24 to 50 with no significant differences between intervention and control group sites. <sep>', 'practices where primary care teams received an educational outreach visit demonstrated a significantly greater improvement in uptake in high-risk groups for pneumococcal but not influenza vaccine. <sep>', 'physicians in arm a had a significant reduction in mean total number of inappropriate tests ordered for problems allocated to arm a whereas the reduction in inappropriate test ordered physicians in arm b for problems allocated to arm b was not statistically significant. <sep>', 'the proportion of requests that were non-rational decreased more in the intervention than in the control groups p  0.009). <sep>', 'this revealed a significant rebound in overall cost by the feedback group for both carotid endarterectomies and lumbar surgery. <sep>', 'both interventions tended to have more impact at lower-volume cabg sites for interaction p .04 for beta-blockade p .02 for ima grafting). <sep>', 'the intervention reduced the mean charge for a prescription by 6.7 p less than 0.025 but with a long latent period and minimal impact on resident knowledge of drug charges. <sep>', 'there was a 3 increase in statin prescribing in cvd patients at 6 months post-intervention for both randomized groups but there was no statistical difference between the groups beta  0.004 95 ci  0.01 to 0.02). <sep>', 'results indicated that the outreach program significantly improved many patient care processes lab work nursing dietary management ventilator management ventilator weaning). <sep>', 'g1 and g2 subgroup with internal qi improved significantly in all criteria and in g1 average treatment cost decreased by 60 p  0.01). <sep>', 'prescribing feedback significantly reduced overall and second-line antibiotic prescribing but academic detailing was not significantly more effective than postal bulletin in changing antibiotic prescribing practice. <sep>', 'among 45 physicians completing all modules 343 patients intervention physicians had numerically but not significantly higher rates of bmd testing 26 vs 16 p .04 rate difference 10 95 ci 1%-20 and bisphosphonate prescribing 24 vs 17 p .09 rate difference 7 95 ci 1 to 16 or met a combined end point of bmd testing or osteoporosis medication prescribing 54 vs 44 p .07 rate difference 10 95 ci 1 to 21 compared with control physicians. <sep>', 'mean percent change in performance between intervention and control physicians for cbc monitoring was 16 versus 10 for creatinine monitoring 0 versus 17 and use of cytoprotective agents 3 versus 1%. <sep>', 'prescriber feedback and management guidelines were shown to influence antibiotic prescribing for urti and choice of antibiotic for tonsillitis/streptococcal pharyngitis. <sep>', 'compliance rates for 12 evidence-based indicators for the management of patients with hypertension hypercholesterolaemia angina pectoris or heart failure. <sep>', 'the intervention resulted in statistically significant improvement for two of the seven outcome measures foot examination odds ratio 1.68 95 confidence interval 1.19-2.39 and eye examination 1.52 1.07-2.16). <sep>', 'we undertook a study to assess the impact of comparative feedback vs general reminders on practice-based referrals to a tobacco cessation quit line and estimated costs for projected quit responses. <sep>', 'hii quality managers perceived the chf project as significantly more successful compared with lii quality managers 63 versus 13 p  .01). <sep>', 'yet 59 of all quality managers perceived the amvt project as being successful to very successful and more efi quality managers perceived success than did wfi managers 71 versus 40%). <sep>', 'compared to physician-feedback alone a dual intervention combining a patient letter with physician feedback produced modest improvements in glycemic lipid and blood pressure control individually but substantial improvement in a combined measure of these three outcomes together. <sep>', 'patients in intervention practices had greater improvements than those in control practices for diagnoses of hypertension improvement difference 15.7 percentage points 95 ci 5.2 to 26.3 percentage points and blood pressure control in patients with hypertension improvement difference 8.0 percentage points ci 0.0 to 16.0 percentage points]). <sep>', 'a moderately intensive outreach intervention to increase rates of breast cancer screening through the development of office systems was modestly successful in increasing indicators of office systems and in documenting mention of mammography but had little impact on actual performance of breast cancer screening. <sep>', 'during both a baseline and subsequent intervention period interns documented significantly more cholesterol management for inpatients with coronary artery disease cad than without cad. <sep>', 'small reductions in inappropriate transfusions were found at the second audit but the change was significant only for the hospitals receiving the letter-only intervention. <sep>', 'compliance increases were greatest for physicians who were older nonwhite with a second speciality in solo practice not members of the ama not residency trained and not board certified. <sep>', 'the proportion of patients who received influenza vaccine improved from 40 to 58 in the experimental group p<.001 vs from 40 to 46 in the comparison group p .02). <sep>', 'however the between group difference in the adjusted combined assessment score whilst non-significant at 6 months early 2.48 se 0.43 vs. delayed 2.26 se 0.33 <sep>', 'prescribing rates in the intervention and control groups for the five main drug groups total prescribing and potential substitute prescribing and ordering before and after the interventions. <sep>', 'for all patients the length of follow up was significantly longer in test practices test 199 days control 167 and a smaller percentage dropped out of active treatment in test practices test 37.5 control 42.1%). <sep>', 'performance of the procedure necessary to diagnose hypercholesterolaemia even deteriorated. <sep>', 'however intensification increased more in the feedback alone and feedback plus reminders groups than for reminders alone and control groups p<.001). <sep>', 'multifaceted interventions involving audit and feedback combined with either academic detailing or seminars appear more effective in changing prescribing practices of antibiotics than audit and feedback alone. <sep>', 'overall compliance with the preventive care protocols was low 10-15 in physicians receiving neither feedback nor reminders increasing to 15-30 in those receiving reminders. <sep>', 'there were no significant differences between the intervention and control groups in meeting patient preferences metabolic status and complication rates. <sep>', 'for process of care measures decreases were seen in all groups with no significant differences in change scores. <sep>', 'we tested the efficacy of an educational program conducted by professional standards review organizations in reducing the inappropriate use of x-ray pelvimetry. <sep>', 'centralized mailings of guideline summaries performance feedback reports and chart reminders had no observable impact on quality of care in this setting. <sep>'], 'population': ['patients with diabetes mellitus <sep> primary care physicians in a single southern state treating medicare beneficiaries with diabetes mellitus <sep>', 'esrd patients <sep>', 'surgical patients <sep> 44 acute care hospitals each of which randomly sampled approximately 100 selected surgical cases cardiac hip or knee replacement and hysterectomy at both the baseline and remeasurement phases <sep>', 'study subjects included 123 primary care physicians and 3,703 eligible adult diabetic patients with elevated a1c or ldl cholesterol <sep>', 'primary care <sep>', '85 primary-care practices 370 family practitioners that request all laboratory tests from one regional centre <sep> patients within primary care <sep> primary care <sep>', 'patients cared for by residents in the intervention group <sep> resident continuity clinic during the 2003-2004 academic year <sep> seventy-eight categorical internal medicine residents caring for 483 diabetic patients participated <sep>', 'hospitals were randomly assigned to receive rapid immediate n  38 hospitals and 2533 patients or delayed 14 months n  38 hospitals and 3142 patients <sep> patients admitted between 4 and 10 months after randomization <sep> patients with ami <sep> patients with ami who were admitted to 76 acute care hospitals in quebec that treated at least 30 ami patients per year between april 1 1999 and march 31 2003 <sep>', 'sixteen ambulatory care practices <sep> 16 primary care 8 medical 8 pediatric group practices was conducted <sep>', '86 hospital corporations in ontario canada with patients admitted for acute myocardial infarction ami or congestive heart failure chf <sep> participating hospital corporations were randomized to early january 2004 or delayed september 2005 <sep>', '2001-2002 23 primary care clinics at group health cooperative in washington state <sep> 3509 women <sep> asymptomatic women <sep> sexually active women ages 14-25 <sep> women making preventive care visits <sep> young women <sep>', 'malaria diarrhoea and pneumonia--a randomized controlled trial at provincial hospitals in lao pdr <sep> prescribers at 24 departments at eight provincial hospitals matched into four pairs <sep>', 'acute uncomplicated cystitis in adult women <sep>', '256 patients participated in the survey of whom 185 72.3 responded to the follow-up 1 year later <sep> 96 general practitioners <sep> asthma patients <sep> asthma care <sep>', 'all patients with ami admitted to study hospitals over 10 months before 1992-1993 n=2409 or after 1995-1996 n=2938 the intervention <sep> acute myocardial infarction <sep> eligible patients receiving each study drug <sep> thirty-seven community hospitals in minnesota <sep> 20 experimental hospitals who influenced peers through small and large group discussions informal consultations and revisions of protocols and clinical pathways <sep> frail elderly patients <sep> eligible elderly patients beta-blockers in all eligible patients for acute myocardial infarction ami and 2 decrease use of a potentially harmful therapy prophylactic lidocaine <sep>', 'nineteen general practitioners <sep>', 'nursing homes <sep> nursing facilities n  113 <sep>', 'all 26 hospital gynaecology units in scotland providing induced abortion care <sep>', '194 community nurses in 157 family practices and 1078 patients with diagnosis of urinary incontinence ui for nurses compliance with evidence-linked review criteria for the assessment and management of ui and impact on psychologic and social well-being and symptoms <sep> people with ui <sep>', 'seventy-five wards in 24 hospitals in the uk <sep>', '20 health centres randomly assigned to four different <sep>', 'physicians and lifestyle modification for patients <sep> eight primary care practices 32 physicians <sep> in community-based primary care clinics <sep> patient mean age was 60 years 61 were women and 37 were black <sep> 574 patients <sep>', 'general practitioners gps in the county of funen denmark 292 gps representing 178 practices <sep>', '299 gps representing 181 practices with 455,843 listed patients in the county of funen denmark <sep>', 'patients with coronary heart disease <sep> coronary heart disease in primary care <sep> 1906 patients aged 55-75 years with established coronary heart disease <sep>', 'practices employing hygienists n  12 and not employing dental hygienists n  12 <sep> randomly selected private general dental practices in adelaide south australia <sep>', '41 primary care physicians who cared for 1,810 randomly selected patients aged 65 to 75 years old at kaiser permanente woodland hills a group-model health maintenance organization in southern california <sep>', 'impacted and unerupted third molars in primary dental care <sep> sixty-three dental practices across scotland <sep> clinical records of all 16-24-year-old patients over two four-month periods in 1999 pre-intervention and 2000 post-intervention <sep>', 'minnesota hospitals <sep> nineteen hospitals were randomized with a total of 1,211 acute ischemic stroke cases preintervention and 1,094 cases postintervention <sep> hospitals <sep>', 'asthma patients in the netherlands norway sweden and slovakia <sep> asthma in four european countries <sep>', 'suspicious skin lesions <sep>', '200 family physicians in british columbia canada <sep> hypertension in primary care <sep> 4394 patients receiving a first-line antihypertensive <sep>', 'one hundred and thirty-three gps completed the project <sep> participants were from general practices in copenhagen and the counties of funen and vejle denmark <sep> general practice <sep>', 'elderly patients exposed to polypharmacy in primary care <sep> elderly 65 years patients exposed to polypharmacy <sep> of the 277 gps invited to participate 41 14.8 volunteered <sep> general practitioners <sep> general practitioners gps <sep> elderly patients in primary care <sep> elderly patients exposed to polypharmacy <sep>', 'primary-care radiology referrals <sep> six radiology departments and 244 general practices that they served <sep> accordance with the uk royal college of radiologists guidelines on lumbar spine and knee radiographs <sep>', 'new york primary care physicians with high volume n  732 or african-american serving n  329 practices <sep>', 'all 356 general practitioners in the county of aarhus denmark <sep>', 'primary care <sep> participants were 251 randomly selected primary care physicians from southern ontario who consented to participate 135 in the feedback group and 116 in the control group <sep>', 'twenty-six midwives and nine obstetricians completed the study according to the protocol <sep> health professionals <sep> obstetricians and midwives explanations to patients of a routine prenatal screening test <sep>', '1624 primary care physicians who wrote at least 10 prescriptions for the target drugs in a 2-month period and randomly assigned these physicians to the intervention group or the control group <sep> 168 physicians agreed to be in the intervention group and 206 in the control group <sep> elderly patients <sep> for elderly patients <sep> ontario residents aged 65 years and over for drugs selected from a minimally restrictive formulary <sep>', 'fourteen physician groups with 120 primary care physician and associate practitioners from 2 group model hmo practices <sep> acute low back pain <sep>', '3158 patients in acute-care hospitals with multiple risk factors for venous thromboembolism <sep> 15 short-stay hospitals in central massachusetts <sep>', '216 physicians and 124,092 episodes of care <sep> pediatric upper respiratory infections uris <sep> primary care physicians managing pediatric respiratory infections in medicaid <sep> participating physicians had their antibiotic prescribing assessed for the period of july 1 1996 to november 30 1997 with an intervention in june 1997 <sep>', 'medicaid managed care <sep>', 'medicaid managed care <sep> women 50 years of age and older in a medicaid health maintenance organization hmo <sep>', 'high-risk patients <sep> patients aged 65 years and over and patients with coronary heart disease chd diabetes and a history of splenectomy <sep> primary care <sep> thirty general practices in the trent region uk <sep> fifteen practices <sep>', 'primary care physicians <sep> primary care physician groups in 5 regions in the netherlands with diagnostic centers recruited from may to september 1998 <sep> thirteen groups of primary care physicians underwent the strategy for 3 clinical problems arm a cardiovascular topics upper and lower abdominal complaints while 13 other groups underwent the strategy for 3 other clinical problems arm b chronic obstructive pulmonary disease and asthma general complaints degenerative joint complaints <sep> twenty-six primary care physician groups including 174 primary care physicians <sep>', 'one group of family doctors n  39 received <sep>', '27 anesthesiology residents <sep> anesthesia <sep>', 'patients 75 years or older <sep> three hundred fifty-nine academic and nonacademic hospitals treating 267 917 patients using cabg surgery participating in the society of thoracic surgeons national cardiac database between january 2000 and july 2002 <sep> patients undergoing coronary artery bypass graft surgery <sep>', 'ambulatory clinic <sep> medical residents of a large county hospital <sep>', ""patients with cardiovascular disease cvd or diabetes <sep> volunteer gp practices n  98 <sep> patients with cvd or diabetes at 3 and 6 months post intervention and ii to evaluate the intervention from a gp's perspective <sep>"", 'patients in rural hospitals <sep> eligible patients a multidisciplinary team of intensive care unit specialists from an academic medical center delivered an educational program with content specific to the findings and capacity of the hospital <sep> 20 rural iowa hospitals as the unit of analysis <sep>', ""ten primary health centres were randomly selected from the centres in the murcia's region <sep>"", 'volunteer general practitioner practices n  98 <sep>', 'physicians who prescribed long-term glucocorticoid therapy to at least 3 patients <sep> one hundred fifty-three participating physicians <sep> long-term glucocorticoid users <sep> patients receiving long-term glucocorticoid therapy <sep>', '101 physicians initially randomized 85 remained eligible 38 internists 36 family physicians 11 rheumatologists postintervention <sep>', 'tonsillitis/streptococcal pharyngitis <sep> general practice trainees in new south wales n  157 <sep> general practice <sep>', 'cardiovascular care <sep> general practitioners gps in cardiovascular care <sep> patients with hypertension hypercholesterolaemia angina pectoris or heart failure <sep> 124 general practices in the netherlands <sep>', '124 practices and 185 gps in the netherlands <sep> general practitioners gps for patients with diabetes <sep> diabetes care <sep> 1410 consultations with type 2 diabetic patients at baseline and 1449 consultations after the intervention period <sep>', 'three hundred eight clinicians participated 171 family medicine 88 internal medicine 49 obstetrics-gynecology from 87 primary care practices in michigan <sep>', 'thirty-two hospitals in 4 states <sep> medicare inpatients with congestive heart failure <sep>', 'twenty-nine hospitals in five states <sep> medicare inpatients with venous thrombosis <sep> medicare beneficiaries who present to the hospital with venous thromboembolic disease <sep>', '417 patients with adult-type 2 diabetes from four primary care clinics <sep>', '20 community-based family or general internal medicine practices in 14 states <sep> 44 physicians 17 midlevel providers and approximately 200 staff members data from the electronic medical records of 87,291 patients <sep>', 'physicians and staff of 62 randomly selected family medicine and general internal medicine practices primarily fee-for-service half group practices and half solo practitioners <sep> eligible women patients aged 50 years and over were done at baseline n  2,887 and follow-up n  2,874 <sep> twenty mostly rural counties in north carolina <sep>', 'inpatients <sep> inpatients with cad <sep> 29 internal medicine interns <sep> inpatients with coronary artery disease cad than without cad <sep> cholesterol with inpatients <sep> internal medicine inpatients n  459 <sep>', 'ten major urban hospitals in sydney new south wales in 1998 and 1999 <sep> medical records of up to 120 patients at each hospital n=1117 <sep> major urban hospitals <sep>', 'sixty-one practices <sep> primary care physicians in small community practices <sep> quarterly chart audits of a defined sample n  11,716 of women patients 50 years of age or older <sep>', 'december 1996 with follow-up through 1998 <sep> seventy community physicians and 2978 fee-for-service medicare patients with diabetes mellitus who were part of the ambulatory care quality improvement project in alabama <sep>', '23 consenting practices <sep> 59 general practices in grampian scotland to participate <sep> acute asthma <sep>', 'general practice in rural australia <sep> general practitioners prescribing in australia <sep> 2440 full time recognised general practitioners practising in non-urban areas <sep>', 'patients with moderate hypertension of a baseline diastolic pressure of greater than 104 mm <sep> sixty family physicians <sep> patients with newly detected hypertension test practices <sep> hypertension in primary care <sep> patients with moderate hypertension <sep> patients with hypertension <sep>', 'thirty-two dutch gps in 20 general practices 3950 patient records <sep> general practitioners gps <sep> 20 general practices <sep>', 'african americans with diabetes ipcaad 8 <sep> 345 internal medicine residents <sep>', 'a total of 1,800 patient encounters 30 from each health center <sep> health centers of khartoum state sudan <sep> twenty health centers <sep>', 'academic general medicine clinic <sep>', 'patients with end-stage renal disease <sep> one hundred fifty-two patients were eligible for monitoring <sep> five of the 10 physician participants <sep>', 'nurses with advanced training-diabetes resource nurses drns)-can improve care for people with diabetes in capitated payment settings <sep> diabetes resource nurse case management and physician profiling in a fee-for-service setting <sep> 22 practices in a fee-for-service metropolitan network with 92 primary care physicians caring for 1891 medicare patients 65 years with diabetes mellitus <sep>', 'physicians with delivery privileges at each study hospital participated in an <sep>', 'patients with chd <sep> persons with coronary heart disease chd <sep> patients with coronary heart disease <sep> patients with chd in a network-model managed-care setting <sep> 700 patients per year 1999-2002 in 131 practices <sep>'], 'interventions': ['intervention that included claims-based feedback about patterns of hba1c measurement educational materials and practice aids <sep> medicare health care quality improvement program hcqip <sep>', 'health care quality improvement program hcqip interventions <sep> feedback alone 2 an intensive intervention that included feedback workshops distribution of educational materials and clinical practice guidelines technical assistance with the development of quality improvement plans and continued monitoring <sep> feedback alone versus intensive intervention <sep>', 'quality improvement collaborative comprising 2 in-person meetings led by experts monthly teleconferences and receipt of supplemental materials over 9 months <sep>', 'customized mailed information or physicians received printed prioritized lists of patients with recommended clinical actions and performance feedback <sep> customized feedback of clinical information as follows 1 patient only 2 physician only 3 both the patient and physician or 4 neither patient nor physician <sep>', 'performance feedback peer-to-peer education academic detailing a practice facilitator and computer information technology support <sep> multicomponent quality improvement intervention to feedback and benchmarking <sep>', 'enhanced feedback and brief educational reminder messages <sep>', 'instruction on diabetes registry use quarterly performance audit feedback and written reports identifying patients needing care and had letters sent quarterly to patients needing hemoglobin a1c or cholesterol testing <sep> usual clinic education <sep>', 'confidential feedback on quality indicators constructed using administrative data <sep>', 'quality assurance <sep>', 'public report cards <sep>', 'control standard or intervention enhanced guideline implementation arms <sep>', 'educational intervention <sep>', 'ofloxacin <sep>', 'quality circles <sep> theophylline <sep> qcs <sep> inhaled steroids <sep>', 'lidocaine <sep> lidocaine <sep> local medical opinion leaders <sep> lifesaving drugs aspirin and thrombolytics <sep> aspirin <sep>', 'benzodiazepine <sep> computerized feedback system <sep> computerized continuing medical education program <sep>', 'quality improvement intervention <sep> workshop and feedback reports only workshop and feedback reports with clinical consultation and control <sep>', 'control units received printed guideline summaries alone <sep> misoprostol <sep>', 'audit and feedback and educational outreach <sep>', 'spc chart feedback 2 wards receiving spc chart feedback in conjunction with structured diagnostic tools and 3 control wards receiving neither type of feedback <sep>', 'multifaceted interventions to improve prescribing <sep> multifaceted interventions <sep> multifaceted interventions <sep>', 'physician intervention or control groups <sep> physician intervention <sep> 12 monthly telephone counseling contacts and focused on weight loss dietary approaches to stop hypertension dietary pattern exercise and reduced sodium intake <sep> physician intervention versus control and/or patient intervention versus control <sep>', 'aggregate data on asthma drug prescribing patterns and a guideline statement and the third group received feedback on an unrelated subject and served as control for the other groups <sep> inhaled steroids <sep>', 'clinical guidelines on the treatment of respiratory tract infections plus postal feedback with aggregated data on their prescribing patterns for antibiotics <sep>', 'summary feedback to primary health care team audit group assistance with setting up a disease register and systematic recall of patients to general practitioner gp recall group assistance with setting up a disease register and systematic recall of patients to a nurse led clinic nurse recall group <sep>', 'continuing education ce <sep>', 'comprehensive intervention group also received peer-comparison feedback and academic detailing <sep>', 'a and f and cal <sep> computer aided learning cal package <sep> copy of sign 42 guideline and had an opportunity to attend a postgraduate education course pgec <sep>', 'performance feedback <sep>', 'inhaled corticosteroids <sep> educational intervention <sep>', 'educational intervention <sep>', 'case-based educational modules and personal prescribing feedback <sep> practice-based small group pbsg learning programme <sep>', 'medical audit <sep>', 'single educational intervention <sep> combined intervention consisting of an interactive educational meeting plus feedback on participating patients medication 2 a single intervention with an interactive educational meeting or 3 a control group no intervention <sep> combined intervention programme <sep>', 'audit and feedback and reminder messages <sep> educational reminder messages <sep>', 'telephone calls directing attention to the mailing and further promoting improvements in ppv coverage or no active follow-up <sep> pneumococcal vaccine ppv immunization <sep> pneumococcal vaccine <sep> telephone intervention <sep>', 'personal information at meetings another received written material about proper use of hypnotics/sedatives and information about their own prescription rate and the third group constituted a control group <sep> hypnotics/sedatives <sep>', 'confidential prescriber feedback and education <sep> mailed intervention combining confidential prescribing feedback with targeted educational bulletins <sep>', 'brief training interventions <sep> training session involving small group discussions focused around a video <sep>', 'benzodiazepine prescription use coupled with evidence-based educational bulletins <sep> benzodiazepines <sep> benzodiazepine <sep> benzodiazepine <sep> feedback and educational bulletins about first-line antihypertension drug prescribing <sep>', 'education and feedback-supported acute low back pain care guideline <sep> multifaceted guideline implementation intervention <sep> guideline education and individual feedback supporting patient education materials both or neither <sep> education and feedback <sep>', 'cme interventions <sep> continuing medical education cme with and without a quality assurance component cme+qa <sep> control group that received no intervention <sep> continuing medical education and quality assurance programs <sep> cme+qa interventions <sep>', 'antibiotic prescribing <sep> 1 performance feedback only 2 patient education materials only 3 both feedback and education materials or 4 no intervention <sep>', 'feedback group where physicians received written feedback about compliance scores a feedback and incentive group where physicians received feedback and a financial bonus <sep>', 'feedback and financial incentives <sep>', 'educational outreach visit to primary healthcare teams <sep> educational outreach visit <sep> audit and feedback alone <sep>', 'practice-based strategy <sep>', 'routine individual feedback <sep> feedback on test-group a electrocardiography endoscopy cervical smears and allergy tests <sep>', 'feedback and control groups for their rotations in neurosurgical anesthesia <sep> written feedback system <sep> propofol and etomidate <sep>', 'cqi interventions designed to increase use of the process-of-care measures <sep> low-intensity cqi interventions <sep> coronary artery bypass graft cabg surgery process-of-care measures preoperative beta-blockade therapy and internal mammary artery ima grafting <sep> ima grafting <sep> measure-specific information including a call to action to a physician leader educational products and periodic longitudinal nationally benchmarked site-specific feedback <sep>', 'simple computerized feedback <sep>', 'statin and antiplatelet/warfarin <sep> feedback using academic detailing compared to postal bulletin <sep> individualized prescribing feedback via academic detailing postal bulletin plus outreach visit n  48 or postal bulletin <sep>', 'outreach educational program <sep> mechanically ventilated intensive care unit icu <sep>', 'g1 committed themselves to the improvement g2 composed by two subgroups with and without quality improvement qi activities  received external feedback g3 received no intervention <sep> internal quality assurance programmes <sep>', 'prescribing feedback via postal bulletin pb n  50 or academic detailing plus postal bulletin ad <sep> academic detailing ad plus postal prescribing feedback versus postal prescribing feedback alone <sep>', 'giop management and incorporated case-based continuing medical education and personalized audit and feedback of giop management <sep> 3-module web-based giop intervention or control course <sep>', 'nonsteroidal anti-inflammatory drugs <sep>', 'education intervention on antibiotic use or to a control group <sep> prescriber feedback and management guidelines <sep>', 'practices to support intervention group or no special attention control group analysis after 2 years <sep>', 'multifaceted intervention <sep> feedback reports and support from a facilitator the control group received no special attention <sep>', 'tobacco cessation quit line <sep> general reminders control <sep>', 'written feedback intervention low-intensity intervention lii or an intervention involving feedback a physician liaison and quality improvement tools high-intensity intervention hii <sep> external feedback <sep>', ""health care financing administration's hcfa's health care quality improvement program hcqip <sep> written feedback model <sep> written feedback intervention wfi with that of an enhanced feedback intervention efi <sep> written hospital-specific feedback wfi of feedback enhanced by the participation of a trained physician quality improvement tools and an anticoagulant management of venous thrombosis amvt project liaison efi <sep>"", 'simple patient intervention to physician feedback <sep> combined physician-patient intervention to physician feedback alone <sep> physician-only intervention or a combined physician-plus-patient intervention <sep>', 'multimethod quality improvement intervention <sep>', 'office system intervention <sep> intensive outreach intervention <sep>', 'control reminder checklists checklists patient-specific feedback feedback or both interventions combined <sep>', 'red blood cell transfusions <sep>', 'education-only control 2 education plus cue enhancement using mammography chart stickers and 3 education plus cue enhancement plus feedback and token rewards <sep> behavioral techniques <sep>', 'multimodal improvement intervention including chart review and physician-specific feedback comparison group n  35 or an identical intervention plus achievable benchmark feedback experimental group n  35 <sep> influenza vaccine <sep>', 'educational programme including feedback of audit results attendance at a multidisciplinary interactive workshop and formulation of development plan by practice teams <sep>', 'feedback <sep>', 'computer feedback <sep> computer feedback <sep>', 'national cholesterol guideline <sep>', 'computerized reminders providing patient-specific recommendations at each visit and/or feedback <sep>', 'multifaceted interventions <sep> no intervention 2 audit and feedback 3 audit and feedback  seminar or 4 audit and feedback  academic detailing <sep>', 'metronidazole <sep>', 'centralized computerized randomization to the intervention group who received 12 center-specific clinical direct reports encouraging the consideration of peritoneal dialysis <sep>', 'physician feedback on process measures using medicare claims data medicare claims feedback plus feedback on clinical measures from medical record mr abstraction or both types of feedback plus a practice-based drn <sep>', 'educational program <sep>', '3-hydroxy-3methylglutaryl coenzyme a hmg coa reductase inhibitors beta-blockers and angiotensin-converting enzyme ace inhibitors <sep> hmg coa reductase inhibitors <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",audit and feedback generally leads to small but potentially important improvements in professional practice. the effectiveness of audit and feedback seems to depend on baseline performance and how the feedback is provided. future studies of audit and feedback should directly compare different ways of providing feedback.
95,"{'outcomes': ['radiological abnormality <sep> suppression upon rectal <sep>', 'got and 1 with increased gpt <sep> therapeutic effect and usefulness evaluated by physicians in charge <sep> eradication rates <sep> rates of efficacy by severity presence or absence of underlying and/or complication diseases daily dose and causative microorganisms <sep> time-courses of improvement of clinical signs and symptoms <sep> frequency of side effects <sep> therapeutic effectiveness rates <sep> gpt <sep>', 'nephro or ototoxicity <sep> bacteriologic failures <sep> median gentamicin treatment durations <sep> mean peak gentamicin concentrations <sep> circulatory compromise and renal cortical scintigraphic defects <sep> mean trough concentrations <sep> safety and efficacy <sep>', 'history of recurrences <sep> rates of cures and recurrence <sep> upper urinary tract infection <sep> urinary tract infections <sep>', 'blood cell count and erythrocyte sedimentation rate p>.05 <sep> resolution of vomiting fever general appearance abdominal tenderness and hydration state p>.05 <sep> urine sterilization rate degree of clinical improvement or subsequent hospital admission rate <sep> white blood cell count and erythrocyte sedimentation rate <sep>', 'persistent infection and 6 infection relapses <sep>', 'reduction in inflammatory indices and percentage with sterile urine <sep> rate of renal scarring <sep>', 'serious adverse effects <sep> bacteriologic efficacy <sep> overall cure rate <sep> successful eradication <sep>', 'renal scarring <sep> mean costs <sep> mean extent of scarring <sep> bacteremia <sep> symptomatic reinfections <sep> mean time to defervescence <sep>', 'efficacy and tolerance <sep> urinary tract infection acute pyelonephritis or cystitis <sep> bacteriological efficacy sterilization of the urine and biological efficacy <sep> severity of the urinary tract infection risk of renal scars <sep> clinical efficacy <sep>', 'renal scarring <sep> rate of recurrent infection <sep> duration of hospitalization <sep> health care expenditure <sep> urine culture <sep>', 'trough serum levels <sep> clinical and bacteriological response rates <sep> efficacy and safety <sep> peak serum levels <sep>', 'renal scarring <sep> recurrence of urinary infection <sep> development of renal scarring <sep> prevalence of scarring <sep> renal scarring <sep>', 'trough level <sep> peak serum netilmicin concentrations <sep> serum creatinine level <sep> no relapse <sep> rate of reinfection <sep> ototoxicity <sep> efficacy and safety <sep> nephrotoxicity <sep>', 'recurrence rate <sep> recurrence rate of first lower uti <sep>', 'drug-related clinical adverse events <sep> satisfactory clinical response <sep> bacteriologic eradication <sep> bacteriologic eradication <sep> safety and efficacy <sep>', 'percentage of patients with sequelae <sep> total or partial persistence of renal abnormalities <sep> late dmsa <sep>'], 'punchline_text': ['single dose therapy had significantly less suppression upon rectal p less than 0.001 and periurethral p less than 0.02 flora. <sep>', 'eradication rates for causative microorganisms were 65.9 for the suppository and 62.5 for the oral form. <sep>', 'no nephro or ototoxicity was identified. <sep>', 'rates of cures and recurrence in the compared groups were not statistically different p greater than 0.05). <sep>', 'at the 48-hour follow-up visit there were no differences between the 2 treatment groups in resolution of vomiting fever general appearance abdominal tenderness and hydration state p>.05). <sep>', 'seven treatment failures 1 persistent infection and 6 infection relapses were identified all of which were in the 2-week treatment group. <sep>', 'intention to treat analysis showed no significant differences between oral n=244 and parenteral n=258 treatment both in the primary outcome scarring scintigraphy at 12 months 27/197 13.7 v 36/203 17.7 difference in risk 4 95 confidence interval 11.1 to 3.1 and secondary outcomes time to defervescence 36.9 hours sd 19.7 v 34.3 hours sd 20 mean difference 2.6 0.9 to 6.0 white cell count 9.8x10(9)/l sd 3.5 v 9.5x10(9)/l sd 3.1 mean difference 0.3 0.3 to 0.9 percentage with sterile urine 185/186 v 203/204 risk difference 0.05 1.5 to 1.4%)). <sep>', 'the overall cure rate was significantly better in the ceftriaxone group than the cefotaxime group in terms of recurrence and reinfections p  0.05). <sep>', 'mean costs were at least twofold higher for children treated intravenously 3577 vs 1473 compared with those treated orally. <sep>', 'time to normalization of the indices of the acute inflammatory response were identical for both groups regardless of the duration of iv antibiotic treatment seven days for amoxycillin/clavulanate 14 days for cefotaxime). <sep>', 'the incidence of renal scarring was 66.6 per cent and 61.1 per cent in the study group and the control group respectively. <sep>', 'isepamicin was shown to be as effective and safe as amikacin in the treatment of children with pyelonephritis and might prove an advantageous alternative in areas with high incidence of resistance to other aminoglycosides. <sep>', 'during follow up 15 children had recurrence of urinary infection with no significant difference between the two treatment groups. <sep>', 'at 4 weeks posttreatment no relapse was detected and the rate of reinfection was essentially identical in the two treatment groups. <sep>', 'the recurrence rate of first lower uti after 10-day therapy was significantly lower than that after 42-day treatment. <sep>', 'cefepime and ceftazidime are equally safe and efficacious treatment for pyelonephritis in pediatric patients. <sep>', 'in group b the percentage of patients with sequelae was significantly higher p<0.01 when the delay was more than 1 week. <sep>'], 'population': ['sixty-nine children with urinary tract infections <sep> urinary infections in children <sep>', 'subjects were in-patients with bacterial urinary tract infections ranging in age 4 months to 11 years 4 months <sep> urinary tract infections <sep>', 'children with urinary tract infections <sep> children with severe urinary tract infections uti <sep> groups were 7.5 5 years old 6.0 5 to 10 years old and 4.5 10 years old <sep> children aged 1 month to 12 years <sep> hospitalized children ages 1 month to 12 years with uti <sep> 179 children enrolled 90 od 89 td <sep>', 'eighteen patients <sep> 18 patients had no recurrences <sep> thirty-seven patients with a median age of 5 years with symptomatic lower or upper urinary tract infection documented by a clean-catch midstream urine culture and sediment examination <sep> children <sep>', ""febrile children aged 6 months to 12 years with a presumptive urinary tract infection based on history physical examination and urinalysis findings <sep> tertiary care children's hospital emergency department <sep> sixty-nine children were enrolled 34 in the im  po group and 35 in the po group <sep> febrile children with urinary tract infections <sep>"", 'patients with positive ct findings <sep> pediatric patients with aln <sep> pediatric patients who had aln with a 3 vs 2-week intravenous plus oral antimicrobial-therapy regimen <sep> 80 patients with aln were enrolled <sep> acute lobar nephronia <sep> acute lobar nephronia aln <sep> patients who were suspected of having an upper urinary tract infection underwent a systematic scheme of ultrasonographic and computed tomographic ct evaluation for aln diagnosis <sep>', '28 paediatric units in north east italy <sep> pyelonephritis in children <sep> children <sep> 278 children with confirmed acute pyelonephritis on scintigraphy at study entry <sep> children with a first episode of acute pyelonephritis <sep> 502 children aged 1 month to 7 years with clinical pyelonephritis <sep>', 'childhood upper urinary tract infections <sep> childhood pyelonephritis <sep> patients with complicated and uncomplicated upper uti <sep> patients with upper urinary tract infections utis <sep>', 'children with fever and urinary tract infection <sep> 306 children 1 to 24 months old with fever and urinary tract infection in terms of short-term clinical outcomes sterilization of the urine and defervescence and long-term morbidity incidence of reinfection and incidence and extent of renal scarring documented at 6 months by 99mtc-dimercaptosuccinic acid renal scans <sep> young febrile children with urinary tract infection <sep> young febrile children <sep>', 'children <sep> children older than one year <sep> urinary tract infection with tissue penetration <sep>', '36 99mtc-dimercaptosuccinic acid dmsa scan proved pyelonephritis patients <sep> acute pyelonephritis in children <sep>', 'children with pyelonephritis <sep> acute pyelonephritis in children <sep> sixteen children were enrolled in the study ten received <sep>', 'children with acute pyelonephritis <sep> acute pyelonephritis <sep> acute pyelonephritis often leaves children with permanent renal scarring <sep> 220 patients aged 3 months to 16 years with positive urine culture and acute renal lesions on initial dmsa scintigraphy <sep>', 'gram-negative pyelonephritis in children <sep>', '235 infants and children <sep>', 'patients 12 years of age and older with uncomplicated and complicated urinary tract infections including pyelonephritis but not in younger patients <sep> pediatric patients younger than 12 years of age <sep> pediatric patients <sep> pyelonephritis <sep> 800 pediatric patients <sep> 300 pediatric cases <sep> two hundred ninety-nine pediatric patients ages 1 month to 12 years with pyelonephritis 300 episodes <sep>', 'children with acute pyelonephritis <sep> 92 children included in the study 87 were followed for at least 6 months 43 in group a and 44 in group b and were eligible for analysis <sep>'], 'interventions': ['gentamicin therapy <sep> gentamicin <sep>', 'ampicillin <sep> ampicillin suppository ks-r 1 <sep> suppository <sep>', 'daily td gentamicin <sep> daily od gentamicin <sep> gentamicin <sep>', 'cefotaxime <sep>', 'ceftriaxone sodium <sep> trimethoprim and sulfamethoxazole hastens urine sterilization <sep> ceftriaxone <sep> trimethoprim-sulfamethoxazole im  po group or oral trimethoprim-sulfamethoxazole alone po group <sep> trimethoprim-sulfamethoxazole <sep>', 'antibiotic treatment regimen <sep> intravenous and oral antibiotic therapy <sep> antimicrobial therapy <sep>', 'antibiotic treatment <sep> parenteral ceftriaxone <sep> dimercaptosuccinic acid dmsa scintigraphy <sep> oral co-amoxiclav <sep> oral antibiotics <sep>', 'cephalosporins ceftriaxone and cefotaxime <sep> ceftriaxone <sep> ceftriaxone and cefotaxime <sep> cefotaxime <sep>', 'oral cefixime <sep> oral cefixime <sep> cefixime <sep> oral versus initial intravenous therapy <sep> oral versus initial intravenous therapy <sep> cefotaxime <sep>', 'amoxycillin/clavulanate <sep> cefotaxime <sep>', 'oral ceftibuten switch therapy <sep> cephalosporin ceftibuten <sep> ceftriaxone <sep> control group ceftriaxone <sep> ceftriaxone <sep> oral ceftibuten switch therapy <sep>', 'amikacin <sep> isepamicin versus amikacin <sep> isepamicin <sep> isepamicin or amikacin <sep> isepamicin and six amikacin <sep> isepamicin versus amikacin <sep>', 'oral cefixime <sep> antibiotics <sep> intravenous ceftriaxone <sep>', 'netilmicin <sep> netilmicin <sep>', 'sulfafurazole <sep> antimicrobial therapy <sep>', 'cefepime and ceftazidime <sep> ceftazidime <sep> trimethoprimsulfamethoxazole <sep> cefepine vs. ceftazidime <sep>', 'technetium-99m dimercaptosuccinic acid dmsa scintigraphy <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>']}",these results suggest that children with acute pyelonephritis can be treated effectively with oral antibiotics cefixime ceftibuten and amoxicillin/clavulanic acid or with short courses 2 to 4 days of iv therapy followed by oral therapy. if iv therapy is chosen single daily dosing with aminoglycosides is safe and effective. studies are required to determine the optimal total duration of therapy.
96,"{'outcomes': ['failure rates <sep> likelihood of extubation failure <sep> fio2 pao2 and respiratory rates <sep> paco2 values <sep> severe apnea and/or respiratory failure <sep> failures <sep>', 'failure rate of extubation <sep>', 'severe apnea or predefined clinical deterioration and extubation success <sep> extubation failure <sep> rates of successful extubation <sep>', 'successfully extubated to ncpap <sep> respiratory distress syndrome <sep> pulmonary status fraction of inspired oxygen fio2 <sep>', 'ventilator rate of 6/minute <sep> individual successful extubation rate of post-extubation <sep> overall success rate of early extubation <sep> stable condition fraction of inspired oxygen fio2 of  or  35 peak inspiratory pressure pip <sep> clinical characteristics <sep>', 'total number of days of ventilation <sep>', 'mean respiratory rate <sep> alveolar-arterial oxygen gradient <sep> birth weight and duration of intubation <sep> postextubation nasal continuous positive airway pressure <sep>', 'intraventricular haemorrhage rate <sep> oxygen dependency <sep> apnoeas and respiratory acidosis requiring rescue nasal cpap <sep> overall nasal cpap <sep>', 'respiratory acidosis <sep> successfully extubated to ncpap <sep> oxygen requirements <sep> total number of days of assisted ventilation or the duration of inpatient stay <sep> failure rate <sep> oxygen requirement greater <sep>'], 'punchline_text': ['there were also no differences in fio2 pao2 and respiratory rates before and after discontinuation of imv among the three groups. <sep>', 'there was no significant difference in the failure rate of extubation among infants randomised to receive nasal cpap or headbox oxygen in either the acute or chronic respiratory distress groups. <sep>', 'after stratification by birth weight there were no significant differences in the rates of successful extubation among the treatment groups. <sep>', 'there were no differences in baseline characteristics between the two groups. <sep>', 'there were no significant differences in clinical characteristics between the two groups. <sep>', 'there was no significant difference between groups with respect to total number of days of ventilation headbox median 4 range 1-24 cpap median 2 range 1-20). <sep>', 'groups were comparable in birth weight and duration of intubation. <sep>', 'overall nasal cpap significantly reduced the need for increased respiratory support relative risk 0.57 95 ci 0.43-0.73 but not for re-intubation relative risk 0.89 95 ci 0.68-1.17). <sep>', 'there was no significant difference between the groups in the total number of days of assisted ventilation or the duration of inpatient stay. <sep>'], 'population': ['87 preterm infants mean <sep> 188 g gestational age 28.8  2.2 weeks who were in the process of being weaned from intermittent mandatory ventilation imv <sep> very low birth weight vlbw infants <sep>', 'sixty infants median gestational age 29 weeks with acute and 60 infants median gestational age 25 weeks with chronic respiratory distress <sep> infants with acute rather than chronic respiratory distress <sep> acute and chronic respiratory distress <sep>', 'eligible infants included patients weighing 600 to 1500 gm at birth who required tracheal intubation within 48 hours of birth and who met specific predetermined criteria for extubation by day 14 of life <sep> very low birth weight infants <sep>', 'very low birth weight neonates <sep> 58 neonates comparing nasal continuous positive airway pressure ncpap vs oxyhood following extubation of neonates weighing less than 1 kg <sep> 23 neonates who failed oxyhood 21 were then given a trial of <sep>', 'all infants weighed less than 1500 g had a gestational age of less than 34 weeks and had been weaning from mechanical ventilation within seven days of life <sep> 50 babies <sep> the reintubation criteria included fio2  or  70 to maintain arterial oxygen tension pao2 of  or  50 mm hg 6.67 kpa or pulse oximetry between 90-96 and ph of  7.25 and arterial carbon dioxide tension paco2 of  60 mm hg 8.00 kpa and severe or recurring apnoea <sep> very low birthweight infants <sep>', 'infants at less than 32 weeks of gestation who had received <sep> ninety-seven babies were entered into the study 48 cpap and 49 headbox oxygen <sep> preterm infants <sep>', '18 neonates recovering from respiratory distress syndrome <sep>', '150 infants median gestational age 30 weeks range 24-34 weeks <sep> premature infants less than 28 days of age <sep> fifteen nasal cpap infants and 25 headbox infants <sep> preterm infants <sep>', ""infants weighing 600 <sep> neonatal intensive care unit of the royal women's hospital melbourne of infants with birthweights between 600 and 1250 g ventilated via an endotracheal tube for more than 12 hours requiring less than 50 oxygen a ventilator rate  or  20/minute considered by the clinical management team to be ready for extubation <sep>""], 'interventions': ['cpap <sep> continuous positive airway pressure cpap via a nasopharyngeal or endotracheal tube <sep> continuous positive airway pressure cpap <sep> direct extubation from imv d.ext n  30 2 preextubation endotracheal cpap et-cpap <sep> postextubation nasopharyngeal cpap np-cpap <sep>', 'headbox or onto 3 cm h2o nasal continuous positive airway pressure cpap <sep> nasal cpap or headbox oxygen <sep>', 'nasopharyngeal continuous positive airway pressure <sep> oxygen supplementation delivered by hood <sep> nasopharyngeal continuous positive airway pressure cpap <sep>', 'nasal continuous positive airway pressure facilitates extubation <sep> ncpap <sep>', 'aminophylline <sep> post-extubation headbox or post-extubation nasal continuous positive airway pressure n-cpap <sep> nasal continuous positive airway pressure <sep>', 'mechanical ventilation <sep> continuous positive airways pressure <sep> cpap <sep> postextubation nasal continuous positive airways pressure cpap with direct extubation into headbox oxygen <sep>', 'cpap <sep> nasal continuous positive airway pressure n-cpap <sep> control group given oxygen by hood <sep>', 'nasal cpap to headbox oxygen <sep> nasal continuous positive airways pressure <sep> nasal continuous positive airways pressure post-extubation <sep> nasal continuous positive airways pressure cpap <sep>', 'ncpap <sep> ncpap or to oxygen administered via a headbox <sep> extubation to nasal continuous airway pressure ncpap <sep> nasal continuous positive airway pressure <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",implications for practice nasal cpap is effective in preventing failure of extubation in preterm infants following a period of endotracheal intubation and ippv. implication for research further definition of the gestational age and weight groups in whom these results apply is warranted. optimal levels of ncpap as well as methods of administration remain to be determined.
97,"{'outcomes': ['bradycardia <sep> proportion of infants with recurrent hypoxaemic episodes <sep> mean proportion of infants with more than six hypoxaemic episodes <sep> transcutaneous oxygen tension tcpo2 and heart rate <sep> gestational age birth weight delivery mode sex distribution and apgar scores <sep> hypoxaemic episodes <sep> mean serum concentration <sep> transcutaneous po2 <sep>', 'death or disability <sep> odds ratios <sep> neurodevelopmental benefits <sep>'], 'punchline_text': ['our results suggest that prophylactic caffeine has little if any effect on the risk of developing hypoxaemic episodes and bradycardia in small preterm infants and the supposed 50 reduction which was considered clinically important at the start of the trial can be rejected with confidence. <sep>', 'the size and direction of the caffeine effect on death or disability differed depending on ppv at randomization p  .03). <sep>'], 'population': ['premature infants <sep> fifty spontaneously breathing preterm infants 48 h old of 32 weeks gestation or less <sep>', 'three subgroups of 2006 participants in the caffeine for apnea of prematurity cap trial <sep> copyright 2010 <sep>'], 'interventions': ['caffeine citrate <sep> placebo <sep> prophylactic caffeine <sep> caffeine <sep>', 'positive pressure ventilation ppv at randomization endotracheal tube ett noninvasive ventilation or none <sep> caffeine <sep> caffeine <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>']}",the results of this review do not support the use of prophylactic caffeine for preterm infants at risk of apnoea. any future studies need to examine the effects of prophylactic methylxanthines in preterm infants at higher risk of apnoea. this should include examination of important clinical outcomes such as need for ippv neonatal morbidity length of hospital stay and long term development.
98,"{'outcomes': ['hypertension <sep> pregnancy induced hypertension <sep> systolic/diastolic blood pressure <sep> pre-eclampsia <sep> duration of pregnancy <sep> reduction of pre-eclampsia <sep> occurrence of pre-eclamsia <sep>', 'frequency of pregnancy-induced hypertension preeclampsia and preterm birth <sep> risk of preeclampsia <sep> risk of preeclampsia and preterm birth <sep> risk of hypertension and preeclampsia <sep> preterm birth <sep> risk of preterm birth <sep> frequency of pregnancy-induced hypertension <sep>', 'serum ionized calcium levels <sep> risk of pregnancy-induced hypertension <sep> pregnancy-induced hypertension <sep> systolic and diastolic blood pressure <sep>', 'rates of hypertensive disorders of pregnancy <sep> risk of both gestational hypertension and preeclampsia <sep> blood pressure <sep> low ratios of urinary calcium to urinary creatinine <sep> diastolic and systolic blood pressure <sep> hypertensive disorders of pregnancy <sep> urinary excretion of calcium and creatinine <sep> hypertensive disorders of pregnancy gestational hypertension and preeclampsia <sep>', 'calcium intake and bp reduction <sep> mean systolic and diastolic bp value <sep> blood pressure <sep> incidence of pregnancy-induced hypertension <sep> initial blood pressure bp <sep>', 'rate of pregnancy induced hypertension <sep> incidence of gestational hypertension <sep> incidence of preeclampsia <sep> incidence of pregnancy induced hypertension <sep>', 'urinary tract infection and chlamydial infection <sep> low birth weight <sep> dietary calcium intake <sep> spontaneous labor and preterm delivery <sep> incidence of preterm delivery <sep> mean duration of calcium supplementation <sep>', 'preeclampsia <sep> risk of preeclampsia <sep> blood pressure and urinary protein excretion <sep> numbers of preterm deliveries small-for-gestational-age births or fetal and neonatal deaths <sep> mean systolic and diastolic blood pressures <sep> preeclampsia <sep> preeclampsia pregnancy-associated hypertension or adverse perinatal outcomes <sep> prevalence of pregnancy-associated hypertension without preeclampsia <sep> incidence or severity of preeclampsia or delay its onset <sep> hypertensive disorders <sep>', 'eclampsia <sep> preeclampsia and preterm delivery secondary outcomes focused on severe morbidity and maternal and neonatal mortality rates <sep> severity maternal morbidity and neonatal mortality <sep> compliance <sep> early preterm delivery <sep> preeclampsia <sep> severe preeclamptic complications index <sep> severe maternal morbidity and mortality index <sep> severe gestational hypertension <sep> neonatal mortality rate <sep>', 'risk of preeclampsia <sep> systolic bp <sep> preeclampsia <sep> diagnosis of preeclampsia <sep> average daily calcium intake <sep> blood pressure bp <sep>'], 'punchline_text': ['no major effect on pregnancy induced hypertension was seen 66 in placebo and 76 in calcium group developed hypertension but the onset of hypertension was delayed 3 weeks in the calcium group. <sep>', 'treatment with calcium reduced the risk of preeclampsia relative risk 0.44 95 ci 0.21-0.90 p  0.02 and the risk of preterm birth relative risk 0.44 95 ci 0.21-0.90 p  0.02). <sep>', 'calcium supplementation was associated with a significantly decreased risk of pregnancy-induced hypertension with 4.1 developing pregnancy-induced hypertension in the treatment group versus 27.9 in the placebo group. <sep>', 'the rates of hypertensive disorders of pregnancy were lower in the calcium group than in the placebo group 9.8 percent vs. 14.8 percent odds ratio 0.63 95 percent confidence interval 0.44 to 0.90). <sep>', 'the incidence of pregnancy-induced hypertension was 11.1 in the placebo group and 4.0 in the calcium group a nonsignificant difference. <sep>', 'the rate of pregnancy induced hypertension was lower in the calcium group than in the placebo group 8.24 vs 29.03 rr  0.28 95 ci 0.14-0.59). <sep>', 'the calcium group had a lower incidence of preterm delivery less than 37 weeks 7.4 vs 21.1 p  0.007 spontaneous labor and preterm delivery 6.4 vs 17.9 p  0.01 and low birth weight 9.6 vs 21.1 p  0.03). <sep>', 'calcium did not reduce the numbers of preterm deliveries small-for-gestational-age births or fetal and neonatal deaths nor did it increase urolithiasis during pregnancy. <sep>', 'the neonatal mortality rate was lower risk ratio 0.70 95 ci 0.56-0.88 in the calcium group. <sep>', 'calcium supplementation was associated with a significantly decreased risk of preeclampsia risk reduction 12.35 p  .001 with 3.2 n  4 developing preeclampsia in the treatment group versus 15.5 n  21 in the placebo group. <sep>'], 'population': ['the inclusion criteria were positive rollover test having at least one risk factor for pre-eclampsia between 28 and 32 weeks of pregnancy and blood pressure less than 140/90 mm hg <sep> iranian women at high risk of pre-eclampsia. thirty pregnant women at high risk of developing pre-eclampsia <sep> iranian women at high risk of developing pre-eclampsia <sep>', '5 maternity hospitals in australia <sep> nulliparous women for the prevention of pregnancy-induced hypertension preeclampsia and preterm birth <sep> 456 nulliparas with a singleton pregnancy <sep>', '106 young healthy nulliparous women residing in quito ecuador <sep>', 'pregnant and nonpregnant women <sep> 1194 nulliparous women who were in the 20th week of gestation at the beginning of the study <sep> hypertensive disorders of pregnancy <sep> pregnant women who receive <sep>', 'during pregnancy <sep> fifty-two healthy pregnant women <sep>', 'nulliparous women <sep> 201 healthy nulliparous women <sep>', 'all participants were 17 years of age or less and clinically healthy <sep>', '4589 healthy nulliparous women who were 13 to 21 weeks pregnant to <sep> healthy nulliparous women <sep>', 'women who were recruited before gestational week 20 received <sep> nulliparous normotensive women from populations with dietary calcium  600 mg/d <sep> pregnant women with low calcium intake reduces preeclampsia and preterm delivery <sep> low calcium intake pregnant women <sep> 8325 women who were assigned randomly <sep>', 'selection criteria were age less than 17.5 years nulliparity first prenatal visit before 20 weeks gestation and residency in quito 2800-m altitude <sep> two hundred sixty teenaged pregnant girls attending the hospital gneco-obsttrico isidro ayora in quito ecuador were included <sep> 125 girls to receive 2000 mg of <sep> pregnant teenagers <sep> ecuadorian pregnant teenagers <sep>'], 'interventions': ['supplementary calcium <sep> calcium <sep> placebo <sep> daily calcium and placebo <sep> calcium supplementation <sep> placebo mean+/-s.d.=37+/-2 for calcium <sep> calcium supplementation <sep>', 'calcium supplementation <sep> calcium <sep> calcium supplementation <sep> calcium 1.8g oral calcium or an oral placebo <sep>', 'placebo <sep> calcium supplementation <sep> elemental calcium per day or a placebo <sep>', 'calcium supplementation <sep> placebo <sep> calcium supplementation <sep> elemental calcium in the form of calcium carbonate 593 women or placebo <sep>', 'placebo <sep> calcium supplementation <sep> elemental calcium per day or a placebo <sep>', 'calcium supplementation <sep> placebo <sep> calcium supplementation <sep> oral elemental calcium <sep>', 'calcium supplementation 2.0 gm of elemental calcium as calcium carbonate <sep> calcium supplementation <sep> placebo <sep>', 'calcium <sep> placebo <sep> receive daily treatment with either 2 g of elemental calcium or placebo <sep> calcium supplementation <sep> calcium <sep> calcium supplementation <sep>', 'calcium supplementation <sep> supplements 1.5 g calcium/d or placebo <sep> placebo <sep> calcium supplementation <sep>', 'calcium supplementation <sep> placebo <sep> calcium supplementation <sep> elemental calcium <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",calcium supplementation appears to approximately halve the risk of pre-eclampsia to reduce the risk of preterm birth and to reduce the occurrence of the composite outcome death or serious morbidity'. we considered the latter benefit to outweigh the increase in hellp syndrome which was small in absolute numbers. there were no other clear benefits or harms.
99,"{'outcomes': ['success rate <sep>'], 'punchline_text': ['the effect of zbd is superior to that of progesterone in treating women of early threatened abortion with dark area surrounding pregnancy sac. <sep>'], 'population': ['women of early threatened abortion with dark area surrounding pregnancy sac <sep> 105 patients with early threatened abortion in whom vaginal bleeding was shown already <sep> treating women of early threatened abortion with dark area surrounding pregnancy sac <sep>'], 'interventions': ['zbd and progesterone <sep> zbd <sep> zhixue baotai decoction zbd <sep> zhixue baotai decoction <sep> progesterone <sep>'], 'punchline_effect': [' sig increase <sep>']}",there was insufficient evidence to assess the effectiveness of chinese herbal medicines alone for treating threatened miscarriage. a combination of chinese herbal and western medicines was more effective than western medicines alone for treating threatened miscarriage. however the quality of the included studies was poor. more high quality studies are necessary to further evaluate the effectiveness of chinese herbal medicines for threatened miscarriage.
100,"{'outcomes': ['forced expiratory flow <sep> gaw/vl <sep> peak theophylline level <sep> serum caffeine concentrations <sep> serum levels of caffeine and theophylline forced expired volume and flow specific airway conductance gaw/vl vital signs and reported symptoms <sep>', 'baseline fev1 and prevented exercise-induced bronchoconstriction <sep> exercise-induced bronchoconstriction <sep> tolerated <sep>', 'pulmonary function <sep> peak caffeine concentration <sep>', 'exhaled nitric oxide feno measurements <sep> serum caffeine levels <sep> exhaled nitric oxide measurements <sep> feno <sep> feno measurements <sep> caffeine consumption increases or decreases feno <sep>', 'average peak serum concentration <sep> airway reactivity <sep> bronchoconstrictor response <sep>', 'histamine responsiveness <sep>', 'reduction in bronchoconstriction <sep> bronchoconstriction <sep>'], 'punchline_text': ['comparable peak increases in the forced expiratory volume in one second fev1 the forced expiratory flow during the middle half of the forced vital capacity fef25-75 and gaw/vl occurred at 120 minutes following aminophylline and the highest dose of caffeine indicating that caffeine is an effective bronchodilator but is only 40 percent as active as an equivalent molar dose of theophylline. <sep>', 'caffeine significantly improved baseline fev1 and prevented exercise-induced bronchoconstriction only at a dose of 7 mg/kg. <sep>', 'there was also a significant difference for percent change in fef25-75 with peak occurring at 4 h. percent change in vmax25 was significantly different at 3.0 h only. <sep>', 'no significant changes in feno occurred after caffeine compared with the control. <sep>', 'these caffeine levels did not produce any appreciable attenuation of the bronchoconstrictor response to carbachol inhalations. <sep>', 'the pc20 for histamine bronchoprovocation after caffeine ingestion was 2.65 95 confidence limits 0.99 7.10 <sep>', 'caffeine 10 mg/kg significantly reduced bronchoconstriction compared to placebo p  0.02). <sep>'], 'population': ['asthmatic subjects <sep> nine asthmatic adults who ingested decaffeinated coffee containing varying amounts of added caffeine mean of 0.2,2.5,5.6 and 7.2 mg/kg of body weight on different days <sep>', 'ten patients with bronchial asthma <sep>', 'asthmatic children <sep> 8 patients 4 men and 4 women with previously documented airway reactivity <sep> adult asthmatics <sep> adults with asthma <sep>', '20 patients with asthma 10 steroid-naive and 10 steroid-treated received a <sep> subjects with asthma <sep> patients with asthma <sep>', 'asthma <sep> 7 patients with asymptomatic asthma <sep>', 'asthma <sep> 10 subjects with mild asthma prechallenge fev1 84 of predicted value <sep>', 'eleven nonsmoking men aged 18 to 42 years with normal baseline spirometry and evidence of exercise-induced bronchospasm <sep>'], 'interventions': ['theophylline <sep> aminophylline mean theophylline <sep> decaffeinated coffee and aminophylline <sep> aminophylline <sep> caffeine <sep>', 'caffeine <sep> placebo and caffeine <sep> caffeine <sep>', 'placebo or 5 mg/kg of caffeine in solution orally and fev1 fvc fef25-75 vmax25 and blood for caffeine concentrations <sep> caffeine and placebo <sep> caffeine <sep> caffeine <sep>', 'caffeine ingestion <sep> standard cup of either caffeinated or noncaffeinated coffee <sep> caffeine <sep>', 'placebo or caffeine <sep> dietary caffeine <sep>', 'placebo <sep> caffeine <sep>', 'placebo <sep> placebo 5 mg/kg caffeine or 10 mg/kg caffeine and then underwent bpc with eucapnic voluntary hyperventilation evh <sep> caffeine <sep> caffeine consumption <sep> caffeine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",caffeine appears to improve airways function modestly for up to four hours in people with asthma. people may need to avoid caffeine for at least four hours prior to lung function testing as caffeine ingestion could cause misinterpretation of the results. drinking caffeinated coffee before taking exhaled nitric oxide measurements does not appear to affect the results of the test but more studies are needed to confirm this.
101,"{'outcomes': ['mean total scag score <sep>', 'tolerance of nicergoline <sep> delayed recall of the auditory verbal learning test avlt <sep> benton visual retention test p  0.002 and attention and concentration letter cancellation test <sep> nine neuropsychological tests exploring memory concentration verbal and motor performances <sep> memory function avlt short term recall <sep> rezek score <sep> wais-r digit symbol subtest <sep> efficacy and safety <sep>', 'therapeutic efficacy and safety <sep> sandoz clinical assessment geriatric scale scag and mini-mental state examination mmse scores <sep> adverse events <sep> clinical global impression 3 subtests of the weschsler adult intelligence scale and blessed a scale for activities of daily living and all endpoints in 2-month intervals <sep> mmse scores itt and vc <sep> efficacy and safety <sep>', 'p300 latency <sep> global improvement cgi item 2 <sep> mini-mental state and the scag score <sep> delta and theta increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum <sep>'], 'punchline_text': ['the safety of nicergoline as judged by hemodynamic changes and drug-related adverse reactions was quite satisfactory. <sep>', 'significant differences were observed for memory function avlt short term recall p  0.026 avlt delayed recall p  0.013 and benton visual retention test p  0.002 and attention and concentration letter cancellation test p  0.043 and wais-r digit symbol subtest p  0.006). <sep>', 'nicergoline was well tolerated and a similar number of adverse events were observed in both the placebo and the nicergoline group. <sep>', 'eeg mapping demonstrated in nic-treated sdat and mid patients a significant decrease in delta and theta increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum as compared with pretreatment while opposite changes occurred in plac-treated sdat and mid patients. <sep>'], 'population': ['mild to moderate dementia <sep> 315 patients suffering from mild to moderate dementia <sep>', '72 non-demented and non-depressive elderly hypertensive patients with evidence of leukoaraiosis on cerebral computed tomography scan rezek score  16 <sep> elderly hypertensive patients with leukoaraiosis <sep>', 'male and female patients 55-85 years of age with a clinical diagnosis of mild to moderate multi-infarct dementia according to dsm-iii to evaluate the <sep> fifteen patients were excluded from the efficacy analyses of valid cases vc due to protocol violations or because they dropped out of the study prematurely <sep> patients with multi-infarct dementia <sep> 252 patients were screened 136 patients entered the double-blind phase and were evaluated as intent-to-treat itt patients <sep>', 'senile dementia of alzheimer type and multi-infarct dementia <sep> 112 patients with mild to moderate dementia diagnosed according to dsm iii-r criteria mms 13-25 living in pensioners homes were included <sep> fifty-six were subdiagnosed as senile dementia of the alzheimer type sdat 56 as multiinfarct dementia mid based on computed tomography and hachinski scores  or  49 sdat  or  7 mid <sep>'], 'interventions': ['placebo <sep> nicergoline <sep> nicergoline versus placebo <sep> nicergoline and placebo <sep> nicergoline <sep>', 'copyright 1999 lippincott williams  wilkins <sep> placebo <sep> nicergoline 30 mg b.i.d <sep> nicergoline <sep>', 'nicergoline <sep> nicergoline <sep> placebo <sep> nicergoline 30 mg b.i.d <sep>', 'placebo <sep> nicergoline <sep> nicergoline nic or 2 x 1 placebo plac orally <sep> nicergoline an ergot alkaloid with metabolic antithrombotic and vasoactive action <sep> run-in period placebo <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",the clinical studies on nicergoline were carried out with diverse criteria and modalities of evaluation. despite this the 14 studies included in this review have presented generally consistent results. results of this meta-analysis provide some evidence of positive effects of nicergoline on cognition and behaviour and these effects are supported by an effect on clinical global impression. there was some evidence that there were increased risk of adverse effects associated with nicergoline. these results were obtained on older patients with mild to moderate cognitive and behavioural impairment of various clinical origins including chronic cerebrovascular disorders and alzheimer's dementia. the few studies specifically performed on patients with alzheimer's disease were performed with too few people to give a definitive answer to the questions concerning the use of nicergoline for this form of dementia.this drug has not been evaluated using current diagnostic categories such as mci or in association with therapeutic agents of different nature such as cholinesterase or antioxidant drugs.
102,"{'outcomes': ['1-month mortality rates <sep> survival outcome <sep> median survival <sep>', 'median survival times <sep>', 'complications of cirrhosis and worsening of the performance status test <sep> survival curves <sep> median survival <sep> cumulative survival <sep> tolerated and no marked side effects <sep> survival <sep>', 'baseline performance status and tumor stage <sep> probability of disease progression <sep> progression of hepatocellular carcinoma <sep> baseline performance status maintenance <sep> survival <sep>', 'complete remission <sep> survival <sep> response <sep>', 'survival <sep> median survival <sep>', 'survival <sep> survival rates <sep> adverse drug reactions <sep> risk of death <sep>', 'tolerated <sep> survival <sep> 1-year survival rate <sep>'], 'punchline_text': ['tamoxifen has no efficacy in the treatment of patients with advanced hcc and response to treatment was not affected by the expression of hormone receptors. <sep>', 'data were further analysed separately for advanced patients and for those eligible to potentially curative locoregional treatments relative hazard of death for patients receiving tamoxifen was equal to 0.98 <sep>', 'complications of cirrhosis and worsening of the performance status test occurred less in the treated patients than in the controls but not significantly so. <sep>', 'tamoxifen had no antitumoral effect with no differences in the survival between groups 1 and 2-year actuarial rate group a 51 and 27 and group b 43 and 29 p  0.75 even when stratifying patients according to baseline status. <sep>', 'this difference was not statistically significant nor was the difference in survival when compared by life-table analysis. <sep>', 'the survival of patients treated with tamoxifen improved significantly compared to the controls logrank-test p  0.04). <sep>', 'three-month survival rates for the p tmx60 and tmx120 groups were 44 41 and 35 respectively with a statistically significant trend difference in survival across the 3 treatment regimens p .011). <sep>', 'the 1-year survival rate was similar in both groups 30 in group 1 vs 37.8 in group 2 p  0.31). <sep>'], 'population': ['66 patients <sep> advanced hepatocellular carcinoma with <sep> patients with advanced hcc <sep> one hundred nineteen patients with advanced and otherwise untreatable hcc <sep> patients with advanced hepatocellular carcinoma hcc <sep>', '496 patients were randomised by 30 institutions from january 1995 to january 1997 <sep> 477 patients <sep> hepatocellular carcinoma hcc <sep> 480 patients <sep> patients with any stage hcc were eligible irrespective of locoregional treatment <sep> hepatocellular carcinoma <sep>', 'patients with advanced hepatocellular carcinoma <sep> thirty-six consecutive patients with advanced hepatocellular carcinoma and chronic liver disease <sep>', 'one hundred twenty patients with this neoplasm who were not suitable for surgery ethanol injection or transarterial embolization were included in a <sep> patients with advanced hepatocellular carcinoma <sep> patients with this neoplasm <sep> 120 patients <sep> patients with terminal diseases were excluded <sep> hepatocellular carcinoma <sep>', 'hepatocellular carcinoma <sep> 59 patients half of whom received <sep>', 'inoperable hepatocellular carcinoma <sep> twenty-two patients were matched and coupled for sex age child <sep> patients with advanced hepatocellular carcinoma <sep> patients with cirrhosis and advanced inoperable hepatocellular carcinoma <sep>', 'inoperable hepatocellular carcinoma <sep> 329 patients from 10 centers in 9 countries in the asia-pacific region enrolled <sep> patients with inoperable hcc <sep> patients with hepatocellular carcinoma hcc <sep> patients with inoperable hcc with respect to survival and quality of life qol <sep>', 'patients with advanced hepatocellular carcinoma <sep> patients with cirrhosis and advanced hepatocellular carcinoma <sep> patients with advanced hepatocellular carcinoma we included 80 patients with cirrhosis and advanced hepatocellular carcinoma <sep>'], 'interventions': ['tamoxifen <sep> tamoxifen <sep> placebo <sep> tamoxifen and placebo <sep>', 'tamoxifen <sep> tamoxifen <sep>', 'tamoxifen <sep> tamoxifen <sep>', 'tamoxifen <sep> tamoxifen <sep> placebo <sep>', 'tamoxifen <sep> doxorubicin and tamoxifen <sep> doxorubicin alone <sep> doxorubicin <sep>', 'tamoxifen or placebo <sep> tamoxifen <sep> antiestrogen tamoxifen <sep> placebo <sep>', 'high-dose tamoxifen <sep> tmx120 <sep> tmx <sep> tamoxifen tmx <sep> tmx 120 mg/d tmx120 against p as a control arm with an intermediate dosage of tmx 60 mg/d tmx60 <sep> tmx versus placebo p <sep>', 'tamoxifen <sep> tamoxifen <sep> placebo <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",these data do not support the use of tamoxifen for patients with hepatocellular carcinoma. further research on the effects of tamoxifen in hepatocellular carcinoma does not seem warranted.
103,"{'outcomes': ['nasogastric intubation <sep> nasogastric reintubation <sep> nausea postoperatively <sep> postoperative fever <sep> nausea <sep> abdominal distention <sep>', 'length of hospital stay duration of postoperative ileus adequacy of intraoperative intestinal decompression gastric dilatation and operative complications <sep>', 'earlier bowel sounds return of flatus oral intake and first bowel movement <sep> presence of atelectasis postoperative fever wound infections and anastomotic leaks <sep> length of hospital stay <sep>', 'time to passage of first flatus time to taking liquid diet length of operation and postoperative hospital stay <sep> postoperative fever nausea vomiting anastomotic leaks or pulmonary or wound complications <sep> subsequent nasogastric decompression <sep> postoperative course morbidity and mortality <sep>', 'overall failure rate <sep> mechanisms of injury injury severity score operative findings ngt removal times morbidity laboratory data and reasons for failure <sep> pain abdominal distention and vomiting <sep> injury severity score morbidity and lab values <sep> overall failure <sep>', 'incidence of mortality complications including vomiting or time to return of intestinal motility <sep> sore throat <sep> nausea <sep> decompression <sep> postoperative nasogastric decompression <sep>', 'volume of gastric juice <sep> length of the first passage of gas by anus and defecation <sep> gastrointestinal decompression <sep> incidence of pharyngolaryngitis <sep> overall incidence of complications <sep> length of hospitalization <sep> gastrointestinal tract pressure <sep> clinical therapeutic outcome and incidence of complication <sep>', 'pulmonary complications <sep> postoperative abdominal distention <sep> morbidity and mortality and hospital stay <sep>', 'incidence of vomiting <sep> morbidity and delayed return of gastrointestinal function <sep> nasogastric output <sep> incidence of vomiting or the duration of intubation <sep> pain with and frequency of swallowing and nose/throat discomfort <sep> duration of postoperative stay <sep> vomiting or abdominal distention <sep> pneumonias <sep> vomiting <sep> aspiration pneumonia gastric dilatation or wound dehiscence <sep> longer time until passage of flatus bowel movement and cessation of intravenous fluids <sep>', 'nausea vomiting time to first passage of flatus and stool time elapsed before adequate tolerance of a regular diet postoperative stay and complications <sep> operative times <sep> postoperative ileus <sep> shorter postoperative stay <sep> feasibility safety and tolerance of early feeding <sep> nausea and vomiting <sep> postoperative complications <sep> hindered deglutition and nasal soreness <sep>', 'prolonged operating times or difficult endotracheal intubation <sep> reinsertion rate <sep> mean length of hospitalization <sep> rate of minor symptoms of nausea vomiting and abdominal distention <sep> nasopharyngeal or gastric bleeding inability to cough effectively respiratory infections wound disruptions reoperation and wound infection rates <sep> abdominal distention nausea and vomiting <sep>', 'first passage of stool <sep> pulmonary infection <sep> median and average days to the first passage of flatus <sep> wound complications <sep> length of postoperative stay <sep> incidence rate of fever pharyngolaryngitis and pulmonary infection <sep> time to first passage of flatus the time to first passage of stool the time elapsed postoperative stay and postoperative complications such as anastomotic leakage acute dilation of stomach wound infection and dehiscense fever pulmonary infection and pharyngolaryngitis <sep> feasibility safety and tolerance <sep> postoperative complications such as anastomotic leakage <sep> fever <sep> postoperative complications <sep> acute dilation of stomach <sep> pharyngolaryngitis <sep>', 'hospital stay <sep> occurrence of nausea and vomiting <sep> occurrence of respiratory complications <sep> adverse events <sep> risk of respiratory complications and the length of hospital stay <sep> tolerance of ngt withdrawal and postoperative complications <sep> nausea and vomiting <sep> intensive care unit stay <sep>', 'incidence of anastomosis leak <sep> mean time of gas passage defecation bs auscultation and the duration of postoperative hospitalization <sep> gas passage defecation and bowel sounds bss auscultation as well as the duration of postoperative hospitalization nausea and vomiting abdominal distension pulmonary complications wound complications anastomosis leak and the need for placing/replacing the ng tube <sep>', 'duration and severity of postoperative paralysis <sep> occurrence and duration of nausea and vomiting postoperative peroral fluid intake and time for defecation <sep> frequencies of postoperative complications <sep>', 'length of hospital stay <sep> severe discomfort <sep> risk of pulmonary complications <sep> hospital mortality <sep> duration of ileus <sep> premature removal of the tube <sep> pneumonia <sep> medical morbidity <sep> overall surgical complications <sep> atelectasis <sep>', 'nasogastric decompression <sep> rate of reinsertion of nasogastric tube and morbidity <sep> morbidity mortality and speed of recovery <sep>', 'rates of major postoperative complications <sep> overall postoperative mortality <sep> postoperative length of hospital stay <sep> postoperative complications mortality and postoperative course <sep> postoperative pain or postoperative abdominal distention <sep> rates of anastomotic leak <sep> anastomotic disruption <sep> mean+/-sd time to passage of flatus <sep>', 'length of hospital stay <sep> preoperative risk factors aortic cross-clamp time estimated blood loss length of procedure length of intensive care unit stay numbers of days with nasogastric tube number of days until clear liquid and regular diets commenced and the length of hospital stay <sep>', 'time to tolerance of a regular diet and hospital stay <sep> average daily nasogastric output <sep> major complications eg pneumonia atelectasis gastrointestinal bleeding and wound breakdown or infection <sep> hematological indices and electrolytes <sep> subjective complaints eg ear pain painful swallowing and nasal soreness <sep> incidence of abdominal distention or nausea and vomiting <sep> longer times to first passage of flatus and tolerance of a clear liquid diet <sep> recurrent nausea and vomiting <sep> febrile morbidity <sep>', 'start of oral intake <sep> gastrointestinal function postoperative course and complications <sep> duration of postoperative perfusion <sep> length of hospital stay <sep> rates of nausea and vomiting <sep> postoperative mortality or morbidity especially fistula or intra-abdominal sepsis <sep> passage of flatus <sep> severe discomfort <sep>', 'postoperative loss of fluid <sep> incidence of postoperative complications <sep> subsequent insertion of a nasogastric tube <sep>', 'duration of hospitalization time to begin peroral fluid intake occurrence of hiccups vomiting nausea parotiditis nasal septum necrosis anastomotic leak and wound dehiscence <sep> abdominal distension pyrosis otalgia dysphagia odynophagia and atelectasis <sep>', 'earlier passage of flatus and feces and the lower incidence of postoperative gastrectasy <sep> occurrence of postoperative nausea vomiting abdominal distension complications and day of clinical release <sep>', 'length of hospital stay <sep> time to pass flatus <sep> incidence of complications <sep> incidence of nasogastric tube insertion <sep> history of upper gastrointestinal bleeding and pyloric obstruction <sep>', 'incidence of vomiting and nasogastric tube insertion <sep> time until the first bowel movement <sep> tolerated <sep> feasibility and safety <sep> complications <sep>', 'rate of abdominal distention nausea and vomiting <sep> incisional hernias <sep> incidence of incisional hernia <sep> postoperative abdominal distention and vomiting <sep>', 'return of bowel function return to a regular diet and postoperative length of hospital stay <sep> emesis <sep> shorter postoperative stay <sep>'], 'punchline_text': ['postoperative fever was noted in 23 patients 58 in group 1 and 14 38 in group 2 p  0.13 atelectasis was diagnosed in 38 per cent of patients in group 1 and 14 per cent in group 2 p  0.03). <sep>', 'no significant difference could be seen in the tubed or no-tube group. <sep>', 'there were no significant differences in the presence of atelectasis postoperative fever wound infections and anastomotic leaks between the two groups. <sep>', 'there were no significant differences between the two groups concerning the presence of postoperative fever nausea vomiting anastomotic leaks or pulmonary or wound complications. <sep>', 'injury severity score morbidity and lab values were not significantly different. <sep>', 'there was no statistically significant difference in the incidence of mortality complications including vomiting or time to return of intestinal motility between the two groups. <sep>', 'no difference in length of the first passage of gas by anus and defecation after operation was found between two groups. <sep>', 'postoperative abdominal distention was more common in patients without nasogastric tubes whereas pulmonary complications were more common in patients with nasogastric tubes. <sep>', 'nasogastric tubes reduced the incidence of vomiting from 28 in the no-tube group to 10 in the tube group p less than 0.05 but most had only one or two episodes. <sep>', 'early oral feeding in patients in arm a was associated with a significantly faster resolution of postoperative ileus p  .01 with a more rapid return to a regular diet p  .01 with an earlier first passage of stool p  .01 and with a shorter postoperative stay p  .05 than patients in arm b. rates of nausea and vomiting were similar in both arms. <sep>', 'there were no significant differences in nasopharyngeal or gastric bleeding inability to cough effectively respiratory infections wound disruptions reoperation and wound infection rates 5 between the two groups. <sep>', 'the postoperative complications such as anastomotic leakage 1.24 vs 2.58 acute dilation of stomach 1.86 vs 0.06 and wound complications 2.48 vs 1.94 were similar in the groups but fever 3.73 vs 9.68 p<0.05 pulmonary infection 0.62 vs 4.52 p<0.05 and pharyngolaryngitis 3.11 vs 23.23 p<0.001 were much more in the control group than in the experimental group. <sep>', 'this study does not support a significant effect of early removal of ngts on nausea and vomiting in patients undergoing open repair of the infrarenal aorta. <sep>', 'the incidence of anastomosis leak was significantly higher in the ng-tube group 6 vs. 0 p=0.016). <sep>', 'however no significant differences were found between the two groups with respect to duration and severity of postoperative paralysis as measured by occurrence and duration of nausea and vomiting postoperative peroral fluid intake and time for defecation. <sep>', 'pneumonia 13.0 versus 5.0 per cent p  0.047 and atelectasis 81 versus 67 per cent p  0.043 were significantly more common in the ngt group. <sep>', 'patients who were not intubated mobilised more quickly and spent less time in hospital. <sep>', 'the rates of anastomotic leak were similar in both groups 6.9 and 5.8 for the njt group and no-njt group respectively p  .71 as were the rates of major postoperative complications 25.9 and 21.5 respectively p  .42 and overall postoperative mortality 0.9 and 0.8 respectively p  .50). <sep>', 'the length of hospital stay was similar in both groups and three patients in each group required a nasogastric tube or reinsertion of one. <sep>', 'the nasogastric and orogastric groups were similar in age case distribution surgery length and blood loss. <sep>', 'duration of postoperative perfusion p  0.02 and length of hospital stay p  0.03 were also significantly longer in the tube group. <sep>', 'there were no significant differences between the two groups in the incidence of postoperative complications. <sep>', 'no significant differences were found between the two groups in the duration of hospitalization time to begin peroral fluid intake occurrence of hiccups vomiting nausea parotiditis nasal septum necrosis anastomotic leak and wound dehiscence. <sep>', 'no statistical difference was recorded concerning the occurrence of postoperative nausea vomiting abdominal distension complications and day of clinical release. <sep>', 'the incidence of nasogastric tube insertion in the tubeless group was similar to the incidence of nasogastric tube reinsertion in the intubated group p=0.747). <sep>', 'the incidence of vomiting and nasogastric tube insertion 21.5 was higher in patients in group i than in those in group ii. <sep>', 'developed incisional hernias compared with 15 6.6 percent of 229 patients who were not decompressed p  0.085). <sep>', 'the return of bowel function return to a regular diet and postoperative length of hospital stay were similar in both groups. <sep>'], 'population': ['forty patients were assigned to group 1 21 males 19 females and 37 to group 2 22 males and 15 females <sep> seventy-seven consecutive patients <sep> elective colorectal surgery <sep> malignant and premalignant lesions <sep>', 'elective colonic surgery <sep> one hundred thirty-eight consecutive patients undergoing elective colonic resections <sep>', 'patients with bowel anastomosis <sep> routine postoperative ng decompression benefited such patients 102 patients <sep> patients with chronic bowel obstruction peritonitis gross fecal contamination or spillage and previous abdominal or pelvic irradiation <sep>', 'university hospital korea <sep> patients with gastric cancer <sep> 136 patients with gastric cancer who underwent radical gastrectomy with d2 or more lymph node dissection <sep> n  69 or not n  67 <sep>', '175 patients 151 sustained penetrating injuries and 24 sustained blunt injuries <sep> trauma patients who have undergone emergency celiotomy to removal based on clinical signs of return of bowel function <sep> postceliotomy trauma patients <sep> all trauma patients who underwent an emergency celiotomy between november 1994 and august 1997 <sep> 151 patients in the penetrating injury group 68 were randomized to the 24-hour pull study group and 83 were randomized to the clinical pull control group <sep> 24 blunt injury patients <sep> patients with duodenal or esophageal injuries those with airway intubations that were 24 hours or those who had undergone same-hospitalization repeat celiotomy <sep> 177 patients qualified for the study <sep>', '97 patients were and 100 were not allocated <sep> after elective abdominal surgery <sep>', 'three hundred and sixty-eight patients with excision and anastomosis of lower digestive tract <sep> 200 general surgeons <sep> patients without undergoing gastrointestinal decompression <sep>', 'fifty-six patients undergoing elective colonic resection <sep>', '200 patients <sep> 200 consecutive patients who underwent major abdominal procedures <sep>', 'patients undergoing surgery for gynecologic malignancies <sep> patients undergoing major surgery for gynecologic malignancies <sep> after major oncologic gynecologic surgery <sep>', 'patients who had emergency surgery with peritonitis extensive fibrous adhesions enterotomies previous pelvic irradiation intra-abdominal infection pancreatitis chronic obstruction <sep> two hundred seventy-four patients received ng decompression salem sump argyle co. division of sherwood medical st. louis mo and two hundred sixty-one did not <sep> five hundred thirty-five patients <sep> benefitted patients undergoing this type of surgery <sep>', 'three hundred and sixteen patients submitted to operations associated with colorectostomy from january 2004 to september 2005 <sep> patients undergoing surgery for colorectal carcinoma <sep> patients rehabilitation after colorectostomy <sep>', 'forty-six patients underwent aortic operations <sep> patients undergoing surgery of the infrarenal aorta <sep> early nasogastric tube removal after infrarenal aortic surgery <sep> six patients were subsequently excluded from the study <sep> between october 2001 and may 2002 consecutive patients underwent scheduled infrarenal aortic operations <sep> 40 randomized subjects 20 patients were included in each group <sep> patients undergoing open repair of the infrarenal aorta <sep>', 'patients with esophageal cancer <sep> postoperative care of esophagectomy <sep>', 'intestinal paralysis after elective colorectal operations <sep> patients with paralytic ileus <sep> stomach after elective colorectal operations 97 patients <sep>', '200 patients who had elective hepatic resection including 68 who had previously had colorectal surgery 100 were randomized to <sep> after elective hepatic resection <sep>', 'patients with gastric cancer <sep> 37 patients <sep> seven patients with gastric outlet obstruction who had not been intubated needed to be so <sep> 74 patients with gastric cancer including 11 with gastric outlet obstruction who underwent <sep> surgical department taichung veterans general hospital taiwan <sep>', 'patients with gastric cancer <sep> two hundred thirty-seven patients undergoing total gastrectomy for gastric cancer <sep> elective total gastrectomy for gastric cancer <sep> patients undergoing total gastrectomy for gastric cancer <sep>', '80 patients undergoing abdominal aortic surgery <sep>', 'gynecologic oncology patients <sep> gynecologic oncology patients undergoing intra-abdominal surgery <sep> gynecologic oncology patients undergoing extensive intra-abdominal surgery <sep> patients with prior irradiation or substantial edema from bowel obstruction <sep> 110 gynecologic oncology patients undergoing extensive intra-abdominal surgery <sep>', 'elective gastrectomy <sep> 84 patients undergoing elective partial or total gastrectomy <sep>', '52 patients with suture lines constructed in the gastrointestinal tract received no <sep>', 'one hundred and nine patients <sep>', '100 patients who had elective uncomplicated abdominal surgery 50 subjects had the early removal of ngt and in 50 patients it was maintained until passage of flatus/feces <sep>', '119 patients with gastric adenocarcinoma <sep>', 'group i n  95 <sep> group ii n  95 <sep> patients who have elective colorectal surgery <sep> patients subjected to elective open colorectal surgery <sep> 190 patients who underwent an elective colon or rectal operation <sep>', 'patients undergoing elective abdominal colorectal surgery <sep> uncomplicated elective abdominal colorectal surgery <sep> 251 patients who received ng decompression 8 3.2 percent <sep>', 'eighteen patients in the <sep> 76 patients who were randomized into two groups those who received <sep> patients having major retroperitoneal or vascular procedures <sep> fifty-eight percent of patients in the selective ngd group who required intubation had had major vascular or retroperitoneal dissections <sep>'], 'interventions': ['group 1--nasogastric decompression was maintained postoperatively until resumption of bowel function group 2--the nasogastric tube <sep> nasogastric decompression <sep> elective colorectal surgery <sep> nasogastric decompression <sep>', 'long intestinal cantor tube preoperatively a nasogastric tube placed intraoperatively or no gastrointestinal tube at all <sep> nasointestinal intubation <sep>', 'routine postoperative nasogastric decompression <sep> routine nasogastric decompression <sep> ng decompression or no-ng tube <sep>', 'nasogastric decompression <sep> routine nasogastric decompression <sep> routine nasogastric decompression <sep> nasogastric decompression <sep>', 'nasogastric tubes ngts <sep> nasogastric tubes <sep>', 'nasogastric tube decompression <sep> nasogastric suction <sep> postoperative nasogastric decompression <sep>', 'postoperative gastrointestinal decompression and the group without postoperative gastrointestinal decompression <sep> gastrointestinal decompression <sep>', 'postoperative nasogastric decompression <sep>', 'cimetidine <sep> prophylactic postoperative nasogastric decompression <sep> cimetidine <sep> limbs no tube-placebo no tube-cimetidine tube-placebo and tube-cimetidine <sep> prophylactic nasogastric decompression <sep>', 'nasogastric decompression <sep> oral feeding and b nasogastric decompression <sep>', 'ng decompression or no decompression <sep> routine ng decompression <sep> elective colon and rectal surgery without nasogastric decompression <sep> nasogastric ng decompression <sep>', 'gastrointestinal decompression and early oral feeding <sep>', 'ngt maintenance <sep> ngt maintenance until the passage of flatus and group 2 ngt removal <sep> ngt decompression <sep> nasogastric tube ngt decompression <sep> ngts <sep>', 'metoclopramide <sep> nasogastric tube application <sep>', 'tube decompression of the stomach <sep> tube decompression <sep> tube decompression <sep> nasogastric tube after colorectal surgery <sep> postoperative treatment with or without nasogastric tubes <sep>', 'routine nasogastric tube ngt decompression <sep> ngt <sep> routine nasogastric decompression <sep> ngt decompression <sep>', 'routine postoperative nasogastric decompression <sep> nasogastric intubation <sep> radical gastrectomy with systematic extensive lymphadenectomy <sep> routine nasogastric tube decompression <sep> radical distal gastrectomy <sep>', 'njt after roux-en-y esophagojejunostomy <sep> nasojejunal tube placement after total gastrectomy <sep> njt placement njt group or not no-njt <sep> nasojejunal tube njt <sep> routine nasojejunal decompression after total gastrectomy with roux-en-y esophagojejunostomy <sep> njt <sep>', 'abdominal aortic surgery without postoperative nasogastric decompression <sep> nasogastric decompression <sep>', 'nasogastric decompression after extensive intra-abdominal surgery <sep> postoperative nasogastric tube versus intra-operative orogastric tube decompression <sep> postoperative nasogastric tube decompression <sep> postoperative nasogastric tube decompression <sep>', 'postoperative nasogastric or nasojejunal tube tube group n  43 or to a group without a tube no-tube group <sep> routine prophylactic nasogastric or nasojejunal decompression <sep> routine prophylactic postoperative nasogastric decompression <sep> nasogastric decompression <sep>', 'nasogastric intubation <sep> postoperative nasogastric drainage unless acute gastric dilation or copious vomiting <sep> routine postoperative nasogastric aspiration <sep>', 'tube decompression <sep> nasogastric tubes <sep>', 'nasogastric tube ngt <sep> ngt <sep> nasogastric tube after elective abdominal surgery <sep>', 'nasogastric decompression <sep> tubeless group <sep> gastric cancer surgery <sep> gastric cancer surgery with versus without nasogastric decompression <sep>', 'immediate oral feeding <sep>', 'nasogastric tubes <sep>', 'postoperative nasogastric decompression <sep> routine postoperative nasogastric decompression ngd <sep> selective ngd <sep> routine ngd <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>']}",routine nasogastric decompression does not accomplish any of its intended goals and so should be abandoned in favour of selective use of the nasogastric tube.
104,"{'outcomes': ['higher rate of minimal residual disability <sep> asymptomatic parenchymal hemorrhages <sep> bleeding complications <sep> major intracranial hemorrhage <sep> asymptomatic hemorrhagic lesions <sep>', 'asymptomatic hemorrhagic transformation <sep> mrs scores <sep> rate of symptomatic hemorrhage <sep> distribution of outcomes at 3 months after stroke using the modified rankin scale mrs based on an ordinal regression model of outcomes adjusting for baseline severity of stroke age and interval from stroke <sep> symptomatic intracranial hemorrhage <sep>'], 'punchline_text': ['asymptomatic parenchymal hemorrhages were detected on post-study agent ct in 4 of 54 abciximab patients 7 and in 1 of 20 placebo patients 5%). <sep>', 'symptomatic intracranial hemorrhage within 5 days was diagnosed in 7 of 195 3.6 patients treated with abciximab and 2 of 199 1 patients given placebo odds ratio or 3.7 p=0.09 95 confidence interval ci 0.7 to 25.9). <sep>'], 'population': ['patients underwent a scheduled follow-up <sep> seventy-four eligible and consenting patients presenting within 24 hours after ischemic stroke onset at 38 study sites <sep> 11 patients with asymptomatic hemorrhage had a baseline national institutes of health stroke scale score 14 <sep> acute ischemic stroke <sep>', 'patients with acute ischemic stroke <sep> 400 patients within 6 hours of onset of ischemic stroke <sep> patients with stroke <sep>'], 'interventions': ['placebo <sep> abciximab <sep> abciximab <sep>', 'placebo <sep> abciximab <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>']}",there is currently not enough evidence from randomised controlled trials regarding the efficacy or safety of gp iib-iiia inhibitors therapy in acute ischaemic stroke. results from ongoing trials will help to understand the risk to benefit ratio of these agents.
105,"{'outcomes': ['unified parkinson disease rating scale <sep> severity of off periods decreased disability and pd severity <sep> motor function <sep> efficacy safety <sep> gastrointestinal and cardiovascular tolerability <sep> time spent in off periods <sep>', 'off-periods <sep>', 'change in hours and percent of daily on time and on time without troublesome dyskinesia unified pd rating scale motor and activities of daily living subscales beck depression inventory-ii pdq-39 subscales of mobility activities of daily living emotional well-being stigma and communication and pd sleep scale <sep> reduction in hours of daily off time <sep> effective and well tolerated <sep> dyskinesia nausea dizziness somnolence hallucinations and orthostatic hypotension and aes led to study withdrawal <sep> mean reduction in daily off time <sep> both motor and non-motor pd symptoms <sep>', ""total daily off-time intention-to-treat population <sep> rasagiline efficacy and safety <sep> updrs scores <sep> cgi scores <sep> daily on-time without troublesome dyskinesia <sep> motor function <sep> mean daily off-time and improves symptoms of parkinson's disease <sep> frequency of adverse events <sep> clinical global improvement cgi score and unified parkinson's disease rating scale updrs scores <sep> mean daily off-time <sep>"", 'time <sep> percentage of on time relief of parkinsonism <sep> percent on time <sep> motor fluctuations <sep>', 'adverse events <sep> mean percentage of asleep time <sep> total number of off hours <sep> daily off time <sep> occurrence of drug-related adverse events <sep> average number of dyskinesia-free <sep> efficacy and safety of zydis selegiline <sep>', ""dopaminergic and nondopaminergic adverse events <sep> unified parkinson's disease rating scale subscale ii <sep> nausea cramps dyskinesia and dystonia <sep> levodopa dosage <sep> levodopa dosage <sep>"", 'dyskinesias <sep> adverse events <sep> overall safety profile <sep> safety and tolerability profile <sep>', 'total score of the webster and the nuds scales <sep> therapeutic effectiveness <sep>', 'improvement of on and off time while awake patient diary and updrs part iv item 39 investigators global assessment the sf-36 health survey and changes in levodopa dosages <sep> efficacy <sep> adverse events laboratory safety and vital signs <sep> efficacy and tolerability <sep> dyskinesias <sep> efficacy and tolerability <sep> updrs overall dyskinesia score <sep>', 'dyskinesia <sep> diarrhea <sep> motor function <sep> number of daily levodopa intakes <sep> motor function and overall efficacy <sep> mean daily levodopa dose requirement <sep>', 'dyskinesia <sep> activity and tolerability <sep> hours off <sep> average hoehn and yahr stage of disease and schwab and england activities of daily living index <sep>', ""unified parkinson's disease rating scale updrs parts ii and iii <sep> safety data <sep> dyskinesia and nausea <sep> advanced pd <sep> updrs part ii <sep> safety tolerance and efficacy <sep>"", ""unified parkinson's disease rating scale updrs part ii activities of daily living adl and the parkinson's disease questionnaire pdq)-39 summary index <sep> parkinsonian disability and health-related quality of life qol <sep> quality of life and activities of daily living <sep> adl global function motor performance and was well tolerated <sep> updrs part iii motor scores <sep> pdq-39 subscores the sf-36 variables or the eq-5d utility score <sep> global assessment of change pdq-39 subscores and the short-form sf)-36 and the european quality of life <sep> adl scores <sep> five-dimension questionnaire eq-5d <sep>"", 'bradykinesia <sep> updrs motor scores <sep> stride length and angular excursion of the hip and knee joints <sep> levodopa/benserazide in walking speed stride length and the range of motion of hip knee and ankle joints <sep>', 'proportion of daily on time <sep> efficacy <sep> absolute on time mean sd <sep> daily off time <sep> levodopa requirement <sep> clinical efficacy and safety <sep> updrs activities of daily living adl <sep> tolerated <sep> adl scores <sep> unified parkinson disease rating scale updrs and recording of daily levodopa dose <sep>', 'responder rates <sep> number of discontinuations <sep> absolute change in total hours off assessed by home diaries <sep>', ""tolerated <sep> mean adjusted total daily off time <sep> motor fluctuations and pd symptoms <sep> rasagiline treatment including scores on an investigator-rated clinical global impression scale and the unified parkinson's disease rating scale activities of daily living in the off state and motor performance in the on state <sep> safety tolerability and efficacy of rasagiline <sep>"", ""number of full-time-employed patients at study end cumulative days of medical absenteeism patient-completed disability assessments diary records and the unified parkinson's disease rating scale-based measures of motor fluctuations and dyskinesias <sep> employment rate <sep> retirement rate <sep> self-perception of disability progression <sep> lower absenteeism rate <sep> employment medical absenteeism and disability perception <sep>"", ""efficacy safety and tolerance <sep> fatigue dyskinesia and vivid dreams <sep> total score of the unified parkinson's disease rating scale updrs <sep> adverse events vital signs laboratory measurements and ecg recordings <sep> mean updrs total score <sep> updrs total scores subscores part ii iii activities of daily living and motor examination and iv complications of therapy <sep> activities of daily living motor function <sep> safety and tolerability <sep>"", ""somnolence <sep> subitems motivation/initiative and depression in a subpopulation with increased unified parkinson's disease rating scale i scores <sep> updrs sum scores <sep>"", 'adverse reactions <sep>', 'dopaminergic adverse events <sep> diarrhea <sep> tolerated <sep> time <sep> off time <sep> beneficial response <sep>', ""efficacy <sep> mean updrs total scores <sep> number of off hours <sep> clinical laboratory test results blood chemistry hematology and urinalysis vital signs and electrocardiograms <sep> efficacy safety and tolerability <sep> mean scores <sep> levodopa <sep> total scores of the updrs part ii part iii and parts ii and iii combined <sep> unified parkinson's disease rating scale updrs <sep> safety and tolerability <sep> efficacy and safety <sep>"", ""quality of life sickness impact profile scores <sep> mean total daily levodopa dose <sep> wearing off <sep> levodopa requirements improvement in patients clinical status duration of improvements and tolerability of tolcapone <sep> dyskinesia <sep> diarrhea <sep> unified parkinson's disease rating scale motor and total scores <sep> tolerated <sep> time <sep> off time <sep>"", ""time increased 1.7 h and off time <sep> efficacy <sep> efficacy and safety <sep> increased dyskinesias <sep> updrs activities of daily living and motor scores <sep> daily levodopa dose <sep> nausea <sep> vital signs ecg or laboratory results <sep> entacapone efficacy <sep> home diaries on and off times unified parkinson's disease rating scale updrs and changes in levodopa dosage and safety by adverse-event inquiry vital signs electro cardiography ecg and laboratory tests <sep> efficacy and safety <sep>"", 'percent awake time spent off <sep> adverse effects <sep> mean daily l-dopa dose <sep>', 'side-effect <sep> tolerated <sep> state <sep> activities of daily living <sep> motor examination <sep>', 'wearing off and symptom severity <sep> frequency of withdrawals because of adverse events <sep> tolerated <sep> levodopa requirements <sep> quality-of-life measures <sep> principal adverse events mainly dyskinesia and nausea <sep> efficacy and tolerability <sep> fluctuations <sep>', ""levodopa requirement <sep> motor function <sep> total on time <sep> united parkinson's disease rating scale motor subscale and on/off and dyskinesia assessments <sep> off time <sep> efficacy and safety <sep> total levodopa requirements <sep>"", 'bromocriptin dosage <sep> side effects orthostatic hypotension exogenous psychotic symptoms <sep>', 'disability <sep> objective quality of the on state <sep> mean hourly self-assessment of gait <sep> mean hourly overall symptom control <sep> nausea light-headedness dyskinesias and hallucinations all of which abated after the sinemet dose <sep> mean daily sinemet dosage decreases <sep>', ""total unified parkinson's disease rating scale updrs score <sep> adverse events <sep> platelet mao-b inhibition <sep> safety and tolerability <sep> safety tolerability <sep>"", 'toxicity <sep> dryness of mouth urine discoloration and diarrhoea <sep> hepatic enzyme activity ecg or haemodynamic parameters <sep> mean daily levodopa dose <sep> efficacy parkinsonian symptoms <sep> safety evaluation of adverse events aes vital signs ecg and laboratory parameters <sep>', 'nonserious dopaminergic adverse events <sep> duration of off periods as assessed by self-scoring diary cards <sep>', 'wearing-off phenomena and frozen gait <sep> side effects <sep> dopamine antagonistic actions <sep>', ""adverse reactions <sep> total parkinson's score scores of activities of daily living motor function number of off hours hoehn and yahr stage and numerous parameters of parkinsonian function including bradykinesia rigidity gait and dexterity <sep> cardiac or electrocardiographic abnormalities <sep>"", ""aggravated parkinsonism <sep> dizziness insomnia nausea and postural hypotension <sep> mean reduction in l-dopa requirement <sep> safe and well tolerated <sep> total score on the unified parkinson's disease rating scale updrs <sep>""], 'punchline_text': ['adverse effects related to the central nervous system were similar to those reported with other dopamine agonists and the gastrointestinal and cardiovascular tolerability of the compound was satisfactory. <sep>', 'the trial demonstrates that with deprenyl the levodopa dosage can be reduced considerably without prejudicing the therapeutic outcome. <sep>', 'there was a mean reduction in daily off time of 2.1 hours in the ropinirole 24-hour group and 0.3 hours with placebo. <sep>', 'both rasagiline and entacapone reduced mean daily off-time 1.18 h rasagiline and 1.2 h entacapone vs placebo 0.4 h p=0.0001 p<0.0001 respectively and increased daily on-time without troublesome dyskinesia 0.85 h vs placebo 0.03 h p=0.0005 for both). <sep>', 'entacapone is effective at increasing the duration of response to levodopa and at relieving parkinsonism in patients experiencing motor fluctuations and was well tolerated during the 24 weeks of treatment. <sep>', 'no apparent differences were detected in the occurrence of drug-related adverse events between the zydis selegiline group and placebo-treated groups. <sep>', 'both tolcapone groups had greater reductions in levodopa dosage than the placebo group at week 6 not statistically different). <sep>', 'adverse events occurred in 79 patients 69.9 in placebo 82 72.6 in 100 mg and 98 86.0 in 200 mg. <sep>', 'the addition of bromocryptine in high doses average daily dose 71 mg induced a significant improvement in the total score of the webster and the nuds scales. <sep>', 'the proportion of patients showing an improvement at the investigators global assessment was significantly higher p  0.0006 in the entacapone-treated group of patients. <sep>', 'we found significant improvements in motor function and overall efficacy in the tolcapone groups p  0.01). <sep>', 'following incremental dose titration patients in the cabergoline group had a significant reduction in hours off per day from 5.0 sd 2.1 to 3.0 sd 2.5 but there was no change in this measure in the placebo group 4.0 2.2 and 3.3 2.3 respectively]. <sep>', 'the updrs part iii showed improvements of 34 for pramipexole p  0.0006 and 23.8 for bromocriptine p  0.01 versus 5.7 for placebo. <sep>', 'there were no significant differences between treatments for any of the pdq-39 subscores the sf-36 variables or the eq-5d utility score. <sep>', 'gait analysis disclosed a significant improvement by levodopa/benserazide in walking speed stride length and the range of motion of hip knee and ankle joints. <sep>', 'in this group of patients adl scores improved in the entacapone group p  0.01 v placebo and there was also a 40 mg reduction in levodopa requirement p  0.01 v placebo). <sep>', 'in terms of change in absolute off time rotigotine was non-inferior to pramipexole. <sep>', 'compared with placebo patients treated with 1.0 mg/d rasagiline had 0.94 hour less off time per day and patients treated with 0.5 mg/d rasagiline had 0.49 hour less off time per day. <sep>', 'ld  ent treatment was associated with a lower retirement rate 2 17 of 12 vs. 6 50 of 12 p  0.12 lower absenteeism rate 21.5 vs. 43.5 days p  0.0001 improved self-perception of disability progression over 2 years change score 1.0 vs. 4.5 p  0.0001 and lower scores for both motor fluctuations and dyskinesia assessments compared to ld monotherapy. <sep>', 'there was a significant improvement of the pramipexole group in updrs total scores subscores part ii iii activities of daily living and motor examination and iv complications of therapy). <sep>', 'differences between the treatment groups became significant at a daily dose of 0.75 mg of pramipexole dihydrochloride. <sep>', 'this resulted in a significant decrease in the amount of levodopa side-effects while maintaining or improving the original parkinsonian clinical stage. <sep>', 'long-term entacapone treatment effectively prolonged the beneficial response to levodopa in parkinsonian patients with the wearing-off phenomenon. <sep>', 'pramipexole was also superior to placebo as measured by improvement in the modified hoehn and yahr scale and a reduction in the number of off hours for patients on concomitant levodopa therapy. <sep>', ""with 200 mg tolcapone tid unified parkinson's disease rating scale motor and total scores were significantly reduced and quality of life sickness impact profile scores were significantly improved. <sep>"", 'in the total population the updrs activities of daily living and motor scores were significantly improved p  0.05 by entacapone vs placebo. <sep>', 'the mean daily l-dopa dose was reduced significantly with ropinirole treatment 242 mg versus 51 mg p  0.001 as was the percent awake time spent off 11.7 versus 5.1 p  0.039). <sep>', 'the cabergoline patients had significantly better activities of daily living p  0.032 and motor examination p  0.031 scores at the conclusion of the trial compared with the placebo group. <sep>', 'investigators global measures of disease severity indicated that significantly more tolcapone-treated patients had reduced wearing off and symptom severity p<.001 vs placebo). <sep>', 'tolcapone is a potent catechol-o-methyltransferase inhibitor that prolongs the plasma half-life of levodopa. <sep>', ""the symptoms of parkinson's disease were favourably influenced with rigor tremor and also walking disturbances responding better than bradykinesia of the hands. <sep>"", 'mean hourly overall symptom control improved in 29 58 taking deprenyl mean 0.34 and in 12 26.1 taking placebo mean 0.15 p less than 0.01 for each parameter). <sep>', 'adverse events were no different than those of patients taking placebo. <sep>', 'dryness of mouth urine discoloration and diarrhoea were more frequent non-dopaminergic aes with entacapone than with placebo. <sep>', 'ropinirole significantly reduced the duration of off periods as assessed by self-scoring diary cards. <sep>', 'no irreversible side effects were noted. <sep>', ""at 6 months patients randomized to pergolide had a statistically significant improvement in total parkinson's score scores of activities of daily living motor function number of off hours hoehn and yahr stage and numerous parameters of parkinsonian function including bradykinesia rigidity gait and dexterity. <sep>"", ""total score on the unified parkinson's disease rating scale updrs for the intent-to-treat population was significantly improved in the pramipexole-treated group compared with the placebo-treated group 16.9  <sep>""], 'population': [""advanced parkinson's disease <sep> advanced pd patients with motor fluctuations under levodopa treatment <sep>"", ""parkinson's disease <sep> 40 patients of both sexes with at least 3 years history of parkinson's disease who were undergoing stabilized levodopa therapy <sep>"", 'patients with parkinson disease pd not optimally controlled with <sep> advanced parkinson disease <sep> 393 subjects with pd <sep> patients with parkinson disease pd and motor fluctuations <sep>', ""patients with parkinson's disease and motor fluctuations largo <sep> 88 13 patients who were assigned treatment did not complete the study 23 rasagiline 30 <sep> treated patients with parkinson's disease and motor fluctuations <sep> 74 hospitals and academic centres in israel argentina and europe trial 687 outpatients <sep>"", ""pd patients with motor fluctuations <sep> levodopa-treated parkinson's disease patients <sep> two hundred five patients <sep>"", ""parkinson's disease patients with motor fluctuations <sep> copyright 2004 movement disorder society <sep> patients with pd <sep> parkinson's disease pd patients who were experiencing motor fluctuations with levodopa <sep>"", ""patients with moderately advanced parkinson's disease with treated wearing-off phenomenon <sep> parkinsonian patients <sep> stable parkinsonian patients <sep> 97 patients <sep>"", ""japanese parkinson's disease pd patients with wearing-off motor fluctuations <sep> fluctuating parkinsonian patients <sep> 341 patients to receive <sep>"", ""23 patients with advanced parkinson's disease <sep>"", ""162 patients with parkinson's disease pd treated with <sep> patients with parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations <sep> and experiencing wearing-off motor fluctuations <sep>"", 'parkinsonian patients with the wearing-off phenomenon <sep> 202 parkinsonian patients who were experiencing the wearing-off phenomenon on levodopa therapy <sep>', 'parkinsonians with motor fluctuations <sep> 19 patients or <sep> 37 patients with severe fluctuations in response to treatment <sep>', ""advanced parkinson's disease <sep> 247 patients with wearing off <sep> advanced parkinson's disease pd patients <sep> patients with advanced pd with motor fluctuations <sep>"", ""subjects with parkinson's disease pd experiencing motor fluctuations <sep> patients experiencing wearing-off type fluctuations <sep> 270 pd patients <sep>"", ""40 patients with wearing-off phenomenon <sep> patients with advanced parkinson's disease <sep>"", ""fluctuating parkinson's disease patients <sep> 172 fluctuating and 128 non-fluctuating patients <sep> cases of parkinson's disease with both fluctuating and non-fluctuating response to treatment <sep> patients with parkinson's disease <sep>"", ""treated patients with advanced parkinson's disease and wearing-off type motor fluctuations <sep> 204 patients <sep> patients with fluctuating parkinson's disease over 6 months of treatment <sep> advanced parkinson's disease <sep> advanced pd <sep> eligible participants <sep>"", 'patients with early illness <sep> parkinson disease patients n  472 with at least 21/2 hours of daily off poor motor function time despite optimized treatment with other anti-pd medications <sep> levodopa-treated pd patients <sep> treated patients with pd and motor fluctuations <sep> treated patients with parkinson disease and motor fluctuations <sep>', ""parkinson's disease <sep> full-time-employed patients with parkinson's disease pd <sep> thirty full-time-employed pd patients disease onset before age 60 years and on optimized monotherapy with ld exhibiting minor motor fluctuations or dyskinesias <sep>"", ""advanced parkinson's disease <sep> seventy eight patients of either sex with advanced parkinson's disease and treatment complications such as motor fluctuations <sep> advanced parkinsonian patients with motor fluctuations <sep> patients with advanced parkinson's disease <sep>"", ""advanced parkinson's disease <sep> 262 patients who were subsequently enrolled into the open-label study featuring a maximum duration of up to 57 months <sep> 354 patients with parkinson's disease pd and motor fluctuations under individually adjusted therapy with <sep>"", ""parkinson's disease <sep> patients with moderately severe parkinson's disease <sep>"", '171 parkinsonian patients with wearing-off-type motor fluctuations <sep> parkinsonian patients with the wearing-off phenomenon <sep> parkinsonian patients with motor fluctuations <sep> patients with pd with wearing-off motor fluctuations <sep>', ""treated patients with parkinson's disease <sep> chinese patients with parkinson's disease <sep> untreated and levodopa-treated chinese patients with early or advanced parkinson's disease <sep>"", '58 patients received <sep> fluctuating parkinsonian patients <sep> treated fluctuating parkinsonian patients <sep>', ""301 pd patients the majority with motor fluctuations received <sep> germany and austria celomen study <sep> parkinson's disease patients with suboptimal levodopa response <sep> parkinson's disease pd patients <sep>"", ""parkinson's disease <sep> pd patients with motor fluctuations <sep>"", ""parkinson's disease <sep> treated patients with suboptimally controlled parkinson's disease pd <sep>"", 'two hundred fifteen referred outpatients with parkinson disease who showed predictable end-of-dose motor fluctuations that were not controlled by a stable levodopa-carbidopa sinemet regimen of at least 4 weeks duration <sep> fifteen parkinson disease clinics <sep> levodopa-treated parkinsonian patients <sep> patients with fluctuating parkinson disease <sep> patients with fluctuating parkinson disease treated with <sep>', ""patients with parkinson's disease experiencing motor fluctuations <sep> pd patients with motor fluctuations <sep> patients with parkinson's disease pd experiencing motor fluctuations from <sep> one hundred fifty-one patients completed the study <sep>"", ""forty patients with severe parkinson's disease 23 men 17 women who had been treated for six years with l-dopa-decarboxylase inhibitor were part of a <sep> progressive stages of parkinson's disease author's transl <sep>"", ""advanced parkinson's disease pd <sep> advanced parkinson's disease <sep> 96 patients with marked symptom fluctuations at three centers to receive either <sep>"", ""parkinson's disease <sep> 70 patients with pd mean age <sep> 57.4 y <sep> patients with early parkinson's disease pd <sep> mean disease duration 5.7 y 32 patients had motor fluctuations <sep>"", ""study population represented typical pd outpatients including patients with varying disease severity and with various concomitant medications <sep> 326 patients with idiopathic parkinson's disease pd <sep> patients with parkinson's disease <sep>"", ""parkinsonian patients with moderate motor disability and motor fluctuations <sep> forty-six patients with parkinson's disease experiencing motor fluctuations and not optimally controlled on <sep> patients with parkinson's disease <sep>"", ""patients who are manifesting various difficulties in levodopa therapy <sep> patients with parkinson's disease manifesting various problems <sep>"", ""parkinson's disease <sep> three hundred and seventy-six subjects with advanced parkinson's disease <sep>"", ""69 patients with advanced parkinson's disease 33 received <sep> advanced parkinson's disease <sep> patients with advanced parkinson's disease <sep>""], 'interventions': ['pramipexole <sep> placebo <sep> pramipexole <sep>', 'deprenyl selegiline combined with levodopa and a decarboxylase inhibitor <sep> placebo <sep>', 'ropinirole <sep> ropinirole 24-hour <sep> placebo <sep> ropinirole <sep> ropinirole 24-hour prolonged release ropinirole 24-hour <sep> levodopa <sep>', 'placebo <sep> entacapone <sep> entacapone 35 placebo <sep> rasagiline <sep> levodopa <sep> rasagiline mesylate <sep> oral rasagiline <sep>', 'levodopa therapy <sep> placebo <sep> entacapone <sep> levodopa <sep> entacapone <sep> entacapone 200 mg or matching placebo <sep>', 'levodopa <sep> placebo <sep> zydis selegiline <sep> drug or placebo <sep>', 'tolcapone <sep> placebo <sep> levodopa <sep> placebo or tolcapone <sep> tolcapone <sep>', 'placebo <sep> entacapone 100 or 200 mg or placebo <sep> placebo <sep> entacapone <sep> levodopa and a dopa decarboxylase inhibitor dci <sep> levodopa/dci <sep>', 'bromocryptine <sep> levodopa <sep> bromocryptine <sep>', 'placebo <sep> entacapone <sep> levodopa <sep> entacapone 200 mg or placebo <sep> entacapone and placebo <sep> levodopa and a dopamine agonist <sep>', 'new catechol-o-methyltransferase inhibitor tolcapone <sep> tolcapone <sep> tolcapone <sep> placebo <sep>', 'levodopa therapy <sep> cabergoline <sep> placebo <sep> dopamine agonist <sep>', 'placebo <sep> bromocriptine and placebo <sep> pramipexole <sep> bromocriptine <sep> pramipexole <sep> pramipexole and bromocriptine <sep> international pramipexole-bromocriptine <sep>', 'placebo <sep> entacapone <sep> levodopa with entacapone <sep> levodopa/dopa decarboxylase inhibitor ddci plus entacapone with levodopa/ddci plus placebo <sep> levodopa/ddci/entacapone <sep> levodopa/ddci/placebo <sep> levodopa <sep> updrs parts <sep> entacapone 200 mg or placebo <sep>', 'levodopa and tolcapone <sep> tolcapone <sep> placebo <sep> levodopa/benserazide and tolcapone <sep>', 'entacapone <sep> placebo <sep> levodopa <sep> entacapone <sep>', 'placebo <sep> pramipexole and transdermal rotigotine <sep> levodopa <sep> rotigotine <sep> pramipexole and 101 to receive placebo <sep> pramipexole and transdermal rotigotine <sep> pramipexole <sep>', 'levodopa <sep> placebo <sep> rasagiline n-propargyl-1[r]-aminoindan mesylate <sep> rasagiline <sep>', 'entacapone ent <sep> entacapone adjunctive therapy <sep> ent adjunctive therapy <sep> placebo <sep> levodopa with a decarboxylase inhibitor ld <sep> ld  ent <sep>', 'placebo <sep> pramipexole <sep> placebo n=44 to a previously stabilised antiparkinsonian medication <sep> ergoline dopamine agonist pramipexole <sep> pramipexole <sep>', 'pramipexole dihydrochloride <sep> placebo <sep> pramipexole and 180 placebo <sep> levodopa <sep> pramipexole <sep>', 'bromocriptine parlodel sandoz <sep> bromocriptine <sep>', 'placebo <sep> entacapone <sep> levodopa <sep> entacapone or identical placebos <sep> entacapone <sep>', 'placebo <sep> pramipexole <sep> placebo/levodopa <sep> ergot dopamine agonist pramipexole <sep> levodopa <sep> pramipexole/levodopa <sep> pramipexole <sep>', 'tolcapone <sep> placebo <sep> tolcapone tid in addition to levodopa/benserazide <sep> levodopa <sep> tolcapone <sep>', 'catechol-o-methyltransferase comt inhibitor entacapone <sep> placebo <sep> entacapone <sep> entacapone withdrawal <sep> placebo with each daily dose of standard or controlled-release cr levodopa <sep> levodopa <sep> entacapone <sep> diarrhoea entacapone <sep>', 'ropinirole <sep> placebo <sep> dopamine agonists <sep> ropinirole <sep> nonergot dopamine agonist ropinirole <sep>', 'placebo <sep> cabergoline <sep> levodopa <sep> levodopa/carbidopa <sep> cabergoline <sep>', 'tolcapone <sep> placebo <sep> levodopa-carbidopa <sep> catechol-o-methyltransferase inhibitor tolcapone <sep> placebo or tolcapone <sep> tolcapone <sep>', 'levodopa/carbidopa <sep> tolcapone <sep> placebo <sep> levodopa <sep> levodopa/carbidopa <sep> tolcapone <sep>', 'bromocriptin <sep> placebo <sep> bromocriptin <sep>', 'deprenyl 5 mg b.i.d. or placebo in parallel fashion in addition to a previously optimized levodopa/carbidopa sinemet regimen <sep> placebo <sep>', 'rasagiline as monotherapy <sep> rasagiline mesylate a new mao-b inhibitor <sep> placebo <sep> rasagiline mesylate tvp-1012 <sep> levodopa <sep> rasagiline <sep>', 'placebo <sep> entacapone <sep> entacapone combined with levodopa and a dopadecarboxylase ddc inhibitor <sep> levodopa <sep> entacapone <sep>', 'ropinirole <sep> levodopa <sep> placebo <sep> nonergoline dopamine agonist ropinirole <sep>', 'levodopa therapy <sep> bromocriptine <sep> bromocriptine or placebo <sep> levodopa <sep>', 'dopamine agonist pergolide mesylate <sep> levodopa <sep> placebo <sep> pergolide <sep>', 'placebo <sep> placebo 36 received pramipexole <sep> copyright lippincott-raven publishers <sep> l-dopa plus a dopa decarboxylase inhibitor <sep> pramipexole <sep> pramipexole snd 919 a potent non-ergot dopamine agonist or placebo <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",compared to placebo adjuvant therapy reduces off-time levodopa dose and improves updrs scores in pd patients who develop motor complications on levodopa therapy. however this is at the expense of increased dyskinesia and numerous other side-effects. indirect comparisons suggest that dopamine agonist therapy may be more effective than comti and maobi therapy which have comparable efficacy. however as indirect comparisons should be interpreted with caution direct head-to-head randomised trials assessing the impact of these different drug classes on overall patient-rated quality of life are needed.
106,"{'outcomes': ['hba(1c reductions <sep> glucose control <sep> tolerated <sep> change in hba(1c <sep> fasting plasma glucose fpg lipids body mass index bmi body composition blood pressure insulin sensitivity estimates using the minimal model glucose and insulin responses to a meal challenge quality of life adverse events or other safety indices <sep> hba(1c <sep>', 'low-density lipoprotein ldl cholesterol <sep> fasting glucose <sep> total cholesterol <sep> hba1c fasting glucose lipids blood pressure and weight <sep>', 'satisfactory and no adverse effects <sep> serum triglyceride <sep> fasting blood sugar <sep> glycosylated haemoglobin hba1c and fasting blood sugar fbs alteration of lipid profile by serum cholesterol ldl vldl hdl and triglycerides <sep> safety and effectiveness <sep> hypoglycemic effect <sep> hdl <sep> mean change with inolter in serum cholesterol <sep>', 'liver function tests hematologic parameters or the kidney function tests <sep> liver enzymes kidney function tests hematologic parameters blood glucose insulin and c-peptide assays <sep> efficacy and safety <sep> levels of fasting and postprandial blood glucose cholesterol triglycerides glycated hemoglobin hb a(1c and fasting insulin <sep>'], 'punchline_text': ['there were no significant treatment-related differences in the fasting plasma glucose fpg lipids body mass index bmi body composition blood pressure insulin sensitivity estimates using the minimal model glucose and insulin responses to a meal challenge quality of life adverse events or other safety indices between treatment groups. <sep>', 'using analysis of co-variance ancova we found no significant differences for clinical outcomes at 6 months between on-study patient groups though trends favored the ayurvedic group. <sep>', 'inolter appears to be an useful adjunctive therapy to exercise and diet control in newly diagnosed type 2 diabetes mellitus. <sep>', 'cogent db did not alter the liver function tests hematologic parameters or the kidney function tests. <sep>'], 'population': ['36 subjects who completed the study were comparable between treatment groups <sep> type 2 diabetes mellitus <sep> type 2 diabetes <sep> patients with type 2 diabetes for  1 year were entered into 2 strata of hemoglobin a(1c hba(1c <sep> type 2 diabetic patients inadequately treated with diet/lifestyle or stable doses of <sep> nineteen subjects entered stratum 1 and 17 entered stratum 2 <sep>', 'newly diagnosed people with type 2 diabetes <sep> control patients attended standard diabetes education classes with primary care clinician follow-up <sep> type 2 diabetes <sep> participants we recruited 60 adult patients with baseline glycosylated hemoglobin hba1c values between 6.0 and 8.0 <sep>', 'newly diagnosed type 2 diabetes mellitus <sep> sixty newly diagnosed patients of type-2 diabetes <sep> type 2 diabetes <sep> newly diagnosed type 2 diabetics <sep>', 'patients with type 2-diabetes <sep> nineteen 19 subjects 10 and 9 from control and treatment groups respectively dropped out of the study leaving a total of 60 subjects 30 each for control and treatment groups who completed the study <sep> 39 cogent db-treated cases and 40 age-matched controls <sep> two major peripheral clinics of kuala lumpur in the klang valley malaysia <sep> patients with type 2 diabetes <sep>'], 'interventions': ['pancreas tonic an ayurvedic herbal supplement <sep> placebo <sep> sulfonylureas and/or metformin <sep> pancreas tonic or matching placebo <sep> ayurvedic herbal supplement <sep>', 'whole-system ayurvedic intervention <sep> whole-system ayurvedic protocol <sep> complementary and alternative medicine cam <sep> exercise an ayurvedic diet meditation instruction and an ayurvedic herb supplement ma 471 <sep> ayurvedic intervention <sep>', 'ldl <sep> vldl <sep> placebo <sep> inolter herbal product <sep>', 'placebo <sep> cogent db 2 tablets three times daily after each meal in addition to the regular allopathic drugs daonil aventis farma sa petaling jaya selangor state malaysia and diamicron sevier bangkok thailand with or without metformin upha corporation bangi selangor state india <sep> cogent db an ayurvedic drug <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",although there were significant glucose-lowering effects with the use of some herbal mixtures due to methodological deficiencies and small sample sizes we are unable to draw any definite conclusions regarding their efficacy. though no significant adverse events were reported there is insufficient evidence at present to recommend the use of these interventions in routine clinical practice and further studies are needed.
107,"{'outcomes': ['hyponatremia <sep> severe complications <sep> blood chemistry liver kidney pituitary and endocrinal functions <sep> blood chemistry liver kidney and endocrine functions <sep> index and lactate dehydrogenase ld of the cystic fluids blood and cerebrospinal fluids and the endocrine function <sep> adephagia obesity and cerebral infarction <sep>'], 'punchline_text': ['at follow-up the volumes of the cysts in groups a and b regressed from 92 to 0 while the drug-free cysts enlarged. <sep>'], 'population': ['a series of cystic craniopharyngiomas <sep>'], 'interventions': ['32)p or bleomycin <sep> bleomycin <sep> intracystic chemotherapy with bleomycin b intracystic chemo-radiotherapy with bleomycin and 32)p c intracystic radiotherapy with 32)p and 0.9 saline <sep> bleomycin <sep> chemotherapy and radiotherapy <sep>'], 'punchline_effect': [' no diff <sep>']}",since no rcts quasi-randomised trials or ccts in which only the use of intracystic bleomycin differed between the treatment groups in the treatment of cystic craniopharyngiomas in children no definitive conclusions could be made about the effects of intracystic bleomycin in these patients. only one low-power rct comparing intracystic bleomycin with intracystic 32p treatment was available but no definitive conclusions can be made about the effectiveness of these agents in children with cystic craniopharyngiomas. based on the currently available evidence we are not able to give recommendations for the use of intracystic bleomycin in the treatment of cystic craniopharyngiomas in children. high quality rcts are needed.
108,"{'outcomes': ['injury rates <sep> incidence of occupational injuries <sep>', 'cost savings <sep> injury rates <sep>'], 'punchline_text': ['training led to a 6 reduction in injury rates which was not statistically significant. <sep>', 'the drug-free workplace intervention was associated p  .05 with a statistically significant decrease in injury rates for three industry groups construction manufacturing and services. <sep>'], 'population': ['workers at construction sites of the high-speed railway line between torino and novara <sep> 2,795 workers involved in a safety training program at the construction sites of the high-speed railway line torino-novara <sep>', 'two hundred and sixty-one companies that enrolled in the drug-free workplace program during the latter half of 1996 were compared with approximately 20,500 nonintervention companies <sep>'], 'interventions': ['training program <sep>', 'publicly sponsored drug-free workplace program <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>']}",the vast majority of technical human and organisational interventions that are recommended by standard texts of safety consultants and safety courses have not been adequately evaluated. there is no evidence that introducing regulations for reducing fatal and non-fatal injuries are effective as such. there is neither evidence that regionally oriented safety campaigns training inspections nor the introduction of occupational health services are effective at reducing non-fatal injuries in construction companies. there is low-quality evidence that company-oriented safety interventions such as a multifaceted safety campaign and a multifaceted drug workplace programme can reduce non-fatal injuries among construction workers. additional strategies are needed to increase the compliance of employers and workers to the safety measures that are prescribed by regulation. continuing company-oriented interventions among management and construction workers such as a targeted safety campaign or a drug-free workplace programme seem to have an effect in reducing injuries in the longer term.
109,"{'outcomes': [""crohn's disease activity index <sep> plasma orosomucoid levels <sep> disease activity <sep> serious adverse events <sep>"", 'full remission <sep>', ""median time to worsening of disease <sep> clinically important worsening of crohn's disease defined as a 100-point increase in the crohn's disease activity index <sep> crohn's disease activity index <sep> mean crohn's disease activity index and quality-of-life scores <sep> use of prednisone and 5-amino-salicylates mean score on the crohn's disease activity index and mean quality-of-life score and the need for surgery <sep>""], 'punchline_text': [""during cyclosporine treatment there was significant improvement in plasma orosomucoid levels p  0.0025 and the crohn's disease activity index p  0.00012). <sep>"", 'at month 12 only 20 95 cl 12%-31 vs. 20 95 cl 12%-31 of the patients had maintained a continuous remission. <sep>', 'the condition of more patients worsened with cyclosporine than with placebo 91 of 151 or 60.3 percent vs. 80 of 154 or 51.9 percent p  0.10). <sep>'], 'population': [""patients with active chronic crohn's disease and resistance to or intolerance of corticosteroids <sep> 71 patients with active chronic crohn's disease who were resistant to or intolerant of corticosteroids to treatment with <sep> active chronic crohn's disease <sep>"", ""chronic active crohn's disease <sep> one hundred eighty-two patients from 33 european centers were included <sep> patient cohort was stratified at entry into a stratum with low crohn's disease activity index cdai   200 and high cdai   200 <sep>"", ""crohn's disease <sep> 193 patients had scores of 150 or less and 112 had scores greater than 150 <sep> adult patients whose disease had been active within the previous two years <sep>""], 'interventions': ['oral cyclosporine <sep> placebo <sep> cyclosporine therapy <sep> cyclosporine <sep>', 'placebo and cyclosporine 5 mg.kg-1.day-1 <sep> cyclosporine <sep> placebo <sep> cyclosporine plus low-dose steroids <sep>', 'cyclosporine <sep> placebo <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",brynskov 1989a enrolled a small number of patients and the modified clinical grading scale used in the study has not been validated in other studies. furthermore statistically significant clinical improvement does not imply induction of clinical remission. indeed brynskov 1989a found no statistically significant differences in the mean crohn's disease activity index score at 12 weeks indicating that cyclosporine was no more effective than placebo for induction of remission in crohn's disease. the results of this review demonstrate that low dose 5 mg/kg/day oral cyclosporine is not effective for the induction of remission in crohn's disease. patients treated with low dose oral cyclosporine are more likely than placebo treated patients to experience adverse events including renal dysfunction. the use of low dose oral cyclosporine for the treatment of chronic active crohn's disease does not appear to be justified. oral dosing at higher levels or parenteral administration of cyclosporine have not been adequately evaluated in controlled clinical trials. higher doses of cyclosporine are not likely to be useful for the long-term management of crohn's disease because of the risk of nephrotoxicity and the availability of other proven interventions.
110,"{'outcomes': ['tumor-free survival <sep> overall survival rate <sep> clinical regression rate rr <sep> pathological macroscopic regression <sep> radical neck dissections of recidive metastases <sep> side effects <sep>', 'total clinical healing of the lesion <sep> favourable response rate <sep> acute mucositis pneumonitis and dermatitis <sep> corresponding recurrence-free rates and five-year survival rates <sep> five-year recurrence-free rates and disease-free survival <sep>', 'overall survival <sep> actuarial dfs <sep> hospitalized with mtx toxicity none died of mtx toxicity <sep> disease-free survival dfs and overall survival <sep> local and regional recurrences <sep> recurrence at death <sep> disease progression <sep> median peak mtx dose <sep> postoperative complications <sep>', 'late reactions and overall rates of secondary neoplasms <sep> locoregional control and overall survival rates <sep> progression-free and freedom from metastases rates <sep> mucositis moist desquamation and erythema <sep>', '3-year overall survival and of 3-year loco-regional control <sep> complete remission <sep>', 'death <sep> toxicity <sep> efficacy and toxicity <sep> objective response rate <sep> leukopenia thrombopenia vomiting and nephrotoxicity <sep>', 'long-term survival rates <sep> local control and overall survival <sep>', 'phlebitis <sep> median time to loco-regional and distant progression <sep> alopecia <sep> 5-yr overall survival <sep> leukopenia <sep> similar activity complete response progression-free and overall survival rates <sep> 5-yr progression-free survival <sep>', 'overall 3-year primary locoregional tumour control disease-specific and overall survival rates <sep> confluent mucositis and dry skin desquamation <sep> incidence or severity of acute and late radiation side effects <sep> haematological side effects of mmc <sep> loco-regional tumour control survival or morbidity <sep> loco-regional control <sep> gender haemoglobin drop tumour site tumour and nodal stage <sep> locoregional control or survival <sep>', 'toxicity <sep> frequency of complete responses <sep> overall survival rates <sep>', 'overall survival <sep> median survival <sep> event-free survival <sep>', 'local disease control or actuarial survival rates <sep>', 'granulocytopenia asthenia and stomatitis <sep> rates of complete tumor resorption <sep> overall immediate effectiveness <sep>', 'progression-free survival <sep> hematologic high-grade toxicity <sep> survival rates <sep> incidence of either acute or late high-grade rt-induced toxicity <sep> survival advantage <sep> lrpfs and dmfs <sep> higher distant metastasis-free survival dmfs <sep> higher locoregional progression-free survival lrpfs <sep>', 'estimated 2-year disease-free and overall survival rates <sep>', 'complete response rate <sep> progression-free survival <sep> morbidity <sep> overall median survival duration <sep> toxicity <sep> progression-free and overall survival <sep> survival at acceptable toxicity <sep>', 'overall survival <sep> serious late morbidity <sep> survival <sep> rate of block dissection of the neck <sep>', 'disease-free survival <sep> disease-free survival or survival <sep> 3-year disease-free survival <sep> superior disease-free survival <sep> metastatic rate <sep> survival advantage <sep>', 'toxic deaths <sep> cardiac toxicity <sep> survival rates <sep> overall survival rates <sep> rates of secondary localization and distant metastasis <sep> tumor objective response rate <sep> complete response rate <sep> grade 3 and 4 toxicity rates <sep> rate of mutilating surgery <sep> locoregional recurrence rates <sep> survival rate <sep> disease-free survival rates <sep> survival curves <sep>', 'locoregional control and distant disease-free survival <sep> overall survival <sep> median time to any treatment failure <sep> radiotherapy <sep> time to any treatment failure secondary end points were locoregional failure metastatic relapse overall survival and late toxicity <sep> late toxicity <sep> locoregional control <sep> failure-free rate <sep> acute toxicity <sep>', 'response rate <sep> clinically tumor free <sep> survival <sep>', 'overall survival <sep> severe grade 3 or higher adverse effects <sep> incidence of late adverse effects <sep> overall survival rate <sep> 5-year kaplan-meier estimates of progression-free survival <sep> rate of progression-free survival <sep> severe mucosal adverse effects <sep> cumulative incidence of local or regional relapses <sep>', 'overall survival <sep> median survival <sep> uncontrolled disease and local recurrence <sep> tumour regression <sep>', '6-year survival rate <sep> occurrence of local toxic effects i.e. mucositis and epidermatitis <sep>', 'median survival <sep> survival <sep>', 'rates of residual and recurrent disease <sep> survival rates <sep>', 'median progression-free survival <sep> progression-free survival <sep> median overall survival <sep> thrombocytopenia nausea vomiting stomatitis and hearing loss <sep> rates of death from toxic effects <sep> progression-free and overall survival <sep> leukopenia and neutropenia <sep> risk of death <sep>', 'toxicity <sep> grade 3 or worse toxicity <sep> 3-year projected overall survival <sep> survival data <sep> survival <sep>', 'confluent mucositis <sep> haematological toxicity grade 3-4 <sep> mucosal reaction <sep> loco-regional tumour control <sep> overall crude survival <sep> local tumour control and survival <sep> overall duration of mucositis <sep>', 'response rate <sep> complete response rate <sep> disease-free survival <sep> oropharyngeal carcinoma only disease-free survival <sep>', 'satisfactory efficacy and acceptable toxicity profile <sep> septic shock <sep> mean duration response <sep> grade 4 cardiac dysfunction <sep> myelosuppression <sep> mucositis <sep> cerebral vascular damage <sep> survival <sep> response cr  pr rate <sep>', 'disease-free survival <sep> overall response rate <sep> complete response <sep> toxicities <sep> survival improvement <sep> survival <sep>', 'cr rates <sep> median progression-free survival and overall survival <sep> rate of radiologic complete response cr <sep> hematologic and non-hematologic toxic effects <sep>', '10-year local-regional recurrence-free survival rates <sep> overall survival rates <sep> 10-year disease-free survival rates <sep> 10-year local-regional recurrence-free survival rates in stage iv disease <sep> local control and survival <sep>', 'year survival <sep> four-year progression-free survival <sep> mucosal tolerance <sep>', '3-year survival <sep> median survival and doubles the probability of survival <sep> median survival <sep> severe mucositis <sep> complete responses <sep> survival of such patients <sep>', 'cr  pr rates <sep> 1-year survival with local control slc <sep> l and 2-year local-regional control lrc rates <sep> 1-year slc <sep> mucosal toxicity <sep>', 'overall survival <sep> actuarial 3-year overall survival and progression free survival <sep> overall survival progression free survival or locoregional control <sep> grade 3 world health organization acute skin and mucosal reactions <sep> acute skin effects and late mucosal and skin toxicities <sep> actuarial 3-year locoregional control rates <sep> median overall survival and progression free survival <sep> local late mucosal and skin toxicities <sep>', 'overall survival and disease-free interval <sep> toxicity <sep> incidence of distant metastasis <sep>', 'response rate <sep> local efficacy <sep> toxic effects and lethal reactions <sep> tumour regression <sep> tumour response rates <sep>', 'overall survival <sep> initial tumor clearance rates <sep> acute morbidity and deaths <sep> median disease-free survival <sep> safety and efficacy <sep>', 'side effects <sep> overall survival os disease-free survival dfs and specific survival ss <sep> grade 3-4 acute mucositis <sep> grade 3-4 neutropenia <sep>', 'overall survival <sep> incidence of distant metastases <sep> complete remission rate and overall survival <sep> local control <sep> disease-free survival <sep> loco-regional failure or in disease-free or overall survival <sep> distant metastases <sep> survival <sep> complete remission rate <sep>', 'remission rate <sep> disease-free survival <sep> survival rates <sep> overall survival <sep>', 'severe late morbidity <sep> 5-year survival and late toxicity <sep> grade 3 to 4 complications <sep> overall survival and locoregional control of stage iii or iv oropharynx carcinoma <sep> prognostic factors of short survival and locoregional failure <sep> overall survival and locoregional control rates <sep> overall survival specific disease-free survival and locoregional control rates <sep> stage iv hemoglobin level <sep>', 'total treatment time <sep> acute mucositis grade <sep> serious late side effects <sep> disease control and survival <sep> acute toxicity <sep> 3-year locoregional control rate <sep> 3-year overall survival rate <sep>', 'response rate <sep> survival rates <sep> response rate to induction chemotherapy for lymph node metastases <sep> local disease-free and disease-free intervals <sep> overall tumor response rates <sep>', 'postoperative quality of life <sep> died of recurrence or regional metastasis <sep> survival rates <sep> survival and postoperative quality of life <sep>', 'overall survival <sep> hematologic adverse events <sep> median overall survival <sep> rates of neutropenia and febrile neutropenia <sep> locoregional control <sep> longer survival <sep> incidence of distant metastases <sep>', 'toxicity <sep> local/regional failure rate <sep> incidence of first failure in the neck nodes <sep> overall incidence of distant metastases <sep> disease-free survival <sep> 4-year actuarial survival rate <sep>', 'overall long-term survival <sep> 5-year disease-free actuarial survival rate <sep> 5-year disease-free actuarial survival rates <sep> rates of distant metastasis <sep>', 'moderate myelosuppression and renal toxicity <sep> incidence of moderate to severe mucositis <sep> cr rate <sep> 2-year survival rate <sep> toxicities <sep> clinical cr rate <sep> response and survival rates <sep> 2-year actuarial survival rate <sep> median survival time <sep> patient refusal or cumulative toxicity <sep>', 'death <sep> survival rates <sep> locoregional recurrence <sep>', 'overall survival <sep> toxic deaths <sep> survival <sep>', 'longer survival time <sep> radiation toxicity <sep> tolerated with moderate hematologic and gastrointestinal toxicity <sep> disease-free survival <sep> complete response rate <sep> actuarial overall survival rates <sep>', 'overall chemotherapy response <sep> chemotherapy responses and toxicities surgical complications radiotherapy toxicities patient compliance survival time and patterns of treatment failure <sep> survival time differences <sep> survival <sep> median survival time <sep>', 'disease free survival <sep>', 'overall survival <sep> serious toxicities <sep> disease-free survival <sep> 2-year disease-free survival <sep>', 'voice quality <sep> quality of life qol <sep> tube feeding <sep> overall qol <sep> voicing and oral intake <sep> nausea and vomiting <sep>', 'complete clinical and pathologic response rate <sep> 5-year overall survival rate <sep> excellent survival <sep> rate of freedom from recurrence <sep> hematologic toxicity <sep> efficacy and toxicity <sep> significant long-term toxicity rate <sep> locoregional control rate <sep> complete lymph node response <sep> cause-specific survival rate <sep>', 'response rates and locoregional control <sep> complete response cr rates <sep> overall response rates <sep> peripheral neuropathy <sep> tolerated <sep> side effects <sep> disease-free survival rates <sep> nausea and vomiting <sep> survival <sep> thrombocytopenia <sep> anemia <sep>', 'poor survival <sep>', '3-and 5-year survival rates <sep> remaining tumour cells <sep> incidence of local recurrences <sep>', 'hematological toxicity <sep> overall response rates <sep> median survival time mst <sep> regional lymph node and distant metastasis control <sep> late high grade toxicity <sep> 5-year lrfs <sep> 5-year survival rates <sep> median time to local recurrence mtlr and 5-year local recurrence-free survival lrfs <sep> acute high grade toxicity <sep>', 'overall survival os <sep> 2-year os rates <sep> 2-year survival rates <sep> failure-free survival time to locoregional failure or quality of life as measured by functional assessment of cancer therapy-head and neck <sep>', 'overall survival <sep> incidence of acute adverse effects <sep> adverse effects <sep> disease-free survival <sep> rates of local and regional control and disease-free survival <sep> rate of local and regional control <sep> year rate of local and regional control <sep>', 'disease-free and overall survival <sep> mucositis and vomiting <sep> favorable outcomes complete response cr plus any grade of toxicity and pr plus grade 0 to 3 toxicity <sep> hematologic toxicity <sep>', 'rate of overall survival <sep> severe complications <sep> confluent mucositis <sep> unresectable disease <sep> relapse-free survival rate <sep> rate of locoregional control of disease <sep>', 'response rate <sep> duration of objectives remission <sep> complete remissions cr and four partial remissions pr <sep> patient survival <sep> median survival <sep>', 'mucosal and skin toxicity <sep> severe hematological toxicity <sep> relapse while no relapses <sep> feasibility and efficacy <sep> rates of complete and partial responses <sep> disease free survival <sep> response rates <sep> severe mucositis who level 5 reactions <sep> toxicity and response <sep>', 'overall response <sep> overall survival <sep> stage iv disease <sep> activity and toxicity <sep> toxicity <sep>', 'overall survival <sep> response rate <sep> relapse-free survival <sep> tolerance <sep> survival <sep> severe side effects affecting mainly digestive tract and bone marrow <sep>', 'toxicity <sep> median overall survival <sep> recurrences new tumours and deaths <sep> overall survival from randomisation and event-free survival efs recurrence new tumour or death <sep> efs events <sep> survival and recurrence <sep> corresponding median efs <sep>', 'febrile neutropenia and grade 3 or 4 late mucous membrane toxicity <sep> acceptable toxicity profiles <sep> locoregional failure-free rates <sep> year failure-free survival rates <sep>', 'overall survival <sep> acute morbidity <sep> fatal nephrotoxicity only hematologic g3 grade 3 or higher acute sequelae <sep> acute toxicity <sep> survival and toxicity <sep> overall survival improvement <sep> occurrence of persistent g3 xerostomia <sep> proportion of patients without relapse <sep> 2-year disease-free survival <sep> g3 acute mucositis <sep> event-free survival <sep> g3 skin s.c. tissue and mucosal late side effects rtog scale <sep>'], 'punchline_text': ['there was no significant difference in the overall survival rate due to the radical neck dissections of recidive metastases. <sep>', 'the corresponding recurrence-free rates and five-year survival rates were 71.8 and 17 and 65.5 and 23.5 respectively. <sep>', 'there was no significant difference between the sites of recurrence at death or last follow-up p  .38). <sep>', 'for c-hart maximum acute reactions of mucositis moist desquamation and erythema were lower than with hart whereas no differences in late reactions and overall rates of secondary neoplasms were observed. <sep>', 'analysis of preliminary results has shown that 1 early and late side effects are similar in both groups 2 after completion of treatment the percentage of patients in complete remission was 71 20/28 in the experimental group and 43 12/28 in the control group this difference was statistically significant among non responders to induction chemotherapy 1/15 versus 13/20 p  0.001 but non significant among responders 11/13 versus 7/8 and 3 there were no differences between both randomized groups in term of 3-year overall survival and of 3-year loco-regional control. <sep>', 'there was no difference in toxicity between the two treatments with regard to leukopenia thrombopenia vomiting and nephrotoxicity. <sep>', 'in our experience the radio-chemotherapy combination according to the described schedules failed to improve both local control and overall survival the comparison with the control group does not suggest that induction or intercalated chemotherapy can increase long-term survival even if initial complete and partial response rates are high. <sep>', 'no statistically significant differences in the 5-yr progression-free survival in the median time to loco-regional and distant progression and in the 5-yr overall survival were observed. <sep>', 'the overall 3-year primary locoregional tumour control disease-specific and overall survival rates were 19 36 and 30 respectively. <sep>', 'however toxicity was more common in patients treated with the two modalities of combined treatment and there were no differences in overall survival rates p  0.706). <sep>', 'overall survival was significantly better p  0.03 in the neoadjuvant chemotherapy group than in the control group with a median survival of 5.1 years versus 3.3 years in the no chemotherapy group. <sep>', 'no significant differences were demonstrated in local disease control or actuarial survival rates at three and five years. <sep>', 'the rates of complete tumor resorption were group a--27.3 group b--19.2 and group c--16.7%. <sep>', 'it also offered higher progression-free survival 46 v 25 at 5 years p .0068 higher locoregional progression-free survival lrpfs 50 v 36 at 5 years p .041 and higher distant metastasis-free survival dmfs 86 v 57 at 5 years p .0013). <sep>', 'estimated 2-year disease-free and overall survival rates were 38.2 and 57.4 for arm 1 48.6 and 69.4 for arm 2 and 51.3 and 66.6 for arm 3. <sep>', 'the overall median survival duration was 33 months for i-fu and 25 months for placebo p  .08). <sep>', 'although there has not been any significant benefit in overall survival the primary control rate is higher in patients who received methotrexate in addition to radiotherapy. <sep>', 'there was superior disease-free survival for patients with n1 disease on the maintenance arm 70 compared with the standard arm 42 p  .024). <sep>', 'at 4 years overall survival rates were 56 and 46 disease-free survival rates were 33 and 30 in the ct+lrt and the lrt groups respectively. <sep>', 'locoregional control and distant disease-free survival were significantly improved with cisplatin log-rank test p  .039 and .011 respectively). <sep>', 'after surgery 62 of the patients randomized to chemotherapy-radiotherapy and 60 of the patients in the standard treatment group were clinically tumor free. <sep>', 'the overall survival rate was also significantly higher in the combined-therapy group than in the radiotherapy group p=0.02 by the log-rank test hazard ratio for death 0.70 95 percent confidence interval 0.52 to 0.95 with five-year kaplan-meier estimates of overall survival of 53 percent and 40 percent respectively. <sep>', 'tumour regression after chemotherapy either complete cr or partial pr greater than 50 was observed in 48 in the fm group and 41 in the poc group and lymph-node regression cr  pr was respectively 15 and 23%. <sep>', 'the occurrence of local toxic effects i.e. mucositis and epidermatitis was significantly greater in the rt-blm group rt-blm 72 vs. rt 21%). <sep>', 'no difference could be detected in the survival of patients who received simultaneous versus sequential chemotherapy. <sep>', 'rates of residual and recurrent disease as well as distant metastases were similar for the two groups. <sep>', 'treatment with tpf resulted in a reduction in the risk of death of 27 p=0.02 with a median overall survival of 18.8 months as compared with 14.5 months in the pf group. <sep>', 'with a median follow-up of 41 months the 3-year projected overall survival for patients enrolled in arm a is 23 compared with 37 for arm b p .014 and 27 for arm c p  not significant). <sep>', 'loco-regional tumour control was 31 after cf 32 after v-chart and 48 after v-chart+mmc respectively p<0.05). <sep>', 'the difference in complete response rate between both treatment groups 24 in group a and 63 in group b was statistically significant p  0.015). <sep>', 'no significant difference in survival existed between the two groups. <sep>', 'no survival improvement was observed. <sep>', 'median progression-free survival and overall survival were respectively 19.7 and 33.3 months arm a and 30.4 and 39.6 months arm b). <sep>', 'the 3 5 and 10-year local-regional recurrence-free survival rates in stage iv disease were statistically better in arm ii 21.5 15.9 and 15.9 than in arm <sep>', 'mucosal tolerance was significantly worse in treatment arm b p less than 0.00004). <sep>', 'the median survival was 16.5 months in the combined-therapy group and 11.7 months in the radiotherapy group p less than 0.05 the 3-year survival was 41 percent and 23 percent respectively. <sep>', 'there was a significantly better 1-year slc after rct 58 compared with rt 44 p  0.05). <sep>', 'actuarial 3-year locoregional control rates were 32 in the alt group and 27 in the pa-rt group. <sep>', 'the incidence of distant metastasis was significantly reduced p less than 0.03 with chemotherapy. <sep>', 'a sequential analysis was used and blm demonstrated a significantly greater local efficacy after the 32nd matched pair was assessed. <sep>', 'acute morbidity and deaths during intervention were higher in the study group p  0.007). <sep>', 'enteral nutrition through gastrostomy tube was more frequent in arm b before treatment and at 6 months p  0.01). <sep>', 'for inoperable patients the combined treatment was significantly associated with an increase in complete remission rate group a 44 as compared with radiotherapy alone group b 30 p  .037). <sep>', 'after a follow-up of 12-96 months overall survival was 58 in arm a and 45 in arm b n.s.). <sep>', 'five-year overall survival specific disease-free survival and locoregional control rates were 22 and 16 log-rank p .05 27 and 15 p .01 and 48 and 25 p .002 in arm b and arm a respectively. <sep>', 'acute mucositis grade 3 or 4 was more frequent in arm b 38 than in arm a 16 p  .001). <sep>', 'after adjustment for these factors the chemotherapy did not seem to improve the effectiveness of the local treatment in terms of loco-regional control and survival. <sep>', 'occurrence of a second carcinoma was 3 times as frequent in the irradiation group 9 patients as in the chemotherapy group 3 patients). <sep>', 'there was better locoregional control in the tpf group than in the pf group p=0.04 but the incidence of distant metastases in the two groups did not differ significantly p=0.14). <sep>', 'disease-free survival at 4 years was 38 on the rt arm compared to 46 on the ct/rt arm p  n.s.). <sep>', 'the rates of distant metastasis were 10 for chemotherapy group and 32 for control group p=0.06). <sep>', 'the incidence of moderate to severe mucositis was significantly higher on arm a than arm b p  0.02). <sep>', 'the percentages were higher after radical surgery alone for locoregional recurrence 31 and 15.6 and for death 28 and 18.6%). <sep>', 'no significant difference in overall survival was found. <sep>', 'patients from both groups with a complete response had a significantly longer survival time than those with a partial response p less than 0.001). <sep>', 'this final analysis demonstrates no benefit in survival using preoperative chemotherapy for advanced stage resectable head and neck squamous cell carcinoma. <sep>', 'this analysis at 12 months showed a disease free survival of 71 in the test arm vs. 45 in the control arm which is statistically highly significant p less than 0.01). <sep>', 'we could not demonstrate a benefit with the addition of carboplatin to postoperative radiotherapy possibly because of insufficient sample size. <sep>', 'iv patients were significantly more fatigued p .006). <sep>', 'the addition of tpz increased hematologic toxicity but did not improve outcomes in patients with resectable stage iv hnscc using the protocol administered this small randomized study. <sep>', 'on the other hand crp-rt gives a significantly higher incidence of stomatitis p=0.0067 and a marginally worse thrombocytopenia p=0.09). <sep>', 'hyperthermia did not confer any benefit. <sep>', 'however bleomycin had no significant effect on the 3-and 5-year survival rates and it did not significantly reduce the incidence of local recurrences. <sep>', 'patients in groups ii and iii had significantly higher overall response rates then those in group i p  0.011 and p  0.0025 respectively with no difference between groups ii and iii p  0.60). <sep>', 'there were no significant differences in failure-free survival time to locoregional failure or quality of life as measured by functional assessment of cancer therapy-head and neck. <sep>', 'disease-free survival was significantly longer in the combined-therapy group than in the radiotherapy group hazard ratio for disease or death 0.78 95 percent confidence interval 0.61 to 0.99 p=0.04 but overall survival was not hazard ratio for death 0.84 95 percent confidence interval 0.65 to 1.09 p=0.19). <sep>', 'mucositis and vomiting predominated in the cddp-fu arm p  .03 p  .001 respectively). <sep>', 'the relapse-free survival rate was higher in the combined-treatment group 61 percent vs. 41 percent p=0.08). <sep>', 'the response rate for the 12 rt  ct patients was four complete remissions cr and four partial remissions pr the 11 rt patients had one cr and three pr. <sep>', 'there was no significant difference in the response rates at the end of treatment but disease free survival at three years was better in the ct/rt group 63.3 vs 20%). <sep>', 'at a median follow-up of 84 months no significant differences have emerged in overall survival 15 vs 37 months or time to progression 8.5 vs 14.5 months for groups 1 and 2 respectively. <sep>', 'among responders the survival was found highly correlated with a good initial general status p less than 0.01 and with the highest total doses of cisplatin p less than 0.02).(abstract truncated at 250 words <sep>', 'concurrent non-platinum chemoradiotherapy reduces recurrences new tumours and deaths in patients who have not undergone previous surgery even 10 years after starting treatment. <sep>', 'three-year locoregional failure-free rates were 84 in the tpz/cis arm 95 ci 71 to 92 and 66 in the chemoboost arm 95 ci 51 to 79 p  .069). <sep>', 'at 24 months the proportion of patients without relapse was 42 for arm c vs. 23 for arm a and 20 for arm b. patients in arm a less frequently developed g3 acute mucositis than their counterparts in arm b or c 14.7 vs. 40.3 vs. 44%). <sep>'], 'population': ['between january 1996 and november 1998 38 patients were treated with <sep> planocellular cancer of the head and neck region <sep>', 'oral cancer <sep> one hundred and fifty-seven previously untreated t3 and t4 and n0 n1 or n2 buccal squamous cell carcinomas <sep>', '60 patients with potentially resectable stage iii or iv squamous head and neck carcinomas <sep> resectable stage iii and iv squamous head and neck carcinomas <sep>', 'three hundred eighty-four stage iii 6 and iv 94 <sep> cancer patients <sep> locally advanced head and neck cancer <sep>', 'from april 1987 to october 1992 67 patients with inoperable squamous cell carcinoma of the head and neck region <sep> advanced cancers of the head and neck <sep>', 'previously untreated squamous cell carcinoma of the head and neck <sep> 136 patients with previously untreated stage iii or iv squamous cell carcinoma of the head and neck <sep> 69 patients group a <sep>', 'advanced head and neck tumors <sep> from january 1981 through december 1983 49 untreated patients with locally advanced head and neck cancers <sep>', 'patients with unresectable locally advanced squamous cell cancer of the head and neck <sep> between february 1986 and february 1991 93 eligible patients with locally advanced unresectable cancer of the head and neck were stratified by who ps t and n class and primary site <sep> unresectable locally advanced cancer of the head and neck <sep> patients with locally advanced unresectable cancer of the head and neck <sep>', 'patients had stage iii n=223 or stage iv n=255 squamous cell carcinoma of the oral cavity n=230 oropharynx n=140 hypopharynx n=65 or larynx n=43 <sep> 478 patients from seven centres <sep> locally advanced head and neck cancer <sep> patients with advanced head and neck cancer <sep> a total of 558 patients were recruited in the trial from february 1996 to december 1999 <sep>', 'advanced unresectable squamous cell carcinoma of the upper respiratory and digestive system <sep> advanced stage iv unresectable head and neck cancer <sep> thirty patients <sep> stage iv head and neck squamous cell carcinoma <sep> from 1983 to 1986 90 patients entered the trial <sep>', 'patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible <sep> 318 patients were enrolled in the study between 1986 and 1992 <sep> oropharyngeal carcinoma <sep> patients with oropharyngeal cancer <sep>', 'advanced head and neck tumors <sep> patients with local treatment failure were surgically salvaged <sep> ninety-six patients with advanced squamous cell carcinoma of the head and neck <sep>', 'intraoral and oropharyngeal cancer <sep>', 'locally advanced squamous cell carcinoma of the head and neck <sep> locally advanced stages iii and iv squamous cell carcinoma of the head and neck <sep> one hundred thirty patients <sep>', 'advanced squamous cell carcinomas of the head and neck <sep> patients with advanced squamous carcinoma of the head and neck <sep> patients with stage iii or iv squamous carcinoma of the oral cavity oropharynx or hypopharynx were eligible <sep> between 1997 and 1999 241 patients were entered onto study 231 were analyzable <sep> group 97-03 <sep>', 'patients with locally advanced squamous cell head and neck cancer schnc <sep> locally advanced head and neck cancer <sep> one hundred seventy-five patients <sep> consenting patients with an eastern cooperative oncology group ecog performance status  or  2 with stage iii or iv schnc of the oral cavity oropharynx hypopharynx or larynx and who were recommended for <sep>', 'patients who receive chemoradiation for head and neck cancer <sep> advanced head and neck cancer <sep> head and neck cancer <sep>', 'patients with advanced head and neck squamous cancer the head and neck contracts program <sep> patients with resectable head and neck cancer <sep> 109 patients with n2 disease <sep> 192 patients with oral cavity cancer <sep> 462 patients <sep> 106 patients with t1 plus t2 disease <sep> since head and neck cancer patients <sep>', 'patients with head and neck cancer <sep> three hundred patients were analyzed 79 had tumors of the oral cavity 106 oropharyngeal tumors and 115 pharyngolaryngeal tumors <sep> one hundred forty-three patients were evaluable for efficacy <sep> head and neck cancer <sep> 324 patients was conducted from january 1988 to july 1991 <sep> one hundred fifty patients underwent ct+lrt 150 patients had lrt alone <sep>', 'from july 1994 to july 2000 224 patients with squamous cell carcinomas of the head and neck excluding nasopharynx and paranasal sinus <sep> locally advanced and/or node-positive nonmetastatic carcinomas of the head and neck <sep> advanced head and neck cancers treated with <sep>', 'four-hundred sixty-one patients from denmark norway and sweden with tumors in oral cavity oropharynx hypopharynx and larynx <sep> advanced squamous cell carcinoma of the head and neck <sep>', 'patients with locally advanced head and neck cancer <sep> massachusetts medical society <sep> locally advanced head and neck cancer <sep> after undergoing surgery with curative intent 167 patients <sep> stage iii or iv head and neck cancer <sep>', 'between february 1978 and january 1984 222 eligible patients <sep> patients were stratified according to the primary site floor of the mouth fm versus posterior oral cavity or oropharynx poc and institution <sep> oral cavity and oropharynx carcinoma <sep>', '2 groups of patients with squamous cell carcinoma of the oropharynx t2 t3 and t4 international union against cancer classification <sep> head and neck carcinoma was initiated in 1973 by the european organization for research and treatment of cancer <sep> epidermoid carcinomas of the oropharynx <sep>', 'head and neck cancer <sep> 79 patients with squamous cell head and neck cancer <sep> squamous cell head and neck cancer <sep> 47 patients were previously untreated and 32 patients had recurrent disease <sep>', 'head and neck cancer <sep> 133 patients with advanced disease 83 were included in the study--43 in the chemotherapy group and 40 in the control group <sep> control advanced squamous cell carcinoma of the head and neck <sep> patients with stage ii disease of the pyriform sinus and stage ii and iv disease of the oral cavity larynx hypopharynx oropharynx nasopharynx and paranasal sinuses were eligible <sep>', 'patients with locoregionally advanced unresectable disease <sep> patients with unresectable squamous-cell carcinoma of the head and neck <sep> squamous-cell carcinoma of the head and neck <sep> unresectable head and neck cancer <sep> eligible patients between the ages of 18 and 70 years who had stage iii or stage iv disease and no distant metastases to receive either <sep> 358 patients underwent randomization with 177 assigned to the tpf group and 181 to the pf group <sep>', 'between 1992 and 1999 295 patients were entered on this trial <sep> patients with unresectable squamous cell head and neck cancer <sep> eligible patients <sep> 362 patients and resulted in premature study closure <sep>', 'head and neck cancers <sep> advanced cases of head and neck cancers <sep> from october 1990 to december 1997 239 patients with squamous cell cancers originating in the head and neck region <sep>', 'patients with inoperable head and neck carcinoma <sep> between march 1991 and october 1993 49 patients with inoperable head and neck carcinoma <sep> inoperable head and neck cancer--preliminary report <sep>', 'patients with unresectable advanced head and neck cancer <sep> patients with a cardiac or vascular history <sep> advanced cancer of the head and neck <sep> 197 eligible patients were paired off successively on the basis of tumor sites and uicc stage <sep> 179 patients tumor beds and cervical lymph nodes were irradiated and 20 patients underwent <sep>', 'fifty-four previously untreated patients with locally advanced resectable squamous cell carcinoma of the head and neck scchn <sep> advanced resectable head and neck cancer <sep> twenty patients completed chemotherapy courses <sep> thirty patients received <sep>', 'a total of 101 patients <sep> locally advanced head and neck cancer <sep> locally advanced squamous cell carcinoma of the head and neck scchn <sep> patients with stage iii-ivm0 scchn eastern cooperative oncology group performance status of zero to one <sep>', 'patients with stage iii and iv unresectable head and neck squamous cell carcinoma <sep> locally advanced inoperable head and neck squamous cell carcinoma <sep> locally advanced unresectable head and neck cancer <sep> from november 1992 through december 1995 a total of 164 patients <sep>', 'between 1983 and 1986 the national institute for cancer research in genoa and affiliated institutions <sep> one hundred sixteen patients <sep> advanced inoperable squamous cell carcinoma of the head and neck <sep>', '80 patients given <sep> patients in the trial had biopsy-confirmed unresectable previously untreated stage iii or iv squamous-cell carcinoma of the oral cavity pharynx or larynx <sep> patients with advanced unresectable squamous-cell carcinoma of the head and neck <sep> advanced squamous-cell carcinoma of the head and neck with <sep> patients with advanced unresectable squamous-cell carcinoma of the head and neck chemotherapy alternating with <sep>', 'advanced head-and-neck cancer <sep> patients with oropharyngeal carcinomas <sep> 240 patients 113 patients with rct and 127 patients with rt qualified for protocol and starting treatment <sep> advanced unresectable head-and-neck cancer <sep> 178 oropharyngeal and 62 hypopharyngeal carcinomas <sep> between july 1995 and may 1999 263 patients were randomized median age 56 years 96 stage iv tumors 4 stage iii tumors <sep> unresectable oro and hypopharyngeal carcinomas <sep> patients with stage iii and iv uicc <sep>', 'copyright 2001 american cancer society <sep> locally advanced squamous cell carcinoma of the head and neck <sep> 136 consecutive patients with previously untreated unfavorable stage ii or stage iii-iv international union against cancer scc of the oral cavity pharynx and larynx were enrolled <sep> patients with locally advanced squamous cell carcinoma of the head and neck scc-hn alternating <sep>', 'advanced head and neck tumors <sep> from march 1983 to december 1989 208 patients with locally advanced squamous cell carcinoma of the head and neck <sep> 100 patients consisted of two cycles of a combination of <sep>', 'patients with neck nodes <sep> carcinoma of the oral cavity <sep> 85 patients with untreated squamous cell carcinomas of the oral cavity <sep>', 'thirty-eight patients <sep> advanced head and neck cancer <sep>', 'unresectable pharyngeal carcinoma <sep> 163 evaluable patients <sep> november 1997 and march 2002 <sep>', 'patients had previously untreated advanced nonmetastatic stages iii and iv squamous cell carcinoma of the oral cavity oropharynx hypopharynx and paranasal sinuses <sep> stage iii or iv head and neck cancers <sep> patients with advanced disease <sep> eligible patients n  237 <sep> advanced stage iii and iv head and neck squamous cell carcinoma i.e. surgery with postoperative radiotherapy in operable patients and radiotherapy alone in inoperable patients <sep>', 'patients with the mentioned disease stages <sep> cancer of the oral cavity and tonsils <sep> patients with advanced stage iii and iv disease <sep> patients with primary resectable carcinomas of the oral cavity and tonsils and stage t2-t3 and n0-n2 disease prior to surgery <sep> head and neck cancer <sep> patients pts <sep>', 'advanced-stage oropharynx carcinoma <sep> a total of 226 patients <sep>', 'from 1989 to 1993 298 patients were enrolled and 270 patients were assessable <sep> advanced head and neck cancer patients <sep> previously untreated patients with unresectable stage iii/iv head and neck cancer <sep> advanced head and neck cancer <sep> patients with locoregionally advanced head and neck cancer <sep>', 'from march 1983 to june 1986 100 patients with locally advanced squamous cell carcinoma of the head and neck <sep> advanced head and neck cancer <sep>', 'patients with tumors of the head and neck <sep> patients with tumors of the oral cavity <sep> one hundred thirty-one patients with operable sublingual or lingual squamous cell carcinoma in stages t2nxm0 to t4mxm0 <sep> copyright 1999 american cancer society <sep>', 'head and neck cancer <sep> squamous-cell carcinoma of the head and neck compared <sep> patients with squamous-cell carcinoma of the head and neck who received <sep> 501 patients all of whom had stage iii or iv disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation to receive either <sep>', 'eligible patients had completely resected tumors of the oral cavity oropharynx hypopharynx or larynx <sep> a total of 442 analyzable patients <sep> patients with locally-advanced but operable squamous cell cancers of the head and neck region a randomized clinical trial was conducted under the auspices of the head and neck intergroup radiation therapy oncology group southwest oncology group eastern oncology group cancer and leukemia group b northern california oncology group and southeast group <sep> patients were categorized as having either low-risk or high-risk treatment volumes depending on whether the surgical margin was greater than or equal to 5 mm there was extracapsular nodal extension and/or there was carcinoma-in-situ at the surgical margins <sep> resectable squamous cell carcinomas of the head and neck <sep>', '29 patients on <sep> head and neck cancer patients <sep> and 34 patients on the control group were analysed <sep> head and neck squamous cell carcinoma <sep> sixty-five patients with stage iii and iv squamous cell carcinomas of oral cavity oropharynx hypopharynx and larynx with no distant metastasis <sep> head and neck carcinoma <sep>', '42 patients who were evaluated 16 were randomized to arm a 13 to arm b and 13 to arm c <sep> patients with resectable disease <sep> previously untreated patients with locally advanced head and neck cancer <sep> locally advanced head and neck cancer <sep> patients with a performance status of 0 to 2 and normal end-organ function <sep> patients with a performance status of greater than 2 or a carbon monoxide diffusion capacity of less than 50 of the predicted value were assigned to the arm <sep>', '141 patients were treated by radical surgery alone whereas 127 patients were treated by <sep> advanced squamous cell carcinoma of the oral cavity and the oropharynx a 3-year follow-up <sep> patients with primary biopsy proven scc of the oral cavity or the oropharynx with tumor nodes metastasis tnm stages t2-4 n0-3 m0 were included in the study <sep> squamous cell carcinoma scc <sep>', 'it included 195 patients <sep> resectable oral cavity squamous cell cancer <sep> patients with advanced resectable oral cavity cancer <sep> patients with advanced oral cavity cancer <sep> multicenter trial enrolling patients with a resectable stage t2-t4 <sep>', 'from 1987 to 1989 42 patients with locally advanced squamous cell carcinoma of the head and neck stages iii-iv mo <sep> advanced head and neck cancer <sep>', 'patients with advanced stage resectable squamous cell carcinoma of the head and neck <sep> advanced stage resectable head and neck squamous cell carcinoma <sep> advanced resectable head and neck cancer <sep> 158 eligible patients <sep>', 'oral cancer <sep> 135 patients of alveolobuccal carcinoma clinically stage iii and iv were entered on the protocol <sep>', 'seventy-six patients were randomized of whom 72 were eligible and analyzable 36 in each arm <sep> patients with macroscopically resected stage iii/iv scchn with high-risk pathologic features  or 3 lymph nodes extracapsular extension perineural or angiolymphatic invasion or involved margins <sep> patients with high-risk head and neck cancer <sep> squamous cell carcinoma of the head and neck scchn <sep>', 'forty-two of 62 employed patients returned to work <sep> advanced head and neck cancer <sep> two hundred seven patients with inoperable stage iv disease-152 men and 55 women mean age 55 years-were included in this study <sep>', 'patients who did not achieve a complete response at 50 grays underwent surgical treatment <sep> sixty-two patients with lymph node-positive resectable tnm stage iv hnscc <sep> patients with resectable stage iv head and neck squamous cell carcinomas <sep> patients with head and neck squamous cell carcinomas hnscc <sep>', 'patients with advanced unresectable squamous-cell carcinoma of the head and neck h&n <sep> locally advanced squamous-cell carcinoma of the head and neck with concurrent <sep> patients with locally advanced h&n cancer <sep> 53 patients are entered in the study 27 in the cddp arm and 26 in the crp <sep>', 'oral squamous cell carcinoma is the commonest male 29 and the second commonest female 18 malignancy in south india <sep> a total of 101 t3 and t4 buccal squamous cancers <sep> locally advanced squamous cell carcinomas of the buccal mucosa <sep>', 'forty-six patients with squamous cell carcinoma of the head and neck region <sep> squamous cell carcinoma of the head and neck region <sep>', 'between january 1988 and december 1991 159 patients with stage iii/iv m0 squamous cell carcinoma of the head and neck <sep> locally advanced unresectable squamous cell carcinoma of the head and neck <sep>', 'patients with previously untreated stage iii or iv excluding t1-2n1 and m1 squamous cell carcinoma of the oral cavity oropharynx hypopharynx or larynx <sep> patients with advanced head and neck cancer <sep> eight hundred sixty-one patients were accrued from 89 sites in 16 countries <sep> advanced squamous cell carcinoma of the head and neck <sep>', 'massachusetts medical society <sep> high-risk patients with resected head and neck cancer <sep> between september 9 1995 and april 28 2000 459 patients were enrolled <sep> after undergoing total resection of all visible and palpable disease 231 patients <sep> high-risk squamous-cell carcinoma of the head and neck <sep>', '95 patients were included <sep> stage iv-m0 head and neck cancer <sep> patients with stage iv-m0 head and neck cancer <sep>', 'patients with advanced head and neck cancer who were treated only with <sep> locally advanced head and neck cancer <sep> 122 patients who underwent randomization 116 were included in the analysis <sep> advanced head and neck cancer <sep>', 'stage iv carcinoma of the head and neck <sep> between 1975 and 1978 23 patients with stage iv unresectable squamous cell carcinoma of the head and neck <sep>', 'from november 2000 to march 2003 eighty histopathologically proven cases of squamous cell head and neck carcinoma were included in this trial 40 patients <sep> patients with locally advanced head and neck carcinomas <sep> advanced head and neck carcinoma <sep> locally advanced head and neck carcinomas <sep>', '34 patients 30 of whom were men with a median age of 57.5 years 79 of this group had a karnofsky performance status of 90 to 100 70 had a squamous and 29 an undifferentiated histology <sep> locally advanced squamous cell head and neck cancer <sep> locally advanced-stage iii or iv mo)-head and neck cancer <sep> 67 patients <sep> 33 patients in group 2 29 were men <sep>', '241 advanced carcinomas of the upper respiratory and digestive tract <sep> two hundred and forty-one patients with advanced squamous cell carcinoma of head and neck <sep>', 'patients who have not undergone previous surgery even 10 years after starting treatment <sep> patients who had previously undergone radical surgery to remove their tumour <sep> between jan 15 1990 and june 20 2000 966 patients were recruited from 34 centres in the uk and two centres from malta and turkey <sep> locally advanced head and neck cancer <sep> patients who have undergone previous surgery for head and neck cancer <sep> all 966 patients were included in the analyses <sep> patients with locally advanced head and neck cancer and who had not previously undergone surgery <sep>', 'locally advanced squamous cell carcinoma scc of the head and neck <sep> patients with locally advanced head and neck cancer <sep> one hundred twenty-two previously untreated patients with stage iii/iv scc of the head and neck <sep>', 'between january 1993 and june 1998 192 previously untreated patients affected with stage iii and iv oropharyngeal carcinoma excluding t1n1 and t2n1 <sep> advanced unresectable epidermoid tumors of oropharynx <sep> locoregionally advanced carcinoma of the oropharynx <sep> advanced oropharyngeal squamous-cell carcinomas <sep>'], 'interventions': ['cisplatin <sep> bleomycin vincristine and methotrexate bvm or the previous medication plus cisplatin bvcm chemotherapy <sep> induction chemotherapy <sep> cisplatin-based combination chemotherapy <sep>', 'placebo <sep> radiotherapy <sep> combined bleomycin and radiotherapy <sep> blm <sep> physiological saline <sep> cobalt-60 teletherapy <sep> bleomycin blm plus radiation against radiation alone <sep>', 'adjuvant methotrexate <sep> adjuvant mtx <sep> standard surgery and postoperative radiation therapy <sep> mtx <sep> adjuvant methotrexate mtx <sep>', 'fluorouracil fu and mitomycin mmc chemotherapy and hyperfractionated accelerated radiation therapy c-hart <sep> hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin <sep> 30 gy 2 gy every day followed by 1.4 gy bid to a total of 70.6 gy concurrently with fu <sep>', 'chemotherapy with cisplatin <sep> induction chemotherapy with cisplatin <sep> concomitant radiotherapy and chemotherapy with radiotherapy alone <sep> radiotherapy alone with the same modalities control group <sep> fluorouracil <sep> concurrent external radiation therapy <sep>', 'cisplatinum versus cisplatinum-etoposide <sep> ddp <sep> etoposide <sep> ddp vs ddp-vp 16 213 etoposide <sep>', 'induction chemotherapy with bleomycin methotrexate and hydroxyurea before definitive external radiotherapy <sep> radiotherapy <sep> chemotherapy or radiotherapy <sep> radiochemotherapy <sep> chemo-radiotherapy <sep>', 'cisplatin and radiotherapy versus radiotherapy <sep> single-modality radiotherapy <sep> conventional radiotherapy simultaneous treatment <sep> neoadjuvant chemotherapy with cisplatin <sep> sequential versus simultaneous chemo-radiotherapy <sep> concomitant chemo-radiation therapy <sep> 5-fluorouracil <sep> cisplatin <sep>', 'primary curative radiotherapy <sep> single agent mitomycin c mmc <sep> radiotherapy <sep> mmc <sep> radiotherapy with or without mitomycin c <sep> radiotherapy alone versus radiotherapy plus mmc <sep>', 'neoadjuvant vs concomitant chemotherapy vs radiotherapy alone <sep> radiotherapy alone <sep> neoadjuvant or concomitant chemotherapy and radiotherapy <sep> radiotherapy alone 70 gy neoadjuvant chemotherapy vinblastine mitomycin cisplatin and bleomycin and radiotherapy concomitant chemotherapy cisplatin and bleomycin and radiotherapy <sep>', 'cisplatin <sep> surgery plus radiotherapy or radiotherapy <sep> surgery plus plus radiotherapy or of radiotherapy alone <sep> fluorouracil <sep> neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy <sep> neoadjuvant chemotherapy <sep>', 'intravenous methotrexate followed by radical irradiation or radiotherapy alone <sep> methotrexate and radiation therapy <sep>', 'distant radiation therapy <sep> combined treatment cisplatin radiotherapy <sep> cisplatin <sep>', 'hfx rt alone hfx rt and concurrent low-dose daily cddp <sep> cddp <sep> hfx rt/chemotherapy <sep> cisplatin cddp to hyperfractionation hfx radiation therapy rt <sep> hfx rt <sep> hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin <sep>', 'concurrent chemoradiotherapy <sep> radiation therapy oncology <sep> paclitaxel 30 mg/m(2 and cisplatin <sep> cisplatin 10 mg/m(2 daily and fluorouracil fu <sep> hydroxyurea 1 g every 12 hours and fu 800 mg/m(2)/d ci delivered with each fraction of radiation <sep> concurrent radiation and chemotherapy <sep>', 'placebo <sep> radiotherapy with curative intent received 66 gy of radiation therapy delivered in 2-gy fractions <sep> placebo <sep> infusional fluorouracil i-fu to standard radiotherapy <sep> standard radiotherapy <sep> infusional fluorouracil <sep>', 'concomitant methotrexate and radiation <sep> methotrexate <sep> radiotherapy <sep> concomitant methotrexate and radiotherapy <sep> methotrexate with radiotherapy <sep>', 'standard surgery and radiation induction chemotherapy cisplatin and bleomycin plus standard therapy and induction chemotherapy plus standard therapy followed by maintenance cisplatin <sep> maintenance chemotherapy <sep> adjuvant chemotherapy <sep>', 'carboplatin <sep> lrt <sep> radiotherapy <sep> ct+lrt <sep> carboplatin/5-fu <sep> neoadjuvant chemotherapy with carboplatin/5-fluorouracil <sep> chemotherapy <sep> neoadjuvant chemotherapy ct with carboplatin and 5-fluorouracil 5-fu followed by locoregional treatment lrt <sep>', 'hyperfractionated radiotherapy <sep> radiotherapy combined with two cycles of concomitant cisplatin <sep> hyperfractionated radiotherapy alone <sep> concomitant cisplatin <sep> cisplatin <sep> cisplatin simultaneously with hyperfractionated radiotherapy <sep>', 'chemotherapy <sep> standard treatment radiotherapy or radiotherapy followed by surgery or neoadjuvant chemotherapy followed by standard treatment <sep> radiotherapy <sep> neoadjuvant chemotherapy with cisplatin and 5-fluorouracil <sep> radiotherapy <sep> neoadjuvant chemotherapy followed by radiotherapy <sep> neoadjuvant chemotherapy with cisplatin and 5-fluorouracil <sep> 5-fluorouracil <sep> cisplatin <sep> chemotherapy-radiotherapy <sep>', 'radiotherapy regimen combined with 100 mg of cisplatin <sep> radiotherapy <sep> radiotherapy alone <sep> concomitant cisplatin and irradiation with radiotherapy alone <sep> postoperative irradiation with or without concomitant chemotherapy <sep> cisplatin with radiotherapy <sep>', 'preoperative intra-arterial chemotherapy <sep> vincristine and bleomycin <sep> surgery or preoperative chemotherapy <sep> postoperative radiotherapy <sep> chemotherapy <sep>', 'radiotherapy and concomitant bleomycin to radiotherapy alone <sep> bleomycin blm <sep> blm <sep> external radiotherapy rt <sep> external rt alone <sep>', 'simultaneous or 1 hour sequential methotrexate-5 fluorouracil <sep> mtx--5-fu chemotherapy <sep> mtx-5 fu chemotherapy <sep> methotrexate-5-fluorouracil chemotherapy <sep> radical radiation therapy <sep>', 'preoperative irradiation followed by radical surgery <sep> surgery and radiotherapy <sep> adjuvant chemotherapy <sep> standard therapy alone or two courses of 5-fluorouracil b-cmf chemotherapy <sep>', 'cisplatin fluorouracil and docetaxel <sep> cisplatin and fluorouracil pf plus docetaxel tpf <sep> tpf docetaxel and cisplatin day 1 fluorouracil by continuous infusion days 1 to 5 or pf <sep> tpf with pf <sep> radiotherapy <sep> pf <sep> docetaxel <sep> tpf <sep> cisplatin and fluorouracil induction chemotherapy <sep>', 'concurrent chemoradiotherapy <sep> identical radiation therapy with concurrent bolus cisplatin <sep> infusional fluorouracil and bolus cisplatin chemotherapy <sep> chemotherapy to radiation <sep> standard radiation therapy <sep>', 'radiation therapy <sep> radiotherapy <sep> m(2 mitomycin c mmc <sep> mmc <sep> continuous hyperfractionated accelerated radiotherapy <sep> continuous hyperfractionated accelerated radiotherapy with/without mitomycin c <sep>', 'mytomycin c bleomycin nicotinamide chlorpromazine and dicoumarol as enhancers of radiotherapy <sep> radiation therapy alone group a or radiotherapy combined with simultaneous application of mitomycin c and bleomycin <sep> radiotherapy combined with simultaneous chemotherapy with mitomycin c and bleomycin <sep> mitomycin c <sep> nicotinamide chlorpromazine and dicoumarol <sep> irradiation mitomycin c and bleomycin <sep> bleomycin <sep>', 'radiotherapy <sep> neoadjuvant chemotherapy protocols cddp  5-fu versus cddp  vp16 <sep> salvage surgical procedures <sep> cisplatin plus 5-fluorouracil <sep> cisplatin plus 5-fu chemotherapy <sep> cddp  5-fu <sep> cddp  5-fu to cddp  vp16 <sep> cisplatin plus etoposide <sep> cddp  vp16 <sep>', 'cisplatin 20 mg/m2 day 1-5 bleomycin 10 mg/m2 continuous infusion from day 3-7 and methotrexate <sep> chemotherapy <sep> combination chemotherapy <sep> induction chemotherapy <sep>', 'cisplatin 20 mg/m(2 days1-4 plus 5-fluorouracil 800 mg/m(2)/day 96 h continuous infusion during weeks 1 and 6 of radiotherapy <sep> tpf arm b docetaxel 75 mg/m(2 and cisplatin 80 mg/m(2 day 1 and 5-fluorouracil 800 mg/m(2)/day 96 h continuous infusion every 3 weeks followed by the same ct/rt <sep> induction docetaxel taxotere cisplatin and 5-fluorouracil tpf before ct/rt versus ct/rt alone <sep> concomitant chemoradiotherapy versus induction docetaxel cisplatin and 5 fluorouracil tpf followed by concomitant chemoradiotherapy <sep> concomitant chemoradiotherapy ct/rt <sep> ct/rt alone <sep>', 'carboplatin <sep> radiotherapy <sep> radiotherapy alone arm i or combined arm ii with daily low-dose carboplatin <sep> radiotherapy alone or with concomitant daily low-dose carboplatin <sep>', 'methotrexate <sep> vinblastine <sep> combined chemotherapy and radiation therapy <sep> combining chemotherapy ct and radiation therapy rt <sep> bleomycin <sep> ct <sep> neoadjuvant ct followed by definitive rt treatment arm a or alternating ct and rt <sep>', 'radiotherapy <sep> radiotherapy alone <sep> alternating chemotherapy and radiotherapy <sep> alternating chemotherapy with radiotherapy <sep> intravenous cisplatin <sep> chemotherapy alternating with radiotherapy <sep> fluorouracil <sep>', 'hyperfractionated accelerated radiochemotherapy hf-acc-rct vs. hyperfractionated accelerated radiotherapy hf-acc-rt <sep> hf-acc-rt alone <sep> m(2)/day)/carboplatinum <sep> prophylactic g-csf <sep> hf-acc-rct <sep> radiochemotherapy rct <sep> accelerated radiotherapy <sep> 5-fu <sep>', 'chemoradiotherapy alt <sep> radiotherapy <sep> alt <sep> intravenous cisplatin <sep> partly accelerated radiotherapy with final concomitant boost technique 75 gy/40 fractions in 6 weeks partly accelerated radiotherapy pa-rt <sep> high-total-dose partly accelerated radiotherapy <sep> alternating chemoradiotherapy versus partly accelerated radiotherapy <sep> 5-fluorouracil <sep>', 'radiotherapy <sep> induction chemotherapy <sep> cisplatin bleomycin vindesine and mitomycin c <sep> combination cisplatin 5-fluorouracil by continuous infusion and vindesine <sep> primary radiotherapy <sep>', 'methotrexate vs bleomycin <sep> mtx <sep> blm <sep>', 'non-cisplatin-based induction chemotherapy and concurrent chemoradiotherapy <sep> induction chemotherapy consisting of cyclophosphamide and methotrexate followed by concomitant 5-fluorouracil and irradiation study group or irradiation alone control group <sep> induction chemotherapy <sep> concomitant chemoradiotherapy <sep>', 'chemotherapy arm b <sep> cisplatin <sep> concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy bircf <sep>', 'induction chemotherapy <sep> loco-regional treatment included resection followed by adjuvant radiotherapy <sep> initial chemotherapy <sep> radical irradiation <sep> initial chemotherapy cisplatin and infusional fluorouracil followed by loco-regional treatment group a n  118 or loco-regional treatment alone <sep> intensive induction chemotherapy <sep>', 'induction chemotherapy <sep> carboplatin/5-fu prior to surgery and radiotherapy arm a 70 pts or standard treatment with surgery and radiotherapy <sep>', 'concomitant radiochemotherapy <sep> radiotherapy alone with concomitant radiochemotherapy <sep> concomitant radiochemotherapy arm b compared with standard radiotherapy <sep> radiotherapy alone <sep> concomitant radiochemotherapy <sep> carboplatin and fluorouracil <sep>', 'fluorouracil 5-fu <sep> simultaneous radiochemotherapy versus radiotherapy alone <sep> leucovorin <sep> simultaneously administered chemotherapy ct and radiotherapy rt <sep> concomitant ct <sep> cisplatin <sep> rt alone arm a or simultaneous rt plus ct <sep> 5-fu <sep>', 'induction chemotherapy <sep> cisplatinum bleomycin vindesine and mitomycin c <sep> induction chemotherapy <sep> chemotherapy prior to local therapy group a or local therapy alone <sep> primary radiotherapy <sep>', 'chemotherapy <sep> preoperative radiation therapy <sep> preoperative chemotherapy and 48 preoperative irradiation <sep> preoperative intra-arterial chemotherapy or preoperative radiotherapy <sep> intra-arterial preoperative cytostatic treatment versus preoperative irradiation <sep> preoperative chemotherapy with cisplatin and epirubicin total doses 200 mg cisplatin 120 mg epirubicin <sep>', 'tpf or pf induction chemotherapy followed by chemoradiotherapy with weekly carboplatin therapy and radiotherapy <sep> cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy <sep> docetaxel plus cisplatin and fluorouracil <sep> induction chemotherapy plus chemoradiotherapy <sep> induction chemotherapy with docetaxel plus cisplatin and fluorouracil tpf with cisplatin and fluorouracil pf followed by chemoradiotherapy <sep> cisplatin and fluorouracil alone or with docetaxel <sep> tpf <sep>', 'sequential chemotherapy <sep> surgery and postoperative radiotherapy <sep> adjuvant chemotherapy <sep> cis-platinum and 5-fu chemotherapy followed by postoperative radiotherapy ct/rt or postoperative radiotherapy alone rt <sep>', 'chemotherapy <sep> levamisole and uft <sep> adjuvant levamisole/uft futraful and uracil chemotherapy <sep> levamisole/uft therapy <sep> post-operative chemotherapy with levamisole and uft <sep>', 'neoadjuvant methotrexate cisplatin and continuous infusion 5-fluorouracil 5-fu mpf arm a or four cycles of bleomycin cisplatin and methotrexate pbm alternating with cisplatin and 5-fu pf arm b <sep> radiation therapy <sep> neoadjuvant and adjuvant chemotherapy <sep> adjuvant chemotherapy <sep> neoadjuvant chemotherapy <sep>', 'combined preoperative radiochemotherapy <sep> cisplatin chemotherapy with 5 x 12.5 mg cisplatin <sep> radical surgery preceded by preoperative radiochemotherapy <sep> conventionally fractioned irradiation <sep> preoperative radiochemotherapy and radical surgery <sep> radical surgery alone <sep> radical surgery <sep>', 'cisplatin and fluorouracil followed by surgery chemotherapy arm or surgery alone control arm <sep> primary chemotherapy <sep> postoperative radiotherapy <sep> chemotherapy <sep> postoperative radiotherapy <sep>', 'carboplatin <sep> induction chemotherapy with carboplatin and ftorafur <sep> radiotherapy <sep> induction chemotherapy followed by radiotherapy <sep>', 'inductive chemotherapy <sep> experimental treatment induction chemotherapy surgery postoperative radiotherapy <sep> conventional treatment surgery and postoperative radiotherapy <sep> preoperative chemotherapy <sep> preoperative chemotherapy <sep>', 'perioperative chemotherapy <sep> methotrexate <sep> perioperative adjuvant chemotherapy <sep>', 'carboplatin <sep> postoperative radiotherapy alone arm a or the same radiotherapy plus carboplatin <sep> postoperative radiotherapy with or without carboplatin <sep> postoperative radiotherapy and carboplatin <sep>', 'intra-arterial radplat <sep> standard radiotherapy <sep> intra-arterial ia versus standard intravenous iv chemoradiation <sep> cisplatin infusions <sep>', 'tirapazamine tpz <sep> simultaneous chemoradiotherapy <sep> tpz <sep> cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine <sep> induction chemotherapy tpz cisplatin and 5-fluorouracil 5-fu followed by simultaneous chemoradiotherapy tpz cisplatin and 5-fu or to receive the same regimen without tpz <sep> chemoradiotherapy <sep>', 'cisplatin versus carboplatin <sep> cddp 80 mg/m2 or crp <sep> radiotherapy <sep> radiochemotherapy <sep> cisplatin cddp)-rt versus carboplatin crp)-rt <sep> chemotherapy and radiotherapy rt <sep> concurrent chemo-radiotherapy <sep>', 'bleomycin <sep> radiotherapy <sep> radiation pepleomycin and hyperthermia <sep> radiotherapy and bleomycin <sep>', 'radical surgery <sep> combined bleomycin treatment and radiation therapy <sep> bleomycin <sep> irradiation or irradiation plus bleomycin <sep>', 'standard fraction rt <sep> same rt plus either 6 mg/m2 of cisplatin cdpp <sep> radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin <sep> carboplatin cbdca <sep>', 'tirapazamine cisplatin and radiation versus cisplatin and radiation <sep> tpz to chemoradiotherapy <sep> definitive radiotherapy <sep> tpz <sep> cis <sep> tpz alone <sep> hypoxic cytotoxin tirapazamine tpz combined with cisplatin cis and radiation <sep>', 'identical treatment plus concurrent cisplatin <sep> radiotherapy <sep> radiotherapy alone <sep> cisplatin and radiotherapy <sep> resection and postoperative radiotherapy <sep> postoperative chemotherapy and radiotherapy <sep> postoperative concurrent radiotherapy and chemotherapy <sep>', 'neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil <sep> chemotherapy <sep> cisplatin cddp and fluorouracil fu versus carboplatin cbdca and fu <sep> cddp-fu <sep> cbdca-fu <sep> radiotherapy <sep> cddp 100 mg/m2 intravenously on day 1 and fu 5,000 mg/m2 over a 120-hour continuous infusion or cbdca <sep>', 'hyperfractionated irradiation <sep> cisplatin and fluorouracil <sep> cisplatin per square meter of body-surface area per day and 600 mg of fluorouracil <sep> radiotherapy <sep> hyperfractionated irradiation with or without concurrent chemotherapy <sep> hyperfractionated irradiation plus concurrent chemotherapy combined treatment <sep>', 'radiotherapy--chemotherapy combination <sep> radiotherapy <sep> sequential bleomycin and cis-platinum <sep> radiotherapy-chemotherapy <sep> rt  ct <sep>', 'gemcitabine <sep> radiotherapy alone <sep> gemcitabine concurrent with radiation therapy <sep> gemcitabine along with radiotherapy <sep> gemcitabine and radiotherapy <sep> gemcitabine <sep>', 'cisplatin/fluorouracil vs cisplatin/uft <sep> 5-fu 1,000 mg/m2/day on days 2 through 6 group 1 or oral administration of uft <sep> cisplatin <sep> locoregional standard radiotherapy <sep> cisplatin/uft <sep> fluorouracil 5-fu cisplatin with the combination tegafur and uracil uft)/cisplatin <sep>', 'induction chemotherapy <sep> cddp <sep> combination chemotherapy <sep> cisplatin 80 mg/m2 given alone cddp regimen or 2 in combination with vincristine 1 mg d 1 methotrexate 10 mg/m2 d 1 2 3 and bleomycin <sep> initial chemotherapy with cisplatin <sep> cisplatin <sep>', 'platinum chemotherapy <sep> methotrexate alone or vincristine bleomycin methotrexate and fluorouracil <sep> chemoradiotherapy <sep> chemotherapy given after radiotherapy with or without concurrent chemotherapy <sep> radiotherapy <sep> concurrent non-platinum chemoradiotherapy <sep> radiotherapy alone n=135 or sim alone <sep> chemotherapy <sep> chemotherapy regimen radical radiotherapy alone n=233 radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy sim alone n=166 or 14 and 28 days after completing radiotherapy sub alone n=160 or both sim+sub <sep>', 'tpz/cis <sep> tirapazamine cisplatin and radiation versus fluorouracil cisplatin and radiation <sep> tirapazamine <sep> definitive radiotherapy <sep> 3 tpz/cis or cisplatin <sep> tirapazamine alone <sep> cisplatin <sep> infusional fluorouracil <sep>', 'conventional fractionation radiation therapy rt arm a vs. split-course accelerated hyperfractionated rt s-ahf arm b vs. conventional fractionation rt plus concomitant chemotherapy ct <sep> radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy <sep> carboplatin and 5-fluorouracil cbdca <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",chemotherapy in addition to radiotherapy and surgery is associated with improved overall survival in patients with oral cavity and oropharyngeal cancers. induction chemotherapy may prolong survival by 8 to 20 and adjuvant concomitant chemoradiotherapy may prolong survival by up to 16%. in patients with unresectable tumours concomitant or alternating chemoradiotherapy may prolong survival by 10 to 22%. there is insufficient evidence as to which agent or regimen is most effective and the additional toxicity associated with chemotherapy given in addition to radiotherapy and/or surgery cannot be quantified.
111,"{'outcomes': ['basal gh <sep> serum gh <sep>'], 'punchline_text': ['in response to l-dopa and arginine hydrochloride stimulation serum gh rose to above 7 mg/ml in all patients. <sep>'], 'population': ['16 children studied with x-linked hypophosphatemia <sep> patients with x-linked hypophosphatemia have short stature <sep> children with x-linked hypophosphatemia <sep> patients with x-linked hypophosphatemia <sep>'], 'interventions': ['insulin-like growth factor-i <sep> oral phosphate and vitamin d therapy <sep>'], 'punchline_effect': [' sig increase <sep>']}",we have found no conclusive evidence to indicate that the use of recombinant human growth hormone therapy in children with x-linked hypophosphatemia is associated with changes in longitudinal growth mineral metabolism endocrine renal function bone mineral density and body proportions.
112,"{'outcomes': ['sustained virological response svr negative hcv-rna <sep> fibrosis index <sep> side effects <sep> overall svr <sep> efficacy and safety <sep> early virological response <sep> svrs <sep>', 'plasma hiv rna level <sep> intracellular peripheral blood mononuclear cells stavudine-triphosphate tp concentrations <sep> plasma hiv rna levels <sep> median residual concentration of intracellular stavudine-tp <sep> peak concentrations <sep>', 'sustained virologic response svr defined as an undetectable hcv rna level <sep> early virologic response <sep> adverse events <sep> safety tolerability and efficacy <sep> deaths or opportunistic infections <sep> svr <sep> serum hcv rna levels <sep> serious adverse event <sep>', 'sustained virological response svr <sep> predictive values of early virological response evr <sep> svr <sep> efficacy and safety <sep> positive predictive value of evr <sep>', 'early virological response <sep> sustained virological response svr <sep> svr rate <sep> frequent blood lactate measurement and relative quantitation of mitochondrial dna mtdna content in peripheral blood mononuclear cells <sep> viral response <sep> hyperlactataemia <sep> hcv rna <sep>', 'sustained virological response svr <sep> cd4 cell count <sep> svr <sep> efficacy and safety <sep> side effects <sep>', 'hiv infection <sep> tolerability and feasibility <sep> cd4 lymphocyte counts and hiv-1 rna remained stable <sep> drug interactions toxicity tolerance and acceptance <sep> normal transaminase levels <sep>', 'histologic activity <sep> sustained virologic responses <sep> clinical and biological events <sep> pancreatitis or symptomatic hyperlactatemia <sep> sustained virologic response <sep> virologic efficacy and safety <sep> serum hcv-rna <sep> hcv-rna <sep> safety and efficacy <sep>', 'response rate <sep> cd4 counts <sep> negative serum hcv-rna values <sep> sustained response <sep> sustained response rates <sep>', 'sustained virological response <sep> hcv-rna levels <sep> efficacy and safety <sep>', 'sustained virological response svr <sep> premature interruptions <sep> rate of drop-outs <sep> evr <sep> svr <sep> efficacy and safety <sep>', 'cd3 cd4 and cd3 cd8 t-cells counts <sep> hla)-dr and cd3 cd8 hla-dr lymphocyte subsets <sep> lymphopenia concerned mainly cd8 t-cells <sep> cd3 cd8 hla-dr t-cell percentages <sep> moderate and transient cd4 lymphopenia <sep> reversible cd4 lymphopenia <sep> serum hcv rna <sep> cd3 cd3 cd4 cd3 cd8 cd3 cd4 human leucocyte antigen <sep>', 'sustained virologic response <sep> chronic hcv infection <sep> serum hcv rna level <sep> neutropenia and thrombocytopenia <sep> rates of sustained virologic response <sep> overall rate of sustained virologic response <sep> efficacy and safety <sep>', 'virologic response or histologic improvement <sep> rate of sustained virologic response an hcv rna level <sep> sustained virologic response <sep> histologic responses <sep> virologic response <sep>'], 'punchline_text': ['among genotypes 1 or corrected 4 svrs were 28 versus 32 p  0.67 and 62 versus 71 p  0.6 in genotypes 2 or corrected 3 for peg 2b and peg 2a respectively. <sep>', 'coprescription of ribavirin and stavudine has no short-term impact on plasma hiv rna level in hiv-hcv-coinfected patients treated with stavudine as a part of their antiretroviral treatment this coprescription can be safely used although an in vivo interaction between ribavirin and stavudine is possible. <sep>', 'however while no deaths or opportunistic infections were observed nearly 30 of subjects stopped treatment due to adverse events and 7 subjects experienced a serious adverse event. <sep>', 'in a per-protocol analysis svr was reached by 54 of patients in arm a genotype 2-3 11/16 genotype 1-4 4/12 and 22 in arm b genotype 2-3 3/15 genotype 1-4 3/12). <sep>', 'peginterferon alpha-2b plus ribavirin was more effective than interferon alpha-2b plus ribavirin in hiv-coinfected patients. <sep>', 'peg-inf  rbv was significantly more effective than inf  rbv for the treatment of chronic hepatitis c in hiv co-infected patients mainly of genotype 1 or 4. <sep>', 'cd4 lymphocyte counts and hiv-1 rna remained stable. <sep>', 'this difference between the treatments was found in patients with hcv genotype 1 or 4 infection 17 for peginterferon vs 6 for standard interferon p  .006 but was not found in patients with hcv genotype 2 3 or 5 44 for peginterferon vs 43 for standard interferon p  .88). <sep>', 'patients with hcv genotypes 2 or 3 had a 7-fold higher response rate than those with hcv genotypes 1 or 4. <sep>', 'amantadine addition and interferon intensification do not improve the low efficacy of combination of interferon alfa plus ribavirin in hiv/hcv co-infected patients. <sep>', 'sustained virological response svr was achieved in 41.8 37.3 in genotype 1 54.6 in genotype 2/3 20 in genotype 4). <sep>', ' 200 cells micro l. hiv infection at inclusion was responsible for higher cd3 cd8 hla-dr t-cell percentages in co-infected patients than in healthy and hcv mono-infected subjects. <sep>', 'neutropenia and thrombocytopenia were more common among patients treated with regimens that contained peginterferon alfa-2a and anemia was more common among patients treated with regimens containing ribavirin. <sep>', 'treatment with peginterferon and ribavirin was associated with a significantly higher rate of sustained virologic response an hcv rna level of less than 60 iu per milliliter 24 weeks after completion of therapy than was treatment with interferon and ribavirin 27 percent vs. 12 percent p=0.03). <sep>'], 'population': ['human immunodeficiency virus patients <sep> 182 human immunodeficiency virus hiv)-hepatitis c virus hcv patients nave for hcv therapy was performed <sep>', '30 patients coinfected with human immunodeficiency virus hiv and hepatitis c virus hcv <sep> hiv-hcv-coinfected patients treated with <sep> patients coinfected with hiv and hepatitis c virus <sep>', 'chronic hepatitis c in hiv-infected persons <sep> 180 randomized subjects 162 received at least 1 dose of study medication constituting the modified intention-to-treat population <sep> subjects in both groups were similar with respect to age gender hcv genotype and hiv disease status <sep> co-infected persons <sep>', 'hiv-positive patients <sep> chronic hepatitis c in hiv-coinfected patients on haart <sep> thirty patients 15 from arm a and 15 from arm b dropped out of the trial prematurely due to side effects <sep> 135 coinfected patients <sep> hiv/hcv-coinfected patients undergoing highly active antiretroviral therapy haart <sep> fifty-five patients 28 from arm a and 27 from arm b completed 48 weeks of therapy <sep>', 'hiv-coinfected patients <sep> chronic hepatitis c in hiv-coinfected patients <sep> one hundred twenty-one hepatitis c virus hcv)-hiv-coinfected patients <sep>', 'patients with detectable hcv-rna alanine aminotransferase <sep> hiv/hcv co-infected patients <sep>', 'seven patients enrolled because of side effects and/or failure of anti-hcv therapy <sep> 1,013 hiv-infected patients were consecutively evaluated <sep> hiv and hcv co-infected patients on stable antiretroviral combination therapy <sep> hiv coinfected individuals on antiretroviral therapy <sep>', 'patients were enrolled from february 2000 to february 2002 and followed up for 72 weeks <sep> human immunodeficiency virus hiv)-infected patients <sep> hiv-infected patients <sep> hiv-hcv coinfected patients <sep> chronic hepatitis c in hiv-infected patients <sep> four hundred twelve hiv-hcv coinfected patients with detectable serum hcv-rna abnormal liver histology a cd4 cell count of at least 200 x 10(6)/l and stable plasma hiv-rna <sep>', 'one hundred six hiv-infected patients with chronic hepatitis c virus hcv infection <sep>', 'hiv/hcv co-infected patients <sep> hiv-infected patients <sep> eighty co-infected patients <sep> human immunodeficiency virus hiv infected patients <sep> chronic hepatitis c in hiv-infected patients <sep>', 'hiv/hepatitis c virus hcv)-coinfected patients without early virological response evr <sep> one hundred and ten patients were included mean age 38.7 years mean weight 68 kg 74 males 74 on highly active antiretroviral therapy mean cd4 t-cell count 564 cells/mm3 <sep> patients without evr <sep> fifty-three had an hcv load <sep> hiv/hcv-coinfected patients with no early virological response <sep> patients without evr at week 12 <sep>', '36 hcv-hiv co-infected patients with chronic hepatitis c t-cd4 cell count  250 cells micro l and a plasma viral load of  10 000 hiv rna copies/ml. patients were given ifn for 48 weeks <sep>', 'persons infected with the human immunodeficiency virus hiv <sep> massachusetts medical society <sep> hiv-infected patients <sep> patients who were also infected with hiv <sep> 868 persons who were infected with both hiv and hcv and who had not previously been treated with <sep>', 'chronic hepatitis c <sep> persons who are also infected with the human immunodeficiency virus hiv <sep> massachusetts medical society <sep> persons coinfected with hiv <sep> weekly for 48 weeks and 67 subjects <sep> 66 subjects <sep> hiv-coinfected persons <sep>'], 'interventions': ['pegylated interferon alpha-2b versus pegylated interferon <sep> peg ifn alfa-2b peg 2b versus peg ifn alfa-2a peg 2a plus ribavirin rbv <sep> peg 2b or peg 2a plus rbv <sep> pegylated interferons peg-ifn <sep> alpha-2a both plus ribavirin <sep> plus rbv <sep>', 'stavudine and ribavirin <sep> ribavirin and stavudine <sep> interferon-ribavirin <sep> stavudine <sep> interferon and ribavirin <sep>', 'ifn alfa-2b 3 miu thrice weekly tiw plus <sep> interferon alfa-2b plus ribavirin <sep> interferon alfa ifn and ribavirin rbv therapy <sep> rbv <sep> ifn alfa-2b 3 miu daily plus rbv <sep>', 'peg-ifn 1.5 microg/kg/week plus rbv <sep> pegylated interferon alpha2b peg-ifn plus ribavirin rbv <sep> peg-ifn plus ribavirin versus peg-ifn monotherapy <sep> peg-ifn <sep> peg-ifn monotherapy <sep>', 'peginterferon alpha-2b <sep> plus ribavirin <sep> interferon alpha-2b plus ribavirin <sep> peginterferon <sep> peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin <sep> peginterferon alpha-2b plus ribavirin <sep> interferon alpha-2b <sep>', 'interferon alfa-2b plus ribavirin <sep> peg-ifn <sep> inf  rbv <sep> rbv <sep> peginterferon alfa-2b plus ribavirin <sep> interferon alfa-2b ifn  ribavirin rbv versus pegylated interferon alfa-2b peg-inf  rbv <sep> peg-inf  rbv <sep>', 'interferon-alpha with and without amantadine <sep> amantadine <sep> amantadine versus interferon-alpha monotherapy <sep> interferon-alpha <sep>', 'peginterferon alfa-2b and ribavirin <sep> peginterferon <sep> peginterferon alfa-2b <sep> pegylated interferon alfa-2b vs standard interferon alfa-2b plus ribavirin <sep> didanosine <sep> standard interferon alfa-2b <sep> peginterferon alfa-2b plus ribavirin vs standard interferon alfa-2b plus ribavirin <sep> ribavirin <sep>', 'ribavirin rbv 400 mg bid plus interferon alpha-2b ifn-alpha <sep> interferon alpha-2b plus ribavirin <sep>', 'interferon alpha 2a <sep> interferon alfa plus ribavirin <sep> interferon <sep> ifn alpha 2a <sep> amantadine <sep> interferon and ribavirin combination therapy <sep> triple antiviral therapy <sep> standard anti-hepatitis c virus hcv <sep> amantadine <sep> ribavirin <sep>', 'pegylated interferon-alpha2a plus ribavirin <sep> pegylated interferon peg-inf)-alpha2a 180 microg/week plus ribavirin <sep>', 'high-dosed ifn anti-hcv therapy <sep> interferon-alfa-2a ifn <sep> interferon-alfa-2a and ribavirin <sep> ribavirin <sep> ribavirin <sep>', 'alfa-2a plus ribavirin <sep> peginterferon alfa-2a monotherapy <sep> peginterferon alfa-2a plus placebo or interferon alfa-2a <sep> peginterferon alfa-2a plus ribavirin <sep> peginterferon alfa-2a plus ribavirin <sep> interferon <sep> peginterferon alfa-2a <sep> interferon alfa-2a plus ribavirin <sep> peginterferon alfa-2a plus placebo <sep> interferon or ribavirin <sep> pegylated interferon alfa-2a peginterferon alfa-2a plus either ribavirin or placebo <sep> ribavirin <sep>', 'peginterferon plus ribavirin with interferon plus ribavirin <sep> peginterferon and ribavirin <sep> interferon and ribavirin <sep> peginterferon alfa-2a plus ribavirin <sep> peginterferon alfa-2a <sep> interferon alfa-2a plus ribavirin <sep> interferon alfa-2a <sep> ribavirin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",peginterferon plus ribavirin may be considered a treatment for patients with chronic hepatitis c and stable hiv who have not received treatment for hepatitis c as the intervention may clear the blood of hcv rna. supporting evidence comes mainly from the analysis of this non-validated surrogate outcome assessed in comparisons against other antiviral treatments. there is no evidence on treatment of patients who have relapsed or did not respond to previous therapy. careful monitoring of adverse events is warranted.
113,"{'outcomes': ['childbirth pain <sep> pain <sep> pain using a visual analogue scale vas and a verbal descriptor scale vds <sep> pain of childbirth <sep> acute pain <sep>', 'labour and delivery performance measures <sep>'], 'punchline_text': ['also women in the biofeedback group labored an average of 2 hr less and used 30 fewer medications. <sep>', 'however no difference between effectively trained electromyographic ineffectively trained skin-conductance and control groups was found on labour and delivery performance measures. <sep>'], 'population': ['forty primigravidae <sep>', 'facilitate childbirth in primiparae <sep>'], 'interventions': ['biofeedback <sep> training sessions in biofeedback and used biofeedback equipment <sep> emg biofeedback <sep>', 'antenatal training programmes normal antenatal classes normal classes plus electromyography biofeedback relaxation training or normal classes plus skin-conductance biofeedback relaxation training <sep> myographic training <sep> biofeedback training <sep> electromyographic and skin-conductance biofeedback relaxation training <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>']}",despite some positive results shown in the included trials there is insufficient evidence that biofeedback is effective for the management of pain during labour.
114,"{'outcomes': ['rate of epithelial healing <sep> rate of healing of corneal epithelial defect visual acuity extent of corneal vascularisation corneal clarity and formation of symblepharon <sep> final visual outcome symblepharon formation corneal clarity and vascularisation with or without amniotic membrane transplantation <sep>'], 'punchline_text': ['there was no overall difference in the final visual outcome symblepharon formation corneal clarity and vascularisation with or without amniotic membrane transplantation. <sep>'], 'population': ['patients with moderate grade burns <sep> acute ocular burns <sep> 50 patients with grade ii-iii burns were graded as moderate burns and 50 patients with grade iv burns were graded as severe burns <sep> patients with acute ocular burns <sep> eyes with acute ocular burns <sep> 100 patients with grade ii to iv acute ocular burns roper hall classification <sep>'], 'interventions': ['conventional medical therapy <sep> amniotic membrane transplantation <sep> amniotic membrane transplantation <sep> amniotic membrane transplantation in addition to conventional medical therapy <sep>'], 'punchline_effect': [' no diff <sep>']}",conclusive evidence supporting the treatment of acute ocular surface burns with amt is lacking. heterogeneity of disease presentation variations in treatment undefined criteria for treatment success and failure and non-uniform outcome measures are some of the factors complicating the search for clear evidence regarding this treatment.
115,"{'outcomes': ['hematocrit values <sep> blood loss <sep> blood loss <sep>', 'postoperative hemoglobin <sep> postoperative hemoglobin and hematocrit values and postcesarean endometritis <sep> postcesarean endometritis <sep> operative blood loss <sep> postcesarean endometritis and operative blood loss <sep> hematocrit <sep> mean maternal age parity gestational age presence and duration of membrane rupture and number of vaginal examinations <sep> blood loss during cesarean section and postoperative endometritis rate <sep> incidence of postoperative endometritis <sep>', 'perioperative blood loss and postpartum maternal infectious morbidity <sep> hematocrit <sep> postpartum maternal infectious morbidity <sep> perioperative hemorrhage <sep> incidence of postpartum infectious morbidity <sep>', 'postcesarean febrile morbidity <sep> febrile morbidity and endometritis rates <sep> febrile morbidity endometritis maximums and durations of elevated temperatures as well as other demographic intrapartum and postpartum variables <sep> endometritis <sep> febrile morbidity <sep>', 'operative blood loss <sep> blood loss <sep> operative blood loss <sep> hemoglobin levels <sep> incidence of endometritis wound infection and the need for blood transfusion <sep> postoperative hemoglobin levels <sep>', 'frequency of febrile morbidity <sep> rate of postoperative endometritis and amount of blood loss <sep> postoperative endometritis or blood loss <sep> manual removal of the placenta and postcesarean endometritis <sep> outcome measures frequency of endometritis and quantitative decrease in hemoglobin <sep> change in hemoglobin reflecting operative blood loss <sep> endometritis <sep>', 'incidence of postoperative infections with spontaneous placental removal <sep> postoperative infections <sep> mean gestational age frequency or duration of ruptured membranes frequency or duration of labor or mean number of vaginal examinations <sep> postdelivery infections <sep> placenta extracted <sep> incidence of postcesarean infections <sep> postcesarean infection defined as postecsarean endometritis or wound cellulitis requiring drainage and antibiotic therapy <sep>', 'risk of post-cesarean endometritis <sep> incidence of endometritis <sep> postoperative endometritis rate <sep> post-cesarean endometritis <sep>'], 'punchline_text': ['uterine position did not significantly affect blood loss in the spontaneous group 1 and 2 p  0.971 or the manual placental removal groups 3 and 4 p  0.061). <sep>', 'the decrease in postoperative hemoglobin p  0.05 and hematocrit p  0.001 was significantly greater in the manual removal groups groups 1 and 3 than in the spontaneous expulsion groups groups 2 and 4 at 48 hr postoperatively. <sep>', 'the incidence of postpartum infectious morbidity was also significantly greater in the manual group rr 15.8 95 ci 2.19-117.5). <sep>', 'there were no statistically significant differences in measures of postcesarean febrile morbidity based on placental delivery method or intraoperative glove change. <sep>', 'manual delivery of the placenta is not associated with a significantly greater risk of operative blood loss decreased postoperative hemoglobin levels or increased incidence of endometritis compared with spontaneous placental separation. <sep>', 'we found no significant difference in either postoperative endometritis or blood loss regardless of the means used to effect delivery of the placenta. <sep>', 'there were no statistically significant differences in mean gestational age frequency or duration of ruptured membranes frequency or duration of labor or mean number of vaginal examinations between the two study groups. <sep>', 'operator glove change did not alter the incidence of endometritis relative risk 1.0 95 confidence interval 0.79-1.3). <sep>'], 'population': ['100 women who were undergoing a cesarean section <sep>', 'patients were excluded if they had received intrapartum antibiotics had chorioamnionitis required an emergency cesarean hysterectomy had rupture of membranes for more than 12 hr had bleeding diathesis and had abnormal placentation or prior postpartum hemorrhage <sep> 840 women who underwent cesarean section <sep>', 'one-hundred-fifty-one were randomized to the manual removal group and 149 to the spontaneous group <sep> three hundred and two patients admitted for abdominal delivery <sep>', 'consenting patients <sep>', '200 women with normal pregnancies undergoing cesarean section <sep>', 'patients who had cesarean delivery assigned either to spontaneous delivery of the placenta group 1 or <sep> patients undergoing emergency cesareans and those with possible placenta accreta or evidence of preexisting infection <sep> study criteria were met for 375 subjects 177 in group 1 and 198 in group 2 <sep>', 'patients were excluded from participation if they had received intrapartum prophylactic antibiotics or had been determined to have chorioamnionitis <sep> parturients undergoing cesarean delivery <sep> a total of 333 women were enrolled in the investigation with 165 assigned to the manual removal group and 168 allocated to have spontaneous removal <sep>', 'women who required cesarean <sep> 760 women entered into the study we included 643 who did not have intrapartum chorioamnionitis or cesarean hysterectomy <sep>'], 'interventions': ['spontaneous placental detachment exteriorized uterine repair 3 manual placental removal in situ uterine repair and 4 manual placental removal exteriorized uterine repair <sep>', 'placental removal method and site of uterine repair <sep> manual placental delivery  exteriorized uterine repair 2 spontaneous placental delivery  exteriorized uterine repair 3 manual placental delivery  in situ uterine repair 4 spontaneous placental delivery  in situ uterine repair <sep>', 'placental removal method at cesarean delivery <sep>', '26)--no glove change with manual placental delivery group b n  27)--no glove change with expressed placental delivery group c n  27)--glove change with manual placental delivery and group d n  28)--glove change with expressed placental delivery <sep>', 'manual removal n=100 or the control group spontaneous separation <sep>', 'manual removal <sep>', 'perioperative prophylactic antibiotics <sep> placenta removed manually or spontaneously <sep>', 'no glove change plus manual placental extraction 2 no glove change plus spontaneous placental delivery 3 glove change plus manual extraction and 4 glove change plus spontaneous delivery <sep> external uterine massage and traction <sep> cephalosporin <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",delivery of the placenta with cord traction at caesarean section has more advantages compared to manual removal. these are less endometritis less blood loss less decrease in haematocrit levels postoperatively and shorter duration of hospital stay. future trials should provide information on interval between the delivery of the infant and of the placenta change in lochia blood splashing during placental removal and uterine pain after operation as well as the effects of delayed cord clamping.
116,"{'outcomes': ['symptomatic limbs reactive hyperemic flow <sep> blood pressure <sep> limb circulation <sep> calf blood flow <sep> heart rate <sep> heart rate blood pressure calf blood flow and vascular resistance <sep>', 'claudication distance <sep> blood pressure changes <sep> walking distance <sep> objective and subjective measures of walking performance and foot temperature <sep> skin temperature <sep>', 'peak flow <sep> calf blood flow and vascular resistance <sep> calf blood flow <sep> vascular resistance <sep> hyperaemic flow <sep> heart rate blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance <sep>', 'mean arterial pressure <sep> symptoms of claudication <sep> blood flow <sep> calf blood flow <sep> postexercise calf blood flow and symptoms of claudication <sep> maximal exercise heart rate <sep>'], 'punchline_text': ['in the less symptomatic limbs reactive hyperemic flow was greater after pindolol than after the other drugs and did not differ from the level recorded after placebo. <sep>', 'there was no evidence of adverse or beneficial effects of atenolol or nifedipine when given singly on peripheral vascular disease. <sep>', 'the peak flow was reduced by 20 p greater than 0.01 with metoprolol and by 15 with methyldopa below the initial level and by 17 and by 12 below the level recorded on placebo respectively. <sep>', 'calf blood flow was not affected by either drug compared with placebo at rest or at either workload. <sep>'], 'population': ['intermittent claudication <sep> seven patients with hypertension and intermittent claudication <sep> patients with peripheral arterial disease <sep>', '49 patients 40 men aged 39-70 with chronic stable intermittent claudication <sep> patients with intermittent claudication <sep>', 'intermittent claudication <sep> 14 hypertensive patients with intermittent claudication <sep>', '19 patients with mild-to-moderate peripheral vascular disease <sep> patients with peripheral vascular disease <sep>'], 'interventions': ['placebo <sep> beta-adrenoceptor blockade <sep> labetalol <sep> labetalol pindolol and propranolol <sep> propranolol <sep> pindolol <sep>', 'atenolol 50 mg plus slow release nifedipine 20 mg twice daily placebo <sep> atenolol plus nifedipine <sep> atenolol plus nifedipine <sep> atenolol <sep> pindolol and labetalol <sep> nifedipine <sep> atenolol and nifedipine and their combination <sep> dihydropyridine calcium antagonist nifedipine <sep> nifedipine <sep> adrenoceptor blocker atenolol <sep> atenolol <sep>', 'metoprolol and methyldopa <sep> placebo <sep> methyldopa <sep> metoprolol <sep>', 'placebo <sep> propranolol <sep> beta-adrenergic blockers <sep> beta 1-selective and a nonselective beta-adrenergic blocker <sep> metoprolol <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>']}",there is currently no evidence that beta blockers adversely affect walking distance in people with intermittent claudication. however due to the lack of large published trials beta blockers should be used with caution if clinically indicated.
117,"{'outcomes': ['rdai score oxygen saturation in room air rate respiratory and heart rate <sep> duration of hospitalization <sep> clinical score oxygen saturation or reduction in duration of hospitalization <sep> respiratory distress assessment instrument rdai score respiratory rate oxygen saturation heart rate and the duration of hospitalization <sep>', 'clinical score and length of hospital stay <sep> respiratory failure <sep>', 'respiratory rate rdi and oxygen saturation <sep> rdi <sep> decrease in respirations <sep> and rdi scores <sep> heart rate respiratory rate oxygen saturation and clinical variables related to respiratory compromise with the use of a standardized respiratory distress index rdi <sep> improvement in respirations <sep> oxygen saturation <sep> heart rate <sep>', 'oxygen saturation rates <sep> improvement rates and duration of hospitalization <sep> clinical scores and oxygen saturation levels <sep> clinical scores <sep> oxygen saturation rates and clinical scores and duration of hospitalization <sep>', 'shortest hospital stay <sep> bronchial obstruction <sep> shorter hospitalization <sep>', 'time for resolution of illness roi duration of fever cough,coryza noisy breathing time to achieve normal feeding and normal sleep and frequency of hospitalization and adverse effects <sep> mild accessory muscle use and respiratory distress assessment instrument rdai score <sep> mean duration of fever cough coryza noisy breathing time to achieve normal feeding and normal sleep and frequency of hospitalization or adverse effects <sep> median se 95 ci duration of resolution of overall illness <sep>', 'respiratory rate <sep> accessory muscle score <sep> oxygen saturation <sep> heart rate <sep>', 'health care revisit and admission rates <sep> time to normal feeding normal sleeping quiet breathing resolved cough and coryza <sep> symptomatology of acute viral bronchiolitis <sep> time to resolution of illness <sep>', 'mean los <sep> length of hospital stay los <sep> time from admission until the infant had normal hydration oxygenation and minimal respiratory distress <sep>', 'oxygen saturation <sep> heart rate <sep> respiratory score <sep> respiratory rate heart rate oxygen saturation and presence of cyanosis wheezing retractions <sep>', 'adverse effects <sep> clinical score oxygen saturation and heart rate <sep>', 'wheeze scores <sep> heart rate or respiratory rate <sep> total scores <sep> oxygen saturation <sep> wheeze and retraction score respiratory and heart rates and pulse oximetry <sep>', 'need for hospital admission or home oxygen <sep> changes in clinical scores and oxygen saturations <sep> clinical scores or oxygen saturations <sep>', 'tidal expiratory flows <sep> vptef/ve and tptef/te <sep> ptef <sep> tidal breathing flow-volume loops <sep> tidal expiratory flow <sep> fraction of tidal volume exhaled at peak tidal expiratory flow ptef to total tidal volume vptef/ve and the fraction of exhaled time at ptef to total expiratory time tptef/te <sep> tidal breathing flow-volume loops <sep> remaining tidal volume tef10 tef25 and tef50 and the wheeze score <sep>', 'length of hospital stay <sep> actual length of hospital stay <sep> improvement in oxygen saturation sao2 during hospitalization and survival analysis to assess the time required to reach preestablished discharge criteria on three measures sao2 accessory muscle use and wheezing <sep> mean sao2 <sep> time to reach discharge criteria as defined by sao2 accessory muscle use or wheezing <sep> oxygen saturation <sep>', 'length of hospitalisation <sep> severity score number of nebulisations required <sep>', 'demographic characteristics initial oxygenation and clinical score <sep> clinical score or hospital duration <sep> oxygen saturation <sep> condition of hospitalised mild bronchiolitis <sep>', 'desaturation <sep> fall in sao2 <sep> arterial oxygen saturation sao2 <sep> sao2 <sep> oxygen saturation <sep>', 'respiratory rate pulse oximetry and a clinical score based on the degree of wheezing and retractions <sep> oxygen saturation <sep> clinical scores <sep> heart rate <sep>', 'peak inspiratory pressure <sep> inspiratory respiratory system resistance <sep> peak inspiratory pressure and respiratory system resistance <sep> bronchodilation <sep> heart rate <sep> bronchodilation peak inspiratory pressure and inspiratory respiratory system resistance <sep>', 'lengths of hospitalization <sep> respiratory syncytial virus rsv positivity and enrollment score <sep> wheezing retractions and respiratory rate <sep> rate of improvement and the final score <sep>', ""ie asleep awake or feeding <sep> respiratory rate and clinical score <sep> heart rate <sep> respiratory and heart rates clinical score oxygen saturation spo2 and the infant's state <sep>"", 'chest radiographs leukocyte counts blood culture specimens and nasal aspirate for viral antigen detection <sep> respiratory rate <sep> respiratory distress <sep> respiratory and heart rates clinical score and oxygen saturation <sep> clinical score <sep> heart rate <sep>'], 'punchline_text': ['nebulized terbutaline therapy does not appear effective in treating moderately ill infants with the first acute bronchiolitis. <sep>', 'average daily improvements as reflected by changes in the clinical score and length of hospital stay was essentially the same for infants treated with placebo salbutamol alone and dexamethasone alone. <sep>', 'children who received saline solution as initial therapy had no significant differences from baseline in any of the assessment measures. <sep>', 'clinical scores and oxygen saturation levels improved more rapidly in the bronchodilator groups than in the placebo group up to 24 h but these drugs did not have a sufficient effect to change the natural course of the disease. <sep>', 'all infants had significantly decreased scores except those in the control group the aminophylline group included a greater percentage of patients who did not abate their scores and they stayed in the hospital for more days than those in the other groups. <sep>', 'oral salbutamol is not superior to placebo in reducing the duration of symptoms in mild cases of acute bronchiolitis in children. <sep>', 'the heart rate rose slightly more in the albuterol group increases 7.76 from baseline versus the placebo group decreases 6.79). <sep>', 'the median 95 confidence interval time to resolution of illness days was similar albuterol 9.0 8-13 placebo 8.0 7-9 p .3 <sep>', 'group differences were not statistically significant in any of the secondary outcomes. <sep>', 'oxygen saturation decreased in group i without reaching statistical significance. <sep>', 'the outcome of patients at 120 min was found significantly better than the baseline values p  0.05). <sep>', 'after two treatments there was a significant improvement in the wheeze scores p less than 0.05 and total scores p less than 0.05 of the albuterol group compared with the placebo group. <sep>', 'racemic epinephrine and albuterol at equivalent doses had no effect on the need for hospitalization or supplemental oxygen in bronchiolitis in the outpatient setting compared to nebulized saline placebo though this study may have missed less dramatic clinical effects due to small sample size. <sep>', 'there were no significant changes in vptef/ve and tptef/te after albuterol or saline treatment. <sep>', 'both groups showed significant improvement in oxygen saturation over time but there was no significant difference in improvement between the two groups. <sep>', 'there was no significant difference between the groups in terms of severity score number of nebulisations required in the nebulised groups and the outcome as measured by the length of hospitalisation. <sep>', 'the change in oxygen saturation of recipients of both agents was significantly better than that of recipients of salbutamol alone or ipratropium bromide alone. <sep>', 'the fall in sao2 with salbutamol was seen whether infants received it as the first or second nebulisation. <sep>', 'there was no difference between the groups in oxygen saturation p  0.74 patients treated with salbutamol had a small increase in heart rate after two treatments 159  <sep>', 'similar statistically significant bronchodilation occurred after all three bronchodilators as indicated by a decrease in peak inspiratory pressure and respiratory system resistance but these changes were small and probably clinically insignificant. <sep>', 'we did not find any significant difference in the rate of improvement and the final score p  0.49 in the four groups. <sep>', 'there were no statistically significant differences in any outcomes among the four treatments except for oral albuterol which produced an increase in heart rate 15 beats per minute p  .005). <sep>', 'nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups. <sep>'], 'population': [""children's hospital of tunis from december 2004 to april 2006 <sep> moderately ill infants with the first acute bronchiolitis <sep> infants less than 12-months-old <sep> 35 patients less than 12 months of age with diagnosis of moderately severe bronchiolitis <sep>"", 'eight blocks of four infants each matched by age and clinical score <sep> acute wheezing in infants <sep> thirty-two infants aged 1 to 12 months hospitalized with acute wheezing were studied <sep> acute wheezing in infancy <sep>', 'wheezing infants and young children <sep> young acutely wheezing children <sep> acutely wheezing infants and young children <sep> 74 children aged 36 months or younger with acute wheezing participated in a double-masked randomized <sep> patients aged 12 months or younger n  37 benefited from metaproterenol treatment improvement in respiratory rate and rdi but not to the same degree as children aged 24 months or older n  23 <sep>', 'patients with moderate-severe bronchiolitis <sep> sixty-nine infants with moderate-severe bronchiolitis hospitalized at their first episode of wheezing or crepitations in the chest <sep>', 'infants under 1 year of age <sep> seventy-nine infants less than one year of age <sep> young infants admitted for acute wheezing aw <sep>', '140 infants of 310 approached with a clinical diagnosis of acute bronchiolitis with respiratory rate or 70 breath/min heart rate or 200 beats/min hemoglobin oxygen saturation spo2 <sep> mild cases of acute bronchiolitis in children <sep> pediatric outpatient department of a tertiary care hospital <sep> n=70 <sep> mild bronchiolitis <sep>', '34 children from whom nasal specimens were obtained by swab for viral identification 24 had positive test results 21 for respiratory syncytial virus 1 for parainfluenza 1 for paramyxovirus and 1 for influenza a <sep> 40 infants between 6 weeks and 24 months of age who had a first episode of wheezing and other signs and symptoms of bronchiolitis <sep> infants with bronchiolitis <sep> acute bronchiolitis <sep> infants younger and those older than 6 months of age <sep>', 'infants with mild-to-moderate illness <sep> infants with mild-to-moderate acute viral bronchiolitis <sep> 129 infants albuterol n  64 placebo n  65 <sep>', 'infants hospitalized with bronchiolitis <sep> infants hospitalized with acute viral bronchiolitis <sep> infants hospitalized for acute viral bronchiolitis <sep> a total of 149 infants were randomized 50 <sep>', 'one hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis <sep> acute bronchiolitis <sep>', 'mildly affected infants with acute bronchiolitis <sep> 186 children mean age 9.5 <sep> mildly affected ambulatory infants with acute bronchiolitis <sep> mild bronchiolitis <sep>', 'infants aged 0 to 24 months who presented to the emergency department with wheezing <sep> twenty-five infants <sep> wheezing infants <sep> wheezing infants in the emergency department <sep>', '2005 <sep> sixty-five patients between ages 6 weeks and 24 months with a diagnosis of bronchiolitis defined as first-time wheezing upper respiratory symptoms and/or fever and a respiratory distress assessment instrument score of at least 4 <sep> acute bronchiolitis <sep>', 'infants with bronchiolitis due to respiratory syncytial virus <sep> pediatric unit in a community teaching hospital <sep> infants with mild bronchiolitis due to respiratory syncytial virus <sep> twenty infants younger than 1 year of age mean age 5.8 <sep> bronchiolitis in infancy <sep>', '52 patients 24 months of age with a diagnosis of moderately severe acute viral bronchiolitis <sep> hospitalized infants with bronchiolitis <sep> infants hospitalized with acute moderate bronchiolitis <sep> december 1995 to march 1996 <sep> hospitalized infants with moderate bronchiolitis <sep>', '120 patients <sep> young children <sep> all children less than 2 years old with bronchiolitis <sep> bronchiolitis <sep> fifty-one 42 had respiratory syncytial virus rsv isolated from their nasopharyngeal aspirates <sep>', 'bronchiolitis <sep> patients who were 2 months to 2 years of age and without underlying cardiac or pulmonary disease received <sep> mild bronchiolitis <sep>', '21 infants admitted with bronchiolitis positive for respiratory syncytial virus had continuous sao2 measurements made before and after <sep> bronchiolitis <sep>', 'young children with acute bronchiolitis we enrolled 83 children median age 6 months range 1 to 21 months <sep> young children with acute bronchiolitis <sep> acute bronchiolitis <sep>', 'infants with respiratory syncytial virus bronchiolitis on mechanical ventilation <sep> tertiary pediatric intensive care unit in a university affiliated hospital in the northeastern united states <sep> twenty-two patients with respiratory syncytial virus bronchiolitis and in respiratory failure were enrolled <sep> patients with respiratory syncytial virus bronchiolitis in respiratory failure <sep>', 'n  20 <sep> young children with bronchiolitis admitted to hospital with moderate illness <sep> eighty-nine patients aged from 23 days to 11 months <sep> bronchiolitis <sep> young children in hospital with bronchiolitis <sep>', 'pediatric emergency department and outpatient clinic at university of maryland in baltimore <sep> infants <sep> eighty-eight infants median age 5.5 months being treated for their first episode of wheezing <sep>', '41 infants with recurrent wheezing <sep> infants with recurrent wheezing <sep> infants with bronchiolitis in egypt <sep> infants with first-time wheezing <sep> bronchiolitis in egypt <sep> 128 egyptian infants with first-time wheezing mean age 5.9 months <sep>'], 'interventions': ['placebo <sep> nebulized terbutaline therapy <sep> nebulized terbutaline or normal saline placebo <sep> terbutaline and placebo <sep> nebulized terbutaline <sep>', 'dexamethasone <sep> dexamethasone or placebo double-blind and salbutamol oral and inhaled or none open <sep> dexamethasone and salbutamol <sep> salbutamol-dexamethasone <sep> placebo salbutamol <sep> corticosteroids <sep>', 'nebulized metaproterenol sulfate <sep> placebo <sep> normal saline solution <sep> nebulized metaproterenol <sep> saline solution <sep> beta-adrenergic agonists <sep>', 'ipratropium bromide and salbutamol <sep> placebo <sep> nebulized salbutamol ipratropium bromide or placebo <sep> salbutamol and ipratropium bromide <sep>', 'nebulized bronchodilators <sep> aminophylline iv <sep> nebulized fenoterol plus ipratropium bromide <sep> fenoterol <sep> fenoterol group 3 fenoterol plus steroids and group 4 aminophylline iv plus steroids and oral fenoterol <sep> nebulized normal saline solution <sep> aminophylline <sep>', 'placebo <sep> oral salbutamol <sep> oral salbutamol <sep>', 'placebo saline solution <sep> nebulized albuterol <sep> placebo <sep> nebulized albuterol <sep>', 'albuterol <sep> placebo <sep> oral albuterol <sep>', 'albuterol and saline <sep> plac <sep> epinephrine epi <sep> racemic epi <sep> epinephrine <sep> albuterol alb or saline placebo plac <sep> nebulized epi or alb <sep> hours sd <sep>', 'placebo <sep> salbutamol or mist <sep> salbutamol <sep> nebulized salbutamol <sep> ml saline ii saline <sep>', 'nebulized salbutamol epinephrin 3 saline and normal saline 0.9 nacl <sep> epinephrine plus 3 saline <sep> epinephrine plus normal saline <sep> nebulized salbutamol-normal saline epinephrine-normal saline and 3 saline <sep> salbutamol plus 3 saline <sep> salbutamol plus normal saline <sep> normal saline alone <sep>', 'placebo saline <sep> nebulized albuterol <sep> placebo <sep>', 'placebo <sep> nebulized albuterol or saline placebo <sep> nebulized saline placebo <sep> nebulized racemic epinephrine <sep> racemic epinephrine and albuterol <sep> nebulized albuterol 5 mg nebulized racemic epinephrine or an equivalent volume of placebo <sep> albuterol and epinephrine <sep>', 'chloral hydrate <sep> albuterol <sep> nebulized albuterol <sep> nebulized albuterol <sep> tidal breathing flow-volume loops <sep>', 'placebo <sep> nebulized albuterol therapy <sep> nebulized albuterol or normal saline placebo <sep> albuterol <sep>', 'salbutamol ipratropium bromide or normal saline <sep> bronchodilators <sep> humidified oxygen without nebulisation <sep>', 'bronchodilators <sep> inhaled bronchodilators <sep> inhaled bronchodilators salbutamol and ipratropium bromide <sep> placebo <sep> ipratropium bromide <sep> drug 1 salbutamol or saline placebo followed one hour later by drug 2 ipratropium bromide or placebo <sep>', 'salbutamol or saline <sep> inhaled salbutamol <sep> salbutamol and saline nebulisation <sep> nebulised salbutamol or placebo <sep> salbutamol <sep>', 'nebulized salbutamol 0.10 mg/kg in 2 ml 0.9 saline solution or a similar volume of 0.9 saline solution placebo <sep> nebulized salbutamol albuterol <sep> salbutamol <sep>', 'normal saline <sep> norepinephrine levalbuterol racemic albuterol and normal saline at 6 hr intervals <sep> racemic epinephrine <sep> bronchodilators <sep>', 'ipratropium bromide <sep> normal saline placebo <sep> ipratropium bromide n  23 group 3--combined salbutamol and ipratropium bromide n  24 group 4--normal saline <sep> bronchodilators salbutamol and ipratropium bromide <sep> placebo as follows group 1--salbutamol <sep> bronchodilators <sep>', 'placebo <sep> nebulized saline <sep> albuterol <sep> oral placebo <sep> neubulized albuterol nebulized saline oral albuterol and oral placebo <sep> oral albuterol <sep> nebulized albuterol <sep> albuterol <sep>', 'placebo <sep> albuterol <sep> nebulized albuterol <sep> nebulized albuterol <sep> nebulized albuterol nebulized saline solution orally administered albuterol and orally administered placebo <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",bronchodilators do not improve oxygen saturation do not reduce hospital admission after outpatient treatment do not shorten the duration of hospitalization and do not reduce the time to resolution of illness at home. the small improvements in clinical scores for outpatients must be weighed against the costs and adverse effects of bronchodilators.
118,"{'outcomes': ['mean pain index <sep> pain index <sep> headache <sep>', 'pain level <sep> emg activity <sep> muscle tension <sep> myogenic headache <sep> quantity of muscle tension motor unit potential spikes per time unit <sep> subjective level of headache <sep>', 'headache <sep> headache reduction <sep>', 'pain/paraesthesia <sep> measured rotation <sep> pain or stiffness in the neck and pain/paraesthesia <sep> lateral flexion <sep>', 'symptoms of cervicogenic headache <sep> headache frequency and intensity and the neck pain and effects <sep> pain on neck movement upper cervical joint tenderness a craniocervical flexion muscle test and a photographic measure of posture <sep> headache intensity and duration the northwick park neck pain index medication intake and patient satisfaction <sep> headache-related and demographic characteristics <sep> cervicogenic headache <sep> change in headache frequency <sep>', 'disability <sep> average response <sep> migraine frequency <sep> morbidity of each episode <sep> standard headache diaries <sep> frequency intensity visual analogue score duration disability associated symptoms and use of medication for each migraine episode <sep>', 'tension headache <sep> pain scores <sep> pain intensity <sep> safety and effectiveness <sep>', 'frequency and intensity of cephalalgia <sep>', 'episodic tension-type headache <sep> headache pain intensity <sep> mean number of analgesics <sep> daily hours of headache pain intensity per episode and daily analgesic use as recorded in diaries <sep> mean daily headache <sep> episodic tension-type headache <sep>', 'tension headache pain <sep> average pain reduction <sep> headache pain <sep> mcgill-melzack pain questionnaire <sep> pain reduction <sep> headache pain levels <sep>', 'intensity of headache <sep> overall function sickness impact profile and mental well-being mood adjective check list and the intensity and frequency of headache <sep> overall function <sep> headache intensity <sep> intensity and frequency of headache <sep>', 'migraine headache <sep> headache index score <sep> headache index scores <sep>', 'headache activity <sep> number of headaches <sep>', 'headache activity <sep> migraine activity <sep> headaches <sep>', 'daily headache intensity weekly headache frequency over-the-counter medication usage and functional health status sf-36 <sep> headache intensity <sep> side effects that included drowsiness dry mouth and weight gain <sep> headache frequency <sep> neck soreness and stiffness <sep> pain <sep> side effects <sep>', 'number of headache hours per day <sep> headache intensity per episode <sep>'], 'punchline_text': ['two weeks after the last treatment the mean pain index was significantly reduced to 43 in the group treated with manual therapy compared with the pretreatment level. <sep>', 'after a follow-up period of 28 weeks there was still a significant reduction of emg activity in both groups. <sep>', 'pt alone is not effective in reducing headache with only 14 of subjects reporting significant headache reduction mean reduction of 15.6 in comparison with 41.3 in rtb). <sep>', 'manipulation also produced a significant increase in measured rotation that was maintained for three weeks and an immediate improvement in lateral flexion that was not maintained. <sep>', 'at the 12-month follow-up assessment both manipulative therapy and specific exercise had significantly reduced headache frequency and intensity and the neck pain and effects were maintained p  0.05 for all). <sep>', 'the average response of the treatment group n  83 showed statistically significant improvement in migraine frequency p  .005 duration p  .01 disability p  .05 and medication use p .001 when compared with the control group n  40). <sep>', 'cranial electrotherapy stimulation is distinct from tens and is safe and often effective in ameliorating the pain intensity of tension headaches. <sep>', 'patients were randomly assigned to treatment groups and received either short term intervention 15 or less treatments or long term intervention greater than 15 treatments). <sep>', 'based on intent-to-treat analysis no significant differences between the manipulation and control groups were observed in any of the 3 outcome measures. <sep>', 'a wilcoxon signed rank test for differences indicated that 90 of the subjects exposed to tt experienced a sustained reduction in headache pain p less than .0001. <sep>', 'the intensity and frequency of headache was significantly reduced in both the physiotherapy group and the acupuncture group. <sep>', 'the reduction in headache index scores during treatment compared with baseline was 49 for amitriptyline 40 for spinal manipulation and 41 for the combined group p  .66. <sep>', 'the number of headaches per week decreased from 4.03 during the baseline period to 0.43 during the initial 2-week follow-up period and to 0.14 during the extended follow-up which averaged 8.1 months. <sep>', 'all showed decreased headache activity 50 good 38 excellent). <sep>', 'change in patient-reported daily headache intensity weekly headache frequency over-the-counter medication usage and functional health status sf-36). <sep>', 'the use of analgesics decreased by 36 in the manipulation group but was unchanged in the soft-tissue group this difference was statistically significant p  .04 chi 2 for trend). <sep>'], 'population': ['post-traumatic headache <sep> 23 patients with post-traumatic headache <sep> 19 patients 83 <sep>', 'tension-neck and headache patients <sep> twenty-two tension-neck and headache patients <sep>', 'migraine <sep> headache patients <sep> patients who fail to improve with relaxation training/thermal biofeedback rtb <sep>', '52 patients in general practice <sep>', '200 participants who met the diagnostic criteria for cervicogenic headache <sep> cervicogenic headache <sep>', 'migraine <sep> one hundred twenty-seven volunteers between the ages of 10 and 70 years were recruited through media advertising <sep>', 'one hundred patients <sep>', '1015 adult patients with primary diagnosis of vascular/migraine or muscle contraction headache participated in the study investigating symptom frequency and severity over a 36 month period after receiving treatment <sep> seven hundred and ninety-three patients returned sufficient data to be included in the analysis <sep> vascular and muscle contraction headache <sep>', 'adults with episodic tension-type headache <sep> episodic tension-type headache <sep> volunteer sample of 26 men and 49 women aged 20 to 59 years who met the diagnostic criteria for episodic tension-type headache as defined by the international headache society <sep> outpatient facility of a national health service-funded chiropractic research institution in denmark <sep>', 'sixty volunteer subjects with tension headaches <sep>', 'patients with tension headache treated with <sep> sixty-two female patients with chronic tension headache <sep>', 'patients with frequent migraine headaches <sep> chiropractic college outpatient clinic <sep> migraine headache <sep> 218 patients with the diagnosis of migraine headache <sep>', '9 subjects kept a 3-week log of headache activity <sep> 23 patients with chronic migraine <sep>', ""22 subjects who had actual exposure received 2 additional weeks of actual exposure after their initial 1-month follow-up <sep> thirteen subjects from the actual exposure group elected not to receive additional exposure <sep> 42 subjects 34 women and 8 men who met the international headache society's criteria for migraine participate in a double-blind placebo-controlled study <sep>"", '150 patients who were enrolled in the study 24 16 dropped out 5 6.6 from the spinal manipulative therapy and 19 27.1 from the amitriptyline therapy group <sep> one hundred and fifty patients between the ages of 18 and 70 with a diagnosis of tension-type headaches of at least 3 months duration at a frequency of at least once per wk <sep> chronic tension-type headaches <sep> 448 people responded to the recruitment advertisements 298 were excluded during the screening process <sep> chiropractic college outpatient clinic <sep> chronic tension-type headache <sep>', 'subjects were recruited from 450 headache sufferers who responded to newspaper advertisements <sep> fifty-three subjects suffering from frequent headaches who fulfilled the international headache society criteria for cervicogenic headache excluding radiological criteria <sep> cervicogenic headache <sep>'], 'interventions': ['cold packs <sep> manual therapy <sep>', 'acupuncture therapy or physiotherapy <sep> acupuncture <sep> acupuncture and physiotherapy <sep>', 'physical therapy with relaxation and thermal biofeedback <sep>', 'cervial spine <sep>', 'manipulative therapy group exercise therapy group combined therapy group and a control group <sep> manipulative therapy and exercise <sep> manipulative therapy and a low-load exercise program <sep> exercise and manipulative therapy <sep> manipulative therapy <sep>', 'chiropractic spinal manipulative therapy <sep> chiropractic spinal manipulative therapy smt <sep> smt <sep> chiropractic smt diversified technique <sep>', 'placebo <sep> placebo <sep> pain suppressor unit a cranial electrotherapy stimulator <sep> cranial electrotherapy stimulation <sep> cranial electrotherapy <sep>', 'relaxation training stepwise relaxation/hypnosis/autogenic training/cognitive behavior therapy biofeedback thermal/photoplethysmograph/emg micro-electrical therapy tens/neurotransmitter modulation or multimodal treatment combination of any of the above two treatments <sep> short term intervention 15 or less treatments or long term intervention <sep>', 'spinal manipulation <sep> spinal manipulation therapy <sep> soft tissue therapy and spinal manipulation the manipulation group and the other receiving soft tissue therapy and a placebo laser treatment <sep>', 'therapeutic touch tt <sep> placebo <sep> tt <sep>', 'acupuncture <sep> acupuncture or physiotherapy <sep> acupuncture and physiotherapy <sep>', 'amitriptyline spinal manipulation <sep> spinal manipulation amitriptyline <sep> amitriptyline <sep>', 'placebo <sep>', 'placebo <sep> pulsing electromagnetic fields <sep> migraine with pulsing electromagnetic fields <sep>', 'spinal manipulative therapy <sep> spinal manipulation vs. amitriptyline <sep> spinal manipulation and pharmaceutical treatment amitriptyline <sep> amitriptyline therapy <sep> amitriptyline <sep> amitriptyline <sep>', 'spinal manipulation <sep> isolated intervention of high-speed low-amplitude spinal manipulation <sep> low-level laser in the upper cervical region and deep friction massage <sep> high-velocity low-amplitude cervical manipulation <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",a few non-invasive physical treatments may be effective as prophylactic treatments for chronic/recurrent headaches. based on trial results these treatments appear to be associated with little risk of serious adverse effects. the clinical effectiveness and cost-effectiveness of non-invasive physical treatments require further research using scientifically rigorous methods. the heterogeneity of the studies included in this review means that the results of a few additional high-quality trials in the future could easily change the conclusions of our review.
119,"{'outcomes': ['symptom scores for cough <sep> forced expiratory volume <sep> symptoms pulmonary function and sputum production <sep> daily sputum production <sep> morning peak expiratory flow rate <sep>', 'sputum leukocyte density and il-1beta il-8 and ltb4 <sep> spirometry 24-h sputum volume sputum leukocyte density bacterial densities and concentrations of interleukin il)-1beta il-8 tumor necrosis factor-alpha tnf-alpha and leukotriene b4 ltb4 <sep> adverse reactions <sep> episodes of exacerbation <sep>', 'eno levels <sep> fev1 fvc 24 h sputum volume or number of bronchiectatic segments <sep> eno <sep> exhaled nitric oxide eno levels <sep>', 'sputum purulence score <sep> sputum volume <sep> 24 hour sputum volume <sep> exacerbation frequency forced expiratory volume in 1 second forced vital capacity or sputum purulence score <sep> exacerbation frequency <sep>', 'sputum production <sep> hrqol <sep> pulmonary function number or severity of exacerbations or microbiological profile of the sputum <sep> quality of life <sep> dyspnea <sep>'], 'punchline_text': ['a small significant improvement in morning peak expiratory flow rate p less than 0.03 and forced expiratory volume in 1 s p less than 0.03 was seen but the absolute changes are unlikely to be of clinical importance. <sep>', 'there were no significant changes in spirometry p  0.05 or any reported adverse reactions in either group. <sep>', 'inhaled fluticasone therapy despite being an effective anti-inflammatory agent has no significant effect on eno production either at individual time points or over the entire 52-week profile in bronchiectasis. <sep>', 'logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume 30 ml p  0.04 exacerbation frequency 2/year p  0.04 and sputum purulence score 5 p  0.03). <sep>', 'the group administered fp 1000 microg daily showed significant improvement in dyspnea 1.03 2.1]-1.24 2.2 points p  0.01-0.04 sputum production p  0.001 <sep>'], 'population': ['20 patients with bronchiectasis <sep> patients with bronchiectasis <sep>', 'bronchiectasis <sep> twenty-four patients 12 female mean age 51 yr <sep> severe bronchiectasis <sep>', 'bronchiectasis <sep> patients with pseudomonas aeruginosa pa infection <sep> 12.7 years were recruited <sep> stable non-smoking bronchiectasis patients <sep> sixty non-smoking patients 38 women mean age 56.4 <sep>', 'bronchiectasis <sep> 35 and 38 patients in the <sep>', 'patients with steady-state bronchiectasis <sep> patients with bronchiectasis remain unknown <sep> patients with steady-state bronchiectasis not due to cystic fibrosis and its repercussions for patient health-related quality of life hrqol <sep> ninety-three patients mean age 68.5 8.4 <sep>'], 'interventions': ['inhaled steroids <sep> placebo <sep> inhaled beclomethasone diproprionate <sep>', 'placebo <sep> fluticasone <sep> inhaled fluticasone <sep> inhaled steroid therapy <sep> inhaled fluticasone <sep>', 'placebo via the accuhaler device <sep> placebo <sep> fluticasone <sep> inhaled fluticasone <sep> placebo therapy <sep> inhaled fluticasone <sep> corticosteroid therapy <sep>', 'placebo <sep> fluticasone <sep> inhaled fluticasone <sep> ics <sep> inhaled corticosteroid ics <sep> fluticasone and placebo <sep>', 'fp <sep> 250 microg bid 500 microg bid or no treatment with inhaled fp <sep> inhalatory fp <sep> inhaled fluticasone propionate fp <sep> inhaled steroids <sep> inhaled steroids <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",the present review indicates that there is insufficient evidence to recommend the routine use of inhaled steroids in adults with stable state bronchiectasis. while a therapeutic trial may be justified in adults with difficult to control symptoms and in certain subgroups this has to be balanced with adverse events especially if high doses are used. no recommendation can be made for the use of ics in adults during an acute exacerbation or in children for any state as there were no studies.
120,"{'outcomes': ['perceived limitations and risks of brca1 testing <sep>', 'realistic personal expectations of the benefits and risks decisional conflict and perceived acceptability of the intervention <sep>', 'prostate cancer <sep>', 'screening interest <sep> crc mortality risk reduction <sep> intent to begin or continue fecal occult blood testing fobt flexible sigmoidoscopy or both <sep>', 'knowledge kn scores <sep> realistic expectations <sep>', 'fecal occult blood testing or flexible sigmoidoscopy <sep>', 'active decision-making role <sep> patient-reported level of control over the decision to be screened <sep> equally sharing decision responsibility <sep> frequency of screening patient knowledge decisional conflict and time spent discussing screening <sep> knowledge questions correctly <sep>', 'initial decision for and the final uptake of the prenatal screening test <sep> imda <sep>', 'number of surgical procedures used improve knowledge or influence satisfaction or anxiety <sep>', 'participants ratings of convenience effort or satisfaction <sep> psa knowledge <sep>', 'decisional conflict <sep> uptake rates of treatment options length of consultation with the surgeon time point of treatment decision making perceived involvement in decision making neither decision related nor general patient satisfaction <sep>', 'decision quality <sep> preferences for watchful waiting <sep> psa screening <sep> knowledge scores <sep> psa test choice prostate cancer treatment preferences knowledge and concern about prostate cancer and decisional conflict <sep>', 'postdecisional regret or actual genetic testing decision <sep> decisional conflict <sep>', 'total decisional conflict score <sep> realistic expectations about the benefits and risks of lung transplantation <sep> decisional conflict <sep> participants knowledge realistic expectations and decisional conflict <sep>', 'questionnaire assessed knowledge attitudes perceived risk and intention to have a psa test <sep> knowledge scores <sep> positive attitudes <sep>', 'decisional self-efficacy preparedness to participate in decision-making and arthritis self-efficacy <sep>', 'decisional conflict <sep> acceptability of information delivery 1-7 knowledge about statins and coronary risk 0-9 and decisional conflict about statin use <sep> knowledge <sep>', 'hysterectomy rates <sep> health status <sep> mean costs <sep>', 'back surgery rates <sep> surgery rate <sep> outcomes and satisfaction surgery rates <sep> surgery rates <sep> symptom and functional outcomes <sep> overall surgery rate <sep> patient satisfaction <sep>', 'knowledge scores relative <sep>', 'number of patients receiving therapy appropriate to their stroke risk <sep> number of patients receiving appropriate care <sep> median duration of nvaf <sep> change in antithrombotic therapy <sep>', 'decisional conflict scale dcs <sep> knowledge of nhps <sep> dcs <sep>', 'unadjusted mean knowledge scores <sep>', 'chd risk <sep> 10-year chd risk <sep>', 'mortality due to early-stage prostate cancer psa screening performance treatment-related complications and disadvantages of screening <sep> number of knowledge questions <sep>', 'greater knowledge <sep> decisional conflict <sep> decisional conflict knowledge state anxiety intentions regarding starting treatment and actual treatment decision <sep> state anxiety <sep> knowledge about hypertension <sep>', 'total score on decisional conflict scale and mode of delivery <sep> national rates of caesarean section <sep> decisional conflict <sep> rate of vaginal birth <sep> decisional conflict and mode of delivery <sep>', 'knowledge about risk management options <sep> decisional conflict <sep> psychological distress <sep>', 'lower decisional conflict <sep> anxiety knowledge or decisional regret <sep>', 'knowledge and perceived risk <sep>', 'icc <sep> physicians decisional conflict scores <sep>', 'elevated self-image expectations <sep> facial appearance <sep>', 'higher knowledge and lower risk-perception scores <sep> anxiety <sep>', 'perceived clarity of values and overall congruence between values and choices <sep> perceived clarity of values a sub-scale of the decisional conflict scale congruence between personal values of benefits and risks measured on 0-10 importance rating scale and choices accept decline unsure regarding preventive hormone therapy hrt <sep>', 'comparable demographics prior computer experience medical literacy and baseline knowledge of breast cancer and genetic testing and both counseling and computer use <sep> perception of absolute risk of breast cancer <sep> decisional conflict scale <sep> mean state anxiety scores <sep> participants knowledge risk perception intention to undergo genetic testing decisional conflict satisfaction with decision anxiety and satisfaction <sep> change in knowledge <sep> knowledge scores <sep> satisfaction-with-decision scale <sep>', 'risk of procedure-related miscarriage <sep> amniocentesis or chorionic villus sampling <sep> diagnostic procedure <sep> knowledge scores <sep> knowledge risk awareness intervention satisfaction decisional conflict and among women aged at least 35 years use of invasive diagnostic testing <sep>', 'screening decisions overall <sep> values clarity <sep>', 'decisional conflict and greater self-advocacy <sep>', 'intrusive thoughts <sep> general health <sep> overall beneficial effect <sep> sdmi improved decision making <sep>', 'decisional conflict and knowledge about genetic testing <sep> knowledge levels <sep>', 'knowledge levels <sep>', 'satisfaction with decision making <sep> patient knowledge and satisfaction <sep>', 'anxiety use of health service resources general health status or utility <sep> mean scores for decisional conflict <sep>', 'decisional conflict <sep> survival rates <sep> knowledge scores <sep>', 'decisional conflict scores <sep> anxiety general health status prostatic symptoms utility or costs excluding costs associated with the video disc equipment <sep> decision decisional conflict scores treatment choice and prostatectomy rate american urological association symptom scale costs anxiety utility and general health status <sep>', ""congruence between personal values and decisions about hrt <sep> general knowledge increased and of women with realistic expectations <sep> anxiety levels <sep> general knowledge of the risks and benefits of hrt personal expectations and values concerning these risks and benefits and women's views on hrt <sep>"", 'test scores of knowledge <sep>', ""match between the patient's preferred and actual roles during consultation with the physician <sep> percentage of preference matches <sep>"", 'colorectal cancer <sep>', 'undergoing psa screening <sep> psa screening <sep> patient interest in undergoing psa screening measured on a 5-point likert scale <sep>', 'knowledge decisional conflict satisfaction with health care provider and self-efficacy <sep>', 'decision making and quality of life <sep> decisional conflict <sep> decisional conflict scale and state-trait anxiety inventory anxiety scale <sep> menorrhagia specific utility quality-of-life scale knowledge about menorrhagia and anxiety and process measures <sep> menorrhagia quality of life <sep> anxiety scores <sep> knowledge about menorrhagia <sep>', 'knowledge <sep> lower levels of decisional conflict <sep>', 'knowledge scores <sep> decisional conflict <sep>', 'decisional conflict scale <sep> patient decision process and the decision outcome <sep> planned screening tests <sep> proportion of colorectal cancer screening plans carried out <sep> decisional conflict regarding colorectal cancer screening decisions <sep>', 'decisional conflict <sep> percentage of women making an informed choice about whether to continue or stop screening and the percentage of women participating in the screening <sep> anxiety <sep> knowledge score <sep>', 'realistic expectations about the risk of stroke and hemorrhage <sep> decisional conflict and satisfaction <sep>', 'state anxiety levels <sep> levels of depression <sep>', 'prostate cancer screening <sep>', 'knowledge satisfaction with decision decisional conflict or ht use <sep> decisional conflict <sep>', 'factual knowledge reduced anxiety <sep> questionnaires assessing knowledge anxiety and satisfaction <sep> mean level of anxiety and increased satisfaction <sep> decreased anxiety increased knowledge and enhanced satisfaction <sep> postoperative satisfaction <sep>', 'likelihood of reaching a management decision <sep> satisfaction <sep> decisional conflict <sep> final management decision decisional conflict decisional satisfaction and receipt of risk reducing mastectomy <sep>', 'patient knowledge measured using 20 questions about knowledge deemed necessary for an informed treatment decision treatment decision patient-angiographer agreement on decision and general health scores <sep> patient satisfaction with the decision-making process <sep> satisfaction with decision-making process scores <sep> quality of life <sep> higher knowledge scores <sep> general health and angina scores <sep> shared decision-making program scores <sep> undergone revascularization <sep>', 'adherence or hba(1c levels <sep> hba(1c levels <sep> adherence and optimize glycemic control <sep> hemoglobin a(1c hba(1c levels <sep>', 'complete screening i.e. having a digital rectal exam dre and prostate specific antigen psa testing and 2 complete or partial screening i.e. having a psa test with or without dre <sep> complete or partial screening <sep> screening frequency <sep>', 'physical functioning <sep> referral for coronary revascularization <sep> mental health functioning <sep> knowledge of coronary artery disease satisfaction self-reported physical and mental health functioning and the proportion of patients who were referred for coronary revascularization <sep>', 'knowledge decisional conflict state anxiety satisfaction use of pnd and pregnancy outcomes <sep> decisional conflict post intervention <sep> knowledge <sep>', 'median consultation times <sep> risk of stroke <sep>'], 'punchline_text': ['the counseling approach but not the educational approach was superior to the control condition in producing significant increases in perceived limitations and risks of brca1 testing p  .01 and decreases in perceived benefits p  .05). <sep>', 'compared with the pamphlet group the decision-aid group had statistically significant p  0.05 improvements in terms of realistic personal expectations of the benefits and risks decisional conflict and perceived acceptability of the intervention. <sep>', 'in the enhanced participation arm patients not eligible for radical prostatectomy chose orchidectomy less frequently and favoured nonsurgical endocrine treatment than in the treatment protocol arm. <sep>', 'there was no difference in screening interest between the control group and the two information groups p .8). <sep>', 'the computerized da improved realistic expectations by 52.7 over baseline versus 27.6 with the audio-booklet p=0.015). <sep>', 'fecal occult blood testing or flexible sigmoidoscopy was ordered for 47.2 of intervention participants and 26.4 of controls difference 20.8 percentage points 95 ci 8.6 to 32.9 percentage points]). <sep>', 'patients exposed to a decision aid answered a greater percentage of knowledge questions correctly 54 control vs 69 web site p .001 and vs 69 brochure p .001 and were less likely to be screened 94 control vs 86 web site p  .06 and vs 85 brochure p  .04). <sep>', ""the use of imda did not affect the women's overall uptake rate of the prenatal screening test for down syndrome. <sep>"", 'treatment decision within 3 months was made more often in the intervention group than in the control group 96 and 89 respectively p  0.02). <sep>', 'there were no between-groups differences in participants ratings of convenience effort or satisfaction following exposure to the decision aid. <sep>', 'the intervention had no effect on uptake rates of treatment options length of consultation with the surgeon time point of treatment decision making perceived involvement in decision making neither decision related nor general patient satisfaction. <sep>', 'participants assigned to view public web sites were less likely to review information 116 participants 76.8 reviewed than those assigned to experimental groups 399 86.7 reviewed p  .004). <sep>', 'a decision aid for individuals considering genetic testing for hnpcc is an effective intervention to reduce uncertainty and assist individuals to make an informed choice regarding genetic testing for hnpcc after genetic counseling. <sep>', 'the total decisional conflict score was significantly lower in the decision aid group 3 weeks postrandomization compared with the usual care group 11.6 vs. 20.4 p  0.0007). <sep>', 'men who received the brief pda had significantly higher knowledge scores p<0.0001 and less positive attitudes p<0.0001 regarding psa testing than men in the control group. <sep>', 'decisional self-efficacy preparedness to participate in decision-making and arthritis self-efficacy were greater in participants randomized to the intervention arm compared to those receiving the information pamphlet  <sep>', 'compared with the pamphlet patients whose clinicians delivered the decision aid during the office visit showed significant improvements in knowledge difference of 1.6 of 9 questions ci 0.3 2.8 and nonsignificant trends toward finding the decision aid more acceptable odds ratio 3.1 ci 0.9 11.2 and having less decisional conflict difference of 7 of 100 points ci 4 18 than when a researcher delivered the decision aid just before the office visit. <sep>', 'hysterectomy rates were lower for women in the interview group 38 adjusted odds ratio or 0.60 95 confidence interval ci 0.38-0.96 than in the control group 48 and women who received the information alone 48 adjusted or 0.52 95 ci 0.33-0.82). <sep>', 'the overall surgery rate was 22 lower in the videodisk group 26 versus 33 p  0.08). <sep>', 'reported use of the video was higher for patients who had greater than a high school education or 1.73 were married or 2.20 and reported no prior abnormal prostate cancer screening test results or 3.39). <sep>', 'the beneficial effect of the decision aid did not persist p  0.44 for differences between study arms after 12 months). <sep>', 'both groups experienced a statistically significant reduction on the dcs 0.55  0.59 p  0.0001 versus 0.52  <sep>', 'unadjusted mean knowledge scores were significantly higher in the computer group than the counselor group p .048 but they were equivalent when adjusted for demographic differences p  0.34). <sep>', 'in pre-post testing the decision aid also appeared to increase the proportion of patients with plans to intervene on their chd risk absolute increase ranging from 21 to 47 for planned medication use and 5 to 16 for planned behavioral interventions). <sep>', 'at 2-week follow-up subjects undergoing videotape intervention showed a 78 improvement in the number of knowledge questions answered correctly p  .001 and knowledge increased about mortality due to early-stage prostate cancer psa screening performance treatment-related complications and disadvantages of screening. <sep>', 'video/leaflet patients had lower decisional conflict than corresponding controls 30.3 versus 36.8 adjusted 95 ci  7.4 to 0.6 p  0.021 greater knowledge 75 versus 65 adjusted 95 ci  6 to 13 p  0.001 and no evidence of increased state anxiety 35.7 versus 36.1 adjusted 95 ci  3.9 to 1.7 p  0.46). <sep>', 'the rate of vaginal birth was higher for women in the decision analysis group compared with the usual care group 37 v 30 adjusted odds ratio 1.42 0.94 to 2.14 but the rates were similar in the information programme and usual care groups. <sep>', 'this form of educational material is successful in increasing knowledge about risk management options and in reducing decisional conflict in the shorter term. <sep>', 'there was no difference in anxiety knowledge or decisional regret across the 2 groups. <sep>', 'results show that the educational intervention reduced intention to obtain genetic testing among women at average risk and increased intention among high-risk women at 6 months. <sep>', ""compared to pamphlets das appear to improve the agreement between women's and physicians decisional conflict about hrt. <sep>"", 'motives for treatment did not differ significantly between the video image and standard cp groups. <sep>', 'women in the decision-aided group had higher knowledge and lower risk-perception scores about both methods more positive attitudes about the medical method lower decisional conflict more stable evaluations of the decision information over time and higher perceived usefulness of information ratings. <sep>', 'there were no statistically significant differences between interventions in perceived clarity of values and overall congruence between values and choices. <sep>', 'mean state anxiety scores were reduced by counseling but were within normal ranges for both groups at baseline and after either intervention regardless of risk status. <sep>', 'women assigned to the interactive prenatal testing decision tool had higher knowledge scores 79.5 compared with 64.9 p<.001 were more likely to correctly estimate their risk of procedure-related miscarriage 64.9 compared with 48.1 p=.002 and carrying a down syndrome-affected fetus 63.5 compared with 15.1 p<.001 were more satisfied with the intervention p<.001 and had less decision uncertainty p<.001 than controls after viewing the intervention. <sep>', 'more da recipients from all education levels were informed p  0.02 particularly in lower education 50.0 da versus 17.8 g and university-educated groups 79.4 da versus 32.1 g). <sep>', 'patients at the low-literacy site were more engaged with the entertainment-based aid than patients at the high-literacy site. <sep>', 'in the long term with respect to well-being patients in the sdmi group had less intrusive thoughts p .05 and better general health p .01 and tended to be less depressed p .07). <sep>', 'the developed decision aid improved patient outcomes better than a control pamphlet when implemented during genetic counseling and given to the patient to take home. <sep>', 'decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk and are most effective before the patient has made a decision which is generally at the point of having blood drawn. <sep>', 'over the entire study period satisfaction with decision making was higher for patients in the decision board arm than for patients in the control arm p .032). <sep>', 'at three months a lower proportion of women in the intervention group than in the control group were undecided about treatment 14 v 26 12 23 to 0.4 and a higher proportion had decided against hormone replacement therapy 46 v 32 14 1 to 28 these differences were no longer apparent by nine months. <sep>', 'patients who used the decision board were more likely to choose bct 94 vs 76 p .03). <sep>', 'no differences were found between the groups for anxiety general health status prostatic symptoms utility or costs excluding costs associated with the video disc equipment). <sep>', 'congruence between personal values and decisions about hrt increased significantly more in the experimental group p  or  .003). <sep>', 'in addition the videotape was more effective than vis alone in increasing short-term knowledge regardless of practice type race/ethnicity or educational level. <sep>', 'the percentage of preference matches did not differ between groups ig 49 cg 51 p  0.71). <sep>', 'colorectal web is more effective than a standard colorectal cancer web site at prompting previously unscreened individuals to choose a preferred colorectal cancer screening test and to be screened for colorectal cancer. <sep>', 'patients who received the informational intervention were significantly less interested in undergoing psa screening than controls mean difference in interest 0.8 on 5-point scale p  .001). <sep>', 'knowledge decisional conflict satisfaction with health care provider and self-efficacy improved following intervention and were maintained for 12 months for all groups. <sep>', 'two weeks after the intervention there was significantly less decisional conflict in the intervention group adjusted difference  16.6 <sep>', 'had significantly improved knowledge 50 of items correct 95 ci 46-53 vs 45 correct 95 ci 42-48 p  0.048 and lower levels of decisional conflict mean 21.6 95 ci 20.7-22.5 vs mean 24.3 95 ci 23.4-25.2 p  0.001). <sep>', 'decisional conflict was significantly lower amongst men receiving the evidence-based booklet p  0.038). <sep>', 'there was no difference between the groups in decision outcomes 52 of patients in the control group and 49 in the experimental group completed planned screening tests p  1.0). <sep>', 'women who received the da the intervention group were better informed than the control group mean increase in knowledge score out of 10 2.62 for the intervention group vs 0.68 for the control group p  .001 and a significantly greater percentage made an informed choice 73.5 vs 48.8 p  .001). <sep>', 'patients in the ab group were more knowledgeable and had more realistic expectations about the risk of stroke and hemorrhage in the ab group 53%-80 correctly estimated different risks in the control group 16%-28 gave correct estimates). <sep>', 'sixty newly diagnosed men were randomly assigned to receive either a self-efficacy information intervention that consisted of a written information package with discussion a list of questions they could ask their physician and an audiotape of the medical consultation n  30 or a written information package alone n  30). <sep>', 'the illustrated pamphlet decision-aid was effective in improving knowledge of prostate cancer screening tests 95 of the experimental group were aware of the possibility of false-negative test results compared with 85 of the comparison group p .01). <sep>', 'there was no difference between groups with respect to the primary outcomes of knowledge satisfaction with decision decisional conflict or ht use. <sep>', 'they also tended to have a reduced mean level of anxiety and increased satisfaction with the treatment choice compared with the control group. <sep>', 'longitudinal analyses revealed that the da was effective among carriers who were initially undecided about how to manage their breast cancer risk. <sep>', 'there was no significant difference in satisfaction with decision-making process scores between the ihd sdp and usual practice groups. <sep>', 'an innovative decision aid effectively involved patients with type 2 diabetes mellitus in decisions about their medications but did not improve adherence or hba(1c levels. <sep>', 'ei group men had a screening frequency two times greater than that of si group men but the difference was not statistically significant 8 vs. 4  or  1.94 fo rcomplete screening and 19 vs. 10 or  2.08 for complete or partial screening. <sep>', 'there were no significant differences between the videotape and usual care groups with respect to satisfaction with the decision making process mean score 73 vs. 77 p  0.37 satisfaction with the decision made mean score 73 vs. 78 p  0.28 physical functioning 38 vs. 38 p  0.76 mental health functioning 49 vs. 49 p  0.94 or in referral for coronary revascularization or 0.60 95 ci 0.22-1.65 p  0.33). <sep>', 'those in the group intervention showed a significantly greater increase in knowledge than those in the individual counseling intervention. <sep>', 'information-giving was the most frequent activity for both gps and patients although gps did this at twice the rate compared to patients and at higher rates in consultations involving computerised decision aids. <sep>'], 'population': ['women at low to moderate risk who have a family history of breast and/or ovarian cancer <sep>', 'postmenopausal women considering long-term preventive hormone therapy <sep>', '210 men who had a histologically confirmed diagnosis of prostate cancer in 1993-94 at four major hospitals in finland <sep> patients with prostate cancer <sep> patients with prostate cancer <sep> men with operable cancer <sep> prostate cancer <sep>', 'elderly patients colorectal cancer crc screening preferences <sep> 399 elderly patients visiting their primary care provider for routine office visits <sep> elderly patients <sep>', 'women considering post-menopausal hormone replacement therapy <sep> fifty-one peri-menopausal women <sep>', '1657 consecutive adult patients 50 to 75 years of age were contacted <sep> for colon cancer screening <sep> 651 39 agreed to participate 249 of the 651 participants 38 were eligible <sep> three community primary care practices in central north carolina <sep> 249 participants <sep> eligible patients had no personal or family history of colon cancer and had not had fecal occult blood testing in the past year or flexible sigmoidoscopy colonoscopy or barium enema in the past 5 years <sep>', '497 men participated 75 control 196 brochure 226 web site <sep> men aged 50 to 70 years undergoing a health maintenance examination at a large family practice were enrolled <sep>', 'two hundred and one women were recruited from the prenatal clinic of a university teaching hospital and randomised into the <sep>', 'a total of 363 randomized trial plus 206 cohort study patients with menorrhagia <sep> gynaecology outpatient clinics in 14 finnish hospitals <sep> women with heavy menstruation <sep>', 'men considering the prostate specific antigen test <sep> men considering the prostate specific antigen psa test <sep> two hundred and twenty-six men aged 50 years or older and scheduled to complete a physical examination at an hmo health appraisal clinic <sep>', 'north american breast cancer outpatients <sep> patients n=111 with a strong suspicion of breast cancer <sep> newly diagnosed breast cancer inpatients <sep> women with a strong suspicion of breast cancer <sep>', 'men older than 50 years n  611 <sep> men considering prostate cancer screening <sep>', '153 individuals <sep> hereditary nonpolyposis colorectal cancer hnpcc <sep> c 2008 american cancer society <sep> individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk <sep>', 'adult patients <sep> patients with advanced cystic fibrosis considering referral for lung transplantation <sep> patients with cystic fibrosis considering lung transplantation <sep> patients with cystic fibrosis considering referral for lung transplantation <sep> 149 adult patients with cystic fibrosis with an fev(1 <sep>', 'nine hundred and ninety of the men who were eligible for the study returned completed questionnaires response rate=54 <sep> men aged 40-75 years selected from 11 general practices in england and wales <sep> men who received the brief pda <sep> prostate cancer <sep>', 'knee pain <sep> patients with knee pain <sep> 87 patients were randomized <sep> patients with knee pain <sep> patients with knee pain in an outpatient primary care clinic setting <sep>', '98 diabetes patients and randomizing them to 1 receive either the <sep>', 'between october 1996 and february 1998 894 women with uncomplicated menorrhagia were recruited from 6 hospitals in southwest england <sep>', 'patients with various diagnoses and on local surgery rates <sep> elective surgery candidates n  393 included 171 patients with herniated disks 110 with spinal stenosis and 112 with other diagnoses <sep>', '1,152 men aged 50 and older from four medical facilities in the united states <sep>', 'patients with nonvalvular atrial fibrillation <sep> patients with nonvalvular atrial fibrillation nvaf <sep> 434 nvaf patients from 102 community-based primary care practices <sep> patients with nvaf <sep> american college of chest physicians accp recommendations <sep>', '90 women aged 45-64 years facing a decision about using nhps for menopausal symptoms received a <sep>', 'seventy-two self-referred women with a first-degree relative with breast cancer received outpatient education and counseling at the clinical center of the national institutes of health nih <sep>', 'patients discussions with their doctor and their plans for chd prevention <sep> 59 were female 73 white and 23 african-american <sep> 41 patients received the decision aid 34 received usual care <sep> convenience sample of adults with no previous history of cardiovascular disease <sep> we enrolled 75 adults <sep> patients discussions with their doctor and their plans for prevention <sep>', 'prostate cancer screening <sep> university-based family practice center <sep> asymptomatic men aged 50 years and older <sep> men aged 45 through 70 years with no history of prostate cancer or treatment for prostate disease n  160 <sep>', 'twenty-one general practices in south-west england uk <sep> 217 patients randomised 212 98 were analysed at the primary follow-up mean age  59 years 49 female <sep> adults aged 32 to 80 years with newly diagnosed hypertension <sep> newly diagnosed hypertensive patients <sep> patients with newly diagnosed hypertension <sep>', 'english speakers were excluded <sep> conducted from may 2004 to august 2006 <sep> mother and baby associated with planned vaginal birth elective caesarean section and emergency caesarean section <sep> women with previous caesarean section <sep> pregnant women with a previous caesarean section <sep> 742 pregnant women with one previous lower segment caesarean section and delivery expected at or=37 weeks <sep> four maternity units in south west england and scotland <sep>', 'women at increased risk of ovarian cancer <sep> 131 women with a family history of breast and/or ovarian cancer or of hereditary nonpolyposis colorectal cancer <sep> 6 familial cancer centers <sep>', 'community surgeons <sep> a subgroup of women who were initially leaning toward mastectomy or were unsure had lower decisional conflict <sep> breast cancer <sep> early breast cancer <sep>', ""female callers n  279 to the national cancer institute's nci's atlantic region cancer information service cis developed and evaluated a theory-based educational intervention designed to increase callers understanding of the following a the kinds of information required to determine inherited risk <sep> women calling the nci's cancer information service <sep>"", ""a total of 40 physicians and 184 women provided data <sep> women's and physicians decisional conflict about hormone replacement therapy <sep> women's and physicians decisional conflict about hormone replacement therapy hrt <sep>"", 'seventy-four patients ranging in age from 15 to 50 and presenting with a moderate to severe dentofacial deformity requiring orthognathic surgery <sep>', 'three hundred and twenty-eight women participated <sep>', ""a woman's decision aid regarding postmenopausal hormone therapy <sep> two-hundred and one women aged 50-69 years from ottawa canada who had never used hormone therapy <sep>"", 'low-risk women <sep> outpatient clinics offering cancer genetic counseling at 6 us medical centers enrolled 211 women with personal or family histories of breast cancer <sep> breast cancer susceptibility <sep> may 2000 to september 2002 <sep>', 'four hundred ninety-six english or spanish-speaking women at 20 or fewer weeks of gestation <sep>', 'colorectal cancer screening <sep> three hundred and fourteen people aged 50-74 years received a <sep>', 'prostate cancer screening <sep> male primary care patients from two clinical sites one characterized as serving patients with low health literacy n=149 and the second as serving patients with high health literacy n=301 <sep> primary care patients with low health literacy <sep> patients with low or high health literacy <sep> patients with lower health literacy <sep>', 'brca1/2 mutation carriers <sep>', 'women considering genetic testing for breast/ovarian cancer risk given during genetic counseling <sep> one hundred and ten 74.3 <sep> one hundred and forty-eight women <sep>', 'women considering genetic testing for breast and ovarian cancer risk <sep> a total of 145 women <sep>', 'lymph node-negative breast cancer <sep> patients with early breast cancer <sep> patients with lymph node-negative breast cancer <sep> between october 1995 and march 2000 176 women with lymph node-negative breast cancer who were candidates for adjuvant chemotherapy <sep>', 'patients and general practitioners perceptions of who made the decision decisional conflict treatment choice menopausal symptoms costs anxiety and general health status <sep> 205 women considering hormone replacement therapy <sep> primary care <sep> 26 general practices in the united kingdom <sep>', 'early stage breast cancer <sep> women with breast cancer <sep> 208 eligible women with newly diagnosed clinical stage i or ii breast cancer seen by study surgeons 201 agreed to be evaluated 94 were assigned to the decision board and 107 to usual practice <sep> general surgeons in the communities of central-west and eastern ontario canada <sep> patients were recruited from november 1999 to april 2002 <sep> breast cancer surgery <sep> twenty surgeons participated in the study <sep>', 'men with benign prostatic hypertrophy <sep> 33 general practices in the united kingdom <sep> 112 men with benign prostatic hypertrophy <sep> on benign prostatic hypertrophy in primary care <sep>', 'menopausal francophone women 45 to 69 years old <sep> quebec city region <sep>', 'parents/guardians of children starting the polio vaccination series <sep> five pediatric offices two university-based two health maintenance organization staff models and one private practice and a local health department immunization clinic in the greater lansing mi area <sep> 287 parents/guardians of 2 to 3-month-olds presenting for well-child care and due for the first set of immunizations including poliovirus vaccine <sep>', 'patients with multiple sclerosis isdims <sep> two hundred and ninety-seven ms patients who were considering or reconsidering immunotherapy participated in a randomized community-based controlled trial in germany <sep>', 'colorectal cancer screening <sep> colorectal cancer screening in urban suburban and rural communities in michigan with high colorectal cancer burden <sep> eighty-nine participants had been screened for colorectal cancer by 24 weeks post-intervention <sep> study participants were age 50 years and older with no previous colorectal cancer screening <sep> 174 eligible adults <sep>', 'men 50 years or older with no prior psa testing and no history of prostate cancer presenting to 1 of 4 university-affiliated primary care practices were eligible for enrollment <sep>', 'midlife women n  248 <sep> menopausal women <sep>', 'one hundred forty-nine women presenting with menorrhagia <sep> menorrhagia <sep> nineteen general practices in the north of england <sep> women consulting their general practitioner with menorrhagia compared with written information alone. of study <sep>', 'men aged 40-70 years were recruited from the practices of 13 local general practitioners gps in sydney australia <sep> 248 eligible men recruited 214 86 response rate returned post-test questionnaires <sep>', '421 men recruited from the community <sep> men about prostate cancer screening <sep>', 'patient decision aid for colorectal cancer screening <sep> 96 patients at average risk for colorectal cancer seen in an internal medicine practice in rochester new york <sep>', 'many women who have participated in mammography screening are now approaching 70 years of age <sep> 70-year-old women <sep> women aged 70 years who had regularly participated in mammography screening were eligible to participate in the trial <sep> women aged 70 years a population-based randomized controlled trial was conducted in new south wales australia <sep>', 'patients with atrial fibrillation who had participated in a major clinical trial <sep> may 1997 to april 1998 <sep> 287 patients from the spaf iii aspirin cohort study in which patients with atrial fibrillation and a relatively low risk of stroke received 325 mg/d of <sep> atrial fibrillation <sep> fourteen centers that participated in the stroke prevention in atrial fibrillation spaf <sep>', 'sixty newly diagnosed men <sep> men with prostate cancer <sep> older men <sep> men newly diagnosed with prostate cancer <sep> respondents were recruited from one community urology clinic in winnipeg manitoba <sep>', '257 men aged 50 to 80 years who were receiving primary care at a department of veterans affairs hospital in milwaukee wisconsin <sep>', '177 post-menopausal women receiving care in a veterans affairs medical center <sep> women and their health care providers <sep>', 'patients contemplating breast reconstruction <sep> breast cancer patients who were candidates for breast reconstruction <sep> breast reconstruction patients <sep> 133 women participated 66 in the control group and 67 in the study group <sep>', '214 female aged 21-75 brca1/brca2 mutation carriers <sep> brca1/brca2 mutation carriers <sep> women with a family history of breast cancer <sep>', 'two hundred forty ambulatory patients with <sep> patients with ischemic heart disease <sep>', 'patients with type 2 diabetes mellitus <sep>', '242 african-american men from three primary care practices who were 40-69 years of age and had no history of prostate cancer <sep> participants completed a baseline survey questionnaire <sep>', 'ischaemic heart disease <sep> 217 patients referred for coronary angiography <sep> university hospital and veterans affairs hospital <sep> patients referred for coronary angiography compared with standard patient-physician decision making usual care <sep>', 'advanced maternal age patients <sep> women of advanced maternal age 35 years and their partners <sep> three hundred and fifty-two women and 225 partners completed <sep>', 'primary care consultations <sep> older patients with atrial fibrillation <sep>'], 'interventions': ['education only educational approach and education plus counseling counseling approach <sep>', 'general educational pamphlet <sep>', 'radical prostatectomy <sep>', 'scripted control message briefly describing crc screening methods or one of two informational interventions simulating an informed consent presentation about crc screening <sep>', 'decision aids das <sep> computerized versus an audio-booklet decision <sep> interactive computerized da <sep> standard audio-booklet version of the da <sep>', 'generic brochure <sep> decision aid consisting of an educational video targeted brochure and chart marker increased performance of colon cancer screening <sep> color-coded educational brochure <sep> videotape-based decision aid <sep> 11-minute video about colon cancer screening intervention group or a video about automobile safety control group <sep>', 'web-based and a paper-based decision aid with no previsit education <sep>', 'interactive multimedia decision aid imda with a leaflet and a video to give information about prenatal screening <sep> intervention group imda video and information leaflet or the control group video and information leaflet <sep> imda <sep> interactive multimedia decision aid with a leaflet and a video to give information about prenatal screening <sep>', 'patient information booklet <sep>', 'internet and video to facilitate patient education <sep> internet and video patient education modalities <sep>', 'decision aid intervention <sep>', '4 internet conditions traditional didactic decision aid providing information about prostate-specific antigen psa screening options and outcomes chronic disease trajectory model for prostate cancer followed by a time-trade-off exercise both the didactic decision aid and the chronic disease trajectory model or links to public prostate cancer-specific web sites from credible sources control condition <sep> patient decision support web sites <sep>', 'decision aid or a control pamphlet at the end of their first genetic counseling consultation <sep> hnpcc <sep>', 'decision aid or usual care <sep> education and counseling session <sep>', 'brief pda and a questionnaire intervention group or a questionnaire alone control group <sep> patient decision aid pda <sep> pda <sep>', 'information pamphlet or to perform a computer task <sep> information pamphlet <sep>', 'decision aid or pamphlet about cholesterol and 2 <sep>', 'decision aids <sep> control group information alone group information or information plus interview group interview <sep>', 'interactive diagnosis-specific videodisk program <sep> interactive video plus a booklet with the booklet alone <sep> interactive video program <sep>', 'prostate cancer screening decision support interventions <sep> pamphlet video or usual care control <sep>', 'patient decision aid on care <sep> usual care <sep> self-administered booklet and audiotape decision aid tailored to their personal stroke risk profile <sep>', 'patient decision aid pda <sep> natural health products nhps <sep> pda experimental group or a general information brochure about menopause control group <sep>', 'individualized counseling from a genetic counselor counseling group 29 received education from an interactive computer program followed by individualized counseling <sep> interactive computer program <sep> computer program <sep>', 'individually-tailored computerized decision aid about chd <sep> decision aid about heart disease prevention <sep>', 'prostate-specific antigen psa screening <sep> psa videotape <sep> videotape intervention <sep>', 'individualized risk assessment and decision analysis or b information video and leaflet about high blood pressure or c both interventions or d neither intervention <sep> information video plus leaflet <sep>', 'two computer based decision aids <sep>', 'general educational pamphlet <sep>', 'decision aid or a control pamphlet <sep>', 'standard care or 2 an educational intervention <sep> educational intervention <sep>', 'tailored decision aid da <sep> decision aids <sep>', 'video imaging <sep> video imaging or a standard case presentation cp <sep>', 'decision-aid leaflet <sep> decision-aid leaflet about termination methods with a control leaflet about contraception <sep>', 'explicit values clarification exercise <sep> graphic weigh-scale values clarification exercise <sep> graphic weigh-scale exercise <sep>', 'standard genetic counseling <sep> computer-based decision aid <sep> standard one-on-one genetic counseling n  105 or education by a computer program followed by genetic counseling <sep> computer-based decision aid with standard genetic counseling <sep>', 'interactive prenatal testing decision tool or the california department of health services educational booklet <sep> computerized prenatal genetic testing decision-assisting tool <sep>', 'self-administered decision aid da booklet about outcomes of biennial faecal occult blood testing fobt screening or government consumer guidelines g <sep> self-administered decision aid <sep>', 'entertainment-based patient decision aid for prostate cancer screening <sep> entertainment education <sep> entertainment-based decision aid for prostate cancer screening or an audiobooklet-control aid with the same learner content but without the entertainment features <sep>', 'shared decision-making intervention sdmi <sep> sdmi <sep>', 'decision aid or a control pamphlet <sep>', 'da or a control pamphlet at the end of their first genetic counseling consultation <sep> tailored decision aid da <sep>', 'decision board plus the medical consultation 83 patients or the medical consultation alone <sep> decision aid for adjuvant chemotherapy <sep> questionnaire assessing their knowledge about breast cancer and chemotherapy <sep>', 'interactive multimedia decision aid on hormone replacement therapy <sep> interactive multimedia programme with booklet and printed summary <sep> intervention <sep>', 'decision aid <sep> mastectomy and breast-conserving therapy <sep>', 'intervention <sep> interactive multimedia programme with booklet and printed summary <sep> interactive multimedia decision aid <sep>', 'hormone replacement therapy hrt <sep>', 'vaccine information statement vis alone or to read the vis and view a 15-minute videotape about polio vaccination and choices of schedules produced by michigan state university <sep> videotape <sep> educational videotape about poliovirus vaccines <sep>', 'evidence-based patient decision aid da <sep> da and a control group cg received standard information <sep>', 'preference-based electronic decision <sep> standard web site <sep>', 'scripted informational intervention simulating an informed consent presentation intervention group n  103 or a single sentence about the psa control <sep>', 'decision support intervention dsi <sep> written information only guided discussion or personalized decision exercise <sep> educational intervention <sep>', 'written information and access to a computerized decision aid or written information alone <sep> computerized decision aid to written information <sep> computerized decision aid in primary care <sep>', 'evidence-based eb booklet <sep> eb booklet or conventional information <sep> eb booklet <sep>', 'two resources meeting criteria for a decision-aid a video n  141 or an evidence-based booklet <sep>', 'multicriteria-based patient decision aid for colorectal cancer screening <sep> patient decision aid based on multicriteria decision-making theory with a simple educational intervention <sep>', 'decision aid da <sep> da providing balanced quantitative information or standard information available from the screening program <sep>', 'audiobooklet ab decision <sep> antithrombotic therapy <sep> ab ab group vs usual care alone control group <sep> aspirin <sep>', 'self-efficacy information intervention that consisted of a written information package with discussion a list of questions they could ask their physician and an audiotape of the medical consultation n  30 or a written information package alone <sep>', 'illustrated pamphlet decision-aid <sep> prostate cancer screening decision-aid consisting of an illustrated pamphlet <sep> prostate cancer screening with serum prostate-specific antigen psa and digital rectal examination dre <sep>', 'computer-based hormone therapy decision-aid <sep> computer-based hormone therapy ht decision-aid versus a control intervention <sep>', 'routine assessment and education <sep> interactive digital education <sep>', 'usual care uc n  114 or usual care plus decision aid <sep>', 'ischemic heart disease shared decision-making program ihd sdp <sep> interactive videodisc decision <sep>', 'decision aid during the clinical encounter and 19 to dispense usual care and an educational pamphlet <sep>', 'standard intervention si group n=121 or an enhanced intervention ei <sep> informed decision-making intervention <sep>', 'educational videotape <sep> coronary angiography <sep> usual care or to receive the videotape in addition to standard patient physician decision making videotape <sep>', 'pre and post-intervention questionnaires <sep> prenatal diagnosis counseling <sep>', 'warfarin anti-coagulation <sep> paper-based guidelines control with two forms of computer-based decision aids implicit and explicit versions of darts ii <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",new for this updated review is evidence that decision aids with explicit values clarification exercises improve informed values-based choices decision aids appear to have a positive effect on patient-practitioner communication and decision aids have a variable effect on length of consultation. consistent with findings from the previous review which had included studies up to 2006 decision aids increase people's involvement and improve knowledge and realistic perception of outcomes however the size of the effect varies across studies. decision aids have a variable effect on choices. they reduce the choice of discretionary surgery and have no apparent adverse effects on health outcomes or satisfaction. the effects on adherence with the chosen option patient-practitioner communication cost-effectiveness and use with developing and/or lower literacy populations need further evaluation. little is known about the degree of detail that decision aids need in order to have positive effects on attributes of the decision or decision-making process.
121,"{'outcomes': ['exercise performance step tests and 6 min walking distance 6mwd <sep> 6mwd or steps achieved while breathing supplemental oxygen <sep> 6mwd and steps <sep> degree of desaturation <sep> quality of life indices <sep> laboratory exercise performance <sep> quality of life <sep> 6mwd or steps <sep>'], 'punchline_text': ['supplemental oxygen increased 6mwd and steps by small statistically significant increments acutely at baseline and after 6 and 12 wk without corresponding falls in borg score. <sep>'], 'population': ['patients with chronic obstructive pulmonary disease and mild hypoxemia <sep> patients with severe copd <sep> 26 patients 24 males had a mean age of 73 <sep>'], 'interventions': ['supplemental air and oxygen <sep> oxygen supplementation <sep>'], 'punchline_effect': [' no diff <sep>']}",evidence available to date does not allow any firm conclusions to be drawn concerning the effectiveness of ambulatory domicilary oxygen therapy in patients with copd. further studies are required in order to understand the role of ambulatory oxygen in the management of patients with copd on long-term oxygen therapy. these studies should separate patients who desaturate from those who do not desaturate.
122,"{'outcomes': ['cumulative incidence of diabetes <sep> baseline bmi and fasting glucose the diet exercise and diet-plus-exercise interventions <sep> rate of development of diabetes <sep> incidence of diabetes <sep>', 'mean blood pressure mbp <sep> insulin resistance and changes in bmi <sep> baseline cross-sectional changes and 1-year changes in insulin resistance fasting serum levels of insulin c-peptide proinsulin glucose and lipids as well as weight mean blood pressure and plasminogen activator inhibitor 1 pai-1 values <sep> total cholesterol <sep> insulin resistance <sep> change insulin resistance <sep> pai-1 <sep> intake of fish and reduced total fat intake <sep> calculated insulin resistance <sep> calculated insulin resistance and bmi <sep>'], 'punchline_text': ['when analyzed by clinic each of the active intervention groups differed significantly from the control clinics p  0.05). <sep>', 'the 1-year diet intervention gave a significant decrease in the calculated insulin resistance from 4.6 to 4.2 and a positive correlation between the changes in insulin resistance and changes in bmi r  0.40). <sep>'], 'population': ['people with impaired glucose tolerance <sep> individuals with impaired glucose tolerance igt <sep> 110,660 men and women from 33 health care clinics in the city of da qing china were screened for igt and niddm <sep>', '219 men and women with diastolic blood pressure of 86-99 mmhg hdl cholesterol  1.20 mmol/l triglycerides <sep>'], 'interventions': ['diet and/or exercise interventions <sep> diet only exercise only or diet plus exercise <sep> diet and exercise interventions <sep> diet and exercise <sep>', 'exercise program entailed supervised endurance exercise <sep> exercise intervention <sep> diet and exercise intervention <sep> diet and exercise group <sep> exercise group <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>']}",there are no high quality data on the efficacy of dietary intervention for the prevention of type 2 diabetes. more well-designed long-term studies providing well-reported high-quality data are required before proper conclusions can be made into the best dietary advice for the prevention of diabetes mellitus in adults.
123,"{'outcomes': ['serum creatinine phosphokinase levels <sep> tardive dyskinesia <sep> extrapyramidal side effects <sep> brief psychiatric rating scale and clinical global impression scale <sep> sedation <sep>', 'efficacy and side effects <sep> minimal side effects <sep> brief psychiatric rating scale bprs clinical global impression cgi and uku side effects scale <sep> bprs and cgi scores <sep>', 'hypokinesia <sep> severity of illness scores <sep> rapid remission of symptoms on the brmas <sep> brief psychiatric rating scale bprs the bech-rafaelsen mania rating scale brmas only manic patients and globally on the clinical global impression cgi <sep>', 'brief psychiatric rating scale bprs and the clinical global impression scale cgi <sep> acute psychosis with aggression <sep> reduction of aggression based on bprs rating <sep> bprs or cgi scores <sep>'], 'punchline_text': ['the two treatments were found to be equally efficacious on the brief psychiatric rating scale and clinical global impression scale. <sep>', 'there was however no difference between the zuclopenthixol acetate and haloperidol group scores on all days p  0.05). <sep>', 'the assessments on the cgi showed that all 3 treatments caused a clear reduction of the severity of illness scores in all 3 diagnostic categories with no differences between treatments. <sep>', 'both zpta and hal were effective in the treatment of acute psychosis with aggression but frequency of administration was lower in the zpta group <sep>'], 'population': ['schizophrenic patients with acute exacerbation <sep> 40 newly admitted schizophrenic patients with acute exacerbation <sep>', '50 subjects entered the study of which 44 completed <sep> suitable subjects diagnosed as having schizophreniform disorder or acute exacerbation of schizophrenia admitted to the psychiatric wards hospital kuala lumpur <sep> acutely disturbed schizophrenic patient <sep> acutely disturbed schizophrenics <sep>', 'acute psychosis <sep> acutely disturbed psychotic patients <sep> patients were stratified into 3 diagnostic categories acute psychoses 48 patients mania 22 patients and exacerbation of chronic psychoses 73 patients <sep> acutely disturbed psychotic patients <sep>', 'psychotic patients with aggression admitted to songkla neuropsychiatric hospital <sep> 70 patients with diagnosis of schizophrenia mania and acute psychosis <sep> acutely disturbed psychotic patients <sep> thirty-eight patients <sep> acute psychotic disturbance with aggression <sep>'], 'interventions': ['haloperidol <sep> zuclopenthixol <sep> zuclopenthixol acetate with liquid oral haloperidol <sep> intramuscular zuclopenthixol acetate and liquid oral haloperidol <sep> benzodiazepines <sep> liquid haloperidol <sep> zuclopenthixol acetate <sep> zuclopenthixol acetate <sep>', 'haloperidol <sep> zuclopenthixol acetate and 21 haloperidol <sep> zuclopenthixol <sep> zuclopenthixol acetate with haloperidol <sep> zuclopenthixol acetate and haloperidol <sep> zuclopenthixol acetate or haloperidol <sep> zuclopenthixol acetate <sep> zuclopenthixol acetate <sep>', 'haloperidol <sep> zuclopenthixol <sep> haloperidol <sep> zuclopenthixol acetate in oil solution haloperidol and zuclopenthixol <sep> haloperidol and zuclopenthixol <sep> zuclopenthixol acetate <sep> zuclopenthixol acetate <sep>', 'zuclopenthixol acetate zpta and haloperidol hal <sep> zpta and hal <sep> hal 5-10 mg <sep> zuclopenthixol acetate and haloperidol <sep> zpta <sep> zpta group and hal <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",recommendations on the use of zuclopenthixol acetate for the management of psychiatric emergencies in preference to standard treatment have to be viewed with caution. most of the small trials present important methodological flaws and findings are poorly reported. this review did not find any suggestion that zuclopenthixol acetate is more or less effective in controlling aggressive acute psychosis or in preventing adverse effects than intramuscular haloperidol and neither seemed to have a rapid onset of action. use of zuclopenthixol acetate may result in less numerous coercive injections and low doses of the drug may be as effective as higher doses. well-conducted pragmatic randomised controlled trials are needed.
124,"{'outcomes': ['incidence of malignant sequelae <sep> stomatitis nausea/vomiting sore throat with oral ulcer and hair loss <sep>', 'tumor resistance and morbidity <sep> complete remission with therapeutic chemotherapy <sep> incidence of persistent trophoblastic disease <sep> until complete remission <sep> persistent trophoblastic disease <sep> time interval from evacuation of the mole to diagnosis of persistent trophoblastic disease <sep>', 'complication of the prophylactic chemotherapy <sep> toxicity <sep> secondary trophoblastic disease <sep> metastatic trophoblastic disease <sep> occurrence of choriocarcinoma <sep> severe complication nor death <sep>'], 'punchline_text': ['the side effects of prophylactic chemotherapy were stomatitis nausea/vomiting sore throat with oral ulcer and hair loss. <sep>', 'after molar evacuation four patients from the treated group 10.3 and ten patients from the untreated group 31.3 developed persistent trophoblastic disease. <sep>', 'choriocarcinoma after the molar pregnancy developed in two patients 0.7 of the prophylactic chemotherapy group and two 1.6 of the control. <sep>'], 'population': ['sixty cases of chm classified as high risk <sep> high-risk complete hydatidiform mole chm <sep> patients with high-risk chm <sep> king chulalongkorn memorial hospital <sep>', 'patients with complete hydatidiform mole <sep> seventy-one patients with complete hydatidiform mole <sep>', '293 patients with prophylactic chemotherapy and 23 18.1 of 127 patients without <sep> 420 patients with molar pregnancy <sep>'], 'interventions': ['prophylactic chemotherapy <sep> actinomycin d <sep> therapeutic chemotherapy <sep> prophylactic actinomycin d <sep> actinomycin d chemoprophylaxis <sep> prophylactic actinomycin d <sep> chemoprophylactic or control group <sep>', 'prophylactic chemotherapy <sep> methotrexate and citrovorum factor rescue as chemoprophylaxis <sep> methotrexate and citrovorum factor rescue <sep>', 'prophylactic chemotherapy <sep> prophylactic chemotherapy <sep> prophylactic chemotherapy control <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",p-chem may reduce the risk of progression to gtn in women with cms who are at a high risk of malignant transformation however current evidence in favour of p-chem is limited by the poor methodological quality and small size of the included studies. as p-chem may increase drug resistance delay treatment of gtn and expose women unnecessarily to toxic side effects this practice cannot currently be recommended.
125,"{'outcomes': ['tumour response assessed by arteriography ultrasonography and serum alphafetoprotein <sep> spontaneous 1-year survival rate <sep> actuarial survival rates <sep> survival time <sep>', ""probability of tumor progression <sep> partial response <sep> probability of complications <sep> pugh's grade okuda stage or performance status test pst <sep> survival <sep> self-limited postembolization syndrome <sep>"", 'local recurrence <sep> risk of hepatocellular carcinoma hcc recurrence <sep> overall recurrence <sep> survival <sep> hcc recurrence and survival <sep>', 'liver failure <sep> survival <sep> objective tumoral response <sep> relative risk of death <sep>', 'nausea and loss of appetite <sep> catheter obstruction <sep> liver decompensation <sep> disease-free survival rates and prognostic factors <sep> tumor size tumor number pvtt location <sep> disease-free survival rate <sep> disease-free survival curve <sep>', 'incidence of portal obstruction <sep> risk of death <sep> liver failure <sep> tumor size and serum alpha-fetoprotein concentration <sep> survival <sep> estimated survival rates <sep>', 'level of bcl-2 protein and ratio of bcl-2 to bax protein of hcc cells <sep> apoptotic index(ai and level of bax protein in hcc cells <sep> expressions of bcl-2 and bax protein <sep> apoptosis of hepatocellular carcinoma hcc cells <sep> apoptosis of hepatocellular carcinoma cells <sep>', 'overall survival <sep> abdominal pain <sep> overall survival and quality of life <sep> 2-year overall survival <sep> pugh score <sep> survival alpha-fetoprotein <sep> spitzer index level assessing the quality of life <sep> survival nor the quality of life <sep> survival <sep>', 'intrahepatic recurrence rate <sep> 4-year survival rates <sep>', 'rate of portal-vein invasion <sep> survival probabilities <sep> survival <sep> survival benefits <sep>', 'recurrence rate the time to tumor recurrence and the median survival <sep> median survival <sep> time to tumor recurrence <sep> recurrence rate <sep> recurrence of hepatocellular carcinoma hcc <sep>', 'survival <sep> death from liver failure <sep> survival <sep> actuarial survival <sep>'], 'punchline_text': ['a complete tumour response assessed by arteriography ultrasonography and serum alphafetoprotein was observed in four patients and a partial response in three other patients from group 1. <sep>', 'eighty-two percent of the patients presented a self-limited postembolization syndrome without treatment-related mortality. <sep>', 'there were four cases of local recurrence in the pta-only group and none in the tae/pta group p=0.043). <sep>', 'an objective tumoral response was more frequently observed in the lipiodol chemoembolization group than in the tamoxifen group 24 versus 5.5 respectively p=0.046). <sep>', 'the disease-free survival curve was significantly different among the three groups as estimated by the kaplan-meier method both p  0.05). <sep>', 'there was no significant difference in survival between the two groups although there was a trend favoring the chemoembolization group estimated relative risk of death in the control group 1.4 95 percent confidence interval 0.9 to 2.2 p  0.13). <sep>', 'the apoptotic index(ai and level of bax protein in hcc cells were significantly higher in groups a b c and d than those in the non-tace group p  0.05). <sep>', 'afp>400ng/ml p=.004 and spitzer index p=.013 as shown by multivariable analysis. <sep>', 'the 1 2 3 and 4-year survival rates were 72.3 52.7 35.1 and 35.1 respectively for the patients who underwent radical resection only and were 97.9 85.5 69.5 and 56.9 for the patients who also underwent tace 3-4 weeks after radical resection p  0.001). <sep>', 'survival probabilities at 1 year and 2 years were 75 and 50 for embolisation 82 and 63 for chemoembolisation and 63 and 27 for control chemoembolisation vs control p=0.009). <sep>', 'for group a b and c the 1 year recurrence rate was 83.3 87.0 and 87.5 p  0.926 respectively. <sep>', 'chemoembolization resulted in a marked tumor response and the actuarial survival was significantly better in the chemoembolization group 1 year 57 2 years 31 3 years 26 than in the control group 1 year 32 2 years 11 3 years 3 p .002). <sep>'], 'population': ['patients with unresectable hepatocellular carcinoma <sep> 42 patients with unresectable hepatocellular carcinoma <sep> hepatocellular carcinoma <sep>', 'patients with advanced hepatocellular carcinoma <sep> patients with nonsurgical hcc <sep> patients with nonsurgical hepatocellular carcinoma hcc <sep> eighty consecutive patients <sep>', 'between march 1997 and april 2001 42 hcc patients were enrolled who satisfied the following inclusion criteria 1 uninodular hcc as determined by angiography under computed tomography 2 arterial hypervascularity and 3 no prior history of hcc treatment <sep> patients with hepatocellular carcinoma <sep>', 'patients with unresectable hepatocellular carcinoma <sep> 37 patients in the <sep> seventy-three patients with unresectable hepatocellular carcinoma but without severe liver disease or portal vein occlusion <sep> 58 patients had died 30 in the <sep> patients with unresectable hepatocellular carcinoma treated with <sep>', 'patients with hepatocellular carcinoma hcc complicated by portal vein tumor thrombosis pvtt <sep> patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis <sep> 112 patients with hcc <sep>', 'patients with unresectable hepatocellular carcinoma <sep> 30 patients assigned to chemoembolization <sep> patients with unresectable hepatocellular carcinoma who did not have severe liver disease and who met additional entry criteria <sep> unresectable hepatocellular carcinoma <sep>', '136 patients with hcc underwent liver resection <sep>', 'unresectable hepatocellular carcinoma in cirrhotic patients fdration francophone de cancrologie digestive 9402 <sep> one hundred and twenty three patients were eligible including 61 in the tamoxifen group and 62 in the tace group <sep> hepatocellular carcinoma with cirrhosis <sep> patients with hcc and cirrhosis <sep> from 1995 to 2002 138 patients <sep>', 'primary liver carcinoma after hepatectomy <sep> from april 1990 to december 1993 140 patients <sep>', 'patients with unresectable hepatocellular carcinoma <sep> 903 patients were assessed and 112 12 patients were finally included in the study <sep> patients with unresectable hepatocellular carcinoma not suitable for curative treatment of child <sep> 25 of 37 patients assigned embolisation 21 of 40 assigned chemoembolisation and 25 of 35 assigned conservative treatment died <sep>', 'from jan 2000 to dec 2002 57 patients with hcc <sep> hepatocellular carcinoma <sep> hcc patients <sep>', 'patients with unresectable hepatocellular carcinoma <sep> from march 1996 to october 1997 80 out of 279 asian patients with newly diagnosed unresectable hepatocellular carcinoma fulfilled the entry criteria <sep> unresectable hepatocellular carcinoma <sep> asian patients with unresectable hepatocellular carcinoma <sep>'], 'interventions': ['chemoembolization <sep> hepatic arterial chemoembolization <sep> repeated chemoembolization with gelfoam powder and doxorubicin group 1 or symptomatic treatment <sep>', 'embolization <sep> transarterial embolization tae without associated chemotherapy <sep> transarterial embolization versus symptomatic treatment <sep> tae <sep>', 'tae combined with rfa tae/rfa <sep> percutaneous ethanol injection therapy peit or radiofrequency ablation rfa <sep> peit <sep> transcatheter arterial embolization tae <sep> transcatheter arterial embolization prior to percutaneous tumor ablation <sep> tae <sep> tae/pta <sep> tae combined with percutaneous ethanol injection therapy tae/peit <sep>', 'lipiodol chemoembolization <sep> lipiodol chemoembolization lipiodol cisplatin 2 mg/kg lecithin and gelatin sponge injected into the hepatic artery plus tamoxifen <sep> tamoxifen alone <sep> tamoxifen <sep> lipiodol chemoembolization <sep> lipiodol chemoembolization plus tamoxifen <sep>', 'operation plus tace <sep> operation plus tace and pvc <sep> pvc <sep> postoperative transarterial chemoembolization tace and portal vein chemotherapy pvc <sep> postoperative transarterial chemoembolization and portal vein chemotherapy <sep>', 'lipiodol chemoembolization <sep> cisplatin 10 ml of lipiodol and gelatin-sponge gelfoam particles delivered through the hepatic artery or conservative management involving treatment of complications and pain <sep> chemoembolization <sep> chemoembolization with lipiodol iodized oil <sep> lipiodol chemoembolization and conservative treatment <sep>', 'tace <sep> liver resection non-tace <sep> preoperative transcatheter arterial chemoembolization <sep> chemotherapy combined with iodized oil <sep> preoperative transcatheter arterial chemoembolization(tace <sep> chemotherapy combined with iodized oil ethanol and gelatin sponge <sep> chemotherapy combined with iodized oil and gelatin sponge <sep>', 'tamoxifen <sep> transarterial lipiodol chemoembolisation tace and tamoxifen with tamoxifen alone <sep> transarterial lipiodol chemoembolisation <sep> tace <sep>', 'chemoembolization <sep> tace <sep> transcatheter hepatic arterial chemoembolization tace <sep>', 'arterial embolisation or chemoembolisation versus symptomatic treatment <sep> regularly repeated arterial embolisation gelatin sponge or chemoembolisation gelatin sponge plus doxorubicin <sep> chemoembolisation <sep>', 'transcatheter hepatic arterial chemoembolization and thymosin alpha1 <sep> hepatectomy plus postoperative tace <sep> hepatectomy plus postoperative tace and t(alpha1 <sep> postoperative transcatheter hepatic arterial chemoembolization tace and thymosin alpha(1 t(alpha1 <sep> postoperative tace plus talpha(1 <sep> hepatectomy only <sep>', 'chemoembolization <sep> transarterial lipiodol lipiodol ultrafluide laboratoire guerbet aulnay-sous-bois france chemoembolization <sep> transarterial lipiodol chemoembolization <sep> lipiodol chemoembolization <sep> emulsion of cisplatin in lipiodol and gelatin-sponge particles injected through the hepatic artery chemoembolization group 40 patients or symptomatic treatment control <sep> chemoembolization <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is no firm evidence to support or refute tace or tae for patients with unresectable hcc. more adequately powered and bias-protected trials are needed.
126,"{'outcomes': ['change of the thi ghsi and hearing <sep> tinnitus handicap inventory thi glasgow health status inventory ghsi and average of hearing threshold at 0.5 1 2 4 khz <sep>', 'verbal fluency test the clock-drawing test the npi the hamilton rating scale for depression hamd and the gottfries-brne-steen scale gbs <sep> efficacy <sep> efficacy and tolerability <sep> skt total score <sep> rate of adverse events <sep> neuropsychiatric inventory npi <sep>'], 'punchline_text': ['the main outcome measures were the tinnitus handicap inventory thi glasgow health status inventory ghsi and average of hearing threshold at 0.5 1 2 4 khz. <sep>', 'under egb 761 treatment the skt total score improved by 3.0+/-2.3 and 3.4+/-2.3 points in patients with ad and vad respectively whereas the patients on placebo deteriorated by 1.2+/-2.5 and 1.5+/-2.2 points respectively p<0.01 for both drug-placebo differences). <sep>'], 'population': ['participants included 66 adult patients with tinnitus and six including our study randomized <sep> patients with tinnitus <sep>', ""761 by type of dementia <sep> three hundred ninety-five patients aged 50 years or above with dementia with neuropsychiatric features <sep> 214 patients were diagnosed with alzheimer's disease probable ad or possible ad with cerebrovascular disease and 181 with probable vascular dementia vad <sep>""], 'interventions': ['placebo <sep> ginkgo biloba <sep>', 'ginkgo biloba extract egb <sep> placebo <sep> egb <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>']}",the limited evidence does not demonstrate that ginkgo biloba is effective for tinnitus when this is the primary complaint.
127,"{'outcomes': [""mean updrs scores <sep> unified parkinson's disease rating scale updrs <sep> updrs scores activities of daily living and motor sections <sep>"", 'velocity <sep> stride length <sep> gait velocity <sep> electromyogram emg patterns and stride parameters <sep>'], 'punchline_text': ['a significant reduction of updrs scores activities of daily living and motor sections was present after the rehabilitation phase in both groups. <sep>', 'patients who trained with ras significantly p  0.05 improved their gait velocity by 25 stride length by 12 and step cadence by 10 more than self-paced subjects who improved their velocity by 7 and no-training subjects whose velocity decreased by 7%. <sep>'], 'population': [""twenty stable nondemented patients with pd entered a 6-week rehabilitation program <sep> moderately disabled patients with pd <sep> parkinsonian patients <sep> patients with idiopathic parkinson's disease pd <sep>"", ""parkinson's disease patients <sep> parkinson's disease pd patients n  15 <sep>""], 'interventions': ['cued physical therapy <sep> external sensory cues <sep> external sensory cues non-cued vs cued <sep>', 'rhythmic auditory stimulation in gait training <sep> rhythmic auditory stimulation ras <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",considering the small number of patients examined the methodological flaws in many of the studies and the possibility of publication bias there is insufficient evidence to support or refute the efficacy of any given form of physiotherapy over another in parkinson's disease. another cochrane review physiotherapy for patients with parkinson's disease found that there was insufficient evidence to support or refute the efficacy of physiotherapy compared to no physiotherapy in parkinson's disease. a wide range of physiotherapy approaches were used in these studies and a survey of uk physiotherapists confirmed that they also use an eclectic combination of techniques in the treatment of parkinson's disease plant 1999). therefore a consensus must be found as to best practice physiotherapy for parkinson's disease. the efficacy of standard physiotherapy should be proved first before examining variations in physiotherapy methods. therefore large well designed randomised controlled trials are needed to judge the effect of physiotherapy in parkinson's disease. after this large rcts are needed to demonstrate the most effective form of physiotherapy in parkinson's disease. outcome measures with particular relevance to patients carers physiotherapists and physicians should be chosen and the patients monitored for at least 6 months to determine the duration of any effect. the trials should be reported according to consort guidelines consort 1996).
128,"{'outcomes': ['polyp size <sep>'], 'punchline_text': ['we found that betamethasone nasal drops showed a statistically significant reduction in polyp size in comparison to placebo. <sep>'], 'population': ['adults with cystic fibrosis <sep> nasal polyps in cystic fibrosis <sep>'], 'interventions': ['nasal polyps <sep> betamethasone <sep> placebo <sep>'], 'punchline_effect': [' sig decrease <sep>']}",this review suggests topical steroids for nasal polyposis in patients with cystic fibrosis have no demonstrable effect on subjective nasal symptom scores. they have some effect in reducing the size of the polyps but due to the small sample size poor study completion rates and lack of follow-up the study is at high risk of bias and evidence for efficacy is limited. overall there is no clear evidence for using topical steroids in people with cystic fibrosis and nasal polyposis. a well-designed randomised controlled trial of adequate power and long-term follow-up is needed. validated measures of symptoms and physical findings should be performed and quality of life issues addressed.
129,"{'outcomes': ['completeness of cytoreduction <sep> median and estimated 5-year survival <sep> cytoreductive outcome and survival <sep> probability of complete cytoreduction <sep> survival <sep> largest size of recurrent tumor <sep>', 'median progression-free interval <sep> recurrent ascites <sep> median survival <sep> residual disease <sep> lengthened survival <sep> prognosis of survival <sep> survival <sep>', 'median survival <sep> residual disease <sep> recurrent epithelial ovarian cancer <sep> number of recurrence sites <sep> survival benefit <sep>', 'median survival time mst <sep> residual disease after scr treatment-free interval tfi <sep> complete optimal cytoreduction coc <sep>', 'prolonged survival <sep> longer survival <sep> international federation of gynecology and obstetrics figo stage at initial diagnosis <sep> performance status ps eastern cooperative oncology group ecog <sep>', 'overall survival <sep> recurrence-free interval rfi <sep> 2-year survival rates <sep> 5-year survival <sep>', 'overall survival <sep> residual disease median survival <sep> median patient age at recurrence <sep> complete cytoreduction <sep> number of radiographic recurrence sites median survival <sep> median postrecurrence survival <sep> median diagnosis-to-recurrence interval <sep> age tumor grade histology ca-125 level ascites and tumor size <sep>'], 'punchline_text': ['survival was influenced by the dfi after primary treatment 6-12 months median 25.0 months vs. 13-36 months median 44.4 months vs.  36 months median 56.8 months p  0.005 the completeness of cytoreduction visibly disease free median 44.4 months vs. any residual disease median 19.3 months p  0.007 the use of salvage chemotherapy before secondary surgery chemotherapy given median 24.9 months vs. chemotherapy not given median 48.4 months p  0.005 and the largest size of recurrent tumor  10 cm median 37.3 months vs.  10 cm median 35.6 months p  0.04). <sep>', 'logistic stepwise regression revealed that recurrent ascites p  0.0072 relative risk  20.36 and residual disease after the second operation p  0.0096 relative risk  5.16 were important determinants of secondary surgical outcome. <sep>', 'on multivariate analysis disease-free interval p  .004 the number of recurrence sites p  .01 and residual disease p .001 were significant prognostic factors. <sep>', 'residual disease after scr treatment-free interval tfi and age were found to be prognostic factors for overall survival os in multivariate analysis. <sep>', 'complete resection was associated with significantly longer survival compared with surgery leaving any postoperative residuals median 45.2 vs. 19.7 months hazard ratio hr 3.71 95 confidence interval ci 2.27-6.05 p  .0001]. <sep>', 'the 2-year survival rates were 22.3 62.9 and 22.7 respectively for patients with rfi 7-12 13-24 and 24 months. <sep>', 'age tumor grade histology ca-125 level ascites and tumor size were not associated significantly with survival. <sep>'], 'population': ['patients with recurrent epithelial ovarian carcinoma <sep> one hundred six patients with a disease free interval dfi  6 months after primary treatment underwent secondary cytoreductive surgery <sep> copyright 2000 american cancer society <sep>', 'individuals with progression-free interval <sep> patients with recurrent epithelial ovarian cancer <sep> between 1986 and 1997 60 patients who received <sep> for stage iii and iv epithelial ovarian cancer experienced disease recurrence at least 6 months after completion of primary therapy and secondary surgical cytoreduction was performed <sep> patients with ascites at disease recurrence however were not suitable for aggressive secondary surgery and redebulking surgery for those with residual disease of 1.0 cm after primary operation should be considered prudently <sep>', '157 patients underwent secondary cytoreduction and 153 of those patients were evaluable <sep> patients who underwent secondary cytoreduction for recurrent platinum-sensitive epithelial ovarian cancer <sep> patients with recurrent epithelial ovarian cancer <sep> patients with recurrent platinum-sensitive epithelial ovarian carcinoma <sep> for recurrent epithelial ovarian cancer from 1987 to 2001 <sep>', '217 had scr and 572 were treated with chemotherapy alone <sep> epithelial ovarian cancer <sep> 789 patients treated at the norwegian radium hospital during 1985-2000 for their initial recurrence <sep>', 'relapsed ovarian cancer <sep> two hundred and sixty-seven patients were included <sep> recurrent ovarian cancer <sep> patients who might benefit from surgery in relapsed ovarian cancer <sep> right patients for cytoreductive surgery in recurrent ovarian cancer <sep> twenty-five member institutions of the arbeitsgemeinschaft gynaekologische onkologie ovarian committee ago oc and ago-ovar boards collected data on their patients with cytoreductive surgery for relapsed invasive epithelial ovarian cancer performed in 2000-2003 <sep>', '17 patients 81 with rfi 24 months were heavily treated with chemotherapy before secondary surgery <sep> patients with recurrent epithelial ovarian carcinoma <sep> patients who have documented gross disease preoperatively should be selected for a secondary debulking operation <sep> patients with recurrent epithelial ovarian cancer <sep> exclusion criteria included secondary cytoreduction during second-look laparotomy interval cytoreduction and palliative surgery in patients with intestinal obstruction or progressive disease <sep>', 'study inclusion criteria required a complete clinical response to primary therapy or=12 months between initial diagnosis and recurrence and or=5 recurrence sites on preoperative imaging studies <sep> patients who underwent secondary surgical cytoreduction for recurrent epithelial ovarian cancer between september 1997 and march 2005 were identified retrospectively from tumor registry databases <sep> patients with 1 or 2 radiographic recurrence sites <sep> fifty-five patients met the study inclusion criteria <sep> patients who had recurrent epithelial ovarian carcinoma <sep>'], 'interventions': ['secondary cytoreductive surgery <sep>', 'cytoreductive surgery <sep> primary cytoreductive surgery and platinum-based chemotherapy <sep>', 'secondary cytoreduction <sep> cytoreductive surgery <sep>', 'mst <sep> secondary cytoreduction scr <sep>', 'cytoreductive surgery <sep>', 'cytoreductive surgery <sep> secondary cytoreductive surgery <sep>', 'secondary cytoreductive surgery <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",in women with platinum-sensitive recurrent ovarian cancer ability to achieve surgery with complete cytoreduction no visible residual disease is associated with significant improvement in overall survival. however in the absence of rct evidence it is not clear whether this is solely due to surgical effect or due to tumour biology. indirect evidence would support surgery to achieve complete cytoreduction in selected women. the risks of major surgery need to be carefully balanced against potential benefits on a case-by-case basis.
130,"{'outcomes': ['frequency of dvt <sep> cerebral bleeding <sep> deep venous thrombosis dvt <sep> thromboembolic complications <sep>', 'deaths and pulmonary emboli <sep> death rate <sep> deep-vein thrombosis rate <sep> haemorrhagic <sep> number of deep-vein thromboses pulmonary emboli and deaths <sep> mortality <sep>', 'deaths <sep> degree of neurologic change incidence of stroke progression <sep> functional activity level of survivors <sep>', 'symptomatic intracranial hemorrhage ich <sep> symptomatic ich <sep> neurologic deficits <sep> asymptomatic ich 7 events major systemic hemorrhage no event or 90-day mortality <sep>', 'deep-vein thrombosis <sep> absence of pulmonary embolism or drug-induced haemorrhage <sep> tolerated <sep> lethal pulmonary embolism <sep>', 'glasgow outcome scale score of i or ii and a modified barthel index <sep> serious intracranial bleeding events <sep>', 'development of dvt <sep> time interval from stroke to admission and lactic dehydrogenase ldh concentration <sep>', 'deep-vein thrombosis <sep> mean factor xa inhibitory activity levels at peak concentration <sep> mortality rate <sep> frequency of dvt <sep> fatal pulmonary embolism <sep> major hemorrhagic complications <sep> frequency of proximal thrombi <sep>', 'tolerated and no side-effects <sep> laboratory values pt ptt alkaline phosphatase got gpt cholesterol and triglycerides fibrinogen blood glucose azotemia and creatinine <sep>', 'deep-vein thrombosis <sep>'], 'punchline_text': ['in the placebo group there were 4 deaths during the trial versus 9 in the kabi-2165-treated group ns). <sep>', 'low-dose calcium heparin given subcutaneously following acute stroke reduced the number of deep-vein thromboses pulmonary emboli and deaths without increasing the number of haemorrhagic strokes in this study. <sep>', 'no statistically significant difference between the two groups was found in degree of neurologic change incidence of stroke progression after 7 days or functional activity level of survivors at 7 days 3 months and at 1 year after treatment. <sep>', 'no significant between-group differences occurred in asymptomatic ich 7 events major systemic hemorrhage no event or 90-day mortality 13.4 overall). <sep>', 'no deep-vein thrombosis was detected by the labelled fibrinogen test in the treated group as against 12 patients in the control group. <sep>', 'at 3 months 482 75.2 of 641 persons assigned to treatment with org 10172 and 467 73.7 of 634 patients treated with placebo had favorable outcomes p=.49 49.5 and 47 respectively of patients in each group had very favorable outcomes at 3 months. <sep>', 'there was no significant difference in the development of dvt by treatment group. <sep>', 'the frequency of dvt was 15 of 42 patients or 36 95 confidence interval 22 to 52 in the lmw heparin group and 17 of 50 patients or 34 21 to 49 in the placebo group. <sep>', 'the mesoglycan influenced only slightly the laboratory values pt ptt alkaline phosphatase got gpt cholesterol and triglycerides fibrinogen blood glucose azotemia and creatinine performed before the beginning of the treatment as their changes after thirty days of therapy were in the normal range. <sep>', 'a statistically significant reduction was observed in deep-vein thrombosis as assessed by isotope leg scanning. <sep>'], 'population': ['thirty patients <sep> stroke patients <sep> ischemic stroke patients kabi 2165 2 x 2,500 anti <sep>', 'three hundred and five elderly patients <sep> patients after acute strokes <sep> patients with lighter strokes <sep>', '225 patients with acute partial stable thrombotic stroke <sep> acute partial stable stroke <sep> patients who have had acute partial stroke <sep>', 'patients with acute ischemic stroke argis-1 <sep> 171 patients with acute  or 12 hours from onset stroke and national institutes of health stroke scale nihss scores of 5 to 22 <sep> acute ischemic stroke <sep>', '30 patients <sep> patients with hemiplegia following cerebral infarction <sep> patients confined to bed due to hemiplegia consecutive to a recent cerebral infarction <sep> 15 patients compared with a control group of 15 untreated patients <sep>', 'persons with stroke <sep> between december 22 1990 and december 6 1997 1281 persons with acute stroke were enrolled at 36 centers across the united states <sep> acute ischemic stroke <sep>', 'stroke patients <sep> stroke patients during rehabilitation <sep> patients during rehabilitation <sep> patients undergoing rehabilitation <sep> patients with dvt on admission prevalent n  61 were compared with the study patients n  360 <sep> three hundred and sixty patients over a 3-year period <sep>', 'all patients underwent thrombosis surveillance with unilateral venography of the paretic limb <sep> 42 of 52 patients randomized to <sep> 103 patients with acute ischemic stroke <sep> acute ischemic stroke <sep> patients with acute ischemic stroke <sep>', '28 patients <sep> acute focal cerebral ischemia <sep> 57 patients with acute cerebral infarct was performed <sep>', 'elderly patients admitted to hospital after an acute stroke <sep>'], 'interventions': ['kabi-2165-treated <sep> placebo <sep> low-molecular-weight heparin kabi 2165/fragmin <sep>', 'calcium heparin <sep> low-dose subcutaneous heparin <sep> low-dose calcium heparin <sep>', 'continuous intravenous heparin therapy or placebo <sep> heparin <sep> placebo <sep> intravenous heparin <sep>', 'placebo <sep> argatroban anticoagulation <sep> argatroban <sep> argatroban anticoagulation <sep> activated partial thromboplastin times aptts 2.25x and 1.75x baseline or placebo <sep> argatroban <sep> continuous intravenous argatroban <sep>', 'weight heparin fraction cy 222 <sep>', 'org 10172 or placebo <sep> unfractionated heparin <sep> placebo <sep>', 'deep vein thrombosis dvt and subsequent pulmonary embolism pe <sep> heparin intermittent pneumatic compression ipc functional electrical stimulation fes or control <sep>', 'lmw heparin <sep> low molecular weight heparin <sep> placebo <sep> lmw heparin kabi 2165 fragmin <sep> venography <sep>', 'mesoglycan <sep> mesoglycan <sep> dexamethasone <sep>', 'low-dose heparin <sep> subcutaneous low-dose heparin <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",since the last version of the review neither of the two new relevant studies have provided additional information to change the conclusions. in patients with acute ischaemic stroke immediate anticoagulant therapy is not associated with net short or long-term benefit. treatment with anticoagulants reduced recurrent stroke deep vein thrombosis and pulmonary embolism but increased bleeding risk. the data do not support the routine use of any the currently available anticoagulants in acute ischaemic stroke.
131,"{'outcomes': ['mpo levels <sep> myeloperoxidase mpo release <sep>', 'inulin clearance <sep> perioperative renal function <sep> renal function <sep> inulin clearance and urinary beta(2)-microglobulin and n-acetyl-beta-d-glucosaminidase nag excretion <sep> low mean arterial pressure at anesthesia induction <sep> tubular damage markers <sep> renal function impairment <sep>', 'lactic acid levels <sep> venous stasis <sep>'], 'punchline_text': ['complement system factors and granulocyte activation represented by myeloperoxidase mpo release were analyzed by eia. <sep>', 'no significant differences were observed between groups 1 and 2 at any perioperative phase except during the anhepatic phase in which a more marked renal function impairment occurred in group 2 patients. <sep>', 'lactate determinations did not contribute to the quantification of the systemic and regional tissue oxygenation during olt. <sep>'], 'population': ['twenty patients <sep> liver transplantation <sep> 20 patients during and 1 day after liver transplantation olt <sep>', 'liver transplantation <sep> 77 patients receiving liver transplants for chronic liver disease <sep>', 'human liver transplantation olt <sep>'], 'interventions': ['veno-venous bypass vvbp circuit surface heparinization <sep> heparin-coated veno-venous bypass circuits <sep> heparin-coated hc vvbp equipment or to otherwise identical noncoated nc circuits <sep>', 'vvbp <sep> venovenous bypass <sep> venovenous bypass vvbp <sep>', 'venovenous bypass <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",there is no evidence to support or refute the use of veno-venous bypass in liver transplantation. there is no evidence to prefer any particular technique of veno-venous bypass in liver transplantation.
132,"{'outcomes': ['mean hazard score <sep> parental safety knowledge <sep>', 'discharge book improved the burn-care-related knowledge of caregivers <sep>', 'rate of burn injuries <sep> injury rate per 100 fires <sep> annualized fire-injury rates <sep>', 'window safety <sep> socket safety <sep> socket covers <sep> fireplace safety <sep> storage of medicines <sep> smoke alarms <sep> safe practice in storage of sharp objects <sep> smoke alarm safety <sep>', 'home hazards requiring major effort to correct <sep>', 'incidence of fires and related injuries <sep> rates of fires and related injuries <sep> admissions to hospital and deaths <sep> installed alarms <sep> working alarms <sep> rates of fires and rates of fire related injury <sep>', 'feasibility acceptability and effectiveness <sep> injury prevention knowledge or behavior <sep> probability of having a working detector <sep>', 'hot-water temperature poison storage and presence of smoke alarms safety gates for stairs and ipecac syrup <sep> number of safety practices <sep> safety practices <sep> parents safety practices <sep>', 'physician counseling and parent satisfaction knowledge beliefs and behaviors <sep> injury prevention counseling <sep> parents knowledge beliefs and home safety behaviors <sep>', 'presence and functional status of smoke alarms <sep> demographic and fire safety data <sep> working smoke alarms <sep> functioning alarms <sep>', 'total costs of care for injuries <sep> home safety modifications <sep> overall occurrence of injuries <sep> injury visits <sep>', 'safety knowledge and practices <sep> safety knowledge and behavior scores <sep>'], 'punchline_text': ['the educational phase of the study was completed by 129 families 65 in the intervention group and 64 in the control group. <sep>', 'stepwise multiple-regression analysis found that the influence of the book was limited to families with children who sustained scald burns p  0.05). <sep>', 'before the intervention the rate of burn injuries per 100,000 population was 4.2 times higher in the target area than in the rest of oklahoma city. <sep>', 'after intervention significantly more families in intervention group used fireguards relative risk 1.89 95 confidence interval 1.18 to 2.94 smoke alarms 1.14 1.04 to 1.25 socket covers 1.27 1.10 to 1.48 locks on cupboards for storing cleaning materials 1.38 1.02 to 1.88 and door slam devices 3.60 2.17 to 5.97). <sep>', 'there was a distinct difference between control and intervention homes with respect to safety knowledge and home hazards requiring minimal to moderate effort to correct. <sep>', 'giving out free smoke alarms in a deprived multiethnic urban community did not reduce injuries related to fire mostly because few alarms had been installed or were maintained. <sep>', 'among families without a working smoke detector at baseline the intervention was associated with an increased probability of having a working detector at follow up relative risk rr 3.3 95 confidence interval ci 1.3 to 8.6). <sep>', 'no significant differences in safety practices were found between study groups. <sep>', 'parents seen by physicians in the intervention group received significantly more injury prevention counseling for 5 of the 6 safety practices and they were significantly more satisfied with the help their physicians provided on safety topics. <sep>', 'only 65 of voucher households had functioning alarms at follow up largely due to failure to redeem vouchers. <sep>', 'the total costs of care for injuries were significantly lower in the intervention group compared with the nonintervention group with a cost of 372 per injury prevented. <sep>', 'households that reported participatory exposure to the interventions had higher safety knowledge and behavior scores than those that received other community exposure or no exposure to intervention activities. <sep>'], 'population': ['parents of 171 children coming to the yale-new haven hospital primary care center for their 6-month checkup <sep> 129 families 65 in the intervention group and 64 in the control group <sep>', 'pediatric burn units with the exception that north american indian nai families were disproportionately admitted with 59 out of the 123 48 admissions from a geographic area that has less than 15 nais <sep> pediatric patients with burns <sep> caregivers we studied children less than 17 years of age admitted with an acute thermal injury to the pediatric burn unit of a large tertiary care hospital in winnipeg canada over a 32 month period <sep>', 'burn injuries in oklahoma city from september 1987 through april 1990 <sep> 34,945 homes in the target area 34 percent did not have smoke alarms <sep> residential-fire injuries <sep> a total of 10,100 smoke alarms were distributed to 9291 homes 45 percent were functioning four years later <sep>', 'families with children under 5 years <sep> 98 165/169 of families with children aged under 5 years registered with the practice <sep> twenty families from intervention and control groups <sep>', 'poor urban african-american community <sep> urban minority communities <sep> urban african-american community <sep>', 'multiethnic urban population <sep> forty electoral wards in two boroughs of inner london united kingdom <sep> primarily households including elderly people or children and households that are in housing rented from the borough council <sep>', 'a total of 213 families 77.8 of those eligible from intervention sites and 149 families 71.9 of those eligible from concurrent comparison sites agreed to participate and completed the trial <sep> families of low income children attending preschool enrichment programs in washington state <sep> children attending preschool head start programs in two regions were eligible <sep>', 'first and second-year pediatric residents and their patient-parent dyads <sep> a hospital-based pediatric resident continuity clinic that serves families living in low-income inner-city neighborhoods <sep> parents of their patients were enrolled when the patient was 6 months or younger and observed until 12 to 18 months of age <sep> parents safety practices <sep>', 'thirty-one residents <sep> families with infants from birth to age 6 months were enrolled in the study n  196 they were followed up until the child was aged 12 to 18 months <sep> pediatric residents <sep>', 'high risk households across the u.s. five states arkansas maine maryland massachusetts and north carolina participated <sep> 90 of households receiving the direct installation intervention <sep> high-risk households <sep> 4,455 households were enrolled in the study installation group 2,206 49.5 voucher group 2,249 50.5 <sep> 1,583 installation group households and 1,545 voucher group households <sep> target population included occupants of high-risk households without working smoke alarms who were approached as part of a door-to-door canvassing program <sep>', 'children 8 years old initially enrolled in an injury case-control study were eligible to participate <sep> the median age was 2 years with males comprising 60 of participants <sep> 5 hospitals in 4 canadian urban centers <sep> children <sep>', 'children ages 0-5 years in the intervention compared with control communities associated with participatory exposure of about 55 percent of households with children ages 0-5 years <sep> children ages 0-5 years <sep> childhood injuries <sep> between september 1980 and june 1982 we implemented five injury prevention projects concurrently in nine massachusetts cities and town five sites matched on selected demographic characteristics were control communities <sep> 42 percent of households with children ages 0-5 years <sep>'], 'interventions': ['routine safety education <sep>', 'discharge teaching book <sep> standard discharge teaching <sep> discharge instructions with the book intervention group or routine discharge teaching without the book comparison group <sep>', 'smoke-alarm-giveaway program <sep>', 'usual care <sep> general practitioner safety advice <sep>', 'trained community outreach workers consisted of 1 home modification for simple prevention measures 2 home inspection accompanied by information about home hazards and 3 education about selected injury prevention practices <sep>', 'intervention 20 050 smoke alarms fittings and educational brochures distributed free and installed on request <sep>', 'injury prevention program delivered by school based home visitors <sep>', ""standard services plus a home-safety visit by a community health worker <sep> safety counseling and referral to the children's safety center from their pediatrician <sep> standard or an enhanced-intervention group <sep>"", 'experiential instruction on injury prevention content and counseling skills safe counseling framework <sep> enhanced anticipatory guidance <sep> 1-hour seminar about injury prevention and the american academy of pediatrics tipp <sep> injury prevention anticipatory guidance training program <sep>', 'residential smoke alarm installation and maintenance <sep>', 'single home visit that included the provision of an information package discount coupons and specific instruction regarding home safety measures <sep> home visit program <sep>', 'community-based injury prevention program <sep> statewide childhood injury prevention program scipp <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",this review found that programmes to promote smoke alarms have at most modest beneficial effects on smoke alarm ownership and function and no demonstrated beneficial effect on fires or fire-related injuries. counselling as part of child health surveillance has a somewhat greater effect on smoke alarm ownership and function but its effects on injuries are unevaluated. community smoke alarm give-away programmes have not been demonstrated to increase smoke alarm prevalence or to reduce fires or fire-related injuries. community-based education programmes have not been shown to reduce burns or fire-related injuries. community smoke alarm installation programmes may increase the prevalence of working alarms and reduce fire-related injuries but these results require confirmation and the cost-effectiveness of such programmes has not been evaluated. efforts to promote smoke alarms through installation programmes should be evaluated by adequately designed randomised controlled trials measuring injury outcomes and cost-effectiveness.
133,"{'outcomes': ['recurrent preterm uterine activity <sep> pregnancy outcomes <sep> frequency of preterm deliveries <sep> mean days to delivery the number of repeat triage visits the incidence of preterm labor <sep> shortest length of triage stay <sep>'], 'punchline_text': ['there were no intergroup differences in the mean days to delivery the number of repeat triage visits the incidence of preterm labor at  34 weeks or the frequency of preterm deliveries at  34 weeks and  37 weeks. <sep>'], 'population': ['women with preterm uterine contractions <sep> women in these three groups were similar with respect to maternal age race parity prior preterm births gestational age at randomization contraction frequency and mean cervical dilatation <sep> consenting women seen in our hospital triage area with preterm uterine contractions <sep> one hundred seventy-nine women <sep> women who had progressive cervical change at  34 weeks were treated with <sep> eligible women had a singleton gestation between 20 and 34 weeks intact membranes more than three contractions in 30 minutes and a cervical dilation  or  1 cm and effacement  80 <sep>'], 'interventions': ['intravenous tocolysis <sep> intravenous hydration <sep> observation alone intravenous hydration or one dose of subcutaneous terbutaline sulfate <sep> subcutaneous terbutaline <sep> terbutaline <sep>'], 'punchline_effect': [' no diff <sep>']}",the data are too few to support the use of hydration as a specific treatment for women presenting with preterm labour. the two small studies available do not show any advantage of hydration compared to bed rest alone. intravenous hydration does not seem to be beneficial even during the period of evaluation soon after admission in women with preterm labour. women with evidence of dehydration may however benefit from the intervention.
134,"{'outcomes': ['fatigue sleep disability and mood <sep> sf-36 physical functioning subscale <sep> satisfactory outcome in physical functioning <sep>', 'fatigue functional capacity and fitness <sep>', 'fatigue <sep> functional work capacity <sep> functional work capacity and fatigue <sep> efficacy and acceptability <sep> health perception <sep> depression <sep>', 'resting systolic blood pressure <sep> physical work capacity as well as in specific psychological and cognitive variables <sep> specific physiological psychological and cognitive functions <sep> net blood lactate production <sep> rating of perceived exertion scores <sep> work capacity w.kg(-1 <sep> depression <sep>'], 'punchline_text': ['intention to treat analysis showed 79 69 of patients in the intervention groups achieved a satisfactory outcome in physical functioning compared with two 6 of controls who received standardised medical care p<0.0001). <sep>', '12 of 22 patients who crossed over to exercise after flexibility treatment rated themselves as better after completing exercise treatment 32 of 47 patients rated themselves as better three months after completing supervised exercise treatment 35 of 47 patients rated themselves as better one year after completing supervised exercise treatment. <sep>', 'exercise significantly improved health perception p  0.012 and fatigue p  0.028 at 28 weeks. <sep>', 'following the graded exercise intervention scores were improved for resting systolic blood pressure p  0.018 work capacity w.kg(-1 <sep>'], 'population': ['148 consecutively referred patients fulfilling oxford criteria for chronic fatigue syndrome <sep> chronic fatigue syndrome <sep> patients with chronic fatigue syndrome <sep> 21 patients dropped out mainly from the intervention groups <sep>', '66 patients with the chronic fatigue syndrome who had neither a psychiatric disorder nor appreciable sleep disturbance <sep> patients with the chronic fatigue syndrome <sep> chronic fatigue clinic in a general hospital department of psychiatry <sep>', 'ninety-six 71 of 136 patients completed the trial <sep> chronic fatigue syndrome <sep> patients with chronic fatigue syndrome <sep>', 'chronic fatigue syndrome <sep> human performance laboratory at the university of western australia <sep> 61 patients aged between 16 and 74 years diagnosed with cfs <sep> people with chronic fatigue syndrome cfs <sep>'], 'interventions': ['telephone intervention group received an additional seven follow up calls and the maximum intervention group an additional seven face to face sessions over four months <sep> patient education to encourage graded exercise <sep> control group received standardised medical care <sep> educational intervention <sep>', 'graded aerobic exercise <sep> graded aerobic exercise or flexibility exercises and relaxation therapy <sep> graded aerobic exercise programme <sep> graded exercise <sep>', 'placebo <sep> graded exercise and antidepressants <sep> fluoxetine and graded exercise <sep> fluoxetine exercise and placebo drug appointments only and 20 mg fluoxetine appointments and placebo drug <sep> fluoxetine <sep>', 'graded exercise with pacing <sep> graded exercise <sep> graded exercise with pacing 32 patients or relaxation/flexibility therapy <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is encouraging evidence that some patients may benefit from exercise therapy and no evidence that exercise therapy may worsen outcomes on average. however the treatment may be less acceptable to patients than other management approaches such as rest or pacing. patients with cfs who are similar to those in these trials should be offered exercise therapy and their progress monitored further high quality randomised studies are needed.
135,"{'outcomes': ['rate of bone turnover and bone loss <sep> rate of bone loss <sep> distal forearm <sep> lumbar spine <sep> bmd and bone biochemical markers <sep> bmd and bone metabolism <sep> bone turnover <sep> bone mineral density and bone metabolism <sep> low bone mineral density bmd <sep> total hip <sep>'], 'punchline_text': ['after 12 months the treatment group n=15 showed a reduced rate of bone loss compared with the control group n=15 in the lumbar spine mean difference 1.9 ci 0.9 to 4.6 <sep>'], 'population': ['adults with cystic fibrosis <sep> these subjects <sep> adult patients with cystic fibrosis <sep> patients were invited to participate if they had a bmd z score of 1 or less in the lumbar spine proximal femur or distal forearm <sep>'], 'interventions': ['calcium and vitamin d supplementation <sep> calcium and vitamin d supplementation <sep> placebo <sep> calcium 1 g+vitamin d 800 iu or placebo daily in addition to their regular vitamin d supplements <sep>'], 'punchline_effect': [' sig decrease <sep>']}",there is no evidence of benefit or harm in the limited number of small-sized published trials. adherence to relevant cf guidelines on vitamin d should be considered until further evidence is available.
136,"{'outcomes': ['lowered lipoprotein(a <sep> hdl2-c and lipoprotein(a <sep> fibrinogen <sep> hdl-c and pai-1 <sep> lipid levels and coagulation parameters <sep> biochemical markers of cardiovascular risk by decreasing ldl-c fibrinogen and lipoprotein(a <sep> change high-density lipoprotein cholesterol hdl-c triglycerides or plasminogen activator inhibitor-1 pai-1 <sep> serum lipids and coagulation factors <sep> pai-1 <sep> low-density lipoprotein cholesterol ldl-c <sep> high-density lipoprotein-2 cholesterol hdl2-c <sep>', 'gh and igf <sep> secretion of growth hormone gh and igf <sep> growth hormone secretion patterns <sep> gh and igf <sep>', 'bone mineral density bmd <sep> bone loss <sep> femoral neck bmd <sep> loss of femoral neck bmd <sep> lumbar bmd <sep>', 'low-density lipoprotein ldl cholesterol <sep> high-density lipoprotein hdl cholesterol-ldl ratio <sep> systolic blood pressure <sep> maximum oxygen uptake <sep> triglycerides <sep> exercise performance <sep> lipids and lipoproteins <sep> cholesterol triglycerides and ldl cholesterol and an increase in the hdl-ldl ratio <sep> apolipoprotein a1 <sep> hdl cholesterol <sep> total cholesterol <sep> lipid metabolism <sep> physical fitness levels <sep> levels of lipids and lipoproteins <sep> total exercise time time spent on the treadmill until exhaustion during testing <sep>', 'bone mineral density <sep> spine density <sep> cortical and trabecular bone <sep> levels of serum triglycerides <sep> spine density and total body density <sep> total body calcium <sep> lipid profile <sep> spine density total body calcium or radial density <sep> serum cholesterol levels <sep> metacarpal cortex <sep> radial density <sep>', 'total body bone mineral content tbbmc <sep> tbbmc <sep>', 'plasma homocysteine <sep> time for homocysteine levels <sep> plasma fasting homocysteine concentrations <sep> plasma homocysteine levels <sep> fasting plasma total homocysteine concentrations <sep> plasma homocysteine concentration <sep> fasting plasma homocysteine concentrations <sep> serum e2 levels <sep> plasma homocysteine levels <sep>', 'glycemic effects <sep> fasting glucose levels <sep> incidence of diabetes <sep> fasting glucose level <sep> fasting glucose level and incident diabetes <sep> fasting glucose levels <sep> weight and waist circumference <sep>', 'height loss <sep> hip and spine bmd <sep> rate of new vertebral fractures <sep> bone mineral density bmd <sep> lumbar spine <sep> bmd <sep> height loss <sep>', 'blood pressure and body mass index <sep> serum cholesterol level <sep> high-density lipoprotein cholesterol/total cholesterol fraction <sep> cardiovascular risk factors <sep> total cholesterol level high-density lipoprotein cholesterol level blood pressure and body mass index <sep>', 'body composition <sep> body weight <sep> urinary creatinine excretion rate <sep> urinary creatinine/body weight ratio <sep> daily creatinine excretion <sep> serum oestradiol and serum oestrone <sep>', 'ldl cholesterol <sep> levels of lipids lipoproteins apolipoproteins fibrinogen and glucose tolerance <sep> ldl cholesterol levels <sep> levels of hdl cholesterol hdl2 hdl3 triglycerides lipoprotein populations and apolipoproteins ai and aii <sep> levels of apolipoprotein b and lipoprotein(a <sep> glucose tolerance or on fibrinogen levels <sep> elevated ldl cholesterol levels <sep> total and ldl cholesterol levels <sep>', 'balance muscle performance and falls <sep> initial levels of oestradiol <sep> levels of follicle-stimulating hormone <sep> muscle performance and balance <sep> muscle performance improve balance or reduce falls <sep> sway leg extensor power and self-paced walking speed <sep> muscle strength <sep> hand grip strength <sep> leg extensor power <sep>', 'bone mineral density <sep> bone turnover including bone-specific alkaline phosphatase and urinary hydroxyproline:creatinine ratios <sep> bone mineralization defects <sep>', 'total serum cholesterol and ldl-cholesterol levels <sep> serum lipoproteins <sep> serum lipids and lipoproteins <sep> vaginal bleedings <sep> hdl-cholesterol levels <sep> serum triglycerides levels <sep>', 'levels of total serum cholesterol and ldl-cholesterol <sep> serum lipids and lipoproteins <sep> serum triglycerides and hdl-cholesterol levels <sep> serum lipids and lipoproteins <sep> total serum cholesterol and ldl-cholesterol <sep>', 'serum lipids or lipoproteins <sep> low-density-lipoprotein ldl cholesterol <sep> high-density-lipoprotein hdl cholesterol <sep> total serum cholesterol levels <sep> serum lipids and lipoproteins <sep>', 'percent of body fat <sep> body weight <sep> extremity/trunk ratio <sep> body cell mass and body fat mass <sep> trunk fat mass <sep> ratio of fat in the trunk/extremities <sep>', 'weight or girth changes <sep> physical activity level <sep> weight gain <sep> waist girth <sep> body weight and waist and hip girths <sep> overall activity <sep> hip work activity <sep> alcohol consumption <sep> hispanic ethnicity <sep>', 'antithrombin iii atiii protein c protein s heparin cofactor ii hcii and plasminogen activator inhibitor <sep> pai-1 levels <sep> fibrinogen factor vii fvii factor viii <sep> final values of fibrinogen fvii atiii protein s and hcii <sep> fibrinogen levels <sep>', 'abdominal fat after menopause <sep> total body fat mass or total lean body mass <sep> serum lipids and lipoproteins <sep> postmenopausal bone loss <sep> cardiovascular risk <sep>', 'ratio of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol <sep> endometrial hyperplasia <sep> triglyceride levels <sep> lipid measures <sep> bone density endometrium and lipids of continuous hormones <sep> bone mineral density <sep> endometrial proliferation and hyperplasia <sep> bmd <sep> bone mineral density bmd <sep> endometrium against hyperplasia <sep> rate of hyperplasia and proliferative status <sep>', 'body weight blood pressure lipoprotein levels antithrombin iii activity and the endometrium <sep> overall values for body weight and blood pressure <sep> weight gain <sep> anthropometry lipoprotein levels antithrombin iii activity and endometrial histology <sep> triglyceride levels <sep> high density lipoprotein hdl cholesterol levels <sep> antithrombin iii activity mean levels <sep> hdl cholesterol level <sep> total and low density lipoprotein cholesterol levels <sep> baseline biochemical values <sep> baseline blood pressures and body weights <sep>', 'skin tolerability <sep> hot flushes <sep> estradiol/estrone ratio <sep> serum estradiol concentrations <sep> vaginal cytology profile maturation index <sep> breast pain <sep> frequency of moderate-to-severe hot flushes <sep> incidence of estrogen-related side effects <sep> efficacy and safety <sep> breakthrough bleeding <sep>', 'triglyceride <sep> changes of other lipid profiles <sep> lipid changes measurement of serum total cholesterol tc triglycerides tg low density lipoprotein ldl high density lipoprotein hdl apolipoprotein a-1 apo-a and apolipoprotein b apo-b <sep>', 'total mortality <sep> total cardiovascular disease arterial and venous disease <sep> overall health risks <sep> estimated hazard ratios hrs <sep> nonfatal myocardial infarction and chd death <sep> stroke pulmonary embolism pe endometrial cancer colorectal cancer hip fracture and death due to other causes <sep> coronary heart disease chd <sep>'], 'punchline_text': ['raloxifene did not significantly change high-density lipoprotein cholesterol hdl-c triglycerides or plasminogen activator inhibitor-1 pai-1 whereas hrt increased hdl-c by 11 and triglycerides by 20 and decreased pai-1 by 29 for all p  .001). <sep>', 'those women who did not receive any hormonal treatment and the postmenopausal women before hrt showed nearly identical gh and igf <sep>', 'the loss of femoral neck bmd was lower in the hrt 0.3 and the hrt  vit d 0.9 groups compared with the vit d 2.4 and the placebo groups 3.7%). <sep>', 'exercise alone was associated with significant decreases in total cholesterol 5.2 p  .05 triglycerides 2 p  .05 and low-density lipoprotein ldl cholesterol 10 p  .01 and a significant increase in the high-density lipoprotein hdl cholesterol-ldl ratio 17.2 p  .01). <sep>', 'the premarin-treated group had an increase in spine density and total body density p less than 0.05 but a decrease in radial density p less than 0.05). <sep>', 'after 1 year tbbmc/w was lower in every group 2.14 p  0.001 in the control group 0.14 p  ns in the hrt group p  0.05 vs. controls 0.18 p  ns in the calcium group p  0.05 vs. controls and 0.06 p  ns in the calcitonin group p  0.01 vs. controls p  0.05 vs. calcium and hrt). <sep>', 'after 15 months of hormone treatment mean plasma homocysteine concentration was lowered by 12.6 compared with baseline p  .001 analysis of variance for repeated measures). <sep>', 'the incidence of diabetes was 6.2 in the hormone therapy group and 9.5 in the placebo group relative hazard 0.65 95 ci 0.48 to 0.89 p  0.006). <sep>', 'patients who received combined therapy had significantly higher bmd in both the vertebrae and in the femora p 0.05 in comparison with patients who were treated with hrt or etidronate alone after 4 years. <sep>', 'the hypocholesterolemic effect was correlated to body mass index in a way that indicated the most pronounced decrease in lean women. <sep>', 'the urinary creatinine excretion rate was significantly increased p less than 0.001 in the group receiving high-dose hormones and the urinary creatinine/body weight ratio was significantly increased p less than 0.05 in all treated groups as compared with the placebo-group. <sep>', 'total and ldl cholesterol levels were reduced by 14 95 ci 11-17 and 19 95 ci 14-23 respectively in the hrt group vs. 3 95 ci 0-7 and 5 95 ci 0-11 in the diet group. <sep>', 'frequent fallers swayed significantly more often than the others but there was no evidence that their muscle strength was poorer or that the group treated with hormone replacement therapy fell less frequently. <sep>', 'patients who received combined therapy had significantly higher bone mineral density in both vertebrae p  0.05 and femora p  0.01 in comparison to patients who were treated with hrt or ice alone. <sep>', 'total serum cholesterol and ldl-cholesterol levels were reduced by approximately 15 and 20 p less than 0.001 respectively in the hormone group but were unchanged in the placebo group. <sep>', 'total serum cholesterol and ldl-cholesterol were reduced by approximately 5 p less than 0.01 and 8 p less than 0.01 respectively after 1 year of combined oestrogen-cpa therapy in comparison with both the initial values and the placebo group but serum triglycerides and hdl-cholesterol levels were unchanged in both groups. <sep>', 'total serum cholesterol levels were significantly reduced by 4-10 p less than 0.05-p less than 0.001 in a dose-related way in the hormone groups. <sep>', 'the percent of body fat increased in each group from baseline measurements with the greatest increase in the hormonal replacement group. <sep>', 'factors that were independently associated with smaller increases in girths were for waist greater overall activity p  0.005 and hispanic ethnicity p  0.02 and for hip work activity p  0.003 and greater alcohol consumption p  0.03). <sep>', 'the continuous treatment group had significantly lower final values of fibrinogen fvii atiii protein s and hcii than the placebo group the cyclic treatment reduced fibrinogen in comparison with placebo but the difference was not significant. <sep>', 'the therapy reduced postmenopausal bone loss significantly p less than .001 whereas it did not have a statistically significant influence on total body fat mass or total lean body mass. <sep>', 'daily treatment with na-ee2 was well tolerated and protected the endometrium from ee2-induced proliferation and hyperplasia. <sep>', 'with treatment there were no differences in overall values for body weight and blood pressure p  0.4 and order of treatment had no significant influence p  0.3). <sep>', 'the reduction in hot flushes for both active treatment groups remained significantly different from placebo throughout the 12-week trial. <sep>', 'however there was no significant difference in changes of other lipid profiles between the two groups at 6 and 12 months non-hrt tc 2.7 0.7 hdl 2.9 5.1 ldl 5.2 4.1 apo-a 0.5 0.9 apo-b 3.8 1.3 hrt tc 1.4 2.8 hdl 4.7 6.2 ldl 1.5 4.9 apo-a 0.9 1.6 apo-b <sep>', 'corresponding hrs nominal 95 cis for composite outcomes were 1.22 1.09-1.36 for total cardiovascular disease arterial and venous disease 1.03 0.90-1.17 for total cancer 0.76 0.69-0.85 for combined fractures 0.98 0.82-1.18 for total mortality and 1.15 1.03-1.28 for the global index. <sep>'], 'population': ['postmenopausal women <sep> 390 healthy postmenopausal women recruited by advertisement <sep> healthy postmenopausal women <sep>', 'postmenopausal women <sep> healthy postmenopausal women <sep> 23 healthy postmenopausal women <sep>', 'postmenopausal women in a 2.5-year randomized <sep> study population was a subgroup of the kuopio osteoporosis risk factor and prevention study ostpre n  13100 <sep> non-osteoporotic early postmenopausal women <sep> 464 early postmenopausal women <sep> early postmenopausal women <sep>', 'postmenopausal women <sep> one hundred one postmenopausal women <sep>', '81 postmenopausal women aged 51.7 <sep> postmenopausal women <sep>', 'a total of 104 naturally or surgically postmenopausal women <sep> group mean age 50 <sep> osteoporosis in natural and surgical postmenopausal women who had been found to have rapid bone loss in analytical studies <sep> 26 patients each the untreated control group mean age 50 <sep> group mean age 48 <sep>', 'postmenopausal women <sep> 27 postmenopausal women <sep> healthy postmenopausal women <sep>', '734 women had diabetes 218 women had impaired fasting glucose and 1811 women were normoglycemic the 2029 women without diabetes were followed for incident diabetes <sep> 2763 postmenopausal women with coronary heart disease who were followed for 4.1 years <sep> 20 u.s. clinical centers <sep>', 'all patients enrolled in this study including the control group n=18 received <sep> women with postmenopausal osteoporosis <sep> postmenopausal women with established osteoporosis <sep> seventy-two postmenopausal women mean age 64.9+/-0.5 years attending metabolic bone disease outpatient clinics with established osteoporosis <sep> postmenopausal women <sep>', 'lean women <sep> 74 postmenopausal women <sep>', '136 post-menopausal women treated for at least 1 yr with <sep> early post-menopausal women <sep>', 'postmenopausal women <sep> hyperlipidaemic postmenopausal women <sep> 76 postmenopausal women aged 43-60 years with ldl cholesterol levels  or  4.2 mmol 1-1 treated with a lipid-lowering diet <sep> hypercholesterolaemia among postmenopausal women <sep>', 'middle-aged women <sep> 116 post-menopausal women aged 45-70 years all of whom had suffered a distal radial fracture during the previous 3 months <sep> post-menopausal women <sep>', 'fifty-eight early postmenopausal women attending metabolic bone disease outpatient clinics <sep> postmenopausal women <sep> early postmenopausal women <sep>', 'postmenopausal women <sep> 44 healthy postmenopausal women every 3 months during 1 year of treatment with either <sep>', '76 healthy postmenopausal women treated for 1 year with either <sep>', 'post-menopausal women <sep> 87 healthy post-menopausal women treated for 1 yr with three different doses of <sep>', '118 women who were within 6 years of menopause was conducted <sep>', '875 women assessing the effects on cardiovascular risk factors of four hormone regimens <sep>', '167 women who took the treatment for at least 6 cycles were evaluable <sep> 255 women in physiological menopause for 1-5 years <sep>', 'sixty-two early postmenopausal women <sep>', 'asymptomatic or mildly symptomatic women aged 40 years or older who had undergone the onset of spontaneous menopause within the last 5 years and who had an intact uterus <sep> twelve hundred sixty-five patients entered the study <sep> outpatients at 65 centers <sep>', 'women in the menopause transition <sep> 105 apparently healthy women in the menopause transition 40-52 years with menstrual function who were experiencing minor menopausal symptoms were selected from the general population by advertising <sep> outpatient clinic of a city hospital <sep>', 'postmenopausal women experiencing menopausal symptoms <sep> postmenopausal women who were experiencing at least 60 moderate-to-severe hot flushes per week <sep> 273 postmenopausal women <sep>', 'postmenopausal women <sep> 93 postmenopausal women <sep>', '16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 us clinical centers in 1993-1998 <sep> healthy postmenopausal women <sep> healthy postmenopausal us women <sep>'], 'interventions': ['raloxifene <sep> raloxifene 60 mg/d raloxifene 120 mg/d hrt conjugated equine estrogen 0.625 mg/d and medroxyprogesterone acetate 2.5 mg/d or placebo <sep> placebo <sep> hrt raloxifene <sep> hormone replacement therapy hrt <sep> raloxifene <sep>', 'hormonal replacement therapy hrt <sep> hormone replacement therapy <sep> orally applicated 2 mg estradiol-valerat e2v and 10 mg dydrogesterone <sep> continuous estrogen cyclic progesterone replacement therapy <sep>', 'vit d supplementation <sep> placebo <sep> hormone replacement therapy hrt and low-dose bone loss <sep> hrt and vit d <sep> hrt  vit d <sep> vitamin d supplementation <sep> vitamin d and hrt <sep> estradiol valerate and 1 mg cyproterone acetate e2val/cpa 2 vitamin d3 cholecalciferol 300 iu/day 3 hrt  vit d and 4 placebo calcium lactate 93 mg ca2+/day <sep> hrt <sep>', 'moderate exercise program with and without oral estrogen replacement <sep> estrogen therapy <sep> moderate exercise program <sep> exercise and estrogen <sep> combined conjugated equine estrogen and exercise <sep> control or sedentary n  20 exercise alone n  25 estrogen replacement using 0.625 mg conjugated equine estrogen n  28 and exercise supplemented with conjugated equine estrogen <sep>', 'placebo <sep> progestin therapy <sep> provera 20 mg premarin 0.6 mg premarin 0.3 mg plus provera 10 mg and a placebo <sep> calcium supplementation <sep> single and dual-photon absorpiometry metacarpal radiogrammetry and computed axial tomography <sep>', 'transdermal 17 beta-estradiol <sep> hormonal replacement treatment hrt <sep> calcitonin <sep> calcium estrogens and/or eelcatonin <sep> eel calcitonin 40 iu/day and with elemental calcium <sep> medroxiprogesterone <sep>', 'e2-dydrogesterone therapy <sep> oral 17beta-estradiol e2 dydrogesterone <sep> oral e2 <sep> dydrogesterone <sep> oral e2 1 mg daily combined sequentially with dydrogesterone <sep> 17beta-estradiol-dydrogesterone <sep>', 'conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate daily or placebo <sep> hormone therapy <sep> placebo <sep> postmenopausal hormone therapy <sep>', 'hrt or etidronate <sep> cyclical estrogen and progesterone the etidronate <sep> 1.0 g elemental calcium and 400 units vitamin d per day <sep> etidronate and hrt <sep> combined hrt plus etidronate <sep> hormone replacement and bisphosphonate alone or in combination <sep> hrt and etidronate <sep> bisphosphonates <sep> calcium and vitamin d <sep> hormone replacement therapy hrt with estrogen <sep> intermittent cyclical etidronate <sep> hrt <sep>', 'estrogen-norethindrone and cholecalciferol treatment <sep> cholecalciferol <sep> norethindrone <sep> placebo <sep> estrogen-norethindrone <sep> cholecalciferol and estrogen-norethindrone <sep>', 'combined oestrogen-progestogen therapy <sep> placebo <sep> oestrogen-progestogen replacement therapy <sep>', 'sequential 17 beta-oestradiol and norethisterone acetate or placebo <sep> sequential hormone replacement therapy <sep> hormone replacement therapy hrt and dietary therapy <sep> hrt <sep>', 'hormone replacement therapy <sep> oral hormone replacement therapy plus calcium <sep> prempak c or premarin <sep> calcium alone <sep> hormone replacement therapy <sep>', 'estrogen or etidronate <sep> ice <sep> hormone-replacement therapy hrt <sep> percutaneously administered hrt <sep> calcium <sep> hrt and ice <sep> estrogen and etidronate <sep> intermittent cyclical etidronate ice <sep> elemental calcium <sep> ice and hrt <sep> calcium alone <sep> etidronate <sep>', 'norethisterone acetate <sep> placebo <sep> continuous oestrogen-norethisterone acetate or placebo <sep> continuous oestrogen-progestogen <sep>', 'combined oestrogen-cpa therapy <sep> placebo <sep> oestradiol valerate sequentially combined with the anti-androgenic progestogen cyproterone acetate cpa or placebo <sep> cyproterone acetate <sep>', 'norethisterone acetate <sep> sequential oestrogen/progestogen 4 mg 2 mg and 1 mg 17 beta-oestradiol cyclically combined with 1 mg norethisterone acetate or placebo <sep> combined oestrogen-progestogen therapy <sep> placebo <sep>', 'hormonal replacement therapy <sep> placebo dietary calcium augmentation and estrogen-progesterone-calcium <sep> dietary calcium augmentation <sep> hormonal replacement therapy and placebo <sep> dual photon absorptiometry <sep>', 'cee <sep> placebo <sep> postmenopausal hormone therapy <sep> hormone therapy <sep> cee in combination with medroxyprogesterone acetate <sep> oral conjugated equine estrogen cee therapy <sep> cee in combination with micronized progesterone <sep>', 'placebo <sep> cyclic transdermal e2 <sep> continuous transdermal e2 <sep> transdermal estradiol e2 combined with progestin <sep> medroxyprogesterone acetate mpa <sep> mpa <sep> transdermal estradiol and oral sequential medroxyprogesterone acetate <sep>', 'placebo <sep> postmenopausal hormone therapy <sep> postmenopausal hormone replacement therapy <sep> combined estrogen-progestogen therapy <sep>', 'na and 1 microg of ee2 0.5 mg of na and 2.5 microg of ee2 1 mg of na and 5 microg of ee2 1 mg of na and 10 microg of ee2 1 microg of ee2 2.5 microg of ee2 5 microg of ee2 or 10 microg of ee2 <sep> na-ee2 <sep> continuous norethindrone acetate na)-ethinyl estradiol ee2 combinations with matching unopposed ee2 or placebo <sep> placebo <sep>', 'active arm--oral conjugated oestrogens <sep> placebo <sep> hormone therapy <sep> cyclic medroxyprogesterone acetate <sep>', 'estradiol matrix transdermal delivery system alora versus placebo <sep> placebo <sep> estradiol matrix transdermal delivery system alora in two strengths 50-microgram/d estradiol and 100-microgram/d estradiol with placebo <sep>', 'hormonal replacement therapy <sep> control group non-hrt 42/93 did not receive any hormone regimen <sep> hormonal replacement <sep> estrogen with or without progestin <sep> hrt <sep>', 'placebo <sep> estrogen plus progestin <sep> medroxyprogesterone acetate <sep> conjugated equine estrogens <sep> combined estrogen plus progestin <sep> estrogen plus progestin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there is no evidence of an effect of unopposed oestrogen or combined oestrogen with progestogen on body weight and on the bmi increase normally experienced at the time of menopause. insufficient evidence currently exists to enable examination of the effect of hrt on waist-hip ratio fat mass or skinfold thickness.
137,"{'outcomes': ['control of air leaks <sep> air leaks <sep> postoperative morbidity and mortality <sep> control of air leaks intraoperatively and the time to postoperative air leak cessation <sep> reduced time to chest tube removal and earlier discharge <sep> mean times to last observable air leak <sep> percentage of patients free of air leakage throughout hospitalization <sep> free of air leaks during hospitalization <sep> time to chest tube removal time to hospital discharge and safety outcomes <sep> air leaks <sep> efficacy and safety <sep>', 'quality of aerostasis the post-operative drainage the persistance of residual collection or faulty reexpansion <sep>', 'overall incidence of air leaks <sep> duration of air leaks <sep> surgical morbidity and costs <sep> incidence of dead pleural space <sep> air leakage <sep> procedure costs <sep>', 'fever intraoperative and postoperative intubation times <sep> incidence of postoperative leakages <sep> duration of stay in hospital <sep> airway-tolerance-pressure test <sep>', 'efficacy and safety <sep> persisting air leakage <sep> mean duration of postoperative air leakage <sep> reduction of intra-operative air leak intensity <sep> postoperative air leakage <sep> reduction of intra-operative air leakage <sep> air leakage <sep> overall incidence of air leakage <sep> incidence of air leakage <sep> postoperative air leakage intensity <sep>', 'median duration of intercostal drainage and in-hospital stay <sep> postthoracotomy alveolar air leak <sep>', 'length of the postoperative hospital stay <sep> mean percentage of patients free of aal <sep> localized empyema and incomplete lung expansion <sep> alveolar air leaks <sep> mean numbers of intraoperative aal after application of sls <sep> mean time to last observable aal <sep>', 'postoperative hospitalisation time <sep> morbidity <sep> air leakage volumes <sep> mean bleeding/exudate volumes <sep> air leakage <sep> air leakage <sep>', 'intraoperative leaks <sep> duration of postoperative chest tube time hospital stay or cost <sep> healing of healthy bronchial and lung tissues <sep> postoperative air leaks <sep> leak-free <sep>', 'duration of air leaks <sep> chest tube drains <sep> duration of air leaks chest tube drainage or hospitalization <sep> postoperative hospitalization <sep> mean air leak duration <sep> postoperative air leaks <sep>', 'hospital stay <sep> intercostal chest drainage <sep> air leak duration chest drainage time and hospital stay <sep> duration of air leak intercostal drainage and hospital stay <sep> shorter median duration of air leaks <sep>', 'incidence of paal <sep> mean time to chest tube removal <sep> paal <sep> mean duration of aal <sep> volume of chest tube drainage or los <sep> incidence and duration of aal prolonged aal paal the volume of pleural drainage the time to tube removal and the postoperative length of stay los as well as any complications related to treatment <sep> overall incidence of aal <sep>', 'mean times to chest drain removal and to hospital discharge <sep> mean time to chest drain removal and mean time to hospital discharge <sep> air leakage volume <sep> alveolar air leaks <sep> mean intraoperative post-treatment air leakage <sep> postoperative leakage <sep> air leakage <sep> postoperative quantification of air leakage on postoperative days 1 and 2 <sep>', 'length of hospitalization <sep> intraoperative air leaks <sep> safety and effectiveness <sep> mortality morbidity duration of chest tubes or immune responses <sep> median length of hospitalization <sep> postoperative air leaks <sep>'], 'punchline_text': ['application of the sealant resulted in control of air leaks in 92 of treated patients p  or  0.001). <sep>', 'no significant statistical difference was observed concerning the quality of aerostasis the post-operative drainage the persistance of residual collection or faulty reexpansion after removal of the latter and the necessity for repeated drainage. <sep>', 'there were no complications related to the use of the patches and a significantly lower incidence of dead pleural space was observed in the es group 5 vs 40 p  .020). <sep>', 'an additional reduction of the duration of post-operative air leakages by the treatment with fibrin glue could not be shown. <sep>', 'the reduction of intra-operative air leak intensity in the subgroup with grades 1-2 was significantly higher for the tc group p=0.015). <sep>', 'statistical analysis revealed no differences between the groups. <sep>', 'in treated patients the mean numbers of intraoperative aal after application of sls were significantly smaller than in untreated patients 38.5 ml versus 59.9 ml p  0.0401). <sep>', 'postoperative hospitalisation time was shorter in the vivostat group than in the control group but the difference was not significant 0.5 days p=0.12). <sep>', 'in the clinical study 100 of intraoperative leaks were sealed versus 18 of control patients p .001). <sep>', 'we conclude that the routine use of a fixed quantity of fibrin glue is not effective in reducing the duration of air leaks chest tube drainage or hospitalization after uncomplicated pulmonary lobectomy. <sep>', 'this study demonstrates clear benefit from bioglue in the treatment of alveolar air leaks through reduction of air leak duration chest drainage time and hospital stay. <sep>', 'statistically significant reductions were found in the experimental group in the overall incidence of aal 34 versus 68 p  0.001 mean duration of aal 1.1 versus 3.1 days p  0.005 mean time to chest tube removal 3.5 versus 5.0 days p  0.02 and the incidence of paal 2 versus 16 p  0.015). <sep>', 'tachosil showed a trend towards reduced incidence of postoperative leakage when measured 48h or 7 days after surgery 30.7 vs 38.96 and 24 vs 32.46 respectively). <sep>', 'intraoperative air leaks were sealed in 77 of the sealant group compared with 16 in the control group p  0.001). <sep>'], 'population': ['after lung resection <sep> 172 patients undergoing thoracotomy <sep>', '50 patients undergoing partial pulmonary excision <sep> 50 patients <sep> partial pulmonary excision surgery <sep>', '20 patients in each of the 2 groups <sep>', '114 patients undergoing pulmonary resections and pneumonectomies <sep>', '189 patients undergoing lobectomy were enrolled in a multi-centre <sep> air leakage after standard lobectomy <sep>', '66 patients undergoing lobectomies segmentectomies or decortication were randomized either to serve as controls n  33 or to have <sep>', '124 patients undergoing standard lobectomy <sep>', 'after pulmonary lobectomy <sep> patients undergoing lobectomy <sep>', '26 consecutive patients <sep> fifteen large white pigs underwent a left upper lobectomy <sep> thoracic operations <sep>', '28 consecutive patients between november 1988 and may 1989 <sep> nine male and 5 female patients with a mean age of 63.8 years were in the fibrin glue experimental group and 8 male and 6 female patients with a mean age of 59 years in the control group <sep> 14 patients and 14 patients served as controls <sep>', 'from december 2002 to january 2005 52 patients were randomized 29 56 of whom were men <sep> the mean age was 59 <sep>', '100 patients <sep> pulmonary resection <sep> 113 patients enrolled 13 became ineligible because of intraoperative findings <sep>', 'patients with grade 0 leakage were excluded <sep> patients with grade 1 or 2 air leaks <sep> lung surgery <sep> 173 patients undergoing lobectomy or segmentectomy <sep>', '161 patients with a median age of 67 years old range 18-85 years old <sep>'], 'interventions': ['novel synthetic sealant <sep> surgical sealant applied to sites at risk for air leak after standard methods of lung closure treatment group or to have standard lung closure only control group <sep> new synthetic bioresorbable surgical sealant <sep>', 'biological glue <sep> fibrin glue <sep>', 'electrocautery dissection and collagen patches coated with human fibrinogen and thrombin tachosil nycomed vienna austria <sep> electrocautery <sep> precision dissection and collagen patches were coated with human fibrinogen and thrombin tachosil nycomed vienna austria for aerostasis in the electrocautery and sealant group es and the approved routine surgical procedure with staplers was used in the stapler group st <sep> completion technique of fissures for lobectomy stapler versus precision dissection and sealant <sep>', 'fibrin glueing <sep> fibrin glue <sep> surgery alone 59 patients or analogous surgical treatment followed by the application of fibrin glue <sep>', 'tachocomb tc <sep> tc <sep> human fibrinogen/thrombin-coated collagen patch tachocomb <sep>', 'fibrin glue <sep> fibrin glue sprayed on the raw lung surface <sep> fibrin glue <sep>', 'standard closure of parenchymal surgical sites with or without sls <sep> sls <sep> synthetic surgical lung sealant sls <sep> synthetic sealant <sep>', 'vivostat fibrin sealant <sep> autologous fibrin sealant vivostat <sep>', 'new synthetic absorbable sealant <sep>', 'routine fibrin glue <sep> fibrin glue <sep> fibrin glue spray <sep>', 'bioglue cryolife europa ltd hampshire united kingdom <sep> bioglue <sep> control arm surgical treatment only or an interventional arm surgical treatment and bioglue <sep>', 'aerosolized fibrin glue <sep> fibrin glue <sep> fibrin glue <sep> no additional intervention <sep>', 'tachosil <sep> fleece-bound sealing tachosil of air leaks <sep>', 'sealant or control <sep> biodegradable polymeric sealant <sep> new biodegradable polymeric sealant <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",surgical sealants reduce postoperative air leaks and time to chest drain removal but this reduction is not always associated with a reduction in length of postoperative hospital stay. therefore systematic use of surgical sealants with the objective of reducing hospital stay cannot be recommended at the moment. more and larger randomized controlled clinical trials are needed.
138,"{'outcomes': ['annual rate of moderate to severe exacerbations <sep> adverse events <sep> rate of moderate to severe exacerbations <sep> morbidity and mortality <sep> reporting of pneumonia <sep> copd exacerbations <sep> annual rate of exacerbations requiring oral corticosteroids <sep> risk of time to first exacerbation <sep>', ""prolonged time to first exacerbation <sep> mean prebronchodilator forced expiratory volume <sep> prebronchodilator peak expiratory flow <sep> fev1 <sep> exacerbations <sep> postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire sgrq <sep>"", ""efficacy <sep> controlling dyspnoea and improving health status st george's respiratory questionnaire <sep> pre-dose forced expiratory volume in 1 second fev1 and 1-hour post-dose fev1. <sep> efficacy and tolerability <sep> tolerated <sep> incidence of pneumonia <sep> pulmonary function and reduced symptoms and exacerbations <sep> rate of copd exacerbations <sep> efficacy and tolerability <sep>"", 'exercise performance <sep> postdose frc and increased inspiratory capacity ic <sep> lung hyperinflation <sep> tidal volume and minute ventilation <sep> predose and postdose spirometry plethysmography and constant-load cycle cardiopulmonary exercise test evaluations <sep> exercise time <sep> lung hyperinflation and exercise endurance <sep> ic <sep> exercise endurance time <sep> postdose ic <sep>', 'lung function measurements symptoms and rescue treatment use the number of exacerbations patient withdrawals and disease-specific health status <sep> pretreatment fev1 <sep> lung function and health status <sep> health status <sep> daily symptoms <sep> pretreatment forced expiratory volume in 1s fev1 <sep> adverse events serum cortisol concentrations skin bruising and electrocardiograms <sep> lung function symptoms and health status and reduced use of rescue medication and frequency of exacerbations <sep> frequency of adverse events bruising or clinically significant falls in serum cortisol concentration <sep>', ""efficacy <sep> number of exacerbations resulting in hospitalization <sep> incidence of individual non-fatal serious adverse events <sep> dyspnoea measured using the breathlessness diary and health-related quality-of-life hr-qol scores based on the st george's respiratory questionnaire total score <sep> efficacy and safety <sep> efficacy for pulmonary function <sep> dyspnoea scores and hr-qol <sep> incidence of pneumonia <sep> tolerated <sep> tolerated relative <sep> efficacy and tolerability <sep> pre-dose forced expiratory volume in 1 second fev(1 and 1-hour post-dose fev(1 <sep>"", '2-hour postdose fev(1 <sep> transition dyspnea index <sep> predose fev(1 <sep> adverse effects <sep> lung function <sep> severity of dyspnea <sep>', 'average daily morning pef <sep> 2-h postdose fev(1 <sep> adverse effects <sep> morning predose ie trough fev(1 for fsc compared with sm and 2-h postdose fev(1 <sep> morning predose fev(1 <sep> dyspnea quality of life and symptoms of chronic bronchitis <sep> morning lung function <sep> lung function <sep> efficacy and safety <sep> morning peak expiratory flow rate pef transition dyspnea index chronic respiratory disease questionnaire chronic bronchitis symptom questionnaire exacerbations <sep>', 'daily beta(2 short acting prn consumption <sep> fev(1 <sep> morning pef l/s the daily symptom score and the number of exacerbations <sep> daily symptoms score <sep> morning pef <sep> respiratory function such as fev(1 morning pef and and symptom score <sep> mean number of exacerbations/yr <sep> mean fev(1 <sep>', 'annualized rate of moderate and severe exacerbations <sep> moderate and severe exacerbations <sep> health-related quality of life peak expiratory flow and use of rescue medication <sep> tolerated <sep> mean time to first exacerbation <sep> frequency of moderate/severe exacerbations <sep> total number of exacerbations <sep>', 'annual rate of moderate/severe exacerbations <sep> worsening symptoms of copd requiring antibiotics oral corticosteroids and/or hospitalization <sep> annual rate of moderate/severe exacerbations requiring hospitalization <sep> albuterol use dyspnea scores and nighttime awakenings and numerical benefits on quality of life <sep> moderate/severe exacerbations <sep> adverse events <sep> copd exacerbations and impact on patient outcomes <sep> moderate/severe exacerbations <sep> annual rate of exacerbations requiring oral corticosteroids <sep> rate of moderate/severe exacerbations <sep> pneumonia <sep>', 'symptom scores and use of reliever beta2-agonists <sep> efficacy and safety <sep> mean number of severe exacerbations <sep> fev1 <sep> severe exacerbations and fev1 primary variables peak expiratory flow pef copd symptoms health-related quality of life hrql mild exacerbations use of reliever beta2-agonist and safety variables <sep> tolerated <sep> morning pef <sep> efficacy and safety <sep>'], 'punchline_text': ['clinical improvements observed during run-in treatment with fluticasone propionate/salmeterol 250/50 were better maintained over 12 months with fluticasone propionate/salmeterol 250/50 than salmeterol. <sep>', ""postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire sgrq by 4.5 units after run-in. <sep>"", 'the rate of copd exacerbations was lower in both budesonide/formoterol groups compared with formoterol and placebo p or 0.004). <sep>', '0.05 l over placebo with associated improvements in tidal volume and minute ventilation p  0.05 vs placebo at week 8). <sep>', 'combination therapy improved pretreatment fev1 significantly more than did placebo treatment difference 133 ml 95 ci 105-161 p<0.0001 salmeterol 73 ml 46-101 p<0.0001 or fluticasone alone 95 ml 67-122 p<0.0001). <sep>', 'dyspnoea scores and hr-qol were significantly improved with both budesonide/formoterol pmdi dosage strengths versus both monocomponents and placebo. <sep>', 'the incidence of adverse effects except for an increase in oral candidiasis with fsc and f was similar among the treatment groups. <sep>', 'the incidence of adverse effects except for an increase in oral candidiasis with fsc and fp were similar among the treatment groups. <sep>', 'morning pef l/min increased in subjects treated with sm&fp anova p<0.001 while it remained unchanged in sm and p group in both anova p=ns). <sep>', 'other endpoints including health-related quality of life peak expiratory flow and use of rescue medication were significantly improved in the combination therapy group. <sep>', 'clinical improvements observed during run-in treatment with fsc 250/50 were better maintained over 52 weeks with fsc 250/50 compared to sal. <sep>', 'morning pef improved significantly on day 1 versus placebo and budesonide after 1 week morning pef was improved versus placebo budesonide and formoterol. <sep>'], 'population': ['patients with copd <sep> 782 patients with copd mean <sep>', 'chronic obstructive pulmonary disease <sep> chronic obstructive pulmonary disease copd <sep>', 'patients with copd <sep> 964 patients aged or 40 years with moderate to very severe copd conducted from 2005 to 2007 at 237 sites in the us europe and mexico <sep> patients with moderate to very severe copd <sep> patients with chronic obstructive pulmonary disease copd who have frequent exacerbations <sep> patients with chronic obstructive pulmonary disease <sep>', 'eligible patients were  or  40 years old with a diagnosis of copd prealbuterol fev(1 <sep> patients with copd <sep> 185 patients mean baseline fev1 of 41 predicted were enrolled <sep> copd <sep>', 'chronic obstructive pulmonary disease <sep> patients with copd <sep> 1465 patients with copd were recruited from outpatient departments in 25 countries <sep> symptomatic chronic obstructive pulmonary disease copd <sep>', 'patients with chronic obstructive pulmonary disease copd who have frequent exacerbations <sep> patients with copd <sep> 1704 patients aged  or 40 years with moderate to very severe copd conducted in 194 centres in the us czech republic the netherlands poland and south africa <sep> patients with moderate to very severe chronic obstructive pulmonary disease <sep>', 'chronic obstructive pulmonary disease <sep> chronic obstructive pulmonary disease copd <sep> 691 patients with copd <sep>', 'seventy-six investigative sites in the united states <sep> patients with copd <sep> seven hundred twenty-three patients  or 40 years of age with copd and a mean baseline fev(1 of 42 predicted <sep>', 'copd patients already treated with <sep> eighteen moderate copd patients <sep> chronic obstructive pulmonary disease copd <sep>', 'chronic obstructive pulmonary disease copd <sep> severe chronic obstructive pulmonary disease <sep> 994 clinically stable patients <sep> patients with severe copd and a history of repeated exacerbations <sep> patients with severe copd <sep>', 'patients with copd <sep> 797 subjects with copd mean fev(1 <sep>', 'patients with moderate-to-severe chronic obstructive pulmonary disease copd <sep> chronic obstructive pulmonary disease <sep> 812 adults mean age 64 yrs mean forced expiratory volume in one second fev1 36 predicted normal <sep> moderate-to-severe chronic obstructive pulmonary disease <sep>'], 'interventions': ['salmeterol <sep> fluticasone propionate/salmeterol 250/50 or salmeterol <sep> fluticasone propionate/salmeterol <sep> fluticasone propionate/salmeterol 250/50 and salmeterol <sep>', 'oral prednisolone <sep> budesonide and formoterol <sep> formoterol <sep> placebo <sep> inhaled budesonide/formoterol 320/9 microg budesonide 400 microg formoterol 9 microg or placebo <sep> budesonide formoterol or placebo <sep> budesonide/formoterol <sep> budesonide/formoterol <sep> monocomponent <sep>', 'placebo <sep> budesonide/formoterol pmdi 80/4.5 microg x two inhalations 160/9 microg formoterol dpi 4.5 microg x two inhalations 9 microg or placebo <sep> formoterol and placebo <sep> budesonide/formoterol <sep> inhaled corticosteroid ics <sep> budesonide/formoterol pmdi <sep> budesonide/formoterol hfa pmdi <sep> hydrofluoroalkane hfa pressurized metered-dose inhaler pmdi <sep> budesonide/formoterol <sep> budesonide/formoterol pmdi <sep>', 'placebo <sep> fluticasone propionate/salmeterol <sep> fsc 250/50 salmeterol 50 microg or placebo <sep> fsc <sep> salmeterol and placebo <sep> fluticasone propionate 250 microg/salmeterol 50 microg combination fsc 250/50 <sep> salmeterol <sep>', 'combined salmeterol and fluticasone <sep> placebo <sep> fluticasone <sep> inhaled long-acting beta2 agonists <sep> salmeterol <sep> salmeterol and 500 microg fluticasone <sep>', 'budesonide pmdi <sep> budesonide and formoterol <sep> placebo <sep> formoterol <sep> formoterol dpi 4.5 microg x two inhalations 9 microg or placebo <sep> previous therapy icss and short-acting bronchodilators <sep> budesonide/formoterol <sep> budesonide/formoterol <sep> inhaled corticosteroid ics <sep> budesonide formoterol and placebo <sep> oral corticosteroids <sep> budesonide <sep> budesonide/formoterol pmdi <sep> hydrofluoroalkane pressurized metered-dose inhaler pmdi <sep> budesonide/formoterol dry powder inhaler dpi <sep> budesonide/formoterol pmdi <sep> budesonide pmdi <sep>', 'placebo <sep> fluticasone propionate and salmeterol combination delivered via the diskus device <sep> combination of f and s fsc s 50 mcg f 500 mcg or placebo <sep> fsc <sep> inhaled corticosteroid fluticasone propionate f with an inhaled long-acting beta(2)-agonist salmeterol s <sep>', 'sm <sep> placebo <sep> fp <sep> fsc fp <sep> inhaled corticosteroid fluticasone propionate fp and the inhaled long-acting beta(2)-agonist salmeterol sm <sep> placebo fsc <sep> fluticasone propionate <sep>', 'sm alone or p <sep> sm&fp <sep> salmeterol  fluticasone <sep> placebo <sep> theophylline <sep> salmeterol  fluticasone <sep> fev(1 <sep> theophylline 400 mg/day and beta(2 short acting prn <sep> salmeterol <sep> sm&fp 50/250 microcg or sm 50 microcg alone or p via diskus inhaler bid for 52 weeks <sep>', 'salmeterol/fluticasone propionate <sep> salmeterol/fluticasone combination 50/500 micro g twice daily and 487 received salmeterol 50 micro g twice daily for 44 wk <sep> salmeterol alone <sep> salmeterol monotherapy <sep> salmeterol <sep> salmeterol/fluticasone <sep>', 'fluticasone propionate/salmeterol <sep> fluticasone propionate/salmeterol 250 mcg/50 mcg fsc 250/50 and salmeterol 50 mcg sal <sep> fsc <sep> fsc 250/50 or sal <sep> sal <sep>', 'placebo <sep> placebo budesonide and formoterol <sep> budesonide/formoterol <sep> budesonide <sep> placebo and budesonide <sep> budesonide/formoterol symbicort 160/4.5 microg delivered dose budesonide 200 microg metered dose formoterol 4.5 microg or placebo <sep> budesonide/formoterol <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",concerns over the analysis and availability of data from the studies bring into question the superiority of ics/laba over laba alone in preventing exacerbations. the effects on hospitalisations were inconsistent and require further exploration. there was moderate quality evidence of an increased risk of pneumonia with ics/laba. there was moderate quality evidence that treatments had similar effects on mortality. quality of life symptoms score rescue medication use and fev1 improved more on ics/laba than on laba but the average differences were probably not clinically significant for these outcomes. to an individual patient the increased risk of pneumonia needs to be balanced against the possible reduction in exacerbations. more information would be useful on the relative benefits and adverse event rates with combination inhalers using different doses of inhaled corticosteroids. evidence from head-to-head comparisons is needed to assess the comparative risks and benefits of the different combination inhalers.
139,"{'outcomes': ['remission of cd cdai  150 and decrease of at least 60 points <sep> median cdai decrease <sep> intention-to-treat basis remission rates <sep> active cd response rates <sep> median auc of the cdai <sep>', ""crohn's disease activity index cdai <sep> small bowel and colon disease <sep> small bowel disease <sep>"", ""severe adverse events <sep> clinical remission defined as a score of 150 or less on the crohn's disease activity index <sep> rates of remission <sep> morning plasma cortisol value <sep> efficacy and safety <sep> numbers of patients with adverse events <sep> respective rates <sep>"", ""response of active crohn's disease to sulphasalazine <sep> serum albumin esr body weight released to height abdominal mass temperature stool consistency bowel resection and extraintestinal symptoms related to crohn's disease <sep> activity index <sep>"", ""clinical improvement in crohn's disease <sep> morphologic remissions <sep> side effects <sep> mean activity index <sep> clinical improvement <sep>"", ""crohn's disease activity index <sep> activity index <sep>"", ""corresponding cdai change <sep> crohn's disease activity index cdai <sep> cdai <sep> efficacy and safety <sep> total numbers <sep>"", 'serious adverse reactions <sep> disease deterioration <sep>', 'clinical activity harvey-bradshaw index or laboratory indicators of inflammation <sep> serious adverse reactions <sep>', ""mean 17-week cdai scores <sep> crohn's disease activity index cdai <sep> achieving partial or complete remission <sep>"", ""72 cdai points <sep> change in the crohn's disease activity index cdai <sep> remission <sep>"", 'remission <sep> cdai median score value <sep>', 'disease activity <sep> faecal granulocyte excretion <sep>', 'response of active symptomatic disease <sep>', 'remission rate or withdrawal rate for active disease <sep> side effects <sep> entered remission or improved their symptoms <sep> diarrhoea <sep>'], 'punchline_text': ['on an intention-to-treat basis remission rates after 8 weeks were 40.0 in the 5-asa group and 56.3 in the 6-mpred group p  0.5867). <sep>', 'sulfasalazine alone was least effective in overall comparison of all patients p less than 0.05 and in all strata. <sep>', 'the numbers of patients with adverse events were similar in the two groups but those assigned to budesonide had fewer severe adverse events. <sep>', ""the response of active crohn's disease to sulphasalazine was significantly better than to placebo. <sep>"", ""clinical improvement in crohn's disease was seen in 87 of patients of the 5-aminosalicylic acid group and in 80 of the salazosulfapyridine group. <sep>"", ""the crohn's disease activity index decreased in the first 6 weeks to a median of 65 interquartile range 57 to 86 in patients receiving sulphasalazine and prednisone and to a median of 75 interquartile range 58 to 101 in patients receiving sulphasalazine alone p  0.13). <sep>"", 'compared with placebo the 4-g/day dose of pentasa was associated with a statistically significant overall improvement in the cdai from baseline to the final visit p  0.04). <sep>', 'in the 5-asa group 40 of the patients improved versus 30 of the placebo-treated group intent to treat basis p greater than 0.1). <sep>', 'no serious adverse reactions occurred. <sep>', 'oral mesalamine was effective in achieving partial or complete remission in 60 of patients as compared with 22 of placebo-treated patients. <sep>', 'patients with ileum-only disease showed a 93-point improvement on 4 g mesalamine compared with a 2-point improvement in similar patients on placebo. <sep>', 'patients taking mesalamine tablets experienced a decrease of cdai median score value of 113.5 95 confidence interval ci 33-149 compared with 123 95 ci 77-155 in the mesalamine microgranular group and 154 95 ci 99-197 in the 6-methylprednisolone group p  0.07 ns]). <sep>', 'after 10 days of treatment faecal granulocyte excretion fell in all patients receiving 5-asa while no consistent change was found in the placebo group. <sep>', 'for patients with quiescent disease none of the drugs was superior to placebo in prophylaxis against flare-up or recurrence. <sep>', 'there was no difference in the remission rate or withdrawal rate for active disease in the two groups. <sep>'], 'population': [""crohn's disease cd <sep> active crohn's ileocolitis <sep> patients with activer cd who are intolerant to or refuse glucocorticoids <sep> 34 patients with active cd cdai  150 were included <sep> 17 patients were in the <sep>"", ""452 patients with crohn's disease <sep> one hundred sixty patients were previously untreated 292 patients were previously treated <sep> one hundred ninety-two patients completed the 2-yr study period <sep> patients with quiescent disease <sep> patients who responded initially to treatment of active disease <sep>"", ""182 patients with scores of 200 to 400 on the crohn's disease activity index with higher scores indicating greater disease activity <sep> active crohn's disease <sep> patients with active crohn's disease affecting the ileum the ascending colon or both <sep> patients with active crohn's disease affecting the ileum the ascending colon <sep>"", ""from august 1977 to august 1979 all patients with established crohn's disease <sep> patients with active crohn's disease <sep>"", ""two groups with 30 patients each with ulcerative colitis and with crohn's disease <sep>"", 'multicenter trial in one university hospital and nine general hospitals <sep> patients with active crohn disease <sep> patients with active crohn disease and a van hees activity index of 140 or more <sep> 71 patients who were randomly assigned 60 completed treatment and were analyzed <sep>', ""adult patients treated with pentasa 4 g/day for active crohn's disease <sep> active crohn's disease <sep> mild to moderate crohn's disease <sep>"", ""crohn's disease <sep> seventeen patients were secondarily excluded and the remaining 50 patients 23 receiving <sep> sixty-seven patients were included of whom 30 were treated with 1500 mg slow-release 5-asa/day pentasa for a scheduled period of 16 weeks <sep> mild and moderately active crohn's disease localized in the small bowel <sep>"", ""active crohn's disease <sep> 40 patients with active crohn's disease <sep>"", ""38 patients for the treatment of mildly to moderately active crohn's colitis or ileocolitis <sep> 38 patients completed the 17-week study <sep> symptomatic crohn's colitis and ileocolitis <sep> patients who fail or are intolerant of <sep>"", ""310 patients <sep> active crohn's disease <sep>"", ""mild to moderate active crohn's ileitis <sep> patients taking mesalamine tablets and 22 of 28 79 <sep> patients taking microgranular mesalamine ns <sep> ninety-four patients with crohn's ileitis crohn's disease activity index cdai 180-350 <sep>"", ""crohn's disease <sep> mild and moderate active crohn's colitis <sep> twelve patients <sep>"", '569 patients in a <sep> patients with colonic involvement <sep>', ""active ulcerative colitis <sep> ninety-one patients from four centres <sep> thirty-five of 46 patients taking olsalazine and 24 of 45 patients taking <sep> patients with mild to moderate attacks of crohn's disease <sep> active crohn's disease <sep> twenty-six patients had ileal disease 43 ileocolonic and 22 colonic <sep>""], 'interventions': ['5-aminosalicylic acid and 6-methylprednisolone <sep> 5-asa <sep> 6-methylprednisolone 6-mpred <sep> 5-aminosalicylic acid 5-asa <sep>', '6-methylprednisolone and sulfasalazine <sep> sulfasalazine <sep> sulfasalazine <sep> 6-methylprednisolone 6-methylprednisolone combined with 3 g of sulfasalazine 3 g of sulfasalazine alone or placebo <sep> 6-methylprednisolone <sep> sulfasalazine and 6-methylprednisolone alone and in combination <sep>', 'glucocorticoids or mesalamine <sep> international budesonide-mesalamine <sep> controlled-ileal-release budesonide capsules and slow-release mesalamine tablets <sep> budesonide and mesalamine <sep> mesalamine <sep> budesonide <sep> budesonide once daily and 89 to receive 2 g of mesalamine <sep>', 'placebo <sep> sulphasalazine <sep>', 'additional methyl-prednisolone <sep> 5-aminosalicylic acid <sep> salazosulfapyridine <sep> oral 5-aminosalicylic acid <sep> 5-aminosalicylic acid <sep>', 'placebo <sep> prednisone <sep> sulphasalazine and prednisone <sep> sulphasalazine alone <sep> prednisone therapy <sep> sulphasalazine and a placebo <sep> sulphasalazine <sep> sulphasalazine and prednisone <sep> sulphasalazine plus prednisone <sep>', 'placebo <sep> slow-release mesalamine pentasa <sep>', 'placebo <sep> 5-asa <sep> 5-aminosalicylic acid <sep> 5-aminosalicylic acid 5-asa <sep>', 'placebo <sep> 5-amino-salicylic acid pentasa <sep> slow-release 5-amino-salicylic acid pentasa <sep>', 'oral mesalamine 5-asa <sep> placebo <sep> oral mesalamine <sep> prednisone <sep> sulfasalazine <sep> oral mesalamine asacol <sep>', 'placebo <sep> mesalamine <sep> mesalamine <sep> sulfasalazine <sep> mesalamine capsules <sep>', 'mesalamine microgranular preparation <sep> mesalamine tablets <sep> mesalamine <sep> 5-aminosalicylic acid mesalamine <sep> 6-methylprednisolone <sep>', ""pentasa or placebo <sep> placebo <sep> 5-asa <sep> slow-release 5'-aminosalicylic acid 5-asa tablet pentasa with placebo <sep> slow-release 5'-aminosalicylic acid preparation <sep>"", 'placebo <sep> prednisone <sep> prednisone sulfasalazine or azathioprine <sep> azathioprine <sep> prednisone or sulfasalazine <sep> sulfasalazine <sep>', 'olsalazine <sep> placebo <sep> placebo tablets <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",sulfasalazine has modest efficacy compared to placebo and is inferior to corticosteroids for the treatment of mild to moderately active crohn's disease. olsalazine and low dose mesalamine 1 to 2 g/day are not superior to placebo. high dose mesalamine 3 to 4.5 g/day is not more effective than placebo for inducing response or remission. high dose mesalamine was inferior to budesonide for inducing remission in a single trial. in conclusion sulfasalazine shows modest efficacy for the treatment of active crohn's disease. however the existing data show little benefit for 5-aminosalicylates.
140,"{'outcomes': ['gm antigenemia <sep> radiologic signs <sep>', 'false-positive reactions <sep> specificity <sep> positive predictive value <sep> diagnostic levels of both bg and gm <sep> sensitivity specificity and positive and negative predictive values for gm and bg <sep>', 'median index of the initial nasba <sep> kinetics of nasba values failure of negative conversion <sep> sensitivity of diagnosis <sep> galactomannan antigenemia <sep>', 'invasive aspergillosis <sep> false-positive tests <sep>', 'overall positive and negative predictive values <sep> eia and latex agglutination test <sep> aspergillus antigenemia <sep>', 'concentration of galactomannan <sep> specificity <sep> predictive positive and negative values <sep> galactomannan antigenemia preceded post-mortem histological diagnosis of invasive aspergillosis <sep> invasive aspergillosis <sep>', 'patient survival <sep> abnormal ct signs <sep> sensitivity and specificity <sep> positive and negative predictive values <sep> positive results for aga od index <sep> serologic positivity <sep>', 'consecutive serum gm titres <sep> rate of false-positive results <sep> positive gm titres <sep>', 'sensitivity <sep>', 'sensitivity and specificity rates <sep>', 'sensitivity and specificity for the elisa test <sep>', 'sensitivity specificity positive predictive value ppv and negative predictive value npv of gm detection in ct-based bal fluid <sep> sensitivity specificity ppv and npv of gm detection in ct-based bal fluid <sep>', 'diagnosis of invasive aspergillosis ia <sep> serum galactomannan gm <sep>', 'roc curve <sep> pcr and bdg tests <sep>', 'sensitivity and specificity of the gm eia <sep> during hospitalization serum galactomannan levels <sep>', 'incidence of proven ifi <sep> occurrence of invasive fungal infection ifis <sep> gm <sep> signs of ifi <sep>', 'overall specificity of the elisa <sep> elisa cutoff value <sep> sensitivity of the elisa <sep>', 'false single-positive rate <sep>', 'pcr and elisa <sep> serum elisa results <sep> fever and pulmonary infiltrates <sep>', 'serum enzyme-linked immunosorbent assay elisa test <sep> false-positive and false-negative results <sep>', 'sensitivity <sep>', 'elisa <sep>', 'positive and negative predictive values <sep> radiologic examination or aspergillus isolation <sep>', 'diagnostic levels of gm <sep> overall sensitivity specificity and positive and negative predictive values <sep>', 'minor pulmonary signs <sep> detection of serum galactomannan gm <sep> major pulmonary signs <sep>', 'sensitivity and specificity <sep> positive predictive and negative predictive values <sep>'], 'punchline_text': ['antigen was detected on at least two sequential sera in 48 of 53 patients with a sensitivity of 90.6%. <sep>', 'a combination of the two tests improved the specificity to 100 and positive predictive value to 100 of each individual test without affecting the sensitivity and negative predictive values. <sep>', 'galactomannan antigenemia index 0.5 was detected with a sensitivity of 86%. <sep>', 'increasing the cutoff value to or 0.66 yielded a sensitivity of 30 specificity of 95 and positive and negative likelihood ratios of 5.5 and 0.74. <sep>', 'after bmt the eia and latex agglutination test were positive in 19 and 4 patients respectively of 25 patients with confirmed aspergillosis and 14 and 7 of 15 patients with probable aspergillosis. <sep>', 'galactomannan antigenemia preceded post-mortem histological diagnosis of invasive aspergillosis in two patients by 17 and 81 days respectively. <sep>', 'fourteen patients showed positive results for aga od index <sep>', 'the double sandwich elisa detecting aspergillus galactomannan gm was prospectively evaluated for the diagnosis of invasive aspergillosis ia in 50 haematological patients at risk for ia. <sep>', 'a quantifiable response to antifungal therapy in clinical samples and the rabbit model supports the development of this assay for early diagnosis and therapeutic monitoring. <sep>', 'sensitivity and specificity rates for the nested-pcr assay were up to 63.6 95 confidence interval ci 30.8-89 and 63.5 95 ci 53.4-72.7 respectively and 33.3 and 98.9 95 ci 7.5-70.1 and 94.2-99.9 for gm respectively. <sep>', 'in the two patients found positive with both methods the elisa test became positive earlier than the la test or remained positive after the la test had become negative. <sep>', 'for gm detection in serially sampled serum the sensitivity was 47 the specificity 93 the ppv 73 and the npv 82%. <sep>', 'fifteen of them had positive gm titers 87 samples and 12 had positive pcrs 20 samples). <sep>', 'in a receiver-operating characteristic roc analysis the area under the roc curve was greatest for elisa using two consecutive positive results 0.97 p  0.036 for elisa versus pcr p  0.055 for elisa versus bdg). <sep>', 'the gm eia is a useful diagnostic toolfor the diagnosis and monitoring of the course ofla in the presented institute. <sep>', 'the incidence of proven ifi was 1/31 3.2 in the allogeneic stem cell transplant sct aspergillus spp 0/26 in the autologous sct and 1/60 1.6 in the induction therapy group c. krusei). <sep>', 'it was lower in children compared with adults p .0001 and in allo-hsct patients compared with non-allo-hsct adults p .0002). <sep>', 'in addition to serial screening for gm antigenemia and radiological surveillance pcr-elisa may improve the rates of early diagnosis of ia and the management of patients with hematological malignancies. <sep>', 'aspergillus species were detected by pcr or elisa with bal fluid samples from five of seven patients who had radiological evidence of ipa. <sep>', 'galactomannan elisa had fewer false-positive and false-negative results in pediatric patients than in adult patients. <sep>', 'reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis ia has been widely variable ranging from 29 to 100 in earlier clinical studies. <sep>', 'twelve of 16 patients with confirmed or suspected ia were elisa positive on two or more occasions compared with 10 of 15 who were la positive. <sep>', 'this statistical profile was better than that of other triggers including unexplained fever new pulmonary infiltrates isolation of aspergillus species and abnormalities seen on computed tomography. <sep>', 'a close relationship was found between clinical course and the kinetics of gm indices in survivors. <sep>', 'univariate and multivariate analyses revealed no significant association between detection of gm by eia and detection of abnormal pulmonary signs by ct. <sep>', 'although the elisa test did not have any role in the anticipation of the diagnosis it clarifies the diagnosis of ia in allo-hsct. <sep>'], 'population': ['neutropenic patients and stem cell transplantation recipients <sep> surveying patients who are at high risk for ia <sep> two adult and pediatric hematology units <sep> 347 children from the pediatric hematology service and 450 patients from the bone marrow transplantation unit at the hpital saint-louis in paris <sep> patients studied 53 presented with confirmed ia n  27 patients or probable ia n  26 patients <sep>', 'patients with ia <sep> 40 neutropenic adult patients at high risk for ia <sep> neutropenic adult patients <sep>', 'patients with hematologic diseases <sep> 14 patients with ia 2 patients with proven ia and 12 with probable ia <sep> neutropenic febrile patients <sep> 128 patients with hematologic diseases during periods of neutropenic fever after undergoing chemotherapy or hematopoietic stem cell transplantation <sep>', '70 consecutive lung transplant recipients <sep> lung transplant recipients <sep> 14 patients had false-positive tests including nine who had cystic fibrosis or chronic obstructive pulmonary disease <sep> patients with cystic fibrosis or chronic obstructive pulmonary disease <sep>', '25 patients with confirmed aspergillosis and 14 and 7 of 15 patients with probable aspergillosis <sep>', 'hematological patients with a high and intermediate risk for invasive aspergillosis <sep> 17 patients a possible invasive aspergillosis <sep> patients who failed to respond to the antifungal treatment <sep> 849 sera from 54 hematological patients with prolonged neutropenia which were classified according to the risk for invasive aspergillosis <sep> patients with proven invasive aspergillosis <sep> patients with proven invasive aspergillosis and 50 for patients with proven and probable invasive aspergillosis <sep> hematological patients with invasive aspergillosis <sep> all patients with proven invasive aspergillosis <sep>', 'from february 2002 to june 2004 74 hemato-oncologic patients undergoing allogeneic stem cell transplantation <sep> patients undergoing allogeneic stem cell transplantation <sep> seven patients were classified with possible ipa and two patients proven ipa <sep>', '50 haematological patients at risk for ia <sep> neutropenic patients <sep>', '986 serum samples from 67 patients <sep>', 'neutropenic patients with haematological malignancies <sep> 165 patients from six centres <sep> neutropenic cancer patients and haematological stem cell transplant recipients <sep>', 'bmt patients <sep> bone marrow transplant recipients <sep>', 'haematological patients at risk for invasive pulmonary aspergillosis <sep> of 160 patients 17 patients 10.6 presented with proven probable or suspected ipa <sep> haemato-oncological patients with neutropenia <sep>', 'fifteen of them had positive gm titers 87 samples and 12 had positive pcrs 20 samples <sep> twenty-two patients had confirmed probable or suspected ia according to clinical and mycologic data <sep> 281 serum samples collected weekly during the period at risk for ia from 41 selected hematology patients <sep> diagnosing invasive aspergillosis <sep> 19 patients without ia 83 samples one had 3 gm-false-positive samples <sep>', 'patients with hematological disorders <sep> 149 consecutive treatment episodes in 96 patients with hematological disorders who were at high risk for ia and diagnosed 9 proven ia cases 2 probable ia cases and 13 possible invasive fugal infections <sep>', '44 patients with 5 proven 12 probable and 33 possible or no ia <sep> neutropenic patients with hematological disorders in the authors institution king chulalongkorn memorial hospital kcmh bangkok thailand <sep> june 2002 to january 2004 in a consecutive series of adult neutropenic patients with hematological disorders who were at risk for developing ia <sep> neutropenic patients with hematological disorders <sep>', '98 consecutive high-risk pediatric patients <sep> pediatric patients with cancer and hematologic disorders <sep> children with high-risk for infection <sep>', 'cancer patients <sep> adult and pediatric oncohematologic patients <sep> four patient groups those with fever of unknown origin fuo during neutropenia suspected pulmonary infection pi or nonpulmonary aspergillosis npa and those undergoing surveillance s after hematopoietic stem-cell transplantation hsct <sep> a total of 3,294 serum samples were collected during 797 episodes fuo 261 pi 297 npa 28 and surveillance 211 and 153 episodes of ia were diagnosed 31 definite 67 probable and 55 possible <sep>', 'patients with hematological malignancies <sep> 201 adult patients with hematological malignancies who were included in the study 55 ia cases were diagnosed <sep>', 'patients receiving treatment for hematological malignancies <sep> 19 patients who were treated for hematological malignancies and who were suspected of having invasive pulmonary aspergillosis ipa <sep>', 'pediatric patients than in adult patients <sep> diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation <sep> in 2004 patients undergoing hsct <sep> 121 sct patients who underwent <sep> patients undergoing hsct <sep> patients undergoing hematopoietic stem cell transplantation hsct <sep>', 'patients at high risk for ia from 2 north american centers <sep> 46 patients with ia and 3005 serum samples obtained from 269 control patients <sep>', 'in total 2026 serum samples from 104 bone marrow transplant recipients <sep> 67 sera from seven patients who had died with confirmed ia 268 sera from nine patients who had died with suspected ia and 1691 sera from 88 patients with no clinical radiological or microbiological signs of ia <sep> invasive aspergillosis ia in bone marrow transplant recipients <sep> bone marrow transplant recipients <sep> twelve of 16 patients with confirmed or suspected ia <sep>', 'allogeneic stem cell transplant recipients <sep>', 'patients at risk of invasive aspergillosis ia <sep> 189 patients at risk of ia during a 1-year period at a tertiary referral center <sep> 189 patients 5 had proven ia <sep> 9 had probable ia 26 had possible ia and 149 had no ia <sep>', 'patients with hematological malignancies <sep> 107 patients 65 allogeneic hsct recipients 30 autologous hsct recipients and 66 induction and/or consolidation chemotherapy recipients <sep> 109 episodes with no ia 32 episodes with possible ia and 20 episodes with probable or proven ia were identified <sep> patients with hematological malignancies who had undergone hematopoetic stem cell transplantation hsct or had received <sep>', 'recipients of allogeneic hematopoietic stem cell transplantation <sep> from january 1999 to january 2001 all consecutive adult patients undergoing allo-hsct were prospectively studied with a <sep> 74 patients underwent an <sep> invasive aspergillosis ia <sep> 66 patients did not fulfill any criteria of ia 2 patients were classified with possible ia 5 patients were classified with probable ia and 1 patient was classified with proven ia <sep>'], 'interventions': ['galactomannan gm <sep> gm immunocapture elisa <sep>', '1->3)-beta-d-glucan chromogenic assay <sep> 3)-beta-d-glucan bg glucatell and galactomannan gm platelia aspergillus <sep>', 'nucleic acid sequence-based amplification nasba and a galactomannan enzyme immunosorbent assay gm-eia <sep> nucleic acid sequence-based amplification <sep>', 'galactomannan <sep> platelia aspergillus galactomannan antigen <sep> platelia trade mark aspergillus galactomannan antigen <sep>', 'enzyme immunoassay and latex agglutination test <sep>', 'galactomannan <sep> galactomannan detection <sep>', 'sequential aspergillus galactomannan antigen detection combined with early radiologic evaluation <sep> chest ct scans <sep> aspergillus galactomannan antigen aga test in combination with chest ct scans <sep> amphotericin b n=5 or caspofungin <sep>', 'elisa <sep> double sandwich elisa detecting aspergillus galactomannan gm <sep>', 'galactomannan antigenemia by enzyme immunoassay <sep>', 'lightcycler-mediated polymerase chain reaction assay a nested-pcr assay and a galactomannan enzyme-linked immunosorbent assay <sep> enzyme-linked immunosorbent assay elisa <sep> invasive aspergillosis ia <sep> lightcycler polymerase chain reaction pcr assay a nested-pcr assay and a galactomannan gm <sep>', 'sandwich enzyme-linked immunosorbent assay elisa platelia aspergillus test and the latex agglutination la pastorex aspergillus test <sep> enzyme immunoassay and a latex agglutination system <sep>', 'galactomannan gm detection in computerized tomography ct)-based broncho-alveolar lavage bal fluid and serum <sep> galactomannan detection <sep>', 'serum galactomannan antigen detection and competitive polymerase chain reaction <sep> competitive polymerase chain reaction pcr and sandwich elisa <sep>', 'real-time pcr double-sandwich enzyme-linked immunosorbent assay for galactomannan and a 1-->3)-beta-d-glucan test <sep> double-sandwich enzyme-linked immunosorbent assay elisa for galactomannan platelia aspergillus <sep>', 'galactomannan antigenemia <sep>', 'amphotericin <sep>', 'aspergillus galactomannan detection <sep> galactomannan elisa <sep> aspergillus galactomannan enzyme-linked immunosorbent assay elisa <sep>', 'pcr-elisa and a galactomannan gm <sep> polymerase chain reaction-elisa <sep>', 'elisa <sep> sandwich enzyme-linked immunosorbent assay elisa which detects aspergillus galactomannan gm <sep> antigen detection and pcr assay using bronchoalveolar lavage fluid <sep>', 'galactomannan elisa <sep> galactomannan elisa <sep> galactomannan testing <sep> galactomannan antigen enzyme-linked immunosorbent assay <sep>', 'galactomannan enzyme immunoassay <sep>', 'commercial aspergillus antigen enzyme linked immunosorbent assay elisa <sep>', 'galactomannan gm <sep> circulating galactomannan screening <sep>', 'platelia aspergillus enzyme immunoassay eia for galactomannan gm antigen <sep> platelia aspergillus enzyme immunoassay <sep>', 'galactomannan <sep> induction and/or consolidation chemotherapy <sep> piperacillin-tazobactam <sep>', 'galactomannan antigenemia assay elisa test <sep> aspergillus galactomannan by enzyme immunoabsorbent assay <sep> immunosuppressive therapy <sep> allo-hsct <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",at a cut-off value 0.5 odi in a population of 100 patients with a disease prevalence of 8 overall median prevalence 2 patients who have ia will be missed sensitivity 78 22 false negatives and 17 patients will be treated or further referred unnecessarily specificity of 81 19 false negatives). if we use the test at cut-off value 1.5 in the same population that will mean that 3 ia patients will be missed sensitivity 64 36 false negatives and 5 patients will be treated or referred unnecessarily specificity of 95 5 false negatives). these numbers should however be interpreted with caution because the results were very heterogeneous.
141,"{'outcomes': ['median heart rate increase oxygen saturation decrease and duration of first cry <sep> sampling duration and numbers of heel lances <sep> pain response <sep> median premature infant pain profile scores <sep> multidimensional acute pain rating scale of the premature infant pain profile heart rate increase oxygen saturation decrease crying behavior duration of first cry cry percentage in 2 minutes and during blood sampling duration of sampling and the number of performed heel lances <sep>', 'premature infant pain profile scale <sep> median pain scores <sep> douleur aigu nouveau-n scores <sep> pain relief <sep> analgesic effect <sep> median pain scores <sep> pain related behaviours evaluated with two acute pain rating scales the douleur aigu nouveau-n scale range 0 to 10 and the premature infant pain profile scale <sep>', 'analgesic effects <sep> medians for crying time and the pain scores <sep> crying times <sep> relieving pain <sep> mean pain scores <sep>', 'analgesic effect <sep> median crying times <sep> pain response <sep> median values of crying time recovery time and percentage change in heart rate <sep> crying time <sep> median recovery time <sep> heart rate <sep>', 'mean oxygen saturation levels <sep> analgesic effect of breast feeding <sep> pain response <sep> neonatal infant pain scale nips <sep> pain <sep> crying time <sep> mean heart rate <sep> heart rates oxygen saturation levels and length of crying <sep> pain reduction <sep>', 'pipp score <sep> median crying times <sep> lowest pain score <sep> crying time <sep> premature infant pain profile pipp <sep> pain and the pipp score and crying time <sep> pain score and crying time with parents assessment <sep> pain <sep> pain reduction <sep> babies pain on a visual analogue scale vas <sep> pain score <sep>', 'crying time and pain <sep> heart rate and oxygen saturation <sep> crying time <sep> behavioural responses to pain <sep> oxygen saturation and heart rate and neonatal infant pain scale <sep> pain and duration of crying <sep>', 'nociceptive reaction <sep> relative crying time and recovery time <sep> relative crying time and recovery time behavioural state <sep> pain reaction <sep>', 'duration of cry and douleur aigu du nouveau <sep> pain of heel pricks <sep> pain scores <sep> total duration of crying <sep> response to pain <sep> crying and pain scores <sep> n dan score <sep>', 'heart rate and oxygen saturation changes and behavioural responses <sep> analgesic effect of skin <sep> clinical characteristics and time spent squeezing the heel <sep> heart rate oxygen saturation changes and length of crying <sep>', 'lowest neonatal facial score <sep> neonatal facial coding system score cry duration and autonomic variables obtained from spectral analysis of heart rate variability before during and after heel-lancing <sep> parasympathetic tone <sep> highest pain manifestation <sep> lowest cry duration <sep> pain relief <sep> heart rate <sep>', 'heart rate despite pain reactivity and extreme crying <sep> heart rate <sep>', 'mean pain scores <sep> median crying time duration of the first cry percent change in heart rate maximum heart rate and neonatal facial coding system scores <sep> crying time duration of the first cry percent change in heart rate or maximum heart rate <sep> relieving pain <sep> heart rate <sep>', 'mean duration of crying <sep> physiological heart rate and oxygen saturation and behavioural parameters duration of crying and modified neonatal facial coding scores nfcs <sep> heart rate and oxygen saturation <sep> analgesic effect <sep> duration of crying <sep>'], 'punchline_text': ['median premature infant pain profile scores were lower in the breastfeeding group 3.0 than in the sucrose-solution group 8.5 and the median group difference was 5.0. <sep>', 'there were significant reductions in both scores for the breast feeding and glucose plus pacifier groups compared with the other two groups p<0.0001 two tailed mann-whitney u tests between groups). <sep>', 'the mean pain scores were 4.60 5.82 3.91 4.94 5 and 4.05 in groups 1-6 respectively p 0.068). <sep>', 'median crying times were 36 52 and 62 s in the sucrose placebo and human milk groups respectively p  0.0009). <sep>', 'during procedure the mean oxygen saturation levels of sucrose group were found significantly higher than the control group but no difference was observed between sucrose and breast feeding groups. <sep>', 'the pipp score was significantly lower in the infants receiving glucose than in those not given glucose p=0.004). <sep>', 'no differences were determined between the groups for heart rate and oxygen saturation in the newborns during painful interventions p  005). <sep>', 'relative crying time and recovery time were significantly less in the sweetener group but not in the glycine and the breast milk group. <sep>', 'at 2 and 4 minutes pain scores were lowest in the nns and rocking groups as compared to sucrose distilled water expressed breast milk and massage. <sep>', 'heart rate oxygen saturation changes and length of crying were significantly reduced in groups 1 and 2 compared with group 3 p<0.001). <sep>', 'infants who breastfed or received an oral formula showed the lowest increase in heart rate 21 and 23 beats per minute respectively vs 36 p  .01 lowest neonatal facial score 2.3 and 2.9 respectively vs 7.1 p  .001 lowest cry duration 5 and 13 seconds respectively vs 49 p  .001 and lowest decrease in parasympathetic tone 2 and 2.4 respectively vs 1.2 p  .02 compared with the other groups. <sep>', 'as has been previously reported sucrose markedly reduced both crying and grimacing and attenuated the rise in heart rate that normally accompanies blood collection p  .002). <sep>', 'statistically significant differences between the three groups were not found in terms of crying time duration of the first cry percent change in heart rate or maximum heart rate p  0.19 p  0.08 p  0.22 and p  0.91 respectively). <sep>', 'the change in heart rate and oxygen saturation was significantly lower in the ebm group and returned to baseline values sooner than in the dw group. <sep>'], 'population': ['for congenital disorders <sep> term neonates <sep> newborn infants <sep> term neonates receiving heel lance <sep> neonatal unit of a public hospital in northern italy on 101 term neonates undergoing <sep>', '180 term newborn infants undergoing <sep> term neonates <sep>', 'healthy term newborns during heel prick blood sampling <sep> during neonatal heel prick <sep> healthy newborns n 142 <sep>', 'healthy infants n  102 <sep> newborns <sep> healthy term newborns <sep>', 'infants undergoing venipuncture <sep> neonates <sep> 102 term infants requiring a venous blood sample for routine screening of phenylketonuria n=26 and hyperbilirubinemia n 76 were included in the study <sep> term neonates <sep>', 'newborns <sep> 120 full term newborns undergoing venipuncture randomly assigned to on of four groups <sep>', ""healthy newborns hospitalised in the gynaecology clinics of trabzon delivery and children's diseases hospital between february 2007-january 2008 <sep> newborns who had blood sampling by heel stick <sep> 120 newborns in turkey <sep> newborns <sep> 2010 blackwell publishing ltd <sep>"", 'eighty healthy term infants four days old with normal birth weight <sep> term newborn infants <sep> infants with fructose intolerance <sep>', '104 stable term neonates <sep> neonates <sep>', 'healthy term neonates <sep> infants had a mean sd birthweight of 3355 270 <sep> 107 neonates undergoing heel-lance <sep>', 'newborns <sep> 180 term newborn infants who were undergoing heel-lancing for routine neonatal screening of phenylketonuria and hypothyroidism <sep> newborns primarily in preterm infants <sep> pain control in newborns and 2 <sep>', 'newborn humans <sep> 60 newborn infants at boston medical center boston ma <sep> newborns undergoing routine heel-lance <sep>', 'sixty-two healthy term infants requiring a heel prick blood sample for screening tests <sep> newborns <sep> newborns undergoing minor painful procedures <sep>', '81 full-term neonates up to 4 wk of postnatal age who needed venepuncture for blood investigations <sep> term neonates <sep>'], 'interventions': ['heel lance with an automated piercing device for routine neonatal screening <sep> sucrose solution <sep> breastfeeding or oral sucrose solution <sep> breastfeeding during blood sampling or to the oral administration of 1 ml of 25 sucrose solution <sep> oral sucrose <sep>', ""oral glucose combined with a pacifier <sep> placebo <sep> venepuncture <sep> held in their mother's arms without breast feeding group 2 given 1 ml of sterile water as placebo group 3 or given 1 ml of 30 glucose followed by pacifier <sep>"", 'double versus single-dose sucrose <sep> double versus single-dose breast milk <sep> sucrose solution <sep> breast milk and sucrose <sep> single-dose breast milk group 2 single-dose sterile water group 3 single-dose 12.5 sucrose group 4 two doses breast milk group 5 two doses sterile water and group 6 two doses 12.5 sucrose before the heel prick <sep>', 'three solutions sucrose human milk sterile water 2 min prior to taking a heel prick blood sample <sep> placebo <sep> sucrose and human milk <sep> 2 ml 25 sucrose and human milk <sep>', 'peripheral venous blood collection <sep> breast feeding and sucrose solutions <sep>', 'oral glucose <sep> feeding and oral glucose--additive <sep> 1-ml placebo ii breast-fed and 1-ml 30 glucose iii fasting and 1-ml placebo and iv fasting and 1-ml <sep>', ""mother's milk sucrose pacifier and control <sep> mother's milk sucrose and pacifier <sep>"", 'glycine <sep> placebo <sep> glycine expressed breast milk or water were given 2 min before a heel prick for the guthrie test <sep> commercially available artificial sweetener 10 parts cyclamate and 1 part saccharin glycine sweet amino acid or breast milk <sep>', 'ebm dw sucrose or massage <sep> nutritive sucking nns rocking massage sucrose 20 percent distilled water dw and expressed breast milk ebm <sep>', ""skin-to-skin contact and breastfeeding <sep> breastfed with skin-to-skin contact group 1 n=35 ii being held in their mother's arms with skin-to-skin contact but no breastfeeding <sep> skin-to-skin contact <sep>"", 'heel-lancing <sep> control no pain relief intervention 2 nonnutritive sucking 3 holding by mother 4 oral glucose solution 5 oral formula feeding or 6 breastfeeding <sep>', 'colostrum delivered via syringe or on a pacifier <sep> colostrum sucrose or water by syringe or on a pacifier <sep>', '2 ml of foremilk hindmilk or sterile water <sep> placebo <sep> foremilk and hindmilk <sep>', 'placebo <sep> control group received 5 ml of distilled water dw as placebo <sep> expressed breast milk ebm <sep> expressed breast milk <sep> 40 babies received 5 ml of ebm <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",if available breastfeeding or breast milk should be used to alleviate procedural pain in neonates undergoing a single painful procedure rather than placebo positioning or no intervention. administration of glucose/sucrose had similar effectiveness as breastfeeding for reducing pain. the effectiveness of breast milk for painful procedure should be studied in the preterm population as there are currently a limited number of studies in the literature that have assessed it's effectiveness in this population.
142,"{'outcomes': ['supportive behaviors <sep>', 'measurable clinical obstetrical and neonatal advantages <sep> back and pelvic pain and headache <sep> dystocic deliveries and cesarean section <sep>', ""women's satisfaction knowledge of risk conditions and perceived mastery in their lives <sep> rates of preterm births <sep> pregnancy outcomes <sep> cesarean deliveries and stays in neonatal intensive care units <sep>"", ""women's self-assessed motivation to attempt vaginal birth <sep> probability of vaginal delivery <sep> rate of vaginal birth <sep> vaginal birth <sep> rates of vaginal birth after cesarean section <sep>""], 'punchline_text': ['findings suggest significant gains in knowledge for the experimental group at t-2 versus t-1 with regard to 1 pregnancy and prenatal care and 2 infant development and child care. <sep>', 'preparation is significantly related to reduction in dystocic deliveries and cesarean section  p(2  0.044). <sep>', 'pregnancy outcomes did not differ significantly between the groups however among patients in augmented care rates of preterm births were lower and cesarean deliveries and stays in neonatal intensive care units occurred in smaller proportions. <sep>', 'rates of vaginal birth after cesarean section were similar in the verbal and document groups verbal 339 of 641 53 document 310 of 634 49 relative risk 1.1 95 confidence interval 1.0 to 1.2. <sep>'], 'population': ['28 black 15-18-year-old adolescent males who volunteered to participate in the study <sep> unwed prospective adolescent fathers <sep> unwed expectant adolescent father <sep>', 'health of the mother and the newborn <sep> women during pregnancy as a national health policy in iran <sep> 200 primigravid women younger than age 35 years with gestational age of 20 weeks <sep>', 'multiple-risk medicaid-eligible african american women <sep> women enrolled were african american were eligible for medicaid had scored 10 or higher on a risk assessment scale were 16 years or older and had no major medical complications <sep> high-risk african american women <sep>', 'women with a single previous cesarean <sep> women with previous cesarean section a prenatal education and support program promoting vaginal birth after cesarean <sep>'], 'interventions': ['prenatal education intervention <sep> prenatal education program <sep>', 'control group received only routine care <sep>', 'augmented prenatal care <sep> usual care <sep>', 'prenatal vaginal birth after cesarean section education and support program <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",the effects of general antenatal education for childbirth or parenthood or both remain largely unknown. individualized prenatal education directed toward avoidance of a repeat caesarean birth does not increase the rate of vaginal birth after caesarean section. note the 58 citations in the awaiting classification section may alter the conclusions of the review once assessed.
143,"{'outcomes': ['oral comfort agents such as artificial saliva hard candy and water <sep> serious drug-related adverse experiences <sep> sweating rhinitis headache nausea and urinary frequency <sep> parotid salivary flow <sep> overall global assessments <sep> side effects <sep> symptomatic relief by questionnaires and visual analog scales vas and for saliva production by sialometry <sep>', 'production of saliva and other manifestations of xerostomia <sep> comfort of the mouth and tongue <sep> saliva production and relieved symptoms of xerostomia <sep> oral dryness <sep> speaking ability <sep> saliva production <sep> symptomatic relief <sep> safety and efficacy <sep>'], 'punchline_text': ['it is concluded that pilocarpine produces clinically significant benefits for the symptomatic treatment of postradiation xerostomia. <sep>', 'pilocarpine improved saliva production and relieved symptoms of xerostomia after irradiation for cancer of the head and neck with minor side effects that were predominantly limited to sweating. <sep>'], 'population': ['head and neck cancer patients <sep> patients with head and neck cancer <sep> one hundred sixty-two head and neck cancer patients who had received at least 40 gy of radiation 117 patients had received  60 gy with clinically significant xerostomia <sep>', 'patients with head and neck cancer <sep> 207 patients who had each received  or  4000 cgy of radiation to the head and neck <sep>'], 'interventions': ['placebo <sep> pilocarpine or placebo <sep> pilocarpine <sep> pilocarpine hydrochloride <sep> pilocarpine <sep>', 'placebo <sep> pilocarpine <sep> oral pilocarpine <sep> pilocarpine hydrochloride <sep> pilocarpine <sep> placebo or pilocarpine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>']}",there is limited evidence to support the use of pilocarpine hydrochloride in the treatment of radiation-induced salivary gland dysfunction. currently there is little evidence to support the use of other parasympathomimetic drugs in the treatment of this condition. available studies suggest approximately half of patients will respond but side effects to responders can be problematic. adverse effects are dose dependant therefore it is important to keep dose to 5 mg tds.
144,"{'outcomes': ['composite of death from all vascular causes non-fatal stroke non-fatal myocardial infarction or major bleeding complication whichever occurred first <sep> mean achieved inr <sep> hr for ischaemic events <sep> major bleeding complications <sep>', 'cerebral infarctions <sep> number of patients with tia/rind <sep> myocardial infarctions <sep> cerebral hemorrhage <sep>', 'bleeding incidence <sep> composite event death from all vascular causes nonfatal stroke nonfatal myocardial infarction or nonfatal major bleeding complication <sep> efficacy and safety <sep>', 'severe stenosis or occlusion of a large artery <sep> recurrent ischemic stroke or death or in the rate of major hemorrhage <sep> rates of major hemorrhage <sep> recurrent ischemic stroke <sep> death or recurrent ischemic stroke <sep> frequency of or time to the primary end point or major hemorrhage <sep>', 'death <sep> myocardial infarction or sudden death <sep> adverse events <sep> major hemorrhage <sep> rate of death from vascular causes <sep> rate of death from nonvascular causes <sep> ischemic stroke brain hemorrhage or death from vascular causes other than stroke <sep>', 'incidences of tia and tia-ir <sep> recurrent cerebral ischemic events <sep> severe hemorrhage <sep> cerebral infarction <sep> gastrointestinal disorders <sep> recurrent cerebral ischemic events <sep>'], 'punchline_text': ['the hr for ischaemic events was 0.73 0.52-1.01 and for major bleeding complications 2.56 1.48-4.43). <sep>', 'compared to the natural history of untreated tia/rind both treatments were found to have a prophylactic effect against cerebral infarction. <sep>', 'the bleeding incidence increased by a factor of 1.43 95 ci 0.96-2.13 for each 0.5 unit increase of the achieved inr. <sep>', 'in the intention-to-treat analysis no significant differences were found between the treatment groups in any of the outcomes measured. <sep>', 'the primary end point occurred in 22.1 percent of the patients in the aspirin group and 21.8 percent of those in the warfarin group hazard ratio 1.04 95 percent confidence interval 0.73 to 1.48 p=0.83). <sep>', 'cerebral infarction was recorded in 4 patients in each of these treatment groups during a mean follow-up period of 20 months. <sep>'], 'population': ['patients with transient ischaemic attack or minor stroke of presumed arterial origin <sep> after cerebral ischaemia of arterial origin esprit <sep>', 'against cerebral infarction in a prospective multicenter study from 5 hospitals in southern sweden <sep> 156 patients with transient ischemic attacks tia or reversible ischemic neurological deficit rind <sep> 135 patients <sep>', 'patients with cerebral ischemia of presumed arterial noncardiac <sep> 1,316 patients participated their mean follow-up was 14 months <sep> patients referred to a neurologist in one of 58 collaborating centers because of a transient ischemic attack or minor ischemic stroke rankin grade  or 3 were eligible <sep>', 'patients who have had an ischemic stroke <sep> patients with a prior noncardioembolic ischemic stroke <sep>', 'patients with intracranial arterial stenosis <sep> patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive <sep> 569 patients had undergone randomization enrollment was stopped because of concerns about the safety of the patients who had been assigned to receive <sep> symptomatic intracranial arterial stenosis <sep>', '241 patients with symptoms of carotid transient attacks of ischemia some of whom recovered completely within 24 hours tia while the others had slight residual symptoms tia-ir <sep>'], 'interventions': ['oral anticoagulants <sep> medium intensity oral anticoagulants versus aspirin <sep> transient ischaemic attack or minor stroke of presumed arterial origin either anticoagulants target inr range 2.0-3.0 n=536 or aspirin <sep> aspirin <sep> aspirin and dipyridamole <sep>', 'anticoagulant vs anti-platelet therapy <sep> ac treatment and one changed to anti-platelet therapy <sep> prophylactic anticoagulant ac treatment <sep>', 'anticoagulant therapy <sep> anticoagulants versus aspirin <sep> anticoagulant therapy versus 6 on aspirin <sep> aspirin <sep> aspirin <sep>', 'warfarin and aspirin <sep> warfarin <sep> aspirin and warfarin <sep> aspirin <sep>', 'aspirin <sep> warfarin and aspirin <sep> warfarin <sep> warfarin <sep> aspirin <sep> warfarin target international normalized ratio 2.0 to 3.0 or aspirin <sep>', 'anticoagulant ac or acetylsalicylic acid asa <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",for the secondary prevention of recurrent ischemic stroke after tia or minor stroke of presumed arterial origin there is sufficient evidence to conclude that vitamin k antagonists in any dose are not more efficacious than antiplatelet therapy and that medium and high intensity anticoagulation leads to a significant increase in major bleeding complications.
145,"{'outcomes': ['adolescents mothering behaviors <sep> actual maternal behaviors <sep> maternal behavior scores <sep>', 'favorable attitudes toward feeding and communication <sep>'], 'punchline_text': ['the effects of videotape instruction and feedback videotherapy on mothering behaviors were evaluated in this longitudinal study. <sep>', 'brief culturally sensitive videotapes may be effective strategies to promote parenting skills and to prevent social and health problems among adolescents. <sep>'], 'population': ['31 adolescents and their healthy infants <sep> adolescents receiving <sep> experimental group subjects reviewed the videotaped 1-month teaching episode and received feedback from a specially trained professional nurse who emphasized positive aspects of maternal behavior <sep>', 'adolescents <sep> six african-american adolescent mothers who were filmed feeding their infants in their homes <sep> adolescent mothers and their infants through videotape <sep> high schools wic women infants and children clinics and family support centers serving low-income families <sep> african-american adolescent mothers <sep> fifty-nine first-time african-american adolescent mothers of infants <sep>'], 'interventions': ['videotape instruction <sep> videotape instruction and feedback <sep> videotape instruction and feedback videotherapy <sep>', 'culturally sensitive videotape <sep> videotape titled feeding your baby with love <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>']}",variation in the measures used the included populations and interventions and the risk of bias within the included studies limit the conclusions that can be reached. the findings provide some evidence to suggest that parenting programmes may be effective in improving a number of aspects of parent-child interaction both in the short and long-term but further research is now needed.
146,"{'outcomes': ['prevalence of central obesity <sep> progression to diabetes <sep> weight waist circumference high-sensitivity c-reactive protein and most of the metabolic syndrome components <sep> hypertriglyceridemia <sep> incidence of diabetes <sep> multiple metabolic/inflammatory abnormalities <sep> total/saturated fat intake and increased polyunsaturated fat/fiber intake and exercise level <sep> metabolic syndrome <sep> metabolic abnormalities <sep>', 'incidence of diabetes <sep>', 'risk of developing diabetes and weight loss <sep> gradual deterioration of behavioral and physiological changes <sep> weight loss <sep> weight losses <sep> behavior weight or physiological parameters <sep> modest weight loss <sep> risk of type 2 diabetes <sep> weight coronary heart disease chd risk factors and incidence of diabetes <sep> glucose tolerance <sep> measures of eating exercise and fitness weight losses <sep>', 'cumulative 4-year incidence of diabetes <sep> plasma glucose values and higher bmi values <sep> body weight <sep> consecutive fasting plasma glucose fpg values <sep> body weight <sep> incidence of diabetes <sep> risk of diabetes <sep> glucose tolerance <sep>', 'cumulative incidence of diabetes <sep> baseline bmi and fasting glucose the diet exercise and diet-plus-exercise interventions <sep> rate of development of diabetes <sep> incidence of diabetes <sep>', 'total fat consumption <sep> short insulin tolerance test itt <sep> obesity and whole body insulin sensitivity <sep> changes from baseline in nutrient intake physical activity anthropometry glucose tolerance and insulin sensitivity <sep> body mass <sep>', 'net loss <sep> cumulative incidence of diabetes <sep> mean sd amount of weight lost <sep> incidence of diabetes <sep> risk of diabetes <sep>', '3-year cumulative incidences of diabetes <sep> type 2 diabetes as diagnosed using world health organization criteria <sep> relative risk reduction <sep>'], 'punchline_text': ['lifestyle intervention significantly reduced metabolic syndrome odds ratio or  0.28 95 ci 0.18-0.44 with a 31 21-41 absolute risk reduction corresponding to 3.2 2-5 patients needing to be treated to prevent 1 case after 12 months. <sep>', 'the lifestyle intervention reduced the incidence by 58 percent 95 percent confidence interval 48 to 66 percent and metformin by 31 percent 95 percent confidence interval 17 to 43 percent as compared with placebo the lifestyle intervention was significantly more effective than metformin. <sep>', 'at 6 months the groups differed significantly on measures of eating exercise and fitness weight losses in the diet and diet-plus-exercise groups were significantly greater than in the exercise and control conditions. <sep>', 'body weight decreased by 0.39 kg in the control group and by 2.18 kg in the intervention group p  0.001). <sep>', 'when analyzed by clinic each of the active intervention groups differed significantly from the control clinics p  0.05). <sep>', 'whole body insulin sensitivity assessed by the short insulin tolerance test itt improved after 12 months in the intervention group 0.52 95 ci 0.15-0.89%/min). <sep>', 'during the trial the risk of diabetes was reduced by 58 percent p<0.001 in the intervention group. <sep>', 'the relative risk reduction was 28.5 with lsm 95 ci 20.5-37.3 p=0.018 26.4 with met 95 ci 19.1-35.1 p=0.029 and 28.2 with lsm  met 95 ci 20.3-37.0 p=0.022 as compared with the control group. <sep>'], 'population': ['three hundred and thirty-five patients participated from a dysmetabolic population-based cohort of 375 adults aged 45-64 years in northwestern italy <sep>', '6.9 persons would have to participate in the lifestyle-intervention program and 13.9 would have to receive <sep> the mean age of the participants was 51 years and the mean body-mass index the weight in kilograms divided by the square of the height in meters was 34.0 68 percent were women and 45 percent were members of minority groups <sep> persons at high risk <sep> 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to <sep>', 'overweight individuals with a family history of diabetes <sep> overweight individuals with a parental history of diabetes <sep> participants n  154 who were 30-100 over ideal body weight had one or both parents with diabetes and were currently nondiabetic <sep>', 'subjects with impaired glucose tolerance igt <sep> igt males <sep> male subjects with igt recruited from health-screening examinees <sep>', 'people with impaired glucose tolerance <sep> individuals with impaired glucose tolerance igt <sep> 110,660 men and women from 33 health care clinics in the city of da qing china were screened for igt and niddm <sep>', 'people with impaired glucose tolerance <sep> people with impaired glucose tolerance igt <sep> participants with igt n=78 diagnosed on two consecutive oral glucose tolerance tests ogtts <sep>', '522 middle-aged overweight subjects 172 men and 350 women mean age 55 years mean body-mass index weight in kilograms divided by the square of the height in meters 31 with impaired glucose tolerance to either the intervention group or the control group <sep> subjects with impaired glucose tolerance <sep>', 'native asian indians with igt who were younger leaner and more insulin resistant than the above populations <sep> asian indian subjects with impaired glucose tolerance idpp-1 <sep> multiethnic american finnish and chinese populations <sep> 531 421 men 110 women subjects with igt mean age 45.9+/-5.7 years bmi 25.8+/-3.5 kg/m(2 into four groups <sep>'], 'interventions': ['lifestyle intervention <sep> lifestyle intervention <sep> intensive lifestyle intervention <sep> general recommendation-based program of lifestyle intervention carried out by trained professionals versus standard unstructured information given by family physicians <sep>', 'metformin <sep> placebo metformin 850 mg twice daily or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week <sep> placebo <sep> placebo metformin <sep>', 'diet decreasing calories and fat intake exercise goal of 1,500 kcal/week of moderate activity or the combination of diet plus exercise or to a no-treatment control group <sep> lifestyle intervention <sep> lifestyle intervention <sep>', 'standard intervention group control group and intensive intervention group intervention group <sep> lifestyle intervention <sep> intensive lifestyle intervention <sep>', 'diet and/or exercise interventions <sep> diet only exercise only or diet plus exercise <sep> diet and exercise interventions <sep> diet and exercise <sep>', 'lifestyle interventions <sep> 2-year lifestyle intervention or to a control group <sep>', 'individualized counseling aimed at reducing weight total intake of fat and intake of saturated fat and increasing intake of fiber and physical activity <sep>', 'metformin <sep> advice on lifestyle modification lsm group 3 was treated with metformin met and group 4 was given lsm plus met <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>']}",interventions aimed at increasing exercise combined with diet are able to decrease the incidence of type 2 diabetes mellitus in high risk groups people with impaired glucose tolerance or the metabolic syndrome). there is a need for studies exploring exercise only interventions and studies exploring the effect of exercise and diet on quality of life morbidity and mortality with special focus on cardiovascular outcomes.
147,"{'outcomes': ['total effective rate <sep> recovery time <sep>', 'vertigo nausea and headache with spontaneous recovery <sep> hearing loss <sep> side effects <sep> rate of side effects <sep> mean hearing loss <sep>', 'pure-tone average and subjective symptoms <sep>'], 'punchline_text': ['the total effective rate was 76.92 in the carbogen group and 50.00 in the control group. <sep>', 'a significant benefit of naftidrofuryl on hearing loss was also found at frequencies between 0.5 and 3 khz. <sep>', 'no significant differences were observed in the improvements of pure-tone average and subjective symptoms between the pge1 and the placebo groups. <sep>'], 'population': ['sudden deafness <sep> fifty-two patients with sudden deafness <sep>', 'sudden deafness <sep> eighty patients with idiopathic sudden deafness existing no longer than 10 days <sep>', 'idiopathic sudden sensorineural hearing loss <sep> 57 consecutive patients with diagnoses of idiopathic sudden sensorineural hearing loss <sep>'], 'interventions': ['dexamethasone vitaminb low molecular dextran salviae miltiorrhizae and intake vitaminc vitamine et al and the other 26 cases received the drugs only <sep>', '10 low-molecular weight dextran or the combination of low-molecular weight dextran with naftidrofuryl <sep> naftidrofuryl <sep> dextran <sep> low molecular weight dextran  naftidrofuryl vs. low molecular weight dextran  placebo <sep>', 'placebo <sep> prostaglandin e1 pge1 <sep> pge1 <sep> continuous infusion containing 60 microg pge1 and 100 mg hydrocortisone <sep> prostaglandin e1 <sep> continuous infusion containing an inactive placebo and 100 mg hydrocortisone <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",the effectiveness of vasodilators in the treatment of isshl remains unproven. the included studies were of relatively poor quality and the number of patients included was small. moreover there were differences in the type dosage and duration of vasodilator used in each study. due to the degree of heterogeneity the results could not be combined to reach a conclusion.
148,"{'outcomes': ['mean pain intensity score <sep> western ontario and mcmaster universities osteoarthritis index questionnaire <sep> average daily pain intensity and average daily pain relief scores <sep> physical function <sep> tolerated and effective <sep> mean  sd pain visual analog score <sep> osteoarthritis flare pain <sep> serious adverse events <sep> nausea vomiting and dizziness <sep> average daily pain intensity and pain relief scores <sep> oa flare pain <sep>', 'efficacy and safety <sep> effective and safe <sep> mean final pain relief rating scores <sep> nausea <sep> constipation <sep> final vas score secondary measures included final pain relief rating scores subject/investigator overall medication assessments rate and time to discontinuation due to lack of efficacy and selected quality-of-life/physical functioning scores <sep> somnolence <sep> mean final vas scores for tramadol/apap plus cox-2 nsaid <sep> efficacy and safety <sep> womac physical function and the medical outcome study short form-36 role-physical measures <sep>', 'efficacy and safety <sep> pain stiffness physical function global status and sleep <sep> arthritis pain intensity vas <sep> arthritis pain intensity visual analogue scale vas western ontario and mcmaster universities arthritis scale womac pain stiffness physical function vas subscales patient and physician global assessment of therapy sleep dropouts due to insufficient therapeutic effect and adverse events <sep> womac pain stiffness and physical function subscales the womac composite scale dropouts due to insufficient therapeutic effect patient and physician global assessment of therapy and sleep <sep> efficacy and safety <sep>', 'adverse event-related withdrawals <sep> pain and functional capability <sep> analgesic effectiveness <sep> adverse events <sep> functional parameters <sep> pain relief <sep> median pain intensity <sep> pain relief and functional improvement in osteoarthritis <sep> multidimensional western ontario and mcmaster universities osteoarthritis index womac questionnaire pain stiffness and functional impairment <sep>', 'rates of response <sep> global tolerability <sep> efficacy and safety demographic data <sep> pain <sep> efficacy of tramadol lp <sep> adverse event <sep> efficacy and tolerability <sep> global efficacy <sep> alleviating pain <sep> lequesne functional discomfort index global efficacy assessed by the patient and the investigator time to improvement and use of acetaminophen as rescue analgesic medication <sep> huskisson visual analog scale for pain <sep> efficacy and tolerability <sep> pain reduction <sep>', 'intestinal function <sep> bowel functions and symptoms <sep> antinociceptive action <sep> pain at rest <sep> electrical sensation and pain thresholds <sep> orocaecal transit time <sep> pain intensities <sep> sensation and pain thresholds <sep> rapid pain relief <sep> antinociceptive effects <sep> colonic transit times <sep>', 'intensity of joint pain <sep> plasma and synovial fluid concentrations of tramadol and its active metabolite o-desmethyl-tramadol m1 <sep> synovial fluid concentrations of interleukin il)-6 and substance p sp <sep> synovial fluid concentrations of sp and il-6 <sep> plasma and synovial fluid the concentrations of m1 <sep> synovial fluid concentrations of sp <sep> synovial fluid concentrations <sep> il-6 synovial fluid concentrations <sep>', 'minimum effective naproxen dose mend <sep> mend <sep> pain scores <sep> pain relief <sep>'], 'punchline_text': ['average daily pain intensity and pain relief scores were significantly improved with tramadol/acetaminophen compared with placebo on the primary assessment of efficacy from days 1 through 5 both p  0.001 and on the assessment of efficacy from days <sep>', 'mean final vas scores for tramadol/apap plus cox-2 nsaid were significantly lower than placebo plus cox-2 nsaid 41.5 vs 48.3 p  0.025 and mean final pain relief rating scores were significantly higher p  0.002). <sep>', 'treatment with tramadol er results in statistically significant and clinically important and sustained improvements in pain stiffness physical function global status and sleep in patients with chronic pain. <sep>', 'more patients reported adverse events with tramadol than with diclofenac 20 vs 3 p  0.0056 but there was no difference in adverse event-related withdrawals p  0.69). <sep>', 'pain was significantly reduced in the tramadol lp group compared with the placebo group on day 7 p  0.002 and day 14 p  0.010). <sep>', 'pain intensities at rest and during movement decreased highly significantly with tramadol and dihydrocodeine from median pre-treatment verbal ratings of over 3 0=none 4=unbearable to 1 and below from the second treatment day onwards anova p<0.0001). <sep>', 'both in plasma and synovial fluid the concentrations of m1 were markedly lower than those of tramadol with a t/m1 ratio of 14.7+/-4.6 and 9.3+/-3.9 respectively. <sep>', 'there was a significant difference p  0.040 in the treatment effect between the naproxen responders and nonresponders thus demonstrating a difference in the way responders and nonresponders react to a decrease in naproxen dosage after the addition of tramadol. <sep>'], 'population': ['9.87 years and were predominantly female 71.8 and white 87.7 <sep> patients had a mean sd age of 60.1 <sep> patients achieving inadequate pain relief from traditional non-steroidal anti-inflammatory drugs nsaids or <sep> three hundred eight patients <sep>', 'subjects receiving a cox-2 nonsteroidal antiinflammatory drug <sep> 307 subjects randomized 306 taking <sep> 43.5 were included in the intent-to-treat population n  153 <sep> subjects with osteoarthritis oa pain inadequately controlled by cox-2 nonsteroidal antiinflammatory drugs nsaid <sep> controlled trial enrolled subjects with symptomatic oa for  1 year who experienced at least moderate pain visual analog scale vas score <sep>', 'patients with chronic pain <sep> chronic pain <sep> eligible patients with radiographically confirmed oa of the knee meeting the american college of rheumatology diagnostic criteria defined by knee pain and presence of osteophytes plus at least age 50 years morning stiffness 30 minutes in duration and/or crepitus entered a 2-7 day washout period during which all analgesics were discontinued <sep> two hundred forty-six patients were <sep> the mean age was 61 years mean duration of oa 12.9 years and the mean <sep> patients with moderate to severe chronic pain of osteoarthritis oa <sep>', '54 patients completed both study periods <sep> patients with oa <sep> oa patients <sep> 60 patients with oa of the hip 19 patients or knee 41 patients without clinical joint inflammation <sep> individual patients with painful osteoarthritis oa <sep>', 'two hundred thirty patients 167 women 63 men <sep> mean sd age 67.1 7.1 and 66.4 92 years respectively female sex 72.1 and 73.1 and mean body weight 74.7 13.6 and 74.6 14.8 kg <sep> patients with osteoarthritis who have not responded to first-line treatment with <sep> symptomatic osteoarthritis of the hip or knee <sep> patients with osteoarthritis of the hip or knee <sep> patients with osteoarthritis of the hip or knee european league against rheumatism criteria <sep> 197 patients 85 <sep>', ""thirty patients with pain controlled by nsaid's alone formed the comparator group <sep> 60 osteoarthritis patients with strong pain despite nsaid's <sep> severe pain from osteoarthritis with slow-release <sep>"", 'patients with knee osteoarthritis <sep> twenty patients were enrolled <sep> patients with knee oa <sep>', 'patients with naproxen-responsive osteoarthritis pain <sep> patients with painful oa of the knee responding to <sep> 236 patients randomized mean age 61 years 147 females 90 were stratified as naproxen responders and 146 as naproxen nonresponders <sep> patients with at least moderate pain  or 40 mm on a 100-mm visual analog scale of oa of the knee after a 1-week medication washout were treated with <sep>'], 'interventions': ['tramadol/acetaminophen combination tablets <sep> placebo <sep> tramadouacetaminophen <sep> cyclooxygenase cox)-2-selective inhibitors <sep> tramadol/acetaminophen <sep> cox-2-selective inhibitor therapy <sep> tramadol/acetaminophen <sep>', 'rofecoxib <sep> placebo <sep> mean tramadol/apap <sep> acetaminophen 325 mg combination tablets tramadol/apap <sep> celecoxib <sep> tramadol/apap 153 placebo <sep> tramadol/acetaminophen tablets ultracet <sep> tramadol/apap <sep> tramadol/apap or matching placebo <sep> tramadol 37.5 mg/apap <sep> tramadol <sep>', 'placebo <sep> tramadol er <sep> tramadol er <sep> randomized tramadol er 124 placebo <sep> tramadol er or placebo <sep> extended-release once-daily tramadol <sep> tramadol hydrochloride tramadol er <sep> tramadol <sep>', 'diclofenac <sep> diclofenac or tramadol <sep> steroidal anti-inflammatory drug nsaid diclofenac <sep> tramadol <sep>', 'placebo <sep> tramadol lp 200 mg once daily or placebo <sep> tramadol 112 placebo <sep> acetaminophen <sep> sustained-release tramadol <sep> opioid analgesics <sep> tramadol lp <sep> tramadol and placebo <sep>', 'tramadol and dihydrocodeine <sep> tramadol 100 mg bid and dihydrocodeine <sep> tramadol <sep> dihydrocodeine <sep> tramadol or dihydrocodeine <sep> opioid analgesics tramadol and dihydrocodeine <sep> tramadol <sep>', 'paracetamol <sep> paracetamol <sep> tramadol <sep>', 'tramadol <sep> placebo <sep> naproxen <sep> tramadol <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",tramadol or tramadol/paracetamol decreases pain intensity produces symptom relief and improves function but these benefits are small. adverse events although reversible and not life threatening often cause participants to stop taking the medication and could limit tramadol or tramadol plus paracetamol usefulness.
149,"{'outcomes': ['adverse events <sep> elevated circulating lymphocyte levels <sep> rescue medication <sep> cdai <sep> change in cdai <sep> circulating b and t lymphocytes <sep> safety and efficacy <sep>', ""remission rates <sep> quality of life and c-reactive protein levels <sep> rate of clinical remission <sep> highest remission rate <sep> rates of adverse events <sep> quality of life <sep> response rates <sep> highest response rate <sep> health-related quality of life and c-reactive protein levels <sep> rates of clinical remission and response <sep> changes in scores for the crohn's disease activity index <sep>"", ""crohn's disease activity index cdai score <sep> response and remission rates <sep> rates of response <sep> rates of sustained response and remission if natalizumab <sep> sustained response through week 36 <sep> remission <sep> higher rates of sustained response <sep> disease remission a cdai score of less than 150 <sep> serious adverse events <sep>""], 'punchline_text': ['the frequency of commonly reported adverse events did not differ significantly between groups. <sep>', 'the quality of life improved in all natalizumab groups c-reactive protein levels improved in groups receiving two infusions of natalizumab. <sep>', 'natalizumab a humanized monoclonal antibody against alpha4 integrin inhibits leukocyte adhesion and migration into inflamed tissue. <sep>'], 'population': [""active crohn's disease <sep> patients with mild to moderately active crohn's disease <sep> crohn's disease patients <sep> thirty patients with active crohn's disease crohn's disease activity index cdai  or 151 and  or 450 <sep>"", ""massachusetts medical society <sep> 248 patients with moderate-to-severe crohn's disease <sep> patients with active crohn's disease <sep>"", ""crohn's disease <sep> 905 patients <sep> patients with active crohn's disease <sep> 339 patients who had a response to natalizumab in the first trial <sep>""], 'interventions': ['humanized monoclonal antibody to alpha4 integrin <sep> placebo <sep> natalizumab <sep> 3-mg/kg infusion of natalizumab <sep> natalizumab infusion <sep> natalizumab therapy <sep>', 'placebo <sep> natalizumab <sep> alpha4 integrin-specific humanized monoclonal antibody natalizumab <sep> placebo one infusion of 3 mg of natalizumab per kilogram of body weight followed by placebo two infusions of 3 mg of natalizumab per kilogram or two infusions of 6 mg of natalizumab per kilogram <sep> natalizumab <sep>', 'placebo <sep> natalizumab induction and maintenance therapy <sep> natalizumab <sep> natalizumab and placebo <sep> natalizumab or placebo <sep> natalizumab <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",pooled data suggest that natalizumab is effective for induction of clinical response and remission in some patients with moderately to severely active crohn's disease. the clinical benefit of induction therapy with natalizumab in crohn's disease should be weighed against the potential risk of serious adverse events. preliminary data from the retrospective investigation of adverse events associated with natalizumab suggest that it may be possible to identify patients at risk for pml by testing for the appearance of jc virus in plasma.
150,"{'outcomes': ['qol <sep> peak flow <sep> body weight and bcm <sep> muscle function and quality of life <sep> age body cell mass bcm muscle function gender distribution and qol <sep> readmissions <sep> functional status qol and rehospitalization <sep> hand-grip strength <sep> body composition muscle function and quality of life qol <sep> subjective global assessment body composition by bioelectrical impedance and anthropometry muscle function with hand-grip strength and peak flow <sep>', 'lower extremity muscle strength <sep> physical performance such as muscle strength balance mobility and activities of daily living as well as nutritional aspects such as energy intake body weight and fat-free mass <sep>', 'nutritional intake and gain in lean body mass lbm <sep> enhanced gain of lbm <sep> nutritional intake <sep> protein intake <sep> intake of protein <sep> regain of lean body mass <sep>', 'leucine oxidation protein catabolism <sep> whole body leucine kinetics and leucine oxidation rate <sep> fat mass <sep> whole body protein metabolism <sep> body composition increased lean mass decreased fat mass <sep> total body weight <sep> weight loss and protein malnutrition <sep> lean body mass determined by bioelectrical impedance analysis <sep> lymphocyte cd4 counts on plasma tnfr 55 tnfr 75 and ilr 2 concentrations and on quality of life <sep>', 'weight loss <sep> total energy intake <sep> fat free mass <sep> body cell mass and weight gain <sep> total energy intake <sep>', 'equal weight loss <sep> total protein and total calorie intake <sep> survival advantage <sep>', 'subjective global assessment <sep> energy intake <sep> nutritional status subjective global assessment and energy and protein intake 3-day food record <sep> progressive loss of kidney function <sep> body composition and dietary intake <sep> body composition body cell mass <sep> energy and protein intake <sep> protein intake <sep> body cell mass <sep>', 'total daily protein and caloric intake food-derived protein and caloric intake and supplement-derived protein and caloric intake <sep> total caloric and protein intake <sep>', 'protein malnutrition assessed by midarm muscle circumference creatinine-height index and serum albumin <sep>', 'energy intake and nutritional status <sep> energy intake or percent ideal body weight <sep> nutritional status <sep>', 'bone metabolism <sep> serum ctx a marker of bone resorption <sep> bone-specific alkaline phosphatase <sep> serum osteocalcin <sep> bone resorption <sep> bmd at the lumbar spine and total hip <sep> weight b mean sd  change in bmd lumbar spine <sep> weight <sep> biochemical markers of bone turnover <sep> bmd at the spine femoral neck and total hip <sep> body composition and bone mineral density bmd <sep> serum osteoprotegerin opg <sep>', 'complications namely wound infection chest infection and antibiotic use <sep> nutritional status morbidity and quality of life <sep> nutritional status <sep> nutritional status qol and morbidity <sep> weight loss <sep> antibiotic prescriptions <sep> maximum mean sd <sep> quality of life qol <sep> weight anthropometry and grip strength <sep> metabolic rate <sep> anthropometry grip strength and qol <sep> weight overall <sep>', 'mean daily energy intake <sep> initial nutritional status <sep> nutritional behaviour and quality of life <sep> factors malaise psychological distress therapy side-effects <sep> nutritional behaviour <sep>', 'serum albumin level and functional scoring <sep> serum albumin level <sep> main outcome measures 1 nutritional status parameters bmi and serum albumin 2 functional status on a 10-point karnofsky scale 3 adverse metabolic effects hyperphosphatemia at start and end of study and 4 subjective scoring for appetite and acceptability of and tolerance to supplement <sep> acceptability and palatability of the hp blend formula ease of use and cost <sep> dry weight and bmi <sep> baseline food intake <sep> mild hyperphosphatemia <sep>', 'response rates median time to progression or overall duration of survival <sep> weight loss serum albumin concentration and presence of liver metastases <sep> tumor response rate <sep> weight loss <sep> caloric intake <sep> median time to progression and overall duration of survival <sep> for colorectal cancer serum albumin alkaline phosphatase lactic dehydrogenase ldh levels and percent targeted caloric intake tci <sep> tumor response rates <sep>', 'bmi <sep> triceps skinfold thickness dietary intake fecal fat and pain score <sep>', 'intake <sep>', ""crohn's disease activity index <sep> incidence of disease remission <sep>"", 'functional status <sep> number of falls <sep> weight gain <sep> changes in handgrip strength general well-being score perception of health and number of falls <sep>', 'involuntary weight loss <sep> qol ratings <sep> weight and qol <sep> shorter time of survival <sep> weight loss <sep> quality of life qol <sep> rapid weight gain <sep> body weight development <sep> dietary intake 24-h recalls body weight and qol eortc-qlq c-30 <sep> energy intake and weight <sep>', 'serum igf-i levels <sep> qol <sep> weight loss and improved adl functions <sep> e.g. insulin-like growth factor <sep> katz adl index <sep> body weight biochemical indices <sep> katz activities of daily living adl index mini mental status examination mmse and quality of life qol <sep> weight maintenance <sep>', 'karnofsky performance status scale <sep> weight and arm muscle circumference <sep> severe loss <sep>', 'weight skinfold thickness measurements or quality of life <sep> energy intake <sep> weight skinfold thickness fat-free mass grip strength quality of life and cognitive function buschke test <sep> fat-free mass and grip strength <sep>', 'food intake <sep> food intake body weight response rate survival and quality of life <sep> daily energy intake <sep> body weight but triceps skinfold measurement <sep> oral intake body weight response rate survival and quality of life <sep> quality of life <sep> quality-of-life index ql-index <sep> response rate and overall survival <sep>', 'skin fold thickness <sep> change of ventilatory parameters <sep> weight gain <sep>', 'efficacy and cost-effectiveness <sep> nutritional repletion <sep> sa levels <sep>', ""medical research council dyspnoea score <sep> weight gain <sep> st george's respiratory questionnaire total score <sep> respiratory function or skeletal and respiratory muscle strength <sep> short form-36 health change score <sep> nutritional status respiratory and skeletal muscle strength respiratory function perceived dyspnoea activities of daily living adl and quality of life <sep>"", 'expiratory muscle strength <sep> inspiratory muscle strength <sep> handgrip strength <sep> weight gain <sep>', 'body weight and somatic protein compartments <sep> maintain nutrient intake <sep>', 'weight <sep> nutritional status <sep>', ""protein intake <sep> overall qol <sep> reduced symptomatology <sep> reduction of incidence/severity of grade 1+2 anorexia nausea/vomiting xerostomia and dysgeusia <sep> nutritional intake <sep> ottery's subjective global assessment and qol determined by the european organization for the research and treatment of cancer quality of life questionnaire version 3.0 eortc qlq-c30 <sep> energy intake after rt <sep> qol function scores <sep> rt toxicity <sep> energy and protein intake <sep> nutritional intake and status <sep> nutritional outcome morbidity and quality of life qol <sep>"", 'weight gain <sep>', ""protein intake <sep> function and symptom scales <sep> adequate intake or nutritional status <sep> nutritional intake diet history status ottery's subjective global assessment and qol european organisation for research and treatment of cancer quality of life questionnaire version 3.0 <sep> patient outcomes <sep> morbidity and quality of life qol <sep> function symptoms and single-item scores <sep> rates of anorexia nausea vomiting and diarrhea <sep> energy intake increased in g1/g2 <sep> g3 <sep> improvement/deterioration of qol <sep>"", 'non-protein nitrogen appearance rate npna <sep> triceps skinfold thickness tsf and midarm muscle area mama <sep> serum albumin <sep> peritoneal transport rate and mama <sep> anthropometric parameters and improved subjective global assessment evaluation <sep> frequency of patients with moderate or severe malnutrition <sep> serum albumin calorie and protein intake and npna <sep> serum albumin levels <sep> calorie and protein intake <sep>', 'lean mass and physical function <sep> body weight <sep> body composition <sep> grip strength <sep> gain in fat mass <sep> total lean mass <sep>', 'energy intake <sep> physical performance <sep> fat-free mass <sep> o(2 saturation and a decrease in paco(2 <sep> goal for energy intake and gained weight <sep> energy intake and gained weight <sep> mean intervention time <sep>', 'weight <sep> body weight and tricipital skinfold <sep> body weight gain <sep> cd4 counts and viral load <sep>', 'immune responses <sep> reactivity to skin test antigens <sep> refeeding and weight gain <sep> absolute lymphocyte count <sep>', 'mean total energy <sep> mean intake per kilogram of body weight <sep> dietary intake <sep> dietary intake protein energy fiber <sep> fiber intake <sep> body weight nutritional status and quality of life <sep> mean protein intake <sep> protein intake <sep>'], 'punchline_text': ['age body cell mass bcm muscle function gender distribution and qol did not differ between ons patients n=38 and dc patients n=42 at baseline. <sep>', 'the intention-to-treat analysis indicated significant improvements in lower extremity muscle strength in both training groups compared with the nutrition group at 1st follow-up. <sep>', 'one month after discharge the control patients had a nutritional intake 3-d diet record comparable with the intake of the general population that did not increase further. <sep>', 'nutritional intervention had no significant effect on lymphocyte cd4 counts on plasma tnfr 55 tnfr 75 and ilr 2 concentrations and on quality of life. <sep>', 'fat free mass increased from baseline to week 8 p<0.05 with no difference between groups a and b p=0.97). <sep>', 'food supplements did not affect treatment response or complications nor did they offer any survival advantage. <sep>', 'the intervention was associated with greater increases in energy and protein intake in women than men interaction p  0.001 for both). <sep>', 'subjects ingesting nutritional supplements between meals significantly increased their total caloric and protein intake above that of controls and did not reduce their food-derived caloric or protein intake compared to controls. <sep>', 'the compliance to the prescribed diet was very high in both groups and no carry over effect of the previous dietary intake was observed during the follow-up period. <sep>', 'there was no significant change in energy intake or percent ideal body weight in either group. <sep>', 'serum osteoprotegerin opg increased significantly in group 2 with a maximal increase 27 observed at 6  p<0.01 and 9 months  p<0.05). <sep>', 'fewer patients in the treatment group 7/52 required antibiotic prescriptions compared with the control group 15/49). <sep>', 'nutritional behaviour correlated with subjective well-being low intake with complaints of tumour treatment side effects and weight loss with malaise. <sep>', 'enteral nutrient supplementation was shown to bring about a significant improvement in serum albumin level even in a short-term study. <sep>', 'nutritional interventions using dietary counselling had no impact on the percent of planned chemotherapy dose administered the degree of toxicity experienced by patients or the frequency of treatment delays. <sep>', 'there were similar improvements in triceps skinfold thickness dietary intake fecal fat and pain score during a period of 3 months in both groups. <sep>', 'no difference was observed between the control and adjunctive groups in clinical status at the end of treatment or in long-term outcome. <sep>', ""individualized dietary counselling for 6 months was associated with a significant decrease in the crohn's disease activity index an increased incidence of disease remission a decreased need for prednisone and salazopyrin therapy a reduction in the number of days spent in hospital and a reduction in the amount of time lost from work due to crohn's disease when compared with control patients who did not receive dietary counselling but who were seen regularly in follow-up under similar circumstances. <sep>"", 'despite adequate statistical power no functional measures differed except that the number of falls was lower among treated subjects vs. controls 0 vs. 21 p  0.05). <sep>', 'there was a numerical difference not statistically significant p  0.3 indicating a shorter time of survival in patients in the gr  sc group. <sep>', 'serum igf-i levels increased in the i-group p<0.001 but were unchanged in the c-group p=0.07 between the groups). <sep>', 'the group-by-time interaction approached significance on the karnofsky performance status scale. <sep>', 'compared with the control group the supplement group had larger increases in fat-free mass and grip strength although the differences did not reach statistical significance. <sep>', 'quality of life measured by the quality-of-life index ql-index increased significantly in both groups but did not differ between groups. <sep>', 'although a weight gain of 7 kg p  0.003 was obtained the difference to the control group was statistically not significant p  0.08). <sep>', 'during follow-up patients in the experimental group were far more likely to maintain nutritional repletion or continue to improve 61 than patients in the control group 14%). <sep>', 'the intervention group consumed more energy difference 194 kcal/day p  0.02 and protein difference 11.8 g/day p<0.001 than controls. <sep>', 'inspiratory muscle strength was also improved intervention  11.4 cm h2o versus control 4.8 cm h2o although this did not quite reach statistical significance. <sep>', 'in general nutrient intake in the experimental group remained similar to that before surgery whereas intake in the control group decreased significantly particularly at the one-week postoperative evaluation. <sep>', 'out-patients lost more weight than in-patients did p  0.05). <sep>', 'after rt qol function scores improved p  .003 proportionally with improved nutritional intake and status in group 1/group 2 p  .05 and worsened in group 3 p  .05 at 3 months patients in group 1 maintained or improved overall qol whereas patients in groups 2 and 3 maintained or worsened overall qol. <sep>', 'it was concluded that preoperative supplementation to achieve weight gain before surgery is of no apparent value. <sep>', 'at radiotherapy completion energy intake increased in g1/g2 p  or  .04 g1 more than g2 p  .001 and decreased in g3 p  .01). <sep>', 'in the study group oral administration of the egg albumin-based supplement significantly improved serum albumin calorie and protein intake and npna and compared to controls this maneuver was associated with a trend to increased anthropometric parameters and improved subjective global assessment evaluation. <sep>', 'patients in the nutritional supplement group n  19 had a significantly greater increase in body weight 2.57  <sep>', 'group a increased their energy intake from a median of 8.7 to 10.1 mj p  0.01 compared with the control group after intervention and gained a mean of 2.9 kg body weight 95 ci 1.2 4.7 p  0.005 compared with the control group while group b increased from 7.4 to 10.8 mj p  0.005 and gained 2.3 kg 1.2 3.3 p  0.002). <sep>', 'the increase in body weight and tricipital skinfold was significant in group i. total body water and fat free-mass remained without changes. <sep>', 'refeeding and weight gain were associated with a significant increase in absolute lymphocyte count and with an increase in reactivity to skin test antigens after 21 days of refeeding. <sep>', 'the nutrition intervention group had a higher mean total energy p=0.029 and protein intake p<0.001 compared with the standard practice group. <sep>'], 'population': ['malnourished patients with non-neoplastic gastrointestinal disease <sep> patients with digestive disease <sep> ons patients n=38 and dc patients n=42 at baseline <sep> eighty malnourished patients with benign digestive disease <sep> malnourished gi patients <sep> malnourished patients with digestive disease <sep>', 'ninety-six community-dwelling elderly people 58 women <sep> frail elderly people <sep> frail elderly people over age 75 <sep> frail community dwelling elderly people over the age of 75 <sep>', 'patients admitted for gastrointestinal surgery <sep> patients who had undergone gastrointestinal surgery <sep>', 'hiv-infected patients <sep> hiv-infected subjects <sep> hiv-infected individuals with a body mass index  21 kg m-2 or cd4-t cells  500 micro l-1 in stable clinical condition <sep>', 'hiv-infected patients with recent weight loss <sep> copyright 1999 harcourt publishers ltd <sep> malnourished hiv-infected patients <sep>', 'head and neck cancer <sep> fifty ambulatory patients with head and neck cancer treated by definitive radiation therapy at the fox chase cancer center <sep>', 'predialysis patients with ckd structured <sep> severe ckd <sep> predialysis patients with chronic kidney disease ckd stages 4 and 5 <sep> 14.0 sd years with ckd <sep> women than men <sep> 56 outpatients men 62 mean age 70.7 <sep>', '40 newly diagnosed patients with cancer beginning external beam radiation therapy <sep> patients undergoing radiotherapy <sep> patients with advanced cancer <sep>', 'patients with child a or b hcv-related liver cirrhosis <sep> 90 consecutive outpatients m/f=52/38 with liver cirrhosis 30 in child class a and 60 in class b. patients <sep> patients with hcv-related liver cirrhosis <sep>', 'malnourished adolescents and adults with cystic fibrosis <sep> 13 malnourished patients 3 males mean age 18.1 years with cystic fibrosis <sep>', '71 ambulant women aged  or 70 years with bmi  or 21 kg/m(2 and osteoporosis at the hip was undertaken <sep> elderly underweight women with osteoporosis <sep> elderly people <sep> elderly community-dwelling women <sep> elderly women with low bmi <sep>', 'postoperative surgical patients <sep> 101 patients 52 <sep> malnourished surgical patients <sep> 49 patients <sep>', 'patients with acute leukaemia <sep> 29 patients with acute leukaemia <sep>', 'hemodialysis hd unit of a tertiary referral care hospital in southern india <sep> maintenance hemodialysis patients <sep> maintenance hemodialysis mhd patients using a high <sep> nondiabetic adult mhd patients with no intercurrent illness on regular thrice weekly mhd for at least 1 month before recruitment with a body mass index bmi 20 and a serum albumin level of 4.0 g/dl. patients <sep>', 'advanced colorectal and non-small-cell lung cancer <sep> lung cancer patients <sep> ninety-three nsclc patients <sep> one hundred ninety-two patients with previously untreated metastatic cancer 102 non-small-cell lung cancer nsclc 90 colorectal cancer <sep> 81 evaluable patients with colorectal cancer <sep>', '10 years male 83 and supplementation group n  31 mean age 28 <sep> patients with chronic pancreatitis cp <sep> patients with cp <sep> 10 years male 84 <sep> consecutive undernourished patients with cp body mass index bmi 18.5 kg/m(2 at a tertiary care hospital <sep> sixty malnourished patients with cp were randomized to counseling group n  29 mean age 32 <sep> chronic pancreatitis <sep>', 'thirteen patients were excluded because of poor prognoses and the ethical need for food supplements <sep> ninety-seven patients with cancer undergoing radiation treatment were studied <sep> patients with malignant disease undergoing treatment <sep>', ""patients with crohn's disease <sep> 137 outpatients with crohn's disease <sep>"", 'frail elderly <sep> free-living frail elderly <sep> frail elderly living at home <sep> subjects n  50 over age 60 mean 78 y requiring community services and at elevated risk of undernutrition excessive weight loss or body mass index  24 kg/m2 <sep>', '67 patients with colorectal or gastric cancer <sep> patients with colorectal and gastric cancer <sep> 70 patients with the same diagnoses randomized to <sep> gi cancer patients by individual support is including nutritional measures <sep> patients with newly diagnosed gi cancer <sep> patients with gastrointestinal gi cancer <sep>', 'geriatric patients at risk of malnutrition <sep> patients at risk of protein-energy malnutrition pem discharged from a geriatric service were evaluated <sep> fifty-four patients 29 in the i-group 86+/-7 years 66 females and 25 in the c-group 85+/-7 years 72 females completed the study according to the protocol <sep> discharged geriatric patients at risk of malnutrition <sep> patients n=108 age 85+/-6 years at risk of malnutrition according to the short form of the mini nutritional assessment <sep>', 'cancer patients <sep> fifty-five subjects completed a four-month intervention period during which they were visited biweekly by a nurse except control subjects <sep> cancer patients assessed as nutritionally at risk <sep>', 'ninety-nine men completed at least 4 weeks of treatment 49 in the supplement group and 50 in the control group <sep> hiv-infected men n=118 who were less than 90 of usual weight for height or who had lost more than 10 of body weight <sep> malnourished hiv-infected patients <sep> malnourished patients infected with the human immunodeficiency virus hiv <sep>', 'cancer patients with solid tumors undergoing aggressive chemotherapy <sep> patients with cancer of the lung small-cell ovary or breast undergoing cyclic chemotherapy <sep> 105 assessable patients 57 were randomized to receive <sep> cancer patients undergoing <sep>', 'twelve months 14 of 30 patients with an average fev1 of 0.8 l <sep> patients with copd <sep> chronic obstructive lung disease <sep>', 'malnourished hemodialysis patients <sep> malnutrition for hemodialysis hd patients <sep> 32 hd patients with mild ha <sep> ten outpatient hemodialysis centers in southeast lower michigan <sep> fourteen hd patients with moderate to severe ha <sep>', 'stable copd <sep> chronic obstructive pulmonary disease copd <sep> outpatients with copd who are at risk of malnutrition <sep> 59 outpatients with copd 6 months intervention and 6 months follow-up <sep>', 'chronic obstructive pulmonary disease copd <sep> underweight patients with copd that combines an initial inpatient investigation controlled nutritional support with a prolonged outpatient follow-up interval <sep> malnourished patients with chronic obstructive pulmonary disease <sep>', 'twenty-four orthognathic surgery patients <sep> orthognathic surgery patient <sep>', 'head and neck cancer <sep> 24 in-patients and 25 out-patients enrolled at the department of otolaryngology national hospital <sep>', 'patients with head and neck cancer undergoing <sep> patients with cancer <sep> seventy-five patients with head and neck cancer who were referred for <sep>', 'orthognathic surgery patients <sep> orthognathic surgery patient <sep>', 'colorectal cancer patients undergoing <sep> 111 colorectal cancer outpatients referred for radiotherapy stratified by staging <sep> cancer patients <sep>', '28 capd patients were allocated to a study n  13 or a control n  15 group <sep> peritoneal dialysis patients <sep> patients on continuous ambulatory peritoneal dialysis <sep> capd patients <sep>', 'patients with newly diagnosed tuberculosis and wasting <sep> patients with tuberculosis and wasting <sep> patients who started antituberculous therapy within the previous 2 wk <sep>', 'our participants were underweight n  42 and normal-weight control group n  29 candidates for lung transplantation <sep> underweight patients <sep> underweight candidates for lung transplantation <sep>', 'patients with human immunodeficiency virus infection <sep> 70 patients 66 of whom were fully evaluated for each study end point after application of prospectively determined evaluability criteria <sep> a group of hiv-infected patients <sep>', 'patients with copd <sep> advanced chronic obstructive pulmonary disease <sep> nine patients with advanced chronic obstructive pulmonary disease copd and recent weight loss resulting in a state of mild malnutrition <sep>', 'sixty consecutive radiation oncology outpatients 51 men and nine women age 61.9+/-14 years mean+/-standard deviation <sep> outpatients receiving radiotherapy <sep>'], 'interventions': ['hospital nutritional intervention with high protein and energy supplements <sep> oral nutritional supplements ons for three months in addition to dietary counselling dc ons patients or only dietary counselling dc patients <sep> protein and energy rich supplements <sep> high protein oral supplements <sep>', 'physical training program aerobic muscle strength balance ii a nutritional intervention program individually targeted advice and group sessions iii a combination of these interventions and <sep> balance training <sep> physical and nutritional intervention program <sep>', 'dietary supplementation <sep> dietary advice and protein-rich supplements <sep>', 'nutritional supplements combined with dietary counselling <sep> oral nutritional supplements containing 2510 kj complete macro and micronutrients and dietary counselling n  8 or 2 identical monitoring but no supplements or specific nutritional advice <sep> nutritional supplements combined with dietary counselling <sep> oral nutritional supplement combined with nutritional counselling <sep>', 'oral supplements <sep> fortified drink supplements with a calorific value of 0.6 to 1.5 kcal/ml <sep> nutritional counseling with and without oral supplements <sep> nutritional counseling <sep> nutritional counseling and oral supplements <sep>', 'oral nutritional supplements <sep>', 'nutritional counseling <sep> nutrition intervention <sep> individualized dietary counseling with regular follow-up aimed at achieving an intake of 0.8 to 1.0 g/kg of protein and greater than 125 kj/kg of energy or control receiving written material only <sep>', 'nutritional supplements <sep> liquid nutritional supplement between meals and at bedtime <sep>', 'appropriate oral diet <sep> adequate diet <sep>', 'dietary counseling <sep> oral dietary supplements <sep>', 'calcium 1 g and vitamin d 800 units of cholecalciferol <sep> nutritional improvement <sep> calcium/vitamin d and one or two cartons of a nutritional supplement drink which provided 300 kcal 12 g protein <sep> dietary improvement <sep>', 'treatment group tg and prescribed a 1.5 kcal/ml nutritional supplement <sep> enteral nutritional supplements <sep> control group cg and continued with routine nutritional management <sep> postoperative nutritional supplementation <sep>', 'oncological polychemotherapy <sep> intensified oral nutrition intervention group or ad libitum nutritional intake during the whole tumour therapy <sep> oral nutrition therapy <sep> nutrition education daily visits by the dietician and record of food intake as well as a weekly assessment of subjective well-being linear analogue self assessment lasa <sep>', 'intermittent enteral nutrient supplementation <sep> short-term enteral nutrient supplementation <sep> respective supplement post-hd <sep> enteral nutrient supplementation <sep> cns or hp blend <sep> calorie and high-protein blend formula low-cost home-prepared hp blend or a commercially available supplement <sep> hp supplement <sep> appropriate monitoring including dietary recall and counselling for the prescribed diet protein intake of 1.2 g/kgibw/d and energy of 35 to 45 kcal/kgibw/d but no specific post-hd supplement <sep>', '5-fluorouracil 5-fu and methotrexate <sep> vindesine and cisplatin <sep> ad lib nutritional intake control group or specific nutritional intervention <sep> calories provided as protein and additional supplements of zinc and magnesium <sep> oral nutritional support versus ad lib nutritional intake during chemotherapy <sep>', 'dietary counseling versus dietary supplements <sep> dietary counseling for regular homemade food or commercial mct-enriched dietary supplements <sep> medium chain triglyceride mct)-enriched commercial dietary supplements with dietary counseling <sep>', 'special dietary counseling and supplements of sustagen or isocal 42 controls received no special advice or supplements <sep>', 'individualized dietary counselling <sep> individualized diet counselling <sep> diet counselling <sep>', 'high energy nutrient dense supplement provided by a dietitian or a control group receiving visits only <sep> nutritional supplementation <sep>', 'nutritional support <sep> nutritional support 2 group rehabilitation gr 3 is  gr isgr or 4 standard care sc <sep> gr or sc <sep>', 'dietary counseling including liquid and multivitamin supplementation i.e. intervention <sep> nutritional supplementation and dietary advice <sep> combined nutritional intervention <sep> combined nutritional treatment <sep>', 'nursing interventions <sep> control group or to one of four intervention groups receiving a nutritional supplementation b relaxation training c both nutritional supplementation and relaxation training or d neither nutritional supplementation nor relaxation training <sep>', 'nutrition counseling with or without oral supplementation <sep> nutrition counseling alone control group vs nutrition counseling plus enteral supplementation <sep> nutrition counseling <sep>', 'chemotherapy <sep> frequent nutritional counseling <sep> dietary counseling <sep> nutritional counseling and 48 to receive no nutritional counseling and consumption of an ad lib oral intake <sep> dietary counseling <sep>', 'high-caloric nutrition <sep> dietary counselling <sep>', 'physician-prescribed oral supplements and dietary counseling to permit comparison of the experimental treatment with current supplementation practices <sep> diet counseling and oral supplementation and the control group received diet counseling only <sep> control group of patients with mild hypoalbuminemia ha serum albumin sa  3.5 to 3.7 g/dl <sep>', 'dietary counselling and food fortification <sep> dietary counselling and food fortification <sep> dietary counselling and advice on food fortification and the controls received a dietary advice leaflet <sep>', 'nutritional therapy <sep> oral supplemental feeding <sep>', 'high-calorie liquid supplement <sep> postoperative nutritional supplementation <sep>', 'tailored dietary information and instruction by a clinical nutritionist or regular dietary information from a nurse <sep> intensive dietary advice <sep> radiotherapy <sep>', 'radiotherapy <sep> dietary counseling or oral supplements <sep> radiotherapy rt <sep> dietary counseling with regular foods <sep> patients who maintained usual diet plus supplements <sep>', 'preoperative nutritional supplementation <sep>', 'protein supplements <sep> dietary counseling regular foods <sep> radiotherapy <sep> dietary counseling or nutritional supplements <sep> dietary counseling <sep>', 'egg albumin-based protein supplement <sep> oral egg albumin-based supplement <sep> conventional nutritional counseling <sep>', 'early nutritional intervention <sep> standard nutritional counseling control group or nutritional counseling to increase their intake through diet and high-energy supplements nutritional supplement group for 6 wk <sep> nutritional supplementation <sep>', 'intensified dietary counselling ready-made liquid nutritional supplements free of charge and regular follow-ups while group b received only one session of individual dietary counselling no supplements and no follow-ups <sep> intensified dietary support <sep>', 'isolated dietary counselling program versus supplement and dietary counselling <sep> nutritional intervention <sep> nutritional supplementation with a standard polymeric formula <sep> oral nutritional supplements <sep> nutritional counselling versus isolated nutritional counselling <sep> standard enteral formula <sep> oral supplements <sep>', 'short-term nutritional intervention <sep>', 'nutrition intervention <sep> radiotherapy <sep> intensive nutrition intervention <sep> nutrition intervention n=29 nutrition counseling following the american dietetic association ada medical nutrition therapy mnt protocol for radiation oncology or standard practice n=31 general nutrition talk and booklet <sep> standard practice <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",evidence of variable quality suggests that dietary advice with or without oral nutritional supplements may improve weight body composition and grip strength. we found no evidence of benefit of dietary advice or oral nutritional supplements given alone or in combination on survival. studies addressing the impact of nutritional interventions on nutritional functional and patient-centred outcomes are needed.
151,"{'outcomes': ['rate of antenatal hospitalization <sep> preterm delivery and birth weight <sep> severe hypertension <sep> gestational age at delivery <sep> systolic and diastolic bp levels <sep> development of severe hypertension <sep>', 'mean dbp <sep> serious maternal complications <sep> control of hypertension <sep> neonatal intensive care unit nicu admission <sep> severe hypertension <sep> serious perinatal and maternal complications <sep> clinician compliance <sep> preterm birth <sep> serious perinatal complications <sep> diastolic blood pressure dbp <sep>'], 'punchline_text': ['tight control of blood pressure reduces the rate of antenatal hospitalization and does not adversely affect perinatal outcomes in women with mild essential or gestational hypertension. <sep>', 'mean dbp was significantly lower with tight control <sep>'], 'population': ['mild essential and gestational hypertension in pregnancy <sep> eligible participants n=125 <sep> mild chronic essential or gestational non-proteinuric hypertension in pregnancy <sep> women with mild essential or gestational hypertension <sep> 2006-2007 in the university of ain shams egypt <sep>', 'inclusion pregnant women dbp 90-109 mmhg pre-existing/gestational hypertension live fetus(es and 20-33(+6 weeks <sep> a total of 132 women were randomised to less tight n  66 seven had no study visit or tight control n 66 one was lost to follow up seven had no study visit <sep> exclusion systolic blood pressure  or  170 mmhg and proteinuria contraindication or major fetal anomaly <sep> seventeen obstetric centres in canada australia new zealand and uk <sep>'], 'interventions': ['tight control of blood pressure <sep> tight or less tight control of mild chronic essential or gestational non-proteinuric hypertension <sep> methyldopa <sep>', 'tight control <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>']}",for pregnant women with non-severe pre-existing or non-proteinuric gestational hypertension there is insufficient evidence to determine how tight control of hypertension should be achieved to improve maternal and fetal-neonatal outcomes.
152,"{'outcomes': ['viral loads <sep> suppression of plasma hiv rna <sep> viral suppression <sep> cd4 cell counts <sep> loss of viral suppression <sep> rates of viral clearance <sep>', 'patients adherence and minimise toxicity <sep> detectable hiv-1 rna <sep> plasma hiv-1 rna concentration <sep> undetectable plasma hiv-1 rna concentration <sep> initial virion-clearance rate <sep>', 'virologic failure <sep> viral suppression <sep> virologic failure loss of hiv suppression <sep> risk of virologic failure <sep>'], 'punchline_text': ['the presence of zidovudine-resistance mutations in hiv rna at base line was strongly predictive of the loss of viral suppression in subjects treated with zidovudine and lamivudine. <sep>', 'the initial virion-clearance rate during induction therapy was higher in five patients on maintenance therapy with a sustained undetectable plasma hiv-1 rna concentration than in nine patients with recurrence of a detectable plasma hiv-1 rna concentration at week 36 0.35 vs 0.19 per day respectively p=0.0008). <sep>', 'similar results were obtained when the one abstract was excluded odds ratio 5.48 95 confidence interval 2.82  10.65). <sep>'], 'population': ['hiv-infected subjects who had cd4 cell counts greater than 200 per cubic millimeter who had been treated with <sep> and who had less than 200 copies of hiv rna per milliliter of plasma after 16 20 and 24 weeks of induction therapy <sep> hiv infected patients with undetectable plasma hiv rna after triple-drug therapy <sep>', '62 patients had been enrolled <sep> 39 <sep> enrolled patients infected with hiv-1 with at least 200 cd4 cells/microl at least 1000 hiv-1 rna copies/ml in plasma and no previous exposure to antiretroviral drugs <sep> hiv-1 infected individuals <sep> patients infected with hiv-1 <sep>', 'hiv-infected adults who had successfully completed three or four-drug antiretroviral induction therapy <sep> years 1982-1999 using the search terms human immunodeficiency virus antiretroviral therapy maintenance therapy <sep>'], 'interventions': ['indinavir zidovudine <sep> indinavir alone or zidovudine and lamivudine <sep> indinavir zidovudine and lamivudine <sep> zidovudine <sep> indinavir alone <sep> continued triple-drug therapy <sep> indinavir lamivudine and zidovudine <sep> lamivudine <sep> zidovudine and lamivudine <sep> indinavir <sep>', 'maintenance therapy either stavudine and nelfinavir or saquinivir and nelfinavir or prolonged induction therapy <sep> induction therapy stavudine lamivudine saquinavir and nelfinavir <sep> haart <sep> highly active antiretroviral therapy haart <sep>', 'medicine <sep> maintenance therapy with three or four drugs or maintenance therapy with two drugs <sep> zidovudine lamivudine indinavir stavudine saquinivir nelfinavir didanosine zalcitabine ritonovir aids anti-hiv agents hiv infection and hiv seropositivity 2 <sep> zidovudine and lamivudine <sep> zidovuine lamivudine and indinavir <sep> zidovudine lamidvudine indinavir stavudine saquinivir nelfinavir didanosine zalcitabine ritonovir anti-hiv agents 3 <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",although it is desirable to reduce the number of antiretroviral drugs given in combination therapy for reasons of compliance and toxicity maintenance regimens with fewer drugs are associated with significantly increased resistance and risk of loss of viral suppression. successful initial therapy as evidenced by suppresion of viral load should not be modified in the maintenance phase unless clinically necessary.
153,"{'outcomes': ['health plan choices <sep>', 'hmo choices <sep>', 'composite ami and chf indicators based on 12 ami and 6 chf process-of-care indicators <sep> mean 30-day ami mortality rates <sep> individual process-of-care indicators a hospital report card impact survey and all-cause ami and chf mortality <sep> quality of cardiac care <sep> hospital mortality rates for chf <sep>'], 'punchline_text': ['we found that cahps information did not affect health plan choices by iowa medicaid beneficiaries similar to previously reported findings for new jersey medicaid. <sep>', 'health plan performance information can influence plan choices by medicaid beneficiaries but will do so only if they actually read it. <sep>', 'public release of hospital-specific quality indicators did not significantly improve composite process-of-care indicators for ami or chf. <sep>'], 'population': ['iowa medicaid beneficiaries <sep> new beneficiaries in iowa medicaid <sep> new cases entering medicaid in selected counties during february through may 2000 <sep>', 'study sample was a statewide sample of all new medicaid cases that chose medicaid health plans during april 1998 <sep> plan choices by new jersey medicaid beneficiaries <sep>', '86 hospital corporations in ontario canada with patients admitted for acute myocardial infarction ami or congestive heart failure chf <sep> participating hospital corporations were randomized to early january 2004 or delayed september 2005 <sep>'], 'interventions': ['standard medicaid enrollment materials <sep> cahps performance information <sep>', 'cahps <sep> cahps health plan performance information <sep>', 'public report cards <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",the small body of evidence available provides no consistent evidence that the public release of performance data changes consumer behaviour or improves care. evidence that the public release of performance data may have an impact on the behaviour of healthcare professionals or organisations is lacking.
154,"{'outcomes': ['total drainage volume hourly zero drainage heart rate or occurrence of arrhythmias <sep> volume of drainage <sep>', 'drainage incidence of cardiac tamponade incidence of surgical reentry hemodynamic values and number of manipulation episodes <sep>'], 'punchline_text': ['four to 16 hours postoperatively a significantly higher volume of drainage occurred in the subjects whose chest tubes had been stripped. <sep>', 'statistical analyses revealed no difference in any of the dependent variables when milking and stripping were used. <sep>'], 'population': ['49 male subjects had their chest tubes milked every 2 hours had them stripped every 2 hours or served as controls i.e. their tubes were neither milked nor stripped <sep>', 'patients after myocardial revascularization surgery <sep> two hundred adult patients immediately after myocardial revascularization <sep> patients undergoing myocardial revascularization <sep> 200 patients 78 did not require any manipulation of the chest tubes in the first 8 hours after surgery <sep>'], 'interventions': ['coronary artery bypass graft procedures <sep>', 'chest tube clearance protocols <sep> specific chest tube manipulation group <sep> clot clearance <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>']}",there are insufficient studies which compare differing methods of chest drain clearance to support or refute the relative efficacy of the various methods in preventing cardiac tamponade. nor can the need to manipulate chest drains be supported or refuted by results from rcts.
155,"{'outcomes': ['severity of headache or requirement for epidural blood patch <sep> 10-cm visual analogue scale severity of headache <sep> postdural puncture headache <sep>', 'relief of pdph measured as delta vas initial vas  vas <sep> postdural puncture headache <sep> pdph <sep> intensity of headache quantitated using a visual analogue pain scale vas <sep>', 'pain <sep> headache <sep> post-puncture headache <sep> mean pain score <sep>', 'severity of the headache <sep>', 'visual analog scale <sep> mean headache intensity <sep> mean of headache intensity <sep> headache <sep> headache <sep> headache intensity <sep>'], 'punchline_text': ['there was no difference in the severity of headache or requirement for epidural blood patch. <sep>', 'relief of pdph measured as delta vas initial vas  vas at 4 h was significantly better in the caffeine than in the placebo group p  0.014). <sep>', 'when the headache was provoked by orthostatic strain the six patients in the verum group showed significantly less pain  <sep>', 'ten patients with postdural puncture headache presenting for an epidural blood patch were given either saline or sumatriptan subcutaneously. <sep>', 'after 24 hours mean headache intensity was 3.87  1.63 in conventionally treated group versus 0.73  0.74 in hydrocortisone group p 0.001). <sep>'], 'population': ['18 parturients with postdural puncture headache following deliberate or accidental dural puncture <sep> postdural puncture headache <sep>', 'forty postpartum patients with postdural puncture headache pdph <sep>', 'lumbar puncture <sep> 11 patients with typical headache following diagnostic lumbar puncture <sep>', 'ten patients with postdural puncture headache presenting for an epidural blood patch <sep> patients presenting for an epidural blood patch for the management of postdural puncture headache <sep> patients who have exhausted conservative management of postdural puncture headache <sep> patients with postdural puncture headache <sep>', 'sixty patients with headache after spinal anesthesia were included <sep> women who underwent cesarean section <sep> patients undergoing this procedure <sep> headache after spinal anesthesia in women who have undergone cesarean section <sep> after spinal anesthesia <sep>'], 'interventions': ['synacthen depot 1 mg 1 ml or 0.9 saline 1 ml intramuscularly <sep> synacthen depot <sep>', 'oral caffeine <sep> placebo <sep> caffeine <sep>', 'theophylline <sep> theophylline euphyllin retard <sep> placebo <sep> placebo <sep> methylxanthines <sep> theophylline <sep>', 'sumatriptan <sep> sumatriptan <sep> saline or sumatriptan subcutaneously <sep>', 'conventional therapy plus intravenous hydrocortisone <sep> hydrocortisone <sep> intravenous hydrocortisone <sep> conventional therapy complete bed rest hydration acetaminophen and pethidine <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",caffeine has shown effectiveness for treating pdph decreasing the proportion of participants with pdph persistence and those requiring supplementary interventions when compared with placebo. gabapentin theophylline and hydrocortisone have also shown a decrease in pain severity scores when compared with placebo or conventional care. there is a lack of conclusive evidence for the other drugs assessed sumatriptan and acth). these conclusions should be interpreted with caution due to the lack of information to allow correct appraisal of risk of bias the small sample sizes of studies and also the limited generalisability as most participants were post-partum women in their 30s.
156,"{'outcomes': ['postoperative wound infections <sep> rate of postoperative wound infection <sep> postoperative wound infection <sep>', 'infection rates <sep> overall incidence of infection <sep> septic complications <sep>', 'rate of postoperative infections <sep> rate of infectious complications <sep> rate of post-operative infections <sep> rate of postoperative infectious complications <sep>', 'incidence of anaerobic wound infection <sep>', 'incidence of wound infection <sep>', 'rate of wound infection <sep> wound infection <sep>', 'toxicity <sep> postoperative wound infections <sep>', 'morbidity and prolongs hospital stay <sep>', 'incidence of complications <sep>', 'postoperative wound infection <sep> wound infection <sep>', 'erythematous rash <sep>', 'frequency of non-clostridial anaerobic infection <sep> anaerobic infection <sep>', 'postoperative infections <sep>', 'majority of wound infections <sep> incidence of postoperative wound infection <sep>', 'incidence or severity of wound infection or post-operative intra-abdominal sepsis <sep>', 'therapeutic concentrations <sep> anaesthetic complication <sep> occurrence of both anaerobic and aerobic bacteria <sep> incidence of postoperative wound infection <sep>', 'post-operative wound sepsis rate <sep> wound infection rate <sep>', 'overall infection rates <sep> duration of postoperative hospital stay <sep> blood levels <sep> anaerobic infection <sep> hospital wound infections <sep> wound infections <sep>', 'days of hospitalization <sep> infection rate <sep> nonperforative appendicitis <sep>', 'incidence of infectious complications <sep>', 'incidence of wound infection <sep> safety and efficacy <sep>', 'incidence of wound infection <sep> infection rate <sep> number of aerobic organisms <sep> overall rate of wound infection <sep>', 'sepsis rates <sep> wound infection <sep>', 'wound infection the hospital stay <sep> infection rate <sep> overall infection rate <sep>', 'late sepsis <sep> postoperative wound infection <sep>', 'wound-infection rate <sep> wound sepsis <sep>', 'postoperative wound infections <sep> septic morbidity <sep>', 'infection rates <sep> infection rate <sep> overall infection rate <sep>', 'wound infection <sep> average length of hospitalization and convalescence <sep>', 'infection rate <sep> sepsis rates <sep>'], 'punchline_text': ['postoperative wound infections were detected in 11.6 of placebo-treated patients and in 1.4 of cephaloridine-treated patients p less than .02). <sep>', 'the three groups of patients were similar in regard to age sex duration of operation and pathologic classification of the appendix. <sep>', 'the rate of infectious complications in group i was 6.3 but only 2.1 and 2.3 in groups ii and iii respectively. <sep>', 'a significant reduction in the incidence of anaerobic wound infection was observed in the treated group p less than 0.02). <sep>', 'no differences occurred in the incidence of wound infection in the two groups. <sep>', 'one of 21 patients who received the placebo had a wound infection none of the 21 patients given cefamandole had infection. <sep>', 'the postoperative wound infection rate is insufficient to demonstrate the efficacy of metronidazole for prophylaxis in nonperforated acute appendicitis although there appears to be a tendency of to assume its efficacy in this regard. <sep>', 'post-appendicectomy sepsis still causes considerable morbidity and prolongs hospital stay. <sep>', 'no significant difference was found in the incidence of complications between the treated and a control group raising doubts as to whether this substance is of value when used intraperitoneally in peritonitis. <sep>', 'significant reduction in wound infection occurred in the study group compared with control subjects irrespective of the underlying pathologic lesion. <sep>', 'there were 13 wound infections as defined by the discharge of pus 12 out of 51 in the saline group and 1 out of 49 in the metronidazole group. <sep>', 'anaerobic infection did not develop in any of the metronidazole-treated patients but infections did develop in nine 19 of the 46 controls. <sep>', 'there were no side-effects due to the drugs. <sep>', 'the majority of wound infections were due to b. fragilis either alone or in association with aerobic organisms but infection due to e. coli and staphylococcus aureus also occurred. <sep>', 'there was no significant difference in the incidence or severity of wound infection or post-operative intra-abdominal sepsis between the metronidazole-treated and placebo groups. <sep>', 'no toxic effects of the antibiotics were detected no anaesthetic complication occurred and resistant strains of bacteria normally sensitive to the antibiotics were not isolated from wounds. <sep>', 'antibiotic prophylaxis lowered the post-operative wound sepsis rate especially following clinically contaminated interventions but this reduction did not reach statistical significance. <sep>', 'blood levels of metronidazole taken at the end of operation showed a wide variation but there was no correlation with subsequent infection. <sep>', 'ceftizoxime decreased the infection rate compared with pla 0 vs. 8 p less than .01). <sep>', 'the 3-day tinidazole treatment as compared with the single-dose prophylaxis did not further improve the outcome. <sep>', 'the study showed for each group a significant reduction of the incidence of wound infection in patients receiving prophylaxis. <sep>', 'cefazolin significantly reduced the number of aerobic organisms isolated from wound infections but did not significantly reduce the incidence of wound infection. <sep>', 'sepsis rates were found to be 27 for the untreated group 9 for the group receiving metronidazole only 8 for the group receiving cotrimoxazole injection only and 2.7 for the group receiving both drugs. <sep>', 'the infection rate differed in both groups antibiotic and placebo only for perforated appendices significantly. <sep>', 'the efficacy of a single 500 mg intravenous intra-operative dose of metronidazole in the prevention of postoperative wound infection following appendicectomy for acute mural appendicitis was studied in a prospective randomized placebo controlled trial. <sep>', 'wound sepsis occurred in 12.3 of metronidazole-treated patients compared with 24 in the povidone-iodine group and 23.5 in an untreated control group. <sep>', 'septic morbidity after appendectomy for nonperforating appendicitis is significantly reduced by systemic antibiotics and brief administration of a single broad-spectrum agent cefoxitin is effective prophylaxis. <sep>', 'in the non-perforated cases the infection rates were 3.4 in the metronidazole and 7.9 in the placebo group. <sep>', '17.5 of the patients in the control group developed a wound infection compared with 3.4 of those receiving metronidazole p less than 0.001). <sep>', 'in those receiving both drugs the infection rate was 3 a highly significant difference from that in the other three groups. <sep>'], 'population': ['patients undergoing surgery for uncomplicated appendicitis <sep> 139 patients studied 70 received <sep>', 'septic complications after emergency appendectomy for nonperforated appendicitis <sep> acute nonperforated appendicitis <sep>', 'children with appendicitis <sep> 544 children operated upon for uncomplicated appendicitis <sep> uncomplicated appendicitis during childhood <sep>', '102 patients with presumptive acute appendicitis <sep> anaerobic infections after emergency appendicectomy <sep>', 'wound infections in appendectomy <sep> 102 consecutive patients undergoing appendectomy through an incision in the right iliac fossa <sep>', '82 patients showed a wound infection rate of 4.8 3 of 53 patients who did not receive antibiotics had a wound infection compared with 1 of 29 patients who received <sep>', 'appendectomy <sep> ninety-eight patients with suspected nonperforated acute appendicitis <sep> twenty-six patients were excluded for the following reasons diagnosis other than acute appendicitis 16 perforation of the appendix 8 administration of other antibiotics 1 and refusal to enter study 1 <sep> thirty patients received <sep> seventy-two patients 47 men and 25 women with a mean age of 27.5 years range 15 to 60 years underwent appendectomy and were studied <sep>', '400 cases of uncomplicated appendicitis operated upon by three senior surgeons <sep> 400 cases <sep>', 'perforated appendicitis <sep> patients with peritonitis due to perforated appendicitis <sep>', 'elderly patients <sep> emergency abdominal surgery <sep>', 'one hundred patients undergoing appendicectomy through a right iliac fossa incision <sep>', 'bacteroides infections after appendicectomy <sep> patients who cannot take oral drugs <sep> 95 patients who had undergone acute appendicectomy 49 received <sep>', '223 consecutive suspected appendicitis patients <sep>', 'patients with perforated appendicitis <sep> 100 patients undergoing <sep> wound infection following appendicectomy <sep>', 'children undergoing appendicectomy <sep> 133 children aged 16 months to 15 years mean 6.7 years with presumptive acute appendicitis <sep>', 'gastrointestinal surgery <sep>', 'this study included 127 patients <sep> 166 patients or the <sep> gastrointestinal surgery <sep>', 'appendicectomy <sep> patients undergoing appendicectomy <sep>', '175 patients studied at two hospitals preoperative guidelines were used to exclude perforative appendicitis <sep> 122 patients with npa <sep> acute nonperforative appendicitis npa <sep>', '588 consecutive patients who were operated on on suspicion of appendicitis <sep>', 'patients receiving prophylaxis <sep> 1735 patients undergoing <sep> patients were divided into three groups patients with a normal appendix patients with an acutely inflamed appendix and patients with a gangrenous appendix <sep> acute nonperforated appendicitis <sep>', 'against wound infection after appendicectomy <sep> two hundred and fifty patients <sep>', 'following appendicectomy from november 1978 to january 1980 <sep> 283 patients was finally accepted into the study <sep>', '25 of 220 patients had to be excluded <sep>', 'acute mural appendicitis <sep>', 'sepsis after emergency appendicectomy <sep> 496 patients <sep> patients over the age of 12 undergoing emergency appendicectomy <sep>', 'acute nonperforating appendicitis <sep> acute nonperforating appendicitis <sep>', '131 patients from 158 appendicectomies <sep>', '203 patients <sep> patients undergoing appendicectomy <sep>', 'two hundred and seventy-one patients were assessed <sep> patients with generalized peritonitis <sep>'], 'interventions': ['cephaloridine <sep> placebo <sep> prophylatic cephaloridine <sep> cephaloridine prophylaxis <sep> placebo prophylaxis <sep>', 'prophylactic antibiotics <sep> group i placebo n  45 group ii cefamandole n  46 and group iii cefamandole plus carbenicillin <sep> short-term 24 hr perioperative antibiotics <sep>', 'no antibiotics <sep> cefuroxime <sep> prophylactic antibiotics <sep> metronidazole <sep>', 'intrarectal metronidazole <sep> intrarectal metronidazole <sep>', 'cefamandole <sep>', 'antibiotics <sep> placebo <sep> cefamandole and placebo <sep>', 'placebo <sep> prophylactic metronidazole <sep> prophylactic metronidazole <sep> 1 gm intravenous metronidazole <sep> metronidazole <sep>', 'aerobes cefazolin or tobramycin <sep> prophylactic antibiotic regime used a placebo <sep> prophylaxis against placebo <sep> anaerobes metronidazole <sep> metronidazole alone c metronidazole and cefazolin d metronidazole and tobramycin <sep>', 'intraperitoneal noxytiolin noxiflex solution <sep> intraperitoneal noxytiolin <sep>', 'single-dose intraoperative antibiotic prophylaxis <sep> gentamicin sulfate and clindamycin phosphate <sep>', 'normal saline or 500 mg metronidazole <sep> metronidazole <sep>', 'metronidazole <sep> placebo <sep> prophylactic metronidazole <sep> metronidazole <sep>', 'tinidazole <sep> tinidazole <sep> parenteral tinidazole or physiological saline <sep>', 'systemic antibiotic therapy <sep> lincomycin <sep> prophylactic lincomycin <sep> appendicectomy <sep>', 'placebo <sep> metronidazole suppositories <sep> metronidazole <sep>', 'tobramycin and lincomycin <sep> single-dose peroperative antibiotic prophylaxis <sep>', 'combination gentamicin and clindamycin <sep> gentamicin <sep>', 'prophylactic metronidazole <sep> metronidazole <sep>', 'antibiotic prophylaxis <sep> ceftizoxime <sep> antibiotics ctz or cfm <sep> ceftizoxime ctz cefamandole cfm and placebo pla <sep>', 'tinidazole <sep> tinidazole prophylaxis <sep> control group no prophylaxis the single-dose group preoperatively 500 mg of tinidazole <sep> tinidazole <sep>', 'appendectomy <sep> antibiotic prophylaxis <sep> cefoxitin <sep>', 'placebo <sep> cefazolin sodium <sep> antibiotic prophylaxis <sep> clindamycin phosphate <sep> clindamycin <sep> clindamycin cefazolin sodium and a placebo <sep> cefazolin <sep> clindamycin <sep>', 'cotrimoxazole injection and placebo suppository metronidazole suppository and cotrimoxazole injection metronidazole suppository and placebo injection or placebo suppository and placebo injection <sep> cotrimoxazole injection <sep> metronidazole and cotrimoxazole <sep> metronidazole <sep>', 'prophylactic cefamandol therapy <sep> placebo <sep> placebos <sep>', 'metronidazole prophylaxis <sep> placebo <sep> metronidazole <sep>', 'intrarectal metronidazole and intraincisional povidone iodine <sep> povidone-iodine <sep> metronidazole or povidone iodine <sep> metronidazole <sep>', 'placebo <sep> cefoxitin <sep> antibiotic prophylaxis <sep> placebo saline n  52 or cefoxitin sodium <sep> single broad-spectrum agent cefoxitin <sep> perioperative systemic antibiotics <sep>', 'metronidazole and a physiological saline placebo <sep> placebo <sep> metronidazole prophylaxis <sep> metronidazole <sep>', 'metronidazole prophylaxis <sep> metronidazole <sep>', 'metronidazole and placebo cefazolin and placebo metronidazole and cefazolin or double placebo <sep> cefazolin <sep> metronidazole <sep> metronidazole and cefazolin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",antibiotic prophylaxis is effective in the prevention of postoperative complications in appendectomised patients whether the administration is given pre peri or post-operatively and could be considered for routine in emergency appendectomies.
157,"{'outcomes': ['fasting blood glucose <sep> effectiveness safety and tolerability <sep> obstetrical outcomes <sep> urine ketones <sep> glycaemia <sep> effectiveness tolerability and safety <sep> ketonuria <sep> glucose concentration <sep> glucose concentration <sep>', 'mean glucose levels <sep> urine ketones <sep> metabolic effects <sep> fasting plasma glucose and glucose tolerance <sep> fasting levels of beta-hydroxybutyrate <sep> fasting plasma insulin <sep>', 'average adherence <sep> energy intake adequacy <sep> adherence <sep> glycemic control <sep> optimal glycemic control <sep> energy intake adequacy <sep> self-perception <sep>', 'energy restriction <sep> mean birthweight <sep> ketonemia <sep> frequency of insulin therapy <sep>', 'dietary intake <sep> adverse pregnancy outcomes <sep> birth weight centile <sep> pregnancy outcomes neonatal anthropometry and maternal metabolic profile <sep> prevalence of gestational diabetes mellitus gdm <sep> pregnancy outcomes <sep> birth weight <sep> prevalence of macrosomia <sep>', 'blood glucose <sep> postprandial glucose values <sep> self-monitored-blood-glucose smbg maternal and infant weight <sep> pre-pregnancy bmi <sep> glycaemic control <sep> dietary intakes <sep>', 'blood pressure and glucose metabolism <sep> insulin sensitivity <sep> blood pressure glycemic control lipids and insulin sensitivity <sep> blood pressure <sep> diastolic blood pressure <sep> diastolic blood pressure and no adverse effects on blood lipids <sep> ambulatory blood pressure blood lipids glycemic control and insulin sensitivity estimated by an intravenous glucose tolerance test <sep>', 'key obstetric and fetal outcomes <sep>'], 'punchline_text': ['no changes in fasting blood glucose were noticed in the group that had followed a low carbohydrate diet although a significant decrease in glucose concentration was observed after breakfast 102  <sep>', 'finally urine ketones increased significantly p less than 0.02 in the calorie-restricted group whereas they remained absent in the control group.(abstract truncated at 250 words <sep>', 'optimal glycemic control was observed in 50 of women no association was found with adherence measured with any of the three methods studied. <sep>', 'energy restriction did not alter the frequency of insulin therapy 17.5 in the intervention group and 16.9 in the control group). <sep>', 'p  0.969 prevalence of macrosomia lgi 2.1 vs. hf 6.7 p  0.157 insulin treatment lgi 53 vs. hf 65 p  0.251 or adverse pregnancy outcomes. <sep>', 'diet gi on control 58 95 ci 56,60 was significantly higher than on low-gi 49 95 ci 47,51 p=0.001). <sep>', 'the h-mufa diet had no advantage to the h-cho diet in ameliorating the decline of insulin sensitivity in third term of pregnancy in gdm. <sep>', 'a low-glycemic index diet is effective as a treatment for individuals with diabetes and has been shown to improve pregnancy outcomes when used from the first trimester. <sep>'], 'population': ['women who experience the highest glycaemia levels after breakfast <sep> women with gdm <sep> women with gestational diabetes <sep> 30 caucasian women newly diagnosed with gdm with a mean age of 28.7 <sep> gestational diabetes mellitus gdm <sep>', 'obese pregnant women with gestational diabetes <sep> obese gestationally diabetic women <sep>', 'pregnant women with diabetes <sep> mexican pregnant women with diabetes <sep> women analyzed in this study n=69 had an age range of 22-42 years 47.8 had type 2 diabetes dm2 and 52.2 had gestational diabetes gdm <sep>', 'obese women with gestational diabetes <sep> gestational diabetes <sep>', 'gestational diabetes mellitus <sep> n  49 <sep> ninety-nine women age 26-42 years mean  sd prepregnancy bmi 24  5 kg/m diagnosed with gdm at 20-32 weeks gestation <sep>', 'participants recruited from the diabetes-in-pregnancy clinic of an inner-city teaching hospital serving a predominantly non-caucasian population <sep> women with gestational diabetes or impaired glucose tolerance of pregnancy <sep> women with gestational hyperglycaemia <sep>', 'women with gestational diabetes mellitus <sep> 27 women with gestational diabetes mellitus in an outpatient clinic <sep>', 'individuals with diabetes <sep> gestational diabetes mellitus <sep> women with gdm <sep> women with gestational diabetes mellitus gdm <sep> women n  63 <sep>'], 'interventions': ['nutrition therapy <sep> carbohydrate diets <sep> low carbohydrate diets <sep> high carbohydrate diet <sep> high and low carbohydrate diets <sep>', '1200-kcal diet <sep> calorie restriction <sep>', 'medical nutrition therapy program <sep> medical nutrition therapy program <sep>', 'dietary energy restriction <sep> moderate 30 maternal dietary energy restriction <sep>', 'conventional hf diet <sep> high-fiber moderate-gi diet hf <sep> low-glycemic index lgi versus a conventional high-fiber diet <sep> lgi <sep> low-glycemic index diet <sep> glycemic index gi <sep>', 'low-gi diet <sep> low-glycaemic-index gi diet <sep> low glycaemic index diet <sep> low-gi <sep>', 'high-carbohydrate diet h-cho or a high-mufa diet h-mufa <sep> unpaired diet intervention <sep> diet rich in monounsaturated fatty acids mufa <sep> high monounsaturated fatty acid diet <sep>', 'low-glycemic index diet <sep> low-glycemic index diet or a conventional high-fiber and higher glycemic index diet <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",data for most comparisons were only available from single studies and they are too small for reliable conclusions about which types of dietary advice are the most suitable for women with gdm. based on the current available evidence we did not find any significant benefits of the diets investigated. further larger trials with sufficient power to assess the effects of different diets for women with gdm on maternal and infant health outcomes are needed. outcomes such as longer-term health outcomes for women and their babies women's quality of life and health service cost should be included.
158,"{'outcomes': ['serum peak and trough concentrations of the antibiotics <sep> response rate <sep> tolerated <sep> duration of fever <sep>', 'unexplained fever <sep> prolonged neutropenia <sep> success rate <sep> incidence of side effects <sep> infection and unexplained fever <sep>', 'clinical sites of infection degree of neutropenia underlying malignancy and organisms <sep> control of infection <sep>', 'febrile neutropenia episodes <sep> proportion of patients that became afebrile <sep> success rates <sep> fever and neutropenia <sep> efficacy and safety <sep>', 'initial clinical response <sep> cost of change of antibiotics <sep> efficacy and cost effectiveness <sep> average cost of antibiotics <sep> initial clinical response rate <sep> cost effective <sep>', 'median duration for defervescence <sep> overall success rate <sep> infection <sep> febrile neutropenia <sep> reversible side effects <sep>', 'cure rates <sep> overall cure rate <sep>', 'depth and duration of granulocytopenia as well the distribution of the infection categories and rate of bacteremia <sep> duration of fever clinical symptoms antibiotic therapy and granulocytopenia <sep>', 'response rates <sep> febrile neutropenia <sep> overall successful outcome <sep>', 'clinical response <sep> leukopenia <sep>', 'six febrile episodes <sep> duration of neutropenia <sep> febrile episodes <sep> infection eradication success <sep> superinfections and toxicity <sep> global response <sep> gram positive cocci <sep>', 'clinical response rates <sep> febrile episodes <sep> gram-positive <sep> rates of superinfection <sep> superinfections of fungal origin <sep> microbiological eradication of gram-negative <sep>', 'bacteremia <sep> initial clinical response rate <sep>', 'febrile episodes <sep> infections and unexplained fever <sep> gram-positive infections <sep> clinical efficacy and tolerability <sep> tolerability <sep> tolerated <sep> nausea/vomiting or seizure <sep> clinical efficacy <sep> febrile infective episodes <sep> tolerated and produced response rates <sep>', 'efficacy <sep> occurrence of gram-negative bacteria <sep> overall clinical rate of response to imipenem <sep> gram-negative <sep>', 'renal failure <sep> efficacy <sep> clinical and laboratory adverse effects <sep> persistent bacteremia <sep> nausea <sep> microbiological adverse effects <sep> cure rates <sep> rates of clinical cure or improvement and of elimination of causative pathogens <sep> persistent staphylococcus aureus bacteremia <sep>', 'severe neutropenia <sep> febrile neutropenia fn <sep> fever of unknown origin <sep> adverse events <sep> febrile neutropenia <sep> acute leukemia <sep> neutrophil counts of 100/microl. microbiologically documented infection <sep>', 'overall response rates <sep> response rates <sep>', 'efficacy and costs <sep> mean total antibiotic drug cost <sep> defervescence <sep>', '876 febrile neutropenic episodes <sep> episodes of profound neutropenia <sep> adverse event <sep> rates for gram-negative rod bacteremia <sep> infectious mortality <sep> satisfactory response eradication of the infecting organism development of superinfections and occurrence of adverse events <sep>', 'efficacy <sep> granulocytopenia <sep>', 'nephrotoxicity nor hypokalemia alone <sep> adverse effects <sep> clinical response rates <sep>', 'efficacy safety and tolerance <sep> febrile neutropenic episodes <sep> success rates <sep>', 'mean neutrophil counts <sep> mean duration of neutropenia <sep> overall success <sep> adverse events <sep> fever and neutropenia <sep>', 'overall initial response <sep> febrile episodes <sep>', 'clinical response <sep> efficacy <sep>', 'morbidity and mortality <sep> febrile neutropenia <sep>', 'response rate <sep> fever and neutropenia <sep> response rate regarding gram-negative infections <sep> skin rash and vomiting <sep>', 'efficacy and safety <sep>', 'adverse experiences drug-related adverse events <sep> successful outcomes <sep> efficacy and tolerability <sep> superinfection <sep> withdrawals or deaths <sep> efficacy and tolerability <sep> efficacy and safety <sep>', 'serum creatinine <sep> infection-related death <sep> median duration of neutropenia and defervescence of fever <sep> febrile neutropenic episodes <sep> febrile neutropenia <sep> nephrotoxicity <sep> efficacy and safety <sep>', 'toxicity <sep> severe hypokalemia <sep> partial response rates <sep> complete response rates <sep>', ""treatment failure <sep> overall success <sep> bacteremia <sep> failure rate <sep> hodgkin's lymphoma nhl <sep> blood cultures <sep>"", 'fifty febrile netropenic episodes <sep> response rate <sep> duration of fever hospitalization and antimicrobial drug administration <sep> costs of the antimicrobial drugs hospitalization and total cost <sep> overall treatment success <sep> febrile neutropenia <sep> costs of hospitalization antimicrobial drugs and supportive therapy <sep> incidence of gram-negative and gram-positive isolates <sep> efficacy safety and cost of cefepime <sep>', 'amikacin levels <sep> serum creatinine <sep> lower potassium level <sep> granulocytopenic episode <sep> 69 febrile granulocytopenic episodes <sep>', 'success or failure <sep>', 'cure rates for gram-negative bacteremias <sep> overall response rate <sep>', 'renal tubular damage <sep> percentages of patients responding to therapy <sep> nausea or vomiting <sep>', 'per episode antibiotic cost <sep> overall treatment costs and duration of hospitalization <sep> adverse events <sep> duration of hospitalization <sep> total episode cost <sep> adverse events duration of hospitalization and cost between both groups <sep>', 'renal side effects <sep> febrile episodes <sep> haematological malignancies <sep> blood cultures <sep> urinary beta-nag <sep> urinary excretion of aap <sep> clinical cure or improvement <sep> serum levels of creatinine urea and beta 2-microglobulin and the urinary excretion of alanine aminopeptidase n-acetyl-beta-d-glucosaminidase beta-nag and beta 2-microglobulin <sep>', 'median durations of neutropenia <sep> success rates <sep> adverse effects <sep> efficacy safety and tolerance <sep> adverse event <sep> allergic reactions <sep> mortality <sep> occurrence of further infections <sep>', 'median neutrophil count <sep> febrile episodes <sep> bacteremia <sep> median duration of antibiotic therapy <sep> success rate <sep> febrile events <sep> leukemia or lymphoma <sep> median total duration of neutropenia <sep> median time to fever defervescence <sep>', 'durations of fever neutropenia and hospitalization <sep> febrile neutropenic episodes <sep> rate of treatment modification <sep> infection-related mortality <sep> infection rate <sep> febrile neutropenia <sep> duration of fever neutropenia and hospitalization mortality and the need for additional antibiotics or antifungal drugs <sep>', 'adverse events <sep> excellent response <sep> early death <sep> febrile neutropenia <sep>', 'gram-positive bacteremia <sep> side effects <sep>'], 'punchline_text': ['duration of fever was significantly shorter in the imi group 4 days vs 7 days p  0.04). <sep>', 'the success rate with unmodified therapy was not significantly different between the meropenem group 72 and the ceftazidime-plus-amikacin group 57%). <sep>', 'control of infection was achieved in 72 of patients treated with latamoxef and 55 treated with cephradine plus tobramycin. <sep>', 'the proportion of patients that became afebrile in the first 24 hours was significantly higher in the cefepime group 41.7 vs 11.1 respectively p  0.012). <sep>', 'the initial clinical response rate to ceftriaxone/gentamicin was 62.5 and 84.6 to imipenem/cilastatin p  0.075). <sep>', 'only minor reversible side effects were noted in both treatment arms. <sep>', 'the overall cure rate for the ceftazidime group was 71 and for the gentamicin plus cefotaxime 47%. <sep>', 'there was no difference with respect to the final response 53 for the monotherapy group versus 48 for the combination group and both regimens appeared to be equally safe. <sep>', 'a total of 733 patients were assessable for efficacy of the drug regimens and an overall successful outcome was reported in 49 179 of 364 of the patients who received monotherapy compared with 53 196 of 369 of patients who received combination therapy p=.2). <sep>', 'in group i clinical response was observed in 10 of 19 febrile episodes 52.6 treated with carbenicillin plus gentamicin and in 10 of 14 71.4 treated with latamoxef p greater than 0.05). <sep>', 'superinfections and toxicity related to antibiotics were minimal in both groups. <sep>', 'cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies and its lack of nephrotoxicity compared to p+g was noteworthy. <sep>', 'the initial clinical response rate for both regimens was 60 p  0.05). <sep>', 'meropenem monotherapy was well tolerated and produced response rates similar to those obtained with ceftazidime/amikacin. <sep>', 'the difference in distribution proved to be statistically significant for gram-negative p  0.0001 as well as gram-positive p  0.025 bacteria indicating that ciprofloxacin effectively prevented the occurrence of gram-negative bacteria and may have contributed to the relatively large number of gram-positive bacteria isolated. <sep>', 'there were no significant differences in terms of efficacy between imipenem/cilastatin and amikacin plus piperacillin but a consistent trend towards higher rates of clinical cure or improvement and of elimination of causative pathogens was noted in the imipenem/cilastatin group. <sep>', 'adverse events were minimal and three early deaths were observed at days 9 16 and 16 among patients treated with a single antibiotic and three in the combination regimen group at days 14 15 and 20. <sep>', 'single-agent therapy with imipenem is as effective as more conventional combination antibiotic therapy for the empirical treatment of febrile episodes in neutropenic patients with cancer. <sep>', 'piperacillin-tazobactam monotherapy is significantly more effective and cost-efficient than ceftriaxone plus gentamicin as first-line therapy in febrile neutropenic patients with hematological malignancies. <sep>', 'ceftazidime alone was as effective but safer than the combination of piperacillin and tobramycin for the empiric treatment of febrile neutropenic patients even those with profound and prolonged granulocytopenia. <sep>', 'isolated bacteria were more sensitive to ceftazidime than to tobramycin with amoxycillin/ampicillin. <sep>', ""fewer adverse effects occurred in the piperacillin-treated group 42 than in the combination-treated group 71 p  0.0399 by fisher's exact test although neither nephrotoxicity nor hypokalemia alone was significantly less frequent in patients receiving piperacillin. <sep>"", 'there was no statistically significant difference between the three treatment regimens with respect to efficacy safety and tolerance chi2 test p>0.05 but while the third and fourth generation cephalosporins  aminoglycosides were comparable for cost the monotherapy regimen was the most expensive. <sep>', 'treatment was successful without the need for modifications in 71 of the episodes in the t group and 81 in the c+a group p=0.23). <sep>', 'the long term response to ceftazidime was 33/71 46.5 per cent and to cefotaxime  tobramycin 31/86 36 per cent). <sep>', 'there was no difference in clinical response between the two therapeutic regimens as assessed 4 and 7 days after treatment began. <sep>', 'there were 18 cures in the cefepime group and 17 in the ceftriaxone plus amikacin group p  0.9). <sep>', 'the response rate regarding gram-negative infections was 10 out of 14 71 in the ipm/cs group and seven out of 12 58 in the lmox+tob group. <sep>', 'thirteen 29 of the patients treated with ceftazidime failed to respond clinically to treatment versus four 9 of the patients treated with ceftazidime/tobramycin p  0.046). <sep>', 'seventy-two hours after the start of therapy no significant between-group differences in treatment outcomes including withdrawals or deaths were seen. <sep>', 'monotherapy with pip/tazo was effective and safe for initial empirical treatment of febrile neutropenic episodes in children with al. <sep>', 'the two groups were equivalent with respect to clinical and laboratory parameters prior to antibiotic therapy and flucloxacillin was added to approximately 25 of the patients in each group on the clinical suspicion of gram positive infection. <sep>', 'the solid tumor group had significantly less bacteremia 4/34 versus 17/56 p  0.05 and treatment failure 3/34 versus 24/56 p  0.001 than the nhl group. <sep>', 'glycopeptide and antifungal drugs were added more frequently in the ceftazidime  amikacin group. <sep>', 'therapy with the combination resulted in a higher serum creatinine p less than 0.001 and a lower potassium level p less than 0.001 in comparison with monotherapy. <sep>', 'there was no significant difference in terms of success or failure between the two treatment groups. <sep>', 'cefoperazone plus amikacin resulted in an 88 overall response rate and cured 14 of 15 patients with bacteremia. <sep>', 'patients in the piperacillin plus gentamicin group experienced significantly more renal tubular damage whereas those who received imipenem suffered more nausea or vomiting. <sep>', 'there was no statistically significant difference in the response to treatment at 72 hr or after necessary antimicrobial modifications. <sep>', 'clinical cure or improvement was noted in 10 of 12 culture verified infections in the tobramycin and cefuroxime group and 11 of 14 episodes in the ceftazidime-group. <sep>', 'the occurrence of further infections assessed in patients for whom the allocated regimen was not modified did not differ between the two groups 12 in both groups). <sep>', 'no significant difference was found between piperacillin tazobactam and ceftazidime plus amikacin in terms of success rate 81 versus 83 empirical addition of vancomycin 42 versus 38 median time to fever defervescence 3.3 versus 2.9 days or median duration of antibiotic therapy 7.2 versus 7.4 days). <sep>', 'there was no difference between the two regimens for durations of fever neutropenia and hospitalization p  .05 for all categories). <sep>', 'at day 3 patients with neutrophil counts of 500 mu l receiving dual therapy had a better response than did those receiving monotherapy 45 vs. 27.6 p=.024). <sep>', 'gram-positive bacteremia responded poorly in the meropenem and ceftazidime/amikacin group 29 versus 25 whereas all gram-negative bacteremias responded except for one in the meropenem group caused by pseudomonas aeruginosa. <sep>'], 'population': ['patients who failed to respond to the initial antibiotic therapy were given <sep> febrile granulocytopenic patients <sep> 143 aplastic episodes with fever in 91 haematological patients with granulocytopenia <sep> patients with bacteriologically proven infections <sep> neutropenic patients with predominantly gram-positive infections <sep>', 'children with malignancy <sep> pediatric cancer patients at the high risk of severe infection <sep> from january 2001 to april 2002 <sep> fifty-four pediatric cancer patients with a total of 100 febrile neutropenic episodes treated at china medical college hospital <sep> 76 assessable febrile episodes 39 with meropenem and 37 with <sep> children with cancer and neutropenia <sep>', 'neutropenic patients with infection <sep> sixty neutropenic patients with infection <sep> neutropenic infection <sep>', 'patients with solid tumors treated with high dose chemotherapy hdc and peripheral blood stem cell support pbscs with febrile neutropenia <sep> patients with solid tumors treated with <sep> fifty-one episodes <sep>', '50 evaluable neutropenic cancer patients admitted for fever <sep> cancer patients <sep> cancer chemotherapy-induced neutropenic fever <sep> 24 patients <sep>', 'neutropenic cancer patients with fever <sep> patients without previous prophylactic antibiotics <sep> seventy seven patients were available for analysis <sep> study group of turkey <sep> eighty three patients with neutropenia and cancer <sep>', 'severe granulocytopenic patients <sep> 87 patients with a neutrophil count of less than 1000/mm3 at the start of the treatment <sep>', '90 granulocytopenic febrile patients presenting with a localized infection <sep> granulocytopenic patients <sep> localized infections in febrile granulocytopenic patients <sep>', '733 patients <sep> 760 febrile adult patients with cancer with chemotherapy-induced profound 500 neutrophils/mm3 and prolonged 10 days neutropenia <sep>', 'patients who had received no cis-platinum <sep> leukopenic febrile patients with solid tumors <sep>', 'fifty two patients 26 female aged 16 to 80 years old with 60 episodes of neutropenia were studied <sep> neutropenic patients <sep> febrile neutropenic patients <sep>', 'neutropenic patients with malignancies <sep> febrile neutropenic cancer patients <sep> 111 patients were enrolled and 99 patients <sep> neutropenic patients with underlying malignancy was conducted at two oncology centers <sep>', 'cancer patients <sep> febrile granulocytopenic cancer patients <sep> of 30 evaluable episodes 15 were treated with <sep> febrile neutropenic cancer patients <sep> febrile neutropenic  1000/mm3 patients with liquids and solid tumours <sep>', 'neutropenic cancer patients <sep> neutropenic patients <sep> a total of 93 febrile episodes 46 meropenem 47 <sep>', 'febrile neutropenic patients receiving either <sep> febrile neutropenic patients <sep>', 'evaluable patients with septicemia <sep> seventy-seven patients 37 were non-evaluable due to effective antibiotic treatment before the trial early institution of other antibiotics during the trial verified non-bacterial infections no neutropenia or other reasons <sep> 210 neutropenic cancer patients <sep> neutropenic patients <sep> neutropenic cancer patients <sep>', 'patients who remained febrile <sep> patients who developed fever with neutrophil counts 1,000/microl <sep> one hundred fifty-three patients were evaluable for response <sep> a total of 165 patients were entered into the trial <sep>', 'febrile episodes in neutropenic patients <sep> febrile neutropenic patients <sep> neutropenic patients with cancer <sep> eligible neutropenic patients with cancer <sep> neutropenic patients with cancer <sep>', '212 consecutive febrile episodes in 130 neutropenic patients with hematological malignancies <sep> febrile neutropenic patients with hematological malignancies <sep> febrile neutropenic patients <sep>', 'fever in the neutropenic patient without evidence of skin infections or anaerobic infections <sep> neutropenic patients with cancer <sep> 696 patients 83 acute leukemia or bone marrow transplantation 92 episodes were excluded from analysis because of protocol violation <sep>', 'patients with granulocytopenia <sep> hematopoietic proliferative diseases <sep> 120 febrile children with neoplastic diseases and granulocytopenia <sep>', 'serious bacterial infections <sep>', 'immunocompromised children with malignancy <sep> febrile neutropenic children <sep> febrile neutropenic children with malignancy in turkey <sep> in our center between january 1998 and january 1999 73 children with hematological malignancies acute lymphoblastic leukemia all acute myeloid leukemia aml 9 children with solid tumors rhabdomyosarcoma neuroblastoma had 87 febrile neutropenic episodes related to chemotherapy <sep> febrile neutropenia <sep>', 'cancer patients in chemotherapy who have fever and neutropenia <sep> patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy <sep> pediatric and adolescent patients with leukemia or lymphoma <sep> pediatric patients with leukemia and lymphoma <sep> seventy patients who presented 136 episodes were evaluated 68 in each arm of the study <sep> patients with a high risk of complications <sep>', 'neutropenic patients <sep> acute leukemia in therapeutic aplasia <sep> 157 patients with prolonged aplasia pmn less than 500/mm3 during more than 21 days hospitalized in a protected environment unit <sep>', 'severely neutropenic children <sep> febrile neutropenic children <sep> immunocompromised neutropenic children undergoing chemotherapy for neoplastic disease <sep>', 'both adults and children <sep> febrile neutropenic patients <sep> patients with acute leukemia and febrile neutropenia <sep> twenty patients were included in each group <sep> acute leukemia patients <sep>', 'patients with lung cancer <sep> leukocytopenic febrile patients less than 3,000 leukocytes per microliters temperature greater than 38 degrees c with lung cancer given induction therapy <sep> febrile neutropenic patients with lung cancer <sep>', 'febrile neutropenic children <sep> febrile neutropenic patients <sep> febrile children range 8 months to 18 years with neutropenia secondary to cancer chemotherapeutic agents <sep>', 'neutropenic cancer patients <sep> c&t patients <sep> 106 adult patients diagnosed with presumed bacterial infection and an underlying malignancy with an absolute neutrophil count anc  500/mm3 were enrolled in this open-label study <sep>', 'febrile neutropenic children with acute leukemia al <sep> children with acute leukemia <sep> seventy-two febrile episodes of 42 patients with a median age of 4.5 years 3.5 months to 19 years <sep> children with al <sep> children with al who had febrile neutropenic episodes <sep>', 'febrile neutropenic patients with hematological disorders <sep> one hundred and two patients with neutropenia less than 1 x 10(9)/l secondary to primary hematological disorders or chemotherapy for hematological malignancies <sep>', 'ninety episodes of neutropenic fever in children 0.7-16.0 mean age 7.7 years with solid tumors in a single center <sep> children with lymphoma and solid tumors <sep>', 'children with cancer <sep> children with febrile neutropenia <sep> pediatric cancer patients <sep>', 'granulocytopenic patients with presumed bacteremia <sep>', 'febrile episodes in leukemia in adults <sep> leukaemic patients with neutropenia <sep> 10 haematology departments of university hospitals on 174 leukaemic patients with prolonged bone marrow aplasia and presenting with a febrile episode <sep>', 'febrile cancer patients with and without granulocytopenia <sep> febrile cancer patients <sep> granulocytopenic and nongranulocytopenic febrile patients <sep> 15 patients with bacteremia <sep>', 'three-hundred and twelve episodes of fever in 234 neutropenic patients with haematological malignancies <sep> febrile neutropenic patients with haematological malignancies <sep>', 'cancer patients <sep> febrile pediatric cancer patients with anticipated prolonged neutropenia <sep> febrile pediatric cancer patients with prolonged neutropenia <sep> 129 febrile episodes in pediatric cancer patients with prolonged neutropenia <sep> pediatric febrile cancer patients <sep>', 'fifty-two immunocompromised patients with suspected septicaemia <sep> immunocompromised patients with ceftazidime or with <sep>', 'granulocytopenic cancer patients <sep> group <sep> persistently granulocytopenic cancer patients <sep> 1,034 randomized patients 958 were assessable in the intent-to-treat analysis for response to antibacterial therapy including 483 in the meropenem group and 475 in the <sep> granulocytopenic patients with cancer <sep>', 'neutropenic cancer patients <sep> between july 1993 and september 1996 107 consecutive febrile episodes in 83 neutropenic cancer patients with a median age of 41 years <sep> febrile neutropenic patients <sep>', 'children with acute lymphoblastic leukemia or acute myeloblastic leukemia <sep> 87 febrile neutropenic episodes that were evaluable for comparison 46 patients received pta and 41 patients were treated with <sep> childhood hematological malignancies <sep> patients aged 2-16 years with hematological malignancies who had febrile neutropenia <sep>', 'febrile neutropenic patients with hematologic disorders <sep> patients with severe neutropenia and leukemia who may benefit from dual therapy <sep> patients with leukemia <sep> febrile neutropenic patients <sep>', 'neutropenic cancer patients <sep> febrile neutropenic patients <sep> seventy-one patients with hematological malignancies 55 or solid tumors 45 neutropenia  500/microliter and fever  38.5 degrees c <sep>'], 'interventions': ['imipenem <sep> vancomycin and aztreonam <sep> imipenem imi or a combination of tobramycin and cefuroxime t/c <sep> tobramycin and cefuroxime <sep> cefuroxime plus tobramycin <sep> adjuvant glycopeptide therapy <sep>', 'meropenem <sep> ceftazidime plus amikacin <sep> ceftazidime-plus-amikacin <sep> meropenem or ceftazidime plus amikacin <sep> meropenem <sep>', 'latamoxef <sep> tobramycin <sep> latamoxef moxalactam alone or with cephradine and tobramycin <sep> cephradine plus tobramycin <sep> latamoxef <sep> latamoxef moxalactam with cephradine plus tobramycin <sep>', 'hdc and pbscs <sep> ceftazidime plus amikacin or cefepime <sep> ceftazidime plus amikacin <sep> monotherapy <sep> ceftazidime and amikacin <sep>', 'monotherapy <sep> ceftriaxone/gentamicin <sep> empiric imipenem/cilastatin or ceftriaxone/gentamicin <sep> imipenem/cilastatin <sep> empiric antibiotic therapy <sep> ceftriaxone plus gentamicin <sep> ceftriaxone plus gentamicin ceftriaxone/gentamicin <sep> ceftriaxone/gentamicin <sep>', 'amikacin plus ceftazidime <sep> meropenem with amikacin plus ceftazidime <sep> meropenem tds or amikacin 15 mg/kg single dose daily plus ceftazidime <sep> meropenem <sep> meropenem monotherapy <sep>', 'ceftazidime <sep> gentamicin plus cefotaxime <sep>', 'aminoglycosides <sep> ceftazidime alone or in combination with amikacin <sep> ceftazidime with or without amikacin <sep> amikacin <sep>', 'piperacillin-tazobactam <sep> placebo <sep> placebo versus piperacillin-tazobactam plus amikacin <sep> piperacillin-tazobactam with and without amikacin <sep>', 'carbenicillin <sep> vitamin k i.v <sep> carbenicillin 10 g every 8 h plus mecillinam 800 mg every 8 h or latamoxef 2 <sep> gentamicin 80 mg every 8 h or latamoxef <sep> carbenicillin plus gentamicin <sep> latamoxef versus carbenicillin plus gentamicin <sep> latamoxef <sep> cis-platinum <sep> carbenicillin plus mecillinam <sep>', 'imipenem/cilastatine <sep> ceftazidime <sep> amikacin 7.5 mg/kg iv bid <sep> ceftazidime with amikacin <sep> imipenem/cilastatine and ceftazidime-amikacin <sep> imipenem/cilastatin <sep> imipenem/cilastatine <sep> ceftazidime-amikacin <sep>', 'cefepime versus piperacillin-gentamicin <sep> cefepime versus piperacillin plus gentamicin p+g <sep>', 'imipenem-cilastatin monotherapy <sep> sulbactam-cefoperazone plus amikacin <sep> imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin <sep> imipenem-cilastatin and sulbactam-cefoperazone with amikacin <sep> imipenem-cilastatin <sep> cefoperazone plus amikacin <sep>', 'amikacin <sep> ceftazidime plus amikacin <sep> ceftazidime <sep> meropenem monotherapy <sep> cilastatin <sep> ceftazidime/amikacin <sep> meropenem <sep> meropenem monotherapy <sep>', 'cefuroxime or cephalothin <sep> imipenem <sep> ciprofloxacin <sep> cefuroxime <sep> combination therapy <sep> imipenem-cilastatin <sep> no prophylaxis or ciprofloxacin <sep> cephalothin <sep> gentamicin <sep> imipenem versus gentamicin <sep> ciprofloxacin prophylaxis oral <sep>', 'amikacin plus piperacillin <sep> imipenem/cilastatin <sep> imipenem/cilastatin <sep> amikacin or piperacillin <sep>', 'cefepime or carbapenem <sep> single antibiotic cefepime or one of the carbapenems or a combination of cefepime and an aminoglycoside <sep> cephalosporin <sep>', 'imipenem <sep> ceftazidime plus amikacin <sep> ceftazidime <sep> imipenem to ceftazidime with or without amikacin <sep> ceftazidime and imipenem <sep> ceftazidime alone imipenem alone ceftazidime plus amikacin <sep> vancomycin <sep> aminoglycoside amikacin <sep> imipenem plus amikacin <sep>', 'piperacillin-tazobactam <sep> piperacillin-tazobactam <sep> meropenem teicoplanin and amphotericin b <sep> teicoplanin plus ciprofloxacin <sep> piperacillin-tazobactam monotherapy <sep> empirical antibacterial therapy <sep> teicoplanin plus gentamicin <sep> ceftriaxone <sep> aminoglycoside <sep> gentamicin <sep> ceftriaxone plus gentamicin <sep>', 'tobramycin <sep> piperacillin and tobramycin <sep> piperacillin and tobramycin with ceftazidime alone <sep> ceftazidime <sep> ceftazidime <sep> piperacillin <sep> intravenous ceftazidime <sep>', 'tobramycin <sep> ceftazidime and tobramycin combined with amoxycillin/ampicillin <sep> ceftazidime <sep> tobramycin combined with amoxycillin/ampicillin <sep> amoxycillin/ampicillin <sep> ceftazidime monotherapy <sep>', 'piperacillin <sep> carboxypenicillin-aminoglycoside combinations <sep> piperacillin <sep> piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens <sep>', 'cefepime plus netilmicin <sep> ceftazidime plus amikacin <sep> amphotericin-b therapy <sep> cefepime  netilmicin or ceftazidime  amikacin <sep> meropenem monotherapy <sep> meropenem as monotherapy <sep> cephalosporin plus aminoglycoside and monotherapy of meropenem with ceftazidime plus amikacin <sep>', 'monotherapy with ticarcillin/clavulanic acid t or ceftriaxone plus amikacin c+a <sep> c+a <sep> ticarcillin/clavulanic acid versus ceftriaxone plus amikacin <sep> ceftriaxone plus amikacin <sep> intravenous monotherapy <sep>', 'cefotaxime  tobramycin <sep> ceftazidime <sep> cefotaxime-tobramycin combination <sep> ceftazidime alone or cefotaxime  tobramycin <sep>', 'ceftriaxone vs. azlocillin and netilmicin <sep> netilmicin and azlocillin <sep> ceftriaxone <sep> aminoglycoside netilmicin and the penicillin azlocillin <sep> cephalosporin ceftriaxone <sep>', 'chemotherapy <sep> ceftriaxone-amikacin <sep> ceftriaxone plus amikacin <sep> cefepime or ceftriaxone plus amikacin <sep> vancomycin <sep> amphotericin b was started <sep>', 'imipenem/cilastatine <sep> ipm/cs monotherapy <sep> latamoxef plus tobramycin <sep> imipenem/cilastatine ipm/cs monotherapy <sep> ipm/cs and 50 with lmox+tob <sep> latamoxef lmox and tobramycin tob <sep>', 'antibiotic monotherapy <sep> ceftazidime/tobramycin <sep> ceftazidime plus tobramycin <sep> ceftazidime <sep> ceftazidime <sep>', 'ceftazidime plus full-course therapy with an aminoglycoside tobramycin <sep> imipenem-cilastatin i-c <sep> imipenem-cilastatin <sep> imipenem-cilastatin versus ceftazidime plus tobramycin <sep>', 'pip/tazo versus pip/tazo plus amikacin <sep> piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin <sep> monotherapy with pip/tazo <sep> piperacillin/tazobactam pip/tazo versus pip/tazo plus amikacin <sep> amikacin with pip/tazo <sep>', 'ceftazidime versus azlocillin plus amikacin <sep> antibiotic therapy and flucloxacillin <sep> azlocillin plus amikacin  flucloxacillin <sep> ceftazidime <sep> azlocillin plus amikacin <sep> flucloxacillin <sep> antibiotic therapy <sep> ceftazidime  flucloxacillin <sep>', 'meropenem <sep> amikacin <sep> piperacillin plus amikacin <sep> piperacillin plus amikacin combination <sep> meropenem monotherapy with combination therapy <sep> piperacillin <sep> monotherapy with meropenem <sep> meropenem monotherapy <sep>', 'ceftazidime  amikacin combination <sep> ceftazidime  amikacin <sep> cefepime 150 mg/kg/day or ceftazidime 150 mg/kg/day combined with amikacin <sep>', 'potassium supplementation <sep> amikacin plus piperacillin <sep> ceftazidime <sep> monotherapy <sep> amikacin plus piperacillin or ceftazidime <sep>', 'ceftazidime <sep> ceftazidime <sep> cefotaxime-amikacin combination <sep>', 'cefoperazone <sep> cefoperazone plus amikacin <sep> single-drug versus combination empirical therapy <sep> cefoperazone plus amikacin <sep>', 'imipenem <sep> piperacillin plus gentamicin <sep> piperacillin and gentamicin <sep>', 'ceftriaxone plus amikacin c  a and imipenem monotherapy control <sep> single or multi-agent antibiotic therapy <sep>', 'tobramycin and cefuroxime <sep> ceftazidime <sep> cefuroxime <sep> tobramycin <sep>', 'meropenem <sep> ceftazidime plus amikacin <sep> monotherapy <sep> meropenem monotherapy <sep> ceftazidime-plus-amikacin <sep> beta-lactams plus aminoglycosides <sep>', 'piperacillin/tazobactam <sep> ceftazidime plus amikacin <sep> piperacillin/tazobactam 4.5 g every 8 h i.v. or ceftazidime 2 g every 8 h plus amikacin <sep> vancomycin <sep> piperacillin tazobactam <sep>', 'piperacillin/tazobactam 80 mg/kg piperacillin/10 mg/kg tazobactam q6h combined with amikacin pta <sep> piperacillin/tazobactam plus amikacin <sep> pta <sep> carbapenem monotherapy <sep> meropenem or imipenem <sep> piperacillin/tazobactam and amikacin combination with carbapenem monotherapy <sep> carbapenems imipenem or meropenem <sep> carbapenem <sep>', 'cefepime/amikacin combination dual therapy <sep> cefepime monotherapy <sep> amikacin <sep>', 'meropenem <sep> amikacin <sep> ceftazidime <sep> ceftazidime/amikacin <sep> ceftazidime and amikacin <sep> meropenem <sep> meropenem monotherapy <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",beta-lactam monotherapy is advantageous compared with beta-lactam-aminoglycoside combination therapy with regard to survival adverse events and fungal super-infections. treatment failure should not be regarded as the primary outcome in open-label trials as it reflects mainly treatment modifications.
159,"{'outcomes': ['psychosocial global score <sep> qol and depressive symptoms <sep> quality of life qol <sep> physical global score <sep> physical global qol score <sep> lean mass <sep> changes in qol cares short form and depressive symptoms ces-d <sep> quality of life <sep> ces-d scores <sep> upper body strength <sep>', 'physical fitness test and qol measures e.g. functional assessment of cancer therapy scales <sep> quality of life qol <sep> physical fitness and quality of life outcomes <sep>', 'quality of life qol <sep> cardiovascular fitness <sep> functional assessment of cancer therapy-colorectal <sep> adherence <sep> change in qol <sep>', 'peak oxygen consumption <sep> overall qol <sep> overall qol <sep> cardiopulmonary function and quality of life qol <sep> peak oxygen consumption <sep> peak oxygen consumption and overall qol <sep> cardiopulmonary function and qol <sep> functional assessment of cancer therapy-breast scale <sep>', 'social functioning <sep> exercise and quality of life <sep> good adherence <sep> quality of life benefits <sep> happiness depressive symptoms anxiety stress self-esteem and quality of life <sep> quality of life <sep> baseline quality of life <sep>', 'depressive and state anxiety scores <sep> maximum heart rate <sep> depression beck depression inventory anxiety speilberger state-trait anxiety inventory and self-esteem rosenberg self-esteem inventory <sep> depression and state and trait anxiety <sep> depressive and anxiety symptoms <sep> depressive and anxiety symptoms and self-esteem <sep> self-esteem and depressive and anxiety symptoms <sep> self-esteem <sep>', 'fatigue <sep> overall qol <sep> changes in qol eg functional assessment of cancer therapy <sep> distressed mood <sep> quality of life <sep> quality of life qol fatigue distressed mood and spiritual well-being <sep>', 'quality of life qol <sep> overall qol <sep> inflammatory marker serum c-reactive protein crp <sep> fatigue t(153 <sep> qol and fatigue <sep> functional assessment of cancer therapy-general and functional assessment of cancer therapy-fatigue <sep> mood disturbance t(122 <sep> inflammation crp <sep> quality of life fatigue mood and inflammation <sep>', 'exercise and dietary behavior fatigue health-related quality of life qol aerobic exercise tolerance functional capacity muscle strength and anthropometery <sep> fatigue p=.005 aerobic exercise tolerance p=.010 chair sit-to-stand performance p=.003 and waist-to-hip ratio <sep> qol <sep> dietary fiber intake <sep> dietary behavior fatigue aerobic exercise tolerance functional capacity and waist-to-hip ratio <sep> adherences <sep> exercise behavior <sep>', '12-month birs total and subscale scores upper and lower body strength and general quality of life qol <sep> strength and qol improvements <sep> strength and qol variables <sep> strength and qol changes <sep> birs total score <sep> strength and health subscale <sep> body image and relationship scale <sep> self-perceptions of appearance health physical strength sexuality relationships and social functioning <sep> baseline birs scores <sep>', 'isometric muscle strength and aerobic capacity <sep> global quality of life physical well-being and functionality <sep> chronic fatigue and quality of life <sep> muscle strength <sep> fatigue and health-related quality of life <sep> cancer-related fatigue <sep>', 'time interaction for overall qol <sep> qol <sep> fatigue social physique anxiety and physical fitness <sep> overall quality of life qol <sep> functional assessment of cancer therapy-breast scale <sep>', 'functional assessment of cancer therapy-breast social/family well-being functional well-being and breast cancer subscale scores <sep> psychological health outcomes <sep> qol depression exercise behavior aerobic fitness outcomes <sep> quality of life qol <sep>', 'body composition measurement quantified walking activity and patient-reported outcomes physical activity fatigue and health-related quality of life <sep> physical performance <sep> quantified physical performance and self-reported physical functioning <sep> physical performance measures <sep>', 'accelerometer physical activity counts <sep> waist-to-hip ratio <sep> back/leg muscle strength <sep> aerobic fitness <sep> physical activity <sep> joint stiffness <sep>', 'fatigue and diurnal salivary cortisol concentration <sep> lower morning and 5 p.m. salivary cortisol and improved emotional well-being and fatigue scores <sep> self-perceived psychosocial function and diurnal salivary cortisol secretion <sep>', 'fatigue sleep disturbance depression and pain <sep> sleep disturbance <sep> fatigue and pain <sep> piper fatigue scale general sleep disturbance scale center for epidemiological studies-depression scale and worst pain intensity scale <sep> depression <sep> mild fatigue levels sleep disturbance and mild pain <sep>', 'pa and improved fitness and specific aspects of psychological well-being <sep> vigor and a reduction in fatigue <sep> body mass index and percent body fat <sep> total minutes of pa more minutes of moderate-intensity pa and higher energy expenditure <sep> overall mood and body esteem <sep>', 'cardiovascular fitness <sep> reductions in distress <sep> body image physical condition and weight concerns subscales <sep> psychological distress <sep>', 'quality of life questionnaire <sep> lower-body flexibility <sep> quality of life <sep> aerobic capacity <sep> body fat <sep> physiological and psychological function <sep>', 'fatigue <sep> self-reported emotional health-related quality of life and symptom outcomes <sep> mental health depression positive affect and spirituality peace/meaning <sep>', 'fatigue p<0.001 depression p<0.001 body mass index <sep> global qol <sep> quality of life and physical performance and activity <sep> qol. physical performance and activity level <sep> physical activity <sep> physical performance <sep> physical activity <sep> eortc qlq-c30 facit-f rbdi and whq for vasomotor symptoms questionnaires <sep> quality of life qol and physical performance and activity <sep> qol. physical activity level <sep>', 'fatigue <sep> median adherence <sep> cardiovascular fitness <sep> physical functioning and quality of life qol <sep> lean body mass <sep> peak cardiovascular fitness <sep> general health <sep> depression <sep> overall qol <sep> patient-rated physical functioning assessed by the trial outcome index-anemia <sep> risk of disease recurrence/progression <sep> objective physical functioning <sep> overall qol psychosocial functioning cardiovascular fitness and body composition <sep> physical functioning and quality of life <sep>', 'physical performance <sep> physical cognitive and emotional status and somatic complaints with the european organization for research and treatment of cancer quality of life questionnaire core module eortc-qlq-30 questionnaire and maximal physical performance <sep> global health <sep> fatigue and physical performance <sep> physical performance <sep> fatigue and global health scores <sep>', 'quality of life <sep> psychosocial adjustment and quality of life <sep> range of motion of the shoulder joint and psychosocial adjustment and quality of life <sep>', 'fatigue and improving energy level quality of life mental and physical fitness vo 2submax and emotional distress <sep> physical quality of life <sep> fatigue energy level and emotional distress <sep>', 'vo(2max <sep> mental distress as assessed by the hospital anxiety and depression scale and hrqol as assessed by the european organisation for research and treatment of cancer core quality of life questionnaire <sep> cardiorespiratory fitness crf mental distress and health-related quality of life hrqol parameters <sep> fatigue score <sep> mental distress or hrqol <sep> change in crf as determined by astrand-rhyming indirect bicycle ergometer test maximum oxygen uptake vo(2max between baseline t0 and follow-up t1 <sep> cardiorespiratory fitness and health-related quality of life <sep>', 'subjective sleep quality <sep> intrusion or avoidance state anxiety depression or fatigue <sep> faster sleep latency <sep> longer sleep duration <sep> quality of life <sep> psychological adjustment and sleep quality <sep> sleep medications <sep> sleep disturbance scores <sep>', 'quality of life over time <sep> sleep quality <sep> mental health dimension of quality of life <sep> taiwanese version of the pittsburgh sleep quality index the medical outcomes study short form-36 the taiwanese version ratings of the perceived exertion scale and a walking exercise log <sep> enhanced sleep quality <sep> bodily pain <sep> sleep quality and quality of life of cancer patients <sep> sleep quality and quality of life <sep>', 'biomarkers fatigue sleep disturbances and depressive symptoms <sep> sleep quality <sep> cortisol serotonin interleukin-6 and bilirubin biomarkers and fatigue sleep disturbances and depressive symptoms <sep> pittsburgh sleep quality index psqi the piper revised fatigue scale and the center for epidemiological studies-depression scale <sep> sleep actigraphy <sep> fatigue sleep disturbances depressive symptoms biomarkers and exercise <sep> psqi <sep> sleep <sep> sleep scores <sep> serotonin levels <sep>', 'health-related quality of life hrql and self-esteem <sep> hrql and self-esteem <sep> tai chi chuan health-related quality of life and self-esteem <sep> self-esteem <sep> hrql <sep>', 'quality of life qol <sep> quality of life and symptoms <sep> symptoms of side effects of cancer treatment and inflammation biomarker crp <sep> global qol scores <sep>', 'shoulder pain and disability <sep> neck dissection impairment fatigue and quality of life <sep> shoulder pain and disability and improved upper extremity muscular strength and endurance <sep> patient-rated shoulder pain and disability <sep> upper extremity strength and endurance range of motion fatigue and quality of life <sep> shoulder pain and disability <sep> upper extremity endurance <sep> upper extremity strength <sep>', 'overall well-being and quality of life <sep> psychosocial i.e. global quality of life emotional function and diarrhea variables <sep> psychosocial variables of emotional irritability gastrointestinal symptoms cognitive disorganization mood disturbance tension depression and confusion <sep>', 'helplessness/hopelessness <sep> higher satisfaction <sep> decreased depression <sep> measures of spiritual integration <sep> quality of life mood and spiritual integration <sep> quality of life <sep> spiritual <sep> initial fighting spirit <sep> decreased confusion <sep> decreased anxiety <sep>', 'anxiety depression body image and health-related quality of life <sep> psychosocial wellbeing individual body image and physical fitness <sep> maximal oxygen uptake vo(2)max/kg <sep> anxiety <sep> anxiety depression body image and quality of life <sep> quality of life and social body image <sep> individual body image <sep> depression <sep>', 'cardiorespiratory fitness strength endurance task specific functional muscle capacity body composition and quality of life qol <sep> peak oxygen uptake vo2peak a dynamic strength endurance test maximum number of repetitions for chest and leg press exercise <sep> qol and the overall physical fitness <sep> cancer qlq-c30 eortc-c30 questionnaire <sep> quality of life <sep> performance in leg press <sep>', 'fatigue <sep> fatigue multidimensional fatigue symptom inventory-short form and functional assessment in chronic illness therapy-fatigue subscale <sep> quality of life physical functioning positive and negative affect depression body composition sleep dysfunction and self-reported physical activity <sep>'], 'punchline_text': ['the psychosocial global score also improved significantly in the treatment group compared with the control group standardized difference  0.52 p  .02). <sep>', 'we also found borderline significant interactions for physical well-being satisfaction with life and flexibility. <sep>', 'adherence in the exercise group was good 75.8 but contamination in the control group was problematic 51.6%). <sep>', 'baseline values for peak oxygen consumption p .254 and overall qol p .286 did not differ between groups. <sep>', 'exercise was not associated with quality of life benefits in the full sample of either study however exercise was associated with improved social functioning among post-treatment survivors who reported low social functioning at baseline p<0.05). <sep>', 'self-esteem did not change significantly. <sep>', 'regression analyses indicated that the control group had a greater decrease in social well-being compared with the intervention group after controlling for baseline social well-being and covariates p  .0001). <sep>', 'this study indicates that mq can improve cancer patients overall qol and mood status and reduce specific side-effects of treatment. <sep>', 'the lifestyle intervention elicited improvements in exercise behavior p=.068 fatigue p=.005 aerobic exercise tolerance p=.010 chair sit-to-stand performance p=.003 and waist-to-hip ratio p=.002). <sep>', 'a differential impact of the intervention on the strength and health subscale was observed for older women 50 years old in the treatment group p  0.03). <sep>', 'the scores for global quality of life physical well-being and functionality increased from t1 to t2 but further improvement in the follow-up t3 was only observed in the training group. <sep>', 'repeated measures analyses of variance revealed a significant group by time interaction for overall qol p<0.001). <sep>', 'significant differences that favored aerobic exercise therapy relative to usual care were recorded for functional assessment of cancer therapy-breast social/family well-being functional well-being and breast cancer subscale scores at 8-week follow-up. <sep>', 'significant intervention effects were observed at both posttreatment and follow-up on physical performance measures. <sep>', 'a behavior change intervention for breast cancer survivors based on the social cognitive theory is feasible and results in potentially meaningful improvements in physical activity and selected health outcomes. <sep>', 'the yoga group had lower morning and 5 p.m. salivary cortisol and improved emotional well-being and fatigue scores. <sep>', 'no group differences were found in the changing scores over time. <sep>', 'the intervention successfully increased pa and improved fitness and specific aspects of psychological well-being among early-stage breast cancer patients. <sep>', 'data showed that the women in the exercise group improved significantly in body image physical condition and weight concerns subscales vs control group participants at post-treatment. <sep>', 'the results revealed statistically significant increases in aerobic capacity p  0.001 and lower-body flexibility p  0.027 a significant decrease in body fat p  0.001 and a significant increase in quality of life p  0.001 and a measure of energy p  0.038 in the exercise group when compared with the control group. <sep>', 'the yoga group demonstrated a significant within-group improvement in fatigue no significant difference was noted for the control group. <sep>', 'the global qol was lower than in general population 69.4 vs 74.7 p<0.001). <sep>', 'aet significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response. <sep>', 'fatigue and global health scores improved in both groups during the intervention fatigue training group 21 relaxation group 19 global health of both groups 19 p for all  or 0.01 however there was no significant difference between changes in the scores of both groups p=0.67). <sep>', 'the results showed an increased range of motion of the shoulder joint and psychosocial adjustment and quality of life were shown to be significantly higher in the intervention group than in the control group. <sep>', 'results showed that participants in the intervention group showed greater improvement in fatigue energy level and emotional distress at 3-month follow-up and physical quality of life at postintervention compared with the participants in the control group. <sep>', 'the fatigue score decreased by 17.0 points in the control group compared with only 5.8 points in the intervention group p  .01). <sep>', 'patients in the ty group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group 5.8 vs. 8.1 p  0.004). <sep>', 'patients in the exercise group reported significant improvements in sleep quality beta  3.54 p  0.01 and the mental health dimension of quality of life beta  10.48 p  0.01). <sep>', 'exercise group scores on the psqi decreased significantly over time indicating improved sleep quality although scores did not change significantly within the control group. <sep>', 'health-related quality of life hrql and self-esteem are often diminished among women diagnosed and treated for breast cancer. <sep>', 'the mq intervention also reduced the symptoms of side effects of cancer treatment and inflammation biomarker crp compare to the control group. <sep>', 'the pret program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage. <sep>', ""there were also trends for group differences in the hypothesized directions for the psychosocial variables of emotional irritability gastrointestinal symptoms cognitive disorganization mood disturbance tension depression and confusion all p's 0.10). <sep>"", 'only the cam group showed increases in measures of spiritual integration p=0.001 which were also significant between groups p=0.003). <sep>', 'patients in the ig improved significantly over time with regard to anxiety p  0.03 d  0.45 depression p  0.05 d  0.43 individual body image p  0.006 d  0.44 and vo(2)max/kg p  0.001 d  0.50 whereas no improvements were observed in the wg. <sep>', 'in response to training qol vo2peak mean 3.9 ml/kg/min 95  ci 0.93 6.90 performance in leg press 17.9 kg 95  ci 12.8 22.4 and sit-stand test  0.67 s 95  ci  0.52  1.2 improved p  or  0.05). <sep>', 'significant differences favouring the intervention group were observed for fatigue at 12 weeks and 6 months follow-up 12 week <sep>'], 'population': ['86 survivors 4-36 months posttreatment <sep> recent breast cancer survivors <sep> breast cancer survivors <sep> breast cancer survivors wtbs study <sep>', 'cancer survivors <sep>', 'recently resected colorectal cancer survivors most of whom were receiving adjuvant therapy <sep> colorectal cancer survivors <sep>', 'postmenopausal breast cancer survivors <sep> postmenopausal breast cancer survivors who had completed surgery radiotherapy and/or chemotherapy with or without current hormone therapy use <sep> fifty-two participants completed the trial <sep> fifty-three postmenopausal breast cancer survivors <sep>', 'diagnosed breast cancer survivors undergoing adjuvant therapy and b a similar trial among post-treatment survivors <sep> breast cancer <sep> fifty newly diagnosed breast cancer survivors <sep> forty-five participants completed the trial for newly diagnosed survivors and 67 completed the trial for post-treatment survivors <sep>', 'midwestern university town <sep> the mean age of the sample was 48.9 years <sep> subjects who received exercise recommendations from their physicians exercised significantly more than subjects who received no recommendation <sep> breast cancer survivors <sep> twenty-four breast cancer survivors mean time following surgery 41.8 months ranging from 1 to 99 months recruited via mail and cancer support groups <sep>', 'breast cancer patients <sep> one hundred twenty-eight patients 42 african american 31 hispanic recruited from an urban cancer center <sep> multiethnic sample of breast cancer patients <sep> sixty-nine percent of intervention participants attended classes mean number of classes attended by active class participants  7.00 <sep>', 'one hundred and sixty-two patients with a range of cancers were recruited <sep> cancer patients <sep>', ' 2011 american congress of rehabilitation medicine <sep> patients who had recently completed surgery and chemotherapy for colon cancer <sep> patients recovering from colon cancer <sep> eighteen n=18 colon cancer survivors mean age=69y range 52-80y dukes stage a to c. participants <sep>', '234 breast cancer survivors 112 with lymphedema who participated in the physical activity and lymphedema pal trial <sep> older women 50 years old <sep> breast cancer survivors with or at risk for lymphedema <sep> study population included two hundred and thirty-four women randomly assigned to <sep>', 'breast cancer patients <sep> breast cancer patients with tumor-related chronic fatigue <sep> 63 breast cancer patients with cancer-related chronic fatigue <sep>', 'breast cancer survivors n=58 within 2 years of completing adjuvant therapy <sep> breast cancer survivors soon after completing adjuvant therapy <sep> breast cancer survivors <sep>', 'women treated for breast cancer <sep> 108 women who had been treated for breast cancer 12 to 36 months previously <sep> cancer patients <sep>', 'patients who had completed hsct up to 6 months earlier <sep> hematopoietic stem-cell transplantation recipients <sep> patients physical performance and psychosocial well-being <sep>', 'most participants 93 were white with mean age of 53 <sep> breast cancer survivors <sep> sedentary breast cancer survivors receiving hormone therapy <sep> forty-one sedentary women on estrogen receptor modulators or aromatase inhibitors for stage i ii or iiia breast cancer <sep>', 'breast cancer survivors <sep> 2010 american academy of nurse practitioners <sep> stage ii-iv breast cancer survivors n  18 <sep> breast cancer survivors <sep> 2010 <sep>', 'participants n  119 <sep> cancer-related fatigue in women during and after chemotherapy with or without radiation therapy <sep>', 'breast cancer patients <sep> eighty-six sedentary women mean age 53.14 years standard deviation 9.70 years who had completed treatment for stage 0 to ii breast cancer <sep> early-stage breast cancer patients <sep>', 'women with breast cancer <sep> 24 women who had been diagnosed with breast cancer within the previous 3 years <sep> women receiving chemotherapy and/or radiation <sep>', 'eighteen survivors of breast or colon cancer 15 female and 3 male 40-65 yr of age served as subjects <sep> cancer survivors <sep> patients rehabilitating from cancer treatment <sep>', 'n=44 mean age 55.8 years enrolled in this study 34 were actively undergoing cancer treatment <sep> women with breast cancer <sep> women with breast cancer <sep> cancer patients <sep> cancer patients and post-treatment survivors <sep>', 'finnish female breast cancer patients shortly after adjuvant treatments <sep> breast cancer patients after adjuvant treatments <sep> 537 disease-free breast cancer survivors aged 35-68 years <sep>', 'edmonton alberta canada between 2005 and 2008 that stratified 122 lymphoma patients by major disease type and current treatment status and randomly assigned them to usual care uc n  62 or 12 weeks of <sep> lymphoma patients <sep>', 'cancer patients <sep> cancer patients after surgery <sep> seventy-two patients who underwent surgery for lung n=27 or gastrointestinal tumours n=42 <sep> patients recovering from surgery for solid tumours <sep>', 'early breast cancer patients in south korea <sep> women with early breast cancer in south korea <sep> early breast cancer patients <sep> fifty-five women with early breast cancer <sep>', 'breast cancer survivors <sep> eighty-seven french-speaking women who had completed their treatments for nonmetastatic breast cancer at a university hospital in quebec city canada <sep>', 'young and middle-aged cancer patients shortly after curative chemotherapy <sep> one hundred eleven patients age 18 to 50 years who had received chemotherapy for lymphomas or breast gynecologic or testicular cancer completed the trial <sep> young and middle-aged cancer patients shortly after chemotherapy <sep>', 'patients with lymphoma <sep> thirty-nine patients with lymphoma who were undergoing treatment or who had concluded treatment within the past 12 months <sep> copyright 2004 american cancer society <sep> patients with cancer <sep>', 'cancer patients <sep> participants were recruited from oncology outpatient clinics in two university-based medical centers <sep> cancer patients who are suffering from sleep disturbances <sep>', 'older women receiving hormonal treatment for their breast cancer <sep> older women with breast cancer receiving hormonal therapy <sep> 20 women aged 55 years or older with breast cancer receiving hormonal treatment <sep> older women receiving hormonal treatment for breast cancer <sep> older women receiving <sep>', 'women diagnosed and treated for breast cancer <sep> 21 women diagnosed with breast cancer who had completed treatment within the last 30 months <sep> breast cancer survivors <sep>', 'cancer patients <sep> thirty patients diagnosed with heterogeneous cancers <sep>', 'head and neck cancer survivors <sep> postsurgical head and neck cancer survivors <sep> fifty-two head and neck cancer survivors <sep> head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage <sep>', 'participants m age=51.18 10.33 92 female included primarily breast cancer survivors on average 55.95 54.39 months post-diagnosis <sep> eligible participants per-screened with par-q/par-med-x <sep> breast cancer survivors <sep> cancer survivors <sep>', 'women with breast cancer <sep> 181 women with breast cancer <sep>', 'breast cancer patients <sep> women with primary nonmetastatic breast cancer after a minimum 4-week period post chemotherapy and/or radiotherapy completion <sep>', 'women breast cancer survivors <sep> breast cancer survivors <sep> sixteen subjects <sep> group n  8 age 51 <sep>', 'twenty five percent of eligible women took part 33/134 <sep> northern ireland regional cancer centre <sep> gynaecological cancer survivors <sep> participants were 8.7 sd=9.1 months post diagnosis with a mean age of 53 sd=10.3 years <sep> gynaecological cancer survivors during and post anti-cancer treatments <sep> managing fatigue with gynaecological cancer survivors <sep> thirty three sedentary gynaecological cancer survivors stage i-iii 3 years post diagnosis experiencing cancer-related fatigue mild-severe took part <sep> the majority of the sample had a diagnosis of ovarian n=12 or endometrial cancer n=11 <sep>'], 'interventions': ['aerobic exercise training <sep> weight training <sep> weight training <sep>', 'psychotherapy gp <sep> physical exercise <sep> gp alone and 11 n=60 to gp plus home-based moderate-intensity exercise gp+ex <sep> psychotherapy and home-based physical exercise <sep>', 'home-based exercise intervention <sep> exercise <sep>', 'exercise training <sep> exercise training <sep> exercise <sep>', 'supervised exercise intervention n=37 or to usual care <sep> home-based exercise program n=25 or a usual care group <sep> exercise <sep>', 'aerobic exercise <sep> aerobic exercise <sep> moderate aerobic exercise <sep> ex and ex  bm <sep> exercise ex exercise-plus-behavior modification ex  bm <sep>', 'yoga intervention <sep>', 'medical qigong mq <sep> medical qigong <sep> mq <sep>', 'pragmatic lifestyle intervention <sep> pragmatic lifestyle intervention <sep> copyright <sep> combined exercise and dietary advice or standard treatment <sep>', 'twice-weekly strength training or control <sep> twice-weekly strength training intervention <sep>', 'structured physical training programs <sep> standard complex rehabilitation program the intervention group a structured physical training program and additional muscle strength and aerobic exercises <sep> structured training program <sep> structured physical training program <sep>', 'combined aerobic and resistance exercise <sep> combined aerobic and resistance training <sep> supervised aerobic and resistance exercise <sep> combined aerobic and resistance exercise program <sep> immediate exercise group ieg n=29 or a delayed exercise <sep>', 'supervised aerobic exercise therapy <sep> exercise-placebo <sep> exercise therapy <sep> aerobic exercise therapy <sep> exercise therapy and exercise-placebo <sep> aerobic exercise interventions <sep> exercise therapy <sep>', 'outpatient physical exercise pe program incorporating aerobic and strength exercises as compared with a usual care control condition <sep> usual care control group <sep> outpatient physical exercise program <sep> supervised pe program <sep> hematopoietic sct hsct <sep>', '12-wk multidisciplinary physical activity behavior change intervention or usual care <sep>', 'iyengar yoga practice <sep> regular iyengar yoga practice <sep>', 'home-based exercise <sep> exercise prescription throughout the study group 2 received their exercise prescription after completing cancer treatment and group 3 received usual care <sep> home-based exercise training intervention the pro-self fatigue control program <sep>', 'home-based physical activity pa intervention <sep> home-based pa intervention <sep> pa or contact control group <sep> home-based physical activity intervention <sep> pa counseling based on the transtheoretical model delivered via telephone as well as weekly exercise tip sheets <sep>', 'supervised aerobic exercise program in a hospital setting or a wait-list control group <sep>', 'aerobic exercise <sep> exercise <sep> low and moderate-intensity exercise <sep> aerobic exercise <sep> low and moderate-intensity aerobic-exercise programs <sep> exercise groups performed lower-body aerobic exercise <sep> control low 25-35 heart rate reserve hrr or a moderate 40-50 hrr intensity exercise group <sep>', 'restorative yoga ry <sep> ry intervention <sep> restorative yoga <sep> waitlist control group <sep>', 'exercise intervention <sep> physical exercise <sep> copyright <sep>', 'supervised aerobic exercise training <sep> aerobic exercise <sep> supervised exercise program <sep> exercise training <sep>', 'progressive relaxation training <sep> aerobic exercise and psychosocial interventions <sep> aerobic exercise group stationary biking 30 min five times weekly or a progressive relaxation training <sep> aerobic exercise and relaxation training <sep> structured aerobic training programme <sep>', 'comprehensive group rehabilitation <sep> comprehensive group rehabilitation program <sep> rehabilitation program comprised psychology-based education exercise and peer support group activity to promote recovery of the affected shoulder joint range of motion alleviate physical symptoms <sep>', 'group intervention experimental or the usual-care control condition <sep> brief group intervention that combines stress management psycho-education and physical activity ie independent variable intervention <sep>', 'physical activity <sep> supervised home-based flexible training program <sep> standard care <sep>', 'tibetan yoga intervention <sep> tibetan yoga ty practices of tsa lung and trul khor <sep> wait-list control group <sep>', 'home-based exercise intervention <sep> walking exercise program <sep> usual care n  35 or a home-based walking exercise intervention <sep> home-based walking exercise program <sep>', 'hormonal treatment <sep> walking exercise intervention <sep> prescribed home-based walking exercise intervention <sep> walking exercise intervention or usual care <sep> exercise <sep> exercise intervention <sep>', 'tai chi chuan tcc and psychosocial support pst <sep> tcc or pst <sep> tcc <sep>', 'medical qigong mq <sep> control group that received usual medical care and an intervention group who participated in a mq program for 8 weeks in addition to receiving usual medical care <sep> medical qigong coordination of gentle exercise and relaxation through meditation and breathing exercise based on chinese medicine theory of energy channels <sep> medical qigong <sep> mq intervention <sep>', 'standardized therapeutic exercise protocol tp <sep> pret <sep> progressive resistance exercise training pret <sep> exercise <sep>', 'yoga program <sep>', 'mind-body-spirit group <sep> cam <sep> standard group support or a 12-week complementary and alternative medicine cam support intervention <sep> standard group combined cognitive-behavioral approaches with group sharing and support <sep>', 'physical exercise program <sep> physical exercise rehabilitation <sep> exercise group program consisted of gymnastics movement games relaxation walking and jogging <sep> physical exercise programs <sep> physical exercise intervention <sep>', 'combined cardiorespiratory and resistance exercise training program <sep> 8-week exercise program consisting of 3 weekly sessions of 90-min duration supervised by an experienced investigator and divided into resistance exercises and aerobic training <sep> combined cardiorespiratory and resistance training <sep> control non-exercising <sep> combined aerobic and resistance training <sep>', 'behavioural change moderate intensity physical activity intervention n=16 or a contact control group <sep> physical activity behavioural change intervention <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",this systematic review indicates that exercise may have beneficial effects on hrqol and certain hrqol domains including cancer-specific concerns e.g. breast cancer body image/self-esteem emotional well-being sexuality sleep disturbance social functioning anxiety fatigue and pain at varying follow-up periods. the positive results must be interpreted cautiously due to the heterogeneity of exercise programs tested and measures used to assess hrqol and hrqol domains and the risk of bias in many trials. further research is required to investigate how to sustain positive effects of exercise over time and to determine essential attributes of exercise mode intensity frequency duration timing by cancer type and cancer treatment for optimal effects on hrqol and its domains.
160,"{'outcomes': ['lung function <sep> wet and dry weight of sputum <sep> shwachman-kulczycki clinical score <sep> wet and dry weights of sputum <sep>', 'lung volumes <sep> mean sem functional residual capacity <sep> functional residual capacity and total lung capacity <sep> positive expiratory pressure breathing <sep> mucus transport <sep> total lung capacity <sep>', 'sputum production symptom score or peak expiratory flow rate <sep> sputum production or change in lung function <sep>', 'skin oxygen tension pso2 <sep> pso2 <sep>', 'residual volume <sep> forced expiratory flow <sep> slow vital capacity <sep> ventilation distribution gas mixing lung volumes expiratory airflow percentage of arterial blood oxyhemoglobin saturation spo(2 and sputum volume <sep> lung function sputum expectoration and spo(2 <sep>', 'fev(1 <sep> pulmonary function <sep> fvc <sep> clinical status and pulmonary function forced vital capacity fvc fev1 and fef25-75 <sep>', 'postural drainage pd <sep> mucus clearance <sep> mean clearance of tracer from the right lung by postural drainage pep and physical exercise <sep>', 'pulmonary function tests pfts <sep> airway resistance raw or specific airway conductance sgaw <sep> forced expiratory volume in the first second of expiration fev1 forced expiratory flow <sep> pulmonary function <sep> pulmonary function studies <sep>', 'lung function parameter <sep> symptoms and lung function <sep> lung function parameters peak expiratory flow forced vital capacity fvc forced expiratory volume in one second maximal midexpiratory flow maximal expiratory flow at 25 of fvc thoracic gas volume total lung capacity residual volume/total lung capacity airway resistance and specific airway conductance and changes in transcutaneous oxygen haemoglobin saturation <sep> acceptability and subjective efficacy <sep> expectoration and lung function <sep>', 'lung function <sep> pep-induced lung function improvement per milliliter of sputum <sep>', 'huang scores <sep> forced expiratory volume <sep> increased hospitalizations <sep> number of hospitalizations and antibiotic use <sep> clinical status pulmonary function and compliance <sep> mean annual rate of decline in forced vital capacity <sep>', 'symptom scores sputum production or simple lung function tests <sep>', 'quantity of sputum <sep> sputum clearance <sep> arterial oxygen saturation fev1 or forced vital capacity <sep> positive expiratory pressure <sep>', 'number of spontaneous coughs <sep> radioactivity content <sep> whole lung or regional tbc <sep> clearance of lung radioactivity <sep> whole lung and regional tracheobronchial clearance tbc <sep> whole lung tbc <sep>', 'regards growth shwachman score chrispin-norman score or pulmonary function tests <sep>'], 'punchline_text': ['no significant differences between the three cpt regimens for both wet and dry weights were found when the number of coughs was taken into account.(abstract truncated at 250 words <sep>', 'lung volumes were higher during breathing with an expiratory pressure of 15 cm h2o than with 5 cm h2o both returned to baseline values immediately after positive expiratory pressure breathing. <sep>', 'there was no significant difference in sputum production or change in lung function between each technique as assessed by the physiotherapist. <sep>', 'in terms of sputum expectorated treatments b and c were superior to treatment d and especially to treatment a p less than 0.05). <sep>', 'residual volume decreased by 13 after no pep by 20 after low pep and by 30 after high pep. <sep>', 'the differences between treatment groups were statistically significant for the changes in fvc p  0.02 and fev(1 p  0.04). <sep>', 'the differences were not statistically significant. <sep>', 'paired t-test statistical analysis from the pft data indicated no significant changes in forced expiratory volume in the first second of expiration fev1 forced expiratory flow from 25 percent to 75 percent of the loop fef25-75 airway resistance raw or specific airway conductance sgaw among the three therapies studied. <sep>', 'no significant changes in any lung function parameter occurred after a single session or after 2 weeks of physiotherapy with either method. <sep>', 'lung function improved significantly after pep ad and pep-ad but pep-induced changes did not exceed those after ad. <sep>', 'there was a significant decline in huang scores p .05 increased hospitalizations 18 vs 5 p .03 and antibiotic use in the flutter group. <sep>', 'no difference was shown in symptom scores sputum production or simple lung function tests. <sep>', 'during treatment a a significantly greater quantity of sputum was produced than during treatments b and c p less than 0.025 and p less than 0.001 respectively). <sep>', 'there was no significant difference in whole lung or regional tbc between the pd  fet and pep  fet treatments. <sep>', 'at the end of the trial no significant difference was found between the programmes as regards growth shwachman score chrispin-norman score or pulmonary function tests. <sep>'], 'population': ['patients hospitalized for pulmonary exacerbations of cystic fibrosis <sep> sixteen patients with cf 8 males 8 females aged 15-27 years mean 20.3  4 met the inclusion criteria 1 age over 14 years 2 mild or moderate airway obstruction 3 sputum volume  30 ml/day 4 being proficient in pd and pep cpt <sep> patients with cystic fibrosis cf hospitalized for an acute pulmonary exacerbation <sep>', 'patients with cystic fibrosis <sep> eight patients with cystic fibrosis <sep>', '10 patients with cystic fibrosis <sep> patients with cystic fibrosis <sep>', '14 patients with cystic fibrosis <sep>', '5 patients with cf mean age=18 years sd=4 range=13-22 after no-pep low-pep 10-20 cm h(2)o and high-pep 20 cm h(2)o breathing conditions <sep> patients with moderate to severe cf lung disease <sep> patients with cystic fibrosis <sep> individuals with cystic fibrosis cf <sep>', 'cystic fibrosis <sep> forty patients ages 6 to 17 years with shwachman scores between 52 and 93 attending the cystic fibrosis clinic <sep>', 'cystic fibrosis <sep> nine clinically stable cystic fibrosis cf patients <sep>', 'cystic fibrosis patients of five to 17 years of age with mild to moderate disease <sep> pediatric cystic fibrosis patients <sep> 15 patients who qualified six completed the study <sep>', 'children with cf <sep> patients with cystic fibrosis cf <sep> 22 patients with cf mean age 12 yrs range 7-17 yrs performed <sep> children with cystic fibrosis <sep>', 'patients with airway hyperreactivity <sep> cystic fibrosis <sep> fourteen patients with cystic fibrosis <sep>', 'forty children with cf <sep> patients with cystic fibrosis cf <sep> cystic fibrosis <sep>', 'cystic fibrosis <sep> older patients <sep>', 'most adolescent and adult patients <sep> 18 patients with cystic fibrosis <sep> cystic fibrosis <sep>', 'cystic fibrosis <sep> patients with cystic fibrosis <sep> ten patients with cystic fibrosis <sep>', 'cystic fibrosis <sep> twenty-eight patients suffering from cystic fibrosis with an age range of 8-21 years <sep>'], 'interventions': ['control-treatment cont <sep> chrispin-norman chest radiography score 18.6 <sep> chest physiotherapy cpt regimens pd postural drainage pep positive expiratory pressure physiotherapy hfcc high-frequency chest compression physiotherapy <sep> chest physiotherapy regimens <sep>', 'positive expiratory pressure breathing <sep> positive expiratory pressure breathing alone and in combination with coughing <sep>', 'positive expiratory pressure pep mask with postural drainage <sep> positive expiratory pressure pep mask <sep> pep mask therapy <sep>', 'postural drainage percussion and vibration treatment b of postural drainage and periodic application of a face mask with positive expiratory pressure pep treatment c of pep <sep>', 'pep breathing <sep> pep therapy <sep> positive expiratory pressure <sep> positive expiratory pressure pep breathing <sep>', 'physiotherapy with the pep technique <sep> physiotherapy by the positive expiratory pressure pep technique with a pep mask astra meditec versus conventional postural drainage and percussion pd&p <sep> conventional postural drainage and percussion versus positive expiratory pressure physiotherapy <sep>', 'postural drainage pep and physical exercise <sep> postural drainage with thoracic expansion exercises  forced expiration technique fet in the left decubitus position 2 positive expiratory pressure pep)-mask breathing  fet and 3 physical exercise on a bicycle ergometer  fet <sep> chest physiotherapy <sep>', 'flutter device <sep> 9000 pep positive expiratory pressure pep therapy <sep>', 'physiotherapy using either the flutter or the pep mask <sep> flutter and pep mask physiotherapy <sep> positive expiratory pressure pep mask <sep>', 'self-administered chest physiotherapy <sep> chest physiotherapy pt techniques high-pressure pep-mask physiotherapy pep and autogenic drainage ad <sep> pep ad pep followed by ad pep-ad ad followed by pep ad-pep <sep>', 'physiotherapy with an oscillating positive pressure device flutter <sep> positive expiratory pressure <sep> physiotherapy with the pep mask or the flutter device for 1 year <sep> pep <sep> positive expiratory pressure versus oscillating positive expiratory pressure flutter physiotherapy <sep>', 'pep mask with forced expiratory coughing was compared with conventional physiotherapy <sep>', 'breathing exercises emphasising inspiration interspersed with the forced expiration technique in gravity assisted positions treatment b comprised breathing exercises with positive expiratory pressure alternating with the forced expiration technique in the same gravity assisted positions and treatment c comprised breathing exercises with positive expiratory pressure and the forced expiration technique in the sitting position <sep>', 'tbc <sep> pd  fet and pep  fet <sep> chest physiotherapy regimens <sep> fet <sep> pep  fet <sep> postural drainage and the forced expiration technique pd  fet and 2 positive expiratory pressure pep-mask and fet pep  fet <sep> postural drainage and positive expiratory pressure physiotherapy <sep>', 'positive expiratory pressure pep mask as a method of chest physiotherapy both on its own and in conjunction with other physiotherapy techniques <sep> pep mask <sep> forced expiratory technique fet alone <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",there was no clear evidence that pep was a more or less effective intervention overall than other forms of physiotherapy. there was limited evidence that pep was preferred by participants compared to other techniques but this finding is from studies of low quality.
161,"{'outcomes': ['toxicity <sep> median survival <sep> severe or worse thrombocytopenia <sep> histologic type astrocytoma with anaplastic foci versus glioblastoma multiforme initial performance status time since first symptoms and presence or absence of seizure <sep> survival <sep>', 'longer survival time <sep> time to progression <sep> percentage of patients alive <sep> median time to progression <sep> survival <sep> median survival time <sep>', 'total survival <sep> survival rate <sep> median survival <sep> cure rate <sep>', 'longer survival <sep>', 'median time <sep> median survival time <sep>', 'transient myelosuppression <sep> median survival times <sep> severe myelotoxicity <sep> longer survival period <sep>', 'median survival time <sep>', 'reversible leukopenia and thrombocytopenia <sep> survival <sep> long-term 18-month survival <sep> survival curves <sep>'], 'punchline_text': ['the combination of methyl-ccnu  dtic was more toxic than bcnu producing severe or worse thrombocytopenia in 23 of the patients as compared to 6 on bcnu. <sep>', 'the percentage of patients alive at 18 and 24 months was 34 and 21 in group 2 compared with 21 and 12 in group 1. <sep>', 'both relapse-free p  0.05 and total survival p  0.03 were significantly improved only in patients who were treated with radiotherapy plus ccnu compared to patients receiving radiotherapy alone after surgery. <sep>', 'significantly longer survival was experienced by patients receiving procarbazine or bcnu alone compared to those receiving only high-dose methylprednisolone. <sep>', 'the median time from diagnosis to crossover groups 1 and 2 or to progression group 3 was 163 99 and 220 days and the mean time was 172 108 and 231 days. <sep>', 'no severe myelotoxicity occurred but combined treatment with ccnu and dbd occasionally caused a transient myelosuppression. <sep>', 'tumor histological malignancy and patients age were found to be the only important prognostic factors irrespective of the treatment modality. <sep>', 'the combination of carmustine plus radiotherapy produced a modest benefit in long-term 18-month survival as compared with radiotherapy alone although the difference between survival curves was not significiant at the 0.05 level. <sep>'], 'population': ['626 patients entered this protocol <sep> malignant gliomas <sep> patients who were younger than age 40 years had an 18-month survival of 64 patients who were age 40-60 years had an 18-month survival of 20 and patients who were older than age 60 had an 18-month survival of 8 <sep> patients with anaplastic astrocytoma <sep>', 'adults with newly diagnosed supratentorial malignant gliomas <sep> adults with malignant gliomas <sep> we enrolled 269 patients 255 of whom were eligible <sep>', 'surgery plus radiotherapy for glioblastoma multiforme <sep> from september 1972 to december 1976 102 consecutive patients operated on for glioblastoma multiforme <sep>', 'patients with poor prognosis <sep> patients with malignant glioma <sep> malignant glioma <sep> 609 patients with histologically demonstrated supratentorial malignant glioma <sep> 527 patients 87 with glioblastoma multiforme in whom the initial protocol specifications were met the valid study group <sep>', 'high-grade supratentorial astrocytomas <sep> forty-one consecutive patients with supratentorial primary brain tumors 38 grade iii and iv astrocytomas one giant-cell astrocytoma and two cases with insufficient tissue for diagnosis <sep>', '91 patients with supratentorial glioblastomas and malignant astrocytomas <sep> malignant gliomas <sep> 84 evaluable patients <sep>', 'brain gliomas <sep> patients receiving radiation therapy alone was 61 <sep> 198 adult patients with supratentorial gliomas <sep>', '358 patients in whom the initial protocol specifications were met the valid study group <sep> malignant glioma after surgery <sep> 467 patients with histologically proved malignant glioma <sep>'], 'interventions': ['methyl-ccnu <sep> control radiation dose plus combination <sep> higher radiation dose control dose plus a booster dose of 1000 rad/1-2 weeks to the tumor 3 control radiation dose plus bcnu <sep> radiotherapy alone <sep> postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy <sep> bcnu and methyl-ccnu  dtic <sep> methyl-ccnu  dtic <sep>', 'adjuvant chemotherapy combining dibromodulcitol dbd and bischloroethylnitrosourea bcnu <sep> radiation therapy along with dbd plus bcnu <sep> dibromodulcitol and bcnu <sep> dbd plus bcnu <sep>', 'bcnu vs. ccnu <sep> radiotherapy <sep> bcnu <sep> radiotherapy <sep> subtotal tumor resection to receive irradiation alone irradiation plus bcnu or irradiation plus ccnu <sep> radiotherapy plus ccnu <sep> bcnu and ccnu <sep> adjuvant chemotherapy <sep>', 'methylprednisolone <sep> carmustine procarbazine and high-dose methylprednisolone <sep> radiotherapy <sep> carmustine bcnu high-dose methylprednisolone procarbazine or bcnu plus high-dose methylprednisolone <sep> procarbazine or bcnu <sep> bcnu and procarbazine <sep>', 'radiation therapy plus ccnu <sep> radiation therapy <sep> radiotherapy and ccnu <sep> 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea ccnu <sep>', 'radiotherapy alone group 2 received dibromodulcitol dbd during radiotherapy and treatment was then continued with dbd and group 3 received dbd during radiotherapy followed by combination chemotherapy of ccnu and dbd <sep> combined radiotherapy and chemotherapy with dibromodulcitol and ccnu <sep>', 'ccnu <sep> postoperative radiotherapy and radiotherapy combined with ccnu chemotherapy <sep>', 'radiotherapy <sep> semustine <sep> carmustine plus radiotherapy <sep> radiotherapy <sep> carmustine plus radiotherapy and semustine plus radiotherapy <sep> semustine meccnu radiotherapy carmustine bcnu plus radiotherapy or semustine plus radiotherapy <sep> radiotherapy and nitrosoureas <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",this small but clear improvement in survival from chemotherapy encourages further study of drug treatment of these tumours
162,"{'outcomes': ['serum and urinary calcium osteocalcin urinary pyridinoline and deoxypyridinoline <sep> lumbar bone mineral density values <sep> serum calcium levels <sep> urinary pyridinoline and deoxypyridinoline <sep> bone turnover and bone-sparing effect <sep> pyridinoline and deoxypyridinoline levels <sep> bone turnover and bone mineral density <sep> lumbar bone mineral density <sep>', 'bone mineral density bmd and bone mineral content bmc <sep> bone density and bone metabolism <sep> urine hydroxyproline and creatinine ratio hop/cr <sep> maximum bone mass <sep> bmd and bmc of lumbar spine and femur and on bone metabolism <sep> bmd and bmc of lumbar <sep> bone mineral density and bone metabolism <sep>', 'urinary pyd and d-pyd levels <sep> serum osteocalcin bgp urinary pyridinoline pyd and deoxypyridinoline d-pyd <sep> bone turnover and bone mineral density bmd <sep> spinal bmd values <sep> urinary levels of pyd and d-pyd <sep> bone turnover and bone mineral density <sep> bone turnover <sep>', '2-year treatment-failure cumulative pregnancy rate <sep> recovery of bmd <sep> efficacy safety and user satisfaction <sep> bone mineral density bmd changes and contraceptive efficacy <sep> adverse events <sep> bmd loss <sep> lumbar spine <sep>', 'bone mineral density <sep> percentage of change from baseline bone mineral density at the lumbar spine <sep> percentage of change from baseline bone mineral density <sep>', 'urinary levels of pyr and d-pyr <sep> levels of sex hormone-binding globulin shbg <sep> bone resorption <sep> bone resorption urinary levels of pyridinoline pyr and dexoxypyridinoline d-pyr <sep> shbg levels <sep> biological estrogenic effect <sep>', 'bone mineral density <sep> mean bmd loss <sep> bone mineral density bmd <sep> bmd <sep> lumbar spine bmd <sep>', 'serum calcium levels <sep> bone metabolism and bone mineral density <sep> bone turnover and bone mineral density bmd <sep> spinal bmd values <sep> lumbar bmd <sep> urinary levels of pyd and d-pyd in calcium levels and in osteocalcin levels <sep> serum and urinary calcium osteocalcin and urinary pyridinoline pyd and deoxypyridinoline d-pyd levels <sep> bone turnover <sep>', 'forearm bone density bmdprox <sep> alkaline phosphatase <sep> bone density <sep> bone formation <sep> bone turnover <sep>', 'low-density lipoprotein cholesterol <sep> protein c antigen <sep> total cholesterol <sep> haemostasis lipids carbohydrates bone metabolism and sex hormone-binding globulin shbg <sep> shbg <sep>', 'baseline demographic or anthropometric characteristics or in bmd of users of either model of implant <sep> bmd <sep> baseline bmd body mass index bmi and difference in bmi <sep> bone mineral density bmd <sep>', 'total cross-sectional area <sep> vertebral abmd <sep> bone geometry and volumetric bone mineral density vbmd <sep> radial trabecular vbmd <sep> skeletal effects <sep> areal bone mineral density abmd of the femoral neck and the lumbar spine <sep> periosteal bone formation <sep>', 'duration of bleeding days <sep> intermenstrual bleeding and spinal bone density <sep> total triglycerides hdl and hdl(2 cholesterol and idl lipoproteins <sep> total and ldl cholesterol and apolipoproteins <sep> incidence of bleeding anomalies <sep> serum lipid and bone density patterns <sep> endometrial hyperplasia <sep>', 'serum calcium levels <sep> urinary levels of pyridinoline and deoxypyridinoline in calcium levels and in bgp levels <sep> urinary pyridinoline and deoxypyridinoline <sep> serum and urinary calcium osteocalcin bgp urinary pyridinoline and deoxypyridinoline <sep> bone turnover and bone mineral density bmd <sep> spinal bmd values <sep> bone turnover and bone mineral density <sep> bone turnover <sep> lumbar bone mineral density <sep>', 'bone mineral density <sep> bone resorption <sep> bmd <sep> mean ntx urine concentrations <sep> maintaining bmd <sep> safe and well-tolerated <sep> bone mineral density bmd and metabolic bone parameters <sep>', 'areal bone density <sep> bone mineral density bmd <sep> femoral neck <sep> mean lumbar spine bmd <sep> greater trochanter <sep> areal bmd <sep> total body <sep>'], 'punchline_text': ['pyridinoline and deoxypyridinoline levels were lower in group a than in group b throughout the study but not significantly. <sep>', 'levonorgestrel releasing contraceptive subdermal implants were not deleterious to the skeleton in women of child-bearing age. <sep>', 'no significant differences in urinary pyd and d-pyd levels were observed between groups a and b during the entire period of treatment. <sep>', 'adverse events were similar in the two groups except that injection site reactions were more common in the dmpa-sc group. <sep>', 'at the femoral neck the percentage of change from baseline bone mineral density was 4.7 in the estradiol cypionate group versus 5.1 in the placebo group  p .001). <sep>', 'during the 12 months of the study a significant decrease of urinary levels of pyr and d-pyr was found in 2 groups of young post-adolescent women taking the pills with 20 and 30 microg of ee2 in comparison with control women subjects of the same age group with normal menstrual cycle who did not use contraception). <sep>', 'observed changes in bmd among dmpa users differed from women who used either type of pill p  .002). <sep>', 'no significant difference was detected between group a and group b in urinary levels of pyd and d-pyd in calcium levels and in osteocalcin levels. <sep>', 'forearm bone density bmdprox increased with 2.94 p  0.006 in women who were prescribed levonorgestrel which was in contrast to stable values in those prescribed depot-medroxy-progesterone acetate group difference at 6 months for bmdprox 3.4 95 ci 1.3 5.5 p  0.025 and bmddist 4.1 95 ci  1.3 9.6 p  0.077). <sep>', 'increases were significantly greater p 0.05 for protein c antigen 11.8 vs. 6.1 and shbg 791 vs. 565 nmol/l and significantly smaller p 0.05 ranks for d-dimer 19 vs. 37 g fe/l). <sep>', 'bmd was significantly lower at 18 months of use at the midshaft of the ulna in both groups of users. <sep>', 'radial trabecular vbmd declined by 1.4+/-1.8 in the deso group while it remained unchanged in the levo group. <sep>', 'a slight decrease in total triglycerides hdl and hdl(2 cholesterol and idl lipoproteins was observed with mesigyna. <sep>', 'no significant difference was detected between groups a and b in urinary levels of pyridinoline and deoxypyridinoline in calcium levels and in bgp levels. <sep>', 'the direction of the change increase or decrease in all investigated bone-related variables was similar in both treatment groups. <sep>', ""differences of lesser statistical magnitude were seen at the femoral neck between group differences at 2 yr 2.7 p  0.24 ward's triangle 5.0 p  0.055 greater trochanter 3.6 p  0.056 total body 1.3 p  0.046 legs 1.3 p  0.065 and trunk 2.0 p  0.029). <sep>""], 'population': ['healthy fertile women treated with <sep> young postadolescent women <sep> young fertile women <sep>', 'women of child-bearing age <sep> female acceptors for 1 year <sep> young women <sep> 61 normal women of child-bearing age <sep>', 'young fertile women <sep> young postadolescent women <sep> young fertile women <sep> nineteen healthy fertile women <sep>', '225 women completed the first 2 years of this study dmpa-sc n=116 dmpa-im n=109 <sep> women receiving dmpa-sc n=266 or dmpa-im n=268 for 2 years with an option to continue for a third year <sep>', 'one hundred twenty-three adolescents who began receiving <sep> adolescent girls who receive <sep> adolescent girls who received <sep> for contraception <sep>', 'young post-adolescent women <sep> young women <sep>', 'women 18-33 years of age with those not using hormonal contraception <sep> 33 women 63 women who chose oral contraception <sep> fifty-nine women who did not use hormonal contraception served as controls <sep> 155 women were analyzed <sep>', '2010 elsevier inc <sep> 40 women desiring contraception <sep> twenty patients underwent no treatment and were used as healthy controls group c n=20 <sep> young postadolescent women <sep> young fertile women <sep>', '22 premenopausal women age 32.6 range 20-45 years <sep> premenopausal women <sep>', '147 healthy women age 18-49 years <sep>', 'one hundred and eleven women 19-43 years of age <sep>', 'fifty-two women 18-24 years <sep> young women <sep> group 36 women served as controls <sep>', 'premenopausal women <sep> 49 pre-menopausal women between 38 and 50 years to 99 women fitted with an iud nova-t <sep> premenopausal users <sep>', 'young postadolescent women <sep> young fertile women <sep> healthy fertile women treated with 30 mcg <sep>', '48 volunteers aged <sep> young fertile women <sep> volunteers participating in the study <sep>', '38 premenopausal women mean age 37 with a minimum 2 yr dmpa use who had a below average baseline lumbar spine bmd t score  or  0 <sep> nineteen women <sep> twenty-seven subjects completed at least 18 months in the study and 26 the full 2 yr with similar numbers dropping out from each group mainly for personal reasons <sep> long-term users of depot <sep>'], 'interventions': ['new 21-day combined oral contraceptive containing 30 microg ethinyl/estradiol plus 3 mg drospirenone <sep> ethinyl/estradiol plus 75 microg gestodene <sep> oral contraceptive containing drospirenone <sep> 30 microg ethinyl/estradiol plus 3 mg drospirenone <sep> 30 microg ethinyl/estradiol plus 75 microg gestodene <sep>', 'norplant long-term contraceptive implants <sep> levonorgestrel releasing contraceptive subdermal implants <sep> levonorgestrel-releasing subdermal contraceptive implants <sep>', 'low-dose 21-day combined oral contraceptive coc containing 20 microg ethinyl estradiol ee and 75 microg gestodene gtd <sep> low-dose and ultra-low-dose combined oral contraceptive <sep> ultra-low-dose 24-day coc containing 15 microg ee and 60 microg gtd <sep>', 'subcutaneous dmpa vs. intramuscular dmpa <sep> dmpa <sep> dmpa-sc <sep> depot medroxyprogesterone acetate dmpa <sep>', 'placebo <sep> estrogen supplementation <sep> depot medroxyprogesterone acetate <sep> estradiol cypionate or placebo <sep> depot medroxyprogesterone acetate injections <sep>', 'ethinylestradiol plus gestodene <sep> progestin compound gestodene ges 75 microg but different doses of ethinylestradiol ee2 <sep> progestin <sep>', 'norethindrone-containing pill <sep> norethindrone <sep> dmpa <sep> depot medroxyprogesterone acetate <sep> depot medroxyprogesterone acetate dmpa <sep> desogestrel-containing pill <sep> hormonal contraception <sep> oral contraceptives oc <sep>', 'vaginal ring releasing a daily dose of 15 mcg of ee and 120 mcg of etonorgestrel nuvaring organon italy <sep> patch delivering a daily dose of 20 mcg of ee and 150 mcg of norelgestromin evra janssen-cilag italy <sep> copyright c <sep> ee and 150 mcg of norelgestromin <sep> combined contraceptive vaginal ring releasing 15 mcg of ethinylestradiol ee <sep> contraceptive patch and the vaginal ring <sep>', 'dmpa <sep> progestogen-only methods for contraception <sep> continuous progestogens for contraception were analyzed depot-medroxyprogesterone acetate dmpa or continuous levonorgestrel treatment with subdermal implants norplant <sep> progestogen-only methods <sep> levonorgestrel <sep>', 'cyclic low-dose combined oral contraceptive <sep> combined oral contraceptive coc <sep> coc either continuously levonorgestrel lng 90 g/ethinylestradiol ee <sep>', 'levonorgestrel <sep> etonorgestrel and levonorgestrel-releasing contraceptive implants <sep>', 'progestogens desogestrel and levonorgestrel <sep> levo <sep> deso <sep> monophasic oral contraceptives containing 20 mug of ethinylestradiol and 100 mug of levonorgestrel levo or 150 mug of desogestrel deso <sep>', 'mesigyna(r <sep>', 'low-dose combined oral contraceptives containing drospirenone <sep> ethinyl estradiol plus 3 mg drospirenone <sep> 21-day combined oral contraceptive containing 30 mcg ethinyl estradiol plus 3 mg drospirenone <sep>', 'ethinylestradiol ee in combination with 100 microg levonorgestrel lng <sep> combined oral contraceptives <sep> ethinylestradiol in combination with levonorgestrel <sep> lng <sep>', 'placebo <sep> oral estrogen replacement therapy <sep> conjugated estrogens <sep> medroxyprogesterone acetate <sep> injectable contraceptive depot medroxyprogesterone acetate dmpa depo-provera <sep> estrogen replacement therapy <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",whether steroidal contraceptives influence fracture risk cannot be determined from existing information. many trials had small numbers of participants and some had large losses to follow up. health care providers and women should consider the costs and benefits of these effective contraceptives. for example injectable contraceptives and implants provide effective long-term birth control yet do not involve a daily regimen. progestin-only contraceptives are considered appropriate for women who should avoid estrogen due to medical conditions.
163,"{'outcomes': ['overall survival <sep> local recurrence rate <sep> disease-free survival <sep>', 'disease-free survival <sep> 5-year disease-free and overall survival <sep> congestive heart failure <sep> survival benefit <sep> overall survival advantage <sep> 5-year disease-free survival <sep> survival <sep> 5-year overall survival <sep>', 'survival <sep> died <sep>', 'freedom from local recurrence and/or metastases and overall survival <sep> local recurrence <sep> overall survival rates <sep> relapse-free survival rates <sep> distant metastases <sep> survival <sep> actuarial percentage survival figures <sep>', 'cardiotoxicity presenting as pulmonary edema <sep> local control metastasis-free survival disease-free survival and survival <sep> died <sep>', 'local recurrence of disease <sep> partial suppression of distant metastasis <sep> survival advantage <sep>', 'actuarial 3-year overall survival <sep> 3-year actuarial disease-free survival <sep> disease-free survival <sep> congestive heart failure <sep> actuarial disease-free survival <sep> overall actuarial survivals <sep> 3-year actuarial disease-free and overall survivals <sep> local control <sep> overall actuarial survival <sep>', 'vaginal recurrence <sep> progression-free interval or survival <sep> recurrence rates in specific cell types leiomyosarcoma homologous mixed mesodermal sarcoma or heterologous mixed mesodermal sarcoma <sep> suffered recurrences <sep>'], 'punchline_text': ['with a median follow-up of 40 months there was no significant difference between the four treatment groups in overall survival group 1 75 group 2 70 group 3 69 group 4 73 disease-free survival group 1 62 group 2 56 group 3 62 group 4 64 or local tumor control group 1 92 group 2 92 group 3 87 group 4 90%). <sep>', 'the 5-year disease-free and overall survival for patients treated with the reduced doses of chemotherapy was 72 and 75 respectively and was not significantly different from the high-dose regimen. <sep>', 'survival was not significantly different between adriamycin or control. <sep>', 'relapse-free survival rates were higher for cyvadic 56 versus 43 p  .007 and local recurrence was significantly reduced in the cyvadic arm at 17 versus 31 p  .004). <sep>', 'while a nonsignificant difference in local control metastasis-free survival disease-free survival and survival was observed for extremity lesions the advantage may be outweighed by the risk of cardiotoxicity. <sep>', 'recent improvement in the survival of patients with soft-tissue sarcomas is not necessarily a result of adjuvant chemotherapy or radiation therapy. <sep>', 'local control was achieved in 46 patients 81 3-year actuarial disease-free and overall survivals were 67 and 77 respectively. <sep>', 'the recurrence rates in specific cell types leiomyosarcoma homologous mixed mesodermal sarcoma or heterologous mixed mesodermal sarcoma were not significantly different although the pattern of recurrence differed with pulmonary metastases being more common in leiomyosarcoma and extrapulmonary recurrence being more common in mixed mesodermal sarcoma. <sep>'], 'population': ['patients with high-grade soft tissue sarcoma <sep> patients undergoing <sep> from january 1981 to february 1986 a total of 240 patients with primary malignancy-grade iii or iv soft tissue sarcoma were entered into an adjuvant chemotherapy multicenter trial conducted by the scandinavian sarcoma group ssg <sep> high-grade soft tissue sarcoma <sep>', 'patients with high-grade extremity sarcomas <sep> eighty-eight patients were entered into this trial which has a median follow-up of 4.4 years <sep> patients with high-grade soft-tissue sarcomas of the extremity <sep> patients receiving <sep> patients with extremity soft-tissue sarcomas <sep>', 'forty-seven patients with stage i ii or iii soft tissue sarcoma <sep> patients with localized soft tissue sarcoma <sep> 32 patients 17 males and 15 females with an age range of 17 to 75 years median 44 years <sep>', '145 eligible patients receiving <sep> 172 control patients <sep> adult patients with soft tissue sarcomas <sep> between january 1977 and june 1988 468 patients entered this randomized study and 317 were considered eligible <sep>', 'sarcomas <sep> forty-two patients with localized intermediate and high-grade sarcoma <sep>', ""between june 1975 and april 1981 61 of the 177 eligible patients whose nonosseous sarcomas of extremity or trunk origin had been completely excised primarily or after local recurrences agreed to participate in a randomized study of <sep> complete excision of nonosseous sarcomas <sep> dermatofibrosarcoma lymphomas myeloma kaposi's sarcoma and embryonal rhabdomyosarcoma were excluded as were patients with significant second primary cancers and those who received either preoperative or postoperative radiation therapy <sep> patients with soft-tissue sarcomas <sep>"", 'adults with soft tissue sarcomas of the head and neck breast and trunk <sep> seventeen patients received <sep> since 1977 31 patients <sep> after aggressive local treatment of high-grade sarcomas of the head neck breast and trunk excluding retroperitoneal sarcomas <sep>', 'uterine sarcomas <sep> 75 patients receiving <sep> 156 evaluable patients with stage i limited to the corpus or stage ii limited to the corpus and cervix uterine sarcomas <sep>'], 'interventions': ['radical surgery <sep> radiotherapy <sep> adjuvant chemotherapy with doxorubicin <sep> postoperative radiotherapy followed by doxorubicin <sep> single-agent doxorubicin <sep> postoperative radiotherapy <sep> adjuvant chemotherapy <sep>', 'doxorubicin cyclophosphamide and methotrexate <sep> doxorubicin and cyclophosphamide without methotrexate <sep> adjuvant chemotherapy <sep> doxorubicin-induced cardiomyopathy <sep> adjuvant chemotherapy <sep>', 'control or adriamycin <sep> adriamycin <sep> adjuvant adriamycin <sep> adjuvant doxorubicin <sep>', 'cyclophosphamide 500 mg/m2 intravenously iv bolus on day 1 vincristine 1.4 mg/m2 iv bolus on day 1 doxorubicin adriamycin adria laboratories columbus oh <sep> dacarbazine dtic <sep> adjuvant chemotherapy with cyvadic <sep> doxorubicin/ifosfamide <sep> adjuvant cyvadic chemotherapy <sep> adjuvant chemotherapy <sep> complete surgical resection with or without radiotherapy <sep>', 'digoxin and diuretics <sep> doxorubicin <sep> adjuvant doxorubicin <sep>', 'salvage surgery <sep> systemic chemotherapy <sep> adjuvant chemotherapy <sep> vincristine/cyclophosphamide/dactinomycin and vincristine/doxorubicin/dacarbazine <sep>', 'chemotherapy <sep> methotrexate <sep> adjuvant chemotherapy <sep> doxorubicin <sep> postoperative radiotherapy <sep> adjuvant chemotherapy consisting of doxorubicin <sep> cyclophosphamide <sep>', 'adjuvant adriamycin <sep> adriamycin <sep> adjuvant chemotherapy with adriamycin <sep> pelvic irradiation external or intracavitary <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",doxorubicin-based adjuvant chemotherapy appears to significantly improve time to local and distant recurrence and overall recurrence-free survival in adults with localised resectable soft tissue sarcoma. there is some evidence of a trend towards improved overall survival.
164,"{'outcomes': ['qmgs <sep> quantified mg clinical score qmgs <sep>', 'quantitative mg score qmg <sep>', 'mss variation <sep> efficacy and tolerance <sep> variation of a myasthenic muscular score mss <sep>', 'dropout rate <sep> qmgs and ivig <sep> duration of improvement <sep> tolerated <sep>', 'quantitative myasthenia gravis qmg score for disease severity <sep> qmg score for disease severity <sep>', 'myasthenic muscular scores <sep> myasthenic muscular score <sep>'], 'punchline_text': ['one week after the treatments the patients who received plasma exchange treatment showed a significant improvement in qmgs compared to baseline but although some improvement was seen after ivig <sep>', 'at day 42 there was no significant difference in primary or secondary outcome measurements between the two groups. <sep>', 'ig was better than that of pe with a total of 14 side effects observed in 9 patients 8 in the pe group and 1 in the i.v. <sep>', 'the dropout rate was the same for both treatment arms and both treatments were well-tolerated. <sep>', 'in ivig-treated patients a clinically meaningful improvement in qmg score for disease severity was observed at day 14 and persisted at day 28. <sep>', 'however the difference between the 2 groups was not significant effect size 3.84 95 confidence interval 1.03 to 8.71 <sep>'], 'population': ['patients suffering from moderate to severe myasthenia gravis mg in a stable phase <sep> patients with chronic moderate to severe myasthenia gravis <sep> twelve patients with generalized moderate to severe mg on immunosuppressive treatment for at least 12 months were included <sep>', 'myasthenia gravis mg <sep> myasthenia gravis <sep> fifteen patients were enrolled 6 to ivig 9 to <sep> 549-552 2002 <sep>', 'eighty-seven patients with mg exacerbation <sep> myasthenia gravis <sep>', 'adult patients with moderate to severe mg within 2 weeks of treatment <sep> patients with moderate to severe mg <sep> patients with myasthenia gravis mg <sep> patients with myasthenia gravis <sep> classification of evidence <sep> 84 patients with moderate to severe mg defined as a quantitative myasthenia gravis score for disease severity qmgs of 10.5 and worsening weakness to ivig gamunex talecris biotherapeutics 1 g/kg/day for 2 consecutive days or plex caridian spectra 1.0 plasma volume exchanges for 5 exchanges <sep>', 'patients with worsening weakness due to myasthenia gravis <sep> fifty-one patients with worsening weakness due to mg <sep> patients with myasthenia gravis mg and worsening weakness <sep> patients with myasthenia gravis <sep>', 'one hundred seventy-three patients aged 15 to 85 years with acute exacerbation of myasthenia gravis <sep> myasthenia gravis exacerbation <sep>'], 'interventions': ['high-dose intravenous immunoglobulin ivig <sep> immunoglobulin treatment versus plasma exchange <sep> ivig <sep>', 'albumin placebo <sep> intravenous immunoglobulin <sep> placebo <sep> intravenous immunoglobulin ivig <sep>', 'plasma exchange pe <sep> intravenous immunoglobulin <sep> plasma exchange and high-dose intravenous immunoglobulin <sep>', 'plex <sep> iv immunoglobulin ivig and plasma exchange plex <sep> ivig and plex <sep>', 'iv immunoglobulin ivig <sep> placebo <sep> iv immunoglobulin <sep>', 'intravenous immunoglobulin <sep> placebo <sep> ivig <sep> intravenous immunoglobulin ivig <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",in exacerbation of myasthenia gravis one rct of ivig versus placebo showed some evidence of the efficacy of ivig and two did not show a significant difference between ivig and plasma exchange. another showed no significant difference in efficacy between 1 g/kg and 2 g/kg of ivig. a further but underpowered trial showed no significant difference between ivig and oral methylprednisolone. in chronic myasthenia gravis there is insufficient evidence from rcts to determine whether ivig is efficacious.
165,"{'outcomes': [""ratio of okt-4/okt-8 <sep> bone atrophy <sep> bone density gs max gs min and sigma gs/d <sep> bone density <sep> percentage of patients with slight improvement <sep> duration of morning stiffness number of joints with pain number of joints with swelling and lansbury's index <sep> efficacy and safety <sep> serum ca value <sep>"", 'serum alkaline phosphatase and 24-h hydroxyproline excretion <sep> esr tenderness on palpation and subjective pain <sep> bmc <sep> activity indexes esr and clinical parameters <sep> side effects <sep> mineral metabolism parameters serum calcium phosphorus alkaline phosphatase 24-h urinary calcium phosphate and 24-h hydroxyproline excretion and radial bone mineral content bmc <sep>'], 'punchline_text': ['the indexes of bone density gs max gs min and sigma gs/d demonstrated that 1 alpha-oh-d3 prevents reduction in bone density. <sep>', 'furthermore serum alkaline phosphatase and 24-h hydroxyproline excretion decreased significantly only in group a and bmc decreased significantly in group b but rose slightly in group a. <sep>'], 'population': ['patients who had been treated with them before participating in the study for oral steroidal preparations the dose was limited to 5 mg/day or less as <sep> patients with rheumatoid arthritis ra <sep> 140 patients with ra admitted to 31 institutes using a <sep>', 'induced osteopenia <sep> twenty-four patients 9 m and 15 f age range 51-82 with polymyalgia rheumatica receiving <sep>'], 'interventions': ['placebo <sep> alpha-oh-d3 <sep> alfacalcidol 1 alpha-oh-d3 <sep> alfacalcidol <sep> prednisolone <sep>', 'placebo <sep> 250hd3 <sep> glucocorticoid <sep> oral 25-hydroxyvitamin d and calcium <sep> 6-methylprednisolone <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",the evidence base for the use of vitamin d for chronic pain in adults is poor at present. this is due to low quality and insufficient randomised controlled trials in this area of research.
166,"{'outcomes': ['driving capacity <sep> psychomotor disturbances <sep> safety and efficacy <sep> adverse reactions <sep>', 'encephalopathy <sep> survival and discharge <sep>', 'index of portal-systemic encephalopathy <sep> neuropsychologic function <sep> semiquantitative nitrogen balance <sep> liver function tests <sep>', 'mental state <sep> recovery rate <sep> consciousness <sep>', 'semiquantitative nitrogen balance <sep> psychomotor functions line tracing tapping steadiness auditory reaction time attention digit table and practical intelligence digit symbol number connection test <sep>', 'renal failure <sep> acute hepatic encephalopathy <sep> coma score <sep> cerebral state and on nitrogen homeostasis <sep> renal and two respiratory failure and one remained encephalopathic <sep> negative nitrogen balance <sep>', 'acute hepatic encephalopathy <sep> plasma aaa/baa ratio <sep>'], 'punchline_text': ['branched-chain amino acids but not placebo significantly improved psychomotor disturbances p  0.01 and driving capacity p  0.002). <sep>', 'the group receiving the modified amino acid mixture demonstrated a statistically significant improvement in encephalopathy as compared to the neomycin group while maintaining nitrogen equilibrium. <sep>', 'two or more parameters of the index improved in 24 patients treated with amino acids 80 confidence limits 61-92 and only in 12 receiving casein 35 confidence limits 20-54 p less than 0.001). <sep>', 'twelve patients 70.6 in group a and eight 47 in group b regained consciousness in a mean time of 27.6 and 31.5 hours respectively. <sep>', 'taking into account the crossover design significant improvements attributable to branched chain amino acid treatment could be demonstrated in psychomotor functions line tracing tapping steadiness auditory reaction time attention digit table and practical intelligence digit symbol number connection test). <sep>', 'the negative nitrogen balance on entry reversed in the amino acid group but not in the glucose group. <sep>', 'no significant difference was noted based on clinical evolution even though the plasma aaa/baa ratio was corrected using the modified aa solution. <sep>'], 'population': ['seventeen patients with impaired driving capacity <sep> patients with stable cirrhosis and latent encephalopathy <sep>', 'hepatic encephalopathy <sep> thirty patients in the f080 group and 29 in the control group completed the trial <sep> seventy-five patients with acute hepatic decompensation superimposed on chronic alcoholic cirrhosis <sep>', 'cirrhotic patients with chronic encephalopathy <sep> chronic hepatic encephalopathy <sep> chronic hepatic encephalopathy in cirrhosis <sep>', '19 patients with grade 3-4 hepatic encephalopathy <sep> patients with chronic liver failure <sep> 40 patients with grade 3-4 hepatic encephalopathy <sep> patients with severe hepatic encephalopathy <sep>', '22 inpatients with liver cirrhosis and obtained evidence of latent subclinical portosystemic encephalopathy using an extensive psychometric test program <sep>', '65 patients with cirrhosis <sep> sixty-five patients <sep> patients with cirrhosis <sep>', '70 cirrhotic patients <sep> cirrhotic patients <sep> acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a <sep> 70 patients <sep>'], 'interventions': ['placebo <sep> long-term branched-chain amino acid supplementation <sep> branched-chain amino acids or placebo <sep> long-term oral supplementation with branched-chain amino acids <sep> branched-chain amino acids <sep>', 'modified amino acid mixture <sep> modified amino acid solution and hypertonic dextrose <sep> enteral neomycin daily along with 25 dextrose by a central venous catheter <sep> placebo resembling neomycin and isocaloric dextrose plus a modified amino acid mixture enriched with branched-chain amino acids to 36 and deficient in aromatic amino acids and methionine <sep>', 'casein-treated patients given branched-chain amino acids <sep> amino acids <sep> casein <sep> equinitrogenous amount of casein <sep> branched-chain amino acids and placebo casein <sep> long-term oral branched-chain amino acid treatment <sep>', 'intravenous branched chain amino acid in 20 dextrose group a or oral lactulose <sep> intravenous solution containing leucine 11 g/l isoleucine 9 g/l and valine 8.4 g/l in 20 dextrose <sep> branched chain amino acids <sep> intravenous branched chain amino acids <sep>', 'placebo <sep> branched chain amino acids or casein <sep> branched chain amino acids <sep>', 'amino acid <sep> branched chain enriched amino acid mixture versus glucose <sep> amino acid mixture with 40 branched chain contents 32 patients or isocaloric glucose <sep> branched chain enriched amino acid <sep>', 'parenteral administration of amino acids <sep> control aminoacid solution a commercially available aa mixture azonutril and 36 patients a modified solution enriched in baa prepared from crystallized aa dissolved in distilled water <sep> modified aa solutions <sep> conventional amino acids mixture <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>']}",we did not find convincing evidence that bcaa had a significant beneficial effect on patients with hepatic encephalopathy. the trials performed in this field were small with short follow-up and most had low methodological quality.
167,"{'outcomes': ['tidal volume <sep> urine volume <sep> total respiratory resistance <sep> pulmonary function <sep> static respiratory compliance <sep>', 'diuresis or renal side effects <sep> tidal volume <sep> pulmonary resistance <sep> lung compliance <sep>', 'hypokalemia chloride deficiency hypercalciuria nephrocalcinosis and rickets <sep> pulmonary mechanics <sep> pulmonary mechanics <sep> pulmonary function measurements <sep> tidal volume <sep> lung compliance and decreased airway resistance <sep> birth weight <sep> efficacy and safety <sep>', 'airway resistance <sep> excretion of urinary electrolytes <sep> tidal volume and pulmonary compliance <sep> pulmonary function <sep> tidal volume and compliance <sep>', 'airway resistance <sep> pulmonary mechanics <sep> urine output <sep> tidal volume <sep> six hour urine output <sep> urinary electrolyte losses <sep> pulmonary function <sep> urinary sodium potassium and chloride losses <sep>'], 'punchline_text': ['also tidal volume increased significantly by 33.8 and 28.7 at 1 and 2 h respectively p  0.004 and 0.009). <sep>', 'doses of 1 mg/kg significantly improved lung compliance 51 at 2 hours after nebulization pulmonary resistance 28 at 1 hour and tidal volume 43 at 1 hour starting as early as 30 minutes after the dose the effect lasted for at least 4 hours in many of the infants and was not associated with diuresis or renal side effects. <sep>', 'there was no significant change in the pulmonary function measurements before treatment and 1 or 2 hours after treatment with either placebo or furosemide. <sep>', 'neither 1 nor 2 mg/kg of body weight of nebulized furosemide had any effect on airway resistance. <sep>', 'single dose nebulised frusemide improves pulmonary function in premature infants with evolving chronic lung disease without adverse effects on fluid and electrolyte balance. <sep>'], 'population': ['infants with chronic lung disease <sep> infants with chronic lung disease without excessive diuresis <sep> premature infants with chronic lung disease <sep>', 'infants with bronchopulmonary dysplasia <sep> eight preterm infants with bronchopulmonary dysplasia who were supported by mechanical ventilation <sep>', 'ventilated infants with bpd <sep> infants with severe bpd who are ventilator dependent at 21 days of age <sep> infants with bronchopulmonary dysplasia bpd <sep> ventilated infants with severe bronchopulmonary dysplasia <sep> patients with asthma <sep> 9 infants with bpd each serving as his own control <sep> gestational age mean <sep> ventilator-dependent infants with severe bpd <sep> 0.1 kg age at study was 47 <sep>', 'ventilated preterm infants <sep> pulmonary mechanics was studied at a mean postnatal age of 24 days range 14 to 50 days in 13 premature infants 24 to 28 weeks gestational age who had been dependent on mechanical ventilation since birth <sep> premature infants with evolving chronic lung disease and b <sep>', 'ventilated premature infants <sep> median postnatal age of 23 range 14-52 days in 19 premature infants at 24 to 30 weeks gestational age who had been dependent on mechanical ventilation since birth <sep> premature infants with evolving chronic lung disease <sep>'], 'interventions': ['aerosolized furosemide <sep> furosemide and placebo <sep> placebo <sep>', 'nebulized furosemide <sep> nebulized furosemide <sep>', '0.02 furosemide dynamic resistance cm h2o/l per second 118  9 to 106  7 placebo <sep> 0.3 furosemide <sep> placebo <sep> furosemide-induced diuresis <sep> inhaled furosemide <sep> 0.5 placebo <sep> furosemide <sep> placebo or furosemide <sep>', 'furosemide <sep> nebulized furosemide <sep>', 'nebulised frusemide <sep> frusemide <sep> nebulised frusemide <sep> frusemide <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",in preterm infants 3 weeks with cld administration of a single dose of aerosolized furosemide improves pulmonary mechanics. in view of the lack of data from randomized trials concerning effects on important clinical outcomes routine or sustained use of aerosolized loop diuretics in infants with or developing cld cannot be recommended based on current evidence. randomized controlled trials are needed to evaluate clinically important effects of aerosolized diuretics.
168,"{'outcomes': [""cognitive function deteriorated <sep> cognitive performance as assessed using the eleven-item cognitive subscale of the alzheimer's disease assessment scale adas-cog/11 <sep> cognitive function <sep> cognition <sep>"", ""global functioning <sep> efficacy <sep> alzheimer's disease assessment scale-cognitive subscale adas-cog/11 and the alzheimer's disease cooperative study-activities of daily living inventory adcs-adl total score <sep> adas <sep> activities of daily living <sep> clinician's interview based on impression of change-plus caregiver input cibic-plus neuropsychiatric inventory and exit-25 for assessment of executive functioning <sep> cognition daily function and behavior <sep> safety and tolerability <sep> improving cognition including executive function <sep> safety and tolerability <sep> adcs-adl score <sep> efficacy and safety <sep>""], 'punchline_text': ['patients with ad  cvd treated with galantamine experienced statistically and clinically significant improvement in cognition at month 6 mean change in adas-cog/11 score 1.1 p  or  0.05 vs. baseline and maintained their cognitive function for the entire 12-month study mean change in adas-cog/11 score 0.1). <sep>', 'patients treated with galantamine had a greater improvement in adas-cog/11 after 26 weeks compared with placebo 1.8 vs 0.3 p  0.001). <sep>'], 'population': [""patients with alzheimer's disease plus cerebrovascular disease <sep> patients with alzheimer's disease plus cerebrovascular disease ad  cvd or mixed dementia <sep> patients with ad  cvd <sep> two hundred and thirty-eight 84 <sep> two hundred and eighty-five patients with ad  cvd <sep>"", 'patients with vascular dementia <sep> patients with vascular dementia vad <sep> 788 patients with probable vad who also satisfied strict centrally read mri criteria <sep> vascular dementia <sep>'], 'interventions': ['placebo <sep> galantamine <sep> placebo/galantamine <sep> galantamine/galantamine <sep> ad  cvd <sep>', 'galantamine and placebo <sep> placebo <sep> galantamine or placebo <sep> galantamine <sep> galantamine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",limited data were available when considering the impact of galantamine on vascular dementia or vascular cognitive impairment. the data available suggest some advantage over placebo in the areas of cognition and global clinical state. in both included trials galantamine produced higher rates of gastrointestinal side-effects. more studies are needed before firm conclusions can be drawn.
169,"{'outcomes': ['frequency of failed brackets <sep> risk of bond failures <sep> strength of adhesion <sep> bracket failures <sep> debonding time for gic <sep>'], 'punchline_text': ['bracket failures for the cut groove base type occurred in 50 per cent with gic and 23 per cent with the acrylic meshed foil bases failed in 22 per cent gic and in 7 per cent with the acrylic respectively. <sep>'], 'population': ['60 patients with a mean age of 13 years 7 months range 10 years 8 months to 19 years 1 month were consecutively selected <sep>'], 'interventions': ['acrylic resin <sep> glass ionomer cement gic <sep>'], 'punchline_effect': [' sig increase <sep>']}",it is difficult to draw any conclusions from this review however suggestions are made for methods of improving future research involving orthodontic adhesives.
170,"{'outcomes': ['negative emotional symptoms <sep> apathy irritability and patient-reported quality of life <sep> relevance of discourse b performance of functional abilities c emotional symptoms d quality of life and e overall global function <sep> discourse abilities functional abilities emotional symptoms and overall global performance <sep> emotional symptoms of apathy and irritability <sep> cognitive-communication neuropsychiatric functional performance and quality of life evaluations <sep>', 'cognitive tests activities of daily living scale neuropsychological battery and scales to evaluate caregivers depressive and anxiety symptoms <sep> mini-mental state examination mmse scores <sep> cognitive and functional performance <sep> backward digit span scores <sep> cognitive and neuropsychological tests <sep> psychiatric symptoms <sep>', ""alzheimer's disease assessment scale--cognition <sep> mini-mental state examination mmse scores <sep> behavioural and functional outcomes <sep>"", ""cognitive and non-cognitive functions <sep> ig(mci <sep> change in global cognitive function as determined by the alzheimer's disease assessment scale-cognitive subscale adas-cog and the mini mental status examination mmse <sep> secondary endpoint montgomery asberg depression rating scale madrs <sep> mmse score <sep> specific cognitive and psychopathological ratings <sep>"", 'cognitive and behavioural measures <sep>', ""quality of life  alzheimer's disease scales <sep> mini-mental state examination <sep> cognitive function and quality of life <sep> alzheimer's disease assessment scale  cognition adas-cog <sep>"", 'scores of mmse osgp and gds <sep>'], 'punchline_text': ['a group x time interaction was found for the donepezil-plus-stimulation group in the emotional symptoms of apathy and irritability as compared with the donepezil-only group. <sep>', 'the combined treatment group showed a better positive treatment effect on cognitive and neuropsychological tests applied to patients and reduction of psychiatric symptoms was observed in their caregivers nonsignificant). <sep>', ""similarly for the alzheimer's disease assessment scale--cognition treatment group mean change 0.4 s.e.=0.8 control group 2.5 s.e.=0.8 p=0.01). <sep>"", 'at the end of the study we found significant improvements in the ig(mci compared to the cg(mci in the adas-cog p  0.02 and for the secondary endpoint montgomery asberg depression rating scale madrs p  0.01 <sep>', 'the group that received reality orientation followed by reminiscence therapy showed improvement in cognitive and behavioural measures which was not found in the other two groups. <sep>', ""at follow-up the intervention group had significantly improved relative to the control group on the mini-mental state examination p=0.044 the alzheimer's disease assessment scale  cognition adas-cog p=0.014 and quality of life  alzheimer's disease scales p=0.028). <sep>"", 'at the end of the 3 months of therapy significant differences emerged in the scores of mmse osgp and gds obtained by the two groups. <sep>'], 'population': [""group n  26 <sep> alzheimer's disease patients treated with <sep> only group n  28 in 54 patients with mild to moderate alzheimer's disease ad mini-mental status examination score of 12 28 ranging in age from 54 to 91 years <sep>"", ""patients with mild alzheimer's disease and can reduce caregivers psychiatric symptoms <sep> patients with mild alzheimer's disease and their relatives <sep> alzheimer's disease patients <sep> six patients <sep> thirteen patients with mild alzheimer's disease treated with <sep>"", ""156 patients treated with <sep> alzheimer's disease <sep> patients with alzheimer's disease <sep>"", ""subjects with amnestic mild cognitive impairment amci and mild ad patients <sep> thirty-nine patients <sep> forty-three subjects with amci and mild ad <sep> amnestic mild cognitive impairment and mild alzheimer's disease <sep> amci subjects <sep> patients with alzheimer's disease ad <sep>"", 'elderly people in a large residential home <sep> elderly confused people <sep>', 'people with dementia <sep> older people with dementia <sep> one hundred and fifteen people <sep> 201 older people with dementia <sep>', 'twenty-three institutionalized subjects confused and disoriented as to time space and persons <sep> elderly patients in the community <sep>'], 'interventions': ['donepezil-plus-stimulation <sep> cognitive-communication program plus an acetylcholinesterase inhibitor donepezil donepezil-plus-stimulation <sep> donepezil alone donepezil <sep> donepezil <sep> cognitive-communication stimulation <sep>', 'cognitive rehabilitation combined with acetylcholinesterase inhibitor ache-i treatment <sep> cognitive rehabilitation combined with drug treatment <sep> cognitive rehabilitation training <sep> combined treatment group ache-i plus cognitive rehabilitation and caregiver support and seven patients to a control group ache-i only and followed up for five months <sep> rivastigmine <sep> cognitive rehabilitation associated with ache <sep>', 'donepezil <sep> donepezil to receive a reality orientation programme <sep> reality orientation therapy combined with cholinesterase inhibitors <sep>', 'cognitive intervention <sep> multicomponent cognitive intervention <sep>', 'reality orientation followed by reminiscence therapy <sep> reminiscence therapy <sep>', 'cognitive stimulation therapy cst <sep> cst <sep> evidence-based cognitive stimulation therapy programme <sep>', 'reality orientation therapy <sep> formal realithy orientation therapy rot <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",there was consistent evidence from multiple trials that cognitive stimulation programmes benefit cognition in people with mild to moderate dementia over and above any medication effects. however the trials were of variable quality with small sample sizes and only limited details of the randomisation method were apparent in a number of the trials. other outcomes need more exploration but improvements in self-reported quality of life and well-being were promising. further research should look into the potential benefits of longer term cognitive stimulation programmes and their clinical significance.
171,"{'outcomes': ['approximal dental caries <sep>', 'dental caries <sep> dental caries incidence <sep>', 'incidence of dental caries <sep>', 'caries increment <sep>'], 'punchline_text': ['fluoride rinsing did not give any additional effect compared with placebo-rinsing when a fluoride dentifrice was used for home care. <sep>', 'it was verified a reduction of 33.97 in the incidence of dental caries in the permanent dentition). <sep>', 'both the dentifrice and mouthrinse reduced the incidence of dental caries but their combined use at the same time had no greater effect than either used alone. <sep>', 'no statistically significant difference in caries increment during the two experimental years was found between the groups. <sep>'], 'population': ['approximal dental caries <sep> all 252 13-14-yr-old children at an elementary school <sep>', '246 students of both sexes aged from 7 to 11 years registered in escola de educao bsica da universidade federal de uberlndia and living in the urbana area of uberlndia state of minas gerais were examined <sep>', '751 14 and 15-year old children completed a 3-year double-blind caries preventive program <sep>', '376 three-year old children <sep> preschool children <sep>'], 'interventions': ['placebo-rinsing <sep> fluoride rinsing <sep> fluoride rinsing <sep> fluoride dentifrice <sep> fluoride varnish <sep> fluoride dentifrice fluoride mouthrinsing and fluoride varnish <sep> placebo dentifrice <sep> placebo mouthrinse <sep> fluoride containing dentifrice mouthrinsing and varnish <sep>', 'semestral topical application of acidulated fluor phosphate <sep> mouthwashes of sodium fluoride aquesus solution <sep> mouthwashes and topical fluorides <sep>', 'dentifrice and mouthrinse <sep> fluoride dentifrice and mouthrinse <sep> supervised toothbrushing with an 0.76 sodium monofluorophosphate dentifrice rinsing with a 0.05 sodium fluoride mouthrinse <sep>', 'fluoride dentifrice <sep> fluoride dentifrice containing 0.025 f acta plus fluoride varnish duraphat <sep> fluoride tablets fludent for daily sucking twice a day plus a placebo dentifrice free of fluoride <sep> low fluoride dentifrice <sep> placebo dentifrice plus fluoride varnish <sep> fluoride varnish <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>']}",topical fluorides mouthrinses gels or varnishes used in addition to fluoride toothpaste achieve a modest reduction in caries compared to toothpaste used alone. no conclusions about any adverse effects could be reached because data were scarcely reported in the trials.
172,"{'outcomes': ['pain and activity scores <sep> visual analog pain scales and roland-morris activity scales <sep>', 'oswestry disability scores <sep> back pain and disability <sep> sick-leaves and visits to health centers <sep> back pain <sep> oswestry disability questionnaire <sep> sick-leaves <sep>', 'mean disability questionnaire scores <sep> roland morris disability questionnaire <sep>', 'sf-36 health survey a 10-cm visual analog scale for overall back pain the roland-morris disability questionnaire lost work or school days because of back pain and satisfaction with back care <sep> back pain greater satisfaction with back care <sep> physical functioning and mental health <sep> back pain and physical functioning and greater satisfaction <sep>', 'pain <sep> spinal flexion <sep> pain scores <sep>', 'pain and better function <sep> pain relief <sep> stabilizing and flexibility exercises the use of modalities and cardiovascular training <sep> recurrent pain and moderate to severe symptoms <sep> visual analogue scale vas for perceived pain the roland morris rm questionnaire for low back function and the sf-36 for overall health status <sep> fd <sep> relief from pain <sep>', 'best extension effort and fatigue time <sep> physical outcome measures range of motion fatigue strength or pain <sep> dropout rate <sep> rates of full compliance <sep> flexion and pain <sep> patient confidence <sep> visual analog scale range of motion maximum voluntary extension effort straight leg raising and biering-sorensen fatigue test <sep>', 'disability <sep> pain disability and perceived recovery <sep> regarding pain risk difference <sep>', 'low back-related disability assessed with the 24-item roland morris disability questionnaire <sep> adjusted mean roland morris disability change scores <sep> lvva-sm and hvla-sm <sep> mean functional status <sep> average in functional status <sep>', 'patient-specific function psfs 3-30 and global perceived effect gpe 5 to 5 at 8weeks <sep>', 'oswestry back pain index neck disability index short-form-36 and visual analogue scales <sep>', 'patient-rated low back pain disability and functional health status <sep>', 'perception of pain and disability <sep> mean pain intensity <sep> mean improvement in rmdq <sep> roland-morris disability questionnaire rmdq and numerical rating scale <sep> levels of disability and perceived pain <sep>', 'physical functioning <sep>', 'intensity of low back pain disability handicap medication and quality of life <sep> disability <sep> pain <sep> measure of dysfunction <sep> pain reduction <sep>', 'leg pain <sep> back pain <sep> pain and disability index <sep> leg and low back pain <sep> leg and low back pain intensity and disability roland-morris disability questionnaire <sep> disability index <sep> pain and disability-score changes <sep>', 'function oswestry scale score decrease <sep> perceived disability <sep> pain visual analogic scale score decrease <sep> vertebral manipulation effectiveness <sep> pain improvement <sep>', 'pain health and functional disability level <sep> pain general health and functional disability levels <sep>', 'average and most severe low back pain intensity in the past week assessed with 0 to 10 numerical rating scales and low back-related disability assessed with the 24-item roland-morris disability questionnaire <sep> 6-month disability outcomes <sep> low back pain intensity and disability <sep>'], 'punchline_text': ['for subacute low back pain combined joint manipulation and myofascial therapy was as effective as joint manipulation or myofascial therapy alone. <sep>', 'visits to health centers for back pain were reduced only in the physiotherapy group p .01 wilcoxon test). <sep>', 'exercise improved mean disability questionnaire scores at three months by 1.4 95 confidence interval 0.6 to 2.1 more than best care. <sep>', 'the subjects who received sham manipulation also reported greater improvements in back pain and physical functioning and greater satisfaction than the no-intervention control subjects. <sep>', 'pain scores were reduced to a significant degree within four weeks of starting treatment only in the group manipulated in the first treatment period. <sep>', 'there were no significant differences between groups on the roland morris and sf-36 outcome measures. <sep>', 'none of the changes in physical outcome measures range of motion fatigue strength or pain were significantly different between any of the groups. <sep>', 'at 7-week and 12-week follow-ups statistically significant differences between the groups were found in all outcomes favoring the index group. <sep>', 'biomechanically distinct forms of sm did not lead to different outcomes in older lbp patients and both sm procedures were associated with small yet clinically important changes in functional status by the end of treatment for this relatively healthy older population. <sep>', 'motor control exercise and spinal manipulative therapy produce slightly better short-term function and perceptions of effect than general exercise but not better medium or long-term effects in patients with chronic non-specific back pain. <sep>', 'comparisons of initial and extended follow-up questionnaires to assess absolute efficacy showed that only the application of spinal manipulation revealed broad-based long-term benefit 5 of the 7 main outcome measures showed significant improvements compared with only 1 item in each of the acupuncture and the medication groups. <sep>', 'individual group comparisons after 5 and 11 wk of intervention on all three main outcome measures did not reveal any clear clinically important or statistically significant differences. <sep>', 'reduction in mean pain intensity at week 8 was 1.8 points greater for the chiropractic group than for the pain-clinic group p  0.023). <sep>', 'manipulative therapy also gave larger improvements in physical functioning difference 0.6 0.1 to 1.3). <sep>', 'both manual therapy and the spinal stabilization program are significantly effective in pain reduction in comparison to an active control. <sep>', 'at the 3-month follow-up point significant improvements had occurred in all groups in leg and low back pain and in the disability index but with no significant differences between the groups. <sep>', 'patients receiving the true manipulations showed significant improvement in pain visual analogic scale score decrease from 71.8+/-18.11 to 49.37+/-16.78 p<0.001 and function oswestry scale score decrease from 15.59+/-6.03 to 12.25+/-5.69 p<0.001). <sep>', 'at the 3-month follow-up significantly more improved individuals were evident in the st group regarding pain general health and functional disability levels. <sep>', 'the mean changes in low back pain intensity and disability of participants in the medical and chiropractic care-only groups were similar at each follow-up assessment adjusted mean differences at 6 months for most severe pain 0.27 95 confidence interval 0.32-0.86 average pain 0.22 0.25-0.69 and disability 0.75 0.29-1.79). <sep>'], 'population': ['subacute low back pain <sep> 206 patients met the specific admission criteria and 200 patients randomly received one of four treatments for 3 weeks <sep> patients with subacute low back pain <sep>', 'prolonged back pain <sep> patients with long-term back pain <sep> one hundred fourteen ambulatory patients of working age with back pain for 7 weeks or more <sep>', 'back pain in primary care <sep> 181 general practices in medical research council general practice research framework 63 community settings around 14 centres across the united kingdom <sep> patients consulting with back pain <sep> 1334 patients consulting their general practices about low back pain <sep>', '199 subjects who responded to recruitment procedures 91 met the eligibility criteria <sep> university-based clinic from 2000 through 2001 <sep> chronic low back pain <sep> chronic nonspecific low back pain <sep>', 'patients with femoral or sciatic root pain <sep> thirty-two patients with chronic low back pain <sep>', '235 subjects met the inclusion/exclusion criteria and signed the informed consent <sep> chronic low back pain <sep> subjects 18 years of age and older with a primary complaint of low back pain 3 months were recruited <sep>', 'subacute low back pain <sep> patients with subacute low back pain <sep>', 'back and neck pain <sep> four hundred and nine patients with pain and disability in the back or neck lasting for at least 2 weeks recruited at 2 large public companies in sweden in 2005 <sep> back and neck pain patients <sep>', 'two hundred forty participants 105 women and 135 men ages 63.1 <sep> older adults <sep> older patients for low back pain lbp <sep> participants at least 55 years old with subacute or chronic nonradicular lbp <sep> adults 55 years and older with subacute or chronic low back pain <sep> older lbp patients <sep>', 'two hundred and forty adults with non-specific low back pain 3months <sep> patients with chronic non-specific back pain <sep> chronic low back pain <sep> patients with chronic back pain <sep>', ""40 patients who had received exclusively the randomly allocated treatment for the whole observation period since randomization <sep> patients with chronic 13 weeks spinal pain syndromes <sep> chronic mechanical spinal pain syndromes <sep> multidisciplinary spinal pain unit of townsville's general hospital between february 1999 and october 2001 <sep> patients with chronic spinal pain syndromes <sep> 115 patients originally randomized 69 had exclusively been treated <sep>"", 'chronic low back pain <sep> 174 patients aged 20-60 yr were admitted to the study <sep> chronic low back pain clbp <sep>', 'national health service nhs hospital outpatient clinic pain clinic in the united kingdom <sep> patients suffering with chronic low-back pain clbp when managed in a hospital by either a regional pain clinic or a chiropractor <sep> randomization placed 12 patients in the pain clinic and 18 in the chiropractic group of which 11 and 16 respectively completed the trial <sep> chronic low-back pain in a national health service outpatient clinic <sep> patients with clbp i.e. symptom duration of 12 weeks referred to a regional pain clinic outpatient hospital clinic <sep>', 'patients with persistent non-specific back and neck complaints <sep> persistent back and neck complaints <sep> 256 patients with non-specific back and neck complaints of at least six weeks duration who had not received <sep>', 'subjects with chronic low back disorder <sep> chronic low back disorder <sep> patients with chronic low back disorder <sep> 346 subjects <sep>', '134 subjects with low back disorders <sep> working adults <sep> participants with acute to chronic first or recurrent low back pain excluding those with red flag criteria <sep>', 'sixty-four patients participated in the study <sep> sixty-four patients <sep>', 'sub-acute and chronic low-back pain <sep> forty-seven patients <sep> patients with sub-acute or chronic low-back pain lbp <sep>', '1,469 eligible patients 681 were enrolled 95.7 were followed through 6 months <sep> medical patients <sep> patients with low back pain <sep> chiropractic patients <sep> low back pain patients in managed care <sep> low back pain patients presenting to a large managed care facility from october 30 1995 through november 9 1998 <sep>'], 'interventions': ['specific therapies <sep> back school joint manipulation myofascial therapy and combined joint manipulation and myofascial therapy <sep>', 'bone-setting light exercise therapy and physiotherapy <sep> exercise or physiotherapy <sep> light exercise therapy and non-manipulative pragmatic physiotherapy <sep> chiropractic manipulation and strenuous exercise therapy <sep>', 'physical treatments <sep> exercise classes spinal manipulation delivered in nhs or private premises or manipulation followed by exercise to best care <sep>', 'sham manipulation <sep> osteopathic manipulative treatment and sham manipulation <sep> osteopathic manipulative treatment <sep> osteopathic manipulative treatment sham manipulation or a no-intervention control group <sep> osteopathic manipulative treatment <sep>', 'codeine phosphate <sep>', 'fd or atep <sep> flexion-distraction fd procedures performed by chiropractors with an active trunk exercise protocol atep performed by physical therapists <sep> flexion-distraction <sep> flexion-distraction with active exercise <sep>', 'manipulation massage corset and transcutaneous muscle stimulation tms <sep> spinal manipulation transcutaneous muscle stimulation massage and corset <sep>', 'naprapathic manual therapy with evidence-based care <sep> naprapathy including spinal manipulation/mobilization massage and stretching index group and support and advice to stay active <sep> naprapathic manual therapy or evidence-based care <sep>', 'sm <sep> chiropractic care <sep> mcmc <sep> care including 12 visits of either high-velocity low-amplitude hvla)-sm low-velocity variable-amplitude lvva)-sm or 3 visits of mcmc <sep> sm and minimal conservative medical care mcmc <sep> spinal manipulation and minimal conservative medical care <sep>', 'general exercise <sep> exercise and manipulative therapy <sep> general exercise motor control exercise and manipulative therapy <sep> spinal manipulative therapy <sep> motor control exercise <sep> general exercise included strengthening stretching and aerobic exercises <sep> motor control exercise <sep> general exercise motor control exercise and spinal manipulative therapy <sep> motor control exercise and spinal manipulative therapy <sep> general exercise motor control exercise or spinal manipulative therapy <sep>', 'medication needle acupuncture and spinal manipulation <sep> medication acupuncture and spinal manipulation <sep>', 'nonspecific therapeutic placebo <sep> spinal manipulative therapy smt combined with trunk strengthening exercises tse vs. smt combined with trunk stretching exercises and b smt combined with tse vs. nonsteroidal anti-inflammatory drug nsaid therapy combined with tse <sep> smt or nsaid therapy <sep> trunk exercise combined with spinal manipulative or nsaid therapy <sep>', 'chiropractic or pain-clinic management <sep> chiropractic management and pain clinic management <sep>', 'placebo <sep> placebo <sep> manipulative therapy and physiotherapy <sep> detuned shortwave diathermy 10 minutes and detuned ultrasound 10 minutes <sep> physiotherapy or manipulative therapy <sep> manipulative therapy <sep> placebo therapy <sep> manipulative therapy and physiotherapy <sep> manipulative therapy physiotherapy <sep> physiotherapy consisted of exercises massage and physical therapy heat electrotherapy ultrasound shortwave diathermy <sep>', 'musculoskeletal physiotherapy <sep> manual therapy a 10-week spinal stabilization rehabilitation program or a minimal intervention control group <sep> musculoskeletal physiotherapy <sep> spinal stabilization program <sep>', 'orthopaedic manual therapy <sep> mckenzie method group n=52 and an advice only to be active group advice-only <sep> physiotherapist with advice-only to stay active <sep> orthopaedic manual therapy mckenzie method or advice <sep>', 'short-term vertebral manipulation <sep> 4 true vertebral manipulations vmg and the other group received sham manipulations sham-vmg <sep> vertebral manipulation <sep>', 'stabilizing training <sep> stabilizing training group st group or a manual treatment group mt <sep> stabilizing training <sep>', 'medical care with and without physical therapy and chiropractic care with and without physical modalities <sep> physical therapy <sep> medical care with and without physical therapy and to chiropractic care with and without physical modalities <sep> medical and chiropractic care <sep> physical therapy <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",high quality evidence suggests that there is no clinically relevant difference between smt and other interventions for reducing pain and improving function in patients with chronic low-back pain. determining cost-effectiveness of care has high priority. further research is likely to have an important impact on our confidence in the estimate of effect in relation to inert interventions and sham smt and data related to recovery.
173,"{'outcomes': ['dizziness 0/14 difficulty with coordination 0/29 depression 7/14 lack of energy or strength 20/43 insomnia 40/43 mood instability <sep> seizure-free <sep>'], 'punchline_text': ['in the lev group 13 patients 87 were seizure-free. <sep>'], 'population': ['postoperative control of glioma-related seizures <sep> glioma-related seizure control following craniotomy <sep> 29 patients <sep>'], 'interventions': ['switching from phenytoin <sep> phenytoin pht <sep> lev versus pht <sep> levetiracetam lev <sep> levetiracetam monotherapy <sep> switching patients from pht to lev monotherapy <sep> lev therapy within 24 h of surgery or to continue pht therapy <sep>'], 'punchline_effect': [' no diff <sep>']}",there is a lack of robust randomised controlled evidence to support the choice of antiepileptic drug for the treatment of seizures in adults with brain tumours. while some authors support the use of non enzyme-inducing antiepileptic drugs reliable comparative evidence to provide clinical justification for this is limited. there is a need for further large randomised controlled trials in this area.
174,"{'outcomes': ['postoperative stay <sep> relative risk for intraperitoneal spillage <sep> surgical difficulty <sep> operative times <sep>', 'mean blood loss <sep> mean hospitalization <sep> surgical times estimated blood loss post-surgical pain time in hospital speed of recovery and complications <sep> post-surgical pain <sep>', 'levels of the interleukin-6 and c-reactive protein <sep> operative morbidity postoperative pain analgesic requirement and recovery period <sep> c-reactive protein interleukin-6 before during and after surgery intensity and duration of postoperative pain and complications and recovery period <sep>', 'intraoperative rupture rate of the cyst <sep> postoperative pain and minor complications <sep> operative time intraoperative complications ileus length of stay and recovery time <sep>', 'post-operative pain duration of stay in hospital and duration of convalescence <sep> recurrence of ovarian teratomas <sep> milder pain faster hospital discharge <sep> recurrence of mature ovarian teratomas <sep>', 'operative morbidity <sep> endometriotic cysts and dermoid cysts <sep> frequency of inadvertent rupture of the ovarian masses <sep> postoperative pain and analgesic requirement hospital stay and recovery period <sep> size of ovarian masses adnexal adhesion score or frequency of bilateral disease <sep> demographic characteristics <sep> operating time <sep>', 'intensity of pain <sep> intensity of postoperative pain <sep> intensity of postoperative pain and the length of convalescence <sep>', 'operative and hospitalization times and postoperative course <sep> operating time <sep> hospitalization time <sep>'], 'punchline_text': ['laparoscopically guided minilaparotomy when compared with laparoscopy is able to reduce intraperitoneal spillage in patients with presumably benign large adnexal masses with minimal increase in patient short and long-term discomfort. <sep>', 'post-surgical pain was significantly less in laparoscopy patients p<0.05). <sep>', 'the levels of the interleukin-6 and c-reactive protein differed significantly between the 2 operative procedures p  .013 in favor of the laparoscopic approach. <sep>', 'concerning postoperative outcomes postoperative pain and minor complications were significantly less in patients undergoing laparoscopy p=0.001 and 0.04). <sep>', 'forty premenopausal non-pregnant women with a unilateral teratoma no larger than 10 cm were randomised to laparoscopy or laparotomy. <sep>', 'there were no differences in demographic characteristics between the two groups nor any difference in the size of ovarian masses adnexal adhesion score or frequency of bilateral disease. <sep>', 'the intensity of postoperative pain was significantly lower p  .05 in the operative laparoscopy group than in the laparotomy group. <sep>', 'no complications were reported in either group. <sep>'], 'population': ['sixty eligible patients affected by nonendometriotic adnexal cysts with diameter between 7 and 18 cm <sep> large adnexal masses <sep> patients with presumably benign large adnexal masses <sep> tertiary referral center from january 2005 to september 2006 <sep>', 'dermoid cysts at the gynecology department of siena university between 1 january 1992 and 31 december 1996 <sep> ovarian dermoid cysts <sep> women with dermoid cysts <sep>', 'elderly patients <sep> patients older than 60 years old <sep> twenty patients with a benign ovarian tumour <sep> patients over 60 years old <sep>', 'hundred and twenty-seven patients <sep> 127 patients affected by adnexal cysts <sep> benign adnexal cysts <sep>', 'forty premenopausal non-pregnant women with a unilateral teratoma no larger than 10 cm <sep>', 'benign ovarian masses <sep> 102 patients requiring surgical management of ovarian masses <sep> 50 in a teaching hospital from july 1994 to september 1995 <sep>', 'nonendometriotic benign adnexal cysts <sep> forty premenopausal nonpregnant women 18-40 years of age and without acute pelvic symptoms were scheduled to undergo surgical management of anechoic unilateral unilocular persistent adnexal cysts from january 1993 through june 1994 at the department of obstetrics and gynecology of the university of cagliari cagliari italy <sep> patients who were analgesic-free on day 2 discharged from hospital within 3 days and feeling fully recuperated on day 15 <sep>', 'thirty-eight women with benign ovarian dermoid cyst <sep> ovarian dermoid cysts <sep>'], 'interventions': ['laparoscopy <sep> laparoscopically guided minilaparotomy <sep> laparoscopically guided minilaparotomy <sep> operative laparoscopy or laparoscopically guided minilaparotomy <sep> operative laparoscopy <sep> laparoscopy <sep>', 'laparoscopic ovarian cystectomy <sep> laparoscopy <sep> surgical approach via laparotomy n=22 or laparoscopy <sep>', 'laparoscopic and open adnexectomy <sep> laparoscopic versus open adnexectomy <sep> laparoscopy <sep> adnexectomy by a laparoscopic or an open surgical procedure <sep>', 'minilaparotomy versus laparoscopy <sep> operative laparoscopy <sep> minilaparotomy <sep> adnexal surgery through a laparoscopic or minilaparotomy approach <sep> minilaparotomy <sep> minilaparotomy and laparoscopy <sep> laparoscopy required conversion to laparotomy <sep> laparoscopy <sep>', 'laparoscopy or laparotomy <sep> laparoscopic cystectomy <sep>', 'laparoscopy with laparotomy <sep> laparoscopy and laparotomy <sep> operative laparoscopy <sep> laparoscopy 52 or laparotomy <sep>', 'operative laparoscopy n  20 or laparotomy <sep> laparoscopy and laparotomy <sep>', 'laparotomy <sep> laparoscopy with laparotomy <sep> laparoscopy and laparotomy <sep> operative laparoscopy <sep> laparoscopy <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>']}",in women undergoing surgery for benign ovarian tumours laparoscopy was associated with a reduction in fever urinary tract infection postoperative complications postoperative pain number of days in hospital and total cost. these findings should be interpreted with caution since only a small number of studies were identified. these included a total of only 769 women and not all of the important outcomes were reported in each study.
175,"{'outcomes': [""analgesic effect <sep> gastrointestinal safety profile <sep> analgesic efficacy and tolerability profile <sep> rescue analgesia <sep> nausea <sep> tolerated the overall incidence of adverse experiences <sep> vomiting <sep> total pain relief over 6 hours topar6 the primary end point and 4 hours topar4 patient's global assessment of treatment at 6 hours global6 and 24 hours global24 summed pain intensity difference over 6 hours spid6 onset of analgesic effect time to perceptible/meaningful pain relief using a 2-stopwatch method peak pain relief peakpr peak pain intensity difference peakpid and duration of analgesic effect time to use of rescue analgesia <sep> nausea and vomiting <sep>"", 'maximum possible pain relief <sep> postsurgical pain <sep> number-needed-to-treat nnt <sep> analgesic efficacy and adverse effects <sep> adverse effects <sep>', 'median times to meaningful pain relief <sep> meaningful pain relief <sep> median times to first rescue medication <sep> time to rescue medication time to pain relief and mean pain intensity difference mpid as well as safety profile <sep> time to rescue medication <sep> time to confirmed perceptible pain relief <sep> tolerated <sep> dizziness and orthostatic blood pressure reduction <sep> analgesic efficacy <sep> time to meaningful pain relief <sep> median time to first rescue medication <sep> median times to confirmed perceptible pain relief <sep> orthostatic blood pressure <sep> analgesic efficacy <sep> pain <sep> mpid <sep>', 'peak effects <sep> longer duration of analgesic effect <sep> efficacy <sep> total pain relief topar sum of pain intensity difference spid and patient global assessment of response to therapy pgart <sep> adverse experiences <sep> adverse events <sep> overall analgesic effect <sep> pain relief and intensity <sep> pain relief <sep> nausea <sep> topar6 <sep> topar over 6 h spid <sep> shorter time to onset of analgesia <sep> duration of analgesic effect <sep> vomiting <sep> adverse experiences of nausea <sep> dizziness <sep>', 'total pain relief <sep> adverse events <sep> gastrointestinal and nervous system adverse events <sep> perceptible pain relief and patient evaluations of pain intensity pain relief and global assessments <sep> analgesic efficacy <sep> topar4 patient global assessment peak pain relief and duration of analgesic effect <sep> analgesic efficacy <sep> median onset of analgesia <sep>', 'ex vivo cox-isoform specific assays serum thromboxane b2 txb2 <sep> analgesic efficacy <sep> analgesic activity <sep> total pain relief totpar <sep>', 'analgesic effect <sep> peak pain relief scores <sep> pain intensity pain relief and global assessments <sep> patient global assessment of response to therapy pgart at 6 hours onset of analgesia peak analgesic effect and duration of analgesia <sep> adverse events <sep> overall analgesic effect <sep> adverse events overall <sep> nausea <sep> vomiting <sep> peak analgesic effect <sep> overall analgesic effect was total pain relief over 6 hours topar6 <sep> duration of analgesic effect <sep> analgesic efficacy <sep> adverse events and nausea <sep> time to rescue analgesia <sep>', 'analgesic effect <sep> total pain relief over 8 hours topar8 and 24 hours topar24 and patient global assessments <sep> pain intensity pain relief and global assessments <sep> moderate pain <sep> overall analgesic efficacy <sep> onset of analgesic effect <sep> peak analgesic effect <sep> overall efficacy total pain relief and patient global assessment <sep> severe pain <sep> tolerated <sep> maximum pain relief <sep> patient global assessment for rofecoxib <sep> incidence of clinical and drug-related adverse events <sep> pain osteoarthritis and rheumatoid arthritis <sep> overall analgesic efficacy <sep> duration of analgesic effect <sep> peak analgesic effect <sep> analgesic efficacy and tolerability <sep> duration of analgesia <sep>', 'pain relief <sep> pain on global evaluations <sep> supplemental narcotic analgesia <sep>', 'pain intensity and pain relief for 24 h using visual analogue scales vas and verbal rating scales vrs <sep> rescue analgesia <sep> time-weighted pain relief score <sep> median times to use of rescue medication <sep> rescue analgesia <sep> tolerated and adverse events <sep>', ""analgesic effect <sep> longer duration of analgesic effect <sep> topar12 <sep> scores of pain intensity pain relief and global assessment at prespecified time intervals <sep> faster onset of analgesic effect <sep> scores topar8 topar12 spid8 spid12 and patient's global assessment <sep> peak pain relief and peak pid <sep> adverse-events ae profile <sep> total pain relief topar score over 8 hours topar8 primary end point topar score over 12 hours topar12 sum of pain intensity difference spid over 8 and 12 hours spid8 and spid12 patient's global assessment of study drug at 8 hours time to confirmed perceptible pain relief ie time to onset of analgesic effect peak pain intensity difference pid peak pain relief time to first dose of rescue medication ie duration of analgesic effect and percentage of patients using rescue medication <sep> greater topar8 scores <sep> overall analgesic efficacy <sep> duration of analgesic effect <sep> peak analgesic effect <sep> nausea postextraction alveolitis and vomiting <sep> analgesic effect and peak analgesic effect <sep>"", 'tolerated <sep> efficacy and tolerability <sep> analgesic efficacy <sep> summed pain intensity difference <sep>', 'efficacy <sep> pain and inflammation <sep> quicker onset of analgesia <sep> tolerated <sep> onset of analgesia pain intensity levels and pain relief over 24 hours time-weighted sum of total pain sum of pain intensity difference the percentage of patients requiring rescue medication and experiencing regimen failure and patients global evaluation <sep> analgesic efficacy <sep> pain relief and lower pain intensity <sep>', 'total pain relief <sep> interference domain <sep> pain <sep> brief pain inventory severity <sep> rescue analgesia <sep> pain relief <sep> 24-h pain severity scores <sep> frequency of patient-reported adverse events <sep> analgesic onset and peak <sep> efficacy and tolerability <sep>', 'overall analgesic effects onset of analgesia and peak analgesic effects <sep> adverse experiences physical findings and laboratory measurements <sep> duration of action <sep> analgesic efficacy <sep> analgesic efficacy <sep> tolerability <sep>', 'peak pain relief <sep> total pain relief onset time and duration of response <sep> adverse experiences <sep> supplemental analgesia sooner <sep> tolerated <sep> pain <sep> adverse experiences <sep> onset of analgesia peak pain relief and duration of response <sep> onset of analgesia <sep> total pain relief over 8 h topar8 <sep> supplemental analgesia <sep>', 'pain intensity pain relief and global evaluations <sep> peak pain relief <sep> overall analgesic effect <sep> safety profile <sep> time to onset of effect <sep> pain severity <sep> duration of effect <sep> total pain relief over 8 hours topar8 <sep> peak pain relief score <sep> duration of analgesic effect <sep> analgesic efficacy <sep> pain <sep> overall analgesic effect onset of action peak effect and duration of effect <sep>', 'analgesic effect <sep> level of pain and pain relief <sep> severe pain <sep> pain relief <sep> analgesic effects <sep>', 'total pain relief <sep> moderate postoperative pain <sep> longer median time to use of rescue medication <sep> topar12 scores <sep> mean topar12 scores <sep> tolerated <sep> median time to use of rescue medication <sep> clinical adverse experiences aes and vital signs <sep> global assessment onset of analgesia or aes <sep> analgesic efficacy <sep> tolerability <sep>', 'analgesic effect <sep> mean time-specific pain intensity difference and pain relief scores <sep> tolerated <sep> onset of action <sep> time-weighted sum of total pain relief <sep> pain intensity difference and pain relief scores <sep> analgesic efficacy <sep>'], 'punchline_text': ['the analgesic effect of rofecoxib was significantly greater than that of oxycodone/acetaminophen at p  0.001 for topar6 topar4 global6 global24 and spid6 at p  0.010 for peakpr and peakpid and at p  0.001 for median time to use of rescue analgesia. <sep>', 'adverse effects were uncommon though post-extraction alveolitis dry socket occurred more often with rofecoxib 50 mg than with placebo nnh 24 14 to 80). <sep>', 'mg had similar analgesic efficacy as equimolar doses of naproxen but noninferiority to rofecoxib was not demonstrated. <sep>', 'patients treated with oxycodone acetaminophen had a shorter time to onset of analgesia than patients treated with rofecoxib 24 vs 35 min p  0.05). <sep>', 'rofecoxib provided superior analgesic efficacy compared with codeine/acetaminophen with fewer gastrointestinal and nervous system adverse events. <sep>', 'all active treatments showed greater improvement than placebo p  .001 <sep>', 'significantly more patients in the codeine/acetaminophen group than in the rofecoxib group experienced adverse events overall p  0.050 and nausea in particular p  0.001). <sep>', 'patient global assessment at 8 hours was also significantly better for rofecoxib compared with enteric-coated diclofenac sodium and placebo. <sep>', 'rofecoxib 50 mg was superior to placebo p  .05 and similar to naproxen sodium for all single-dose measures of pain relief. <sep>', 'rofecoxib and dexketoprofen trometamol are effective treatments for acute pain using a dental pain model and are well tolerated. <sep>', 'time to onset of analgesic effect and peak analgesic effect were similar for rofecoxib 50 mg and celecoxib 400 mg. <sep>', 'patient global evaluation of lumiracoxib was comparable to rofecoxib and superior to celecoxib and placebo. <sep>', 'patients receiving valdecoxib experienced a significantly quicker onset of analgesia significantly improved pain relief and lower pain intensity compared with patients receiving rofecoxib and greater satisfaction with their study medication after a single dose. <sep>', 'although analgesic onset and peak were significantly better for h/a than for both rofecoxib p  0.01 p  0.05 respectively and placebo p  0.05 p  0.001 respectively rofecoxib patients used significantly less rescue analgesia p  0.001 over 24 h. rofecoxib also provided better brief pain inventory severity p  0.008 and interference domain p  0.045 scores at 24 h compared to placebo and had lower 24-h pain severity scores than h/a p  0.05). <sep>', 'rofecoxib 50 mg exhibited overall analgesic effects onset of analgesia and peak analgesic effects that were not significantly different from those of ibuprofen 400 mg with a significantly longer duration of action p  0.05). <sep>', 'rofecoxib patients used significantly less p  0.001 supplemental analgesia than placebo patients over days 2-3 1.1 tablets/day vs. 2.1 tablets/day and days 2-5 0.9 tablets/day vs. 1.8 tablets/day). <sep>', 'the results showed that compared with celecoxib rofecoxib had superior analgesic effects on all measures of analgesic efficacy including overall analgesic effect topar8 18.3 vs. 12.5 p<0.001 time to onset of effect 30 vs. 60 minutes p  0.003 peak pain relief score 2.8 vs 2.3 p<0.05 and duration of effect 24 vs. 5.1 hours p<0.001). <sep>', 'paracetamol and rofecoxib combined improved the analgesic effect compared with rofecoxib alone for the first 1.5 h. rofecoxib alone and the combination of paracetamol and rofecoxib had a significantly better analgesic effect than paracetamol alone from 3 h onwards. <sep>', 'there were no significant differences in total pain relief at 4 or 8 hours patients global assessment onset of analgesia or aes between active treatments in either study. <sep>', 'onset of action was significantly faster with valdecoxib 40 mg 30 minutes compared with rofecoxib 50 mg 45 minutes as measured by pain intensity difference and pain relief scores p or 0.05). <sep>'], 'population': ['two hundred twelve patients 63 female 37 male 76 white 24 other mean sd age 20.9 4.4 years age range 16-41 years <sep> patients with moderate to severe pain after dental surgery <sep> patients with pain after dental surgery <sep> patients with moderate to severe postoperative pain in the third molar extraction model <sep> acute pain <sep> patients experiencing moderate to severe postoperative pain after extraction of  or 2 third molars including  or 1 mandibular impaction <sep>', 'acute postoperative pain <sep>', '282 patients <sep> postoperative dental pain <sep> 52 126/242 were women the mean sd age was 25.1 4 years mean weight was 69.0 kg and the mean sd body mass index bmi was 23.7 3 kg/m2 <sep> 242 patients <sep> acute postoperative dental pain after the removal of an impacted mandibular third molar ie wisdom tooth <sep> 58 164/282 were women the mean sd age was 27 6.4 years mean weight was 71 kg and mean sd bmi was 24.2 3 kg/m2 <sep>', 'acute pain following oral surgery <sep> 271 patients <sep> patients with moderate to severe pain after surgical extraction of or 2 third molars including one mandibular impaction <sep>', 'acute dental pain <sep> patients n  390 experiencing moderate or severe pain postextraction of 2 or more third molars with at least 1 mandibular impaction <sep>', '102 patients with dental pain <sep>', 'postoperative dental pain <sep> patients experiencing moderate or severe pain after the surgical extraction of  or  2 third molars at least 1 of which was a mandibular impaction <sep> a total of 393 patients were enrolled 182 received <sep>', 'patients with moderate to severe pain after oral surgery <sep> patients experiencing moderate to severe pain after the surgical extraction of  or  2 third molars <sep> postoperative dental pain <sep> 305 patients <sep> patients with moderate to severe pain associated with oral surgery <sep>', 'post-orthopedic surgery pain <sep> two hundred eighteen patients enrolled <sep>', '120 patients undergoing surgical removal of a single mandibular third molar at the edinburgh dental institute <sep> surgical dentistry <sep>', 'treating pain after dental surgery <sep> patients who experienced moderate or severe pain after surgical extraction of at least 2 third molars <sep> 482 patients 358 females 124 males mean age 22.1 years were enrolled <sep>', 'post-operative dental pain <sep> n  155 <sep> patients with moderate-to-severe post-operative dental pain <sep>', 'patients undergoing oral surgery <sep>', 'treating pain after arthroscopy of the knee <sep> patients with post-arthroscopic pain <sep> enrolling patients experiencing moderate or severe pain after knee arthroscopy <sep> patients with moderate-to-severe postoperative pain <sep>', 'postoperative dental pain <sep> 151 patients 50.3 women mean age 18.3 years 93.4 white experiencing moderate-to-severe pain <sep> post-dental surgery pain <sep>', 'acute pain after bunionectomy surgery <sep> 252 patients with moderate-to-severe pain the day after first metatarsal bunionectomy <sep> post-bunionectomy pain <sep>', 'postoperative dental pain <sep> two hundred and seventy-two patients experiencing pain after the removal of  or 2 third molars <sep> patients with postoperative dental pain <sep> ambulatory patients <sep> patients with acute postoperative dental pain <sep>', 'acute pain relief after third molar surgery <sep> 120 patients with moderate to severe pain after third molar surgery <sep>', 'acute postoperative dental pain <sep> adults and adolescents with postoperative pain after third molar extraction <sep> patients in both studies were female approximately 54 and white  approximately 66 with a mean age of approximately 22 years and a mean weight of approximately 75 kg <sep> patients with pain after dental surgery <sep> 200 patients <sep> patients undergoing extraction of  or 2 third molars with  or 1 mandibular impaction who experienced moderate or severe pain after extraction <sep> 51 patients <sep>', 'patients experiencing moderate or severe pain received <sep> patients following oral surgery <sep> acute postsurgical pain <sep>'], 'interventions': ['rofecoxib <sep> rofecoxib oxycodone/acetaminophen <sep> placebo <sep> oxycodone/acetominophen <sep> rofecoxib and oxycodone plus acetaminophen <sep> rofecoxib <sep> rofecoxib 50 mg oxycodone/acetaminophen 5/325 mg or placebo <sep> opiates acetaminophen <sep> oxycodone/acetaminophen <sep>', 'rofecoxib <sep> placebo <sep> nnt for rofecoxib <sep> placebo nnh <sep>', 'rofecoxib <sep> placebo <sep> 4-(nitrooxy)butyl-(2s)-2-(6-methoxy-2-naphthyl propanoate azd3582 <sep> azd3582 <sep> cyclooxygenase-inhibiting nitric oxide donor azd3582 <sep> naproxen and rofecoxib <sep> azd3582 and naproxen <sep> naproxen <sep> azd3582 750 <sep>', 'rofecoxib <sep> placebo <sep> oxycodone acetaminophen <sep> multidose oxycodone acetaminophen regimen <sep> multidose oxycodone/acetaminophen <sep> rofecoxib 50 mg oxycodone/acetaminophen 10/650 mg singledose phase followed by 5/325 mg every 6h as needed multidose phase or placebo <sep> oxycodone/acetaminophen <sep>', 'acetaminophen/codeine <sep> rofecoxib <sep> placebo <sep> rofecoxib <sep> codeine/acetaminophen <sep>', 'rofecoxib <sep> aspirin ibuprofen and indomethacin inn indometacin <sep> placebo <sep> rofecoxib <sep> rofecoxib and indomethacin <sep> placebo and ibuprofen <sep> indomethacin <sep> ibuprofen <sep>', 'rofecoxib <sep> placebo <sep> codeine <sep> codeine 60 mg/acetaminophen <sep> acetaminophen <sep> placebo rofecoxib 50 mg or codeine 60 mg/acetaminophen <sep> rofecoxib <sep> ibuprofen <sep> codeine/acetaminophen <sep> rofecoxib codeine/acetaminophen <sep>', 'rofecoxib and enteric-coated diclofenac sodium <sep> rofecoxib <sep> placebo <sep> topar24 <sep> rofecoxib 50 mg 3 doses of enteric-coated diclofenac sodium <sep> rofecoxib <sep> diclofenac sodium <sep> enteric-coated diclofenac sodium <sep> ibuprofen <sep> naproxen sodium <sep> diclofenac sodium <sep> enteric-coated diclofenac sodium 50 mg and placebo <sep> diclofenac sodium and placebo <sep> enteric-coated diclofenac sodium <sep>', 'rofecoxib <sep> placebo and naproxen sodium <sep> placebo <sep> single-dose and multidose rofecoxib <sep> placebo rofecoxib 50 mg or naproxen sodium <sep> rofecoxib <sep> naproxen sodium <sep>', 'rofecoxib <sep> placebo <sep> dexketoprofen trometamol <sep> rofecoxib <sep> rofecoxib a selective cyclooxygenase-2 inhibitor and dexketoprofen trometamol <sep>', 'rofecoxib <sep> placebo <sep> rofecoxib 50 mg celecoxib 400 mg celecoxib 200 mg ibuprofen 400 mg or placebo <sep> celecoxib <sep> rofecoxib <sep> rofecoxib and celecoxib selective cyclooxygenase-2 inhibitors <sep> ibuprofen <sep>', 'rofecoxib <sep> placebo <sep> rofecoxib celecoxib and placebo <sep> lumiracoxib 400 mg rofecoxib 50 mg celecoxib 200 mg or placebo <sep> celecoxib <sep> lumiracoxib <sep> lumiracoxib rofecoxib or placebo <sep> lumiracoxib <sep> celecoxib and placebo <sep>', 'valdecoxib <sep> cyclooxygenase cox)-2 enzyme <sep> placebo <sep> rofecoxib <sep> valdecoxib <sep> rofecoxib and placebo <sep> valdecoxib rofecoxib and placebo <sep> valdecoxib and rofecoxib <sep>', 'rofecoxib hydrocodone/acetaminophen <sep> rofecoxib <sep> hydrocodone/acetaminophen <sep> placebo <sep> rofecoxib <sep>', 'rofecoxib <sep> placebo <sep> placebo rofecoxib 50 mg or ibuprofen <sep> cyclooxygenase-2-specific inhibitor rofecoxib <sep> rofecoxib <sep> ibuprofen <sep>', 'diclofenac <sep> rofecoxib <sep> diclofenac <sep> placebo <sep> rofecoxib 50 mg or placebo <sep> rofecoxib diclofenac sodium and placebo <sep> rofecoxib <sep> diclofenac sodium <sep> enteric-coated diclofenac sodium <sep> rofecoxib diclofenac <sep>', 'nonsteroidal anti-inflammatory drugs nsaids <sep> rofecoxib <sep> placebo <sep> celecoxib <sep> cyclooxygenase-2 cox-2 inhibitor rofecoxib <sep> cox-2 inhibitors rofecoxib <sep> ibuprofen <sep> rofecoxib and celecoxib two cyclooxygenase-2 inhibitors <sep> ibuprofen 400 mg and placebo <sep> celecoxib rofecoxib <sep>', 'rofecoxib <sep> placebo <sep> paracetamol and rofecoxib <sep> paracetamol <sep> paracetamol with a selective cyclooxygenase-2 inhibitor <sep> rofecoxib <sep> rofecoxib  paracetamol rofecoxib alone paracetamol alone or placebo <sep> paracetamol and rofecoxib <sep> paracetamol <sep>', 'rofecoxib and valdecoxib <sep> rofecoxib <sep> placebo <sep> valdecoxib <sep> rofecoxib 50 mg 50 to valdecoxib <sep> reofecoxib 50 mg valdecoxib 40 mg or palcebo <sep> rofecoxib <sep> rofecoxib 50 mg valdecoxib 20 mg or placebo <sep>', 'valdecoxib <sep> rofecoxib <sep> single-dose valdecoxib <sep> cyclooxygenase-2 specific inhibitors valdecoxib and rofecoxib <sep> valdecoxib <sep> rofecoxib 50 mg n=101 or placebo <sep> valdecoxib and rofecoxib <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",rofecoxib 50 mg two to four times the standard daily dose for chronic pain is an effective single dose oral analgesic for acute postoperative pain in adults with a relatively long duration of action.
176,"{'outcomes': ['frequency of dietician referral <sep> frequencies of dietician referral and documentation of weight <sep>', 'health status <sep> frequency of problem detection or intervention <sep> hearing loss <sep> detection of and intervention for conditions screened and health status 6 months <sep> malnutrition/weight loss visual impairment hearing loss cognitive impairment urinary incontinence depression physical limitations and reduced leg mobility <sep>', 'costs <sep> average weight <sep> number of hospital acquired infections <sep> admittance and discharge and hospital-acquired infections and pressure sores were scored and costs related to nutrition infections and length of hospital stay <sep> body mass <sep> cost-effectiveness <sep> number of patients with pressure sores <sep> nutritional status hospital-acquired infections and pressure sores <sep>'], 'punchline_text': ['the nurses in charge of the wards felt that introduction of the screening tool had raised awareness of nutrition-related care. <sep>', 'a brief measure to screen for common conditions in older persons was associated with more frequent detection and follow-up assessment of hearing loss. <sep>', 'the number of hospital acquired infections was significantly lower in the intervention group 33/140 versus 58/158 p=0.01 but no significant difference in number of patients with pressure sores 23/140 versus 33/158 was found. <sep>'], 'population': ['district general hospital <sep> two similar general medical wards in a united kingdom uk district general hospital with the help of staff and patients n  175 admitted during two study periods may 1999 and january 2000 <sep>', 'older persons <sep> older persons seen in office practice <sep> two hundred and sixty-one patients aged  or  70 years and seeing these physicians for a new visit or a physical examination participated in the study <sep> twenty-six community-based office practices of internists and family physicians in los angeles <sep>', '298 older patients 60 years <sep> inpatient geriatric service of a university hospital umc nijmegen and a geriatric ward of a non-academic teaching hospital rijnstate hospital arnhem <sep> older people <sep> geriatric inpatients to prevent malnutrition <sep> all non-terminally ill patients admitted for more than two days were included <sep>'], 'interventions': ['nutrition screening tool <sep>', 'office-based screening <sep>', 'interdisciplinary intervention <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",current evidence is insufficient to support the effectiveness of nutritional screening although equally there is no evidence of no effect. therefore more high quality studies should be conducted to assess the effectiveness of nutritional screening in different settings.
177,"{'outcomes': ['area under the serial plasma uric acid concentration curves <sep> initial plasma uric acid levels <sep> antirasburicase antibodies <sep>', 'plasma uric acid <sep> response rates <sep> uric acid levels <sep> efficacy safety and pharmacokinetic profile of rasburicase <sep>', 'incidence of sepsis <sep> tls or anuria <sep> incidence of tumor lysis syndrome <sep> incidence of tls and anuria <sep> anuria <sep> highest risk to develop a tls <sep> tls <sep>', 'metabolic problems <sep> severe allergic reaction to urate-oxidase <sep> hyperphosphatemia <sep> renal dialysis <sep> metabolic problems that included hypocalcemia <sep> rate of renal and metabolic complications <sep> metabolic complications <sep>', 'initial uric acid level <sep> blood levels of uric acid creatinine phosphorus calcium lactate dehydrogenase and complete blood count <sep> acute renal failure <sep>'], 'punchline_text': ['for pediatric patients with advanced stage lymphoma or high tumor burden leukemia rasburicase is a safe and effective alternative to allopurinol during initial chemotherapy. <sep>', 'rasburicase is effective and well tolerated for the management of hyperuricemia in japanese pediatric patients at high risk of developing tls. <sep>', ""patients with b-all had the highest risk to develop a tls 26.4 followed by b-all/burkitt's lymphoma and a ldh  or 500 u/l 14.9%). <sep>"", 'in the other 27 cases metabolic problems were successfully resolved using urate-oxidase in combination with alkaline hyperhydration. <sep>', 'initial uric acid level decreased significantly by 4 hours from 343 micromol/l to 58 micromol/l p<0.001 except for one steroid-resistant patient who required hemodialysis on day 14 after having introduced combined cytostatic treatment. <sep>'], 'population': ['children with lymphoma or leukemia at high risk for tumor lysis <sep> pediatric patients with advanced stage lymphoma or high tumor burden leukemia <sep> patients at high risk for tumor lysis who received rasburicase compared to <sep> pediatric patients with leukemia or lymphoma at high risk for tumor lysis <sep>', 'japanese patients <sep> patients with hematologic malignancies <sep> pediatric patients with hematologic malignancies <sep> pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome <sep> japanese pediatric patients at high risk of developing tls <sep> patients aged 18 years at high risk for tls with newly diagnosed hematologic malignancies <sep>', ""children with b-cell acute lymphoblastic leukemia b-all or stage iii/iv burkitt's lymphoma and a lactate dehydrogenase ldh level  or 500 u/l before and after the introduction of a protocol amendment to use urate oxidase for the prophylaxis of tls <sep> 1791 children with nhl enrolled in the two subsequent multicenter studies nhl-bfm 90 and 95 were evaluated <sep> children with advanced stage burkitt's lymphoma/leukemia <sep> from november 1997 all children with b-all or stage iii and iv b-nhl and ldh  or 500 u/l should receive <sep> children with non-hodgkin's lymphoma nhl <sep>"", ""patients with b-cell advanced-stage non-hodgkin's lymphoma nhl and l3 leukemia at initiation of chemotherapy including the use of urate-oxidase <sep> 410 patients with stage iii and iv b-cell nhl and l3 leukemia treated in france and prospectively registered in the lmb89 protocol <sep> patients with b-cell lymphoma and leukemia treated in the socit franaise d'oncologie pdiatrique lmb89 protocol <sep>"", ""children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-hodgkin's lymphoma <sep> 12 patients receiving rasburicase with that of a historic cohort of 14 patients treated with <sep> children with leukemia and non-hodgkin's lymphoma <sep> children with leukemia and lymphoma <sep>""], 'interventions': ['uric acid-lowering agent for 5 to 7 days during induction chemotherapy <sep> rasburicase and allopurinol <sep> allopurinol <sep>', 'chemotherapy <sep> intravenous rasburicase <sep>', 'urate oxidase prophylactically <sep> urate oxidase <sep>', 'urate-oxidase <sep>', 'recombinant urate oxidase rasburicase <sep> allopurinol <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",although urate oxidase might be effective in reducing serum uric acid it is still unclear whether this translates into a reduction in mortality or renal failure. clinicians should weigh the potential benefits of reducing uric acid and uncertain benefits of preventing renal failure or mortality from tls against the potential risk of adverse effects.
178,"{'outcomes': ['adverse effects <sep> ph values of gastric fluid <sep>', 'apgar score cord blood gas analysis and neurobehavioural assessment <sep> gastric ph <sep> median gastric fluid ph <sep> incidence and severity of nausea and vomiting <sep> pain intensity score on sitting and sedation <sep> nalbuphine consumption <sep> pain relief <sep>', 'smaller volumes of aspirated gastric contents <sep> gastric ph <sep> alkaline values of gastric ph <sep> gastric ph and aspirated gastric volumes <sep> narrowest range of ph values of gastric contents <sep>', 'risk of acid aspiration of gastric contents <sep> pi ph <sep>', 'gastric aspirate ph and volume <sep>', 'volume of the gastric content <sep> mean ph <sep> gastric ph less <sep>', 'gastric volumes <sep> mean gastric ph <sep> gastric ph <sep> gastric ph <sep>', 'mean ph1 and mean ph2 values <sep> mean ph1 and ph2 values <sep> mean ph1 and ph2 values <sep> gastric ph <sep>', 'gastric volumes <sep> gastric ph <sep> gastric contents <sep> volume and ph of the gastric contents <sep> gastric volume and ph <sep>', 'gastric volumes <sep> gastric ph <sep>', 'risk of acid aspiration <sep> mean ph <sep> gastric volumes <sep>', 'gastric volume <sep> gastric ph <sep>', 'gastric secretion <sep> intragastric ph and volume <sep>', 'intragastric ph and volume <sep> higher intragastric ph but larger intragastric volumes <sep> intragastric ph less <sep>', 'gastric content <sep> effective means to control and neutralize gastric secretion <sep> neutralize acidity <sep> innate ph of gastric juice <sep> gastric volume <sep>'], 'punchline_text': ['no adverse effects were observed in newborn infants whose mothers had received cimetidine and there was no significant difference in ph values of gastric fluid from the newborn in the two groups. <sep>', 'nalbuphine consumption in the first 24 h after operation was reduced by 35 in the tramadol group. <sep>', 'sodium citrate 0.3 mol litre-1 mixture resulted in the narrowest range of ph values of gastric contents mean a 5.4 b 5.9 range 3.9-7.7). <sep>', 'pi ph in patients receiving ranitidine/citrate mean 5.2 sd 0.8 was significantly higher than in patients receiving citrate alone mean 4.9 sd 1.1). <sep>', 'at induction of anaesthesia treatment was judged successful ph  or  2.5 and volume  25 ml in 87 73 100 and 81 of patients in groups 1-4 respectively. <sep>', 'at 10 min none patient in group c had a gastric ph less than 2.5 in the opposite to 92 of patients in the control group t. the alkalinizing effect of the citrate lasted throughout the evaluation time. <sep>', 'gastric ph was significantly higher in the short interval group than in either the control group or in patients receiving their sodium citrate more than 60 min in advance. <sep>', 'percentages of patients with ph1 less than or equal to 2.5 in groups 1 2 and 3 were respectively 75 13.8 and 1.6. <sep>', 'the gastric ph was found to be higher after omeprazole than after ranitidine immediately after intubation 5.89  <sep>', 'seven patients in the cimetidine group and four in the antacid group had gastric volumes in excess of 50 ml after induction of anaesthesia while two patients in each group had gastric ph less than 2.5 after induction. <sep>', 'mean ph in patients receiving omeprazole was significantly higher p  0.001 than in the control group. <sep>', 'in the cimetidine treated group only one patient had a gastric ph below 2.5 while in the control group 11 patients had a ph below this limit. <sep>', 'six patients 19 in the ranitidine group had aspirates of ph less than 3.5 a significant difference from the omeprazole group p less than 0.05). <sep>', 'the use of sodium citrate resulted in higher intragastric ph but larger intragastric volumes p less than 0.05). <sep>', 'patients receiving omeprazole in single oral dose regimen retained a greater gastric volume  or  0.4 ml/kg than those who received famotidine or ranitidine p  0.005). <sep>'], 'population': [""mendelson's syndrome before elective caesarean section <sep> patients undergoing elective caesarean section received eitherrr <sep> patients undergoing elective caesarean section <sep>"", 'given before caesarean section under general anaesthesia <sep> i parturients undergoing elective caesarean section <sep>', 'obstetrics <sep> 78 obstetric patients during elective a or emergency b surgery <sep>', 'mothers undergoing emergency cesarean section under general anesthesia <sep> patients with both ph  3.5 and volume <sep> at emergency cesarean section <sep>', 'elective obstetric anaesthesia <sep> gastric contents during general anaesthesia for elective caesarean section <sep>', '52 unpremedicated women undergoing elective caesarean section under general anaesthesia <sep> elective cesarean section <sep>', 'elective cesarean section patients <sep> thirty-two healthy term parturients undergoing elective cesarean section randomly received either <sep>', 'obstetric anaesthesia <sep> one hundred and forty-seven patients undergoing elective or emergency caesarean section under general anaesthesia <sep>', 'obstetric patients undergoing emergency caesarean section <sep> women undergoing emergency caesarean section <sep> patients with gastric volume  25 ml and ph <sep> 80 consecutive women undergoing emergency caesarean section <sep>', '17 patients undergoing elective caesarean section <sep> elective caesarean section <sep> pregnant patients with the need for preventative measures against aspiration during the induction of anaesthesia <sep>', 'mothers undergoing emergency cesarean section under general anesthesia <sep> patients with both ph  3.5 and volume <sep> 282 patients in the study group and 259 in the control group <sep> at emergency cesarean section <sep>', 'aspiration pneumonia in obstetrics <sep> 30 parturients provided for elective cesarean section <sep>', 'women undergoing elective caesarean section <sep> obstetric patients <sep> sixty-five women scheduled to undergo elective caesarean section under general anaesthesia <sep>', 'one hundred and sixty-two chinese women undergoing emergency caesarean section <sep> prophylaxis against aspiration pneumonitis in emergency caesarean section <sep>', 'regional anesthesia for elective cesarean section <sep> elective cesarean section under regional anesthesia <sep> one hundred and sixty patients undergoing elective cesarean section under spinal anesthesia <sep> parturients <sep>'], 'interventions': ['magnesium trisilicate mixture bpc <sep> cimetidine and magnesium trisilicate mixture regimens <sep> oral cimetidine 400 mg or magnesium trisilicate mixture bpc 20 ml before anaesthesia <sep> cimetidine <sep>', 'famotidine <sep> sixty asa <sep> tramadol <sep>', 'sodium citrate 0.3 mol litre-1 mixture <sep> cimetidine <sep> magnesium trisilicate mixture b.p.c <sep> antacid regimens magnesium trisilicate 12-172 ml sodium citrate <sep> cimetidine <sep> magnesium trisilicate mixture b.p.c. sodium citrate mixture or cimetidine <sep>', 'placebo <sep> intravenous ranitidine <sep> ranitidine/citrate <sep> 30 ml of 0.3 m sodium citrate <sep> ranitidine <sep>', 'oral omeprazole doses stated above and in addition metoclopramide <sep> oral omeprazole <sep> gastric antisecretory agent omeprazole <sep> omeprazole <sep> omeprazole with and without metoclopramide <sep> metoclopramide <sep>', 'sodium citrate <sep> oral sodium citrate <sep> antacids and group c n  26 receiving orally 30 ml of 0.3 m sodium citrate solution <sep>', 'sodium citrate pretreatment <sep> sodium citrate <sep> 30 ml of 0.3 molar sodium citrate less than 60 min preoperatively n  11 or 30 ml of 0.3 molar sodium citrate <sep> no antacid <sep>', 'cimetidine-sodium citrate mixture and sodium citrate <sep> 0.3-molar sodium citrate 15 ml sodium citrate <sep> effervescent cimetidine-sodium citrate combination cimetidine 400 mg with sodium citrate 0.9 g after entering the operating room <sep> no premedication <sep>', 'ranitidine and omeprazole <sep> ranitidine 50 mg or omeprazole <sep> omeprazole <sep> omeprazole and ranitidine <sep> ranitidine <sep>', 'antacid <sep> oral antacid premedication <sep> cimetidine <sep> cimetidine premedication <sep>', 'omeprazole 40 mg intravenously or placebo <sep> endotracheal intubation pi and before tracheal extubation pe <sep> proton pump inhibitor omeprazole <sep> omeprazole <sep> metoclopramide and 30 ml of 0.3 m sodium citrate <sep>', 'no specific medication for prophylaxis of aspiration pneumonia or 400 mg cimetidine <sep> cimetidine <sep>', 'omeprazole 40 mg or ranitidine <sep> omeprazole <sep> omeprazole and ranitidine <sep> ranitidine <sep>', 'sodium citrate <sep> sodium citrate and ranitidine <sep> chemoprophylaxis against acid aspiration ranitidine 150 mg 6 hourly with sodium citrate at induction of anaesthesia omeprazole 40 mg 12 hourly with sodium citrate or omeprazole 40 mg 12 hourly alone <sep> omeprazole <sep> omeprazole and ranitidine <sep> ranitidine <sep>', 'famotidine <sep> fiberoptic gastric aspiration <sep> placebo <sep> ranitidine famotidine and omeprazole <sep> famotidine or ranitidine <sep> famotidine ranitidine omeprazole with placebo <sep> ranitidine 300 mg and group o <sep> prophylaxis against acid aspiration <sep> famotidine 40 mg group r <sep> omeprazole 40 mg <sep> omeprazole <sep> ranitidine or famotidine <sep> ranitidine <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",the quality of the evidence was poor but the findings suggest that the combination of antacids plus h2 antagonists was more effective than no intervention and superior to antacids alone in preventing low gastric ph. however none of the studies assessed potential adverse effects or substantive clinical outcomes. these findings are relevant for all women undergoing caesarean section under general anaesthesia.
179,"{'outcomes': ['bronchopulmonary exacerbations <sep> forced vital capacity fvc forced expiratory volume in 1 sec fev(1 and forced mid-expiratory flow fef(25-75 <sep> fvc and secondarily on fev(1 fef(25-75 the number of days on antibiotic therapy the shwachman score a nutritional index weight/height(2 the change in sputum bacterial flora and nocturnal cough <sep>', 'time to reach peak fev1 <sep> time to reach peak fvc <sep> forced expiratory volume in one second fev1 and forced vital capacity fvc <sep> respiratory function <sep>', 'forced expiratory volume in one second forced vital capacity oxygen saturation body weight sputum volume culture and rheology serum urea and electrolytes white cell count and erythrocyte sedimentation rate <sep> frequency of infective exacerbations <sep>', 'forced expiratory volume <sep> fev1 <sep> 1-hour rates of mucus clearance <sep> respiratory symptoms <sep> forced vital capacity fvc the forced expiratory flow <sep> 24-hour rates of mucus clearance <sep> lung function <sep> total lung capacity rv:tlc <sep> mucus clearance and lung function <sep> volume of airway surface liquid restore mucus clearance and improve lung function <sep> mucus clearance and improved lung function <sep>'], 'punchline_text': ['the effects on fvc and secondarily on fev(1 fef(25-75 the number of days on antibiotic therapy the shwachman score a nutritional index weight/height(2 the change in sputum bacterial flora and nocturnal cough were assessed. <sep>', 'both forced expiratory volume in one second fev1 and forced vital capacity fvc showed improvements over the course of treatment although there was no difference in respiratory function between the two groups at any of three time periods during the study. <sep>', 'no significant changes occurred in forced expiratory volume in one second forced vital capacity oxygen saturation body weight sputum volume culture and rheology serum urea and electrolytes white cell count and erythrocyte sedimentation rate during either treatment period. <sep>', 'a comparison of the changes in lung function in the two groups showed no significant difference. <sep>'], 'population': ['cystic fibrosis patients <sep> patients chronically colonized with pseudomonas received <sep> sixty-four patients were chronically colonized with pseudomonas aeruginosa <sep> cystic fibrosis patients more than 5-years-old n  137 <sep>', 'respiratory exacerbations of cystic fibrosis <sep> 27 cystic fibrosis patients mean age 12.8 years <sep> two hospitals in leeds uk <sep>', 'fourteen patients completed the study <sep> 23 patients with cystic fibrosis <sep> patients with cystic fibrosis <sep>', 'cystic fibrosis with hypertonic saline <sep> 24 patients with cystic fibrosis <sep> patients with cystic fibrosis <sep>'], 'interventions': ['placebo <sep> amiloride <sep> nebulized amiloride <sep> nebulized colimycine <sep> amiloride or placebo <sep> sodium channel blocker <sep> amiloride <sep> amiloride over placebo <sep>', 'placebo <sep> amiloride <sep> nebulised amiloride <sep> nebulised amiloride <sep> amiloride <sep>', 'placebo <sep> nebulized amiloride <sep> amiloride or placebo <sep>', 'amiloride <sep> hypertonic saline with placebo <sep> hypertonic saline and placebo <sep> inhaled hypertonic saline 5 ml of 7 percent sodium chloride four times daily with or without pretreatment with amiloride <sep> hypertonic saline <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",we found no evidence that the topical administration of a short-acting sodium channel blocker improves respiratory condition in people with cystic fibrosis and some limited evidence of deterioration in lung function.
180,"{'outcomes': ['endocervical cells <sep>', 'incidence of smears with endocervical cells <sep>', 'cytological detection of persistent cervical intraepithelial neoplasia <sep> rocket samples <sep> detection rate of dyskaryosis <sep> multispatula samples <sep>', 'smear quality and endocervical cell recovery <sep> endocervical cells <sep> cervex-brush <sep>', 'contain immature metaplastic cells <sep> proportion of smears containing one or other type of indicator cell <sep>', 'presence or absence of endocervical cells <sep> number of adequate smears <sep>', 'endocervical cells <sep> cytologic abnormalities <sep>', 'detection of endocervical cells <sep>', 'endocervical or metaplastic cells <sep>', 'adequacy of ectocervical smears <sep> presence of columnar cells or squamous metaplasia <sep>', 'bloody papanicolaou smears <sep> serious adverse events <sep> detection of endocervical cells <sep> endocervical cell yield <sep>', 'rate of cervical intraepithelial neoplasia cin diagnosis <sep> endocervical detection of cin <sep>', 'dyskaryotic smears <sep> cellular quality of the smears <sep> risk of bleeding <sep>', 'effectiveness in obtaining satisfactory papanicolaou smears <sep>'], 'punchline_text': ['endocervical cells were found more often and in greater numbers with cytobrush also in women over 50 years of age. <sep>', 'the same incidence 3.6 of dyskaryotic smears was found using the ayre spatula 74/2077 as the aylesbury spatula 72/2003). <sep>', ""significantly fewer ayre's samples contained endocervical cells than aylesbury samples 47 vs 59 difference 12 95 ci 3%-21 p less than 0.001 rocket samples 47 vs 67 difference 20 95 ci 12%-32 p less than 0.001 or multispatula samples 47 vs 76 difference 29 95 ci 19-38 p less than 0.001). <sep>"", 'for pregnant patients smear quality was improved with both cytobrush-spatula and bayne pap brush versus cotton swab-spatula <sep>', 'no significant difference was found in the proportion of smears containing one or other type of indicator cell or in the yield of abnormal smears. <sep>', 'within each subgroup the endocervical brush consistently produced a higher number of adequate smears than did the cotton swab after cryosurgery 86 vs. 82 p  .7242 after laser ablation 95 vs. 88 p  .61 after conization 76 vs. 47 p  .0675. <sep>', 'five of the 15 cytologically positive cases had histologic verification the cytologic findings were predictive of the histologic findings in all. <sep>', 'there was no statistically significant difference between the cytobrush-ayre spatula and the cervex brush sampling methods were equally effective in obtaining endocervical cells in papanicolaou smears. <sep>', 'also the number of samples classed as inadequate was significantly greater with cervex brush smears 4.0 than with cytobrush-ayre spatula smears 0.3 p  .0003). <sep>', 'the adequacy of ectocervical smears as measured by the presence of columnar cells or squamous metaplasia differed significantly among the four techniques studied. <sep>', 'there was an increased detection of endocervical cells in pregnant patients with both the cytobrush and modified ayers spatula 90.7 and the cervex-brush 83.3 methods compared with the cotton swab and modified ayers spatula 70.8 p  .0001 and p  .0233 respectively). <sep>', 'correct methods of sampling are essential for obtaining adequate smears for cytological diagnosis of cervicovaginal abnormalities. <sep>', 'the efficiency of the spatula in obtaining dyskaryotic cells and improving the cellular quality of smears was compared with that of the ayre spatula in a controlled trial. <sep>', 'the sampling methods had similar abilities to obtain a satisfactory smear cytobrush/spatula 63 cotton swab/spatula 57 p  .23). <sep>'], 'population': ['107 women <sep> vaginal smears <sep>', 'women attending the department of genitourinary medicine during a 16 month period <sep>', '358 women were reported <sep> remaining patients with normal colposcopy 130 <sep> persistent cervical intraepithelial neoplasia cin <sep> 856 patients 130 had histologically proven persistent cin <sep> 856 patients who had received local therapy co2 laser or cold coagulation for cin ii or iii between 9 and 30 months earlier <sep>', 'cervical cytology <sep> two thousand fifteen patients undergoing routine cervical smears at the university of tennessee obstetrics and gynecology clinics <sep>', '533 women who were attending a colposcopy clinic either for investigation of cytological abnormality or for review after treatment of cin <sep>', '203 patients with a history of cryosurgery laser ablation or cone biopsy were randomized into two groups 114 patients had cervical smears done with a cotton swab and 89 patients with an endocervical brush <sep> patients after treatment for cervical dysplasia <sep>', '192 patients ranging in age from 18 to 82 yr were referred to the gynecologic/oncologic clinic for follow-up of an atypical papanicolaou smear or of a previously diagnosed and treated cervical vulvar or endometrial lesion <sep> 192 patients 149 were premenopausal 15 of whom were pregnant 12 were perimenopausal and 31 were postmenopausal <sep> 10 pregnant patients 40 and 14 of 18 postmenopausal patients 78 contained endocervical cells.(abstract truncated at 250 words <sep>', 'collected 346 smears over a 6-month period 110 with the cervex brush 125 with the cotton swab plus ayre spatula and 111 with the cytobrush plus ayre spatula <sep> papanicolaou smears <sep>', '802 women at initial follow-up after laser treatment of cervical lesions 421 smears prepared using the cervex brush were compared with 381 smears prepared using the combination of a <sep>', 'one hundred ninety-six 59 percent of 332 ectocervical smears obtained with a curved brush were adequate compared with 190 59 percent of 323 ectocervical smears obtained with a spatula <sep>', 'pregnant women <sep> 352 pregnant women undergoing initial obstetric evaluation <sep>', '89 patients who underwent repeat smear and colposcopic examinations because of abnormal screening smears <sep>', 'more than 17,000 smears were taken from women aged 14-86 years by more than 200 smear takers from 74 centres <sep>', ""los angeles county  university of southern california <sep> women's hospital colposcopy clinic <sep> participants were all nonpregnant patients referred to the colposcopy clinic for abnormal papanicolaou smears <sep>""], 'interventions': ['cytobrush and papaplast <sep>', 'traditional ayre spatula with the new aylesbury spatula <sep>', 'local ablative treatment <sep> local ablative therapy for cin <sep>', 'cotton swab-spatula and cytobrush-spatula <sep> cytobrush-spatula and bayne pap brush versus cotton swab-spatula <sep> cotton swab-spatula cytobrush-spatula cervex-brush or bayne pap brush <sep>', 'ayre and rocket cervical spatulas <sep>', 'cervical cytology after cryosurgery laser ablation and conization <sep>', 'modified ayre spatula exocervix plus zelsmyr cytobrush endocervix 90 cases and 2 modified ayre spatula exocervic plus bulb aspirator endocervix <sep> modified ayre spatula/zelsmyr cytobrush versus the modified ayre spatula/bulb aspirator <sep>', '3 cervical smear sampling devices <sep>', 'cervex brush versus cytobrush-ayre spatula sampling <sep> cytobrush plus an ayre spatula <sep>', 'curved cytologic sampling brush or ayre spatula <sep>', 'cotton swab and modified ayers spatula cytobrush and modified ayers spatula or cervex-brush <sep> endocervical cytobrush and cervex-brush <sep>', 'cytobrush versus cotton <sep> sampling ayre spatula cotton swab and cytobrush <sep>', 'new cervical spatula <sep>', 'cytobrush and cotton swab <sep> cytobrush/spatula or the cotton swab/spatula <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",extended tip spatulas of various designs appear to be better for collecting endocervical cells than the commonly used ayre spatula. the most effective combination appears to be the cytobrush with an extended tip spatula. the rate of detection of endocervical cells appears to be a valid and convenient surrogate for the ability to detect dyskaryosis and for adequate smear rates. the ability of the extended tip spatula with the cytobrush compared with the extended tip spatula alone to detect disease needs to be evaluated in a trial.
181,"{'outcomes': ['mean sitting diastolic blood pressure <sep> antihypertensive efficacy and safety <sep> incidence of adverse events <sep> antihypertensive efficacy safety and tolerability <sep> mean sitting systolic blood pressure <sep> blood pressure <sep> mean sitting systolic/diastolic blood pressure <sep> successful treatment response diastolic blood pressure <sep>', 'plasma renin activity pra <sep> msdbp and mean sitting systolic blood pressure mssbp <sep> control rates <sep> bp maximum mssbp/msdbp reduction <sep> tolerated <sep> pra <sep> change in msdbp <sep> bp lowering <sep>', 'mean sitting diastolic blood pressure <sep> rates of adverse events and laboratory abnormalities <sep> efficacy and safety <sep> blood pressure <sep>', 'adverse event rates <sep> bp <sep> mean sitting diastolic bp <sep> tolerated <sep> hypokalemia <sep> bp reductions mean sitting systolic bp/mean sitting diastolic bp <sep> bp reductions <sep>', 'antihypertensive efficacy and safety <sep> trough sbp <sep> adverse events and number of patients discontinuing therapy <sep> mean sitting dbp <sep> trough mean sitting dbp and systolic blood pressure sbp <sep> safety and tolerability <sep> safety and tolerability profile <sep> antihypertensive effect <sep>', 'mean sitting diastolic bp msdbp <sep> bp reduction <sep> tolerated <sep> mean sitting systolic <sep> tolerability <sep> blood pressure bp reduction <sep> efficacy and tolerability <sep> msdbp <sep>', 'mean sitting diastolic bp dbp <sep> mean sitting dbp and systolic bp sbp <sep> dbp and sbp <sep> blood pressure <sep> safety and tolerability profile <sep> antihypertensive effect <sep>'], 'punchline_text': ['aliskiren produced significant dose-dependent reductions in mean sitting diastolic blood pressure p<0.0005 vs. placebo for each dose and mean sitting systolic blood pressure p<0.001 vs. placebo for each dose). <sep>', ""aliskiren monotherapy was superior to placebo p  0.001 overall dunnett's test in reducing msdbp and mean sitting systolic blood pressure mssbp). <sep>"", 'rates of adverse events and laboratory abnormalities were similar in all groups. <sep>', 'adverse event rates were similar with aliskiren 65.2 and hydrochlorothiazide-based therapy 61.5%). <sep>', 'aliskiren 300 and 600 mg lowered mean sitting dbp significantly more than irbesartan 150 mg p<0.05). <sep>', 'at end point aliskiren 150 and 300 mg significantly reduced msdbp both p  0.001 and mean sitting systolic this study found a positive linear dose-response relationship in bp reduction with aliskiren 75 150 and 300 mg dosed once daily but only aliskiren 150 and 300 mg provided statistically significant reductions from baseline compared with placebo. <sep>', 'once-daily oral treatment with aliskiren 300 mg significantly p  .0001 lowered mean sitting dbp and systolic bp sbp compared with placebo aliskiren monotherapy demonstrated a safety and tolerability profile comparable to placebo. <sep>'], 'population': ['forty hundred and fifty-five japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmhg <sep> japanese patients with hypertension <sep>', '2776 patients aged or=18 years with mean sitting diastolic blood pressure msdbp 95-109 <sep> hypertensive patients <sep>', 'patients with hypertension <sep> 1797 patients with hypertension mean sitting diastolic blood pressure 95-109 mm hg and 8-h daytime ambulatory diastolic blood pressure  or 90 mm hg <sep>', '1124 patients mean sitting diastolic blood pressure bp 95 to 109 mm hg <sep> patients with essential hypertension <sep>', 'patients with mild-to-moderate hypertension mean sitting diastolic blood pressure dbp  or 95 and 110 mm hg <sep> hypertensive patients <sep> patients with mild-to-moderate hypertension <sep> 652 patients <sep>', 'adult patients with stage 1 or 2 essential hypertension <sep> patients aged  or 18 years with stage 1 or 2 essential hypertension entered a 3 to 4-week single-blind placebo run-in period <sep> eligible patients <sep> 642 patients mean sd age 52.0 10.73 years 60.0 male 80.8 white mean body weight 89.2 18.4 kg range 50-160 kg were included in the study <sep>', 'patients with hypertension <sep> 1123 patients with mild-to-moderate hypertension underwent a 3 to 4 week single-blind <sep>'], 'interventions': ['aliskiren 75 150 or 300 mg or placebo <sep> placebo <sep> aliskiren <sep> placebo and aliskiren <sep> aliskiren <sep>', 'aliskiren/hctz <sep> placebo <sep> hctz <sep> aliskiren monotherapy <sep> hctz monotherapy <sep> aliskiren and hctz or placebo <sep> hydrochlorothiazide hctz <sep> aliskiren <sep> hydrochlorothiazide <sep> aliskiren <sep>', 'placebo <sep> aliskiren/valsartan <sep> monotherapy aliskiren <sep> valsartan <sep> aliskiren 300 mg and valsartan <sep> aliskiren and valsartan <sep> aliskiren <sep> valsartan 160 mg 455 a combination of aliskiren 150 mg and valsartan 160 mg 446 or placebo <sep>', 'diuretic hydrochlorothiazide <sep> placebo <sep> oral direct renin inhibitor aliskiren <sep> aliskiren-based therapy <sep> aliskiren-based therapy <sep> direct renin inhibitor aliskiren <sep> aliskiren <sep> hydrochlorothiazide <sep> diuretics <sep> amlodipine <sep> aliskiren <sep> forced titration <sep> aliskiren 300 mg or hydrochlorothiazide <sep>', 'placebo <sep> irbesartan 150 mg or placebo <sep> novel oral renin inhibitor aliskiren with placebo <sep> aliskiren <sep> aliskiren <sep>', 'placebo <sep> aliskiren 75 150 or 300 mg or placebo <sep> aliskiren a direct renin inhibitor <sep> aliskiren <sep> aliskiren <sep>', 'valsartan monotherapy <sep> placebo <sep> aliskiren monotherapy <sep> aliskiren and valsartan <sep> valsartan <sep> oral direct renin inhibitor aliskiren alone or in combination with the angiotensin receptor blocker valsartan <sep> aliskiren and valsartan <sep> valsartan/hydrochlorothiazide <sep> aliskiren and valsartan in combination or valsartan/hydrochlorothiazide <sep> placebo aliskiren monotherapy <sep> aliskiren <sep> placebo aliskiren monotherapy <sep> aliskiren <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>']}",aliskiren has a dose-related blood pressure lowering effect better than placebo. this effect is similar to that determined for ace inhibitors and arbs.
182,"{'outcomes': ['preterm birth rates <sep> preterm birth rate <sep>'], 'punchline_text': ['there was no evidence to suggest that the secondary interventions provided added benefit over the primary intervention protocol of preterm birth prevention education and increased visits. <sep>'], 'population': ['eight west los angeles prenatal county clinics <sep> high-risk patients n  1774 in experimental clinics were offered a program of education and more frequent visits <sep> control clinic patients n  880 received <sep> high-risk women <sep>'], 'interventions': ['standard county care <sep> various secondary intervention protocols in addition to the basic interventions of education and more frequent visits <sep> preterm birth prevention education plus increased clinic visits and selected prophylactic interventions <sep>'], 'punchline_effect': [' no diff <sep>']}",there is no evidence either supporting or refuting the use of bed rest at home or in hospital to prevent preterm birth. although bed rest in hospital or at home is widely used as the first step of treatment there is no evidence that this practice could be beneficial. due to the potential adverse effects that bed rest could have on women and their families and the increased costs for the healthcare system clinicians should not routinely advise women to rest in bed to prevent preterm birth. potential benefits and harms should be discussed with women facing an increased risk of preterm birth. appropriate research is mandatory. future trials should evaluate both the effectiveness of bed rest and the effectiveness of the prescription of bed rest to prevent preterm birth. note the two citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
183,"{'outcomes': ['severe secretion <sep> effective and safe <sep> severe redness <sep> pain-relieving tablets <sep> css <sep> change of the css from visit 1 to the study termination and the changes in the subscores and of a visual analog scale for pain <sep> redness pain and secretion <sep> change of an aggregate clinical symptom score css subscores redness swelling pain and secretion <sep> efficacy and safety <sep>', 'clinical or microbiological and clinical cure <sep> cure <sep> rates of adverse events <sep> safety and efficacy <sep>', 'clinical response <sep> clinical cure rates <sep> signs and symptoms of aoe including ear inflammation tenderness edema and discharge <sep> efficacy and safety <sep> tolerated <sep> reduction in ear inflammation <sep> frequency of adverse events <sep> cure microbiologic eradication <sep> efficacy and safety <sep> microbiologic eradication rates <sep>', 'overall clinical-microbiological response <sep> eradication rates <sep> equivalent cure rates <sep> pain severity <sep> efficacy safety and ear-pain resolution <sep> overall clinical response <sep> efficacy safety and pain relief <sep> overall cure rates <sep>', 'inflammation score <sep> visual analogue scale and a six-step infection score <sep> efficacy and tolerability <sep> tolerability and efficacy <sep>', 'frequency and type of adverse events <sep> clinical symptom score <sep> clinical symptom score consisting of the subscores redness swelling pain and secretion and of the visual analogue scale vas rating for pain <sep> reduction of swelling <sep> swelling <sep> severe symptom score <sep> efficacy and safety <sep>', 'resolution of discharge <sep> swelling pain and redness <sep> tolerated <sep> resolution of discharge swelling pain and redness and the incidence of adverse side effects <sep> efficacy and tolerability <sep>', 'median time to end of pain <sep> low systemic exposure absence of ototoxicity <sep> time to end of pain symptom scores otalgia and tenderness and microbiological eradication <sep>', 'glacial acetic acid <sep> glacial acetic acid dexamethasone and neomycin sulphate <sep> infected mastoid cavities <sep>', 'pain parameters <sep>', 'success rates <sep> efficacy and tolerance <sep> audiometric measurements <sep>', 'ear pain <sep> relief of severe pain <sep> edema <sep> severe pain <sep> pain <sep> pain relief <sep> relief of pain <sep> inflammation <sep> relief of significant pain moderate or severe pain <sep>', 'recurrence of symptoms <sep> cure rate according to general practitioner completed questionnaires and recurrence of symptoms between days 21 and 42 <sep> duration of symptoms days according to patient diaries <sep> overall cure rates <sep>', 'staphylococcus aureus and pseudomonas pyocyanea <sep>'], 'punchline_text': ['in the steroid group there was a slightly larger though not significant reduction in css at visit 2 and visit 3 versus baseline. <sep>', 'there were no statistically significant differences in clinical or microbiological and clinical cure or in the rates of adverse events between treatment groups. <sep>', '7 days treatment with cip/dex otic suspension administered twice daily is clinically and microbiologically superior to n/p/h otic suspension administered 3 times daily in the treatment of mild to severe aoe and is equally well tolerated. <sep>', 'the overall clinical-microbiological response was cure in the microbiologically evaluable patients demonstrated by both clinical cure and microbiological eradication. <sep>', 'this difference became highly significant on days 4 to 7 p .01 each). <sep>', 'there was also a significantly greater decrease in the clinical symptom score from visit 1 to visit 2 in the pn+dx group in patients who had at least a moderately severe symptom score with more than seven points at visit 1 p  0.01 and in patients suffering from their current episode of otitis externa for more than 2 days p  0.02). <sep>', 'at visit 2 the patients in the glycerin group showed a significantly greater resolution of discharge. <sep>', 'response to therapy was higher for chc 95.71 vs 89.83 but was statistically noninferior lower confidence limit 4.98 to nph  amx. <sep>', 'patients on glacial acetic acid had only 38 12/32 resolution after 4 weeks p  0.0005). <sep>', 'although there was a statistically significant improvement of pain parameters in the tac group we found no significant differences in clinical findings between the two groups. <sep>', 'success rates in the com subgroup were 95 for ciprofloxacillin and 96 for gentamicin p  0.082 and in the deo subgroup 87 for ciprofloxacillin and 79 for gentamicin p  0.19). <sep>', 'higher percentages of cip/dex-treated patients had relief of severe pain over time p=.0013 and relief of significant pain moderate or severe pain over time p=.0456 compared with nph-treated patients. <sep>', 'ear drops containing corticosteroids are more effective than acetic acid ear drops in the treatment of acute otitis externa in primary care. <sep>', 's. aureus seemed to be most resistant to treatment while p. pyocyanea was less of a therapeutic problem. <sep>'], 'population': ['151 patients with a unilateral acute bacterial otitis externa <sep> acute otitis externa aoe <sep> acute otitis externa <sep>', '247 adults and 227 children were considered clinically evaluable ce and those for 98 children and 98 adults were microbiologically evaluable me <sep> twenty-three primary care and referral ambulatory care sites per trial <sep> 314 adults 12 years and older and 287 children younger than 12 years <sep> children and adults <sep> otitis externa in adults and children <sep>', 'patients of either sex and older than 1 year with a clinical diagnosis of mild moderate or severe aoe and intact tympanic membranes were recruited to participate <sep> otitis externa <sep> patients with acute otitis externa aoe <sep> patients enrolled numbered 468 <sep> pediatric and adult patients <sep>', '208 patients were clinically evaluable and those for 90 patients were microbiologically evaluable <sep> pediatric patients with otitis externa <sep> 34 centers in 278 pediatric oe patients aged 6 months to 12 years <sep> children with oe <sep>', 'acute otitis externa <sep> acute otitis externa <sep> fifty patients suffering from acute otitis externa <sep>', 'acute bacterial otitis externa <sep> patients with acute bacterial otitis externa aoe <sep> parallel group multi-center clinical trial in ear nose and throat ent specialist practices with a planned interim analysis for sample size adaptation <sep> 338 patients aged 18-76 who had a previous episode of otitis externa within the last year <sep>', 'acute external otitis <sep> 33 patients <sep>', 'adults and children <sep> otitis externa <sep> acute otitis externa aoe <sep> patients were  or 1 year of age had aoe 2 days with at least mild symptoms and gave informed consent <sep> 206 patients were enrolled chc 106 nph  amx 100 <sep>', 'otitis externa and infected mastoid cavities <sep> outpatients derby royal infirmary derby uk <sep> emergency and gp referrals with acute otitis externa n  53 and infected mastoid cavities n  56 <sep> patients with active otitis externa 71 15/21 resolved with <sep>', '64 patients were studied <sep> severe acute otitis externa <sep>', '47 patients with com and 54 patients with deo <sep> simple chronic otitis media com and diffuse external otitis deo <sep> simple chronic otitis media and diffuse external otitis <sep>', 'patients with acute otitis externa treated with <sep> patients with acute otitis externa <sep> otitis externa pain <sep>', 'acute otitis externa in primary care <sep> 213 adults with acute otitis externa <sep> 79 general practices netherlands <sep>', '55 patients with acute external otitis <sep> external otitis <sep>'], 'interventions': ['hydrocortisone acetate <sep> hydrocortisone acetate <sep> polymyxin-b sulfate 7,500 i.e./g  bacitracin 300 i.e./g alone ab or the same antibiotic ointment with 10 mg hydrocortisone acetate/g ointment ab  hc <sep> antibiotics ointment <sep> ab  hc <sep>', 'ofloxacin otic solution <sep> ofloxacin otic solution <sep> ofloxacin <sep> ofloxacin <sep> cortisporin <sep> cortisporin otic solutions neomycin sulfate polymyxin b sulfate and hydrocortisone <sep>', 'cip/dex <sep> ciprofloxacin 0.3%/dexamethasone 0.1 cip/dex otic suspension <sep> cip/dex 3-4 drops twice daily or n/p/h 3-4 drops three times daily <sep> topical ciprofloxacin/dexamethasone versus neomycin/polymyxin b/hydrocortisone <sep> neomycin 0.35%/polymyxin <sep> cip/dex otic suspension <sep> hydrocortisone 1.0 n/p/h otic suspension <sep>', 'ofloxacin otic solution versus neomycin sulfate/polymyxin b sulfate/hydrocortisone otic suspension <sep> ofloxacin otic solution <sep> polymyxin b sulfate/hydrocortisone otic suspension <sep> polymyxin b sulfate/hydrocortisone otic suspension cortisporin otic suspension <sep> ofloxacin <sep> otitis externa oe <sep> neomycin sulfate/polymyxin b sulfate/hydrocortisone <sep> ofloxacin otic solution 0.3 floxin otic solution <sep> ofloxacin otic solution 0.3 versus neomycin sulfate/polymyxin b sulfate/hydrocortisone otic suspension <sep> neomycin sulfate/polymyxin b sulfate/hydrocortisone otic suspension <sep>', 'antibiotic component drops otosporin containing neomycin polymyxin b and hydrocortisone <sep> endogenous antiseptic n-chlorotaurine nct <sep> n-chlorotaurine <sep> nct <sep> 1 ml of 1 aqueous nct solution the reference group with 1 ml of otosporin <sep>', 'dexamethasone <sep> polymyxin sulfate 7500 iu/neomycin sulfate 3500 iu/dexamethasone phosphate 0.1 pn+dx otic solution with polymyxin sulfate 7500 iu/neomycin sulfate 3500 iu pn-dx <sep> dexamethasone phosphate <sep> pn+dx or pn-dx <sep> dexamethasone phosphate to polymyxin b/neomycin <sep>', 'ciprofloxacin <sep> glycerin formulation of ototopical 0.3 ciprofloxacin <sep> ototopical ciprofloxacin <sep>', 'ciprofloxacin and hydrocortisone <sep> nph 4 drops adults or 2 drops children with amx <sep> topical ciprofloxacin and hydrocortisone chc cipro hc and topical neomycin/polymyxin b/hydrocortisone nph cortisporin with systemic amoxicillin amx amoxil <sep>', 'glacial acetic acid <sep> neomycin sulphate otomize stafford-miller ltd <sep> dexamethasone <sep> glacial acetic acid dexamethasone and neomycin sulphate <sep> glacial acetic acid dexamethasone and of neomycin sulphate <sep> antibiotic/steroid combination <sep> glacial acetic acid versus glacial acetic acid neomycin sulphate and dexamethasone spray <sep> antibacterial antibiotic and steroid agents <sep> glacial acetic acid dexamethasone and neomycin sulphate <sep>', 'glycerine-ichthammol <sep> glycerine-ichthammol gi solution and triadcortyl <sep>', 'topical ciprofloxacillin <sep> topical ciprofloxacin vs topical gentamicin <sep> topical gentamicin <sep> gentamicin <sep>', 'ciprofloxacin/dexamethasone with neomycin/polymyxin/hydrocortisone <sep> ciprofloxacin 0.3%/dexamethasone 0.1 cip/dex and neomycin 0.35%(polymyxin b 10,000 iu/ml/hydrocortisone 1.0 nph <sep> nph <sep> cip/dex <sep>', 'ear drops containing acetic acid corticosteroid and acetic acid and steroid and antibiotic <sep> steroid and acetic acid or steroid and antibiotic ear drops <sep> acetic acid ear drops <sep> acetic acid <sep>', 'topical framycitin/gramicidin sofradex or oxytetracycline/hydrocortisone terracortril with polymyxin b tpb ear-drops <sep> topical preparations framycitin/gramicidin and oxytetracycline/hydrocortisone with polymyxin b <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",there is a paucity of high quality trials evaluating interventions for acute otitis externa. the results of this systematic review are largely based on odds ratios calculated from single trials most of which have very broad 95 confidence intervals because of small to modest sample sizes. the findings may not be wholly generalisable to primary care for a variety of reasons only two of the 19 trials included in the review were conducted in a primary care population setting and in 11 of the 19 trials ear cleaning formed part of the treatment an intervention unlikely to be available in primary care). despite these reservations some meaningful conclusions can be drawn from the evidence available topical treatments alone as distinct from systemic ones are effective for uncomplicated acute otitis externa. in most cases the choice of topical intervention does not appear to influence the therapeutic outcome significantly. any observed differences in efficacy were usually minor and not consistently present at each follow-up visit. acetic acid was effective and comparable to antibiotic/steroid at week 1. however when treatment needed to be extended beyond this point it was less effective. in addition patient symptoms lasted two days longer in the acetic acid group compared to antibiotic/steroid. the evidence for steroid-only drops is very limited and as yet not robust enough to allow us to reach a conclusion or provide recommendations. further investigation is needed. given that most topical treatments are equally effective it would appear that in most cases the preferred choice of topical treatment may be determined by other factors such as risk of ototoxicity risk of contact sensitivity risk of developing resistance availability cost and dosing schedule. factors such as speed of healing and pain relief are yet to be determined for many topical treatments and may also influence this decision. patients prescribed antibiotic/steroid drops can expect their symptoms to last for approximately six days after treatment has begun. although patients are usually treated with topical medication for seven to 10 days it is apparent that this will undertreat some patients and overtreat others. it may be more useful when prescribing ear drops to instruct patients to use them for at least a week. if they have symptoms beyond the first week they should continue the drops until their symptoms resolve and possibly for a few days after for a maximum of a further seven days. patients with persisting symptoms beyond two weeks should be considered treatment failures and alternative management initiated.
184,"{'outcomes': ['tolerated and the rate of drop-outs <sep> number of tender joints <sep> disease activity according to composite symptoms paulus index of arthritis <sep> disease activity <sep>', 'ritchie score <sep> weight <sep> grip strength <sep> esr crp thermographic joint score or functional score <sep>', 'food intolerance reduced gastrointestinal permeability <sep>', ""pain intensity morning stiffness haq-score number of swollen joints joint tenderness erythrocyte sedimentation rate and patient's global assessment of health <sep> average level of pain <sep> haq-score <sep> body mass index <sep> clear remission <sep>"", 'objective signs of improvement <sep> controls concerning symptoms drug consumption or clinical and biochemical variables <sep> pain stiffness medication and clinical and biochemical findings <sep> reduced pain stiffness consumption of analgetics several clinical variables and serum concentration of orosomucoid <sep>', 'assessments of duration of early morning stiffness ems pain on a 10 cm visual analog scale vas the ritchie articular index rai swollen joint score the stanford health assessment questionnaire global patient and physician assessment body weight erythrocyte sedimentation rate esr c-reactive protein crp and haemoglobin <sep> vas and rai <sep> esr crp and haemoglobin <sep> swollen joint score <sep>', 'immunoglobulin g igg antibody levels against gliadin and beta-lactoglobulin <sep> radiological destruction <sep> furthermore levels of antibodies against gliadin and beta-lactoglobulin <sep>', 'rheumatologic laboratory immunologic radiologic or nutritional findings <sep>', 'physical function and improved vitality <sep> a composite disease activity index das28 a physical function index health assessment questionnaire haq a health survey of quality of life short form-36 sf-36 and the daily consumption of non-steroidal anti-inflammatory drugs <sep> inflammatory activity <sep> das28 <sep> vitality <sep>', 'thrombocyte count <sep> disease activity variables <sep> erythrocyte sedimentation rate esr <sep> number of tender joints <sep>'], 'punchline_text': [""percentage of patients with global 20 or 50 response didn't differ between experimental and control group after the 24-week of diet treatment. <sep>"", 'after the elemental diet there was a statistically significant improvement in the diet group in grip strength p  0.008 and ritchie score p  0.006 but not in esr crp thermographic joint score or functional score. <sep>', 'in a blind placebo-controlled study of dietary manipulation therapy in outpatients with rheumatoid arthritis there was significant objective improvement during periods of dietary therapy compared with periods of placebo treatment particularly among good responders"". <sep>', 'the diet resulted in a transient but statistically significant improvement in the average level of pain p  0.02 in haq-score p=0.03 and a significant reduction in body mass index p=0.001). <sep>', 'the fasting patients showed reduced pain stiffness consumption of analgetics several clinical variables and serum concentration of orosomucoid. <sep>', 'all clinical parameters improved in both groups p<0.05 except the swollen joint score in the elemental diet group. <sep>', 'the immunoglobulin g igg antibody levels against gliadin and beta-lactoglobulin decreased in the responder subgroup in the vegan diet-treated patients but not in the other analysed groups. <sep>', 'improvement averaged 29 for patients on placebo and 32 for patients on experimental diets. <sep>', 'a composite disease activity index das28 a physical function index health assessment questionnaire haq a health survey of quality of life short form-36 sf-36 and the daily consumption of non-steroidal anti-inflammatory drugs were used as primary efficacy variables. <sep>', 'a significant improvement was found in the number of tender joints p  0.04 in the experimental group whereas improvement was found in the erythrocyte sedimentation rate esr p  0.03 and in the thrombocyte count p  0.02 in the control group. <sep>'], 'population': ['fifty ra patients <sep> patients with rheumatoid arthritis ra <sep> rheumatoid arthritis <sep>', 'rheumatoid arthritis ra <sep> rheumatoid arthritis <sep>', 'outpatients with rheumatoid arthritis <sep> rheumatoid arthritis <sep>', 'rheumatoid arthritis with a peptide diet <sep> patients with active ra <sep> thirty patients were included and followed for six months <sep>', '16 patients with classical rheumatoid arthritis ra <sep> rheumatoid arthritis <sep>', 'patients with active rheumatoid arthritis <sep> thirty patients with active rheumatoid arthritis <sep>', 'sixty-six patients with active ra <sep>', 'patients with active rheumatoid arthritis ra <sep> patients with longstanding progressive active ra <sep> twenty-six patients completed the study 11 were on an <sep> rheumatoid arthritis <sep> selected patients with rheumatic disease <sep>', 'patients with rheumatoid arthritis <sep> patients with rheumatoid arthritis ra <sep> patients with well controlled although active ra of at least two years duration who were receiving stable pharmacological treatment were invited to participate <sep>', 'unselected ra patients <sep> rheumatoid arthritis <sep>'], 'interventions': ['diet therapy <sep> dietary regimens an experimental diet high in unsaturated fats low in saturated fats with hypoallergenic foods vs. a control well-balanced diet <sep> diet therapy <sep>', 'elemental diet and subsequent food reintroduction <sep> elemental diet e028 and a small number of foods <sep>', 'placebo <sep> dietary manipulation therapy <sep> placebo <sep>', 'artificial peptide diet <sep> liquid elemental peptide-diet <sep>', 'fasting and lactovegetarian diet <sep> lactovegetarian diet <sep>', 'oral prednisolone <sep> elemental diet <sep> elemental diet with oral prednisolone <sep> prednisolone <sep>', 'vegan diet free of gluten 38 patients or a well-balanced non-vegan diet <sep>', 'diet therapy <sep> experimental diet a specific popular diet free of additives preservatives fruit red meat herbs and dairy products and 15 were on a placebo diet <sep> placebo <sep>', 'ordinary western diet <sep> mediterranean diet md <sep> mediterranean diet intervention <sep> md or the control diet cd <sep>', 'control soup consisting of milk meat fish shellfish orange pineapples tomatoes peas and flour of wheat and corn <sep> elemental diet <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",the effects of dietary manipulation including vegetarian mediterranean elemental and elimination diets on rheumatoid arthritis are still uncertain due to the included studies being small single trials with moderate to high risk of bias. higher drop-out rates and weight loss in the groups with dietary manipulation indicate that potential adverse effects should not be ignored.
185,"{'outcomes': ['sustained maximal voluntary isometric contraction <sep> recovery of isometric grip strength <sep> grip strength <sep> isometric grip strength <sep> grip strength <sep> pain <sep>', 'complication rate <sep> distal radial fractures <sep>', 'angulation of the distal radius <sep> function <sep>', 'colles type distal radial fracture <sep> radiological signs of post-traumatic arthritis <sep> excellent or good outcome and patient satisfaction <sep> overall function range of movement and activities of daily living <sep> radial shortening <sep>', 'transient sensory disturbance <sep> noncomplicated pin-tract infection <sep>', 'radiographic evaluation and range of motion <sep> upper extremity mfa scores jebsen taylor scores sf-36 bodily pain scores and grip strength <sep> upper extremity function <sep> better length and palmar tilt restoration <sep> global function and pain <sep> upper extremity mfa domain scores overall jebsen taylor scores and pinch and grip strength tests <sep> mean jebsen taylor scores and sf 36 bodily pain scores <sep>', 'roentgenographic loss of position during fracture union <sep>'], 'punchline_text': ['a significant difference was registered between women with plaster casts and women with external fixators six weeks after the fracture. <sep>', 'this randomized prospective study demonstrated no advantage in using an external fixator to immobilize reduced distal radial fractures over closed reduction and plaster cast immobilization in patients less than 60 years of age. <sep>', 'functional results at six weeks three and six months and at one year however showed no difference between any of the four groups. <sep>', 'the fixator group had significantly less radial shortening p<0.05). <sep>', ""after 1 year the patients allocated to primary external fixation had a better radiographic and functional end result according to lidstrm's grading 19/22 were excellent or good after external fixation as compared with 12/19 after plaster-cast treatment. <sep>"", 'by 2 years mean jebsen taylor scores and sf 36 bodily pain scores for patients in both groups were similar to scores for normal age and gender-matched population controls. <sep>', 'the external fixator was more effective at holding the manipulated position and the roentgenographic loss of position during fracture union was minimal compared with that seen in patients treated in plaster. <sep>'], 'population': ['colles fracture <sep> 28 females and 5 males with displaced colles fracture involving the distal radio-ulnar joint <sep>', 'patients less than 60 years of age <sep> distal radial fractures <sep>', '120 patients with redisplaced fractures of the distal radius comparing four methods of treatment <sep> redisplaced unstable fractures of the distal radius <sep>', 'eighty-five patients were reviewed 7 years after prospective randomization to <sep> for treatment of a colles type distal radial fracture <sep>', '47 severely displaced colles fractures 23 had external fixation and 24 had a dorsal plaster cast <sep> severely displaced colles fractures <sep> 46 patients <sep>', 'multicenter study at 3 university teaching hospitals <sep> 113 skeletally mature patients with distal radius fractures with metaphyseal displacement but without joint incongruity <sep>', '70 patients between the ages of 20 and 45 years with comminuted intra-articular fractures of the distal radius of types iii to viii graded according to frykman <sep> patients under 45 years of age <sep> patients less than 45 years of age <sep>'], 'interventions': ['immobilization with plaster cast or with external fixation <sep>', 'plaster cast immobilization <sep> external fixation and plaster cast immobilization <sep>', 'remanipulation and plaster open reduction and bone grafting and closed external fixation with and without mobilisation of the wrist at three weeks <sep>', 'bridging external fixation or plaster immobilization <sep>', 'external fixation or plaster cast <sep> primary external fixation <sep> external-fixation <sep>', 'metaphyseal displacement but without joint incongruity closed reduction and casting versus closed reduction spanning external fixation and optional percutaneous k-wires <sep> closed reduction and casting with closed reduction and external fixation with optional k-wire fixation <sep> closed reduction and casting n  59 or closed reduction and external fixation <sep>', 'plaster cast versus clyburn external fixation <sep> closed reduction and forearm plaster 35 patients or by application of a clyburn dynamic external fixator <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is some evidence to support the use of external fixation for dorsally displaced fractures of the distal radius in adults. though there is insufficient evidence to confirm a better functional outcome external fixation reduces redisplacement gives improved anatomical results and most of the excess surgically-related complications are minor.
186,"{'outcomes': ['adverse reactions <sep>'], 'punchline_text': ['over a battery of cognitive tests indomethacin patients improved 1.3  <sep>'], 'population': [""alzheimer's disease <sep>""], 'interventions': ['placebo <sep> indomethacin <sep>'], 'punchline_effect': [' sig increase <sep>']}",on the basis of this one trial and subsequent analysis of data as reported by the authors indomethacin cannot be recommended for the treatment of mild to moderate severity alzheimer's disease. at doses of 100-150 mg daily serious side effects will limit its use.
187,"{'outcomes': ['exercise tolerance <sep> exercise endurance of the forearm muscles <sep>', 'exercise tolerance <sep> peak oxygen consumption or level of leg fatigue <sep>', 'intensity of exercise-induced pain in working muscles <sep> limitation of daily activities <sep> electromyographic amplitude <sep> work capacity <sep> body mass index <sep> serum creatine and serum creatine kinase levels phosphorus 31 magnetic resonance spectroscopy and surface electromyograms <sep> neurologic adverse effects <sep> phosphorus 31 magnetic resonance spectroscopy variables <sep>', 'depletion of phosphocreatine <sep> muscle complaints with creatine <sep> phosphocreatine depletion <sep> skeletal muscle function <sep> median frequency in surface electromyograms during contraction <sep>', 'tolerance to everyday activities <sep> calorific intake <sep> heart rate and perceived exertion <sep> maximal oxidative work capacity <sep>', 'bcaa meal tripled plasma bcaa levels increased bcaa catabolism <sep> exercise capacity <sep> mean peak free fatty acid levels and reduced exercise capacity <sep> plasma glutamine and alanine <sep>', 'heart rate level of perceived exertion and venous blood glucose levels <sep> mean plasma glucose level <sep> exercise tolerance <sep> level of perceived exertion fell <sep> mean se heart rate <sep>', 'exercise tolerance <sep> exercise capacity <sep> monitoring heart rate and perceived exertion during exercise <sep>'], 'punchline_text': ['although an improved exercise endurance of the forearm muscles was demonstrated with both short-acting and depot-glucagon this was not statistically significant when compared with placebo or no treatment. <sep>', 'there was no significant difference between pre-treatment exercise tests for peak oxygen consumption or level of leg fatigue. <sep>', 'there were no significant changes in phosphorus 31 magnetic resonance spectroscopy variables. <sep>', 'force-time integrals p .03 and depletion of phosphocreatine p .04 increased significantly during ischemic exercise with creatine. <sep>', 'during the constant workload heart rate and perceived exertion were consistently lower p<0.0005 on the carbohydrate versus protein-rich diet. <sep>', 'the bcaa meal tripled plasma bcaa levels increased bcaa catabolism as indicated by greater exercise increases in plasma glutamine and alanine but lowered mean peak free fatty acid levels and reduced exercise capacity in five of six patients. <sep>', 'supplemental sucrose increased the mean plasma glucose level by more than 36 mg per deciliter 2.0 mmol per liter and resulted in a marked improvement in exercise tolerance in all patients. <sep>', 'both sucrose treatments dramatically improved exercise tolerance compared with the placebo. <sep>'], 'population': [""mcardle's disease <sep> patient with myophosphorylase deficiency <sep> patients with myophosphorylase deficiency mcardle's disease <sep>"", ""patients with mcardle's disease <sep> mcardle's disease <sep> a group of 5 patients with mcardle's disease <sep>"", 'nineteen patients with mcardle disease <sep> patients with mcardle disease <sep> mcardle disease <sep>', 'nine patients with biochemically and genetically proven mcardle disease were treated <sep> myophosphorylase deficiency mcardle disease <sep> mcardle disease <sep>', 'seven patients with mcardle disease <sep> healthy subjects <sep> patients with mcardle disease <sep> mcardle disease <sep>', ""six fasting patients with mcardle's disease <sep>"", ""patients with mcardle's disease <sep> massachusetts medical society <sep> 12 patients with mcardle's disease drank 660 ml of a beverage that had been sweetened with artificial sweeteners placebo or with 75 g of sucrose after an overnight fast <sep>"", 'six patients with biochemically and genetically diagnosed mcardle disease <sep> patients with mcardle disease <sep> mcardle disease <sep>'], 'interventions': ['glucagon <sep> depot-glucagon <sep> glucagon <sep> placebo <sep>', 'placebo <sep>', 'placebo <sep> high-dose cr therapy <sep> cr or placebo <sep> high-dose creatine therapy <sep> low-dose creatine cr <sep>', 'placebo <sep> creatine or placebo <sep> oral creatine monohydrate supplementation <sep> creatine supplementation <sep> creatine therapy <sep> creatine <sep>', 'carbohydrate and protein-rich diets <sep> protein-rich diet <sep> carbohydrate or protein-rich diet <sep>', 'control noncaloric beverage 30 minutes before exercise <sep> oral branched-chain amino acids <sep> oral branched-chain amino acids bcaas <sep> bcaa <sep>', 'placebo <sep> supplemental sucrose <sep> oral sucrose <sep>', 'placebo <sep> placebo <sep> placebo 40 minutes before exercise or 37 g of sucrose or a placebo <sep> oral sucrose <sep> oral sucrose <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",although there was low quality evidence of improvement in some parameters with creatine oral sucrose ramipril and a carbohydrate rich diet none was sufficiently strong to indicate significant clinical benefit.
188,"{'outcomes': ['length of hospital stay <sep> longer duration of oxygen therapy <sep> adverse events <sep> ass <sep> length of stay in hospital <sep> asthma severity score ass <sep>', 'oxygen tension <sep> blood gas pressures <sep> mean proportionate increase in fev <sep> pulse rate of 8 beats per minute and 2 beats per minute <sep>', 'relative tachycardia <sep> rate of recovery <sep>', 'peak expiratory flow rates <sep> synergistic bronchodilator effect <sep>', 'nausea <sep> clinical asthma score over time length of pediatric intensive care unit stay or incidence of adverse events <sep> clinical asthma score over time length of pediatric intensive care unit stay and incidence of adverse events <sep> median hospital cost of medication and theophylline blood levels <sep>'], 'punchline_text': ['a similar improvement in ass to 2 hours was seen in the two groups mean difference 0.08 95 ci 0.97 to 0.80 there was a trend p=0.07 towards a longer duration of oxygen therapy in the salbutamol group 17.8 hours 95 ci 8.5 to 37.5 v 7.0 hours 95 ci 3.4 to 14.2 and a significantly p=0.02 longer length of hospital stay in the salbutamol group 85.4 95 ci 66.1 to 110.2 hours v 57.3 hours 95 ci 45.6 to 72.0)). <sep>', 'differences in results did not reach conventional levels of significance and no serious side effects were noted. <sep>', 'hydrocortisone was given after 2 hours but did not appear to affect the rate of recovery. <sep>', 'peak expiratory flow rates showed a significant improvement after 15 minutes treatment with aminophylline and the combined infusion but this was not seen until 60 minutes with the salbutamol infusion. <sep>', 'the median hospital cost of medication and theophylline blood levels was significantly lower in group 1 compared with groups 2 and 3 280 us dollars vs. 3,908 us dollars vs. 4,045 us dollars respectively p  .0001). <sep>'], 'population': ['children with severe asthma <sep> severe acute childhood asthma <sep> forty four subjects were enrolled with 18 randomly allocated to receive <sep> children aged 1-16 years with acute severe asthma <sep>', 'acute asthma <sep> 23 patients with acute exacerbations of asthma <sep>', 'severe acute asthma in childhood <sep>', 'twenty-one patients admitted to hospital with acute severe asthma <sep> acute severe asthma <sep>', ""forty critically ill children between the ages of 3 and 15 yrs with impending respiratory failure secondary to status asthmaticus <sep> critically ill children with status asthmaticus who are already receiving continuous nebulized albuterol and intravenous corticosteroids <sep> critically ill asthmatic children <sep> critically ill children with status asthmaticus <sep> pediatric intensive care unit of a tertiary-care children's medical center <sep>""], 'interventions': ['aminophylline infusion <sep> salbutamol and ipratropium <sep> saline infusion or an aminophylline infusion <sep> intravenous salbutamol <sep> aminophylline and salbutamol <sep> aminophylline <sep> salbutamol <sep>', 'salbutamol <sep> salbutamol and aminophylline <sep> salbutamol 100mug <sep> aminophylline <sep> salbutamol <sep>', 'aminophylline with salbutamol <sep> hydrocortisone <sep> salbutamol <sep> iv salbutamol with iv aminophylline <sep>', 'aminophylline <sep> aminophylline or salbutamol <sep> intravenous hydrocortisone <sep> aminophylline salbutamol <sep> salbutamol <sep> aminophylline <sep> potassium chloride 4 g in 2 litres of 5 dextrose infused over 24 hours amd 35 oxygen given via a ventimask <sep> salbutamol <sep>', 'theophylline <sep> theophylline terbutaline or theophylline combined with terbutaline treatment <sep> methylprednisolone and continuous nebulized albuterol <sep> terbutaline <sep> terbutaline plus placebo <sep> theophylline and terbutaline <sep> theophylline plus placebo <sep> theophylline <sep> theophylline versus terbutaline <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",in the included rcts there was no consistent evidence favouring either iv beta2-agonists or iv aminophylline for patients with acute asthma. the opportunity to draw clear conclusions is limited by the heterogeneity of outcomes evaluated and the small sample sizes in the included studies. it is recommended that these data should be viewed carefully alongside the conclusions from separate cochrane reviews comparing iv beta2-agonists plus inhaled beta2-agonists versus inhaled beta2-agonists alone and iv aminophylline plus inhaled beta2-agonists versus inhaled beta2-agonists alone.
189,"{'outcomes': ['serum total cholesterol concentration blood pressure distance walked in 6 minutes confirmed smoking cessation and body mass index <sep> body mass index <sep> lipid concentrations serum total cholesterol <sep> health outcome <sep> blood pressure diastolic pressure <sep>', 'consultation rates process of care measures <sep>', 'low density lipoprotein cholesterol <sep> low density lipoprotein cholesterol <sep> concentration of low density lipoprotein cholesterol <sep>', 'cotinine levels <sep> total cholesterol <sep> mean blood pressure <sep> risk factors blood pressure cholesterol and smoking status prescribing of hypotensive agents lipid lowering drugs and antiplatelet drugs blood pressure serum cholesterol level and plasma cotinine levels <sep>', 'dietary habits <sep> smoking habit systolic or diastolic blood pressure cholesterol concentration or body mass index <sep> taking daily physical exercise <sep> restriction of everyday activities dietary habit smoking habit frequency of physical exercise blood pressure body mass index and serum total cholesterol concentration <sep>', 'limits systolic blood pressure <sep> systolic blood pressure <sep> total cholesterol concentration <sep> number of patients admitted to hospital <sep> blood pressure and total cholesterol concentration <sep> diastolic blood pressure <sep>', 'satisfaction score <sep> total national health service cost <sep> quality of life sf-36 <sep> appropriate treatment derived from the national service framework nsf health status sf-36 eq-5d and an economic evaluation <sep> numbers on aspirin or lifestyle measures <sep> patient risk of cardiovascular death and satisfaction <sep>', 'non-fatal cardiovascular event <sep> quality of life <sep> event rates and all-cause mortality <sep> blood pressure and high-density lipoprotein cholesterol <sep>'], 'punchline_text': ['there was no significant difference between the intervention and control groups in smoking cotinine validated quit rate 19 v 20 lipid concentrations serum total cholesterol 5.80 v 5.93 mmol/l blood pressure diastolic pressure 84 v 85 mm hg or fitness distance walked in 6 minutes 443 v 433 m). <sep>', 'the computerised decision support system had no significant effect on consultation rates process of care measures including prescribing or any patient reported outcomes for either condition. <sep>', 'low density lipoprotein cholesterol was reduced by 0.5 mmol/l 95 confidence interval 0.2 to 0.8 mmol/l 9.3 2.9 to 15.8 from baseline in patients in the intervention group and by 0.5 0.1 to 0.9 mmol/l compared with controls p<0.05). <sep>', 'setting up a register and recall system improved patient assessment at 18 months follow up but was not consistently better than audit alone in improving treatment or risk factor levels. <sep>', 'the intervention group also reported eating a healthier diet than the control group and less restriction by angina in any everyday activity. <sep>', 'at the 18 month follow-up there were no significant differences between intervention and control groups in the numbers proportions of patients above the recommended limits systolic blood pressure intervention 98/360 27.2 v control 133/405 32.8 odds ratio 1.51 95 confidence interval 0.99 to 2.30 p=0.06 diastolic blood pressure intervention 32/360 8.9 v control 40/405 9.9 1.40 0.75 to 2.64 p=0.29 and total cholesterol concentration intervention 52/342 15.2 v control 64/391 16.4 1.13 0.63 to 2.03 p=0.65). <sep>', 'there were few differences in quality of life sf-36 between the intervention and control groups at baseline or follow-up or with overall eq-5d score over time. <sep>', 'blood pressure and high-density lipoprotein cholesterol were more frequently within recommended levels in the intervention group than in controls odds ratio 1.63 95 confidence interval 1.05-2.51 and odds ratio 2.61 95 confidence interval 1.32-5.18 respectively. <sep>'], 'population': ['patients with myocardial infarction and angina <sep> 597 adult patients 422 with myocardial infarction and 175 with a new diagnosis of angina who were recruited during hospital admission or attendance at a chest pain clinic between april 1995 and september 1996 <sep> all 67 practices in southampton and south west hampshire england <sep> 559 surviving patients at 1 year 502 90 were followed up <sep>', 'setting 60 general practices in north east england <sep> asthma and angina in adults in primary care <sep> general practitioners and practice nurses in the study practices and their patients aged 18 or over with angina or asthma <sep>', '255 consecutive patients with coronary artery disease <sep> patients with coronary artery disease <sep> primary care patients with coronary artery disease <sep> general practitioners <sep> guidelines were mailed to all general practitioners n=54 and presented at a common lecture <sep>', 'patients with coronary heart disease <sep> coronary heart disease in primary care <sep> 1906 patients aged 55-75 years with established coronary heart disease <sep>', '18 general practices in the greater belfast area <sep> patients at high cardiovascular risk <sep> 688 patients aged less than 75 years and known to have had angina for at least six months 342 randomised to receive education and 346 to no education <sep> patients with angina <sep>', 'general practices in northern ireland and the republic of ireland regions with different healthcare systems <sep> patients with coronary heart disease <sep> heart disease in general practice <sep> 903 patients with established coronary heart disease registered with one of 48 practices <sep>', '1493 patients 980 intervention and 513 control 62 pharmacists and 164 gps <sep> patients with coronary heart disease <sep> patients with coronary heart disease <sep> nine sites in england <sep>', '983 patients aged 30-79 were included <sep> coronary patients in primary care <sep> patients with stable coronary disease <sep>'], 'interventions': ['southampton heart integrated care project ship <sep>', 'computerised evidence based guidelines <sep>', 'case method learning <sep> intervention group participated in recurrent case method learning dialogues <sep>', 'summary feedback to primary health care team audit group assistance with setting up a disease register and systematic recall of patients to general practitioner gp recall group assistance with setting up a disease register and systematic recall of patients to a nurse led clinic nurse recall group <sep>', 'personal health education <sep> eating a healthier diet than the control group and less restriction by angina in any everyday activity <sep> health promotion <sep>', 'tailored practice and patient care plans <sep>', 'intervention or control <sep> initial consultation with a community pharmacist to review appropriateness of therapy compliance lifestyle social and support issues <sep> community pharmacy-led medicines management <sep> standard care <sep>', 'periodic postal reminders <sep> intensive prevention program <sep> usual care <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is weak evidence that regular planned recall of patients for appointments structured monitoring of risk factors and prescribing and education for patients can be effective in increasing the proportions of patients within target levels for cholesterol control and blood pressure. further research in this area would benefit from greater standardisation of the outcomes measured.
190,"{'outcomes': ['reduction of depression scores <sep> brms scores <sep> severity of depression assessed with the bech-rafaelsen melancholy scale brms and the center for epidemiologic studies depression scale ces-d <sep>', 'lower ham-d scores <sep> major depressive disorder mdd and a ham-d score <sep> hamilton depression rating scale ham-d <sep> remission rates <sep>', 'symptoms of depression <sep> hamilton rating scale for depression hrsd <sep> inventory of depressive symptoms clinician and self-report hrsd scores at 24 weeks cardiorespiratory fitness self-efficacy and quality of life <sep>', 'depression according to hrsd <sep> depressive symptoms <sep> geriatric depression scale clinical global impression and patient global impression <sep> 17-item hamilton rating scale for depression hrsd <sep>', 'oxygen consumption <sep> mood nor metabolic parameters <sep> weight loss <sep> mood and energy regulation in seasonal and non-seasonal depression <sep> mood body weight and oxygen consumption <sep>', 'depressive symptoms <sep> somatic symptoms of the bdi <sep> psychological subscale of the beck depression inventory bdi <sep>', 'measures of both emotional clinician and self-report and physical observed and self-report functioning <sep> sf-36 mental health scores and clinician-rated depression scores <sep> physical functioning <sep>', 'mean change in ham-d(17 score <sep> cognitive abilities <sep> percentage of days absent from work during the last 10 working days <sep> strength measured by 1 repetition maximum for chest press <sep> 17-item hamilton rating scale for depression ham-d(17 <sep> ham-d(17 score <sep> maximal oxygen uptake <sep>', 'trait anxiety and a standard psychiatric interview <sep> psychiatric scores <sep>', 'health and wellbeing <sep> muscle strength <sep> strength <sep> depressive status physical and mental health and quality of life <sep> depressive symptoms <sep> lower depression scores <sep>', ""depression measured by the cornell scale for depression in dementia mood measured by the dementia mood assessment scale and the alzheimer's mood scale and affect measured by the observed affect scale <sep> depression <sep>"", 'ham-d gaf and cgi score <sep> gaf and cgi scores <sep>', 'depressive state <sep> depressive state hormonal response to stress and physiological fitness <sep> ces-d rating scale urinary cortisol and epinephrine levels and cardiorespiratory factors at rest and during exercise endurance test <sep> resting heart rate <sep> ces-d total depressive score <sep> depression neuroendocrine stress hormones and physiological fitness <sep> peak oxygen uptake and lung capacity <sep>', 'aerobic capacity <sep> aerobic capacity <sep> depression <sep>', 'ham-d or bdi scores <sep> fastest initial response <sep> depressive symptoms <sep> severe depressive symptoms <sep> ham-d and bdi scores <sep> presence and severity of mdd using diagnostic and statistical manual of mental disorders fourth edition criteria and hamilton rating scale for depression ham-d and beck depression inventory bdi scores <sep> aerobic capacity life satisfaction self-esteem anxiety and dysfunctional cognitions <sep>', 'social functioning <sep> role emotional <sep> depression scores <sep> hamilton rating scale of depression <sep> adverse events <sep> strength morale and quality of life <sep> vitality <sep> strength <sep> physiologic capacity quality of life morale function and self-efficacy without adverse events <sep> median compliance <sep> depression measures beck depression inventory <sep> quality of life subscales of bodily pain <sep>'], 'punchline_text': ['after 10 days reduction of depression scores in the exercise group was significantly larger than in the placebo group brms 36 v 18 ces-d 41 v 21 p for both  0.01 the proportion of patients with a clinical response reduction in the brms scores by more than six points was also larger for the exercise group 65 v 22 p<0.01). <sep>', 'all treatment groups had lower ham-d scores after treatment scores for the active treatment groups were not significantly different from the placebo group p  .23). <sep>', 'secondary outcome measures were the inventory of depressive symptoms clinician and self-report hrsd scores at 24 weeks cardiorespiratory fitness self-efficacy and quality of life. <sep>', 'at 10 weeks a significantly higher proportion of the exercise group 55 v. 33 experienced a greater than 30 decline in depression according to hrsd or=2.51 p=0.05 95 ci 1.00-6.38). <sep>', 'winter depression responded equally well to exercising and light while a significant therapeutic difference in favor of exercising was found in non-seasonal depression. <sep>', 'exercise and social contact both resulted in significant reductions in both the total and the psychological subscale of the beck depression inventory bdi). <sep>', 'there were trends for the superiority of the exercise and sertraline conditions over usual care in improving sf-36 mental health scores and clinician-rated depression scores. <sep>', 'at 4 months the mean change in ham-d(17 score was 1.3 <sep>', 'in the first trial an aerobic exercise group had a superior outcome compared with a control group in terms of trait anxiety and a standard psychiatric interview. <sep>', 'there were modest improvements in health and wellbeing over time but many scores were lower than reported in non-depressed people. <sep>', 'exercise as a behavioural approach to treatment of depression in nursing home residents with severe ad evidenced a clear benefit to participants in this study. <sep>', 'in the control group ham-d gaf and cgi scores do not show any statistically significant differences between t0 and t8. <sep>', 'after the sessions of exercise the ces-d total depressive score showed a significant decrease whereas no effect was observed after the period of usual daily activities anova). <sep>', 'the results indicated that subjects in the aerobic exercise condition evidenced reliably greater improvements in aerobic capacity than did the subjects in either of the other conditions p less than .002 in both cases and that the subjects in the aerobic exercise condition evidenced reliably greater decreases in depression than did subjects in the placebo condition p  .05 or subjects in the no-treatment condition p  .001). <sep>', 'after 16 weeks of treatment the groups did not differ statistically on ham-d or bdi scores p  .67 adjustment for baseline levels of depression yielded an essentially identical result. <sep>', 'quality of life subscales of bodily pain p  .001 vitality p  .002 social functioning p  .008 and role emotional p  .02 were all significantly improved by exercise compared to controls. <sep>'], 'population': ['38 inpatients with a major depression episode undergoing standard clinical antidepressant drug treatment <sep> patients with major depression <sep>', 'major depressive disorder <sep> between october 2000 and november 2005 <sep> patients with mdd <sep> 202 adults 153 women 49 men diagnosed with major depression <sep>', 'eighty men and women who were diagnosed with a structured clinical interview for depression and who had mild hrsd 12-16 to moderate hrsd 17-25 mdd <sep> participants diagnosed with mdd <sep> mild to moderate major depressive disorder mdd in adults ages 20 to 45 years <sep>', 'older people with poorly responsive depressive disorder <sep> older people <sep> older adults with poorly responsive depressive disorder <sep>', 'age-matched groups of female subjects with winter depression non-seasonal depression or without depression <sep>', 'thirty community-dwelling moderately depressed elderly <sep> moderately depressed elderly <sep>', 'or usual care 32 participants completed the 16-week study <sep> older adults with minor depression <sep> older adults <sep> participants were 37 older adults with minor depression who were randomized to <sep>', 'patients with unipolar depression conducted from january 2005 through july 2007 <sep> patients with mild to moderate depression <sep> adults with clinical depression <sep> patients were referred from general practitioners or psychiatrists and were eligible if they fulfilled the international classification of diseases tenth revision criteria for unipolar depression and were aged between 18 and 55 years <sep> patients n  165 <sep>', 'depression <sep>', 'eligible people n  45 <sep> depressed chronic stroke survivors <sep> participants median age was 69 years 27 were male <sep> chronic post stroke patients with depression <sep>', ""nursing home residents with ad <sep> nursing home residents with alzheimer's disease ad <sep> depressed older adults with alzheimer's disease <sep> forty-five nursing home residents with moderate to severe ad <sep> nursing home residents with severe ad <sep>"", 'patients with major depressive disorders <sep> patients with mdd <sep> controls 20 patients undergoing only pharmacological therapy <sep> inclusion criteria female between 40 and 60 years diagnosis of major depressive disorders dsm-iv tr resistant to the ongoing treatment <sep> major depressive disorders <sep> patients selected from the clinical activity registries of the psychiatric unit of the university of cagliari italy <sep>', 'adolescent females with depressive symptoms <sep> depressive persons <sep> forty-nine female volunteers aged 18-20 years mean 18.8  0.7 years with mild-to-moderate depressive symptoms as measured by the centre for epidemiologic studies depression ces-d scale <sep>', 'forty-three depressed women <sep>', 'one hundred fifty-six men and women with mdd age  or  50 years <sep> patients with mdd <sep> older patients with major depressive disorder mdd <sep> older persons <sep> older patients <sep> older patients with major depression <sep>', 'elderly people <sep> 32 subjects aged 60-84 mean age 71.3 <sep> depressed elders <sep> volunteers aged 60 and above with major or minor depression or dysthymia <sep>'], 'interventions': ['placebo <sep> exercise <sep> short-term endurance training programme <sep> endurance exercise <sep> exercise walking n  20 or placebo low-intensity stretching and relaxation exercises <sep>', 'placebo <sep> placebo <sep> exercise and pharmacotherapy <sep> aerobic exercise training <sep> standard antidepressant medication sertraline <sep> supervised exercise in a group setting home-based exercise antidepressant medication sertraline 50-200 mg daily or placebo pill <sep>', 'stretching and flexibility exercises <sep> exercise dose <sep> exercise <sep>', 'exercise classes or health education talks <sep> exercise <sep>', 'physical exercise <sep> physical exercise or bright light <sep> two non-drug treatments physical exercise and bright light <sep> physical exercise 1-h pedaling on a bicycle ergometer <sep>', 'experimenter-accompanied exercise in the form of walking a social contact control condition and a wait-list control <sep> exercise <sep>', 'sertraline and exercise <sep> sertraline <sep> exercise sertraline <sep> exercise program and anti-depressant treatment <sep>', 'exercise training <sep> strength versus aerobic versus relaxation training <sep> strength training <sep> supervised strength aerobic or relaxation training <sep>', 'aerobic exercise programme with low intensity exercise <sep> aerobic exercise <sep> aerobic exercise <sep> aerobic exercise programme <sep>', 'community-based progressive resistance training prt program <sep> prt <sep> strength-training program <sep>', 'exercise <sep> comprehensive exercise supervised walking or social conversation <sep> comprehensive exercise routine to supervised walking and social conversation <sep> exercise training <sep>', 'adjunctive physical activity <sep> placebo <sep> pharmacological treatment plus physical activity <sep> exercise activity <sep> physical activity <sep>', 'physical exercise <sep> jogging exercise <sep> exercise regimen or usual daily activities <sep> regular physical exercise <sep>', 'strenuous exercise <sep> aerobic exercise <sep> aerobic exercise treatment condition in which they participated in strenuous exercise b a placebo treatment condition in which they practiced relaxation exercises or c a no-treatment condition <sep>', 'exercise training <sep> exercise training program <sep> standard medication ie antidepressants <sep> aerobic exercise antidepressants sertraline hydrochloride or combined exercise and medication <sep> aerobic exercise program <sep>', 'progressive resistance training prt <sep> supervised prt program three times a week or an attention-control group <sep> prt <sep> progressive resistance training <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",exercise seems to improve depressive symptoms in people with a diagnosis of depression when compared with no treatment or control intervention however since analyses of methodologically robust trials show a much smaller effect in favour of exercise some caution is required in interpreting these results.
191,"{'outcomes': ['induced hypotension <sep> incidence of sore throat hoarseness or tracheal irritability <sep> post-operative side-effects <sep> sore throat and hoarseness <sep> endotracheal cuff pressures <sep> cuff pressure <sep> incidence of side-effects <sep> number of side-effects <sep>', 'incidence of sore throat <sep> severity of sore throat <sep> postoperative sore throat <sep>', 'sore throat cough and hoarseness <sep>', 'cough and restlessness before tracheal extubation <sep> sore throat <sep> arterial blood pressure and heart rate <sep> nausea vomiting dysphonia and hoarseness <sep>', 'visual analog scale <sep> ett tolerance <sep> no laryngospasm rupture of ett cuff or depression of the swallowing reflex <sep> sore throat <sep> hoarseness bucking dysphonia dysphagia cough restlessness and postoperative nausea and vomiting <sep>', 'incidence or severity of postoperative sore throat hoarseness or dysphagia <sep> sore throat hoarseness or dysphagia <sep> sore throat and dysphagia <sep> incidence and severity of postoperative sore throat hoarseness and dysphagia <sep> postoperative sore throat hoarseness and dysphagia <sep> postoperative throat problems <sep>', 'disturbance of haemodynamic responses <sep> haemodynamic changes <sep> plasma concentrations <sep> peak cuff pressures the incidence of reaction bucking <sep> incidence and severity of sore throat <sep> plasma lidocaine concentrations <sep> peak cuff pressure <sep>', 'pressure and volume changes of tracheal tube cuff <sep> pressure and volume of a tracheal tube cuff <sep>', 'sore throat incidence <sep> postoperative airway symptoms of sore throat cough and sputum <sep> postoperative airway symptoms <sep> cough incidence <sep> sore throat and cough <sep> sputum incidence <sep> incidence or severity of sputum <sep> postoperative sore throat and cough <sep>', ""postoperative sore throat including endotracheal cuff design endotracheal tube size intubation technique laryngoscopy blade airway placement suctioning technique and anesthetic technique <sep> postoperative sore throat <sep> postoperative sore throat occurs <sep> verbal analogue scale melzack's present pain intensity scale of the mcgill pain questionnaire <sep>"", 'frequency of postoperative cough and sore throat <sep> postoperative cough and sore throat <sep> frequency of sore throat <sep>'], 'punchline_text': ['women were more prone to have side-effects especially sore throat and hoarseness than men p less than 0.05). <sep>', 'the incidence of sore throat was significantly different at the 24-hour evaluation 59 air vs. 32 lidocaine p  0.01). <sep>', 'there were no significant differences between the two groups which suggests that topical anaesthesia of the mucosa of the upper airway is ineffective as a means of ameliorating airway complaints in connection with tracheal intubation. <sep>', 'after extubation nausea vomiting dysphonia and hoarseness were greater for patients with air-filled cuffs compared with the lidocaine-filled cuffs. <sep>', 'no laryngospasm rupture of ett cuff or depression of the swallowing reflex were recorded. <sep>', 'however there was no significant difference in the incidence or severity of postoperative sore throat hoarseness or dysphagia between the lidocaine group and the placebo group throughout the study. <sep>', 'in group l patients the haemodynamic changes were less p  0.05 and the peak cuff pressure was lower p  0.01 than for group s. <sep>', 'the pressure and volume of a tracheal tube cuff increased with air decreased with mixture of n2o  o2 and almost remained the same with saline and 4 lidocaine. <sep>', 'there were significant differences in the incidences p  0.01 and severity p  0.01 of sore throat and cough in groups c and l groups l1  l2). <sep>', 'analysis using the kruskal-wallis test suggested that there was no statistical difference in postoperative sore throat among the 3 groups. <sep>', 'the frequency of sore throat was significantly different among the six groups at 1 hour and at 24 hours with greater frequency in the g3 g2 and g6 groups. <sep>'], 'population': ['114 patients during n2o-o2 anaesthesia and in 54 patients after the replacement of n2o with nitrogen <sep> 94 surgical patients <sep>', '106 asa physical status i and ii patients <sep>', '193 asa i-ii surgical patients <sep> sore throat hoarseness and cough in connection with tracheal intubation <sep>', 'n=20 patients in each group that included a group who received an <sep>', 'adult patients scheduled for total thyroidectomy surgery were consecutively enrolled n  20 for each group <sep>', 'after total intravenous anaesthesia <sep> 122 asa i-iii patients aged 15-87 years <sep>', 'intubated patients <sep> seventy asa class <sep>', '80 patients 33 male  47 female <sep>', '80 patients undergoing elective operations <sep> 20 patients were given <sep>', 'participants were all asa physical status i ii or iii female adult patients undergoing general endotracheal anesthesia for gynecological procedures <sep>', '204 asa physical status i and ii patients scheduled for cataract surgery with general anesthesia <sep> university-affiliated hospital <sep>'], 'interventions': ['lignocaine jelly and spray with endotracheal intubation <sep> laryngeal lignocaine spray and/or lignocaine <sep> lignocaine <sep>', 'local anesthetic delivered via endotracheal tube ett cuff <sep> lidocaine <sep> lidocaine <sep>', 'aerosolized lidocaine <sep> standardized general anaesthesia <sep> prophylactic laryngo-tracheal aerosolized lidocaine <sep> no spray <sep>', 'lidocaine <sep> alkalinized lidocaine-filled ett cuff in combination with water-soluble gel lubrication <sep> alkalinized lidocaine <sep> alkalinized lidocaine solution <sep> water-soluble gel lubrication <sep> alkalinized lidocaine-filled cuff with ett lubrication with water group w or an air-filled cuff with ett lubrication with water group c <sep> alkalinized lidocaine-filled ett cuff with lubrication of the tube using water-soluble gel <sep> gel lubrication <sep>', 'lidocaine <sep> alkalinized lidocaine <sep> lidocaine hydrochloride l-hcl <sep> sodium bicarbonate nahco3 <sep> alkalinized-lidocaine <sep> nahco3 <sep>', 'lidocaine <sep> placebo <sep> lidocaine spray <sep> laryngo-tracheal lidocaine spray <sep> laryngo-tracheal lidocaine <sep> lidocaine or placebo <sep> lidocaine 40 mg or normal saline as placebo <sep>', 'saline <sep> lidocaine <sep> lidocaine <sep>', 'lidocaine <sep> tracheal tube-cuff inflated with air mixture of n2o  o2 saline and 4 lidocaine <sep> nitrous oxide anesthesia <sep>', 'lidocaine <sep> normal saline <sep> lidocaine 1.5 mg.kg(-1 <sep>', 'lidocaine <sep> lidocaine saline and air <sep> lidocaine saline or air to inflate the endotracheal tube cuff <sep>', 'lidocaine <sep> lidocaine application method <sep> intravenous iv lidocaine <sep> lidocaine application <sep> intracuff lidocaine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",our systematic review establishes the effectiveness of topical and systemic lidocaine for the prevention of postoperative sore throat resulting from intubation. the risk and severity of postoperative sore throat tended to be reduced. the effect size of lidocaine appeared to be affected by drug concentration and route of administration management of cuff pressure during anaesthesia the included population and the type of outcome measured.
192,"{'outcomes': ['seminal volume sperm motility and abnormal sperm morphology <sep> sperm parameters and pregnancy rate <sep> sperm density and total motile sperm count <sep> pregnancy rate <sep>', 'subclinical or recurrent varicoceles normal semen parameters and azoospermia <sep> spontaneous pregnancy rate <sep> spontaneous pregnancy <sep> occurrence of adverse events <sep> progressive motility <sep>', 'sperm concentration increased and sperm motility <sep> male fertility <sep> pregnancy rate <sep>', 'semen parameters regardless of pregnancy occurrence <sep> pregnancy rate pr <sep>', 'pregnancy <sep> cumulative pregnancy rates <sep> sperm density and motility <sep> seminal improvement and pregnancy rates <sep> pregnancy rates <sep> sperm parameters sperm density motility and morphology <sep> mean <sep> seminal improvement and pregnancy rate <sep>', 'infertility such as anovulation or tubal blockage <sep> semen analysis and hormonal parameters <sep> semen parameters <sep> sperm concentration <sep>'], 'punchline_text': ['there were no significant differences between groups 1 and 2 regarding change in seminal volume sperm motility and abnormal sperm morphology. <sep>', 'in between-arm analysis all semen parameters improved significantly in the ta versus ca p<0.0001). <sep>', 'in the group of patients without treatment the pregnancy rate in the women was higher 22/41 or 53.7 than in the group receiving treatment 13/38 or 34.2%). <sep>', 'after operation in all patients of both groups there was significant improvement in semen parameters regardless of pregnancy occurrence. <sep>', 'all seminal parameters increased after both surgical and medical treatment but only increases in sperm density and motility following varicocelectomy were statistically significant. <sep>', 'when entering the study there were no significant differences in semen analysis and hormonal parameters between the two groups nor between the subgroups undergoing treatment. <sep>'], 'population': ['85 patients with a subclinical varicocele diagnosed by scrotal thermography presented with infertility <sep> patients with subclinical varicocele <sep>', '145 participants ca n=72 ta n=73 with a mean age plus or minus standard deviation of 29.35.7 in the ca and 28.45.7 in the ta p=0.34 <sep> married men 20-39 yr of age who had experience infertility 1 yr had palpable varicoceles and with at least one impaired semen parameter sperm concentration 20 million/ml progressive motility 50 or normal morphology 30 were eligible <sep> male infertility from an evidence-based perspective <sep>', '26 patients varicocele was treated surgically and 12 patients <sep> ninety-six patients with varicocele <sep> varicocele and male fertility <sep> forty-one patients with varicocele had no therapy <sep> seventeen patients were excluded from the study in accordance with exclusion criteria <sep>', 'infertile men with clinical varicocele <sep> infertile men with abnormal semen analysis because of varicocele only <sep> infertile men <sep>', '42 infertile men with left subclinical varicocele <sep> subclinical varicocele <sep> patients with subclinical varicocele <sep>', 'infertile patients with varicocele <sep> 47 couples in the treatment group 23 ligations and 24 embolizations and 48 in the non-treatment group concluded the study <sep> subjects fulfilling the admission criteria <sep> infertile patients with varicocele <sep>'], 'interventions': ['varicocelectomy <sep> subclinical varicocele ligation <sep>', 'subinguinal microsurgical varicocelectomy <sep> varicocelectomy <sep> copyright <sep>', 'sclerosation or embolization <sep>', 'spermatic vein ligation <sep>', 'clomiphene citrate versus varicocelectomy <sep> varicocelectomy <sep> clomiphene citrate <sep> clomiphene citrate <sep>', 'doppler sonography ultrasonography of the scrotal contents semen analysis according to world health organization guidelines and serum follicle stimulating hormone luteinizing hormone and testosterone measurements <sep> spermatic vein by surgical or angiographic techniques <sep> ligation embolization or no treatment <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",there is evidence suggesting that treatment of a varicocele in men from couples with otherwise unexplained subfertility may improve a couple's chance of pregnancy. however findings are inconclusive as the quality of the available evidence is very low and more research is needed with live birth or pregnancy rate as the primary outcome.
193,"{'outcomes': ['tolerated <sep> sleep latency <sep>', 'adverse events vital signs and physical neurologic and laboratory examinations <sep> mean plasma concentrations of ltg <sep>'], 'punchline_text': ['the analysis of all the sleep logs disclosed a significant treatment effect of melatonin on sleep latency p  0.019). <sep>', 'mean plasma concentrations of ltg were linearly related to dose although there was substantial interindividual variation. <sep>'], 'population': ['twenty-five patients 16 males nine females aged from 3.6 to 26 years mean 10.5 years all affected with mental retardation mostly with epileptic seizures <sep> children adolescents and young adults with wake-sleep disorder and mental retardation most of them on chronic anticonvulsant therapy for epileptic seizures <sep> young patients with mental disabilities and epileptic seizures <sep> children adolescents and young adults with mental retardation with or without epilepsy <sep> young epileptic patients <sep>', 'typical absence seizures in children <sep> newly diagnosed typical absence seizures in children and adolescents aged 3-15 years n  45 <sep>'], 'interventions': ['placebo <sep> melatonin <sep> mlt <sep> melatonin mlt <sep> melatonin <sep> oral synthetic fast-release mlt or placebo <sep>', 'placebo <sep> ltg <sep> lamictal lamotrigine monotherapy <sep> lamotrigine ltg monotherapy <sep> ltg monotherapy <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",although ethosuximide lamotrigine and valproate are commonly used to treat people with absence seizures we have insufficient evidence to inform clinical practice and the few trials included in this review were of poor methodological quality and did not have sufficient number of participants. more trials of better quality are needed.
194,"{'outcomes': ['coma or hyperparasitemia <sep> level of consciousness became normal <sep> parasitemia <sep>', 'complications including pneumonia and gastrointestinal bleeding <sep> cerebral malaria <sep> neurologic sequelae <sep>'], 'punchline_text': ['there were no significant differences between the placebo and dexamethasone-treated groups in time until patients became afebrile median 51 vs. 19 h the level of consciousness became normal mean 80 vs. 83 h or parasitemia was cleared mean 2.1 vs. 3.4 d or in the incidence of complications. <sep>', 'there were eight deaths in the dexamethasone group and nine in the placebo group no significant difference p  0.8 at post-mortem examination the brain showed features diagnostic of cerebral malaria in all but one patient who died. <sep>'], 'population': ['quinine-treated patients with cerebral malaria <sep> patients were 18 mo to 42 y of age geometric mean 10.2 y and the 19 patients in each group were comparable on admission <sep> 28 comatose patients with cerebral malaria <sep>', '100 comatose patients <sep> 28 children six to 14 years old <sep> 100 comatose patients with strictly defined cerebral malaria <sep>'], 'interventions': ['intravenous quinine therapy <sep> placebo and dexamethasone <sep> placebo <sep> dexamethasone <sep>', 'placebo <sep> dexamethasone <sep> dexamethasone <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>']}",there is currently no evidence of benefit from corticosteroids but the small number of participants means it is difficult to exclude an effect on death in either direction. data on clinical complications are difficult to assess.
195,"{'outcomes': ['contrast sensitivity cs <sep> cs score <sep>', 'mean zinc serum level <sep> visual loss <sep> visual acuity contrast sensitivity color discrimination and retinal grating acuity as well as serum levels of zinc and copper red blood cell count hemoglobin and morphologic changes detected by grading of monochrome fundus photographs and fluorescein angiograms <sep> functional parameters <sep> serous pigment epithelial detachment developed without angiographic evidence of cnv <sep> serum levels of copper hemoglobin and red blood cell count <sep> choroidal neovascular membrane cnv <sep> nonexudative alterations drusen size drusen confluence hyperpigmentation and focal degeneration of the retinal pigment epithelium <sep>', 'contrast sensitivity <sep> macular light flash recovery time <sep> visual acuity <sep> gastrointestinal irritation rate <sep> visual acuity contrast sensitivity and light flash recovery time <sep> macular function <sep>', 'vfo-14 questionnaires conceming subjective glare recovery <sep> snellen equivalent visual acuity <sep> mean eye macular pigment optical density <sep> net subjective improvement <sep>', 'contrast sensitivity cs and national eye institute visual function questionnaire nei vfq-25 scores <sep> stabilization of va <sep> final mean nei vfq-25 composite scores <sep> va cs and visual function <sep> mean changes in visual acuity va <sep> visual acuity and visual function <sep>', 'visual and retinal acuity color vision and contrast sensitivity <sep>', 'macular degeneration <sep> visual acuity outcome <sep> visual loss <sep>'], 'punchline_text': ['the difference between these values is not statistically significant z=-0.903 p=0.376). <sep>', 'in the treatment group the mean zinc serum level increased significantly p  0.0001 from 79  <sep>', 'zmc 25 mg twice daily was well tolerated and was associated with improved macular function in comparison to a placebo in persons with dry amd. <sep>', 'in groups 1 l and 2 l/a mean eye macular pigment optical density increased approximately 0.09 log units from baseline snellen equivalent visual acuity improved 5.4 letters for group 1 l and 3.5 letters for group 2 l/a and contrast sensitivity improved. <sep>', 'an improvement in cs p=0.001 and final mean nei vfq-25 composite scores at 12 and 24 months higher in treated group compared to nontreated group were also shown p<0.001). <sep>', 'the effect of the treatment was not statistically different between the two groups admittedly small in number in terms of visual and retinal acuity color vision and contrast sensitivity. <sep>', 'although some eyes in the zinc-treated group lost vision this group had significantly less visual loss than the placebo group after a follow-up of 12 to 24 months. <sep>'], 'population': ['age-related macular disease <sep> age-related maculopathy arm and atrophic age-related macular degeneration amd participants <sep> n=10 or active n=15 groups <sep> people with age-related macular disease armd <sep>', '112 white patients with age-related macular degeneration and exudative lesions choroidal neovascularization pigment epithelial detachment or both in one eye and a visual acuity of better than 20/40 and macular degeneration without any exudative lesion in the second eye was performed <sep> 14 patients during the treatment period nine in the treatment group five in the placebo group <sep> patients with an exudative form of the disease in the first eye <sep> patients who have an exudative form of the disease in one eye <sep> age-related macular degeneration <sep>', 'persons with dry amd <sep> groups enrolled 40 participants with best corrected visual acuity 20/25 to 20/70 macular drusen and pigment changes <sep> persons with dry age-related macular degeneration amd <sep> age-related macular degeneration <sep>', 'urban midwestern veterans administration hospital from august 1999 to may 2001 <sep> age-related macular degeneration armd <sep> ninety patients with atrophic armd were referred by ophthalmologists at two chicago-area veterans medical facilities <sep> atrophic age-related macular degeneration <sep>', '145 patients <sep>', '20 patients in an early stage of amd were included <sep> patients over the age of 65 years <sep> age-related macular degeneration amd <sep> age-related macular degeneration <sep>', 'macular degeneration <sep> 151 subjects with drusen or macular degeneration <sep> older persons <sep>'], 'interventions': ['placebo <sep> lutein and antioxidant dietary supplementation <sep> lutein supplementation <sep> lutein combined with vitamin and mineral supplementation <sep> lutein combined with vitamins and minerals <sep>', 'placebo <sep> oral zinc sulfate or placebo <sep> oral zinc substitution <sep> oral zinc substitution <sep> oral zinc <sep>', 'zinc-monocysteine zmc supplement <sep> zmc and placebo <sep> placebo <sep> zmc 25 mg or placebo <sep> novel zinc-monocysteine <sep> zmc <sep>', 'lutein antioxidant supplementation trial last <sep> placebo <sep> lutein and antioxidant supplementation <sep> lutein alone or lutein <sep> lutein or lutein together with antioxidants vitamins and minerals <sep> lutein 10 mg l in group 2 a lutein 10 mg/antioxidants/vitamins and minerals broad spectrum supplementation formula l/a and in group 3 a maltodextrin placebo <sep>', 'zeaxanthin <sep> lutein/zeaxanthin and astaxanthin <sep> astaxanthin 4 mg azyr sifi catania italy and antioxidants/vitamins supplementation formula or no dietary supplementation <sep>', 'visaline <sep> vitamins and trace minerals <sep> placebo <sep>', 'oral zinc <sep> placebo <sep> oral zinc administration <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",people with amd may experience delay in progression of the disease with antioxidant vitamin and mineral supplementation. this finding is drawn from one large trial conducted in a relatively well-nourished american population. the generalisability of these findings to other populations is not known. although generally regarded as safe vitamin supplements may have harmful effects. a systematic review of the evidence on harms of vitamin supplements is needed.
196,"{'outcomes': ['sbp and dbp <sep> systolic blood pressures sbp <sep> diastolic blood pressures dbp <sep> heart rate rhythm dysrhythmias blood pressure transcutaneous oxygen tcpo2 rate pressure product and behavioral state <sep>', 'pain control <sep> heart rate and oxygen saturation changes <sep> pain relief <sep> elevation of heart rates <sep> oxygen saturation <sep> loss of oxygen saturation data <sep>', 'pulse rate and oxygen saturation <sep> average oxygen saturation <sep> pulse rate <sep> total number <sep>', 'oxygen perfusion blood pressure respiratory rate heart rate and cardiac rhythm <sep> stress reactions <sep> physiologic and subjective stress reactions <sep> crying duration and type vomiting gagging breath holding and jitteriness <sep>', 'uncomplicated pregnancies and vaginal deliveries <sep> pain distress percentage of time crying and heart rate <sep> behaviors clarity of cues and responsiveness <sep> heart rate and crying time <sep> sensitivity to cues and social-emotional growth-fostering scales <sep>', 'neonatal infant pain scale nips score secondary heart rate respiratory rate <sep> mild erythema <sep> nips scores <sep> severe pain <sep> penile edema <sep> small hematomas <sep> pain reduction <sep> heart rate <sep>', 'facial actions indicative of pain <sep> facial activity <sep> spectral crying parameters <sep> pain response <sep> heart rate transcutaneous oxygen saturation facial activity and crying <sep> pain responses <sep> higher oxygen saturation <sep> oxygen saturation <sep> heart rate <sep>', 'heart rate cry and methemoglobin level <sep> crying and lower heart rates <sep> physiological and behavioral monitoring <sep> methemoglobin level <sep> circumcision choking and apnea <sep> methemoglobin levels <sep> heart rate and high-pitched cry <sep>', 'heart rate and less crying <sep> heart rate transcutaneous oxygen saturation and crying <sep> cortisol levels <sep> heart rate smaller drops in oxygen saturation and less crying <sep> postoperative cortisol levels <sep>', 'pain reduction <sep> facial expressions <sep> cardiac rate rhythm blood pressure and transcutaneous oxygen <sep> mean heart rate <sep> pain <sep>', 'arousal <sep> indices of perceived pain including crying time behavioral state oxygen saturation and heart and respiratory rates <sep> respiratory rate <sep> baseline behavioral state <sep> oxygen saturation <sep> heart rate <sep>', 'pain-related measurements <sep> percentage of circumcision procedure time a neonate spent crying <sep> percentage change in heart rate from baseline the percentage of oxygen saturation and the score from the modified behavioral pain scale <sep> pain and physiologic stress <sep> percentage of the procedure time neonates spent crying <sep>', 'diastolic <sep> crying <sep> blood pressure <sep> systolic <sep> heart rate oxygen saturation and crying time <sep> mean peak heart rates <sep> shortened crying time <sep> behavioral and physiologic indicators of neonatal pain <sep> blood pressure <sep> neonatal stress indicators <sep> heart rate better <sep> oxygen saturation <sep>', 'pain crying agitation and physiologic stress <sep> peak plasma concentrations <sep> local or systemic complications <sep> oxygen saturation <sep> heart rate and blood pressure <sep>', 'behavioral characteristics and amount of crying <sep> heart rates and oxygen saturations <sep> heart rate and oxygen saturation and subjective determinations of behavioral state <sep> effective level of anesthesia <sep>', 'behavioral distress and adrenocortical responses <sep> stress reactions <sep> behavioral distress <sep> distress and cortisol response <sep>', 'subjective observation measurement of heart rate and the percent of time spent crying <sep> newborn distress <sep> agitation <sep> infant pain response <sep> heart rate during circumcision <sep>', 'adrenal response <sep> pre and postcircumcision cortisol levels <sep> neonatal cortisol response <sep> adrenal cortisol response to surgery <sep>', 'serum beta-endorphin concentrations <sep> safety and efficacy <sep> mean systolic blood pressure <sep> preoperative and postoperative serum beta-endorphin and lidocaine concentrations <sep> mean increase in their occurrence <sep> safety and efficacy <sep>', 'transcutaneous oxygen levels crying time heart rate and respiratory rate <sep> transcutaneous oxygen pressure levels <sep> physiologic stress reduction <sep> time spent crying <sep> heart rate <sep>', 'baseline cry duration tissue oxygenation and heart rate <sep> excursion from baseline heart rate tissue oxygenation and cry duration <sep> neonatal stress <sep>', 'facial-activity scores <sep> efficacy and safety <sep> spent less time crying <sep> facial activity <sep> demographic characteristics such as gestational age and birth weight <sep> behavioral facial activity and time spent crying and physiologic heart rate and blood pressure responses <sep> blood methemoglobin concentrations <sep> heart-rate <sep> plasma <sep> efficacy and safety <sep> heart rate <sep>', 'distress <sep> distress scores <sep> plasma cortisol levels <sep> plasma for cortisol levels <sep> behavioral observations <sep>', 'crying <sep>', 'pain <sep> heart rate respiratory rate and behavioral distress scoring <sep> respiratory rates <sep> distress scores and heart rates <sep>', 'pain of neonatal circumcision <sep> heart rate changes and total crying time <sep> crying <sep> percentage of crying time and percentage of sao2 change <sep> heart rate respiratory rate sao2 cortisol changes and duration of crying <sep> mean gomco time 209 seconds and percentage of respiratory rate change <sep> neonatal circumcision pain <sep> salivary cortisol changes <sep> heart rate respiratory rate and oxygen saturation sao2 <sep> neonatal circumcision pain with and without dorsal penile nerve block dpnb <sep>', 'physiologic variables heart rate blood pressure oxygen saturation and respiratory rate and behavioral score 20 minutes <sep> redness and blistering of the foreskin <sep> heart rate respiratory rate and behavioral score <sep> surgical complications and adverse effects <sep>', 'infant state salivary cortisol levels and respiratory rates <sep> observational pain intensity rating scale and the physiologic parameters of heart rate respiratory rate oxygen saturation levels salivary cortisol levels and length of cry <sep> pain responses <sep> pain <sep> pain response <sep> pain ratings <sep> oxygen saturation differences <sep> heart rate <sep>', 'pain <sep> heart rate oxygen saturation systolic and diastolic blood pressure and crying time <sep> pain response <sep> pain responses sucrose alone <sep> physiologic and behavioral parameters <sep> pain of circumcision <sep>', 'feeding behavior <sep> heart rate respiratory rate and crying during circumcision <sep> postoperative pain <sep> postoperative comfort scores <sep> heart rate respiratory rate and crying time <sep>'], 'punchline_text': ['sbp and dbp differed significantly between groups during two of the noninvasive steps and tcpo2 differed significantly during six steps. <sep>', 'sucrose gave significant p  .001 <sep>', 'the average oxygen saturation of the control groups decreased by 5.6 from baseline p less than 0.001 and that of the lidocaine group decreased by 1.0 which was not a significant change. <sep>', 'there were no significant differences between groups except on physiologic and subjective stress reactions during circumcision. <sep>', 'ancova revealed significant group differences in subscales of the ncafs <sep>', 'there was a significantly greater increase in heart rate over the duration of the circumcision in the emla group than in the dpnb group 49 vs 9 beats per minute). <sep>', 'compared with placebo emla significantly attenuated the pain response as shown by lower heart rate of an average of 25 beats per minute f 1 25  14.92 p  .001 higher oxygen saturation of 5 particularly during the clamping and lysis phases f 1 25  19.83 p  .0001 20 less facial activity f 1 25  12.01 p  .002 and 15 less crying during the clamping gomco clamp application and incision of the foreskin. <sep>', 'newborns in the untreated placebo group exhibited homogeneous responses that consisted of sustained elevation of heart rate and high-pitched cry throughout the circumcision and following. <sep>', 'cortisol levels measured 30 minutes postoperatively were lower in the local-anesthesia group than in either the controls or the dorsal penile nerve block group p less than .05). <sep>', 'mean heart rate was above normal limits during all steps of the circumcision for the control group and during some of the steps for the other two groups. <sep>', 'for all operative intervals combined anesthetized infants had a smaller decrease in oxygen saturation p  .001 and a smaller increase in respiratory rate p  .005 than did controls. <sep>', 'the dpnb group had significantly lower pain-related measurements p lt.05). <sep>', 'during tightening of the bell clamp significantly less crying was seen in the 5 lidocaine-prilocaine group 13  <sep>', 'there were no local or systemic complications. <sep>', 'to determine if buffered lidocaine provided a more effective nerve block in a short time than plain lidocaine for neonatal circumcision. <sep>', 'dorsal penile nerve block was found to be a safe and easy technique that was effective in reducing behavioral distress and modifying the adrenocortical stress response. <sep>', 'infants who had dpnb with lidocaine cried 50 percent less during circumcision compared to combined controls p less than 0.01). <sep>', 'the adrenal cortisol response to surgery was not significantly reduced by the administration of lidocaine. <sep>', 'comparisons of the vital signs precircumcision and postcircumcision showed no differences between the placebo and treatment groups with the exception of mean systolic blood pressure which significantly increased in the placebo-treated newborns p  .05). <sep>', 'n  20 experienced significantly less stress as evidenced by smaller decreases in transcutaneous oxygen pressure levels less time spent crying and smaller increases in heart rate than infants circumcised in an identical manner without anesthetic n  10). <sep>', 'five groups of 15 neonates were matched for weight age and apgar scores and randomly assigned to a control group one lidocaine group and three chloroprocaine groups with 2 3 and 5-minute postinjection waiting periods. <sep>', 'facial-activity scores were 12 to 49 percent lower during various steps of the procedure in the lidocaine-prilocaine group. <sep>', 'the pacifier dipped in sucrose had a distress-reducing effect during both the post-dpnb injection and circumcision periods. <sep>', 'crying was reduced further to 31 p less than .05 by providing infants with a sucrose-flavored pacifier to suck. <sep>', 'respiratory rates were higher in the eutectic mixture group but did not reach statistical significance. <sep>', 'fifty-six percent of infants circumcised with the mogen clamp and dpnb did not cry at all during the procedure. <sep>', 'statistically significant differences were noted in heart rate respiratory rate and behavioral score when comparing the dpnb group with controls during and after circumcision. <sep>', 'oxygen saturation differences were statistically significant for the music group p .02 and approached significance for the emla group. <sep>', 'physiologic and behavioral parameters indicated significantly p  0.05 decreased pain response in all treatment groups compared with that in the control group. <sep>', 'feeding behavior deteriorated in breast and bottle-fed neonates in both groups and acetaminophen did not seem to influence this deterioration. <sep>'], 'population': ['121 neonates undergoing unanesthetized circumcision <sep>', 'university teaching hospital general care nursery <sep> one hundred nineteen full-term male normal birth weight neonates 12 hours old or older <sep>', 'infants undergoing circumcisions with 1 <sep> infant circumcision <sep>', 'unanesthetized newborn males and a group having dorsal penile nerve block dpnb <sep> thirty newborn males who met the selection criteria <sep>', 'level iii nursery at a midwestern hospital <sep> newborn behavior and mother/infant interaction <sep>', 'neonatal circumcision <sep> tertiary referral neonatal intensive care nursery in a university teaching hospital <sep> fifty infants 341/2 weeks postmenstrual age and stable for discharge at time of circumcision gestational age at birth 25 to 41 weeks birth weight 600 to 4390 g age at study 3 to 105 days <sep> an additional cohort of term newborns n  20 <sep>', 'normal newborn nursery in a university teaching hospital <sep> twenty-seven newborn full-term male neonates aged 1 to 3 days <sep> newborn infants <sep>', 'neonatal circumcision <sep> a consecutive sample of 52 healthy full-term male newborns aged 1 to 3 days <sep> antenatal units in 2 tertiary care hospitals in edmonton alberta <sep>', 'thirty infants <sep>', 'eighteen control infants received <sep> fifty-eight neonates <sep>', 'forty healthy male newborns <sep> neonates undergoing the procedure with ring block and those receiving no anesthesia <sep>', 'infants undergoing circumcision <sep> analgesia in infant circumcision <sep> 71 patients who were recruited from the inpatient nursery of a military community hospital over a 5-month period <sep>', 'sixty-one neonates <sep> neonatal circumcision <sep>', 'newborn circumcision <sep> twenty infants receiving penile nerve block for circumcision were compared with ten infants having circumcision without anesthesia <sep>', 'one hundred ninety-four newborn males <sep>', 'subjects were healthy male newborns whose parents had requested circumcision <sep> equal numbers n  20 <sep>', 'regional anesthesia during newborn circumcision <sep> fifteen infants had dpnb with <sep> physicians who circumcise newborns <sep>', 'uncircumcised control infants <sep> eleven male newborns <sep>', 'neonatal circumcision <sep> thirty newborns <sep>', '30 healthy full-term infants including <sep> newborn circumcision <sep>', 'neonatal circumcision <sep> five groups of 15 neonates were matched for weight age and apgar scores <sep>', '68 full-term male neonates <sep> pain during circumcision <sep> a total of 68 and 59 neonates <sep> pain from circumcision in neonates <sep> neonates undergoing circumcision <sep>', 'eighty healthy term newborn male infants scheduled for routine neonatal circumcision <sep>', 'newborn infants was assessed during two standard painful hospital procedures blood collection via heel lance and circumcision <sep> newborn infants <sep> infant rats <sep>', 'pain relief during circumcision <sep>', '48 healthy full-term infants <sep>', 'palliation of pain associated with circumcision in low-birth-weight infants <sep> g at the time of circumcision who were discharged from the hospital between may 1994 and june 1995 <sep> fifty infants were enrolled in the study 19 randomized to the dpnb group 19 to the control group and 12 to the emla group <sep> fifty neonates with weights of 1600 to 2500 <sep> twenty-five infants who were otherwise eligible were excluded because of parental refusal of consent to participate <sep> low-birth-weight neonates <sep>', 'neonates undergoing circumcision <sep> 23 neonates <sep> neonatal circumcision pain <sep>', '80 male infants <sep>', 'neonatal circumcision <sep> 44 healthy full-term neonates undergoing circumcision was conducted <sep>'], 'interventions': ['noninvasive pain reduction interventions <sep> classical music intrauterine sounds pacifier music and pacifier intrauterine sounds and pacifier or control no nurses present and no pain reduction interventions used <sep>', 'oral sucrose via a nipple compared with no treatment and dorsal penile nerve block dpnb <sep> sucrose pacifier <sep> dpnb or sucrose <sep>', 'saline solution <sep> lidocaine <sep> saline solution injections or no injections <sep> lidocaine dorsal penile nerve blocks <sep>', 'circumcision anesthesia <sep>', 'acetaminophen <sep> placebo <sep> acetaminophen or placebo <sep> ncafs <sep>', 'lidocaine <sep> analgesia <sep> dorsal penile nerve block dpnb <sep> dpnb <sep> emla cream <sep> local anesthesia eutectic mixture of local anesthetic emla cream <sep> emla <sep>', 'topical anesthesia <sep> topical anesthetic cream eutectic mixture of local anesthetics emla <sep> placebo emla <sep> emla <sep>', 'placebo <sep> ring block dorsal penile nerve block and topical anesthesia <sep> local anesthetics emla and topical placebo <sep> emla <sep>', 'dorsal penile nerve block versus local anesthesia <sep> unanesthetized control group a group given dorsal penile nerve block and a group given local anesthesia <sep>', 'routine care <sep>', 'ring block or no anesthesia <sep>', 'placebo <sep> oral glucose solution <sep> dextrose solution <sep> dpnb <sep>', 'lidocaine cream anesthetics <sep> lidocaine <sep> lidocaine-prilocaine <sep> placebo <sep> lidocaine creams <sep> control group that received an acid-mantle cream <sep> lidocaine-prilocaine <sep> topical lidocaine-prilocaine <sep> prilocaine-lidocaine <sep>', 'lidocaine <sep>', 'plain lidocaine <sep> lidocaine <sep> plain and buffered lidocaine <sep> dorsal penile nerve block preparations for circumcision <sep>', 'lidocaine saline or no injection <sep> lidocaine hydrochloride without epinephrine <sep> local anesthesia <sep>', 'regional anesthesia by dorsal penile nerve block dpnb <sep> lidocaine <sep>', 'lidocaine <sep> venipuncture alone <sep>', 'lidocaine <sep> placebo <sep> topical anesthetic <sep> topical 30 lidocaine cream <sep> topical lidocaine cream <sep> lidocaine cream <sep>', 'lidocaine 1 xylocaine <sep> dorsal penile nerve block <sep>', 'lidocaine <sep> chloroprocaine groups with 2 3 and 5-minute postinjection waiting periods <sep> chloroprocaine <sep> chloroprocaine versus lidocaine <sep> chloroprocaine dpnb <sep> dorsal penile nerve blocking dpnb <sep>', 'placebo <sep> lidocaine-prilocaine <sep> lidocaine-prilocaine cream emla <sep> lidocaine <sep> lidocaine prilocaine <sep> placebo cream <sep> prilocaine <sep> lidocaine-prilocaine cream <sep> lidocaine-prilocaine cream <sep>', 'rigid plastic restraint board b standard dpnb <sep> lidocaine <sep> lidocaine hydrochloride used for dpnb and 3 offering a pacifier dipped in a 24 sucrose solution during the dpnb and circumcision <sep> placebo <sep> lidocaine hydrochloride <sep>', 'sucrose <sep>', 'lidocaine <sep> local anesthetic cream lidocaine and prilocaine <sep> placebo cream and lidocaine dorsal penile nerve block <sep> local anesthetic cream and sodium chloride solution dorsal penile nerve block <sep>', 'lidocaine <sep> mogen and gomco clamps <sep> dpnb <sep> gomco vs mogen with  or without  dpnb <sep> placebo injection <sep>', 'dorsal penile nerve block dpnb and eutectic mixture of lidocaine emla <sep> dorsal penile nerve block vs topical placebo <sep> dpnb emla <sep> lidocaine hydrochloride or topical emla <sep> sham anesthesia with topical placebo acid mantle cream <sep> emla <sep>', 'pain management interventions <sep> music and eutectic mixture of local anesthetics emla <sep> emla <sep>', 'control water-dipped pacifier only sucrose alone emla alone or sucrose and emla <sep> sucrose and emla <sep> sucrose-dipped pacifier and an analgesic cream emla <sep>', 'acetaminophen analgesia <sep> placebo <sep> acetaminophen analgesia <sep> acetaminophen <sep> acetaminophen <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",dpnb was the most frequently studied intervention and was the most effective for circumcision pain. compared to placebo emla was also effective but was not as effective as dpnb. both interventions appear to be safe for use in newborns. none of the studied interventions completely eliminated the pain response to circumcision.
197,"{'outcomes': ['symptomatic or had radiological evidence of bone disease <sep> initial serum 1,25(oh)2d levels <sep> renal function <sep> bone histology <sep> serum phosphorus and alkaline phosphatase concentrations <sep> parathyroid hormone levels <sep>', 'elevated resorption and osteoid indices <sep> mineralizing activity <sep> resorption indices <sep> risk of hypercalcemia <sep> preservation of ob <sep> mineralizing boundaries m.bd <sep> serum ca rose steadily and cr.cl <sep>', 'incidence of hypercalcemia serum calcium concentration <sep> renal function <sep> glomerular filtration rate <sep> height z scores <sep>', 'histological indices of bone turnover <sep> renal bone disease <sep> biochemical radiographic and histological indices of bone metabolism <sep> rate of progression of renal failure <sep> hypercalcaemic episodes <sep> mean serum alkaline phosphatase activity and intact parathyroid hormone concentration <sep> bone disease <sep>', 'mean serum calcium or phosphorus or urinary calcium levels or incidence of hypercalcemia hyperphosphatemia or hypercalciuria <sep> serum calcium and phosphorus levels <sep> pth levels <sep> adverse-event rates and changes in gfr <sep> ipth level <sep> ipth level reductions <sep> glomerular filtration rate gfr <sep> serum c and n-telopeptide and bone-specific alkaline phosphatase levels <sep> parathyroid hormone pth levels <sep> mean plasma ipth level <sep> plasma ipth serum calcium and phosphorus urinary calcium bone-specific serum markers and serum lalpha,25-dihydroxyvitamin d levels <sep>', 'intestinal absorption of calcium and in plasma-calcium <sep> plasma-phosphorus plasma-alkaline-phosphatase or in the degree of bone mineralisation <sep> bone mineral content <sep>', 'bone alkaline phosphatase <sep> final s-creatinine or change in s-creatinine <sep> s-calcium s-phosphate and urinary excretion of calcium <sep> hypercalcaemia or hyperphosphataemia <sep> terminal renal failure <sep> baseline 1,84 ipth concentrations <sep>', 'bone mineral density <sep> bone mineral density <sep> femoral neck and lumbar spine <sep>', 'bone metabolism and bone density <sep> femoral neck <sep> plasma levels of parathyroid hormone <sep> bone mineral density bmd estimated by dual energy x-ray absorptiometry and plasma levels of biochemical markers of bone turnover osteocalcin bone alkaline phosphatase propeptide of type-i collagen picp and telopeptide of type-i collagen and parameters of calcium homeostasis <sep> picp <sep> bmd <sep> gfr <sep> p-osteocalcin and bone alkaline phosphatase <sep> plasma levels of vitamin d metabolites <sep>', 'ipth without causing hypercalcemia <sep> creatinine clearances <sep> renal function <sep> serum ipth <sep> serum ipth allegro nichols 1-25 vitamin d irma-mab total and ionized calcium nova 8 pabish serum phosphate alkaline phosphatase and creatinine clearance <sep> ipth <sep>', 'respective median ipth concentrations <sep> mean ipth decrease <sep> ipth concentration <sep> hypercalcemia <sep> median intact pth ipth level <sep> parathyroid hormone pth suppression <sep>', 'renal function <sep> 1,25(oh)2d3 quickly corrected hypocalcaemia reduced serum-alkaline-phosphatases and serum-immunoreactive-parathyroid-hormone <sep> percentage fall in creatinine clearance <sep> hypercalcaemia <sep> urinary excretion rate of calcium <sep>', 'serum a1 levels <sep> renal function <sep> serum pth urinary camp excretion and bone resorption indices <sep> serum al levels <sep> serum calcium and ionized calcium concentrations <sep>', 'serum ipth calcium and phosphorus levels <sep> glomerular filtration rate <sep> urinary calcium and phosphorus excretion or deterioration in kidney function <sep> calcium levels phosphorus balance and kidney function <sep> ipth levels <sep> incidences of hypercalcemia hyperphosphatemia and elevated calcium-phosphorus product levels <sep>'], 'punchline_text': ['1,25(oh)2d3 treatment was associated with a significant fall in serum phosphorus and alkaline phosphatase concentrations as well as with histological evidence of an amelioration of hyperparathyroid changes. <sep>', 'whereas in group a serum ca rose steadily and cr.cl declined in group b both parameters levelled off between t6 and t9. <sep>', 'there was no significant difference between calcitriol and dihydrotachysterol in promoting linear growth or causing hypercalcemia in children with chronic renal insufficiency. <sep>', 'histological indices of bone turnover significantly improved in patients given alfacalcidol and significantly deteriorated in controls among patients with abnormal bone histology before treatment bone disease resolved in 23 42 of those given alfacalcidol compared with two 4 of the controls p  0.001). <sep>', 'after 6 weeks ipth level reductions with doxercalciferol treatment exceeded those with placebo at all subsequent intervals p 0.001). <sep>', 'no significant changes were induced in plasma-phosphorus plasma-alkaline-phosphatase or in the degree of bone mineralisation as measured by the phosphorus/hydroxyproline ratio in bone. <sep>', 's-calcium s-phosphate and urinary excretion of calcium did not change significantly on either placebo or on calcitriol. <sep>', 'after 1 year of study an increase in bone mineral density in the calcitriol group measured by dual-energy x-ray absorptiometry was seen for the femoral neck and lumbar spine when compared to the placebo group p  0.001 and p  0.01 respectively). <sep>', 'a significant difference in bmd between the treatment groups in favour of the alfacalcidol-treated patients was found in the spine 4.2 the femoral neck 4.9 and the total femur 3.0 p<0.05). <sep>', 'daily oral intake of 0.5 micrograms of calcitriol prevents an increase of ipth without causing hypercalcemia but only oral boluses b and c decreased ipth from 270  <sep>', 'calcitriol reduced the ipth concentration in 23/29 patients in the daily group and in 21/30 in the intermittent group. <sep>', '1,25(oh)2d3 quickly corrected hypocalcaemia reduced serum-alkaline-phosphatases and serum-immunoreactive-parathyroid-hormone and more than doubled the urinary excretion rate of calcium. <sep>', 'serum pth urinary camp excretion and bone resorption indices decreased in the treatment group indicating suppression of parathyroid hyperfunction. <sep>', 'paricalcitol capsule was well tolerated and effectively decreased ipth levels with minimal or no impact on calcium levels phosphorus balance and kidney function in patients with stages 3 and 4 ckd. <sep>'], 'population': ['sixteen patients with chronic renal impairment creatinine clearance 20 to 59 ml per min received either <sep> moderate renal failure <sep> patients with mild to moderate renal failure <sep>', '24 non-dialyzed patients with chronic renal insufficiency cri matched pairwise as to age sex and creatinine clearance cr.cl <sep> predialysis renal insufficiency <sep> patients with high ob <sep>', 'ninety-four patients completed a mean of 8.0 months of control observations <sep> children aged 1 1/2 through 10 years with a calculated glomerular filtration rate between 20 and 75 ml/min per 1.73 m2 and with elevated serum parathyroid hormone concentrations <sep> children with chronic renal insufficiency <sep> children with renal diseases investigators <sep>', '176 patients aged 18-81 with mild to moderate chronic renal failure creatinine clearance 15-50 ml/min and with no clinical biochemical or radiographic evidence of bone disease <sep> 89 patients given alfacalcidol and the 87 controls given <sep> 132 patients had histological evidence of bone disease at start of study <sep> patients with mild to moderate renal failure <sep> 17 nephrology centres from belgium france the netherlands and the united kingdom <sep> mild to moderate renal failure <sep>', 'fifty-five adults with stage 3 or 4 ckd and an intact pth ipth level greater than 85 pg/ml ng/l <sep> patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4 <sep> patients with chronic kidney disease ckd <sep>', 'chronic renal failure <sep> 24 patients with chronic renal failure glomerular filtration-rate g.f.r. 5-25 ml/min participated in a double-blind <sep>', 'patients with moderate renal failure prospective <sep> patients with moderate renal failure and elevated of 1,84 ipth <sep> patients with renal secondary hyperparathyroidism <sep> 45 patients with mild to moderate renal failure <sep>', 'patients with crf <sep> thirteen patients in the predialysis phase of chronic renal failure crf <sep>', '36 patients with a glomerular filtration rate gfr of 6-60 ml/min <sep> patients with pre-dialysis chronic renal failure crf <sep> patients with mild to moderate chronic renal failure <sep>', '16 years creatinine clearance 22.9 <sep> sixteen 16 patients mean age 51 <sep> control group of fifteen 15 patients mean age 47 <sep> predialytic chronic renal failure <sep> patients with predialytic renal failure <sep> 121 to 323 <sep>', 'children with chronic renal failure prior to dialysis <sep> children with renal failure <sep> children with chronic renal failure <sep> 59 children mean age 8.4+/-4.7 years with chronic renal insufficiency mean ccr 22.4+/-11.6 ml/min per 1.73 m2 and secondary hyperparathyroidism <sep>', '18 non-dialysed patients with chronic renal failure c.r.f <sep> non-dialysed patients with c.r.f <sep> patients with a creatinine clearance below 35 ml/min and mild renal osteodystrophy were selected <sep>', 'patients with predialysis chronic renal failure <sep> 30 patients with predialysis chronic renal failure <sep>', 'two hundred twenty patients participated n  107 paricalcitol n  113 <sep> patients with chronic kidney disease ckd stage 5 <sep> patients with stages 3 and 4 ckd with shpt <sep> secondary hyperparathyroidism in stages 3 and 4 ckd <sep> between 15 and 60 ml/min/1.73 m2 0.25 and 1.00 ml/s/1.73 m2 an average of 2 consecutive intact parathyroid hormone ipth levels greater than 150 pg/ml ng/l 2 consecutive serum calcium levels between 8.0 and 10.0 mg/dl 2.00 and 2.50 mmol/l and 2 consecutive serum phosphorus levels of 5.2 mg/dl or less  or  1.68 mmol/l <sep> patients with stages 3 and 4 ckd <sep>'], 'interventions': ['1,25(oh)2d3 <sep> placebo <sep> 1,25(oh)2d3 administration <sep>', 'alpha-(oh)d3 alone group a or with 1 alpha-(oh)d3 plus a high dosage of 24,25-(oh)2d3 <sep> 24r,25-dihydroxyvitamin d3 in combination with 1 alpha-hydroxyvitamin d3 <sep> 24r,25-dihydroxyvitamin d3 24,25-(oh)2d3 and 1 alpha-hydroxyvitamin d3 1 alpha-(oh)d3 <sep>', 'calcitriol <sep> calcitriol dosage mean <sep> calcitriol and dihydrotachysterol <sep> calcitriol versus dihydrotachysterol <sep>', 'alfacalcidol 0.25 micrograms titrated according to serum calcium concentration or placebo <sep> placebo <sep> alfacalcidol <sep>', 'placebo <sep> doxercalciferol <sep> doxercalciferol <sep> doxercalciferol or placebo <sep> doxercalciferol 1alpha-hydroxyvitamin d2 <sep> calcitriol <sep>', '1apha-hydroxycholecalciferol <sep> alpha-hydroxycholecalciferol 1alpha-h.c.c <sep> placebo <sep>', 'placebo <sep> placebo and calcitriol <sep> low-dose calcitriol <sep> calcium carbonate <sep> calcitriol <sep> calcitriol <sep>', 'calcitriol <sep> placebo <sep>', 'placebo <sep> alfacalcidol <sep> alfacalcidol treatment <sep>', 'calcitriol <sep> calcitriol oral therapy <sep> calcitriol regimens <sep> oral daily calcitriol 0.5 micrograms/die treatment a three oral boluses of 2 micrograms of calcitriol <sep>', 'calcitriol oral pulse therapy <sep> vitamin d <sep> calcitriol pulse therapy <sep> intermittent oral calcitriol <sep> calcitriol pulse therapy <sep> daily oral calcitriol <sep> calcitriol <sep> calcitriol <sep> calcitriol therapy <sep>', 'potent vitamin-d metabolite 1 25-dihydroxycholecalciferol 1,25[oh]2d3 and vitamin d3 <sep> 25 oh)2d3 or vitamin d3 in initial daily doses of 1microgram and 4000 i.u. respectively combined with 0.5 g calcium <sep> 1,25-dihydroxycholecalciferol <sep> vitamin d3 <sep>', 'calcitriol <sep> calcitriol less than or equal to 0.50 micrograms/day on parathyroid and renal function bone histomorphometry and aluminum al metabolism <sep> calcitriol <sep> calcitriol versus placebo <sep>', 'placebo <sep> paricalcitol capsule <sep> paricalcitol <sep> paricalcitol injection <sep> paricalcitol <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",there are not sufficient data to determine the effect of vitamin d compounds on mortality and cardiovascular outcomes in people with ckd not requiring dialysis. while vitamin d compounds reduce serum pth 49.3 pg/ml 5.6 pmol/l compared with placebo the relative clinical benefits of pth lowering versus treatment-related increases in serum phosphorus and calcium remain to be understood.
198,"{'outcomes': ['cord vein po2 <sep> cord gas values <sep> oxygenation <sep> cord artery po2 <sep> cord vein-artery po2 differential <sep>', 'umbilical cord arterial blood <sep> demographic or hemodynamic variables time from uterine incision to fetal extraction neonatal birth weight presence of umbilical cord abnormalities type of resuscitation required by the neonate or apgar score <sep> oxygen saturation in maternal blood by pulse oximetry <sep> po2 in venous blood <sep>', 'blood gases and the products of lipid peroxidation 8-isoprostane malondialdehyde mda hydroperoxide ohp and purine metabolites <sep> maternal and fetal oxygenation and lipid peroxidation <sep> maternal arterial po2 <sep> umbilical arterial and venous blood <sep> umbilical venous po2 <sep> oxygen free radical activity <sep> maternal and umbilical plasma concentrations of lipid peroxides 8-isoprostane mda ohp <sep> fetal oxygenation <sep> free radical activity and lipid peroxidation <sep> maternal arterial blood <sep> maternal and fetal oxygenation and oxygen free radical activity <sep>', 'mean values of the uv blood samples <sep> maternal fio2 and umbilical arterial ua and venous uv po2 pco2 ph and neonatal apgar score <sep> ua and uv po2 <sep> mean values of the ua blood samples <sep> ua and uv blood samples <sep>', 'umbilical arterial and venous blood samples <sep> umbilical arterial or venous ph partial pressure of oxygen and partial pressure of carbon dioxide <sep>', 'neonatal rso(2 ua ph uv ph and ua base excess be <sep> umbilical artery ua and venous uv blood samples <sep> apgar score <sep> maternal mean arterial pressure heart rate and peripheral oxygen saturation <sep> maternal and neonatal regional cerebral oxygenation rso(2 <sep> mean maternal rso(2 <sep> neonatal rso(2 and apgar scores <sep>'], 'punchline_text': ['the cord artery po2 of the oxygen group was also significantly higher p less than 0.05 at 20 mm hg sd 6 versus 15 mm hg sd 6). <sep>', 'oxygen saturation in maternal blood by pulse oximetry was higher after 10 minutes in the group of women who received supplemental oxygen through face masks. <sep>', 'maternal and umbilical plasma concentrations of lipid peroxides 8-isoprostane mda ohp were greater in the oxygen group than in the air group p<0.05). <sep>', 'there was a significant increase in ua and uv po2 when using a simple o2 mask p  0.001).(abstract <sep>', 'the results showed that there were no significant differences in the umbilical arterial or venous ph partial pressure of oxygen and partial pressure of carbon dioxide between any of the three groups. <sep>', 'the apgar score 1 min in group fm was lower than that of group ra p  0.046). <sep>'], 'population': ['thirty-two healthy pregnant women at term who were to undergo cesarean section following epidural anesthesia <sep>', 'healthy parturients under spinal anesthesia <sep> full-term parturients who had received prenatal care during pregnancy <sep> one hundred thirty women were enrolled <sep> they were scheduled for delivery by cesarean section under spinal anesthesia <sep>', 'forty-four healthy parturients <sep> parturients having caesarean section under spinal anaesthesia <sep> parturients undergoing caesarean section under regional anaesthesia <sep>', '45 patients receiving cesarean section under epidural anesthesia <sep>', 'elective caesarean section under spinal anaesthesia <sep> sixty-nine women undergoing elective caesarean section <sep> mothers undergoing elective caesarean section under spinal anaesthesia <sep>', 'ninety parturients <sep> newborn for elective cesarean deliveries under spinal anesthesia <sep>'], 'interventions': ['face mask room air or oxygen for more than 10 minutes <sep> maternal oxygen administration <sep>', 'breathe room air or air providing an inspired oxygen fraction of 40 through a face mask <sep> bicarbonate 22.19 meq l(-1 <sep>', 'oxygen supplementation <sep> breathe either 21 air group or 60 oxygen oxygen group intraoperatively via a ventimask <sep> high inspired oxygen fraction fio2 <sep> high inspired oxygen fraction <sep>', 'simple o2 mask <sep> epidural anesthesia with supplementary oxygen <sep> xylocaine <sep> adrenaline <sep>', 'oxygen 40 by facemask air by facemask or oxygen at 2 l x min(-1 by nasal cannulae <sep> supplementary oxygen <sep> supplementary oxygen administration <sep>', '5 l/min oxygen by either nasal cannula group nc n  30 or face mask <sep> nasal cannula or face mask versus room air <sep> maternal supplementary oxygen <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",current evidence suggests that supplementary oxygen given to healthy term pregnant women during elective caesarean section under regional anaesthesia is associated with higher maternal and neonatal oxygen levels maternal spo2 pao2 uapo2 and uvpo2 and higher levels of oxygen free radicals. however the intervention was neither beneficial nor harmful to the neonate's short-term clinical outcome as assessed by apgar scores.
199,"{'outcomes': ['quinine toxicity <sep> peak concentrations <sep> insulin concentrations <sep> all blood concentrations <sep> time taken to clear parasites <sep> hypoglycemia after admission <sep> mean peak concentrations <sep> mean high and low quinine concentrations <sep>', 'cardiovascular toxicity <sep> case-fatality rates <sep> coma mean durations <sep> evolution of parasitemia <sep> cardiovascular side effects <sep> body temperature <sep> cerebral malaria <sep> lethality rate <sep> mean cost <sep>', 'mild toxic effects <sep> clinical and parasitological response <sep> fever clearance time <sep> parasite clearance time <sep> mean trough and peak plasma quinine levels <sep> transient partial hearing loss <sep> hypoglycaemia <sep>'], 'punchline_text': ['all blood concentrations exceeded the 99 in vitro inhibitory concentration ec99 of 0.89 mg/l or less of quinine for 60 isolates of plasmodium falciparum which were taken from children with malaria during the same period. <sep>', 'coma mean durations were similar in the two groups <sep>', 'transient partial hearing loss occurred significantly more in the study than control group p  0.05). <sep>'], 'population': ['african children <sep> 59 children with severe malaria <sep> severe malaria in africa <sep>', 'african children <sep> seventy-two children eight months to 15 years of age with cerebral malaria were included <sep>', 'severe falciparum malaria at kenyatta national hospital kenya <sep> from july 1989 to february 1990 17 non-pregnant patients with severe falciparum malaria aged 14 years and above received an <sep>'], 'interventions': ['quinine treatment <sep> intramuscular quinine <sep>', 'quinine mefloquine or halofantrine <sep> intravenous quinine 15 mg salt/kg 13.1 mg of base dissolved in 15 ml/kg of 5 glucose <sep> intravenous quinine <sep>', 'initial intravenous quinine dihydrochloride loading dose of 20 mg/kg in 500 mls of normal saline or 5 dextrose <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",quinine loading dose reduced fever clearance time and parasite clearance time. data are insufficient to directly demonstrate an impact of loading dose on risk of death.
200,"{'outcomes': ['contralateral icad <sep> subsequent stroke <sep>', 'recurrence stroke and death and clinical outcome at 6 months <sep> complete recanalization of vertebral dissections <sep> recanalization <sep> recurrent ischemic stroke <sep>', 'intracranial haemodynamics <sep> carotid recanalization <sep> stagnating blood flow velocities <sep>', 'rates for death and stroke <sep> modified rankin scale mrs and barthel index bi <sep> functional outcome <sep> hemorrhagic complications <sep> seizures <sep> ischemic and hemorrhagic complications occurrence of seizure and rates of arterial recanalization <sep> arterial recanalization <sep>', 'hemorrhagic adverse events <sep> new ischemic events <sep> new cerebral ischemic events defined as ischemic stroke tia or retinal ischemia 2 symptomatic intracranial hemorrhage and 3 major extracranial bleeding <sep> retinal ischemia in 8 and local symptoms and signs headache neck pain horner syndrome cranial nerve palsy <sep> retinal ischemia <sep> efficacy and safety <sep>', 'deficit fair moderate deficit needing some assistance poor requiring institutionalization and dead <sep> neurologic outcomes <sep> bleeding complications <sep> neurologic outcome <sep> extracranial bleeding complications <sep>', 'massive stroke embolic mechanism and lack of local recanalization <sep> subjective bruit or painful <sep> resolution of the angiographic appearances <sep> cerebral ischaemia <sep>', 'arterial hypertension <sep> traumatic extracranial ccad <sep> recurrent ischemic stroke <sep>', 'ischemic optic neuropathy <sep> severe ipsilateral headache and orbital pain <sep> central retinal artery occlusion or ischemic ocular syndrome <sep> cerebral infarction <sep> ischemic optic neuropathy ion <sep>', 'recurrence of a dissection <sep> good recovery and early reopening of the occluded ica <sep>', 'initiation of anticoagulation <sep> initiation of heparin <sep>', 'visual aura <sep> migraine <sep> verified cad recurrence <sep> brain infarction <sep>'], 'punchline_text': ['none of the 21 patients had a subsequent stroke. <sep>', 'complete recanalization of vertebral dissections was associated with a favorable prognosis or 3.2 95 ci 1.1-8.8 p  0.02)]. <sep>', 'the follow-up investigations moreover demonstrated that intracranial haemodynamics may change from day to day in patients suffering from internal carotid artery dissection. <sep>', 'four anticoagulated patients developed seizures compared to 2 patients with antiplatelets p  0.05). <sep>', 'during follow-up ischemic events were rare ischemic stroke 0.3 tia 3.4 retinal ischemia 1 their frequency did not significantly differ between patients treated with anticoagulants 5.9 and those treated with aspirin 2.1%). <sep>', 'bleeding complications from full anticoagulation were higher than with antiplatelet agents p  0.05). <sep>', 'cerebral ischaemia was present in 90 of cases and occurred within a month of the initial event in all cases but one and was the first symptom in 53 of cases. <sep>', 'the internal carotid artery ica was the most frequently involved vessel 63 followed by the vertebral artery 30 and multivessel involvement in two patients 7%). <sep>', 'ischemic optic neuropathy occurred after a mean of 5.3 days range 3-8 days following the first symptom which was headache in 1 patient transient monocular blindness in 2 and hemispheric transient ischemic attack in 1. <sep>', 'early heparin sodium therapy may help prevent intraluminal clotting without carrying an important risk of extending the dissection but its clinical benefit remains unproven. <sep>', 'all recovered without deficits. <sep>', 'seven 2.3 patients died during the follow-up mean 4.0 years 1186 patient years). <sep>'], 'population': ['the records from 1976 to 1995 of 24 patients who had 28 <sep> seventeen patients who had 19 icad underwent a duplex scan at the time of presentation <sep> six patients subsequently had an operation for residual occlusive disease or aneurysm <sep> patients who have icad often have prodromal symptoms before stroke <sep> nine patients had visual symptoms or headache 10 had transient focal neurologic symptoms tia and five had stroke <sep>', 'mean age was 35.4 years 4 patients died 3 and 126 were followed for 3,906 person/years 17 patients 13 had a heralding ischemic cerebral event 6 strokes 11 tias about 8 days before the diagnosis of dca <sep> 130 patients with angiographically-proven dca admitted to the neurology institute in mexico city mexico and analyzed clinical and neuroimaging data treatment and outcome <sep> 130 consecutive cases <sep> patients with dissection of cervical arteries dca <sep>', 'patients suffering from internal carotid artery dissection <sep> patients with spontaneous carotid dissection <sep> 11 patients aged between 34 and 57 years with clinical and angiographic findings typical of carotid dissection <sep>', '33 consecutive eicad patients initially treated either with anticoagulation n  25 or with antiplatelets n  8 a standardized interview was performed after 28 <sep> anticoagulated patients was bi 92 <sep>', '298 consecutive patients with sicad 56 men mean age 46 <sep> patients with spontaneous dissection of the cervical carotid artery <sep> patients with spontaneous dissection of the cervical carotid artery sicad <sep> 298 patients <sep>', 'seven patients with four major bleeding complications requiring cessation of heparin and blood transfusions <sep> twenty-two adult trauma patients were diagnosed with bci for an incidence of 0.45 in the 8-year study period <sep> eight patients were not anticoagulated five because of intracranial injuries two who had surgical cca repairs and one with an aortic injury <sep> 22 patients who presented with bci and assessed neurologic and survival outcomes on the basis of injury grade and treatment with anticoagulation or antiplatelet therapy <sep> blunt carotid injury <sep>', '68 patients <sep> 68 patients aged 20 to 71 mean 46 <sep>', 'selected patients who have failed medical therapy <sep> eighteen patients received <sep> 27 patients with extracranial ccad who were evaluated treated and/or followed by our stroke service from september 1995 to august 2001 <sep> patients having an ischemic stroke or tias <sep> 15 men 56 and 12 women 44 with mean ages of 38 and 43 years respectively <sep> one patient presented only with a painful post-ganglionic horner syndrome another patient with neck pain and post-ganglionic horner syndrome another patient solely with protracted unilateral headaches three with transient ischemic attacks tia and 21 with ischemic strokes <sep> young adults <sep>', '4 patients with ion 2 anterior and 2 posterior due to internal carotid artery dissection of a consecutive series of 110 patients with internal carotid artery dissection 3.6 <sep>', '1200 consecutive patients with a first stroke had a spontaneous dissection with occlusion of the cervical internal carotid artery ica <sep> spontaneous carotid dissection with acute stroke <sep>', 'twelve patients with either unilateral or bilateral carotid mural injury were anticoagulated <sep> patients with this injury <sep> twenty patients with blunt mechanism injuries to the internal carotid artery <sep> sixteen patients 80 survived the majority with normal neurologic function <sep>', '301 consecutive finnish patients diagnosed from 1994 to 2007 <sep> women were younger than men <sep> 301 finnish patients <sep>'], 'interventions': ['duplex scans <sep> internal carotid artery dissection icad <sep> aspirin and anticoagulation therapy <sep> duplex scanning <sep> aspirin <sep>', 'aspirin <sep>', 'transcranial doppler ultrasound follow-up studies <sep> transcranial doppler ultrasound tcd <sep>', 'extracranial internal carotid artery dissection eicad <sep>', 'aspirin <sep> aspirin and anticoagulants <sep> aspirin alone <sep> aspirin <sep> anticoagulants alone <sep>', 'heparin <sep> antiplatelet therapy <sep> head computed tomography and four-vessel cerebral arteriography <sep> antiplatelet therapy <sep>', 'magnetic resonance imaging <sep> doppler ultrasonography and magnetic resonance imagery <sep>', 'percutaneous balloon angioplasty and stenting <sep> cervicocephalic arterial dissections ccad <sep> anticoagulant therapy and nine platelet anti-aggregants <sep> extracranial cervicocephalic arterial dissections <sep> percutaneous balloon angioplasty/stenting <sep>', 'internal carotid artery dissection <sep>', 'heparin sodium therapy <sep>', 'heparin anticoagulant <sep> heparin <sep> aspirin <sep>', 'adult cervicocerebral artery dissection <sep> icad <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there were no randomised trials comparing either anticoagulants or antiplatelet drugs with control thus there is no evidence to support their routine use for the treatment of extracranial internal carotid artery dissection. there were also no randomised trials that directly compared anticoagulants with antiplatelet drugs and the reported non-randomised studies did not show any evidence of a significant difference between the two.
201,"{'outcomes': ['objective systemic reactions <sep> systemic reaction after a deliberate sting challenge <sep>', 'vespid allergy quality of life questionnaire vqlq burden of treatment and expectation of outcome <sep> vqlq score <sep> health-related quality of life hrql <sep> health-related quality of life <sep> hrql <sep>', 'size and duration of large local reactions <sep> size and duration of the large local reactions <sep>', 'generalized urticaria <sep> median of the peak maximal diameter of the llrs <sep>', '18 systemic reactions <sep> accidental stings <sep> systemic reaction <sep> recurrences of systemic reactions <sep> positive skin-test reaction <sep>'], 'punchline_text': ['objectively defined systemic reactions to sting challenges arose in 21 of 29 participants 72 on placebo 8 reactions were associated with hypotension and none of 23 on vit p<0.0001). <sep>', 'vit results in a clinically significant improvement of hrql in most patients with reactions limited to the skin following yellow jacket stings. <sep>', 'sting challenge in 41 patients with previous large local reactions and positive venom skin tests caused large local reactions 16 cm or larger in 34 patients and 29 consented to treatment. <sep>', 'sublingual immunotherapy slit proved effective and safe in respiratory allergy and thus its use in hymenoptera allergy can be hypothesized. <sep>', ""sixteen of these 18 reactions were judged to be milder than the patient's reaction to the first sting 2 were similar in severity and none were more severe. <sep>""], 'population': ['otherwise healthy adults <sep> 68 healthy volunteers aged 20-63 years who were allergic to m pilosula venom to placebo 33 and vit 35 <sep>', 'adult patients with dermal reactions following yellow jacket stings <sep> patients with solely dermal reactions <sep> 55 patients eligible for the study 29 consented to randomization 15 to vit 14 to epipen <sep>', '41 patients with previous large local reactions and positive venom skin tests caused large local reactions 16 cm or larger in 34 patients and 29 consented to treatment <sep>', 'thirty patients 18 male patients mean age 44.5 years were enrolled and 26 completed the study with 1 dropout in the active group and 3 dropouts in the placebo group <sep> patients with llrs who were monosensitized to honeybee <sep>', '242 children 2 through 16 years of age each of whom had had a systemic allergic reaction affecting only the skin to an insect sting <sep> children with allergy to insect stings <sep>'], 'interventions': ['m pilosula vit <sep> placebo <sep> immunotherapy in accordance with the semirush hyposensitisation regimen or placebo <sep> m pilosula venom immunotherapy vit <sep> ant venom immunotherapy <sep>', 'vit <sep> vit or epipen <sep> immunotherapy <sep> epinephrine auto-injector and not venom immunotherapy vit <sep>', 'venom immunotherapy <sep> venom immunotherapy <sep>', 'sublingual immunotherapy <sep> placebo <sep> slit or placebo <sep> slit <sep> sublingual immunotherapy slit <sep>', 'immunotherapy with insect venom <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",we found venom immunotherapy using extracted insect venom to be an effective therapy for preventing further allergic reactions to insect stings which can improve quality of life. the treatment carries a small but significant risk of systemic adverse reaction.
202,"{'outcomes': ['disability <sep> cortical excitability <sep> motor function recovery <sep> rating scales <sep> cortical excitability <sep>', 'simple and choice reaction time and improved performance of the purdue pegboard test <sep> motor function <sep>', 'fugl-meyer score barthel index and central spinal cord motor conduction time cmct <sep> effective rate <sep> motor function <sep> fugl-meyer scores <sep>', 'neuropsychologic battery and electroencephalogram <sep> cognitive performance and electroencephalogram <sep> motor function performance <sep> motor function and corticospinal excitability <sep> motor function improvement and corticospinal excitability change <sep> safety <sep> corticospinal excitability <sep>', 'motor-evoked potential frequency <sep> frequency of motor-evoked potentials in biceps and triceps muscle function torque about elbow and purposeful movement action research arm test <sep>', 'ham-d scores response and remission rates <sep> reduction of ham-d scores and frontal gray and white matter volumes <sep> depressive symptoms <sep> mild adverse effects <sep> cognitive functioning <sep> poststroke recovery and mortality <sep>', 'cortical excitability and walking performance <sep> spatial asymmetry of gait <sep> motor-evoked potential mep lower-extremity fugl-meyer score and gait performance <sep> motor control and walking ability <sep>', 'excitability <sep> pinch force <sep> motor learning <sep> motor function <sep>', 'dexterity force interhemispheric inhibition and corticospinal excitability <sep> greater behavioral and neurophysiologic outcomes <sep> cumulative rebalance of excitability <sep>', 'disability scales <sep>', 'wolf motor function test wmft and the motor activity log mal)--amount of use and on secondary outcome measures including the box and block test bbt and the mal <sep> motor learning <sep>', 'standardized behavioral inattention test bit <sep> bit scores <sep> neglect symptoms <sep> hyperexcitability of lh parieto-frontal circuits <sep> safety and efficacy <sep>', 'cortical excitability <sep> basal rating scales <sep> clinical disability <sep> excitability of the non-stroke hemisphere and increased excitability of the stroke hemisphere <sep> motor function recovery <sep> motor disability <sep> rating scales <sep> cortical excitability <sep> excitability of the stroke hemisphere <sep>', 'age laterality indices or mean aachen aphasia test scores <sep> change in laterality indices as quantified by activation positron emission tomography <sep> clinical efficacy <sep> aachen aphasia test total score <sep> activation shift toward the right hemisphere <sep>', 'mean grip strength <sep> grip strength <sep> grip strength and the melbourne assessment of upper extremity function mauef <sep> arterial ischaemic stroke ais <sep> day 10 mauef score <sep>', 'nhpt baseline repetitions <sep> motor function <sep> stimulus intensity <sep>'], 'punchline_text': ['a significant rtms x time interaction was obtained indicating that real and sham rtms had different effects on rating scales. <sep>', 'patients showed a significant decrease in simple and choice reaction time and improved performance of the purdue pegboard test with their affected hand after rtms of the motor cortex in the intact hemisphere as compared with sham rtms. <sep>', 'the effective rate was 90.5 in the rehabilitation subgroup and 68.3 in the control group p  0.05). <sep>', 'these effects were not observed in the sham rtms group affected and unaffected hand and in the unaffected hand in the active rtms group. <sep>', 'in the real-rtms  realvmc group motor-evoked potential frequency increased 14 for biceps and 20 for triceps whereas in the placebo-rtms  placebovmc group it decreased 12 for biceps and 6 for triceps. <sep>', 'there were no significant changes in cognitive functioning between the active and the sham stimulation groups. <sep>', 'outcomes including motor-evoked potential mep lower-extremity fugl-meyer score and gait performance were measured before and after training. <sep>', 'these improvement in the motor function lasted for one week after rtms and motor training p  0.001).conclusion rtms improved the motor learning of the affected hand in patients after stroke thus it can apply as anew rehabilitation strategy for patients after stroke. <sep>', 'treatment induced cumulative rebalance of excitability in the 2 hemispheres and a reduction of interhemispheric inhibition in the rtms(r groups. <sep>', 'repetitive transcranial magnetic stimulation rtms or sham stimulation was given over the motor cortex daily for 10 days to two randomly assigned groups of 26 patients with acute ischemic stroke. <sep>', 'regardless of group assignment participants demonstrated significant gains on the primary outcome measures the wolf motor function test wmft and the motor activity log mal)--amount of use and on secondary outcome measures including the box and block test bbt and the mal <sep>', 'we also found that hyperexcitability of lh parieto-frontal circuits was reduced following treatment with real but not sham ctbs. <sep>', 'at the 3-month time point both of the real rtms groups had improved significantly more in different rating scales than the sham group in addition the 1 hz group performed better than the 3 hz group. <sep>', 'positron emission tomography revealed an activation shift toward the right hemisphere in the control group p=0.0165 which was absent in the intervention group. <sep>', 'contralesional inhibitory rtms was safe and feasible for patients with paediatric subcortical ais and seemed to improve hand function in patients with hemiparesis. <sep>', 'increasing evidence suggests that the contralesional motor cortex m1 inhibits the ipsilesional m1 in stroke patients. <sep>'], 'population': ['forty-eight patients with acute ischemic stroke <sep> acute stroke patients <sep> acute ischemic stroke <sep>', 'stroke patients <sep> patients within 12 months of a stroke <sep>', 'two hundred twenty and three patients with the initial attack of cerebral infarction <sep> 2 sixty patients were divided into three subgroups according to the age 35 approximately 55 n  11 56 approximately 75 n  20 and over 76 n  30 <sep> one hundred twenty and three patients were randomly further divided into rehabilitation subgroup n  63 aged 64.0 <sep> 3 forty patients aged 56 approximately 75 <sep> patients with cerebral infarction <sep>', 'stroke patients <sep> fifteen patients with chronic stroke <sep>', 'mean age 75 years mean 27 days after middle cerebral artery infarct 24 subjects completed outcome measures <sep>', 'patients with refractory depression and stroke <sep> patients with poststroke depression psd who do not respond to antidepressants <sep> poststroke depression <sep> patients with refractory psd <sep>', '24 patients with average fugl-meyer lower limb scores of 17.88  5.27 and average walking speeds of 63.81  18.25 cm/s <sep> individuals with chronic stroke <sep>', 'twenty patients with chronic subcortical stroke <sep> chronic stroke patients <sep> patients with chronic stroke <sep>', 'thirty patients <sep> chronic stroke patients with mild motor disabilities <sep> patients with chronic deficits more than 6 months poststroke <sep> chronic stroke <sep> classification of evidence <sep> chronic stroke patients with mild motor impairment <sep>', '26 patients with acute ischemic stroke <sep> acute ischemic stroke <sep>', 'nineteen individuals one or more years poststroke <sep> stroke survivors undergoing <sep>', 'patients with hemispatial neglect due to a right hemispheric rh stroke <sep> subacute stroke patients <sep> subacute ischemic stroke patients <sep> classification of evidence <sep>', 'acute ischaemic stroke <sep> 36 patients with acute ischaemic stroke participated in the study <sep>', 'aphasic stroke <sep> patients with aphasic stroke <sep> subjects with poststroke aphasia in the subacute stage <sep>', ""patients with hemiparesis <sep> patients were eligible for this parallel randomised trial if they were in the sickkids children's stroke program and had subcortical ais more than 2 years previously had transcallosal sparing were more than 7 years of age had hand motor impairment had no seizures or dyskinesia and were taking no drugs that alter cortical excitability <sep> children <sep> ten patients with paediatric stroke were enrolled median age 13.25 iqr 10.08-16.78 years mean time post-stroke 6.33 sd 3.56 years four with mild weakness two with moderate weakness and four with severe weakness <sep> patients were paired for age and weakness <sep> patients with paediatric subcortical ais <sep> chronic hemiparesis in subcortical paediatric stroke <sep>"", 'acute stroke patients <sep> acute stroke <sep> twelve patients early after subcortical stroke mean 7 days received <sep>'], 'interventions': ['repetitive transcranial magnetic stimulation <sep> real rtms <sep> rtms <sep>', 'rtms <sep> slow-frequency repetitive transcranial magnetic stimulation rtms <sep>', 'tms <sep> transcranial magnetic stimulation <sep> transcranial magnetic stimulation tms <sep>', 'active or sham rtms <sep> repetitive transcranial magnetic stimulation rtms <sep> repetitive transcranial magnetic stimulation <sep> rtms <sep>', 'placebo-rtms  placebovmc <sep> transcranial magnetic stimulation and muscle contraction <sep> repetitive transcranial magnetic stimulation rtms and voluntary muscle contraction vmc <sep> real-rtms  placebovmc c placebo-rtms  realvmc and d placebo-rtms  placebovmc <sep> placebo-rtms <sep>', 'repetitive transcranial magnetic stimulation <sep> active versus sham left prefrontal rtms <sep> rtms <sep> repetitive transcranial magnetic stimulation rtms <sep> sham left prefrontal rtms <sep>', 'rtms experimental group or sham rtms control group followed by task-oriented training <sep> rtms followed by task-oriented training <sep> repetitive transcranial magnetic stimulation rtms <sep> rtms <sep> rtms combined with task-oriented training <sep> repetitive tms <sep>', 'low-frequency repetitive transcranial magnetic stimulation rtms <sep> motor training <sep> hz rtms <sep> rtms <sep> sub-threshold rtms over the unaffected hemisphere 1 hz 25 minutes or sham stimulation <sep>', 'pt rtms(r)-pt <sep> stimulation was either real rtms(r or sham rtms(s <sep> hz rtms <sep> combined time-locked repetitive transcranial magnetic stimulation rtms and physical therapy pt intervention <sep>', 'repetitive transcranial magnetic stimulation <sep> repetitive transcranial magnetic stimulation rtms or sham stimulation <sep> real rtms <sep>', 'constraint-induced therapy cit <sep> repetitive transcranial magnetic stimulation <sep> repetitive transcranial magnetic stimulation rtms <sep> rtms <sep> rtms  cit <sep> sham rtms  cit <sep>', 'continuous theta-burst stimulation ctbs <sep> bifocal transcranial magnetic stimulation tms <sep> ppc <sep> lh <sep>', 'hz repetitive transcranial magnetic stimulation <sep> rtms <sep> hz repetitive transcranial magnetic stimulation rtms <sep> real rtms 1 and 3 hz and third group received sham stimulation daily for 5 days <sep>', '1-hz repetitive transcranial magnetic stimulation <sep> conventional speech and language therapy multiple sessions of repetitive transcranial magnetic stimulation either over the right-hemispheric inferior frontal gyrus intervention group or over the vertex control group <sep> positron emission tomography <sep> repetitive transcranial magnetic stimulation <sep> repetitive transcranial magnetic stimulation <sep>', 'sham treatment or inhibitory low-frequency rtms over contralesional motor cortex <sep> contralesional inhibitory rtms <sep> contralesional repetitive transcranial magnetic stimulation <sep> contralesional inhibitory repetitive transcranial magnetic stimulation rtms <sep> rtms <sep>', 'placebo <sep> placebo rtms <sep> dexterity by single session low-frequency repetitive transcranial magnetic stimulation <sep> 1200 stimuli of real and placebo rtms <sep> inhibitory 1~hz repetitive transcranial magnetic stimulation rtms <sep> rtms <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",current evidence does not support the routine use of rtms for the treatment of stroke. further trials with larger sample sizes are needed to determine a suitable rtms protocol and the long-term functional outcome.
203,"{'outcomes': ['total assessment scores of measures of cognition clinical status activities of daily living affect and behavior <sep>', 'slow cognitive decline <sep> cog score 1-step worsening on the global clinical dementia rating scale 15-point decline on the adcs activities of daily living inventory institutionalization or death <sep> 1-year change in the alzheimer disease assessment scale-cognitive adas-cog subscale score <sep> fatigue dizziness and hypertension <sep> 1-year mean sd change in adas-cog scores <sep> serious adverse events <sep> clinical dementia rating scale sum-of-boxes the neuropsychiatric inventory the quality of life-ad and the time to attainment of significant end points 4-point decline from baseline adas <sep> alzheimer disease progression <sep>', 'mean badls score <sep> bleeds that led to admission to hospital <sep> cognition assessed with the mini-mental state examination mmse and functional ability assessed with the bristol activities of daily living scale badls <sep> fatal cerebral bleeds <sep> intention to treat <sep> mean mmse score <sep> time to formal domiciliary or institutional care progress of disability behavioural symptoms caregiver wellbeing and care time <sep>', ""alzheimer's disease <sep> cognitive subscale of the ad assessment scale adas-cog and score on the clinician's interview based impression of change with caregiver input cibic <sep>"", ""withdrawal rates <sep> efficacy and safety <sep> alzheimer's disease assessment scale cognitive and noncognitive subsections global deterioration scale clinical global impression of change mini-mental state examination instrumental activities of daily living physical self-maintenance scale and a caregiver-rated global impression of change <sep>"", ""cognitive progression of alzheimer's disease <sep> adas-cog score worsening <sep> alzheimer disease assessment scale cognitive adas-cog subscale score <sep> changes in mmse cdr basic and instrumental activities of daily living scales and neuropsychiatric inventory npi <sep>"", 'adverse reactions <sep>', ""alzheimer's disease progression <sep> cognitive subscale of the ad assessment scale adas-cog <sep> mini-mental state examination the clinician's interview based impression of change with caregiver input the noncognitive subscale of the adas the neuropsychiatric inventory and the interview for deterioration in daily life in dementia <sep>"", ""alzheimer's disease assessment scale-cognitive behavior adas-cog composite score and the week 52 clinician's interview-based impression of change plus cibic <sep> cibic scores <sep> tolerated <sep> efficacy and safety <sep> change in adas-cog scores <sep>"", '1-year change in the cognitive subscale of the ad assessment scale <sep> rate of cognitive decline <sep> cognitive decline <sep> behavioral decline <sep>'], 'punchline_text': ['short-term therapy with nimesulide compared with placebo had no significant effect on total assessment scores of measures of cognition clinical status activities of daily living affect and behavior. <sep>', 'fatigue dizziness and hypertension were more commonly reported in the active drug groups and more serious adverse events were found in the active treatment group than in the placebo group. <sep>', 'there were no obvious differences between the groups in any other outcome measurements. <sep>', 'no significant differences between treatments were found on the mean change from baseline error score for the adas-cog rofecoxib  4.84 placebo  5.44 difference  0.60 or mean score on the cibic rofecoxib  4.90 placebo  4.87 difference  0.03 over 12 months. <sep>', 'there were no serious drug-related adverse events. <sep>', 'fifty-one patients 77 in the ibuprofen vs 46 70 in the placebo group completed the protocol p>0.20). <sep>', 'over a battery of cognitive tests indomethacin patients improved 1.3  <sep>', 'this difference 1.5 points ci 4.5-7.5 was not statistically significant and neither were any of the secondary outcome measures. <sep>', 'at 52 weeks change in adas-cog scores from baseline was similar for placebo and celecoxib 200 mg bid groups 5.00 and 4.39 respectively). <sep>', 'there was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis or in a secondary analysis considering completers only. <sep>'], 'population': [""forty persons with probable ad most of whom were taking cholinesterase inhibitors <sep> participants who tolerated the drug well and perceived benefit were invited to continue open-label nimesulide treatment <sep> alzheimer's disease <sep>"", ""participants with inflammatory diseases that might respond to the study medications were excluded <sep> participants with mild-to-moderate ad mini-mental state examination score of 13-26 were recruited from december 1999 to november 2000 using clinic populations referrals from community physicians and local advertising <sep> patients with mild-to-moderate ad <sep> forty ambulatory treatment centers affiliated with the alzheimer's disease cooperative study consortium <sep> 474 participants screened 351 were enrolled <sep>"", ""alzheimer's disease ad2000 <sep> 310 community-resident patients who had ad and who had no potential indication or definite contraindication for <sep> patients with ad <sep> patients had a median age of 75 years 156 patients had mild ad 154 had moderate ad and 18 had concomitant vascular dementia <sep>"", 'four hundred eighty-one patients 70 completed assessments and remained on treatment at 12 months <sep> 692 patients with mild or moderate ad aged 50 years or older <sep> patients with established ad <sep>', ""alzheimer's disease ad <sep> 41 patients with mild-moderate ad <sep> alzheimer's disease <sep>"", 'patients with mild to moderate ad <sep> seven ad outpatient treatment centers screened 530 patients 132 of whom were enrolled <sep> participants with mild-moderate ad mini-mental state examination score 15 26 clinical dementia rating 0.5-1 65 years or older with reliable caregivers were recruited between april 2003 and september 2004 <sep>', ""alzheimer's disease <sep>"", ""patients with alzheimer's disease ad <sep> may 2000 and september 2005 in two hospitals in the netherlands <sep> 51 patients with mild to moderate ad <sep> group 19 out of 25 patients completed the study and 19 out of 26 patients in the <sep>"", ""elderly population with a complex chronic medical condition <sep> alzheimer's disease <sep> patients  or 50 years with established mild-to-moderate ad <sep>"", ""138 subjects <sep> alzheimer's disease <sep> subjects with ad <sep>""], 'interventions': ['placebo <sep> active drug <sep> nimesulide 100 mg by mouth twice daily or matching placebo <sep> nonsteroidal anti-inflammatory drugs nsaid <sep> nimesulide <sep>', 'rofecoxib <sep> traditional nonselective nsaid naproxen <sep> placebo <sep> rofecoxib or naproxen vs placebo <sep> cholinesterase inhibitors estrogen low-dose aspirin and vitamin e <sep> naproxen sodium 220 mg or placebo <sep> selective cyclooxygenase cox 2 inhibitor rofecoxib <sep> naproxen <sep>', 'aspirin <sep> open-label aspirin n=156 one 75-mg enteric-coated tablet per day to continue indefinitely or to avoid aspirin <sep> aspirin <sep>', 'rofecoxib <sep> rofecoxib or placebo <sep> rofecoxib <sep>', 'nsaid <sep> placebo <sep> diclofenac <sep> diclofenac/misoprostol <sep> misoprostol d/m <sep>', 'ibuprofen or flurbiprofen <sep> placebo <sep> esomeprazol or placebo <sep> non-selective nsaid ibuprofen <sep> ibuprofen <sep> ibuprofen <sep>', 'placebo <sep> indomethacin <sep>', 'indomethacin or placebo <sep> placebo <sep> indomethacin <sep> nonselective nonsteroidal anti-inflammatory drug nsaid indomethacin <sep> omeprazole <sep>', 'placebo <sep> placebo and celecoxib <sep> celecoxib <sep> celecoxib <sep> cyclooxygenase-2 cox-2 <sep>', 'prednisone <sep> placebo <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",based on the studies carried out so far the efficacy of aspirin steroid and nsaids traditional nsaids and cox-2 inhibitors is not proven. therefore these drugs cannot be recommended for the treatment of ad.
204,"{'outcomes': ['baseline modified mini-mental state examination scores <sep> dementia or mci incidence <sep> overall hr for probable dementia <sep> dementia or cognitive decline <sep> mild cognitive impairment mci <sep> incidence rates <sep>', 'mean sd time <sep> mild cognitive impairment <sep> hazard ratio hr for probable dementia <sep> health risks <sep> incidence of dementia and mild cognitive impairment <sep>', 'immediate recall condition <sep> memory performance <sep> estradiol levels and mood changes <sep> verbal memory performance <sep> estradiol levels <sep> cognitive performance <sep> memory and mood verbal memory changes <sep>', 'plasma estrone and estradiol levels <sep> immediate or delayed recall of visual material delayed recall of paragraphs or digit span scores <sep> memory function <sep>', 'mood cognitive function and quality of life <sep> beck depression inventory bdi scores <sep> mental state and quality of life <sep> mood cognition and quality of life <sep> quality of life scores as measured by the sf-36 and cognitive function camcog block design memory for faces california verbal learning test cvlt and verbal fluency vf <sep> cognitive function mood and quality of life <sep> adverse reactions <sep>', 'cognitive test scores or on the 36-item short-form general health survey <sep> health-related quality of life in physical and mental domains <sep> bone density <sep> cognition and health-related quality of life <sep> change in cognitive or 36-item short-form general health survey scores <sep> cognitive function and quality of life <sep> cognitive function or in health-related quality of life <sep> global cognitive function verbal and visuospatial memory language executive function and semantic memory <sep>', 'overall quality of life <sep> beck depression inventory <sep> income management scale of the profile of adaptation to life <sep> minnesota multiphasic personality inventory-168 the profile of adaptation to life and the beck depression inventory <sep> psychological function <sep> wechsler adult intelligence scales measuring both digit span and digit symbol <sep> wechsler adult intelligence scales <sep>', 'cognitive performance <sep> change from baseline and rate of change from baseline for the following psychometric tests verbal fluency test weschler paired associate learning and 20 min delayed recall trailmaking a and b tests cancellation random letter and random form tests <sep> cognitive performance measures <sep>', 'associative verbal memory <sep> state anxiety <sep> correct reproductions <sep> aggressivity <sep> pupillary and skin conductance variables <sep> verbal and visual memory <sep> extraversion <sep> somatic complaints and trait anxiety <sep> performance mood and personality <sep> noopsyche thymopsyche personality and psychophysiological measures <sep>', 'balance scores performance measures <sep> physical performance <sep> physical activity scale of the elderly <sep> physical measures of mobility ability to rise from a chair self-reported activities of daily living physical activity scores or falls <sep> instrumental activities of daily living <sep> physical performance measures functional ability physical activity falls and cognitive function <sep> cognition or balance <sep> time to rise from a chair timed walking balance instrumental activities of daily living physical activity scale of the elderly folstein mini-mental state examination and falls <sep> rising time <sep> walking normal <sep> folstein mini-mental state examination <sep>', 'specific cognitive functions <sep> negative affect or depressive symptoms <sep> verbal memory <sep> figural memory <sep>', 'cortisol plasma levels <sep> plasma estradiol levels <sep> cognitive effects <sep> frontal lobe functions <sep> visuospatial abilities <sep> memory frontal lobe functions inhibition and planning and visuospatial abilities mental rotation <sep> memory function <sep> cortisol plasma levels <sep> hpa response to task-induced stress <sep> memory visuospatial abilities and frontal lobe function <sep> mental rotation task <sep> estrogen plasma levels <sep>', 'executive functioning <sep> cognitive functioning <sep>', 'error rates <sep> cognitive performance <sep> serum estradiol e2 and fsh levels <sep> cognitive speed and accuracy attention and memory <sep> cognitive performance and serum e2 levels <sep> cognitive performance <sep> cognition <sep>', 'working memory <sep> verbal memory <sep>', 'central processing speed or postural stability <sep> cognitive performance <sep> postural stability <sep> postural instability and falls <sep>', 'actual performance of the verbal and nonverbal memory tasks <sep> brain activation patterns <sep>'], 'punchline_text': ['incidence rates for probable dementia in the estrogen-alone trial were statistically similar to those in the estrogen plus progestin trial 45 vs 22 per 10 000 person-years for cee plus mpa vs placebo respectively p .11). <sep>', 'treatment effects on mild cognitive impairment did not differ between groups hr 1.07 95 ci 0.74-1.55 63 vs 59 cases per 10 000 person-years p .72). <sep>', 'cognitive performance was tested at baseline and after 2 weeks of estradiol or placebo treatment using verbal semantic and spatial memory tests as well as a mental rotation task and the stroop. <sep>', 'no hormonal effects were apparent on the immediate or delayed recall of visual material delayed recall of paragraphs or digit span scores. <sep>', 'intention-to-treat analysis showed that the active and placebo groups did not differ in their response to treatment in any of the outcome measures p>0.05). <sep>', 'there was no consistent evidence that the effect of treatment on change in cognitive or 36-item short-form general health survey scores depended on the level of baseline endogenous estradiol. <sep>', 'the income management scale of the profile of adaptation to life improved p less than .05 with estrogen as did the beck depression inventory p less than .05 but these results were not dose-related. <sep>', 'at baseline women in the hrt group reported a younger age of onset of menopause and a higher prevalence of hysterectomy but otherwise did not differ from women in the placebo group. <sep>', 'the freiburger personality inventory showed an improvement in aggressivity after regimen a as compared with the preceding placebo as well as an improvement in striving after dominancy after both regimen a and regimen ev as compared with pre-treatment but also after regimen a as compared with regimen ev. <sep>', 'over 3 years except for balance scores performance measures declined significantly all p<.05). <sep>', 'cee  mpa had a negative impact on verbal memory p or 0.01 and a trend to a positive impact on figural memory p  0.012 over time compared with placebo but other cognitive domains were not affected. <sep>', 'ehr was found to increase the hpa response to task-induced stress as indicated by an increase in cortisol plasma levels. <sep>', 'body mass index a gross estimate of circulating estrogen was significantly positively related to change in attentional and psychomotor processes regardless of treatment group and to a weaker extent verbal memory but only in the estrogen-treated group. <sep>', 'on the most demanding test of working memory the reaction times p  .045 and error rates p  .043 differed between treatments yet this finding proved to be an effect of learning rather than treatment. <sep>', 'before hormone supplementation working memory tested with the subject ordered pointing test sop was worse in older subjects than younger subjects and there was no evidence of gender differences at either age. <sep>', 'results indicate that those receiving estrogen had no significant improvement in postural stability at 2 and 8 months of treatment relative to those receiving placebo. <sep>', 'treatment with estrogen increased activation in the inferior parietal lobule during storage of verbal material and decreased activation in the inferior parietal lobule during storage of nonverbal material. <sep>'], 'population': ['n  4532 or to february 29 2004 estrogen-alone n  2947 in 39 of the 40 whi clinical centers <sep> 65 years of age or older <sep> community-dwelling women aged 65 to 79 years conducted from june 1995 to july 8 2002 <sep> 93 participants receiving cee were diagnosed with either probable dementia or mci vs 69 receiving <sep> 76 participants were diagnosed with mci in the cee group vs 58 in the <sep> women <sep> postmenopausal women <sep> older women <sep> 47 participants were diagnosed with probable dementia of whom 28 were assigned to <sep>', ""women receiving combined hormone therapy <sep> enrolling participants from the women's health initiative whi estrogen plus progestin trial in may 1996 <sep> postmenopausal women aged 65 years or older <sep> 61 women were diagnosed with probable dementia 40 66 in the <sep> 4894 eligible participants of the whi study 4532 92.6 postmenopausal women free of probable dementia aged 65 years or older and recruited from 39 of 40 whi clinical centers were enrolled in the whims <sep> postmenopausal women <sep> postmenopausal women <sep>"", 'healthy postmenopausal women <sep> postmenopausal elderly women <sep> women who had been menopausal for an average of 17 years <sep> 38 healthy elderly women <sep>', '19 women who required a hysterectomy and bilateral oophorectomy for benign disease <sep> surgically menopausal women <sep>', 'one hundred and fifteen women <sep> nineteen women treated with <sep> older women <sep> women aged 70 years and older <sep> women at increased risk of cognitive decline aged 70 years and over <sep>', 'postmenopausal women <sep> nine clinical centers in the united states <sep> postmenopausal women n  417 aged 60 to 80 years with a normal bone density for age and an intact uterus <sep>', '36 asymptomatic women aged 45-60 <sep> postmenopausal women <sep> asymptomatic postmenopausal women <sep>', 'women over 75 years who do not have dementia or depression <sep> elderly women <sep> women aged 75 years and older <sep> fifty-two elderly postmenopausal women age range 75-91 years without known contraindications to hrt or evidence of dementia or depression were enrolled <sep>', 'menopausal syndrome patients <sep> 49 women 16 17 16 valid patients per arm aged between 46 and 67 years mean 58 58 56 years respectively with the diagnoses of insomnia g 47.0 related to postmenopausal syndrome n 95.1 <sep>', 'community-dwelling elderly women <sep> elderly women <sep> 373 community-dwelling women aged 65 years and older to receive <sep>', ""postmenopausal women <sep> older women <sep> postmenopausal women 1416 aged 65 yr and older free of probable dementia and enrolled in whi and the whi memory study whims trial of combination estrogen and progestin for a mean of 3 yr and followed for a mean of 1.35 yr were studied <sep> participants were women from 14 of 40 clinical centers of the women's health initiative whi <sep>"", 'healthy elderly women <sep> elderly healthy female subjects <sep> women in a clinical setting who either needed or wished to have the estrogen replacement and are mostly in the perimenopausal age-band <sep> elderly female subjects who did not suffer any of the postmenopausal symptoms and had never taken estrogen hormone replacement ehr previously <sep> elderly healthy females <sep>', 'postmenopausal women <sep> healthy postmenopausal women <sep>', 'postmenopausal women <sep> sixty-two women completed the study <sep> 70 healthy postmenopausal women aged 47-65 years with previous hysterectomy <sep>', 'older men <sep> older men and women <sep>', '87 elderly female subjects age  69 <sep> women with dementia <sep> healthy older female population <sep>', 'postmenopausal women during working memory tasks <sep> forty-six postmenopausal women aged 33 to 61 years mean sd age 50.8 4.7 years <sep> postmenopausal women in specific brain regions <sep> postmenopausal women <sep> 1996 through 1998 <sep> community volunteers tested in a hospital setting <sep>'], 'interventions': ['conjugated equine estrogens cee plus medroxyprogesterone acetate mpa <sep> cee <sep> placebo <sep> hormone therapy <sep> estrogen plus progestin <sep> cee vs matching placebo <sep> estrogen therapy <sep> cee estrogen-alone trial or cee plus mpa estrogen plus progestin trial <sep> estrogen alone and estrogen plus progestin <sep> cee alone and cee plus mpa <sep> conjugated equine estrogens <sep> mpa <sep>', '1 daily tablet of 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate <sep> matching placebo <sep> placebo <sep> estrogen plus progestin therapy <sep> estrogen plus progestin <sep> estrogen plus progestin therapy <sep> estrogen plus progestin <sep>', 'placebo <sep> estradiol replacement <sep> estradiol or placebo <sep> transdermal estradiol treatment <sep> transdermal estradiol <sep>', 'estrogen <sep> placebo pl injections <sep> estrogen e <sep>', 'placebo <sep> hormone replacement estrogen plus progestin <sep> estradiol <sep> estradiol replacement therapy <sep> unopposed estradiol replacement therapy ert <sep>', 'unopposed ultra-low-dose transdermal estradiol <sep> placebo <sep> ultra-low dose of unopposed transdermal estradiol <sep> ultra-low-dose unopposed transdermal estradiol <sep> ultra-low-dose transdermal estradiol <sep>', 'estrogen <sep> placebo and conjugated equine estrogens <sep>', 'hormone replacement therapy <sep> hormone replacement therapy hrt <sep> placebo <sep> placebo or conjugated estrogens at 0.625 mg/d plus trimonthly medroxyprogesterone acetate <sep>', 'placebo <sep> climodien 2/3  estradiol valerate cas 979-32-8 2 mg  the progestin dienogest cas 65928-58-7 3 mg  regimen a estradiol valerate 2 mg  regimen ev and placebo  regimen p <sep> climodien 2/2 estradiol valerate 2 mg  dienogest 2 mg  regimen <sep> combined estrogen-progestin regimen versus estrogen alone <sep> combined estrogen-progestin regimen climodien <sep>', 'hormone replacement <sep> placebo <sep> conjugated equine estrogen 0.625 mg/day plus or minus medroxyprogesterone 2.5 mg/day vs placebo <sep>', 'placebo <sep> cee  mpa <sep> hormone therapy <sep> medroxyprogesterone acetate mpa <sep> combination estrogen plus progestin hormone treatment <sep> conjugated equine estrogen cee <sep>', 'estrogen hormone replacement <sep> placebo <sep> estrogens <sep> estradiol <sep> ehr <sep> ehr progynova ts transdermal estradiol <sep>', 'placebo <sep> ert <sep> 17-beta estradiol <sep> estrogen replacement therapy ert <sep> estrogen replacement therapy <sep> progesterone <sep>', 'short-term estrogen replacement therapy <sep> estrogen replacement therapy <sep> estrogen replacement therapy <sep> placebo <sep>', 'testosterone supplementation <sep> sex steroid supplementation <sep> estrogen replacement <sep>', 'estrogen replacement therapy <sep> estrogen therapy versus placebo <sep> placebo <sep> estrogen replacement therapy <sep>', 'placebo <sep> functional magnetic resonance imaging <sep> conjugated equine estrogens <sep> estrogen <sep> estrogen <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is good evidence that both ert and hrt do not prevent cognitive decline in older postmenopausal women when given as short term or longer term up to five years therapy. it is not known whether either specific types of ert or hrt have specific effects in subgroups of women although there was evidence that combined hormone therapy in similarly aged women was associated with a decrement in a number of verbal memory tests and a small improvement in a test of figural memory. there is insufficient evidence to determine whether subgroups of women using specific types of hormone therapy could benefit from treatment. it remains to be determined whether factors such as younger age 60 years of age type of menopause surgical or natural and type of treatment type of estrogen with or without a progestagen mode of delivery transdermal oral or intramuscular and dosage have positive effects at a clinically relevant level. in addition whether the absence or presence of menopausal symptoms can modify treatment effects should be investigated in more detail. large rcts currently underway in the usa may be able to provide answers to these uncertainties by the year 2010. in the meantime based on the available evidence ert or hrt cannot be recommended for overall cognitive improvement or maintenance in older postmenopausal women without cognitive impairment.
205,"{'outcomes': ['free water clearance values <sep> renal dysfunction <sep> creatinine clearance <sep> renal function <sep> prevalence of postoperative hemodialysis <sep> renal functions <sep> postoperative renal functions <sep> creatinine levels <sep>', 'differential white cell counts <sep> postoperative neutrophil counts <sep> central venous blood samples <sep> cd11b surface expression on neutrophils <sep> neutrophil counts <sep> neutrophil activation <sep> cd11b expression <sep> white cell and neutrophil counts <sep> cd11b levels <sep> interleukin 8 concentrations <sep>', 'glucose homeostasis <sep> insulin-like growth factor-1 <sep> average blood glucose <sep> insulin-like growth factor-1 standard deviation score <sep> fasting blood glucose <sep> glucose homeostasis <sep> blood glucose <sep> mortality and morbidity <sep> insulin-like growth factor binding protein-1 <sep> ratio of insulin-like growth factor-1 concentration <sep> serum insulin insulin-like growth factor-1 and its binding protein <sep>', 'cardiac troponin i concentration <sep> total amount of cardiac troponin i released <sep> lower release of cardiac troponin <sep> i concentrations <sep>', 'preoperative characteristics and risk factors <sep> early mortality <sep> mean mechanical ventilation time <sep> mean number of anastomoses <sep> postoperative stay <sep> major postoperative complications <sep> myocardial infarction <sep> survival free of any cardiac-related event <sep> intensive care unit stay <sep> mechanical ventilation support and length of intensive care unit and postoperative stay <sep>', 'postoperative et levels <sep> pulmonary artery pressures ventilation requirement and hospital stay <sep> pulmonary artery pressures ventilation requirement and hospital stay <sep> postoperative systemic arterial et levels <sep> et levels <sep>', 'macce <sep> cardiac-related death <sep> myocardial infarction <sep> all-cause mortality <sep> mortality <sep> composite of major adverse cardiac and cerebrovascular events macce including all-cause mortality acute myocardial infarction cardiac arrest with successful resuscitation low cardiac output syndrome/cardiogenic shock stroke and coronary reintervention <sep>', 'graft-patency rates <sep> troponin t levels <sep> area under the curve of troponin t levels <sep> graft-patency rate <sep> median postoperative length of stay <sep> myocardial damage <sep> patency rate <sep>', 'neurocognitive impairment <sep> deterioration in scores <sep> incidence of neurocognitive impairment <sep> major deterioration <sep>', 'revascularization <sep> death neurological injury renal failure respiratory failure and operative myocardial infarction <sep> postoperative mortality and morbidity <sep> morbidity <sep> hospital mortality and morbidity <sep> hospital deaths <sep>', 'oxidative stress <sep> oxidative stress and inflammation <sep> complement c3a and elastase levels <sep> il-8 tnf-alpha and se-selectin <sep> nitrotyrosine <sep> prior anesthesia values of lipid hydroperoxides <sep> protein carbonyls <sep>', 'elevated d-dimer levels <sep> roteg signs of hyperfibrinolysis <sep> roteg signs of fibrinolysis <sep>', 'demographic makeup parsonnet score functional status and extent of coronary revascularization <sep> urinary rbp <sep> serum cr and blood urea <sep> glomerular and tubular injury <sep> urinary excretion of microalbumin and retinol binding protein rbp indexed to creatinine cr <sep> negative fluid balance <sep> fluid balance serum cr and blood urea <sep> renal complication or serum markers of kidney dysfunction <sep> cr <sep> mortality or renal complication <sep>', 'main morbidity and hospital moratlity <sep> creatine kinase-mb ck-mb release the amount of bleeding and intensive care unit icu stay p<0.05 <sep> hospital mortality and morbidity <sep>', 'cd97 expression of granulocytes pmn and monocytes mc <sep> leukocyte activation <sep> expression of adhesion molecules <sep> rate of active cd97-positive lymphocytes <sep> expression of cd97 and adhesion molecules cd11 cd18 <sep>', 'wbc and neutrophil counts <sep> expression of adhesion molecules cd11 cd18 of leukocytes <sep> adhesion molecule expression <sep> cd11a and cd18 expression of leukocytes <sep> plasma level of proinflammatory cytokine tumor necrosis factor tnf)-alpha <sep> inflammatory response reactions <sep> white blood cell wbc and neutrophil count <sep> level of tnf-alpha <sep>', 'ptx3 levels <sep> cpb ptx3 levels <sep>', 'oxidative stress <sep> oxidative stress <sep> mda levels <sep> sod levels <sep> glutathione peroxidase levels <sep> serial blood samples plasma malondialdehyde mda as index of lipid peroxidation red blood cells glutathione peroxidase gpx and superoxide dismutase sod <sep> blood collection times <sep>', 'c-reactive protein and systemic levels of tnf-alpha tnf specific receptors rp1 and rp2 interleukin-6 il-6 and soluble il-2 receptors sil-2r <sep> systemic nitric oxide production total nitrate/nitrite nox <sep> expression of systemic proinflammatory cytokines <sep> nitric oxide <sep> c-reactive protein levels <sep> systemic nox levels <sep> systemic inflammatory response syndrome and early catecholamine requirement <sep> tnf-system and sil-2r <sep> il-6 expression <sep>', 's100 levels <sep> peak s100 levels <sep> s100 concentration <sep> nonfatal myocardial infarctions <sep> neurologic deficit <sep> resternotomy for bleeding <sep> hospital death <sep>', 'respiratory morbidity <sep> forced expiratory volumes <sep> average stay in the intensive care unit <sep> pulmonary function <sep> earliest extubation time <sep> forced vital capacity fvc values <sep>', 'peak and total s100 levels and n-acetyl-glucosaminidase activity <sep> inflammatory response myocardial neurologic and renal injury <sep> interleukin-6 interleukin-8 c3a and troponin i levels after surgery <sep> renal tubular function <sep> inflammatory markers troponin i protein s100 and free hemoglobin <sep> free hemoglobin levels <sep> organ function and inflammatory response <sep> hospital deaths or major postoperative complications <sep> inflammatory response and organ function <sep>', 'hospital stay <sep> reoperation for bleeding <sep> serum levels of cardiac troponin i <sep> hospital mortality <sep> time of inotrope drugs support <sep> early mortality and morbidity <sep> myocardial function <sep> contractile cardiac function <sep> incidence of in-hospital death <sep> incidence of in-hospital death and outcomes low cardiac output syndrome prolonged mechanical and pharmacologic cardiac support prolonged mechanical ventilation support and postoperative length of stay in intensive care unit and hospital <sep> evaluation of myocardial infarct size measured by the perioperative serum release of cardiac troponin <sep> cardiac-related late deaths <sep> time of mechanical ventilation <sep> incidence of low cardiac output syndrome <sep> intensive care unit stay <sep>', 'levels of creatine kinase mass <sep> hemoglobin levels <sep> levels of the same markers and blood lactate <sep> intraoperative and postoperative data <sep> release of troponin t <sep> levels of tumor necrosis factor-alpha <sep> cardiac release of interleukin-6 tumor necrosis factor-alpha and blood lactate <sep> release of interleukin-6 <sep> plasma levels of interleukin-6 and tumor necrosis factor-alpha <sep>', 'cardiac troponin <sep> heart-type fatty acid-binding protein levels <sep> total amount of heart-type fatty acid-binding protein cardiac troponin <sep>', 'early graft patency <sep> neuron-specific enolase levels <sep> operation time <sep> maximum creatine kinase-mb levels <sep> overall early graft patency rate <sep> frequency of no need for transfusion <sep> s-100 protein levels <sep> perioperative complications <sep> clinical outcomes and s-100 protein neuron-specific enolase and maximum creatine kinase-mb levels <sep> number of arterial grafts <sep> rate without stenosis <sep> stenosis-free patency rate <sep> hospital deaths <sep>', 'deterioration of deltapo(2 <sep> systemic release of il-8 <sep> systemic inflammatory response <sep> crp <sep> release of il-6 <sep> il-10 <sep> neutrophils <sep> systemic release of interleukin il)-6 8 <sep> oxygenation and release of inflammatory mediators <sep> and 10 c-reactive protein crp and neutrophils <sep> opcab <sep> oxygenation shunt  and ventilation-perfusions mismatch described as deltapo(2 kpa <sep>', 'gastric intramucosal ph phi gastric-arterial carbon dioxide partial pressure difference co(2 gap whole-body oxygen delivery do(2 and consumption vo(2 and whole-body oxygen extraction fraction <sep> mean sd <sep> gastric mucosal oxygenation <sep> gastric mucosal hypoxia <sep> cpb time <sep>', 'cec numbers and proportions of endothelial apoptosis <sep> endothelial apoptosis and circulating endothelial cells <sep> number of circulating endothelial cells and apoptotic endothelial cell death <sep> apoptotic and normal cells <sep> cec numbers and proportions of apoptotic hec <sep> hec apoptosis <sep> cec and proportions of apoptotic hec <sep> mean cec-number <sep> endothelial response <sep>', 'early graft patency <sep> graft patency <sep> proportion of patent grafts <sep> major adverse events and neuropsychological functioning <sep> graft patency <sep> occluded graft <sep> coronary artery bypass graft patency <sep> functional class and positive treadmill exercise tests <sep> mean number of grafts <sep> overall graft patency rate <sep> coronary bypass graft patency <sep> thirty-day complications neuropsychological functioning and one-year clinical and functional outcomes <sep> raw graft patency rate <sep> clinical outcomes and neuropsychological functioning <sep>', 'troponin-t and creatine kinase isoenzyme mb ck-mb levels <sep> interleukin-6 il-6 levels <sep> interleukin-1 interleukin-6 and myocardial enzyme response <sep> interleukin-1 il-1 <sep> il-6. il-1 <sep>', 'plasma il-6 levels <sep> serum ck-mb mass fraction troponin i and interleukin il)-6 il-8 and il-10 levels <sep> troponin i <sep> serum cytokine levels <sep> levels of troponin i and activation of cytokines <sep> serum cytokines and myocardial tissue markers <sep> myocardial damage <sep> demographic hemodynamic and respiratory parameters <sep>', 'neurocognitive function assessed using a 19-test neurocognitive battery at baseline discharge and 6 months <sep> neurocognitive deficit <sep> index admission mortality stroke low-output cardiac failure return to the operating room for bleeding and postoperative troponin release <sep> frequency of neurocognitive deficit <sep> risk ratios <sep> troponin release <sep> neurocognitive outcomes <sep> neurocognitive deficit <sep> mortality or morbidity <sep>', 'inflammatory reaction and myocardial metabolism <sep> gsh levels <sep> release of creatinine kinase <sep> myocardial metabolism and inflammation glutathione gsh superoxide dismutase sod and myeloperoxidase mp and plasma samples for indicators of oxidative stress conjugated dienes s-bdc oxidative products of proteins s-ox-prot and low-density lipoprotein ldl)-total peroxyl radical trapping antioxidant potential s-trap <sep> myocardial metabolism <sep> monobasic mb fraction of the creatinine kinase 24 h after the operation <sep>', 'quality-of-life <sep> neuropsychologic and quality-of-life outcomes <sep> quality of life <sep> neuropsychologic and quality-of-life outcomes <sep> cognitive deficits <sep>', 'isoprostanes and oxidative stress <sep> total antioxidant status <sep> plasma total antioxidant status <sep> urinary isoprostane ipf2alpha-iii levels plasma levels of free malondialdehyde and total antioxidant status <sep> cabg ipf2alpha-iii levels <sep> opcab and sharp increases during cabg <sep> perioperative oxidative stress <sep> opcab ipf2alpha-iii excretion <sep>', 'intensive care unit stay duration of intubation hospital stay and bleeding <sep> age gender new york heart association class canadian cardiovascular society functional classification of angina grade and number of cabg <sep> plasmatic creatinine urinary creatinine creatinine clearance proteinuria or osmolality <sep> urinary albumine excretion <sep> renal tubular and glomerular functions <sep>', 'levels of tissue-plasminogen activator <sep> d-dimers release <sep> discharge in vitro bleeding times <sep> platelet function and increased thrombin formation <sep> overall tissue factor production <sep> platelet function <sep> blood samples <sep> vitro bleeding time <sep> thrombin formation <sep>', 'clinical angiographic neurocognitive and quality of life outcomes <sep> graft patency <sep> shorter hospital stay <sep> graft patency <sep> shorter duration of mechanical ventilation <sep> patency of grafts better clinical outcome shorter hospital stay and better neurocognitive function <sep> neurocognitive function <sep> health related quality of life <sep> blood transfusions <sep>', 'stroke risk score <sep> stroke nor transient ischemic attack <sep> severely stenosed carotid arteries <sep> inferotemporal retinal arterial embolization and microinfarction <sep>', 'platelet activity <sep> aggregation <sep> platelet activity <sep> expression of p-selectin <sep> aspirin efficacy <sep> platelet activity and aspirin efficacy <sep> platelet activity and aspirin efficacy <sep> blood samples <sep> p-selectin expression <sep> arachidonic acid-induced platelet aggregation <sep>', 'postoperative atrial fibrillation <sep> rate of atrial fibrillation <sep> nuclear derangement <sep> postoperative atrial fibrillation <sep>', 'allogeneic blood transfusion <sep> right ventricular function <sep> diastolic function <sep> right ventricular systolic and diastolic function <sep> peak systolic and early diastolic velocities <sep> echocardiographic markers of right ventricular function <sep> right ventricular function <sep> systolic and diastolic function <sep> global systolic right ventricular function <sep> global systolic function and tricuspid early/late atrial ratio as a marker of the global diastolic function <sep>', 'hospital stay <sep> mean number of bypass grafts <sep> complete revascularization <sep> myocardial infarction <sep>', 'inflammatory response and myocardial ischaemia <sep> cumulative release of myoglobin <sep> troponin i release <sep> inflammatory response and myocardial injury <sep> release of il-6 <sep> ck-mb mass release <sep> inflammatory response interleukin il)-6 interleukin-10 icam-1 p-selectin and of myocardial injury myoglobin creatine kinase-mb ck-mb troponin i <sep> minor adverse events wound infection <sep> atrial fibrillation <sep> immediately postoperatively il-10 levels <sep>', 'permanence on the ventilator <sep> postoperative bleeding <sep> postoperative red cell count hemoglobin level and hct <sep> respiratory failure <sep> length of stay in icu <sep> length of the operation <sep>', 'interstitial lactate levels <sep> intramyocardial lactate/pyruvate ratio <sep> cumulative blood release of troponin-t <sep> energetic metabolism <sep> intramyocardial levels of glucose pyruvate and urea <sep> myocardial metabolism <sep> myocardial ischemic markers <sep> blood glucose and lactate <sep> intramyocardial concentrations of glucose urea and lactate <sep>', 'mean cardiac index <sep> low svr index <sep> mean temperature <sep> cardiac index <sep> incidence of high svr <sep> svr index responses <sep> mean svr index <sep> temperature svr index cardiac index and blood pressure <sep> 30-day mortality no stroke and no acute renal failure <sep> blood pressure responses <sep> cardiac outputs and clinical outcomes <sep> incidence of low svr and patterns of svr changes <sep>', 'quality-of-life assessments <sep> quality of life <sep> health status <sep> mean on-pump and off-pump sf-36 scores <sep>', 'peak s-100 protein <sep> peak creatine kinase <sep> circulating markers of inflammation and organ injury 2 operative results and 3 outcome at 1-year follow-up <sep> release of inflammatory markers <sep> length of hospital stay and use of blood products <sep> angina recurrence <sep> postoperative morbidity <sep> operative mortality and morbidity <sep>', 'renal failure and lesions of the circumflex artery and its branches <sep> transient neurologic dysfunction <sep> total operation time 205.10 <sep> bleeding <sep> hospital mortality and morbidity <sep> preoperative clinical characteristics <sep> hospital mortality <sep> myocardial infarction <sep> intensive care stay <sep>', 'c3a and neopterin concentrations <sep> postoperative inflammatory response <sep> tnf-alpha and il-8 <sep> plasma levels of complement c3a cytokines il-8 tnf-alpha endothelin-1 and neopterin <sep> peripheral endothelial function <sep> endothelial function <sep> tnf-alpha and il-8 release or endothelial function <sep>', 'number of hits <sep> cerebral microemboli <sep> mean intraoperative s100 <sep>', 'inflammatory response <sep> blood loss <sep> shorter ventilatory support <sep> leukocyte elastase platelet beta-thromboglobulin and complement c3a <sep> inflammatory markers <sep> systemic inflammatory response postoperative morbidity and hospital stay <sep> postoperative hospital stay <sep>', 'mean number of grafts per patient <sep> renal function and clinical outcomes <sep> deterioration renal function <sep> adverse renal outcome <sep> worsening of renal function <sep> mdrd gfr and serum creatinine levels <sep>', 'pancreatic function <sep> permeability and absorption <sep> pancreatic function <sep> monoethylglycinexylidide/lidocaine ratios and by serial measurements of transaminases aspartate transaminase and alanine-amino transferase bilirubin and alkaline phosphatase <sep> postoperative hepatocellular injury <sep> liver function <sep> aspartate transaminase and alanine-amino transferase levels <sep> serial measurements of insulin/glucagon ratio amylase and glucose <sep> amylase levels <sep> hepatic metabolic function <sep> bilirubin level <sep> splanchnic organ injury <sep> small intestine function <sep>', 'hospital stay <sep> death myocardial infarction further revascularization surgery or angioplasty or stroke <sep> higher incidence of atrial fibrillation <sep> number of grafts per patient <sep> time to extubation <sep> length of icu stay <sep> blood requirements <sep>', 'graft patency <sep> cardiac outcomes and health-related quality of life <sep> graft patency clinical and quality-of-life outcomes and cost <sep> graft patency <sep> rates of death stroke myocardial infarction angina and reintervention <sep> inhospital outcomes similar completeness of revascularization and shorter lengths of stay <sep> mean total hospitalization cost per patient at hospital discharge <sep> health-related quality of life <sep> 1-year graft patency cost and quality-of-life outcomes <sep>', 'postoperative cognitive testing <sep> neurocognitive status <sep> postoperative impairment <sep> median value of hits <sep> postoperative s-100 serum levels <sep> venous serum levels of s-100 protein <sep>', 'saphenous graft patency <sep> saphenous graft patency per patient <sep> 1-year angiographic patency <sep> arterial graft patency <sep> collateralized chronic total occlusions of native coronary arteries <sep>', 'pulmonary abnormalities <sep> alveolar-arterial oxygen gradient <sep> postoperative gas exchange <sep> mean static and dynamic lung compliance postoperatively <sep> postoperative pulmonary shunt <sep> arterial partial pressure of oxygen <sep> hemodynamic variables including creatine kinase-mb and troponin levels intubation time postoperative bleeding and blood transfusions <sep> static and dynamic lung compliance measurements <sep>', 'myocardial metabolism <sep> transcardiac ph differences <sep> myocardial preservation <sep> postoperative peak values of creatine kinase-mb mass <sep> myocardial energy metabolism and tissue injury during cabg <sep> maximum myocardial lactate production <sep>', 'postoperative tissue factor and p-selectin expression <sep> plasma tissue factor levels <sep> platelet expression of p-selectin <sep> soluble p-selectin levels in plasma <sep>', 'dialysate concentrations of glucose and lactate <sep> lactate/pyruvate ratio and the lactate/glucose ratio indicating the aerobic and anaerobic tissue metabolism status <sep> pyruvate and glycerol interstitial concentrations lactate/pyruvate ratio and lactate/glucose ratio <sep> interstitial concentrations of the glucose glycerol pyruvate and lactate <sep> glucose lactate pyruvate and glycerol as markers of basic metabolism and tissue perfusion <sep> postoperative clinical outcome icu stay ventilation duration length of hospital stay <sep> aerobic metabolic activity <sep> pyruvate concentrations <sep> dialysate concentrations of ethanol <sep> peripheral tissue metabolism and microvascular blood flow <sep> peripheral tissue skeletal muscles energy metabolism <sep> local blood flow <sep>', 'mortality or perioperative myocardial infarction <sep> homologous blood consumption <sep> hemodynamic data cardiac index systemic vascular resistance left and right-ventricular stroke-work indices inotropic and mechanical support needs and enzyme levels ck-mb and sgot as well as mortality perioperative infarction rate homologous transfusion requirements and the symptomatology in the first follow-ups <sep> inotropic <sep> safety and efficacy <sep>', 'mammary artery patency <sep> appearance of graft patency myocardial function and clinical outcome <sep> angiographic graft patency <sep> global myocardial function <sep> functional class and exercise capacity <sep> exercise capacity improvement and attenuation of symptoms <sep> vein graft patency <sep>', 'overall rate of graft patency <sep> worse composite outcomes and poorer graft patency <sep> composite of death from any cause a repeat revascularization procedure or a nonfatal myocardial infarction <sep> neuropsychological outcomes or short-term use of major resources <sep> composite of death or complications reoperation new mechanical support cardiac arrest coma stroke or renal failure <sep> neuropsychological outcomes or use of major resources <sep> completeness of revascularization graft patency at 1 year neuropsychological outcomes and the use of major resources <sep> rate of the 1-year composite outcome <sep> rate of the 30-day composite outcome <sep>', 'ophthalmic function <sep> retinal microvascular damage <sep> postoperative va <sep> doppler high-intensity transient signals hits <sep> retinal microvascular damage <sep> resolution visual acuity va and cerebral injury by transcranial doppler ultrasound-detected emboli and s100 protein values <sep> microvascular damage <sep> protein s100 levels <sep>', 'tnf-alpha and elastase levels <sep> inflammation activation <sep> postoperative increases in fibrinogen and hs-crp <sep> cabg and opcab in inflammatory markers <sep> il-6 <sep> cabg and opcab <sep> high-sensitivity c-reactive protein hs-crp and fibrinogen <sep> systemic inflammation <sep> plasma tumor necrosis factor-alpha tnf-alpha and interleukin-6 il-6 levels <sep> neutrophil elastase levels <sep>', 'cerebral perfusion with opcab <sep> chest tube drainage <sep> clinical morbidity and costs <sep> neurologic and clinical morbidity <sep> cabg performance <sep> fresh frozen plasma <sep> rey auditory verbal learning test total and recognition scores <sep> cerebral perfusion <sep> neurologic and clinical morbidity <sep>', 'vo(2 and do(2 <sep> cabg and opcab <sep> oxygen metabolism <sep> cabg and opcab in oxygen consumption vo(2 delivery do(2 or extraction exo(2 <sep> oxygen consumption vo(2 and delivery do(2 <sep> strength of the relationship between vo(2 and do(2 <sep> oxygen metabolism variables <sep> time on the relation between vo(2 and do(2 <sep> postoperative vo(2 do(2 and exo(2 levels <sep>', 'overall t lymphocytes <sep> lymphocyte activation <sep> expression of lymphocyte activation markers <sep> expression of cd25 cd26 cd69 and dr on t cd3 and b cd19 lymphocytes on peripheral blood <sep> response of t lymphocytes and their activation markers as well as b lymphocytes and their activation markers <sep> early activation of cd69 and late activation of cd25 on t lymphocytes <sep>', 'gastrointestinal complications <sep> cpb inclusive of cardioplegic arrest left ventricular ejection fraction 50 emergency surgery prolonged aortic cross clamp and cpb time post-operative low cardiac output syndrome post-operative inotropic requirement new onset atrial fibrillation af excessive post-operative blood loss and redo thoracotomy <sep> gastrointestinal complications <sep> post-operative gastrointestinal complications <sep>', 'coagulation parameters <sep> pre and postoperatively prothrombin time and partial thromboplastin time <sep> volume of intraoperative autologous blood transfusion postoperative mediastinal blood loss and homologous blood transfusion requirements <sep> volume of homologous blood transfusion <sep> postoperative blood loss <sep> haemoglobin concentration <sep> intraoperative blood loss and homologous blood transfusion <sep> homologous blood <sep> intraoperative mediastinal blood loss <sep> homologous transfusion <sep> salvaged mediastinal blood available for autologous transfusion <sep> postoperative morbidity and blood loss <sep> postoperative morbidity <sep> blood loss and homologous blood transfusion requirements <sep>', 'occurrence of cardiovascular events all-cause mortality stroke myocardial infarction and coronary reintervention anginal status and quality of life <sep> cognitive decline <sep> cognitive outcomes <sep> 5-year cognitive or cardiac outcomes <sep> anginal status or quality of life <sep> cardiovascular event <sep>'], 'punchline_text': ['the off-pump group had significantly less increase in creatinine levels when compared with the on-pump group p<.05). <sep>', 'cd11b levels were significantly higher in the cpb group at 60 minutes p  .002). <sep>', 'insulin-like growth factor-1 decreased more p=0.01 and insulin-like growth factor binding protein-1 increased more p<0.001 with cardiopulmonary bypass than without. <sep>', 'the total amount of cardiac troponin i released was higher in the arrested heart revascularization group than in the beating heart revascularization group 8.25  <sep>', 'early mortality was 2.3 in group 1 and 3.4 in group 2 p  not significant). <sep>', 'postoperative systemic arterial et levels were significantly increased by 200 in the cpb group and 50 in the opcab group. <sep>', 'all-cause mortality was significantly increased in the off-pump group 24 vs 15 hr 1.66 95 ci 1.02 to 2.73 p=0.04 but cardiac-related death was not significantly different 10 vs 7 hr 1.30 95 ci 0.64 to 2.66 p=0.47). <sep>', 'there was no significant difference in the median postoperative length of stay between the two groups seven days in each group). <sep>', 'the on-pump group showed a significantly greater deterioration in scores for two and three tests at 1 week and 10 weeks postoperatively respectively than the off-pump group. <sep>', 'there were no hospital deaths in off-pump patients and 2 patients 5 undergoing onpump cabg died early following surgery p .2). <sep>', 'significant increases from prior anesthesia values of lipid hydroperoxides 190 at 4 hours protein carbonyls 250 at 0.5 hours and nitrotyrosine 510 at 0.5 hours were seen in the cpb group but they were abolished or significantly reduced in the off-pump group. <sep>', 'a certain degree of roteg signs of fibrinolysis was noticed at time t2 in both groups and in group b these marks were quite widely but not significantly expressed p for intergroup differences for lysis on set time at 60 and 150 minutes were p  0.190 and p  0.122 respectively borderline differences were found for maximum clot firmness p  0.082 with a lower mean value for group b arithmetic means <sep>', 'no mortality or renal complication were observed. <sep>', 'there was no diference between the two groups of patients regarding incidence of main morbidity and hospital moratlity. <sep>', 'the rate of active cd97-positive lymphocytes showed a marked gradual increase until postoperative day 3 and remained elevated up to day 7 after cpb. <sep>', 'the wbc and neutrophil counts rose markedly in both groups following the operation and remained at this increased level during the observation period. <sep>', 'compared to baseline levels the highest ptx3 value p<0.000 was attained on the 1(st postoperative day in both on-pump and off-pump patients. <sep>', 'glutathione peroxidase levels were not changed according to blood collection times in both of cabg group or opcab group p  0.05). <sep>', 'coronary revascularization with cpb was associated with a significant expression increase in the tnf-system and sil-2r when compared to the opcab patients. <sep>', 'peak s100 levels were four times higher in group a than in group b 2.1 microg/l versus 0.5 microg/l p  001). <sep>', 'forced vital capacity fvc values were significantly lower than the preoperative values in all three groups p  0.05). <sep>', 'interleukin-6 interleukin-8 c3a and troponin i levels after surgery were significantly higher in the cpb group compared with the off-pump and rvad groups. <sep>', 'statistically significant differences were found between the 2 groups concerning the incidence of low cardiac output syndrome p  .001 time of inotrope drugs support p  .001 time of mechanical ventilation p  .006 reoperation for bleeding p  .04 intensive care unit stay p  .01 and in-hospital stay p  .02). <sep>', 'levels of creatine kinase mass were statistically higher in the miniaturized extracorporeal circulation group than in the off-pump coronary artery bypass grafting group but only at the end of the operation p  .0001). <sep>', 'i and high-sensitivity c-reactive protein released was significantly higher in the on-pump group than in the off-pump group. <sep>', 'maximum creatine kinase-mb levels were significantly p=0.046 lower in the off-pump group than in the on-pump group 17.1+/-16.7 iu/l versus 21.5+/-10.6 iu/l). <sep>', 'opcab was followed by an attenuated systemic release of il-8 <sep>', 'global oxygen utilization measurements showed superior do(2 and vo(2 in the opcab group throughout the study. <sep>', 'cec numbers and proportions of apoptotic hec were significantly elevated during and after surgery in both groups p<0.01). <sep>', 'thirty-day complications neuropsychological functioning and one-year clinical and functional outcomes were not statistically different between the two techniques. <sep>', 'troponin-t and creatine kinase isoenzyme mb ck-mb levels were significantly higher in cpb procedures p<0.0056 multivariate general linear model). <sep>', 'troponin i was significantly lower in the opcab than in the ccab group either at the end of ischemia end of surgery 6-hour and 24-hour postoperatively 4  <sep>', 'the off-pump coronary artery bypass graft group had fewer patients with troponin release than the conventional coronary artery bypass graft group. <sep>', 'gsh levels from the biopsies were increased in the perfusion group early in the reperfusion time showing that myocardial tissue was well protected and recovered more rapidly after cross-clamping than after the occlusion of the coronary arteries. <sep>', 'the proportions of neuropsychologic deficits and improvement in quality-of-life were comparable regardless of whether patients were randomized to receive off-pump coronary artery bypass graft surgery or conventional coronary artery graft surgery with cardiopulmonary bypass. <sep>', 'urinary isoprostane ipf2alpha-iii levels plasma levels of free malondialdehyde and total antioxidant status were measured before during and up to 24 hours after surgery. <sep>', 'values were less important in the opcab group and return to the baseline was faster than in the cpb group. <sep>', 'thrombin formation was more elevated in the on-pump group p  .001 particularly during the operation prothrombin fragment 1.2 discharge values were higher than the preoperative ones p  .002). <sep>', 'patients who underwent off-pump coronary artery bypass surgery showed similar patency of grafts better clinical outcome shorter hospital stay and better neurocognitive function than patients who underwent conventional coronary artery bypass grafting surgery using cardiopulmonary bypass. <sep>', 'patients undergoing opcab had more severely stenosed carotid arteries p=0.075 higher incidence of slightly diseased ascending aorta p=0.087 and higher northern new england cardiovascular study group <sep>', 'the platelet activity is higher in the early postoperative period in off-pump compared with on-pump coronary artery bypass grafting. <sep>', 'however in multivariate analysis fibrosis was confounded by myocyte vacuolization p  .002 and nuclear derangement p  .016 representing independent atrial fibrillation predictors. <sep>', 'there were no significant intergroup differences in any of the echocardiographic markers of right ventricular function. <sep>', 'clinical outcome and hospital stay were comparable in both groups. <sep>', 'ck-mb mass release was 323.5+/-221.2 microg/l 24 h postoperatively in operated patients without cpb and 1030. <sep>', 'the length of stay in icu was significantly different 33.8+/-16.2 hours for group <sep>', 'interstitial lactate levels were higher during off-pump surgery p<0.05). <sep>', 'the extent and pattern of svr index responses were similar in both groups p  0.840). <sep>', 'there were no significant differences between on-pump and off-pump patients in any of the eight subscales at both stages. <sep>', 'a residual perfusion defect at myocardial nuclear scan was less frequent among patients in the mecc group 3 versus 9 cases p=0.14 odds ratio 0.32 95 confidence interval 0.07 to 1.32). <sep>', 'we did not find any statistical difference in hospital mortality and morbidity using on-pump or off-pump techniques for low-risk patients. <sep>', 'plasma levels of complement c3a cytokines il-8 tnf-alpha endothelin-1 and neopterin were measured before and during surgery and 2 and 24 h after surgery. <sep>', 'the mean intraoperative s100 in the on-pump group was 1.6 times greater compared to that in the off-pump group 95 ci 0.88-2.8 p=0.01). <sep>', 'in the group that underwent minimally invasive coronary artery bypass grafting leukocyte elastase platelet beta-thromboglobulin and complement c3a were unchanged at the end of the procedure compared with their baseline concentrations whereas these inflammatory markers were increased significantly in the group that underwent conventional coronary artery bypass grafting with cardiopulmonary bypass. <sep>', 'preoperative characteristics were comparable between the two groups. <sep>', 'aspartate transaminase and alanine-amino transferase levels were higher in the cabg-cpb group for the first postoperative day but levels converged by day 3 interaction of surgery type and time p  0.0001 and p  0.04 respectively). <sep>', 'after 5-year follow-up the primary composite end point was not different between groups hazard ratio 0.71 95 ci 0.41 to 1.22 p=0.21). <sep>', 'cardiac outcomes and health-related quality of life at 30 days and 1 year were similar and patients incurred a lower cost. <sep>', 'postoperative s-100 serum levels were 3.76 0.13 to 11.2 microg/l conventional versus 0.13 0.04 to 1.01 microg/l off-pump p less than 0.0001. <sep>', 'saphenous graft patency was 59 on pump versus 49 off pump p=ns). <sep>', 'the mean static and dynamic lung compliance postoperatively was lower in the stabilization group although not statistically significant p  0.06). <sep>', 'the maximum myocardial lactate production was significantly higher p  0.02 in the group operated with cpb 0.56 mmol/l than without it 0.17 mmol/l). <sep>', 'the postoperative tissue factor and p-selectin expression did not differ between the on-pump and off-pump coronary artery bypass grafting groups. <sep>', 'the lactate/pyruvate ratio and the lactate/glucose ratio indicating the aerobic and anaerobic tissue metabolism status were lower in the off-pump group. <sep>', 'there was no mortality or perioperative myocardial infarction in either group. <sep>', 'there were no differences in exercise capacity improvement and attenuation of symptoms between the groups. <sep>', 'at 1 year of follow-up patients in the off-pump group had worse composite outcomes and poorer graft patency than did patients in the on-pump group. <sep>', 'protein s100 levels were higher in the cabg-cpb than in the opcab group 1 hour after surgery p<0.001). <sep>', 'plasma tumor necrosis factor-alpha tnf-alpha and interleukin-6 il-6 levels significantly increased with respect to baseline from protamine administration up to eight postoperative days whereas high-sensitivity c-reactive protein hs-crp and fibrinogen increased after surgery up to eight postoperative days in both groups. <sep>', 'compared with base line opcab patients performed better on the rey auditory verbal learning test total and recognition scores at both 2 weeks and at 1 year p  or  0.05 whereas cabg performance was statistically unchanged for all cognitive measures. <sep>', 'no significant differences between cabg and opcab were detected in postoperative vo(2 do(2 and exo(2 levels. <sep>', 'the response of t lymphocytes and their activation markers as well as b lymphocytes and their activation markers was similar after on and off-pump surgery. <sep>', 'cardiopulmonary bypass inclusive of cardioplegic arrest is the main independent predictor of post-operative gastrointestinal complications in patients undergoing coronary revascularisation. <sep>', 'off-pump cabg is potentially associated with reduced intraoperative blood loss and homologous blood transfusion in comparison to on-pump cabg. <sep>', 'in low-risk patients undergoing cabg surgery avoiding the use of cardiopulmonary bypass had no effect on 5-year cognitive or cardiac outcomes. <sep>'], 'population': ['patients who underwent cabg <sep> patients undergoing cabg <sep> sixty patients with normal preoperative renal functions undergoing cabg <sep>', 'twenty patients undergoing primary isolated cabg <sep> patients undergoing opcab versus those undergoing cabg with cardiopulmonary bypass cpb <sep>', 'after coronary artery bypass surgery <sep> diabetic patients undergoing coronary bypass surgery <sep>', 'patients undergoing first elective coronary artery bypass graft with <sep> seventy patients <sep>', 'patients with significant risk factors for cpb-related morbidity <sep> total arterial myocardial revascularization <sep> 176 patients undergoing total arterial myocardial revascularization and assigned them at random to one of two groups group 1 was composed of 88 patients undergoing <sep>', 'patients undergoing cardiopulmonary bypass <sep> patients undergoing coronary artery bypass surgery using either cardiopulmonary bypass or off-pump techniques and 2 <sep> patients undergoing coronary artery bypass grafting using either off-pump techniques opcab group n  25 or <sep>', 'main exclusion criteria were previous heart surgery poor left ventricular function ejection fraction 30 or unstable preoperative condition <sep> patients with three-vessel disease and a high-risk operative profile <sep> 341 patients with three-vessel disease and a euroscore of 5 or greater <sep>', 'the mean age of the patients was 63 years and 87 percent were men <sep> massachusetts medical society <sep>', 'patients with triple vessel disease <sep> university hospital of wales cardiff <sep> coronary artery bypass graft surgery <sep> participants <sep> 60 patients undergoing <sep>', '37 patients averaging 70 <sep> high-risk patients <sep> between october 2001 and september 2002 65 high-risk patients <sep> twenty-eight patients averaging 70 <sep> patients with known risk factors for mortality and morbidity <sep> recruited patients had at least 3 of the following criteria age greater than 65 years high blood pressure diabetes serum creatinine greater than 133 mol/l left ventricular ejection fraction lower than 45 chronic pulmonary diseas e unstable angina congestive heart failure repeat cabg anemia and carotid atherosclerosis <sep> 6 years of age underwent 3.4 <sep> 8 years of age underwent 3 <sep>', 'patients operated under cardiopulmonary bypass cpb <sep>', 'twenty patients scheduled for <sep>', 'low-risk patients undergoing either opcab or on-pump coronary artery bypass oncab <sep> low risk patients <sep> forty low-risk patients with normal preoperative cardiac and renal functions awaiting elective cabg <sep> coronary artery surgery coronary artery bypass grafting cabg <sep>', 'sixty patients with multivessels coronary artery diseases were scheduled to undergo coronary artery bypass grafting from january 15 2006 to june 30 2007 in our institution <sep> population with multivessels coronary artery disease <sep>', 'patients receiving coronary surgery with or without cpb <sep> 30 patients were enrolled and scheduled for coronary bypass surgery under cpb 20 patients group a and with off-pump op operation 10 patients group b <sep> patients undergoing coronary artery bypass surgery <sep>', 'group 10 patients <sep>', 'cardiac surgical patients operated on either with or without the use of cardiopulmonary bypass cpb <sep>', '30 patients undergoing opcab off-pump coronary artery bypass grafting 12 patients undergoing cabg on-pump coronary artery bypass grafting and 18 healthy controls <sep> patients undergoing coronary artery bypass operation <sep> 88.90 <sep>', 'patients undergoing coronary revascularization by comparing them with patients receiving coronary artery bypass grafts using off-pump opcab techniques <sep> twenty-six patients <sep> critically ill patients <sep>', '108 randomized patients undergoing coronary bypass operation 67 patients group a were operated on with <sep>', 'patients with copd <sep> patients with chronic obstructive pulmonary disease copd <sep> fifty eight patients with severe obstructive pulmonary disease had elective isolated coronary surgery <sep> coronary artery bypass grafting cabg <sep> 21 patients group 3 <sep> patients with chronic obstructive pulmonary disease <sep>', 'sixty patients <sep> patients undergoing coronary artery bypass grafting <sep>', 'between february 2002 and october 2007 128 patients with st-segment elevation myocardial infarction who underwent myocardial revascularization within 48 hours from the onset of symptoms <sep> patients with st-segment elevation myocardial infarction <sep>', 'sixty consecutive patients <sep>', 'fifty patients <sep> patients undergoing coronary artery bypass grafting with or without cardiopulmonary bypass <sep>', 'between july 2002 and september 2004 167 consecutive unselected patients referred for elective primary cabg <sep>', 'low-risk patients scheduled for elective coronary revascularization <sep>', 'low-risk patients undergoing coronary artery bypass grafting cabg with and without cpb <sep> fifty-four patients undergoing primary cabg by the same surgeon <sep>', '30 patients undergoing cabg randomly assigned to two groups 15 patients off <sep>', 'one hundred and fifty patients <sep>', 'patients referred to single-vessel coronary artery bypass grafting <sep> ten patients eight male two female aged 59.6+/-11.0 years mean+/-sd group 2 median sternotomy and off-pump in ten patients seven male three female aged 65.1+/-10.0 years group 3 minithoracotomy with cpb in ten patients seven male three female aged 61.2+/-10.4 years group 4 minithoracotomy and off-pump in ten patients nine male one female aged 62.9+/-9.8 years <sep>', 'one hundred twenty patients <sep> patients undergoing on <sep> patients undergoing cardiac surgery <sep>', '201 patients undergoing <sep> n  99 <sep>', '50 cases <sep> fifty coronary artery bypass patients <sep>', 'sixty-six patients undergoing coronary artery bypass graft surgery and a control group of 50 participants not undergoing cardiac surgery <sep> patients undergoing off <sep>', 'fifty low-risk coronary patients <sep>', 'seventy-one diabetic patients 36 and 35 patients in the cpb and opcab groups respectively <sep> diabetic patients between on-pump cpb and off-pump opcab coronary artery bypass graft cabg <sep> diabetic patients <sep> acute kidney injury aki <sep>', 'thirty-two patients <sep> patients undergoing coronary artery bypass surgery on-pump or off-pump techniques <sep> patients having on-pump bypass grafting <sep>', '168 patients 27 women requiring primary isolated coronary artery bypass grafting surgery <sep> tertiary cardiothoracic centre in middlesex england <sep>', 'twenty patients <sep>', 'eighty patients <sep>', 'seventy patients undergoing elective coronary revascularization <sep>', 'fifty patients scheduled for elective coronary artery bypass surgery <sep>', 'elective low-risk patients with multivessel disease <sep> eighty selected low-risk patients were enrolled <sep> twenty-six of 40 65 patients undergoing cabg without cpb underwent complete revascularization <sep>', 'multivessel disease with versus without cpb <sep>', 'thirty-seven patients operated upon in our institution between april 1997 and april 1998 showed an obstructive and/or restrictive pulmonary disease <sep> patients with pulmonary disease <sep> twenty-one patients were operated on without cbpb group a while 16 patients were operated using <sep> patients with advanced pulmonary disease <sep>', 'twenty-six low-risk patients <sep>', 'one hundred consecutive patients <sep>', 'patients after on-pump and off-pump coronary artery bypass graft surgery and compare the data with an age-matched and sex-matched standard population <sep> two hundred twelve patients admitted for elective coronary artery bypass graft surgery <sep> patients who have undergone off-pump coronary artery bypass graft surgery <sep>', '150 patients underwent coronary surgery with the use of mecc and 150 underwent opcabg <sep>', 'patients with severe left ventricular dysfunction fe <sep> one hundred and sixty selected low-risk patients were enrolled 80 patients were operated on <sep> one hundred and five were male and ages ranged from 39 to 70 years old mean 58.81 <sep> low-risk patients with one or two vessel disease <sep> patients with lesions in the left descending artery alone or associated with the right coronary artery <sep> low-risk patients <sep>', '30 patients 2-4 h after surgery <sep> fifty-two patients submitted for elective cabg <sep> twenty-six patients were operated with and 26 without cardiopulmonary bypass cpb <sep>', 'thirty-five patients admitted for cabg <sep>', '167 versus 788 <sep> from june 1995 to june 1996 62 consecutive patients with isolated stenosis of the left anterior descending coronary artery <sep> patients who undergo minimally invasive coronary artery bypass grafting without cardiopulmonary bypass <sep> patients undergoing minimally invasive coronary artery bypass grafting <sep> patients who undergo minimally invasive coronary artery bypass grafting <sep> patients who underwent minimally invasive coronary artery bypass grafting had a shorter duration of operation 104 <sep>', 'patients with preoperative non-dialysis dependent renal insufficiency <sep> diabetic patients with non-dialysis dependent renal insufficiency <sep> patients with normal renal function <sep> patients with non-dialysis dependent renal insufficiency <sep> patients undergoing coronary bypass <sep> patients undergoing coronary artery revascularization with cardiopulmonary bypass <sep> from august 2004 through october 2005 116 consecutive patients with preoperative non-dialysis-dependent renal insufficiency glomerular filtration rate measured using the modification of diet in renal disease equation mdrd gfr  or  60 ml x min(-1 x 1.73 m(-2 undergoing primary coronary artery bypass grafting <sep>', 'forty patients were recruited 20 per group <sep>', '308 patients undergoing coronary artery bypass graft surgery <sep>', 'patients while in the hospital and at 1-year follow-up <sep> patients unselected for coronary anatomy ventricular function or comorbidities between march 10 2000 and august 20 2001 at a us academic center <sep> unselected patients with angiographic follow-up <sep> 200 patients were enrolled 3 patients were withdrawn after randomization for mitral valve repair or replacement <sep>', 'patients who underwent <sep> forty patients <sep>', '400 consecutive nonselected cardiac surgery candidates into group a on pump n=192 and group b off <sep> 255 patients <sep>', 'patients undergoing <sep> patients undergoing coronary artery bypass grafting procedures <sep> fifty-eight patients <sep>', '22 patients 11 with and 11 without cpb <sep>', 'thirty patient candidates for coronary surgery <sep>', '40 patients randomized to two groups <sep> twenty patients on-pump group <sep>', 'two similar groups of 25 patients off-pump and on-pump groups <sep>', 'one hundred twenty patients <sep>', '1371 patients who underwent 4093 grafts <sep> 2203 patients scheduled for urgent or <sep>', 'twenty patients were randomized <sep>', 'thirty patients candidates for coronary surgery <sep>', 'sixty patients 30 cabg and 30 opcab <sep>', 'twenty-five patients <sep>', '28 patients randomized to off-pump n  13 or on <sep>', 'patients undergoing coronary revascularisation <sep> 150 patients 114 men mean age 64 45-75 years with mild hypothermic 32c cpb and cardioplegic arrest of the heart or 2 off-pump surgery 150 patients 113 men mean age 64 38-66 years on the beating heart <sep> three hundred patients <sep>', 'eighty patients <sep> patients undergoing cabg on <sep> patients undergoing cardiac surgery <sep>', 'netherlands which enrolled 281 low-risk cabg patients between 1998 and 2000 <sep> 123 and 117 patients in the off-pump and on-pump groups respectively <sep>'], 'interventions': ['pump and on-pump coronary artery bypass grafting <sep> conventional revascularization with cpb on-pump or beating heart revascularization off-pump <sep> coronary artery bypass grafting cabg with cardiopulmonary bypass cpb <sep> pump technique with on-pump technique <sep>', 'coronary artery bypass grafting cabg surgery <sep> pump coronary artery bypass opcab surgery <sep> opcab <sep> cabg with cpb <sep> off-pump coronary artery bypass surgery <sep>', 'cardiopulmonary bypass <sep> primary coronary artery bypass grafting <sep> cardiopulmonary bypass <sep> continuous insulin infusions <sep> surgery with or without cardiopulmonary bypass <sep>', 'cardiac troponin <sep> conventional coronary artery bypass graft with cardioplegic arrest <sep> beating or arrested heart revascularization group <sep> cardiac troponin i release <sep> cardiac troponin <sep> beating and arrested heart revascularization <sep>', 'opcab procedure <sep> pump coronary artery bypass surgery technique <sep> pump coronary artery bypass opcab surgery <sep> coronary surgery with cardiopulmonary bypass cpb <sep>', 'conventional cardiopulmonary bypass cpb <sep> pump versus conventional coronary artery bypass surgery <sep> opcab <sep> endothelin <sep> coronary artery bypass surgery <sep>', 'pump versus on-pump coronary artery bypass surgery <sep> pump versus on-pump coronary artery bypass grafting cabg <sep> cabg <sep>', 'pump and on-pump multivessel coronary-artery bypass surgery <sep> undergo on-pump coronary-artery bypass grafting and 54 to undergo off-pump surgery <sep> coronary-artery bypass surgery without cardiopulmonary bypass and cardiac arrest off pump <sep> pump surgery with conventional on-pump surgery <sep>', 'pump or on-pump technique <sep> pump and on-pump techniques <sep> coronary artery bypass graft surgery <sep> off-pump coronary artery bypass graft surgery <sep>', 'pump or o n-pump cabg <sep> pump coronary artery bypass grafting cabg <sep> pump to on-pump coronary artery bypass grafting <sep> pump to onpump cabg <sep>', 'pump coronary bypass graft operations <sep> cardiac stabilizer octopus tissue stabilizer medtronic inc minneapolis mn <sep>', 'rotation thromboelastography roteg <sep> coronary bypass grafting <sep>', 'cardiopulmonary bypass cpb <sep> pump coronary surgery opcab <sep> opcab <sep> beating heart coronary surgery <sep> oncab <sep>', 'pump or on-pump surgery with intermittent cross-clamping of aorta and ventricular fibrillation <sep> pump coronary artery bypass graft cabg myocardial revascularisation versus off-pump coronary artery bypass graft opcab myocardial revascularisation <sep>', 'op surgery <sep>', 'pump coronary artery bypass grafting opcab <sep> opcab <sep> coronary revascularization with or without cardiopulmonary bypass <sep> coronary artery bypass grafting cabg <sep>', 'pentraxin 3 ptx3 <sep> cabg surgery performed either with on-pump or without off-pump cpb <sep> ptx3 <sep>', 'pump versus on-pump coronary artery bypass surgery <sep>', 'conventional coronary artery bypass grafting <sep> opcab procedure using a suction device and regular sternotomy n  13 or were treated conventionally using extracorporeal circulation blood cardioplegia and hypothermic arrest <sep>', 'pump operations without heart-lung machines <sep> pump beating heart revascularization <sep> extracorporeal circulation and cardioplegic cardiac arrest <sep>', 'standard cabg <sep> minimally invasive direct coronary artery bypass grafting midcabg <sep> cabg techniques <sep>', 'conventional surgery with cardiopulmonary bypass cpb and cardioplegic arrest beating heart surgery off-pump or beating heart surgery with the rvad <sep> pump coronary surgery with right ventricular assist device <sep> right ventricular assist devices rvads <sep> med rvad <sep>', 'pump versus on-pump myocardial revascularization <sep> conventional cardioplegic arrest coronary artery bypass grafting <sep>', 'miniaturized extracorporeal circulation n  30 or off-pump coronary revascularization off-pump coronary artery bypass grafting <sep> myocardial revascularization with miniaturized extracorporeal circulation versus off pump <sep> miniaturized extracorporeal circulation <sep> coronary surgery with the miniaturized extracorporeal circulation system <sep>', 'pump coronary artery bypass grafting <sep> pump or off-pump coronary artery bypass grafting <sep> coronary artery bypass grafting <sep> cardiac troponin <sep>', 'multiple arterial off-pump cabg n=81 or on-pump cabg <sep> pump and on-pump coronary artery bypass grafting cabg <sep> pump and on-pump multiple arterial coronary revascularization <sep> pump and on-pump cabg <sep>', 'cardiopulmonary bypass cpb <sep> conventional coronary artery bypass grafting cabg <sep>', 'gastric mucosal oxygenation together with whole-body oxygen flux <sep> cardiopulmonary bypass cpb <sep> splanchnic hypoxia during beating-heart and conventional coronary revascularization <sep> mild hypothermic <sep> perioperative monitoring with continuous tonometry and cardiac output devices <sep> oncab <sep>', 'pump and 15 on-pump cardiopulmonary bypass cpb <sep> pump coronary artery bypass grafting cabg <sep> bypass grafting with and without cardiopulmonary bypass <sep>', 'pump and on-pump coronary bypass surgery <sep> pump and on-pump multivessel coronary artery bypass grafting cabg <sep> pump cabg <sep>', 'median sternotomy with cpb <sep> median sternotomy and cardiopulmonary bypass cpb <sep> left internal mammary artery graft to the left anterior descending artery lad <sep> coronary artery bypass grafting <sep> conventional and minimally invasive coronary artery bypass grafting <sep> cpb <sep> conventional and three minimally invasive surgical techniques <sep>', 'ccab <sep> troponin <sep> opcab <sep> pump ccab or off-pump opcab coronary artery bypass surgery <sep> pump coronary artery bypass surgery <sep>', 'pump versus on-pump coronary artery bypass <sep> pump coronary artery bypass graft <sep> off-pump coronary artery bypass graft surgery <sep> conventional coronary artery bypass graft group <sep> nonemergent isolated coronary artery bypass graft surgery to conventional coronary artery bypass graft surgery n  102 or off-pump coronary artery bypass graft surgery <sep> conventional coronary artery bypass graft surgery <sep> coronary artery bypass surgery <sep>', 'trap <sep> pump surgery <sep> pump or on-pump operations <sep>', 'pump coronary artery bypass graft surgery or conventional coronary artery graft surgery with cardiopulmonary bypass <sep> coronary artery bypass grafts without cardiopulmonary bypass <sep> coronary artery bypass graft surgery with cardiopulmonary bypass <sep> coronary artery bypass surgery with and without cardiopulmonary bypass <sep> coronary artery bypass graft surgery using conventional cardiopulmonary bypass <sep> pump coronary artery bypass surgery <sep> coronary artery bypass graft surgery <sep> coronary artery bypass graft surgery without the use of cardiopulmonary bypass <sep>', 'cabg or opcab <sep> opcab <sep> cabg <sep> pump coronary bypass surgery <sep> conventional on-pump coronary artery bypass grafting cabg <sep>', 'surgical revascularization strategy <sep> opcab <sep>', 'pump or off-pump coronary artery bypass grafting <sep> heparin <sep> coronary artery bypass grafting <sep>', 'conventional coronary artery bypass grafting surgery using cardiopulmonary bypass <sep> pump coronary artery bypass surgery with conventional coronary artery bypass grafting surgery <sep> conventional coronary artery bypass grafting surgery using cardiopulmonary bypass n  84 or off-pump coronary artery bypass surgery <sep> pump coronary artery bypass surgery <sep>', 'pump and on-pump coronary artery bypass surgery <sep> pump coronary artery bypass surgery opcab over conventional on-pump coronary artery bypass surgery ccab <sep> retinal fluorescein angiography and 60 degrees black-and-white <sep> opcab <sep> opcab or ccab <sep>', 'pump compared with on-pump coronary artery bypass surgery <sep>', 'coronary bypass surgery <sep> conventional coronary artery bypass grafting and off-pump coronary artery bypass grafting <sep> pump conventional surgery conventional coronary artery bypass grafting n  35 or off-pump surgery on the beating heart off-pump coronary artery bypass grafting <sep> pump coronary artery bypass grafting and conventional coronary artery bypass grafting <sep> pump coronary artery bypass grafting procedures <sep>', 'pump versus off-pump coronary artery bypass graft surgery <sep> cardiopulmonary bypass <sep> conventional or off-pump surgery <sep> conventional bypass surgery <sep>', 'standard operation with cpb <sep> cabg <sep> beating heart without cardiopulmonary bypass cpb <sep> cpb <sep> coronary artery bypass grafting with and without cardiopulmonary bypass <sep>', 'cabg <sep> coronary artery bypass grafting with or without cardiopulmonary bypass <sep> cabg either with n=16 or without cpb <sep> coronary artery bypass grafting cabg without cardiopulmonary bypass cpb <sep>', 'cpbp <sep> coronarv artery bypass grafting cabg with cardiopulmonary bypass cpbp <sep> surgical myocardial revascularization cabg <sep> cardiopulmonary bypass <sep>', 'on and off-pump coronary bypass surgery <sep> copyright <sep> pump versus on-pump surgery <sep>', 'off-pump coronary artery bypass grafting opcab <sep> opcab or oncab <sep> pump coronary artery bypass grafting oncab <sep> conventional on-pump versus off-pump coronary artery bypass graft surgery <sep>', 'pump versus off-pump coronary artery bypass graft surgery <sep> coronary artery bypass graft surgery <sep> pump coronary artery bypass graft surgery <sep>', 'minimal extracorporeal circulation system mecc <sep> pump coronary revascularization opcabg <sep> opcabg <sep> coronary bypass grafting with minimal extracorporeal circulation system mecc versus off-pump coronary surgery <sep> mecc <sep>', 'pump versus off-pump <sep> pump versus on-pump myocardial revascularization <sep> pump coronary artery bypass grafting cabg <sep> pump off-pump coronary artery bypass opcab <sep>', 'pump cabg opcab <sep> opcab <sep>', 'bilateral transcranial doppler ultrasonography <sep> pump coronary artery bypass surgery <sep> microemboli high-intensity transient signals or hits <sep>', 'conventional coronary artery bypass grafting with cardiopulmonary bypass <sep> minimally invasive coronary artery bypass grafting <sep>', 'pump coronary artery bypass grafting <sep> coronary artery bypass grafting with or without cardiopulmonary bypass <sep>', 'monoethylglycinexylidide/lidocaine <sep> cabg-cpb <sep> opcab <sep> coronary surgery with or without cardiopulmonary bypass <sep> pump coronary artery bypass grafting opcab or coronary artery bypass grafting with cardiopulmonary bypass cabg-cpb <sep>', 'pump coronary artery bypass graft surgery opcab <sep> opcab and 153 to on-pump cab oncab <sep> opcab <sep> coronary artery bypass graft surgery with cardiopulmonary bypass <sep> pump and on-pump stable multivessel coronary artery bypass grafting <sep>', 'pump vs conventional coronary artery bypass grafting <sep> elective opcab or cabg with cardiopulmonary bypass <sep> pump coronary artery bypass opcab <sep> conventional coronary artery bypass grafting cabg <sep> opcab <sep>', 'neurobiochemical marker protein s-100 <sep> intensive transient signals hits <sep> conventional procedure using cardiopulmonary bypass cpb <sep> transcranial doppler ultrasound tcd <sep> pump versus conventional coronary bypass operation <sep> coronary artery bypass operation without cardiopulmonary bypass off-pump cabg <sep>', 'coronary bypass graft patency <sep>', 'coronary arterial bypass grafting operation cardiopulmonary bypass versus mechanical stabilization <sep> coronary artery bypass grafting operation with stabilization or coronary artery bypass grafting operation with cardiopulmonary bypass <sep> cardiopulmonary bypass <sep> arterial partial pressure of oxygen on 100 inspired oxygen the alveolar-arterial oxygen gradient and pulmonary shunt <sep> coronary artery bypass grafting operation using cardiac stabilization technique <sep> coronary artery bypass grafting operations using cardiac stabilization and thereby avoiding cardiopulmonary bypass <sep>', 'coronary surgery with and without cardiopulmonary bypass <sep> cabg <sep> coronary artery bypass grafting cabg without cardiopulmonary bypass cpb <sep>', 'pump coronary artery bypass grafting n  15 or on-pump coronary artery bypass grafting <sep>', 'surgical revascularization coronary artery bypass grafting cabg <sep> cardiopulmonary bypass <sep> cardiopulmonary bypass cpb and operations without cpb off-pump <sep>', 'coronary artery bypass grafting without using extracorporeal circulation with standard cardiopulmonary bypass technique <sep> coronary artery bypass grafting with and without extracorporeal circulation <sep>', 'pump and on-pump surgery <sep> pump or on-pump coronary surgery <sep> pump coronary surgery <sep>', 'cabg without cardiopulmonary bypass off-pump cabg <sep> elective cabg to either on-pump or off-pump procedures <sep> pump versus off-pump coronary-artery bypass surgery <sep> coronary-artery bypass grafting cabg <sep>', 'retinal and cerebral microembolization <sep> coronary artery bypass grafting cabg with cardiopulmonary bypass cpb and off-pump opcab grafting <sep> opcab <sep> fluorescein angiography <sep> coronary artery bypass surgery <sep>', 'coronary bypass surgery performed both on <sep> opcab <sep> pump and off-pump coronary bypass surgery <sep> cabg <sep>', 'coronary artery bypass grafting cabg <sep> dopamine <sep> pump cabg opcab <sep> coronary artery bypass grafting <sep> pump bypass <sep> cabg <sep> cabg opcab <sep> bilateral middle cerebral artery transcranial doppler scanning <sep>', 'cardiopulmonary bypass cpb <sep> cardiopulmonary bypass <sep> opcab <sep> cabg <sep> pump cabg and off-pump opcab <sep>', 'coronary artery bypass surgery <sep> pump n  15 coronary artery bypass surgery <sep> pump coronary bypass surgery <sep>', 'pump conventional coronary artery surgery <sep> cardiopulmonary bypass cpb <sep> conventional and beating heart coronary surgery <sep>', 'cpb with cell saver blood transfusion csbt b on-cpb without csbt c off-pump with csbt and d off-pump without csbt <sep> on <sep> autologous cell saver blood transfusion <sep> cardiopulmonary bypass <sep> cell saver autologous blood transfusion <sep> autologous blood transfusion in both on and off-pump cabg surgery <sep>', 'pump vs on-pump coronary artery bypass graft surgery <sep> conventional coronary artery bypass graft surgery <sep> avoiding cardiopulmonary bypass off-pump cabg <sep> pump cabg and on-pump cabg surgery <sep> cardiopulmonary bypass on-pump cabg <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>']}",our systematic review did not demonstrate any significant benefit of off-pump compared with on-pump cabg regarding mortality stroke or myocardial infarction. in contrast we observed better long-term survival in the group of patients undergoing on-pump cabg with the use of cardiopulmonary bypass and cardioplegic arrest. based on the current evidence on-pump cabg should continue to be the standard surgical treatment. however off-pump cabg may be acceptable when there are contraindications for cannulation of the aorta and cardiopulmonary bypass. further randomised clinical trials should address the optimal treatment in such patients.
206,"{'outcomes': ['glomerular filtration rate and effective renal plasma flow determined with inulin and para-aminohippuric acid clearances <sep> mesangial matrix volume and mesangial volume <sep> diabetic glomerulopathy <sep> microalbuminuria and/or hypertension <sep> blood pressure <sep> office blood pressure <sep> blood pressure kidney biopsies and kidney function tests <sep>', 'side effects <sep> systolic blood pressure <sep> systolic blood pressure 24-h systolic blood pressure reduction <sep> seated and 24-h ambulatory systolic blood pressure <sep>', 'complete renal-biopsy and retinopathy data <sep> 5-year cumulative incidence of microalbuminuria <sep> fraction of glomerular volume occupied by mesangium in kidney-biopsy specimens <sep> retinopathy severity scale <sep> blood pressure <sep> retinopathy progression <sep> mesangial fractional volume <sep> chronic cough <sep>', 'aer <sep> hypoglycaemic events <sep> urinary albumin excretion rate aer <sep> renal disease <sep> glycated haemoglobin <sep> renal disease <sep> prevalence of microalbuminuria <sep> risk of hypoglycaemic events <sep> resting blood pressure <sep>', 'doubling of serum creatinine <sep> albuminuria <sep> composite renal outcome <sep> estimated gfr <sep> renal outcomes <sep> major renal outcomes <sep> composite renal outcome of dialysis or doubling of serum creatinine changes in estimated glomerular filtration rate gfr and changes in albuminuria <sep>', 'new microalbuminuria 3 or 4 collections of urinary albumin excretion rate <sep> urinary albumin excretion rate <sep> risk for microalbuminuria <sep> microalbuminuria incidence or rate of change in albuminuria <sep> microalbuminuria and albumin excretion rate <sep> rate of change in albuminuria <sep> microalbuminuria <sep> annual rate of change in albuminuria <sep>', 'systolic and diastolic blood pressure captopril <sep> systolic and diastolic blood pressure <sep> duration of diabetes and hypertension systolic and diastolic blood pressure at rest degree of lvh metabolic control and albumin excretion rate aer <sep> left ventricular end-diastolic volume index nor the left ventricular ejection fraction <sep> fasting plasma glucose and glycated hemoglobin hba1c levels and both maintain constant aers <sep> efficacy and tolerability <sep>', 'composite of dialysis doubling of serum creatinine and death <sep> estimated glomerular filtration rate egfr <sep> secondary renal outcome dialysis or doubling of serum creatinine <sep> number of events <sep> urinary albumin excretion <sep> hazard ratio hr <sep>', 'blood pressure systolic/diastolic <sep> fasting and post-prandial plasma glucose glycosylated haemoglobin and plasma lipids <sep> tolerated <sep> albumin excretion rate aer <sep> microalbuminuria <sep> antihypertensive effect <sep> geometric mean x:tolerance factor <sep> plasma glucose insulin or lipid concentrations <sep>', 'metabolic parameters <sep> bp <sep> tolerated <sep> uae rate <sep> antihypertensive effects <sep> antiproteinuric effect of losartan <sep> efficacy and safety <sep> blood pressure bp creatinine clearance ccr and urinary albumin excretion uae <sep>', 'long-term antihypertensive efficacy tolerability and metabolic effects <sep> serum triglycerides <sep> glycosylated hemoglobin and 12-hr urinary microalbuminuria <sep> antihypertensive efficacy <sep> ldl cholesterol <sep> adverse events <sep> mean fall in the systolic and diastolic blood pressure <sep> blood sugar and glycosylated hemoglobin <sep> serum lipid fractions <sep> fbs and 2-hr pmbs <sep> incidence of side effects <sep> total cholesterol <sep> bp response <sep> serum lipids <sep> total cholesterol hdl cholesterol and ldl cholesterol <sep> response sbp and/or dbp normalized or dbp fall <sep> beneficial effect on triglycerides <sep>', '24-hour uae creatinine clearance ccr and the regression coefficient of the yearly plasma creatinine reciprocal beta-1/cr <sep> mean low-density lipoprotein cholesterol <sep> highest frequency of clinical events <sep> albuminuria <sep> renal function <sep> baseline uae <sep> urinary albumin excretion uae measurements <sep> clinical outcomes <sep> rate of deterioration in renal function <sep> 24-hour uae <sep> high-density lipoprotein cholesterol <sep> renal function <sep> death cardiovascular events and/or renal events need for renal replacement therapy or doubling of baseline plasma creatinine <sep> likely to revert to being normoalbuminuric <sep> mean ccr <sep>', 'diabetic vascular complications <sep> progression to incipient and overt diabetic nephropathy <sep> microalbuminuria to overt albuminuria <sep> normoalbuminuria to microalbuminuria <sep> progression of diabetic retinopathy <sep> change in creatinine clearance <sep> mean bp <sep> urinary albumin excretion progression of retinopathy and neuropathy and the incidence of cardiovascular disease <sep> creatinine clearance <sep> incidence of stroke <sep>', 'values of gfr aer and systolic and diastolic bp <sep> gfr decline per year <sep> diastolic blood pressure bp <sep> glomerular filtration rate gfr <sep> kidney function <sep> microalbuminuria <sep> albumin excretion rate aer <sep> gfr <sep> plasma clearance of 51cr-labeled edta <sep> hba1c triglycerides and bmi <sep> gfr decline <sep> mean bp diastolic  1/3 pulse pressure <sep> particularly hba1c bmi triglycerides and cholesterol plasma values <sep>', 'absolute risk reduction <sep> hemoglobin a1c values <sep> transition to microalbuminuria <sep> renal function <sep> albumin excretion <sep> degree of albuminuria at 24 hours creatinine clearance blood pressure and hemoglobin a1c values <sep> mean blood pressure <sep> creatinine clearance <sep> renal function and albuminuria <sep>', 'urinary albumin excretion uae <sep> mean entrance bp <sep> urinary albumin excretion <sep> progression of uae <sep> mean bp <sep> creatinine clearance or serum creatinine <sep>', 'lower systolic bp levels <sep> baseline systolic or diastolic bp <sep> risk for renal events <sep> renal events <sep>', 'systolic blood pressure sbp and diastolic blood pressure dbp <sep> urinary albumin excretion rate <sep> glycemic control and blood pressure <sep> duration of diabetes <sep> microalbuminuria <sep> sbp <sep> dbp <sep> albumin excretion rate <sep> overnight albumin excretion rate <sep>', 'normal glomerular filtration rate gfr <sep> mbp or gfr <sep> urine albumine/creatinine ratio acr mean blood pressure mbp and index of glomerular filtration rate gfr based on s-creatinine <sep> acr <sep>', 'lowering blood pressure <sep> total serum cholesterol hdl cholesterol hba1c fasting serum glucose or plasma insulin <sep> serum lipids and diabetes control <sep> risk of major vascular events <sep> cardiovascular events <sep> acute myocardial infarction stroke or hospitalized angina <sep> biochemical measures <sep> serum lipids and glucose metabolism <sep>', 'time to the onset of microalbuminuria <sep> time to the first onset of microalbuminuria <sep> blood-pressure control <sep> higher rate of fatal cardiovascular events <sep> blood pressure <sep> microalbuminuria <sep> serum creatinine level <sep> times to the onset of renal and cardiovascular events <sep> nonfatal cardiovascular events--81 <sep> rate of death from cardiovascular causes <sep> target blood pressure <sep>'], 'punchline_text': ['office blood pressure was significantly lower in the candesartan group at follow-up than in the placebo group. <sep>', 'reduction in systolic blood pressure 24-h systolic blood pressure reduction was obtained in both treatment arms mean reduction at final follow-up dual blockade 6 mmhg vs. lisinopril 2 mmhg but no significant difference was found between dual-blockade and lisinopril 40 mg once daily p  0.10). <sep>', 'early blockade of the renin-angiotensin system in patients with type 1 diabetes did not slow nephropathy progression but slowed the progression of retinopathy. <sep>', 'on intention-to-treat analysis at 2 years aer was 2.2 micrograms/min lower in the lisinopril than in the placebo group a percentage difference of 18.8 95 ci 2.0-32.7 p  0.03 adjusted for baseline aer and centre absolute difference 2.2 micrograms/min. <sep>', 'versus placebo 46 patients 1.55 hazard ratio 1.29 95 ci 0.87 to 1.89 <sep>', 'microalbuminuria in diabetes is strongly predictive of nephropathy end-stage renal disease and premature cardiovascular morbidity and mortality. <sep>', 'neither drug showed any negative side effects on fasting plasma glucose and glycated hemoglobin hba1c levels and both maintain constant aers. <sep>', 'the increase in urinary albumin excretion was less with telmisartan p=0.004 or with combination therapy p=0.001 than with ramipril. <sep>', 'fasting and post-prandial plasma glucose glycosylated haemoglobin and plasma lipids appeared to be unaffected by either agent. <sep>', 'bp was significantly decreased in both groups at the end of the 1st and 6th month to a similar extent. <sep>', 'treatment with prazosin gits resulted in a favourable effect on serum triglycerides at the end of 8 weeks p  0.017 and 16 weeks p  0.011 and no detrimental effect or a marginal beneficial effect on total cholesterol hdl cholesterol and ldl cholesterol. <sep>', 'treatment with enalapril was associated with a greater reduction in albuminuria than with nifedipine in the entire patient group and especially in those with microalbuminuria. <sep>', 'although no difference was demonstrated in creatinine clearance p  0.43 a lower percentage of patients in the intensive group progressed from normoalbuminuria to microalbuminuria p  0.012 and microalbuminuria to overt albuminuria p  0.028). <sep>', 'no significant changes were observed concerning other clinical and biochemical features between the two antihypertensive therapies and particularly hba1c bmi triglycerides and cholesterol plasma values. <sep>', '10 mg/24 h at 6 years p  0.001 for enalapril compared with placebo). <sep>', 'no difference was observed in change in creatinine clearance or serum creatinine from baseline between the two groups. <sep>', 'during a mean follow-up of 4.3 yr active treatment reduced the risk for renal events by 21 p  0.0001 which was driven by reduced risks for developing microalbuminuria and macroalbuminuria both p  0.003). <sep>', 'in the whole group at baseline the overnight albumin excretion rate correlated with hba1c r  0.50 p  0.01 and the duration of diabetes r  0.39 p  0.05 and sbp correlated with both the overnight r  0.42 p  0.05 and the exercise-induced r  0.48 p  0.05 albumin excretion rate. <sep>', 'during treatment a significant increase in acr in the placebo group p=0.007 wilcoxon matched paired test was observed. <sep>', 'at the end of follow-up between the two groups there was no significant difference in total serum cholesterol hdl cholesterol hba1c fasting serum glucose or plasma insulin. <sep>', 'slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients 3.6 as compared with 91 of 2215 patients 4.1 p=0.37)--but a greater number had fatal cardiovascular events--15 patients 0.7 as compared with 3 patients 0.1 p=0.01 a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease 11 of 564 patients 2.0 vs. 1 of 540 0.2 p=0.02). <sep>'], 'population': ['type 1 diabetes patients <sep> diabetes glomerulopathy <sep> young normoalbuminuric and normotensive patients with type 1 diabetes <sep> 13 patients aged 24 years at baseline <sep>', 'patients with hypertension and diabetes <sep> 75 type 1 and type 2 diabetic patients aged 35-74 years <sep> hypertensive patients with diabetes <sep>', '12 patients receiving <sep> 285 normotensive patients with type 1 diabetes and normoalbuminuria and who <sep> 2009 massachusetts medical society <sep> type 1 diabetes <sep> patients with type 1 diabetes <sep>', 'normotensive iddm patients <sep> normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria <sep> 530 men and women with iddm aged 20-59 years with normoalbuminuria or microalbuminuria <sep> people with insulin-dependent diabetes iddm <sep> patients were recruited from 18 european centres and were not on medication for hypertension <sep>', 'adults with vascular disease <sep> 5927 adults with known cardiovascular disease or diabetes with end-organ damage but without macroalbuminuria or heart failure who cannot tolerate angiotensin-converting enzyme inhibitors <sep> 17 participants had dialysis <sep> adults at high vascular risk <sep>', '309 secondary care centers <sep> diabetes <sep> 793 patients discontinued therapy and 63 were lost to follow-up <sep> mainly normotensive patients with type 1 or type 2 diabetes <sep> 3326 and 1905 patients with type 1 and type 2 diabetes respectively <sep> mainly normotensive patients or patients with well-controlled hypertension who were at low overall vascular risk which resulted in a low rate of microalbuminuria <sep>', 'hypertensive diabetic patients with left ventricular hypertrophy lvh <sep> hypertensive type 2 diabetic patients <sep> 167 <sep> 75 patients enrolled in this study presented stable type 2 diabetes not treated with insulin and mild-to-moderate hypertension with a left ventricular mass  or  75 g/m2 by two-dimensional echocardiography <sep>', '25 620 participants <sep> 784 patients permanently discontinued randomised therapy during the trial because of hypotensive symptoms 406 on combination therapy 149 on <sep> patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage <sep> people at high vascular risk the ontarget study <sep>', 'hypertension and non-insulin-dependent diabetes <sep> 23 microalbuminuric patients on <sep> 162 non-insulin-dependent diabetic hypertensive patients for a 24-week period <sep>', 'thirty-three type 2 diabetic hypertensive patients <sep> twenty patients <sep> diabetic patients <sep> hypertensive type 2 diabetic patients <sep>', 'males and females aged 30 to 70 yrs with hypertension of jnc v stage 1 or 2 at the end of a 2-week placebo run-in period and diabetes mellitus with at least acceptable glycaemic control fbs  or  140 mg/dl 2-hr pmbs  or  200 mg/dl and glycosylated hemoglobin  or  9.5 <sep> hypertensive patients with diabetes mellitus <sep> 20 physicians in mumbai india <sep>', '102 hypertensive type 2 diabetic patients <sep> hypertensive type 2 diabetic patients <sep> 102 hypertensive type 2 diabetic patients with varying degrees of albuminuria followed up for a mean duration of five years we observed the importance of good metabolic and blood pressure control on the progression of albuminuria and renal function <sep>', '480 normotensive type 2 diabetic patients <sep> normotensive type 2 diabetic patients on albuminuria retinopathy and strokes <sep> normotensive type 2 diabetic patients <sep> normotensive type 2 diabetic subjects <sep> hypertensive type 2 diabetic patients <sep>', ""hypertensive niddm patients <sep> patients 26 were normoalbuminuric and 18 microalbuminuric <sep> niddm patients attending the outpatient's clinic of the internal medicine departments of the university of padova and sassari 44 participated in the present study <sep> hypertensive niddm patients with or without incipient nephropathy <sep> hypertensive <sep> hypertensive niddm patients during antihypertensive therapy <sep> normoalbuminuric and microalbuminuric patients <sep>"", 'normotensive normoalbuminuric patients with type 2 diabetes mellitus <sep> eight outpatient clinics coordinated by a department of medicine in a university hospital <sep> diabetic patients with microalbuminuria <sep> normotensive normoalbuminuric patients with type 2 diabetes <sep> 156 patients in whom type 2 diabetes was diagnosed after 40 years of age who had a baseline mean blood pressure less than 107 mm hg and albuminuria albumin excretion  or  30 mg/24 h <sep> patients with type 2 diabetes <sep>', 'hg without overt albuminuria <sep> 129 type 2 diabetic patients with a bp of 140/80 to 90 mm <sep> normotensive patients with type 2 diabetes <sep>', '11,140 patients who had type 2 diabetes and participated in the action in diabetes and vascular disease preterax and diamicron-mr controlled evaluation advance study <sep> patients with diabetes <sep> type 2 diabetes <sep>', 'normoalbuminuric normotensive iddm patients <sep> n  13 age 36 <sep> normotensive normoalbuminuric iddm patients <sep> 26 iddm patients with normoalbuminuria <sep>', 'normotensive patients with type 1 diabetes mellitus with normal serum creatinine and no microalbuminuria were treated with either <sep> normotensive normoalbuminuric patients with type 1 diabetes mellitus <sep>', 'exclusion criteria included a history of coronary heart disease or stroke serum creatinine  1.5 mg/dl albuminuria <sep> patients with hypertension and niddm <sep> niddm patients with hypertension <sep> inclusion criteria included a diagnosis of niddm and hypertension systolic blood pressure of  140 mmhg or diastolic blood pressure of  90 mmhg <sep> 380 hypertensive diabetics <sep>', '4447 patients with type 2 diabetes to receive <sep> patients with type 2 diabetes and normoalbuminuria <sep> patients with preexisting coronary heart disease <sep>'], 'interventions': ['candesartan <sep> placebo <sep> candesartan or placebo <sep>', 'candesartan and lisinopril <sep> candesartan 16 mg once daily and lisinopril <sep> lisinopril <sep> candesartan and lisinopril with high-dose lisinopril <sep> candesartan <sep>', 'losartan <sep> enalapril <sep> placebo <sep> renin-angiotensin system <sep> enalapril and losartan <sep>', 'placebo <sep> lisinopril <sep> lisinopril <sep> ace inhibitor lisinopril <sep> angiotensin-converting enzyme ace <sep>', 'angiotensin-receptor blockers <sep> matching placebo <sep> placebo <sep> telmisartan and placebo <sep> telmisartan <sep> telmisartan <sep>', 'angiotensin-receptor blocker candesartan <sep> candesartan <sep> placebo <sep> candesartan <sep>', 'nitrendipine random allocation <sep> nitrendipine <sep> captopril <sep> lvh nitrendipine <sep> nitrendipine <sep>', 'ramipril <sep> telmisartan ramipril <sep> angiotensin receptor blockers arb and angiotensin converting enzyme ace inhibitors <sep> ramipril and 229 on telmisartan <sep> telmisartan <sep> ramipril an ace inhibitor telmisartan an arb <sep>', 'lisinopril and slow-release nifedipine <sep> lisinopril and nifedipine <sep> lisinopril <sep> angiotensin-converting enzyme inhibitor and a calcium antagonist <sep> nifedipine <sep> angiotensin-converting enzyme lisinopril <sep> calcium antagonist nifedipine <sep>', 'losartan <sep> losartan and fosinopril <sep>', 'enalapril <sep> enalapril <sep> prazosin gits and enalapril <sep> prazosin gits with enalapril <sep> prazosin gits <sep> enalapril <sep> sbp <sep> prazosin gits <sep>', 'placebo <sep> calcium channel-blocking agents <sep> enalapril <sep> enalapril versus nifedipine slow release <sep> angiotensin-converting enzyme ace inhibitors <sep> ace inhibition <sep> nifedipine <sep> angiotensin-converting enzyme inhibition and metabolic control <sep> nifedipine slow release <sep>', 'placebo <sep> aggressive blood pressure control <sep> nisoldipine or enalapril <sep> enalapril or nisoldipine <sep> intensive versus moderate diastolic blood pressure dbp control <sep>', 'cilazapril <sep> cilazapril and amlodipine <sep> amlodipine <sep> ace inhibitors cilazapril inibace roche milan italy and ca(2+)-channel blockers amlodipine norvasc pfizer rome italy <sep> cilazapril or amlodipine <sep> cilazapril <sep>', 'ml <sep> enalapril <sep> placebo <sep> enalapril <sep> ace inhibitors <sep> prolonged ace inhibition <sep> angiotensin-converting enzyme ace inhibitors <sep>', 'intensive blood pressure control with valsartan <sep> valsartan <sep> aggressive blood pressure bp therapy <sep> intensive bp control diastolic bp goal 75 mm hg using an angiotensin ii receptor blocker valsartan versus moderate bp control diastolic bp 80 to 90 mm hg with placebo <sep>', 'perindopril-indapamide or placebo <sep> perindopril-indapamide <sep>', 'lisinopril <sep> placebo <sep> lisinopril therapy <sep> lisinopril <sep>', 'placebo or perindopril an ace inhibitor <sep> placebo <sep> ace inhibitor <sep> perindopril <sep>', 'fosinopril and amlodipine <sep> open-label fosinopril <sep> fosinopril and amlodipine <sep> amlodipine <sep> lipid-lowering drugs aspirin or antihypertensive agents other than beta-blockers or diuretics <sep> fosinopril versus amlodipine <sep> ace inhibitors and calcium antagonists <sep>', 'placebo <sep> olmesartan <sep> additional antihypertensive drugs except angiotensin-converting-enzyme inhibitors or arbs <sep> olmesartan <sep> angiotensin-receptor blocker arb <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",acei were found to prevent new onset dkd and death in normoalbuminuric people with diabetes and could therefore be used in this population. more data are needed to clarify the role of arb and other drug classes in preventing dkd.
207,"{'outcomes': ['bone loss <sep> bone remodeling alkaline phosphatase and osteocalcin <sep> severe side effects <sep> bone mineral density bmd <sep>', 'biochemical parameters <sep> bone mass <sep> spinal bone loss <sep> bone loss <sep> generalised pruritus <sep> spinal bone mass <sep> bone turnover assessed by biochemical markers bone loss assessed by serial measurement of lumbar spine density and rates of bone fractures <sep>', 'mean bmd <sep> bone loss <sep> bmd <sep> axial bone loss <sep> bone mineral density bmd <sep>', 'cortical and cortical and trabecular bone mineral content <sep> back pain <sep>', 'dual-energy x-ray absorptiometry dxa of the lumbar spine and hip and spine radiographs to detect vertebral fractures <sep> bone preservation <sep> bone density <sep> bone loss <sep> incidence of vertebral fracture <sep> dxa lumbar spine density <sep>', 'bone loss at the femoral neck and distal radius <sep> risk of osteoporosis and fracture <sep> bone loss <sep> bone density <sep> lumbar bone loss <sep> lost lumbar bone <sep>', 's.d. bone mineral density of the lumbar spine <sep> efficacy and safety <sep> percentage change in bone mineral density of the lumbar spine <sep> loss of bone in the lumbar spine <sep>'], 'punchline_text': ['parameters of bone remodeling alkaline phosphatase and osteocalcin decreased significantly in the calcitonin-treated group but not in the control group. <sep>', 'the bone mass in the calcitonin group increased by 2.7 in the first year while in the group receiving calcium alone it decreased by 2.8 this difference was significant. <sep>', 'there were no significant differences between groups in bone loss over 12 months at the lumbar spine l1-l4 although analysis of the upper segment l1-l2 suggested some possible benefit of sct. <sep>', 'in the controls there were significant decrements of 1.4 and 3.5 respectively in cortical and cortical and trabecular bone mineral content whereas in subjects on calcitonin there were increments of 2.6 and 2.7 respectively. <sep>', 'the incidence of vertebral fracture was 12.5 calcitonin plus calcium 11 versus placebo plus calcium 14 ns with four fractures in the first year and one fracture in the second year. <sep>', 'there were no significant differences between groups with respect to age underlying disease initial bone density or corticosteroid dose during the first year. <sep>', 'nasal salmon calcitonin prevented loss of bone in the lumbar spine as measured by dual-energy x-ray absorptiometry. <sep>'], 'population': ['sixty-two steroid-dependent asthmatics who had not received any form of treatment to prevent <sep> corticosteroid-dependent asthma <sep> 20 patients who completed the 12-month follow-up period were analyzed and compared with 20 sex-matched patients from the control group <sep>', 'patients on long term glucocorticoid therapy for asthma <sep> 44 steroid-dependent asthmatic patients <sep>', 'patients with rheumatoid arthritis ra taking low dose glucocorticoids <sep> 32 women with ra <sep> patients with active rheumatoid arthritis receiving low dose <sep>', 'thirty-six patients with steroid-dependent chronic obstructive lung disease and associated steroid osteoporosis <sep> corticoid-induced osteoporosis <sep>', '23 patients <sep> 48 patients with newly diagnosed polymyalgia rheumatica temporal arteritis and other vasculitides <sep>', 'one hundred three patients starting long-term corticosteroid therapy <sep>', 'corticosteroid-treated patients with polymyalgia rheumatica <sep> the setting was a tertiary care university-affiliated hospital and a total of 31 patients were enrolled <sep>'], 'interventions': ['elemental calcium taken daily plus 100 iu of salmon calcitonin <sep> calcium supplementation <sep> calcitonin <sep>', 'salmon calcitonin nasal spray <sep> calcitonin <sep> calcium supplement <sep> calcium alone <sep> nasal calcitonin <sep> calcitonin <sep> injectable calcitonin <sep>', 'sct 100 iu/day and calcium ca <sep> intranasal salmon calcitonin <sep> glucocorticoid therapy <sep> intranasal sct <sep> ca alone <sep> intranasal salmon calcitonin sct <sep> sct and ca <sep>', 'salmon calcitonin <sep> salmon calcitonin <sep> calcitonin <sep>', 'placebo <sep> salmon calcitonin <sep> supplemental calcium carbonate <sep> vitamin d3 <sep> placebo plus calcium <sep> calcium and vitamin d3 alone <sep> corticosteroids salmon calcitonin with calcium and vitamin d3 <sep> high-dose or long-term corticosteroids <sep>', 'corticosteroid <sep> calcitriol and calcium used prophylactically with or without calcitonin <sep> prolonged corticosteroid therapy <sep> calcitriol plus a placebo nasal spray or double placebo <sep> calcium per day orally and either calcitriol 0.5 to 1.0 microgram per day orally plus salmon calcitonin <sep> calcium calcitriol 1,25-dihydroxyvitamin d3 and calcitonin <sep> calcium calcitriol and calcitonin <sep> calcitriol <sep> calcitonin plus calcitriol <sep> calcitriol <sep>', 'nasal salmon calcitonin <sep> salmon calcitonin nasal spray <sep> placebo <sep> nasal salmon calcitonin <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",calcitonin appears to preserve bone mass in the first year of glucocorticoid therapy at the lumbar spine by about 3 compared to placebo but not at the femoral neck. our analysis suggests that the protective effect on bone mass may be greater for the treatment of patients who have been taking corticosteroids for more than three months. efficacy of calcitonin for fracture prevention in steroid-induced osteoporosis remains to be established.
208,"{'outcomes': ['proportion of patients experiencing no emesis <sep> tolerated <sep> number of emetic episodes <sep> diarrheal episodes <sep> antiemetic activity <sep> nausea and vomiting <sep>', 'vomiting <sep> frequency of emesis during an 8-h-period after enrollment <sep>', 'return visits to the emergency department <sep> vomiting <sep> proportion who vomited while receiving oral rehydration <sep> greater oral intake <sep> mean length of stay in the emergency department <sep> number of episodes of vomiting <sep> rates of hospitalization <sep>', 'hospitalization rates <sep> tolerance of oral fluids <sep> hospital admission <sep> tolerated oral hydration <sep> hospital admission rate <sep> number of mean episodes of vomiting or repeat visits to health care <sep> oral fluid tolerance <sep>', 'free of vomiting <sep> weight gain <sep> frequency of vomiting <sep> mean number of vomiting episodes <sep> number of vomiting episodes fluid intake parents assessment of well-being number of diarrheal episodes and admission rate to hospital <sep> hospital admission rate fluid intake general well-being of the children and potential adverse effects <sep> change of weight <sep> number of diarrhea episodes <sep> vomiting <sep> efficacy and safety <sep>', 'admission rate <sep> median number of episodes of vomiting <sep> rates of intravenous fluid administration and hospital admission <sep> diarrhea <sep> vomiting episodes <sep> number of episodes of emesis <sep> revisit rate <sep> rank sum of episodes of diarrhea <sep> vomiting <sep> vomiting and diarrhea <sep>', 'admission rates <sep> vomiting and diarrhea <sep> intravenous hydration <sep>'], 'punchline_text': ['during 0-24 h the number of emetic episodes experienced was significantly greater p  0.048 with placebo mean  5 than ondansetron mean  2 and the proportion of patients experiencing no emesis was significantly greater p  0.039 with ondansetron 58 than placebo 17%). <sep>', 'as compared with the children who received placebo children who received ondansetron were less likely to vomit both during the first 8-h follow-up in the emergency department relative risk rr 0.33 95 ci 0.19-0.56 nnt 2 95 ci 1.6-3.5 and during the next 24-h follow-up rr 0.15 95 ci 0.07-0.33 nnt 2 95 ci 1.3-2.1). <sep>', 'although the mean length of stay in the emergency department was reduced by 12 percent in the ondansetron group as compared with the placebo group p=0.02 the rates of hospitalization 4 percent and 5 percent respectively p=1.00 and of return visits to the emergency department 19 percent and 22 percent p=0.73 did not differ significantly between groups. <sep>', 'there were no differences in number of mean episodes of vomiting or repeat visits to health care at 24 and 72 hours in the ondansetron dexamethasone or ns groups. <sep>', 'the mean number of vomiting episodes between randomization and follow-up visit was 0.64 in the dimenhydrinate group and 1.36 in the placebo group. <sep>', 'a lower proportion of patients receiving ondansetron compared with placebo required intravenous fluid therapy p .015). <sep>', 'eleven of 51 21.6 95 confidence interval ci 11.3 to 35.3 of subjects who received ondansetron required intravenous hydration and 30 of 55 54.5 95 ci 40.6 to 68 of placebo subjects required intravenous hydration p 0.001 for a difference of 32.9 95 ci 14.54 to 48.37%). <sep>'], 'population': ['paediatric patients <sep> three groups of 12 patients each receiving either a single i.v <sep> acute gastroenteritis <sep>', 'children aged 5 months to 8 years <sep> a hundred and nine patients were enrolled 54 received <sep>', 'children with gastroenteritis and dehydration <sep> 215 children 6 months through 10 years of age who were treated in a pediatric emergency department for gastroenteritis and dehydration <sep> gastroenteritis in a pediatric emergency department <sep> children with gastroenteritis <sep>', 'tertiary care pediatric emergency department <sep> a total of 166 subjects were enrolled data for analysis were available for 44 ns-treated patients 46 ondansetron-treated patients and 47 dexamethasone-treated patients <sep> children with dehydration secondary to vomiting from acute viral gastritis <sep> patients with other medical causes were excluded <sep> children <sep> children aged 6 months to 12 years presenting with more than three episodes of vomiting in the past 24 hours mild/moderate dehydration and failed oral hydration were included <sep> children presenting to the emergency department with refractory vomiting from viral gastritis who had failed attempts at oral hydration <sep> discharged patients were evaluated at 24 and 72 hours for vomiting and repeat health care visits <sep>', 'children with no or mild dehydration were included <sep> children with mild dehydration <sep> 243 children with presumed gastroenteritis and vomiting to rectal dimenhydrinate or <sep> children with acute gastroenteritis <sep> children with infectious gastroenteritis <sep> children with gastroenteritis in countries such as canada and germany <sep>', ""children between the ages of 6 months and 12 years who had vomited at least 5 times during the preceding 24 hours <sep> one hundred forty-five patients were enrolled of whom 51 n=74 <sep> patients with vomiting from gastroenteritis in a pediatric emergency department <sep> children with vomiting from acute gastroenteritis <sep> children suffering from acute gastroenteritis interferes with the oral rehydration process and equally frustrates parents and health care providers <sep> university-affiliated children's hospital ed <sep>"", 'children with acute gastritis or acute gastroenteritis and mild to moderate dehydration who fail initial oral rehydration therapy <sep> we enrolled 106 subjects 51 received <sep> subjects requiring iv hydration corrected in each group <sep> subjects with acute gastritis/acute gastroenteritis and mild to moderate dehydration <sep> convenience sample of subjects 1 to 10 years old with acute gastritis or acute gastroenteritis who failed oral rehydration therapy in the emergency department ed <sep> children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy <sep>'], 'interventions': ['ondansetron <sep> placebo <sep> ondansetron <sep> placebo sterile saline <sep> metoclopramide <sep>', 'ondansetron 0.2 mg/kg or placebo <sep> ondansetron <sep> ondansetron <sep> placebo <sep>', 'placebo <sep> oral rehydration <sep> oral ondansetron <sep> oral-rehydration therapy <sep> ondansetron <sep> ondansetron tablets or placebo <sep>', 'placebo <sep> dexamethasone <sep> ondansetron or dexamethasone <sep> ondansetron <sep> intravenous ns <sep> intravenous fluid therapy alone <sep> ondansetron dexamethasone <sep> ondansetron 0.15 mg/kg or placebo normal saline ns <sep> ondansetron with intravenous rehydration <sep>', 'placebo <sep> dimenhydrinate or placebo <sep> oral rehydration therapy <sep> dimenhydrinate <sep> dimenhydrinate <sep>', 'ondansetron <sep> oral ondansetron or a taste and color-matched placebo <sep> placebo <sep> antiemetic ondansetron <sep> ondansetron <sep> promethazine and metoclopramide <sep> oral rehydration <sep>', 'placebo <sep> iv hydration corrected <sep> weight-based dose of ondansetron <sep> placebo and oral rehydration therapy <sep> oral ondansetron <sep> ondansetron <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>']}",oral ondansetron increased the proportion of patients who had ceased vomiting and reduced the number needing intravenous rehydration and immediate hospital admission. intravenous ondansetron and metoclopramide reduced the number of episodes of vomiting and hospital admission and dimenhydrinate as a suppository reduced the duration of vomiting.
209,"{'outcomes': ['urinary protein to creatinine ratio <sep> risk of clinical end points <sep> renal disease progression <sep> rate of change in gfr <sep> renal outcomes <sep> gfr <sep> composite index of the clinical end points of reduction in gfr of more than 50 or 25 ml/min per 1.73 m(2 end-stage renal disease or death <sep> mean gfr decline <sep>', 'lowering blood pressure <sep> total serum cholesterol hdl cholesterol hba1c fasting serum glucose or plasma insulin <sep> serum lipids and diabetes control <sep> risk of major vascular events <sep> cardiovascular events <sep> acute myocardial infarction stroke or hospitalized angina <sep> biochemical measures <sep> serum lipids and glucose metabolism <sep>', 'blood pressure 168.9 <sep> asthenia <sep> systolic and diastolic blood pressures <sep> total serum cholesterol <sep> occurrence of cardiovascular events <sep> adverse events <sep> hypokalemia <sep> rates of hyperuricemia plasma urate <sep> antihypertensive efficacies tolerabilities and cardiovascular event rates <sep> diastolic blood pressure <sep> blood pressure of the sitting subject heart rate and a standard clinical safety profile electrocardiogram laboratory tests adverse events cardiovascular events and deaths <sep> total cholesterol high-density lipoprotein cholesterol ratio <sep> hyperuricemia and hypokalemia <sep> blood pressure clinical safety <sep> heart rate <sep>', 'fatal or nonfatal myocardial infarction <sep> nonstroke hemorrhage <sep> cardiovascular disease-related death <sep> systolic and diastolic blood pressure <sep> fatal or nonfatal stroke <sep> cardiovascular disease <sep> stroke myocardial infarction or cardiovascular disease-related death <sep> cardiovascular disease-related events <sep>', 'cardiovascular mortality <sep>', 'incidence and progression of complications of diabetes <sep> fatal and nonfatal myocardial infarctions <sep> cardiovascular outcomes <sep> blood pressure blood glucose and lipid concentrations and smoking behavior <sep> myocardial infarction <sep> fatal and nonfatal myocardial infarction <sep>', 'blood pressure goals <sep> systolic blood pressure <sep> blood pressure control <sep> jnc vi blood pressure goals <sep> occurrence of death all cause nonfatal myocardial infarction or nonfatal stroke other cardiovascular death angina adverse experiences hospitalizations and blood pressure control at 24 months <sep> diastolic blood pressure <sep> mortality and morbidity outcomes <sep>', 'plaque progression <sep> plaque regression <sep> relative risk for stroke major cardiovascular events and mortality <sep> clinic blood pressure reductions <sep> cardiovascular events <sep> 24-hour ambulatory systolic/diastolic blood pressure changes <sep> 4-year cbm(max progression <sep> carotid imt progression and number of plaques per patient <sep> yearly imt progression rate <sep>', 'blood pressure <sep> cardiac disease <sep> cardiac morbidity and mortality <sep> blood pressure <sep> cardiac mortality and morbidity <sep>', 'blood pressure change side effects and quality-of-life indices incidence of electrocardiographic and echocardiographic abnormalities and incidence of cardiovascular clinical events including death <sep>', 'time to cardiovascular death myocardial infarction congestive heart failure strokes and coronary revascularization <sep> serum creatinine levels end-stage renal disease and death from any cause <sep> rate of myocardial infarction <sep> congestive heart failure <sep> composite of cardiovascular events <sep> strokes <sep> rates of cardiovascular events <sep> cardiovascular outcomes <sep> composite cardiovascular event rate <sep> adverse cardiovascular events <sep>', 'systolic blood pressure <sep> treatment blood pressures <sep> mean diastolic values <sep> composite of cardiovascular and cerebrovascular events <sep> diastolic blood pressure <sep> cardiovascular events and total mortality <sep> marked systolic blood pressure reduction <sep> total mortality <sep>', 'fatal and non-fatal stroke <sep> incidence of developing diabetes <sep> major cardiovascular events <sep> blood pressure <sep> non-fatal myocardial infarction including silent myocardial infarction and fatal chd <sep> total cardiovascular events <sep>', 'triglyceride level <sep> cardiovascular disease and total mortality <sep>', 'peripheral oedema <sep> deaths <sep> overall cardiovascular or cerebrovascular complications <sep> overall mean blood pressure <sep> morbidity and mortality <sep> serious adverse events <sep> cardiovascular mortality and morbidity <sep> cardiovascular death myocardial infarction heart failure or stroke <sep>', 'vascular events <sep> sd systolic and diastolic blood pressure sbp and dbp respectively of 149.7 <sep> nonmajor vascular events and procedures eg transient ischemic attack dysrhythmia aortic valve replacement and femoral popliteal bypass graft <sep> rate of progression of mean maximum intimal-medial thickness imt <sep> mean dbp <sep> rate of progression of mean maximum imt <sep> rate of progression of mean maximum imt <sep> incidence of vascular events <sep> major vascular events eg myocardial infarction stroke congestive heart failure angina and sudden death <sep> sbp <sep> mean sbp <sep>', 'cardiovascular morbidity or mortality <sep> fatal and non-fatal stroke myocardial infarction and other cardiovascular death <sep> fatal and non-fatal stroke <sep> fatal and non-fatal myocardial infarction <sep> cardiovascular morbidity and mortality <sep> systolic and diastolic blood pressure <sep>'], 'punchline_text': ['ramipril compared with amlodipine retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria. <sep>', 'at the end of follow-up between the two groups there was no significant difference in total serum cholesterol hdl cholesterol hba1c fasting serum glucose or plasma insulin. <sep>', 'similar antihypertensive efficacies tolerabilities and cardiovascular event rates were observed with verapamil and with chlorthalidone. <sep>', 'nonstroke hemorrhage was more common with participants in the coer-verapamil group n  118 compared with the atenolol or hydrochlorothiazide group n  79 hr 1.54 95 ci 1.16-2.04 p .003). <sep>', 'statistical calculations indicate that 6,600 patients followed for four years will be needed 2p  0.05 power 90 to obtain significance if there is a 25 difference between the new and the established therapy. <sep>', 'in this population of patients with diabetes and hypertension we found a significantly higher incidence of fatal and nonfatal myocardial infarction among those assigned to therapy with the calcium-channel blocker nisoldipine than among those assigned to receive enalapril. <sep>', 'two-year blood pressure control was similar between groups. <sep>', 'a significant p<0.0001 effect of lacidipine was found compared with atenolol with a treatment difference in 4-year cbm(max progression of 0.0227 mm intention-to-treat population and 0.0281 mm completers). <sep>', 'blood pressure was reduced by both treatments but the effects of the amlodipine-based regimen were more pronounced especially in the early period blood pressure 4.0/2.1 mm hg lower in amlodipine than valsartan group after 1 month <sep>', 'six classes of drugs were studied 1 acebutolol <sep>', 'the composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan amlodipine or placebo in addition to conventional antihypertensive therapy. <sep>', 'treatments were similarly effective in males and females and in age groups between 60 and 69 years n  763 70 and 79 years n  744 and  or  80 years n  375). <sep>', 'the amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol-based regimen. <sep>', 'will lowering ldl cholesterol in moderately hypercholesterolemic older individuals reduce the incidence of cardiovascular disease and total mortality <sep>', 'deaths were mainly non-vascular nifedipine 176 vs co-amilozide 172 p=0.81). <sep>', 'there was no difference in the rate of progression of mean maximum imt between isradipine and hydrochlorothiazide over 3 years p=.68). <sep>', 'fatal and non-fatal stroke occurred in 159 patients in the diltiazem group and in 196 in the diuretic and beta-blocker group 6.4 vs 7.9 events per 1000 patient-years 0.80 0.65-0.99 p=0.04 and fatal and non-fatal myocardial infarction in 183 and 157 patients 7.4 vs 6.3 events per 1000 patient-years 1.16 0.94-1.44 p=0.17). <sep>'], 'population': ['1094 african americans aged 18 to 70 years with hypertensive renal disease glomerular filtration rate gfr of 20-65 ml/min per 1.73 m(2 enrolled between february 1995 and september 1998 <sep> hypertensive renal disease progression <sep> hypertensive nephrosclerosis <sep> african americans <sep> in september 2000 <sep> patients with hypertensive renal disease and proteinuria <sep>', 'exclusion criteria included a history of coronary heart disease or stroke serum creatinine  1.5 mg/dl albuminuria <sep> patients with hypertension and niddm <sep> niddm patients with hypertension <sep> inclusion criteria included a diagnosis of niddm and hypertension systolic blood pressure of  140 mmhg or diastolic blood pressure of  90 mmhg <sep> 380 hypertensive diabetics <sep>', 'members of a large population of hypertensive patients <sep> 1414 hypertensive patients 692 men and 722 women aged 53.2 <sep> sd <sep>', 'a total of 16 602 participants diagnosed as having hypertension and who had 1 or more additional risk factors for cardiovascular disease were enrolled between september 1996 and december 1998 and followed up until december 31 2000 <sep> hypertensive patients <sep> 661 centers in 15 countries <sep> 8241 participants received 180 mg of <sep>', 'elderly hypertensives <sep> patients in primary health care 300 centres <sep> old patients with hypertension stop-hypertension 1 was conducted in men and women aged 70-84 years <sep> old patients with hypertension <sep> hypertensive patients <sep> patients started in september 1992 and so far more than 100 patients/week have been included <sep> old patients with hypertension <sep>', 'group 237 patients and the enalapril group 233 patients throughout five years of follow-up <sep> subgroup of patients in the abcd trial who had hypertension <sep> patients with non-insulin-dependent diabetes mellitus and hypertension <sep> patients with non-insulin-dependent diabetes and hypertension <sep> patients with diabetes and hypertension <sep> 470 patients in the trial who had hypertension base-line diastolic blood pressure  or  90 mm hg <sep>', 'patients with heart failure diabetes or renal impairment <sep> patients with coronary artery disease <sep> 22 576 hypertensive cad patients aged 50 years or older which was conducted september 1997 to february 2003 at 862 sites in 14 countries <sep> hypertensive cad patients <sep> coronary artery disease cad <sep> hypertensive patients <sep> less than 140 mm hg systolic and less than 90 mm hg diastolic and less than 130 mm hg systolic and less than 85 mm hg diastolic if diabetes or renal impairment was present <sep> patients with hypertension and cad treated with a calcium antagonist strategy cas or a non-calcium antagonist strategy ncas <sep>', '2334 patients with hypertension <sep>', 'hypertensive patients at high cardiovascular risk <sep> hypertensive patients at high cardiovascular risk treated with regimens based on <sep> 15?245 patients aged 50 years or older with treated or untreated hypertension and high risk of cardiac events <sep>', 'patients with mild hypertension <sep>', '1715 adults with type 2 diabetic nephropathy and hypertension serum creatinine levels of 89 micromol/l 1.0 mg/dl to 266 micromol/l 3.0 mg/dl in women and 106 micromol/l 1.2 mg/dl to 266 micromol/l 3.0 mg/dl in men and urinary protein excretion rates of at least 900 mg/d <sep> patients with type 2 diabetes and overt nephropathy <sep> patients with type 2 diabetes and overt nephropathy treated with <sep> patients with diabetes <sep> patients with type 2 diabetic nephropathy who received <sep> 209 centers in the americas europe israel and australasia <sep>', '1882 males and females outpatients  or  60 years <sep> patients were recruited if sitting systolic blood pressure was  or  160 mmhg with a diastolic blood pressure equal or lower than 95 mmhg <sep> males and females and in age groups between 60 and 69 years n  763 70 and 79 years n  744 and  or  80 years n  375 <sep> elderly patients with isolated systolic hypertension <sep> isolated systolic hypertension <sep> elderly patients with isolated systolic hypertension in a prospective study with an open design <sep>', 'the study was stopped prematurely after 5.5 years median follow-up and accumulated in total 106 153 patient-years of observation <sep> 19 257 patients with hypertension who were aged 40-79 years and had at least three other cardiovascular risk factors <sep>', ""moderately hypercholesterolemic older individuals <sep> allhat's main eligibility criteria are 1 age 55 or older 2 systolic or diastolic hypertension and 3 one or more additional risk factors for heart attack eg evidence of atherosclerotic disease or type ii diabetes <sep> 20,000 moderately hypercholesterolemic patients a subset of the 40,000 with a <sep> 40,000 high-risk hypertensive patients <sep>"", 'patients had at least one additional cardiovascular risk factor <sep> high-risk patients with hypertension <sep> 6321 patients aged 55-80 years with hypertension blood pressure  or  150/95 mm hg or  or  160 mm hg systolic <sep>', '883 patients with baseline mean <sep> patients receiving <sep> nine medical center clinics <sep>', 'hypertensive patients <sep> enrolled 10,881 patients aged 50-74 years at health centres in norway and sweden who had diastolic blood pressure of 100 mm hg or more <sep> hypertension <sep>'], 'interventions': ['ramipril <sep> amlodipine intervention <sep> ramipril and amlodipine <sep> dihydropyridine calcium channel blocker amlodipine and a beta-blocker metoprolol <sep> ramipril vs amlodipine <sep> angiotensin-converting enzyme ace inhibitor ramipril <sep> amlodipine <sep> ramipril <sep> metoprolol <sep>', 'fosinopril and amlodipine <sep> open-label fosinopril <sep> fosinopril and amlodipine <sep> amlodipine <sep> lipid-lowering drugs aspirin or antihypertensive agents other than beta-blockers or diuretics <sep> fosinopril versus amlodipine <sep> ace inhibitors and calcium antagonists <sep>', 'verapamil <sep> chlorthalidone <sep> placebo <sep> verapamil and chlorthalidone <sep> captopril <sep> 240 mg sustained-release verapamil <sep> verapamil <sep>', 'coer verapamil <sep> calcium-channel therapy <sep> atenolol <sep> controlled-onset extended-release coer verapamil <sep> atenolol or hydrochlorothiazide <sep> calcium antagonist <sep> hydrochlorothiazide <sep> coer-verapamil <sep>', 'ace-inhibitors enalapril and lisinopril <sep> placebo <sep> calcium antagonists isradipine and felodipine <sep>', 'nisoldipine with enalapril <sep> calcium-channel blocker nisoldipine or the angiotensin-converting-enzyme inhibitor enalapril <sep> enalapril <sep> nisoldipine <sep> calcium-channel blockers <sep> moderate control of blood pressure target diastolic pressure 80 to 89 mm hg with those of intensive control of blood pressure diastolic pressure 75 mm hg <sep> calcium-channel blocker nisoldipine <sep>', 'trandolapril <sep> verapamil-trandolapril <sep> atenolol-hydrochlorothiazide <sep> trandolapril <sep> antihypertensive agents <sep> trandolapril and/or hydrochlorothiazide <sep> atenolol <sep> ncas <sep> calcium antagonist <sep> cas verapamil sustained release or ncas atenolol <sep> hydrochlorothiazide <sep> verapamil-trandolapril <sep> cas <sep>', 'calcium antagonist lacidipine <sep> lacidipine or atenolol <sep> lacidipine <sep> atenolol <sep>', 'amlodipine <sep> valsartan <sep> valsartan or amlodipine <sep>', 'amlodipine calcium antagonist 3 chlorthalidone diuretic 4 doxazosin alpha 1 antagonist <sep> enalapril <sep> angiotensin-converting enzyme inhibitor and 6 placebo <sep> nutritional-hygienic advice to reduce weight and sodium and alcohol intakes <sep> acebutolol <sep>', 'placebo <sep> angiotensin-converting enzyme inhibitors <sep> conventional antihypertensive therapy with an angiotensin-receptor blocker irbesartan or a calcium-channel blocker amlodipine or placebo <sep> angiotensin-receptor blockers <sep> amlodipine <sep> irbesartan amlodipine or placebo <sep>', 'chlorthalidone <sep> lacidipine <sep> lacidipine and chlorthalidone <sep> chlorthalidone 12.5 mg o.d. or lacidipine 4 mg o.d <sep> lacidipine or chlorthalidone <sep>', 'amlodipine 5-10 mg adding perindopril 4-8 mg as required amlodipine-based regimen n=9639 or atenolol 50-100 mg adding bendroflumethiazide 1.25-2.5 mg and potassium as required atenolol-based regimen <sep> amlodipine adding perindopril <sep> atenolol <sep> amlodipine <sep> thiazide versus amlodipine with perindopril <sep>', '3-hydroxymethylglutaryl coenzyme a hmg coa reductase inhibitor pravastatin <sep> calcium antagonist amlodipine <sep> angiotensin converting enzyme inhibitor lisinopril and an alpha-adrenergic blocker doxazosin <sep> diuretic chlorthalidone <sep>', 'calcium-channel blocker nifedipine <sep> long-acting calcium-channel blocker or diuretic <sep> atenolol 25-50 mg or enalapril <sep> nifedipine <sep> diuretic combination co-amilozide <sep> nifedipine 30 mg in a long-acting gastrointestinal-transport-system gits formulation n=3157 or co-amilozide hydrochlorothiazide 25 mg corrected plus amiloride <sep> nifedipine <sep>', 'isradipine vs hydrochlorothiazide <sep> isradipine <sep> hydrochlorothiazide <sep>', 'diuretics and beta-blockers <sep> calcium antagonists <sep> diltiazem or diuretics beta-blockers or both <sep> diltiazem <sep> calcium antagonists <sep> diltiazem <sep> diuretics beta-blockers <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",diuretics are preferred first-line over ccbs to optimize reduction of cardiovascular events. the review does not distinguish between ccbs ace inhibitors or arbs but does provide evidence supporting the use of ccbs over -blockers. many of the differences found in the current review are not robust and further trials might change the conclusions. more well-designed rcts studying the mortality and morbidity of patients taking ccbs as compared with other antihypertensive drug classes are needed for patients with different stages of hypertension different ages and with different co-morbidities such as diabetes.
210,"{'outcomes': ['rate of reintubation <sep> simplified acute physiologic score ii <sep> rate of reintubation <sep> duration of mechanical ventilation length of intensive care unit stay mortality rate of tracheotomy secondary end points <sep>', 'icu <sep> duration of mechanical ventilation <sep> icu length of stay <sep> hospital mortality <sep> rates of reinstituting mechanical ventilation <sep>', 'shorter durations of mechanical ventilation <sep> hospital cost savings <sep> median duration of mechanical ventilation <sep> duration of mechanical ventilation from tracheal intubation until discontinuation of mechanical ventilation <sep> hospital mortality rates <sep> need for reintubation length of hospital stay hospital mortality rate and hospital costs <sep> rate of successful weaning <sep>', 'synchronized intermittent mandatory ventilation rate and pressure support ps based on predetermined limits of patient respiratory rate rr and tidal volume tv <sep> number of minutes per hour outside acceptable limits <sep> simv rate and ps reduction <sep> arterial blood gas samples shorter weaning times and less time spent outside acceptable rr and tv parameters <sep> pulse oximeter oxygen saturation <sep> average time on mechanical ventilation prior to weaning <sep> number of arterial blood gas samples drawn <sep>', 'duration of mechanical ventilation <sep> complications  removal of the breathing tube by the patient reintubation tracheostomy and mechanical ventilation <sep> total costs <sep> number of days of intensive care and hospital care <sep> median interval <sep> hospital costs <sep> discontinuation of mechanical ventilation <sep> severe disease <sep>', 'successful extubation <sep> tracheostomies <sep> overall complications included death <sep> median time of mechanical ventilation <sep> glasgow coma scale gcs score <sep> partial pressure of arterial oxygen/fraction of inspired oxygen ratio <sep>', 'intubation time <sep> mv interval and hospital length of stay <sep> pao2/fio2 ratio <sep> icu length of stay <sep>', 'median time to successful extubation <sep> estimated probability of reaching separation potential <sep> median time <sep> rates of reintubation non-invasive ventilation post-extubation tracheostomy sedation neuromuscular blockade and use of corticosteroids <sep>', 'duration of mechanical ventilation <sep> mortality and ventilator discontinuation failure rates <sep> vap <sep> incidence of ventilator-associated pneumonia vap <sep> vap frequency <sep> weaning time and incidence of ventilator-associated pneumonia <sep> incidence of vap <sep>'], 'punchline_text': ['simplified acute physiologic score ii adjusted odds ratio 1.042 per unit 95 confidence interval 1.006-1.080 p  0.022 and inclusion in the control group adjusted odds ratio 2.393 95 confidence interval 1.000-5.726 p  0.05 were the only two independent predictive factors for the risk of extubation failure. <sep>', 'there were no significant baseline differences in patient characteristics between groups. <sep>', 'the hospital mortality rates for the two treatment groups were similar protocol-directed 22.3 vs. physician-directed 23.6 p  .779). <sep>', 'the study suggests that use of the computer-directed weaning system results in fewer arterial blood gas samples shorter weaning times and less time spent outside acceptable rr and tv parameters. <sep>', 'total costs for the intensive care unit were lower in the intervention group median 15,740 vs. 20,890 in the controls p=0.03 hospital costs were lower though not significantly so median 26,229 and 29,048 respectively p=0.3). <sep>', 'overall complications included death 36 reintubation 16 and pneumonia 9%). <sep>', 'intubation time was significantly lower in group i than group ii and fast track recovery group p=0.05). <sep>', 'the study groups showed comparable rates of reintubation non-invasive ventilation post-extubation tracheostomy sedation neuromuscular blockade and use of corticosteroids. <sep>', 'twelve patients in the surgical control group had vap compared with 5 in the surgical vmp group p  0.061). <sep>'], 'population': ['mechanically ventilated neurosurgical and neurologic patients <sep> patients with neurologic disorders <sep> patients with neurologic diseases <sep> three hundred eighteen intubated patients who had been receiving mechanical ventilation for at least 12 hrs and were able to trigger the ventilator <sep>', 'adult patients requiring <sep>', 'nurses and respiratory therapists with traditional physician-directed weaning <sep> medical and surgical intensive care units in two university-affiliated teaching hospitals <sep> patients requiring mechanical ventilation n  357 <sep>', '15 patients who had required prolonged mechanical ventilation and met predetermined weaning tests <sep> patients with complex medical problems from mechanical ventilation and appropriately respond to signs of respiratory failure more effectively than traditional physician-directed weaning methods <sep>', 'in medical and coronary intensive care units <sep> 300 adult patients receiving <sep> adults receiving <sep>', 'mechanically ventilated medical patients <sep> neurosurgical patients <sep> forty 82 <sep> 100 patients over a 14-mo period <sep> neurosurgical nsy patients <sep> patients in the intervention n  49 and control n  51 groups had similar demographic characteristics illness severity and neurologic injuries <sep>', 'patients that underwent cardiac surgery and cardiopulmonary bypass <sep> cardiac surgery <sep> forty-nine patients with low and medium higgins risk score who underwent between february and november 1999 elective surgery at our institution <sep>', '102 patients were equally divided between smartcare/ps and control <sep> one australian intensive care unit <sep>', 'medical patients <sep> university medical center <sep> three hundred eighty-five patients receiving mechanical ventilation between june 1997 and may 1998 <sep> medical and surgical patients by respiratory care practitioners and nurses <sep>'], 'interventions': ['systematic approach to weaning and extubation intervention <sep>', 'mechanical ventilation <sep> uc <sep> protocol-based weaning to usual physician-directed weaning in a closed medical intensive care unit icu with high physician staffing levels and structured system-based rounds <sep> daily screening and a spontaneous breathing trial by respiratory and nursing staff without physician intervention <sep> usual care uc or protocol weaning <sep> discontinue mechanical ventilation <sep>', 'protocol-guided weaning of mechanical ventilation <sep> protocol-directed versus physician-directed weaning from mechanical ventilation <sep> protocol-directed n  179 or physician-directed n  178 weaning from mechanical ventilation <sep> protocol-directed weaning from mechanical ventilation <sep>', 'automatic computer-directed weaning or 2 physician-controlled weaning <sep> computer-directed weaning system <sep>', 'mechanical ventilation <sep> spontaneous breathing <sep>', 'respiratory therapist-driven weaning protocol incorporating daily screens spontaneous breathing trials sbt <sep>', 'mechanical ventilation mv <sep> extubated with the aid of a weaning protocol and group ii control group  25 patients extubated with conservative weaning <sep>', 'conventional versus automated weaning from mechanical ventilation using smartcare/ps <sep> automated weaning system smartcare/ps <sep> smartcare/ps <sep> mechanical ventilation <sep>', 'single ventilator management protocol vmp <sep> protocol weaning of mechanical ventilation <sep> vmp <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",there is some evidence of a reduction in the duration of mechanical ventilation weaning duration and icu los with use of standardized protocols but there is significant heterogeneity among studies and an insufficient number of studies to investigate the source of this heterogeneity. although some study authors suggest that organizational context may influence outcomes these factors were not considered in all included studies and therefore could not be evaluated.
211,"{'outcomes': ['regional functional status scale <sep> time to sustained disability <sep> expanded disability status scale edss <sep> sensitive disability measure and relapse rate <sep> edss hazard ratio hr <sep> disability measures <sep> annual relapse rate <sep>', 'neurological deterioration <sep> time to confirmed progression in disability <sep> time to becoming wheelchair-bound relapse rate and severity number of steroid treatments and hospital admissions <sep> time to confirmed progression of disability <sep>', 'clinical relapses newly active mri lesions and accumulated burden of disease on t2-weighted mri <sep> neutralizing antibodies to ifnbeta-1b <sep> time to progression by  or 1.0 edss point 0.5 point if edss score <sep> tolerated <sep> edss scores <sep> mean change in edss score from baseline relapse-related measures mri activity and a standardized neuropsychological function test <sep> efficacy and safety <sep>', 'msfc progression relapses quality of life and mri activity <sep> first time in a large-scale ms trial <sep> median msfc z-score change <sep> new or enlarging t2-hyperintense brain mri lesions and gadolinium-enhancing lesions <sep> ms functional composite msfc comprising quantitative tests of ambulation timed 25-foot walk arm function nine-hole peg test 9hpt and cognition paced auditory serial addition test pasat <sep> 11 ms quality of life inventory subscales <sep> neutralizing antibodies <sep>'], 'punchline_text': ['annual relapse rate was 0.27 with placebo and 0.25 with ifn rate ratio  0.90 95 ci 0.64 to 1.27 p  0.55). <sep>', 'positive results were also obtained regarding time to becoming wheelchair-bound relapse rate and severity number of steroid treatments and hospital admissions as well as on magnetic resonance imaging variables. <sep>', 'there was no significant difference in time to confirmed progression of edss scores between placebo-treated patients and either of the ifnbeta-1b treatment groups. <sep>', 'new or enlarging t2-hyperintense brain mri lesions and gadolinium-enhancing lesions were reduced at months 12 and 24 both p  0.001). <sep>'], 'population': ['patients with secondary progressive ms <sep> secondary progressive multiple sclerosis <sep> 371 patients with clinically definite spms <sep>', '358 patients with sp-ms <sep> outpatients with sp-ms having scores of 3.0-6.5 on the expanded disability status scale edss received either <sep> secondary progressive multiple sclerosis <sep> patients had been in the study for at least 2 years <sep> patients with sp-ms <sep> patients in the relapsing-remitting phase of multiple sclerosis ms <sep> patients who are in the secondary progressive phase of the disease sp-ms <sep>', 'secondary progressive ms <sep> subjects with secondary progressive multiple sclerosis spms <sep> 939 subjects from the united states and canada with spms and expanded disability status scale edss scores ranging from 3.0 to 6.5 <sep>', '436 subjects with spms and expanded disability status scale edss score 3.5 to 6.5 <sep>'], 'interventions': ['interferon ifn beta <sep> placebo <sep> placebo or subcutaneous ifn beta-1a <sep>', 'interferon beta <sep> placebo <sep> interferon <sep> placebo <sep> interferon <sep> 8 million iu interferon beta-1b every other day subcutaneously or placebo <sep>', 'placebo or ifnbeta-1b <sep> placebo <sep> interferon <sep> interferon beta-1b ifnbeta-1b <sep>', 'interferon beta-1a <sep> ifnbeta-1a 60 micro g or placebo <sep> interferon beta-1a ifnbeta-1a avonex <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",well designed rcts evaluating a high number of patients were included in the review. recombinant ifn beta does not prevent the development of permanent physical disability in spms. we were unable to verify the effect on cognitive function for the lack of comparable data. this treatment significantly reduces the risk of relapse and of short term relapse-related disability. overall these results show that ifns anti-inflammatory effect is unable to retard progression when established. in the future no new rcts for ifns versus placebo in spms will probably be undertaken because research is now focusing on innovative drugs. we believe that this review gives conclusive evidence on the clinical efficacy of ifns versus placebo in spms.
212,"{'outcomes': ['readmitted or died <sep> 1-year cumulative incidence of readmission or death <sep> incidence of readmission mortality and emergency department admission <sep> emergency department admission <sep> readmission and death rates <sep>', 'cardiovascular-related emergency room visits <sep> cost of care <sep> ace inhibitor adherence <sep> hospitalization days <sep> ace inhibitor use <sep>', 'hard cardiac events <sep> cost/utility ratio <sep> cost/utility ratios <sep> appearance of hard events <sep> nyha functional class <sep> cost savings <sep> performance effectiveness and cost/utility ratio <sep> management rate of readmissions therapeutic interventions functional parameters new york heart association nyha functional class left ventricular diameters and ejection fraction deceleration time of early diastolic mitral flow peak oxygen uptake and mitral regurgitation and hard outcomes cardiac death and urgent cardiac transplantation <sep> heterogeneous changes in nyha functional class <sep> mortality and morbidity <sep> cardiac death <sep> effectiveness and cost/utility ratio <sep>', 'quality of life and death or hospital readmissions <sep> death or hospital readmission <sep> quality of life and reduced total hospital admissions and total bed days <sep> physical dimension of quality of life <sep>', 'length of hospital stay <sep> cause death and heart failure hospital admissions <sep> cost-effective <sep> functional status quality of life and beta-blocker prescription rate <sep>', 'events readmission or death <sep> quality of life improved and overall cost of care <sep> time to first event time to first all-cause and hf readmission and time to death <sep> hospital readmissions improved survival and quality of life <sep>', 'cause hospital admission rates and total number of days in hospital at 6 months <sep> quality of life which was self-assessed using the minnesota living with heart failure questionnaire <sep> total number of emergency department visits quality of life and total mortality <sep> required readmission to hospital <sep> number of hospital readmissions and hospital days and improved quality of life <sep> total number of emergency department visits <sep> mortality <sep>', 'mean time to readmission <sep> time to readmission days in hospital and health care costs <sep> health care costs <sep> number of days in hospital <sep> year survival rate <sep> hospitalisation and health care costs <sep>', 'qol or health care consumption <sep> target doses of angiotensin converting enzyme ace inhibitors <sep> qol or readmission rate <sep> quality of life qol and secondary end points were hospitalisation and mortality <sep>', 'hospital-based costs <sep> unplanned readmissions and survival <sep> quality of life <sep> frequency of unplanned readmission plus out-of-hospital death <sep> rate of unplanned readmissions and associated health-care costs prolong event-free and total survival <sep> unplanned readmissions <sep>', 'six-minute walking distance <sep> median total public health care and personal care costs <sep> re-admission rates <sep> median number of re-admissions <sep> number of unplanned re-admissions six-minute walking distance london handicap scale and public health care and personal care costs <sep> handicap in independence <sep> rate of unplanned re-admission <sep> effectiveness and cost-effectiveness <sep>', 'survival and self-care behaviour <sep> deaths <sep> higher self-care scores <sep> admissions <sep> events death or admission <sep> mortality morbidity and self-care behaviour <sep>', 'unplanned outpatient visits <sep> cause readmissions and all-cause deaths <sep> hospital readmissions <sep>', 'risk of readmission <sep> year readmission or mortality and costs of care <sep> adverse clinical outcomes and costs <sep> rate of readmission or death and hospital costs <sep> hospital readmission costs <sep> total number of readmissions <sep> readmission or died <sep>', 'rate of all-cause rehospitalization <sep> rate of rehospitalization for heart failure <sep> died <sep> rate of first rehospitalization for heart failure <sep> heart failure <sep>', 'readmitted with heart failure <sep> admissions for heart failure <sep> spent fewer days in hospital for heart failure <sep> readmissions for any reason <sep>', ""self-care abilities <sep> self-care and quality of life <sep> self-care abilities self-care behavior and quality of life <sep> symptom frequency and symptom distress <sep> quality of life <sep> self-care abilities appraisal of self-care agency scale self-care behavior heart failure self-care behavior scale 3 dimensions of quality of life functional capabilities symptoms and psychosocial adjustment to illness and overall well-being cantril's ladder of life <sep>"", 'unplanned readmission <sep> recurrent hospital stay <sep> risk of death or readmission <sep> death or unplanned readmission event-free survival and rate of recurrent all-cause readmission within 6 months of hospital discharge <sep> recurrent hospitalisation <sep> unplanned readmissions <sep> c+hbi <sep> greater uptake of beta-blocker therapy <sep> recurrent readmission and event-free survival <sep>', 'cardiovascular hospitalizations <sep> cause hospitalizations and total hospital days <sep> hospital days <sep>', 'satisfaction scale <sep> hospital re-admissions days of hospital stay treatment compliance satisfaction with the care received and quality of life euroqol <sep> higher level of treatment compliance <sep> mean days of hospital stay <sep> quality of life <sep> lower risk of re-admission <sep> hospital costs <sep>', 'readmitted because of hf or died <sep> number of days lost to death or hospitalization <sep> hospitalizations <sep> time to death or rehospitalization because of hf and the number of days lost to death or hospitalization <sep> moderate to severe hf <sep> all-cause mortality <sep> number of short hospitalizations <sep> lower mortality <sep>', 'hospital admissions or mortality <sep> minnesota living with heart failure questionnaire scores <sep> hospital admissions <sep> mortality and quality of life minnesota living with heart failure questionnaire and eq-5d <sep> 134 admissions <sep> eq-5d scores <sep> total hospital readmissions <sep>', 'physical dimension of quality of life <sep> mean total costs <sep> overall quality of life <sep> time to first readmission or death <sep> readmissions <sep> length of time between hospital discharge and readmission or death reduced total number of rehospitalizations and decreased healthcare costs <sep> time to first rehospitalization or death number of rehospitalizations quality of life functional status costs and satisfaction with care <sep> patient satisfaction <sep>', '59 chf hospital admissions and 13 deaths <sep> 43 chf hospital admissions and 7 deaths <sep> composite of the number of chf hospital admissions and deaths <sep> quality-of-life score <sep> chronic heart failure chf hospital readmissions and mortality <sep>'], 'punchline_text': ['at 1-year follow-up 62 of the 137 patients 45.3 in the intervention group had been readmitted or died compared with 75 of the 142 52.8 in the control group relative risk=0.86 p=.232). <sep>', 'ace inhibitor use increased from 58 on admission to 83 at discharge p  .0001 and the daily dose in enalapril equivalents increased from 11.3  <sep>', 'patients allocated to usual-care management showed heterogeneous changes in nyha functional class 13 improved and 16 worsened p  ns in contrast the dh group showed significant changes in nyha functional class 23 improved and 11 worsened p  0.009). <sep>', 'there was no significant difference between the intervention and control groups for the combined end-point of death or hospital readmission. <sep>', 'dmp patients reported compared to baseline significant improvements in functional status quality of life and beta-blocker prescription rate. <sep>', 'this comprehensive hospital discharge and outpatient management program prolonged time to first event reduced hospital readmissions improved survival and quality of life of patients hospitalized for hf while reducing cost of management. <sep>', 'compared with usual care care at a multidisciplinary specialized congestive heart failure outpatient clinic reduced the number of hospital readmissions and hospital days and improved quality of life. <sep>', 'the one year survival rate was 71.8 n  79 in the control group and 70.0 n  56 in the intervention group ns). <sep>', 'a nurse based management programme is more effective than follow up in primary care in optimising medication for elderly patients with heart failure. <sep>', 'more intervention-group than usual-care patients remained event-free 38 vs 51 p=0.04). <sep>', 'community nurse-supported post-discharge programme was effective in preserving independence and was probably effective in reducing the number of unplanned re-admissions. <sep>', 'there were fewer patients with events death or admission after 12 months in the intervention group compared to the control group 29 vs 40 p=0.03 and fewer deaths after 12 months 7 vs 20 p=0.005). <sep>', 'there were 81 all-cause hospital readmissions in the intervention group and 82 in the control group p  ns). <sep>', 'the intervention was associated with a 39 decrease in the total number of readmissions intervention group 49 readmissions control group 80 readmissions p  0.06). <sep>', 'to determine whether a telephone-mediated nurse care management program for heart failure reduced the rate of rehospitalization for heart failure and for all causes over a 1-year period. <sep>', 'compared with usual care patients in the intervention group had fewer readmissions for any reason 86 v 114 p=0.018 fewer admissions for heart failure 19 v 45 p<0.001 and spent fewer days in hospital for heart failure mean 3.43 v 7.46 days p=0.0051). <sep>', 'the 3 dimensions of quality of life improved after hospitalization in both groups with no differences between intervention and control group as measured at each follow-up measurement. <sep>', 'c+hbi was associated with a non-significant 45 reduction in the risk of death or readmission when adjusting for potential confounders rr 0.55 95 ci 0.28-1.08 p=0.08). <sep>', 'intervention patients showed a trend toward reduced all-cause hospitalizations and total hospital days. <sep>', 'no differences were recorded in quality of life but the intervention group had a higher score in the satisfaction scale at two months 9.0 sd=1.3 versus 8.2 sd=1.8 p=0.026]. <sep>', 'there were slightly more hospitalizations in the 2 intervention groups basic intervention group p  .89 and intensive support group p  .60). <sep>', 'this community pharmacist intervention did not lead to reductions in hospital admissions in contrast to those found in trials of specialist nurse led interventions in heart failure. <sep>', 'a comprehensive transitional care intervention for elders hospitalized with heart failure increased the length of time between hospital discharge and readmission or death reduced total number of rehospitalizations and decreased healthcare costs thus demonstrating great promise for improving clinical and economic outcomes. <sep>', 'there were 43 chf hospital admissions and 7 deaths in the intervention group as compared with 59 chf hospital admissions and 13 deaths in the nonintervention group p  0.09). <sep>'], 'population': ['patients discharged from hospital following admission for heart failure <sep> 279 hf patients who were discharged from a tertiary-care hospital between february 2001 and june 2002 <sep> heart failure hf patients implemented in a home care unit <sep> patients with dementia terminal non-cardiac disease or chronic obstructive pulmonary disease were excluded <sep>', 'in stage 1 766 patients <sep> hospitalized patients with heart failure <sep> patients with hf <sep> patients with heart failure hf remain poor <sep>', '234 prospective patients discharged by a hf unit were randomized to two management strategies 122 patients to usual community care and 112 patients to a <sep> chronic heart failure <sep> chf patients <sep> chronic heart failure chf outpatients <sep>', 'patients with chronic heart failure <sep> one hundred and ninety-seven patients admitted to auckland hospital with an episode of heart failure were enrolled in the study <sep> patients with heart failure <sep>', 'elderly patients benefit from disease management programmes dmps <sep> elderly heart failure patients <sep> consecutive older outpatients <sep> elderly heart failure patients <sep> 6 years 48 women <sep> elderly patients with heart failure <sep> 173 patients aged  or 70 years mean age 77 <sep>', 'patients admitted with decompensated hf <sep> a non-selected cohort of patients hospitalized for hf <sep>', 'multidisciplinary congestive heart failure clinic <sep> 230 eligible patients who had experienced an acute episode of congestive heart failure to standard care n  115 or follow-up at a multidisciplinary specialized heart failure outpatient clinic n  115 <sep>', '190 patients aged 65-84 years 52.3 men hospitalised because of heart failure <sep> patients with heart failure discharged after hospitalisation reduces health care costs and the need for readmission <sep> university hospital with a primary catchment area of 250,000 inhabitants <sep>', 'patients with heart failure new york heart association class ii-iv and left ventricular systolic dysfunction aged 60 years or more <sep> all patients were scheduled for three observational study visits at six month intervals <sep> 208 participants 58 were men mean age was 75 years and mean ejection fraction 34 <sep> elderly patients discharged with heart failure from a university hospital <sep> elderly patients with heart failure <sep> patients with initial low qol had a poor prognosis <sep> heart failure <sep>', 'chronic chf patients discharged home after acute hospital admission <sep> patients with chronic congestive heart failure <sep> patients with congestive heart failure chf <sep> patients with chronic chf <sep>', '105 hospitalized patients aged 60 years or over with chronic heart failure and history of hospital admission(s in previous year <sep> older chronic heart failure patients <sep> older patients with chronic heart failure <sep>', '106 patients <sep> patients with heart failure <sep> patients hospitalised due to heart failure for 12 months after discharge <sep>', 'two hundred consecutive patients admitted to the internal medicine department with a diagnosis of hf <sep>', 'patients with hf <sep> patients with heart failure hf <sep> patients with heart failure <sep> patients with hf including medical components <sep> patients hospitalized with hf <sep>', '5 northern california hospitals in a large health maintenance organization <sep> patients hospitalized for heart failure from may 1998 through october 2001 <sep> patients care with primary care physicians <sep> patients with heart failure at low risk <sep> patients with chronic illness <sep> 2786 patients screened 462 met clinical criteria for heart failure and were randomly assigned 228 to intervention and 234 to usual care <sep> low-risk patients with heart failure <sep>', '165 patients admitted with heart failure due to left ventricular systolic dysfunction <sep> patients with chronic heart failure <sep> acute medical admissions unit in a teaching hospital <sep> heart failure <sep> patients admitted to hospital with heart failure <sep>', 'patients with advanced heart failure <sep> university hospital in maastricht the netherlands <sep> patients with advanced new york heart association class iii-iv heart failure <sep> 179 patients mean age 73 years 58 men new york heart association classification iii and iv admitted to a university hospital with symptoms of heart failure <sep>', 'patients with chf <sep> chronic heart failure <sep> chf patients with evidence of left ventricular systolic dysfunction admitted to two hospitals in northern england <sep> chf patients <sep>', '200 patients with high baseline use of approved hf pharmacotherapy <sep> heart failure hf <sep>', 'patients admitted for hf <sep> 134 patients were included with a mean age of 75 years and a low educational level <sep> patients with heart failure <sep> patients with heart failure hf <sep>', '1023 patients were enrolled after hospitalization because of hf <sep> patients with heart failure <sep> heart failure coach <sep>', 'heart failure patients <sep> 293 patients diagnosed with heart failure were included 149 intervention 144 control after an emergency admission <sep> patients with heart failure <sep>', 'two hundred thirty-nine eligible patients were aged 65 and older and hospitalized with heart failure <sep> older adults hospitalized with heart failure <sep> six philadelphia academic and community hospitals <sep> mean age of patients control n=121 intervention n=118 enrolled was 76 43 were male and 36 were african american <sep> elders hospitalized with heart failure <sep>', 'two hundred patients hospitalized with chf at increased risk of hospital readmission <sep> heart failure outpatients at high risk of hospital readmission <sep> hospitalized high-risk patients with chf <sep> the median age of the study patients was 63.5 years and 39.5 were women <sep>'], 'interventions': ['primarily educational intervention <sep> home care unit intervention <sep>', 'patient support program psp education about hf self-monitoring adherence aids newsletters telephone hotline <sep> angiotensin-converting enzyme ace inhibitors and other hf medications <sep> disease management program <sep>', 'hf management program delivered by the dh <sep> heart failure hf management program delivered by day-hospital dh and usual care <sep>', 'usual care <sep> personal diary to record medication and body weight information booklets and regular clinical follow-up alternating between the general practitioner and heart failure clinic <sep>', ""dmp <sep> usual care <sep> disease management programme <sep> hybrid dmp <sep> intervention consisted in combined hospital-based cardiologists and nurse-coordinators from two heart failure clinics and home-based patient's general practitioner visits care <sep>"", 'discharge and outpatient management program <sep> comprehensive hospital discharge and outpatient heart failure management program <sep> usual care n=174 or an intervention n=164 consisting of a comprehensive hospital discharge planning and close follow-up at a hf clinic <sep>', 'structured outpatient clinic environment with complete access to cardiologists and allied health professionals <sep>', 'education on heart failure and self management with follow up at an easy access nurse directed outpatient clinic <sep> management programme <sep>', 'nurse based outpatient management programme <sep>', 'multidisciplinary home-based intervention <sep>', 'community nurse-supported post-discharge programme <sep> community nurse visits <sep> community nurse-supported hospital discharge programme <sep>', 'nurse-led heart failure clinic or to usual care <sep> nurse-led heart failure clinics <sep>', 'intervention group nurse-led education programme facilitated telephone communication and follow-up visits with an internist at 15 days 1 and 6 months or to the usual care group follow-up by their primary care physician <sep> hf management programme <sep>', 'targeted education and support intervention <sep> formal education and support intervention <sep> education and support intervention <sep>', 'nurse care management provided structured telephone surveillance <sep> telephone-mediated nurse care management program <sep> usual care with nurse management versus usual care alone <sep>', 'specialist nurse intervention <sep>', 'supportive educational intervention <sep> supportive educational nursing intervention <sep> routine care <sep> systematic education and support by a nurse in the hospital and at home <sep>', 'nurse-led clinic and home-based intervention <sep> hybrid c+hbi program of care <sep> c+hbi lasting 6 months post-discharge n=58 or to usual post-discharge care uc n=48 via a cluster randomization protocol <sep> hybrid program of clinic plus home-based intervention c+hbi <sep>', 'standard hf therapy <sep> hf dm <sep> disease management dm <sep>', 'postdischarge pharmaceutical care program <sep> intervention group received information about the disease drug therapy diet education and active telephone follow-up <sep> multifactorial educational intervention <sep>', 'control group follow-up by a cardiologist and 2 intervention groups with additional basic or intensive support by a nurse specializing in management of patients with hf <sep> moderate or intensive disease management program <sep>', 'usual care <sep> lifestyle advice intervention <sep>', 'transitional care intervention <sep> comprehensive transitional care intervention <sep> advanced practice nurses apns <sep>', 'multidisciplinary program or usual care <sep> multidisciplinary outpatient management program <sep> multidisciplinary care <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>']}",amongst chf patients who have previously been admitted to hospital for this condition there is now good evidence that case management type interventions led by a heart failure specialist nurse reduces chf related readmissions after 12 months follow up all cause readmissions and all cause mortality. it is not possible to say what the optimal components of these case management type interventions are however telephone follow up by the nurse specialist was a common component. multidisciplinary interventions may be effective in reducing both chf and all cause readmissions. there is currently limited evidence to support interventions whose major component is follow up in a chf clinic.
213,"{'outcomes': ['brief psychiatric rating scale bprs clinical global impression cgi and modified scale for the assessment of negative symptoms sans summary scores <sep> negative symptoms <sep> bprs total bprs positive-symptom cluster and cgi severity of illness item scores <sep> positive symptoms <sep>', 'global evaluation bprs and target symptom ratings <sep> moderate eps and drowsiness <sep> efficacy rapidity of therapeutic onset and safety <sep>', 'panss negative score <sep> safety and tolerability evaluations included extrapyramidal symptoms eps weight gain serum prolactin level and qtc interval <sep> efficacy and safety <sep> panss total panss positive panss-derived bprs core and cgi-severity scores <sep> body weight <sep> efficacy safety and tolerability <sep> qtc interval <sep> positive and negative syndrome scale panss total panss positive panss negative panss-derived brief psychiatric rating scale bprs core clinical global impressions cgi)-severity of illness and mean cgi-improvement scores <sep> eps or prolactin elevation <sep>', 'tardive dyskinesia <sep> antidyskinetic effect <sep> total positive and negative syndrome scale panss score and positive subscale superiority to placebo <sep> total panss general psychopathology and brief psychiatric rating scale subscales <sep>', 'incidence of extrapyramidal symptoms <sep> incidence of extra-pyramidal side effects <sep> positive symptom scores <sep> total scores on the positive and negative syndrome scale for schizophrenia <sep> clinical improvement <sep> extrapyramidal symptom rating scale <sep> safety and efficacy <sep>', 'remission state <sep> number of days of remission <sep>', 'variables basic data mmpi amdp ham-a ham-d <sep>', 'serum prolactin levels <sep> relapse rate <sep> prolactin levels <sep> number of symptom-free days dose <sep>', 'bprs scores and plasma aag levels <sep> mean plasma haloperidol levels <sep> plasma aag levels <sep> plasma aag levels <sep> brief psychiatric rating scale bprs and abnormal involuntary movement scale <sep> plasma alpha-one acid glycoprotein and haloperidol concentrations <sep> blood samples to measure plasma alpha-one acid glycoprotein aag haloperidol and reduced haloperidol concentrations <sep> blood samples <sep> bprs scores <sep>', 'quicker onset of antipsychotic activity <sep> signs of tardive dyskinesia <sep> assessment scales of extrapyramidal side effects <sep>', 'negative symptoms sans]-composite olz-l and olz-h <sep> overall symptomatology improvement brief psychiatric rating scale bprs]-total olz-m olz-h and hal <sep> acute dystonia <sep> positive symptom improvement bprs-positive olz-m olz-h and hal <sep> rate of hal and akathisia <sep> somnolence agitation asthenia and nervousness <sep> prolactin elevations <sep>'], 'punchline_text': ['quetiapine was no different from placebo across the dose range studied regarding incidence of extrapyramidal symptoms or change in prolactin concentrations. <sep>', 'the overall results indicated that the 5 mg and 2 mg haloperidol doses were significantly superior to the 1 mg haloperidol and 25 mg chlorpromazine doses and to placebo. <sep>', 'aripiprazole 15 mg and haloperidol 10 mg significantly improved panss negative score compared with placebo. <sep>', 'risperidone 6 mg was superior to haloperidol on the total panss general psychopathology and brief psychiatric rating scale subscales. <sep>', 'the incidence of extra-pyramidal side effects measured by the extrapyramidal symptom rating scale was significantly higher in patients treated with 16 mg of risperidone or 20 mg of haloperidol than placebo. <sep>', 'at the end of the 3-year trial both chlorpromazine and haloperidol significantly prolonged the remission state as compared to the other three drugs. <sep>', 'in group comparison no antipsychotic action of trazodone in schizophrenic patients could be proved. <sep>', 'propericiazine at 10 mg and 30 mg also increased the number of symptom-free days dose-dependently but at 60 mg the number decreased. <sep>', 'significant correlations between decreasing bprs scores and plasma aag levels were not found with only a strong trend at week 2 r  0.445 p  0.073). <sep>', 'risperidone did not differ from placebo on assessment scales of extrapyramidal side effects but produced significantly less than did haloperidol. <sep>', 'the most common treatment-emergent adverse events included somnolence agitation asthenia and nervousness. <sep>'], 'population': ['patients with acute exacerbation of schizophrenia <sep> three hundred sixty-one patients from 26 north american centers <sep> controlled trial with acute exacerbation of chronic schizophrenia dsm-iii-r <sep>', '50 acute psychotic patients requiring rapid control <sep>', '414 patients with a primary dsm-iv diagnosis of schizophrenia or schizoaffective disorder <sep> conducted at 36 u.s. centers between july 1997 and june 1998 compared <sep> patients with schizophrenia and schizoaffective disorder <sep>', 'patients with severe dyskinesia <sep> 135 inpatients with a diagnosis of chronic schizophrenia <sep> chronic schizophrenic patients <sep>', '388 schizophrenic patients drawn from 20 sites in the united states <sep> schizophrenic patients <sep>', '55 schizophrenics in remission <sep> symptom-free schizophrenics <sep>', '45 patients with major depressive disorder and 75 patients with acute schizophrenia <sep> patients with depressive symptoms <sep> schizophrenic patients <sep>', 'symptom-free schizophrenics <sep> remitted schizophrenic outpatients <sep>', 'thirty six schizophrenic patients <sep> psychiatric patients <sep> schizophrenic patients <sep>', '36 schizophrenic patients in acute exacerbation <sep> schizophrenia <sep>', '335 patients who met the dsm-iii-r criteria for schizophrenia <sep>'], 'interventions': ['haloperidol <sep> placebo <sep> haloperidol and placebo <sep> atypical antipsychotic seroquel quetiapine <sep> quetiapine and haloperidol <sep> seroquel quetiapine <sep> quetiapine <sep> quetiapine <sep>', 'haloperidol <sep> placebo <sep> intramuscular haloperidol <sep> chlorpromazine <sep> parenteral haloperidol <sep>', 'haloperidol <sep> aripiprazole <sep> placebo <sep> aripiprazole <sep> haloperidol aripiprazole <sep> placebo with haloperidol <sep> haloperidol separated from placebo <sep> aripiprazole and haloperidol <sep>', 'haloperidol <sep> placebo <sep> haloperidol 20 mg/day or placebo <sep> risperidone and haloperidol <sep> haloperidol and risperidone <sep> risperidone a new central 5-hydroxytryptamine2 and dopamine d2 antagonist <sep> risperidone <sep> risperidone <sep> placebo and risperidone <sep>', 'haloperidol <sep> placebo <sep> haloperidol daily <sep> risperidone <sep> risperidone <sep>', 'imipramine <sep> psychotropic drugs <sep> haloperidol 3 mg <sep> haloperidol <sep> placebo <sep> chlorpromazine and haloperidol <sep> diazepam <sep> neuroleptics <sep> chlorpromazine <sep> placebo diazepam or imipramine <sep> placebo diazepam 15 mg imipramine 50 mg chlorpromazine <sep>', 'trazodone <sep> amitriptyline daily 20 mg haloperidol daily or placebo daily <sep> amitriptyline <sep>', 'propericiazine <sep> haloperidol <sep> placebo <sep> haloperidol and propericiazine <sep> haloperidol or propericiazine <sep> haloperidol <sep> placebo haloperidol <sep> neuroleptics <sep> propericiazine <sep>', 'placebo or haloperidol <sep> haloperidol <sep> placebo <sep> haloperidol <sep>', 'haloperidol <sep> placebo <sep> risperidone vs. haloperidol and placebo <sep> risperidone <sep> risperidone <sep>', 'haloperidol <sep> placebo <sep> olanzapine <sep> olanzapine <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",haloperidol is a potent antipsychotic drug but has a high propensity to cause adverse effects. where there is no treatment option use of haloperidol to counter the damaging and potentially dangerous consequences of untreated schizophrenia is justified. however where a choice of drug is available people with schizophrenia and clinicians may wish to prescribe an alternative antipsychotic with less likelihood of adverse effects such as parkinsonism akathisia and acute dystonias. haloperidol should not be a control drug of choice for randomised trials of new antipsychotics.
214,"{'outcomes': ['degree of control of dietary protein and blood pressure and the frequency of angiotensin-converting enzyme inhibitor administration <sep> blood pressure <sep> chronic renal failure <sep> residual renal function <sep> survival rate <sep> cumulative renal survival rates <sep> renal survival rate <sep>', 'clearances of inulin and p-aminohippurate fractional excretions of albumin and immunoglobulin g cardiac output plasma renin activity and aldosterone concentration <sep> renal function cardiac output plasma renin activity and aldosterone <sep> slope of l/serum creatinine <sep> hematocrit <sep> slope of l/serum creatinine with time <sep> cardiac output plasma renin activity and aldosterone <sep> renal function <sep> hematocrit increased with r-huepo <sep>', 'deterioration of renal function <sep> blood pressure and hematocrit <sep> tolerated <sep> energy levels and work capacity <sep> serum creatinine and reciprocal of serum creatinine <sep>', 'packed cell volume pcv <sep> erythroid megakaryocyte and granulocyte-monocyte progenitor cells <sep> 51cr red cell mass <sep>', 'maximal oxygen consumption during exercise <sep> hematocrit mean hematocrit <sep> anemia <sep> erythrocyte mass <sep>', 'serial gfrs <sep> gfr mean arterial blood pressure and daily protein intake <sep> renal function <sep> glomerular filtration rate gfr <sep> hematocrit <sep> residual renal function <sep> anemia <sep>', 'median hematocrit <sep> appetite activity level and sense of well-being <sep> blood pressure <sep> rate of the response <sep> hypertension <sep> rate of the decline in renal function <sep> hematocrit rose <sep>', 'exercise capacity <sep> hemoglobin concentration <sep> thb <sep> total hemoglobin thb <sep> renal function <sep> gfr <sep> physical exercise capacity <sep>', 'progression of renal failure 1/serum creatinine v time or change in serum potassium <sep> renal function <sep> anemia <sep> serum ferritin and percent transferrin saturation plasma iron/total iron-binding capacity <sep> quality of life <sep> average systolic and diastolic blood pressure <sep> safety and efficacy <sep>'], 'punchline_text': ['cr doubled in 26 patients 84 in group i as compared with 22 52 in group ii and 21 60 in group iii. <sep>', '22 weeks of r-huepo therapy the slope of l/serum creatinine did not worsen in any patient.(abstract truncated at 250 words <sep>', 'correction of anemia hematocrit of 40 for males 35 for females occurred in 87 of those given 150 u/kg 64 of those given 100 u/kg 46 of those given 50 u/kg rhuepo and in 3 of the placebo group. <sep>', 'there were lesser responses in pcv at the two lower doses of r-huepo and no response in the placebo group. <sep>', 'subjects who received active r-huepo showed a dose-dependent rise in hematocrit mean hematocrit increased 41 from 0.27  <sep>', 'there was a statistically significant increase in hematocrit for the r-huepo-treated group that was not associated with acceleration of deterioration in residual renal function. <sep>', 'all the patients reported improvements in appetite activity level and sense of well-being. <sep>', 'there was a significant correlation between the increase in thb and the increase in exercise capacity in the epo group r  0.81 p less than 0.005). <sep>', 'six of seven treated patients had a significant decrease in serum ferritin and percent transferrin saturation plasma iron/total iron-binding capacity). <sep>'], 'population': ['anemic patients at the predialysis stage with a serum creatinine cr concentration ranging from 2 to 4 average 2.9 mg/dl and a hematocrit ht of less than 30 <sep> nondiabetic patients <sep> renal anemia in dialysis patients <sep> patients with nonsevere or moderate anemia <sep>', 'predialysis chronic renal failure patients <sep> chronic renal failure patients <sep>', 'hypertensive patients <sep> one hundred seventeen patients with anemia related to chronic renal failure not severe enough to require maintenance dialysis <sep> anemia associated with chronic renal failure in predialysis patients <sep>', 'predialysis patients with recombinant human erythropoietin <sep> 12 patients with chronic renal insufficiency creatinine clearances of 0.17-0.51 ml/second 10-30 ml/minute and uremic anemia <sep>', 'predialysis renal patients <sep> pre-dialysis patients <sep> fourteen adult subjects with renal insufficiency mean serum creatinine 473 mumol/l <sep> 61 <sep>', 'forty patients <sep> 83 anemic predialysis serum creatinine 3 to 8 mg/dl patients <sep> chronic renal failure predialysis patients <sep> chronic renal insufficiency patients <sep> predialysis patients <sep>', '17 patients with anemia and progressive renal failure who did not yet require dialysis serum creatinine level 353 to 972 mumol per liter 4.0 to 11.0 mg per deciliter <sep> patients with progressive renal failure without affecting renal function <sep> 14 patients before therapy developed during therapy in 2 of the normotensive patients and worsened in 9 patients who required additional antihypertensive medications <sep>', '89 to 466 <sep> 12 years 6 men 6 women with a mean glomerular filtration rate gfr of 10  4 ml/min x 1.73 m2 <sep> 124 and 357 <sep> patients with moderate renal failure <sep> 12 predialytic uremic patients epo group mean age 46 <sep> predialytic uremic patients <sep>', 'fourteen nondialyzed patients with chronic renal insufficiency serum creatinine 265 to 972 mumol/l 3.0 to 11.0 mg/dl and severe anemia hematocrit less than 30 <sep> predialysis patients without adverse effects on renal function over a 12-week period <sep>'], 'interventions': ['epo <sep> human recombinant erythropoietin epo <sep> erythropoietin therapy <sep> calcium antagonists and angiotensin-converting enzyme inhibitors <sep>', 'erythropoietin therapy <sep> placebo <sep> r-huepo <sep> recombinant human erythropoietin r-huepo therapy <sep>', 'recombinant human erythropoietin <sep> rhuepo <sep> placebo <sep> recombinant human erythropoietin rhuepo <sep>', 'placebo <sep> recombinant human erythropoietin <sep> open label r-huepo <sep> recombinant human erythropoietin r-huepo <sep> r-huepo <sep>', 'placebo <sep> recombinant human erythropoietin r-huepo <sep> recombinant human erythropoietin <sep>', 'recombinant human erythropoietin <sep> r-huepo therapy <sep> huepo therapy <sep> recombinant human erythropoietin r-huepo <sep>', 'recombinant human erythropoietin <sep> erythropoietin therapy <sep> erythropoietin <sep>', 'epo <sep> erythropoietin treatment <sep> erythropoietin epo <sep> hemoglobin 93 <sep>', 'recombinant human erythropoietin <sep> placebo <sep> recombinant human erythropoietin r-huepo or a placebo <sep> r-huepo <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",treatment with rhu epo in pre-dialysis patients corrects anaemia avoids the requirement for blood transfusions and also improves quality of life and exercise capacity. we were unable to assess the effects of rhu epo on progression of renal disease delay in the onset of dialysis or adverse events. based on the current evidence decisions on the putative benefits in terms of quality of life are worth the extra costs of pre-dialysis rhu epo need careful evaluation.
215,"{'outcomes': ['mortality of tetanus <sep> mortality <sep>'], 'punchline_text': ['in the other age group of 13-30 years there were 27 and 38 patients in the treatment and control groups respectively. <sep>'], 'population': ['tetanus patients aged 1-30 years <sep> tetanus <sep> young chicks <sep>'], 'interventions': ['1000 mg ascorbic acid aa <sep> strychnine <sep> conventional antitetanus therapy without aa <sep> ascorbic acid <sep>'], 'punchline_effect': [' sig increase <sep>']}",a single non-randomised poorly reported trial of vitamin c as a treatment for tetanus suggests a considerable reduction in mortality. however concerns about trial quality mean that this result must be interpreted with caution and that vitamin c cannot be recommended as a treatment for tetanus on the basis of this evidence. new trials should be carried out to examine the effect of vitamin c on tetanus treatment.
216,"{'outcomes': ['binge eating and depression <sep>', 'binge eating and purging rates <sep> dietary preoccupation and hunger <sep>', 'recurrence of symptoms <sep> items restraint weight concern and shape concern <sep> energy intake and lost a modest amount of weight <sep> bulimic symptomatology <sep> eating disorder examination ede <sep>', 'symptoms of depression and anxiety <sep> target-eating behaviors <sep> eating behavior <sep>', 'tolerated and had only minor adverse effects <sep> body weight <sep> eating attitudes eating behavior and general psychopathology <sep>'], 'punchline_text': ['cognitive-behavioral therapy was superior to supportive psychotherapy in reducing behavioral symptoms of bulimia nervosa binge eating and vomiting). <sep>', 'at 16 weeks both cognitive-behavioral therapy and the combined treatment were superior to medication given for 16 weeks in reducing binge eating and purging. <sep>', 'nutritional counselling is an effective means of treating bulimia nervosa with improvement maintained up to 3 months follow-up. <sep>', 'the addition of antidepressant treatment to the intensive group psychotherapy component did not significantly improve outcome over intensive group psychotherapy combined with placebo treatment in terms of eating behavior but did result in more improvement in the symptoms of depression and anxiety. <sep>', 'in self-ratings and expert ratings concerning attitudes towards eating eating behavior and general psychopathology significant improvements over time were observed in both groups. <sep>'], 'population': ['bulimia nervosa binge eating and vomiting <sep> 120 women with bulimia nervosa <sep> bulimia nervosa <sep>', 'seventy-one patients meeting dsm-iii-r criteria for bulimia nervosa recruited from an eating disorders clinic or by advertisements <sep> bulimia nervosa <sep>', 'sixty-seven patients referred to specialist eating disorder services who fulfilled strict diagnostic criteria were treated with <sep> bulimia nervosa <sep> patients for whom intensive nutritional counselling or other structured psychological programs <sep>', 'outpatients with bulimia nervosa <sep> bulimic outpatients <sep> bulimia nervosa <sep>', 'bulimic inpatients undergoing intensive psychotherapy <sep> 40 patients with bulimia nervosa according to dsm iii-r criteria <sep> patients participated in an intensive inpatient behavioral psychotherapy program <sep>'], 'interventions': ['desipramine <sep> placebo <sep> fluoxetine <sep> cognitive-behavioral therapy was superior to supportive psychotherapy <sep> psychodynamically oriented supportive psychotherapy <sep> medication and psychotherapy <sep> second antidepressant fluoxetine <sep> cognitive-behavioral therapy <sep>', 'pharmacologic and cognitive-behavioral treatment <sep> continuing cognitive-behavioral therapy <sep> desipramine cognitive-behavioral therapy <sep> desipramine withdrawn at 16 or 24 weeks combined treatment medication withdrawn at 16 or 24 weeks and cognitive-behavioral therapy <sep> cognitive-behavioral therapy <sep>', 'nutritional counselling <sep> intensive nutritional counselling <sep> fluoxetine <sep> fluoxetine 3 x 20 mg/day or placebo <sep> intensive nutritional counselling <sep> fluoxetine <sep>', 'imipramine hydrochloride treatment 2 placebo <sep> placebo <sep> antidepressants and structured intensive group psychotherapy <sep> imipramine treatment combined with intensive group psychotherapy and 4 placebo treatment combined with intensive group psychotherapy <sep>', 'placebo <sep> fluoxetine <sep> placebo control group <sep> fluoxetine or placebo <sep> fluoxetine <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",using a more conservative statistical approach combination treatments were superior to single psychotherapy. this was the only statistically significant difference between treatments. the number of trials might be insufficient to show the statistical significance of a 19 absolute risk reduction in efficacy favouring psychotherapy or combination treatments over single antidepressants. psychotherapy appeared to be more acceptable to subjects. when antidepressants were combined with psychological treatments acceptability of the latter was significantly reduced.
217,"{'outcomes': ['several instances oppositional/aggressive symptoms internalizing symptoms teacher-rated social skills parent-child relations and reading achievement <sep>'], 'punchline_text': ['for most adhd symptoms children in the combined treatment and medication management groups showed significantly greater improvement than those given intensive behavioral treatment and community care. <sep>'], 'population': ['attention-deficit/hyperactivity disorder <sep> children with adhd <sep> 579 children with adhd combined type aged 7 to 9.9 years <sep>'], 'interventions': ['pharmacotherapy and behavior therapy <sep> medication management titration followed by monthly visits intensive behavioral treatment parent school and child components with therapist involvement gradually reduced over time the two combined or standard community care treatments by community providers <sep>'], 'punchline_effect': [' sig increase <sep>']}",further research examining the effectiveness of family therapy versus a no-treatment control condition is needed to determine whether family therapy is an effective intervention for children with adhd. there were no results available from studies investigating forms of family therapy other than behavioural family therapy.
218,"{'outcomes': ['tolerability <sep>', 'sumpi totpar and maximum par maxpar <sep> marginal numerical superiority <sep> analgesic efficacy <sep> pain intensity pi and pain intensity difference pid <sep> pain relief par <sep> analgesic efficacy measures sum pi sumpi sum pid spid and total par totpar <sep>', 'analgesic efficacy <sep> peak pain intensity difference visual analog scale summed pain intensity differences total pain relief peak pain relief time to reduction of pain <sep> duration of analgesic effect <sep>', 'later time to taking escape analgesics <sep> pain scores <sep> pain relief <sep> overall pain scores <sep> overall pain scores auc(0,360 min maximum pain relief pain relief at 1 h after dosage and the number of patients taking escape analgesics <sep>', 'analgesic effect <sep> total and peak analgesia <sep> analgesia <sep>', 'patient self-rating of pain intensity pain relief time to meaningful pain relief need for additional analgesic medication and patient global evaluation <sep> overall analgesic effect <sep> tolerated <sep> analgesic efficacy <sep> relative onset of analgesic response overall analgesic efficacy duration of effect and safety <sep>', 'number of patients requiring rescue medication <sep> rapid analgesia <sep> pain intensity <sep> pain <sep> pain intensity <sep> adverse reaction <sep>', 'side effects <sep> analgesic efficacy <sep> pain intensity pain relief and side effects <sep> pain intensity difference pain relief and global evaluation <sep> analgesic efficacy <sep> severe postoperative pain <sep>', 'incidence of adverse events <sep> pain relief <sep> overall pain relief <sep> analgesic efficacy <sep> efficacy and safety <sep>', 'side effects <sep> serious adverse events <sep> analgesic efficacy and safety <sep> analgesic efficacy and safety <sep>', 'frequency of adverse effects <sep> number of hours until remedication <sep> total and peak analgesia <sep> pain intensity differences peak pain intensity differences total relief peak relief and hours of 50 relief <sep>', 'faster relief and superior overall efficacy <sep> time to onset of relief and overall analgesic efficacy <sep> pain relief and pain intensity difference <sep> postoperative dental pain <sep> serious adverse effects <sep> onset of meaningful relief <sep> pain intensity and relief and stopwatch onset of meaningful relief <sep> median times to onset of relief <sep> meaningful relief <sep>', 'peak and overall analgesic effects <sep> ratings of pain intensity and pain relief <sep> pain relief pain intensity difference total pain relief totpar and summed pain intensity difference spid <sep> rapid onset to meaningful relief <sep> analgesic efficacy and tolerability <sep> meaningful relief <sep> onsets of first perceptible relief and meaningful relief <sep> drug tolerability <sep>', 'postoperative dental pain <sep>', 'small additive effects <sep> sum pain intensity difference total relief of pain and overall evaluation parameters <sep> intensity of pain relief of pain and side effects <sep>', 'frequency of adverse effects <sep> analgesia <sep>', 'relative analgesic efficacy and safety <sep> adverse reactions <sep> pain relief <sep> mean scores <sep> mean response with zomepirac <sep> postsurgical dental pain <sep> analgesic effects <sep>', 'analgesia <sep> pain intensity and pain relief and summary measures <sep> pain relief <sep> median time to onset of analgesia <sep> median time to meaningful pain relief <sep> analgesic efficacy <sep>'], 'punchline_text': ['piroxicam-beta-cyclodextrin and paracetamol were more rapid than piroxicam in inducing analgesia. <sep>', 'the combination was statistically superior to apap 1000 mg on sumpi totpar and maximum par maxpar). <sep>', 'time to remedication a measure of duration of analgesic effect was significantly longer p  0.001 with naproxen sodium median 9.9 hours than with either acetaminophen median 3.1 hours or placebo median 2.0 hours). <sep>', 'at 1 h after dosage pain scores were significantly less p  0.01 after both doses of ketoprofen when compared with placebo. <sep>', 'although efficacy was lower for the acetaminophen-phenyltoloxamine combination than for acetaminophen alone for every variable the contrast for interaction was not statistically significant. <sep>', 'ibuprofen lysine had a significantly p  or  0.05 faster onset of action with greater peak and overall analgesic effect than did effect than did acetaminophen. <sep>', 'there were no significant differences between treatment groups with respect to the number of patients requiring rescue medication however the time to dosing was significantly longer for those taking soluble aspirin when compared with placebo hazard ratio 2.34 95 ci 1.41 to 3.88 p<0.001). <sep>', 'both doses of flurbiprofen resulted in significant analgesia in comparison with placebo acetaminophen and acetaminophen plus codeine as measured by pain intensity difference pain relief and global evaluation. <sep>', 'pain relief after the initial dose of diclofenac-k 2 x 12.5 mg was superior to placebo p  .01 for all efficacy outcomes and comparable to paracetamol 2 x 500 mg). <sep>', 'r ketoprofen possesses analgesic activity and an acceptable side-effect profile in the oral surgery pain model. <sep>', 'flurbiprofen was significantly superior to the acetaminophen codeine combination with respect to the number of hours until remedication. <sep>', 'in addition both ibuprofen and ketoprofen showed statistical superiority over acetaminophen at earlier time points on the time-effect curves for pain relief and pain intensity difference. <sep>', 'ibuprofen liquigel 200 and 400 mg were also significantly more efficacious than acetaminophen 1000 mg on the summary measures totpar 6 and spid 6 p  0.01 and p  0.001 respectively). <sep>', 'a positive dose-effect relationship was evident for both acetaminophen 500 mg. <sep>', 'all four active treatments were statistically superior to placebo for sum pain intensity difference total relief of pain and overall evaluation parameters. <sep>', 'analgesia was similar for ketorolac 10 and 20 mg and ibuprofen 400 mg however these treatments were superior to acetaminophen alone and the acetaminophen-codeine combination. <sep>', 'for many efficacy variables all active treatments were significantly p less than or equal to 0.05 more effective than placebo. <sep>', 'at 4 hours after administration the pain relief was significantly better with tablet acetaminophen than with effervescent acetaminophen. <sep>'], 'population': ['two hundred ninety-eight patients with post-operative pain after the surgical removal of an impacted third molar <sep> post-operative oral surgery pain <sep>', 'acute postoperative pain <sep>', 'postoperative dental pain <sep>', 'patients with post-operative pain after third molar surgery over a 6 h investigation period <sep> postoperative pain after third molar surgery <sep>', 'patients with headache and musculoskeletal pain <sep> 148 outpatients with pain after oral surgery <sep> postoperative oral surgery pain <sep>', 'patients with postoperative dental pain <sep> 240 patients with moderate-to-severe postoperative dental pain <sep>', 'postoperative pain after third molar surgery <sep> patients with postoperative pain after third molar surgery <sep> 3470 <sep> one hundred and sixty-seven patients consented to take part in the study but only 153 were medicated <sep> one hundred and sixty-seven 104 female patients who required the removal of their impacted third molars under general anaesthesia <sep>', 'subjects undergoing the surgical removal of impacted third molars <sep> ambulatory patients <sep>', 'postoperative dental pain <sep> patients with moderate or severe pain within 8 hours of extraction of impacted third molars <sep> pain resulting from extraction of impacted third molar teeth <sep>', 'postoperative dental pain <sep> 177 patients experiencing moderate to severe pain after surgical removal of their impacted third molars <sep>', 'eighty-eight outpatients with postoperative pain after the surgical removal of impacted third molars <sep> postoperative oral surgery pain <sep>', '239 patients with moderate or severe pain following third molar extractions <sep>', 'oral surgery pain <sep> 210 patients experiencing moderate or severe postoperative pain <sep> patients experiencing moderate or severe pain after surgical removal of impacted third molars <sep>', 'outpatients who experienced moderate to severe pain after surgical removal of inpacted third molars <sep>', 'postsurgical dental outpatients as subjects <sep>', 'two-hundred six outpatients with postoperative pain after the surgical removal of impacted third molars <sep> postoperative oral surgery pain <sep>', '182 patients entered the study with moderate pain from a third molar extraction and were evaluated for six hours <sep>', 'postoperative dental pain <sep> 242 patients with moderate or severe pain following dental surgery <sep>'], 'interventions': ['placebo <sep> piroxicam-beta-cyclodextrin and paracetamol <sep> piroxicam <sep> piroxicam 20 mg or piroxicam-beta-cyclodextrin equivalent to 20 mg piroxicam or paracetamol 500 mg or placebo <sep> piroxicam-beta-cyclodextrin piroxicam paracetamol and placebo <sep> paracetamol <sep>', 'apap <sep> apap 1000 mg plus codeine phosphate 60 mg apapcod and placebo pbo <sep> placebo <sep> codeine <sep> acetaminophen <sep> acetaminophen <sep> acetaminophen 1000 mg and codeine phosphate 60 mg versus placebo <sep> acetaminophen apap <sep>', 'placebo <sep> acetaminophen <sep> naproxen sodium <sep> naproxen sodium <sep> naproxen sodium acetaminophen and placebo <sep>', 'placebo <sep> ketoprofen <sep> ketoprofen and paracetamol acetaminophen <sep> paracetamol <sep> racemic ketoprofen <sep>', 'acetaminophen <sep> acetaminophen phenyltoloxamine <sep> acetaminophen-phenyltoloxamine <sep> acetaminophen 650 mg phenyltoloxamine 60 mg a combination of acetaminophen 650 mg with phenyltoloxamine 60 mg or placebo <sep>', 'placebo <sep> ibuprofen lysine 400 mg and acetaminophen <sep> ibuprofen lysine <sep> acetaminophen <sep> ibuprofen lysine and acetaminophen <sep> ibuprofen lysine 400 mg with acetaminophen 1000 mg and placebo <sep>', 'placebo <sep> soluble aspirin and solid paracetamol <sep> soluble aspirin 900 mg and paracetamol <sep> soluble aspirin 900 mg solid paracetamol 1,000 mg or placebo <sep> soluble aspirin <sep> paracetamol <sep>', 'placebo <sep> acetaminophen 650 mg plus codeine <sep> acetaminophen acetaminophen plus codeine and placebo <sep> acetaminophen <sep> placebo acetaminophen and acetaminophen plus codeine <sep> acetaminophen plus codeine <sep> acetaminophen and codeine <sep> flurbiprofen <sep>', 'placebo <sep> diclofenac-k 12.5 mg tablets vs paracetamol 500 mg tablets and placebo <sep> paracetamol and placebo <sep> low-dose diclofenac <sep> diclofenac-k <sep> paracetamol <sep>', 'placebo <sep> acetaminophen 1,000 mg and placebo <sep> r ketoprofen <sep> acetaminophen <sep> ketoprofen <sep> both r ketoprofen <sep> acetaminophen 1,000 mg r ketoprofen <sep> r ketoprofen <sep>', 'placebo <sep> acetaminophen codeine <sep> acetaminophen <sep> flurbiprofen <sep> flurbiprofen 100 mg acetaminophen 600 mg a combination of acetaminophen 600 mg with codeine 60 mg or placebo <sep> acetaminophen-codeine combination and placebo <sep> acetaminophen-codeine <sep> flurbiprofen acetaminophen <sep> flurbiprofen <sep>', 'liquigel ibuprofen <sep> placebo <sep> placebo ketoprofen ibuprofen <sep> acetaminophen <sep> ibuprofen <sep> ketoprofen <sep> ibuprofen and ketoprofen <sep> ibuprofen <sep> liquigel ibuprofen 400 mg ketoprofen <sep> acetaminophen and ketoprofen <sep>', 'placebo <sep> ibuprofen liquigel 200 mg ibuprofen liquigel 400 mg acetaminophen caplets 1000 mg and placebo <sep> ibuprofen liquigel <sep> acetaminophen <sep> ibuprofen <sep>', 'oxycodone and acetaminophen <sep> oxycodone <sep> placebo <sep> acetaminophen <sep> acetaminophen and oxycodone <sep> oxycodone <sep>', 'acetaminophen <sep> acetaminophen 650 of acetaminophen with 60 mg of codeine 650 mg of acetaminophen with 100 mg of d-propoxyphene n and a placebo <sep> placebo <sep> indoprofen <sep>', 'ketorolac tromethamine 10 and 20 mg ibuprofen 400 mg acetaminophen 600 mg a combination of acetaminophen 600 mg plus codeine 60 mg or placebo <sep> placebo <sep> acetaminophen <sep> acetaminophen-codeine <sep> ketorolac <sep> ketorolac ibuprofen acetaminophen and an acetaminophen-codeine combination <sep> ibuprofen <sep>', 'placebo <sep> codeine <sep> acetaminophen alone and placebo <sep> acetaminophen <sep> flurbiprofen ansaid upjohn <sep> flurbiprofen zomepirac sodium acetaminophen plus codeine and acetaminophen <sep> acetaminophen plus codeine <sep> acetaminophen acetaminophen plus codeine or placebo <sep> zomepirac sodium 650 mg of acetaminophen plus 60 mg of codeine <sep> flurbiprofen <sep>', 'acetaminophen <sep> effervescent acetaminophen <sep> tablet acetaminophen <sep> placebo <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",paracetamol is a safe effective drug for the treatment of postoperative pain following the surgical removal of lower wisdom teeth.
219,"{'outcomes': ['chronic obstructive pulmonary disease copd <sep> clinical and functional status quality of life lifestyle and self-management <sep> evolution of dyspnea lung function quality of life scores lifestyle factors or medical treatment <sep> body mass index <sep> risk factors of copd readmission <sep>', 'exercise behavior exercise performance copd exacerbations and mediators such as self-efficacy and social support <sep> forced expiratory volume <sep> self-efficacy for managing dyspnea <sep> physical functioning <sep> chronic respiratory questionnaire <sep> dyspnea with adl <sep> self-reported endurance exercise time <sep>', 'readmissions and mortality <sep>', 'technical quality of vvs <sep> telehomecare quality perception satisfaction <sep>', 'mortality <sep> hospitalisation rate <sep>', 'hospital admissions for exacerbation of copd <sep> unscheduled physician visits <sep> emergency department visits <sep> admissions for other health problems <sep> hospital utilization <sep> number of hospitalizations secondary outcomes included emergency visits and patient health status <sep> impact subscale and total quality-of-life scores <sep>', 'total mean costs of care excluding home health care costs <sep> quality indicators medication compliance knowledge of disease and ability for self-care extent of use of services degree of patient satisfaction <sep> quality indicators patient satisfaction or use <sep>', 'sf-36 general health subscale <sep>', 'questionnaires visual analog scales and other psychosocial measures <sep> serum theophylline levels <sep> unnecessary clinic visits <sep> pulmonary function tests and dyspnea index scores <sep>', 'pulmonary rehabilitation programme <sep> patient self-efficacy <sep> numbers of visits to an accident and emergency department hospitalizations and unscheduled visits by physicians <sep> health care use <sep> self-efficacy scores <sep> chinese self-efficacy scale <sep>', 'hospitalisations and secondly exacerbations general practitioner gp calls and related cost-effectiveness of tele-assistance ta <sep> hospitalisations <sep> acute exacerbations <sep> average overall cost <sep> urgent gp calls <sep> hospitalisations emergency room admissions urgent gp calls or exacerbations <sep> mortality <sep>'], 'punchline_text': ['there were no differences in the evolution of dyspnea lung function quality of life scores lifestyle factors or medical treatment. <sep>', 'self-reported endurance exercise time p  .001 physical functioning p  .04 and self-efficacy for managing dyspnea p  .02 also showed positive improvements over time in both groups with no significant differences with respect to program modality. <sep>', 'results suggest that integrated home telemedicine services can support health professionals caring for patients with chronic disease and improve their health. <sep>', 'there were a total of 567 virtual and 1,057 actual visits conducted for the 53 subjects completing the study. <sep>', 'after 12 months follow-up ic showed a lower hospitalisation rate 1.5+/-2.6 versus 2.1+/-3.1 and a higher percentage of patients without re-admissions 49 versus 31 than uc without differences in mortality 19 versus 16 respectively). <sep>', 'emergency department visits were reduced by 41.0 p .02 and unscheduled physician visits by 58.9 p .003). <sep>', 'remote video technology in the home health care setting was shown to be effective well received by patients capable of maintaining quality of care and to have the potential for cost savings. <sep>', 'although those receiving telehealth had worse ratings on the sf-36 general health subscale after the intervention this measure was only significant when controlling for a number of key variables in the model. <sep>', 'results indicated a significantly lower p less than 0.05 number of changes in concomitant drug therapy in the home tdm group compared with controls. <sep>', 'studies of cardiac and diabetic patients have shown that telephone follow-up care is an effective approach to increasing self-efficacy. <sep>', 'only copd patients as a separate group had fewer hospitalisations emergency room admissions urgent gp calls or exacerbations. <sep>'], 'population': ['113 exacerbated copd patients 14 female mean sd age 73(8 years fev(1 <sep>', 'people living with copd <sep> 39 participants who completed the study female 44 age 69.5 <sep> people with chronic obstructive pulmonary disease copd <sep> 50 participants with moderate to severe copd who were current internet users to either the edsmp n  26 or <sep> patients with chronic obstructive pulmonary disease <sep>', 'chronic patients suffering from chronic obstructive pulmonary disease copd <sep> telemedicine experience for chronic care in copd <sep> patients with chronic disease <sep>', 'subjects receiving <sep> congestive heart failure chronic obstructive pulmonary disease and chronic wound-care patients receiving skilled home nursing care <sep> 567 virtual and 1,057 actual visits conducted for the 53 subjects completing the study <sep> telehomecare linking homebound patients with their home health-care nurses over the <sep>', '155 exacerbated copd patients 17 females were recruited after hospital discharge from centres in barcelona spain and leuven belgium <sep> chronic obstructive pulmonary disease patients <sep> copd patients <sep> hospital admissions due to chronic obstructive pulmonary disease copd exacerbations <sep>', 'chronic obstructive pulmonary disease copd <sep> 7 hospitals from february 1998 to july 1999 <sep> copd patients <sep> all patients had advanced copd with at least 1 hospitalization for exacerbation in the previous year <sep> patients with chronic obstructive pulmonary disease <sep> patients with moderate to severe disease <sep>', 'newly referred patients diagnosed as having congestive heart failure chronic obstructive pulmonary disease cerebral vascular accident cancer diabetes anxiety or need for wound care were eligible for random assignment to intervention n  102 or control n  110 groups <sep> quasi-experimental study conducted from may 1996 to october 1997 <sep>', 'patients diagnosed with copd and/or chf who were prescribed home health-care services <sep> patients with chronic obstructive pulmonary disease copd and/or congestive heart failure chf <sep>', 'outpatients with chronic obstructive pulmonary diseases copd or asthma who were receiving long-term theophylline therapy <sep>', 'cardiac and diabetic patients <sep> 60 participants 30 telephone follow-up 30 control with chronic obstructive pulmonary disease were recruited from an acute care hospital in hong kong <sep> patients with chronic obstructive pulmonary disease <sep> chronic obstructive pulmonary disease <sep>', '240 patients 101 with chronic obstructive pulmonary disease copd <sep> chronic respiratory failure patients <sep> chronic respiratory patients requiring oxygen or home mechanical ventilation experience frequent exacerbations and hospitalisations with related costs <sep>'], 'interventions': ['integrated care intervention <sep> individually tailored care plan at discharge shared with the primary care team and access to a specialized case manager nurse through a web-based call centre <sep> integrated care ic n=44 or usual care uc <sep>', 'dyspnea self-management programs internet-based edsmp and face-to-face fdsmp <sep> fdsmp <sep> internet-based versus face-to-face dyspnea self-management program <sep>', 'integrated home telemedicine services <sep>', 'physiological monitoring and video conferencing/internet access <sep> control standard home health care hhc and two intervention standard care plus video conferencing/internet access the above plus physiological monitoring <sep> plain old telephone system pots <sep>', 'integrated care ic n  65 age mean+/-sd 70+/-9 yrs forced expiratory volume in one second fev(1 <sep>', 'self-management interventions <sep> self-management program or to usual care <sep> comprehensive patient education program administered through weekly visits by trained health professionals over a 2-month period with monthly telephone follow-up <sep>', 'remote video technology <sep> routine home health care home visits and telephone contact <sep>', 'home health care through a combination of traditional face-to-face and telemedicine visits <sep> control group where only conventional home care <sep> home telehealth <sep>', 'theophylline levels <sep> theophylline <sep> home therapeutic drug-monitoring tdm <sep> home tdm or traditional tdm controls <sep>', 'nurse-initiated telephone follow-up <sep>', 'oxygen or home mechanical ventilation <sep> 1-yr ta programme while controls received traditional care <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>']}",telehealthcare in copd appears to have a possible impact on the quality of life of patients and the number of times patients attend the emergency department and the hospital. however further research is needed to clarify precisely its role since the trials included telehealthcare as part of more complex packages.
220,"{'outcomes': [""overall clinical response rate <sep> efficacy and safety <sep> 70-point reduction in crohn's disease activity index <sep>""], 'punchline_text': ['lenalidomide was generally well tolerated with only one serious adverse event a deep vein thrombosis being attributed to treatment. <sep>'], 'population': [""crohn's disease <sep> subjects with moderately severe active crohn's disease <sep> 89 subjects <sep> moderately severe active crohn's disease <sep>""], 'interventions': ['lenalidomide an analogue of thalidomide <sep> placebo <sep> lenalidomide 25 mg daily 5 mg daily or placebo <sep> lenalidomide <sep> lenalidomide <sep>'], 'punchline_effect': [' no diff <sep>']}",the results of one well designed study using lenalidomide did not show any statistically significant benefit over placebo. the use of thalidomide or lenalidomide for induction of remission in crohn's disease is not recommended until data from a definitive study are available.
221,"{'outcomes': ['diary symptoms and quality of life <sep> area under the curve for forced expiratory volume in 1 s fev(1 <sep> area under the curve for fev(1 <sep> symptoms <sep> quality of life <sep>', 'salmeterol xinafoate <sep> dyspnea <sep> lung function <sep> efficacy and safety <sep> adverse effects <sep>', 'bronchodilator response <sep> tolerated <sep>', 'specific airway conductance sgaw <sep> daytime symptom scores and morning peak expiratory flow <sep> fev1 <sep> bronchodilator response <sep> fev1 and sgaw <sep> airways obstruction <sep> efficacy and safety <sep>'], 'punchline_text': ['compared with placebo both doses of formoterol significantly improved symptoms all p  or  0.007 and quality of life p  0.01 for total scores whereas ipratropium did not show significant effects all p  or  0.3). <sep>', 'both salmeterol and ipratropium reduced dyspnea related to activities of daily living compared with placebo this improvement was associated with reduced use of supplemental albuterol. <sep>', 'salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with copd including those unresponsive to albuterol. <sep>', 'there was added benefit from the combination therapy in terms of improvement in airways obstruction but not for improvement in symptom control or need for rescue salbutamol. <sep>'], 'population': ['chronic obstructive pulmonary disease <sep> chronic obstructive pulmonary disease copd <sep> 780 patients with copd <sep>', 'patients with copd <sep> four hundred eleven symptomatic patients with copd <sep> copd <sep>', 'patients with copd <sep> four hundred and five patients with copd <sep> patients were stratified on the basis of bronchodilator response to albuterol  12 and  200-ml improvement <sep> chronic obstructive pulmonary disease copd <sep> patients with chronic obstructive pulmonary disease <sep>', 'patients with severe stable chronic obstructive pulmonary disease <sep> patients n=144 age 64+/-7 yrs forced expiratory volume in one second fev1 44+/-11 pred participated in a three-centre double-blind double <sep> patients with stable chronic obstructive pulmonary disease <sep>'], 'interventions': ['formoterol and ipratropium <sep> placebo <sep> formoterol <sep> ipratropium bromide <sep> ipratropium bromide 40 microg four times daily or placebo <sep> inhaled formoterol <sep> ipratropium <sep> inhaled formoterol dry powder versus ipratropium bromide <sep>', 'inhaled ipratropium bromide <sep> placebo <sep> placebo and ipratropium <sep> inhaled salmeterol <sep> salmeterol xinafoate <sep> ipratropium <sep> salmeterol and ipratropium <sep> ipratropium bromide and inhaled placebo <sep> salmeterol <sep>', 'anticholinergic bronchodilator and placebo <sep> salmeterol <sep> ipratropium <sep> salmeterol 42 microg twice daily ipratropium bromide 36 microg four times daily or placebo <sep> salmeterol <sep> long-acting inhaled beta2-adrenergic agonist salmeterol xinafoate <sep>', 'placebo <sep> salmeterol alone or salmeterol plus ipratropium <sep> salmeterol plus ipratropium <sep> ipratropium <sep> salmeterol <sep> salmeterol 50 microg b.i.d. salmeterol 5 microg b.i.d. plus ipratropium 40 microg q.i.d. or placebo <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",the available data from the trials suggest that there is little difference between regular long term use of ipb alone and salmeterol if the aim is to improve copd symptoms and exercise tolerance. however salmeterol was more effective in improving lung function variables. in terms of post-bronchodilator lung function combination therapy conferred modest benefits a significant improvement in hrql and reduced supplemental short-acting beta-agonist requirement although this effect was not consistent. additional studies are needed to assess the relative effects of combining therapies using validated subjective measurements and should consider concordance and the convenience of people having to use different inhaler devices.
222,"{'outcomes': ['relapse rates <sep> goiter size <sep> dropout rate <sep> relapse of overt hyperthyroidism <sep> relapse of hyperthyroidism <sep>', 'gastrointestinal side effects or leucopenia <sep> drug intolerance symptoms <sep> rapid goitre growth <sep> frequency of graves disease complications and thyrotoxicosis recurrence <sep> complications of graves disease <sep> disease relapse <sep> ophthalmic symptoms <sep>', 'remission rate <sep>', 'relapse rate <sep> serum tsh <sep> relapse <sep> clinical parameters thyroid hormones or tsh binding inhibitory immunoglobulins tbii levels <sep> relapse of hyperthyroidism <sep>', 'antibodies to tsh receptors <sep> tsh secretion <sep> level of antibodies to tsh receptors further <sep> production of antibodies to tsh receptors and the frequency of recurrence of hyperthyroidism <sep> levels of antibodies to tsh receptors <sep> recurrences of hyperthyroidism <sep> level of antibodies to tsh receptors <sep> mean serum thyroxine concentration <sep>', 'relapse rates of graves disease <sep> rate of normalization of serum thyroid function tests or in serum thyroid auto-antibody levels <sep> relapse of graves disease <sep> 2-year post-treatment remission rates <sep> median relapse-free interval <sep> rate of normalization of serum thyroid function tests changes in serum thyroid auto-antibody levels and the rate of side-effects <sep>', 'serum thyrotropin concentration <sep> recurrence rates <sep> normal serum thyrotropin concentration <sep> hyperthyroidism <sep> recurrence rate 20 times lower <sep> recurrence of hyperthyroidism <sep> serum thyrotropin concentrations <sep>', 'relapse rates <sep> remission rates <sep> long-term remission rates <sep> remission rates or delays relapse <sep> target tsh concentration <sep>', 'lasting remission <sep> goiter size frequency of ophthalmopathy tsh and trab levels <sep> relapse rate <sep> serum levels of ft4 t3 stsh and tsh receptor antibody trab <sep> suffered relapse <sep>', 'serum free t4 and t3 and tsh concentrations <sep> recurrence risk <sep> regular cigarette smoking <sep> positive tshr-ab <sep> serum total t4 and tri-iodothyronine t3 free t4 and t3 tsh tsh-receptor antibodies tshr-ab thyroid scintigraphy and echography <sep> remission rate <sep> final outcome and recurrence rates <sep> tshr-ab titers <sep> overall relapse rate <sep>', 'high trab levels and goiter weight <sep> recurrence rate <sep> trab levels and goiter weight <sep> recurrence rate <sep> plasma trab levels <sep> recurrence of hyperthyroidism <sep> recurrence of graves disease <sep>', 'thyroid volume <sep> relapse rate <sep> relapse rates <sep> number of side-effects <sep>', 'relapse of hyperthyroidism <sep> remission rates <sep> area of low-to-moderate iodine intake prevalence of 24h urinary iodine excretion <sep> total t3 tsh-receptor antibodies <sep>', 'relapse rates of graves disease <sep> relapse rates <sep> relapse rates of graves disease <sep> relapse rate <sep> relapse <sep> thyrotropin-receptor antibody trab positive <sep>', 'relapse rates <sep> serum tsh <sep> course of endocrine eye signs <sep> thyroid volume <sep> thyroid echostructure <sep> remission rate <sep> overall relapse rate <sep>', 'relapse of hyperthyroidism initial thyroid size <sep> normalize elevated tsh serum concentrations <sep> thyroid volume <sep> relapse of hyperthyroidism <sep> recurrence of hyperthyroidism <sep> serum tri-iodothyronine t3 and thyroxine t4 concentrations <sep>', 'thyroid antibodies serum thyroglobulin and pertechnetate uptake <sep> cigarette smoking <sep> recurrence <sep> frequency of relapse <sep> goitre size pertechnetate uptake and presence of detectable plasma tsh <sep> recurrence of hyperthyroidism <sep>'], 'punchline_text': ['levothyroxine therapy did not influence tsh-receptor antibody nor did it reduce goiter size. <sep>', 'patients of group i and in 3 8.3 of group ii the difference was statistically significant p<0.01). <sep>', 'after the third year of follow-up this difference was not significative p  0.06). <sep>', 'patients who relapsed had bigger goiters at baseline p  0.02 and at the end of treatment p  0.03). <sep>', 'in the patients who received placebo and methimazole the mean serum thyroxine concentration decreased and the level of antibodies to tsh receptors did not change. <sep>', 'there was no significant difference in 2-year post-treatment remission rates on an intention-to-treat basis between the two treatment groups 18.7 vs. 5.9 p  ns). <sep>', 'there was no difference between the recurrence rates in the two groups despite the fact that serum thyrotropin concentrations were undetectable in 73 percent of patients in the carbimazole-t4 group on at least 75 percent of their visits. <sep>', 'there were no significant differences in relapse rates after stopping methimazole. <sep>', 'serum levels of ft4 t3 stsh and tsh receptor antibody trab were measured before starting treatment and at regular intervals during treatment and follow-up after drug withdrawal. <sep>', 'l-t4 administration both during and after atd treatment did not improve the final outcome and recurrence rates were similar in placebo and l-t4-treated patients 30%). <sep>', 'at the beginning of the follow-up period patients who were going to recur had significantly higher trab levels and goiter weight than patients who were not p  0.05). <sep>', 'the corresponding relapse rates calculated on an intention to treat basis were 51.7 vs. 66.7 62.1 vs. 81.5 72.4 vs. 81.5 ns). <sep>', 'no significant difference p>0.05 chi square was seen in relapse of hyperthyroidism after a mean follow-up of 16 months range 12-31 months <sep>', 'there was no difference in relapse rates between the treatment groups p=0.217 log--rank test). <sep>', ""patients who relapsed and patients who remained in remission did not differ with respect to age goitre size ophthalmopathy median iodine excretion serum t4 or serum t3 crook's therapeutic index and thyroid uptake at the time of study entry. <sep>"", 'in conclusion we were unable to detect a preventive effect of exogenous tsh suppression on the recurrence of hyperthyroidism. <sep>', 'by 2 years after stopping treatment recurrence had occurred in 50 of the hd and 66 of the td group. <sep>'], 'population': ['39 patients showed early relapse within 4 weeks 61 endogenous tsh suppression 7 tsh elevation and 14 had to be excluded <sep> patients with successful outcome of 12 to 15 months antithyroid drug therapy were stratified for risk factors <sep> 346 patients with graves disease enrolled 225 were euthyroid 4 weeks after antithyroid drug withdrawal <sep>', '64 patients 47 females and 17 males aged 20-43 years for the first time diagnosed with graves disease <sep> patients with contraindications to the radical graves disease treatment and in prophylaxis of its complications <sep> 28 patients treated only with antithyroid drugs the remaining 36 subjects additionally receiving <sep>', '197 randomly and equally distributed patients <sep>', 'spanish patients <sep> sixty patients with graves disease gd hyperthyroidism <sep> graves disease <sep>', 'patients with graves disease <sep> 109 patients with hyperthyroidism due to graves disease <sep> sixty patients <sep>', 'graves disease with high-dose <sep> thirty-seven patients with a first episode of graves disease were enrolled <sep>', 'patients with graves hyperthyroidism who are treated with an antithyroid drug <sep> 111 patients 89 women and 22 men who had graves hyperthyroidism <sep> patients with hyperthyroidism due to graves disease <sep> patients with graves hyperthyroidism <sep>', 'north american population 199 patients were treated with methimazole until they were euthyroid <sep> one hundred forty-nine patients have been followed for at least 6 months after stopping methimazole mean 27 months <sep> graves disease <sep>', 'patients who stayed in remission and who had relapse <sep> graves hyperthyroid patients <sep> fifty-two untreated graves hyperthyroid patients <sep>', 'graves hyperthyroidism treated with antithyroid drugs <sep> eighty-two consecutive patients 70 women and 12 men mean age 36 years with a first episode of graves hyperthyroidism <sep> patients with graves hyperthyroidism treated with atd <sep>', 'sd and 86 females age 41.7 <sep> graves disease 108 patients with graves disease 22 males age 49.8 <sep>', 'outpatient clinic with patients referred from primary care <sep> 19 patients in the high and 22 in the low-dose group completed 6 months with methimazole <sep> fifty-six patients were included <sep>', '135 newly diagnosed patients with hyperthyroidism due to graves disease <sep> graves disease <sep>', 'patients with graves disease <sep> 218 patients with graves disease <sep>', ""patients after a mean observation period of 4.3 <sep> three hundred and thirteen patients with graves disease <sep> patients who relapsed and patients who remained in remission did not differ with respect to age goitre size ophthalmopathy median iodine excretion serum t4 or serum t3 crook's therapeutic index and thyroid uptake at the time of study entry <sep> graves disease <sep>"", 'patients with graves disease <sep> fifty patients with recent onset of hyperthyroidism <sep>', '70 patients with graves disease the patients being assigned randomly to one or other regimen <sep>'], 'interventions': ['discontinue levothyroxine <sep> levothyroxine therapy <sep> antithyroid drug therapy <sep> levothyroxine in a variable thyrotropin tsh)-suppressive dose for 2 years or no treatment <sep> levothyroxine <sep>', 'immunosuppressive agents mostly steroids <sep> immunosuppressive therapy <sep> azathioprine <sep>', 'synthetic antithyroid drugs <sep>', 'carbimazole plus t4 <sep> carbimazole by a titration regimen <sep> thyroxine <sep>', 'placebo and methimazole <sep> placebo <sep> thyroxine <sep> placebo and 10 mg of methimazole <sep> thyroid-stimulating hormone tsh receptors <sep> methimazole <sep> thyroxine and 10 mg of methimazole <sep> thyroxine or placebo <sep>', 'carbimazole plus thyroxine versus low-dose carbimazole <sep> carbimazole 6 months of 100 mg carbimazole per day plus thyroxine <sep>', 'carbimazole alone <sep> thyroxine t4 <sep> thyroxine <sep> carbimazole plus t4 <sep>', 'methimazole alone <sep> methimazole daily plus sufficient t4 to suppress tsh below 0.6 miu/l <sep> methimazole daily plus sufficient t4 to maintain tsh <sep> methimazole with or without l-thyroxine <sep>', 'carbimazole <sep>', 'taking 100 microg/day l-t4 vs placebo <sep> placebo <sep> l-thyroxine administration tsh-receptor antibodies and smoking <sep>', '100 microg t4 or 25 microg t3 or placebo <sep> t4 and t3 <sep> tsh <sep>', 'methimazole <sep> methimazole 60 mg day-1 combined with thyroxine <sep>', 'exogenous t3 <sep> methimazole alone and in combination with triiodothyronine <sep> triiodothyronine t3 with conventional antithyroid drug therapy <sep>', 'atd combined with l-thyroxine l-t(4 or atd alone <sep> antithyroid drug atd regimens <sep> antithyroid therapy <sep>', 'methimazole <sep> hyperthyroidism with antithyroid drugs <sep> levothyroxine supplementation <sep>', 'tsh suppressive treatment with thyroxine <sep> thyroxine <sep> exogenous tsh suppression <sep> tsh suppressive therapy alone <sep> serum thyrotropin with thyroxine <sep> tsh suppressive treatment <sep>', 'thyroxine <sep> high-dose hd carbimazole 60 mg plus thyroxine 100-150 micrograms daily and titration-dose td regimens of carbimazole <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",the evidence suggests that the optimal duration of antithyroid drug therapy for the titration regimen is 12 to 18 months. the titration low dose regimen had fewer adverse effects than the block-replace high dose regimen and was no less effective. continued thyroxine treatment following initial antithyroid therapy does not appear to provide any benefit in terms of recurrence of hyperthyroidism. immunosuppressive therapies need further evaluation.
223,"{'outcomes': ['number of visits of the general practitioner <sep>', 'reduction of anxiety and depression scores <sep> psychophysiological questionnaire <sep> external chance scale <sep> external control subscale <sep> baseline characteristics anxiety depression psychophysiological disorders emotional reactions to asthma attacks panic-fear etc and cognitive variables external control psychological stigma internal beliefs external chance etc. involved in the perceived illness <sep>', 'feasibility and effectiveness <sep> measures of perceived stress <sep> lung function <sep> feasibility and efficacy <sep>', 'bronchial hyper-reactivity <sep> peak expiratory flow rates <sep> bronchial hyper-responsiveness <sep>', 'mcmaster asthma quality of life questionnaire asthma symptom checklist negative emotionality scale knowledge attitude and self-efficacy asthma questionnaire adherence scale and peak flow measurements <sep> symptoms obstruction fatigue better quality of life activity symptoms emotions decreased negative affectivity and increased adherence <sep> cognitive variables knowledge attitude towards asthma self-efficacy and day and night peak flow ratings <sep> asthma morbidity and asthma-related behaviour and cognitions <sep>', 'panic and asthma outcomes <sep> morning peak-flow expiratory rate and asthma-related quality of life <sep>', 'choices sub-scale <sep> total power scores <sep> pulmonary function asthma symptoms quality of life depression anxiety and power differ over time <sep> pulmonary function <sep> spirometry fev1 2 medication use 3 asthma quality of life questionnaire 4 beck depression inventory 5 spielberger anxiety scales a-state and a-trait <sep>', 'daily asthma symptoms and twice-daily peak expiratory flows <sep> oscillation resistance <sep> asthma symptoms <sep> heart rate variability hrv biofeedback <sep> occurrence of severe asthma flares <sep> pulmonary function <sep>', 'ctam bti reduced wheezing and chance loc increased internal loc <sep> 6 poms-bi scores <sep> wlc bti reduced wheezing anxiety and chance loc and increased asthma knowledge attitude and self-efficacy <sep> poms-bi scores except anxiety increased internal loc and reduced problematic behaviors <sep> for bti data collection symptoms lung function <sep> asthma symptoms wheezing coughing sleep activity attacks peak flow and self-report assessments of profiles of mood states poms-bi anxiety hostility depression uncertainty fatigue confusion knowledge attitude and self-efficacy asthma questionnaire kase-aq health attribution test hat for locus of control loc and the revised asthma problem behavior checklist rapbc <sep> asthma knowledge attitude self-efficacy internal loc and peak flow <sep> symptoms and asthma management <sep>', 'forced expiratory flow <sep> pulmonary function <sep> asthma symptoms <sep>', 'pulmonary impedance <sep> respiratory impedance <sep> relaxation <sep> relaxation during emg or rsa biofeedback <sep> respiratory sinus arrhythmia rsa <sep>', 'forced vital capacity fvc forced expiratory volume in the first sec fev1 forced expiratory flow <sep> mesoexpiratory flow <sep> respiratory function <sep>'], 'punchline_text': [""nevertheless the treatment group's sympathomimetics use was significantly reduced by 1 year of treatment p less than 0.05 the use of steroids decreased as well. <sep>"", 'only the asthma rehabilitation group reported lower scores on the psychophysiological questionnaire and on the external control subscale after 1 year. <sep>', 'the treatment group showed significant improvement in measures of lung function compared with the placebo group but analysis revealed no differences in measures of perceived stress. <sep>', 'daily home recordings of symptoms improved by 41 p less than 0.01 peak expiratory flow rates improved by 5.5 p less than 0.01 and use of bronchodilators decreased by 26.2 p less than 0.05). <sep>', 'compared with controls the programme group reported less symptoms obstruction fatigue better quality of life activity symptoms emotions decreased negative affectivity and increased adherence immediately after finishing the programme and at 3 months follow-up. <sep>', 'the results demonstrate that the cbt-ae program is capable of producing substantial and durable antipanic and antianxiety treatment effects and led to substantial but nonsustained improvement in morning peak-flow expiratory rate and asthma-related quality of life. <sep>', 'persons who reduced or discontinued their medications showed neither an increase in pulmonary function prior to medication discontinuation nor a fall in these parameters following discontinuation. <sep>', 'compared with the two control groups subjects in both of the two hrv biofeedback groups were prescribed less medication with minimal differences between the two active treatments. <sep>', 'compared to wlc bti reduced wheezing anxiety and chance loc and increased asthma knowledge attitude and self-efficacy. <sep>', 'listening to music produced greater decreases in peaks of tension than progressive relaxation and it produced greater compliance with relaxation practice but it did not produce any specific therapeutic effects on asthma. <sep>', 'subjects did not report significantly more relaxation during emg or rsa biofeedback than during the control condition. <sep>', 'no significant changes were observed in the control group. <sep>'], 'population': ['90 asthma patients were registered for the treatment in the heidelberg medical clinic <sep> 31 patients who were interested in taking part <sep> asthma patients <sep>', 'forty consecutive asthmatics were randomly enrolled all of whom were diagnosed treated and followed-up according to the international guidelines <sep> patients enrolled in an asthma rehabilitation group arg and in a control group cg <sep> asthmatic patients <sep>', 'individuals with chronic illnesses such as asthma <sep> young adults with asthma <sep> individuals with asthma <sep>', 'a control group 17 patients and 10 patients undergoing treatment with low susceptibility to hypnosis had no change in either bronchial hyper-responsiveness or any of the symptoms recorded at home <sep> patients with moderate asthma after treatment with a hypnotic technique <sep> 39 adults with mild to moderate asthma graded for low and high susceptibility to hypnosis <sep> adult asthmatics who are moderately to highly susceptible to hypnosis <sep>', 'mild-to-moderate asthma patients n=23 <sep> asthmatic subjects who reported complaints and impairment despite adequate medical treatment <sep>', 'adults with asthma and coexisting panic disorder <sep> adults with asthma suffering from coexisting panic disorder <sep> forty-eight women with a confirmed diagnosis of asthma and panic disorder <sep> panic disorder combined with asthma education ae <sep>', 'adults with asthma who do and do not practice mental imagery mi <sep> 16 experimental participants also completed the 4-session imagery protocol <sep> adults with asthma who practice mental imagery <sep> adults with asthma <sep> sixty-eight adults with symptomatic asthma <sep>', 'asthma <sep> the psychophysiology laboratory at the university of medicine and dentistry of new jersey-robert wood johnson medical school and the private outpatient offices of participating asthma physicians <sep> ninety-four adult outpatient paid volunteers with asthma <sep>', 'seventy 70 adults 53 women 17 men with asthma <sep> adult asthma patients <sep>', 'asthma among patients prestabilized on asthma medication <sep> one hundred six asthmatic subjects <sep>', 'asthma <sep> asthmatic adults <sep>', 'homogeneous groups of asthmatic patients n  24 <sep> chronic asthmatic patients with autogenic therapy <sep>'], 'interventions': ['exchange of information discussion sessions on the illness as well as autogenic training or functional relaxation <sep>', 'educational programme and a cognitive-behavioural intervention <sep> psychological intervention <sep> cognitive behavioural intervention <sep>', 'placebo <sep> placebo intervention <sep> 4-week stress management treatment <sep> several behavioral medicine interventions e.g. relaxation training and written emotional expression <sep> self-administered manual-based stress management intervention <sep>', 'hypnotic technique <sep> hypnotherapy <sep>', 'programme or waiting list condition <sep>', 'nurse-administered 8-week group treatment program <sep> cognitive behavioral treatment cbt <sep> cognitive-behavioral treatment combined with asthma education <sep> wait-list control condition <sep>', 'individual imagery instruction <sep>', 'placebo <sep> full protocol ie hrv biofeedback and abdominal breathing through pursed lips and prolonged exhalation 2 hrv biofeedback alone 3 placebo eeg biofeedback and 4 a waiting list control <sep> hrv biofeedback <sep>', 'bti <sep> ctam <sep> imagery critical thinking and asthma education <sep>', 'relaxation and music therapies <sep>', 'rsa biofeedback n  6 and emg biofeedback <sep> respiratory sinus arrhythmia versus neck/trapezius emg and incentive inspirometry biofeedback <sep> emg and incentive inspirometry biofeedback <sep> rsa biofeedback <sep>', 'autogenic therapy and the control group with supportive group psychotherapy <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",this review was unable to draw firm conclusions for the role of psychological interventions in asthma due to the absence of an adequate evidence base. larger well-conducted and reported randomised trials are required in this area in order to determine the effects of these techniques in the treatment of asthma in adults.
224,"{'outcomes': ['random nasal eosinophils <sep> methacholine challenges and random circulating and sputum eosinophils <sep>', 'bronchial reactivity <sep> baseline lung function <sep> histamine sensitivity pc20 <sep>', 'positive reactions <sep> adverse reactions <sep>'], 'punchline_text': ['methacholine challenges and random circulating and sputum eosinophils did not differentiate patients with a negative challenge from those with a positive challenge. <sep>', 'there was no change in baseline lung function after tartrazine but histamine sensitivity pc20 increased significantly in four of the children. <sep>', 'only 4 of 156 patients all polish had positive reactions in a double-blind test as evidenced by a fall in fev1 greater than 25 from baseline and corresponding clinical symptoms. <sep>'], 'population': ['50 patients with a suspicious history studied in detail 96 of those with asa idiosyncrasy had sinusitis and 71 had nasal polyps <sep> adult asthmatic patients <sep>', 'childhood asthma <sep> ten asthmatic children who gave a history of cough or wheeze after orange drinks <sep>', 'one hundred and fifty-six german italian and polish patients with confirmed aspirin-induced asthma <sep> induced asthma <sep>'], 'interventions': ['tartrazine sodium salicylate or acetaminophen <sep> sodium salicylate <sep> acetaminophen <sep> aspirin asa tartrazine <sep> aspirin <sep>', 'placebo capsule <sep> oral tartrazine <sep> tartrazine <sep> oral tartrazine <sep>', 'tartrazine <sep> aspirin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",due to the paucity of available evidence it is not possible to provide firm conclusions as to the effects of tartrazine on asthma control. however the six rcts that could be included in this review all arrived at the same conclusion. routine tartrazine exclusion may not benefit most patients except those very few individuals with proven sensitivity.
225,"{'outcomes': ['hernia recurrence nerve damage testicular atrophy and patient satisfaction <sep> patient satisfaction <sep> hernia recurrence <sep> nerve injuries <sep>', 'recurrence rates <sep>', 'pain scale 1-10 need for analgesia ambulation evaluated by a four-point scale complications and return to work <sep> ambulation grades <sep> postoperative complications return to work and recurrences rate <sep> operative time postoperative pain <sep> pain of a higher scale <sep>', 'complication rate <sep>', 'recurrence rate <sep> duration of surgery the technique of anesthesia the perioperative complications the duration of postoperative care <sep>', 'sliding hernias <sep> lowest recurrence rates <sep>', 'operating time <sep> chronic groin pain <sep> recurrence rate technical difficulty convalescence and chronic pain <sep>', 'recurrence rate <sep> hernia recurrence rate <sep> chronic groin pain <sep>', 'recurrence rate <sep> recurrence <sep>', 'narcotic analgesics <sep> postoperative pain narcotic use and time to resumption of usual activities and employment <sep> postoperative pain duration of narcotic use and time to resumption of usual activity and employment <sep>', 'duration of operation postoperative pain assessed by visual analogue scale vas complications within 30 days duration of sick leave and recurrence within one year <sep> duration of operation pain score or incidence of postoperative complications <sep> sick leave <sep> cost-effective <sep> number of recurrences <sep>', 'recurrence rate <sep> actuarial recurrence rate <sep>', 're-recurrence rate <sep> direct hernia repair for recurrent hernia hernial sac diameter <sep> redoubtable and litigious sequelae of testicular atrophy and chronic ilioinguinal pain <sep> recurrence rate <sep> actual not actuarial recurrence rates <sep> actual 2-year recurrence rate <sep>', 'recurrence of hernia <sep> recurrence rates symptoms including patient satisfaction and infections <sep>'], 'punchline_text': ['nerve injuries were significantly more frequent after open shouldice and lichtenstein repairs. <sep>', 'the life-table method showed the following longterm 12-15 years recurrence rates group i bassini-stetten 33 versus ring narrowing 34 group ii bassini-stetten 32 versus shouldice 15 p  0.033). <sep>', 'there was no significant difference in the two groups with respect to postoperative complications return to work and recurrences rate 2-year follow-up). <sep>', 'the complication rate was high but similar for both techniques 18%). <sep>', 'both operations gave almost the same results in the perioperative period and nearly identical recurrence rate 4.44 in shouldice and 5.0 in bassini-kirschner group). <sep>', 'after a mean follow-up of 30 range 24-48 months there were seven recurrences in the shouldice group and four in the plication darn group p  0.05). <sep>', 'after a follow-up of 36-77 months seven recurrences were found in the shouldice group 95 per cent confidence interval c.i. <sep>', 'hernia recurrence rate was lichtenstein 8 mcvay 10 shouldice 5  p>0.1 at 6-9 years follow-up. <sep>', 'the recurrence rate was no different for staff surgeons and trainees 5.9 versus 5.6 per cent p not significant). <sep>', 'there was no difference between the herniorrhaphy methods with respect to postoperative pain duration of narcotic use and time to resumption of usual activity and employment. <sep>', 'for surgeons in training the lichtenstein open mesh technique is a better method of inguinal hernia repair than the shouldice technique. <sep>', 'fewer recurrences 5.9 were observed with the stainless steel wire shouldice repair than with polypropylene version 6.5 but the difference was not significant. <sep>', 'for repair of recurrent hernia the superiority of the shouldice technique was not statistically significant re-recurrence rate 7.6 versus 13.5 for the original bassini group b. repair of recurrent hernia was the only patient-related risk factor of equal significance as the method of repair. <sep>', 'both types of hernia repair are comparable and effective but long-term results favor the lichtenstein technique for reducing recurrences to a p value of .10 ease of technical mastery and application to the outpatient setting by use of a local anesthetic. <sep>'], 'population': ['280 men with a primary hernia <sep>', '89 patients with 100 hernia repairs had died and for 30 repairs the patients could not be located <sep> from july 1980 to may 1983 102 indirect primary inguinal hernias with a firm posterior wall group i and 263 primary inguinal hernias with a weakened posterior wall group ii were included <sep> for primary inguinal hernia repair <sep>', 'young patients <sep> young patients having a primary hernia <sep> 50 cases age group 18-40 years <sep>', '142 adult male and female patients for primary inguinal hernias by the shouldice or the bassini-kirschner surgical technique <sep>', '129 adult patients mean age 54 17-87 years underwent operation on primary inguinal hernias in their department <sep> 85 patients of 129 <sep> primary inguinal hernia repair <sep>', 'for inguinal hernia <sep> patient age was 58.3(1.5 <sep> range 20-84 years for shouldice repair and 57.0(1.2 range 18-85 years for plication darn <sep> fourteen surgeons in training not familiar with shouldice repair received <sep> fifteen general surgeons operated on 322 patients <sep> 322 inguinal hernias <sep>', 'three hundred patients with primary inguinal hernia <sep>', 'in a u.s. veterans administration hospital 150 primary hernia repairs <sep> primary inguinal hernia repair by surgical trainees <sep>', 'between 1986 and 1992 265 men of mean age 51 range 16-75 years with a primary inguinal hernia <sep>', 'one hundred five adult patients <sep>', 'district hospital sweden <sep> 178 patients were available for evaluation n  89 in each group <sep> inguinal hernia operated on by surgeons in training <sep> 200 men with primary inguinal hernias <sep>', 'between 1983 and 1989 1578 adult males with a total of 1706 nonrecurrent inguinal hernias <sep> 1578 patients <sep> male adult <sep> fifty-nine hernia repairs <sep>', 'seven hundred fifty inguinal hernia repairs <sep>', 'a total of 717 repairs in 672 patients including 45 bilateral repairs have been monitored to date <sep> six hundred seventy-two men with inguinal hernias aged 20 to 90 years seen at the hernia center between january 1 1990 and december 31 1995 <sep> a private suburban hernia center <sep>'], 'interventions': ['shouldice tension-free lichtenstein or laparoscopic tapp repair <sep> shouldice lichtenstein and transabdominal preperitoneal tapp hernia repair <sep> shouldice lichtenstein and transabdominal preperitoneal hernia repairs <sep>', 'shouldice repair <sep> bassini-stetten shouldice and high ligation with narrowing of the internal ring <sep> high ligation and ring narrowing with bassini-stetten repair <sep>', ""shouldice's repair sr and moloney's darn repair dr <sep> shouldice's herniorrhaphy versus moloney's darn herniorrhaphy <sep>"", 'inguinal hernia repair <sep> bassini-kirschner operation <sep>', 'shouldice and bassini-kirschner operation technique <sep>', 'shouldice technique and plication darn <sep> shouldice repair or plication darn <sep> constant supervision <sep>', 'shouldice repair or to a tension-free lichtenstein repair <sep> lichtenstein versus shouldice hernia repair <sep> lichtenstein hernia repair <sep>', 'lichtenstein mcvay or shouldice repair <sep> lichtenstein repair <sep>', 'modified bassini versus shouldice inguinal hernia repair <sep> modified bassini operation transversalis fascia not divided but included in the repair or shouldice procedure <sep> undergo surgery by staff surgeon or surgical resident <sep>', 'mesh or shouldice herniorrhaphy <sep> mesh or shouldice inguinal hernia repair <sep>', 'lichtenstein mesh repair or shouldice repair <sep> lichtenstein <sep> shouldice inguinal hernia repair <sep> lichtenstein open mesh technique or shouldice repair <sep>', ""shouldice repair stainless steel or polypropylene <sep> shouldice hernia repair <sep> shouldice inguinal hernia repair <sep> bassini's repair cooper's ligament or shouldice repair with polypropylene or a shouldice repair with stainless steel <sep>"", 'polypropylene sutures and group d shouldice with two rows of polypropylene sutures <sep> bassini with nonabsorbable sutures polyester <sep> bassini with absorbable sutures polyglycolic acid <sep>', 'shouldice and lichtenstein hernia repair procedures <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",shouldice herniorrhaphy is the best non-mesh technique in terms of recurrence though it is more time consuming and needs a slightly longer post-operative hospital stay. the use of mesh is associated with a lower rate of recurrence. the quality of included studies assessed with jaded scale were low. patients have similar characteristic in the treatment and control group but seems more healthy than in general population this features may affect the dimension of effect in particularly recurrence rate could be higher in general population. lost to follow-up were similar in the treatment and control group but the reasons were often not reported. the length of follow-up vary broadly among the studies from 1 year to 13.7 year.
226,"{'outcomes': ['duration or severity of cold symptoms <sep> cold duration or severity <sep> duration of symptoms and cold episodes cumulative symptom severity scores <sep> shortest duration of nasal systemic and overall symptoms <sep>', 'mean illness <sep> overall complicated illness rate <sep> throat cultures yielding beta-hemolytic streptococcus <sep> plasma ascorbic acid levels <sep> number of episodes <sep> mean illness duration <sep>', 'shorter duration of severe symptoms <sep> colds <sep>', 'incidence and severity of winter illness <sep> side effects <sep> sickness experience <sep>', 'development of symptoms of urt infection <sep> duration and severity of symptoms of urt infections <sep> postrace symptoms of upper-respiratory-tract infection <sep> symptoms of urt infections <sep> incidence of symptoms of upper-respiratory-tract urt infections <sep>', 'total number of days of upper respiratory tract infection <sep>', 'personality trait of neuroticism <sep> reduction of colds <sep>', 'rate of respiratory infections <sep> severity of uris <sep> duration of respiratory infections <sep> duration of infections <sep> rate length or severity of uris <sep> incidence of uris <sep> duration and severity of respiratory infections <sep>', 'upper respiratory or general constitutional symptoms <sep> colds <sep>', 'duration and severity of colds <sep>', 'incidence or morbidity of the common cold and other respiratory illnesses <sep> whole-blood ascorbic acid levels <sep> incidence or duration of colds <sep>', 'cold symptoms <sep> severe illness episodes <sep> daily observations of cold symptoms and multiple biochemical anthropometric and psychological measurements <sep> severity <sep>', 'severe illness <sep> respiratory symptoms <sep> sickness experience <sep>', 'duration or severity of the common cold <sep> total number of common colds <sep>'], 'punchline_text': ['although differences were not significant the placebo group had the shortest duration of nasal systemic and overall symptoms and the lowest mean severity score at 14 days and the second lowest at 7 and 28 days. <sep>', 'children receiving vitamin c had fewer throat cultures yielding beta-hemolytic streptococcus six versus 13 p less than 0.10 but no difference in overall complicated illness rate 24 versus 25). <sep>', 'compared with the placebo group the active-treatment group had significantly fewer colds 37 vs 50 p<.05 fewer days challenged virally 85 vs 178 and a significantly shorter duration of severe symptoms 1.8 vs 3.1 days p<.03). <sep>', 'none of the groups receiving vitamin c showed a difference in sickness experience that was statistically significant from that of the placebo groups but the results obtained were compatible with an effect of small magnitude from both the prophylactic and therapeutic regimens and an effect of somewhat greater magnitude from the combination regimen. <sep>', 'sixty-eight percent of the runners in the placebo group reported the development of symptoms of urt infection after the race this was significantly more p  0.01 than that reported by the vitamin c-supplemented group 33%). <sep>', 'no proven biochemical effects were obtained. <sep>', 'no side effects of substantive changes in serum biochemistry could be attributed to the vitamin c dose. <sep>', 'vitamin c had no effect on the incidence of uris rate ratio  1.01 95 confidence interval ci  0.70-1.46). <sep>', 'among the men who had any colds at all significantly fewer on active than on placebo treatment had two or more colds however this effect was not seen in women. <sep>', 'analysis of these data showed that ascorbic acid had at best only a minor influence on the duration and severity of colds and that the effects demonstrated might be explained equally well by a break in the double blind. <sep>', 'whole-blood ascorbic acid levels measured six weeks after initiation of the study were significantly higher in the vitamin c group. <sep>', 'paired comparisons showed no significant overall treatment effect on cold symptoms but the response was not uniform in all sub-groups. <sep>', 'there were no consistent or significant differences in the sickness experience of the subjects receiving the sustained-release vitamin capsules compared to those receiving the vitamin tablets but subjects in both vitamin groups experienced less severe illness than subjects in the placebo group with approximately 25 per cent fewer days spent indoors because of the illness p smaller than 0.05). <sep>', 'no apparent reduction was seen for the severity and duration of the common cold. <sep>'], 'population': ['149 participants returned records for 184 cold episodes <sep> healthy adult volunteers <sep> 400 healthy volunteers were recruited from staff and students of the australian national university canberra act between may 1998 and november 1999 <sep>', '868 children <sep> navajo school children <sep>', 'one hundred sixty-eight volunteers <sep>', 'between december 1972 and february 1973 2349 volunteers participated <sep>', 'after participation in a competitive ultramarathon race  42 km <sep> ultramarathon runners with age-matched controls <sep> ultramarathon runners <sep>', '172 children in the age group 8-9 <sep> healthy children with <sep> children <sep> 642 children of the same age <sep>', '95 pairs of identical twins aged 14-64 who took part in a double-blind trial of <sep>', '39 competitive young swimmers mean age 13.8  1.6 years in jerusalem israel <sep> adolescent swimmers <sep> male and female swimmers <sep> male swimmers <sep> competitive swimmers <sep> people who are under heavy physical stress including recreational and competitive swimmers <sep>', 'altogether 1524 volunteers were recruited from a number of working groups in different parts of the country 482 developed colds <sep>', 'one hundred ninety volunteers completed the study <sep> three hundred eleven employees of the national institutes of health volunteered to take 1 gm of <sep>', '674 marine recruits during an eight-week period <sep> marine recruits <sep>', '44 school-aged monozygotic twins <sep>', '448 subjects who completed an average of 15 weeks in the study of total of 635 episodes of illness were recroded <sep> 622 volunteers received either <sep>', 'participants in annual screening programs for circulatory diseases conducted under the national health and welfare services law for the aged and diagnosed as having atrophic gastritis <sep> 439 eligible subjects 144 and 161 <sep>'], 'interventions': ['mega-dose vitamin c <sep> placebo <sep> vitamin c <sep> vitamin c at daily doses of 0.03g placebo <sep>', 'vitamin c <sep> vitamin c versus placebo <sep> vitamin c <sep>', 'placebo or a vitamin c supplement <sep> vitamin c supplement <sep> placebo <sep> vitamin c <sep>', 'vitamin c <sep> placebo <sep>', 'vitamin c <sep> vitamin c supplementation <sep> placebo <sep> vitamin c supplementation <sep>', 'vitamin c <sep> vitamin c <sep>', 'vitamin c and the other took a well-matched placebo <sep> placebo <sep> vitamin c <sep> vitamin c <sep> vitamin c tablets <sep>', 'vitamin c <sep> vitamin c supplementation <sep> placebo <sep> vitamin c <sep>', 'ascorbic acid <sep> placebo <sep> ascorbic acid <sep>', 'ascorbic acid or lactose placebo <sep> placebo or ascorbic acid <sep> placebo <sep> ascorbic acid <sep> ascorbic acid <sep>', 'vitamin c prophylaxis <sep> placebo prophylaxis <sep> vitamin c <sep> vitamin c prophylaxis <sep>', 'vitamin c <sep>', 'placebo <sep> ascorbic acid and a regular tabet containing a mixture of sodium and calcium ascorbate <sep> vitamin c or placebo <sep> vitamin c <sep> supplementary vitamin c <sep>', 'vitamin c <sep> vitamin c supplementation <sep> daily vitamin c supplementation <sep> intervention <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",the failure of vitamin c supplementation to reduce the incidence of colds in the general population indicates that routine vitamin c supplementation is not justified yet vitamin c may be useful for people exposed to brief periods of severe physical exercise. regular supplementation trials have shown that vitamin c reduces the duration of colds but this was not replicated in the few therapeutic trials that have been carried out. nevertheless given the consistent effect of vitamin c on the duration and severity of colds in the regular supplementation studies and the low cost and safety it may be worthwhile for common cold patients to test on an individual basis whether therapeutic vitamin c is beneficial for them. further therapeutic rcts are warranted.
227,"{'outcomes': ['adverse effects <sep> disability scale <sep>', 'pain diaries to score pain intensity twice daily analgesic intake and quality of sleep daily and activity level weekly <sep> return to work quality of sleep and analgesic intake <sep> pain intensities <sep>', 'spinal arom and isokinetic trunk concentric strength <sep> pain disability and functional improvement scores <sep> numerical rating scale nrs <sep> nrs and aberdeen lbp scale <sep> aberdeen lbp scale lumbar spinal active range of movement arom and the isokinetic strength <sep>', 'low back pain <sep>', 'analgesic effect <sep> intensity of pain <sep> pain reduction <sep> mcgill pain questionnaire <sep>', 'pain or stiffness <sep> pain or stiffness vas physical tests <sep> analgetic drugs <sep> relapse of low back pain and number of days on sickness leave <sep> new episodes of low back pain <sep> gastro-enteric side effects <sep> side effects <sep>', ""activity related to pain mobility verbal descriptors of pain and the patient's subjective assessment of his condition <sep>"", 'vas <sep> nhp <sep> pain severity on visual analogue scale vas 2 pain subscale of nottingham health profile nhp 3 number of analgesic tablets consumed in previous week 4 spinal flexion from c7 to s1 <sep> mean spinal flexion <sep> vas and nhp <sep> tablet count <sep> spinal flexion <sep>', 'mpq scores <sep> mcgill pain questionnaire mpq and visual analog scales vas for pain <sep>', 'neck pain <sep> spinal manipulation <sep> scores of the 1 oswestry back pain disability index 2 <sep> neck disability index and 3 three visual analogue scales of local pain intensity <sep> neck disability index and 3 reductions on the visual analogue scale <sep>', 'pain intensity <sep> pain disability <sep> psychological distress <sep> pain intensity and in pain disability and secondary in psychological distress and in spine flexion <sep>', 'pain relief scale 100 mm visual analogue scale vas and a lbp score recommended by the japanese orthopaedic association joa score <sep> low back pain <sep> mean vas value <sep> joa score <sep>', ""pain <sep> estimates of pain on a visual analogue scale and disability by both physician and patient physical measures of trunk strength and spine range of motion as well as the patient's perceptions of the relative contribution of the education exercise training and the electrical stimulation <sep> visual analogue scale measure of average pain <sep>"", 'medication-related side-effects <sep> modified roland disability questionnaire rdq <sep> mean global transition score <sep> change in rdq score <sep> rdq score <sep>', 'pain <sep> average pain score <sep> pain scores <sep> pain reduction <sep>', ""pain rating scores <sep> psychotropic drug intake <sep> pain scores <sep> initial pain severity <sep> initial pain levels correlated with state-anxiety depression pain duration and abnormal illness behavior measures <sep> individual patient's pain score <sep> analgesic drug intake <sep> chronic low back pain <sep> depression neuroticism and hypochondriasis scores <sep> pain score <sep>""], 'punchline_text': ['massage was also superior to acupuncture on the disability scale 5.89 vs 8.25 respectively p .01). <sep>', 'there was a significant improvement in return to work quality of sleep and analgesic intake in subjects treated with acupuncture. <sep>', 'significantly better scores in the nrs and aberdeen lbp scale were found in the exercise plus ea group immediately after treatment and at 1-month follow-up. <sep>', 'in all five measures of efficacy chosen for study the acupuncture group achieved better responses than the placebo group four of the five inter-group differences were statistically significant. <sep>', 'a statistical difference existed between the two groups at the 3-month follow up with a better result in the deeply stimulated group. <sep>', 'there were no differences in pain or stiffness vas physical tests at inclusion nor in the reduction of pain or stiffness over a six month evaluation. <sep>', 'after 6 weeks patients receiving treatment showed significant improvement p  0.05 to p  0.001 on three of the four measures compared to the untreated controls. <sep>', 'significant improvements were shown on vas p  0.001 nhp p  0.001 and tablet count p  0.05 between baseline and completion in both groups these improvements remaining significant comparing baseline with follow-up with a further non-significant improvement in vas and nhp in the acupuncture group. <sep>', 'analysis of results using t tests showed that in both groups there were significant pre-post improvements for all scores except for mpq scores in the placebo-tens group. <sep>', 'neither of the other interventions showed any significant improvement on any of the outcome measures. <sep>', 'acupuncture was superior to the control condition physiotherapy regarding pain intensity p=0.000 pain disability p=0.000 and psychological distress p=0.020 at the end of treatment. <sep>', 'mean vas value during the 2-weeks experimental period of the ea group was significantly smaller than that of the tens group 65 mm vs 86 mm 95 ci 4.126  37.953). <sep>', 'there were no significant differences between treatment groups with respect to their overall rehabilitation. <sep>', 'outcome was measured by the modified roland disability questionnaire rdq at weeks 0 2 6 and 9. <sep>', 'the short-term controls the delayed treatment group had no reduction whatsoever in their pain scores at the comparable followup period. <sep>', 'during the first phase of treatment patients receiving acupuncture had a greater but not significantly different reduction in pain rating scores compared with those receiving placebo t  0.52 p greater than 0.6). <sep>'], 'population': ['262 patients aged 20 to 70 years who had persistent back pain to receive <sep> chronic low back pain <sep> n  94 therapeutic massage n  78 or self-care educational materials n  90 <sep>', 'chronic low back pain <sep> fifty consecutive patients 33 women 17 men mean age 49.8 years with chronic low back pain mean pain duration 9.5 years and without rhizopathy or history of acupuncture treatment were included in the study <sep> a tertiary-level pain clinic at a swedish university hospital <sep> patients with chronic nociceptive low back pain <sep>', 'subjects and interventions <sep> patients with chronic low-back pain lbp <sep> chronic low-back pain <sep> a total of 52 patients <sep>', 'chronic low back pain <sep>', '42 patients with lumbar myofascial pain <sep> pain service unit of the university of padova <sep> lumbar myofascial pain <sep> patients with chronic lumbar myofascial pain <sep>', 'acute low back pain in general practice <sep> 60 consecutively included patients with acute low back pain 30 patients <sep> acute lumbago <sep>', 'patients fulfilling clinical criteria for chronic low back pain of nociceptive origin <sep> chronic nociceptive low back pain <sep> forty patients <sep> ten patients were put on the waiting list for treatment but served as the untreated control group <sep>', 'sixty patients aged 60 or over with back pain for at least 6 months were recruited from general practitioner referrals <sep> elderly patients with chronic back pain both <sep> chronic back pain in the elderly <sep>', '46 patients completed the trial and were followed up at 6 months <sep> chronic low back pain <sep> patients n  60 with chronic low back pain <sep>', 'specialized spinal pain syndrome out-patient unit at townsville general hospital queensland australia <sep> managing chronic 13 weeks duration spinal pain syndromes <sep> patients with chronic spinal pain syndromes spinal manipulation <sep> seventy-seven patients without contraindication to manipulation or medication were recruited <sep> chronic spinal pain syndromes <sep>', '131 consecutive out-patients of the department of orthopaedics university goettingen germany age=48.1 years 58.5 female duration of pain 9.6 years with non-radiating lbp for at least 6 months and a normal neurological examination <sep> chronic low-back pain <sep> chronic lbp <sep>', 'twenty subjects who suffered from low back pain lbp without sciatica were recruited using leaflets in tsukuba city <sep> low back pain <sep> tsukuba college of technology clinic in japan <sep>', 'fifty-four patients treated in a 3-week inpatient rehabilitation program <sep> chronic low back pain patients <sep>', 'fifty-five patients were enrolled with eight drop-outs <sep> twenty-four subjects <sep> older patients <sep> chronic low back pain lbp in older patients <sep>', 'low back pain <sep> people with low back pain <sep>', '77 patients <sep> chronic back pain <sep>'], 'interventions': ['traditional chinese medical acupuncture <sep> acupuncture <sep> traditional chinese medical acupuncture therapeutic massage and self-care education <sep> massage <sep> therapeutic massage <sep>', 'manual acupuncture electroacupuncture or active placebo mock transcutaneous electrical nerve stimulation <sep> placebo <sep> needle acupuncture <sep> acupuncture <sep> acupuncture <sep>', 'electro-acupuncture <sep> electro-acupuncture ea <sep> exercise plus ea <sep> exercise group <sep>', 'superficial acupuncture <sep> superficial acupuncture <sep> placebo <sep> acupuncture <sep>', 'acupuncture needles <sep> superficial and deep acupuncture <sep>', 'standardised acupuncture <sep> entero-soluble naproxen <sep> acupuncture <sep> acupuncture and antiphlogistica <sep> standardised acupuncture <sep> naproxen <sep>', 'acupuncture <sep> manual stimulation of needles ms electrical low frequency stimulation at 2 hz lf and high-frequency stimulation at 80 hz hf <sep> acupuncture stimulation <sep>', 'acupuncture and tens <sep> acupuncture <sep> acupuncture and 28 to tens <sep> acupuncture <sep> transcutaneous electrical nerve stimulation <sep> acupuncture or transcutaneous electrical nerve stimulation tens <sep>', 'acupuncture <sep> acupuncture <sep> acupuncture therapy or placebo transcutaneous electrical nerve stimulation tens <sep>', 'acupuncture nonsteroidal anti-inflammatory medication or chiropractic spinal manipulation <sep> acupuncture <sep> needle acupuncture medication tenoxicam with ranitidine and spinal manipulation <sep>', '20 sessions of traditional acupuncture and the sham-acupuncture group n=45 20 sessions of minimal acupuncture <sep> placebo <sep> traditional acupuncture <sep> acupuncture <sep> acupuncture <sep> sham-acupuncture acupuncture <sep> active physiotherapy <sep>', 'transcutaneous electrical nerve stimulation tens <sep> electroacupuncture ea <sep> tens <sep> electroacupuncture <sep> electroacupuncture and tens <sep> realistic acupuncture interventions <sep>', 'acupuncture <sep> tens low intensity transcutaneous nerve stimulation n  18 and tens dead-battery placebo <sep> electroacupuncture <sep> electroacupuncture and tens <sep> treatment electroacupuncture tens placebo <sep>', 'acupuncture <sep> acupuncture with electrical stimulation <sep> acupuncture <sep> usual care as directed by their physicians i.e. nsaids muscle relaxants paracetamol and back exercises <sep>', 'acupuncture <sep>', 'acupuncture <sep> acupuncture <sep> placebo <sep> acupuncture or placebo <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",the data do not allow firm conclusions about the effectiveness of acupuncture for acute low-back pain. for chronic low-back pain acupuncture is more effective for pain relief and functional improvement than no treatment or sham treatment immediately after treatment and in the short-term only. acupuncture is not more effective than other conventional and alternative treatments. the data suggest that acupuncture and dry-needling may be useful adjuncts to other therapies for chronic low-back pain. because most of the studies were of lower methodological quality there certainly is a further need for higher quality trials in this area.
228,"{'outcomes': [""relapse free after ileocolic resection <sep> quality of life qol body image and cosmesis <sep> body image and cosmesis scores <sep> qol <sep> reoperation readmission and repeat resection rates for recurrent crohn's disease <sep> incisional hernia and adhesion-related problems <sep> overall reoperation rates <sep>"", 'minor complications <sep> flatus and first bowel movement <sep> amount of morphine equivalents <sep> forced expiratory volume one second and forced vital capacity <sep> median length of the incision <sep> major complications <sep> clinical recurrences <sep> median length of stay <sep>', 'qol <sep> sf-36 and giqli questionnaire <sep> median operating time <sep> conversion rate <sep> operating time morbidity hospital stay postoperative morphine requirement pain and costs <sep> hospital stay <sep> number of patients with postoperative morbidity <sep> sf-36 and giqli questionnaires <sep> giqli score <sep> median overall costs <sep> morbidity hospital stay and costs <sep> postoperative quality of life qol <sep>', 'demographic data recurrence rates need for additional surgery related to primary procedure and medication use <sep> incidences of anorectal disease anorectal surgery endoscopic or radiologic recurrence and medication use <sep> incisional hernia repair <sep>'], 'punchline_text': [""overall reoperation rates for recurrent crohn's disease incisional hernia and adhesion-related problems were two of 29 versus six of 26 risk difference 16 3 to 35 per cent). <sep>"", ""within a single institution single surgical team prospective randomized trial laparoscopic techniques offered a faster recovery of pulmonary function fewer complications and shorter length of stay compared with conventional surgery for selected patients undergoing ileocolic resection for crohn's disease. <sep>"", 'although qol measured by sf-36 and giqli questionnaires was not different for laparoscopic-assisted compared with the open ileocolic resection morbidity hospital stay and costs were significantly lower. <sep>', 'oc patients requiring operation during follow-up were significantly more likely than lc to require multiple operations p  .006). <sep>'], 'population': [""crohn's disease <sep> sixty patients who underwent ileocolic resection between 1999 and 2003 were followed prospectively <sep>"", ""31 patients assigned to laparoscopic and 29 to the conventional group all had isolated crohn's disease of the terminal ileum plus or minus the cecum <sep> two laparoscopic patients <sep> 60 patients 25 males median age 34.4 range 10-60.1 years undergoing <sep> selected patients undergoing ileocolic resection for crohn's disease <sep> for refractory crohn's disease <sep> refractory ileocolic crohn's disease <sep>"", ""crohn's disease <sep> primary crohn's disease <sep> sixty patients <sep>"", ""crohn's disease <sep> patients previously enrolled <sep> ileocolic crohn's disease cd <sep>""], 'interventions': ['laparoscopically assisted versus open ileocolic resection <sep> laparoscopically assisted ileocolic resection <sep>', 'laparoscopic vs. conventional surgery <sep> elective ileocolic resection <sep> conventional surgery <sep> laparoscopic vs. conventional techniques <sep>', 'laparoscopic-assisted and open ileocolic resection <sep> laparoscopic-assisted or open surgery <sep> laparoscopic-assisted versus open ileocolic resection <sep>', 'laparoscopic versus open ileocolic resection <sep> laparoscopic lc and open ileocolectomy oc <sep> lc <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",laparoscopic surgery for small bowel cd may be as safe as the open operation. there was no significant difference in the perioperative outcomes and the long term reoperation rates for disease-related or non-disease related complications of cd.
229,"{'outcomes': ['bilirubin measurements <sep> moderated hyperbilirubinemia and reduced phototherapy pt time <sep> exchange transfusion or interruption of breast-feeding <sep>', 'median hours to case closure <sep> severe hyperbilirubinemia <sep> number of bilirubin determinations <sep>'], 'punchline_text': ['a single dose of snmp entirely supplanted the need for pt in jaundiced term and near-term newborns and significantly reduced medical resource use to monitor hyperbilirubinemia. <sep>', 'no adverse effects of snmp use were observed. <sep>'], 'population': ['controlling hyperbilirubinemia in term and near-term newborns <sep> male term infants study ii infants of both sexes and gestational age ga 245-265 days <sep>', 'healthy full-term breastfed infants with a pbc between 256.5 micromol/l and 307.8 micromol/l <sep> full-term breastfed infants with plasma bilirubin concentrations pbc of 256.5 micromol/l and 307.8 micromol/l <sep>'], 'interventions': ['sn-mesoporphyrin snmp <sep> snmp and pt <sep> snmp or pt <sep> sn-mesoporphyrin <sep> snmp <sep>', 'phototherapy <sep> snmp <sep> sn-mesoporphyrin snmp <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>']}",treatment of neonatal unconjugated hyperbilirubinemia with metalloporphyrins may reduce neonatal bilirubin levels and decrease the need for phototherapy and hospitalization. there is no evidence to support or refute the possibility that treatment with a metalloporphyrin decreases the risk of neonatal kernicterus or of long-term neurodevelopmental impairment due to bilirubin encephalopathy. there is no evidence to support or refute the possibility that cutaneous photosensitivity is increased with metalloporphyrin treatment. routine treatment of neonatal unconjugated hyperbilirubinemia with a metalloporphyrin cannot be recommended at present.
230,"{'outcomes': ['job turnover <sep>', 'psychophysiologic health level <sep> mean scores on the nurse stress checklist nsc and the chinese general health questionnaire cghq <sep>', 'semantic differential questionnaire occupational stress <sep> attitudes communication skills and occupational stress <sep> nursing stress scale and communication skills <sep> level of occupational stress <sep>', 'knowledge and attitudes and increase in burnout <sep> burnout rates <sep> knowledge and attitudes about serious mental illness <sep>', 'facilitative behaviours open questions <sep> nursing stress scale attitudes with a semantic differential questionnaire cs <sep> attitudes communication skills and occupational stress <sep> inhibitory behaviours <sep> nurses satisfaction levels <sep> educated guesses <sep> stress levels <sep>', 'mean change in physiologic parameters <sep> anxiety <sep> anxiety stress self-care and caring relationships <sep> pre and post-treatment anxiety scores <sep> importance of touch in nursing care stress reduction increased self-awareness the need for self-care <sep> visual analog scale vas and increased relaxation <sep>', 'multiple burnout and mood dimensions <sep> cost savings <sep> cost savings <sep> total mood disturbance tmd <sep> tmd scores <sep>', 'perceived stress scale pss and rathus assertiveness schedule ras <sep> levels of stress <sep>', 'chinese version of state-trait anxiety inventory and the chinese version of the general health questionnaire <sep> mental health status <sep> mental health <sep>', 'job satisfaction burnout and sick leave <sep> sick leave <sep>', 'anxiety measures <sep> work-related anxiety <sep>'], 'punchline_text': ['results showed that although the burnout level did not change as a result of primary nursing psychiatric nurses and the practical nurses seemed able to work according to the principles of primary nursing. <sep>', 'the mean scores on the nurse stress checklist nsc and the chinese general health questionnaire cghq differed significantly between the experimental and control group in posttest 2 at week 5. <sep>', 't.s. were significantly more in control of the interview than c.s. p  0.02). <sep>', 'staff in the experimental group showed significant improvements in their knowledge and attitudes about serious mental illness and a significant decrease in burnout rates whilst staff in the control group showed a small but nonsignificant improvement in knowledge and attitudes and increase in burnout. <sep>', 'positive training effects were found on cs used during the simulated interview a significant increase in facilitative behaviours open questions <sep>', 'while both groups demonstrated decreased anxiety after intervention the experimental group consistently showed greater differences between pre and post-treatment anxiety scores. <sep>', 'a cost-effective 6-session rmm protocol reduces burnout and mood dimensions as well as tmd in long-term care workers. <sep>', 'subjects were randomly assigned to one of two treatments assertiveness training at or alternate treatment control atc which served as a control and contained updated knowledge of new computer technology for in patient settings. <sep>', 'participants were assessed at the pretreatment session the fourth posttreatment session and at the 1-month follow-up session. <sep>', 'emotion-oriented care is used in the care for cognitively impaired elderly persons and is mainly based on the validation approach. <sep>', 'results suggested that stress management training was effective in reducing work-related anxiety among inexperienced nurses but not among experienced nurses. <sep>'], 'population': ['161 psychiatric nurses was followed for 2.5 years <sep> psychiatric nurses in long-stay settings <sep>', 'chinese nurses working in modern hospitals in taiwan <sep> twenty-three subjects in the experimental group and 23 in the control group from each hospital participated in the study <sep> 137 subjects were selected randomly from three first-ranked teaching hospitals <sep> chinese nurses who are employed in large teaching hospitals in taiwan <sep> chinese registered nurses employed in large teaching hospitals to reduce their work stress in taiwan republic of china <sep>', 'oncology <sep> seventy-two oncology nurses <sep>', 'twenty of the nurses volunteered to be included in a psi training course <sep> mental health nurses working in secure environments with patients suffering from serious mental illness <sep>', 'oncology <sep> a total of 115 oncology nurses <sep>', '24 nurses working 12-hour shifts <sep> nurses <sep>', '112 employees participated in a <sep> long-term care workers <sep>', '60 volunteer chinese-speaking nurses participated in the study <sep> stress and assertiveness experienced by nurses in taiwan republic of china <sep> professional nurses in taiwan <sep> nurses in taiwan republic of china <sep>', 'nurse managers <sep> 65 nurse managers in hong kong <sep> nurse managers in hong kong <sep>', 'three hundred professional caregivers were included in the study <sep> professional caregivers in homes for elderly persons <sep> sixteen homes for the aged <sep> cognitively impaired elderly persons <sep>', 'nurses working in a burn treatment unit <sep>'], 'interventions': ['primary nursing <sep>', ""relaxation training based on smith's 1988 cognitive behavioral model of relaxation <sep> relaxation training combining imagery and meditation <sep> relaxation training <sep>"", 'psychological training programs p.t.p <sep> 24-h psychological training program <sep>', 'training or to a waiting list control group <sep> psychosocial intervention training psi <sep>', '105-h ptp or to a waiting list <sep> 105 hours psychological training program <sep> psychological training programs ptps <sep> ptp <sep> trained tg and control cg <sep>', 'touch therapy <sep> amma <sep>', '6-session rmm protocol focusing on building support communication and interdisciplinary respect utilizing group drumming and keyboard accompaniment <sep> 6-session recreational music-making rmm protocol <sep> recreational music-making <sep>', 'atc <sep> assertiveness training at or alternate treatment control atc <sep> assertiveness training <sep>', 'cognitive relaxation training <sep> stretch-release relaxation <sep> cognitive relaxation <sep> relaxation training methods <sep> relaxation training <sep>', 'training program in emotion-oriented care <sep> emotion-oriented care <sep> emotion-oriented care <sep>', 'stress management training <sep> individual training in cognitive behavioral stress management skills <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",limited evidence is available for the effectiveness of interventions to reduce stress levels in healthcare workers. larger and better quality trials are needed.
231,"{'outcomes': ['lateral pinch strength value <sep> patient satisfaction <sep> functional status scale and a symptom severity scale <sep>', 'electrophysiologic signs clinical signs or significant symptoms <sep>', 'numbness tingling burning and pain <sep> beginning pain pain at 15 minutes pain at 30 minutes or pain <sep> pain reduction <sep> pain <sep> visual analogue scale <sep>', 'carpal bone mobilization and median nerve mobilization <sep> pain perception and function and lastly numbers of patients continuing to surgery <sep> active range of wrist movement rom flexion and extension upper limb tension test with a median nerve bias ultt2a <sep> pain relief scale <sep>', ""median nerve sensory and motor distal latency <sep> sensory distal latency improvement <sep> sensory distal latency <sep> superior distal latency improvement <sep> symptoms and functional deficits <sep> symptom severity <sep> functional deficits <sep> levine's self-administered questionnaire and physiologic impairment <sep> occasional daytime wear <sep> symptoms function and impairment in carpal tunnel syndrome cts <sep>"", 'relief of symptoms <sep>', 'sensory antidromic nerve conduction velocity <sep> score of subjective symptom ratings assessed by visual analogue scale electroneurographic measures for example motor distal latency and sensory antidromic nerve conduction velocity <sep> electroneurographic variables motor distal latency <sep>', 'grip strength pain intensity sleep disturbance phalen sign and tinel sign and in median nerve motor and sensory conduction time <sep> sleep disturbance tinel sign and median nerve motor and sensory conduction time <sep> grip strength <sep> pain reduction <sep> phalen sign <sep> grip strength and pain <sep>', 'phalen test time <sep> hand pain <sep> hand function or median nerve latency <sep>', 'clinical findings pain severity functional hand status and comfort <sep> pain severity and greater satisfaction <sep> pain severity and hand function <sep>', 'mean median nerve motor distal latency mnmdl median nerve sensory velocity mnsv and global symptom score gss <sep> mean mnmdl mnsv and gss <sep>', 'pain <sep> pain/paresthesia <sep> motor nerve conduction velocity and increased motor distal latency <sep> frequency of awakening at night <sep>', 'standardized symptom questionnaire rating five categories of symptoms pain numbness paresthesia weakness/clumsiness and nocturnal awakening on a scale from 0 no symptoms to 10 severe <sep> global symptom score gss <sep> mean score <sep>', 'carpal tunnel syndrome <sep>', 'pre and postassessments of self-reported physical and mental distress nerve conduction studies and vibrometry <sep> perceived comfort and function nerve conduction and finger sensation overall <sep> manipulation of the soft tissues and bony joints of the upper extremities and spine <sep>', 'pain and other symptoms of carpal tunnel syndrome cts <sep> global symptom scores <sep>'], 'punchline_text': ['the improvement in group 2 was slightly greater but the difference between the groups was not significant except for the lateral pinch strength value. <sep>', 'no differences in outcome were found in electrophysiologic signs clinical signs or significant symptoms. <sep>', 'the use of a magnet for reducing pain attributed to carpal tunnel syndrome was no more effective than use of the placebo device. <sep>', 'only scores on a pain relief scale p<0.01 demonstrated highly significant differences between the three groups when analyzed using kruskal-wallis test. <sep>', 'subjects receiving full-time wear instructions showed superior distal latency improvement both motor .35 vs .07msec p  .04 and sensory .46 vs . <sep>', 'the results indicate that the neutral angle provided superior symptom relief and that the relief did not often improve between 2 weeks and 2 months of wear. <sep>', 'improvement was significantly more pronounced in actively treated than in sham treated wrists for both subjective symptoms p  0.001 paired t test and electroneurographic variables motor distal latency p  0.001 paired t test sensory antidromic nerve conduction velocity p  0.001 paired t test). <sep>', 'subjects in the yoga groups had significant improvement in grip strength increased from 162 to 187 mm hg p  .009 and pain reduction decreased from 5.0 to 2.9 mm p  .02 but changes in grip strength and pain were not significant for control subjects. <sep>', 'subjects assigned keyboard a experienced a decrease in hand pain between weeks 6 and 12 when compared with keyboard b subjects p  0.05 and demonstrated an improvement in the phalen test time right hand p  0.006 left hand p  0.06). <sep>', 'compared to placebo kb3 and to a lesser extent kb1 groups demonstrated an improving trend in pain severity and hand function following 6 months of keyboard use. <sep>', 'a more significant improvement in the mean mnmdl mnsv and gss was observed in the insulin group when compared with the placebo group. <sep>', 'although there was no statistically significant before-after difference in electrophysiologic studies slightly decreased motor nerve conduction velocity and increased motor distal latency were noted in groups a and b but not in group c. ultrasound therapy in cts was comparable to placebo ultrasound in providing symptomatic relief and the probability of a negative effect on motor nerve conduction needs to be considered. <sep>', 'no significant reduction from baseline gss was seen at second and fourth weeks in the placebo nsaid-sr and diuretic groups. <sep>', 'vitamin b6 seems to have no advantage over conservative therapy for carpal tunnel syndrome. <sep>', 'there was significant improvement in perceived comfort and function nerve conduction and finger sensation overall but no significant differences between groups in the efficacy of either treatment. <sep>', 'we evaluated the effectiveness of low-dose short-term oral prednisone in ameliorating the pain and other symptoms of carpal tunnel syndrome cts in a randomized double-blind placebo-controlled study of patients with mild to moderate cts. <sep>'], 'population': ['carpal tunnel syndrome with nerve and tendon gliding exercises <sep> carpal tunnel syndrome <sep> 28 patients with the diagnosis of carpal tunnel syndrome in 36 hands <sep>', 'idiopathic carpal tunnel syndrome <sep> thirty-two patients with the disease <sep>', 'wrist pain attributed to carpal tunnel syndrome <sep> 30 patients with pain attributed to carpal tunnel syndrome had either a 1000 gauss magnet or a placebo metal disk applied to the carpal tunnel area using a velcro wrap for a period of 45 minutes <sep>', 'carpal tunnel syndrome <sep> patients experiencing carpal tunnel syndrome <sep>', 'twenty-one patients 30 hands were enrolled and 17 patients 24 hands completed the study <sep> veterans administration medical center outpatient clinic <sep> carpal tunnel syndrome <sep> outpatients with untreated cts were consecutively recruited from our electrodiagnostics lab <sep>', 'carpal tunnel syndrome cts <sep> carpal tunnel syndrome <sep> wearers of splints immobilized at 20 degrees extension and at neutral <sep>', 'carpal tunnel syndrome <sep> mild to moderate idiopathic carpal tunnel syndrome <sep> 45 patients with mild to moderate bilateral carpal tunnel syndrome <sep> outpatient clinic of a university department of physical medicine and rehabilitation in vienna <sep> patients with mild to moderate idiopathic carpal tunnel syndrome <sep>', 'a geriatric center and an industrial site in 1994-1995 <sep> forty-two employed or retired individuals with carpal tunnel syndrome median age 52 years range 24-77 years <sep> carpal tunnel syndrome <sep>', 'twenty computer users <sep> computer users with hand paresthesias <sep>', 'eighty computer users with musculoskeletal disorders <sep> computer users with upper extremity musculoskeletal disorders <sep>', 'patients with non-insulin-dependent diabetes niddm mellitus who have mild-to-moderate carpal tunnel syndrome ts <sep> niddm patients with carpal tunnel syndrome <sep> niddm patients with mild-to-moderate cts who opt for conservative treatment <sep>', 'carpal tunnel syndrome cts <sep> eighteen women with diagnosis of cts in 30 hands <sep> carpal tunnel syndrome <sep> university hospital pm&r department outpatient clinic and neurology department electromyography laboratory <sep>', 'mild to moderate carpal tunnel syndrome cts <sep> carpal tunnel syndrome <sep> patients with clinical symptoms and signs of cts confirmed by standard electrodiagnosis <sep>', 'carpal tunnel syndrome <sep>', 'ninety-one of 96 eligible subjects who reported symptoms that were confirmed by clinical exam and nerve conduction studies <sep> wolfe-harris center for clinical studies at northwestern college of chiropractic in bloomington minnesota <sep> carpal tunnel syndrome <sep>', 'patients with mild to moderate cts <sep> carpal tunnel syndrome <sep>'], 'interventions': ['neutral volar wrist splint <sep> nerve and tendon gliding exercises <sep>', 'placebo <sep> pyridoxine <sep>', 'placebo <sep> magnet therapy <sep>', 'carpal bone mobilisation and neurodynamic mobilisation <sep>', 'thermoplastic custom-molded neutral wrist splints with subjects receiving either full-time or night-only wear instructions <sep> neutral wrist splints <sep> neutral wrist splinting <sep>', 'wrist splinting <sep>', 'electroneurography <sep> ultrasound treatment <sep> ultrasound treatment <sep>', 'yoga-based intervention <sep> wrist splinting <sep> wrist splint to supplement their current treatment <sep> yoga-based intervention consisting of 11 yoga postures designed for strengthening stretching and balancing each joint in the upper body along with relaxation <sep> yoga-based regimen <sep>', 'keyboard keyswitch design <sep>', 'placebo <sep> apple adjustable keyboard kb1 comfort keyboard system kb2 microsoft natural keyboard kb3 and placebo <sep> computer keyboards <sep>', 'methylprednisolone <sep> placebo <sep> placebo or nph insulin <sep> prednisolone <sep> local insulin injection <sep> local insulin injection <sep>', 'placebo <sep> repeated ultrasound treatment <sep>', 'diuretic trichlormethiazide <sep> placebo <sep> prednisolone <sep> nsaid-slow release sr tenoxicam-sr <sep>', 'vitamin b6 <sep> placebo <sep> vitamin b6 <sep>', 'conservative medical care with chiropractic care <sep> ibuprofen <sep> conservative medical and chiropractic treatments <sep>', 'prednisone <sep> low-dose short-term oral prednisone <sep> placebo <sep> prednisone <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",current evidence shows significant short-term benefit from oral steroids splinting ultrasound yoga and carpal bone mobilisation. other non-surgical treatments do not produce significant benefit. more trials are needed to compare treatments and ascertain the duration of benefit.
232,"{'outcomes': ['leukocyte count and the secondary end-points were clinical and lung function parameters pseudomonas quantification in sputum and inflammation markers immunoglobulin g c-reactive protein in serum <sep> leukocyte count and inflammation markers <sep> toxicity and practicability <sep> hearing impairment <sep> mean body weight <sep> forced vital capacity <sep> pa density <sep> forced mid expiratory flow rate <sep> forced expiratory volume <sep> nephrotoxicity <sep>', 'bilateral impairment <sep> respiratory function <sep> renal function <sep> variables forced expiratory volume in one second and forced mid-expiratory flow  pred and serum creatinine levels <sep> serum potassium and magnesium levels equivalence <sep> respiratory function and changes in renal function and hearing <sep> efficacy and safety <sep>', 'forced vital capacity fvc <sep> efficacy <sep> weight/height <sep> efficacy tolerance and pharmacokinetics <sep> serum peak concentration of tobramycin <sep> forced expiratory flow <sep> forced expiratory volume <sep> cochlear and renal tolerance <sep> serum trough <sep> tobramycin concentrations <sep> tobramycin concentration <sep> plasma prealbumin <sep>', 'change in serum creatinine <sep> acute dizziness <sep> hearing loss <sep> mean change in fev1 <sep> creatinine <sep> mean change in fev1 <sep> change in forced expiratory volume in 1s fev1 over the 14 days of treatment expressed as a percentage of the predicted normal value for age sex and height <sep> nephrotoxic <sep> safety and efficacy <sep>'], 'punchline_text': ['forced expiratory volume increased by approximately 5 of the predicted volume forced vital capacity increased by 2 of predicted capacity and forced mid expiratory flow rate increased by 7 a or 4 b of the predicted normal value although these changes were not statistically significant. <sep>', 'for changes in forced vital capacity  predicted and serum potassium and magnesium levels equivalence was demonstrated. <sep>', 'improvement was not significantly different between groups. <sep>', 'the mean change in fev1  predicted over 14 days was similar on the two regimens 10.4 once daily vs 10.0 three-times daily adjusted mean difference 0.4 95 ci 3.3 to 4.1]). <sep>'], 'population': ['chronic pseudomonas aeruginosa pa infection in cystic fibrosis cf <sep> clinically stable patients with cf <sep> 30 patients 20 female mean age 11.2 years mean age range 1.7-18.1 years <sep> pediatric cystic fibrosis patients <sep>', 'sixty adult patients with an acute respiratory exacerbation <sep> adult patients with cystic fibrosis <sep>', 'cystic fibrosis patients <sep> patients with cystic fibrosis <sep> 22 patients with cystic fibrosis mean sd age 11 3.4 years range 5.6-19.3 with pulmonary pseudomonas exacerbations <sep> pseudomonas exacerbations in cystic fibrosis <sep>', 'patients with cystic fibrosis who have chronic pseudomonas aeruginosa infection <sep> patients <sep> children <sep> 219 patients 107 once daily 112 three-times daily completed the study per protocol <sep> pulmonary exacerbations of cystic fibrosis <sep> 244 patients from 21 cystic-fibrosis centres in the uk <sep>'], 'interventions': ['tobramycin once vs thrice-daily <sep> tobramycin <sep> tobramycine infusion <sep>', 'x kg(-1 tobramycin <sep> tobramycin <sep> 10 mg x kg(-1 tobramycin once-daily or 3.3 mg <sep>', 'tobramycin <sep> ceftazidime <sep>', 'tobramycin <sep> intravenous tobramycin <sep> ceftazidime <sep> tobramycin treatment <sep> tobramycin with ceftazidime <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",once and three-times daily aminoglycoside antibiotics appear to be equally effective in the treatment of pulmonary exacerbations of cystic fibrosis. there is evidence of less nephrotoxicity in children.
233,"{'outcomes': ['level of depression self-esteem and socialization <sep> socialization and self-esteem <sep> functional independence measure fim brunnstrom stages of motor recovery timed mobility tasks and the jebson hand evaluation <sep>', 'rivermead mobility index scores <sep> self-care independence <sep> barthel activity of daily living index bi scores poor global outcome defined as deterioration in bi score or death and the rivermead mobility index <sep>'], 'punchline_text': ['the treated group improved in terms of socialization and self-esteem as evidenced by a lower sickness impact profile whereas the controls tended to get worse. <sep>', 'at 3 months bi score in survivors had increased by 0.6 sd 3.9 in the intervention group and decreased by 0.9 2.2 in the control group a difference of 1.5 95 ci allowing for cluster design 0.5 to 3.5). <sep>'], 'population': ['postacute stroke survivors <sep> forty-nine stroke survivors who were at least l yr mean 2.9 yr poststroke <sep> postacute stroke patients <sep>', 'twelve homes 118 residents were randomly allocated to either intervention 6 homes 63 residents or control 6 homes 55 residents <sep> residents with stroke in uk care homes <sep> residents with stroke-related disability living in care homes <sep>'], 'interventions': ['intensive outpatient therapy <sep> intensive outpatient rehabilitation program <sep>', 'usual care <sep> occupational therapy <sep> occupational therapy intervention <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",this review highlights the dearth of evidence investigating long-term therapy-based rehabilitation interventions for patients with stroke.
234,"{'outcomes': ['maier subscale <sep> duloxetine escitalopram and placebo rates of remission or response <sep> primary efficacy measure maier subscale <sep> response and remission rates <sep> adverse events <sep> nausea dry mouth vomiting yawning and irritability <sep> 17-item hamilton rating scale for depression hamd(17 <sep> probabilities of meeting onset criteria <sep> onset of antidepressant efficacy <sep> rate of discontinuation due to adverse events <sep>', 'efficacy safety and tolerability measures <sep> madrs total score <sep> efficacy and safety <sep> mean baseline madrs total scores <sep>', 'discontinuation-emergent adverse events <sep> systolic blood pressure <sep> remission at endpoint 17-item hamilton depression rating scale <sep> nausea <sep> hamd17 total score and subscales hama cgi-s and pgi-i. safety and tolerability were assessed via analysis of reasons for discontinuation treatment-emergent adverse events teaes discontinuation-emergent adverse events and changes in vital signs weight and laboratory analytes <sep> gbr assessment <sep> safety measures <sep>', 'discontinuation rates <sep> tolerability assessments included discontinuation rates adverse events aes vital signs and laboratory tests <sep> cgi-i madrs and ham-d(6 <sep> ham-d(17 <sep> ham-d(17 total score <sep> tolerated <sep> cgi-i madrs cgi-s and ham-d(6 <sep> clinical global impressions-improvement cgi-i score montgomery asberg depression rating scale madrs score clinical global impressions-severity cgi-s score and 6-item hamilton rating scale for depression bech version ham-d(6 <sep> efficacy and tolerability <sep>', 'efficacy <sep> treatment-emergent adverse events teae vital signs weight laboratory analyses and electrocardiograms <sep> 17-item hamilton rating scale for depression hamd(17 <sep> hamd(17 subscales hamilton rating scale for anxiety clinical global impressions-severity patient global impressions-improvement somatic symptoms inventory and visual analog scales vas for pain <sep> number of early discontinuations and overall teae <sep> nausea and palpitations <sep> laboratory values vital signs weight or electrocardiograms <sep> efficacy and safety <sep> vas back pain <sep>', 'adverse events teaes vital signs and weight <sep> deaths <sep> hamd(17 total score <sep> mean change from baseline in the 17-item hamilton rating scale for depression hamd(17 total score <sep> acute phase efficacy and safety/tolerability outcomes <sep> teae reporting rates <sep> major depressive disorder mdd <sep> mean change on the hamd(17 <sep> tolerability <sep> safety and tolerability <sep> efficacy and safety <sep>', 'clinical global impressions cgi)-severity of illness scale score <sep> 17-item hamilton rating scale for depression ham-d-17 total score <sep> montgomery-asberg depression rating scale cgi-severity of illness and cgi-improvement and patient global impression of improvement <sep> occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes <sep> ham-d-17 total score <sep> tolerated and safe <sep> therapeutic efficacy and safety/tolerability <sep> tolerated <sep> estimated probabilities of response and remission <sep> safety <sep> insomnia and asthenia <sep>', 'mean madrs total score <sep> response rates <sep> dry mouth sedation and somnolence for quetiapine xr and nausea headache dizziness and dry mouth for duloxetine <sep> remission rates madrs score <sep> madrs total score <sep> safety and tolerability <sep> change from baseline to week 6 in montgomery-asberg depression rating scale madrs total score <sep> efficacy and tolerability <sep> hamilton rating scale for depression hamilton rating scale for anxiety and clinical global impressions-severity of illness total scores and the proportion of patients with clinical global impressions-improvement scores <sep>', 'madrs hama cgi-s and pgi-i scales <sep> estimated probabilities of remission <sep> incidence of acute treatment-emergent sexual dysfunction <sep> increased sweating <sep> hamd(17 total score <sep> efficacy and tolerability <sep> 17-item hamilton rating scale for depression hamd(17 <sep> rate of discontinuation due to adverse events <sep> constipation <sep> adverse events vital signs ecgs laboratory tests and the arizona sexual experiences scale asex <sep> somnolence <sep> total score hamd(17 subscales the montgomery-asberg depression rating scale madrs the hamilton anxiety rating scale hama visual analog scales vas for pain the clinical global impression of severity cgi-s and patient global impression of improvement pgi-i scales the 28-item somatic symptom inventory ssi and the sheehan disability scale sds <sep> safety and tolerability <sep> safety and efficacy <sep>', 'insomnia <sep> madrs <sep> overall withdrawal rates <sep> constipation <sep> total madrs score <sep> withdrawal rate due to adverse events <sep> efficacy and tolerability <sep>'], 'punchline_text': ['no differences were found between duloxetine escitalopram and placebo rates of remission or response at 8 weeks. <sep>', 'at week 8 escitalopram treatment resulted in significantly greater improvement compared with duloxetine on the prospectively defined primary efficacy endpoint of mean change from baseline in madrs total score using the locf approach least-squares mean difference lsmd 2.42 95 ci 4.73 0.11 p  0.05). <sep>', 'there were no significant differences between duloxetine 60 mg/day and venlafaxine 150 mg/day as measured by gbr assessment at the end of 6 weeks 1.418 vs. 1.079 p  0.217 or 12 weeks 0.349 vs. 0.121 p  0.440 nor were there significant differences between treatment groups on the majority of efficacy measures. <sep>', 'no significant differences were observed in any scale between the desvenlafaxine 50 mg/d and placebo groups. <sep>', 'non-inferiority of duloxetine to paroxetine was demonstrated because the upper bound of the confidence interval for mean difference in hamd(17 change 0.71 was less than the non-inferiority margin. <sep>', 'paroxetine was not significantly different from placebo p=0.089 on mean change on the hamd(17). <sep>', 'duloxetine was superior to placebo in change on the ham-d-17 p  .009). <sep>', 'remission rates madrs score or 8 were significantly higher for quetiapine xr 300 mg/day and duloxetine versus placebo p  .05 but not for quetiapine xr 150 mg/day. <sep>', 'both duloxetine 80 and 120 mg/day and paroxetine treatment groups had significantly greater improvement compared with placebo in madrs hama cgi-s and pgi-i scales. <sep>', 'the difference in mean change from baseline in madrs total score favoured escitalopram at weeks 1 2 4 8 12 and 16 p  0.05). <sep>'], 'population': ['patients with major depressive disorder <sep> patients  or  18 years meeting dsm-iv criteria for major depressive disorder mdd received <sep>', 'major depressive disorder <sep> 20 april 2005 to 10 march 2006 in independent psychiatric research facilities with principal investigators who were board certified in psychiatry <sep> 278 outpatients of 382 patients screened with diagnostic and statistical manual of mental disorders 4th edition)-diagnosed major depressive disorder montgomery-asberg depression rating scale madrs total score  or 26 <sep> patients with moderate to severe major depressive disorder <sep>', 'patients with major depressive disorder <sep>', '21 centers across the united states <sep> participants were outpatients aged  or 18 years with diagnostic and statistical manual of mental disorders fourth edition-defined mdd and a 17-item hamilton rating scale for depression ham-d(17 score  or 20 <sep> 925 patients who were screened 287 did not meet entry criteria and 638 patients enrolled in the study the intent-to-treat itt population included 615 patients who were evaluated for efficacy mean sd age range 38.8-40.7 12.1-13.2 years mean weight range 83.3-87.0 22.8-23.9 kg female sex 398 64.7 white race 458 74.5 <sep> major depressive disorder <sep> 1388 patients mean sd age range 38.8-45.7 12.1-12.6 years mean weight range 73.1-87.0 17.6-23.9 kg female sex 896 64.6 white race 1136 81.8 <sep>', 'major depressive disorder <sep> china korea taiwan and brazil <sep> patients with non-psychotic mdd <sep> major depressive disorder mdd <sep>', 'major depressive disorder <sep> patients who had a  or 30 reduction from baseline in the hamd(17 total score at the end of the acute phase <sep> patients age  or 18 meeting dsm-iv criteria for mdd <sep>', 'major depressive disorder <sep> 173 patients aged 18-65 years with dsm-iv major depressive disorder <sep>', 'major depressive disorder <sep> 612 patients with diagnostic and statistical manual of mental disorders fourth edition dsm-iv)-defined mdd <sep> major depressive disorder mdd <sep>', 'major depressive disorder <sep> or 18 years meeting dsm-iv criteria for mdd received <sep> patients who had a or 30 reduction from baseline in hamd(17 total score during the acute phase <sep> adult outpatients age <sep>', 'patients with major depressive disorder <sep> major depressive disorder mdd <sep>'], 'interventions': ['duloxetine versus escitalopram and placebo <sep> placebo <sep> escitalopram 10 mg qd <sep> duloxetine 60 mg once daily qd <sep> duloxetine <sep>', 'placebo <sep> escitalopram and duloxetine <sep> escitalopram <sep> duloxetine <sep> escitalopram versus duloxetine <sep>', 'venlafaxine xr <sep> duloxetine <sep> norepinephrine reuptake inhibitors snris duloxetine and venlafaxine <sep> venlafaxine <sep> duloxetine and venlafaxine <sep> duloxetine 60 mg/day or venlafaxine extended release xr <sep> duloxetine <sep>', 'duloxetine-referenced placebo <sep> placebo <sep> desvenlafaxine <sep> desvenlafaxine <sep> duloxetine <sep> desvenlafaxine with duloxetine <sep> duloxetine <sep>', 'duloxetine <sep> paroxetine <sep>', 'placebo <sep> paroxetine <sep> paroxetine <sep> duloxetine <sep> duloxetine <sep>', 'duloxetine hydrochloride <sep> placebo <sep> fluoxetine <sep> serotonin and norepinephrine <sep> duloxetine <sep> fluoxetine 20 mg q.d <sep> duloxetine <sep>', 'quetiapine xr and duloxetine <sep> placebo <sep> quetiapine xr monotherapy <sep> quetiapine fumarate quetiapine xr <sep> duloxetine <sep> quetiapine fumarate monotherapy <sep> duloxetine 60 mg/day active control or placebo <sep> quetiapine xr <sep>', 'headache paroxetine <sep> placebo <sep> paroxetine <sep> paroxetine 20 mg qd <sep> duloxetine <sep> duloxetine and paroxetine <sep> serotonin 5-ht and norepinephrine ne <sep> diarrhea duloxetine <sep> duloxetine <sep>', 'escitalopram and duloxetine <sep> escitalopram versus duloxetine <sep> duloxetine <sep> escitalopram <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",duloxetine did not seem to provide a significant advantage in efficacy over other antidepressive agents for the acute-phase treatment of major depression. no differences in terms of efficacy were found even though duloxetine was worse than some ssris most of all escitalopram and newer antidepressants like venlafaxine in terms of acceptability and tolerability. unfortunately we only found evidence comparing duloxetine with a handful of other active antidepressive agents and only a few trials per comparison were found in some cases we retrieved just one trial). this limited the power of the review to detect moderate but clinically meaningful differences between the drugs. as many statistical tests have been used in the review the findings from this review are better thought of as hypothesis forming rather than hypothesis testing and it would be very comforting to see the conclusions replicated in future trials. most of included studies were sponsored by the drug industry manufacturing duloxetine. as for all other new investigational compounds the potential for overestimation of treatment effect due to sponsorship bias should be borne in mind. in the present review no trials reported economic outcomes. given that several ssris and the great majority of antidepressants are now available as generic formulation only escitalopram desvenlafaxine and duloxetine are still on patent more comprehensive economic estimates of antidepressant treatment effect should be considered to better inform healthcare policy.
235,"{'outcomes': ['incidence of diarrhea and acute respiratory infection ari <sep> incidence of diarrhea <sep> mean number of diarrheal episodes <sep>', 'infant mortality <sep> serum retinol concentrations <sep> hazard ratios <sep>', 'breast milk retinol levels <sep> serum retinol of infants and the breast milk retinol levels <sep> cord blood levels <sep> subclinical vitamin a deficiency <sep> serum retinol levels <sep> subclinical vitamin a deficiency <sep> infant serum retional and the breast milk retinol level <sep>', 'relative risk of vad <sep> serum retinol and incidence of illness <sep> vad <sep> morbidity and mortality <sep> tolerated <sep> safety and efficacy <sep>', 'milk vitamin <sep> mean mrdr ratio <sep> mean maternal serum retinol concentrations <sep> serum retinol concentrations <sep> lower maternal mrdr ratios <sep> maternal and infant serum retinol concentrations modified relative dose-response mrdr ratios and breast milk vitamin a concentrations <sep> liver stores and higher milk vitamin a concentrations <sep> mrdr ratios <sep>', 'mean <sep> duration of respiratory tract infection and febrile illness <sep> serum retinol levels <sep> maternal serum and breastmilk retinol levels and infant morbidity and anthropometry <sep> mean incidence of febrile illness <sep> breastmilk retinol concentration <sep> breastmilk retinol concentration <sep> mean duration of respiratory tract infection <sep>', 'antipolio antibody titer antitetanus toxoid antibodies and avidity of antibodies to tetanus <sep> antibody titers <sep>', 'maternal pneumococcal carriage <sep> clinic attendances <sep> infant pneumococcal carriage <sep> adverse events <sep> h pylori infection <sep> maternal vitamin a concentration <sep> levels of maternal and infant plasma vitamin a h pylori infection pneumococcal carriage and gut epithelial integrity <sep> infant gut mucosal damage <sep> maternal and infant plasma vitamin a reduce infant helicobacter pylori infection and nasopharyngeal pneumococcal carriage and improve infant gut epithelial integrity <sep>', 'maternal serum retinol <sep> gram fat milk retinol <sep> vitamin a status <sep> milk retinol <sep> serum retinol <sep> infant serum retinol <sep> serum retinol and infant stores <sep> milk retinol <sep> infant retinol stores <sep>', 'prevalences of low vitamin a stores <sep> milk retinol concentrations <sep> low serum retinol concentration <sep> mothers serum retinol concentrations <sep>'], 'punchline_text': ['prophylactic administration of mega doses of vitamin a to the mother soon after delivery and to the infant at six months do not have any beneficial impact on the incidence of diarrhea and ari in infancy. <sep>', 'hazard ratios 95 ci for 12 mo mortality among infants in the maternal-supplemented and infant-supplemented groups were 1.17 0.87 1.58 and 1.08 0.80 1.46 respectively. <sep>', 'postpartum vitamin a supplementation had a beneficial impact on the infant serum retional and the breast milk retinol level but no effect on infant growth. <sep>', 'serum retinol and incidence of illness did not differ significantly between the 2 groups. <sep>', 'irrespective of treatment group over 50 of women produced milk with low vitamin a concentrations 1.05 micromol/l or 0.28 micromol/g fat throughout the study. <sep>', 'infants of the supplemented mothers had reduced mean duration of respiratory tract infection of 3.1 2.7 3.5 days compared to 3.7 3.3 4.2 days p  0.03 and mean incidence of febrile illness 0.1 0.1 0.1 compared to control infants 0.3 0.3 0.3 days p  0.002). <sep>', 'we found no evidence that vitamin a supplementation affects infants antibody responses to tetanus toxoid or oral polio vaccine delivered at epi contacts. <sep>', 'no differences were found in the primary outcomes for high-dose versus who schedule maternal vitamin a concentration at 2 months 0.02 micromol/l 95 ci 0.10 to 0.15 infant vitamin a at 5 months 0.01 micromol/l 0.06 to 0.08 h pylori infection at 12 months 0.3 14.7 to 14.2 maternal pneumococcal carriage at 12 months 2.0 13.7 to 9.7 infant pneumococcal carriage at 12 months 4.1 15.8 to 7.6 infant gut mucosal damage at 12 months 5.2 8.7 to 19.2). <sep>', 'infant serum retinol was not different between groups. <sep>', 'the milk retinol concentrations of the vitamin a group were higher than those of the placebo group by 0.48 to 1.18 mumol/l at 1-8 mo postpartum p  0.05). <sep>'], 'population': ['51 villages in two contiguous primary health centers in villupuram health unit district of tamil nadu south india <sep> mother and infant on morbidity in infancy <sep> 909 newly delivered mother-and-infant pairs <sep>', 'infants born to hiv-negative mothers in zimbabwe <sep> young infants <sep> 14,110 mothers and their infants 9208 of the mothers were hiv-negative at delivery remained such during the postpartum year and were retained in the current analysis <sep> infants of hiv-negative women with an apparently adequate vitamin a status <sep>', '109 apparently healthy primi and second gravida women registered at the antenatal clinic were included in the study and followed up for three months postpartum <sep> pregnant mothers in their third trimester 35-37 weeks and <sep> 53 mothers who received a single dose of 2 lakh units of <sep> pregnant women in their third trimester using maternal serum retinol levels as the indicator and ii <sep> pregnant women <sep>', '780 newborn infants and their mothers to a randomized double-blind controlled trial in ifakara in southern tanzania <sep> infants aged 1-3 mo <sep> children living in areas endemic for vitamin a deficiency <sep> tanzanian infants <sep>', 'lactating bangladeshi women benefits mothers and infants <sep>', 'malnourished mothers <sep> mothers and morbidity of their infants <sep> fifty low income women <sep>', 'young infants n  1085 <sep> infants immune responses to tetanus and polio vaccines <sep>', 'rural gambia 220 mother-infant pairs <sep> mothers and infants <sep> 197 infants <sep> gambian mothers and infants <sep>', '564 women <sep> mothers and infants <sep> kenyan mother-infant pairs <sep> kenya <sep>', 'breast-feeding indonesian mothers <sep> 153 indonesian mothers 1-3 wk postpartum <sep> lactating mothers <sep>'], 'interventions': ['placebo <sep> vitamin a supplementation <sep> placebo <sep> vitamin a <sep> vitamin a but infant received placebo <sep> vitamin a supplementation <sep>', 'placebo <sep> vitamin a aa mothers received vitamin a and infants received placebo ap mothers received placebo and infants received vitamin a pa and both mothers and infants received placebo pp <sep> neonatal vitamin <sep> postpartum maternal or neonatal vitamin a supplementation <sep> vitamin <sep>', 'vitamin <sep> vitamin a orally <sep>', 'vitamin a supplementation <sep> 2 vitamin a supplementation <sep> routine vitamin <sep> vitamin <sep> vitamin a palmitate <sep> vitamin a supplementation <sep>', 'beta-carotene 7.8 mg 1300 re <sep> placebo <sep> placebos vitamin a supplementation <sep> 200,000 international units 60,000 retinol equivalents re <sep> maternal vitamin a or beta-carotene supplementation <sep> vitamin a followed by daily placebos <sep> maternal postpartum vitamin a or beta-carotene supplementation <sep> placebos <sep>', 'vitamin <sep> vitamin a supplementation <sep> vitamin a supplementation <sep> 209 micromol of vitamin a or none at delivery <sep>', 'placebo <sep> placebos <sep> vitamin a supplementation <sep> supplementing vitamin <sep> retinol equivalent re vitamin a within 4 wk of delivery 2 expanded program on immunization epi)-linked supplementation of infants with 7.5 mg re vitamin <sep> vitamin a supplementation <sep>', 'early supplementation scheme of high-dose vitamin a versus standard who protocol <sep> vitamin a supplementation <sep> ivacg <sep>', 'maternal vitamin a 400,000 iu or placebo 24 h postpartum and infant vitamin a 100,000 iu or placebo <sep> maternal and infant vitamin a supplementation <sep> placebo <sep>', 'vitamin <sep> capsule containing 312 mumol of vitamin a as retinyl palmitate or a placebo <sep> placebo <sep> vitamin a supplementation <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",the lack of effect on maternal and infant mortality and morbidity with exception of some improved infant morbidity in one small study and the improvement in maternal vitamin a status suggest that maternal postpartum vitamin a supplementation offers limited benefits.
236,"{'outcomes': ['pain control <sep> heart rate and oxygen saturation changes <sep> pain relief <sep> elevation of heart rates <sep> oxygen saturation <sep> loss of oxygen saturation data <sep>', 'analgesic effects <sep> medians for crying time and the pain scores <sep> crying times <sep> relieving pain <sep> mean pain scores <sep>', 'pain responses <sep> nfcs scores <sep> pain relief <sep> neonatal facial coding system nfcs <sep> crying time duration of the first cry and tachycardia time needed for return to baseline heart rate and the average and 1 and 5-minute nfcs scores <sep>', 'neonatal heel prick responses <sep> neonatal pain <sep> analgesic effects <sep> crying time and pain score <sep>', 'frequency distribution of ct <sep> nips scores <sep> neonatal infant pain scale nips score on crying time ct and subsequent nips score <sep> ct and subsequent nips scores <sep> pain reaction <sep> ct and nips scores <sep>', 'crying in response to heel stab <sep> duration of crying <sep>', 'mean sao2 <sep> adverse effects such as apnoea or oxygen desaturation <sep> pain response <sep> heart rate oxygen saturation sao2 neonatal facial coding score and presence or absence of cry <sep> behavioural and physiological pain response <sep> neonatal facial coding score during nasogastric tube passage <sep> pain response measurements <sep> heart rate <sep>', 'pain scores <sep> premature infant pain profile pipp a validated behavioral acute pain scale <sep> mean pain score <sep> pain relief <sep> pain scores <sep> lowest pain scores <sep>', 'duration of cry and douleur aigu du nouveau <sep> pain of heel pricks <sep> pain scores <sep> total duration of crying <sep> response to pain <sep> crying and pain scores <sep> n dan score <sep>', 'cerebral blood volume <sep> cerebral blood volume <sep> crying <sep> heart <sep> heart rate and duration of crying <sep> heart rate thoracic movements and transcutaneous blood gases <sep> pain reaction <sep> duration of crying <sep>', 'procedural pain relief <sep> efficacy and safety <sep> pain response <sep> severity of illness postnatal age or number of painful procedures <sep> pain responses <sep> premature infant pain profile scores <sep> lowest mean premature infant pain profile scores <sep> efficacy pain response as measured using the premature infant pain profile <sep> efficacy and safety <sep>', 'pipp score <sep> pain responses <sep> pain responses <sep> distress responses <sep> premature infant pain profile pipp <sep> mean pipp scores <sep>', 'episodes of desaturations or bradycardia <sep> behavioural and physiological pain responses <sep> pain scores <sep> mean gestational age at birth mean birth weight or corrected gestational age <sep> median neonatal pain agitation and sedation scale n-pass score <sep>', 'longer crying time <sep> pain and distress <sep> pain response <sep> vital signs <sep> vital signs i.e. pulse rate respiratory rate and oxygen saturation crying time and time for the vital signs to return to baseline values <sep>', 'analgesic effect <sep> pain scores <sep> pain response <sep> baseline pain scores <sep> pain scores less crying <sep> pain scores crying or time to return to baseline behavior <sep> cry with catheterization <sep>', 'crying time and pain <sep> heart rate and oxygen saturation <sep> crying time <sep> behavioural responses to pain <sep> oxygen saturation and heart rate and neonatal infant pain scale <sep> pain and duration of crying <sep>', 'mean sd plasma lidocaine level <sep> adverse events and lidocaine levels <sep> local skin reactions <sep> incidence of spitting up <sep> pain <sep> facial grimacing scores <sep> safety <sep>', 'median interquartile pain scores <sep> median pain scores <sep> analgesic effects <sep>', 'crying and the total procedure time <sep> neonatal pain <sep> neonatal facial coding system nfcs <sep> nfcs score <sep>', 'crying duration <sep>', 'heart rate <sep>', 'facial expression <sep> pipp score <sep> pain-specific brain activity evoked by one time-locked heel lance recorded with electroencephalography and identified by principal component analysis <sep> nociceptive brain activity <sep> behavioural and physiological pain scores <sep> pain-specific brain and spinal cord activity <sep> baseline behavioural and physiological measures observational pain scores pipp and spinal nociceptive reflex withdrawal activity <sep> magnitude or latency of the spinal nociceptive reflex withdrawal <sep>', 'sg neonates crying <sep> neonates facial activity nfcs behavioral state and heart rate <sep> responses of neonates to pain and distress <sep> pain relief <sep> sg neonates with facial actions signaling pain <sep>', 'crying time and the level of behavioural state <sep> crying time behavioural state skin conductance and heart rate <sep> skin conductance number and amplitude of the waves and heart rate <sep> pain response <sep> crying time <sep>', 'facial scores <sep> facial scores <sep> pain assessment <sep> physiological responses of heart rate and oxygen saturation <sep> pain <sep> facial expression score incidence and duration of crying heart rate and oxygen saturation changes <sep> blood collection incidence and duration of crying <sep> duration of crying whilst the blood collection <sep>', 'pain <sep> pain response <sep> efficacy and safety <sep> pain response and clinical outcomes e.g. health status and neurodevelopmental status <sep>', 'pain <sep> mean dan and nfcs scores <sep> newborn acute pain scale dan and with the neonatal facial coding system nfcs <sep>', 'pain response <sep> procedural pain control <sep> pain responses <sep> pain <sep> procedural pain <sep> pipp scores <sep> immediate pain response <sep> pain <sep> premature infant pain profile pipp scoring system <sep>', 'negative electroencephalographic response <sep> relative right frontal eeg activation <sep> electroencephalographic eeg activity heart rate activity and infants facial behaviors <sep> heart rate <sep> frontal eeg asymmetry scores <sep> heart rate <sep>', 'median heart rate increase oxygen saturation decrease and duration of first cry <sep> sampling duration and numbers of heel lances <sep> pain response <sep> median premature infant pain profile scores <sep> multidimensional acute pain rating scale of the premature infant pain profile heart rate increase oxygen saturation decrease crying behavior duration of first cry cry percentage in 2 minutes and during blood sampling duration of sampling and the number of performed heel lances <sep>', 'validated infant pain measure the premature infant pain profile pipp which includes measures of facial expressions heart rate and oxygen saturation and takes behavioral state and gestational age into consideration <sep> mean pipp score <sep> analgesic effects <sep> pain <sep> pipp scores <sep> mean pipp scores <sep>', 'distress <sep> distress scores <sep> plasma cortisol levels <sep> plasma for cortisol levels <sep> behavioral observations <sep>', 'pain vocalizations <sep>', 'pain <sep> lower pipp scores single sucrose pain scores <sep> sucrose pain scores <sep> premature infant pain profile pipp scores <sep>', 'pulse rate variability <sep> cortisol response <sep> standard deviation of pulse rate and number of doses of sucrose <sep> salivary cortisol <sep> overall physiological stability <sep> pulse rate <sep>', 'pain scores <sep> overall mean pain score <sep> pain <sep> effectiveness and safety of sucrose <sep> mean glucose levels <sep>', 'pain reduction <sep> pain and discomfort <sep> pain and discomfort <sep> median premature infant pain profile score <sep> pain and distress <sep> pain relief <sep> lowest pain score <sep> pain relief <sep>', 'pain-related behaviour <sep> time spent crying <sep> pain-induced crying <sep>', 'behavioral crying and facial activity and physiological heart rate vagal tone responses <sep> crying <sep> facial activity <sep> newborn infant pain responses <sep> heart rate and lower vagal tone <sep>', 'facial actions indicative of pain <sep> facial expression of pain <sep> pain response <sep> quiet sleep <sep> facial actions <sep> pain or heart rate <sep> heart rate <sep> physiological heart rate and behavioural facial actions responses <sep>', 'time crying <sep> average score on the scale of discomfort <sep> discomfort and crying <sep> scores of the scale of discomfort <sep> average crying time <sep>', 'crying time <sep> duration of crying <sep> overall crying time and heart rate <sep> crying and the autonomic effects <sep>', 'analgesic effect <sep> median crying times <sep> pain response <sep> median values of crying time recovery time and percentage change in heart rate <sep> crying time <sep> median recovery time <sep> heart rate <sep>', 'analgesic effect <sep> mean recovery time <sep> mean crying times <sep> pain response <sep> maximum heart rate <sep> crying time <sep> mean crying time recovery time maximum heart rate and percent change in heart rate <sep> relieving pain <sep> heart rate <sep>', 'motor development and vigor and alertness and orientation components of the neurobehavioral assessment of the preterm infant <sep> neonatal acute physiology <sep> neuro-biological risk score nbrs <sep> motor development and vigor and alertness and orientation at 36 weeks lower motor development and vigor <sep>', 'physiologic or behavioral responses to the eye exam <sep> pain/distress <sep> pain and distress <sep> hr bp and pain score <sep> o(2 saturation <sep> majority of time actively crying <sep> hr rr o(2 saturation bp pain premature infant pain profile and percent of time spent crying during the eye exam <sep>', 'pain behaviors <sep> duration of cry vagal tone and salivary cortisol <sep> procedural pain <sep> vagal tone <sep>', 'efficacy and immediate and long-term adverse events <sep> neurobiological risk status <sep> effective and safe for relieving pain <sep> adverse events clinical outcomes or neurobiological risk status <sep> efficacy and safety <sep>', 'analgesic effect <sep> mean sd dan pain scores <sep> douleur aigu nouveau-n dan behavioral scale <sep> venipuncture-induced pain <sep> pain <sep> pain scores <sep>'], 'punchline_text': ['sucrose gave significant p  .001 <sep>', 'the mean pain scores were 4.60 5.82 3.91 4.94 5 and 4.05 in groups 1-6 respectively p 0.068). <sep>', 'there were significant reductions in crying time duration of the first cry and tachycardia time needed for return to baseline heart rate and the average and 1 and 5-minute nfcs scores in the hindmilk group when compared with the distilled water group. <sep>', 'there was a significant reduction in crying time and pain score 3 minutes after the painful stimulus in all groups compared with the controls. <sep>', 'nips scores before the heel prick correlated significantly and positively with ct and subsequent nips scores in both the sucrose and the placebo groups. <sep>', 'the duration of crying in response to sampling did not differ in the two groups but was related to level of arousal at the time of stimulation. <sep>', 'infants who received sucrose demonstrated a significantly lower neonatal facial coding score during nasogastric tube passage compared with the placebo group median 1 range 0-4 vs 3 0-4 p  0.004). <sep>', 'the synergistic effect of the combination of sucrose and non-nutritive sucking was clinically effective and safe in relieving the pain of simple procedures such as venipuncture or heel stick in preterm and term infants but further research is needed on these interventions alone and in combination with other behavioral interventions in neonates. <sep>', 'at 2 and 4 minutes pain scores were lowest in the nns and rocking groups as compared to sucrose distilled water expressed breast milk and massage. <sep>', 'cerebral blood volume decreased in 5 of 14 infants after sucrose and in 6 of 14 infants after placebo difference not significant). <sep>', 'significant differences in pain response existed among treatment groups f  22.49 p .001 with the lowest mean premature infant pain profile scores in the sucrose and nonnutritive sucking group. <sep>', 'infants randomised to pacifiers scored lower than those without pacifiers p  0.003). <sep>', 'there was no difference in mean gestational age at birth mean birth weight or corrected gestational age at first examination between both groups. <sep>', 'the participants in the control group had a trend of longer crying time but this trend did not reach a level of statistical significance. <sep>', 'there was no overall treatment effect when using an oral sucrose solution before bladder catheterization in infants younger than 90 days of age. <sep>', 'no differences were determined between the groups for heart rate and oxygen saturation in the newborns during painful interventions p  005). <sep>', 'facial grimacing scores were lower in the sucrose group compared with those in the liposomal lidocaine group mean difference 27 95 confidence interval ci 36 to 19 p  .001 and for the sucrose plus liposomal lidocaine group compared with those in the liposomal lidocaine group mean difference 23 <sep>', 'differences between group medians for these comparisons were 3 2 to 5 3 1 to 5 and 1 0 to 2 respectively. <sep>', 'oral sucrose significantly reduced the score of the hl group 58 v 47 p<0.01 and also tended to reduce the score of the vp group 23 v 2 p<0.1). <sep>', 'neither water nor lactose were effective during or after blood collection. <sep>', 'grimacing was reduced to almost naught by procedures that essentially eliminated crying and markedly reduced heart rate during the blood harvesting procedure. <sep>', 'no significant difference was recorded between the sucrose and sterile water groups in the magnitude or latency of the spinal nociceptive reflex withdrawal recorded from the biceps femoris of the stimulated leg. <sep>', 'there were significantly fewer sg neonates crying during a ass.2 p ass.2 and ass.4 and d ass.3). <sep>', 'the increase from before to during heel prick in skin conductance number and amplitude of the waves and heart rate correlated with the crying time p  0.01). <sep>', 'physiological responses of heart rate and oxygen saturation were not attenuated by sucrose at any time point during or following the blood collection. <sep>', 'the pacifier with sucrose f  24.09 p  .0001 and pacifier with sterile water f  9.00 p  .003 significantly reduced pain. <sep>', 'pain was assessed with the newborn acute pain scale dan and with the neonatal facial coding system nfcs). <sep>', 'for 3 of the 5 definitions of pain response patients experienced significantly less pain at speculum insertion with sucrose than with placebo. <sep>', 'infants who received water showed increased relative right frontal eeg activation from baseline to the post-heelstroke phase a pattern that typifies negative affect. <sep>', 'median premature infant pain profile scores were lower in the breastfeeding group 3.0 than in the sucrose-solution group 8.5 and the median group difference was 5.0. <sep>', 'the mean pipp score was 8.8 for the sucrose group and 11.4 for the water group  t  2.87 p  .008 two-tailed). <sep>', 'the pacifier dipped in sucrose had a distress-reducing effect during both the post-dpnb injection and circumcision periods. <sep>', 'two-week-old infants who received either the sterile water or sucrose solution cried significantly less than infants who received no intervention f=5.92,p<.005). <sep>', 'both sucrose groups had lower pipp scores single sucrose pain scores 6.8-8.2 p  0.07 repeated sucrose pain scores 5.3-6. 2 p  0.01 than water pain scores 7.9-9.1 and in the last block the repeated dose had lower scores than the single dose 6.2 vs. 8. 2 p  0.05). <sep>', 'there were no group differences in the cortisol response to a painful stimulus or in pulse rate variability over time. <sep>', 'we found that pain scores during intramuscular injection did not differ significantly between the sucrose and placebo groups for newborns of diabetic or nondiabetic mothers newborns of nondiabetic mothers mean difference <sep>', 'insertion of a feeding tube in preterm infants leads to a measurable degree of pain and discomfort according to the premature infant pain profile assessment tool. <sep>', 'the time spent crying was reduced in the group treated with the sweetest solution s24 n  8 mean  19.1 s). <sep>', 'for physiological measures the interventions interacted with each other and preintervention levels to reduce heart rate and lower vagal tone more during the procedure in infants in whom heart rate and vagal tone were higher before intervention. <sep>', 'the groups that received sucrose alone or in combination with simulated rocking showed less facial actions indicative of pain than the rocking alone or control group. <sep>', 'the comparative analysis between groups of non-nutritive sucking sucrose and placebo showed no significant differences. <sep>', 'there was a significant reduction in overall crying time and heart rate after three minutes in the babies given 50 sucrose as compared with controls. <sep>', 'median crying times were 36 52 and 62 s in the sucrose placebo and human milk groups respectively p  0.0009). <sep>', 'although mean recovery time was shorter in the sucrose group 102 seconds there was neither a significant difference between the groups 10 glucose 121 seconds 30 glucose 109 seconds control group 132 seconds p .09 nor was there a difference in maximum heart rate and percent change in heart rate at 1 2 and 3 minutes after heel prick p .14 p .05 p  <sep>', 'repeated use of sucrose analgesia in infants 31 weeks pca may put infants at risk for poorer neurobehavioral development and physiologic outcomes. <sep>', 'no significant differences were seen between groups in physiologic or behavioral responses to the eye exam. <sep>', 'repeated measures analysis of variance anova revealed that the sugar-coated pacifier group demonstrated significantly lower vagal tone during heelstick than the oral sucrose solution and control groups. <sep>', 'there was a significant main effect of intervention p  0.03 between the sucrose plus pacifier group and the standard care group p  0.01 but there was no main effect of time p  0.72). <sep>', 'the combination of sucrose and emla cream revealed a higher analgesic effect than sucrose alone during venipuncture in these preterm infants. <sep>'], 'population': ['university teaching hospital general care nursery <sep> one hundred nineteen full-term male normal birth weight neonates 12 hours old or older <sep>', 'healthy term newborns during heel prick blood sampling <sep> during neonatal heel prick <sep> healthy newborns n 142 <sep>', 'term neonates <sep> term newborns during heel stick <sep>', 'sixty infants <sep>', 'population of newborns when cuddled and comforted during heel prick for diagnosis of phenylketonuria <sep> 100 healthy full-term infants <sep> newborns during heel prick <sep>', '52 infants received either <sep>', '20 stable preterm infants who required nasogastric tube insertion for feeding randomised on 51 occasions <sep> 23 <sep> neonates <sep> preterm infants <sep>', '36 preterm infants mean 31 weeks gestational age range 27 to 36 weeks <sep> neonates <sep> preterm infants <sep>', '104 stable term neonates <sep> neonates <sep>', 'neonatal intermediate care unit in a level 3 perinatal center <sep> patients studied were 16 preterm infants birth weight 900-1900 g gestational wk 27-34 corrected postmenstrual age at time of investigation 33-36 wk <sep> preterm infants <sep>', 'preterm and acutely ill term neonates <sep> 190 neonates were stratified by gestational age <sep> preterm and term neonates <sep> preterm and acutely ill term neonates who are hospitalized in a neonatal intensive care unit <sep>', 'infants undergoing screening for retinopathy of prematurity <sep> forty infants 32 weeks gestation or 1500 g birth weight in two neonatal units <sep> infants at risk of retinopathy of prematurity <sep> retinopathy of prematurity <sep>', '40 infants were included in the study <sep> 40 infants undergoing primary eye examination for rop screening <sep>', 'fourteen study infants were swaddled held and given 24 sucrose solution during the examination <sep> preterm infants <sep> 30 stable preterm infants who underwent initial rop screening examinations <sep> preterm infants undergoing screening for retinopathy of prematurity <sep>', 'infants younger than 90 days of age <sep> infants  or  90 days of age and requiring bladder catheterization <sep> infants undergoing bladder catheterization in an emergency department ed population <sep> eighty-three patients were enrolled 40 <sep> older infants <sep> infants younger than 90 days of age who require bladder catheterization in the pediatric emergency department <sep> infants with prior bladder catheterization previous painful procedures that day or neurological or genital abnormalities <sep>', ""healthy newborns hospitalised in the gynaecology clinics of trabzon delivery and children's diseases hospital between february 2007-january 2008 <sep> newborns who had blood sampling by heel stick <sep> 120 newborns in turkey <sep> newborns <sep> 2010 blackwell publishing ltd <sep>"", 'newborns <sep> term newborns <sep> 330 healthy term newborns <sep>', '150 term newborns undergoing <sep> term neonates <sep>', '100 healthy full term newborn infants being screened for inborn errors of metabolism <sep> newborn infants <sep> newborn infants undergoing painful procedures <sep>', 'newborns during and after blood collection for phenylketonuria evaluation <sep> human newborns <sep>', 'healthy term newborn humans undergoing the painful routine procedure of heel lance and blood collection <sep> human newborns <sep>', 'many infants admitted to hospital undergo repeated invasive procedures <sep> newborn infants <sep> 29 infants <sep> 59 newborn infants at university college hospital london uk <sep>', 'preterm neonates with no side effects <sep> thirty-three preterm neonates <sep>', 'preterms prior to heel prick <sep> 12 healthy preterm infants with a median gestational age of 32 wk and a median postnatal age of 14 d <sep>', 'sick hospitalized infants <sep> institutions caring for sick babies <sep> a total of 128 infants were included <sep>', 'very low birth weight neonates <sep> 122 vlbw neonates using the premature infant pain profile following four randomly ordered interventions during consecutive routine heel lance procedures <sep> very low birth weight vlbw neonates <sep>', 'neonates with a gestational age below 33 weeks of gestation and older than 8 days of life <sep> thirty-three neonates were included representing 265 injections <sep> preterm infants <sep> preterm newborns <sep>', 'neonates born at  or  30 weeks gestation <sep> premature infants during eye examinations for retinopathy of prematurity <sep> twenty-three infants were studied with 12 receiving sucrose and 11 receiving <sep> newborns <sep> premature infants undergoing eye examination for rop <sep>', 'newborns <sep> 34 newborns <sep>', 'for congenital disorders <sep> term neonates <sep> newborn infants <sep> term neonates receiving heel lance <sep> neonatal unit of a public hospital in northern italy on 101 term neonates undergoing <sep>', '30 preterm infants <sep> preterm infants <sep> retinopathy of prematurity <sep>', 'eighty healthy term newborn male infants scheduled for routine neonatal circumcision <sep>', 'infants during immunization injections <sep> a consecutive sample of 285 infants <sep> infants age range 2 weeks to 18 months <sep> ambulatory care clinic of a large tertiary care center <sep>', 'preterm neonates <sep> infants n  48 in the first week of life with a mean gestational age of 31 weeks received <sep>', 'preterm neonates <sep> infants born 31 weeks of gestational age and recruited within 48 h of life <sep>', 'newborns undergoing various medical procedures within 2 days of birth <sep> 240 newborns 120 from diabetic mothers 120 from nondiabetic mothers <sep> newborns of nondiabetic mothers <sep> newborns of diabetic mothers <sep> newborns undergoing painful medical procedures <sep> newborns or 36 weeks gestation of diabetic mothers and nondiabetic mothers <sep>', 'preterm infants who cannot feed by themselves <sep> 24 preterm infants with postmenstrual age 28 to 32 weeks who were in stable condition <sep> preterm infants <sep>', 'preterm infants a sample of 28 healthy neonates 15m 13f gestational age at procedure less than 37 weeks who were having routine blood drawn by arm venipuncture was studied <sep> preterm infants <sep>', 'eighty-five normally developing newborn infants were studied with a mean gestational age of 39.4 weeks on the 2nd or 3rd day of life <sep> newborn infants <sep>', 'preterm infants n  85 between 25-34 weeks post-conceptual age pca and 2-10 days postnatal age pna <sep> preterm neonates undergoing routine heelstick procedure in the neonatal intensive care unit nicu <sep> preterm infants <sep> infants <sep> preterm neonates <sep>', '150 term infants in three randomised groups from the maternity unit of our hospital for a period of three months <sep> 50 newborns <sep> healthy newborns requiring blood test by a heel-prick procedure and compare different pain management methods <sep>', 'healthy normal babies <sep> full term infants <sep> neonates <sep> 60 healthy infants of gestational age 37-42 weeks and postnatal age 1-6 days <sep>', 'healthy infants n  102 <sep> newborns <sep> healthy term newborns <sep>', '113 infants whose heels were pricked for the guthrie test were included in the study <sep> neonates <sep> healthy term newborns <sep>', 'preterm neonates in neonatal intensive care units <sep> 107 preterm neonates who were born at 31 weeks postconceptional age pca entered this double-blind randomized controlled trial within 48 hours of birth at 3 level iii university-affiliated neonatal intensive care units in canada and 103 completed the study <sep> neonates younger than 31 weeks postconceptional age <sep> preterm infants <sep>', '32 infants about to undergo rop screening exams <sep>', 'healthy neonates <sep> 84 newborns undergoing heelstick <sep> newborns <sep> neonates <sep>', 'preterm neonates <sep> sixty-six preterm infants <sep> preterm neonates undergo numerous painful procedures in the neonatal intensive care unit nicu <sep>', 'preterm neonates <sep> 76 children 37 in the s group 39 in the s+e group <sep> preterm infants <sep>  2011 by the american academy of pediatrics <sep> infants younger than 37 weeks gestational age during 1 routine venipuncture for blood sampling <sep>'], 'interventions': ['oral sucrose via a nipple compared with no treatment and dorsal penile nerve block dpnb <sep> sucrose pacifier <sep> dpnb or sucrose <sep>', 'double versus single-dose sucrose <sep> double versus single-dose breast milk <sep> sucrose solution <sep> breast milk and sucrose <sep> single-dose breast milk group 2 single-dose sterile water group 3 single-dose 12.5 sucrose group 4 two doses breast milk group 5 two doses sterile water and group 6 two doses 12.5 sucrose before the heel prick <sep>', 'placebo <sep> hindmilk 12.5 sucrose and distilled water groups <sep>', 'non-sucrose sweet tasting solution <sep> heel stab blood sampling sterile water placebo 25 or 50 sucrose weight/volume and the commercial sweet-tasting solution <sep>', 'sucrose <sep> sucrose solution or 2 ml sterile water <sep> placebo <sep>', 'sucrose <sep> 2 ml of 7.5 sucrose or 2 ml of sterile water before heel stab blood sampling <sep>', 'lingual sucrose <sep> placebo <sep> lingual 24 sucrose or water placebo <sep> lingual sucrose <sep> nasogastric tube insertion <sep> nasogastric tube insertion <sep>', 'sucrose and non-nutritive sucking <sep> oral sucrose and a pacifier <sep> sucrose glucose and a pacifier <sep> pacifier 0.5 ml sterile water without pacifier 0.5 ml sucrose 24 with pacifier 0.5 ml sucrose 24 without pacifier pacifier alone and control group <sep> pharmacologic sucrose water and a non-pharmacologic measures pacifier <sep>', 'ebm dw sucrose or massage <sep> nutritive sucking nns rocking massage sucrose 20 percent distilled water dw and expressed breast milk ebm <sep>', 'sucrose <sep> placebo <sep>', 'sucrose <sep> sucrose and nonnutritive sucking <sep> sucrose alone n  62 or c sterile water and nonnutritive sucking control <sep>', 'oral sucrose and/or pacifier <sep> sucrose and non-nutritive sucking <sep> placebo <sep> 1 ml 33 sucrose solution <sep> sucrose and pacifier <sep> oral sucrose and non-nutritive sucking <sep> 1 ml 33 sucrose solution with pacifier <sep>', 'placebo <sep> rop screening <sep> 0.2 ml of sucrose 24 given by mouth using a syringe and a soother <sep> sucrose combined with nns <sep> oral sucrose combined with swaddling and non-nutritive suck nns <sep>', 'comfort care <sep> rop screening <sep>', 'sucrose analgesia <sep> placebo <sep> sucrose solution to placebo <sep> oral sucrose solution <sep>', ""mother's milk sucrose pacifier and control <sep> mother's milk sucrose and pacifier <sep>"", 'liposomal lidocaine <sep> liposomal lidocaine cream topically 2 2 ml of 24 sucrose solution orally or 3 sucrose and liposomal lidocaine <sep> liposomal lidocaine and sucrose alone <sep> sucrose plus liposomal lidocaine <sep> sucrose and sucrose plus liposomal lidocaine <sep> liposomal lidocaine sucrose and their combination <sep>', 'placebo <sep> placebo 2 ml sterile water 2 ml 30 glucose 2 ml 30 sucrose a pacifier and 2 ml 30 sucrose followed by a pacifier <sep> sucrose plus pacifier <sep> venepuncture <sep> glucose and sucrose and pacifiers <sep> sucrose glucose and pacifiers <sep> sucrose and pacifiers <sep> placebo sterile water <sep>', 'oral sucrose or water <sep> placebo <sep> venepuncture vp <sep> vp or hl with or without sucrose <sep> oral sucrose <sep> venepuncture <sep>', 'milk-induced hypoalgesia <sep>', 'sucking-induced analgesia <sep> suckling and sucrose-induced analgesia <sep>', '05 ml 24 sucrose solution or 05 <sep> sucrose administration <sep> sterile water sucrose <sep> ml sterile water <sep> oral sucrose <sep>', 'sucrose <sep> sucrose group sg=17 and the control group cg=16 <sep> oral sucrose <sep>', 'food intake and oral sucrose <sep>', '1 ml 25 sucrose or 1 ml water 2 min prior to a heel lance procedure <sep> 25 oral sucrose <sep> placebo <sep> oral sucrose <sep>', 'sensitive behavioral interventions nonnutritive sucking via a pacifier positioning and sucrose <sep> sensitive interventions and sucrose <sep>', 'saccharose <sep> emla cream and saccharose solution <sep> epo <sep> nutritive pacifier sucking t oral administration of 0.2-0.5 ml of a 30 saccharose solution with non nutritive pacifier sucking s local application of emla with non nutritive pacifier sucking e and oral administration of 0.2-0.5 ml of a 30 saccharose solution with local application of emla and with non nutritive pacifier sucking s  e <sep> nutritive pacifier sucking oral administration of a 30 saccharose solution local application of emla and their association for subcutaneous injection of erythropoietin epo <sep>', 'sucrose <sep> proparacaine hcl ophthalmic solution 0.5 plus 2 ml of sucrose 24 or proparacaine hcl ophthalmic solution 0.5 plus 2 ml of sterile water placebo <sep> placebo <sep> topical anesthetic <sep> sweet solutions <sep> oral sucrose <sep>', '2 ml of water or sucrose solution <sep>', 'heel lance with an automated piercing device for routine neonatal screening <sep> sucrose solution <sep> breastfeeding or oral sucrose solution <sep> breastfeeding during blood sampling or to the oral administration of 1 ml of 25 sucrose solution <sep> oral sucrose <sep>', 'local anesthetic eye drops a pacifier plus three doses of sterile water or local anesthetic eye drops a pacifier plus three doses of 24 sucrose during the eye examination <sep> oral sucrose and pacifier <sep> sucrose and a pacifier <sep> oral sucrose <sep>', 'rigid plastic restraint board b standard dpnb <sep> lidocaine <sep> lidocaine hydrochloride used for dpnb and 3 offering a pacifier dipped in a 24 sucrose solution during the dpnb and circumcision <sep> placebo <sep> lidocaine hydrochloride <sep>', 'no intervention or drank 2 ml of sterile water or 2 ml or a 12 sucrose solution <sep> sterile water or sucrose solution cried <sep>', 'sucrose <sep> placebo <sep> 0.05 ml of 24 sucrose solution or sterile water by mouth 1 2 min prior to actual lancing of the heel 2 just prior to lancing <sep>', '24 sucrose or sterile water placebo <sep> sucrose analgesia <sep> placebo <sep>', 'vitamin k venipuncture <sep> sucrose analgesia <sep> placebo <sep> placebo solution <sep>', 'pacifier or no pacifier combined with no fluid sterile water or 30 sucrose <sep>', 'oral sweet solution <sep> oral sucrose <sep>', 'heel-stick procedure <sep> receive 1 no holding and water taste control participants 2 no holding and sucrose taste sucrose group 3 holding and water taste holding group or 4 holding and sucrose taste holding and sucrose group <sep>', 'oral sucrose and simulated rocking <sep> rocking alone or control group <sep> sucrose alone or in combination with simulated rocking <sep> sucrose and simulated rocking alone and in combination <sep> sucrose alone 0.05 ml of 24 sucrose was placed on the anterior surface of the tongue just prior to the lancing of the heel 2 simulated rocking alone 15 min prior to and during the heelstick procedure the infant was swaddled and put on an oscillating mattress 3 combination of sucrose and simulated rocking and 4 placebo <sep>', 'placebo <sep> non-nutritive sucking-placebo and non-nutritive sucking-24 sucrose respectively <sep> no specific analgesic intervention during blood tests except our usual nursing intervention facilitated tucking <sep>', 'sucrose <sep> placebo <sep> sterile water control <sep> concentrated sucrose solution <sep>', 'three solutions sucrose human milk sterile water 2 min prior to taking a heel prick blood sample <sep> placebo <sep> sucrose and human milk <sep> 2 ml 25 sucrose and human milk <sep>', 'oral glucose and sucrose solutions <sep> receiving 2 ml of 30 sucrose 10 glucose 30 glucose or distilled water <sep>', 'sucrose <sep> sucrose analgesia <sep> routine sucrose analgesia <sep>', 'oral s <sep> oral sucrose <sep> oral sucrose s n=16 or sterile water c <sep> oral sucrose <sep>', 'pacifiers and sugar alone and in combination <sep> sugar-coated pacifier <sep> sugar coated pacifier <sep> water-moistened pacifier b sugar-coated pacifier c 2 cc of a 12 oral sucrose solution or d control <sep>', 'standard care positioning and swaddling n  21 sterile water plus pacifier <sep> sucrose plus pacifier <sep>', 'sucrose and emla cream <sep> sucrose and the local anesthetic cream emla <sep> emla cream and oral sucrose <sep> copyright <sep> sucrose plus application of a placebo cream s group or sucrose plus emla cream s+e group before venipuncture <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",sucrose is safe and effective for reducing procedural pain from single events. an optimal dose could not be identified due to inconsistency in effective sucrose dosage among studies. further investigation on repeated administration of sucrose in neonates and the use of sucrose in combination with other non-pharmacological and pharmacological interventions is needed. sucrose use in extremely preterm unstable ventilated or a combination of these neonates needs to be addressed. additional research is needed to determine the minimally effective dose of sucrose during a single painful procedure and the effect of repeated sucrose administration on immediate pain intensity and long-term neurodevelopmental outcomes.
237,"{'outcomes': [""benefit of ethyl-epa <sep> unified huntington's disease rating scale uhdrs <sep> adverse events <sep> motor function <sep> tms-4 <sep> behavioral severity and frequency <sep> total motor score 4 subscale tms-4 <sep>"", ""unified huntington's disease rating scale uhdrs <sep> maximal static torque <sep> functional checklist of the uhdrs <sep> muscle functional capacity <sep> peak oxygen uptake <sep> functional neuromuscular and cognitive status <sep> cognitive functioning bimanual coordination ability and general motor function total motor scale uhdrs <sep>"", 'tfc <sep> progression of early huntington disease <sep> symptomatic improvement <sep> total functional capacity tfc score <sep> rate of deterioration <sep> chorea <sep> quantified neurological examination and a set of cognitive and motor tests <sep>', ""huntington's disease activities of daily living scale adl-an index of functional status and the quantified neurologic examination qne <sep>"", 'neurologic and neuropsychiatric symptoms <sep> neurologic and neuropsychologic symptoms <sep> neurologic symptoms <sep>', 'total functional capacity <sep>'], 'punchline_text': ['in the pp cohort ethyl-epa proved better than placebo on the chi2 test on tms-4 p  0.05 but missed significance on ancova p  0.06). <sep>', 'scores on the functional checklist of the uhdrs p  0.05 maximal static torque p  0.05 and peak oxygen uptake p  0.05 decreased from the start to the end of the study independent of the treatment received. <sep>', 'both the lamotrigine and the placebo group deteriorated significantly on the tfc in the lamotrigine group by 1.89 and the placebo group by 2.11 points. <sep>', ""there were no significant differences between groups on the primary outcome measures of the huntington's disease activities of daily living scale adl-an index of functional status and the quantified neurologic examination qne). <sep>"", 'treatment with d-alpha-tocopherol had no effect on neurologic and neuropsychiatric symptoms in the treatment group overall. <sep>', 'total functional capacity was not favorably influenced by baclofen treatment. <sep>'], 'population': ['135 patients with hd <sep> patients with high vs low cag repeats <sep> huntington disease <sep> huntington disease hd <sep> 121 patients completed 12 months and 83 did so without protocol violations pp cohort <sep>', ""healthy subjects and patients with neuromuscular disease 5 g/day <sep> huntington's disease hd <sep> huntington's disease <sep> 41 patients with hd stage i through iii <sep>"", '64 patients with motor signs of less than 5 years duration who were randomly assigned to either <sep> fifty-five patients 28 on lamotrigine 27 on <sep> huntington disease hd <sep>', ""ninety-one patients completed the study <sep> one hundred patients with clinically diagnosed huntington's disease hd <sep> huntington's disease <sep>"", ""73 patients with huntington's disease <sep> huntington's disease <sep>"", ""early huntington's disease <sep> sixty patients with early hd <sep> patients with early huntington's disease hd <sep>""], 'interventions': ['placebo <sep> ethyl-epa <sep> ethyl-epa <sep> ethyl-epa vs placebo <sep> pure ethyl-eicosapentaenoate ethyl-epa <sep> ethyl-eicosapentaenoate ethyl-epa <sep>', 'placebo <sep> exercise test on an isokinetic dynamometer to assess strength of the elbow flexor muscles 3 a maximal exercise test on a bicycle ergometer to evaluate cardiorespiratory fitness and 4 a test to assess bimanual coordination ability <sep> creatine supplementation <sep> creatine <sep> creatine cr supplementation <sep>', 'placebo <sep> lamotrigine <sep> placebo or lamotrigine <sep>', 'idebenone an antioxidant and enhancer of oxidative metabolism or placebo <sep> idebenone <sep>', 'placebo <sep> d-alpha-tocopherol <sep> d-alpha-tocopherol or placebo <sep> antioxidant therapy <sep> high-dose d-alpha-tocopherol treatment <sep>', 'chronic baclofen <sep> placebo <sep> baclofen <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",only pharmacological interventions were included and none proved to be effective as a disease-modifying therapy for hd. further trials with greater methodological quality should be conducted using more sensitive biological markers. pre-symptomatic mutation carriers should be included in future studies.
238,"{'outcomes': ['maximum plasma concentration cmax and area under the curve auc <sep> severe toxicity <sep> objective tumor regression <sep>', '5-year survival rates <sep> multiple lung metastases <sep> peripheral blood stem cells pbscs <sep>', 'multiple organ toxicity including venoocclusive disease refractory thrombocytopenia and hypertension <sep> excessive renal and gastrointestinal toxicity <sep> toxicity <sep> objective tumor regression <sep>', 'toxicity six died of disease <sep> rhabdomyoblastic differentiation <sep>', 'overall survival os <sep> survival <sep>', 'hemopoietic recovery <sep>', 'hepatic veno-occlusive disease no serious complications <sep>', 'regional lymph node invasion <sep> progressive disease <sep> complete remission cr <sep> patient died of infection <sep> antitumor effect <sep> partial remission pr <sep>', 'peripheral leukocyte count <sep>', 'toxicity <sep>', 'feasibility safety and efficacy <sep> mortality <sep> 5-year progression-free survival pfs and overall survival os <sep>', 'overall survival <sep> complete remission cr <sep> response durations <sep> median time to wbc recovery <sep> toxicity <sep>', 'toxicity <sep> toxicity of and event-free survival <sep> partial remission <sep>', 'ttp and survival rates <sep> progressive disease <sep> early discontinuation of therapy due to toxicities <sep> efficacy and toxicity <sep> median time to progression ttp and overall survival <sep> median pbsc collection <sep>', 'total 5-year survival rate <sep> total 2-year survival rate <sep>', 'haematological and gastrointestinal toxicities <sep> glomerular filtration rate <sep> life-threatening or fatal toxicity <sep>', 'survival benefit <sep> median os <sep> median pfs <sep>', 'severe mucositis and erythema with superficial peeling <sep> complete remission cr and three in partial remission pr <sep>', 'partial response <sep>', 'abdominal distention vague abdominal pain and vomiting <sep> recurrence <sep>', 'tumor response to chemotherapy <sep> desmoplastic round cell tumor dsct <sep> median survival <sep> progressive disease <sep>', 'absolute neutrophil granulocyte count <sep> died of progressive disease and one child died of therapy-associated complications <sep> median hospital stay <sep> complete remission <sep>', 'karnofsky index  80 r 0 resection and first-line asct <sep> median overall survival os <sep> partial remission pr and stable disease <sep> sustained complete remission cr <sep>', 'local recurrence and metastasis rate <sep>', 'side effects <sep> growth of metastatic nodules <sep> delayed-type hypersensitivity responses <sep>', 'died of toxicity <sep> toxicity <sep> 5-year survival and 5-year event-free survival estimates <sep> delayed hematologic recovery <sep> major nonhematologic toxic effects were mucositis nutritional impairment hypotension and peripheral neuropathy <sep> reversible grade 4 myelosuppression <sep>', 'time to disease progression <sep> disease recurrence or progression <sep> recurrences or deaths <sep>', 'median time to progression and median overall survival time <sep> prolonged infection <sep> leukopenia <sep> partial response and partial response <sep>', 'complete remission <sep>', 'progression-free survival <sep> disease-free survival <sep> hematopoietic recovery time <sep> rate of relapse in site of distant organs <sep> frequency of relapse <sep> food intolerance <sep>', 'platelet transfusion independence <sep> pbsc <sep> peripheral blood stem cells pbsc <sep> median number of granulocyte-macrophage colony forming units in the reinfused pbsc <sep> toxic death <sep> neutrophil recovery <sep>', 'toxicity <sep> progressive disease <sep> hematopoietic toxicity <sep> 2-year event free survival efs rate <sep> 2-year efs rate <sep> cr rate <sep> mean di <sep> complete response cr <sep>', 'probability of disease-free survival <sep> mortality trm <sep> interval between hdct1 and hdct2 <sep> hematologic recovery <sep> hematologic recovery in hdct2 <sep> rate of trm <sep>'], 'punchline_text': ['pharmacokinetic evaluation of melphalan in 20 patients revealed a dose-related increase in maximum plasma concentration cmax and area under the curve auc). <sep>', 'relapse-free intervals until the 1st 2nd and 3rd relapses were 40 19 and 22 months respectively. <sep>', 'further dose escalation was precluded by the development of multiple organ toxicity including venoocclusive disease refractory thrombocytopenia and hypertension. <sep>', 'the ews-wt1 transcript was detected in six of seven tumors tested. <sep>', 'overall survival os was 63 95 ci 47-79 at 1 year and 33 95 ci 16-50 at 3 years. <sep>', 'we report a very rapid engraftment after reinfusion of bone marrow cells derived from g-csf-primed bone marrow in a small child. <sep>', 'complications related to the treatment were limited to one patient who developed hepatic veno-occlusive disease no serious complications were seen in the other patients. <sep>', 'five patients received local radiotherapy three were not assessable for response but in two patients antitumor effect was evident. <sep>', 'cytogenetic study showed translocation 9;22)(q34;q11). <sep>', 'a response exceeding 50 was observed in 6/18 patients response rate 33%). <sep>', 'no treatment-related mortality occurred and grade 3 or 4 toxicity was clinically tolerable. <sep>', 'median time to wbc recovery greater than or equal to 1,000/microl was 13 days post-abmt range nine to 22 days and to a platelet count of greater than or equal to 50,000/microl 22 days range 13 to 83 days). <sep>', 'eighteen of 49 patients survive event-free 22 to 55 months median 33 after transplantation including nine of 16 treated before recurrence and nine of 33 treated after recurrence. <sep>', 'however ttp and survival rates remained poor. <sep>', ""the total 5-year survival rate of patients with ewing's sarcoma is 65.6 the total 2-year survival rate of patients with soft tissue sarcomas is 62.2 and the total 2-year survival rate of children with osteosarcoma is 76%. <sep>"", 'haematological and gastrointestinal toxicities were severe. <sep>', 'median os was 23.7 months range 12-34 vs 10.8 months range 0-39 respectively. <sep>', 'topotecan appears to be relatively unaffected by the most common multidrug resistance mechanisms may potentiate cytotoxicity of alkylators has good penetration into the central nervous system is active against a variety of neoplasms and has myelosuppression as its paramount toxicity. <sep>', 'in these five cases a partial response was observed in two of the three who had measurable response parameters but all of them died because of disease progression in a short period of time. <sep>', 'radical surgical excision radiotherapy and peripheral blood stem cell transplantation does not seem to improve prognosis significantly. <sep>', 'metastatic seeding to the omentum was most common followed by spread of disease to liver distant lymph nodes lung and occasionally to scrotum or to ovary. <sep>', 'the disease-free survival of children with malignant disorders has increased impressively over the last three decades due to better understanding of tumour biology and the resultant improvement in diagnosis and therapy. <sep>', 'at a median follow-up of 100.6 months after asct 11 patients are alive with nine in sustained complete remission cr and each one in partial remission pr and stable disease. <sep>', 'two years after primary diagnosis metastases were found in the lung trunk gluteus region upper extremities and brain. <sep>', 'no side effects were observed. <sep>', 'reversible grade 4 myelosuppression was the most common toxicity. <sep>', 'there were no recurrences or deaths beyond 10 months after diagnosis. <sep>', 'c-reactive protein in neutropenic pts as an indicator for infection after tecc chemotherapy was detectable after 36 of 39 chemotherapy courses leading to further supportive therapy median 10.4 mg/dl range 1.1-28.3 mg/dl sd 6.67 mg/dl). <sep>', 'the child remains in complete remission at 36 months after completion of treatment. <sep>', 'the progression-free survival was similar in three types of transplants 57 abmt 43 pbsct vs. 50 abmt  pbsct). <sep>', 'in some patients pbsc failed to influence engraftment and the use of combined chemotherapy and growth factor priming for pbsc collection may give improved results. <sep>', 'to increase the dose intensity di of chemotherapy for pediatric patients with metastatic sarcomas including the ewing sarcoma family of tumors esft and rhabdomyosarcoma rms the authors tested the feasibility of an intensive regimen supported by granulocyte-colony stimulating factor g-csf and peripheral blood stem cells pbsc). <sep>', 'the probability of disease-free survival at 2 years after hdct2 in the shg and dhg were 66.7 and 25.0 respectively p-value=0.031). <sep>'], 'population': ['23 patients <sep> 20 patients <sep>', 'two patients with recurrent sts who were treated with tandem hdc supported by autologous peripheral blood stem cell transplantation pbsct <sep> recurrent soft tissue sarcoma <sep> patients with recurrent soft tissue sarcoma sts <sep>', 'twenty-nine patients were treated with 31 courses of high-dose combination <sep>', 'nine 82 patients had metastatic disease <sep> 2006 <sep> cohort included 1 female and 10 male patients <sep> 11 pediatric patients with dsrct at our institution <sep> patients with localized extra-abdominal disease <sep> median age at diagnosis was 14 years range 5-21 years <sep>', ""patients with a diagnosis of ewing's sarcoma es or desmoplastic small round cell tumor dsrct <sep> patients with metastatic or relapsed es and dsrct <sep> high-risk ewing's sarcoma and other pediatric solid tumors <sep> transplanted 36 patients on two consecutive protocols with a variety of histological diagnoses <sep>"", 'child with disseminated fibrosarcoma <sep>', ""10 patients with refractory bone and soft tissue sarcoma 2 patients with primitive neuroectodermal tumor 4 patients with ewing's sarcoma 3 patients with synovial sarcoma and one patient with osteosarcoma <sep>"", 'n  8 ascites or pleural effusion n  7 and metastases to liver n  5 lungs n  4 distant lymph nodes n  3 spleen n  2 and skeleton n  2 <sep>', 'chronic myelocytic leukemia after chemotherapy for malignant fibrous histiocytoma <sep> at the age of 28 a 33-year-old male was diagnosed with malignant fibrous histiocytoma mfh with a primary lesion in the right maxillary sinus <sep> chronic myelocytic leukemia cml <sep>', 'pediatric malignant mesenchymal tumors <sep> between 1986 and 1998 18 patients previously treated with conventional therapy for metastatic or refractory mmt entered the study <sep>', ""patients with high-risk or metastatic/recurrent sarcoma with some patients achieving long-term pfs and os <sep> such patients <sep> thirteen patients were enrolled onto this study <sep> patients with locally advanced or metastatic sarcoma <sep> patients with locally advanced or metastatic/recurrent soft tissue and ewing's sarcoma ews <sep>"", 'responders included eight of nine evaluable patients with breast carcinoma two of five with melanoma two of two with sarcoma and four of four with colon carcinoma <sep> twenty-six adults ages 27 to 60 with refractory metastatic solid tumors <sep>', 'nineteen patients had medulloblastomas 12 had glial tumors <sep> 49 patients with recurrent or poor-prognosis cns malignancies with high-dose chemotherapy regimens followed by <sep> certain patients with high-risk cns malignancies <sep> patients with recurrent and high-risk pediatric brain tumors <sep>', 'copyright 2004 american cancer society <sep> patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis <sep> ten patients had pelvic osteosarcomas os 6 had malignant fibrous histiocytomas 5 had metastatic os and 16 had miscellaneous histologies <sep> between december 1994 and january 2001 37 patients 20 males and 17 females with a median age of 38 years range 18-63 years entered the study <sep> adult patients with osteosarcomas and variants with a poor prognosis <sep>', 'children with malignant tumors of the musculoskeletal system <sep>', 'thirty children <sep> patients with good renal function <sep> patients with high-risk tumours <sep> children with advanced stage or chemoresistant solid tumours <sep> children with solid tumours <sep>', 'patients with metastatic soft tissue sarcomas <sep> patients with metastatic soft tissue sarcoma <sep> enrolled 34 soft tissue sarcoma patients with advanced and/or metastatic disease <sep>', 'children and young adults <sep> 11 patients with neuroblastoma <sep>', 'nine patients with high grade metastatic sarcomas <sep> patients with metastatic sarcomas <sep> high-grade metastatic sarcomas <sep>', 'five children with diffuse idsrct managed with aggressive chemotherapy surgery radiotherapy and peripheral blood stem cell transplantation <sep> during the last decade five patients four males and one female mean age 9.6 years with diffuse idsrct were managed in our department <sep> male adolescents and young adults <sep> three patients with inoperable tumor on admission were submitted initially to <sep>', 'three adolescent boys with dsct <sep> the median age was 21 years range 6-38 years with 78 male patients and 23 female patients <sep> children and young adults <sep> three patients with dsct and reviewed the clinical experience with this newly described tumor as reported in the literature <sep>', ""children with advanced solid tumors <sep> children with malignant disorders <sep> children with advanced and relapsed solid tumours such as brain tumour alveolar rhabdomyosarcoma ewing's sarcoma or neuroblastoma <sep> 11 children aged between 2.8 and 17.2 years with brain tumours soft tissue sarcomas germ-cell tumours and neuroblastomas were analysed over a 2-year-period <sep>"", '35 consecutive adult patients with poor-risk es or rhabdomyosarcoma n  11 and sts n  24 <sep> adult patients with high-risk or advanced ewing and soft tissue sarcoma <sep>', '33-year-old woman <sep>', 'synovial sarcoma in an 11-year-old japanese girl relapsed 5 months after autologous stem cell transplantation <sep> synovial sarcoma <sep>', 'prospective high-risk sarcoma hirisa <sep> high-risk sarcomas <sep> eleven of 24 patients median age 14.9 years had <sep> pediatric patients with high-risk sarcomas <sep> patients with high-risk pediatric sarcomas <sep> 2006 american cancer society <sep> patients who responded to the protocols were eligible for myeloablative consolidation with autologous stem cell support <sep> ewing sarcoma family of tumors 9 patients had rhabdomyosarcoma and 4 patients had unresectable desmoplastic small round cell tumors <sep>', 'patients with advanced disease stage <sep> five patients had renal primary tumors and 9 patients had extrarenal tumors <sep> consecutive patients with mrt at childrens hospital los angeles over the 20 years from 1983 to 2003 <sep> fourteen children were diagnosed with mrt over the 20-year study period <sep> children with mrt <sep> extracranial malignant rhabdoid tumors in childhood <sep> eleven of 14 patients had stage iii or iv disease at diagnosis <sep> patients with localized disease and complete surgical resection <sep>', 'nine patients pts with soft tissue sarcoma refractory to conventional therapy incomplete response or relapse intensified <sep> patients with high risk soft tissue sarcoma sts <sep>', 'synovial sarcoma of the neck in a child <sep> 10-year-old boy with syt-ssx1 positive left parapharyngeal ss resistant to front-line vaia chemotherapy who obtained a good partial response by <sep>', 'sixteen consecutive stem cell transplantations sct <sep> patients with high-risk solid tumors of childhood <sep>', '11 patients aged 7-17 years <sep>', 'copyright 2002 american cancer society <sep> children and adolescents with metastatic sarcomas <sep> pediatric patients with metastatic sarcomas including the ewing sarcoma family of tumors esft and rhabdomyosarcoma rms <sep> twenty-three children and adolescents with metastatic sarcomas <sep> pediatric patients with metastatic sarcomas <sep>', 'patients who had received prior chemotherapy before hdct1 <sep> patients with high-risk pediatric solid tumors <sep>'], 'interventions': ['cyclophosphamide cisplatin and melphalan with autologous bone marrow support <sep> melphalan <sep> cyclophosphamide cisplatin and melphalan <sep>', 'ifosfamide and epirubicin <sep> high-dose chemotherapy hdc <sep> autologous peripheral blood stem cell transplantation <sep> ice regimen <sep> ifosfamide 3 g/m2 on days-7 to 3 carboplatin 400 mg/m2 on days-7 5 and 3 etoposide <sep>', 'cyclophosphamide cisplatin and carmustine bcnu with and without melphalan with autologous bone marrow support <sep> melphalan <sep> cyclophosphamide cisplatin and bcnu <sep> high-dose combination alkylating agents with autologous bone marrow support <sep>', 'dsrct <sep> chemotherapy <sep> surgical resection seven received primary site radiation and four received myeloablative chemotherapy with stem-cell support <sep> copyright c <sep>', 'autologous stem cell transplantation <sep> asct <sep> autologous stem cell transplantation asct <sep>', 'autologous transplantation of g-csf mobilized bone marrow cells <sep>', 'busulfan 4 mg/kg x 4 melphalan 140 mg/m2 and thiotepa 200 mg/m2 x 3 were used in the high-dose chemotherapy <sep> autologous peripheral blood stem cell transplantation pbsct <sep> high-dose chemotherapy with autologous peripheral blood stem cell transplantation <sep>', 'cyclophosphamide <sep> carboplatin <sep> etoposide <sep> ifosfamide 12 g/m2 and etoposide <sep> intensive alkylator-based therapy <sep> local radiotherapy <sep> thiotepa/carboplatin <sep> doxorubicin 75 mg/m2 and vincristine hd-cav <sep> ifosfamide 9 <sep>', 'mfh <sep> arterial infusion chemotherapy pirarubicin hydrochloride and carboplatin <sep> autologous peripheral blood stem cell transplantation with high-dose chemotherapy combination of ifosphamide carboplatin and etoposide <sep>', 'high-dose thiotepa and hematopoietic stem cell transplantation <sep> hematopoietic stem cell rescue consisting of bone marrow transplantation or peripheral stem cell transplantation <sep> hdt <sep>', 'ifosfamide <sep> tandem high-dose chemotherapy <sep> mesna <sep> doxorubicin <sep> tandem high-dose chemotherapy hdct <sep> cisplatin <sep> tandem hdct <sep> melphalan <sep> autologous stem cell transplantation asct <sep>', 'autologous bone marrow transplantation abmt <sep> high-dose cyclophosphamide cy  carmustine bcnu <sep>', 'carboplatin <sep> busulfan 37.5 mg/m2 every 6 hours x 16 and melphalan <sep> high-dose chemotherapy with autologous stem-cell rescue <sep> chemotherapy with cyclophosphamide <sep> autologous marrow rescue with or without peripheral-blood stem-cell augmentation <sep> melphalan <sep> standard supportive care <sep>', 'cisplatin doxorubicin and ifosfamide with peripheral blood stem cell support <sep> ifosfamide <sep> ifosfamide 10 g/m(2 followed by granulocyte-colony-stimulating factor g-csf <sep> doxorubicin <sep> cisplatin <sep> cisplatin ifosfamide and doxorubicin with peripheral blood stem cell pbsc <sep>', 'chemotherapy <sep>', 'autologous stem cell rescue <sep> carboplatin <sep> high-dose carboplatin <sep> melphalan 180 mg/m2 and carboplatin followed by autologous stem cell rescue <sep> melphalan followed by autologous stem cell rescue <sep> carboplatin and melphalan <sep> melphalan combined with a carboplatin <sep>', 'chemotherapy <sep> consolidation with high-dose chemotherapy and stem cell support <sep> high-dose chemotherapy <sep> doxorubicin and ifosfamide <sep> standard chemotherapy <sep>', 'topotecan <sep> topotecan combined with myeloablative doses of thiotepa and carboplatin <sep> radiotherapy alone four patients or plus biological agents <sep> topotecan <sep>', 'high dose chemotherapy hdc <sep> chemotherapy ct <sep> hdc <sep> hdc followed by autologous bone marrow transplantation <sep> high-dose chemotherapy and autologous bone marrow transplantation <sep>', 'radical surgical excision radiotherapy and peripheral blood stem cell transplantation <sep> radiotherapy <sep> open biopsy followed by aggressive chemotherapy <sep> peripheral blood stem cell transplantation <sep> multiagent chemotherapy <sep>', 'dsct <sep> doxorubicin <sep> vincristine 2 mg/m2 doxorubicin 75 mg/m2 cyclophosphamide 1.8 g/m2 alternating with 5-day cycles of etoposide 100 mg/m2/day ifosfamide <sep> doxorubicin cisplatin cyclophosphamide etoposide and/or 5-fluorouracil <sep> 5-fluorouracil <sep> additional radiotherapy <sep>', 'single or double hdt with autologous pbsct <sep> morphine therapy <sep> double hdt by autologous peripheral blood stem cell transplantation pbsct <sep> total parenteral nutrition <sep> single and double high-dose chemotherapy with autologous stem cell transplantation <sep> myeloablative high-dose chemotherapy hdt <sep>', 'high-dose chemotherapy hdct with autologous peripheral blood stem cell transplantation asct <sep> high-dose chemotherapy and autologous peripheral blood stem cell transplantation <sep> hdct <sep>', 'radiotherapy and conventional chemotherapy <sep> autologous peripheral blood stem-cell transplantation and radiotherapy <sep>', 'immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides <sep> autologous dendritic cells dcs <sep>', 'vincristine doxorubicin cyclophosphamide ifosfamide and etoposide <sep> vincristine doxorubicin cyclophosphamide ifosfamide and etoposide <sep> intensive vincristine ifosfamide etoposide cyclophosphamide and doxorubicin vacie <sep> intensive chemotherapy <sep> intensified chemotherapy <sep> vincristine cyclophosphamide and doxorubicin week 9 and vincristine and ifosfamide <sep>', 'multimodal therapy including both chemotherapy and surgery with or without radiation <sep> hsct <sep> high-dose chemotherapy with hematopoietic stem cell rescue hsct <sep>', 'tecc chemotherapy <sep> chemotherapy <sep> autologous hematopoietic stem cell support <sep> granulocyte colony stimulating factor gcsf <sep> topotecan 100 mg/m 2 etoposide 100 mg/m 2 carboplatin and 200 mg/m 2 cyclophosphamide <sep> serial intense chemotherapy combining topotecan etoposide carboplatin and cyclophosphamide tecc <sep>', 'salvage regimen i(3)ve  cev  i(3)ve and local radiotherapy <sep>', 'pbsct <sep> myeloablative chemotherapy and autologous stem cell transplantation <sep> myeloablative chemotherapy <sep> autologous bone marrow transplantation abmt seven received peripheral blood stem cell transplantation pbsct and two received abmt  pbsct <sep>', 'melphalan <sep> autologous bone marrow transplantation abmt <sep> busulphan 16 mg/kg orally with melphalan <sep> autologous bone marrow transplantation <sep>', 'g-csf <sep> vincristine doxorubicin cyclophosphamide ifosfamide sodium mercaptoethanesulfonate mensa and etoposide vacime chemotherapy consisting of 8 courses of vincristine 2 mg/m(2 on day 0 doxorubicin 37.5 mg/m(2 per day on days 0-1 cyclophosphamide 360 mg/m(2 per day on days 0-4 ifosfamide 1800 <sep> surgical resection followed course 6 and radiotherapy <sep> etoposide <sep> doxorubicin <sep> pbsc-supported multicycle chemotherapy <sep>', 'successive double high-dose chemotherapy with peripheral blood stem cell rescue collected <sep> chemotherapies hdct <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",due to a lack of comparative studies it is unclear whether participants with nrsts have improved survival from autologous hsct following hdct. owing to this current gap in knowledge at present hdct and autologous hsct for nrsts should only be used within controlled trials.
239,"{'outcomes': ['frequency of extra-neurological infections and of asymptomatic pulmonary bacterial colonization <sep> meningitis <sep> frequency of asymptomatic bacteriuria <sep>', 'incidence of meningitis <sep> overall incidence of infectious complications <sep>', ""rates of meningitis <sep> overall rate of meningitis <sep> patient's glasgow coma scale score sex and age as well as for an intradural location of air air volume presence of cerebrospinal fluid csf rhinorrhea or csf otorrhea radiological sign of a skull base fracture or intracranial hemorrhage <sep>"", 'basilar skull fractures <sep>'], 'punchline_text': ['the frequency of extra-neurological infections and of asymptomatic pulmonary bacterial colonization was similar in both groups but frequency of asymptomatic bacteriuria was higher in the placebo-treated patients. <sep>', 'there was no significant difference between the ceftriaxone group and the ampicillin/sulphadiazine group. <sep>', 'the results of this study do not substantiate the efficacy of ceftriaxone used in the prevention of meningitis in patients with traumatic pneumocephalus after mild head injury or in any specific subgroup of these patients. <sep>', 'the efficacy of chemoprophylaxis in the treatment of basilar skull fractures was studied in 129 patients over a 2-year period antibiotics were found ineffective in preventing central nervous system infections and in some cases may have proved harmful. <sep>'], 'population': ['patients with injury to the head and face which had caused rhinorrhea or otorrhea <sep> 52 patients was studied 26 in each treatment group <sep> patients with rhinorrhea or otorrhea <sep>', 'group a  46 patients or <sep> open and basilar fractures of the skull <sep> 157 patients <sep>', 'patients with traumatic pneumocephalus after mild head injury or in any specific subgroup of these patients <sep> 109 patients <sep> 109 patients with mild head injury and traumatic pneumocephalus <sep> patients with acute traumatic pneumocephalus <sep> meningitis after traumatic pneumocephalus <sep>', '129 patients over a 2-year period antibiotics <sep>'], 'interventions': ['placebo <sep> penicillin <sep> antimicrobial prophylaxis <sep>', 'combination ampicillin/sulphadiazine <sep> antibiotic prophylaxis <sep> ceftriaxone <sep> ampicillin/sulphadiazine <sep> prophylactic antibiotics <sep> no antibiotics <sep>', 'antibiotic medication ceftriaxone <sep> ceftriaxone <sep> prophylactic antibiotics therapy <sep>', 'chemoprophylaxis <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",currently available evidence from rcts does not support prophylactic antibiotic use in patients with bsf whether there is evidence of csf leakage or not. until more research is completed the effectiveness of antibiotics in patients with bsf cannot be determined because studies published to date are flawed by biases. large appropriately designed rcts are needed.
240,"{'outcomes': ['infection rate at sbd key sites abdomen bloodstream surgical wound and lungs <sep> stool colonization <sep> overall rates of bacterial and/or yeast infections <sep> gastrointestinal intolerance and noncompliance <sep>', 'sepsis episodes sepsis-related deaths and rejection <sep> white blood cell count <sep> biopsy-proven rejection and nosocomial pneumonias <sep> nosocomial pneumonias <sep> microbiologically-documented infection biopsy-proven rejection number of treatments for rejection length of stay in the intensive care unit and hospital graft survival death and adverse events <sep> serious adverse events <sep> biopsy-proven rejection <sep> incidence of infection <sep> median peak white blood cell count <sep> infection rejection or survival <sep> length of stay <sep> graft loss <sep> infection and rejection <sep>', 'mean number of postoperative infectious episodes <sep> mean number of postoperative bacterial and fungal infections <sep> postoperative infection <sep> total costs <sep>', 'death <sep> aerobic gram-positive flora anaerobes and yeast <sep> rates of infection death and charges for medical care <sep> charges for medical care <sep> rates of infection <sep>', 'portal and systemic endotoxemia colonization and infection rates severity of illness organ system failures acute physiology and chronic health evaluation ii score therapeutic intervention scoring system score antibiotic costs and hospital survival rates <sep> pulmonary infections and enteric aerobic and gram-negative bacillary colonization <sep> survival rates <sep>', 'bacterial infection rates <sep> thirty-day infection rate length of hospital stay duration of antibiotic therapy non-infectious complications and side effects of enteral nutrition <sep> severe infections <sep> tolerated <sep> incidence of post-operative bacterial infections <sep> duration of antibiotic therapy <sep> infection rate <sep>'], 'punchline_text': ['overall rates of bacterial and/or yeast infections were nearly equal among control patients 42 and sbd patients 39%). <sep>', 'biopsy-proven rejection and nosocomial pneumonias were more common in patients treated with g-csf compared with those taking the placebo. <sep>', 'infections involving gram-negative aerobic bacteria and candida species were significantly less frequent in patients receiving sdd p .001 and p .05). <sep>', 'rates of infection 32.4 vs. 27.9 death 5.4 vs. 4.7 or charges for medical care median 194,000 vs. 163,000 were not reduced in patients assigned to sbd. <sep>', 'the financial costs of the selective decontamination regimen outweighed the advantages gained from an associated reduction in antibiotic usage. <sep>', 'the incidence of post-operative bacterial infections was significantly reduced being 48 with only fibers and 3 with lab and fibers. <sep>'], 'population': ['patients awaiting cadaver liver transplants <sep> liver transplant patients <sep> 69 patients randomly assigned to receive <sep> liver transplantation <sep>', 'liver transplant patients <sep> liver transplant recipients <sep> adult patients with a united network organ sharing classification of 1 or 2 <sep>', 'adult patients undergoing elective liver transplantation 26 patients receiving sdd and 29 patients receiving a <sep> liver transplant patients <sep> patients undergoing elective transplantation of the liver <sep> patients undergoing elective liver transplantation <sep> patients undergoing sdd <sep>', 'patients undergoing liver transplantation <sep> 43 patients <sep> liver transplantation <sep> eighty candidates for liver transplantation <sep>', 'fifty-nine adult patients were recruited into the study and underwent liver transplantation <sep> thirty-two patients were randomized to standard treatment control group and 27 patients <sep> patients undergoing elective orthotopic liver transplantation <sep> critically ill patients <sep> patients undergoing elective liver transplantation <sep>', 'liver transplantation <sep> bacterial infections frequently occur early after liver transplantation <sep> 66 liver transplant recipients <sep>'], 'interventions': ['selective bowel decontamination <sep> nonabsorbable antibiotics <sep> conventional prophylaxis with systemic antibiotics control patients or conventional prophylaxis plus oral nonabsorbable antibiotics <sep>', 'g-csf <sep> placebo <sep> placebo 100 microg/day of g-csf or 300 microg/day of g-csf <sep> granulocyte colony-stimulating factor g-csf <sep> granulocyte colony-stimulating factor <sep>', 'placebo <sep> norfloxacin <sep> colistin 1.8 mg of tobramycin <sep> selective decontamination of the digestive tract sdd <sep> placebo drugs <sep> amphotericin b <sep>', 'selective bowel decontamination sbd <sep> nystatin alone <sep> gentamicin 80 mg+polymyxin <sep>', 'selective decontamination <sep> selective antibiotic decontamination <sep> selective decontamination or standard antibiotic prophylaxis <sep>', 'pre and probiotics <sep> enteral nutrition immediately post-operatively <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>']}",currently there is no clear evidence for any intervention offering significant benefits in the reduction of bacterial infections and wound complications in liver transplantation. selective bowel decontamination increases the risk of infection and hospital stay compared to prebiotics and probiotics. the use of prebiotics and probiotics offers promise. further randomised clinical trials are necessary.
241,"{'outcomes': ['lumbar spine degeneration <sep>', 'contusion or abrasion <sep> abnormal physical examination <sep> tenderness <sep> multiple positive findings <sep>'], 'punchline_text': ['the overall prevalence of fracture possible infection possible tumour was low in our study population 4 0.8 and 0.7 respectively. <sep>', 'four clinical findings were present in significantly different frequencies between the positive group and others an abnormal physical examination 90 vs 61.5 respectively p less than .0001 tenderness 72.5 vs 41.2 p less than .0005 multiple positive findings 42.5 vs 20.7 p less than .005 and contusion or abrasion 15 vs 2.7 p less than .0005). <sep>'], 'population': ['low back pain <sep> patients older than 55 years of age <sep> older patients <sep> 2007 radiographic reports of patients referred with low back pain for lumbar spine radiography to a large radiology department was performed <sep> patients referred with low back pain by general practitioners <sep>', '552 consecutive emergency department patients for whom lumbar spine x-rays were ordered <sep>'], 'interventions': ['lumbar spine radiography <sep>', 'lumbar spine x-ray series <sep> lumbar spine x-rays <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>']}",the available evidence does not support the use of many red flags to specifically screen for vertebral fracture in patients presenting for lbp. based on evidence from single studies few individual red flags appear informative as most have poor diagnostic accuracy as indicated by imprecise estimates of likelihood ratios. when combinations of red flags were used the performance appeared to improve. from the limited evidence the findings give rise to a weak recommendation that a combination of a small subset of red flags may be useful to screen for vertebral fracture. it should also be noted that many red flags have high false positive rates and if acted upon uncritically there would be consequences for the cost of management and outcomes of patients with lbp. further research should focus on appropriate sets of red flags and adequate reporting of both index and reference tests.
242,"{'outcomes': ['cd4 cell count <sep> m. avium complex infection <sep> adverse events <sep> rna levels <sep> cd4 <sep> cell count <sep> plasma hiv-1 <sep> rate of m. avium complex infection <sep>', 'episodes of confirmed m. avium complex disease <sep> m. avium complex disease or bacterial pneumonia <sep> median cd4 cell count <sep> hiv rna value <sep> rate of progression of hiv disease nor the mortality rate <sep> bacterial pneumonia <sep> median prior nadir cd4 cell count <sep> adverse effects <sep>', 'ranges of minimal inhibitory concentrations <sep> episodes of non-mac bacterial infection <sep> time to death or number of deaths <sep> mac infection followed by death <sep> mac infection <sep>', 'frequency of more severe adverse events <sep> m. avium complex infection <sep> rectal disorders <sep> incidence of taste perversion <sep> mortality <sep> efficacy and safety <sep>', 'mac disease <sep> adverse effects <sep> survival differences <sep> risk of mac disease <sep> efficacy and safety <sep>', 'm. avium complex bacteremia <sep> delayed fatigue fever decline in the karnofsky performance score <sep> elevation in alkaline phosphatase and hospitalization <sep> signs and symptoms associated with disseminated m. avium complex infection adverse events hospitalization and survival <sep> adverse events <sep> substantial morbidity and reduces survival <sep> overall survival <sep> bacteremia <sep> frequency of disseminated m. avium complex infection <sep> hemoglobin level <sep>', 'disseminated mac infection <sep> cd4 lymphocyte count <sep> safety and efficacy <sep>'], 'punchline_text': ['plasma hiv-1 <sep>', 'during follow-up over a median period of 12 months there were no episodes of confirmed m. avium complex disease in either group 95 percent confidence interval for the rate of disease in each group 0 to 1.5 episodes per 100 person-years). <sep>', 'for deaths due to all causes there was no difference in time to death or number of deaths between the two groups. <sep>', 'm. avium complex infection developed in 19 of the 333 patients 6 percent assigned to clarithromycin and in 53 of the 334 16 percent assigned to placebo adjusted hazard ratio 0.31 95 percent confidence interval 0.18 to 0.53 p<0.001). <sep>', 'combination therapy was not more effective than clarithromycin rr 0.79 95 ci 0.48-1.31 p=.36). <sep>', 'the distribution of minimal inhibitory concentrations of rifabutin among the isolates of m. avium complex did not differ significantly between the treatment groups. <sep>', 'reduction in cd4 lymphocyte count to  50/mm3 is a significant predictor of the development of disseminated mac infection. <sep>'], 'population': ['patients with antiretroviral therapy <sep> 643 hiv-1-infected patients with a previous cd4 cell count less than 0.05 x 10(9 cells/l and a sustained increase to greater than 0.10 <sep> adults with hiv infection who experience increases in cd4 <sep> patients with increased cd4 <sep> 29 university-based clinical centers in the united states <sep>', 'hiv-infected patients whose cd4 cell counts had increased from less than 50 to more than 100 per cubic millimeter in response to antiretroviral therapy <sep> 19 patients assigned to receive <sep> patients with advanced human immunodeficiency virus hiv infection <sep> hiv-infected patients who have a response to antiretroviral therapy <sep> 520 patients entered the study the <sep>', 'patients with aids <sep> patients with aids and a cd4 cell count of  100/mm3 <sep>', 'patients with advanced acquired immunodeficiency syndrome <sep> patients with advanced aids <sep> patients with advanced stages of the acquired immunodeficiency syndrome aids <sep> patients with aids in the united states and europe <sep>', '1178 patients with aids who had  or 100 cd4 t cells/microl <sep> patients with aids <sep>', 'patients with aids and cd4 counts  or  200 per cubic millimeter <sep> patients with the acquired immunodeficiency syndrome aids <sep>', 'subjects were 110 patients with a first episode of pneumocystis carinii pneumonia 2-4 months before enrollment or cd4 lymphocyte counts  or  100/mm3 <sep> patients with human immunodeficiency virus hiv disease <sep> seventeen patients died 9 in the treatment group and 8 receiving no treatment <sep> patients with hiv disease <sep>'], 'interventions': ['matching placebo <sep> mycobacterium avium complex prophylaxis <sep> placebo <sep> azithromycin <sep> azithromycin <sep>', 'azithromycin <sep> placebo <sep> azithromycin prophylaxis <sep>', 'placebo <sep> azithromycin therapy <sep> azithromycin <sep> azithromycin <sep> clarithromycin <sep>', 'clarithromycin <sep> placebo <sep>', 'clarithromycin or rifabutin <sep> clarithromycin and rifabutin alone <sep> placebo <sep> clarithromycin or rifabutin alone <sep> clarithromycin <sep> clarithromycin <sep> rifabutin <sep>', 'rifabutin and placebo <sep> placebo <sep> rifabutin <sep> rifabutin <sep> rifabutin prophylaxis <sep>', 'clofazimine <sep> clofazimine daily or no treatment <sep> clofazimine <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",based on limited data azithromycin or clarithromycin appeared to be a prophylactic agent of choice for mac infection. further studies are needed especially direct comparison of clarithromycin and azithromycin. in additions studies that will compare different doses and regimens are needed.
243,"{'outcomes': ['peak flow <sep> calf blood flow and vascular resistance <sep> calf blood flow <sep> vascular resistance <sep> hyperaemic flow <sep> heart rate blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance <sep>', 'lying and standing blood pressures <sep> lying diastolic pressure <sep>', 'tolerated and the side-effects <sep> rate of normalization <sep> normotension diastolic blood pressure dbp <sep> cardiovascular and gastrointestinal complaints headaches and sleep and sexual disorders <sep> efficacy and adverse reactions <sep> safety and efficacy <sep>', 'blood pressure and peripheral resistance <sep> blood pressure arterial blood flow and peripheral resistance <sep> blood pressure and in peripheral resistance <sep> blood pressure <sep> arterial blood flow <sep> peripheral blood flow <sep> peripheral arterial circulation <sep>', 'adverse effects <sep> drug fever <sep> mean supine blood pressure <sep> lowering supine and standing systolic and diastolic blood pressure <sep> supine and standing blood pressure and heart rate <sep>', 'systolic diastolic and mean arterial blood pressures <sep> blood pressures <sep> blood pressure <sep> antihypertensive efficacy <sep> adverse effects <sep>', 'blood pressure impaired card-sorting time and digital symbol substitution score <sep> psychometric performance <sep>'], 'punchline_text': ['the peak flow was reduced by 20 p greater than 0.01 with metoprolol and by 15 with methyldopa below the initial level and by 17 and by 12 below the level recorded on placebo respectively. <sep>', 'thic combination had similar effects to those of the combination of methyldopa with the cardioselective agent practolol except that it reduced lying diastolic pressure further. <sep>', 'the most common adverse reactions reported were cardiovascular and gastrointestinal complaints headaches and sleep and sexual disorders mostly by patients taking methyldopa. <sep>', 'no acute effect was observed on the placebo or on indapamide the latter induced a decrease in blood pressure and in peripheral resistance along with an increase in arterial blood flow during long-term treatment after four weeks of therapy. <sep>', 'the mean supine blood pressure was not significantly affected by placebo. <sep>', 'there were no significant differences in blood pressures as measured with the patients lying down however with the patients standing the systolic diastolic and mean arterial blood pressures were significantly lower p  0.05 after treatment with alpha-methyldopa or the combination product. <sep>', 'methyldopa 250 mg tid for 14 days significantly reduced blood pressure impaired card-sorting time and digital symbol substitution score and caused trends for impairment of other psychometric tests. <sep>'], 'population': ['intermittent claudication <sep> 14 hypertensive patients with intermittent claudication <sep>', '24 carefully selected patients with moderate hypertension mean initial lying blood pressure 189/117 mm hg <sep> moderate hypertension <sep>', '368 men aged 40 to 65 years with mild-to-moderate essential hypertension <sep> hypertension <sep>', 'twenty-four patients with arterial hypertension without target organ damage <sep> hypertensive patients with concomitant lesions <sep>', 'eighteen patients with hypertension <sep> hypertension <sep>', 'twenty-two white men and two white women with uncomplicated essential hypertension <sep>', '16 patients with mild to moderate hypertension <sep>'], 'interventions': ['metoprolol and methyldopa <sep> placebo <sep> methyldopa <sep> metoprolol <sep>', 'methyldopa <sep> methyldopa combined with propranolol <sep> methyldopa combined with a a non-selective and b a selective beta-adrenoceptor antagonist <sep> methyldopa and propranolol or practolol <sep> methyldopa 750 mg/day propranolol 240 mg/day practolol 600 mg/day methyldopa 750 mg/day combined with propranolol 240 mg/day methyldopa 750 mg/day combined with practolol 600 mg/day and placebo <sep> propranolol practolol <sep>', 'isradipine <sep> placebo <sep> methyldopa <sep> isradipine and methyldopa <sep> isradipine <sep> captopril <sep> isradipine methyldopa and placebo <sep>', 'captopril methyldopa and indapamide <sep> indapamide <sep> placebo <sep> methyldopa and indapamide <sep> captopril 500 mg methyldopa or 2.5 mg indapamide <sep> captopril and methyldopa <sep>', 'placebo <sep> methyldopa <sep> trimazosin <sep> trimazosin methyldopa and placebo <sep> trimazosin <sep> trimazosin and methyldopa <sep>', 'alpha-methyldopa chlorothiazide and supres-150 alpha-methyldopa-chlorothiazide <sep> chlorothiazide <sep> placebo with alpha-methyldopa <sep>', 'methyldopa <sep> methyldopa <sep> methyldopa with placebo <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",methyldopa lowers blood pressure to varying degrees compared to placebo for patients with primary hypertension. its effect on clinical outcomes however remains uncertain.
244,"{'outcomes': ['antipsychotic effect <sep>', 'clinical response side effects striatal 11c]-raclopride-positron emission tomography pet and extrastriatal 11c]-flb 457-pet d2 receptors <sep> positive psychotic symptoms <sep> striatal and extrastriatal occupancies <sep> d2 occupancies <sep> negative symptoms <sep>'], 'punchline_text': ['the antipsychotic effect was highly significant and clinically relevant under both risperidone and clozapine. <sep>', 'striatal d2 occupancy predicted response in positive psychotic symptoms r=0.62 p=0.01 but not for negative symptoms r=0.2 p=0.5). <sep>'], 'population': ['schizophrenic patients with acute symptoms <sep> 59 patients with paranoid hallucinatory psychoses <sep>', 'fourteen patients with recent onset psychosis <sep>'], 'interventions': ['risperidone <sep> clozapine <sep> risperidone <sep>', 'olanzapine <sep> risperidone <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",there is still lack of strong evidence for an optimal dose for clinical practice. the quality of trials suggests that an over estimate of effect is likely and we think this is most probably for the mid-range doses. one such dose standard-lower dose range 4-<6 mg/day does seem optimal for clinical response and adverse effects. weak evidence suggests that low doses 2-<4 mg/day may be of value for people in their first episode of illness. high doses 10 mg/day did not confer any advantage over any other dose ranges and caused more adverse effects especially for movement disorders. ultra low dose 2 mg/day seemed useless. we advise the use of dosages from low dose to standard-lower dose for different kinds of individual patients. future trials should focus on specific populations e.g. those in their first episode with acute exacerbation in relapse or refractory to treatment and should also test the optimal dose of risperidone over a longer period of time and in the community.
245,"{'outcomes': ['viral infections <sep> incidence timing or severity of symptomatic cmv infections <sep> major non-cmv including no ebv viral infections <sep> death or graft loss <sep>', 'moderate hypogammaglobulinemia <sep> cmv infection <sep> severe hypogammaglobulinemia <sep> average episodes of  or grade 2 rejection <sep>', 'incidence of infection <sep> reactivation infections <sep> cmv reactivation infections <sep> incidence of reactivation infections <sep>', 'severity of cmv infection <sep> number of days febrile and days hospitalized secondary to cmv illness <sep>', 'survival episodes of rejection bacteremia or fungemia use of immunosuppressive agents and incidence of leukopenia or thrombocytopenia <sep> incidence of cmv disease <sep>', 'occurrence of viral infections <sep> graft loss <sep>', 'graft survival <sep> cytomegalovirus and herpes simplex virus infections <sep> cytomegalovirus viremia <sep> reversible leukopenia and thrombocytopenia <sep> incidence of viremia <sep> cytomegalovirus excretion began earlier and viremia <sep>', 'cytomegalovirus viremia <sep> acute rejection or bronchiolitis obliterans syndrome <sep> 1-year survival <sep> cytomegalovirus pneumonitis <sep> cmv viremia <sep> acute rejection and bronchiolitis obliterans syndrome and the survival rate <sep> cmv viremia or pneumonitis <sep> attack rate of cmv pneumonitis <sep> incidence of positive shell vial assays <sep>', 'mild cmv disease <sep> cmv disease <sep> severe disease <sep>', 'serum creatinine levels <sep> adverse effects <sep> incidence of cmv disease and visceral involvement <sep> mild leukopenia <sep> cmv disease <sep>', 'patient and allograft survival <sep> renal transplantation <sep> tolerated <sep> incidence of invasive cmv infection <sep> efficacy safety and cost <sep>', 'symptomatic cmv infections <sep> transplant survival or patients survival rates <sep> symptomatic herpes-simplex infections <sep>', 'toxicity <sep> onset of cmv excretion <sep> severity of the cmv infection <sep> cmv reactivation <sep> incidence of cmv excretion <sep> incidence of rejection and graft loss <sep> duration of cmv excretion <sep> site of cmv excretion <sep> number of positive cmv isolates from urine and saliva <sep>', 'cmv-related death <sep> incidence of cmv isolation viremia or disease <sep>', 'incidence of posttransplant cmv disease <sep> actuarial patient or allograft survival <sep> cmv disease <sep> patient and allograft survival <sep> cmv disease slightly later <sep>', 'marked leukopenia <sep> cytomegalovirus disease <sep> serious cmv-associated disease <sep> incidence of virologically confirmed cmv-associated syndromes <sep> rates of viral isolation or seroconversion <sep> fungal or parasitic superinfections <sep> incidence of cmv pneumonia <sep>', 'opportunistic superinfections aspergillus fumigatus and pneumocystis carinii <sep> clinical signs of cytomegalovirus infection <sep> survival <sep> cytomegalovirus-associated glomerulopathy <sep> cytomegalovirus reactivation syndromes <sep> minimal toxicity <sep>', 'cmv infection <sep>', 'incidence of cmv transmission <sep> incidence of primary cmv infection <sep> severity of primary cmv infection <sep> rejection treatment with okt3 or atg severity of cmv disease and graft loss <sep>', 'episode of viremia <sep> rate of cmv disease <sep> severity score <sep> incidence of cmv disease <sep>', 'disease onset <sep> cmv infection <sep> cmv infection and disease <sep>', 'severity or duration of fever leukopenia or hepatic enzyme elevations <sep> moderately severe cmv infections <sep>'], 'punchline_text': ['no death or graft loss was due to viral infection. <sep>', 'a significant reduction in cmv infection was noted in the cytogam group compared with the placebo group 15.4 2/13 vs 60 6/10 p  .039). <sep>', 'patients receiving polyimmune gammaglobulin along with n/r-ats had an incidence of infection of only 10%. <sep>', 'there were no significant complications related to the intravenous immunoglobulin infusions. <sep>', 'there was no difference between groups in terms of survival episodes of rejection bacteremia or fungemia use of immunosuppressive agents and incidence of leukopenia or thrombocytopenia. <sep>', 'ten patients were excluded from further analysis because of graft loss due to surgical complications side effects of rifna2c and because of lack of compliance. <sep>', 'cytomegalovirus excretion began earlier and viremia was more frequent in placebo-treated than in interferon-treated patients. <sep>', 'cytomegalovirus viremia was detected in 13 of 22 recipients without prophylaxis and in 16 of 22 recipients with cmv-igiv prophylaxis p  0.19). <sep>', 'the towne strain of attenuated cmv vaccine was compared with placebo in seronegative renal transplants who later received kidneys from seropositive donors. <sep>', 'the incidence of cmv disease and visceral involvement was much higher in the cmv immunoglobulin group than in the ganciclovir group 40 versus 6 respectively p  0.03). <sep>', 'both prophylactic regimens significantly reduced the incidence of invasive cmv infection p  .05 and were well tolerated. <sep>', 'there were also significantly fewer symptomatic herpes-simplex infections in the treatment n  6 than in the control group n  25). <sep>', 'the incidence of rejection and graft loss was not different between the two groups. <sep>', 'passive immunization completely prevented cmv-related death although it did not reduce the incidence of cmv isolation viremia or disease. <sep>', 'cmv disease occurred in fewer patients n  28 21.0 in the acv group while significantly more patients n  42 31.6 in the gcv  hig group developed group developed cmv disease slightly later 2.83  0.70 months than those who received gcv/hig 2.15  0.21 months p  0.01). <sep>', 'the incidence of virologically confirmed cmv-associated syndromes was reduced from 60 percent in controls to 21 percent in recipients of cmv immune globulin p less than 0.01). <sep>', 'opportunistic superinfections aspergillus fumigatus and pneumocystis carinii occurred only in patients given placebo. <sep>', 'serological and cellular immune responses developed in most vaccines but were lower in the transplant patients than in healthy volunteers and some of the seronegative patients failed to mount responses. <sep>', 'incidence of primary cmv infection was equal in both groups 50 and no influence on the severity of primary cmv infection was seen. <sep>', 'the incidence of cmv disease was 31 in the acv group and 20 in the acv  cmv ig group n.s.). <sep>', 'acyclovir with or without ivig did not prevent primary cmv infection or disease in d+r solid organ transplant recipients at our institution. <sep>', 'among those who developed cmv infections prophylactic igg had no effect on the severity or duration of fever leukopenia or hepatic enzyme elevations. <sep>'], 'population': ['combined pancreas-kidney transplant recipients <sep>', 'cardiac transplant recipients with moderate hypogammaglobulinemia <sep> cardiac transplant recipients with severe hypogammaglobulinemia <sep> 300 heart transplant recipients <sep> moderately hypogammaglobulinemic patients <sep> patients with moderate hypogammaglobulinemia <sep>', 'transplant patients with previous cmv exposure who will be receiving prolonged anti-t-cell therapy because of acute rejection or primary nonfunction <sep> kidney and kidney/pancreas transplantation consenting recipients with serologic evidence of previous cmv disease <sep> kidney and kidney/pancreas transplant recipients <sep>', 'high-risk renal transplant patients at risk for secondary cmv infection would benefit from prophylactic intravenous immunoglobulin infusions <sep> renal transplant recipients who are at high risk for developing cmv infection both primary and secondary <sep> renal transplant recipients <sep> renal transplant recipients who were considered at high risk for secondary cmv infection was performed <sep> thirty-four patients were studied 16 receiving the intravenous immunoglobulin infusions and 18 being untreated controls <sep>', 'children receiving liver transplants <sep> and 27 recipients of ivig alone <sep>', 'renal transplant recipients <sep> 50 renal graft recipients immunosuppressed with <sep>', 'renal-transplant recipients receiving <sep> renal transplantation <sep>', '44 cmv-seropositive lung transplant recipients <sep> cmv-seropositive lung transplant recipients <sep>', 'seronegative renal transplant recipients <sep> seronegative renal transplants who later received kidneys from seropositive donors <sep>', 'cmv-seropositive heart transplant recipients treated with okt3 <sep> 31 cmv-seropositive heart transplant recipients who had received early immunoprophylaxis with okt3 monoclonal antibodies <sep>', 'fifty-one consecutive cmv-seronegative patients who received renal allografts from seropositive donors between march 1990 and april 1992 <sep> recipients at risk for primary cmv disease <sep> 650-bed tertiary medical center hospital <sep> renal transplant recipients <sep> renal transplant recipients at risk for primary cytomegalovirus cmv disease <sep>', 'kidney transplantation <sep>', '74 renal transplant recipients <sep> renal transplant recipients <sep>', 'kidney transplant recipients treated for rejection <sep> 39 kidney transplant recipients treated for rejection with rabbit antithymocyte globulin <sep> cmv-seronegative recipients of a cmv-seropositive kidney donor <sep> seronegative recipients of seropositive allograft donors treated for rejection <sep>', '311 patients were stratified according to allograft type age and presence or absence or diabetes mellitus <sep> 266 patients acv n  133 gcv+hig n  133 <sep> cytomegalovirus infection after solid organ transplantation <sep>', 'renal-transplant recipients <sep> renal-transplant recipients at risk for primary cmv disease <sep> fifty-nine cmv-seronegative patients who received kidneys from donors who had antibodies against cmv <sep>', '42 patients before transplant surgery was performed <sep> recipients of kidney transplants <sep> renal-transplant recipients <sep> seropositive renal-transplant recipients <sep>', '91 renal transplant candidates <sep> cytomegalovirus disease after renal transplants <sep>', 'older patients with older donors <sep> 28 cytomegalovirus cmv)-seronegative heart and kidney recipients with cmv-seropositive donors who were extensively monitored for active cmv infection and cmv disease <sep>', 'renal transplant patients <sep> high-risk renal transplant patients d+/r by <sep> 28 patients we show that in cytomegalovirus cmv)-seronegative renal transplant recipients r receiving a cmv-seropositive graft d high doses of acyclovir acv i.e. 3,200 mg/day during the first 3 months after transplantation <sep>', 'recipients of solid organ transplants <sep> high-risk recipients of solid organ transplants <sep> fifteen of 21 patients 71 who received prophylaxis fulfilled criteria for cmv disease <sep> 21 cmv-seronegative organ transplant recipients with seropositive donors d+r <sep>', 'unselected cadaver renal transplant recipients <sep> and cytomegalovirus infection after renal transplantation <sep> cytomegalovirus cmv infection after cadaver renal transplantation 28 patients <sep>'], 'interventions': ['cmv hyperimmune globulin <sep> oral acyclovir <sep> standard intravenous immunoglobulin ivig 0.5 g/kg for 6 doses and oral acyclovir <sep> intravenous ganciclovir <sep> antilymphocyte therapy <sep> viral prophylaxis after combined pancreas-kidney transplantation pkt <sep> standard ivig <sep> ganciclovir <sep>', 'cytogam <sep> cytomegalovirus cmv immunoglobulin ig replacement cytogam <sep> placebo <sep> placebo <sep>', 'polyimmune gammaglobulin <sep> monoclonal anti-cd-3 therapy <sep> polyimmune gammaglobulin prophylaxis <sep> identical induction and rejection immunosuppressive therapy <sep>', 'immunoglobulin infusions <sep> intravenous immunoglobulin infusions <sep> sandoglobulin sandoz <sep> prophylactic immunoglobulin infusions <sep>', 'placebo <sep> ganciclovir plus intravenous immune globulin ivig with ivig alone <sep> intravenous immune globulin ivig <sep> ganciclovir plus ivig <sep> ganciclovir <sep> ganciclovir with ivig <sep>', 'recombinant interferon-alpha-2c rifna2c prophylaxis <sep> placebo <sep> low-dose prophylactic human recombinant leukocyte interferon-alpha treatment <sep> cyclosporine <sep> cyclosporine and methylprednisolone <sep>', 'interferon and placebo <sep> placebo <sep> interferon <sep> prophylactic human-leukocyte interferon <sep> interferon prophylaxis <sep> antithymocyte globulin <sep> interferon nor antithymocyte globulin <sep> standard immunosuprressive therapy with or without antithymocyte globulin <sep>', 'cmv-igiv alone <sep> cytogam alone <sep> cytogam a cmv hyperimmune globulin cmv-igiv <sep> cmv-igiv and no prophylaxis <sep>', 'cmv vaccine <sep> towne strain attenuated virus vaccine <sep> placebo <sep>', 'cytomegalovirus cmv immunoglobulin <sep> cmv immunoglobulin <sep> anti-cytomegalovirus cmv immunoglobulin <sep> ganciclovir <sep>', 'low-dose intravenous ganciclovir <sep> prophylactic low-dose ganciclovir <sep> ganciclovir vs immunoglobulin <sep> prophylactic ganciclovir therapy <sep> intravenous immunoglobulin <sep> ganciclovir <sep> immunoglobulin <sep>', 'intravenous infusions of 2 ml/kg bodyweight of cmv-polyglobin <sep> cmv hyperimmunoglobulin <sep>', 'human lymphoblastoid interferon prophylaxis <sep> placebo <sep> interferon <sep>', 'placebo <sep> prophylactic anti-cmv immunoglobulin <sep>', 'acyclovir <sep> ganciclovir gcv)-based regimen <sep> long-duration acv prophylaxis <sep> short-duration gcv <sep> ganciclovir <sep> antirejection therapy plus human immune globulin hig sandoglobulin or minnesota cmv immune globulin <sep>', 'cmv immune globulin <sep> intravenous cmv immune globulin or no treatment <sep> cytomegalovirus immune globulin <sep> intravenous cytomegalovirus cmv immune globulin <sep>', 'placebo <sep> interferon-alpha <sep> interferon or placebo <sep>', 'placebo <sep> towne strain cytomegalovirus cmv vaccine or placebo <sep>', 'prophylaxis with hyperimmune globulin hig <sep> hyperimmune globulin prophylaxis <sep>', 'hyperimmune cmv <sep> hyperimmune cmv immunoglobulins cmv igs plus high doses of acv <sep> ganciclovir <sep> acv <sep> acyclovir with or without hyperimmune cmv immunoglobulins <sep> cmv prophylaxis <sep> acv  cmv <sep>', 'acyclovir with or without immune globulin <sep> ganciclovir <sep> oral acyclovir <sep> acyclovir ivig <sep> acyclovir and intravenous immune globulin ivig <sep> ganciclovir <sep> acyclovir with or without ivig <sep>', 'polyvalent immune globulin <sep> polyvalent immune globulin igg <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",currently there are no indications for igg in the prophylaxis of cmv disease in recipients of solid organ transplants.
246,"{'outcomes': ['smoking rates <sep> rates of cigarette smoking <sep> efficacy and cost-effectiveness <sep> smoking outcomes <sep>', 'kidney infections <sep> birth weight and length of gestation <sep> incidence of preterm delivery <sep>', 'intervention increased end-of-pregnancy cessation rates <sep> efficacy <sep> cotinine-validated 7-day tobacco abstinence rates <sep>', 'co level <sep>', 'self esteem <sep> lower trait anxiety <sep> stress scores <sep> late pregnancy <sep> psychosocial measures <sep>', 'birth weight <sep> smoking cessation <sep>', 'diet cigarette and alcohol consumption maternal physical strain lactation at 40 days postpartum and utilization of health facilities <sep> distribution of risk factors and demographic obstetric and psychologic characteristics <sep> perinatal outcome health-related behavior or utilization of health facilities <sep> knowledge of seven of the nine alarm signs <sep> behavior and utilization of health resources <sep>', 'self-report exhaled carbon monoxide and urinary cotinine <sep> cigarette consumption <sep> smoking status <sep>', 'number of cigarettes they smoked <sep> number of cigarettes smoked <sep> number who quit smoking <sep>', 'salivary cotinine levels <sep>', 'levels of smoking status assessment by clinic staff 2 proportion of women identifying as having been smokers at their first visit who reported receiving cessation advice 3 proportion of these women who had quit self report and expired air carbon monoxide co and 4 smoking prevalence <sep>', 'relapse rates <sep> average number of days abstinent <sep> smoking status <sep> long-term relapse rates <sep> urinary cotinine/creatinine ratio <sep> urinary cotinine/creatinine ratios <sep>', 'larger quit rates <sep>', 'postpartum relapse to smoking <sep> prevalent abstinence <sep> relapse <sep>', 'smoking cessation <sep>', 'exhaled carbon monoxide levels <sep> quit rate <sep> acceptability and efficacy <sep> opinions about content and acceptability of the videotape and smoking behavior change during pregnancy <sep>', 'mean birthweight <sep> birthweight <sep> rate of low birthweight <sep>', 'rates of full breast feeding <sep> stopped smoking or maintained smoking changes <sep> rates of cessation or reduction <sep> smoking behaviour <sep>', 'birth weight and preterm delivery <sep> mean birth weight difference <sep> smoking cessation <sep> rate of preterm delivery <sep> mean value of cotinine in saliva <sep> birth weight <sep> rate of low birth weight <sep>', 'cigarette smoking <sep>', 'postnatal telephone questionnaire measured client satisfaction <sep>', '30-day abstinence rates <sep> smoking abstinence <sep>', 'cessation rates <sep> number of cigarettes smoked per day confidence in ability to quit exposure to passive smoke and educational level <sep> cessation rates <sep>', 'relapse rates <sep> reducing smoking <sep> quit rates <sep>', 'relapse prevention <sep>', 'self-report and urinary cotinine/creatinine ratios <sep> quitting rates <sep> quitting rates <sep> smoking status <sep>', 'efficacy and effectiveness <sep> mean infant birthweight <sep> chance of quitting smoking <sep>', 'prevalence abstinence <sep> quitting <sep>', 'smoking habits <sep> smoking habits <sep> frequency of smoking during pregnancy <sep> rates of smoking cessation <sep>', 'quit rate <sep> mean birth-weight <sep> smoking status based on self-report combined with a urinary cotinine level of 115 ng/ml and birth-weight <sep> smoking cessation <sep>', 'cigarette smoking <sep> serum thiocyanate or end expiratory carbon monoxide <sep> late pregnancy <sep>', 'birth weight <sep> salivary thiocyanate level and reported smoking <sep> weight related to smoking <sep> mean birth weight <sep>', '7-day abstinence <sep> smoking behavior <sep> 7-day abstinence continuous abstinence and partner smoking at 6 weeks post-intervention t1 and 6 weeks postpartum t2 <sep>', 'rate of negative birth outcomes <sep>', 'smoking status <sep>', 'mean action stage of readiness and motivation to quit scores <sep>', 'body length <sep> birth weight <sep> cigarette consumption <sep> self-reported cigarette consumption <sep>', 'self-reported smoking cessation <sep> smoking cessation rate <sep> cotinine-validated cessation rates during pregnancy <sep> adjusted odds ratio or for smoking cessation <sep> self-reported cessation rates during pregnancy <sep> cessation rates <sep>', 'smoking cessation rates <sep>', 'estimated fetal weight femur length and abdominal circumference <sep> point-prevalence abstinence <sep> fetal growth outcomes <sep>', 'quit rate <sep>', 'scn levels <sep>', 'number of cigarettes smoked daily <sep> quit smoking <sep> expired carbon monoxide <sep> infant birth weight <sep> cigarette abstinence rates <sep> absolute quit rates <sep> birth weight <sep>', 'size at birth <sep> birthweight and length <sep>', 'cost-to-benefit ratios <sep> quit rates <sep>', 'smoking cessation rates <sep> cotinine validated rates <sep> median self reported daily cigarette consumption <sep> degree of clustering at the midwife level <sep> smoking status and cigarette consumption <sep> smoking cessation validated by cotinine measurement at the end of the second trimester of pregnancy <sep> validated smoking cessation rates <sep> quit rates <sep>', 'smoking habit and 4 increased their consumption <sep> smoking consumption <sep>', 'self-report and saliva cotinine assessments of tobacco exposure <sep> smoking cessation rates <sep> patients quit smoking <sep>'], 'punchline_text': ['this model for intervention was cost-effective and was associated with significantly lower smoking rates at end of pregnancy. <sep>', 'positive effects of the program on birth weight and length of gestation were present for the offspring of young adolescents less than 17 years of age and smokers. <sep>', 'the intervention increased end-of-pregnancy cessation rates among 201 light smokers  10 cigarettes/day at study enrollment intervention 19.1 versus control 8.4 or 2.58 95 ci 1.1-6.1 number needed to treat  9.3 and among 193 smokers who attempted to quit in pregnancy before enrollment intervention 18.1 versus control 6.8 or 3.02 ci 1.15-7.94 number needed to treat  8.8 63 of the sample n  267 was in one of these subgroups. <sep>', 'twenty percent of intervention subjects and 10 of controls reported cessation which was verified by co level p  .052). <sep>', 'the intervention failed to alter smoking but the intervention women did report more use of community resources p  0.02 and were less likely to skip meals p  0.03). <sep>', 'fewer women in the intervention group reported smoking more 18 5.1 v 44 10.7 relative risk 0.48 95 confidence interval 0.28 to 0.81). <sep>', 'an intervention of psychosocial support and health education during pregnancy failed to show any benefit on perinatal outcome health-related behavior or utilization of health facilities. <sep>', 'however significantly greater proportions of intervention group women reported either not smoking or reducing their cigarette consumption by 50 or more at their second visit 43 vs 29 p  0.02 at their 36th-week visit 40 vs 25 p  0.01 and at 1 year postpartum 26 vs 14 p  0.02). <sep>', 'there were no significant differences among the three groups for either the number who quit smoking or who reduced the number of cigarettes smoked. <sep>', 'only one of the two women abstinent at delivery was still abstinent 3 months after birth the last contact point of the study. <sep>', 'there were no significant differences between the groups on change on any outcome. <sep>', 'long-term relapse rates were not significantly different intervention group 50.9 usual care group 50.0%.(abstract truncated at 250 words <sep>', 'pregnant smokers attending a local health department wic clinic were randomly assigned to one of two self-help smoking cessation programs or usual care. <sep>', 'prevalent abstinence was significantly greater for the pre/post intervention group than for the other groups at 8 weeks booklet group 30 prepartum group 35 pre/post group 39 p  .02 <sep>', 'the tfsb group consistently achieved greater smoking cessation across all measures when compared to the subjects in the other two groups. <sep>', 'this exploratory study examined the acceptability and efficacy of a videotape modeling smoking cessation as an adjunct to smoking cessation advice delivered during prenatal care. <sep>', 'the smoking intervention programme led to a significant 66 g increase in mean birthweight p  0.03 95 ci+9 to 123 g and to a 30 reduction in the rate of low birthweight in pregnancies managed by the 70 physicians who secured the highest rate of obtaining repeat serum samples for cotinine measurements in their intervention group. <sep>', 'there was no difference in rates of full breast feeding between the control and intervention groups for women who planned to breast feed. <sep>', 'mean birth weight difference was 186 g 95 ci 35 336 g higher in the nicotine than placebo group and there was an insignificantly lower rate of low birth weight under 2500 g in the former group. <sep>', 'it was concluded that the intervention had either a small or no influence on cigarette smoking. <sep>', ""tools have been developed to answer the question can proactive opportunistic home-based motivational interviewing help pregnant smokers reduce their habit?'. <sep>"", 'there was a statistically significant difference in 30-day abstinence rates between si 26 and uc 12 conditions at the end of pregnancy among women who had not quit spontaneously with pregnancy odds ratio  <sep>', 'neither a computerized telephone cessation program nor systematic provision of motivational counseling improved cessation rates over a tailored self-help booklet delivered within the context of brief advice from prenatal providers. <sep>', 'after one year the results showed quit rates of 9 in the treatment group and 0 in the control group. <sep>', 'biochemical confirmation of continuous abstinence through delivery revealed that 16 of the women in the experimental self-help program relapsed compared with 20 of usual care controls ns). <sep>', 'at the long-term follow-up reported quitting rates were significantly greater among intervention group women cared for in the publicly supported clinic than among those receiving the usual care 14.5 versus 2.5 p  0.01. <sep>', 'the midwife-assisted smoking cessation intervention seems to be an effective tool to help pregnant smokers make a decision to quit smoking. <sep>', 'midwives in these practices delivered three interventions a standard care b ttm based self help manuals and c ttm based self help manuals plus sessions with an interactive computer program giving individualised smoking cessation advice). <sep>', 'there was no difference in the rates of smoking cessation between the screened group and the control group. <sep>', 'babies born to women receiving the intervention were on average 84 g heavier than babies born to controls p=0.04). <sep>', 'the magnitude of this difference persisted through late pregnancy 11.8 vs. 4.3 ns and delivery 10.6 vs. 4.7 ns). <sep>', 'at the eighth month of pregnancy differences between the two groups in salivary thiocyanate level and reported smoking were statistically significant. <sep>', 'nineteen percent of the experimental group reported 7-day abstinence compared to 7 of the control group at t1 and 21 and 12 respectively at t2. <sep>', 'women in the cbt+nrt arm were almost three times more likely than women in the cbt-only arm to have biochemically validated cessation at both pregnancy time points after 7 weeks 24 vs 8 p=0.02 at 38 weeks gestation 18 vs 7 p=0.04 but not at 3 months postpartum 20 vs 14 p=0.55). <sep>', 'the intervention and usual care groups differed in post-delivery point prevalence abstinence rates for recent ex-smokers 65 vs. 53 p  0.05 one-tailed but not in other outcome measures. <sep>', 'compared to controls smokers exposed to the intervention were more likely to have quit 14.5 versus 7.7 or take actions toward quitting and had higher mean action stage of readiness and motivation to quit scores. <sep>', 'self-reported cigarette consumption fell significantly p  0.001 in the intervention group with 16.2 giving up and 33.3 significantly reducing their cigarette consumption. <sep>', 'self-reported cessation rates during pregnancy were significantly higher in the intervention group 14 than in the group receiving usual care 5.0 p  0.0001 <sep>', 'smoking during pregnancy has been linked to health problems including the risk of low birthweight preterm labour spontaneous abortion and perinatal death. <sep>', 'serial ultrasound examinations indicated significantly greater growth in terms of estimated fetal weight femur length and abdominal circumference in the contingent compared to the non-contingent conditions. <sep>', 'the intervention consisted of individual skills instruction and counseling by a peer health counselor on the use of a self-help cessation guide and routine clinic reinforcement. <sep>', 'results of this trial indicate that health education methods tailored to the pregnant smoker are more effective in changing smoking behavior than the standard clinic information and advice to quit and/or the use of smoking cessation methods not tailored to the needs of the pregnant smoker. <sep>', 'compared with usual care peer counseling reduced smoking 9.1 versus 4.5 cigarettes daily p .03 but did not affect absolute quit rates 24 versus 21 at 36 weeks gestation. <sep>', 'it was found that the planned educational intervention was incompletely carried out and was given more effectively to primigravidae in whom subsequent reduction of smoking was more evident. <sep>', 'black e and c group patients had higher quit rates than white e and c group patients. <sep>', 'smoking cessation rates were low the cotinine validated rates were 18.8 113/600 in the intervention group and 20.7 144/695 in the normal care group difference 1.9 95 confidence intervals 3.5 to 7.3%). <sep>', '11 in the intervention group did not change their smoking habit and 4 increased their consumption compared to 36 and 22 respectively in the control group. <sep>', 'a significantly higher percentage of patients quit smoking in the experimental group 17.3 than in the control group 8.8%). <sep>'], 'population': ['women who receive obstetric care through publicly funded prenatal clinics <sep> subjects were 105 low income predominantly hispanic pregnant patients in an urban prenatal clinic <sep> pregnant women n=105 <sep> ethnically diverse sample of pregnant smokers <sep>', 'offspring of young adolescents less than 17 years of age and smokers <sep> young adolescents who were visited by nurses gave birth to newborns who were an average of 395 g heavier and women who smoked and were visited by nurses <sep> children born to primiparous women who were either teenagers unmarried or of low socioeconomic status <sep>', 'pregnant smokers <sep> women who had attempted cessation earlier in pregnancy <sep> 442 pregnant smokers referred by prenatal providers and a managed care plan <sep>', ""pregnancy in an academic clinic <sep> resident-staffed prenatal clinics at the university of north carolina <sep> women's hospital <sep> two hundred fifty prenatal patients who smoked were enrolled at their first visit <sep>"", ""woman's psychosocial status during pregnancy <sep> study sample were women recruited from an antenatal clinic and general practice surgeries who were less than 20 weeks gestation and either single or in a relationship where the partner was unemployed <sep> pregnant women <sep> 66 women in the control group and 65 women in the intervention group <sep> all women were interviewed initially and at 34 weeks gestation <sep>"", 'by midwives to help pregnant smokers quit or cut down <sep> pregnant women <sep> clinics attached to two maternity hospitals in glasgow <sep> 762/1684 pregnant women who were regular smokers at antenatal booking 351 in intervention group and 411 in control group <sep> addictions-provided at home by specially trained midwives helps pregnant smokers to quit <sep>', 'four cities of latin america on pregnant women at risk <sep>', 'pregnant women who smoked <sep>', 'city pregnant women n  193 who completed one of three interventions a <sep> pregnant women in an urban setting <sep>', ""40 high-risk pregnant smokers who expressed interest in stopping smoking <sep> women's and children's hospital adelaide a public tertiary teaching hospital in south australia with almost 4000 births annually <sep> pregnant women who attempt to stop smoking by highlighting three women who used nicotine patches <sep> all participants were given pregnancy-specific cessation counselling and the 20 women in the treatment arm were offered <sep> pregnant women <sep> three pregnant smokers <sep>"", 'public antenatal clinics <sep> 22 antenatal clinics in new south wales australia <sep> 5849 women pre-dissemination 2374 sd 3475 id and weighted sample of 5145 women post-dissemination 2302 sd 2843 id <sep> public hospital antenatal clinics <sep>', 'one hundred and seventy-five pregnant women who were smoking early in their pregnancy but had quit by first prenatal visit <sep> obstetricians and nurse midwives usual advice during prenatal care <sep>', 'pregnant smokers attending a local health department wic clinic <sep> pregnant women at a wic clinic <sep>', 'women who quit smoking during pregnancy <sep> pregnant smokers at 2 managed care organizations <sep> smokers who quit during pregnancy <sep>', 'pregnant adolescents <sep> forty-six subjects completed the post-intervention assessment of smoking status <sep> pregnant teens <sep>', '60 women <sep> pregnant women quit smoking <sep>', '139 physician offices and clinic sites in maine providing antenatal care <sep> 2848 pregnant women who smoked 10 or more cigarettes daily enrolled at between 15 and 20 weeks gestation from a population base of approximately 18,000 pregnancies <sep> 2700 singleton viable pregnancies <sep>', 'sixty-one midwives recruited a total of 297 women <sep>', 'pregnant smokers <sep> pregnant women <sep> pregnant women who smoked ten or more cigarettes after the first trimester n  250 <sep>', 'cigarette smoking by public prenatal patients <sep> 170 subjects multiple measures of smoking and data collection before the intervention and six weeks later <sep> public prenatal patients <sep>', 'pregnant women <sep> clients were 100 consecutive self-reported smokers booking at clinics in glasgow from march to may 1997 <sep>', 'pregnant and postpartum women <sep> five community health centers <sep> women who did not quit spontaneously <sep> women infants and children wic clinics on smoking and relapse rates in pregnant and postpartum women <sep> subjects n 601 were current smokers or had quit with pregnancy <sep>', '390 english-speaking women 18 years of age or older who self-reported to be active smokers at their initial prenatal appointment <sep> pregnant women <sep> heavier smokers <sep>', 'twenty-six midwives <sep> pregnant women stop smoking <sep> midwives with <sep>', 'women who stop smoking early in pregnancy <sep> smokers who have stopped before entering prenatal care--""spontaneous quitters <sep> spontaneous quitters <sep> the population n  171 of spontaneous quitters was an ethnically diverse group of women enrolled in a large health maintenance organization <sep> women who are smoking during pregnancy <sep>', '600 pregnant women who smoked <sep> women in public maternity clinics <sep>', 'pregnant women <sep> and 144 current smokers and 37 spontaneous quitters were included in the control group <sep> one hundred and forty nine current smokers and 56 spontaneous quitters <sep> pregnant women from the maternity centers in ld central poland <sep>', '918 pregnant smokers 100 general practices <sep> antenatal clinics in west midlands uk general practices <sep> pregnant women comparing interventions based on the transtheoretical stages of change model to standard care <sep> pregnant women stop smoking of two interventions pro-change for a healthy pregnancy <sep>', 'multiple practices in six states <sep> women who present with a history of smoking <sep> women who registered for prenatal care at participating practices <sep>', 'pregnant smokers <sep> 393 evaluable women in the control group received <sep> women who reported smoking at their first antenatal visit and satisfied the inclusion criteria were asked to participate in the trial <sep>', 'pregnant women <sep> three hundred and forty-six women who reported smoking one or more cigarettes per day prior to the 20th week of gestation <sep> 284 women smoking five or more cigarettes a day at booking <sep> 319 women <sep>', 'nine hundred thirty-five pregnant smokers <sep>', 'dutch pregnant women and their partners <sep> four provinces with 42 practices including 118 midwives <sep>', 'pregnant smokers <sep> smoking cessation in pregnancy <sep> data were collected from 2003 through 2005 analyses were conducted in 2006 and 2007 <sep> pregnant women <sep>', '1120 pregnant women in the third month of pregnancy 249 recent ex-smokers and 871 current smokers <sep> pregnant women practicable routinely by midwives <sep> pregnant women in nine hospital and community trusts <sep> women who would have been eligible to take part in the trial were actually recruited by 178 recruiting midwives with lack of time being cited as the main barrier <sep>', '33 prenatal family planning and pediatric services in 12 public health clinics <sep> women in public health clinics <sep> subjects were 683 baseline and 1,064 experimental smokers with measurements of smoking outcomes at both times <sep>', '856 pregnant women <sep>', 'pregnant smokers <sep> all pregnant smokers in the usual care group n  320 received <sep> 647 pregnant smokers <sep>', 'a total of 119 women <sep> pregnant women <sep> 217 women into the study and followed them up at 20 weeks gestation to ascertain smoking cessation and to measure process variables <sep> pregnant women and one-to-one interviews of nurses and doctors <sep>', 'pregnant women <sep> 82 smokers entering prenatal care participated in the trial <sep>', 'pregnant women in an urban prenatal clinic <sep> urban prenatal clinic serving predominantly low-income african-american women <sep> 391 smokers <sep>', 'smokers in public health maternity clinics <sep> pregnant smoker in public health maternity clinics to quit during pregnancy <sep> three hundred and nine pregnant women from three public health maternity clinics <sep>', 'pregnant smokers <sep> one hundred forty-two pregnant predominantly hispanic women <sep>', 'infant size at birth <sep>', 'pregnant smokers in public health maternity clinics <sep> pregnant smokers <sep> 814 female smokers at four public health maternity clinics <sep> four hundred patients <sep>', 'pregnant women <sep> 1527 women who smoked at the start of pregnancy <sep> pregnant women and midwives <sep> pregnancy <sep>', 'heavy smokers <sep> 104 pregnant women smoking 10 cigarettes or more daily at the time of routine ultrasound screening around the 18th week of pregnancy <sep> pregnant heavy smokers <sep> pregnant women to aid smoking cessation during a 10 day program <sep>', 'pregnant smokers <sep> pregnant smokers in medicaid maternity care <sep> pregnant medicaid recipients <sep> 265 pregnant smokers <sep>'], 'interventions': ['usual care standard cessation advice from the health care provider or an intervention conducted in the prenatal clinic consisting of 1.5 h of counseling plus telephone follow-up delivered by a masters prepared mental health counselor <sep> clinic-based counseling intervention <sep>', 'nutritional supplementation program <sep>', 'proactive pregnancy-tailored telephone counseling <sep> proactive pregnancy-tailored telephone counseling did not outperform a brief best practice intervention <sep> brief smoking counseling <sep> best-practice brief-counseling control <sep> telephone counseling <sep> trained counselors using cognitive-behavioral and motivational interviewing methods called intervention <sep> telephone counseling <sep>', 'usual-care group <sep> physician-based intervention <sep> smoking cessation intervention <sep>', 'telephone calls <sep> telephone support <sep> telephone support program <sep>', 'standard health promotion information <sep> motivational interviewing--a behavioural therapy <sep> home based motivational interviewing <sep> motivational interviewing at home <sep>', 'health education <sep> home intervention of four to six visits dealing with psychosocial support and education about health-related habits alarm signs hospital facilities antismoking and antialcohol programs and a reinforcement of adequate health services utilization for the pregnant woman and a support person <sep> routine prenatal care <sep>', 'structured advice from their physician and referral to individual behavior change counseling during prenatal care or to receive brief advice to stop smoking and a quit smoking booklet <sep> physician training <sep>', ""special video program based on their perceptions of the effects of smoking during pregnancy the american lung association's freedom from smoking for you and your baby program or the usual physician's advice <sep>"", 'nicotine patches <sep> nicotine-replacement therapy nrt <sep> nicotine replacement therapy <sep> nrt <sep>', 'smoking cessation programme <sep> simple dissemination sd condition 11 clinics which received a mail-out of programme resources or to an intensive dissemination id condition 11 clinics which included the mail-out plus feedback training and ongoing support with midwife facilitator <sep>', 'smoking relapse prevention counseling <sep> individualized smoking relapse prevention counseling <sep> usual advice from their obstetrician or nurse midwife or usual advice plus individual relapse prevention counseling <sep>', 'smoking cessation interventions <sep> self-help smoking cessation programs or usual care <sep>', 'self-help booklet only prepartum relapse prevention or prepartum and postpartum relapse prevention <sep>', 'teen freshstart with a buddy program tfsb a teen freshstart program tfs without peer support and the usual care uc control group <sep> tfsb <sep> peer support in smoking cessation programs <sep> smoking cessation intervention <sep>', 'brief smoking cessation advice and a tipsheet to the same advice and tipsheet plus provision of the videotape <sep> videotape modeling smoking cessation <sep>', 'cotinine-assisted smoking intervention programme with an existing antenatal maternal serum alpha-fetoprotein afp screening service <sep> cotinine-assisted intervention <sep> usual anti-smoking advice <sep> interpreted measurement of the serum cotinine reported through the physician to the woman along with a self-help smoking cessation booklet and a repeat serum cotinine measurement one month later again interpreted and reported through the physician to the woman <sep>', 'smoking education and breast-feeding interventions <sep> programme of education and support for smoking cessation or reduction a programme of education and support for breast feeding or both programmes <sep>', 'nicotine patches <sep> nicotine patches <sep> placebo <sep> placebo patches <sep> nicotine <sep>', 'observing carbon monoxide level <sep>', 'motivational interviewing <sep> median of four home-based motivational interviewing sessions from one specially trained midwife <sep> midwife home-based motivational interviewing <sep> behavioural intervention <sep>', 'special intervention si or usual care uc <sep> provider counseling and office systems intervention <sep> community health center smoking-cessation intervention <sep>', 'self-help booklet tailored to smoking patterns stage of change and lifestyle of pregnant smokers 2 the booklet plus access to a computerized telephone cessation program based on interactive voice response technology or 3 the booklet plus proactive telephone counseling from nurse educators using motivational interviewing techniques and strategies <sep>', 'fuller training <sep>', 'relapse prevention program <sep>', 'individualized smoking cessation counseling <sep> individual smoking cessation counseling <sep> individualized smoking cessation counseling <sep> usual advice from their obstetrician or nurse-midwife or the usual advice plus individualized smoking cessation counseling <sep>', 'smoking cessation program <sep> smoking cessation intervention <sep> midwife-assisted smoking cessation intervention <sep> anti-smoking counseling <sep> standard written information about the health risk from maternal smoking to the fetus <sep>', 'b ttm based self help manuals and c ttm based self help manuals plus sessions with an interactive computer program giving individualised smoking cessation advice <sep> smoking cessation <sep>', 'ultrasound screening <sep> ultrasound screening <sep>', 'usual antenatal care <sep> usual antenatal care plus the intervention <sep> smoking cessation intervention <sep>', 'health education <sep> health educational counselling to stop or reduce cigarette smoking <sep>', 'smoking intervention <sep>', 'smoking cessation counseling <sep> routine care <sep> health counseling method by midwives using a rct <sep>', 'cbt+nrt <sep> cbt-only versus cbt+nrt <sep> nicotine replacement and behavioral therapy <sep> nrt to cbt <sep> nicotine replacement therapy nrt to cognitive-behavioral therapy cbt <sep>', 'midwife-delivered brief smoking cessation intervention <sep> experimental intervention or usual care <sep> brief motivational intervention those who wanted to stop received an intervention designed to assist them and those that had stopped recently recent ex-smokers received a relapse prevention intervention <sep> brief smoking cessation intervention <sep>', 'multicomponent motivational smoking cessation intervention <sep> motivational smoking cessation intervention <sep> experimental period matchedpair random assignment of clinics to intervention or control conditions <sep>', 'anti-smoking counselling <sep>', 'initial individual smoking cessation counseling supplemented by an invitation to join individually or in a group a smoking cessation program with nicotine replacement therapy <sep> multimodal intervention <sep> multimodal smoking cessation intervention regimen <sep> standard counseling from a midwife <sep> nicotine replacement therapy <sep>', 'new-materials group or a usual-care group <sep> antenatal smoking cessation programs <sep>', 'contingent or non-contingent voucher conditions <sep> voucher-based incentives <sep> voucher-based reinforcement therapy vbrt <sep> vbrt <sep>', 'usual clinic information plus a prenatal and postpartum intervention or to a control c group to receive only usual clinic information <sep> individual skills instruction and counseling by a peer health counselor on the use of a self-help cessation guide and routine clinic reinforcement <sep> smoking cessation intervention <sep>', ""smoking cessation methods <sep> control group a group receiving the american lung association's freedom from smoking manual and those receiving a pregnant woman's self-help guide to quit smoking <sep>"", 'peer counseling intervention <sep> peer counseling <sep> peer-led smoking cessation program or to usual care <sep>', 'anti-smoking health education <sep> educative intervention <sep>', 'health education methods <sep>', 'self help smoking cessation <sep>', 'low cost multicomponent intervention program <sep>', 'standardized risk information and were advised to quit smoking <sep> evidence-based patient education methods including the videocassette commit to quit <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",smoking cessation interventions in pregnancy reduce the proportion of women who continue to smoke in late pregnancy and reduce low birthweight and preterm birth. smoking cessation interventions in pregnancy need to be implemented in all maternity care settings. given the difficulty many pregnant women addicted to tobacco have quitting during pregnancy population-based measures to reduce smoking and social inequalities should be supported.
247,"{'outcomes': ['full-scale iq scores <sep> neurodevelopmental outcomes <sep> verbal iq performance iq and achievement scores <sep> mullen scales of early learning wechsler preschool and primary scale of intelligence-revised wechsler intelligence scale for children wide-range achievement test and child behavioral checklist <sep> cognitive attention and achievement scores <sep>'], 'punchline_text': ['subjects with moderate ch had higher full-scale iq scores than subjects with severe ch regardless of the initial treatment dose. <sep>'], 'population': ['severe and moderate congenital hypothyroidism ch <sep> congenital hypothyroidism <sep> 31 subjects included the <sep>'], 'interventions': ['initial l-thyroxine <sep>'], 'punchline_effect': [' sig increase <sep>']}",there is currently only one randomised controlled trial evaluating the effects of high versus low dose of initial thyroid hormone replacement for cht. there is inadequate evidence to suggest that a high dose is more beneficial compared to a low dose initial thyroid hormone replacement in the treatment of cht.
248,"{'outcomes': ['grade 10 smoking rates <sep> regular smoking rates <sep> extracurricular activities <sep>', 'adolescent alcohol marijuana and cigarette use <sep>', 'health knowledge and nonsmoking intentions <sep> communication self-instruction self-praise cigarette refusals and noncompliance to smoke <sep> weekly cigarette smoking <sep>', 'refusal/self-efficacy smoking intentions or behavior <sep> knowledge and prevalence estimates and significant interactions of classroom and tv programming on knowledge negative disapproval of parental smoking and coping effort <sep>', 'enhanced school commitment and class participation <sep> social and school work skills <sep>', 'smoking prevalence rates <sep> smoking prevalence <sep> changes in knowledge <sep> smoking behaviour <sep>', 'prevalence rate of smoking <sep> smoking behaviour <sep> uptake of smoking <sep> prevalence rates of the uptake of smoking relative <sep> prevalence rate <sep>', 'prevalence initiation and cessation rates <sep> cannabis initiation and prevalence <sep>', 'several cognitive attitudinal and personality variables <sep> smoking drinking drunkenness inhalant use and polydrug use relative <sep>', 'self-efficacy condition <sep> objectively assessed smoking carbon monoxide breath measure <sep> smoking <sep> smoking uptake <sep>', 'risk of smoking initiation <sep>', 'smoking behaviour health knowledge beliefs or values <sep> health knowledge beliefs and values <sep>', 'tobacco use and violence <sep>', 'dichotomous measures of substance use cigarette alcohol marijuana and hard drugs <sep>', 'proportion of non-smokers <sep> social pressure <sep> efficacy <sep>', 'rate of passive smoking <sep> knowledge and attitudes related to tobacco use <sep> rate of attempting smoking <sep>', 'students general and specific attitudes toward drugs the capability to resist peer pressure and estimated level of drug use by peers <sep>', 'uptake smoking <sep> positive norms and social pressure to smoke <sep>', 'smoking knowledge <sep> smoking behavior <sep> pre-test smoking odds ratio or <sep>', 'self-efficacy and resistance skills <sep> decisional balance against smoking and decreased temptations to smoke <sep> smoking cessation <sep> smoking initiation rates <sep>', 'drinking or antisocial behavior <sep> early adolescent substance use and antisocial behavior <sep> growth trajectories of smoking drinking and antisocial behavior <sep> smoking progression <sep> friends who smoke outcome expectations for smoking and smoking progression <sep>', 'prevalence of smokeless tobacco <sep> prevalence of weekly cigarette use <sep>', 'self-reported past-month and past-year use of tobacco alcohol and marijuana <sep> negative effect <sep>', 'alcohol cigarettes marijuana cocaine and other drugs as well as on knowledge <sep> knowledge of alcohol pressures effects and skills to resist <sep>', 'behavioral determinants and smoking <sep>', 'past month use of cigarettes based on a self-reported questionnaire <sep> 30-day smoking <sep> intervention response <sep> smoking prevalence <sep>', 'diastolic blood pressure plasma total and high-density lipoprotein hdl cholesterol serum thiocyanate ponderosity index triceps skinfold thickness and postexercise pulse recovery rate <sep> diastolic blood pressure and thiocyanate <sep>', 'smoking rates <sep> smoking intentions <sep> smoking intentions smoking knowledge perceived peer and adult smoking norms drug refusal skills and risk taking <sep>', '30-day smoking prevalence <sep>', 'smoking rates <sep>', 'regular smoking <sep> adolescents smoking-related knowledge <sep> probability of baseline non-smokers initiating smoking <sep> students smoking-related knowledge attitudes and behaviour <sep> mean knowledge scores <sep> attitude scores <sep> probability of baseline experimental smokers escalating to regular smoker <sep>', 'lifetime and 30-day use of cigarettes alcohol marijuana and inhalants <sep> past 30-day use of alcohol <sep> adolescents lifetime and 30-day use of cigarettes alcohol marijuana and inhalants <sep>', 'effectiveness of project towards no drug abuse tnd <sep> lowering marijuana use <sep>', 'cigarette smoking <sep> resistance skill training <sep>', 'weekly smoking onset <sep> smoking-related beliefs <sep> negative attitude towards smoking increased social self-efficacy levels <sep> adolescents smoking behaviour <sep>', 'students resistance or decision-making skills substance use intentions expectancies or normative beliefs or lifetime and recent substance use <sep>', 'sfa effectiveness and the general thrust of school-based life skills-based prevention programs <sep> self-efficacy <sep> behavioral intentions perceptions of harm or perceived peer norms <sep>', 'new regular cigarette smoking <sep> new cigarette smoking <sep> several cognitive attitudinal and personality variables <sep>', 'normative expectations and knowledge concerning substance use interpersonal skills and communication skills <sep> cigarette smoking marijuana use and immoderate alcohol use <sep>', 'odds ratio of being a smoker <sep> high risk of regular smoking uptake <sep>', 'adjusted prevalence odds ratio por <sep> daily cigarette smoking <sep> episodes of drunkenness <sep>', '1-year covariate-adjusted smoking rate <sep> rate of smoking <sep>', 'odds of baseline nonsmokers initiating smoking <sep>', 'control schools <sep> girls smoking rates <sep>', 'social variables e.g. peer resistance skills <sep>', 'new smokers <sep> knowledge and personality variables <sep>', 'coronary heart disease risk factors <sep> risk factors systolic and diastolic pressures hdl cholesterol ratio of total to hdl cholesterol fitness postexercise pulse recovery rate and smoking <sep> systolic and diastolic blood pressures ponderosity index triceps skinfold thickness postexercise pulse recovery rate serum total and high density lipoprotein hdl cholesterol and serum thiocyanate <sep> blood pressure reduction <sep> health knowledge and attitude toward smoking <sep> ponderosity and improved fitness and increased hdl cholesterol <sep>', 'grade 8 smoking rates <sep>', 'quit smoking <sep>', 'tried smoking and 30-day smoking prevalence <sep> response rate <sep> student smoking behavior and curriculum implementation <sep> rates of smoking initiation and regular smoking <sep> mean 30-day smoking prevalence rates <sep>', 'weekly smoking and monthly smoking <sep>', '30-day use of alcohol marijuana and illegal drugs excluding marijuana and drinking to intoxication <sep> illegal drugs excluding marijuana <sep>', 'relapse rates <sep> smoking behavior <sep>', 'knowledge level attitudes and the development of refusal decision-making and problem-solving skills <sep>', 'multiple measures of initiation and current use of alcohol tobacco and marijuana <sep>', 'cigarette smoking <sep>', 'tobacco knowledge attitudes offers use and intentions <sep>', 'rates of tobacco alcohol and marijuana use <sep> outcome assessment batteries measured youths reported use of smoked and smokeless tobacco alcohol and marijuana <sep> smokeless tobacco alcohol and marijuana <sep>', 'rate of smoking <sep>', 'alcohol consumption alcohol initiation behaviors alcohol use risk and protective factors drug use behaviors and exercise habits and at 12-months for alcohol use risk and protective factors cigarette use and cigarette initiation <sep> adolescent alcohol and cigarette use and other health behaviors <sep>', 'likelihood of heavy cigarette use adoption <sep> resistance to smoking behavioral intentions to smoke and cigarette use <sep>', 'smoking rates <sep>', 'sensation seeking physical maturity antisocial behavior and parental smoking <sep>', 'rates of substance use and antisocial behavior <sep>', 'substance initiation index sii measuring lifetime use of alcohol cigarettes and marijuana and by rates of each individual substance <sep>', 'lower probabilities of tobacco use <sep>', 'cigarette smoking <sep> school-level clustering effects socio-economic status gender and family smoking <sep>', 'diastolic pressure <sep> systolic and diastolic blood pressures plasma total and high-density lipoprotein hdl cholesterol serum thiocyanate ponderosity index triceps skinfold thickness and postexercise pulse recovery rate <sep> total cholesterol <sep> systolic pressure <sep> total cholesterol/hdl cholesterol ratio and for thiocyanate <sep>', 'self-reported use of cigarettes bidis small hand-rolled often flavored cigarettes and chewing tobacco and future intentions to smoke or use chewing tobacco <sep> cigarette smoking or bidi smoking <sep>', 'smoking prevalence and use of smokeless tobacco st <sep>', 'tobacco use <sep>'], 'punchline_text': ['there were no significant differences among grade 10 smoking rates for females or for students of either gender with previous smoking experience in grade 8. <sep>', 'results indicated significant p  .05 intervention effects in growth trajectories for frequency of alcohol and marijuana use but not for use versus nonuse. <sep>', 'self-control skills subjects had better 15-month follow-up scores than subjects in the other two conditions on measures of communication self-instruction self-praise cigarette refusals and noncompliance to smoke. <sep>', 'there were no consistent program effects on refusal/self-efficacy smoking intentions or behavior. <sep>', 'the girls in the group also evidenced lower rates of substance use initiation while the boys exhibited increased social and school work skills. <sep>', ""inadequate implementation of the programme by some teachers may have been associated with adverse effects on the children's behaviour attitudes and knowledge. <sep>"", 'in girls both the teacher-led and peer-led programmes maintained their effects over the two years of follow-up with adjusted differences in prevalence rates of the uptake of smoking relative to the control group of 6.6 95 cl 17.3 4.0 and 8.1 95 cl 18.9 2.7 respectively after two years. <sep>', 'this adaptation of mi was not demonstrated to be effective in either intention-to-treat or sub-group analyses for any outcome. <sep>', 'mediational analyses showed that prevention effects on some drug use outcomes were mediated in part by risk-taking behavioral intentions and peer normative expectations regarding drug use. <sep>', 'there were no differences between the two control conditions and the self-efficacy condition. <sep>', 'the classroom-centered cc intervention was designed to reduce the risk for tobacco smoking by enhancing teachers behavior management skills in first grade and thereby reducing child attention problems and aggressive and shy behavior-known risk behaviors for later substance use. <sep>', 'knowledge about effects of smoking rose in all groups from a mean score of 5.4 in 1988 to 6.4 in 1989 and 6.5 in 1990. <sep>', 'plus significantly enhanced the effectiveness of the d.a.r.e. curriculum among boys and was more effective than the delayed program controls underscoring the potential for multiyear multicomponent prevention programs and demonstrating sex differences in response to intervention programs. <sep>', 'across all program schools the two different curricula failed to significantly reduce dichotomous measures of substance use cigarette alcohol marijuana and hard drugs at one-year follow-up. <sep>', 'social pressure associated with starting to smoke friends sibsters parents smokers measured before intervention had no demonstrable influence on efficacy. <sep>', 'the rate of attempting smoking decreased form 7.8 to 2.6 and the rate of passive smoking from 53.6 to 41.8%. <sep>', 'no significant differences were observed between intervention and comparison schools with respect to cigarette alcohol or marijuana use during the 7th grade approximately 1 year after completion of the program or over the full 5-year measurement interval. <sep>', 'in the short-term an intervention based on peer pressure decreases the proportion of adolescents with lower education who start smoking. <sep>', 'the program was successful in improving smoking knowledge but not attitudes in intervention versus control group p  0.001). <sep>', 'differences between groups in self-efficacy and resistance skills were not significant. <sep>', 'latent growth curve analyses demonstrated significant treatment group effects including reducing increases in friends who smoke outcome expectations for smoking and smoking progression but had non-significant effects on drinking or antisocial behavior. <sep>', 'the community programme had significant effects on the prevalence of weekly cigarette use at times 2 and 5 and the effect approached significance at time 4. <sep>', 'subgroup analyses indicated that the negative effect occurred among nonusers at baseline and mostly among white students of both genders. <sep>', 'repeated measures analysis of variance resulted in significant treatment by occasion interactions on the use of alcohol cigarettes marijuana cocaine and other drugs as well as on knowledge. <sep>', 'the intervention group had a higher intention not to smoke =0.13 95 confidence interval=0.01-0.24 and started to smoke less often than the control group odds ratio=0.59 95 confidence interval=0.35-0.99 smoking increased from 2.5 to 3.6 in the intervention group and from 3.2 to 6.5 in the control group. <sep>', 'the two experimental curricula both produced similar overall reductions in smoking prevalence that were not significantly different from each other or the control group. <sep>', 'after one year of intervention the program was found to be acceptable to school administrators teachers parents and children. <sep>', 'a school-based drug abuse prevention approach previously found to be effective among white youth significantly reduced smoking initiation and escalation among urban minority girls. <sep>', 'the amount of program exposure was low in many classes but program use displayed a dose-response relationship with reduced smoking prevalence. <sep>', 'the most successful program was the si program with boosters which resulted in a significantly lower increase in smoking rates 5.6 and 9.7 respectively compared to the control group 12.6 and 14.9 respectively at both 12 and 18 months follow-up. <sep>', 'the mean knowledge scores from baseline to the 1 and 2-year follow-ups increased more in the intervention group than in the control group whereas there was little change in attitude scores. <sep>', 'at baseline students in the intervention condition were slightly to moderately more likely to report use for each of the 8 measures examined than were students in the control condition. <sep>', 'there were no differences in the effects of the two program conditions. <sep>', 'there were main effects of normative education for summary measures of alcohol p  0.0011 marijuana p  0.0096 and cigarette smoking p  0.0311). <sep>', 'the programme embraced the social influence approach and concentrated on enhancing self-efficacy and the acquisition of cigarette refusal skills. <sep>', 'the 5th grade kir curriculum generally appeared no more effective than the control schools programming in changing students resistance or decision-making skills substance use intentions expectancies or normative beliefs or lifetime and recent substance use. <sep>', 'baseline binge drinkers in sfa schools were less likely to report recent binge drinking than students in control schools p<.01 there were no treatment differences among baseline nonbinge drinkers. <sep>', 'results indicated that the prevention program was able to reduce new cigarette smoking by 50 at the end of the first year and by 55 at the end of the second year for the intensive format condition. <sep>', 'prevention effects were also found for normative expectations and knowledge concerning substance use interpersonal skills and communication skills. <sep>', 'the odds ratio of being a smoker in intervention compared with control schools was 0.75 95 ci 0.55-1.01 immediately after the intervention n=9349 students 0.77 0.59-0.99 at 1-year follow-up n=9147 and 0.85 0.72-1.01 at 2-year follow-up n=8756). <sep>', 'program effects were found for daily cigarette smoking por=0.70 0.52-0.94 and episodes of drunkenness in the past 30 days por=0.72 0.58-0.90 for at least one episode por=0.69 0.48-0.99 for three or more episodes while effects on cannabis use in the past 30 days were of marginal statistical significance por=0.77 0.60-1.00). <sep>', 'the analyses for nonsmokers however showed no significant effects and the program did not affect self-reported alcohol or marijuana use. <sep>', 'among boys who were recent smokers at baseline the prevention program significantly reduced risk of remaining recent smokers at follow-up or=0.45 with 95 ci=0.23 0.88). <sep>', 'although prevalence decreased in intervention schools and increased in control schools in year 2 the significant difference between the two groups at baseline was not overcome by the intervention and increases in prevalence were observed in both groups in years 3 and 4. <sep>', ""results from a longitudinal evaluation of the program in 36 schools in illinois provide only limited support for dare's impact on student's drug use immediately following the intervention and no support for either continued or emerging impact on drug use 1 or 2 years after receiving dare instruction. <sep>"", 'there were significantly fewer new smokers in the experimental school than in the control school at both the initial posttest p less than .01 and the three-month followup p less than .05 along with significantly greater changes on some of the knowledge and personality variables. <sep>', 'blood pressure reduction was associated with decreased ponderosity and improved fitness and increased hdl cholesterol was associated with decreased ponderosity. <sep>', 'there were no significant differences in outcome as a function of training method and no significant differences in outcome between teacher-provided and nurse-provided interventions in high and medium-risk schools. <sep>', 'we conclude that this peer pressure resistance skill program was effective in preventing experimentation with tobacco among sixth graders in tijuana mexico. <sep>', 'intervention and control groups were comparable in terms of tobacco use gender ethnicity behavioral environmental and psychosocial characteristics. <sep>', 'students in the program condition experienced a greater reduction in weekly smoking and monthly smoking at 6-and-12-month follow-ups. <sep>', 'using hierarchical linear modeling we found that students in the control schools reported significantly less use of illegal drugs excluding marijuana than those in the intervention group at the first posttest however this effect did not persist one year later. <sep>', 'the smoke-free class competition did not prevent smoking among adolescents and does not appear to be an effective substitute to the complete ban of tobacco advertising the abolition of vending machines and the creation of smoke-free environments in german schools. <sep>', 'students in the school health intervention program had statistically significant positive effects regarding knowledge level attitudes and the development of refusal decision-making and problem-solving skills. <sep>', 'it is concluded that brief family skills-training interventions designed for general populations have the potential to reduce adolescent substance use and thus have important public health implications. <sep>', 'at 24-month follow-up youths who received health information and skills intervention had lower intentions to smoke and less cigarette use than youths who received health information alone and youths who received no intervention. <sep>', 'intervention students were significantly less likely than controls to have been offered received experimented with or have intentions to use tobacco. <sep>', 'community intervention components appeared to exert no added beneficial influence on youths substance use beyond the impact of skills intervention components alone. <sep>', 'there were two experimental conditions one group participated in a school-based intervention and were prompted to participate in a multi-media intervention and the other group had access to the multi-media intervention however they were not prompted to participate. <sep>', ""project sport participants demonstrated significant positive effects at 3-months postintervention for alcohol consumption alcohol initiation behaviors alcohol use risk and protective factors drug use behaviors and exercise habits and at 12-months for alcohol use risk and protective factors cigarette use and cigarette initiation p's  0.05). <sep>"", 'the smoking zine intervention provided cessation motivation for smokers most resistant to quitting at baseline and prevented nonsmoking adolescents from becoming heavy smokers at 6 months. <sep>', 'after 2 years of treatment smoking rates in the treatment group vs the control group were lower for 30-day 7-day and 24-hour smoking. <sep>', 'at follow-up the proportion of smokers had increased by 8.3 percentage points in group a control and by 1.9 percentage points in group b most extensive intervention). <sep>', 'relative to randomized matched controls adolescents whose parents engaged in the family check-up exhibited less growth in alcohol tobacco and marijuana use and problem behavior during ages 11 through 17 along with decreased risk for substance use diagnoses and police records of arrests by age 18. <sep>', 'relative reduction rates for alcohol initiation were 30.0 for the combined intervention and 4.1 for lst only. <sep>', 'for alcohol use no effect of intervention during childhood was found. <sep>', 'the school-based adolescent harm minimization intervention appears to have been more effective than the abstinence-based social influences programme at reducing regular smoking. <sep>', 'significant net changes in the favorable direction also were observed for total cholesterol/hdl cholesterol ratio and for thiocyanate. <sep>', 'findings showed that students in the intervention group were significantly less likely than were students in the control group to exhibit increases in cigarette smoking or bidi smoking over the 2-year study period. <sep>', 'the impact of yat is consistent with experimental and nonexperimental evaluations of media campaigns to influence young people not to smoke. <sep>', ""the two pedagogical methods that were used in the present study influenced the young people's attitudes towards tobacco use only to a small extent. <sep>""], 'population': ['eligible subjects n  3,028 had participated in a randomized trial of an elementary school smoking prevention curriculum <sep>', 'ten public schools which comprised 959 1st and 2nd-grade students 54 male students 18 minority 28 low socioeconomic status <sep> healthy children rhc <sep>', 'smoking with middle school subjects <sep>', 'southern california <sep>', 'elementary schools <sep>', 'schoolchildren <sep> 10-12 year old primary schoolchildren <sep> hunter region of new south wales australia using a sample of over 6000 children <sep>', 'children who were in their seventh year at school <sep>', '416 students aged 16-19 years old recruited in 12 london further education colleges without regard to substance use status <sep>', 'in a sample of predominantly minority students n  3,621 in 29 new york city schools <sep> minority adolescents <sep> predominantly white middle-class adolescent populations <sep>', 'classes of adolescents aged 11-12 years <sep> sample of adolescents <sep> adolescents <sep>', '678 urban predominately african-american public school students were randomly assigned to one of three grade 1 classrooms at entrance to primary school age 6 <sep> two primary school intervention strategies to prevent early onset tobacco smoking <sep>', 'two projects taught under normal classroom conditions <sep> 39 schools in wales and england matched for size and catchment profile <sep> all first year pupils in the schools were included and were assessed on three occasions 4538 before teaching 1988 3930 immediately after teaching 1989 3786 at one year follow up 1990 <sep> two school smoking education programmes under normal classroom conditions <sep>', 'all seventh-grade students in 24 schools in the academic year 1999-2000 n  6237 at baseline 67.3 were white and there was 84.0 retention at final follow-up <sep> 24 schools with 3 conditions d.a.r.e. only d.a.r.e. plus and delayed program control <sep>', 'school students n=2734 by project health educators and regular classroom teachers <sep> high schools in southern california n=18 <sep>', 'italian students <sep> males and females students <sep> adolescents <sep> 792 children of 12-13 years of age from the health district of rozzano mi were the study base <sep>', '566 pupils in grade 4 and grade 5 of two schools <sep> elementary school students in xuhui district shanghai <sep> elementary school students <sep>', 'twenty-three elementary schools <sep>', 'adolescents with lower education <sep> adolescents in lower education <sep> 26 dutch schools that provided junior secondary education <sep> 1444 students in the intervention and 1118 students in the control group all in the first grade average age 13 years <sep> students with lower education smoke <sep>', 'a cohort of adolescents in 22 public secondary schools in the hunter region of new south wales australia. pre-test surveys were completed by students in the first 2 years of secondary school with a 2-year post-test survey <sep> 1852 students who completed both surveys <sep> australian secondary schools <sep>', 'sixteen predominantly minority inner-city high schools <sep> high school students <sep> a total of 1160 students 1098 of whom were nonsmokers and 62 smokers at baseline were included <sep> culturally diverse high-school students <sep>', 'seven middle schools <sep> early adolescents <sep>', 'eight pairs of small oregon communities population 1700 to 13 500 <sep>', '17,320 students who completed a baseline survey <sep> students who were substance-free or who used substances at baseline <sep> students who used marijuana at baseline <sep> 19,529 seventh graders were enrolled in the 5-year study <sep> eighty-three school clusters representing school districts from six metropolitan areas <sep> adolescent substance abuse prevention study <sep> trained drug abuse resistance education <sep>', 'students n  442 <sep> students who received seven lessons on alcohol in grade six and eight lessons on tobacco alcohol marijuana and cocaine in grade seven taught by their regular classroom teachers after a 6-hour training in the social pressures resistance skills curriculum <sep>', 'elementary schools prepare children for secondary school <sep> in 2002 121 schools in the netherlands <sep> 3173 students completed the questionnaire 57 completed all questionnaires <sep> children in elementary school for secondary school <sep>', 'five thousand two hundred sixty-six students completed the baseline survey <sep> south african youth <sep> thirty-six public schools from two south african provinces kwazulu-natal and the western cape <sep> for black african students <sep> south african high school students <sep>', 'children in six school districts in westchester county new york <sep> childhood <sep>', 'minority youth <sep> urban minority girls <sep> early adolescent girls <sep> predominantly minority junior high school girls <sep> girls from 29 new york city public schools who received the program n  1,278 were compared to smoking rates in a control group of girls n  931 who did not <sep>', 'australian children using consider <sep> american children <sep> australia n  2,077 and the united states n  1,234 in schools containing grades 6 through 9 <sep> adolescents <sep>', 'fifty-two schools <sep>', 'adolescent cigarette smoking in guangzhou china <sep> 7th and 8th grade students n  2343 in four junior high schools in southern china during 2004-06 <sep> chinese adolescents <sep>', 'schools from 11 states were enrolled in 2 successive cohorts from 2004 to 2008 <sep> all public schools in the united states that included grades 6 through 8 and enrolled at least 100 students in sixth grade were recruited <sep> 40 schools that began the study 34 17 per condition completed it <sep> students were surveyed before the onset of the intervention as sixth graders and after the completion of the 2-year intervention as seventh graders <sep> 5883 unique participants <sep>', 'a total of 65 high schools from 14 school districts across the united states <sep>', 'junior high schools in los angeles and orange counties california <sep> adolescents <sep>', 'romanian adolescents <sep> twenty schools <sep> romanian junior high school students aged 13-14 years <sep>', '10 schools were randomly assigned to the intervention in 5th grade with follow-up boosters in 6th grade 13 schools <sep> elementary school students <sep>', 'baseline binge drinkers in sfa schools <sep> thirty-four schools n=7426 consented sixth graders 71 of the eligible population <sep> 5691 eighth graders 77 of those who completed the sixth-grade survey and 87 of those who completed the seventh-grade survey <sep>', '902 seventh graders from seven junior high schools in suburban new york over 2 years <sep>', 'students n  4,466 attending 56 schools in new york state <sep> students who received at least 60 of the prevention program n  3,684 <sep>', '10 730 students aged 12-13 years in 59 schools in england and wales <sep> 29 schools 5372 students <sep>', 'seven european countries participated in the study 170 schools 7079 pupils 12-14 years of age <sep>', 'after 1 year using school 22 middle/elementary schools 15 high schools <sep>', '1998 with 7th grade students in seven schools with seven matched control schools <sep> adolescents in urban wuhan china <sep> chinese adolescents <sep>', 'high school students <sep> 20 schools 10 intervention 10 control in south central louisiana <sep> the 9th grade cohort n  4,763 mean age  15.4 yrs 51 female 61 caucasian 30-day smoking prevalence at baseline  25 was followed over four years for 30-day smoking prevalence with the school as the unit of analysis <sep>', '36 schools in illinois <sep>', 'eighth ninth and tenth graders n  281 from two schools in suburban new york participated <sep>', 'black students in the district of columbia who were in grades 4-6 at baseline was begun in 1983 <sep> black schoolchildren <sep> 1,234 students were eligible for the screening in which the following target risk factors were measured <sep>', 'one hundred elementary schools were stratified by school risk score high risk  high smoking rate among senior students <sep>', 'six elementary schools in tijuana mexico were included in this prospective study with the participation of 168 sixth-graders <sep> mexican schoolchildren <sep>', '20 schools in hawaii with close to 4000 participating students were recruited <sep> 20 public schools in hawaii <sep> middle school students <sep> multi-ethnic cohort of youth in hawaii <sep>', '1097 students in 6 program and 6 control alternative high schools <sep>', 'adolescents substance <sep> two successive cohorts of alternative high schools <sep>', ""heidelberg children's panel study 1998 and 2000 a longitudinal sample of 1704 pupils was examined 948 in the intervention group and 756 in the control group <sep> young non-smokers from taking up smoking <sep> german pupils <sep>"", 'thai high school students <sep> thai high school students through life skills training <sep> 170 thai students in grades 7-12 were randomly selected <sep>', 'general population families of young adolescents <sep> thirty-three public schools <sep> 667 6th graders and their families <sep>', 'cigarette smoking among adolescents <sep> 689 adolescents <sep>', 'thirty schools in new delhi india <sep> adolescents <sep>', 'native american youth <sep> substance abuse among native american youth <sep> 1,396 third through fifth-grade native american students from 27 elementary schools in five states <sep>', 'new smokers within the adolescent population in a black community <sep> black students <sep>', 'a total of 604 participants 335 9th and 269 11th grade students from a suburban high school in northeast florida participated in this study <sep> participants randomly assigned within grade levels to receive either a <sep> adolescents using marijuana and/or cigarettes prior to intervention <sep> adolescents <sep> high school-aged adolescents <sep>', '1,402 male and female students in grades 9 through 11 from 14 secondary schools in toronto canada <sep> schools <sep>', 'adolescents living in a high tobacco production area <sep> students in 10 experimental schools completed the <sep> adolescents living in a tobacco-producing region <sep>', 'subgroups of adolescents <sep> 4441 students at 99 schools 195 classes <sep> pupils in norwegian secondary schools <sep>', 'adolescents whose parents engaged in the family check-up exhibited less growth in alcohol tobacco and marijuana use and problem behavior during ages 11 through 17 along with decreased risk for substance use diagnoses and police records of arrests by age 18 <sep> students ages 11-17 <sep>', 'thirty-six rural schools <sep>', 'tobacco and alcohol use from age 10 to 13 years was available for 477 children 72 of original sample <sep> second grade classrooms children aged 7 years <sep> childhood disruptive behavior problems on tobacco and alcohol initiation from age 10 to 13 years <sep>', '4000 students were recruited to participate and schools <sep> a school-based cluster randomized trial was conducted in perth western australia in 30 government high schools from 1999 to 2000 <sep>', 'chronic disease in childhood <sep> 1980 among children in 22 elementary schools in the bronx new york <sep>', 'young people in india <sep> 2 cohorts of 6th and 8th-grade students in 2004 14,063 students took part in the study and completed a survey in 2004 2005 or 2006 <sep> students from 32 schools in delhi and chennai india <sep> adolescents in an urban area of india <sep>', '40 middle schools with a prevalence of tobacco use at or above the oregon median <sep> adolescents <sep> middle school students of family <sep>', ""patients born in 1989 and 1992 who were judged by the dental personnel as potentially at risk for dental diseases a total of 301 individuals were included <sep> young people's attitudes towards tobacco use only to a small extent <sep> young people's attitudes toward tobacco use <sep>""], 'interventions': ['usual-care control condition <sep> high school smoking reduction intervention <sep> school tobacco control intervention <sep>', 'copyright 2005 apa <sep> intervention or control conditions <sep> rhc intervention <sep>', 'discussion-oriented intervention employing health education methods to prevent smoking <sep> placebo <sep> self-control skills intervention <sep> placebo <sep> placebo and test-only control <sep> self-control skills intervention covering self-instruction self-reinforcement problem solving and interpersonal communication <sep>', 'classroom training and tv programming <sep> treatment as usual and an attention control <sep>', 'parent training and provided child social skills training <sep>', 'smoking prevention programme <sep>', 'school-based educational programme <sep>', 'standard practice classroom-delivered drug awareness intervention <sep> motivational interviewing mi <sep> motivational interviewing <sep>', 'school-based drug abuse preventive intervention <sep>', 'implementation intentions <sep>', 'classroom-centered cc intervention <sep> school partnership fsp intervention <sep>', 'family smoking education project fse the smoking and me project sam both projects in sequence fse/sam or no intervention at all <sep> fse <sep>', 'additional components included a peer-led parental involvement classroom program called on the verge youth-led extracurricular activities community adult action teams and postcard mailings to parents <sep>', 'cognitive perception information curriculum cognitive perception information+behavioral skills curriculum or standard care control <sep>', 'smoking prevention program <sep>', 'school-based smoking prevention and control intervention program <sep>', 'protocol-driven instruction and students in the comparison schools received a drug education unit as part of the health curriculum <sep> drug abuse resistance education dare <sep> dare <sep> drug abuse resistance education project dare <sep>', 'antismoking intervention <sep>', 'health promoting schools program <sep> multicomponent health promoting schools hps intervention program <sep>', ""smoking prevention interactive experience aspire an interactive multimedia smoking prevention and cessation curriculum <sep> smoking prevention interactive experience aspire a theoretically sound computer-based smoking prevention and cessation curriculum <sep> aspire curriculum or standard care receipt of the national cancer institute's clearing the air self-help booklet <sep>"", 'school-based intervention <sep>', 'school based prevention programme or the school based programme plus a community programme <sep> community intervention <sep> comprehensive community wide programme <sep> media advocacy b youth anti-tobacco activities c family communications about tobacco use and d reduction of youth access to tobacco <sep>', 'universal school-based substance abuse prevention program take charge of your life tcyl <sep> universal substance abuse prevention program <sep>', 'school-based substance abuse prevention program <sep>', 'smoking prevention program <sep> usual care <sep>', 'usual tobacco use education <sep> standard health education program <sep> life skills training curriculum <sep> hm intervention <sep> harm minimization curriculum <sep> school-based smoking prevention <sep> school-based smoking prevention programs <sep>', 'curriculum focusing on nutrition physical fitness and cigarette smoking prevention <sep> coronary heart disease prevention <sep>', 'drug abuse prevention program <sep> school-based prevention intervention <sep>', 'internet-delivered smoking prevention program <sep>', 'social influence si program and a si program with an additional decision-making component si(dm <sep> social influence approach and boosters to smoking prevention <sep> si program the si(dm program or a control group <sep>', 'school-based prevention programme <sep>', 'manualized classroom-based substance use prevention curriculum <sep> project alert <sep>', 'regular workshop training comprehensive implementation support or standard care control <sep>', 'pressure resistance training <sep> experimental curricula placebo comparison b resistance skill training alone c normative education alone or d both resistance skill training and normative education <sep>', 'peer-led smoking prevention programme <sep> school-based smoking prevention programme <sep>', ""control condition implementing the school's pre-existing substance use prevention programming <sep> keepin <sep>"", 'standard care in deterring and delaying substance use through middle school <sep>', 'session psychosocial smoking prevention strategy <sep> regular classroom teachers and consisted of a cognitive component dealing with the immediate consequences of cigarette smoking a decision-making component a relaxation-training component a social skills training component and a self-improvement component <sep>', 'prevention program with formal provider training and implementation feedback b the prevention program with videotaped provider training and no feedback or c no treatment <sep> cognitive-behavioral approach to substance abuse prevention <sep> multimodal cognitive-behavioral approach <sep>', 'control group to continue their usual smoking education <sep> informal school-based peer-led intervention <sep> training influential students to act as peer supporters during informal interactions outside the classroom to encourage their peers not to smoke <sep>', 'program consisted in 12-hour class-based curriculum based on a comprehensive social-influence approach <sep> school-based drug abuse prevention program <sep>', 'social-influence prevention programs versus standard care <sep> school-based smoking prevention program <sep>', 'culturally specific smoking prevention programs <sep> school-based smoking prevention curriculum with a social normative approach <sep>', 'school-based environmental program <sep> school-based environmental intervention <sep>', 'dare <sep>', '10-session comprehensive psychosocial smoking prevention program <sep>', 'cardiovascular risk factor prevention <sep> know your body program <sep>', 'teacher/self-preparation 2 teacher/workshop 3 nurse/self-preparation 4 nurse/workshop and 5 control <sep> workshop training <sep> provider nurse or teacher and training method workshop or self-preparation <sep> social influences smoking prevention program <sep>', 'no intervention <sep> program emphasizing training <sep> program of smoking prevention <sep>', 'school-based smoking prevention intervention <sep>', 'classroom-based smoking prevention and cessation intervention program <sep> project ex-4 <sep>', 'intervention or control group yielding seven schools per condition <sep>', 'school-based campaign smoke-free class competition <sep> smoke-free class competition <sep>', 'tobacco and drug education curriculum normally provided the intervention group received a lst program that provided information and skills specifically related to drug and tobacco use <sep> school health intervention program using life skills training lst <sep> lst program <sep>', '5-session preparing for the drug free years program the 7-session iowa strengthening families program and a minimal contact control condition <sep>', 'skills intervention <sep> health information and skills intervention had lower intentions to smoke and less cigarette use than youths who received health information alone and youths who received no intervention <sep>', 'school-based and family-based intervention school-based intervention only or control group <sep>', 'intervention arms learned cognitive and behavioral skills <sep> skills intervention <sep>', 'school-based intervention <sep> program combined a school-based curriculum with a comprehensive media intervention <sep> comprehensive prevention program <sep>', 'multi-health behavior intervention integrating physical activity and alcohol use prevention messages <sep> brief consultation and prescription with a mailed reinforcing follow-up flyer project sport or a minimal intervention control consisting of a wellness brochure provided in school and a pamphlet about teen health and fitness mailed to the home <sep>', 'tailored web-assisted tobacco intervention or an interactive control condition task conducted during a single classroom session with e-mail follow-up <sep> smoking zine intervention provided cessation motivation <sep> smoking zine http://www.smokingzine.org integrated into a program that included a paper-based journal a small group form of motivational interviewing and tailored e-mails <sep> classroom-based web-assisted tobacco intervention addressing smoking prevention <sep>', 'tobacco prevention program and a booster intervention <sep> health education as usual <sep> social-influences tobacco prevention program <sep> tobacco prevention program <sep>', 'school-based smoking prevention program <sep>', 'family-centered intervention <sep> multilevel intervention that included a a universal classroom-based intervention <sep>', 'intervention combining family and school-based competency-training intervention components <sep> classroom-based life skills training lst and the strengthening families program <sep>', 'preventive intervention <sep> school based universal preventive intervention <sep>', 'school-based harm minimization smoking intervention <sep> harm minimization intervention or a standard abstinence-based programme <sep>', 'curriculum focusing on nutrition physical fitness and cigarette smoking prevention <sep>', 'behavioral classroom curricula school posters a parental involvement component and peer-led activism <sep>', 'communications fc activities designed to mobilize parental influences against tobacco use and youth anti-tobacco activities yat <sep> intervention or no intervention <sep> yat <sep>', 'behavioural interventions <sep> brief individual motivational interview and an adapted school lecture <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",pure prevention cohorts showed a significant effect at longest follow-up with an average 12 reduction in starting smoking compared to the control groups. however no overall effect was detected at one year or less. the combined social competence and social influences interventions showed a significant effect at one year and at longest follow-up. studies that deployed a social influences programme showed no overall effect at any time point multimodal interventions and those with an information-only approach were similarly ineffective. studies reporting change in smoking behaviour over time did not show an overall effect but at an intervention level there were positive findings for social competence and combined social competence and social influences interventions.
249,"{'outcomes': ['psychophysiologic health level <sep> mean scores on the nurse stress checklist nsc and the chinese general health questionnaire cghq <sep>', 'perceived stress scale pss and rathus assertiveness schedule ras <sep> levels of stress <sep>', 'anxiety measures <sep> work-related anxiety <sep>', 'burnout symptoms relaxation and life satisfaction <sep>'], 'punchline_text': ['the mean scores on the nurse stress checklist nsc and the chinese general health questionnaire cghq differed significantly between the experimental and control group in posttest 2 at week 5. <sep>', 'subjects were randomly assigned to one of two treatments assertiveness training at or alternate treatment control atc which served as a control and contained updated knowledge of new computer technology for in patient settings. <sep>', 'results suggested that stress management training was effective in reducing work-related anxiety among inexperienced nurses but not among experienced nurses. <sep>', 'in comparison with 14 wait-list control participants 16 participants in the mindfulness intervention experienced significant improvements in burnout symptoms relaxation and life satisfaction. <sep>'], 'population': ['chinese nurses working in modern hospitals in taiwan <sep> twenty-three subjects in the experimental group and 23 in the control group from each hospital participated in the study <sep> 137 subjects were selected randomly from three first-ranked teaching hospitals <sep> chinese nurses who are employed in large teaching hospitals in taiwan <sep> chinese registered nurses employed in large teaching hospitals to reduce their work stress in taiwan republic of china <sep>', '60 volunteer chinese-speaking nurses participated in the study <sep> stress and assertiveness experienced by nurses in taiwan republic of china <sep> professional nurses in taiwan <sep> nurses in taiwan republic of china <sep>', 'nurses working in a burn treatment unit <sep>', 'one such group-nurses and nurse aides <sep> nurses and nurse aides <sep>'], 'interventions': [""relaxation training based on smith's 1988 cognitive behavioral model of relaxation <sep> relaxation training combining imagery and meditation <sep> relaxation training <sep>"", 'atc <sep> assertiveness training at or alternate treatment control atc <sep> assertiveness training <sep>', 'stress management training <sep> individual training in cognitive behavioral stress management skills <sep>', 'mindfulness-based stress reduction intervention <sep> mindfulness-based stress reduction programs <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",there is insufficient evidence for the effectiveness of stress management training interventions to reduce job stress and prevent burnout among healthcare workers beyond the intervention period. low quality evidence suggests that longer-term interventions with refresher or booster sessions may have more sustained positive effect but this needs to be rigorously evaluated in further trials. low quality evidence exists to show that management interventions may improve some measures of job satisfaction. however further trials are needed to assess whether this finding is replicable in other settings. there was insufficient evidence of the benefit of management interventions on staff absenteeism. rigorous trials are needed to assess the effects of longer-term stress management training and management interventions in primary care and developing country settings.
250,"{'outcomes': ['active range of motion and surface emg potentials <sep>', 'knee and ankle minimum flexion angles <sep> velocity of gait cycle time and symmetry of stance phases <sep>', 'electromyographic activity <sep>', 'higher arm function scores <sep>', 'timed ambulation <sep> ankle active range of motion <sep> gains in knee and ankle joint angle measurements <sep>', 'orientation memory spatial performance language and iq <sep> mild emg severe emg mild control and severe control <sep> physical scores for active movement mobility and adl over time <sep> active movement muscle tone sensation proprioception mobility and activities of daily living adl <sep>', 'emg feedback and the restoration of motor control <sep>', 'muscle strength <sep>', 'recovery of functional locomotion <sep> adams scale <sep> basmajian scale <sep> recovery of foot-drop <sep> muscle strength <sep>'], 'punchline_text': ['the results showed that there were statistically significant improvements in all variables in both groups but the improvements in active range of motion and surface emg potentials were significantly greater in the emg biofeedback group at the end of the treatment. <sep>', 'combined therapy with bfb and fes resulted in improvements in both knee and ankle minimum flexion angles during swing phase that were statistically significant with p  0.05 and p  0.02 respectively. <sep>', 'electromyography through auditory and visual display was found effective in improving electromyographic activity but more limited in training effective function as measured by active range of motion. <sep>', 'patients with severe impairment were shown to benefit most from emg biofeedback <sep>', 'one patient in the experimental group who was given 12 additional training sessions showed further gains in knee and ankle joint angle measurements during walking. <sep>', 'scores on the psychological tests were within normal limits and there was no difference in performance between the emg and control groups. <sep>', 'the results indicated no significant differences between the two methods. <sep>', 'electromyographic biofeedback was compared with simple exercise therapy as to its effectiveness in improving foot-drop in 22 stroke patients. <sep>', 'electromyographic biofeedback patients showed significantly increased scores on the adams scale p  .05 and basmajian scale p  .01). <sep>'], 'population': ['27 patients <sep> hemiplegic patients <sep>', 'stroke rehabilitation <sep> thirty-six hemiplegic patients undergoing rehabilitation after stroke <sep> patients with hemiplegia after stroke <sep> thirty-two subjects completed the study <sep>', 'patients with hemiplegia <sep> neuromuscular retraining in hemiplegia <sep>', 'patients who had impaired arm function and were between 2 and 8 weeks after stroke <sep> patients with severe impairment <sep>', 'chronic hemiplegic patients <sep> hemiplegic patients <sep>', 'twenty-one patients were included in the study <sep> subjects were acute stroke patients who had been admitted on to the medical and elderly wards <sep> scunthorpe general hospital in north lincolnshire <sep>', '12 patients <sep> 12 hemiparetic patients <sep>', 'patients tested were aged and had stroke of long duration <sep> stroke patients <sep> 22 stroke patients <sep>', 'patients with hemiparesis and foot-drop after cerebral ischemia <sep> stroke patients <sep> sixteen patients with ischemic stroke <sep> foot-drop after stroke <sep>'], 'interventions': ['electromyographic emg biofeedback treatment <sep> placebo <sep> emg biofeedback or placebo emg biofeedback <sep> electromyographic biofeedback <sep> exercise program <sep> emg biofeedback <sep>', 'bfb and fes <sep> biofeedback and functional electric stimulation <sep> control fes bfb or combined therapies <sep> functional electric stimulation fes and biofeedback bfb <sep>', 'electromyographic feedback and physical therapy <sep> electromyographic feedback <sep> physical therapy <sep>', 'emg biofeedback <sep> electromyographic emg biofeedback <sep> emg biofeedback or a control treatment in addition to their routine physiotherapy <sep>', 'control standardized therapeutic exercise regimen and experimental therapeutic exercise regimen combined with electromyographic biofeedback <sep> electromyographic biofeedback <sep>', 'emg <sep> emg machine <sep> electromyographic emg biofeedback training <sep> electromyographic biofeedback for gait training <sep> emg biofeedback <sep> emg biofeedback or control groups <sep>', 'conventional physical therapy procedure ndt <sep>', 'electromyographic feedback <sep> simple exercise therapy <sep> electromyographic biofeedback <sep> similar therapy with emg feedback <sep> exercise therapy <sep>', 'electromyographic biofeedback treatment <sep> physical therapy <sep> electromyographic biofeedback treatment together with physical therapy <sep> electromyographic biofeedback <sep> electromyographic biofeedback <sep> rehabilitation of walking with electromyographic biofeedback <sep> electromyographic biofeedback technique <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",despite evidence from a small number of individual studies to suggest that emg-bfb plus standard physiotherapy produces improvements in motor power functional recovery and gait quality when compared to standard physiotherapy alone combination of all the identified studies did not find a treatment benefit. overall the results are limited because the trials were small generally poorly designed and utilised varying outcome measures.
251,"{'outcomes': ['impairments motor function grip strength gross and fine manual dexterity and motor co-ordination 2 arm disabilities in tasks related to daily activities and 3 functional independence in activities of daily living adl and instrumental adl iadl <sep>', 'reaction time <sep>', 'muscle activity <sep> electromyographic emg activity <sep>', 'motor control performance <sep> slower movement lower maximal movement velocity feedback control dominant and discontinuous movements <sep> active elbow range of motion <sep>', 'motor impairment scale <sep>', 'functional outcome <sep> changes in activation <sep> hemispheric activation <sep> fmri response <sep> activation in precentral p<.001 and postcentral gyri <sep> brain activation during elbow movement assessed by functional magnetic resonance imaging fmri and functional outcome assessed using arm function scores <sep>', 'fma <sep> online error correction <sep> kinematic analyses assessing motor control strategies for unilateral and bimanual reaching and clinical measures involving the fugl-meyer assessment fma of motor-impairment severity and the functional independence measure fim and the motor activity log mal evaluating functional ability <sep> motor impairment <sep> temporal and spatial efficiency <sep> motor control and functional performance <sep> motor control and motor function <sep>', 'functional task 2 chronometric reaction times to initiate movements and 3 sustained muscle contraction capability <sep> chronic hemiparesis <sep>', 'functional gains <sep> proximal ul motor impairment <sep> distal part score of the fma <sep> motor performance daily functions and quality of life <sep> fugl-meyer assessment fma functional independence measure fim motor activity log mal and stroke impact scale sis <sep> motor performance daily function functional use of the affected arm and quality of life <sep>', 'electromyogram emg activation levels <sep> voluntary emg activation levels <sep> emg activation levels <sep> higher muscle activation levels <sep> motor capabilities <sep>', 'movement time of the impaired limb and increased upper limb functional ability <sep> upper limb function <sep>', 'modified barthel index hospital anxiety and depression scale and nottingham health profile <sep> arat pinch section <sep> action research arm test arat rivermead motor assessment upper-limb scale and nine-hole peg test 9hpt <sep>', 'bilateral symmetrical activities <sep> mss and measures of strength <sep> motor assessment scale mas motor status scale mss and muscle strength <sep> upper arm function scale <sep>', 'motor reaction time peripheral component and 4 faster total reaction time <sep>', 'total movement time <sep> positive intralimb transfer <sep> movement time higher peak limb velocity <sep>'], 'punchline_text': ['an arm training programme based on repetition of unilateral and symmetrical bilateral practice did not reduce impairment and disabilities nor improve functional outcomes in the subacute phase after stroke more than the usual therapy. <sep>', 'this work was designed to study the effects of bilateral elbow flexion on the reaction and movement times of the impaired upper extremity of patients with hemiparesis. <sep>', 'small increases in muscle activity were demonstrated by both experimental and control subjects during most bilateral practices in both actions. <sep>', 'patients with moderate upper extremity motor impairment performed more discontinuous movements and less active elbow range of motion during bilateral reaching tasks however those with mild upper extremity motor impairment performed smoother movements and demonstrated greater active elbow range of motion during bilateral reaching tasks. <sep>', 'combined unilateral and bilateral training yielded functional gains that were similar to the gains from equivalent doses of unilateral-only robotic training although the combined group had more hypertonia and less movement out of synergy at baseline. <sep>', 'changes in activation were observed in the contralesional cerebrum and ipsilesional cerebellum p  .009). <sep>', 'the bat group showed a significantly greater improvement in the fma than the control group but not in the fim and mal. <sep>', 'significant findings for the 1 number of blocks moved in a functional task 2 chronometric reaction times to initiate movements and 3 sustained muscle contraction capability all favored the coupled bilateral movement training and emg-triggered neuromuscular stimulation protocol group. <sep>', 'enhanced performance was found for the distributed cit group in the mal the subtest of locomotion in the fim and certain domains of the sis eg adl/iadl). <sep>', 'this robust analysis revealed higher emg activation levels for the coupled bilateral movement/stimulation group than the unilateral movement/stimulation group. <sep>', 'individuals receiving bilateral training showed a reduction in movement time of the impaired limb and increased upper limb functional ability compared to individuals receiving unilateral training. <sep>', 'baseline severity significantly influenced improvement in all upper-limb outcomes p<.05 but this was irrespective of the treatment group. <sep>', 'the bilateral group had significantly greater improvement on the upper arm function scale a subscale of the mas-upper limb items). <sep>', 'the analyses revealed distinct cumulative treatment evidence later in training in comparison to the baseline motor capabilities 1 higher number of blocks moved 2 higher percentage of blocks moved by the impaired hand 3 faster motor reaction time peripheral component and 4 faster total reaction time. <sep>', 'during the posttest the coupled bilateral group displayed improved movement time higher peak limb velocity less variability in peak velocity and less percentage of total movement time in the deceleration phase than during the pretest. <sep>'], 'population': ['arm during the subacute phase after stroke <sep> forty-one people who had had a stroke in the subacute phase receiving conventional arm occupational and physical therapy <sep> people in the subacute phase after stroke <sep>', 'patients with hemiparesis <sep> patients with hemiparesis for unilateral and bilateral elbow flexion <sep> patients with hemiparesis n  25 and a control group of age-matched healthy volunteers n  26 <sep>', 'subjects with acute and chronic problems with one and two bilateral practice phases <sep>', 'twenty unilateral stroke patients were recruited <sep> patients with moderate upper extremity motor impairment <sep>', 'subacute stroke subjects <sep> subacute stroke patients <sep>', 'patients who have chronic motor impairment following stroke <sep> 21 patients median iqr 50.3 34.8-77.3 months after unilateral stroke <sep> chronic stroke <sep>', 'patients with chronic stroke. <sep> 33 stroke patients mean age  53.85 years 6 to 67 months after onset of a first stroke <sep> chronic stroke <sep>', 'twenty-five cva subjects volunteered to participate in this motor recovery protocol study <sep>', '60 patients <sep> stroke survivors <sep> patients with hemiparetic stroke <sep> subjects with mild to moderate chronic hemiparesis <sep>', 'chronic cerebrovascular accident individuals with partial paralysis <sep> stroke subjects voluntarily initiated their impaired wrist and finger extensor muscles <sep> twenty subjects <sep>', 'individuals receiving <sep> chronic stroke patients <sep> twelve chronic stroke patients <sep>', 'early poststroke rehabilitation <sep>', 'upper extremity hemiparesis in stroke <sep> individuals with moderate upper limb hemiparesis <sep> chronic stroke survivors with moderate upper extremity impairment <sep>', 'sixteen chronic stroke subjects <sep>', 'twenty-six volunteers completed one of three motor recovery protocols according to group assignments 1 <sep>'], 'interventions': ['unilateral and symmetrical bilateral task training <sep> additional usual arm therapy <sep> training programme combining repetition of unilateral and symmetrical bilateral tasks <sep>', 'bilateral elbow flexion <sep>', 'bilateral training <sep>', 'discontinuous movements and less active elbow range of motion during bilateral reaching tasks <sep>', 'robot-assisted treatment bilateral unilateral and combined bilateral and unilateral <sep> mime robotic device <sep> mirror image movement enabler mime robotic device <sep> combined unilateral and bilateral training <sep> conventional therapy <sep>', 'bilateral arm training with rhythmic auditory cueing batrac n  9 or standardized dose-matched therapeutic exercises dmte <sep> repetitive bilateral arm training and motor cortex activation <sep> specific rehabilitation therapy <sep>', 'bat program concentrating on both upper extremities moving simultaneously in functional tasks by symmetric patterns or ci control treatment <sep> bat <sep> bat with control intervention ci <sep> bilateral arm training <sep> bilateral arm training bat <sep>', 'coupled protocol of emg-triggered stimulation and bilateral movement n=10 2 emg-triggered stimulation and unilateral movement n=10 or 3 control <sep> electromyogram emg)-triggered neuromuscular stimulation and bilateral coordination training <sep>', 'constraint-induced therapy versus bilateral arm training <sep> distributed cit bat or a control intervention of less specific but active therapy <sep> distributed constraint-induced therapy cit and bilateral arm training bat <sep> bat <sep> intensive training <sep>', 'active neuromuscular stimulation <sep> unilateral movement/stimulation group or a bilateral movement/stimulation group <sep>', 'transcranial magnetic stimulation tms <sep> bilateral movement training <sep> bilateral and unilateral movement training <sep> bilateral training <sep> dowel placement task performed either with both impaired and unimpaired arm moving synchronously bilateral training group or with only the impaired arm moving unilateral training <sep>', 'bilateral task training with unilateral task training <sep> bilateral training n=56 or unilateral training <sep> bilateral training <sep> supervised bilateral or unilateral training <sep> bilateral and unilateral upper-limb task training <sep>', 'bilateral training with unilateral training <sep> bilateral training <sep> 2 groups bilateral training vs unilateral training <sep> bilateral and unilateral training <sep> bilateral training <sep>', 'emg-triggered neuromuscular stimulation and coupled bilateral movements <sep>', 'transverse plane target aiming movements 29 cm with vision available <sep> coupled bilateral involved concurrent wrist/finger movements on the unimpaired limb coupled with active stimulation on the impaired limb 2 unilateral/active stimulation involved neuromuscular electromyogram-triggered stimulation on the impaired wrist/fingers and 3 no protocol control group <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is insufficient good quality evidence to make recommendations about the relative effect of simultaneous bilateral training compared to placebo no intervention or usual care. we identified evidence that suggests that bilateral training may be no more or less effective than usual care or other upper limb interventions for performance in adl functional movement of the upper limb or motor impairment outcomes.
252,"{'outcomes': ['neuroleptic-induced akathisia <sep> akathisia <sep>'], 'punchline_text': ['neither propranolol nor placebo treated patients showed a significant improvement in akathisia. <sep>'], 'population': ['eleven schizophrenic patients <sep>'], 'interventions': ['propranolol <sep> placebo <sep> propranolol <sep>'], 'punchline_effect': [' no diff <sep>']}",there are insufficient data to recommend beta-blocking drugs for akathisia. these drugs are experimental for this problem and this review highlights the need for more evaluative studies.
253,"{'outcomes': ['overdose mortality <sep>', 'rates of opioid-positive urine samples <sep> illicit opioid use <sep> detoxification <sep>', 'retention rate <sep>', 'rates of abstinence from illicit opioids <sep> prognostic factors <sep> lifetime sedative dependence <sep> rates of abstinence from illicit opioids <sep> rates of cocaine abstinence <sep> rates of cocaine-positive urine samples <sep>', 'abstinence orientation scale <sep>', 'objective and subjective measures of efficacy urine toxicology retention craving and withdrawal symptoms <sep> retention opioid use and opioid craving <sep>', 'retention rate <sep>', 'percentage of opiate-negative urine specimens <sep> duration of sustained abstinence <sep> opiate-negative urine specimens thrice weekly urinalysis <sep> abstinence reinforcement <sep> reduced self-reported frequency of use and self-reported craving <sep>', 'safety <sep> relative efficacy <sep> illicit drug use program retention and attendance and global staff judgments <sep>', 'cocaine-positive urine samples <sep> rate of opioid-positive urine samples <sep>', 'percentage of urine samples negative for opioids <sep> retention time <sep> retention rates <sep>', 'retention rate <sep>'], 'punchline_text': ['compared to idu not in maintenance the adjusted relative risk for overdose mortality among those receiving 5-50 mg 55-70 mg and 75 mg were 0.35 0.13 and 0.11 respectively p  .05). <sep>', 'through day 210 no significant difference was evident between dose groups in treatment retention high-dose group mean retention 159 days moderate-dose group mean retention 157 days). <sep>', 'dropouts were more likely among patients who enrolled in the first rh 6.2 95 ci 2.3-16.7 and second rh 1.9 95 ci 0.6-5.6 years of the programme compared with subsequent years rh 1.0). <sep>', 'rates of abstinence from illicit opioids were significantly higher for females within the buprenorphine 4-mg group females also had significantly better retention lower rates of opioid-positive urine samples and higher rates of abstinence from illicit opioids. <sep>', 'the influence of program orientation on retention was greater the higher the maximum dose of methadone. <sep>', 'patients assigned to high-dose methadone maintenance performed significantly better on measures of retention opioid use and opioid craving than either the low-dose methadone or the buprenorphine group at both 26-week and 52-week time points. <sep>', 'in 370 opioid-dependent patients included consecutively in a low-threshold methadone maintenance program the effect of different variables on the retention rate was assessed. <sep>', 'contingent vouchers and a methadone dose increase each significantly increased the percentage of opiate-negative urine specimens during intervention. <sep>', 'relative efficacy was evaluated by illicit drug use program retention and attendance and global staff judgments. <sep>', 'only the 50-mg treatment group had a reduced rate of opioid-positive urine samples 56.4 versus 67.6 and 73.6 for the 20-mg and 0-mg groups respectively p  0.05 and cocaine-positive urine samples 52.6 versus 62.4 and 67.1 for the 20 and 0-mg groups respectively p  0.05). <sep>', 'for the entire 25 weeks retention rates for buprenorphine 30 p less than .01 and methadone 60 mg <sep>', 'patients taking  or  60 mg/day and 30-59 mg/day were respectively 70 and 50 more likely to remain in treatment than those receiving a  30 mg daily dose. <sep>'], 'population': ['498 dutch injecting drug users idu provided 1,969 person years of follow-up 1989-1995 <sep> low-threshold maintenance programs <sep>', 'outpatient substance abuse treatment research clinic at the johns hopkins university bayview campus baltimore md <sep> june 1992 and ending in october 1995 <sep> opioid dependence <sep> 40 to 50 mg n  97 or 80 to 100 mg n  95 with concurrent substance abuse counseling <sep> one hundred ninety-two eligible clinic patients <sep>', 'all patients who initiated treatment between february 1991 and january 1995 <sep> patients who have a long history of drug use and who have a stable income were more likely to stay in methadone maintenance treatment <sep> patient retention in a newly established methadone maintenance treatment programme <sep> 111 patients contributed 164.4 person-years of follow-up <sep>', 'maintained patients <sep> eighty male and 36 female patients <sep>', 'two hundred and eighty patients recently enrolled in single-person private methadone programs were interviewed and followed for 8 years <sep>', 'two hundred twenty-five treatment-seeking opioid addicts 46 women 179 men <sep> opioid dependence <sep>', 'patients age sex family situation employment status length of heroin use current route of drug consumption previous treatments current consumption of cocaine alcohol and benzodiazepines needle sharing hiv serostatus and methadone dose <sep> 370 opioid-dependent patients included consecutively in a low-threshold methadone maintenance program <sep>', 'patients enrolled in a methadone-maintainence program who continued to use heroin abstinence reinforcement and a <sep>', '430 street heroin addicts from 12 veterans administration hospitals <sep> 142 patients receiving <sep> heroin addicts <sep> 146 patients receiving <sep>', 'participants n  247 were opioid-dependent patients with a high rate of cocaine use <sep> opioid dependence <sep>', 'one hundred sixty-two volunteers seeking treatment for opioid dependence <sep> opioid dependence <sep>', 'heroin users in italy <sep> 1503 heroin users attending public treatment centres in 1995 was studied <sep>'], 'interventions': ['low-threshold methadone maintenance <sep> methadone <sep>', 'methadone hydrochloride <sep> moderate vs high-dose methadone <sep> daily oral methadone hydrochloride <sep> methadone <sep> moderate vs high-dose methadone <sep>', 'methadone <sep> methadone <sep>', 'buprenorphine <sep> methadone <sep> oral methadone <sep> buprenorphine <sep> daily sublingual buprenorphine <sep>', 'methadone <sep>', 'buprenorphine maintenance <sep> buprenorphine <sep> methadone <sep> buprenorphine <sep> buprenorphine 30 mg/d of methadone or 80 mg/d of methadone maintenance <sep> methadone maintenance <sep> long-term fixed-dose buprenorphine <sep>', 'methadone <sep>', '4 interventions 1 contingent vouchers for opiate-negative urine specimens <sep> daily methadone hydrochloride maintenance <sep> methadone hydrochloride <sep> methadone <sep> combined contingent vouchers and methadone <sep> methadone maintenance <sep> methadone <sep>', 'methadyl acetate and methadone <sep> methadyl acetate <sep> methadone hydrochloride <sep> methyadyl acetate and high-dose methadone <sep> low-dose methadone <sep>', 'placebo <sep> individual counseling and group therapy <sep> active methadone <sep> methadone <sep>', 'buprenorphine <sep> buprenorphine 8 mg/d methadone <sep> buprenorphine <sep> methadone <sep>', 'methadone maintenance drug-free program and naltrexone <sep> naltrexone <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",methadone dosages ranging from 60 to 100 mg/day are more effective than lower dosages in retaining patients and in reducing use of heroin and cocaine during treatment. to find the optimal dose is a clinical ability but clinician must consider these conclusions in treatment strategies.
254,"{'outcomes': ['gynecological examination the level of beta-hcg and ultrasonography <sep> success rate complete abortion <sep> efficacy or side effects <sep> intrauterine pregnancy and gestational age <sep> tolerance and efficacy <sep> blood samples for blood group hemoglobin beta-chorion-gonadotrophin aspartate-aminotransferase and creatinine <sep>', 'complete abortion rates <sep>', 'timing of expulsions and duration of bleeding <sep> efficacy <sep> amenorrhoea length <sep> complete abortion <sep> risk of failure of complete abortion <sep> duration of bleeding <sep> side effects timing of expulsion and duration of bleeding <sep> crude complete abortion rate <sep>', 'serious adverse events <sep> complete medical abortion rates <sep> cramping and nausea <sep> blood transfusions <sep>', 'shivering <sep> experience diarrhoea <sep> unpleasant mouth taste <sep> satisfaction <sep> need for surgical evacuation <sep>', 'nausea vomiting or diarrhoea <sep> complete abortions <sep>', 'efficacy and side-effects <sep> rate of complete abortion <sep> duration and amount of bleeding <sep> incidence of side-effects such as diarrhoea <sep> vomiting <sep> rate of complete abortion and the side-effects <sep>', 'complete abortion <sep> complete abortion rate <sep> days of bleeding <sep> number of women who passed the fetus within 4 h of receiving the prostaglandin <sep>', 'success rate determined by the number of women who aborted without surgery <sep> success rates <sep> success rate <sep> side effects <sep> incomplete abortions with symptoms requiring a surgical aspiration <sep>', 'overall successful termination rate <sep>', 'side effects such as vomiting and fall in haemoglobin as well as the need for emergency curettage and blood transfusion <sep> side effects <sep> relative risk of failure <sep> success rate <sep>', 'pain <sep> successful abortion without surgery <sep> efficacy adverse effects and acceptability <sep> efficacy and adverse effects <sep>', 'complete abortion without surgical intervention <sep> rate of continuing pregnancies <sep> rate of complete abortion <sep> rate of continuing pregnancy <sep> complete abortion rate <sep> efficacy of medical termination of pregnancy <sep>', 'complete abortion <sep> blood transfusion <sep> side effects <sep> mean duration of uterine bleeding <sep> incidence of complete abortion hemoglobin levels duration of vaginal bleeding and incidence of side effects <sep>', 'failure to complete abortion <sep> rate of complete abortion <sep> efficacy outcome <sep> adverse effects <sep>', 'efficacy of treatment to achieve complete abortion and to terminate pregnancy <sep> efficacy outcomes <sep> complete abortion <sep> complete abortion rates <sep>', 'complete abortion <sep> rates for complete abortion incomplete abortion and treatment failure <sep> detectable fetal heart activity <sep> efficacy and side-effects <sep>', 'abortion success <sep> successful medical abortions <sep> success rate of complete abortion <sep>', 'vaginal bleeding <sep> nausea and/or vomiting <sep> complete abortion <sep> complete abortion <sep> measured blood loss <sep> onset of crampy abdominal pain <sep> vaginal bleeding followed by complete abortion <sep> mean duration range of vaginal bleeding <sep>', 'complete abortion <sep> human chorionic gonadotropin-beta level <sep> vaginal bleeding <sep> surgical termination <sep> successful abortions <sep>', 'fever or chills <sep> side effects <sep> complete abortion <sep> abortion status <sep>', 'vomiting and diarrhea <sep> expulsion of the conceptus without the need for a surgical procedure <sep> expulsion of the conceptus without the need for a surgical procedure and abortion <sep> rate of continued pregnancy <sep> abortions <sep>', 'risk of failure to abort <sep> complete abortion <sep> likelihood of complete abortion <sep> complete abortion rate <sep> percentage of women with continuing pregnancies <sep> frequency of side effects <sep>', 'overall ongoing pregnancy rate <sep> incidence of diarrhoea <sep> overall success rate <sep> pregnancy rate <sep> blood pressure <sep> troubled by diarrhoea <sep> diastolic pressure <sep> gastrointestinal side effects <sep> complete abortion rates the frequency and severity patients perception of gastrointestinal side effects and blood pressure changes <sep>', 'median amount <sep> actual blood loss <sep> vaginal bleeding <sep> incidence of diarrhoea <sep> complete abortion rate <sep> prolonged vaginal bleeding <sep> duration and amount of vaginal bleeding <sep>', 'serum levels <sep> clearance rates <sep> complete abortion <sep> methotrexate clearance rates <sep> maximum concentration of methotrexate and the area under the curve <sep> methotrexate levels <sep>', 'median duration of vaginal bleeding <sep> fever chills and gastrointestinal side-effects nausea vomiting and diarrhoea <sep> complete abortion <sep> complete abortion rate <sep> serious complication <sep>', 'bleeding duration <sep> complete abortion rate <sep> side effects <sep>', 'side effects <sep> complete abortions <sep> suction aspiration <sep> overall complete abortion without surgical intervention <sep>', 'nausea diarrhea and warmth or chills <sep> abortion rates <sep> complete abortion rate <sep> efficacy adverse effects and acceptability <sep> adverse effects <sep>', 'vaginal bleeding <sep> complete abortion <sep> diarrhea <sep> beta-hcg level <sep> nausea and vomiting <sep> incomplete abortion <sep> successful abortion duration of vaginal bleeding side effects and change in beta-human chorionic gonadotropin beta-hcg level <sep> safety and efficacy <sep>', 'pain and subject acceptability <sep> nausea vomiting and heavy bleeding <sep> side effects <sep> complete abortion rates <sep> side effects <sep>', ""surgical abortion <sep> pain <sep> pregnancy-related symptoms nausea vomiting breast tenderness fatigue dizziness headache drug-related side effects diarrhoea fever rash and blood pressure change side effects related to the abortion process lower abdominal pain and women's perceptions of the method <sep> lower abdominal pain <sep> pregnancy-related symptoms <sep> nausea vomiting and diarrhoea <sep> fever <sep> nausea and vomiting <sep> diarrhoea <sep> side effects <sep>"", 'continued pregnancy <sep> rates of complete abortion <sep> incidence of side-effects such as vomiting nausea headache diarrhea and lower abdominal pain <sep> successful abortion <sep> incomplete abortion <sep> duration and amount of vaginal bleeding <sep>', 'efficacy <sep> tolerated <sep> bleeding necessitating a blood transfusion no serious side effects <sep>', 'complete abortion <sep> vaginal bleeding <sep> complete abortion rate <sep> incomplete abortion rate <sep> mean gestational age of the successful abortions <sep>', 'vaginal bleeding <sep> pregnancy <sep> complete abortion <sep>', 'pregnancy advanced <sep> satisfaction and acceptability <sep> success rates <sep> efficacy safety and acceptability <sep> fever and chills <sep> ongoing pregnancy <sep>', 'time elapsed between ru 486 intake and expulsion of the conceptus <sep> heavy bleeding necessitating emergency curettage <sep> nausea/vomiting and headache/dizziness <sep> complete abortion <sep> shorter bleeding time and a lower volume of blood loss <sep>', 'side-effects and number of complete abortions <sep> number requesting opiate <sep> rate of complete abortion <sep> nausea and vomiting <sep>', 'uterine sensitivity <sep> complete abortion <sep> rate of complete abortion <sep> longer duration of induced bleeding <sep> uterine contractility <sep> incomplete abortions <sep>', 'cortisol <sep> pregnancy outcome time of onset and duration of vaginal bleeding subjective complaints and hormone changes <sep> frequency of complaints bleeding patterns and changes in hemoglobin beta-human chorionic gonadotropin estradiol and progesterone <sep> overall complete abortion rate <sep> prolactin <sep>', 'complete abortion without surgical intervention <sep> efficacy rate <sep> nausea <sep>', 'severe pain <sep> complete abortion <sep>', 'success rates <sep> complete abortion <sep> total bleeding 11.2 <sep> vaginal bleeding <sep> pain <sep> successful abortion complete abortion without requiring a surgical procedure and side effects <sep> safety and efficacy <sep> side effects <sep>', 'incidence of diarrhoea <sep> lower abdominal pain <sep> treatment failures <sep> vomiting <sep> complete abortion rate <sep> efficacy and side effects <sep> incomplete abortion <sep>', 'number of women who had aborted by day 8 side effects and acceptability <sep> overall acceptability and route acceptability <sep> side effects and acceptability <sep> side effects <sep>', 'rates of success side effects or acceptability <sep> effectiveness side effects and acceptability <sep> side effects and acceptability <sep> success rate <sep>', 'side effects <sep> complete medical abortion by the first or by the second follow-up visits <sep> complete abortion rate <sep> early medical abortion <sep>'], 'punchline_text': ['there was no difference in efficacy or side effects whether the prostaglandin was administered 24 or 48 hours after mifepristone intake which suggests that the treatment period can be reduced from the conventional 48 hours. <sep>', 'five of the seven regimens resulted in complete abortion rates of 60 or less. <sep>', 'for amenorrhoea length  or 57 days vaginal misoprostol is more effective than oral when continued with 0.4 mg oral misoprostol twice daily for seven days. <sep>', 'cramping and nausea were the most common adverse effects reported with similar percentages of patients in all 3 groups reporting such effects. <sep>', 'women receiving misoprostol sublingually were more likely to experience diarrhoea p  0.01 shivering p  0.01 and unpleasant mouth taste p  0.01). <sep>', 'nausea vomiting or diarrhoea in women using the standard regimen group 2 occurred in 68 36 and 20 respectively. <sep>', 'the rate of complete abortion was very high 95 in both groups but significantly higher after treatment with misoprostol than with gemeprost 436/453 98.7 versus 451/457 96.2 p  0.019 difference 2.5 confidence interval 0.4-4.7 and there were fewer ongoing pregnancies n  1 versus n  8 p  0.018). <sep>', 'however the complete abortion rate was significantly higher in women  or  49 days compared to women 50-63 days amenorrhoea 97.5 versus 89.1 respectively p  0.02). <sep>', 'in phase 1 the success rate was higher in the methotrexate group 93.0 compared to the tamoxifen group 85.7 p  0.045). <sep>', 'repeat administration of misoprostol or surgical treatment was required in 23 women 11 in the 6-hour group and 8 women 4 in the 36 to 48-hour group. <sep>', 'the relative risk of failure to have a complete abortion with the lower dose of mifepristone was 1.6 95 ci 1.1-2.3 times that with the higher dose. <sep>', 'efficacy and adverse effects did not differ significantly across the three study groups. <sep>', 'while an additional oral dose of 400 microgram misoprostol did not significantly increase the rate of complete abortion without surgical intervention the additional dose did significantly reduce the rate of continuing pregnancies without compromising the acceptability and ease of use of the method. <sep>', 'there were no differences in either group between earlier 49 days and later 50-56 days gestations. <sep>', 'equivalence was also evident for the two intervals of administration the rate of complete abortion was 93.5 for 24-hour interval and 91.7 for the 48-hour interval difference 1.8 95 ci 4.0 to 0.5). <sep>', 'complete abortion rates at 2-week follow-up were recorded for 431 84 in the sublingual and for 434 85 women in the vaginal group when misoprostol was given at 3-h intervals difference 0.4 95 ci 4.0 to 4.9 p=0.85 equivalence shown and for 399 78 in the sublingual and for 425 83 in the vaginal 12-h groups 4.6 0.2 to 9.5 p=0.06 equivalence not shown). <sep>', 'only three of the six women with treatment failure still had detectable fetal heart activity when the pregnancy was terminated by vacuum aspiration two weeks after the start of treatment. <sep>', 'a regimen of mifepristone and misoprostol was significantly more effective for termination of pregnancies  or  56 days than misoprostol alone. <sep>', 'vaginal bleeding followed by complete abortion occurred in 18 of 19 women who received ru486  1 mg pg pessary as compared to only 12 of 20 women who received ru486 alone p less than 0.01). <sep>', 'treatment failures in group 1 were four continuing pregnancies 9 two incomplete abortions 4 and two women who requested surgical termination after receiving both medications 4%). <sep>', 'complete abortion occurred in 98.7 of the sublingual group and 94.0 of the oral group p value=.006 rr 1.05 95 ci=1.01--1.09). <sep>', 'vomiting and diarrhea were reported more frequently by the women who received oral misoprostol than by those who received vaginal misoprostol p  0.04 and p  0.002 respectively). <sep>', 'the efficacy of the mifepristone-prostaglandin regimen was not reduced by decreasing the dose of mifepristone from 600 mg to 200 mg. <sep>', 'the incidence of diarrhoea was significantly lower for women receiving the sequential dose and no significant differences were found in the incidence of the other gastrointestinal side effects. <sep>', 'the incidence of diarrhoea was significantly higher 66 55.1 and 12.5 respectively in the groups with oral misoprostol after abortion. <sep>', 'methotrexate levels peaked within 1 to 2 hours and were nondetectable within 48 hours in all patients in group 1 and 72 hours in group 2. <sep>', 'fever chills and gastrointestinal side-effects nausea vomiting and diarrhoea were significantly more common in the sublingual group. <sep>', 'there was no difference of side effects between the two groups. <sep>', 'side effects occurred with similar frequency in both treatment groups. <sep>', 'mifepristone and oral misoprostol are typically used for medical abortion in women up to 49 days of gestation with a 36 to 48-hour interval between the medications. <sep>', 'complete abortion occurred in 28 90 of 31 patients in group 1 and 14 47 of 30 patients in group 2 p  .001). <sep>', 'complete abortion rates for groups 1 and 2 were 503 of 525 95.8 95 confidence interval 93.7 97.3 and 521 of 531 98.1 95 confidence interval 96.6 99.1 respectively which were statistically equivalent. <sep>', 'oral administration of misoprostol was associated with a higher frequency of nausea and vomiting than vaginal administration at 1 hour after administration. <sep>', 'the incidence of side-effects such as vomiting nausea headache diarrhea and lower abdominal pain was similar in the two groups. <sep>', 'in each treatment group women who subsequently aborted completely had significantly lower pretreatment levels of hcg than women with incomplete abortion or continuing pregnancy. <sep>', 'the complete abortion rate in group 3 was significantly higher than that of both group 1 and group 2 p  0.05). <sep>', 'intramuscular methotrexate followed by vaginal misoprostol has been shown to be effective for abortion at  or  49 days gestation. <sep>', 'success rates in the oral and buccal groups were 91.3 389 of 426 and 96.2 405 of 421 respectively p=.003 relative risk rr 0.95 95 confidence interval ci 0.92-0.98). <sep>', 'the time elapsed between ru 486 intake and expulsion of the conceptus was significantly shorter in the ru 486+pg group n  97 31 days than that in the ru 486 alone group n  95 4.4 4.4 days). <sep>', 'there was no significant difference in the rate of complete abortion between group <sep>', 'women with complete abortions had significantly lower pretreatment levels of progesterone and a longer duration of induced bleeding than those who did not abort. <sep>', 'cortisol at 12 and 36 hours after mifepristone and prolactin at 12 hours were significantly higher in the single 600-mg dose group. <sep>', 'nausea was the most commonly reported side effect affecting 70 in the buccal group and 62 in the vaginal group. <sep>', 'there were few gastro-intestinal side effects following prostaglandin. <sep>', 'no significant statistical differences were found in the success rates when misoprostol was given days 3 4 or 5 after the administration of methotrexate p  0.69). <sep>', 'the incidence of diarrhoea in pg05 group 38.7 was significantly higher than that in the other two groups 21.6 and 20.1 p  0.001 and so was vomiting. <sep>', 'overall acceptability and route acceptability were similar in the two groups. <sep>', 'there were no differences in rates of success side effects or acceptability between groups receiving oral and injected methotrexate. <sep>', 'surgical intervention was indicated for continuing pregnancy at the second follow-up visit excessive bleeding or persistent products of conception 5 weeks later. <sep>'], 'population': ['sixty-four healthy women applying for abortion within the first 8 weeks of pregnancy <sep>', 'women up to 56 days of gestation in order to potentially identify an optimal regimen <sep> women requesting early abortion <sep> early abortion <sep>', 'early medical abortion <sep> 2219 healthy pregnant women requesting medical abortion with  or 63 days of amenorrhoea <sep> fifteen gynaecological clinics in 11 countries <sep>', 'patients with continuing pregnancy excessive bleeding or retained pregnancy tissue 5 weeks later received an <sep> 2295 healthy patients aged 18 years or older who were 56 or fewer days pregnant <sep> fifty-five subjects aborted before taking misoprostol 9 had early surgery and 103 did not take <sep> march 1998 to june 1999 <sep> early medical abortion <sep>', 'women undergoing medical abortion under the terms of the 1967 abortion act <sep> medical abortion up to 13 weeks of gestation <sep> a total of 340 women were recruited 171 sublingual and 169 vaginal <sep>', 'women undergoing medical termination of pregnancy whose pregnancies have a gestational age up to 49 days <sep> early termination of pregnancy <sep> eighty-six women requesting elective termination of a pregnancy which has a gestational age of  or  49 days <sep>', 'abortion up to 63 days gestation <sep> 999 women undergoing an abortion at gestational age <sep> a total of 89 cases was excluded from full analysis of outcome because either they aborted after mifepristone alone n  2 had an ectopic pregnancy n  1 or because the outcome was uncertain as they failed to attend their follow-up appointment n  86 <sep>', 'women n  220 requesting abortion in early pregnancy  or  63 days amenorrhoea <sep>', '198 women presenting for medical abortion at  7 weeks gestation <sep> 200 women <sep>', 'four hundred and fifty women undergoing medical termination of pregnancy at up to 63 days of gestation <sep> one hundred and sixty-five women 79 in the 6-hour group and 197 women 92 in the 36 to 48-hour group had a successful termination at first follow-up ultrasound or presumed on the basis of other considerations those not seen for ultrasound but deemed successful by negative pregnancy test products passed on ward or long-term assessment of notes <sep> those women with a nonviable gestation sac at the follow-up scan <sep> eligible women <sep> 23 women 11 in the 6-hour group and 8 women 4 in the 36 to 48-hour group <sep> women with a continuing pregnancy were managed with surgical termination <sep>', 'thirteen hospital gynaecological units in different continents <sep> early abortion <sep> 1,224 healthy pregnant women requesting medical abortion at 57 days from last menses <sep>', 'early medical abortion <sep> consenting women presenting for abortion services with gestations less than 56 days and who met inclusion criteria <sep> women of reproductive age <sep>', '300 women seeking an abortion with amenorrhoea of 8 weeks or less <sep>', '150 healthy women with pregnancies of 56 days gestational age who desired pregnancy termination <sep> administered vaginally for elective termination of early pregnancies <sep> early pregnancy termination <sep>', '2,126 women 97.5 excluding 55 lost to follow up <sep> 13 departments of obstetrics and gynecology in nine countries <sep> 2,181 women with 63 days or less gestation requesting medical abortion <sep> termination of early pregnancy <sep>', 'early pregnancy <sep> 2046 women 99 excluding 20 lost to follow-up <sep> 2066 healthy pregnant women requesting medical abortion with 63 days or less of gestation <sep>', 'early pregnancy amenorrhoea up to 49 days <sep>', 'elective termination of early pregnancy <sep> 250 women with gestations  or  56 days <sep>', '39 women in early pregnancy less than 56 days amenorrhea with the <sep>', 'women requesting an abortion at  or  56 days gestation <sep> eighty-six women <sep> early abortion <sep>', 'eligible and consenting women <sep> after mifepristone medical abortion through 63 days gestational age <sep>', '270 women seeking abortion within 63 days after the onset of amenorrhea <sep> women treated initially with mifepristone <sep>', 'within gestational age strata <sep> seventeen centres internationally <sep> early medical abortion <sep> women with menstrual delay of  or  35 days <sep> 1,589 healthy pregnant women with menstrual delay of  or  35 days who were requesting nonsurgical abortion <sep>', '150 women of 56 days gestation or less allocated to receive <sep> seventy-one 95 women who received a single dose of <sep> for early pregnancy termination <sep>', '150 women gestation or=63 days <sep>', 'women requesting an abortion at  or  49 days gestation <sep> women receiving methotrexate 50 mg and 60 mg per square meter for early abortion <sep> twenty women <sep>', 'medical abortions of less than 9 weeks gestation <sep> medical abortion for early pregnancy <sep> early pregnancies up to 63 days <sep> 224 women who requested legal termination of pregnancy up to 63 days <sep>', '1,621 women requesting medical abortion at  or  49 days from 9 hospitals was conducted in hebei women <sep> study group n  1,118 women took <sep>', 'eighty participants received <sep> women at up to 49 days gestation <sep>', '1,128 participants swallowed <sep> women who had not aborted were offered a second dose of <sep> women up to 63 days of gestation <sep>', 'pregnant women at 56 days gestation or less seeking elective abortion <sep> sixty-three women volunteered for the trial 61 completed the study and are included in the analysis <sep> early abortion <sep> 14 women with successful abortions <sep>', 'subjects who had not aborted were offered a second dose of <sep>', 'early medical abortion <sep> 2219 healthy pregnant women requesting medical abortion with  or 63 days of amenorrhoea <sep> fifteen gynaecological clinics in 11 countries <sep> patients perceptions of medical abortion <sep>', '480 women who were 49 days or less pregnant <sep> early medical abortion <sep>', 'one-hundred-fifty-three healthy women with a gestational length less than 49 days from the last menstrual period <sep> early human pregnancy <sep>', 'subjects who successfully aborted began within 16 <sep> 108 subjects who had requested elective termination of pregnancy and medical abortion at 9 weeks gestation or less <sep>', 'early abortion <sep> twenty pregnant women <sep>', '966 women seeking abortions to <sep> mifepristone medical abortion <sep>', '422 women <sep> early pregnancy less than or equal to 49 days of amenorrhea using ru 486 have been conducted in china including 2321 subjects <sep>', '800 women seeking an abortion at gestational age  or  63 days amenorrhoea <sep>', 'untreated and ru 486-treated early pregnant women <sep> women receiving ru 486 mifepristone for termination of early pregnancy <sep> pregnant women amenorrhoea of less than or equal to 49 days with ru 486 25 mg twice daily for 4 days and <sep>', 'ten gynecological services mostly in academic hospitals <sep> three hundred eighty-five healthy women up to 35 years of age with amenorrhea less than or equal to 49 days requesting pregnancy termination <sep>', 'four hundred forty-two women were enrolled in the study and complete data were available on 429 <sep> healthy women with pregnancies through 56 days since the last menstrual period lmp as indicated by sonogram <sep>', 'one-hundred-and-twenty women of less than 56 days amenorrhoea <sep>', 'early abortion <sep> 300 pregnant women seeking elective abortion <sep>', 'six-hundred women in early pregnancy who requested medical abortion <sep> early pregnancy amenorrhoea   49 days <sep>', 'medical abortions <sep> participants were women presenting for abortion at 49 days or less gestation <sep> early abortion <sep>', 'one hundred women in an urban primary care practice <sep>', 'early medical abortion <sep> one thousand one hundred sixty-eight women were enrolled <sep> healthy adult women up to 63 days pregnant and wanting a medical abortion <sep>'], 'interventions': ['mifepristone <sep> mifepristone <sep> prostaglandin <sep>', 'misoprostol-alone abortion <sep> misoprostol <sep> misoprostol <sep>', 'mifepristone <sep> oral misoprostol <sep> misoprostol <sep> misoprostol <sep> mifepristone <sep> vaginal misoprostol <sep>', 'oral mifepristone <sep> vaginal misoprostol <sep> aspiration curettage <sep> misoprostol <sep> self-administer 800 microg of vaginal misoprostol <sep> mifepristone <sep> vaginal misoprostol <sep>', 'mifepristone <sep> misoprostol <sep> mifepristone <sep> misoprostol 400 microg sublingually or vaginally <sep>', 'misoprostol <sep> mifepristone <sep>', 'misoprostol <sep> mifepristone <sep>', 'misoprostol <sep> mifepristone and misoprostol <sep> mifepristone <sep> mifepristone and gestation <sep> prostaglandin <sep>', 'misoprostol self-administered vaginally or 50 mg/m2 of methotrexate <sep> methotrexate <sep> misoprostol <sep> tamoxifen <sep> tamoxifen <sep> methotrexate and misoprostol <sep>', 'vaginal misoprostol 800 micrograms or suction termination of pregnancy <sep> oral mifepristone <sep> mifepristone 200 mg orally followed by vaginal misoprostol <sep> misoprostol <sep> mifepristone and misoprostol <sep> mifepristone <sep> vaginal misoprostol <sep> oral mifepristone <sep>', 'mifepristone <sep>', 'misoprostol with mifepristone <sep> oral misoprostol <sep> oral misoprostol and group iii 800 micrograms of vaginal misoprostol <sep> misoprostol <sep> misoprostol <sep> mifepristone <sep>', 'placebo <sep> misoprostol <sep> mifepristone <sep> 400 microgram oral misoprostol <sep>', 'placebo <sep> saline-moistened misoprostol <sep> placebo and moistened misoprostol <sep> misoprostol <sep> oral tamoxifen <sep> tamoxifen and misoprostol <sep> tamoxifen <sep>', '800 microg vaginal misoprostol <sep> misoprostol <sep> mifepristone <sep> placebo <sep>', 'misoprostol <sep>', 'antiprogestin ru 486 and the intramuscular pge2 analogue sulprostone <sep> ru 486 mifepristone <sep> prostaglandin analogue sulprostone <sep>', 'placebo and vaginal misoprostol <sep> placebo <sep> mifepristone and misoprostol with misoprostol <sep> vaginal misoprostol <sep> misoprostol <sep> mifepristone and misoprostol <sep> mifepristone and vaginal misoprostol <sep> mifepristone <sep> vaginal misoprostol <sep> mifepristone orally or placebo followed 48 h later by 800 microg vaginal misoprostol <sep>', 'prostaglandin analogue gemeprost <sep> ru486 <sep> pg analogue 16,16-dimethyl-trans-delta 2-pge1 <sep> progesterone antagonist ru486 alone <sep> ru486 <sep>', 'methotrexate <sep> vaginal misoprostol <sep> misoprostol <sep> methotrexate <sep> methotrexate and vaginal misoprostol <sep>', 'sublingual misoprostol <sep> misoprostol <sep> sublingual and oral misoprostol <sep> misoprostol sublingually or orally 24 h after 200 mg of mifepristone <sep> mifepristone <sep>', 'mifepristone ru 486 and oral or vaginal misoprostol <sep> oral misoprostol <sep> misoprostol <sep> prostaglandin e1 analogue misoprostol <sep> mifepristone <sep> vaginal misoprostol <sep> mifepristone ru 486 and a prostaglandin analogue <sep>', 'misoprostol 400 microg by mouth <sep> misoprostol <sep> mifepristone <sep> mifepristone-prostaglandin <sep>', 'oral misoprostol <sep> mifepristone and oral misoprostol <sep> misoprostol <sep> mifepristone 200 mg orally <sep> prostaglandin <sep> mifepristone <sep> 800 micrograms misoprostol <sep>', 'placebo <sep> oral mifepristone <sep> oral misoprostol <sep> misoprostol <sep> mifepristone and misoprostol <sep> mifepristone <sep> misoprostol and vaginal placebo <sep> vaginal misoprostol and oral placebo <sep>', 'intramuscular methotrexate <sep> methotrexate <sep> misoprostol <sep> methotrexate 50 <sep> methotrexate <sep>', 'mifepristone with sublingual or vaginal misoprostol <sep> sublingual misoprostol <sep> placebo <sep> oral mifepristone <sep> misoprostol <sep> mifepristone and misoprostol <sep> mifepristone <sep> vaginal misoprostol <sep>', 'mifepristone with misoprostol <sep> mifepristone <sep> misoprostol <sep> mifepristone <sep>', 'mifepristone <sep> mifepristone with misoprostol <sep> misoprostol <sep> mifepristone <sep> vaginal misoprostol <sep>', 'mifepristone and oral misoprostol <sep> mifepristone <sep> misoprostol <sep> mifepristone and misoprostol <sep> mifepristone <sep>', 'methotrexate <sep> misoprostol <sep> misoprostol <sep> methotrexate <sep> methotrexate and vaginal misoprostol <sep> methotrexate and misoprostol <sep> methotrexate and misoprostol vs misoprostol <sep> antiprogestin and prostaglandin <sep>', 'mifepristone <sep> misoprostol <sep> mifepristone and vaginal misoprostol <sep> mifepristone <sep> transvaginal ultrasonography 7 <sep>', 'placebo <sep> mifepristone <sep> oral misoprostol <sep> misoprostol <sep> misoprostol <sep> mifepristone <sep> oral misoprostol and the vaginal-only group v-only group with oral placebo <sep>', 'placebo <sep> misoprostol <sep> mifepristone <sep>', 'hcg <sep>', '50 mg/m2 intramuscular i.m. methotrexate <sep> 50 mg/m2 methotrexate intramuscularly followed 3 days later by 800 micrograms vaginal misoprostol <sep> 800 micrograms vaginal misoprostol <sep> methotrexate and misoprostol <sep> methotrexate and misoprostol <sep> methotrexate and misoprostol alone or in combination <sep>', 'methotrexate <sep> intramuscular methotrexate <sep> misoprostol <sep> oral methotrexate <sep> oral methotrexate and vaginal misoprostol <sep> vaginal misoprostol <sep> methotrexate 25 mg or 50 mg followed 7 days later by misoprostol 800 micrograms vaginally <sep>', 'oral misoprostol <sep> misoprostol <sep> oral or buccal misoprostol 800 mcg 24-36 hours after mifepristone 200 mg with 7-14-day follow-up <sep> mifepristone <sep> oral immediately swallowed and buccal misoprostol <sep> oral misoprostol <sep> buccal misoprostol <sep>', 'vaginal suppository containing the chinese domestic prostaglandin pgo5 <sep> ru 486 mifepristone <sep> ru 486+pg <sep> ru 486 alone ru 486  pg <sep>', '0.5 mg gemeprost by vaginal pessary <sep> mifepristone <sep> misoprostol <sep> respectively).(abstract <sep> mifepristone <sep>', 'antiprogestin ru 486 mifepristone <sep> oral prostaglandin e2 <sep> placebo <sep> pge2 <sep>', 'mifepristone and gemeprost <sep> mifepristone <sep> mifepristone <sep> prostaglandin <sep>', 'misoprostol <sep> mifepristone-misoprostol medical abortion <sep> mifepristone <sep> mifepristone and buccal or vaginal misoprostol <sep>', 'mifepristone and prostaglandin <sep> prostaglandin pessary gemeprost <sep> mifepristone ru486 <sep> mifepristone in combination with half or a whole 1 mg gemeprost vaginal pessary <sep> prostaglandin <sep>', 'methotrexate and misoprostol <sep> misoprostol <sep> methotrexate <sep> oral methotrexate and vaginal misoprostol <sep>', 'mifepristone was given but dl-15-methyl pgf2 alpha pg05 <sep> vaginal suppository <sep> mifepristone with misoprostol and mifepristone with pg05 <sep> misoprostol <sep> mifepristone plus a single oral dose of misoprostol <sep> mifepristone <sep> mifepristone 200 mg was given and misoprostol <sep> mifepristone with misoprostol and mifepristone <sep>', 'misoprostol <sep> buccal misoprostol <sep> methotrexate <sep>', 'methotrexate <sep> misoprostol <sep> oral methotrexate <sep> 50 mg/m(2 methotrexate <sep> methotrexate and misoprostol <sep> injected methotrexate <sep>', 'mifepristone <sep> oral misoprostol <sep> misoprostol <sep> oral misoprostol 400 microg taken 2 h apart or misoprostol 800 microg vaginally <sep> mifepristone <sep> vaginal misoprostol chi(2 <sep> vaginal misoprostol <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",safe and effective medical abortion methods are available. combined regimens are more effective than single agents. in the combined regimen the dose of mifepristone can be lowered to 200 mg without significantly decreasing the method effectiveness. vaginal misoprostol is more effective than oral administration and has less side effects than sublingual or buccal. some results are limited by the small numbers of participants on which they are based. almost all trials were conducted in settings with good access to emergency services which may limit the generalizability of these results.
255,"{'outcomes': ['bone loss <sep> mean lumbar bone loss <sep> bone loss <sep> estradiol and biochemical markers of bone metabolism <sep>', 'bone density <sep> bone density <sep> serum calcium phosphorus alkaline phosphatase and fasting urinary calcium/creatinine ratios <sep> bone turnover <sep> bone mineral density changes <sep> serum calcium phosphorus alkaline phosphatase and urinary calcium/creatinine ratios <sep>', 'bone metabolism <sep> urinary calcium/creatinine ratio <sep> bone demineralization seen <sep>', 'association of b-alp and d-pyr <sep> positive spine bmd changes <sep> bone biochemical markers <sep> biochemical markers except urinary calcium and hydroxyproline <sep> bmd changes <sep> z scores <sep> bmd <sep> crosslaps ctx and deoxypyridinoline d-pyr <sep> bone alkaline phosphatase b-alp and osteocalcin oc <sep> bone mineral density bmd <sep>', 'serum calcium levels <sep> bone mineral density and pyridinium crosslinks <sep> lumbar spine bone mineral density bmd <sep> endometriosis dysmenorrhea and pelvic pain effects <sep> urinary levels of pyridinium crosslinks <sep>', 'trabecular bmc of the 3rd lumbar vertebra <sep> bmc <sep> slight gain in bmc <sep> serum estrogen levels <sep> bone resorption <sep> serum estradiol and the biochemical parameters of bone metabolism <sep> bone mineral content bmc <sep> cumulative bone loss <sep>', 'bone loss <sep> bone resorption markers <sep> bone formation and resorption markers <sep> bone mineral density <sep> bone resorption markers <sep> bone mineral density of the lumbar spine <sep> bone formation markers <sep> bone formation markers <sep>', 'mean sd deep dyspareunia scores <sep> verbal rating scale <sep> serum follicle stimulating hormone fsh levels <sep> efficacy and acceptability <sep> tolerability <sep> menstrual pain scores <sep> chronic pelvic pain <sep> serum luteinizing hormone lh and 17 beta-oestradiol concentrations <sep> lumbar spine bone mineral density <sep> mean sd endometriosis scores <sep>', 'pelvic pain scores <sep> efficacy and safety <sep> pelvic pain scores <sep> bone density <sep>', 'pelvic endometriosis <sep> adverse hypoestrogenic effects <sep> libido <sep> bone mineral density loss <sep> hypoestrogenic effects <sep>', 'mean serum oestradiol levels <sep> significant loss of bone mineral <sep> spinal trabecular bone mineral content <sep> vertebral trabecular bone mass <sep> bone mineral measurement <sep> bone mineral <sep>', 'bone mass <sep> lumbar spine and femoral neck <sep> bone loss <sep> bone assessments <sep> serum estradiol e2 levels <sep> trabecular bone mineral content of the lumbar spine and femoral neck <sep> urinary calcium-creatinine ratio and serum alkaline phosphatase <sep> control values urinary calcium-creatinine ratio <sep> serum e2 levels <sep> bone densities <sep> serum alkaline phosphatase <sep> lumbar spine values <sep> lumbar spine and femoral neck bone mineral content <sep>', 'vertebral bone mass and serum estradiol and calcitonin <sep> serum e2 levels <sep> bone mass <sep> sustained hypoestrogenemia and significant bone loss <sep> calcitonin levels <sep> gain or loss of bone mass <sep> trabecular vertebral bone mass serum e2 and serum calcitonin <sep> bone loss with la <sep> serial serum levels of e2 and calcitonin <sep>', 'endometriosis scores <sep> bone loss and symptomatic side effects <sep> daily symptom diary for hot flushes and bleeding episodes laparoscopic scoring of endometriosis endocrine and biochemical changes and bone mineral density scans <sep> frequency of hot flushes and sweating episodes <sep> lumbar spine bone mineral density <sep> bone loss and vasomotor symptoms <sep>', 'revised american fertility society score <sep> bone mineral density <sep> hot flushes <sep>', 'loss of bone density <sep> serum estrone and estradiol levels <sep> frequency of genital bleeding <sep>', 'revised afs endometriosis score <sep> efficacy <sep> physical examination laboratory indices occurrence of adverse events and bone mineral density changes <sep> mean bone mineral density <sep> pelvic signs and symptoms scores and revised afs endometriosis scores <sep> mean subjective signs and symptoms scores <sep> endometrial implants score <sep> androgenic side effects <sep> endocrine effects <sep> hypoestrogenic effects <sep> serum estradiol levels <sep>', 'hypoestrogenic side effects <sep> hot flushes and sweating <sep> total pelvic pain scores <sep> bone loss at the lumbar spine <sep> total revised afs score <sep>'], 'punchline_text': ['there was no difference in bone loss in the three groups at all sites. <sep>', 'significant increases in serum calcium phosphorus alkaline phosphatase and urinary calcium/creatinine ratios were noted in the placebo group. <sep>', 'six months after stopping nafarelin with or without norethisterone bone mass was not different from baseline. <sep>', 'biochemical markers except urinary calcium and hydroxyproline measured at 6 months were positively correlated with the bmd changes at the lumbar spine. <sep>', 'the gnrha  placebo group had significantly higher serum calcium levels and a significantly higher loss of lumbar spine bone mineral density bmd). <sep>', 'parameters of bone resorption tended to increase in the buserelin group. <sep>', 'bone mineral density was reduced in all four groups but the percent changes varied slightly at  5.25 group a 3.72 p  0.05 vs. group a group b 4.13 group c and 3.59 p  0.01 vs. group a group d respectively. <sep>', 'the monthly depot caused a slightly more marked inhibition of serum follicle stimulating hormone fsh levels with respect to the 3-monthly preparation. <sep>', '2.3 p  or  .001 loss in bone density after 52 weeks of treatment whereas bone density was preserved in all three add-back groups. <sep>', 'hypoestrogenic side effects of hot flushes and loss of libido were significantly less in the group that received hrt. <sep>', 'significant loss of bone mineral 9.6 g/l 5.9 p less than 0.001 was demonstrated after 6 months treatment with nafarelin. <sep>', 'before treatment the trabecular bone mineral content of the lumbar spine and femoral neck was not significantly different between endometriosis patients and age-matched controls n  26). <sep>', 'serum e2 levels usually were  25 pg/ml conversion factor to si unit 3.671 with la but  47.3 pg/ml with danazol. <sep>', 'lumbar spine bone mineral density decreased significantly from baseline in the placebo group 5.1 but not in the tibolone group 1.1%). <sep>', 'all three treatment groups showed significant decreases in bone mineral density compared with baseline but smaller losses were generally observed in the add-back groups. <sep>', 'at the end of treatment serum estrone and estradiol levels in the add-back group n  11 were significantly higher than those in the control group n  10). <sep>', 'both treatments significantly p  .0001 reduced mean subjective signs and symptoms scores both during and after therapy. <sep>', 'total revised afs score as well as total pelvic pain scores decreased significantly p  .001 in both groups. <sep>'], 'population': ['40 patients with endometriosis <sep>', 'thirty-one premenopausal subjects who needed treatment with <sep>', 'ninety-four women with a subjective complaint of heavy menstrual blood loss or objective evidence of endometriosis received <sep> thirty-one patients 33 left the study prematurely and three patients were non-compliant with the study drug <sep> premenopausal women <sep>', '28 patients treated for 6 months with a gnrh agonist <sep> women with ovarian deficiency <sep> postmenopausal women with high bone turnover treated with hrt <sep>', 'patients with endometriosis treated with gonadotropin-releasing hormone agonists <sep> 27 patients with endometriosis who were given <sep>', 'patients with endometriosis <sep> japanese women with endometriosis <sep> nineteen women with laparoscopically confirmed endometriosis <sep>', 'one hundred ten women mean age 46.2+/-0.5 yr receiving leuprolide therapy for estrogen-dependent diseases such as endometriosis and uterine leiomyomas <sep>', '30 women aged 18-38 years <sep> women with endometriosis <sep> symptomatic endometriosis <sep>', 'endometriosis <sep> two hundred and one patients <sep>', 'endometriosis <sep> fifty premenopausal women with laparoscopically diagnosed endometriosis revised american fertility score for endometriosis implants equal to four or greater and significant symptoms of dysmenorrhoea dyspareunia and other pelvic pain <sep>', 'patients with endometriosis <sep> 24 women treated with either nafarelin 15 patients or <sep>', 'endometriosis patients treated with <sep>', 'academic university hospital and department of obstetrics and gynecology <sep> pelvic endometriosis <sep> twelve women with symptomatic pelvic endometriosis diagnosed and staged by laparoscopy <sep>', 'twenty-nine patients with endometriosis and two with fibroids <sep> patients treated with the <sep>', 'patients with uterine fibroids <sep> patients with endometriosis compared with immediate therapy <sep> patients with endometriosis being treated with <sep>', 'women with endometriosis <sep> japanese women with symptomatic endometriosis <sep> japanese women with endometriosis <sep>', 'endometriosis <sep> three hundred fifteen patients with stages <sep> premenopausal women with endometriosis <sep>', 'endometriosis <sep> forty premenopausal women with laparoscopically proven endometriosis entered the study <sep>'], 'interventions': ['nasal salmon calcitonin sct <sep> triptoreline <sep> calcium <sep> placebo sct 100 iu daily and sct 200 iu daily <sep> gonadotropin releasing hormone gnrh agonists <sep>', 'placebo <sep> leuprolide lupron <sep> cyclic intermittent etidronate therapy <sep> gonadotropin-releasing hormone treatment <sep> etidronate or placebo <sep> etidronate <sep>', 'placebo <sep> nafarelin acetate and norethisterone <sep> oral norethisterone or placebo <sep> oral norethisterone <sep> norethisterone <sep> intra-nasal nafarelin <sep>', 'hormone replacement therapy hrt <sep>', 'placebo <sep> gnrha with or without hormone add-back therapy  20 microg of ethinyl estradiol with 0.15 mg desogestrel <sep> gnrha  placebo <sep> gonadotropin-releasing hormone agonists gnrha <sep> back therapy <sep>', 'gnrh agonist and danazol <sep> danazol <sep> buserelin <sep> buserelin <sep>', 'vitamin k2 menatetrenone and 1,25-dihydroxyvitamin d3 <sep> vitamin k2 and 1,25-dihydroxyvitamin d3 1,25-(oh)2d3 <sep> vitamin k2 <sep> leuprolide with vitamin k2 group c leuprolide with 1,25-(oh)2d3 and group d leuprolide with vitamin k2 and 1,25-(oh)2d3 <sep> leuprolide <sep> gnrh agonist gnrh-a leuprolide <sep>', 'depot injection <sep> leuprolide <sep> leuprolide <sep>', 'norethindrone acetate and conjugated equine estrogens <sep> norethindrone acetate <sep> norethindrone acetate 5 mg daily and placebo <sep> placebos for progestin and estrogen <sep> gnrh agonist leuprolide acetate depot alone and in combination with three hormonal add-back regimens <sep> norethindrone acetate 5 mg and conjugated equine estrogens <sep> leuprolide acetate depot <sep> leuprolide acetate depot <sep> norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg daily <sep>', 'gnrh analogue gnrh-a goserelin combined with continuous estrogen and progestogen hormone replacement therapy hrt <sep> gonadotropin-releasing hormone analogue goserelin plus hormone replacement therapy <sep> medroxyprogesterone acetate <sep> goserelin alone <sep> goserelin <sep> hrt <sep>', 'nafarelin and danazol <sep> danazol nine patients for endometriosis <sep> single and dual-energy quantitative computed tomography qct <sep> danazol <sep>', 'danazol <sep> gnrh agonist implant or danazol <sep>', 'placebo tablets <sep> jm depot la <sep> danazol <sep> depot leuprolide acetate versus danazol <sep> danazol <sep> depot leuprolide acetate la or danazol <sep> depot la <sep> danazol daily with a monthly placebo injection <sep>', 'tibolone <sep> tibolone livial <sep> gonadotropin-releasing hormone agonist triptorelin decapeptyl <sep> placebo <sep>', 'zoladex goserelin acetate <sep> placebo <sep> goserelin <sep> placebo with medrogestone <sep>', 'cee <sep> conjugated equine estrogen and medroxyprogesterone acetate <sep> conjugated equine estrogen cee and 2.5 mg medroxyprogesterone acetate mpa <sep> mpa <sep> gnrh agonists gnrh-a treatment <sep>', 'danazol <sep> zoladex goserelin acetate <sep> zoladex <sep> zoladex goserelin acetate implant <sep>', 'cee  5 mg ma <sep> la combined with 1.25 mg oral conjugated equine estrogen cee and 5 mg oral medroxyprogesterone acetate ma <sep> la <sep> la  hrt <sep> leuprolide acetate la <sep> gonadotropin-releasing hormone analogue plus hormone replacement therapy <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>']}",both danazol and progesterone oestrogen add-back have been shown to be protective of bmd while on treatment and up to six and 12 months later respectively. however by 24 months of follow-up there was no difference in bmd in those women who had hrt add-back. studies of danazol versus gnrha did not report long-term follow-up. the significant side effects associated with danazol limit its use.
256,"{'outcomes': ['self-reported disability score range 1-5 <sep> disability physical performance and pain <sep> car task <sep> knee pain questionnaire <sep> knee pain score range 1-6 performance measures of physical function x-ray score aerobic capacity and knee muscle strength <sep> time to lift <sep> physical disability questionnaire <sep> mean se time to get in and out of a car <sep> pain score <sep> x-ray scores <sep> faster times on the lifting and carrying task <sep> overall compliance <sep> mean se time to climb and descend stairs <sep>', 'pain quality of life activity restrictions knowledge about oa self-efficacy body mass index bmi and mobility measures <sep> range of motion and functional tasks <sep> pain quality of life strength of the left m. quadriceps knowledge self-efficacy bmi physically active lifestyle and visits to the physical therapist <sep>', 'isometric strength gain <sep> total activity vector magnitude <sep> muscle strength and walking performance <sep> daily steps <sep> physical activity daily step counts and total activity vector magnitude as measured by a pedometer and tritrac-r3d accelerometer quadriceps femoris strength isometric peak torque and functional performance tasks 100-foot walk-turn-walk timed stair climb timed chair rise and pain status <sep> physical activity <sep> physical activity muscle strength and functional performance <sep>', 'abdominal muscle strength <sep> balance <sep> flexibility and upper-body or knee muscle strength <sep> arthritic symptoms balance and physical functioning <sep> pain <sep> physical functioning <sep> pain balance muscle strength and perceived difficulties in physical functioning <sep> physical symptoms and fitness body mass index cardiovascular functioning and perceived difficulties in physical functioning <sep>', 'knee pain <sep> reduction in pain <sep> pain <sep> self reported score for knee pain on the western ontario and mcmaster universities womac osteoarthritis index <sep> knee specific physical function and stiffness scored on womac index general physical function scored on sf-36 questionnaire psychological outlook scored on hospital anxiety and depression scale and isometric muscle strength <sep>', 'quadriceps strength on knee pain and disability <sep> womac pain score <sep> vas scores for pain <sep> physical function scores <sep> knee pain western ontario mcmaster osteoarthritis index womac <sep> visual analogue scales vas for pain on stairs and walking and womac physical function scores <sep>', 'rate of loss <sep> mean rate of joint space narrowing jsn <sep> frequency of knee oa progression in jsn consensus ratings <sep> incidence and progression of knee osteoarthritis <sep> incidence and progression of knee oa <sep> extremity strength <sep> isokinetic lower-extremity strength and highly standardized knee radiographs <sep> strength and exhibited less frequent progressive jsn <sep>', 'safe effective and well tolerated <sep> pain measurements <sep> pain scores <sep> functional capacity <sep> functional capacity rising from a chair walking stair climbing and descending and pain during rest and activities peak torque and cross-sectional area csa <sep> functional capacity and symptoms <sep> functional capacity and decrease pain <sep> functional capacity especially stair climbing <sep> peak torque and csa of knee muscles <sep>', 'self-reported pain function and quality of life <sep> koos subscales assessing pain other symptoms or function in daily life or in sport and recreation <sep> pain or function <sep> koos subscale quality of life <sep> knee injury and osteoarthritis outcome score koos <sep> quality of life <sep>', 'psychological disability <sep> physical fitness strength pain coping and self-efficacy <sep> physical fitness <sep> leg flexion and extension <sep> self-efficacy <sep>', 'knee pain <sep> knee joint pain <sep> knee pain <sep> time to descend and ascend stairs <sep> time to perform all 4 functional tasks <sep> pain and functioning <sep>', 'pain reductions <sep> global improvement <sep> pain and disability <sep> pain <sep> womac knee pain scale sf-36 assessment of quality of life index quadriceps strength and balance test <sep> global improvement <sep> pain measured by visual analogue scale and patient global change <sep>', 'western ontario and mcmaster universities osteoarthritis womac index pain and physical function subscales <sep> physical function <sep> clinical signs and symptoms of osteoarthritis oa <sep> physical performance quality of life and self-efficacy <sep> strength pain physical function and quality of life <sep> pain <sep> knee extension strength <sep> self-reported physical function <sep> clinical knee examination muscle strength physical performance measures and questionnaires to measure quality of life variables <sep>', 'mean baseline function score <sep> knee pain <sep> mean reductions in pain scores <sep> function scores <sep> mean baseline womac pain score <sep> change in western ontario and mcmaster universities osteoarthritis index womac <sep>', 'health status physical capacity and joint tenderness <sep> joint tenderness <sep> quadriceps and hamstring strength <sep> perception of changes relating to osteoarthritis of the knee and general condition <sep> arthritis pain <sep> aerobic capacity <sep> isokinetic strength of the quadriceps <sep> health perception <sep> hamstring and low back flexibility <sep> ability to walk and bend <sep>', ""walking speed <sep> disability <sep> pain and disability <sep> muscle peak torques <sep> lequesne's index knee range of motion peak muscle torques of knee flexion and extension and ambulation speed <sep> range of motion and ambulation speed <sep> muscular strength <sep> visual analog scale pain and rates of attrition <sep>"", 'exercise tolerance disease-related measures and self-reported health status <sep> retention rate <sep> aerobic capacity 50-foot walking time depression anxiety and physical activity <sep> change scores for flexibility number of clinically active joints duration of morning stiffness or grip strength <sep>', 'pain and physical function scores <sep> physical performance measures <sep> physical function <sep> sf-12 physical component summary score <sep> physical activity <sep> pain and physical function western ontario and mcmaster universities osteoarthritis index general health status medical outcomes study short form 12 health survey sf-12 version 2 psychological well-being and physical performance up and go test 50-foot walk time timed stair climb <sep>', 'knee pain <sep> changes in joint space width <sep> body weight <sep> 6-minute walk distance <sep> stair-climb time <sep> physical function pain and mobility <sep> self-reported physical function <sep> weight-loss <sep> weight loss 6-minute walk distance stair-climb time womac pain and stiffness scores and joint space width <sep> self-reported physical function as measured with the western ontario and mcmaster universities osteoarthritis index womac <sep>', '6-minute walk distance and womac score <sep> womac scores <sep> undergone knee arthroplasty <sep> baseline womac scores and walking distance <sep> average womac scores <sep> average 6-minute walk distances <sep> function pain and stiffness subscores of the western ontario and mcmaster universities osteoarthritis index womac <sep> average distance walked <sep>', 'walking speed <sep> changes of muscle power of leg flexion and extension <sep> pain reduction disability reduction <sep> visual analogue scale ambulation speed and lequesne index <sep> exercise knee pain <sep> angular velocity peak torques <sep> walking speed and decrease of disability <sep> muscle-strength gain <sep> pain reduction <sep> joint stability or walking endurance <sep>', ""strength gains <sep> overall status <sep> positive functional outcomes <sep> pain scores <sep> isokinetic and isometric quadriceps strength pain and function determined by categorical and visual analog scales and overall status using physician and patient global evaluations by the arthritis impact scale version 2 western ontario mcmaster's arthritis index and medical outcome study short form 36 <sep> pain and function <sep>"", 'knee extensor strength and fast walking speed <sep> self-report measures womac sf-36 and objective measures of physical performance gait analysis and muscle strength <sep> pain physical function and health related quality of life <sep> physical function gait and knee extensor strength <sep>', 'pain and disability <sep> reduction of pain <sep> muscle strength of the hip <sep> observed disability <sep> pain medication use nonsteroidal antiinflammatory drugs nsaid and observed disability <sep>', 'synovial fluid keratan sulfate ks and hydroxyproline <sep> pain levels <sep> levels of ks and hydroxyproline <sep> health status and a visual analog scale for pain assessment <sep> synovial fluid <sep>', 'pain <sep> quadriceps strength of the index knee <sep> pain in the worse knee by 100 mm visual analog scale score the disability domain of the western ontario and mcmaster university oa index womac and quadriceps muscle strength by maximum voluntary contraction <sep> knee pain scores and quadriceps muscle strength <sep>', 'arthritis activity <sep> all strength measures <sep> pain and stiffness <sep> functional health status <sep> mobility <sep> right leg flexion and left leg extension <sep> extension and flexion strength of the right and left legs the 50-foot walk time range of motion at the knee joint the osteoarthritis screening index oasi and the arthritis impact measurement scale aims <sep>', 'walking speed <sep> frequency of crepitus <sep> frequency of palpable joint effusions <sep> adverse effects <sep> pain <sep> leg isometric strength <sep> isokinetic quadriceps strength <sep> muscle strength across the knee extension and flexion algofunctional index afi pain 0 to 10 point scale walking speed clinical findings <sep>', 'pain and physical functioning <sep> activity and activity related pain <sep> activity related pain vas and improvement in spw and sps test time passive range of motion and pase <sep> pain using the western ontario mcmaster womac pain physical disability and stiffness subscales and a 10 point visual analog scale vas before and after self-paced walking spw and stepping sps functional tasks 2 physical function using the time to complete a self-paced 40 m walk spw and 20 cycles of 2 steps sps 3 physical activity level using the physical activity scale for elderly pase 4 clinical measures of knee functioning range of motion <sep>', 'functional status pain and use of medication <sep> walking distance relative <sep> arthritis pain <sep> 6-minute test of walking distance and scores on the physical activity arthritis impact pain and medication subscales of the arthritis impact measurement scale aims <sep> arthritis impact subscale <sep> aims physical activity subscale <sep>', '6-min distance walk <sep> exercise efficacy <sep> lower extremity pain <sep> adverse health effects <sep> exercise adherence <sep> efficacy and adherence measures <sep> lower extremity stiffness <sep>'], 'punchline_text': ['older disabled persons with osteoarthritis of the knee had modest improvements in measures of disability physical performance and pain from participating in either an aerobic or a resistance exercise program. <sep>', 'significant manova group x time effects p  0.05 one-sided were found for pain quality of life strength of the left m. quadriceps knowledge self-efficacy bmi physically active lifestyle and visits to the physical therapist. <sep>', 'in older adults with symptomatic knee oa walk  appears to increase walking with improvements in muscle strength and walking performance. <sep>', 'in the physical fitness test there were significant improvements in balance t  3.34 p  0.002 and abdominal muscle strength t  2.74 p  0.009 for the tai chi exercise group. <sep>', 'at 24 months highly significant reductions in knee pain were apparent for the pooled exercise groups compared with the non-exercise groups mean difference 0.82 95 confidence interval 1.3 to 0.3). <sep>', 'womac pain score reduced by 22.5 in the exercise group and by 6.2 in the control group between group difference p  0.05 unpaired t test). <sep>', 'compared with rom st decreased the mean rate of joint space narrowing jsn in osteoarthritic knees by 26 p  not significant). <sep>', 'both training groups showed marked decreases p .001 in pain scores and increases p .001 in functional capacity together with increases p .05--.01 in peak torque and csa of knee muscles. <sep>', 'no significant differences in the koos subscales assessing pain other symptoms or function in daily life or in sport and recreation were seen at any time point between exercisers and controls. <sep>', 'alone groups had significant improvements in physical fitness compared to sa-cst alone and patients in sa-cst  et and et alone had significant improvements in leg flexion and extension compared to sa-cst alone and sc 2 pain coping patients in sa-cst  et and sa-cst alone groups had significant improvements in coping attempts compared to et alone or sc and spouses in sa-cst  et rated their partners as showing significant improvements in coping attempts compared to et alone or sc and 3 self-efficacy <sep>', 'in the isometric group time to perform all 4 functional tasks decreased p<.05 by 16 to 23%. <sep>', 'the physiotherapy programme tested in this trial was no more effective than regular contact with a therapist at reducing pain and disability. <sep>', 'high intensity home based strength training can produce substantial improvements in strength pain physical function and quality of life in patients with knee oa. <sep>', 'significantly fewer participants in the physiotherapy group reported consulting their general practitioner for knee pain in the follow-up period and use of non-steroidal anti-inflammatory drugs was lower in the physiotherapy and pharmacy groups than in the control group. <sep>', 'after 3 months significantly greater improvements were observed in the experimental group than the control group in terms of arthritis pain p  0.02 ability to walk and bend p  0.03 aerobic capacity p  0.0001 hamstring and low back flexibility p  0.003 quadriceps and hamstring strength p 0.01 and the perception of changes relating to osteoarthritis of the knee and general condition p  0.0001). <sep>', 'both group ii and group iii had significant gains in muscular strength after treatment and at followup group iii showed the greatest gains. <sep>', 'the aquatics and walking exercise groups showed significant improvement over the control group in aerobic capacity 50-foot walking time depression anxiety and physical activity after the 12-week exercise program. <sep>', 'both class allocations achieved significant improvements in the sf-12 physical component summary score but only allocation to hydrotherapy achieved significant improvements in the physical performance measures. <sep>', 'in the diet plus exercise group significant improvements in self-reported physical function p  0.05 6-minute walk distance p  0.05 stair-climb time p  0.05 and knee pain p  0.05 relative to the healthy lifestyle group were observed. <sep>', 'clinically and statistically significant improvements in 6-minute walk distance and womac score at 4 weeks and 8 weeks were seen in the treatment group but not the placebo group. <sep>', 'a significant muscle-strength gain in 180 degrees second angular velocity peak torques was found only in the isokinetic group after treatment. <sep>', 'both treatment groups showed significant strength gains p  .05 which occurred over a wider velocity spectrum for the exercise group. <sep>', 'improvements in the self-report measures were substantiated by significant correlated improvements in knee extensor strength and fast walking speed rho 0.36-0.42). <sep>', 'additional beneficial effects p  0.05 were found for the use of paracetamol effect size 0.33 global effect as perceived by the patient effect size 0.68 and muscle strength of the hip effect size 0.34). <sep>', 'levels of ks and hydroxyproline did not change. <sep>', 'the treatment package produced small improvements in knee pain scores and quadriceps muscle strength 10 weeks after the end of the treatment period. <sep>', 'the experimental group significantly increased in all strength measures while the control group increased in only right leg flexion and left leg extension across the training period. <sep>', 'there was an increase in the frequency of palpable joint effusions p  .01 on the most affected side. <sep>', 'addition of a progressive exercise program to nonsteroidal antiinflammatory therapy in patients with knee oa can improve measures of activity and activity related pain more than medication alone. <sep>', 'although changes in scores on the arthritis impact subscale were similar in the two groups p  0.093 the walking group experienced a decrease in arthritis pain of 27 cl 9.6 to 41.4 p  0.003). <sep>', 'program participants also experienced a significant decrease in lower extremity pain and a borderline significant improvement in efficacy to adhere to exercise over time at 6 months p .052). <sep>'], 'population': ['older disabled persons with osteoarthritis of the knee <sep> 18 months conducted at 2 academic medical centers <sep> a total of 365 83 participants completed the trial <sep> 439 community-dwelling adults aged 60 years or older with radiographically evident knee osteoarthritis pain and self-reported physical disability <sep> older adults with knee osteoarthritis <sep>', 'inclusion criteria were diagnosis of oa of the hip or knee according to acr clinical and radiographic criteria and age 55 to 75 years <sep> older adults with osteoarthritis for the hip or knee <sep> patients with osteoarthritis oa of the hip or knee <sep>', 'older adults with osteoarthritis of the knee <sep> older adults with osteoarthritis oa <sep> participants assigned to walk  n  17 mean age <sep> thirty-four community-dwelling adults aged 60 and older with symptomatic knee oa and self-reported functional impairment <sep> 6.7 or edu n  17 age  70.8 <sep> older adults with symptomatic knee oa <sep>', 'older women with osteoarthritis <sep> older women with osteoarthritis oa <sep> seventy-two patients with oa <sep> older women with oa <sep>', 'knee pain and knee osteoarthritis <sep> 600 76.3 participants completed the study <sep> patients with knee pain <sep> two general practices in nottingham <sep> 786 men and women aged <sep>', '191 men and women with knee pain aged 40-80 were recruited from the community and randomised to exercise n  113 or <sep> pain and disability from osteoarthritis of the knee <sep>', '221 older adults mean age 69 years <sep>', 'patients with osteoarthrosis of the knee <sep> patients with osteoarthrosis oa of both knees <sep> patients with oa of the knee <sep> copyright 2002 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation <sep> twenty-three volunteers ages 41 to 75 years <sep>', 'patients aged 36-65 with oa grade iii kellgren  lawrence <sep> sixty-one subjects mean age 56 sd 6 51  women mean bmi 29.5 sd 4.8 <sep> middle-aged patients with knee osteoarthritis <sep> middle-aged patients with moderate to severe radiographic knee oa <sep> elderly subjects <sep> knee osteoarthritis oa <sep> subjects in this study were middle-aged with symptomatic and definite radiographic knee osteoarthritis <sep>', 'patients having persistent osteoarthritic knee pain <sep> seventy-two married osteoarthritis oa patients with persistent knee pain and their spouses <sep> patients suffering from pain due to osteoarthritis <sep> patients with osteoarthritic knee pain <sep>', 'patients with knee oa <sep> adults with osteoarthritis of the knee <sep> patients with knee osteoarthritis oa <sep> 102 volunteer subjects with oa of the knee randomized to isometric n=32 and dynamic n=35 resistance training groups or a control n=35 <sep>', '10 physiotherapists in private practices for 12 weeks <sep> knee joint osteoarthritis <sep> 140 community volunteers with knee osteoarthritis participated and 119 completed the trial <sep>', 'patients with knee oa <sep> forty-six community dwelling patients aged 55 years or older with knee pain and radiographic evidence of knee oa <sep> older adults with knee osteoarthritis <sep>', 'older adults with knee pain <sep> people aged over 55 presenting to primary care <sep> 325 adults aged 55 years or over mean 68 years consulting with knee pain 297 91 reached six month follow-up <sep> people aged 55 or over with knee pain <sep> 15 general practices in north staffordshire <sep>', 'older persons with osteoarthritis of the knee <sep> 137 volunteers ages <sep> individuals with osteoarthritis of the knee <sep> persons with osteoarthritis of the knee <sep>', 'patients with knee osteoarthritis <sep> patients with knee osteoarthritis oa <sep> 140 subjects with bilateral knee oa altman grade ii <sep>', 'people who have rheumatoid arthritis or osteoarthritis <sep> 120 patients with rheumatoid arthritis or osteoarthritis volunteered to be subjects for this study of <sep> patients with rheumatoid arthritis and osteoarthritis <sep>', 'osteoarthritis management <sep> sedentary individuals with chronic hip or knee oa <sep> individuals with chronic symptomatic hip or knee osteoarthritis oa <sep> 152 older persons with chronic symptomatic hip or knee oa <sep>', 'three hundred sixteen community-dwelling overweight and obese adults ages 60 years and older with a body mass index of  or 28 kg/m(2 knee pain radiographic evidence of knee oa and self-reported physical disability <sep> overweight and obese older adults with knee osteoarthritis <sep> 316 randomized participants 252 80 completed the study <sep> older overweight and obese adults with knee osteoarthritis oa <sep> older overweight and obese adults with knee oa <sep>', 'n  41 19 men and 22 women mean age 62 <sep> patients with osteoarthritis of the knee and may delay or prevent the need for surgical intervention <sep> osteoarthritis of the knee <sep> 83 patients with osteoarthritis of the knee who were randomly assigned to receive treatment n  42 15 men and 27 women mean age 60 <sep> outpatient physical therapy department of a large military medical center <sep>', 'patients with knee osteoarthritis <sep> patients with knee osteoarthritis oa <sep> one hundred thirty-two patients with bilateral knee oa altman grade ii <sep> patients with oa with exercise knee pain <sep>', 'older persons with knee osteoarthritis <sep> one hundred thirteen men and women between 50 and 80 years old with diagnosed osteoarthritis of the knee <sep> outpatient veterans affairs medical center clinic and an affiliated university hospital <sep> osteoarthritis of the knee <sep>', 'patients with knee oa <sep> 126 patients <sep> patients with osteoarthritis oa of the knee <sep> patients with osteoarthritis of the knee <sep>', 'patients with osteoarthritis of the hip or knee <sep> patients with osteoarthritis oa of the hip or knee <sep> patients with hip or knee oa by american college of rheumatology criteria were selected <sep> 201 patients were randomized <sep>', 'oa of the knee <sep> knee joints with osteoarthritis <sep>', 'eighty-seven patients were recruited to the study 43 <sep> patello-femoral joint pfj osteoarthritis oa <sep> participants who had knee pain and predominant pfj oa were recruited from a large population based study <sep> knee osteoarthritis with predominant patello-femoral joint involvement <sep>', 'patients with osteoarthritis of the knee joint <sep> twenty volunteers with osteoarthritis of the knee joint <sep>', 'patients with severe oa of the knee <sep> patients participated in 96 of 96 assessments 100 and in 218 of 280 training sessions 77.9 <sep> patients with oa of the knee <sep> patients with severe osteoarthritis oa of the knees during and after a general physical training program <sep> patients with osteoarthritis of the knees <sep> 25 patients 3 men 22 women with oa of the knees according to the criteria of the american college of rheumatology acr <sep>', '6 yrs with radiographic evidence of mild/moderate medial compartment oa <sep> older community dwelling patients with unilateral knee osteoarthritis oa <sep> patients with knee oa <sep> one hundred seventy-nine men and women mean age 74 <sep> older patients with knee osteoarthritis <sep>', 'inpatient and outpatient services of an orthopedic hospital in an academic medical center <sep> 102 patients with a documented diagnosis of primary osteoarthritis of one or both knees participated in the study <sep> patients with osteoarthritis of the knee <sep>', 'older adults in the united states with osteoarthritis <sep> older adults with osteoarthritis <sep> older adults with lower extremity osteoarthritis <sep>'], 'interventions': ['aerobic exercise <sep> aerobic exercise program a resistance exercise program and a health education program <sep> structured exercise programs <sep> aerobic training <sep> aerobic exercise and resistance exercise with a health education program <sep>', 'health education by a peer and physical exercises taught by a physical therapist <sep> health educational and exercise program <sep> self-management program <sep>', 'home-based pedometer-driven walking program with arthritis self-management education walk <sep> individualized instruction <sep> home-based pedometer-driven walking program <sep> home-based pedometer-driven program <sep>', 'sun-style tai chi exercise <sep> tai chi exercise <sep>', 'home based exercise programme <sep> home based exercise programme <sep> regular telephone contact alone <sep> placebo health food tablet <sep> exercise therapy monthly telephone contact exercise therapy plus telephone contact or no intervention <sep>', 'home exercise <sep> exercise group performed strengthening exercises daily <sep> home based exercise programme <sep> no intervention <sep> home quadriceps exercises <sep>', 'rom st <sep> strength training <sep> strength training st or range-of-motion rom exercises <sep> lower-extremity strength training <sep>', 'con <sep> con-ecc <sep> concentric and coupled concentric-eccentric isokinetic resistance training <sep> isokinetic resistance training <sep> nontx <sep> concentric versus combined concentric-eccentric isokinetic training <sep> concentric-eccentric training <sep> concentric-eccentric con-ecc n  8 and nontreatment nontx n  6 <sep>', 'intensive exercise program <sep> six-week high-intensity exercise program <sep> short-term high-intensity exercise program <sep>', 'exercise training <sep> sa-cst alone sa-cst plus et et alone or standard care sc <sep> sa-cst  et <sep> spouse-assisted pain coping skills training sa-cst and exercise training et <sep> spouse-assisted coping skills training and exercise training <sep> et <sep> exercise program <sep>', 'strength exercises <sep> isometric versus dynamic resistance training <sep> dynamic versus isometric resistance training <sep> dynamic or isometric resistance training <sep>', 'placebo <sep> placebo <sep> physiotherapy included exercise massage taping and mobilisation followed by 12 weeks of self management <sep> physiotherapy and placebo interventions <sep> physiotherapy management <sep> multimodal physiotherapy programme including taping exercises and massage <sep>', 'strength training <sep> progressive strength training program or a nutrition education program attention control <sep> home based progressive strength training <sep> high intensity home-based progressive strength training program <sep>', 'community physiotherapy and enhanced pharmacy review <sep> physiotherapy advice about activity and pacing and an individualised exercise programme control advice leaflet reinforced by telephone call <sep>', 'cross-training exercise program <sep> physical activity program incorporating aerobic strength and stretching exercises <sep>', 'integrated therapy <sep> isokinetic exercises <sep> isokinetic exercise and pulse ultrasound for periarticular soft tissue pain group iii received isokinetic exercise pulse ultrasound and intraarticular hyaluronan therapy <sep>', 'physical conditioning exercise <sep> exercise program of aerobic walking aerobic aquatics or nonaerobic range of motion controls <sep> conditioning exercise <sep> aerobic versus nonaerobic exercise <sep>', 'hydrotherapy or tai chi classes <sep> tai chi classes <sep> waiting list control group <sep> hydrotherapy classes <sep> tai chi or hydrotherapy classes <sep>', 'exercise and dietary weight loss <sep> healthy lifestyle control diet only exercise only and diet plus exercise groups <sep>', 'manual physical therapy and exercise <sep> placebo <sep> manual physical therapy and supervised exercise <sep> physical therapy <sep> standardized knee exercise program <sep> manual therapy <sep> subtherapeutic ultrasound <sep>', 'isokinetic exercise <sep> muscle-strengthening exercises <sep> various therapeutic exercises <sep> isotonic muscle-strengthening exercise group iii received isometric muscle-strengthening exercise <sep> isokinetic muscle-strengthening exercise <sep> isotonic exercise <sep>', 'patient education <sep> isokinetic exercise <sep> isokinetic quadriceps exercise versus an educational intervention <sep> isokinetic exercise <sep> isokinetic exercise of the quadriceps muscle three times weekly over 8 weeks or a series of 4 discussions and lectures led by health care professionals <sep>', 'physical therapy <sep> small group format program n  40 and waiting list control <sep>', 'exercise therapy <sep> exercise therapy <sep>', 'thrice-weekly 12-week low intensity exercise program and a weekly educational program and a minimal treatment min rx group n  15 received only the education program <sep> low intensity weight-bearing exercise <sep> exercise ex <sep> exercise <sep>', 'physiotherapy including quadriceps exercises and patellar taping <sep> intervention package with standard nonphysiotherapy treatment <sep> physiotherapy intervention was delivered in local community health centers and clinics and comprised education quadriceps and functional exercises and patellar taping delivered by a single physiotherapist <sep> complex physical therapy based intervention <sep>', '8-week isokinetic muscle-strength-training program <sep> muscle-strength training <sep>', 'general physical training <sep> training focused on general fitness balance coordination stretching and lower extremity muscle strength and included a daily home exercise program <sep> physical training program <sep>', 'oxaprozin <sep> combined home based progressive exercise program <sep> progressive home based knee exercise program <sep> control program <sep> progressive exercise program <sep> oxaprozin alone <sep> nonsteroidal medication oxaprozin <sep> home based exercise therapy <sep>', 'supervised fitness walking and patient education <sep> walking program <sep> supervised fitness walking and patient education or standard routine medical care <sep> supervised fitness walking <sep>', 'multicomponent physical activity intervention <sep> fit and strong intervention <sep> training program consisted of range of motion resistance training aerobic walking and education-group problem solving regarding self-efficacy for exercise and exercise adherence <sep> facility-based multiple-component training program <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is platinum level evidence that land-based therapeutic exercise has at least short term benefit in terms of reduced knee pain and improved physical function for people with knee oa. the magnitude of the treatment effect would be considered small but comparable to estimates reported for non-steroidal anti-inflammatory drugs.
257,"{'outcomes': ['contamination rates <sep> rate of bacterial contamination of ebm <sep> rate of bacterial contamination <sep> ebm <sep> gram-negative bacilli <sep>', 'milk output <sep> efficiency efficacy comfort and convenience <sep> onset of milk ejection <sep> efficiency and efficacy <sep> efficiency efficacy comfort and convenience of the symphony breast pump medela mchenry il sbp <sep>', 'milk production <sep> milk production <sep> adequate production <sep>', 'duration of breastfeeding <sep> breastfeeding study bibs <sep> bibs <sep>', 'volume of milk expressed per expression and its fat content <sep> milk production <sep> volume of milk expressed and its fat content <sep> fat concentration <sep> milk volume and fat content <sep>', 'average stai scores average prolactin levels and weekly averages for number of pumping sessions hours of pumping and milk production in milliliters <sep> several demographic characteristics stai scores prolactin levels number of pumping sessions per week or weekly milk production <sep> daily milk production log weekly serum prolactin levels and a weekly state-trait anxiety inventory stai <sep>', 'morbidity and mortality rates <sep> mean daily mmv <sep> maternal milk volume <sep>', 'milk volume <sep> fat content of the breast milk <sep>', 'breastfeeding duration <sep>', 'bacterial colony counts <sep>', 'milk volume fat content and pattern of milk flow <sep> milk volume or fat content <sep>', 'milk flow <sep> shorter expression times <sep> milk flow and total volume <sep>', ""exclusive breastfeeding <sep> breastfeeding knowledge and practices <sep> mother's knowledge <sep> gradual improvement in breastfeeding practices i.e. started breast milk expression earlier and had more breast milk expression frequency <sep> breastfeeding problems <sep> breastfeeding knowledge questionnaire observational checklist of mother's breastfeeding practices breastfeeding diary infant's and mother's profile form and demographic information <sep>"", 'maternal response <sep> prolactin response <sep> milk extraction milk fat content maternal hormone response maternal satisfaction long-term milk production and duration of breastfeeding following return to the workforce <sep> 24-hour milk production <sep> 24-hour milk volume <sep> milk extraction efficiency <sep>'], 'punchline_text': ['when breast milk was expressed at home the rates of bacterial contamination by staphylococci p 0.003 and gram-negative bacilli p 0.002 were significantly higher in the breast-pump group than the manual group. <sep>', 'the onset of milk ejection was quicker p  0.05 for the single versus multiphase patterns in the sbp suggesting that mothers had become conditioned to the unphysiolologic single-phase pattern in the cbp. <sep>', 'in multivariate analysis mothers using sim produced a similar amount of milk by weight during weeks 2 to 5 postpartum compared to those using seq. <sep>', 'when analyses were adjusted for this there was no difference in bibs 1 between targeted and usual care groups and in bibs 2 among the treatment groups in the proportion of women still breastfeeding at the times studied. <sep>', 'milk yield per expression was sequential pumping with no massage <sep>', 'the two groups did not differ on several demographic characteristics stai scores prolactin levels number of pumping sessions per week or weekly milk production. <sep>', 'the tukey revealed significant differences p  0.01 between electric breast pump expression and hand expression but not between the electric and pedal pump or the pedal pump and hand expression. <sep>', 'the fat content of the breast milk in the two groups was not significantly different. <sep>', 'this difference did not reach statistical significance. <sep>', ""a student's t-test revealed a significant difference between the two groups women who performed special breast cleansing before breast pumping had significantly lower bacterial colony counts in their cultured breast milks. <sep>"", 'the mp was rated significantly better overall and more comfortable and pleasant to use. <sep>', 'mothers who used the ep who frequently double pumped showed shorter expression times but produced no more milk than mothers who used the mp. <sep>', ""mother's knowledge significantly increased for the intervention group but not the control group p  0.041). <sep>"", 'milk extraction efficiency was greater p  0.001 with the standard pump. <sep>'], 'population': ['mothers of very low birthweight infants <sep> mothers of very low birthweight vlbw infants 1501 g <sep> 28 mothers of such babies and 92 specimens of ebm were collected 41 specimens from 13 mothers assigned to the manual group and 51 specimens from 15 mothers in the breast-pump group <sep>', '35 mothers who compared each of three suction patterns in the sbp on two separate occasions six observations in the neonatal intensive care unit and used the cbp for all other pumpings <sep> all 100 mothers initiated lactation with the cbp <sep> mothers of very low birthweight infants <sep> 65 mothers who compared single and multiphase patterns in the sbp for 7 days and then returned to the cbp for 5 days <sep>', '39 lactating mothers of non-nursing preterm infants from 2 tertiary care centers <sep> mothers of non-nursing preterm infants <sep>', 'enrolled obese women who intended to breastfeed in two randomized trials <sep> 40 women received <sep> obese mothers <sep> 34 obese mothers <sep> obese women <sep>', '36 women were analysed 19 women used simultaneous pumping and 17 used sequential pumping <sep>', 'thirty-two breastfeeding mothers of premature infants <sep> mothers of premature infants <sep> mothers of premature infants <sep>', '228 ml n  22 463 <sep> funded by west virginia university department of research and graduate studies hsc <sep> mothers of premature or sick infants in special care nurseries scn <sep> 65 mothers whose infants were cared for in two scn in africa kenya and nigeria and were unable to feed directly at the breast <sep> african nurseries <sep>', 'premature infants with a relaxation/imagery audiotape <sep>', 'wic women returning to work or school in hawaii <sep> women with greater education breastfed for a shorter duration <sep> women infants and children wic branch of the hawaii department of health encourages and assists mothers in breastfeeding <sep> 280 women with the duration of breastfeeding analyzed in 229 of these women <sep>', 'sixty-five women whose infants were being cared for in a nicu and who wished to pump their breasts for future breast milk feedings <sep>', 'mothers of term infants <sep>', ""94 of united kingdom neonatal units with a <sep> 145 women who delivered infants of 35 weeks gestation to use the mp or the ep and measured total milk volume expressed while using the randomized pump during the infant's hospital stay pattern of milk output and creamatocrit of milk expressed during a test period in the second week and pump characteristics by maternal questionnaire <sep> mothers who delivered preterm infants <sep> preterm infants <sep>"", '60 mothers and their preterm infants who were born before 37 weeks of gestation <sep> breastfeeding preterm infants <sep> mothers of preterm infants in cairo egypt <sep> egyptian mothers of preterm infants <sep> mothers of preterm infants <sep>', 'n  58 and maternal ranking of pump performance n  56 <sep> healthy women intending to return to work or school and to breastfeed exclusively for or=4 months were enrolled in late pregnancy n  62 <sep>'], 'interventions': ['expressed breast milk ebm obtained by manual expression and breast pumps <sep> breast milk obtained by manual expression and breast pumps <sep>', 'classic breast pump medela cbp <sep> sbp <sep>', 'sequential single seq or simultaneous double sim breast-pumping regimen <sep> pumping style <sep>', 'manual or electric breast pump <sep> targeted breastfeeding support in the hospital and via telephone or usual care <sep>', 'sequential and simultaneous breast pumping <sep> simultaneous both breasts simultaneously or sequential one breast then the other milk expression <sep> breast massage <sep> massage or non-massage first <sep>', 'control single or the experimental bilateral breast pump group <sep> bilateral breast pumping system <sep>', 'electric breast pump <sep>', '20-minute audio cassette tape based on relaxation and visual imagery techniques <sep> relaxation/imagery approach <sep> mechanical ventilation <sep>', 'electric breast pump vs. a manual pump <sep> manual and electric breast pumps <sep>', 'control group were instructed to wash their hands thoroughly before breast pumping and members of an experimental group were instructed to wash their hands thoroughly and were given special instructions on breast cleansing <sep>', 'novel manual breast pump mp <sep> mini-electric pump mep <sep> novel manual breast pump with a mini-electric breast pump <sep>', 'novel manual breast pump with a standard electric breast pump <sep> standard electric pump ep egnell <sep> novel manual pump mp avent isis <sep>', 'breastfeeding educational program <sep> educational program <sep>', 'novel embrace playtex westport ct or standard pump <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",the most suitable method for milk expression may depend on the time since birth purpose of expression and the individual mother and infant. low cost interventions including early initiation when not feeding at the breast relaxation hand expression and lower cost pumps may be as effective or more effective than large electric pumps for some outcomes. small sample sizes large standard deviations small number of studies reviewed and the diversity of the interventions argue caution in applying these results beyond the specific method tested in the specific settings.
258,"{'outcomes': ['qol <sep> qol change <sep> disease-free survival <sep> postoperative serious adverse events <sep> operating time <sep> functional assessment of cancer therapy-general fact-g questionnaire <sep> adverse events <sep> quality of life qol <sep> quality of life <sep> intraoperative adverse events <sep> emotional and social wellbeing measures of fact and the visual analogue scale <sep>', 'shorter hospital stay less pain and quicker resumption of daily activities <sep> proportion of patients with a minor complication <sep> blood loss <sep> proportion of major complications <sep> pain medication <sep> shorter hospital stay <sep> conversion to laparotomy <sep> postoperative major complication <sep> major complication rate <sep> complication rate <sep> proportion of patients with an intraoperative major complication <sep>', 'perioperative morbidity <sep> overall and recurrence-free survival <sep> yield of pelvic and para-aortic lymph nodes duration of surgery and incidence of postoperative complications <sep> blood loss and transfusion rates <sep>', 'mean length of hospital stay <sep> mean blood loss <sep> mean operative time <sep> feasibility safety and morbidity <sep>', 'operative time <sep> pelvic and para-aortic nodes <sep> overall detection of advanced stage stage iiia iiic or ivb <sep> 6-week morbidity and mortality hospital length of stay conversion from laparoscopy to laparotomy recurrence-free survival site of recurrence and patient-reported quality-of-life outcomes <sep> bleeding <sep> intraoperative complications <sep> metastatic cancer <sep> hospitalization <sep> recurrence or disease-free survival <sep> severe postoperative adverse events <sep>', 'wound infections <sep> longer hospital stay <sep> pelvic lymph node metastases <sep> operative morbidity <sep> mean number of harvested lymph nodes <sep> lymph node number and detection of lymph node metastasis <sep>', 'deaths <sep> disease-free p  .512 survival <sep> cumulative recurrence rates <sep> safety and efficacy data <sep>', 'operative time blood loss blood transfusion intraoperative complications postoperative complications duration of hospital stay and number of lymph nodes obtained <sep> blood loss and shorter hospitalization <sep>'], 'punchline_text': ['improvements in qol up to 6 months after surgery continued to favour tlh except in the emotional and social wellbeing measures of fact and the visual analogue scale of the euroqol five dimensions euroqol-vas). <sep>', 'tlh was associated with significantly less blood loss p<0.0001 less use of pain medication p<0.0001 a shorter hospital stay p<0.0001 and a faster recovery p=0.002 but the procedure took longer than tah p<0.0001). <sep>', 'overall and recurrence-free survival did not differ significantly for both groups. <sep>', 'the mean operative time was 136 min+/-31 95 ci 118-181 in the lps group and 123 min+/-29 95 ci 111-198 in the lpt group p<0.01). <sep>', 'hospitalization of more than 2 days was significantly lower in laparoscopy versus laparotomy patients 52 v 94 respectively p  .0001). <sep>', 'pelvic lymph node metastases were detected in 7.7 of the patients in the laparoscopy group and 15.4 in the laparotomy group and the difference was not significant. <sep>', 'no significant differences in overall p  .535 and disease-free p  .512 survival were observed. <sep>', 'this procedure is associated with significantly less blood loss and shorter hospitalization however it is associated with significantly longer operating time. <sep>'], 'population': ['patients with histologically confirmed stage i endometrioid adenocarcinoma and eastern cooperative oncology group performance status less than 2 were randomly assigned to tlh n=190 or tah n=142 stratified by histological grade and study centre <sep> 2010 elsevier ltd <sep> 361 participants were enrolled in the qol substudy at 19 centres across australia new zealand and hong kong 332 completed the qol analysis <sep> stage i endometrial cancer lace began in 2005 <sep> stage i endometrial cancer lace <sep> eight of 332 patients 2.4 had treatment conversion-seven from tlh to tah and one from tah to tlh patient preference <sep> cancer council queensland cancer council new south wales cancer council victoria cancer council western australia <sep>', '2010 elsevier ltd <sep> 21 hospitals in the netherlands and 26 gynaecologists with proven sufficient skills in tlh participated <sep> women with early-stage endometrial cancer <sep> 283 patients with stage i endometrioid adenocarcinoma or complex atypical hyperplasia <sep> obese women <sep> early-stage endometrial cancer <sep>', '25 patients by laparoscopy and in 24 patients by laparotomy <sep> patients with endometrial cancer <sep> between july 1995 and august 1999 70 patients with endometrial cancer figo stage i-iii <sep> thirty-seven patients were treated in the laparoscopic versus 33 patients in the laparotomy group <sep>', 'patients with early endometrial cancer <sep> 159 women the <sep> 159 patients with clinical stage i endometrial cancer <sep> early-stage endometrial cancer <sep>', '1,682 patients and completed without conversion in 1,248 patients 74.2 <sep> patients with clinical stage <sep> i to iia uterine cancer <sep>', 'fifty-two patients with endometrial cancer who underwent surgical staging consisting of total hysterectomy bilateral salpingo-oophorectomy with pelvic lymph node dissection and cytology between 1998 to 2002 were included in the study <sep> 52 patients 26 underwent laparotomy and the remaining 26 underwent <sep> early stage endometrial cancer <sep> endometrial cancer <sep>', '84 patients with clinical stage i endometrial cancer laparoscopic surgery group 40 women laparotomy group 38 women <sep> early stage endometrial cancer <sep>', 'stage i endometrial cancer <sep> from july 1996 to july 1998 61 patients with clinical stage i endometrial cancer were treated at the gynaecology oncology unit at the royal north shore of sydney australia <sep> twenty-nine patients were treated with <sep> stage i endometrial cancer with the traditional transabdominal approach <sep>'], 'interventions': ['total laparoscopic hysterectomy tlh with total abdominal hysterectomy tah <sep> tlh <sep> tah <sep> total laparoscopic hysterectomy versus total abdominal hysterectomy <sep>', 'intervention group tlh n=187 or control group tah <sep> laparoscopy versus laparotomy <sep> tlh versus tah <sep> total abdominal hysterectomy tah and bilateral salpingo-oophorectomy <sep> tlh <sep> total laparoscopic hysterectomy tlh and bilateral salpingo-oophorectomy <sep>', 'laparoscopic-vaginal approach <sep> laparoscopic-vaginal approach with the conventional abdominal approach <sep> laparoscopic-assisted vaginal versus abdominal surgery <sep> laparoscopic-assisted simple or radical vaginal hysterectomy or simple or radical abdominal hysterectomy with or without lymph node dissection <sep>', 'total laparoscopic hysterectomy lps and abdominal hysterectomy with lymphadenectomy lpt <sep> total laparoscopic hysterectomy versus abdominal hysterectomy with lymphadenectomy <sep> laparoscopy <sep> lpt <sep> lps or lpt approach <sep>', 'open laparotomy <sep> laparoscopy <sep> laparoscopy versus laparotomy <sep> laparotomy <sep> hysterectomy salpingo-oophorectomy pelvic cytology and pelvic and para-aortic lymphadenectomy <sep> laparoscopic surgical staging <sep> laparoscopy <sep>', 'laparotomy and laparoscopy <sep> adjuvant radiotherapy <sep> laparoscopic surgery <sep> laparoscopy or laparotomy <sep> laparoscopic staging surgery <sep> laparoscopy <sep>', 'laparoscopic surgery vs laparotomy <sep> laparoscopic surgery and laparotomy approaches <sep> laparoscopic surgery approach <sep>', 'laparoscopically assisted vaginal hysterectomy versus abdominal hysterectomy <sep> traditional laparotomy and underwent total abdominal hysterectomy tah and bso plus minus pelvic lymphadenectomy pla <sep> laparoscopic assisted vaginal hysterectomy lavh and bilateral salpingo-oophrectomy bso plus minus laparoscopic pelvic lymphadenectomy lpla <sep> laparoscopic treatment <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",this review has found evidence to support the role of laparoscopy for the management of early endometrial cancer. for presumed early stage primary endometrioid adenocarcinoma of the endometrium laparoscopy is associated with similar overall and disease-free survival. laparoscopy is associated with reduced operative morbidity and hospital stay. there is no significant difference in severe post-operative morbidity between the two modalities.
259,"{'outcomes': ['incontinence quality-of-life questionnaire score <sep> adverse events <sep> pad usage <sep> stress urinary incontinence and urethral hypermobility <sep>', 'pad testing stamey continence grading and urodynamics including abdominal leak point pressures <sep>', 'continence <sep> postoperative contentness <sep> flow rate <sep> mucp and ful <sep> maximum urethral closure pressure mucp functional urethral length ful maximum flow rate and cough test <sep>', 'urinary retention <sep> standardized questionnaire pad test cough test and urodynamics <sep> standardized incontinence questionnaire 1-hour pad test and cough test <sep> urge incontinence <sep>', 'short-term risk of urgency and urinary retention <sep> adverse events <sep> continence grade and pad weight testing <sep> improvement of 1 continence grade <sep>', 'proportion of women who achieved a 50 reduction in urinary leakage on provocation testing <sep>'], 'punchline_text': ['there was a significant higher increase of incontinence quality-of-life questionnaire score in the mpq group compared to controls p  0.017). <sep>', ' long-term follow-up demonstrated that durasphere had greater success than contigen in providing improved continence grades. <sep>', 'both midurethral and bladder neck collagen injections improve patients satisfaction almost equally with a small advantage for midurethral injections. <sep>', 'complications included cystitis in 9 of 189 injections urinary retention in 6 in the fat injection group urge incontinence in 9 of 68 patients and pulmonary fat embolism resulting in death in 1 of 189 procedures. <sep>', 'at 12 months after the first injection the two materials were equivalent with respect to the improvement in continence grade and pad weight testing. <sep>', 'outcomes at 12 months from last treatment failed to demonstrate that mid-urethral injected zuidex was equivalent to cystoscopically injected contigen in primary and secondary outcome variables. <sep>'], 'population': ['women <sep> women with sui and urethral hypermobility <sep> women with urodynamic stress urinary incontinence sui and urethral hypermobility after an unsuccessful conservative treatment <sep> women without previous incontinence surgery <sep>', 'stress urinary incontinence caused by intrinsic sphincter deficiency isd <sep> durasphere patients and 21/26 81 <sep> stress urinary incontinence <sep> 26 patients in each group 25/26 96 <sep> fifty-two women diagnosed with stress urinary incontinence caused by isd <sep> durasphere patients and 3/21 14 <sep>', 'female urodynamic stress incontinence <sep> female stress urinary incontinence <sep> 30 elderly female patients with urodynamic stress incontinence to either <sep>', 'female stress urinary incontinence <sep> 68 women enrolled 35 received fat and 33 received <sep> women with stress incontinence <sep> 56 patients completed the study including 27 in the fat and 29 in the placebo group for a total of 189 injections 91 fat and 98 saline <sep>', '355 women diagnosed with sui due to isd and used a standardized pad test and the stamey continence grade as the primary endpoints <sep> stress urinary incontinence <sep> all patients had an abdominal leak point pressure of less than 90 cm h(2)o average 51 <sep> stress urinary incontinence sui due to intrinsic sphincter deficiency isd <sep> participants ages ranged from 26 to 84 years <sep>', 'adult women <sep> 344 women with intrinsic sphincter deficiency at 23 north american sites and followed up for 1 year from last treatment <sep> women with intrinsic sphincter deficiency <sep>'], 'interventions': ['macroplastique implantation system <sep> pelvic floor muscle exercises home program <sep> macroplastique(r <sep> mpq <sep> mpq implantation system mis <sep>', 'durasphere and contigen <sep> durasphere carbon metal technologies st. paul mn compared with contigen c. r. bard covington ga <sep>', 'midurethral and bladder neck collagen injections <sep> transurethral collagen injection midurethrally or to the bladder neck <sep>', 'placebo <sep> saline injections <sep> periurethral injections of autologous fat treatment group or saline placebo <sep> periurethral autologous fat injection <sep> periurethral autologous fat injection <sep>', 'durasphere <sep> bovine collagen <sep>', 'zuidex via the implacer versus proximal urethral injection of contigen cystoscopically <sep> zuidex-implacer vs proximal urethral cystoscopic injections of contigen <sep> zuidex <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",the available evidence base remains insufficient to guide practice. in addition the finding that placebo saline injection was followed by a similar symptomatic improvement to bulking agent injection raises questions about the mechanism of any beneficial effects. one small trial comparing silicone particles with pelvic floor muscle training was suggestive of benefit at three months but it is not known if this was sustained and the treatment was associated with high levels of postoperative retention and dysuria. greater symptomatic improvement was observed with surgical treatments though the advantages need to be set against likely higher risks. no clear-cut conclusions could be drawn from trials comparing alternative agents although dextranomer hyaluronic acid was associated with more local side effects and is no longer commercially available for this indication. there is insufficient evidence to show superiority of mid-urethral or bladder neck injection. the single trial of autologous fat provides a reminder that periurethral injections can occasionally cause serious side effects.
260,"{'outcomes': ['recurrent episodes of bleeding <sep> safety efficacy and costs <sep> neonatal morbidity <sep> blood transfusion <sep> mean number of maternal hospital days <sep> neonatal deaths <sep> mean birth weights <sep> presence of respiratory distress syndrome intracranial hemorrhage or culture-proved sepsis <sep>', 'gestational age at delivery <sep> prolongation of pregnancy number of patients bleeding <sep> maternal and neonatal morbidity <sep> units of blood transfused birth weight hospital stay and costs and admission to neonatal intensive care unit <sep>'], 'punchline_text': ['the mean number of maternal hospital days differed significantly between the two groups inpatients required an average of 28.6  <sep>', 'no statistically significant differences were observed between the two groups studied. <sep>'], 'population': ['fifty-three women with the initial diagnosis of placenta previa at 24 to 36 weeks gestation who required hospitalization for vaginal bleeding <sep> symptomatic placenta previa <sep> all subjects who reached 36 weeks gestation with persistent placenta previa underwent amniocentesis <sep> outpatients with recurrent bleeding were readmitted for evaluation <sep> twenty-six outpatients were discharged home after  or  72 hours of hospitalization <sep> women with symptomatic placenta previa initially diagnosed before 37 weeks gestation are treated as outpatients <sep>', 'women with placenta previa <sep> thirty-nine pregnant women with an initial diagnosis of placenta previa at 24 to 30 weeks gestation <sep>'], 'interventions': ['inpatient or outpatient expectant management <sep>', 'cervical cerclage <sep> cervical cerclage <sep> conservative management <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>']}",there are insufficient data from trials to recommend any change in clinical practice. available data should however encourage further work to address the safety of more conservative policies of hospitalisation for women with suspected placenta praevia and the possible value of insertion of a cervical suture. note the six citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
261,"{'outcomes': ['reaction rates <sep> rate of injection site reactions such as erythema induration and subcutaneous nodules <sep> injection site reactions <sep> peak anti-pa igg antibody levels <sep> peak anti-pa igg antibody response <sep>', 'geometric mean titers gmt for lethal toxin neutralization activity tna <sep> geometric mean concentrations gmc <sep> clinically serious or dose-related toxicity or reactogenicity <sep> immunogenicity and tolerance <sep> local reactogenicity mostly pain <sep> antibody response <sep> tna response <sep> systemic reactogenicity mostly headache <sep>', 'igg geometric mean concentration gmc geometric mean titer gmt and proportion of responders with a 4-fold rise in titer <sep> immunogenicity and safety <sep> odds ratio for ordinal end point pain <sep> occurrence of systemic aes <sep> occurrence of injection site aes <sep>', 'safety reactogenicity and immunogenicity <sep> safety reactogenicity and immunogenicity <sep> peak antibody responses <sep>'], 'punchline_text': ['following the first sq dose of ava compared to males females had a significantly higher rate of injection site reactions such as erythema induration and subcutaneous nodules p<0.001). <sep>', 'systemic reactogenicity mostly headache was more common among rpa102 vaccinees but only following the first vaccination 49.4 versus 15.8 p  0.025). <sep>', 'the odds ratio for ordinal end point pain reported immediately after injection was reduced by 50 for the 4-im vs 4-sq groups p  .001). <sep>', 'peak antibody responses to adjuvanted rpa given intramuscularly were equivalent to ava given either intramuscularly or subcutaneously when measured by either assay. <sep>'], 'population': ['humans <sep> 173 volunteers <sep>', 'hundred healthy volunteers <sep>', 'healthy adults <sep>', 'healthy adults aged 18-40 years <sep> healthy adults <sep>'], 'interventions': ['aluminum hydroxide adsorbed vaccine <sep> ava once im or sq <sep> im or sq <sep> ava <sep> anthrax vaccine adsorbed ava <sep> ava doses administered intramuscularly im or sq <sep>', 'new recombinant protective antigen rpa102 anthrax vaccine <sep> rpa102 <sep> recombinant protective antigen rpa102 anthrax vaccine <sep> aluminum hydroxide adjuvant <sep>', 'anthrax vaccine adsorbed ava <sep> saline injections <sep> anthrax vaccine <sep>', 'recombinant protective antigen anthrax vaccine <sep> anthrax immunization with either licensed anthrax vaccine adsorbed ava biothrax or an experimental recombinant protective antigen vaccine rpa <sep> recombinant protective antigen anthrax vaccine <sep> rpa vaccine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",one cluster-rct provides limited evidence that a live-attenuated vaccine is effective in preventing cutaneous anthrax. vaccines based on anthrax antigens are immunogenic in most vaccinees with few adverse events or reactions. ongoing randomized controlled trials are investigating the immunogenicity and safety of anthrax vaccines.
262,"{'outcomes': ['tolerated and the number of reported side-effects <sep>', 'headache frequency headache severity nausea frequency or severity <sep> reduced duration of headache <sep>', 'platelet aggregability <sep> plasma concentration or serum production of txb2 <sep> platelet and plasma camp levels <sep> adp-induced platelet aggregability platelet camp atp and adp levels plasma camp and txb2 concentration as well as the serum production of txb2 <sep> platelet function <sep>', 'migraine index <sep> migraine index frequency duration severity of attacks and headache days <sep> plasma concentrations <sep>', 'number of migraine attacks <sep> adverse experiences <sep> migraine attacks <sep> tolerated <sep> mean duration of migraine in hours h per month <sep> efficacy and tolerability <sep>', 'headache parameters <sep> migraine symptoms <sep> migraine <sep>', 'mean frequency of attacks <sep> migraine index <sep> global evaluation <sep> migraine index frequency of attacks and global evaluation <sep>', 'headache or nausea <sep> number of sickleave days and the use of symptomatic drugs <sep>', 'migraine frequency <sep> migraine frequency <sep>', 'attack frequency <sep> tolerated and safe <sep> adverse events <sep> efficacy and tolerability <sep> efficacy and tolerability <sep> mean attack frequency <sep>', 'frequency and severity of headaches <sep>', 'frequency of attacks <sep> propranolol sleep disturbances including nightmares 6 tiredness 8 mental changes e.g. irritability 3 and weight gain 4 <sep> weight gain <sep> patient profile onset of response to therapy final response to therapy incidence of dropout from the trial or incidence of side-effects <sep>', 'headache index <sep> number of headache days or the number of migraine attacks <sep>', 'duration of the attacks and the number of analgesics <sep> frequency of migraine attacks <sep>', 'mean frequency of attacks <sep> headache index <sep> headache index <sep> side effects <sep> mean duration of attacks <sep> mean severity of attacks <sep>', 'severity nor duration of migraines <sep> weight gain <sep> frequency of migraines and use of rescue analgesics <sep> number of attacks <sep> blood pressure and heart rate flunarizine <sep> cardiovascular function <sep> efficacy and safety <sep>', 'percentage and severity of side-effects <sep> number duration and severity of attacks <sep>', 'average number of monthly crises <sep> systolic blood pressure and heart rate <sep> frequency of migraine attacks <sep> efficacy and safety <sep>', 'vep latency <sep> veps <sep> vep amplitude <sep> vep amplitudes and longer latencies <sep> frequency intensity and duration of migraine attacks nor on amplitude and latency of the veps <sep> headache diaries <sep> vep amplitudes <sep>', 'blood brain barrier <sep>', 'symptomatological profile of individual migraine attacks <sep> efficacy <sep> adverse drug reaction <sep> efficacy variables headache attacks days with headache analgesic consumption <sep>', 'frequency of the attacks <sep> prolactin prl luteinizing hormone lh and growth hormone gh levels <sep> hormones levels <sep> serum prolactin <sep>', 'average duration or severity of migraine attacks <sep> migraine attacks <sep> frequency of attacks and their total duration <sep>', 'prophylactic effectiveness <sep>', 'efficacy parameter <sep> efficacy parameters migraine hours migraine days and migraine intensity <sep> migraine attacks <sep> dizziness fatigue and fall in blood pressure <sep>', 'headache response to medication <sep> migraine headache <sep> anxiety or depression <sep>', '5-ht supersensitivity <sep> consumption of analgesic drugs <sep>', 'median intensity of pain and the number of attacks <sep> mild adverse reactions <sep> number of attacks the total duration of attacks and additional drugs taken <sep>', 'headache <sep> medication relieving attacks <sep> attack frequency and headache index <sep>', 'tolerated <sep> efficacy <sep> attack frequency migraine days severity score consumption of acute medication and subjective evaluation <sep> migraine symptoms <sep>'], 'punchline_text': ['both drugs were generally well tolerated and the number of reported side-effects was similar to those reported during the run-in period placebo). <sep>', 'there were no significant differences between the three treatment periods in headache frequency headache severity nausea frequency or severity. <sep>', 'after propranolol treatment the patients showed lower adp threshold values for producing irreversible platelet aggregation and lower platelet and plasma camp levels as compared to metoprolol. <sep>', 'compared to the pretreatment period prp and asa reduced migraine index frequency duration severity of attacks and headache days. <sep>', 'adverse experiences were reported by 13 patients 16.0 treated with cyclandelate by 5 patients 9.1 treated with placebo and by 19 patients 24.4 treated with propranolol. <sep>', 'based on arima statistics 39.3 of the patients showed a significant improvement of migraine during treatment with cyclandelate compared with 29.4 placed on propranolol. <sep>', 'it was not found statistical differences between groups nevertheless there was a trend in the group using two drugs reaching lower values in migraine index frequency of attacks and global evaluation. <sep>', 'statistical analysis did not show any significant difference between the two drugs in respect to headache or nausea. <sep>', 'no significant difference was identified between divalproex and propranolol for the prophylaxis of migraine without aura. <sep>', 'both flunarizine groups were at least as effective as propranolol p<0.001 in one-sided test). <sep>', 'all three groups reported improvement the most noticeable being in those patients who received 80 mg of nadolol daily. <sep>', 'there was no significant difference between the two groups in terms of patient profile onset of response to therapy final response to therapy incidence of dropout from the trial or incidence of side-effects. <sep>', 'in the 37 patients who completed the trial there was no significant difference between propranolol 160 mg and femoxetine 400 mg with respect to the number of headache days or the number of migraine attacks during the last 2 months of each treatment propranolol however was superior to femoxetine when the headache index was used  <sep>', 'the treatment with both substances resulted in a statistically significant reduction in frequency of migraine attacks. <sep>', 'headache index 0.95 propranolol and 23 patients on placebo experienced side effects p less than 0.05). <sep>', 'both treatments led to a significant reduction in the frequency of migraines and use of rescue analgesics with a significantly greater decrease in number of attacks for flunarizine after 1 and 4 months. <sep>', 'concerning the frequency and intensity of attacks additional analgesics consumption and overall evaluation both drugs proved to be highly effective in the practice as well as in the hospital study. <sep>', 'la.p was significantly more effective than placebo in reducing the frequency of migraine attacks p  0.01 by variance analysis). <sep>', 'at baseline migraine patients had significantly higher vep amplitudes and longer latencies than did a group of 87 healthy control subjects. <sep>', 'inderal seemed to be more effective than d-propranolol but the difference was not statistically significant p greater than 0.05). <sep>', 'both drugs showed a significant reduction in all the efficacy variables headache attacks days with headache analgesic consumption with no difference between treatments. <sep>', 'a statistically significant reduction in the frequency of the attacks was demonstrated in both groups. <sep>', 'there were no significant effects of mefenamic acid or propranolol on average duration or severity of migraine attacks. <sep>', 'a statistically significant difference in effect could not be ascertained. <sep>', 'no statistical significant difference in any efficacy parameter was found between the two drugs level 2 alpha  0.05 alpha  0.10). <sep>', 'the effectiveness of neither drug correlated with a decrease in anxiety or depression demonstrated by psychological testing. <sep>', 'chronic treatments of methysergide and propranolol drugs exerting antagonist action at 5-ht receptors induced a significant amelioration in 256m sufferers. <sep>', 'both tolfenamic acid and propranolol significantly reduced the number of attacks the total duration of attacks and additional drugs taken when compared with placebo. <sep>', 'a significant reduction in the use of medication relieving attacks was observed during the propranolol treatment as compared with the pre-treatment period. <sep>', 'it is concluded from the results that there are no differences in efficacy between metoprolol and propranolol regarding the studied parameters. <sep>'], 'population': ['56 patients with classical or common migraine <sep> migraine prophylaxis <sep>', 'thirty patients with severe classical and common migraine <sep>', 'twelve patients with classical migraine were included <sep> migraine patients <sep>', 'migraine <sep>', 'migraine <sep> 214 patients <sep>', '84 patients <sep>', 'fourty-five migraine without aura patients <sep> migraine without aura prophylaxis <sep>', 'migraine <sep>', 'private practice of a general neurologist with a special interest in headache disorders <sep> migraine without aura <sep> 37 patients 30 women and 7 men selected 32 completed the study <sep>', '142 subjects discontinued the trial prematurely mainly because of adverse events n=58 <sep> 808 subjects <sep>', 'migraine <sep> forty-eight patients 13 men and 35 women <sep>', 'fifty-eight patients <sep> patients in whom beta-blockers were contraindicated were excluded from the trial <sep>', '37 patients <sep> twelve patients withdrew because of drug failure or failure to attend checkups 6 side effects 4 or other non-drug related causes 2 <sep> forty-nine patients commenced the trial <sep>', 'migraine <sep> 39 migraine patients <sep>', '83 patients <sep> common migraine sufferers 25 males 71 females with a history of 2-6 attacks per month participated in a 4-centre trial <sep>', 'migraine with or without aura <sep> 94 patients <sep>', '400 patients <sep> eighty-seven patients from 12 outpatient departments were admitted to the first study while 434 patients from 99 medical practices participated in the second study <sep> patients suffering predominantly from classical migraine <sep>', 'forty-one patients completed the study <sep> fifty-five of the 74 patients who entered the trial were included at the end of the run-in period <sep> migraine prophylaxis <sep>', '87 healthy control subjects <sep> patients with migraine <sep> 58 patients with common or classical migraine <sep>', 'migraine <sep> 20 migraine patients <sep>', 'forty migraineurs 10 males 30 females <sep>', 'patients suffering from migraine <sep> 11 patients were treated with <sep>', '29 patients <sep> migraine prophylaxis <sep>', '18 migraine patients <sep> group of 19 migraine patients <sep>', '76 patients with migraine with or without aura <sep> twenty patients discontinued the study 12 patients on <sep>', '30 patients in a double-blind <sep>', '134 m sufferers <sep> 256m sufferers <sep>', '31 patients with at least 3 migraine attacks <sep>', '24 patients who continued the study to the end the periods of <sep> 29 patients commenced the experiment <sep>', 'thirty-six patients with classical or common migraine were included <sep> classical and common migraine <sep>'], 'interventions': ['propranolol <sep> metoprolol and propranolol <sep> metoprolol <sep> 1-selective beta-blocker metoprolol <sep> metoprolol <sep>', 'propranolol la 160 mg once daily or placebo <sep> propranolol la <sep> placebo <sep> propranolol <sep>', 'metoprolol <sep> blockade propranolol <sep> beta 1-selective metoprolol 50 mg b.i.d. or non-selective propranolol <sep> propranolol <sep>', 'acetylsalicylic acid asa <sep> propranolol and acetylsalicylic acid <sep> propranolol prp <sep>', 'placebo and propranolol <sep> cyclandelate and propranolol <sep> placebo <sep> propranolol <sep>', 'cyclandelate and propranolol <sep> cyclandelate versus propranolol <sep> placebo <sep> propranolol <sep>', 'propranolol 60 mg/day plus flunarizine <sep> flunarizine <sep> flunarizine plus propranolol <sep> propranolol <sep> propranolol <sep> propranolol 60 mg/day to flunarizine <sep>', 'clonidine <sep> propranolol inderal and clonidine catapressan <sep> propranolol and clonidine <sep>', 'placebo <sep> divalproex sodium depakote <sep> divalproex or propranolol <sep> divalproex <sep> valproate sodium trough level was 68.5 mg/l. propranolol <sep> propranolol <sep> divalproex with propranolol and placebo <sep> divalproex and propranolol <sep> propranolol hydrochloride and placebo <sep>', 'flunarizine <sep> propranolol <sep>', 'nadolol <sep> placebo <sep> propranolol <sep> nadolol and propranolol <sep>', 'flunarizine <sep> flunarizine and propranolol <sep> calcium-entry blocker flunarizine sibelium janssen <sep> propranolol <sep>', 'propranolol and femoxetine a ht-uptake inhibitor <sep> femoxetine <sep> propranolol <sep> 5-ht uptake inhibitor femoxetine <sep> propranolol <sep> propranolol frekven r <sep>', 'placebo <sep> 5-hydroxytryptophan <sep> propranolol <sep> 5-hydroxytryptophan or propranolol <sep> 5-hydroxytryptophan and propranolol <sep>', 'propranolol and timolol <sep> propranolol vs placebo <sep> placebo <sep> timolol <sep> propranolol <sep> timolol <sep>', 'placebo <sep> flunarizine 10 mg daily or propranolol <sep> flunarizine <sep> flunarizine <sep> propranolol <sep> propranolol <sep> flunarizine a cerebro-specific calcium channel antagonist and propranolol <sep>', 'flunarizine <sep> flunarizine vs. propranolol <sep> propranolol <sep>', 'la.p <sep> placebo <sep> long-acting propranolol la.p <sep> propranolol <sep>', 'visual potentials evoked by pattern reversal veps <sep> calcium channel blocker nifedipine the beta-1-selective blocker metoprolol and the nonselective beta adrenoreceptor blocker propranolol <sep> nifedipine <sep>', 'placebo <sep> propranolol 40 mg q.i.d. and placebo <sep> propranolol <sep> propranolol <sep> phopranolol in racemic form inderal d-propranolol and placebo <sep>', 'alpha-dihydroergocryptine mesylate <sep> alpha-dihydroergocryptine <sep> alpha-dihydroergocryptine <sep> propranolol <sep> noradrenergic and dopaminergic cold pressor bromocriptine <sep> bromocriptine <sep>', 'nimodipine <sep> flunarizine <sep> propranolol <sep> nimodipine <sep> chronic nimodipine and propranolol <sep>', 'propranolol or placebo <sep> placebo <sep> mefenamic acid and propranolol with placebo <sep> antiprostaglandin agent mefenamic acid <sep> mefenamic acid or propranolol <sep> mefenamic acid therapy or propranolol therapy <sep> mefenamic acid and propranolol <sep>', 'propranolol <sep> placebo <sep> propranolol <sep>', 'placebo <sep> tolfenamic acid versus propranolol <sep> tolfenamic acid <sep> tolfenamic acid 100 mg three times daily or propranolol <sep> propranolol <sep> tolfenamic acid and propranolol <sep>', 'propranolol and amitriptyline <sep> placebo <sep>', '5-ht <sep> ergotamine and sumatriptan <sep> methysergide and propranolol <sep>', 'placebo <sep> tolfenamic acid propranolol and placebo <sep> tolfenamic acid <sep> propranolol <sep> tolfenamic acid and propranolol <sep> tolfenamic acid <sep>', 'femoxetine <sep> 5-ht uptake inhibitor femoxetine <sep> femoxetine  a new 5-ht uptake inhibitor  and propranolol <sep> propranolol <sep>', 'blocker propranolol <sep> propranolol <sep> metoprolol and propranolol <sep> 1-selective beta-blocker metoprolol <sep> metoprolol <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>']}",although many trials have relevant methodological shortcomings there is clear evidence that propranolol is more effective than placebo in the short-term interval treatment of migraine. evidence on long-term effects is lacking. propranolol seems to be as effective and safe as a variety of other drugs used for migraine prophylaxis.
263,"{'outcomes': ['overall survival <sep> survival <sep> time of diagnosis <sep> recurrence <sep>', 'five-year survival rate <sep> local recurrence <sep> local recurrences <sep> rectal cancer <sep> curative re-resection <sep>', 'probability of overall survival <sep> survival and recurrence resectability <sep> overall survival <sep>', 'investigations number and timing of recurrences and deaths <sep> recurrence time to detection and death rates <sep> scores for quality of life physical component score <sep> anxiety <sep> quality of life sf-12 physical and mental component scores 2 anxiety and depression hospital anxiety and depression scale and 3 patient satisfaction patient visit-specific questionnaire <sep> patient satisfaction <sep>', 'earlier detection of hepatic metastases <sep> asymptomatic chest radiography-detected lung metastasis <sep> number of curative hepatectomies <sep> asymptomatic ct-detected liver metastasis <sep> survival benefit <sep> survival <sep>'], 'punchline_text': ['patients subjected to intensive follow-up have recurrence diagnosed earlier and have more operations for recurrence but the survival results suggest that any major improvement by intensive follow-up is unlikely. <sep>', 'the five-year survival rate in group a was 58.3 percent and in group b was 73.1 percent. <sep>', 'after a median follow-up of 48 months there was no difference in the probability of overall survival in the whole series hazard ratio hr  0.87 95 ci 0.49 to 1.54 p  .62). <sep>', 'at 12 and 24 months there were no differences in scores for quality of life physical component score p=0.88 at 12 months p=0.28 at 24 months mental component score p=0.51 p=0.47 adjusted anxiety p=0.72 p=0.11 depression p=0.28 p=0.80 or patient satisfaction p=0.06 24 months). <sep>', 'on completion of 5-year follow-up there was no significant difference in survival between the two groups. <sep>'], 'population': ['colorectal cancer <sep> 597 patients less than 76 years old treated with radical surgery for colorectal cancer were included in the study from 1983 to 1994 <sep>', 'patients with rectal cancer <sep> 2 patients in group a who had curative re-resections died as a result of cancer <sep> between 1987 and 1990 207 consecutive patients who underwent curative resections for primary untreated large-bowel carcinoma <sep> colorectal cancer <sep>', 'patients with colorectal cancer who have undergone curative resection <sep> a total of 259 patients were included 132 were observed according to the simple strategy and 127 were observed according to the intensive strategy <sep> patients with stage ii or iii colorectal cancer <sep> patients with colorectal cancer <sep> patients with stage ii colorectal cancer or those with rectal tumors <sep>', 'patients with colon cancer <sep> patients after treatment for colon cancer by either general practitioners or surgeons <sep> 170 patients were available for follow-up at 12 months and 157 at 24 months <sep> 203 consenting patients who had undergone potentially curative treatment for colon cancer <sep> colon cancer patients <sep>', 'three hundred twenty-five patients who underwent curative resection of colorectal cancer <sep> colorectal cancer patients <sep>'], 'interventions': ['radical surgery <sep>', 'radical surgery <sep>', 'simple surveillance strategy including clinical evaluation and serum carcinoembryonic antigen monitoring or an intensive strategy in which abdominal computed tomography or ultrasonography chest radiograph and colonoscopy were added <sep> intensive surveillance strategy <sep>', 'general practice vs surgical-based follow-up <sep>', 'liver ct <sep> intensive follow-up of yearly colonoscopy computerized tomography ct of the liver and chest radiography and clinical review and simple screening vs. structured clinical review and simple screening tests only <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",the results of our review suggest that there is an overall survival benefit for intensifying the follow up of patients after curative surgery for colorectal cancer. because of the wide variation in the follow-up programmes used in the included studies it is not possible to infer from the data the best combination and frequency of clinic or family practice visits blood tests endoscopic procedures and radiological investigations to maximise the outcomes for these patients. nor is it possible to estimate the potential harms or costs of intensifying follow up for these patients in order to adopt a cost-effective approach in this clinical area. large clinical trials underway or about to commence are likely to contribute valuable further information to clarify these areas of clinical uncertainty.
264,"{'outcomes': ['hrsd items psychic anxiety somatic anxiety agitation <sep> mean score of hamilton rating scale for depression hrsd <sep> scores of the items suicide psychic anxiety somatic anxiety agitation and insomnia <sep>', 'proportion of rem sleep <sep> rem latency <sep> objective measures of sleep i.e. suppression of rem sleep <sep> sleep efficiency total sleep time stage 2 sleep and shorter wake time <sep> rem sleep parameters <sep>', 'adverse event <sep> tolerated <sep> nausea and headache <sep> overall response <sep> depressive symptoms and concomitant anxiety <sep> efficacy and safety <sep>', 'weight loss <sep> response rates whether defined by end-of-treatment hamilton rating scale for depression ham-d score <sep> ham-d scores <sep> sleep <sep> dizziness <sep>', 'nausea <sep> average total scores on the hamilton rating scale for depression ham-d <sep> safety and efficacy <sep>', 'nausea <sep> anticholinergic effects dizziness drowsiness somatosensory disturbance and excessive sweating <sep> tolerated <sep>', 'anxiety and suicidality <sep> hamilton depression rating scale hdrs <sep> total hrds score or in subscores for anxiety or suicidality <sep> anticholinergic side effects <sep>', 'excessive sweating <sep> drowsiness/sedation and excessive sweating <sep> mean values <sep> dry mouth and dizziness/lightheadedness <sep> symptoms of major depressive illness effectively <sep> efficacy and safety <sep>', 'adverse events <sep> hamd-total score <sep>', 'mean scores for most depression scales <sep> adverse effects <sep> clinical efficacy and safety <sep> effective antidepressant activity <sep>', 'mean scores of all depression rating scales <sep> weight loss <sep> clinical efficacy and safety <sep> nausea and diarrhoea <sep> total number of adverse events <sep>', 'efficacy and safety <sep> final madrs scores <sep> efficacy and safety <sep>', 'change of hamd17 total score <sep>', 'complaints of dry mouth constipation and dizziness <sep> agitation nausea fatigue and insomnia <sep>', 'quality-of-life improvements <sep> utilisation of medical resources <sep> clinical evaluation montgomery-asberg depression rating scale madrs clinical global impressions cgi and quality of life functional status questionnaire fsq <sep> number of hospitalisations and duration of stay <sep> work or productivity losses <sep>', 'mean total endpoint hdrs scores and percentages of cgi very good and good responses <sep> hamilton depression rating scale hdrs-17 items and clinical global impression cgi scale <sep> hdrs score <sep> tolerability <sep> efficacy and tolerability <sep> frequency and severity of volunteered adverse events <sep>', 'efficacy <sep> tremor rash nausea and headache occurring with fluoxetine and drowsiness dizziness and visual disturbance with dothiepin <sep>', 'discontinuations for adverse events <sep> efficacy <sep> response and remission rates <sep> headache <sep> constipation <sep> mean <sep> somnolence <sep>', 'overall symptoms of depression <sep> efficacy <sep> weight increase and somnolence <sep> nausea and influenza-like symptoms <sep> mean reductions in ham-d total score <sep> ham-d and clinical global impressions scale <sep> efficacy and tolerability <sep> tolerability and efficacy <sep>', 'hamilton depression score <sep> hamilton rating scale for depression <sep> side effects <sep> hamilton depression mood item <sep> efficacy and safety <sep> heart rate <sep> steady-state levels <sep>', 'self evaluation scales <sep>', 'efficacy <sep> rates of treatment response <sep> hamilton depression rating scale the clinical global impression severity and improvement scales and the patient global impression improvement scale <sep>', 'efficacy <sep> 21-item hamilton rating scale for depression ham-d and clinical global impressions scale for severity and improvement <sep> nausea <sep> depressive symptoms <sep> ham-d scores <sep> efficacy and tolerability <sep>', 'hamilton depression scale score <sep> response rate <sep>', 'mood and cognitive functions <sep> hamilton rating scale for depression ham-d and the clinical anxiety scale <sep> cognitive functions <sep> good antidepressant efficacy <sep> cognitive performance <sep> good tolerability and safety profile <sep>', 'clinical global impressions cgi)-severity of illness scale score <sep> 17-item hamilton rating scale for depression ham-d-17 total score <sep> montgomery-asberg depression rating scale cgi-severity of illness and cgi-improvement and patient global impression of improvement <sep> occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes <sep> ham-d-17 total score <sep> tolerated and safe <sep> therapeutic efficacy and safety/tolerability <sep> tolerated <sep> estimated probabilities of response and remission <sep> safety <sep> insomnia and asthenia <sep>', 'remission rates <sep> madrs score <sep> nausea <sep> adverse events <sep> effective and well tolerated <sep> clinical global impression cgi score <sep> efficacy and tolerability <sep> final hamilton depression rating scale ham-d score <sep>', 'objective subjective and clinician-rated measures of sleep disturbance <sep> objective subjective and clinician-rated measures of sleep <sep> antidepressant efficacy <sep> mood and on objective subjective and clinician-rated measures of sleep <sep> rapid-eye-movement rem sleep or increase rem latency <sep> percentage of awake and movement time <sep> sleep efficiency or number of awakenings stage 1 or rem sleep or rem latency <sep> sleep efficiency number of awakenings percentage of awake and movement time percentage of rem and stage 1 sleep and rem latency <sep> sleep efficiency and rem sleep <sep> sleep measures <sep> number of awakenings stage 1 sleep and rem latency <sep> some clinician and patient-rated sleep disturbance scores <sep> equivalent antidepressant efficacy <sep>', 'adverse events tolerability profiles <sep> efficacy <sep> ham-d <sep> body weight <sep> mean total 17-item ham-d scores <sep> ham-d clinical global impressions the visual analogue mood rating scale vamrs and the quality of life enjoyment and satisfaction questionnaire qlesq <sep> efficacy and tolerability <sep>', 'antidepressant efficacy <sep>', 'ecg or stis <sep> cardiac function <sep> sinus cycle length <sep> stis <sep> qrs duration <sep> pr interval <sep> electrocardiogram ecg and systolic time intervals stis <sep>', 'efficacy <sep> ham-d response rate <sep> ham-d remission rate <sep> ham-d depressed mood item <sep> hamilton rating scale for depression ham-d hamilton rating scale for anxiety <sep> ham-a response rate <sep> efficacy and safety <sep> incidence of discontinuation for adverse events <sep>', 'madrs score <sep> efficacy and safety <sep> efficacy madrs cgi covi or in terms of safety except for the cgi severity of illness <sep>', 'success rate <sep> efficacy and safety <sep> montgomery and asberg depression rating scale madrs score <sep> assessment criteria geriatric depression scale gds and clinical global impression cgi <sep>', '17-item hamilton depression rating scale hdrs the montgomery-asberg depression rating scale madrs and the clinical global impression cgi <sep> weight loss <sep> hdrs total score <sep> antidepressant efficacy and safety <sep> madrs total score <sep> overall efficacy ratings <sep> hdrs or madrs total scores <sep> efficacy and safety <sep> heart rate <sep>', 'hamilton depression scale scores <sep> health transition scale of the 36-item short-form health survey questionnaire <sep> hamilton depression rating scale <sep>', 'depression anxiety and quality of life <sep> individual ham-d items including item 4 insomnia onset <sep> depression ham-d had cgi <sep> i cgi-s anxiety covi sleep leeds sleep evaluation scale and quality of life sip <sep> leeds sleep evaluation scale and on sip items relating to sleep and rest emotional behaviour and ambulation <sep> tolerability <sep> side effects <sep>', 'hamd score <sep> efficacy <sep> 17-item hamilton rating scale for depression hamd the von zerssen depression scale ds clinical global impression cgi and patients overall evaluation <sep> adverse reactions <sep>', 'central nervous system events <sep> agitation anxiety suicidality and global impressions <sep> ham-d17 ham-d17 response and ham-d17 remission rates <sep>', 'degree of depression and anxiety improvement <sep> antidepressant and antianxiety efficacies <sep> rates or mean numbers of adverse events <sep> covi anxiety scale <sep> efficacy and tolerability <sep> baseline and endpoint depression and anxiety severity <sep> safety and tolerability profiles <sep>', 'mean hdrs <sep> weight loss <sep> suicidal feelings <sep> sleep <sep> hamilton depression rating scale hdrs and the montgomery  asberg depression rating scale madrs <sep> nausea and vomiting <sep> side effects <sep>', 'side-effects <sep> antidepressant efficacy <sep>', 'full remission of their depression ham-d21 total score <sep> remission rates <sep> adverse events <sep> efficacy and tolerability <sep> depression ratings <sep> final ratings on the hamilton rating scale for depression ham-d21 total score ham-d21 depressed mood item montgomery-asberg depression rating scale total score and clinical global impressions scale <sep>', 'hamilton depression rating scale and the montgomery-asberg depression rating scale montgomery and asberg 1979)--and a self-rating scale--levine pilowsky depression questionnaire <sep> clinical efficacy and safety <sep>', 'social functioning <sep> remission clinical global impression severity of illness and global improvement scores and montgomery-asberg depression rating scale <sep> social adaptation self-evaluation scale total scores <sep> tolerated <sep> total hamilton depression rating scale score <sep> effective and well tolerated antidepressant <sep> efficacy and tolerability <sep>', 'antidepressant efficacy and tolerability <sep> efficacy hdrs cgi or safety adverse events laboratory examination vital signs <sep> cgi <sep> sexual dysfunction <sep> efficacy and tolerability <sep>', '21-item hamilton rating scale for depression ham-d and the clinical global impressions-improvement scale cgi-i with scores of  or  7 on the ham-d and  or  2 on the cgi <sep> efficacy and response time <sep> response rates <sep> rate of positive treatment response <sep> positive treatment response rates <sep>', 'antidepressant efficacy and tolerability <sep> clinical global impressions <sep> efficacy and tolerability <sep>', 'mild depressive episodes <sep> adverse drug reactions adrs <sep>', 'established rating scales madrs ham-d bprs <sep> symptoms of anxiety <sep> sleep and anxiety <sep> drowsiness and disturbed sleep <sep>', '21-item hamilton rating scale for depression ham-d and depressive symptoms <sep> final on-therapy scores on the ham-d montgomery-asberg depression rating scale madrs and clinical global impressions severity of illness cgi-s and improvement cgi-i scales <sep> nausea headache and dizziness with venlafaxine and nausea headache and insomnia with fluoxetine <sep> efficacy and tolerability <sep> mean ham-d madrs and cgi-s scores <sep>', 'anticholinergic side-effects <sep> hamilton rating scale of depression scores <sep> weight gain <sep>', 'efficacy and safety <sep> blood pressure pulse or weight <sep>', 'efficacy <sep> nausea other gastrointestinal symptoms nervousness dizziness and sleep disorders <sep> antidepressant efficacy <sep> antidepressant efficacy and quality of life in depression <sep> nausea <sep> dimensions measuring depression or mental health <sep> quality of life <sep> general health survey sf-20 and 15d measure of quality of life <sep> hdrs <sep> hamilton depression rating scale hdrs montgomery-asberg depression rating scale and clinical global impression cgi <sep>', 'patient and observer ratings of depression <sep>', 'incidence of treatment-emergent adverse events <sep> vital signs and adverse experiences <sep> ham-d scores <sep> hamilton rating scale for depression hamilton rating scale for anxiety clinical global impressions-severity and clinical global impressions-improvement <sep> ham-a scores <sep> relieving depression and accompanying symptoms of anxiety <sep> efficacy and safety <sep>', 'total rem sleep time <sep> rem latency and suppressed rem sleep <sep> sleep quality <sep> normal objective and clinician and patient-rated assessments of sleep <sep> sleep efficiency <sep> depressive symptoms <sep> number of awakenings <sep> sleep electroencephalographic eeg recordings <sep> sleep <sep> rem sleep <sep> sleep disturbances <sep> sleep continuity and increased rapid eye movement rem sleep <sep>', 'mean scores on the hamilton depression rating scale <sep> insomnia <sep> anxiety <sep> headache <sep> effective and well tolerated <sep> nausea <sep> generalized tremor <sep> sleepiness <sep> mean scores on the montgomery-asberg depression rating scale <sep> patient response <sep> dizziness <sep> efficacy and safety <sep>', 'hamd total score <sep> clinical global improvement severity of illness score <sep> hamd sleep disturbance scale <sep> percentage of hamd responders <sep> depression subscale of the irritability depression and anxiety scale <sep> hamilton depression rating scale hamd total score <sep> efficacy and safety <sep>', 'hamilton depression rating scale <sep> sedation nausea and vomiting <sep> frequencies of occurrence of adverse reactions <sep>', 'memory performance <sep>', 'total score on the hamilton rating scale for depression and the global improvement score on the clinical global impressions scale <sep>', 'nausea vomiting and diarrhoea <sep> weight changes <sep> ham-d scores <sep> hamilton psychiatric rating scale for depression ham-d <sep> haematological or clinical chemistry changes <sep> tiredness drowsiness and diarrhoea <sep> anxiety scores <sep> adverse effects <sep>', 'low insomnia <sep> incidence of aes suggestive of activation or sedation <sep> depression and insomnia <sep> depression improvement <sep> ham-d sleep disturbance factor <sep> ham-d-17 total score <sep> overall depression <sep> ham-d sleep disturbance factor score <sep> tolerated <sep> insomnia improvement <sep> efficacy and tolerability <sep> acute treatment efficacy and tolerability <sep> safety assessments included treatment-emergent adverse events aes reasons for discontinuation and aes leading to discontinuation <sep> hamilton rating scale for depression ham-d sleep disturbance factor score <sep>', 'total ham-d score <sep> efficacy and safety <sep>', 'efficacy and tolerance <sep> clinical status at base line diagnosis history and duration of the depressive illness madrs and hard diagram scores).(abstract <sep> hamilton anxiety rating scale hars and of sleep disturbances <sep> montgomery asberg depression rating scale madrs the hard diagram the check list for somatic symptoms and side-effects <sep> sleep questionnaire covers the complaints listed in criteria for insomnia disorders <sep> montgomery asberg depressive rating scale madrs <sep> clinical global impression cgi therapeutic index ti tolerance global impression <sep>', 'side-effects <sep> tolerated <sep>', 'nausea and vomiting <sep> 21-item hamilton rating scale for depression hrsd <sep> adverse events <sep> number of responders <sep> anxiety symptoms <sep> efficacy and tolerability <sep> efficacy using the hrsd montgomery-asberg depression rating scale and clinical global impression for tolerability adverse events <sep>', ""hamilton psychiatric rating scale for depression ham-d the montgomery-asberg depression rating scale madrs and the clinician's global impressions-severity of illness scale cgi-si <sep> madrs <sep> symptoms of depression <sep> ham-d madrs and cgi-si <sep>"", 'ham-d responder rate <sep> hamilton rating scale for depression ham-d clinical global impression and subjective mood ratings 45-item self-rating scale <sep> efficacy <sep> subjective mood ratings <sep> ham-d scores <sep> efficacy and tolerability <sep> tolerability ratings <sep>', 'incidence of adverse events <sep> hamilton rating scales for depression and anxiety the montgomery asberg depression rating scale clinical global impressions scale zung self-rating scale for anxiety and the leeds sleep evaluation questionnaire <sep> agitation anxiety and insomnia <sep> adverse events <sep> efficacy and safety <sep>', 'overall depression and anxiety <sep> individual ham-d items 9 agitation 10 psychic anxiety and 11 somatic anxiety <sep> tolerated <sep> somatization factor scores <sep> anxiety anxious depression <sep> efficacy and tolerability <sep> ham-d-17 and ham-d-anxiety <sep>', 'nausea dyspepsia anorexia and insomnia <sep> anxiety measured by ham-a total mean score <sep> adverse events <sep> widlcher psychomotor retardation scale sheehan disability scale and cgi <sep> number of patients reporting at least one adverse event <sep> mean total score <sep> baseline montgomery and asberg depression rating scale madrs total score <sep>', 'complaints of dry mouth and dizziness on standing <sep> sleep disturbances nausea and headaches <sep>', 'digit symbol substitution test <sep> body weight <sep> measures of depression including remission of depressive symptoms <sep> rate of adverse events <sep> shaking. <sep> cognitive functioning <sep>', 'mean endpoint scores for all rating scales <sep> nervousness/anxiety and nausea <sep> dry mouth drowsiness/sedation constipation and dizziness/lightheadedness <sep>', 'nausea and nervousness for fluoxetine and dry mouth dizziness and drowsiness for amitriptyline <sep> efficacy and safety <sep>', 'efficacy and acceptability <sep> retardation pole of the mood anxiety retardation danger scale <sep>', 'effectiveness and good tolerability <sep> therapeutic efficacy <sep> hrsd zung self rating scale for depression montgomery-asberg scale for depression clinical global impression for severity and improvement of depressive symptoms <sep> hamilton rating scale for depression hrsd <sep> efficacy and safety <sep> body weight blood pressure pulse rate temperature physical conditions laboratory tests adverse experiences and concomitant medication <sep>', 'esrs scores for akathisia <sep> antianxiety effects <sep> anxiolytic activity <sep> antidepressant and anxiolytic efficacy <sep> motor nervousness or restlessness <sep> agitation and psychic anxiety symptoms <sep> psychic anxiety item <sep> constipation dyspepsia tremor sweating and abnormal ejaculation <sep> esrs scale for akathisia <sep> weight loss <sep> nausea and nervousness <sep> antidepressant efficacy ham-d cgi <sep> overall incidence of adverse effects <sep>', 'psychological dimensions of general health and moderately impaired on physical dimensions <sep>', 'cgi-improvement responder rates <sep> raskin depression scale the covi anxiety scale and the leeds sleep questionnaire <sep> efficacy <sep> ham-d and cgi-severity scores <sep> headache and nausea <sep> effective and well tolerated <sep> incidence of early patient withdrawals due to treatment-emergent adverse events <sep> anxiety symptoms <sep> 17-item hamilton rating scale for depression ham-d and the clinical global impressions cgi scale <sep> total ham-a score <sep> hamilton rating scale for anxiety <sep> efficacy and safety <sep>', 'global improvement <sep> severe depression <sep> antidepressant efficacy <sep> tolerated <sep> frequency of adverse events <sep> safety and efficacy <sep>', '24-item hamilton rating scale for depression and clinical global impressions scale ratings <sep> safe and well tolerated <sep> clinician and patient-rated measures of depression symptoms and factors cognitive functioning and quality of life as well as plasma drug concentrations <sep> cognitive improvement on several measures <sep> quality of life and cognitive function <sep> efficacy and safety <sep>', 'cardiovascular effects <sep> baseline hamilton rating scale for depression score <sep> dropout rates <sep> hamilton depression rating scale a side-effect checklist and a regular ecg assessment <sep> efficacy and safety <sep>', 'overall effectiveness <sep> initial hamilton rating scale for depression ham-d <sep> compliance <sep> initial ham-d score <sep> dropout rate due to side effects <sep> adherence and efficacy and adherence <sep>', 'mean hamilton rating scale for depression 21-item ham-d total score <sep> additional efficacy assessments montgomery-asberg depression rating scale clinical global impression <sep> ham-d or remission <sep> mean ham-d total score <sep>', 'antidepressant efficacy <sep> overall tolerance <sep> ham-d <sep>', 'efficacy <sep> weight change weight loss <sep> efficacy <sep> frequency or in severity of adverse events <sep> success rates <sep> weight gain <sep> adverse events scale <sep> hamilton depression rating scale the raskin depression scale the covi anxiety scale and a clinical global impression <sep>', 'sleep polygraphic recordings <sep> adverse effects <sep> number of awakenings <sep> sleep continuity <sep> rem sleep <sep> hamilton depression scale <sep>', 'montgomery and asberg depression scale madrs the hamilton depression scale the clinical global impressions cgi and a checklist of symptoms and side-effects <sep> symptoms of dizziness <sep> five individual items hamilton depression scale <sep>', 'headache and nausea <sep> headache and blurred vision <sep> safety and efficacy <sep> dry mouth <sep>', 'hamd sleep factor <sep> 21-item hamilton rating scale for depression hamilton rating scale for anxiety clinical global impressions raskin depression scale and covi anxiety scale <sep>'], 'punchline_text': ['between groups the mean score of hamilton rating scale for depression hrsd was significantly different only after 3 weeks of treatment am 14.7+/-5.7 vs fx 17.3+/-6.2 p  0.02 whereas at the end of the trial it was similar am 8.15+/-6.9 fx 8.96+/-6.6). <sep>', 'in sleep eeg measures trimipramine demonstrated clear-cut effects on sleep measures resulting in higher values for sleep efficiency total sleep time stage 2 sleep and shorter wake time. <sep>', 'venlafaxine and fluoxetine were well tolerated with the most frequently experienced adverse events being nausea and headache. <sep>', 'for fluoxetine ham-d scores were significantly lower at weeks 1 and 2 compared with those of trazodone. <sep>', 'fluoxetine was associated more frequently with nausea p less than .05 while nortriptyline was associated more frequently with dry mouth p less than .05). <sep>', 'fluoxetine produced greater improvement than placebo on all major efficacy parameters and was comparable to imipramine with respect to the primary indicators of depression. <sep>', 'both patient groups had significantly lower mean scores on the hamilton depression rating scale hdrs 6 weeks after entry to the trial p  0.001 but there were no differences between the groups either at baseline or after 6 weeks in total hrds score or in subscores for anxiety or suicidality. <sep>', 'mean values for all efficacy measurements were improved over baseline with fluoxetine and imipramine treatment p less than .001). <sep>', 'significantly fewer fluoxetine-treated patients discontinued due to adverse events than did imipramine-treated patients 7 vs. 30 respectively). <sep>', 'mean scores for most depression scales improved more in patients taking fluoxetine than in those receiving imipramine p less than .05). <sep>', 'a double-blind clinical trial was undertaken to evaluate the clinical efficacy and safety of fluoxetine compared with imipramine in the treatment of 59 outpatients suffering from major depressive disorder. <sep>', 'madrs responders were 58 and 56 with tianeptine and fluoxetine respectively p  0.710). <sep>', 'a significant difference was observed in females fluoxetine 17.8 maprotiline 13.9 p=0.017 between treatment groups but not in males. <sep>', 'compared to imipramine fluoxetine was associated with fewer complaints of dry mouth constipation and dizziness. <sep>', 'the 2 treatment groups were similar in terms of number of hospitalisations and duration of stay whether related to depression or not. <sep>', 'there were no significant differences in secondary efficacy outcome measures but more patients achieved a  or  50 decrease in hdrs score on moclobemide 71 vs 38 p  0.05). <sep>', 'no differences in efficacy were observed but the profile of side-effects differed with tremor rash nausea and headache occurring with fluoxetine and drowsiness dizziness and visual disturbance with dothiepin. <sep>', 'discontinuations for adverse events were comparable fluoxetine 21.4 imipramine 22.6%). <sep>', 'at day 42 the mean reductions in ham-d total score compared with baseline were 11.8 and 10.6 for the mirtazapine and fluoxetine groups respectively however the changes were not statistically significant. <sep>', 'improvement on the hamilton rating scale for depression was significant for both treatments from week 1 through the end of the study and did not differ between the two treatments at any week. <sep>', 'fluoxetine was found to have a more marked therapeutic effect than that of amineptine better efficacy fewer side-effects and quicker and better improvement on the self evaluation scales. <sep>', 'efficacy was measured by the hamilton depression rating scale the clinical global impression severity and improvement scales and the patient global impression improvement scale. <sep>', 'there were differences in the side-effect profiles with fluvoxamine being associated with less nausea than fluoxetine. <sep>', 'regardless of how strict the definition of response we found fluoxetine to be as effective as doxepin in our group of melancholic outpatients. <sep>', 'cognitive performance was evaluated by means of the buschke selective reminding test the blessed information and memory test the clifton assessment schedule the cancellation task test and the wechsler paired word test the hamilton rating scale for depression ham-d and the clinical anxiety scale were administered to assess the course of depressive and anxiety symptoms respectively. <sep>', 'duloxetine was superior to placebo in change on the ham-d-17 p  .009). <sep>', 'a final hamilton depression rating scale ham-d score  7 was attained in 41 of venlafaxine-treated and 36 of fluoxetine-treated patients. <sep>', 'fluoxetine significantly decreased sleep efficiency and rem sleep and increased number of awakenings stage 1 sleep and rem latency compared with baseline. <sep>', 'the decrease from baseline on the ham-d was larger in the mirtazapine than in the fluoxetine group throughout the treatment period reaching statistical significance at days 21 and 28. <sep>', 'important differences were found in the side-effects profile of each group their incidence being significantly lower and tending to disappear during the course of treatment in the group of patients treated with fluoxetine. <sep>', 'amitriptyline 150-200 mg daily shortened the sinus cycle length by a mean of 12 prolonged the pr interval by 8 and the qrs duration by 10%. <sep>', 'venlafaxine xr but not fluoxetine was significantly better than placebo at week 2 on the ham-d depressed mood item. <sep>', 'no significant difference was shown between the two drugs either in terms of efficacy madrs cgi covi or in terms of safety except for the cgi severity of illness which was lower at the end point with tianeptine than with fluoxetine. <sep>', 'the success rate at the end of the treatment madrs  or  10 was significantly higher in the fluoxetine group fluoxetine group 48.4 vs tianeptine group 28.1 p  0.005). <sep>', 'side-effect profiles were not significantly different between groups except for a significantly greater frequency of dose-related increase in heart rate  or  100 bpm in milnacipran recipients and a significantly greater weight loss in fluoxetine recipients. <sep>', 'patients in the fluoxetine group reported superior response on the health transition scale of the 36-item short-form health survey questionnaire and numerically greater improvement on the hamilton depression rating scale. <sep>', 'at study endpoint both treatments produced a significant improvement over baseline on all efficacy variables p  0.001). <sep>', 'significant decreases p<.001 of 50 in the hypericum group and 58 in the fluoxetine group in the hamd score and of 42 and 52 on the ds spoke to the efficacy of both medications. <sep>', 'both compounds proved to be similarly effective as measured by change in ham-d17 ham-d17 response and ham-d17 remission rates. <sep>', 'there were no statistically significant differences in rates or mean numbers of adverse events between paroxetine-treated patients and fluoxetine-treated patients. <sep>', 'suicidal feelings were reduced to a greater degree on fluoxetine than on mianserin and placebo at weeks 6 and 7. <sep>', 'patients taking fluoxetine reported less side-effects than those taking amitriptyline. <sep>', 'the percentages of patients who achieved full remission of their depression ham-d21 total score  or  7 at the end of treatment were 37 22 and 18 for the venlafaxine xr fluoxetine and placebo groups respectively. <sep>', 'a double-blind clinical trial was undertaken to evaluate clinical efficacy and safety of fluoxetine in comparison with the standard tricyclic antidepressant imipramine in the treatment of depressive illness. <sep>', 'both treatments resulted in some improvement in social adaptation self-evaluation scale total scores and this was more evident for those patients treated with reboxetine who achieved remission. <sep>', 'no statistically significant differences between the two treatment groups were noted regarding efficacy hdrs cgi or safety adverse events laboratory examination vital signs). <sep>', 'primary outcome measurements included the 21-item hamilton rating scale for depression ham-d and the clinical global impressions-improvement scale cgi-i with scores of  or  7 on the ham-d and  or  2 on the cgi <sep>', 'the efficacy and tolerability of moclobemide 300 or 600 mg daily and fluoxetine 20 or 40 mg daily were compared in a 6-week double-blind study of 25 inpatients and 24 outpatients who had major depressive episodes without psychotic features dsm-iii-r). <sep>', 'during the six-week course of treatment with lohyp-57 the hamilton global score fell from 16.60 points at entry to 7.91 points and in the fluoxetine sample it fell from 17.18 to 8.11 points. <sep>', 'the impact of both drugs on sleep measured using the leeds sleep evaluation questionnaire showed no significant differences between treatments however drowsiness and disturbed sleep were reported more frequently as side effects with dothiepin. <sep>', 'both venlafaxine and fluoxetine produced significant reductions from baseline to day 56 in mean ham-d madrs and cgi-s scores but no significant differences were noted between groups. <sep>', 'both groups showed a significant amelioration at the end point for hamilton rating scale of depression scores compared to the baseline value. <sep>', 'both agents were effective according to weekly and endpoint analyses and there was no evidence of significant effects on blood pressure pulse or weight. <sep>', 'the most commonly reported adverse events were nausea other gastrointestinal symptoms nervousness dizziness and sleep disorders. <sep>', 'recent memory improved significantly in the fluoxetine group but not in the amitriptyline group. <sep>', 'ham-a scores decreased by 59 for both treatment groups. <sep>', 'nefazodone was associated with normal objective and clinician and patient-rated assessments of sleep when compared with fluoxetine. <sep>', 'in both treatment groups mean scores on the hamilton depression rating scale decreased significantly between baseline 27.8 venlafaxine 29.2 fluoxetine and the end of the study 8.7 venlafaxine 8.2 fluoxetine). <sep>', 'both drugs were effective and there were no statistically significant differences between them in the area under the curve of change from baseline in the hamilton depression rating scale hamd total score. <sep>', 'the frequencies of occurrence of adverse reactions were also similar but sedation nausea and vomiting were reported more frequently with fluoxetine and insomnia was experienced with moclobemide. <sep>', 'we found that although clinically both drugs were equally effective the improvement of memory performance in the fluoxetine-treated patients was significantly greater compared with that of the desipramine-treated patients. <sep>', 'the total score on the hamilton rating scale for depression and the global improvement score on the clinical global impressions scale favored trazodone at the end of 3 weeks of treatment. <sep>', 'subset analyses of ham-d scores associated with anxiety and sleep revealed no statistically significant differences between the 2 treatments though improvement in anxiety scores was marginally greater for those receiving fluoxetine by the end of the trial. <sep>', 'analyses revealed no significant differences between treatments in the percentages of patients with substantial worsening any worsening worsening at endpoint or improvement at endpoint in the ham-d sleep disturbance factor in either insomnia subgroup. <sep>', 'among patients who increased their dose at 2 weeks venlafaxine was significantly p  0.05 superior from week 3 onward on the ham-d. 6. <sep>', 'assessment of anxiety using the hamilton anxiety rating scale hars and of sleep disturbances using a sleep questionnaire was carried out before treatment and at week 4. <sep>', 'there were no consistently significant differences between the two active drugs although a trend favored imipramine on a number of measures. <sep>', 'paroxetine and fluoxetine showed comparable efficacy at the end of the 6-week treatment period but a statistically significant difference in the number of responders at week 3 in favour of paroxetine was observed. <sep>', 'patients taking fluoxetine also showed significant improvements at endpoint on the madrs and earlier in the study on the ham-d. no new or unusual safety concerns were generated during this study. <sep>', 'efficacy was measured by the hamilton rating scale for depression ham-d clinical global impression and subjective mood ratings 45-item self-rating scale). <sep>', 'both treatment groups showed a statistically significant improvement from baseline at one week and this was maintained until the end of treatment for all of the following measures hamilton rating scales for depression and anxiety the montgomery asberg depression rating scale clinical global impressions scale zung self-rating scale for anxiety and the leeds sleep evaluation questionnaire. <sep>', 'patients also demonstrated similar change-over-time improvement in ham-d-17 and ham-d-anxiety <sep>', 'no significant differences between treatment groups were found in the reductions in mean total score with the madrs <sep>', 'the drugs did not differ with respect to psychiatrists ratings but amitriptyline was slightly superior with respect to patients ratings. <sep>', 'significantly greater improvement for the sertraline group was apparent on the digit symbol substitution test but not on two other measures of cognitive functioning. <sep>', 'common side effects of doxepin were dry mouth drowsiness/sedation constipation and dizziness/lightheadedness. <sep>', 'the most frequently reported side effects were nausea and nervousness for fluoxetine and dry mouth dizziness and drowsiness for amitriptyline. <sep>', 'intragroup analysis showed that amineptine was significantly superior to fluoxetine on the retardation pole of the mood anxiety retardation danger scale. <sep>', 'the results confirm the effectiveness and good tolerability of fluoxetine in the treatment of depressive disorders. <sep>', 'constipation dyspepsia tremor sweating and abnormal ejaculation were more common in paroxetine-treated subjects whereas nausea and nervousness were more frequent in fluoxetine-treated patients. <sep>', 'before treatment patients on average rated themselves as very impaired on psychological dimensions of general health and moderately impaired on physical dimensions compared with population norms. <sep>', 'as measured by ham-d and cgi-severity scores there was a significant p  .001 improvement from baseline to each follow-up visit in both treatment groups with no statistically significant difference between groups. <sep>', 'on comparing treatment by psychiatrist and general practitioner no significant differences were found regarding age sex number of previous episodes and duration of the recent episode and outcome. <sep>', 'both drugs produced a similarly positive response on the primary efficacy measures with 12-week responder rates of 73 for sertraline and 71 for fluoxetine. <sep>', 'no significant differences were observed between dropout rates in the two groups but anti-cholinergic side-effects were significantly more frequent with nortriptyline than with fluoxetine but there was no significant difference in cardiovascular effects in particular qtc prolongation. <sep>', 'side effects were not predictive of being adherent or not but a higher initial ham-d score predicted a higher adherence to the medication regimen. <sep>', 'a significantly greater proportion of patients treated with either reboxetine or fluoxetine also achieved a response  <sep>', 'venlafaxine was superior in efficacy to fluoxetine total scores for both the madrs and the ham-d were significantly p  or  0.05 lower in the venlafaxine group than in the fluoxetine group at weeks 4 and 6. <sep>', 'no differences in efficacy were found between the two groups. <sep>', 'as indicated by the significant decrease in the hamilton depression scale and the montgomery asberg depression scale fluoxetine showed similar antidepressant effects to amitriptyline with significantly fewer adverse effects. <sep>', 'on visual analogue scales assessing the clinical profile of the compounds fluoxetine was rated as exhibiting more psychostimulating activity than milnacipran p  0.0008). <sep>', 'headache and blurred vision were reported significantly more often p  0.05 in the fluoxetine group whereas significantly more dry mouth was reported p  0.05 in the moclobemide group. <sep>', 'fluoxetine was comparable to amitriptyline in all efficacy measures except the hamd sleep factor. <sep>'], 'population': ['142 outpatients affected by major depression with relevant anxiety and agitation <sep>', '19 depressed geriatric patients <sep> geriatric depression <sep>', '146 moderately depressed patients with associated anxiety <sep> outpatients with depression and concomitant anxiety <sep> patients with depression and anxiety <sep>', 'outpatients with major depression <sep> 43 outpatients with major depression after a 1-week single-blind <sep>', 'major depression <sep> 205 outpatients with acute major depression of moderate severity <sep>', 'depressed patients in double-blind <sep> outpatients with major depressive disorder <sep>', 'one hundred and eighty three patients with dsm-iii-r major depressive illness <sep> major depressive illness <sep>', 'patients with major depressive disorder <sep> patients with major depressive illness <sep>', '89 patients with bipolar depression <sep> patients with bipolar depressive disorder <sep>', '40 depressed outpatients <sep> depressed patients <sep>', '59 outpatients suffering from major depressive disorder <sep> outpatients with major depressive disorder <sep>', '387 patients with depressive episode or recurrent depressive disorder or bipolar affective disorder icd-10 <sep>', 'women as men <sep> 105 depressed patients <sep> young women to non-tricyclic antidepressants <sep> depressed patients <sep>', 'outpatients with major depression <sep> moderately depressed ambulatory outpatients <sep>', 'primary-care setting in france outpatients fulfilling dsm iv criteria for a major depressive episode <sep> primary-care setting in france <sep> 231 patients 116 receiving sertraline 115 receiving <sep>', 'patients n  42 with double depression dsm-iii-r dysthymia with superimposed major depressive episode <sep> double depression <sep>', 'patients with major depressive illness <sep> major depressive illness <sep>', '118 men and women ages 18 to 70 years hospitalized for major depressive disorder <sep> inpatient depression <sep>', 'depressed chinese patients <sep> thirty patients in the mirtazapine group and 22 in the <sep> sample population consisting of chinese patients suffering moderate-to-severe depression <sep> 133 patients with a diagnosis of major depressive episode dsm-iv and scoring 15 or more on the 17-item hamilton rating scale for depression ham-d <sep>', 'major depressive disorder <sep> twenty-five were studied while hospitalized for treatment and 33 were studied as outpatients <sep> patients with major depression <sep>', '63 outpatients with major depressive disorders of mild or moderate severity <sep> outpatients with major depressive disorders <sep>', '42 patients randomized 2 patients never received drugs and 2 <sep> patients with mood-reactive atypical depression <sep> forty-two patients with atypical depression by the columbia criteria <sep> atypical depression <sep>', '100 outpatients with major depressive disorder <sep> major depression <sep>', '36 depressed ambulatory patients with <sep> met diagnostic criteria for melancholic depression <sep> depressed patients <sep>', 'depressed nondemented elderly patients <sep> sd age  75.4 <sep> elderly depressed patients icd-10 criteria <sep> 242 patients were enrolled mean <sep>', 'major depressive disorder <sep> 173 patients aged 18-65 years with dsm-iv major depressive disorder <sep>', 'hospitalized patients with major depression and melancholia <sep> 109 patients with major depression and melancholia <sep> 55 patients on <sep> inpatients with major depression and melancholia <sep> hospitalized and day care patients with dsm-iv major depression and melancholia and a baseline montgomery-asberg depression rating scale madrs score of  or  25 were eligible <sep>', '43 evaluable patients 23 <sep> forty-four outpatients with moderate to severe nonpsychotic major depressive disorder dsm-iii-r and insomnia <sep> depressed patients <sep>', 'patients with a major depressive episode dsm-iii-r a baseline score of  or=21 on the 17-item hamilton rating scale for depression ham-d and  or=2 on ham-d item 1 depressed mood <sep> depressed inpatients and outpatients <sep> patients with moderate to severe major depressive disorder <sep>', 'a sample of 120 patients all of whom met dsm-iii criteria for major unipolar depressive disorder <sep> sixty patients were treated with <sep> depressed patients <sep>', 'depressed patients <sep>', '359 outpatients <sep> patients who met dsm-iv criteria for major depressive disorder and satisfied eligibility criteria <sep> outpatients with major depression and concomitant anxiety <sep> outpatients with depression and anxiety <sep>', '178 patients with major depression <sep> major depression <sep>', '237 patients <sep> subjects over the age of 65 years <sep> elderly depressed patients followed in general practice <sep> elderly patients suffering from major depressive episode defined according to dsm iii-r criteria newcastle depression scale  or  20 without associated dementia mini mental status mmse treated by general practitioners in ten different french regions during 3 months <sep>', '289 inpatients with endogenous depression <sep> depressed inpatients <sep>', 'major depressive disorder in primary care <sep> 152 patients treated in 10 primary care practices in the united kingdom <sep>', 'two-hundred and thirty-four patients were included in an itt analysis up to last visit 116 <sep> major depressive episode in outpatients <sep> outpatients fulfilling dsm-iii-r criteria for major depressive disorder <sep> 88 patients in the <sep>', 'mild to moderate depression <sep> 70 patients mean age 49.7 years suffering from mild to moderate depression received one tablet of either <sep>', 'subjects with major depression subtype agitated the risk <sep> 124 subjects with research diagnostic criteria-compatible agitated depression <sep>', 'outpatients with major depression <sep> all 128 patients completed a 1-week <sep> 12.6 63 men and 65 women with moderate to moderately severe major depression without a history of mania or hypomania were recruited between 1993 and 1994 <sep> 128 outpatients mean age 41.3 <sep>', 'depressed outpatients <sep> 81 depressed patients were included <sep> 52 patients completed the study <sep>', 'depressive illness <sep> fifty-six patients fluoxetine n  23 amitriptyline n  23 completed the 6 week study <sep> fifty-eight patients with dsm-iii-r depression <sep>', 'outpatients 18 years and older who met dsm-iv criteria for major depressive disorder were included n  301 randomized 232 completed <sep> depressed outpatients <sep>', 'depressive illness <sep>', 'major depressive disorder <sep> patients with severe depression <sep> one hundred and sixty-eight patients with acute major depressive episodes <sep>', '65 inpatients and 34 outpatients suffering from major depressive episodes dsm iii-r <sep>', '44 psychiatric outpatients with dsm-iv unipolar major depressive disorder <sep> unipolar major depressive disorder <sep>', 'major depressive episodes <sep> 25 inpatients and 24 outpatients who had major depressive episodes without psychotic features dsm-iii-r <sep>', 'six patients were prematurely withdrawn from treatment with the study medication for this reason <sep> 72 of these patients were assigned to the icd 10 diagnostic criterion f32.0 mild depressive episode while 77 patients were suffering from moderate depressive episodes corresponding to f32.1 <sep> elderly patients with mild or moderate depressive episodes according to icd 10 international statistical classification of diseases and related health problems <sep> 149 out-patients 129 females and 20 males <sep>', '125 patients with major depression treated for an initial phase of 6 weeks and then followed up for a further 6 months <sep>', 'outpatients with major depression <sep> three hundred eighty-two patients <sep> outpatients with dsm-iii-r major depression a minimum score of 20 on the <sep>', 'twenty-eight elderly inpatients suffering from major depressive episodes diagnosed according to dsm iii <sep> elderly depression <sep>', '27 subjects began active treatment <sep> depressed geriatric patients <sep> geriatric depressed patients but only 13 completed 6 weeks on study medication <sep> patients who had received an adequate trial of medication indicated a trend toward relatively more fluoxetine-treated patients meeting clinical criteria for resolved depression <sep>', '209 patients with new episodes of depression selected from 612 consecutive depressed patients representative of those consulting psychiatric services in finland <sep>', 'patients were diagnosed as having major depression according to dsm-iii criteria when interviewed with the diagnostic interview schedule <sep> major depression <sep>', '61 patients <sep> severely depressed outpatients who fulfilled the dsm-iii-r criteria for nonpsychotic major depressive disorder and had a score of 20 or more on the hamilton rating scale for depression 21 item participated in this two-center study <sep> depressed outpatients <sep>', 'outpatients with nonpsychotic major depressive disorder and insomnia <sep> n  64 with <sep> outpatients with major depressive disorder <sep>', 'outpatients with major depression <sep> one hundred forty-five patients <sep> depressed outpatients <sep> the mean age was 37 years and 70 of the patients were female <sep>', 'outpatients with major depressive episode 184 patients <sep> major depressive episode <sep>', '122 patients with major depressive illness <sep> depressive disorders <sep> 49 patients receiving <sep> and 43 patients receiving <sep>', 'seventeen patients with major depressive episode <sep>', 'outpatients with major depression <sep> 40 patients <sep>', '27 patients given <sep> depression in general practice <sep> 100 depressed patients male and female drawn from 8 general practices <sep>', 'patients n  284 with dsm-iv major depressive disorder <sep> major depressive disorder patients <sep> depressed patients <sep>', 'outpatients with major depression who do not respond early to treatment <sep> outpatients with major depression <sep> three hundred fourteen patients <sep> major depression in outpatients <sep>', '65 depressed out-patients <sep> ambulatory therapy of depressed patients <sep>', 'outpatients with major depression <sep> 198 outpatients with dsm-iii major depression of whom 145 completed at least 2 weeks of active treatment <sep>', 'one hundred patients were recruited into the study of whom 78 were evaluable for the efficacy analysis <sep> patients suffering from dsm-iii major depression and with a score of 18 or more on the <sep> depressed patients <sep>', '174 patients with major depression with or without melancholia and without psychotic features <sep> patients with major depression <sep> all patients who received one dose of study medication were included in the observed-case analysis no missing data were replaced <sep>', 'fifty-three patients mean age 40 years 22 men 31 women <sep> inpatients with major depression <sep> seventy inpatients with a dsm-iii-r major depression <sep>', 'major depression dsm-iii-r <sep> 108 out-patients from nine italian centres entered into the study of whom 88 were evaluable 48 <sep> major depression <sep>', 'patients n  108 with dsm-iv major depression and high levels of anxiety <sep> anxious depression <sep> patients with anxious depression <sep> patients with high levels of baseline anxiety symptoms during the acute treatment of major depression <sep> depressed patients with high levels of anxiety <sep>', 'female patients <sep> patients with dysthymia or major depression in partial remission <sep> 281 patients with dsm iii-r diagnosis of dysthymia or a single episode of major depression in partial remission <sep>', '64 depressed out-patients <sep> fifty patients completed the 6-week trial <sep> depressed out-patients <sep>', 'patients age 70 or over with major depression <sep> n=33 in patients over age 70 with a diagnosis of major depressive disorder <sep>', 'geriatric patients with major depressive disorder <sep> geriatric out-patients with major depressive illness <sep> elderly depressed patients <sep>', 'patients with major depressive disorder <sep> 44 outpatients with major depressive disorder <sep>', '169 patients with major depression <sep> major depression <sep>', 'major depressive disorders <sep> 30 hospitalized patients <sep>', 'major depressive disorder <sep> patients with moderate to severe depression <sep> 203 patients <sep>', 'major depression with atypical features <sep> one hundred fifty-four subjects with dsm-iv major depression who met the columbia criteria for atypical depression <sep> atypical depression <sep>', 'patients with major depression and associated anxiety <sep> outpatients with major depression <sep> 124 evaluable patients in each treatment group <sep> 286 psychiatric outpatients with dsm-iii-r major depression or bipolar disorder depressed <sep>', '8 general practitioners and 7 specialists in the field of psychiatry and neurology participated <sep> ambulatory patients with a depressive syndrome in a clinical trial with private practitioners <sep> 139 patients <sep>', 'depressed elderly outpatients <sep> two hundred thirty-six outpatients 60 years of age and older who met dsm-iii-r criteria for major depressive disorder received 1 week of <sep>', 'patients with moderate to severe major depression <sep> moderate to severe major depression <sep> 48 adult outpatients who met the diagnostic and statistical manual of mental disorders dsm iv forth edition for major depression based on the structured clinical interview for dsm iv participated in the trial <sep>', '66 patients suffering from major depressive disorder and treated in a double-blind manner with <sep>', '381 patients treated with <sep> patients with major depression <sep>', '68 patients hospitalized with major depression and melancholia <sep> patients hospitalized for major depression and melancholia <sep>', 'major depression <sep> hospitalized patients with dsm-iii major depression without psychotic features <sep>', '34 patients fitting the research diagnostic criteria for a major depressive disorder <sep> major depression <sep>', '93 major depressive outpatients <sep> major depression <sep>', 'major depressive disorder in adults <sep> a total of 150 patients were enrolled in the study <sep> 128 patients eligible to be randomized with 66 patients receiving <sep> and 62 patients receiving <sep> adult patients with major depressive disorder <sep> major depressive disorder <sep>', 'major depressive disorder with associated anxious symptoms anxious depression <sep> major depression with associated anxiety anxious depression <sep> a total of 157 patients <sep>'], 'interventions': ['placebo <sep> fluoxetine fx <sep> fluoxetine <sep> fx <sep> amitriptyline am <sep> amitriptyline <sep>', 'trimipramine and fluoxetine <sep> trimipramine a tricyclic antidepressant tca with atypical pharmacological properties and fluoxetine a selective serotonine reuptake inhibitor ssri <sep> fluoxetine <sep>', 'fluoxetine <sep> venlafaxine or 20 mg/d fluoxetine <sep> venlafaxine <sep> venlafaxine and fluoxetine <sep> venlafaxine vs. fluoxetine <sep> venlafaxine <sep>', 'placebo <sep> fluoxetine <sep> trazodone <sep> trazodone <sep> fluoxetine and trazodone <sep> fluoxetine <sep>', 'nortriptyline and fluoxetine <sep> nortriptyline <sep> fluoxetine <sep> fluoxetine <sep>', 'imipramine <sep> placebo <sep> fluoxetine <sep> fluoxetine <sep> imipramine and placebo <sep> fluoxetine vs. imipramine and placebo <sep>', 'fluoxetine and lofepramine <sep> fluoxetine <sep>', 'imipramine <sep> placebo <sep> fluoxetine imipramine and placebo <sep> fluoxetine <sep>', 'imipramine <sep> placebo <sep> fluoxetine <sep> fluoxetine imipramine and placebo <sep> fluoxetine imipramine and placebo <sep>', 'imipramine <sep> fluoxetine and imipramine <sep> fluoxetine <sep> fluoxetine <sep>', 'imipramine <sep> fluoxetine and imipramine <sep> fluoxetine <sep> fluoxetine <sep>', 'fluoxetine <sep> tianeptine <sep> tianeptine with fluoxetine <sep> tianeptine and fluoxetine <sep> ssris such as fluoxetine <sep>', 'fluoxetine and maprotiline <sep> maprotiline <sep> ssri fluoxetine <sep> norepinephrinergic tetracyclic antidepressant maprotiline <sep>', 'placebo <sep> fluoxetine <sep> imipramine fluoxetine <sep> fluoxetine <sep>', 'sertraline and fluoxetine <sep> sertraline <sep> fluoxetine <sep>', 'selective reversible monoamine oxidase a inhibitor moclobemide <sep> selective serotonin uptake inhibitor fluoxetine <sep> moclobemide <sep> moclobemide <sep> fluoxetine <sep>', 'fluoxetine and dothiepin <sep> fluoxetine <sep> fluoxetine or dothiepin <sep>', 'imipramine 27.0 <sep> imipramine <sep> fluoxetine and imipramine <sep> fluoxetine <sep> fluoxetine and imipramine <sep> fluoxetine <sep>', 'fluoxetine <sep> mirtazapine <sep> mirtazapine or fluoxetine <sep> mirtazapine and fluoxetine <sep>', 'desipramine <sep> fluoxetine <sep> fluoxetine and desipramine <sep> desipramine <sep> fluoxetine and desipramine <sep>', 'fluoxetine or amineptine <sep> amineptine <sep> fluoxetine <sep>', 'fluoxetine and phenelzine <sep> fluoxetine <sep> fluoxetine 20-60 mg/day or phenelzine <sep> phenelzine-treated patients dropped out prior to completion <sep> phenelzine <sep> fluoxetine <sep>', 'fluvoxamine <sep> fluvoxamine and fluoxetine <sep> fluoxetine <sep>', 'tricyclic antidepressants tcas <sep> placebo <sep> fluoxetine <sep> fluoxetine and doxepin <sep> doxepin <sep> doxepin or fluoxetine <sep>', 'selective serotonin reuptake inhibitors <sep> fluoxetine <sep> paroxetine <sep> paroxetine <sep>', 'duloxetine hydrochloride <sep> placebo <sep> fluoxetine <sep> serotonin and norepinephrine <sep> duloxetine <sep> fluoxetine 20 mg q.d <sep> duloxetine <sep>', 'fluoxetine <sep> venlafaxine 225 mg/day or fluoxetine <sep> venlafaxine and fluoxetine <sep> venlafaxine <sep> venlafaxine 150 mg/day or fluoxetine <sep> venlafaxine <sep>', 'fluoxetine and nefazodone <sep> nefazodone <sep> fluoxetine <sep> nefazodone 20 fluoxetine nefazodone and fluoxetine <sep> nefazodone <sep> nefazodone and fluoxetine <sep> fluoxetine <sep>', 'placebo <sep> mirtazapine and fluoxetine <sep> fluoxetine <sep> mirtazapine <sep> mirtazapine-fluoxetine <sep> mirtazapine <sep>', 'fluoxetine vs. clomipramine <sep> clomipramine <sep> fluoxetine <sep>', 'fluoxetine and amitriptyline <sep> fluoxetine 60-80 mg daily or amitriptyline <sep> fluoxetine 40 mg daily or amitriptyline <sep> fluoxetine <sep> amitriptyline <sep>', 'venlafaxine xr <sep> placebo <sep> fluoxetine <sep> venlafaxine xr and fluoxetine <sep> venlafaxine xr <sep> venlafaxine <sep> venlafaxine xr fluoxetine or placebo <sep> venlafaxine extended release xr and fluoxetine <sep>', 'tianeptine <sep> tianeptine and fluoxetine <sep> tianeptine and fluoxetine <sep> fluoxetine <sep>', 'fluoxetine versus tianeptine <sep> tianeptine <sep> fluoxetine <sep>', 'milnacipran and fluoxetine <sep> fluoxetine <sep> placebo <sep> milnacipran <sep>', 'antidepressant medication <sep> fluoxetine <sep> fluoxetine and dothiepin <sep> tricyclic antidepressant <sep> antidepressant medications <sep>', 'selective serotonin reuptake inhibitors ssris <sep> fluoxetine <sep> sertraline <sep> sertraline 118 fluoxetine <sep> sertraline and fluoxetine <sep>', ""st. john's wort hypericum perforatum extract calmigen or fluoxetine hydrochloride prozac <sep> hypericum <sep> hypericum perforatum versus fluoxetine <sep> fluoxetine <sep>"", 'imipramine imi or fluoxetine flu <sep> imipramine <sep> fluoxetine <sep>', 'placebo <sep> paroxetine <sep> fluoxetine <sep> paroxetine and fluoxetine <sep> paroxetine fluoxetine and placebo <sep>', 'placebo <sep> fluoxetine <sep> mianserin and placebo <sep> mianserin <sep> fluoxetine mianserin and placebo <sep> fluoxetine <sep>', 'amitriptyline <sep> fluoxetine or amitriptyline <sep> fluoxetine <sep>', 'venlafaxine xr <sep> placebo <sep> venlafaxine xr fluoxetine and placebo <sep> fluoxetine <sep> venlafaxine <sep> venlafaxine xr <sep>', 'imipramine <sep> fluoxetine <sep>', 'reboxetine and fluoxetine <sep> fluoxetine <sep> reboxetine <sep> oral fluoxetine <sep> oral reboxetine <sep> reboxetine <sep>', 'moclobemide <sep> moclobemide <sep> fluoxetine <sep>', 'sertraline <sep> sertraline 50 mg/day sertraline <sep> fluoxetine <sep>', 'moclobemide <sep> moclobemide <sep> fluoxetine <sep>', 'lohyp-57 <sep> fluoxetine <sep>', 'fluoxetine <sep> fluoxetine and dothiepin <sep> dothiepin <sep> fluoxetine <sep> antidepressants <sep>', 'venlafaxine and fluoxetine <sep> venlafaxine <sep> fluoxetine <sep>', 'fluoxetine <sep> fluoxetine <sep> amitriptyline <sep>', 'trazodone <sep> fluoxetine <sep> trazodone and fluoxetine <sep>', 'moclobemide and fluoxetine <sep> moclobemide <sep> fluoxetine <sep>', 'fluoxetine <sep> fluoxetine and amitriptyline <sep> fluoxetine <sep> amitriptyline <sep>', 'bupropion and fluoxetine <sep> placebo <sep> bupropion or fluoxetine <sep> fluoxetine <sep> bupropion <sep>', 'nefazodone <sep> fluoxetine <sep> nefazodone <sep> nefazodone and fluoxetine <sep> nefazodone and fluoxetine <sep> fluoxetine <sep>', 'fluoxetine <sep> venlafaxine and fluoxetine <sep> venlafaxine <sep> venlafaxine 37.5 mg twice daily or fluoxetine <sep>', 'fluvoxamine <sep> fluvoxamine <sep> fluvoxamine and fluoxetine <sep> fluoxetine <sep>', 'moclobemide or 20-40 mg/day for fluoxetine <sep> moclobemide <sep> fluoxetine <sep> moclobemide and fluoxetine <sep> moclobemide and fluoxetine <sep>', 'desipramine deprexan <sep> desipramine <sep> fluoxetine prozac <sep> fluoxetine <sep>', 'trazodone <sep> fluoxetine <sep>', 'fluoxetine and dothiepin <sep> fluoxetine <sep> fluoxetine <sep>', 'fluoxetine paroxetine or sertraline <sep> paroxetine <sep> fluoxetine sertraline and paroxetine <sep> fluoxetine <sep> sertraline and paroxetine <sep> fluoxetine sertraline <sep>', 'fluoxetine <sep> venlafaxine 37.5 mg twice daily or fluoxetine <sep> venlafaxine and fluoxetine <sep> venlafaxine <sep> venlafaxine <sep>', 'fluoxetine <sep> mianserin and fluoxetine <sep> mianserin <sep> mianserin with fluoxetine <sep>', 'imipramine <sep> placebo <sep> fluoxetine <sep> imipramine and placebo <sep> fluoxetine-placebo <sep> fluoxetine imipramine and placebo <sep> imipramine and fluoxetine <sep> fluoxetine <sep>', 'placebo <sep> paroxetine <sep> fluoxetine <sep> paroxetine and fluoxetine <sep> paroxetine <sep> paroxetine with fluoxetine <sep> paroxetine or fluoxetine <sep>', 'placebo <sep> fluoxetine <sep> pramipexole fluoxetine and placebo <sep> pramipexole <sep> pramipexole a dopamine d2 receptor agonist <sep> fluoxetine prozac at 20 mg and placebo <sep> pramipexole <sep>', 'moclobemide <sep> placebo <sep> moclobemide <sep> fluoxetine <sep> moclobemide versus fluoxetine <sep>', 'sertraline 40 fluoxetine <sep> fluoxetine <sep> sertraline <sep> sertraline <sep> sertraline vs. fluoxetine <sep>', 'paroxetine <sep> fluoxetine sertraline and paroxetine <sep> sertraline and paroxetine <sep> fluoxetine sertraline <sep> fluoxetine sertraline or paroxetine <sep> fluoxetine <sep>', 'fluoxetine <sep> amisulpride <sep> amisulpride 50 mg/day or fluoxetine <sep> amisulpride <sep>', 'amitriptyline <sep> fluoxetine <sep> fluoxetine and amitriptyline <sep> fluoxetine a selective serotonin uptake inhibitor <sep>', 'sertraline <sep> sertraline vs. fluoxetine <sep> fluoxetine <sep>', 'fluoxetine and doxepin <sep> doxepin <sep> fluoxetine <sep> fluoxetine <sep>', 'fluoxetine or amitriptyline <sep> placebo <sep> fluoxetine and amitriptyline <sep> fluoxetine <sep> amitriptyline <sep>', 'amineptine and fluoxetine <sep> amineptine <sep> amineptine versus fluoxetine <sep> fluoxetine <sep>', 'fluoxetine vs clomipramine <sep> clomipramine <sep> fluoxetine <sep>', 'paroxetine <sep> selective serotonin reuptake inhibitors paroxetine and fluoxetine <sep> fluoxetine <sep> paroxetine and fluoxetine <sep> paroxetine <sep> paroxetine or fluoxetine <sep>', 'imipramine <sep> placebo <sep> fluoxetine <sep> imipramine <sep> selective serotonin reuptake inhibitor ssri fluoxetine <sep> fluoxetine imipramine or placebo <sep> monoamine oxidase inhibitors <sep> fluoxetine and imipramine <sep>', 'sertraline and fluoxetine <sep> sertraline <sep> sertraline <sep> fluoxetine <sep>', 'fluoxetine and 50 mg clomipramine <sep> clomipramine <sep> fluoxetine <sep>', 'fluoxetine <sep> sertraline <sep> ssri <sep> sertraline <sep> sertraline and fluoxetine <sep> single-blind placebo <sep> selective serotonin reuptake inhibitor ssri medications <sep>', 'nortriptyline <sep> fluoxetine and nortriptyline <sep> fluoxetine <sep>', 'amitriptyline <sep> fluoxetine or amitriptyline <sep> fluoxetine 20 mg/day or amitriptyline <sep> fluoxetine <sep>', 'placebo <sep> reboxetine or fluoxetine <sep> fluoxetine <sep> reboxetine <sep> fluoxetine and placebo <sep> reboxetine <sep>', 'fluoxetine <sep> venlafaxine and fluoxetine <sep> venlafaxine <sep> venlafaxine <sep>', 'fluoxetine and maprotiline <sep> maprotiline <sep> placebo <sep> fluoxetine <sep>', 'selective inhibitor of the reuptake of 5-ht <sep> fluoxetine <sep> amitriptyline <sep>', 'milnacipran and fluoxetine <sep> noradrenaline and serotonin reuptake <sep> fluoxetine <sep> milnacipran <sep>', 'moclobemide <sep> moclobemide or fluoxetine <sep> placebo <sep> moclobemide <sep> fluoxetine <sep>', 'fluoxetine or amitriptyline <sep> placebo <sep> fluoxetine <sep> fluoxetine <sep> amitriptyline <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",there are statistically significant differences in terms of efficacy and tolerability between fluoxetine and certain ads but the clinical meaning of these differences is uncertain and no definitive implications for clinical practice can be drawn. from a clinical point of view the analysis of antidepressants safety profile adverse effect and suicide risk remains of crucial importance and more reliable data about these outcomes are needed. waiting for more robust evidence treatment decisions should be based on considerations of clinical history drug toxicity patient acceptability and cost. we need for large pragmatic trials enrolling heterogeneous populations of patients with depression to generate clinically relevant information on the benefits and harms of competitive pharmacological options. a meta-analysis of individual patient data from the randomised trials is clearly necessary.
265,"{'outcomes': ['sural nerve zenarestat level and sorbitol suppression <sep> ncv <sep> nerve conduction velocity ncv <sep> density of small-diameter <sep>', 'lying-to-standing heart rate ratio <sep> vibration perception <sep> deep-breathing maximum/minimum heart rate expiration/inspiration ratio <sep> nerve functions <sep> postural hypotension deteriorated <sep> side effects <sep> postural hypotension <sep>', 'diabetic neuropathy <sep> peripheral nerve function <sep> vibration perception thresholds nerve conduction velocities and nerve action potential amplitudes <sep>', 'nerve function <sep> vibration perception <sep> cardiovascular reflex tests squatting vagal and sympathetic tests pressure gain deep breathing lying-to-standing valsalva maneuver and orthostatic hypertension vibration thresholds tendon reflexes and muscle strength <sep> squatting vagal test <sep>', 'symptoms of pain numbness or paresthesia <sep> posterior tibial nerve conduction velocity <sep>', 'electrophysiological measure <sep> subjective symptoms including numbness spontaneous pain sensation of rigidity paresthesia in the sole upon walking heaviness in the foot and hypesthesia <sep> median nerve fcv <sep> median nerve fcv and minimal latency <sep> electrophysiological measurements of median and tibial motor nerve conduction velocity f-wave minimum latency f-wave conduction velocity fcv and median sensory nerve conduction velocity forearm and distal as well as an assessment of subjective symptoms <sep>', 'oesophageal transit time and cholecystic motility <sep> efficacy and safety evaluation <sep> tendon reflexes and blood pressure fall <sep> vibration perception <sep> oesophageal motility and vibration perception <sep> transit time <sep> cholecystic function <sep>', 'analysed symptoms pain and paraesthesias and objective assessments ncv-db <sep>', 'heart rate variation and e/i ratio <sep> neuropathic symptom scores <sep> motor and sensory nerve conduction thermal and vibration sensation thresholds heart rate variation at rest e/i ratio pupillary dilation velocity and pupillary reflex latency <sep> adverse reactions <sep>', 'motor and sensory nerve conduction velocity <sep> deterioration of motor nerve conduction velocity and vibration threshold <sep> deterioration of vibration threshold <sep>', 'peripheral or autonomic nerve function <sep> peripheral nerve function <sep>', 'fibrinolytic activities of the extrinsic tissue-type plasminogen activator t-pa or in the intrinsic factor xii-dependent or factor xii-independent urokinase-like plasminogen activator systems <sep> objective neurophysiological variables biothesiometry electromyography nyctometri <sep>', 'median motor median sensory and peroneal nerves <sep> early clinical signs and symptoms of diabetic neuropathy <sep> worsening of clinical measures of distal symmetric polyneuropathy <sep> median motor and median sensory nerves changes in velocities <sep>', 'pupillary light reflex <sep> pupillary light reflex test cardiovascular autonomic function tests and nerve conduction study <sep> pupillary light reflex and f-wave latency <sep> constriction ratio <sep> motor or sensory nerve conduction velocity <sep> maximum velocity of constriction <sep> cardiovascular autonomic nerve functions the ratio of the longest expiratory r-r interval to the shortest inspiratory r-r interval during deep breathing <sep> pupillary light reflex and minimum latency of the f-wave <sep> minimum latencies of f-wave of median and tibial motor nerves <sep>', 'diabetic neuropathy <sep> hypersensitivity reaction <sep> metabolic control and severity of neuropathy <sep>', 'resting lvef <sep> lv stroke volume <sep> exercise cardiac output <sep> stroke volume <sep> exercise lvef <sep> exercise lvef <sep> resting diastolic filling rates <sep> coronary artery disease left ventricular hypertrophy and valvular heart disease <sep> cardiac output <sep> end diastolic volume <sep> cardiac abnormalities <sep> blood pressure insulin use or the presence of baseline abnormal heart rate variability <sep>', 'median motor ncv <sep> mean motor ncv <sep> mild reversible elevations of hepatic transaminases <sep> painful symptoms <sep> painful and paraesthetic symptoms vibration sensory threshold and nerve conduction velocity ncv <sep> deterioration in mean vibration threshold <sep> mean ncv of the four motor nerves <sep> paraesthetic symptoms <sep>', 'motor nerve conduction velocities and paraesthetic symptom scores <sep> symptomatic diabetic neuropathy <sep> painful and paraesthetic symptoms <sep> painful symptoms <sep> tibial and peroneal motor nerve conduction velocities <sep> paraesthetic symptoms <sep>', 'number of fibers <sep> nerve conduction <sep> percentage of regenerating myelinated nerve fibers <sep> nerve sorbitol content <sep> number of myelinated fibers per unit of cross-sectional area of nerve <sep>', 'cardiovascular reflexes pupil reflexes and skin vasomotor reflexes <sep>', 'diabetic neuropathy <sep>', 'sensory electrophysiological and autonomic function <sep> motor ulnar median and peroneal or sensory ulnar and radial nerve conduction velocities vibration perception thresholds adjectival symptom scores or tests of autonomic function mean electrocardiographic r-r interval variability on deep breathing and orthostatic blood pressure response <sep> glycaemic control <sep>', 'severe symptomatic chronic peripheral neuropathy <sep> collagen and adenosine diphosphate adp <sep> median deterioration in aer <sep> vitro platelet aggregation albumin excretion rate aer or muscle capillary basement membrane thickness <sep> muscle capillary basement membrane thickness <sep> change in aer <sep> baseline neurophysiological parameters duration of diabetes and presence of retinopathy <sep> platelet reactivity and microalbuminuria <sep>'], 'punchline_text': ['dose-dependent increments in sural nerve zenarestat level and sorbitol suppression were accompanied by significant improvement in ncv. <sep>', 'compared with baseline values postural hypotension decreased by a value of 5.9 mm hg 95 cl 1.6 to 8.7 deep-breathing maximum/minimum heart rate expiration/inspiration ratio increased by a value of 0.026 cl 0.015 to 0.036 and lying-to-standing heart rate ratio 30:15 ratio increased by a value of 0.032 cl 0.027 to 0.052). <sep>', 'overall no beneficial effect of ponalrestat on vibration perception thresholds nerve conduction velocities and nerve action potential amplitudes was detected. <sep>', 'at 12 months nerve function significantly improved in patients receiving tolrestat and deteriorated in patients taking placebo. <sep>', 'no significant changes were observed in symptoms of pain numbness or paresthesia between ponalrestat and placebo groups and there were no improvements in vpt or tt at several sites. <sep>', 'over the course of the study five of the eight electrophysiological measures assessed showed significant improvement from baseline in the fidarestat-treated group whereas no measure showed significant deterioration. <sep>', 'the vibration perception threshold at two sites of the dominant leg improved by at least 3 volts in the tolrestat group and remained unchanged or slightly deteriorated in the control group. <sep>', 'after six months an improvement of analysed symptoms pain and paraesthesias and objective assessments ncv-db was observed in patients treated with tolrestat group a significantly higher than in patients treated with placebo group b). <sep>', 'it is concluded that one-year treatment with ponalrestat has no beneficial effects on symptoms or electrophysiological parameters in diabetic neuropathy. <sep>', 'following the double-blind phase motor and sensory nerve conduction velocity had significantly deteriorated in the placebo group which did not occur during treatment with tolrestat. <sep>', 'measurement of erythrocyte sorbitol concentrations demonstrated very significant inhibition of aldose reductase activity with sorbinil treatment but no concomitant improvement in either peripheral or autonomic nerve function was observed. <sep>', 'neither did sorbinil induce marked changes in the fibrinolytic activities of the extrinsic tissue-type plasminogen activator t-pa or in the intrinsic factor xii-dependent or factor xii-independent urokinase-like plasminogen activator systems. <sep>', 'for the median motor median sensory and peroneal nerves there were no benefits in maximum amplitudes over the follow-up period. <sep>', 'minimum latencies of f-wave of median and tibial motor nerves were significantly shortened by epalrestat p  0.002 and p  0.001 respectively however no significant effects were observed in motor or sensory nerve conduction velocity. <sep>', 'no beneficial effect of sorbinil was demonstrated on either the clinical manifestation or on the neurophysiological measurements made in these neuropathic diabetic patients over 12 months of treatment. <sep>', 'in placebo-treated subjects there were decreases in exercise cardiac output p  0.03 stroke volume p  0.02 and end diastolic volume p  0.04). <sep>', 'the deterioration in mean vibration threshold of the tolrestat group was less than placebo at 24 weeks at all 3 sites measured and reached significance at the carpal site p less than 0.05). <sep>', 'tolrestat 200 mg once daily was significantly better than placebo in producing concordant improvements in both motor nerve conduction velocities and paraesthetic symptom scores at 24 weeks p  0.01 42 weeks p  0.01 and 52 weeks p  0.02). <sep>', 'they also had quantitative improvement in terms of the degree of paranodal demyelination segmental demyelination and myelin wrinkling. <sep>', 'neither symptom scores nor cardiovascular reflexes pupil reflexes and skin vasomotor reflexes improved after statil therapy which led us to conclude that statil is not effective in the treatment of diabetic autonomic neuropathy. <sep>', 'neurophysiological measurements particularly of sensory amplitude were considerably more sensitive than measurements of temperature and vibration sensation and remain of fundamental importance in measuring diabetic neuropathy at an early and potentially reversible stage. <sep>', 'at 52 weeks no significant differences were observed between the ponalrestat and placebo groups in motor ulnar median and peroneal or sensory ulnar and radial nerve conduction velocities vibration perception thresholds adjectival symptom scores or tests of autonomic function mean electrocardiographic r-r interval variability on deep breathing and orthostatic blood pressure response). <sep>', 'in vitro platelet responsiveness to collagen and adenosine diphosphate adp increased in the placebo group median change max collagen  8 2 to 30 adp 4.5 0 to 20 compared with a fall in the sorbinil treated patients median change collagen 17.5 2 to 40 p less than 0.05 adp 4 0 to 25 p less than 0.05). <sep>'], 'population': ['diabetic neuropathy <sep> patients with mild to moderate dpn <sep> diabetic peripheral polyneuropathy dpn <sep>', 'twenty patients <sep> mild diabetic neuropathy <sep> forty-five diabetic patients with asymptomatic autonomic neuropathy identified by at least one pathologic cardiovascular reflex test result <sep> university hospital clinic <sep> patients with mild diabetic autonomic and peripheral neuropathy <sep>', 'patients with an abnormal heart rate reaction to standing abnormal 30:15 ratio n  84 <sep> diabetes mellitus patients with signs of peripheral neuropathy <sep> diabetic patients with signs of autonomic neuropathy <sep> 259 diabetes mellitus patients with peripheral neuropathy defined by abnormal vibration perception threshold and abnormal peroneal motor conduction velocity in a double-blind placebo-controlled clinical trial running for 18 months <sep> 259 diabetic patients with peripheral neuropathy treated with <sep>', 'diabetic neuropathy <sep> fifty-seven patients <sep> patients with subclinical diabetic neuropathy <sep>', 'chronic symptomatic diabetic peripheral neuropathy <sep> patients with vibration perception thresholds vpts greater than 35 v at the great toe or thermal difference thresholds tts greater than 10 degrees c on the dorsum of the foot were excluded from the trial <sep> fifty-four diabetic patients median age 56 yr range 25-65 yr with chronic neuropathic symptoms <sep>', 'diabetic peripheral neuropathy <sep> 279 patients with diabetic neuropathy <sep> patients with type 1 and type 2 diabetes and associated peripheral neuropathy <sep>', 'type 2 diabetic patients with asymptomatic diabetic neuropathy <sep> type-2 diabetic patients with asymptomatic diabetic neuropathy <sep> sixty-six patients <sep>', 'diabetic peripheral neuropathy <sep> 74 diabetics affected by peripheral neuropathy <sep>', '60 patients <sep> forty-six patients 30 of whom were treated with ponalrestat and 16 with <sep>', 'patients with confirmed diabetic neuropathy <sep> symptomatic diabetic sensory polyneuropathy <sep>', '22 diabetic patients with subclinical abnormalities of nerve function <sep> asymptomatic diabetic neuropathy <sep>', 'diabetics n  19 into a group n  12 <sep>', '192 patients <sep> 497 patients aged 18 to 56 years with insulin-dependent diabetes mellitus for 1 to 15 years duration to treatment with sorbinil an aldose reductase inhibitor or to a <sep>', '30 diabetic patients with subclinical or mild diabetic neuropathy <sep> patients with mild diabetic neuropathy <sep> type 2 diabetic patients <sep>', 'diabetic neuropathy <sep> neuropathic diabetic patients <sep>', 'diabetic patients with neuropathy <sep> diabetic subjects with neuropathy n  81 with either a low diastolic peak filling rate or impaired augmentation of left ventricular lv ejection fraction lvef during maximal bicycle exercise were identified by gated radionuclide ventriculography <sep> diabetic patients with neuropathy <sep>', 'one hundred and ninety patients with symptomatic diabetic peripheral neuropathy took part <sep> patients with symptomatic diabetic peripheral neuropathy <sep>', 'chronic symptomatic diabetic sensorimotor neuropathy <sep> patients with symptomatic diabetic neuropathy <sep>', 'patients with diabetic neuropathy treated with sorbinil <sep> accompany symptomatic diabetic peripheral polyneuropathy <sep> 16 diabetic patients with neuropathy <sep> subjects with diabetes <sep>', '34 diabetic patients with documented cardiac autonomic neuropathy <sep> fifteen patients treated with statil and 12 with <sep>', '39 patients with diabetic neuropathy <sep> patients with established diabetic neuropathy <sep>', '50 patients with chronic symptomatic distal symmetrical diabetic neuropathy <sep> patients with established symptomatic disease <sep> patients with chronic symptomatic diabetic neuropathy <sep>', '21 diabetic patients <sep> chronic peripheral diabetic neuropathy <sep>'], 'interventions': ['aldose reductase inhibitor ari zenarestat <sep> placebo <sep> aldose reductase inhibition <sep>', 'tolrestat <sep> placebo <sep> tolrestat <sep>', 'aldose reductase inhibitor ponalrestat <sep> ponalrestat an aldose reductase inhibitor or placebo <sep> placebo <sep>', 'tolrestat <sep> placebo <sep> tolrestat <sep> tolrestat and placebo <sep>', 'aldose reductase inhibitor ponalrestat <sep> placebo or aldose reductase inhibition 300 or 600 mg ponalrestat ici 128436 <sep> placebo <sep>', 'fidarestat a novel aldose reductase ar inhibitor <sep> placebo <sep> fidarestat a novel aldose reductase inhibitor <sep> placebo or fidarestat <sep> fidarestat-treatment <sep>', 'tolrestat <sep> tolrestat 200 mg once daily 33 patients or were left without specific treatment <sep> tolrestat an aldose-reductase inhibitor <sep>', 'tolrestat <sep> aldose reductase inhibitor tolrestat <sep> tolrestat <sep> placebo <sep>', 'placebo <sep> 600 mg ponalrestat or placebo <sep>', 'tolrestat <sep> tolrestat <sep> placebo <sep>', 'placebo <sep> aldose reductase inhibitor sorbinil <sep>', 'given daily 250 mg sorbinil a potent aldose reductase inhibitor <sep> aldose reductase inhibitor or placebo <sep> placebo <sep>', 'placebo <sep>', 'aldose reductase inhibitor epalrestat <sep> aldose reductase inhibition <sep>', 'placebo <sep> aldose reductase inhibition <sep> sorbinil <sep>', 'aldose reductase inhibitor ari <sep> placebo or the ari zopolrestat 500 or 1,000 mg daily for 1 year <sep> placebo <sep>', 'tolrestat <sep> placebo <sep> aldose-reductase inhibitor tolrestat <sep> placebo or tolrestat <sep> tolrestat <sep>', 'tolrestat <sep> aldose-reductase inhibitor tolrestat <sep> placebo <sep> tolrestat <sep>', 'investigational aldose reductase inhibitor sorbinil <sep> aldose reductase inhibitors <sep> placebo <sep>', 'placebo <sep> aldose reductase inhibitor ponalrestat statil <sep> aldose reductase inhibitor <sep> 600 mg statil or placebo <sep>', 'aldose reductase inhibitor sorbinil <sep> placebo <sep>', 'aldose reductase inhibitor ponalrestat <sep> placebo <sep>', 'aldose reductase inhibitor sorbinil <sep> placebo <sep> prolonged aldose reductase inhibition <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",we found no statistically significant difference between aldose reductase inhibitors and placebo in the treatment of diabetic polyneuropathy. any future clinical trials of aldose reductase inhibitors should be restricted to compounds proven to have substantial biological or preclinical advantages over previously tested agents.
266,"{'outcomes': ['time and cotinine values <sep> throat/mouth irritation and coughing <sep> efficacy <sep> success rates <sep> craving <sep> cotinine levels <sep> failure <sep>', 'relapse risks <sep> success rates <sep> safety and efficacy <sep>', 'carbon monoxide concentration <sep> abstinence rates <sep> quitting rate <sep>', 'abstinence rate <sep> abstinence rates <sep>', '7-day point prevalence abstinence <sep> continuous abstinence cotinine-verified abstinence daily cigarette consumption withdrawal symptoms and adverse events <sep> self-reported 7-day point prevalence smoking abstinence 6 months after quit day <sep> adverse events <sep> smoking abstinence <sep> cessation rates <sep>', '7-day point prevalence abstinence rates <sep> smoking abstinence rates <sep> 7-day point prevalence smoking abstinence rate <sep> short-term smoking abstinence rates <sep>', 'smoking cessation rates <sep> expired carbon monoxide concentration <sep> withdrawal severity <sep> erythema with edema <sep> adverse effects <sep> smoking cessation rates <sep> vomiting <sep> serious adverse events <sep> frequency of nausea <sep> efficacy and safety <sep> abstinence <sep>', 'quit rates and tobacco withdrawal symptoms <sep> tobacco withdrawal symptoms and enhanced smoking cessation rates <sep> smoking cessation efficacy <sep> tobacco withdrawal symptoms <sep> smoking cessation rates and tobacco withdrawal symptoms <sep> self-reported quit rates <sep> abstinence <sep>', 'weight gain <sep> adverse events <sep> abstinence rates <sep> higher long-term rates of smoking cessation <sep> abstinence rates <sep> insomnia and headache <sep>', '12-month abstinence <sep> 1-year abstinence rates <sep> 6 month quit rates <sep> 1-year quit rates <sep> highest quit rates <sep> abstinence rates <sep>', 'abstinence rates <sep> abstinence rates <sep> demographic characteristics smoking history depression symptoms and body mass index <sep>', 'continuous abstinence <sep>', 'efficacy and tolerance <sep> systemic side effects <sep> transient mild or moderate erythema <sep> severe localized erythema <sep> tenseness difficulty in concentration and feelings of hunger <sep> abstinence rates <sep> withdrawal symptoms <sep>', 'breath carbon monoxide co <sep> higher quit rates <sep> quit rates <sep>', 'increase abstinence <sep>', 'risk for smoking lapses <sep> chances of recovery from lapses <sep> point-prevalence abstinence and continuous abstinence <sep> continuous and prolonged abstinence lapse and recovery events cost per additional quitter and side effects and adherence <sep> rates of point-prevalence abstinence <sep> quit rates <sep> point-prevalence abstinence <sep> side effects and adverse events <sep> continuous abstinence <sep> time to relapse <sep> prolonged abstinence <sep>', 'cessation rates <sep> sustained cessation <sep> smoking cessation rate <sep> cessation rate <sep>', 'cessation rates and postcessation weight gain <sep> weight change and cessation rates <sep> body weight nor cessation rates <sep> likelihood of quitting smoking <sep>', 'throat irritation inhaler and itching patch <sep> complete abstinence rates <sep> mean nicotine substitution <sep> complete abstinence self-reported and expired carbon dioxide concentration less <sep> cessation rates <sep> frequency of respiratory symptoms <sep>', 'point-prevalence abstinence rates <sep>', 'skin reactions <sep> substantial relapse rate <sep> rate of smoking <sep> 6-week smoking-cessation rate <sep>', 'percentage of nicotine replacement <sep> higher smoking cessation rates <sep> dividing serum nicotine and cotinine levels <sep> withdrawal symptoms <sep> serum levels of nicotine and cotinine at baseline and withdrawal symptom relief <sep>', 'overall rate of relapse <sep> quit smoking <sep> nicotine dependence <sep>', 'sleep disturbance and local skin irritation <sep> continuous abstinence rates <sep> abstinence rates <sep> severity of some withdrawal symptoms <sep>', 'prevalence abstinence rate <sep>', 'abstinence <sep> validated point prevalence abstinence at discharge <sep> cigarette consumption <sep>', 'effectiveness and safety <sep> efficacy of the skin patch <sep> nicotine dependence and severity of withdrawal symptoms <sep> successfully quit smoking <sep> smokers nicotine withdrawal symptoms <sep>', 'rate of success <sep> success rate <sep>', 'smoking cessation rates <sep> weight gain <sep> weight and smoking status <sep> weight gained and relapse <sep> smoking cessation rates <sep> smoking cessation <sep>', 'abstinence rate <sep> abstinence rates <sep>', 'sustained abstinence rates <sep>', 'relapse <sep> successful abstinence <sep> mean success rates <sep>', 'time to smoking relapse and prolonged abstinence <sep> smoking outcomes <sep> smoking cessation <sep> alcohol outcomes <sep> drinking outcomes <sep>', 'abstinence outcomes <sep>', 'continuous abstinence rates <sep> overall rate of treatment-related adverse events <sep> relative success rate <sep>', 'abstinence rates <sep>', 'success rate <sep> plasma nicotine and cotinine values expired carbon monoxide and withdrawal symptoms <sep> withdrawal symptoms <sep>', 'birth weight and preterm delivery <sep> mean birth weight difference <sep> smoking cessation <sep> rate of preterm delivery <sep> mean value of cotinine in saliva <sep> birth weight <sep> rate of low birth weight <sep>', 'rates of abstinence <sep> abstinence rate <sep> smoking cessation <sep>', 'compliance rates for return visits <sep> quit rates <sep> quit rates <sep> short-term quit rates <sep> smoking cessation <sep>', 'smoking cessation rates <sep> cessation success rates <sep> sgrq score <sep> carbon monoxide-verified abstinence rates and st. george respiratory questionnaire sgrq <sep> sgrq scores <sep> mean scores <sep>', '28-day continuous abstinence <sep> smoking reduction <sep> initial abstinence <sep> continuous abstinence <sep>', 'probability of lapsing <sep> quit rates <sep> 7-day point prevalence rates <sep> prolonged abstinence rates co<10 ppm <sep> prolonged abstinence from 2 weeks post-quit day through 6 months <sep>', 'tolerated and adverse event profiles <sep>', 'longer length of alcohol abstinence <sep> nicotine abstinence rates <sep> smoking quit rates <sep>', 'abstinence <sep> level of self-efficacy <sep> withdrawal tension fatigue and coping frequency with decreased coping effort coping-to-urge ratio <sep> general distress <sep>', 'higher cessation rates <sep> specific withdrawal symptoms anger anxiety awakening difficulty concentrating depression hunger impatience and craving <sep> smoking cessation and suppression of withdrawal severity <sep> smoking cessation rates <sep> withdrawal symptoms including craving <sep> smoking cessation efficacy <sep> sustained rate of smoking cessation <sep>', 'abstinence rates <sep>', 'relapse <sep> level of abstinence <sep>', 'respective success rates <sep> efficacy and safety <sep>', 'transient local erythema <sep> body weight <sep> craving and withdrawal symptoms <sep> tolerated <sep>', 'minor skin reactions <sep> expired air carbon monoxide measurement <sep> cessation rates <sep> nausea <sep> fagerstrom score <sep> severe skin reactions <sep>', 'analyzed craving and withdrawal symptoms <sep> 28-day abstinence <sep> safety and efficacy <sep> reduced craving and withdrawal <sep>', 'craving for alcohol <sep> smoking abstinence <sep> smoking abstinence <sep>', 'abstinence rates <sep> skin irritation <sep>', '7-day point prevalence smoking abstinence <sep>', 'initial cessation number of days to lapse number of days to relapse and latency to relapse <sep> abstinence rates <sep>', 'birth weight and gestational age <sep> cotinine concentration <sep> quit rates <sep> number of cigarettes smoked <sep> smoking-cessation rates <sep> safety and efficacy <sep> birth weights <sep>', 'subjects smoking 16 cigarettes/day sustained cessation rates <sep> daily cigarette consumption and severity of withdrawal symptoms wisconsin scale <sep> overall sustained abstinence <sep> early withdrawal symptoms <sep> sustained abstinence rates <sep> withdrawal symptoms and abstinence rates <sep> withdrawal symptoms composite score and abstinence rates <sep> adverse event rates <sep> withdrawal symptoms <sep>', 'systemic and local adverse drug events <sep> abstinence rates <sep> time to relapse <sep> abstinence rates <sep> or <sep>', 'success rate <sep> year smoking cessation rates <sep> success rates <sep>', 'baseline mucosal lesions <sep> efficacy and safety <sep> smoking cessation rate <sep> craving <sep> adverse events <sep> tolerated <sep>', 'abstinence rates <sep> serious adverse events <sep> retention rates <sep>', 'study death myocardial infarction cardiac arrest and admission to the hospital due to increased severity of angina arrhythmia or congestive heart failure the secondary end points admission to the hospital for other reasons and outpatient visits necessitated by increased severity of heart disease any side effects of therapy and abstinence from smoking <sep> cardiovascular events <sep> abstinence rates <sep> rate of abstinence from smoking <sep>', 'quit rates <sep> expired carbon monoxide co and serum and salivary cotinine <sep>', 'co or thiocyanate concentrations <sep> numbers of cigarettes smoked <sep> mean saliva cotinine concentrations <sep> smoking reduction cpd and thiocyanate concentrations <sep> mean smoking rates <sep> mean compliance <sep> safety and efficacy <sep> prolonged abstinence assessed through self-report and verified with exhaled carbon monoxide co levels <sep> co-confirmed prolonged abstinence rates <sep> abstinence rates <sep> tolerated and adverse events <sep> safety and efficacy <sep>', 'rates of abstinence <sep>', 'rate of abstinence from the quit date until delivery <sep> rate of abstinence from smoking until delivery or the risk of adverse pregnancy or birth outcomes <sep> abstinence from the date of smoking cessation until delivery as validated by measurement of exhaled carbon monoxide or salivary cotinine <sep> safety <sep> rates of adverse pregnancy and birth outcomes <sep> adverse pregnancy and birth outcomes <sep> efficacy and safety <sep>', 'severe reactions <sep> difficulty in sleeping <sep> sustained smoking cessation <sep> efficacy and safety <sep>', 'salivary cotinine levels <sep> withdrawal symptom reporting <sep> weight gain <sep> saliva cotinine <sep>', 'lack of power contamination and low attendance <sep>', 'rates of sustained abstinence <sep> success rate in quitting smoking <sep> absolute rate of abstinence <sep> safety and efficacy <sep>', 'exhaled carbon monoxide <sep> reduction of smoking <sep>', 'relapse <sep>', 'overall duration and level of nicotine gum use <sep> abstinence outcomes <sep>', 'abstinence <sep> abstinence rates <sep>', '7-day point prevalence abstinence at 1 week 8 weeks and 6 months after quitting and number of days to relapse <sep> six-month abstinence rates <sep> abstinence <sep>', 'side effects <sep> success rates <sep>', 'equivalent 1-year abstinence rates <sep>', 'adverse effects <sep> craving for smoking <sep> levels of expired co <sep>', 'rates of abstinence <sep>', 'rate of continuous smoking abstinence <sep> compensatory smoking of low tar and nicotine cigarettes <sep>', 'mood disturbance <sep> mood withdrawal symptoms pleasant activities and events self-efficacy and optimism and pessimism <sep> abstinence rates <sep>', 'blood pressure <sep> ad lib smoking smoking satisfaction and craving <sep> duration of continuous smoking abstinence abstinence rates <sep>', 'smoking abstinence cotinine plus carbon monoxide <sep> smoking abstinence rates <sep> cigarette consumption <sep> 4-week abstinence rates <sep> abstinence rates <sep>', 'continuous abstinence through 7 weeks after cessation <sep> point abstinence <sep> continuous abstinence rate <sep> expired air carbon monoxide measurements <sep> point abstinence at 7 weeks continuous abstinence at 6 and 12-month follow-up and self-reported withdrawal symptoms <sep> craving for cigarettes negative affect and appetite <sep>', 'toxin intake <sep> overall success rate for sustained smoking reduction <sep> point prevalence cessation rates <sep> number of daily cigarettes <sep> plasma cotinine exhaled carbon monoxide and plasma thiocyanate <sep> smoking reduction promotes smoking cessation <sep> smoking reduction <sep>', 'tolerated <sep> smoking abstinence rates <sep> continuous abstinence rates <sep> abstinence rates <sep>', 'stopped smoking <sep> quitting rates <sep> behavioural therapy <sep> quitting rate <sep>', 'daily cigarette consumption or craving <sep> daily cigarette smoking and cigarette craving <sep> daily cigarette smoking on cigarette craving <sep> smoking abstinence <sep> smoking abstinence rates <sep> efficacy and safety <sep>', 'daily cigarette consumption <sep> cigarette taste <sep> abstinence rates <sep> psychological smoking cessation <sep>', 'rate of continuous abstinence <sep> cessation <sep> eventually achieving long-term abstinence <sep> withdrawal symptoms <sep>', 'success rates <sep> success rate <sep> smoking cessation <sep> mild or moderate side effects <sep> efficacy and safety <sep>', 'quit rates <sep> educational level duration of smoking number of cigarettes smoked per day concomitant disease states or drug use or fagerstrom score <sep> smoking cessation <sep>', 'side effects <sep> smoking behavior and compliance <sep> smoking cessation rates <sep> smoking status <sep>', 'abstinence proportions <sep> abstinence proportions ratios <sep>', 'smoking abstinence verified by saliva cotinine and expired carbon monoxide cessation self-efficacy and physical fitness and body weight <sep> reduction rates and b psychological and physiological processes <sep> 7-day point prevalence <sep> functional exercise capacity <sep> smoking rates <sep> functional exercise capacity and delays weight gain <sep> cessation efficacy <sep> cessation rates <sep> continuous abstinence rates <sep> knowledge coping and support resources <sep>', 'co reductions <sep> successful quitting <sep> 10-wk continuous smoking abstinence <sep> self-reported abstinence and end-expired air carbon monoxide co <sep>', 'abstinence rates <sep>', 'rate of negative birth outcomes <sep>', 'safety and efficacy <sep> abstinence rates <sep>', 'total abstinence <sep> efficacy and safety <sep> smoking status <sep> quit rate <sep> quit rates <sep> quit rates <sep> safety <sep> efficacy and safety <sep>', 'expired carbon monoxide co levels <sep> co-validated abstinence rates <sep> adverse events <sep> efficacy and safety <sep> abstinence rates <sep>', 'signs of nicotine toxicity <sep> monitoring blood cotinine levels <sep> withdrawal symptom relief <sep> withdrawal symptom relief <sep> 8-week smoking abstinence rate <sep> baseline smoking rate and baseline trough and peak blood cotinine levels <sep> cigarette smoking rates <sep> withdrawal symptoms and nicotine toxicity <sep> 6-day inpatient stay daily nicotine and cotinine levels <sep> nicotine toxicity and withdrawal symptom relief <sep> short and long-term smoking cessation rates <sep>', 'relapse rate <sep> success rate <sep>', 'ratings of adverse effects <sep>', 'respective success rates <sep> mean nicotine substitution based on cotinine determinations <sep> continuous smoking abstinence <sep> tolerated and no serious adverse events <sep>', 'cessation rates <sep> quit rates <sep>', 'quit rates <sep> rates of dropouts due to adverse events <sep> abstinence rates <sep> quit rates <sep>', 'smoking cessation rates <sep> self-reported smoking abstinence confirmed by expired carbon monoxide measurements <sep> efficacy and safety <sep> adverse cardiovascular events <sep>'], 'punchline_text': ['survival analysis showed active inhaler was superior to placebo p  0.01). <sep>', 'a new faster-acting nicotine nasal spray nns can provide easily self-administered relief from cigarette withdrawal. <sep>', 'after one year these rates declined to 23 and 16 respectively p=0.476 and converged to 18 and 14 p=0.797 respectively at 5-year follow-up. <sep>', 'short tns treatment 3 weeks is at least as effective as a longer one 6 weeks which is relevant both medically and economically. <sep>', 'relative risk 1.08 95 ci 0.86 1.35 p  0.4 risk difference 1.7 95 ci 3.2 6.6%). <sep>', 'at 6 weeks the 7-day point prevalence smoking abstinence rate for the patch alone 21.1 was superior to the spray 13.6 but was significantly lower than the rate for combination therapy 27.1%). <sep>', 'smoking cessation rates for the two nicotine patch doses and three levels of counseling did not differ significantly at either 8 weeks or 26 weeks following the quit date. <sep>', 'the differences in quit rates and tobacco withdrawal symptoms between the two active groups were not statistically significant. <sep>', 'weight gain at seven weeks was significantly less in the combined-treatment group than in the bupropion group and the placebo group p<0.05 for both comparisons). <sep>', 'compared with placebo control subjects participants assigned nicotine patches had higher 3-month 23.4 vs 11.4 p  .01 and 6-month <sep>', 'abstinence rates for the transdermal nicotine and nicotine nasal spray groups were not significantly different at 6-month follow-up 15.0 vs. 12.2 respectively p  0.2). <sep>', 'after corrections for marital status and income 10 of those who received nicotine gum and 7 of those who received placebo gum reported continuous abstinence for 11 months and passed observer and biochemical verification this difference was not statistically significant). <sep>', 'tenseness difficulty in concentration and feelings of hunger were consistently and in part significantly lessened in the tns group. <sep>', 'a logistic regression model of eot quit rates showed smokers who preferred transdermal nicotine were not reactive to smoking cues and did not use nicotine to alleviate distress or stimulate cognitive function had higher quit rates on transdermal nicotine. <sep>', 'decreased cost also increased cessation attempts and 1-week cessation p less than 0.05 and appeared to increase abstinence at 6-month follow-up 19 vs 6 vs 8 p less than 0.10). <sep>', 'time to relapse was slower with extended versus standard therapy hazard ratio 0.50 ci 0.35 to 0.73 p  0.001). <sep>', 'by 6 months there was no significant difference between the two groups 22/136 16 as+nrt and 15/109 14 as). <sep>', 'attendance to sessions did appear to consistently increase the likelihood of quitting smoking at posttest and at each of the follow-ups. <sep>', 'at 12 months the frequency of respiratory symptoms in abstinent subjects fell significantly and lung function showed a trend toward improvement. <sep>', 'there were no significant differences between conditions in point-prevalence abstinence rates or in time to first slip. <sep>', 'the rate of smoking was significantly reduced in volunteer subjects by providing effective nicotine replacement self-help material and weekly visits with a nurse for 6 weeks. <sep>', 'higher smoking cessation rates were also observed in subjects assigned to the active patch who had lower serum levels of nicotine and cotinine at baseline and withdrawal symptom relief was better in the active patch group compared with placebo. <sep>', 'results showed that smokers with high levels of nicotine dependence were significantly more likely to quit smoking during treatment if they received nicotine gum 31.9 than high-dependence smokers who did not receive the gum 12.2%). <sep>', 'six-months continuous abstinence rates were also significantly higher among the active nicotine group 25 compared with placebo 12%). <sep>', 'although significant differences in the percentage of abstainers were observed between groups sbcn and sbc three weeks after treatment 39 vs. 26 the point prevalence abstinence rate for patients at 12 months declined to 19 18 and 12 for groups sbcn sbc and an respectively. <sep>', 'the difference between the groups was significant for validated point prevalence abstinence at discharge 55 43 37 respectively p=0.045 and at 12 months 17 6 8 p=0.03). <sep>', 'nineteen 63 95 confidence interval ci 46%-80 of the smokers treated with the transdermal nicotine patch had successfully quit smoking at the end of the program 6 weeks and nine 30 95 ci 14%-46 remained abstinent 1 year later. <sep>', 'the success rate was 35.1 in the first group and 13.2 in the second p less than 0.03 thus confirming the effectiveness of nicotine chewing gum. <sep>', 'there was no significant relationship between weight gained and relapse in individuals. <sep>', 'the abstinence rates were 51 39 and 29 after 6 weeks 3 and 6 months respectively as compared to 24 19 and 18 in the placebo group p=0.0003 p=0.003 p=0.050). <sep>', 'sustained abstinence rates for the patch and nasal spray group and patch only group were 51 v 35 after 6 weeks odds ratio 1.97 95 confidence interval 1.17 to 3.32 p=0.011(chi2 37 v 25 after 3 months 1.76 1.01 to 3.08 p=0.045 31 v 16 after 6 months 2.40 1.27 to 4.50 p=0.005 27 v 11 after 12 months 3.03 1.50 to 6.14 p=0.001 and 16 v 9 after 6 years 2.09 0.93 to 4.72 p=0.08 corrected]. <sep>', 'between six months and one year relapse in the nicotine group accounted for the 30 vs. 20 success rates for nicotine and placebo observed at one year. <sep>', 'all participants received open-label transdermal nicotine patches and were randomized to receive either 2 mg nicotine gum or placebo gum under double-blind conditions. <sep>', 'the results at 12 months were that long follow-up showed a trend p less than 0.12 toward being better than short follow-up while nicotine gum was significantly better than no gum p less than 0.05 in maintaining abstinence. <sep>', 'nicotine mouth spray delivered significantly higher <sep>', 'a double-blind trial of a smoking-withdrawal chewing gum containing 2 mg nicotine was conducted with 100 consecutive patients in a smoking cessation clinic. <sep>', 'replacement was similar in groups lc-15 and hc-25 but the success rate was significantly lower in hc-25 group despite similar levels of withdrawal symptoms. <sep>', 'mean birth weight difference was 186 g 95 ci 35 336 g higher in the nicotine than placebo group and there was an insignificantly lower rate of low birth weight under 2500 g in the former group. <sep>', 'however at 6-month follow-up the subjects who had received behavioral treatment had a significantly better abstinence rate 36.7 than those receiving education 17.5%). <sep>', 'the nicotine patch significantly improves short-term quit rates in inner-city african americans who are interested in trying to quit smoking. <sep>', 'smoking cessation rates were statistically significantly superior with sublingual nicotine vs placebo for all measures of abstinence 6-month point prevalence 23 vs 10 12-month point prevalence 17 vs 10%. <sep>', 'smokers on active gum were significantly more likely to achieve initial cessation 2 mg or=1.42 4 mg or=1.90 28-day continuous abstinence 2 mg or=2.01 4 mg or=4.66 and continuous abstinence at 6 months 2 mg or=1.80 4 mg or=5.96). <sep>', 'prolonged abstinence rates co<10 ppm did not differ among gradual abrupt and minimal treatment conditions 4 7 and 5 nor did 7-day point prevalence rates 7 11 and 11%). <sep>', 'the results of this trial do not support the routine use of higher dose nicotine patch therapy in the treatment of nicotine dependence. <sep>', 'nicotine abstinence rates in the 21 and 42-mg np conditions on week 36 follow-up were 16.9 and 9.2 respectively. <sep>', 'more general distress was observed among bt versus btp participants i.e. increased withdrawal tension fatigue and coping frequency with decreased coping effort coping-to-urge ratio). <sep>', 'smoking cessation efficacy was maintained 6 months after initiation of treatment 34 percent vs 21 percent p  0.08 in study 1 and 18 percent vs 7 percent p  0.05 in study 2). <sep>', 'abstinence rates for daily nicotine gum users n  64 at 12 months and again at 24 months remained 48.4 as compared with 26.1 and 31.9 for the daily placebo gum users n  69). <sep>', 'at 2 months tnp produced a higher level of abstinence 36 than placebo 20 p  .001. <sep>', 'significantly more participants who had used the nicotine inhalers were continuously abstinent compared with those who had used the placebo inhalers. <sep>', 'the patches were generally well tolerated although 25 of subjects in the nicotine group and 13 in the placebo group had transient local erythema after application of the patch 5 members of the nicotine group withdrew because of poor cutaneous tolerance. <sep>', 'cessation rates in smokers attending special clinics or their general practitioners can be increased by transdermal nicotine tns). <sep>', 'the nicotine lozenge is a safe and effective new treatment for smoking cessation in low and high-dependence smokers. <sep>', 'smoking abstinence was not lower and the odds ratio for nicotine patch therapy was not greater in smokers with a history of alcohol dependence than in smokers with no such history. <sep>', 'abstinence rates at 6 weeks 3 months and 6 months were 29.5 21.8 and 20.5 in the active group and 8.8 3.8 and 2.5 in the placebo group p  or  .001 for each comparison respectively. <sep>', 'subjects who received transdermal nicotine were significantly more likely than placebo-treated subjects to remain abstinent from smoking during treatment but not at the 1-year follow-up. <sep>', 'all pharmacotherapies differed from placebo when examined without protection for multiple comparisons odds ratios 1.63-2.34). <sep>', 'biochemically validated smoking-cessation rates were not significantly higher with nicotine gum compared with placebo after 6 weeks of treatment 13 compared with 9.6 p=.45 at 32-34 weeks of gestation 18 compared with 14.9 p=.56). <sep>', 'overall sustained abstinence was documented in 17 of subjects at 6 months 22 and 12 for ap and pp respectively p  0.03). <sep>', 'time to relapse is significantly longer in group 1 as compared to that of group 2 p  0.041 whereas no significant differences between groups 2 and 3 were observed. <sep>', 'the 12 month sustained success rates were 25 mg patch for 22 weeks l-25 15.4 25 mg patch for 8 weeks s-25 15.9 15 mg patch for 22 weeks l-15 13.7 15 mg patch for 8 weeks s-15 11.7 and placebo p-0 9.9 placebo versus 15 mg p<0.05 25 mg versus 15 mg p<0.03 25 mg versus placebo p<0.001 chi-squared test). <sep>', 'the nicotine sublingual tablet increased the smoking cessation rate compared to placebo reduced craving in highly dependent smokers and was well tolerated. <sep>', 'retention rates were highest in the bup group 59.3 and lowest in the nrt group 50.5%). <sep>', 'transdermal nicotine does not cause a significant increase in cardiovascular events in high-risk outpatients with cardiac disease. <sep>', 'seven-day quit rates for nicotine gum were no better than for the placebo group 14.2 versus 11.1 p  0.232 at 6 months. <sep>', 'mean compliance across groups was higher for the patch mean 78.4-82.8 than for the gum mean 38.5-50.7%). <sep>', 'the ncg group had higher rates of abstinence at all follow-up points but the difference approached statistical significance at 3 months only p less than .10). <sep>', 'there was no significant difference in the rate of abstinence from the quit date until delivery between the nicotine-replacement and placebo groups 9.4 and 7.6 respectively unadjusted odds ratio with nicotine-replacement therapy 1.26 95 confidence interval 0.82 to 1.96 although the rate was higher at 1 month in the nicotine-replacement group than in the placebo group 21.3 vs. 11.7%). <sep>', 'at 12 weeks 21/315 6.7 subjects allocated to active treatment had stopped smoking compared with 6/314 1.9 allocated to placebo absolute difference 4.7 95 confidence interval 1.6 to 7.9 p  0.003). <sep>', 'biological verification of gum use and smoking abstinence were assessed in community volunteers who attended an intensive behavioral counseling program for smoking cessation while using nicotine gum for 3 months. <sep>', 'in no treatment group was the outcome significantly different from that for one-time counselling at the p less than 0.05 level. <sep>', 'rates of sustained abstinence were significantly better with active treatment than with placebo 53 41 24 and 17 percent of those in the nicotine-patch group were abstinent after 6 12 26 and 52 weeks respectively as compared with 17 10 5 and 4 percent of those in the placebo-patch group p less than 0.0001). <sep>', 'corresponding figures after two years were 19 9.5 and 6 3.0 p=0.012). <sep>', 'compared with the no-gum group relapse occurred at a significantly lower rate in the gum group for the entire 12 months of follow-up odds of relapse in the gum group was 0.72 95 confidence interval 0.62 to 0.83). <sep>', 'effects for gum were no longer significant at later follow-ups however overall duration and level of nicotine gum use were considerably less than optimal. <sep>', 'abstinence at 1 year was.77 in the otc condition versus 3.08 in the hcp condition p<.01]. <sep>', 'in this comparative effectiveness study of 5 tobacco dependence treatments combination pharmacotherapy significantly increased abstinence compared with monotherapies. <sep>', 'familiarizing with the gum as compared with regular use gave fewer reports of side effects 15 vs 34 p  0.001. <sep>', 'skills training produced higher initial cessation and more coping responses posttreatment than did support. <sep>', 'more subjects in the nicotine group 70/94 v 45/93 reported that the gum reduced the craving for smoking. <sep>', 'the differences in outcomes were significant at the 5 percent level for all comparisons with the exception of the 2-mg nicotine gum versus the placebo gum at one year. <sep>', 'results showed that precessation nicotine patch treatment was associated with a significantly higher rate of continuous smoking abstinence at 4 weeks regardless of cigarette condition. <sep>', 'no treatment differences were found in trends over time for measures of mood withdrawal symptoms pleasant activities and events self-efficacy and optimism and pessimism. <sep>', 'precessation mecamylamine significantly prolonged the duration of continuous smoking abstinence abstinence rates at the end of treatment were 47.5 with mecamylamine and 27.5 without mecamylamine. <sep>', 'eight weeks after the target quit date self-reported 4-week abstinence rates were 41.6 in the precessation treatment group and 44.4 in the usual care group p  .61). <sep>', 'point abstinence at 7 weeks was 58 for mecamylamine versus 29 for placebo p  0.044. <sep>', 'the overall success rate for sustained smoking reduction was significantly higher at all time-points for active versus placebo gum 6.3 versus 0.5 after 24 months). <sep>', 'the treatment mainly benefited smokers with lower levels of dependence based on fagerstrm test for nicotine dependence score. <sep>', 'in this latter group there were significant differences p=0.03 between those who had follow up in clinics 39 stopped compared to those who were followed up telephone sessions 30%). <sep>', 'the opioid antagonist naltrexone was not found to be effective for smoking cessation and had no significant effect on daily cigarette consumption or craving. <sep>', 'nicotine-treated subjects reached significantly higher abstinence rates during and at the end of treatment than both placebo and control-subjects 69 in the nicotine condition 51.2 and 44.4 under placebo and control conditions respectively. <sep>', 'nicotine patch treatment doubled the rate of continuous abstinence up to 1 year nicotine 9.6 placebo 4.8 p  0.01 it most likely worked by reducing withdrawal symptoms. <sep>', ""subjects with high scores  7 on fagerstrm's tolerance questionnaire had a significantly lower success rate with placebo than with the nicotine spray. <sep>"", 'at baseline there were no significant differences among the three treatment groups with regard to age gender educational level duration of smoking number of cigarettes smoked per day concomitant disease states or drug use or fagerstrom score. <sep>', 'there was a significant increase in smoking cessation rates after 8 weeks of follow-up but only among smokers who started on 21-mg/day patches. <sep>', 'after multiple adjustments the abstinence proportions ratios seemed to follow a dose-response pattern compared to gb the ratios were 0.85 g1-g2 1.13 g3-g4 1.51 gba 1.66 g1a-g2a and 1.75 g3a-g4a). <sep>', 'there were significant differences in a 7-day point prevalence but not continuous abstinence rates between treatment groups across targeted end points. <sep>', 'nrt dose level of nicotine dependence and genotype scores displayed significant interactive effects on successful quitting. <sep>', 'relative to the pp group the aa and ap groups were each significantly more likely to be abstinent at 1 week end of treatment and 6 months but not at 12 months postquit. <sep>', 'women in the cbt+nrt arm were almost three times more likely than women in the cbt-only arm to have biochemically validated cessation at both pregnancy time points after 7 weeks 24 vs 8 p=0.02 at 38 weeks gestation 18 vs 7 p=0.04 but not at 3 months postpartum 20 vs 14 p=0.55). <sep>', 'at 6-month follow-up abstinence rates for the three treatments were 4.9 6.5 and 9.7 for the mc cpp and cap treatments respectively. <sep>', 'at least 1 adverse event was reported by 57 receiving the nicotine patch and 39 receiving placebo p<.001). <sep>', 'after 6 weeks of treatment co-validated abstinence rates were 48 in the active group and 23 in the placebo group p  0.0001). <sep>', 'a higher percentage of cotinine replacement was associated with the higher 8-week smoking abstinence rate p  .03 an association not found at long-term follow-up. <sep>', 'this study was designed to see whether the offer and prescription of nicotine chewing gum would enhance the efficacy of general practitioners advice to stop smoking. <sep>', 'over the next 6 months the two higher doses appeared to support more gum self-administration than the two lower doses 4 mg  2 mg greater than 0.5 mg  0 mg in the subsample of long-term quitters n  20). <sep>', 'continuous smoking abstinence was significantly higher for the active nicotine inhaler group compared with the placebo inhaler group. <sep>', 'the interaction of nicotine-gum dose and dependence group was not significant p  0.42 nor did the 2-mg and 4-mg doses differ significantly in effectiveness though both 2-mg and 4-mg gum were significantly more effective than placebo gum. <sep>', 'quit rates were dose-related at all follow-ups p  0.01). <sep>', 'a slight increase in adverse cardiovascular events was noted only in the open label-pay group in comparison with the placebo group. <sep>'], 'population': ['smoking cessation <sep>', 'smoking cessation <sep> two hundred and fifty-five smokers <sep>', '112 smokers <sep> 311 hospital health professionals included in the study there were 112 36 smokers 44 39 of them were physicians and 68 61 nurses <sep> health care workers with a smoking habit in split croatia <sep> health care workers <sep>', '160 smokers <sep> 300 smokers <sep>', 'eleven hundred adult dependent smokers who called the new zealand quitline between march 2006 and may 2007 for support to stop smoking <sep>', '1384 smokers randomized to the study 20 were abstinent from smoking at 6 weeks and 8 were abstinent at 6 months <sep> 15 regional cancer control oncology centers within the north central cancer treatment group <sep> treating smokers <sep>', '504 participants were enrolled at two sites <sep> daily cigarette smokers  or  15 cigarettes per day for at least 1 year who volunteered to participate in a study of smoking cessation treatment <sep>', '158 smokers <sep>', '160 subjects for smoking cessation <sep> smokers with clinical depression <sep> 244 subjects <sep> 311 subjects 34.8 percent discontinued one or both medications <sep>', 'twenty-one primary care sites in nebraska <sep> 369 smokers of 20 or more cigarettes per day <sep>', '299 treatment-seeking smokers who were followed for 6 months after the target quit date <sep> 2 university-based smoking cessation research programs <sep> tobacco dependence <sep> smokers who have greater or lesser abstinence rates with either <sep> individual patients with tobacco dependence <sep>', 'three hundred fifteen smokers who attended a family practice clinic and wished to quit smoking <sep>', '112 young nicotine-dependent cigarette smokers were treated for nine weeks with tns n  56 or <sep>', ""smoking cessation <sep> 12 medical sites participating in the national cancer institute's community clinical oncology program <sep>"", 'one hundred six smokers seen in a family practice received <sep>', 'adult smokers <sep> participants and all research personnel except the database manager <sep> 568 adult smokers <sep> september 2004 to february 2008 <sep>', 'healthy volunteers <sep> patients referred by their hospital doctor to the smoking cessation counsellor and who agreed to participate in the study <sep> 245 patients were randomised 136 as+nrt and 109 as <sep> hospital patients also given advice and support <sep>', 'women <sep> all participants attended a 13-week cognitive behavioral smoking cessation program and were given <sep> participants were 439 females who met rigorous screening criteria <sep> 13-week cognitive behavioral smoking cessation program targeted for women <sep>', '400 subjects who had smoked 10 or more cigarettes per day for 3 years or longer <sep> nicotine-dependent smokers <sep> smoking cessation <sep>', 'all smokers met individually with their counselor for six rp sessions <sep> 129 smokers <sep> one hundred and twenty-nine cigarette smokers recruited through newspaper advertisements <sep>', 'volunteer subjects <sep>', 'two-hundred forty healthy volunteers who were smoking at least 20 cigarettes per day <sep>', 'one hundred seventy-three smokers classified as high or low on nicotine dependence using the fagerstrom tolerance questionnaire <sep>', 'mean age was 42 years 48 were male mean cigarette consumption was 29 per day and mean duration of smoking was 24 years <sep> three hundred and thirteen smokers recruited from the local community <sep> six months follow-up of those who returned to the hospital-based outpatients smoking cessation clinic <sep>', 'a total of 450 smoking patients <sep> forty-eight percent of the 450 patients made an attempt to stop smoking and 89 reduced their cigarette consumption at some point during the study <sep>', 'hospital inpatients <sep> 274 inpatient smokers were enrolled <sep> smokers admitted to hospital <sep> medical and surgical inpatients who were current smokers at the time of admission <sep>', '30 heavy smokers who had smoked more than 20 cigarettes per day for more than a year were treated with <sep> chinese smokers <sep> smoking cessation <sep> and 32 heavy smokers were given <sep>', '106 individuals out of the 200 recruited in three health centers started the treatment <sep>', '417 women smokers <sep>', '157 smokers <sep>', '237 smokers aged 22-66 years living in or around reykjavik <sep> n=119 <sep> smoking cessation <sep>', 'in smoking cessation <sep> sixty subjects <sep>', 'in a sample of alcohol-dependent tobacco smokers in an early phase of out-patient alcohol treatment <sep> participants were 96 men and women with a diagnosis of alcohol abuse or dependence and smoking 15 or more cigarettes per day <sep> two out-patient substance abuse clinics <sep>', 'physician-based smoking cessation <sep> 151 patients were advised to stop smoking and were asked to participate in the program if judged sufficiently motivated by the physicians <sep> 13 physicians working in the open health care system <sep>', '479 smokers  1 cigarette per day who were treated with either active n=318 or <sep> smoking cessation <sep>', '100 consecutive patients in a smoking cessation clinic <sep> smoking cessation <sep>', 'those with baseline cotinine  or  250 ng.ml-1 low cotinine <sep> smoking cessation <sep> two hundred and ninety seven adult smokers were enrolled <sep>', 'pregnant smokers <sep> pregnant women <sep> pregnant women who smoked ten or more cigarettes after the first trimester n  250 <sep>', 'eighty-nine smokers <sep>', 'inner-city african americans <sep> 410 patients randomized mean age was 48 years 65 were female 41 had less than a high school education 51 had an annual household income of less than 8,000 and the average number of cigarettes smoked per day was 20 <sep>', 'patients with copd using nicotine sublingual tablets and behavioral support <sep> pulmonary outpatient clinics <sep> three hundred seventy copd patients who smoked a mean of 19.6 cigarettes per day mean 42.7 pack-years mean fev(1 56 of predicted <sep> two hundred eighty-eight of 370 patients were evaluable for the final study end points <sep> copd patients <sep>', '3297 smokers who were interested in quitting gradually <sep> 1999-2000 and 2007-2008 <sep>', 'n=150 among smokers who wanted to quit now and preferred to quit gradually <sep> participants were recruited via newspaper and radio advertisements <sep> smokers actively trying to quit <sep>', 'heavy smokers n  408 smoking more than 25 cigarettes/day <sep>', 'heavy smokers with a history of alcohol dependence <sep> one hundred thirty participants <sep> smokers with a history of alcohol dependence <sep>', '64 participants <sep>', 'adult volunteers motivated to quit smoking <sep> eighty-eight study 1 and 112 study 2 <sep>', '182 smokers <sep> of participants with a high nicotine-dependence score <sep>', '424 smokers <sep> cigarette smoking cessation <sep>', 'two hundred forty-seven smokers who smoked at least 10 cigarettes per day and who had previously made a serious attempt to stop smoking using nicotine chewing gum were recruited through advertisements <sep> 123 participants receiving <sep>', 'participants who smoked more than 20 cigarettes a day were treated with the 30 cm2 patch and the others with the 20 cm2 patch <sep> tobacco withdrawal <sep>', 'patients attending hospital with smoking-related diseases <sep> 234 inpatients and outpatients with smoking-related respiratory or cardiovascular disease aged 18-75 years who were willing to try to stop smoking were advised by their hospital doctor to stop smoking <sep> patients attending hospital with smoking-related diseases to stop smoking <sep> smokers attending special clinics or their general practitioners <sep>', 'low-dependence smokers <sep> smokers n  1818 <sep>', 'one hundred fifteen smokers with a history of alcohol dependence median of 5 years previously <sep> heavy smokers with a history of alcoholism benefit from nicotine patch treatment <sep> smokers with a history of alcohol dependence <sep> smokers with a history of alcoholism <sep>', 'one hundred fifty-nine healthy volunteers who smoked at least one pack of cigarettes per day and desired to quit smoking <sep>', 'postmenopausal women <sep> women with a history of depression <sep> postmenopausal smokers <sep> postmenopausal smokers n=152 received <sep>', 'one thousand five hundred four adults who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking <sep> participants were excluded if they reported using any form of tobacco other than cigarettes current use of bupropion having a current psychosis or schizophrenia diagnosis or having medical contraindications for any of the study medications <sep>', 'pregnant smokers <sep> pregnant women who smoked daily received <sep> n  94 groups were comparable in age race/ethnicity and smoking history <sep> women who did not quit smoking <sep>', 'smokers subsequently quitting with the nicotine patch <sep> healthy smokers n  200 45 female <sep>', 'healthy subjects 374 <sep> controlled trial 149 subjects to <sep>', 'thirty-six chest clinics enrolled a total of 3,575 smokers <sep>', '247 adult smokers smoking  or  10 cigarettes/day for  or  3 years of whom 123 received active and 124 placebo treatment <sep> smoking cessation <sep> smokers using the 2-mg tablet for 3-6 months with follow-up to 12 months <sep>', '167 primary care settings <sep> 467 current smokers were enrolled <sep>', 'as an aid to smoking cessation <sep> patients with cardiac disease <sep> high-risk outpatients with cardiac disease <sep> 10 veterans affairs medical centers we randomly assigned 584 outpatients of whom 576 were men with at least one diagnosis of cardiovascular disease to a 10-week course of <sep>', 'african american light smokers <sep> 755 african american light smokers 66 female mean age  45 were enrolled at a community health center over a 16-month period <sep>', 'a total of 120 participants were randomized 72 white 70 female age 15.2 <sep> 1.33 years smoking 18.8  8.56 cpd fagerstrom test of nicotine dependence score 7.04 <sep> adolescent smokers <sep> adolescent tobacco addiction <sep> participants started smoking at 11.2 <sep> thirteen to 17-year-old adolescents who smoked  or 10 cigarettes per day cpd scored  or 5 on the fagerstrom test of nicotine dependence and were motivated to quit smoking <sep> inner-city outpatient clinic on the east coast <sep> adolescents who want to quit smoking <sep> 1.98 years of age and had been smoking daily for 2.66 <sep>', '289 patients in a family practice setting <sep> smoking cessation in family practice <sep>', '1050 participants 521 were randomly assigned to <sep> recruited participants from seven hospitals in england who were 16 to 50 years of age with pregnancies of 12 to 24 weeks gestation and who smoked five or more cigarettes per day <sep>', '629 smokers who had unsuccessfully attempted to stop smoking by using active transdermal nicotine and brief behavioural counselling <sep> relapsed smokers <sep>', '42 abstinent subjects <sep> community volunteers who attended an intensive behavioral counseling program for smoking cessation while using nicotine gum for 3 months <sep> one hundred seventy-seven volunteers <sep>', 'general practice in italy <sep> forty-four nonsmoking general practitioners volunteered for the study <sep> patients of primary care physicians to quit smoking and sustain cessation <sep> 923 smoking clients unselected for motivation toward quitting to four different intervention groups i <sep>', '289 smokers 207 women and 82 men enrolled in the study 145 were treated with <sep> smoking cessation <sep>', 'two university hospital pulmonary clinics in switzerland <sep> 400 healthy volunteers recruited through newspaper advertisements willing to reduce their smoking but unable or unwilling to stop smoking immediately <sep>', 'smokers aged 18 to 65 years n  1,044 who were able to quit for 24 hr <sep> smoking relapse prevention <sep>', 'two-hundred and seventy-three persons <sep>', 'five hundred twenty healthy smokers <sep>', '5 smokers attending a routine primary care appointment was willing to make a serious quit attempt that included evidence-based counseling and medication <sep> primary care clinics <sep> patients were referred to a telephone quit line for cessation counseling <sep> 7128 eligible smokers  or 10 cigarettes per day attending routine primary care appointments 1346 18.9 were enrolled in the study <sep> 1346 primary care patients attending routine appointments were recruited by medical assistants in 12 primary care clinics <sep>', 'participating smokers n  322 <sep> one hundred sixty-eight smokers <sep>', 'smokers n  126 <sep>', 'smoking cessation <sep>', 'n  33 and the 113 smokers with <sep> 60 highly dependent smokers <sep> persons who are attempting to stop smoking <sep> subjects who were attempting to stop smoking <sep>', 'subjects smoked a their usual brands of cigarettes b conventional low tar and nicotine cigarettes or c denicotinized cigarettes <sep>', 'history-positive smokers <sep> smokers with a history of major depressive disorder mdd <sep> smokers with a history of mdd <sep> participants were 201 smokers 22 with a history of mdd <sep>', 'smoking cessation <sep>', 'before smoking cessation <sep> 314 daily smokers mean 23.7 cigarettes/d enrolled through the internet and by physicians in switzerland from november 2005 to january 2007 <sep>', 'forty-eight healthy smokers who smoked at least one pack per day were studied at an outpatient smoking cessation research clinic <sep> subjects ranged in age from 20 to 40 years <sep>', 'smokers unwilling to quit <sep> smokers not motivated or not able to quit smoking with regard to smoking reduction and smoking cessation <sep> 411 healthy smokers highly motivated to reduce cigarette use <sep>', 'four groups of smokers n  100 per group who received either <sep>', '717 smokers <sep> 1843 smokers who received high intensity cognitive therapy <sep> 2560 active smokers <sep> hospitalised patients <sep>', 'one hundred cigarette smokers <sep>', '131 smokers <sep>', '96 subjects <sep> general practice <sep> 1200 heavy smokers  or  15 per day attending 30 general practices in 15 english counties received <sep>', ""two hundred forty-eight smokers <sep> subjects were recruited through advertisements in newspapers and among patients referred to the smoking cessation clinic at sahlgren's hospital gteborg sweden <sep> 34 abstinent subjects in the <sep>"", 'all smokers participated in a behavior modification program <sep> 208 smokers treated with <sep> smoking cessation <sep>', 'denmark <sep> regular healthy smokers <sep> customers with chronic diseases and pregnant or breastfeeding women <sep> smoking cessation among over-the-counter customers in denmark <sep> smoking cessation <sep> forty-two pharmacies in the areas of aarhus and copenhagen in denmark participated in the trial and 522 customers who smoked 10 or more cigarettes per day <sep>', 'smoking cessation among adults in rio de janeiro brazil <sep> participated 1,199 adults volunteers in rio de janeiro brazil randomly assigned to 10 different groups <sep>', 'women <sep> women smokers <sep> one-hundred and forty-two inactive female smokers <sep>', 'four hundred seventy-nine smokers <sep> smokers <sep>', '608 participants <sep>', 'pregnant smokers <sep> smoking cessation in pregnancy <sep> data were collected from 2003 through 2005 analyses were conducted in 2006 and 2007 <sep> pregnant women <sep>', 'patients hospitalized for a smoking-related illness such as respiratory disease <sep> one hundred eighty-five patients <sep> hospital inpatients and to identify variables associated with long-term smoking cessation following hospitalization <sep> hospitalized patients <sep> patients carrying a wide range of diagnoses <sep>', '802 adults mean age 39 years and was 89 white and 54 female <sep>', 'two hundred and forty-one adult smokers  or  10 cigarettes/day for at least 3 years used <sep> january 1996 and may 1997 <sep>', 'seventy-one cigarette smokers stratified according to light n  23 moderate n  24 and heavy n  24 smoking rates <sep> heavy smokers <sep>', ""general practitioners advice to stop smoking <sep> general practitioner's advice against smoking <sep> cigarette smokers who attended the surgeries including those who did not wish to stop and those in the gum group who did not try the gum 47 <sep> 1938 cigarette smokers who attended the surgeries of 34 general practitioners in six group practices <sep>"", 'seventy-eight smokers trying to quit <sep>', 'medical outpatient clinic with physicians experienced in smoking cessation assistance <sep> 286 volunteers who smoked at least 10 cigarettes daily recruited through a local newspaper <sep>', '608 cigarette smokers planning a cessation attempt as low or high in nicotine dependence <sep> subjects within each level of dependence <sep>', '1039 smokers  or  30 cigarettes/day at 12 clinical sites in the usa and one in australia <sep>', 'participants n  958 were 18 years or older had smoked at least 15 cigarettes daily for at least 6 months and were enrolled at 3 study sites <sep> smoking cessation <sep> the years of study were 1994 to 1995 <sep>'], 'interventions': ['placebo <sep> nicotine <sep> nicotine patch <sep>', 'placebo <sep> nicotine gum <sep> nns <sep> nicotine replacement <sep> piperine placebo <sep> nicotine nasal spray nns <sep> nicotine nasal spray <sep>', 'transdermal nicotine system tns or placebo patch <sep> nicotine replacement therapy <sep>', 'placebo <sep> transdermal nicotine system <sep> transdermal nicotine system tns <sep> tns <sep> tns or placebo <sep>', 'nicotine patches and/or gum prior to their target quit day followed by usual care 8 weeks of patches and/or gum plus support calls from a quitline adviser or to usual care alone <sep> nicotine patches and/or gum <sep>', 'nicotine patch therapy <sep> nicotine patch alone versus nicotine nasal spray alone <sep> combination nicotine nasal spray and nicotine patches <sep> nicotine nasal spray <sep>', 'varying nicotine patch dose and type of smoking cessation counseling <sep> transdermal nicotine therapy <sep> 44-mg transdermal nicotine therapy <sep> transdermal nicotine therapy <sep> self-help pamphlet minimal a self-help pamphlet a brief physician motivational message and three brief  15 minutes follow-up visits with a nurse individual or the pamphlet the motivational message and eight weekly 1-hour group smoking cessation counseling visits <sep>', 'transdermal nicotine patches <sep> placebo <sep> 15-cm2 patches 1 24-hour nicotine delivery 2 nicotine delivery during wakeful hours only and 3 placebo <sep> transdermal nicotine <sep>', 'sustained-release bupropion <sep> placebo <sep> bupropion and a nicotine patch 245 subjects and placebo <sep> sustained-release bupropion a nicotine patch or both for smoking cessation <sep> nicotine-patch therapy <sep> nicotine-replacement therapies <sep> bupropion <sep> nicotine patch alone or placebo <sep> nicotine patch <sep>', 'transdermal nicotine therapy <sep> placebo <sep> nicotine patch therapy <sep> placebo-patch therapy <sep> nicotine patch therapy <sep>', 'transdermal nicotine and nicotine nasal spray <sep> individualizing nicotine replacement therapy <sep> nicotine nasal spray or transdermal nicotine <sep> transdermal or nasal spray nicotine <sep> transdermal nicotine <sep>', 'nicotine vs placebo gum <sep> placebo gum <sep> nicotine <sep> nicotine gum <sep>', 'placebo <sep> transdermal nicotine patch <sep> nicotine <sep> transdermal nicotine system tns <sep> tns <sep>', 'transdermal nicotine vs. nicotine lozenge <sep> nicotine replacement therapies <sep> transdermal nicotine <sep> transdermal nicotine or nicotine lozenge <sep> nicotine patch vs. nicotine lozenge <sep> transdermal nicotine <sep>', 'nicotine gum <sep> brief physician advice and a prescription for nicotine gum <sep>', 'standard therapy nicoderm cq glaxosmithkline research triangle park north carolina <sep> placebo <sep> transdermal nicotine <sep> extended-duration transdermal nicotine therapy <sep> placebo for 16 weeks or extended therapy nicoderm cq <sep>', 'nicotine replacement treatment <sep> carbon monoxide co breath testing <sep> nicotine replacement therapy nrt <sep> nicotine patch daily and a nicotine inhalator on an as needed basis plus advice and support as+nrt or to receive just advice and support as <sep> nrt <sep>', 'placebo <sep> pharmacotherapy nicotine and phenylpropanolamine ppa gums <sep> phenylpropanolamine and nicotine gum <sep> intervention groups ppa gum nicotine gum or placebo gum <sep> specific instructions on gum chewing <sep>', 'nicotine replacement therapy <sep> placebo <sep> placebo patch <sep> nicotine inhaler plus placebo patch <sep> nicotine inhaler plus nicotine patch vs nicotine inhaler plus placebo patch <sep> nicotine inhaler and nicotine patch <sep> nicotine inhaler plus nicotine patch delivering 15 mg of nicotine <sep> nicotine inhaler plus nicotine patch <sep>', 'relapse prevention treatment conditions 1 brief cognitive behavioral 2 cognitive behavioral and nicorette gum 3 cognitive behavioral and cue exposure and 4 cognitive behavioral and cue exposure with nicorette gum <sep> cue exposure treatment <sep> initial counseling session <sep>', 'placebo <sep> transdermal nicotine patch--a randomized double-blind placebo <sep> nicotine-replacement therapy <sep> nicotine-replacement therapy <sep> nicotine-replacement therapy with a transdermal nicotine patch nicolan <sep>', '22-mg nicotine patch combined with the national cancer institute program <sep> placebo <sep> nicotine or placebo patch <sep> nicotine patch therapy <sep> transdermal nicotine <sep>', 'counseling sessions combined with a self-help manual provided by the american lung association <sep> nicotine gum <sep> nicotine gum 2 mg chewed ad libitum or to not receive nicotine gum <sep> nicotine replacement <sep> nicotine replacement therapy nicotine gum <sep>', 'placebo <sep> cognitive-behavioural intervention <sep> transdermal nicotine patch <sep> active nicotine <sep> nicotine patch <sep>', 'structured behavioral change with nicotine gum group sbcn structured behavioral change without nicotine gum group sbc or gp advice with nicotine gum <sep>', 'smoking cessation interventions <sep> usual care no additional advice at admission counselling alone 20 minute intervention with written materials or nrt plus counselling counselling intervention with a 6 week course of nrt <sep> counselling alone or minimal intervention <sep> nicotine replacement therapy nrt plus brief counselling brief counselling alone and minimal intervention <sep> behavioural counselling and nicotine replacement therapy nrt <sep> nrt <sep>', 'placebo <sep> transdermal nicotine patch <sep> placebo patches <sep> 30-mg transdermal nicotine patches <sep> nicotine supplement systems <sep> 30-mg transdermal nicotine patch <sep>', 'nicotine chewing gum <sep> placebo <sep> nicotine chewing gum and follow up in the programmed usual consulting room <sep>', 'nicotine gum <sep> standard smoking cessation program the program plus nicotine gum the program plus behavioral weight control or the program plus both nicotine gum and behavioral weight control <sep>', 'nicotine nasal solution nns <sep> placebo <sep> nicotine <sep> nicotine nasal spray <sep> nns one dose containing 1 mg of nicotine <sep>', 'placebo <sep> nicotine patch with placebo spray <sep> nicotine nasal spray with nicotine patch <sep> nicotine <sep> nicotine nasal spray <sep> supportive treatment <sep> nicotine patch <sep> nicotine patch <sep>', 'placebo <sep> nicotine gum <sep> nicotine gum <sep> nicotine and placebo <sep> nicotine <sep> nicotine gum with placebo gum <sep>', 'nicotine patch plus nicotine gum <sep> combination nicotine replacement <sep> nicotine patch plus placebo gum <sep> placebo <sep> monotherapy nicotine patch <sep> nicotine patch plus active gum <sep> active nicotine patch plus active nicotine gum <sep> behavioral alcohol and smoking treatment <sep> nicotine gum or placebo gum under double-blind conditions <sep> combination therapy nicotine patch plus gum <sep> open-label transdermal nicotine patches <sep>', 'nicotine chewing gum <sep> nicotine gum vs no gum <sep>', 'nicotine mouth spray <sep> placebo <sep> carbon monoxide-verified continuous abstinence <sep> placebo n=161 spray for 12 weeks and low-intensity counselling at three smoking cessation clinics in denmark and germany <sep> nicotine mouth spray <sep>', 'placebo <sep> nicotine gum <sep> usual psychological treatment <sep> smoking-withdrawal chewing gum containing 2 mg nicotine <sep> placebo chewing gum control group <sep>', 'placebo <sep> nicotine replacement <sep> placebo lc-p or to 15 mg 16 h nicotine patches lc-15 and those with baseline cotinine  250 ng.ml-1 high cotinine were randomly assigned to 15 mg hc-15 or 25 mg hc-25 16 h nicotine patches <sep> transdermal nicotine replacement <sep> nicotine patch <sep>', 'nicotine patches <sep> nicotine patches <sep> placebo <sep> placebo patches <sep> nicotine <sep>', 'nicotine gum <sep> nicotine gum treatments for smoking cessation behavioral treatment plus a fixed schedule of nicotine gum behavioral treatment plus an ad lib schedule education plus a fixed schedule and education plus an ad lib schedule <sep> behavioral skills training <sep> nicotine gum administration <sep>', 'nicotine transdermal patch <sep> transdermal nicotine patch <sep> placebo <sep> nicotine patch <sep>', 'placebo <sep> sublingual nicotine vs placebo <sep> nicotine sublingual tablets <sep> nicotine sublingual tablet or placebo <sep> nrt <sep> nicotine replacement therapy nrt <sep>', 'nicotine gum <sep> nicotine gum versus placebo <sep>', 'nicotine lozenge via mail <sep> nrt-aided gradual vs. abrupt cessation <sep> gradual cessation n=297 vs. abrupt cessation n=299 vs. minimal treatment <sep>', 'nicotine patch therapy <sep>', 'nicotine patch therapy <sep> nicotine patch np therapy <sep> transdermal nicotine <sep>', 'transdermal nicotine patch <sep> btp <sep> smoking cessation program using behavior therapy alone bt or behavior therapy plus the nicotine patch btp <sep>', 'transdermal nicotine therapy with brief individual counseling study 2 <sep> nicotine patches <sep> placebo <sep> transdermal nicotine <sep> transdermal nicotine therapy <sep> nicotine patch <sep>', 'placebo <sep> nicotine polacrilex gum containing 4 mg of nicotine <sep> nicotine <sep> nicotine polacrilex gum <sep> nicotine polacrilex gum with supportive measures <sep>', 'placebo <sep> nicotine patch and self-help video <sep> transdermal nicotine path tnp <sep> tnp <sep> nicotine replacement therapy <sep>', 'nicotine replacement therapy <sep> placebo <sep> nicotine via inhaler supplies nicotine <sep> nicotine inhalers and 124 receiving placebo inhalers <sep> nicotine <sep>', 'transdermal nicotine patch <sep> placebo <sep> nicotine <sep>', 'tns <sep> transdermal nicotine <sep> placebo <sep> transdermal nicotine tns <sep>', 'placebo <sep> nicotine lozenge <sep> nicotine lozenges <sep> 4-mg nicotine n  450 or placebo <sep> nicotine polacrilex lozenge <sep> 2-mg nicotine <sep>', '21-mg nicotine patch or placebo <sep> placebo <sep> nicotine patch therapy <sep> nicotine patch <sep>', 'placebo <sep> nicotine <sep> telephone counseling <sep> telephone counseling <sep> nicotine or placebo patches <sep> nicotine patch <sep>', 'placebo <sep> placebo patch <sep> intensive smoking cessation counseling <sep> transdermal nicotine <sep> hrt <sep> 21-mg nicotine patch <sep> transdermal nicotine <sep>', 'nicotine lozenge nicotine patch sustained-release bupropion nicotine patch plus nicotine lozenge bupropion plus nicotine lozenge or placebo <sep> placebo <sep> nicotine patch plus nicotine <sep> 6 individual counseling sessions <sep>', 'placebo <sep> nicotine gum <sep> nicotine gum or placebo <sep> nicotine gum <sep> nicotine-replacement therapy <sep> nicotine <sep> 2-mg nicotine gum <sep> individualized behavioral counseling <sep>', 'nicotine patch <sep> active nicotine patches <sep> nicotine <sep> active nicotine-patch ap 15 mg daily n  100 or placebo-patch <sep> transdermal nicotine <sep>', 'placebo <sep> nicotine gum <sep> placebo patch  gum <sep> nicotine patch against the placebo <sep> placebo nicotine gum <sep> active nicotine patch  active gum group 1 150 to active nicotine patch  placebo gum <sep> nicotine patch and gum <sep> nicotine patch <sep>', 'placebo <sep> nicotine patch therapy <sep> placebo p-0 9.9 placebo <sep> placebo and either standard or higher dose nicotine patches <sep> nicotine patch <sep>', 'nicotine sublingual tablet <sep> placebo <sep> smoking cessation programme <sep> nicotine 2-mg sublingual tablet <sep>', 'minimal intervention mi n  81 cognitive-behavioral therapy cbt n  175 bupropion bup n  108 and nicotine replacements <sep> bupropione nicotine replacements cbt <sep> copyright <sep>', 'transdermal nicotine therapy <sep> placebo <sep> transdermal nicotine <sep> transdermal nicotine or placebo <sep> nicotine <sep> transdermal nicotine <sep>', 'nicotine gum plus health education he 2 mg nicotine gum plus motivational interviewing mi placebo gum plus he and placebo gum plus mi <sep> nicotine gum and counseling <sep> nicotine gum and six counseling sessions <sep> placebo <sep> nicotine gum 2 mg versus placebo and counseling motivational interviewing versus health education <sep>', 'placebo <sep> nicotine gum <sep> cognitive-behavioral group therapy <sep> nicotine patch therapy combined with cognitive-behavioral intervention <sep> placebo patch and gum <sep> nicotine patch or gum therapy with cognitive-behavioral therapy <sep> nicotine patch and gum <sep> nicotine patch <sep>', 'ncg <sep> advice and nicotine chewing gum prescription <sep> nicotine chewing gum ncg prescription <sep> physician anti-smoking intervention <sep>', 'nicotine patches <sep> placebo <sep> nicotine-replacement therapy patches <sep> nicotine patch <sep> placebo patches <sep> nicotine-replacement therapy <sep> active nicotine patches <sep> nicotine-replacement therapy <sep> behavioral cessation support <sep>', 'placebo <sep> nicotine <sep> active transdermal nicotine patches or placebo <sep> transdermal nicotine <sep>', 'nicotine gum <sep> nicotine gum <sep>', 'minimal intervention consisting of one single counselling session and a brief handout on quitting techniques ii repeated counselling including reinforcing sessions at months 1 3 6 and 9 iii repeated counselling and use of nicotine gum and iv repeated counselling and spirometry <sep> smoking cessation interventions <sep>', 'nicotine patches <sep> placebo <sep> placebo patch <sep> transdermal nicotine patch <sep> 16-hour nicotine patch 15 <sep> placebo patches <sep> nicotine skin patch <sep> nicotine <sep> nicotine chewing gum combined with psychological support <sep> 16-hour transdermal nicotine patch <sep>', 'nicotine <sep> placebo <sep> oral nicotine <sep>', 'nicotine gum to no gum use and self-help materials to no use of materials <sep> nicotine gum <sep> nicotine gum and self-help behavioral treatment <sep>', 'nicotine gum <sep>', 'nicotrol nicotine <sep> otc nicotine <sep> nicotine <sep>', 'bupropion sr  lozenge <sep> monotherapies nicotine patch nicotine lozenge and bupropion hydrochloride sustained release sr and 2 combination therapies patch  lozenge and bupropion sr  lozenge <sep> 5 smoking cessation pharmacotherapies <sep>', 'nicotine gum 2 and 4 mg for nicotine dependence <sep> placebo <sep> nicotine gum <sep> nicotine replacement <sep> gum containing 4 mg of nicotine 87 or 2 mg of nicotine 81 and the smokers with medium or low dependence were given gum containing 2 mg 76 or a placebo gum <sep>', 'skills training <sep> 6-session smoking cessation treatments consisting of 1 of 2 counseling strategies skills training or support and 1 of 2 nicotine exposure strategies nicotine gum or rapid smoking <sep>', 'placebo <sep> 2-mg nicotine chewing gum <sep> nicotine chewing gum <sep> nicotine <sep> nicotine chewing gum <sep>', 'gum containing 4 mg of nicotine <sep> nicotine gum <sep> medium or low dependence were given gum containing 2 mg of nicotine <sep> chewing gum containing nicotine <sep> placebo gum <sep> nicotine <sep> nicotine chewing gum <sep>', 'nicotine skin patch <sep> nicotinic antagonist mecamylamine <sep> nicotine replacement therapy nrt <sep> nicotine <sep> nrt <sep>', 'mood management and nicotine gum <sep> placebo <sep> 10-session mood management mm intervention <sep> mm intervention to a contact-equivalent health education intervention he and 2 mg to 0 mg of nicotine gum <sep>', 'nicotine-mecamylamine <sep> nicotine skin patches <sep> precessation mecamylamine <sep> mecamylamine capsules <sep> mecamylamine <sep> nicotine plus mecamylamine <sep> nicotine plus mecamylamine nicotine alone mecamylamine alone or no drug <sep> nicotinic antagonist mecamylamine <sep> nicotine  mecamylamine <sep> mecamylamine <sep>', 'nicotine gum <sep> nicotine gum treatment <sep> nicotine <sep> nicotine polacrilex gum <sep>', 'mecamylamine nicotine antagonist <sep> placebo <sep> mecamylamine <sep> nicotine skin patch 6 to 8 weeks plus oral mecamylamine <sep> nicotine skin patch <sep> nicotine skin patch treatment <sep> mecamylamine <sep> nicotine patch plus placebo <sep> nicotine patch with oral mecamylamine <sep>', 'placebo <sep> nicotine gum <sep> nicotine gum <sep> nicotine gum versus placebo <sep> nicotine gum and placebo <sep>', 'usual brands of cigarettes or switched to low-tar and nicotine cigarettes a 2 nicotine patch <sep> placebo patch treatment <sep> standard nicotine patch <sep> nicotine replacement therapy <sep> nicotine patch <sep>', 'high intensity behavioural-cognitive intervention <sep> cognitive orientation program with and without nicotine replacement therapy <sep> nicotine replacement therapy nrt <sep> copyright <sep> nrt <sep>', 'placebo <sep> naltrexone active vs. placebo <sep> opioid antagonist naltrexone <sep> brief behavioral intervention <sep> placebo-only naltrexone-only placebo with nicotine patches or naltrexone with nicotine patches <sep> naltrexone alone or in combination with nicotine patches <sep> naltrexone <sep> nicotine patch and naltrexone <sep> nicotine patches active vs. none <sep>', 'placebo <sep> behavioral training alone <sep> nicotine patches continuously releasing nicotine <sep> placebo patches <sep> transdermal nicotine substitution <sep> self-controlled smoking cessation <sep> nicotine <sep> transdermal nicotine <sep>', 'placebo <sep> transdermal nicotine patches <sep> transdermal nicotine patch <sep> nicotine patch <sep> brief gp advice <sep>', 'nicotine spray <sep> placebo <sep> nicotine replacement therapies <sep> nicotine per single spray or to a placebo <sep> nicotine nasal spray <sep> nicotine <sep> nicotine nasal spray <sep> nicotine gum or nicotine patch <sep>', 'fixed-dose transdermal nicotine <sep> transdermal nicotine <sep> tapered-dose transdermal nicotine <sep> buspirone <sep> fixed-dose transdermal nicotine <sep> buspirone <sep> fixed-dose transdermal nicotine tapered-dose transdermal nicotine and buspirone <sep>', 'nicotine patches <sep> placebo <sep> 24-hour nicotine patches <sep> nicotine patches or placebo <sep> nicotine <sep>', 'cognitive-behavioral approach and nicotine replacement therapy with nicotine patches <sep> intensive brief counseling group gb with 1 or 2 sessions g1-g2 and with 3 or 4 sessions g3-g4 with/without nicotine replacement therapy nrt <sep> nicotine replacement transdermal patches <sep> cognitive-behavioral approach <sep> nrt <sep>', 'supervised and intensive exercise <sep> cbt <sep> exercise and nicotine replacement therapy <sep> exercise and nicotine replacement therapy nrt <sep> exercise+nicotine patch exercise+no nicotine patch cognitive behavior therapy cbt)+nicotine patch and cbt+no nicotine patch <sep> exercise combined with nrt <sep> nrt <sep>', 'nrt <sep> nicotine replacement therapy nrt <sep>', 'nicotine gum <sep> placebo <sep> active bupropion and active 4-mg gum aa n  228 active bupropion and placebo gum ap n  224 or placebo bupropion and placebo gum <sep> bupropion <sep>', 'cbt+nrt <sep> cbt-only versus cbt+nrt <sep> nicotine replacement and behavioral therapy <sep> nrt to cbt <sep> nicotine replacement therapy nrt to cognitive-behavioral therapy cbt <sep>', 'brief counseling and the nicotine patch <sep> nicotine patch therapy <sep> transdermal nicotine replacement <sep> nicotine patches versus placebo <sep> smoking cessation interventions 1 a minimal care mc condition consisting of a brief physician-delivered motivational message to stop smoking 2 a counseling  active nicotine patch cap condition in which patients received the motivational message a 6-week supply of nicotine patches and extended bedside and telephone counseling and 3 a counseling  placebo patch cpp condition identical to the cap condition except the supplied patches contained no nicotine <sep> nicotine patch <sep>', 'transdermal nicotine patch <sep> nicotine patches <sep> placebo <sep> package instructions and a smoking cessation self-help booklet <sep>', 'nicotine sublingual tablet and placebo <sep> nicotine sublingual tablet <sep> placebo <sep> nicotine 2-mg sublingual tablet <sep>', 'nicotine patch therapy <sep> placebo <sep> nicotine dependence <sep> transdermal nicotine <sep>', 'non-intervention controls b advice plus booklet and c advice plus booklet plus the offer of nicotine gum <sep> nicotine chewing gum <sep>', 'nicotine gum <sep> nicotine <sep>', 'nicotine inhalers <sep> placebo <sep> nicotine <sep>', 'nicotine gum <sep> placebo 2-mg or 4-mg nicotine gum treatment <sep>', 'nicotine patches <sep> nicotine replacement <sep>', 'nicotine patch therapy <sep> placebo <sep> no-cost 22-mg 24-hour nicotine patch therapy <sep> nicotine patch <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",all of the commercially available forms of nrt gum transdermal patch nasal spray inhaler and sublingual tablets/lozenges can help people who make a quit attempt to increase their chances of successfully stopping smoking. nrts increase the rate of quitting by 50 to 70 regardless of setting. the effectiveness of nrt appears to be largely independent of the intensity of additional support provided to the individual. provision of more intense levels of support although beneficial in facilitating the likelihood of quitting is not essential to the success of nrt.
267,"{'outcomes': ['cumulative remission rate <sep> failure rates <sep> symptom scores <sep> symptomatic remission <sep> symptom scores <sep> symptom scores and lower oesophageal sphincter pressure oesophageal barium column height and oesophageal diameter <sep> pneumatic dilatation <sep> pneumatic dilatation <sep>', 'symptoms and esophageal function <sep> initial failure <sep> superior long-term success <sep> surgical management of perforation <sep>', 'esophageal retention <sep> relieving symptoms and improving esophageal function <sep> lower esophageal sphincter pressure <sep> symptom score esophageal manometry and scintigraphy <sep> recurrent dysphagia <sep> symptom score and esophageal function test <sep>', 'symptom scores <sep> recurrence of symptoms <sep> botulinum toxin injection <sep> relevant complication <sep> equal success rates <sep>', 'chi-squares wilcoxon rank-sum test kaplan-meier method and log-rank tests <sep> les pressure <sep> cumulative dysphagia-free state <sep> les pressure and maximum esophageal diameter <sep>', 'cumulative remission rate <sep> symptom scores <sep> clinical relapse <sep> major complications <sep> cumulative 12-month remission rate <sep>'], 'punchline_text': ['botulinum toxin produced significant reduction in symptom scores p<0.001 but no reduction in objective parameters. <sep>', 'had superior long-term success   0.01). <sep>', 'no significant difference in symptom score and esophageal function test results was found between patients treated with botulinum toxin injections and those undergoing dilation. <sep>', 'the symptom scores showed no significant differences between the two groups before and one month after treatment. <sep>', 'there was no difference in les pressure and maximum esophageal diameter in the barium esophagogram in the two groups before therapy. <sep>', 'the cumulative 12-month remission rate was significantly higher after a single pneumatic dilatation 53 compared to a single botulinum toxin injection 15%)(p  0.01). <sep>'], 'population': ['20 patients median age 56 years <sep> 22 patients median age 57 years or <sep> symptomatic patients with achalasia <sep> achalasia <sep>', 'primary achalasia <sep> patients with treatment failure crossed over to the alternative treatment <sep> thirty four patients were studied and 31 completed the trial <sep> patients with achalasia <sep>', 'sixteen patients received <sep> achalasia <sep>', '24 patients with definitive esophageal achalasia <sep>', 'patients with tortuous megaesophagus and previous failed pneumatic dilatation <sep> seventeen consecutive patients with achalasia cardia diagnosed during a period between december 1997 and february 2000 <sep> achalasia cardia <sep>', 'forty adults with newly diagnosed achalasia <sep> achalasia <sep> patients with achalasia <sep>'], 'interventions': ['botulinum toxin versus pneumatic dilatation <sep> botulinum toxin <sep> botulinum toxin <sep> pneumatic dilatation <sep>', 'pneumatic dilatation to botox <sep> botox into the les or witzel balloon dilatation <sep> intrasphincteric botulinum toxin versus pneumatic balloon dilation <sep> witzel dilatation <sep> botulinum toxin botox <sep>', 'botulinum toxin placebo and pneumatic dilation <sep> botulinum toxin <sep> placebo <sep> botulinum toxin injections <sep> botulinum toxin injection versus placebo and pneumatic dilation <sep> random intrasphincteric injections of either botulinum toxin or saline <sep> achalasia with botulinum toxin <sep>', 'balloon dilation or injection of botulinum toxin <sep> botulinum toxin <sep> botulinum toxin a versus balloon dilation <sep> botulinum toxin injection <sep>', 'bt injection by sclerotherapy needle into four quadrants of lower esophageal sphincter les <sep> intrasphincteric botulinum toxin a injection versus balloon dilatation <sep> bt <sep> botulinum toxin bt injection <sep> pneumatic dilatation by rigiflex dilator <sep>', 'botulinum toxin <sep> botulinum toxin injection or pneumatic dilatation <sep> botulinum toxin injection with pneumatic dilatation <sep> single pneumatic dilatation <sep> botulinum toxin injection to pneumatic dilatation <sep> pneumatic dilatation <sep> pneumatic dilatation <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",the results of this meta-analysis would suggest that pd is the more effective endoscopic treatment in the long term greater than six months for patients with achalasia.
268,"{'outcomes': ['static text reading speed <sep> saccadic amplitude <sep> text reading <sep>', 'visual field size <sep> restoration of vision <sep>', 'visual functioning <sep> visual skills categories <sep> visual skills areas of recognition mobility peripheral detection scanning tracking and visual memory <sep>', ""stimulus detection in hrp <sep> patient's testimonials concerning their visual abilities <sep> spatial attention and alertness <sep>"", 'overall and separate skill improvement scores <sep>', 'stimulus detection in high-resolution perimetry hrp <sep> detection performance <sep> visual field size <sep> fixation performance <sep> detection performance <sep>', 'ability to detect visual stimuli <sep>', 'outcome variables response times rts during natural search number of fixations during natural scene exploration fixation stability visual fields and quality-of-life scores <sep> saccadic behavior <sep> fixation stability <sep> saccadic behavior or visual fields <sep> seeing side <sep> natural search rt <sep> saccadic behavior natural search and scene exploration <sep> social domain <sep>'], 'punchline_text': ['mt therapy was associated with a direction-specific effect on saccadic amplitude for rightward but not leftward reading saccades. <sep>', 'in the area of the cue restoration of vision was significantly greater than during vrt without cueing cued patients showed a much more pronounced shift of the visual field border toward the blind area than that observed in the cg or in uncued regions of the eg. <sep>', 'the patients with homonymous hemianopsia showed improvements in visual functioning using prism lenses although these improvements were smaller than those found in previous studies with central or bilateral peripheral vision loss groups who were trained to use other optical enhancement devices for navigation and driving using a similar curriculum. <sep>', 'a more detailed analysis of trained versus untrained visual field areas in 16 patients revealed a superiority of the trained area of only 1.1 in hrp and between 3.5 os and 4.4 od in tap. <sep>', 'patients receiving treatment had overall and separate skill improvement scores that were significantly higher than those for control patients. <sep>', 'in group 2 detection performance improved after standard vrt by 2.9 p  .05 and after extrastriate vrt by 2.9 p  .05). <sep>', 'in post-chiasma patients vrt led to a significant improvement 29.4 over baseline in the ability to detect visual stimuli in optic nerve patients the effects were even more pronounced 73.6 improvement). <sep>', 'only with est did the number of fixations during natural scene exploration increase toward the blind and decrease on the seeing side follow-up/pre difference 238%). <sep>'], 'population': ['patients with ha <sep> nineteen patients with ha <sep> patients with hemianopic alexia ha <sep> patients with hemianopic alexia <sep>', 'patients with postgenicular visual system lesions who received either <sep> patients with postgenicular lesions of the visual system areas of residual vision arvs <sep> patients with visual field defects <sep>', 'patients with homonymous hemianopsia and 2 <sep> patients with peripheral vision loss <sep> hemianopic patients <sep> patients with homonymous hemianopsia <sep>', 'patients n  23 with stable homonymous field deficits after trauma cerebral ischemia or hemorrhage lesion age  6 months carried out either a <sep> 16 patients <sep>', 'acute stroke patients <sep> acute stroke patients regain important thinking skills <sep> patients in a community hospital stroke program were pre-tested in three skill areas--visual scanning visual-spatial orientation and time judgment--and randomly assigned to a treatment n  16 or control n  17 group <sep>', 'patients with visual field defects <sep> 18 patients with visual field defects with prior vrt experience <sep>', 'patients with visual-field defects <sep> patients with optic nerve n  19 or post-chiasmatic brain injury n  19 <sep> partial blindness <sep>', 'hemianopia <sep> patients with homonymous hemianopia are disabled on everyday exploratory activities <sep> twenty-eight hemianopic patients <sep>'], 'interventions': ['optokinetic therapy <sep> mt therapy <sep> specific eye movement based therapy <sep> practiced reading moving text mt <sep> optokinetic nystagmus inducing therapy <sep> visual rehabilitation method that induced small-field optokinetic nystagmus okn <sep>', 'visuospatial cue <sep> standard vrt control group cg n  10 or vrt with attentional cueing <sep> attentional cueing improves vision restoration therapy <sep> tubingen automated perimetry and computer-based high-resolution perimetry hrp <sep>', 'prism lenses and trained to use them for navigation and driving <sep> orientation and mobility and driving training with fresnel prisms and the gottlieb visual field awareness system <sep>', 'double-stimulation approach <sep> vision training <sep> standard vrt with a single stimulation n  9 or vision therapy with b a parallel costimulation n  7 or c a moving costimulation paradigm <sep> vision restoration therapy <sep>', 'cognitive skill remediation <sep> cognitive skill retraining <sep> cognitive skills remediation program <sep>', 'vision restoration therapy vrt <sep> extrastriate vrt followed by conventional standard vrt <sep> vision restoration through extrastriate stimulation <sep>', 'computer-based training <sep> vrt <sep> placebo training <sep> computer-based visual restitution training vrt <sep>', 'explorative saccade training <sep> est <sep> est a digit-search task or ft blind-hemifield stimulation by flickering letters <sep> flicker-stimulation training <sep> compensatory exploration training <sep> explorative saccade and flicker training <sep> flicker-stimulation training ft <sep> explorative saccade training est <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is limited evidence which supports the use of compensatory scanning training for patients with visual field defects and possibly co-existing visual neglect to improve scanning and reading outcomes. there is insufficient evidence to reach a conclusion about the impact of compensatory scanning training on functional activities of daily living. there is insufficient evidence to reach generalised conclusions about the benefits of visual restitution training vrt restitutive intervention or prisms substitutive intervention for patients with visual field defects after stroke.
269,"{'outcomes': ['microalbuminuria and organ dysfunction <sep> ii score and the sequential organ failure assessment sofa score <sep> microalbuminuria and organ failure <sep> severity of illness and degree of organ failure <sep> cardiovascular sofa score <sep> macr <sep> microalbuminuria/creatinine ratio macr <sep> sofa scores <sep> apache acute physiology and chronic health evaluation <sep>', 'mortality <sep> progression of multisystem organ failure <sep> mortality and the required days of inotropic support mechanical ventilation and intensive care <sep>', 'whole-blood lactate levels <sep> hemodynamic effects of n-acetylcysteine <sep> hemodynamic response to n-acetylcysteine <sep> oxygen transport and uptake <sep> oxygen extraction <sep> hemodynamic variables oxygen delivery do2 oxygen consumption vo2 and oxygen extraction <sep> do2 and vo2 <sep> vo2 when do2 <sep> vo2 <sep>', 'mortality rate <sep> nac improved oxygenation increase in pao(2)/fio(2 <sep>', 'serum creatinine <sep> acute renal failure <sep> absolute change in serum creatinine <sep> renal function <sep> relative change in serum creatinine peak serum creatinine level serum cystatin c and in urinary output <sep> serum cystatin c <sep> renal replacement therapy length of ventilation and length of stay in the intensive care unit and hospital <sep>', 'levels of the major cytokines duration of ventilation and intensive care unit stay gastric intramucosal ph and arterial oxygen tension/inspired fractional oxygen ratio <sep> cytokine levels outcomes or gastric intramucosal ph <sep> haemodynamic parameters nasopharyngeal temperature arterial blood gas changes plasma cytokine levels biochemical parameters intramucosal ph length of stay in the intensive care unit duration of of mechanical ventilation and mortality <sep> cytokine levels and gastric intramucosal ph <sep> serum cytokine levels and gastric intramucosal ph <sep>', 'mpo and mda values <sep> aagp and crp values <sep> myeloperoxidase mpo malondialdehyde mda interleukin-6 alpha1-acid glycoprotein aagp and c-reactive protein crp <sep>', 'systemic vascular resistance <sep> vo2 and gastric intramucosal ph <sep> higher survival rate <sep> stable clinical conditions hemodynamic values body temperature hemoglobin fio2 <sep> oxygen delivery cardiac index stroke index and left ventricular stroke work index <sep> survival rate <sep> whole-body oxygen consumption vo2 gastric intramucosal ph and veno-arterial co2 gradient veno-arterial pco2 <sep> ii scores multiple organ failure scores <sep> vo2 <sep> gastric intramucosal ph <sep> veno-arterial pco2 <sep> tissue oxygenation <sep>', 'tolerated improved respiratory function and shortened icu stay <sep> static lung compliance <sep> shorter ventilator requirement <sep> plasma concentrations of tumor necrosis factor-alpha tnf interleukin il)-6 il-8 il-10 and soluble tumor necrosis factor-alpha receptor-p55 stnfr-p55 <sep> plasma tnf il-6 or il-10 levels <sep> il-8 and stnfr-p55 levels <sep> systemic and pulmonary hemodynamics oxygen delivery and oxygen consumption <sep> mortality <sep> hemodynamics oxygen transport variables and plasma levels of cytokines <sep> pulmonary artery catheter-derived hemodynamics blood gases hemoglobin and arterial lactate <sep>', 'cardiac index ci left ventricular stroke work index lvswi <sep> systemic vascular resistance <sep> st segment depression <sep> cardiac output <sep> mean decrease of vo2 <sep> venoarterial carbon dioxide gradient pvaco2 <sep> vo2 oxygen delivery ci lvswi and pvaco2 <sep>', 'mild vasodilatation improve oxygen delivery and consumption <sep> mortality morbidity or postoperative graft function <sep>', 'aminotransferases prothrombin time and monoethylglycinexylidide test <sep> hemodynamic parameters oxygen consumption oxygen delivery oxygen extraction ratio and lactates <sep> hemodynamics and postoperative graft function <sep> hemodynamics and graft function <sep> postoperative graft function <sep> oxygen extraction ratio by the liver <sep> hemodynamic data and calculated tissue oxygenation parameters <sep> hemodynamics and survival rates <sep>', 'cellular composition and mediators <sep> total antigenic human neutrophil elastase <sep> complex formation between elastase and alpha 1-proteinase inhibitor <sep> plasma neutrophil elastase activity <sep> partial pressure of oxygen in arterial blood/fractional inspired oxygen 4 h after surgery <sep> release of myeloperoxidase mpo <sep> total number of neutrophils elastase mpo and interleukin-8 <sep>', 'oxidative response of neutrophils <sep> oxidative burst response of neutrophils <sep>', 'psh level <sep> oxidative stress and inflammation <sep> gsh level <sep> plasma il-6 <sep> oxidative stress inflammation fluid requirement multiple organ dysfunction mod score and vasoactive drug requirement <sep> mod score use of vasopressor agents and fluid utilisation <sep> mod score <sep> oxidative stress and inflammation generate edema <sep> concentrations of tnf- il-6 il-8 and il-10 <sep> levels of malondialdehyde protein sulfhydril psh groups reduced gluthation gsh activity of myeloperoxidase catalase and superoxide dismutase enzymes and induced free radical generating capacity <sep>', 'fio2 <sep> 1-month mortality rate <sep> oxygenation index pao2/fio2 <sep> adverse effects <sep> development of ards and mortality <sep> ards <sep> still receiving ventilatory support <sep> lung injury score lis <sep> simplified acute physiology score saps <sep> severe adult respiratory distress syndrome ards and mortality rate <sep> systemic oxygenation <sep> cardiovascular state liver function and kidney function <sep> respiratory dysfunction <sep>', 'clearance of indocyanine green <sep> liver blood flow <sep> splanchnic blood flow <sep> fractional liver blood flow index cardiac index-related liver blood flow index <sep> cardiac index <sep> arterial and gastric mucosal carbon dioxide tension <sep> nutritive blood flow <sep> liver function <sep> liver blood flow hepatosplanchnic oxygen transport-related variables and liver function <sep> plasma appearance of monoethylglycinexylidide megx <sep> absolute liver blood flow index <sep> megx <sep> microsomal liver function <sep> hepatosplanchnic flow and function <sep> hepatosplanchnic blood flow <sep> liver blood flow index <sep> liver blood flow index and megx <sep>', 'urinary albumin/creatinine ratio <sep> nag/creatinine ratio and the albumin/creatinine ratio <sep> renal injury as measured by the increases in urinary n-acetyl-beta-d-glucosaminidase nag)/creatinine ratio indicator of renal tubular injury and urinary albumin/creatinine ratio indicator of glomerular injury <sep> plasma creatinine and serum cystatin c concentrations <sep> plasma creatinine and serum cystatin c values <sep> renal function <sep> urinary nag/creatinine ratio <sep>', 'demographic characteristics ards categories severity of illness simplified acute physiology score saps ii <sep> mortality rate <sep> lis <sep> lis and pao2/fio2 ratio <sep> mortality rate the need of ventilatory support the intensive care unit stay and the pao2/fio2 evolution <sep> ventilatory support <sep> percentage of patients receiving ventilatory support <sep> pao2/fio2 ratio <sep> systemic oxygenation <sep> fio2 <sep>', 'postoperative atrial fibrillation <sep> rate of af <sep> incidence of postoperative af <sep>', 'postoperative a-a oxygen gradient <sep> malondialdehyde mda <sep> perioperative hemodynamic and pulmonary data <sep> systemic oxygenation <sep> postoperative tracheal extubation <sep> pulmonary function <sep> postoperative increases in a-a oxygen gradient <sep> intubation time <sep> hemodynamic and pulmonary data pulmonary capillary wedge pressure pulmonary vascular resistance pvr cardiac index ci shunt flow dynamic lung compliance and static lung compliance <sep> postoperative clinical course <sep>', 'six organ dysfunction parameters length of intensive care stay days of mechanical ventilation and mortality <sep> cardiovascular renal hepatic haematological and central nervous system <sep> organ function <sep> progression of early postoperative organ dysfunction and improve oxygenation <sep> postoperative organ dysfunction <sep>', 'plasma creatinine <sep> levels of urinary nag/creatinine ratio plasma creatinine and serum cystatin c <sep> urine n-acetyl-beta-d-glucosaminidase nag and urine creatinine ratio plasma creatinine and serum cystatin c levels indicated renal function <sep> serum cystatin c <sep> renoprotective effect <sep> urine nag/creatinine ratio <sep>', 'number of days of acute lung injury <sep> cardiac index <sep> levels of glutathione and cysteine <sep> mortality <sep> rbc glutathione <sep>', 'interleukin-6 production <sep> incidence of death myocardial infarction bleeding transfusion requirements intubation time and hospital length of stay <sep> postoperative biochemical markers troponin t creatine kinase mb creatinine hemoglobin and platelets <sep> postoperative clinical data death myocardial infarction low-output syndromes arrhythmias bleeding transfusion requirements and intensive care unit and hospital lengths of stay and biochemical markers creatine kinase mb troponin t creatinine hemoglobin and platelet levels <sep>', 'hospital mortality rate <sep> a daily organ failure score <sep> mean sd pooled mean arterial pressure map and cardiac index <sep> daily organ failure score <sep> map cardiac index and left ventricular stroke work index <sep> 15 sd yrs and acute physiology and chronic health evaluation <sep> respectively oxygen transport indices arterial blood gas analyses pao2/fio2 ratio and shunt <sep> hemodynamic and oxygen transport indices <sep>', 'admission parasitemia <sep> parasite clearance time <sep> systemic oxidative stress <sep> coma recovery times <sep> urinary f2-isoprostane metabolites <sep> mortality lactate clearance times <sep> efficacy and safety <sep>', 'overall incidence of arf <sep> development of arf <sep> baseline scr and calculated gfr <sep> overall mortality <sep> icu mortality and icu length of stay <sep> length of icu stay <sep>', 'pulmonary compliance <sep> pulmonary fibrin uptake <sep> pao2/fio2 ratio <sep> chest radiograph or on survival rate <sep>', 'left ventricular cardiomyocyte staining <sep> cardiomyocyte staining <sep> myocardial oxidative stress <sep> hemodynamics and clinical outcomes <sep> global left ventricular function <sep> reactive oxygen species-mediated myocardial stress <sep>', 'periprocedural myocardial injury <sep> myocardial damage <sep> creatine kinase mb isoform ck-mb mass levels <sep> ck-mb>5 times normal value <sep> ck-mb <sep> ctnt levels <sep>', 'expired ethane and malondialdehyde mda and oxidized gssg and reduced glutathione gsh <sep> gsh <sep> lipid peroxidation of the lung epithelium <sep> ethane and mda concentrations <sep>', 'myocardial ischemia-reperfusion injury <sep> tumor necrosis factor-alpha levels <sep> luminol specific for oh h(2)o(2 and hocl radicals and lucigenin specific for o(2  levels and the difference ratios after reperfusion <sep> creatine kinase-mb levels <sep>', 'hepatorenal ischaemia-reperfusion injury <sep> baseline scr levels <sep> gsh levels <sep> serum creatinine scr levels <sep> renal or hepatic injury <sep> liver function tests renal function tests graft survival patient survival plasma gsh and duration of hospital and icu stay <sep> baseline serum bilirubin <sep> liver graft performance <sep> survival graft function or risk of aki <sep>', 'postoperative renal dysfunction interventions complications or mortality <sep> renal dysfunction <sep> icu and hospital length of stay <sep> renal function <sep> patients experiencing postoperative renal dysfunction <sep> morbidity and mortality <sep> proportion of patients with postoperative renal dysfunction <sep> postoperative interventions and complications the need for rrt <sep> serum creatinine level <sep> serious adverse events hospital mortality <sep> proportion of patients developing postoperative renal dysfunction <sep> postoperative interventions and complications the requirement for renal replacement therapy rrt adverse events hospital mortality and icu and hospital length of stay <sep>', 'mechanical ventilation <sep> postoperative acute renal failure <sep> acute renal failure <sep> hospital mortality and need for renal replacement therapy <sep> hospital mortality <sep>', 'glomerular filtration rate egfr <sep> percent change in egfr <sep> median percent change in egfr <sep> renal replacement therapy mortality atrial fibrillation vasoactive medications and adverse effects <sep> postoperative egfr <sep> cause mortality <sep>', 'hypotension requiring inotropic support <sep> cerebral oedema <sep> fulminant hepatic failure <sep> survival incidence of cerebral oedema renal failure and hypotension requiring inotropic support liver function <sep> rates of deterioration and recovery of liver function <sep> adverse reactions <sep> rate of survival <sep>', 'nuclear factor-kappa b activation <sep> activation <sep> plasma interleukin-6 interleukin-8 and soluble intercellular adhesion molecule-1 concentrations <sep> nuclear factor-kappa b activation <sep> nuclear factor-kappa b activation interleukin-6 interleukin-8 and intercellular adhesion molecule-1 expression <sep> soluble intercellular adhesion molecule-1 concentrations <sep> interleukin-6 concentrations <sep> interleukin-8 <sep> nuclear factor-kappa b activation and circulating cytokine and adhesion molecules <sep>', 'overall survival <sep> benefits of transplant-free survival <sep> transplant-free survival and rate of transplantation <sep> transplantation rate <sep> overall survival <sep> transplant-free survival <sep> transplant-free survival <sep> tolerated only nausea and vomiting <sep>'], 'punchline_text': ['2.1 p  0.05 nac vs placebo respectively at 24 h and at 48 h). <sep>', 'there was no statistically significant difference between the two groups regarding outcome as indicated by mortality and the required days of inotropic support mechanical ventilation and intensive care. <sep>', 'n-acetylcysteine infusion did not increase oxygen extraction or result in an improvement in whole-blood lactate levels or base excess during the study period. <sep>', 'the results indicated that nac improved oxygenation increase in pao(2)/fio(2 and decreased mortality rate in treated patients compared to control group p<0.05). <sep>', 'there was no significant attenuation in the increase in serum creatinine from baseline to peak when comparing n-acetylcysteine with placebo 64.5  <sep>', 'no differences were found between groups in levels of the major cytokines duration of ventilation and intensive care unit stay gastric intramucosal ph and arterial oxygen tension/inspired fractional oxygen ratio p  0.05). <sep>', 'the aagp and crp values were both elevated during cpb in the two groups without a significant difference but 6 and 24 h post-cpb the values were significantly higher in the control group than in the study group. <sep>', 'the n-acetylcysteine responders had a higher survival rate 69 than the non-responders 19 and were studied earlier after onset of sepsis 37 hrs than the nonresponders 61 hrs). <sep>', 'plasma concentrations of tumor necrosis factor-alpha tnf interleukin il)-6 il-8 il-10 and soluble tumor necrosis factor-alpha receptor-p55 stnfr-p55 were measured by sensitive immunoassays at 0 2 4 6 and 24 h. <sep>', 'there were no significant differences between groups in any of the measurements before treatment and after the return to baseline f1o2 at the end of the study respectively. <sep>', 'there were no significant effects on mortality morbidity or postoperative graft function. <sep>', 'this study failed to show any beneficial effect of the intraoperative administration of nac on hemodynamics and graft function in liver transplantation in patients with chronic liver disease. <sep>', 'in group 2 the partial pressure of oxygen in arterial blood/fractional inspired oxygen 4 h after surgery was significantly higher than in group 1 213  <sep>', 'the oxidative burst response of neutrophils in the patients receiving nac was significantly low at all times during bypass. <sep>', 'plasma il-6 was lower on days 4-5 p<0.05 il-8 on days 4-6 p<0.05 and il-10 on days 4-6 p<0.05 in nac group. <sep>', 'the nac and placebo groups 32 and 29 patients respectively were comparable at icu admission for severity of illness assessed by the simplified acute physiology score saps 10.8  <sep>', 'the difference between arterial and gastric mucosal carbon dioxide tension decreased p  .05 and megx increased p  .04). <sep>', 'the urinary nag/creatinine ratio increased significantly from baseline to before crossclamp and remained increased on day 5 in both groups. <sep>', 'in both groups the fio2 was significantly lower and the pao2/fio2 ratio was significantly higher than the initial values during the evolution fio2 at day 3 p  .01 for nac and p <sep>', 'the rate of af was lower in nac group compared with placebo group three patients in nac group 5.2 and 12 patients in placebo group 21.1 had postoperative af odds ratio or 0.20 95 confidence interval ci 0.05 to 0.77 p  0.019). <sep>', 'both groups exhibited significant postoperative increases in a-a oxygen gradient p  0.01 but patients in group ii exhibited significantly lower increases in postoperative a-a oxygen gradient p  0.006). <sep>', 'there was no significant difference between the two groups in any of the six organ dysfunction parameters length of intensive care stay days of mechanical ventilation and mortality. <sep>', 'levels of urinary nag/creatinine ratio plasma creatinine and serum cystatin c did not significantly differ between nac and placebo groups during five postoperative days. <sep>', 'there was no difference in mortality among groups placebo 40 nac 36 otz 35%). <sep>', 'no differences were found in postoperative biochemical markers troponin t creatine kinase mb creatinine hemoglobin and platelets between the groups. <sep>', 'there was no difference in either daily organ failure score over time p  .01 repeated-measures analysis of variance or hospital mortality rate 90 n-acetyl-l-cysteine group 50 placebo group p  .1 logistic regression between the two groups. <sep>', 'nac had no significant effect on mortality lactate clearance times p  0.74 or coma recovery times p  0.46). <sep>', 'the overall mortality was 23 10/42 and was not different p  0.209 in nac group 33.3 when compared with control 16.7 the same occurring with the length of icu stay 2.93  <sep>', 'no improvement could be demonstrated in the pao2/fio2 ratio in the study group as compared with the control group on any day. <sep>', 'the change in left ventricular cardiomyocyte staining end of cardiopulmonary bypass--before cardiopulmonary bypass differed significantly between groups for both primary measures 8-iso-prostaglandin-f(2)alpha 1.8  <sep>', 'creatine kinase mb isoform ck-mb mass levels did not significantly differ between the groups at both preoperative and postoperative periods. <sep>', 'ethane and mda concentrations were significantly reduced in the treatment groups after day 6. <sep>', 'creatine kinase-mb levels at 6 and 12 hours were significantly lower in the nac group p  0.02). <sep>', 'iv nac did not affect survival graft function or risk of aki. <sep>', 'there was no difference in the proportion of patients with postoperative renal dysfunction 29.7 vs 29.0 p  .89 relative risk rr 1.03 95 confidence interval ci 0.72-1.46 in the n-acetylcysteine and placebo groups respectively. <sep>', 'intravenous administration of n-acetylcysteine does not clearly prevent postoperative acute renal failure in patients with renal insufficiency undergoing cardiac surgery. <sep>', 'the median percent change in egfr was 5.2 better absolute difference in the n-acetylcysteine arm 95 confidence interval 2.4 worse to 12.1 better p=0.22). <sep>', 'acetylcysteine treated patients had a lower incidence of cerebral oedema 40 10/25 v 68 17/25 p  0.047 95 confidence interval for difference in incidence 2 to 54 and fewer developed hypotension requiring inotropic support 48 12/25 v 80 20/25 p  0.018 95 confidence interval 7 to 57%). <sep>', 'interleukin-8 decreased significantly only in those who received n-acetylcysteine p .0081). <sep>', 'the transplantation rate was lower in the nac group but was not significantly different between groups 32 vs 45 p  .093). <sep>'], 'population': ['acute severe sepsis <sep> thirty-five patients included within 4 h of fulfilling consensus criteria of severe sepsis <sep>', '100 patients recruited 14 withdrew 86 patients were studied <sep> critically ill patients <sep>', 'patients with severe fulminant hepatic failure <sep> x m[-2 <sep> 11 patients with severe fulminant hepatic failure <sep> patients with fulminant hepatic failure <sep>', '27 icu patients with ali/ards <sep>', 'high-risk cardiac surgery patients <sep> operating rooms and intensive care units of two tertiary referral hospitals <sep> cardiac surgery patients at higher risk of postoperative renal failure <sep> 60 cardiac surgery patients at higher risk of postoperative renal failure <sep>', 'humans suffering from severe sepsis <sep> patients with severe sepsis <sep> severe sepsis <sep> fifty-three patients were included in the study <sep>', 'cardiopulmonary bypass cpb <sep> forty patients undergoing coronary artery bypass grafting cabg <sep>', 'septic shock patients admitted to the intensive care unit <sep> septic shock patients <sep> fifty-eight patients requiring hemodynamic monitoring radial and pulmonary artery catheters due to septic shock <sep>', 'twenty-two patients included within 4 h of diagnosis of septic shock <sep> patients with septic shock <sep>', 'thirty patients requiring hemodynamic monitoring radial and pulmonary artery catheters because of cardiac risk factors <sep> cardiac risk patients during hyperoxia <sep> cardiac risk patients <sep> 22 <sep>', 'orthotopic liver transplantation <sep> patients with chronic liver disease undergoing orthotopic liver transplantation by giving nac during operation <sep> 50 patients <sep> patients with fulminant hepatic failure <sep>', 'sixty patients with chronic end-stage liver disease <sep> liver transplantation <sep> patients with fulminant hepatic failure <sep> patients with chronic liver disease <sep>', 'bronchoalveolar lavage fluid <sep> 18 patients who underwent <sep> cardiac surgery patients <sep> cardiac surgery patients <sep> patients with acute lung injury <sep>', 'twenty-four adult patients undergoing coronary artery bypass were included in the study <sep>', 'burns <sep> after severe burn <sep>', 'sixty-one adult patients presenting with mild-to-moderate acute lung injury and various predisposing factors for ards received either <sep> acute lung injury in man <sep> patients with mild-to-moderate acute lung injury <sep>', 'patients who benefit from nac treatment in early septic shock <sep> septic shock patients <sep> 60 septic shock patients within 24 hrs after onset of sepsis <sep> septic shock patients admitted to an interdisciplinary surgical intensive care unit <sep>', 'patients undergoing abdominal aortic surgery <sep> kidney injury in abdominal aortic surgery <sep> seventy patients without previously documented renal dysfunction <sep>', '42 patients with established ards receiving either <sep> acute respiratory distress syndrome <sep> namely established adult respiratory distress syndrome ards <sep> patients with an acute lung injury <sep>', '115 patients undergoing coronary artery bypass and/or valve surgery <sep>', 'patients undergoing coronary artery bypass grafting cabg procedures <sep> twenty patients undergoing elective cabg and early tracheal extubation <sep> patients undergoing cabg <sep> patients undergoing elective cabg with <sep> patients undergoing coronary artery bypass surgery with cardiopulmonary bypass <sep>', 'major abdominal tumour surgery <sep> 93 patients 47 received n-acetylcysteine and 46 were given <sep>', '80 patients with mild to moderate renal failure undergoing elective heart surgery with cardiopulmonary bypass were recruited <sep> patients with mild renal failure undergoing cardiac surgery <sep> acute renal failure arf after cardiac surgery <sep> patients with chronic renal failure undergoing cardiac surgery <sep> patients with pre-existing renal failure undergoing cardiac surgery <sep>', 'patients with ards <sep> patients with acute lung injury/ards <sep> patients meeting a predetermined definition of ards and requiring mechanical ventilation <sep>', 'one hundred patients mean age 60.5 years range 43-78 years 89 male undergoing coronary artery bypass grafting at the montreal heart institute <sep> patients undergoing coronary artery bypass grafting with cardiopulmonary bypass <sep> coronary artery bypass surgery with cardiopulmonary bypass <sep> coronary artery bypass surgery <sep>', 'twenty patients n <sep> group n  10 15 male and five female of mean age 64 <sep> patients with septic shock <sep> multidisciplinary intensive care unit at a university teaching hospital <sep> patients with newly diagnosed septic shock <sep>', '56 patients were treated with <sep> a provincial hospital in western thailand and a tertiary referral hospital in chittagong bangladesh <sep> severe malaria <sep> one hundred eight adult patients with severe falciparum malaria <sep> patients with uncomplicated malaria and healthy volunteers <sep>', 'acute renal failure related to elective aortic aneurysm repair <sep> forty-two patients n  18 for nac group and n  24 for control <sep> patients with stable renal function <sep>', 'patients with ards <sep> adult respiratory distress syndrome ards in man <sep> adult respiratory distress syndrome <sep> sixty-six icu patients with ards <sep>', '9 years 9 women and 31 men <sep> forty patients undergoing coronary artery surgery mean age <sep> patients undergoing cardiac surgery <sep> hearts of patients subjected to cardiopulmonary bypass and cardioplegic arrest <sep>', 'patients undergoing coronary artery by-pass grafting cabg <sep> 40 patients undergoing on-pump cabg <sep>', 'patients with early adult respiratory distress syndrome ards <sep> 36 patients who developed ards less than 24 hours before enrollment in the study <sep> adult respiratory distress syndrome <sep>', 'bypass surgery <sep> twenty patients undergoing elective coronary bypass operation with cardiopulmonary bypass <sep>', 'patients undergoing orthotopic liver transplantation <sep> 100 patients 50 received <sep>', '295 patients required elective or urgent cabg and had at least 1 of the following preexisting renal dysfunction at least 70 years old diabetes mellitus impaired left ventricular function or undergoing concomitant valve or redo surgery <sep> high-risk patients undergoing cabg surgery with cpb compared with <sep> operating rooms and general intensive care units icus of 2 ontario tertiary care centers <sep> high-risk patients undergoing cabg surgery <sep>', 'university cardiology center <sep> patients with chronic renal insufficiency undergoing cardiac surgery <sep> two hundred fifty-four consecutive patients with chronic renal insufficiency estimated creatinine clearance  or  60 ml/min undergoing elective cardiac surgery <sep> patients with renal insufficiency undergoing cardiac surgery <sep>', 'cardiac surgery patients with pre-existing moderate renal insufficiency <sep> eighty-nine were randomized to <sep> acute kidney injury after cardiac surgery <sep> one-hundred-seventy-seven cardiac surgery patients with moderate pre-existing renal insufficiency egfr or 60 mlxmin(-1 <sep>', 'patients with fulminant hepatic failure after paracetamol overdose <sep> 50 consecutive patients 21 male aged 16-60 with fulminant hepatic failure after paracetamol overdose who had not previously received acetylcysteine <sep>', 'eight-bed intensive care unit in a university teaching hospital <sep> patients with sepsis <sep> twenty consecutive patients within 12 hrs of fulfilling the consensus criteria for sepsis <sep> critically ill patients <sep>', 'early stage non-acetaminophen acute liver failure <sep> patients with advanced coma grades do not benefit from nac and typically require emergency liver transplantation <sep> patients with non-acetaminophen-related acute liver failure <sep> patients with early stage non-acetaminophen-related acute liver failure <sep> 59 patients with coma grades <sep> 173 patients received <sep> acute liver failure patients without clinical or historical evidence of acetaminophen overdose were stratified by site and coma grade <sep>'], 'interventions': ['nac <sep> placebo <sep> n-acetylcysteine nac <sep> n-acetylcysteine <sep>', 'placebo <sep> n-acetylcysteine nac <sep> 5 dextrose <sep> n-acetylcysteine treatment <sep> nac <sep>', 'placebo infusions <sep> placebo <sep> n-acetylcysteine <sep>', 'glutathione-s-transferase gst m1 p1 and t1 <sep> n-acetylcysteine <sep> glutathione-s-transferase polymorphisms <sep> nac treatment iv nac <sep>', 'placebo <sep> high-dose n-acetylcysteine infusion <sep> high-dose n-acetylcysteine <sep>', 'nac <sep> continuously infused n-acetyl-l-cystein nac <sep> dextrose <sep> n-acetyl-l-cystein infusion <sep>', 'saline <sep> given 50 mg kg(-1 <sep> n-acetylcysteine <sep>', 'placebo <sep> acetylcysteine or placebo <sep> intravenous n-acetylcysteine or placebo <sep> n-acetylcysteine <sep> apache <sep> sulfhydryl donor and oxygen radical scavenger n-acetylcysteine <sep>', 'nac <sep> placebo <sep> adjunctive treatment with n-acetyl-l-cysteine nac <sep>', 'placebo <sep> 150 mg kg-1 nac <sep> sulfhydryl group donor and o2 radical scavenger n-acetylcysteine nac <sep> nac <sep> hyperoxic ventilation <sep> prophylactically administered n-acetylcysteine <sep>', 'nac <sep> placebo <sep> n-acetylcysteine nac <sep> intraoperative n-acetylcysteine <sep>', 'nac <sep> placebo <sep> n-acetylcysteine nac <sep>', 'no premedication only placebo <sep> ecc <sep> n-acetylcysteine nac <sep> extracorporeal circulation ecc <sep> nac <sep>', 'nac <sep> placebo <sep> n-acetylcystein nac <sep>', 'nac <sep> n-acetylcysteine treatment <sep> n-acetylcysteine nac <sep>', 'placebo <sep> intravenous n-acetylcysteine nac <sep> intravenous nac <sep> nac and placebo <sep> n-acetylcysteine <sep> nac <sep>', 'placebo <sep> bolus of 150 mg/kg iv nac <sep> aacetylcysteine nac <sep> n-acetylcysteine <sep> nac <sep>', 'iv n-acetylcysteine <sep> n-acetylcysteine 150 mg/kg mixed in 250 ml of 5 dextrose <sep> placebo <sep> n-acetylcysteine <sep>', 'intravenous nac <sep> placebo <sep> intravenous n-acetylcysteine nac <sep> nac and placebo <sep> n-acetylcysteine <sep> nac <sep>', 'placebo saline <sep> placebo <sep> antioxidant agent n-acetylcysteine nac <sep> n-acetylcysteine <sep> nac <sep> standard medical therapy <sep>', 'physiologic salt solution as a placebo <sep> placebo <sep> cardiopulmonary bypass cpb <sep> n-acetylcysteine nac <sep> n-acetylcysteine <sep> nac <sep> cpb <sep>', 'placebo <sep> placebo 5 dextrose <sep> n-acetylcysteine n-acetylcysteine <sep> prophylactic n-acetylcysteine <sep> n-acetylcysteine <sep>', 'nac <sep> placebo <sep> n-acetylcysteine nac <sep> n-acetylcysteine <sep>', 'placebo <sep> nac or otz <sep> n-acetylcysteine nac and l-2-oxothiazolidine-4-carboxylate procysteine clintec technologies inc chicago otz <sep> nac <sep> antioxidants n-acetylcysteine and procysteine <sep> otz <sep>', 'intravenous n-acetylcysteine before skin incision followed by perfusion at 12.5 mg x kg(-1 <sep> placebo <sep> n-acetylcysteine <sep> intravenous n-acetylcysteine <sep>', 'placebo <sep> acetyl-l-cysteine <sep> n-acetyl-l-cysteine <sep> adjunctive therapy with parenteral n-acetyl-l-cysteine <sep> acetyl-l-cysteine group or the equivalent volume of 5 dextrose placebo <sep> n-acetyl-l-cysteine in 5 dextrose <sep> adjunctive therapy with n-acetyl-l-cysteine <sep>', 'placebo <sep> nac or placebo <sep> parenteral nac <sep> n-acetylcysteine <sep> nac <sep> antioxidant n-acetylcysteine nac <sep>', 'placebo <sep> elective aortic aneurysm repair <sep> n-acetylcysteine nac <sep> nac or placebo control <sep> nac <sep>', 'placebo <sep> antioxidant treatment with n-acetylcysteine <sep> antioxidant n-acetylcysteine <sep>', 'immunocytochemical staining against 8-iso-prostaglandin-f(2)alpha <sep> placebo <sep> reactive oxygen species scavenger n-acetylcysteine <sep> reactive oxygen species scavenging with n-acetylcysteine <sep> n-acetylcysteine <sep>', 'placebo saline <sep> intravenous nac <sep> placebo <sep> intravenous n-acetylcysteine <sep> n-acetylcysteine nac <sep> nac <sep> standard medical therapy <sep>', 'n-acetylcysteine and rutin <sep> n-acetylcysteine nac and rutin <sep> nac <sep> nac 50 mg/kg  rutin 5 mg/kg in 5 dextrose <sep> receiving 250 ml 5 dextrose in water group 1 nac 50 mg/kg body weight in 5 dextrose <sep>', 'n-acetylcysteine <sep> coronary artery bypass grafting cabg operations <sep> n-acetylcysteine <sep> nac <sep> control group operated with a routine cabg protocol and one where nac <sep> n-acetylcysteine nac <sep>', 'placebo <sep> glutathione gsh <sep> n-acetylcysteine <sep> nac <sep> loading dose of 140 mg/kg of intravenous iv nac <sep> iv nac <sep>', 'placebo <sep> coronary artery bypass graft cabg surgery performed with cardiopulmonary bypass cpb <sep> perioperative n-acetylcysteine <sep> iv n-acetylcysteine <sep> n-acetylcysteine an antioxidant and vasodilator <sep> perioperative intravenous iv n-acetylcysteine <sep>', 'intravenous n-acetylcysteine <sep> placebo <sep> n-acetylcysteine <sep> antioxidant n-acetylcysteine <sep>', 'placebo <sep> n-acetylcysteine <sep>', 'intravenous acetylcysteine <sep> acetylcysteine <sep> acetylcysteine <sep> conventional intensive liver care plus either acetylcysteine <sep> paracetamol <sep>', 'placebo <sep> antioxidant therapy with n-acetylcysteine <sep> kg n-acetylcysteine in 100 ml of 0.9 saline <sep> n-acetylcysteine <sep>', 'intravenous n-acetylcysteine <sep> nac or placebo dextrose <sep> placebo <sep> intravenous nac <sep> n-acetylcysteine nac <sep> nac <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>']}",overall this meta-analysis puts doubt on the safety and utility of intravenous n-acetylcysteine as an adjuvant therapy in sirs and sepsis. at best n-acetylcysteine is ineffective in reducing mortality and complications in this patient population. at worst it can be harmful especially when administered later than 24 hours after the onset of symptoms by causing cardiovascular depression. unless future rcts provide evidence of treatment effect clinicians should not routinely use intravenous n-acetylcysteine in sirs or sepsis and academics should not promote its use.
270,"{'outcomes': ['reduction of lower extremity clinical abnormalities <sep> dermatologic abnormalities <sep> serious foot lesions <sep>', 'baseline foot risk category <sep> hemoglobin a(1c levels <sep> quality of life <sep> self-management behavior <sep> incidence of diabetes mellitus <sep> diabetes-related quality-of-life scores <sep> hospitalized with diabetes or vascular-related admissions <sep>', 'knowledge and foot self-care scores <sep> prevalence of some minor foot problems <sep> self-care <sep> knowledge of diabetic foot care <sep>'], 'punchline_text': ['an intervention designed to reduce risk factors for lower extremity amputations positively affected patient self-foot-care behavior as well as the foot care given by health care providers and reduced the prevalence of lower extremity clinical disease in patients with diabetes. <sep>', 'there was a significant improvement in self-management behavior in all six categories evaluated in the study group versus the control group. <sep>', 'patients in the podiatrist group had greater improvement in knowledge of diabetic foot care p  0.004 and self-care p  0.001 scores compared with control subjects. <sep>'], 'population': ['395 patients with non-insulin-dependent diabetes who underwent the initial patient assessment 352 completed the study <sep> patients with diabetes <sep> diabetic patients <sep> patients with non-insulin-dependent diabetes mellitus <sep> patients with non-insulin-dependent diabetes <sep>', 'patients with diabetes mellitus <sep> eighty-three patients <sep> patients with diabetes mellitus who develop end-stage renal disease <sep>', '733 patients aged 10-79 years identified from the national diabetes register <sep> diabetic subjects <sep> diabetic patients <sep> patients without recent visits to a podiatrist and without an obvious need for foot care <sep>'], 'interventions': ['foot-care education and entered into a behavioral contract for desired self-foot care which was reinforced through telephone and postcard reminders <sep> patient health care provider and systems intervention <sep>', 'diabetes education program and were followed up by a care manager who provided self-management education diabetes self-care monitoring/management motivational coaching and foot checks <sep>', 'podiatrist care <sep> podiatric care group education and primary prevention measures <sep> podiatrist activities <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is no high-quality research evidence evaluating complex interventions for preventing diabetic foot ulceration and insufficient evidence of benefit.
271,"{'outcomes': ['incidence of diarrhea improved glucose tolerance lower serum triglycerides reduced total number of infectious episodes and trends toward improved preservation of muscle mass <sep> wound infection <sep> deaths <sep> age percent total and third-degree burn resting energy expenditure and calorie and protein intake <sep>', 'serum free cortisol <sep> nitrogen balance urinary 3-methylhistidine excretion urinary cortisol and clinical status <sep> nitrogen balance <sep> 3-methylhistidine excretion <sep> corticosteroid-binding globulin and total and free serum cortisol <sep> infectious morbidity and shortens length of stay <sep> pneumonia <sep> protein metabolism morbidity and length of care <sep> better respiratory and nutrition status and shorter time to healing <sep>'], 'punchline_text': ['data analysis demonstrated significant superiority of mtf in the reduction of wound infection p less than 0.03 and length of stay/percent burn p less than 0.02). <sep>', 'there was no difference in nitrogen balance between groups and 3-methylhistidine excretion was higher and serum free cortisol was lower in log-fat--fed patients than in controls. <sep>'], 'population': ['burn patients <sep> fifty patients 3 to 76 years of age with burns ranging from 10 to 89 total body surface area <sep>', 'severely burned adults <sep> burn patients <sep> 43 patients <sep>'], 'interventions': ['enteral dietary regimens <sep> mtf <sep> modular tube feeding recipe mtf <sep>', 'low-fat solution ie 15 of total calories as fat low-fat with fish oil <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>']}",the available evidence suggests that use of high-carbohydrate high-protein low-fat enteral feeds in patients with at least 10 tbsa burns might reduce the incidence of pneumonia compared with use of a low-carbohydrate high-protein high-fat diet. the available evidence is inconclusive regarding the effect of either enteral feeding regimen on mortality. note that the available evidence is limited to two small studies judged to be of moderate risk of bias. further research is needed in this area before strong conclusions can be drawn.
272,"{'outcomes': ['treatment failure <sep> failure rate <sep> muscular score and functional grade <sep>', 'level of function <sep>', 'efficacious and safe <sep> mean duration of improvement after ivmp <sep> severe side effects <sep> muscle function <sep> positive treatment response <sep> acetylcholine receptor antibody concentrations <sep> efficacy and safety <sep>'], 'punchline_text': ['no difference was observed between the two groups in muscular score and functional grade assessed at the end of each treatment year or in tolerance. <sep>', 'the side effects of prednisone were manageable. <sep>', 'no severe side effects were found. <sep>'], 'population': ['myasthenia gravis <sep> from january 1983 to october 1990 41 patients with generalised myasthenia gravis <sep>', 'myasthenia gravis <sep> ten patients with myasthenia gravis <sep>', 'patients with moderate mg <sep> myasthenia gravis <sep>'], 'interventions': ['prednisone or azathioprine <sep> prednisone <sep> azathioprine <sep> prednisone and azathioprine <sep>', 'prednisone <sep> azathioprine <sep> azathioprine or prednisone <sep>', 'placebo <sep> methylprednisolone ivmp pulse therapy <sep> ivmp vs placebo <sep> methylprednisolone pulse <sep> ivmp <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",limited evidence from randomised controlled trials suggests that corticosteroid treatment offers short-term benefit in myasthenia gravis compared with placebo. this supports the conclusions of observational studies and expert opinion. limited evidence from randomised controlled trials does not show any difference in efficacy between corticosteroids and either azathioprine or intravenous immunoglobulin.
273,"{'outcomes': ['response rate <sep> median survival <sep> duration of complete plus partial remission <sep> incidence of complete and partial remission <sep>', 'median survival <sep> objective response rates <sep> gastrointestinal toxicity <sep> severe complaints of asthenia <sep> median duration of response <sep>', 'median progression-free interval <sep> response rate <sep> complete remission rates <sep> complete remission rates response duration progression-free interval and survival times <sep> median duration of response <sep> response rates <sep> serum creatinine level <sep> myelosuppression and nephrotoxicity <sep> complete remission rate response duration progression-free interval or survival <sep> median survival time <sep> nausea and vomiting <sep>', 'response rate <sep> toxicity <sep> leukopenia and thrombocytopenia <sep> partial responses <sep> partial response <sep>', 'response rate <sep> survival time <sep> response rate of adriamycin <sep> survival <sep> frequency of severe toxicity <sep>', 'overall survival <sep> response rate <sep> longer progression-free survival pfs time <sep> median times to progression or death <sep> leukopenia renal toxicity peripheral neurotoxicity and cns toxicity <sep> survival <sep> initial performance score <sep> survival <sep> response rate and pfs duration <sep>', 'response rate and progression-free survival pfs <sep> response and pfs <sep> patients quality of life qol <sep> qol assessment <sep> pain scores <sep> rate of qol <sep> overall qol scores <sep> qol <sep> overall survival os <sep> greater myelosuppression <sep> overall fact-g scores <sep> myelosuppression <sep> quality of life qol outcomes <sep> neurotoxicity subscale <sep> overall qol and pain <sep>', 'pulmonary toxicity <sep>', 'hematologic toxicity <sep> response rates <sep> renal otic and peripheral nervous system toxicities <sep> gastrointestinal toxicity <sep> response and adverse effects <sep> gastrointestinal toxicity <sep> percentage of planned dosages <sep>', 'lower risk of death <sep> rate of failure <sep> progression-free survival pfs or overall survival <sep> grade 3/4 toxicities were leukopenia neutropenia anemia thrombocytopenia and nausea and vomiting <sep> response rates <sep> response rate pfs survival and toxicity profile <sep> incidence of these toxicities <sep> pfs and survival <sep>', 'leukopenia <sep> diarrhea <sep> antitumor responses <sep> toxicity <sep> mild diarrhea <sep> nausea and vomiting <sep> mild thrombocytopenia <sep> anemia <sep> episodic hypersensitivity <sep>', 'overall survival <sep> myelosuppression nausea and vomiting mucositis rash and hepatotoxicity <sep> unadjusted hazard ratio for overall survival <sep> median overall survival <sep>', 'overall response rate <sep> overall survival os with response rate progression-free survival pfs and quality of life qol <sep> hematologic toxicity <sep> qol <sep> functional assessment of cancer therapy-cervix fact-cx neurotoxicity subscale fact/gog-ntx subscale and brief pain inventory bpi <sep> qol scores <sep>', 'response rate <sep> response rates survival side effects and quality of life <sep> median survival <sep> response and survival rates <sep> thrombocytopenia and leukopenia <sep>', 'or rate <sep> median os <sep> neurotoxicity <sep> median pfs <sep> objective response or rate progression-free survival pfs and overall survival os <sep>', 'response rate <sep> nausea and vomiting <sep> nephrotoxicity peripheral neuropathy myelosuppression and ototoxicity <sep>'], 'punchline_text': ['despite adequate dosage the incidence of complete and partial remission was low 10 vs 20 and not superior to that usually obtained with single agent chemotherapy. <sep>', 'objective response rates were similar 2 complete regressions crs and 10 partial regressions prs were recorded both in the 46 evaluable patients treated with cbdca response rate 26.1 95 confidence interval 15-41 and in the 40 evaluable patients treated with chip response rate 30 95 confidence interval 17-47%). <sep>', 'the difference in response rates for regimens 1 and 2 is statistically significant p  .015 but less than the magnitude originally considered clinically significant. <sep>', 'the toxicity of the four-drug regimen was significantly greater than that of the two-drug regimen while the response rate was greater among those patients treated with two drugs. <sep>', 'hexamethylmelamine had a greater frequency of severe toxicity 50 10/20 than adriamycin 10.5 2/19 p  0.014 and cytoxan 10 2/10 p  0.014). <sep>', 'cifx had a higher response rate 31.1 v 17.8 p  .004 and longer progression-free survival pfs time p  .003 compared with cisplatin alone. <sep>', 'the cp arm produced a significantly higher response rate and progression-free survival pfs but not overall survival os). <sep>', 'although 19 of 43 44 evaluable patients receiving bcap and 16 of 42 38 evaluable patients receiving bp experienced tumor regression only 22 of those receiving bcap and 21 of those on bp survived 1 year after beginning treatment. <sep>', 'response rates were similar for both agents 15 for carboplatin 11 for iproplatin and appear to be inferior to those noted with the parent compound cisplatin. <sep>', 'patients with a ps of 0 experienced a lower rate of failure p .013 and a lower risk of death p .009 compared with patients with ps of 2. <sep>', 'neither trimetrexate nor didemnin b at these doses and schedules is recommended for the treatment of advanced squamous carcinoma of the uterine cervix. <sep>', 'the unadjusted hazard ratio for overall survival between treatment arms was 0.76 <sep>', 'mvac produced a 22 overall response rate 95 ci 0.13 to 0.34 and median pfs and os of 4.4 months and 9.4 months respectively. <sep>', 'the response rate for the pif regimen was 40 4 partial remissions and 9 for the cisplatin group 1 complete remission). <sep>', 'or rate was significantly higher in the itp group 59 versus 33 p  0.002). <sep>', 'the continuous infusion regimen was associated with a significantly greater percentage of patients who experienced no nausea and vomiting 34 versus 18 p  0.002). <sep>'], 'population': ['advanced carcinoma of the uterine cervix <sep> 34 consecutive patients with advanced or recurrent carcinoma of uterine cervix <sep>', 'cervical cancer <sep> from july 1984 to november 1987 89 patients with recurrent measurable squamous-cell cancer of the uterine cervix <sep>', 'four hundred ninety-seven evaluable patients have been accrued on this study <sep> squamous-cell carcinoma of the cervix <sep>', 'thirty-five patients with epithelial carcinomas not considered to be surgically resectable <sep> squamous cell carcinoma <sep> patients with squamous cell carcinoma of the head and neck <sep>', '59 patients with recurrent squamous carcinoma of the cervix originally treated with <sep> recurrent carcinoma of the cervix <sep> 37 patients with easily evaluable disease <sep>', '454 patients entered 438 were eligible and analyzed for response and survival <sep> advanced cervix cancer <sep> advanced squamous carcinoma of the cervix <sep>', 'advanced cervical cancer <sep> cervical cancer patients <sep>', 'advanced cervical carcinoma <sep> 45 patients with advanced cervical carcinoma <sep>', 'advanced squamous carcinoma of the uterine cervix <sep> 23 patients ineligible for the study and 10 patients who were not evaluable the remaining 361 patients <sep> 394 patients with advanced measurable squamous carcinoma of the uterine cervix and no prior chemotherapy <sep>', 'women with histologically proven advanced recurrent or persistent squamous cell carcinoma of the cervix <sep> squamous carcinoma of the cervix <sep> patients with advanced cervical cancer <sep> eligible women <sep> three hundred three women were enrolled onto this trial of which 287 were assessable <sep>', 'advanced squamous carcinoma of the uterine cervix <sep> twenty-seven eligible patients <sep> patients with measurable metastatic or recurrent squamous carcinoma of the uterine cervix who had failed prior surgery or radiation therapy <sep> metastatic or recurrent squamous carcinoma of the uterine cervix <sep> sixteen patients <sep>', 'advanced cervical cancer <sep> women with stage ivb recurrent or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy <sep> stage ivb recurrent or persistent cervical cancer <sep> 293 eligible patients <sep> ovarian cancer and small-cell lung cancer <sep>', 'advanced cervical cancer <sep> eligible patients <sep> one hundred eighty-six patients c  60 tc  63 mvac  63 <sep> carcinoma of the uterine cervix <sep>', 'twenty-four patients were included 3 of which not eligible and of the remaining 21 patients <sep> recurrent cervical cancer <sep>', 'patients with recurrent or metastatic cancer of the uterine cervix <sep> one hundred and fifty-three patients <sep> recurrent or metastatic carcinoma of the uterine cervix <sep>', 'squamous cell carcinoma of the uterine cervix <sep> 331 patients with advanced or recurrent squamous cell carcinoma of the cervix no longer amenable to control with surgery or radiotherapy <sep>'], 'interventions': ['drug combinations adriamycin plus bleomycin versus cyclophosphamide plus vincristine <sep> radiotherapy plus adjuvant chemotherapy <sep> adriamycin plus bleomycin <sep> cyclophosphamide plus vincristine <sep> adriamycin plus bleomycin <sep>', 'carboplatin or iproplatin <sep> carboplatin cbdca or iproplatin chip <sep>', 'cisplatin <sep>', 'ccnu bleomycin methotrexate and vinblastine <sep> ccnu followed by bleomycin <sep> ccnu-bleomycin <sep>', 'single-agent chemotherapy <sep> hexamethylmelamine adriamycin or cytoxan <sep> cytoxan <sep> radiotherapy <sep> adriamycin <sep> hexamethylmelamine <sep>', 'cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide <sep> cisplatin plus ifosfamide and cisplatin plus mitolactol <sep> cisplatin plus ifosfamide cifx <sep> cisplatin mitolactol dibromodulcitol and ifosfamide <sep> cifx <sep> cisplatin <sep> cisplatin alone <sep> cisplatin 50 mg/m2 or the same dose of cisplatin plus mitolactol c  m <sep>', 'cisplatin plus paclitaxel <sep> cisplatin <sep> cisplatin c versus cisplatin plus paclitaxel cp <sep> chemotherapy <sep>', 'bcap <sep> cisplatin-based chemotherapy regimens <sep> bleomycin cyclophosphamide doxorubicin and cisplatin bcap and 45 others received bleomycin plus cisplatin bp <sep> bleomycin cyclophosphamide doxorubicin and cisplatin and bleomycin and cisplatin <sep> bleomycin <sep>', 'carboplatin <sep> carboplatin and iproplatin <sep> iproplatin <sep> cisplatin <sep> carboplatin or iproplatin <sep>', 'cisplatin and ifosfamide <sep> ifosfamide <sep> cisplatin and ifosfamide with or without bleomycin <sep> cisplatin <sep> bleomycin <sep> bleomycin 30 units over 24 hours on day 1 followed by cisplatin <sep>', 'm2/day iv trimetrexate <sep> trimetrexate or didemnin b <sep> didemnin b <sep>', 'topotecan <sep> cisplatin <sep> topotecan plus cisplatin tc <sep> cisplatin monotherapy <sep>', 'doxorubicin 30 mg/m2 day 2 and cisplatin <sep> mvac combination methotrexate vinblastine doxorubicin and cisplatin <sep> methotrexate <sep> methotrexate vinblastine doxorubicin and cisplatin mvac with topotecan and cisplatin tc or cisplatin alone c <sep> vinblastine <sep> cisplatin <sep> mvac <sep> cisplatin 50 mg <sep>', 'ifosfamide <sep> cisplatin vs. cisplatin/ifosfamide 5-fluorouracil <sep> cisplatin monotherapy <sep> 5-fluorouracil 500 mg/m(2 on days 1  2 and folinic acid <sep> cisplatin ifosfamide and 5-fluorouracil pif with cisplatin monotherapy <sep> cisplatin <sep>', 'itp <sep> ip regimen ifosfamide 1.5 g/m(2 daily on days 1-3 and cisplatin 70 mg/m(2 on day 2 or the same combination with the addition of paclitaxel 175 mg/m(2 on day 1 ifosfamide paclitaxel and cisplatinum itp regimen <sep> cisplatin and ifosfamide ip combination <sep> cisplatin and ifosfamide with or without paclitaxel <sep> paclitaxel taxol <sep>', 'cisplatin <sep> metoclopramide <sep> rapid versus prolonged 24 hr infusion of cisplatin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",combination cisplatin-based chemotherapy could be a viable option for patients of good performance status with recurrent/metastatic cervical cancer but further trials that report adequate survival and qol data are sought. response rates and improvements in survival are low. cisplatin-based combinations have significant toxicity. outcomes are poor and novel cytotoxic/biological agents and optimal scheduling need further investigation. future trials need to stratify for and perform planned subgroup analysis with respect to previous treatment and site of recurrence.
274,"{'outcomes': ['hair regrowth <sep> subcutaneous skin damage requiring plastic surgery <sep> absence of clinical signs hair regrowth or negative mycology <sep>', 'adverse effects <sep> adverse effects <sep> mycologic cure and either clinical cure <sep>', 'clinical deterioration <sep>', 'adverse reactions <sep>', 'cure rate <sep> efficacy and safety <sep> trichophyton violaceum <sep>', 'efficacy cost and compliance <sep>', 'microsporum canis <sep> trichophyton mentagrophytes <sep> time for complete scalp clearing <sep> mean time to a sterile culture <sep>', 'cure rates <sep> microsporum audouinii <sep> trichophyton violaceum <sep>', 'cure rates <sep> therapeutic efficacy <sep> cure rate <sep>', 'efficacy and tolerability <sep> overall outcome or tolerability <sep> rapid clearance of tinea capitis <sep>', 'vomiting <sep> side effects <sep>', 'hepatotoxicity or other adverse reactions <sep>', 'side effects <sep> therapeutic efficacy <sep> cure rate <sep>', 'treatment efficacy <sep>', 'mycological cure <sep> complete cure <sep> mycological cure <sep> clinical cure <sep> complete cure <sep>'], 'punchline_text': ['the responsible organisms were microsporum canis 17 cases and trichophyton verrucosum 7 cases). <sep>', 'discontinuation from therapy due to adverse effects occurred only in the griseofulvin group nausea in one patient). <sep>', 'after 6 weeks of therapy there was clinical and mycologic cure or improvement of the lesions in 92 of patients treated with ketoconazole group a and in 76 of those given griseofulvin group b). <sep>', 'the treatment groups were comparable in terms of age weight sex race duration of infection length of therapy and initial disease severity. <sep>', 'trichophyton violaceum was the major pathogen in both groups 82.1 and 88.9 respectively). <sep>', 'at the end of study effective treatment defined as negative culture and low scores on signs and symptoms was achieved in 56 69 and 65 of patients who were treated with terbinafine for 1 2 and 4 weeks respectively. <sep>', 'the time for complete scalp clearing was significantly longer in patients who received ketoconazole median 108 days compared with those who were treated with griseofulvin median 60 days <sep>', 'isolated pathogens included trichophyton violaceum 71.5 t. tonsurans 14.9 t. verrucosum 4.3 microsporum audouinii 4.3 m. canis 2.5 t. schoenleinii 1.9 and t. mentagrophytes 0.6%). <sep>', 'mycologic examinations disclosed trichophyton verrucosum in 40 of patients t. violaceum in 40 and microsporum canis in 20%. <sep>', 'although the 4-week course of terbinafine resulted in a trend to more rapid clearance of tinea capitis there were no statistically significant differences between the two drugs in terms of overall outcome or tolerability apart from in a subgroup of patients with trichophyton infections and weighing  20 kg who responded better to terbinafine than to griseofulvin at 4 weeks. <sep>', 'fifteen of 17 patients were cured by itraconazole 88 and 15 of 17 patients by griseofulvin 88%). <sep>', 'no significant hepatotoxicity or other adverse reactions were observed. <sep>', 'no significant side effects were reported. <sep>', 'two pulses of standard dose terbinafine were found to be sufficient for treating most cases of microsporum spp. <sep>', 'complete cure was observed at the end of study in 62 patients treated with terbinafine for 6 weeks in 60 treated for 8 weeks and in 84 patients treated with griseofulvin for 12 weeks. <sep>'], 'population': ['fourteen children <sep> tinea capitis in children <sep> 19 patients had cleared completely with good new hair regrowth <sep> twenty four patients 16 male 8 female <sep> seven patients presented with kerion the remainder with a scaling and patchy alopecia pattern of tinea capitis <sep> twenty four consecutive patients with culture proven tinea capitis <sep>', 'tinea capitis caused by trichophyton species <sep> centers in canada and south africa <sep> patients who discontinued therapy or were lost to follow-up were <sep>', '47 children with dermatophytosis and positive fungal culture <sep> dermatophytoses in children <sep> dermatophytoses <sep>', 'all patients had positive initial mycologic cultures <sep> tinea capitis in childhood <sep> children with tinea capitis <sep> twenty-two patients were enrolled and 14 completed the protocol <sep>', '2 weeks in tinea capitis <sep> patients with tinea capitis <sep>', '159 patients had culture-confirmed tinea capitis attributable to trichophyton species and constituted the intent-to-treat population used for efficacy analysis 50 55 and 54 patients in the 1 2 and 4-week arms respectively <sep> 176 patients with a clinical diagnosis of tinea capitis <sep> trichophyton tinea capitis <sep> trichophyton tinea capitis in a north american population <sep> patients with trichophyton tonsurans tinea capitis <sep>', 'patients ranged in age from 2.1 to 11 years median 5.2 years <sep> 80 children with tinea capitis without kerion <sep> tinea capitis <sep> sixty-three patients <sep>', 'tinea capitis <sep> 161 evaluable patients 53 were treated with <sep>', 'patients ranged in age from 1 to 16 years 80 were boys and 20 were girls <sep> 40 patients with a clinical and mycologic diagnosis of tinea capitis <sep> tinea capitis <sep>', 'one hundred and forty-seven patients were evaluable terbinafine 77 griseofulvin 70 <sep> tinea capitis in children <sep> patients with microsporum audouinii infections <sep> tinea capitis <sep> two hundred and ten children aged 2--16 years with mycologically confirmed tinea capitis <sep>', 'tinea capitis in children <sep> thirty-four children and one adult with clinical signs and symptoms of tinea capitis and with positive culture and microscopy for dermatophytes <sep> fifteen of these 17 itraconazole patients and 14 of the 15 griseofulvin patients had infections caused by microsporum canis <sep> children <sep> tinea capitis <sep>', 'forty-eight patients 26 <sep> treating tinea capitis <sep> tinea capitis <sep> seventy-nine patients were enrolled 46 received <sep>', 'patients ages ranged from 1 to 14 years <sep> fifty-four percent were girls and 46 were boys <sep> tinea capitis <sep> 50 patients with a clinical and mycologic diagnosis of tinea capitis <sep>', '42 individuals <sep>', 'children with tinea capitis due to microsporum species <sep> europe and south america <sep>'], 'interventions': ['griseofulvin and terbinafine <sep> griseofulvin <sep> griseofulvin and terbinafine <sep> terbinafine <sep>', 'terbinafine 0/4 and fluconazole <sep> terbinafine itraconazole and fluconazole <sep> terbinafine itraconazole and fluconazole <sep> itraconazole <sep> griseofulvin terbinafine itraconazole and fluconazole <sep> fluconazole <sep> griseofulvin <sep> griseofulvin microsize <sep> terbinafine <sep> griseofulvin <sep>', 'ketoconazole and griseofulvin <sep> griseofulvin <sep> ketoconazole and griseofulvin <sep> ketoconazole <sep>', 'placebo <sep> ketoconazole and griseofulvin <sep> ketoconazole <sep> griseofulvin <sep> ketoconazole <sep>', 'itraconazole <sep> oral itraconazole <sep> terbinafine <sep>', 'oral terbinafine <sep> terbinafine therapy <sep> terbinafine <sep> terbinafine <sep>', 'griseofulvin <sep> griseofulvin and ketoconazole <sep> ketoconazole <sep> ketoconazole vs. griseofulvin <sep>', 'oral terbinafine <sep> terbinafine <sep>', 'fluconazole <sep> fluconazole <sep> griseofulvin versus fluconazole <sep> griseofulvin <sep> griseofulvin <sep>', 'griseofulvin <sep> terbinafine <sep> terbinafine <sep>', 'ultramicronized griseofulvin <sep> itraconazole <sep> itraconazole <sep> griseofulvin therapy <sep> griseofulvin <sep> griseofulvin <sep>', 'potassium hydroxide <sep> ketoconazole <sep> griseofulvin <sep> griseofulvin and ketoconazole <sep> griseofulvin 22 ketoconazole <sep> ketoconazole replace griseofulvin <sep>', 'placebo <sep> terbinafine and griseofulvin <sep> terbinafine <sep> griseofulvin <sep> terbinafine <sep> griseofulvin <sep>', 'oral terbinafine <sep> pulsed oral terbinafine <sep> pulsed terbinafine <sep> terbinafine <sep>', 'terbinafine <sep> terbinafine and open-label high-dose griseofulvin <sep> griseofulvin <sep> terbinafine <sep> griseofulvin 20 mg x kg(-1 <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",the best evidence suggests that newer treatments including terbinafine itraconazole and fluconazole may be similar to griseofulvin in children with tinea capitis caused by trichophyton species. newer treatments may be preferred because shorter treatment durations may improve treatment adherence although they may be more expensive. there is not enough evidence on the use of systemic treatments in children with microsporum infections. not all treatments for tinea capitis are available in paediatric formulations but all have reasonable safety profiles.
275,"{'outcomes': ['hospital mortality <sep> partial lysis <sep> bleeding complications <sep> blood flow <sep>', 'cumulative survival rate <sep> limb salvage and survival <sep> duration of hospitalization <sep> incidence of in-hospital cardiopulmonary complications <sep> dissolution of the occluding thrombus <sep> cumulative limb salvage rate <sep> patient survival rates <sep> frequency of in-hospital cardiopulmonary complications <sep> hospital cost <sep>', 'mean ankle-brachial blood-pressure index <sep> topas <sep> risk of amputation or death <sep> major hemorrhage <sep> complete dissolution of thrombus <sep> intracranial hemorrhage <sep> amputation-free survival rates <sep> amputation-free survival rate <sep>'], 'punchline_text': ['thrombectomy resulted in an immediate restitution of blood flow in six out of nine cases in three cases a bypass procedure was performed and one of these failed with a resultant amputation. <sep>', 'the mortality differences seemed to be primarily attributable to an increased frequency of in-hospital cardiopulmonary complications in the operative treatment group 49 vs 16 p  0.001). <sep>', 'amputation-free survival rates in the urokinase group were 71.8 percent at six months and 65.0 percent at one year as compared with respective rates of 74.8 percent and 69.9 percent in the surgery group the 95 percent confidence intervals for the differences were 10.5 to 4.5 percentage points at six months p=0.43 and 12.9 to 3.1 percentage points at one year p=0.23). <sep>'], 'population': ['acute arterial occlusion <sep> twenty patients with a need for intervention owing to ischaemia lasting more than 24 h but less than 14 days were included <sep>', 'acute peripheral arterial ischemia <sep> 57 patients <sep> patients with limb-threatening ischemia of less than 7 days duration <sep> peripheral arterial occlusive disease <sep> patients diagnosed with acute limb-threatening peripheral arterial occlusion <sep> group and 57 patients <sep> patients with acute peripheral arterial occlusion <sep>', 'acute arterial occlusion of the legs <sep> all patients 272 per group had had acute arterial obstruction of the legs for 14 days or less <sep> 113 north american and european sites <sep>'], 'interventions': ['thrombolytic treatment <sep> percutaneous transluminal angioplasty <sep> epidural anaesthesia <sep> surgical thrombectomy te and thrombolysis tl using recombinant tissue plasminogen activator rt-pa <sep> te <sep> tl group received 30 mg rt-pa <sep> surgical treatment versus thrombolysis <sep>', 'thrombolytic therapy <sep> thrombolytic therapy <sep> thrombolytic therapy with operative revascularization <sep> intraarterial thrombolytic therapy <sep> intraarterial catheter-directed urokinase therapy or operative intervention <sep> balloon dilation or operation <sep> operative intervention <sep> intraarterial urokinase infusion <sep> intraarterial thrombolytic therapy <sep>', 'thrombolysis or peripheral arterial surgery <sep> vascular surgery e.g. thrombectomy or bypass surgery with thrombolysis by catheter-directed intraarterial recombinant urokinase <sep> thrombolytic therapy <sep> recombinant urokinase with vascular surgery <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",universal initial treatment with either surgery or thrombolysis cannot be advocated on the available evidence. there is no overall difference in limb salvage or death at one year between initial surgery and initial thrombolysis. thrombolysis may be associated with a higher risk of ongoing limb ischaemia and haemorrhagic complications including stroke. the higher risk of complications must be balanced against risks of surgery in each person.
276,"{'outcomes': ['severity of pain and burning sensation using visual analog scales <sep> clinical response pain burning sensation area of reticulation erythema and ulceration <sep> clinical scoring and grid measurement of the target lesion reticulation erythema ulceration <sep>', 'side effects <sep>', 'vas scores <sep> erosive areas and recorded visual analog scale vas scores <sep> recurrence rates <sep> swelling or burning sensation <sep>', 'visual analog scale vas and clinical improvement including lesion type and size <sep> partial improvement <sep> partial to complete clinical improvement <sep> vas scores a partial to complete response <sep> serious side-effects <sep> vas scores <sep> partial response no response and worsening of the symptoms <sep>', 'mean lesion sizes and mean pain measures <sep>', 'initial therapeutic response <sep>', 'soreness scores <sep> log diary recording oral function and soreness scores <sep> soreness relief following immediate application oral function and size of erosive/ulcerative area <sep> ulcerative areas <sep> size of the erosive/ulcerated area <sep>', 'eolp <sep> patient documentation measurement of pimecrolimus levels and blood counts <sep> severe adverse events <sep> safety <sep> mucosal erosions and pain sensation <sep> sustained remission of eolp <sep>', 'symptom-free state <sep> quality of life <sep> side effects <sep> mean scores <sep> relapse <sep> symptoms and side effects <sep> severity score <sep> efficacy and safety <sep>', 'hospital anxiety-depression had scale <sep> adverse effects <sep> total quality of life score <sep> complete pain remission <sep> relation to pain <sep> psychological disability domain and total ohip-49 score <sep>', ""reticulation <sep> blood levels <sep> visual analogue scale vas <sep> discomfort scores <sep> efficacy relative safety and tolerability <sep> ulceration alpha  0.068 and erythema <sep> oelp lesion size <sep> vas scores <sep> patient's pain scores <sep>"", 'adverse effects <sep> complete remission <sep> good or partial response <sep>', 'good response <sep> clinical and symptomatological improvement of olp <sep> complete clinical remission <sep> burning pain <sep> serious side-effects <sep> symptomatology <sep> erosive and ulcerative lesions <sep>', 'symptom scores <sep> pain severity burning sensation and mucosal lesion extension <sep>', 'clinical response <sep> side-effects <sep> daily cost of ciclosporin treatment <sep> symptomatology <sep> daily cost of ciclosporin <sep>', 'visual analogue scale vas the mcgill pain score the oral health impact profile ohip and oral health quality of life ohqol questionnaires <sep> surface area of oral lesions <sep> total surface area of the lesions including all white erythematous and ulcerative lesions <sep> patient quality of life <sep> efficacy ease of application and adverse effects <sep> quality of life <sep> painful symptoms <sep> acceptability and efficacy <sep>', 'clinical improvement <sep> efficacy and safety <sep>', 'signs and symptoms of olp <sep> clinical candidosis <sep> symptoms and extension of lesions adverse effects <sep> clinical and subjective improvement <sep>', 'change in symptoms <sep> clinical signs and occurrence of side effects <sep>', 'systemic side effects <sep> psoriatic lesions <sep> erosion <sep> pain <sep> erythema <sep> blood cyclosporine levels <sep>', 'blood concentrations of pimecrolimus <sep> mean score <sep> tolerated and only transient burning sensations <sep> condition improved subsequently relapsed <sep> blood level of pimecrolimus <sep>', 'pain score by linear visual analogue scale 0-100 ii clinical score iii clinical resolution and iv patient compliance <sep> painful symptoms <sep>', 'oral health impact profile score <sep> blood levels <sep> painful symptoms measured by visual analog scale the oral health impact profile score and objective clinical score <sep> transient burning sensation <sep> visual analog scale score <sep> clinical score <sep> efficacy and safety <sep>'], 'punchline_text': ['although clinical response pain burning sensation area of reticulation erythema and ulceration at week 4 were all worse in patients receiving cyclosporine than in those receiving steroid the differences were not statistically significant. <sep>', 'the results showed that 13 treated sites compared with six control sites responded significantly favorable to puva therapy. <sep>', 'there were no statistical differences in the recurrence rates 33.3 vs. 45.5 p  0.386 and intervals 80.89  <sep>', 'a significant decrease in vas scores was seen at the end of the study period p  0.001). <sep>', 'mean lesion sizes and mean pain measures differed between control and treatment groups favouring ignatia p<0.05). <sep>', 'topical tacrolimus 0.1 ointment induced a better initial therapeutic response than triamcinolone acetonide 0.1 ointment. <sep>', 'application of topical ha produced a significant reduction p  0.05 in soreness scores when compared with placebo for up to 4 h post-application. <sep>', 'the clinical eolp composite score including mucosal erosions and pain sensation was significantly reduced in the pimecrolimus-treated group compared with vehicle p  0.025). <sep>', 'the difference in the mean scores within each group was statistically significant from the fourth week onward in group a and eighth week onward in group b whereas in patients with erosive disease it was second and twelfth week onward respectively. <sep>', 'in relation to quality of life significant differences were observed between the two groups in the psychological disability domain and total ohip-49 score. <sep>', 'the experimental group showed a decrease in ulceration alpha  0.068 and erythema alpha  0.005 at the mid-point with continued reduction of erythema at the final alpha  0.075 time measurement. <sep>', 'no adverse effects were noted during follow-up period. <sep>', 'no serious side-effects were found in both groups. <sep>', 'at the end of the treatment period symptom scores were significantly lower in the tacrolimus group than in the clobetasol group. <sep>', 'clobetasol is more effective than ciclosporin in inducing clinical improvement but the two drugs have comparable effects on symptoms. <sep>', 'both fp and bsp mouthwash caused both a statistically significant reduction in painful symptoms as measured by the vas and improvement in quality of life as measured by the ohip and ohoql indices. <sep>', 'no statistical differences were found in comparing the two different formulations. <sep>', 'the addition of miconazole did not affect in a significant way the signs and symptoms of olp. <sep>', 'the first interim analysis did not show a significant difference between the placebo and curcuminoids groups. <sep>', 'after eight weeks the eight recipients of cyclosporine had marked improvement in erythema p  0.003 erosion p  0.02 reticulation presence of white lacelike lesions p  0.007 and pain p  0.002 whereas the eight recipients of vehicle had no change or minimal improvement. <sep>', 'the 1 pimecrolimus cream seems to be an effective and well-tolerated treatment for oral erosive lichen planus. <sep>', 'both formulations were found to be similar for parameters ii iii and iv although with a better general trend for formulation a a significant difference was registered for formulation a in terms of a reduction in painful symptoms parameter i at time t2 p  0.02). <sep>', 'there was no significant difference between changes from baseline median values of pimecrolimus and triamcinolone groups after treatment termination in terms of visual analog scale score 9.8  <sep>'], 'population': ['oral lichen planus <sep> one hundred thirty-nine biopsy-proven olp patients <sep>', 'eighteen patients with long-standing bilateral and severe olp of the buccal mucosa participated in the investigation <sep>', '56 olp patients <sep> erosive oral lichen planus <sep> a total of 49 of 56 patients were followed up <sep>', 'oral lichen planus <sep> 37 biopsy-proven symptomatic olp patients <sep> oral lichen planus olp <sep>', '30 consecutive patients with oral lesions consistent clinically and histologically with erosive <sep> and/or atrophic olp <sep>', 'patients with oral lichen planus <sep> twenty patients group i were treated with <sep>', '124 patients with erosive olp <sep>', 'twenty patients <sep>', 'oral lichen planus <sep> patients with moderate to severe oral lichen planus <sep> patients with symptomatic moderate to severe oral lichen planus <sep> 49 patients with moderate to severe oral lichen planus <sep>', 'patients with oral lichen planus <sep> 64 patients with olp <sep> patients with olp <sep>', 'oral erosive lichen planus oelp <sep> twenty patients with oelp <sep> oral erosive lichen planus <sep>', 'forty consecutive patients with oral lichen planus diagnosed on the basis of histopathologic and immunofluorescence findings participated in this study <sep> patients with symptomatic oral lichen planus <sep>', 'fifty-four consecutive patients 34 women and 20 men participated in the study <sep> oral lichen planus <sep> fifty-four patients <sep> patients with olp <sep>', 'patients with oral lichen planus <sep> 32 patients 20 females and 12 males all white italian origin mean age of 43.6+/-18.4 years 16 patients per treatment group were treated with <sep>', 'forty consecutive patients <sep> atrophic and erosive oral lichen planus <sep>', 'symptomatic oral lichen planus <sep> 48 patients with biopsy-proven symptomatic olp and 44 patients 92 completed the study <sep>', 'thirty-five consecutive patients <sep> atrophic-erosive oral lichen planus <sep>', 'oral lichen planus <sep> unit of oral medicine and pathology of the university of milan <sep> thirty-five outpatients with histologically proven olp <sep>', 'october 2004 using data from the first 33 subjects <sep> 100 consecutive eligible patients with olp presenting to the oral medicine clinic at the university of california san francisco were to be selected <sep> february 2003 and september 2004 <sep>', 'oral lichen planus <sep> 16 patients with symptomatic oral lichen planus <sep>', 'outpatients of the department of dermatology university hospital of nice from december 21 2004 to april 19 2005 <sep> fourteen consecutive patients with oral erosive lichen planus confirmed by histological examination and with a clinical score superior to 3 <sep> 14 patients 2 did not meet the inclusion criteria and 12 were enrolled in the trial <sep>', 'fifty patients with symptomatic olp <sep> atrophic/erosive oral lichen planus <sep> 45 patients 12 males and 33 females mean age 61.1 years <sep>', 'oral lichen planus <sep> eighteen patients in <sep> 40 patients <sep> patients with olp <sep>'], 'interventions': ['steroid with cyclosporine <sep> cyclosporine solution versus triamcinolone acetonide <sep> cyclosporine 68 or steroid <sep> cyclosporine <sep> topical cyclosporine <sep>', 'puva <sep> photochemotherapy with 8-methoxypsoralen and long-wave ultraviolet light puva <sep> 8-methoxypsoralen <sep> puva therapy <sep>', 'intralesional injection of 0.5 ml bcg-psn <sep> topical intralesional bcg-psn injection <sep> intralesional bcg-psn injection <sep> topical intralesional bcg-psn injection <sep> triamcinolone acetonide ta <sep>', 'purslane <sep> placebo <sep> antioxidant-rich purslane <sep>', 'ignatia or placebo <sep> ignatia homeopathic 30c <sep>', 'topical tacrolimus <sep> topical tacrolimus ointment <sep> triamcinolone acetonide <sep> triamcinolone acetonide 0.1 ointment 4 times daily <sep> triamcinolone acetonide ointment <sep> topical tacrolimus <sep> topical tacrolimus and triamcinolone acetonide ointment <sep>', 'placebo <sep> topical ha <sep> topical hyaluronic acid ha gel preparation <sep> topical ha gel <sep> topical ha preparation <sep> topical hyaluronic acid <sep> topical ha <sep>', 'pimecrolimus cream <sep> vehicle cream <sep> erosive oral lichen planus eolp <sep> pimecrolimus <sep> pimecrolimus cream <sep> open-label pimecrolimus <sep> pimecrolimus eolp <sep>', 'topical triamcinolone acetonide <sep> triamcinolone <sep> betamethasone oral mini-pulse omp therapy <sep> betamethasone oral mini-pulse therapy <sep> triamcinolone acetonide <sep> betamethasone omp <sep> topical triamcinolone acetonide 0.1 paste <sep> betamethasone omp <sep> betamethasone <sep> omp <sep>', 'topical aloe vera <sep> placebo <sep> aloe vera av <sep>', 'pimecrolimus cream <sep> pimecrolimus <sep> placebo cream <sep>', 'fluocinonide <sep> placebo <sep> fluocinonide <sep>', 'av gel or placebo <sep> aloe vera gel <sep> oral lichen planus olp <sep> placebo <sep>', 'tacrolimus <sep> oral lichen planus olp <sep> tacrolimus or clobetasol ointment <sep>', 'clobetasol and ciclosporin <sep> ciclosporin vs. clobetasol <sep> hydroxyethyl cellulose bioadhesive gel <sep> ciclosporin <sep> clobetasol propionate or ciclosporin <sep> oral lichen planus olp <sep> antimycotic prophylaxis <sep>', 'betamethasone sodium phosphate mouthrinse <sep> fp <sep> topical fluticasone propionate spray fp and betamethasone sodium phosphate mouthrinse bsp <sep> symptomatic oral lichen planus olp <sep> bsp <sep> fluticasone propionate spray <sep>', 'placebo <sep> hydroxyethyl cellulose bioadhesive gel <sep> topical clobetasol <sep> clobetasol propionate <sep> oral lichen planus olp <sep>', 'placebo <sep> miconazole <sep> miconazole <sep> topical steroids <sep> clobetasol propionate and miconazole or clobetasol propionate and placebo <sep> clobetasol propionate with and without a topical antifungal drug miconazole <sep>', 'placebo or curcuminoids <sep> placebo <sep> prednisone <sep>', 'topical cyclosporine or its vehicle <sep> topical cyclosporine rinse <sep> cyclosporine <sep> cyclosporine <sep> systemic cyclosporine <sep>', 'oral erosive lichen planus with 1 pimecrolimus cream <sep> pimecrolimus cream <sep> placebo <sep> pimecrolimus <sep> pimecrolimus cream <sep>', 'clobetasol propionate formulation a <sep> clobetasol-17-propionate lipid-loaded microspheres 0.025 compared with a conventional formulation lipophilic ointment <sep>', 'triamcinolone <sep> triamcinolone acetonide paste <sep> triamcinolone acetonide <sep> topical pimecrolimus <sep> triamcinolone acetonide therapy <sep> pimecrolimus <sep> pimecrolimus 1 cream or triamcinolone acetonide <sep> pimecrolimus cream <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",although topical steroids are considered to be first line treatment we identified no rcts that compared steroids with placebo in patients with symptomatic olp. from the trials in this review there is no evidence that one steroid is any more effective than another. there is weak evidence that aloe vera may reduce the pain of olp and improve the clinical signs of disease compared to placebo. there is weak and unreliable evidence that cyclosporin may reduce pain and clinical signs of olp. there is no evidence that other calcineurin inhibitors reduce pain compared to either steroids or placebo. from the 28 trials included in this systematic review the wide range of interventions compared means there is insufficient evidence to support the effectiveness of any specific treatment as being superior.
277,"{'outcomes': ['asthma control <sep> steroid dosage visual analogue symptom scores response to beta 2 agonist and peak expiratory flow rate pfr measurement <sep> symptom scores of pfr measurement <sep>'], 'punchline_text': ['in this study an 8 week treatment with hydroxychloroquine was of no benefit to patients with chronic steroid dependent asthma. <sep>'], 'population': ['patient with severe chronic asthma <sep> a group of nine steroid dependent adult asthmatic patients <sep> patients with chronic steroid dependent asthma <sep>'], 'interventions': ['hydroxychloroquine <sep> placebo <sep> hydroxychloroquine and placebo <sep> hydroxychloroquine <sep> hydroxychloroquine or placebo <sep> prednisolone <sep>'], 'punchline_effect': [' no diff <sep>']}",there is insufficient evidence to support the use of chloroquine as an oral steroid-sparing agent in chronic asthma. further trials should optimise oral steroid dosage before addition of the steroid-sparing agent.
278,"{'outcomes': ['neonatal necrotizing enterocolitis <sep> necrotizing enterocolitis nec <sep> incidence of nec <sep>', 'protection against necrotising enterocolitis <sep> longer duration of hospital stay <sep> necrotising enterocolitis <sep> necrotising enterocolitis <sep> mortality <sep>'], 'punchline_text': ['this difference in the incidence of nec between the treatment and control group was significant at the .05 level. <sep>', 'infants with necrotising enterocolitis were associated with a significant increase in mortality p  0.026 and longer duration of hospital stay p  0.002). <sep>'], 'population': ['42 high-risk neonates <sep> selected babies at high risk for nec particularly those born prematurely and those who have a history of perinatal asphyxia or umbilical artery catheterization or both <sep>', 'and 19 of 69 infants receiving the <sep> a tertiary referral centre of a university teaching hospital was conducted on 140 very low birthweight infants consecutively admitted to the neonatal unit <sep> infants with necrotising enterocolitis <sep> necrotising enterocolitis in preterm very low birthweight infants <sep> 71 infants receiving <sep>'], 'interventions': ['gentamicin sulfate <sep> dextrose-and-water placebo <sep> oral gentamicin therapy <sep> gentamicin sulfate therapy <sep> gentamicin <sep>', 'placebo <sep> prophylactic oral vancomycin <sep> oral vancomycin <sep> vancomycin <sep> placebo solution <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>']}",evidence suggests that oral antibiotics reduce the incidence of nec in low birth weight infants. however concerns about adverse outcomes persist particularly related to the development of resistant bacteria. to address this question further a large trial would be required with a sample size sufficient to examine all the important benefits and harms. adverse outcomes associated with infection should be evaluated and microbiological studies looking for the development of resistant bacteria should be undertaken
279,"{'outcomes': ['clinical hemostasis <sep> mean pretransfusion bleeding times <sep> prolonged bleeding times and transfusion intervals <sep> mean 1-hour posttransfusion template bleeding times <sep> hemostatic efficacy <sep> plt count increments and ccis <sep> posttransfusion plt count increments <sep> mean 1-hour posttransfusion plt corrected count increments ccis <sep> time to next plt transfusion <sep> bleeding times <sep>', 'cci(1hour <sep> plt and red blood cell utilization <sep> blood product utilization <sep> risk of bleeding <sep>', 'overall median time to next transfusion <sep> 1-hour corrected count increment cci <sep> 1-hour count increment time to next transfusion hemostasis transfusion reactions and serious adverse events <sep>', 'therapeutic efficacy and safety <sep> 24-hour plt count <sep> transfusion-associated bacteremia <sep> number frequency and dose of plt transfusions acute transfusion reactions and adverse events <sep> therapeutic efficacy and safety <sep> clinical refractoriness <sep>', 'clinical hemostasis hemorrhagic adverse events and overall adverse events <sep> platelet transfusion dose pretransfusion storage duration and patient size <sep>', 'incidence of grade 3 or 4 bleeding <sep> proportion of patients with world health organization who grade 2 bleeding <sep> posttransfusion platelet count increments and days to next transfusion <sep> incidence of grade 2 bleeding <sep> average number of days to next platelet transfusion <sep> number of platelet transfusions <sep> therapeutic efficacy and safety <sep> mean 1-hour posttransfusion platelet corrected count increment cci <sep> transfusion reactions <sep>'], 'punchline_text': ['pct plts provided correction of prolonged bleeding times and transfusion intervals not significantly different than reference plts despite significantly lower plt count increments and ccis. <sep>', 'plt and red blood cell utilization in the two groups was not significantly different suggesting that the slightly lower ccis prt-plts did not increase blood product utilization. <sep>', 'hemostasis was adequate and no transfusion reactions or serious adverse events were reported. <sep>', 'forty-three patients with transfusion-dependent thrombocytopenia were randomly assigned to receive either pct or reference plt transfusions for up to 28 days. <sep>', 'platelet transfusion dose pretransfusion storage duration and patient size were significant covariates p .001 for posttransfusion platelet counts. <sep>', 'transfusion reactions were fewer following pct platelets 3.0 pct versus 4.4 control p .02). <sep>'], 'population': ['29 patients receiving <sep> 32 patients with thrombocytopenia received one transfusion of pct and/or one transfusion of untreated reference apheresis plts <sep> 20.8 x 10(9 and 52.3 x 10(9 <sep> patients with thrombocytopenia <sep>', 'patients with chemotherapy-induced thrombocytopenia six centers <sep> 118 patients <sep>', 'twenty patients with thrombocytopenia <sep> patients with thrombocytopenia <sep>', 'forty-three patients with transfusion-dependent thrombocytopenia <sep> thrombocytopenic patients <sep>', 'thrombocytopenic patients requiring repeated <sep> 103 patients received one or more transfusions of either pct test 311 transfusions or <sep>', 'patients with thrombocytopenia <sep> 645 patients 318 pct and 327 control <sep>'], 'interventions': ['paired pct <sep> pct <sep> amotosalen hcl and ultraviolet a light <sep> photochemical treatment pct with amotosalen hcl with ultraviolet a illumination <sep>', 'riboflavin and ultraviolet light treatment <sep> prt-plts <sep> prt-plts mirasol prt caridianbct biotechnologies or reference platelet plt products <sep> platelets treated with mirasol pathogen reduction technology <sep>', 'photochemical treatment pct of platelets plts with amotosalen and ultraviolet a light to inactivate bacteria <sep> transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets <sep>', 'pct or reference plt transfusions <sep> apheresis platelets plts photochemically treated pct with amotosalen and ultraviolet <sep> pct plts <sep>', 'platelet transfusions <sep> nucleic acid-targeted photochemical treatment pct using amotosalen hcl s-59 and ultraviolet a uva light <sep> conventional reference <sep>', 'photochemically treated pct or conventional control platelets <sep> synthetic psoralen amotosalen hcl <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>']}",we found no evidence of a difference in mortality clinically significant or severe bleeding transfusion reactions or adverse events between pathogen-reduced and standard platelets. for a range of laboratory outcomes the results indicated evidence of some benefits for standard platelets over pathogen-reduced platelets. these conclusions are based on data from 1422 patients included in 10 trials. results from ongoing or new trials are required to determine if there are clinically important differences in bleeding risk between pathogen-reduced platelet transfusions and standard platelet transfusions. given the variability in trial design bleeding assessment and quality of outcome reporting it is recommended that future trials apply standardised approaches to outcome assessment and follow-up including safety reporting.
280,"{'outcomes': ['days of mechanical ventilation <sep> death from any cause during the 28-day period after randomization <sep> mean sd numbers of days spent in the icu <sep> mortality <sep> proportion of patients with new single-organ and multiple-organ failure <sep>', 'blood pressure <sep> survival <sep> blood pressure ph and urine output <sep> blood pressure <sep>', 'coagulation parameters prothrombin time partial thromboplastin time fibrinogen and factor viii <sep> serum albumin <sep> serum colloid oncotic pressure <sep> normal blood pressure and urine output <sep> ventilatory parameters blood gases pulmonary function tests ventilator days or hospital days <sep>', 'qs/qt and aado2 <sep> oxygen consumption and cardiac output <sep> hemodynamic pulmonary and renal variables <sep> significant diuresis <sep>', 'nausea and vomiting use of rescue antiemetics severe pain periorbital edema and double vision <sep> maintenance of arterial blood pressure heart rate and urine output <sep> nausea and vomiting <sep> postoperative nausea and vomiting and improves postoperative outcomes <sep> quality of postoperative recovery <sep>', 'cardiac index <sep> extravascular lung water and cardiac index <sep> ejection fractions <sep> fluid for successful resuscitation <sep> lung water <sep> total body blood flow <sep> cardiac index and myocardial contractility ejection fraction and mean rate of internal fiber shortening vcf <sep> hemodynamic response and lung water following thermal injury <sep>', 'maximum sequential organ function scores <sep> lactate clearance <sep> safety measures <sep> renal injury <sep> time to recovery of bowel function or mortality <sep> plasma lactate concentrations <sep> renal function and lactate clearance <sep> severe trauma with respect to resuscitation fluid volume gastrointestinal recovery renal function and blood product requirements <sep> blood products packed red blood cell volumes <sep> haemodynamic data <sep>', 'hemodynamic effects <sep> mortality rates <sep> endovenous volumes <sep> sbp <sep> blood pressure infused volumes necessary to maintain sbp and overall survival rates <sep>', 'cardiac output and pulmonary wedge pressure <sep> cardiac output and pulmonary wedge pressure pwp <sep> left ventricular stroke work index and pwp <sep> adequate cardiac output <sep>', 'concentrations of molecular markers of activated coagulation and fibrinolysis <sep> prothrombin fragment f1  2 <sep> tissue plasminogen activator <sep> plasmin/alpha 2-antiplasmin complex <sep> factor xiii <sep> plasminogen activator inhibitor-1 <sep> thrombin/antithrombin complex <sep> concentrations of coagulation factor xiii <sep> response profile <sep>', 'overall survival rate hypertonic infusion <sep> overall complication rates <sep> survival rate <sep> sex age cause of hypovolemia revised trauma score rts glasgow index and mean arterial pressure map on admission <sep> hemodynamic parameters <sep> number of blood transfusions <sep>', 'cop <sep> evlw <sep> blood loss <sep> extravascular lung water evlw <sep> cardiac output evlw pcwp serum colloid osmotic pressure cop and intrapulmonary shunt fraction qs/qt <sep> cardiac output and qs/qt <sep> urine flow rates <sep> urine flow rate <sep>', 'mean arterial pressure map <sep> volumes of crystalloids and blood required in their resuscitation <sep> incidence of complications <sep> systolic pressure <sep> mortality rate <sep> calculated plasma volume expansion <sep> severe hypovolemia <sep> plasma volume expansion <sep>', 'hemodynamic stabilization heart rate capillary refill time systolic bp in normal range plasma volume at the end of fluid resuscitation and incidence of organ dysfunction <sep> plasma volume and hemodynamic stability <sep> hemodynamic parameters heart rate capillary filling time pulse volume and blood pressure <sep> requirement of inotropes incidence of organ dysfunction and case fatality rate <sep> extracellular fluid volume total body water and interstitial fluid volume <sep> initial hemodynamic stabilization <sep> mean sd plasma volume saline--53.4 <sep>', 'predicted survival <sep> survival rates <sep>', 'pao/fio:248.4  17.0,lactate clearance rate <sep> incidence of mods <sep> mortality <sep> arterial lac <sep> mean arterial pressure map oxygenation index pao/fio),arterial lactate lac),lactate clearance rate acute physiology and chronic health evaluation ii(apacheii score,fluid infusion volume urine output as well as incidence of multiple organ dysfunction syndrome mods and mortality <sep> apache ii score <sep> lactate clearance rate <sep> severe sepsis <sep> map arterial lac lactate clearance rate and apacheii score <sep>', 'release of pro-inflammatory cytokines il-6 and il-8 <sep> inflammatory response <sep> serum concentrations of sicam-1 <sep> serum concentrations of interleukin il)-6 il-8 and il-10 and soluble adhesion molecules selam-1 and sicam-1 <sep> biometric and perioperative data hemodynamics and oxygenation <sep> values of selam-1 <sep>', 'frequency of adult respiratory distress syndrome ards <sep> frequency of adult respiratory distress syndrome <sep>', 'tissue oxygen tension ptio(2 <sep> systemic hemodynamics and oxygenation pao(2 paco(2 <sep> tissue oxygenation <sep>', 'cop <sep> fluid balance total fluid infused sodium balance total sodium infused cop or cop-pcwp <sep> fluid balance <sep> operation time estimated blood loss and transfusions <sep> qt <sep> cop-pcwp <sep> pulmonary edema <sep> serum colloid osmotic pressure cop co pcwp the gradient between cop and pcwp cop-pcwp and intrapulmonary shunt qs/qt <sep> blood loss <sep>', 'malaria status <sep> 48-hour mortality <sep> severity of shock and status with respect to malaria coma sepsis acidosis and severe anemia <sep> clinical severity <sep> 4-week mortality <sep> neurologic sequelae <sep> pulmonary edema or increased intracranial pressure <sep> 48-hour mortality secondary end points included pulmonary edema increased intracranial pressure and mortality or neurologic sequelae at 4 weeks <sep> mortality <sep>', 'filling pressures of the heart and improved cardiac output <sep> filling pressures of the heart with improved cardiac output <sep> intrapulmonary venous admixture and improved pao2 <sep> fluid balance and cardiorespiratory functions <sep> diuresis <sep> cumulative fluid balance <sep> cardiorespiratory functions <sep>', 'worst multiple organ dysfunction score mods excluding the cardiovascular component to day 14 <sep> multiple organ dysfunction <sep> burden of mods <sep>', 'length of intensive care unit stay icu-los <sep> coagulation and fibrinolytic system <sep> icu-los <sep> levels of plasma pai <sep> prothrombin time pt activated partial thromboplastin time aptt and levels of plasma tissue plasminogen activator t-pa and plasminogen activator inhibitor pai <sep>', 'cop measure <sep> accuracy of colloid oncotic pressure cop <sep>', '28-day survival-hsd <sep> systolic blood pressure  70 mm hg or systolic blood pressure <sep> higher mortality <sep> superior 28-day survival <sep> 28-day survival <sep> survival <sep> blood transfusions <sep>', 'cop <sep> mean cop <sep> larger amounts of fluid <sep> plasma colloid osmotic pressure cop <sep>', 'blood pressure bp <sep> hemorrhagic shock <sep> urine output and improvement of the glasgow coma score <sep>', 'mortality coagulation or pruritus <sep> total quantity <sep> hemodynamic efficacy and safety <sep> adverse events <sep> icu and hospital los and area under the curve of sofa score <sep> acute renal failure <sep> time to reach hds <sep>', 'anaphylactoid reactions <sep> crossmatching of blood <sep> central pontine myelinolysis bleeding <sep>', 'severe bleeding <sep> risk of death <sep> death or end-stage kidney failure dependence on dialysis <sep>', 'left ventricular stroke work index <sep> cardiac index <sep> cardiac index <sep> plasma volume <sep> preload-recruitable cardiac and left ventricular stroke work indices <sep> plasma volume and global end-diastolic volume confirming plasma volume and preload augmentation <sep> biochemical variables and haemodynamics transpulmonary thermodilution <sep> cardiac response <sep> colloid osmotic pressure cop <sep>', 'perioperative blood loss sum of bleeding during the intraoperative and postoperative 24-h period transfusion requirements modified thromboelastography and coagulation variables hemodynamic parameters and fluid balance <sep> perioperative blood loss and coagulation profiles <sep> perioperative blood loss <sep> postoperative hemoglobin level <sep> degree and duration of coagulation impairment <sep> blood loss and coagulation <sep>', 'plasma oncotic pressure renal function and peripheral oedema <sep> renal and thromboembolic complications <sep> renal function and morbidity <sep> arm and thigh circumferences <sep> circulatory variables alveolo-arterial oxygen tension difference incidence of wound infection or postoperative restoration of intestinal activity <sep> serum albumin and plasma oncotic pressure <sep>', 'blood volume deficit <sep> pop fell <sep> postoperative lung function and circulatory adaptation <sep> cardiac filling pressures <sep> pop and mpaop <sep> pop mpaop pop-mpaop difference total sodium intake or net supply of non-colloid fluids <sep> mean pulmonary arterial occlusion pressure mpaop <sep> mean plasma oncotic pressure pop <sep> haemodynamic or lung function variables <sep>', 'oxygen delivery index <sep> ecfv <sep> plasma volume pv ecfv cardiac index and arterial oxygen content <sep> pv and ecfv <sep> baseline values for pv isfv ecfv and oxygen delivery index <sep> interstitial fluid volume isfv <sep>', 'mean arterial blood pressure map systolic and diastolic pressure central venous pressure cvp and pulmonary artery occlusion pressure paop <sep> physical parameters and hemodynamic variables <sep> cvp and paop <sep> hemodynamic response <sep>', 'hematocrit hemoglobin protein albumin blood urea nitrogen bun and creatinine <sep> oliguria during a course of therapy weight gain number of il-2 doses tachycardia hypotension vasopressor use hospital stay and clinical response rates <sep> albumin <sep> total protein <sep> total number of saline and albumin fluid boluses <sep> hypotension tachycardia and oliguria <sep>', 'subcutaneous oxygen tension and collagen accumulation <sep> total postoperative fluid support <sep> psco2 <sep>', 'maximum gradient of platelet aggregation <sep> maximum platelet aggregation <sep> postbypass blood loss <sep> platelet volume <sep> platelet function <sep> platelet function <sep> maximum aggregation maximum gradient of aggregation and platelet volume <sep> blood loss and change in platelet aggregation.(abstract truncated at 250 words <sep> platelet aggregation <sep>', 'evlwi pulmonary shunt fraction and time on mechanical ventilation <sep> total volume <sep> haemodynamic parameters and pulmonary function <sep> mean arterial pressure central venous pressure pulmonary capillary wedge pressure and cardiac index <sep> likewise chest tube drainage <sep> itbv <sep> haemodynamic stability <sep> total blood volume index tbvi intrathoracic blood volume index itb-vi and extravascular lung water index evlwi <sep> pulmonary function <sep>', 'extravascular lung water evlw  double indicator dilution technique <sep>', 'body weight <sep> total intravascular albumin <sep> plasma volume pv loss <sep> intraoperative urine volumes <sep> pulmonary artery occlusion pressure <sep> pv expansion <sep>', 'requirement for rescue colloid <sep> efficacy <sep> requirement for rescue colloid at any time after administration of the study fluid <sep> relative risk of requirement for rescue colloid <sep> time to initial recovery <sep> bleeding manifestations coagulation derangements and severity of fluid overload <sep> adverse reactions <sep>', 'thrombotic risk <sep> blood loss <sep> platelet function and hemostasis <sep> bleeding time <sep> activated partial thromboplastin time postsurgery <sep> thrombin/antithrombin iii complex prothrombin f1 2 fragment platelet activation betatg and compromised coagulation <sep> platelet activation platelet aggregation <sep>', 'tissue oxygenation <sep> splanchnic oxygenation <sep> arterial lactate acid concentration <sep> splanchnic blood flow and tissue oxygenation <sep> estimated blood losses ebl <sep> gastric intramucosal psco(2 and arterial paco(2 ps-aco(2 gap gastric intramucosal ph phi and arterial lactate acid concentration 30 min after induction of anesthesia baseline value 1 h and 2 h after skin incision and at the end of surgery <sep>', 'fluid retention <sep> fluid balance and pulmonary functions <sep> intrapulmonary venous admixture arterial oxygen tension or time on respirator <sep> serum colloid osmotic pressure <sep> cumulative fluid balance <sep> net lung capillary filtration pressure <sep>', 'change in aado2 <sep> gain of body weight <sep> postoperative plasma volume <sep> creatinine clearance values <sep> pulmonary arteriovenous admixture <sep> postoperative values of albumin concentration circulating albumin mass and pis <sep> plasma volume serum oncotic pressure pis serum albumin and total protein concentration alveolar to arterial oxygen tension differences aado2 fio2  1.0 creatinine clearance body weight and fluid and sodium intake <sep>', 'urine output <sep> serum albumin a/g ratio and colloid oncotic pressure <sep> colloid oncotic pressures serum albumin and albumin/globulin a/g ratios <sep> weight <sep> serum sodium <sep> sodium balances <sep>', 'systemic vascular resistances <sep> left ventricular preload and left ventricular ejection fraction <sep> cardiac index <sep> pulmonary capillary wedge pressure and ventricular arrhythmias <sep> adverse events <sep> ejection fraction <sep> left ventricular end-diastolic area <sep> hs-hes and hs <sep> plasma sodium <sep>', 'stat-crit accuracy <sep> hct using the stat-crit coulter and centrifuge methods and sodium na potassium k chloride cl white blood cell count total protein tp and albumin <sep>', 'longest recovery times <sep>', 'cardiac index colloid osmotic pressure cop pulmonary capillary wedge pressure pcwp cop-pcwp gradient right and left ventricular stroke work indices and amount of constant positive airway pressure <sep> intrapulmonary shunt qs/qt <sep>', 'cop <sep> plasma colloid osmotic pressure cop <sep> intestinal edema <sep>', 'plasma sodium content <sep> levels of urea and creatinine <sep> cardiac index <sep> larger diuresis <sep> positive balance <sep> pulmonary capillary wedge pressure <sep> cardiac index central venous pressure pulmonary capillary wedge pressure systemic and pulmonary vascular resistance indices arterial oxygen tension plasma osmolarity electrolytes and urinary output <sep> cardiorespiratory recovery with shorter extubation time <sep> plasma sodium content and cardiac index <sep> systemic vascular resistance index <sep> plasma creatinine urea electrolytes urinary volume and sodium excretion <sep> pulmonary vascular resistance index <sep> cardiac index with increasing pulmonary capillary wedge pressure <sep>', 'mortality rate <sep> percentage reduction in base deficit at 8 h. secondary end points included death the requirement for rescue therapies and neurological sequelae in survivors <sep> resolution of acidosis <sep>', 'pao2 <sep> etvl <sep> cardiac index <sep> perioperative weight gains <sep> pulmonary artery wedge pressure wp and the wp-cop gradient <sep> alveolar-arterial oxygen partial pressure difference <sep> next morning am1 cop <sep> colloid osmotic pressure cop <sep> wedge pressure <sep> transcapillary fluid flux <sep> pulmonary shunt fraction qsp/qt <sep> pulmonary extravascular thermal volume etvl <sep>', 'mechanical ventilation <sep> fluid balance major organ complications the acute physiology and chronic heath evaluation ii score and the serum levels of c-reactive protein interleukin-6 and interleukin-8 <sep> iap <sep> negative fluid balance <sep> risk of intra-abdominal hypertension <sep>', 'left ventricular stroke work index <sep> hydrostatic pressures <sep> hemodynamic stability <sep> stroke index <sep>', 'sequential organ failure assessment score mean arterial pressure lactate or central venous oxygen saturation <sep> sublingual capillary density <sep> sublingual microcirculation <sep> capillary microvascular flow index percent of perfused capillaries and perfused capillary density <sep> sublingual microcirculation <sep>', 'systolic blood pressure <sep> survival to hospital discharge <sep> low baseline glasgow coma scale scores <sep> baseline glasgow coma scale scores <sep> overall survival <sep> blood pressure <sep> survival <sep> blood pressure response survival <sep> survival <sep> survival to hospital discharge <sep>'], 'punchline_text': ['the proportion of patients with new single-organ and multiple-organ failure was similar in the two groups p=0.85). <sep>', ""blood pressure in the hypertonic/hyperoncotic group increased 49 mmhg during transport p less than 0.005 blood pressure in patients given lactated ringer's solution increased 19 mmhg ns). <sep>"", 'there was no difference in ventilatory parameters blood gases pulmonary function tests ventilator days or hospital days between the two groups. <sep>', 'there were significant increases in qs/qt and aado2 48 hours after operation in group 3. <sep>', 'both the hs-ns and hs-bs colloid groups had a significantly less frequent incidence of nausea and vomiting use of rescue antiemetics severe pain periorbital edema and double vision. <sep>', 'the measured lung water in each treatment group was significantly different from one another p less than 0.001). <sep>', 'in penetrating trauma maximum sequential organ function scores were lower with hes than with saline median 2.4 vs 4.5 p=0.012). <sep>', 'mortality rates were similar in the two groups p  0.725). <sep>', 'there was no significant correlation between left ventricular stroke work index and pwp in these patients either at the completion of resuscitation or during the following three days. <sep>', 'during knee replacement surgery a pronounced activation of the coagulation/fibrinolytic system was observed regardless of whether patients received crystalloid or colloid fluids. <sep>', 'there was a significant difference p  .03 in overall 30 days survival rate between hsd 73 and is 64 groups. <sep>', 'cardiac output and qs/qt increased in both groups. <sep>', 'infusion of 250 ml hypertonic saline solution in patients with severe hypovolemia was not related to any complications nor did it affect mortality rates it improved map significantly acutely expanded plasma volume by 24 and reduced significantly the volumes of crystalloids and blood required in their resuscitation. <sep>', 'both normal saline and gelatin polymer solution were equally effective as resuscitation fluid with respect to restoration of plasma volume and hemodynamic stability. <sep>', 'the 7.5 nacl solution significantly improved upon the predicted survival for the entire cohort and for high-risk patients when compared with the survival estimates from the triss methodology. <sep>', 'there was no significant difference in apache ii score between hs+hes group 13.2  1.9 and hes group 14.0  1.6 and the apacheii score in hs+hes group was significantly lower than that in rl group 15.2  1.7 p 0.01). <sep>', 'serum concentrations of interleukin il)-6 il-8 and il-10 and soluble adhesion molecules selam-1 and sicam-1 were measured after induction of anesthesia four hours after the end of surgery as well as 24 hr and 48 hr postoperatively. <sep>', 'the frequency of adult respiratory distress syndrome ards was significantly lower p less than 0.05 in the dextran group 0 of 12 than in the ringer group 4 of 11). <sep>', 'systemic hemodynamics and oxygenation pao(2 paco(2 did not differ significantly between the two volume groups throughout the study. <sep>', 'maximum decrease in cop was 40 p less than 0.001 in the rl group and was insignificant in the alb group. <sep>', 'the results were consistent across centers and across subgroups according to the severity of shock and status with respect to malaria coma sepsis acidosis and severe anemia. <sep>', 'despite reduced need for extra i.v. fluid and decreased cumulative fluid balance after hsd infusion the patients had increased filling pressures of the heart with improved cardiac output. <sep>', 'treatment with 5 percent albumin from day 0 to day 14 does not decrease the burden of mods in adult burn patients. <sep>', 'pt aptt and the levels of t-pa showed no significant differences between two groups at different time points but the levels of plasma pai g/l of the hes group decreased gradually and was significantly lower than that before resuscitation and rl group at 24 hours after resuscitation 41.76  25.95 vs. 89.11  14.27 55.08  35.43 both p  0.05). <sep>', 'there was high correlation r  0.951 between measured cop and values calculated from tpri in patients receiving hypertonic fluid colloid containing hypertonic fluid or no fluid:cop  4.08 tpri)--4.61. <sep>', 'there was no difference in 28-day survival-hsd 74.5 0.1 95 confidence interval ci 7.5 to 7.8 <sep>', 'one liter of saline resulted in a 12 decrease in cop p less than 0.05). <sep>', 'the differences between groups were significant throughout 24 h. urine output and improvement of the glasgow coma score were also higher in h/h patients than in the control group p less than 0.05). <sep>', 'there was no difference between akin and rifle criteria among groups and no difference in mortality coagulation or pruritus up to 90 days after treatment initiation. <sep>', 'there were no cases of central pontine myelinolysis bleeding was not potentiated. <sep>', ""at 90 days after randomization 201 of 398 patients 51 assigned to hes 130/0.42 had died as compared with 172 of 400 patients 43 assigned to ringer's acetate relative risk 1.17 95 confidence interval ci 1.01 to 1.36 p=0.03 1 patient in each group had end-stage kidney failure. <sep>"", 'colloid osmotic pressure cop decreased in the saline group and increased in the colloid groups p 0.001). <sep>', 'perioperative blood loss and coagulation profiles were similar between the groups but the postoperative hemoglobin level was higher in the crystalloid group. <sep>', 'there were no apparent differences in circulatory variables alveolo-arterial oxygen tension difference incidence of wound infection or postoperative restoration of intestinal activity between the groups. <sep>', 'there was no significant correlation between venous admixture on the one hand and pop mpaop pop-mpaop difference total sodium intake or net supply of non-colloid fluids on the other. <sep>', 'baseline values for pv isfv ecfv and oxygen delivery index did not differ between treatment groups. <sep>', 'the cvp and paop increased significantly more in the modified fluid gelatin resuscitation group. <sep>', 'although patients receiving saline boluses had significantly more oliguria during a course of therapy weight gain number of il-2 doses tachycardia hypotension vasopressor use hospital stay and clinical response rates did not significantly differ between arms. <sep>', 'in conclusion postoperative fluid substitution with dextran has no advantages over crystalloids only with regard to granulation tissue formation if postoperative fluid support is optimum according to psco2 measurements. <sep>', 'maximum platelet aggregation ranging from 23 to 44 relative from baseline value and maximum gradient of platelet aggregation ranging from 26 to 45 relative from baseline values were reduced only in the hmw-hes patients. <sep>', 'haemodynamic stability was achieved in both groups throughout the study period as judged from mean arterial pressure central venous pressure pulmonary capillary wedge pressure and cardiac index. <sep>', 'with regard to hemodynamic efficiency and the change in laboratory data no relevant differences between group i ii and iii could be seen. <sep>', 'total intravascular albumin decreased from 0.7 g/kg 1.4 to 0.7 g/kg in both groups corresponding to a plasma volume pv loss of 13 mg/kg without fluid infusions. <sep>', 'the primary outcome measure--requirement for rescue colloid--was similar for the different fluids in the two severity groups. <sep>', 'all three colloids led to a transient increase in activated partial thromboplastin time postsurgery and also a transient fall in the concentration of factor viii which were accompanied by a transient increase in bleeding time but there was no measurable increase in blood loss. <sep>', 'in patients undergoing major surgery volume resuscitation with medium molecular weight hes improves the splanchnic blood flow and tissue oxygenation. <sep>', 'patients in the colloid groups postoperatively had a higher serum colloid osmotic pressure s-cop but a higher net lung capillary filtration pressure delta p only on the second postoperative day than the rac group. <sep>', 'postoperative values of albumin concentration circulating albumin mass and pis were significantly greater in the albumin group in comparison to the electrolyte group. <sep>', 'ml/kg/per cent burn rl-colloid at 48 h p less than 0.01). <sep>', 'adverse events were observed only with hypertonic solution administration hypotensive episodes sudden increases in pulmonary capillary wedge pressure and ventricular arrhythmias. <sep>', 'the accuracy of the stat-crit hematocrit hct was compared to coulter and centrifuge methods in this study of the interrelationship between non-red cell blood constituents and accuracy of conductivity-based hct measurements. <sep>', ""all the children survived and there was no clear advantage to using any of the 4 fluids but the longest recovery times occurred in the lactated ringer's group. <sep>"", 'for the duration of the study and at 48 hours there was no statistically significant difference between groups with respect to the following cardiac index colloid osmotic pressure cop pulmonary capillary wedge pressure pcwp cop-pcwp gradient right and left ventricular stroke work indices and amount of constant positive airway pressure required for treatment. <sep>', ""the effects of intraoperative changes in plasma colloid osmotic pressure cop on the formation of intestinal edema were studied in patients during modified whipple's operation hemipancreato-duodenectomy). <sep>"", 'the group receiving saline solution had better cardiorespiratory recovery with shorter extubation time p  0.033 and earlier increase in cardiac index with a positive correlation between plasma sodium content and cardiac index. <sep>', 'there was no significant difference in the resolution of acidosis between the groups however the mortality rate was significantly lower among patients who received albumin 3.6 2 of 56 patients than among those who received saline 18 11 of 61 relative risk 5.5 95 confidence interval 1.2-24.8 p=.013). <sep>', 'pulmonary shunt fraction qsp/qt did not change in groups a and c but decreased during cpb in group h from 0.22  <sep>', 'in the hes group the iap was significantly lower in 2 to 7 days and fewer patients received mechanical ventilation 15.0 vs 47.6%). <sep>', 'after volume loading the stroke index increased in both groups but the left ventricular stroke work index increased in group 2 only. <sep>', 'sublingual capillary density was similar in both groups 21  8 versus 20  3 vessels/mm(2 but capillary microvascular flow index percent of perfused capillaries and perfused capillary density were higher in 6 hes 130/0.4 2.5  0.5 versus 1.6  0.7 84  15 versus 53  26 and 19  6 versus 11  5 vessels/mm(2 respectively p  .005). <sep>', ""survival to hospital discharge in patients with baseline glasgow coma scale scores of 8 or less was correlated with treatment group p  .05 by logistic regression and p  .01 by cox proportional-hazards analysis with survival in the hypertonic saline solution group 34 vs lactated ringer's solution group 12%]). <sep>""], 'population': ['6997 patients who underwent randomization 3497 were assigned to receive <sep> patients who had been admitted to the icu to receive either <sep> massachusetts medical society <sep> heterogeneous population of patients in the icu <sep>', 'injured patients in the field <sep>', ""41 patients 21 pentastarch 20 ringer's lactate presenting with hemorrhagic shock <sep> patients with hemorrhagic shock <sep>"", '24 patients scheduled for major abdominal aortic operations <sep>', 'ninety patients participated in the study with 30 patients in each group <sep> patients undergoing major elective noncardiac surgery <sep>', 'lung water following thermal injury 79 patients <sep>', 'blunt and penetrating trauma <sep> severely injured patients requiring 3 litres of fluid resuscitation <sep> a total of 115 patients were randomized of which 109 were studied <sep>', 'trauma patients admitted to the emergency room with hemorrhagic hypovolemia systolic blood pressure sbp  90 mmhg <sep> trauma patients <sep> patients with hemorrhagic hypovolemia <sep> hypovolemic trauma patients <sep>', 'trauma patients <sep> 20 patients suffering from multiple trauma and shock <sep>', 'patients undergoing knee replacement surgery randomly received <sep> orthopaedic patients <sep>', 'patients admitted to the emergency room with hemorrhagic hypovolemia in a prospective double-blind fashion <sep> patients n  212 <sep> patients admitted to the emergency room <sep> hypovolemic patients <sep>', '18 patients <sep>', 'one hundred five adult patients admitted in hypovolemic shock systolic blood pressure less than 80 mm hg <sep> patients admitted to the emergency room <sep> severe hypovolemia <sep> hypovolemic shock <sep>', 'pediatric emergency and intensive care unit of a tertiary care referral and teaching hospital <sep> sixty patients between 1 month to 12 years of age with septic shock without clinical evidence of organ failure at admission or underlying immunodeficiency <sep> pediatric septic shock <sep> pneumonia n  22 36 gut-associated sepsis n  13 and dengue hemorrhagic fever n  11 were the common primary diagnosis <sep> children with septic shock <sep> 31 patients <sep>', 'hypotensive trauma patients with 7.5 <sep> trauma patients transported by ambulance to the hospital with a systolic blood pressure of 90 mm hg or less were given 250 ml of 1 <sep> trauma patients with severe injuries <sep>', 'intensive care unit icu of the affiliated hospital of jianghan university <sep> one hundred and thirty five patients with severe sepsis <sep>', 'patients undergoing major abdominal surgery <sep> thirty-six patients scheduled for elective abdominal surgery <sep> 152 ng*ml(-1 <sep> patients undergoing major surgery <sep>', 'twenty-three patients aged 20-58 years in a serious state of shock and suffering from major pelvic and femoral fractures sustained in traffic accidents <sep> 12 patients received <sep> man after traumatic-haemorrhagic shock <sep> adult respiratory distress syndrome <sep> patients 460 <sep>', 'patients undergoing major abdominal surgery <sep> forty-two consecutive patients scheduled for elective major abdominal surgery <sep> patients undergoing major abdominal surgery a colloid-based with <sep>', '29 patients undergoing abdominal aortic surgery <sep>', 'children with severe febrile illness and impaired perfusion to receive <sep> critically ill children <sep> children with shock and life-threatening infections who live in resource-limited settings <sep> african children with severe infection <sep> halting recruitment after 3141 of the projected 3600 children in stratum a were enrolled <sep> children with severe hypotension <sep> children with malnutrition or gastroenteritis <sep>', 'twenty patients with 3-vessel coronary artery disease undergoing elective coronary artery bypass surgery were studied <sep> patients with impaired perfusion <sep>', 'forty-two patients were randomly assigned <sep> eligible adults 15 years suffering from thermal injury not more than 12 hours before enrollment received <sep> adult burn patients <sep>', 'forty-two consecutive patients with septic shock diagnosed between september 2009 and june 2011 <sep> patients with septic shock <sep> group with 22 patients <sep>', 'hypovolemia treated with halfd <sep> 38 critically burned patients with symptomatic hypovolemia being treated by <sep>', 'may 2006 to august 2008 114 emergency medical services agencies in north america within the resuscitation outcomes consortium <sep> 853 treated patients were enrolled among whom 62 were with blunt trauma 38 with penetrating <sep> injured patients with hypovolemic shock <sep> inclusion criteria injured patients age  15 years with hypovolemic shock <sep> after traumatic hypovolemic shock <sep>', '26 patients with hypovolemic circulatory shock <sep>', 'patients with hemorrhagic shock due to upper gastrointestinal bleeding <sep> 49 patients <sep>', 'severe sepsis patients <sep> 174 out of 196 patients reached hds 88 and 86 patients for hes and nacl respectively <sep> patients with severe sepsis <sep>', '106 critically injured patients in two prospective double-blinded emergency department trials <sep> traumatic shock <sep>', 'patients with severe sepsis assigned to <sep> 804 patients who underwent randomization 798 were included in the modified intention-to-treat population <sep> severe sepsis <sep> patients with severe sepsis <sep>', 'patients n=67 <sep> hypovolaemic hypotension after cardiac and major vascular surgery <sep>', 'patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery <sep> patients with recent exposure to dapt undergoing opcab <sep> patients with continued dapt within 5 days of opcab <sep> within 5 days of opcab <sep> patients undergoing off-pump coronary artery bypass surgery opcab <sep>', 'major surgery <sep> 30 adult patients undergoing elective major abdominal surgery <sep>', 'major surgery <sep> 18 patients subjected to reconstruction of the abdominal aorta <sep>', 'septic patients <sep> critically ill patients n  18 <sep> in septic critically ill patients <sep>', 'medical center university hospital in a surgical resuscitation room in the emergency department <sep> patients with traumatic or neurogenic shock <sep> emergency resuscitation of hypovolemic shock patients <sep> 34 patients with either hypovolemic or neurogenic shock who were admitted to the emergency room <sep> emergency room patients suffering from shock <sep>', 'patients receiving bolus il-2-based therapy for metastatic cancer <sep> 107 patients who completed one cycle of therapy on study 76 completed a full treatment course two cycles on study <sep>', 'surgical patients <sep> twenty-nine patients subjected to major abdominal surgery <sep>', 'patients undergoing cardiopulmonary bypass <sep> 60 patients undergoing elective aortocoronary bypass grafting using cardiopulmonary bypass cpb <sep> fifteen untreated patients served as a control <sep>', 'heart surgery <sep>', '55 patients undergoing elective aorto-coronary bypass surgery efficacy of a low concentrated hydroxyethylstarch 3 hes 200/0.5 was tested after <sep>', 'five patients had abdominal aneurysm 12 had aortic obstruction disease and three had aortic renal bypass surgery <sep> 20 consecutive patients undergoing elective aortic reconstructive surgery <sep> consecutive patients mean age 64 yr <sep>', '383 children with moderately severe shock to receive <sep> dengue shock syndrome <sep> vietnamese children with dengue shock syndrome <sep> children with moderately severe dengue shock syndrome <sep> 129 children with severe shock to receive one of the colloids <sep> children with severe shock <sep>', '55 patients undergoing primary unilateral total hip replacement <sep> elective hip surgery <sep> patients following major surgery <sep>', 'patients undergoing cytoreductive surgery for ovarian carcinoma <sep> patients with ovarian carcinoma <sep> patients undergoing major surgery volume resuscitation with <sep>', 'forty patients <sep>', 'abdominal aortic operations <sep> 16 patients undergoing abdominal vascular reconstructive procedures <sep>', 'severely burned children <sep> children and young people ranging in age from 5 months to 21 years with burns covering greater than or equal to 30 per cent of the body surface area <sep>', 'twenty-six patients who underwent mitral valve repair <sep> immediately after mitral valve repair <sep> patients who have undergone mitral valve repair postoperative infusion of <sep> postoperative mitral valve repair patients <sep> patients with valvular cardiomyopathy <sep> all patients included in the study were discharged from the hospital before the 10th postoperative day <sep> two patients were excluded during the study <sep>', '31 patients undergoing elective cardiac procedures <sep>', 'dengue shock syndrome <sep> 230 vietnamese children with dss <sep> asian children <sep> children presenting with lower pulse pressures who received one of the colloids <sep>', 'forty-six patients with severe pulmonary insufficiency <sep> patients with severe pulmonary insufficiency <sep>', ""eighteen patients asa physical status i or ii <sep> patients during modified whipple's operation hemipancreato-duodenectomy <sep> intestinal edema during gastrointestinal surgery <sep>"", 'early postoperative period after coronary artery bypass grafting <sep> in early postoperative period after coronary artery bypass surgery <sep>', 'patients with a base deficit of 15 mmol/l <sep> 150 children recruited for the trial 61 received saline 56 received albumin and 33 served as control subjects <sep> kenyan children with severe malaria <sep> children with severe falciparum malaria <sep> children with severe malaria <sep> children with severe malaria and metabolic acidosis base deficit 8 mmol/l to receive <sep>', 'index of pulmonary extravascular water after coronary artery bypass grafting <sep> pulmonary extravascular water in the postoperative period after coronary artery bypass grafting <sep>', 'severe acute pancreatitis <sep> forty-one patients with sap <sep> severe acute pancreatitis sap in early stages <sep>', '18 patients received 56 <sep>', 'septic patients <sep> patients with severe sepsis <sep>', 'injured patients with systolic blood pressures less than 90 mm hg at any time in the field or during helicopter transport <sep> hypotensive trauma patients <sep> injured patients with 7.5 <sep> trauma patients <sep>'], 'interventions': ['4 percent albumin or normal saline for intravascular-fluid resuscitation <sep> albumin and 3500 to receive saline <sep> albumin and saline <sep> fluid resuscitation with albumin or saline <sep> albumin or normal saline <sep>', 'nacl/dextran <sep>', ""pentastarch and lactated ringer's solution <sep>"", ""albumin and 5 dextrose <sep> dextrose in lactated ringer's solution intraoperatively <sep> 5 dextrose in water plus albumin group 2 received 5 dextrose in 0.45 sodium chloride solution and group 3 received 5 dextrose in lactated ringer's solution <sep>"", ""intraoperative colloid administration <sep> 6 hetastarch in saline hs-ns 6 hetastarch in balanced salt hs-bs or lactated ringer's solution lr <sep> colloid and crystalloid resuscitation <sep>"", ""crystalloid and colloid resuscitation <sep> lactated ringer's solution or 2.5 albumin-lactated ringer's solution <sep>"", 'hydroxyethyl starch <sep> saline vs hydroxyethyl starch hes <sep> hes <sep>', 'isotonic 0.9 nacl solution <sep> 10 pentastarch solution ps <sep> pentastarch solution <sep>', 'colloid resuscitation <sep> crystalloid resuscitation <sep>', ""perioperatively administered crystalloids and colloids <sep> isovolemic amounts of lactated ringer's solution 6 hydroxyethyl starch 200/0.5 or 4 modified gelatine <sep> crystalloid or colloid fluids <sep> crystalloid or colloid solutions <sep>"", 'crystalloid infusions <sep> hypertonic 7.5 nacl  6 dextran hsd n  101 or isotonic 0.9 nacl solutions <sep> hsd <sep> hypertonic/hyperoncotic solution <sep> hypertonic solution <sep> hypertonic solutions <sep>', ""ringer's lactate rl and a colloid containing salt solution plasmanate pl <sep> red blood cell replacement either rl or pl was infused 1 to maintain the cardiac output co equal to or greater than the preoperative value 2 to maintain the pulmonary capillary wedge pressure pcwp plus or minus 2 mmhg of preoperative values and 3 to keep the urinary output greater than or equal to 30 cc/hr <sep>"", 'isotonic solution <sep> 250 ml hypertonic saline solution <sep> hypertonic saline plus dextran <sep> bolus infusion of 7.5 nacl or 7.5 nacl plus 6 dextran <sep> hypertonic solution <sep> isotonic saline solution <sep> hypertonic saline solution <sep> hypertonic solutions <sep> hypertonic saline solution or hypertonic saline plus dextran <sep>', 'crystalloid normal saline and colloid polymer from degraded gelatin <sep> fluid resuscitation with crystalloid saline and colloid polymer from degraded gelatin in saline <sep> normal saline and gelatin polymer solution <sep> normal saline and 29 to gelatin polymer <sep> normal saline or polymer from degraded gelatin haemaccel <sep> normal saline upto 110 ml/kg and gelatin polymer solution <sep>', 'hypertonic saline combined with dextran <sep> normal saline ns 2 7.5 nacl hs for hypertonic saline or 3 7.5 nacl in 6 dextran 70 hsd <sep> nacl with added dextran <sep> nacl <sep>', 'hypertonic saline and hydroxyethyl starch <sep> hs+hes <sep> hypertonic saline hs and 6 hydroxyethyl starch hes <sep> lactated ringer solution <sep> hes <sep> hes 130/0.4 <sep>', ""fluid therapy <sep> il-8 <sep> intravascular volume replacement therapy <sep> il-6 <sep> hes <sep> 6 hydroxyethylstarch 130,000 dalton mean molecular weight degree of substitution 0.4 n  18 hes-group or lactated ringer's solution rl-group n  18 for intravascular volume replacement <sep>"", ""ringer's acetate alone <sep> dextran daily while the ringer group did not receive any colloidal solution <sep> dextran <sep> dextran 70 over ringer acetate solution <sep> crystalloid treatment to counteract shock <sep> dextran 70 1000-1500 ml together with ringer's acetate solution <sep>"", ""colloids versus crystalloids and tissue oxygen tension <sep> 6 hydroxyethyl starch hes <sep> hydroxyethyl starch hes <sep> hes 130/0.4 2920 <sep> intravascular volume replacement regimens <sep> crystalloid-based with lactated ringer's solution rl volume replacement regimen was compared regarding tissue oxygen tension ptio(2 measured continuously by microsensoric implantable catheters <sep> lactated ringer's solution rl n  21 for intravascular volume replacement <sep>"", 'alb <sep> hemodynamic resuscitation with protein-containing or balanced salt solution <sep> crystalloid vs. colloid resuscitation <sep>', 'fluid resuscitation <sep> boluses of 20 to 40 ml of 5 albumin solution albumin-bolus group or 0.9 saline solution saline-bolus group per kilogram of body weight or no bolus control group at the time of admission to a hospital in uganda kenya or tanzania stratum a <sep>', ""hypertonic saline and dextran <sep> extracorporeal circulation <sep> hsd infusion <sep> ringer's acetate solution <sep> hypertonic saline with dextran <sep> hsd or isotonic saline <sep> hypertonic saline <sep>"", ""albumin resuscitation <sep> 5 percent human albumin <sep> fluid resuscitation with ringer's lactate n=23 or 5 percent human albumin plus ringer's lactate n=19 by protocol to achieve recommended american burn association resuscitation endpoints <sep>"", 'lactate ringer solution rl versus hydroxyethyl starch 130/0.4 hes130/0.4 solution <sep> lactate ringer solution versus hydroxyethyl starch <sep> rl resuscitation group rl group with 20 patients and hes130/0.4 resuscitation group hes <sep>', ""ringer's lactate solution five receiving a hypertonic solution 240 mosm na and 26 receiving a hypertonic solution containing albumin <sep> intravenous fluids <sep>"", 'placebo <sep> hs <sep> initial resuscitation fluid 250 ml of either 7.5 saline per 6 dextran 70 hypertonic saline/dextran hsd 7.5 saline hypertonic saline hs or 0.9 saline normal saline ns <sep> hs or hsd <sep> hypertonic fluids <sep> hospital hypertonic resuscitation <sep> hypertonic fluids <sep>', 'saline resuscitation <sep> fluid resuscitation with 6 hetastarch 5 albumin or 0.9 saline solutions <sep> hetastarch <sep> colloid osmotic pressure and fluid resuscitation with hetastarch albumin and saline solutions <sep>', ""peripheral vein infusion of 250 ml of 7.5 nacl/6 dextran <sep> intravenous or intraosseous infusion of 250 ml of 7.5 nacl and 6 dextran 60 h/h was compared with intravenous ringer's lactate rl <sep> intravenous crystalloid solutions <sep> hypertonic saline dextran solution <sep>"", 'hes 130/0.4 and nacl <sep> hydroxyethylstarch 130/0.4 vs. 0.9 nacl fluid replacement <sep> hds <sep>', 'sodium chloride resuscitation <sep> sodium bicarbonate <sep> rapidly infusing 250 ml of either 7.5 sodium chloride or 7.5 sodium chloride per 6 dextran <sep>', ""hydroxyethyl starch hes corrected <sep> renal-replacement therapy <sep> fluid resuscitation with hes <sep> icu with either 6 hes 130/0.42 tetraspan or ringer's acetate <sep> ringer's acetate <sep> hydroxyethyl starch 130/0.42 versus ringer's acetate <sep>"", 'saline <sep> 90-min filling pressure-guided fluid challenge with saline 0.9 or the colloids gelatin 4 hydroxyethyl starch 6 or albumin 5 <sep> colloids or crystalloids <sep>', 'crystalloid infusion hes group n=53 or crystalloid only crystalloid <sep> clopidogrel and aspirin <sep> hydroxyethyl starch hes solutions <sep> hydroxyethyl starch <sep> hes <sep>', '20 albumin solution <sep>', 'infusion of 5 albumin and balanced salt solutions <sep>', 'normal saline or 5 albumin <sep> normal saline <sep> normal saline and 5 albumin infusions <sep>', ""rapid infusion of 1000 ml of modified fluid gelatin group a or 1000 ml of lactated ringer's solution <sep> lactated ringer's solution <sep> modified fluid gelatin <sep> additional central venous line or swan-ganz catheters <sep>"", 'maintenance crystalloid fluid administration <sep> dopamine <sep> interleukin-2 il-2)-based therapy <sep> colloid versus crystalloid resuscitation <sep> crystalloid 0.9 normal saline or colloid 5 human serum albumin fluid boluses <sep> crystalloid and colloid fluid resuscitation <sep> interleukin-2 therapy <sep>', 'subcutaneous oxygen tension measurements psco2 <sep> dextran and crystalloids <sep> crystalloids and colloids dextran 70 <sep> two tubes of expanded polytetrafluoroethylene eptfe <sep>', 'intravascular volume therapies <sep> albumin 810 <sep> hmw-hes <sep> hmw-hes 840 <sep> gelatin 950 <sep> lmw 850 <sep> gelatin or 5 albumin were infused preoperatively to double reduced filling pressure pulmonary capillary wedge pressure pcwp <sep> high-molecular weight hydroxyethyl starch solution hmw-hes mean molecular weight <sep> intravascular volume replacement <sep>', ""fluid therapy with ringer's solution versus haemaccel following coronary artery bypass surgery <sep> crystalloid and colloid infusion <sep> coronary artery bypass grafting <sep> ringer's solution group r to haemaccel <sep>"", 'new hydroxyethyl starch preparation <sep> 1,000 ml autologous washed erythrocytes cell saver and 400 ml fresh frozen plasma ffp <sep> extracorporeal circulation ecc <sep>', ""ringer's lactate with or without 3 dextran-60 <sep> solution of 3 dextran-60 d60 in ringer's lactate rl with rl alone <sep>"", ""ringer's lactate 6 percent dextran 70 a colloid or 6 percent hydroxyethyl starch a colloid <sep> ringer's lactate <sep> dextran 70 and 6 percent hydroxyethyl starch <sep> dextran <sep>"", 'intravenous fluids <sep> three colloids haemaccel gelofusine and albumin and also saline <sep> albumin infusion <sep>', ""medium molecular weight hydroxyethyl starch solution hes <sep> lactated ringer's solution lrs equal to three times the ebl lrs group n  22 or a volume of 6 hes equal to the ebl hes <sep> medium molecular weight hes <sep> lrs <sep> cytoreductive surgery <sep> volume replacement with hydroxyethyl starch solution <sep> hes <sep>"", ""ringer's acetate rac <sep> coronary artery bypass surgery ringer's acetate <sep> dextran polygeline or albumin <sep> rac polygeline 35 mg.ml-1 haemaccel dextran 70 <sep> coronary artery bypass cab surgery <sep> ringer's acetate <sep>"", 'albumin vs. electrolyte solutions <sep> albumin or a sodium-rich intraoperative fluid regimen <sep>', ""hypertonic lactated saline hls and ringer's lactate-colloid rl-colloid <sep> hypertonic lactated saline v. ringer's lactate-colloid <sep>"", 'hypertonic saline 7.2%-hydroxyethyl starch 6 molecular weight 200,000 hydroxyethylation ratio 0.5 solution hs-hes group hypertonic saline 7.2 solution hs group or hydroxyethyl starch 6 solution hes <sep> hypertonic solutions <sep> hypertonic or colloid infusions <sep> hypertonic saline and/or colloid solutions <sep> hypertonic saline solutions <sep>', 'isotonic crystalloid <sep> protein colloid replacement <sep> 5 albumin <sep> isotonic hemodilution and albumin administration <sep>', ""4 fluids dextran gelatin lactated ringer's and normal saline <sep> colloid and crystalloid <sep>"", 'crystalloid or colloid <sep> crystalloid versus colloid <sep>', ""lactated ringer's rl group n  6 10 hydroxyethyl starch hes group n  6 or 20 human albumin ha group n  6 as a volume replacement solution which was given to maintain central venous pressure cvp <sep> hes <sep> intraoperative fluid administration and colloid osmotic pressure <sep>"", 'saline solution <sep> gelatin <sep> gelatin infusion <sep> hypertonic saline solution compared with gelatin <sep> saline solution or gelatin <sep>', 'albumin or saline <sep> fluid resuscitation with either 4.5 albumin or normal saline <sep> albumin to saline <sep>', ""colloid or crystalloid <sep> lactated ringer's solution <sep> lactated ringer's solution intravenously and the cardiopulmonary bypass cpb circuit prime included 5 albumin <sep> 6 hydroxyethyl starch <sep> postoperative fluid management <sep> 5 albumin <sep>"", ""ringer's lactate rl <sep> hydroxyethyl starch hes <sep> 6 hes <sep> hydroxyethyl starch resuscitation <sep> hes <sep>"", ""dextran <sep> crystalloid <sep> ringer's acetate-gluconate solution with 6 dextran-70 <sep> prophylactic nitroglycerin <sep>"", 'hydroxyethyl starch hes <sep> hydroxyethyl starch 130/0.4 and saline solution <sep> normal saline solution ss <sep> ss <sep>', ""prehospital infusion of 250 ml of 7.5 sodium chloride <sep> 250 ml of a 7.5 sodium chloride solution both with and without added dextran <sep> lactated ringer's 2 7.5 sodium chloride hypertonic saline 3 7.5 sodium chloride combined with 6 dextran 70 and 4 7.5 sodium chloride combined with 12 dextran 70 <sep> hypertonic saline <sep> sodium chloride <sep> hypertonic saline solution without added dextran <sep> hypertonic saline solution <sep>""], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is no evidence from randomised controlled trials that resuscitation with colloids reduces the risk of death compared to resuscitation with crystalloids in patients with trauma burns or following surgery. furthermore the use of hydroxyethyl starch might increase mortality. as colloids are not associated with an improvement in survival and are considerably more expensive than crystalloids it is hard to see how their continued use in clinical practice can be justified.
281,"{'outcomes': ['adherence <sep> depressive psychopathology <sep> adherence and adherence levels <sep> completion of 28 days of pep <sep> overall adherence <sep>'], 'punchline_text': ['the intervention was associated with the reading of the pamphlet p=0.07 and an increased use of the diary p=0.01 but did not reduce depressive psychopathology. <sep>'], 'population': ['western and eastern cape and 279 rape survivors <sep>'], 'interventions': ['telephonic psycho-social support leaflet and adherence diary intervention <sep> telephonic psycho-social support <sep>'], 'punchline_effect': [' sig increase <sep>']}",we found only one rct with a moderate risk of bias which showed that providing pep support by phone calls did not result in higher adherence to pep. however the rct was conducted in an upper-middle-income country with high hiv prevalence on a high-risk population and the applicability of its results on other settings and contexts is unclear. there is a need for robust evidence from various settings on the effectiveness of using phone calls for providing pep support and for other hiv prevention interventions.
282,"{'outcomes': ['incidence of later candidiasis <sep> adverse response <sep>'], 'punchline_text': ['no adverse response to ceftazidime was noted and the incidence of later candidiasis was similar to that after other broad-spectrum antibiotic combinations. <sep>'], 'population': ['fifty-five infants less than 48 h old with suspected sepsis <sep> neonates less than forty-eight hours old <sep> 22 infants more than 48 h old with clinical evidence of sepsis <sep>'], 'interventions': ['penicillin and gentamicin <sep> ceftazidime or penicillin and gentamicin <sep> ceftazidime or gentamicin plus benzylpenicillin <sep> ceftazidime <sep> ceftazidime <sep>'], 'punchline_effect': [' no diff <sep>']}",there is no evidence from randomised trials to suggest that any antibiotic regimen may be better than any other in the treatment of presumed early neonatal sepsis. more studies are needed to resolve this issue.
283,"{'outcomes': ['barnes akathisia scale <sep> extrapyramidal symptoms <sep> clinical response <sep> mean change in simpson angus scale <sep> efficacy and tolerability <sep>'], 'punchline_text': ['olanzapine was superior to conventional neuroleptic haloperidol in treatment safety with lower frequency and severity of extrapyramidal symptoms. <sep>'], 'population': ['patients with amphetamine psychosis <sep> fifty-eight patients experiencing episode of amphetamine psychosis <sep> amphetamine psychosis <sep>'], 'interventions': ['conventional neuroleptic haloperidol <sep> haloperidol <sep> olanzapine <sep> olanzapine <sep> haloperidol n=29 in 1:1 olanzapine haloperidol ratio <sep> olanzapine with haloperidol <sep> olanzapines and haloperidol <sep>'], 'punchline_effect': [' sig increase <sep>']}",only one rct of treatment for amphetamine psychosis has been published. outcomes from this trial indicate that antipsychotic medications effectively reduce symptoms of amphetamine psychosis the newer generation and more expensive antipsychotic medication olanzapine demonstrates significantly better tolerability than the more affordable and commonly used medication haloperidol. there are other two studies that did not meet the inclusion criteria for this review. the results of these two studies show that agitation and some psychotic symptoms may be abated within an hour after antipsychotic injection. whether this limited evidence can be applied for amphetamine psychotic patients is not yet known. the medications that should be further investigate are conventional antipsychotics newer antipsychotics and benzodiazepines. however naturalistic studies of amphetamine psychotic symptoms and the prevalence of relapse to psychosis in the presence of amphetamine are also crucial for advising the development of study designs appropriate for further treatment studies of amphetamine psychosis.
284,"{'outcomes': ['peak expiratory flow pef <sep> mean sd urine sodium <sep> index of asthma lability <sep> peak expiratory flow <sep> sodium intake <sep> pef or pef amplitude <sep> pef measurements <sep> severity of bronchial asthma <sep> bronchial reactivity <sep> peak flow rate <sep>', 'lung function <sep> peak expiratory flow rate <sep>', 'regressing pd10 against urinary excretion of electrolytes <sep> fev1 pd20 <sep>', 'forced expiratory volume in 1 s fev1 <sep> forced vital capacity fvc forced expiratory flow rate at 25%-75 fvc and peak expiratory flow rate <sep> deterioration of post-exercise pulmonary function <sep> pre-exercise baseline pulmonary function <sep>', 'postexercise pulmonary capillary blood volume <sep> pre and postexercise spirometry pulmonary diffusion capacity dlco and its subdivisions and induced sputum <sep> fev1 <sep> dietary salt airway inflammation and diffusion capacity <sep> postexercise-induced sputum neutrophil and eosinophil differential cell counts and induced sputum supernatant concentration of eosinophil cationic protein interleukin il)-1beta il-8 leukotriene lt c(4)-e(4 ltb(4 and prostaglandin d(2 <sep>', 'postexercise pulmonary function values <sep> forced vital capacity and peak expiratory flow rates <sep> forced expiratory volume in 1 s fev1 <sep> preexercise pulmonary function values <sep> fev1 <sep> pulmonary function <sep> lsd improved and hsd worsened postexercise pulmonary function values <sep> pulmonary function <sep> exercise-induced asthma eia <sep>', 'symptom score <sep> peak expiratory flow rate <sep> deleterious alterations <sep> bronchial reactivity and mortality <sep> morbidity <sep> diary cards to record twice daily peak expiratory flow rates daily symptom scores and bronchodilator consumption <sep> evening peak expiratory flow rate <sep> bronchodilator consumption <sep> spirometry and degree of bronchial responsiveness methacholine challenge test <sep> mean forced expiratory volume <sep> bronchial reactivity rose on slow sodium <sep> urinary sodium excretion <sep>'], 'punchline_text': ['there were no significant differences in pef or pef amplitude highest--lowest pef an index of asthma lability between the three dietary salt periods. <sep>', 'statistical analysis showed that salt loading worsened symptoms p  0.06 and increased the use of inhaled steroids p  0.05). <sep>', 'the dose of histamine causing a 20 fall in fev1 pd20 was 1.51 doubling doses lower when the men were taking sodium than when they were taking placebo p less than 0.05). <sep>', 'similar patterns were observed for forced vital capacity fvc forced expiratory flow rate at 25%-75 fvc and peak expiratory flow rate. <sep>', 'however postexercise pulmonary capillary blood volume significantly increased p  0.05 by 6.3 and 9.6 ml on nsd and hsd respectively compared with baseline values with no significant change p  0.05 being observed on lsd. <sep>', 'diet had no effect on preexercise pulmonary function values in either group and had no effect on postexercise pulmonary function values in control subjects. <sep>', 'median differences between treatments were 5.6 2.2 to 9.8 for morning and 7.8 3.9 to 12.9 for evening peak expiratory flow rate. <sep>'], 'population': ['patients with mild asthma <sep> 17 patients with mild asthma <sep> men with asthma <sep>', 'patients with bronchial asthma <sep> patients with asthma <sep>', '36 subjects having a low sodium diet <sep>', 'subjects with exercise-induced asthma eia <sep> control subjects <sep> eia subjects <sep> eight subjects who suffered from eia and eight subjects who did not control took part in a double-blind crossover study <sep>', 'asthmatic subjects <sep> asthmatic patients <sep>', 'eight subjects with eia and eight subjects without eia control <sep> eia subjects <sep> subjects with eia <sep> exercise-induced asthma <sep> persons with asthma <sep>', 'twenty seven mild to moderate asthmatic patients <sep> male asthmatic patients <sep> asthma in men <sep> adult male asthmatic patients <sep> twenty two patients completed the study <sep>'], 'interventions': ['changing dietary salt intake <sep> dietary sodium <sep>', ""salt loading  6.1 <sep> sodium citrate in nearly equimolar concentrations  140  40 ml shohl's solution   120  30 mmol na <sep>"", 'slow sodium <sep> changing dietary sodium <sep> placebo <sep> histamine <sep>', 'low nacl diet lsd low sodium low chloride or a sodium bicarbonate diet nahco3 diet high sodium low chloride <sep> dietary sodium chloride nacl <sep> low sodium low chloride diet and a high sodium low chloride diet <sep> normal nacl diet nsd <sep> dietary sodium or chloride <sep>', 'dietary salt loading <sep> low-salt diet lsd or high-salt diet hsd <sep> normal salt diet nsd <sep>', 'elevated and restricted salt diets <sep> lsd <sep> dietary salt restriction <sep> normal salt sodium chloride diet nsd a low salt diet lsd and a high salt diet hsd <sep>', 'dietary salt consumption <sep> placebo <sep> placebo sodium supplementation <sep> dietary sodium <sep> low sodium diet <sep> 200 mmol/day slow sodium or matching placebo <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",this review did not find any evidence that dietary sodium reduction significantly improves asthma control. although dietary sodium reduction may result in improvements in lung function in exercise-induced asthma the clinical significance of this effect is unclear.
285,"{'outcomes': ['mean shoulder score <sep> shorter operative time <sep> lower complication rate <sep> smaller wound size <sep>', 'rate of delayed union <sep> peri-operative outcome index delayed union revision surgery and symptoms beyond 16 weeks <sep>'], 'punchline_text': ['knowles pinning requires significantly shorter operative time p<.001 smaller wound size p<.001 shorter hospital stay p=.03 less meperidine use p=.02 lower complication rate p=0.04 and less symptomatic hardware p=.015). <sep>', 'the superior plate group had a higher rate of delayed union and had more symptomatic patients than the 3d group p  0.05). <sep>'], 'population': ['elderly patients <sep> 62 elderly patients <sep> 62 elderly patients 50 years with midclavicular fractures <sep>', 'patients with displaced fractures of the clavicle treated by open reduction and fixation by a reconstruction plate which was placed either superiorly or three-dimensionally <sep> between 2003 and 2006 133 consecutive patients with a mean age of 44.2 years 18 to 60 with displaced midshaft fractures of the clavicle <sep>'], 'interventions': ['pin versus plate <sep> knowles pins and plates <sep>', 'ct <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>']}",there is limited evidence from single trials only regarding the effectiveness of different methods of surgical fixation of fractures and non-union of the middle third of the clavicle.
286,"{'outcomes': ['signs and symptoms of tmd <sep> pantographic reproducibility index pri <sep> clicking and pain <sep> signs and symptoms of temporomandibular disorders <sep> prevalence of tmd <sep>', 'number of sb episodes <sep> muscle activity <sep> efficacy and safety <sep>', 'wear facets <sep> nocturnal bite plate <sep>', 'number of bruxism episodes per hour of sleep epi/h the number of bursts per hour bur/h and the bruxism time index <sep> sb outcome variables <sep> sleep bruxism <sep>'], 'punchline_text': ['the occlusal splint and tens did not significantly improve the signs and symptoms of tmd in these patients with bruxism. <sep>', 'a statistically significant reduction in the number of sb episodes per hour decrease of 41 p  0.05 and sb bursts per hour decrease of 40 p  0.05 was observed with the two devices. <sep>', 'on the other hand of the 5 children that used nocturnal bite plate showed no increase of wear facets even after the removal of the device. <sep>', 'neither occlusal stabilization splints nor palatal splints had an influence on the sb outcome variables or on the sleep variables measured on a group level. <sep>'], 'population': ['patients with bruxism <sep> 24 patients with bruxism <sep>', 'tooth-grinding subjects <sep> nine subjects with sleep bruxism sb <sep>', 'children with bruxism <sep> 3 to 5 year old children <sep>', 'group n  11 mean age  34.2 <sep> twenty-one participants <sep> 13.1 years or a palatal splint ie an acrylic palatal coverage group n  10 mean age  34.9 <sep>'], 'interventions': ['occlusal splint with transcutaneous electric nerve stimulation tens <sep> occlusal splint and transcutaneous electric nerve stimulation <sep>', 'occlusal splint os vs. a palatal control device pcd <sep> occlusal splints <sep> oral splint devices <sep>', 'nocturnal bite plate <sep>', 'occlusal splint <sep> occlusal stabilization splints <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",there is not sufficient evidence to state that the occlusal splint is effective for treating sleep bruxism. indication of its use is questionable with regard to sleep outcomes but it may be that there is some benefit with regard to tooth wear. this systematic review suggests the need for further investigation in more controlled rcts that pay attention to method of allocation outcome assessment large sample size and sufficient duration of follow up. the study design must be parallel in order to eliminate the bias provided by studies of cross-over type. a standardisation of the outcomes of the treatment of sleep bruxism should be established in the rcts.
287,"{'outcomes': ['d-dimer <sep> hemostatic system activation <sep>', 'recurrent venous thromboembolism <sep> therapeutic anticoagulant response <sep> initial anticoagulant response <sep>', 'retroperitoneal or intramuscular bleedings <sep> non-fatal pulmonary emboli <sep>', 'episodes of major bleeding <sep> recurrent thromboembolic events <sep> overall mortality <sep> incidence of major bleeding <sep>', 'deep vein thrombosis <sep> thrombus size <sep> symptomatic non-fatal pulmonary embolism and one major bleeding episode <sep> mean phlebographic score <sep>', 'minor bleedings <sep> rate of symptomatic pulmonary embolism <sep> therapeutic efficiency <sep> major bleeding <sep> thrombosis of deep veins of the lower extremities <sep> deep vein thrombosis <sep>', 'recurrent venous thromboembolism <sep> major bleeding <sep>', 'pulmonary embolism lh and only 1 minor bleeding episode uh <sep>', 'fatal pulmonary embolism <sep> thromboembolic complications <sep> pain and edema <sep>', 'hemorrhagic complications <sep> frequency of hemorrhagic complications <sep> pulmonary embolism <sep> efficacy and safety <sep> rate of new pulmonary embolism <sep>', 'thrombus size <sep> incidence of serious complications <sep> complete lysis <sep> safety and efficacy <sep>', 'incidence of pulmonary embolism and of bleeding complications <sep> bleeding complications <sep> maximal venous outflow mvo <sep> median improvement of mvo and vc <sep> clinical pulmonary embolism <sep> mvo <sep>', 'hospital stay <sep> recurrent or extension of dvt bleeding the number of days spent in hospital and costs of treatments <sep> recurrence or extension of dvt <sep> hospital stay <sep> average treatment costs <sep> bleedings <sep>'], 'punchline_text': ['significant associations were observed between f1+2 and tat r=.66 p<.001 tat and d-dimer r=.36 p<.005 and f1+2 and d-dimer r=.30 p<.050). <sep>', 'intermittent subcutaneous heparin as administered in this trial was inferior to continuous intravenous heparin in preventing recurrent venous thromboembolism. <sep>', 'retroperitoneal or intramuscular bleedings occurred in four patients two in each group. <sep>', 'few reports have addressed the value of unfractionated heparin ufh or low-molecular-weight heparin in treating the full spectrum of patients with venous thromboembolism vte including recurrent vte and pulmonary embolism. <sep>', 'it is concluded that subcutaneous fixed dose fraxiparine is safe and at least as effective as subcutaneous adjusted ufh in the treatment of deep vein thrombosis. <sep>', 'no significant difference was observed in the therapeutic efficiency as judged by phlebographic examinations and in rate of symptomatic pulmonary embolism between the two groups. <sep>', 'recurrent venous thromboembolism occurred in 13 patients in the unfractionated heparin group 3.8 compared with 12 patients in the low-molecular-weight heparin group 3.4 absolute difference 0.4 95 confidence interval 2.6 to 3.3%). <sep>', 'there was 1 incidence of pulmonary embolism lh and only 1 minor bleeding episode uh). <sep>', 'as judged by repeated thrombin time determination anticoagulation was ineffective on at least one day in 39 of patients treated subcutaneously and in 60 of patients treated intravenously. <sep>', 'five of forty-seven patients in the subcutaneous group and 5 of 49 in the intravenous group developed pulmonary embolism 95 confidence interval ci for the difference 13.1 to 12.2%). <sep>', 'there were no significant differences between the two groups in the incidence of serious complications although almost half of those receiving intravenous heparin had some minor problem with the constant infusion pump and just over half of those receiving subcutaneous heparin had some bruising at the injection site. <sep>', '9 major bleeding complications occurred in the intravenous group 1 fatal and 5 in the subcutaneous group 1 fatal). <sep>', 'hospital stay in patients treated with lmwh was 1.2+/-1.4 days in comparison with 5.4+/-1.2 in those treated with standard heparin. <sep>'], 'population': ['59 consecutive patients with deep vein thrombosis dvt <sep>', '115 patients with acute proximal deep-vein thrombosis <sep> proximal-vein thrombosis <sep>', 'one-hundred and forty-one patients with clinical signs of acute deep venous thrombosis dvt in the legs <sep> patients with deep-vein thrombosis <sep>', 'patients with venous thromboembolism vte including recurrent vte and pulmonary embolism <sep> 720 consecutive patients with acute symptomatic vte including 119 noncritically ill patients 16.5 with pulmonary embolism and 102 14.2 with recurrent vte <sep>', '149 consecutive patients with phlebographically proven proximal and/or distal deep vein thrombosis of the leg <sep>', 'ninety-four patients with deep vein thrombosis of inferior limbs <sep>', 'patients with acute venous thromboembolism <sep> 708 patients aged 18 years or older with acute venous thromboembolism from 6 university-affiliated clinical centers in canada and new zealand conducted from september 1998 through february 2004 <sep> acute treatment of venous thromboembolism <sep>', 'deep venous thrombosis <sep> patients with phlebographically proven deep venous thrombosis dvt <sep>', '23 patients <sep> 48 patients with acute deep venous thrombosis of the lower limbs <sep>', 'patients <sep> acute deep vein thrombosis <sep> setting university-affiliated general hospital <sep> 111 consecutive patients considered 103 had acute proximal or calf vein thrombosis confirmed by ascending venography and met all other eligibility criteria <sep> patients with acute deep vein thrombosis <sep> acute proximal deep vein thrombosis <sep>', '49 patients who received <sep> one hundred patients with phlebographically proved acute deep vein thrombosis of the legs <sep> 47 patients who received <sep> established acute deep vein thrombosis of the legs <sep>', '271 patients with acute symptomatic deep venous thrombosis of lower limbs confirmed by strain-gauge plethysmography and/or venography <sep>', '294 patients with acute proximal dvt deep venous thrombosis <sep> 325 patients included 294 completed the study <sep>'], 'interventions': ['prothrombin fragments f1+2 thrombin-antithrombin complexes tat <sep> subcutaneous uh <sep> f1+2 and tat <sep> subcutaneous unfractionated heparin uh administered in two to three subcutaneous doses adjusted to activated partial thromboplastin time aptt or with low-molecular weight heparin lmwh dalteparin <sep> subcutaneous unfractionated or low-molecular weight heparin <sep>', 'intermittent subcutaneous heparin <sep> heparin <sep> heparin with intermittent subcutaneous heparin <sep>', 'heparin <sep>', 'oral anticoagulant therapy <sep> subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin <sep> subcutaneous ufh with dose adjusted by activated partial thromboplastin time by means of a weight-based algorithm preceded by an intravenous loading dose or fixed-dose adjusted only to body weight subcutaneous nadroparin calcium <sep> unfractionated heparin ufh <sep> subcutaneous ufh <sep> ufh <sep>', 'fraxiparine <sep> low molecular weight heparin cy 216 fraxiparine in a fixed dose or unfractionated heparin ufh <sep> ufh <sep> subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin <sep>', 'intravenous heparin <sep> sodium salt of heparin <sep> sodium heparin <sep> subcutaneous heparin <sep>', 'unfractionated heparin <sep> fixed-dose subcutaneous unfractionated heparin <sep> unfractionated heparin <sep> heparin <sep> low-molecular-weight heparin dalteparin or enoxaparin <sep> fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin <sep>', 'subcutaneous heparin <sep> unfractionated heparin uh n  27 or low molecular weight heparin lh <sep> unfractionated and low molecular weight heparin <sep> heparin <sep> lh <sep> subcutaneous heparin <sep> uh or lh <sep>', 'heparin <sep> sodium heparin <sep>', 'calcium heparin <sep> heparin <sep> adjusted subcutaneous calcium heparin <sep> subcutaneous or intravenous heparin <sep>', 'subcutaneous calcium heparin <sep> subcutaneous calcium heparin <sep> sodium heparin <sep> subcutaneous calcium heparin versus intravenous sodium heparin <sep> heparin <sep> subcutaneous heparin <sep> intravenous sodium heparin <sep>', 'subcutaneous vs intravenous heparin <sep> intermittent subcutaneous heparin calcium or heparin sodium <sep> heparin <sep> subcutaneous intermittent heparin <sep> heparin <sep>', 'standard heparin <sep> lmwh heparin <sep> intravenous standard heparin <sep> low-molecular-weight heparin lmwh nadroparin 0.1 ml equivalent to 100 axa iu per kg of body weight subcutaneously twice daily administered primarily at home outpatients or alternatively in hospital 97 patients or subcutaneous calcium heparin schep <sep> standard heparin or lmwh <sep> schep <sep> heparin <sep> lmwh <sep> lmwh and schep <sep> low-molecular-weight heparin administered primarily at home with unfractionated heparin <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",subcutaneous unfractionated heparin for the treatment of venous thromboembolism cannot be considered non-inferior to other treatment modalities in terms of recurrent dvt and pe at three months but seems as safe and effective with regards to rates of major bleeding and death.
288,"{'outcomes': ['maternal mood and mother-infant interaction <sep> rates of depression <sep> clinical global impression cgi and the hamilton depression scale measured recovery <sep> edinburgh postnatal depression scale the beck depression inventory and the hamilton depression rating scale <sep>'], 'punchline_text': ['the interpersonal psychotherapy treatment group showed significant improvement compared to the parenting education control program on all three measures of mood at termination. <sep>'], 'population': ['pregnant women with chronic stressors <sep> for antepartum depression to a parenting education control program <sep> thirty-eight women remained in the study and were included in the data analysis <sep> depressed pregnant women <sep> fifty outpatient antepartum women who met dsm-iv criteria for major depressive disorder <sep>'], 'interventions': ['apa <sep> interpersonal psychotherapy versus parenting education program <sep> interpersonal psychotherapy <sep> interpersonal psychotherapy or a didactic parenting education program <sep> interpersonal psychotherapy treatment <sep> interpersonal psychotherapy <sep>'], 'punchline_effect': [' sig increase <sep>']}",the evidence is inconclusive to allow us to make any recommendations for interpersonal psychotherapy for the treatment of antenatal depression. the one trial included was too small with a non-generalisable sample to make any recommendations. note the 12 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
289,"{'outcomes': ['myocardial injury <sep> saccadic latency deterioration <sep> serum troponin <sep> saccadic latency deteriorations <sep>', 'rates of renal impairment or major adverse cardiac events <sep> urinary biomarkers of renal injury <sep> serum and urinary markers of renal and cardiac injury <sep> median urinary albumin:creatinine ratio <sep> urinary retinol binding protein rbp levels <sep>', 'urinary retinol binding protein rbp and albumin-creatinine ratio acr <sep> renal outcome indices <sep> renal injury <sep> median urinary rbp <sep> median urinary rbp level <sep> preoperative urinary rbp <sep> renal damage <sep>', 'cardiac troponin <sep> protective effect of ripc on myocardial injury <sep> postoperative myocardial injury myocardial infarction and renal impairment <sep> myocardial injury <sep> incidence of myocardial injury <sep> myocardial infarction <sep> renal impairment <sep> incidence of myocardial and renal injury <sep>'], 'punchline_text': ['although there were fewer saccadic latency deteriorations in the ripc arm this did not reach statistical significance 32 versus 53 p  .11). <sep>', 'urinary retinol binding protein rbp levels increased 10-fold from a median of 235 micromol/l to 2356 micromol/l at 24 hours p  0.0001). <sep>', 'although control patients median urinary rbp level was 5 times greater at 3 hours there were no statistically significant differences in renal outcome indices. <sep>', 'in patients undergoing elective open abdominal aortic aneurysm repair ripc reduces the incidence of postoperative myocardial injury myocardial infarction and renal impairment. <sep>'], 'population': ['70 patients were randomized of whom 55 completed the neurological surveillance protocol <sep> patients with cea <sep> carotid endarterectomy <sep>', 'eighteen patients mean age 74 years range 72-81 <sep> forty patients all men mean age 76+/-7 years with abdominal aortic aneurysms averaging 6.3+/-0.8 cm in diameter were enrolled in the trial from november 2006 to january 2008 <sep> patients undergoing elective evar <sep> twenty-two patients mean age 76 years range 66-80 <sep>', 'renal protection during elective open infrarenal abdominal aortic aneurysm repair <sep> elective open infrarenal abdominal aortic aneurysm aaa repair <sep> elective open aneurysm surgery <sep>', 'abdominal aortic aneurysm repair <sep> patients undergoing elective open abdominal aortic aneurysm repair <sep> myocardial and renal injury after elective abdominal aortic aneurysm repair <sep>'], 'interventions': ['remote ischemic preconditioning <sep> carotid endarterectomy cea <sep> ripc <sep> remote ischemic preconditioning ripc <sep>', 'remote ischemic preconditioning <sep> remote ischemic preconditioning ip <sep> endovascular aneurysm repair <sep> remote preconditioning <sep>', 'remote ischemic preconditioning <sep> remote ischemic preconditioning ip <sep> sequential common iliac clamping <sep>', 'remote ischemic preconditioning <sep> abdominal aortic aneurysm repair with ripc or conventional abdominal aortic aneurysm repair control <sep> remote ischemic preconditioning ripc <sep> remote preconditioning <sep> ripc <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",based on current evidence from small pilot trials there are too few data to be able to say whether remote ischaemic preconditioning has any beneficial or harmful effects. the safety of this technique needs to be confirmed in adequately powered trials. therefore further randomised trials on this technique are required.
290,"{'outcomes': ['cumulative acetylsalicylic acid requirements <sep> pain scores vas <sep>', 'pain level amount of oral intake or pain on full jaw opening <sep> adverse effects <sep> pain medication <sep> pain level 2 oral intake 3 number of pain medication doses and 4 level of pain on jaw opening <sep>', 'analgesia <sep> visual analogue pain scores <sep> pain scores <sep> pain <sep> postoperative analgesic consumption <sep>', 'pain relief <sep> postoperative pain relief <sep>', 'visual analogue scale vas <sep> supplementary analgesic consumption <sep> global vas pain scores <sep> postoperative pain <sep> pain scores <sep> quality of postoperative analgesia <sep>'], 'punchline_text': ['there were no significant differences between groups in pain scores vas at rest or during drinking of 100 ml of water as measured at 4 h postoperatively or on the 1st 2nd 3rd and 8th postoperative days. <sep>', 'no difference was noted in pain level amount of oral intake or pain on full jaw opening. <sep>', 'visual analogue pain scores measured during swallowing in the recovery room and on the ward postoperatively were significantly less overall in uvulopalatoplasty patients who had received a block p  0.004). <sep>', 'the efficacy of benzydamine hydrochloride difflam spray to relieve pain from postoperative tonsillectomy was assessed but it was found that it did not relieve the symptoms after operation when compared to matching placebo. <sep>', 'global vas pain scores were lower in the groups treated with bupivacaine infiltration during the first 24 h after surgery p  0.05). <sep>'], 'population': ['thirty-five healthy patients aged 15-36 years scheduled for bilateral tonsillectomy <sep> pain after tonsillectomy <sep>', 'fifty-one patients undergoing tonsillectomy with local anesthesia <sep> adult population <sep> adult local tonsillectomy <sep> adult patients undergoing local tonsillectomy <sep> pediatric patients undergoing tonsillectomy <sep>', '30 patients undergoing uvulopalatoplasty and 38 of 78 patients having tonsillectomy received bilateral glossopharyngeal nerve blocks using <sep> pain after elective adult tonsillectomy and uvulopalatoplasty <sep>', 'after tonsillectomy <sep>', 'after tonsillectomy <sep> patients undergoing tonsillectomy <sep> 68 consecutive healthy patients ranging in age from 8 to 65 years <sep>'], 'interventions': ['bupivacaine <sep> placebo <sep> morphine <sep> tonsillar infiltration with 0.25 bupivacaine 5 min before surgical incision <sep> isotonic saline <sep> bupivacaine postoperative bupivacaine <sep>', 'bupivacaine <sep> bupivacaine <sep> placebo <sep> bupivacaine hydrochloride and saline placebo <sep> bupivacaine or saline placebo <sep>', 'glossopharyngeal nerve block and intravenous morphine <sep> morphine alone <sep> elective adult tonsillectomy and uvulopalatoplasty <sep> bupivacaine 0.5 and adrenaline 1:200,000 or no intervention <sep> glossopharyngeal nerve block <sep>', 'placebo <sep> benzydamine hydrochloride spray <sep> benzydamine hydrochloride difflam spray <sep>', 'bupivacaine <sep> acetaminophen <sep> pre vs postoperative tonsillar infiltration with local anesthetics <sep> normal saline <sep> peritonsillar infiltration with 0.25 bupivacaine <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",there is no evidence that the use of perioperative local anaesthetic in patients undergoing tonsillectomy improves post-operative pain control. the trials identified were of small size and several involved the perioperative co-administration of intravenous opiates which may have masked any beneficial effect of the local anaesthetic. further randomised controlled trials are necessary.
291,"{'outcomes': ['number of high-risk <sep>'], 'punchline_text': ['the option of telephone notification significantly increased the proportion of youth who received posttest counseling and results following community-based testing. <sep>'], 'population': ['adolescents most likely to receive their results were female older 19-24 years and white and those who reported high-risk behaviors <sep> high-risk youth <sep> 351 youth who were tested 48 followed up to receive test results and posttest counseling <sep>'], 'interventions': ['posttest counseling either in a face-to-face manner or with the option of telephone notification <sep> telephone vs. face-to-face notification <sep> oral hiv testing and counseling <sep>'], 'punchline_effect': [' sig increase <sep>']}",we found only one eligible study. although this study showed the use of the telephone for hiv test results notification was more effective than face-to-face delivery it had a high-risk of bias. the study was conducted about 13 years ago in a high-income country on a high-risk population with low hiv prevalence and the applicability of its results to other settings and contexts is unclear. the study did not provide information about telephone hiv test results notification of hiv positive people since none of the intervention group participants were hiv positive. we found no information about the acceptability of the intervention to patients and providers its economic outcomes or potential adverse effects. there is a need for robust evidence from various settings on the effectiveness of telephone use for hiv test results notification.
292,"{'outcomes': ['bioavailability of itraconazole <sep> clinical response rates <sep> lower response rate <sep> safety and efficacy <sep> relapse <sep> efficacy and safety <sep>', 'likely to remain asymptomatic <sep> elevated serum glutamic-oxaloacetic transaminase levels <sep>', 'mild adverse events <sep> clinical cure <sep> clinical efficacy and tolerability <sep> candida albicans maximum recorded plasma d0870 concentration cfu of culture or cd4 cell count <sep>', 'efficacy safety and tolerability <sep> efficacy <sep>', 'histoplasmosis and cryptococcosis <sep> prophylaxis failure due to recurrent or refractory mucosal candidiasis <sep> invasive fungal infections <sep> failure of prophylaxis <sep> tolerated <sep> survival benefit <sep> delayed time to onset of histoplasmosis <sep>', 'percentage of patients with negative cultures <sep> oropharyngeal candidiasis erythema soreness/burning extent of oral lesions and the presence/absence of candida species on fungal culture <sep> efficacy <sep> negative culture plus clinical response <sep>', 'efficacy and safety <sep> soreness change in taste erythema removable white plaque and extent of lesions <sep>', 'clinical success cure or improvement <sep> durability of clinical success <sep> mycological success <sep> adverse events <sep> clinical success <sep> clinical relapse <sep>', 'safety and efficacy <sep>', 'gastrointestinal disorders and drug-related adverse events <sep> clinical response rate <sep> dysphagia <sep> tolerated <sep> microscopy time to cure symptom scores and safety outcomes <sep> efficacy and safety <sep>', 'resistance <sep> safety and effectiveness <sep> absolute risk reduction <sep> oropharyngeal candidiasis <sep> vaginal candidiasis <sep> episode of candidiasis <sep> safe and effective in preventing oropharyngeal and vaginal candidiasis <sep> esophageal candidiasis <sep>', 'time to oral candidiasis as determined by potassium hydroxide koh smear and fungal culture <sep> cd4 count <sep> history of oral candidiasis <sep> initial outbreak or recurrence of oral candidiasis <sep> delaying onset of oral candidiasis <sep> candida albicans carriage <sep>', 'severity of disease <sep> clinical response rate <sep>', 'resolution of clinical lesions of oral candidiasis <sep>', 'efficacy tolerability and development of resistance <sep> microbiological resistance <sep> clinical failure <sep> relapse-free <sep> microbiological resistance <sep> oropharyngeal candidiasis relapses <sep> relapses of oropharyngeal candidiasis <sep>', 'clinical response <sep> drug tolerability <sep> complete response clearance of all symptoms and signs or marked improvement <sep>', 'liver enzyme values <sep> clinical cure <sep> rates of colonization <sep> clinical cure colonization at the end of treatment relapse at day 28 and relapse <sep> efficacy and safety <sep>', 'frequency of episodes of oral candidiasis <sep> occurrence of oral candidiasis <sep> frequent relapses of oral candidiasis <sep>', 'nausea two hepatotoxicity and one rash <sep> toxicity rash <sep> efficacy and toxicity <sep>', 'efficacy <sep> dermatophytosis and onychomycosis and cryptococcuria <sep> episodes of candida esophagitis <sep> 35 episodes of thrush one of esophagitis one of cryptococcemia and one of dermatophytosis and preexisting dermatophytosis and onychomycosis <sep> fungal colonization <sep>', 'clinical cure <sep> severe nausea <sep> efficacy and toxicity <sep> transient rises in alanine or aspartate aminotransferase <sep>', 'alcohol consumption <sep> candidiasis on gingiva <sep> total lymphocyte <sep> time to recurrence of oral candidiasis <sep> maintenance of oral candidiasis-free period <sep> time of recurrence frequency of antifungal therapy <sep>', 'side effects diarrhea and abdominal pain <sep> efficacy and safety <sep> higher clinical and mycological cure rates <sep> rate of relapse <sep>', 'oropharyngeal infection <sep> adverse events <sep> rates of clearing of infection <sep> oropharyngeal and/or esophageal candidiasis and the rate of post-treatment relapse <sep> mean rates of infection relapse <sep> cdc classification cd4 cell counts and number of previous episodes of oropharyngeal or esophageal candidiasis <sep> esophageal candidiasis <sep> oropharyngeal and esophageal candidiasis <sep>', 'resistance <sep> microbiological resistance <sep> relapses and colonization <sep> median annual relapse rates <sep> proportion of resistant isolates <sep>', 'efficacy and tolerance <sep> clinical relapse of oropharyngeal candidiasis <sep> tolerated <sep> median time to relapse <sep> clinical relapse <sep>', 'time to development of fluconazole-refractory opc or ec <sep> episodes of orophayngeal candidiasis opc or esophageal candidiasis ec <sep> fluconazole-refractory opc or ec infections <sep> rate of fungal infection <sep> opc or ec <sep> invasive fungal infections <sep> time to development of a fluconazole-refractory infection <sep> survival <sep>', 'oral candidiasis <sep> oropharyngeal candidiasis <sep> eradication rate with nystatin <sep>', 'recurrence of oropharyngeal candidiasis <sep> seven with oesophageal candidiasis <sep>', 'tolerance efficacy and pharmacokinetics <sep> severe chills <sep> clinical side effects <sep> clinical tolerance fever chills sweats nausea arterial pressure and pulse rate biological tolerance serum creatinine electrolyte and magnesium values clinical score of candidiasis and serum concentrations of amphotericin <sep> oral candidiasis score <sep> serum amphotericin concentrations <sep> magnesium concentration <sep> clinical and renal toxicity <sep> treatment creatine concentration <sep>', 'esophageal lesions <sep>'], 'punchline_text': ['in the fluconazole group 15 of 20 75 patients were clinically cured on day 8 three 15 were clinically improved and two 10 were treatment failures. <sep>', 'both treatments were clinically effective 98 of evaluable fluconazole-treated patients and 94 of evaluable clotrimazole-treated patients were cured or showed improvement p  ns). <sep>', 'no association was found between clinical outcome minimum inhibitory concentration of d0870 pre-therapy for candida albicans maximum recorded plasma d0870 concentration cfu of culture or cd4 cell count at entry. <sep>', 'similar trends were found in the subgroups with esophageal involvement a history of fluconazole failure and cd4 counts of  or 50/mm(3). <sep>', 'itraconazole significantly delayed time to onset of histoplasmosis p  .03 log-rank test and cryptococcosis p  .0005 log-rank test). <sep>', 'efficacy was judged by changes from baseline in symptoms of oropharyngeal candidiasis erythema soreness/burning extent of oral lesions and the presence/absence of candida species on fungal culture. <sep>', 'pons v greenspan d debruin m. therapy for oropharyngeal candidiasis in hiv-infected patients a randomized prospective multicenter study of oral fluconazole versus clotrimazole troches. <sep>', 'fewer posaconazole recipients than fluconazole recipients experienced clinical relapse 31.5 vs. 38.2%). <sep>', 'in the analysis of the participants who actually completed the trial the lemon juice showed better results than the gentian violet aqueous solution 0.5 in the treatment of oral thrush in an hiv-positive population p<0.02). <sep>', 'a per-protocol analysis of 332 patients demonstrated that miconazole nitrate was not statistically significantly inferior to ketoconazole treatment. <sep>', 'weekly fluconazole was effective in preventing oropharyngeal candidiasis rr 0.50 cl 0.33 to 0.74 p  0.001 and vaginal candidiasis rr 0.64 <sep>', 'a multivariate proportional hazards model showed that four factors were significant p  0.001 in predicting time to oral candidiasis nystatin treatment hazard ratio 0.59 history of oral candidiasis 3.58 candida albicans carriage 2.79 and cd4 count at randomization 0.65). <sep>', 'itraconazole oral solution is well tolerated and offers an alternative at least as effective as fluconazole in the treatment of oropharyngeal candidiasis. <sep>', 'both formulations of the melaleuca oral solution appear to be effective alternative regimens for patients with aids suffering from oropharyngeal candidiasis refractory to fluconazole. <sep>', 'there were no significant treatment group differences in microbiological resistance whether comparisons were made for all cases or for cases up to 1 month post-study. <sep>', 'drug tolerability was comparable between the three groups. <sep>', 'also rates of colonization at the end of therapy and relapse at days 28 and 42 were less with fluconazole tablets than with clotrimazole troches. <sep>', 'in the prophylaxis group receiving 50 mg/day group 2 two out of 18 patients had four relapses. <sep>', 'after 1 week of treatment 75 and 82 of the patients on itraconazole and ketoconazole respectively had responded clinically. <sep>', 'dermatophytosis and onychomycosis and cryptococcuria also improved in the fluconazole-treated patients and fungal colonization was significantly decreased. <sep>', 'cultures were negative at the end of therapy in 87 of the fluconazole group and 69 of the ketoconazole group. <sep>', 'the time to recurrence of oral candidiasis between the chlorhexidine and the saline group was not statistically significant p  0.05). <sep>', 'follow-up examinations 2 and 4 weeks post-treatment showed a comparably high rate of relapse in both patient groups. <sep>', 'itraconazole is marginally more efficacious than ketoconazole in the treatment of oropharyngeal and esophageal candidiasis in hiv-positive patients and both drugs appear safe and well tolerated. <sep>', 'microbiological resistance developed in 9 of 16 56 patients on continuous treatment compared with 13 of 28 46 on intermittent treatment p  0.75). <sep>', 'fluconazole was well tolerated and prevented clinical relapse of oropharyngeal candidiasis in 71 of patients who completed three months of treatment 95 confidence interval ci 55-86 and 58 95 ci 41-75 who completed six months of treatment. <sep>', 'continuous fluconazole therapy is not associated with significant risk of fluconazole-refractory opc or ec compared with episodic fluconazole therapy in hiv-infected patients with access to active antiretroviral therapy. <sep>', 'fluconazole eradicated candida organisms from the oral flora in 60 vs. a 6 eradication rate with nystatin p  .001). <sep>', 'fluconazole 150 mg once weekly was found to be effective in maintaining patients both clinically and mycologically free of oropharyngeal candidiasis. <sep>', 'serum amphotericin concentrations were significantly lower and the volume of distribution of the drug higher after infusion of amphotericin-fat emulsion than after amphotericin-glucose. <sep>', 'patients enrolled in this study had a very high mortality probability of death 41.6 after 14 days). <sep>'], 'population': ['40 hiv-positive patients with oropharyngeal candidiasis <sep> oropharyngeal candidiasis in human immunodeficiency virus hiv)-positive patients <sep> aids-related oropharyngeal candidiasis <sep>', 'oropharyngeal candidiasis in hiv-infected patients <sep> 334 hiv-infected patients with oral candidiasis <sep>', 'hiv-positive patients with oral candidiasis <sep> hiv-positive patients who had no history of clinical resistance to fluconazole <sep>', 'oropharyngeal and esophageal candidiases <sep> hiv-infected patients with oropharyngeal and/or esophageal candidiasis <sep> 140 enrolled patients 63 had esophageal involvement and 98 were infected with the human immunodeficiency virus hiv median cd4 count 30/mm(3 <sep>', 'patients with advanced human immunodeficiency virus infection <sep> 149 patients with advanced human immunodeficiency virus hiv infection <sep> patients with hiv infection <sep>', 'immunocompromised subjects composed primarily of patients with human immunodeficiency virus hiv)/acquired immunodeficiency syndrome aids <sep> a total of 162 patients <sep> oropharyngeal candidiasis in immunocompromised patients <sep>', 'oropharyngeal candidiasis in hiv-infected patients <sep> twenty-nine patients 20 men and nine women with a mean age of 32 years 15-62 years <sep> patients were excluded if they had been treated with any antifungal agents 2 weeks prior to the study entry were pregnant or nursing or had significant liver disease <sep> j acquir immune defic syndr 1993 6 1311-1316. <sep> oral candidosis in aids patients <sep> oropharyngeal candidosis in acquired immunodeficiency syndrome aids patients <sep>', 'three hundred fifty subjects received <sep> oropharyngeal candidiasis in subjects with hiv/aids <sep> subjects with hiv infection and oropharyngeal candidiasis <sep> persons infected with human immunodeficiency virus hiv <sep>', '90 patients 83 completed the study <sep> inclusion criteria included being hiv-positive with a diagnosis of oral thrush <sep> oral thrush in hiv/aids patients <sep> primary health clinic patients <sep> ninety patients <sep>', '357 patients <sep> n  179 in hiv-positive patients with oropharyngeal candidiasis <sep> hiv-positive patients with oropharyngeal candidiasis <sep>', '323 women with hiv infection and cd4 cell counts of 300 cells/mm3 or less <sep> women who had a history of mucosal candidiasis rr 0.5 <sep> mucosal candidiasis in women <sep> women with hiv infection <sep> hiv-infected women who are at risk for recurrent mucosal candidiasis <sep> 14 sites participating in the community programs for clinical research on aids cpcra <sep> women infected with hiv <sep>', 'patients with cd4 counts  200 who are carriers of c. albicans and have a history of oral candidiasis <sep> hiv-associated oral candidiasis <sep> subjects were 128 hiv-infected men aged 27-60 years who either had had no documented episode of oral candidiasis in the previous year or had been clinically clear of oral candidiasis for at least 72 h before randomization <sep>', '12 centers in the united states <sep> one hundred seventy-nine hiv-positive patients with mycologically documented oropharyngeal candidiasis <sep> oropharyngeal candidiasis in hiv/aids patients <sep> oropharyngeal candidiasis <sep> individuals who are positive for the human immunodeficiency virus hiv and those who have progressed to aids <sep>', 'patients with aids <sep> 27 patients with aids and oral candidiasis clinically refractory to <sep> patients with aids and fluconazole-refractory oropharyngeal candidiasis <sep> thirteen patients were enrolled into cohort 1 and 14 patients were enrolled into cohort 2 <sep> patients with aids suffering from oropharyngeal candidiasis refractory to <sep> university-based inner city hiv/aids clinic <sep>', 'hiv-positive patients treated with <sep> for secondary prevention of oropharyngeal candidiasis <sep> 12 patients eight in the <sep> 138 hiv-infected patients <sep>', '244 patients <sep> oropharyngeal candidiasis in patients with aids <sep>', 'patients with hiv infection for several years <sep> thrush in hiv infection <sep> patients with hiv infection <sep>', 'sixty-five hiv-positive patients were included in the study from may 1989 to january 1990 <sep> hiv-positive patients <sep> patients with advanced stages of hiv-infection cd4 cell count less than 100/mm3 <sep>', 'patients infected with hiv <sep> buccal and oesophageal candidiasis 111 hiv-infected patients with microscopically-confirmed candidiasis <sep>', 'patients with acquired immunodeficiency syndrome <sep> patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex <sep> twenty-five patients with one to four previous thrush episodes who had no thrush at the outset of the study <sep>', '20 episodes 18 patients were treated with <sep> oropharyngeal candidiasis in aids <sep> patients with acquired immunodeficiency syndrome aids and aids-related complex arc <sep>', '75 hiv/aids subjects with oral candidiasis <sep> oral candidiasis-free period in hiv infection <sep> n  38 aged 22-55 years mean 38 years <sep> n  37 aged 22-52 years mean 34 years and 0.9 <sep>', '46 pediatric patients with oropharyngeal candidiasis and aids or hiv infection <sep> oropharyngeal candidiasis in hiv-infected children <sep>', 'hiv-positive patients with oropharyngeal or esophageal candidiasis <sep> patients with oropharyngeal and esophageal candidiasis <sep> 129 evaluable patients 98 had oropharyngeal candidiasis and 31 esophageal infection <sep> human immunodeficiency virus <sep> 143 adult hiv-positive patients with oropharyngeal and/or esophageal candidiasis <sep>', 'oropharyngeal candidiasis in hiv-infected patients <sep> human immunodeficiency virus hiv)-positive patients with cd4 cell count 350 x 10(6)/l and oropharyngeal candidiasis <sep>', 'for oropharyngeal candidiasis <sep> hiv-infected patients <sep> patients with moderate to severe human immunodeficiency virus hiv infection <sep> eighty-four patients with moderate to severe hiv infection who had successfully completed two to four weeks treatment with <sep>', 'patients with advanced hiv infection and a history of oropharyngeal candidiasis <sep> hiv-infected persons with cd4 t cell counts of 150 cells/mm3 and a history of opc <sep> 413 subjects <sep>', 'patients with aids <sep> 167 human immunodeficiency virus hiv)-infected patients with oropharyngeal candidiasis <sep>', '14 patients <sep> patients with aids and aids-related complex <sep> patients with aids and aids-related complex with severe oropharyngeal and oesophageal candidiasis <sep>', 'hiv patients with candidiasis <sep> 11 patients were enrolled in each group <sep> 22 hiv positive patients with oral candidiasis <sep> hiv infected patients with candidiasis <sep>', 'oropharyngeal candidiasis <sep> oropharyngeal and esophageal candidiasis in zairian aids patients <sep> oropharyngeal and esophageal candidiasis was conducted in kinshasa zaire among 141 inpatients with aids and oropharyngeal candidiasis of whom 136 also had esophageal candidiasis <sep>'], 'interventions': ['itraconazole <sep> fluconazole 150 mg or seven daily doses of itraconazole <sep> fluconazole <sep>', 'fluconazole <sep> fluconazole discontinued therapy <sep> clotrimazole <sep> fluconazole <sep> oral fluconazole <sep>', 'new triazole antifungal d0870 <sep>', 'amphotericin <sep> conventional amphotericin <sep> caspofungin versus amphotericin b <sep> caspofungin acetate <sep> amphotericin b <sep> caspofungin <sep>', 'placebo <sep> itraconazole <sep> itraconazole capsules <sep> itraconazole <sep> itraconazole prophylaxis <sep>', 'itraconazole oral solution <sep> clotrimazole <sep> itraconazole oral solution versus clotrimazole <sep> clotrimazole troches <sep> itraconazole <sep> intraconazole oral solution <sep>', 'itraconazole oral solution <sep> fluconazole <sep> clotrimazole <sep> clotrimazole troche vs. itraconazole oral solution <sep> clotrimazole troche <sep>', 'posaconazole <sep> posaconazole <sep> posaconazole or fluconazole oral suspension <sep> fluconazole <sep>', 'gentian violet aqueous solution 0.5 <sep> gentian violet <sep> gentian violet aqueous solution <sep> gentian violet <sep> gentian violet lemon juice or lemon grass <sep> lemon juice and lemon grass cymbopogon citratus <sep>', 'miconazole nitrate mucoadhesive buccal tablet <sep> miconazole mucoadhesive tablet <sep> ketoconazole <sep> ketoconazole <sep> miconazole nitrate <sep>', 'open-label fluconazole <sep> placebo <sep> fluconazole prophylaxis <sep> fluconazole <sep>', 'nystatin pastilles <sep> nystatin <sep> placebo <sep> nystatin 200,000 u and one placebo pastille or two nystatin pastilles <sep>', 'itraconazole <sep> itraconazole oral solution <sep> fluconazole tablets <sep> itraconazole oral solution <sep> fluconazole <sep> itraconazole and fluconazole tablets <sep> itraconazole <sep>', 'alcohol-based or alcohol-free melaleuca oral solution <sep> alcohol-based and alcohol-free melaleuca oral solution <sep> fluconazole <sep>', 'fluconazole 150 mg once weekly matched to placebo <sep> placebo <sep> fluconazole <sep>', 'fluconazole capsules <sep> itraconazole oral solution and fluconazole <sep> itraconazole oral solution <sep> fluconazole <sep> itraconazole <sep> itraconazole oral solution and fluconazole capsules <sep>', 'clotrimazole <sep> fluconazole <sep> clotrimazole <sep> fluconazole <sep>', 'fluconazole prophylaxis <sep> fluconazole prophylaxis <sep> ketoconazole <sep> fluconazole <sep> 0.01).(abstract <sep>', 'itraconazole <sep> ketoconazole <sep> itraconazole <sep> ketaconazole <sep> itraconazole and ketoconazole <sep>', 'placebo <sep> 100-mg oral fluconazole <sep> fluconazole <sep> continuous fluconazole <sep> fluconazole or placebo <sep>', 'fluconazole and ketoconazole <sep> fluconazole <sep> ketoconazole <sep> fluconazole <sep> fluconazole-treated and 4 of 19 ketoconazole <sep>', 'clotrimazole <sep> chlorhexidine <sep> normal saline <sep> chlorhexidine <sep>', 'oral ketoconazole <sep> fluconazole <sep> fluconazole <sep> ketoconazole <sep> oral fluconazole <sep>', 'itraconazole <sep> itraconazole <sep> ketoconazole <sep> itraconazole or ketoconazole <sep> itraconazole ketoconazole <sep> itraconazole and ketoconazole <sep>', 'fluconazole resistance <sep> continuous fluconazole <sep> intermittent therapy <sep> fluconazole <sep>', 'placebo or fluconazole. pre <sep> placebo <sep> fluconazole <sep> fluconazole <sep>', 'episodic fluconazole <sep> episodic fluconazole therapy <sep> fluconazole prophylaxis <sep> fluconazole <sep> episodic therapy <sep> continuous fluconazole <sep>', 'nystatin oral suspensions <sep> fluconazole <sep> fluconazole <sep> liquid suspension fluconazole <sep> liquid nystatin <sep> fluconazole oral suspension <sep>', 'placebo <sep> fluconazole <sep> fluconazole <sep>', 'amphotericin <sep> conventional amphotericin <sep> amphotericin deoxycholate fungizone <sep> amphotericin-fat emulsion <sep> amphotericin-glucose infusions <sep> amphotericin <sep> amphotericin-glucose <sep> glucose versus fat emulsion <sep> glucose amphotericin-glucose or parenteral fat emulsion at a final concentration of 2 g/l fat emulsion amphotericin-fat emulsion <sep> amphotericin-fat emulsion infusions <sep>', 'gentian violet <sep> ketoconazole <sep> gentian violet mouth washes 1.5 ml 0.5 aqueous solution b.i.d. oral ketoconazole <sep> nystatin <sep> gentian violet ketoconazole and nystatin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",five new studies were added to the review but their results do not alter the final conclusion of the review. implications for practicedue to there being only one study in children it is not possible to make recommendations for treatment or prevention of oc in children. amongst adults there were few studies per comparison. due to insufficient evidence no conclusion could be made about the effectiveness of clotrimazole nystatin amphotericin b itraconazole or ketoconazole with regard to oc prophylaxis. in comparison to placebo fluconazole is an effective preventative intervention. however the potential for resistant candida organisms to develop as well as the cost of prophylaxis might impact the feasibility of implementation. no studies were found comparing fluconazole with other interventions. the direction of findings suggests that ketoconazole fluconazole itraconazole and clotrimazole improved the treatment outcomes. implications for researchit is encouraging that low-cost alternatives are being tested but more research needs to be on in this area and on interventions like gentian violet and other less expensive anti-fungal drugs to treat oc. more well-designed treatment trials with larger samples are needed to allow for sufficient power to detect differences in not only clinical but also mycological response and relapse rates. there is also a strong need for more research to be done on the treatment and prevention of oc in children as it is reported that oc is the most frequent fungal infection in children and adolescents who are hiv positive. more research on the effectiveness of less expensive interventions also needs to be done in resource-poor settings. currently few trials report outcomes related to quality of life nutrition or survival. future researchers should consider measuring these when planning trials. development of resistance remains under-studied and more work must be done in this area. it is recommended that trials be more standardised and conform more closely to consort.
293,"{'outcomes': ['overall survival <sep> endometrial-cancer-related death rates <sep> locoregional recurrence <sep> locoregional recurrence and death with treatment-related morbidity and survival after relapse <sep> locoregional control and survival <sep> survival after relapse <sep> treatment-related complications <sep> 2-year survival after vaginal recurrence <sep> 5-year actuarial locoregional recurrence rates <sep> grade 3-4 complications <sep> median duration <sep> actuarial 5-year overall survival rates <sep>', 'gastrointestinal toxic effects <sep> rates of acute grade 1-2 gastrointestinal toxicity <sep> 5-year <sep> disease-free survival <sep> vaginal recurrence <sep> rates of locoregional relapse vaginal or pelvic recurrence or both <sep> rates of distant metastases <sep> isolated pelvic recurrence <sep> quality of life <sep> vaginal recurrences <sep> estimated 5-year rates of vaginal recurrence <sep>', 'distant metastases <sep> vaginal and pelvic recurrences <sep> 5-year survival rate <sep> deaths and recurrences <sep>', 'toxicity date and location of recurrence and overall survival <sep> risk of recurrence and death <sep> 2-year cumulative incidence of recurrence cir <sep> pelvic and vaginal recurrences <sep> estimated 4-year survival <sep>', 'rate of vaginal recurrences <sep> dysuria frequency and incontinence <sep> locoregional recurrence rate <sep> late intestinal problems <sep> overall recurrence rate and survival <sep> distant metastases <sep> side effects <sep>'], 'punchline_text': ['5-year actuarial locoregional recurrence rates were 4 in the radiotherapy group and 14 in the control group p<0.001). <sep>', 'rates of acute grade 1-2 gastrointestinal toxicity were significantly lower in the vbt group than in the ebrt group at completion of radiotherapy 12.6 27/215 vs 53.8 112/208]). <sep>', 'during the follow-up period of 3 to 10 years a significant reduction in vaginal and pelvic recurrences was found in group b as compared with group a 1.9 versus 6.9 p  .01). <sep>', 'the estimated 4-year survival was 86 in the nat arm and 92 for the rt arm not significantly different rh 0.86 p=0.557). <sep>', 'the rate of vaginal recurrences was 1.2 in the treatment group versus 3.1 in the control group. <sep>'], 'population': ['endometrial carcinoma <sep> 715 patients from 19 radiation oncology centres <sep> patients with stage-1 endometrial carcinoma <sep> patients with stage-1 endometrial carcinoma below 60 years and patients with grade-2 tumours with superficial invasion <sep> patients with stage-1 endometrial carcinoma grade 1 with deep  or 50 myometrial invasion grade 2 with any invasion or grade 3 with superficial 50 invasion were enrolled <sep> international federation of gynaecology and obstetrics figo stage-1 endometrial carcinoma <sep> 715 patients 714 could be evaluated <sep>', 'patients with endometrial cancer of high-intermediate risk portec-2 <sep> patients with endometrial carcinoma of high-intermediate risk <sep> 19 dutch radiation oncology centres 427 patients with stage i or iia endometrial carcinoma with features of high-intermediate risk <sep>', 'from 1968 to 1974 540 patients with stage i adenocarcinoma of the corpus uteri <sep> 540 patients <sep>', 'four hundred forty-eight consenting patients with intermediate risk endometrial adenocarcinoma <sep> women with endometrial adenocarcinoma receive <sep> intermediate risk endometrial adenocarcinoma <sep> women with endometrial cancer international federation of gynaecology and obstetrics figo stages ib ic and ii occult disease <sep> three hundred ninety-two women met all eligibility requirements 202 nat 190 rt <sep> a high intermediate risk hir subgroup of patients was defined as those with 1 moderate to poorly differentiated tumor presence of lymphovascular invasion and outer third myometrial invasion 2 age 50 or greater with any two risk factors listed above or 3 age of at least 70 with any risk factor listed above <sep>', 'low-risk international federation of gynecology and obstetrics figo stage ia-ib endometrial carcinoma <sep> 645 evaluable low-risk endometrial carcinoma patients from 6 european gynecologic cancer centers <sep> i low-risk endometrial cancer <sep> 319 patients were treated with <sep> figo stage <sep> patients with low-risk endometrial carcinoma <sep>'], 'interventions': ['radiotherapy <sep> surgery and postoperative radiotherapy versus surgery alone <sep> pelvic radiotherapy 46 gy or no further treatment <sep> radiotherapy <sep> postoperative pelvic radiotherapy <sep> total abdominal hysterectomy and bilateral salpingo-oophorectomy without lymphadenectomy <sep> postoperative radiotherapy <sep>', 'radiotherapy <sep> pelvic external beam radiotherapy ebrt <sep> ebrt <sep> computer-generated biased coin minimisation procedure to pelvic ebrt <sep> vaginal brachytherapy vbt <sep> vaginal brachytherapy versus pelvic external beam radiotherapy <sep> vbt <sep>', 'intravaginal radium irradiation <sep> postoperative external pelvic irradiation <sep> no further treatment controls group b received additional high-voltage irradiation to the pelvic field with a dose of 4000 rads to the pelvic lymph nodes <sep>', 'surgery with or without adjunctive external pelvic radiation therapy <sep> adjunctive external beam irradiation <sep> surgery to either no additional therapy nat or whole pelvic radiation therapy rt <sep> postoperative radiation therapy rt <sep> adjunctive rt <sep>', 'intravaginal brachytherapy <sep> high-dose-rate afterloading equipments iridium <sep> postoperative brachytherapy <sep> postoperative vaginal irradiation with surgery alone <sep> surgery plus vaginal irradiation <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",ebrt reduces the risk of locoregional recurrence but has no significant impact on cancer-related deaths or overall survival. it is associated with significant morbidity and a reduction in quality of life. there is no demonstrable survival advantage from adjuvant ebrt for high-risk stage i endometrial cancer however the meta-analyses of this subgroup were underpowered and also included high-intermediate risk women therefore we cannot exclude a small benefit in the high-risk subgroup. ebrt may have an adverse effect on endometrial cancer survival when used to treat uncomplicated low-risk ia/b grade 1/2 endometrial cancer. for the intermediate to high-intermediate risk group vbt alone appears to be adequate in ensuring vaginal control compared to ebrt. further research is needed to guide practice for lesions that are truly high risk. in addition the definitions of risk should be standardised.
294,"{'outcomes': ['overall corrected perinatal survival <sep> neonatal morbidity <sep> risk of maternal infections <sep>', 'pregnancy outcome ie birth weight intraventricular hemorrhage necrotizing enterocolitis sepsis respiratory distress syndrome and perinatal death <sep> antepartum hospitalization <sep> mean gestational ages at delivery <sep> incidence of chorioamnionitis and antepartum hospitalization <sep>', 'chorioamnionitis and fetal heart rate abnormalities <sep> proven sepsis <sep> hospitalization <sep> hospitalization assessment for fetal heart rate abnormalities chorioamnionitis and labor <sep> prolonged antimicrobial therapy <sep> prolonged latencies to labor delivery and maternal hospitalization <sep> duration of hospitalization and infection <sep>', 'neonatal sepsis <sep> maternal hospital stay <sep> ultrasonographically estimated fetal weight <sep> chorioamnionitis <sep>', 'incidence of respiratory distress syndrome <sep> postpartum febrile morbidity <sep> incidence of maternal and neonatal complications <sep>', 'maternal age gestation at prom maximum maternal temperature birth weights maternal hospital days respiratory distress maternal sepsis or delivery routes <sep>', 'maternal outcome including chorioamnionitis and cesarean section rates <sep> mean birth weights perinatal death rates neonatal infections or incidences of respiratory distress <sep> endometritis rate <sep> frequency of prolonged hospital stay <sep>'], 'punchline_text': ['neonatal morbidity was similar in each group. <sep>', 'however there was a significant increase in the incidence of chorioamnionitis and antepartum hospitalization in the women managed expectantly. <sep>', 'infants received more frequent p  0.001 and prolonged antimicrobial therapy after expectant management p  0.003 with no reduction in proven sepsis 6.8 vs 4.4%). <sep>', 'chorioamnionitis occurred more often 16 vs 2 p  0.007 and maternal hospital stay 5.2  <sep>', 'there was no significant difference in the incidence of respiratory distress syndrome. <sep>', 'there were no significant differences in maternal age gestation at prom maximum maternal temperature birth weights maternal hospital days respiratory distress maternal sepsis or delivery routes in the three groups. <sep>', 'neonatal outcome did not differ in mean birth weights perinatal death rates neonatal infections or incidences of respiratory distress. <sep>'], 'population': ['ninety-nine patients with premature rupture of the membranes prom before 36 weeks gestation and documented fetal pulmonary maturity <sep>', 'sixty-eight women with prom were managed expectantly and 61 were delivered intentionally <sep> women hospitalized for prom at 30-34 weeks gestation <sep> pregnancies complicated by preterm rupture of membranes prom at 30-34 weeks gestation <sep>', '71 women who did not participate <sep> women with preterm premature rupture of the membranes at 32 to 36 weeks with mature surfactant profiles <sep> premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks <sep> women with preterm premature rupture of the membranes and documented fetal pulmonary maturity <sep> 164 women with preterm premature rupture of the membranes at 32 weeks to 36 weeks 6 days gestation 93 eligible and consenting women <sep>', 'n  57 or observation n  63 <sep> labor with preterm rupture of membranes between 34 and 37 weeks gestation with expectant management <sep> 321 gm vs 2297 <sep> estimated gestational age at rupture of membranes 34.3 <sep> 120 gravid women at  or  34 weeks 0 days and  36 weeks 6 days of gestation <sep>', 'women with preterm prematurely ruptured membranes with <sep> 73 patients <sep> preterm prematurely ruptured membranes <sep>', 'premature rupture of membranes <sep> patients in the 28th to 34th week of pregnancy with premature rupture of the membranes prom <sep>', 'patients with chorioamnionitis advanced labor and fetal distress as well as those with mature lecithin/sphingomyelin ratios <sep> patients with premature rupture of the membranes and premature gestations <sep> a total of 160 patients were randomized 80 in each group <sep> patients with premature rupture of the membranes between the twenty-eighth week and the thirty-fourth week of pregnancy was conducted <sep> premature rupture of the membranes and the premature gestation <sep>'], 'interventions': ['conservative management <sep>', 'expectant management <sep>', 'induction of labor <sep> expectant management <sep>', 'oxytocin induction <sep>', 'hydrocortisone <sep> steroids and timed delivery <sep>', 'betamethasone and early delivery early delivery alone and expectant management <sep>', 'betamethasone <sep> corticosteroids <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there is insufficient evidence to guide clinical practice on the benefits and harms of immediate delivery compared with expectant management for women with pprom. to date all of the clinical trials have had methodological weaknesses and have been underpowered to detect meaningful measures of infant and maternal morbidity.
295,"{'outcomes': ['negative coping strategies <sep> hostility <sep> memory verbal fluency and problem-solving ability and caregivers were assessed on marital interaction emotional status and physical health along with stress coping and social support <sep> depressive symptoms <sep> improvement over time in cognitive outcomes <sep>', 'regional cerebral metabolic rate for glucose using positron emission tomography and 18f-2-fluoro-2-deoxy-d-glucose <sep> brain function <sep>', 'recall of personal information face-name recall and performance on the verbal series attention test <sep> additional neuropsychologic measures of dementia severity verbal memory visual memory word generation or motor speed or to caregiver-assessed patient quality of life <sep>', 'cognitive behavioural and functional assessment <sep>', 'goal performance and satisfaction assessed using the canadian occupational performance measure <sep> behavioral changes <sep> ratings of goal performance and satisfaction <sep> questionnaires assessing mood quality of life and career strain and a brief neuropsychological test battery <sep>', 'completed activities of daily living adls and everyday memory questionnaires <sep> recall and recognition of test material <sep>', 'cognitive and behavioral functioning <sep> cognitive and behavioral performance <sep>', 'specific cognitive and functional tasks <sep> memory and functional performance <sep> face-name association tasks object recall training functional tasks e.g. making change paying bills orientation to time and place visuo-motor speed of processing and the use of a memory notebook <sep> cognitive rehabilitation <sep> gains in recall of face-name associations orientation cognitive processing speed and specific functional tasks <sep>', 'episodic memory perceived burden or depressive symptoms <sep> episodic memory performance <sep>'], 'punchline_text': ['repeated measures procedures showed that patients in the cognitive stimulation group demonstrated more improvement over time in cognitive outcomes and caregivers decreased in depressive symptoms. <sep>', 'before treatment the groups were comparable in respect to resting and activated glucose pattern achieved by a visual recognition task. <sep>', 'during the intervention ad patients showed significant improvement in recall of personal information face-name recall and performance on the verbal series attention test. <sep>', 'preliminary results show a significant performance decline only in the control group at the 9-month follow-up compared to both baseline and the 3-month follow-up. <sep>', 'cr produced significant improvement in ratings of goal performance and satisfaction whereas scores in the other two groups did not change. <sep>', 'no significant main effects of group training vs. control or time were observed on any outcome measures nor were any significant interactions found. <sep>', 'care recipients in the experimental group improved in cognitive and behavioral performance with treatment but returned to former level of functioning by the 9th month. <sep>', 'a systematic program of cognitive rehabilitation can result in maintained improvement in performance on specific cognitive and functional tasks in mildly impaired ad patients. <sep>', 'the results showed that following collaborative intervention recall performance in two collaborative tasks became more equally shared between the spouses reflected in a decrease in recall for the caregiver and in an increase in recall for the spouse with dementia between pre and post-test whereas for the other two groups the caregivers dominated collaborative recall both at pre and post-test. <sep>'], 'population': ['caregivers 65 women 38 men and their dementia-diagnosed spouses patients <sep>', ""four groups of patients with alzheimer's disease <sep> alzheimer's disease <sep> 70 patients with probable alzheimer's disease <sep>"", 'alzheimer disease <sep> 37 patients 16 men 21 women with probable alzheimer disease ad <sep> patients with ad <sep>', ""patients with mild cognitive decline <sep> dementia <sep> 11 patients with diagnosis of alzheimer's disease ad and mild cognitive decline randomly assigned to treatment a or control b condition i.e. specific vs. aspecific treatment <sep>"", 'early-stage alzheimer disease ad <sep> sixty-nine individuals 41 women 28 men mean age 77.78 years standard deviation 6.32 range  56-89 with a diagnosis of ad or mixed ad and vascular dementia and a mini-mental state examination score of 18 or above and receiving a stable dose of acetylcholinesterase-inhibiting medication <sep> people with early-stage alzheimer disease <sep>', ""34 patients with probable alzheimer's disease ad <sep> mildly impaired alzheimer's disease patients <sep>"", ""care recipients <sep> older care recipients with the diagnosis of dementia of the alzheimer's type <sep> 78 community-dwelling care recipients <sep> care recipients with dementia <sep>"", 'twenty-five participants in the cognitive rehabilitation cr condition participated <sep> nineteen participants in the mental stimulation ms condition had equivalent therapist contact and number of sessions which consisted of interactive computer games involving memory concentration and problem-solving skills <sep> mildly impaired ad patients <sep> mildly impaired alzheimer disease patients on cholinesterase inhibitors <sep> mildly impaired alzheimer disease ad patients receiving a cholinesterase inhibitor <sep>', 'dementia caregiver participation matters <sep> persons with dementia and their spousal caregivers <sep>'], 'interventions': ['treatment programs cognitive stimulation dyadic counseling dual supportive seminar and early-stage day care or to a wait-list control group <sep>', 'social support 18 cognitive training twice a week in 17 cognitive training was combined with pyritinol 2 x 600 mg/day and in 18 cognitive training was combined with phosphatidylserine 2 x 200 mg/day <sep> phosphatidylserine pyritinol and cognitive training <sep> phosphatidylserine treatment <sep>', 'cognitive intervention or a mock placebo intervention <sep> cognitive intervention <sep> placebo <sep> cognitive intervention <sep>', 'computer cognitive rehabilitation <sep> computer-based cognitive intervention <sep> computer based cognitive training <sep>', 'cr with relaxation therapy <sep> functional magnetic resonance imaging fmri <sep> cognitive rehabilitation cr <sep> goal-oriented cognitive rehabilitation <sep>', 'memory training <sep> placebo <sep> didactic presentations but no formal memory training <sep> cognitive intervention group or a control group <sep> donepezil <sep> memory-training program <sep>', 'active cognitive stimulation training <sep> placebo passive activity or wait-list control conditions <sep> placebo <sep> dyadic remediation program <sep> cognitive remediation intervention <sep>', 'cognitive rehabilitation <sep> new cognitive rehabilitation program <sep>', 'individual intervention where the person with dementia received the same training but without the participating caregiver and to a control group of couples receiving no training <sep> collaborative memory intervention <sep> collaborative memory intervention <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",available evidence regarding cognitive training remains limited and the quality of the evidence needs to improve. however there is still no indication of any significant benefit derived from cognitive training. trial reports indicate that some gains resulting from intervention may not be captured adequately by available standardised outcome measures. the results of the single rct of cognitive rehabilitation show promise but are preliminary in nature. further well-designed studies of cognitive training and cognitive rehabilitation are required to obtain more definitive evidence. researchers should describe and classify their interventions appropriately using available terminology.
296,"{'outcomes': ['positive and negative symptom scale ratings <sep> tolerated without any serious adverse effects <sep> cognitive functions of visual sustained attention and visual and movement skills <sep> sustained attention and visual and movement skills <sep> clinical symptoms side effects and quality-of-life scores <sep> efficacy and safety <sep>'], 'punchline_text': ['compared with placebo dhea administration did not produce significant improvement in clinical symptoms side effects and quality-of-life scores. <sep>'], 'population': ['fifty-five of 62 inpatients and outpatients with diagnostic and statistical manual of mental disorders fourth edition diagnosis of schizophrenia completed the trial <sep> schizophrenia <sep>'], 'interventions': ['placebo <sep> dhea and placebo <sep> placebo dhea <sep> dhea <sep> dehydroepiandrosterone dhea augmentation <sep>'], 'punchline_effect': [' no diff <sep>']}",results are inconclusive with most outcomes being either non-significant or producing contradictory findings. currently adjunctive dhea should remain an experimental treatment for people with schizophrenia.
297,"{'outcomes': ['pain and enhances upper limb motor function <sep> visual analogue scale score of pain at rest on movement and brush-induced tactile allodynia <sep> motor function as assessed by the wolf motor function test and motor activity log. <sep>', 'blinded rating on the action research arm test <sep> motor recovery <sep>', 'scores of the brunnstrom stages for the hand and upper extremity and the fim self-care score <sep> brunnstrom stages of motor recovery spasticity assessed by the modified ashworth scale mas and hand-related functioning self-care items of the fim instrument <sep>', 'activation balance <sep> fma <sep> grip force spasticity pain dexterity hand-use in daily life and quality of life <sep> neural activation patterns <sep> fugl-meyer motor assessment fma <sep> motor recovery and cortical reorganization <sep>', 'muscle tone <sep> fugl-meyer assessment score in the wrist hand and coordination as well as power of wrist <sep> power of hand flexion wrist flexion and wrist extension <sep> fugl-meyer scores of hand wrist coordination and power of hand extension <sep> muscle tone fugl-meyer assessment and power of wrist and hand <sep>', 'sensory and attentional deficits <sep> recovery of surface sensibility <sep> distal function <sep>', 'brunnstrom stages of motor recovery spasticity assessed by the modified ashworth scale mas walking ability functional ambulation categories fac and motor functioning motor items of the fim instrument <sep> fim motor score <sep> fac <sep>'], 'punchline_text': ['the mean scores of both the primary and secondary end points significantly improved in the mirror group p  .001). <sep>', 'no differences between the treatment groups were found at baseline or outcome on the action research arm test ancova statistical p=0.77 and effect size partial 2=0.005 or any of the secondary outcome measures. <sep>', 'in our group of subacute stroke patients hand functioning improved more after mirror therapy in addition to a conventional rehabilitation program compared with a control treatment immediately after 4 weeks of treatment and at the 6-month follow-up whereas mirror therapy did not affect spasticity. <sep>', 'no changes were found on the other outcome measures all ps .05). <sep>', 'the mirror and nmes group showed significant improvements in the fugl-meyer scores of hand wrist coordination and power of hand extension compared to the other groups. <sep>', 'mt stimulated recovery from hemineglect. . <sep>', 'mirror therapy combined with a conventional stroke rehabilitation program enhances lower-extremity motor recovery and motor functioning in subacute stroke patients. <sep>'], 'population': ['stroke patients <sep> stroke patients with upper limb crpst1 <sep> 208 patients with first episode of unilateral stroke admitted to the authors rehabilitation center 48 patients with crpst1 of the affected upper limb <sep> patients with acute stroke. <sep>', 'mental practice with motor imagery in stroke recovery <sep> 39 patients involved in 4 weeks of <sep> 121 stroke patients with a residual upper limb weakness within 6 months following stroke on average 3 months post-stroke <sep> stroke patients with persistent upper limb motor weakness <sep>', 'subacute stroke <sep> inpatients with subacute stroke <sep> 40 inpatients with stroke mean age 63.2y all within 12 months poststroke <sep>', 'patients with chronic stroke with moderate upper extremity paresis <sep> chronic stroke patients <sep> 40 chronic stroke patients mean time post <sep>', 'stroke patients than nmes or mirror therapy only <sep> sixty patients with hemiparesis after stroke were included 41 males and 19 females average age 63.3 years <sep> twenty patients had nmes applied only and twenty patients underwent mirror therapy only <sep> stroke patients <sep> twenty patients had nmes applied and simultaneously underwent mirror therapy <sep>', 'thirty-six patients with severe hemiparesis because of a first-ever ischemic stroke in the territory of the middle cerebral artery were enrolled no more than 8 weeks after the stroke <sep> severe hemiparesis <sep>', '40 inpatients with stroke mean age 63.5 y all within 12 months poststroke and without volitional ankle dorsiflexion <sep> motor functioning after stroke <sep> patients with subacute stroke <sep> subacute stroke patients <sep>'], 'interventions': ['mirror therapy <sep> mirror therapy <sep> mirror therapy group or placebo control group <sep>', '31 patients who performed equally intensive non-motor mental rehearsal and 32 patients receiving normal care without additional training <sep> mental practice with motor imagery <sep> mental rehearsal of upper limb movements <sep>', 'mirror therapy <sep> mirror therapy program a day consisting of wrist and finger flexion and extension movements or sham therapy <sep> mirror therapy <sep> conventional rehabilitation program <sep>', 'home-based mirror therapy and subsequent cortical reorganization <sep> mirror therapy <sep>', 'mirror therapy and neuromuscular electrical stimulation nmes <sep> nmes <sep> mirror therapy and neuromuscular electrical stimulation <sep> nmes and mirror therapy <sep>', 'mirror therapy <sep> random assignment to either mirror therapy mt or an equivalent control therapy ct <sep>', 'mirror therapy <sep> mirror therapy using motor imagery training <sep> mirror therapy combined with a conventional stroke rehabilitation program <sep> nonparetic ankle dorsiflexion movements or sham therapy in addition to a conventional stroke rehabilitation program <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",the results indicate evidence for the effectiveness of mirror therapy for improving upper extremity motor function activities of daily living and pain at least as an adjunct to normal rehabilitation for patients after stroke. limitations are due to small sample sizes of most included studies control interventions that are not used routinely in stroke rehabilitation and some methodological limitations of the studies.
298,"{'outcomes': ['mean tender point pain threshold number of tender points fiq fatigue tiredness on awakening and stiffness scores clinical global impression of severity cgi-severity scale patient global impression of improvement pgi-improvement scale brief pain inventory short form medical outcomes study short form 36 quality of life in depression scale and sheehan disability scale <sep> cgi-severity <sep> fiq total score <sep> number of tender points <sep> brief pain inventory average interference from pain score <sep> fiq stiffness score <sep> tolerated <sep> several quality-of-life measures <sep> brief pain inventory average pain severity score <sep> pain reduction <sep> fibromyalgia impact questionnaire fiq total score score range 0-80 with 0 indicating no impact and fiq pain score <sep> mean tender point pain threshold <sep> fibromyalgia symptoms and pain severity <sep> fiq pain score <sep> pgi-improvement <sep> efficacy and safety <sep>', 'remaining brief pain inventory pain severity and interference scores fibromyalgia impact questionnaire clinical global impression of severity patient global impression of improvement and several quality-of-life measures <sep> effective and safe <sep> tolerated <sep> brief pain inventory average pain severity score <sep> pain reduction <sep> efficacy and safety <sep>', 'pain and other symptoms <sep> global status <sep> rates of fm composite responders and fm pain composite responders <sep> adverse events <sep> physical function sf-36 physical functioning domain-100 <sep> adverse events <sep> headache <sep> patient global impression of change pgic scale and physical function a  or  6-point improvement on the 36-item short-form health survey sf-36 physical component summary score <sep> pain <sep> fatigue multidimensional fatigue inventory <sep> nausea <sep> constipation <sep> efficacy and tolerability <sep> fm composite responders <sep> fm pain composite responders <sep>', 'nausea headache constipation dry mouth dizziness diarrhea and hyperhidrosis <sep> bpi average pain severity patient-rated scales assessing mood anxiety pain sleep and stiffness clinical global impression of severity cgi-s multidimensional fatigue inventory cognitive and physical functioning questionnaire beck depression inventory bdi beck anxiety inventory and medical outcome study short-form health survey sf-36 <sep> fibromyalgia fm symptoms assessed by the patient global impression of improvement pgi-i scale <sep> global improvement with mean pgi-i scores <sep> pain reduction <sep> mood stiffness fatigue and functioning <sep> bpi average pain severity mood including bdi total anxiety patient-rated only stiffness cgi-s fatigue all sf-36 domains except role-physical and physical component summary and being less bothered by pain or sleep difficulties <sep>', ""efficacy and safety <sep> tolerated <sep> multidimensional fatigue inventory total score <sep> 24-hour and weekly recall pain score pgic score sf-36 pcs and mental component summary scores average pain severity score on the brief pain inventory fibromyalgia impact questionnaire total score <sep> pain global status fatigue and physical and mental function <sep> physical function on the short form 36 sf-36 physical component summary pcs score <sep> pain score and a rating of very much improved or much improved on the patient's global impression of change pgic scale <sep> efficacy and safety <sep>"", 'efficacy and safety <sep> brief pain inventory bpi average pain severity score and patient global impressions of improvement pgi-i score <sep> pain severity <sep> vital signs laboratory measures or ecg measures <sep> adverse events and changes in vital sign laboratory and ecg measures <sep> safe and efficacious <sep> safety <sep> bpi score <sep> efficacy and safety <sep>', 'fiq total score <sep> sf-36 mental component summary <sep> short-form 36 health survey sf-36 physical component summary <sep> multiple ability self-report questionnaire <sep> visual analog scale 24-hour morning recall and a rating of very much or much improved on the patient global impression of change scale <sep> pain <sep> fibromyalgia impact questionnaire fiq <sep> safe and well tolerated nausea hyperhidrosis and headache <sep> efficacy and safety <sep> multidimensional fatigue inventory <sep>', 'nausea <sep> overall discontinuation rates <sep> fibromyalgia impact questionnaire pain score bpi least pain score and average interference score clinical global impressions of severity scale area under the curve of pain relief multidimensional fatigue inventory mental fatigue dimension beck depression inventory-ii total score and 36-item short form health survey mental component summary and mental health score <sep> brief pain inventory bpi average pain severity <sep> efficacy and safety <sep>', 'pain intensity <sep> efficacy and safety <sep> overall improvement <sep>', 'fatigue <sep> significant pain reductions <sep> pgic <sep> pain visual analog scale 24-h morning recall patient global impression of change pgic and physical functioning sf-36 physical component summary <sep> safe and well tolerated <sep> pain realtime daily and weekly recall <sep> nausea and headache <sep> efficacy and safety <sep>'], 'punchline_text': ['compared with placebo-treated subjects duloxetine-treated subjects had significantly greater reductions in brief pain inventory average pain severity score p  0.008 brief pain inventory average interference from pain score p  0.004 number of tender points p  0.002 and fiq stiffness score p  0.048 and had significantly greater improvement in mean tender point pain threshold p  0.002 cgi-severity p  0.048 pgi-improvement p  0.033 and several quality-of-life measures. <sep>', 'compared with placebo both duloxetine-treated groups improved significantly more p<0.001 on the brief pain inventory average pain severity score. <sep>', 'p<0.001 for both doses physical function sf-36 physical functioning domain-100 <sep>', 'significantly more duloxetine versus placebo-treated patients 57 vs 32 p  0.001 reported feeling much or very much better pgi-i score  2). <sep>', 'milnacipran administered at a dosage of 100 mg/day improved pain global status fatigue and physical and mental function in patients with fibromyalgia. <sep>', 'compared with placebo treatment with duloxetine 60 mg/day also significantly improved the co-primary measures at 3 months and bpi at 6 months. <sep>', 'significant improvements were also observed in multiple secondary efficacy endpoints including short-form 36 health survey sf-36 physical component summary p  0.025 sf-36 mental component summary p  0.007 multidimensional fatigue inventory p  0.006 and multiple ability self-report questionnaire p  0.041). <sep>', ""there were no significant differences between treatment groups on the co-primary efficacy outcome measures change in the brief pain inventory bpi average pain severity from baseline to endpoint p  0.053 and the patient's global impressions of improvement pgi-i at endpoint p  0.073). <sep>"", 'the study evaluated the efficacy and safety of milnacipran for the treatment of pain and associated symptoms such as fatigue depressed mood and sleep. <sep>', 'milnacipran was safe and well tolerated by the majority of patients during 27 weeks of treatment nausea and headache were the most common adverse events. <sep>'], 'population': ['subjects with or without major depressive disorder <sep> 18 outpatient research centers in the us <sep> subjects with primary fibromyalgia with or without current major depressive disorder <sep> 207 subjects meeting the american college of rheumatology criteria for primary fibromyalgia were enrolled 89 female 87 white mean age 49 years 38 with current major depressive disorder <sep> female subjects <sep> fibromyalgia patients with or without major depressive disorder <sep>', 'women with fibromyalgia with or without major depressive disorder <sep> patients 90 caucasian mean age 49.6 years 26 with current major depressive disorder <sep> female patients with or without major depressive disorder <sep> 354 female patients with primary fibromyalgia with or without current major depressive disorder <sep>', 'fibromyalgia in adults <sep> adult patients age 18-70 years who met 1990 american college of rheumatology criteria for fm <sep> 2270 patients screened 1196 <sep> the population had a mean age of 50.2 years a mean baseline weight of 180.8 pounds and a mean baseline body mass index of 30.6 kg/m(2 <sep>', 'fibromyalgia <sep> outpatients  18 years of age who met american college of rheumatology criteria for fm and had  4 score on the brief pain inventory bpi average pain item <sep>', '1,025 patients with fibromyalgia <sep> patients with fibromyalgia <sep>', '520 patients meeting american college of rheumatology criteria for fibromyalgia <sep> patients with or without major depressive disorder <sep> patients with fibromyalgia <sep> patients both with and without major depressive disorder <sep> fibromyalgia patients with or without current major depressive disorder <sep>', 'outpatients diagnosed with fm according to 1990 american college of rheumatology criteria n  884 <sep> fibromyalgia fm in a european population <sep>', 'fibromyalgia <sep> patients with fibromyalgia during six months of treatment <sep>', 'fibromyalgia <sep> 125 patients <sep>', '888 patients with fm <sep> fibromyalgia fm <sep>'], 'interventions': ['duloxetine with placebo <sep> placebo <sep> duloxetine a serotonin and norepinephrine reuptake inhibitor <sep> duloxetine <sep> duloxetine <sep>', 'duloxetine 60 mg once daily qd <sep> duloxetine <sep> placebo <sep> duloxetine a selective serotonin and norepinephrine reuptake inhibitor <sep>', 'placebo <sep> milnacipran 100 mg/d milnacipran 200 mg/d or placebo <sep> pgic <sep> milnacipran <sep> fm <sep> milnacipran <sep>', 'duloxetine <sep> placebo <sep> flexible dosed duloxetine <sep>', 'placebo <sep> milnacipran <sep> milnacipran <sep>', 'duloxetine <sep> placebo <sep> duloxetine <sep>', 'placebo <sep> milnacipran <sep> milnacipran <sep>', 'duloxetine <sep> placebo <sep> duloxetine <sep>', 'placebo or milnacipran <sep> placebo <sep> milnacipran <sep>', 'placebo <sep> milnacipran <sep> placebo milnacipran <sep> milnacipran <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",the snris duloxetine and milnacipran provided a small incremental benefit over placebo in reducing pain. the superiority of duloxetine and milnacipran over placebo in reducing fatigue and limitations of qol was not substantial. duloxetine and milnacipran were not superior to placebo in reducing sleep problems. the dropout rates due to adverse events were higher for duloxetine and milnacipran than for placebo. the most frequently reported symptoms leading to stopping medication were nausea dry mouth constipation headache somnolence/dizziness and insomnia. rare complications of both drugs may include suicidality liver damage abnormal bleeding elevated blood pressure and urinary hesitation.
299,"{'outcomes': ['physiologic indicators of gastric cardiac or pulmonary functions occurred <sep> global evaluation scores <sep> seizure counts and safety <sep> voice alteration and dyspnea <sep> total seizure frequency <sep> efficacy and safety <sep>'], 'punchline_text': ['no changes in physiologic indicators of gastric cardiac or pulmonary functions occurred. <sep>'], 'population': ['partial-onset seizures <sep> patients with refractory partial-onset seizures <sep> patients had at least six partial-onset seizures over 30 days involving complex partial or secondarily generalized seizures <sep> patients receiving high stimulation 94 patients ages 13 to 54 years <sep>'], 'interventions': ['vagus nerve stimulation <sep> vagus nerve stimulation therapy <sep> chronic intermittent left vagus nerve stimulation <sep> presumably therapeutic high vagus nerve stimulation with less low stimulation <sep>'], 'punchline_effect': [' no diff <sep>']}",vns for partial seizures appears to be an effective and well tolerated treatment. adverse effects of hoarseness cough pain paresthesias and dyspnea are associated with the treatment but appear to be reasonably well tolerated as dropouts were rare. typical central nervous system adverse effects of antiepileptic drugs such as ataxia dizziness fatigue nausea and somnolence were not statistically significantly associated with vns treatment.
300,"{'outcomes': ['pain relief <sep> mobility <sep> pain mobility and functional ability <sep> subjective pain relief and appreciation of improvement of mobility <sep>', 'maximum incisal opening and pain scores the overall success rate <sep> therapeutic success <sep> interincisal opening lateral excursions occlusal evaluation deviation on opening and tenderness to palpation <sep> pain joint noise jaw mobility and dietary alterations <sep>', 'pain and improved mandibular function <sep> visual analog scale for pain and a questionnaire concerning mandibular functional impairment <sep> maximum interincisal opening and protrusion recording of clicking and crepitation and palpation for tenderness of the tmj and jaw muscles <sep>', 'pain and improved mandibular function <sep> joint tenderness <sep> mfiq vas maximum opening and protrusion lateral joint tenderness muscle tenderness crepitation and clicking <sep> joint tenderness and pain on lateral palpation <sep> muscle tenderness and pain <sep> visual analog scale vas for pain and a mandibular functional impairment questionnaire mfiq <sep> severity of pain <sep>', 'craniomandibular index cmi and symptom severity index ssi for jaw function and tmj pain respectively <sep>', 'pain <sep> arthroscopic lysis and lavage all <sep>'], 'punchline_text': ['patients treated with arthroscopic surgery reported more pain relief and more improvement of mobility than patients treated non-surgically although clinical assessment results were comparable between the two groups. <sep>', 'therapeutic success was not significantly different for arthroscopy and arthrocentesis both surgical modalities are useful for decreasing patient reports of pain while increasing functional mobility of the mandible. <sep>', 'discectomy reduced pain somewhat more effectively than arthroscopic lysis and lavage. <sep>', 'in both the open and arthroscopy groups mandibular function improved significantly p  .005). <sep>', 'using an intention-to-treat analysis we observed no between-group difference at any follow-up for cmi p  or  0.33 or ssi p  or  0.08). <sep>', 'both groups had significantly less pain in the joint and better jaw opening one year postoperatively. <sep>'], 'population': ['twenty-one patients appeared to obey strict criteria for participation <sep> patients with temporomandibular joint tmj osteoarthrosis and internal derangement <sep>', 'temporomandibular joint disorders <sep> nineteen patients with clinical and radiographic documentation of internal derangement of the temporomandibular joint(s unresponsive to nonsurgical therapy <sep>', 'twenty-two patients with a clinical diagnosis of chronic closed lock <sep> patients with chronic closed lock of the temporomandibular joint tmj <sep> chronic closed lock of the temporomandibular joint <sep> twenty patients completed the study <sep>', 'patients with chronic closed lock of the temporomandibular joint tmj <sep> chronic closed lock of the temporomandibular joint <sep> symptomatic patients with a diagnosis of chronic closed lock of the tmj <sep> twenty patients with a clinical and radiologic diagnosis of chronic closed lock <sep>', '106 individuals with tmj closed lock <sep>', 'patients with stage iii or above tmj internal derangement who had not responded to three months of non-surgical treatment <sep> thirty-five patients 41 joints had all and 66 patients 73 joints had aalcr <sep>'], 'interventions': ['arthroscopic surgery <sep> arthroscopic surgery followed by post-operative physical therapy n  9 or non-surgical treatment <sep> arthroscopic surgery with non-surgical treatment <sep> temporomandibular joint osteoarthrosis and internal derangement <sep>', 'arthroscopic lysis and lavage under general anesthesia or arthrocentesis hydraulic distention and lavage under intravenous sedation <sep> arthroscopy and arthrocentesis <sep>', 'discectomy or arthroscopic lysis and lavage <sep> discectomy and arthroscopic lysis and lavage <sep>', 'arthroscopic lysis lavage and capsular stretch <sep> open-surgery high condylectomy and disc repositioning and the arthroscopic procedure of lysis lavage and capsular stretch <sep> open surgery or arthroscopy <sep> high condylectomy and disc repositioning <sep> open-surgery high condylectomy and disc repositioning and the arthroscopic procedure of lysis lavage and capsular stretch <sep>', 'medical management rehabilitation arthroscopic surgery with post-operative rehabilitation or arthroplasty with post-operative rehabilitation <sep>', 'arthroscopic surgery <sep> arthroscopic surgery <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",both arthroscopy and nonsurgical treatments reduced pain after 6 months. when compared with arthroscopy open surgery was more effective at reducing pain after 12 months. nevertheless there were no differences in mandibular functionality or in other outcomes in clinical evaluations. arthroscopy led to greater improvement in maximum interincisal opening after 12 months than arthrocentesis however there was no difference in pain.
301,"{'outcomes': ['quality of life clinical manifestations plasma virus loads or cd4 cell counts <sep> symptoms hiv disease progression hiv-1 rna plasma viral loads cd4 and cd8 cell counts and scores on standard questionnaires for quality of life depression anxiety and coping <sep> median cd4 cell counts <sep> seriously ill or depressed and average coping and quality of life scores <sep> median hiv-1 plasma viral loads <sep> toxicities <sep> plasma viral loads cd4 cell counts symptoms and psychometric parameters <sep> hiv-1 rna level <sep> gastrointestinal disturbances <sep>', 'abnormal stool frequency of three abnormal stools <sep> abnormal stool frequency <sep> stool weight <sep> safe and well tolerated <sep> mean reduction from baseline stool weight <sep> safety and effectiveness <sep> stool weight and frequency <sep> stool frequency and weights <sep> serious adverse events or laboratory abnormalities <sep> safety and efficacy <sep>', 'pain intensity pain relief sensory perception quality of life mood and function <sep> current pain scores <sep> dropout rate <sep> relieving pain <sep> current pain worst pain pain relief sensory perception quality of life mood or function at study entry or at any time <sep>', 'therapeutic failures <sep> efficacy and safety <sep> viral load <sep> cd4 cell count <sep> rate of disease progression <sep> efficacy and safety <sep> severe side-effects <sep>', 'number of symptoms <sep> adherence and changes in weight cd4 count depression anxiety physical and social function and mental health <sep> mild adverse events ae <sep> life satisfaction and symptoms <sep> life satisfaction <sep> changes in life satisfaction perceived health and number and severity of symptoms <sep> life satisfaction or symptoms <sep>'], 'punchline_text': ['patients taking chinese herbs reported significantly more gastrointestinal disturbances 79 versus 38 p  .003 than those receiving placebo. <sep>', 'there were no serious adverse events or laboratory abnormalities. <sep>', 'there were no other statistically significant differences between the capsaicin and vehicle groups with respect to current pain worst pain pain relief sensory perception quality of life mood or function at study entry or at any time during the 4-week trial. <sep>', 'there was a statistically significant difference in therapeutic failures between groups in favor of spv(30 <sep>', 'number of symptoms was reduced in subjects receiving herbs 2.2 95 ci 4.1 0.3 but not in those receiving placebo 0.3 95 ci 3.2 2.7). <sep>'], 'population': ['university-based hiv outpatient clinic <sep> 68 hiv-infected adults with cd4 cell counts <sep> hiv-infected persons <sep> 0.5 x 10(9)/l. participants <sep> hiv-1-infected individuals <sep>', '41 subjects 80 were receiving antiretroviral therapy and 39 subjects 77 were receiving at least one protease inhibitor <sep> patients with aids and diarrhea <sep> patients with aids <sep> 26 subjects received <sep> hiv-positive subjects with a history of a cd4 count 200 or an aids-defining illness were admitted to an inpatient study unit and screened for diarrhea defined as at least three abnormal i.e. soft or watery stools and 200 g of abnormal stool weight over a 24-h period <sep>', 'twenty-six subjects were enrolled in the study <sep> patients with hiv-associated dspn <sep> hiv-associated peripheral neuropathy <sep>', 'hiv-infected asymptomatic patients <sep> 145 previously untreated subjects with asymptomatic hiv infection cdc group iv and cd4 cell counts between 250 and 500  10(6)/1 were recruited <sep>  1998 <sep> hiv asymptomatic patients <sep>', 'thirty adults with symptomatic hiv infection no previous aids-defining diagnosis and cd4 counts of 0.200-0.499 x 10(9)/l 200-499/mm3 <sep> human immunodeficiency virus hiv infection <sep> a university-affiliated acquired immunodeficiency syndrome aids clinic at a public general hospital <sep> hiv-associated symptoms <sep>'], 'interventions': ['35 chinese herbs or placebo <sep> chinese medicinal herbs <sep> placebo <sep> chinese herb therapy <sep>', 'sp-303 <sep> sp-303 or placebo <sep> placebo <sep>', 'capsaicin <sep> capsaicin <sep> topical capsaicin <sep> topical capsaicin <sep>', 'placebo <sep> spv(30 <sep> copyright <sep> buxus sempervirens l. preparations spv(30 <sep>', '31 chinese herbs or a cellulose placebo <sep> placebo <sep> chinese medicinal herb preparation <sep> chinese herbal treatment <sep> chinese herbs <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",there is insufficient evidence to support the use of herbal medicines in hiv-infected individuals and aids patients. potential beneficial effects need to be confirmed in large rigorous trials.
302,"{'outcomes': ['mean frequency of the target behavior <sep> target behavior <sep> reading condition b and the singing condition c <sep>'], 'punchline_text': ['the singing condition was significantly more effective than the reading condition only in case study iii. <sep>'], 'population': ['participants in the study were four first and second-grade students with a primary diagnosis of autism attending an elementary school in eastern iowa <sep> students with autism <sep>'], 'interventions': ['musically adapted social stories <sep> musical presentation of social story information <sep>'], 'punchline_effect': [' sig increase <sep>']}",the included studies were of limited applicability to clinical practice. however the findings indicate that music therapy may help children with autistic spectrum disorder to improve their communicative skills. more research is needed to examine whether the effects of music therapy are enduring and to investigate the effects of music therapy in typical clinical practice.
303,"{'outcomes': ['excessive number of groin relapses <sep> progression-free interval <sep> metastatic involvement of the groin nodes <sep> survival <sep> groin relapses <sep>'], 'punchline_text': ['the groin dissection regimen had significantly better progression-free interval p  0.03 and survival p  0.04). <sep>'], 'population': ['carcinoma of the vulva <sep> patients with squamous carcinoma of the vulva and n0-1 nodes <sep> members of the gynecologic oncology group randomized 58 patients with squamous carcinoma of the vulva and nonsuspicious n0-1 inguinal nodes to receive either <sep>'], 'interventions': ['radiation therapy <sep> groin dissection versus groin radiation <sep> post-operative radiation <sep> groin dissection or groin radiation each in conjunction with radical vulvectomy <sep>'], 'punchline_effect': [' sig increase <sep>']}",primary radiotherapy to the groin results in less morbidity but may be associated with a higher risk of groin recurrence and decreased survival when compared with surgery. due to the small numbers in this trial and criticisms regarding the depth of radiotherapy applied corroboration of these findings by larger rcts using a standardised radiotherapy method is desirable. however until better evidence is available surgery should be considered the first choice treatment for the groin nodes in women with vulvar cancer. individual patients not physically able to withstand surgery may be treated with primary radiotherapy.
304,"{'outcomes': ['side effects <sep> improvement or remission <sep>', 'efficacy <sep>', 'time of initial presentation symptom resolution and endoscopic and histologic improvement <sep> recovery <sep>', 'mean disease activity index <sep> rectal bleeding <sep> distal ulcerative colitis proctosigmoiditis and proctitis <sep> efficacy and safety <sep>', 'efficacy <sep> pgi ratings <sep> cgi scores <sep> mean dai scores <sep> adverse event reports clinical laboratory tests and physical examination <sep> adverse events primarily headache and nausea <sep> very much improved or much improved <sep> physician-rated disease activity index dai which included symptom evaluations and sigmoidoscopic findings by physician-rated clinical global improvement cgi scores and by patient global improvement pgi scores <sep> efficacy and safety <sep>', 'clinical and endoscopic remission <sep> clinical remission endoscopic remission histological changes global assessment and standard safety measures <sep>', 'a disease activity index dai <sep> median dais <sep> practicality and patient compliance <sep>', 'tolerated <sep> remission rates <sep> clinical remission <sep> remission rates <sep>', 'clinical score <sep>', 'clinical activity <sep> side effects <sep> clinical and endoscopic activity <sep>', 'clinical remission rate <sep> morning cortisol levels <sep> tolerated <sep> disease activity index dai score <sep> dai score <sep> efficacy and safety <sep> adrenal function monitoring of adverse events vital signs and laboratory parameters <sep>', 'clinical remission rate <sep> symptoms number of bowel movements per day quality of stools presence of blood and mucus and state of well-being <sep> adverse events <sep> haematology chemistry and adverse events <sep> endoscopy and histopathology scores <sep> efficacy and safety <sep>', 'endoscopic clinical and histologic improvement <sep> distal ulcerative colitis <sep>', 'amount of blood in stools urgency straining at stools and abdominal pain in daily diaries <sep> absence of blood in stools <sep> disease status <sep> tolerated <sep> total dai scores and abbreviated dai scores <sep> total dai scores <sep> tolerated and produced earlier and more complete relief of rectal bleeding <sep>', 'clinical remission rates <sep> severe discomfort pain and retention problems <sep> efficacy and safety <sep> clinical remission <sep>', 'complete clinical remission <sep> endoscopic and histological evaluation of colonic mucosa <sep> adverse events <sep> tolerated <sep> complete relief of symptoms and endoscopic and histological evidence of remission or improvement <sep> efficacy tolerance and acceptance <sep> clinical remission <sep>', 'frequency of patients with an endoscopic remission <sep> clinical activity index endoscopic index histological index and global efficacy assessment <sep> clinical remission <sep> efficacy and tolerability <sep> disease activity <sep> histological index <sep> laboratory variables and vital signs <sep> recording of adverse events laboratory variables and vital signs <sep>', 'disease activity index <sep> clinical improvement remission and relapse <sep> acute response and safety profile <sep> safety and efficacy <sep> complete mucosal healing <sep> median duration of response to alicaforsen enema treatment <sep>', 'efficacy <sep> disease activity index <sep> disease activity index value <sep> safety profile <sep> mesalazine enema disease activity index <sep> tolerability and safety <sep> tolerability and efficacy <sep>', 'abdominal bloating <sep> efficacy safety and patient tolerability <sep> clinical symptoms endoscopic and histological findings <sep> tolerated <sep> discomfort <sep> treatment tolerability and acceptability <sep> histological remission <sep> endoscopic remission rates <sep> clinical remission <sep> difficulty in retention <sep>', ""histologic activity <sep> disease activity index which represents a score with four variables stools frequency rectal bleeding mucosal appearance and physician's assessment of disease severity <sep> adverse events <sep> rate of histologic remission <sep> mean disease activity index score <sep> active ulcerative proctitis <sep> efficacy and safety <sep> disease activity index scores <sep>"", 'clinical and sigmoidoscopic remission <sep> efficacy tolerance and acceptance <sep> quicker clinical and sigmoidoscopic remission <sep> tolerability and practicality <sep> sigmoidoscopic remission <sep> clinical remission <sep>', 'histologic remission <sep> clinical remission rates <sep> compliance <sep> endoscopic remission <sep> endoscopic and histologic remissions <sep> clinical remission clinical activity index <sep>', 'remission rates <sep> anal burning <sep> efficacy and tolerability <sep> remission <sep> efficacy tolerability and overall acceptability <sep>', 'liquid stools <sep> sigmoidoscopic and histological remission rates <sep> tolerated <sep> histological remission <sep> distal ulcerative colitis <sep> symptoms <sep> sigmoidoscopic remission <sep> clinical remission <sep> efficacy and safety <sep>', ""absorbed radioactivity <sep> disease activity index dai <sep> daily evacuations more than usual evacuations containing blood sigmoidoscopy appearance and physician's overall assessment <sep>"", 'sigmoidoscopic and improved histological score <sep> bdp and 5-asa <sep>', 'determination of clinical endoscopic and histologic remission rates <sep> efficacy and tolerability <sep> clinical remission <sep>'], 'punchline_text': ['improvement or remission was seen in 77 of the 5-aminosalicylic acid-treated patients and in 72 of the prednisolone-treated patients p greater than 0.05). <sep>', 'no difference could be observed in terms of efficacy however it was the patients opinion that treatment with suppositories was easier than that with enemas p less than 0.01). <sep>', 'there was no significant difference with respect to age male/female ratio past history of proctosigmoiditis length of colorectum involved at the time of initial presentation symptom resolution and endoscopic and histologic improvement among the three treatment groups. <sep>', 'mean disease activity index declined 55 for patients on 5-aminosalicylic acid and 24 for patients on placebo p  0.0001). <sep>', 'adverse events primarily headache and nausea occurred significantly more frequently p  0.02 in the sas than in the 5-asa group 83 vs 42%). <sep>', 'the foam enema was shown to be as efficacious as the reference even though the daily dose in the foam treatment contained only half as much active drug as in the reference treatment. <sep>', 'the difference between the treatment groups was statistically significant p  0.02 due to a better effect of mesalazine in patients with proctitis. <sep>', 'remission rates at w2 were 48.1 versus 50.6 in itt 97.5 ci 12.8 and 49.1%versus 52.1 in pp 97.5 ci 13.8 in foam versus liquid respectively. <sep>', 'improvement in clinical score was achieved in seven of nine 5-asa enema-treated patients versus one of nine hydrocortisone enema-treated patients p less than 0.05). <sep>', 'fifty-two patients with mild to moderate distal ulcerative colitis were randomized under double-blind conditions to receive a rectal preparation of either pentasa 1 g/day or cortenema 100 mg/day for 3 wk. <sep>', 'a significant decrease in the dai score p  0.05 was observed in both treatment groups with a clinical remission rate of 36.7 in the bdp group and of 29.2 in the 5-asa group. <sep>', 'budesonide and 5-asa enemas both resulted in a significant improvement in endoscopy and histopathology scores but no difference could be demonstrated between the two treatment groups. <sep>', 'endoscopic clinical and histologic improvement were comparable in the two treatment groups. <sep>', 'the combination of oral and rectal mesalamine therapy was well tolerated and produced earlier and more complete relief of rectal bleeding than oral or rectal therapy alone. <sep>', 'the low-volume foam was associated with a lower frequency of severe discomfort pain and retention problems. <sep>', 'patient evaluation of therapy showed that foam was much better accepted than enema because foam was more comfortable more practical easier to retain and interfered less with daily living.(abstract truncated at 250 words <sep>', 'the foam enemas were generally well-tolerated and no treatment-related changes on laboratory variables and vital signs were noted. <sep>', 'alicaforsen is an antisense oligonucleotide inhibitor of intercellular adhesion molecule 1 protein expression with activity in subjects with ulcerative colitis and pouchitis. <sep>', 'the disease activity index lowered at t8 versus t4 in the beclomethasone diproprionate enema and foam <sep>', 'endoscopic remission rates at week 4 were 51 and 52 for the mesalazine gel and foam enemas respectively p  0.925). <sep>', 'improvement in mean disease activity index score was significantly greater with suppositories compared with oral mesalazine both at two-week and four-week visits mean disease activity index scores at baseline two and four weeks suppositories  7.7 2.59 and 1.48 tablets  7.42 5.72 and 3.48 respectively p  0.001)). <sep>', 'the patients evaluation for tolerability and practicality showed that the pentasa suppository was significantly superior to the claversal suppository. <sep>', 'endoscopic remission was achieved by 45.0 of patients on 5-asa mmx and by 36.8 of those on enema whereas 15.0 and 8 of patients respectively showed histologic remission. <sep>', 'salofalk foam and enema are equally effective for the treatment of proctitis proctosigmoiditis and left-sided ulcerative colitis. <sep>', 'in this study mesalazine foam enema was superior to prednisolone foam enema with regards to clinical remission this was supported by favourable trends in sigmoidoscopic and histological remission rates. <sep>', 'patients with active distal proctitis received either 5-aminosalicylic 5-asa acid or identical placebo suppositories 500 mg t.i.d. for 6 weeks. <sep>', 'the combination of bdp and 5-asa was significantly superior to single-agent therapy in terms of both improved sigmoidoscopic and improved histological score. <sep>', 'at 4 weeks clinical remission was achieved in 7 of 31 39 patients with placebo in 22 of 32 69 patients in the 1 g mesalazine group and 23 of 31 74 patients in the 1.5 g mesalazine group. <sep>'], 'population': ['outpatients with mild to moderate proctosigmoiditis <sep> patients with slightly to moderately active proctosigmoiditis <sep> ulcerative proctosigmoiditis <sep> seven gastroenterological departments <sep> a total of 123 patients were included of whom 114 completed the study 53 <sep>', 'thirty-nine patients with documented active distal proctitis less than 20 cm <sep> twenty patients received enemas while 19 patients received <sep>', 'patients presenting to the ferguson clinic with the diagnosis of idiopathic proctosigmoiditis were evaluated for age sex prior history of proctitis duration of symptoms prior to presentation endoscopic scoring and mucosal biopsies <sep>', '153 patients with ulcerative colitis involving up to 50 cm of distal colon <sep>', 'thirty-seven patients <sep> patients with active mild to moderate distal ulcerative colitis <sep> active distal ulcerative colitis in adults <sep>', 'distal ulcerative colitis <sep> patients with active distal ulcerative colitis <sep> patients with active distal ulcerative colitis <sep>', 'seventy-nine patients with distal ulcerative colitis <sep> patients with distal ulcerative colitis <sep> patients with proctitis <sep>', 'patients with mild-to-moderate active proctitis and proctosigmoiditis <sep> patients with active left-sided ulcerative colitis uc <sep> 375 patients with mild-to-moderate uc <sep> inclusion criteria were disease extension at least 5 cm from anorectal junction and not above splenic flexure and clinical activity index cai 1-4  or  4 <sep> active left-sided ulcerative colitis <sep>', 'refractory distal ulcerative colitis <sep> patients with distal ulcerative colitis <sep> 18 patients with persistent active distal ulcerative colitis after at least a 3-wk course of treatment with 100-mg <sep>', 'fifty-two patients with mild to moderate distal ulcerative colitis <sep> active ulcerative colitis <sep>', 'distal active ulcerative colitis with <sep> patients with active uc without interference with pituitary adrenal axis <sep> patients with mild to moderate distal active uc <sep> 217 patients were enrolled and treated with bdp n  111 or 5-asa n  106 <sep>', 'active distal ulcerative colitis and proctitis <sep> active distal ulcerative colitis <sep> ninety-seven patients <sep>', 'distal ulcerative colitis <sep> twenty-nine patients with attacks of distal ulcerative colitis <sep>', 'distal ulcerative colitis <sep> sixty outpatients with ulcerative colitis at least 5 cm above the anal verge and not more than 50 cm inclusive and a total disease activity index dai score between 4 and 10 inclusive <sep> patients with active mild-to-moderate distal ulcerative colitis <sep>', 'patients with active distal ulcerative colitis clinical activity index cai  4 endoscopic index  or  4 <sep> 330 patients were evaluable for <sep> active distal ulcerative colitis <sep>', '233 patients from 12 outpatient clinics in italy <sep> 116 patients with moderate attacks <sep> 117 patients with mild attacks <sep> active ulcerative colitis <sep>', 'distal ulcerative colitis <sep> mildly to moderately active ulcerative colitis <sep> patients with distal ulcerative colitis <sep> 111 patients with mildly to moderately active proctitis proctosigmoiditis or left-sided ulcerative colitis received <sep>', 'subjects with mild to moderate active left-sided ulcerative colitis <sep> subjects with ulcerative colitis and pouchitis <sep> mild to moderate left-sided ulcerative colitis <sep>', 'distal ulcerative colitis <sep> 15 referral gastrointestinal units 99 patients with distal ulcerative colitis were enrolled <sep> mild active distal ulcerative colitis <sep> mild-moderate distal ulcerative colitis <sep>', '103 patients with mild to moderate left-sided colitis or proctosigmoiditis <sep> left-sided ulcerative colitis <sep> patients with acute left-sided ulcerative colitis <sep>', '58 patients with active histologically confirmed ulcerative proctitis  or  15 cm <sep> ulcerative proctitis <sep> patients with active ulcerative proctitis <sep>', 'proctitis and distal proctosigmoiditis <sep> patients with ulcerative proctitis or distal proctosigmoiditis <sep> fifty patients with active ulcerative colitis extending not beyond 20 cm from the anus on sigmoidoscopy <sep>', 'patients with left-sided ulcerative colitis <sep> seventy-nine patients were enrolled <sep> patients with active left-sided disease and 2 <sep>', 'active distal ulcerative colitis <sep> 112 patients were in remission and only 59 patients <sep> patients with active proctitis proctosigmoiditis and left-sided ulcerative colitis as evaluated by the clinical activity index cai  or 4 and endoscopic index ei  or 6 <sep> patients with at least one post-treatment efficacy evaluation were included in the intent-to-treat analysis n=89 foam n=96 enema <sep> a total of 195 patients were enrolled <sep>', 'n  149 evaluable patients and <sep> patients aged over 18 years presenting with a relapse of distal ulcerative colitis <sep> patients with acute distal ulcerative colitis <sep>', '27 patients randomized 14 received <sep> patients with active distal proctitis <sep> 14 patients with initial mean dai 7.1 <sep> 6 patients with inflammatory bowel disease and 6 healthy volunteers <sep>', 'sixty patients with active distal ulcerative colitis <sep> active ulcerative proctitis <sep>', '94 patients with mild to moderate distal proctosigmoiditis less than 20 cm <sep> ulcerative proctitis or distal proctosigmoiditis <sep> patients with active distal proctosigmoiditis <sep> eleven patients nine receiving <sep>'], 'interventions': ['5-aminosalicylic acid <sep> topical 5-aminosalicylic acid versus prednisolone <sep> slightly acidic buffered suspension of 1000 mg 5-aminosalicylic acid pentasa <sep> prednisolone <sep> 5-aminosalicylic acid 61 prednisolone <sep>', '5-aminosalicylic acid 5-asa enemas <sep> suppositories <sep> 5-aminosalicylic acid <sep>', 'corticosteroid enemas cs--100 mg of hydrocortisone/60 cc p.r <sep> mesalamine enemas 5-asa--4 g/60 cc p.r. q.h.s. n  19 and short-chain fatty acid enemas scfa--60 cc p.r. b.i.d. n  14 for the treatment of proctosigmoiditis <sep> short-chain fatty acid enemas <sep>', 'active medication <sep> placebo <sep> sulfasalazine <sep> 5-aminosalicylic acid <sep> 4-g 5-aminosalicylic acid enemas <sep> 5-aminosalicylic acid enema <sep> 5-aminosalicylic acid enemas <sep>', 'mesalamine suspension enema and oral sulfasalazine <sep> sas <sep> rectal mesalamine <sep> 5-asa <sep> mesalamine 5-asa suspension enema versus oral sulfasalazine sas <sep> oral sulfasalazine <sep>', 'mesalazine 5-aminosalicylic acid <sep> mesalazine foam enema claversal foam <sep> foam enema 2 g mesalazine <sep>', 'mesalazine suppositories <sep> hydrocortisone <sep> hydrocortisone foam both given twice daily <sep> hydrocortisone foam <sep> mesalazine <sep> topical treatment <sep> mesalazine suppositories <sep>', 'mesalamine foam 1 g/80 ml/day or mesalamine liquid enema <sep> mesalamine <sep> mesalamine <sep> mesalamine liquid enema <sep>', 'placebo <sep> 5-aminosalicylic acid 5-asa <sep> hydrocortisone enemas with or without oral sulfasalazine <sep> hydrocortisone <sep> 5-asa <sep> sulfasalazine <sep> 5-aminosalicylic acid enemas <sep> hydrocortisone enemas <sep>', '5-aminosalicylic acid <sep> hydrocortisone 100 mg/day enema cortenema <sep> low pentasa dosage versus hydrocortisone <sep> rectal preparation of either pentasa 1 g/day or cortenema <sep> hydrocortisone enemas <sep>', 'topically acting cs beclomethasone dipropionate bdp versus mesalamine 5-asa <sep> 5-asa <sep> bdp <sep> corticosteroids cs <sep> bdp 3 mg enema <sep> 5-asa 1 <sep> beclomethasone dipropionate or mesalamine <sep>', '5-asa enema mesalazine <sep> budesonide enema <sep> budesonide <sep> budesonide and 5-aminosalicylic acid enemas <sep>', '5-aminosalicylic acid <sep> 5-asa <sep> prednisolone phosphate sodium enemas <sep> 5-aminosalicylic acid 5-asa <sep> prednisolone phosphate sodium pp enemas <sep>', 'mesalamine rectal enema n  18 once nightly oral mesalamine <sep> rectal mesalamine <sep> placebo <sep> mesalamine rectal suspension enema rowasa alone oral mesalamine tablets asacol alone and the combination of mesalamine enema and mesalamine tablets <sep> mesalamine <sep> oral and rectal mesalamine therapy <sep> mesalamine tablets combination-therapy <sep>', 'low-volume vs. a high-volume mesalazine foam <sep> low-volume vs. a high-volume 5-aminosalicylic acid foam <sep> 2 x 1 g/30 ml low-volume n  163 or 2 x 1 g/60 ml high-volume 5-aminosalicylic acid foam <sep> mesalazine mesalamine 5-aminosalicylic acid <sep>', '5-asa colonic foam versus 5-asa liquid enema <sep> 5-asa colonic foam <sep> 5-asa <sep>', 'placebo <sep> mesalazine foam enema salofalk foam <sep> mesalazine <sep> mesalazine foam enema or placebo enema 2 g mesalazine <sep> mesalazine <sep>', 'alicaforsen <sep> alicaforsen enema <sep> nightly enema of 120 mg alicaforsen <sep> alicaforsen enema to standard of care mesalazine mesalamine <sep> mesalazine enema <sep> mesalazine <sep> alicaforsen <sep>', 'topical beclomethasone diproprionate 3mg enema and foam versus mesalazine <sep> beclomethasone dipropionate <sep> beclomethasone diproprionate and mesalazine <sep> random preparations beclomethasone diproprionate enema beclomethasone diproprionate foam mesalazine enema mesalazine foam <sep> beclomethasone <sep> topical beclomethasone diproprionate <sep> mesalazine <sep>', 'mesalazine gel enema <sep> mesalazine 2 g gel enema <sep> mesalazine <sep> mesalazine 2 g foam enema <sep> mesalazine rectal gel preparation without propellant gas <sep> mesalazine foam enema <sep> mesalazine gel preparation <sep>', 'oral mesalazine <sep> mesalazine suppositories <sep> rectal mesalazine <sep> suppositories <sep> mesalazine <sep>', 'mesalazine suppositories <sep> claversal suppositories <sep> mesalazine <sep> pentasa suppositories <sep> mesalazine suppositories <sep> claversal mesalazine 500 mg suppository b.d <sep>', '5-asa mmx three times per day plus placebo enema or 4 g of 5-asa enema plus placebo <sep> 5-asa <sep> mesalazine <sep> 5-asa enemas and mmx <sep> multi-matrix mmx <sep>', 'mesalazine rectal foam salofalk foam with mesalazine enema <sep> mesalazine <sep> mesalazine foam salofalk foam <sep> mesalazine <sep> mesalazine enema <sep> mesalazine foam 2 <sep>', 'prednisolone foam enemas <sep> mesalazine foam enema <sep> prednisolone <sep> oral or rectal mesalazine <sep> prednisolone foam enema <sep> mesalazine foam enemas <sep> prednisolone <sep> mesalazine <sep>', '5-asa suppositories <sep> placebo <sep> 99mtc-labelled 5-aminosalicylic acid suppositories <sep> active medication and 13 placebo <sep> 5-aminosalicylic 5-asa acid or identical placebo suppositories <sep>', '5-asa or bdp <sep> beclomethasone dipropionate <sep> 5-aminosalicylic acid <sep> 5-asa <sep> beclomethasone dipropionate bdp enema <sep> bdp/5-asa <sep> 5-aminosalicylic acid 5-asa enemas <sep>', 'mesalazine suppositories <sep> placebo <sep> mesalazine 5-aminosalicylic acid suppositories <sep> mesalazine <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",rectal 5-asa should be considered a first-line therapy for patients with mild to moderately active distal uc. the optimal total daily dose and dose frequency of 5-asa remain to be determined. future research should define differences in efficacy among patient subgroups defined by proximal disease margin and disease activity. there is a strong need for consensus standardization of outcome measurements for clinical trials in ulcerative colitis.
305,"{'outcomes': ['pain relief <sep> immediate lessening of pain <sep> duration of pain relief <sep>', 'pain muscular contracture and mobility <sep>', 'disability <sep> pain visual analogue scale <sep> duration of sick leave <sep> cost-effectiveness ratio for pain disability and quality of life <sep> clinical effectiveness and cost-effectiveness <sep> low back pain visual analogue scale <sep> effectiveness and cost-effectiveness <sep> median intensity of pain <sep> median duration of pain <sep>'], 'punchline_text': ['neuroreflexotherapy intervention seems to be a simple and effective treatment for rapid amelioration of pain episodes in patients with chronic low back pain. <sep>', 'patients in the treatment group showed immediate clinically and statistically significant improvements p  0.0001 in pain muscular contracture and mobility allowing them to discontinue pharmacological treatment and keeping them free of symptoms during the study period. <sep>', 'moreover neuroreflexotherapy intervention was associated with a significantly p  0.035 lower number of consultations to private or public specialists fewer indications of radiographs by primary care physicians lower cost of drug treatment and less duration of sick leave throughout the follow-up period. <sep>'], 'population': ['exacerbations of chronic low back pain <sep> three physicians who had no connection with the research team <sep> 78 patients with chronic low back pain <sep> patients with chronic low back pain <sep>', '43 patients <sep> non specified low back pain <sep> ninety-one patients with a confirmed diagnosis of nonspecific low back pain were referred for treatment from primary health care facilities in the spanish national health system <sep>', 'physicians recruited patients who had low back pain that had lasted for 14 or more days despite drug treatment and who did not meet criteria for surgery <sep> twenty-one primary care physicians working in seven primary care centers of the spanish national health service in palma de mallorca spain <sep> 45 patients recruited by physicians from the control group were treated according to the standard protocol whereas the 59 patients recruited by physicians from the intervention group were in addition referred to <sep> subacute and chronic low back pain in routine general practice <sep>'], 'interventions': ['neuroreflexotherapeutic intervention <sep> neuroreflexotherapy intervention <sep> local and remote sustained trigger point therapy <sep> neuroreflexotherapy <sep> neuroreflexotherapy <sep>', 'neuro-reflexotherapic intervention <sep> single neuro-reflexotherapic intervention <sep> reflexotherapic intervention <sep> neuro-reflexotherapy intervention <sep>', 'neuroreflexotherapy <sep> neuroreflexotherapy <sep> neuroreflexotherapy intervention <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",nrt appears to be a safe and effective intervention for the treatment of chronic non-specific lbp. the efficacy is less clear for sub-acute lbp. however these results are limited to three trials conducted by a small number of specifically trained and experienced clinicians in a limited geographical location. no data are available on the ease and time-frame needed to achieve that level of expertise. rcts by other practitioners in other locations that replicate the effects reported in this review are needed before recommending a broader practice.
306,"{'outcomes': ['cognitive behavioral or quality-of-life measures <sep> defense and veterans head injury program dvhip <sep> greater return-to-duty rate <sep>', 'average length of stay <sep> length of stay <sep>', 'functional independence measure fim primary outcome and neurobehavioural cognitive status examination ncse total scores <sep> maximum fim total score <sep> maximum glasgow outcome scale gos score <sep>', 'index of activities of daily living <sep>', 'severe post-concussion symptoms <sep> rivermead head injury follow up questionnaire a validated and reliable measure of social disability <sep> social disability <sep> social morbidity and severity of post-concussion symptoms <sep>', 'emotional distress and how well-informed they felt about tbi and available resources <sep>', 'level of depression self-esteem and socialization <sep> socialization and self-esteem <sep> functional independence measure fim brunnstrom stages of motor recovery timed mobility tasks and the jebson hand evaluation <sep>', 'rate of pcs and in life satisfaction <sep>', 'hospital anxiety and depression scale <sep> median changes on individual subscales <sep> barthel index bi and the brain injury community rehabilitation outcome-39 bicro-39 focused on levels of activity and participation <sep> indices of socializing productive employment anxiety or depression <sep> bi and the bicro-39 total score and self organisation and psychological wellbeing subscales <sep> functional independence measure and the functional assessment measure fim+fam <sep>', ""motor functional and cognitive outcomes <sep> spasticity <sep> spasticity changes <sep> ashworth scale motor status with brunnstrom's stages functional status with the fim instrument and cognitive status with the mini-mental state examination <sep>"", 'levels of distress <sep> barthel index the functional independence measure fim and the newcastle independence assessment form niaf <sep> general health questionnaire <sep> injury severity and shorter hospital stay <sep>', 'activity level <sep> activity assessed with the assessment of motor and process skill <sep>', 'shorter length of hospital stay <sep> longer hospital stay <sep>'], 'punchline_text': ['at 1-year follow-up there was no significant difference between patients who had received the intensive in-hospital cognitive rehabilitation program vs the limited home rehabilitation program in return to employment 90 vs 94 respectively p=.51 difference 4 <sep>', 'after controlling for confounders and case mix as expressed by type of therapy required patients in the experimental group showed a significant 14-day reduction in length of stay 0.01). <sep>', 'there were significantly more patients in the high intensity group than in the control group who achieved a maximum fim total score at the third month 47 vs. 19 p  0.015 and a maximum glasgow outcome scale gos score at the second 28 vs. 8 p  0.034 and third months 34 vs. 14 p  0.044). <sep>', 'improvement was greatest in those receiving intensive treatment intermediate in those receiving conventional treatment and least in those receiving no routine treatment. <sep>', 'the early interventions offered by a specialist service significantly reduced social morbidity and severity of post-concussion symptoms in trial group patients at six months after head injury. <sep>', 'two outcomes were compared at 6 months post-injury carers emotional distress and how well-informed they felt about tbi and available resources. <sep>', 'the treated group improved in terms of socialization and self-esteem as evidenced by a lower sickness impact profile whereas the controls tended to get worse. <sep>', 'no statistical differences were found between the intervention and control groups. <sep>', 'outreach participants were significantly more likely to show gains on the bi and the bicro-39 total score and self organisation and psychological wellbeing subscales. <sep>', 'intense inpatient rehabilitation services for stroke survivors provide significantly more favorable functional and cognitive outcomes with relatively low complications than did nonintense rehabilitation efforts in home settings. <sep>', 'the comparison group despite initial lower injury severity and shorter hospital stay did not demonstrate equivalent gains or any posttreatment effect. <sep>', 'there were no significant differences between the groups on any of the four assessments. <sep>', 'the different intensities of therapy employed in this study showed no evidence of a ceiling effect and the intervention group made significantly more rapid progress on tests of dependency during the period of admission. <sep>'], 'population': ['patients with moderate-to-severe tbi <sep> patients with tbi <sep> traumatic brain injury <sep> traumatic brain injury tbi <sep> one hundred twenty active-duty military personnel who had sustained a moderate-to-severe closed head injury manifested by a glasgow coma scale score of 13 or less or posttraumatic amnesia lasting at least 24 hours or focal cerebral contusion or hemorrhage on computed tomography or magnetic resonance imaging <sep> january 1992 through february 1997 at a us military medical referral center <sep> young adults <sep>', 'patients in a rehabilitation unit <sep> patients were under 65 primarily with stroke but also with other conditions such as traumatic brain injury and multiple sclerosis <sep>', 'sixty-eight patients age 12-65 years with moderate-to-severe tbi were included <sep> patients with traumatic brain injury tbi <sep>', '1094 patients with a confirmed stroke admitted to northwick park a district general hospital 364 33 died while in hospital 215 20 were fully recovered when discharged and 329 30 were too frail or too ill from diseases other than stroke to be considered for active rehabilitation <sep> 12 patients referred direct to outpatients <sep> after stroke <sep>', '132 trial and 86 control patients <sep> all patients aged 16-65 years admitted to hospital after a head injury of any severity with or without other injuries entered the trial <sep> patients posttraumatic amnesia ranged from mild n=79 40 and moderate n=62 32 to severe n=38 19 and very severe n=17 9 <sep> patients admitted to hospital with a head injury benefit from a routinely offered early intervention service <sep> a mixed rural and urban health district of 560000 people with two accident and emergency departments provided the setting <sep> 314 patients were registered 184 <sep>', 'traumatic brain injury <sep> subjects were 96 adult carers of people consecutively admitted to two local hospitals <sep> carers of people with traumatic brain injury tbi <sep>', 'postacute stroke survivors <sep> forty-nine stroke survivors who were at least l yr mean 2.9 yr poststroke <sep> postacute stroke patients <sep>', 'mild traumatic brain injury mtbi patients by rehabilitation specialists <sep> patients who suffered several pcs and accepted rehabilitation did not recover after one year <sep> 78 patients were mainly referred to an occupational therapist <sep> mild traumatic brain injuries <sep> 1719 consecutive patients with mtbi 395 individuals 16-60 years of age met the mtbi definition <sep>', 'of 110 initially allocated 48 outreach and 46 information participants were successfully followed up <sep> participants were aged 16-65 had sustained severe tbi between 3 months and 20 years previously and had no other neurological conditions <sep> after severe traumatic brain injury <sep>', 'sixty patients age range 43-80yr who had a stroke between 1996 and 1999 and had been referred after medical stabilization <sep> copyright 2001 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation <sep> stroke survivors who received rehabilitation services in an acute inpatient rehabilitation setting multidisciplinary rehabilitation team with outcomes in survivors in a home-based setting family caregivers limited team supervision <sep>', 'traumatic brain injury <sep> fifty-six consecutive severe head injury admissions with an identified main caregiver referred for rehabilitation within 4 weeks of their injury <sep> severe head injury provided at hunters moor regional rehabilitation centre <sep> people with severe traumatic head injury <sep>', 'younger patients with stroke <sep> home of the patient or the ordinary day rehabilitation clinic at the university hospital <sep> fifty-eight patients median age 53 years consecutively discharged from inpatient rehabilitation with a first occurrence of stroke participated in training directly after discharge <sep>', 'fifty-six people with moderate and severe head injury consecutively admitted to southampton and poole hospitals between june 1995 and september 1997 <sep> after brain injury <sep> two district general hospitals on the south coast of england <sep>'], 'interventions': ['inpatient cognitive rehabilitation <sep> cognitive rehabilitation <sep> hospital cognitive rehabilitation program n=67 or a limited home rehabilitation program with weekly telephone support from a psychiatric nurse n=53 <sep>', 'therapy physiotherapy and occupational therapy <sep>', 'intensive rehabilitation <sep> control 2-hour/day intensity rehabilitation programmes <sep>', 'conventional rehabilitation and with a third regimen which included no routine rehabilitation <sep> remedial therapy <sep>', 'outpatient intervention or additional support by telephone <sep> additional service by a specialist team or a group receiving existing standard services <sep>', 'new rehabilitation service <sep> neuropsychological rehabilitation <sep>', 'intensive outpatient therapy <sep> intensive outpatient rehabilitation program <sep>', 'regular care <sep>', 'community based rehabilitation <sep> multidisciplinary community based outreach rehabilitation <sep>', 'inpatient rehabilitation group 2 home-based rehabilitation <sep> therapeutical and neuromuscular exercises with occupational therapy with professional supervision group 2 conventional exercises with family caregiver and limited professional supervision <sep>', 'coordinated multidisciplinary regional rehabilitation service <sep> coordinated multidisciplinary rehabilitation service <sep> multidisciplinary rehabilitation <sep> coordinated multidisciplinary rehabilitation <sep>', 'individually tailored training <sep> intervention <sep>', 'intensive therapy <sep> rehabilitation therapy <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",problems following abi vary. consequently different interventions and combinations of interventions are required to suit the needs of patients with different problems. patients presenting acutely to hospital with moderate to severe brain injury should be routinely followed up to assess their needs for rehabilitation. intensive intervention appears to lead to earlier gains. the balance between intensity and cost-effectiveness has yet to be determined. patients discharged from in-patient rehabilitation should have access to out-patient or community-based services appropriate to their needs. those with milder brain injury benefit from follow up and appropriate information and advice. not all questions in rehabilitation can be addressed by randomised controlled trials or other experimental approaches. some questions include which treatments work best for which patients over the long term and which models of service represent value for money in the context of life-long care. in future such questions will need to be set alongside practice-based evidence gathered from large systematic longitudinal cohort studies conducted in the context of routine clinical practice.
307,"{'outcomes': ['fasting insulin and fasting c-peptide levels <sep> carbohydrate metabolism <sep> fasting blood glucose <sep> tolerated <sep> area under the curve auc for glucose <sep>', 'markers of lipid carbohydrate and coagulation profiles <sep> lipid carbohydrate and coagulation profiles <sep>', 'haemostasis lipids carbohydrate metabolism c-reactive protein crp and sex hormone-binding globulin shbg <sep> crp <sep> haemostatic indices <sep> change from baseline to cycle 6 for all indices <sep> glucose and insulin parameters <sep> lng/ee high-density lipoprotein cholesterol decreased and low-density lipoprotein cholesterol and triglycerides <sep> haemostasis lipids and carbohydrate metabolism <sep> shbg <sep>', 'risk of diabetes or cardiovascular disease <sep> mean glucose insulin and log homeostatic model assessment <sep> total cholesterol hdl and triglycerides <sep> change in glucose <sep> fasting serum glucose insulin triglycerides and total low-density lipoprotein ldl and high-density lipoprotein hdl cholesterol <sep> carbohydrate and lipid metabolism <sep>', 'carbohydrate metabolism adrenal or thyroid function <sep> carbohydrate metabolism and adrenal and thyroid function <sep> insulin <sep> levels of dehydroepiandrosterone sulfate <sep> thyroid stimulating hormone levels <sep> carbohydrate metabolism adrenal and thyroid function <sep> concentrations of cortisol binding globulin and total cortisol <sep> carbohydrate metabolism glucose insulin glycosylated hemoglobin adrenal function total cortisol cortisol binding globulin dehydroepiandrosterone sulfate thyroid function thyroid stimulating hormone free thyroxine <sep> free thyroxine levels <sep>', 'total cholesterol hdl-cholesterol ldl-cholesterol vldl-cholesterol and triglycerides <sep> triglycerides <sep> fasting glucose and insulin levels and in glucose rate of disappearance <sep> euglycemic glucose clamp test lipid metabolism <sep> cholesterol and ldl-cholesterol <sep> lipid metabolism <sep> carbohydrate metabolism <sep> total cholesterol hdl-cholesterol and vldl-cholesterol <sep>', 'carbohydrate metabolism <sep> glucose or insulin levels <sep> mean insulin levels <sep> mean plasma glucose levels <sep>', 'insulin sensitivity si <sep> total cholesterol and hdl cholesterol <sep> si decreased during ocs <sep> si <sep> triglycerides <sep> total high-density lipoprotein hdl and low-density lipoprotein cholesterol and triglycerides <sep> si and glucose utilization independent of insulin sg <sep>', 'insulin sensitivity si <sep> hdl/low-density lipoprotein cholesterol <sep> si modifications <sep> response of c-peptide to glucose <sep> si <sep> c-peptide/insulin response <sep> high-density lipoprotein hdl cholesterol p=.02 and triglycerides <sep> apoprotein a1 apo-a1 <sep> si decreased with ee/dsg <sep> insulin sensitivity and lipid metabolism <sep> si and glucose utilization independent of insulin sg <sep>', 'triglycerides <sep> hdl-cholesterol changes <sep> fasting and 2-hour glucose triglycerides total cholesterol hdl-cholesterol bilirubin alkaline phosphatase albumin and total protein but not aspartate aminotransferase <sep> hdl-cholesterol <sep>', 'triglyceride levels <sep> carbohydrate metabolism <sep> serum cholesterol levels <sep> hdl fractions <sep>', 'carbohydrate metabolism <sep> blood glucose and pyruvate plasma insulin and glucagon levels as well as erythrocyte insulin receptors <sep> glucose tolerance <sep>', 'insulin response <sep> coagulatory activity <sep> incidence of adverse events <sep> hemostatic balance blood lipid levels and carbohydrate metabolism <sep> fibrinolytic activity <sep> cycle control <sep> hemostatic measurements lipid profile glucose tolerance and adverse events <sep> hemostatic balance lipid metabolism and glucose tolerance <sep> glucose response <sep> lipid profile <sep> efficacy and tolerability <sep> hemostatic activity <sep>', 'ldl cholesterol <sep> lipid and biochemical changes <sep> fasting glucose levels <sep> hemoglobin hematocrit and total protein levels but alkaline phosphatase bilirubin and aspartate transaminase sgot <sep> number of abnormal parameters <sep> atherogenic index ldl/hdl cholesterol <sep> total cholesterol <sep> total hdl and ldl cholesterol and sgot <sep> glucose and triglyceride <sep>', 'insulin response <sep> glucose tolerance and insulin secretion <sep> glucose tolerance and insulin secretion <sep> total insulin area <sep> relative hyperglycemia <sep>', 'carbohydrate metabolism <sep> adverse metabolic effects <sep> pancreatic beta-cell function <sep> basal insulin resistance homa-ir <sep> free androgen and dehydroepiandrosterone sulfate levels <sep> insulin sensitivity index is(ogtt <sep> basal hormonal metabolic and lipid levels <sep>', 'triglycerides hdl-cholesterol and apoprotein a1 <sep> fasting blood glucose levels <sep> sbp and cbg <sep> renin substrate and hemostatic parameters <sep> renin substrate <sep> metabolic and hemostatic effects <sep> antithrombin iii total and free protein s and fibrinogen <sep> hemostatic and metabolic effects <sep>', 'mean levels of hba1c and fasting glucose levels <sep> mean levels of fasting insulin and c-peptide <sep> carbohydrate metabolism <sep> mean index for insulin resistance homeostasis model assessment of insulin resistance homa-ir <sep> mean insulin sensitivity index isi composite <sep> insulin secretion <sep> glucose tolerance and insulin resistance <sep>', 'carbohydrate metabolism <sep> a(1)c levels <sep> mild insulin resistance <sep> glycosylated hemoglobin <sep> fasting glycosylated hemoglobin <sep> area under the curve for both glucose and insulin <sep> serum glucose levels <sep> fasting samples and plasma samples <sep> oral glucose tolerance test ogtt <sep> fasting plasma glucose values <sep> carbohydrate parameters <sep>', 'glucose and increased insulin responses <sep> carbohydrate metabolism <sep> apolipoprotein b levels <sep> lng-oc decreased hdl(2)-c and increased hdl(3)-c hdl-c <sep> shbg increased 3-fold with dsg-oc <sep> procoagulant and profibrinolytic parameters <sep> dsg-oc increased hdl-c hdl(2)-c and hdl(3)-c ldl-c <sep> ldl-c <sep> vldl-c and triglycerides <sep> fasting glucose and insulin levels <sep>', 'cholesterol concentration <sep> adverse events <sep> percentages of normal menstrual cycles and the percentages of cycles with intermenstrual and withdrawal bleeding <sep> triglyceride and glucose concentrations <sep> withdrawal bleeding episode <sep>', 'glucose metabolism and liver function <sep> rise in bilirubin <sep> alkaline phosphatase <sep> carbohydrate metabolism and liver function <sep> glucose response <sep> glucose tolerance <sep> enzyme serum levels <sep>', 'high-density lipoprotein hdl and low-density lipoprotein ldl)-cholesterol levels <sep> changes in other lipid hemostatic and carbohydrate parameters <sep> lipid hemostatic or carbohydrate parameters <sep> ldl-cholesterol <sep> hdl-cholesterol <sep> lipids hemostatic parameters and carbohydrate metabolism <sep> blood glucose and c-peptide levels <sep>', 'mean  sd prothrombin fragment 1  2 and d-dimer levels <sep> lipid parameters haemostatic parameters sex hormone-binding globulin shbg cortisol-binding globulin cbg carbohydrate metabolism parameters blood pressure and body weight <sep> body weight and blood pressure <sep> lipid markers <sep> hepatic-induced parameters shbg cbg and carbohydrate metabolism <sep> metabolic and haemostatic effects <sep> mean  sd hdl cholesterol <sep> metabolic and haemostatic effects <sep> mean  sd ldl cholesterol <sep> mean intraindividual relative changes from baseline to cycle 7 in high-density lipoprotein hdl and low-density lipoprotein ldl cholesterol levels <sep> metabolic and haemostatic parameters <sep>', 'serum resistin and insulin levels <sep> circulating levels of resistin <sep> serum resistin level <sep> serum resistin levels <sep>'], 'punchline_text': ['fasting blood glucose at cycle 13 was significantly p  0.01 higher for both treatment groups compared to baseline. <sep>', 'no statistically significant differences were found between the two contraceptive regimens with respect to carbohydrate or lipid profiles or in the parameters related to coagulation. <sep>', 'the monophasic coc nomac/e2 had less influence on haemostasis lipids and carbohydrate metabolism than the coc lng/ee. <sep>', 'obesity had little effect on any oc-induced changes in carbohydrate or lipid metabolism except for a borderline adverse interaction between obesity and oc dose with respect to fasting glucose and a positive interaction between obesity and oc use with respect to ldl cholesterol. <sep>', 'thyroid stimulating hormone levels increased significantly more in the ring group at cycle 3 p  0.0016 but free thyroxine levels were unchanged in both groups. <sep>', 'at the end of treatment no difference was found within or between groups in fasting glucose and insulin levels and in glucose rate of disappearance. <sep>', 'overall there were no statistically significant differences among the three formulations in their effects on carbohydrate metabolism as measured by glucose or insulin levels after 6 months of treatment. <sep>', 'triglycerides increased during both oral p=.01 and vaginal p=.032 contraceptive use. <sep>', 'high-density lipoprotein hdl cholesterol p=.02 and triglycerides p=.02 and p=.01 increased in both groups but hdl/low-density lipoprotein cholesterol p=.02 apoprotein a1 apo-a1 p=.04 and apo-a1/apoprotein b p=.048 increased significantly only with ee/cma. <sep>', 'both pills induced changes in fasting and 2-hour glucose triglycerides total cholesterol hdl-cholesterol bilirubin alkaline phosphatase albumin and total protein but not aspartate aminotransferase. <sep>', 'marvelon and triquilar users showed rises in triglyceride levels while microgynon 30 users had no change after one year of treatment. <sep>', 'the glucose-induced suppression of plasma glucagon levels seemed less effective for treatment with the desogestrel-containing preparations than with the levonorgestrel-containing oral contraceptives. <sep>', 'hemostatic activity was increased in both groups but a counteracting increase in fibrinolytic activity occurred together with an increase in coagulatory activity. <sep>', 'both groups had no change in hemoglobin hematocrit and total protein levels but alkaline phosphatase bilirubin and aspartate transaminase sgot were suppressed. <sep>', 'the insulin response measured in 48 treated and eight control subjects also increased over 12 months in both treated groups but the total insulin area was within the range of the reference laboratory. <sep>', 'the lower-dose nonoral hormonal ring had a lesser impact on carbohydrate metabolism and greater reduction of free androgen and dehydroepiandrosterone sulfate levels than pill treatment. <sep>', 'in both groups there was a significant increase in triglycerides hdl-cholesterol and apoprotein a1 the same increase was observed for sbp and cbg. <sep>', 'the mean levels of fasting insulin and c-peptide underwent comparable increases in both regimens suggesting a similar readjustment of glucose metabolism via slightly increased insulin secretion. <sep>', 'there was a significant increase in the area under the curve for both glucose and insulin during ogtt within each group with increasing duration of use. <sep>', 'lng-oc decreased hdl(2)-c and increased hdl(3)-c hdl-c was unchanged and ldl-c decreased transiently. <sep>', 'most mean changes from baseline laboratory values were comparable between groups although the mean increase in cholesterol concentration was statistically significantly lower in the levonorgestrel with ethinyl estradiol group. <sep>', 'with regard to liver function both preparations induced a rise in bilirubin a decrease in alkaline phosphatase and no change in enzyme serum levels. <sep>', 'although slightly elevated in both groups blood glucose and c-peptide levels measured during oral glucose tolerance tests were within normal reference ranges at cycle 7. <sep>', 'mean  sd prothrombin fragment 1  2 and d-dimer levels remained essentially unchanged in the e(2)v/dng group 0.6  30.3 and 2.1  43.5 respectively but increased in the ee/lng group by 117.3  358.0 and 62.9  99.5 respectively). <sep>', 'we found that serum resistin level remained unchanged in women receiving ethinylestradiol/desogestrel and was reduced in women treated with formulations containing gestodene. <sep>'], 'population': ['thirty-six women <sep>', '78 participants mean age 27.8 years <sep>', '121 healthy women 18-50 years of age <sep>', 'normal-weight women <sep> 71 normal-weight and 38 obese women initiating the oc <sep>', 'healthy women aged 18-40 years <sep>', '60 women before and after 6 months of treatment <sep>', 'one hundred thirty women <sep>', 'subjects were healthy lean young women needing a hormonal contraceptive <sep>', 'twenty-eight young healthy women <sep>', 'seven who collaborating centres for research in human reproduction <sep> a total of 847 subjects <sep> 195 women using an iud served as a comparison group <sep>', 'chinese women <sep> ethnic chinese women are presented <sep>', 'women who used oral contraceptives containing <sep> 38 normal women before and after 6 months use of one of three new <sep>', '124 healthy women <sep>', 'singaporean women <sep>', 'fifty-seven women <sep>', 'forty-two women completed the study <sep> sixty-five women <sep>', 'forty-nine women participated <sep>', '59 women treated with <sep>', 'healthy women <sep>', '66 healthy women using phasic formulations of ocs containing either dsg dsg-oc or lng lng-oc <sep>', '167 women for 1 to 4 cycles of treatment <sep> 155 healthy women <sep>', '357 volunteers from four centers hangzhou havana jakarta and shanghai <sep>', 'healthy women <sep>', 'germany over seven cycles healthy women aged 18-50 years received <sep>', 'women taking combined oral contraceptives containing <sep> women <sep> fifty-three women were enrolled in the study <sep> thirteen patients received <sep>'], 'interventions': ['combinedoral contraceptives cocs <sep> 20 microg ethinyl estradiol ee and 75 microg gestodene gsd or 20 microg ethinyl estradiol and 150 microg desogestrel dsg <sep> ethinyl estradiol <sep> gestodene and desogestrel <sep> low estrogen dose oral contraceptives containing gestodene or desogestrel <sep>', 'contraceptive pill containing ethinylestradiol <sep> ethinylestradiol and drospirenone <sep> drospirenone <sep>', 'combined oral contraceptive coc containing nomegestrol acetate and 17-oestradiol <sep> levonorgestrel and ethinylestradiol <sep> nomac/e2 <sep> lng/ee <sep> monophasic combined oral contraceptive containing nomegestrol acetate and 17-oestradiol <sep>', 'obesity and low-dose oral contraceptives <sep> combination oral contraceptives ocs <sep> ethinyl estradiol ee)/150 mcg levonorgestrel lng or 20 mcg ee/100 <sep> mcg lng <sep>', 'combined contraceptive vaginal ring nuvaring nv organon oss the netherlands <sep> contraceptive vaginal ring nuvaring and an oral contraceptive <sep> vaginal ring delivering 15 microg ethinylestradiol and 120 microg of etonogestrel per day or a combined oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel <sep>', 'norethisterone-containing hormonal contraceptives mesigyna and trinovum <sep> norethisterone <sep>', 'carbohydrate metabolism <sep> triphasic oral contraceptives <sep> ethinyl estradiol and norethindrone <sep> ethinyl estradiol and levonorgestrel <sep>', 'hormonal contraceptives <sep> oral contraceptive oc containing 30 mcg ethinylestradiol ee)/150 mcg desogestrel dsg <sep> contraceptives containing desogestrel/etonorgestrel and insulin sensitivity <sep> vaginal ring contraceptive releasing per day 15 mcg ee/120 mcg etonorgestrel the active dsg metabolite <sep> oc containing 20 mcg ee/150 mcg dsg <sep>', 'ethinylestradiol ee <sep> oral contraceptives containing chlormadinone acetate or desogestrel <sep> ee and 150 mcg of desogestrel dsg n=14 or 30 mcg of ee and 2 mg of chlormadinone acetate cma <sep> ee/cma <sep>', 'combined oral contraceptive preparations <sep> norethisterone lmg/ethinyl estradiol 35 micrograms net/ee or levonorgestrel 150 micrograms/ethinyl estradiol 30 micrograms lng/ee <sep> low-dose combined oral contraceptives <sep>', 'low-dose levonorgestrel-ethinyl oestradiol combined oral contraceptive microgynon 30 a desogestrel-ethinyl oestradiol-containing pill marvelon and a levonorgestrel-ethinyl oestradiol triphasic preparation triquilar <sep> combined oral contraceptive pills <sep>', 'levonorgestrel or desogestrel <sep> oral contraceptives containing low doses of 19 nortestosterone-derived progestogens levonorgestrel and desogestrel <sep> levonorgestrel-containing oral contraceptives <sep>', 'gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol <sep> gestodene gtd 60 microg/ethinylestradiol ee 15 microg and desogestrel dsg 150 microg/ee 20 microg mercilon <sep>', '2 low-dose combined oral contraceptives <sep> norethisterone 1 mg/ethinyl estradiol 35 micrograms net/ee or levonorgestrel 150 micrograms/ethinyl estradiol 30 micrograms lng/ee and a control group of 23 women using intra-uterine devices iud <sep>', 'ocs containing ethinyl estradiol and either levonorgestrel or norethindrone <sep> long-term triphasic oral contraceptive <sep> low-dose triphasic oral contraceptives ocs <sep> nonhormonal contraception <sep>', 'contraceptive vaginal ring ring releasing 15 mcg ethinyl estradiol ee and 120 mcg etonogestrel per day nuvaring organon usa inc. roseland nj versus a low-dose oral contraceptive pill containing 20 mcg ee and 100 mcg levonorgestrel daily aviane barr pharmaceuticals inc. pomona ny <sep> ring or pill <sep>', 'oral contraceptives containing desogestrel <sep> oral contraceptives containing 150 mcg desogestrel and 20 mcg ethinyl-estradiol ee <sep> ethinyl-estradiol <sep>', 'ee/dng <sep> combined oral contraceptive ethinylestradiol <sep> combined oral contraceptives cocs <sep> coc containing 30 microg ethinylestradiol and 2 mg dienogest ee/dng <sep>', 'implanon and norplant implants <sep> implanon contraceptive implants <sep> 80 implant implanon and norplant acceptors <sep>', 'plasma lipids glucose insulin hemostasis and sex hormone binding globulin shbg <sep> phasic oral contraceptives containing desogestrel or levonorgestrel <sep> lng <sep> desogestrel dsg <sep>', 'levonorgestrel with ethinyl estradiol <sep> levonorgestrel with 20 microg ethinyl estradiol alesse or loette <sep> triphasic norethindrone with ethinyl estradiol <sep> levonorgestrel <sep> ethinyl estradiol <sep> oral contraceptive regimens <sep> norethindrone with 35 microg ethinyl estradiol ortho-novum 7/7/7 or trinovum <sep> levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol <sep>', 'two once-a-month injectable steroidal contraceptives mesigyna and cyclofem <sep> injectable contraceptive preparations mesigyna norethisterone enanthate 50 mg and estradiol valerate 5 mg and cyclofem medroxyprogesterone acetate 25 mg and estradiol cypionate <sep>', 'drospirenone or desogestrel <sep> ethinyl estradiol 20 microg/drospirenone 3 mg ee 20 microg/drsp <sep> drsp <sep> ee 20 microg/dsg <sep> ethinyl estradiol <sep> ethinyl estradiol 20 microg/desogestrel 150 microg ee 20 microg/dsg <sep>', 'placebo <sep> ee/lng ee 0.03 mg/lng 0.05 mg on days 1-6 ee 0.04 mg/lng 0.075 mg on days 7-11 ee 0.03 mg/lng 0.125 mg on days 12-21 placebo <sep> combined oral contraceptives cocs <sep> novel coc comprising estradiol valerate/dienogest e(2)v/dng with ethinylestradiol/levonorgestrel ee/lng <sep> estradiol valerate/dienogest a novel oral contraceptive <sep> e(2)v/dng e(2)v 3 mg on days 1-2 e(2)v 2 mg/dng 2 mg on days 3-7 e(2)v 2 mg/dng 3 mg on days 8-24 e(2)v 1 <sep>', 'ethinylestradiol/150 microg desogestrel and 14 with 30 microg ethinylestradiol/75 microg gestodene <sep> desogestrel or gestodene <sep> gestodene <sep> ethinylestradiol combined with desogestrel or gestodene <sep> 20 microg ethinylestradiol/150 microg desogestrel <sep> 20 microg ethinylestradiol/75 microg gestodene <sep> ethinylestradiol/desogestrel <sep> combined oral contraceptives containing desogestrel or gestodene <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",current evidence suggests no major differences in carbohydrate metabolism between different hormonal contraceptives in women without diabetes. we cannot make strong statements due to having few studies that compared the same types of contraceptives. many trials had small numbers of participants and some had large losses. many of the earlier studies had limited reporting of methods. we still know very little about women at risk for metabolic problems due to being overweight. more than half of the trials had weight restrictions as inclusion criteria. only one small trial stratified the groups by body mass index obese versus normal).
308,"{'outcomes': ['small bowel and colon ascending colon and overall colonic transit <sep> overall colonic transit <sep> gastrointestinal transit <sep> small-bowel and colon transit <sep> mean colonic geometric center <sep> colonic transit were geometric center of the colonic counts at 24 hours and time for 50 ascending colon emptying <sep> gastric emptying small-bowel and colonic transit <sep> colonic transit <sep> codeine delayed gastric small-bowel proximal and overall colonic transit <sep> gastric small-bowel and colonic transit time <sep>', 'time to gastrointestinal gi recovery measured by toleration of solid food and passage of flatus/stool gi-3 <sep> time to gi-2 recovery toleration of solid food and passage of stool and hospital discharge order written dco <sep> gi recovery <sep> accelerated time to gi-2 <sep> adverse events <sep>', 'mean whole-gut transit time <sep> whole-gut transit time <sep> urgency to defecate <sep> intestinal transit <sep>', 'oral-cecal transit time <sep> morphine-induced delay in oral-cecal transit time <sep> oral-cecal transit time <sep> gastrointestinal motility and transit without affecting analgesia <sep> transit time and the drug plasma concentration <sep> safety and efficacy <sep>', 'small bowel transit time sbtt measured by the lactulose/hydrogen breath test pain scores and the occurrence of adverse events <sep> laxative effects <sep> return of pain <sep> marked laxative effect <sep>', 'gastrointestinal motility and transit without affecting analgesia <sep> analgesic effect <sep> oral-cecal transit time <sep> analgesia <sep> oral-cecal transit time <sep> pain intensity and pain bothersomeness ratings <sep> morphine-induced delay in oral-cecal transit time <sep>', 'average time to first bowel movement <sep> nausea vomiting and constipation <sep> efficacy <sep> gastrointestinal recovery <sep> adverse events <sep> frequent bowel movement and better bowel movement quality <sep> safety and efficacy <sep> time to first bowel movement <sep>', 'proportion of patients having at least one bowel movement bm <sep> bm <sep> median times to first bm <sep> weekly bms and overall patient satisfaction <sep>', 'hospital stay contribute to readmission and increase morbidity <sep> mean time to gastrointestinal recovery <sep> mean time to the hospital discharge order written <sep> adverse events <sep> time to the hospital discharge order written <sep> tolerated <sep> passage of flatus or stool and tolerating solid food <sep> nausea vomiting and hypotension the incidence of nausea and vomiting <sep> time to return of gastrointestinal function <sep>', 'oral-cecal transit times <sep> average sd change <sep> adverse effects <sep> laxation response oral-cecal transit time and central opioid withdrawal symptoms <sep> laxation response <sep> laxation and reverse slowing of oral cecal-transit time <sep>', 'frequency of pneumonia <sep> gastric tube reflux the frequency of pneumonia and the time until first defecation <sep> time until first defecation ventilation time and length of intensive care unit stay <sep> gastrointestinal motility <sep> gastric tube reflux and frequency of pneumonia <sep> fentanyl requirements <sep> median gastric tube reflux volume <sep>', 'gastrointestinal transit time <sep> morphine analgesia and pupil constriction <sep> analgesia and pupil constriction <sep> gastrointestinal transit time lactulose hydrogen breath test <sep>', 'gastral reflux <sep> gastric reflux <sep> duodenogastral reflux <sep> incidence of gastritis and esophagitis <sep> frequency of gastritis and esophagitis <sep> volume of enteral feeding <sep> gi motility <sep> esophageal or gastral mucosal injuries <sep>', 'bowel frequency <sep> constipation and analgesia <sep> complete reversal of analgesia <sep> reversal of analgesia <sep> stool frequency and symptoms related to constipation <sep>', 'morbidity and extend hospitalization <sep> postoperative ileus poi <sep> time to hospital discharge order written <sep> time to recovery of gi function <sep> adverse events <sep> tolerated <sep> recovery of gastrointestinal gi function <sep> gi recovery and time to hospital discharge <sep> composite of time to recovery of upper and lower gi function <sep>', 'intestinal hypomotility <sep> restoration of bowel function and visual analog scales vas for pain during rest and movement <sep> bowel motility and analgesia <sep> bowel motility and increased transit time <sep> shorter time to the first postoperative passage of flatus <sep> resting or active vas <sep>', 'recovery of gastrointestinal function <sep> median time until patients were ready for discharge <sep> postoperative pain relief <sep> median time to the first passage of flatus <sep> median time to the first bowel movement <sep>', 'serum acetaminophen concentrations <sep> maximum concentration or area under the concentration curve <sep> gastric emptying <sep> rate of gastric emptying <sep> maximum concentrations and area under the concentration curve <sep> risk of vomiting and pulmonary aspiration <sep>'], 'punchline_text': ['codeine delayed gastric small-bowel proximal and overall colonic transit p  .05). <sep>', 'alvimopan also significantly accelerated time to gi-2 <sep>', 'naloxone both alone and with codeine significantly shortened the mean whole-gut transit time compared with the control period respectively from 53.1 to 42.1 h p=0.005 and to 40.7 h p=0.024). <sep>', 'oral methylnaltrexone 19.2 mg/kg completely prevented morphine-induced increase in oral-cecal transit time 110.4  <sep>', 'no significant difference between placebo and naloxone occurred in the 14 remaining patients receiving total daily doses of naloxone 10 or less of the 24 h dose of morphine. <sep>', 'methylnaltrexone did not affect the analgesic effect of morphine on both pain intensity and pain bothersomeness ratings. <sep>', 'alvimopan significantly accelerated the time to first bowel movement hazard ratio 2.33 p .001). <sep>', 'weekly bms and overall patient satisfaction were increased after the 1-mg dose p  .001 at weeks 1 and 2 vs placebo and p  .046 respectively). <sep>', 'mean time to the hospital discharge order written was significantly accelerated in patients treated with alvimopan 6 mg hazard ratio  1.50 p  0.001). <sep>', 'no opioid withdrawal was observed in any subject and no significant adverse effects were reported by the subjects during the study. <sep>', 'median gastric tube reflux volume 54 vs. 129 ml p .03 and frequency of pneumonia 34 vs. 56 p .04 were significantly lower in the naloxone group. <sep>', 'morphine analgesia and pupil constriction were unaffected by adl 8-2698 and differed from placebo p  .002). <sep>', 'in the naloxone group gastral reflux as well as need for propulsive medication were significantly lower. <sep>', 'all the patients who received oral naloxone had some improvement in their bowel frequency. <sep>', 'alvimopan accelerated gi recovery and time to hospital discharge order written compared with placebo in patients undergoing laparotomy and was well tolerated. <sep>', 'low doses of intravenous naloxone reduce morphine-induced pruritus without reversing analgesia but the effect of epidural naloxone on bowel motility has not been studied. <sep>', 'the median time to the first passage of flatus decreased from 70 to 49 hours p=0.03 the median time to the first bowel movement decreased from 111 to 70 hours p=0.01 and the median time until patients were ready for discharge decreased from 91 to 68 hours p=0.03). <sep>', 'no difference in maximum concentration or area under the concentration curve from 0 to 90 min was noted between placebo and methylnaltrexone coadministered with morphine. <sep>'], 'population': ['healthy volunteers <sep> seventy-four healthy participants 43 women <sep>', 'postoperative ileus after major abdominal surgery <sep> patients undergoing open laparotomy bowel resection n  418 hysterectomy n  197 <sep> patients undergoing open laparotomy <sep>', 'in four sets of studies 12 male volunteers <sep> volunteers taking codeine <sep>', '14 healthy volunteers <sep> human volunteers <sep>', 'patients with far-advanced cancer <sep> seventeen patients entered the first phase of the study <sep> patients with advanced cancer <sep>', 'twelve healthy volunteers <sep> oral-cecal transit time without affecting analgesia <sep>', 'women who undergo simple total abdominal hysterectomy <sep> patients who undergo simple total abdominal hysterectomy <sep> women n  519 <sep>', '168 patients with opioid-induced bowel dysfunction obd who were receiving chronic opioid therapy minimum 1 month for nonmalignant pain n  148 or opioid dependence n  20 <sep>', 'postoperative ileus after major abdominal surgery <sep> patients undergoing major abdominal surgery <sep> patients undergoing partial colectomy or simple or radical hysterectomy <sep>', 'twenty-two subjects 9 men and 13 women mean sd age 43.2 5.5 years enrolled in a methadone maintenance program and having methadone-induced constipation <sep> may 1997 and december 1998 <sep> patients who require long-term opioid administration such as patients with advanced cancer <sep>', 'mechanically ventilated patients with fentanyl analgesia <sep> ventilated patients <sep> university hospital intensive care unit <sep> eighty-four mechanically ventilated fentanyl-treated patients without gastrointestinal surgery or diseases <sep> critical care patients during opioid analgesia <sep>', '14 volunteers with oral and intravenous <sep> 45 patients <sep>', 'mechanically ventilated patients <sep> treated patients without gastrointestinal surgery or diseases <sep>', 'nine patients were recruited for the study <sep> patients taking stable doses of opioids with complaints of constipation <sep>', '510 patients scheduled for bowel resection or radical hysterectomy <sep> patients undergoing laparotomy for bowel resection or radical hysterectomy <sep> 469 patients 451 bowel resection and 18 radical hysterectomy patients <sep>', 'forty-three patients having combined thoracic epidural and general anesthesia for subtotal gastrectomy <sep>', '79 patients--including 1 whose surgery was <sep> 26 patients in each of the three groups all received <sep> fifteen patients underwent <sep>', '11 healthy volunteers <sep> humans <sep>'], 'interventions': ['alvimopan/placebo <sep> placebo <sep> codeine <sep> alvimopan <sep> placebo/placebo <sep> alvimopan 12 mg twice daily in the presence and absence of codeine sulfate 30 mg 4 times/day or codeine or placebo alone <sep> alvimopan <sep> alvimopan and codeine <sep> placebo/codeine <sep> alvimopan/codeine <sep>', 'dco <sep> placebo <sep> alvimopan 6 or 12 mg or placebo <sep> alvimopan <sep>', 'placebo <sep> codeine <sep> naloxone <sep> naloxone <sep> placebo capsules <sep>', 'placebo and intravenous morphine <sep> placebo <sep> oral methylnaltrexone <sep> methylnaltrexone <sep> oral methylnaltrexone <sep> methylnaltrexone <sep> morphine <sep> morphine <sep>', 'naloxone <sep> morphine <sep> naloxone <sep> placebo <sep>', 'placebo <sep> methylnaltrexone <sep> placebo placebo plus 0.05 mg/kg morphine or 0.45 mg/kg methylnaltrexone plus 0.05 mg/kg morphine <sep> methylnaltrexone <sep> morphine <sep> morphine <sep>', 'placebo <sep> alvimopan <sep> alvimopan <sep>', 'placebo <sep> alvimopan <sep> alvimopan 0.5 or 1 mg versus placebo <sep> chronic opioid therapy <sep> alvimopan <sep>', 'placebo <sep> alvimopan <sep> alvimopan <sep>', 'methylnaltrexone <sep> methylnaltrexone <sep> placebo <sep> methylnaltrexone and placebo <sep>', 'enteral naloxone <sep> placebo <sep> naloxone or placebo <sep> enteral naloxone <sep> naloxone <sep> opioid analgesia <sep> naloxone and 43 placebo <sep> enteral opioid antagonists <sep>', 'placebo <sep> placebo oral placebo and intravenous morphine <sep> adl 8-2698 4 mg or placebo and intravenous morphine <sep> morphine <sep> morphine <sep>', 'enteral naloxone <sep> placebo <sep> naloxone or placebo <sep> naloxone <sep> fentanyl <sep>', 'oral naloxone <sep> placebo <sep> naloxone <sep> opioid therapy <sep> oral naloxone or placebo <sep>', 'alvimopan 6 mg alvimopan 12 mg or placebo <sep> placebo <sep> alvimopan <sep> alvimopan <sep>', 'epidural morphine <sep> naloxone <sep> epidural naloxone <sep> epidural morphine <sep> morphine <sep> bupivacaine 0.125 with either no naloxone control group n  18 or a calculated dose of 0.208 microg x kg(-1 <sep>', 'placebo <sep> partial colectomy <sep> total abdominal hysterectomy <sep> opioids <sep> canceled--to receive one capsule containing 1 mg or 6 mg of adl 8-2698 or an identical-appearing placebo capsule two hours before major abdominal surgery <sep>', 'placebo <sep> naloxone <sep> placebo saline 0.09 mg/kg morphine or 0.09 mg/kg morphine plus 0.3 mg/kg methylnaltrexone <sep> methylnaltrexone <sep> morphine <sep> morphine <sep> opioid-induced delay <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",insufficient evidence exists for the safety or efficacy of naloxone or nalbuphine in the treatment of obd. long-term efficacy and safety of any of the opioid antagonists is unknown as is the incidence or nature of rare adverse events. alvimopan and methylnaltrexone both show promise in treating obd but further data will be required to fully assess their place in therapy.
309,"{'outcomes': ['mechanical ventilation <sep> neonatal survival rate <sep> overall survival rate <sep>', 'incidence of pulmonary air-leak <sep> mortality requirement for mechanical ventilation or incidence of pulmonary sequelae <sep> mortality and complication rates <sep> outcome of hmd <sep> oxygenation <sep>', 'length of stay or the duration of oxygen treatment <sep> risk of pneumothorax <sep> morbidity or death <sep> pneumothorax <sep> death length of nursery stay time receiving oxygen therapy cost of care and other measures of morbidity <sep> up-transfer or treatment failure <sep>', 'mortality cranial ultrasound abnormalities and pneumothoraces <sep> total duration of oxygen therapy <sep> mean levels <sep> mortality respiratory outcome the presence of cerebral ultrasound abnormalities patent arterial duct necrotizing enterocolitis and retinopathy <sep> mean total duration of oxygen therapy <sep> chronic lung disease of prematurity <sep>'], 'punchline_text': ['11 out of 12 infants in the cip-treated group and 10 out of 12 in the control group survived. <sep>', 'there was no significant difference between treatment and control groups in mortality requirement for mechanical ventilation or incidence of pulmonary sequelae. <sep>', 'hudson prong bubble continuous positive airway pressure therapy reduces the need for up-transfer of infants with respiratory distress in nontertiary centers. <sep>', 'secondary analysis showed that the use of cnep was associated with an increase in mortality cranial ultrasound abnormalities and pneumothoraces which were not statistically significant. <sep>'], 'population': ['infants with severe hyaline membrane disease were admitted who did not meet the criteria for entry to the trial <sep> hyaline membrane disease <sep> infants with severe hyaline membrane disease who weighed more than 1000 g at birth <sep>', 'severe hyaline membrane disease hmd <sep> patients requiring mechanical ventilation for apnea or hypercapnia pco2 greater than 65 mm hg <sep> patients were admitted to the study if the po2 was less than 50 mm hg with fio2 greater than 0.6 <sep>', '151 infants who received continuous positive airway pressure therapy 35 either were up-transferred or experienced treatment failure as did 60 of the 149 infants given <sep> infants with respiratory distress in nontertiary centers <sep> infants with respiratory distress in non tertiary care centers <sep> 300 infants at 30 weeks of gestation with respiratory distress to receive either <sep> 14 infants in the continuous positive airway pressure group and 5 in the headbox group <sep> infants with respiratory distress from nontertiary centers <sep>', 'neonates with respiratory failure <sep> matched pairs of infants <sep> two hundred forty-four patients birth weight 1.53 <sep> sd gestational age 30.4 <sep> neonatal respiratory failure <sep>'], 'interventions': ['elective intervention with continuous inflating pressure cip <sep> oxygen f1o2 greater than 0-60 spontaneously without any ventilatory assistance <sep> continuous inflating pressure <sep>', 'cpap <sep> spontaneously breathing patients and peep <sep> oxygen and were mechanically ventilated if they had apnea hypercapnia or po2 less than 50 mm <sep> continuous positive airway pressure cpap and positive end-expiratory pressure peep <sep>', 'headbox oxygen treatment <sep> continuous positive airway pressure therapy <sep> continuous positive airway pressure therapy <sep> hudson prong bubble continuous positive airway pressure therapy <sep> hudson prong bubble continuous positive airway pressure therapy or headbox oxygen treatment standard care <sep>', 'standard neonatal intensive care or standard care plus continuous negative extrathoracic pressure cnep 4 to 6 cmh2o applied within a purpose-designed neonatal incubator <sep> cnep <sep> continuous negative pressure <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",in preterm infants with respiratory distress the application of cdp either as cpap or cnp is associated with reduced respiratory failure and reduced mortality. cdp is associated with an increased rate of pneumothorax. four out of six of these trials were done in the 1970's. therefore the applicability of these results to current practice is difficult to assess. where resources are limited such as in developing countries cpap for rds may have a clinical role. further research is required to determine the best mode of administration and the role of cdp in modern intensive care settings
310,"{'outcomes': ['neuropsychological wm-demanding tests rated occupational performance satisfaction with performance and rated overall health <sep> subjects cognitive functioning <sep> neuropsychological wm-test results <sep> trained wm tasks <sep> rated quality-of-life <sep>', 'problem solving skills <sep> individuals problem-solving skills and self-efficacy <sep> self-efficacy <sep> cognitive functions <sep>', 'wisconsin card sorting test wcst performance <sep> external inhibition increased stimulus salience <sep> wcst performance <sep>', 'change in rbans total score <sep> change in rbans delayed memory score <sep> global cognitive functioning <sep> performance in neuropsychological tests assessing memory and executive functions <sep> verbal and visual memory functions <sep> cognitive outcome <sep> neuropsychological status rbans and trail-making controlled oral word association wechsler adult intelligence scale-iii similarities and stroop tests <sep> rbans total score <sep>', 'meal preparation performance <sep>', 'assessment of motor and process skills amps <sep> standardized measures of general self-awareness with collateral reports by informants e.g. awareness questionnaire task-specific self-awareness e.g. assessment of awareness of disability and self-regulation skills inventory srsi <sep> self-awareness during iadl task performance <sep> iadl performances and self-regulation <sep> self-awareness <sep> task-specific self-awareness general self-awareness or community integration <sep>', 'computerized version of the paced auditory serial addition task pasat and two computerized matching tasks <sep>', 'self-awareness of deficits interview sadi the functional independence measure fim and the lawton instrumental activities of daily living score lawton iadl <sep> level of awareness <sep>', 'symptoms of cognitive problems <sep> wm and attention <sep> cognitive functions <sep>', 'cognitive behavioral or quality-of-life measures <sep> defense and veterans head injury program dvhip <sep> greater return-to-duty rate <sep>', 'role resumption list rrl and two other follow-up measures the treatment goal attainment tga and the executive secretarial task est were indications of daily life executive functioning <sep> daily life functioning <sep> executive functioning <sep>', 'np functioning perceived self-efficacy and community-based employment <sep> community integration questionnaire ciq and perceived quality of life scale pqol <sep> productivity <sep> np functioning <sep> sustained moderate or severe tbi <sep> ciq effect size es]=0.59 and pqol <sep> community functioning and quality of life <sep> self-efficacy <sep>'], 'punchline_text': ['the training probably has an impact on the rehabilitation outcome returning to work as well as on daily activities for individuals with verified wm impairments. <sep>', 'the continuous human touch characteristics of the therapist-administered group showed significant better improvements in self-efficacy in problem-solving. <sep>', 'external inhibition of learned rules reduced perseverative errors while increased stimuli salience reduced random errors committed by patients with abi. <sep>', 'we found a difference among the 3 treatment groups in change in rbans total score p  .01 and rbans delayed memory score p  .01). <sep>', 'gmt but not motor skills training was associated with significant gains on everyday paper-and-pencil tasks designed to mimic tasks that are problematic for patients with goal neglect. <sep>', 'no significant treatment effect was observed for task-specific self-awareness general self-awareness or community integration. <sep>', 'weekly measures included a computerized version of the paced auditory serial addition task pasat and two computerized matching tasks. <sep>', 'after aip training the participants in the experimental group demonstrated significant improvement in their level of awareness as compared to the control group. <sep>', 'there was a significant decrease in symptoms of cognitive problems as measured by the cfq p  0.005). <sep>', 'at 1-year follow-up there was no significant difference between patients who had received the intensive in-hospital cognitive rehabilitation program vs the limited home rehabilitation program in return to employment 90 vs 94 respectively p=.51 difference 4 <sep>', 'the experimental group improved significantly more over time than the controls on the rrl and attained significantly higher scores on the tga and est. <sep>', 'intensive cognitive rehabilitation participants showed greater improvements on the ciq effect size es]=0.59 and pqol es=0.30 as well as improved self-efficacy for the management of symptoms es=0.26 compared with standard neurorehabilitation treatment. <sep>'], 'population': ['a consecutive sample of 21 subjects <sep> patients suffering from acquired brain injury <sep> individuals with verified wm impairments <sep> patients suffering from working memory deficits after acquired brain injury <sep>', 'persons with abi <sep> people with acquired brain injury abi <sep> 103 persons with acquired brain injury <sep>', 'patients with acquired brain injury <sep> patients with acquired brain injury abi <sep> 24 patients with abi <sep> participants with abi <sep>', 'one hundred twenty-nine patients <sep> n  43 with <sep>', 'patients with brain damage <sep> patients with traumatic brain injury tbi <sep>', 'persons with acquired brain injury <sep> 10 participants with moderate-to-severe brain injury received <sep> participants with acquired brain injury on levels of self-awareness and functional performance <sep>', 'new york city metropolitan area <sep> adults with acquired brain injuries <sep> thirty adults with abi were matched according to severity of injury gender age and time post-injury and randomly assigned to the remedial or compensatory group <sep> adults with acquired brain injuries abi <sep>', 'persons with traumatic brain injury <sep> twenty-one patients with traumatic brain injury <sep> people with traumatic brain injury <sep>', 'group 18 participants 12 males in a vocational age group mean age 54 years <sep> adult patients with stroke <sep>', 'patients with moderate-to-severe tbi <sep> patients with tbi <sep> traumatic brain injury <sep> traumatic brain injury tbi <sep> one hundred twenty active-duty military personnel who had sustained a moderate-to-severe closed head injury manifested by a glasgow coma scale score of 13 or less or posttraumatic amnesia lasting at least 24 hours or focal cerebral contusion or hemorrhage on computed tomography or magnetic resonance imaging <sep> january 1992 through february 1997 at a us military medical referral center <sep> young adults <sep>', 'executive dysfunction after acquired brain injury on indications of executive functioning in daily life <sep> seventy-five abi patients <sep>', 'after traumatic brain injury <sep> postacute brain injury rehabilitation center within a suburban rehabilitation hospital <sep> people with traumatic brain injury tbi <sep> participants with tbi were recruited from clinical referrals and referrals from the community <sep> sixty-eight participants who met inclusion criteria <sep>'], 'interventions': ['computerized training of working memory <sep> computerized wm training <sep> computerized working memory wm training programme <sep>', '20-session analogy problem-solving skill training groups namely online training through computer video conferencing with interactive software computer-assisted training through interactive patient-directed software therapist administered training face-to-face therapist guided training activities and a no-treatment control group <sep> tele-analogy-based problem-solving programme <sep>', 'switching attention <sep>', 'escitalopram <sep> placebo-controlled comparison of escitalopram <sep> placebo <sep> problem solving therapy <sep>', 'gmt or motor skills training <sep> rehabilitation of executive functioning <sep> training procedure goal management training gmt <sep> gmt <sep>', 'daily living iadls <sep> six sessions of the self-awareness training while they performed iadls experimental group and 10 participants performed the same iadls but received conventional therapeutic practice control group <sep>', 'cognitive rehabilitation program <sep> remedial and compensatory interventions <sep> remedial intervention <sep> compensatory intervention <sep>', 'systematic intervention programme <sep> awareness intervention programme aip and a conventional rehabilitation programme <sep>', 'computerized working memory training <sep> computerized training <sep> passive control <sep> working memory wm training <sep>', 'inpatient cognitive rehabilitation <sep> cognitive rehabilitation <sep> hospital cognitive rehabilitation program n=67 or a limited home rehabilitation program with weekly telephone support from a psychiatric nurse n=53 <sep>', 'multifaceted treatment program <sep> multifaceted strategy training for executive dysfunction or a control treatment computerized cognitive function training <sep>', 'intensive cognitive rehabilitation <sep> comprehensive holistic np rehabilitation <sep> standard neurorehabilitation consisted primarily of individual discipline specific therapies <sep> holistic neuropsychologic rehabilitation <sep> comprehensive holistic neuropsychologic np rehabilitation compared with standard multidisciplinary rehabilitation <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",we identified insufficient high-quality evidence to reach any generalised conclusions about the effect of cognitive rehabilitation on executive function or other secondary outcome measures. further high-quality research comparing cognitive rehabilitation with no intervention placebo or sensorimotor interventions is recommended.
311,"{'outcomes': ['frequency of side effects <sep>', 'rate of thrombosis of expanded polytetrafluoroethylene eptfe grafts <sep> risk of thrombosis <sep> relative risk of thrombosis <sep> actuarial analysis of type <sep> rate of thrombosis <sep> cumulative thrombosis rates <sep>', 'overall rate of occlusion <sep> risk of early occlusion <sep>', 'ptfe graft survival <sep> time to graft failure <sep> six major bleeds <sep> likelihood of graft survival <sep>', 'thrombi <sep> incidence of thrombosis <sep>', 'venous outflow resistance and systemic bp <sep> survival analysis <sep> vascular perturbations underlying synthetic graft thrombosis <sep> incidence of thrombosis <sep> primary patency rates <sep>'], 'punchline_text': ['this effect was achieved without an increased frequency of side effects compared with placebo. <sep>', 'the relative risk of thrombosis with dipyridamole was 0.35 <sep>', 'limited risk factor analysis did not clearly identify any subgroup other than females at greater risk of early thrombosis nor any subgroup deriving particular benefit from ticlopidine treatment. <sep>', 'the time-to-event analysis revealed no significant difference in the likelihood of graft survival between the two groups odds ratio 1.76 in favor of placebo 95 confidence interval 0.72 to 4.34). <sep>', 'the incidence of thrombosis was reduced from 0.46 thrombi per patient month in the placebo group to 0.16 thrombi per patient month in the aspirin group p less than 0.005). <sep>', 'survival analysis revealed a significant difference between fish oil-treated and untreated patients p  0.03 mantel-cox test with a power of 90%. <sep>'], 'population': ['chronic renal failure patients <sep> arteriovenous fistulas for haemodialysis <sep> chronic uremic patients up to 4 weeks after construction of an arteriovenous fistula <sep> chronic uremic patients <sep> 42 patients were recruited and 36 completed the trial <sep>', 'graft thrombosis <sep> patients with prior thrombosis of eptfe grafts <sep> hd patients <sep> patients with new eptfe grafts <sep> one hundred and seven patients were followed for 18 months or until the first thrombotic episode <sep>', 'two hundred and fifty-eight patients with uremia who were offered surgery for placement of an arteriovenous fistula for hemodialysis were recruited in nine regional dialysis centers <sep> av-fistula surgery in uremia <sep>', 'patients with esrd <sep> 107 patients 56 allocated to <sep> patients with end-stage renal disease esrd <sep> patients on hemodialysis <sep> patients with esrd and newly placed ptfe grafts were studied at community and academic dialysis centers in southwestern ontario <sep>', '24 patients with thrombi and both groups had been under observation for a mean of nearly five months <sep> 44 patients on chronic hemodialysis <sep> patients on hemodialysis by low-dose <sep> patients on hemodialysis <sep>', 'twenty-four patients <sep>'], 'interventions': ['ticlopidine <sep> ticlopidine <sep> placebo <sep> placebo or ticlopidine <sep>', 'anti-platelet therapy <sep> dipyridamole and/or aspirin <sep> placebo <sep> dipyridamole and aspirin <sep> aspirin <sep> dipyridamole nor aspirin <sep> type i--with a new eptfe graft and type ii--with thrombectomy and/or revision of a previously placed eptfe graft <sep> dipyridamole <sep>', 'ticlopidine <sep> placebo <sep> platelet aggregation inhibitory compound ticlopidine 250 mg b.d. or matching placebo <sep>', 'placebo <sep> low-intensity warfarin <sep> polytetrafluoroethylene ptfe dialysis grafts <sep> warfarin <sep> warfarin or matching placebo <sep>', 'placebo <sep> aspirin <sep>', '4000 mg of fish oil or 4000 mg of control oil <sep> antioxidants and deodorized with peppermint <sep> hemodialysis graft thrombosis with fish oil <sep> control oil <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",the meta-analysis confirmed the beneficial effect of anti-platelet treatment as an adjuvant used to increase the patency of a-v fistulae and grafts in the short term.
312,"{'outcomes': ['elevated liver enzyme levels <sep> forced expiratory volume in 1 second and pulmonary function <sep> efficacy and safety <sep> blood chemistry and hematology adrenal function assessment bone densitometry and muscle strength testing <sep>', 'bronchial hyperresponsiveness <sep> glucocorticoid pharmacokinetics and airway hyperresponsiveness <sep> methylprednisolone clearance <sep> symptom scores blood chemistries pulmonary function tests airway response to methacholine and glucocorticoid pharmacokinetics <sep> methacholine response <sep> mpn clearance <sep>', 'unfavorable response <sep> serum igg fasting blood sugar serum cholesterol and progression of osteoporosis <sep> determination of the lowest stable methylprednisolone dose and assessment of corticosteroid side effects <sep> corticosteroid side effects <sep>'], 'punchline_text': ['two patients who received tao had elevated liver enzyme levels one required discontinuation of tao and one experienced spontaneous resolution without intervention. <sep>', 'troleandomycin decreased mpn clearance by an average of 62 but did not alter prednisolone clearance. <sep>', 'differences were observed between the two treatment groups in serum igg fasting blood sugar serum cholesterol and progression of osteoporosis. <sep>'], 'population': ['patients who are unable to tolerate tapering of their glucocorticoid dosage <sep> children with severe steroid-requiring asthma <sep> 18 children with severe steroid-requiring asthma <sep>', 'severely asthmatic children <sep> fifteen hospitalized asthmatic children 8 to 18 years old <sep>', '30 patients receiving tao and 27 patients receiving placebo completed 1 yr 17 on tao and 8 on placebo completed 2 yr of double-blind participation <sep> 75 subjects with asthma requiring daily corticosteroids for control <sep> asthmatic subjects who require daily corticosteroids <sep>'], 'interventions': ['low-dose troleandomycin therapy <sep> troleandomycin tao <sep> tao and methylprednisolone mpn combination tao and prednisone and mpn alone <sep> tao <sep> tao-prednisone <sep>', 'low-dose troleandomycin <sep> methylprednisolone <sep> placebo-controlled comparison of combination methylprednisolone and placebo troleandomycin prednisone and troleandomycin p-tao or methylprednisolone-tao mpn-tao <sep> troleandomycin <sep> tao <sep>', 'methylprednisolone <sep> placebo <sep> troleandomycin and methylprednisolone <sep> methylprednisolone <sep> methylprednisolone alone <sep> troleandomycin combined with methylprednisolone <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there is insufficient evidence to support the use of troleandomycin in the treatment of steroid dependent asthma.
313,"{'outcomes': ['ophthalmologic and systemic complications <sep> eleven intraoperative complications <sep> incidence of ophthalmologic and systemic complications <sep> systemic adverse events <sep> systemic adverse event <sep>', 'rates of intraoperative events <sep> hypertension and arrhythmia principally bradycardia <sep> overall rate of complications <sep> postoperative events <sep> medical tests electrocardiography complete blood count and measurement of serum levels of electrolytes urea nitrogen creatinine and glucose <sep>', 'rate of complications <sep> cumulative rate of medical events <sep>'], 'punchline_text': ['systemic adverse events occurred intraoperatively in four patients whereas no systemic adverse event was recorded at 1 month in either group. <sep>', 'there were also no significant differences between the no-testing group and the testing group in the rates of intraoperative events 19.2 and 19.7 respectively per 1000 operations and postoperative events 12.6 and 12.1 per 1000 operations). <sep>', 'the cumulative rate of medical events was similar in the two groups 9.6 in the routine-testing group and 9.7 in the selective-testing group p  0.923). <sep>'], 'population': ['patients who undergo cataract surgery without preoperative tests compared to subjects undergoing cataract surgery preceded by preoperative tests <sep> 1276 consecutive patients admitted to the institute of ophthalmology of the university of modena and reggio emilia for cataract surgery <sep> cataract surgery <sep>', '18,189 patients at nine centers to be preceded or not preceded by a standard battery of <sep> 9408 patients who underwent 9626 cataract operations that were not preceded by routine testing and in 9411 patients who underwent 9624 operations that were preceded by routine testing <sep> cataract surgery <sep> patients scheduled to undergo cataract surgery <sep>', 'academic medical center in brazil between 10 february 2000 and 10 january 2001 <sep> 1,025 patients scheduled to undergo cataract surgery was comprised of 512 assigned to the routine-testing group and of 513 assigned to the selective-testing group <sep> scheduled cataract operations <sep> adults <sep>'], 'interventions': ['preoperative testing <sep> preoperative evaluation based on routine medical tests and electrocardiograms the other 638 underwent preoperative evaluation based on said tests <sep>', '19,557 elective cataract operations <sep>', 'routine medical testing before cataract surgery <sep> routine testing the routine-testing group or 2 not to be preceded by routine medical testing the selective-testing group <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",this review has shown that routine pre-operative testing does not increase the safety of cataract surgery. alternatives to routine preoperative medical testing have been proposed including self-administered health questionnaires which could substitute for health provider histories and physical examinations. such avenues may lead to cost-effective means of identifying those at increased risk of medical adverse events due to cataract surgery. however despite the rare occurrence adverse medical events precipitated by cataract surgery remain a concern because of the large number of elderly patients with multiple medical comorbidities who have cataract surgery in various settings. the studies summarized in this review should assist recommendations for the standard of care of cataract surgery at least in developed settings. unfortunately in developing country settings medical history questionnaires would be useless to screen for risk since few people have ever been to a physician let alone been diagnosed with any chronic disease.
314,"{'outcomes': ['remnant ablation rates <sep> billewicz scale <sep> short form-36 health assessment scale scores <sep> quality of life <sep> quality of life <sep> serum thyroglobulin concentration less <sep> rate of radiation clearance from blood thyroid remnant and whole body <sep>', 'ablation rate <sep> tsh tg and tgab <sep> safe and effective and avoids hypothyroidism <sep> small thyroid remnants <sep>', 'basal and rhtsh-stimulated serum thyroglobulin <sep> successful thyroid ablation rate <sep> successful ablation <sep>', 'mbq <sep> levels of thyroid stimulating hormone tsh <sep> tsh serum level <sep> remnant cumulated activity per unit administered activity <sep>'], 'punchline_text': ['euthyroid patients had a statistically significant one third lower radiation dose to the blood compared with patients in the hypothyroid group. <sep>', 'at follow-up 90.0 of patients from group a and 85.0 of patients from group b had tg levels 1 ng/ml no uptake was observed in 95.2 and in 90.5 of patients from group a or b respectively with no statistical differences for both ablation criteria. <sep>', 'successful ablation no visible uptake in the diagnostic whole-body scan after rhtsh stimulation was achieved in 88.9 of group a and b patients. <sep>', 'the rh-tsh pre-treated patients seem to have a lower uptake compared to those in hypothyroidism induced by l-t4 withdrawal. <sep>'], 'population': ['patients prepared for 131i remnant ablation with 3.7 gbq by either administering rhtsh or withholding thyroid hormone <sep> differentiated thyroid carcinoma <sep> euthyroid patients on l-thyroxine therapy euthyroid group to ablate remnant thyroid tissue with 3.7 gbq 100 mci 131i compared with that with conventional remnant ablation performed in the hypothyroid state hypothyroid group <sep>', 'low-risk patients <sep> thyroid cancer <sep>', 'differentiated thyroid cancer <sep> 72 patients with dtc <sep> 1850 mbq 131)i had a similar successful rate to 3700 mbq in patients prepared with rhtsh <sep> differentiated thyroid cancer dtc patients showed that 3700 mbq 131-iodine 131)i after <sep>', '14 hypothyroid patients <sep> thyroid cancer patients <sep> forty-six dtc patients submitted to i ablative therapy <sep>'], 'interventions': ['radioiodine <sep> recombinant human tsh rhtsh <sep> recombinant human thyrotropin <sep> radioiodine ablation <sep>', 'rhtsh <sep> low-activity 2 gbq 54 mci <sep> mci radioiodine post-surgical remnant ablation <sep> neck ultrasound 131)i neck scintigraphy and radioiodine uptake <sep> 131)i ablation using l-thyroxine withdrawal or rhtsh stimulation <sep>', 'recombinant thyrotropin-stimulated postoperative thyroid remnant ablation <sep> rhtsh <sep> recombinant human tsh rhtsh <sep>', 'recombinant human tsh rh-tsh <sep> rh-tsh <sep> 131i ablative therapy after rh-tsh stimulation <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",results from four randomised controlled clinical trials suggest that rhtsh is as effective as thw on iodine-131 thyroid remnant ablation with limited data on significant benefits in decreased whole body radiation exposure and health-related quality of life. it is still uncertain whether lower iodine-131 doses 1110 mbq or 1850 mbq versus 3700 mbq are equally effective for remnant ablation under rhtsh stimulation. randomised controlled clinical trials are needed to guide treatment selection for metastatic differentiated thyroid cancer.
315,"{'outcomes': ['symptoms related to atrial fibrillation <sep> walking distance <sep> pharmacological restoration of sinus rhythm <sep> quality of life <sep> incidence of hospital admission <sep>', 'majority of strokes <sep> adverse drug effects <sep> overall mortality <sep> left ventricular function <sep> left atrium <sep> survival advantage <sep>'], 'punchline_text': ['walking distance in a 6 min walk test was better in group b compared with group a but assessment of quality of life showed no differences between groups. <sep>', 'of the 3311 patients with echocardiograms the left atrium was enlarged in 64.7 percent and left ventricular function was depressed in 26.0 percent. <sep>'], 'population': ['252 patients with atrial fibrillation of between 7 days and 360 days duration which compared rate group a 125 patients with rhythm control group b 127 patients <sep> patients with atrial fibrillation <sep> atrial fibrillation piaf <sep>', 'massachusetts medical society <sep> patients with atrial fibrillation <sep> 70.8 percent had a history of hypertension and 38.2 percent had coronary artery disease <sep> 4060 patients mean sd age 69.7+/-9.0 years were enrolled in the study <sep> patients with atrial fibrillation and a high risk of stroke or death <sep> 3311 patients with echocardiograms <sep>'], 'interventions': ['amiodarone <sep> diltiazem <sep> amiodarone <sep>', 'warfarin <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",there is no evidence that pharmacological cardioversion of atrial fibrillation to sinus rhythm is superior to rate control. rhythm control is associated with more adverse effects and increased hospitalisation. it does not reduce the risk of stroke. the conclusions cannot be generalised to all people with atrial fibrillation. most of the patients included in these studies were relatively older 60 years with significant cardiovascular risk factors.
316,"{'outcomes': ['basal cell carcinoma bcc <sep> adverse events <sep> local skin reactions <sep> clinical efficacy <sep> safety and efficacy <sep>', 'complete response rates <sep> lesion clearance <sep> good cosmetic outcome <sep> sustained response rate at 12 months and cosmetic outcome <sep> tumor-free rates <sep> cosmesis and lesion recurrence <sep>', 'cure rates <sep> 4-year actuarial failure rate <sep> basal cell carcinomas bccs <sep> failure rate persistent or recurrent disease <sep>', 'highest clearance rate <sep>', 'response rate <sep> efficacy <sep> complete response rate <sep> response rates <sep> safety and efficacy <sep> highest histologically complete response rate <sep>', 'complete response cr <sep> partial response pr <sep>', 'composite clearance rates clinical and histological assessments and histological clearance rates <sep> safety and clinical efficacy <sep> histological clearance <sep> composite clearance <sep> adverse events and scoring of local skin reactions lsrs <sep> composite response rates proportion of subjects with clinical and histological clearance and response rates solely based on histology proportion of subjects with histological clearance <sep>', 'clinical complete response rate <sep> clinical and cosmetic responses <sep> pathologic response <sep> systemic adverse events <sep>', 'cure rate <sep>', 'initial inflammatory response <sep> noduloulcerative and superficial lesions <sep> cure of lesions <sep> size of lesions <sep>', 'complete response rate based on histologic assessment <sep> response rate tolerance and patient compliance <sep> safety tolerance and efficacy <sep> systemic adverse events <sep>', 'complete response rates <sep>', 'clearance rates <sep> increasing severity of erythema erosion and scabbing/crusting <sep> composite clearance rates <sep> histological clearance rates <sep> efficacy and safety <sep>', 'serious adverse events <sep> cosmetic outcome <sep> cost and safety <sep>', 'recurrence of carcinoma <sep> rates of recurrence of facial basal-cell carcinoma <sep> recurrence rates <sep> total operative costs of mms <sep>', 'histologic clearance <sep>'], 'punchline_text': ['bcc cleared on the basis of histologic examination in all 15 patients 100 dosed twice daily once daily and 3 times weekly in 3 of 5 60 patients dosed twice weekly 2 of 4 50 dosed once weekly and in 1 of 11 9 treated with vehicle. <sep>', 'more patients treated with methyl aminolevulinate pdt than surgery had an excellent or good cosmetic outcome at all time points significant at 12 and 24 months on patient assessment p<.05 and at 3 12 and 24 months on investigator evaluation p<.001). <sep>', 'the 4-year actuarial failure rate 95 ci was 0.7 0.1-3.9 in the surgery group compared with 7.5 4.2-13.1 in the radiotherapy group log-rank p  0.003). <sep>', 'topical 5 imiquimod cream is well tolerated and most effective in treating nodular bcc when applied once daily for 7 days per week for either 12 or 6 weeks. <sep>', 'imiquimod 5 cream has been investigated for non-surgical treatment of superficial and nodular basal cell carcinoma bcc tumours. <sep>', 'interferons ifn especially alfa-2a and 2b are potent inhibitors of normal and malignant cell growth and effective choices in the treatment of basal cell carcinoma bcc). <sep>', 'histological clearance was demonstrated in 80 and 6 of subjects treated with imiquimod and vehicle cream respectively. <sep>', 'overall 65 95 confidence interval 58%-71 of tumors were judged to have good to excellent cosmesis at 24 months. <sep>', 'there was a 90 cure rate 9/10 in those lesions treated with 5 5-fu in pc cream and a 57 cure rate 4/7 in those treated with 5 5-fu in a petrolatum-based cream. <sep>', 'side effects of treatment mainly flu-like symptoms were usually mild and transient and occurred more commonly in the interferon-treated group. <sep>', 'no clinically significant treatment-related systemic adverse events occurred. <sep>', 'complete response rates were 100 10/10 87.1 27/31 80.8 21/26 and 51.7 15/29 for patients in the twice daily once daily 5 times a week and 3 times a week imiquimod groups respectively and 18.8 6/32 in the vehicle group. <sep>', 'histological clearance rates for the 5 and 7x/week imiquimod groups were 82 and 79 respectively. <sep>', 'a complete response was achieved in 95 lesions 86 in the laser group and 110 lesions 82 in the bl group 6 months after treatment. <sep>', 'total operative costs of mms were higher than those of se primary 405.79 euros vs 216.86 euros recurrent 489.06 euros vs 323.49 euros both p<0.001). <sep>', 'intention-to-treat analysis revealed 100 3/3 histologic clearance in the twice-daily regimen 87.9 29/33 clearance in the once every day regimen 73.3 22/30 clearance in the twice-daily 3 times/week regimen and 69.7 23/33 clearance in the once-daily 3 times/week regimen. <sep>'], 'population': ['35 patients with bcc 24 received <sep>', 'nodular basal cell carcinoma bcc <sep> thirteen patients with a noncomplete response to pdt at 3 months 24 lesions were retreated <sep> 101 adults with previously untreated nodular bcc <sep> 97 patients 105 lesions <sep> university dermatology departments <sep> nodular basal cell carcinoma <sep>', '173 patients in the <sep> 347 patients were treated <sep> 174 patients in the surgery group 71 had local anaesthesia and 91 frozen section examination <sep> basal cell carcinoma of the face <sep> primary bcc of the face measuring less than 4 cm <sep>', 'primary nodular basal cell carcinoma bcc <sep> patients were at least 18 years old and had a biopsy-confirmed diagnosis of nodular bcc <sep> 99 patients enrolled in the 6-week study and 92 patients in the 12-week study <sep> twenty-four public and private dermatology clinics in australia and new zealand 6-week study and the united states 12-week study participated <sep> nodular basal cell carcinoma <sep>', ""superficial and nodular basal cell carcinoma bcc tumours <sep> patients diagnosed with bcc were enrolled into either the superficial 93 patients or nodular 90 patients study depending on the histological confirmation of the patient's tumour subtype <sep> superficial and nodular basal cell carcinoma <sep>"", 'basal cell carcinoma <sep> 45 patients with histopathologically confirmed bcc <sep>', '166 subjects were enrolled in this study <sep> superficial basal cell carcinoma <sep> subjects who had at least one histologically confirmed sbcc tumour <sep> 26 centres in europe <sep>', '4 north american university-based dermatology clinics <sep> patients with multiple synchronous nonmelanoma skin cancers <sep> fifty-four patients with 421 multiple nonmelanoma skin cancers including superficial and nodular basal cell carcinoma and squamous cell carcinoma in situ bowen disease <sep> patients with multiple nonmelanoma skin cancers <sep> multiple nonmelanoma skin cancers <sep>', 'thirteen patients with 17 biopsy-proven moderate thickness bccs <sep>', 'patients with noduloulcerative or superficial basal cell carcinomas <sep> basal cell carcinoma <sep> 172 patients at four medical centers <sep>', 'patients with bccs <sep> basal cell carcinomas bccs <sep> 122 patients with biopsy-proven bccs <sep>', 'superficial basal cell carcinoma <sep> superficial basal cell carcinoma sbcc <sep>', 'superficial basal cell carcinoma <sep> subjects with one sbcc <sep>', '83 patients with 245 superficial bcc <sep> superficial basal cell carcinoma <sep> superficial basal cell carcinomas bcc <sep>', '397 primary 198 mms 199 se and 201 recurrent 99 102 tumours were actually treated <sep> 66 primary and 13 recurrent carcinomas <sep> each 204 primary 102 recurrent and received treatment at two hospitals in the netherlands <sep> 408 primary and 204 recurrent facial carcinomas 374 and 191 patients respectively <sep>', 'superficial basal cell carcinoma <sep> superficial basal cell carcinoma sbcc <sep> ninety-nine patients <sep>'], 'interventions': ['imiquimod 5 cream <sep> imiquimod <sep> vehicle cream <sep>', 'methyl aminolevulinate pdt <sep> photodynamic therapy pdt <sep> methyl aminolevulinate pdt <sep> photodynamic therapy <sep> sensitizer methyl aminolevulinate and standard excision surgery <sep> topical methyl aminolevulinate vs surgery <sep> methyl aminolevulinate cream <sep>', 'interstitial brachytherapy <sep> radiotherapy <sep> surgery and radiotherapy <sep> surgery or radiotherapy <sep> conventional radiotherapy <sep>', 'topical 5 imiquimod cream <sep> imiquimod or placebo cream vehicle <sep> topical 5 imiquimod cream <sep> imiquimod cream <sep> imiquimod <sep>', 'topical imiquimod <sep> imiquimod 5 cream 2 or 3 days per week either with or without occlusion <sep> imiquimod 5 cream <sep>', 'intralesional ifn alfa-2a <sep> ifn alfa-2a <sep> intralesional interferon alfa-2a <sep> interferons ifn <sep>', 'imiquimod and vehicle cream <sep> imiquimod aldaratrade mark <sep> imiquimod <sep> imiquimod <sep> imiquimod 5 cream <sep> imiquimod or vehicle cream <sep>', 'verteporfin and red light-emitting diodes <sep> verteporfin <sep> photodynamic therapy <sep> verteporfin pdt <sep> photodynamic therapy pdt with verteporfin and red light <sep>', 'placing 5-fluorouracil fu <sep> excisional biopsy <sep> cream a 5 5-fu in a pc vehicle or cream b efudex(r 5 5-fu <sep> 5-fu <sep> 5-fluorouracil <sep> phosphatidyl choline pc <sep>', 'placebo <sep> intralesional interferon therapy <sep> interferon <sep> interferon alfa-2b <sep>', '5-fluorouracil/epinephrine injectable gel 5-fu/epi gel <sep> intralesional 5-fluorouracil/epinephrine injectable gel <sep> 5-fu/epi gel <sep>', 'imiquimod <sep> imiquimod <sep> imiquimod 5 cream <sep>', 'imiquimod <sep> imiquimod <sep> imiquimod or vehicle cream <sep> imiquimod 5 cream <sep>', '5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid <sep> dimethylsulfoxide dmso <sep> laser or broadband halogen light in photodynamic therapy with topical 5-aminolevulinic acid ala <sep> ethylendiaminetetraacetic acid <sep> photodynamic therapy <sep>', 'micrographic surgery mms <sep> se or mms <sep> surgical excision vs mohs micrographic surgery <sep> mms <sep> se <sep>', 'imiquimod <sep> imiquimod 5 cream <sep> imiquimod <sep> imiquimod 5 cream <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",overall there has been very little good quality research on treatments for bcc. most trials have only evaluated bccs in low risk locations. surgery and radiotherapy appear to be the most effective treatments with surgery showing the lowest failure rates. although cosmetic outcomes appear good with pdt long-term follow-up data are needed. other treatments might have some use but few have been compared to surgery. an ongoing study comparing imiquimod to surgery should clarify whether imiquimod is a useful option.
317,"{'outcomes': ['tetanus neonatorum death rate <sep>', 'mortality rate <sep> neonatal mortality <sep> reduction in deaths <sep>'], 'punchline_text': ['those in the control group given 2 or 3 injections had a tetanus neonatorum death rate of 7.8 deaths per 100 births and the corresponding subjects in the study group had none. <sep>', 'in the period up to 20 months following vaccination the reduction in deaths among 4-14-day-old infants after a single dose of tetanus-diptheria toxoids was about the same as that after two doses. <sep>'], 'population': ['1618 women was conducted between 1961 and 1966 in a rural area of colombia with an estimated existing tetanus neonatorum death rate of 11.6 per 100 births <sep>', 'non-pregnant women <sep> non-pregnant women in rural bangladesh with two doses of <sep>'], 'interventions': ['influenza-virus vaccine <sep> aluminium-phosphate-adsorbed tetanus toxoid <sep>', 'aluminium-adsorbed tetanus-diphtheria toxoids <sep> aluminium-adsorbed tetanus toxoid <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>']}",available evidence supports the implementation of immunisation practices on women of childbearing age or pregnant women in communities with similar or higher levels of risk of neonatal tetanus to the two study sites. more information is needed on possible interference of vaccination by malaria chemoprophylaxis on the roles of malnutrition and vitamin a deficiency and on the quality of tetanus toxoid production and storage.
318,"{'outcomes': ['complete blood count urinalysis liver and renal function prothrombin time and activity <sep> blood loss <sep> bleeding from placental delivery <sep> quantity of blood <sep> complications or side effects <sep> quantity of total blood from placental delivery <sep>', 'total blood loss <sep> average blood loss <sep> blood loss <sep> vaginal bleeding <sep> postpartum blood loss <sep> occurrences of postpartum hemorrhage <sep>'], 'punchline_text': ['tranexamic acid statistically reduces the extent of bleeding from placental delivery to 2 h postpartum and its use was not associated with any side effects or complications. <sep>', 'the average blood loss of group i and ii was significantly less than group iii and iv p  0.01 however there was no significant difference between group i and group ii p  0.05). <sep>'], 'population': ['one hundred and eighty primiparas <sep> 91 women received <sep>', 'group i n  94 <sep> four hundred primipara with term singleton pregnancy vertex presentation spontaneous delivery were enrolled <sep>'], 'interventions': ['tranexamic acid <sep> tranexamic acid at caesarian section cs <sep> tranexamic acid <sep>', 'transamin tranexamic acid <sep> transamin <sep> oxytocin <sep> tranexamic acid <sep> aminomethylbenzoic acid <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>']}",tranexamic acid decreases postpartum blood loss after vaginal birth and after caesarean section based on two rcts of unclear quality which reported on only a few outcomes. further investigations are needed to confirm efficacy and safety of this regimen for preventing pph. these results also provide a basis for the investigation of tranexamic acid for the treatment of pph.
319,"{'outcomes': ['pregnancy and implantation rates <sep>', 'implantation rate <sep> pregnancy and implantation rates <sep> pregnancy rates <sep> pregnancy rate <sep>', 'clinical pregnancy rate <sep> frequency of easy transfers <sep> pregnancy rates <sep> implantation rate <sep> pregnancy and implantation rates <sep>', 'abortion rate <sep> implantation and pregnancy rates <sep>', 'rate of implantation and clinical pregnancy <sep> clinical pregnancy rates <sep>', 'highest pregnancy rate 32.3%/et <sep> pregnancy rate <sep>', 'clinical pregnancy rate <sep> ectopic pregnancy miscarriage and multiple pregnancy <sep> ongoing pregnancy rate <sep> implantation rate <sep>', 'clinical pregnancy rate for ultrasound-guided embryo transfer <sep> clinical pregnancy rates and live birth rates <sep> pregnancy rates <sep> clinical pregnancy or live birth rates <sep>', 'number of clinical pregnancies <sep> live-birth/ongoing pregnancy and clinical pregnancy rates <sep> ongoing pregnancy/live-birth and clinical pregnancy rates <sep> live-birth/ongoing pregnancy rate <sep> incidences of difficult transfers blood and/or mucus on the catheter tip spontaneous miscarriages and ectopic pregnancies <sep>', 'degree of confidence and satisfaction <sep> clinical pregnancy rate <sep> pregnancy rate <sep>'], 'punchline_text': ['however both pregnancy and implantation rates in group 1 34.4 and 19.8 respectively were significantly higher than the corresponding values 19.7 and 11.9 in group 2. <sep>', 'there were no statistically significant differences between the two groups with respect to age cause of infertility and in the characteristics of the ivf cycle. <sep>', 'us-guided transfer was associated with a decrease in the difficulty of the transfers 97 of transfers were easy in the us-guided group compared with 81 in the clinical touch group p  0.05). <sep>', 'implantation and pregnancy rates were similar p  0.51 p  0.29 for group i 19.6 42 and group ii 16.3 30 as also was the abortion rate p  0.55 <sep>', 'for the cases n  178 ultrasound-guided was used controls n  152 was performed using routine methods. <sep>', 'a better pregnancy rate 19.4%/et can be achieved when tdt catheter was used under ultrasound guidance. <sep>', 'the implantation rate was slightly higher in the ultrasound-guided group 15.3 than the clinical touch group 12.0 p  0.048). <sep>', 'there was no difference in clinical pregnancy or live birth rates between the two groups. <sep>', 'the live-birth/ongoing pregnancy rate was significantly higher in the us et group 68 of 183 40.98 than in the clinical touch et group 50 of 190 28.42 odds ratio  1.66 <sep>', 'although the clinical pregnancy rate was not statistically different 18.5 in the ultrasound-guided group vs. 17.4 in the clinical touch group the use of abdominal ultrasound during the embryo transfer procedure provided a greater degree of confidence and satisfaction to both patients and physicians. <sep>'], 'population': ['frozen-thawed embryo transfer <sep> 184 consecutive patients undergoing thawed embryo transfer cycles with hormone replacement under pituitary suppression <sep>', 'between october 1998 and january 1999 <sep> 362 patients from our in-vitro fertilization ivf)-embryo transfer programme <sep>', 'n  255 women with clinical touch embryo transfer n  260 <sep>', '100 patients identified as likely to have easy transfer after mock transfer <sep>', '330 patients <sep>', '400 consecutive embryo transfers ets <sep>', 'a total of 800 embryo transfers was studied 400 <sep>', 'people with fertility problems <sep>', 'three hundred seventy-three women <sep>', 'patients undergoing in vitro fertilization 50 fresh cycles with day 3 embryo transfer were studied 27 patients <sep>'], 'interventions': ['ultrasound-guided embryo transfer <sep> ultrasound-guided group 1 and 91 had clinical touch group 2 embryo transfer <sep> ultrasound guidance <sep>', 'ultrasound guidance in embryo transfer <sep> embryo transfer under ultrasound guidance <sep> ultrasound-guided embryo replacement and 180 had clinical touch embryo transfer <sep>', 'ultrasound-guided embryo transfer <sep> embryo transfer under abdominal us guidance <sep> us-guided embryo transfer <sep>', 'ultrasound guidance <sep> ultrasound us to guide embryo transfer et <sep> us-guided et <sep>', 'ultrasound-guided embryo transfer <sep> ultrasound-guided embryo transfer with the traditional method <sep> abdominal ultrasound-guided embryo transfer <sep> ultrasound-guided embryo transfer <sep>', 'embryo transfer catheters <sep>', 'ultrasound-guided embryo transfer <sep> ultrasound-guided transfers <sep> embryo transfer under ultrasound guidance <sep>', 'ultrasound-guided embryo transfer <sep> 2295 ultrasound-guided embryo transfers <sep>', 'ultrasound-guided et <sep> transcervical intrauterine et with or without us guidance <sep> ultrasound guidance during embryo transfer <sep>', 'ultrasound-guided transfers <sep> abdominal ultrasound-guided embryo transfer <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",the studies are limited by their quality with only two studies reporting details of both computerised randomisation techniques and adequate allocation concealment. ultrasound guidance does appear to improve the chances of live/ongoing and clinical pregnancies compared with clinical touch methods. the quality of future studies should be improved with adequate reporting of randomisation allocation concealment and power calculations. the primary outcome measure of future studies should be the reporting of live births per woman randomised.
320,"{'outcomes': ['1 full neurologic grade <sep> complications and mortality <sep> functional independence measure fim <sep> motor recovery rates <sep> motor recovery <sep> 6-month fim <sep> severe sepsis and severe pneumonia <sep>', 'postoperative discomfort <sep> postoperative pain and length of hospital stay <sep> shorter hospital stay <sep> complete relief of back and radicular pain <sep> postoperative complications and functional outcome <sep> postoperative narcotic analgesia <sep>', 'motor and sensory functions <sep> mortality and major morbidity <sep> motor function neurologic change scores <sep> sensation to pinprick <sep> neurologic recovery <sep> neurologic outcomes <sep> efficacy and safety <sep>', 'total number of sick days <sep> sick-leave profile <sep> disabling symptoms <sep>', 'pulmonary side effects <sep> pulmonary complication with mpss <sep> recovery of motor function <sep> pulmonary complications <sep> gastrointestinal complication <sep>'], 'punchline_text': ['the effect of the 48-hour methylprednisolone regimen was significant at 6 weeks p=.04 and 6 months p=.01 among patients whose therapy was initiated 3 to 8 hours after injury. <sep>', 'postoperative complications and functional outcome were not different between the groups. <sep>', 'mortality and major morbidity were similar in all three groups. <sep>', 'at the follow-up examination 6 months after initial treatment there was a significant difference in disabling symptoms between the actively treated patients and the placebo group p  0.047 total number of sick days p  0.01 and sick-leave profile p  0.003). <sep>', 'aged patients with cervical spinal injury may be more likely to have pulmonary side effects p  0.029 after high-dose therapy with mpss and thus deserve special care. <sep>'], 'population': ['acute spinal cord injury <sep> patients with acute spinal cord injury <sep> patients with acute spinal cord injury who receive <sep> sixteen acute spinal cord injury centers in north america <sep> 499 patients with acute spinal cord injury diagnosed in national acute spinal cord injury study nascis centers within 8 hours of injury <sep>', 'lumbar disc disease <sep> 32 patients at a university-based veterans administration hospital undergoing lumbar microdiscectomy <sep> all 32 patients presented with radicular symptoms and had radiographic confirmation of a herniated nucleus pulposus <sep>', 'patients with acute spinal-cord injury <sep> patients with acute spinal-cord injury 95 percent of whom were treated within 14 hours of injury <sep> acute spinal-cord injury <sep>', 'cases of whiplash injury in car accidents <sep> forty patients 22 men and 18 women with a mean age of 35 years range 19-65 <sep>', 'they were treated without surgery for spinal cord injury in the cervical spine and were enrolled in the trial if a diagnosis had been made and treatment had begun within 8 hours <sep> forty-six patients 42 men and 4 women mean age 60.6 years range 18-84 were included in the study 23 in the mpss group and 23 in the placebo group <sep> patients with acute cervical spinal cord injury <sep> aged patients with cervical spinal injury <sep> acute cervical spinal cord injury <sep>'], 'interventions': ['methylprednisolone infusion <sep> methylprednisolone <sep> tirilazad mesylate <sep> methyprednisolone <sep> intravenous bolus of methylprednisolone <sep> tirilazad <sep>', 'bupivacaine <sep> 160 mg intramuscular depo-medrol methylprednisolone acetate and 250 mg intravenous solu-medrol methyl-prednisolone sodium succinate <sep> corticosteroids and bupivacaine <sep> bupivacaine infiltrated into the paraspinal musculature at skin incision and at closure <sep> bupivacaine and corticosteroids <sep> saline-soaked fat graft <sep> lumbar microdiscectomy without corticosteroids or bupivacaine <sep>', 'methylprednisolone <sep> placebo <sep> methylprednisolone and naloxone <sep> naloxone <sep> naloxone <sep> methylprednisolone <sep> placebos <sep> methylprednisolone or naloxone <sep>', 'methylprednisolone <sep> methylprednisolone <sep> placebo <sep> methylprednisolone with placebo <sep>', 'methylprednisolone sodium succinate mpss <sep> mpss <sep> methylprednisolone sodium succinate <sep> placebo <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",high-dose methylprednisolone steroid therapy is the only pharmacologic therapy shown to have efficacy in a phase three randomized trial when administered within eight hours of injury. one trial indicates additional benefit by extending the maintenance dose from 24 to 48 hours if start of treatment must be delayed to between three and eight hours after injury. there is an urgent need for more randomized trials of pharmacologic therapy for acute spinal cord injury.
321,"{'outcomes': ['median cumulative doxorubicin <sep> left-ventricular ejection fraction assessed by serial multigated radionuclide angiography scans or congestive heart failure chf <sep> cardiotoxicity and grade 4 neutropenia <sep> reduced cardiotoxicity and preserved antitumor efficacy <sep> antitumor efficacy <sep> grade 4 neutropenia <sep> median survival <sep> cardiotoxicity <sep> median time to progression <sep> objective tumor response rates world health organization criteria time to progression and survival <sep> objective response rates <sep> doxorubicin cardiotoxicity <sep> cardiotoxicity <sep>', 'response rate <sep> complete plus partial response rate <sep> gastrointestinal and hematological toxicities <sep> nausea and vomiting stomatitis and leukopenia <sep> alopecia <sep> median survival <sep> efficacy and toxicity <sep> symptomatic congestive heart failure <sep> median duration of response <sep>', 'superior response rate <sep> vomiting mucositis and leukopenia <sep> left ventricular ejection fraction <sep> complete plus partial response <sep> median duration of response and the median survival <sep> left ventricular failure <sep>', 'response overall response  complete  partial response rates time to disease progression overall survival and cardiac function left ventricular ejection fraction <sep> overall response rates <sep> median survival times <sep> median time to disease progression <sep> median time to treatment failure <sep> cardiotoxicity <sep> neutropenia and stomatitis/mucositis <sep> injection site toxicity <sep> efficacy and tolerability <sep>', 'activity <sep> median time to progression <sep> congestive heart failure chf <sep> overall response rate complete response and partial response cr  pr <sep> median survival time <sep> leukopenia anemia nausea and vomiting <sep>', 'response rate <sep> overall response rate <sep> clinical toxicities <sep> left ventricular ejection fraction lvef <sep> disease progression or unacceptable toxicity <sep> efficacy and toxicity <sep> cardiotoxicity <sep> median ttp <sep> median survival <sep> palmar-plantar erythrodysesthesia <sep> protocol-defined cardiotoxicity <sep> median cumulative doxorubicin dose at onset of cardiotoxicity <sep> cardiac function <sep>'], 'punchline_text': ['antitumor efficacy of mc versus ac was comparable objective response rates 43 versus 43 median time to progression 5.1 versus 5.5 months median time to treatment failure 4.6 versus 4.4 months and median survival 19 versus 16 months. <sep>', 'gastrointestinal and hematological toxicities were moderate for both the drugs with fewer episodes of nausea and vomiting stomatitis and leukopenia following epi administration. <sep>', 'vomiting mucositis and leukopenia were documented less frequently following administration of epirubicin as compared to doxorubicin. <sep>', 'overall response rates were 46 and 39 for mc and ec treatment respectively p=0.42). <sep>', 'the overall response rate complete response and partial response cr  pr was not significantly different 53.6 for fec and 56.5 for fac. <sep>', 'clinical toxicities commonly associated with doxorubicin appeared less common with tlc d-99 although the difference was not statistically significant. <sep>'], 'population': ['metastatic breast cancer <sep> metastatic breast cancer mbc <sep> two hundred ninety-seven patients with mbc and no prior chemotherapy for metastatic disease <sep>', 'patients with advanced breast cancer <sep> advanced breast cancer <sep> forty-nine patients with advanced breast cancer who had failed from first-line <sep>', '42 patients with advanced breast cancer 23 of whom were in relapse from prior <sep> advanced breast cancer <sep>', 'patients with metastatic breast cancer <sep> metastatic breast cancer <sep> one hundred and sixty anthracycline-nave metastatic breast cancer patients <sep>', 'advanced breast cancer <sep> 443 patients 222 in the fec arm and 221 in the fac arm <sep> from february 1983 to january 1985 497 patients with advanced breast cancer <sep>', 'copyright 2002 american cancer society <sep> two hundred twenty-four patients with mbc and no prior therapy for metastatic disease <sep> metastatic breast carcinoma <sep> patients were removed from study if lvef declined 20 or more ef units from baseline to a final value of greater than or equal to 50 or by 10 or more units to a final value of less than 50 or onset of clinical congestive heart failure chf <sep> metastatic breast carcinoma mbc <sep>'], 'interventions': ['conventional doxorubicin and cyclophosphamide <sep> mc <sep> doxorubicin <sep> myocet liposome-encapsulated doxorubicin <sep> 60 mg/m(2 of myocet m or conventional doxorubicin a in combination with 600 mg/m(2 of cyclophosphamide c <sep> doxorubicin and cyclophosphamide <sep> cyclophosphamide <sep>', 'cyclophosphamide methotrexate and 5-fluorouracil cmf regimen chemotherapy <sep> epirubicin epi or doxorubicin dox <sep> weekly epirubicin versus doxorubicin <sep> dox <sep>', 'doxorubicin versus epirubicin <sep> cyclophosphamide methotrexate and 5-fu cmf chemotherapy <sep> doxorubicin and epirubicin <sep> doxorubicin therapy <sep> epirubicin <sep> doxorubicin <sep> epirubicin <sep> doxorubicin and its epimerized analog epirubicin <sep>', 'non-pegylated liposomal doxorubicin myocet and epirubicin combined with cyclophosphamide <sep> doxorubicin <sep> epirubicin <sep> epirubicin and cyclophosphamide <sep> liposomal doxorubicin and cyclophosphamide <sep> myocet m 75 mg/m(2 or epirubicin e 75 mg/m(2 in combination with cyclophosphamide <sep>', 'fluorouracil 5-fu <sep> fluorouracil epirubicin and cyclophosphamide v fluorouracil doxorubicin and cyclophosphamide <sep> fec <sep> epirubicin or doxorubicin 50 mg <sep> fac <sep> epirubicin <sep> epirubicin or doxorubicin <sep> epirubicin and 550 mg/m2 for doxorubicin <sep> cyclophosphamide <sep>', 'liposome-encapsulated doxorubicin <sep> liposome-encapsulated doxorubicin tlc d-99 myocet elan pharmaceuticals princeton nj and conventional doxorubicin <sep> doxorubicin <sep> tlc d-99 <sep> conventional doxorubicin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",we are not able to favour either epirubicin or doxorubicin when given with the same dose. based on the currently available evidence on heart failure we conclude that in adults with a solid tumour liposomal-encapsulated doxorubicin should be favoured over doxorubicin. for both epirubicin versus doxorubicin and liposomal-encapsulated doxorubicin versus conventional doxorubicin no conclusions can be made about the effects of treatment in children treated with anthracyclines and also not in patients diagnosed with leukaemia. more research is needed. for other combinations of anthracycline derivates not enough evidence was available to make definitive conclusions about the occurrence of cardiotoxicity in patients treated with anthracyclines.
322,"{'outcomes': ['syncopal recurrences <sep> rate of positive responses <sep>', 'blood pressure <sep> time to syncope <sep> orthostatic tolerance <sep>', 'recurrence of vasovagal syncope vvs <sep> recurrence of two vvss <sep> pacemaker implantation <sep> occasional presyncope and their quality of life <sep> recurrences of syncope <sep> vasovagal syncope <sep> paced heart rate and avoid bradycardia arterial hypotension and syncope <sep> baroreceptor afferent flow <sep> cls mode and no syncope <sep> myocardial contractility <sep> heart rate <sep>', 'syncope <sep> positive for syncope <sep> recurrence of syncope <sep> prevention of syncope or presyncope provoked by head-up tilt testing <sep> heart rate <sep>', 'intra-arterial monitoring impedance cardiography arterial blood sampling and tracer kinetics of simultaneously infused 3h]noradrenaline and 3h]adrenaline <sep> svri systemic vascular resistance index and magnitude of plasma adrenaline <sep> plasma adrenaline <sep> tilt-induced vasodilatation syncope or elevated plasma adrenaline <sep> svri <sep> plasma adrenaline and systemic hypotension <sep> hypotension and syncope duration of tilt tolerance <sep>', 'heart rate electrocardiography phasic blood pressure digital photoplethysmography and thoracic fluid index transthoracic impedance plethysmography <sep> heart rate <sep> particular physical function <sep> positive therapeutic response <sep> energy and vitality <sep> tilt induced syncope <sep> serious adverse effects <sep> baseline supine systolic blood pressure <sep> venous return <sep> quality of life scoring scale <sep> change in health status <sep> global assessment of therapeutic response <sep> symptom frequency symptoms during head up tilt and quality of life <sep> symptom events <sep>', 'syncopal recurrence <sep> spontaneous episodes of vasovagal syncope <sep> median time to the first syncopal recurrence <sep> incidence of first syncopal recurrence <sep> recurrence of syncope <sep>', 'recurrent neurocardiogenic syncope <sep> first recurrence of syncope <sep>', 'recurrence of cardioinhibitory vasovagal syncope <sep> syncopal episodes <sep> recurrence of syncope <sep> mean duration of follow <sep>', 'permanent cardiac pacing recurrence of syncope <sep> first recurrence of syncope <sep>', 'free of syncope <sep> occurrence of symptoms <sep> occurrence of syncope <sep> recurrence of syncope <sep>', 'cumulative risk of syncope <sep> risk of syncope <sep> recurrent syncope <sep> risk of recurrent syncope <sep> lead dislodgement or repositioning <sep> median of 4 episodes of syncope <sep> relative risk reduction in time to syncope with ddd pacing <sep>', 'syncope <sep> symptoms requiring the withdrawal of vvi pacing and premature dvi/ddd reprogramming <sep> pacemaker effect <sep> orthostatic hypotension <sep> systolic pressure fall caused by carotid sinus massage <sep> symptomatic pacemaker effect <sep> ventriculo-atrial conduction <sep>', 'mean 24-hour ambulatory bp <sep> symptom reporting and mean sbp decrease after csm <sep> symptom reproduction and bp and heart rate changes <sep> initial mean <sep> rate of symptom reporting and attenuated sbp decreases <sep> mean+/-standard deviation sbp decrease <sep> ambulatory 24-hour bp monitoring took place <sep> 24-hour ambulatory bp <sep> mean sbp decrease <sep>', 'postrandomization risk of syncope <sep> first recurrence of syncope <sep> likelihood of syncope <sep> vasovagal syncope <sep> heart rate <sep>', 'profound hypotension <sep> cardiovascular tests vasodepression during carotid sinus massage pacemaker effect postural blood pressure measurements and response to head up tilt and symptoms <sep> symptomatic hypotension <sep> vvi vvi 31 sd 19 <sep> upright pacemaker effect <sep> postural blood pressure measurements <sep> orthostatic hypotension while pacing ddi <sep>', 'median time to first syncopal recurrence <sep> syncopal recurrence burden <sep> asystolic response to tilt testing <sep> syncopal recurrences <sep> vasovagal syncope international study vasis <sep> median number of previous syncopal episodes <sep> likelihood of syncope <sep> recurrence of syncope <sep>', 'syncope recurrence <sep> acute tilt-induced syncope recurrence rates <sep> syncope <sep> vasovagal syncope <sep>', 'refractory vasovagal syncope <sep> response rates negative tilt test <sep> vasovagal syncope <sep>', 'concentration of plasma ca increase and prevented syncope <sep> plasma ca concentration norepinephrine ne and epinephrine e <sep> plasma ca concentrations <sep> catecholamine ca concentration <sep> plasma ca concentrations and syncope <sep>', 'syncopal recurrences <sep> actuarial rates of absence of syncopal recurrences <sep> syncope <sep> low recurrence rate of syncope <sep>', 'syncope <sep> abnormal response to carotid sinus massage <sep> actuarial rate of absence of minor symptoms <sep> actuarial rate of absence of syncopal recurrence <sep> reproducibility of carotid sinus reflex <sep>', 'mean interval between escape beats <sep>', 'mean time to a vasovagal episode syncope or presyncope <sep> distribution of time of vasovagal events syncopes or presyncopes <sep> therapeutic efficacy <sep> syncopal and presyncopal episodes and graded their well-being expressed as the general evaluation of life general activities and everyday activities <sep> vasovagal syncope <sep> presyncopes and total vasovagal events <sep>', 'severe side effects <sep>', 'recurrence of symptoms <sep> abolishing syncope <sep> withdrawal symptoms and side effects <sep> time to syncope and severity of hypotension <sep> recurrence of syncope <sep>', 'syncopal events <sep> number of falls during one year of follow-up <sep> falls without loss of consciousness <sep> injurious events <sep> syncopal events <sep>', 'median time to first syncope <sep> risk of syncope relapse <sep> recurrent tilt-induced vasovagal syncope <sep> syncopal recurrence <sep> asystolic response <sep> recurrence of syncope <sep> vasovagal syncope <sep>', 'blood pressure or heart rate <sep> responses to head-up tilt <sep> neurally mediated syncope <sep> orthostatic tolerance <sep>', 'total number of syncopal and presyncopal attacks <sep> syncope recurrence <sep> presyncopal attacks <sep> vasovagal syncope <sep> recurrence of syncope and presyncope <sep> spontaneous syncopal and presyncopal episode recurrence <sep>', 'symptomatic recurrences <sep> mean number of syncopal episodes <sep> qol <sep> numbers of episodes of syncope and presyncope and quality-of-life qol <sep> sympathetic activity preceding syncope <sep> qol scores <sep>', 'syncope <sep> pre-syncope <sep> recurrent syncope <sep> milder symptoms <sep> rate of syncope <sep> syncope recurrences <sep>', 'vasovagal syncope <sep>', 'syncopal attacks <sep> vasovagal syncope <sep> acute reproducibility <sep> vasovagal syncope <sep>', 'haemodynamic patterns of tilt-induced vasovagal reflex <sep> haemodynamic modifications heart rate and/or blood pressure fall <sep> vasovagal syncope <sep>', 'systolic blood pressure <sep> response rates negative ttt <sep> diastolic blood pressure <sep> mitral valve prolapse <sep> severity of attack <sep> heart rate <sep>', 'recurrence of neurocardiogenic syncope <sep> recurrent syncopal episodes <sep> time to first recurrence of syncope <sep> vasovagal syncope <sep>', 'risk of syncope <sep> first recurrence of syncope <sep> likelihood of recurrent syncope <sep> vasovagal syncope <sep>', 'repeat tilt testing <sep>'], 'punchline_text': ['oral etilefrine 10 mg three times a day was not superior to placebo in preventing a positive response to head-up tilt testing. <sep>', 'the pacemakers prevented bradycardia but had no effect on the time to syncope in a progressive test of head-up tilt followed by the addition of graded lower body suction. <sep>', 'the 41 patients programmed to cls had a mean follow-up of 19+/-4 months none reported vvs only four 10 reported occasional presyncope and their quality of life greatly improved. <sep>', 'intravenous disopyramide was ineffective for the prevention of neurally mediated syncope provoked by head-up tilt testing. <sep>', 'svri was inversely associated with fractional increase in plasma adrenaline during both phases. <sep>', 'midodrine had a conspicuous beneficial effect on symptom frequency symptoms during head up tilt and quality of life. <sep>', 'during follow-up the group treated with etilefrine had a similar incidence of first syncopal recurrence to that of placebo group both in the intention-to-treat analysis 24 versus 24 and in on treatment analysis 26 versus 24%). <sep>', 'during the 1-year of follow-up 20 patients of group a and 8 of group b had no recurrence. <sep>', 'the head-up tilt test performed 1 month after pacemaker implantation was positive in 3 of 12 patients 25 with ddd pacing with rate drop response function and in 5 of 8 patients 62.5 with ddi pacing with rate hysteresis. <sep>', 'ddd pacing with rate-drop response function is more effective than beta-blockade for the prevention of syncopal recurrences in highly symptomatic vasovagal fainters with relative bradycardia during tilt-induced syncope. <sep>', 'no statistically significant difference was observed between the two groups with respect to recurrence of syncope p=0.47). <sep>', 'in this double-blind randomized trial pacing therapy did not reduce the risk of recurrent syncope in patients with vasovagal syncope. <sep>', '14 mmhg and a higher prevalence of symptomatic pacemaker effect 50 vs 0 of ventriculo-atrial conduction 78 vs 44 and of orthostatic hypotension 50 vs 11 while the entity of the systolic pressure fall caused by carotid sinus massage was similar in the two groups either during vvi mode group a 51  <sep>', 'the differences in symptom reporting and mean sbp decrease after csm were both significant p<.01 and p=.03 respectively). <sep>', 'dual-chamber pacing with rate-drop response reduces the likelihood of syncope in patients with recurrent vasovagal syncope. <sep>', '11 patients developed profound hypotension during upright carotid sinus massage while pacing vvi compared with only two while pacing ddi. <sep>', 'one patient 5 in the pacemaker arm experienced recurrence of syncope compared with 14 patients 61 in the no-pacemaker arm p=0.0006). <sep>', 'no significant differences in acute tilt-induced syncope recurrence rates were obtained among groups at test repetition since 70.2 of group a 69.6 of group b and 62.5 of group c experienced syncope. <sep>', 'during follow-up spontaneous syncope was reported in six patients 17.6 in the paroxetine group as compared to 18 patients 52.9 in the placebo group p  0.0001). <sep>', 'before administration of enalapril plasma ca concentrations were significantly increased during hut compared with those in the supine position in contrast administration of the enalapril 10 mg/day for 1 year inhibited the concentration of plasma ca increase and prevented syncope in all 12 patients p  0.05 however placebo had no effect on plasma ca concentrations and syncope disappeared in only two of 12 patients after administration of placebo. <sep>', 'thus the outcome of either treated or untreated patients was favorable with a low recurrence rate of syncope and the usefulness of tilting-guided medical therapy remains uncertain. <sep>', 'syncope recurred in 16 patients 57 of the nopacing group mean follow-up 36  <sep>', 'at baseline the randomized patient groups were similar in their demographic and health characteristics and in the results of their atp tests for example the mean cardiac pause 21.4  <sep>', 'among the remaining 94 no difference between groups was observed regarding the distribution of time of vasovagal events syncopes or presyncopes during follow-up log-rank test). <sep>', 'one patient had to discontinue taking midodrine due to severe side effects and another six patients experienced minor side effects that did not require drug discontinuation. <sep>', 'during an average follow up of 15 3 months there was a significant reduction in the recurrence of symptoms compared with the previous year in patients who had tilt up guided treatment 18 metoprolol 1 clonidine). <sep>', 'syncopal events were also reduced during the follow-up period but there were much fewer syncopal events than falls-28 episodes in paced patients and 47 in controls. <sep>', 'there was also no significant difference in the subgroups of patients who had had a mixed response and in those who had had an asystolic response during head-up tilt testing. <sep>', 'the responses to head-up tilt were significantly different on the midodrine and the placebo day on the placebo day 67 8/12 of the subjects suffered neurally mediated syncope whereas only 17 2/12 of the subjects developed neurally mediated syncope on the midodrine day p  0.02). <sep>', 'all drugs improved the patients well-being anova chi-square  61.9 p  0.0001). <sep>', 'qol was similar in the two pacing modes. <sep>', 'at 12 months the rate of syncope in the np group was 40 n  12 compared with 10 n  3 in the p group p  0.008). <sep>', 'this double-blind randomized trial of transdermal scopolamine demonstrated no significant effect of preventing vasovagal syncope. <sep>', 'vasovagal syncope was induced in 24 patients during hut alone and in 30 patients during the hut with isoproterenol. <sep>', 'atropine was administered to 43 patients and was effective in 30 cases 69.7 p<0.01 vs placebo). <sep>', 'eight patients in gr 1 and six patients in gr 2 had mitral valve prolapse p  0.5). <sep>', 'the primary hypothesis was that atenolol is not superior to placebo for the treatment of vasovagal syncope. <sep>', 'the likelihood of recurrent syncope was not significantly different between groups. <sep>', 'of the 15 patients initially given metoprolol 2 13.3 did not respond both were crossed over to verapamil to which they remained unresponsive. <sep>'], 'population': ['30 consecutive patients with syncope and a baseline positive head-up tilt test <sep> patients with vasovagal syncope <sep>', 'patients with vasovagal syncope <sep> vasovagal syncope <sep>', 'vasovagal syncope invasy <sep> fifty patients 27 males mean age 59+/-18 year with severe and recurrent vasovagal syncope and positive head <sep> 24 patients recruited in the second stage of the study second year were programmed in ddd-cls mode <sep>', 'eleven patients <sep> twenty-two consecutive patients with recurrent neurally mediated syncope and two or more successive positive head-up tilt test responses <sep> patients with neurally mediated syncope <sep> 15 patients <sep>', 'eight subjects with recurrent neurocardiogenic syncope and previously documented tilt-induced syncope with elevated plasma adrenaline levels participated in the present study <sep>', '16 outpatients mean sd age 56 18 years five men with frequent hypotensive symptoms more than two syncopal episodes and fewer than 20 symptom free days per month and reproducible syncope with glyceryl trinitrate gtn during head up tilt <sep> patients with frequent symptoms <sep> fourteen patients who were given <sep> patients with neurocardiogenic syncope <sep>', '20 participating centers 126 patients with recurrent vasovagal syncope at least 3 episodes in the last 2 years and a positive baseline head-up tilt response <sep> patients with vasovagal syncope <sep> patients with recurrent vasovagal syncope <sep>', 'fifty-six patients 44+/-18 years 36 women with recurrent syncope  1 event in the last 6 months of suspected neurocardiogenic origin were included in the study <sep> recurrent syncope in patients with a positive or negative response to head-up tilt test <sep>', 'cardioinhibitory vasovagal syncope <sep> 20 patients 12 males and 8 females mean age 61.1 <sep> patients with cardioinhibitory vasovagal syncope <sep> 14 yrs with recurrent syncope mean number of prior episode  6.8 range 5-11 and cardioinhibitory responses during two head-up tilt tests the first diagnostic and the second during drug therapy with either <sep>', 'recurrent vasovagal syncope <sep> patients from 14 centers <sep> patients with recurrent vasovagal syncope <sep> inclusion criteria were age 35 years 3 syncopal spells in the preceding 2 years and positive response to tilt table testing with syncope occurring in association with relative bradycardia <sep> 93 patients 38 men and 55 women mean age 58.1+/-14.3 years had been enrolled and randomized although follow-up data were available for all patients 46 patients in the pacemaker arm 47 patients in the pharmacological arm <sep>', 'patients with neurally-mediated syncope <sep> 19.3 years who had at least one episode of syncope per month during previous 6-months and had positive tilt test <sep> from october 2003 to december 2004 62 patients 32 men mean age 44.8 <sep>', 'patients with vasovagal syncope <sep> 100 patients <sep> patients with recurrent vasovagal syncope <sep> outpatients referred to syncope specialists at 15 centers from september 1998 to april 2002 <sep> patients with recurrent severe vasovagal syncope <sep> patients with severe recurrent vasovagal syncope <sep>', 'patients with mixed carotid sinus syndrome <sep> 23 patients 21 m two f mean age 69 <sep> 14 patients who preferred dvi/ddd period group a and the remaining nine patients who noted no preference between dvi/ddd and vvi period group b <sep>', 'carotid sinus hypersensitivity carotid sinus syndrome css <sep> ten older adults 4 male 6 female mean age 75 range 66-86 years with a history of unexplained syncope who displayed an asymptomatic decrease in systolic bp sbp of more than 50 mmhg or a symptomatic decrease of more than 30 mmhg within 30 seconds of carotid sinus massage csm <sep>', '54 patients enrolled <sep> patients with  or  6 lifetime episodes of syncope and with a tilt-table test that induced syncope or presyncope as well as a relative bradycardia <sep> patients with frequently recurrent vasovagal syncope <sep> patients with recurrent vasovagal syncope <sep> 284 patients was originally planned and a pilot study of 60 patients was initiated <sep> severe recurrent vasovagal syncope <sep>', '30 consecutive patients aged over 60 years with carotid sinus syndrome referred for cardiac pacing <sep> elderly patients with carotid sinus syndrome <sep> elderly patients with carotid sinus syndrome <sep> eleven patients were unable to tolerate vvi pacing and had to be withdrawn early from this limb of the study group a <sep>', 'neurally mediated tilt-positive cardioinhibitory syncope <sep> forty-two patients from 18 european centers <sep> patients with severe cardioinhibitory tilt-positive neurally mediated syncope <sep>', 'one hundred and sixty-nine consecutive patients with vasovagal syncope and positive baseline or nitrate-potentiated tilt test 60 degrees upright position for 45 min or until syncope occurred 5 mg <sep> patients with neurocardiogenic syncope <sep>', 'patients resistant to or intolerant of previous traditional therapies <sep> sixty-eight consecutive patients 26 men and 42 women mean age 44.7+/-16.5 years with recurrent syncope and positive head-up tilt test and in whom standard therapies with beta-adrenergic blocking agents vagolytic negative inotropic or mineral corticoid agents were ineffectual or poorly tolerated were referred for study <sep>', 'elderly patients <sep> 24 elderly subjects who had reproducible nms induced with head-up tilt test hut <sep> elderly subjects <sep>', '21 years who had syncope reproduced in 2 consecutive head-up tilt-table tests without pharmacologic intervention n  20 or during <sep> tilt-induced neurally mediated syncope <sep> patients affected by tilt-induced neurally mediated syncope <sep> 30 patients 10 men and 20 women mean age 42 <sep>', 'patients with severe carotid sinus syndrome <sep> 28 patients to no therapy nonpacing group and 32 to vvi n  18 or ddd n  14 <sep> 60 patients affected by carotid sinus syndrome whose symptoms were judged to involve risk of major trauma or interfered with their daily activity <sep>', 'syncopal elderly patients with vasovagal syndrome <sep> vasovagal patients with severe cardioinhibitory reflex <sep> twenty patients hospitalized for syncope which was considered to be vasovagal and exhibiting an abnormal atp test--defined by a longer than 10 s cardiac pause <sep> vasovagal patients with abnormal response to atp testing <sep>', 'patients with vasovagal syncope vvs <sep> patients with recurrent vvs <sep> ninety-six consecutive patients with vvs <sep> eighteen patients discontinued therapy <sep>', 'patients who had at least monthly occurrences of syncope and a positive tilt-table test were included in the study <sep> patients with severely symptomatic neurocardiogenic syncope <sep> 61 patients <sep> patients with neurocardiogenic syncope <sep>', 'patients with malignant vasovagal syncope <sep> malignant vasovagal syncope <sep> 20 patients 9 men and 11 women mean age 33 sd 17 range 14 to 62 years with severe symptoms <sep> patients with malignant vasovagal syndrome <sep>', '10 years 60 women <sep> older adults with cardioinhibitory carotid sinus hypersensitivity csh <sep> older adults safe pace <sep> one hundred seventy-five eligible patients mean age 73 <sep> older adults who have non-accidental falls <sep> carotid sinus syndrome <sep> consecutive older patients 50 years attending an accident and emergency facility because of a non-accidental fall <sep>', 'patients with severe recurrent tilt-induced vasovagal syncope <sep> patients with vasovagal syncope <sep> 16 years 19 women with severe recurrent tilt-induced vasovagal syncope median 12 syncopes in the lifetime and 1 syncopal relapse after head-up tilt testing underwent implantation of a pacemaker <sep> twenty-nine patients 53 <sep>', 'patients with recurrent neurally mediated syncope <sep> neurally mediated syncope <sep> twelve patients with history of recurrent neurally mediated syncope which was reproduced during head-up tilt <sep> patients without structural heart disease <sep>', '30 consecutive patients with recurrent vvs and a positive head-up tilt test <sep> recurrent vasovagal syncope vvs <sep>', '15.2 years 19 men with recurrent vvs were enrolled at seven european centers and underwent <sep> patients with recurrent vvs <sep> inclusion criteria were 1  6 cumulative syncopal episodes or  or  1 syncope within 6 months of a positive hut and 2 a positive hut with bradycardia <sep> vasovagal syncope <sep> twenty-three patients age 61.8 <sep> selected patients with recurrent vasovagal syncope vvs <sep>', 'patients treated with pacing for induced cardioinhibitory carotid sinus syndrome <sep> patients with induced cardioinhibitory carotid sinus syndrome icss <sep> sixty patients with a history of syncope or pre-syncope and icss <sep>', 'patients with unexplained syncope provoked during head-up tilt testing <sep> vasovagal syncope <sep>', 'patients with unexplained syncope <sep> 24 patients during hut alone and in 30 patients during the hut with <sep> 54 patients with recurrent unexplained syncope <sep> patients in whom reproducibility of the hut response was demonstrable in the initial study <sep>', 'one hundred and thirteen consecutive patients 62 male and 51 female mean age 46.3 years with recurrent syncope no evidence of cardiac neurological or metabolic disease and a positive head-up tilt test were included in the study <sep> patients with vasovagal syncope <sep> copyright 1999 <sep>', 'forty-two patients were enrolled in the study <sep> 13 years vs 43 <sep> patients with vasovagal syncope after 1 month of treatment <sep> two groups all patients referred to our unit who had had at least one episode of syncope or two episodes of presyncope 1 month before presentation and had a positive isuprel tilt table test ttt <sep> patients with unexplained syncope and positive upright tilt table test results <sep>', 'five patients <sep> patients with vasovagal syncope <sep> patients with recurrent vasovagal syncope <sep> neurally mediated syncope in a highly symptomatic population <sep> twenty patients 40 had a positive tilt test <sep> fifty patients with recurrent vasovagal syncope <sep>', 'patients with vasovagal syncope <sep> all patients had 2 syncopal spells and a positive tilt test <sep> 75 patients with  or 1 recurrence of syncope <sep> 208 patients mean age 42+/-18 years with a median of 9 syncopal spells over a median of 11 years <sep>', 'patients with recurrent unexplained syncope <sep> patients with syncope and a positive tilt test response <sep> patients with syncope and positive head-up tilt test response <sep> twenty-eight patients with a positive head-up tilt test <sep> patients with syncope <sep>'], 'interventions': ['placebo <sep> oral etilefrine <sep> etilefrine or placebo <sep> oral etilefrine <sep> etilefrine 5 with placebo <sep> etilefrine <sep>', 'dual chamber pacing <sep> cardiac pacing <sep>', 'inotropy controlled pacing <sep> closed loop stimulation <sep> dual-chamber rate-adaptive closed loop stimulation cls <sep> cls pacing <sep>', 'disopyramide or placebo <sep> intravenous and oral disopyramide phosphate <sep> placebo <sep> disopyramide <sep> intravenous disopyramide <sep> intravenous and oral disopyramide <sep> oral disopyramide <sep>', 'propranolol or placebo <sep> placebo <sep> propranolol <sep>', 'placebo or midodrine <sep> placebo <sep> midodrine <sep> midodrine <sep>', 'oral etilefrine <sep> placebo <sep> etilefrine <sep> etilefrine <sep>', 'beta-blockers <sep> no pharmacological therapy <sep> lipophilic beta-blockers <sep> metoprolol or propanolol <sep>', 'ddi pacing with rate hysteresis 8 patients or ddd pacing with rate drop response function <sep> ddi with rate hysteresis pacing <sep> cardiac pacing <sep> beta-blockade or etilephrine <sep>', 'ddd pacemaker provided with rate-drop response function or the beta-blocker atenolol <sep> permanent cardiac pacing versus medical treatment <sep> permanent dual-chamber cardiac pacing with pharmacological therapy <sep>', 'cardioselective and non-cardioselective beta-blockers <sep> oral beta-blockers <sep> propranolol <sep> propranolol <sep> cardioselective and noncardioselective oral beta-blockers <sep> metoprolol <sep>', 'pacemaker therapy <sep> pacemaker therapy <sep> dual-chamber pacing ddd with rate drop response or to have only sensing without pacing odo <sep> pacing therapy <sep>', 'vvi pacing <sep> carotid sinus massage in the standing position during vvi and dvi temporary pacing <sep> permanent ddd pacemaker <sep>', 'tilt-table digital arterial photoplethysmography and 24-hour ambulatory blood pressure bp monitoring equipment <sep> placebo <sep> midodrine <sep>', 'permanent pacemaker implantation <sep> dual-chamber pacing with rate-drop response <sep> pacemaker therapy <sep> dual-chamber pacemaker or not <sep> permanent cardiac pacing <sep>', 'single chamber ventricular demand vvi pacing <sep> dual chamber pacemaker implantation <sep> vvi and ddi pacing <sep>', 'dual-chamber pacing <sep> ddi pacemaker programmed to 80 bpm with hysteresis of 45 bpm 19 patients or no pacemaker <sep> ddi pacemaker with rate hysteresis with no implant <sep>', 'sublingual isosorbide dinitrate <sep> diverse therapeutic treatments <sep> control patients discharged without medical therapy group b 56 patients discharged with 75 mg/die ethylephrine group c 56 patients discharged with 80 mg/die propranolol <sep> ethylephrine or propranolol <sep>', 'paroxetine hydrochloride <sep> placebo <sep> paroxetine <sep> paroxetine <sep>', 'enalapril <sep> placebo and ace-inhibitor groups <sep> angiotensin-converting enzyme ace inhibitor <sep> placebo <sep>', 'placebo <sep> cafedrine n  1 or elastic compression stockings alone or in association with drugs <sep> domperidone <sep> atenolol <sep> dihydroergotamine <sep> isoproterenol infusion <sep> medical treatment <sep>', 'pacemaker implant pacing group <sep>', ""implantation with a dual-chamber pacemaker and half to usual medical care <sep> adenosine-5'-triphosphate intravenous atp 20 mg <sep>"", 'placebo <sep> fluoxetine <sep> placebo propranolol or fluoxetine <sep> propranolol and placebo <sep> fluoxetine vs. propranolol <sep> placebo propranolol and fluoxetine <sep> fluoxetine <sep>', 'midodrine or with fluid salt tablets and counseling <sep> midodrine <sep> midodrine <sep>', 'metoprolol and clonidine <sep> treatment guided by head up tilting <sep> metoprolol <sep> clonidine <sep>', 'dual-chamber pacemaker implant paced patients or standard treatment controls <sep> cardiac pacing <sep>', 'pacemaker implantation <sep> placebo <sep> permanent cardiac pacing <sep> active pacing versus inactive pacing <sep> pacing therapy <sep> pacemaker on or to pacemaker off <sep>', 'placebo <sep> midodrine <sep> midodrine <sep>', 'propranolol nadolol and placebo <sep> propranolol nadolol or placebo <sep> propranolol nadolol and placebo <sep>', 'implantation of a minilivingd/best pacing system <sep> conventional ddi pacing <sep> dddr pacing driven by contractility versus ddi pacing <sep> head-up tilt testing hut <sep>', 'icss <sep> permanent pacemaker p group n  30 or no pacing np <sep>', 'transdermal scopolamine <sep>', 'pharmacological agent propranolol 60 mg/day disopyramide <sep> disopyramide <sep> propranolol <sep> propranolol <sep> isoproterenol <sep> head-up tilt test hut <sep> pharmacological therapy <sep>', 'atropine <sep> placebo <sep> atropine or placebo <sep> placebo isotonic saline solution <sep> atropine <sep>', 'placebo <sep> atenolol <sep> placebo medication <sep> oral atenolol <sep>', 'placebo <sep> atenolol <sep> atenolol 50 mg/day 24 patients placebo <sep> intravenous atenolol <sep> atenolol vs. the placebo <sep>', 'placebo <sep> metoprolol or matching placebo <sep> beta-blockers <sep> metoprolol <sep> metoprolol <sep>', 'verapamil <sep> head-up tilt testing <sep> metoprolol and verapamil <sep> metoprolol or verapamil <sep> metoprolol <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there is insufficient evidence to support the use of any of the pharmacological or pacemaker treatments for vasovagal syncope and carotid sinus syncope. larger studies using patient relevant outcomes are needed.
323,"{'outcomes': ['vital signs o2 saturation by pulse oximetry pefr forced vital capacity forced expiratory volume at 1 second and physical examination <sep> pefr <sep> forced expiratory volume <sep> serum magnesium concentrations <sep> blood pressure <sep> forced vital capacity <sep> short-term pulmonary function <sep>', 'hospitalization <sep> peak expiratory flow <sep>', 'peak expiratory flow rate <sep>', 'pefr and sao2 <sep> clinical asthma score <sep>', 'pulmonary function and decrease admission rate <sep> admission rate and improved fev1 <sep> fev1 <sep> admission rates <sep> hospital admission rates <sep>', 'pefr and fev1 <sep> pefr <sep> expiratory flow <sep> fev1 <sep>'], 'punchline_text': ['at 50 minutes the magnesium group had a significantly greater percentage of improvement from baseline in forced expiratory volume at 1 second 34 vs 1 p  0.05 this improvement was sustained and even greater at 110 minutes 75 vs 5 p  0.01). <sep>', '90 minutes in the control group 95 ci 209 to 247 minutes p  .832). <sep>', 'in addition the number admitted vs discharged was significantly better for the treatment group 7 vs 12 than the placebo group 15 vs 4). <sep>', 'mgso4 group showed early and significant improvement as compared to placebo group in pefr and sao2 at 30 min and 1 2 3 and 7 hours after stopping the infusion p ranging from  0.05 to  0.01). <sep>', 'for the severe group admission rates were 78.6 11/14 for the placebo-treated group and 33.3 7/21 for the magnesium-treated group p  0.009). <sep>', 'magnesium sulfate administration did not at any time significantly improve either fev1 f  0.036 p  0.96 or pefr f  0.51 p  0.61). <sep>'], 'population': ['moderate to severe asthma exacerbations in pediatric patients <sep> urban pediatric emergency department <sep> thirty-one patients aged 6 to 18 years who were being treated for an acute asthma exacerbation with peak expiratory flow rate pefr less than 60 of the predicted value after receiving three beta 2-adrenergic nebulizer treatments <sep> moderate to severe pediatric asthma <sep>', 'discharged patients was 224 <sep> one hundred twenty consecutive patients aged 18 to 65 years with acute asthma unresponsive to a single albuterol treatment <sep> acute asthma <sep> urban teaching hospital emergency department <sep> patients with acute asthma <sep>', 'acute asthma in the emergency department <sep> thirty-eight patients suffering from acute exacerbations of moderate to severe asthma <sep> nineteen patients <sep> patients with moderate to severe asthma <sep>', 'given at an interval of 20 min each <sep> children with acute severe asthma not responding to conventional therapy <sep> acute severe asthma not responding to conventional therapy <sep> 47 children aged between 1-12 years with acute severe asthma showing inadequate or poor response to 3 doses of <sep> pediatric emergency service of a large teaching hospital <sep>', 'patients presenting to the emergency department with exacerbations of asthma <sep> acute asthma <sep> one hundred thirty-five patients were studied <sep> patients with acute severe asthma <sep> asthmatics aged 18 to 65 years during acute exacerbation with fev1 less than 75 predicted both before and after a single albuterol treatment <sep> patients with moderate asthma <sep> emergency departments of a university-affiliated voluntary hospital and municipal hospital <sep> patients with acute asthma <sep>', 'forty-eight asthmatic patients aged 18 to 60 years with initial peak expiratory flow rate pefr  200 l/min who failed to double their initial pefr after two standardized albuterol treatments <sep> patients with acute severe exacerbations of asthma <sep> urban emergency department <sep> patients with moderate to severe asthma exacerbations <sep> acute asthma exacerbations <sep>'], 'interventions': ['placebo <sep> intravenous magnesium ivmg therapy <sep> intravenous magnesium infusions <sep> intravenous magnesium therapy <sep> magnesium <sep> magnesium sulfate infusion 25 mg/kg maximum 2 gm or equivolume saline solution <sep>', 'magnesium sulfate <sep> intravenous magnesium <sep> magnesium <sep> iv magnesium <sep> methylprednisolone and hourly albuterol inhalation therapy <sep>', 'placebo <sep> magnesium sulfate <sep> conventional nebulized beta-agonist therapy <sep> intravenous magnesium sulfate <sep> saline placebo <sep>', 'placebo <sep> oxygen nebulized salbutamol i.v <sep> mgso4 <sep> intravenous magnesium sulfate <sep> aminophylline and corticosteroids <sep> intravenous magnesium sulfate <sep> normal saline infusion <sep> nebulized salbutamol <sep> mgso4 solution and normal saline <sep>', 'inhaled beta-agonists at regular intervals and intravenous iv steroids <sep> intravenous mgso4 <sep> placebo <sep> intravenous magnesium sulfate <sep> mgso4 or placebo <sep> intravenous magnesium sulfate mgso4 <sep> 2 g iv mgso4 or iv placebo <sep>', 'iv magnesium sulfate <sep> placebo <sep> magnesium sulfate <sep> magnesium <sep> magnesium sulfate 2 g over 20 min followed by placebo infusion bolus or placebo loading dose and infusion placebo <sep> magnesium sulfate <sep> intravenous magnesium sulfate <sep> standardized aminophylline and steroid therapy <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",current evidence does not support routine use of intravenous magnesium sulfate in all patients with acute asthma presenting to the emergency department. magnesium sulfate appears to be safe and beneficial in patients who present with severe acute asthma.
324,"{'outcomes': ['monosymptomatic nocturnal enuresis <sep>', 'maximum functional bladder capacity mfbc <sep> prechange and postchange in mfbc <sep> bladder capacity <sep> fewest wetting episodes <sep>', 'achenbach child behavior checklist cbcl <sep> changes in cbcl staic and nslc scores <sep> wetting frequency <sep> p-h scale <sep> piers-harris self-concept scale p-h the state-trait anxiety scale staic and the nowicki-strickland locus of control test nslc <sep> background demographic variables <sep>', 'enuresis tolerance scale <sep> subjects level of emotional and behavioral adjustment <sep>', 'cumulative response <sep> treatment efficacy <sep>', 'complete and partial response rates <sep> wetting frequency <sep>', ""achenbach child behavior checklist cbcl <sep> behavioral and self-concept changes <sep> piers-harris children's self-concept scale and harter's perceived competence scale for children pcsc <sep> total score and positive changes over time in only 2 subscales scholastic and social <sep> piers-harris subscales and in the cbcl internalizing and externalizing scores and the social thought and attention problems subscales <sep>"", 'number of wet nights <sep> bed-wetting frequency <sep> bed-wetting frequency <sep>', 'weekly wetting frequency <sep> rate of apparatus malfunction <sep>', 'levels of extroversion <sep> levels of neuroticism <sep> rate of cure <sep>', 'response rate <sep> success rate of arousal training <sep> success rate <sep>', 'mean number of dry nights <sep>', 'history of upsetting life events and previous child psychiatric contact <sep>', 'improvement rate without cure <sep>', 'maternal anger <sep>', 'relapse rates <sep> remission rates <sep> dry nights <sep> remission rates <sep> rate of sustained continence <sep> remission 28 continuous dry nights and relapse <sep>', 'serious side effects <sep> improvement rate <sep>'], 'punchline_text': ['desmopressin offers better short-term results than enuresis alarm but the latter is significantly more efficient in the long term. <sep>', 'the 10 children who terminated treatment prematurely had lower self-esteem and more parent-reported conduct problems than the 40 children who completed treatment. <sep>', 'significant improvements in the p-h scale p  0.04 and three of its subscales occurred in children in the treatment group compared with those in whom treatment was delayed. <sep>', 'the enuresis tolerance scale was found to be a highly significant predictor of early termination from conditioning treatment. <sep>', 'in nonresponders the cumulative response after desmopressin treatment increased to 80 and 62 respectively. <sep>', 'the wetting frequency decreased during treatment by 46 52 and 73 in groups 1 2 and 3 respectively. <sep>', 'after 6 months of treatment there were significant changes over time unrelated to outcome or treatment in the piers-harris subscales and in the cbcl internalizing and externalizing scores and the social thought and attention problems subscales. <sep>', 'a significantly greater reduction in the number of wet nights was observed after the first 3 weeks of treatment in group 1. <sep>', 'results indicated a significantly higher rate of apparatus malfunction for the delayed model of alarm. <sep>', 'the patients in group 2 who were older had a higher rate of cure than did the patients in group 1. <sep>', 'the success rate of arousal training was still significantly higher 92 continent when compared to the urine device with specific instructions 77 and urine alarm only 72%). <sep>', 'at the end of treatment there was a significant difference in the mean number of dry nights per week between the two groups 6.3 in the alarm and desmopressin group and 4.8 in the alarm group and also in the number of children becoming reliably dry. <sep>', 'uristop a commercially available alarm device based on a theory somewhat different from those used in the common alarm devices was tried in a prospective randomized double-blind study. <sep>', 'improvement rate without cure during treatment was higher for the children treated with imipramine than for those treated with the detector but at follow-up the reverse was true. <sep>', ""both procedures were equally effective and in the total sample a better response to treatment was predicted by the child's report of being teased by siblings. <sep>"", 'although remission rates were similar children treated with desmopressin had significantly more dry nights during treatment than those in the placebo group. <sep>', 'the improvement rate was 70 in the group given desmopressin and 86 in the group treated with alarm the difference was not significant. <sep>'], 'population': ['in group d n  62 only 27 children were included since 12 19 were switched to alarm and 23 37 were excluded because they were either non-compliant or lost to follow-up <sep> were enrolled between january 1992 and december 1994 <sep> healthy school children <sep> patients n  135 aged 6 to 16 years <sep> inclusion criteria were primary monosymptomatic nocturnal enuresis in healthy children age  or  6 years absence of previous treatment using either <sep> isolated nocturnal enuresis <sep>', 'youngsters <sep> 10 children who terminated treatment prematurely had lower self-esteem and more parent-reported conduct problems than the 40 children who completed treatment <sep> childhood nocturnal enuresis <sep> small mfbc children treated with the ua plus rct and large mfbc youngsters <sep> study participants were fifty 5 to 13-year-old children 33 boys and 17 girls with nocturnal enuresis of at least 3 months duration <sep> 40 youngsters who completed treatment 37 92.5 achieved the treatment goal of 14 consecutive dry nights <sep>', 'nocturnal enuresis <sep> 121 children aged 8 to 14 years to receive <sep>', 'nocturnal enuresis <sep>', 'eighty-four patients aged 6 to 14 years old were studied <sep> children over 7 years of age <sep> monosymptomatic nocturnal enuresis <sep>', '105 children aged 7-15 years to receive alarms group 1 35 patients <sep> chinese enuretic children <sep> chinese children with monosymptomatic primary nocturnal enuresis <sep>', 'inner-city hospital clinic <sep> subjects were 182 children referred or recruited through media publicity <sep> children with central nervous system disorders or developmental delays and those currently on ddavp or alarm <sep> included were children 7 years old with pne no daytime symptoms bladder capacity 50 expected and wetting 3 times a week <sep> children with nocturnal enuresis <sep>', '93 patients 47 <sep> children with nocturnal enuresis <sep> monosymptomatic nocturnal enuresis <sep>', 'nocturnal enuresis <sep> 39 children who exhibited primary nocturnal enuresis <sep>', 'older children with primary nocturnal enuresis <sep> sixty-two children with primary nocturnal enuresis <sep> primary enuresis on psychologic functioning in children <sep> seventeen children from group 1 and 18 from group 2 were tested with the age-appropriate form of the cattell personality questionnaire on three occasions at the time of entry into the study 2 months later and at follow-up an average of 16 months later <sep>', 'nocturnal enuresis with non-clinical children between 6 and 12 years of age <sep> non-clinical enuretic children between 6 and 12 years of age <sep> children suffering from nocturnal enuresis <sep>', 'nocturnal enuresis <sep> children with severe wetting and those with family and behavioural problems <sep> seventy-one children with nocturnal enuresis <sep>', '134 enuretic children who were examined on an out-patient ward 53 were selected for inclusion in this study on the basis of certain criteria <sep> primary nocturnal enuresis pne <sep> primary nocturnal enuresis <sep>', '169 children with primary enuresis <sep>', '74 enuretic children <sep>', 'nocturnal enuresis <sep> 207 defined as nonresponders 50 reduction in wet nights <sep> patients with nocturnal enuresis n=358 age range 6-16 years <sep> children with nocturnal enuresis who are desmopressin nonresponders adjunct <sep>', 'nocturnal enuresis <sep> fifty children with primary nocturnal enuresis <sep>'], 'interventions': ['desmopressin <sep> desmopressin minirin spray ferring sa <sep> desmopressin <sep> desmopressin d or alarm a <sep> desmopressin or alarm <sep>', 'urine alarm ua alone or with the urine alarm supplemented with retention control training ua plus rct <sep> rct <sep> behavioral interventions <sep>', 'conditioning therapy <sep>', 'behavioral conditioning with a urine alarm pharmacotherapy with imipramine hydrochloride <sep>', 'alarm or alarm plus desmopressin <sep> desmopressin <sep> desmopressin and oxybutynin <sep> desmopressin alone <sep>', 'desmopressin <sep> combined therapy <sep> desmopressin <sep> oral desmopressin <sep> enuresis alarms oral desmopressin <sep>', 'placebo <sep> ddavp or placebo <sep> conditioning alarm or desmopressin acetate ddavp <sep>', 'desmopressin <sep> placebo <sep> alarm therapy combined with desmopressin <sep> alarm and desmopressin versus alarm monotherapy <sep> alarm therapy <sep> alarm therapy and placebo <sep> intranasal desmopressin <sep> desmopressin combined with alarm therapy <sep> placebo both groups received an additional 3 weeks of alarm monotherapy <sep>', 'behavioral conditioning with a contiguous model of alarm behavioral treatment with a delayed model of alarm or a clinical waiting list <sep>', 'imipramine <sep> imipramine hydrochloride <sep>', 'arousal training <sep> arousal training <sep> bibliotherapy <sep>', 'desmopressin and alarm <sep> desmopressin <sep> intranasal desmopressin desmospray <sep> enuresis alarm and desmopressin <sep>', 'functioning device or in a control group with a non-functioning device <sep> uristop <sep>', 'imipramine <sep> special diet imipramine or a waking device the mozes detector <sep>', 'enuresis alarm alone with a brief version of dry bed training <sep>', 'desmopressin <sep> 4-week run-in course of intranasal desmopressin <sep> placebo <sep> desmopressin <sep>', 'desmopressin and enuresis alarm <sep> desmopressin <sep> desmopressin ddavp and enuresis alarm <sep> 20 micrograms intranasal desmopressin <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",alarm interventions are an effective treatment for nocturnal bedwetting in children. alarms appear more effective than desmopressin or tricyclics because around half the children remain dry after alarm treatment stops. overlearning giving extra fluids at bedtime after successfully becoming dry using an alarm dry bed training and avoiding penalties may further reduce the relapse rate. better quality research comparing alarms with other treatments is needed including follow-up to determine relapse rates.
325,"{'outcomes': ['disease-free survival dfs <sep> 5-year dfs <sep> 5-year overall survival <sep>', 'overall survival <sep> disease-free and overall survival <sep> relapse-free survival <sep> relapse or death from breast cancer <sep>', 'disease-free survival rates <sep>', 'disease-free survival overall survival or the time to recurrence <sep> myelodysplastic syndrome or acute myeloid leukemia <sep> risk of relapse <sep> time to recurrence <sep>', '4-year event-free survival intention-to-treat analysis <sep> overall survival <sep> mean number of positive nodes <sep> event-free survival <sep>', 'relapse-free or overall survival advantage <sep> septic death <sep> 3-year relapse-free survival rates <sep> frequent morbidity <sep> 3-year survival rates <sep> morbidity <sep>', '4-year overall and relapse-free survivals <sep> survival <sep> overall and disease-free survival <sep>', 'overall survival <sep> 3-year disease-free survival <sep>'], 'punchline_text': ['the 5-year overall survival was 70 for di-ec and 61 for sd-ct with a hazard ratio of 0.79 95 ci 0.56 to 1.11 p  .17). <sep>', 'no significant difference was observed in relapse-free survival hazard ratio 1.06 95 ci 0.74-1.52 p  0.76 or overall survival hazard ratio 1.18 95 ci 0.80-1.75 p  0.40]. <sep>', 'arm b with its less dose-intensive therapy requires considerably less support to apply the treatment. <sep>', 'among the 511 eligible patients there was no significant difference in disease-free survival overall survival or the time to recurrence between those who received caf alone and those who received caf plus high-dose chemotherapy and stem-cell transplantation. <sep>', 'the corresponding overall survival was 75 69-82 versus 70 64-77 p=0.02). <sep>', 'no relapse-free or overall survival advantage was associated with the use of high-dose chemotherapy and morbidity was increased with its use. <sep>', 'there was no significant difference in survival between the patients on conventional therapy and those on high-dose therapy. <sep>', 'the pegase 01 adjuvant therapy trial showed that 3-year disease-free survival was significantly better in the hdc arm but overall survival was unchanged. <sep>'], 'population': ['three hundred forty-four patients <sep> women with hormone receptor-positive tumors <sep> women with high-risk primary breast cancer <sep> patients with early-stage breast cancer and a high risk of relapse defined as stage ii disease with 10 or more positive axillary nodes or an estrogen receptor-negative or stage iii tumor with five or more positive axillary nodes <sep>', 'primary breast cancer patients with four or more lymph nodes involved long-term <sep> patients had to be free of overt metastatic disease and be  or 60 years of age <sep> two hundred and eighty one patients entered into a randomised clinical trial <sep> patients with primary breast cancer and four or more histologically involved lymph nodes <sep>', 'cancer and leukemia group b <sep> women with primary breast cancer involving 10 or more axillary lymph nodes <sep> patients with primary breast cancer involving multiple axillary lymph nodes <sep> patients with operable stage ii or iii breast cancer involving 10 or more axillary lymph nodes calgb protocol 9082 <sep>', 'massachusetts medical society <sep> high-risk breast cancer <sep> 417 patients fulfilling strict eligibility criteria <sep> 511 eligible patients <sep> patients with primary breast cancer and at least 10 involved axillary lymph nodes <sep> 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of <sep> women with primary breast cancer and 10 or more involved axillary lymph nodes <sep> patients at high risk for relapse <sep>', 'high-risk breast cancer <sep> patients with at least nine positive nodes <sep> 403 patients were enrolled 201 were assigned high-dose chemotherapy and 202 conventional treatment <sep>', 'thirty-nine patients <sep> patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support <sep> high-risk primary breast carcinoma <sep> and patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary neoadjuvant chemotherapy were eligible <sep> seventy-eight patients 48 after primary surgery and 30 after primary chemotherapy <sep> postmenopausal patients with estrogen receptor-positive tumors and chest wall <sep>', 'patients with breast cancer and multiple metastases to the axillary lymph nodes <sep> operable breast cancer with extensive axillary lymph-node involvement <sep> 97 women aged younger than 60 years who had breast cancer with extensive axillary-node metastases confirmed by a tumour-positive infraclavicular lymph-node biopsy <sep>', 'breast cancer <sep>'], 'interventions': ['intensive epirubicin and cyclophosphamide chemotherapy administered with filgrastim and progenitor cell support di-ec with standard-dose anthracycline-based chemotherapy sd-ct <sep> di-ec epirubicin 200 mg/m2 plus cyclophosphamide 4 gm/m2 with filgrastim and progenitor cell support <sep> tamoxifen <sep> sd-ct <sep> multicycle dose-intensive chemotherapy <sep>', 'high dose chemotherapy and autologous stem cell transplantation <sep> autologous stem-cell support <sep> standard conventional treatment 5-fluorouracil epirubicin and cyclophosphamide-fec for six cycles or fec <sep> conventional anthracycline containing chemotherapy <sep> cyclophosphamide thiotepa and carboplatin and stem cell rescue hdt <sep> anthracycline containing chemotherapy <sep> conventional chemotherapy <sep>', 'cyclophosphamide doxorubicin and fluorouracil <sep> cyclophosphamide and doxorubicin and fluorouracil radiation therapy and tamoxifen <sep> high-dose with autologous bone marrow support versus low-dose cyclophosphamide cisplatin and carmustine <sep> cyclophosphamide cisplatin and carmustine <sep>', 'adjuvant chemotherapy with cyclophosphamide doxorubicin and fluorouracil caf or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation <sep> adjuvant chemotherapy with caf <sep> autologous hematopoietic stem-cell transplantation <sep> conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation <sep> conventional-dose adjuvant chemotherapy <sep> caf <sep>', 'cyclophosphamide methotrexate and fluorouracil <sep> rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy <sep> filgrastim support conventionally dosed epirubicin and cyclophosphamide followed by two courses of high-dose chemotherapy epirubicin cyclophosphamide and thiotepa supported by peripheral-blood progenitors or four identical cycles of epirubicin and cyclophosphamide <sep> intensive double-cycle high-dose chemotherapy <sep>', 'high-dose chemotherapy and blood cell autografts <sep> radiotherapy <sep> 5-fluorouracil doxorubicin adriamycin and cyclophosphamide fac <sep> cyclophosphamide etoposide and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy <sep> fac <sep> tamoxifen <sep> fac followed by high-dose chemotherapy <sep> standard-dose chemotherapy <sep>', 'chemotherapy <sep> carboplatin <sep> high-dose chemotherapy and haemopoietic progenitor-cell support <sep> up-front chemotherapy fe120c <sep> adjuvant high-dose chemotherapy <sep> conventional therapy fourth course of fe120c followed by radiation therapy and 2 years of tamoxifen 40 patients or high-dose therapy identical treatment but an additional high-dose regimen and peripheral-blood progenitor-cell pbpc <sep> cyclophosphamide 500 mg/m2 epirubicin 120 mg/m2 and 5-fluorouracil <sep> cyclophosphamide <sep>', 'intensive chemotherapy <sep> high-dose chemotherapy <sep> high-dose chemotherapy hdc <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is insufficient evidence to support the routine use of high dose chemotherapy with autograft for women with early poor prognosis breast cancer.
326,"{'outcomes': [""adas-cog <sep> safety compliance and drug dispensation <sep> cgic <sep> alzheimer's disease assessment scale-cognitive subscale adas-cog geriatric evaluation by relative's rating instrument gerri and clinical global impression of change cgic <sep> efficacy and safety <sep> number of patients reporting adverse events <sep> gerri score <sep>"", ""patient's performance <sep>"", ""cognitive performance and global assessment scores <sep> little cognitive and functional decline <sep> cognitive subscale of the alzheimer's disease assessment scale adas-cog alzheimer's disease cooperative study clinical global impression of change adcs-cgic <sep>"", 'digit copying sub-test of the kendrick battery <sep> cognitive function <sep>', 'clinical global impression score <sep> efficacy and tolerability <sep> degree of severity of dementia <sep>', 'number connection test <sep> saccade duration <sep>', 'cerebral disorders <sep>', 'clinical global impressions cgi item 2 for psychopathological assessment the syndrom-kurztest skt <sep> frequency of therapy responders <sep> tolerated <sep> clinical efficacy <sep>', 'psychometric tests trailmaking test adas cgi and electrophysiological investigations eeg topography <sep> adas cognitive and non-cognitive subscales <sep> sum score in the skt-test for the determination of attention and memory <sep>', 'learning rate <sep> mental performance <sep> shortterm memory <sep> mental/mnestic performance <sep>', 'depression <sep> self-rating scale for instrumental activities of daily living nrnberger-alters-alltagsaktivittenskala <sep> psychopathology and cognitive performance <sep> activities of daily living as assessed by the nrnberger-alters-beobachtungsskala nab <sep>', 'number of gastrointestinal side effects <sep> mental control test emct measuring attention and concentration benton test of visual retention-revised measures short term visual memory rey test part 1 measures short term memory and learning curve beck depressive inventory bdi measuring the presence and severeness of a depression in order to exclude depressive patients and rey test part 2 measures long term memory recognition <sep> percentage of baseline scores <sep> furthermore subjective perception of memory and concentration <sep>'], 'punchline_text': ['regarding the safety profile of egb no significant differences compared with placebo were observed in the number of patients reporting adverse events or in the incidence and severity of these events. <sep>', ""significant improvements in the patient's performance were observed under verum compared to the placebo preparation which was administered to a control group of patients among which the relevant disorder were distributed homogeneously. <sep>"", 'for a subgroup of patients with neuropsychiatric symptoms there was a greater decline of placebo-treated patients and significantly better cognitive performance and global assessment scores for the patients on gbe. <sep>', 'performance on the digit copying sub-test of the kendrick battery was significantly improved at both 12 and 24 weeks while the median speed of response on a computerized version of a classification task also showed a significant superiority over placebo at 24 weeks. <sep>', ""our study suggests that there is no evidence of relevant differences in the efficacy of egb 761 and donepezil in the treatment of mild to moderate alzheimer's dementia so the use of both substances can be justified. <sep>"", 'a highly significant difference could already been seen after 4 weeks of therapy and also after 8 weeks in the results of both the saccadic test and the psychometric tests compared to the placebo control group. <sep>', 'the difference between control and treatment groups became significant at 3 months and increased during the following months. <sep>', ""the frequency of therapy responders in the two treatment groups differed significantly in favor of egb 761 with p  0.005 in fisher's exact test. <sep>"", 'although the active-treatment group with a mean sum score of 19.67 points in the s.k.t. had a poorer baseline level than the placebo group 18.11 points it experienced an improvement to 16.78 points under treatment with egb 761 whereas the placebo group deteriorated to 18.89 points. <sep>', 'statistically significant improvement in the shortterm memory after 6 weeks and of the learning rate after 24 weeks in the test substance group but not in the placebo group longitudinal analysis). <sep>', 'after therapy patients of the active substance group scored significantly better p  0.05 on each outcome measure than those who received placebo. <sep>', 'in the subjective test the emct the rey 1 and rey 2 no significant differences in improvement in time between the groups were observed. <sep>'], 'population': ['severely demented outpatients with alzheimer disease or multi-infarct dementia without other significant medical conditions <sep> dementia <sep> 309 patients included in an intent-to-treat analysis 202 provided evaluable data for the 52-week end point analysis <sep>', '90 outpatients with cerebral insufficiency caused by old age results of a placebo-controlled double-blind trial <sep>  1994 <sep> 90 outpatients with cerebral insufficiency <sep>', ""dementia of the alzheimer's type <sep> 513 outpatients with uncomplicated dementia of the alzheimer's type scoring 10 to 24 on the mini-mental state examination and less than 4 on the modified hachinski ischemic score free of other serious illnesses and not requiring continuous treatment with any psychoactive drug <sep> mild to moderate dementia of the alzheimer type <sep> patients with various forms of cognitive impairment or dementia <sep> outpatient clinics of universities and private research centers specialized in dementia <sep>"", 'thirty-one patients over the age of 50 years and showing a mild to moderate degree of memory impairment <sep> 27 patients 15 in the placebo group and 12 in the active treatment group <sep> elderly outpatients with mild to moderate memory impairment <sep>', ""mild to moderate alzheimer's dementia <sep> alzheimer's dementia in a randomized <sep> patients aged 50-80 years suffering from mild to moderate dementia <sep> dementia of the alzheimer type with special respect to moderately severe stages <sep> patients with dementia of the alzheimer type in slowing down the disease's degenerative progression and the patients cognitive impairment <sep>"", 'thirty-six patients with classical symptoms of organic syndrome <sep> patients receiving unpermitted supplementary medication or suffering from acute cardiovascular disturbances or digestive and metabolic disorders <sep> patients with psychotic organic brain syndrome <sep> patients presenting with pathological findings for at least two of the four test criteria were admitted to the trial <sep>', '166 patients <sep>', 'outpatients suffering from mild to moderate primary degenerative dementia of the alzheimer type or multi-infarct dementia <sep> 216 patients <sep> outpatients with presenile and senile primary degenerative dementia of the alzheimer type dat and multi-infarct dementia mid according to dsm-iii-r <sep> 156 patients who completed the study in accordance with the study protocol <sep> 761 in dementia of the alzheimer type and multi-infarct dementia <sep>', 'psychiatric illnesses associated with old age primary degenerative dementia of the alzheimer type dat <sep> 20 outpatients <sep> 761 in dementia of the alzheimer type <sep>', 'patients seventy-two outpatients with cerebral insufficiency at three test centers <sep> patients with cerebral insufficiency <sep>', '40 patients with a mean age of 68  12.5 years suffering from moderate dementia alzheimer vascular or mixed type according to dsm-iii-r criteria were included <sep> 761 in dementia of the vascular and alzheimer type <sep> patients with moderate dementia <sep>', '197 patients completed the study <sep> 241 non-institutionalised patients in the age range 55-86 years <sep> elderly individuals with memory and/or concentration complaints <sep>  1998 <sep> elderly individuals with cognitive impairment <sep>'], 'interventions': ['placebo <sep> ginkgo biloba <sep> egb <sep>', 'placebo <sep> ginkgo biloba <sep> copyright <sep> ginkgo biloba special extract li <sep>', 'placebo <sep> gbe <sep> ginkgo biloba extract gbe <sep> ginkgo biloba extract <sep>', 'standardized ginkgo biloba extract <sep> placebo <sep> ginkgo biloba extract <sep> ginkgo biloba extract tanakan <sep> ginkgo biloba extract or identical placebo 3-times daily <sep>', 'cholinesterase inhibitor with ginkgo biloba <sep> placebo <sep> ginkgo biloba <sep> ginkgo biloba special extract egb <sep> ginkgo biloba and donepezil <sep> donepezil and placebo <sep> donepezil <sep> ginkgo biloba e.s. flavogin <sep> ginkgo biloba special extract e.s <sep>', 'placebo capsules of identical external appearance <sep> placebo <sep> ginkgo biloba extract <sep> ginkgo biloba extract egb 761 rkan <sep> egb <sep>', 'ginkgo biloba extract <sep> placebo <sep>', 'egb 761 or placebo <sep> placebo <sep> ginkgo biloba special extract egb <sep>', 'ginkgo biloba special extract egb <sep> placebo <sep> ginkgo bilabo special extract egb 761 tebonin forte manufactured by dr willmar schwabe karlsruhe <sep>', 'ginkgo-biloba extract <sep> placebo <sep> ginkgo biloba extract egb <sep>', 'egb 761 or placebo <sep> ginkgo biloba special extract egb <sep> placebo <sep> egb <sep>', 'alcohol/water extract of ginkgo biloba <sep> ginkgo extracts <sep> placebo <sep> ginkgo biloba alcohol/water extract in a high dose hd a low dose ld or a placebo pl <sep> ginkgo biloba extract <sep> copyright <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",ginkgo biloba appears to be safe in use with no excess side effects compared with placebo. many of the early trials used unsatisfactory methods were small and publication bias cannot be excluded. the evidence that ginkgo biloba has predictable and clinically significant benefit for people with dementia or cognitive impairment is inconsistent and unreliable.
327,"{'outcomes': ['frequency of gastroesophageal reflux dis-ease symptoms <sep> symptoms ph control and overall quality of life health index <sep> overall gastroesophageal reflux disease symptom score <sep> symptom relapse requiring titration <sep> satisfactory symptom remission <sep>', 'mean gastrointestinal symptom and general well-being scores <sep> lower oesophageal sphincter pressure <sep> psychological general well-being index and the gastrointestinal symptom rating scale <sep> mean demeester acid exposure score <sep> quality of life <sep> chronic gastro-oesophageal reflux <sep>', 'postoperative complications <sep> time to treatment failure kaplan-meier analysis <sep> tolerated <sep>'], 'punchline_text': ['surgical patients had improved symptoms ph control and overall quality of life health index after surgery at 1 year compared with the medical group. <sep>', 'the differences in both of these scores were significant between the two groups at 12 months p  0.003). <sep>', 'the proportions of patients who remained in remission after 3 years were similar for the two therapies 90 of surgical patients compared with 93 medically treated for the intention to treat population p  0.25 <sep>'], 'population': ['patients with chronic gastroesophageal reflux disease <sep> n  52 <sep> patients with gastroesophageal reflux disease compared <sep> n  52 with <sep>', 'gastro-oesophageal reflux disease gord <sep> between july 1997 and august 2001 340 patients with a history of gord for at least 6 months were investigated by endoscopy 24-h ph monitoring and manometry <sep>', 'dedicated centres in 11 european countries <sep> patients with chronic gastro-oesophageal reflux disease <sep> gastro-oesophageal reflux disease gord <sep> 554 patients <sep>'], 'interventions': ['laparoscopic nissen fundoplication versus proton pump inhibitors <sep> optimized medical therapy using proton pump inhibitor <sep> laparoscopic nissen fundoplication <sep> proton pump inhibitor therapy <sep>', 'lnf <sep> proton-pump inhibitors <sep> laparoscopic nissen fundoplication lnf and proton-pump inhibitor ppi therapy <sep> laparoscopic nissen fundoplication <sep>', 'laparoscopic antireflux surgery with esomeprazole <sep> lars and esomeprazole eso <sep> laparoscopic antireflux surgery lars <sep> lars <sep> eso <sep> laparoscopic total fundoplication and continuous eso <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",there is evidence that laparoscopic fundoplication surgery is more effective than medical management for the treatment of gord at least in the short to medium term. surgery does carry some risk and whether the benefits of surgery are sustained in the long term remains uncertain. treatment decisions for gord should be based on patient and surgeon preference.
328,"{'outcomes': ['relapse of symptoms <sep> vertiginous symptoms <sep> vertigo <sep> relief of vertiginous symptoms <sep>', 'complete resolution <sep> earlier recovery of eng lateralization <sep> occurrence of symptoms and signs degree of caloric lateralization presence of other eng pathologic findings and dizziness handicap inventory scores <sep> symptoms and signs caloric lateralization on the electronystagmography eng the presence of other pathologic findings in the eng and dizziness handicap inventory scores <sep>', 'recovery of peripheral vestibular function <sep> severity of vestibular paresis <sep> peripheral vestibular function <sep> vestibular function <sep>'], 'punchline_text': ['the electronystagmogram returned to normal within 1 month in all 16 patients taking methylprednisolone but remained abnormal in 2 of the 4 patients treated with placebo. <sep>', 'no differences were found between the groups in the occurrence of symptoms and signs degree of caloric lateralization presence of other eng pathologic findings and dizziness handicap inventory scores at the end of the study. <sep>', 'analysis of variance showed a significant effect of methylprednisolone p<0.001 but not of valacyclovir p=0.43). <sep>'], 'population': ['acute vestibular vertigo we randomly selected 20 patients so that half took <sep> 10 patients receiving <sep> acute vestibular vertigo <sep> patients with acute vestibular vertigo <sep>', 'vestibular neuritis vn <sep> vestibular neuritis <sep> thirty vn patients 15 in the study and 15 in the control group were the subjects of the study <sep>', 'patients with vestibular neuritis <sep> massachusetts medical society <sep> vestibular neuritis <sep> patients with acute vestibular neuritis <sep> 141 patients who underwent randomization 38 received <sep>'], 'interventions': ['methylprednisolone and half took placebo <sep> methylprednisolone <sep> placebo <sep> corticosteroids <sep>', 'prednisone <sep> prednisone <sep> placebo and similar vestibular sedatives <sep> corticosteroids <sep> prednisone therapy <sep>', 'methylprednisolone <sep> placebo <sep> valacyclovir <sep> placebo methylprednisolone valacyclovir or methylprednisolone plus valacyclovir <sep> methylprednisolone-plus-valacyclovir <sep> methylprednisolone <sep> placebo 35 methylprednisolone 33 valacyclovir and 35 methylprednisolone plus valacyclovir <sep> methylprednisolone valacyclovir <sep> methylprednisolone and valacyclovir <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",overall there is currently insufficient evidence from these trials to support the administration of corticosteroids to patients with idiopathic acute vestibular dysfunction. we found no trials with a low risk of methodological bias that used the highest level of diagnostic criteria and outcome measures. we recommend that future studies should include health-related quality of life and symptom-based outcome measures in addition to objective measures of vestibular improvement such as caloric testing and electronystagmography.
329,"{'outcomes': ['functional outcomes <sep> pain range of movement or functional outcomes <sep> skin reactions <sep> presence of neglect or sensory loss <sep> functional independence measure fim motor assessment scale mas and rankin disability index measured functional outcomes <sep> visual analogue scale vas <sep> final upper limb function <sep> pain <sep> pain sromp assessed passive range of movement and pain <sep>'], 'punchline_text': ['intention to treat analysis showed no significant difference in pain range of movement or functional outcomes after the intervention phase or at the final assessment. <sep>'], 'population': ['hemiplegic stroke patients <sep> ninety-eight subjects participated 49 strapped 49 controls <sep> post-stroke shoulder pain <sep> care of the elderly wards in a teaching hospital christchurch new zealand <sep> all patients admitted with an acute hemiplegic stroke who had persisting weakness of shoulder abduction <sep>'], 'interventions': ['strapping <sep> shoulder strapping versus no strapping <sep>'], 'punchline_effect': [' no diff <sep>']}",there is insufficient evidence to conclude whether slings and wheelchair attachments prevent subluxation decrease pain increase function or adversely increase contracture in the shoulder after stroke. there is some evidence that strapping the shoulder delays the onset of pain but does not decrease it nor does it increase function or adversely increase contracture.
330,"{'outcomes': ['acute rejection rate trough blood cyclosporine concentrations blood pressure number of antihypertensive drugs hospitalization rate and adverse event rate <sep> renal graft function <sep> serum creatinine <sep> graft function assessed by serum creatinine concentration and glomerular filtration rate measured as plasma iohexol clearance <sep> graft function plasma iohexol clearance renal plasma flow anastomotic arterial blood flow deterioration of renal function blood pressure acute rejection and hospitalization rate <sep> renal plasma flow and anastomotic blood flow <sep> allograft function <sep>', 'renal function and rejection <sep> rate of delayed graft function the rate of rejections time to first rejection whole blood csa concentration or graft function <sep> cadaveric kidney transplantation <sep> thrombosis leading to graft loss <sep> blood concentration <sep> donor or recipient characteristics hla-mismatching and ischaemic time <sep>', 'incidence and severity of delayed graft function <sep> primary graft function <sep> severe signs of cyclosporin a csa nephrotoxicity <sep> rejection episodes <sep> plasma levels of soluble interleukin-2 receptors <sep>', 'episodes of acute tubular necrosis <sep>', 'estimated graft survival <sep> actuarial graft survival <sep> renal parenchymal diastolic blood flow velocities <sep> graft survival <sep>'], 'punchline_text': ['graft function assessed by serum creatinine concentration and glomerular filtration rate measured as plasma iohexol clearance was persistently better in lacidipine-treated patients from 1 year onwards respectively p<0.01 and p<0.05). <sep>', 'for the remaining 35 grafts no beneficial effect of treatment with diltiazem was found for the rate of delayed graft function the rate of rejections time to first rejection whole blood csa concentration or graft function. <sep>', 'primary graft function occurred more commonly in the groups receiving diltiazem. <sep>', 'a trend developed showing a decrease in episodes of acute tubular necrosis in gallopamil versus placebo and became statistically significant when the outcome of kidneys from donors older than 50 years was analyzed separately gallopamil 6/14 42 vs. placebo 10/11 91 p 0.01 corrected chi2]. <sep>', 'actuarial graft survival at 1 yr was different when the two groups were compared p less than 0.05). <sep>'], 'population': ['treated recipients <sep> 118 recipients were available for intention-to-treat analysis on efficacy <sep> 131 de novo recipients of a cadaveric renal allograft on cyclosporine therapy <sep>', 'renal allograft recipients receiving triple-drug immunosuppression <sep> 39 graft recipients <sep>', '11 control subjects and 10 diltiazem subjects <sep> 22 control patients and 20 diltiazem patients received <sep> human renal transplantation <sep> 19 control subjects who received no specific treatment 16 subjects who received <sep> 16 subjects who were given iloprost and 14 subjects who received both <sep>', 'cadaveric renal transplantation <sep> kidneys from aged donors <sep>', '59 cadaver renal transplant patients evaluates the outcome from perioperative treatment with vp n  30 administered <sep> cadaver renal transplantation <sep> cadaver renal transplant crt recipients <sep>'], 'interventions': ['placebo <sep> dihydropyridine ccb <sep> calcium channel blockers <sep> lacidipine <sep> cyclosporine <sep> calcium channel blockade <sep> lacidipine <sep>', 'diltiazem or placebo <sep> placebo <sep> calcium-channel blocker <sep> diltiazem <sep> calcium-channel blocker diltiazem <sep> prednisone azathioprine and csa <sep>', 'diltiazem iloprost or both drugs <sep> diltiazem <sep> calcium antagonists <sep> grafts perfused with either vehicle or diltiazem 20 mg/liter in the euro-collins solution <sep> diltiazem to the perfusion solution <sep> prostacyclin analogue iloprost <sep> iloprost and diltiazem <sep>', 'placebo <sep> calcium channel blocker gallopamil <sep> gallopamil <sep> calcium channel blockers <sep> gallopamil <sep>', 'azathioprine corticosteroids and antilymphocyte globulin with subsequent overlapping with csa <sep> verapamil <sep> verapamil vp <sep> intraoperatively into the renal artery <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",these results suggest that calcium channel blockers given in the peri-operative period may reduce the incidence of atn post-transplantation. the result should be treated with caution due to the heterogeneity of the trials which made comparison of studies and pooling of data difficult.
331,"{'outcomes': ['birth weight stratum <sep> mean 24-hour weight gains <sep>'], 'punchline_text': ['no infant in either group lost weight after successful weaning and mean 24-hour weight gains were similar for both groups. <sep>'], 'population': ['thirty pairs of healthy growing preterm infants <sep> two infants were weaned at 1800 g requiring return to the incubator due to hypothermia and four infants weaned at 1700 g likewise requiring return to the incubator <sep> the number weaned at 1700 g who had birth weight of 1000 g or less and who developed hypothermia appeared substantial three of six such infants <sep>'], 'interventions': ['thermal weaning <sep>'], 'punchline_effect': [' no diff <sep>']}",medically stable preterm infants can be transferred to unheated open cots at a lower body weight of 1600 grams without adverse effects on temperature stability or weight gain. earlier transfer does not necessarily result in earlier discharge.
332,"{'outcomes': ['frequency of relapses and the formation of active brain lesions <sep> relapse rate <sep> clinical and mri-monitored disease activity <sep> safe and well tolerated <sep> cumulative number of confirmed relapses <sep> total number of confirmed relapses <sep> rate ratio <sep> clinical and mri measures of inflammation and neurodegeneration <sep>', 't2 lesion volumes <sep> intention-to-treat analysis of time to 1 <sep> disability status scale change entry expanded disability status scale <sep> enhancing lesions <sep> survival curves <sep>', 'disability <sep> relapse rate and improves disability <sep> tolerated <sep> ms relapse rate <sep> final 2-year relapse rate <sep> expanded disability status scale edss <sep>', 'overall survival curves <sep> progression rates <sep> kurtzke expanded disability status scale <sep> unconfirmed progression and progression of 0.5 edss units <sep>', 'disabled on entry kurtzke disability score <sep>'], 'punchline_text': ['5 mg and 50 mg glatiramer acetate administered orally on a daily basis do not affect relapse rate or other clinical and mri parameters of disease activity and burden in patients with relapsing-remitting multiple sclerosis. <sep>', 'post hoc analysis showed that survival curves for ga-treated male patients diverged early from pbo-treated male subjects hazard ratio 0.71 95 confidence interval 0.53-0.95 <sep>', '0.13 for those receiving placebo a 29 reduction in favor of copolymer 1 p  0.007 annualized rates  0.59 for copolymer 1 and 0.84 for placebo). <sep>', 'progression rates at 12 and 24 months were higher for the placebo group p  0.088 with 2-year probabilities of progressing of 20.4 for cop 1 and 29.5 for placebo. <sep>', 'more disabled patients worsened by 0.3 cop 1 group and 0.4 placebo group unit. <sep>'], 'population': ['patients with relapsing multiple sclerosis <sep> 1912 patients with relapsing-remitting multiple sclerosis <sep> patients with relapsing-remitting multiple sclerosis <sep> 1644 patients who took at least one dose of study <sep>', 'primary progressive multiple sclerosis <sep> male patients <sep> 943 patients with primary progressive multiple sclerosis <sep>', 'two hundred fifty-one patients <sep> patients with relapsing-remitting multiple sclerosis ms <sep> relapsing-remitting multiple sclerosis <sep> patients receiving copolymer 1 and 1.68 <sep>', '106 chronic-progressive patients <sep> chronic progressive multiple sclerosis <sep>', '50 patients with the exacerbating-remitting form of multiple sclerosis who self-injected either 20 mg of <sep> alone daily for two years <sep>'], 'interventions': ['oral glatiramer acetate <sep> placebo <sep> glatiramer acetate or placebo <sep> glatiramer acetate <sep> medication 50 mg glatiramer acetate n=543 5 mg glatiramer acetate n=553 placebo <sep>', 'placebo <sep> glatiramer acetate ga <sep> ga <sep> ga or placebo pbo <sep> glatiramer acetate <sep>', 'placebo <sep> copolymer 1 <sep> copolymer 1 copaxone <sep>', 'placebo <sep>', 'placebo <sep> cop 1 dissolved in 1 ml of saline or saline <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",glatiramer acetate did show a partial efficacy in rr ms in term of relapse related clinical outcomes without any significant effect on clinical progression of disease measured as sustained disability. the drug is not effective in progressive ms patients.
333,"{'outcomes': ['blood transfusion <sep> thrombotic complications <sep> transfusion requirements <sep> perioperative blood transfusion requirements <sep> total amount of blood transfused <sep>', 'blood loss <sep> adverse drug effects <sep> blood loss transfusion requirements coagulation parameters and complications <sep> intraoperative blood loss <sep> bleeding and transfusion requirements <sep> amount of blood transfused <sep>', 'perioperative blood loss and the need for autologous blood transfusion <sep> intraoperative or postoperative thromboembolic complications <sep> postoperative suction drainage <sep> perioperative blood loss <sep>', 'transfusion requirement <sep> blood loss <sep>', 'blood loss <sep> blood loss and transfusion requirements <sep> estimated blood loss <sep> blood loss transfusion requirements days in the intensive care unit and days in hospital <sep> transfusion requirements <sep> duration of intensive care unit admission <sep>'], 'punchline_text': ['no thrombotic complications were detected in either group. <sep>', 'administration of tranexamic acid was a multivariate predictor of blood loss as was american society of anesthesiologists physical status and preoperative platelet count. <sep>', 'patients in the amicar group demonstrated a statistically significant decrease in perioperative blood loss and the need for autologous blood transfusion. <sep>', 'although the difference was not significant statistically the benefit of aprotinin in reducing blood loss in spinal surgery for idiopathic scoliosis was consistent. <sep>', 'the study demonstrated a significant reduction in estimated blood loss aprotinin 545 cc placebo 930 cc and transfusion requirements aprotinin 1.1 u placebo 2.2 u). <sep>'], 'population': ['pediatric patients who undergo posterior spinal fusion surgery to correct scoliosis often require multiple blood transfusions <sep> cardiac surgery and total knee arthroplasty <sep> h(-1 <sep> scoliosis surgery <sep> forty patients 9-18 yr of age <sep> patients with scoliosis undergoing posterior spinal fusion surgery <sep> patients with scoliosis who are undergoing posterior spinal fusion surgery <sep>', 'forty-four patients scheduled to undergo elective spinal fusion <sep> pediatric patients undergoing scoliosis surgery <sep> children with scoliosis <sep>', '36 patients with idiopathic scoliosis <sep> 28 consecutive patients receiving amicar compared to a historical control group of the 31 previous consecutive patients with the same study criteria <sep> idiopathic scoliosis <sep> patients with idiopathic scoliosis undergoing posterior spinal fusion and segmental spinal instrumentation <sep> patients with idiopathic scoliosis undergoing a posterior spinal fusion and segmental spinal instrumentation <sep> two groups of essentially identical patients undergoing a posterior spinal fusion for idiopathic scoliosis <sep> idiopathic scoliosis age at surgery 11 to 18 years posterior spinal fusion and segmental spinal instrumentation only autogenous iliac crest bone graft or homologous cancellous bone graft and a signed agreement to participate in the study <sep> patients undergoing spinal surgery <sep>', 'spinal fusion for idiopathic scoliosis <sep> forty-three patients with idiopathic scoliosis underwent spinal fusion and instrumentation <sep> spinal fusion surgery for idiopathic scoliosis <sep>', 'pediatric patients with spinal deformities undergoing posterior spinal fusions of seven or greater segments <sep> spinal surgery in children <sep> children <sep> cardiac surgical patients <sep> pediatric and adolescent scoliosis surgical patients at increased risk for intraoperative bleeding <sep> 44 children and adolescents <sep>'], 'interventions': ['tranexamic <sep> prophylactic tranexamic acid <sep> placebo isotonic saline <sep> tranexamic acid <sep> tranexamic acid <sep>', 'tranexamic acid <sep> placebo <sep> surgery tranexamic acid group or 0.9 saline placebo <sep> tranexamic acid <sep>', 'amicar epsilon aminocaproic acid <sep> operating room pharmacy into an amicar and control group <sep>', 'placebo <sep> aprotinin <sep> aprotinin <sep>', 'aprotinin <sep> aprotinin or placebo <sep> aprotinin <sep> aprotinin versus placebo <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>']}",the effect of antifibrinolytic drugs on mortality could not be assessed. antifibrinolytic drugs reduced blood loss and the amount of blood transfused in children undergoing scoliosis surgery however their effect on the number of children requiring blood transfusion remains unclear. aprotinin tranexamic acid and aminocaproic acid seem to be similarly effective.
334,"{'outcomes': ['qualify for vasopressor infusion <sep> duration of normotension meeting criteria for second bolus meeting criteria for vasopressor support and cost comparison <sep> normotensive state <sep> arterial blood pressure <sep> overall cost <sep>', 'weight gain <sep> volume expander to maintain normal blood pressure <sep> number of infants requiring inotropic support and death or chronic lung disease <sep>', 'pulmonary perfusion and/or ventilation <sep> mortality rate <sep> case fatality rate <sep> survival <sep> ratio of fio2 to pao2 <sep>', 'ccr <sep> creatinine clearance ccr or the urinary sodium excretion rate <sep> plasma potassium concentrations <sep> renal function <sep> fractional urinary sodium excretion <sep>', 'blood pressure <sep> hypotensive systolic blood pressure less <sep>', 'lvo <sep> global cerebral blood flow <sep> mean arterial blood pressure mabp left ventricular output lvo and global cerebral blood flow cbf <sep>'], 'punchline_text': ['those receiving alb n=49 alb and 52 ns were more likely to achieve a normotensive state alb=57.1 ns=32.1 p=0.01 1 h following the initial bolus therapy. <sep>', 'outcome as assessed by the number of infants requiring inotropic support and death or chronic lung disease did not differ between the groups. <sep>', 'in the groups receiving exchange transfusion the mortality rate was 41 whereas the groups receiving either plasma or supportive care alone the mortality was 80%. <sep>', 'ffp did not significantly influence creatinine clearance ccr or the urinary sodium excretion rate either in g less than 30 or g 30-34. <sep>', 'there was no significant difference in the blood pressure of the three groups before or one hour after beginning the infusion. <sep>', 'dopamine was effective in increasing mabp both treatments increased lvo whereas no significant difference between the treatment groups and the control group could be demonstrated with regard to cbf. <sep>'], 'population': ['hypotension in neonates <sep> neonates <sep>', 'hypotensive preterm infants <sep> preterm infants <sep> mechanically ventilated preterm infants <sep> sixty three preterm infants weighing 540 to 1950 g at birth and with gestational ages of 23 to 34 weeks who developed hypotension mean arterial pressure  25 30 and 35 mm hg for infants with birthweight  1 1-1.49 and 1.5-1.99 kg respectively within the first 2 hours of life <sep>', 'infants with severe rds <sep> 19 infants with birth weights of less than 1,000 gm without severe respiratory distress and in the management of 82 infants birth weights less than 2,000 gm with severe respiratory distress whose disease manifested itself within the first 24 hours of life <sep> low-birth-weight infants with and without severe respiratory distress syndrome <sep> infants receiving exchange transfusion <sep>', 'preterm infants in intensive care they were divided into two groups those with gestational ages less than 30 weeks g less than 30 and those with gestational ages of 30-34 weeks g 30-34 <sep> 35 infants was studied <sep> preterm infants <sep>', 'hypotensive preterm infants <sep> sixty preterm infants <sep> preterm infants <sep>', '36 preterm neonates <sep> preterm neonates <sep> sick preterm infants <sep>'], 'interventions': ['bolus infusion of 5 albumin alb or normal saline ns <sep> dopamine therapy <sep> normal saline-bolus therapy <sep> ns or alb <sep> alb <sep> albumin-bolus therapy <sep>', 'isotonic saline <sep> colloid or crystalloid <sep> colloid 5 albumin and a crystalloid isotonic saline solution <sep> intravenous infusions at 10 ml/kg of either 5 albumin <sep> dopamine infusion <sep> isotonic 0.9 saline <sep>', 'fresh frozen plasma or conventional supportive care alone <sep> exchange transfusions <sep>', 'ffp the other not yielding four study groups g less than 30 and no ffp 8 infants g less than 30 and ffp 8 infants g 30-34 and no ffp <sep> ffp <sep> maturation and early freshly frozen plasma infusion ffp <sep>', 'colloid infusions <sep> receive 5 ml/kg 20 albumin 15 ml/kg fresh frozen plasma or 15 ml/kg 4.5 albumin <sep> colloid infusions <sep>', 'dopamine <sep> dopamine 5 microg/kg per min volume expansion with albumin 20 15 ml/kg or no treatment <sep> dopamine <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there is no evidence from randomised trials to support the routine use of early volume expansion in very preterm infants without cardiovascular compromise. there is insufficient evidence to determine whether infants with cardiovascular compromise benefit from volume expansion. there is insufficient evidence to determine what type of volume expansion should be used in preterm infants if at all or to determine the benefit of using early red cell transfusions. the significance of the finding of a significant increase in blood pressure in hypotensive preterm infants in one trial comparing albumin and saline is unclear but the overall meta-analyses found no other significant clinical benefit in using albumin compared to saline.
335,"{'outcomes': ['missed initial appointments <sep>'], 'punchline_text': ['the orientation statement only group had significantly fewer missed initial appointments than the control group 28 vs. 56%). <sep>'], 'population': ['individuals who called for an intake appointment <sep>'], 'interventions': ['orientation statement at the time the appointment was made orientation statement plus phone prompt or phone prompt only <sep>'], 'punchline_effect': [' sig decrease <sep>']}",there is evidence that a simple prompt to attend clinic very close to the time of the appointment may encourage attendance and a simple orientation-type letter may be more effective than a telephone prompt. this simple intervention could be a more cost effective means of encouraging compliance at first attendance but supplementing these data with the results of large well designed conducted and reported randomised studies would be desirable.
336,"{'outcomes': [""airways resistance via active anterior rhinomanometry and the volume and area section via acoustic rhinometry <sep> morning serum cortisol <sep> adrenal suppression <sep> adverse events <sep> nasal scores <sep> serum morning cortisol values <sep> nasal airway patency's parameters <sep> total number of drug-related adverse events <sep> efficacy and safety <sep> nasal and ocular symptoms <sep>"", 'recurrence rate of chronic rhinosinusitis and nasal polyps <sep> number of patients withdrawn because of recurrent or persistent diseases <sep> recurrence rate of nasal polyps and chronic rhinosinusitis <sep>', 'allergic sinusitis <sep> bacterial sinusitis <sep> percentage of nasal deobstruction <sep>', 'tnf-alpha level <sep> levels of il-1beta and il-8 <sep> subjective nasal clinical symptoms nasal discharge nasal obstruction postnasal drip and headache 2 x-ray photographs ethmoid and maxillary sinuses and 3 cytokine levels il-1beta il-8 and tnf-alpha by enzyme-linked immunosorbent assay <sep> total nasal symptom scores <sep> total x-ray photograph scores <sep>', 'symptom scores <sep> density of cells expressing interleukin4 <sep> eosinophils <sep> cd-3 <sep> interleukin-5 messenger rna <sep>', 'symptoms diary card and rigid endoscopy scores acoustic rhinometry middle meatal swabs blood tests--crp esr wbc and eosinophil count <sep> risk of developing an infection <sep> diary card scores <sep>', 'symptomatic response and improvement in nasal mucociliary clearance nasal airway resistance sinus radiographs and intranasal bacteriology and appearance <sep>', 'healing with mfns <sep> wound healing <sep> endoscopic combination score for inflammation oedema and polyps a total symptoms score <sep> tolerated <sep> total endoscopic scores <sep> wound healing leading to recurrences of sinusitis and polyps <sep> total symptom scores <sep> postoperative mean total score for several endoscopic parameters scores <sep>', 'morning combined symptom scores css <sep> efficacy and tolerability <sep> peak nasal inspiratory flow pnif <sep> patients sense of smell <sep> nasal congestion and discharge scores <sep> pnif <sep> efficacy and tolerability <sep>', 'adverse effects <sep> clinical outcome <sep> facial pain and sensitivity <sep> nasal symptoms <sep> clinical efficacy and adverse effects <sep> mucosal thickening <sep>'], 'punchline_text': ['significant improvements over the baseline were reported in both groups for the primary variable sum of nasal scores 53.7 in the once-daily group and 59.7 in the twice-daily group as well as for each nasal and ocular symptoms without differences between the groups. <sep>', 'no differences in the number of patients withdrawn because of recurrent or persistent diseases were found between the patients treated with fpans and patients treated with placebo. <sep>', 'the percentage of nasal deobstruction was significantly higher with tixocortol pivalate-neomycin than with neomycin alone by the fifth examination 9th day regardless of the etiology of the sinusitis allergic or bacterial). <sep>', 'in both ns and betamethasone patients the levels of il-1beta and il-8 had significantly decreased by the 3rd and 2nd weeks after therapy respectively. <sep>', 'twenty-six patients with allergy to house dust mites who had previously had surgery and who had persistent symptoms of disabling rhinorrhea or pressure-pain resistant to oral antibiotics and intranasal corticosteroids were recruited. <sep>', 'when patients were considered as one group there was an improvement in the diary card scores p  0.054 comparing baseline to 8 or 16 weeks. <sep>', 'both active preparations with antibiotic 14 of 20 patients responded without antibiotic 12 of 20 patients responded were more effective than the placebo 2 of 10 patients responded). <sep>', 'mfns led to greater although not significant reductions in total endoscopic scores in all subjects compared with placebo. <sep>', 'in allergic patients bans significantly p  0.001 reduced both morning 1.40 <sep>', 'budesonide and antral irrigations reduced nasal symptoms more effectively than placebo and there was a significantly greater reduction in facial pain and sensitivity in the budesonide group than in the placebo group. <sep>'], 'population': ['allergic and non-allergic chronic rhinosinusitis <sep> adult patients n=112 with allergic or non-allergic chronic rhinosinusitis <sep>', '162 patients aged 18 years and older requiring fess for chronic rhinosinusitis or nasal polyps <sep> patients with nasal polyps high score at fess or no previous sinus surgery <sep> patients were withdrawn from the trial but still included in the study for statistical purposes if there were recurrent or persistent diseases defined as progressive regrowth of nasal polyps recurrent signs and symptoms of chronic sinusitis combined with abnormalities on computed tomography scan and persistent complaints for at least 2 months after fess <sep>', 'chronic allergic and bacterial sinusitis <sep> 60 patients aged 15-51 years with chronic allergic or bacterial maxillary sinusitis <sep>', '25 patients 39 sides with chronic sinusitis <sep> patients with chronic sinusitis using the yamik sinus catheter with and without <sep>', 'allergic patients with chronic rhinosinusitis <sep> allergic patients with chronic rhinosinusitis following surgery <sep> twenty-six patients with allergy to house dust mites who had previously had surgery and who had persistent symptoms of disabling rhinorrhea or pressure-pain resistant to oral antibiotics and intranasal corticosteroids were recruited <sep>', 'chronic rhinosinusitis <sep> chronic rhinosinusitis crs <sep> patients with crs <sep>', '50 patients with chronic mucopurulent rhinosinusitis <sep> chronic mucopurulent rhinosinusitis <sep>', 'subjects with a chronic rhinosinusitis with/without nasal polyps <sep> after endoscopic sinus surgery <sep> approximately 20 patients with chronic rhinosinusitis undergoing <sep> subjects with nasal polyps <sep> ninety-nine subjects <sep>', 'patients with chronic rhinosinusitis <sep> patients n  167 with persistent rhinosinusitis symptoms despite 2-weeks antibiotic treatment <sep> chronic rhinosinusitis patients <sep> non-allergic patients <sep>', 'maxillary sinusitis <sep> 40 patients with chronic or recurrent maxillary sinusitis <sep>'], 'interventions': ['beclomethasone dipropionate aqueous nasal spray <sep> nasal aqueous beclomethasone dipropionate bdp <sep>', 'placebo <sep> functional endoscopic sinus surgery fess <sep> fpans 800 microg b.i.d. or placebo <sep> fluticasone propionate aqueous nasal spray <sep> fluticasone propionate aqueous nasal spray fpans <sep> fess combined with peri-operative systemic corticosteroids <sep> fpans <sep> local corticosteroids <sep>', 'endonasal neomycin-tixocortol pivalate irrigation <sep> endonasal irrigations of tixocortol pivalate pivalone)-neomycin and neomycin <sep>', 'yamik sinus catheter yamik <sep> normal saline ns <sep> betamethasone <sep> betamethasone solution <sep>', 'placebo <sep> topical budesonide <sep> budesonide <sep> budesonide daily or placebo <sep> topical budesonide <sep>', 'placebo <sep> topical corticosteroids <sep> topical corticosteroid agent--fluticasone propionate aqueous nasal spray fpans <sep> fpans <sep> fluticasone propionate aqueous nasal spray <sep>', 'nasal sprays of dexamethasone tramazoline and neomycin dexamethasone and tramazoline with no antibiotic or matched placebo propellant alone <sep> placebo <sep>', 'placebo <sep> mometasone furoate nasal spray mfns 200 microg bid or placebo <sep> mfns <sep> oral local steroids <sep> corticosteroids <sep> functional endoscopic sinus surgery fess <sep>', 'placebo <sep> bans <sep> budesonide <sep> budesonide aqueous nasal spray <sep> bans 128 micrograms b.i.d <sep>', 'placebo <sep> topical steroid therapy <sep> erythromycin therapy <sep> topical steroid treatment <sep> budesonide <sep> budesonide <sep> corticosteroid therapy 400 micrograms daily or placebo <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",topical steroid is a beneficial treatment for crs without polyps and the adverse effects are minor. it may be included in a comprehensive treatment of crs without polyps. direct delivery of steroid to the sinuses may bring more beneficial effect. further studies comparing different topical drug delivery methods to the sinuses with appropriate treatment duration longer than 12 weeks are required.
337,"{'outcomes': ['rate of response based on intention <sep> median ttf <sep> skin reactions <sep> cutaneous reactions <sep>'], 'punchline_text': ['the rate of response based on intention to treat patients was 33.3 for miltefosine solution compared with 3.7 for placebo p  .006). <sep>'], 'population': ['52 patients with inoperable progressive skin lesions from histologically or cytologically confirmed breast cancer not manageable by radiotherapy or systemic treatment with superficial or flat skin lesions estimated depth of invasion  or  1 cm <sep> cutaneous metastases from breast cancer <sep>'], 'interventions': ['placebo <sep> miltefosine solution <sep> miltefosine <sep> 6 miltefosine solution or placebo <sep> miltefosine solution miltex asta medica frankfurt germany <sep> topical chemotherapy <sep>'], 'punchline_effect': [' no diff <sep>']}",there is weak evidence from one small trial that 6 miltefosine solution applied topically to people with superficial fungating breast lesions smaller than 1cm who have received either previous radiotherapy surgery hormonal therapy or chemotherapy for their breast cancer may slow disease progression. there is insufficient evidence in this review to give a clear direction for practice with regard to improving quality of life or managing wound symptoms associated with fungating wounds. more research is needed.
338,"{'outcomes': ['failure rates <sep> libido and impotence <sep> partial seizures <sep> nausea vomiting dizziness and sedation <sep> efficacy and toxicity <sep> overall treatment success <sep> intolerable acute toxic effects <sep> dysmorphic effects and hypersensitivity <sep>', 'recurrence of convulsion and side effects <sep> serum drug levels <sep> hyperactivity <sep> proportion of children with recurrence <sep> side effects <sep>', 'free of seizures <sep> efficacy <sep> 1-year remission <sep>', 'efficacy <sep>', 'efficacy <sep> preschool behaviour screening questionnaire bsq <sep> conners parent rating scale <sep> odds ratio for behavioural problems <sep> acceptability and efficacy <sep> mean log-transformed scores on the behaviour rating scales <sep> frequency of behavioural side-effects behaviour <sep>'], 'punchline_text': ['carbamazepine provided complete control of partial seizures more often than primidone or phenobarbital p less than 0.03). <sep>', 'the proportion of children with recurrence did not differ among the 3 groups. <sep>', 'we found no significant differences between the drugs for either measure of efficacy at 1 2 or 3 years of follow-up. <sep>', 'no significant differences between the four drugs were found for either measure of efficacy at one two or three years of follow up. <sep>', 'the mean log-transformed scores on the behaviour rating scales did not differ significantly between the phenobarbital and phenytoin groups conners 2.64 sd 0.71 vs 2.65 0.89 p  0.97 n  32 in each group bsq 2.12 1.31 vs 2.18 1.02 p  0.94 n  4 vs 3). <sep>'], 'population': ['adults with partial or generalized tonic-clonic seizures or with both <sep> partial and secondarily generalized tonic-clonic seizures <sep> partial and secondarily generalized tonic-clonic seizures in 622 adults <sep>', '127 children remained in the study <sep> out-patients in a tertiary care hospital <sep> 151 children with gtc aged 4-12 yrs from madras city were enrolled <sep>', 'children with newly diagnosed epilepsy <sep> between 1981 and 1987 167 children aged 3-16 years who had had at least two previously untreated tonic-clonic or partial seizures with or without secondary generalisation <sep> adult patients <sep> newly diagnosed childhood epilepsy <sep>', 'between 1981 and 1987 243 adult patients aged 16 years or over newly referred to two district general hospitals with a minimum of two previously untreated tonic-clonic or partial with or without secondary generalised seizures <sep> newly diagnosed adult epilepsy <sep> patients with newly diagnosed tonic-clonic or partial with or without secondary generalised seizures <sep> newly diagnosed epileptic patients <sep>', 'childhood epilepsy in rural india <sep> between august 1995 and february 1996 109 unselected children aged 2-18 years with partial and generalised tonic-clonic epilepsy were identified by population screening <sep> 94 children <sep>'], 'interventions': ['carbamazepine phenobarbital phenytoin or primidone <sep> carbamazepine phenobarbital phenytoin and primidone <sep> carbamazepine <sep> carbamazepine <sep> carbamazepine and phenytoin <sep> phenytoin <sep>', 'phenobarbitone pb phenytoin pht and sodium valproate svp <sep> svp <sep> placebo tablets <sep> phenobarbitone phenytoin with sodium valproate <sep>', 'phenytoin <sep> phenobarbitone phenytoin carbamazepine or sodium valproate <sep> carbamazepine <sep> phenobarbitone <sep> sodium valproate <sep>', 'phenytoin <sep> phenobarbitone phenytoin carbamazepine or sodium valproate <sep> phenobarbitone phenytoin carbamazepine or sodium valproate <sep> carbamazepine <sep> sodium valproate <sep>', 'phenobarbital as monotherapy <sep> phenobarbital <sep> phenobarbital and phenytoin <sep> phenytoin <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",the results of this review show that phenobarbitone was significantly more likely to be withdrawn than phenytoin. given that no significant differences for seizure outcomes were found the higher withdrawal rate with phenobarbitone may be due to adverse effects. several factors may have confounded the results of this review.
339,"{'outcomes': ['antibody responses <sep> occurrence of pneumococcal bacteremia <sep>', 'morbidity and mortality <sep> incidence of infection <sep>', 'higher infection rates <sep> pneumococcal isolations <sep>'], 'punchline_text': ['serotype-specific igg antibody responses to reimmunization varied according to pneumococcal serotype but in general were mediocre or poor the poorest response was to serotype 6b. <sep>', 'the children were randomly assigned to receive either 125 mg of penicillin v potassium 105 children or placebo 110 children twice daily. <sep>', 'no pneumococcal isolations occurred in the penicillin group while receiving penicillin although four isolations occurred within one year of stopping penicillin. <sep>'], 'population': ['children with sickle cell anemia and 2 <sep> children with sickle cell anemia <sep> children with sickle cell anemia who received <sep> children with sickle cell anemia who had been treated with prophylactic penicillin for at least 2 years before their fifth birthday <sep>', 'children with sickle cell anemia <sep> children with sickle cell anemia <sep> children with sickle cell anemia who were under the age of three years at the time of entry <sep>', 'homozygous sickle cell ss disease <sep> 242 children aged 6 months to 3 years at entry <sep> children with homozygous sickle cell disease <sep>'], 'interventions': ['penicillin prophylaxis or to receive placebo treatment <sep> placebo <sep> pneumococcal polysaccharide vaccine <sep>', 'penicillin v potassium 105 children or placebo <sep> oral penicillin <sep> placebo <sep> penicillin <sep>', 'prophylactic penicillin and of 14 valent pneumococcal vaccine <sep> penicillin <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",prophylactic penicillin significantly reduces risk of pneumococcal infection in children with homozygous sickle cell disease and is associated with minimal adverse reactions. further research may help to determine the ideal age to safely withdraw penicillin.
340,"{'outcomes': ['good response <sep> fine wrinkling mottled hyperpigmentation and roughness <sep> global response <sep> epidermal and granular layer thickness decreased melanin content and compaction of the stratum corneum <sep> safe and effective <sep> safety and efficacy <sep>', 'corrected epidermal atrophy and atypia and improved skin hydration properties <sep> efficacy and safety <sep> skin roughness <sep>', 'changes in skin biopsies and silicone skin surface replicas <sep> appearance of photo damaged skin <sep> overall severity of photodamage <sep> skin wrinkles tightness colour and pores <sep> mean epidermal thickness <sep> appearance of photo-damaged skin <sep> efficacy and safety <sep> skin wrinkles mottled hyperpigmentation laxity lentigines and roughness <sep>', ""investigator's global evaluation <sep> dryness peeling and acne <sep> adverse experiences <sep> roughness mottled hyperpigmentation fine wrinkling and lentigines <sep> tolerated and skin irritation <sep>"", 'permanent hyperpigmentation hypopigmentation or scarring <sep> rate of resolution of erythema <sep> duration of crusting <sep> duration of crusting swelling and itching postoperatively <sep> duration of itching <sep> swelling <sep> erythema crusting pain itching swelling pigmentary changes and the day of first make-up application <sep> facial rhytids <sep> crusting <sep> medium to deep grade iii <sep>', 'rhytide scores <sep> improvement in rhytides patients subjective reports of postoperative pain time to reepithelialization degree of postoperative crusting and duration of postoperative erythema <sep> postoperative erythema <sep> pain <sep> postoperative crusting and more rapid reepithelialization <sep>', 'frequency of erythema <sep> wrinkles and severity and duration of adverse effects <sep> posttreatment erythema <sep> wrinkle improvement and duration of adverse effects <sep> skin biopsies <sep> wrinkle improvement <sep>', 'average upper lip dermabrasion-treated wrinkle score <sep> wrinkle score <sep> average upper lip laser-treated wrinkle score <sep>', 'histologic evaluation <sep> fine wrinkling and pigmentation <sep>', 'general skin texture and discoloration <sep> photoaging effects <sep>', 'global responses <sep> mottled hyperpigmentation and fine wrinkles <sep> safety and efficacy <sep> local adverse events <sep>', 'mottles and telangiectasis <sep> epidermal thickness <sep> vivida <sep> elasticity index <sep> dermal thickness <sep>', 'photographs for erythema pigmentation and wrinkle improvement <sep> hyperpigmentation and wrinkle reduction <sep> overall modest wrinkle improvement <sep> erythema <sep>', 'efficacy <sep> vascularity <sep> irritant side effects erythema and scaling <sep> histologic features keratinocyte expression of hla-dr and intercellular adhesion molecule-1 numbers of epidermal langerhans cells and epidermal and dermal t lymphocytes and vascularity as measured by dermal endothelial cell area <sep> immunologic markers <sep> epidermal thickening <sep>', 'significant lightening of hyperpigmented lesions <sep> clinical and microscopical manifestations of liver spots <sep> degree of compaction of stratum corneum thickness of the granular cell layer and epidermal thickness <sep> degree of epidermal pigmentation <sep>', 'variable pulse <sep> duration of crusting <sep> erythema crusting pain and pigmentary changes <sep> permanent hyperpigmentation hypopigmentation or scarring occurred <sep> postoperative erythema <sep>', 'fine wrinkling mottled hyperpigmentation roughness and laxity <sep> overall improvement in photodamaged skin <sep> side effects of erythema peeling and stinging were usually mild and well tolerated <sep>', 'epidermal thickness <sep> mean erythemal index <sep> skin condition <sep> elasticity index <sep> mean epidermal thickness <sep> dermal thickness <sep> efficacy and safety <sep>', 'erythemal index <sep> adverse effects <sep> epidermal thickness <sep> skin condition <sep> skin elasticity index <sep> dermal thickness <sep>', 'fine wrinkling tactile roughness coarse rhytids skin laxity/tone sallowness/yellowing and overall features <sep> adverse effects burning stinging redness peeling dryness discoloration itching and rash <sep> overall investigator scores <sep> ra and shadows north-south facial axis values <sep> photodamaged skin topography <sep> rz ra and shadows <sep>', 'safe and effective <sep> safety and efficacy <sep> tolerated overall <sep>', 'overall appearance of photodamaged skin <sep> local irritation and adverse events <sep> treatment response <sep> plasma retinoid levels <sep> appearance of photodamaged skin <sep> efficacy and safety <sep>', 'mottled hyperpigmentation <sep> efficacy and tolerability <sep> overall severity of photodamage and sallowness <sep> overall severity of photodamage <sep>', 'average upper lip phenol-treated wrinkle score <sep> wrinkle score <sep> average upper lip laser-treated wrinkle score <sep>', 'erythema score <sep> skin state <sep> intraoperative pain <sep> objective skin changes <sep> perioral wrinkles <sep> restoring actinic damage <sep>'], 'punchline_text': ['mild to moderate skin reactions such as erythema peeling and burning were the most common side effects and although most prevalent in the group using the 0.05 concentration generally did not limit tretinoin use. <sep>', 'it was more efficacious than vehicle in reducing skin roughness and fine wrinkling based on objective measurements. <sep>', 'improvement in overall severity of photodamage was significantly greater for tretinoin treated subjects and was progressive over the study period. <sep>', 'tretinoin-treated forearms showed significantly greater improvement in roughness mottled hyperpigmentation fine wrinkling and lentigines at 24 and 48 weeks. <sep>', 'the addition of the er:yag laser following co2 laser resurfacing reduces the duration of crusting swelling and itching postoperatively. <sep>', 'both dermabrasion and carbon dioxide laser resurfacing are effective in the treatment of perioral rhytides. <sep>', 'posttreatment erythema was noted at 2 weeks in 14 subjects 67 on the er:yag laser-treated side and 20 subjects 95 on the co2 laser-treated side. <sep>', 'the degree to which the wrinkle score improved after laser treatment compared with that after dermabrasion was not statistically significant p .216). <sep>', 'ninety percent 9/10 of patients felt that overall they noticed significant improvement however there was no distinction between the two treatment options. <sep>', 'overall there were trends towards greater improvement or less worsening in the glycolic acid group for all clinical assessments for photoaging. <sep>', 'tazarotene cream and tretinoin cream significantly improved mottled hyperpigmentation and fine wrinkles. <sep>', 'the effects of vivida cream on mottles and telangiectasis were also significantly p  0.01 greater than those of placebo. <sep>', 'both co2 and er:yag laser-treated sites showed overall modest wrinkle improvement compared to the pretreatment photographs. <sep>', 'before and after treatment we assessed histologic features keratinocyte expression of hla-dr and intercellular adhesion molecule-1 numbers of epidermal langerhans cells and epidermal and dermal t lymphocytes and vascularity as measured by dermal endothelial cell area. <sep>', 'after one month of treatment the patients treated with tretinoin had significant lightening of hyperpigmented lesions as compared with the patients who received vehicle p less than 0.002). <sep>', 'laser wavelength/pulse duration options and new techniques continue to shorten the healing phase associated with laser skin resurfacing while maintaining clinical efficacy. <sep>', 'significant reductions were found in fine wrinkling mottled hyperpigmentation roughness and laxity after 0.05 tretinoin therapy when compared with controls. <sep>', 'subjective assessment revealed statistically significant improvements in skin condition in both treatment groups but vivida was significantly p less than 0.01 more effective than imedeen for all parameters. <sep>', 'clinical examinations after 45 and 90 days treatment showed significant improvements in skin condition in the actively treated group but not in the placebo group p less than 0.001). <sep>', 'clinical assessment demonstrated significant improvement with active treatment greater than control for fine wrinkling tactile roughness coarse rhytids skin laxity/tone sallowness/yellowing and overall features. <sep>', 'results indicate statistically significant improvement in fine wrinkling coarse wrinkling and yellowing with the use of tretinoin cream 0.02 at week-24 end point compared with placebo. <sep>', 'treatment response increased throughout the 36-week treatment period and the overall appearance of photodamaged skin was significantly better than with the vehicle alone. <sep>', 'l-lactic acid cream was significantly superior to the vehicle in reducing the overall severity of photodamage p  .05 mottled hyperpigmentation p  .05 sallowness p  .05 and roughness on the forearms p  .05 at week 22. <sep>', ""treatment of upper lip wrinkles with baker's phenol resulted in greater improvement than treatment with the 950 microsec dwell time co2 laser. <sep>"", 'the laser treatment had a significantly higher erythema score at 1 month and a small but significantly greater improvement in perioral wrinkles at 6 months. <sep>'], 'population': ['296 subjects with photodamaged facial skin <sep> photodamaged skin <sep>', 'ten healthy female volunteers aged 45 to 65 years with moderately photodamaged forearm skin applied tazarotene 0.1 gel to one arm and vehicle gel to the other once daily for 12 weeks <sep> photodamaged dorsal forearm skin <sep>', 'photo-damaged australian skin <sep> subjects with cutaneous facial photodamage <sep>', 'photoaged skin <sep> 40 patients with photoaged skin of the face and forearms <sep>', 'forty treatment sites on 20 patients <sep>', 'perioral rhytides <sep> university hospital-based dermatologic surgery clinic <sep> fifteen healthy fair-skinned volunteers with moderate to severe perioral rhytides and no history of prior cosmetic surgical procedures to the same anatomic area <sep>', 'nineteen female and 2 male volunteers with skin type i to iii and wrinkle class <sep> resurfacing of facial rhytides <sep> 21 subjects with facial rhytides <sep>', 'upper lip wrinkles <sep> twenty female subjects with moderate to severe upper lip wrinkles <sep>', 'twelve healthy subjects with at least a moderate degree of photodamage <sep> photodamaged skin <sep>', 'facial and neck photoaging <sep> seventy-five volunteers <sep>', 'three hundred forty-nine subjects with facial photodamage <sep> university hospitals and clinical research centers <sep> facial photodamage <sep>', '30 women with moderate to severe sun-damaged facial skin applied <sep> sun-damaged or age-damaged facial skin <sep>', 'thirteen patients with facial wrinkles <sep> rhytides <sep>', '99 photoaged patients completed a 48-week study using 0.1 <sep>', 'fifty-eight patients <sep> 24 patients with facial lesions <sep> 28 patients with facial lesions <sep> fifteen patients who responded well were than randomly assigned to <sep>', 'forty-two treatment sites on 21 patients <sep>', '251 subjects with mild to moderate photodamaged facial skin <sep> photodamaged skin <sep>', 'sun-damaged skin in women aged 40-60 years <sep> sun-damaged skin in females <sep>', 'a group of 15 women were <sep> sun-damaged skin in females <sep> women aged 40-60 years <sep>', 'nineteen evaluable volunteer sample patients aged between 36 and 72 years with fitzpatrick skin types i ii and iii who were in good physical and mental health with mild to moderately photodamaged facial skin were considered for analysis <sep> photodamaged facial skin <sep>', 'moderate-to-severe facial photodamage <sep> photodamaged facial skin <sep>', '800 patients with moderate to severe photodamaged skin <sep>', 'seventy-four women aged 40 to 70 years with moderately severe photodamaged facial skin were enrolled in the study <sep> outpatient clinical research unit at the massachusetts general hospital boston <sep> photodamaged skin <sep>', 'upper lip wrinkles <sep> twenty female subjects with moderate to severe upper lip wrinkles <sep>', 'perioral wrinkles <sep> twenty female patients provided informed consent and participated in the study <sep>'], 'interventions': ['tretinoin <sep> tretinoin <sep> tretinoin emollient cream <sep> tretinoin emollient cream <sep>', 'tazarotene <sep> tazarotene <sep> tazarotene 0.1 gel <sep>', 'topical tretinoin <sep> tretinoin 0.05 cream retin-a <sep> tretinoin <sep> tretinoin 62 or vehicle 63 cream <sep>', 'tretinoin <sep> placebo <sep> tretinoin emollient cream <sep>', 'laser resurfacing of facial rhytids <sep> combined co2/erbium:yag laser resurfacing <sep> combined co2/er:yag laser <sep> co2 laser resurfacing alone or with the same co2 laser treatment followed by 3 passes with the er:yag laser <sep> pulsed carbon dioxide co2 laser resurfacing <sep> carbon dioxide laser alone <sep> co2 and the pulsed erbium:yag er:yag laser <sep> co2 laser resurfacing <sep>', 'carbon dioxide laser resurfacing to one side of the perioral area and dermabrasion to the other side <sep> dermabrasion and superpulsed carbon dioxide laser <sep> lx-20sp novapulse carbon dioxide laser luxar corp bothell wash and the other half was treated with dermabrasion using either a hand engine-driven diamond fraise or a medium-grade drywall sanding screen <sep> carbon dioxide laser resurfacing <sep>', 'co2 laser treatment <sep> co2 laser-treated side <sep> erbium:yag er:yag and carbon dioxide co2 laser treatment <sep> er:yag laser <sep> erbium:yag laser <sep> co2 laser and other side with an er:yag laser <sep> erbium:yag and carbon dioxide lasers <sep>', 'co2 laser <sep> 950 microsec dwell time carbon dioxide laser to manual tumescent dermabrasion <sep> manual tumescent dermabrasion and 950 microsec dwell time co2 laser resurfacing <sep> high-energy pulsed or computer-scanned continuous-wave carbon dioxide co2 laser resurfacing <sep> 950 microsec dwell time co2 laser on one side of the upper lip and manual tumescent dermabrasion on the other <sep> 950 microsec dwell time co2 laser to that of manual tumescent dermabrasion <sep>', 'glycolic acid <sep> glycolic acid-based moisturizer twice daily <sep> short contact 70 glycolic acid peels <sep> glycolic acid-based refresher peels <sep> monthly serial 70 glycolic acid peels <sep>', 'placebo <sep> placebo cream <sep> glycolic acid cream <sep> glycolic acid <sep> daily glycolic acid <sep> unneutralized 5 glycolic acid topical cream <sep>', 'tazarotene creams with 0.05 tretinoin emollient cream <sep> tazarotene cream and tretinoin cream <sep> tazarotene <sep> tazarotene cream <sep> tazarotene cream <sep>', 'placebo <sep> placebo cream <sep> vivida cream <sep>', 'co2 laser <sep> short-pulsed co2 laser with an er:yag laser <sep> pulsed co2 and er:yag lasers <sep> yag laser resurfacing <sep> pulsed co2 laser and the other with an er:yag laser <sep>', 'tretinoin creams <sep> topical tretinoin all-trans-retinoic acid <sep> tretinoin <sep> topical tretinoin retinoic acid <sep> tretinoin cream <sep> tretinoin <sep>', 'topical tretinoin retinoic acid <sep> topical 0.1 percent tretinoin retinoic acid <sep> continue tretinoin therapy or use vehicle alone <sep> tretinoin <sep> topical 0.1 percent tretinoin <sep>', 'variable pulse erbium:yag laser skin resurfacing <sep> variable pulse erbium:yag er:yag <sep> variable pulse <sep> er:yag laser resurfacing <sep> laser resurfacing of facial rhytides <sep> laser skin resurfacing <sep> pulsed carbon dioxide co(2 <sep> laser resurfacing <sep> upper lip region with co(2 <sep> upper lip rhytides with a variable pulse <sep> carbon dioxide laser <sep>', 'topical tretinoin <sep> tretinoin <sep> topical tretinoin <sep>', 'natural cartilage polysaccharides <sep>', 'special natural cartilage polysaccharides <sep> treated orally with 500 mg/day active substance vivida <sep> placebo <sep> natural cartilage polysaccharides <sep>', 'topical ascorbic acid application <sep> topical ascorbic acid <sep>', 'tretinoin cream <sep> placebo <sep> tretinoin cream <sep>', 'isotretinoin or matching vehicle cream <sep> placebo <sep> isotretinoin <sep> isotretinoin versus vehicle cream <sep>', 'glycolic acid l-lactic acid or vehicle creams <sep> topical 8 glycolic acid and 8 l-lactic acid creams <sep> topical alpha-hydroxy acids at low concentrations 8 glycolic acid and 8 lactic l-isoform acid creams <sep> glycolic acid cream <sep> l-lactic acid cream <sep>', ""baker's phenol on one side of the upper lip and the 950 microsec dwell time co2 laser on the other side <sep> baker's phenol <sep> 950 microsec dwell time co2 laser to that of unoccluded baker's phenol chemical peel <sep> co2 laser to phenol <sep> 950 microsec dwell time carbon dioxide laser with unoccluded baker's phenol chemical peel <sep> carbon dioxide laser co2 laser <sep>"", 'facial skin treatments with laser resurfacing dermabrasion and chemical peels <sep> laser resurfacing versus dermabrasion <sep> dermabrasion versus co2 laser resurfacing <sep> ultrapulse co2 laser <sep> co2 laser resurfacing <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is conclusive evidence that topical tretinoin improves the appearance of mild to moderate photodamage on the face and forearms in the short-term. however erythema scaling/dryness burning/stinging and irritation may be experienced initially. there is limited evidence that tazarotene and isotretinoin benefit patients with moderate photodamage on the face both are associated with skin irritation and erythema. the effectiveness of other interventions remains uncertain.
341,"{'outcomes': ['pregnancy rate <sep>', 'midluteal estradiol levels <sep> pregnancy rate <sep> late-midluteal estradiol levels <sep> pregnancy rate <sep>', 'luteal e(2 level <sep> similar levels of luteal e2 <sep> probability of pregnancy in intracytoplasmic sperm injection icsi cycles <sep> e2 levels <sep> luteal serum e(2 and p profiles <sep> highest pregnancy rate <sep> lower e2 levels <sep>', 'pregnancy and implantation rates <sep> pregnancy rate <sep>', 'serum progesterone p and 17-beta-estradiol e2 and e2/p ratio levels of the luteal phase <sep> luteal p values <sep> serum p levels <sep> pregnancy rate <sep> e2/p ratio <sep>', 'early pregnancy loss <sep> multiple pregnancy rate <sep> ongoing pregnancy rate <sep> implantation rate per embryo transfer <sep> hormonal levels <sep> pregnancy rate per embryo transfer early pregnancy loss multiple pregnancy rate and midluteal p and e(2 levels <sep> implantation rate <sep>', 'conception rate <sep> mean number of oocytes retrieved and embryos <sep> levels of oestradiol and progesterone <sep>', 'rate of positive beta-human chorionic gonadotrophin per transfer <sep> clinical pregnancy rate per transfer and implantation rate <sep> live birth rate per transfer <sep>', 'bleeding episodes <sep> duration of lps <sep> miscarriage rate <sep>', 'clinical pregnancy rate <sep> ongoing pregnancy rate <sep> sd number of oocytes <sep> implantation rate <sep> luteal serum progesterone and oestrogen concentrations <sep> number of embryos transferred <sep> late luteal progesterone concentrations <sep>', 'efficacy <sep> pregnancy rates <sep>', 'luteal phase serum p4 levels <sep> p4 levels <sep> elevation of serum progesterone <sep> serum p4 levels <sep>', 'pregnancy and live birth rates <sep> pregnancy rates pr <sep> clinical pregnancy ongoing pregnancy and live birth rates <sep> live birth rates <sep> embryo quality <sep>', 'number of beta-hcg-positive results <sep>', 'implantation rate per embryo <sep> clinical pregnancy rates <sep> progesterone levels <sep>', 'progesterone profiles and pregnancy outcomes <sep> plasma progesterone concentrations <sep> pregnancy outcome <sep>', 'live birth rates <sep> safe and well tolerated <sep> pregnancy rates and live birth rates <sep> biochemical rates <sep> adverse event profiles <sep> pregnancy rates <sep> efficacy and safety <sep>', 'probability of pregnancy <sep> pregnancy rates <sep> demographics stimulation parameters and embryological data <sep>', 'implantation rates <sep> pregnancy rate and live birth rate <sep> clinical pregnancy rates <sep> pregnancy and embryo implantation rates <sep> endometrial thickness <sep>', 'live birth rates <sep> clinical pregnancy <sep> pregnancy embryo implantation and live birth rates <sep> embryo implantation <sep> lower embryo implantation clinical pregnancy and live birth rates <sep>', 'pregnancy rates and ongoing pregnancy rates <sep> pregnancy rates <sep>', 'ongoing pregnancy rate <sep> efficacy and tolerability <sep> implantation rate <sep> comparative efficacy and tolerability <sep> rate of implantation and abortion number and reasons of withdrawals as well as adverse events assessment of tolerability and acceptance <sep> ongoing pregnancy rates <sep> abortion rate <sep> rate of withdrawals at the individual visits <sep> tolerability <sep>', 'pregnancy or implantation rates <sep> demographic parameters infertility etiologies number of gonadotropin ampules used number of mature oocytes recovered rates of testicular sperm usage number of embryos transferred and cycle and transfer cancellation rates <sep> clinical pregnancy rates implantation rates and live birth rates <sep>', 'rates of successful pregnancies <sep> efficacy safety and tolerability <sep> vaginal discharge or irritation <sep>', 'pregnancy rates or implantation rates <sep> pregnancy rates and the implantation rates <sep> vitro fertilization-embryo transfer ivf-et <sep> vitro fertilization and embryo transfer <sep> pregnancy and implantation rates <sep>', 'living birth rates per transfer <sep> plasma p and 17 beta-estradiol concentrations <sep> luteal plasmatic values <sep>', 'clinical outcome of intracytoplasmic sperm injection icsi and embryo transfer et cycles <sep> implantation clinical pregnancy and multiple pregnancy rates <sep> pregnancy rates <sep> pregnancy rate <sep>', 'clinical pregnancy rate <sep> implantation rate <sep> implantation rate <sep> clinical pregnancy rate <sep> progesterone <sep>', 'pregnancy rate rate of spontaneous abortion proportion of normally developing fetuses or rate of chemical pregnancy <sep>', 'spontaneous abortion rates <sep> efficacy <sep> delivery rates <sep> pregnancy and delivery rates <sep> ratio of newborn babies per embryo transferred <sep> serious adverse events <sep> pregnancy rates per transfer <sep> safety parameters <sep> specific symptoms and usual safety monitoring <sep>', 'implantation and live birth rates <sep> icsi clinical outcomes <sep> ongoing pregnancy rate <sep> luteal-phase gnrh agonist administration increased luteal-phase serum hcg estradiol and progesterone concentrations <sep> implantation and live birth rates <sep>', 'pregnancy rates ongoing/delivered failed pregnancy rates and product satisfaction scores <sep> patient satisfaction scores <sep> failed pregnancy rates <sep>', 'clinical pregnancy rate <sep> probability of conception <sep> clinical pregnancy <sep> clinical pregnancy rates <sep> ongoing pregnancy rates <sep> clinical pregnancy rates <sep>', 'lh <sep> estradiol e2 <sep> median progesterone levels <sep> lh levels <sep>', 'clinical prs <sep> pregnancy rates prs <sep> pr per retrieval <sep> e2 or p levels endometrial thickness <sep>', 'overall pregnancy rate and miscarriage rate <sep> demographic profile and pregnancy and miscarriage rates <sep>', 'serum levels of p and e2 <sep> live birth rates <sep> e2 or p levels <sep> pregnancy rates prs and live birth rates per et <sep>', 'rates of implantation and clinical pregnancy rates <sep> pregnancy implantation and live birth rates <sep> multiple pregnancy and live birth rates <sep> number of embryos transferred and the grade of the embryos <sep>', 'number of good quality embryos <sep> furthermore estradiol e(2 progesterone p levels and endometrial thickness <sep> implantation and pregnancy rate <sep> implantation and pregnancy rates <sep>'], 'punchline_text': ['the pregnancy rate was significantly higher with dydrogesterone than with progesterone in group d 39.1 vs. 26.7 p  0.01 group e 41.2 vs. 35.6 p  0.01 and group f 48.2 vs. 33.9 p  0.001). <sep>', 'pregnancy rate in women with low late-midluteal estradiol levels was significantly lower compared to that with medium 100-500 pg/ml and high  500 pg/ml levels 13.3 26.8 and 36.3 respectively). <sep>', 'similar levels of luteal e2 were documented in groups b and c. p levels were similar in the three groups. <sep>', 'estradiol supplementation during the luteal phase in women undergoing ivf/icsi-et has a beneficial effect on the outcome without at least as seems from this study having any adverse effects. <sep>', 'im significantly decreased e2/p ratio p  0.05). <sep>', 'hormonal levels did not differ between groups. <sep>', 'the two groups did not differ in the mean number of oocytes retrieved and embryos replaced nor in the mean age of the patients and the amount of hmg used. <sep>', 'the rate of positive beta-human chorionic gonadotrophin per transfer was 38.4 with imp 35.0 with vpg once daily and 43.1 with vpg twice daily. <sep>', 'bleeding episodes were 15.9 in group a compared with 20.8 in group b or  0.72 95 ci  0.38-1.36). <sep>', 'following low dose vaginal treatment a significantly higher implantation rate 30.7 versus 10.7 p  0.01 but similar clinical pregnancy rate 47.0 versus 33.3 and ongoing pregnancy rate 41.1 versus 20.0 was observed compared with oral treatment. <sep>', 'efficacy was assessed using the pregnancy rates which was per transfer statistically significantly higher in group a than in group b 32.5 vs. 18.3 respectively). <sep>', 'with oral micronized p4 supplementation the p4 levels were higher p less than .001 and the luteal phase longer p less than .05). <sep>', 'despite higher embryo quality in group 1 than in group 2 60.3 vs. 51.6 clinical 63.0 vs. 62.7 and ongoing 58.7 vs. 51.0 pregnancy rates pr were not significantly different. <sep>', 'in 148 out of 288 cycles the luteal phase was supported only by vaginal micronized progesterone group i). <sep>', 'the implantation rate per embryo was significantly higher in the im group 40.9 than in the oral group 18.1%). <sep>', 'these progesterone regimes produced no significant differences. <sep>', 'pregnancy rates were high and similar in all treatment groups with biochemical rates exceeding 50 clinical and ongoing rates or=40 and live birth rates at 35%-38%. <sep>', 'twenty-six ongoing pregnancies were achieved in the progesterone 26 and 30 in the progesterone/e2 group 29.7%). <sep>', 'there were no significant differences in the clinical pregnancy rates 25 vs. 20 and in the implantation rates 12.7 vs. 9.1 of patients who received im progesterone and oral chlormadinone acetate. <sep>', 'the women randomized to luteal phase supplementation with im progesterone had significantly higher clinical pregnancy 48.5 vs. 30.4 odds ratio or 2.16 95 confidence interval ci 1.21 3.87 embryo implantation 24.1 vs. 17.5 or 1.89 95 ci 1.08 3.30 and live birth rates 39.4 vs. 24.5 or 2.00 95 ci 1.10 3.70 than women randomized to crinone 8%. <sep>', 'because pregnancy rates and ongoing pregnancy rates were similar with and without estrogen supplementation 50.0 vs. 55.2 and 36.6 vs. 34.4 respectively we concluded that luteal estrogen supplementation in fixed multidose gnrh antagonist cycles did not change the pregnancy rates significantly. <sep>', 'ongoing pregnancy rates were 25.2 in the utrogest 200 group and 22.2 in the crinone 8 group when patients were analyzed who normally completed the trial. <sep>', 'extending gnrha treatment through the luteal phase appeared not to have a significant impact on pregnancy or implantation rates in intracytoplasmic sperm injection cycles. <sep>', 'significantly p<0.05 more patients given dydrogesterone than micronised progesterone were satisfied with the tolerability of their treatment. <sep>', 'there were no significant differences in pregnancy rates or implantation rates between groups. <sep>', 'the ongoing pregnancy and the living birth rates per transfer were significantly higher in the patients supplemented with intramuscular p than in those treated with vaginal gel <sep>', 'gnrh agonist administration in the luteal phase was reported to beneficially affect the clinical outcome of intracytoplasmic sperm injection icsi and embryo transfer et cycles. <sep>', 'implantation rate was significantly higher with the vaginal ring compared with i.m. <sep>', 'there was no difference between the groups in pregnancy rate rate of spontaneous abortion proportion of normally developing fetuses or rate of chemical pregnancy. <sep>', 'safety parameters were similar in both groups except for drowsiness which was more significantly frequent in the oral progesterone group than in the crinone group at all time points. <sep>', 'administration of 0.1 mg of gnrh agonist triptorelin on day 6 after icsi led to a significant improvement of implantation and live birth rates after icsi as compared with placebo. <sep>', 'pregnancy rates ongoing/delivered failed pregnancy rates and product satisfaction scores for patients supplemented with crinone vaginal gel and with imp. <sep>', 'there were however no differences in clinical pregnancy rates between the two groups in patients who used either the gnrh antagonist or microdose gnrh agonist protocols. <sep>', 'the luteal phase was significantly shorter in groups b c and d whereas group e was comparable with group a 13.5 and 13.0 days respectively. <sep>', 'they did not differ in terms of e2 or p levels endometrial thickness on the day of hcg number of follicles  16 mm in diameter mature oocytes retrieved or embryos transferred. <sep>', 'the overall pregnancy rate and miscarriage rate were comparable among the three groups. <sep>', 'no advantage was found in the addition of e2 valerate to p luteal phase support of gnrh-a and hmg-induced ivf-et cycles. <sep>', 'when the two groups were compared there were also statistically significant differences in multiple pregnancy and live birth rates  p  0.05). <sep>', 'although there was no significant difference in the number of good quality embryos transferred in both groups the implantation and pregnancy rate were significantly higher in the gnrh-a  treated group compared with placebo controls. <sep>'], 'population': ['675 patients <sep> 498 patients were divided into three groups <sep>', 'patients with low late-midluteal estradiol levels <sep> patients with low late-midluteal estradiol levels in ivf cycles <sep> 436 women undergoing first ivf cycles with long protocol and luteal support with <sep> unsuccessful women with low late-midluteal estradiol levels  100 pg/ml proceeded with the exploratory second ivf cycles <sep>', 'women undergoing icsi cycles with controlled ovarian hyperstimulation using long agonist protocol <sep> private and university fertility centers <sep> copyright 2010 american society for reproductive medicine <sep>', 'women undergoing ivf/icsi-et <sep> patients undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer ivf/icsi-et cycles <sep> ivf unit of a university hospital we studied patients who were undergoing ivf <sep> patients undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer <sep>', '176 women treated for assisted procreation <sep>', 'ivf-icsi patients <sep> university-affiliated assisted reproduction center <sep> one hundred seventy-six patients <sep> women undergoing agonist as well as antagonist protocol 2 women undergoing ivf/icsi with good-quality embryos available <sep>', '60 patients <sep>', '412 patients aged between 28 and 37 years <sep> vaginal gel vgp at two different doses for luteal support in ivf <sep>', '132 patients in group a continued <sep> 257 women who were pregnant after icsi on day of first ultrasound into two groups to <sep>', '64 high responder patients requiring intracytoplasmic sperm injection due to male factor infertility <sep>', 'vitro fertilization <sep> vitro fertilization ivf <sep> 43 patients who received the support of luteal phase through the <sep> 86 ivf patients undergoing embryo transfer <sep>', 'vitro fertilization <sep> vitro fertilization ivf <sep>', 'vitro fertilization and embryo transfer <sep> one hundred one patients were enrolled 48 in group 1 53 in group 2 <sep> mean age 31.8 years vs. 32.7 years and reasons for infertility <sep> copyright c 2010 american society for reproductive medicine <sep> women<or=37 years old <sep>', 'the age range of 252 women was 19-41 years and the total number of cycles was 310 <sep> 310 icsi cycles were carried out in 252 infertile couples between january 2001 and march 2003 <sep> patients were accepted for treatment in the art unit of selcuk university meram faculty of medicine between january 2001 and march 2003 <sep>', 'women <sep> vitro fertilization <sep> patients undergoing ivf who are treated with a gnrh agonist <sep> 40 years of age who were undergoing ivf with luteal gnrh pituitary down-regulation <sep> university-based ivf center <sep>', 'subjects undergone down regulated <sep>', 'twenty-five u.s. art centers <sep> 1,211 art patients <sep>', 'patients stimulated with recombinant fsh rfsh and gnrh antagonist for ivf who received <sep> patients stimulated with gnrh antagonist/rfsh for ivf <sep>', 'patients undergoing assisted reproductive technology art treatment who were treated with a <sep> 40 patients with normal and high response serum estradiol  2,000 pg/ml in gnrha down-regulation <sep>', 'vitro fertilization-embryo transfer cycles <sep> two hundred and one women undergoing ivf-et.intervention(s women <sep>', 'normal responder ivf patients treated with <sep> normal responder patients treated with fixed multidose gnrh antagonist <sep>', 'four hundred thirty women who underwent their first ivf or intracytoplasmic sperm injection cycle were randomized after successful transfer of two or three embryos from july 1999 through september 2001 <sep> pregnant women <sep> seventeen german ivf centers <sep>', 'one hundred eighty-one women underwent a <sep>', '430 women underwent <sep>', '197 women undergoing ivf-et cycles with human <sep> women with fibroids or difficult oocyte retrieval <sep>', '156 patients <sep>', 'five hundred and seventy women undergoing et following controlled ovarian stimulation with a long gnrh agonist protocol were included <sep>', 'after oocyte aspiration 505 women <sep> women treated with ivf-embryo transfer and for agonadal women participating in an oocyte donation programme <sep> 153 women <sep> ivf-embryo transfer trial <sep>', 'patients undergoing in-vitro fertilization ivf <sep> one-hundred-and-fifty-six patients undergoing <sep>', 'a total of 283 patients <sep> patients undergoing an in-vitro fertilization ivf procedure <sep>', 'six hundred women about to undergo ovarian stimulation for icsi 300 using a long gnrh agonist protocol and 300 using a gnrh antagonist protocol <sep>', 'four hundred sixty-eight patients were randomized and 407 completed the study <sep> women under age 40 years with day-3 follicle-stimulating hormone levels <sep> 2010 american society for reproductive medicine <sep> university-affiliated ivf unit <sep>', 'patients undergoing ivf treatment <sep> university-based tertiary fertility center <sep> one hundred sixty-six patients undergoing their first cycle of ivf treatment <sep>', 'patients undergoing assisted reproduction techniques art <sep> ivf/icsi patients <sep> twenty-three patients were randomized <sep>', 'ninety-three infertile women underwent a total of 143 ivf-et cycle using cc for ovulation induction <sep> infertile women volunteers in an academic research environment <sep>', '1,373 women undergoing in vitro fertilization <sep> woman undergoing ivf <sep> 1,373 infertile women undergoing ivf participated <sep>', 'vitro fertilization-embryo transplant cycles <sep> one hundred consecutive patients undergoing et after ivf <sep>', '164 patients who underwent <sep> patients who received gnrh antagonist for pituitary suppression <sep>', 'patients with thin endometrium or=7 mm <sep> patients with thin endometrium or=7 mm after ivf treatment <sep> one-hundred-and-twenty women were eligible for this study <sep>'], 'interventions': ['placebo <sep> micronized progesterone <sep> micronized vaginal progesterone <sep> gonadotropin-releasing hormone agonists <sep> dydrogesterone <sep> long protocol and not at risk of ovarian hyperstimulation syndrome ohss group a long protocol and at risk of ohss group b and those in a donor oocyte program <sep> progesterone <sep>', 'human chorionic gonadotropin combined with progesterone <sep> human chorionic gonadotropin hcg <sep> progesterone alone p protocol or hcg progesterone p+hcg protocol <sep> hcg <sep> progesterone <sep>', 'estradiol e2 valerate <sep> 6 mg e(2 valerate <sep>', 'luteal estrogen supplementation <sep> estradiol <sep> gonadotropin-releasing hormone agonist/human recombinant gonadotropin <sep> estradiol supplementation <sep> progesterone supplementation <sep>', 'vaginal cream <sep> gonadotrophin releasing hormone agonists <sep> human chorionic gonadotrophin hcg <sep> progesterone vaginal cream <sep> vaginal cream and natural p <sep> progesterone <sep>', 'progesterone p only as luteal support 200 mg bid starting the following night after oocyte retrieval or 2 e(2 and p <sep> serum e(2 <sep> transdermal e(2 <sep> estradiol supplementation <sep>', 'gonadotrophin-releasing hormone agonist gnrha and human menopausal gonadotrophin hmg <sep> progesterone or human chorionic gonadotrophin hcg <sep> hcg <sep> human chorionic gonadotrophin <sep> progesterone <sep>', 'vpg <sep> intramuscular progesterone imp and progesterone <sep> vgp <sep> progesterone vaginal gel <sep> vaginal gel versus intramuscular progesterone <sep> imp <sep>', 'continue lps <sep> lps <sep> progesterone <sep> icsi <sep>', 'gonadotrophin-releasing hormone agonist <sep> gonadotrophin-releasing hormone agonist either orally 200 mgx4/day or vaginally 100 mgx2/day <sep> micronized progesterone <sep>', '17alpha-hydroxyprogesterone <sep> saline solution as placebo <sep> 17alpha-hydroxyprogesterone caproate 17-ohpc <sep> intramuscular administration of 17-ohpc <sep>', 'oral micronized progesterone <sep> oral micronized p4 supplementation <sep> oral micronized p4 <sep> oral micronized progesterone p4 supplementation <sep>', 'short p-in-oil protocol <sep> progesterone-in-oil support <sep>', 'vaginal micronized progesterone <sep> estradiol with progesterone <sep> micronized progesterone <sep> copyright c <sep> progesterone or progesterone  estradiol <sep> vaginal micronized progesterone plus transdermal estradiol <sep> transdermal estradiol 100 microg/day  600 mg/day vaginal micronized progesterone <sep>', 'oral micronized progesterone <sep> oral versus intramuscular progesterone <sep> im progesterone <sep> oral progesterone <sep>', 'hcg or progesterone <sep> crinone gel <sep> utrogestan n=55 and hcg <sep> various luteal support regimes hcg and progesterone <sep> luteal supplement <sep> utrogestan administered vaginally crinone gel progesterone administered vaginally and cyclogest progesterone administered rectally supplementation <sep>', 'vaginal progesterone p(4 insert endometrin <sep> endometrin <sep> endometrin 100 mg twice daily n  404 endometrin 100 mg three times daily <sep>', 'micronized progesterone vaginally n=100 progesterone group or 600 mg of micronized progesterone and 4 mg of e2 valerate <sep> estradiol to progesterone <sep> micronized progesterone <sep> rfsh and gnrh antagonist <sep> progesterone <sep>', 'im progesterone <sep> oral chlormadinone acetate or im progesterone <sep> oral progestogen chlormadinone acetate <sep> oral chlormadinone acetate and im progesterone <sep> oral progestogen chlormadinone acetate and intramuscular im progesterone <sep> im progesterone and oral chlormadinone acetate <sep> oral progestogen versus intramuscular progesterone <sep> gonadotropin-releasing hormone agonist gnrha <sep>', 'supplementation with crinone 8 90 mg once daily or im progesterone <sep> intramuscular progesterone supplementation <sep> crinone 8 intravaginal progesterone gel vs. im progesterone <sep> im progesterone <sep>', 'luteal estrogen supplementation <sep> vaginal 600 mg/d micronized progesterone for luteal phase supplementation with or without transdermal estrogen supplementation <sep> recombinant fsh and fixed multidose gnrh antagonist <sep>', 'capsules containing 200 mg of p utrogest 200 or crinone 8 gel for luteal phase and early pregnancy support during assisted reproduction techniques art <sep> progesterone gel crinone 8 <sep> vaginal progesterone capsules <sep>', 'chorionic gonadotropin administration <sep> gonadotropin-releasing hormone agonist gnrha <sep> down-regulation protocol of gnrha <sep>', 'ivf/intracytoplasmic sperm injection icsi treatment <sep> dydrogesterone and micronised progesterone <sep> intravaginal micronised progesterone <sep> intravaginal micronised progesterone 200 mg three times daily n=351 or oral dydrogesterone <sep> human chorionic gonadotropin <sep> dydrogesterone <sep> vaginal micronised progesterone with oral dydrogesterone <sep> oral dydrogesterone <sep>', 'hcg support <sep> micronized progesterone <sep> chorionic gonadotropin hcg <sep> early luteal-phase vaginal progesterone supplementation <sep>', 'vaginal gel <sep> exogenous natural progesterone <sep> progesterone <sep>', 'triptorelin <sep> placebo <sep> triptorelin or placebo <sep> gnrh agonist protocol <sep>', 'progesterone replacement with a vaginal ring or i.m <sep> micronized oestradiol <sep> progesterone supplementation with vaginal ring or i.m <sep> vaginal ring releasing progesterone <sep> progesterone supplementation <sep> polysyloxane vaginal ring containing 1g of natural progesterone <sep> progesterone <sep>', 'placebo p.o <sep> human menopausal gonadotropin hmg and human chorionic gonadotrophin <sep> human chorionic gonadotrophin or dydrogesterone <sep> ivf <sep> hcg <sep> dydrogesterone <sep>', 'progesterone per day crinone or 300 mg progesterone administered orally utrogestan <sep> oral progesterone <sep> progesterone <sep> micronized progesterone <sep>', 'placebo <sep> luteal-phase gnrh agonist <sep> gnrh agonist or placebo <sep> gnrh agonist <sep> gnrh agonist triptorelin <sep>', 'crinone vaginal gel or imp <sep> crinone vaginal gel <sep> copyright <sep> crinone vaginal gel and intramuscular progesterone imp <sep> crinone vaginal gel and imp <sep> intramuscular progesterone <sep>', 'no e(2 supplementation <sep> luteal phase vaginal estradiol supplementation <sep> e(2 supplementation <sep> luteal phase vaginal e(2 supplementation <sep>', 'buserelin <sep> gnrh agonist <sep> hcg <sep> micronized progesterone <sep>', 'no luteal support control group or luteal support with both oral e2 2 mg three times daily starting on the day of retrieval and vaginal p suppositories <sep> clomiphene citrate cc)-stimulated ivf-et <sep> estradiol and progesterone <sep> clomiphene citrate stimulation <sep>', 'micronized vaginal p gel and micronized p capsule <sep> oral dydrogestrone with progesterone gel and micronized progesterone <sep> oral dydrogesterone <sep> oral dydrogesterone <sep> micronized p gel p capsule and oral dydrogesterone <sep>', 'progesterone alone and estrogen and progesterone support <sep> oral e2 valerate <sep> gnrh agonists gnrh-a and hmg-induced ivf-et cycles <sep> e2 valerate <sep>', 'intracytoplasmic sperm injection icsi after ovulation induction by gonadotrophins and gnrh antagonist <sep> intravaginal 600 mg micronized progesterone <sep> gnrh agonist 0.5 mg leuprolide acetate <sep> single-dose gnrh agonist <sep> single-dose gonadotrophin-releasing hormone gnrh agonist <sep>', 'gonadotrophin-releasing hormone agonist gnrh-a <sep> triptorelin 0.1 mg on the day of ovum pickup opu <sep> placebo <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",this review showed a significant effect in favour of progesterone for luteal phase support favouring synthetic progesterone over micronized progesterone. overall the addition of other substances such as estrogen or hcg did not seem to improve outcomes. we also found no evidence favouring a specific route or duration of administration of progesterone. we found that hcg or hcg plus progesterone was associated with a higher risk of ohss. the use of hcg should therefore be avoided. there were significant results showing a benefit from addition of gnrh agonist to progesterone for the outcomes of live birth clinical pregnancy and ongoing pregnancy. for now progesterone seems to be the best option as luteal phase support with better pregnancy results when synthetic progesterone is used.
342,"{'outcomes': ['moderate level of pain <sep> farther walking distance of 2 miles <sep> pain relief <sep> level of walking claudication pain <sep> level of pain <sep> blood flow <sep>', 'red cell rigidity <sep> ankle systolic blood pressure ratio  asbp ratio <sep> walking distance <sep> median of the maximal walking distance <sep> walking distance and blood rheology <sep> whole blood or plasma viscosity <sep> red cell rigidity <sep>', 'maximal walking distances <sep> painfree walking distance <sep> maximal and painfree walking distances and blood viscosity <sep> blood viscosity <sep>', 'red blood cell filterability plasma fibrinogen concentration and blood viscosity resting and post-ischemic calf muscle blood flow and the resting and post-exercise ankle/brachial systolic pressure ratio <sep> exercise tolerance <sep> serum levels of pentoxifylline and its hydroxy-metabolite <sep> claudication distance and walking distance <sep>', 'subjective side effects <sep> clinical efficacy and safety <sep> walking performance absolute walking time and walking distance on a treadmill ergometer and by acral plethysmography <sep>', 'erythrocyte deformability <sep> subjective response claudication and maximum walking distances ankle systolic indices maximum blood flow in the lower limb by gravimetric plethysmography plasma fibrinogen erythrocyte deformability and whole blood viscosity <sep> claudication distance and mean plasma fibrinogen concentration <sep> subjective response ankle systolic indices maximum limb blood flow or whole blood viscosity <sep> mean erythrocyte deformability <sep>', 'deaths and serious adverse event rates <sep> withdrawal rates <sep> walking distances <sep> cilostazol <sep> frequency of minor side effects <sep> maximal walking distance with constant-speed variable-grade treadmill testing <sep> side effects including headache palpitations and diarrhea <sep> mean maximal walking distance <sep> mean maximal walking distance <sep>', 'duration of coad <sep>', 'initial claudication toe peak-flow time pulse reappearance time prt/2 and maximum postischemic flow time <sep> distal pressure and resting microcirculatory blood flow <sep> postexercise distal flow ratios and pressures and enabling faster recuperation of basal pulse rates <sep> walking performance resting toe pressure resting and postexercise ankle/brachial pressure ratio and basal/postischemic toe-pulse ratio <sep> absolute subjective claudication distance <sep>', 'aef <sep> pain-free walking distance pfwd <sep> efficacy safety and cost <sep> serious drug-related side effects <sep> tolerated <sep> flux <sep> efficacy and tolerability <sep> walking distance <sep> exercise flux aef <sep>', 'absolute claudication distance acd <sep> walking distance and quality of life <sep> initial claudication distance and quality of life assessment <sep> quality of life <sep> exercise performance or quality of life <sep> acd <sep> peak acd <sep>', 'pain-free walking distance <sep> walking performance <sep> adverse reactions <sep>', 'ankle-brachial index <sep> maximal walking distance <sep> diabetes mellitus <sep> vascular endothelial growth factor <sep> exercise tolerance <sep> vegf levels <sep> circulating vegf levels <sep> plasma levels of vegf <sep> levels of vegf <sep>', 'nausea <sep> initial and absolute claudication distances <sep>', 'efficacy safety and tolerance <sep> initial and absolute claudication distances <sep> reduction of lower limb paresthesias <sep> pentoxifylline efficacy <sep> blood viscosity <sep>', 'tolerated <sep> pxf improved walking distance <sep> efficacy safety and cost <sep> total walking distance twd <sep>'], 'punchline_text': ['the level of pain did not change significantly with either aspirin or pentoxifylline but the walking distance was farther with the pentoxifylline group. <sep>', 'pmax which was initially elevated decreased significantly p less than 0.05 during both medication periods but there were no significant differences between the two drugs. <sep>', 'after one and eight weeks but not after twelve weeks the maximal walking distances were significantly longer in group a than in group b. <sep>', 'this was shown by a therapeutic effect ratio of 0.98 for treadmill claudication distance and 0.96 for treadmill walking distance after within-patient analysis at the end of the cross-over where a ratio of 1.0 means the test drug and placebo effects are identical). <sep>', 'the clear improvement shown for both variables was greater and statistically significant p less than or equal to 0.05 after treatment with pentoxifylline. <sep>', 'the placebo group showed a significant improvement p less than 0.05 in claudication distance and mean plasma fibrinogen concentration but no such improvements were observed in the oxpentifylline group. <sep>', 'side effects including headache palpitations and diarrhea were more common in the cilostazol-treated patients but withdrawal rates were similar in the cilostazol 16 and pentoxifylline 19 groups. <sep>', 'the results of the overall intention-to-treat analysis of the study population show statistically significant superiority of pentoxifylline over placebo for all absolute claudication distance summary and end point measures. <sep>', 'significant differences within groups were also noted for initial claudication toe peak-flow time pulse reappearance time prt/2 and maximum postischemic flow time together with significant intergroup variables. <sep>', 'microcirculatory evaluation indicated an increase in flux p  0.05 in the pxf group not significant in the placebo group the after-exercise flux aef was increased p<0.05 in both groups at 6 months but the increase in aef was greater in the pxf group at 12 month. <sep>', 'pentoxifylline increased acd by 13.9 relative to placebo p  0.039). <sep>', 'there was a significant 60 increase in pain-free walking distance in either pentoxifylline treatment periods whereas there were no clinically relevant changes in the placebo periods. <sep>', 'patients given either cilostazol or pentoxifylline showed a significant improvements in maximal walking distance compared with the placebo group 34 m and 33 m respectively compared with 5 m both p<0.05). <sep>', 'nausea was the only drug side effect noted. <sep>', 'pentoxifylline given orally in doses up to 1200 mg/day was significantly more effective than placebo in increasing both the initial and absolute claudication distances in patients with coad. <sep>', 'there was a 38 difference at 6 months and 39 at 12 months in favor of pxf. <sep>'], 'population': ['patients sixty-five years or older with claudication <sep> walking leg pain in the elderly with pvd <sep> 90 patients who participated 45 received <sep>', 'claudication <sep> thirty-one patients mean age 60 years range 45-80 years with a typical history and objective symptoms of intermittent claudication with a reported maximal walking distance less than 500 m were included in a cross-over study <sep>', 'forty outpatients <sep>', '38 subjects with stable severe to moderately severe intermittent claudication <sep>', '23 returned for follow-up and 30 patients receiving <sep> patients with peripheral arterial disease fontaine stage ii or iii with 30 patients receiving <sep> 24 returned for follow-up <sep>', 'patients with intermittent claudication <sep> 40 patients receiving <sep>', 'enrolled patients with moderate-to-severe claudication from 54 outpatient vascular clinics including sites at air force veterans affairs tertiary care and university medical centers in the united states <sep> 922 consenting patients 698 met the inclusion criteria <sep> patients with intermittent claudication <sep>', 'enrolled 150 patients with moderately severe chronic occlusive arterial disease coad at three centers in scandinavia <sep> patients with moderately severe chronic occlusive peripheral arterial disease <sep>', '45 patients with peripheral arterial disease fontaine stage ii <sep> intermittent claudication of the lower limbs <sep>', 'severe intermittent claudication <sep> 120 included patients 101 completed the study 56 in the pxf group and 45 in the placebo group <sep>', 'patients with pad who have intermittent claudication <sep> 430 patients with intermittent claudication <sep> patients with intermittent claudication <sep>', ""24 patients 19 males 5 females aged between 40 and 71 years suffering from peripheral occlusive arteriopathy of stage ii severity fontaine's classification <sep> patients with intermittent claudication <sep>"", 'non-diabetic patients <sep> 50 patients with intermittent claudication <sep> human subjects <sep> patients with intermittent claudication <sep>', 'twenty-six patients with severe short-distance claudication <sep> intermittent claudication <sep>', 'chronic occlusive arterial disease patients <sep> patients with coad <sep> 128 outpatients <sep> intermittent claudication associated with chronic occlusive arterial disease coad <sep>', '194 included patients 135 completed the study 75 in the pxf group and 60 in the placebo group <sep> long-range 400 m interval intermittent claudication <sep>'], 'interventions': ['aspirin or pentoxifylline <sep> aspirin and pentoxifylline <sep> aspirin <sep> aspirin or pentoxifylline <sep> aspirin <sep> pentoxifylline <sep>', 'flunarizine and pentoxifylline <sep> pentoxifylline <sep> flunarizine <sep> placebo <sep>', 'placebo <sep> same exercise program <sep> placebo plus exercise <sep> pentoxifylline per day or group b placebo <sep> pentoxifylline <sep>', 'placebo tablets or 400 mg slow-release pentoxifylline tablets <sep> pentoxifylline <sep> placebo <sep> xanthine derivative pentoxifylline trental or bl191 hoechst-roussel <sep>', 'pentoxifylline trental 400 mg coated tablets and nylidrin hcl <sep> nylidrin hcl <sep> pentoxifylline <sep> vasodilator-nylidrin <sep>', 'oxpentifylline <sep> placebo <sep>', 'cilostazol and pentoxifylline <sep> placebo <sep> pentoxifylline and placebo <sep> cilostazol <sep> pentoxifylline <sep>', 'pentoxifylline <sep> placebo <sep>', 'pentoxifylline <sep> pentoxifylline <sep> nifedipine <sep> pentoxifylline buflomedil and nifedipine <sep> buflomedil <sep> pentoxifylline treatment <sep> buflomedil and nifedipine <sep>', 'pentoxifylline pxf <sep> placebo <sep> pxf <sep> laser doppler flowmetry <sep> pxf and placebo <sep> pentoxifylline <sep>', 'placebo <sep> pentoxifylline <sep> placebo <sep> oral iloprost <sep> iloprost <sep> pentoxifylline or placebo <sep> iloprost nor pentoxifylline <sep>', 'pentoxifylline <sep> pentoxifylline <sep> placebo <sep> placebo <sep>', 'cilostazol or pentoxifylline <sep> cilostazol and pentoxifylline <sep> placebo <sep> cilostazol <sep> cilostazol and pentoxifylline <sep> cilostazol <sep> vegf <sep> cilostazol nor pentoxifylline <sep> pentoxifylline <sep>', 'pentoxifylline <sep>', 'pentoxifylline <sep> pentoxifylline <sep> placebo <sep> pentoxifylline trental hoechst-roussel pharmaceuticals inc <sep>', 'pentoxifylline pxf <sep> placebo <sep> pxf <sep> pxf and placebo <sep> pentoxifylline <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",given the generally poor quality of the published studies and the large degree of heterogeneity in the interventions and the results the overall benefit of pentoxifylline for patients with fontaine class ii intermittent claudication remains uncertain. pentoxifylline is generally well tolerated. based on the totality of the available evidence it is possible that pentoxifylline could have a place in the treatment of ic as a means of improving walking distance and as a complimentary treatment assuming all other essential measures such as lifestyle change exercise and treatment for secondary prevention have been taken into account. however the response to pentoxifylline should be assessed on an individual basis.
343,"{'outcomes': ['complete recovery <sep> pain visual analogue scale and procedure time <sep> transcutaneous partial pressure of carbon dioxide <sep> mean arterial blood pressure <sep> patient satisfaction <sep>', 'patient satisfaction <sep> oxygen saturation and hemodynamics <sep> endoscopist satisfaction <sep> heart and respiratory rates blood pressure and oxygen saturation <sep> patient cooperation endoscopist satisfaction and level of sedation <sep>', 'pain scores <sep> sedation and pain scores <sep> success difficulty or duration of the colonoscopy <sep> recollection of pain <sep>', 'minor complications 1 hypotension and bradycardia 2 hypotension alone and 1 tachycardia <sep> oxygen desaturation develop <sep> 10-point visual analog scale <sep> overall mean satisfaction <sep> patient satisfaction procedure and recovery times neuropsychological function and complications <sep> depth of sedation <sep> tests reflective of learning memory working memory span and mental speed <sep> mean time to sedation <sep>', 'six minor complications <sep> overall satisfaction <sep> 10-cm visual analog scale <sep> full recovery sooner <sep> depth of sedation <sep> tests reflective of learning memory working memory span and mental speed <sep> mean time to sedation <sep> oxygen desaturation requiring mask ventilation and 4 episodes of hypotension <sep> patient satisfaction procedure and recovery times neuropsychologic function and complications <sep> episodes of hypotension 1 episode of bradycardia and 1 rash <sep> patient satisfaction <sep>', 'time to recover from sedation <sep> safety and efficacy <sep>', 'analgesia median pain score <sep> lighter sedation median sedation score <sep> systolic blood pressure <sep> pain and sedation score <sep> faster recovery time <sep>', 'recovery of cognitive and psychomotor functions <sep> efficacy safety and recovery characteristics <sep> recovery of cognitive function <sep> visual analogue scale <sep> early recovery <sep> pain <sep> hypoventilation <sep> digit symbol substitution test score <sep> dot test score <sep> arterial pressure and heart rate <sep>', ""observer's scale for sedation and alertness ossa score <sep> drugs cost for naps <sep> cardiopulmonary complication rates pain scores satisfaction scores and patients willingness to repeat colonoscopy <sep> safety and efficacy <sep>"", 'effective analgesia sedation amnesia patient comfort and stable recovery profile without respiratory depression <sep> pain and discomfort scores <sep> severe pain and discomfort <sep> respiratory rate and oxygen saturation values <sep> mean arterial pressure heart rate and end-tidal co2 <sep> discharge times <sep> hemodynamic and respiratory data pain discomfort and sedation scores patient and gastroenterologist satisfaction and recovery profiles <sep> duration of colonoscopy <sep> nausea and vomiting <sep> nausea and vomiting <sep>', 'synergistic sedation <sep>'], 'punchline_text': ['there were no differences between the groups with respect to pain visual analogue scale and procedure time. <sep>', 'although more sedated intraoperatively sedation score 4 vs. 2 p  0.03 for a single test of hypothesis correction for multiple testing of data removes this significance patients in the propofol pcs group were more alert by 30 minutes and discharged earlier mean and sd times were 43.3 12.1 min compared with 61.0 29.7 min p  0.001. <sep>', 'patients in the pcs group recovered significantly faster median 5 min vs 35 min p  0.0001 and left the department more quickly median 40 min vs 75 min p  0.0001). <sep>', 'at discharge the propofol group had better scores on tests reflective of learning memory working memory span and mental speed. <sep>', 'after recovery the propofol group scored better on tests reflective of learning memory working memory span and mental speed. <sep>', ""the endoscopist's evaluation of patient sedation and cardiorespiratory parameters were similar in both groups and in all age groups. <sep>"", 'pcs provided lighter sedation median sedation score 3 versus 4 p=0.0001 less analgesia median pain score 1 versus 0 p=0.004 a smaller maximum fall in systolic blood pressure 23 mmhg versus 33 mmhg p=0.02 and a faster recovery time median 10 min versus 40 min p=0.0001 irrespective of the dose administered compared with a diazemuls-pethidine combination. <sep>', 'early recovery was delayed in the propofol group p  0.002). <sep>', 'there were no significant differences in cardiopulmonary complication rates pain scores satisfaction scores and patients willingness to repeat colonoscopy with the same sedation. <sep>', 'pain and discomfort scores were better in group r than in group p. sedation levels were higher in group p than in group r. group p needed more supplemental doses than group r. the time to reach an aldrete score of nine or more was shorter in group r but discharge times were similar in the two groups. <sep>', 'all patients treated with the synergistic sedation were able to participate p=0.002 and performed better. <sep>'], 'population': ['one hundred fifty patients undergoing colonoscopy on an outpatient basis <sep>', '88 patients <sep>', 'sixty-seven patients undergoing colonoscopy <sep> patient-controlled sedation for colonoscopy <sep>', 'eighty outpatients asa class i or ii undergoing colonoscopy <sep> outpatient colonoscopy <sep>', 'one hundred outpatients undergoing colonoscopy <sep> outpatient colonoscopy <sep>', '120 consecutive patients undergoing <sep> conscious sedation in colonoscopy in a group of patients that included a sufficient number of elderly patients with several comorbidities <sep> colonoscopies <sep>', '66 patients undergoing colonoscopy <sep>', 'patients undergoing colonoscopy <sep> forty patients <sep>', 'between july 2005 and june 2006 88 patients <sep>', 'one hundred patients <sep>', '79 patients presenting for colonoscopies <sep> colonoscopies <sep> patients undergoing <sep>'], 'interventions': ['alfentanil without restriction <sep> propofol and alfentanil <sep> midazolam <sep> continuous infusion with 0.048 mg/kg propofol and 0.12 microg/kg alfentanil <sep> meperidine <sep> midazolam/meperidine <sep> intravenous premedication with 0.035 mg/kg midazolam <sep> propofol <sep> propofol/alfentanil <sep>', 'patient-controlled sedation pcs <sep> intravenous midazolam <sep> propofol with anesthetist-administered midazolam <sep> pcs with propofol <sep> propofol pcs <sep> propofol <sep> pcs <sep>', 'propofol and alfentanil <sep> propofol and alfentanil with physician-administered midazolam and pethidine <sep> midazolam <sep> diazepam and pethidine <sep> pethidine <sep> benzodiazepine <sep> sedation with either pcs <sep> propofol and alfentanil or a bolus of midazolam and pethidine <sep> midazolam and pethidine <sep> pcs <sep>', 'midazolam and meperidine <sep> propofol or midazolam plus meperidine <sep> midazolam/meperidine <sep> midazolam plus meperidine <sep> propofol <sep> propofol <sep>', 'propofol to midazolam plus fentanyl <sep> propofol vs. midazolam and fentanyl <sep> propofol or midazolam plus fentanyl administered by a registered nurse and supervised only by an endoscopist <sep> midazolam plus fentanyl <sep> midazolam and fentanyl <sep> midazolam/fentanyl <sep> propofol <sep> propofol <sep>', 'opioid pethidine <sep> colonoscopy <sep> midazolam <sep> midazolam combined with propofol <sep> pethidine <sep> midazolam and propofol <sep> midazolam and pethidine <sep> propofol <sep>', 'propofol and alfentanil <sep> patient-controlled sedation pcs <sep> narcotic/benzodiazepine <sep> pethidine <sep> intravenous diazemuls and pethidine <sep> alfentanil <sep> diazemuls 10-20 mg prior to colonoscopy or were connected to an infusion pump containing propofol <sep>', 'remifentanil <sep> remifentanil 0.5 microg kg(-1 followed by 0.2 microg kg(-1 <sep> propofol <sep> remifentanil or propofol <sep> propofol <sep> remifentanil <sep>', 'dps hong kong dollars hkd <sep> propofol-alfentanil sedation <sep> naps <sep> pca pumps with diazemuls-pethidine sedation dps <sep> nurse-administered propofol sedation naps and patient-controlled sedation using patient-controlled analgesia pca pumps <sep> pethidine <sep> opioid-benzodiazepine sedation <sep> propofol <sep> outpatient colonoscopy with sedation by either naps or dps <sep>', 'propofol <sep> remifentanil <sep>', 'additional nalbuphine <sep> benzodiazepines and long-acting opiates <sep> colonoscopy <sep> midazolam <sep> midazolam and propofol <sep> synergistic sedation <sep> propofol <sep> midazolam and repeated injections of propofol <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",propofol for sedation during colonoscopy for generally healthy individuals can lead to faster recovery and discharge times increased patient satisfaction without an increase in side-effects. for the comparison of propofol administration by anaesthesiologists to that by non-anesthesiologists we found insufficient high quality evidence. there is a need for better quality studies with double blind randomizations reporting of allocation concealment and more standardized reporting of outcomes.
344,"{'outcomes': ['pain <sep> pain relief <sep>', 'analgesia <sep> adverse effects <sep> pain relief <sep> adverse effects and/or inadequate relief <sep> nausea vomiting and drowsiness <sep>'], 'punchline_text': ['patients who received ibuprofen as supplementary medication also experienced less pain and had greater pain relief than those receiving dihydrocodeine as supplementary medication even when their post-operative treatment had been placebo. <sep>', 'dihydrocodeine 60 mg produced four times the number of patients affected by adverse effects compared with ibuprofen and dihydrocodeine 30 mg three times as many. <sep>'], 'population': ['for treating moderate to severe pain following the removal of unilateral impacted mandibular third molar teeth under local anaesthesia <sep> 148 patients to compare 400 mg <sep> relieving pain following wisdom teeth removal <sep>', '68 patients undergoing two-stage bilateral lower third molar removal <sep>'], 'interventions': ['placebo <sep> dihydrocodeine df118 <sep> dihydrocodeine <sep> ibuprofen <sep> ibuprofen and dihydrocodeine <sep> dihydrocodeine or placebo <sep> ibuprofen <sep> dihydrocodeine and placebo <sep> ibuprofen or dihydrocodeine <sep>', 'dihydrocodeine <sep> ibuprofen and dihydrocodeine <sep> dihydrocodeine <sep> ibuprofen and dihydrocodeine <sep> ibuprofen <sep> ibuprofen 400 mg and dihydrocodeine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",a single 30 mg dose of dihydrocodeine is not sufficient to provide adequate pain relief in postoperative pain. statistical superiority of ibuprofen 400 mg over dihydrocodeine 30 mg or 60 mg was shown. since the last version of this review no new relevant studies have been identified.
345,"{'outcomes': ['antiemetic medication <sep> nausea vomiting retching pain relief itching and adverse effects <sep> severity or incidence of pain or requests for analgesic or antipruritic medication <sep> nausea vomiting and retching <sep> frequency of retching or vomiting <sep> nausea and vomiting <sep> side effects <sep>', 'nausea and vomiting <sep> total incidence of nausea and vomiting <sep> frequent incidence of restlessness <sep>', 'nausea retching and vomiting intraoperatively <sep> blood pressure <sep> total ephedrine consumption <sep> nausea retching and vomiting <sep> nausea and vomiting <sep>', 'incidence of vomiting <sep> antiemetic efficacy <sep> vomiting prior to delivery <sep> hypotension after delivery <sep> nausea <sep> pulse rate or blood pressure <sep> nausea and vomiting <sep>', 'neurobehavioral exam results <sep> nausea and/or vomiting <sep> antiemetic efficacy and safety <sep> neonatal acid-base status and neurobehavioral exams <sep> nausea and vomiting <sep> efficacy and safety <sep>', 'intraoperative nausea and vomiting ionv <sep> incidence and severity of ionv <sep>', 'mean arterial pressure <sep> vasopressor <sep> haemodynamic response <sep> blood pressure heart rate and vasopressor requirements <sep> nausea and vomiting <sep> hypotension and vasopressor use <sep>', 'incidence rates for intraoperative nausea <sep> maternal characteristics <sep> emesis <sep> antiemetic effect <sep> intraoperative vomiting <sep> nausea and vomiting <sep> nausea and vomiting <sep>', 'intraoperative nausea <sep> retching or vomiting 1  vomiting or retching 0  no vomiting or retching <sep> cumulative nausea vomiting and pain scores <sep> intraoperative nausea and vomiting <sep> cumulative pain score <sep> incidence of vomiting and treatment for vomiting <sep> cumulative perioperative pain score <sep> nausea scores <sep> supplementary intraoperative analgesia <sep> perioperative nausea <sep> verbal pain score <sep>', 'nausea and vomiting <sep> nausea or vomiting <sep>', 'intraoperative nausea <sep> nausea <sep> nausea and vomiting <sep> intraoperative nausea and vomiting <sep> nausea and vomiting <sep>', 'incidence of vomiting <sep> incidence of nausea <sep> perioperative nausea and vomiting <sep> incidence of intra and postoperative nausea or vomiting <sep> postoperative nausea and vomiting <sep> nausea and vomiting <sep>', 'frequency and severity of postoperative 24-hour pruritus nausea and vomiting surgical pain and side effects <sep> frequency and the severity of nausea and vomiting <sep> pruritus nausea and vomiting <sep> frequency and severity of the nausea and vomiting episodes <sep> pruritus <sep> nausea and vomiting <sep> pain scores <sep> safety and efficacy <sep>', 'postoperative nausea and vomiting/retching <sep> nausea and vomiting <sep> postoperative nausea or vomiting <sep> incidence of intra or postoperative nausea or vomiting/retching <sep>', 'respiratory depression <sep> frequency of respiratory depression <sep> emetic symptoms <sep> sedation scores <sep> neonatal outcome <sep> frequency of nausea and vomiting sedative score respiratory depression and side effects <sep> respiratory depression respiratory rate <sep> frequency of intraoperative nausea and vomiting <sep> nausea and vomiting <sep> efficacy and safety <sep>', 'frequency of vomiting <sep> frequency of intraoperative nausea <sep> nausea than vomiting <sep> nausea <sep> maximum analog sedation score <sep> overall patient satisfaction <sep> frequency of intraoperative and postoperative vomiting <sep> frequency of nausea <sep> episodes and severity of nausea and vomiting rescue antiemetic requirement patient satisfaction and side effects <sep>', 'neonatal apgar scores <sep> ephedrine requirements <sep> frequency <sep> nausea <sep> severity of nausea <sep> severity of hypotension <sep> incidence and severity of nausea <sep>', 'total number of parturients with no vomiting and/or no antiemetic medication <sep> nausea and vomiting <sep> incidence of ponv and side effects <sep> total incidence of nausea and vomiting incidence of  4 vomiting episodes <sep>', 'antiemetic efficacy <sep> emesis free <sep> severe emetic symptoms <sep> incidence and severity of intraoperative emetic symptoms <sep> intraoperative antiemetic efficacy <sep> nausea and vomiting <sep> nausea free <sep>', 'incidence of vomiting <sep> severity of vomiting nor the incidence of nausea <sep> vomiting <sep> severity of nausea <sep> nausea and vomiting <sep> incidence of vomiting and the severity of nausea <sep>', 'severity of pruritus score <sep> nausea/vomiting score pain score sedation score or shivering score <sep> pruritus score <sep> pruritus <sep>', 'efficacy and tolerability <sep> nausea and vomiting <sep> nausea or vomiting <sep> nausea and vomiting <sep>', 'sedation scores <sep> nausea and vomiting sedative score pain score and side effects <sep> incidence of restlessness <sep> postoperative nausea and vomiting <sep> nausea and vomiting <sep>', 'nausea and vomiting <sep> intraoperative postdelivery nausea <sep> nausea <sep> intraoperative postdelivery vomiting <sep> postoperative vomiting <sep>', ""number of women who complained of nausea <sep> analgesia and nausea <sep> patient's perception of the control of nausea and their overall satisfaction <sep> patient satisfaction <sep>"", 'antiemetic effect <sep> nausea and vomiting <sep> nausea and vomiting <sep>', 'antiemetic efficacy <sep> severity of nausea and vomiting <sep> incidence of nausea <sep> maternal satisfaction <sep> severity of nausea and number of vomiting episodes <sep> postoperative nausea and vomiting <sep> nausea and vomiting <sep> overall satisfaction with postoperative care <sep>', 'overall rates for all emesis <sep> antiemetic efficacy <sep> nausea and vomiting <sep> emesis <sep>', 'pruritus nausea and vomiting <sep> nausea and vomiting <sep> incidence and severity of nausea and vomiting <sep> side effects <sep> incidence onset duration and severity of pruritus the onset and severity of pain and satisfaction <sep>', 'incidence of intraoperative/postoperative nausea <sep> complete response <sep> vomiting <sep> nausea scores number of vomiting episodes or patient satisfaction with postoperative nausea and vomiting management <sep> nausea and vomiting <sep> need for rescue antiemetics <sep>'], 'punchline_text': ['no differences were found between the groups in terms of severity or incidence of pain or requests for analgesic or antipruritic medication. <sep>', 'both dexamethasone and droperidol significantly decreased the total incidence of nausea and vomiting compared with saline with incidences of 18 21 and 51 for the three treatments respectively p<0.01 and p<0.05 respectively). <sep>', 'the incidence of nausea retching and vomiting was significantly higher in the control group compared to the propofol and midazolam groups. <sep>', 'no extrapyramidal symptoms or significant changes in pulse rate or blood pressure were associated with droperidol administration. <sep>', 'patients in the group receiving metoclopramide had a significantly lower incidence of nausea and vomiting both before and after delivery than the control group 14 versus 81 overall). <sep>', 'control variables were similar in the two groups. <sep>', 'patients in group o required significantly less vasopressor p=0.009 and had significantly lower incidences of nausea and vomiting p=0.049). <sep>', 'incidence rates for intraoperative nausea were 64 acupressure group and 71 control group p  0.416 with an incidence of intraoperative vomiting of 22 acupressure group and 27 control group p  0.506). <sep>', 'intraoperative nausea was decreased in the it fentanyl group compared with the iv ondansetron group the median interquartile range difference in nausea scores was 1 1 2 p  0.03. <sep>', 'the use of acupressure reduced the incidence of nausea or vomiting from 53 to 23 compared with placebo 95 confidence interval ci 0.34-0.25 p  0.002 during the operation and from 66 to 36 compared with placebo 95 ci 0.34-0.19 p  0.003 after the operation. <sep>', 'acupressure is an effective non-pharmacologic method to reduce intraoperative nausea during elective cesarean section in the awake patient. <sep>', 'the administration of supplemental oxygen from anesthetic induction until the end of the surgery did not reduce the incidence of intra and postoperative nausea or vomiting in women undergoing cesarean section under subarachnoid block. <sep>', 'prophylactic iv ondansetron 8 mg is safe and effective in reducing the frequency and the severity of nausea and vomiting but not pruritus following cesarean delivery with intrathecal sufentanil-morphine. <sep>', 'there was no significant difference overall between the two groups in the incidence of intra or postoperative nausea or vomiting/retching. <sep>', 'neonatal outcome was similar in the two groups and all the neonates had apgar scores  or  8 at one and five minutes. <sep>', 'maximum analog sedation score was higher in group m compared to groups o and p p  0.05). <sep>', 'patients in the group pretreated with glycopyrrolate reported a reduction in the frequency p  0.02 and severity p  0.03 of nausea. <sep>', 'parturients who received dexamethasone either 10 mg or 5 mg were different from those who received saline alone in the following parameters the total incidence of nausea and vomiting incidence of  4 vomiting episodes number the of parturients requiring rescue antiemetics and the total number of parturients with no vomiting and/or no antiemetic medication p  0.05 to p  0.01). <sep>', 'this study showed a significantly lower incidence of nausea and vomiting and a tendency toward less severe emetic symptoms in the ondansetron and the droperidol groups than in the placebo group but the ondansetron group was not statistically different from the droperidol group. <sep>', 'the incidence of vomiting was lower following ondansetron 36 compared with the control group 58 p  0.028). <sep>', 'there were no differences among groups in nausea/vomiting score pain score sedation score or shivering score at 4 8 and 24 h after surgery. <sep>', 'ondansetron was effective in reducing the incidence of nausea and vomiting in patients receiving intrathecal morphine for caesarean section. <sep>', 'the incidence of nausea and vomiting within 6 h postoperatively was lower and incidence of no nausea and vomiting for 24 h postoperatively was significantly higher for the combination group compared to the placebo group and the dexamethasone only group. <sep>', 'twelve women 30 in the metoclopramide group versus eight 20 in the droperidol group had intraoperative postdelivery nausea p  ns). <sep>', ""however there was no statistically significant difference between the two groups in the patient's perception of the control of nausea and their overall satisfaction. <sep>"", 'the incidence of nausea and vomiting was significantly decreased from 43 and 27 in the control group to 3 and 0 in the acupressure group respectively p  0.05). <sep>', 'reduces the incidence of nausea compared with dexamethasone 8 mg i.v. <sep>', 'the greatest reduction in emesis in the scopolamine group when compared with placebo was in the 6-24 h time period. <sep>', 'droperidol reduced nausea and vomiting but did not prevent itching and that epidural droperidol failed to prevent all side effects. <sep>', 'there was also no difference between the two groups in nausea scores number of vomiting episodes or patient satisfaction with postoperative nausea and vomiting management. <sep>'], 'population': ['healthy patients undergoing elective cesarean section and receiving epidural morphine for postoperative analgesia <sep> patients who have delivered by cesarean section and received <sep> 203 patients had either <sep> patients receiving epidural morphine <sep>', '120 parturients n=40 in each group receiving <sep> post-caesarean section analgesia <sep>', '90 parturients with asa physical status i and ii between the ages of 20 and 38 years undergoing spinal anesthesia for elective cesarean delivery <sep> spinal anesthesia for cesarean section <sep> peripartum nausea and vomiting during regional anesthesia for elective cesarean section in order to prevent emesis in at least 50 of patients <sep> anesthesiology department hacettepe university turkey hospitalized care <sep> parturients undergoing cesarean section under spinal anesthesia <sep> x kg(-1 <sep>', 'during epidural anesthesia for cesarean section <sep> term parturients undergoing non-urgent cesarean section with epidural anesthesia without producing unwanted side-effects <sep> 128 term parturients undergoing elective and non-urgent cesarean section with epidural anesthesia <sep>', '42 asa physical status i-ii parturients at term <sep> elective cesarean delivery during spinal anesthesia <sep>', 'cesarean section <sep> 60 women asa i-ii receiving <sep> 31 women and the propofol group 29 of whom 3 were excluded <sep>', 'fifty-two parturients scheduled for elective caesarean section <sep> parturients undergoing elective caesarean section <sep> parturients undergoing caesarean section <sep>', '110 parturients scheduled for elective cesarean delivery were enrolled in the study <sep> parturients during spinal anesthesia for cesarean delivery <sep>', 'during cesarean delivery with spinal anesthesia <sep> during cesarean deliveries performed with spinal anesthesia <sep> thirty healthy parturients presenting for elective cesarean delivery with standardized bupivacaine spinal anesthesia <sep>', 'during and after spinal anaesthesia for caesarean section <sep> ninety-four patients scheduled for caesarean section were included <sep>', 'seventy-five patients <sep> spinal anesthesia for cesarean section <sep> during elective cesarean section under spinal anesthesia <sep>', '94 parturients undergoing surgical delivery <sep> patients under general anesthesia <sep> women undergoing cesarean section under subarachnoid block <sep> cesarean sections under subarachnoid block <sep>', '100 nonbreastfeeding women undergoing elective cesarean delivery with <sep>', 'after caesarean section under spinal anaesthesia with added <sep> after caesarean section <sep>', 'parturients patients undergoing caesarean section under spinal anaesthesia <sep> caesarean section under spinal anaesthesia with <sep> 80 women undergoing elective caesarean section under spinal anaesthesia using 0.5 bupivacaine 10 mg <sep> caesarean delivery under spinal anaesthesia <sep> parturient patients undergoing caesarean section <sep>', 'cesarean section patients given <sep> cesarean section patients given epidural anesthesia <sep> nonemergent cesarean section patients given epidural anesthesia intraoperatively and for the first 24-hour period after delivery <sep> inpatient obstetric unit at a university hospital center <sep> 164 nonemergent cesarean section patients given epidural anesthesia <sep>', 'fifty women <sep>', 'for post-cesarean analgesia <sep> one hundred and eighty parturients n=45 in each of four groups requiring <sep> post-cesarean analgesia <sep>', 'cesarean section patients or in patients under epidural anesthesia for abdominal surgery <sep> forty-eight asa physical status i-ii parturients requiring nonemergent cesarean section gave their consent <sep> cesarean section patients under epidural anesthesia <sep>', 'elective caesarean section under spinal anaesthesia <sep> during caesarean section under spinal anaesthesia <sep>', 'two-hundred-forty parturients <sep> intrathecal morphine-induced pruritus after cesarean delivery <sep>', 'patients receiving intrathecal morphine for caesarean section <sep> patients receiving <sep> 120 women undergoing caesarean section under spinal anaesthesia with <sep>', 'cesarean section <sep> 120 women undergoing elective cesarean section under spinal anesthesia using 0.5 <sep>', 'epidural anesthesia for cesarean section <sep> during and after elective cesarean section with epidural anesthesia <sep>', 'eighty-one consenting women undergoing elective caesarean section under spinal anaesthesia <sep> women using pca after caesarean section <sep>', 'for post-cesarean section pain relief <sep> post-cesarean section pain relief <sep> parturients given epidural morphine for post-cesarean section pain relief <sep> sixty parturients receiving <sep>', 'ninety-nine women undergoing elective caesarean section under spinal anaesthesia <sep> caesarean section <sep>', 'two-hundred forty women undergoing cesarean delivery under spinal anesthesia <sep> parturients receiving intrathecal morphine while undergoing cesarean delivery <sep> after cesarean delivery <sep>', '97 such women <sep> after cesarean section <sep> 97 pregnant women undergoing cesarean section <sep> women who have undergone cesarean section <sep>', 'during and after cesarean delivery under spinal anesthesia <sep> 94 patients undergoing cesarean delivery with spinal anesthesia to receive <sep>'], 'interventions': [""placebo <sep> morphine sulphate <sep> lactated ringer's solution iv and given 2.0 lidocaine with 1:200,000 epinephrine <sep> transdermal scopolamine <sep> epidural morphine <sep> tds <sep> transdermal scopolamine tds <sep>"", 'droperidol and saline <sep> placebo <sep> dexamethasone <sep> dexamethasone and droperidol <sep> droperidol <sep> epidural morphine <sep> dexamethasone <sep> droperidol 1.25 mg and saline <sep>', 'placebo saline <sep> placebo <sep> subhypnotic doses of propofol and midazolam <sep> midazolam <sep> subhypnotic <sep> bupivacaine hydrochloride <sep> fentanyl <sep> midazolam and propofol <sep> propofol <sep>', 'droperidol <sep> droperidol or normal saline <sep> droperidol <sep>', 'prophylactic metoclopramide <sep> metoclopramide <sep> 10-mg intravenous metoclopramide <sep> metoclopramide <sep>', 'intradural anesthesia for elective or deferred emergency cesarean delivery <sep> propofol <sep> equal volume of intralipid <sep>', 'ondansetron <sep> placebo <sep> spinal anaesthesia group o <sep> ondansetron <sep> normal saline <sep> intravenous ondansetron <sep>', 'acupressure bands or placebo <sep> p6 neiguan acupoint <sep> p6 acupressure <sep>', 'ondansetron <sep> intrathecal fentanyl <sep> 20 microg it fentanyl group f or 4 mg iv ondansetron <sep> intrathecal it fentanyl with iv ondansetron <sep>', 'acupressure vs placebo <sep> placebo <sep> acupressure <sep> acupressure <sep>', 'placebo <sep> metoclopramide <sep> acupressure <sep> acupressure and intravenous iv metoclopramide <sep> acupressure bands  2 mliv saline <sep> acupressure or metoclopramide <sep> placebo wrist bands  2 ml iv saline <sep> metoclopramide <sep> placebo wrist bands  10 mg iv metoclopramide <sep>', 'supplemental oxygen <sep> 4 l.min-1 of oxygen group o or medical air group s under nasal cannula throughout the procedure <sep> standardized subarachnoid block <sep>', 'prophylactic ondansetron <sep> placebo <sep> intrathecal sufentanil-morphine <sep> sufentanil-morphine-bupivacaine anesthesia <sep> ondansetron <sep> prophylactic iv ondansetron <sep>', 'intrathecal morphine <sep> acupressure or placebo <sep> acupressure <sep> acupressure <sep>', 'midazolam <sep> midazolam 2 mg or metoclopramide <sep> midazolam or metoclopramide <sep> metoclopramide <sep> midazolam and metoclopramide <sep>', 'prophylactic ondansetron <sep> placebo <sep> prophylactic metoclopramide ondansetron and placebo <sep> ondansetron <sep> epidural anesthesia prophylactic ondansetron <sep> metoclopramide group m or 10 ml normal saline <sep> metoclopramide <sep>', 'ephedrine and fluids <sep> glycopyrrolate 200 micrograms or saline placebo <sep> glycopyrrolate <sep> glycopyrrolate <sep> spinal anaesthesia with 2.5 ml of 0.5 isobaric bupivacaine <sep>', 'placebo <sep> dexamethasone <sep> milligrams epidural morphine <sep> saline i.v <sep> saline alone <sep> epidural morphine <sep> dexamethasone <sep>', 'placebo <sep> droperidol <sep> placebo-controlled protocol <sep> ondansetron <sep> droperidol or saline <sep> ondansetron and droperidol <sep> prophylactic ondansetron <sep>', 'umbilical-cord clamping ondansetron 4 mg or 0.9 saline <sep> ondansetron <sep> ondansetron <sep> placebo <sep>', 'placebo <sep> iv 4 mg of nalbuphine 4 mg of ondansetron 8 mg of ondansetron and 4 ml of normal saline <sep> nalbuphine and ondansetron <sep> nalbuphine versus ondansetron <sep> nalbuphine and ondansetron <sep>', 'intrathecal morphine <sep> ondansetron <sep> placebo <sep> intrathecal morphine 0.1 mg received intravenous ondansetron <sep> droperidol 1.25 mg n  40 or saline <sep> droperidol <sep> ondansetron <sep>', 'intrathecal morphine <sep> intrathecal morphine <sep> bupivacaine and morphine <sep> dexamethasone and droperidol <sep> dexamethasone <sep> placebo <sep> droperidol <sep> dexamethasone droperidol <sep> dexamethasone 8 mg droperidol 1.25 mg dexamethasone 4 mg and droperidol 0.625 mg or placebo <sep> bupivacaine 10 mg and morphine <sep>', 'low-dose droperidol <sep> droperidol <sep> metoclopramide <sep> fentanyl <sep> metoclopramide hydrochloride <sep> metoclopramide <sep>', 'prophylactic ondansetron <sep> ondansetron <sep> morphine via pca syringe <sep> morphine solution in the pca syringe <sep>', 'acupressure bands or placebo bands on the p-6 acupoint bilaterally before the administration of spinal anesthesia <sep> p-6 acupressure <sep> epidural morphine <sep> p-6 neiguan acupoint <sep>', 'hyperbaric bupivacaine <sep> placebo <sep> dexamethasone <sep> cyclizine dexamethasone and placebo <sep> cyclizine 50 mg dexamethasone 8 mg or placebo <sep> low-dose intrathecal spinal morphine <sep> spinal morphine <sep> cyclizine <sep> cyclizine dexamethasone and placebo <sep> dexamethasone and placebo <sep> fentanyl 10 micro g and spinal morphine 0.2 mg <sep>', 'intrathecal morphine <sep> transdermal scopolamine 1.5 mg ondansetron 4 mg or placebo <sep> placebo <sep> transdermal scopolamine iv ondansetron and placebo <sep> scopolamine <sep> ondansetron <sep> transdermal scopolamine <sep> scopolamine <sep>', 'epidural morphine <sep> droperidol <sep> standard continuous epidural anesthesia <sep> droperidol <sep> epidural or i.v <sep> epidural morphine with either no droperidol injection 2.5 mg of epidural droperidol <sep> epidural morphine <sep>', 'transcutaneous acupoint electrical stimulation with the reliefband <sep> transcutaneous acupoint electrical stimulation using the reliefband at the p6 point active group or an active reliefband applied to the dorsum of the wrist sham control group <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",this review indicates that many different interventions have efficacy in preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section. there is little evidence that combinations of treatment are better than single agents.
346,"{'outcomes': ['ulcer area <sep> maceration <sep> adverse events <sep> odour maceration absorption capacity and leakage <sep> ulcer area and healing <sep>', 'mean wear time <sep> exudate level <sep> wound area <sep> delayed healing ulcers <sep>', 'clinical infection <sep> lymphangitis and/or fever <sep> wound severity score <sep> closure rate <sep> poor dressing acceptability <sep> total masepsis score <sep> and/or tolerability <sep>'], 'punchline_text': ['after 1 and 4 weeks odour was present in significantly less of the ulcers in the contreet foam group 17 and 19 respectively compared with the allevyn hydrocellular group 47 and 39 respectively and at the final visit there were significantly fewer leakages in the contreet foam group 19 compared with the allevyn hydrocellular group 49%). <sep>', 'wound area was reduced by 50 with the silver foam and 34 with lbp less slough and maceration a faster reduction in exudate level and more positive wound progress was achieved with the silver foam. <sep>', 'according to the investigators fewer wounds developed a clinical infection over the four-week follow-up in the test group 33 versus 46 p  0.223). <sep>'], 'population': ['critically colonised venous leg ulcers with delayed healing <sep> critically colonised chronic venous leg ulcers <sep> critically colonised venous leg ulcers <sep> one hundred and twenty-nine patients were included contreet foam <sep> critically colonised chronic wounds <sep>', 'ulcers with delayed healing <sep> 619 patients with ulcers of varying aetiologies <sep>', 'colonised chronic wounds <sep> fifty-one and 48 patients were randomised in the test and control groups respectively 28 pressure ulcers and 71 venous leg ulcers <sep> chronic wounds with signs of local infection <sep> thirteen centres recruited 99 patients with either a venous leg ulcer or a pressure ulcer <sep>'], 'interventions': ['traditional moist foam wound healing dressing <sep> sustained silver-releasing dressings <sep> sustained silver-release foam dressing contreet foam with a foam dressing allevyn hydrocellular without added silver <sep>', 'sustained silver-releasing dressing <sep> silver foam dressing or lbp <sep> sustained silver-releasing foam dressing contreet foam coloplasta/s with local best practice lbp <sep>', 'silver-releasing hydroalginate dressing silvercel the test group or a pure calcium alginate dressing algosteril the control group <sep> silver-releasing hydroalginate dressing <sep> silver-releasing dressings <sep> systemic antibiotics <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>']}",only three trials with a short follow-up duration were found. there is insufficient evidence to recommend the use of silver-containing dressings or topical agents for treatment of infected or contaminated chronic wounds.
347,"{'outcomes': ['symptom relief <sep> circumference measurements <sep> wellbeing score <sep>', 'number of patients subjectively improving <sep> leg circumference <sep>', 'volume losses <sep> volume losses <sep> mean volume losses <sep>'], 'punchline_text': ['a perceived wellbeing score revealed the lymphatic technique group p<0.0001 significantly increased their wellbeing the most followed closely by relaxing techniques p<0.001 and then the control rest group p<0.03). <sep>', 'the number of patients subjectively improving in the active drug group was significantly greater than in the placebo group patients receiving hr also showed a small but significant decrease in leg circumference. <sep>', 'analysis of covariance revealed significant mean volume losses for both experimental and control groups with ponderal index the only significant covariate. <sep>'], 'population': ['healthy pregnant women with foot oedema <sep> late pregnancy <sep> fifty-five women in the third trimester <sep>', '69 patients <sep>', 'healthy pregnant women with dependent leg edema <sep> control women n  18 <sep> thirty-five healthy pregnant women with severe pedal edema <sep>'], 'interventions': ['relaxing reflexology techniques or a specific lymphatic reflexology technique for 15 min with pre and post-therapy ankle and foot circumference measurements and participant questionnaire <sep>', 'o-(beta-hydroxyethyl rutoside hr <sep> placebo <sep> o-(beta-hydroxyethyl)rutoside <sep>', 'external pneumatic intermittent compression epic <sep> epic <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",rutosides appear to help relieve the symptoms of varicose veins in late pregnancy. however this finding is based on one small study 69 women and there are not enough data presented in the study to assess its safety in pregnancy. it therefore cannot be routinely recommended. reflexology appears to help improve symptoms for women with leg oedema but again this is based on one small study 43 women). external compression stockings do not appear to have any advantages in reducing oedema.
348,"{'outcomes': ['fetal tachycardia and repetitive late decelerations <sep>'], 'punchline_text': ['when misoprostol is used in women with previous cesareans there is a high frequency of disruption of prior uterine incisions. <sep>'], 'population': ['women with previous cesarean delivery <sep> suspected uterine rupture <sep> women with previous cesareans <sep> women with prior cesareans <sep>'], 'interventions': ['misoprostol <sep> misoprostol to oxytocin <sep>'], 'punchline_effect': [' sig increase <sep>']}",there is insufficient information available from randomised controlled trials on which to base clinical decisions regarding the optimal method of induction of labour in women with a prior caesarean birth.
349,"{'outcomes': ['maternal side effects <sep> suppression of preterm labor <sep> neonatal deaths <sep> neonatal outcome <sep> efficacy and safety <sep>', 'efficacy and maternal fetal and neonatal outcome <sep> fetal and neonatal outcome <sep> maternal side effects <sep>', 'recurrent labor <sep> efficacy and safety <sep> number of entry variables including cervical examination contraction frequency and gestational age <sep> side effects <sep> efficacy and safety <sep>', 'number of neonates admitted into intensive care nor the premature infant center <sep> percentage of deliveries <sep> maternal pulse rate <sep> headaches and with salbutamol tremors and palpitations <sep> systolic and diastolic blood pressure <sep> apgar scores <sep> mean term of delivery <sep>', 'maternal and fetal complications <sep>', 'neonatal complications <sep> success rate <sep>', 'severe maternal side effects <sep> apgar scores and umbilical artery and vein phs <sep> number of admissions to the neonatal intensive care unit nicu <sep> delay of delivery <sep> maternal side effects <sep>', 'fetal vascular blood flow <sep> delay of delivery <sep> maternal side-effects <sep> tocolytic efficacy and maternal tolerance <sep>', 'maternal side effects <sep> mean arterial and diastolic blood pressure <sep> maternal side effects and haemodynamic changes <sep> maternal heart rate <sep> prolongation of pregnancy <sep>', 'maternal demographic characteristics <sep> birth weight estimated gestational age at delivery or neonatal complications <sep> adverse medication effects and recurrent preterm labor <sep> adverse side effects mainly nausea and vomiting <sep> time to uterine quiescence <sep> recurrence of preterm labor necessitating further tocolytic attempts <sep> time to uterine quiescence time gained in utero recurrence of preterm labor failure of tocolysis and pertinent maternal and neonatal outcomes <sep> efficacy and safety <sep>'], 'punchline_text': ['maternal side effects were significantly less common in the nifedipine group than in the ritodrine group however after 7 days of therapy there was no difference between the two groups. <sep>', 'maternal side effects were more common and more serious in the group of patients who received ritodrine compared with those who received nifedipine 18 of 38 versus 5 of 38 p less than 0.01 however fetal and neonatal outcome appeared to be similar when the groups were compared. <sep>', 'both groups were comparable in terms of a number of entry variables including cervical examination contraction frequency and gestational age. <sep>', 'there was no statistically significant difference in the number of neonates admitted into intensive care nor the premature infant center between the two groups. <sep>', 'ritodrine and nifedipine proved to be equally effective in the suppression of preterm labor. <sep>', 'the success rate was similar in both groups 72 for the ritodrine group and 63.33 for the nifedipine group. <sep>', 'more women in the ritodrine group delivered within 24 hours 22 versus 11 p  .006 within 48 hours 29 versus 21 p  .03 within 1 week 45 versus 36 p  .009 and within 2 weeks 52 versus 43 p  .005 compared with those receiving nifedipine. <sep>', 'no significant differences were found in the delay of delivery but significantly fewer maternal side-effects were found in the nifedipine group. <sep>', 'maternal side effects were significantly less common in the nifedipine group 27 than in the ritodrine group 77 p  0.001). <sep>', 'the patients in the magnesium sulfate group had more adverse side effects mainly nausea and vomiting p .004). <sep>'], 'population': ['fifty-five women <sep> 102 pregnant women with gestational ages under 34 weeks including 24 with twin pregnancies and 45 on betasympathicomimetic drugs who had regular uterine contractions with either observed cervical changes or preterm rupture of membranes <sep> after stratification women <sep>', '66 patients <sep>', 'preterm labor <sep> 100 patients 80 were considered eligible of whom 39 were randomized to the <sep> singleton pregnancies at  34 weeks in preterm labor <sep>', 'ninety patients admitted to the saint-antoine hospital paris france for premature labor <sep> patients presenting premature labor in order to propose <sep> and 3019 <sep> premature labor <sep> 45 patients <sep>', 'preterm labor <sep> 42 women <sep> preterm labor with beta-sympathomimetics <sep>', '62 patients after random selection <sep> threatened premature labor <sep>', 'preterm labor <sep> one hundred eighty-five singleton pregnancies with preterm labor <sep>', ""52 singleton pregnancies with preterm labor between 26 and 34 week's gestation <sep> threatened preterm labor <sep>"", 'seventy-one women including 11 with twin pregnancies who had uterine contractions and observed cervical changes <sep>', 'preterm labor <sep> preterm labor with those of parenteral magnesium sulfate <sep> patients between 24 and 34 weeks gestation with documented preterm labor <sep>'], 'interventions': ['nifedipine and ritodrine <sep> nifedipine <sep> ritodrine intravenously or nifedipine orally <sep> ritodrine <sep> nifedipine <sep>', 'nifedipine or ritodrine <sep> ritodrine <sep> nifedipine <sep> nifedipine <sep>', 'magnesium sulfate <sep> oral terbutaline <sep> nifedipine <sep> oral nifedipine <sep> oral nifedipine or intravenous magnesium sulfate <sep> nifedipine versus magnesium sulfate <sep> nifedipine <sep> nifedipine versus terbutaline <sep> oral nifedipine <sep>', 'nicardipine and salbutamol <sep> nicardipine <sep> nicardipine <sep> salbutamol <sep>', 'ritodrine and nifedipine <sep> nifedipine and ritodrine <sep> nifedipine to ritodrine <sep> nifedipine <sep> ritodrine <sep> nifedipine <sep>', 'nifedipine versus ritodrine <sep> calcium inhibitor nifedipine <sep> nifedipine <sep> ritodrine <sep>', 'nifedipine and ritodrine <sep> nifedipine with ritodrine <sep> nifedipine <sep> ritodrine <sep> ritodrine <sep> nifedipine <sep>', 'nifedipine vs. ritodrine <sep> nifedipine with ritodrine <sep> nifedipine <sep> nifedipine <sep>', 'nifedipine and ritodrine <sep> ritodrine <sep> nifedipine <sep> nifedipine <sep>', 'oral nicardipine <sep> magnesium sulfate <sep> oral nicardipine <sep> parenteral magnesium sulfate <sep> tocolytic therapy <sep> intravenous magnesium sulfate <sep> nicardipine <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>']}",when tocolysis is indicated for women in preterm labour calcium channel blockers are preferable to other tocolytic agents compared mainly betamimetics. further research should address the effects of different dosage regimens and formulations of calcium channel blockers on maternal and neonatal outcomes. note the 39 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
350,"{'outcomes': ['overall incidence of intraventricular hemorrhage <sep> incidence of ventricular dilatation <sep> neurodevelopmental handicaps <sep>', 'motor activity and intraventricular hemorrhage <sep> incidence of intraventricular hemorrhage ivh <sep>', 'intraventricular hemorrhage <sep> hemorrhage <sep> hemorrhages <sep>', 'brain hemorrhage <sep> ivh/pvh percentage <sep>'], 'punchline_text': ['the overall incidence of intraventricular hemorrhage was 32 in treated and 46 in control infants a nonsignificant difference. <sep>', 'although phenobarbital significantly suppressed movement it was associated with an increased incidence of intraventricular hemorrhage ivh). <sep>', 'the results of this study indicate no effect of phenobarbital on the incidence of subependymal-intraventricular hemorrhage but a possible beneficial effect on the severity of hemorrhage. <sep>', 'we found that ivh/pvh percentage is lowest in newborns from group iii followed by newborns from group ii and group i. <sep>'], 'population': ['preterm infants weighing 1500 g or less at birth <sep> very low birth weight infants <sep>', 'preterm infants with respiratory disease weighing less than 1500 grams <sep> 19 low birthweight premature infants with respiratory disease <sep>', 'forty-two premature infants less than 24 hours of age with normal admission echoencephalograms <sep> high-risk infants <sep>', '130 premature infants of less than 32 weeks gestation with a very low birth weight vlbw and extremely low birth weight elbw <sep> infants with low and extremely low birth weight and infants treated with surfactants <sep> prematurely born infants with intraventricular haemorrhage ivh <sep>'], 'interventions': ['early high-dose phenobarbital treatment <sep>', 'phenobarbital <sep> prophylactic phenobarbital <sep>', 'phenobarbital <sep> control or phenobarbital <sep> prophylactic phenobarbital <sep>', 'indocid and phenobarbital surfactant <sep> indocid <sep> indocid and phenobarbital <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",postnatal administration of phenobarbital cannot be recommended as prophylaxis to prevent ivh in preterm infants and is associated with an increased need for mechanical ventilation.
351,"{'outcomes': [""weight length and other anthropometric indicators <sep> morbidity growth and micronutrient status <sep> plasma zinc and other indicators of micronutrient status <sep> children's morbidity and physical growth <sep> supplement consumption <sep> change in plasma zinc <sep> vomiting <sep> morbidity <sep> morbidity information <sep> fever and cough <sep> episodes of diarrhea dysentery and respiratory illness <sep> childhood morbidity <sep> prevalence of cough <sep>"", 'diarrheal morbidity <sep> development assessed by use of the griffiths mental development scales length and weight <sep> weekly morbidity histories <sep> developmental quotient hearing and speech and performance <sep>', 'diarrhea incidence <sep> plasma zinc concentration morbidity and growth of young children <sep> adverse effects <sep> incidence of diarrhea <sep> markers of copper or iron status <sep> indicators of copper or iron status <sep> plasma zinc concentration <sep> plasma zinc concentrations <sep>', 'incidence of infections and hospital admissions <sep> number of hospitalizations and decreased number of vaso-occlusive pain crisis <sep> lymphocyte and granulocyte zinc <sep> zinc deficiency affects adversely t-helper1 th1 functions and cell mediated immunity and interleukin il)-2 production <sep> bacteriologically positive infections <sep> interleukin-2 production <sep>', 'plasma hiv-1 viral load and the percentage of cd4 t lymphocytes <sep> get watery diarrhoea <sep> safety and efficacy <sep> mean percentage of cd4 t lymphocytes and median haemoglobin concentrations <sep> watery diarrhoea <sep> diarrhoea and pneumonia morbidity <sep> diarrhoea and pneumonia <sep> plasma hiv-1 viral load <sep> mean log(10 hiv-1 viral load <sep>', 'severity of malaria episodes prevalence of malaria parasite mean parasite densities mean packed cell volume prevalence of other morbidity and all cause mortality <sep> all cause mortality <sep> incidence of symptomatic falciparum malaria <sep> falciparum malaria <sep> mean temperature and mean parasite densities during malaria episodes nor in malaria parasite rates mean parasite densities and mean packed cell volume <sep> diarrhoea <sep> mean number of malaria episodes <sep>', 'growth and indexes of body composition and gross motor development <sep> growth morbidity and motor development <sep> growth morbidity or motor development <sep> growth development or risk of infection <sep> morbidity data <sep> baseline characteristics attained weight or length at 10 mo growth velocity gross motor development and morbidity <sep>', 'energy intake <sep> delayed hypersensitivity skin reactions enhanced lymphoproliferative response to pha and increased salivary iga concentrations <sep> immunocompetence growth and zinc copper and iron status <sep> linear growth gain <sep>', 'pneumonia-related deaths <sep> pneumonia and mortality <sep> incidence of diarrhoea <sep> growth final serum copper and final haemoglobin <sep> incidence of pneumonia and diarrhoea <sep> rates of other respiratory tract infections <sep> serum copper and haemoglobin concentrations <sep> rate of pneumonia and diarrhoea <sep> small gain in height <sep> incidents of pneumonia <sep> clinical pneumonia and diarrhoea <sep>', 'mean plasma zinc concentration <sep> acute lower respiratory tract infection <sep> incidence of pneumonia <sep>', 'growth psychomotor development and incidence of infectious disease <sep> morbidity <sep> weight-for-age z score <sep> bsid psychomotor development index <sep> growth and psychomotor development <sep> anthropometric indexes developmental indexes bayley scales of infant development bsid and morbidity <sep> knee-heel length <sep> iron and zinc for weight-for-age z score knee-heel length and bsid psychomotor development <sep>'], 'punchline_text': ['the zn group had fewer episodes of diarrhea dysentery and respiratory illness and a lower prevalence of fever and cough than did the zn+vm group and a lower prevalence of cough than did the placebo group p  0.05). <sep>', 'zinc benefited the developmental quotient only in children who received stimulation and benefits from zinc to hand and eye coordination were greater in stimulated children. <sep>', 'the change in plasma zinc concentration from baseline was positively related to the zinc dose p  0.001). <sep>', 'prolonged zinc supplementation resulted in an increase in lymphocyte and granulocyte zinc p  0.0001 and an increase in interleukin-2 production p  0.0001 decreased incidence of documented bacteriologically positive infections p  0.0026 decreased number of hospitalizations and decreased number of vaso-occlusive pain crisis p  0.0001). <sep>', 'the mean percentage of cd4 t lymphocytes and median haemoglobin concentrations were also similar between the two groups after zinc supplementation. <sep>', 'zinc supplementation was significantly associated with a reduced prevalence of diarrhoea 0.87 0.79 to 0.95). <sep>', 'the baseline characteristics attained weight or length at 10 mo growth velocity gross motor development and morbidity did not differ significantly between groups even after control for potentially confounding variables. <sep>', 'although energy intake was similar in both groups the zinc-supplemented infants had significantly higher linear growth gain and their immune function improved as demonstrated by conversion of their delayed hypersensitivity skin reactions enhanced lymphoproliferative response to pha and increased salivary iga concentrations. <sep>', 'there were no pneumonia-related deaths in the zinc group but ten in the placebo group p=0.013). <sep>', 'zinc supplementation resulted in a lower incidence of pneumonia than placebo absolute risk reduction 2.5 95 confidence interval 0.4 to 4.6%). <sep>', 'weight-for-age z score was higher in the zn group than in the placebo and fe+zn groups knee-heel length was higher in the zn and fe groups than in the placebo group and the bsid psychomotor development index was higher in the fe group than in the placebo group. <sep>'], 'population': ['young peruvian children <sep> two hundred forty-six children aged 6-35 mo with persistent diarrhea <sep>', 'undernourished children <sep> undernourished jamaican children <sep> undernourished children <sep> subjects were 114 children aged 9-30 mo and below 1.5 z scores of the national center for health statistics weight-for-age references who were recruited from 18 health clinics <sep>', 'young children <sep> young ecuadorian children at risk of zinc deficiency <sep> young children in high-risk populations <sep> 631 ecuadorian children who were 12-30 mo old at baseline and who had initial length-for-age z scores 1.3 <sep>', 'patients with scd <sep> sickle cell disease scd <sep> 32 scd subjects <sep> adult sickle-cell disease scd patients <sep>', ""at grey's hospital in pietermaritzburg south africa <sep> children with hiv-1 infection <sep> hiv-1-infected children <sep> 96 children with hiv-1 infection <sep> children with hiv-1 infection in south africa <sep>"", 'west african children <sep> young children living in an area holoendemic for malaria in west africa <sep> children in rural west africa <sep> 709 children were enrolled 685 completed the trial <sep> 18 villages in rural northwestern burkina faso <sep>', 'healthy term breastfed infants <sep> eighty-five infants were enrolled and 70 completed the study <sep> breastfed infants aged 4-10 mo <sep>', 'severely malnourished infants <sep> malnourished infants <sep> 19 infants fed a <sep> marasmic infants during nutritional rehabilitation <sep>', 'young children <sep> 103 children in the treatment group and 44 in the control group withdrew <sep> children younger than 2 years <sep> 34 children <sep> children younger than 5 years <sep> 809 children were assigned zinc and 812 <sep> children younger than 2 years in an urban low-income population in bangladesh <sep> 1665 poor urban children aged 60 days to 12 months <sep>', 'urban slum <sep> children aged 6 months to 3 years <sep> children on the incidence of acute lower respiratory tract infections and pneumonia <sep> 2482 children aged 6 to 30 months <sep>', 'indonesian infants <sep> indonesian infants n  680 <sep>'], 'interventions': ['placebo <sep> daily supplement of 10 mg zn alone zn n  81 zinc plus vitamins and other minerals at 1-2 times recommended daily intakes zn+vm n  82 or placebo <sep> zn+vm <sep> zinc supplementation <sep> daily supplementation with zinc or multiple micronutrients <sep> zinc supplements <sep>', 'placebo <sep> stimulation alone zinc supplementation alone both interventions and control routine care only <sep> zinc or placebo <sep> zinc supplementation <sep> zinc supplementation and psychosocial stimulation <sep> zinc supplementation and psychosocial stimulation <sep>', 'zinc supplementation <sep> supplemental zinc <sep> prophylactic zinc supplements <sep> zinc supplementation <sep> zn as zinc sulfate 10 mg zn  0.5 mg cu as copper sulfate or placebo <sep>', 'placebo <sep> zinc supplementation <sep> prolonged zinc supplementation <sep> zinc acetate <sep>', 'elemental zinc as sulphate or placebo <sep> placebo <sep> zinc supplementation <sep>', 'zinc 12.5 mg zinc sulphate or placebo <sep> placebo <sep> zinc supplementation <sep> zinc supplementation <sep>', 'zinc supplementation <sep> zinc supplementation <sep> zinc supplementation <sep> placebo <sep>', 'zinc nutrition <sep> zinc supplementation <sep> zinc-fortified formula <sep>', 'zinc supplements <sep> zinc <sep> placebo <sep>', 'placebo <sep> routine zinc supplementation <sep> zinc supplementation <sep> daily zinc supplementation <sep> single massive dose of vitamin a <sep> vitamin a <sep>', 'daily supplementation with 10 mg fe fe group 10 mg zn zn group 10 mg fe and 10 mg zn fe+zn group or placebo <sep> placebo <sep> combined iron and zinc supplementation <sep> combined iron and zinc supplementation <sep> simultaneous supplementation with iron and zinc <sep> iron and zinc supplementation <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",evidence on whether zinc supplementation can reduce the incidence of om in healthy children under the age of five years living in low and middle-income countries is mixed. there is some evidence of benefit in children being treated for marasmus severe malnutrition but this is based on one small trial and should therefore be treated with caution.
352,"{'outcomes': ['pain control <sep> quality of life <sep> cornell medical index m-r scales greater emotional disturbance <sep>', 'pain mood disturbance and concerns <sep> health perceptions <sep> symptom distress enforced social dependency and health perceptions <sep> symptom distress and social dependency <sep>', 'apmi score at baseline patients level of physical functioning patients level of social functioning the extent of adherence to pain medication patients pain knowledge <sep> amsterdam pain management index apmi consisting of an integrated score of patients present pain intensity average pain intensity and worst pain intensity <sep> quality of pain treatment <sep>', 'pain control <sep> average and worst pain <sep> average pain <sep> average and worst pain levels <sep> pain relief <sep> pain levels <sep>', 'symptom distress fatigue level quality of life and healthcare usage <sep> symptom distress scale brief fatigue inventory and functional assessment of cancer therapy scale-general version <sep> symptom distress fatigue quality of life and healthcare usage <sep>', 'depressive symptoms symptom distress functional status comorbidities length of hospital stay age of patient and stage of disease <sep> relative hazard of death <sep> length of survival <sep> 2-year survival <sep> survival <sep>', 'quality of life <sep> physical well-being dimension of health-related quality of life <sep>', 'quality of life outcomes <sep> symptom distress and better sf-12 mental and physical qol over time <sep> qol assessments included the center for epidemiological studies-depression scale  the ambiguity subscale of the mishel uncertainty in illness scale  the symptom distress scale and the short-form health survey sf-12 <sep>', 'symptoms or quality of life <sep> usual pain intensity <sep> pain brief pain inventory secondary outcomes of interest were all other symptoms memorial symptom assessment scale and quality of life functional assessment of cancer therapy scale <sep>', 'vomiting <sep> presence and severity of physical symptoms psychiatric morbidity use of and satisfaction with services and carers problems <sep>', 'sexual functioning and cancer worry <sep> 1 disease-specific quality of life including sexual urinary and bowel outcomes and cancer worry 2 depression 3 dyadic adjustment and 4 general quality of life <sep> quality of life <sep> quality-of-life outcomes <sep>', 'psychosocial morbidity <sep> role-emotional and mental health subscales <sep> psychological functioning <sep> psychosocial functioning anxiety and depression <sep> mental health <sep> quality of life <sep> depression <sep>', 'patient satisfaction <sep> satisfaction <sep>', 'pain intensity interference because of pain adequacy of analgesics used or pain relief <sep> knowledge and beliefs <sep>', 'patient satisfaction arm morbidity impact on community nurses health service costs surgical cancellations and in-patient nursing dependency <sep> quality of life or patient satisfaction <sep> quality of life and carer burden <sep>', 'normal arm function <sep> patient satisfaction and arm function on the affected side 2 months after diagnosis <sep> breast reconstruction surgery <sep> type and use of cancer-specific therapies <sep> axillary dissection <sep>', 'confidence <sep> telephone questionnaire <sep> knowledge confidence and satisfaction <sep> confidence treating patients who were receiving ct confidence knowledge of adverse effects and reasons to refer the patient to the treatment center knowledge and satisfaction with information and shared care of patients satisfaction <sep> satisfaction <sep>', 'health services utilization <sep> total per capita health care costs including hbhc <sep> patient survival activities of daily living adl cognitive functioning or morale <sep> patient functioning and patient and caregiver morale and satisfaction with care <sep>', 'survival <sep> synergistic effects <sep> functional decline <sep> sf-36 subscales activities of daily living and physical performance <sep> mental health <sep> total costs <sep> survival and health-related quality of life measured with the use of the medical outcomes study 36-item short-form general health survey sf-36 one year after randomization <sep> sf-36 mental health subscale <sep> costs <sep> ability to perform activities of daily living physical performance utilization of health services and costs <sep> mortality <sep>', 'symptom severity <sep>', 'qol over time measured by the functional assessment of cancer therapy-lung questionnaire and the palliative care quality of life index discussion of patient problems and satisfaction with communication and general care <sep> satisfaction with care communication or the discussion of patient problems <sep> qol summary scores total and overall qol <sep>', 'mean sd scores <sep> global health status emotional functioning and cognitive functioning <sep> satisfaction with communication participation in care or quality of life <sep> emotional functioning <sep> global health status <sep> cognitive functioning <sep>', 'explicit use of hrql data <sep> chronic nonspecific symptoms <sep> measuring quality of life <sep> hrql improvement <sep> discussion of pain and role function <sep> hrql <sep> patient hrql over time measured by the functional assessment of cancer therapy-general questionnaire physician-patient communication and clinical management measured by content analysis of tape-recorded encounters <sep>', 'continuity of care <sep> contact rates <sep> patient satisfaction and confidence <sep> patient satisfaction or gp confidence <sep>', 'physical and emotional functioning pain and psychologic distress assessed monthly by using the european organization for research and treatment of cancer quality of life questionnaire-c30 eortc qlq-c30 questionnaire and impact of event scale ies <sep> patients quality of life <sep> quality of life <sep> quality-of-life scores <sep> eortc qlq-c30 scales/items <sep>', 'investigations number and timing of recurrences and deaths <sep> recurrence time to detection and death rates <sep> scores for quality of life physical component score <sep> anxiety <sep> quality of life sf-12 physical and mental component scores 2 anxiety and depression hospital anxiety and depression scale and 3 patient satisfaction patient visit-specific questionnaire <sep> patient satisfaction <sep>', 'physical symptoms and health-related quality of life hrqol <sep> satisfaction with care <sep> symptoms hrqol mood and emotional bother in full-pct <sep>', 'quality of life and cost outcomes <sep> qol indicators <sep> uncertainty mood states well-being charges and reimbursement <sep> subscales of complexity inconsistency and unpredictability <sep> qol outcomes <sep> quality of life qol and cost outcomes <sep>', 'depression <sep> cancer needs qol or psychosocial functioning <sep> qol psychosocial functioning or satisfaction <sep> qol and psychosocial functioning and satisfaction with overall care received <sep>', 'pain medication level <sep> incidence of pain <sep> pain level <sep> pain management index pmi <sep> analgesic prescriptions <sep>', 'ratings of pain intensity <sep>'], 'punchline_text': ['pain problems later in the course of cancer seem to be predictable in those patients with higher scores on the cornell medical index m-r scales greater emotional disturbance and on the rotter locus of control <sep>', 'at the end of the study there were no differences in pain mood disturbance and concerns among the three groups. <sep>', 'while the level of inadequacy in the control groups remained relatively stable at all assessment points a slight increase in the percentage of patients being treated inadequately was found in the intervention group patients over time. <sep>', 'after 3 weeks the average and worst pain experienced by patients randomized to the clinical intervention group was significantly inferior to the average pain experienced by patients in the control group 2.9/10 vs. 4.4/10 and 4.2/10 vs. 5.5/10 respectively). <sep>', 'participants in both groups completed the symptom distress scale brief fatigue inventory and functional assessment of cancer therapy scale-general version 4 at eight intervals over six months. <sep>', 'overall the specialized home care intervention group was found to have increased survival p  .002 using stratified log-rank test). <sep>', 'analysis of variance revealed no differences in the physical well-being dimension of health-related quality of life between patients who received telephone follow-up and a control group who did not. <sep>', 'the apn intervention resulted in significantly less uncertainty than the attention control intervention 6 months after surgery. <sep>', 'there were no significant differences in other symptoms or quality of life between the two treatment groups. <sep>', '554 patients expected to survive less than one year entered the trial and were randomly allocated to a coordination or a control group. <sep>', 'patients in the intervention arm experienced long-term improvements in quality-of-life outcomes related to sexual functioning and cancer worry compared with patients who received standard care. <sep>', 'further work is needed to determine why depression and mental health were affected yet physical health and symptoms did not differ between groups. <sep>', 'furthermore in the general practice group there was a significant increase in satisfaction over baseline a similar significant increase in satisfaction over baseline was not found in the hospital group. <sep>', 'continued access to pain related information using either a patient or provider-initiated format did not affect long-term pain outcomes. <sep>', 'nurse-led early discharge had no adverse effects on quality of life or patient satisfaction had little effect on carer burden improved communication between primary and secondary care reduced cancellations and was safely implemented in a mixed rural/urban setting. <sep>', 'of women undergoing breast-conserving surgery greater percentages in the case management group received adjuvant radiation 78.3 vs 44.8 p=.001 and axillary dissection 71.4 vs 44.8 <sep>', 'gps receiving the ct sheet found correspondence significantly more useful p  .001 and instructive p  .001 than gps who received standard correspondence alone. <sep>', 'findings included no differences in patient survival activities of daily living adl cognitive functioning or morale but a significant increase in patient p  .02 and caregiver p  .005 satisfaction with care at one month. <sep>', 'there were significant reductions in functional decline with inpatient geriatric evaluation and management and improvements in mental health with outpatient geriatric evaluation and management with no increase in costs. <sep>', 'compared with conventional care alone the experimental intervention was effective among patients who entered the trial with higher levels of symptom severity. <sep>', 'no effects were found in relation to satisfaction with care communication or the discussion of patient problems. <sep>', 'a supplementary patient-held record for radiotherapy outpatients appears to have no effect on satisfaction with communication participation in care or quality of life. <sep>', 'patients in the intervention and attention-control groups had better hrql than the control group p .006 and p .01 respectively but the intervention and attention-control groups were not significantly different p .80). <sep>', 'while no statistically significant improvements in patient satisfaction or gp confidence were shown the data suggested that gps value contact to meet patient information needs. <sep>', 'during the initial 4 months of follow-up the compliance was good 72 and comparable among treatment groups. <sep>', 'at 12 and 24 months there were no differences in scores for quality of life physical component score p=0.88 at 12 months p=0.28 at 24 months mental component score p=0.51 p=0.47 adjusted anxiety p=0.72 p=0.11 depression p=0.28 p=0.80 or patient satisfaction p=0.06 24 months). <sep>', 'there were highly significant improvements in symptoms hrqol mood and emotional bother in full-pct at 1 week maintained over the 4-week follow-up. <sep>', 'unmarried women and women with no family history of breast cancer benefited from nurse interventions in mood states and well-being. <sep>', 'there were no significant differences between the two arms with respect to changes in cancer needs qol or psychosocial functioning between the baseline and follow-up assessments nor with respect to satisfaction with care. <sep>', ""a decrease in the incidence of pain described as more than life's usual aches and pains was found for the intervention group p  .05). <sep>"", 'patients in the augmented group improved significantly over the control group in ratings of pain intensity at its worst whereas patients in the basic group had better ratings of pain intensity on average. <sep>'], 'population': ['home visiting nurse practitioners <sep> patients with incurable cancer and an estimated prognosis of three months to one year <sep> patients with advanced cancer <sep>', 'lung cancer patients <sep> patients with progressive lung cancer <sep> one hundred sixty-six patients <sep>', 'cancer patients with chronic pain <sep> 313 chronic cancer patients <sep> cancer patients in chronic pain <sep> patients both with and without district nursing <sep>', 'sixty-four patients <sep> outpatients with cancer <sep> outpatients with cancer treated by radiation therapy <sep>', 'sample 113 patients with lung cancer and 77 patients with breast cancer <sep> ambulatory patients with breast or lung cancer during active treatment <sep> three outpatient ambulatory oncology clinics in a large university health center in quebec canada <sep> patients with lung or breast cancer <sep>', 'post-surgical cancer patients <sep> three hundred seventy-five patients aged 60 to 92 newly diagnosed with solid cancers were treated surgically between february 1993 and december 1995 <sep> older post-surgical cancer patients <sep> one hundred ninety patients were randomized to the intervention groups and 185 to the usual care group <sep> discharged older cancer patients after surgery at a comprehensive cancer center in southeastern pennsylvania <sep> older post-surgical cancer patients who received a <sep> older cancer patients after cancer surgery <sep> surgical cancer patients <sep>', 'one hundred fifty patients with cancer who were discharged to home from the hospital <sep> patients with cancer <sep>', 'post-surgical women with gynecological cancers <sep> women recovering from cancer surgery and undergoing <sep> women with gynecological cancers <sep>', 'eighty-one cancer patients aged 37 to 76 years were enrolled onto a prospective longitudinal randomized controlled study from the outpatient clinic settings of 26 western washington-area medical oncologists <sep> cancer pain management <sep>', 'terminally ill cancer patients and their families of coordinating the services available within the nhs and from local authorities and the voluntary sector <sep> cancer patients were routinely notified from 1987 to 1990 <sep> terminally ill cancer patients <sep> 554 patients expected to survive less than one year entered the trial <sep>', '99 patients along with their partners <sep> patients with prostate carcinoma <sep>', '109 patients newly diagnosed with breast colon or lung cancer who were receiving chemotherapy 54 received standard care and 55 participated in the intervention group <sep> newly diagnosed patients with cancer <sep> newly diagnosed patients with cancer undergoing treatment <sep> patients and families experiencing cancer <sep> a large urban midwestern tertiary-cancer center and a community-based cancer center in a medium-sized midwestern city <sep>', 'two hundred and ninety-six women with breast cancer in remission receiving regular follow-up care at two district general hospitals in england were included in the study <sep> breast cancer patients <sep> breast cancer patients in specialist clinics <sep> women with breast cancer in remission from hospital outpatient clinics to general practice <sep> breast cancer patient satisfaction with follow-up in primary care versus specialist care <sep> patients with breast cancer <sep>', 'patients with cancer-related pain and their primary caregivers <sep> sixty-four patients and their primary caregivers were recruited <sep>', 'breast cancer <sep> 108 patients undergoing axillary clearance with mastectomy or wide local excision for breast cancer <sep> patients with breast cancer who require axillary clearance traditionally remain in hospital until their wound drains are removed <sep>', 'older women with breast cancer <sep> three hundred thirty-five women 166 control and 169 intervention aged 65 and older newly diagnosed with breast cancer <sep> sixty surgeons practicing at 13 community and two public hospitals in southeast texas <sep>', 'ninety-seven gps managed 97 patients receiving 23 types of ct <sep> patients with cancer <sep> patients due to commence ct <sep>', 'all admissions to a 1,100-bed department of veterans affairs va hospital were screened to identify 171 terminally ill patients with informal caregivers <sep>', 'frail patients 65 years of age or older who were hospitalized at 11 veterans affairs medical centers <sep> 1388 patients were enrolled and followed <sep>', 'patients n  237 were accrued from comprehensive and community cancer centers <sep> patients diagnosed with solid tumors and undergoing a first course of <sep>', 'inoperable lung cancer patients <sep> 115 patients with inoperable lung cancer <sep> palliative care patients <sep>', 'patients with cancer holding their own records <sep> six hundred and fifty radiotherapy outpatients with any form of cancer <sep>', '28 oncologists 286 cancer patients <sep> cancer patients hrql <sep>', 'general practitioners and hospitals <sep> 200 patients admitted to a gynaecological oncology ward and their gps <sep> patients undergoing major gynaecological surgery by increasing their general practitioners contact with the hospital and providing a comprehensive discharge summary <sep>', 'palliative cancer care <sep> 235 intervention patients and 199 controls were included <sep> patients from these districts who had malignant disease and survival expectancy between 2 to 9 months were entered onto the trial <sep> community health care districts defined as the clusters <sep>', 'patients with colon cancer <sep> patients after treatment for colon cancer by either general practitioners or surgeons <sep> 170 patients were available for follow-up at 12 months and 157 at 24 months <sep> 203 consenting patients who had undergone potentially curative treatment for colon cancer <sep> colon cancer patients <sep>', 'the trial recruited 261 out of 684 new inpatient referrals 175 were allocated to <sep>', 'midwestern suburban community <sep> 210 women with newly diagnosed breast cancer with an age range of 30-85 years <sep> women diagnosed with breast cancer <sep> unmarried women and women with no family history of breast cancer <sep>', '450 people with cancer <sep> patients with cancer <sep>', '510 cancer outpatients and 13 oncologists was conducted at 23 clinics in indiana <sep> outpatients with cancer <sep> 320 patients who reported cancer-related pain were used in the analysis 160 to 260 in the control group and 160 of 250 in the intervention group <sep>', '300 nurses were randomized and outcomes of 673 of their patients were reviewed <sep> eligible cancer patient with pain <sep> nurses from a large urban non-profit home care organization <sep>'], 'interventions': ['called intensive received home visits by a nurse practitioner acting as an extension of a multidisciplinary team the other termed nonintensive did not receive such visits <sep>', 'home nursing care <sep> oncology home care group ohc that received care from oncology home care nurses a standard home care group shc that received care from regular home care nurses or an office care group oc that received whatever care they needed except for home care <sep>', 'pain education programme pep <sep> tailored pain education programme <sep> pep <sep>', 'clinical intervention <sep> clinical intervention including an information session the use of a pain diary and the possibility to contact a physician to adjust the pain medication or the usual treatment of pain by the staff radiation oncologist <sep> multicomponent clinical intervention <sep>', 'pivot nurse <sep> intervention group n  93 with care by a pivot nurse in oncology and usual care by clinic nurses or to a control group n  97 with usual care only <sep>', 'specialized home care intervention provided by advanced practice nurses apns with that of patients who received usual follow-up care in an ambulatory setting <sep> specialized home care intervention <sep> comprehensive clinical assessments monitoring and teaching including skills training <sep>', 'telephone <sep>', 'psychiatric consultation-liaison nurse pcln <sep> chemotherapy <sep> nursing intervention <sep> apn plus pcln intervention <sep> 6 months of specialized care by an advanced practice nurse apn <sep>', 'pain algorithm <sep>', 'coordinating care <sep>', 'oncology nurse intervenor who helped patients identify their quality-of-life needs using an interactive computer program <sep> cancer care intervention or to receive standard care <sep> nurse-driven intervention <sep>', 'computer-based nursing intervention <sep> cancer-care nursing interventions <sep>', 'routine follow-up either in hospital outpatient clinics or from their own general practitioner <sep>', 'usual care b pain hot line and c weekly provider-initiated follow-up calls for 1 month post-education <sep> brief pain education program <sep>', 'nurse-led early discharge or conventional stay <sep> nurse-led early discharge after breast cancer surgery <sep>', 'adjuvant radiation <sep> radiation therapy <sep> breast-conserving surgery <sep> nurse case management <sep>', 'usual correspondence with or without the faxed patient/regimen-specific information <sep> gps about chemotherapy ct <sep>', 'va hospital-based team home care hbhc n  85 or customary care <sep> va hospital-based home care <sep> hbhc <sep>', 'care in an inpatient geriatric unit or usual inpatient care followed by either care at an outpatient geriatric clinic or usual outpatient care <sep>', 'cognitive behavioral intervention <sep> chemotherapy <sep> conventional care <sep> conventional care alone <sep>', 'standard care or a structured qol diary european organisation for research and treatment of cancer quality of life questionnaire c30 and the related lung cancer module lc13 <sep> qol questionnaire without appropriate feedback to health care professionals <sep> patient-held quality-of-life qol diary <sep>', 'hold a supplementary record or to receive normal care <sep>', 'intervention group regular completion of european organization for research and treatment of cancer-core quality of life questionnaire version 3.0 and hospital anxiety and depression scale on touch-screen computers in clinic and feedback of results to physicians attention-control group completion of questionnaires but no feedback or control group no hrql measurement <sep>', 'personal invitation <sep>', 'comprehensive palliative care <sep>', 'general practice vs surgical-based follow-up <sep>', 'hospital palliative care team pct <sep> limited telephone advice telephone-pct <sep> full-pct 86 to telephone-pct <sep>', ""advanced nursing care <sep> apn interventions <sep> standard care plus apn interventions based on brooten's cost-quality model and the oncology nursing society's standards of advanced practice in oncology nursing qol was measured using the functional assessment of cancer therapy mishel uncertainty <sep> standard medical care <sep> advanced practice nurses apns interventions <sep>"", 'coordinated psychosocial interventions <sep>', 'clinical-practice intervention <sep>', 'augmented intervention supplemented the initial e-mail reminder with provider prompts patient education material and clinical nurse specialist outreach <sep> patient-specific one-time e-mail reminder highlighting six pain-specific clinical recommendations <sep> two nurse-targeted e-mail-based interventions <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",results from this cochrane review do not allow us to conclude on the effectiveness of included interventions to improve continuity of care on patient healthcare provider or process of care outcomes. future research should evaluate interventions that target an improvement in continuity as their primary objective and describe these interventions with the categories proposed in this review. also of importance continuity measures should be validated with persons with cancer who have been followed in various settings.
353,"{'outcomes': ['tibial components <sep>', 'red blood cell count hemoglobin level and hematocrit returned to the preoperative levels <sep> perioperative blood loss <sep> total blood loss <sep> perioperative blood loss <sep>', 'quality of the fixation <sep> progressive radiolucent lines <sep>'], 'punchline_text': ['after two years rotation of the femoral components in the transverse longitudinal and sagittal planes did not differ between the cemented and the hydroxyapatite-coated implants p  0.2 to 0.9). <sep>', 'the red blood cell count hemoglobin level and hematocrit returned to the preoperative levels within 3 months in both groups. <sep>', 'between 1 and 2 years 4 of 24 ha-coated and 10 of 23 cemented implants migrated 0.2 mm and were categorized unstable which has been shown to have a prognostic value as regards future aseptic loosening. <sep>'], 'population': ['50 patients 54 knees with osteoarthritis of the knee who <sep>', 'knee arthroplasty <sep> 57 patients 60 knees who underwent <sep> cementless or hybrid total knee arthroplasty without patellar resurfacing <sep>', 'total knee arthroplasty <sep> fifty-three consecutive patients 57 knees mean age 69 years <sep> 40 patients 19 ha-coated 21 cemented remaining at 5 years <sep>'], 'interventions': ['hydroxyapatite-coated femoral component for total knee replacement <sep> cemented versus hydroxyapatite fixation <sep>', 'total knee arthroplasty with 30 knees or without 30 knees tibial cement to evaluate perioperative blood loss <sep>', 'hydroxyapatite coating versus cemented fixation of the tibial component <sep> hydroxyapatite-coated and cemented tibial components with 5-year follow-up using radiostereometry <sep> fixation of hydroxyapatite ha)-coated 29 knees with cemented 28 knees tibial components in the tricon ii total knee arthroplasty <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there was a smaller displacement of the cemented tibial component in relation to the cementless fixation in studies with osteoarthritis and rheumatoid arthritis participants who underwent primary total knee prosthesis with a follow-up of two years however the cemented fixation presented a greater risk of future aseptic loosening than cementless fixation.
354,"{'outcomes': ['benign paroxysmal positional vertigo <sep> vss <sep> vdi-hrqol mean scores <sep> vertigo dizziness imbalance questionnaire vdi which consists of two subscales the vdi symptom subscale vdi-ss and the vdi health-related quality of life vdi-hrqol subscale and the vertigo symptom scale vss <sep> vsi mean scores vdiss mean scores and vss mean scores <sep> mean scores of the vdi <sep>', 'dizziness <sep> symptoms postural stability and dizziness-related handicap <sep> baseline 3-month and 6-month assessment of self-reported spontaneous and provoked symptoms of dizziness dizziness-related quality of life and objective measurement of postural stability with eyes open and eyes closed <sep>', 'reduced symptoms anxiety handicap and negative beliefs about dizziness <sep> reduced handicap <sep> subjective improvement in health enablement ability to understand and cope with symptoms and adherence <sep> symptoms handicap anxiety and depression and negative beliefs about symptoms <sep> adherence levels <sep>', 'eyes-opened length of the oscillations and eyes-opened and eyes-closed surface of the body sway <sep> reductions of eyes-opened length and of eyes-opened correlation function between length and surface <sep> reduction of symptoms <sep> static balance and a dizziness handicap <sep>', 'parameters vas dhi bbs mctsib <sep> symptom disability balance and postural stability <sep> symptom disability balance and postural stability in chronic unilateral vestibular dysfunction <sep> symptoms visual analog scale vas disability dizziness handicap inventory dhi balance berg balance scale bbs and postural stability modified clinical test for sensory interaction on balance mctsib <sep> postexercise vas dhi emotional functional physical total bbs and mctsib standing on a firm surface with eyes open standing on a foam surface with eyes open standing on a foam surface with eyes closed mctsib mean <sep>', 'cure rates <sep> cure rate <sep> subsequent relapse <sep>', 'dynamic gait index <sep> single leg stance <sep> balance ability and functional gait performance <sep> static balance tests tandem walk test dynamic gait index and subjective rating of the intensity of vertigo <sep>', 'odds ratios <sep> physical indices of balance and subjective indices of symptoms and distress <sep>', 'dizziness only vestibular rehabilitation also improves balance <sep> dizziness and imbalance <sep>', 'symptom remission <sep>', 'dynamic gait index <sep> balance performance <sep> timed up and go test tandem gait and dynamic gait index <sep> balance scores <sep> standing balance timed up and go test and tandem gait <sep>', 'motion sensitivity and dizziness handicap <sep> equilibrium scores in dynamic posturography asymmetry index in rotation testing motion sensitivity quotient msq and dizziness handicap inventory dhi <sep>', 'vertigo intensity and frequency <sep> vertigo <sep>', 'demographics data and duration and intensity of symptoms <sep> visual analogue scale physical examination and need to use the medication <sep>', 'vertigo intensity and frequency low-frequency vestibulo-ocular reflex vor posturography and path integration <sep>', 'dynamic visual acuity <sep> dynamic visual acuity dva <sep> visual acuity <sep> dva-predictable <sep> changes in oscillopsia <sep>', 'vor response <sep> optokinetic reflex okn response to 60 degrees/s constant velocity optokinetic stimuli <sep> vestibulo-ocular reflex vor <sep> vor gain vor time constant and okn gain <sep> balance performance <sep> balance performance <sep> peak-to-peak magnitude and total amount of anterior-posterior body sway and of horizontal shear ground reaction force <sep> standing balance performance <sep>', 'clear locomotor gains <sep> gait velocity and stability <sep> locomotor stability <sep>', 'anxiety and depression levels <sep> visual vertigo symptoms <sep> visual vertigo scq <sep> posturography and subjective scores <sep> vestibular time constants <sep> visual vertigo symptom scores <sep> dynamic posturography vestibular time constants and questionnaires concerning symptoms symptom-triggers and emotional status <sep> psychological symptoms <sep> posturography scores <sep>', 'visual analogue scales <sep> hearing ability tinnitus and dizziness <sep> hearing improvement <sep> changes of pitch and loudness <sep> ability to hear <sep> tinnitus dizziness or increasing hearing ability <sep>', 'dizziness handicap questionnaire and a visual analogue scale for anxiety <sep> visual analogue scale anxiety score <sep> visual dependence <sep> dynamic gait index results and anxiety <sep>', 'total sp values <sep> subjective visual vertical svv for perception and 3 the total sway path sp values <sep> normalization of ot and svv <sep> central vestibulospinal compensation <sep> vestibulospinal compensation <sep> persisting peripheral vestibular deficit <sep>', 'perception of dysequilibrium <sep> dysequilibrium and nausea <sep> postural stability <sep>'], 'punchline_text': ['there were significant differences between groups regarding the change in the mean scores of the vdi p  .001 and the vss p  .001 at the end of the study in favour of the exercise group. <sep>', 'vestibular rehabilitation delivered by nurses in general practice improves symptoms postural stability and dizziness-related handicap in patients with chronic dizziness. <sep>', 'at 3 months the vr group had reduced symptoms anxiety handicap and negative beliefs about dizziness the sc group had reduced handicap but the control group showed no improvement. <sep>', 'rehabilitation therapy is proved to be effective in reducing disability in patients with persistent symptoms of disequilibrium after acute unilateral peripheral vestibular deficit. <sep>', 'significant improvements were seen in symptom disability balance and postural stability in chronic unilateral vestibular dysfunction after an exercise program. <sep>', 'at the one-week follow-up similar cure rates were obtained with the semont and epley maneuver 74 and 71 respectively both cure rates being significantly higher than that obtained with brandt  daroff exercises 24%). <sep>', 'compared with the control group subjects in the experimental group demonstrated a statistically significant improvement in single leg stance with eyes closed at the two-week assessment p<0.05). <sep>', 'odds ratios for improvement in treated patients relative to untreated patients were 3.1:1 at six weeks 95 ci  1.4-6.8 and 3.8:1 at six months 95 ci  1.6-8.7). <sep>', 'patients with positional and/or movement-related dizziness and abnormal posturography were randomly assigned to the three treatment groups. <sep>', 'the sm was effective in 80 of the patients at 15 days of treatment versus 45 of those receiving only vre. <sep>', 'however older subjects receiving vestibular rehabilitation performed significantly p<0.05 better on standing balance timed up and go test and tandem gait when compared with the older group that received only general instructions. <sep>', 'a multiple comparison of the overall outcome measures showed no significant differences in group performance over an 8-week period. <sep>', 'multilevel analyses showed that vertigo decreased significantly after lm crp and brandt-daroff exercise those three groups did not differ significantly. <sep>', 'vestibular exercises are effective in reducing the duration of symptoms and the need of medication of patients in the early stages of peripheral vestibular disorders. <sep>', 'vor on the unoperated side returned to normal values but on the lesioned side did not. <sep>', 'as a group patients who performed vestibular exercises showed a significant improvement in dva-predictable p<.001 and dva-unpredictable p<.001 while those performing placebo exercises did not p .07). <sep>', ""balance performance was assessed by measuring the peak-to-peak magnitude and total amount of anterior-posterior body sway and of horizontal shear ground reaction force during six test conditions in which visual and somatosensory orientation cues were reduced or altered by rotation of the visual surround or support surface in proportion to the subject's sway and in which vision was eliminated eyes closed). <sep>"", 'group a 6 weeks of vr significantly p  0.01 increased their gait velocity and stability compared with group b 6 weeks of strengthening exercise but there was a smaller difference p  0.05 between groups at 12 weeks when both had had vr there were no group differences at 1 year. <sep>', 'a statistically significant improvement for visual vertigo symptom scores was noted only for group s p  0.01 total improvement 53.5 . <sep>', 'the results from this study did not show tns to be superior to ar in reducing tinnitus dizziness or increasing hearing ability. <sep>', 'the greatest difference in the rehabilitated subjects compared with the control group was for the dynamic gait index test however this difference was not statistically significant. <sep>', 'although normalization of ot and svv was similar in the control and physiotherapy groups the total sp values on day 30 after symptom onset differed significantly 3.2  <sep>', 'the use of exercises in the treatment of patients with vestibular deficits has become increasingly popular and evidence exists that these exercises are beneficial in patients with chronic vestibular deficits. <sep>'], 'population': ['patients with benign paroxysmal positional vertigo bppv <sep> outpatient clinic of a university hospital <sep> 13 years diagnosed as having bppv <sep> thirty-eight patients 10 males 28 females mean age 46 <sep> patients with persistent or chronic vertigo <sep>', '20 general practices in southern england <sep> patients with chronic dizziness <sep> chronic dizziness <sep> 170 adult patients with chronic dizziness <sep>', 'participants n  360 <sep> mnire disease <sep>', '28 patients using static posturography and.the dizziness handicap inventory short form <sep> patients with persistent symptoms of disequilibrium after acute unilateral peripheral vestibular deficit <sep> patients with recent unilateral vestibular disorders <sep> unilateral peripheral vestibular deficit <sep>', 'patients with chronic unilateral vestibular dysfunction <sep> patients n=42 with chronic vestibular dysfunction <sep>', '106 bppv patients <sep> patients with bppv <sep> benign paroxysmal vertigo <sep> benign paroxysmal positional vertigo <sep>', 'twenty-six subjects with benign paroxysmal positional vertigo involving the unilateral posterior semicircular canal <sep> patients with benign paroxysmal positional vertigo who had already undergone the canalith repositioning manoeuvre <sep> patients with benign paroxysmal positional vertigo <sep>', 'patients with persistent dizziness <sep> dizzy patients in primary care <sep> adults consulting their general practitioner gp with dizziness or vertigo <sep> dizziness and vertigo in primary care <sep>', 'patients with positional and/or movement-related dizziness and abnormal posturography <sep> patients with chronic vestibular symptoms of at least 6 months duration <sep> patients with chronic peripheral vestibular disorders <sep>', 'benign paroxysmal postural vertigo <sep> forty patients with the clinical and electronystagmographic diagnosis of bppv <sep> benign paraoxysmal postural vertigo bppv <sep>', 'fifty-three patients after surgery <sep> after stratification for age 50 years or=50 years <sep> older subjects receiving <sep> patients over 50 early vestibular rehabilitation facilitates recovery of postural control after acoustic neuroma surgery <sep> patients after acoustic neuroma surgery <sep> acoustic neuroma resection <sep>', 'twenty-four subjects <sep>', 'patients n  124 with bppv of the posterior semicircular canal <sep> benign paroxysmal positional vertigo of the posterior canal <sep>', 'acute vertigo <sep> all patients were adults and symptomatic for less than 5 days <sep>', 'acoustic neuroma resection acutely postoperative patients <sep>', 'twenty-one patients with unilateral vestibular hypofunction aged 20 to 86 years <sep> patients with unilateral vestibular hypofunction <sep> unilateral vestibular hypofunction <sep>', 'patients with chronic peripheral vestibular dysfunction <sep>', '18 years old with unilateral n  51 or bilateral n  73 vestibular hypofunction of whom 86 completed a 12-week intervention <sep> 124 patients 59 <sep>', 'patients with refractory dizziness <sep> patients with chronic vestibular symptoms <sep> forty chronic peripheral vestibular patients who had previously undergone conventional vestibular rehabilitation without notable improvement <sep>', ""patients with menire's disease <sep> 20 patients diagnosed with menire's disease transcutaneous nerve stimulation tns and applied relaxation ar <sep>"", 'dizzy patients after recent acute vestibular disturbance <sep> forty patients recently hospitalised for an acute episode of rotational vertigo which lasted days <sep> patients following acute onset of vestibular disturbance <sep> rehabilitation after acute vestibular disorders <sep>', 'patients with acute peripheral vestibular lesions <sep> patients with an acute/subacute unilateral vestibular lesion vestibular neuritis <sep> after vestibular neuritis <sep> acute unilateral peripheral vestibular lesions in humans <sep> 19 patients with and 20 patients without vestibular exercises <sep>', 'patients during the acute stage after resection of acoustic neuroma <sep> patients with chronic vestibular deficits <sep> patients with vestibular deficits <sep> acoustic neuroma resection <sep> patients with acute unilateral vestibular loss <sep>'], 'interventions': ['cawthorne-cooksey exercises six times/day for 4 weeks <sep> exercise or a medication group <sep> betahistine <sep> home-based exercise program <sep>', 'vestibular rehabilitation <sep> nurse-delivered vestibular rehabilitation <sep> usual medical care <sep> primary care-based vestibular rehabilitation <sep> vestibular rehabilitation <sep>', 'booklet-based self-management <sep> waiting list control group or to receive either a vr or an sc self-management booklet <sep> booklet-based education in vestibular rehabilitation vr and symptom control sc techniques <sep>', 'vestibular electrical stimulation <sep> oculomotor exercises <sep> oculomotor rehabilitation and vestibular electrical stimulation <sep> rehabilitation therapy <sep> oculomotor rehabilitation <sep>', 'vestibular rehabilitation <sep> customized exercise program <sep> control group did not receive any treatment <sep> customized exercise programs <sep>', 'brandt and daroff exercises semont and epley maneuver <sep>', 'canalith repositioning manoeuvre <sep> canalith repositioning manoeuvre and vestibular stimulated exercise training <sep> additional exercise training <sep> additional vestibular stimulated exercise programme <sep>', 'individualized 30-minute therapy session in which they were taught head eye and body exercises designed to promote vestibular compensation <sep> vestibular rehabilitation vr <sep> exercise therapy <sep>', 'vestibular rehabilitation <sep> vestibular rehabilitation general conditioning exercises and vestibular suppressant medication <sep> vestibular rehabilitation <sep> specific exercise approach <sep>', 'vestibular rehabilitation exercises vre <sep> sm  vre <sep> semont maneuver and vestibular rehabilitation exercises <sep> semont maneuver sm <sep>', 'vestibular rehabilitation <sep> early customized vestibular rehabilitation with general instructions <sep> general instructions or customized vestibular rehabilitation protocols <sep> customized vestibular rehabilitation <sep> customized vestibular rehabilitation <sep> early customized vestibular rehabilitation <sep>', 'ablative vestibular surgery <sep> rom exercises <sep> vestibular rehabilitation vr and social reinforcement sr <sep> vr with sr vr without sr or general range of motion rom exercises with sr <sep> vestibular rehabilitation and social reinforcement <sep>', ""standard educational lecture about bppv <sep> modified canalith repositioning maneuver crp modified liberatory maneuver lm sham maneuver brandt and daroff's exercise and vertigo habituation exercises <sep>"", 'exercises for adaptation of the vestibulo-ocular reflex the control group <sep> placebo <sep> vestibular exercises <sep> placebo exercises <sep> vestibular rehabilitation exercises <sep> vestibular rehabilitation exercises <sep> dimenhydrinate <sep>', 'attention without exercise <sep> exercise subjects underwent passive and active head movements and walking with augmented head movements <sep>', 'vestibular exercises designed to enhance the vestibulo-ocular reflex <sep> placebo <sep> placebo exercises <sep> vestibular exercises <sep>', '45-minute training sessions <sep> comprehensive exercise program that consisted of balance retraining and goal-directed eye-head exercises under combinations of varied visual and somatosensory sensory conditions <sep> exercise programs <sep>', 'vestibular rehabilitation <sep> vestibular rehabilitation vr <sep> placebo <sep> vestibular rehabilitation <sep>', 'customised exercise regime group c for customised versus treatment additionally incorporating simulator based desensitisation exposure group s for simulator integrating whole-body or visual environment rotators <sep>', 'tns <sep> transcutaneous nerve stimulation tns and applied relaxation ar <sep>', 'supervised exercise programme <sep>', 'vestibular exercises <sep> specific physiotherapy <sep> specific vestibular exercises <sep>', 'vestibular adaptation exercises <sep> vestibular adaptation exercises <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is moderate to strong evidence that vr is a safe effective management for unilateral peripheral vestibular dysfunction based on a number of high quality randomised controlled trials. there is moderate evidence that vr provides a resolution of symptoms and improvement in functioning in the medium term. however there is evidence that for the specific diagnostic group of bppv physical repositioning manoeuvres are more effective in the short term than exercise-based vestibular rehabilitation although a combination of the two is effective for longer-term functional recovery. there is insufficient evidence to discriminate between differing forms of vr.
355,"{'outcomes': ['surgical outcome <sep> collagen synthesis <sep> serum markers of collagen synthesis <sep>', 'success rate <sep> complications <sep> shallow anterior chamber <sep> hyphema <sep> choroidal detachment <sep> probability of success <sep> mean postoperative iop <sep>', 'overall iop control <sep> life-table success rates <sep> preoperative iops and visual acuities <sep> cumulative success rate <sep> visual acuities implant-related complications and average iops <sep> postoperative iops visual acuities number of medications used and implant-related complications <sep> overall success rates <sep> complications <sep> visual acuities <sep>', 'preoperative mean iop <sep> success rate <sep> incidence of complications <sep> mean iop <sep> iop reductions <sep> intraocular pressure iop and the appearance of the bleb <sep>', 'mean preoperative intraocular pressures <sep> final visual acuity <sep> complications or inadequate pressure control requiring further surgical intervention <sep> mean intraocular pressure <sep>', 'rate of hypertension <sep> mean number of preoperative antiglaucoma medication <sep> complete success rate <sep> postoperative antiglaucoma medication <sep> hypertensive phase <sep>', 'short or intermediate-term success rates <sep> efficacy and safety <sep> postoperative intraocular pressure iop <sep> survival rates <sep> success rates <sep> mean iop <sep> iop reduction <sep> probability of success <sep> postoperative complications <sep> mean iop number of glaucoma medications and complications <sep> surgical success <sep> mean numbers of postoperative antiglaucoma medications <sep>', 'adjunctive medication requirement <sep> mean intraocular pressures <sep> intraocular pressures <sep> frequency of complications <sep> intraocular pressure from preoperative level <sep> visual acuity visual field lens status and final anterior chamber depth <sep> rate of complications <sep> cumulative probabilities of success intraocular pressure <sep>', 'intraocular pressure <sep> rate of hypotony and surgical complications <sep> incidence of complications and the success rate <sep> successful intraocular pressure control <sep> early postoperative hypotony <sep> final success rate <sep>', 'cumulative probabilities of success <sep> adjunctive medication requirement <sep> lower iops <sep> iops and the cumulative probabilities of success <sep> intraocular pressures iop <sep> postoperative visual acuity visual field anterior chamber depth and short-term or long-term complications <sep>', 'intraocular pressure iop visual acuity and complication rates <sep> intraocular pressure visual acuity and complications <sep> preoperative iop log mean angle of resolution logmar visual acuity or number of preoperative medications <sep> molteno tube shunt surgery <sep> complications <sep>', 'final postoperative visual acuities <sep> preoperative visual acuities <sep> devastating complication <sep> final intraocular pressure iop <sep> transient elevations of iop <sep> choroidal hemorrhages and/or effusions corneal decompensation flat anterior chambers and phthisis bulbi <sep> 1 and 2-year life-table success rates success survival <sep>', 'shallow or flat anterior chambers with hypotony <sep> postoperative pressure spikes <sep> postoperative intraocular pressure <sep>', 'iop <sep> cataract formation <sep> severe complications <sep> visual acuity <sep> success rate with mmc and without mmc <sep> elevated iop <sep> introcular pressure iop <sep>'], 'punchline_text': ['the serum markers indicated a systemic effect of oral prednisolone on collagen synthesis in group b but it did not improve the surgical outcome as compared to the controls. <sep>', 'complications included choroidal detachment ahmed 17.64 ecp 2.94 shallow anterior chamber ahmed 17.64 ecp 0.0 and hyphema ahmed 14.7 ecp 17.64%). <sep>', 'the overall success rates were 87 for the 350-mm2 group and 70 for the 500-mm2 group p  0.05). <sep>', 'in eyes undergoing ahmed valve implantation for neovascular glaucoma pctr with mmc augmentation showed no additional benefits or complications over mmc augmentation alone no avascular bleb was obtained with this technique. <sep>', 'complications or inadequate pressure control requiring further surgical intervention were seen in nine 47 of 19 eyes in the molteno group and 12 57 of 21 eyes in the actseb group.(abstract truncated at 250 words <sep>', 'complete success rate was 90 in the e-agv group and 70 in the agv group p  0.291). <sep>', 'there were no significant differences in survival rates between the 2 groups with either criterion p  0.75 and p  0.37 respectively). <sep>', 'with a mean follow-up of 9.7 months the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 12.6 mm <sep>', 'early postoperative hypotony occurred in 1 of 16 6.3 patients with partial ligation and 4 of 16 25 patients without ligation. <sep>', 'no statistically significant differences between groups were noted for postoperative visual acuity visual field anterior chamber depth and short-term or long-term complications. <sep>', 'except for week 1 there were no differences between the groups at any of the clinic visits with respect to iop and percent change from baseline iop. <sep>', 'the final postoperative visual acuities were within one line of the preoperative visual acuities or had improved in 73 and 80 of patients respectively. <sep>', 'postoperative intraocular pressure was significantly higher at day 1 and week 2 in the suture-ligation implant group although the final pressure at 12 weeks was not different between the two groups. <sep>', 'the success rate with mmc and without mmc were 90.0 77.3 p  0.05 at the 1st year 87.1 67.3 p  0.05 at the 2nd year 83.3 61.1 p  0.05 at the 3rd year 81.3 56.7 p  0.05 at the 4th year and 75.0 50.0 p  0.05 at the 5th year using kaplan-meier life-table analysis. <sep>'], 'population': ['twenty-two patients requiring single stage single-plate molteno implantation <sep>', 'refractory glaucoma <sep> sixty-eight eyes of 68 patients with refractory glaucoma <sep> eyes that were included were pseudophakic with a history of at least one trabeculectomy with antimetabolite an intraocular pressure iop equal to or above 35 mm hg on maximum tolerated medical therapy and a visual acuity better than light perception <sep> exclusion criteria included eyes that had had previous glaucoma drainage device implantation or a cyclodestructive procedure <sep>', 'between march 1991 and april 1993 107 patients with uncontrolled intraocular pressure iop due to non-neovascular glaucoma associated with aphakia pseudophakia or failed filters <sep>', 'eyes undergoing ahmed glaucoma valve insertion <sep> four latin american countries argentina brazil colombia and peru <sep> 92 eyes from 92 patients were included in the study <sep> ahmed glaucoma valve implant surgery <sep>', 'eyes with aphakia/pseudophakia uveitis previous penetrating keratoplasty previous unsuccessful trabeculectomy and neovascular glaucoma <sep> eyes with complicated glaucoma <sep>', 'ten eyes of agv implant surgery using pericardial membrane preclude that were designed to have surface area of 300 mm e-agv group and 10 eyes of agv implant surgery without surface area extension agv group <sep> complicated glaucoma <sep> ahmed glaucoma valve implant surgery <sep>', 'sixty eyes of 60 patients with refractory glaucoma <sep> eyes undergoing ahmed glaucoma valve implantation <sep> sixty patients with refractory glaucoma <sep> ahmed glaucoma valve implantation <sep>', '117 patients 62 were randomized to <sep> consecutive patients requiring glaucoma surgery for intraocular pressure control <sep> glaucoma <sep>', 'ahmed glaucoma valve implantation <sep> thirty-two korean patients <sep>', 'consecutive patients with primary glaucoma and without prior intraocular surgery <sep> large university-affiliated eye hospital in columbo sri lanka <sep> 123 patients 64 were randomized to <sep>', 'molteno implant surgery <sep> twenty-five eyes of twenty-five consecutive patients undergoing double-plate molteno implant surgery <sep>', 'from march 1988 to february 1990 132 patients who underwent molteno implantation for medically uncontrollable non-neovascular glaucomas in aphakia or pseudophakia <sep> glaucomas in aphakia and pseudophakia <sep>', 'thirty eyes <sep>', 'refractory glaucoma <sep> 154 cases 159 eyes with refractory glaucoma underwent hunan aqueous drainage had implantation from july 1995 to july 2001 <sep>'], 'interventions': ['postoperative systemic corticosteroid treatment and molteno implant surgery <sep> prednisolone <sep> systemic prednisolone treatment group b. serum markers of collagen metabolism were monitored <sep>', 'endoscopic cyclophotocoagulation <sep> ahmed tube shunt implantation <sep> endoscopic cyclophotocoagulation ecp <sep> ecp <sep> ecp or ahmed tube shunt implantation <sep>', 'surgical placement of either the 350-mm or the 500-mm2 baerveldt implant at the doheny eye institute <sep>', ""adjunctive mitomycin c mmc <sep> partial tenon's capsule resection with adjunctive mitomycin c <sep> ptcr group a and without pctr <sep> partial intraoperative tenon's capsule resection ptcr with adjunctive mitomycin c <sep>"", 'double-plate molteno implant with those of the anterior chamber tube shunt to encircling band actseb procedure <sep> double-plate molteno drainage implant <sep>', 'ahmed glaucoma valve agv implant with and without surface area expansion using pericardial membrane preclude <sep>', 'intraoperative mitomycin c mmc <sep> mmc <sep> balanced salt solution <sep> intraoperative mmc <sep> adjunctive mitomycin c <sep> mitomycin c <sep>', 'glaucoma valve implant vs trabeculectomy <sep> glaucoma surgical procedures trabeculectomy and ahmed glaucoma valve implant <sep> trabeculectomy <sep> trabeculectomy or the ahmed implant <sep>', 'silicone tube of ahmed glaucoma valve implantation <sep> partial ligation of silicone tube <sep>', 'trabeculectomy and ahmed glaucoma valve implant <sep> primary glaucoma surgery with ahmed glaucoma valve implant versus trabeculectomy <sep> trabeculectomy <sep> trabeculectomy or the ahmed implant <sep>', 'placebo <sep> mitomycin c <sep> mmc <sep> balanced salt solution <sep> mitomycin c mmc 0.4 mg/ml for 2 minutes or a control balanced salt solution <sep> adjunctive mitomycin c <sep>', 'single-plate versus double-plate molteno implantation <sep> single or double-plate implants <sep> double-plate molteno implantation <sep> single versus double-plate molteno implantation <sep>', 'pressure-ridge molteno implantation versus a standard molteno implantation with suture ligation of the tube <sep> pressure-ridge double-plate molteno implant or a standard double-plate molteno molteno implant with suture ligation of the tube <sep> pressure-ridge molteno implants versus molteno implants with suture ligation <sep>', 'mmc <sep> hunan aqueous drainage had implantation with and without adjunctive intraoperative mitomycin c mmc <sep> hunan aqueous drainage implantation combined with mitomycin c <sep> had implantation <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",relatively few randomized trials have been published on aqueous shunts and methodology and data quality among them is poor. to date there is no evidence of superiority of one shunt over another.
356,"{'outcomes': ['time to androgen-independence of the tumor <sep> biopsy gleason score and baseline serum psa levels <sep> 3-year progression rate <sep> median cycle length and percentage of time off therapy <sep> serum prostate-specific antigen psa measurements <sep> serum psa levels despite androgen blockade <sep>', 'gleason score <sep> biochemical failure <sep> median psa level <sep>'], 'punchline_text': ['the estimated 3-year progression rate was significantly lower in the iad group 7.0  <sep>', 'of the 157 cases treated with ebrt 153 cases 97.5 had no biochemical failure in the mean follow-up of 17.3 months. <sep>'], 'population': ['patients with advanced prostate cancer <sep> 68 evaluable patients with hormone-naive advanced or relapsing prostate cancer <sep> patients with advanced hormone-naive prostate cancer <sep>', 'between 2001 and 2003 215 patients with locally advanced prostate cancer were enrolled in the study <sep> patients with psa levels below 10 ng/ml after the 6-month endocrine treatment <sep> 2004 <sep> patients with locally advanced prostate cancer <sep> patients were registered as primary candidates of the study and were treated with 6 months of lhrh agonist with short-term of antiandrogen treatment for flare-up prevention <sep> men with locally advanced prostate cancer <sep>'], 'interventions': ['cad <sep> intermittent versus continuous total androgen blockade <sep> combined androgen blockade <sep> total intermittent androgen deprivation iad versus total continuous androgen deprivation cad <sep>', 'continuous androgen ablation arm 1 or intermittent androgen ablation arm 2 <sep> adjuvant intermittent endocrine therapy <sep> copyright c <sep> adjuvant endocrine therapy after external beam radiation therapy ebrt <sep> neoadjuvant endocrine therapy and external beam radiation therapy <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>']}",data from rcts comparing ias to cas are limited by small sample size and short duration. there are no data for the relative effectiveness of ias versus cas for overall survival prostate cancer-specific survival or disease progression. limited information suggests ias may have slightly reduced adverse events. overall ias was also as effective as cas for potency but was superior during the interval of cycles 96%).
357,"{'outcomes': ['cardiac events <sep> subjective state hemodynamic parameters and arrhythmias <sep> hemodynamic parameters of left-ventricular performance <sep>', 'severe worsening of heart failure <sep> maximal treadmill exercise time <sep> died <sep> maximal oxygen consumption <sep>', 'adverse cardiac events and physical activities <sep> mean specific activity scale score <sep> morbidity <sep> combined adverse cardiac events <sep> cumulative incidence of combined adverse cardiac events <sep> physical activity <sep> death and hospitalization for cardiac causes <sep>', 'mortality and quality of life <sep> physical mobility score <sep> quality of life <sep> quality of life <sep> survival <sep>', 'hospitalizations <sep> adverse effect <sep> syncope <sep> morbidity and mortality <sep> cardiovascular mortality <sep> mortality <sep> serious adverse cardiovascular reactions including hypotension <sep>', 'exercise capacity <sep> exercise capacity and adverse events <sep> degree of dyspnea and patient and physician assessments of clinical status <sep> ventricular arrhythmias <sep> adverse events <sep> quality of life and for increased arrhythmias <sep>', 'oxygen consumption <sep> exercise capacity <sep> exercise duration bicycle ergometry <sep> tolerated <sep> quality of life <sep> hazard of death <sep> proarrhythmic effects 24-hour electrocardiography <sep>', 'new york heart association classification <sep> symptom limited exercise tolerance <sep>', 'adverse events <sep> cardiac status <sep> adverse events <sep> left ventricular ejection fraction <sep> exercise time <sep> exercise tolerance ventricular function and symptoms of heart failure <sep> mean heart rate and ventricular ectopic activity <sep> heart failure symptoms <sep> diuretic doses <sep> heart rate ventricular ectopic activity and mortality rate <sep>', 'deaths <sep> mortality <sep> sudden death <sep> mortality and morbidity <sep> longer survival <sep> quality of life <sep> adverse effect on survival <sep> survival <sep> agranulocytosis <sep>', 'mean ejection fraction <sep> imazodan mortality <sep> exercise performance <sep> placebo mortality <sep> exercise time ejection fraction frequency of ventricular premature complexes or ventricular tachycardia <sep> exercise time <sep>', 'exercise tolerance and quality of life <sep> efficacy <sep> overall lwhf score <sep> treadmill exercise time responses to the minnesota living with heart failure questionnaire lwhf and clinical assessments <sep> median exercise time <sep>', 'worsening heart failure <sep> early mortality <sep> morbidity and mortality <sep> reduction in risk <sep> quality of life <sep> lower morbidity and mortality <sep> mortality <sep> reversible neutropenia <sep>', 'dropout rate <sep> symptom score <sep> symptoms or exercise duration <sep> adverse effects <sep>', 'exercise tolerance and quality of life <sep> exercise duration <sep> quality of life measured with the minnesota living with heart failure questionnaire <sep> headache <sep> ejection fraction and plasma norepinephrine <sep> exercise duration peak vo2 and quality of life <sep> peak vo2 <sep> borderline significance <sep> efficacy and safety <sep>', 'frequency of decompensation from heart failure <sep> frequency of worsened heart failure <sep> treadmill exercise time <sep> left ventricular ejection fraction at rest <sep> exercise tolerance <sep> increased ventricular arrhythmias <sep>'], 'punchline_text': ['after 3 months pimobendan-treated patients showed a significant clinical improvement p  0.03). <sep>', 'maximal oxygen consumption increased by 1.7 ml/kg per min in the flosequinan group n  17 but by only 0.6 ml/kg per min in the placebo group n  23 p  0.05 between the groups. <sep>', 'death and hospitalization for cardiac causes occurred in 12 patients in the pimobendan group 10.1 vs 19 patients in the placebo group 15.3 but without significant difference. <sep>', 'with the nottingham health profile questionnaire the physical mobility score was improved after three months in the enoximone group median 21.3 compared with 41.8 in the placebo group p  0.008). <sep>', 'patients treated with milrinone had more hospitalizations 44 vs. 39 percent p  0.041 were withdrawn from double-blind therapy more frequently 12.7 vs. 8.7 percent p  0.041 and had serious adverse cardiovascular reactions including hypotension p  0.006 and syncope p  0.002 more often than the patients given placebo. <sep>', 'twelve weeks of treatment with low-dose enoximone improves exercise capacity in patients with chf without increasing adverse events. <sep>', 'no significant effects on oxygen consumption assessed in a subgroup of patients and on quality of life assessed by questionnaire were observed. <sep>', 'new york heart association classification was improved at week 16 in the flosequinan group relative to those randomised to placebo p  0.01). <sep>', 'enoximone produced significantly greater increases in exercise time than placebo treatment at weeks 4 and 8 p  0.012 p  0.029 respectively but not after 12 weeks. <sep>', 'the quality of life had improved significantly more in the 60-mg vesnarinone group than in the placebo group at 8 weeks p<0.001 and 16 weeks p=0.003 after randomization. <sep>', 'there was no significant difference observed between the placebo group and any of the treated groups with regard to exercise time ejection fraction frequency of ventricular premature complexes or ventricular tachycardia. <sep>', 'flosequinan 100 mg once daily also improved the overall lwhf score significantly compared with placebo both active therapies decreased the physical component but 75 mg flosequinan twice daily was associated with a trend toward worsening of the emotional component. <sep>', 'furthermore quality of life improved to a greater extent in the vesnarinone group than in the placebo group over 12 weeks p  0.008). <sep>', 'the dropout rate was significantly higher p less than 0.02 with enoximone 46 than with placebo 25%). <sep>', 'there were no significant differences between the placebo and pimobendan groups with respect to changes in ejection fraction and plasma norepinephrine measured at baseline and at the completion of the 12-week study proarrhythmic effect or the number of patients with a significant adjustment in background therapy. <sep>', 'treatment with milrinone or digoxin significantly increased treadmill exercise time as compared with placebo by 82 and 64 seconds respectively 95 percent confidence limits 44 and 123 and 30 and 100). <sep>'], 'population': ['chronic heart failure <sep> patients with congestive heart failure <sep> patients with congestive heart failure nyha classes ii and iii <sep>', 'patients with chronic heart failure <sep> patients with chronic heart failure who remain symptomatic despite treatment with digoxin and diuretic drugs <sep> one hundred ninety-three patients with chronic heart failure new york heart association functional class ii or iii and left ventricular ejection fraction  40 receiving digoxin and diuretic drugs <sep>', 'chronic heart failure chf <sep> 306 patients with stable new york heart association class iim or iii chf and a radionuclide or echocardiographic left ventricular ejection fraction lvef <sep> patients with mild to moderate chronic heart failure <sep> patients with mild to moderate chf <sep>', 'severe heart failure <sep> patients with severe heart failure who remain incapacitated despite conventional treatment <sep> group 27 deaths compared with 18 in the <sep> planned 200 patients with severe symptomatic heart failure despite treatment with diuretics and where appropriate and tolerated angiotensin converting enzyme inhibitors and digoxin <sep> district general hospitals and cardiological referral centres in the united kingdom <sep> patients with severe end stage heart failure <sep>', 'severe chronic heart failure <sep> 1,088 patients with severe chronic heart failure new york heart association class iii or iv and advanced left ventricular dysfunction to double-blind treatment with 40 mg of <sep> 527 patients <sep> patients with severe chronic heart failure <sep> 561 patients or <sep> patients with chronic heart failure <sep>', '105 patients with new york heart association class ii to iii ischemic or nonischemic chronic heart failure chf <sep> heart failure patients <sep> chronic heart failure <sep> patients with chf <sep>', 'outpatient cardiology clinics in six european countries <sep> patients with heart failure <sep> 317 patients with stable symptomatic heart failure objectively impaired exercise capacity and an ejection fraction of 45 or lower who were treated with at least an angiotensin converting enzyme inhibitor and a diuretic and who tolerated a test dose of pimobendan <sep> patients with chronic heart failure <sep> patients with chronic heart failure who are also on conventional treatment <sep>', 'moderate heart failure <sep> one hundred-thirty five patients with moderate heart failure recruited from 18 centres <sep> fifteen patients in the <sep>', 'chronic heart failure <sep> 164 patients with new york heart association functional class ii or iii heart failure <sep> all patients were receiving digitalis and/or diuretics and had left ventricular ejection fractions less than or equal to 45 <sep>', '3833 patients who had symptoms of new york heart association class iii or iv heart failure and a left ventricular ejection fraction of 30 percent or less despite optimal treatment <sep> patients with severe heart failure <sep>', '147 patients with congestive heart failure to determine clinical efficacy and safety <sep> chronic congestive heart failure <sep>', '322 patients with predominantly new york heart association class ii or iii congestive heart failure and left ventricular ejection fractions of 35 or less who were stabilized on a diuretic angiotensin converting enzyme inhibitor and <sep> patients with congestive heart failure who remain symptomatic on diuretic digoxin and an angiotensin converting enzyme inhibitor <sep>', 'patients with symptomatic heart failure <sep> patients with chronic congestive heart failure <sep> patients with heart failure <sep> 253 patients <sep> patients with congestive heart failure <sep> patients receiving concomitant therapy with digoxin 87 percent and an angiotensin-converting-enzyme inhibitor 90 percent who had ejection fractions of 30 percent or less <sep>', 'patients with moderate to moderately severe congestive heart failure <sep> 102 outpatients 50 receiving <sep> with moderate to moderately severe congestive heart failure <sep>', 'one hundred fifty-eight 80 patients were taking a converting enzyme inhibitor cei and 28 14 patients were taking a non-cei vasodilator <sep> one hundred ninety-eight ambulatory patients with symptoms of moderate to severe heart failure despite therapy with digitalis and diuretics with or without a single vasodilator <sep> patients with heart failure <sep>', 'patients with chronic heart failure <sep> 230 patients in sinus rhythm with moderately severe heart failure to treatment with <sep>'], 'interventions': ['pimobendan 5 mg bid or placebo orally in addition to a basic therapy diuretics digitalis <sep> pimobendan <sep> placebo <sep> pimobendan udcg 115 bs <sep>', 'flosequinan <sep> placebo <sep> flosequinan <sep>', 'pimobendan <sep> placebo <sep>', 'enoximone <sep> enoximone <sep> placebo <sep>', 'placebo <sep> oral milrinone <sep> milrinone <sep> oral milrinone daily <sep> placebo milrinone <sep> conventional therapy with digoxin diuretics and a converting-enzyme inhibitor <sep> milrinone <sep>', 'enoximone <sep> placebo <sep> placebo or enoximone <sep> low-dose enoximone <sep> treadmill maximal exercise testing <sep> enoximone <sep>', 'pimobendan <sep> pimobendan <sep> placebo <sep>', 'placebo <sep> placebo <sep> flosequinan <sep>', 'enoximone <sep> enoximone <sep> oral enoximone therapy <sep> placebo <sep>', 'vesnarinone <sep> vesnarinone <sep> placebo <sep>', 'imazodan <sep> placebo <sep> diuretics digoxin and an angiotensin-converting enzyme inhibitor <sep>', 'placebo <sep> flosequinan <sep> flosequinan twice daily or matching placebo <sep> flosequinan-ace inhibitor trial facet <sep> flosequinan <sep> digoxin <sep> angiotensin converting enzyme inhibitors diuretics and digoxin <sep>', 'double-blinded therapy with 60 mg of vesnarinone per day 120 mg of vesnarinone per day or placebo <sep> vesnarinone <sep> placebo <sep> inotropic therapy <sep>', 'enoximone <sep> placebo <sep> enoximone and 52 receiving placebo <sep> digoxin and diuretics without vasodilators and converting enzyme inhibitors <sep> oral enoximone <sep> enoximone <sep>', 'pimobendan <sep> placebo <sep>', 'placebo <sep> oral milrinone digoxin and their combination <sep> milrinone <sep> digoxin milrinone both or placebo <sep> milrinone or digoxin <sep> milrinone and digoxin <sep> digoxin <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>']}",our results confirm that pdis are responsible for an increase in mortality rate compared with placebo in patients suffering from chronic heart failure. currently available results do not support the hypothesis that the increased mortality rate is due to additional vasodilator treatment. consequently the chronic use of pdis should be avoided in heart failure patients.
358,"{'outcomes': ['rates of pulmonary embolism <sep> symptomatic venous thromboembolism <sep> occurrence of symptomatic venous thromboembolism <sep> rates of venous thromboembolism <sep> rates of deep-vein thrombosis <sep> venous thromboembolism <sep> rates of bleeding episodes <sep> pulmonary embolism or deep-vein thrombosis <sep> provoked venous thromboembolism <sep>'], 'punchline_text': ['the rates of pulmonary embolism were 0.09 in the rosuvastatin group and 0.12 in the placebo group hazard ratio 0.77 95 ci 0.41 to 1.45 p=0.42 whereas the rates of deep-vein thrombosis only were 0.09 and 0.20 respectively hazard ratio 0.45 95 ci 0.25 to 0.79 p=0.004). <sep>'], 'population': ['2009 massachusetts medical society <sep> 17,802 apparently healthy men and women with both low-density lipoprotein ldl cholesterol levels of less than 130 mg per deciliter 3.4 mmol per liter and high-sensitivity c-reactive protein levels of 2.0 mg per liter or higher to receive <sep> apparently healthy persons <sep>'], 'interventions': ['statin therapy <sep> placebo <sep> rosuvastatin 20 mg per day or placebo <sep> rosuvastatin <sep>'], 'punchline_effect': [' no diff <sep>']}",available evidence showed that rosuvastatin was associated with a reduced incidence of vte but the evidence was limited to a single rct. randomised controlled trials of statins including rosuvastatin are needed to evaluate the efficacy of statins in the prevention of vte.
359,"{'outcomes': ['immune response and the peripheral white blood cell count <sep> seroconversion rate <sep> hemagglutination inhibition titer <sep>', 'antibody titers <sep> seroresponse rates <sep> seroconversion rates <sep> seroconversion and seroresponse rates <sep>', 'hi titers <sep> protective titers <sep> immunoglobulin levels and neutropenia <sep> hemagglutination inhibition hi titers <sep>', 'geometric mean titers gmt and 4-fold rises in hai titers <sep> hai titers <sep> hemagglutinin-inhibition hai antibody titers <sep> immune responses <sep>', 'seroresponse rates <sep> protective responses <sep> response rates <sep> tolerated <sep>', 'response rate <sep> protective titer rates <sep> low white blood cell wbc count <sep> hemagglutinin-inhibition hi antibody titers <sep> immune response <sep> response rates <sep> immune response <sep>', 'protective antibody titres <sep> total white cell count or neutrophil count at immunisation type of cancer or length of time on treatment for acute lymphoblastic leukaemia <sep> protective response <sep> influenza virus susceptibility <sep>', 'antibody titers <sep> antibody titers <sep> titer of antibody <sep> antibody responses <sep>'], 'punchline_text': ['there was no correlation between the immune response and the peripheral white blood cell count except at counts less than or equal to 1,000. <sep>', 'children with all developed significant antibody titers to a/panama 2007 99 antigen 4 weeks after the second immunization. <sep>', 'there was a difference in hi titers to a/vic/75 between patients on and off chemotherapy after a single injection 34 vs. 71 p less than 0.001 for a four-fold rise. <sep>', 'although post-immunization gmt were lower in children with all compared to healthy children for the h1n1 antigen p<0.001 the h3n2 antigen p=0.03 and for the influenza b antigen p=0.003 at least 60 of children with all had at least a 4-fold rise in hai titers to each of the influenza antigens. <sep>', 'seroresponse rates 4-fold rise in hi for h1n1 h3n2 and b were 52 33 and 51 in 65 episodes. <sep>', 'multivariate analysis revealed that factors significantly associated with a lower immune response were low igg p  0.001 and administration of chemotherapy p  0.003 for h1n1 administration of chemotherapy p  0.008 for h3n2 and low white blood cell wbc count p  0.030 and low igg p  0.030 for influenza b. influenza vaccination given to children with cancer was safe and induced immune reaction comparable to healthy children although patients on chemotherapy and/or with chemotherapy-related conditions had a limited ability to produce a sufficient immune response. <sep>', 'older age was associated with increased response to the h1n1 and h3n2 vaccine components but total white cell count or neutrophil count at immunisation type of cancer or length of time on treatment for acute lymphoblastic leukaemia did not affect response. <sep>', 'after the second immunization children off therapy showed significantly higher antibody titers to both antigens than did children receiving therapy or controls p less than 0.01 for both a/nj/76 and a/vic/75). <sep>'], 'population': ['children with acute lymphocytic leukemia and other malignancies between three and 17 years of age were immunized with <sep> individuals with malignancy and other immunodeficient states <sep> immunosuppressed children <sep>', 'children with leukemia undergoing chemotherapy <sep> children with either all or asthma in taiwan <sep> children with all who received <sep> 65 children under 15 years old were studied including 25 children with all undergoing chemotherapy 30 with asthma in remission who were regularly followed at clinics and 10 healthy children <sep> children with acute lymphoblastic leukemia all <sep>', 'children with neoplastic diseases <sep> 1976 147 children with neoplastic diseases received <sep> thirteen normal siblings served as controls <sep>', 'children with all and healthy controls <sep> children receiving <sep> children receiving maintenance chemotherapy for acute lymphoblastic leukemia <sep> children with acute lymphoblastic leukemia all receiving maintenance chemotherapy with those in healthy children <sep>', 'children with solid tumours and lymphoma <sep> sixty six children were assessed prior to 69 episodes of vaccination <sep> children with non-leukaemic malignant disease <sep> children with solid tumours <sep>', 'children with cancer <sep> forty-four children with various types of malignancies <sep>', 'eighty four children with cancer were tested for susceptibility to the circulating strains of influenza virus in autumn 1995 and 1996 <sep> children being treated for cancer <sep> children with cancer <sep> cancer <sep> 40 against all three of the prevalent influenza virus strains <sep>', '22 children receiving maintenance chemotherapy for acute lymphoblastic leukemia all 16 children no longer receiving therapy for all and 50 sibling controls <sep> children with acute lymphoblastic leukemia <sep> children with all who are receiving <sep>'], 'interventions': ['influenza immunization <sep> bivalent influenza vaccine containing a/new jersey/76 and a/victoria/75 <sep>', 'influenza vaccine contained antigens b/yamanashi/166/98 a/new caledonia/20/99 h1n1 and a/panama/2007/99 h3n2 <sep> panama/2007/99(h3n2 <sep> influenza vaccine <sep> reinduction chemotherapy <sep>', 'influenza immunization <sep> wyeth split-product bivalent influenza vaccine <sep>', 'influenza vaccine <sep> influenza immunization <sep> maintenance chemotherapy <sep> gmt <sep>', 'influenza vaccine <sep> trivalent split virus influenza vaccine <sep> influenza vaccine <sep> influenza immunisation <sep>', 'influenza vaccine <sep> influenza vaccine <sep> influenza vaccination <sep> inactivated trivalent split influenza vaccine <sep>', 'continuing chemotherapy <sep> trivalent split virus influenza vaccine <sep> influenza vaccine <sep> influenza immunisation <sep>', 'chemotherapy <sep> bivalent influenza vaccine containing a/victoria/75 a/vic/75 and a/new jersey/76 a/nj/76 viral antigens <sep> influenza vaccine <sep> influenza immunization <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",paediatric oncology patients receiving chemotherapy are able to generate an immune response to the influenza vaccine but it remains unclear whether this immune response protects them from influenza infection or its complications. we are awaiting results from well-designed rcts addressing the clinical benefit of influenza vaccination in these patients.
360,"{'outcomes': ['community-acquired pneumonia <sep>', 'treatment failure <sep> treatment failure persistence of lower chest indrawing or new danger signs <sep> hypoxia <sep> very fast breathing <sep>'], 'punchline_text': ['the results support the use of co-trimoxazole as the antibiotic of first choice in outpatient management of young children with pneumonia in developing countries. <sep>', 'treatment failure was 19 in each group 161 patients pencillin 167 amoxillin risk difference 0.4 95 ci 4.2 to 3.3 at 48 h. infancy age 3-11 months odds ratio 2.72 95 ci 1.95 to 3.79 very fast breathing 1.94 1.42 to 2.65 and hypoxia 1.95 1.34 to 2.82 at baseline predicted treatment failure by multivariate analysis. <sep>'], 'population': ['young gambian children <sep> young children with pneumonia in developing countries <sep> 134 gambian children under 5 years of age with severe pneumonia as defined by the world health organisation classification of acute respiratory infections <sep>', 'severe pneumonia in children aged 3-59 months <sep> children aged 3-59 months with severe pneumonia were admitted for 48 h and if symptoms improved were discharged with a 5-day course of oral <sep> severe pneumonia in children aged 3 to 59 months <sep> who-defined severe pneumonia lower chest indrawing <sep> tertiary-care centres in eight developing countries in africa asia and south america <sep> 1702 children <sep>'], 'interventions': ['co-trimoxazole <sep> oral co-trimoxazole <sep> fortified procaine penicillin and 5 days of oral ampicillin <sep> ampicillin or procaine penicillin <sep> procaine penicillin with ampicillin <sep> co-trimoxazole <sep>', 'parenteral penicillin <sep> oral amoxicillin <sep> injectable penicillin <sep> injectable penicillin <sep> injectable penicillin and oral amoxicillin <sep> amoxicillin <sep> oral amoxicillin <sep> oral amoxicillin and parenteral penicillin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>']}",oral therapy appears to be an effective and safe alternative to parenteral antibiotics in hospitalised children with severe pneumonia who do not have any serious signs or symptoms.
361,"{'outcomes': ['recall of having discussed side effects <sep> patient satisfaction with communication mood state or quality of life <sep> degree of information provision audiotape satisfaction and use communication satisfaction with oncologist mood state and cancer-specific quality of life <sep>', 'recall of the information given during the consultation <sep> patient satisfaction <sep>', 'total recall <sep> satisfaction <sep> spontaneous ie unprompted recall <sep> patient satisfaction psychologic adjustment and recall of information <sep> average recall <sep>', 'state anxiety levels <sep> levels of depression <sep>', 'perception of being informed about clinical trials knowledge of information relevant to providing informed consent to a clinical trial and satisfaction with communication during the consultation <sep>', 'degree of information provision audiotape satisfaction and use communication satisfaction with oncologist mood state and cancer-specific quality of life <sep> patient satisfaction with communication mood state or quality of life <sep>', 'patient recall anxiety and depression satisfaction with and use of the communication aids and patient preferences for six communication options <sep> recall anxiety or depression <sep>'], 'punchline_text': ['patients receiving the consultation audiotape had significantly better recall of having discussed side effects of treatment than patients who did not receive the audiotape. <sep>', '2.0 on a scale of 0-10 p  0.04 and significantly improved recall of the information given during the consultation 88  <sep>', 'satisfaction with the tape itself was higher in patients who received the consultation tape satisfaction score 61 compared with those who received the general tape 43%). <sep>', 'sixty newly diagnosed men were randomly assigned to receive either a self-efficacy information intervention that consisted of a written information package with discussion a list of questions they could ask their physician and an audiotape of the medical consultation n  30 or a written information package alone n  30). <sep>', 'the consultation audiotapes contained less trial-related information than the standardized audiotape but there were no differences in clinical trial knowledge or perception of being informed across the intervention groups. <sep>', 'audiotape benefit was not significantly related to patient satisfaction with communication mood state or quality of life at 12 weeks post-consultation and was not significantly affected by choice of receiving the audiotape. <sep>', 'satisfaction with the tape and letter were uniformly high and they did not differentially affect recall anxiety or depression. <sep>'], 'population': ['participants included 628 women newly diagnosed with breast cancer and 40 oncologists from six cancer centers in canada <sep> women with breast cancer <sep> women with breast cancer <sep>', 'physicians and advanced cancer patients <sep> copyright 1999 american cancer society <sep> sixty patients with advanced cancer <sep> patients with advanced cancer <sep>', 'patients n  142 <sep>', 'sixty newly diagnosed men <sep> men with prostate cancer <sep> older men <sep> men newly diagnosed with prostate cancer <sep> respondents were recruited from one community urology clinic in winnipeg manitoba <sep>', 'participants were 69 women with newly diagnosed breast cancer and 21 oncologists from 5 canadian cancer centers <sep> 2006 <sep>', 'participants included 425 men newly diagnosed with prostate cancer and 15 radiation oncologists from 4 cancer centers in canada <sep> men with prostate cancer with an audiotape of their primary treatment consultation <sep> men with prostate cancer <sep>', 'one hundred eighty-two cancer patients <sep> patients after their first consultation with a medical oncologist <sep>'], 'interventions': ['primary adjuvant treatment consultations <sep> standard care control not audiotaped audiotaped no audiotape given audiotaped patient given audiotape and audiotaped patient offered choice of receiving audiotape or not <sep> consultation audiotape <sep>', 'tape recording of their consultation or receive no tape <sep>', 'audiotape of their consultation 2 an audiotape describing cancer in general terms or 3 no tape <sep>', 'self-efficacy information intervention that consisted of a written information package with discussion a list of questions they could ask their physician and an audiotape of the medical consultation n  30 or a written information package alone <sep>', 'standardized audiotape versus recorded consultation to enhance informed consent <sep> standardized audiotape 2. consultation audiotape <sep> copyright c <sep>', 'consultation audiotape <sep> audio-taped--patient given audiotape <sep>', 'audiotape of the consultation versus individualized summary letters <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",the provision of recordings or summaries of key consultations may benefit most adults with cancer. although more research is needed to improve our understanding of these interventions most patients find them very useful. practitioners should consider offering people recordings or written summaries of their consultations
362,"{'outcomes': ['initial tumour relapse <sep> probability of remaining free of recurrent disease <sep> 5-year survival <sep>', 'median disease free interval after hepatectomy <sep> adverse effect <sep> dead of disease <sep> recurrence <sep> 1-year 3-year and 5-year cumulative survival rates <sep> 1-year 2-year and 3-year disease free survival rates <sep> disease free survival <sep>', '5-year survival rate <sep> median survival <sep> median time to progression <sep> grade 3 and 4 toxicities world health organization mainly stomatitis <sep> nausea <sep> rate of intrahepatic recurrence and improve survival <sep> intrahepatic recurrence <sep> colorectal carcinoma develop liver metastases <sep> survival <sep> risk of death <sep>', 'ttf and survival <sep> two and 5-year cumulative survivals <sep> median survival <sep> survival <sep> median time to failure ttf <sep> ttf <sep>', '4-year liver recurrence-free rate <sep> median survival <sep> time to recurrence and hepatic disease-free survival not overall survival <sep> 4-year recurrence-free rate <sep>'], 'punchline_text': ['the initial tumour relapse was shifted towards extrahepatic sites in group-a patients but no difference was obtained regarding the definite distribution of recurrent disease. <sep>', 'significant prolongation of disease free survival was observed in the hai group p  0.045). <sep>', 'the median time to progression was 14.2 months for the chemotherapy group versus 13.7 months for the control group. <sep>', 'arm a2 had an improved ttf when compared with arm a1 p  .03). <sep>', 'the 4-year liver recurrence-free rate was 43 in the control group and 67 in the chemotherapy group p .03). <sep>'], 'population': ['high-risk patients <sep> colorectal liver metastases <sep> thirty patients with mesenteric lymph-node metastases dukes c <sep> from july 1984 to december 1985 a total of 42 consecutive patients underwent r0 resection of colorectal liver metastases <sep> 12 patients with no mesenteric lymph-node metastases dukes a/b <sep>', 'copyright 2000 american cancer society <sep> curative resection of colorectal liver metastases <sep> nineteen patients who underwent curative hepatectomy for metastatic colorectal carcinoma <sep>', 'liver metastases of colorectal cancer <sep> between april 5 1991 and december 31 1996 patients with colorectal liver metastases from 26 hospitals were stratified by the number of metastases and the site of the primary tumor and randomized to resection of the liver metastases followed by <sep> patients with resection of colorectal liver metastases <sep> german cooperative on liver metastases arbeitsgruppe lebermetastasen <sep> patients with radical resection of colorectal liver metastases <sep>', 'colorectal cancer metastatic to the liver <sep> 91 patients with solitary or multiple metastases from colorectal cancer <sep>', 'resectable metastatic colorectal carcinoma <sep> patients with one to three potentially resectable metastases <sep> patients undergoing hepatic resection of liver metastases from colorectal cancer <sep>'], 'interventions': ['adjuvant hepatic-artery infusion chemotherapy <sep> mitomycin c <sep> adjuvant regional chemotherapy <sep> adjuvant intra-arterial chemotherapy <sep> 5-fluorouracil <sep> hepatic artery port catheter <sep> adjuvant chemotherapy <sep>', 'hai <sep> prophylactic hepatic arterial infusion chemotherapy <sep> hepatic arterial infusion hai chemotherapy <sep> continuous intraarterial infusion of 5-fluorouracil 5-fu <sep> 5-fu <sep>', 'chemotherapy <sep> 5-fluorouracil 5-fu <sep> folinic acid <sep> liver resection only <sep> surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid <sep> adjuvant hai of 5-fu <sep> adjuvant hepatic arterial infusion hai <sep>', 'arm a1 resection only arm a2 resection and continuous hepatic artery infusion chai of fluorodeoxyuridine fudr group b-arm b1 resection and chai arm b2 chai only group c-arm c1 chai arm c2 systemic fluorouracil followed by chai <sep>', 'combined-modality treatment <sep> postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil chemotherapy <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",though recurrence in the remaining liver happened less in the hepatic artery chemotherapy group overall survival was not improved and even favoured the control group though not significantly. this added intervention cannot be recommended at this time.
363,"{'outcomes': ['age sex pain measured with an analog visual scale and adverse events <sep> headache <sep> pain <sep> mild pain <sep> pain <sep>', 'intensity of pain <sep> mean pain duration activity of the extremity and hours of sleep <sep> free of symptoms <sep> headache <sep>', 'asymptomatic with activities of daily living <sep> external rotation <sep> internal rotation impingement <sep> internal rotation <sep> pain scores range of motion internal rotation impingement muscular force and patient outcomes <sep> subscapularis pushoff <sep> shoulder pain with activity <sep> range of motion in abduction and internal rotation <sep>'], 'punchline_text': ['the difference between groups was statistically significant. <sep>', 'the mean pain duration activity of the extremity and hours of sleep also improved in the ntg group with no significant modification in the placebo group. <sep>', 'topical glyceryl trinitrate treatment significantly improved pain scores range of motion internal rotation impingement muscular force and patient outcomes in patients with supraspinatus tendinopathy. <sep>'], 'population': ['semirural basic health area in the garraf region of barcelona province spain with a population of public health service users of 12000 <sep> rotator cuff tendinitis <sep> patients with rct <sep> mean age was 61 years <sep> patients diagnosed as having rct of less than 6 weeks evolution who had not responded to treatment with oral nonsteroid antiinflammatory drugs <sep> a total of 48 patients were included 33 69 were women and 15 31 were men <sep> patients with rotator cuff tendinitis rct <sep>', '20 patients with shoulder pain syndrome caused by supraspinatus tendinitis <sep>', 'patients with supraspinatus tendinopathy <sep> chronic supraspinatus tendinopathy <sep> fifty-three patients 57 shoulders <sep>'], 'interventions': ['transdermal nitroglycerin <sep> ntg <sep> transdermal nitroglycerin ntg <sep> local infiltration via a posterior approach with a depot corticosteroid and local anesthesia and b group b treated for 3 days with a 5-mg ntc patch <sep>', 'placebo <sep> transdermal nitroglycerin <sep> transdermal nitroglycerin ntg <sep> 5-mg ntg nitroplast patch <sep> ntg <sep>', 'placebo <sep> topical glyceryl trinitrate therapy <sep> topical glyceryl trinitrate application <sep> continuous topical glyceryl trinitrate treatment 1.25 mg/24-h glyceryl trinitrate <sep> topical glyceryl trinitrate <sep> glyceryl trinitrate <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is some evidence from one study at high risk of bias that topical glyceryl trinitrate is more effective than placebo for rotator cuff disease among patients with acute symptoms seven-days duration but there is insufficient evidence to be certain about their longer-term effects. headache was a common side effect in one trial and any benefits of treatment need to be balanced against the risk of headache. further high quality research is needed to determine the effectiveness and safety of this new therapy.
364,"{'outcomes': ['consumption index <sep> mean arterial pressure systemic vascular resistance pulmonary vascular resistance and left and right ventricular stroke work <sep> global hemodynamic variables oxygen consumption urine flow creatinine clearance and arterial blood lactate levels <sep> oxygen delivery index <sep> cardiac index and oxygen consumption <sep> cardiac index <sep> stroke volume <sep> mean arterial blood pressure <sep> blood lactate concentrations <sep> blood pressure <sep> urine flow and creatinine clearance <sep> renal function <sep> heart rate <sep>', 'mortality organ-failure-free days length of critical care unit stay and adverse events <sep> time to vasoactive-free hemodynamic stability <sep> adverse event rate ratios <sep> mortality <sep> length of stay <sep> efficacy and safety <sep>', '90-day mortality <sep> overall rates of serious adverse events <sep> 28-day mortality <sep> mortality rate <sep> 28-day mortality rate <sep> mortality rates <sep> mortality <sep> severe septic shock <sep>', 'phi <sep> splanchnic tissue oxygen utilization <sep> hemodynamic profile oxygen delivery oxygen consumption determined by indirect calorimetry and gastric intramucosal ph phi determined by gastric tonometry <sep> systemic vascular resistance index <sep> oxygen delivery and oxygen consumption <sep> splanchnic oxygen requirements <sep> systemic and splanchnic oxygen utilization <sep>', 'mean arterial pressure <sep> cardiac index <sep> oxygen transport <sep> systemic and pulmonary hemodynamic or blood gas <sep> gastric mucosal blood flow <sep> systemic and pulmonary hemodynamics arterial and swan-ganz catheters gastric mucosal blood flow laser doppler flowmetry technique hepatic function indocyanine green clearance and blood gases <sep>', 'mean arterial pressure <sep> catecholamine pressors withdrawn and blood pressure <sep> systolic arterial pressure <sep> arterial pressure and systemic vascular resistance <sep> died of refractory hypotension <sep> arterial pressure <sep> peripheral vasoconstriction systemic vascular resistance <sep>', 'time spent with systolic arterial blood pressure <sep> intraoperative maximum and minimum values of blood pressure and heart rate and the time spent with systolic arterial blood pressure <sep> intraoperative refractory arterial hypotension <sep> systolic arterial blood pressure and heart rate <sep> normal systolic arterial blood pressure <sep> terlipressin and norepinephrine corrected arterial hypotension <sep>', 'mean arterial pressure <sep> oscillation frequency of the doppler signal before ischaemia <sep> cutaneous vascular reactivity and flow motion response <sep> mean arterial blood pressure <sep> cutaneous reactive hyperaemia or the oscillatory pattern of vascular tone <sep> cutaneous microcirculatory response <sep> reactive hyperaemia and oscillatory changes in the doppler signal <sep> norepinephrine requirements <sep> milrinone requirements <sep>', 'time course of sofa score <sep> 28-day all-cause mortality <sep> time to haemodynamic success <sep> mortality rates <sep> time to vasopressor withdrawal <sep> efficacy and safety <sep> hospital discharge <sep> rates of serious adverse events <sep>', 'systemic pulmonary and regional haemodynamic variables <sep> cardiac output and global oxygen supply <sep> terlipressin-linked decrease in svo2 <sep> norepinephrine requirements <sep> maintain mean arterial pressure map <sep>', 'oxygen uptake <sep> peripheral blood flow or on renal blood flow <sep>', 'arrhythmic events <sep> number of days without need for organ support and the occurrence of adverse events <sep> adverse events <sep> rate of death <sep>', 'regional blood flow and oxygen transport <sep> septic shock <sep> splanchnic blood flow and vo2 <sep> oxygen consumption vo2 <sep> systemic blood flow and vo2 <sep> blood flow distribution and regional oxygen transport <sep> systemic and regional hemodynamics and oxygen transport <sep>', 'median time to achieve the map goal <sep> time to achieve map goals <sep> mean arterial pressure map goal <sep> achievement of map goal 24 h without vasopressors <sep> 90-day mortality <sep> acute circulatory failure <sep>', 'mean arterial pressure cardiac index stroke volume index and left ventricular stroke work index <sep> gastrointestinal perfusion <sep> total bilirubin concentrations <sep> new-onset tachyarrhythmias <sep> heart rate ne requirements and incidence of new-onset tachyarrhythmias <sep> gastric tonometry <sep>', 'incidence of sinus tachycardia with da <sep> efficacy and safety <sep> cardiac arrhythmias <sep> arrhythmia <sep> 28-day mortality rate <sep> cause 28-day mortality <sep> organ dysfunction hospital and intensive care unit length of stay and safety primarily occurrence of arrhythmias <sep> acute physiologic and chronic health evaluation ii score <sep> efficacy and safety <sep>', 'phi <sep> systemic hemodynamic measurements <sep> hemodynamics lactate metabolism and gastric tonometric variables <sep> gastric mucosal ph phi <sep> partial pressure of carbon dioxide pco2 gap tonometer pco2-arterial pco2 <sep> gastric mucosal acidosis and global metabolic changes <sep> lactate levels <sep> hemodynamic and tonometric parameters arterial and mixed venous gases and lactate and pyruvate blood levels <sep> lactate/pyruvate ratio <sep>', 'mean arterial pressure <sep> hemodynamic parameters and sequential organ failure assessment sofa score <sep> systemic vascular resistance <sep> cardiac output by decreasing heart rate increased creatinine clearance and improved sofa score <sep> renal function and sofa score <sep> hemodynamic variables organ dysfunction and adverse events <sep> acute coronary syndrome <sep>', 'mean arterial pressure pao2/fio2 and survival time <sep> mean stay in the picu <sep> mean arterial pressure and pao2/fio2 <sep> blood urea nitrogen creatinine ast alt and urine output <sep> oxygenation pao2/fio2 heart rate mean arterial pressure and mortality <sep> mortality <sep> heart rate <sep> pao2/fio2 rates length of stay and mortality rate in picu <sep>', 'rebound hypotension <sep> bilirubin concentrations <sep> systemic and regional hemodynamics <sep> platelet count <sep> catecholamine requirements <sep>'], 'punchline_text': ['in patients with hyperdynamic septic shock both norepinephrine and terlipressin were effective to raise mean arterial blood pressure. <sep>', 'there were no significant differences with respect to organ failure-free days 22 vs. 25.5 days p  0.11 ventilator-free days 16.5 23 days p  0.15 length of stay 8 vs. 8.5 days p  0.93 or adverse event rate ratios 12.0 95 confidence interval 2.6 to 26.7 p  0.15). <sep>', 'there were no significant differences in the overall rates of serious adverse events 10.3 and 10.5 respectively p=1.00). <sep>', 'although oxygen delivery and oxygen consumption increased in both groups of patients the phi increased significantly in those patients treated with norepinephrine whereas the phi decreased significantly in those patients receiving dopamine p  .001 for corrected 3-hour value). <sep>', 'in patients with septic shock at doses that induced the same mean arterial pressure epinephrine enhanced more gastric mucosal blood flow than the combination of dobutamine at 5 microg/kg per minute and norepinephrine. <sep>', 'arterial pressure and systemic vascular resistance were statistically unaffected in the placebo group. <sep>', 'the intraoperative maximum and minimum values of blood pressure and heart rate and the time spent with systolic arterial blood pressure below 90 mmhg and above 160 mmhg were used as indices of hemodynamic stability. <sep>', 'mean arterial blood pressure significantly increased p  0.001 and norepinephrine requirements significantly decreased p  0.001 in the avp/norepinephrine group. <sep>', 'there is no evidence for a difference in efficacy and safety between epinephrine alone and norepinephrine plus dobutamine for the management of septic shock. <sep>', 'svo2 at 4 h 59 11 vs 69 12 p=0.028]. <sep>', 'in the great majority of the study patients norepinephrine was able to increase mean perfusing pressure without apparent adverse effect on peripheral blood flow or on renal blood flow since urine flow was reestablished). <sep>', 'a subgroup analysis showed that dopamine as compared with norepinephrine was associated with an increased rate of death at 28 days among the 280 patients with cardiogenic shock but not among the 1044 patients with septic shock or the 263 with hypovolemic shock p=0.03 for cardiogenic shock p=0.19 for septic shock and p=0.84 for hypovolemic shock in kaplan-meier analyses). <sep>', 'splanchnic blood flow and vo2 p  .05 were increased in septic shock during hypotension and during vasopressor therapy. <sep>', 'there was no difference in the time to achieve map goals in the subgroups of patients with severe sepsis n  158 rr 0.81 95 ci 0.59-1.12 p  0.18 or those with acute circulatory failure n  192 rr 0.89 95 ci 0.62-1.27 p  0.49 between epinephrine and norepinephrine. <sep>', 'mean arterial pressure cardiac index stroke volume index and left ventricular stroke work index were significantly higher in avp patients. <sep>', 'there was a significantly greater incidence of sinus tachycardia with da 24.6 33/134 than ne 5.9 7/118 and arrhythmias noted with da treatment 19.4 26/134 compared with ne treatment 3.4 4/118 p  0.0001 respectively. <sep>', 'no statistical difference was found between epinephrine and norepinephrine-dobutamine for systemic hemodynamic measurements. <sep>', 'compared to baseline avp increased systemic vascular resistance decreased exposure to ne decreased cardiac output by decreasing heart rate increased creatinine clearance and improved sofa score. <sep>', 'blood urea nitrogen creatinine ast alt and urine output of patients in the tp group did not change after terlipressin. <sep>', 'there were no differences among groups in terms of systemic and regional hemodynamics. <sep>'], 'population': ['patients with hyperdynamic septic shock <sep> 131 to 701 <sep> twenty adult patients with hyperdynamic septic shock after fluid resuscitation <sep> hyperdynamic septic shock <sep> intensive care unit of a university tertiary and referral center <sep>', 'sixty-five of 69 children 94 who were randomized received the study drug 33 <sep> children with vasodilatory shock <sep> adults and children <sep> pediatric vasodilatory shock <sep>', 'patients who had septic shock and were receiving a minimum of 5 microg of <sep> patients with septic shock who were being treated with conventional catecholamine vasopressors <sep> 778 patients underwent randomization were infused with the study drug 396 patients received <sep> patients with septic shock <sep> patients with septic shock who were treated with catecholamine vasopressors <sep>', 'septic patients <sep> twenty septic patients with a cardiac index greater than 3.2 l-min-1.m-2 and either a mean arterial pressure map less than 60 mm hg or a systemic vascular resistance index <sep> patients with hyperdynamic sepsis <sep> hyperdynamic sepsis <sep>', 'septic shock <sep> patients with septic shock <sep>', 'patients admitted to a trauma intensive care unit with vasodilatory septic shock <sep> 218 to 1,190 <sep>', '42 patients scheduled for elective carotid endarterectomy 20 had arterial hypotension following general anesthesia that was refractory to <sep> patients who have received long-term treatment with renin-angiotensin system inhibitors <sep> patients chronically treated with renin-angiotensin system inhibitors <sep>', 'advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome <sep> 18 patients who had undergone cardiac or major surgery and had a mean arterial blood pressure below 65 mmhg despite infusion of more than 0.5 microg/kg per min <sep> patients with advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome <sep>', 'septic shock <sep> 330 patients with septic shock admitted to one of 19 participating intensive care units in france <sep>', 'university hospital intensive care unit <sep> septic shock patients requiring a continuous infusion of norepinephrine 0.9 microg kg(-1 <sep> patients with catecholamine-dependent septic shock <sep> patients with septic shock <sep>', 'adult patients with hyperdynamic septic shock after fluid resuscitation <sep> ten of 11 patients who did not respond to dopamine and remained hypotensive and oliguric <sep>', '1679 patients of whom 858 were assigned to <sep> shock <sep> patients with shock to receive either <sep> 2010 massachusetts medical society <sep>', 'ten patients with hyperdynamic septic shock ages ranging from 45.1 <sep> ten patients with hyperdynamic septic shock during hypotension and after <sep> 16.6 yrs and a control group of 11 postoperative cardiac surgery patients ages ranging from 54.8 <sep> septic shock <sep>', 'intensive care icu patients <sep> patients who required vasopressors for any cause at randomisation <sep> critically ill patients <sep> two hundred and eighty patients <sep> patients with septic shock and acute circulatory failure <sep> four australian university-affiliated multidisciplinary icus <sep>', 'patients with catecholamine-resistant vasodilatory shock <sep> advanced vasodilatory shock <sep> forty-eight patients with catecholamine-resistant vasodilatory shock <sep> critically ill patients <sep>', 'medical intensive care unit comparing da with ne as the initial vasopressor in fluid-resuscitated 252 adult patients with septic shock <sep> septic shock patients who were managed with a specific treatment protocol <sep> septic shock <sep>', '30 patients with a cardiac index ci  3.51 x min(-1 x m(-2 and a mean arterial pressure map  or  60 mmhg after volume loading and dopamine 20 microg/kg per min and either oliguria or hyperlactatemia <sep> septic shock <sep> adult medical/surgical intensive care unit in a university hospital <sep>', 'twenty-three patients with early 12h hyperdynamic septic shock in two teaching hospitals <sep> early hyperdynamic septic shock <sep>', 'pediatric intensive care unit of a university hospital <sep> children with septic shock refractory to high doses of <sep> 58 children with septic shock and refractory hypotension despite fluid loading and high doses of catecholamines randomly enrolled to terlipressin tp n=30 or control n=28 <sep> children <sep>', 'septic shock patients <sep> septic shock terlivap <sep> enrolled septic shock patients n  45 with a mean arterial pressure below 65 mmhg despite adequate volume resuscitation <sep>'], 'interventions': ['norepinephrine <sep> norepinephrine or terlipressin <sep> norepinephrine and terlipressin <sep> terlipressin or norepinephrine <sep>', 'placebo <sep> low-dose vasopressin <sep> vasopressin <sep> vasopressin 32 placebo <sep> vasopressin and placebo <sep> vasopressin <sep>', 'norepinephrine <sep> norepinephrine per minute to receive either low-dose vasopressin <sep> norepinephrine infusion <sep> vasopressin <sep> vasopressin and 382 norepinephrine <sep> vasopressin <sep>', 'norepinephrine <sep> dopamine <sep> norepinephrine <sep> dopamine and norepinephrine <sep> dopamine or norepinephrine <sep> dopamine <sep>', 'dobutamine and norepinephrine <sep> epinephrine or norepinephrine <sep> epinephrine <sep> epinephrine and dobutamine-norepinephrine <sep> epinephrine <sep> dobutamine <sep> dobutamine <sep> dobutamine-norepinephrine epinephrine <sep>', 'vasopressin vp <sep> placebo <sep> vp <sep> low-dose vasopressin <sep> discontinue norepinephrine phenylephrine and/or dopamine <sep> vasopressin <sep>', 'renin-angiotensin system inhibitors <sep> norepinephrine <sep> terlipressin <sep> norepinephrine infusion <sep> intravenous terlipressin <sep> terlipressin versus norepinephrine <sep> terlipressin and norepinephrine <sep> ephedrine <sep>', 'norepinephrine <sep> supplementary arginine vasopressin avp infusion <sep> avp/norepinephrine or norepinephrine alone <sep> supplementary avp infusion <sep> vasopressin <sep> laser doppler flowmeter <sep> avp/norepinephrine <sep>', 'norepinephrine plus dobutamine <sep> dopamine or norepinephrine <sep> norepinephrine plus dobutamine <sep> epinephrine <sep> epinephrine alone <sep>', 'dobutamine and terlipressin <sep> norepinephrine infusion control n=20 ii a single dose of terlipressin 1 mg n=19 or iii a single dose of terlipressin 1 mg followed by dobutamine infusion titrated to reverse the anticipated reduction in svo2 <sep> dobutamine <sep>', 'norepinephrine <sep> dopamine and norepinephrine <sep> norepinephrine or dopamine <sep> dopamine <sep>', 'dopamine <sep> norepinephrine <sep> dopamine and norepinephrine <sep> dopamine or norepinephrine <sep> norepinephrine open-label norepinephrine epinephrine or vasopressin <sep>', 'indocyanine green infusion <sep> vasopressor therapy norepinephrine or dopamine <sep> dopamine and norepinephrine <sep> dopamine or norepinephrine <sep>', 'epinephrine <sep> epinephrine <sep> epinephrine and norepinephrine <sep> epinephrine or norepinephrine <sep>', 'arginine vasopressin <sep> arginine vasopressin avp <sep> ne <sep> avp and ne <sep> avp and norepinephrine ne or ne infusion alone <sep>', 'dopamine versus norepinephrine <sep> phenylephrine <sep> norepinephrine ne and dopamine da <sep>', 'norepinephrine-dobutamine <sep> norepinephrine-dobutamine or epinephrine <sep> epinephrine <sep> norepinephrine and dobutamine to epinephrine <sep> norepinephrine and dobutamine <sep>', 'vasopressin or norepinephrine <sep> 48[symbol see text]h to achieve mean arterial pressure at or above 70mmhg <sep> avp and ne <sep> single agent or ne <sep> arginine-vasopressin avp and norepinephrine ne <sep>', 'tp <sep> terlipressin <sep> dopamine/dobutamine and adrenaline <sep> terlipressin <sep>', 'vasopressin or terlipressin <sep> norepinephrine <sep> terlipressin <sep> vasopressin and terlipressin <sep> open-label norepinephrine <sep> continuous terlipressin versus vasopressin infusion <sep> vasopressin <sep> terlipressin 1.3 microg.kg-1.h-1 vasopressin .03 u.min-1 or norepinephrine <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",there is some evidence of no difference in mortality between norepinephrine and dopamine. dopamine appeared to increase the risk for arrhythmia. there is not sufficient evidence of any difference between any of the six vasopressors examined. probably the choice of vasopressors in patients with shock does not influence the outcome rather than any vasoactive effect per se. there is not sufficient evidence that any one of the investigated vasopressors is clearly superior over others.
365,"{'outcomes': ['eventual presence of urinary keton bodies and hypoglycemic crisis <sep> need of insulin the maternal body weight gain the week and mode of delivery the neonatal weight and the maternal and fetal complications <sep> blood glucose levels <sep> mean glycemic values <sep>', 'metabolic parameters considered 24-hour mean blood glucose and glycosylated hemoglobin <sep> mean insulin requirement <sep> mean insulin requirements <sep> control of foetal growth <sep>'], 'punchline_text': ['in both the groups the mean glycemic values during fast and two hours after meals and the eventual presence of urinary keton bodies and hypoglycemic crisis were evaluated during the course of pregnancy these parameters turned out to be identical in the two groups. <sep>', 'no significant differences in mean insulin requirement at the different stages of gestation were found between the patients receiving csii and those receiving ict of either group. <sep>'], 'population': ['ten pregnant women affected by type i diabetes mellitus observed for the first time during the ii-iii month of pregnancy <sep> pregnant women with type 1 diabetes mellitus <sep>', 'i and fourteen with type ii diabetes <sep> type i and type ii diabetic pregnancy <sep> patients with type <sep> ten non-diabetic pregnant women <sep> pregnant diabetic women <sep> pregnant diabetic women fifteen with type <sep> patients with type ii diabetes <sep>'], 'interventions': ['intensified traditional insulin therapy and micropump therapy <sep> continuous subcutaneous insulin infusion with micropump cpi 9100 lilly group b underwent intensified insulin therapy <sep>', 'csii <sep> ict <sep> continuous subcutaneous insulin infusion versus intensive conventional insulin therapy <sep> csii or to ict and the subgroups compared with respect to glycaemic control insulin requirement and perinatal out-come <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>']}",there is little evidence to support the use of one particular form of insulin administration over another for pregnant women with diabetes. the data are few there are only a small number of trials appropriate for meta-analysis a small number of women included and questionable generalisability of the trial population. conclusions cannot be made from the available data. well-designed randomised trials are needed. these trials should be adequately powered to assess the effect of csii versus mdi on important outcomes for women with diabetes and their infants.
366,"{'outcomes': ['absolute risk reduction <sep> acute cholangitis <sep> normal biliary tracts <sep> acute cholangitis <sep> malignant distal strictures <sep>', 'post-ercp pancreatitis <sep> diagnosis of acute pancreatitis <sep> hyperamylasemia <sep> crp level and leukocyte count <sep> risk of pancreatitis <sep> serum amylase level <sep> cholangitis <sep> lack of antibiotic prophylaxis <sep> c-reactive protein crp level <sep> leukocyte count and liver function values <sep> clinical signs of acute pancreatitis with leukocytosis crp reaction and pain <sep> serum amylase levels <sep> liver chemical values <sep>', 'bacteremia <sep> frequency of cholangitis following ercp <sep>', 'bacteriologic failure bacteremia <sep> septic complications <sep> absence of fever cholangitis and clinical signs of sepsis <sep> clinical success <sep>', 'complications pancreatitis pancreatic and biliary sepsis <sep> frequency of pancreatitis and bacterial complications <sep> frequency duration and extent of such temporary symptoms as abdominal discomfort fever leukocytosis hyperamylasemia hyperamylasuria and cholestasis <sep> total rate of complications <sep>', 'incidence of bacteraemia <sep> septicaemia rate <sep> number of septicaemias bacteraemia with fever rigor circulatory reactions leukocytosis or leukopenia <sep>'], 'punchline_text': ['single-dose prophylaxis with piperacillin is not associated with a clinically significant reduction in the incidence of acute cholangitis after ercp in patients suspected of having biliary tract stones or distal common bile duct stricture. <sep>', 'in a multivariate analysis the lack of antibiotic prophylaxis odds ratio 6.63 p  0.03 and sphincterotomy odds ratio 5.60 p  0.05 were independent risk factors for the development of post-ercp pancreatitis. <sep>', 'the frequency of cholangitis following ercp was not significantly reduced by antibiotic prophylaxis 4 vs. 2%). <sep>', 'all seven instances of bacteriologic failure bacteremia involved patients in the placebo group p  .01). <sep>', 'statistical comparison of the groups produced no significant differences i.e. neither the antibiotic nor the infusion prophylaxis proved advantageous with respect to the frequency of pancreatitis and bacterial complications. <sep>', 'incidence of bacteraemia was 6.1 3 of 49 in group a 16 8 of 50 in group b but this difference is not statistically significant. <sep>'], 'population': ['patients suspected of having biliary tract stones or distal common bile duct stricture <sep> seventeen of the 281 patients who received <sep> 551 consecutive patients were enrolled <sep> cholangitis after endoscopic retrograde cholangiopancreatography <sep> patients who had ercp for suspected biliary tract stones or distal common bile duct stricture were eligible <sep> patients having ercp <sep>', '321 consecutive patients <sep> patients who were allergic to cephalosporins patients with immune deficiency or any other condition requiring antibiotic prophylaxis patients with clinical jaundice and pregnant patients were excluded <sep> all patients admitted to the hospital for ercp who had not taken any antibiotics during the preceding week were included <sep>', 'ninety-six patients who underwent 100 endoscopic retrograde cholangiopancreatographies were included in the study <sep>', '82 uninfected patients with cholestasis due to biliary tree obstruction of single or multiple causes <sep> 68 clinically evaluable patients underwent 81 therapeutic ercp procedures <sep> infectious complications after therapeutic endoscopic retrograde cholangiopancreatography <sep> patients presenting with cholestasis <sep>', '118 patients <sep>', 'a patients n  50 <sep> bile duct endoscopy <sep> 56 patients with indwelling biliary drainage <sep> 99 patients 51 men 48 women mean age 60.6 <sep>'], 'interventions': ['piperacillin <sep> placebo <sep> piperacillin 4 g or placebo <sep> piperacillin <sep> antibiotic prophylaxis <sep> endoscopic retrograde cholangiopancreatography ercp <sep>', 'cephtazidime intravenously 30 minutes before ercp and 2 a control group n  160 that received no antibiotics <sep> endoscopic retrograde cholangiopancreatography ercp <sep>', 'ercp <sep> endoscopic retrograde cholangiopancreatography <sep> antibiotic prophylaxis cefotaxime 2 g i.v <sep>', 'antibiotic prophylaxis before diagnostic and therapeutic endoscopic retrograde cholangiopancreatography ercp <sep> placebo <sep> piperacillin or placebo <sep> piperacillin <sep> antibiotic prophylaxis <sep>', 'ercp <sep> ercp treatment group a no treatment group b oral prophylaxis with broad spectrum tetracycline group c bedrest for 36 hours fasting stomach catheter and infusion prophylaxis <sep>', 'percutaneous transhepatic cholangiography with drainage ptcd together with simultaneous stone extraction dilatation or stent implantation <sep> cefuroxime <sep> endoscopic retrograde cholangiopancreatography ercp <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",prophylactic antibiotics reduce bacteriaemia and seem to prevent cholangitis and septicaemia in patients undergoing elective ercp. in the subgroup of patients with uncomplicated ercp the effect of antibiotics may be less evident. further research is required to determine whether antibiotics can be given during or after an ercp if it becomes apparent that biliary obstruction cannot be relieved during that procedure.
367,"{'outcomes': ['disability scores <sep> pyramidal function <sep> kurtzke functional and expanded disability status scales <sep> clinical disability scores <sep>', 'p3 peak latency <sep> erps <sep>', 'cns igg production <sep> frequency of improvement <sep> rate of cns igg synthesis <sep> bout duration <sep>', 'scripps neurological rating scale nrs and kurtzke expanded disability status scale <sep> vas scores <sep> nrs score and answers to an efficacy questionnaire <sep> serious adverse events <sep> expanded disability status scale score <sep> visual analog scale vas <sep> nrs scores <sep> nrs and vas scores <sep>'], 'punchline_text': ['in patients with relapse there was a significant decrease in clinical disability scores at 1 and 4 weeks in the methylprednisolone treated group compared with controls p less than 0.05 for each comparison). <sep>', 'after hdmp therapy the p3 peak latency was significantly shortened p=0.006 while peak latencies of other waves i.e. n1 p2 and n2 remained unchanged. <sep>', 'the frequency of improvement was significantly higher and the bout duration significantly lower in the mp group than in the placebo group. <sep>', 'changes in nrs scores among methylprednisolone and placebo-treated patients differed significantly in the first 3 weeks and after 8 weeks p  0.005 and p  0.0007). <sep>'], 'population': ['50 individuals with multiple sclerosis 22 patients were in acute relapse and 28 had chronic progressive disease <sep> patients with multiple sclerosis <sep>', 'forty-four consecutive inpatients were randomly assigned in two clinically similar groups of 22 subjects each one treated with <sep> patients with clinically active multiple sclerosis <sep> patients with multiple sclerosis <sep>', 'multiple sclerosis <sep> 23 patients with acute ms <sep>', 'twenty-five patients with an attack of ms lasting less than 4 weeks <sep> attacks of ms <sep>'], 'interventions': ['methylprednisolone <sep> placebo <sep> saline placebo <sep>', 'methylprednisolone <sep> placebo <sep> methylprednisolone hdmp <sep> hdmp <sep> intravenous hdmp <sep>', 'methylprednisolone <sep> placebo <sep> corticosteroids <sep> high-dose parenteral 6-methylprednisolone mp and placebo <sep>', 'methylprednisolone <sep> placebo <sep> methylprednisolone and placebo <sep> methylprednisolone therapy <sep> oral high-dose methylprednisolone therapy <sep> oral methylprednisolone <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",we found evidence favouring the corticosteroid mp for acute exacerbation in ms patients. data are insufficient to reliably estimate effect of corticosteroids on prevention of new exacerbations and reduction of long-term disability.studies assessing long term risk/benefit and adverse effects of corticosteroids in ms patients are urgently needed.
368,"{'outcomes': ['significant relief from menstrual pain <sep> continued relief of menstrual pain <sep>', 'urinary urgency <sep> relief of dysmenorrhea pelvic pain and deep dyspareunia after surgery according to a multidimensional and an analog pain scale <sep> midline component of menstrual pain <sep> frequency and severity of dysmenorrhea pelvic pain and dyspareunia <sep>', 'acceptable pain <sep> frequency and severity of postoperative pain <sep> postoperative ischemic pain <sep> age history of abdominopelvic surgery intraperitoneal adhesions endometriosis concomitant surgery and operating time <sep> abdominal pain postoperatively <sep> dysmenorrhea <sep> dysmenorrhea improvement <sep>', 'frequency and severity of dysmenorrhea <sep> recurrence of moderate or severe dysmenorrhea <sep> moderate or severe dysmenorrhea <sep>', 'efficacy of lpsn <sep>', 'frequency and severity of dysmenorrhea dyspareunia and chronic pelvic pain <sep> cure rate <sep>', 'relief of lateral pain back pain and dyspareunia <sep> recurrence of pain <sep> relief of midline pain <sep>'], 'punchline_text': ['in a double-blind study of 21 patients with primary dysmenorrhea 81 9 of 11 reported significant relief from menstrual pain after the surgery. <sep>', 'presacral neurectomy markedly reduced the midline component of menstrual pain but no statistically significant differences were observed between the two groups in the frequency and severity of dysmenorrhea pelvic pain and dyspareunia in the long-term follow-up. <sep>', 'the frequency and severity of postoperative pain were less in group a than in group b both p 0.05). <sep>', 'insertion of an lng-iud after laparoscopic surgery for symptomatic endometriosis significantly reduced the medium-term risk of recurrence of moderate or severe dysmenorrhea. <sep>', 'the efficacy of both surgical methods was almost equal 87.9 vs. 82.9 at the 3-month postoperative follow-up visit but the efficacy of lpsn was significantly better than that of luna 81.8 vs 51.4 at the 12-month visit. <sep>', 'the cure rate was significantly higher in group b compared with group a at a follow-up examination at 6 months 87.3 vs 60.3 and 12 months 85.7 vs 57.1%). <sep>', 'relief of lateral pain back pain and dyspareunia was variable in both groups. <sep>'], 'population': ['21 patients with primary dysmenorrhea 81 9 of 11 reported <sep> primary dysmenorrhea with laparoscopic uterine nerve ablation <sep>', 'pelvic pain associated with endometriosis <sep> tertiary institution 71 patients with moderate or severe endometriosis and midline dysmenorrhea <sep>', '44 women assigned to have <sep> women with dysmenorrhea caused by uterine myomas treated by laparoscopic bipolar coagulation of uterine vessels lbcuv <sep> eighty-five women with uterine leiomyomas and associated dysmenorrhea <sep> women with uterine myomas and dysmenorrhea <sep> private practice university-affiliated hospital <sep> eighty women completed 1 3 and 6-month follow-up <sep> 85 patients who entered the study 41 were assigned to undergo <sep>', 'women with symptomatic endometriosis in whom a levonorgestrel-releasing intrauterine device lng-iud <sep> parous women with moderate or severe dysmenorrhea undergoing first-line operative laparoscopy for symptomatic endometriosis <sep> patients with endometriosis <sep> symptomatic endometriosis <sep>', 'sixty-eight patients with primary dysmenorrhea and a poor response to medical treatment <sep> primary dysmenorrhea <sep>', 'women who are treated with conservative laparoscopic surgery for severe dysmenorrhea caused by endometriosis <sep> one hundred forty-one sexually active women of fertile age with chronic severe dysmenorrhea caused by endometriosis <sep> women with severe dysmenorrhea caused by endometriosis that was treated with conservative surgical intervention <sep> women with severe dysmenorrhea caused by endometriosis who were treated with <sep>', 'patients undergoing resection of endometriosis but not presacral neurectomy n  9 <sep> all patients had moderate to severe dysmenorrhea and stage iii-iv endometriosis <sep> midline dysmenorrhea <sep>'], 'interventions': ['laparoscopic uterine nerve ablation <sep> laparoscopic technique <sep>', 'presacral neurectomy <sep> conservative surgery and presacral neurectomy <sep> presacral neurectomy combined with conservative surgery <sep> conservative surgery alone <sep>', 'laparoscopic uterine nerve ablation luna <sep> laparoscopic uterine nerve ablation to laparoscopic bipolar coagulation <sep> laparoscopic bipolar coagulation of uterine vessels with or without luna <sep> lbcuv <sep> lbcuv-luna <sep> successful surgery <sep> luna <sep>', 'levonorgestrel-releasing intrauterine device <sep>', 'lpsn <sep> laparoscopic presacral neurectomy and laparoscopic uterine nerve ablation <sep> laparoscopic uterine nerve ablation luna <sep> laparoscopic presacral neurectomy lpsn <sep> luna <sep>', 'laparoscopic conservative surgery <sep> conservative laparoscopic surgery <sep> presacral neurectomy <sep> presacral neurectomy <sep>', 'presacral neurectomy <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",there is insufficient evidence to recommend the use of nerve interruption in the management of dysmenorrhoea regardless of cause. future methodologically sound and sufficiently powered rcts should be undertaken.
369,"{'outcomes': ['cmv <sep> cmv infection <sep> delayed infections <sep> infection rates <sep> surveillance blood cultures <sep> delayed cmv infection <sep> symptomatic cmv disease <sep> time to cmv infection and disease the first 6 months after transplantation <sep>', 'probability of presenting cmv disease <sep> cytomegalovirus cmv infection and disease <sep> cytomegalovirus disease <sep> incidence of cmv disease <sep>', 'pcr evidence for cmv viremia <sep> time to disease <sep> cmv disease and infection <sep> cmv viremia <sep> time to cmv viremia <sep> cmv disease <sep>', 'tissue invasive disease <sep> leukopenia <sep> incidence of symptomatic disease or viremia <sep> time to cmv disease or viremia <sep> ganciclovir resistance <sep> incidence of cmv disease <sep> incidence of allograft rejection <sep> tissue-invasive infection <sep>', 'cmv infection disease and disease severity without increased ganciclovir resistance or toxicity <sep> cmv infection <sep> freedom from cmv disease syndrome or tissue-invasive <sep> disease severity <sep> cmv disease severity cmv infection acute rejection opportunistic infections ganciclovir resistance and safety <sep> rates of acute rejection opportunistic infections adverse events cmv ul97 ganciclovir-resistance mutations and laboratory abnormalities <sep> cmv disease <sep>', 'cytomegalovirus disease <sep> incidence of cmv infection <sep> symptomatic herpes-simplex infections <sep> safety and efficacy <sep> cmv infection cmv disease rejection opportunistic infections and possible drug toxicity <sep> incidence of cmv disease <sep> cmv disease <sep>', 'symptomatic cytomegalovirus disease <sep> cytomegalovirus disease <sep> cytomegalovirus pneumonia <sep> incidence of documented cytomegalovirus infection <sep> rate of viral shedding <sep> rates of recovery of virus from the blood and urine <sep> frequency of adverse events <sep> rate of cytomegalovirus infection and disease without affecting the survival rate <sep>', 'cmv infection <sep> episodes of biopsy proven allograft rejections <sep> cytomegalovirus infection <sep> cmv-specific immunoglobulin m antibodies cmv immunofluorescence assay standard culture tube and shell vial blood and virus isolation urine and tissue <sep> occurrence of cmv infections <sep>', 'urine cultures positive for cmv <sep> cmv illness <sep> serum creatinine concentrations <sep>', 'cmv disease <sep> infection with candida albicans <sep> cmv infection <sep> cmv infection and cmv disease and secondary endpoints rates of fungal and bacterial infection allograft rejection and survival after transplantation <sep>', 'concanavalin a stimulation <sep> allograft survival <sep> lower activated t-cell count cd3(+)hla-dr cells <sep> lymphocyte function <sep> lymphocyte proliferation <sep>', 'rates of cmv viremia and viruria herpes simplex virus disease and the use of inpatient medical resources <sep> rate of biopsy-confirmed acute graft rejection <sep> incidence of cmv disease 90 days after transplantation <sep> risk of cmv disease <sep> hallucinations and confusion <sep> rates of other adverse events <sep> incidence or delayed the onset of cmv disease <sep> incidence of cmv disease <sep> laboratory-confirmed cmv disease <sep>', 'number of rejection steroid pulses and okt3 treatments <sep> delay between transplantation and cmv infection <sep> rate of cmv infection and cmv disease <sep> cytomegalovirus infection <sep> severe cmv disease <sep>', 'frequency of clinical infections <sep> liver function tests <sep> leucopaenia <sep>', 'tolerated <sep> cmv disease <sep>', 'biopsy-confirmed acute rejection rate <sep> average cmv-associated costs per patient <sep> risk of acute renal allograft rejection <sep> 12-month incidence of cmv disease <sep> risk of acute rejection <sep> demography immunosuppression or donor/recipient cmv serology <sep> incidence of cytomegalovirus cmv disease <sep> efficacy and safety <sep>', 'cmv infection <sep> tolerated <sep> incidences of leukopenia thrombocytopenia renal failure and other adverse events <sep> incidence of cmv infection in both cmv antibody positive <sep> symptomatic cmv disease <sep>', 'incidence of overt cmv shedding and/or pneumonitis <sep> cumulative incidence of all cmv infections including seroconversions <sep> cmv and ob <sep> prevalence of obliterative bronchiolitis ob <sep> sequelae of cytomegalovirus cmv infections <sep>', 'rate of cmv disease <sep> rate of ebv disease <sep> cmv disease <sep> frequency of cmv or ebv disease <sep>', 'acute rejection episodes <sep> cmv infection <sep> cmv serostatus cmv disease graft outcome and ganciclovir side effects <sep> rate of cmv infection <sep> cmv diseases <sep> efficacy and safety <sep>', 'detection of cmv dna virus infections other than cmv acute rejection episodes and serum creatinine levels <sep> adverse reactions <sep> safety and efficacy <sep> number of bacterial infections <sep> demographics primary renal disease graft source hla matching immunosuppressive therapy and donor-recipient cmv antibody status <sep> estimated cost of valacyclovir treatment <sep> cmv disease <sep>', 'adverse events <sep> incidence of cmv disease and viremia <sep> rate of biopsy-proven acute rejection <sep> cmv viremia <sep> efficacy and safety <sep> confirmed cmv disease <sep>', 'severity of cmv disease <sep> cytomegalovirus cmv disease <sep> transplant function <sep> peripheral blood leukocytes pp 65 shell vial culture blood and virus isolation/early antigen detection urine <sep> duration of disease <sep> cmv disease <sep>', 'total mortality <sep> cmv infection <sep> cytomegalovirus disease <sep> neurotoxicity <sep> incidence of cmv disease and delayed the onset of cmv infection <sep> nephrotoxicity <sep> time to cmv disease <sep> cmv disease <sep>', 'incidence of cytomegalovirus disease <sep> cytomegalovirus disease <sep> actuarial incidence of cytomegalovirus disease <sep> morbidity <sep> morbidity of cytomegalovirus disease <sep> pneumonitis and myocarditis <sep> adverse reactions <sep>', 'delayed acute rejection <sep> cmv infection symptomatic cmv infection and cmv disease <sep> time to asymptomatic cmv infection symptomatic cmv infections and end-organ cmv disease <sep> time to development of cmv antigenemia <sep> opportunistic or other herpesvirus infections <sep> opportunistic infections and acute graft rejection <sep> efficacy and safety <sep> median time to cmv antigenemia <sep>', 'length of hospitalization <sep> renal transplantation <sep> incidence and severity of cmv disease length of hospitalization and patient and allograft survival <sep> tolerated <sep> incidence of cmv disease <sep> efficacy safety and cost <sep>', 'cmv infection <sep> cytomegalovirus disease <sep> median time to onset of cmv infection <sep> tissue invasive disease and recurrent cmv disease <sep> median time to onset of cmv disease <sep>', 'cytomegalovirus disease <sep> cytomegalovirus <sep> excessive occurrence of cytomegalovirus disease <sep> cytomegalovirus disease <sep> adverse events <sep> cytomegalovirus disease and cytomegalovirus viremia <sep>', 'incidence of investigator-treated cmv disease events <sep> time-to-onset of cmv disease and to viremia <sep> cytomegalovirus disease <sep> efficacy and safety <sep> neutropenia with valganciclovir <sep> cytomegalovirus cmv disease <sep> cmv disease plasma viremia acute graft rejection graft loss and safety <sep> safety profile <sep> acute allograft rejection <sep> clinically effective and well-tolerated <sep> cmv viremia <sep> efficacy and safety <sep> cmv disease <sep>', 'leukopenia <sep> infection disease or sequelae of cytomegalovirus infection <sep> obliterative bronchiolitis or time to onset of grade 2 bronchiolitis obliterans syndrome <sep> cytomegalovirus syndromes <sep> overall patient survival <sep> survival advantage <sep>', 'reversible leukopenia <sep> tolerated <sep> death from cmv disease <sep> cmv colitis <sep> cmv disease <sep> efficacy and safety <sep>'], 'punchline_text': ['infection rates for acyclovir vs. ganciclovir respectively stratified by cmv serology were d+r 54 vs. 0 p=0.0008 d+r 43 vs. 6.6 p=0.01 d-r 8.3 vs. 0 p=ns. <sep>', 'the incidence of cmv disease was significantly lower in the acyclovir group 5 than in the control group 27 p  0.05). <sep>', 'no patients in the ganciclovir group compared with 14 of 23 patients 61 in the deferred-therapy group p<0.0001 developed cmv disease during the first 12 weeks. <sep>', 'leukopenia was more common in the ganciclovir group p<0.05 but in no case did it require drug discontinuation. <sep>', 'significant reductions were observed with cmv infection 64 vs. 10 p  0.001 and disease severity 110 000 vs. 3200 copies/ml p  0.009 with extended treatment. <sep>', 'oral ganciclovir reduced the incidence of cmv infection placebo 79 51.5 of 154 ganciclovir 37 24.5 of 150 p  0.001 and also reduced symptomatic herpes-simplex infections kaplan-meier estimates placebo 36 23.5 of 154 ganciclovir five 3.5 of 150 p  0.001). <sep>', 'there were no differences between the groups in the frequency of adverse events or in the rate of survival of either grafts or patients. <sep>', 'neither the cmv status of donors and recipients nor the treatment for acute rejection had any significant impact on the occurrence of cmv infections. <sep>', 'from day 15 through day 60 the patients who took ganciclovir had significantly fewer urine cultures positive for cmv but by day 90 there was no difference. <sep>', 'cmv disease developed in 23 of patients treated with acv and in 11 of patients treated with gcv  acv p=0.03). <sep>', 'antiviral prophylaxis against cytomegalovirus has been associated with reduced risk of allograft rejection and improved allograft survival after renal transplantation. <sep>', 'treatment with valacyclovir reduced the incidence or delayed the onset of cmv disease in both the seronegative patients p<0.001 and the seropositive patients p=0.03). <sep>', 'there was no significant difference between the two groups for age immunosuppressive regimen number of rejection steroid pulses and okt3 treatments. <sep>', 'prophylactic ganciclovir was associated with a lower incidence of serologically diagnosed secondary infection and the development of the igm anti-cmv antibody. <sep>', 'cmv disease occurred in 3 of 32 patients 9.3 receiving oral ganciclovir and in 4 of 32 patients 12.5 receiving iv ganciclovir within the first year after transplantation p>0.2). <sep>', 'the 12-month incidence of cmv disease was 67 in the def group compared with 6 in the gan group and 3 in the val group p<0.001 gan or val vs. def p=0.575 gan vs. val). <sep>', 'ganciclovir reduced the incidence of cmv infection in both cmv antibody positive 37 vs 4 p  0.001 and negative patients 42 vs 11 p  0.06). <sep>', 'at termination of study enrollment the cumulative incidence of all cmv infections including seroconversions was increased in group a compared with that in group g 75 versus 15 p  0.01 as was the incidence of overt cmv shedding and/or pneumonitis 50 versus 15 p  0.043). <sep>', 'the rate of ebv disease among patients treated with the combination regimen eight 33 of 24 was similar to that among patients treated with ganciclovir alone five 21 of 24 p  not significant). <sep>', 'oral and intravenous ganciclovir showed no significant difference to reduce the rate of cmv infection among high-risk kidney recipients. <sep>', 'no difference was observed between the two treatment groups with respect to detection of cmv dna virus infections other than cmv acute rejection episodes and serum creatinine levels at 3 and 6 months following transplantation. <sep>', 'significantly fewer patients in the 200-day group versus the 100-day group developed confirmed cmv disease up to month 12 posttransplant 16.1 vs. 36.8 p  0.0001). <sep>', 'the onst of cmv disease was not delayed significantly in acyclovir-treated patients compared with controls acy 47  <sep>', 'the time to cmv disease was significantly prolonged in patients on acyclovir as compared to patients on placebo p=0.013). <sep>', 'ganciclovir prophylaxis reduced the actuarial incidence of cytomegalovirus disease from 71 to 11 in cytomegalovirus-mismatched patients p  0.01). <sep>', 'there was also a trend for delayed acute rejection and fewer opportunistic or other herpesvirus infections occurred in the valacyclovir group. <sep>', 'preemptive ganciclovir therapy significantly reduced the incidence of cmv disease p  .05 in cmv-seropositive renal transplant patients who were treated with ala and was well tolerated. <sep>', 'with respect to primary cmv infection there was no difference in the rates in the 2 groups but tissue invasive disease and recurrent cmv disease were less frequent in the ganciclovir group. <sep>', 'cytomegalovirus was isolated from buffy-coat specimens from 17 of patients 11 of 64 receiving preemptive ganciclovir and from 35 of controls 17 of 49 p  0.03). <sep>', 'cmv viremia during prophylaxis was significantly lower with valganciclovir 2.9 vs. 10.4 p=0.001 but was comparable by 12 months 48.5 valganciclovir vs 48.8 ganciclovir). <sep>', 'there were no significant differences between the daily and 3-times-weekly groups with respect to survival free from cytomegalovirus infection or survival free from cytomegalovirus disease. <sep>', 'this superior protection against cmv disease extends up to 1 year after transplantation and is not associated with ganciclovir resistance. <sep>'], 'population': ['high-risk kidney transplant recipients <sep> 101 recipients of cadaveric 83 and zero haplotype-matched live donor 18 kidney transplants <sep> recipients of seronegative donor kidneys <sep> recipients of seropositive donor kidneys <sep> kidney transplant recipients <sep> twenty-seven d+r 29 d+r and 23 d-r patients <sep>', 'seventy-three adult liver transplant recipients seropositive for cmv <sep> cmv-seropositive liver transplant recipients <sep>', 'renal transplant recipients during prophylaxis <sep> renal transplant recipients <sep> renal transplant recipients using either <sep>', 'organ transplant patients at risk for primary infection donor seropositive recipient seronegative d+r <sep> primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis <sep> 155 evaluable d+r organ transplant recipients from 13 transplant centers <sep>', 'adult lung transplant recipients <sep> 136 lung transplant recipients who completed 3 months of valganciclovir prophylaxis <sep> 11 u.s. lung transplant centers <sep> cytomegalovirus after lung transplantation <sep>', 'cmv disease after orthotopic liver transplantation <sep> seronegative recipients of seronegative livers <sep> seronegative recipients <sep> orthotopic liver transplantation <sep> between december 1993 and april 1995 304 liver-transplant recipients <sep> liver-transplant recipients <sep>', '118 patients enrolled in the study 104 completed at least 30 days on the study medication and were included in our analysis of the results <sep> patients who undergo renal transplantation and cytomegalovirus disease <sep> seronegative patients who had received a kidney from a seropositive donor <sep> recipients of renal allografts <sep> recipients of renal allografts from cadavers <sep>', 'post-kidney transplant patients <sep> renal transplant patients <sep> renal transplant recipients treated prophylactically with <sep>', '37 seronegative patients <sep> cytomegalovirus disease after heart transplantation <sep> patients were stratified into two groups those who were seropositive for cmv before transplantation and those who were seronegative but who received hearts from seropositive donors <sep>', 'orthotopic liver-transplant patients <sep> liver transplantation <sep> one hundred sixty-seven liver-transplant recipients <sep> liver-transplant patients with 14 days of <sep>', 'adult renal transplant recipients <sep> renal transplant recipients <sep> patients treated with modern immunosuppression <sep> patients after renal transplantation <sep>', 'cytomegalovirus disease after renal transplantation <sep> 208 cmv-negative recipients of a kidney from a seropositive donor and 408 cmv-positive recipients <sep>', 'renal-transplant recipients <sep> cmv seronegative recipients of a renal allograft from cmv seropositive donors <sep> renal transplant recipients <sep> thirty-two patients were included in this study 15 in the control group 17 in the ganciclovir group <sep>', '65 patients after liver transplantation <sep> after liver transplantation in adults <sep>', 'high-risk cmv-seronegative liver transplant recipients with cmv-seropositive donors <sep> high-risk patients <sep> cytomegalovirus cmv)-seronegative liver transplant recipients with cmv-seropositive donors <sep> high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors <sep>', 'a total of 83 patients <sep> cmv disease after renal transplantation <sep> after renal transplantation <sep>', 'liver transplant recipients <sep> liver-transplant recipients <sep>', 'lung transplant recipients <sep> cytomegalovirus after lung transplantation <sep> after lung transplantation 25 allograft recipients <sep>', 'cytomegalovirus cmv and epstein-barr virus ebv disease after pediatric liver transplantation <sep> cytomegalovirus and epstein-barr virus disease after liver transplantation in children <sep>', 'thirty-four cytomegalovirus cmv <sep> seropositive recipients of kidneys from seropositive donors who had undergone antilymphocytic immunosuppressive therapy <sep> sixteen patients in the oral group and 14 in the intravenous group completed the study <sep> high-risk kidney recipients <sep>', 'renal transplant recipients <sep> eighty-three renal transplant recipients <sep>', '326 high-risk d+/r kidney allograft recipients <sep> high-risk kidney transplant recipients <sep>', 'high-risk renal transplant recipients cmv-seropositive donor seronegative recipient treated prophylactically with <sep> cmv high-risk renal transplant recipients <sep> cytomegalovirus cmv disease after renal transplantation tx <sep>', 'fifty-five patients <sep> liver recipients <sep> liver transplant patients <sep>', 'cytomegalovirus-positive recipients <sep> cytomegalovirus disease after heart transplantation <sep> fifty-six consecutive patients were stratified into two groups cytomegalovirus-positive recipients n  40 and cytomegalovirus-negative recipients of organs from cytomegalovirus-positive donors n  16 <sep> all patients with clinical cytomegalovirus disease <sep> clinical cytomegalovirus disease after heart transplantation <sep>', 'twenty-seven cmv seropositive adults due to receive a heart transplant <sep> cytomegalovirus reactivation after heart transplantation <sep> heart transplant recipients <sep>', 'forty consecutive cmv-seropositive renal allograft recipients who underwent transplantation between january 1992 and january 1994 and were treated with ala for induction immunosuppression or acute rejection therapy <sep> cmv-seropositive patients treated with ala <sep> 18 control patients who did not receive prophylaxis for cmv disease group 2 <sep> cytomegalovirus cmv)-seropositive renal transplant recipients treated with antilymphocyte antibody ala preparations <sep> 650-bed tertiary medical center hospital <sep> cytomegalovirus-seropositive renal transplants recipients <sep>', 'adult liver transplant recipients <sep> one hundred forty-three patients <sep>', 'renal transplant recipients who were positive for cytomegalovirus antibody <sep> cytomegalovirus antibody-positive renal transplant recipients <sep> 6 university-affiliated transplantation centers <sep> renal transplant recipients who are positive for cytomegalovirus antibody <sep> 113 renal transplant recipients who were positive for cytomegalovirus antibody <sep>', 'high-risk seronegative solid organ transplant sot recipients of organs from seropositive donors d+/r <sep> 364 cmv d+/r patients received <sep> solid organ transplant recipients <sep>', 'seventy-two consecutive subjects who had either donor or recipient cytomegalovirus seropositivity <sep> after lung and heart-lung transplantation <sep>', 'cytomegalovirus-seropositive liver transplant recipients <sep> cmv-seropositive liver transplant recipients <sep> after liver transplantation <sep>'], 'interventions': ['acyclovir <sep> oral acyclovir <sep> oral ganciclovir <sep> cmv immune globulin <sep> acyclovir vs. ganciclovir <sep> ganciclovir <sep> oral ganciclovir <sep> oral acyclovir <sep>', 'acyclovir <sep> oral acyclovir <sep>', 'acyclovir <sep> ganciclovir <sep> prophylactic oral ganciclovir <sep> oral ganciclovir <sep> prophylactic oral acyclovir intravenous ganciclovir or immunoglobulins <sep> prophylactic oral ganciclovir or deferred therapy with intensive monitoring with polymerase chain reaction pcr analysis <sep> ganciclovir <sep> oral ganciclovir <sep>', 'acyclovir <sep> oral acyclovir <sep> oral ganciclovir <sep> intravenous ganciclovir <sep> ganciclovir <sep>', 'placebo <sep> oral valganciclovir <sep> central automated system to treatment or placebo <sep> valganciclovir prophylaxis <sep>', 'placebo <sep> oral ganciclovir <sep> oral ganciclovir 1000 mg or matching placebo <sep> ganciclovir <sep> oral ganciclovir <sep>', 'acyclovir <sep> placebo <sep> acyclovir <sep> oral acyclovir <sep> acyclovir or placebo <sep>', 'controls controls n  22 who did not receive any anti-viral prophylaxis <sep> oral ganciclovir <sep> ganciclovir <sep>', 'ganciclovir <sep> placebo <sep> ganciclovir <sep>', 'acv 800 mg orally four times daily n=84 or 14 days of gcv 5 mg/kg intravenously every 12 hr followed by oral acv <sep> intravenous ganciclovir gcv <sep> oral acyclovir acv <sep> gcv  acv <sep> intravenous gcv <sep> acv <sep> ganciclovir and acyclovir to acyclovir <sep>', 'antiviral agents <sep> valacyclovir <sep> valganciclovir <sep> valganciclovir prophylaxis against cytomegalovirus <sep> valganciclovir <sep>', 'valacyclovir or placebo <sep> valacyclovir <sep> placebo <sep> valacyclovir <sep>', 'prophylactic ganciclovir <sep> ganciclovir <sep> gangiclovir prophylaxis <sep> ganciclovir <sep>', 'prophylactic ganciclovir <sep> prophylactic ganciclovir <sep> ganciclovir <sep>', 'ganciclovir oral ganciclovir <sep> sequential intravenous iv and oral ganciclovir with prolonged iv ganciclovir <sep> sequential intravenous and oral ganciclovir <sep> oral ganciclovir <sep> ganciclovir <sep>', 'def <sep> valacyclovir <sep> oral ganciclovir <sep> gan <sep> valacyclovir and oral ganciclovir <sep> oral valacyclovir <sep> valacyclovir <sep> ganciclovir and valacyclovir <sep>', 'acyclovir <sep> cmv <sep> ganciclovir <sep> ganciclovir and acyclovir <sep> prophylactic ganciclovir <sep> ganciclovir with high-dose acyclovir <sep> ganciclovir and high-dose acyclovir <sep> ganciclovir <sep>', 'acyclovir <sep> ganciclovir prophylaxis <sep> ganciclovir and acyclovir <sep> ganciclovir <sep>', 'acyclovir <sep> acyclovir with intravenous ganciclovir alone <sep> ganciclovir alone <sep> intravenous ganciclovir 10 mg/[kg.d followed by 50 weeks of high-dose oral acyclovir <sep> ganciclovir <sep>', 'intravenous ganciclovir <sep> oral ganciclovir <sep> ganciclovir prophylaxis <sep> ganciclovir <sep>', 'valacyclovir and oral ganciclovir <sep> valacyclovir <sep> oral ganciclovir <sep> valacyclovir vs. oral ganciclovir <sep> ganciclovir <sep>', 'valganciclovir prophylaxis <sep> valganciclovir cytomegalovirus prophylaxis <sep>', 'acyclovir <sep> acyclovir prophylaxis <sep> oral acyclovir <sep>', 'prophylactic high-dose acyclovir therapy <sep> acyclovir prophylaxis <sep> acyclovir <sep> placebo <sep> acyclovir <sep> acyclovir vs. 27 on placebo <sep>', 'ganciclovir <sep> placebo <sep> matching placebo <sep> equine antithymocyte globulin induction <sep> ganciclovir prophylaxis <sep> ganciclovir <sep> cyclosporine azathioprine and prednisolone <sep>', 'acyclovir <sep> valacyclovir <sep> oral valacyclovir 2000 mg or oral acyclovir <sep> valacyclovir prophylaxis <sep> valacyclovir <sep> oral valacyclovir <sep>', 'ganciclovir <sep> preemptive ganciclovir therapy <sep> ala <sep> preemptive ganciclovir therapy <sep>', 'acyclovir <sep> ganciclovir-high dose acyclovir <sep> high dose oral acyclovir <sep> transplantation acyclovir group or intravenous ganciclovir <sep> ganciclovir <sep>', 'preemptive ganciclovir therapy <sep> antilymphocyte antibody therapy <sep> preemptive ganciclovir therapy <sep> antilymphocyte antibody therapy was administered or 2 no anticytomegalovirus therapy <sep> ganciclovir <sep> antilymphocyte antibodies <sep> preemptive ganciclovir <sep>', 'valganciclovir and ganciclovir <sep> oral ganciclovir <sep> valganciclovir vs. oral ganciclovir <sep> ganciclovir <sep> valganciclovir 900 mg once daily or oral ganciclovir <sep> valganciclovir <sep>', 'ganciclovir <sep> ganciclovir prophylaxis <sep> prophylactic ganciclovir <sep> ganciclovir <sep> daily or 3-times-weekly ganciclovir <sep>', 'acyclovir <sep> ganciclovir and oral acyclovir <sep> oral acyclovir <sep> oral ganciclovir <sep> oral ganciclovir with oral acyclovir <sep> ganciclovir <sep> intravenous iv ganciclovir <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",prophylaxis with antiviral medications reduces cmv disease and cmv-associated mortality in solid organ transplant recipients. these data suggest that antiviral prophylaxis should be used routinely in cmv positive recipients and in cmv negative recipients of cmv positive organ transplants.
370,"{'outcomes': ['maximal grade of toxicity duration of grade 2 or worse mucositis quality-of-life scores percentage of weight loss use of pain medications hydration requirement oral infections and prolonged radiation breaks <sep> mean quality-of-life scores <sep> radiation-induced mucositis <sep> radiation-related mucositis <sep> tolerance to head-and-neck radiotherapy decrease mucositis reduce soreness <sep>', 'survival outcomes <sep> rates of percutaneous endoscopic gastrostomy placement <sep> severity of mucositis <sep> shorter mean radiotherapy duration <sep> overall survival <sep> severity of mucositis <sep> need for percutaneous endoscopic gastrostomy placement <sep> mucositis <sep>', 'mean duration of at least grade 3 mucositis who <sep> tolerance problems vomiting liver enzyme elevation generalized erythema <sep> severity and duration of mucositis <sep> mean duration of the use of this feeding tube <sep> acute mucositis <sep> local-regional control <sep>', 'number of severe i.e. grade 3 mucositis scores <sep> incidence and severity of oral/oropharyngeal mucositis <sep> severity of radiation-induced oral/oropharyngeal mucositis <sep>', 'symptomatic grade 3/4 mucositis <sep> positive gain in body weight <sep>', 'acute gvhd incidence or severity survival or day 100 relapse rates <sep> edema infection skin pain or rash <sep> reduced incidence and mean severity of mucositis <sep> neutrophil and platelet engraftment <sep> engraftment acute gvhd or survival <sep> safety and tolerability <sep> total of 11 dose-limiting toxicities most often skin respiratory or oral mucositis <sep>', 'rtog grade 3 or greater mucositis <sep> toxicity <sep> oral mucositis <sep> grade 3 or greater mucositis with morning rt <sep> oral mucositis <sep> weight loss <sep> longer interval to the development of grade 3 or greater mucositis <sep>', 'grade 2 mucositis and dermatitis earlier and sooner <sep> severe mucositis and dermatitis <sep> mucositis and dermatitis <sep> tumor growth and patient survival <sep> weight changes <sep> milder mucositis and dermatitis <sep> development of grade 3 mucositis and dermatitis <sep> healing of mucositis and dermatitis <sep> degree of mucositis and dermatitis <sep>', 'severe mucositis <sep> estimated odds ratio placebo/active of developing an intermediate or thick pseudomembrane <sep> mucositis grade <sep> mucositis distribution <sep> percentage of patients who developed intermediate or thick pseudomembranes <sep> weight loss <sep> dysphagia <sep> mucositis area <sep> radiation mucositis <sep> radiation mucositis pain dysphagia and weight loss <sep>', 'mean maximal intensity for nci score <sep> worsens oral mucositis <sep> oral mucositis <sep> oral mucositis <sep> oral mucositis omas nci score oral pain vas oral function and salivary flow rate <sep> visual analogue scale for oral pain and oral function <sep> mean duration of oral mucositis <sep> safety tolerability and efficacy <sep> safety and efficacy <sep>', 'complete remission cr rate <sep> 4-year survival <sep> median survival <sep> incidence of severe mucositis <sep> cr rate <sep> cr <sep> median duration of fever <sep>', 'oral mucositis and selective elimination of oral flora <sep> mean weight loss <sep> severe mucositis <sep> colonisation index of candida species and gram-negative bacilli <sep> mucositis changes in the oral flora quality of feeding and changes of total body weight <sep> mucositis score <sep> mucositis <sep> nasogastric tube feeding <sep>', 'mucositis <sep> mean toxicity score <sep> mean toxicity score for cryotherapy <sep>', 'oral mucositis <sep> incidence mean duration and mean area under the curve auc of severe oral gross mucositis <sep> oral mucositis <sep> incidence of severe mucositis <sep> severity and duration of chemotherapy-induced oral mucositis <sep> mean auc of gross/functional scores and duration of moderate gross mucositis <sep>', 'acute radiation morbidity <sep> influenza type symptoms <sep> tolerated <sep> severity of mucositis <sep> grade of mucositis skin reactions and related parameters <sep> tumour control rates <sep> acute mucositis <sep> mucositis <sep>', 'mucositis scores <sep> severity of subsequent mucositis <sep> protective effect against 5-fu-induced mucositis <sep> mean patient-judged mucositis scores <sep> mucositis <sep>', 'median ip test score <sep> urinary excretion of 51cr-edta and the severity of mucositis <sep> ip test score <sep> mucositis/stomatitis <sep> mucositis <sep> intestinal permeability ip <sep> mucositis/stomatitis of grade 2-4 <sep> severity of stomatitis <sep>', 'morbidity of concurrent chemotherapy and radiotherapy <sep> adverse events <sep> median duration of grade or 2 mucositis <sep> tolerated <sep> mucositis dysphagia and xerostomia <sep> tumor response or survival <sep> acute mucositis <sep> efficacy and safety <sep>', 'skin and oral events <sep> frequency of grade 2 to 4 mucositis <sep> oral mucositis <sep>', 'whole saliva production <sep> mucositis <sep> acute and chronic xerostomia <sep> nausea and/or vomiting <sep> nausea vomiting hypotension and allergic reactions <sep> median saliva production <sep> 2-year local-regional control disease-free survival and overall survival <sep> antitumor treatment efficacy <sep> chronic xerostomia grade <sep> incidence of grade  or 2 acute xerostomia grade  or 3 acute mucositis and grade  or 2 late xerostomia <sep> grade  or 2 acute xerostomia <sep>', 'frequency and duration of severe oral mucositis <sep> severe oral mucositis <sep> standard error of the mean maximum mucositis scores <sep> severity of mucositis <sep> mean duration <sep> pain requiring opioids chi(2 exact test ns <sep> oral pain <sep> severity of stomatitis <sep>', 'mucositis <sep>', 'incidence of hsv infection <sep> oral mucositis <sep> duration of severe mucositis <sep> severe oral mucositis <sep>', 'minimal or absent mucosal inflammation pain or dysphagia <sep> weight loss <sep> mild radiation side-effects <sep> local effectivity <sep> mucosal reactions pain and difficulty in swallowing <sep>', 'mucositis <sep> mucositis scores <sep> 5-fu-induced mucositis <sep>', 'adm-induced mucositis <sep> adm-induced oral mucositis <sep> oral mucositis <sep> mucositis and adm-induced leukopenia <sep> incidence and duration of adm-induced oral mucositis <sep>', 'oral mucositis <sep>', 'oral mucositis <sep> treatment-emergent adverse events teaes <sep> incidence of teaes <sep> om severity <sep> safety and for om incidence and severity <sep>', 'mean questionnaire scores <sep> acute xerostomia <sep> salivary gland function <sep> incidence and severity of acute mucositis acute and late xerostomia <sep>', 'mean pain sure and mucositis grade <sep> buccal toxicity <sep> oral mucositis <sep> pain and mucositis <sep>', 'oral mucositis <sep> tumor response rate <sep> oral mucositis pain xerostomia and taste disturbance <sep> incidence rates of mucositis pain xerostomia and taste disturbance <sep> amount of food intake <sep>', 'skin reaction <sep> severity maximum extent of acute radiation therapy side effects <sep> severity of acute side effects <sep> dysphagia <sep> feasible and well-tolerated <sep> mucositis skin reaction dysphagia <sep> mucositis <sep>', 'similar time to engraftment <sep> adverse events <sep> tolerated <sep> pain on swallowing and use of pain medication specifically for mucositis <sep> frequency of grade 2 to 4 mucositis <sep> mucositis <sep>', 'grade 3/4 thrombocytopenia <sep> protective activity <sep> incidence and severity of acute and late toxicities <sep> disease-free survival <sep> incidence of grade 3/4 mucositis <sep> incidence of grade 2 late xerostomia <sep> incidence of loss of taste <sep> complete responses cr and 6 24 partial responses pr <sep> acute grade 2 xerostomia <sep>', 'frequency of culture-positive herpes simplex virus <sep> frequency or type of mouth lesions <sep> radiation and chemotherapy-induced mouth lesions <sep>', 'incidence of grades 3-4 mucositis <sep> grade 3-4 mucositis <sep> severity and duration of oral mucositis <sep> total parenteral nutrition tpn narcotic use hospitalization weight loss and resumption of oral caloric intake <sep> narcotics and tpn <sep> length of hospitalization or weight loss <sep> pain <sep> pain swallowing drinking eating sleeping and taste alterations <sep>', 'hypotension <sep> cumulative asthenia <sep> delays in radiotherapy because of grade 3 mucositis <sep> incidence of acute perineal skin and bladder toxicity <sep> tolerated <sep> nausea <sep> pharyngeal esophageal and rectal mucositis <sep>', 'median interval to observation of grade  or 2 mucositis <sep> grade of mucositis <sep> intensity of mucositis <sep> frequency of mucositis grade <sep> highest grade of mucositis <sep> grade  or 3 mucositis <sep>', 'oral mucositis <sep> adverse effects <sep> numeric rating scale scores <sep> need for feeding tubes <sep> pain <sep> severity of mucositis <sep> objective mucositis score oms and the world health organization who grading system <sep> mucositis <sep> number of patients with severe objective mucositis <sep> incidence of mucositis <sep> safety and efficacy <sep>', 'mucositis <sep> pain visual analogue scale vas scores mucositis index scores and medical and nursing charts <sep> intensity of pain severity of mucositis and use of opioids <sep> mucositis <sep>', 'skin and mucosal reactions <sep> skin and mucosa reactions <sep> skin desquamation <sep>', 'demographic parameters medical status quality of life survey and mucosal injury scoring table based on world health organization scales for mucositis <sep> occurrence of mucositis <sep> mucositis <sep>', 'burning sensation <sep> number of days with fever number of oral lesions plaque score gingival bleeding score or occurrence of candidiasis <sep> oral health <sep> numbers of salivary enterococci enterobacteria and/or pseudomonas <sep>', 'median grade of oral mucositis <sep> median progression-free or overall survival times <sep> frequency of severe who grades 3 or 4 mucositis <sep> frequency and severity of therapy-induced oral mucositis <sep> toxicity engraftment supportive care response and survival <sep>', 'oral mucositis <sep> duration of mouth pain <sep> severity of oral pain <sep> duration and severity of chemotherapy-associated stomatitis <sep> duration and severity of stomatitis <sep>', 'occurrence rate of skin oral mucosal pelvic visceral and systematic adverse reaction <sep> leukopenia <sep> adverse effect of sod injection <sep>', 'oral mucositis daily fraction <sep> oral mucositis <sep> duration and severity of subjective oral mucositis <sep> duration and severity of objective oral mucositis <sep> duration of  or  grade 3 subjective mucositis <sep> duration of objective oral mucositis <sep> mean body weight change <sep> mean maximum grade of objective oral mucositis <sep> world health organization who step analgesic medication and body weight change <sep>', 'degree toxicity <sep> hematological toxicity <sep> iv degree toxicity <sep> complete remission <sep> oropharyngeal toxicity <sep> partial remission <sep> degree of oropharyngeal and hematological toxicity radiotherapy duration and curative effect <sep> platelet toxicity <sep> radiotherapy duration <sep> acute oropharyngeal toxicity <sep> oropharyngeal mucositis <sep> neutrophilic granulocyte toxicity <sep> wbc toxicity <sep>', 'severe mucositis <sep> cumulative incidence of moderate to severe grade 2 or higher mucositis <sep> incidence and severity of mucositis <sep> outcome questionnaire and daily symptom record diary <sep> severe grade 3 or 4 mucositis <sep> oral assessment of mucositis by using world health organization who oral toxicity scale <sep> thickening of oral mucosa <sep> mucositis <sep> mucositis <sep> severe oral mucositis <sep>', 'peak stomatitis nci-ctc grade <sep> efficacy and safety <sep> stomatitis severity incidence of uom peak mouth pain peak difficulty swallowing amount of opiate analgesics used or adverse event type or incidence <sep>', 'oral pain <sep> oral mucositis <sep> oral mucositis <sep> pain <sep> oral ulcerative mucositis <sep> mucositis <sep>', 'mucositis and dysphagia <sep> severity of late xerostomia <sep> grade 4 mucositis <sep> proportion of patients with grade 2 xerostomia <sep> mucositis and xerostomia <sep> dysphagia <sep> treatment duration hematologic toxicity and clinical outcome <sep> acute toxicities mucositis and dysphagia <sep> grade 2 xerostomia <sep> grade 2 mucositis <sep> grading of acute and late nonhematologic toxicities mucositis dysphagia xerostomia <sep>', 'percentage of patients with positive cultures of agnb <sep> mucositis grade <sep> objective and subjective mucositis scores <sep> mucositis reduction <sep> complete eradication of agnb <sep> objective and subjective mucositis scores and microbiologic counts of the oral flora <sep>', 'oral mucositis <sep> oral mucositis <sep> incidence of use of total parenteral nutrition <sep> occurrence of mucositis the median duration of oral mucositis <sep> adverse events mainly rash pruritus erythema mouth and tongue disorders and taste alteration <sep> duration and severity of oral mucositis <sep> median duration of mucositis <sep> soreness of the mouth and throat <sep> incidence of oral mucositis of world health organization who grade 3 or 4 <sep> incidence of grade 4 oral mucositis <sep>', 'oral ulceration <sep> ulcerative om <sep> maximum severity of mouth pain and difficulty swallowing <sep> nausea <sep> oral mucositis om <sep> frequency <sep> severity of om <sep> severity of oral mucositis <sep> mouth pain and difficulty swallowing <sep>', 'grade of radiation mucositis and blood cell counts <sep> toxicity <sep> salivary lactoferrin <sep> severity of radiation-induced mucositis <sep> radiation-induced mucositis <sep> bone pain <sep> nausea <sep> eosinophil counts <sep> skin reactions <sep> fever <sep> median maximum neutrophil counts <sep> oral mucositis grade oral pain use of analgesic drugs weight loss or survival <sep> salivary lactoferrin concentrations <sep>', 'degree of mucositis <sep> oral mucositis <sep> oral mucositis and symptoms <sep> varying degrees of radiation-induced mucositis <sep> quality of life by impairing eating swallowing and talking and by disturbing sleep <sep> grade 4 mucositis <sep> oral mucositis and pain <sep> grade 3 mucositis <sep> intensity of radiation-induced mucositis and oral discomfort <sep> mucositis <sep>', 'quality of life <sep> oral discomfort <sep> severe mucosal reactions <sep> mucositis <sep>', 'xerostomia and mucositis <sep> qol scales <sep> amelioration of mucositis <sep> average unstimulated salivary flow <sep> salivary flow and qol scores <sep> radiation-associated xerostomia <sep> salivary flow xerostomia mucositis and quality of life qol <sep>', 'grade 2 or higher late xerostomia <sep> toxicity <sep> locoregional failure progression-free survival and overall survival <sep> xerostomia and mucositis <sep> adverse events <sep> toxicity incidences <sep> grade 3 or higher acute mucositis <sep> grade 2 or higher acute xerostomia <sep> efficacy and safety <sep>', 'grade iii skin reaction <sep>', 'nutritional status and overall patient outcome as assessed by days receiving tpn number of days required until oral intake resumed length of hospitalization number of days and highest grade of mucositis and quantity and number of days of diarrhea <sep> median length of stay and the median number of days of total parenteral nutrition tpn <sep>', 'mucositis grade 3-4 <sep> frequency and duration of om <sep> severity ctc-grading and duration of om <sep>', 'incidence of severe grade 3-4 oral mucositis <sep> oral mucositis <sep> incidence of oral mucositis grade 2-4 and the duration of oral mucositis grade <sep> severe oral mucositis <sep> severe oral mucositis <sep>', 'severe mucositis <sep> elevated mucositis score <sep> c-reactive protein crp increase 50mg/l <sep> crp 50mg/l <sep> numbers of aerobic and anaerobic bacteria <sep> body temperature or application of antibiotics <sep> crp increase <sep> aerobic <sep> mucositis <sep> severe leukopenia <sep>', 'radiation-induced early oral mucositis <sep> oral mucositis <sep> average mucositis score <sep> maximum mucositis scores <sep> earlier onset of mucositis <sep> tolerated <sep>', 'mucositis <sep> tumor response or survival <sep> mucosal toxicity <sep> incidence and severity of mucositis <sep>', 'persistent clinical oral candidiasis <sep> total oral streptococci <sep> deaths from disseminated candidiasis <sep> oral soft tissue disease and oral microbial burden <sep> incidence and severity of oral mucositis <sep> mucositis <sep> mucositis <sep> oral mucosal complications <sep> oral candida <sep>', 'oral complications <sep> tooth staining <sep> oral candidiasis <sep> dental plaque levels and the degree of gingivitis and mucositis <sep>', 'oropharyngeal ecology <sep> suppression of oral flora and a lowering of the severity of mucositis <sep> colonization patterns of candida species streptococcus faecalis staphylococci and enterobacteriaceae pseudomonadaceae and acinetobacter species <sep> oral flora and irradiation mucositis <sep> severity of mucositis <sep> development and severity of mucositis <sep> colonization index of viridans streptococci <sep>', 'pain control <sep> duration of neutropenia <sep> oral mucositis <sep> who toxicity scale for mucositis oral assessment scale and a subjective pain scale <sep> oral mucositis <sep> documented infections use of broad-spectrum antibiotics and number of days with fever <sep> median subjective pain scores who scores and oral assessment scores <sep> duration of hospitalization <sep> parenteral nutrition and morphine incidence of fever and infections and duration of neutropenia and hospitalization <sep> mucositis <sep>', 'probability of grade  or  3 mucositis <sep> leukocyte recovery <sep> detectable plasma concentration of gm-csf <sep> mucositis <sep> frequency of chemotherapy-induced mucositis <sep> mucositis <sep> functional activation of wbc <sep>', 'serum cytokine levels and the severity of oral mucositis <sep> skin toxicity <sep> stage iv disease <sep> grade 2 xerostomia <sep> c-reactive protein levels <sep> toxicity data <sep> overall survival rate <sep> proinflammatory cytokines tumor necrosis factor interleukin il]-1 and il-6 and lower levels of anti-inflammatory cytokines il-13 <sep> median time to percutaneous endoscopic gastrostomy removal <sep> levels of selected cytokines and mucositis severity <sep> saliva production <sep> neck dissection <sep> alive without disease recurrence <sep> efficacy/toxicity <sep> major toxicities <sep> rates of xerostomia and mucositis <sep> mucositis <sep> median number of amifostine doses <sep> percutaneous endoscopic gastrostomy <sep>', 'oral mucomembranous reaction <sep> degree of mucomembranous reaction <sep> average repairing time <sep> average time for oral lesion <sep>', 'type of mouthwash incidence days to onset and severity of chemotherapy-induced oral mucositis <sep> oral mucositis <sep> incidence of mucositis <sep> incidence days to onset and severity of mucositis <sep>', 'incidence of mucositis requiring morphine sulfate mso4 <sep> hematologic toxicity transfusion requirements duration of fever and hepatic toxicity <sep> morbidity and mortality <sep> incidence of grade  or  2 graft-versus-host disease <sep> incidence of renal insufficiency <sep> highest serum creatinine value <sep>', 'erythema and ulceration <sep> oral mucositis <sep> incidence of adverse events <sep> ulcer free <sep> effective safe and well tolerated <sep> adverse events <sep> erythema ulceration and pain associated with oral mucositis <sep> safety and efficacy <sep>', 'severe mucositis <sep> toxicity profiles <sep> median time to development of severe mucositis <sep> severity of mucositis <sep> oral toxicities <sep> severity and duration of mucositis pain measurement radiation therapy interruption and quality of life <sep> mucositis <sep> time to development of severe mucositis <sep>', 'grade three or four mucositis <sep> grade four mucositis <sep> grade three mucositis <sep> radiation mucositis <sep> aerobic pathogenic bacteria <sep> candida colonisation <sep> mucositis <sep>', 'frequency of fever and infections <sep> delayed emesis <sep> nephrotoxicity gastrointestinal side effects haematopoietic recovery <sep> engraftment of neutrophil <sep> acute toxicity <sep> stomatitis grade iii/iv <sep> lower number of days with fever and a shortened duration of hospital stay <sep> gfr <sep> albumin and low molecular weight protein urinary excretion <sep> acute nausea/vomiting <sep> median fall of the glomerular filtration rate gfr <sep>', 'degree of mucositis <sep> mucositis <sep> plasma levels <sep>', 'oral mucositis <sep> mean total duration of mucositis <sep> incidence severity and duration of oral mucositis <sep> mean onset of mucositis <sep> mean auc values <sep> mucositis <sep>', 'progression of mucositis using the oral mucositis assessing scale omas <sep> mucositis <sep> radiation-induced mucositis <sep>', 'incidence of radiation therapy oncology group grade 3 mucositis <sep> severe mucositis <sep> soreness <sep> mean area under the mucositis curve <sep> severity of radiation-induced mucositis <sep> simple visual analogue scale <sep> radiation-induced mucositis <sep>', 'severity of radiation mucositis <sep> hemoglobin level <sep> anorexia <sep> swallowing difficulty <sep> objective severity of mucositis anorexia and swallowing difficulty <sep> serum interleukin-6 <sep> mean of grade 1-4 mucositis anorexia difficulty in swallowing and body weight change <sep> acute mucositis <sep>', 'oral mucositis <sep> om <sep> oral mucositis om <sep> om characteristics fever of unknown origin fuo and other infections <sep>', 'neutrophil functions and prevention of chemotherapy-induced side-effects <sep> oral mucositis <sep> complete blood count <sep> development of infection mucositis and diarrhoea <sep> neutrophil phagocytosis superoxide anion generation sag prevention of chemotherapy-induced side-effects and cost-effectiveness <sep> percentage of neutrophil phagocytosis and the sag levels <sep> neutrophil phagocytic function <sep> severe oral mucositis <sep>', 'grade 3 mucositis <sep> weight loss <sep> additional toxicity <sep> time until healing <sep> weight loss mucositis pain nutritional intake <sep> interval to healing <sep>', 'degree of mucositis <sep> severity and duration of oral mucositis <sep> frequency of severe pain <sep> pain relief <sep> grade 3 mucositis <sep>', 'oral mucositis <sep> hospitalization for mucositis <sep> radiation-induced mucositis <sep> tolerated <sep> mucosal pain <sep> radiation mucositis and body weight serum prealbumin level and blood cell counts <sep> weight prealbumin level or blood cell count <sep> healing of mucositis <sep>', 'acute xerostomia <sep> acute xerostomia and mucositis <sep> karnofsky performance status body weight cutaneous side effects and alopecia <sep> acute toxicity <sep> mucositis <sep>', 'severe mucositis <sep> occurrence of severe oral and intestinal mucositis <sep> total body irradiation tbi <sep> mucositis <sep> diarrhoea <sep>', 'oral mucositis <sep> median time of mucositis occurrence <sep> duration of moderate/severe mucositis <sep> moderate/severe mucositis <sep> mucositis <sep> risk of mucositis <sep>', 'hazard ratio hr <sep> om grade who <sep> oral mucositis assessment scale omas and the world health organization who scale <sep> prevention and reduction of severity of conditioning-induced oral mucositis om <sep>', 'stomatitis <sep>', 'alleviate oral mucositis <sep> some mucositis <sep> frequency or severity of oral mucositis <sep>', 'mucositis <sep> subsequent mucositis <sep> mucositis <sep>', 'median total tumour and biologically effective dose bed gy10 <sep> total duration of treatment <sep> intensity or duration of mucositis <sep>', 'degree of mucositis <sep> oral mucositis <sep> radiation-induced oropharyngeal mucositis <sep> confluent mucositis <sep> grade 2 mucositis <sep> grade 3-4 mucositis <sep> grade 0 mucositis <sep>', 'nausea <sep> equal rate of non-compliance <sep> objective score of edema erythema erosion and ulcerations <sep>', 'incidences of grade iii-iv mucositis and infection <sep> duration of hospitalization <sep> platelet recovery erythrocyte recovery incidence of veno-occlusive disease gvhd severity relapse or survival <sep> absolute neutrophil count of  0.5 x 10(9 cells/l <sep>', 'radiation reactions <sep> degree of mouth-opening <sep> cervical muscular sclerosis <sep> degree of oropharyngeal mucosa reaction dryness in mouth and radiation dermatitis in cervical region <sep>', 'oral mucositis <sep> oral mucositis om and diarrhea <sep> safe and well tolerated <sep> mucositis scores <sep> incidence or severity of diarrhea or in overall survival <sep> incidence of om and diarrhea safety disease progression and survival <sep> incidence of who grade 2 or higher om <sep>', 'grade of oral mucositis <sep> grades of mucositis <sep> oral mucositis <sep> mucositis <sep>', 'subjective intolerance mucositis dysphagia dermatitis and nausea <sep> mean weight loss <sep> weight <sep>', 'severity of mucositis <sep> salivation and decrease oral mucositis <sep>', 'later onset of stomatitis <sep> degree of oral injury <sep>', 'cure rates extend survival and reduce morbidity <sep> delayed mucositis <sep> radiation mucositis <sep>', 'mucositis <sep> mean mucositis scores <sep> mucositis scores <sep> radiation-induced oral mucositis <sep>', 'incidence of severe oral mucositis <sep> grade of mucositis <sep>', 'tolerated and no adverse events <sep> oral mucositis <sep> oral mucositis om <sep> mucositis and oral pain <sep> severity of oral mucositis and pain scores <sep>', 'mucositis and mouthwash toxicity <sep> toxicity eg mouthwash-induced discomfort taste alteration and teeth staining <sep> alleviation of radiation-induced mucositis <sep> mucositis <sep>', 'occurrence rate of grade 3-4 mucositis <sep> survival time <sep> 5-year overall survival rate <sep> patients weight taste oral mucous reaction and tongue mucous reaction <sep> occurrence rate of grade 1-2 mucositis of the oral cavity <sep>', 'clinical evolution of iatrogenic tissue damage <sep> oral mucositis <sep>', 'expression of ki-67 and pcna antigens in breast carcinoma <sep> intestinal permeability <sep> expression of ki-67 and pcna antigens <sep> lactulose-mannitol ratio <sep> grades of stomatitis and diarrhea <sep> plasma glutamine level intestinal permeability lactulose-mannitol test and tumor size <sep> stomatitis and diarrhea <sep> plasma glutamine level <sep>', 'who grade 1-4 oral mucositis <sep> oral mucositis <sep> risk of oral mucositis <sep> severe oral mucositis <sep>', 'oral pain <sep> preexisting colonization <sep> gastrointestinal bleeding <sep> subjective reporting of discomfort objective scoring of the severity of mucositis and the maximal percent of body weight lost <sep> mucositis <sep>', 'mucositis <sep> mucositis incidence and severity <sep>', 'mucositis the inflammation and necrosis of mucosal membranes <sep> oral mucositis <sep> oral mucositis <sep> incidence of chemotherapy-related oral mucositis <sep> unadjusted chi-square test and time to first episode of mucositis <sep> episodes of mucositis <sep> episode of febrile neutropenia <sep> mucositis <sep>', 'stomatitis scores <sep> mean area under the curve stomatitis scores <sep> stomatitis <sep>', 'mucositis or oral pain <sep> radiation-induced mucositis <sep> anesthetic mouth washing and their salivary lactoferrin and albumin levels <sep>'], 'punchline_text': ['oral aloe vera did not improve tolerance to head-and-neck radiotherapy decrease mucositis reduce soreness or otherwise improve patient well-being. <sep>', 'overall survival was significantly greater in the granulocyte-colony stimulating factor arm hazard ratio 0.37 p  0.037). <sep>', 'the distribution of grade 4 mucositis who was 1 case versus 8 cases with and without amifostine respectively. <sep>', 'no statistically significant between-group differences were seen in mean worst scores across time using repeated measures analysis of variance hickey p  0.231 who p 0.288). <sep>', 'there was significant reduction in the symptomatic grade 3/4 mucositis among honey-treated patients compared to controls i.e. 20 versus 75  p 0.00058). <sep>', 'palifermin was associated with reduced incidence and mean severity of mucositis in patients conditioned with cy/tbi but not bu/cy. <sep>', 'of 205 evaluable patients 52.9 vs. 62.4 developed rtog grade 3 or greater mucositis after morning vs. afternoon rt respectively p  0.17). <sep>', 'patients in the control group developed grade 2 mucositis and dermatitis earlier and sooner than patients in the experimental group. <sep>', 'there was a reduction in mucositis distribution p  0.002 mucositis area p  0.028 dysphagia p  0.006 and weight loss p  0.009 in the active arm. <sep>', 'visual analogue scale for oral pain and oral function was not significantly different between the two groups. <sep>', 'csf only improved the incidence of severe mucositis during the induction course p  0.003 and probably also improved the median duration of fever p  0.07). <sep>', 'colonisation index of candida species and gram-negative bacilli was reduced in the pta group and not in the placebo group p<0.05). <sep>', 'mucositis was significantly reduced by cryotherapy considering both the first cycle of therapy the mean toxicity score for cryotherapy was 0.59 and it was 1.1 for the control group p  or  0.05 and all the chemotherapeutic courses the mean toxicity score for cryotherapy was 0.36 when it was 0.69 for the control group p  or  0.05). <sep>', 'analysis of variance indicated significant direct gm-csf treatment effects on the mean auc of gross/functional scores and duration of moderate gross mucositis grade  or  2 over both periods. <sep>', 'the severity of mucositis was reduced in the gm-csf arm p<0.05). <sep>', 'there were no substantial differences in mucositis attributable to the two mouthwashes in the patients who crossed-over on their second cycle of chemotherapy. <sep>', 'ip test score was significantly higher than those of the control group 6.78 4.63 10.66 vs. 2.17 1.38 2.40 p<0.001]. <sep>', 'palifermin appeared to reduce mucositis dysphagia and xerostomia during hyperfractionated radiotherapy n  40 but not standard radiation therapy n  59). <sep>', 'the frequency of grade 2 to 4 mucositis was 43 in patients treated with kgf compared with 67 in patients treated with placebo p .06). <sep>', 'amifostine reduced grade  or 2 acute xerostomia from 78 to 51 p<.0001 and chronic xerostomia grade  or  2 from 57 to 34 p=.002). <sep>', 'both study and control groups were compared with respect to the frequency 30 versus 36 chi(2 exact test not significant ns and mean duration 4.8  <sep>', 'both cryotherapy groups had similar degrees of mucositis. <sep>', 'the duration of severe mucositis did not differ between pge and placebo groups chi-square 0.95 p  ns). <sep>', 'local effectivity appeared to be less in the hypopharynx due to shorter time of application compared with mouth and oropharynx. <sep>', 'there were no significant differences or substantial trends in the mucositis scores between the two study arms as measured by either the physicians or the patients. <sep>', 'g-csf therapy reduced both the incidence and duration of adm-induced oral mucositis and a positive correlation was also seen between the incidence of mucositis and adm-induced leukopenia  2,000/mm3). <sep>', 'the supplement was well tolerated with no apparent adverse effects but failed to have any significant effect on oral mucositis assessed by the patients or investigator. <sep>', 'assessment of the area under the curve revealed statistically significant reductions in om severity in the rhitf-treated groups versus placebo. <sep>', 'amifostine significantly reduced the mean questionnaire scores from 6.49 to 3.73 the incidence of grade  or  2 mucositis from 75 to 36 and acute xerostomia from 82 to 39%. <sep>', 'the result showed a significant difference in pain and mucositis p<0.001 between the two groups. <sep>', 'the incidence rates of mucositis pain xerostomia and taste disturbance were all markedly lower in polaprezinc group than in control. <sep>', 'the severity maximum extent of acute radiation therapy side effects was significantly less in enzyme-treated patients than in control patients mucositis mean 1.3 vs 2.2 p  0.001 skin reaction 1.2 vs 2.4 p  0.001 and dysphagia 1.4 vs 2.2 p  0.001). <sep>', 'the frequency of grade 2 to 4 mucositis was 100 for patients in the placebo group 64 for patients in the 25 microg/kg group p  0.041 versus placebo and 50 for patients in the 50 microg/kg group p  0.006 versus placebo). <sep>', 'there was a significant reduction in the incidence of grade 3/4 mucositis p  0.0001 acute grade 2 xerostomia p  0.0001 and grade 3/4 thrombocytopenia p  0.012 in these patients who received a. <sep>', 'although the frequency of culture-positive herpes simplex virus was low in the untreated group it was significantly lower zero in the acyclovir-treated group. <sep>', 'compared to the normal saline group patients using cryotherapy experienced less grade 3-4 mucositis 14 vs 74 p=0.0005. <sep>', 'amifostine significantly reduced the incidence of acute perineal skin and bladder toxicity p .0006). <sep>', 'the highest grade of mucositis during the treatment time was significantly different between two groups p  0.049). <sep>', 'l-alanyl-l-glutamine patients experienced less pain three highest numeric rating scale scores of 1.3/10 vs. 6.3/10 respectively p  0.008 and need for feeding tubes 14 vs. 60 respectively p  0.020 compared with placebo patients. <sep>', 'opioids than the control group. <sep>', 'no statistically significant difference was found between the results with na sos and those with placebo for any of the variables with the exception of skin desquamation which showed a significant difference in the placebo group. <sep>', 'the analysis showed that the higher education level and the use of dentures significantly reduced the occurrence of mucositis and allopurinol mouth rinse 1 mg/ml was ineffective in the prophylaxis of fluorouracil-induced mucositis. <sep>', 'chlorhexidine had no effects of any clinical significance on parameters such as number of days with fever number of oral lesions plaque score gingival bleeding score or occurrence of candidiasis. <sep>', 'conversion to complete remission post-asct occurred in 30 and 14 of the amifostine and control groups respectively p=0.09). <sep>', 'in previous studies oral glutamine was found to protect animals from the effects of whole abdominal radiation and methotrexate-induced enteritis. <sep>', 'injection of 4000u sod immediately after receiving radiotherapy significantly reduced the occurrence rate of skin oral mucosal pelvic visceral and systematic adverse reaction only the reduction of leukopenia did not reach the statistical significant level. <sep>', 'the duration of objective oral mucositis  or  grade 1 p  0.0097 grade 2 p  0.0232 and grade 3 p  0.0168 was shorter in the glutamine arm. <sep>', 'wbc toxicity z=-0.604,p=0.546 neutrophilic granulocyte toxicity z=-0.226,p=0.821 and platelet toxicity z=-0.099,p=0.922 were compared there was no statistic significance of difference p 0.05 <sep>', 'compared with placebo palifermin reduced the cumulative incidence of moderate to severe grade 2 or higher mucositis 44 vs. 88 p  0.001 difference 44 percentage points 95 ci 71 to 16 percentage points and severe grade 3 or 4 mucositis 13 vs. 51 p  0.002 difference 38 percentage points ci 67 to 9 percentage points]). <sep>', 'there was no significant difference between the cohorts in stomatitis severity incidence of uom peak mouth pain peak difficulty swallowing amount of opiate analgesics used or adverse event type or incidence. <sep>', 'early during radiation therapy less oral pain was reported in the sucralfate group but as treatment progressed all patients experienced pain. <sep>', 'the treatment duration was significantly shorter in the amifostine-treated group p  0.013 because treatment interruptions were more frequent in the control group. <sep>', 'no statistically significant difference for the objective and subjective mucositis scores was observed between the two study arms p  0.33). <sep>', 'as compared with placebo palifermin was associated with significant reductions in the incidence of grade 4 oral mucositis 20 percent vs. 62 percent p<0.001 patient-reported soreness of the mouth and throat area-under-the-curve score 29.0 range 0 to 98 vs. 46.8 range 0 to 110 p<0.001 the use of opioid analgesics median 212 mg of morphine equivalents range 0 to 9418 vs. 535 mg of morphine equivalents range 0 to 9418 p<0.001 and the incidence of use of total parenteral nutrition 31 percent vs. 55 percent p<0.001). <sep>', 'adverse events leading to study drug discontinuation and death did not differ significantly between groups. <sep>', 'we found no significant difference between the molgramostim and the control groups in the oral mucositis grade oral pain use of analgesic drugs weight loss or survival. <sep>', 'patients in the sucralfate group experienced significantly lower degree of mucositis than placebo group p  0.05). <sep>', 'the study demonstrated that the proportion of patients with severe mucosal reactions was significantly lower in the sucralfate group than in the placebo group. <sep>', 'the results of the qol scales did not reveal any significant difference between the pilocarpine and placebo groups with regard to xerostomia and mucositis. <sep>', 'one-year rates of locoregional failure progression-free survival and overall survival were not significantly different between treatments. <sep>', 'oral enzymes act as a potent antiinflammatory antiedematous agents thereby decreasing acute toxigenic effect of radiation and increasing compliance quality of life of our patients. <sep>', 'the trends of decreased median length of stay and the median number of days of total parenteral nutrition tpn were seen in the group supplemented with the 0.285-g/kg the recommended dosage dose of glutamine however there was no statistically significant difference in the nutritional status and overall patient outcome as assessed by days receiving tpn number of days required until oral intake resumed length of hospitalization number of days and highest grade of mucositis and quantity and number of days of diarrhea. <sep>', 'duration was significantly longer in b than in both a p .035 and c p .003). <sep>', 'in univariate and multivariate analysis severe oral mucositis correlated with tbi in the conditioning regimen and lack of folinic acid rescue following mtx administration. <sep>', 'in the chlorhexidine-based group a significant decrease of the aerobic p=0.042 and anaerobic p=0.008 bacterial flora was identified. <sep>', 'for the maximum mucositis scores no statistically significant differences were found between the placebo and the verum group. <sep>', 'propantheline is effective in reducing the incidence and severity of mucositis in patients receiving high-dose etoposide. <sep>', 'concomitant reductions in total oral streptococci p less than 0.02-p less than 0.001 and oral candida p less than 0.004 were seen in patients using chlorhexidine. <sep>', 'the prophylactic value of twice-daily mouth rinses with a solution of 0.1 chlorhexidine gluconate in minimizing oral complications during remission-induction chemotherapy was tested in sixteen patients with acute myeloblastic leukemia. <sep>', 'the colonization index of viridans streptococci was significantly reduced only after 5 weeks of chlorhexidine 0.1 treatment. <sep>', 'no differences were found in the median subjective pain scores who scores and oral assessment scores between the placebo and the gm-csf groups. <sep>', 'a 42 risk 15/36 of mucositis grade  or  3 was evident on day 15 in patients receiving gm-csf compared to 2 of 9 patients on the placebo arm. <sep>', 'amifostine given subcutaneously did not improve the rates of xerostomia and mucositis with this fairly intensive chemoradiotherapy regimen. <sep>', 'the chinese herbal preparation yhd could alleviate oral mucomembranous reaction to radiation applied in patients with head-neck tumor. <sep>', 'no significant differences existed between the two mouthwashes in regard to incidence days to onset and severity of mucositis. <sep>', 'no significant difference was observed in hematologic toxicity transfusion requirements duration of fever and hepatic toxicity between the treatment groups. <sep>', 'the safety and efficacy of 0.15 benzydamine oral rinse in preventing or decreasing erythema ulceration and pain associated with oral mucositis during rt were evaluated in a randomized placebo-controlled trial conducted in patients with head and neck carcinoma. <sep>', 'there were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician in oral toxicities as recorded by patients or in radiotherapy delays. <sep>', 'positive cultures for aerobic pathogenic bacteria were observed in 15 per cent of the treatment group and 65 per cent of the control group during or after radiotherapy p  0.007). <sep>', 'acute nausea/vomiting was frequently observed immediately during or after the application of amifostine despite intensive antiemetic prophylaxis consisting of 5-ht3-receptor antagonists/dexamethasone/trifluorpromazine. <sep>', 'however there was significantly less mucositis p  0.01 analysis of variance from weeks 3--6 in the 17 patients treated with misoprostol at loyola compared to the 18 placebo-treated patients. <sep>', 'the mean total duration of mucositis was 2.75 weeks in treatment patients and 9.25 weeks in control patients. <sep>', 'a significant reduction in mucositis among honey-received patients compared with controls p=0.000 occurred. <sep>', 'we could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo. <sep>', 'the clinical trial showed that application of ir can reduce the severity of radiation mucositis p  0.01 anorexia p  0.002 and swallowing difficulty p  0.002). <sep>', 'om occurred significantly more often in females than in males 86 vs 60 p=0.0016 and was worse and of longer duration. <sep>', 'the gln-treated patients lost significantly less weight tended to have shorter in-patient duration and had less severe oral mucositis than controls. <sep>', 'grade 3 mucositis was more common in patients receiving chemotherapy p  0.05 or bid fractionation p  0.04 or having a poor kps p  0.02). <sep>', 'grade 3 mucositis occured with a frequency of 35.2 without lel and of 7.6 with lel p<0.01). <sep>', 'patients who received gm-csf had less mucosal pain p  0.058 and were less often prescribed opioids for pain p  0.042). <sep>', 'amifostine provided reduction in acute xerostomia and mucositis but had no obvious influence on karnofsky performance status body weight cutaneous side effects and alopecia. <sep>', 'the main endpoint was severe mucositis that was more frequent in the placebo group than in the sucralfate group 47 vs. 29 p  0.07). <sep>', 'duration of moderate/severe mucositis was although not significantly lower in the int group 17 days s.d.  12 than in the lim group 19 days s.d.  13). <sep>', 'remarkably the hazard ratio hr for grades 2 3 and 4 om was 0.41 range 0.22-0.75 p  .002 and for grades 3 and 4 it was 0.07  <sep>', 'in the control group stomatitis occurred in 9 of the 10 patients receiving pf therapy and in all of the 5 receiving vac. <sep>', 'there was no difference in the frequency or severity of oral mucositis between the sucralfate and the placebo-treated group. <sep>', 'subsequent mucositis was significantly reduced in the group assigned to receive cryotherapy as judged by the attending physicians p  .0002 and by the patients themselves p  .0001). <sep>', 'a trend favouring shorter treatment interruptions in the prednisone arm was also found but not a reduction in the intensity or duration of mucositis. <sep>', 'in the zinc sulfate group grade 3-4 mucositis was not detected in any patient grade 0 mucositis was detected in 2 and grade 1 in 8 and grade 2 in 5 patients. <sep>', 'patient preference favored sucralfate but this preference failed to reach statistical significance p  0.06). <sep>', 'the incidences of grade iii-iv mucositis and infection were significantly reduced p  0.005 p  0.001 respectively and duration of hospitalization was modestly shortened by 1 day p  0.02 in rhgm-csf treated patients. <sep>', 'sfr has definite effect in preventing and treating radiation reaction and late stage radiation injury in patients with head and neck tumor. <sep>', 'fu dose reductions in the second chemotherapy cycle were more frequent in the placebo group 31 than in the palifermin group 14%). <sep>', 'there was no significant difference between groups concerning the grades of mucositis on day 8 p  0.234 or on day 15 p  0.208). <sep>', 'comparing the time course of the mean scores for subjective intolerance mucositis dysphagia dermatitis and nausea no statistically significant differences between the two treatment arms sucralfate n  38 placebo n  45 were observed. <sep>', 'pilocarpine has no benefit for the moderation of the incidence severity or duration of mucositis in patients receiving autologous blood stem cell transplantation. <sep>', 'our findings revealed that the patients in the e2 group not only had later onset of stomatitis than those in the control and the e1 groups but also had lesser degree of oral injury measured by the overall assessment score. <sep>', 'evaluation of the data showed delayed mucositis in the experimental group for grades 1 to 3 with a significant difference at grade 3 compared with controls. <sep>', 'their scores were also significantly lower when compared to the salt/soda and chlorhexidine groups from the fourth and fifth week respectively after radiotherapy. <sep>', 'we evaluated the efficacy of topically applied human recombinant epidermal growth factor rhegf for the treatment of oral mucositis induced by radiotherapy rt with or without chemotherapy in patients with head and neck cancer. <sep>', 'the 650 nm wavelength reduced the severity of oral mucositis and pain scores. <sep>', 'there was a trend for more mucositis and there was substantially more toxicity eg mouthwash-induced discomfort taste alteration and teeth staining on the chlorhexidine arm. <sep>', 'the occurrence rate of grade 1-2 mucositis of the oral cavity was higher in trial group than in control group 73.68 vs. 62.50 but the occurrence rate of grade 3-4 mucositis was lower in trial group than in control group 26.32 vs. 37.50 p=0.470). <sep>', 'the benzydamine topical application was more effective than placebo in the control of mucositis symptoms and signs produced by radiotherapy and/or intra-arterial antineoplastic chemotherapy. <sep>', 'prophylactic oral glutamine could ameliorate the neoadjuvant chemotherapy-induced increase in intestinal permeability but had no significant positive clinical effect on stomatitis and diarrhea and did not interfere with the antitumor effect of chemotherapy. <sep>', 'in patients receiving less toxic regimens a decrease in who grade 1-4 oral mucositis was noted in the gum arm compared with the standard arm 49 vs. 72 p=0.03). <sep>', 'patients given sucralfate suspension were less likely than subjects receiving placebo to acquire colonization with potentially pathogenic microorganisms 14 58 of 24 versus 22 92 of 24 respectively p  0.008). <sep>', 'we found no differences regarding myelosuppression infections or other chemotherapy complications. <sep>', 'during cycle 1 placebo-treated patients had more episodes of mucositis 47 compared with those patients randomized to filgrastim 28%). <sep>', 'stomatitis worsened in only 7 patients 47 in the traumeel s treatment group compared with 14 patients 93 in the placebo group. <sep>', 'no difference in the visually assessed degree of mucositis or oral pain reported by the patients was found between the study and the control groups. <sep>'], 'population': ['58 head-and-neck cancer patients between <sep> patients with head-and-neck neoplasms <sep> head-and-neck cancer patients <sep> patients had to be treated with radiotherapy with curative intent at stanford university between february 1999 and march 2002 <sep>', 'squamous head and neck cancer <sep> forty patients were evaluable for planned outcomes <sep> forty-one patients were enrolled 132 planned <sep> patients undergoing prior <sep> stage ii-iv squamous head and neck cancer <sep>', 'between may 1996 and february 1998 26 patients with an inoperable nonmetastatic stage iv hnscc <sep> 13 patients who received <sep> patients with advanced head and neck squamous cell carcinoma hnscc <sep> head and neck squamous cell carcinoma <sep>', 'fourteen of a planned 54 patients <sep>', 'radiation mucositis <sep> forty patients diagnosed with head and neck cancer requiring radiation to the oropharyngeal mucosal area <sep>', 'n  31 in patients conditioned with <sep> allogeneic hematopoietic stem cell transplantation hsct recipients <sep>', '216 patients <sep> patients receiving primary or postoperative rt alone were eligible <sep> patients with head-and-neck cancer <sep>', 'patients with cancers of the head and neck <sep> patients after radiotherapy for head-and-neck cancers <sep>', '54 patients were unevaluable 24 active 30 placebo <sep> 275 patients with t1-t4 tumours entered the study 136 <sep> patients undergoing radical radiotherapy for head and neck cancer <sep>', '45 patients post-hsct <sep> patients post hematopoietic stem cell transplantation <sep> hematopoietic stem cell transplantation hsct patients <sep> hsct patients <sep>', 'adult patients with all 1 <sep> patients up to age 45 years who had an hla-identical sibling <sep> copyright 1999 american cancer society <sep> adults with acute lymphoblastic leukemia <sep> between november 1990 and april 1992 67 patients ages 15-55 years with de novo <sep>', 'sixty-five patients with a malignant tumour in the head and neck regions <sep> in the head and neck region develop oral mucositis <sep> head and neck cancer patients receiving <sep> head and neck irradiation patients <sep>', '84 patients treated with a <sep>', 'head and neck cancer patients after <sep> twenty patients with stage iv squamous cell carcinoma of head and neck were studied <sep>', 'patients undergoing accelerated radiotherapy <sep> over 3 weeks for early stage laryngeal cancer <sep> head and neck cancer <sep> 29 patients who were to receive <sep> laryngeal cancer <sep> patients undergoing accelerated radiotherapy for laryngeal cancer <sep>', 'seventy-seven patients receiving their first 5-day course of chemotherapy with 5-fu <sep>', '18 healthy volunteers <sep> fifty-one patients with advanced or metastatic cancer <sep>', 'locally advanced head and neck cancer <sep> patients receiving concurrent chemoradiotherapy for advanced head and neck squamous cell carcinoma <sep> head and neck squamous cell carcinoma <sep> patients receiving intensive therapy for hematologic cancers <sep>', 'patients with metastatic colorectal cancer <sep>', 'head and neck cancer <sep> head and neck cancer causes acute and chronic xerostomia and acute mucositis <sep> patients with previously untreated head and neck squamous cell carcinoma were eligible <sep>', 'ninety consecutive patients affected by solid tumors and undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue <sep> patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue <sep>', 'patients who were receiving their first course of a <sep> 178 evaluable patients were studied <sep>', 'between october 1988 and december 1990 60 patients with leukaemia 25 with aml 19 all and 16 cml undergoing bmt <sep> patients with hsv infection receiving <sep>', 'head-neck neoplasms <sep> 21 patients receiving <sep>', 'patients receiving <sep> sixty-six patients <sep>', 'patients with advanced breast cancer <sep> 14 patients who received intraarterial i.a <sep>', 'twenty-eight patients with gastrointestinal cancers <sep>', 'patients with colorectal cancer who are receiving fluorouracil-based chemotherapy <sep> patients with cancer <sep> patients with colorectal cancer <sep> ninety-nine patients with colorectal cancer who had moderate to severe om who grade or 2 in the first cycle of chemotherapy <sep>', 'sixty-seven head and neck cancer patients <sep> head and neck cancer patients who had normal or mild impaired salivary gland function <sep> head and neck cancer patients <sep> head and neck cancer patients who had radiotherapy <sep>', 'head and neck cancer patients <sep> cancer patients <sep> head  neck cancer patients <sep> patients with carcinoma of oral cavity with stages ii-iv a being uniformly treated with curative total tumour dose of 66 gy in 33 fractions over 6 wk were selected for the study <sep>', 'patients with head and neck cancer <sep>', 'patients with stage t3/t4 head and neck cancer were eligible <sep> one hundred patients from two centres were entered into the study <sep> patients with head and neck cancer receiving conventional fractionated radiation therapy <sep> patients with head and neck cancers <sep> head and neck region <sep>', 'patients undergoing autologous hematopoietic stem cell transplantation <sep>', 'head and neck cancer <sep> patients with head and neck cancer received <sep>', 'patients with head and neck tumors treated with <sep>', 'forty patients with multiple myeloma scheduled to receive <sep> patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation <sep>', 'sixty patients with thoracic 40 with head and neck and 40 with pelvic tumors who were undergoing <sep>', 'head and neck cancers <sep> one hundred patients <sep> patients with head and neck cancers who were referred in 2004-2005 received an oral rinse of either <sep> 19 patients were excluded from the analysis because they did not use the medication for the assigned period <sep>', 'twenty-nine patients received the <sep> thirty-two patients with head-and-neck cancer <sep> patients with head-and-neck cancer receiving <sep> patients with head-and-neck cancer <sep>', 'patients treated with myeloablative therapy before bone marrow transplantation bmt <sep> patients who receive myeloablative therapy before bmt <sep> eighty patients 18 years and older scheduled for bmt <sep> patients treated with myeloablative therapy before bmt <sep>', 'head and neck cancers <sep> patients with head and neck cancer <sep> sixty patients <sep>', '33 patients with malignant disorders who were going to receive <sep> mean ages were 56.9 <sep>', 'twenty-eight patients <sep> patients with acute leukemia <sep> patients receiving treatment for acute leukemia <sep>', 'myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation <sep> 90 patients undergoing autologous stem cell transplantation asct <sep>', 'twenty-four patients 16 children and 8 adults <sep> after cytotoxic cancer chemotherapy <sep> cancer patients receiving chemotherapy <sep> cancer <sep> humans <sep>', '159 patients <sep>', 'head and neck cancer <sep> from july 1997 through june 1998 17 patients with head and neck cancer receiving primary or adjuvant irradiation <sep>', 'nasopharyngeal carcinoma <sep> patients with local advanced npc <sep> 101 patients in stage iii iva fuzhou 1992 <sep> local advanced npc patients <sep> nasopharyngeal carcinoma npc treated with <sep>', 'patients receiving multicycle chemotherapy <sep> patients undergoing hematopoietic stem-cell transplantation <sep> patients with cancer <sep> patients who had severe mucositis received <sep> 48 patients with sarcoma <sep>', 'patients receiving stomatotoxic chemotherapy <sep> between november 2001 and june 2002 502 patients <sep> patients receiving <sep>', 'patients who develop mucositis during radiation therapy <sep>', 'fifty patients <sep> head-and-neck cancer <sep> patients with head-and-neck cancer <sep>', 'irradiated cancers of the head and neck <sep> head-and-neck cancer patients <sep> seventy-seven patients were evaluable <sep>', 'hematologic cancers <sep> 212 patients with hematologic cancers 106 patients received <sep>', 'a total of 545 patients <sep> head-and-neck cancer <sep> patients receiving radiotherapy for head-and-neck malignancy <sep> patients receiving primary rt primary chemoradiotherapy or postoperative rt <sep>', 'forty head and neck cancer patients <sep>', 'twenty-eight patients with head and neck cancer <sep> patients receiving head and neck radiotherapy <sep>', 'of head and neck malignancies <sep> 50 consecutive patients <sep> malignancies in the head and neck region <sep> patients treated with curative intent for malignancies in the head and neck region <sep>', 'head and neck cancer patients <sep> patients with head and neck cancer <sep> selected patients were required to have  or  50 of the volume of the major salivary glands receive  or  50gy <sep> 245 evaluable patients <sep>', 'head-and-neck cancer <sep> for head-and-neck cancer <sep>', 'head and neck cancers <sep> fifty patients <sep>', 'patients receiving bone marrow transplant bmt and peripheral blood progenitor cell transplant pbpct experience gastrointestinal gi toxicity from the preparative regimen of <sep> 58 autologous and allogeneic bmt patients <sep> bone marrow transplantation <sep>', 'patients with previously untreated gi cancer receiving bolus <sep> large adult patient population with solid tumors receiving highly om-inducing chemotherapy <sep> gastrointestinal malignancies <sep> 225 patients randomized 206 answered the questionnaire 70 64 and 63 patients in arms a b and c respectively and were well balanced with respect to diagnoses stage age sex smoking habits and performance status <sep> gastrointestinal gi cancer <sep>', 'patients undergoing myeloablative ahsct <sep> patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation <sep> one hundred and thirty patients undergoing myeloablative ahsct and mtx-containing gvhd prophylaxis <sep> patients undergoing myeloablative allogeneic hsct <sep>', '47 patients <sep> cancer patients with chemotherapy-induced leukopenia benefit from an <sep> 47 patients developed <sep> cancer chemotherapy patients <sep> patients undergoing <sep>', '69 patients with carcinomas of the oropharynx or the oral cavity were enrolled between 1996 and 2000 in five centers 54 of these were recruited in dresden <sep> patients treated for head-and-neck tumors <sep> head-and-neck tumors particularly oral mucositis <sep> 69 patients 61 dresden 46 were available for analysis <sep>', 'patients receiving high-dose etoposide <sep> twelve patients receiving etoposide 1800 mg/m2 as part of a myeloablative pre-transplant regimen <sep>', 'patients undergoing bone marrow transplantation <sep> patients undergoing marrow transplantation <sep> marrow transplantation <sep> 51 bone marrow transplant patients <sep>', 'acute leukemia <sep> sixteen patients with acute myeloblastic leukemia <sep>', 'patients with head and neck cancer <sep> patients with head and neck cancer who have irradiation mucositis <sep> 30 patients with head and neck cancer who had comparable irradiation portals <sep>', '36 consecutive patients undergoing a stem cell transplantation <sep> patients undergoing a stem cell transplantation <sep> after stem cell transplantation <sep>', 'patients with breast cancer during the first treatment cycle of a combination chemotherapy regimen which has historically produced dose-limiting grade  or  3 mucositis in approximately 39 of patients <sep>', 'fifty-eight patients were enrolled 29 in each arm <sep> patients with locally advanced head and neck cancer <sep> patients with locally advanced squamous cell carcinoma of the head and neck scchn <sep> 2009 american cancer society <sep> 13 patients in arm a and 11 patients in arm b of subjects at baseline and then on alternate weeks <sep> patient population with advanced scchn <sep> patients with newly diagnosed locally advanced stage iii or iv scchn received 4 weekly doses of <sep>', 'patients with head-neck tumor undergoing radiotherapy <sep> patients with head-neck tumor <sep> forty-forty-two patients with head-neck tumor undergoing <sep>', '222 patients who were starting a cycle of mucositis-inducing chemotherapy <sep> patients receiving chemotherapy <sep> 23 outpatient clinics and office practices in california <sep>', 'n  89 <sep> 140 patients undergoing either allogeneic n  51 or <sep> patients undergoing bmt <sep>', 'patients with head and neck carcinoma for treatment of radiation-induced oral mucositis <sep> copyright 2001 american cancer society <sep> patients with head and neck carcinoma <sep>', 'patients with head and neck cancer <sep> one hundred thirty-seven eligible patients <sep> conventionally treated patients with head and neck cancer <sep>', 'head and neck cancer <sep> patients with head and neck cancer <sep> assiut university hospital egypt between january 2005 and july 2006 <sep> forty patients diagnosed with head and neck cancer <sep>', '40 patients with solid tumours <sep> patients with high-dose vic chemotherapy plus autologous blood stem cell transplantation <sep>', 'thirty-four hines va and 35 loyola university patients were accrued 69 total over a 2-year period <sep> healthy volunteers <sep> postsurgical patients who had no detectable cancer and who were referred for postoperative irradiation were candidates for this study <sep> irradiated head and neck cancer patients from radiation mucositis <sep>', 'patients during antineoplastic radiochemotherapy <sep> 40 patients <sep>', '40 patients with head and neck cancer requiring radiation to the oropharyngeal mucosa <sep>', 'patients undergoing head and neck radiotherapy <sep> patients with head and neck cancer <sep> patients receiving radical dose radiotherapy <sep> patients experiencing radiation-induced mucositis <sep> between 1999 and 2002 83 patients were recruited into the study at westmead and nepean hospitals sydney <sep>', 'patients with head and neck cancer receiving radiotherapy at tian sheng memorial hospital taiwan were recruited for this trial <sep> twenty 20 patients <sep> radiation-induced mucositis <sep>', 'patients after high-dose chemotherapy and apbsct--results of a randomized multicentre study <sep> 132 patients <sep>', 'acute myeloid leukaemia aml patients receiving chemotherapy <sep> acute myeloid leukaemia patients <sep> sixteen aml patients <sep>', 'head and neck cancers <sep> patients receiving curative intent rt for advanced head and neck cancers <sep> head neck 21 760-766 1999 <sep>', 'patients with head and neck cancer <sep> from september 1994 to march 1998 30 patients were randomized <sep> patients with carcinoma of the oropharynx hypopharynx and oral cavity treated by <sep>', 'forty patients with radically operated head-and-neck cancer <sep>', 'patients with head and neck cancer <sep> 50 patients were evaluable 25 patients in the <sep> head and neck cancer <sep> 56 patients with oro-/hypopharynx or larynx cancer t1-2 n1-2 g3 t3-4 n0-2 g1-3 <sep> patients with laryngeal cancer <sep>', 'bone marrow transplantation <sep>', 'patients treated with high-dose chemotherapy and bone marrow transplantation <sep> between february 1986 and november 1989 166 patients who were candidates for a bone marrow transplantation <sep> intensive oral hygiene care included an initial treatment of dental lesions and tooth and gum brushing during aplasia <sep> patients with and without total body irradiation tbi and in patients with a good or bad ios <sep>', '38 patients who underwent <sep> bone marrow transplantation patients <sep> hematopoietic stem cell transplantation hsct <sep>', 'gynecologic patients <sep>', '81 patients with colorectal cancer were enrolled <sep> induced mucositis <sep>', '95 patients scheduled to receive their first cycle of <sep>', 'head and neck cancer <sep> patients with head and neck cancer <sep>', 'thirty patients with head-and-neck cancer <sep> radiation-induced oropharyngeal mucositis <sep> patients with head-and-neck cancer <sep>', 'forty patients receiving <sep>', 'patients undergoing hla-identical allogeneic bmt <sep> allogeneic bone marrow transplantation <sep>', 'patients with head and neck tumor <sep> one hundred and forty patients with head and neck tumor including nasopharyngeal carcinoma carcinoma of tonsil or tongue <sep>', 'patients with metastatic colorectal cancer crc receiving <sep> patients with metastatic colorectal cancer treated with <sep> patients n  64 <sep> patients with metastatic crc <sep>', 'patients had a diagnosis of leukemia or lymphoma and 25 42 had solid tumors <sep> twenty-nine patients <sep> sixty patients were evaluable for analysis thirty-nine 65 were males 35 58 <sep> children with cancer receiving chemotherapy <sep> patients from 3 to 18 years of age treated with chemotherapy or hematopoietic stem-cell transplantation between may 2003 and february 2005 were eligible <sep> children and adolescents with cancer treated with <sep>', 'head and neck cancers <sep> one hundred two patients <sep> head and neck cancer treated with <sep> patients with head and neck cancer treated by <sep>', 'subjects were seen every other day and evaluated for gingival oral and oropharyngeal mucositis nutrition oral hygiene eating speaking sleeping pain at rest and/or with swallowing and mouth dryness <sep> oral mucositis during autologous blood stem cell transplantation <sep> patients receiving head and neck <sep> patients receiving autologous blood stem cell transplantation <sep> autologous blood stem cell transplantation <sep>', 'nasopharyngeal cancer patients undergoing radiotherapy 30 eligible patients with a mean age of 56.2 years <sep> nasopharyngeal cancer patients undergoing <sep>', '19 patients received 300 rad/day of <sep> unresectable head and neck cancer <sep> advanced head and neck cancers <sep>', 'eighty patients with head and neck malignancies scheduled to undergo curative radiotherapy <sep> 76 patients who completed the study patients in the <sep> patients with head and neck malignancies <sep> patient had cancer of oral or extraoral regions <sep>', 'patients with head and neck cancer <sep> patients receiving definitive chemoradiotherapy definitive rt or postoperative rt to the oral cavity or oropharynx were recruited from 6 institutions and enrolled <sep> patients undergoing radiotherapy with or without chemotherapy for head and neck cancer <sep> 113 patients included in the study 28 received <sep> patients undergoing rt for head and neck cancer <sep>', 'hct patients conditioned with chemotherapy or chemoradiotherapy <sep> patients undergoing hematopoietic cell transplantation <sep> seventy patients <sep>', 'patients scheduled to receive radiation therapy to include greater than one third of the oral cavity mucosa were selected for study <sep> patients receiving radiation therapy to the oral mucosa <sep> twenty-five patients <sep>', 'primary npc patients in radiotherapy by pushing the tongue and a part of oral mucous membrane away from the radiation fields <sep> 43 patients <sep> primary npc patients in radiotherapy <sep> primary nasopharyngeal carcinoma patients <sep>', 'for neoplasms of the head and neck <sep>', 'patients with breast cancer <sep> sixty patients with breast cancer <sep>', '145 children receiving chemotherapy regimens expected to induce who grade 3-4 oral mucositis in at least 30 of patients <sep> children receiving chemotherapy <sep>', 'forty-eight children and adolescents with newly diagnosed acute nonlymphocytic leukemia <sep>', 'from april 1993 to september 1993 15 patients with lymphoid or solid neoplasms underwent 16 non-cryopreserved peripheral stem cell transplantation courses using the <sep>', 'patients with newly diagnosed small-cell lung cancer sclc <sep> patients receiving chemotherapy <sep>', 'children undergoing bone marrow transplantation <sep> 30 evaluable patients 15 were assigned <sep> children undergoing stem cell transplantation <sep> 32 patients ages 3-25 years who had undergone allogeneic 16 patients or autologous 16 patients stem cell transplantation <sep> copyright 2001 american cancer society <sep>', 'forty patients with head and neck cancer <sep>'], 'interventions': ['aloe and placebo <sep> oral aloe vera <sep> oral aloe vera and placebo <sep> oral aloe vera gel <sep> oral aloe vera versus placebo <sep>', 'placebo <sep> granulocyte-stimulating factor <sep> granulocyte-colony stimulating factor during postoperative radiotherapy <sep> granulocyte-colony stimulating factor during radiotherapy <sep> postoperative radiotherapy <sep> radiotherapy or chemotherapy <sep> granulocyte-colony stimulating factor or placebo <sep>', 'amifostine definitive interruption of amifostine <sep> accelerated radiotherapy with and without amifostine <sep> amifostine ethyol u.s. bioscience 15-30 min prior to each radiation session <sep> amifostine <sep> feeding tube nasogastric tube or medical gastrostomy <sep>', 'placebo <sep> filgrastim or placebo <sep> filgrastim <sep> chemotherapy/radiation therapy-naive patients receiving external-beam irradiation <sep> filgrastim 6 placebo <sep> filgrastim <sep> filgrastim r-methug-csf <sep>', 'radiation alone or radiation plus topical application of pure natural honey <sep>', 'cyclophosphamide and fractionated total-body irradiation cy/tbi or busulfan and cyclophosphamide bu/cy and given methotrexate along with a calcineurin inhibitor cyclosporine a tacrolimus <sep> placebo <sep> allogeneic hematopoietic stem cell transplantation hsct <sep> palifermin <sep> palifermin <sep>', 'morning radiotherapy rt <sep> early morning versus late afternoon radiotherapy <sep> afternoon 4-6 pm <sep>', 'placebo <sep> radiotherapy <sep> zinc supplementation <sep> zinc supplementation <sep> zinc supplement <sep>', 'placebo <sep> radical radiotherapy <sep> amphotericin polymyxin and tobramycin <sep>', 'topical histamine gel <sep> placebo <sep> topical gel containing histamine dihydrochloride hdc <sep> placebo gel <sep> histamine dihydrochloride <sep>', 'idarubicin methylprednisolone and high dose ara-c <sep> mitoxantrone etoposide and methylprednisolone followed by autologous unpurged bmt <sep> allogeneic bone marrow transplantation bmt <sep> rgm <sep> rgm-csf or placebo <sep> cytosine arabinoside <sep> recombinant granulocyte-macrophage-colony stimulating factor rgm-csf <sep> granulocyte-macrophage-colony stimulating factor support <sep>', 'placebo <sep> radiotherapy <sep> polymyxin e 2 mg tobramycin 1.8 mg and amphotericin b 10 mg pta <sep> placebo lozenges <sep> primary curative or postoperative radiotherapy <sep>', '5-fluorouracil 5fu)-induced stomatitis <sep> cryotherapy <sep> control arm or to receive oral cryotherapy <sep> oral cooling cryotherapy <sep> oral cooling cryotherapy <sep> 5-fu-containing regimen <sep> 5-fluorouracil-induced stomatitis <sep>', 'granulocyte-macrophage colony-stimulating factor <sep> 5-fu 800 mg/m2/d leucovorin <sep> cisplatin fluorouracil and leucovorin chemotherapy <sep> pfl chemotherapy <sep> gm-csf <sep> granulocyte-macrophage colony-stimulating factor gm-csf <sep> cisplatin fluorouracil 5-fu and leucovorin pfl chemotherapy with cisplatin <sep> pfl chemotherapy gm-csf <sep>', 'subcutaneous gm-csf <sep> radical radiotherapy <sep> subcutaneous molgramostin granulocyte-macrophage colony stimulating factor gm-csf injections <sep> gm-csf <sep>', 'placebo <sep> allopurinol <sep> leucovorin <sep> mouthwash containing 20 mg of allopurinol or a placebo <sep> allopurinol mouthwash <sep>', '5-fluorouracil/leucovorin <sep> oral glutamine supplements ogs <sep> fu/lv chemotherapy <sep> glutamine supplementation <sep> systemic chemotherapy <sep> ogs <sep> bsc <sep> 5-fluorouracil/leucovorin fu/lv)-induced mucositis/stomatitis <sep> chromium 51-ethylene diaminetetra-acetate 51cr-edta <sep> oral glutamine <sep>', 'hyperfractionated radiotherapy <sep> palifermin 60 microg/kg or placebo <sep> placebo <sep> palifermin a recombinant human keratinocyte growth factor deltan23-kgf <sep> chemotherapy included cisplatin 20 mg/m(2 for 4 days and continuous-infusion fluorouracil <sep> palifermin and concurrent chemoradiation <sep> palifermin <sep> standard radiotherapy <sep> palifermin <sep> standard radiation therapy <sep>', 'recombinant human keratinocyte growth factor kgf <sep> placebo <sep> fu plus leucovorin <sep> fluorouracil fu <sep> kgf <sep> recombinant human keratinocyte growth factor plus chemotherapy <sep> fu 425 mg/m2/d iv bolus plus leucovorin <sep> kgf to placebo <sep>', 'radioprotector <sep> radiotherapy <sep> amifostine <sep> radiotherapy <sep> amifostine <sep>', 'placebo <sep> gm-csf mouthwashes <sep> placebo versus gm-csf mouthwash 150 micro g/day <sep> granulocyte-macrophage colony-stimulating factor gm-csf mouthwashes <sep>', '5-fu therapy <sep> 5-fu-based chemotherapy <sep> 5-fluorouracil-related stomatitis <sep> oral cryotherapy <sep> 5-fu plus leucovorin chemotherapy regimen <sep> oral cryotherapy inhibits 5-fluorouracil 5-fu)-induced stomatitis <sep>', 'prostaglandin e2 pge prostin e2 0.5 mg per tablet or placebo <sep> placebo <sep> prostaglandin e2 <sep> pge <sep>', 'sucralfate ulcogant <sep> sucralfate prophylaxis <sep> sucralfate suspension <sep> standard oral hygiene consisting of frequent tooth cleaning and disinfection of the oral and pharyngeal mucosa <sep>', 'oral glutamine or a placebo preparation <sep> oral cryotherapy before chemotherapy <sep> 5-fu-based chemotherapy regimen <sep> fluorouracil 5-fu)-based chemotherapy <sep> glutamine <sep> amino acid glutamine <sep> 5-fu-based chemotherapy <sep> placebo preparation <sep>', 'granulocyte colony-stimulating factor g-csf <sep> g-csf <sep> adriamycin adm <sep> g-csf therapy <sep>', '5-fluorouracil 5-fu and folinic acid <sep> placebo <sep> glutamine <sep> oral glutamine supplementation <sep> 5-fluorouracil and folinic acid <sep>', 'placebo <sep> rhitf 80 mg/ml ie high dose by oral spray <sep> placebo rhitf 10 mg/ml <sep> recombinant human intestinal trefoil factor oral spray <sep> recombinant human intestinal trefoil factor rhitf <sep>', 'amifostine <sep> radiotherapy or radiotherapy plus amifostine <sep>', 'radiotherapy <sep> low level helium-neon he-ne laser therapy <sep> he-ne laser wavelength 632.8 nm and output of 10mw and control group patients were given oral analgesics local application of anaesthetics 0.9 per cent saline and povidine wash during the course of radiotherapy <sep> low level laser lel <sep> radiotherapy or chemotherapy <sep> low-level helium-neon he-ne laser <sep>', 'polaprezinc <sep> radiochemotherapy <sep> azulene oral rinse <sep> polaprezinc zinc l-carnosine <sep> neoadjuvant radiochemotherapy <sep> polaprezinc <sep> radiotherapy or radiochemotherapy <sep>', 'placebo <sep> enzyme therapy with conventional fractionated radiation therapy <sep> oral enzyme therapy <sep> oral proteolytic enzyme preparation <sep> hydrolytic enzymes <sep> 60co gamma-radiation <sep> enzyme tablets orally t.i.d <sep>', 'placebo <sep> repifermin <sep> autologous hematopoietic stem cell transplantation auto-hsct <sep> repifermin keratinocyte growth factor-2 <sep> intravenous repifermin <sep>', 'carboplatin <sep> radiotherapy <sep> rct <sep> rct <sep> radiochemotherapy with amifostine cytoprotection <sep> rct alone <sep> radiochemotherapy rct <sep> amifostine <sep>', 'acyclovir <sep> chemotherapy or radiation therapy <sep> acyclovir or placebo <sep>', 'high-dose melphalan <sep> melphalan 200 mg/m(2 followed by autologous stem cell transplantation <sep> oral cryotherapy or room temperature normal saline rinses <sep> cryotherapy <sep>', 'subcutaneous amifostine <sep> radical radiotherapy <sep> radiotherapy <sep> amifostine <sep> fractionated radiotherapy <sep> amifostine wr-2721 <sep> amifostine therapy <sep> amifostine <sep>', 'placebo <sep> benzydamine <sep> benzydamine oral rinse <sep> benzydamine oral rinse <sep> benzydamine <sep> benzydamine or placebo <sep>', 'placebo <sep> crt intravenous l-alanyl-l-glutamine <sep> l-alanyl-l-glutamine <sep> intravenous l-alanyl-l-glutamine 0.4 g/kg weight/day or an equal volume of saline placebo <sep> chemoradiotherapy crt radiotherapy daily up to 70 gy plus cisplatin/5-fluoruracil <sep> intravenous l-alanyl-l-glutamine <sep> chemoradiotherapy <sep> crt <sep>', 'oral cryotherapy <sep> oral cryotherapy <sep> oral cryotherapy or standard oral care <sep>', 'na-sucrose octasulfate <sep> placebo <sep> na sucrose octasulfate na sos <sep>', 'allopurinol mouth rinse <sep> 5-fluorouracil containing chemotherapy <sep> placebo <sep> allopurinol and placebo <sep> allopurinol <sep> allopurinol mouth rinse <sep> allopurinol mouthwash 1 mg/ml or placebo <sep>', 'chlorhexidine solution <sep> chlorhexidine <sep> chlorhexidine mouthrinse <sep> chlorhexidine <sep>', 'amifostine 910 mg/m(2 prior to melphalan 200 mg/m(2 <sep> asct <sep> amifostine cytoprotection <sep> amifostine <sep> amifostine <sep>', 'placebo <sep> oral glutamine <sep> cytotoxic chemotherapy <sep> glutamine <sep> glutamine <sep> glutamine or placebo glycine suspension 2 g amino acid/m2/dose twice daily to swish and swallow on days of chemotherapy <sep> placebo wilcoxon <sep> oral glutamine <sep>', 'sod <sep> radiotherapy <sep> superoxide dismutase <sep>', 'oral glutamine <sep> glutamine <sep> placebo normal saline <sep> glutamine suspension <sep> oral glutamine <sep>', ""radiotherapy <sep> radiotherapy single agent cisplatin ddp,30 mg/m(2 <sep> traditional chinese medicine <sep> chemoradiotherapy <sep> chinese medicine daily and those of control group took 5-8 times of dobell's solution daily <sep> chemotherapy <sep> chinese medicine <sep> chinese medicine <sep>"", 'palifermin or placebo <sep> placebo <sep> doxorubicin-based chemotherapy <sep> open-label palifermin <sep> placebo palifermin <sep> palifermin <sep> multicycle chemotherapy <sep> palifermin and placebo <sep> palifermin <sep>', 'placebo <sep> stomatotoxic therapy <sep> iseganan <sep> oral rinse consisting of iseganan 9mg or placebo <sep> iseganan 251 or placebo <sep> bone marrow or peripheral blood allogeneic or autologous stem cell transplantation sct <sep> iseganan <sep>', 'placebo <sep> sucralfate suspension <sep> sucralfate <sep> sucralfate <sep> radiation therapy <sep>', 'carboplatin <sep> amifostine <sep> radiochemotherapy <sep> conventional radiotherapy rt 2-gy fractions <sep> amifostine <sep>', 'aerobic gram-negative bacteria agnb <sep> external beam radiation therapy ebrt <sep> placebo <sep> placebo or a combination of the antibiotics polymyxin e tobramycin and amphotericin b pta group <sep>', 'placebo <sep> conditioning therapy fractionated total-body irradiation plus high-dose chemotherapy <sep> placebo palifermin <sep> autologous hematopoietic stem-cell transplantation <sep> palifermin <sep> palifermin recombinant human keratinocyte growth factor <sep> intensive chemotherapy and radiotherapy <sep> palifermin <sep>', 'placebo <sep> iseganan or placebo <sep> antimicrobial intervention <sep> radiotherapy rt <sep> iseganan oral solution plus standard-of-care oral hygiene soc placebo plus soc or soc alone <sep> iseganan hcl oral solution <sep> iseganan hcl iseganan <sep>', 'granulocyte macrophage-colony stimulating factor gm-csf and sucralfate <sep> radiotherapy <sep> sucralfate alone <sep> sucralfate <sep> gm-csf and sucralfate <sep> sucralfate <sep> molgramostim gm-csf <sep>', 'placebo <sep> sucralfate suspension <sep> radiotherapy-induced mucositis <sep> placebo washing <sep> sucralfate <sep> sucralfate mouth washing <sep> sucralfate <sep>', 'radiotherapy <sep> sucralfate <sep> placebo <sep> aluminium hydroxide complex of sulphated sucrose <sep>', 'radiation therapy <sep> placebo <sep> pilocarpine or placebo <sep> pilocarpine <sep> pilocarpine <sep>', 'intravenous amifostine <sep> placebo <sep> radiochemotherapy <sep> intravenous i.v. or subcutaneous s.c. amifostine <sep> amifostine 200 mg/m2 or placebo before radiotherapy <sep> chemoradiotherapy <sep> amifostine placebo <sep> radiotherapy or radiochemotherapy <sep> carboplatin 70 mg/m2 and radiotherapy <sep> amifostine <sep>', 'enzyme and radiotherapy <sep> wobe-mugos <sep> radiotherapy alone <sep>', 'oral glutamine <sep> oral glutamine or placebo <sep> oral glutamine supplementation <sep> chemotherapy with or without radiation oral glutamine <sep>', 'placebo <sep> double-blind placebo normal saline <sep> fluorouracil 5-fu)-based chemotherapy <sep> oral cooling cryotherapy <sep> cryotherapy with crushed ice 45 minutes during chemotherapy <sep> prophylactic chlorhexidine <sep> chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy <sep> chlorhexidine mouthrinse <sep> 5-fu/leucovorin chemotherapy <sep> chlorhexidine <sep> placebo and with oral cooling cryotherapy <sep>', 'cryotherapy <sep> allogeneic hematopoietic stem cell transplantation ahsct <sep> mtx <sep> cryotherapy <sep> cryotherapy during mtx <sep>', 'chlorhexidine-based product chlorhexidine concentration 0.3 n=24 or with an amine-stannous fluoride combination <sep> antiseptic chlorhexidine <sep> chlorhexidine <sep> cancer chemotherapy <sep>', 'placebo <sep> radiotherapy <sep> wobe-mugos e proteolytic enzymes <sep> wobe-mugos e <sep> papain 100 mg trypsin 40 mg and chymotrypsin 40 mg <sep> radiotherapy <sep>', 'propantheline <sep> etoposide <sep> propantheline 30 mg or placebo <sep>', 'prophylactic chlorhexidine mouthrinse <sep> chlorhexidine digluconate mouthrinse <sep> placebo <sep> chlorhexidine rinse <sep> chlorhexidine digluconate oral rinse <sep> conditioning chemoradiotherapy <sep> chlorhexidine mouthrinse <sep> chlorhexidine <sep>', 'chlorhexidine gluconate <sep> placebo <sep> chlorhexidine <sep> chlorhexidine mouth rinse regimen <sep>', 'chlorhexidine rinsing <sep> placebo <sep> chlorhexidine <sep>', 'locally applied gm-csf <sep> placebo <sep> parenteral nutrition <sep> myeloablative chemo and radiotherapy <sep> gm-csf <sep> morphine <sep>', 'placebo <sep> gm-csf mouthwash <sep> gm-csf mol-gramostim mouthwash <sep> placebo mouthwash 0.1 percent albumin or one of four concentrations of gm-csf mouthwash <sep> gm-csf <sep>', 'carboplatin <sep> subcutaneous daily amifostine <sep> amifostine <sep> concomitant chemoradiotherapy <sep> carboplatin/paclitaxel <sep> carboplatin/paclitaxel with or without daily subcutaneous amifostine <sep> no amifostine <sep> combining concomitant boost radiation and weekly carboplatin/paclitaxel with or without amifostine <sep> paclitaxel <sep>', 'yangyin humo decoction <sep> lidocaine 20 ml dexamethasone 5 mg gentamycin 80,000 units vitamin b(12 5 mg dissolved in saline 250 ml and 5 sodium bicarbonate solution <sep> yangyin humo decoction yhd <sep> radiotherapy <sep>', 'placebo <sep> nurse-initiated systematic oral hygiene teaching program-pro-self <sep> chlorhexidine <sep>', 'autologous bmt <sep> pentoxifylline <sep> pentoxifylline ptx <sep> ptx <sep>', 'placebo <sep> benzydamine <sep> benzydamine oral rinse <sep> benzydamine oral rinse <sep> benzydamine <sep> radiation therapy rt <sep> benzydamine hcl <sep>', 'placebo <sep> radiotherapy <sep> unconventional fractionation or with concomitant chemotherapy <sep> antimicrobial lozenge <sep> placebo lozenge <sep> economically viable antimicrobial lozenge bacitracin clotrimazole and gentamicin bcog <sep> conventional radiotherapy <sep>', 'radiochemotherapy <sep> concomitant chemotherapy and radiotherapy with a significant area of directly visible oral and/or oropharyngeal mucosa included in the radiation fields plus prior topical application of pure natural honey or the control group receiving concomitant chemotherapy and radiotherapy without honey <sep>', 'carboplatin <sep> ifosfamide <sep> prophylactic application of g-csf 5 microg kg(-1)subcutaneously <sep> etoposide <sep> amifostine cytoprotection <sep> amifostine <sep> high-dose chemotherapy hd-vic plus autologous bone marrow transplant hdct <sep> hd-vic chemotherapy <sep> 5-ht3-receptor antagonists/dexamethasone/trifluorpromazine <sep> hdct <sep> carboplatin and ifosfamide <sep> hd-vic chemotherapy with or without amifostine <sep> amifostine <sep>', 'placebo <sep> conventional fractionated radiotherapy <sep> placebo <sep> misoprostol <sep> misoprostol <sep> analog <sep> misoprostol a prostaglandin e(1 <sep>', 'povidone-iodine <sep> antineoplastic radiochemotherapy <sep> povidone-iodine <sep> nystatin dexpanthenol rutoside and immunoglobulin <sep>', 'rinse with 20 ml of saline <sep> standard head and neck radiation therapy based on a standard protocol <sep>', 'placebo <sep> topical misoprostol <sep> radiotherapy <sep> misoprostol <sep> misoprostol <sep> misoprostol or placebo <sep>', 'indigowood root isatis indigotica fort <sep> controls with only normal saline and group 2 as the indigowood root ir group <sep> extracts from indigowood root isatis indigotica fort <sep>', 'povidone-iodine and normal saline mouthwashes <sep> povidone-iodine diluted 1:100 n=67 mouthwashes for om prophylaxis and treatment after high-dose chemotherapy comprising beam or hd-l-pam followed by autologous peripheral stem cell transplantation <sep> normal saline <sep>', 'parenteral glutamine dipeptide supplementation <sep> parenteral glutamine dipeptide gln supplementation <sep> intravenous supplementation with gln <sep> standard amino acid mixture control on days 1  5 of chemotherapy <sep> parenteral gln supplementation <sep>', 'radiation therapy rt <sep> sucralfate vs placebo <sep> radical radiotherapy <sep> placebo <sep> sucralfate to placebo <sep> sucralfate <sep> concurrent chemotherapy <sep> sucralfate prophylaxis <sep> sucralfate <sep>', 'lel or placebo <sep> low-energy helium-neon laser lel <sep> lel therapy <sep> lel <sep> radiotherapy alone 65 gy at a rate of 2 gy/fraction 5 fractions per week without prior surgery or concomitant chemotherapy <sep>', 'sucralfate n  19 mouthwashes during postoperative radiotherapy rt <sep> granulocyte-macrophage colony-stimulating factor gm-csf mouthwashes with sucralfate mouthwashes <sep> conventionally fractionated rt <sep> sucralfate <sep> granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes <sep> gm-csf <sep>', 'carboplatin <sep> radiochemotherapy rt  ct <sep> amifostine <sep> radiochemotherapy plus amifostine rc  ct  a <sep> rc  ct alone or rc  ct  a. patients were irradiated up to 60 gy r0 or 70 gy r1/2 and received chemotherapy 70 mg/m(2 carboplatin day 1-5 in week 1 and 5 of radiotherapy <sep> amifostine a <sep> rc  ct <sep> postoperative radiochemotherapy <sep> amifostine <sep>', 'sucralfate <sep> placebo <sep>', 'limited oral hygiene care lim and intensive oral hygiene care int <sep>', 'low-power laser therapy lplt <sep> low-power laser <sep> lplt <sep> autologous at or allogeneic al hsct <sep>', '5-fu+cddp pf <sep> allopurinol <sep> vincristine and actinomycin-d+cyclophosphamide vac <sep> allopurinol <sep>', '5-fluorouracil 5fu <sep> placebo <sep> sucralfate suspension or a placebo suspension <sep> sucralfate mouthwash <sep> chemotherapy with 5fu and leucovorin lv <sep> oral cryotherapy <sep> sucralfate <sep> 5-fluorouracil <sep>', 'leucovorin <sep> fluorouracil 5fu <sep> 5fu plus leucovorin <sep> oral cryotherapy <sep> fluorouracil-induced stomatitis by oral cryotherapy <sep>', 'prednisone <sep> placebo <sep> corticosteroids <sep>', 'zinc sulfate or placebo <sep> telecobalt radiotherapy at conventional fractionation <sep> placebo <sep> zinc sulfate <sep> zinc sulfate <sep> oral zinc sulphate supplementation <sep>', 'sucralfate and placebo <sep> sucralfate <sep> prophylactic sucralfate suspension <sep> cisplatin and continuous infusion with 5-fluorouracil 5-fu <sep>', 'hla-identical sibling marrow and cyclosporine and prednisone <sep> placebo <sep> recombinant human granulocyte-macrophage colony-stimulating factor rhgm-csf <sep> yeast-derived rhgm-csf 250 micrograms/m2/day or placebo <sep> rhgm-csf <sep>', 'shenqi fanghou recipe <sep> radiotherapy alone <sep> shenqi fanghou recipe sfr <sep> modified sfr as adjuvant to radiotherapy <sep>', 'placebo <sep> fluorouracil-based chemotherapy <sep> fluorouracil/leucovorin fu/lv chemotherapy <sep> placebo or palifermin <sep> palifermin <sep> chemotherapy with fu/lv <sep> palifermin <sep>', 'chemotherapy <sep> low-energy laser <sep> laser application <sep>', 'sucralfate <sep> placebo <sep> radiotherapy <sep>', 'placebo <sep> radiotherapy <sep> pilocarpine <sep> pilocarpine hydrochloride <sep> pilocarpine <sep> pilocarpine hydrochloride <sep> pilocarpine or a placebo <sep>', 'radiotherapy <sep>', 'placebo <sep> radiotherapy <sep> prostaglandin inhibitor and radiotherapy <sep> radiotherapy <sep> indomethacin <sep>', 'alcohol-free povidone-iodine mouthwash <sep> alcohol-free test mouthwashes 0.12 chlorhexidine 1 povidone-iodine or salt/soda or a control <sep> povidone-iodine <sep> alcohol-free mouthwashes <sep> chlorhexidine <sep>', 'placebo <sep> recombinant human epidermal growth factor rhegf <sep> egf <sep> topically applied human recombinant epidermal growth factor rhegf <sep> radiotherapy rt with or without chemotherapy <sep>', 'placebo <sep> low level laser therapy <sep> 650 nm laser 780 nm laser or placebo <sep> lle laser <sep> low level gaalas diode lasers <sep> daily direct laser treatment <sep> low level laser therapy <sep>', 'chlorhexidine mouthwash <sep> placebo mouthwash <sep> chlorhexidine <sep> chlorhexidine mouthwash or a placebo mouthwash <sep>', 'individual dental stent <sep> dental stent during radiotherapy <sep> individual dental stent in radiotherapy <sep>', 'polychemotherapy and/or radiotherapy <sep> placebo <sep> benzydamine <sep> benzydamine against oral radio-chemomucositis <sep> benzydamine and placebo <sep> antineoplastic radiotherapy and/or intra-arterial chemotherapy <sep>', 'chemotherapy <sep> oral glutamine supplementation <sep> placebo <sep> oral glutamine <sep> oral glutamine or placebo pre-neoadjuvant chemotherapy cef regimen <sep> glutamine <sep> prophylactic oral glutamine <sep>', 'chewing gum <sep>', 'placebo <sep> sucralfate or placebo <sep> oral sucralfate suspension <sep> sucralfate suspension <sep> sucralfate <sep> sucralfate <sep> sucralfate and placebo <sep>', 'placebo <sep> misoprostol <sep> oral misoprostol or placebo <sep> ice ifosfamide carboplatin etoposide program <sep> misoprostol prophylaxis <sep>', 'placebo <sep> unblinded filgrastim <sep> filgrastim recombinant methionyl human granulocyte colony-stimulating factor r-methug-csf <sep> filgrastim r-methug-csf <sep> filgrastim <sep> cae chemotherapy cyclophosphamide doxorubicin and etoposide and placebo or filgrastim <sep>', 'placebo <sep>', 'sucralfate mouth washing 1 g six times daily during irradiation n  20 or to placebo washing <sep> sucralfate mouth washing <sep> placebo <sep> sucralfate <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>']}",ten interventions were found to have some benefit with regard to preventing or reducing the severity of mucositis associated with cancer treatment. the strength of the evidence was variable and implications for practice include consideration that benefits may be specific for certain cancer types and treatment. there is a need for further well designed and conducted trials with sufficient numbers of participants to perform subgroup analyses by type of disease and chemotherapeutic agent.
371,"{'outcomes': ['subjective symptoms of cmd <sep>', 'disclusion time as well as myofascial pains muscular symptom remissions <sep> disclusion times <sep> myofascial pains symptom status <sep> symptom remissions <sep> disclusion time <sep>'], 'punchline_text': ['the difference between the groups in the increase of sites tender to palpation was less clear showing only a trend. <sep>', 'additionally mock icagd occlusal adjustments did not appear to be a factor in the control subjects treatment response as this group showed no statistically significant symptom remissions. <sep>'], 'population': ['young adults <sep> sixty-two dental students judged not to be in need of treatment for craniomandibular disorder cmd <sep>', 'chronic myofascial pain dysfunction patients <sep> dental student population <sep> twenty-five dental students who exhibited symptomatology consistent with myofascial pains patient <sep>'], 'interventions': ['placebo <sep>', 'icagd <sep> icagd occlusal adjustments <sep> mock icagd <sep> mock icagd with tooth polishing <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>']}",there is an absence of evidence from rcts that occlusal adjustment treats or prevents tmd. occlusal adjustment cannot be recommended for the management or prevention of tmd. future trials should use standardised diagnostic criteria and outcome measures when evaluating tmd.
372,"{'outcomes': ['df levels <sep> prevalence of aesthetically important df mild and moderate <sep>', 'risk of dental fluorosis prevalence <sep>', 'prevalences of fluorosis <sep> prevalences of tf <sep> dental fluorosis tf index <sep>', 'prevalence of fluorosis <sep> prevalence of dental fluorosis <sep> social deprivation <sep> jarman score <sep>', 'tfi score <sep> thystrup-fejerskov index tfi scores <sep> tfi scores <sep> overall levels of fluorosis <sep>', 'tf index the child and tooth prevalence of opacities <sep> prevalence of caries <sep> enamel opacities and dental caries <sep> thylstrup and fejerskov tf index for fluorosis and the modified developmental defects of enamel dde index <sep>', 'early forming fluorosis risk index fri classification i enamel surfaces <sep> risk factor exposure <sep>', 'early toothbrushing habits <sep> fluorosis risk index fri <sep> risk factor exposure <sep>', 'fluorosis prevalence <sep> fluorosis community index fci <sep>', 'dental caries experience <sep> dental fluorosis prevalences <sep> fluorosis prevalence <sep> mean dmft values <sep> overall prevalence <sep>', ""child's birth weight and liking for or swallowing of toothpaste <sep>"", 'prevalence of fluorosis <sep> prevalence of fluorosis by tf1 case definition <sep>', 'prevalence of fluorosis <sep> severity of fluorosis <sep>', 'risk of fluorosis <sep> fluorosis <sep>', 'dental fluorosis <sep> prevalence of dental caries <sep> prevalence of dental fluorosis <sep>', 'risk of enamel fluorosis <sep> risk of fluorosis <sep> risk factor exposure <sep>', 'mainly tfi score <sep> fluorosis <sep>'], 'punchline_text': ['the prevalence of aesthetically important df mild and moderate was low and similar in both communities and considerably lower than the expected level at water fluoridation concentrations of 1 ppm. <sep>', 'there was no statistically significant increased risk of dental fluorosis prevalence associated with any of the fluoride exposure risk factors examined including reported usage of 1000 ppm fluoride toothpaste from time of first deciduous tooth eruption. <sep>', 'in the deprived districts the prevalences of fluorosis were 25.2 and 19.5 p  0.2). <sep>', 'multivariate analysis indicated that area of residence odds ratio  4.5 jarman score odds ratio  0.99 per jarman unit and type of toothpaste odds ratio  1.6 were statistically significantly related to presence or absence of fluorosis the risk factors were--fluoridated area affluence and use of adult toothpaste. <sep>', 'higher fluoride exposure slightly increased the likelihood that a child had a higher tfi score especially when more fluoridation technologies were used at home. <sep>', 'there was no significant difference in the prevalence of caries in either primary or permanent teeth although the trend in both cases was for slightly more disease in children who had used the test paste. <sep>', 'a very strong association was observed with inappropriate fluoride supplement use or  23.74 95 ci 3.43-164.30). <sep>', 'there was a strong association between mild-to-moderate fluorosis on later forming fri classification ii enamel surfaces and both supplement use or  7.97 95 ci 2.98-21.33 and early toothbrushing habits or  4.23 95 ci 1.72-10.41). <sep>', 'the multivariate model showed that the effect of the supplementary fluoride sources was different between children that started brushing with toothpaste before two years of age or  6.15 ic 95  2.03-18.67 and after or  2.14 ic 95  1.16-3.94). <sep>', 'mean dmft values in perth and bunbury were 0.32 and 0.28 p  0.05). <sep>', ""the child's birth weight and liking for or swallowing of toothpaste did not influence the prevalence of fluorosis. <sep>"", 'the prevalence of fluorosis by tf1 case definition declined from 34.7 to 22.1 and by tf2 case definition from 17.9 to 8.3%. <sep>', 'swallowed fluoride toothpaste in the early years of life has been postulated to be a risk factor for fluorosis but the epidemiological evidence is weakened by the fact that most of the relevant studies were done in developed countries where an individual is exposed to multiple sources of fluoride. <sep>', 'the risk of fluorosis was significantly greater for children who had greater exposure to fluoridated water and who used larger amounts of fluoridated toothpaste up to age eight. <sep>', 'children with dental fluorosis were 1.75 times more likely to be free of caries or  1.75-ci:0.43 6.68). <sep>', 'an odds ratio of 1.7 associated with infant formula use was suggestive of an increased risk of enamel fluorosis as was an odds ratio of 2.9 associated with fluoride dentifrice use. <sep>', 'logistic regression established tooth brushing frequency and fluoride supplement use in addition to tap water fluoride concentrations above 0.7 mg/l as significant risk factors when the presence of fluorosis on at least one tooth was used as outcome variable. <sep>'], 'population': ['school-age children <sep> permanent teeth in children whose domestic water supply was fluoridated since birth with that in a community where fluoridated salt was available <sep> a representative random sample of 12-year-old children was examined in water fluoridated dublin ireland and non-water fluoridated freiburg germany <sep> 377 children in dublin and 322 children in freiburg were examined <sep>', ""1039 parents enquired into their child's early oral health behaviors and included a photographic toothpaste menu <sep> children aged 7-9 years from non-water-fluoridated halmstad sweden <sep> children from non-water-fluoridated halmstad sweden <sep>"", 'children who received toothpaste containing either 440 or 1,450 ppm f from the age of 12 months in deprived and less deprived communities <sep> children were resident in non-fluoridated districts in the north-west of england <sep> children n  1,268 were 8-10 years old <sep> upper central incisors of children from socially diverse backgrounds who had received either 440 or 1,450-ppm f toothpaste from 12 months of age <sep>', 'children aged 8-9 years who had been continuous residents in fluoridated newcastle or fluoride-deficient northumberland <sep> permanent incisor teeth in young children in a fluoridated and a fluoride-deficient community <sep> dental fluorosis in permanent incisor teeth in relation to water fluoridation social deprivation and toothpaste use in infancy <sep>', '8,277 children <sep> children who began brushing with <sep> children aged 10 years <sep> children in two canadian communities exposed to fluoride <sep> permanent teeth of canadian children <sep>', 'pre-school children who were 2-years-old at the start of the 3-year trial <sep> permanent incisor teeth and of caries in children who had taken part <sep> 1,523 children were examined in schools and had photographs taken of their upper permanent incisor teeth <sep> children who used a low fluoride toothpaste between 2 and 5 years of age <sep>', 'enamel fluorosis in a fluoridated population <sep> 401 residents of fluoridated communities in connecticut who were 12-16 years old and born prior to 1980 <sep>', 'nonfluoridated communities <sep> 460 10 to 13-year-old children born after 1979 who were residents of six nonfluoridated communities in massachusetts and connecticut <sep>', 'children two years of age and younger <sep> school children aged 6-9 <sep> 320 children attending elementary schools protected by a public preventive dental program in the city of campeche mexico <sep> schoolchildren of campeche mexico <sep>', 'between may-july 2000 582 10-year-olds were examined for dental fluorosis tf index and dental caries dmft in school dental clinics <sep> children  6 years of age <sep>', 'all children n  551 born 1988 in a municipality in norway were invited to participate <sep> 8-year-old children <sep> 383 children <sep>', 'australian children <sep> south australian children born in 1989-1994 was selected in 2002/2003 stratified by fluoridation status and urban/rural residence <sep> south australian children <sep> 677 children for fluorosis using the thylstrup and fejerskov tf index <sep>', '1189 seventh grade children with a mean age of 12.2 years <sep>', 'pediatric dental patients <sep> pediatric patients seeking dental treatment in a university pediatric dental clinic <sep> 157 children aged 8 to 17 years were examined for dental fluorosis using the tooth surface index of fluorosis tsif <sep>', 'dental caries and fluorosis prevalence study in a nonfluoridated brazilian community <sep> sample subjects are randomly selected schoolchildren who were examined with a dental probe and buccal mirror under natural light <sep> dental caries and dental fluorosis in eleven and twelve-year-olds in a non-fluoridated brazilian community  0.2 ppm f <sep> children with dental fluorosis <sep>', 'eight hundred fifty 11 to 14-year-old residents of nonfluoridated communities in massachusetts and connecticut who were born between 1972 and 1975 were investigated in a case-control study of the possible association between enamel fluorosis and exposure to fluoride supplements infant formula and/or fluoride dentifrice <sep> subjects in the middle median household income group who had used <sep>', 'flemish schoolchildren <sep> children aged 11 years 4,128 children examined <sep>'], 'interventions': ['fluoride toothpaste <sep>', 'fluoride toothpaste <sep>', 'high fluoride 1,450 ppm f toothpastes <sep> 440 or 1,450-ppm f toothpaste <sep>', ""fluoride toothpaste <sep> child's toothpaste with lower fluoride concentration <sep> fluoride toothpastes <sep>"", 'fluoride toothpaste <sep>', 'low 550 ppm fluoride toothpaste <sep> standard 1050 ppm control paste <sep>', 'fluoride toothpaste and/or fluoride supplements <sep>', 'fluoride toothpaste <sep>', 'fluoride <sep>', 'toothpaste ingestion and to promote low fluoride toothpaste <sep> low f toothpaste <sep> tf <sep> fluoride supplements <sep>', 'fluoride supplements <sep> fluoride toothpaste <sep> systemic fluoride exposure supplements and toothpaste <sep>', 'fluoride <sep>', 'fluoride toothpaste <sep> fluoride toothpaste <sep> swallowed fluoride toothpaste <sep>', 'fluoride <sep> fluoride toothpaste <sep> fluoridated toothpaste <sep> fluoride history questionnaires <sep>', 'fluoride toothpaste <sep>', 'fluoride supplements <sep>', 'fluoride-containing toothpaste <sep> systemic fluoride supplements <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there should be a balanced consideration between the benefits of topical fluorides in caries prevention and the risk of the development of fluorosis. most of the available evidence focuses on mild fluorosis. there is weak unreliable evidence that starting the use of fluoride toothpaste in children under 12 months of age may be associated with an increased risk of fluorosis. the evidence for its use between the age of 12 and 24 months is equivocal. if the risk of fluorosis is of concern the fluoride level of toothpaste for young children under 6 years of age is recommended to be lower than 1000 parts per million ppm). more evidence with low risk of bias is needed. future trials assessing the effectiveness of different types of topical fluorides including toothpastes gels varnishes and mouthrinses or different concentrations or both should ensure that they include an adequate follow-up period in order to collect data on potential fluorosis. as it is unethical to propose rcts to assess fluorosis itself it is acknowledged that further observational studies will be undertaken in this area. however attention needs to be given to the choice of study design bearing in mind that prospective controlled studies will be less susceptible to bias than retrospective and/or uncontrolled studies.
373,"{'outcomes': ['mean arterial pressure map <sep> vasoactive and inotropic drugs and fluid balance <sep> systemic vascular resistance svr <sep> haemodynamic effects <sep> mean pulmonary arterial pressure <sep> haemodynamic effects <sep>', 'splanchnic blood flow nor oxygen delivery and consumption <sep> procalcitonin pct tumor necrosis factor tnf-alpha soluble tnf receptor human soluble intercellular adhesion molecule-1 c-reactive protein crp and leukocyte count <sep> splanchnic blood flow <sep> pct tnf-alpha and leukocyte count <sep>', 'pulmonary shunt and alveolo-arterial oxygen difference <sep> spirometric data arterial oxygenation pulmonary shunt haemodynamics use of vasoactive drugs and fluid balance <sep> oxygen delivery and mixed venous oxygen saturation <sep> forced vital capacity forced expiratory volume in 1 s fev1.0 and peak expiratory flow rate pefr <sep> time to awakening and time to extubation <sep> pulmonary function <sep> lung volumes and pulmonary function follows cardiac surgery <sep>', 'myocardial damage inflammatory and stress response <sep> myocardial cell damage inflammatory and stress responses <sep> myocardial inflammatory and stress responses <sep> major postoperative complications <sep> c3alpha troponin i 8-isoprostane and cortisol release <sep> il-6 and il-8 levels <sep> levels of il-10 <sep> troponin i 8-isoprostane cortisol c3alpha interleukin il)-6 il-8 and il-10 <sep>', 'hemodynamic stability <sep> ventilator dependency and analgesia <sep> plasma levels <sep> plasma levels of bactericidal permeability-increasing protein lipopolysaccharide-binding protein and c-reactive protein <sep> faster extubation times <sep> postoperative pain <sep> il-6 <sep> interleukin-6 levels <sep>', 'pif <sep> subcutaneous interstitial tissue <sep> transcapillary cop-gradient coppl-copif <sep> interstitial fluid colloid osmotic pressure copif and interstitial fluid pressure pif <sep> transcapillary fluid balance <sep> simultaneously plasma colloid osmotic pressure coppl <sep> the starling forces coppl copif pif <sep> transcapillary forces coppl copif pif <sep>', 'effective analgesia <sep> postoperative stress <sep> adequate postoperative pulmonary and cardiovascular functions nausea and vomiting <sep> pain relief <sep> levels of postoperative stress serum cortisol and beta-endorphin <sep> postoperative pain relief and stress hormones <sep> serum morphine <sep>', 'cardiac troponin <sep> regional left ventricular function <sep> postoperative complications recorded to 14 days and mortality recorded to 720 days <sep> natriuretic peptide concentrations <sep> regional left ventricular function after myocardial revascularization assessed by transesophageal echocardiography <sep> plasma concentrations of cardiac troponin <sep> brain natriuretic peptide <sep> postoperative ischemia <sep> global and regional myocardial function <sep> mean sd peak concentrations of atrial natriuretic peptide <sep> regional left ventricular function <sep> i concentrations <sep>', 'elisa crp and sap mere measured with rocket immunoelectrophoresis rie <sep> transient and almost simultaneous proinflammatory and anti-inflammatory cytokine response <sep> sap plasma levels <sep> serum amyloid p-component sap <sep> cytokine levels <sep> crp concentrations <sep> cytokine production <sep> release of il-6 il-8 and il-10 <sep>', 'hypoxemia <sep> overall incidence of episodic hypoxemia <sep> episodic hypoxemia <sep> constant hypoxemia <sep>', 'troponin t release <sep> mean troponin t levels <sep> ischaemic damage <sep>', 'hospital stay <sep> pain score <sep> vasoactive medication mean arterial blood pressure <sep> heart rate <sep>', 'intramyocardial oxygen partial pressure <sep> intramyocardial partial oxygen pressure <sep> myocardial oxygen availability <sep>', 'plasma cortisol <sep> hemodynamics plasma epinephrine and norepinephrine cortisol the myocardial-specific contractile protein troponin t and other cardiac enzymes <sep> release of troponin t <sep> postoperative heart rate <sep> myocardial ischemia <sep> perioperative stress response and postoperative myocardial ischemia <sep> plasma epinephrine increased perioperatively <sep> cardiopulmonary bypass and surgery-associated stress response and incidence of myocardial ischemia <sep> myocardial sympathetic response <sep>', 'blood flow of the ita <sep> immunoreactivity rates <sep> immunostaining intensity <sep> flow and endothelium of internal thoracic artery <sep> ita free blood flow significantly via increased vegf i-nos and adenosine-a2b receptor expressions <sep> mean ita free flow <sep> ita free blood flow <sep>', 'cardiac function <sep> intensity of the immunostaining <sep> number of patients showing ventricular fibrillation vf atrial fibrillation or heart block after release of the acc <sep> number of bcl-2 positive cardiomyocytes <sep> bcl-2 positive cardiomyocytes <sep> hemodynamic function and reduced arrhythmias <sep> ci <sep>', 'cardiac renal and neurologic outcomes <sep> time to extubation <sep> consumption of anesthetics <sep> postoperative length of stay time to eligibility for hospital discharge pain and sedation scores degree of ambulation lung volumes and organ morbidities <sep> postoperative hospital length of stay and patients perception of their quality of recovery <sep> quality of recovery score <sep> hospital length of stay quality of recovery or morbidity <sep> length of stay and time to eligibility for hospital discharge <sep> postoperative global quality of recovery score <sep> pain relief degree of sedation ambulation and lung volumes <sep> stress response and pain scores <sep> pneumonia <sep>', 'incidence of perioperative arrhythmias such as atrial fibrillation serum epinephrine levels heart rate variability and hemodynamic parameters <sep> epinephrine serum levels <sep> perioperative arrhythmia <sep> intraoperative sinus bradycardia <sep> serum epinephrine levels <sep> incidence of perioperative dysarrhythmias <sep> perioperative arrhythmias such as atrial fibrillation <sep> perioperative atrial fibrillation <sep> mean systolic arterial pressure <sep> heart rate <sep> hemodynamic changes <sep>', 'mean arterial pressure <sep> peak expiratory flow rate <sep> extubation <sep> postoperative pain <sep> arterial oxygen tension <sep> pain scores <sep> physiotherapy cooperation <sep> intraoperative hemodynamics or ventricular function <sep> psychologic morbidity intraoperative hemodynamics ventricular function lung function and physiotherapy cooperation <sep> pain <sep> minnesota multiphasic personality inventory <sep> postoperative depression <sep> pain <sep> posttraumatic stress subscales <sep>', 'metabolic lactate or electrocardiographic signs of myocardial ischemia <sep> total and cardiac sympathetic activity <sep> cardiac norepinephrine spillover map systemic vascular resistance index svri pulmonary capillary wedge pressure pcwp gcvf and reg-mvo2 <sep> myocardial oxygen demand <sep> mean arterial pressure map great cardiac vein flow gcvf and regional myocardial oxygen consumption reg-mvo2 <sep> myocardial ischemia <sep> cardiac sympathetic nerve activity myocardial blood flow and metabolism and central hemodynamics <sep> hemodynamic measurements and blood sampling <sep> cardiac sympathetic activity myocardial blood flow and metabolism and central hemodynamics <sep>', 'time to tracheal extubation duration of postoperative intensive care unit stay duration of postoperative hospitalization pain control urinary free cortisol cardiopulmonary complication rate and total hospital charges <sep>', '30-day survival free from myocardial infarction pulmonary complications renal failure and stroke <sep> survival free from myocardial infarction pulmonary complications renal failure and stroke <sep> thirty-day survival free from myocardial infarction pulmonary complications renal failure and stroke <sep> postoperative pain scores <sep>', 'time to tracheal extubation <sep> analgesia <sep> postoperative analgesia <sep> mean arterial blood pressure poststernotomy and systemic vascular resistance <sep> troponin <sep> biochemical markers of myocardial damage <sep> troponin i time to tracheal extubation and analgesia <sep> troponin release <sep>', 'levels of impairment for all pain domains and reduced morphine usage <sep> median postoperative stay <sep> arrhythmia inotropic support intubation time perioperative myocardial infarction neurologic events intensive care stay pain scores and analgesia requirement <sep> need vasoconstrictors intraoperatively <sep> length of postoperative hospital stay <sep> incidence of arrhythmias and the median intubation time <sep> incidence of postoperative arrhythmias and improves pain control and overall quality of recovery allowing earlier extubation and hospital discharge <sep>', 'heart rate and mean arterial pressure <sep> cardiac index <sep> cortisol response <sep> catecholamine response <sep> blood glucose values <sep>', 'length of hospital stay <sep> postoperative spirometry or chest radiograph changes <sep> tracheal intubation time and length of hospital stay <sep> postoperative myocardial ischemia or infarction <sep> rapid recovery and shorter hospital stay <sep> hospital discharge time <sep> lower visual analog scores with coughing postextubation <sep> length of stay <sep>', 'mean arterial pressure <sep> extensive bilateral atelectasis <sep> shunt va/q matching or oxygenation <sep> morphine analgesia <sep> va/q matching oxygenation or atelectasis formation <sep> arterial and mixed venous blood gases and hemodynamic variables <sep> paco2 <sep> ventilation-perfusion va/q relationships atelectasis and oxygenation <sep>', 'respiratory tract infections <sep> neurologic complications <sep> acute renal failure <sep> new supraventricular arrhythmias <sep> quality of recovery <sep> incidence of stroke <sep> pulmonary function maximal inspiratory lung volume <sep> acute confusion <sep>', 'vital capacity <sep> forced vital capacity and forced expiratory volume <sep> peak expiratory flow rate <sep> time to endotracheal extubation oxygen withdrawal time and intensive care unit length of stay <sep> visual analogue scale at rest and on coughing <sep> analgesia early tracheal extubation and shorter icu stay <sep> perioperative lung functions and pain scores <sep> abg values and pao2/fio2 ratio <sep> tracheal extubation time oxygen withdrawal time and icu stay <sep>', 'atrial fibrillation af <sep> af <sep>'], 'punchline_text': ['during bypass svr and mean arterial pressure map were significantly higher and pump flow lower in the hf group compared to the lf+tea group. <sep>', 'increases of pct tnf-alpha and leukocyte count were significantly attenuated in the dpx and epi groups at different time points. <sep>', 'a 50-70 reduction in forced vital capacity forced expiratory volume in 1 s fev1.0 and peak expiratory flow rate pefr was seen after surgery but higher fev1.0 and pefr on days 2 and 3 were seen in the epidural group than in the control group. <sep>', 'the c3alpha troponin i 8-isoprostane and cortisol release was similar in the two groups throughout p  or  0.12). <sep>', 'the increase in the plasma levels of bactericidal permeability-increasing protein lipopolysaccharide-binding protein and c-reactive protein showed the same pattern in all groups and no significant differences among the 4 groups were observed. <sep>', 'preoperatively no intergroup differences were observed in the starling forces coppl copif pif). <sep>', 'this method of analgesia was also associated with minimal side effects and provides an alternate approach for treatment of pain after cardiac operations. <sep>', 'high tea was effective in all patients of this group the somatosensory block extended from t1 through t7 vertebrae. <sep>', 'like il-10 opioids downregulate the immune responses in vivo and in vitro including the activity of the cytokine-producing monocytes and granulocytes. <sep>', 'more than 30 episodes of hypoxemia developed on the second night in 22 of patients 11 of 50 patients and on the third night in 30 of patients 14 of 46 patients). <sep>', 'mean troponin t levels at 24 h were not significantly different between the groups p  0.41). <sep>', 'pain score in the epidural group was lower on the first postoperative day than in the extubated group with general anesthesia 3.0 plus minus 1.6 visual analog scale v 4.6 plus minus 1.8 visual analog scale p  0.01). <sep>', 'there were no demographic or hemodynamic differences between the groups before intervention. <sep>', 'both tea and clonidine reduced the postoperative heart rate compared with the control group without jeopardizing cardiac output or perfusion pressure. <sep>', 'immunostaining intensity in the sections after incubation with each primary antibody increased in the ga  tea group compared with the ga group. <sep>', 'in the tea+ga group the bcl-2 positive cardiomyocytes were distinctly statistically increased compared to the ga group p<0.001). <sep>', 'time to extubation was shorter p  0.001 and consumption of anesthetics was lower in the patient-controlled thoracic epidural analgesia group. <sep>', 'the incidence of perioperative dysarrhythmias was significantly lower p  .01 in the ga+tea group 3 than in the ga group 23.7%). <sep>', 'htea showed improved physiotherapy cooperation p  0.001 arterial oxygen tension p  0.041 and peak expiratory flow rate p  0.001). <sep>', 'during sternotomy there was a pronounced increase in cardiac norepinephrine spillover map systemic vascular resistance index svri pulmonary capillary wedge pressure pcwp gcvf and reg-mvo2 in the control group. <sep>', 'no statistically significant differences between the 2 study groups were found in these main measurements. <sep>', 'thirty-day survival free from myocardial infarction pulmonary complications renal failure and stroke was 85.2 in the tea group and 89.7 in the ga group p  0.23). <sep>', 'there were no differences in troponin <sep>', 'the gae compared with ga group reported significantly lower levels of impairment for all pain domains and reduced morphine usage odds ratio  0.07 95 ci 0.03-0.17 p  0.001). <sep>', 'there were no significant differences in cardiac index between the two groups of patients although heart rate and mean arterial pressure decreased before surgery in patients who received extradural analgesia. <sep>', 'there were no differences in postoperative spirometry or chest radiograph changes or in markers for postoperative myocardial ischemia or infarction. <sep>', 'on the first postoperative day a slight reduction in paco2 was seen in the tea group but no differences in shunt va/q matching or oxygenation compared with the ga group. <sep>', 'extubation was achieved earlier p  0.0001 and with significantly fewer lower respiratory tract infections in group tea tea  31 of 206 ga  59 of 202 p  0.0007). <sep>', 'forced vital capacity and forced expiratory volume in one second followed the same pattern for first four postoperative days and peak expiratory flow rate remained statistically high till second postoperative day. <sep>', 'in group e 22 of 44 50 in group e+a 10 of 35 28.6 in group a 10 of 36 27.8 and in the control group 20 of 48 41.7 patients developed af odds ratio amiodarone/nonamiodarone 0.47 0.24-0.90 p  0.02). <sep>'], 'population': ['30 male patients  65 years old and with ejection fraction  0.5 <sep> patients with coronary heart disease going through major surgery <sep>', '40 patients scheduled for <sep>', 'fifty-four male patients under 65 years and with an ejection fraction of more than 0.5 <sep> after coronary artery bypass surgery <sep>', 'patients undergoing opcabg surgery <sep> patients undergoing off-pump coronary artery bypass graft opcabg surgery <sep> seventy-four patients 66 male 89 mean age 65.2 years sd 9.6 undergoing opcabg surgery <sep>', 'major university teaching hospital <sep> cardiac surgery with cardiopulmonary bypass <sep> sixty patients undergoing elective surgery <sep>', 'patients undergoing <sep> sixteen male patients <sep> subcutaneous tissue <sep> patients having general anesthesia only <sep> patients undergoing aortocoronary bypass surgery <sep>', 'pain relief after cardiac operations <sep>', '73 randomized patients 37 were control subjects who received general anesthesia only and 36 were in the group who received <sep> 36 patients who received high tea and 3 of 37 controls died <sep> after coronary artery bypass grafting <sep> 73 patients scheduled for coronary artery bypass grafting who had a left ventricular ejection fraction of 50 or more conducted from february 1 2000 through august 31 2000 at university hospital mnster germany <sep> patients undergoing coronary artery bypass grafting <sep>', 'sixteen patients submitted to elective coronary artery bypass grafting cabg surgery <sep> patients undergoing cardiac surgery <sep>', '50 patients undergoing elective cabg surgery <sep> patients undergoing elective coronary bypass graft cabg surgery <sep> cardiac surgery unit at a university hospital <sep> patients undergoing elective coronary bypass surgery <sep>', 'patients undergoing emergency surgery and those with unstable angina were excluded <sep> 30 patients randomly allocated to receive either <sep>', 'patients were divided into 3 groups 30 patients had general anesthesia and were extubated immediately after surgery extubated group 30 patients had a <sep> patients n  90 scheduled for elective midcab surgery <sep> patients with thoracic epidural anesthesia and supplemental general anesthesia <sep>', 'fifty adult patients <sep> patients scheduled for cardiothoracic surgery including coronary artery bypass grafting <sep> coronary surgery patients <sep> coronary diseased patients prior to surgical revascularization without deleterious hemodynamic disturbances <sep> patients submitted for surgical revascularization <sep>', 'seventy patients scheduled for elective coronary artery bypass graft cabg received general anesthesia with <sep> patients undergoing coronary artery bypass grafting <sep>', 'thirty patients scheduled for elective cabg surgery <sep> patients with ischemic heart disease <sep> coronary artery bypass graft surgery <sep>', 'eighty patients scheduled for elective cabg <sep> humans before cardiopulmonary bypass cpb <sep>', 'one hundred thirteen patients undergoing elective cardiac surgery <sep> after cardiac surgery <sep>', '132 patients undergoing elective off-pump coronary bypass grafting using either general anesthesia ga n  66 or <sep> patients undergoing off-pump coronary artery bypass grafting <sep> patients undergoing coronary artery bypass grafting <sep>', 'eighty patients <sep>', '20 patients undergoing coronary artery bypass grafting cabg <sep>', 'elective cardiac surgical patients who receive <sep> patients managed with general anesthesia alone during surgery followed by parenteral opiate analgesia after surgery <sep> sixty participants <sep> sixty patients scheduled for elective cardiac surgery with cardiopulmonary bypass <sep>', '654 elective cardiac surgical patients <sep> cardiac surgery <sep> cardiac surgical patients who require full heparinization <sep>', 'one-hundred-twenty patients <sep>', 'patients undergoing off-pump coronary artery bypass surgery <sep> two hundred and twenty-six patients <sep>', 'nine patients undergoing coronary artery bypass surgery <sep> cardiac surgery <sep>', 'fifty patients received <sep> after coronary artery surgery <sep> cardiac surgery <sep>', 'cardiothoracic clinic at a major university referral center <sep> twenty-eight patients undergoing elective cabg <sep> 14 patients and 14 patients receiving ga alone served as controls <sep>', '420 patients undergoing <sep> patients undergoing coronary artery bypass grafting <sep>', 'sixty obese patients with body mass index 30 kg/m2 for elective opcab <sep> obese patients with body mass index of more than 30 kg/m2 for off pump coronary artery bypass surgery <sep> obese patients undergoing opcab <sep> obese patients undergoing off pump coronary artery bypass surgery opcab <sep>', 'tertiary health care center associated with a university <sep> one hundred sixty-three patients scheduled for coronary artery bypass graft surgery <sep> atrial fibrillation after coronary artery bypass grafting <sep>'], 'interventions': ['thoracic epidural analgesia tea <sep> nitroglycerine <sep> ketanserin <sep> tea <sep> thoracic epidural analgesia <sep> fentanyl hf group receiving high-dose fentanyl 55 micrograms.kg-1 anaesthesia the hf+tea group receiving the same fentanyl dose+tea with 10 ml bupivacaine <sep> fentanyl lf  tea group receiving low-dose fentanyl 15 micrograms.kg-1 anaesthesia+tea <sep> aortocoronary bypass surgery <sep> ephedrine <sep>', 'bupivacaine <sep> dopexamine and epidural anesthesia <sep> elective coronary bypass surgery <sep> cardiopulmonary bypass cpb <sep> dopexamine <sep>', 'thoracic epidural analgesia <sep> epidural analgesia <sep> control group receiving high-dose fentanyl anaesthesia and an epidural group receiving low-dose fentanyl anaesthesia  thoracic epidural analgesia <sep>', 'pump coronary artery bypass graft surgery with thoracic epidural anesthesia <sep> thoracic epidural anesthesia <sep> general anesthesia plus epidural gae n  36 or general anesthesia <sep> thoracic epidural anesthesia <sep>', 'thoracic epidural group in combination with a propofol target-controlled infusion <sep> fast-track anesthetic techniques <sep> low-dose remifentanil <sep> alfentanil <sep> remifentanil <sep>', 'thoracic epidural analgesia <sep> anesthesia bupivacaine 50 mg via an epidural catheter <sep> tea <sep> aortocoronary bypass surgery with thoracic epidural analgesia tea <sep>', 'morphine <sep> coronary artery bypass grafting <sep>', 'tea <sep> general anesthesia and high tea <sep> reversible cardiac sympathectomy by high thoracic epidural anesthesia <sep> thoracic epidural anesthesia tea <sep> high tea <sep>', 'cardiac surgery with cardiopulmonary bypass cpb <sep> opioids <sep> opioids fentanyl <sep> anaesthesia <sep> low-dose opioid anaesthesia consisting of thoracic epidural analgesia combined with inhalational anaesthesia group i or high-dose fentanyl anaesthesia <sep>', 'thoracic epidural analgesia <sep> con <sep> conventional iv anesthesia <sep> tea <sep> perioperative thoracic epidural analgesia <sep> conventional iv anesthesia con or general anesthesia combined with thoracic epidural anesthesia followed by postoperative epidural analgesia tea with bupivacaine <sep>', 'anaesthetic technique <sep> propofol isoflurane or isoflurane and high thoracic epidural analgesia <sep> troponin <sep> pump coronary artery bypass surgery <sep>', 'immediate postoperative extubation and postoperative ventilation after minimally invasive direct coronary artery bypass midcab surgery <sep> minimally invasive direct coronary artery bypass surgery <sep> thoracic epidural and general anesthesia and were extubated immediately after surgery epidural group and 30 patients had general anesthesia and were ventilated after surgery intubated group <sep> epidural anesthesia <sep>', 'epidural blockade <sep> high thoracic epidural blockade <sep> ropivacaine <sep> normal saline or 0.3 ropivacaine <sep>', 'tea <sep> clonidine <sep> general anesthesia <sep> sufentanil and propofol <sep> clonidine <sep> cardiopulmonary bypass and cardiac surgery <sep> tea and clonidine <sep> thoracic epidural anesthesia combined with general anesthesia <sep> thoracic epidural anesthesia tea <sep>', 'bupivacaine <sep> ga  tea <sep> tea <sep> thoracic epidural anesthesia <sep> ga <sep> thoracic epidural anesthesia tea <sep>', 'tea plus ga <sep> thoracic epidural anesthesia tea together with general anaesthesia ga <sep> ga <sep> general anesthesia with thoracic epidural anesthesia <sep> tea+ga <sep> acc tea+ga <sep>', 'morphine <sep> thoracic epidural versus intravenous patient-controlled analgesia <sep> patient-controlled thoracic epidural analgesia with patient-controlled analgesia with intravenous morphine <sep> combined thoracic epidural analgesia and general anesthesia followed by patient-controlled thoracic epidural analgesia or general anesthesia followed by to patient-controlled analgesia with intravenous morphine <sep> elective cardiac surgery thoracic epidural analgesia combined with general anesthesia followed by patient-controlled thoracic epidural analgesia <sep>', 'combined general and high thoracic epidural anesthesia ga+tea <sep> pump coronary bypass grafting <sep> thoracic epidural anesthesia <sep>', 'thoracic epidural analgesia <sep> acetaminophen indomethacin and tramadol <sep> htea or intravenous morphine analgesia control <sep> coronary artery bypass surgery cabg with cardiopulmonary bypass <sep> high thoracic epidural analgesia htea <sep> epidural analgesia <sep> morphine <sep> coronary artery bypass surgery <sep>', 'tea <sep> thoracic epidural anesthesia <sep> fentanyl-nitrous oxide anesthesia <sep> thoracic epidural anesthesia tea <sep> coronary artery bypass surgery <sep>', 'control group received general anesthesia during surgery and intravenous opiate analgesia after surgery <sep> epidural anesthesia during surgery and epidural analgesia <sep> thoracic epidural anesthesia combined with general anesthesia during surgery and epidural analgesia <sep> epidural anesthesia and analgesia <sep>', 'tea <sep> thoracic epidural anesthesia <sep> fast-track cardiac anesthesia without epidural anesthesia <sep> combined ga and tea versus ga alone <sep> fast-track ga plus tea <sep> thoracic epidural anesthesia tea <sep>', 'morphine infusion <sep> general anesthesia ga group or a ga plus htea <sep> general anesthesia alone <sep> ropivacaine 0.2 and fentanyl <sep> epidural anesthesia <sep> fentanyl <sep> high thoracic epidural anesthesia/analgesia htea <sep> htea for elective cabg surgery <sep> coronary artery bypass surgery <sep> coronary artery bypass grafting cabg surgery <sep>', 'general anesthesia only ga <sep> general anesthesia plus epidural gae <sep> thoracic epidural anesthesia <sep> thoracic epidural anesthesia <sep>', 'bupivacaine <sep> general anaesthesia alone <sep> thoracic extradural analgesia <sep> sufentanil <sep>', 'thoracic epidural anesthesia <sep> tea <sep> morphine patient-controlled analgesia <sep> propofol infusion 6 mg x kg(-1 <sep> high t1 to t4 thoracic epidural anesthesia tea with ropivacaine 1 4-ml bolus 3-5 ml/h infusion with fentanyl <sep> epidural analgesia <sep> fentanyl 15 microg/kg and propofol 5 mg x kg(-1 <sep> morphine <sep> epidural anesthesia <sep>', 'thoracic epidural anesthesia <sep> tea <sep> coronary artery bypass graft surgery cabg <sep> perioperative and postoperative tea <sep> thoracic epidural anesthesia tea <sep>', 'routine coronary artery bypass graft surgery with or without thoracic epidural anesthesia and analgesia tea <sep> tea <sep> continuous tea <sep> conventional narcotic analgesia <sep> supplementary oral analgesia <sep> standardized general anesthetic <sep> thoracic epidural anesthesia and analgesia <sep> narcotic analgesia <sep>', 'tea <sep> thoracic epidural analgesia <sep> general anesthesia <sep> tea and conventional opioid based analgesia <sep> perioperative thoracic epidural analgesia tea <sep>', 'tea <sep> coronary artery bypass grafting cabg <sep> perioperative tea group e+a had tea and amiodarone <sep> amiodarone <sep> amiodarone and group c served as control <sep> amiodarone administration high thoracic epidural anesthesia tea <sep> amiodarone and thoracic epidural analgesia <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>']}",this meta-analysis of studies identified to 2010 showed that the use of tea in patients undergoing coronary artery bypass graft surgery may reduce the risk of postoperative supraventricular arrhythmias and respiratory complications. there were no effects of tea with ga on the risk of mortality myocardial infarction or neurological complications compared with ga alone.
374,"{'outcomes': ['postoperative analgesia <sep> analgesic effects <sep> frequency of vomiting <sep> time interval between operation and subsequent analgesic administration and the number of analgesic doses <sep>', 'postoperative analgesia <sep>', 'incidence of vomiting <sep> duration of analgesia <sep> analgesia <sep>', 'level of consciousness and apparent pain <sep> recovery of consciousness <sep> pain relief <sep> postoperative pain and recovery <sep> pain and caudal analgesia <sep>', 'induction-incision time <sep> efficacy complication rates and parental satisfaction <sep>', 'incidence of adverse effects <sep>', 'time to first requirement for analgesia or number of doses of paracetamol <sep> postoperative pain <sep> modified objective pain score and the time taken to first requirement of analgesia <sep> time to first micturition <sep> ponv eating sleeping or behavioural disturbance <sep> motor weakness <sep> motor weakness time to first micturition postoperative nausea and vomiting ponv eating habits sleep disturbance and behaviour <sep>'], 'punchline_text': ['the only detectable difference between the groups was a more rapid but transient recovery in the group receiving plain bupivacaine only. <sep>', 'caudal analgesia is shown to be significantly better than morphine by means of a linear analogue scale designed to quantify behaviour immediately after operation. <sep>', 'subjects in the dnb group micturated earlier p less than 0.05 and stood unaided earlier p less than 0.025 than patients in the caudal group. <sep>', 'for 90 minutes following circumcision there was significantly less pain and caudal analgesia but better pain relief could not be demonstrated following inguinal herniotomy and orchidopexy. <sep>', 'for caudal block 1 ml.kg(-1 body weight of 0.25 bupivacaine was administered. <sep>', 'incidence of adverse effects was the same in the two groups. <sep>', 'there was no difference between the groups in time to first requirement for analgesia or number of doses of paracetamol given in the first 24 h. almost half the boys in the caudal group had motor weakness and there was a significant increase in time to first micturition in that group. <sep>'], 'population': ['boys undergoing circumcision <sep> children <sep>', 'boys <sep> forty boys were studied <sep>', 'fifty boys presenting for day case circumcision <sep>', '181 children who had undergone either circumcision inguinal herniotomy or orchidopexy performed under general anaesthesia <sep> children <sep>', '100 asa 1 and 2 boys aged 3 to 8 years who were undergoing circumcision for religious reasons <sep> children undergoing circumcision with respect to <sep> one patient undergoing penile block and nine patients undergoing caudal block vomited <sep>', '40 children scheduled for circumcision <sep> children <sep>', 'sixty boys undergoing elective circumcision <sep> paediatric circumcision <sep>'], 'interventions': ['diamorphine <sep> morphine sulphate <sep> diamorphine caudal analgesia with 0.5 bupivacaine plain and caudal analgesia with 0.5 bupivacaine plain <sep> plain bupivacaine <sep> morphine <sep>', 'intramuscular morphine <sep> morphine <sep> caudal analgesia 1.5 mg/kg bupivacaine <sep> caudal analgesia and intramuscular morphine <sep>', 'dnb <sep> caudal analgesia or dorsal nerve block dnb <sep>', 'dihydrocodeine with caudal bupivacaine <sep>', 'bupivacaine <sep> penile block and group 2 caudal block <sep> inhalation anesthesia was administered with oxygen  nitrous oxide 1  2 and halothane <sep>', 'acetaminophen <sep> ambulatory surgery <sep>', 'local anaesthetic dorsal nerve block and caudal bupivacaine with ketamine <sep> ketamine <sep> bupivacaine 0.15 with ketamine 0.5 mg x kg-1 n  30 or dorsal nerve block of the penis with bupivacaine <sep> bupivacaine/ketamine <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",differences in the need for rescue or other analgesia could not be detected between caudal parenteral and penile block methods. in day-case surgery penile block may be preferable to caudal block in children old enough to walk due to the possibility of temporary leg weakness after caudal block. evidence from trials is limited by small numbers and poor methodology. there is a need for properly designed trials comparing caudal epidural block with other methods such as morphine simple analgesics and topical local anaesthetic creams emulsions or gels.
375,"{'outcomes': ['dental caries <sep> caries incidence <sep>', 'mean approximal caries increment including initial caries lesions <sep> approximal caries <sep>', 'incidence of caries <sep> plaque indices <sep> fluoride levels <sep> caries development <sep> caries incidence and plaque accumulation <sep>'], 'punchline_text': ['the apf gel provided a 34.3 reduction in caries incidence p-value  0.03 among the children with 3-14 cavities on their primary teeth at the beginning of the study. <sep>', 'after 3 years the mean approximal caries increment including initial caries lesions was 2.8 in the naf 2.4 in the snf2 and 4.0 in the placebo gel group p 0.05 for snf2 vs placebo a reduction compared to the placebo of 30 and 39 in the naf and snf2 groups respectively. <sep>', 'only the group that brushed with the 1.25 amf gel showed a significant decrease in caries development compared to the group that brushed with the 0.125 amf toothpaste. <sep>'], 'population': ['488 children 6 yr old presenting at least three cavities on proximal surfaces of their primary teeth <sep> high-risk children living in non-fluoridated communities <sep> high-risk children <sep>', 'two-hundred-and-eighty 13-year-old schoolchildren <sep> caries development on approximal tooth surfaces <sep> 13-16-year-old schoolchildren <sep>', 'caries-prone subjects <sep> schoolchildren at caries risk after brushing the teeth fortnightly with gels containing 0 0.4 f 1.25 f as amine fluoride amf or the common <sep>'], 'interventions': ['bi-annual apf gel topical applications <sep> bi-annual topical apf gel applications <sep> placebo <sep> apf <sep>', 'placebo <sep> naf or snf2 gel <sep> placebo gel <sep> naf <sep> naf gel 1 snf2 gel or placebo gel <sep> professional flossing with naf and snf2 gels <sep> professional flossing with naf or snf2 gel <sep>', 'fortnightly tooth brushing with amine fluorides <sep> fluoride <sep> amine fluoride toothpaste <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is clear evidence of a caries-inhibiting effect of fluoride gel. the best estimate of the magnitude of this effect based on the 14 placebo-controlled trials is a 21 reduction 95 ci 14 to 28 in d(m)fs. this corresponds to an nnt of 2 95 ci 1 to 3 to avoid 1 d(m)fs in a population with a caries increment of 2.2 d(m)fs/year or an nnt of 24 95 ci 18 to 36 based on an increment of 0.2 d(m)fs/year. there is little information concerning the deciduous dentition on adverse effects or on acceptability of treatment. future trials should include assessment of potential adverse effects.
376,"{'outcomes': ['attention-deficit/hyperactivity disorder(ad/hd symptoms <sep> ad/hd-related symptoms <sep> symptoms of attention-deficit/hyperactivity disorder <sep> attention deficit hyperactivity and impulsivity ad/hd-related symptoms according to dsm-iv criteria 2 aggression assessed by both parents and teachers 3 visual perception finding symbols out of a table 4 visual and auditory short-term memory 5 development of visual-motor integration 6 continuous performance 7 impatience <sep> visual short-term memory and errors of commission continuous performance <sep>', 'attention problem and motor excess of the revised behavior problem checklist <sep> baseline efa concentrations <sep>', ""symptoms of adhd <sep> plasma phospholipid fatty acid patterns scores on laboratory measures of inattention and impulsivity test of variables of attention children's color trails test while not taking stimulant medication and scores on parental behavioral rating scales child behavior checklist conners rating scale <sep> symptoms of attention-deficit/hyperactivity disorder adhd <sep> objective or subjective measure of adhd symptoms <sep> plasma phospholipid dha content <sep>"", 'efficacy measure was conners parent/teacher rating scales cprs/ctrs <sep> teacher-rated behaviour and oppositional symptoms <sep> lower epa concentrations <sep> total omega-6/omega-3 ratios <sep> aa/dha <sep> omega-6 fatty acid concentrations <sep> fatty acids <sep> higher aa/dha ratios <sep> higher aa/epa <sep> epa improved ctrs inattention/cognitive subscale <sep> ctrs total score <sep> serum phospholipids and red blood cell membranes rbc <sep>', 'efficacy <sep> sustained efficacy <sep> tolerated <sep> subscales scores <sep> adhd symptoms <sep> conners parent and teacher rating scales crs-p,t strengths and difficulties questionnaire sdq and child health questionnaire chq <sep> parent impact-emotional pe subscale <sep>', 'investigator-rated adhd rating scale-iv and clinical global impression cgi scale <sep> cgi scores <sep> adhd symptoms <sep>', 'parent version of the conners questionnaire <sep> symptoms <sep> n-3 pufa safety and tolerability <sep> inattention and global diagnostic and statistical manual of mental disorders fourth edition total conners subscales <sep> adhd clinical symptoms <sep> fatty acid fa composition <sep> eicosapentaenoic and docosahexaenoic acids <sep> plasma pufa composition <sep>', 'ability to switch and control attention creature counting <sep> cognitive performance <sep> cognitive measures <sep>', 'alterations in fas and increased tova scores <sep> fo <sep> plasma and erythrocyte fa profile and continuous performance test results test of variables of attention tova <sep> blood fatty acid composition and visual sustained attention performance <sep> total tova scores <sep>', 'blood fa composition and behavior <sep> alpha-tocopherol concentrations <sep> disruptive behavior <sep> epa and dha in the rbc and the teachers disruptive behavior disorders dbd rating scale for attention <sep> abbreviated symptom questionnaire asq <sep> oppositional defiant behavior <sep> multiple outcomes <sep> proportions of epa dha and alpha-tocopherol in the plasma phospholipids and red blood cell rbc total lipids <sep>'], 'punchline_text': ['however visual short-term memory and errors of commission continuous performance significantly improved in the control group compared with the changes over time in the dha group p=0.02 and 0.001 respectively). <sep>', 'supplementation was also associated with significant changes on two performance tasks and with significant improvement to parent ratings on the subscales designated as attention problem and motor excess of the revised behavior problem checklist. <sep>', 'plasma phospholipid dha content of the dha-supplemented group was 2.6-fold higher at the end of the study than that of the placebo group 4.85  <sep>', 'epa improved ctrs inattention/cognitive subscale p  0.04 but not conners total score. <sep>', 'children that switched to ps-omega3 treatment from placebo showed a significant reduction in subscales scores of both crs-p and the crs-t as compare to baseline scores. <sep>', 'however a subgroup of 26 responded with more than 25 reduction of adhd symptoms and a drop of cgi scores to the near-normal range. <sep>', 'a statistically significant improvement in symptoms was noted based on the parent version of the conners questionnaire from baseline to the end of phase 1 and this amelioration continued from phases 1 to 2 although the latter changes from phases 1 and 2 were not statistically significant in any of the subscales except for the subscale measuring inattention in group b. <sep>', 'this improvement was also observed in the placebo group after taking pufa from weeks 16 to 30 n=104). <sep>', 'a significant correlation between the alterations in fas and increased tova scores mainly occurred in the pl-n-3 group. <sep>', 'conduct problems rated by parents 42.7 vs. 9.9 n  47 p  0.05 and attention symptoms rated by teachers 14.8 vs. 3.4 n  47 p  0.03). <sep>'], 'population': ['ad/hd children <sep> subjects of a dha group n=20 took <sep> 40 ad/hd including eight ad/hd-suspected children of 6-12 y of age who were mostly without medication <sep>', 'thirty-one children selected for marked inattention and overactivity <sep> hyperactive children <sep>', '6 to-12-year-old children with adhd all receiving effective maintenance therapy with stimulant medication <sep> sixty-three <sep> children with attention-deficit/hyperactivity disorder <sep>', '92 children 7-12 years with adhd <sep> children with attention deficit hyperactivity disorder adhd <sep> 2010 <sep> children with adhd <sep>', 'two hundred adhd children <sep> children <sep>', 'attention deficit hyperactivity disorder <sep> children and adolescents <sep> 75 children and adolescents 8-18 years followed by 3 months with omega 3/6 for all <sep>', 'canadian youth with adhd <sep> children with attention-deficit hyperactivity disorder <sep> patients with attention-deficit hyperactivity disorder adhd <sep> 37 children only 26 children completed the study from zero to 16 weeks <sep> french canadian primary school children <sep>', '7-12-year-old children with symptoms 2 s.d. on conners adhd index were given <sep> children with attention deficit hyperactivity disorder symptoms <sep> children with adhd symptoms <sep>', 'children with inattention <sep> children aged 8-13 y with impaired visual sustained attention performance received <sep> patients with psychiatric disorders <sep> children <sep> sixty of the 83 children enrolled completed the interventions n  18-21 per group <sep>', 'fifty children <sep> children with behavioral disorders <sep> children with attention-deficit/hyperactivity disorder ad/hd)-like symptoms also reporting thirst and skin problems <sep> children with inattention hyperactivity and other disruptive behaviors <sep>'], 'interventions': ['docosahexaenoic acid-containing food administration <sep> placebo <sep> active foods containing fish oil fermented soybean milk bread rolls and steamed bread 3.6 g dha/week from these foods <sep> control group n=20 took indistinguishable control foods without fish oil <sep> docosahexaenoic acid dha supplementation <sep> dha supplementation <sep>', 'placebo <sep> efa supplementation <sep> essential fatty acid supplementation <sep> efa supplementation evening primrose oil efamol <sep> essential fatty acid efa supplementation <sep>', 'docosahexaenoic acid supplementation <sep> placebo <sep> docosahexaenoic acid dha supplementation <sep> dha supplementation <sep>', 'epa or placebo <sep> eicosapentaenoic acid epa <sep> epa supplementation <sep> placebo <sep>', 'placebo <sep> phosphatidylserine containing omega3 fatty-acids <sep> copyright <sep> phosphatidylserine ps containing omega3 <sep> ps-omega3 or placebo <sep> long-chain polyunsaturated fatty acids attached to its backbone ps-omega3 <sep>', 'omega 3/6 fatty acids eye q <sep> omega 3/6 placebo <sep> placebo <sep> omega-3/omega-6 fatty acids <sep>', 'placebo <sep> omega-3 fatty acid treatment <sep> n-3 pufa <sep> n-3 pufa supplement and group b received n-6 pufa sunflower oil <sep> n-3 polyunsaturated fatty acid pufa <sep> n-3 pufa supplements <sep> n-3 pufa supplement <sep> active n-3 pufa supplement <sep> n-3 pufa supplementation <sep>', 'pufa and micronutrient supplementation <sep> placebo <sep> pufa+mvm <sep> polyunsaturated fatty acids <sep> pufa pufa+multivitamins/minerals mvm or placebo <sep>', 'placebo 250 mg/d epa  dha esterified to pl-n-3 300 mg/d phosphatidylserine or fo <sep> placebo <sep> n-3 fatty acid fa supplementation <sep> dietary n-3 fatty acids containing phospholipids <sep> epa and dha to phospholipid pl-n-3 or to triacylglycerol fish oil fo <sep> dietary eicosapentaenoic acid epa and docosahexaenoic acid dha <sep>', 'pufa supplement providing a daily dose of 480 mg dha 80 mg epa 40 mg arachidonic acid aa 96 mg gla and 24 mg alpha-tocopheryl acetate or an olive oil placebo <sep> efa supplementation <sep> supplementation with pufa <sep> olive oil supplementation <sep> n-3 fa and vitamin e <sep> pufa supplementation <sep> olive oil <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",overall there is little evidence that pufa supplementation provides any benefit for the symptoms of adhd in children and adolescents. the majority of data showed no benefit of pufa supplementation although there were some limited data that did show an improvement with combined omega-3 and omega-6 supplementation. it is important that future research addresses current weaknesses in this area which include small sample sizes variability of selection criteria variability of the type and dosage of supplementation short follow-up times and other methodological weaknesses.
377,"{'outcomes': ['recurrent vte <sep> recurrence <sep>', 'major bleeding episodes <sep> recurrence of venous thromboembolism <sep> episodes of pulmonary embolism <sep> recurrence of symptomatic objectively confirmed venous thromboembolism <sep> rate ratio <sep>', 'recurrent thrombosis <sep> incidence of recurrence <sep> non-fatal major bleeding <sep> recurrence of venous thromboembolism <sep> idiopathic deep venous thrombosis <sep> recurrence of symptomatic objectively confirmed venous thromboembolism <sep>', 'recurrences and major minor or fatal bleeding complications <sep> 23 recurrences of venous thromboembolism <sep> rate of recurrence <sep>', 'recurrent venous thromboembolism <sep> major bleeds <sep> rate of recurrent venous thromboembolism <sep> incidence of recurrent venous thromboembolism <sep>', 'odds ratio for recurrence <sep> mortality or the rate of major hemorrhage <sep> recurrence rate <sep> rates of recurrence <sep> 123 recurrences of venous thromboembolism <sep>', 'relative risk of major hemorrhage <sep> 26 recurrences of venous thromboembolism <sep> rate of recurrence <sep> relative risk of recurrence <sep> duration of oral anticoagulant therapy <sep> higher risk of major hemorrhage <sep> pulmonary embolism <sep> initial episodes of deep-vein thrombosis <sep> mortality <sep>', 'nonfatal major bleeding <sep> rates of recurrent symptomatic venous thromboembolism and bleeding <sep> gastrointestinal bleeding and one genitourinary bleeding <sep> recurrent episode of venous thromboembolism <sep> risk of recurrent venous thromboembolism <sep>'], 'punchline_text': ['nineteen of the 192 patients with an abnormal four week ipg experienced recurrence during the nine months after discontinuing warfarin. <sep>', 'among 165 patients assigned to extended anticoagulant therapy 15 patients 9.1 had a recurrence of venous thromboembolism 3.1 per patient-year average follow-up 34.9 months as compared with 18 of 161 patients 11.2 assigned to discontinue treatment 4.1 per patient-year average follow-up 32.7 months the rate ratio was 0.81 95 ci 0.42 to 1.56). <sep>', 'in patients with idiopathic deep venous thrombosis continuing anticoagulant therapy beyond three months is associated with a reduced incidence of recurrent thrombosis during the period of therapy. <sep>', 'subgroup analysis demonstrated that the rate of recurrence was lower for c-dvt than for p-dvt or pe. <sep>', 'of 84 patients assigned to placebo five 6.0 had recurrent venous thromboembolism compared with three of 81 3.7 assigned to warfarin resulting in an absolute risk difference of 2.3%[95 confidence interval ci  5.2 10.0]. <sep>', 'after two years of follow-up there had been 123 recurrences of venous thromboembolism that met the diagnostic criteria 80 in the six-week group 18.1 percent 95 percent confidence interval 14.5 to 21.6 and 43 in the six-month group 9.5 percent 95 percent confidence interval 6.8 to 12.2). <sep>', 'a consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism. <sep>', 'warfarin resulted in a 95 percent reduction in the risk of recurrent venous thromboembolism 95 percent confidence interval 63 to 99 percent). <sep>'], 'population': ['212 patients with continuing risk factors.(abstract truncated at 250 words <sep> patients with an abnormal four week ipg received <sep> nineteen of the 192 patients with an abnormal four week ipg experienced <sep> 301 patients who received three months of <sep> patients with proximal deep vein thrombosis <sep> patients with venographically confirmed acute proximal dvt who had received four weeks of warfarin after initial heparin and whose four week ipg was normal <sep> patients with acute proximal deep vein thrombosis dvt <sep>', 'patients with idiopathic venous thromboembolism 11 of 90 patients assigned to extended anticoagulation and 11 of 91 patients assigned to <sep> 19 italian hospitals <sep> patients with pulmonary embolism <sep> 326 patients who had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding <sep> patients with a first episode of pulmonary embolism <sep> 165 patients assigned to <sep>', 'patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy with warfarin in 97 percent of the cases and acenocoumarol in 3 percent <sep> patients with idiopathic deep venous thrombosis <sep>', '736 patients were enrolled <sep> patients with idiopathic venous thromboembolism or permanent risk factors <sep> proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis <sep>', 'patients who had completed 1 month of anticoagulant therapy for a first episode of venous thromboembolism provoked by a transient risk factor <sep>', 'patients who had a first episode of venous thromboembolism <sep> 902 patients enrolled 5 were later excluded because they had congenital protein c deficiency 443 <sep>', 'patients who had had a second episode of venous thromboembolism <sep> 227 patients enrolled 111 <sep>', 'randomly assigned patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolism to continue receiving warfarin with the dose adjusted to achieve an international normalized ratio of 2.0 to 3.0 or to receive <sep> patients with a first episode of idiopathic venous thromboembolism <sep> 162 patients had been enrolled and followed for an average of 10 months <sep> patients who have a first episode of venous thromboembolism in the absence of known risk factors for thrombosis idiopathic thrombosis <sep>'], 'interventions': ['placebo <sep> warfarin <sep> oral anticoagulant therapy <sep> continue warfarin <sep> normal impedance plethysmogram ipg <sep>', 'discontinue <sep> oral anticoagulant therapy <sep> extended anticoagulant therapy <sep>', 'oral anticoagulant therapy <sep> warfarin <sep>', 'oral anticoagulant therapy <sep>', 'continue warfarin or to placebo <sep> placebo <sep> anticoagulant therapy <sep> warfarin <sep>', 'oral anticoagulant <sep> oral anticoagulant therapy <sep> oral anticoagulant therapy with a targeted international normalized ratio inr <sep> warfarin or dicumarol <sep>', 'oral anticoagulant therapy with anticoagulant therapy <sep> anticoagulant therapy <sep>', 'placebo <sep> anticoagulant therapy <sep> warfarin <sep> warfarin <sep> extended anticoagulant therapy <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",in conclusion this meta-analysis shows that treatment with vitamin k antagonists reduces the risk of recurrent venous thromboembolism for as long as it is used. however the absolute risk of recurrent venous thromboembolism declines over time while the risk for major bleeding remains. thus the efficacy of vitamin k antagonist administration decreases over time since the index event.
378,"{'outcomes': ['menstrual distress questionnaire mdq normative t scores the proportion of subjects with acne and menstrual symptoms <sep> emotional well-being <sep> symptoms of water retention <sep> symptoms of water retention and impaired concentration <sep> somatic and psychological symptoms <sep> proportion of subjects with acne <sep>', 'adrenal and peripheral androgens <sep> androgenic markers and acne <sep> lng reduced androgen levels <sep> bioavailable <sep> tolerated <sep> shbg with neta than lng bioavailable testosterone t <sep>', 'blood pressure and weight <sep> acne lesion counts and clinician global assessment <sep> clinician global and patient self-assessment scores <sep> inflammatory noninflammatory and total lesion counts <sep> changes in weight <sep>', 'number of acne lesions <sep>', 'contraceptive efficacy <sep> pre-existing acne <sep> blood pressure and body weight <sep> efficacy and acceptability <sep> incidences of irregular bleeding and minor side-effects <sep>', 'relative numbers of comedones papules pustules and nodules at cycle 6 <sep> number and severity of acne lesions <sep> severe acne category <sep> number of comedones papules pustules and nodules <sep>', 'blood pressure and body weight <sep> efficacy and acceptability <sep> blood pressure and body weight <sep> acne <sep> irregular bleeding and side effects <sep> irregular bleeding and minor side effects <sep>', 'free testosterone <sep> mean acne lesion counts <sep> sex hormone-binding globulin shbg dehydroepiandrosterone sulfate dheas and free and total testosterone <sep> clinical efficacy <sep> mean shbg <sep> mean age body mass index acne lesion counts shbg dheas or free and total testosterone <sep>', 'hepatic tolerance <sep>', 'moderate papulopustular acne of the dcollet <sep> median reduction in papules/pustules <sep> excellent improvement or complete resolution of moderate acne <sep> lesion numbers <sep> number of papules and/or pustules of the face from admission to medication cycle 6 <sep>', 'estimated pearl indices for nomac/e2 and drsp/ee <sep> type and frequency of adverse events <sep> intracyclic bleeding/spotting <sep> contraceptive efficacy <sep> efficacy and tolerability <sep> scheduled withdrawal bleedings <sep> efficacy cycle control and tolerability <sep>', 'total lesion count <sep> tolerated <sep> therapeutic effect sebum production and hormone levels <sep> inflammatory lesion count <sep> efficacy and tolerability <sep> level of sex hormone-binding globulin shbg <sep> facial acne <sep>', '3 alpha-17 beta-androstanediol <sep> number of lesions and the degree of severity <sep> shbg <sep> total testosterone and 3 alpha-17 beta-androstanediol glucuronide <sep>', 'relative frequency of women with complete resolution <sep> acne resolution rates <sep> number of papules/pustules per half of the face present on admission <sep>', 'sebum production and hair growth on the upper lip and chin <sep> median total acne lesion count <sep> acne lesions sebum production and hair growth on the upper lip chin and chest <sep> acne and seborrhea <sep> levels of shbg <sep> levels of total and free testosterone androstenedione dehydroepiandrosterone sulfate dheas sex hormone-binding globulin shbg and luteinizing hormone lh <sep> facial acne <sep>', 'reduction rates <sep> reduction sd rates <sep> facial acne <sep> inflammatory and total lesion count and the percentage of patients with acne improvement according to the investigator global assessment <sep>', 'efficacy and safety <sep> inflammatory noninflammatory and total lesion counts <sep> efficacy and safety <sep>', 'elevated total t <sep> signs of biochemical hyperandrogenism including elevated fai <sep> normalization of biochemical hyperandrogenism <sep> shbg and acne scores <sep> echogenic texture of the ovaries <sep> initial values of plasma shbg <sep> acne lesions and plasma androstenedione a total testosterone t sex hormone binding globulin shbg and free androgen index fai <sep> normalization of the echogenic ovarian texture <sep> shbg <sep>', 'clinician global and patient self-assessments <sep> number of inflammatory and total lesions <sep> acne lesion counts and clinician global assessment <sep> biochemical markers of androgenicity <sep> efficacy and safety <sep>', ""efficacy <sep> facial acne lesion counts the investigator's global assessment and the subject's self-assessment <sep> free testosterone <sep> sex hormone-binding globulin <sep> hormone levels <sep> inflammatory lesions <sep> total lesions <sep>"", 'time serum free testosterone <sep> shbg elevation <sep> serum total an unbound testosterone t and sex hormone binding globulin shbg levels <sep> acne <sep> severity of acne and shbg <sep> serum total and unbound testosterone and sex hormone binding globulin shbg <sep> shbg <sep>', 'acne lesion counts and investigator static global assessment scale ratings <sep> tolerated <sep> acne lesion counts <sep> investigator static global assessment rating of acne <sep> total lesions <sep>', ""facial acne lesion counts an investigator's global assessment a subject's self-assessment and an analysis of within-cycle variation cycle 6 in lesion counts <sep> inflammatory lesion count <sep> total lesion count <sep> efficacy measures total comedones open comedones closed comedones papules pustules and the subject's self-assessment of study treatment <sep>"", 'mean acne score <sep> percentage of severe/moderate acne <sep> objective and subjective severity of acne and related biochemical variables such as sex hormone-binding globulin and free and total testosterone <sep> plasma levels of sex hormone binding globulin <sep> mean objective acne score <sep>'], 'punchline_text': ['more subjects in the drsp 3 mg/ee 30 microg group reported improved physical well-being compared with the lng 150 microg/ee 30 microg group. <sep>', 'low-dose oc ee 20 micrograms are effective in reducing circulating androgens and acne lesions without causing weight gain. <sep>', 'inflammatory noninflammatory and total lesion counts at cycle 6 with lng/ee were significantly lower compared to placebo. <sep>', 'after only 4 months of treatment the patients on diane and diane mite had a significantly greater reduction in the number of acne lesions compared with those on neovletta.(abstract truncated at 250 words <sep>', 'cycle control was observed to be excellent the incidences of irregular bleeding and minor side-effects were low in both groups and decreased after an initial increase in the first cycle. <sep>', 'the number of comedones papules pustules and nodules significantly decreased in both groups over the 6-month study. <sep>', 'the incidences of irregular bleeding and minor side effects in both groups were very low and decreased after an initial increase in the first cycle. <sep>', 'at baseline the two treatment groups did not differ in the mean age body mass index acne lesion counts shbg dheas or free and total testosterone. <sep>', 'it was not possible to establish a significant difference between the two preparations in the case of hirsutism in its various locations from the limited number of cases observed. <sep>', 'for comedonal lesions of the face the reduction in lesion numbers was 54.8 ee/cma compared with 32.4 placebo). <sep>', 'estimated pearl indices for nomac/e2 and drsp/ee were 0.38 and 0.81 in women aged35 years and 0.31 and 0.66 for all women 18-50 years respectively. <sep>', 'the preparation containing ee/drsp was superior to ee/ngm for reduction in total lesion count 3.3 in favor of ee/drsp 95 ci 6.5 to 0.1 p  .020 and for investigators assessment of therapeutic effect on facial acne 3.6 in favor of ee/drsp 95 ci 0.8 to 6.3 p  .006]). <sep>', 'in both treatment groups a decrease in total testosterone and 3 alpha-17 beta-androstanediol glucuronide was observed and an increase in shbg. <sep>', 'ee/cma is an efficient treatment for women with mild and moderate papulopustular acne of the face and related disorders reflecting the well-known anti-androgenic properties of the progestogen cma. <sep>', 'a 3-fold increase in the levels of shbg was observed in both treatment groups and levels of androgens and lh decreased. <sep>', 'all primary analyses proved that ee/dng was superior to placebo and non-inferior to ee/cpa p<.05). <sep>', 'ee 24/4 regimen coc was significantly more effective than placebo in treating moderate acne vulgaris. <sep>', 'by the end of the third cycle of treatment the hormonal changes observed in both groups included significant decreases with normalization of individual elevated levels of t and a 3-fold rise of the initial values of plasma shbg which showed a further gradual increase at cycle 9 of ee-dsg administration. <sep>', 'at the end of the study the number of inflammatory and total lesions was significantly lower with ee/lng compared with placebo p .05). <sep>', 'free testosterone decreased significantly and sex hormone-binding globulin increased significantly in the oc group but remained unchanged in the placebo group. <sep>', 'ater six months treatment a 250 increase in shbg was seen in desogestrel/ee group and no significant change in shbg in levonorgestrel/ee group. <sep>', 'the percentage reduction from baseline to endpoint for total lesions is 46.3 for 3-mg drospirenone/20-microgram ethinyl estradiol 24/4 combination oral contraceptive group and 30.6 for placebo group p<.001). <sep>', 'of the 160 subjects in whom efficacy could be evaluated the oc group showed a statistically significantly greater improvement than the placebo group for all primary efficacy measures. <sep>', 'both preparations increased plasma levels of sex hormone binding globulin and seemed to decrease those of total and free testosterone but no statistically significant relationships between acne severity and biochemical variables could be detected. <sep>'], 'population': ['healthy female subjects <sep> women with acne <sep> healthy women <sep>', 'fifty-eight healthy women 18-28 years old <sep>', 'moderate acne <sep> outpatient dermatology clinics <sep> women  or 14 years old n  350 with normal menstrual cycles and moderate acne <sep> intervention(s <sep>', '133 women were recruited at eight different centers <sep> a woman was eligible for the study if she was found by a dermatologist to have at least eight acne lesions sum of papules pustules cysts and nodules on her face was otherwise healthy and without medication <sep>', '595 women enrolled 274 86.7 in the <sep>', '172 women randomized to treatment with either <sep>', 'six family planning centers and outpatient gynaecological clinics in urban areas in thailand 783 healthy women who were at risk for pregnancy and did not have contraindications to oral contraceptive use <sep> thai women <sep> 389 women during 6 cycles <sep> caucasian women <sep> 394 women and an oral contraceptive with the same amount of <sep>', 'acne vulgaris <sep> thirty-four women with acne <sep>', '88 patients took part in the study <sep>', 'three hundred seventy-seven women <sep> moderate acne resolution <sep> papulopustular acne of the face dcollet low neck and back on moderate comedonal acne of the face and on seborrhea alopecia and hirsutism <sep>', 'women aged 18-50 years <sep>', 'female patients with mild to moderate acne <sep> female subjects <sep>', 'women with acne <sep> one-hundred-and-eighty-three women <sep>', 'women with mild and moderate papulopustular acne of the face and related disorders <sep> mild to moderate papulopustular acne of the face and acne-related disorders in comparison to ee/levonorgestrel lng microgynon <sep> 199 female acne patients <sep>', 'women with androgen-dependent disorders who also require contraception <sep> 128 women with mild-to-moderate facial acne with or without seborrhea and/or hirsutism <sep>', 'healthy women between 16 and 45 years old with mild to moderate facial acne <sep> women seeking oral contraception <sep> papulopustular acne in comparison with <sep>', 'healthy females aged 14-45 years old with moderate facial acne <sep> acne vulgaris <sep> moderate acne vulgaris <sep>', 'young women with acne vulgaris <sep> 19 patients aged 18-35 years affected with postpubertal or persistent non-severe acne vulgaris <sep>', 'healthy female subjects n  371 14 years old with regular menstrual cycles and moderate facial acne <sep> moderate acne <sep>', 'subjects were 15-49 years old and had moderate acne vulgaris <sep> moderate acne vulgaris <sep> two hundred fifty women <sep> acne vulgaris <sep> moderate acne vulgaris in women with no known contraindication to oc therapy <sep>', 'female acne patients treated with two different oral contraceptives <sep> fifty-four female acne patients <sep>', 'healthy females aged 14-45 years with moderate acne <sep> moderate acne vulgaris <sep>', 'two hundred fifty-seven healthy female subjects 15 to 49 years of age with moderate acne vulgaris <sep> moderate acne vulgaris <sep> treating moderate acne vulgaris <sep> patients with acne <sep> moderate acne vulgaris in women with no known contraindication to oc therapy <sep>', '32 women using marvelon and 34 using diane were followed for 6 treatment cycles <sep> oriental women suffering from acne <sep>'], 'interventions': ['oral contraceptives containing ethinylestradiol <sep> levonorgestrel 150 microg/ee 30 microg lng 150 microg/ee 30 microg microgynon <sep> drsp <sep> drospirenone or levonorgestrel <sep> contraceptive yasmin drospirenone 3 mg plus ethinylestradiol 30 microg drsp <sep> drsp 3 mg/ee 30 microg and lng 150 microg/ee <sep>', 'low-dose oral contraceptives <sep> neta/ee <sep> ethinyl estradiol ee 20 micrograms but different progestins levonorgestrel lng 100 micrograms and norethindrone acetate neta <sep> lng/ee <sep> oral contraceptives oc <sep>', 'placebo <sep> low-dose oral contraceptive oc containing 100 microg of levonorgestrel lng and 20 microg of ethinyl estradiol ee <sep> contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel <sep> lng/ee or placebo <sep> oc containing 20 microg of ee and 100 microg of lng <sep>', 'cyproterone acetate ca <sep> ca 2 mg  ee 50 micrograms diane ca 2 mg  ee 35 micrograms diane mite levonorgestrel 150 micrograms  ee <sep> ca <sep> cyproterone acetate versus levonorgestrel combined with ethinyl estradiol <sep> ca in combination with ethinylestradiol ee <sep>', 'desogestrel/ethinylestradiol and gestodene/ethinylestradiol <sep> gestodene/ethinylestradiol <sep> desogestrel/ethinylestradiol <sep> ethinylestradiol plus 150 micrograms desogestrel <sep> ethinylestradiol plus 75 micrograms gestodene <sep> monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene <sep>', 'antiandrogen cyproterone acetate <sep> combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate <sep> desogestrel and 30 microg ethinylestradiol <sep> cyproterone acetate and 35 microg ethinylestradiol <sep> combiphasic oral contraceptive containing ethinylestradiol and desogestrel combiphasic ee/dsg <sep> ethinylestradiol and cyproterone acetate ee35/cpa <sep> ee35/cpa <sep> combiphasic ee/dsg 25 microg desogestrel and 40 microg ethinylestradiol <sep>', 'ethinylestradiol and 150 mcg desogestrel <sep> ethinylestradiol and 75 mcg gestodene <sep> monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene <sep> two third generation oral contraceptives <sep>', 'oral contraceptives containing ee/desogestrel and ee/levonorgestrel <sep> oral contraceptive containing 0.3 mg of ethinyl estradiol ee)/0.15 mg of desogestrel or 0.3 mg of ee/0.15 mg of levonorgestrel <sep> second versus third-generation oral contraceptives <sep>', ""ovulation inhibitor with no antiandrogenic effect neogynon <sep> antiandrogen preparation sh b 209 ab against neogynon author's transl <sep> cyproterone acetate <sep>"", 'placebo <sep> monophasic combined oral contraceptive containing ethinyl estradiol ee 0.03 mg and chlormadinone acetate cma 2 mg ee/cma <sep> cma <sep> oral contraceptive containing ee 0.03 mg and cma <sep> ee/cma <sep>', 'nomac/e2 <sep> drsp/ee <sep> monophasic combined oral contraceptive coc containing nomegestrol acetate nomac and 17-oestradiol e2 <sep> monophasic combined oral contraceptive containing nomegestrol acetate and 17-oestradiol <sep> oral contraceptive containing ethinylestradiol and drospirenone <sep> coc containing drospirenone drsp and ethinylestradiol ee <sep>', 'ee/drsp <sep> ee/ngm <sep> combined contraceptive containing drospirenone <sep> norgestimate ee/ngm <sep> contraceptive ee/drsp <sep> combined oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone <sep> drospirenone <sep>', 'ctr-24 <sep> desogestrel and 30 micrograms ethinylestradiol <sep> biphasic oral contraceptive containing a daily dosage of 25 micrograms desogestrel and 40 micrograms ethinylestradiol <sep> diane-35 containing a daily dosage of 2.0 mg cyproterone acetate and 30 micrograms ethinylestradiol <sep>', 'ee/cma belara and ee/lng microgynon <sep> monophasic oral contraceptive ethinylestradiol/chlormadinone acetate ee/cma <sep> ee/cma <sep> ee/cma or ee/lng <sep>', 'drospirenone drsp <sep> ee/drsp <sep> ee/drsp or ee/cpa <sep> drsp <sep> ethinyl estradiol ee)/3 mg drsp ee/drsp <sep> drospirenone or cyproterone acetate <sep> cyproterone acetate ee/cpa diane-35 schering ag berlin germany <sep>', 'placebo <sep> placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate <sep> combined oral contraceptives cocs containing anti-androgenic progestogens <sep> ethinylestradiol ee)/dng n=525 ee/cpa n=537 or placebo <sep> cyproterone acetate cpa <sep> coc containing the anti-androgen dienogest dng <sep> combined oral contraceptive <sep>', 'ee 24/4 regimen coc <sep> drospirenone/20 mcg ethinylestradiol oral contraceptive <sep> placebo <sep> drospirenone drsp)/20 mcg ethinylestradiol ee combined oral contraceptive coc <sep>', 'ee-gtd <sep> ee-dsg <sep> estrogen and progestin ep <sep> gestodene 75 micrograms gtd versus desogestrel 150 micrograms dsg combined with 30 micrograms of ethinylestradiol ee <sep> ethinylestradiol combined with gestodene and desogestrel <sep>', 'placebo <sep> ethinyl estradiol and 100 microg of levonorgestrel ee/lng <sep> contraceptive containing ee/lng <sep> low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel <sep> ee/lng or placebo <sep> low-dose oral contraceptive containing 20 microg of ee and 100 microg of lng <sep>', 'placebo <sep> triphasic combination oral contraceptive oc norgestimate-ethinyl estradiol <sep> norgestimate and ethinyl estradiol <sep> norgestimate-ethinyl estradiol <sep> norgestimate and ethinyl estradiol <sep> active oc treatment followed by 1 week of inactive drug or 4 consecutive weeks of color-matched placebo tablets <sep>', 'levonorgestrel plus 0.03 mg ee <sep>', 'placebo <sep> 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive <sep> drospirenone/20-microgram ethinyl estradiol 24/4 combination oral contraceptive <sep> drospirenone/20-microgram ethinyl estradiol 3-mg drospirenone/20-microgram ethinyl estradiol <sep> 3-mg drospirenone/20-microgram ethinyl estradiol <sep> drospirenone/20-microgram ethinyl estradiol <sep>', 'placebo <sep> ethinyl estradiol 0.035 mg and increasing doses of norgestimate <sep> triphasic combination oc ortho tri-cyclen ortho-mcneil pharmaceutical raritan n.j. norgestimate/ethinyl estradiol <sep> norgestimate <sep> ethinyl estradiol <sep> norgestimate and ethinyl estradiol <sep> oral contraceptives ocs <sep> inactive drug or placebo color-matched tablets <sep>', 'oral contraceptives containing desogestrel and cyproterone acetate <sep> low-dose oral contraceptive containing desogestrel marvelon and an anti-androgenic preparation containing cyproterone acetate diane <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",this update yielded six new trials but no change in conclusions. the six cocs evaluated in placebo-controlled trials are effective in reducing inflammatory and non-inflammatory facial acne lesions. few important and consistent differences were found between coc types in their effectiveness for treating acne. how cocs compare to alternative acne treatments is unknown since only one trial addressed this issue. the use of standardized methods for assessing acne severity would help in synthesizing results across trials as well as aid in interpretation.
379,"{'outcomes': ['pain <sep> acute headaches <sep> recurrence <sep> therapeutic gain <sep>', 'efficacy and safety <sep> safe and well tolerated <sep> pain relief <sep> analgesic efficacy <sep> pain intensity differences maximum pain intensity difference number of patients with at least 50 pain reduction time to 50 pain reduction maximum pain relief and total pain relief <sep> efficacy and safety <sep>', 'duration of the aura <sep>', 'nausea photophobia and phonophobia <sep> pain <sep>'], 'punchline_text': ['the patients receiving dipyrone showed a statistically significant improvement p<0.05 of pain compared to placebo up to 30 min after drug administration. <sep>', 'the analgesic efficacy of 0.5 and 1 g metamizol vs. placebo was highly statistically significant alpha 0.025 one-sided for sum of pain intensity differences maximum pain intensity difference number of patients with at least 50 pain reduction time to 50 pain reduction maximum pain relief and total pain relief. <sep>', 'dipyrone and chlorpromazine reduced the duration of the aura when compared to placebo 60 minutes following their administration. <sep>', 'patients receiving dipyrone demonstrated a statistically superior improvement p<.05 and p<.01 in pain and all associated symptoms compared with control subjects. <sep>'], 'population': ['episodic tension-type headache <sep> sixty patients <sep>', '417 patients with moderate episodic tension-type headache <sep> eligibility criteria included 18-65 years of age history of at least two episodes of tension-type headache per month in the 3 months prior to enrollment and successful previous pain relief with a non-opioid analgesic <sep> patients with moderate episodic tension-type headache <sep>', 'migrainous aura <sep> patients presenting migrainous aura <sep> brazilian public health units <sep> 86 patients during an acute migrainous attack with aura at the moment of the evaluation <sep>', 'migraine without aura and migraine with aura <sep>'], 'interventions': ['placebo <sep> dipyrone <sep> placebo intravenous injection of 10 ml saline or 1 g dipyrone in 10 ml saline <sep> dipyrone metamizol <sep> intravenous dipyrone <sep>', 'metamizol <sep> placebo <sep> metamizol vs. acetylsalicylic acid <sep> metamizol vs. 1 g acetylsalicylic acid asa <sep> metamizol vs. placebo <sep>', 'dipyrone and chlorpromazine <sep> placebo <sep> magnesium sulphate <sep> placebo dipyrone chlorpromazine and magnesium sulphate <sep>', 'dipyrone or placebo <sep> placebo <sep> 10 ml 0.9 physiological saline <sep> dipyrone <sep> dipyrone <sep> dipyrone metamizol <sep> intravenous dipyrone <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",evidence from a small number of trials suggests that dipyrone is effective for etth and migraine. no serious adverse events were observed in the included trials but agranulocytosis is rare and would probably not be observed in such a relatively small sample. a study now ongoing in latin america may clarify the true risk of agranulocytosis associated with dipyrone use.
380,"{'outcomes': ['analgesic effect <sep> pain levels twice daily using a visual analogue scale <sep> mean postoperative days of analgesic use <sep> postoperative hemorrhage <sep> mean postoperative days of pain <sep> analgesic efficacy <sep>', 'visual analog scale <sep> pain <sep> pain scores <sep>', 'pain relief <sep> postoperative pain relief <sep>'], 'punchline_text': ['mean postoperative days of pain were 10.3 and 8.3 respectively and differed significantly p  .008). <sep>', 'in the seventh post-operative day the results of bupivacaine dexamethasone lidocaine and placebo groups were similar p>0.05). <sep>', 'the efficacy of benzydamine hydrochloride difflam spray to relieve pain from postoperative tonsillectomy was assessed but it was found that it did not relieve the symptoms after operation when compared to matching placebo. <sep>'], 'population': ['thirty-seven patients from 5 to 14 years old undergoing <sep> thirty-seven patients completed the study 21 in the treatment group and 16 in the control group <sep>', '80 patients were analyzed <sep> children between 6 and 14 years of age referred to our department for bilateral tonsillectomy for either recurrent tonsillitis or tonsillar hypertrophy <sep> eighty patients were enrolled in the study in ent clinic firat university and in ent clinic elazi ssk hospital elazi turkey <sep> pain after tonsillectomy <sep>', 'after tonsillectomy <sep>'], 'interventions': ['electrocautery tonsillectomy <sep> hydrogen peroxide h2o2 mouth rinse <sep> h2o2 mouth rinse or the water rinse control <sep> hydrogen peroxide mouth rinse <sep>', 'bupivacaine <sep> lidocaine <sep> placebo <sep> dexamethasone <sep> lidocain hydrochloride <sep> dexamethasone bupivacaine and topical lidocaine spray <sep> bupivacaine-placebo dexamethasone-placebo <sep> bupivacaine hydrochloride dexamethasone and lidocaine hydrochloride <sep> bupivacaine-dexamethasone bupivacaine-lidocaine and dexamethasone-lidocaine <sep> bupivacaine dexamethasone and lidocaine nasal aerosol <sep> bupivacaine hydrochloride <sep> bupivacaine dexamethasone lidocaine and placebo <sep> lidocaine-placebo <sep>', 'placebo <sep> benzydamine hydrochloride spray <sep> benzydamine hydrochloride difflam spray <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",the risk of bias was high in most of the included trials and poor reporting quality and inadequate data did not permit comprehensive and reliable conclusions to be made. future trials should be well-constructed and pay more attention to the methods used to assess outcomes the timing of the assessments and the quality of reporting and subsequent analysis of the data.
381,"{'outcomes': ['overall response rates <sep>', 'longer survival <sep> survival <sep>', 'response rate <sep> life-threatening case of pulmonary embolism <sep> median survival times <sep> moderate toxicities <sep>', 'survival rates <sep>', 'response rate <sep> median durations of progression-free survival <sep> overall response rate <sep> median survival durations <sep> serum levels and response rates <sep> probability of response included initial performance status age histologic grade and progesterone receptor concentration <sep> poorer progression-free and overall survival times <sep> mpa levels <sep>'], 'punchline_text': ['using a multivariate analysis of the results this difference is significant p value 0.05). <sep>', 'the group of patients who received progestagens had significantly longer survival than the control group without hormonotherapy logrank test p  0.001). <sep>', 'only mild and moderate toxicities were observed on megestrol compared with more toxic complications observed on the combination of megestrol and tamoxifen including a life-threatening case of pulmonary embolism. <sep>', 'survival rates were much higher in the differentiated than in the undifferentiated carcinomas. <sep>', 'the adjusted relative odds of responding to the high-dose regimen compared with the low-dose regimen was 0.61 90 confidence interval 0.36 to 1.04). <sep>'], 'population': ['forty-six eligible women with metastatic endometrial cancer <sep> 8 patients with operable endometrial cancer negative estrogen receptor concentration er less than 15 fmole/mg protein and grade 3 disease the clinical course was aggressive in 4 patients with systemic and local relapse <sep>', 'endometrial cancer after surgery <sep> two hundred and five patients <sep> patients with endometrial cancer after hysterectomy <sep> postoperative endometrial cancer <sep>', '41 patients <sep> advanced endometrial cancer 66 patients were entered in this study <sep> advanced endometrial carcinoma <sep> patients with advanced endometrial cancer <sep>', 'advanced endometrial adenocarcinoma <sep> advanced endometrial carcinoma <sep> 93 patients with stage iii or iv endometrial adenocarcinoma after random allocation to therapy with <sep>', 'two hundred ninety-nine eligible women with advanced or recurrent endometrial carcinoma <sep> patients with a well-differentiated histology and positive progesterone receptor status <sep> advanced or recurrent endometrial carcinoma <sep>'], 'interventions': ['caf cyclophosphamide adriamycin 5-fluorouracil or caf plus provera 200 mg daily for 3 weeks followed cyclically by tamoxifen <sep> sequential cyclical hormonal therapy with er and progesterone receptor analysis <sep> sequential cyclical hormonal therapy <sep> adjuvant cyclical hormonal therapy <sep>', 'adjuvant progestagen therapy <sep> adjuvant hormonotherapy <sep> adjuvant progestagen treatment or were given no additional therapy <sep>', 'tamoxifen to megestrol <sep> megestrol <sep> megestrol and tamoxifen <sep> megestrol and tamoxifen <sep> standard progestin therapy of megestrol or to the combination of megestrol and tamoxifen <sep> megestrol plus tamoxifen <sep>', 'tam and mpa <sep> tamoxifen <sep> medroxyprogesterone acetate mpa <sep> medroxyprogesterone therapy <sep> tamoxifen tam <sep> tam <sep>', 'progestins <sep> progestin therapy <sep> oral mpa <sep> mpa <sep> oral medroxyprogesterone acetate <sep> oral medroxyprogesterone acetate mpa <sep> oral mpa <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",we found insufficient evidence that hormonal treatment in any form dose or as part of combination therapy improves the survival of patients with advanced or recurrent endometrial cancer. however a large number of patients would be needed to demonstrate an effect on survival and none of the included rcts had a sufficient number of patients to demonstrate a significant difference. in the absence of a proven survival advantage and the heterogeneity of patient populations the decision to use any type of hormonal therapy should be individualised and with the intent to palliate the disease. it is debatable whether outcomes such as quality of life treatment response or palliative measures such as relieving symptoms should take preference over overall and pfs as the major objectives of future trials.
382,"{'outcomes': ['incidence of parkinson disease pd <sep>', ""risk of parkinson's disease <sep>"", 'odds ratios <sep> risk reduction <sep>', 'pd risk <sep>', 'total caffeine consumption <sep> pd and environmental measures history status dosage duration and intensity of smoking coffee caffeine nonsteroidal anti-inflammatory drugs and non-aspirin nonsteroidal anti-inflammatory drugs <sep> increasing intensity of coffee drinking <sep> nonsteroidal anti-inflammatory drugs and pd <sep>', 'lower risk of pd <sep> risk of pd <sep>', 'protective effect <sep> risk of pd <sep>', 'relative risks <sep> pd risk <sep> onset of pd <sep>'], 'punchline_text': ['the odds ratios 95 ci for ever vs never use were 0.93 0.80 to 1.08 for nonaspirin nsaids 1.29 1.05 to 1.58 for aspirin and 1.16 1.00 to 1.35 for acetaminophen. <sep>', ""there was an increased risk of parkinson's disease in men who had 1-2 years of regular non-aspirin nsaid use odds ratio 1.35 1.07 to 1.70 a finding that remained significant after matching for confounder scores as well odds ratio 1.35 1.05 to 1.75)). <sep>"", 'the two-way and three-way combinations were associated with risk reduction of 37 to 49 and 62 respectively. <sep>', 'users of ibuprofen had a significantly lower pd risk than nonusers relative risk rr adjusted for age smoking caffeine and other covariates  0.62 95 confidence interval ci 0.42-0.93 p  0.02). <sep>', 'increasing dosage trend p  .009 and intensity trend p  .01 of total caffeine consumption were also inversely associated with high dosage presenting a significant inverse association for pd odds ratio  0.58 95 confidence interval 0.34-0.99). <sep>', 'nonsteroidal anti-inflammatory drugs nsaids reduce dopaminergic neuron degeneration in animal models of parkinson disease pd). <sep>', 'markers of neuroinflammation including activated microglia and increased levels of circulating proinflammatory cytokines have been observed in the brains and csf of patients with parkinson disease pd). <sep>', 'compared with nonusers the relative risks were 0.73 for users of fewer than 2 tablets/week 0.72 for 2 to 6.9 tablets/week and 0.62 for 1 or more tablets/day p trend  0.03). <sep>'], 'population': ['1,258 pd cases and 6,638 controls from the general practice research database <sep>', ""22,007 male physicians aged 40-84 years without indications for or contraindications to regular nsaid use and free of parkinson's disease at baseline <sep> up to five controls were matched to each of 616 cases by age and 565 cases by age and confounder scores <sep>"", '1,186 pd patients and 928 controls was conducted <sep> 2007 movement disorder society <sep>', '136,197 participants in the nurses health study nhs and the health professionals follow-up study hpfs free of pd at baseline 1998 for nhs and 2000 for hpfs <sep> 291 incident pd cases during 6 years of follow-up <sep>', 'families with parkinson disease <sep> 356 case subjects and 317 family controls who self-reported environmental exposures <sep>', 'parkinson disease pd <sep> 415 incident pd cases 236 men and 179 women <sep> 44 057 men and 98 845 women free of pd stroke or cancer health professionals follow-up study 1986-2000 and nurses health study 1980-1998 <sep>', 'parkinson disease pd <sep> 293 incident idiopathic pd cases and 286 age race and gender-matched controls from three rural california counties <sep> patients with parkinson disease pd <sep>', ""parkinson's disease pd in a large cohort of us men and women <sep>""], 'interventions': ['acetaminophen <sep> nonaspirin nsaid <sep> aspirin <sep>', 'aspirin <sep> aspirin nsaid or aspirin <sep> nsaid <sep> non-steroidal anti-inflammatory drugs nsaids <sep>', 'smoking coffee and nsaids <sep>', 'nonsteroidal anti-inflammatory drugs nsaid <sep> ibuprofen or other nsaids <sep> acetaminophen <sep> ibuprofen <sep> aspirin <sep>', 'caffeine coffee tea and soft drinks and nonsteroidal anti-inflammatory drugs aspirin ibuprofen and naproxen <sep> smoking caffeine and nonsteroidal anti-inflammatory drugs <sep>', 'nonsteroidal anti-inflammatory drugs nsaids <sep> nonaspirin nsaids or aspirin <sep> aspirin <sep>', 'nonsteroidal anti-inflammatory drugs <sep> aspirin nsaid <sep>', 'ibuprofen <sep> aspirin <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",there is currently no evidence for the use of nsaids in the secondary prevention of pd. non-aspirin nsaids particularly ibuprofen may reduce the risk of developing pd. however little is known of the effects of other individual drugs and at present no recommendations can be made regarding their use in primary prevention.
383,"{'outcomes': ['severe pain radiation or neurological deficit <sep> severity of pain duration nature and accompaniments of their pain the arhus low back pain index and in laboratory indices of organ system function <sep> severe and radiating pain accompanied by neurological deficit <sep> pain free without the permitted rescue medication tramadol <sep> numbers of pain <sep> severe and unbearable pain <sep>', 'severity duration nature and accompaniments of their pain and in laboratory indices of organ system function <sep> pain <sep> pain free <sep>', 'compound pain subscore of the arhus low back rating scale continuous variable and a response criterion of a reduction in pain subscore=30 <sep> efficacy and tolerance <sep> responder rate <sep> systemic side-effects <sep> partial pain scores disability and mobility restriction subscores the total score of the arhus low back rating scale the global evaluation of efficacy by investigator and patient adverse events <sep> adverse local drug reactions <sep> compound pain subscore <sep> efficacy rating symptomfree or improved <sep>', 'main efficacy parameter vas reduction <sep> number of subjects with adverse events aes withdrawals due to an ae and adverse drug reactions adrs <sep> vas reduction <sep> pain <sep> efficacy and safety <sep>', 'effectiveness <sep> pain component <sep> adverse events <sep> number of pain-free patients visual analogue scale score <sep> modified arhus index its pain component and the total pain index <sep> total pain index <sep>', 'severe allergic reaction <sep> numbers of pain <sep> proportion of patients who were pain-free without tramadol <sep>', 'adverse effects <sep> pain scores <sep> pain without rescue medication <sep>', ""spontaneous pain muscular contracture and in both the patient's and physician's opinions <sep> finger-floor distance and the degree of lumbar extension <sep>"", 'human platelet aggregation <sep> maximal platelet aggregation induced by arachidonic acid <sep> platelet aggregation <sep> mean maximal arachidonic acid induced platelet aggregation <sep> platelet aggregation <sep>'], 'punchline_text': ['there was no evidence for harpagophytum-related side-effects except possibly for mild and infrequent gastrointestinal symptoms. <sep>', 'the percentage change was greater in those patients who received harpagophytum extract than in those who received placebo but inferential testing mann whitney allowed only 94 degree of confidence that this had not arisen by chance. <sep>', 'after 3 weeks treatment with capsicum and placebo plaster respectively the compound pain subscore was reduced by 42 capsicum and 31 placebo from values on entry. <sep>', 'spiroflor srl gel is preferable to capsicum-based products for the topical treatment of low back pain because of the lower risk of adverse effects. <sep>', 'after 4 weeks of treatment the arhus index had improved by about 20 its pain component by about 30 and the total pain index by about 35%. <sep>', 'significantly more patients in the placebo group required tramadol p 0.001 during each week of the study. <sep>', 'ten paid and 5 nsaid patients reported no pain without rescue medication for at least 5 days of the 6th week of treatment. <sep>', ""statistically significant improvements in spontaneous pain muscular contracture and in both the patient's and physician's opinions occurred by day 3. <sep>"", 'acetylsalicylate had a significant inhibitory effect on platelet aggregation compared to salicis cortex extract p  0.001 and placebo p  0.001). <sep>'], 'population': ['183 patients completed the study <sep> exacerbation of low back pain <sep> 197 patients with chronic susceptibility to back pain and current exacerbations that were producing pain worse than 5 on a 0-10 visual analogue scale <sep>', ' 1996 <sep> 118 patients with chronic back problems seeking treatment for acute attacks of pain <sep> acute low back pain <sep> 109 patients completed the study <sep>', '320 patients were randomly assigned to two groups of n=160 subjects treated by the active or the <sep> non-specific low back pain <sep> chronic low back pain with a capsicum plaster <sep>', 'one hundred and sixty-one subjects suffering from acute low back pain <sep> patients with acute low back pain <sep> acute low back pain <sep> practices of 19 gps in the districts of bristol and manchester uk <sep>', '114 patients <sep> out-patients clinic on two groups of patients aged 18 to 80 yr presenting over a 6-month period with acute exacerbations of low back pain <sep>', '191 patients completed the study <sep> 210 patients with an exacerbation of chronic low back pain who reported current pain of 5 or more out of 10 on a visual analog scale <sep>', 'forty-three paid and 36 nsaid patients completed the study <sep> low back pain <sep> acutely exacerbated low back pain <sep> 21 paid patients and 13 nsaid patients <sep>', 'forty patients with acute mechanical low-back pain <sep> mechanical low-back pain <sep>', 'thirty-five patients suffering from acute exacerbations of chronic low back pain <sep> sixteen patients with stable chronic ischemic heart disease <sep> patients with impaired thrombocyte function <sep> a total of 51 patients were enrolled in the study <sep>'], 'interventions': ['oral harpagophytum extract ws <sep> placebo <sep> harpagophytum extract ws <sep> tramadol <sep>', 'placebo <sep> harpagophytum procumbens <sep> harpagophytum extract <sep> copyright <sep> supplementary pain-killer tramadol <sep> daily consumption equal to 6,000 mg of crude preparation <sep>', 'capsicum and placebo plaster <sep> placebo <sep> capsicum plaster <sep> placebo plaster <sep>', 'srl or with ccc <sep> spiroflor srl gel <sep> homeopathic gel spiroflor srl gel srl <sep> cremor capsici compositus fna ccc <sep> homeopathic gel <sep> ccc <sep>', 'rofecoxib <sep> herbal or synthetic anti-rheumatic <sep> herbal extract containing 240 mg of salicin paid phyto-anti-inflammatory drug <sep> synthetic cox-2 inhibitor rofecoxib nsaid non-steroidal anti-inflammatory drug <sep> proprietary extract of willow bark assalix and a selective inhibitor rofecoxib <sep> willow bark extract <sep>', 'placebo <sep> willow bark extract <sep> oral willow bark extract with either 120 mg low dose or 240 mg high dose of salicin or placebo with tramadol <sep> willow salix bark extract <sep> tramadol <sep>', 'tramadol <sep> doloteffin a proprietary extract of harpagophytum and rofecoxib <sep> doloteffin and vioxx <sep> doloteffin containing inter alia 60 mg of harpagoside for 6 weeks and 44 non-steroidal anti-inflammatory drug-nsaid-group received 12.5 mg/day of rofecoxib <sep> tramadol <sep>', 'topical massage with rado-salil ointment <sep> rado-salil or placebo <sep>', 'adenosine di-phosphate <sep> salicis cortex extract <sep> placebo <sep> arachidonic acid <sep> salicis cortex extract <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",harpagophytum procumbens salix alba and capsicum frutescens seem to reduce pain more than placebo. additional trials testing these herbal medicines against standard treatments are needed. the quality of reporting in these trials was generally poor. trialists should refer to the consort statement extension for reporting trials of herbal medicine interventions.
384,"{'outcomes': ['arterial oxygen tension <sep> lung volume or air flow obstruction <sep> bronchial responsiveness <sep> lung function <sep> heart rate <sep>', 'maximum flow at frc vmaxfrc <sep> concentration of histamine <sep> bronchial response <sep>', 'symptom score or pulmonary function <sep> mean daily symptom score <sep> clinical symptoms or pulmonary function <sep> symptoms of wheeze and cough <sep> number of symptom free days <sep> compliance and forced expiratory flows <sep>', 'clinical status respiratory rate degree of wheezing and accessory muscle use total clinical score and arterial oxygen saturation <sep> arterial oxygen saturation <sep>', 'symptom score <sep> sgaw <sep> values of thoracic gas volume tgv airway conductance gaw and specific airway conductance sgaw <sep> pulmonary hyperinflation <sep> clinical status and lung function <sep> improvement of gaw <sep>', 'number of treatment failures <sep>', 'clinical effect <sep>'], 'punchline_text': ['bronchial responsiveness decreased significantly after the administration of salbutamol by babyhaler the pc30 provoking concentration of methacholine causing a 30 fall in maximal flow at functional residual capacity by the squeeze technique increasing from a median of 3.8 g/l after placebo to 12.5 g/l after salbutamol. <sep>', 'all of the infants responded to low concentrations of histamine during control tests before and after nebulised saline mean pc30 1.07 and 0.51 g/l). <sep>', 'in wheezy infants with an atopic background there was no significant beneficial effect of salbutamol on either clinical symptoms or pulmonary function. <sep>', 'none of the patients in the albuterol group experienced a decrease of arterial oxygen saturation of greater than or equal to 2%. <sep>', 'no significant differences were found between the bdp-s and s group and/or between the s and p groups. <sep>', 'there was no difference in the number of treatment failures between babies treated with a combination of salbutamol and placebo and those treated with salbutamol and prednisolone relative risk 0.71 95 confidence intervals for relative risk 0.18-2.80). <sep>', 'no significant difference in clinical effect was shown between albuterol and saline in the youngest group of children. <sep>'], 'population': ['wheezy infants <sep>', 'wheezy infants <sep> five wheezy infants aged 3-12 months <sep>', 'forty eight infants completed the diary study 40 infants underwent pulmonary function testing <sep> wheezy infants <sep> eighty infants under 1 year with persistent or recurrent wheeze and a personal or family history of atopy <sep> infants who wheeze <sep>', '28 children younger than 2 years of age who visited the emergency department during an episode of acute asthma were studied <sep> infants and young children <sep> children younger than 2 years of age with acute asthma <sep>', 'wheezy infants <sep> twenty-nine of initially 42 infants with recurrent wheeze 20 male and 9 female with an age range of 2.1-25.2 months <sep>', 'acute episodes of wheezing in infants under 15 months of age <sep> acute episodes of wheezing in infancy <sep> sixty-two acute episodes of wheezing were studied in 59 babies age range 3-14 months mean 7 months who had all suffered at least one previous wheezy episode <sep>', '28 acutely ill children younger than 18 months and in 13 children 18 to 36 months of age <sep> children older than 18 months <sep>'], 'interventions': ['new valved spacer device the babyhaler inhaler glaxo <sep> placebo <sep> methacholine <sep> salbutamol <sep>', 'nebulised histamine <sep> nebulised salbutamol <sep>', 'inhaled salbutamol <sep> placebo <sep> salbutamol <sep> salbutamol <sep>', 'placebo normal saline with oxygen 1 hour apart <sep> nebulized albuterol <sep> placebo <sep>', 'beclomethasone dipropionate and salbutamol <sep> placebo <sep> 100 micrograms beclomethasone dipropionate bdp combined with 200 micrograms salbutamol <sep> salbutamol <sep>', 'placebo <sep> oral salbutamol <sep> salbutamol and prednisolone <sep> salbutamol and placebo <sep> oral salbutamol and oral prednisolone <sep> oral salbutamol and prednisolone <sep> salbutamol and prednisolone salbutamol and placebo or double placebo <sep> salbutamol <sep>', 'albuterol <sep> nebulized albuterol salbutamol <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",there is no clear benefit of using b2-agonists in the management of recurrent wheeze in the first two years of life although there is conflicting evidence. at present further studies should only be performed if the patient group can be clearly defined and there is a suitable outcome parameter capable of measuring a response.
385,"{'outcomes': ['tidal volume <sep> arterial oxygen saturation <sep> transcutaneous carbon dioxide tension values <sep> spontaneous respiratory rate <sep> blood gases and ventilation volume <sep> heart rate <sep>', 'mean length of the weaning process <sep> low birthweight and respiratory distress syndrome <sep> heart rate respiratory rate transcutaneous oxygen saturation and ventilatory parameters <sep> cardiorespiratory stability and weaning outcome <sep> respiratory rate heart rate and transcutaneous oxygen saturation however oxygen desaturation episodes <sep>', 'static compliance and the work of breathing of spontaneous breaths <sep> tidal volume <sep> arterial oxygen saturation <sep> pulmonary resistance <sep> lung mechanics and blood gases <sep> breathing increased and static compliance <sep> minute ventilation <sep> blood gases and lung mechanics <sep>', 'tcpo2 and tcpco2 <sep> mean tcpo2 or tcpco2 <sep> sleep state <sep> median fraction of inspiratory oxygen <sep> transcutaneous tc oxygen tcpo2 and carbon dioxide measurements tcpco2 <sep>', 'episodes of oxygen desaturation <sep> motor activity <sep> duration of spo(2 <sep> oxygen saturation spo(2 desaturation episodes spo(2  90 and or 20 seconds and motor activity <sep> vigorous motor activity and crying <sep> decreased activity and oxygen desaturation <sep>', 'thoracic gas volumes <sep> transcutaneous oxygen and carbon dioxide pressures <sep> functional residual capacity tidal volume or dynamic lung compliance <sep> transcutaneous carbon dioxide pressure <sep> proportion of ventilation to the good lung <sep> transcutaneous oxygen pressure <sep>', 'tcpco2 and paco2 values <sep> mean tcpco2 values <sep> tcpco2 <sep> transcutaneous carbon dioxide tension <sep>'], 'punchline_text': ['the prone position resulted in a significant increase in arterial oxygen saturation before and after feeding whereas the tidal volume demonstrated an increase only before feeding. <sep>', 'ventilatory parameters decreased faster and reintubation was less frequent in the prone group 4 versus 33%). <sep>', 'in the supine position work of breathing increased and static compliance decreased significantly with time while in the prone position those values did not change significantly. <sep>', 'a significant difference in mean tcpo2 or tcpco2 was not detected for any of the positions. <sep>', 'no significant differences in duration of spo(2 less than 90 85 and 80 were found between the 2 positions. <sep>', 'there were no significant changes with position in functional residual capacity tidal volume or dynamic lung compliance. <sep>', 'there were no statistically significant differences in mean tcpco2 values between the three positions f  .45 df 2,39 p  .64). <sep>'], 'population': ['six extremely immature infants who were being mechanically ventilated because of chronic lung disease <sep> mean postnatal age of 47.5 days range 21 to 85 days <sep> infants with chronic lung disease before and after feeding <sep> their mean birthweight and gestational age were 722.7 g range 540 to 994 and 24.9 weeks range 23.9 to 26.0 respectively <sep>', '42 preterm infants with birthweight  2,000 g mechanically ventilated in the first week of life <sep> preterm infants during weaning from mechanical ventilation <sep> preterm infants <sep>', 'infants with chronic lung disease during tube feeding <sep> very low birthweight infants with chronic lung disease cld <sep>', 'eighteen stable very-low-birth-weight vlbw mechanically ventilated infants with chronic lung disease <sep> vlbw infants <sep> neonates were studied at a median postnatal age of 31 days range 17 to 57 days and had median birth weights and gestational ages of 975 g range 570 to 1360 g and 27.5 weeks range 24 to 30 weeks respectively <sep>', 'neonatal intensive care units at 2 tertiary care centers in taiwan <sep> sick preterm infants <sep> ventilated preterm infants <sep> prone ventilated preterm infants <sep> 28 infants receiving <sep> ventilated preterm infants during their first postnatal week <sep>', '10 infants with unilateral lung disease <sep> four of the infants <sep> infants <sep> adults with unilateral lung disease <sep> infants with unilateral lung disease <sep>', 'fourteen ventilated infants <sep> neonates with respiratory distress <sep>'], 'interventions': ['body position <sep>', 'prone positioning <sep> preterm infant position on weaning from mechanical ventilation <sep>', 'body position and feeding <sep> body position <sep>', 'transcutaneous oxygen and carbon dioxide <sep>', 'supine/prone or prone/supine position sequence <sep> mechanical ventilation <sep>', 'body position <sep>', 'transcutaneous carbon dioxide tension tcpco2 <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",the prone position was found to slightly improve the oxygenation in neonates undergoing mechanical ventilation. however we found no evidence concerning whether particular body positions during the mechanical ventilation of the neonate are effective in producing sustained and clinically relevant improvements.
386,"{'outcomes': ['delivery time <sep> rates of cesarean section and induction of labor <sep> time elapsed from the time of randomization to delivery <sep> mean time to delivery <sep> likely to deliver by cesarean section <sep> labor spontaneously <sep>', 'overall duration of labor and first and second stage of labor <sep> labor <sep> cervical length <sep>', 'shorter duration of active phase <sep> duration of labor <sep> length of birth and use of oxytocin <sep> duration of active labor the amount of oxytocin given and number of inductions <sep>'], 'punchline_text': ['acupuncture is well tolerated among term nulliparous women and holds promise in reducing interventions that occur in post-term pregnancies. <sep>', 'labor was induced in 20 of women in the ag n  5 and in 35 in the cg n  7 p  0.3). <sep>', 'duration of labor was significantly reduced mean difference 1.7 h p=0.03 and there was significant reduction in the need for oxytocin infusion to augment labor in the study group compared to the control group odds ratio 2.0 p=0.018). <sep>'], 'population': ['nulliparous women at 39 4/7 weeks or greater with a singleton gestation and bishop score of less than 7 were randomized to <sep> nulliparous women <sep> fifty-six women <sep> term nulliparous women <sep>', '45 women were evaluated ag n  25 cg n  20 <sep> exclusion criteria were as follows cervical dilation  3 cm active labor premature rupture of membranes previous cesarean section pathologies in mother or fetus <sep>', 'women with prelabor rupture of membranes <sep> 100 healthy parturients with spontaneous rupture of membranes at term <sep>'], 'interventions': ['acupuncture <sep> outpatient acupuncture <sep> acupuncture <sep> usual medical care control group versus usual care and three outpatient acupuncture treatments acupuncture group <sep>', 'acupuncture <sep> acupuncture group ag or a control group cg <sep> acupuncture <sep> oxytocin <sep>', 'acupuncture <sep> acupuncture <sep> oxytocin <sep> acupuncture or no acupuncture <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",there is a need for well-designed randomised controlled trials to evaluate the role of acupuncture to induce labour and for trials to assess clinically meaningful outcomes. note the 15 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
387,"{'outcomes': ['conversion rate of hbsag <sep> adverse effects <sep>'], 'punchline_text': ['adverse effects were not observed in all patients receiving the plant. <sep>'], 'population': ['chronic carriers <sep> sixty-five adult asymptomatic chronic carriers of hepatitis b virus <sep> thirty-four received <sep>'], 'interventions': ['placebo <sep>'], 'punchline_effect': [' no diff <sep>']}",based on one low quality trial the medicinal herb jianpi wenshen recipe may have an antiviral activity in asymptomatic carriers of hepatitis b virus. however rigorous randomised double-blind placebo-controlled trials are needed before herbs should be used for this condition.
388,"{'outcomes': ['response rate <sep> efficacy <sep> toxicity <sep> disease recurrence <sep> local and systemic side effects <sep>', 'complete response cr disease-free interval and recurrence rate <sep> pulmonary tuberculosis <sep>'], 'punchline_text': ['no statistical differences were observed in toxicity between the two strains of bcg but local and systemic side effects were more frequent in the bcg groups versus the mitomycin group. <sep>', 'the result was in favour of bcg as shown by the measurements with complete response cr disease-free interval and recurrence rate. <sep>'], 'population': ['patients with papillary tumors <sep> patients with pta-pt1 papillary carcinoma and carcinoma in situ of the urinary bladder <sep> 469 patients with pta/pt1 carcinoma and cis of the urinary bladder after tur <sep> 437 evaluable patients 50 had cis 254 had pta tumors and 133 had pt1 tumors <sep> dutch south east cooperative urological group <sep>', 'superficial bladder cancer <sep> 91 patients with frequently recurrent superficial ta-t1 bladder cancer <sep>'], 'interventions': ['mitomycin <sep> mitomycin versus bcg-tice versus bcg-rivm <sep> mitomycin and bcg-rivm <sep> mitomycin versus bacillus calmette-gurin-tice versus bacillus calmette-gurin rivm <sep> immunomodulator bacillus calmette-gurin bcg <sep>', 'intravesical mitomycin c mmc and bacillus calmette-gurin bcg <sep> intravesical chemotherapy mitomycin c <sep> mmc <sep> pasteur strain f <sep> immunotherapy bacillus calmette-gurin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>']}",the data from the present meta-analysis indicate that tumour recurrence was significantly reduced with intravesical bcg compared to mmc only in the subgroup of patients at high risk of tumour recurrence. however there was no difference in terms of disease progression or survival and the decision to use either agent might be based on adverse events and cost.
389,"{'outcomes': ['total direct health care costs <sep> rating scale or standard gamble utilities <sep> health care costs <sep> indirect costs <sep> quality of life <sep> rating scale utilities <sep>', 'exercise level since <sep> helplessness number of days feeling bad physical dysfunction and pain in the tender points <sep> self-efficacy <sep> fibromyalgia fms symptoms and increasing physical and psychological well being <sep> fibromyalgia impact questionnaire <sep> quality of life and self-efficacy <sep>', 'pain control <sep> knowledge about fm <sep> pain coping <sep>', 'pain reductions <sep> pain ratings <sep> chronic pain <sep> pain <sep> pain medicine use activity and depression <sep>', 'work stability <sep>', 'self-efficacy <sep> health status <sep> ases-s <sep> arthritis self-efficacy scale ases-s <sep>', 'patient made drawing of pain distribution dolorimetry of tender points ergometer cycle test global subjective improvement and vas registrations of pain disturbed sleep lack of energy and depression <sep>', 'helplessness and passive coping <sep> pain depression disability pain behaviors and intervening variables <sep> depression self-reported pain behaviors observed pain behaviors and myalgia scores <sep>'], 'punchline_text': ['however no significant differences in either rating scale or standard gamble utilities were found between the eco and edi groups immediately after treatment or at the 6 or 12 month followups. <sep>', 'longterm followup of 67 treated subjects showed significant positive changes on the fibromyalgia impact questionnaire primarily in the physical training group. <sep>', 'edi patients improved on pain coping p  0.005 and pain control p  0.002). <sep>', 'applied relaxation plus the operant programme was significantly better than relaxation for medicine reduction and applied relaxation was better than relaxation and operant conditioning for a patient evaluation of reaching treatment goals. <sep>', 'the results concerning return to work and re-sick-listing during a follow-up period of five years were evaluated for swedes and immigrants separately. <sep>', 'evidence of construct validity of the ases-s was revealed in the factor analysis which produced a three factor solution similar to previous results. <sep>', 'ae was the overall most effective treatment despite being subject to the most sceptical patient attitude prior to the study. <sep>', 'although improvement across time was found in depression self-reported pain behaviors observed pain behaviors and myalgia scores no differences in these criteria were found between the behavioral and education/control conditions. <sep>'], 'population': ['fibromyalgia <sep> 131 patients with fibromyalgia <sep>', 'ninety-nine women with fms <sep> women with fibromyalgia <sep>', 'fibromyalgia <sep> patients with the fibromyalgia fm syndrome <sep> 131 patients with fm <sep>', 'waiting patients <sep> chronic pain <sep> chronic back/joint pain patients <sep>', 'general population with 90 days of sick-leave due to non-specific musculoskeletal pain <sep> patients with non-specific musculoskeletal pain <sep>', 'people with fibromyalgia <sep> ninetynine women with fibromyalgia fs <sep> patients with fs <sep>', 'fibromyalgia <sep> fibromyalgia 60 patients <sep>', 'fibromyalgia <sep> patients with fibromyalgia fm <sep>'], 'interventions': ['cognitive-educational treatment <sep> wlc <sep> 6 week educational/cognitive intervention eco <sep> educational discussion intervention edi and a waiting list condition wlc <sep> eco edi or wlc intervention <sep>', 'education and physical training <sep> self-management education and physical training <sep>', 'wlc <sep> cognitive-educational treatment <sep> combined cognitive/educational intervention eco an attention control condition consisting of group education plus group discussion edi and a waiting list control wlc <sep> outpatient group cognitive/educational treatment <sep>', 'waiting-list control or to either 2 an applied relaxation or 3 an applied relaxation plus operant conditioning treatment programme <sep> applied relaxation and applied relaxation plus operant procedures <sep> relaxation and operant therapies <sep>', 'multidisciplinary rehabilitation programme <sep>', 'fibromyalgia efficacy-based self-management education and physical training <sep>', 'aerobic exercise <sep> aerobic exercise ae stress management treatment smt and treatment-as-usual tau <sep> ae smt or tau <sep>', 'comprehensive behavioral intervention with an education/control condition <sep> behavioral and educational interventions <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",we conclude that there appears to be little scientific evidence for the effectiveness of multidisciplinary rehabilitation for these musculoskeletal disorders. however multidisciplinary rehabilitation is a commonly used intervention for chronic musculoskeletal disorders which cause much personal suffering and substantial economic loss to the society. there is a need for high quality trials in this field.
390,"{'outcomes': ['thoracic objectivity <sep> body temperature cough thoracic objectivity respiratory function indices <sep> fever <sep> rate of regression of thoracic symptomatology <sep>', ""sedative effects <sep> child's runny nose nasal congestion cough and sleep status <sep> symptom improvement <sep> uri symptoms <sep>"", 'symptoms of upper respiratory tract infection <sep> proportion of children considered better overall <sep>', 'cough frequency and the subjective severity of cough <sep> cough frequency and subjective scores of cough severity <sep>', 'side effects <sep> sneezing and total symptom scores <sep>', 'symptom scores for the cough frequency and severity during the day sputum quantity or ease of expectoration <sep> cough <sep> suppression of cough at night <sep>', 'cough severity <sep> severity of cough nasal obstruction nasal discharge and throat-clearing <sep> cough <sep>', 'cspls cough frequency or subjective symptom scores <sep> cough cough sound-pressure levels cspls <sep> cough <sep>', 'insomnia <sep> frequency of drowsiness <sep> nasal congestion sneezing postnasal drainage and nasal discharge <sep> nervousness <sep>', 'night-time symptom relief and sleep satisfaction assessments <sep> individual symptoms <sep> nasal congestion/runny nose/cough/pain relief scores <sep> satisfaction on sleep <sep> overall night-time relief <sep>', 'sputum thickness <sep> diurnal variation in cough frequency <sep> sputum quantity <sep> cough frequency <sep>', 'quality of sleep <sep> sleep quality <sep> nocturnal cough and sleep quality <sep> sleep quality <sep> drowsiness <sep> insomnia <sep> frequency severity and bothersome nature of the nocturnal cough <sep> nocturnal cough and sleep difficulty associated with upper respiratory infections <sep> nocturnal symptom relief <sep>', 'speed of action and objective and subjective measures <sep> subjective methods and cough counts <sep> cough counts latency and total effort <sep> cough counts intensity latency and total effort expended <sep>', 'cough bouts cough components and cough effort <sep> 30-min intervals cough bouts cough components cough effort cough intensity and cough latency <sep> cough latency <sep>', 'mean cspl changes <sep> cough sound pressure level cspl cough frequency cf and subjective scores for cough severity <sep>'], 'punchline_text': ['it is concluded that treatment with letosteine leads to a significant increase in the rate of regression of thoracic symptomatology and a faster more substantial reduction in fever in children suffering from acute bronchitis. <sep>', 'there were no statistically significant differences in symptom improvement between the adc and the placebo group runny nose p  0.48 nasal congestion p  0.94 cough p  0.66). <sep>', 'there were no differences among the three study groups in the proportion of children considered better overall by the parent 48 hours after the initial assessment drug 67 placebo 71 no treatment 57 p  0.53). <sep>', 'cough frequency and subjective scores of cough severity were significantly decreased during the 3-h laboratory phase but at no time point was there a significant difference between the codeine and placebo-treated groups. <sep>', 'evaluations by both subjects and physicians suggest that terfenadine at 120 mg given twice daily marginally improved sneezing and total symptom scores at day 4. <sep>', 'no statistically significant differences between the treatments were shown in the symptom scores for the cough frequency and severity during the day sputum quantity or ease of expectoration. <sep>', 'antihistamine-decongestant therapy reduced postnasal drip and significantly decreased the severity of cough nasal obstruction nasal discharge and throat-clearing during the first few days of the common cold. <sep>', 'on study day 1 a highly significant p  0.0001 decrease in all three measures of cough was found after treatment with both placebo and codeine yet there was no significant difference between the treatment groups. <sep>', 'differences between groups for the following side effects were found dry mouth 9 for the combination vs 2 for placebo insomnia 6 vs 3 and nervousness 4 vs 2%). <sep>', 'improvement in individual symptoms after 3 hours was obtained in 16-42 more subjects in group t than in group p whereas the percentage of subjects in group t having good or very good relief the morning after dosing increased by 25-68 compared to subjects in group p. 14 subjects 5 in group t 9 in group p reported aes but none of these occurred with an incidence greater than 1%. <sep>', 'twenty-three of 26 88 percent patients receiving guaifenesin also reported reduction in sputum quantity compared to 15 of 24 62.5 percent receiving the vehicle p  0.07 fisher exact test). <sep>', 'diphenhydramine and dextromethorphan are not superior to placebo in providing nocturnal symptom relief for children with cough and sleep difficulty as a result of an upper respiratory infection. <sep>', 'reproducible cough suppressant effects were demonstrated after a single 30 mg dose using objective measures of cough counts latency and total effort. <sep>', 'it demonstrated significantly greater overall reductions in cough bouts cough components and cough effort and an increase in cough latency for patients treated with dextromethorphan hydrobromide 30 mg vs those treated with placebo. <sep>', 'the results showed similar trends in both treatment groups with statistically significant reductions p  0.05 in cough sound pressure level cspl cough frequency cf and subjective scores for cough severity within treatment groups but little difference between the treatment groups during the study period. <sep>'], 'population': ['acute febrile bronchitis in children <sep> children suffering from acute bronchitis <sep> paediatric patients suffering from acute febrile bronchitis <sep> forty children were recruited for the research 20 were treated with <sep>', 'children 6 months through 5 years of age with a uri of less than 7 days duration <sep> preschool children <sep>', 'young children with the common cold <sep> young children by randomly assigning 96 children <sep>', 'cough associated with acute upper respiratory tract infection <sep>', 'rhinitis symptoms associated with the common cold <sep> forty-nine subjects <sep>', '108 out-patients with cough associated with acute respiratory infection <sep>', 'volunteers with uncomplicated common colds <sep>', '82 subjects 51 females and 31 males mean age 23.5 years range 18-46 years with cough owing to acute urti were included in the study <sep> cough associated with common cold <sep>', 'one hundred forty-two 142 subjects were treated with the <sep>', 'eligible subjects had to have at least moderate nasal congestion and a runny nose at least mild cough and at least mild pain with one or more of the following sore throat sore chest headache or body pain/aches <sep> 485 subjects who took the study product 432 224 in group t 208 in group p were evaluable for analysis <sep> subjects with multiple cold symptoms <sep> subjects with multiple common cold symptoms <sep>', '26 patients with productive cough receiving <sep> young adults with natural colds <sep> young adults with acute respiratory disease <sep>', 'children with cough <sep> parents of 100 children with upper respiratory infections <sep> coughing children and their parents <sep>', 'patients with productive cough due to chronic bronchopulmonary disease <sep> man <sep>', 'acute cough <sep> one study was conducted in durban south africa and five studies were conducted in bombay india <sep> seven hundred ten adult patients with cough due to uncomplicated urti who were otherwise healthy and who satisfied the inclusion/exclusion criteria for the meta-analysis <sep> patients with cough due to uncomplicated upper respiratory tract infection urti <sep>', 'patients with cough associated with acute upper respiratory tract infection <sep> forty-three patients 30 females and 13 males mean age 22.9 years range 18-46 years with acute dry or slightly productive cough and otherwise healthy were included in the study <sep> cough associated with acute upper respiratory tract infection <sep>'], 'interventions': ['placebo <sep> letosteine <sep> letosteine activity <sep>', 'antihistamine-decongestant combination adc <sep> placebo <sep> adc brompheniramine maleate-phenylpropanolamine hydrochloride or placebo <sep> antihistamine <sep>', 'antihistamine-decongestant combination <sep> antihistamine-decongestant placebo <sep> placebo <sep> antihistamine-decongestant combinations <sep>', 'placebo <sep> codeine <sep> codeine <sep> codeine syrup b.p <sep> syrup vehicle <sep>', 'placebo <sep> nonsedating antihistamine terfenadine <sep> terfenadine <sep> terfenadine <sep>', 'dextromethorphan or placebo <sep> placebo <sep> dextromethorphan and dextromethorphan-beta 2-sympathomimetic combination <sep> antitussive-beta 2-sympathomimetic combination dextromethorphan-salbutamol <sep> dextromethorphan-salbutamol <sep> plain antitussive dextromethorphan <sep>', 'standardized questionnaire and undergoing a physical examination throat-culturing and pulmonary function testing subjects took the active drug or identical-appearing placebo <sep> antihistamine-decongestant therapy <sep> antihistamine-decongestant therapy <sep> placebo <sep>', 'codeine <sep> placebo <sep> codeine <sep> codeine or matched placebo <sep>', 'antihistamine/decongestant combination <sep> placebo <sep> non-sedating antihistamine loratadine 5 mg plus pseudoephedrine <sep> nonsedating antihistamine loratadine plus pseudoephedrine <sep> loratadine/pseudoephedrine <sep>', 'dextromethorphan hydrobromide 7.5 mg doxylamine succinate 600 mg paracetamol and 8 mg ephedrine sulfate <sep> placebo <sep> placebo placebo syrup <sep> paracetamol dextromethorphan hydrobromide doxylamine succinate and ephedrine sulfate <sep> syrup containing paracetamol dextromethorphan hydrobromide doxylamine succinate and ephedrine sulfate <sep> group t test syrup or group p placebo syrup <sep>', 'guaifenesin <sep>', 'dextromethorphan <sep> placebo <sep> dextromethorphan and diphenhydramine <sep> dextromethorphan diphenhydramine and placebo <sep> diphenhydramine <sep> diphenhydramine and dextromethorphan <sep>', 'guaiphenesin and bromhexine <sep> dextromethorphan <sep> placebo <sep>', 'dextromethorphan hydrobromide 30 mg vs placebo <sep> placebo <sep> dextromethorphan hydrobromide <sep> computerized cough acquisition system <sep>', 'dextromethorphan treatment <sep> dextromethorphan <sep> dextromethorphan <sep> placebo <sep> cspl <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",there is no good evidence for or against the effectiveness of otc medicines in acute cough. the results of this review have to be interpreted with caution due to differences in study characteristics and quality. studies often showed conflicting results with uncertainty regarding clinical relevance. higher quality evidence is needed to determine the effectiveness of self care treatments for acute cough.
391,"{'outcomes': ['rectal histological activity scores <sep> powell-tuck index inflammatory bowel disease questionnaire ibdq score and rectal histological activities <sep> ibdq scores <sep> rectal histological scores <sep> powell-tuck index ibdq score and histological disease activity scoring <sep> moderate side effects <sep> depression of the disease activity <sep> powell-tuck index <sep> active left-sided ulcerative colitis <sep> ibdq score <sep>', 'median prestudy clinical activity index cai <sep> steroid reduction <sep> reduction of the cai of 6 points or greater response <sep> median endoscopic index <sep> complete response <sep> seven serious adverse events <sep> efficacy and safety <sep>', 'clinical response <sep> ulcerative colitis scoring system ucss symptoms score and induction of endoscopically confirmed remission <sep> baseline characteristics and disease severity <sep> efficacy and tolerability <sep> remission <sep>', 'clinical remission rates <sep> levels of c reactive protein <sep> serious adverse events <sep>'], 'punchline_text': ['in the enema group significant improvements were found in the powell-tuck index p  0.0009 whereas no significant improvements were detected in the ibdq scores p  0.055 or rectal histological scores p  0.052). <sep>', 'rifn-beta-1a was safe but not significant at the dosage and/or duration of treatment used in steroid-refractory ulcerative colitis. <sep>', 'most adverse reactions associated with ifn-beta-1a were influenza-like symptoms or injection site reactions and were mild or moderate in severity. <sep>', 'the higher pegifn dose was associated with a significant decrease in levels of c reactive protein p=0.003 day 0 v 85). <sep>'], 'population': ['left-sided ulcerative colitis <sep> thirteen patients in the <sep> sixteen ulcerative colitis patients <sep>', 'steroid-refractory ulcerative colitis <sep> outpatients with active steroid-refractory ulcerative colitis <sep>', 'ulcerative colitis <sep> patients n=18 with moderately active ulcerative colitis <sep> 17 patients are included in this report 10 patients in the ifn-beta-1a group and seven patients in the placebo group <sep>', 'patients with ulcerative colitis <sep> sixty patients with a clinical activity score cai of 6 <sep> active ulcerative colitis <sep> patients with active ulcerative colitis <sep> patients receiving 5-aminosalicylates steroids and/or azathioprine in stable dosages were included <sep>'], 'interventions': ['subcutaneous interferon-alpha-2a ifn-alpha-2a injections <sep> systemic interferon-alpha-2a and prednisolone enemas <sep> prednisolone/ml <sep> prednisolone enemas <sep> prednisolone <sep> ifn-alpha-2a <sep>', 'interferon-beta-1a <sep> 3 miu rifn-beta-1a <sep> placebo <sep> recombinant interferon-beta-1a rifn-beta-1a <sep>', 'ifn-beta-1a or placebo <sep> placebo <sep> interferon beta-1a <sep> interferon ifn)-beta <sep>', 'placebo <sep> interferon alpha ifn-alpha <sep> pegylated interferon alpha <sep> pegifn 0.5 microg/kg n=19 or pegifn 1.0 microg/kg body weight n=21 once weekly pegintron schering-plough usa <sep> pegylated interferon alpha pegifn <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",the existing literature does not support the efficacy of type i ifns for induction of remission in patients with uc. given concerns regarding the tolerability of ifn therapy we suggest that the results of two ongoing trials are evaluated for efficacy and safety prior to development or commencement of further randomised controlled trials of type i ifns in uc.
392,"{'outcomes': ['orocecal transit time <sep> vomiting and meteorism <sep> flatus <sep> week stool frequency <sep> complained abdominal pain <sep>', 'stool consistency and frequency <sep> side-effect <sep> chronic functional constipation <sep> number of stools <sep> compliance rates <sep>', 'abdominal pain and flatulence scores <sep> fecal incontinence frequency <sep> serious adverse effects <sep> defecation frequency <sep> consistency of stools <sep> incontinence frequency stool consistency presence of abdominal pain and flatulence necessity for step-up medication and dry weight of feces <sep>', 'vomiting and flatulence <sep> total protein albumin iron electrolytes and vitamins b9 folates a and d 25ohd3 <sep> clinical tolerance <sep> peg regarding stool consistency appetite fecaloma and use of additional laxatives <sep>', 'number of days on which normal stools <sep> number and frequency of the side-effects <sep>', 'laboratory tests and physical examinations <sep> median weekly frequency of bowel movement <sep> bristol score of stool consistency <sep> abdominal pain <sep> clinical complete remission rate of constipation <sep> bowel movement frequency stool consistency clinical complete remission rate of constipation and abdominal symptoms and the safety of forlax and lactulose <sep> stool consistency <sep>', 'abdominal faecal masses presence and consistency of rectal mass perineal soiling <sep> effective clearance of abdominal and rectal lumps <sep> faecal impaction <sep> efficacy and acceptability <sep> frequent bowel movements <sep> vomiting <sep>', 'frequency of incontinence episodes and resolution of abdominal pain <sep> frequency of bowel movements <sep> efficacy safety acceptance and 1-year outcomes <sep> resolution of constipation fecal incontinence and abdominal pain <sep> compliance rates <sep>', 'constipation <sep> stool consistency frequency of bowel movements fecal incontinence abdominal pain straining and acceptance of the drugs <sep>', 'mean number of complete defaecations <sep> adverse events <sep> safe and well tolerated <sep> straining on defaecation p<0.001 stool consistency p<0.001 and percentage of hard stools <sep> pain on defaecation <sep> total number of complete and incomplete defaecations per week pain on defaecation straining on defaecation faecal incontinence stool consistency global assessment of treatment adverse events and physical examination <sep> efficacy and safety <sep>', 'adverse events <sep> encopresis frequency meaningfully <sep> success rate <sep> clinical efficacy <sep>', 'peg  e <sep> taking peg  e <sep> total incidence rate of adverse events seen <sep>', 'side effects <sep> paediatric constipation and evaluate clinical efficacy/side effects <sep> defecation and encopresis frequency/week and successful treatment <sep> encopresis frequency <sep> abdominal pain straining and pain at defecation <sep> defecation frequency <sep>', 'total colonic transit time <sep>', 'abdominal pain and fecal incontinence <sep> bm <sep> stool consistency <sep> tolerated <sep> proportion of patients with a successful treatment response or=3 bowel movements bm <sep>', 'successful rectal disimpaction defecation and fecal incontinence frequencies occurrence of abdominal pain and watery stools ctts before and after disimpaction and behavior scores <sep> successful disimpaction <sep> abdominal pain <sep> fecal incontinence <sep> fecal incontinence and watery stools <sep> tolerated and colonic transit time ctt <sep> behavior scores <sep> defecation frequency <sep>'], 'punchline_text': ['a statistically significant increase of week stool frequency was found after treatment both with lactitol or lactulose p  0.001). <sep>', 'improvement in the number of stools per week was also significantly higher in the liquid paraffin group during the last 4 weeks of therapy p  0.05). <sep>', 'no difference was found between the groups after the treatment period concerning defecation frequency p  0.481 and fecal incontinence frequency p  0.084). <sep>', 'vitamin a values were above normal range in 56 and 41 of children at baseline versus 33 and 36 at day 84 in the peg and lactulose groups respectively. <sep>', 'there was a significant difference in favour of lactulose in the number of days on which normal stools were passed during the treatment weeks. <sep>', 'abdominal pain disappeared in 75 of patients in the forlax group but in only 57 in the lactulose group by week 2 of treatment p  0.05). <sep>', 'however they had some vomiting and were less compliant p  0.01 when compared to mineral oil patients. <sep>', 'at each follow-up visit significant improvement was seen in both groups with significant increases in the frequency of bowel movements decreases in the frequency of incontinence episodes and resolution of abdominal pain. <sep>', 'all variables analyzed improved for both groups with no statistically significant differences. <sep>', 'the mean number of complete defaecations per week was significantly higher for children on peg+e than on placebo 3.12 sd 2.05 v 1.45 sd 1.20 respectively p<0.001). <sep>', 'compared with the baseline defecation frequency week increased significantly and encopresis frequency meaningfully decreased in two groups during the period of the study. <sep>', 'the total incidence rate of adverse events seen was higher in the lactulose group 83 than in the peg  e group 64%). <sep>', 'however success was significantly higher in the peg group 56 compared with the lactulose group 29%). <sep>', 'peg 3350 significantly decreased the total colonic transit time compared to lactulose 47.6+/-2.7 vs 55.3+/-2.4 hours mean  <sep>', 'there was a significant increase in bm p  .001 and straining improvement p  .05 with the different peg3350 doses. <sep>', 'successful disimpaction was achieved with enemas 80 and peg 68 p  .28). <sep>'], 'population': ['fifty-one children affected by chronic idiopathic constipation 23 males 28 females ranging in age from 8 months to 16 years were enrolled in the study 42 completed the trial <sep> chronic idiopathic constipation in childhood <sep> chronic idiopathic constipation in children <sep>', 'children with constipation <sep> 40 children with chronic functional constipation <sep> 20 children <sep>', '147 children were eligible 12 children wished not to participate <sep> 97 children completed the study <sep> childhood constipation <sep> children <sep>', 'constipated children <sep> 96 ambulatory constipated children aged 6 months to 3 years treated daily with 4-8 g peg or 3.33 g-6.66 g lactulose <sep> 96 constipated children aged 6 months to 3 years confirms the long-term tolerance of peg 4000 in pediatrics and indicates a peg efficacy similar to or greater than that of lactulose <sep> pediatric patients <sep>', 'constipation in childhood <sep> twenty-one children under 15-years old with chronic constipation <sep>', '216 patients <sep> constipation in children over 8 years old <sep> childhood constipation <sep> children over 8 years old <sep> 216 children with constipation from 8-18 years old from 7 hospitals across china who were matched with a uniform entry criteria were enrolled in this study <sep>', 'thirty-six patients over 2 years of age <sep> children <sep>', 'thirty-nine children <sep> seventy-nine children with chronic constipation and fecal incontinence <sep> children with constipation and fecal incontinence <sep>', 'seventeen children <sep> chronic functional constipation in children <sep> thirty-eight children <sep>', 'six uk paediatric departments <sep> 51 children 29 girls 22 boys aged 24 months to 11 years with chronic constipation lasting  or 3 months defined as  or 2 complete bowel movements per week and one of the following pain on defaecation on 25 of days  or 25 of bowel movements with straining  or 25 of bowel movements with hard/lumpy stools <sep> 47 children <sep> chronic constipation in children <sep>', 'one hundred and sixty children of 2-12 years old with functional constipation <sep> pediatric functional constipation <sep> children with functional constipation in sari toba clinic during the period of 2008-2009 <sep> children with a history of functional constipation <sep>', 'children aged 2 to 11 years with a clinical diagnosis of faecal impaction <sep> faecal impaction in children <sep>', 'one hundred patients aged 6 months-15 years with paediatric constipation <sep> 91 patients 49 male completed the study <sep> childhood functional constipation <sep>', '37 children aged 2 to 16 years <sep> chronic constipation in children <sep>', '103 children mean 8.5 <sep> children with functional constipation <sep> 3.1 years were enrolled <sep> childhood constipation <sep>', 'ninety-five patients were eligible of whom 90 participated male n  60 mean age 7.5 <sep> childhood constipation <sep> children 4-16 years with functional constipation and rfi participated <sep>'], 'interventions': ['lactitol <sep> lactulose <sep>', 'two laxatives liquid paraffin and lactulose <sep> liquid paraffin and 20 with lactulose <sep> liquid paraffin and lactulose <sep> liquid paraffin <sep> liquid paraffin <sep>', 'fiber mixture and 70 to treatment with lactulose <sep> dietary fiber mixture versus lactulose <sep> polyethylene glycol <sep> fiber mixture or lactulose <sep>', 'polyethylene glycol peg 4000 laxative without additional salts <sep> polyethylene glycol 4000 versus lactulose <sep>', 'lactulose <sep> lactulose or senna <sep> lactulose and standardized senna <sep>', 'oral forlax <sep> forlax <sep> lactulose <sep> polyethylene glycol 4000 forlax <sep>', 'lavage solution <sep> mineral oil or flavoured lavage solution <sep> mineral oil and oral lavage solution <sep> mineral oil or pineapple-flavoured isotonic intestinal lavage solution containing polyethylene glycol-3350 colyte <sep> mineral oil <sep>', 'polyethylene glycol or milk of magnesia <sep> polyethylene glycol and milk of magnesia <sep> polyethylene glycol and 40 to receive milk of magnesia <sep> polyethylene glycol <sep> polyethylene glycol 3350 without electrolytes and milk of magnesia <sep> polyethylene glycol and milk of magnesia <sep> polyethylene glycol <sep>', 'magnesium hydroxide <sep> polyethylene glycol 4000 without electrolytes or magnesium hydroxide <sep> polyethylene glycol <sep> polyethylene glycol 4000 without electrolytes and magnesium hydroxide <sep>', 'peg+e <sep> placebo <sep> polyethylene glycol 3350 plus electrolytes <sep> polyethylene glycol 3350 plus electrolytes peg+e <sep>', 'peg <sep> polyethylene glycol 3350 versus liquid paraffin <sep> polyethylene glycol <sep> peg 3350 solution and liquid paraffin <sep> peg and paraffin <sep>', 'polyethelene glycol plus electrolytes pge  e <sep> peg  e versus lactulose <sep> peg  e <sep> lactulose <sep> peg  e and lactulose <sep> polyethylene glycol 3350 plus electrolytes peg  e movicol <sep>', 'lactulose <sep> peg 3350 transipeg versus lactulose <sep> polyethylene glycol peg 3350 <sep> peg 3350 transipeg polyethylene glycol with electrolytes with lactulose <sep>', 'polyethylene glycol 3350 and lactulose <sep> polyethylene glycol peg 3350 and lactulose <sep> lactulose <sep> polyethylene glycol <sep>', 'placebo <sep> polyethylene glycol peg)3350 <sep> peg3350 <sep>', 'enemas and polyethylene glycol peg <sep> enemas once daily or peg <sep> oral peg <sep> rectal fecal impaction treatment <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>']}",the pooled analyses suggest that peg preparations may be superior to placebo lactulose and milk of magnesia for childhood constipation. grade analyses indicated that the overall quality of the evidence for the primary outcome number of stools per week was low or very low due to sparse data inconsistency heterogeneity and high risk of bias in the studies in the pooled analyses. thus the results of the pooled analyses should be interpreted with caution because of quality and methodological concerns as well as clinical heterogeneity and short follow up. however peg appears safe and well tolerated. there is also evidence suggesting the efficacy of liquid paraffin mineral oil which was also well tolerated.there is no evidence to demonstrate the superiority of lactulose when compared to the other agents studied although there is a lack of placebo controlled studies. further research is needed to investigate the long term use of peg for childhood constipation as well as the role of liquid paraffin.
393,"{'outcomes': ['bprs cgi or nosie items or factors or in the reduction of overall psychopathology <sep> nosie scale manifest psychosis <sep> severity of illness on the cgi scale <sep> behavioral extrapyramidal and sedative <sep> bprs scores <sep>', 'anticholinergic effects excitement dizziness and faintness <sep>', 'improvement rating of moderate or marked <sep> dystonic reactions and akathisia <sep> global severity of illness rating of mild or better <sep> number and severity of adverse experiences <sep>', 'adverse reactions <sep>', 'clinical efficacy <sep>', 'incidence and severity of side effects <sep> discharge and termination rates <sep> bprs and cgi <sep>', 'side effects <sep> therapeutic efficacy and safety <sep> demonstrable anti-psychotic activity <sep>', 'drowsiness and extrapyramidal signs <sep>', 'clinical global impressions and brief psychiatric rating scales <sep> median time to tranquilization <sep> side effects <sep>', 'brief psychiatric rating scale bprs clinical global impression cgi <sep> diastolic blood pressure lying and standing <sep> bprs cgi scale nurses observation scale for in-patient evaluation nosie or side-effect records <sep>'], 'punchline_text': ['there were no significant treatment differences in bprs cgi or nosie items or factors or in the reduction of overall psychopathology. <sep>', 'side-effects were similar with the two drugs but anticholinergic effects excitement dizziness and faintness occurred rather more commonly with loxapine. <sep>', 'intramuscular loxapine was at least as effective as haloperidol in the initial management of hostile and aggressive schizophrenic patients. <sep>', 'adverse reactions were also less troublesome with loxapine. <sep>', 'the authors compared loxapine with chlorpromazine in inpatients with paranoid schizophrenia and found no difference in clinical efficacy. <sep>', 'the discharge and termination rates of the two groups were not significantly different and the incidence and severity of side effects most frequently extrapyramidal signs were similar in both groups. <sep>', 'both lox and tfp displayed essentially the same profile and incidence of side effects. <sep>', 'the principal side effects were drowsiness and extrapyramidal signs. <sep>', 'median time to tranquilization was significantly less with loxapine 60 minutes than with thiothixene 95 minutes during the oral phase there were no significant differences between the two treatment groups. <sep>', 'after 3-weeks treatment no significant differences were found between the two treatment groups according to the brief psychiatric rating scale bprs clinical global impression cgi <sep>'], 'population': ['chronic schizophrenia <sep> 50 hospitalized chronic schizophrenic patients <sep>', '57 acute and chronic schizophrenic patients <sep> acute and chronic schizophrenic patients <sep>', 'hostile and aggressive schizophrenic patients <sep> hostile and aggressive acutely schizophrenic patients <sep> 54 acutely psychotic schizophrenics <sep>', 'paranoid schizophrenia <sep> newly admitted paranoid schizophrenic patients n  68 <sep>', 'inpatients with paranoid schizophrenia <sep>', 'newly admitted schizophrenic patients <sep>', '49 chronic schizophrenic inpatients <sep> chronic schizophrenic patients <sep>', 'chronic schizophrenia <sep> chronic schizophrenic inpatients using 50 mg <sep>', 'acutely disturbed psychotic patients <sep>', 'psychotic patients <sep> 47 psychotic patients <sep> twenty-five patients were included in diagnostic group ii cases of chronic schizophrenia <sep> 22 patients were included in diagnostic group i cases of acute schizophrenia and psychogenic reactive psychoses <sep>'], 'interventions': ['loxapine succinate <sep> chlorpromazine <sep> loxapine succinate <sep>', 'loxapine and trifluoperazine <sep> trifluoperazine <sep>', 'parenteral loxapine and haloperidol <sep> haloperidol <sep> intramuscular loxapine <sep> loxapine <sep> loxapine or haloperidol <sep>', 'loxapine or chlorpromazine <sep> loxapine <sep> loxapine versus chlorpromazine <sep> loxapine <sep> chlorpromazine <sep>', 'loxapine <sep> loxapine with chlorpromazine <sep> chlorpromazine <sep>', 'loxapine succinate <sep> trifluoperazine <sep> loxapine succinate and trifluoperazine <sep> loxapine succinate <sep>', 'lox <sep> loxapine succinate lox and trifluoperazine hydrochloride <sep> loxitane--loxapine succinate and trifluoperazine hydrochloride <sep> loxapine <sep> trifluoperazine <sep>', 'lox <sep> placebo <sep> loxapine succinate <sep>', 'loxapine and thiothixene <sep> loxapine <sep> thiothixene with loxapine <sep>', 'loxapine <sep> perphenazine <sep> loxapine versus perphenazine <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>']}",loxapine is an antipsychotic which is not clearly distinct from typical or atypical drugs in terms of its effects on global or mental state. loxapines profile of adverse effects is similar to that of the older generation of antipsychotic drugs.
394,"{'outcomes': ['pain-free walking time <sep> pain-free walking distance and community-based physical activity <sep> maximal walking time <sep> ambulatory ability <sep> walking performance <sep> cardiovascular events <sep> change in treadmill exercise time and patient-reported measures of physical activity and quality of life based on questionnaires <sep> 2 quality of life instruments the walking impairment questionnaire <sep> walking distance <sep>', 'reduction of lower limb symptoms <sep> absolute claudication distance <sep> serious vascular aes <sep> walking distances <sep> tolerated <sep> adverse events ae <sep> initial claudication distance <sep> efficacy and tolerability <sep> ankle/arm pressure ratio <sep>', 'blood pressure red cell deformability fibrinogen and lipid levels <sep> blood viscosity <sep> mean arterial blood pressure <sep> fibrinogen levels <sep> walking distances and pressure indices <sep> blood lipids <sep> blood pressure blood lipids and platelet responsiveness <sep> viscosity <sep> red cell deformability <sep>', 'mean plasma total cholesterol <sep> mean plasma triglycerides <sep> progression of atherosclerosis <sep> plasma ldl cholesterol concentration <sep> plaque area <sep> edge irregularity index <sep> femoral atherosclerosis <sep> mean low density lipoprotein ldl cholesterol <sep>', 'arterial edge roughness or amount of aorto-femoral atherosclerosis <sep> lumen volume <sep> change in atheroma volume estimated as change in lumen volume of the femoral artery assessed by quantitative arteriography <sep> low-density lipoprotein cholesterol <sep> density lipoprotein2 cholesterol levels <sep> serum cholesterol <sep> exercise tests or ankle/arm blood pressure <sep> total high-density lipoprotein cholesterol <sep> femoral atherosclerosis <sep> roughness of the femoral artery <sep>', 'incidence of coronary heart disease and stroke <sep> beneficial effects on non-fatal events <sep> coronary heart disease and of stroke <sep> severity of intermittent claudication <sep>', ""hdl-cholesterol and positive instrumental changes <sep> blood triglycerides and fibrinogen <sep> rest flow values--and consequently also winsor's index <sep>"", 'fibrinogen <sep> tolerated <sep> maximum walking distance <sep> walking ability of peripheral arterial obstructive disease <sep> plasma fibrinogen <sep> pain-free walking distance <sep> doubling of the pain-free walking distance <sep>', 'ankle-brachial index <sep> walking performance and symptoms of intermittent claudication <sep> walking performance ankle-brachial pressure indexes and symptoms of claudication <sep> walking performance ankle-brachial indexes and questionnaire scores <sep> pain-free and total walking distance resting and postexercise ankle-brachial indexes and questionnaire scores <sep> walking performance <sep> mean pain-free walking distance <sep> total walking distance <sep> claudication symptoms <sep>', 'nonfatal myocardial infarction <sep> initial claudication distance icd <sep> absolute claudication distance acd <sep> changes in icd and acd <sep> 6 adverse events ae <sep> walking distances <sep> total cholesterol tc and low-density lipoprotein-cholesterol ldl-c <sep> tolerated <sep> quality of life domains <sep> ldl-c <sep> density lipoprotein-cholesterol hdl-c levels <sep> fibrinogen levels <sep>', 'vascular events <sep> absolute claudication distance <sep> ankle/arm pressure index <sep> frequency of patients reporting improvement of lower limb symptoms <sep> initial claudication distance <sep> mild adverse events <sep> claudication distance values <sep> total of 10 serious adverse events <sep>'], 'punchline_text': ['a physical activity questionnaire demonstrated improvement in ambulatory ability for the 10 and 80-mg groups p=0.011 whereas 2 quality of life instruments the walking impairment questionnaire and short form 36 questionnaire did not show significant change. <sep>', 'policosanol increased significantly p  0.01 the initial claudication distance from 132.5+/-13.5 m baseline to 205.7+/-36.3 m after therapy and the absolute claudication distance p<0.0001 from 229.5+/-22.0 m to 365.4+/-46.9 m meanwhile both variables remained unchanged in the placebo group p<0.05). <sep>', 'no significant changes in walking distances and pressure indices during rest and after exercise occurred despite a significant increase in red cell deformability in the fish oil group. <sep>', 'the mean increase in plaque area mm2/segment/year in the treatment group was only one third of that in the usual-care group. <sep>', 'in the control group lumen volume increased p  0.001 and roughness of the femoral artery decreased p  0.05).(abstract truncated at 250 words <sep>', 'there were 150 and 160 events in the active and placebo groups respectively relative risk 0.96 95 confidence interval 0.76 to 1.21). <sep>', ""compared with the fifteen control patients treated with placebo the fifteen patients treated with sulodexide showed a significant decrease in blood triglycerides and fibrinogen as well as a significantly increased hdl-cholesterol and positive instrumental changes at the end of treatment peak and rest flow values--and consequently also winsor's index--were significantly increased only in patients treated with sulodexide. <sep>"", 'sulodexide improved the walking ability of peripheral arterial obstructive disease patients to a significantly greater extent than placebo with a concurrent significant decrease in fibrinogen. <sep>', 'high-dose short-term therapy with simvastatin may improve walking performance ankle-brachial pressure indexes and symptoms of claudication in hypercholesterolemic patients with peripheral vascular disease. <sep>', 'policosanol significantly p  0.001 lowered total cholesterol tc and low-density lipoprotein-cholesterol ldl-c by 17.5 and 31.0 respectively and meanwhile increased p  0.01 high-density lipoprotein-cholesterol hdl-c levels by 31.5%. <sep>', 'after 6 months of therapy policosanol significantly increased p  0.01 the initial claudication distance from 125.9  <sep>'], 'population': ['patients with atherosclerosis including those with peripheral arterial disease <sep> 354 persons with claudication attributable to peripheral arterial disease <sep> patients with peripheral arterial disease <sep> patients with intermittent claudication <sep>', '62 patients <sep> patients with intermittent claudication <sep>', 'patients with stable claudication <sep> 32 patients with stable claudication <sep> patients with claudication <sep>', 'hyperlipidaemic patients with stable intermittent claudication <sep> 24 patients <sep>', 'seventeen percent had intermittent claudication and 24 had angina pectoris <sep> twenty-nine patients were excluded because of inadequate primary end point measurements <sep> the mean age of the remaining 274 subjects 158 were men was 55 years <sep> three hundred three patients with visible atherosclerosis <sep> hypercholesterolemic persons with probucol for 3 years affected femoral atherosclerosis <sep>', '85 general practices and nine hospital vascular clinics <sep> 1568 men mean age 68.2 years range 35 to 92 at recruitment <sep> 785 men <sep> men with lower extremity arterial disease <sep> older men <sep>', 'thirty patients suffering from peripheral vascular disease stage-ii according to fontaine <sep>', '286 patients with leriche-fontaine stage ii peripheral arterial obstructive disease <sep> patients with type ii diabetes <sep> patients with peripheral arterial obstructive disease require treatment to prevent major cardiovascular events and to relieve intermittent claudication <sep> peripheral arterial obstructive disease patients <sep>', 'hypercholesterolemic patients with peripheral vascular disease <sep> eighty-six patients with peripheral arterial disease fontaine stage ii intermittent claudication and total cholesterol levels <sep>', 'twenty-eight patients who met study entry criteria <sep> patients with moderately severe intermittent claudication <sep> patients with intermittent claudication <sep>', 'intermittent claudication <sep> patients with moderately severe intermittent claudication <sep> fifty-six patients who met study entry criteria <sep> patients with intermittent claudication <sep>'], 'interventions': ['placebo <sep> atorvastatin <sep> cholesterol modification <sep> atorvastatin <sep> placebo atorvastatin <sep>', 'policosanol <sep> treadmill constant speed <sep> placebo <sep> policosanol <sep>', 'six capsules of fish oil 1.8 g eicosapentaenoic acid and 1.2 g docosahexaenoic acid versus six capsules of corn oil 3 g linoleic acid <sep> fish oil supplementation <sep>', 'hyperlipidaemia <sep> biplanar arteriography <sep> plasma lipid reduction <sep> dietary advice and cholestyramine nicotinic acid or clofibrate depending on their lipoprotein phenotype <sep>', 'placebo <sep> probucol <sep> diet and cholestyramine <sep>', 'bezafibrate <sep> bezafibrate <sep> placebo <sep>', 'glycosaminoglycans <sep> placebo <sep> sulodexide <sep> high-dose glycosaminoglycan gag sulodexide <sep>', 'sulodexide <sep> sulodexide <sep> placebo <sep> sulodexide a glycosaminoglycan containing fast moving heparin and dermatan sulphate <sep>', 'placebo <sep> simvastatin <sep>', 'treadmill constant speed <sep> lovastatin <sep> lovastatin <sep> policosanol <sep> policosanol and lovastatin <sep> policosanol <sep> policosanol 10 mg or lovastatin <sep>', 'placebo <sep> policosanol <sep> policosanol therapy <sep> policosanol <sep> placebo or policosanol <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with pad. it may also improve local symptoms. until further evidence on the relative effectiveness of different lipid-lowering agents is available use of a statin in people with pad and a blood cholesterol level  3.5 mmol/litre is most indicated.
395,"{'outcomes': ['overall specificity <sep> smear status and culture time-to-positivity <sep> overall xpert mtb/rif <sep> rifampicin resistance <sep> reduced sensitivity <sep> negative predictive value <sep> rapid tb case detection rate <sep>', 'sensitivity of the mtb/rif ruo assay <sep> is6110 ldt sensitivities <sep>', 'bactec 460tb 12b bd diagnostic usa lwenstein-jensen lj culture and direct microscopy of smears stained with ziehl <sep> sensitivity specificity positive and negative predictive values of xpert mtb/rif test <sep>', 'xpert mtb/rif assay <sep>', 'sensitivity and specificity of mtbdr for detection of isoniazid resistance <sep> mtbdr xpert and liquid culture <sep> mycobacteria or mycobacterial dna <sep> direct fluorescence microscopy genotype mtbdrplus assay mtbdr xpert mtb/rif assay xpert and liquid mycobacterial culture <sep>', 'immediate identification of rifampicin rif resistance <sep> hiv prevalence <sep> sensitivity of the xpert mtb/rif test <sep>', 'mtb/rif test sensitivity <sep> median time to detection of tuberculosis <sep> mtb/rif test sensitivity for rifampicin resistance <sep> median time to detection of resistance <sep> indeterminate rate of mtb/rif testing <sep> unlike microscopy mtb/rif test sensitivity <sep>', 'rifampin resistance <sep> sensitivity specificity and positive and negative predictive values <sep>', 'sensitivity and specificity of pcr <sep>', 'rapid diagnosis of tuberculosis and detection of rifampin rif resistance <sep>'], 'punchline_text': ['in patients infected with hiv compared with patients uninfected with hiv xpert mtb/rif showed a trend to reduced sensitivity p=0.09 and significantly reduced negative predictive value p=0.01). <sep>', 'both molecular assays are suitable for the detection of m. tuberculosis isolates in smear-positive pulmonary and extrapulmonary specimens while the sensitivity of the detection of m. tuberculosis isolates in smear-negative specimens was variable. <sep>', 'high consistency was detected between the results of bactec 460tb and xpert mtb/rif when bactec 460tb was considered as the gold standard method r 0.943 p 0.000). <sep>', 'xpert mtb/rif assay achieved 88.4 95%ci  78.4 to 94.9 sensitivity among patients with a positive culture and 99 95%ci  94.7 to 100.0 specificity in patients who had no tb. <sep>', 'sensitivity and specificity of mtbdr for detection of isoniazid resistance were 83.3 and 100 respectively. <sep>', 'the xpert mtb/rif test has superior performance for rapid diagnosis of mycobacterium tuberculosis over existing afb smear microscopy and other molecular methodologies in an hiv and tb-endemic region. <sep>', 'median time to detection of tuberculosis for the mtb/rif test was 0 days iqr 0-1 compared with 1 day 0-1 for microscopy 30 days 23-43 for solid culture and 16 days 13-21 for liquid culture. <sep>', 'the genexpert assay was highly effective for tuberculosis diagnosis and identification of rifampin-resistant strains in smear-negative samples. <sep>', 'the sensitivity and specificity of pcr were respectively 100 and 100 and 85.7 and 97.3 for respiratory and non-respiratory samples. <sep>', 'the genexpert mtb/rif assay is a novel integrated diagnostic device for the diagnosis of tuberculosis and rapid detection of rif resistance in clinical specimens. <sep>'], 'population': ['patients infected with hiv especially those with advanced immunosuppression warrants further study <sep> 496 south african patients with suspected tb <sep>', '112 specimens from 90 patients including 89 pulmonary specimens and 23 extrapulmonary specimens <sep>', 'a total of 85 clinical specimens 50 sputum 25 bronchoalveolar lavage five thorasynthesis fluid and five urine samples obtained from tuberculosis-suspected patients were included to the study <sep>', 'patients with active tb <sep> 172 hiv-infected patients 58.9 of all participants <sep> 292 consecutively enrolled adults from mbeya tanzania with suspected tb were subject to analysis by the xpert mtb/rif assay <sep>', '140 consecutive pulmonary tuberculosis patients <sep>', 'consecutive adults with suspected tb attending a primary health care clinic in johannesburg south africa were prospectively enrolled and evaluated for tb according to the guidelines of the national tb control programme including assessment for smear-negative tb by chest x-ray clinical evaluation and hiv testing <sep>', 'adults 18 years with suspected tuberculosis or multidrug-resistant tuberculosis consecutively presenting with cough lasting at least 2 weeks to urban health centres in south africa peru and india drug-resistance screening facilities in azerbaijan and the philippines and an emergency room in uganda <sep> we enrolled 6648 participants between aug 11 2009 and june 26 2010 <sep>', 'patients with substantial clinical indications of tuberculosis and smear-negative microscopy results <sep>', '132 patients suspected of tuberculosis tb <sep>', 'two hundred fifty-three pulmonary and 176 extrapulmonary specimens obtained from 429 patients were included in the study <sep> 319 patients without tuberculosis studied <sep> one hundred ten 89 culture positive and 21 culture negative for m. tuberculosis of the 429 patients were considered to have tuberculosis <sep> pulmonary and extrapulmonary specimens <sep>'], 'interventions': ['xpert mtb/rif assay <sep> rifampicin <sep>', 'xpert mtb/rif ruo assay and is6110 real-time pcr <sep>', 'xpert mtb/rif <sep>', 'xpert mtb/rif assay <sep>', 'mtbdr and xpert <sep>', 'xpert mtb/rif with other nucleic acid technologies <sep>', 'mtb/rif <sep> xpert mtb/rif test <sep>', 'cepheid genexpert mtb/rif assay <sep>', 'new commercial real-time polymerase chain reaction pcr assay xpert mtb/rif <sep>', 'genexpert mtb/rif assay <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",this review shows that xpert used as an initial diagnostic test for tb detection and rifampicin resistance detection in patients suspected of having tb mdr-tb or hiv-associated tb is sensitive and specific. xpert may also be valuable as an add-on test following microscopy for patients who have previously been found to be smear-negative. an xpert result that is positive for rifampicin resistance should be carefully interpreted and take into consideration the risk of mdr-tb in a given patient and the expected prevalence of mdr-tb in a given setting. studies in this review mainly assessed sensitivity and specificity of the test when used in reference laboratories in research investigations. most studies were performed in high tb burden countries. ongoing use of xpert in high tb burden countries will contribute to the evidence base on the diagnostic accuracy and clinical impact of xpert in routine programmatic and peripheral health care settings including settings where the test is performed at the point of care.
396,"{'outcomes': ['oxygen tension <sep> blood gas pressures <sep> mean proportionate increase in fev <sep> pulse rate of 8 beats per minute and 2 beats per minute <sep>', 'oxygen to maintain oxygen saturation <sep> recovery time <sep> recovery time no longer requiring inhaled salbutamol and persistent moderate to severe asthma <sep>', 'production of side-effects <sep>', 'pao2 <sep> pulse rate and blood pressure <sep> peak expiratory flow rate <sep> mean pao2 <sep>', 'relative tachycardia <sep> rate of recovery <sep>', 'beta agonist-induced hypokalemia <sep> mean increase in pef <sep> pa(co2 values <sep>', 'peak expiratory flow rate <sep> cardiovascular side effects <sep> relief of pulsus paradoxus <sep> severe acute asthma <sep> heart rate <sep>', 'side effects i.e. tachycardia blood pressure changes and tremor <sep> simple clinical score the heart and respiratory rates the peak expiratory flow pef and the blood gases <sep>', 'pef <sep> peak expiratory flow <sep> systemic side-effects <sep> plasma theophylline concentration <sep>'], 'punchline_text': ['differences in results did not reach conventional levels of significance and no serious side effects were noted. <sep>', 'the intravenous salbutamol group were ready for discharge from the emergency department 9.7 h earlier than the control group. <sep>', 'there was no difference in the production of side-effects. <sep>', 'pao2 initially was 7.55 kpa in the intravenous group and rose by 1.4 after 60 minutes p less than .02 and by 1.33 after 120 minutes p less than .01). <sep>', 'hydrocortisone was given after 2 hours but did not appear to affect the rate of recovery. <sep>', '66 l/min p  0.01 as well as the decrease in pa(co2 values 10 <sep>', 'salbutamol given intravenously produced a mean increase in heart rate of over 20 beats/min five minutes after treatment compared with the relief of tachycardia that occurred after administration by ippb. <sep>', 'age severity and maintenance therapy of asthma and severity of the acute episode were not significantly different in both groups. <sep>', 'there was a significantly larger increase in peak expiratory flow after the first inhaled dose in the group that received inhalation treatment than in the i.v. <sep>'], 'population': ['acute asthma <sep> 23 patients with acute exacerbations of asthma <sep>', 'children who did not improve were eligible to enter phase one of the study <sep> acutely sick child with asthma <sep> acute asthma in children <sep> children who presented to the emergency department of westmead hospital sydney australia with asthma were assessed with a clinical assessment scale and those with severe acute asthma <sep> acute severe asthma in children <sep> children with acute severe asthma <sep>', 'patients with acute severe asthma <sep> acute severe asthma <sep>', 'twenty-three patients with acute severe asthma <sep> patients with acute severe asthma <sep>', 'severe acute asthma in childhood <sep>', 'hypercapnic acute asthma <sep> 47 patients admitted to hospital with severe acute asthma defined as a peak expiratory flow pef below 150 l/min and hypercapnia pa(co2  or  40 mm hg <sep>', 'life-threatening asthma <sep> 22 episodes of life-threatening asthma in 19 patients to compare <sep>', '20 children age range 0.8-14.7 years with acute severe asthma <sep> children with acute severe asthma <sep> severe asthma attacks in childhood <sep> 10 children reproterol-group received <sep> 10 children control-group received <sep>', '176 adult patients 53 men with severe acute asthma peak expiratory flow pef 15-50 of predicted values <sep> severe acute asthma <sep>'], 'interventions': ['salbutamol <sep> salbutamol and aminophylline <sep> salbutamol 100mug <sep> aminophylline <sep> salbutamol <sep>', 'nebulised salbutamol <sep> salbutamol or saline <sep> hydrocortisone <sep> intravenous salbutamol <sep> saline <sep> salbutamol <sep>', 'inhaled and intravenous terbutaline <sep> terbutaline <sep>', 'intravenous terbutaline two times at an hour interval 6 micrograms/kg or inhaled terbutaline <sep> terbutaline <sep> nebulized terbutaline <sep>', 'aminophylline with salbutamol <sep> hydrocortisone <sep> salbutamol <sep> iv salbutamol with iv aminophylline <sep>', 'nebulized versus intravenous albuterol <sep> hydrocortisone succinate <sep> neb <sep> nebulized 5 mg x 2 and intravenous 0.5 mg albuterol salbutamol <sep>', '5 solution administered by intermittent positive-pressure breathing ippb <sep> intravenous salbutamol <sep> salbutamol <sep> salbutamol given intravenously and by intermittent positive-pressure breathing <sep> salbutamol <sep>', 'prednisolone adequate fluids intake and oxygen insufflation <sep> salbutamol inhalation <sep> reproterol a beta-2-mimetic agent <sep> reproterol infusion <sep> reproterol infusion 0.2-2.0 micrograms/kg/min in saline and inhaled saline only <sep> theophylline <sep>', 'salbutamol combined with theophylline <sep> inhaled salbutamol <sep> salbutamol.(abstract <sep> theophylline <sep> salbutamol <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is no evidence to support the use of iv beta2-agonists in patients with severe acute asthma. these drugs should be given by inhalation. no subgroups were identified in which the iv route should be considered.
397,"{'outcomes': ['remission of depression <sep> remission rates <sep> depression anxiety hopelessness stress and quality of life <sep> 17-item hamilton rating scale for depression <sep> covariate-adjusted hamilton scores <sep>', 'severe cardiovascular adverse events <sep> cgi-i and ham-d measures <sep> ham-d score of at least 18 and history of 2 or more prior episodes of mdd <sep> major depressive disorder mdd <sep> ventricular premature complex vpc <sep> qtc interval <sep> cgi-i responder rates for sertraline <sep> left ventricular ejection fraction lvef secondary measures included surrogate cardiac measures and cardiovascular adverse events as well as scores on the ham-d scale and clinical global impression improvement scale cgi-i <sep> safety and efficacy <sep> mean sd lvef <sep>', '12-week ham-d scores <sep> bdi-ii scores <sep> 24-item ham-d administered blindly during centralized telephone interviews <sep> remission rates <sep> mean ham-d response <sep> depressive symptoms <sep> mean ham-d difference favoring clinical management <sep> baseline 24-item hamilton depression rating scale ham-d scores of 20 or higher <sep> self-reported beck depression inventory ii bdi-ii score <sep>', 'infection depression and immunity <sep> hospital fevers and infectious illness <sep> depressive symptoms inflammatory biomarkers and post-cabg infections <sep> depressive symptoms <sep> beck depression inventory 2 natural killer cell cytotoxicity nkcc measured by 51cr-release assay 3 infectious illness episodes measured by the modified health review 4 interleukin il)-6 and c reactive protein crp <sep> postoperative infectious illnesses <sep> il-6 <sep>', 'depressive symptomatology on the 17-item hamilton-depression rating scale ham-d and secondary outcomes the beck depression inventory bdi and depression subscale of the symptom check list 90 items dscl-90 as well as the clinical global impression cgi scale <sep> antidepressant efficacy <sep> ham-d bdi and cgi <sep> bdi dscl-90 and cgi scale <sep>', 'efficacy cardiovascular effects and safety <sep> heart rate <sep> blood pressure or conduction intervals <sep> rate of serious adverse cardiac events <sep> hamilton rating scale for depression <sep> adverse cardiac events <sep> heart rate variability <sep> cardiovascular safety heart rate and rhythm supine and standing systolic and diastolic blood pressures electrocardiogram conduction intervals indexes of heart rate variability and rate of adverse events <sep> heart rate or rhythm or indexes of heart rate variability <sep>', ""hads and the workplace social adjustment scale wsas <sep> depression symptoms <sep> patient's emotional and functional outcomes <sep> hospital and anxiety depression scale hads <sep>"", 'beck depression inventory scores <sep> psychosocial outcomes <sep> death or recurrent mi <sep> increase event-free survival <sep> mean sd change in hrsd score <sep> change in hrsd for depression or essi scores for lpss <sep> 17-item hamilton rating scale for depression hrsd lpss <sep> mortality and recurrent infarction <sep> survival <sep> mean sd change in essi score <sep> event-free survival <sep> depression and social isolation <sep>', 'recovery rate of cardiac autonomic function <sep> rate of recovery of hrv <sep> rate of recovery of sdnn <sep> rapid rate of recovery <sep> sd of 24-hour n-n intervals sdnn <sep> depression <sep>', 'response rate <sep> hamd-17 scores <sep> safety of fluoxetine cardiac function <sep> cardiac function <sep> efficacy and safety <sep> depression and hostility <sep> hostility <sep> hostility scores <sep> emotional distress <sep> 17-item hamilton depression rating scale hamd-17 and the hostility scale of the 90-item symptom check list scl-90 <sep> antidepressive efficacy <sep> efficacy and safety <sep>'], 'punchline_text': ['cognitive behavior therapy was superior to usual care at most points on secondary measures of depression anxiety hopelessness stress and quality of life. <sep>', 'in the latter 2 groups both cgi-i and ham-d measures were significantly better in those assigned to sertraline. <sep>', 'mean ham-d response 52.8 vs 40.1 p  .03 and remission rates 35.9 vs 22.5 p  .01 and the reduction in bdi-ii scores difference 3.6 points 98.3 ci 0.58-6.64 p  .005 effect size  0.33 also favored citalopram. <sep>', 'clinically depressed post-cabg women exhibited decreased nkcc and a higher incidence of in-hospital fevers and infectious illness in the first 6 months after cabg. <sep>', 'using mixed models analysis over the entire 24 weeks of treatment n  40 we did find a significant difference favoring mirtazapine to placebo on the ham-d bdi and cgi but on the dscl-90 this difference was not significant. <sep>', 'paroxetine had no sustained effects on heart rate or rhythm or indexes of heart rate variability whereas patients treated with nortriptyline had a sustained 11 increase in heart rate from a mean of 75 to 83 beats per minute p<.001 and a reduction in heart rate variability as measured by the sd of all normal r-r intervals over a 24-hour period from 112 to 96 p<.01). <sep>', 'findings confirmed that the intervention group had a 27 improvement in depression symptoms p=.05 27 in anxiety p=.02 and a 38 improvement in home limitations p=.04 compared with controls. <sep>', 'there were also no differences in survival between the psychosocial intervention and usual care arms in any of the 3 psychosocial risk groups depression lpss and depression and lpss patients). <sep>', 'there was a linear rate of increase in the sd of 24-hour n-n intervals sdnn in the sertraline-treated group that paralleled that of the nondepressed reference group. <sep>', 'also hostility scores at week 25 were significantly reduced among patients receiving fluoxetine p  .02). <sep>'], 'population': ['one hundred twenty-three patients who met the dsm-iv criteria for major or minor depression within 1 year after surgery <sep> outpatient research clinic at washington university school of medicine st louis missouri <sep>', '369 patients with mdd 64 male mean age 57.1 years mean 17-item hamilton depression ham-d score 19.6 mi 74 unstable angina 26 <sep> 40 outpatient cardiology centers and psychiatry clinics in the united states europe canada and australia <sep> patients with recent mi or unstable angina and without other life-threatening medical conditions <sep> patients hospitalized for acute myocardial infarction mi or unstable angina and free of other life-threatening medical conditions <sep> patients with unstable ischemic heart disease <sep> patients with acute mi or unstable angina <sep>', 'patients with coronary artery disease <sep> patients with cad and found no evidence of added value of ipt over clinical management <sep> all patients met diagnostic and statistical manual of mental disorders fourth edition criteria for diagnosis of major depression of 4 weeks duration or longer and had <sep> patients with coronary artery disease cad <sep> 284 patients with cad from 9 canadian academic centers <sep> patients with cad and major depression <sep>', 'fifteen clinically depressed women in the first month after cabg along with a comparison group of 37 non-depressed postcabg women <sep> two urban tertiary care centers <sep> inclusion criteria were  or  75 years old english-speaking undergoing first-time cabg available for 6 months offollow-up and without malignancy or autoimmune disorders <sep> depressed post-cabg women <sep> women after coronary artery bypass <sep>', 'patients with post-myocardial infarction mi depressive disorder <sep> post-myocardial infarction depressive disorder <sep> 2177 patients with mi were evaluated for depressive disorder during the first year post mi <sep> ninety-one patients who met the diagnostic and statistical manual of mental disorders 4th edition dsm-iv criteria for major or minor depressive disorder <sep>', '4 university centers <sep> eighty-one outpatients meeting diagnostic and statistical manual of mental disorders fourth edition criteria for major depressive disorder and with documented ischemic heart disease <sep> patients with heart disease need a safe and effective treatment for depression <sep> depressed patients with ischemic heart disease <sep>', 'mean age was 60 67 of the patients were male <sep> cardiac patients <sep> we enrolled 100 patients <sep>', 'patients enrolled within 28 days after mi.design setting and randomized clinical trial conducted from october 1996 to april 2001 in 2481 mi patients 1084 women 1397 men enrolled from 8 clinical centers <sep> coronary heart disease patients enrichd <sep>', 'twenty-seven patients completed the randomization <sep> patients with depression <sep> eleven stable post-mi nondepressed patients <sep> thirty-eight post-mi depressed patients <sep> depressed patients after acute myocardial infarction <sep>', 'patients with cardiovascular disease <sep> patients with major depression after first myocardial infarction <sep> fifty-four patients with major depression after mi <sep> patients with depression after their first mi <sep>'], 'interventions': ['cognitive behavior therapy <sep> cognitive behavior therapy or supportive stress management <sep> cognitive behavior therapy <sep> cognitive behavior therapy and supportive stress management <sep> coronary artery bypass surgery <sep> nonpharmacological interventions <sep>', 'sertraline <sep> mdd <sep> placebo <sep> sertraline <sep>', 'matching placebo <sep> placebo <sep> ipt plus clinical management n  142 or clinical management only <sep> citalopram and interpersonal psychotherapy <sep> citalopram <sep> citalopram or sertraline <sep> citalopram <sep> selective serotonin reuptake inhibitor citalopram and interpersonal psychotherapy ipt <sep>', 'cognitive behavioral therapy cbt <sep> cbt <sep> cognitive behavioral therapy <sep> coronary artery bypass graft cabg surgery <sep>', 'dual-acting antidepressant mirtazapine <sep> mirtazapine <sep> placebo <sep> mirtazapine <sep>', 'paroxetine and nortriptyline <sep> placebo <sep> paroxetine <sep> tricyclic antidepressant nortriptyline hydrochloride <sep> nortriptyline <sep> nortriptyline <sep> paroxetine <sep> specific serotonin reuptake inhibitor paroxetine <sep>', 'usual care <sep> telephone-based intervention <sep> telephone counseling sessions <sep>', 'depression and low perceived social support lpss <sep> social support instrument essi <sep> cognitive behavior therapy <sep> treating depression and low perceived social support <sep> lpss with cognitive behavior therapy cbt supplemented with a selective serotonin reuptake inhibitor ssri antidepressant <sep>', 'sertraline <sep> sertraline 50 mg per day or placebo <sep> placebo <sep>', 'placebo <sep> fluoxetine <sep> antidepressant fluoxetine <sep> fluoxetine or placebo <sep> echocardiography and electrocardiography <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",psychological interventions and pharmacological interventions with ssris may have a small yet clinically meaningful effect on depression outcomes in cad patients. no beneficial effects on the reduction of mortality rates and cardiac events were found. overall however the evidence is sparse due to the low number of high quality trials per outcome and the heterogeneity of examined populations and interventions.
398,"{'outcomes': ['positive expression of platelet cd62p and the serum tnf-alpha and il-6 <sep> levels of platelet cd62p and serum tnf-alpha and il-6 <sep> platelet level of cd62p and serum content of tnf-alpha and il-6 <sep> total curative effect <sep> positive expression rate of cd62p in platelet and content of tumor necrosis factor-alpha tnf-alpha and interleukin-6 il-6 <sep>'], 'punchline_text': ['the total curative effect in the treated group were significantly higher than that in the control group p  0.05). <sep>'], 'population': ['aci patients <sep> patients with acute cerebral infarction aci <sep> patients with acute cerebral infarction <sep> sixty-eight patients with aci <sep>'], 'interventions': ['erigeron injection el <sep> erigeron injection <sep>'], 'punchline_effect': [' sig increase <sep>']}",due to the generally low methodological quality and small sample size of the included trials in this systematic review we could not draw a firm conclusion.
399,"{'outcomes': ['local infection <sep> leucocytosis and temperature <sep>', 'infection rate with antibiotics <sep> rates of infection <sep> craniotomy infections <sep>', 'incidence of infections occurring <sep> incidence of shunt malfunction <sep> incidence of shunt infection or malfunction <sep> csf infection <sep>', 'postoperative wound sepsis <sep> wound sepsis <sep>', 'infection rates <sep> infection rate <sep>', 'time of development of cerebrospinal fluid infection <sep> cerebrospinal fluid infections <sep>', 'overall rate of shunt infection <sep> infection rate <sep>', 'infection rates <sep> classical infection parameters <sep>', 'postoperative ventriculoperitoneal shunt infections <sep> postoperative infection <sep> postoperative shunt infection <sep>', 'risk of shunt malfunction <sep> infection or overall malfunction rate <sep>', 'thirteen shunt infections <sep> average time to infection <sep>', 'efficacy <sep> ventricular catheter <sep> risk of catheter-related infections <sep> positive csf cultures <sep>', 'adverse reactions <sep> hypotension <sep>', 'infection rate <sep>'], 'punchline_text': ['no case of local infection was observed in either group and the percentage of patients with remote infections was the same in both groups. <sep>', 'the rates of infection in areas of the body other than the surgical wound were no different in the antibiotic-treated and nontreated groups. <sep>', 'we did not find that the perioperative use of sulfamethoxazole and trimethoprim reduced the incidence of shunt infection or malfunction. <sep>', ""twelve of the 205 patients treated with placebo developed postoperative wound sepsis and four of the 192 piperacillin-treated patients developed wound sepsis--a statistically significant difference p less than 0.05 fisher's exact test). <sep>"", 'the antibiotic protected against early infections nine of the 60 patients in group 2 against none of the patients in group 1 but not against late infections four of the 62 in group 1 compared with five of the 60 in group 2). <sep>', 'six patients in the control group developed cerebrospinal fluid infections 20 as compared with only a single patient in the oxacillin group 3.3 this difference was statistically significant p less than 0.05). <sep>', 'in the high risk subgroup infection rate was 14.3 with and 26.3 without cefotiam as opposed to 4.3 and 6.9 respectively in the normal risk subgroup. <sep>', 'fifty children of up to 14 years of age suffering from hydrocephalus of various etiologies were treated prophylactically and compared with a similar untreated group. <sep>', 'postoperative infection developed in 6 of the treatment group compared with 10 of the placebo group a difference that was not statistically significant although a clinical significance may have been masked by the small sample size. <sep>', 'the risk of shunt malfunction in the 2nd to 6th month after surgery was significantly greater in the placebo group 7 of 26 patients than in the methicillin-treated group 1 of 26 patients). <sep>', 'staphylococcus species accounted for the majority of shunt infections 83 all 10 control shunts were found to have a positive culture of staphylococci whereas none of the aiss had any staphylococci p  0.038). <sep>', 'positive csf cultures were seven times less frequent in patients with antibiotic-impregnated catheters compared with those in the control group 1.3 compared with 9.4 respectively p  0.002). <sep>', 'in the 35 cases that could be evaluated shunt-associated infections developed in three 17 of 18 patients who received vancomycin and in four 23 of the 17 placebo recipients. <sep>', 'among the patients receiving antibiotics there was an infection rate of 12 versus 19 among patients receiving placebo. <sep>'], 'population': ['neurosurgery <sep>', 'sixteen patients none of whom developed infections were excluded from final statistical analysis because they had inadvertently been entered into the study while failing to meet entry criteria <sep> clean neurosurgical operations <sep> 846 patients treated between october 1979 and june 1984 <sep>', 'ventriculoperitoneal shunt surgery <sep> after ventriculoperitoneal shunt surgery <sep> 120 patients who completed the study according to protocol 55 received <sep>', 'elective neurosurgery <sep> twenty cases were excluded from analysis because either an unforeseen second operation was performed or <sep> 417 patients undergoing clean elective neurosurgical operative procedures <sep>', 'between 1980 and 1983 122 patients undergoing shunting procedures <sep> 52 patients undergoing ventriculostomy only <sep> ventriculostomy or shunting operations <sep>', '60 hydrocephalic patients <sep> 60 hydrocephalic patients being shunted for the first time <sep> cerebrospinal fluid shunt procedures <sep>', '129 patients undergoing cerebrospinal fluid shunting <sep> cerebrospinal fluid shunting <sep> 129 patients <sep>', 'fifty children of up to 14 years of age suffering from hydrocephalus of various etiologies <sep> hydrocephalic patients <sep>', 'children with hydrocephalus <sep> sixty-three children who presented for elective vp shunt insertion between january 1982 and december 1985 and who did not have a history of shunt infections <sep>', '74 children <sep>', 'hydrocephalus <sep> one hundred ten patients were recruited 60 received <sep>', '306 patients enrolled in the study data from 288 were included in the final analysis <sep> 288 patients 139 were assigned to the control group and 149 to the treatment group <sep> all hospitalized patients 18 years or older who required placement of an evd catheter were eligible for inclusion in the study <sep> eighteen patients were excluded from analysis 14 because the <sep> six academic medical centers <sep>', '37 children undergoing csf shunt procedures in two different countries <sep>', 'cerebrospinal fluid shunt surgery <sep> sick children from march 1984 to october 1987 in which 243 patients undergoing 300 cerebrospinal fluid csf shunting procedures <sep>'], 'interventions': ['shunt placement and craniotomy <sep> perioperative cefamandole prophylaxis <sep> antibiotic prophylaxis <sep>', 'antibiotics <sep> perioperative antibiotic prophylaxis <sep> perioperative antibiotic prophylaxis <sep> cefazolin and gentamicin <sep>', 'placebo <sep> prophylactic sulfamethoxazole and trimethoprim <sep> sulfamethoxazole <sep> antibiotic prophylaxis <sep> trimethoprim <sep> sulfamethoxazole and trimethoprim <sep>', 'piperacillin <sep> placebo <sep> perioperative prophylactic antibiotics <sep> broad-spectrum antibiotic piperacillin or placebo <sep> antibiotic therapy <sep>', 'trimethoprim-sulfamethoxazole combination <sep> trimethoprim-sulfamethoxazole <sep> placebo <sep> trimethoprim-sulfamethoxazole prophylaxis <sep>', 'antibiotics <sep> oxacillin prophylaxis <sep> oxacillin <sep>', 'antibiotic prophylaxis <sep> cefotiam a cephalosporin <sep> cefotiam <sep>', 'antibiotic cefazedone <sep>', 'placebo <sep> ventriculoperitoneal vp shunt <sep> prophylactic cephalothin <sep> antibiotic prophylaxis <sep> cephalothin <sep> multivitamin placebo <sep> cephalothin prophylaxis <sep>', 'prophylactic methicillin <sep> placebo <sep> prophylactic methicillin <sep>', 'control shunt systems and 50 received ais systems <sep> ais system against an identical control shunt system <sep> antibiotic-impregnated shunt ais system <sep> antibiotic-impregnated shunt system <sep>', 'minocycline and rifampin <sep> evd with a catheter impregnated with minocycline and rifampin or a standard untreated catheter control group <sep> antimicrobial-impregnated external ventricular drain catheters <sep>', 'vancomycin hydrochloride <sep> placebo <sep> vancomycin <sep> placebo saline <sep>', 'rifampin/trimethoprim <sep> placebo <sep> rifampin/trimethoprim and placebo <sep> perioperative rifampin-trimethoprim <sep> perioperative rifampin/trimethoprim <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",we could demonstrate a benefit of systemic prophylactic antibiotics for the first 24 hours postoperatively to prevent shunt infection regardless of the patient's age and the type of internal shunt used. the benefit of its use after this period remains uncertain. however this data derives from the rate of shunt infection which is an intermediary outcome. future trials should evaluate the effectiveness of different regimens of systemic antibiotics rather than placebo and should include all-cause mortality shunt revision and adverse events as additional outcomes. evidence suggests that antibiotic-impregnated catheters reduce the incidence of shunt infection although more well-designed clinical trials testing the effect of antibiotic-impregnated shunts are required to confirm their net benefit.
400,"{'outcomes': ['rate of umbilical-artery metabolic acidosis <sep> operative delivery for fetal distress <sep> rates of umbilical-artery metabolic acidosis <sep>', 'proportion of babies who had an umbilical arterial ph <sep> rates of operative intervention and neonatal outcome <sep> fetal distress <sep> frequency of unsuspected acidaemia <sep> neonatal outcome <sep>', 'metabolic acidosis <sep> caesarean section rate <sep> neonatal acidemia umbilical artery ph 7.10 neonatal metabolic acidosis umbilical artery ph 7.05 and base excess 12 mmol/l and operative interventions caesarean section rate vacuum outlet vo rate and fbs rate <sep> fetal blood sampling fbs <sep> neonatal acidemia <sep> vo rate <sep> rate of neonatal acidemia <sep> incidence of fbs <sep>', 'metabolic acidosis <sep> operative deliveries for fetal distress <sep> low 5-minute apgar scores <sep>', 'incidence of metabolic acidosis <sep> apgar score neonatal admissions hypoxic-ischemic encephalopathy or operative deliveries <sep> metabolic acidosis in blood operative deliveries apgar scores neonatal admissions and hypoxic-ischemic encephalopathy <sep> metabolic acidosis defined as an umbilical cord artery ph <sep> number of operative deliveries low apgar scores neonatal admissions and newborns with hypoxic-ischemic encephalopathy <sep> fetal blood sampling rate <sep>'], 'punchline_text': ['the ctg+st group showed significantly lower rates of umbilical-artery metabolic acidosis than the cardiotocography group 15 of 2159 0.7 vs 31 of 2079 2 relative risk 0.47 95 ci 0.25-0.86 p=0.02 and of operative delivery for fetal distress 193 of 2519 8 vs 227 of 2447 9 0.83 <sep>', 'there was a trend towards fewer operative interventions for presumed fetal distress in the time-interval analysis plus cardiotocography group 63 13 vs 78 16 but this was not significant relative risk 0.80 95 ci 0.59-1.08 p=0.17). <sep>', 'intrapartum fetal monitoring by means of automatic stan did not improve the neonatal outcome or decrease the caesarean section rate. <sep>', 'there was a 46 reduction p  0.001 odds ratio 1.85 1.35-2.66 in operative deliveries for fetal distress and a trend to less metabolic acidosis p  0.09 odds ratio 0.38 0.13-1.07 and fewer low 5-minute apgar scores p  0.12 odds ratio 0.62 0.35-1.08 in the st waveform plus cardiotocogram arm. <sep>', 'the number of operative deliveries low apgar scores neonatal admissions and newborns with hypoxic-ischemic encephalopathy was comparable in both groups. <sep>'], 'population': ['4966 women with term fetuses in the cephalic presentation entered the trial during labour after a clinical decision had been made to apply a fetal scalp electrode for internal cardiotocography <sep> intrapartum fetal monitoring <sep>', '515 women <sep> five hospitals in the uk hong kong the netherlands and singapore <sep> 1038 women undergoing high-risk labours <sep>', 'labour ward in tertiary-level university hospital <sep> 1483 women in active labour with singleton term fetus in cephalic presentation <sep>', '2400 cases <sep> 2434 high-risk labors in a district general hospital in plymouth england <sep>', 'laboring women with a high-risk singleton pregnancy in cephalic presentation beyond 36 weeks of gestation <sep> 5,681 women to the two groups 2,832 index 2,849 control <sep>'], 'interventions': ['cardiotocography plus st analysis ctg+st group or cardiotocography only ctg group <sep> cardiotocography combined with automatic st-waveform analysis <sep> ctg <sep> ctg+st <sep> cardiotocography alone <sep> cardiotocography <sep>', 'cardiotocography only versus cardiotocography plus pr-interval analysis <sep> cardiotocography and 523 cardiotocography plus fetal ecg <sep> gold standard cardiotocography with cardiotocography plus time-interval analysis of the fetal electrocardiogram <sep> cardiotocography alone or cardiotocography plus fetal electrocardiography ecg <sep>', 'ctg <sep> intrapartum automated fetal electrocardiography and conventional cardiotocography <sep> stan or by ctg <sep>', 'st waveform plus cardiotocogram <sep> conventional cardiotocogram with those monitored by st waveform plus the cardiotocogram <sep> cardiotocogram <sep>', 'cardiotocography combined with st <sep> cardiotocography with st analysis index or cardiotocography only control <sep> cardiotocography <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>']}",these findings provide some modest support for the use of fetal st waveform analysis when a decision has been made to undertake continuous electronic fetal heart rate monitoring during labour. however the advantages need to be considered along with the disadvantages of needing to use an internal scalp electrode after membrane rupture for ecg waveform recordings.
401,"{'outcomes': ['persistent undetectable serum hcv-rna <sep> serum alanine aminotransferase <sep> serum hcv-rna measured by reverse transcription-polymerase chain reaction <sep> serum hcv-rna <sep>', 'biochemical and virological parameters <sep> normal alt levels and no hcv rna <sep> normal alt levels <sep> normal alt and no hcv rna <sep> normal serum alt activity <sep>', 'aminotransferase flare-ups <sep> rate of chronic evolution of acute hepatitis c <sep> duration of the acute phase of hepatitis <sep> chronicity rate <sep>', 'raised serum aminotransferase concentrations <sep> serum hepatitis c virus rna <sep> normal serum aminotransferase <sep>', 'persistent liver damage <sep> recurrence <sep>', 'severe hepatic lesions with lower histological activity <sep> serum alt levels <sep> biochemical histological and serological parameters <sep> severe side effects of interferon-alpha <sep>'], 'punchline_text': ['two 13 patients in the control group had persistent undetectable serum hcv-rna p  0.08). <sep>', 'thirty-nine percent had normal alt and no hcv rna compared with none of the controls p  0.035). <sep>', 'beta interferon at the suggested regimen is well tolerated but does not seem to significantly influence the natural course of acute hepatitis c. <sep>', ""4 patients in the treatment group who continued to have raised serum aminotransferase concentrations after a year's follow-up were given a second course of interferon. <sep>"", 'the effect of ifn therapy was 93.8 in the treated group and only 12.5 in the control group p  0.005). <sep>', 'anti-hepatitis c virus seroconversion occurred later and at a lower rate in the group of patients who received interferon-alpha. <sep>'], 'population': ['33 acute post-transfusion hepatitis c patients 16 patients received <sep> chinese patients with acute post-transfusion hepatitis c <sep> patients with acute post-transfusion hepatitis c <sep>', 'patients with acute transfusion-associated hepatitis c <sep> twenty-six patients 22 with hcv <sep> thirty-eight patients had hepatitis c virus infection and 7 had non-a non-b non-c hepatitis <sep> 45 consecutive patients with transfusion-associated hepatitis <sep>', '21 cases and was positive in 19 cases at baseline and in 15/17 chronic and 1/4 non chronic cases at the end of follow-up <sep> forty acute hepatitis c patients <sep> northern italy in 1991 <sep> acute type-c hepatitis patients <sep>', '25 patients 11 were treated for an average of 30 days with a mean of 52 megaunits of interferon and 14 acted as controls <sep>', 'patients with acute hepatitis c <sep> patients with acute hcv infection <sep> sixteen patients with acute hepatitis c having a duration of illness more than three months without recovery <sep>', '28 patients with acute posttransfusion hepatitis <sep> acute posttransfusion hepatitis c <sep>'], 'interventions': ['3 million units of subcutaneously injected recombinant interferon alpha-2b <sep> recombinant interferon alpha-2b <sep>', 'recombinant interferon-alpha <sep> interferon-alpha <sep> recombinant interferon-alpha 2b <sep>', 'natural beta interferon <sep> natural beta interferon <sep> beta-interferon <sep>', 'interferon <sep> natural beta interferon <sep>', 'interferon-a2b <sep> ifn therapy <sep> interferon ifn <sep> ifn <sep>', 'interferon-alpha <sep> recombinant interferon-alpha three times weekly for 12 wk or no treatment <sep> interferon-alpha <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",interferon alfa is effective in improving biochemical outcomes and achieving sustained virologic clearance in patients with transfusion-acquired acute hepatitis c. the effect on long-term clinical outcomes could not be assessed due to limitations in the current data.
402,"{'outcomes': ['analgesic efficacy <sep> side effects <sep> pain intensity differences pid <sep>', 'episiotomy pain <sep> uterine pain <sep>', 'greatest analgesic response <sep> pain intensity pain relief and side effects <sep> dizziness and drowsiness <sep>', 'pain intensity difference spid scores <sep> analgesic effects <sep> aspirin analgesia <sep> mean pain intensity scores began within 1 hr and had similar time-effect patterns <sep>', 'drowsiness <sep> stronger analgesia <sep> relative efficacy safety and time course of analgesia <sep> pain intensity pain relief and side effects <sep> highest summed analgesic ratings <sep>', 'pain intensity difference spid <sep> uterine cramp episiotomy or surgical pain <sep>', 'uterine cramp and episiotomy pain <sep> pain intensity differences and total pain relief <sep> adverse effects <sep>', 'analgesic response <sep> analgesic effects <sep> postpartum pain relief <sep>', 'side effects <sep> relative efficacy safety and time course of analgesia <sep> highest mean rating for summed pain intensity differences <sep> pain intensity pain relief and side effects <sep>'], 'punchline_text': ['side effects were not significant with any of the treatments. <sep>', 'paracetamol was significantly superior to placebo at the 5 level. <sep>', 'side effects were unremarkable except for dizziness and drowsiness after the 120-mg codeine dose. <sep>', 'there was no significant side effects. <sep>', 'highest summed analgesic ratings over placebo were induced by anirolac 100 mg p less than or equal to 0.001 and naproxen p less than or equal to 0.001 followed by anirolac 50 mg p less than or equal to 0.005). <sep>', 'in their ability to distinguish codeine from placebo patients with uterine cramp episiotomy or surgical pain did not appear to differ. <sep>', 'there were significant differences for sum of pain intensity differences and total pain relief between the active drugs and placebo but not between n and c. time to onset of analgesia favored n mean  0.65 min over c mean  0.74 min but the analgetic effect of n diminished more rapidly at this dose. <sep>', 'in patients with severe episiotomy pain aspirin-caffeine was more effective than 650 mg aspirin p less than 0.05 at the second and third hours. <sep>', 'ketorolac 10 mg gave the highest mean rating for summed pain intensity differences 13.6 p  0.0002 versus placebo followed by aspirin 11.9 p  0.012 ketorolac 5 mg 10.9 p  0.072 and placebo 8.6). <sep>'], 'population': ['postpartum uterine pain <sep> two separate trials involving 140 and 90 patients respectively with postpartum uterine pain in a single-dose <sep>', '75 patients were included in the trial whereas in a fixed sample study 90 patients <sep>', '159 hospitalized women with moderate or severe postpartum uterine cramps <sep> postpartum uterine pain <sep> patients with postpartum uterine pain <sep>', '100 patients with postpartum uterine pain in a single oral dose <sep> postpartum uterine pain <sep>', '120 hospitalized women with moderate or severe postpartum uterine pain <sep> postpartum uterine pain <sep>', '850 patients participated in the trial <sep> postpartum patients included women with episiotomy pain and with uterine cramping <sep>', 'postpartum pain <sep> one hundred twenty-one patients with postpartum pain caused by uterine cramp or episiotomy pain <sep>', 'patients with moderate to severe uterine or episiotomy pain <sep> women with severe uterine pain <sep> 140 women <sep>', '120 hospitalized women 4 groups of 30 with moderate or severe postpartum uterine pain treated with single oral doses of <sep> postpartum uterine pain <sep>'], 'interventions': ['placebo <sep> aspirin and codeine <sep> oral naproxen and its sodium salt <sep> naproxen sodium and aspirin <sep> naproxen sodium <sep> aspirin <sep> naproxen aspirin and codeine <sep> naproxen <sep>', 'paracetamol and placebo <sep> placebo <sep> paracetamol <sep>', 'flurbiprofen and aspirin <sep> placebo <sep> codeine <sep> aspirin <sep> flurbiprofen ansaid upjohn <sep> flurbiprofen 650 mg of aspirin 60 or 120 mg of codeine sulfate or placebo <sep> flurbiprofen <sep> flurbiprofen aspirin codeine and placebo <sep>', 'fendosal and aspirin <sep> aspirin and placebo <sep> aspirin <sep>', 'single oral doses of anirolac 50 or 100 mg naproxen sodium 550 mg or placebo <sep> anirolac vs. naproxen <sep> placebo <sep> naproxen <sep>', 'placebo <sep> codeine <sep> codeine from placebo <sep> fenoprofen and codeine analgesia <sep> codeine and placebo <sep> fenoprofen <sep>', 'codeine c <sep> oral nalbuphine <sep> placebo <sep> oral nalbuphine <sep>', 'aspirin and to placebo <sep> aspirin and 64 mg caffeine aspirin-caffeine <sep> aspirin <sep> aspirin-caffeine <sep> aspirin and aspirin-caffeine <sep>', 'placebo <sep> ketorolac 5 mg and 10 mg aspirin 650 mg or placebo <sep> ketorolac tromethamine <sep> ketorolac <sep> aspirin ketorolac <sep> aspirin <sep> ketorolac <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>']}",non-steroidal anti-inflammatory drugs nsaid including aspirin were better than placebo at relieving pain from uterine cramping/involution following vaginal birth. nsaids were better than paracetamol and paracetamol was not better than placebo though numbers of participants for these comparisons were small. data for opioids compared with nsaids and opioids compared with placebo were conflicting with some measures showing similar effect and others indicating nsaids were better than opioids and opioids were not better than placebo. there were insufficient data to make conclusions regarding the effectiveness of opioids at relieving pain from uterine cramping/involution. the median year of publication of included studies was 1981 therefore more research is needed to assess the effectiveness of current pharmacological and non-pharmacological analgesia at relieving pain from uterine cramping/involution following vaginal birth.
403,"{'outcomes': ['exercise tolerance disease-related measures and self-reported health status <sep> retention rate <sep> aerobic capacity 50-foot walking time depression anxiety and physical activity <sep> change scores for flexibility number of clinically active joints duration of morning stiffness or grip strength <sep>', 'swollen joints <sep> erythrocyte sedimentation rate tender joints or morning stiffness <sep> disease activity <sep>', 'activities of daily living and reduced joint pain and fatigue <sep> aerobic capacity exercise time and joint counts <sep> aerobic capacity <sep>', 'aerobic capacity joint mobility and muscle strength <sep> aerobic capacity muscle strength and joint mobility <sep> muscle strength and joint mobility in the high intensity exercise programme <sep> aerobic capacity <sep> deterioration of disease activity <sep> physical condition muscle strength joint mobility daily functioning haq and disease activity <sep>', 'emotional status and disease activity <sep> radiographic damage <sep> effectiveness and safety <sep> radiographic progression in large joints <sep> functional ability <sep> emotional status <sep> functional ability assessed by the mcmaster toronto arthritis mactar patient preference disability questionnaire and the health assessment questionnaire haq <sep> disease activity <sep> haq score <sep> median radiographic damage of the large joints <sep> mactar questionnaire score <sep>', 'plasma concentrations of interleukin-1 alpha interleukin-1 beta and interleukin-6 <sep> maximal o2 uptake <sep> resting levels of a number of immune parameters <sep> heart rate at stage 2 and rate of perceived exertion <sep> blood mononuclear cell subpopulations proliferative response or natural killer cell activity <sep>', 'disease activity <sep> morning stiffness a pain score number of swollen joints a health assessment score a functional score esr hb the cost of medicine and progression using x-rays of hands and feet <sep>'], 'punchline_text': ['the aquatics and walking exercise groups showed significant improvement over the control group in aerobic capacity 50-foot walking time depression anxiety and physical activity after the 12-week exercise program. <sep>', 'no significant changes were noticed in erythrocyte sedimentation rate tender joints or morning stiffness. <sep>', 'all exercise groups improved their aerobic capacity exercise time and joint counts. <sep>', 'intensive dynamic training is more effective in increasing aerobic capacity joint mobility and muscle strength than rom exercises and isometric training in rheumatoid arthritis patients with well controlled disease. <sep>', 'intensive exercise does not increase radiographic damage of the large joints except possibly in patients with considerable baseline damage of the large joints. <sep>', 'maximal o2 uptake increased significantly whereas heart rate at stage 2 and rate of perceived exertion decreased significantly in the training group compared with the controls. <sep>', 'the results showed no effect of training on the disease activity or on the progression of the disease. <sep>'], 'population': ['people who have rheumatoid arthritis or osteoarthritis <sep> 120 patients with rheumatoid arthritis or osteoarthritis volunteered to be subjects for this study of <sep> patients with rheumatoid arthritis and osteoarthritis <sep>', 'elderly rheumatoid arthritis patients <sep> elderly fragile patients with rheumatoid arthritis ra <sep> 24 patients who had been treated with low-dose steroids for 2 years <sep> elderly rheumatoid arthritis patients on steroid treatment <sep>', 'women with rheumatoid arthritis <sep> rheumatoid arthritis patients with severe limitations <sep> rheumatoid arthritis <sep>', 'rheumatoid arthritis patients with well controlled disease <sep> 100 consecutive rheumatoid arthritis patients on stable medication <sep>', 'patients with rheumatoid arthritis ra <sep> rheumatoid arthritis patients in training rapit with those of physical therapy termed usual care uc <sep> ra patients <sep> patients with rheumatoid arthritis <sep> three hundred nine ra patients <sep>', 'patients with rheumatoid arthritis <sep> 18 patients with rheumatoid arthritis and moderate disease activity <sep>', 'patients with rheumatoid arthritis <sep> 75 patients participating <sep> rheumatoid arthritis <sep>'], 'interventions': ['physical conditioning exercise <sep> exercise program of aerobic walking aerobic aquatics or nonaerobic range of motion controls <sep> conditioning exercise <sep> aerobic versus nonaerobic exercise <sep>', 'physical training <sep> steroid treatment tolerate physical training <sep> treatment group receiving training or to an untrained control group <sep>', '3 low intensity aerobic exercise protocols <sep> graded aerobic exercise training <sep>', 'isometric exercises <sep> intensive dynamic exercises <sep> rom exercises and isometric training <sep> intensive dynamic group exercises which included full weight bearing exercises and conditioning exercises on a stationary bicycle while the heart rate was maintained at 70-85 of the age predicted maximum heart rate 2 range of motion rom exercises and isometric exercises in a group 3 individual isometric and rom exercises and 4 home instructions for isometric and rom exercises <sep> intensive dynamic training <sep> high and low intensity training <sep>', 'intensive exercise program <sep> intensive exercise <sep> rapit program or uc <sep> intensity exercise program <sep>', 'bicycle training <sep> progressive bicycle training <sep>', 'longterm physical training <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",based on the evidence aerobic capacity training combined with muscle strength training is recommended as routine practice in patients with ra.
404,"{'outcomes': ['cumulative pregnancy rate <sep> pain symptoms <sep> pain symptoms <sep> side effects <sep> weight gain and acne <sep>', 'symptom score <sep> emotional balance <sep> sleep disturbances and anxiety-depression score <sep> anxiety-depression score <sep> paid working life <sep> quality of life <sep> pain pattern and quality of life <sep> anxiety-depression and sleep disturbances <sep> quality of life such as sleep disturbances and anxiety-depression <sep>', 'dysmenorrhea <sep> pelvic pain <sep> symptom scores <sep> efficacy and safety <sep>', 'pain <sep> natural history of endometriosis or prs <sep> endometriosis scores pregnancy rates prs and pain <sep>', 'side effects <sep> endometriosis scores <sep> mean total endometriosis scores <sep> efficacy and safety <sep>', 'painful symptoms of endometriosis <sep> pelvic pain <sep> mean lumbar bmd <sep> bleeding episodes <sep> visual analogue scale vas <sep> bone resorption <sep> safety and tolerability <sep> vas score <sep> adverse event profile laboratory parameters bone mineral density bmd bone markers and bleeding patterns <sep> hypoestrogenic effects <sep>', 'pain symptoms <sep> pelvic pain and dysmenorrhea <sep> breakthrough bleeding <sep> body weight increase <sep>', 'mild moderate or severe degrees of lower abdominal pain dysmenorrhoea and deep dyspareunia <sep> lack of efficacy pregnancy elevated hepatic function tests <sep> leg cramps <sep> hirsutism <sep> frequency <sep> weight <sep> severity of dysmenorrhoea <sep> total american fertility society scoring <sep>'], 'punchline_text': ['pain symptoms recurred during the follow-up in 57 of the gestrinone and 53 of the danazol group. <sep>', 'factors of importance for quality of life such as sleep disturbances and anxiety-depression improved significantly after treatment with nafarelin or medroxyprogesterone acetate. <sep>', 'twenty nine of 40 subjects 72.5 in the depot medroxyprogesterone acetate group were satisfied after 1 year of therapy compared with 23 of 40 57.5 in the oral contraceptive plus danazol group chi 2(1  <sep>', 'pain was reduced significantly during treatment with 60 mg dydrogesterone and this improvement still was evident at 12-month follow-up. <sep>', 'a total of 67 of patients reported side effects. <sep>', 'dienogest 2 mg/day orally demonstrated equivalent efficacy to depot la at standard dose in relieving the pain associated with endometriosis although offering advantages in safety and tolerability. <sep>', 'a significant improvement of both pelvic pain and dysmenorrhea was observed following each type of treatment p<0.001). <sep>', 'the results showed a significant reduction in the severity of dysmenorrhoea by the third month in the danazol group and at 6 months in both groups. <sep>'], 'population': ['endometriosis <sep> thirty-nine infertile patients with laparoscopic diagnosis of endometriosis <sep>', 'endometriosis <sep> women with endometriosis <sep> 30 women who participated all through the study and the 18 who dropped out <sep> 48 women with verified endometriosis the <sep>', 'women with endometriosis <sep> pelvic pain associated with endometriosis <sep> twenty nine of 40 subjects 72.5 in the <sep> eighty patients with endometriosis and moderate or severe pelvic pain <sep>', 'women with minimal to mild endometriosis <sep> sixty-two premenopausal women with complaints of pain n  12 and infertility with or without pain n  50 with minimal to mild endometriosis diagnosed at laparoscopy <sep> minimal to mild endometriosis <sep> thirty-nine women had a laparoscopy after treatment and 56 women <sep>', 'endometriosis <sep>', 'patients with confirmed endometriosis <sep> a total of 252 women <sep>', 'recurrent pelvic pain after conservative surgery for endometriosis <sep> women with endometriosis n=40 who showed recurrent dysmenorrhea and/or pelvic pain after conservative surgery and did not desire a pregnancy <sep>', '101 patients receiving gestrinone and 72.7 in 99 patients receiving <sep> an additional 22 patients including 10 from the gestrinone group and 12 from the <sep> 269 patients with confirmed endometriosis <sep> 15 patients from the gestrinone group including four patients with hirsutism and 17 patients from the danazol group including six patients with headache withdrew because of adverse symptoms <sep>'], 'interventions': ['danazol <sep> gestrinone 2.5 mg twice weekly 20 patients or danazol <sep> gestrinone versus danazol <sep> gestrinone <sep>', 'nafarelin or medroxyprogesterone acetate <sep>', 'cyclic monophasic oral contraceptive ethinyl estradiol 0.02 mg desogestrel 0.15 mg combined with oral danazol <sep> oral contraceptive plus danazol <sep> depot medroxyprogesterone acetate <sep> depot medroxyprogesterone acetate <sep> oral contraceptive combined with very-low-dose danazol <sep> intramuscular depot medroxyprogesterone acetate <sep>', 'placebo <sep> dydrogesterone with placebos <sep> luteal phase dydrogesterone duphaston <sep> dydrogesterone <sep> luteal phase dydrogesterone <sep>', 'oral gestrinone <sep> gestrinone <sep>', 'la <sep> depot la <sep> leuprolide acetate <sep> dienogest against leuprolide acetate la <sep>', 'progestogen only preparation containing desogestrel <sep> desogestrel <sep> oral contraceptive <sep> new progestin progestogen only pill desogestrel <sep> desogestrel progestogen <sep> combined oral contraceptive ethinyl estradiol 20 microg plus desogestrel 150 microg <sep>', 'danazol <sep> gestrinone <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",there is only limited evidence to support the use of progestagens and anti-progestagens for pain associated with endometriosis.
405,"{'outcomes': ['adverse events <sep> intracranial hypertension <sep> median survival <sep> csf leak <sep> survival benefit <sep> risk of death <sep>', '6-month survival <sep> adverse reactions <sep> median survival <sep>', 'median time from surgery to death <sep> survival times of patients after the operations and the application of an active drug or placebo <sep>', 'median survival <sep> survival proportions <sep> survival benefit <sep> survival <sep> survival advantage <sep>'], 'punchline_text': ['time to decline in kps and in 10/11 neuroperformance measures was statistically significantly prolonged in the bcnu wafer-treated group  p  0.05). <sep>', 'there were no clinically important adverse reactions related to the carmustine polymer either in the brain or systemically. <sep>', 'the median time from surgery to death was 58.1 weeks for the active treatment group versus 39.9 weeks for the placebo group p  0.012). <sep>', 'this survival advantage was maintained at 1 2 and 3 years and was statistically significant p  0.01 at 3 years. <sep>'], 'population': ['32 patients with newly diagnosed malignant glioma <sep> patients with newly diagnosed malignant glioma <sep> patients with recurrent glioblastoma multiforme <sep> two hundred forty patients <sep> patients with primary malignant glioma <sep>', 'recurrent gliomas <sep> 222 patients with recurrent malignant brain tumours requiring re-operation <sep>', 'departments of neurosurgery of the university hospitals of helsinki tampere and turku in finland and trondheim in norway <sep> 100 patients but had to be terminated prematurely because the drug that was being used had become unobtainable <sep> patients with high-grade gliomas <sep> high-grade gliomas <sep> 32 patients 16 in each treatment group enrolled between march 23 1992 and march 19 1993 <sep> 27 patients with grade iv tumors <sep>', 'primary malignant glioma patients beyond 12-18 months <sep> malignant glioma patients treated with <sep> 207 gbm patients <sep> 59 patients available for long-term follow-up 11 were alive at 56 months 9 had received bcnu wafers and 2 had received <sep>'], 'interventions': ['placebo <sep> bcnu <sep> bcnu or placebo <sep> external beam radiation postoperatively <sep> local chemotherapy with biodegradable carmustine bcnu <sep>', 'carmustine <sep> placebo <sep> placebo <sep> surgically implanted biodegradable polymer discs with or without 3.85 carmustine <sep> interstitial chemotherapy <sep> chemotherapy <sep>', 'placebo <sep> carmustine <sep> interstitial chemotherapy with carmustine-loaded polymers <sep> carmustine bischloroethyl-nitrosourea combined with a biodegradable polymer <sep>', 'adjuvant systemic chemotherapy <sep> placebo <sep> radiation therapy <sep> bcnu <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",carmustine impregnated wafers gliadel result in improved survival without an increased incidence of adverse events over placebo wafers when used for primary disease therapy. there is no evidence of benefit for any other outcome measures. in recurrent disease gliadel does not appear to confer any additional benefit.
406,"{'outcomes': ['plasma sulpiride levels and therapeutic response <sep>', '16-item brief psychiatric rating scale bprs <sep> total bprs scores <sep>', 'number of patients in remission <sep> adverse reactions <sep>', 'rate of side-effects and abnormal laboratory test results <sep> final global improvement rating <sep> emotional withdrawal and hallucinatory behavior <sep>', 'antipsychotic efficacy <sep> brief psychiatric rating scale bprs scale for the assessment of positive symptoms saps scale for the assessment of negative symptoms and hamilton rating scale for depression <sep> positive and negative psychotic symptoms <sep> baseline saps scores <sep>', 'side-effects <sep> motor retardation delusion hallucination or disturbance of self-consciousness social isolation or withdrawal and recreation or work <sep> time course of the total psychiatric rating scales prs <sep> total prs <sep>'], 'punchline_text': ['there was an association between plasma sulpiride levels and therapeutic response after four weeks treatment. <sep>', 'for patients suffering from chronic schizophrenia a statistically significant decline was observed in total bprs scores at 4 months compared with pretreatment scores in both sulpiride and perphenazine groups. <sep>', 'both timiperone and sulpiride increased the number of patients in remission and decreased the number of patients who relapsed compared with the placebo group. <sep>', 'regarding bprs items and compared to sulpiride bromperidol was particularly effective to relieve emotional withdrawal and hallucinatory behavior although the only significant between group difference was in favour of sulpiride for improvements of somatic concern. <sep>', 'the clozapine-sulpiride group exhibited substantially greater and significant improvements in positive and negative psychotic symptoms. <sep>', 'the time course of the total psychiatric rating scales prs showed a progressive decline during treatment for both drugs and at the end of treatment clocapramine proved significantly lower in total prs than did sulpiride. <sep>'], 'population': ['chronic schizophrenic patients <sep> 38 chronic schizophrenic patients <sep>', 'seventeen patients with acute schizophrenia and 30 with chronic schizophrenia <sep>', 'symptom-free schizophrenics <sep> remitted schizophrenic outpatients <sep> remitted schizophrenic outpatients <sep>', 'fourty-five schizophrenic inpatients <sep> schizophrenic hospitalized patients <sep> hospitalized schizophrenics <sep>', 'twenty-eight people with schizophrenia previously unresponsive to typical antipsychotics and only partially responsive to current treatment with <sep> patients with chronic schizophrenia <sep> people with schizophrenia partially responsive to <sep>', '52 hospitalized chronic schizophrenic patients using a single-blind method during an 8-week trial period <sep> hospitalized chronic schizophrenic patients <sep>'], 'interventions': ['trifluoperazine <sep> sulpiride <sep>', 'perphenazine <sep> sulpiride and perphenazine <sep> sulpiride and perphenazine <sep>', 'placebo <sep> haloperidol and propericiazine <sep> placebo timiperone 1 mg 3 mg 6 mg sulpiride <sep> timiperone and sulpiride <sep> neuroleptics <sep> timiperone or sulpiride <sep>', 'bromperidol or sulpiride <sep> bromperidol <sep> bromperidol and sulpiride <sep>', 'clozapine treatment <sep> placebo <sep> sulpiride or placebo <sep> clozapine-sulpiride <sep> clozapine <sep>', 'clocapramine and sulpiride <sep> clocapramine <sep> clocapramine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",sulpiride may be an effective antipsychotic drug but evidence is limited and data relating to claims for its value against negative symptoms is not trial-based.
407,"{'outcomes': ['healing time <sep> pressure ulcers <sep> wound healing <sep>'], 'punchline_text': ['results showed that us/uvc treatment had a greater effect on wound healing than did nursing care either alone or combined with laser. <sep>'], 'population': ['patients with spinal cord injury <sep> twenty patients 22 wounds <sep> patients with spinal cord injury who have pressure ulcers <sep>'], 'interventions': ['standard wound care consisting of wound cleaning twice daily application of moist dressings <sep> nursing care combined with either laser treatment or a regimen of ultrasound and ultraviolet-c us/uvc <sep> ultrasound/ultraviolet-c <sep> ultrasound/ultraviolet-c and laser <sep>'], 'punchline_effect': [' sig increase <sep>']}",there is no evidence of benefit of ultrasound therapy in the treatment of pressure ulcers. however the possibility of beneficial or harmful effect cannot be ruled out due to the small number of trials some with methodological limitations and small numbers of participants. further research is needed.
408,"{'outcomes': ['basal serum retinol concentration <sep> remission of respiratory signs <sep> duration of signs of pneumonia <sep>', 'duration of hospital stay <sep> relative mortality <sep> mean number of days of hospitalization <sep> mean number of days of fever rapid respiratory rate or hypoxia <sep>', 'overall duration of pneumonia and incidence of adverse outcomes <sep>'], 'punchline_text': ['duration of clinical signs was less in children with basal serum retinol concentrations 200 microg/l who received vitamin a supplements than in children with similar concentrations who received placebo 69.9  <sep>', 'there were no differences between the vitamin a and placebo groups in the duration of hospital stay when examined within categories of children stratified by age sex breast-feeding status nutritional status at baseline or quartile of dietary vitamin a intake in the 4 mo before admission to the hospital. <sep>', 'children who received vitamin a however were less likely to have fever by day 3 p  0.008 and were 29 less likely to fail to respond to the first line antibiotic p  0.054). <sep>'], 'population': [""uncomplicated pneumonia in underweight or normal-weight children aged 5 y <sep> children with high basal serum retinol concentrations <sep> children aged 2-59 mo with pneumonia and weight-for-age 50th percentile who had been admitted to the baca ortz children's hospital in quito ecuador were randomly assigned to receive 50,000 iu aged 2-12 mo or 100,000 iu aged 12-59 mo <sep> children with pneumonia <sep> pneumonia in underweight and normal-weight children <sep> 287 children enrolled 145 received <sep>"", 'hospitalized tanzanian children <sep> tanzanian children who are admitted to the hospital with nonmeasles pneumonia <sep> children <sep> children admitted to the hospital in dar es salaam tanzania <sep> six hundred eighty-seven children <sep>', '472 children aged 6 to 59 months with clinical diagnosis of pneumonia <sep> childhood pneumonia <sep> study children were recruited at a public hospital in recife north east brazil an area of marginal vitamin a deficiency <sep> non-measles childhood pneumonia <sep>'], 'interventions': ['placebo <sep> vitamin a or a placebo <sep> vitamin a supplements <sep> vitamin a supplementation <sep> vitamin a <sep>', 'placebo or vitamin a <sep> placebo <sep> vitamin a supplementation <sep> vitamin a <sep>', 'vitamin a in oil or similar capsules of placebo <sep> vitamin a treatment <sep> placebo <sep> vitamin a <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",the evidence does not suggest a significant reduction in mortality measures of morbidity nor an effect on the clinical course of pneumonia with vitamin a adjunctive treatment in children with non-measles pneumonia. however not all studies measured all outcomes which limited the number of studies that could be incorporated into the meta-analyses so that there may have been a lack of statistical power to detect statistically significant differences.
409,"{'outcomes': ['anxiety scores <sep> conversion symptoms <sep>', 'stanford hypnotic clinical scale <sep> video rating scale for motor conversion symptoms the d(isabilities code items from the international classification of impairments disabilities and handicaps and the symptom checklist-90 <sep> hypnotisability <sep>'], 'punchline_text': ['paradoxical intention-treated patients appeared to have greater improvements in anxiety scores z=2.43 p<0.015 and conversion symptoms t=2.27 p=0.034 than the diazepam-treated patients. <sep>', 'significant treatment results for all outcome measures were found for the total sample. <sep>'], 'population': ['subjects were selected by the emergency unit psychiatrist from patients who were admitted to the emergency unit with pseudoseizure <sep> 30 patients with conversion disorders <sep>', 'patients with long-standing conversion symptoms <sep> patients with conversion disorder of the motor type <sep> study population consisted of 45 in-patients between 18 and 65 years of age meeting the dsm-iii-r criteria for conversion disorder of the motor type or somatisation disorder with motor conversion symptoms <sep> patients with a persistent conversion disorder of the motor type 2 <sep>'], 'interventions': ['diazepam <sep> paradoxical therapy <sep>', 'hypnosis <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>']}",randomised studies are possible in this field. the use of psychosocial interventions for conversion disorder requires more research and it is not possible to draw any conclusions about their potential benefits or harms from the included studies.
410,"{'outcomes': ['probability of gram-negative infection <sep> six gram-negative bacilli infections <sep> overall rate of infection or in survival <sep> severe infections spontaneous bacterial peritonitis neutrocytic ascites and bacteremia <sep>', 'spontaneous bacterial peritonitis <sep> spontaneous bacterial peritonitis or spontaneous bacteremia <sep> median duration of follow <sep> death <sep> efficacy and safety <sep>', 'probability of survival <sep> 1-year probability of developing spontaneous bacterial peritonitis <sep> hepatorenal syndrome <sep> renal function serum creatinine level <sep> 1-year probability of survival <sep> 1-year probability of development of spontaneous bacterial peritonitis and hepatorenal syndrome <sep> survival <sep>', 'spontaneous bacterial peritonitis sbp <sep> adverse effects <sep> incidence of sbp <sep> duration of hospitalization <sep>', 'probability of spontaneous bacterial peritonitis recurrence <sep> spontaneous bacterial peritonitis recurrences <sep> spontaneous bacterial peritonitis recurrence <sep> bacterial peritonitis recurrences <sep> overall probability of spontaneous bacterial peritonitis recurrence <sep>', 'lower incidence of extraperitoneal infections <sep> incidence of infections <sep> spontaneous bacterial peritonitis <sep> rate of mortality <sep>', 'probability of survival <sep> gastrointestinal bleeding <sep> sbp and sepsis <sep> probability of remaining free of bacterial infections <sep> sbp <sep>', 'spontaneous bacterial peritonitis <sep> spontaneous bacterial peritonitis <sep> death <sep> extraperitoneal infections <sep> mean time of observation <sep> side effects <sep>', 'e. coli counts quinolone susceptibility and drug concentrations in feces <sep> cumulative one-year probability of peritonitis recurrence <sep> peritonitis recurrence <sep>'], 'punchline_text': ['severe infections spontaneous bacterial peritonitis neutrocytic ascites and bacteremia developed in nine patients in the placebo group 17 and in one patient in the norfloxacin group 2 p<0.03). <sep>', 'trimethoprim-sulfamethoxazole was efficacious safe and cost-effective for the prevention of spontaneous bacterial peritonitis in patients with cirrhosis. <sep>', 'norfloxacin administration reduced the 1-year probability of developing spontaneous bacterial peritonitis 7 vs 61 p  .001 and hepatorenal syndrome 28 vs 41 p  .02 and improved the 3-month 94 vs 62 p  .003 and the 1-year 60 vs 48 p  .05 probability of survival compared with placebo. <sep>', 'there were no adverse effects in the treated group. <sep>', 'the overall probability of spontaneous bacterial peritonitis recurrence at 1 yr of follow-up was 20 in the norfloxacin group and 68 in the placebo group p  0.0063 and the probability of spontaneous bacterial peritonitis recurrence caused by aerobic gram-negative bacilli at 1 yr of follow-up was 3 and 60 respectively p  0.0013).(abstract <sep>', 'we found a significantly lower incidence of infections 1/32 3.1 vs. 13/31 41.9 p less than 0.005 and spontaneous bacterial peritonitis 0/32 0 vs. 7/31 22.5 p less than 0.05 in patients receiving norfloxacin. <sep>', 'in the ciprofloxacin group sbp occurred almost four times less frequently than in the placebo group but it was not statistically significant. <sep>', 'spontaneous bacterial peritonitis occurred in three patients receiving norfloxacin 9.4 and in four patients receiving trimethoprim-sulfamethoxazole 16.0%). <sep>', 'norfloxacin was more effective in the prevention of peritonitis recurrence due to enterobacteriaceae 0 vs 22 p  .01). <sep>'], 'population': ['one hundred and seven patients <sep> cirrhotic patients with low ascitic fluid protein levels 15 g/l <sep> cirrhotic patients with ascites <sep> hospitalized cirrhotic patients with low ascitic fluid protein concentrations <sep> patients had no history of infection since cirrhosis diagnosis and no active infection <sep> cirrhotic patients with low ascitic fluid total protein levels <sep>', '60 consecutive patients with cirrhosis and ascites <sep> consecutive patients <sep> university-affiliated veterans affairs medical center <sep> patients with cirrhosis and ascites <sep> patients with cirrhosis <sep> spontaneous bacterial peritonitis in cirrhosis <sep>', 'patients with advanced cirrhosis <sep> patients with cirrhosis and low protein ascitic levels 15 g/l with advanced liver failure child <sep> cirrhosis <sep>', '60 cirrhotic patients with low ascitic fluid protein levels  15 g/l <sep> cirrhotic patients <sep> spontaneous bacterial peritonitis <sep> twelve patients developed an intercurrent disorder and 10 patients died during the trial <sep>', 'eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis <sep> cirrhosis <sep>', '32 cirrhotic patients with low ascitic fluid total protein levels <sep> hospitalized cirrhotic patients with low ascitic fluid total protein levels <sep>', 'patients with cirrhosis and low protein concentration in ascitic fluid <sep> one hundred cirrhotic patients with 1.5 g/dl of total protein in ascitic fluid <sep> primary prophylaxis of spontaneous bacterial peritonitis <sep>', 'patients with cirrhosis and ascites <sep> fifty seven patients with cirrhosis and ascites were evaluated between march 1999 and march 2001 <sep> patients with chronic liver disease and spontaneous bacterial peritonitis <sep> spontaneous bacterial peritonitis in cirrhosis <sep>', 'fecal escherichia coli <sep> 79 patients who received either <sep> 12 patients <sep> patients on long-term quinolone prophylaxis <sep>'], 'interventions': ['placebo <sep> norfloxacin <sep> norfloxacin <sep>', 'trimethoprim-sulfamethoxazole <sep> no prophylaxis or trimethoprim-sulfamethoxazole <sep> trimethoprim-sulfamethoxazole <sep>', 'placebo <sep> norfloxacin <sep> norfloxacin <sep>', 'ciprofloxacin <sep> ciprofloxacin <sep> placebo <sep>', 'placebo <sep> norfloxacin <sep> norfloxacin <sep>', 'selective intestinal decontamination <sep> selective intestinal decontamination <sep> norfloxacin <sep>', 'ciprofloxacin <sep> ciprofloxacin <sep> placebo <sep>', 'trimethoprim-sulfamethoxazole and norfloxacin <sep> trimethoprim-sulfamethoxazole versus norfloxacin <sep> norfloxacin <sep> trimethoprim-sulfamethoxazole <sep> norfloxacin daily <sep>', 'rufloxacin <sep> norfloxacin <sep> norfloxacin <sep> norfloxacin 400 mg/day or rufloxacin <sep> rufloxacin with daily norfloxacin <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",the pooled estimates suggest that antibiotic prophylaxis might be prudent among cirrhotic patients with ascites and no gastrointestinal bleeding. however poor trial methodology and report coupled with findings suggesting systematic bias in publication and design reflect the fragility of these findings. potential hazard to society and the patients themselves from resistant pathogens should be considered when promoting long-lasting antibiotic prophylaxis. it seems that recommending antibiotic prophylaxis is still far from being a substantiated prevention strategy. trials of better design well reported and of longer follow-up are greatly needed.
411,"{'outcomes': ['therapeutic response <sep> frequency of withdrawal symptoms <sep> withdrawal symptoms <sep>', 'myocarditis sudden infant death syndrome and homicide <sep> hypertension hypotension bradycardia or desaturations <sep> amount of opium required to control symptoms number of treatment failures and differences in blood pressure heart rate and oxygen saturation <sep> treatment failures <sep> median length of therapy <sep> total length of treatment/observation <sep> duration of opioid therapy <sep> restarting opium <sep>', 'average duration of outpatient phenobarbital use <sep> time with mild withdrawal <sep> severity of withdrawal and hospital cost <sep> duration of hospitalization <sep> severity of now <sep> shorter duration of hospitalization less severe withdrawal and reduced hospital cost <sep> hospital cost <sep>', 'bayley scales of mental development <sep> developmental status <sep>'], 'punchline_text': ['no significant differences were determined in therapeutic response among those infants treated with methadone phenobarbital and diazepam. <sep>', 'higher dosages of opium were required by 40 of the infants in the placebo group versus 20 in the clonidine group. <sep>', 'the duration of hospitalization was reduced by 48 79-38 days p .001 and hospital cost per patient reduced by 35,856 p .001 for the dto and phenobarbital group. <sep>', 'results of one way analysis of variance revealed no differences in developmental status between groups p greater than 0.10 f  0.25). <sep>'], 'population': ['110 infants born to mothers who were either in a methadone maintenance program using heroin or recently detoxified were studied during the neonatal period <sep>', 'infants with intrauterine exposure to methadone or heroin and neonatal abstinence syndrome 2 consecutive modified finnegan scores of  or 9 were enrolled at 2 hospitals during 2002-2005 and followed until final hospital discharge <sep> neonatal abstinence syndrome <sep> all enrolled infants 80 received <sep>', '20 term infants exposed to methadone and/or heroin in utero were studied <sep> neonatal opiate withdrawal in term infants <sep>', 'infants born to drug-dependent women undergo neonatal abstinence syndrome nas <sep> infants who required pharmacotherapy <sep> 85 infants born to drug-dependent women who were maintained on methadone during pregnancy <sep>'], 'interventions': ['diazepam <sep> methadone <sep>', 'placebo <sep> oral clonidine <sep> clonidine <sep> clonidine <sep> oral diluted tincture of opium according to a standardized algorithm <sep>', 'diluted tincture of opium dto and phenobarbital versus dto alone <sep> dto and placebo <sep> dto and phenobarbital <sep>', 'paragoric phenobarbital titration phenobarbital loading and diazepam <sep> diazepam <sep> phenobarbital paregoric and diazepam <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>']}",infants with nas due to opiate withdrawal should receive initial treatment with an opiate. where a sedative is used phenobarbitone should be used in preference to diazepam. in infants treated with an opiate the addition of phenobarbitone or clonidine may reduce withdrawal severity. further studies are needed to determine the role of sedatives in infants with nas due to opiate withdrawal and the safety and efficacy of adding phenobarbitone or clonidine in infants treated with an opiate for nas.
412,"{'outcomes': ['cystic periventricular leukomalacia <sep> perinatal survival <sep> free of neurologic complications <sep> survival of at least one twin at six months of age and survival without neurologic complications <sep> survival <sep> efficacy and safety <sep>'], 'punchline_text': ['infants in the laser group also had a lower incidence of cystic periventricular leukomalacia 6 percent vs. 14 percent p=0.02 and were more likely to be free of neurologic complications at six months of age 52 percent vs. 31 percent p=0.003). <sep>'], 'population': ['pregnant women with severe twin-to-twin transfusion syndrome before 26 weeks of gestation <sep> severe twin-to-twin transfusion syndrome <sep> massachusetts medical society <sep> 72 women had been assigned to the laser group and 70 to the amnioreduction group <sep>'], 'interventions': ['endoscopic laser coagulation of anastomoses <sep> laser therapy or amnioreduction <sep> endoscopic laser surgery versus serial amnioreduction <sep>'], 'punchline_effect': [' sig decrease <sep>']}",endoscopic laser coagulation of anastomotic vessels should be considered in the treatment of all stages of twin-twin transfusion syndrome to improve perinatal outcome. further research on the effect of treatment on milder forms of twin-twin transfusion syndrome quintero stage 1 and 2 are required. the long-term outcomes of survivors from the studies included in this review are required.
413,"{'outcomes': ['ptsd-non-related symptom scale <sep> re-experiencing symptoms <sep> total ptss-c scores ptsd-related symptom scale and the subscales re-experiencing and avoidance <sep> posttraumatic stress symptom scale <sep>', 'symptoms and functioning <sep>', 'posttraumatic stress disorder symptoms and self-reports of fear and anxiety <sep> relation to parent-completed measures and clinician ratings of global functioning <sep> efficacy of cognitive-behavioral therapy <sep>', 'multiple traumas and higher levels of depression <sep> symptoms of ptsd feelings of shame and abuse-specific parental distress <sep> symptoms of ptsd <sep> severe abuse-specific distress <sep> total number of ptsd symptoms <sep>', ""children's reaction inventory cri <sep> revised children's manifest anxiety scale rcmas and the children's depression inventory cdi <sep> rcmas and cdi scores <sep> health visits <sep> ptsd symptoms <sep> cri scores <sep>"", ""ptsd diagnostic remission <sep> total child ptsd symptoms assessed using child and parent structured interview kiddie schedule for affective disorders and schizophrenia present and lifetime version <sep> children's ipv-related ptsd and anxiety <sep> scores on the k-sads-pl ptsd symptom clusters screen for child anxiety related emotional disorders scared anxiety children's depression inventory depression kaufman brief intelligence test cognitive functioning and child behavior checklist total behavior problems <sep> k-sads-pl avoidance <sep> scared <sep> total k-sads-pl <sep> serious adverse events <sep> k-sads-pl hyperarousal <sep>"", 'preintervention and postintervention scores <sep> ptsd symptom scores <sep> ptsd symptoms <sep>', 'posttraumatic stress disorder and depression and increased functioning <sep> global functioning <sep> posttraumatic stress disorder and depression symptom severity <sep>', 'symptoms of ptsd and trauma-related feelings of guilt <sep> depression symptoms severity of suicidal ideation feelings of guilt and perceived stigmatization <sep> waiting-list <sep> ptsd symptoms <sep> symptoms of ptsd depression and related impairment <sep> ptsd symptom change <sep> ptsd symptom severity <sep>', 'recovery rates <sep> severity of ptsd symptoms level of functioning and physical health <sep> ptsd symptoms and impairment in functioning <sep>', 'cbt gains <sep> maladaptive cognitions <sep> symptoms of ptsd depression and anxiety <sep>'], 'punchline_text': ['post-treatment scores of the emdr group were significantly lower than the wlc indicating improvement in total ptss-c scores ptsd-related symptom scale and the subscales re-experiencing and avoidance among subjects in the emdr group while untreated children improved in ptsd-non-related symptom scale. <sep>', 'significant treatment by time interactions on all ptsd-relevant variables indicated that the kidnet group but not the controls showed a clinically significant improvement in symptoms and functioning. <sep>', 'compared with controls children who received treatment exhibited significant improvements in posttraumatic stress disorder symptoms and self-reports of fear and anxiety. <sep>', 'children and caregivers assigned to tf-cbt continued to have fewer symptoms of ptsd feelings of shame and abuse-specific parental distress at 6 and 12-month assessments as compared to participants assigned to cct. <sep>', 'treatment resulted in substantial reductions in both groups cri scores and in significant though more modest reductions in rcmas and cdi scores. <sep>', 'the tf-cbt completers experienced significantly greater ptsd diagnostic remission (2  4.67 p  .03 and had significantly fewer serious adverse events. <sep>', 'students in the immediate intervention group had significantly lower ptsd symptom scores following the intervention than those in the wait-list control group f  29.8 df  1,76 p  .001). <sep>', 'pe-a exhibited a greater decrease of posttraumatic stress disorder and depression symptom severity and a greater increase in global functioning than did tdlp-a. <sep>', 'narrative exposure therapy produced a larger within-treatment effect size cohen d  1.80 than academic catch-up d  0.83 and wait-listing d  0.81). <sep>', 'in both treatment conditions ptsd symptoms and impairment in functioning were significantly reduced at one month post-test and remained stable over time. <sep>', 'compared to the wl group participants who received cbt showed significantly greater improvement in symptoms of ptsd depression and anxiety with significantly better functioning. <sep>'], 'population': ['children with ptsd <sep> children suffering from ptsd <sep> children <sep> children with post-traumatic stress disorder ptsd <sep> thirty-three 6-16-year-old children with a dsm-iv diagnosis of ptsd <sep>', 'refugee children living in exile <sep> traumatized refugee children <sep> twenty-six children traumatized by organized violence <sep>', 'thirty-six sexually abused children aged 5-17 years <sep> sexually abused children with posttraumatic stress symptoms <sep> treating sexually abused children with posttraumatic stress symptoms <sep>', 'children with sexual abuse-related ptsd symptoms <sep> 183 children 8 to 14 years old and their primary caregivers <sep>', 'children suffering disaster-related ptsd <sep> to 32 of these children who met clinical criteria for ptsd <sep> elementary school children with disaster-related posttraumatic stress disorder <sep>', 'of 140 consecutively referred 7 to 14-year-old children 124 participated <sep> posttraumatic stress disorder for children exposed to intimate partner violence <sep> children with intimate partner violence ipv)-related posttraumatic stress disorder ptsd symptoms <sep> children and mothers <sep>', 'war-traumatized high school students <sep> postwar kosovar adolescents <sep> september 2004 to may 2005 by the center for mind-body medicine at a high school in the suhareka region of kosovo <sep> eighty-two adolescents meeting criteria for ptsd according to the harvard trauma questionnaire which corresponds with 16 of the 17 diagnostic criteria for ptsd in dsm-iv <sep>', 'adolescents pe-a <sep> thirty-eight adolescents 12 to 18 years old <sep> adolescent ptsd <sep>  2010 american academy of child and adolescent psychiatry <sep> adolescent victims of single-event traumas <sep>', '85 former child soldiers with ptsd from a population-based survey of 1113 northern ugandans aged 12 to 25 years conducted between november 2007 and october 2009 in camps for internally displaced persons <sep> northern uganda <sep> posttraumatic stress disorder ptsd in formerly abducted individuals <sep>', 'in north-east sri lanka <sep> 31 children who presented with a preliminary diagnosis of ptsd <sep> refugee camp in a severely affected community <sep>', '24 children and young people 8-18 years old who met full dsm-iv ptsd diagnostic criteria after experiencing single-incident traumatic events motor vehicle accidents interpersonal violence or witnessing violence <sep> children and adolescents <sep> children and young people <sep>'], 'interventions': ['emdr sessions or the wlc <sep> wlc <sep> waiting list control group wlc <sep> emdr <sep>', 'narrative exposure therapy <sep> narrative exposure therapy <sep>', 'child-alone cognitive-behavioral treatment condition a family cognitive-behavioral treatment condition or a waiting-list control condition <sep>', 'cognitive-behavioral therapy tf-cbt and child-centered therapy cct <sep> cct <sep> tf-cbt <sep>', 'eye movement desensitization and reprocessing emdr treatment <sep> psychosocial intervention <sep>', 'tf-cbt or usual care child-centered therapy <sep> usual community treatment <sep> community-provided trauma-focused cognitive behavior therapy tf-cbt <sep> self-report university of california at los angeles ptsd reaction index <sep>', '12-session mind-body group program or a wait-list control group <sep> school teachers in consultation with psychiatrists and psychologists and included meditation guided imagery and breathing techniques self-expression through words drawings and movement autogenic training and biofeedback and genograms <sep>', 'prolonged exposure versus dynamic therapy <sep> prolonged exposure therapy versus active psychotherapy <sep> active control time-limited dynamic therapy tldp-a <sep> copyright <sep> pe-a or tldp-a <sep> tldp <sep>', 'academic catch-up program with elements of supportive counseling <sep> mental health interventions <sep> community-implemented trauma therapy <sep> narrative exposure therapy <sep> community-based intervention <sep>', 'six sessions narrative exposure therapy for children kidnet or six sessions of meditation-relaxation med-relax <sep> exposure therapy and meditation-relaxation <sep>', 'individual trauma-focused cognitive-behavioral therapy cbt <sep> individual cbt or to placement on a waitlist wl <sep> cbt <sep> cognitive-behavioral therapy <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",there is evidence for the effectiveness of psychological therapies particularly cbt for treating ptsd in children and adolescents for up to a month following treatment. at this stage there is no clear evidence for the effectiveness of one psychological therapy compared to others. there is also not enough evidence to conclude that children and adolescents with particular types of trauma are more or less likely to respond to psychological therapies than others. the findings of this review are limited by the potential for methodological biases and the small number and generally small size of identified studies. in addition there was evidence of substantial heterogeneity in some analyses which could not be explained by subgroup or sensitivity analyses. more evidence is required for the effectiveness of all psychological therapies more than one month after treatment. much more evidence is needed to demonstrate the relative effectiveness of different psychological therapies or the effectiveness of psychological therapies compared to other treatments. more details are required in future trials in regards to the types of trauma that preceded the diagnosis of ptsd and whether the traumas are single event or ongoing. future studies should also aim to identify the most valid and reliable measures of ptsd symptoms and ensure that all scores total and sub-scores are consistently reported.
414,"{'outcomes': ['success rate for delivery of placenta blood pressure pulse rate blood loss and various side effects <sep> successful delivery of placenta while removal of placenta <sep>'], 'punchline_text': ['no adverse effects of clinical importance were registered. <sep>'], 'population': ['twenty-four women <sep>'], 'interventions': ['nitroglycerin <sep> placebo <sep> sublingual nitroglycerin <sep> sublingual nitroglycerin <sep> nitroglycerin or placebo tablets sublingually if intravenous oxytocin and controlled umbilical cord traction had failed to expel the placenta <sep>'], 'punchline_effect': [' no diff <sep>']}",sublingual nitroglycerin given when oxytocin fails seems to reduce both the need for manual removal of placenta and blood loss during the third stage of labour when compared to placebo. further trials are needed to confirm its clinical role and safety. its routine use cannot be recommended based on a single small study. there is no evidence available for other types of tocolytics.
415,"{'outcomes': ['icu <sep> 90-day survival <sep> hospital stays <sep> septic shock <sep> shorter mechanical ventilation and length of stay less need for tracheotomy lower incidence of complications and improved survival <sep> lower incidence of nosocomial pneumonia <sep> shorter periods of invasive ventilation <sep> intensive care unit icu <sep> need for tracheotomy to withdraw ventilation <sep>', 'probability of survival and weaning during ventilation <sep> arterial blood gases duration of mechanical ventilation time in the intensive care unit occurrence of nosocomial pneumonia and survival at 60 days <sep> rate of weaning failure <sep> severe hypercapnic respiratory failure <sep> survival rates <sep> time in the intensive care unit <sep> nosocomial pneumonia <sep> incidence of nosocomial pneumonia <sep> 60-day survival rates <sep> mean duration of mechanical ventilation <sep>', 'total duration of ventilatory support <sep> durations of icu and hospital stays and the 3-mo survival <sep> type of chronic respiratory failure crf pulmonary function data age simplified acute physiology score saps ii and severity of acrf on admission <sep> mean period of daily ventilatory support <sep> duration of etmv <sep>', 'durations of ricu stay and hospital stay <sep> occurrence of vap reintubation and hospital mortality <sep> mv duration the length of ricu stay and hospital stay <sep> durations of invasive mechanical ventilation mv and total mv <sep> incidence of ventilation associated pneumonia vap <sep> hospital mortality <sep> similar age sex apache scores rr hr map pao2 and paco2 at the time of commencement and pic window <sep> time of pic window <sep> incidence of reintubation <sep>', 'shorter duration of invasive mv <sep> lower rate of ventilator associated pneumonia vap <sep> lower hospital mortality <sep> duration of invasive mv the risk of vap and hospital mortality <sep>'], 'punchline_text': ['the conventional-weaning approach was an independent risk factor of decreased icu odds ratio 6.6 p  0.035 and 90-day survival odds ratio 3.5 p  0.018). <sep>', 'among patients who received noninvasive ventilation the probability of survival and weaning during ventilation was higher p  0.002 and time in the intensive care unit was shorter 15.1+/-5.4 days compared with 24.0+/-13.7 days for patients who received invasive ventilation p  0.005). <sep>', 'niv like ipsv significantly and similarly improved gas exchange in relation to that achieved during 2 h-wt p  0.05). <sep>', 'the incidence of ventilation associated pneumonia vap was 18.4 7/38 in the niv group 39.5 15/38 in the control group respectively p  0.05). <sep>', '11 days p  0.047 and lower hospital mortality 1/47 vs 7/43 p  0.025). <sep>'], 'population': ['patients with persistent weaning failure <sep> 43 mechanically ventilated patients who had failed a weaning trial for 3 consecutive days <sep> persistent weaning failure <sep>', 'intubated patients with chronic obstructive pulmonary disease and acute hypercapnic respiratory failure <sep> patients with respiratory failure due to chronic obstructive pulmonary disease <sep> patients with acute exacerbations of chronic obstructive pulmonary disease <sep>', '53 consecutively intubated patients admitted for acrf <sep> acute-on-chronic respiratory failure acrf <sep> intensive care unit icu patients <sep> patients with acrf who are difficult to wean <sep> 33 patients who failed a 2-h t-piece weaning trial 2 h-wt although they met simple criteria for weaning <sep> acute-on-chronic respiratory failure <sep> 16 patients ipsv group and niv was applied immediately after extubation in 17 patients niv group <sep>', 'chronic obstructive pulmonary disease copd patients with severe respiratory failure <sep> copd patients with severe respiratory failure <sep> copd patients requiring intubation and mechanical ventilantion who have severe respiratory failure <sep> from november 2001 to october 2004 76 case of copd patients with severe respiratory failure due to pulmonary infection were intubated and recruited in the study <sep> thirty eight cases among 76 patients were in the niv group and the rest in the control group <sep>', 'patients with exacerbated hypercapnic respiratory failure caused by chronic obstructive pulmonary diseases copd <sep> severe respiratory failure of chronic obstructive pulmonary diseases <sep> eleven teaching hospitals respiratory or medical intensive care units in china <sep> study group n  47 and control group n  43 had similar clinical characteristics initially and at the time of pic window <sep> ninety intubated copd patients with severe hypercapnic respiratory failure triggered by pulmonary infection pneumonia or purulent bronchitis <sep> copd patients requiring intubation and invasive mv for hypercapnic respiratory failure <sep>'], 'interventions': ['noninvasive ventilation <sep> noninvasive ventilation niv <sep>', 'noninvasive pressure support ventilation <sep> noninvasive ventilation <sep> noninvasive mechanical ventilation <sep> noninvasive pressure support ventilation by face mask and 2 invasive pressure support ventilation <sep>', 'conventional invasive pressure support ventilation ipsv <sep> ipsv <sep> noninvasive ventilation <sep> noninvasive ventilation niv <sep> endotracheal mechanical ventilation etmv <sep>', 'conventional invasive synchronized intermittent mandatory ventilation simv plus pressure support ventilation psv <sep> noninvasive mechanical ventilation via facial mask with bilevel positive airway pressure mode immediately in the niv group <sep> noninvasive veatiation group niv and control group <sep> sequential noninvasive following invasive mechanical ventilation <sep>', 'early extubation and sequential noninvasive mv <sep> pulmonary infection control window <sep> invasive mechanical ventilation mv <sep> noninvasive mv via facial mask immediately or control group invasive mv was received continuously after pic window by using conventional weaning technique <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>']}",summary estimates from 12 small studies of moderate to good quality that included predominantly copd patients demonstrated a consistent positive effect on mortality and ventilator associated pneumonia. the net clinical benefits associated with noninvasive weaning remain to be fully elucidated.
416,"{'outcomes': ['delayed union and breakage of screws <sep> malunion <sep> duration of fluoroscopy <sep> average total duration of the procedures performed without reaming <sep> average estimated blood loss <sep>', 'screw failure <sep> proximal screw failure <sep>', 'mal-union delayed union and device failure <sep> durations of hospital stay and time needed to achieve union <sep> union and infection rate <sep>', 'anterior knee pain <sep> isokinetic thigh-muscle strength <sep> elective nail removal <sep> chronic anterior knee pain or functional impairment <sep>', 'deltap values <sep> compartment pressures and deltap diastolic blood pressure  compartment pressure <sep> deep posterior compartment pressures <sep> tibia fractures <sep> peak average pressures <sep>', 'time to fracture healing <sep> average time to fracture healing <sep> nonunions time to fracture healing and rate of malunions <sep> healing and complications <sep>', 'union time <sep> open type i and ii fractures <sep> average blood loss <sep>'], 'punchline_text': ['a screw fractured after two procedures with reaming and after ten without reaming p  0.012 multiple screws fractured after three procedures in the latter group. <sep>', 'one distal screw failed 59.1 per cent significantly more often than two distal screws 5 per cent). <sep>', 'union and infection rate were higher in the ender group p<0.05). <sep>', 'fourteen 67 of the twenty-one patients treated with transtendinous nailing reported anterior knee pain at the final evaluation. <sep>', 'the deep posterior compartment pressures were lower in the reamed group than in the unreamed group at ten twelve fourteen sixteen eighteen twenty twenty-two and twenty-four hours postoperatively p  0.05 at each of these times. <sep>', 'unreamed nailing in patients with tibial shaft fractures may be associated with higher rates of secondary operations and malunions compared with reamed nailing. <sep>', 'ender nail still has its superior usefulness in some aspects of treatment of less comminuted unstable tibial shaft fractures but for the more comminuted unstable tibial shaft fractures the interlocking nail is undoubtedly better used. <sep>'], 'population': ['one hundred and fifty-two patients who had 154 closed fractures of the shaft of the tibia <sep> seventy-two patients seventy-three fractures who had been managed with nailing with reaming and sixty-three patients sixty-three fractures who had been managed with nailing without reaming were available for follow-up at an average of twelve months range three to thirty-three months postoperatively <sep> thirteen patients who had been randomized to treatment without reaming were switched to the group that had reaming because of technical reasons these patients were excluded from the analysis of the results <sep> closed fractures of the tibial shaft <sep>', 'of eligible patients 22 had one distal locking screw and 20 had two distal locking screws <sep> skeletally mature patients with diaphyseal tibial fractures <sep>', 'sixty-seven patients underwent surgery with interlocking nails and 64 with ender nails <sep> 131 patients with tibial fractures of the central two thirds of the tibia were admitted to the emergency ward of shohada hospital tabriz iran <sep> tibial shaft fractures <sep>', 'fifty patients with a tibial shaft fracture requiring intramedullary nailing <sep> anterior knee pain after intramedullary nailing of fractures of the tibial shaft <sep>', 'forty-eight adults with forty-nine fractures treated with <sep> closed tibial shaft fractures <sep> university hospital/level <sep>', 'forty-five patients with displaced closed and open gustilo type i-iiia fractures of the central two thirds of the tibia <sep> patients with tibial shaft fractures <sep>', 'unstable tibial fractures with <sep> one hundred and seven cases of unstable tibial shaft fractures <sep>'], 'interventions': ['nailing without reaming <sep> interlocking intramedullary nailing with and without reaming <sep> interlocking intramedullary nailing either with or without reaming <sep> nailing with reaming <sep>', 'distal locking screws <sep> unreamed tibial nails <sep>', 'unreamed nailing <sep> ender tibial nail or an undreamed interlocking tibial nail as their primary treatment <sep> ender nails and unreamed interlocking nails <sep> unreamed interlocking <sep> unreamed interlocking nails <sep>', 'transtendinous nailing <sep> paratendinous or transtendinous nailing <sep> paratendinous nailing <sep> intramedullary nailing of a tibial shaft fracture <sep>', 'acute reamed versus unreamed intramedullary nailing <sep> reamed intramedullary nailing <sep> reamed and unreamed intramedullary nailing <sep> intramedullary nailing <sep> unreamed intramedullary nailing or reamed intramedullary nailing <sep>', 'unreamed nailing <sep> reamed and unreamed nailing <sep> reamed nailing <sep> stainless steel reamed nail or a solid titanium unreamed nail <sep> unreamed nails <sep>', 'ender nail and the interlocking nail <sep> interlocking nails and 46 with ender nails <sep> interlocking nail versus ender nail <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",overall there is insufficient evidence to draw definitive conclusions on the best type of or technique for intramedullary nailing for tibial shaft fractures in adults. moderate quality evidence suggests that there is no clear difference in the rate of major re-operations and complications between reamed and unreamed intramedullary nailing. reamed intramedullary nailing has however a lower incidence of implant failure than unreamed nailing. low quality evidence suggests that reamed nailing may reduce the incidence of major re-operations related to non-union in closed fractures rather than in open fractures. low quality evidence suggests that the ender nail has poorer results in terms of re-operation and malunion than an interlocking nail.
417,"{'outcomes': ['movement rating scales eps-related adverse events and use of anti-eps medications <sep> extrapyramidal symptoms eps <sep> panss bprs and cgi <sep> positive and negative syndrome scale panss brief psychiatric rating scale bprs and clinical global impression cgi <sep> cgi final improvement score <sep> eps-related events <sep> effective well tolerated <sep>', 'tolerated <sep> free of hospitalization for exacerbation of schizophrenia <sep> eps <sep> time to treatment failure <sep>'], 'punchline_text': ['a dose-related improvement was observed for panss bprs and cgi with statistically significant mean differences p  0.05 between placebo and 20-mg/day sertindole decreases from baseline of 5.8 versus 16.9 for panss 4.8 versus 10.4 for bprs respectively). <sep>', 'time to treatment failure was numerically superior in sertindole-treated patients compared with haloperidol-treated patients although this difference was not statistically significant. <sep>'], 'population': ['hospitalized schizophrenic patients n  205 <sep> patients with schizophrenia <sep>', '282 clinically stable neuroleptic-responsive outpatients with schizophrenia <sep> schizophrenia <sep>'], 'interventions': ['sertindole <sep> placebo <sep> sertindole <sep>', 'haloperidol <sep> sertindole or haloperidol <sep> sertindole or 10 mg/day haloperidol <sep> sertindole <sep> sertindole <sep> sertindole and haloperidol <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>']}",sertindole at a dose of 20mg/day was found to be more antipsychotic than placebo. when used at 8 12 or 20mg/day it appears to be as acceptable as placebo in terms of various adverse events including movement disorders and somnolence but seems to be associated with more cardiac problems 8 12 or 20mg/day and an increase in weight gain 20mg/day than placebo. sertindole at a dose of 24mg/day was better tolerated than haloperidol in terms of participants leaving the study early). it was also found to be was associated with fewer movement disorders at 8 16 20 or 24mg/day and sedation 8 or 24mg/day than haloperidol. however it was shown to cause more cardiac anomalies 16 20 or 24mg/day weight gain all doses combined rhinitis 16 or 24mg/day and problems with sexual functioning 24mg/day than haloperidol. one short term study reported that sertindole 16mg/day was the most optimal dose.
418,"{'outcomes': ['clinical score <sep> respiratory rate <sep> inspiratory expiratory and total pulmonary resistance <sep> clinical score and pulmonary mechanics <sep>', 'mean los <sep> length of hospital stay los <sep> time from admission until the infant had normal hydration oxygenation and minimal respiratory distress <sep>', 'heart rate respiratory rate and respiratory distress assessment instrument rdai score <sep> rdai score values <sep>', 'hospital admissions <sep> hospital admission within 7 days after the day of enrollment the initial visit to the emergency department <sep>', 'relapse rate <sep> mean clinical score respiratory rate and room air saturation over time <sep> room air oxygen saturation elapsed time to meeting clinical criteria for ed discharge hospitalization rate and proportion of patients relapsed within 72 hours of ed discharge relapse rate <sep> clinical score and respiratory rate <sep> ed discharge <sep> median time <sep> adverse effects <sep>', 'need for hospital admission or home oxygen <sep> changes in clinical scores and oxygen saturations <sep> clinical scores or oxygen saturations <sep>', 'adverse effects <sep> clinical score oxygen saturation and heart rate <sep>', 'mean percent oxygen saturation <sep>', 'oxygen saturation and mrdai score <sep> acute bronchiolitis but l-adrenaline <sep> oxygen saturation and clinical modified respiratory distress assessment instrument mrdai scores <sep>', 'respiratory rate rr heart rate hr oxygen saturation spo(2 respiratory distress assessment instrument rdai and activity levels <sep> rr <sep> spo(2 or rdai <sep>', 'degree of change in the respiratory rate the heart rate and the respiratory-effort score and the time that supplemental oxygen was required <sep> length of the hospital stay and the time until the infant was ready for discharge <sep> respiratory rate blood pressure or respiratory-effort scores <sep> heart rate <sep> length of the hospital stay <sep>'], 'punchline_text': ['thirty minutes later there was a significant decrease in clinical score after treatment with racemic epinephrine compared with the baseline score p  0.001 this difference was not present after salbutamol inhalation p  0.42). <sep>', 'group differences were not statistically significant in any of the secondary outcomes. <sep>', 'there were no significant differences between the outcome variables of the four groups within the first 120 min and at 24 hours or between the rates of requirement of a second dose of the same bronchodilator. <sep>', 'among infants with bronchiolitis treated in the emergency department combined therapy with dexamethasone and epinephrine may significantly reduce hospital admissions. <sep>', 'both treatment groups experienced a similar pattern of change in mean clinical score respiratory rate and room air saturation over time. <sep>', 'racemic epinephrine and albuterol at equivalent doses had no effect on the need for hospitalization or supplemental oxygen in bronchiolitis in the outpatient setting compared to nebulized saline placebo though this study may have missed less dramatic clinical effects due to small sample size. <sep>', 'the outcome of patients at 120 min was found significantly better than the baseline values p  0.05). <sep>', 'the mean percent oxygen saturation at 60 minutes was significantly higher in the epinephrine group. <sep>', 'after 02 doses of nebulizations by the studied drugs a significant improvement in respect to oxygen saturation and mrdai score were noted among the children in both the groups compared to their baseline status p=0.000). <sep>', 'supportive therapy prior to study treatment resulted in significant reductions in rr by 4.3 breaths/min and hr by 4.6 beats/min there were no changes in spo(2 or rdai. <sep>', 'there were no significant overall differences between the groups in the length of the hospital stay p=0.16 or the time until the infant was ready for discharge p=0.86). <sep>'], 'population': ['infants with their first episode of acute bronchiolitis <sep> twenty-four infants 4.6  0.5 mean <sep> infants with bronchiolitis <sep> acute bronchiolitis <sep>', 'infants hospitalized with bronchiolitis <sep> infants hospitalized with acute viral bronchiolitis <sep> infants hospitalized for acute viral bronchiolitis <sep> a total of 149 infants were randomized 50 <sep>', 'outpatients with acute bronchiolitis <sep> treated infants with acute bronchiolitis <sep> 69 infants aged 2-21 months who were admitted to the pediatrics department of the faculty of medicine mersin university with acute bronchiolitis <sep>', '2009 massachusetts medical society <sep> 800 infants 6 weeks to 12 months of age with bronchiolitis who were seen in the pediatric emergency department <sep> children with bronchiolitis <sep> infants with bronchiolitis treated in the emergency department combined therapy with <sep> infants with bronchiolitis <sep>', 'moderately ill infants with bronchiolitis <sep> sixty-six patients between 0 and 12 months of age with new-onset wheezing an antecedent upper respiratory tract infection and a clinical score respiratory distress assessment instrument of 8 to 15 <sep> emergency department treatment of bronchiolitis <sep>', '2005 <sep> sixty-five patients between ages 6 weeks and 24 months with a diagnosis of bronchiolitis defined as first-time wheezing upper respiratory symptoms and/or fever and a respiratory distress assessment instrument score of at least 4 <sep> acute bronchiolitis <sep>', 'mildly affected infants with acute bronchiolitis <sep> 186 children mean age 9.5 <sep> mildly affected ambulatory infants with acute bronchiolitis <sep> mild bronchiolitis <sep>', 'infants with acute bronchiolitis <sep> infants with acute bronchiolitis seen in an emergency department <sep> acute bronchiolitis <sep>', 'children with acute bronchiolitis <sep> 60 children aged less than 02 years admitted in the department of pediatrics dhaka medical college hospital during january through december 2005 with acute bronchiolitis <sep>', 'infants with moderately severe acute bronchiolitis <sep> thirty eight infants were recruited 19 in each treatment group <sep> bronchiolitis <sep>', 'massachusetts medical society <sep> 194 infants admitted to four hospitals in queens-land australia with a clinical diagnosis of bronchiolitis <sep> infants admitted to the hospital with bronchiolitis <sep> infants with bronchiolitis <sep> infants with acute bronchiolitis <sep>'], 'interventions': ['racemic epinephrine and salbutamol <sep> combined alpha and beta-receptor agonist <sep> racemic epinephrine <sep> racemic epinephrine with salbutamol <sep> nebulized salbutamol 0.03 ml/kg or racemic epinephrine <sep> salbutamol <sep>', 'albuterol and saline <sep> plac <sep> epinephrine epi <sep> racemic epi <sep> epinephrine <sep> albuterol alb or saline placebo plac <sep> nebulized epi or alb <sep> hours sd <sep>', 'nebulized l-epinephrine <sep> sal  pla <sep> salbutamol  placebo <sep> placebo <sep> dexamethasone <sep> epi  dex <sep> dex <sep> intramuscular dexamethasone <sep> dexamethasone combination and bronchodilators alone <sep> epinephrine  dexamethasone <sep> dexamethasone 0.6 mg/kg or placebo pla <sep> nebulized l-epinephrine epi and intramuscular dexamethasone dex combination therapy with nebulized salbutamol sal <sep> epinephrine  placebo <sep> epi  pla <sep> nebulized salbutamol or l-epinephrine <sep> nebulized l-epinephrine or salbutamol therapies <sep> salbutamol  dexamethasone <sep> salbutamol <sep>', 'placebo <sep> dexamethasone <sep> epinephrine and dexamethasone <sep> nebulized epinephrine 3 ml of epinephrine <sep> nebulized placebo and oral dexamethasone the dexamethasone <sep> dexamethasone and epinephrine <sep> nebulized placebo and oral placebo <sep> epinephrine <sep> nebulized epinephrine <sep> nebulized epinephrine and oral placebo the epinephrine <sep> epinephrine-dexamethasone <sep>', 'nebulized 2.25 racemic epinephrine <sep> epinephrine <sep> nebulized albuterol <sep> nebulized 0.5 albuterol sulfate <sep> nebulized epinephrine vs albuterol <sep> nebulized epinephrine <sep>', 'placebo <sep> nebulized albuterol or saline placebo <sep> nebulized saline placebo <sep> nebulized racemic epinephrine <sep> racemic epinephrine and albuterol <sep> nebulized albuterol 5 mg nebulized racemic epinephrine or an equivalent volume of placebo <sep> albuterol and epinephrine <sep>', 'nebulized salbutamol epinephrin 3 saline and normal saline 0.9 nacl <sep> epinephrine plus 3 saline <sep> epinephrine plus normal saline <sep> nebulized salbutamol-normal saline epinephrine-normal saline and 3 saline <sep> salbutamol plus 3 saline <sep> salbutamol plus normal saline <sep> normal saline alone <sep>', 'nebulized epinephrine with salbutamol <sep> epinephrine <sep> nebulized epinephrine <sep> epinephrine with salbutamol <sep> salbutamol <sep>', 'l-adrenaline <sep> nebulized salbutamol  ipratropium bromide <sep> salbutamol plus ipratropium bromide and other group with l-adrenaline alone <sep> salbutamol  ipratropium bromide <sep> combined nebulized salbutamol with ipratropium bromide and nebulized adrenaline <sep> l-adrenaline and combined salbutamol  ipratropium bromide <sep>', 'inhaled adrenaline <sep> levo-adrenaline 3 mg or 0.9 saline placebo <sep> placebo <sep> nebulised adrenaline and saline placebo <sep> adrenaline <sep>', 'epinephrine <sep> nebulized epinephrine <sep> placebo <sep> nebulized single-isomer epinephrine with placebo <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>']}",this review demonstrates the superiority of epinephrine compared to placebo for short-term outcomes for outpatients particularly in the first 24 hours of care. exploratory evidence from a single study suggests benefits of epinephrine and steroid combined for later time points. more research is required to confirm the benefits of combined epinephrine and steroids among outpatients. there is no evidence of effectiveness for repeated dose or prolonged use of epinephrine or epinephrine and dexamethasone combined among inpatients.
419,"{'outcomes': ['postextubation problems <sep> clinical or radiologic incidence of pneumonia <sep>'], 'punchline_text': ['there was no difference in the clinical or radiologic incidence of pneumonia. <sep>'], 'population': ['neonates requiring ventilatory assistance <sep> 91 neonates to be intubated via either of the two routes 46 infants were assigned to the ot group and 45 infants were assigned to the nt group <sep>'], 'interventions': ['orotracheal and nasotracheal intubation <sep> ot intubation <sep> orotracheal ot and nasotracheal nt intubation for ventilatory assistance <sep>'], 'punchline_effect': [' no diff <sep>']}",post extubation atelectasis may be more frequent after nasal intubation particularly in very low birth weight infants. one route of intubation does not seem to be preferable to the other. there is a need for further randomized controlled trials containing larger numbers of infants.
420,"{'outcomes': ['alcohol consumption <sep> diagnostic interview schedule <sep>', 'substance abuse and personality disorders <sep> personality disorder psychiatric symptoms early maladaptive schemas interpersonal problems and addiction-related psychosocial impairment <sep> psychiatric symptoms criminality and psychosocial impairment <sep> rates of cluster b personality disorders <sep>', 'parasuicide events <sep> frequency of self-harm episodes <sep> total costs <sep> personality disturbance <sep> cost effective <sep>', 'lower anger expression <sep> problem-solving skills <sep> comparison of scores on the social problem solving inventory and the social functioning questionnaire <sep> overall social functioning <sep>', 'problematic drinking social functioning and beliefs about others <sep> occurrence of any acts of verbal or physical aggression <sep> alcohol misuse mental state beliefs and social functioning <sep>', 'counseling attendance and some indication of lower psychosocial impairment <sep>'], 'punchline_text': ['participants randomized to receive the first offender incarceration and treatment program reported greater reductions in alcohol consumption from baseline levels when compared with participants who were only incarcerated. <sep>', 'fifty-two homeless clients were assessed after program admission and randomly assigned to receive either individual psychotherapy focused on personality disorder and substance abuse relapse prevention dual-focus schema therapy dfst or standard group substance abuse counseling sac). <sep>', 'total costs were significantly greater in those with personality disorder and were reduced in those allocated to mact this saving was reversed in those with borderline disorder. <sep>', 'primary outcome was comparison of scores on the social problem solving inventory and the social functioning questionnaire between intervention and control arms at the conclusion of treatment on average at 24 weeks after randomisation. <sep>', 'cbt did not improve outcomes more than usual treatment for men with aspd who are aggressive and living in the community in this exploratory study. <sep>', 'the experimental intervention increased attendance in subjects with low and high levels of psychopathy and with and without other psychiatric comorbidity. <sep>'], 'population': ['274 participants were available for analysis <sep> first offenders intervention outcomes and interactions with antisocial personality disorder among a primarily american-indian sample <sep> dwi offenders with aspd <sep> intoxicated dwi offenders who are primarily american indian <sep> 244 participants <sep> conjunction with 28 days of incarceration of a treatment program incorporating motivational interviewing principles for first-time dwi offenders <sep> 305 offenders including 52 diagnosed as aspd by the <sep>', 'personality-disordered substance abusers receiving services within a homeless drop-in center <sep> fifty-two homeless clients <sep> homeless drop-in center clients <sep>', '480 patients <sep> recurrent deliberate self-harm and personality disturbance <sep>', 'adults with personality disorder <sep> adults with personality disorder in the community under conditions resembling routine clinical practice <sep>', 'men with aspd who were aggressive <sep> violent men with antisocial personality disorder in the community <sep> fifty-two adult men with a diagnosis of aspd with acts of aggression in the 6 months prior to the study <sep> antisocial personality disorder aspd <sep> men with aspd <sep>', 'patients with apd <sep> antisocial personality disorder apd <sep> opioid-dependent patients with antisocial personality <sep> subjects n  100 met diagnostic and statistical manual of mental disorders criteria for opioid dependence and apd using a structured clinical interview <sep> subjects with low and high levels of psychopathy and with and without other psychiatric comorbidity <sep>'], 'interventions': ['dwi intervention program <sep>', 'individual psychotherapy focused on personality disorder and substance abuse relapse prevention dual-focus schema therapy dfst or standard group substance abuse counseling sac <sep>', 'tau <sep> manual assisted cognitive behavior therapy <sep> cognitive therapy manual-assisted cognitive behavior therapy mact versus treatment as usual tau <sep> mact <sep>', 'brief psychoeducation plus 16 problem-solving group sessions n=87 or to waiting-list control <sep> social problem-solving plus psychoeducation <sep> problem-solving intervention <sep> social problem-solving therapy <sep> problem-solving plus psychoeducation <sep>', 'cognitive behaviour therapy cbt <sep> usual tau plus cbt or usual treatment alone <sep> cognitive behaviour therapy <sep> cbt <sep>', 'behavioral approach <sep> highly structured contingency management intervention or a control condition <sep> methadone treatment <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",results suggest that there is insufficient trial evidence to justify using any psychological intervention for adults with aspd. disappointingly few of the included studies addressed the primary outcomes defined in this review aggression reconviction global functioning social functioning adverse effects). three interventions contingency management with standard maintenance cbt with standard maintenance driving whilst intoxicated program with incarceration appeared effective compared to the control condition in terms of improvement in at least one outcome in at least one study. each of these interventions had been originally developed for people with substance misuse problems. significant improvements were mainly confined to outcomes related to substance misuse. no study reported significant change in any specific antisocial behaviour. further research is urgently needed for this prevalent and costly condition.
421,"{'outcomes': ['blood pressure and increases insulin resistance <sep> plasma lipids insulin resistance and blood pressure <sep> plasma lipids <sep> idlc <sep> arterial intima-media thickness imt of the carotid and femoral arteries and fasting lipid parameters <sep> plasma lipid levels <sep> visits systolic blood pressure <sep> imt of combined carotid and femoral arterial walls <sep> fasting lipids and on progression of peripheral atherosclerosis <sep> imt <sep> arterial wall thickness <sep> hdlc <sep> arterial imt <sep> concentration of triglycerides <sep>', 'thickening of the intima/media complex <sep> marked reduction in septal thickness <sep> intima/media thickness <sep> rate of restenosis <sep> tolerated <sep> recurrent stenosis <sep> thickness of the intima/media complex degree of stenosis interventricular septal thickness crurobrachial pressure ratios of dorsalis pedis and posterior tibial arteries distance to claudication and total vessel diameter <sep>', 'risk of clinical outcomes <sep> major cardiovascular events <sep> morbidity and mortality <sep> ankle brachial blood pressure index <sep> mortality <sep> ankle blood pressure index abi <sep>', 'number of angina attacks <sep> blood pressure <sep>'], 'punchline_text': ['a significant reduction of the imt of combined carotid and femoral arterial walls was shown in both treatment groups p  0.005). <sep>', 'the rate of restenosis was also significantly lower in the verapamil group p  0.001). <sep>', 'a low abi was a strong predictor of morbidity and mortality during the follow-up even in patients with no clinical symptoms of pad n=6769). <sep>', 'blood pressure was effectively reduced by perindopril irrespective of the associated disease. <sep>'], 'population': ['hypertensive males with hypercholesterolaemia the daphne study <sep> patients with peripheral vascular disease and hypercholesterolaemia <sep> eighty males 45 to 70 years with peripheral atherosclerotic disease and increased cholesterol levels 5.2-8.0 mmol/l were treated for essential hypertension with either <sep> hypertensives in the netherlands <sep>', '98 patients with peripheral occlusive arterial disease poad stable angina pectoris mild hypertension and at least one additional risk factor increasing the likelihood of restenosis after angioplasty <sep> patients at high risk for reoccurrence after successful percutaneous transluminal coronary angioplasty ptca <sep>', '3099 patients and normal in 5887 patients <sep> patients with evidence of clinical or subclinical peripheral arterial disease <sep> 8986 patients <sep> patients with no clinical symptoms of pad n=6769 <sep> patients with subclinical pad <sep> patients with clinical as well as subclinical pad <sep> pad patients included in the heart outcomes prevention evaluation hope study <sep>', 'patients with mild essential hypertension and concomitant diseases and therapies <sep> many hypertensive patients <sep> essential hypertensive patients with concomitant diseases <sep> 490 patients with mild essential hypertension and any one of the following concomitant diseases hyperlipidemia type ii diabetes mellitus ischemic heart disease cardiac arrhythmia peripheral arterial occlusive disease nephropathy with proteinuria chronic obstructive pulmonary disease or degenerative joint disease treated with nonsteroidal anti-inflammatory drugs nsaids <sep>'], 'interventions': ['hctz <sep> doxazosin or hctz <sep> doxazosin <sep> hydrochlorothiazide hctz <sep> doxazosin <sep> hydrochlorothiazide <sep> doxazosin and hctz <sep> alpha-blocker doxazosin <sep>', 'calcium antagonists <sep> verapamil <sep> placebo <sep> verapamil <sep>', 'ramipril <sep> ramipril or placebo <sep> ramipril <sep>', 'matching placebo <sep> placebo <sep> perindopril <sep> ace-inhibitor perindopril <sep> antihypertensive therapy <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>']}",evidence on various anti-hypertensive drugs in people with pad is poor so that it is unknown whether significant benefits or risks accrue from their use. lack of data specifically examining outcomes in pad patients should not detract from the compelling evidence of the benefit of treating hypertension and lowering blood pressure.
422,"{'outcomes': ['bladder and tympanic temperature <sep> mild hypothermia <sep> median tympanic temperature <sep> lactate concentration and o2 extraction ratio <sep> complications <sep> median tympanic temperature at admission <sep> haemodynamics electrolytes lactate arterial ph cao2 cvo2 and o2 extraction ratio <sep> cvo2 <sep>', 'improved survival <sep> relative risk of death by intractable shock <sep> six-month survival curves <sep> survival with a follow-up time of six months <sep> cardiac arrest hf with or without ht <sep> survival <sep>', 'frequency of adverse events <sep> lower cardiac index higher systemic vascular resistance and hyperglycemia <sep> survival to hospital discharge with sufficiently good neurologic function to be discharged to home or to a rehabilitation facility <sep> neurologic outcome <sep>'], 'punchline_text': ['mild hypothermia induced by a helmet device was feasible easy to perform inexpensive and effective with no increase in complications. <sep>', 'compared to control group the relative risk of death by intractable shock was 0.29 95 ci 0.09 to 0.91 in the hf+ht group and 0.21 95 ci 0.05 to 0.85 in the hf group. <sep>', 'there was no difference in the frequency of adverse events. <sep>'], 'population': ['thirty patients were eligible for the study 16 were randomised into the hg and 14 <sep> patients with cardiac arrest due to asystole or pulseless electrical activity pea who remained unconscious after restoration of spontaneous circulation rosc <sep>', 'sixty-one patients admitted between may 2000 and march 2002 in the intensive care units of two hospitals in france <sep>', 'patients with coma after resuscitation from out-of-hospital cardiac arrest <sep> study subjects were 77 patients who were randomly assigned to treatment with <sep> patients who remained unconscious after resuscitation from out-of-hospital cardiac arrest <sep> comatose survivors of out-of-hospital cardiac arrest with induced hypothermia <sep>'], 'interventions': ['normothermic group ng and a hypothermic group hg <sep>', 'hf with mild ht <sep> control hf 200 ml/kg/h over 8 h or hf+ht <sep> high-volume hemofiltration <sep> hf <sep> isovolumic high-volume hemofiltration hf alone or combined with mild hypothermia ht <sep>', 'hypothermia <sep> spontaneous circulation and maintained at that temperature for 12 hours or normothermia <sep> moderate hypothermia and normothermia <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",conventional cooling methods to induce mild therapeutic hypothermia seem to improve survival and neurologic outcome after cardiac arrest. our review supports the current best medical practice as recommended by the international resuscitation guidelines.
423,"{'outcomes': ['high-sensitivity c-reactive protein values <sep> troponin i myoglobin creatine kinase-mb mass and high-sensitivity c-reactive protein <sep> peak postoperative values of troponin <sep> creatine kinase-mb mass <sep> myocardial damage <sep> myocardial disease <sep>', 'serum levels of the proinflammatory cytokines il-6 il-8 tnf-alpha and leukocytes and the sirs score <sep> inflammatory response <sep> plasma levels of interleukins il-6 il-8 tnf-alpha and systemic inflammatory response score sirs <sep> systemic inflammatory responses <sep> preoperative and postoperative course <sep> cytokine levels <sep> levels of il-6 il-8 tnf-alpha and sirs score <sep> systemic inflammatory response and perioperative morbidity <sep>', 'concentrations of soluble p-selectin sp-selectin <sep> length of icu and hospital stay <sep> blood samples <sep> p-selectin levels <sep> sp-selectin values <sep> intraoperative inotropic agents <sep>', 'levels of interleukin il-6 and il-8 tumor necrosis factor alpha sdf-1alpha granulocyte colony-stimulating factor and vascular endothelial growth factor <sep> levels of proinflammatory cytokines <sep> sdf-1alpha granulocyte colony-stimulating factor and vascular endothelial growth factor <sep> plasma levels of cytokines and cholesterol <sep> endothelial progenitor cells <sep> epc count <sep> plasma levels of any cytokine and number of epcs <sep> amount of epcs <sep>', 'postoperative crp level <sep> occurrence of postoperative af secondary endpoints were major adverse in-hospital cardiac and cerebrovascular events and identification of variables predicting postoperative af <sep> incidence of postoperative af and the postoperative peak c-reactive protein crp level <sep> postoperative af <sep> atrial fibrillation af <sep>', 'systemic inflammatory response <sep> operation time blood loss need for inotropic support intubation time and length of intensive care unit or hospital stay <sep> neutrophil-endothelial adhesion <sep> peak levels <sep> cytokine release and neutrophil adhesion <sep> systemic inflammatory response <sep> cd11b expression on neutrophils <sep> systemic inflammatory response syndrome score <sep> postoperative serum levels of both interleukin-6 and interleukin-8 <sep> systemic inflammatory response and perioperative morbidity <sep>', 'incidence of major adverse cardiac and cerebrovascular events and persistent af <sep> postoperative af <sep> postoperative atrial fibrillation <sep> major adverse cardiac and cerebrovascular events persistent af at 1 month and identification of the markers to predict inhospital postoperative af <sep> higher postoperative peak n-terminus pro-b-type natriuretic peptide levels <sep> occurrence of postoperative af <sep> incidence of postoperative af <sep> atrial fibrillation af <sep> incidence of af <sep> postoperative peak n-terminal pro-brain natriuretic peptide levels <sep>', 'postoperative clinical outcomes <sep> inflammatory response <sep> plasma levels of interleukins 6 and 8 p-selectin soluble intercellular adhesion molecule-1 and lactoferrin <sep> leukocyte-endothelial cell interactions <sep> expression of nf-kappab <sep>', 'c-reactive protein crp <sep> plasma crp levels <sep> sd values <sep> plasma levels of selected inflammatory mediators <sep> postoperative interleukin-6 il-6 levels <sep> plasma il-1 and tnf-alpha <sep> plasma levels <sep> mean <sep> precocious modulation of il-6 expression <sep>', 'hospital stay <sep> myocardial dysrhythmia <sep> high postoperative crp levels <sep> incidence of postoperative af secondary end points were length of stay 30-day major adverse cardiac and cerebrovascular events and postoperative c-reactive protein crp variations <sep> peak crp levels <sep> risk of af <sep> risk of complications length of stay and cost of care <sep> postoperative atrial fibrillation <sep> incidence of major adverse cardiac and cerebrovascular events <sep> incidence of postoperative af <sep> atrial fibrillation af <sep> incidence of af <sep> length of stay <sep>'], 'punchline_text': ['high-sensitivity c-reactive protein values were increased in 58 of pretreated versus 88 of the control patients 15.4  <sep>', 'in both groups the serum levels of the proinflammatory cytokines il-6 il-8 tnf-alpha and leukocytes and the sirs score increased significantly over the baseline though no significant differences were observed between the two groups. <sep>', 'there was less use of intraoperative inotropic agents in the fluvastatin group  p  0.015 and the difference in the length of icu and hospital stay showed a significantly shorter stay for the fluvastatin group. <sep>', 'statin did not affect levels of sdf-1alpha granulocyte colony-stimulating factor and vascular endothelial growth factor. <sep>', 'atorvastatin significantly reduced the incidence of postoperative af and the postoperative peak c-reactive protein crp level vs placebo 14 vs 34 p=0.009 126.5 22.3 vs 145.2 31.6 mg/l p<0.0001). <sep>', 'postoperative serum levels of both interleukin-6 and interleukin-8 increased significantly over baseline but the peak levels observed 4 hrs postoperatively were significantly lower in the atorvastatin group. <sep>', 'postoperative peak n-terminal pro-brain natriuretic peptide levels were significantly higher in the patients with af p  .03). <sep>', 'plasma levels of interleukins 6 and 8 p-selectin soluble intercellular adhesion molecule-1 and lactoferrin were measured by enzyme-linked immunosorbent assay elisa). <sep>', 'pravastatin reduced postoperative interleukin-6 il-6 levels significantly at 24 and 48 hours and at seven days. <sep>', 'atorvastatin significantly reduced the incidence of af versus placebo 35 versus 57 p=0.003). <sep>'], 'population': ['myocardial damage after coronary surgery <sep> two hundred patients undergoing coronary surgery were enrolled <sep>', 'patients undergoing coronary artery bypass grafting with cardiopulmonary bypass <sep> cardiopulmonary bypass <sep> forty-four subjects undergoing elective coronary artery bypass grafting who fulfilled the inclusion criteria <sep>', 'forty-six patients referred to cabg operation were included in the study <sep> patients with coronary heart disease undergoing coronary artery bypass grafting surgery cabg <sep> patients undergoing open heart surgery <sep>', 'patients with coronary artery disease <sep> after cardiac surgery <sep> 50 patients undergoing elective coronary surgery <sep>', 'patients undergoing <sep> atrial fibrillation following off-pump coronary artery bypass grafting <sep> 140 consecutive patients undergoing elective off-pump cabg without a history of af or previous statin treatment <sep>', 'coronary bypass surgery <sep> patients undergoing coronary artery bypass grafting with cardiopulmonary bypass <sep> forty patients <sep>', 'one hundred twenty-four patients without a history of af or previous statin use who were scheduled to undergo elective off-pump cabg were enrolled <sep> after off-pump coronary artery bypass grafting surgery <sep>', 'twenty patients undergoing valve or coronary operations with tepid 34 degrees c cpb <sep> cardiac surgical patients <sep>', 'forty three patients undergoing cpb <sep>', 'patients who have undergone previous <sep> patients undergoing cardiac surgery <sep> two hundred patients undergoing elective cardiac surgery with cardiopulmonary bypass without previous statin treatment or history of af were enrolled <sep>'], 'interventions': ['placebo <sep> electrocardiography and echocardiography <sep> troponin <sep> rosuvastatin <sep> statin <sep>', 'preoperative simvastatin <sep> simvastatin <sep>', 'placebo <sep> placebo placebo <sep> fluvastatin <sep>', 'placebo <sep> atorvastatin <sep> cardiopulmonary bypass cpb surgery <sep> endothelial progenitor cells epcs <sep> atorvastatin <sep> cpb <sep> atorvastatin or placebo <sep>', 'control group placebo <sep> statin atorvastatin <sep> coronary artery bypass grafting cabg <sep> atorvastatin <sep> atorvastatin <sep> preoperative atorvastatin therapy <sep> preoperative statin therapy <sep>', 'atorvastatin <sep> placebo <sep> preoperative atorvastatin <sep>', 'atorvastatin <sep> coronary artery bypass graft <sep>', 'atorvastatin <sep> cardiopulmonary bypass cpb <sep>', 'pravastatin <sep> pravastatin <sep>', 'placebo <sep> atorvastatin <sep> statin therapy <sep> armyda-3 atorvastatin <sep> atorvastatin <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>']}",preoperative statin therapy reduces the odds of post-operative af and shortens the stay on the icu and in the hospital. statin pretreatment had no influence on perioperative mortality stroke myocardial infarction or renal failure. since analysed studies included mainly patients undergoing myocardial revascularizations the results cannot be extrapolated to patients undergoing other cardiac procedures such as heart valve or aortic surgery.
424,"{'outcomes': ['recurrence of clinical symptoms <sep> clostridium difficile-associated diarrhoea rcdad <sep>', 'effectiveness <sep> initial cdd recurrence rate <sep> serious adverse reactions <sep> recurrence of cdd <sep> relative risk rr of cdd recurrence <sep> safety and efficacy <sep> recurrence of active cdd <sep>', 'serious adverse reactions <sep> recurrences <sep>'], 'punchline_text': ['although the small sample size does not allow any conclusion to be drawn concerning the efficacy of l. plantarum in patients with rcdad these results may contribute to the ongoing discussion about the benefits of probiotics in patients with rcdad and encourage the performance of larger multicentre studies. <sep>', 'the efficacy of s boulardii was significant recurrence rate 34.6 compared with 64.7 on placebo p  .04 in patients with recurrent cdd but not in patients with initial cdd recurrence rate 19.3 compared with 24.2 on placebo p  .86). <sep>', 'no serious adverse reactions were observed in these patients. <sep>'], 'population': ['recurrent clostridium difficile-associated diarrhoea <sep> patients with rcdad <sep>', 'patients with clostridium difficile-associated disease cdd <sep> clostridium difficile disease <sep> patients with active cdd <sep> national referral study of ambulatory or hospitalized patients from three main study coordinating centers <sep> patients with recurrent cdd <sep> 124 eligible consenting adult patients including 64 who were enrolled with an initial episode of cdd and 60 who had a history of at least one prior cdd episode <sep> patients who were immunosuppressed due to acquired immunodeficiency syndrome or cancer chemotherapy within 3 months were not eligible <sep>', 'recurrent clostridium difficile disease <sep> recurrent clostridium difficile disease cdd <sep>'], 'interventions': ['lactobacillus plantarum <sep> placebo <sep> metronidazole <sep>', 's boulardii <sep> placebo <sep> standard antibiotics and s boulardii or placebo <sep> antibiotic vancomycin hydrochloride or metronidazole <sep> standard antibiotics and s boulardii <sep> saccharomyces boulardii <sep> oral s boulardii <sep>', 'placebo <sep> vancomycin combined with saccharomyces boulardii <sep> biotherapeutic agent saccharomyces boulardii <sep> vancomycin <sep> vancomycin and placebo <sep> boulardii <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",there is insufficient evidence to recommend probiotic therapy as an adjunct to antibiotic therapy for c. difficile colitis. there is no evidence to support the use of probiotics alone in the treatment of c. difficile colitis.
425,"{'outcomes': ['sexual consequences <sep> self-efficacy <sep>', 'intention to engage in sex and increased abstinence <sep> sexual risk <sep> sexual intentions abstinence and a trend toward fewer virgins initiating intercourse <sep>'], 'punchline_text': ['they also reported less intention to have sex before finishing high school 0.4 vs. 0.5 and more frequent parent-child communications about prevention 1.6 vs. 1.0 and sexual consequences 1.6 vs. 1.1). <sep>', 'hierarchical logistic regression analyses showed significant effects for the intervention on sexual intentions abstinence and a trend toward fewer virgins initiating intercourse for the first time 19 weeks after baseline. <sep>'], 'population': ['351 middle school students <sep> young adolescents risk for early onset of sexual intercourse <sep> middle school adolescents <sep>', 'african-american seventh graders <sep> twenty middle school classes of african-american seventh graders <sep> african-american seventh grade students <sep>'], 'interventions': ['parent-child communications intervention <sep> classroom instruction alone or the classroom instruction enhanced by five homework assignments designed to be completed by the students and their parents <sep>', 'adult identity mentoring <sep> standard health education control curriculum <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>']}",evidence does not indicate that abstinence-only interventions effectively decrease or exacerbate hiv risk among participants in high-income countries trials suggest that the programs are ineffective but generalizability may be limited to us youth. should funding continue additional resources could support rigorous evaluations with behavioral or biological outcomes. more trials comparing abstinence-only and abstinence-plus interventions are needed.
426,"{'outcomes': ['limb salvage <sep> overall patency <sep> patency and limb salvage <sep> limb salvage or survival rates <sep> level of the reconstruction survival <sep> patency limb salvage and survival <sep> survival <sep> serious bleeding complications <sep>', 'median blood loss <sep> patent reconstruction at day 1 perioperative blood loss and the percentage of patients requiring protamin <sep> mortality rate <sep> 30-day graft patency operative blood loss and hemorrhagic complications <sep> rate of occlusion and bleeding <sep> patency rate <sep> 30-day data for mortality repeat operation and recurrent occlusion <sep>', 'overall complication rate <sep> ages indications bypass graft types risk classifications ie conduit runoff or graft failure or comorbid conditions except diabetes mellitus <sep> limb salvage rates <sep> perioperative blood transfusions and complications <sep> cumulative limb salvage rates <sep> duration of patency limb salvage rates and complication rates <sep> immediate postoperative primary graft patency rates <sep> cumulative 5-year survival rate <sep> incidence rate of wound hematomas <sep> limb salvage rate <sep> rest pain or tissue loss <sep> incidence rate of postoperative hematoma <sep> patency rate <sep> secondary patency rates <sep> graft patency rates limb salvage rates and survival rates <sep>', 'primary patency rate <sep> graft patency <sep> major complication rates and cardiovascular morbidity <sep> patency <sep> primary patency of peripheral arterial bypass grafts pabg <sep>', 'major bleeding events <sep> graft patency <sep>', 'excessive bleeding <sep> clotting of blood within the grafts or native vessels <sep> operative procedure complication rate and hospital course <sep>', 'soluble fibrin measured as fibrin monomers fm and fibrinopeptide a fpa <sep> fibrinogen prothrombin complex thrombin-antithrombin complex platelets and antithrombin <sep> levels of fm <sep> heparin levels anti xa <sep> levels of fibrinogen fpa thrombin antithrombin complex and fm <sep> fpa <sep> graft occlusion <sep> reoperation because of bleeding <sep> anti xa levels <sep>', 'median durations of primary patency and limb salvage <sep> graft reocclusion and limb loss <sep> graft patency limb salvage and survival <sep> graft performance <sep> survival <sep>', 'benefits morbidity and mortality <sep> risk of morbidity and mortality <sep> bypass patency and mortality and morbidity <sep> patency rate <sep> patient mortality morbidity and bypass patency rates <sep> major hemorrhagic events <sep>', 'early graft patency <sep> heart failure <sep> patency <sep> patency <sep>', 'intraoperative graft thrombosis <sep> elevated levels of fibrinogen fibrinopeptide a fpa and thrombin-antithrombin t-at complexes <sep> levels of fpa <sep> fpa levels <sep>'], 'punchline_text': ['as expected limb salvage was lower in patients with critical ischemia p less than 0.03 and this was also true for survival p less than 0.04 which was also influenced by the level of the reconstruction survival was lower in patients with femoro-distal reconstructions p less than 0.001). <sep>', 'lmwh was comparable to ufh during peripheral vascular reconstruction in terms of 1-day and 30-day graft patency operative blood loss and hemorrhagic complications. <sep>', 'the incidence rate of postoperative hematoma 32 vs 3.7 p  .004 was greater in the war group but no differences were seen between the war group and the aspirin group in the number of packed red blood cells transfused in the incidence rate of overall nonhemorrhagic wound complications or in the overall complication rate 62 vs 52%). <sep>', 'major complication rates and cardiovascular morbidity were not different between the two groups. <sep>', 'stratified survival analysis showed that this benefit was confined to those having salvage surgery log rank test p  0.0006 for those having surgery for claudication there was no significant benefit. <sep>', 'no clotting of blood within the grafts or native vessels was noted during the conduct of the surgical procedures in either group. <sep>', 'increased levels of fibrinogen fpa thrombin antithrombin complex and fm were recorded prior to surgery. <sep>', 'following autologous vein bypass surgery in the treated group the results were superior in terms of graft patency limb salvage and survival. <sep>', 'in the prosthetic bypass group there was no significant difference in patency rate in the 8-mm bypass subgroup but there was a significant difference in patency rate in the 6-mm bypass subgroup femoral-popliteal 71.4 in the wasa group versus 57.9 in the asa group p .02). <sep>', 'there was no difference in patency at any time point between the two regimens the crude 90 days patency being 88 and 83 respectively. <sep>', 'preoperatively and during surgery the patients had elevated levels of fibrinogen fibrinopeptide a fpa and thrombin-antithrombin t-at complexes. <sep>'], 'population': ['116 randomized patients 61 in the study group and 55 in the control group <sep> after peripheral arterial reconstructive surgery <sep>', '20 swedish surgical and vascular surgical departments that report to the swedish vascular registry swedvasc <sep> 849 patients included 817 were followed up to 30 days <sep> study subjects included patients undergoing peripheral vascular procedures except carotid surgery <sep>', 'infrainguinal vein bypass grafting at high risk for failure <sep> patients at high risk for graft failure <sep> sixty-one of the 64 bypass grafts <sep> patients with marginal venous conduit poor arterial runoff and prior failed bypass grafts <sep> fifty-six patients who were at high risk for graft failure <sep> university tertiary care hospital and in a veterans affairs hospital <sep>', '284 patients with lower limb ischemia most with pre-operative ischemic ulceration or partial gangrene from 12 hospitals <sep> lower limb ischemia patients <sep>', 'patients with critical limb ischaemia undergoing salvage surgery <sep> patients undergoing femoropopliteal bypass grafting <sep> 94 patients <sep> after femoropopliteal bypass grafting <sep>', '28 patients requiring infrainguinal bypass surgery <sep>', 'eighteen patients <sep> patients undergoing infrainguinal bypass surgery <sep>', '130 patients had electively received a <sep> femoropopliteal atherosclerosis <sep>', '831 patients who underwent <sep> patients with peripheral arterial bypass procedures <sep> patients with lower extremity arterial bypass surgery <sep>', 'early occlusion following arterial bypass surgery distal to the groin <sep> three hundred and fourteen patients <sep> patients with a potential heart insufficiency <sep>', 'infrainguinal bypass surgery <sep> patients suffering from atherosclerosis <sep>'], 'interventions': ['heparin <sep> coumarin treatment <sep> coumarin <sep> dicumarol a coumarin derivative <sep>', 'lmwh 40 mg of enoxaparin <sep> ufh 5000 iu heparin <sep> low molecular weight heparin lmwh <sep> unfractionated heparin ufh <sep> lmwh <sep> ufh <sep>', 'aspirin and warfarin <sep> anticoagulation therapy after autogenous vein infrainguinal revascularization <sep> warfarin underwent anticoagulation therapy with heparin <sep> war <sep> warfarin <sep> heparin <sep> warfarin <sep> aspirin <sep> warfarin therapy <sep>', 'acetylsalicylic acid asa <sep> placebo <sep> low molecular weight heparin dalteparin <sep> dalteparin or placebo <sep> asa <sep> dalteparin <sep> dalteparin fragmin pharmacia corp treatment <sep>', 'aspirin with 100 mg dipyridamole <sep> low-molecular weight heparin <sep> aspirin and dipyridamole <sep>', 'ancrod or heparin <sep> heparin <sep>', 'unfractionated heparin <sep> low molecular mass heparin lmmh <sep> lmmh <sep> unfractionated heparin ufh <sep> ufh or lmmh <sep> ufh <sep>', 'phenprocoumon <sep> autologous vein bypass surgery <sep> femoropopliteal vein graft <sep> vein bypass surgery <sep>', 'asa <sep> peripheral arterial bypass surgery <sep> aspirin therapy alone asa <sep> warfarin plus aspirin therapy wasa <sep> oral anticoagulant therapy <sep> aspirin therapy <sep> wasa <sep> warfarin therapy <sep>', 'low molecular weight heparin enoxaparin <sep> perioperative dextran and low molecular weight heparin <sep> dextran 70 or the low molecular weight heparin enoxaparin <sep> dextran <sep>', 'at or heparin <sep> thrombin <sep> heparin <sep> antithrombin or heparin <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",patients undergoing infrainguinal venous graft are more likely to benefit from treatment with vka than platelet inhibitors. patients receiving an artificial graft benefit from platelet inhibitors aspirin). however the evidence is not conclusive. randomised controlled trials with larger patient numbers are needed in the future to compare antithrombotic therapies with either placebo or antiplatelet therapies.
427,"{'outcomes': ['positive caregiver experience <sep> preparedness to care self-efficacy competence and anxiety <sep>', 'partners ratings of their self-efficacy <sep> levels of caregiver strain <sep>', 'quality of life scores <sep> actigraphs measured latency duration efficiency and wake after sleep onset waso scores <sep> sleep quality and depressive symptoms <sep> psqi and ces-d scores <sep> pittsburgh sleep quality index psqi center for epidemiological studies-depression scale ces-d and caregiver quality of life-cancer scale cqolc <sep> stimulus control relaxation cognitive therapy and sleep hygiene elements <sep> sleep quality depressive symptoms and quality of life <sep>', 'stress <sep> legacy activity <sep> legacy improved family communication <sep> social interaction <sep> caregiving stress <sep> breathing difficulty and increased religious meaning <sep>', 'quality of life more self-efficacy better communication and less negative appraisal of caregiving uncertainty hopelessness and symptom distress <sep> appraisal variables appraisal of illness or caregiving uncertainty hopelessness coping resources coping strategies self-efficacy communication symptom distress and quality of life <sep>', 'vomiting <sep> presence and severity of physical symptoms psychiatric morbidity use of and satisfaction with services and carers problems <sep>', 'brief symptom inventory beck depression inventory and social adjustment scale <sep> distress and depression <sep> global family functioning <sep> brief symptom inventory and beck depression inventory <sep> depression <sep>', 'quality of life qol <sep> overall caregiving mastery caregiver mastery specific to caregiving tasks problem-focused or emotion-focused coping <sep> caregiving task burden <sep> burden of patient symptoms <sep> family caregivers qol burden coping and mastery <sep> caregiver qol reducing burden related to patients symptoms and caregiving tasks <sep> caregiver qol <sep> caregiver qol caregiver burden due to patient symptoms caregiver burden due to tasks and caregiver mastery <sep>', 'negative appraisal of caregiving <sep> quality of life <sep> quality of life and other psychosocial outcomes <sep> quality of life of dyads <sep> hopelessness and less negative appraisal of illness <sep>'], 'punchline_text': ['no intervention effects were identified with respect to preparedness to care self-efficacy competence and anxiety. <sep>', 'data analyses revealed that the partner-guided pain management protocol produced significant increases in partners ratings of their self-efficacy for helping the patient control pain and self-efficacy for controlling other symptoms. <sep>', 'improvement was seen across groups however intervention caregivers showed more improvement in psqi and ces-d scores than control caregivers. <sep>', 'intervention caregivers showed reduced caregiving stress in comparison with control group caregivers who showed increases in stress. <sep>', 'at 4-month follow-up intervention patients reported less uncertainty and better communication with spouses than control patients but they reported no other effects. <sep>', '554 patients expected to survive less than one year entered the trial and were randomly allocated to a coordination or a control group. <sep>', 'global family functioning did not change. <sep>', 'the coping skills intervention was effective in improving caregiver qol reducing burden related to patients symptoms and caregiving tasks compared with hospice care alone or hospice plus emotional support. <sep>', 'the intervention consisted of five sessions and addressed family involvement optimistic attitude coping effectiveness uncertainty reduction and symptom management. <sep>'], 'population': ['family caregivers of patients receiving palliative care <sep> participants n  106 received <sep> family caregivers of patients dying of cancer at home <sep>', 'patients who are at the end of life <sep> seventy-eight advanced cancer patients meeting criteria for hospice eligibility and their partners <sep> patients homes that <sep>', 'family caregivers of persons with cancer <sep> family caregivers of persons with advanced stage cancer <sep> caregivers of persons with cancer <sep> thirty adult caregivers participated <sep>', 'individuals with chronic life-limiting illnesses and their family caregivers <sep>', '235 couples 123 couples in the control group and 112 couples in the experimental group <sep> prostate cancer patients and their spouses <sep> 2007 american cancer society <sep> 263 patient-spouse dyads <sep> men with prostate cancer and their spouses <sep> men with prostate cancer <sep>', 'terminally ill cancer patients and their families of coordinating the services available within the nhs and from local authorities and the voluntary sector <sep> cancer patients were routinely notified from 1987 to 1990 <sep> terminally ill cancer patients <sep> 554 patients expected to survive less than one year entered the trial <sep>', '53 families 233 individuals or a control condition 28 families 130 individuals <sep> 257 families of patients dying from cancer 183 71 were at risk and 81 of those 44 participated in the trial <sep>', 'patient/caregiver dyads <sep> 354 family caregivers of community dwelling hospice patients with advanced cancer <sep> copyright 2005 american cancer society <sep> family caregivers of hospice patients with cancer <sep>', 'patients with advanced breast cancer and their family caregivers who participated in a family based intervention <sep> women with recurrent breast cancer and their family caregivers <sep> 134 patients and their family caregivers <sep> patients with advanced cancer <sep>'], 'interventions': ['psycho-educational intervention <sep> standard home-based palliative care services n  52 or these services plus the new intervention <sep>', 'partner-guided cancer pain management protocol <sep> integrated educational information about cancer pain with systematic training of patients and partners in cognitive and behavioral pain coping skills <sep> partner-guided pain management training intervention or usual care control condition <sep>', 'caregiver sleep intervention casi <sep> behavioral sleep intervention <sep> casi <sep> behavioral interventions <sep>', 'innovative family-based intervention <sep> supportive telephone calls <sep> three home visits in which the interventionist actively worked with the family to construct a personal legacy usually a scrapbook with photographs or audiotaped stories <sep>', 'control group standard care or the experimental group standard care plus a 5-session family intervention <sep> family intervention <sep>', 'coordinating care <sep>', 'grief therapy <sep>', 'standard hospice care <sep> hospice plus a coping skill training intervention <sep> structured caregiver skill-training interventions <sep> coping skills intervention <sep> standard hospice care plus three supportive visits and a group n  111 who received standard care plus three visits to teach a coping skills intervention <sep>', 'usual care control or to usual care plus the family intervention experimental condition <sep> family intervention <sep> standard care alone <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",there is evidence that supportive interventions may help reduce caregivers psychological distress. these findings suggest that practitioners should enquire about the concerns of caregivers and should consider that they may benefit from additional support. there is however a need for further research to explore the benefits identified and to assess the interventions effects on physical health and potential harms. trials need to report their methods fully.
428,"{'outcomes': ['pain relief peroperative pain clouding of memory and the surgeons assessment of operating conditions <sep> pain scores <sep> efficacy and acceptability <sep> mean sd pain score <sep> oxygen saturation levels <sep>', 'mean and maximum pain and pain now <sep> pain relief secondary end-points were costs time to discharge and clinical outcome parameters <sep> time to discharge and costs <sep> pain relief <sep> a visual analogue scale vas <sep> abdominal pain <sep> pain <sep> pain and anxiety <sep> vas ratings <sep>', 'harmful to oocytes or embryos <sep> follicular cortisol <sep> rate of gestation <sep> adverse effects <sep> prolactin <sep>', 'analgesia requirements <sep> pain tolerance <sep>', 'number of oocytes retrieved and fertilization cleavage and clinical pregnancy rates <sep> levels of sedation and co-operation <sep> oversedation or peri-operative complications <sep> intra-operative sedation and co-operation <sep> fertility outcomes <sep> 5-point scale while severity of pain and doctor and patient satisfaction <sep> pain score <sep>', 'pain thresholds <sep> cumulative scores of pain <sep>', 'incidence rate of abdominal pain <sep> pain rating and pain score <sep>', 'time and drug consumption <sep> state trait anxiety inventory stai <sep> visual analogue scale vas <sep> pain-relieving effect <sep> pain and subjective expectations and experiences <sep> pain levels <sep> vas pain ratings <sep> time and costs for drug consumption <sep> time for mobilization and costs for time and drug consumption <sep>', 'hemodynamic variables sedation pain the aldrete recovery score and side effects <sep> hemodynamic parameters pain sedation and recovery score <sep> nausea <sep> hemodynamic parameters <sep> hemodynamic variables sedation and pain scores and the number of patients with the maximum aldrete recovery score <sep>', 'severity of nausea vomiting dizziness and drowsiness <sep> median abdominal pain levels <sep> median pain levels <sep> levels of vaginal and abdominal pain <sep> pain levels <sep>', 'pain relief <sep> pain <sep> mean sd pain score <sep>', 'rate of embryo transfers and pregnancies <sep> number of oocytes <sep> postoperative abdominal pain <sep> overall patient satisfaction <sep> pain sensation <sep>', 'anaesthetic effect <sep> pain directly related to oocyte aspiration adequacy of anaesthesia during oocyte aspiration abdominal pain or degree of nausea <sep> visual analogue scales vas <sep> implantation rate <sep> pregnancy rate <sep> level of stress <sep> take home baby rate <sep>', 'abdominal pain other pain nausea and stress <sep> npy concentrations in ff <sep> pregnancy rate and npy concentrations <sep> ivf pregnancy rate <sep> adequate peroperative analgesia <sep> pregnancy rate <sep> postoperative abdominal pain nausea and stress <sep> neuropeptide y npy concentrations in follicular fluid ff <sep> visual analogue scale <sep> analgesic effects <sep>', 'hr map etco2 spo2 fev1 and fvc <sep> heart rate hr mean arterial pressure map peripheral oxygen saturation spo2 end tidal carbon dioxide etco2 tension forced expiratory volume in 1 second fev1 and forced vital capacity fvc and amount of remifentanil <sep> plasma remifentanil concentrations <sep> plasma remifentanil concentrations and pulmonary function tests <sep> plasma remifentanil concentrations <sep>', 'postoperative nausea <sep> average alfentanil dosage requirements <sep> intraoperative analgesia <sep>', 'pain relief and subjective well-being <sep> pain-relieving effect <sep> nausea <sep> pain intensity and analgesic consumption <sep> pain intensity and psychological well-being were assessed by means of visual analogue scales vas tiredness nausea and vomiting and analgesic drug consumption <sep>'], 'punchline_text': [""women's satisfaction with pain relief peroperative pain clouding of memory and the surgeons assessment of operating conditions were evaluated. <sep>"", 'directly after opu the ea group reported significantly higher mean and maximum pain and pain now than the cma group. <sep>', 'plasma increases in prolactin and hormonal responses to follicular puncture were fully attenuated by spinal anesthesia and partially attenuated by the techniques requiring sedation. <sep>', 'analysis of pain perception using visual analogue scoring showed a similar pain tolerance in both groups for the procedures of vaginal ultrasound scanning needle insertion and follicular aspiration. <sep>', 'there were no oversedation or peri-operative complications. <sep>', 'for the patients with pain thresholds of 0.5 ma 2.5 ma and 3 ma in cumulative scores of pain there were no significant differences between the two groups p  0.05). <sep>', 'the acupuncture compound anesthesia group was significantly better than the simple pethidine group in the pain rating and pain score p  0.01 the incidence rate of abdominal pain at 1 h and 2-5 h after oocyte retrieval in the acupuncture compound anesthesia group was lower than that in the simple pethidine group p  0.01). <sep>', 'although vas pain ratings were significantly higher at oocyte aspiration p  0.0001 and after retrieval p  0.01 in the ea than in the ca group they were similar 60 min after surgery. <sep>', 'the number of patients in group iii with the maximum aldrete recovery score 5 min after the procedure was significantly lower than that in groups i and ii. <sep>', 'there were no significant differences between the two groups in the severity of nausea vomiting dizziness and drowsiness. <sep>', 'significantly more fentanyl 97.5 microg was used in the pca group than in the other group 84.6 microg p  0.03). <sep>', 'sedated patients were more arousable than anaesthetized patients during the procedure and experienced less postoperative abdominal pain at 30 min. <sep>', 'before oocyte aspiration the level of stress was significantly higher in the ea group than in the alfentanil group p  0.05 and the ea group experienced discomfort for a significantly longer period during oocyte aspiration p  0. 01). <sep>', 'after 2 h the ea group reported significantly less abdominal pain other pain nausea and stress than the alfentanil group. <sep>', 'both anesthesia regimens provided satisfactory analgesia without affecting fev1 and fvc but significantly higher plasma remifentanil concentrations were calculated when only ri was used as an anesthetic technique. <sep>', 'the incidence of postoperative nausea was the same in both treatment groups 8%). <sep>', 'auricular ea significantly reduces pain intensity and analgesic consumption of the opioid remifentanil during oocyte aspiration in ivf treatment. <sep>'], 'population': ['thirty-eight women in the inhalation group 67 and 41 75 women in the intravenous group were very satisfied with their analgesia p  0. 41 <sep> 57 women undergoing outpatient oocyte recovery <sep>', 'two hundred patients undergoing opu <sep>', 'vitro fertilization <sep> patients in an assisted reproduction program <sep> 90 patients <sep>', '30 patients comparing <sep>', '106 patients <sep>', 'patients of different pain thresholds <sep> seven hundred cases of infertility who will be taken ova under ultrasound guidance via the va gina and receive in vitro fertilization and embryo transfer ivf-et <sep>', 'three hundred and sixteen cases undergoing in vitro fertilization and embryo transfer ivf-et <sep>', '160 women undergoing ivf <sep> oocyte aspiration and patients experiences of well-being after surgery <sep>', 'sixty-nine women were scheduled for oocyte retrieval <sep>', 'patients receiving a paracervical block pcb with and without conscious sedation <sep> 150 patients undergoing egg collection <sep>', 'thirty-nine women <sep>', '50 patients with no premedication <sep>', '150 women undergoing in-vitro fertilization ivf and embryo transfer <sep>', 'follicular fluid <sep> 286 women undergoing oocyte aspiration <sep>', 'subjects receiving <sep> forty american society ofanesthesiologists i subjects requiring tugor <sep> after ovarian hyperstimulation subjects <sep>', '80 healthy women undergoing vaginal ovum pickup procedures <sep> outpatients undergoing minor diagnostic and therapeutic procedures associated with intermittent discomfort <sep>', '94 women undergoing ivf <sep>'], 'interventions': ['conventional intravenous sedation with patient-controlled inhalational isodesox <sep> isodesox <sep> fentanyl and midazolam <sep> inhalational analgesia <sep>', 'acupuncture <sep> pain relief with either ea in combination with a paracervical block pcb n  100 or conventional medical analgesia cma in combination with a pcb <sep> cma <sep> electro-acupuncture ea <sep>', 'midazolam <sep> general anesthesia spinal anesthesia or sedation with alfentanil and midazolam plus paracervical block <sep> alfentanil <sep> remifentanil plus paracervical block <sep> remifentanil <sep>', 'transvaginal follicular aspiration <sep> intraprocedure intravenous fentanyl with normal saline as a placebo <sep>', 'transvaginal ultrasound-guided oocyte retrieval tugor <sep> propofol and alfentanil and physician-administered sedation using diazepam and pethidine <sep> pas <sep> patient-controlled sedation pcs with physician-administered sedation pas <sep> pcs <sep>', 'electroacupuncture at shenshu bl 23 ciliao bl 32 baihui gv 20 sanyinjiao sp 6 etc <sep> acupuncture compound anesthesia <sep> simple dolantin group <sep> intramuscular injection of dolantin and simple intramuscular injection of do lantin <sep>', 'pethidine <sep> simple pethidine <sep> transvaginal ultrasound-guided oocyte retrieval acupuncture compound anesthesia <sep> electroacupuncture combined with intramuscular injection of pethidine <sep> acupuncture compound anesthesia <sep>', 'ea <sep> electro-acupuncture versus conventional analgesia <sep> electro-acupuncture analgesia ea and conventional analgesia ca comprising opiates <sep> ca <sep>', 'remifentanil <sep>', 'pcb <sep> placebo <sep> paracervical block with and without conscious sedation <sep> conscious sedation sedation group <sep>', 'patient-controlled analgesia pca <sep> fentanyl <sep> pca <sep>', 'fentanyl/propofol/isoflurane anaesthesia <sep> midazolam 0.06 mg/kg and ketamine <sep> general anaesthesia with fentanyl 0.017 mg/kg propofol 2.5 mg/kg and isoflurane <sep> propofol <sep> midazolam/ketamine sedative combination <sep> midazolam and ketamine <sep>', 'paracervical block pcb <sep> electro-acupuncture <sep> electro-acupuncture ea or intravenous alfentanil <sep> ea plus pcb or alfentanil plus pcb <sep> alfentanil <sep>', 'paracervical block pcb <sep> ea <sep> alfentanil group alfentanil plus a pcb <sep> pcb and alfentanil <sep> alfentanil <sep> electro-acupuncture <sep> electro-acupuncture ea <sep> ea group ea plus a pcb <sep>', 'transvaginal ultrasound-guided oocyte retrieval tugor <sep> ri with pcb <sep> remifentanil <sep> remifentanil infusion ri versus ri with paracervical block pcb <sep> remifentanil with paracervical block <sep> ri <sep> remifentanil <sep>', 'intraoperative patient-controlled analgesia <sep> alfentanil using a patient-controlled analgesia device <sep> intravenous opioid analgesics <sep> alfentanil <sep>', 'opioid remifentanil <sep> auricular electro-acupuncture ea analgesia auricular acupuncture a and conventional analgesia with remifentanil co <sep> auricular electro-acupuncture <sep> patient-controlled analgesia pca with remifentanil <sep> auricular acupuncture with ea n  32 or without a n  32 continuous 1 hz auricular stimulation using a battery-powered miniaturized stimulator p-stim or with adhesive tapes instead of needles and no electrical stimulation control group co n  30 at the auricular acupuncture <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",the evidence from this review of 21 randomised controlled trials did not support one particular method or technique over another in providing effective conscious sedation and analgesia for pain relief during and after oocyte recovery. the simultaneous use of more than one method of sedation and pain relief resulted in better pain relief than one modality alone. the various approaches and techniques reviewed appeared to be acceptable and were associated with a high degree of satisfaction in women. as women vary in their experience of pain and in coping strategies the optimal method may be individualised depending on the preferences of both the women and the clinicians and resource availability.
429,"{'outcomes': ['hyperlipidemia and proteinuria <sep> serum creatinine triglyceride cholesterol urine protein and creatinine clearance <sep>', 'serum albumin levels <sep> proteinuria <sep> diminution of their proteinuria <sep> proteinuria <sep> fractional decline in gfr <sep> average csa level and proteinuria change <sep> efficacy and safety <sep> prestudy serum cholesterol levels <sep>', 'partial remission <sep> complete remission <sep> efficacy and safety <sep> number of adverse events <sep>', 'remission <sep> sustained remissions <sep>', 'serum albumin levels <sep> proteinuria <sep> proteinuria and serum albumin levels <sep> proteinuria <sep>', 'steady-state blood pressure and serum concentrations of serum angiotensin-converting enzyme ace and plasma renin activity or angiotensin ii at-ii <sep> values of 24-h urinary protein excretion <sep> proteinuria and alleviated renal tubular damage <sep> serum concentrations of urinary retinol-binding protein and beta(2)-microglobulin <sep> blood pressure and components of the renin-angiotensin system ras <sep> blood pressure and components of systemic ras <sep>', 'ua/uc ratio <sep> urine albumin-to-creatinine ua/uc ratio and the percentage reduction <sep> baseline clinical biochemical and histological features <sep> median ua/uc ratio <sep> nephrotic-range proteinuria <sep> systolic and diastolic blood pressure reductions <sep>', 'complete resolution of proteinuria <sep> treatment failure <sep> serum creatinine <sep>', 'partial remission urinary protein-creatinine ratio <sep> proportion of patients who experienced relapse <sep> efficacy and safety <sep> complete remission urinary protein-creatinine ratio <sep> remission <sep> rates of remission <sep> blood cholesterol levels <sep> cosmetic side effects hypertrichosis and gum hypertrophy <sep>', 'mean score <sep> blood pressure <sep> mean urinary protein excretion the mean serum proteins and plasma cholesterol <sep> remission of the nephrotic syndrome <sep> severe renal or extrarenal toxicity <sep> serum creatinine and creatinine clearance <sep>', 'complete remission <sep> cushingoid features and serious infections <sep> hypertension and hypokalemia while vomiting and reversible alopecia <sep>'], 'punchline_text': ['the results showed no statistically significant difference in serum creatinine triglyceride cholesterol urine protein and creatinine clearance between fish oil supplemented group and placebo group. <sep>', 'the fractional decline in gfr over the course of the study was not significantly different between the csa and placebo-treated groups. <sep>', 'cph patients responded p  0.05 intention-to-treat). <sep>', 'the children who received iv cyclophosphamide had more sustained remissions longer periods without proteinuria and fewer significant side effects this was achieved at a lower cumulative dose. <sep>', 'there were no significant changes in serum albumin levels in either group during the trial. <sep>', 'patients in group i showed lower serum concentrations of urinary retinol-binding protein and beta(2)-microglobulin p<0.01 at the end of the study but the patients blood pressure and components of the renin-angiotensin system ras had no change during treatment. <sep>', 'the median ua/uc ratio at the end of 20 weeks was 1.1 and 1.8 in groups a and b respectively  p>0.05). <sep>', 'treatment failure occurred in 36 of the control group and 57 of the experimental group p  0.1). <sep>', 'rates of remission at 12 months were also similar rr 1.14 95 ci 0.84 to 1.55). <sep>', 'at month 6 the mean urinary protein excretion the mean serum proteins and plasma cholesterol had significantly improved in the csa group but were not changed in the controls. <sep>', 'following treatment complete remission was seen in 53.8 and 47.8 patients in groups i and ii respectively p  0.6). <sep>'], 'population': ['children with steroid-resistant nephrotic syndrome <sep> childhood nephrotic syndrome <sep>', 'children with corticosteroid-resistant fsgs <sep> children <sep> twenty-five patients with fsgs <sep>', 'children with steroid-resistant nephrotic syndrome <sep> patients with proteinuria <sep> children with newly diagnosed primary steroid-resistant nephrotic syndrome and histologically proven minimal change disease focal segmental glomerulosclerosis or mesangial hypercellularity <sep>', '13 children with biopsy-proven steroid-resistant mcns <sep>', 'eight patients with steroid-resistant nephrotic syndrome four with idiopathic minimal lesion nephrotic syndrome and four with focal segmental glomerulosclerosis <sep> patients with steroid-resistant minimal lesion nephrotic syndrome or focal segmental glomerulosclerosis <sep> steroid-resistant nephrotic syndrome <sep>', 'normotensive children with srins <sep> normotensive children with steroid-resistant idiopathic nephrotic syndrome srins <sep> children under this treatment <sep> forty-five normotensive patients with srins <sep> children with steroid-resistant idiopathic nephrotic syndrome <sep>', 'children with srns <sep> steroid-resistant nephrotic syndrome <sep> 25 consecutive patients with steroid-resistant nephrotic syndrome srns <sep>', 'kidney disease in children <sep> children with steroid-resistant fsgs <sep> patients with focal segmental glomerulosclerosis <sep> sixty children with biopsy diagnosed focal segmental glomerulosclerosis fsgs and with unremitting nephrotic syndrome despite intensive therapy with adrenocortical steroids <sep>', 'tertiary-care hospital 41 consecutive patients with idiopathic srns estimated glomerular filtration rate greater than 60 ml/min/1.73 m(2 and histological characteristics showing minimal change disease focal segmental glomerulosclerosis or mesangioproliferative glomerulonephritis <sep> children with steroid-resistant nephrotic syndrome <sep> patients with srns <sep> patients with steroid-resistant nephrotic syndrome srns <sep>', 'adults and children <sep> patients with steroid-resistant idiopathic nephrotic syndrome ins <sep> patients with steroid-resistant ins <sep> steroid-resistant idiopathic nephrotic syndrome <sep> forty-five patients with steroid-resistant ins <sep>', 'patients with srns <sep> steroid-resistant nephrotic syndrome <sep> during april 2001 to december 2003 52 consecutive patients with idiopathic srns normal renal function and renal histology findings showing minimal change disease focal segmental glomerulosclerosis or mesangioproliferative glomerulonephritis were enrolled into the study <sep> patients with steroid-resistant nephrotic syndrome srns <sep>'], 'interventions': ['placebo <sep> tuna fish oil and placebo <sep> tuna fish oil <sep>', 'hypercholesterolemia <sep> placebo <sep> csa and placebo <sep> cyclosporine csa <sep> csa <sep> steroids alone and steroids plus cyclophosphamide <sep> cyclosporine <sep> placebo or csa <sep>', 'cyclosporin a csa versus cyclophosphamide pulses cph <sep> cph pulses <sep> csa therapy or methylprednisolone pulses <sep> cph <sep> cyclosporin <sep> csa <sep> cyclophosphamide <sep>', 'oral cyclophosphamide <sep> iv cyclophosphamide <sep> cyclophosphamide <sep> intravenous pulse cyclophosphamide <sep>', 'cyclosporine therapy <sep> cyclosporine therapy <sep> cyclosporine <sep>', 'fosinopril <sep> prednisone <sep> fosinopril and prednisone <sep>', 'low 0.2 mg/kg daily and high-dose 0.6 mg/kg daily enalapril <sep> enalapril <sep> enalapril <sep> concomitant therapy with daily oral or intravenous steroids alkylating agents cyclosporine non-steroidal anti-inflammatory drugs and other antihypertensive medications <sep> prednisolone <sep>', 'cyclophosphamide <sep> prednisone <sep> cyclophosphamide therapy <sep> prednisone regimen plus a 90-day course of daily cyclophosphamide <sep>', 'tacrolimus <sep> csa <sep> tacrolimus <sep> tacrolimus or csa <sep> cyclosporine <sep> cyclosporine csa <sep> prednisolone and enalapril <sep>', 'csa <sep> supportive therapy or csa <sep> cyclosporine <sep> cyclosporine csa <sep> supportive therapy <sep>', 'dexamethasone <sep> intravenous pulse cyclophosphamide <sep> cyclophosphamide therapy <sep> cyclophosphamide and prednisolone <sep> oral cyclophosphamide therapy <sep> prednisolone <sep> dexamethasone and oral cyclophosphamide <sep> dexamethasone and oral cyclophosphamide therapy <sep> cyclophosphamide <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",further adequately powered well designed rcts are needed to confirm the efficacy of cyclosporin and to evaluate other regimens for idiopathic srns including high dose steroids with cyclosporin.
430,"{'outcomes': ['medication adherence <sep>', 'number of cocaine-negative urine tests <sep> cocaine dependence <sep> total number of weeks abstinent from cocaine <sep> continuous cocaine abstinence <sep> rates of cocaine-negative urine tests <sep>', 'weekly assessments of the frequency and quantity of drug and alcohol use weekly urine toxicology screens and breathalyzer readings <sep> quantity and frequency of cocaine <sep>', 'positive urinalysis <sep> visual analogue scales vas <sep>'], 'punchline_text': ['more patients taking the disulfiram-naltrexone combination achieved 3 consecutive weeks of abstinence in treatment than placebo-treated patients. <sep>', 'the number of cocaine-negative urine tests during the trial were also higher on disulfiram 14.7 than on placebo 8.6 furthermore subjects in the disulfiram group achieved consistently higher rates of cocaine-negative urine tests in each 3-week interval and the increase over time was faster in the disulfiram compared with placebo. <sep>', 'disulfiram treated subjects decreased the quantity and frequency of cocaine use significantly more than those treated with placebo. <sep>', 'results show that cbt treated subjects remained in treatment longer than those assigned to either dis/cbt or ntx/cbt therapies. <sep>'], 'population': ['208 patients <sep> treating co-occurring cocaine and alcohol dependence <sep> patients with co-occurring cocaine and alcohol dependence <sep>', 'maintained subjects <sep> dependent subjects n  20 <sep> maintained patients <sep> fifteen subjects completed the study including 8 subjects randomized to disulfiram 72.7 and 7 subjects randomized to <sep>', 'sixty-seven cocaine-dependent methadone-maintained opioid-dependent subjects 52 female 51 caucasian <sep> maintained opioid addicts <sep> urban methadone maintenance clinic <sep> individuals with comorbid alcohol and cocaine abuse <sep> cocaine dependence in methadone-maintained opioid addicts <sep>', '12 subjects enrolled in the study only 4 33 completed the 12-week treatment <sep> cocaine abusers <sep> 12 subjects co-abusers of <sep>'], 'interventions': ['placebo <sep> disulfiram <sep> disulfiram and naltrexone <sep> disulfiram naltrexone <sep> disulfiram-naltrexone <sep> naltrexone <sep>', 'placebo <sep> opioid and cocaine <sep> disulfiram versus placebo <sep> disulfiram <sep> buprenorphine <sep> disulfiram versus placebo <sep> buprenorphine maintenance <sep>', 'placebo <sep> disulfiram or placebo <sep> disulfiram treatment <sep> methadone <sep> cocaine <sep>', 'cocaine and alcohol <sep> cbt <sep> ntx/cbt <sep> disulfiram dis 400mg daily or naltrexone ntx 50mg daily associated with cognitive behaviour therapy cbt <sep> cbt alone in terms of i stay in treatment ii drug-free urinalyses for cocaine and cocaethylene iii reduction of alcohol and cocaine craving <sep> disulfiram or naltrexone <sep> cocaine <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",there is low evidence at the present supporting the clinical use of disulfiram for the treatment of cocaine dependence. larger randomised investigations are needed investigating relevant outcomes and reporting data to allow comparisons of results between studies. results from ongoing studies will be added as soon as their results will be available.
431,"{'outcomes': ['pain reduction <sep> time to a first or a complete cessation of pain <sep> postherpetic neuralgia <sep> adverse events <sep> frequency of postherpetic neuralgia <sep> progression of the rash <sep>', 'relieved pain <sep> post-herpetic neuralgia <sep>', 'risk ratios <sep> total crusting <sep> time to return to uninterrupted sleep <sep> resolution of pain <sep> laboratory adverse events <sep> accelerated time to cessation of acute neuritis <sep> quality of life <sep> chronic pain and quality-of-life outcomes <sep> lesion healing resolution of pain return to usual activity and return to uninterrupted sleep <sep> time to return to usual daily activity <sep> analgesic requirements each day and adverse events and laboratory abnormalities <sep> time to total crusting and healing <sep>'], 'punchline_text': ['no significant differences were detected between the four groups in the progression of the rash p  0.1). <sep>', '18 23 of the patients had post-herpetic neuralgia at 6 months after the acute zoster 9 24.3 having received prednisolone and 9 22.5 placebo. <sep>', 'time to total crusting and healing was accelerated for patients receiving acyclovir plus prednisone compared with patients receiving two placebos the risk ratios were 2.27 <sep>'], 'population': ['acute herpes zoster <sep> patients with acute herpes zoster <sep> patients with a rash of less than 72 hours duration <sep> 400 patients recruited 349 completed the study <sep>', 'post-herpetic neuralgia 78 patients with herpes zoster whose pain and exanthema <sep>', '15 university hospitals or affilliated clinics <sep> herpes zoster <sep> 208 immunocompetent patients older than 50 years of age who had localized herpes zoster that developed less than 72 hours before study enrollment <sep> relatively healthy persons older than 50 years of age who have localized herpes zoster combined <sep>'], 'interventions': ['acyclovir <sep> acyclovir <sep> prednisolone therapy <sep> prednisolone to acyclovir therapy <sep> prednisolone or placebo or acyclovir <sep> prednisolone <sep> acyclovir therapy <sep> corticosteroids <sep> prednisolone or placebo <sep>', 'prednisolone <sep> placebo <sep> prednisolone <sep> acyclovir <sep>', 'placebo <sep> acyclovir <sep> placebos <sep> acyclovir and prednisone <sep> acyclovir plus prednisone acyclovir plus prednisone placebo prednisone plus acyclovir placebo <sep> acyclovir and prednisone therapy <sep> prednisone <sep> acyclovir plus prednisone <sep> acyclovir with and without prednisone <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",there is moderate quality evidence that corticosteroids given acutely during zoster infection are ineffective in preventing postherpetic neuralgia. in people with acute herpes zoster the risks of administration of corticosteroids do not appear to be greater than with placebo based on moderate quality evidence. corticosteroids have been recommended to relieve the zoster-associated pain in the acute phase of disease. if further research is designed to evaluate the efficacy of corticosteroids for herpes zoster long-term follow-up should be included to observe their effect on the transition from acute pain to postherpetic neuralgia. future trials should include measurements of function and quality of life.
432,"{'outcomes': ['length of hospitalization <sep> cumulative proportion of in-hospital stay <sep> shorter hospitalization period <sep> wheeze and hospitalization rates <sep> clinical score oxygen saturation or iv fluid requirement <sep>', 'disease severity <sep>', 'duration of hospital admission time taken to become symptom free re-admission rates general practitioner consultation rates and use of anti-wheeze medication <sep> median time <sep> respiratory syncytial viral rsv bronchiolitis <sep> respiratory re-admission rates <sep>', 'hospital admissions <sep> hospital admission within 7 days after the day of enrollment the initial visit to the emergency department <sep>', 'frequency of hospital release <sep> heart and respiratory rate respiratory distress index oxygen saturation and silverman andersen scores <sep>', 'respiratory assessment change score racs <sep> racs <sep> poor racs <sep>', 'hospital admission after 4 hours of emergency department observation <sep> respiratory assessment change score racs <sep> mean 4-hour racs <sep> rate of hospital admission the respiratory status <sep> hospital stay later medical visits or admissions and adverse events <sep> admission rate <sep>', 'length of hospital stay <sep> time to clinical resolution <sep> length of hospital stay duration of oxygen therapy and time to clinical improvement during the hospitalization <sep> prevalence of post-bronchiolitis wheezing <sep> duration of oxygen therapy <sep> prevalence of post-bronchioltis wheezing <sep>', 'heart rate respiratory rate and respiratory distress assessment instrument rdai score <sep> rdai score values <sep>', 'mean duration of oxygen therapy <sep> time from study entry to resolution of respiratory distress determined by a clinical score derived from the respiratory rate occurrence of wheezing chest retraction and oxygen saturation <sep> time needed for resolution of respiratory distress <sep> mean duration of symptoms <sep> mean length of hospital stay <sep>', 'respiratory distress assessment instrument rdai heart and respiratory rates and transcutaneous haemoglobin oxygen saturation spo(2 <sep> hospital admission rate <sep> respiratory status <sep> hospitalisation rate <sep> baseline characteristics and respiratory status <sep> rate of hospitalisation or respiratory status <sep> rdai improvement <sep> rdai heart and respiratory rate and spo(2 <sep>', 'clinical score or in the sao2 <sep> duration of illness prior to enrollment pretrial medication use clinical severity of bronchiolitis history of atopy and family history of atopy <sep> chronic respiratory symptoms <sep> oxygen saturation sao2 <sep>', 'prevalence of wheeze respiratory symptom scores or proportion requiring bronchodilators or steroids <sep> symptoms of acute bronchiolitis or prevented postbronchiolitic wheezing <sep> mean oxygen requirements or length of hospital stay <sep> postbronchiolitic wheezing <sep>', 'oxygen saturation respiratory rate and rdai score <sep> rdai score <sep> oxygen saturation respiratory rate rdai measurement twice daily for the first 4 days and the length of hospitalization <sep> median length of stay <sep>', 'evolution of respiratory rate oxygen saturation clinical score or pulmonary function tests <sep>'], 'punchline_text': ['inhaled dexamethasone may reduce the length of hospitalization among infants with acute viral bronchiolitis especially among those born prematurely. <sep>', '1.5 in all patients evaluated p  0.05 than placebo whereas there was no detectable difference on day 6 suggesting that addition of prednisolone to albuterol transiently accelerates recovery from bronchiolitis. <sep>', 'there are no short or long term clinical benefits from the administration of nebulised corticosteroids in the acute phase of rsv bronchiolitis. <sep>', 'among infants with bronchiolitis treated in the emergency department combined therapy with dexamethasone and epinephrine may significantly reduce hospital admissions. <sep>', 'the administration of salbutamol plus dexamethasone is more effective in the control of respiratory distress in children with bronchiolitis compared with the use of salbutamol alone. <sep>', 'poor racs occurred in 41 and 17 of the placebo and dexamethasone groups respectively p .034). <sep>', 'both groups had respiratory improvement during observation the mean 4-hour racs was 5.3 for dexamethasone as compared with 4.8 for placebo absolute difference 0.5 <sep>', 'no reduction was observed in the prednisolone group compared with the control group in terms of length of hospital stay 6.0 vs 5.0 days p  0.7 duration of oxygen therapy 24.0 vs 24.0 h p  0.4 and time to clinical resolution 4.0 vs 4.0 days p  0.8). <sep>', 'there were no significant differences between the outcome variables of the four groups within the first 120 min and at 24 hours or between the rates of requirement of a second dose of the same bronchodilator. <sep>', 'a single-dose dexamethasone injection versus placebo produced a significant 1 decrease in the time needed for resolution of respiratory distress hazard ratio 1.56 95 ci 1.14-2.13 p  0.005 <sep>', 'the hospitalisation rate was similar between groups 21  vs. 25  p  0.9 respectively independently of the virus identified. <sep>', 'after 3 and 7 days of treatment both groups showed similar clinical improvement and there were no statistically significant differences between the two groups in the clinical score or in the sao2. <sep>', 'no significant differences were found between the budesonide and placebo groups in change in clinical score 48 hours after trial entry mean oxygen requirements or length of hospital stay during the acute illness. <sep>', 'there were no significant differences between the two groups in change in oxygen saturation respiratory rate and rdai score at any assessment period. <sep>', 'no significant differences were found between the groups in evolution of respiratory rate oxygen saturation clinical score or pulmonary function tests on day 3. <sep>'], 'population': ['infants with acute viral bronchiolitis <sep> sixty-one infants with bronchiolitis aged 3 to 12 mo were included <sep> rsv bronchiolitis <sep>', 'mild to moderate bronchiolitis with bronchiodilators and corticosteroids we treated 51 young children with first-time wheezing and symptoms of respiratory tract infection with albuterol plus either <sep> for 5 days <sep> mild to moderate bronchiolitis <sep>', 'acute respiratory syncytial viral bronchiolitis <sep> 161 infants were studied <sep> infants admitted to hospital with their first episode of rsv positive bronchiolitis <sep> median respiratory related general practitioner attendances <sep>', '2009 massachusetts medical society <sep> 800 infants 6 weeks to 12 months of age with bronchiolitis who were seen in the pediatric emergency department <sep> children with bronchiolitis <sep> infants with bronchiolitis treated in the emergency department combined therapy with <sep> infants with bronchiolitis <sep>', 'children with bronchiolitis <sep> 49 patients between 1-18 months diagnosed with bronchiolitis with three days or less of disease evolution <sep> patients with bronchiolitis <sep> acute bronchiolitis <sep>', '70 children  24 months old in the emergency department with respiratory disease assessment instrument  or  6 <sep> outpatients with acute bronchiolitis <sep> outpatients with moderate-to-severe acute bronchiolitis <sep> acute bronchiolitis <sep>', '600 children age range 2 to 12 months with a first episode of wheezing diagnosed in the emergency department as moderate-to-severe bronchiolitis defined by a respiratory distress assessment instrument score  or 6 <sep> infants with acute moderate-to-severe bronchiolitis <sep> bronchiolitis <sep> enrolled patients at 20 emergency departments during the months of november through april over a 3-year period <sep>', 'twenty-eight patients <sep> hospitalized infants with bronchiolitis <sep> federal university of rio grande rio grande-rs brazil <sep> hospitalized infants with acute bronchiolitis <sep>', 'outpatients with acute bronchiolitis <sep> treated infants with acute bronchiolitis <sep> 69 infants aged 2-21 months who were admitted to the pediatrics department of the faculty of medicine mersin university with acute bronchiolitis <sep>', 'acute bronchiolitis in young hospitalized children <sep> acute bronchiolitis in hospitalized children <sep> previously healthy young children hospitalized with acute bronchiolitis <sep> pediatric wards of a university hospital and its affiliated hospital in thailand included 174 previously healthy children under 2 years of age hospitalized with acute bronchiolitis <sep>', 'infants with moderate to severe bronchiolitis presenting to an emergency department <sep> 65 infants 33 in the dexamethasone vs. 32 in the placebo group finished the study <sep> 240 infants who consulted with acute respiratory illness fulfilled the inclusion criteria <sep> infants with moderate-severe bronchiolitis <sep> outpatients with bronchiolitis <sep>', 'thirty-eight infants were enrolled in the study 20 received <sep> infants with mild to moderate bronchiolitis defined as the first episode of wheezing associated with low grade fever rhinitis tachypnea and increased respiratory effort in a previously healthy infant during the winter months <sep> infants with bronchiolitis <sep> acute bronchiolitis <sep> infants with mild to moderate bronchiolitis <sep> infants with mild to moderate bronchiolitis who are also treated with an inhaled beta2-agonist <sep>', ""forty infants with bronchiolitis 83 rsv mean age 13.5 weeks range 4 to 41 weeks were admitted to the royal alexandra children's hospital brighton uk <sep>"", 'treated inpatients with acute bronchiolitis <sep> children hospitalized with bronchiolitis <sep> participants children aged 6 weeks to 15 months admitted with first-time wheezing were eligible if their oxygen saturation was less than 95 on admission to the hospital and their respiratory distress assessment instrument rdai score was greater than 6 <sep> children admitted to the hospital with bronchiolitis treated with nebulized salbutamol <sep> patients were excluded if they had any one of the following an underlying disease that might affect cardiopulmonary status asthma recent treatment with steroids within 2 weeks or any history of adverse reaction to steroids <sep> inpatient wards of a pediatric tertiary care hospital <sep>', 'primary respiratory syncytial virus bronchiolitis <sep> respiratory syncytial virus bronchiolitis <sep> 29 previously healthy infants median age 194 days <sep>'], 'interventions': ['equivalent amount of normal saline <sep> placebo <sep> dexamethasone inhalations <sep> inhaled dexamethasone <sep> nebulizations with 0.25 mg dexamethasone <sep> epinephrine nebulizations <sep> dexamethasone versus nebulization of 0.9 saline <sep> inhaled dexamethasone <sep>', 'placebo <sep> prednisolone <sep> prednisolone or placebo <sep> prednisolone plus albuterol versus albuterol alone <sep>', 'placebo <sep> nebulised corticosteroids <sep> nebulised budesonide bud or placebo pla <sep> nebulised budesonide <sep> corticosteroids <sep>', 'placebo <sep> dexamethasone <sep> epinephrine and dexamethasone <sep> nebulized epinephrine 3 ml of epinephrine <sep> nebulized placebo and oral dexamethasone the dexamethasone <sep> dexamethasone and epinephrine <sep> nebulized placebo and oral placebo <sep> epinephrine <sep> nebulized epinephrine <sep> nebulized epinephrine and oral placebo the epinephrine <sep> epinephrine-dexamethasone <sep>', 'nebulized salbutamol or salbutamol plus dexamethasone <sep> dexamethasone vs. nebulized salbutamol <sep> nebulized salbutamol <sep> nebulized salbutamol and dexamethasone <sep> salbutamol plus dexamethasone <sep>', 'oral dexamethasone or placebo <sep> placebo <sep> oral dexamethasone <sep> dexamethasone <sep>', 'oral dexamethasone <sep> placebo <sep> dexamethasone <sep> corticosteroids <sep>', 'prednisolone <sep> standard care alone <sep> prednisolone <sep>', 'nebulized l-epinephrine <sep> sal  pla <sep> salbutamol  placebo <sep> placebo <sep> dexamethasone <sep> epi  dex <sep> dex <sep> intramuscular dexamethasone <sep> dexamethasone combination and bronchodilators alone <sep> epinephrine  dexamethasone <sep> dexamethasone 0.6 mg/kg or placebo pla <sep> nebulized l-epinephrine epi and intramuscular dexamethasone dex combination therapy with nebulized salbutamol sal <sep> epinephrine  placebo <sep> epi  pla <sep> nebulized salbutamol or l-epinephrine <sep> nebulized l-epinephrine or salbutamol therapies <sep> salbutamol  dexamethasone <sep> salbutamol <sep>', 'placebo <sep> dexamethasone <sep> systemic corticosteroids <sep> dexamethasone injection <sep> dexamethasone injection versus placebo <sep>', 'oral dexamethasone <sep> placebo <sep> dexamethasone <sep> adrenaline <sep>', 'placebo <sep> oral prednisone <sep> prednisone <sep> oral corticosteroids <sep> nebulized albuterol <sep> corticosteroids <sep> corticosteroids <sep> oral corticosteroid therapy <sep>', 'nebulized budesonide <sep> budesonide <sep> placebo <sep> nebulized placebo <sep>', 'oral dexamethasone therapy <sep> placebo <sep> dexamethasone <sep> dexamethasone <sep> nebulized salbutamol <sep> oral dexamethasone <sep> salbutamol <sep>', 'dexamethasone therapy <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>']}",current evidence does not support a clinically relevant effect of systemic or inhaled glucocorticoids on admissions or length of hospitalisation. combined dexamethasone and epinephrine may reduce outpatient admissions but results are exploratory and safety data limited. future research should further assess the efficacy harms and applicability of combined therapy.
433,"{'outcomes': ['number of days with migraine <sep> satisfaction with tolerability <sep> quality of life <sep> number of migraine days <sep> number of days on acute medication <sep>', 'reduction in mean monthly frequency intensity duration rescue medication use migraine associated symptoms and adverse events <sep> adverse events <sep> headache frequency and migraine associated symptoms <sep> responder rate <sep> responder rate for frequency <sep> efficacy and safety <sep>', 'mean monthly migraine frequency <sep> mean monthly migraine frequency <sep> rescue medication use <sep> responder rate <sep> paresthesia fatigue and nausea <sep> responder rate proportion of patients with  or 50 reduction in monthly migraine frequency reductions in mean number of monthly migraine days severity duration and days a month requiring rescue medication and adverse events <sep> efficacy and safety <sep>', 'migraine frequency responder rate migraine days and daily rescue medication usage <sep> monthly migraine frequency <sep> efficacy and safety <sep> mean monthly migraine frequency <sep>', 'migraine frequency <sep> alpha-band phase synchronization <sep> eeg synchronization <sep>', 'visual analog scale and headache duration <sep> migraine headache frequency intensity and duration <sep> mean sd of monthly migraine frequency <sep> headache intensity <sep> headache duration <sep> monthly headache frequency <sep> efficacy and safety <sep>', 'responder rate <sep> frequency intensity and duration of migraine headaches as well as midas score and symptomatic medications <sep> symptoms with migraine <sep> reduction of headache severity <sep> frequency intensity duration associated symptoms with headaches analgesics use as well as drugs side effects <sep>', 'reduction in mean monthly migraine days and severity of headache <sep> efficacy reduction in mean monthly migraine frequency <sep> mean monthly days and severity of headache <sep> mean weight loss <sep> average weight change <sep> adverse reactions and weight changes <sep> monthly headache frequency <sep> efficacy safety and side effects <sep> side effects <sep>', 'migraine status quality of life level of physical activity and oxygen uptake <sep> mean reduction of the frequency of migraine attacks <sep>', 'fatigue <sep> efficacy-evaluable <sep> transformation of episodic migraine <sep> mean number of migraine days <sep> headache days and migraine headache days and generally well tolerated <sep> headache days <sep> development of cdh <sep> paresthesia <sep> migraine and headache days <sep> nausea <sep> chronic daily headache <sep> dizziness <sep>', 'mean monthly 28-day rate of days with migraine mean monthly rate of days with headache migraine and nonmigraine <sep> dry mouth <sep> weight satisfaction <sep> paresthesia <sep> migraine episodes <sep> migraine-specific quality of life questionnaire msq and the weight satisfaction scale questionnaire <sep> role function-restrictive role function-preventive and emotional function domains of the msq <sep> fatigue <sep> teaes of mild or moderate severity <sep> overall deterioration in weight satisfaction <sep> mean weight gain <sep> somnolence <sep> mean monthly severity of migraine-associated symptoms photophobia phonophobia and nausea change in the mean monthly frequency f migraine-associated vomiting and response rates based on monthly migraine days and total headache days <sep> mean monthly number of migraine episodes <sep> rate of mean monthly migraine episodes <sep> mean weight loss <sep> weight loss and improved weight satisfaction <sep> weight increase <sep> nausea <sep> hypoesthesia <sep> dizziness <sep> mean functional disability scores <sep> mean monthly rate of acute abortive medication use mean monthly migraine duration and mean monthly migraine severity <sep> efficacy and tolerability <sep>', 'frequency of migraine crises <sep> tolerated <sep> side effects <sep> quantity of symptomatic drugs taken <sep> number of days of disability <sep> efficacy and tolerability <sep>', 'visual analog scale vas and headache duration <sep> mean sd of monthly headache frequency <sep> mean standard deviation sd of monthly migraine frequency <sep> headache intensity <sep> migraine headache <sep> duration monthly frequency and intensity of headache <sep> headache duration <sep> efficacy and safety <sep>', 'paresthesia fatigue nausea anorexia and taste per version <sep> mean monthly migraine frequency <sep> sd monthly migraine frequency <sep> monthly migraine frequency <sep> responder rate time to onset of action mean change in migraine days per month and mean change in rescue medication days per month <sep> efficacy and safety <sep>', 'migraine frequency <sep> tolerated <sep> 28-day migraine frequency <sep> paresthesia weight loss altered taste anorexia and memory impairment <sep> mean 28-day migraine frequency <sep> adverse effects <sep> efficacy and safety <sep>', 'fatigue <sep> mean monthly migraine frequency <sep> serious aes depression abdominal pain leg pain <sep> weight loss <sep> paresthesia <sep> efficacy and tolerability <sep> nausea <sep> dizziness <sep>'], 'punchline_text': ['patients in the placebo group had a greater number of days on acute medication than did those in the topiramate group mean difference between groups 0.95 1.49 to 0.41 p=0.0007). <sep>', 'topiramate showed statistically significant benefits p  .017 in most of the secondary efficacy measures while lamotrigine was beneficial for reduction in headache frequency and migraine associated symptoms. <sep>', 'statistically significant reductions p<.05 occurred within the first month with topiramate at 100 and 200 mg/d. <sep>', 'the tpm 100 mg/d and prop groups were similar with respect to reductions in migraine frequency responder rate migraine days and daily rescue medication usage. <sep>', 'both levetiracetam and topiramate significantly decreased migraine frequency compared with placebo. <sep>', 'the topiramate group showed a reduction in the mean sd of monthly migraine frequency from 6.07 1.89 to 1.83 1.39 episodes per month headache intensity from 7.1 1.45 to 3.67 2.1 based on the visual analog scale and headache duration from 16.37 7.26 to 6.23 5.22 hours p  0.001). <sep>', 'the reduction of headache severity in the topiramate group was significantly more than that in the valproate group p  .027). <sep>', 'the mean monthly days and severity of headache in the three groups also declined and was more significant in the flunarizine plus topiramate group than in the flunarizine group and the topiramate group p<0.05). <sep>', 'the primary efficacy variable showed a mean reduction of 0.93 95 confidence interval ci 0.31-1.54 attacks in the exercise group 0.83 <sep>', 'compared with placebo topiramate treatment was associated with statistically significant reductions in mean number of migraine days 6.6 vs. 5.3/28 days p  .001 and headache days 6.6 vs 5.3/28 days p  .001). <sep>', 'topiramate was associated with improvement in some quality-of-life indicators compared with amitriptyline and was associated with weight loss and improved weight satisfaction. <sep>', 'in the tpm group side effects were transient and well tolerated. <sep>', 'a total of 64 patients with migraine headache aged 14 to 57 years were randomly allocated to the 2 treatment groups. <sep>', 'significantly more topiramate-treated patients 50 mg/d 35.9 p .04 100 mg/d 54.0 p .001 and 200 mg/d 52.3 p .001 exhibited a 50 or more reduction in monthly migraine frequency than placebo-treated patients 22.6%). <sep>', 'the mean 28-day migraine frequency was reduced by 36 in patients receiving topiramate as compared with 14 in patients receiving placebo p .004). <sep>', 'a significantly larger proportion of tpm-treated subjects had a  or 75 reduction in monthly migraine frequency compared with placebo p=0.03). <sep>'], 'population': ['559 patients 68.3 completed the open-label phase 514 entered the double-blind phase and were assigned to <sep> 818 patients who have migraines were enrolled from 88 clinics in 21 countries <sep>', 'fifty-seven patients comprised the intent-to-treat population <sep> sixty patients with frequent migraine more than 4 attacks per month from the headache clinic at a tertiary referral centre in india <sep> patients with frequent migraine <sep>', 'outpatient treatment at 52 north american clinical centers <sep> patients were aged 12 to 65 years and had a 6-month history of migraine international headache society criteria and 3 to 12 migraines a month but no more than 15 headache days a month during a 28-day prospective baseline phase <sep> migraine prevention <sep> 483 patients randomized 468 provided at least 1 postbaseline efficacy assessment and comprised the intent-to-treat population <sep>', 'subjects with episodic migraine with and without aura <sep> five hundred and seventy-five subjects were enrolled from 61 centres in 13 countries <sep>', 'forty-five migraine without aura outpatients mo <sep> 24 non-migraine healthy controls <sep> alpha rhythm in migraine <sep>', '62 patients with frequent migraine headaches  or  3 attacks per month <sep> migraine prophylaxis <sep>', '56 patients who completed the course of study <sep> migraine prophylaxis <sep>', '150 patients with migraine recruited into the study and randomly assigned to one of three conditions 126 completed the trial in their group <sep> migraine prophylaxis <sep>', 'adults with migraine <sep> patients who do not benefit from or do not want to take daily medication <sep>', '159 topiramate subjects and 171 placebo subjects <sep> adult subjects with high-frequency episodic migraine hfem 9-14 migraine headache days/month <sep> subjects with hfem <sep> 100 <sep>', 'adults with 3 to 12 migraines per month <sep> adult migraineurs <sep> migraine prevention <sep> 331 subjects 172 topiramate 159 amitriptyline 84.9 female 84.6 white mean sd age 38.8 11.0 years mean weight 77.1 20.1 kg who provided at least 1 efficacy assessment <sep> 118 subjects 66.7 in the topiramate group and 112 subjects 66.3 in the amitriptyline group <sep>', '35 patients completed the study in the tpm group and 37 patients in the <sep> one hundred and fifteen patients <sep> migraine prophylaxis <sep>', 'october 2003 to september 2004 <sep> migraine prevention <sep> 64 patients with migraine headache aged 14 to 57 years <sep>', 'four hundred eighty-seven patients were randomized and 469 composed the intent-to-treat population <sep> patients with migraine <sep> migraine prevention <sep> patients patients were aged 12 to 65 years had a 6-month international headache society migraine history and experienced 3 to 12 migraines per month but had 15 or fewer headache days per month during the 28-day baseline period <sep>', 'adults and children <sep> n  21 20 women 1 man <sep> forty patients aged 19 to 62 years mean 38.2 years <sep> migraine prevention <sep>', '45 subjects who discontinued the study in the tpm group 21 discontinued during the titration period compared with 3 of 13 subjects who discontinued in the placebo group <sep> adult subjects with a history of migraine with or without aura <sep> 211 subjects 138 tpm 73 placebo mean sd mean weight 76.7 18.7 kg <sep> migraine with/without aura in adults <sep>'], 'interventions': ['topiramate <sep> migraine preventive therapy with topiramate prompt <sep> placebo <sep>', 'topiramate/lamotrigine or matching placebo <sep> placebo <sep> topiramate <sep> topiramate and lamotrigine <sep> lamotrigine <sep> lamotrigine <sep>', 'topiramate <sep> placebo <sep> topiramate <sep>', 'placebo <sep> topiramate tpm <sep> topiramate vs placebo <sep> topiramate <sep> tpm <sep> tpm 200 mg/d prop 160 mg/d active control or placebo <sep> propranolol <sep> propranolol prop <sep>', 'topiramate <sep> levetiracetam or placebo treatment <sep> placebo <sep> levetiracetam <sep> levetiracetam and topiramate <sep> levetiracetam vs topiramate and placebo <sep> topiramate and levetiracetam vs placebo <sep>', 'topiramate and propranolol <sep> topiramate vs propranolol <sep> topiramate 50 mg/day and propranolol <sep> propranolol <sep>', 'topiramate <sep> topiramate <sep> topiramate and valproate <sep> topiramate and valproate <sep> low-dose topiramate <sep> valproate <sep> sodium valproate <sep>', 'topiramate flunarizine <sep> topiramate <sep> flunarizine and topiramate <sep> topiramate <sep> flunarizine <sep> flunarizine with topiramate <sep> flunarizine topiramate <sep> flunarizine 39 topiramate 44 and flunarizine plus topiramate <sep> flunarizine and or toparamate alone <sep> flunarizine plus topiramate <sep>', 'relaxation and topiramate <sep>', 'topiramate <sep> placebo <sep> topiramate <sep> topiramate intervention <sep> topiramate 100 mg/day and placebo <sep> placebo topiramate <sep>', 'topiramate <sep> topiramate or amitriptyline <sep> topiramate <sep> topiramate and amitriptyline <sep> amitriptyline <sep>', 'topiramate <sep> placebo <sep> topiramate tpm or placebo <sep> topiramate <sep> tpm <sep>', 'topiramate <sep> topiramate and sodium valporate <sep> topiramate <sep> sodium valporate <sep>', 'topiramate <sep> placebo <sep> topiramate <sep> placebo or topiramate <sep>', 'topiramate <sep> placebo <sep> topiramate <sep>', 'topiramate <sep> placebo <sep> tpm 200 mg/d or placebo <sep> tpm <sep> topiramate tpm <sep> tpm and placebo <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",meta-analysis demonstrates that topiramate in a 100 mg/day dosage is effective in reducing headache frequency and reasonably well-tolerated in adult patients with episodic migraine. this provides good evidence to support its use in routine clinical management. more studies designed specifically to compare the efficacy or safety of topiramate versus other interventions with proven efficacy in the prophylaxis of migraine are needed.
434,"{'outcomes': ['symptomatic relief of heartburn <sep> percentage of heartburn-free days and antacid-free nights <sep> symptoms of mild-moderate gastroesophageal reflux disease gerd <sep> effective and safe <sep> diarrhea <sep> tolerated <sep> total use of rescue antacid medication <sep> percentage of patients self-rated as having minimal or better symptomatic improvement <sep> concordance analyses daytime and nighttime heartburn with antacid usage <sep> early satiety <sep> total regurgitation <sep> daytime and nighttime heartburn <sep> efficacy and safety <sep>', 'gerd-associated symptoms e.g. regurgitation belching early satiety <sep> rapidity of symptom relief and 4-week efficacy <sep> median time to first 24-hour heartburn-free interval <sep> complete heartburn relief <sep>', 'relieving heartburn <sep> adequate control of heartburn <sep> adverse events <sep> symptom control <sep> mild heartburn <sep> relief of non-reflux symptoms <sep>', 'heartburn <sep> heartburn <sep> rapid relief of heartburn <sep>', 'efficacy and safety <sep> completely symptom free <sep> gerd symptoms heartburn acid eructation and pain on swallowing <sep> relief from key gerd symptoms heartburn acid eructation and pain on swallowing <sep> adverse events and laboratory assessments <sep> tolerated <sep> free from key gerd symptoms <sep> gastrointestinal symptoms epigastric pain vomiting nausea flatulence retching and retrosternal feeling of tightness and safety profiles <sep>', 'reflux index scores quality of life sf-36 and the hospital anxiety and depression had scale and symptom relief <sep> overall quality-of-life measures or the had scale <sep> gerdq index <sep>', 'rates of complete control of gord symptoms <sep> frequency and severity of heartburn using the gastrointestinal symptom rating scale gsrs and a patient heartburn diary <sep>', 'heartburn relief <sep> heartburn-dominant uninvestigated dyspepsia <sep> cumulative relapse rates <sep> heartburn-free <sep> median times to relapse <sep>', 'heartburn <sep> patient quality of life <sep> reflux dimension of the gastrointestinal symptom rating scale gsrs score <sep> quality of life <sep> regurgitation and epigastric pain <sep> symptoms and quality of life <sep>', 'frequency and degree of symptoms <sep> gastro-oesophageal reflux disease symptoms <sep>', 'complete endoscopic healing <sep> antacid consumption <sep> gastroesophageal reflux disease and heals erosions and ulcerations <sep> esophageal erosions or ulcerations <sep> global scores <sep> proportion of patients with complete relief of daytime heartburn <sep>', 'symptom relief <sep> total heartburn relief defined as no heartburn symptoms <sep> total heartburn relief <sep> gastroesophageal reflux disease gerd <sep> total heartburn relief <sep> heartburn symptoms <sep>', 'pathological gastroesophageal reflux <sep> similar sensitivity <sep>', 'esophageal acid sensitivity <sep> relief of symptoms of gastroesophageal reflux <sep> esophageal endoscopic appearance or sphincter pressures <sep> esophagoscopy esophageal acid sensitivity and lower esophageal pressures <sep> symptom frequency and severity <sep>', 'percentages of 24-h heartburn-free days primary and nights without heartburn secondary <sep> tolerated <sep> median percentages of 24-h heartburn-free days <sep> nights without heartburn <sep> quality of life and symptom severity questionnaires <sep> daytime and nighttime heartburn <sep> quality of life improvements <sep>', 'complete resolution of heartburn <sep> resolution of heartburn <sep> percentage of heartburn-free days and the time to first and sustained resolution of heartburn <sep> chronic heartburn <sep> efficacy and safety <sep> percentage of heartburn-free days <sep>', 'evidence of erosions and ulcerations <sep> frequency and the severity of heartburn <sep> endoscopic appearance of the esophageal mucosa <sep> endoscopic classification <sep> healing <sep> heartburn symptoms <sep> heartburn symptoms of reflux disease <sep>', 'complete relief <sep> reflux score irrespective of h. pylori infection <sep> reflux score <sep> frequency of gastro-oesophageal reflux disease symptoms and health-related quality of life <sep> gastro-oesophageal reflux disease symptoms <sep> health-related quality of life <sep> complete relief rate <sep>', 'symptom relief <sep> reflux <sep> erosive reflux oesophagitis symptom relief <sep> oesophagitis <sep>', 'quality-of-life effects <sep> mean heartburn pain scores <sep> heartburn-specific questionnaire <sep> mean number of heartburn episodes <sep> frequency and severity of symptoms <sep> rate of adverse events <sep> quality of life <sep> general health status dimensions of physical functioning bodily pain and vitality <sep> clinical outcomes and quality of life <sep> heartburn severity <sep>', 'relief of heartburn <sep> median number of days off active treatment <sep> total time off active treatment time to failure of intermittent treatment and outcomes ranked from best to worst <sep> recurrences of moderate or severe heartburn <sep>', 'endoscopic healing <sep> complete relief from upper gi symptoms <sep> complete upper gi symptom relief <sep> symptomatic relapse <sep> complete relief <sep>', 'efficacy and safety <sep> rate of complete resolution of heartburn <sep> rate of sufficient relief from heartburn <sep> tolerated <sep> effective and well tolerated <sep> efficacy and safety <sep>', 'response of low-esophageal-sphincter pressure <sep> lower-esophageal-sphincter pressure <sep> mean basal pressure <sep> symptomatic improvement <sep>', 'erosive oesophagitis <sep> heartburn relief <sep> heartburn <sep> proportion of patients in whom heartburn <sep> severity of heartburn and endoscopic grade <sep> lower severity of heartburn <sep> relief of heartburn <sep>', 'symptom relief <sep> free of regurgitation <sep> alginate/antacid relief medication <sep> symptom relief <sep> free of heartburn <sep> anxiety <sep> reflux symptom relief <sep>', 'oesophageal acid hypersensitivity <sep> severity of oesophagitis or frequency of positive acid perfusion tests <sep> symptomatic response <sep>', 'safety and symptom relief efficacy <sep> incidence of possible or probable treatment-related adverse reactions <sep> abdominal pain and diarrhea <sep> nonerosive gastroesophageal reflux disease <sep> pain severity of both day and night heartburn <sep>', 'acid regurgitation dysphagia epigastric pain and nausea <sep> erosive esophagitis <sep> heartburn <sep> complete resolution of heartburn <sep> daily proportions of patients with no heartburn <sep> symptomatic relief <sep> efficacy and safety <sep>', 'relapse rate <sep>'], 'punchline_text': ['compared with placebo cisapride significantly reduced scores for daytime and nighttime heartburn p  0.001 total regurgitation p  0.001 eructation p  0.04 and early satiety p  0.04). <sep>', 'complete heartburn relief at week 4 was 32 with rabeprazole and 3.8 with placebo p  or  .001). <sep>', 'omeprazole 20 mg once daily was highly effective in relieving heartburn whereas cisapride 20 mg twice daily was not significantly more effective than placebo. <sep>', 'at 4 weeks the proportion of patients with complete absence of heartburn was 46 95 confidence interval 39-53 with 20 mg omeprazole 31 25-38 with 10 mg omeprazole and 13 7-20 with placebo. <sep>', 'pantoprazole is significantly superior to ranitidine in the treatment of key and associated gastrointestinal symptoms of gerd and is well tolerated. <sep>', 'patients in the esomeprazole group n  85 demonstrated statistically significant reductions in their gerdq index from 19.45 to 15.37 and to 14.32 p  0.013 p  0.005 at weeks 4 and 8 respectively. <sep>', 'pantoprazole was associated with significantly higher rates of complete control of gord symptoms than ranitidine at four weeks 40 v 19 p  0.001 eight weeks 55 v 33 p  0.001 six months 71 v 56 p  0.007 and 12 months 77 v 59 p  0.001). <sep>', 'daily diaries documented heartburn relief score  or  3/7 on  or  of 7 prior days and relapse score  or  4 on  or  2 of 7 prior days). <sep>', 'quality of life was improved in all treatment groups and the improvement in the reflux dimension of the gastrointestinal symptom rating scale gsrs score was significantly different between groups p  0.002). <sep>', 'at two weeks cimetidine was significantly more effective than placebo. <sep>', 'both famotidine regimens resulted in a significantly greater proportion of patients with complete endoscopic healing than placebo with the bid dosing being numerically superior to the 40-mg hs dose. <sep>', 'proportions of patients with total heartburn relief were higher in patients with eo 71%-80 of patients from day 4 onwards compared to those without eo 52%-67 of patients from day 4 onwards). <sep>', 'there was a significant correlation between the ph registration result and response to omeprazole p  0.04 chi2 but not to placebo p  0.16). <sep>', 'significant p less than 0.05 decreases in symptom frequency and severity were noted throughout the study in the cimetidine-treated patients as compared with the placebo group. <sep>', 'dexlansoprazole mr 30 and 60 mg were superior to placebo in providing 24-h heartburn-free days and nights in nerd patients. <sep>', 'the percentage of heartburn-free days was significantly higher with esomeprazole 40 mg 63 66 or 20 mg 63 68 than with placebo 46 36 p  or  0.001 in each of the two studies. <sep>', 'there were no differences between the groups with respect to changes in esophageal mucosal sensitivity to acid perfusion or changes in histologic grading of esophageal mucosal biopsy specimens. <sep>', 'omeprazole significantly improved reflux score irrespective of h. pylori infection while famotidine significantly improved reflux score in h. pylori-positive patients but not in h. pylori-negative patients. <sep>', 'symptom relief after 4 weeks was achieved by 61 om20 49 om10 and 40 ran patients om20 versus om10 p  0.0167 om20 versus ran p  0.0001 om10 versus ran p  0.01). <sep>', 'ranitidine-treated patients had more favorable scores on the general health status dimensions of physical functioning bodily pain and vitality p  .05 and more favorable scores on all dimensions of the heartburn-specific questionnaire p  .05). <sep>', 'patients with heartburn and normal endoscopy results or mild erosive changes received omeprazole 10 mg or 20 mg daily or ranitidine 150 mg twice daily for 2 weeks. <sep>', 'endoscopic healing at 4 weeks occurred in 76 of oesophagitis patients on ome20 and in 56 on ome10. <sep>', 'the rate of complete resolution of heartburn in week 4 was significantly higher in patients treated with omeprazole 10 mg 32.3 95 confidence interval ci 22.9%-41.6 or 20 mg 25.8 95 ci 16.9%-34.7 than in the placebo group 12.0 95 ci 5.3%-18.6%). <sep>', 'in both treatment periods metoclopramide-treated patients had significantly more symptomatic improvement than the control group p less than 0.05). <sep>', 'we conclude that omeprazole is superior to cimetidine for the relief of all grades of heartburn in gerd whether or not the patient has unequivocal endoscopic oesophagitis. <sep>', 'on completion symptom relief favoured omeprazole 57 of patients on omeprazole were free of heartburn vs. 19 on placebo 75 were free of regurgitation 47 and 43 were completely asymptomatic 14 each with p  0.0001. <sep>', 'ranitidine was superior to placebo with regard to effect on symptoms improvement of oesophagitis as assessed by endoscopy and biopsy and decrease of oesophageal acid hypersensitivity. <sep>', 'lansoprazole therapy is more effective than standard dosages of ranitidine or placebo in relieving symptoms in patients with endoscopically confirmed non-erosive reflux esophagitis. <sep>', 'omeprazole was significantly p or .003 more effective than placebo for the treatment of acid regurgitation dysphagia epigastric pain and nausea. <sep>', 'at two weeks there was no significant difference between placebo and ranitidine regarding the proportion of patients with complete relief from symptoms or satisfied with treatment. <sep>'], 'population': ['patients with moderate intensity heartburn and no history of erosive esophagitis <sep> chronic mild to moderate gastroesophageal reflux disease <sep> 398 patients who continued to experience moderate intensity heartburn <sep>', 'run-in period patients n  261 <sep> patients with moderately severe nonerosive gastroesophageal reflux disease <sep> symptomatic gastroesophageal reflux disease <sep>', 'setting 65 primary care practices in norway <sep> 483 untreated patients with complaints of heartburn 3 days a week with at most grade 1 reflux oesophagitis <sep> patients with or without reflux oesophagitis <sep> primary care patients <sep>', 'patients without endoscopic oesophagitis <sep> patients without oesophagitis <sep> patients with heartburn without endoscopic signs of oesophagitis <sep>', 'gastroesophageal reflux disease gerd <sep> patients 338 intention-to-treat itt population 284 per-protocol pp population <sep> patients with symptomatic gastroesophageal reflux disease <sep> patients suffering from symptomatic gerd <sep>', 'patients with a clinical diagnosis of gastroesophageal reflux and a locally validated reflux index the chinese gerdq of equal to or greater than 12 <sep> 175 patients were randomized <sep> chinese patients with non-erosive reflux disease <sep> non-erosive reflux disease in chinese patients <sep> chinese patients <sep>', 'patients with symptomatic gord <sep> patients with gastro-oesophageal reflux disease gord <sep> 76 general practices in north-west sydney and newcastle new south wales australia from 19 january 1999 to 22 september 2000 <sep> 307 patients aged 18 years or over presenting with symptomatic gord <sep> uninvestigated heartburn in primary care <sep>', 'heartburn-dominant uninvestigated dyspepsia patients from 46 primary care centres <sep>', 'gastro-oesophageal reflux disease <sep> following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease <sep>', 'patients with stage 0 gastro-oesophageal reflux disease <sep> one hundred and twenty-five patients with symptoms of heartburn and acid regurgitation but without endoscopic abnormalities <sep>', '338 patients were randomized 135 to receive <sep>', 'patients with heartburn following treatment with <sep> 440 patients <sep> 114 patients had gerd defined by ph-monitoring <sep> 240 patients had erosive esophagitis eo and <sep> patients with heartburn <sep> patients with heartburn for  or  6 months <sep>', 'forty-one patients <sep> gastroesophageal reflux disease gerd <sep> gastroesophageal reflux disease <sep> patients with symptoms suggestive of gerd underwent upper gastrointestinal endoscopy and 24-h esophageal ph monitoring <sep> patients with reflux esophagitis grade 0 or 1 were included in the study <sep> ninety-eight patients were included however 13 were excluded from the final analysis because of protocol violation <sep> of the remaining 85 patients 54 had no signs of esophagitis at endoscopy and 31 had esophagitis grade 1 <sep>', 'symptomatic gastroesophageal reflux <sep> patients with chronic gastroesophageal reflux <sep>', 'nerd patients <sep> patients with non-erosive reflux disease <sep> patients receiving <sep> 947 nerd patients randomly received <sep>', 'patients without erosive oesophagitis <sep> patients with frequent heartburn for or  6 months and no evidence of erosive oesophagitis on endoscopy <sep> patients with chronic heartburn but with no endoscopic evidence of erosive oesophagitis require gastric acid suppression to relieve symptoms <sep>', 'patients with gastroesophageal reflux disease <sep> 284 patients with gastroesophageal reflux disease <sep> gastroesophageal reflux disease <sep>', 'japanese patients with non-erosive gastro-oesophageal reflux disease <sep> non-erosive gastro-oesophageal reflux disease in japan <sep> non-erosive gastro-oesophageal reflux disease <sep>', 'gastro-oesophageal reflux disease in general practice <sep> patients n  994 presenting with heartburn to their general practitioner underwent endoscopy to exclude peptic ulcer disease <sep> gastro-oesophageal reflux disease gord <sep>', 'gastroesophageal reflux disease gerd <sep> eligible patients included those who were at least 18 years old and had at least a 3-month history of heartburn or heartburn therapy and a minimum of 4 days with at least one heart-burn episode in the week preceding the baseline visit <sep> gastroesophageal reflux disease patients <sep> patients with gerd <sep>', 'patients with uncomplicated gastro-oesophageal reflux disease <sep> 677 patients with gastro-oesophageal reflux disease <sep> patients who were symptomatic or mildly symptomatic were followed up for 12 months <sep> patients with symptomatic gastro-oesophageal reflux disease <sep> patients with heartburn and normal endoscopy results or mild erosive changes received <sep> hospitals and primary care practices between 1994 and 1996 <sep> patients with erosive and non-erosive disease <sep> symptomatic gastro-oesophageal reflux disease <sep> 704 patients were randomised 677 were eligible for analyses 318 reached the end of the study with intermittent treatment without recourse to maintenance antisecretory drugs <sep>', 'gastro-oesophageal reflux disease in primary care <sep> patients with oesophagitis <sep> patients presenting with troublesome reflux symptoms <sep> patients were recruited using a symptom-based questionnaire for diagnosis of gastro-oesophageal reflux disease <sep> patients with or without endoscopic oesophagitis <sep> patients without endoscopic oesophagitis <sep>', ""patients with heartburn for at least 2 days a week during the month before entry into the study and no endoscopic signs of a mucosal break grade m or n according to hoshihara's modification of the los angeles classification <sep> japanese patients with nonerosive reflux disease <sep> patients with nerd regardless of their endoscopic classification <sep> japanese patients with nerd <sep> 355 patients were enrolled of whom 284 <sep>"", 'eighteen patients <sep> symptomatic gastroesophageal reflux <sep> patients with gastroesophageal reflux <sep> 31 patients with chronic heartburn <sep>', '221 patients with heartburn and oesophageal mucosa grade 0 normal n  51 1 no macroscopic erosions n  52 2 isolated erosions n  97 or 3 confluent erosions n  21 <sep> patients with symptomatic non-ulcerative oesophagitis and in those with heartburn but without oesophagitis <sep> patients with endoscopically verified oesophagitis but excluded the substantial group of gastro-oesophageal reflux disease gerd patients with reflux symptoms but without endoscopic abnormality <sep>', 'patients with symptoms typical of gastro-oesophageal reflux disease but without endoscopic evidence of oesophagitis <sep> patients without unequivocal oesophagitis <sep> patients with essentially normal oesophageal mucosa <sep> patients n  209 <sep>', 'gastro-oesophageal reflux disease <sep> patients with gastro-oesophageal reflux paired comparison in 38 patients <sep> patients with reflux disease <sep>', 'patients with endoscopically confirmed non-erosive reflux esophagitis <sep> 901 patients with symptomatic reflux disease which was confirmed by endoscopy to be nonerosive received <sep> patients with nonerosive reflux disease <sep> patients with esophagitis <sep>', 'patients with a history of heartburn  or 12 months and episodes of moderate to severe heartburn on 4 or more of the 7 days before endoscopy <sep> symptomatic gerd without erosive esophagitis <sep> patients with symptomatic gerd <sep> eligible patients <sep> 359 randomized patients 355 were included in the statistical analysis intention-to-treat population <sep> symptomatic acid reflux disease without esophagitis <sep> patients with gastroesophageal reflux disease gerd <sep>', 'patients with reflux symptoms <sep> four hundred and twenty-seven patients were randomised <sep> patients with reflux symptoms <sep>'], 'interventions': ['placebo cisapride <sep> placebo <sep> cisapride <sep> cisapride <sep>', 'rabeprazole 20 mg once daily or placebo <sep> placebo <sep> rabeprazole <sep> rabeprazole <sep>', 'cisapride or placebo <sep> placebo <sep> omeprazole and cisapride <sep> omeprazole <sep> antacid <sep> omeprazole v cisapride and placebo <sep> cisapride <sep> omeprazole <sep> cisapride v placebo <sep>', 'omeprazole 20 or 10 mg once daily or placebo <sep> omeprazole <sep> placebo <sep> omeprazole <sep>', 'pantoprazole placebo <sep> pantoprazole <sep> pantoprazole <sep> proton pump inhibitor pantoprazole and the h2 antagonist ranitidine <sep> ranitidine placebo <sep> ranitidine <sep>', 'esomeprazole 20 mg daily or placebo <sep> placebo <sep> proton pump inhibitor <sep> esomeprazole <sep>', 'ranitidine <sep> pantoprazole <sep> pantoprazole <sep>', 'proton pump inhibitor-start or an h(2)-receptor antagonist-start with step-up therapy <sep> omeprazole 20 mg daily proton pump inhibitor-start or ranitidine 150 mg bid h2-receptor antagonist-start for the first 4-8 weeks stepping up to omeprazole <sep>', 'omeprazole and cisapride <sep> omeprazole <sep> omeprazole 20 or 10 mg once daily or cisapride <sep> cisapride <sep> omeprazole <sep>', 'placebo <sep> cimetidine suspension <sep> placebo suspension <sep> cimetidine <sep> cimetidine suspension four times daily or placebo <sep>', 'famotidine <sep> placebo <sep> famotidine 40 mg administered at bedtime hs <sep> famotidine <sep> famotidine 40 mg hs <sep>', 'esomeprazole 40 mg o.d. esomeprazole 20 mg b.i.d. or placebo <sep> placebo <sep> esomeprazole <sep> esomeprazole <sep>', 'omeprazole <sep> omeprazole or placebo <sep> omeprazole <sep> placebo <sep>', 'cimetidine <sep> placebo <sep> cimetidine <sep> placebo tablets <sep>', 'proton pump inhibitor dexlansoprazole mr <sep> placebo <sep> dexlansoprazole mr 30 and 60 mg were superior to placebo <sep> dexlansoprazole mr <sep> dexlansoprazole mr <sep> dexlansoprazole mr 30 mg 60 mg or placebo <sep> proton pump inhibitor ppi therapy <sep>', 'esomeprazole <sep> placebo <sep> esomeprazole <sep>', 'placebo <sep> ranitidine <sep> placebo or ranitidine <sep> ranitidine therapy <sep> ranitidine therapy <sep> ranitidine <sep>', 'famotidine <sep> famotidine 20 mg b.d <sep> omeprazole <sep> acid-suppressive drugs <sep> famotidine vs. omeprazole <sep> histamine2-receptor antagonists or placebo <sep> famotidine and omeprazole <sep> omeprazole <sep>', 'omeprazole <sep> omeprazole daily om20 10 mg omeprazole daily om10 and 150 mg ranitidine ran <sep> omeprazole 20 milligrams once daily or ranitidine <sep> omeprazole <sep> histamine <sep>', 'histamine h2)-receptor antagonist ranitidine <sep> placebo <sep> ranitidine <sep> ranitidine and placebo <sep> ranitidine vs placebo <sep> ranitidine <sep>', 'omeprazole <sep> omeprazole 10 mg or ranitidine <sep> omeprazole or ranitidine <sep> omeprazole <sep> ranitidine <sep>', 'omeprazole 10 mg ome10 or placebo <sep> omeprazole <sep> placebo <sep> placebo-controlled comparison <sep>', 'omeprazole <sep> placebo <sep> omeprazole <sep> omeprazole 10 mg or 20 mg or placebo <sep>', 'placebo <sep> metoclopramide <sep>', 'omeprazole 20 mg daily or cimetidine 400 mg q.d.s <sep> omeprazole <sep> cimetidine <sep> omeprazole <sep> omeprazole and cimetidine <sep>', 'omeprazole <sep> placebo <sep> omeprazole <sep>', 'ranitidine and placebo <sep> placebo <sep> ranitidine <sep> ranitidine <sep>', 'lansoprazole 15 or 30 mg once daily ranitidine <sep> lansoprazole with ranitidine <sep> placebo <sep> ranitidine or placebo <sep> lansoprazole <sep> lansoprazole <sep> proton pump inhibitors <sep> ranitidine <sep> lansoprazole therapy <sep>', 'omeprazole <sep> placebo <sep> omeprazole <sep> omeprazole 20 mg once daily omeprazole <sep>', 'placebo <sep> placebo and ranitidine <sep> ranitidine <sep> ranitidine <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>']}",ppis are more effective than h2ras in relieving heartburn in patients with gord who are treated empirically and in those with enrd although the magnitude of benefit is greater for those treated empirically.
435,"{'outcomes': ['wound area <sep> efficacy and safety <sep> wound size <sep> complete healing <sep>', 'efficacy and tolerance <sep> pain on dressing change <sep> total number of dressing changes <sep> adverse events <sep> success rate <sep> efficacy and tolerance <sep> pain on dressing changes the number of dressing changes and adverse events <sep> proportion of patients with granulation tissue <sep>', 'overall ulcer improvement and less deterioration <sep> diabetic foot ulcers dfus <sep> adverse events <sep> dfu healing <sep> mean time to healing <sep> healing outcomes and primarily healing speed <sep> all ulcer healing outcomes <sep> aqag-treated ulcers <sep>'], 'punchline_text': ['thirty-nine 78 patients treated with the collagen-alginate dressing achieved  or  75 wound area reduction compared with 15 60 of gauze-treated patients. <sep>', 'pain on dressing change was lower in the calcium alginate group p=0.047 and the total number of dressing changes tended also to be lower p=0.07). <sep>', 'there was more overall ulcer improvement and less deterioration in aqag subjects p  0.058 particularly in the subset initially using antibiotics p  0.02). <sep>'], 'population': ['diabetic foot ulcers <sep> seventy-five patients with foot ulcers <sep>', 'seventy-seven patients were enrolled <sep> diabetic foot lesions <sep> 13 patients <sep>', 'managing out-patients with type 1 or 2 diabetes mellitus and non-ischaemic wagner grade 1 or 2 dfus <sep> patients stratified by antibiotic use on enrolment <sep> non-ischaemic diabetic foot ulcers <sep>'], 'interventions': ['collagen-alginate topical wound dressing fibracol collagen-alginate wound dressing <sep> collagen-alginate test dressing or the gauze dressing <sep> collagen-alginate wound dressing <sep> regular gauze moistened with normal saline <sep>', 'calcium alginate <sep> alginate wound dressing with a vaseline gauze dressing <sep> vaseline gauze calcium alginate <sep> vaseline gauze dressings <sep> vaseline gauze <sep> calcium alginate or vaseline gauze dressings <sep>', 'aquacel hydrofiber dressings containing ionic silver aqag <sep> aqag <sep> hydrofiber dressing containing ionic silver or calcium alginate dressings <sep> algosteril calcium alginate ca dressings <sep> ca n  67 primary dressings and secondary foam dressings for 8 weeks or until healing <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",currently there is no research evidence to suggest that alginate wound dressings are more effective in healing foot ulcers in people with diabetes than other types of dressing however many trials in this field are very small. decision makers may wish to consider aspects such as dressing cost and the wound management properties offered by each dressing type e.g. exudate management.
436,"{'outcomes': ['severe preterm birth <sep> 30 fetal deaths <sep> birth outcomes and counts of t lymphocyte subsets <sep> pregnancy outcomes and t cell counts <sep> cd4 cd8 and cd3 counts <sep> risk of low birthweight <sep>', 'risk of fetal death <sep> hiv disease progression or pregnancy outcomes <sep> child survival <sep> maternal mortality <sep> maternal cd4 cell counts or viral load <sep> neonatal or overall child mortality <sep> reduced risk of low birth weight <sep> cd4 cell counts viral load pregnancy outcomes and maternal and infant mortality <sep> risk of child mortality <sep>', 'risk of fetal death <sep> adverse pregnancy outcomes <sep> risk of low birth weight <sep> early infant death <sep> mean birth weights <sep> risk of adverse pregnancy outcomes <sep> risk of preterm birth <sep>', 'hemoglobin concentrations <sep> cd4 cd8 or cd3 cell counts <sep> adverse birth outcomes <sep> birth weight duration of gestation or fetal and neonatal mortality <sep> pregnancy outcomes hematologic indicators and t cell counts <sep> red blood cell count and in packed cell volume <sep> birth outcomes hematologic indicators and counts of t lymphocyte subsets <sep> rise in hemoglobin <sep>'], 'punchline_text': ['multivitamin supplementation decreased the risk of low birthweight 2500 g by 44 0.56 0.38-0.82 p=0.003 severe preterm birth 34 weeks of gestation by 39 0.61 0.38-0.96 p=0.03 and small size for gestational age at birth by 43 0.57 0.39-0.82 p=0.002). <sep>', 'the regimen had no significant effect on maternal mortality rr  1.02 95 ci  0.51 2.04 p  0.96). <sep>', 'there were no significant differences between the 2 groups in the risk of fetal death p  0.99 or early infant death p  0.19). <sep>', 'however the rise in hemoglobin over this period was significantly lower p  0.03 in the zinc group x  <sep>'], 'population': ['hiv-1-infected women in tanzania <sep> 1075 hiv-1-infected pregnant women at between 12 and 27 weeks gestation received <sep> hiv-1-infected women <sep> such women <sep>', 'hiv-infected pregnant women in tanzania <sep> 913 hiv-infected pregnant women <sep> eligible women between 12 and 27 wk of gestation were given <sep>', 'hiv-infected women in tanzania <sep> hiv-infected women <sep> 1129 hiv-infected pregnant women in tanzania <sep> eligible women between 12 and 27 gestational weeks <sep>', 'hiv-1-infected women in tanzania <sep> 400 hiv-infected pregnant women <sep> hiv-infected women <sep> pregnant hiv-infected women <sep> eligible women between 12 and 27 wk of gestation <sep>'], 'interventions': ['vitamin a and multivitamins <sep> placebo <sep> multivitamin supplementation <sep> vitamin a supplementation <sep> vitamin supplements <sep> multivitamins and vitamin <sep> vitamin a n=269 multivitamins excluding vitamin a n=269 or multivitamins including vitamin a <sep>', 'selenium supplements <sep> placebo <sep> daily selenium 200 mug as selenomethionine or placebo <sep> daily selenium supplements <sep> prenatal iron folic acid and multivitamin supplements <sep>', 'supplementation with multivitamins vitamin b complex vitamin c and vitamin e <sep> multivitamin supplements <sep> multivitamin supplements <sep> daily oral supplements of either single or multiple rda multivitamins <sep>', 'zinc supplements <sep> iron folic acid and multivitamin supplements <sep> placebo <sep> daily oral supplementation with either 25 mg zn or placebo <sep>'], 'punchline_effect': [' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",in keeping with previous world health organization who recommendations everything possible should be done to promote and support adequate dietary intake of micronutrients while recognising that this may not be sufficient to correct specific micronutrient deficiencies in all hiv-infected individuals. specific recommendations for pregnant and lactating women infected with hiv would be to include the provision of multivitamin supplements in single rda formulations during the antenatal period and at least for 6 weeks post-partum especially for women who are breast-feeding. there is no conclusive evidence to provide stand-alone zinc or selenium supplementation to hiv-infected pregnant and lactating women. micronutrient supplementation should not be used as a substitute for provision of recommended antiretroviral medication for preventing mother-to-child transmission of hiv and treating maternal hiv infection when this is recommended. further trials of single supplements are required to build the evidence base. the long-term clinical benefits adverse effects and optimal formulation of multiple micronutrient supplements require further investigation in pregnant women at different stages of hiv infection.
437,"{'outcomes': ['ttp and survival <sep> response rates <sep> median survival <sep> median time to progression ttp <sep> constitutional hemodynamic and myelosuppressive toxic effects <sep>', 'poor performance status ps hepatic metastases and weight loss <sep> five crs and 20 prs <sep> severe and life-threatening toxic events <sep> toxicity <sep> response rate ttf or survival <sep> durable responses <sep> ttf or survival <sep> nine complete crs and 18 partial responses prs <sep> response rate time to treatment failure ttf overall survival and toxicity <sep> overall median survival <sep> survival <sep> overall median ttf <sep>', 'tolerated with only additive toxicity <sep> complete and partial response rate <sep> prolonged survival <sep>', '1-year survivals <sep> response rates overall survival and tolerability <sep> response or disease stabilization <sep> grade 3 or 4 nonhematologic toxicities <sep> median survival <sep>', 'drug safety <sep> nonhematologic toxicities <sep> health-related qol <sep> overall survival progression-free survival pfs objective response and safety and to assess health-related quality of life qol and pharmacokinetics of both drugs and their metabolite 5-(3-methyltriazen-1-yl)imidazole-4-carboximide mtic <sep> median pfs time <sep> median survival time <sep> tolerated and produced a noncumulative transient myelosuppression late <sep>', 'toxicity <sep> acceptable level of toxicity <sep> overall survival os <sep> os time to progression or or <sep> severe toxicity <sep> median os <sep>', 'objective response complete plus partial remission cr  pr <sep> toxicity <sep> median time to treatment failure ttf and median survival <sep>', 'toxicity <sep> median survival <sep> toxicities <sep> objective responses survival and toxicity <sep> duration of partial responses <sep> survival <sep> survival advantage <sep>', 'overall response rate <sep> median progression free survival <sep> median overall survival <sep>', 'death <sep> median survival <sep> quality of life <sep> 6-month survival <sep> quality of life <sep> survival benefit <sep> survival <sep>', 'fatigue <sep> median durations of response <sep> complete response cr and seven partial responses pr <sep> percentage of cd4 or cd4 t-cell subsets <sep> lymphopenia evidence of immune activation <sep> efficacy and toxicity <sep> percentage of cd56 nk cells and cd3/hla-dr-positive activated t cells subsets <sep> overall response rate of bcdt with il-2/ifn-alpha <sep> severe thrombocytopenia <sep> response rates <sep> incidence of grade 3/4 flu-like symptoms <sep> progression-free survival or overall survival <sep>', 'median duration of response <sep> functional living index <sep> response rates <sep> fatigue nausea and anorexia flu-like symptoms and neutropenia <sep> response or survival <sep> quality of life <sep> toxicity <sep> total response rate <sep> survival <sep>'], 'punchline_text': ['response rates were 48 for biochemotherapy and 25 for chemotherapy p .001 six patients given biochemotherapy and two given chemotherapy had complete responses. <sep>', 'neither ifn tmx nor the combination significantly improved the response rate ttf or survival when added to dacarbazine but ifn significantly increased toxicity. <sep>', 'in addition patients receiving the combined treatment schedule had a significantly prolonged survival median 19 months when compared to a median of 10 months for interferon alone and 5 months for vindesine alone. <sep>', 'grade 3 or 4 nonhematologic toxicities were similar in each arm except for infection which was more frequent with 8-hourly temozolomide. <sep>', 'temozolomide therapy improved health-related qol more patients showed improvement or maintenance of physical functioning at week 12. <sep>', 'the addition of low-dose immunotherapy did not produce a statistically significant advantage in os time to progression or or. <sep>', 'median time to treatment failure ttf and median survival are significantly better on the combination arm with some long-term crs observed. <sep>', 'objective responses survival and toxicity in the two groups were evaluated at a median potential follow-up of 42 months. <sep>', 'there was no significant difference in median progression free survival 0 months vs 4 months and in median overall survival 12 months vs 13 months for combined chemoimmunotherapy and for chemotherapy respectively. <sep>', 'there was no significant difference in survival between the two treatment arms chi2 unadjusted  0.15 p  0.70 chi2 adjusted  0.01 p  0.91). <sep>', 'there was no difference between the two groups in progression-free survival or overall survival median survival 5 months for bcdt with il-2/ifnalpha and 5.5 months for bcdt alone). <sep>', 'toxicity was worse in the combination arm with more patients experiencing fatigue nausea and anorexia flu-like symptoms and neutropenia. <sep>'], 'population': ['metastatic melanoma <sep> 190 patients enrolled 91 were assessable for biochemotherapy and 92 for chemotherapy <sep> metastatic melanoma patients who had not previously received <sep> patients with metastatic melanoma <sep>', 'two hundred seventy-one patients 258 were eligible <sep> patients with metastatic melanoma treated with <sep> patients with metastatic malignant melanoma <sep>', '60 patients <sep> advanced malignant melanoma <sep> metastatic malignant melanoma <sep>', 'one hundred eighty-one patients with metastatic melanoma <sep> metastatic malignant melanoma <sep> patients with advanced metastatic melanoma <sep>', '305 patients with advanced metastatic melanoma <sep> patients with advanced metastatic malignant melanoma <sep> patients with advanced metastatic melanoma <sep>', 'outpatients with metastatic melanoma <sep> advanced melanoma outpatients <sep> one hundred seventy-six eligible patients with advanced melanoma <sep>', 'sixty-four patients with histologically confirmed metastatic malignant melanoma <sep> six patients on dtic and in 16 patients on dtic plus ifn alfa-2b <sep> patients with metastatic malignant melanoma <sep>', 'patients with metastatic melanoma using <sep> one hundred two patients with metastatic melanoma <sep> patients with metastatic melanoma <sep>', 'cooperative advanced malignant melanoma chemoimmunotherapy group acimm <sep> 124 patients <sep>', 'metastatic melanoma <sep> 61 patients were randomized between april 1995 and april 1998 <sep> patients receiving ifn-alpha in combination with dtic <sep> patients with metastatic melanoma <sep> fifty-seven patients died during the study <sep>', 'sixty-five patients with metastatic melanoma ecog performance status 0 or 1 <sep> patients with metastatic melanoma <sep>', 'eighty seven patients were randomized to the combination and 83 patients to <sep> symptomatic measurable metastatic malignant melanoma <sep> metastatic malignant melanoma <sep>'], 'interventions': ['chemotherapy <sep> biochemotherapy <sep> cvd plus interleukin-2 and interferon alfa-2b <sep> biochemotherapy <sep> vinblastine <sep> chemotherapy or biochemotherapy <sep> cisplatin and vinblastine <sep> dacarbazine <sep> sequential biochemotherapy versus chemotherapy <sep> chemotherapy cisplatin vinblastine and dacarbazine cvd <sep> interferon alfa-2b by subcutaneous injection <sep>', 'dacarbazine with interferon alpha-2b and tamoxifen <sep> dacarbazine alone dacarbazine plus interferon ifn dacarbazine plus tamoxifen tmx or dacarbazine plus ifn plus tmx <sep> tmx <sep> dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen <sep> dacarbazine <sep>', 'vindesine <sep> vindesine plus interferon-alpha 2b <sep> interferon alone <sep> vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone <sep> vindesine 3 mg/m2/week plus interferon-alpha 2b 6 u <sep>', 'temozolomide <sep> temozolomide with interferon alfa-2b and separately with thalidomide <sep> temozolomide/interferon <sep> dacarbazine <sep> temozolomide/thalidomide <sep> interferon alfa-2b or thalidomide <sep> thalidomide <sep> temozolomide and thalidomide <sep> temozolomide <sep> temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 mu million international units subcutaneously three times a week or temozolomide <sep>', 'temozolomide <sep> oral temozolomide <sep> temozolomide and dacarbazine dtic <sep> dacarbazine <sep> dtic <sep> temozolomide <sep>', 'cisplatin dacarbazine with or without subcutaneous interleukin-2 and interferon alpha-2b <sep> ct cisplatin and dacarbazine with or without carmustine every 21 days or bioct comprising the same ct regimen followed by low-dose subcutaneous il-2 <sep> interleukin-2 il-2 and interferon alpha-2b ifn alpha-2b <sep> il-2 and ifn alpha-2b <sep> ct with biochemotherapy bioct <sep>', 'interferon alfa-2b to dacarbazine <sep> dacarbazine dtic alone or dtic plus interferon ifn alfa-2b <sep>', 'chemotherapy <sep> tamoxifen cisplatin and dacarbazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2 <sep> chemotherapy with cisplatin dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b <sep> chemoimmunotherapy <sep>', 'carmustine <sep> sequential immunotherapy <sep> oral tamoxifen 20 mg m(-2 daily in combination with n=64 or without n=60 sequential subcutaneous il-2 and ifn-alpha <sep> combination chemoimmunotherapy <sep> intravenous cisplatin <sep> combination chemotherapy with or without s.c. il-2 and ifn-alpha <sep> dacarbacine <sep>', 'dacarbazine dtic <sep> interferon-alpha ifn-alpha <sep> dtic ifn-alpha <sep> dacarbazine dtic versus dtic plus interferon-alpha ifn-alpha <sep> dtic <sep>', 'combination biochemotherapy <sep> cisplatin 25 mg m(-2 <sep> intravenous bcnu <sep> interferon alpha ifn-alpha and interleukin il-2 <sep> combination chemotherapy <sep> bcdt carmustine bcnu cisplatin dacarbazine dtic and tamoxifen <sep> chemotherapy alone <sep> oral tamoxifen <sep> il-2/ifnalpha <sep> subcutaneous il-2 and ifnalpha to bcdt chemotherapy <sep>', 'dacarbazine and interferon-alpha 2a <sep> interferon-alpha 2a <sep> interferon <sep> dacarbazine <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>']}",we failed to find any clear evidence that the addition of immunotherapy to chemotherapy increases survival of people with metastatic melanoma. further use of combined immunotherapy and chemotherapy should only be done in the context of clinical trials.
438,"{'outcomes': ['diagnosis of depression <sep> benzodiazepine hypnotics <sep> psychotic disorder <sep> proportion of residents with any psychotropic drug polymedicine and therapeutic duplication and proportion of residents with nonrecommended and acceptable drugs <sep> prescribing of psychotics <sep> diagnosis of dementia <sep>', 'intervention delayed time to first attendance with acute asthma <sep> percentage of participants attending with acute asthma <sep>', 'influenza and pneumococcal immunisation rates <sep> influenza and pneumococcal vaccination rates <sep> pneumococcal vaccination rates <sep> influenza vaccination <sep> vaccination rates <sep>', 'loss of memory <sep> anxiety <sep> index of psychoactive-drug use measuring both the magnitude and the probable inappropriateness of medication use <sep> cognitive function <sep> discontinuation of long-acting benzodiazepines <sep>', 'antibiotic dispensing <sep>', 'acute respiratory tract infection <sep> antibiotic use diazepam prescribing drug costs per patient and a composite process index for diabetes care <sep>', 'initial prescriptions <sep> anxiety and insomnia diagnosis rates <sep> overall benzodiazepine prescribing rate fell <sep> prescribing for anxiety diagnoses <sep>', 'physical activity functional status self rated health immunisation status social contacts psychological wellbeing drug usage and rate of influenza vaccination <sep> health outcomes <sep> drug usage rate of influenza vaccination functional status or psychological wellbeing <sep> frequency of pleasurable activities and c self rated health <sep>', 'numbers of patients at risk of stroke <sep>', 'average prescribing cost <sep>', 'global scores in 4 areas--quality of care charting prevention and overall use of medications--and patient ratings of satisfaction with care and preventive practices <sep> blood pressure <sep> mean global scores <sep> mean scores <sep> personal care scores <sep>', 'physician reporting of adverse drug reactions <sep> adr reporting rates <sep> reporting adrs overall <sep> adr reports <sep>', 'back pain unit <sep>', 'blood pressure <sep> hypertension control <sep> blood pressure control defined as a blood pressure measurement <sep>', 'patient care processes lab work nursing dietary management ventilator management ventilator weaning <sep> hospital ventilator days <sep> total length of stay and icu length of stay fell <sep> quality of care <sep> clinical outcomes of mortality or nosocomial events <sep> patient care processes patient morbidity and mortality outcomes and resource use <sep> quality of rural icu care <sep>', 'minimal intervention components of the kit ratings of overall acceptability of delivery perceptions of cultural and structural barriers to using the kit and ratings of the overall acceptability of the kit <sep>', 'overall cost <sep>', 'reduced mortality <sep> days of enteral nutrition <sep> mean stay in hospital <sep> mean stay in the icu <sep>', 'prescription of first-line lipid-lowering drugs <sep> number of prescriptions of lipid-lowering drugs per month <sep>', 'cde recommendation and performance <sep> baseline-adjusted cde recommendation and performance rates <sep> cde recommendation and performance rates <sep>', 'mammography completion <sep>', 'proportions of gps implementing the programme and numbers of patients screened and intervened with <sep> effectiveness and cost-effectiveness <sep>', 'higher self-reported and observed rates for several risk assessment questions and counseling recommendations <sep> risky sexual behavior <sep>', 'total costs <sep> discontinuation rates <sep> processes of care patient symptoms quality of life costs and work days lost <sep> helicobacter pylori testing <sep> patient quality of life or symptoms <sep>', 'mean costs of inappropriate prescriptions per practitioner per patient visit <sep> mean rate of inappropriate prescribing per control practitioner <sep> mean cost <sep>', 'overall index of preventive performance <sep> preventive care performance <sep> index of preventive performance <sep>', 'antimicrobial usage <sep> oral rehydration solution ors usage <sep> levels of knowledge of prescribers about the appropriate management of acute diarrhoea <sep>', 'cerebral and peripheral vasodilators cpvd and antibiotics <sep> relative reduction in r05c1 prescription <sep> prescription of cpvd <sep>', 'quantity of cholesterol testing <sep> quality of selective case finding and quality of diagnostic procedures <sep>', 'rates of diuretic or beta-blocker use <sep> blood pressure control <sep>', 'blood transfusion practice <sep> transfusion risks eg viral hepatitis <sep>', 'preventive cardiovascular care <sep> diagnoses of hypertension <sep> blood pressure control <sep>', 'blood pressure and total cholesterol values <sep> hyperlipidaemia or <sep> raised total cholesterol <sep>', 'moderate rates of improvement <sep>', 'percentage of records containing at least one periodontal diagnostic notation <sep>', 'risk factors <sep> angina pectoris <sep> compliance rates <sep> hypertension <sep>', 'weight and physical activity level <sep> frequency and quality of counseling <sep>', 'total antimicrobial use <sep> suspected urinary tract infections <sep> admissions to hospital or mortality <sep>', 'benzodiazepine prescribing <sep> prescribing behaviour <sep> overall benzodiazepine prescribing <sep>', 'antidiarrhoeal sales <sep> knowledge about diarrhoea <sep> discussion of dehydration during pharmacy visits <sep> child diarrhoea <sep>', 'tranexamic acid <sep> referral rates <sep> prescribing of tranexamic acid <sep>', 'length of stay intensive care unit transfers readmission rates and in-hospital death rates <sep> rate of unnecessary use of the 2 target antibiotics <sep> number of days that unnecessary levofloxacin or ceftazidime <sep>', 'prescribing practice <sep>', 'endorsement of psa screening by professional bodies <sep> psa testing rates and gp knowledge in key areas relating to prostate cancer and psa testing <sep> median psa testing rate <sep> proportion of correct responses <sep>', 'clinical breast examination <sep> provision of preventive care <sep> patient satisfaction scores <sep> rates of preventive services <sep> mammography <sep> pneumococcal immunization <sep> tetanus immunization <sep> influenza immunization <sep>', 'proportion of prescribing of the five most frequently used drugs <sep> prescribing quality and volume <sep> volume of prescribing for ibuprofen diclofenac and naproxen as a percentage of total nsaid prescribing <sep> primary outcome measure practices receiving outreach visits <sep>', 'effectiveness and efficiency <sep> proportion of appropriate outcomes following educational outreach odds ratio or <sep> appropriateness based upon the guidelines of sale or no sale of otc anti-fungals <sep>', 'patient recall of fp advice about nicotine replacement patches and gum <sep> patient recall of assessment of smoking status and fp use of quit dates behavioral advice and written materials <sep>', 'total number of antibiotic prescriptions <sep> respiratory infections <sep> total cost of antibiotics prescribed by doctors <sep>', 'antibiotics in caesarean section and use of polyglycolic acid sutures <sep> rates of ventouse delivery <sep>', 'time to symptom resolution <sep> antibiotic prescribing rates and patients symptom resolution <sep>'], 'punchline_text': ['experimental homes participated in an outreach program that was designed to influence drug use through improved teamwork among physicians pharmacists nurses and nurses assistants. <sep>', 'asthma specialist nurses using a liaison model of care reduced unscheduled care for asthma in a deprived multiethnic health district. <sep>', 'practices where primary care teams received an educational outreach visit demonstrated a significantly greater improvement in uptake in high-risk groups for pneumococcal but not influenza vaccine. <sep>', 'in the experimental nursing homes residents who were initially taking antipsychotic drugs showed less deterioration on several measures of cognitive function than similar residents in the control facilities but they were more likely to report depression. <sep>', 'a limited simultaneous educational outreach intervention for parents and providers reduced antibiotic use among children in primary care practices even in the setting of substantial secular trends toward decreased prescribing. <sep>', 'clinical guidelines implemented with workshops and educational outreach visits improved some but not all aspects of prescribing in the short-term. <sep>', 'after adjusting for confounders there was a differential downward trend in prescriptions per diagnosis of insomnia but not to a statistical level. <sep>', 'no change was seen in drug usage rate of influenza vaccination functional status or psychological wellbeing as a result of the intervention. <sep>', 'there were no differences between the intervention and control groups for the three month fall rate. <sep>', 'intervention produced a significant increase p less than 0.005 in the prescribing cost of ibuprofen the non-steroidal promoted as first choice agent which was sustained for at least 5 months. <sep>', 'a total of 64.3 of the physicians rated the par as useful 26.5 found the cmep to be useful and 41.0 considered the mentor strategy to be a useful form of continuing medical education. <sep>', 'the adjusted increase in adr reporting rates attributable to intervention was 90.19 for total adrs <sep>', 'there were no significant differences between study groups in the proportion of patients who were referred for x-ray issued with a sickness certificate prescribed opioids or muscle relaxants or who were referred to secondary care but significantly more patients in the intervention group were referred to physiotherapy or the back pain unit difference in proportion  12.2 95 confidence interval ci  2.8 to 21.6%). <sep>', 'adjusted odds ratios were 1.03 95 confidence interval 0.78-1.36 in patients whose blood pressure was controlled at baseline and 1.25 95 confidence interval 0.94-1.65 in those whose blood pressure was not. <sep>', 'results indicated that the outreach program significantly improved many patient care processes lab work nursing dietary management ventilator management ventilator weaning). <sep>', 'there were no significant differences in use of minimal intervention components of the kit ratings of overall acceptability of delivery perceptions of cultural and structural barriers to using the kit and ratings of the overall acceptability of the kit. <sep>', 'prescribing in both the intervention and control group moved towards that recommended by the guidelines but there was no difference between the groups in either the proportion of prescriptions in line with the guidelines or the overall cost. <sep>', 'the mean stay in the icu did not differ between the control and intervention groups 10.9 v. 11.8 days p  0.7). <sep>', 'the number of prescriptions of lipid-lowering drugs per month increased in the intervention health centres and the increase was statistically different from the corresponding change in the control health centres among women in the age group 30-65 years p  0.03). <sep>', 'at endpoint cde recommendation and performance rates were both significantly higher for the intervention as compared to the control practices or  2.28 95 ci 1.37 3.78 and or  1.63 95 ci 1.06 2.50 respectively). <sep>', 'mammography completion within 8 weeks of clinic visits was significantly higher among intervention 49 than control 22 <sep>', 'practice-based training plus support telephone calls was the most effective and cost-effective strategy to encourage implementation of sbi by gps. <sep>', 'physicians in the combined intervention group had higher self-reported and observed rates for several risk assessment questions and counseling recommendations than did physicians in the control group or the group that only received educational materials. <sep>', 'compared with usual practice disease management was associated with improvements in helicobacter pylori testing 61 vs 9 p  .001 use of recommended h pylori treatment regimens 96 vs 10 p  .001 and discontinuation rates of proton pump therapy after treatment 70 vs 36 p  .04). <sep>', 'no differences in appropriateness were found between the two intervention groups but in the first postintervention month the mean rate of inappropriate prescribing per control practitioner was 80 versus less than 32 for the intervention groups p less than 0.01). <sep>', 'the tailored multifaceted intervention delivered by nurse facilitators was effective in modifying physician practice patterns and significantly improved preventive care performance. <sep>', 'they were also partially effective in improving the appropriate use of drugs reducing the use of non-rehydration medications. <sep>', 'the use of oral cephalosporins increased in the ig and was reduced in the cg p less than 0.01). <sep>', 'performance of the procedure necessary to diagnose hypercholesterolaemia even deteriorated. <sep>', 'both group and individual academic detailing improved antihypertensive prescribing over and above usual care but may require reinforcement to sustain improvements. <sep>', 'brief focused educational outreach visits by transfusion specialists can substantially improve the appropriateness and cost-effectiveness of blood product use in surgery. <sep>', 'patients in intervention practices had greater improvements than those in control practices for diagnoses of hypertension improvement difference 15.7 percentage points 95 ci 5.2 to 26.3 percentage points and blood pressure control in patients with hypertension improvement difference 8.0 percentage points ci 0.0 to 16.0 percentage points]). <sep>', 'practices were randomized to receive either the intervention for hyperlipidaemia or for hypertension practices acted as control for the intervention not received. <sep>', 'printed educational materials alone may be as effective as audit and feedback and educational outreach in improving nurses performance and outcomes of care for people with ui. <sep>', 'practices participating in the intervention showed increases in the percentage of records containing at least one periodontal diagnostic notation and those practices employing hygienists showed an increase in the percentage of records with at least one preventive notation and one treatment item.(abstract truncated at 250 words <sep>', 'compliance rates for 12 evidence-based indicators for the management of patients with hypertension hypercholesterolaemia angina pectoris or heart failure. <sep>', 'scores on a counseling measure also significantly increased from a mean of 2.7 to 9.9 in the counseling group whereas scores in the control group remained low and stable 2.3 and 1.9 respectively). <sep>', 'a multifaceted intervention using algorithms can reduce the number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes. <sep>', 'a marked decrease in benzodiazepine prescribing was seen over the course of the study in both intervention and control groups but no differential effect due to the educational outreach visit was found. <sep>', 'after training there was a significant increase in knowledge about diarrhoea and its treatment among counter attendants in kenya where these changes were measured. <sep>', 'there were significantly fewer referrals 20 v 29 odds ratio 0. <sep>', 'length of stay intensive care unit transfers readmission rates and in-hospital death rates were similar in both groups p or .10 for all). <sep>', 'smaller practices improved their performance in line with the guidelines by 13.5 95 ci  6 to 20.9 attributable to outreach while larger practices improved by only 1.4 95 ci  2.4 to 5.3 p-value for interaction 0.001). <sep>', 'in the 6 months post-intervention median psa testing rate in the eov group was significantly lower than in the postal group which in turn was significantly lower than the control group p  0.001). <sep>', 'patient satisfaction scores improved significantly in the comprehensive intervention group by 0.06 points on a 1 to 5 scale p  0.02 but not in the education only group by 0.02 points p  0.42 however the improvement was not significantly greater in the comprehensive intervention group p  0.20). <sep>', 'no significant differences were observed for the primary outcome measure practices receiving outreach visits prescribed only 2.1 95 confidence interval ci 0.8 to 5.0 more of the three recommended nsaids than the control practices did and 1.6 95 ci 1.4 to 4.7 more than practices that received guidelines only. <sep>', 'neither strategy was effective in improving the appropriateness of otc management of vulvovaginal candidiasis by community pharmacy staff. <sep>', 'improvements between baseline and posttest in patient recall of fp advice about nicotine replacement patches and gum were significantly greater in the intervention than in the control group p  0.0056 and p  0.0002 respectively). <sep>', 'we conclude that the academic detailing process was successful in modifying prescribing patterns and that it also decreased prescription numbers and costs. <sep>', 'rates of ventouse delivery increased significantly in intervention units but not in control units there was no difference between the two types of units in uptake of other practices. <sep>', 'no significant differences were found between the groups for the time to symptom resolution. <sep>'], 'population': ['experimental homes participated in an outreach program that was designed to influence drug use through improved teamwork among physicians pharmacists nurses and nurses assistants <sep> 1854 long-term care residents with an average age of 83 years <sep> 33 nursing homes 15 experimental homes and 18 control homes representing 5 of all swedish nursing homes <sep> swedish nursing homes <sep>', '44 general practices in two boroughs in east london <sep> 324 people aged 4-60 years admitted to or attending hospital or the general practitioner out of hours service with acute asthma 164 50 were south asian patients 108 34 were white patients and 52 16 were from other largely african and afro-caribbean ethnicities <sep> asthma specialist nurses using a liaison model of care reduced unscheduled care for asthma in a deprived multiethnic health district <sep> a deprived multiethnic area <sep>', 'high-risk patients <sep> patients aged 65 years and over and patients with coronary heart disease chd diabetes and a history of splenectomy <sep> primary care <sep> thirty general practices in the trent region uk <sep> fifteen practices <sep>', 'nursing homes <sep> six matched pairs of nursing homes at one randomly selected nursing home in each pair physicians nurses and aides participated in an educational program in geriatric psychopharmacology <sep>', 'twelve practices affiliated with 2 managed care organizations mcos in eastern massachusetts and northwest washington state <sep> the practices cared for 14 468 and 13 460 children in the 2 study years respectively 8815 children contributed data in both years <sep> all enrolled children younger than 6 years old <sep> children <sep> children younger than 6 years old <sep>', 'eighteen nurse-led health centres <sep> nurses run primary health centres in thailand <sep> children and tranquilizer in adults <sep>', 'unselected population of general practitioners <sep> prescribing in general practice <sep> an approximately representative sample of 286 general practitioners <sep>', 'elderly patients <sep> general practitioners on health promotion for elderly people <sep> elderly people <sep> general practitioners on the health behaviours and wellbeing of elderly patients <sep> metropolitan general practices in melbourne australia <sep> 42 general practitioners and 267 of their patients aged over 65 years <sep>', 'data were available from case notes at baseline n  897 and seven months follow-up n  902 452 residential care staff were surveyed and 121 physicians were involved with 61 receiving outreach visits <sep> 715 participants <sep> residential care <sep>', 'academic representative on prescribing by general practitioners <sep> 101 general practitioners selected at random from the leeds family practitioner committee fpc <sep>', 'participants were 56 family physicians and general practitioners 27 in the par group and 29 in the cmep group in southern ontario who agreed to participate in the interventions and provide data <sep> family practice <sep> 2395 patients randomly sampled from the practices returned questionnaires and consented to have their medical records abstracted <sep> family physicians in ontario <sep>', 'national health system physicians in the north of portugal with intervention in march 2004 through july 2004 and 13 to 16 months of follow-up <sep> 1388 physicians were assigned in 4 spatial clusters to the intervention group and 5063 were assigned in 11 clusters to the control group <sep>', 'twenty-four centres were randomised <sep> two thousand one hundred and eighty-seven eligible patients presented with acute low back pain during the study period 1049 in the intervention group and 1138 in the control group <sep> patients presenting with low back pain to primary care <sep> general practitioners gps <sep> primary care teams in north-west england <sep> royal college of general practitioners rcgp <sep> acute low back pain <sep> twenty-four health centres <sep>', '10,696 patients with a diagnosis of hypertension cared for by 93 primary care providers <sep> patients with hypertension <sep>', 'patients in rural hospitals <sep> eligible patients a multidisciplinary team of intensive care unit specialists from an academic medical center delivered an educational program with content specific to the findings and capacity of the hospital <sep> 20 rural iowa hospitals as the unit of analysis <sep>', 'australian general practitioners <sep> 264 randomly selected general practitioners <sep>', 'one hundred and two out of 140 practitioners in intervention group practices received at least one visit from an industry representative <sep>', 'patients at least 16 years of age with an expected icu stay of at least 48 hours were enrolled in the study n  499 <sep> 11 community and 3 teaching hospitals between october 1997 and september 1998 <sep>', '67 intervention health centres <sep> groups of doctors at 134 community health centres <sep> swedish primary care <sep>', 'colorectal cancer screening <sep> four hundred seventy primary care physicians pcps in 318 practices participated in the study <sep> persons with an abnormal screening fecal occult blood test fobt result <sep>', 'city women <sep> general internal medicine clinic in the university-affiliated county hospital serving metropolitan seattle <sep> breast cancer screening guidelines among inner-city women <sep> women aged 50 to 74 years with at least one routine clinic appointment when they were due for mammography during the study period were enrolled in the trial n  314 <sep> inner-city women <sep>', 'subjects were 128 gps one per practice from the former northern and yorkshire regional health authority who agreed to use the drink-less sbi programme in an earlier dissemination trial <sep> general practitioners gps <sep>', 'office-based primary care physicians family or general practice internal medicine and obstetrics-gynecology <sep> patients regarding sexually transmitted diseases and the human immunodeficiency virus hiv <sep> sexually transmitted diseases <sep> patients for sexually transmitted diseases and hiv infection <sep>', '406 patients comparing a disease management program with usual practice <sep> enrolled patients included those presenting with new dyspepsia and chronic users of antisecretory drugs in 8 geographically separate physician offices associated with the orlando health care group <sep> patients with acid-related disorders <sep>', 'outpatients in a health maintenance organization hmo <sep> after a control group n  8 was selected prescribers n  16 <sep> outpatients in an hmo <sep>', 'forty-six health service organizations hsos were recruited from 100 sites in ontario <sep> an 18-month july 1997 to december 1998 <sep>', 'acute diarrhoea <sep> districts were randomly assigned into 3 groups and 15 health centers were selected from each district <sep> 6 districts in yogyakarta and central java provinces indonesia <sep> patients under five years old with acute diarrhoea <sep>', 'primary care <sep> 244 physicians of the management area <sep>', 'thirty-two dutch gps in 20 general practices 3950 patient records <sep> general practitioners gps <sep> 20 general practices <sep>', 'subjects n=9820 were patients with newly treated hypertension in the year preceding the intervention n=3692 the 9 months following the intervention n=3556 and the second year following intervention n=2572 <sep>', 'one hundred one transfusing staff surgeons and attending medical physicians <sep> surgical and medical services of two pairs of matched community and teaching hospitals in massachusetts <sep>', '20 community-based family or general internal medicine practices in 14 states <sep> 44 physicians 17 midlevel providers and approximately 200 staff members data from the electronic medical records of 87,291 patients <sep>', 'from 44 practices 10 303 subjects presenting in general practice with raised blood pressure <sep> patients with diabetes in primary care <sep> patients with diabetes <sep>', '194 community nurses in 157 family practices and 1078 patients with diagnosis of urinary incontinence ui for nurses compliance with evidence-linked review criteria for the assessment and management of ui and impact on psychologic and social well-being and symptoms <sep> people with ui <sep>', 'practices employing hygienists n  12 and not employing dental hygienists n  12 <sep> randomly selected private general dental practices in adelaide south australia <sep>', 'cardiovascular care <sep> general practitioners gps in cardiovascular care <sep> patients with hypertension hypercholesterolaemia angina pectoris or heart failure <sep> 124 general practices in the netherlands <sep>', ""eleven physicians <sep> patients with obesity were surveyed immediately after their visit to the physician's office <sep>"", 'residents of nursing homes <sep> 12 nursing homes allocated to a <sep> suspected urinary tract infections in residents of nursing homes <sep> 4217 residents <sep> 24 nursing homes in ontario canada and idaho united states <sep>', 'practice registrars n  157 in new south wales <sep>', 'kenyan pharmacy employees after training <sep> diarrhoea treatment in pharmacies <sep> countries n  107 pharmacies in kenya n  87 in indonesia <sep> trained surrogate patients posing as mothers of a child under five with diarrhoea we measured sales of oral rehydration salts ors sales of antidiarrhoeal agents and history-taking and advice to continue fluids and food <sep> cases of diarrhoea in children in 194 private pharmacies in two developing countries <sep>', '100 practices 348 doctors in primary care <sep> general practices in east anglia <sep> women with regular heavy menstrual loss menorrhagia over 1 year <sep>', '17 general medical oncology and cardiology services either received <sep>', 'general practices in 12 health authorities in england <sep> community pharmacists on prescribing in uk general practice <sep>', 'general practices in southern adelaide <sep> australian primary care <sep>', '41 primary care physicians who cared for 1,810 randomly selected patients aged 65 to 75 years old at kaiser permanente woodland hills a group-model health maintenance organization in southern california <sep>', 'general practitioners gps in the latter group received two one-to-one outreach visits from community pharmacists <sep> 20 general practices within avon england <sep> general practice <sep>', '60 community pharmacies in the grampian region of scotland <sep>', 'sixty fps in 39 practices participated <sep>', '112 general practitioners <sep>', '25 obstetric units <sep> 4508 pregnancies <sep> 25 of the 26 district general obstetric units in two former nhs regions <sep>', 'thirty-six of 42 gps received the intervention and 35 of 43 gps served as controls 1503 patients were eligible for analysis <sep> acute cough in general practice <sep> adult patients with acute cough consulting in the periods february-april 2000 and 2001 <sep>'], 'interventions': ['regular multidisciplinary team interventions <sep>', 'specialist nurse intervention <sep>', 'educational outreach visit to primary healthcare teams <sep> educational outreach visit <sep> audit and feedback alone <sep>', 'psychoactive drugs <sep> antihistamine hypnotics <sep> benzodiazepines or antihistamine hypnotic agents <sep>', 'practice with a physician peer leader using cdc-endorsed summaries of judicious prescribing recommendations feedback <sep> simultaneous educational outreach intervention <sep> educational outreach intervention <sep>', 'adults diazepam prescribing and diabetes management or b usual care <sep> diazepam <sep> training workshop plus educational outreach visit <sep>', 'benzodiazepine <sep> specific education <sep> educational visit and supporting material from a doctor or pharmacist ostensibly unconnected with the surveys <sep>', 'educational intervention <sep>', 'aspirin <sep> outreach intervention <sep>', 'ibuprofen <sep> piroxicam <sep>', 'cmep <sep> 2 educational interventions <sep> par cmep and mentor interventions <sep>', 'educational outreach visits <sep> educational intervention <sep>', 'rcgp guidelines <sep> outreach visits to promote national guidelines <sep>', 'multifaceted educational intervention <sep> two-part educational intervention <sep>', 'outreach educational program <sep> mechanically ventilated intensive care unit icu <sep>', 'marketing smoking cessation programmes <sep> personal delivery and presentation by an educational facilitator with a follow up visit six weeks later b delivery to the receptionist by a friendly volunteer courier with a follow up phone call six weeks later or c postal delivery with a follow up letter six weeks later <sep>', 'collaborative health authority/industry intervention <sep> health authority/pharmaceutical company collaborative intervention <sep>', 'critical-care enteral and parenteral therapy accept <sep>', 'academic group detailing <sep> group detailing <sep> lipid-lowering drugs <sep>', 'reminder-feedback and educational outreach intervention <sep> physician-oriented intervention <sep> cde i.e. colonoscopy or combined flexible sigmoidoscopy plus barium enema x-ray <sep> screening program and the intervention <sep>', 'clinic-based mammography intervention targeting <sep> usual care <sep> patient education materials and appointment reminders and emphasizing nursing involvement <sep> clinic-based intervention program <sep> intervention program emphasized nursing involvement and included physician education provider prompts use of audiovisual and printed patient education materials transportation assistance in the form of bus passes preappointment telephone or postcard reminders and rescheduling assistance <sep>', 'programme plus practice-based training in programme usage trained and supported gps <sep> programme with written guidelines only trained gps <sep> programme plus practice-based training and a support telephone call every two weeks <sep>', 'mailed educational materials alone or coupled with a simulated patient instructor office visit <sep> mailed educational materials combined with an office visit by a simulated patient instructor for role-play and feedback <sep>', 'disease management program <sep> acid-peptic disease management program <sep>', 'vivid interventions or nonvivid interventions <sep> cimetidine ranitidine and sucralfate <sep>', 'multifaceted intervention delivered by 1 of 3 nurse facilitators 23 practices or no intervention 23 practices <sep>', 'educational intervention <sep>', 'oral cephalosporins <sep> educational intervention <sep>', 'national cholesterol guideline <sep>', 'individual academic detailing to increase diuretic or beta-blocker <sep> antihypertensive medications <sep>', 'educational outreach <sep>', 'multimethod quality improvement intervention <sep>', 'specialist nurse delivered education <sep> educational outreach <sep>', 'audit and feedback and educational outreach <sep>', 'continuing education ce <sep>', 'practices to support intervention group or no special attention control group analysis after 2 years <sep>', 'physician counseling <sep> training in behavioral and motivational weight control techniques <sep> obesity-counseling skills training group or to a control group <sep>', 'multifaceted intervention and 12 allocated to usual care <sep> multifaceted intervention <sep>', '20 minute educational outreach visit or a control group <sep> benzodiazepines <sep> benzodiazepine <sep> educational outreach or academic detailing program <sep> benzodiazepine <sep>', 'face-to-face educational outreach <sep>', 'tranexamic acid <sep> norethisterone <sep> educational package <sep>', 'levofloxacin or ceftazidime <sep> academic detailing or did not <sep>', 'educational outreach <sep>', 'prostate-specific antigen psa testing <sep> educational outreach visits eovs and mailout strategies targeting psa testing <sep>', 'comprehensive intervention group also received peer-comparison feedback and academic detailing <sep>', 'control mailed guidelines mailed guidelines plus educational outreach visits <sep>', 'postal dissemination control educational outreach visit or attendance at a continuing professional education session <sep>', 'nicotine replacement therapy <sep>', 'doxycycline <sep> amoxycillin <sep> roxithromycin <sep>', 'educational visits <sep> perineal suturing with polyglycolic acid ventouse delivery prophylactic antibiotics <sep> educational visit or control group <sep>', 'tailored professional intervention <sep> clinical practice guideline for acute cough an educational outreach visit and a postal reminder to support its implementation <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",eovs alone or when combined with other interventions have effects on prescribing that are relatively consistent and small but potentially important. their effects on other types of professional performance vary from small to modest improvements and it is not possible from this review to explain that variation.
439,"{'outcomes': ['length of neonatal intensive care unit stay and incidence of sepsis and phlebitis <sep> incidence of phlebitis <sep> length of the neonatal intensive care unit stay and in the incidence of sepsis <sep>', 'incidence of sepsis <sep> number of courses of antibiotics <sep> total duration of iv use <sep> number of painful iv procedures <sep> number of total catheters utilized <sep> number of insertion attempts required for total iv therapy <sep>', 'systemic infection or death <sep> systemic infection defined as a positive blood or cerebrospinal fluid csf culture treated for at least 5 days or death <sep> systemic infection or death <sep> skin punctures <sep> number of skin punctures <sep>', 'sepsis rates and efficacy of pn delivery <sep> sepsis rates <sep>'], 'punchline_text': ['there were no statistically significant differences in the length of the neonatal intensive care unit stay and in the incidence of sepsis between groups. <sep>', 'the number of insertion attempts required for total iv therapy was significantly lower in the picc group than in the piv group p  .008). <sep>', 'there was no significant difference in systemic infection or death expressed either as a combined outcome or as separate component outcomes between the groups. <sep>', 'interim analysis 49 neonates revealed no difference in sepsis rates cvc group 46 cannula group 40 p  0.57). <sep>'], 'population': ['newborns in the neonatal intensive care unit <sep> newborns <sep> seventy-four high-risk newborns <sep>', '63 vlbw infants 1,251 g who required iv therapy <sep> infants with very low birth weight vlbw <sep> infants with very low birth weight <sep>', '96 infants  or 1250 g or  or 30 weeks gestation <sep> preterm infants with <sep>', 'neonates <sep> neonates receiving pn by cvc and by peripheral cannula <sep>'], 'interventions': ['peripherally inserted central catheter and peripheral intravenous catheter <sep>', 'piv or a picc catheter and followed up prospectively until an iv was no longer required or the infant was transferred out of the neonatal intensive care unit <sep> peripherally inserted central venous catheters and peripheral intravenous catheters <sep> percutaneously inserted central venous catheters picc and peripheral intravenous catheters piv <sep>', 'pcvl or continued use of piv catheters <sep> percutaneous central venous lines versus peripheral intravenous lines <sep> elective percutaneous central line pcvl placement versus peripheral intravenous catheter piv placement <sep>', 'percutaneously inserted central venous catheters cvcs <sep> percutaneous longlines and peripheral cannulae <sep> cvc <sep> pn either by cvc or by peripheral cannula <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>']}",data from one small study suggest that using a percutaneous central venous catheter to deliver parenteral nutrition improves nutrient input. the significance of this in relation to long-term growth and developmental outcomes is unclear. three studies suggested that the use of a percutaneous central venous catheter decreases the number of catheters/cannulae needed to deliver the nutrition. no evidence was found to suggest that percutaneous central venous catheter use increased the risk of adverse events particularly systemic infection.
440,"{'outcomes': ['cough frequency or score irrespective of the presence of ahr <sep> ambulatory cough meter kept cough diaries <sep> frequency of cough <sep>'], 'punchline_text': ['salbutamol or beclomethasone had no effect on cough frequency or score irrespective of the presence of ahr. <sep>'], 'population': ['children with recurrent cough without other evidence of airway obstruction <sep> 43 children age 6-17 years with recurrent cough <sep> children with recurrent cough <sep> recurrent cough <sep>'], 'interventions': ['salbutamol or beclomethasone <sep> placebo <sep> inhaled salbutamol or placebo <sep> inhaled salbutamol and beclomethasone <sep> beclomethasone <sep> salbutamol or beclomethasone <sep> beclomethasone or placebo <sep>'], 'punchline_effect': [' no diff <sep>']}",salbutamol was no different from placebo in reducing the frequency of cough measured objectively or scored subjectively.
441,"{'outcomes': ['histological improvement <sep> serum alt levels <sep> portal inflammation <sep> hepatic inflammation <sep> relapses <sep> antiviral activity serum hepatitis delta virus rna and intrahepatic hepatitis delta antigen <sep>', 'serum alt levels <sep> biological and/or virological relapse <sep> clearance of serum hdv-rna <sep>', 'sustained biochemical or virologic response <sep> viral replication <sep> serum alanine aminotransferase values <sep> alanine aminotransferase values <sep> complete response normal levels of alanine aminotransferase and no detectable serum hepatitis delta virus hdv rna <sep> histologic deterioration <sep> histologic findings reduced periportal necrosis and portal and lobular inflammation <sep> serum alanine aminotransferase level becomes normal hdv rna <sep>', 'hdv-rna negative <sep> anti-hd titer igm anti-hd and hbsag concentration <sep> serum hdv-rna <sep> alt levels <sep> hdv-rna levels <sep>', 'positive for hepatitis d virus rna <sep> normal serum alt levels <sep> normalization of serum alt levels <sep> percentage of hepatitis d virus rna positivity <sep> hepatitis d virus rna levels <sep>'], 'punchline_text': ['measures of antiviral activity serum hepatitis delta virus rna and intrahepatic hepatitis delta antigen showed similar levels in treated and control patients. <sep>', 'moreover in seven of nine treated patients interferon was associated with the clearance of serum hdv-rna associated with amelioration of the histological picture whereas this occurred in only four of 11 untreated patients. <sep>', 'treatment with 9 million units of interferon was associated with a marked improvement in the histologic findings reduced periportal necrosis and portal and lobular inflammation whereas in the untreated controls there was considerable histologic deterioration. <sep>', 'no changes in anti-hd titer igm anti-hd and hbsag concentration were detected. <sep>', 'a decrease in the percentage of hepatitis d virus rna positivity was observed in both groups at the end of treatment. <sep>'], 'population': ['patients with chronic hepatitis d <sep> chronic delta type d hepatitis <sep> 61 italian patients with this disease <sep>', 'chronic delta hepatitis 22 patients <sep> nine treated patients completed the trial one was withdrawn with hyperthyroidism and one committed suicide <sep>', '42 patients with chronic hepatitis d <sep>', 'a total of 20 hbsag anti-hd carriers with a chronic active hepatitis <sep> hepatitis b virus chronic carriers <sep>', 'chronic hepatitis delta virus infection <sep>'], 'interventions': ['interferon-alpha-2b <sep> recombinant interferon-alpha <sep> recombinant human interferon-alpha <sep> interferon-alpha therapy <sep>', 'interferon <sep> interferon alpha-2b <sep> recombinant interferon-a2b <sep>', 'interferon alfa-2a <sep> interferon <sep> recombinant interferon alfa-2a <sep>', 'superinfection by hepatitis delta virus hdv <sep> interferon therapy <sep> recombinant human interferon alpha <sep> recombinant interferon alpha rifn-alpha <sep>', 'interferon-alpha 2a vs. that of daily low doses 3 mu <sep> interferon-alpha 2a <sep> interferon-alpha <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",interferon alpha does not seem to cure hepatitis d in most patients. the agent seems effective in suppressing viral and liver disease activity in some patients but this improvement is not sustained in the majority of patients. we cannot exclude overestimation of benefits and underestimation of harms due to high risk of bias systematic errors and high risk play of chance random errors). therefore more randomised trials with large sample sizes and less risk of bias are needed before interferon can be recommended or refuted.
442,"{'outcomes': ['core anxiety symptoms <sep> ham-a total scores <sep> ham-a psychic anxiety factor scores <sep> response rates <sep> hamilton rating scale for anxiety <sep>', 'ham-a scores <sep>', 'anxiety <sep> residual gad symptoms <sep> headache weight increase and increased appetite <sep> change from baseline to week 4 endpoint in parts-a. improvement from baseline to week 4 endpoint in parts-a total score <sep> residual gad symptoms <sep>', 'rates of remission <sep> hamilton anxiety scale hama-a score <sep> clinical global impression-severity scale cgi-s end point score <sep> average weight gain <sep>', 'drowsiness and dry mouth <sep> sad <sep> brief social phobia scale bsps social phobia inventory spin liebowitz social anxiety scale and sheehan disability scale as well as clinical global impression-improvement ratings <sep> negligible weight gain <sep>', 'social anxiety disorder sad <sep> social phobia inventory spin and the sheehan disability inventory sdi <sep> bsps score <sep> brief social phobia scale bsps and the clinical global impression of improvement scale cgi <sep> cgi-i <sep>'], 'punchline_text': ['adjunctive risperidone was associated with statistically significant improvements in core anxiety symptoms as demonstrated by greater reductions in ham-a total scores p  .034 and ham-a psychic anxiety factor scores p  .047 compared with placebo. <sep>', 'those remaining symptomatic hamilton anxiety scale ham-a or 7 at week 10 were randomized to quetiapine or placebo augmentation flexibly dosed from 25 to 400 mg/day. <sep>', 'headache weight increase and increased appetite were the most frequently reported adverse events in both groups. <sep>', 'there were no other statistically significant differences for olanzapine compared with placebo augmentation in outcome measures though rates of remission ham-a or 7 on olanzapine were higher at the level of a trend fet p  .1). <sep>', 'in the intent-to-treat analysis olanzapine yielded greater improvement than placebo on the primary measures bsps p  0.02 and spin p  0.01). <sep>', 'there was no significant difference in responders cgi-i score of 1 or 2 versus non-responder cgi-i score of 3 or more across the groups. <sep>'], 'population': ['symptomatic gad patients <sep> forty patients with a primary diagnosis of dsm-iv gad who continued to experience gad symptoms despite current anxiolytic treatment of at least 4 weeks duration <sep> generalized anxiety disorder <sep> june 2001 through march 2003 <sep>', 'individuals with gad remaining symptomatic with initial paroxetine cr pharmacotherapy <sep> patients with generalized anxiety disorder gad remaining symptomatic despite initial pharmacotherapy <sep> adult outpatients with gad were recruited from 2004 to 2007 at two academic centers <sep> those remaining symptomatic hamilton anxiety scale ham-a or 7 at week 10 were randomized to <sep> refractory generalized anxiety disorder <sep>', 'primary care and psychiatry clinicians enrolled adults n  417 with gad and a clinical global impressions of severity rating  4 despite  8 weeks of anxiolytic treatment <sep> generalized anxiety disorder <sep> patients with more severe gad <sep>', 'refractory generalized anxiety disorder <sep> patients with generalized anxiety disorder gad who remain symptomatic despite initial pharmacotherapy <sep> patients remaining symptomatic on fluoxetine <sep> twenty-four of 46 fluoxetine-treated patients were randomized <sep>', '12 patients with the dsm-iv diagnosis of sad <sep> social anxiety disorder <sep>', 'fifteen patients <sep> social anxiety disorder <sep>'], 'interventions': ['adjunctive risperidone <sep> placebo <sep> risperidone <sep> placebo or risperidone <sep>', 'placebo <sep> open-label paroxetine cr <sep> paroxetine cr <sep> quetiapine <sep> quetiapine <sep> paroxetine cr ham-a reduction mean <sep> quetiapine or placebo <sep>', 'adjunctive risperidone <sep> placebo <sep> adjunctive risperidone or placebo <sep> risperidone and placebo <sep> risperidone <sep>', 'olanzapine or placebo <sep> placebo <sep> olanzapine <sep> fluoxetine <sep> olanzapine <sep>', 'olanzapine and placebo <sep> placebo <sep> olanzapine <sep> olanzapine <sep>', 'quetiapine monotherapy <sep> placebo <sep> quetiapine <sep> atypical antipsychotic quetiapine <sep> quetiapine <sep>'], 'punchline_effect': [' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>']}",we identified eligible trials on quetiapine risperidone and olanzapine. the available data on olanzapine and risperidone are too limited to draw any conclusions. monotherapy with quetiapine seems to be efficacious in reducing symptoms of generalised anxiety disorder and this effect may be similar to that of antidepressants. however quetiapine's efficacy must be weighed against its lower tolerability.
443,"{'outcomes': ['amplitude of the compound motor action potential cmap <sep> overall improvement of clinical stage <sep>', 'house-brackmann scores <sep> safety and potential efficacy <sep> house-brackmann scale <sep>', 'facial grading scale scores <sep> facial grading scale change scores <sep> facial grading scale <sep> facial grading scale subcomponents <sep>'], 'punchline_text': [""when applied at an early stage kabat's rehabilitation was shown to provide a better and faster recovery rate in comparison with non-rehabilitated patients. <sep>"", 'the house-brackmann scale of the control group improved between 17 and 50 with a mean of 30%. <sep>', ""individualized facial neuromuscular re-education is more effective in improving facial symmetry in patients with bell's palsy than conventional therapeutic measures. <sep>""], 'population': [""20 consecutive patients 10 males 10 females aged 35-42 years affected by bell's palsy classified according to the house-brackmann hb grading system and grouped on the basis of undergoing or not early physical rehabilitation according to kabat i.e. a proprioceptive neuromuscular rehabilitation <sep> bell's palsy patients <sep> bell's palsy <sep>"", ""16 patients with bell's palsy of less than 30 days duration <sep> early bell's palsy <sep> adult patients with clinical diagnosis of bell's palsy <sep>"", ""patients with bell's palsy <sep> fifty-nine patients diagnosed with bell's palsy <sep>""], 'interventions': ['kabat physical rehabilitation <sep>', 'electrical stimulation <sep> heat massage exercises and a home program <sep>', 'individualized facial neuromuscular re-education <sep> conventional therapeutic measures while the facial neuromuscular re-education <sep> facial neuromuscular re-education <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",there is no high quality evidence to support significant benefit or harm from any physical therapy for idiopathic facial paralysis. there is low quality evidence that tailored facial exercises can help to improve facial function mainly for people with moderate paralysis and chronic cases. there is low quality evidence that facial exercise reduces sequelae in acute cases. the suggested effects of tailored facial exercises need to be confirmed with good quality randomised controlled trials.
444,"{'outcomes': ['weight gain <sep> total score on the positive and negative syndrome scale <sep> general antipsychotic efficacy <sep> efficacy and safety <sep> total and negative symptom scores <sep>', 'core symptoms of schizophrenia and motor side effects <sep> quality of life qol measure <sep> brief psychiatric rating scale scale for the assessment of negative symptoms and montgomery and asberg depression rating scale scores <sep> dyskinetic symptoms <sep> psychological domain of the world health organisation-quality of life brief who-qol-bref scale <sep> motor side-effects efficacy safety and quality of life qol <sep> psychological qol <sep> who-qol-bref physical psychological and health satisfaction domains <sep>', 'efficacy <sep> extrapyramidal symptoms <sep> frequency and severity of extrapyramidal symptoms <sep> positive and negative syndrome scale factors for positive symptoms and anxiety/depression <sep> body weight <sep> total positive and negative syndrome scale scores and scores on the five positive and negative syndrome scale factors <sep> greater weight gain <sep> severity of extrapyramidal symptoms <sep> severity of positive and affective symptoms <sep> tolerated and efficacious <sep> safety and efficacy <sep>', 'total scores on the extrapyramidal symptom rating scale <sep> weight gain <sep> mean duration of illness <sep> five panss factor scores positive symptoms negative symptoms disorganized thoughts and anxiety/depression <sep> severity of psychotic and extrapyramidal symptoms <sep> panss total scores <sep> changes in positive and negative syndrome scale panss total scores and rates of extrapyramidal symptoms eps <sep> eps-related adverse events <sep>', 'obsessive-compulsive symptoms <sep> ocs <sep> yale-brown obsessive compulsive scale ybocs <sep> severity of ocs <sep> severe ocs <sep> severity of obsessive-compulsive symptoms ocs <sep>', 'positive and negative syndrome scale panss total brief psychiatric rating scale bprs total and panss general psychopathology scores <sep> response rates <sep> panss total score <sep> efficacy safety <sep> quality of life scale qls intrapsychic foundation and medical outcomes study short form 36-item instrument sf-36 role functioning limitations-emotional subscale scores <sep> panss positive and negative scores and clinical global impression-severity of illness scale cgi-s <sep>', 'psychotic symptoms <sep> positive and negative syndrome scale panss total score derived brief psychiatric rating scale bprsd total score as well as panss and bprsd subscales <sep> panss positive scale scores <sep> tolerated <sep>', 'extrapyramidal side effects hyperprolactinemia and sexual dysfunction <sep> overall response rate <sep> adverse events <sep> efficacy in negative symptoms scale for assessment of negative symptoms summary score <sep> positive and negative syndrome scale total score <sep> safe and effective <sep>', 'hooper visual organization test <sep> neuropsychological change <sep> general cognitive index <sep> comprehensive battery of tests to assess 1 motor skills 2 attention span 3 verbal fluency and reasoning 4 nonverbal fluency and construction 5 executive skills and 6 immediate recall <sep>'], 'punchline_text': ['clozapine risperidone and olanzapine but not haloperidol resulted in statistically significant improvements in total score on the positive and negative syndrome scale. <sep>', 'after switching from a conventional antipsychotic olanzapine and risperidone were associated with improvement in core symptoms of schizophrenia and motor side effects. <sep>', 'total positive and negative syndrome scale scores and scores on the five positive and negative syndrome scale factors were improved in both groups at week 8 subjects who completed the study and endpoint all subjects including dropouts). <sep>', 'total scores on the extrapyramidal symptom rating scale were reduced in both groups at endpoint between-treatment differences were not significant. <sep>', 'the 35 subjects treated with olanzapine at both assessments had significantly p  .01 more severe ocs at week 6 than the 20 subjects treated with risperidone at both assessments. <sep>', 'olanzapine and risperidone were equivalent in their improvement of panss positive and negative scores and clinical global impression-severity of illness scale cgi-s at endpoint. <sep>', 'treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia. <sep>', 'the incidence of extrapyramidal side effects hyperprolactinemia and sexual dysfunction was statistically significantly lower in olanzapine-treated than risperidone-treated patients. <sep>', 'exploratory within-group analyses of the 6 cognitive domains after a conservative bonferroni adjustment revealed a significant improvement with olanzapine only on the immediate recall domain and similar analyses of the 17 individual tests revealed a significant improvement with olanzapine only on the hooper visual organization test. <sep>'], 'population': ['patients with chronic schizophrenia or schizoaffective disorder <sep> 157 inpatients with a history of suboptimal treatment response <sep> patients with chronic schizophrenia and schizoaffective disorder <sep>', '66 patients were randomised mean age 69.6 sd <sep> elderly patients with schizophrenia <sep> elderly patients with schizophrenia from conventional antipsychotics to <sep> elderly patients with schizophrenia <sep>', 'schizophrenia or schizoaffective disorder <sep> subjects n=377 who met dsm-iv criteria for schizophrenia or schizoaffective disorder <sep>', 'stable elderly patients with chronic schizophrenia receiving appropriate doses of <sep> patients outpatients hospital inpatients and residents of nursing or boarding homes <sep> elderly patients with schizophrenia <sep> subjects were 175 patients age 60 years or over with schizophrenia or schizoaffective disorder <sep> 175 elderly patients with chronic schizophrenia <sep>', 'treatment n  23 prior to admission continued with that medication if they showed initial clinical response <sep> patients who were drug-naive or were treated with typical antipsychotics before admission n  36 <sep> 113 patients with recent-onset schizophrenia or related disorders <sep> prior to admission <sep> patients who had started olanzapine n  39 or <sep> consecutively hospitalized young patients mean age  22.4 years with dsm-iv schizophrenia or related disorders n  113 who were treated with <sep>', '65 patients who met dsm-iv criteria for schizophrenia schizoaffective disorder or schizophreniform disorder <sep> australia and new zealand <sep> schizophrenia <sep>', 'patients with an acute exacerbation of schizophrenia <sep> patients n  249 who met dsm-iv criteria for schizophrenia <sep> patients hospitalized for acute exacerbation of schizophrenia <sep> acutely hospitalized patients with schizophrenia <sep>', 'schizophrenia and other psychotic disorders <sep> 339 patients who met dsm-iv criteria for schizophrenia schizophreniform disorder or schizoaffective disorder <sep>', 'cognitive impairment in early phase schizophrenia <sep> people with schizophrenia <sep>'], 'interventions': ['haloperidol <sep> olanzapine <sep> clozapine risperidone and olanzapine <sep> atypical antipsychotics clozapine olanzapine and risperidone <sep> clozapine olanzapine risperidone and haloperidol <sep> risperidone <sep> olanzapine and clozapine <sep> clozapine <sep> clozapine olanzapine risperidone or haloperidol <sep> clozapine <sep>', 'olanzapine <sep> atypical antipsychotics risperidone or olanzapine <sep> olanzapine or risperidone <sep> risperidone <sep> olanzapine and risperidone <sep>', 'risperidone and olanzapine <sep> olanzapine <sep> risperidone <sep>', 'olanzapine <sep> atypical antipsychotics risperidone and olanzapine <sep> risperidone and olanzapine <sep> risperidone or olanzapine <sep> risperidone <sep>', 'olanzapine or risperidone <sep> olanzapine <sep> olanzapine or risperidone <sep> risperidone or olanzapine <sep> risperidone <sep> olanzapine and risperidone <sep>', 'olanzapine <sep> olanzapine <sep> risperidone <sep> olanzapine and risperidone <sep> olanzapine and risperidone <sep>', 'divalproex <sep> antipsychotic agent <sep> divalproex <sep> olanzapine or risperidone <sep> olanzapine and risperidone <sep> antipsychotic monotherapy <sep> olanzapine monotherapy risperidone monotherapy divalproex plus olanzapine or divalproex plus risperidone <sep>', 'olanzapine <sep> olanzapine and risperidone <sep> olanzapine <sep> risperidone <sep>', 'haloperidol <sep> olanzapine <sep> risperidone <sep> olanzapine risperidone or haloperidol <sep> novel antipsychotic medications <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",we know very little of the effects of these drugs regarding service outcomes general functioning and behaviours engagement with services and treatment satisfaction from evaluative studies. there was generally a high rate of attrition in the trials and there appears to be little to differentiate between risperidone and olanzapine except on issues of adverse effects. both drugs are associated with a reduction in psychotic symptoms but both commonly cause unpleasant adverse effects.
445,"{'outcomes': ['tiredness <sep> activities of daily living adl <sep> serious or systemic side effects <sep>', 'efficacy and safety <sep> tsui scores <sep> adverse events <sep> pain scores <sep> pain-free <sep> efficacy and safety profile <sep>', 'involuntary activity <sep> mean amplitude and increased ratio turns/amplitude <sep>', 'neck posture <sep> head position and pain <sep> side effects <sep>', 'serious side effects <sep> direction of head turning severity of torticollis and presence or absence of jerky movements <sep> severity of torticollis disability pain and degree of head turning <sep>', 'dystonia and neck pain <sep> neck pain <sep> spontaneous remission <sep>'], 'punchline_text': ['no serious or systemic side effects were noted. <sep>', 'open phase treatment produced improvements in tsui p  0.001 and pain scores p=0.011 and 23/24 patients were classified as responders. <sep>', 'six weeks after the first bt treatment the sternocleidomastoid muscle contralateral to the involuntary head rotation and the ipsilateral and contralateral posterior neck muscles pnm showed a reduction of involuntary activity as indicated by reduced turns/sec and mean amplitude at rest. <sep>', 'toxin was more effective than placebo for improving both head position and pain which was measured by an objective rating scale and videofilm assessments. <sep>', 'compared with placebo botox produced statistically significant improvement in the severity of torticollis disability pain and degree of head turning. <sep>', 'the remaining 18 patients completed the study and showed a significant improvement after the injections of botulinum toxin in comparison with that of the placebo. <sep>'], 'population': ['23 patients suffering from intractable spasmodic torticollis st <sep> twenty-three patients <sep>', 'patients with rotational cervical dystonia cd <sep> patients with the major clinical types of cervical dystonia <sep> 21 patients 11 dysport 10 <sep> population of cd patients more representative of those seen in a typical dystonia clinic <sep> and 47 patients 24 dysport 23 <sep> 68 patients with moderate to severe cd tsui score  or  9 <sep> heterogeneous cervical dystonia population <sep> dysport patients and 14/33 42 <sep>', 'cervical dystonia <sep> 19 patients with cervical dystonia <sep>', '39 patients with pain <sep> 19 patients in a double-blind <sep> 60 patients with torticollis received toxin in a total of 117 treatment periods <sep> spasmodic torticollis <sep>', 'spasmodic torticollis <sep>', 'cervical dystonia <sep> patients with complex cervical dystonia <sep> 23 patients with cervical dystonia <sep>'], 'interventions': ['botulinum toxin a <sep> placebo <sep> botulinum toxin <sep> botulinum toxin a bta or normal saline <sep>', 'electromyographic guidance <sep> placebo <sep> dysport clostridium botulinum toxin type <sep> dysport clostridium botulinum toxin type a haemaglutinin complex <sep> botulinum toxin type a btxa injections <sep>', 'botulinum toxin bt <sep> placebo <sep>', 'placebo <sep> botulinum toxin <sep> toxin <sep> botulinum toxin <sep>', 'placebo or botox <sep> placebo <sep> botulinum toxin injections <sep> botulinum toxin botox injections <sep> botox <sep> placebo botox <sep>', 'botulinum a toxin and placebo <sep> placebo <sep> botulinum toxin <sep> botulinum toxin injections <sep> botulinum toxin injections <sep> botulinum toxin injection <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",a single injection cycle of bta is effective and safe for treating cervical dystonia. enriched trials using patients previously treated with bta suggest that further injection cycles continue to work for most patients.
446,"{'outcomes': ['fvc <sep> forced vital capacity fvc forced expiratory volume at 1 second fev1 and forced expiratory flow <sep> pulmonary function <sep> fev1 <sep>', 'crp <sep> systemic concentrations of interleukin-6 il-6 interleukin-1 il-1 tumor necrosis factor tnf and c-reactive protein crp <sep> cytokine levels <sep> pre and postoperative white blood cell wbc counts postoperative body temperature and length of postoperative hospitalization <sep> il-1 and tnf response <sep> systemic acute-phase response <sep> plasma il-6 levels <sep> serum crp concentrations <sep>', 'total cost of each case included cost of investigations cost of disposable articles for operation cost of drugs cost of hospital stay and cost of operation including anesthesia <sep> success or failure <sep> operation without injury to bile duct viscera or vessels minimal pain and discomfort at 4 weeks no wound infection <sep> total cost for lc <sep>', 'physical and social functioning <sep> physical functioning and depression scores <sep> pain and depression <sep> mean operation time <sep> incidence of complications <sep> shorter hospital stay less postoperative dysfunction and quicker return to normal activities <sep> hospital costs <sep> median post-operative hospital stay <sep>', 'hospital stay <sep> median time off work <sep> hospital costs and social costs <sep> hospital and social costs <sep> hospital stay and time off work <sep> operative time <sep>', 'hospital stay <sep> successful hospital stay <sep> complications <sep> conversion to open cholecystectomy <sep> postoperative analgesia requirements <sep>', 'serious bile duct injury <sep> median operating times <sep> postoperative complication rate <sep> median hospital stay <sep> median sick leave and time for return to normal recreational activities <sep> intraoperative complications <sep>', 'mean hospital stay <sep> rate of return to normal activities <sep> duration of convalescence <sep> quality of life scores <sep>', 'partial arterial oxygen pressure <sep> monocyte superoxide anion o2 and tumor necrosis factor release neutrophil o2 levels and chemotaxis total white blood cell counts partial arterial oxygen pressure and serum cortisol and c-reactive protein levels <sep> plasma cortisol or c-reactive protein levels <sep> immune function <sep> monocyte release of o2 and tumor necrosis factor neutrophil release of o2 and chemotaxis and white blood cell count <sep> postoperative septic complications <sep>', 'hospital stay or postoperative recovery <sep> hospital stay postoperative nights in hospital <sep> time to full activity <sep> time back to work for employed persons <sep>', 'postoperative hospital stay <sep> duration of anesthesia and operation time perioperative complications or postoperative need for analgetics <sep> postoperative pain less restriction of total vital capacity <sep>'], 'punchline_text': [""the percent reduction of fvc p  0.0170 fev1 p  0.0191 and fef25-75 p  0.0045 was smaller after laparoscopic cholecystectomy than after kocher's incision cholecystectomy. <sep>"", 'systemic concentrations of interleukin-6 il-6 interleukin-1 il-1 tumor necrosis factor tnf and c-reactive protein crp were measured before and after the operation. <sep>', 'success was defined as operation without injury to bile duct viscera or vessels minimal pain and discomfort at 4 weeks no wound infection up to 4 weeks and resumption of work within 2 weeks of operation. <sep>', 'at 4 weeks only physical functioning and depression scores were better in the laparoscopic group and by 3 months there were no differences. <sep>', 'operative time median time 35 minutes and hospital stay median stay 3 days were the same for both surgical procedures. <sep>', 'if laparoscopic cholecystectomy was successful hospital stay was significantly shorter than for mini-cholecystectomy 2 versus 3 days respectively but overall the hospital stay was not significantly different. <sep>', 'intraoperative complications were less frequent in the mc group but there was no difference in the postoperative complication rate between the groups. <sep>', 'although there was significant postoperative improvement in all of three quality of life scores in both groups lc patients improved more quickly than did mc patients. <sep>', 'there were significant increases p  .001 in monocyte release of o2 and tumor necrosis factor neutrophil release of o2 and chemotaxis and white blood cell count in the open vs laparoscopic cholecystectomy study groups with a concommitant decrease in partial arterial oxygen pressure. <sep>', 'laparoscopic cholecystectomy takes longer to do than small-incision cholecystectomy and does not have any significant advantages in terms of hospital stay or postoperative recovery. <sep>', 'patients with lcce had significant less postoperative pain less restriction of total vital capacity and a shorter postoperative hospital stay as parameters of a diminished operative trauma. <sep>'], 'population': ['forty-five patients <sep>', '40 patients were studied <sep>', 'one hundred adult subjects with painful gallstone disease <sep> cases with acute cholecystitis and raised alkaline phosphatase <sep> gallstone disease <sep> patients with gallstones shown on ultrasound with normal common bile duct and no history of icterus were included after an informed consent <sep>', '302 patients <sep> laparoscopic patients <sep>', 'one hundred and eighty-one patients with simple symptomatic gallstone disease were included in the study of these 9 cases were excluded because of conversion to conventional cholecystectomy <sep>', 'three hundred and ten patients having elective cholecystectomy <sep> 155 patients in each group <sep>', 'of 1,705 cholecystectomies performed at participating units during the randomization period 724 entered the trial and 362 patients <sep> all surgeons normally performing cholecystectomy both trainees under supervision and consultants operated on randomized patients <sep>', '70 patients with ultrasound-proven cholelithiasis were randomly allocated lc 38 or mc 32 <sep>', 'patients undergoing open vs laparoscopic cholecystectomy <sep> two similar groups of patients randomized to open n  22 vs laparoscopic n  22 cholecystectomy <sep>', '200 patients which was designed to eliminate bias for or against either technique <sep>', '77 patients with symptomatic cholelithiasis <sep>'], 'interventions': [""mini-incision or kocher's incision cholecystectomy <sep> laparoscopic cholecystectomy <sep>"", 'laparoscopic cholecystectomy lc and mini-laparotomy cholecystectomy oc <sep> laparoscopic cholecystectomy <sep> laparoscopic and open cholecystectomy <sep>', 'mc <sep> lc <sep> laparoscopic versus minilaparotomy cholecystectomy <sep> minilaparotomy cholecystectomy mc and laparoscopic cholecystectomy lc <sep>', 'laparoscopic or minilaparotomy cholecystectomy <sep> laparoscopic versus minilaparotomy cholecystectomy <sep> laparoscopic cholecystectomy <sep> laparoscopic <sep> minilaparotomy cholecystectomy laparoscopic cholecystectomy <sep>', 'laparoscopic cholecystectomy and 86 mini-cholecystectomy <sep> laparoscopic or mini-cholecystectomy <sep> laparoscopic cholecystectomy <sep> laparoscopic versus mini-cholecystectomy <sep>', 'laparoscopic cholecystectomy or mini-cholecystectomy <sep> laparoscopic cholecystectomy and mini-cholecystectomy <sep> laparoscopic cholecystectomy <sep> mini-cholecystectomy <sep>', 'lc versus mc <sep> lc <sep> minilaparotomy cholecystectomy mc <sep> laparoscopic cholecystectomy lc <sep> laparoscopic cholecystectomy versus mini-laparotomy cholecystectomy <sep> open small-incision surgery minilaparotomy and laparoscopic surgery <sep>', 'laparoscopic versus mini cholecystectomy <sep> lc <sep> laparoscopic cholecystectomy lc <sep> mini cholecystectomy mc <sep>', 'laparoscopic surgery <sep> laparoscopic surgery <sep>', 'laparoscopic cholecystectomy <sep> laparoscopic versus small-incision cholecystectomy <sep> laparoscopic and small-incision cholecystectomy <sep> small-incision cholecystectomy <sep>', 'laparoscopic cholecystectomy lcce <sep> mini-lap cce <sep> lcce <sep> laparoscopic cholecystectomy versus mini-lap-cholecystectomy <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig decrease <sep>']}",laparoscopic and small-incision cholecystectomy seem to be equivalent. no differences could be observed in mortality complications and postoperative recovery. small-incision cholecystectomy has a significantly shorter operative time. complications in elective cholecystectomy are prevalent.
447,"{'outcomes': ['incidence of diarrhea and acute respiratory infection ari <sep> incidence of diarrhea <sep> mean number of diarrheal episodes <sep>', 'adverse events <sep> cause of death <sep> pregnancy-related mortality and all-cause female mortality <sep>', 'mean ri values <sep> potential acute side-effects <sep> intracranial haemorrhage <sep> mean ri fell <sep> rates of any sign or symptom <sep> ri <sep> intracranial pressure <sep>', 'vitamin a status signs of acute toxic effects anthropometric indicators and severe morbidity <sep> vitamin a deficiency <sep> rate ratio to compare all deaths <sep> mortality <sep> anthropometric status or on overall or severe morbidity <sep>', '24-wk mortality rate <sep> rate of fetal loss <sep> fetal loss and early infant mortality <sep> fetal loss and survival <sep> fetal or early infant survival <sep> miscarriage stillbirth maternal death or live birth <sep>', 'child growth <sep> linear or ponderal growth or infectious disease morbidity <sep> morbidity and child growth <sep>', 'mortality rate ratios <sep> mortality the mortality rate ratio <sep> mortality <sep> mortality rate ratio <sep>', 'seroconversion to opv and geometric means of antibody titers <sep> vitamin a intakes <sep> breast milk retinol levels <sep> serum retinol levels <sep>', 'antipolio antibody titer antitetanus toxoid antibodies and avidity of antibodies to tetanus <sep> antibody titers <sep>', 'episodes of bulging of the fontanelle <sep>', 'side effects <sep> acute toxicity <sep> cumulative effect of toxicity <sep> safety and toxicity <sep> episodes of bulging of the fontanelle <sep>', 'mortality <sep> relative risk of mortality <sep>', 'infant survival <sep> infant mortality <sep> mortality through 24 weeks of age <sep> risk of death <sep>', 'maternal serum retinol <sep> gram fat milk retinol <sep> vitamin a status <sep> milk retinol <sep> serum retinol <sep> infant serum retinol <sep> serum retinol and infant stores <sep> milk retinol <sep> infant retinol stores <sep>', 'mortality <sep> mrr of vitamin a supplementation <sep> mortality calculated as mortality rate ratios mrrs <sep>'], 'punchline_text': ['prophylactic administration of mega doses of vitamin a to the mother soon after delivery and to the infant at six months do not have any beneficial impact on the incidence of diarrhea and ari in infancy. <sep>', 'in the itt analysis there were 39 601 pregnancies and 138 pregnancy-related deaths in the vitamin a supplementation group 348 deaths per 100 000 pregnancies compared with 39 234 pregnancies and 148 pregnancy-related deaths in the placebo group 377 per 100 000 pregnancies adjusted odds ratio 0.92 95 ci 0.73-1.17 p=0.51. <sep>', 'a bulging fontanelle was not associated with increased rates of any sign or symptom or with an increase in ri. <sep>', 'at the 6-month follow-up there was a small decrease in vitamin a deficiency in the vitamin a group compared with controls serum retinol  or 0.70 micromol/l 101 29.9 vs 122 37.1 95 ci of the difference 14.3 to 0.2%]). <sep>', 'the rate of fetal loss was 92.0/1000 pregnancies in the placebo group comparable with rates in the vitamin a and beta-carotene groups which had relative risks of 1.06 95 ci 0.91 1.25 and 1.03 95 ci 0.87 1.19 respectively. <sep>', 'vitamin a supplementation had no apparent impact upon linear or ponderal growth or infectious disease morbidity in the first 15 mo of age when integrated with the expanded programme on immunization. <sep>', 'vitamin a supplementation was not significantly associated with mortality the mortality rate ratio was 1.07 95 confidence interval 0.79 to 1.44). <sep>', 'seroconversion to opv and geometric means of antibody titers to the three types of polio viruses were comparable between the groups of infants belonging to the experimental and control mothers. <sep>', 'we found no evidence that vitamin a supplementation affects infants antibody responses to tetanus toxoid or oral polio vaccine delivered at epi contacts. <sep>', 'the finding that increased numbers of vitamin a doses were associated with a higher probability of bulging of the fontanelle suggests a cumulative effect. <sep>', 'no other side effects were noted. <sep>', 'there were 130 deaths 51.6/1000 child-y in the control group and 150 deaths 57.1/1000 child-y in the vitamin a group yielding a relative risk of 1.11 95 ci 0.86 1.42 which is indicative of no overall effect on early infant mortality. <sep>', 'relative to control subjects the risk of death in vitamin a-supplemented infants was 0.85 reflecting a 15 reduction in all-cause mortality. <sep>', 'infant serum retinol was not different between groups. <sep>', 'vitamin a supplementation at birth was not significantly associated with mortality the mrr of vitamin a supplementation compared with placebo controlled for randomisation to early bcg versus no early bcg was 1.08 95 ci 0.79 to 1.47). <sep>'], 'population': ['51 villages in two contiguous primary health centers in villupuram health unit district of tamil nadu south india <sep> mother and infant on morbidity in infancy <sep> 909 newly delivered mother-and-infant pairs <sep>', 'women in ghana <sep> 1326 women died in 292 560 woman-years in the <sep> all women of reproductive age 15-45 years who gave informed consent and who planned to remain in the area for at least 3 months were recruited <sep> 1086 small geographical clusters of compounds with fieldwork areas consisting of four contiguous clusters <sep> seven districts in brong ahafo region in ghana <sep> women of reproductive age on maternal survival in ghana <sep> and 542 clusters 103 297 women <sep> 544 clusters 104 484 women <sep>', '2067 indonesian neonates <sep>', '3933 93 of the eligible 4212 infants on vitamin a and 3938 93 of the eligible 4227 controls <sep> 4716 mothers of infants in the <sep> 4708 mothers and their infants received <sep> from january 1995 we enrolled 9424 mother-infant pairs from ghana india and peru <sep> early infancy <sep>', 'infants aged 6 mo <sep> a total of 43559 women were enrolled 15832 contributed 17373 pregnancies and 15987 live born infants to the trial <sep> married women of reproductive age in 270 wards of sarlahi district nepal were eligible to participate <sep> infants 6 mo of age <sep>', 'in west java indonesia 467 six-week-old infants <sep>', 'participants 4345 infants due to receive bcg <sep> african setting with high infant mortality <sep> 174 children died during follow-up mortality=47/1000 person-years <sep> guinea-bissau covering approximately 90,000 inhabitants <sep> older children <sep> infants in guinea-bissau <sep>', 'women within 24 hrs after delivery on response to ppv administered to the newborn <sep> one hundred mothers having uncomplicated deliveries <sep> breastfed infants <sep>', 'young infants n  1085 <sep> infants immune responses to tetanus and polio vaccines <sep>', 'one hundred and sixty-seven infants <sep> bangladesh <sep> early infancy using dpt/opv immunization contracts <sep>', 'rural bangladesh <sep> infancy <sep> 191 infants <sep>', '11,918 infants  1 mo and 1-5 mo of age with vitamin a 15,000 and 30,000 micrograms retinol equivalents or 50,000 and 100,000 iu respectively or a <sep> infants  6 mo of age supplemented with <sep>', '19 unions in rural northwest bangladesh <sep> on all-cause infant mortality through 24 weeks of age <sep> rural bangladesh <sep> dosed infants n  15902 <sep> study-defined sectors n  596 <sep> 17116 live-born infants 99.8 of all eligible among whom 15937 93.1 were visited to be supplemented 30 days after birth and for whom vital status at 24 weeks of age was known <sep>', '564 women <sep> mothers and infants <sep> kenyan mother-infant pairs <sep> kenya <sep>', 'guinea-bissau <sep> neonates who weighed less than 2.5 kg <sep> low birthweight neonates <sep> 1717 low birthweight neonates born at the national hospital <sep> normal birthweight neonates <sep>'], 'interventions': ['placebo <sep> vitamin a supplementation <sep> placebo <sep> vitamin a <sep> vitamin a but infant received placebo <sep> vitamin a supplementation <sep>', 'placebo capsule <sep> placebo <sep> vitamin a supplementation and two to placebo <sep> obaapavita <sep> vitamin a supplement <sep> vitamin <sep> vitamin a supplementation <sep>', 'oral vitamin <sep> placebo <sep> vitamin a <sep>', 'placebo <sep> vitamin a group received 200000 iu vitamin a <sep> maternal postpartum and infant vitamin a supplementation <sep> vitamin <sep> vitamin a supplementation <sep> diphtheria-tetanus-pertussis dpt and poliomyelitis immunisations and with a fourth dose with measles immunisation <sep>', '7000 microg retinol equivalents as retinyl palmitate vitamin a 42 mg all-trans-beta-carotene or placebo <sep> placebo <sep> maternal low-dose vitamin a or beta-carotene supplementation <sep> vitamin a or beta-carotene <sep> maternal vitamin a or beta-carotene supplementation <sep> vitamin a supplementation <sep>', 'placebo <sep> vitamin a supplementation <sep> retinol equivalent re 15 mg re or placebo <sep> vitamin <sep> vitamin a supplementation <sep>', '50,000 iu vitamin a or placebo <sep> placebo <sep> vitamin a supplementation given with bcg vaccine <sep> vitamin a supplementation <sep> 50,000 iu vitamin a given with bcg vaccine <sep> vitamin a supplementation given with bcg vaccine <sep> vitamin a supplementation <sep>', 'opv <sep> 200,000 iu vitamin <sep> placebo control <sep> vitamin <sep> oral polio vaccine <sep> vitamin a <sep>', 'placebo <sep> placebos <sep> vitamin a supplementation <sep> supplementing vitamin <sep> retinol equivalent re vitamin a within 4 wk of delivery 2 expanded program on immunization epi)-linked supplementation of infants with 7.5 mg re vitamin <sep> vitamin a supplementation <sep>', 'vitamin a or a placebo <sep> placebo <sep> vitamin <sep> vitamin a supplementation <sep>', 'placebo <sep> vitamin a given with vaccines <sep> vitamin <sep> vitamin a or placebo <sep> vitamin a supplementation <sep>', 'placebo <sep> vitamin a <sep>', 'placebo <sep> newborn vitamin <sep> placebo-controlled weekly maternal vitamin a or beta-carotene supplementation <sep> supplementing newborns with 50000 iu of vitamin a <sep> vitamin a 50000 iu or placebo <sep> newborn vitamin a supplementation <sep>', 'maternal vitamin a 400,000 iu or placebo 24 h postpartum and infant vitamin a 100,000 iu or placebo <sep> maternal and infant vitamin a supplementation <sep> placebo <sep>', 'neonatal vitamin a supplementation <sep> vitamin a supplementation and bcg vaccination <sep> placebo <sep> vitamin a supplementation <sep> vitamin a or placebo as well as to early bcg vaccine or the usual late bcg vaccine <sep> neonatal vitamin <sep> vitamin a supplementation and bcg vaccination <sep> vitamin a supplementation <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",there is no convincing evidence that either maternal postpartum or infant vitamin a supplementation results in a reduction in infant mortality or morbidity in low and middle income countries.
448,"{'outcomes': ['clinical success rate <sep> failure frequencies <sep> presence of marginal gaps <sep> number of failures <sep>'], 'punchline_text': ['there was no difference between the number of failures caused by post decementations and the presence of marginal gaps observed in the 2 groups 95 confidence intervals 9.7 to 16.2 and 17.8 to 9.27). <sep>'], 'population': ['subjects included in this study had one maxillary or mandibular premolar for which endodontic treatment and crown build up was indicated and met specific inclusion/exclusion criteria <sep> only premolars with class ii carious lesions and preserved cusp structure were included <sep> sixty teeth were included in the first group and 57 in the second <sep>'], 'interventions': ['fiber posts and direct composite restorations <sep> teeth endodontically treated and restored with adhesive techniques and composite or 2 teeth endodontically treated restored with adhesive techniques and composite and then restored with full-coverage metal-ceramic crowns <sep>'], 'punchline_effect': [' no diff <sep>']}",there is insufficient evidence to support or refute the effectiveness of conventional fillings over crowns for the restoration of root filled teeth. until more evidence becomes available clinicians should continue to base decisions on how to restore root filled teeth on their own clinical experience whilst taking into consideration the individual circumstances and preferences of their patients.
449,"{'outcomes': ['frequent sexual activity <sep> adolescent compliance <sep> noncompliance level <sep>', 'study termination rates <sep> menstrual changes <sep> cumulative life table discontinuation rates <sep>', 'prolonged bleeding <sep> rate of continuation and the rate of on-time injections <sep>', 'levels of condom and contraceptive use and rates of pregnancy and stds <sep> condom and contraceptive use rates of pregnancy and stds and other outcomes and mediators <sep> clinic utilization or satisfaction <sep>', 'number of missed pills per cycle <sep> oral contraceptive pill adherence <sep> mean number of missed pills per cycle <sep>', 'questionnaire data <sep> repeat pregnancy <sep> knowledge of ocs <sep>'], 'punchline_text': ['adolescents with more frequent sexual activity p less than or equal to .027 with one sexual partner p less than .04 and who worried that they might become pregnant p less than or equal to .01 had significantly lower levels of noncompliance when counseled by a peer than by a nurse. <sep>', 'study termination rates were significantly lower in the structured counseling group than in the control group. <sep>', 'the rate of continuation and the rate of on-time injections did not differ between groups. <sep>', 'although contraceptive use increased from baseline to follow-up at six months in both groups levels of condom and contraceptive use and rates of pregnancy and stds did not differ between the intervention and control groups at any of the follow-up assessments. <sep>', 'this randomized controlled trial estimated whether there was an effect of daily text-message reminders on oral contraceptive pill adherence of new oral contraceptive pill users. <sep>', 'more women in the intervention group were not pregnant and still using contraception and were able to successfully switch contraceptive methods compared to women in the control group. <sep>'], 'population': ['fifty-seven females aged 14 to 19 years from a lower socioeconomic background <sep>', 'mexican women receiving <sep> 350 mexican women participated 175 received <sep>', 'women receiving depot <sep>', 'female adolescent clinic patients <sep> between 2005 and 2007 a total of 805 females aged 14-18 attending a reproductive health clinic in san francisco <sep> adolescent females <sep>', 'eighty-two women <sep> participants were 79 white non-hispanic 99 high school graduates and 99 nulliparous with a mean age of 22 years <sep> new oral contraceptive pill users <sep>', 'young african american women in the year following an unplanned pregnancy <sep> 43 young pregnant women attending prentice ambulatory care northwestern hospital were enrolled and 33 <sep>'], 'interventions': ['peer counselors <sep> peer v nurse counseling program <sep> oral contraceptives <sep>', 'detailed structured pretreatment counseling <sep> depot-medroxyprogesterone acetate <sep> pretreatment counseling upon discontinuation of 150 mg depot-medroxyprogesterone acetate depo-provera <sep>', 'discontinue depot medroxyprogesterone <sep> mail and telephone reminders <sep> medroxyprogesterone injections <sep> depot medroxyprogesterone acetate <sep>', 'regular clinic services or regular clinic services plus nine follow-up phone calls over 12 months <sep> copyright <sep>', 'daily reminder text message <sep> oral contraceptives <sep> daily text-message reminders <sep>', 'antepartum multicomponent intervention consisting of counseling a videotape about ocs and written material or resident-physician counseling usual care <sep> postpartum educational intervention <sep> oral contraceptives <sep> oral contraception ocs <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig increase <sep>']}",most studies to date have shown no benefit of strategies to improve adherence and continuation. these trials have important limitations however. three had small sample sizes four had high losses to follow up and the intervention and its intensity varied across the studies. high-quality research is a priority since adherence and continuation are fundamentally important to the successful use of hormonal contraceptives.
450,"{'outcomes': [""iron stores <sep> odds for anemia <sep> mean infant ferritin and hb <sep> infant's hemoglobin and serum ferritin 3 months after delivery <sep>"", ""delayed clamping of the umbilical cord increases the infant's iron endowment at birth and haemoglobin concentration <sep> total body iron <sep> ferritin <sep> infant haematological status and iron status at 6 months of age and analysis was by intention-to-treat <sep> 6-month iron stores <sep> mean corpuscular volume <sep> iron and haematological status <sep>"", 'haematological effects <sep> polycythaemia without symptoms <sep> maternal haemoglobin <sep> bilirubin concentration <sep> infant haematological status <sep> total serum bilirubin levels <sep> mean infant haemoglobin level <sep> clinical jaundice or plethora <sep> maternal haematological status <sep> red cell mass <sep>', 'duration of cord adherence and neonatal and maternal outcomes <sep> rate of breast feeding <sep> rate of jaundice <sep>', 'maternal and cord ferritin and hemoglobin values <sep> iron stores <sep> serum ferritin and hemoglobin <sep>', 'maternal perceptions of her infant and the experience of giving birth <sep> shorter active labors <sep> maternal or newborn morbidity in infant behavior in the first hour of life <sep>', 'delayed cord clamping and haemoglobin levels <sep> adverse events <sep> infant and maternal safety <sep> haematological status <sep> beneficial haematological effect <sep> odds ratio for iron deficiency anaemia <sep> haemoglobin hb change from cord values <sep>'], 'punchline_text': ['the odds for anemia 100 g/l at 3 months was 7.7 95 ci 1.84-34.9 times higher in the early compared to the delayed clamping group. <sep>', ""delayed clamping of the umbilical cord increases the infant's iron endowment at birth and haemoglobin concentration at 2 months of age. <sep>"", 'it is a safe simple and low cost delivery procedure that should be incorporated in integrated programmes aimed at reducing iron deficiency anaemia in infants in developing countries. <sep>', 'there appeared to be a higher rate of jaundice in the late clamped group which did not reach statistical significance. <sep>', ""the groups were comparable for maternal age parity weight supplemental iron intake in pregnancy infant's birth weight gestation and sex. <sep>"", ""no differences were noted in maternal or newborn morbidity in infant behavior in the first hour of life at 24 or 72 hours post partum or at eight months of age or in maternal perceptions of her infant and the experience of giving birth except that eight months after delivery mothers who had used the leboyer method were more likely to say that the event had influenced their child's behavior p  0.05). <sep>"", 'throughout the observation period infant hb levels in both groups declined but more rapidly in controls than in the dcc group difference in hb change from baseline at 4 months 1.1 g/dl 95 confidence interval ci 0.2 2.1]. <sep>'], 'population': ['neonates born to anemic mothers <sep> infants born to anemic mothers at 3 months of age <sep> infants born to anemic mothers <sep> infants born to mothers with hemoglobin hb)<100 g/l <sep> 102 neonates randomized to early n  43 or delayed cord clamping n  59 <sep>', '476 mother-infant pairs were recruited at a large obstetrics hospital in mexico city mexico randomly assigned to <sep> mexican infants <sep> 358 75 mother-infant pairs completed the trial <sep> infants born to mothers with low ferritin at delivery breastfed infants not receiving iron-fortified milk or formula and infants born with birthweight between 2500 g and 3000 g. a cord clamping delay of 2 minutes increased <sep>', 'term infants 24 h after birth in libya <sep> mother-infant pairs <sep> term infants born to libyan mothers <sep> 104 mother-infant pairs <sep>', '554 women <sep>', '107 infants <sep> infants at 3 months <sep> term infants at 3 months of age <sep> 107 term neonates born to mothers with uncomplicated pregnancies and with hemoglobin more than 10 g/dl <sep>', '56 women to either a <sep>', 'infancy <sep>'], 'interventions': ['delayed cord clamping <sep> cord clamping <sep> immediate cord clamping early group or cord clamping delayed till descent of placenta into vagina delayed group <sep>', ""delayed clamping <sep> delayed clamping 2 min after delivery of the infant's shoulders or early clamping <sep> umbilical cord clamping <sep>"", 'early cord clamping within 10s after delivery or delayed clamping <sep> delayed cord clamping <sep> umbilical cord clamping <sep>', 'late and early umbilical cord clamping <sep>', 'cord clamping <sep>', 'leboyer or a conventional delivery <sep>', 'randomly assigned women delivering term babies in mpongwe mission hospital zambia to delayed cord clamping dcc n  46 or immediate cord clamping <sep> dcc <sep> umbilical cord clamping <sep>'], 'punchline_effect': [' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>']}",one definition of active management includes directions to administer an uterotonic with birth of the anterior shoulder of the baby and to clamp the umbilical cord within 30-60 seconds of birth of the baby which is not always feasible in practice). in this review delaying clamping of the cord for at least two to three minutes seems not to increase the risk of postpartum haemorrhage. in addition late cord clamping can be advantageous for the infant by improving iron status which may be of clinical value particularly in infants where access to good nutrition is poor although delaying clamping increases the risk of jaundice requiring phototherapy.
451,"{'outcomes': ['cardiovascular fitness v(o2)max <sep> cardiovascular fitness <sep> cardiovascular fitness maximal workload gait speed and paretic lower-extremity muscle strength <sep> maximal workload muscle strength gait speed and the berg balance scale score <sep>', 'functional capacity physical aspects pain general state of health vitality social aspects and mental health <sep> quality of life <sep> generic health-related quality of life survey sf-36 <sep> motor behaviour <sep>', 'muscle strength and gait <sep> berg balance scale score and weight-bearing ability as measured by vertical ground reaction force during four standing tasks rising from a chair and weight-shifting forward backward and laterally <sep> berg balance scale scores forward and backward weight-bearing abilities of the affected limbs and knee flexor strength <sep> postural balance and knee flexor strength <sep> postural balance and muscle strength <sep>'], 'punchline_text': ['the experimental group attained significant improvements over the control group in cardiovascular fitness maximal workload gait speed and paretic lower-extremity muscle strength. <sep>', 'doing physical exercises in water tends to improve motor behaviour with a greater degree of independence significant improvements in functional capacity and other aspects linked to physical aptitude. <sep>', 'postural balance and knee flexor strength were improved after aquatic therapy based on the halliwick and ai chi methods in stroke survivors. <sep>'], 'population': ['people with chronic stroke <sep> 12 community-dwelling people with stroke with mild to moderate residual motor deficits <sep> people with stroke <sep>', '15 subjects aged 50.3 <sep> 13 subjects aged 52.5  7.7 years <sep> patients who have had an ischaemic cva <sep>', 'ambulatory chronic stroke patients n  25):13 in an aquatic therapy group and 12 in a conventional therapy group <sep> stroke survivors <sep> rehabilitation department of a university hospital <sep>'], 'interventions': ['water-based exercise <sep> hand exercises while sitting <sep> water-based exercise program experimental group with that of an upper-extremity function program control group <sep>', 'aquatic physical exercises <sep>', 'conventional therapy group performed gym exercises <sep> aquatic therapy <sep> aquatic therapy programme <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig increase <sep>', ' sig increase <sep>']}",the evidence from randomised controlled trials so far does not confirm or refute that water-based exercises after stroke might help to reduce disability after stroke. there is a lack of hard evidence for water-based exercises after stroke. better and larger studies are therefore required.
452,"{'outcomes': ['quality of mask induction <sep>', ""children's perioperative anxiety <sep> anxiety <sep> anxious <sep>"", 'anxiety and compliance during induction of anesthesia <sep> analgesia <sep> emergence delirium <sep> perioperative outcomes <sep> anxiety and distress <sep> lower anxiety <sep>', 'anxious <sep> anxiety mypas and compliance icc <sep> post hospitalization behavior questionnaire <sep> postoperative behavioral changes <sep> sensory stimuli and anxiety <sep>', 'parental anxiety <sep> anxiety <sep> parental anxiety <sep> parental satisfaction <sep> anxiety and satisfaction <sep>', 'anxiety <sep> parental anxiety scores <sep> observed anxiety in the holding area t1 entrance to the operating room t2 and introduction of the anesthesia mask t3 <sep> percentage of inductions in which compliance of the child <sep> anxiety of the parent and compliance of the child during induction <sep>', 'mean arterial pressure <sep> anxiety <sep> fear and anxiety <sep> reducing anxiety <sep> level of anxiety postoperatively <sep> level of parental anxiety <sep>', 'maternal anxiety <sep> maternal blood pressure and heart rate <sep> anxious on entrance to the operating room <sep> parental preoperative anxiety <sep> behavioral and physiologic anxiety <sep>', 'postoperative behavior changes <sep> change in anxiety <sep> anxiety <sep> anxiety changes <sep> preoperative anxiety <sep> pediatric preoperative anxiety <sep> posthospital behavior questionnaire phbq <sep>', 'parental anxiety <sep> anxiety levels <sep> anxiety <sep> amsterdam preoperative anxiety and information scale apais questionnaires <sep> anxiety and desire for information <sep>', 'scl changes over time <sep> parental hr and scl <sep> parental heart rate hr parental blood pressure and parental skin conductance level scl <sep> incidence of electrocardiogram abnormalities <sep> parental hr <sep> state anxiety and blood pressure <sep>', 'modified yale preoperative anxiety scale mypas score <sep> postoperative behavioral disorders <sep> frequency of behavior disorders <sep> behavioral disorders <sep> posthospitalization behavioral questionnaire phbq <sep> number of anxious children <sep> preoperative anxiety <sep>', 'median induction coping vas level <sep> preoperative anxiety levels <sep> a visual analog scale vas and modified child dental anxiety scale mcdas <sep> median recovery coping vas levels <sep> preoperative anxiety <sep>'], 'punchline_text': ['the children in the midazolam group showed a better quality of mask induction compared with those in the ppia group the addition of parental presence to oral midazolam did not provide additional improvement of mask induction. <sep>', 'children in the midazolam group were the least anxious even after controlling for therapist effect p  0.05). <sep>', 'children in the advance group exhibited a lower incidence of emergence delirium after surgery p=0.038 required significantly less analgesia in the recovery room p=0.016 and were discharged from the recovery room earlier p=0.04 as compared with children in the three other groups. <sep>', 'we found that the lssg was significantly less anxious compared with the control group on entrance to the or p  0.03 and on the introduction of the anesthesia mask p  0.003). <sep>', 'anxiety in the holding area at entrance to the operating room and at introduction of the anesthesia mask did not differ significantly between the two groups f[2,192  1.26 p  0.28). <sep>', 'post hoc analysis indicated that children in the midazolam group exhibited significantly less anxiety compared with the children in the parental-presence group or control group p  0.0171). <sep>', 'mean arterial pressure for children in group 1 was significantly lower during preoperative holding and following induction p  .05). <sep>', 'there were no significant differences in maternal blood pressure and heart rate between the two groups. <sep>', 'there was a statistically significant increase in anxiety p<0.01 in groups m and pp at induction of anesthesia compared with baseline but not in vg group. <sep>', 'there was a statistically significant reduction in anxiety and desire for information in the intervention group compared with the control group p  0.05). <sep>', 'state anxiety and blood pressure following induction of anesthesia did not differ significantly between groups  p nonsignificant). <sep>', 'the number of anxious children was less during induction of anesthesia in the hypnosis group t3 39 vs 68 p  0.05). <sep>', 'the mann-whitney u-test showed that the computer group coped significantly better than the control group at induction p  0.014 and significantly better than the cartoon group upon recovery p  0.016). <sep>'], 'population': ['children undergoing general anesthesia <sep> children <sep> pediatric anesthesia <sep> sixty children <sep>', 'children undergoing outpatient surgery <sep> preoperative anxiety in children <sep>', 'children undergoing surgery that targets the family as a whole <sep> children <sep> children and their parents n  408 <sep>', 'children undergoing anesthesia and surgery <sep> children undergoing anesthesia and surgery <sep> children undergoing surgery <sep>', 'children with sedatives alone <sep> subjects n  103 <sep> children undergoing surgery <sep>', 'children n  88 <sep> children <sep>', 'eighty patients requiring an inhalation anesthetic induction <sep>', 'mothers of children who were scheduled to undergo surgery <sep> children of mothers who underwent <sep>', '112 children aged 4-12 years undergoing outpatient surgery anxiety was assessed after admission and again at mask induction of anesthesia using the modified yale preoperative anxiety scale mypas <sep> female and male patients <sep> children <sep>', ""one hundred and eleven parents <sep> parents before their child's induction of anesthesia <sep> elective pediatric procedures <sep>"", 'children and their parents n  80 <sep> parents <sep>', 'children scheduled for surgery <sep> fifty children from 2 to 11 years of age <sep> children <sep>', ""children undergoing dga induction <sep> 198 children <sep> children's median age was 5 range 3-10 years 57 were boys a median of seven teeth were extracted range 1-20 <sep> children undergoing dental general anesthetic dga tooth extraction <sep> children prior to dental general anesthesia <sep>""], 'interventions': ['midazolam  ppia <sep> midazolam <sep> midazolam premedication <sep> sedative group 0.5 mg/kg oral midazolam <sep> ppia group or a sedative and ppia group <sep> anesthesia ppia <sep> sevoflurane <sep>', 'interactive music therapy <sep> oral midazolam <sep> music therapy <sep> midazolam <sep> interactive music therapy <sep> music therapist interactive music therapy <sep>', 'midazolam <sep> control received standard of care 2 parental presence received standard parental presence during induction of anesthesia 3 advance received family-centered behavioral preparation and 4 oral midazolam <sep>', ""lssg <sep> low sensory stimulation group lssg n  33 or to control group <sep> behavioral intervention <sep> dimmed operating room or lights 200 lx and soft background music bach's air <sep>"", 'sedative and ppia group <sep> sedative group 0.5 mg/kg oral midazolam <sep> midazolam <sep>', 'midazolam 2 parental presence during induction of anesthesia or 3 control no parental presence or premedication <sep> midazolam <sep>', 'information pamphlet only <sep> video demonstrating pediatric mask induction <sep>', 'parental auricular acupuncture <sep> parental auricular acupuncture <sep> acupuncture <sep> acupuncture intervention group auricular press needles at relaxation tranquilizer point and master cerebral point or a sham acupuncture control group auricular press needles at the shoulder wrist and extraneous auricular point <sep> acupuncture intervention <sep>', 'distraction with a hand-held video game <sep> parent presence pp pp+a hand-held vg and pp+0.5 mg.kg-1 oral midazolam m <sep> cognitive distraction <sep> interactive distraction a hand-held video game vg <sep>', 'videotaped preoperative information <sep>', 'ppia 2 ppia plus 0.5 mg/kg oral midazolam and 3 control no ppia or midazolam <sep> anesthesia ppia <sep>', 'hypnosis <sep> hypnosis as premedication group m were given 0.5 mg x kg(-1 midazolam <sep> hypnosis <sep> midazolam <sep>', 'paper-based cartoon and an interactive computer <sep>'], 'punchline_effect': [' sig increase <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig decrease <sep>', ' no diff <sep>', ' sig increase <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig increase <sep>']}",this review shows that the presence of parents during induction of general anaesthesia does not reduce their child's anxiety. promising non-pharmacological interventions such as parental acupuncture clown doctors hypnotherapy low sensory stimulation and hand-held video games needs to be investigated further.
453,"{'outcomes': ['pressure or pain <sep> cell loss or adverse events <sep> discomfort <sep> pain <sep> discomfort pain scores <sep> discomfort or pain <sep> intraocular sensation <sep>', 'systolic blood pressure pulse rate oxygen saturation and pain score <sep> level of intraoperative pain <sep> systolic and diastolic blood pressure pulse rate and peripheral oxygen saturation <sep> minimal discomfort <sep> diastolic blood pressure <sep>', 'mean pain score <sep> pain scores <sep> 10-point visual analogue scale <sep> level of intraoperative discomfort <sep>', 'no sensation <sep> safety and efficacy <sep> cell density parameters or kowa laser flare-cell meter measurements <sep> intraocular sensation <sep> safety and efficacy <sep>', 'patient-reported pain scores for delivery of anesthesia <sep> blood pressure <sep> visual analog pain scale <sep> patient cooperation <sep> tissue manipulation <sep> operative conditions patient cooperation and intraoperative complications <sep>', 'patients subjective experience of pain <sep> endothelial cell loss <sep> rate of potential visual acuity recovery <sep> bcva improvement <sep> 5-point satisfaction scale <sep> mean pain score <sep> 4-point pain scale <sep> best corrected visual acuity bcva <sep> surgeon satisfaction score <sep> patient satisfaction <sep> central endothelial cell counts <sep> subjective experience of pain <sep>', 'visual analog scale <sep> pain scores <sep> intraoperative discomfort postoperative discomfort and discomfort <sep> discomfort <sep>', 'intraoperative pain scores <sep> intraoperative pain <sep> intraoperative pain <sep>'], 'punchline_text': ['twenty-six percent in the control group and 9 in the lidocaine group had discomfort pain scores of 2 or more 10 in the bss group felt increased pressure or pain during phacoemulsification. <sep>', 'this study found no additional benefit of intracameral unpreserved lignocaine when performing routine clear corneal phacoemulsification under topical anaesthesia. <sep>', 'the difference between the pain scores for the two groups was statistically significant p  0.0053). <sep>', ""seventy-eight percent of lidocaine patients and 56 of controls reported no sensation p  .048 fisher's exact test). <sep>"", 'there was no significant difference in patient-reported pain scores for delivery of anesthesia p  0.902 surgery p  0.170 or after surgery p  0.680). <sep>', ""the advantage of using intracameral lidocaine 1 over a placebo was a significant decrease in the patients subjective experience of pain and in the surgeon's satisfaction with the anesthesia used. <sep>"", 'there was a small reduction in the discomfort caused by the operating microscope when intracameral lidocaine was used p  0.04). <sep>', 'in a rigorously double-masked prospective randomized controlled trial there was no significant reduction in intraoperative pain when intracameral 1 lidocaine was used during phacoemulsification under topical anesthesia. <sep>'], 'population': ['outpatient ambulatory surgical center <sep> comparable eligible patients <sep>', 'routine clear corneal phacoemulsification under topical anaesthesia <sep> cataract surgery under topical anaesthesia <sep> one hundred and thirty-five consecutive cases undergoing clear corneal phacoemulsification <sep>', 'between january and july 1997 a total of 162 patients 162 eyes scheduled for cataract surgery <sep> cataract surgery <sep>', 'carolina eye associates southern pines north carolina usa <sep> ninety-three patients completed the study <sep> 100 patients having phacoemulsification under topical anesthesia <sep>', 'both men and women between 45 and 85 years of age who were scheduled for elective cataract surgery while under topical anesthesia participated <sep> sixty-eight patients <sep>', 'patients having phacoemulsification with iol implantation <sep> fifty-nine consecutive patients 60 eyes having phacoemulsification with implantation of a foldable acrylic iol acrysof <sep> phacoemulsification with intraocular lens iol implantation <sep> cataract surgery <sep>', 'routine phacoemulsification under topical anesthesia <sep> 204 patients undergoing phacoemulsification surgery with lens implantation under planned topical anesthesia <sep>', 'phacoemulsification under topical anesthesia <sep> 200 patients undergoing routine phacoemulsification under topical 1 <sep>'], 'interventions': ['intraoperative lidocaine <sep> lidocaine <sep> sutureless small incision cataract surgery and intraocular lens iol implantation <sep> topical anesthesia <sep> 0.1 cc balanced salt solution bss control group in double-masked fashion <sep> intraoperative unpreserved lidocaine <sep>', 'placebo <sep> intracameral unpreserved lignocaine <sep> lignocaine with placebo <sep> intracameral unpreserved lignocaine 1 or placebo balanced salt solution <sep> cataract surgery under topical anaesthesia with and without intracameral lignocaine <sep> lignocaine <sep>', 'placebo group topical anesthesia with intracameral balanced salt solution group 1 n  81 or the interventional group combined topical-intracameral anesthesia <sep> lidocaine <sep> 0.5-ml injection of balanced salt solution <sep> lidocaine hydrochloride <sep> phacoemulsification and implantation of a foldable intraocular lens iol while under topical lidocaine alone or in combination with intracameral lidocaine <sep> intracameral injection <sep> combined topical-intracameral anesthesia <sep> 0.5-ml injection of 1 lidocaine <sep> temporal clear corneal phacoemulsification and implantation of a foldable silicone iol <sep> topical lidocaine <sep>', 'intracameral injection of unpreserved lidocaine 0.5 cc of a 1 unpreserved solution or balanced salt solution <sep> lidocaine <sep> intracameral injections of unpreserved lidocaine <sep> intracameral injections of unpreserved lidocaine <sep>', 'lidocaine <sep> placebo <sep> topical anesthesia versus topical anesthesia and intracameral lidocaine <sep> topical anesthesia plus intracameral 1 preservative-free lidocaine or intracameral balanced salt solution <sep> intraocular lidocaine <sep> topical anesthesia plus intracameral lidocaine <sep>', 'lidocaine <sep> placebo <sep> topical tetracaine <sep> topical tetracaine <sep> intracameral lidocaine <sep> intracameral bss <sep> tetracaine plus intracameral lidocaine <sep> topical tetracaine 0.5 with preservative-free intracameral lidocaine <sep> intracameral balanced salt solution bss group received topical tetracaine 0.5 plus intracameral bss <sep>', 'intracameral lidocaine <sep> topical anesthesia plus 0.5 ml intracameral balanced salt solution or topical anesthesia plus 0.5 ml preservative-free 1 intracameral lidocaine <sep> supplementary intracameral lidocaine <sep>', 'epinephrine-free 1 lidocaine or placebo <sep> lidocaine <sep> intracameral lidocaine <sep> tetracaine <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>', ' sig decrease <sep>', ' sig decrease <sep>', ' no diff <sep>']}",the use of intracameral unpreserved 1 lidocaine is an effective and safe adjunct to topical anaesthesia for phacoemulsification cataract surgery.
454,"{'outcomes': ['number of analgesic medications <sep>', 'pain alleviation <sep> vas pain evaluation <sep> total consumption of analgesics <sep> processing time or time to operation <sep> processing time <sep>', 'pain suffered analgesia required frequency of pressure sores or ease of operation <sep>', 'repositioning and percentage of united fractures <sep> pain experienced the need for supplementary analgesics or complications during the hospital stay <sep>', 'pain relief <sep> pain reduction <sep> visual analog scale vas <sep> pain <sep> pain relief treatment <sep>', 'analgesic requirement <sep> peak pain score pattern <sep> pain score <sep>', 'pain medication <sep> pain relief <sep> pain <sep> intertrochanteric fractures <sep> femoral neck fractures <sep>', 'vas pain evaluation <sep> pain alleviation <sep> consumption of analgesics of no clinical importance <sep> visual analogue scale vas <sep>'], 'punchline_text': ['the number of analgesic medications needed was no higher in patients without traction. <sep>', 'there was no difference in the total consumption of analgesics in the emergency department or on the ward and no effect of immobilization type on the processing time or time to operation. <sep>', 'no differences were found between the groups in terms of pain suffered analgesia required frequency of pressure sores or ease of operation. <sep>', 'no differences were found between the groups in terms of pain experienced the need for supplementary analgesics or complications during the hospital stay. <sep>', 'patients treated without a weight-loaded skin traction kit had better pain relief compared to the other two groups this outcome was statistically significant. <sep>', 'we found a significant difference in pain score on the evening of admission and the first morning after admission between the groups with traction compared the group without. <sep>', 'these patients also requested a statistically significant lower amount of pain medication p  0.01). <sep>', 'there was a small significant increase in consumption of analgesics of no clinical importance in patients with skin traction and no effect of traction type on the processing time or time to operation. <sep>'], 'population': ['patients awaiting operation for hip fracture <sep> patients with hip fractures <sep> 80 patients with cervical trochanteric or subtrochanteric hip fractures <sep>', '123 patients <sep> hip fractures <sep> 123 consecutive patients with displaced cervical and trochanteric hip fractures <sep>', '252 patients awaiting surgery for fractures of the proximal femur <sep> fractures of the proximal femur <sep> patients with fractures of the upper femur <sep>', 'patients with hip fractures <sep> one hundred twenty patients with cervical or trochanteric hip fractures <sep>', '108 pre-operative patients with hip fractures <sep> patients with persistent pain <sep> patients with collum and intertrochanteric femur fractures <sep> patients with acute proximal femur fracture <sep>', '311 patients <sep>', 'patients with hip fractures <sep> one hundred consecutive patients with hip fractures admitted to the authors institution who met inclusion criteria were enrolled <sep> fifty patients were enrolled in each intervention group <sep> average patient age was seventy-eight years <sep> university-affiliated teaching institution <sep> hip fracture patients <sep>', 'hip fracture <sep> 153 consecutive patients with displaced cervical and trochanteric hip fractures <sep> 78 patients <sep> 75 were excluded because of senile confusion and the remaining 78 were randomized to skeletal or skin traction preoperatively <sep> patients with skin traction <sep>'], 'interventions': ['preoperative traction <sep> treatment without traction skin traction or skeletal traction <sep>', 'skin traction placement in a special foam pillow lasse pillow and comfortable placement with an ordinary pillow under the hip from admission to operation <sep> preoperative skin traction or pillow nursing <sep>', 'nursed free in bed or to receive hamilton-russell skin traction <sep> preoperative skin traction <sep> skin traction <sep>', 'preoperative skin traction <sep> preoperative skin traction <sep> skin traction or no special treatment while awaiting surgery <sep> skin traction <sep>', 'skin traction with 2 kg of weights group 2 skin traction without weights and group 3 pillow placement under the affected limb <sep> weight-loaded skin traction kit <sep> skin traction and placebo <sep> skin traction device with or without weights <sep>', 'pre-operative skin traction <sep>', 'preoperative skin traction <sep> skin traction <sep>', 'preoperative traction <sep> skin and skeletal traction <sep>'], 'punchline_effect': [' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' no diff <sep>', ' sig increase <sep>', ' no diff <sep>', ' sig decrease <sep>', ' no diff <sep>']}",from the evidence available the routine use of traction either skin or skeletal prior to surgery for a hip fracture does not appear to have any benefit. however the evidence is also insufficient to rule out the potential advantages for traction in particular for specific fracture types or to confirm additional complications due to traction use. given the increasing lack of evidence for the use of pre-operative traction the onus should now be on clinicians who persist in using pre-operative traction to either stop using it or to use it only in the context of a well-designed randomised controlled trial.
455,"{'outcomes': ['average union time <sep> rate of union and functional outcome <sep> restriction of shoulder movements <sep> ases scores <sep> union time union rate functional outcome and the incidence of complications <sep> union rate <sep> american shoulder and elbow surgeons score ases <sep>', 'elbow rom <sep> shoulder range of motion rom <sep> fracture healing radial nerve recovery infection and elbow and shoulder discomfort <sep> elbow pain <sep> fracture alignment time to healing delayed union and nonunion <sep> shoulder pain <sep>', 'function of the shoulder and elbow as determined by the american shoulder and elbow surgeons score the visual analogue pain score range of movement or the time taken to return to normal activity <sep> complications <sep>', 'healing times <sep> radial nerve palsy <sep> internal fixation of humeral shaft fractures <sep> rate of non-union <sep>'], 'punchline_text': ['the average union time was found to be significantly lower for imn as compared to dcp p<0.05). <sep>', 'a decrement in elbow rom was significantly associated with plt p  0.03 especially for fractures of the distal third of the diaphysis whereas elbow pain was not p  0.123). <sep>', 'there were no significant differences in the function of the shoulder and elbow as determined by the american shoulder and elbow surgeons score the visual analogue pain score range of movement or the time taken to return to normal activity. <sep>', 'healing times did not differ between the two treatment groups p>0.05). <sep>'], 'population': ['forty-seven patients with diaphyseal fracture of the shaft of the humerus <sep> diaphyseal fractures of the humerus <sep> patients with pathological fractures grade 3 open fractures refractures and old neglected fractures of the humerus were excluded from the study <sep>', 'patients requiring surgical treatment of a humeral shaft fracture <sep> patients admitted consecutively to a university-affiliated level i trauma center <sep> group n  46 <sep> all skeletally mature patients admitted to harborview medical center with acute humeral shaft fractures requiring surgical stabilization <sep> humeral diaphyseal fractures <sep>', '44 patients with fractures of the shaft of the humerus to open reduction and <sep>', 'humerus fractures <sep> 60 patients 43 males 17 females mean age 38 years range 19 to 61 years with humerus fractures <sep> and 27 patients with dynamic compression plates <sep>'], 'interventions': ['humerus intramedullary nail and dynamic compression plate <sep> dcp <sep> humerus intramedullary nail imn and dynamic compression plate dcp <sep> internal fixation with imn or dcp <sep> imn <sep> internal fixation by imn and 24 by dcp <sep> reamed antegrade nailing <sep>', 'humeral shaft fracture fixation intramedullary nails versus plates <sep> locking antegrade intramedullary humeral nails russell-taylor design smith and nephew richards or with 4.5-millimeter dynamic compression and limited contact dynamic compression plates ao design synthes <sep> plt <sep> intramedullary nailing and compression plating <sep> intramedullary nailing imn group n  38 and those treated by compression plating plt <sep> locked intramedullary im nails and plates <sep>', 'internal fixation by either an intramedullary nail imn or a dynamic compression plate dcp <sep> dynamic compression plate or intramedullary nail <sep> dcp <sep>', 'intramedullary nailing and compression plate fixation <sep> dynamic compression plate <sep> intramedullary nails <sep> intramedullary nail or a dynamic compression plate <sep> intramedullary nailing <sep>'], 'punchline_effect': [' sig decrease <sep>', ' sig increase <sep>', ' no diff <sep>', ' no diff <sep>']}",the available evidence shows that intramedullary nailing is associated with an increased risk of shoulder impingement with a related increase in restriction of shoulder movement and need for removal of metalwork. there was insufficient evidence to determine if there were any other important differences including in functional outcome between dynamic compression plating and locked intramedullary nailing for humeral shaft fractures.
456,"{'outcomes': ['infection rate <sep>', 'deep infection <sep> superficial thromboplebitis <sep> number of infections <sep>'], 'punchline_text': ['three different antibiotics regimes were compared with no difference in the infection rate therefore the simplest and surest method a single pre-operative dose and a single post-operative dose is recommended. <sep>', 'a statistically significant difference was found between the number of infections in the antibiotic groups and the number in the placebo group. <sep>'], 'population': ['85 adult patients with open fractures of the distal phalanges of less than 6 hours duration treated by conventional surgery <sep>', 'fifty-eight patients with closed malleolar fractures <sep> open and closed fractures <sep> twelve patients with grade ii  iii wounds <sep> 90 patients with open fractures of various bones and 180 patients with closed malleolar fractures treated by open surgery <sep> patients with grade i wounds 17 received <sep>'], 'interventions': ['antibiotics <sep> no antibiotic therapy or cephradine <sep>', 'dicloxacillin and benzyl penicillin <sep> placebo <sep> dicloxacillin <sep> dicloxacillin 21 benzyl penicillin and 17 saline <sep> benzyl penicillin and 13 with saline <sep> dicloxacillin 59 benzyl penicillin and 63 saline <sep> prophylactic antibiotics <sep> benzyl penicillin or placebo <sep> antibiotic prophylaxis <sep> saline placebo <sep>'], 'punchline_effect': [' no diff <sep>', ' sig decrease <sep>']}",antibiotics reduce the incidence of early infections in open fractures of the limbs. further placebo controlled randomised trials are unlikely to be justified in middle and high income countries except for open fractures of the fingers. further research is necessary to the determine the avoidable burden of morbidity in countries where antibiotics are not used routinely in the management of open fractures.
